nct_id,title,official_title,primary_drug,all_drug_names,drug_count,study_type,phases,primary_phase,primary_purpose,primary_condition,all_conditions,keywords,overall_status,why_stopped,start_date,completion_date,primary_outcomes,secondary_outcomes,outcome_count,min_age,max_age,sex,healthy_volunteers,lead_sponsor,sponsor_class,collaborator_count,enrollment_count,enrollment_type,collected_date,api_version,is_interventional,has_drug_interventions,is_completed,is_failed,has_safety_outcomes,failure_reason
NCT03990688,A Study to Assess the Effect of AK3280 on Renal Function in Healthy Subjects,"A Phase I, Randomised, Double-blind, Placebo-controlled Study to Assess the Effect of Multiple Oral Doses of AK3280 on Renal Function in Healthy Subjects",AK3280,"['AK3280', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2019-10-03,2020-09-21,"[{'measure': 'Directly measured absolute glomerular filtration rate (mGFR) results.', 'description': 'The effect of AK3280 treatment on GFR is measured by iohexol plasma clearance.', 'timeFrame': 'Days -1, 7, and 14.'}, {'measure': 'Change from baseline mGFR results.', 'description': 'To compare the difference of effect of AK3280 treatment on GFR.', 'timeFrame': 'Days 7 and 14.'}]","[{'measure': 'Frequency, intensity, and seriousness of Adverse Events (AEs)', 'description': 'An AE can be any unfavorable and unintended sign (including an abnormal safety laboratory finding), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.', 'timeFrame': 'From Day -1 to Day 28.'}, {'measure': 'Change in blood renal function biomarkers', 'description': 'Blood renal function biomarkers include cystatin C, beta-trace protein, p-myoglobin, etc.', 'timeFrame': 'Screening, Days -2, 7, 14, and 21.'}, {'measure': 'Change in urine renal function biomarkers', 'description': 'Urine renal function biomarkers include electrolytes, albumin, alpha1-microglobulin, etc.', 'timeFrame': 'From Day -1 to Day 21.'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'description': 'The maximum observed plasma concentration of AK3280 and its major metabolite, AK3280-M2.', 'timeFrame': 'Days 1, 7, and 14.'}, {'measure': 'Concentration at the end of the dosing interval (Ctau)', 'description': 'The concentration of AK3280 and its major metabolite, AK3280-M2, at the end of the dosing interval.', 'timeFrame': 'Days 1, 7, and 14.'}, {'measure': 'trough plasma concentration (Ctrough)', 'description': 'The trough observed plasma concentration of AK3280 and its major metabolite, AK3280-M2.', 'timeFrame': 'Days 1, 7 and 14.'}, {'measure': 'trough plasma concentration (Ctrough)', 'description': 'The trough observed plasma concentration of AK3280 and its major metabolite, AK3280-M2.', 'timeFrame': 'Days 1, 7, and 14.'}, {'measure': 'Area under the plasma concentration-time curve from time zero up to time (AUC 0-t)', 'description': 'The area under the plasma concentration-time curve from time zero up to the last analytically quantifiable concentration of AK3280.', 'timeFrame': 'Days 1, 7, and 14.'}]",10,18 Years,45 Years,ALL,True,"Shanghai Ark Biopharmaceutical Co., Ltd.",INDUSTRY,0,48.0,ACTUAL,2025-09-01T16:18:20.962162,v2_robust,True,True,True,False,True,
NCT04154488,A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders,"A Phase 1b/2, Open-Label, Multicenter Study of Mavorixafor in Patients With Congenital Neutropenia and Chronic Neutropenia Disorders",Mavorixafor,"['X4P-001', 'Mavorixafor']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Neutropenia,['Neutropenia'],"['Chronic congenital neutropenia', 'Chronic idiopathic neutropenia', 'SCN', 'CIN', 'CXCR4', 'Mavorixafor', 'Neutropenia glycogen storage disease type 1b', 'GSD1b', 'G6PC3', 'SLC37A4', 'GATA2']",COMPLETED,,2021-10-16,2024-08-27,"[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of Mavorixafor', 'timeFrame': 'Baseline through Day 1 and 7 days follow-up'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Multiple Doses of Mavorixafor', 'timeFrame': 'Baseline through Month 6 and 30 days follow-up'}, {'measure': 'Change From Baseline in Absolute Neutrophil Count (ANC) to 8 hours Post-dose On Day 1', 'timeFrame': 'Baseline, 8 hours Post-dose On Day 1'}, {'measure': 'Change From Baseline in ANC to Month 6', 'timeFrame': 'Baseline, Month 6'}]","[{'measure': 'Serum Concentration of Mavorixafor in Relation to ANC and Area Under the Curve (AUC) for ANC (AUCANC)', 'timeFrame': '0 (pre-dose), 60 minutes and 2, 3, 4, 6, and 8 hours post-dose on Day 1'}, {'measure': 'Serum Concentrations of Mavorixafor', 'timeFrame': '0 (pre-dose) up to Month 6'}, {'measure': 'Change from Baseline in Absolute Lymphocyte Count (ALC)', 'timeFrame': 'Baseline, Month 6'}, {'measure': 'Change from Baseline in Total White Blood Cells (WBC)', 'timeFrame': 'Baseline, Month 6'}, {'measure': 'Change from Baseline in Absolute Monocyte (AMC)', 'timeFrame': 'Baseline, Month 6'}, {'measure': 'AUC of ANC (AUCANC)', 'timeFrame': 'Baseline up to Month 6'}, {'measure': 'AUC of ALC (AUCALC)', 'timeFrame': 'Baseline up to Month 6'}, {'measure': 'AUC of AMC (AUCAMC)', 'timeFrame': 'Baseline up to Month 6'}, {'measure': 'AUC of WBC (AUCWBC)', 'timeFrame': 'Baseline up to Month 6'}]",13,12 Years,,ALL,False,X4 Pharmaceuticals,INDUSTRY,0,32.0,ACTUAL,2025-09-01T16:18:20.962173,v2_robust,True,True,True,False,True,
NCT01352988,Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus,"Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus: A Mono-Centre, Open-Label, Prospective Pilot Study",Fumaric acid esters,"['Fumaderm® initial', 'Fumaderm®', 'Fumaric acid esters']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,"Lupus Erythematosus, Cutaneous","['Lupus Erythematosus, Cutaneous']","['C17.300.475', 'C17.800.480']",COMPLETED,,2011-07,2014-02,"[{'measure': 'Primary efficacy outcome is the response rate at week 24 or at the latest assessment for patients who withdrew prematurely.', 'description': 'Response is defined as a reduction of 50% in the total RCLASI activity for skin lesions, compared to the baseline value (""RCLASI 50"").', 'timeFrame': 'Week 24 or at the latest assessment for patients who withdrew prematurely (Last Observation Carried Forward, LOCF).'}]","[{'measure': 'Proportion of patients with RCLASI 50 at week 12 of treatment', 'timeFrame': 'Week 12 of treatment'}, {'measure': 'Proportion of patients with at least partial response at end of therapy (with regard to RCLASI activity score for skin lesions)', 'timeFrame': 'End of therapy (up to 24 weeks)'}, {'measure': 'Time from start of treatment to first RCLASI 50 assessment (time to response).', 'timeFrame': 'Time to response (up to 24 weeks)'}, {'measure': ""Patient's global assessment and VAS for itch and pain 12 weeks after the beginning of treatment and at the end of therapy."", 'timeFrame': '12 weeks after the beginning of treatment and at the end of therapy (up to 24 weeks).'}, {'measure': 'Number of Participants with Adverse Events (AEs) and their severity.', 'timeFrame': '24 weeks of treatment + 4 weeks of follow up'}]",6,18 Years,70 Years,ALL,False,University Hospital Muenster,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:20.962218,v2_robust,True,True,True,False,True,
NCT02671188,"A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis","A Multi-centre, Randomised, Double-blind (Sponsor Open), Placebo-controlled, Repeat Dose, Proof of Mechanism Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis",GSK3050002,"['GSK3050002', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Autoimmune Diseases,['Autoimmune Diseases'],"['C-C chemokine receptor', 'Psoriatic arthritis', 'Chemokine (C-C motif) ligand 20', 'Monoclonal antibody', 'psoriasis', 'Humanized Immunoglobulin G']",WITHDRAWN,"This study was stopped before any subjects were treated, consequently there are no results for the study.",2018-06-01,2019-08-09,"[{'measure': 'Number of subjects with Adverse Events (AE)', 'description': 'An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.', 'timeFrame': 'Up to Day 116'}, {'measure': 'Number of subjects with Serious Adverse Events', 'description': 'An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the subjects or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, and is associated with drug-induced liver injury.', 'timeFrame': 'Up to Day 116'}, {'measure': 'Composite of clinical laboratory assessments as a measure of safety and tolerability.', 'description': 'Clinical laboratory assessments will include hematology, clinical chemistry and urinalysis.', 'timeFrame': 'Up to Day 116'}, {'measure': 'Composite of vital signs as a measure of safety and tolerability.', 'description': 'Vital signs to be measured in semi-supine position after at least 5 minutes rest and will include temperature, systolic and diastolic blood pressure, and pulse rate.', 'timeFrame': 'Up to Day 116'}, {'measure': 'Electrocardiogram (ECG) assessment as a measure of safety and tolerability.', 'description': 'A single 12-lead ECG will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and corrected QT (QTc) intervals.', 'timeFrame': 'Up to Day 116'}]","[{'measure': 'GSK3050002- CCL20 complex levels in serum', 'description': 'Blood samples will be collected on baseline (Day-10 to -1), at pre-dose and at 120 minutes post start of infusion, immediately after infusion has ceased on D 15 and D 29, D 43, D 85, D 113 +/- 3 days', 'timeFrame': 'Baseline and Up to Day 116'}, {'measure': 'Change from baseline in the number of CD3+ T cells synovial tissue and skin biopsy in samples', 'description': 'Synovial and skin lesion biopsy tissue will be collected and evaluated for general appearance and inflammatory infiltrate including CD3+ T-cells', 'timeFrame': 'Baseline and Day 43'}, {'measure': 'Change from baseline in Disease Activity Score 28 (DAS28)', 'description': 'DAS28 is a composite arthritis disease activity index comprising swollen and tender joint count (28 joints), patient global assessment of disease activity, and C-reactive protein.', 'timeFrame': 'Baseline and Up to Day 116'}, {'measure': 'Changes in American College of Rheumatology (ACR) responders', 'description': 'ACR is a composite score of the patient assessment of joint pain, the patient global assessment of disease activity, the physician global assessment of disease activity, the 66/68 swollen/tender joint count, the Disability Index of the Health Assessment Questionnaire (HAQ-DI) questionnaire, and C-reactive protein. The ACR is reported as % improvement (20%, 50% or 70%), between two discrete timepoints, as calculated by improvement in the 66/68 swollen/tender joint count, and improvement in at least three of the remaining five composite parameters.', 'timeFrame': 'Baseline and Up to Day 116'}, {'measure': 'Changes from baseline in Psoriatic Arthritis Disease Activity Score (PASDAS)', 'description': 'PASDAS is a composite disease activity index for psoriatic arthropathies comprising the 66/68 swollen/tender joint count, patient global assessment of disease activity, physician global assesment of disease activity, Leeds enthesitis index, dactylitis score, SF-36 questionnaire and C-reactive protein', 'timeFrame': 'Baseline and Up to Day 116'}, {'measure': 'Changes in Psoriasis Lesion Severity Score (PLSS)', 'description': 'The PLSS is the sum of the erythema, scaling and plaque thickness scores.', 'timeFrame': 'Baseline and Up to Day 116'}, {'measure': 'Changes in Psoriasis Area Severity Index (PASI)', 'description': 'The PASI scoring system is a widely-used standard clinical tool for assessing the severity of psoriasis that takes into account the overall severity of erythema (redness), thickness (induration), and scale, as well as the extent of body surface area (BSA) affected with psoriasis. Higher scores indicate more severe disease. PASI is a static measurement made without reference to previous scores', 'timeFrame': 'Baseline and Up to Day 116'}, {'measure': 'Incidences of serum anti- GSK3050002 antibody levels', 'description': 'Serum samples will be collected from all subjects at pre-dose and various time points post-dosing. An assay for detecting Anti-drug Antibodies (ADAs) against GSK3050002 will be done using validated electrochemiluminescent (ECL) bridging assay and the Meso-Scale Discovery (MSD) technology.', 'timeFrame': 'Baseline and Up to Day 116'}, {'measure': 'Titres of serum anti- GSK3050002 antibody levels', 'description': 'The serum which contain potential anti-GSK3050002 antibodies will be confirmed by immunocompetition using excess drug. Confirmed samples with ADA will be further analyzed for titers.', 'timeFrame': 'Baseline and Up to Day 116'}, {'measure': 'Maximum serum concentrations (Cmax) after repeat dosing of GSK3050002', 'description': 'Blood samples were collected at pre-dose and at 120 minutes post start of infusion, immediately after infusion has ceased on Day (D)1, D15, and D29. Blood samples were also collected D 8, D 22, D 43, D 57, D 85 and D 113 +/-3 days.', 'timeFrame': 'Up to Day 116'}, {'measure': 'Area under curve over the dosing interval AUC (0- tau) after repeat dosing of GSK3050002', 'description': 'Blood samples were collected at pre-dose and at 120 minutes post start of infusion, immediately after infusion has ceased on Day (D)1, D15, and D29. Blood samples were also collected D 8, D 22, D 43, D 57, D 85 and D 113 +/-3 days.', 'timeFrame': 'Up to Day 116'}, {'measure': 'Systemic clearance (CL) after repeat dosing of GSK3050002', 'description': 'Blood samples were collected at pre-dose and at 120 minutes post start of infusion, immediately after infusion has ceased on Day (D)1, D15, and D29. Blood samples were also collected D 8, D 22, D 43, D 57, D 85 and D 113 +/-3 days.', 'timeFrame': 'Up to Day 116'}, {'measure': 'Volume of distribution (V) after repeat dosing of GSK3050002', 'description': 'Blood samples were collected at pre-dose and at 120 minutes post start of infusion, immediately after infusion has ceased on Day (D)1, D15, and D29. Blood samples were also collected D 8, D 22, D 43, D 57, D 85 and D 113 +/-3 days.', 'timeFrame': 'Up to Day 116'}]",18,18 Years,75 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:20.962236,v2_robust,True,True,False,True,True,"This study was stopped before any subjects were treated, consequently there are no results for the study."
NCT01155388,A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease,"A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared With Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Nondialysis-dependent Chronic Kidney Disease",Ferumoxytol,"['Ferumoxytol', 'Ferrous fumarate', 'Oral Iron']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Iron Deficiency Anemia,"['Iron Deficiency Anemia', 'Nondialysis-dependent Chronic Kidney Disease']","['Iron deficiency anemia', 'Feraheme', 'ferumoxytol', 'CKD', 'pediatric', 'nondialysis-dependent']",TERMINATED,Several factors contributed to significant challenges in enrollment and led the Sponsor to discontinue the AMAG-FER-CKD-252 study as designed.,2011-10-17,2014-06-24,"[{'measure': 'Mean Change In Hemoglobin From Baseline To Week 5', 'description': 'Mean changes in hemoglobin from Baseline to Week 5 were to be presented. Despite efforts to complete the studies as designed, several factors contributed to significant challenges in enrollment and led the sponsor to discontinue the combined AMAG FER-CKD-252 and AMAG FER-CKD-251 studies. Blood samples were collected, but not run through an analysis to obtain outcome measure data. As such, the data set for this primary outcome measure cannot be summarized nor can the statistical analysis, as described in the protocol, be provided in a way that will provide any significant data based upon the limited study datasets.', 'timeFrame': 'Baseline, Week 5'}]","[{'measure': 'Pharmacokinetics: Area Under The Curve Of Ferumoxytol', 'description': 'Ferumoxytol concentrations were to be determined using a drug-specific nuclear magnetic resonance assay. Blood samples were to be collected at specified times predose and postdose at the time of the first dose from 6 participants in each age-dose group. Sampling for participants \\<6 years of age will be minimized to the fewest number of time points required for population PK analysis based on preliminary PK data from the first 2 age cohorts. Blood samples were collected, but not run through an analysis to obtain outcome measure data. As such, the data set for this secondary outcome measure cannot be summarized in a way that will provide any significant data based upon the limited study datasets.', 'timeFrame': 'Baseline; 10, 30, 120, and 360 minutes postdose; 24, 48, and 72 hours postdose'}]",2,6 Months,17 Years,ALL,False,"AMAG Pharmaceuticals, Inc.",INDUSTRY,0,14.0,ACTUAL,2025-09-01T16:18:20.962301,v2_robust,True,True,False,True,False,Several factors contributed to significant challenges in enrollment and led the Sponsor to discontinue the AMAG-FER-CKD-252 study as designed.
NCT06230588,A Clinical Trial of TQH3906 Capsules in Healthy Volunteers,"A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of TQH3906 Capsules in Healthy Volunteers",TQH3906 capsule,"['TQH3906 capsule', 'TQH3906 placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Psoriasis,['Psoriasis'],[],COMPLETED,,2024-02-02,2025-04-27,"[{'measure': 'Adverse events (AE)', 'description': 'Incidence of adverse events (AE)', 'timeFrame': 'Up to 18 days'}, {'measure': 'Serious Adverse Events (SAE)', 'description': 'Incidence of serious adverse events (SAE)', 'timeFrame': 'Up to 18 days'}, {'measure': 'Treatment-emergent adverse events (TEAEs)', 'description': 'Incidence of treatment-emergent adverse events (TEAEs)', 'timeFrame': 'Up to 18 days'}]","[{'measure': 'Time to peak concentration (Tmax)', 'description': 'The time it takes to reach the peak concentration', 'timeFrame': 'Up to 18 days'}, {'measure': 'Peak concentration (Cmax)', 'description': 'Maximum plasma drug concentration', 'timeFrame': 'Up to 18 days'}, {'measure': 'Area under the blood concentration-time curve', 'description': 'The amount of drug absorbed into the circulation after administration of a single dose can be estimated from the area under the blood concentration-time curve, with Auc in units of concentration \\* time.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Apparent volume of distribution (Vd/F)', 'description': 'It is the ratio of the amount of drug in the body to the blood concentration of the drug when the drug reaches dynamic equilibrium in the body is called the apparent volume of distribution.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Plasma clearance (CL/F)', 'description': 'It is the sum of drug clearance by the liver and kidneys, etc., i.e., how many volumes of plasma are cleared of drug per unit of time in L/h, or L/(kg-h) if calculated on the basis of body weight.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Plasma elimination half-life (t1/2)', 'description': 'The time required for the concentration of a drug in the blood or the amount of drug in the body to be reduced to 1/2. The time required for absorption, distribution and elimination of half the amount of drug (or blood concentration) in the body becomes the absorption half-life, distribution half-life and elimination half-life, respectively.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Steady-state peaking time (Tmax, ss)', 'description': 'The time required to reach a steady-state peak concentration after administration.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Steady state peak concentration (Cmax, ss)', 'description': 'The steady-state blood drug concentration is a serrated plasma drug concentration curve, with the highest steady-state blood drug concentration being the peak steady-state blood drug concentration.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Steady state valley concentration (Cmin, ss)', 'description': 'The steady-state blood drug concentration is a serrated plasma drug concentration curve, with the lowest steady-state blood drug concentration being the trough of the steady-state blood drug concentration.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Average steady-state blood drug concentration (Cav, ss)', 'description': 'The average concentration reached when the drug concentration reaches a steady state after a continuous given dose of medication.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Area under steady-state blood drug concentration time curve (AUC0- τ)', 'description': 'After a single dose administration, the amount of medication absorbed into the human bloodstream can be estimated using the area under the blood drug concentration time curve, with the unit of Auc being concentration \\* time.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Accumulation ratio (Rac)', 'description': 'The ratio of the required dose for a single administration to the total dose required for a split administration.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Renal clearance rate (CLr/F)', 'description': 'The ability of both kidneys to completely remove a substance equivalent to several milliliters of plasma within one minute.', 'timeFrame': 'Up to 18 days'}, {'measure': 'INF-γ release', 'description': 'Inhibition efficiency of INF-γ release by TQH3906 in IL-12/IL-18-stimulated peripheral blood mononuclear cells from subjects.', 'timeFrame': 'Up to 18 days'}, {'measure': 'QTcF interval', 'description': 'Effect of TQH3906 on the QTcF interval in healthy subjects.', 'timeFrame': 'Up to 18 days'}]",18,18 Years,55 Years,ALL,True,"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",INDUSTRY,0,96.0,ACTUAL,2025-09-01T16:18:20.962340,v2_robust,True,True,True,False,True,
NCT03018288,Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM),"A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)",Pembrolizumab,"['Pembrolizumab', 'Keytruda', 'Temodar', 'Temozolomide']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Glioblastoma,['Glioblastoma'],"['Malignant Gliomas', 'Immunotherapy']",TERMINATED,Study closed early due to poor accrual.,2017-09-21,2022-12-20,"[{'measure': 'One-year Overall Survival (OS) Rate', 'description': 'One-year overall survival (OS) rate is defined as the percentage of participants who from time of registration survived to one year in newly diagnosed O6-methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT) unmethylated Glioblastoma (GBM) participants treated with radiation therapy (RT) + Temozolomide (TMZ) + Pembrolizumab followed by Pembrolizumab + TMZ +/- heat-shock protein peptide complex-96 (HSPPC-96) x 6 cycles (1 cycle is 9 weeks) months. Rate of OS is measured by Kaplan-Meier method.', 'timeFrame': 'One year'}]","[{'measure': 'Response Rate', 'description': 'Response was determined by the Response Assessment in Neuro-Oncology Criteria (RANO) criteria and reported with 95% confidence intervals using exact binomial probability distributions. Complete response is no T1 gadolinium enhancing disease or stable or decreasing T2/fluid-attenuated inversion recovery (FLAIR). Partial response is ≥ 50% decrease in T1 gadolinium enhancing disease or stable or decreasing T2/FLAIR. Stable disease is \\<50% decrease but \\<25% increase in T1 gadolinium enhancing disease or stable or decreasing T2/FLAIR. Progressive disease is ≥25% incT1 gadolinium enhancing disease, appearance of new lesions or increase in T2/FLAIR.', 'timeFrame': 'After treatment, up to 26 months'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from registration to the time of death. Kaplan-Meier curves will be used to analyze overall survival.', 'timeFrame': 'Time from registration to the time of death or off study up to 26 months'}, {'measure': 'Overall Survival at 6, 12 and 24 Months, Post-registration', 'description': 'Participants who are alive at 6, 12 and 24 months, post-registration determined from the level of the Kaplan-Meier curves at these time points.', 'timeFrame': '6, 12 and 24 months, post-registration'}, {'measure': 'Vaccine Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab', 'description': 'Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. And Grade 5 is death related to adverse event.', 'timeFrame': 'Start of treatment until participant is off study, approximately 61.5 months'}, {'measure': 'Placebo Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab', 'description': 'Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. And Grade 5 is death related to adverse event.', 'timeFrame': 'Start of treatment until participant is off study, approximately 61.5 months'}, {'measure': 'Ancillary Treatment Cohort: Number of Adverse Events Grades 2-5, Unrelated, Unlikely, Possibly, Probably, and/or Definitely Related to Pembrolizumab', 'description': 'Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. And Grade 5 is death related to adverse event.', 'timeFrame': 'Start of treatment until participant is off study, approximately 61.5 months'}, {'measure': 'Mean Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT).', 'description': 'To evaluate the occurrence of symptoms and correlate to disease progression and tolerance to treatment using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). Participants rate their symptoms on a questionnaire using an 11-point scale (0-10). 0 is ""not present"" and 10 is ""as bad as you can imagine."" Differences of at least 2 points will be classified as the minimum clinically meaningful change in the symptom severity measures. Higher score indicates worse severity.', 'timeFrame': 'Baseline, end of treatment or discontinuation, and 30 days after last dose'}, {'measure': 'Mean Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT).', 'description': 'To evaluate the occurrence of symptoms and correlate to disease progression and tolerance to treatment using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). Participants rate their symptoms on a questionnaire using an 11-point scale (0-10) of how much symptoms interfered with different aspects of a patient\'s life in the last 24 hours such as general activity, mood, work, relations with other people, walking and enjoyment of life. 0 is ""not present"" and 10 is ""as bad as you can imagine."" Differences of at least 2 points will be classified as the minimum clinically meaningful change in the symptom severity measures.', 'timeFrame': 'Baseline, end of treatment or discontinuation, and 30 days after last dose'}, {'measure': 'Percentage of Participants Rating Their Symptom Severity to Be 5 or Greater (on a 0-10) Scale Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)', 'description': 'Percentage of participants rating their symptom severity to be 5 or greater (on a 0-10) scale using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). Participants rate their symptoms on a questionnaire using an 11-point scale (0-10). 0 is ""not present"" and 10 is ""as bad as you can imagine.""', 'timeFrame': 'Baseline, end of treatment or discontinuation, and 30 days after last dose'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'PFS is defined as the time from registration to the time of confirmed progression. Progression was measured by the immunotherapy response assessment for neuro-oncology (iRANO) criteria. Progressive disease is ≥25% increase in the sum of bi-perpendicular diameters of enhancing disease or new lesions or significant worsened T2/fluid-attenuated inversion recovery (FLAIR) or significant clinical decline.', 'timeFrame': 'Time from registration to the time of confirmed progression, an average of 9 months'}]",11,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,90.0,ACTUAL,2025-09-01T16:18:20.962349,v2_robust,True,True,False,True,True,Study closed early due to poor accrual.
NCT03324503,A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis,"A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis",Glucocorticoid (prednisone or prednisolone),"['Glucocorticoid (prednisone or prednisolone)', 'prednisone or prednisolone']",2,INTERVENTIONAL,['NA'],,,"Sarcoidosis, Pulmonary","['Sarcoidosis, Pulmonary']","['Pulmonary Sarcoidosis', 'HRCT', 'Glucocorticoid', 'Prednisone', 'FRI', 'Prednisolone']",COMPLETED,,2017-12-08,2019-11-15,"[{'measure': 'Change from baseline in high-resolution computed tomography (HRCT)', 'description': 'Is defined as measurements of lobar volumes total lung capacity (TLC) in response to glucocorticoid induction therapy in subjects with pulmonary sarcoidosis.', 'timeFrame': 'Up to approximately 8 weeks'}]",[],1,18 Years,65 Years,ALL,False,Celgene,INDUSTRY,0,8.0,ACTUAL,2025-09-01T16:18:20.962393,v2_robust,True,True,True,False,False,
NCT02661503,HD21 for Advanced Stages,HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD,Bleomycin,"['Etoposide', 'Dacarbazine', 'Vincristine', 'Bleomycin', 'Doxorubicin', 'Brentuximab Vedotin', 'Procarbazine', 'Cyclophosphamide', 'Prednisone', 'Dexamethasone']",10,INTERVENTIONAL,['PHASE3'],PHASE3,,Classical Hodgkin Lymphoma,['Classical Hodgkin Lymphoma'],[],ACTIVE_NOT_RECRUITING,,2016-07,2025-09,"[{'measure': 'Progression Free Survival', 'timeFrame': '5 years'}, {'measure': 'Treatment Related Morbidity', 'timeFrame': 'during 6 cycles of chemotherapy (21-day cycles)'}]",[],2,18 Years,60 Years,ALL,False,University of Cologne,OTHER,0,1500.0,ACTUAL,2025-09-01T16:18:20.962439,v2_robust,True,True,False,False,False,
NCT00520403,A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.,An Open-label Study to Assess the Effect of First-line Treatment With Avastin in Combination With Standard Therapy on Progression-free Survival in Patients With Metastatic Renal Cell Cancer.,bevacizumab [Avastin],"['Vinblastine', 'Interferon alfa-2a', 'bevacizumab [Avastin]']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Renal Cell Cancer,['Renal Cell Cancer'],[],COMPLETED,,2007-09,2010-03,"[{'measure': 'Percentage of Participants With Disease Progression or Death', 'description': 'Disease progression was evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST) using computed tomography (CT) scans (preferred method), magnetic resonance imaging (MRI) scans, X-ray, bone scans, or clinical examination.', 'timeFrame': 'Days 0, 91, 182, 273, 365, 456, and 547'}, {'measure': 'PFS - Time to Event', 'description': 'PFS was defined as the time in days from the date of treatment start to the date of first documented disease progression or death. Disease progression was evaluated according to RECIST using CT scans (preferred method), MRI scans, X-ray, bone scans, or clinical examination. Median PFS was estimated using the Kaplan-Meier method', 'timeFrame': 'Days 0, 91, 182, 273, 365, 456, and 547'}]","[{'measure': 'Percentage of Participants With Objective Response (OR)', 'description': 'Percentage of participants with OR based on assessment of confirmed complete remission (CR) or confirmed partial remission (PR) according to RECIST.', 'timeFrame': 'Baseline and Cycles 3, 6, 9, 13, and 17'}, {'measure': 'Overall Survival (OS)', 'description': 'OS was defined as the duration from treatment start to death from any cause. Overall survival was censored at the last contact for surviving participants and missing data points.', 'timeFrame': 'Baseline, Day 1 of every cycle to disease progression or death (up to Week 102)'}]",4,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,25.0,ACTUAL,2025-09-01T16:18:20.962448,v2_robust,True,True,True,False,False,
NCT04933903,"BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab","BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab for Patients With Resectable Stage IB - III Non-Small Cell Lung Cancer",Ipilimumab,"['Ipilimumab', 'Nivolumab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Non Small Cell Lung Cancer,['Non Small Cell Lung Cancer'],[],RECRUITING,,2021-10-05,2025-12-01,"[{'measure': 'Number of Patients with a Pathologic Response', 'description': 'Assess Pathologic Response (major pathologic response and complete pathologic response) following neoadjuvant low dose SBRT, Ipilimumab and Nivolumab.', 'timeFrame': 'From beginning of study treatment to approximately day 49-63 on study.'}]","[{'measure': 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]', 'description': 'Assess safety and operative morbidity following neoadjuvant low dose SBRT, Ipilimumab and Nivolumab and surgery.', 'timeFrame': 'Beginning of study treatment through 90 days post study treatment completion.'}]",2,18 Years,,ALL,False,Brown University,OTHER,1,25.0,ESTIMATED,2025-09-01T16:18:20.962467,v2_robust,True,True,False,False,True,
NCT02028403,Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy,"Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study",BMS-936559,"['Placebo for BMS-936559', 'BMS-936559']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,HIV Infections,['HIV Infections'],[],COMPLETED,,2014-06,2015-11,"[{'measure': 'Occurrence of a Grade 3 or greater adverse event (AE), including sign/symptom, lab toxicity, or clinical event that is definitely, probably, or possibly related to study treatment', 'description': 'As judged by the core team, blinded to treatment arm; any time from study treatment administration until 28 days after the administration.', 'timeFrame': 'Measured through Day 28'}, {'measure': 'Occurrence of a Grade 1 or > AE of all incident adrenal insufficiency or adrenal crisis (confirmed), myocarditis, pneumonitis, uveitis, immune-mediated hyperthyroidism or hypothyroidism, that is definitely, probably, or possibly related to study', 'description': 'As judged by the core team, blinded to treatment arm; any time from study treatment administration until 28 days after the administration.\n\n(Pneumonitis is Category A, B, or C)', 'timeFrame': 'Measured through Day 28'}, {'measure': 'Frequency of HIV-1 Gag-specific CD8 T-cells by intracellular staining for interferon (IFN)-gamma at baseline and after treatment (through Day 28)', 'timeFrame': 'Measured through Day 28'}, {'measure': 'HIV-1 RNA by single copy assay (SCA) at baseline and after treatment (through Day 28)', 'timeFrame': 'Measured through Day 28'}]","[{'measure': 'PK parameters from non-compartmental analysis (area under curve [AUC], Cmax, V, Tmax, CL/F, t1/2)', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Exploratory pharmacodynamic parameters (Emax, EC50)', 'timeFrame': 'Measured through Week 48'}, {'measure': 'HIV-1 DNA at baseline and after treatment', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Programmed cell death 1 ligand 1 (PD-L1) receptor occupancy', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Proportion of total and HIV-1 gag-specific CD8 T-cells expressing programmed cell death 1 (PD-1), PD-L1, and other exhaustion markers', 'timeFrame': 'Measured through Week 48'}, {'measure': 'CD107a mobilization and carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution of HIV-1 gag-specific CD8 T-cells', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Polyfunctionality of HIV-1 specific CD8 and CD4 T-cells', 'timeFrame': 'Measured through Week 48'}, {'measure': 'CD38 and human leukocyte antigen-DR (HLA-DR) expression on CD8 T-cells', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Gene expression profiles in whole blood', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Detection of antibody to study treatment in plasma', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Occurrence of a Grade 3 or greater AE, including sign/symptom, lab toxicity, or clinical event that is definitely, probably, or possibly related to study treatment', 'description': 'As judged by the core team, blinded to treatment arm; any time greater than or equal to 29 days after the study treatment administration', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Occurrence of a Grade 1 or > AE of all incident adrenal insufficiency or adrenal crisis (confirmed), myocarditis, pneumonitis, uveitis, immune mediated hyperthyroidism or hypothyroidism, that is definitely, probably, or possibly related to study', 'description': 'As judged by the core team, blinded to treatment arm; any time greater than or equal to 29 days after the study treatment administration', 'timeFrame': 'Measured through Week 48'}, {'measure': '2-long terminal repeat (2LTR) circle DNA at baseline and after treatment', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Cell-associated HIV-1 RNA at baseline and after treatment', 'timeFrame': 'Measured through Week 48'}, {'measure': 'RNA/DNA ratios in total CD4 cells at baseline and after treatment', 'timeFrame': 'Measured through Week 48'}, {'measure': 'Expression of programmed cell death 1 ligand 2 (PD-L2) on dendritic cells and monocyte-derived macrophages', 'timeFrame': 'Measured through Week 48'}]",20,18 Years,70 Years,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,8.0,ACTUAL,2025-09-01T16:18:20.962529,v2_robust,True,True,True,False,True,
NCT02527603,Spaso Versus Self-assisted Maneuver for Anterior Shoulder Dislocation,Randomized Clinical Trial Comparing the Spaso Maneuver Versus the Self-assisted Boss-Holzach-Matter for Anterior Shoulder Dislocations,"Anti-Inflammatory Agents, Non-Steroidal","['Anti-Inflammatory Agents, Non-Steroidal', 'Pain Killer, ""Enantyum®""']",2,INTERVENTIONAL,['NA'],,,Shoulder Dislocation,['Shoulder Dislocation'],[],COMPLETED,,2015-08,2017-03,"[{'measure': 'Change From Baseline in Pain that the patient experiences during the reduction procedure', 'description': 'Pain the patient feels during the reduction maneuver. The patient will be asked after reduction to fill out a form with a analog visual scale with scores ranging from 0 \\[no pain\\] to 10 \\[worst possible pain\\].', 'timeFrame': 'Patients will be assessed throughout their visit to the Trauma Unit. No further following should be necessary.There will be no change in pain measurement, only the amount of pain felt during the manoeuvre.'}]",[],1,18 Years,65 Years,ALL,True,Corporacion Parc Tauli,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:20.962561,v2_robust,True,True,True,False,False,
NCT02834403,L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients,Clinical Phase Ib/II Trial of L-NMMA Plus Taxane Chemotherapy in the Treatment of Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients,L-NMMA,"['Amlodipine', 'TAXOTERE', 'L-NMMA', 'NG-monomethyl-l-arginine', 'Enteric-coated aspirin', 'acetylsalicylic acid', 'Pegfilgrastim', 'NEULASTA', 'besylate salt of amlodipine; NORVASC', 'Docetaxel']",10,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Metastatic Triple Negative Breast Cancer,['Metastatic Triple Negative Breast Cancer'],"['breast cancer', 'nitric oxide synthase', 'docetaxel', 'L-NMMA']",COMPLETED,,2016-11,2021-01,"[{'measure': 'Asses the Maximum Tolerated Dose (MTD) of L-NMMA When Combined With Docetaxel/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients, Based on the Number of Dose Limiting Toxicities (DLTs) Per Dose Level.', 'description': 'The Phase Ib portion of the study is designed to investigate the combination at two dose levels of docetaxel (75 and 100 mg/m2) and 7 dose levels of L-NMMA (5, 7.5, 10, 12.5, 15, 17.5, and 20 mg/kg). The starting dose will be L-NMMA at 7.5 mg/kg and docetaxel at 75 mg/m2. As patients are accrued, a standard Bayesian model averaging continual reassessment method (CRM) approach will be used to determine the appropriate dosage. For a dose level to be chosen as the MTD, at least 4 patients must have received said dose without experiencing a significant number of DLTs based on the Bayesian Model Averaging Continual Reassessment Method.', 'timeFrame': 'DLTs assessment window is the duration required for completing one full cycle (through Day 21).'}, {'measure': 'Clinical Benefit Rate', 'description': 'Primary Outcome Measure for Phase II: Determine the number of participants with complete response, partial response, or stable disease after 6 cycles of L-NMMA combined with taxane chemotherapy (docetaxel, paclitaxel, or nab-paclitaxel)/amlodipine, as assessed by the RECIST 1.1.\n\n* CR (complete response) = disappearance of all target lesions\n* PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions\n* PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions\n* SD (stable disease) = small changes that do not meet above criteria\n* Treatment Failure: taken off the study because of adverse events before the first restaging scan after cycle 2', 'timeFrame': 'The approximate length of the study from Cycle 1, Day 1 will be approximately seven months (approximately four months of treatment plus three months of follow-up).'}, {'measure': 'Asses the Maximum Tolerated Dose (MTD) of Docetaxel When Combined With L-NMMA/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients, Based on the Number of Dose Limiting Toxicities (DLTs) Per Dose Level.', 'description': 'The Phase Ib portion of the study is designed to investigate the combination at two dose levels of docetaxel (75 and 100 mg/m2) and 7 dose levels of L-NMMA (5, 7.5, 10, 12.5, 15, 17.5, and 20 mg/kg). The starting dose will be L-NMMA at 7.5 mg/kg and docetaxel at 75 mg/m2. As patients are accrued, a standard Bayesian model averaging continual reassessment method (CRM) approach will be used to determine the appropriate dosage. For a dose level to be chosen as the MTD, at least 4 patients must have received said dose without experiencing a significant number of DLTs based on the Bayesian Model Averaging Continual Reassessment Method.', 'timeFrame': 'DLTs assessment window is the duration required for completing one full cycle (through Day 21).'}]","[{'measure': 'Dose Limiting Toxicities (DLTs) and Other Adverse Events', 'description': 'Describe the DLTs and other adverse events associated with L-NMMA when combined with docetaxel/amlodipine, as assessed by the CTCAE v4.03 Any Grade ≥ 3 Adverse Events (AE) unless there is clear alternative evidence that the AE was not caused by the study treatment.', 'timeFrame': 'The approximate length of the study from Cycle 1, Day 1 will be approximately seven months (approximately four months of treatment plus three months of follow-up).'}, {'measure': 'Recommended Phase 2 Dose (RP2D) of the L-NMMA and Docetaxel Combination', 'description': ""Determine the RP2D of the L-NMMA and docetaxel combination based on the occurrence of DLTs during Phase Ib portion of the study.\n\nAs patients are accrued, they will start with 7.5 mg/kg of L-NMMA and 75 mg/m2 of docetaxel and their DLTs will be assessed after completion of the first cycle. This will determine the next cohort dose, until at least 4 patients receive the dose with minimal DLTs that won't require dose reduction."", 'timeFrame': 'The Dose Limiting Toxicities (DLT) assessment window is the duration required for completing one full cycle (through Day 21).'}, {'measure': 'Antitumor Activity', 'description': 'Assess the antitumor activity of L-NMMA when combined with taxane chemotherapy (docetaxel, paclitaxel, or nab-paclitaxel)/amlodipine, as assessed by the RECIST 1.1.\n\n* CR (complete response) = disappearance of all target lesions\n* PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions\n* PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions\n* SD (stable disease) = small changes that do not meet above criteria\n* Treatment Failure: taken off the study because of adverse events before the first restaging scan after cycle 2', 'timeFrame': 'The approximate length of the study from Cycle 1, Day 1 will be approximately seven months (approximately four months of treatment plus three months of follow-up).'}, {'measure': 'Time to Maximum Plasma Concentration of L-NMMA and Docetaxel', 'description': 'Determine the time to maximum plasma concentration of the L-NMMA and docetaxel combination.', 'timeFrame': 'Blood samples will be collected predose (10-30 minutes before L-NMMA infusion) on Days 1, 2, and 5 of Cycle 1 and Days 1 and 5 of Cycle 2 for determination of L-NMMA plus docetaxel plasma PK.'}]",7,18 Years,,FEMALE,False,The Methodist Hospital Research Institute,OTHER,0,37.0,ACTUAL,2025-09-01T16:18:20.962576,v2_robust,True,True,True,False,True,
NCT01553903,Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not,Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not,"Tamoxifen,","['Tamoxifen,', 'Exemestane', 'Anastrozole', 'Letrozole']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Breast Cancer,['Breast Cancer'],"['Hormonal therapy', 'Breast Cancer', 'AEBS', 'Oxysterols']",COMPLETED,,2011-12,2013-05,"[{'measure': 'Determination of Oxysterols (OCDO, CT and CE)plasma concentrations by Gaz Chromatography coupled to mass spectrometry (GC/MS)in human.', 'description': 'Oxysterols measured are the following : OCDO (6-oxo-cholestan-3 beta, 5 alpha-diol), CE (cholesterol-5,6-eposides) and CT (cholestane-3 beta, 5 alpha, 6 beta-triol).\n\nCalibration curve will be established for each Oxysterol by GC/MS using deuterated analogues of each oxysterols for the quantification.', 'timeFrame': '2 time points (D0 and D28) over a period of 2 years'}]","[{'measure': 'Measure of Oxysterols (OCDO, CT and CE) plasma concentrations in patient treated with Tamoxifen', 'description': 'Plasma concentrations of Oxysterols evaluated by Gaz chromatography coupled to mass spectrometry (GC/MS)in patients after 28 days of hormonal therapy with Tamoxifen in order to determine the impact of the treatment on these plasmatic concentrations(D28 oxysterols plasma concentrations will be compared to D0 oxysterols plasma concentrations)', 'timeFrame': '2 time points (D0 and D28) over a period of 2 years'}, {'measure': 'Measure of Oxysterols (OCDO, CT and CE) plasma concentrations in patient treated with anti-aromatase.', 'description': 'Plasma concentrations of Oxysterols evaluated by Gaz chromatography coupled to mass spectrometry (GC/MS)in patients after 28 days of hormonal therapy with anti-aromatase (Anastrozole, Letrozole or Exemestane) in order to determine the absence of impact of the treatment on these plasmatic concentrations (D28 oxysterols plasma concentrations will be compared to D0 oxysterols plasma concentrations).', 'timeFrame': '2 time points (D0 and D28) over a period of 2 years'}]",3,18 Years,,FEMALE,False,Institut Claudius Regaud,OTHER,0,29.0,ACTUAL,2025-09-01T16:18:20.962628,v2_robust,True,True,True,False,False,
NCT02597803,Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1,"A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye: ARISE-1",RGN-259,"['Thymosin Beta 4', 'Tβ4', 'Placebo', 'RGN-259', 'Vehicle Control']",5,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Dry Eye Syndrome,['Dry Eye Syndrome'],"['Dry Eye Syndrome', 'Dry Eye', 'DES']",COMPLETED,,2015-09,2016-07,"[{'measure': 'Total corneal fluorescein staining score at day29', 'timeFrame': '29 days after first dosing'}, {'measure': 'Total ocular discomfort score at day29', 'timeFrame': '29 days after first dosing'}]","[{'measure': 'Tear film break-up time at day 8, 15, 29', 'timeFrame': '8, 15, 29 days after first dosing'}, {'measure': ""Unanesthetized Schirmer's Test at day 8, 15, 29"", 'timeFrame': '8, 15, 29 days after first dosing'}, {'measure': 'Ocular Surface Disease Index (OSDI)© at day 8, 15, 29', 'timeFrame': '8, 15, 29 days after first dosing'}]",5,18 Years,,ALL,False,"ReGenTree, LLC",INDUSTRY,0,317.0,ACTUAL,2025-09-01T16:18:20.962648,v2_robust,True,True,True,False,False,
NCT06204003,Cannabinoids for Pain Management and Neuroprotection From Concussion,Naturally Produced Cannabinoids for Pain Management and Neuroprotection From Concussion During Participation in Contact Sports: Dose Escalation,Cannabis/Hemp Isolate Extract,"['Cannabis/Hemp Isolate Extract', 'Herbal Extract with a high CBD']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],RECRUITING,,2024-02-15,2026-12,"[{'measure': 'Change in cerebrovascular and cardiovascular physiology', 'description': ""Monitor the participant's cerebrovascular and cardiovascular physiology before and after the dosage regimen"", 'timeFrame': 'Every 15 days from Day 0 to Day 104'}, {'measure': 'Incidence of potential harmful side effects', 'description': 'Follow the participants enrolled in these studies at set intervals to monitor for potential harmful side effects of the high CBD cannabis/hemp extract. This will include bloodwork to assess for possible hematopoietic, renal or hepatic dysfunction, and pharmacokinetic and pharmacodynamic analysis of the dose escalation protocol', 'timeFrame': 'Every 15 days from Day 0 to Day 104'}]","[{'measure': 'Assessment of GABAergic activity', 'description': 'Assess the inhibitory neurotransmitter δ-aminobutyric acid (GABAergic activity)', 'timeFrame': 'Every 15 days from Day 0 to Day 104'}, {'measure': 'Change in pain intensity', 'description': 'Pain Behaviour Measurement system (PBM) scale', 'timeFrame': 'Every 15 days from Day 0 to Day 104'}, {'measure': 'Cerebral blood flow (transcranial Doppler)', 'description': 'Assessment of cerebral hemodynamic activity', 'timeFrame': 'Every 15 days from Day 0 to Day 104'}, {'measure': 'Cerebral oxygenation (near infrared spectroscopy)', 'description': 'Assessment of cerebral hemodynamic activity', 'timeFrame': 'Every 15 days from Day 0 to Day 104'}, {'measure': 'Change in QoL', 'description': 'Assess quality of life (QOL) in study participants by scores on health questionnaires and medication use', 'timeFrame': 'up to day 104'}, {'measure': 'Incidence of AEs', 'description': 'Assess adverse events (AEs) in study participants by looking at sleepiness/lethargy, irritability, nausea/vomiting and diarrhea', 'timeFrame': 'Through study completion, From Day 0 to Day 104'}]",8,18 Years,35 Years,MALE,True,University of Regina,OTHER,2,35.0,ESTIMATED,2025-09-01T16:18:20.962729,v2_robust,True,True,False,False,True,
NCT04911127,Therapeutic Response of Cannabidiol in Rheumatoid Arthritis,"Randomized, Double Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Cannabidiol (CBD) in Moderate to Severe Rheumatoid Arthritis",200mg Cannabidiol by capsules twice daily,"['400mg Cannabidiol by capsules twice daily', '200mg Cannabidiol by capsules twice daily', 'Placebo', 'CBD', 'Placebo capsules']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Rheumatoid Arthritis,"['Rheumatoid Arthritis', 'Cannabis']",[],COMPLETED,,2021-10-05,2023-12-31,"[{'measure': 'Change from Baseline in Disease Activity Score (DAS28/ESR)', 'description': 'The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen joint counts (SJC) and tender joint counts (TJC), both scored 0-28 (higher scores indicate higher disease activity), as well as acute phase response (APR) determined as erythrocyte sedimentation rate (ESR), and general health (GH), both scored 1-100 (higher scores indicate higher disease activity). DAS28 was calculated according to the following formula: DAS28 equals (=) \\[0.56 multiplied by (\\*) the square root (√) of TJC\\] plus (+) \\[0.28 \\* √ of SJC\\] + (0.70 \\* the natural logarithm (ln) ESR in millimeters per hour (mm/h)\\] + \\[0.014 \\* GH in mm visual analogue assessment (VAS)\\]. A negative change from randomization indicated improvement.', 'timeFrame': 'Baseline, 12 Weeks'}, {'measure': 'Tolerability as assessed by participant attrition', 'description': 'Tolerability will be evaluated based on the number of participants that drop out due to treatment emergent adverse events or serious adverse events.', 'timeFrame': '12 weeks'}]","[{'measure': 'Change in Power Doppler Synovitis Score (PDUS)', 'description': '34 joints will be evaluated using a 0 to 3 point scale for each joint and the sum of these represents PDUS. PDUS ranges from 0 to 102. Scores of 0 indicate the least amount of inflammation of the joint while scores of 3 indicate the most amount of inflammation. A higher value of the total score for PDUS represents more severe disease level.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change in Grey Scale Synovial Hypertrophy Score (GSUS)', 'description': '34 joints will be evaluated using a 0 to 3 point scale for each joint and the sum of these represents GSUS. GSUS ranges from 0 to 102. Scores of 0 indicate the least amount of inflammation of the joint while scores of 3 indicate the most amount of inflammation. A higher value of the total score for GSUS represents more severe disease level.', 'timeFrame': 'Baseline, 12 weeks'}]",4,18 Years,,ALL,False,"University of California, Los Angeles",OTHER,0,67.0,ACTUAL,2025-09-01T16:18:20.962823,v2_robust,True,True,True,False,True,
NCT01353027,Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus,"A Phase I Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-6002 in Healthy Adult Volunteers",Placebo,"['AVI-6002', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Ebola Hemorrhagic Fever,['Ebola Hemorrhagic Fever'],[],COMPLETED,,2010-05,2011-11,"[{'measure': 'Number of participants with adverse events', 'description': 'The frequency and severity of adverse events will be monitored through 28 days post administration.', 'timeFrame': '28 Days'}]","[{'measure': 'Drug concentration in plasma', 'timeFrame': '28 days'}, {'measure': 'Drug concentration in urine', 'timeFrame': '28 days'}]",3,18 Years,50 Years,ALL,True,"Sarepta Therapeutics, Inc.",INDUSTRY,1,30.0,ACTUAL,2025-09-01T16:18:20.962852,v2_robust,True,True,True,False,True,
NCT03500627,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers","A Phase 1 Open-Label Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 (Dendrimer N-Acetyl-Cysteine) After Intravenous Administration in Healthy Volunteers",OP-101,['OP-101'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Adrenoleukodystrophy (ALD)', 'Childhood Cerebral Adrenoleukodystrophy (ccALD)', 'OP-101', 'Dendrimer', 'N-Acetyl-Cysteine (NAC)']",COMPLETED,,2018-03-30,2018-07-20,"[{'measure': 'Number of Participants with Treatment Emergent Adverse Events Graded as Assessed by CTCAE Version 4.0', 'description': 'Evaluate the safety and tolerability of OP-101 after single IV doses in healthy subjects by monitoring and documenting all adverse events, which include laboratory test variables.', 'timeFrame': 'Screening to Day 15.'}]","[{'measure': 'Pharmacokinetic (PK) Profile Analysis', 'description': 'Determine the PK profile of OP-101 after single IV doses in healthy subjects as determined by plasma concentrations using the PK Concentration Population.', 'timeFrame': 'Days 1, 2, 3, 4, 8, and 15.'}]",2,18 Years,65 Years,ALL,True,"Orpheris, Inc.",INDUSTRY,0,8.0,ACTUAL,2025-09-01T16:18:20.962883,v2_robust,True,True,True,False,True,
NCT05509127,Evaluation of Cervical Restorations Performance Using Modified Universal Adhesive,Evaluation of Cervical Restorations Performance Using Modified Universal Adhesive Compared to Conventional Universal Adhesive: A Randomized Clinical Trial,Modified universal adhesive,"['3M ESPE™ Single Bond Universal Adhesive', 'Conventional universal adhesive', 'Modified universal adhesive', '3M ESPE™ Scotchbond Universal Plus Adhesive']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Clinical Performance,['Clinical Performance'],"['Performance', 'Carious', 'Cervical', 'Universal adhesive', 'USPHS criteria']",ACTIVE_NOT_RECRUITING,,2023-01-01,2025-01-01,"[{'measure': 'Change in Marginal adaptation', 'description': 'using Modified USPHS criteria', 'timeFrame': 'Baseline, 6 months, 12 months, 18 months and 24 months.'}]","[{'measure': 'Marginal discoloration', 'description': 'using Modified USPHS criteria', 'timeFrame': 'Baseline, 6 months, 12 months, 18 months and 24 months.'}, {'measure': 'Post-operative sensitivity', 'description': 'using Modified USPHS criteria', 'timeFrame': 'Baseline, 6 months, 12 months, 18 months and 24 months.'}, {'measure': 'Retention', 'description': 'using Modified USPHS criteria', 'timeFrame': 'Baseline, 6 months, 12 months, 18 months and 24 months.'}, {'measure': 'Secondary caries', 'description': 'using Modified USPHS criteria', 'timeFrame': 'Baseline, 6 months, 12 months, 18 months and 24 months.'}]",5,20 Years,40 Years,ALL,True,Cairo University,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:20.962902,v2_robust,True,True,False,False,False,
NCT05259527,Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy,Impact of Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy,Ergocalciferol Capsules,"['Ergocalciferol Capsules', 'Vitamin D2']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Neuropathic Pain,['Neuropathic Pain'],"['Neuropathic pain', 'Neuropathy', 'Vitamin-D']",SUSPENDED,Staffing,2022-12-19,2027-03-31,"[{'measure': 'Self-reported neuropathic pain- sensory symptoms', 'description': 'The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN (EORTC-QLQ-CIPN20) is a 20-item self-report questionnaire that includes a 9-item subscale assessing sensory symptoms of peripheral neuropathy. The questionnaire asks respondents to think about their past week and indicate to what extent they experienced symptoms of peripheral neuropathy: not at all; a little; quite a bit; or very much. The EORTC-QLQ-CIPN20 will be administered at baseline and at 12 weeks in order to assess change in scores over time.', 'timeFrame': '12 Weeks'}, {'measure': 'Self-reported neuropathic pain- motor symptoms', 'description': 'The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN (EORTC-QLQ-CIPN20) is a 20-item self-report questionnaire that includes a 8-item subscale assessing motor symptoms of peripheral neuropathy. The questionnaire asks respondents to think about their past week and indicate to what extent they experienced symptoms of peripheral neuropathy: not at all; a little; quite a bit; or very much. The EORTC-QLQ-CIPN20 will be administered at baseline and at 12 weeks in order to assess change in scores over time.', 'timeFrame': '12 weeks'}, {'measure': 'Self-reported neuropathic pain- autonomic symptoms', 'description': 'The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN (EORTC-QLQ-CIPN20) is a 20-item self-report questionnaire that includes a 3-item subscale assessing autonomic symptoms of peripheral neuropathy. The questionnaire asks respondents to think about their past week and indicate to what extent they experienced symptoms of peripheral neuropathy: not at all; a little; quite a bit; or very much. The EORTC-QLQ-CIPN20 will be administered at baseline and at 12 weeks in order to assess change in scores over time.', 'timeFrame': '12 weeks'}]","[{'measure': 'Self-reported neuropathic pain', 'description': 'The number of participants with self reported neuropathic pain using the PROMIS Scale v. 2.0 - Neuropathic Pain Quality 5a. This 5-item questionnaire asks respondents to indicate the extent to which they experienced symptoms of peripheral neuropathy in the past week on a scale from 1 (""not at all"") to 5 (""very much""). The PROMIS Scale v. 2.0 - Neuropathic Pain Quality 5a will be administered at baseline and at 12 weeks in order to assess change in scores over time.', 'timeFrame': '12 Weeks'}, {'measure': 'Clinical diagnosis of peripheral neuropathy', 'description': 'The number of participants with a clinical diagnosis of peripheral neuropathy. Chart review will be performed in order to determine whether an independent clinical diagnosis of peripheral neuropathy has been made for study participants.', 'timeFrame': '12 Weeks'}]",5,18 Years,,ALL,False,Virginia Commonwealth University,OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:20.962917,v2_robust,True,True,False,True,False,Staffing
NCT01714427,Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment,Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment,Dexamethasone,"['Sterile isotonic saline', 'Dexamethasone']",2,INTERVENTIONAL,['NA'],,,Experimental Lung Inflammation,['Experimental Lung Inflammation'],[],COMPLETED,,2011-07,2012-06,"[{'measure': 'The effects of LPS instillation on a putative microvascular leak formation in a lung subsegment by radiologic imaging (magnetic resonance imaging, computed tomography) will be quantified.', 'timeFrame': '6/24 hours after LPS Instillation'}]",[],1,19 Years,40 Years,ALL,True,Medical University of Vienna,OTHER,0,36.0,ACTUAL,2025-09-01T16:18:20.962976,v2_robust,True,True,True,False,False,
NCT00571727,Long-Term Treatment With rhIGF-1 in GHIS,A Study of Long-Term Human Recombinant Insulin-Like Growth Factor-1 (rhIGF-1) in Children With Short Stature Due to Growth Hormone Insensitivity Syndrome (GHIS),mecasermin,"['Increlex', 'mecasermin']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Growth Hormone Insensitivity Syndrome,['Growth Hormone Insensitivity Syndrome'],"['growth', 'insulin like growth factor', 'Laron syndrome']",COMPLETED,,1991-05-20,2011-12-15,"[{'measure': 'Annualized Height Velocity Up to 12 Years', 'description': 'Height velocity is the difference between 2 height measurements, divided by years elapsed between measurements.', 'timeFrame': 'Baseline (Pre-dose) and up to 12 years'}, {'measure': 'Number of Naive Participants With Height Velocity <5 cm/y at the End of 1 Year of Study Treatment', 'description': 'Height measurements were performed using wall-mounted stadiometers for analysis of growth data.', 'timeFrame': 'Baseline (Pre-dose) and 1 year'}]","[{'measure': 'Height Velocity Standard Deviation Score Up to 12 Years', 'description': 'Center for disease control growth charts from the US were used as reference for age and gender-dependent mean and standard deviation. Height velocity-standard deviation score was calculated as height velocity minus reference mean height velocity divided by standard deviation of the reference mean height velocity. Greater height velocity standard deviation score indicates better outcome.', 'timeFrame': 'Baseline (Pre-dose) and up to 12 years'}, {'measure': 'Height Standard Deviation Score Up to 12 Years', 'description': 'Center for disease control growth charts from the US were used as reference for age and gender-dependent mean and standard deviation. Height standard deviation score was calculated as height minus reference mean height divided by standard deviation of the reference mean height. A higher height standard deviation score indicates a better outcome.', 'timeFrame': 'Baseline (Pre-dose) and up to 12 years'}, {'measure': 'Approximate Increase in Height Over Expected for Naïve Participants With Near-Adult Height', 'description': 'Height measurements were performed using wall-mounted stadiometers for analysis of growth data.', 'timeFrame': 'Baseline (Pre-dose) and up to 19 years'}]",5,2 Years,21 Years,ALL,False,Ipsen,INDUSTRY,1,92.0,ACTUAL,2025-09-01T16:18:20.962984,v2_robust,True,True,True,False,False,
NCT05970627,Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma,"Perioperative Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) for Treatment of Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Phase II Study",Toripalimab,"['Toripalimab', 'Oxaliplatin', 'S1']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Adenocarcinoma of the Stomach,"['Adenocarcinoma of the Stomach', 'Adenocarcinoma of Esophagogastric Junction', 'Epstein-Barr Virus-Associated Gastric Carcinoma']","['Gastric Adenocarcinoma', 'Esophagogastric Junction Adenocarcinoma', 'Perioperative Chemotherapy', 'Toripalimab', 'Epstein-Barr Virus-associated gastric cancer']",NOT_YET_RECRUITING,,2023-07-28,2029-07-28,"[{'measure': 'Rate of pathological complete responses (pCR)', 'description': 'Percentage of patients with pCR referring to the total number of enrolled and eligible patients, as evaluated centrally by a reference pathologist.', 'timeFrame': 'From enrollment to surgery after pre-operative treatment (up to approximately 36 months)'}]","[{'measure': 'Overall survival', 'description': 'The duration of overall survival (OS) will be determined by measuring the time interval from enrollment to the end of follow up or death from any cause', 'timeFrame': 'From randomization to the last follow-up or death from any cause (up to approximately 72 months)'}, {'measure': 'Progression-free survival', 'description': 'Progression-free survival (PFS) was defined as the time from randomization to the last follow-up or the time of disease progression or relapse or death from any cause.', 'timeFrame': 'From randomization to the last follow-up or the time of disease progression or relapse or death from any cause (up to approximately 72 months)'}, {'measure': 'The incidences and types of adverse events (AE) and severe adverse events (SAE)', 'description': 'The incidences and severity of adverse events that occur during treatment will be evaluated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.3', 'timeFrame': 'From enrollment to 90-day after the last dose administration (up to approximately 39 months)'}]",4,18 Years,80 Years,ALL,False,Yu jiren,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:20.963034,v2_robust,True,True,False,False,True,
NCT01602627,Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies,"A Phase I Dose Escalation, Single Center, Open-Label Study of AUY922 Administered IV on a Once-Weekly Schedule in Adult Patients 75 Years of Age or Older With Advanced Solid Malignancies",Hsp90 inhibitor AUY922,"['AUY922', 'Hsp90 inhibitor AUY922']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Unspecified Adult Solid Tumor, Protocol Specific","['Unspecified Adult Solid Tumor, Protocol Specific']",[],TERMINATED,Slow accrual,2011-09,2012-02,"[{'measure': 'MTD of Hsp90 inhibitor AUY922', 'description': 'A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as clinically relevant, and occurs \\< 28 days following the first dose of AUY922. Toxicity will be measured by CTCAE criteria (Version 4.02). The MTD will be determined using a standard design.', 'timeFrame': 'at 28 days'}]","[{'measure': 'Toxicity by CTCAE (v 4.02)', 'timeFrame': 'at 28 days'}, {'measure': 'Pharmacokinetic parameters, including area under the curve (AUC), clearance, volume of distribution (VD), time to the maximum concentration (Tmax), maximum plasma concentration (Cmax), and elimination half-life', 'description': 'Prior to 1st infusion; 30 minutes after start infusion; end infusion; 5, 30 minutes post-infusion; 1, 2, 4, 5, 24, 48 hours post-infusion course 1 days 8 (pretreatment) and 15 (pretreatment/end infusion); and course 2 day 1 (pretreatment/end infusion)', 'timeFrame': 'at baseline and at 28 days (first cycle)'}, {'measure': 'Tumor response will be measured by RECIST criteria (complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD], overall response [OR], response rate [RR])', 'description': 'Imaging with CT or MRI will be obtained at baseline (within 21 days of study Day 1) and every other cycle commencing at the end of cycle 2 (beginning of cycle 3). These scans should be schedule within 7 days of the start of the cycle. Imaging will be obtained at the end of the study.', 'timeFrame': 'at baseline and at end of cycle 2 (8 weeks)'}, {'measure': 'Geriatric assessment will be made including Mini Mental Exam, Get up and Go, assessment of comorbidity, and Geriatric Depression Scale', 'description': 'This trial will incorporate geriatric assessment to determine the relationship between functional ability or comorbidity and treatment response or toxicity. Patients will be have a geriatric assessment which will included a range of assessments, such as mini mental status, up and go test, and the geriatric depression scale, at baseline and after every 2 cycles of therapy.', 'timeFrame': 'at baseline and at end of cycle 2 (8 weeks)'}, {'measure': 'Evaluation of responses to a bioethics questionnaire will be used to assess patient factors influencing enrollment in this elderly-specific phase I trial', 'timeFrame': 'Baseline'}, {'measure': 'Number of Circulating Tumor Cells (CTC) at baseline and after treatment with Hsp90 inhibitor AUY922', 'description': 'Blood will be collected for measurement of CTCs on Cycle 1 Day 1 pre-infusion, Cycle 2 Day 1 pre-infusion, Cycle 3 Day 1, pre-infusion, then Day 1 of every other cycle until the end of the study.', 'timeFrame': 'at baseline and end of treatment'}, {'measure': 'Level of HSP70 at baseline and after treatment with Hsp90 inhibitor AUY922', 'timeFrame': 'at baseline and at 28 days (first cycle)'}, {'measure': 'Level of M30 and M65 at baseline and following therapy with Hsp90 inhibitor AUY922', 'timeFrame': 'at baseline and at 28 days (first cycle)'}]",9,75 Years,,ALL,False,"Dale Shepard, MD, PhD",OTHER,1,2.0,ACTUAL,2025-09-01T16:18:20.963111,v2_robust,True,True,False,True,True,Slow accrual
NCT02465827,Ultrasound-guided Selective Blockade of the Saphenous and Obturator Nerves Following Total Knee Arthroplasty,Selective Blocks for Total Knee Arthroplasty,nerve block with ropivacaine,"['Saphenous and obturator nerve block with ropivacaine', 'nerve block with ropivacaine', 'saphenous and obturator nerve block with saline', 'nerve block with saline', 'Saph block with ropivacaine and obtur block with saline', 'nerve block with ropivacaine and with saline']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,"Knee Arthroplasty, Total","['Knee Arthroplasty, Total']",[],COMPLETED,,2014-01,2015-03,"[{'measure': 'Dynamic pain (pain upon movement) quantified as area-under-the-curve (AUC) 24-hours post-operatively', 'description': 'NRS 0-10', 'timeFrame': '24 hours'}]","[{'measure': 'Pain at rest quantified as area-under-the-curve (AUC) 24-hours post-operatively', 'description': 'NRS 0-10', 'timeFrame': '24 hours'}, {'measure': 'Total opioid consumption', 'description': 'mg', 'timeFrame': '24 hours'}, {'measure': 'Nausea and vomiting', 'description': 'NRS 0-10', 'timeFrame': '24 hours'}, {'measure': 'Time to first mobilization', 'description': 'hours', 'timeFrame': '24 hours'}, {'measure': 'Length of stay in recovery and hospital', 'description': 'hours', 'timeFrame': '72 hours'}, {'measure': 'Number of clinical complications', 'description': 'total number', 'timeFrame': '72 hours'}]",7,18 Years,,ALL,False,Bispebjerg Hospital,OTHER,0,75.0,ACTUAL,2025-09-01T16:18:20.963122,v2_robust,True,True,True,False,False,
NCT07134127,A Study of IBI3032 in Chinese Healthy Subjects,"A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of IBI3032 in Participants",placebo,"['IBI3032', 'placebo']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Healthy,['Healthy'],[],NOT_YET_RECRUITING,,2025-08-25,2025-12-31,"[{'measure': 'Number of Participants with One Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug', 'description': 'A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module', 'timeFrame': '(Cohoet1,2,4) Baseline up to Day 15 (Cohoet3) Baseline up to Day 15'}, {'measure': 'Number of Participants with More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug', 'description': 'A summary of other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module', 'timeFrame': '(Cohoet1,2,4) Baseline up to Day 15 (Cohoet3) Baseline up to Day 15'}, {'measure': 'Number of Participants with adverse events (AEs)', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.', 'timeFrame': '(Cohoet1,2,4) Baseline up to Day 15 (Cohoet3) Baseline up to Day 15'}]","[{'measure': 'Under the Serum Concentration-time Curve (AUC) of IBI3032', 'description': 'To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.', 'timeFrame': 'Predose up to 168 hours postdose'}, {'measure': 'maximum concentration (Cmax) of IBI3032', 'description': 'To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.', 'timeFrame': 'Predose up to 168 hours postdose'}, {'measure': 'time to maximum concentration (Tmax) of IBI3032', 'description': 'To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.', 'timeFrame': 'Predose up to 168 hours postdose'}, {'measure': 'clearance (CL) of IBI3032', 'description': 'To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.', 'timeFrame': 'Predose up to 168 hours postdose'}, {'measure': 'apparent volume of distribution (V) of IBI3032', 'description': 'To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.', 'timeFrame': 'Predose up to 168 hours postdose'}, {'measure': 'elimination half-life (T1/2) of IBI3032', 'description': 'To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.', 'timeFrame': 'Predose up to 168 hours postdose'}]",9,18 Years,65 Years,ALL,True,Innovent Biologics Technology Limited (Shanghai R&D Center),INDUSTRY,0,40.0,ESTIMATED,2025-09-01T16:18:20.963138,v2_robust,True,True,False,False,True,
NCT02789527,Human Genomic Population Structure and Phenotype-genotype Variation in ADME Genes in Four Populations,"Exploratory Study of the Variability, in Five Human Populations, of ADME (Administration, Distribution, Metabolism, Excretion) Genotypes and Phenotypes After the Intake of the ""Geneva Micrococktail""",Phenotyping,['Phenotyping'],1,INTERVENTIONAL,['NA'],,,Healthy,['Healthy'],['healthy volunteers'],COMPLETED,,2015-11,2017-04,"[{'measure': 'Frequencies of genotypes and haplotypes of genes involved in drug responses (240,000 Single Nucleotide Polymorphisms) in 4 human populations : 100 Ethiopian, 100 Omani, 100 Czech and 100 Greek', 'description': 'Estimation of genotype/allele/haplotype frequencies of variants in genes involved in drug responses', 'timeFrame': 'through study completion, an average of 2 years'}, {'measure': 'Activities of 6 cytochrome P450 enzymes and P-gp in 4 human populations : 100 Ethiopian, 100 Omani, 100 Czech and 100 Greek', 'description': ""Estimation of frequency distributions of classes of drug metabolizers (metabolizers' profiles: slow/normal/rapid)"", 'timeFrame': 'through study completion, an average of 2 years'}]","[{'measure': ""Comparison of frequency distributions of variants in genes involved in drug responses and of associated metabolizers' profiles in 4 human populations : 100 Ethiopian, 100 Omani, 100 Czech and 100 Greek"", 'description': 'Estimation of indices of population genetic/phenotypic diversity and differentiation (expected heterozygosity, Fst). Inferences on the evolutionary mechanisms explaining the estimated diversity among and between populations.', 'timeFrame': 'through study completion, an average of 3 year'}]",3,18 Years,50 Years,ALL,True,Estella S. Poloni,OTHER,1,367.0,ACTUAL,2025-09-01T16:18:20.963146,v2_robust,True,True,True,False,False,
NCT01384227,Evaluation of a Miniaturized Microscope Device for the Detection of Barrett's Neoplasia: A Pilot Study,Evaluation of a Miniaturized Microscope Device for the Detection of Barrett's Neoplasia: A Pilot Study,Proflavine Hemisulfate,"['Proflavine Hemisulfate', 'Proflavine']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Barrett's Esophagus,"[""Barrett's Esophagus""]","[""Barrett's esophagus"", 'in vivo imaging', 'image guide microscope']",COMPLETED,,2009-02,,"[{'measure': 'To determine whether tissue is neoplastic or non-neoplastic', 'timeFrame': '1 day'}]",[],1,18 Years,,ALL,False,"Anandasabapathy, Sharmila, M.D.",INDIV,1,40.0,ACTUAL,2025-09-01T16:18:20.963174,v2_robust,True,True,True,False,False,
NCT00146627,Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis,Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase,Eflornithine,"['Nifurtimox', 'Eflornithine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Trypanosomiasis, African","['Trypanosomiasis, African']","['Human African Trypanosomiasis', 'Combination', 'Trypanosoma brucei gambiense Human African Trypanosomiasis']",COMPLETED,,,2008-06,[],[],0,15 Years,70 Years,ALL,False,Drugs for Neglected Diseases,OTHER,6,280.0,ESTIMATED,2025-09-01T16:18:20.963182,v2_robust,True,True,True,False,False,
NCT03864627,"A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis","A Randomized, Double-blind, Placebo-controlled, Multicentre Phase 2 Study to Evaluate the Safety and Tolerability of Subcutaneous MOR106 Administered Concomitantly With Topical Corticosteroids for Eight Weeks, in Adult Subjects With Moderate to Severe Atopic Dermatitis",MOR106,"['MOR106', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Atopic Dermatitis,['Atopic Dermatitis'],[],TERMINATED,MOR106 clinical development in atopic dermatitis was stopped for futility,2019-03-25,2020-02-27,"[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Event of Special Interest (AESIs), Serious Adverse Events (SAEs)', 'description': 'An Adverse Events (AE) was any untoward medical occurrence, new or worsening of any pre-existing condition, in a clinical study participant administered a medicinal product and which did not necessarily had to have a causal relationship with the treatment. TEAEs: AES with an onset date on or after the start date of the IMP administration. AESIs: skin-related events (SRE) (except exacerbation and infective exacerbation of AD) or injection site reactions (ISRs) as per common terminology criteria for AEs (Grade 3: ulceration or necrosis; severe tissue damage; operative intervention indicated, Grade 4: life-threatening consequences; urgent intervention indicated, Grade 5: death ). An SAE: AE that resulted in any of the following outcomes: death; life threatening; results in persistent or significant disability/incapacity; requires in-patient hospitalization or prolongation of existing hospitalization; congenital anomaly/birth defect; is medically significant.', 'timeFrame': 'Day 1 up to Day 169/Early discontinuation(ED)'}]","[{'measure': 'Serum Concentrations of MOR106', 'timeFrame': 'Day 1, Day 4, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141, Day 155 and Day 169'}, {'measure': 'Number of Participants With Anti-drug Antibodies (ADAs)', 'timeFrame': 'Day 1 up to Day 169/ED'}]",3,18 Years,65 Years,ALL,False,Galapagos NV,INDUSTRY,0,33.0,ACTUAL,2025-09-01T16:18:20.963188,v2_robust,True,True,False,True,True,MOR106 clinical development in atopic dermatitis was stopped for futility
NCT00000227,Alternate-Day Buprenorphine Administration. Phase VIII - 9,Alternate-Day Buprenorphine Administration. Phase VIII,Buprenorphine,['Buprenorphine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Opioid-Related Disorders,['Opioid-Related Disorders'],[],COMPLETED,,1994-08,,"[{'measure': 'Drug use'}, {'measure': 'Opioid withdrawal'}, {'measure': 'Opioid agonist effects'}, {'measure': 'Dose choice'}]",[],4,25 Years,48 Years,ALL,False,University of Vermont,OTHER,1,0.0,,2025-09-01T16:18:20.963202,v2_robust,True,True,True,False,False,
NCT02413827,A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,"A Phase 1 Safety Pilot/Phase II, Open-label Study of Varlilumab (CDX-1127) in Combination With Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or Stage IV Melanoma",Combination of varlilumab and ipilimumab,"['Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC', 'Combination of varlilumab and ipilimumab']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Unresectable Stage III or Stage IV Melanoma,['Unresectable Stage III or Stage IV Melanoma'],"['Yervoy™, CDX-1401']",TERMINATED,Feasibility concerns due to changes in standard of care,2015-04,2016-11-09,"[{'measure': 'Phase l: Safety and tolerability of varlilumab in combination with ipilimumab as measured by incidences of drug related adverse events (AEs), serious drug related AEs, dose-limiting toxicities and laboratory test abnormalities.', 'timeFrame': 'Safety follow-up is 70 days from last study drug dose.'}, {'measure': 'Phase ll: The objective response rate (ORR) is defined as the proportion of patients who achieve radiographic partial or complete response (PR or CR) according to the mWHO tumor response criteria.', 'timeFrame': 'Up to 24 weeks'}]",[],2,18 Years,,ALL,False,Celldex Therapeutics,INDUSTRY,0,9.0,ACTUAL,2025-09-01T16:18:20.963219,v2_robust,True,True,False,True,True,Feasibility concerns due to changes in standard of care
NCT04766827,Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor,A Prospective Randomized Controlled Clinical Study of Albumin-bound Paclitaxel Combined With Cisplatin (AP Regimen) Versus Docetaxel Combined With Cisplatin (TP Regimen) Induced Chemotherapy in Advanced Head and Neck Squamous Tummor,albumin-bound paclitaxel,"['Docetaxel', 'albumin-bound paclitaxel']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Squamous Cell Carcinoma of Head and Neck,['Squamous Cell Carcinoma of Head and Neck'],[],UNKNOWN,,2020-12-12,2021-12,"[{'measure': 'Objective response rate', 'description': 'ORR=CR+PR', 'timeFrame': '21 days'}]","[{'measure': 'Surgical resection rate', 'description': 'the rate of Surgical resection in all samples', 'timeFrame': '1 month'}, {'measure': 'pathological response rate', 'description': 'the rate of pathological response in all samples', 'timeFrame': '1 month'}, {'measure': 'PFS', 'description': 'progression-free survival', 'timeFrame': '5 year'}, {'measure': 'OS', 'description': 'overall survival', 'timeFrame': '5 year'}]",5,18 Years,,ALL,False,Tianjin Medical University Cancer Institute and Hospital,OTHER,0,116.0,ESTIMATED,2025-09-01T16:18:20.963237,v2_robust,True,True,False,False,False,
NCT00963027,Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil,An Evaluation of Single Dose UT-15C SR (Treprostinil Diethanolamine) Pharmacokinetics Following Repeated Dosing With the Proton Pump Inhibitor Esomeprazole in Healthy Adult Volunteers,Treprostinil diethanolamine,"['Oral treprostinil', 'Esomeprazole', 'UT-15C', 'Treprostinil diethanolamine', 'UT-15C SR', 'Nexium']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,"Hypertension, Pulmonary","['Hypertension, Pulmonary', 'Pulmonary Arterial Hypertension']","['Hypertension, Pulmonary', 'Treprostinil', 'Pharmacokinetics', 'Treprostinil Diethanolamine', 'Pulmonary Arterial Hypertension', 'Esomeprazole']",COMPLETED,,2009-09,2009-10,"[{'measure': 'Treprostinil pharmacokinetics in healthy volunteers following a single oral dose of a 1 mg treprostinil diethanolamine sustained release tablet before and after repeated dosing with esomeprazole.', 'timeFrame': 'Within 10 minutes prior to through 36 hours post treprostinil diethanolamine dosing'}, {'measure': 'Adverse event monitoring', 'timeFrame': 'Time Frame: From the first dose of treprostinil diethanolamine through study end (Study Day 9/10)'}]","[{'measure': 'Clinical laboratories', 'timeFrame': 'Study Days 0 and 9'}]",3,18 Years,55 Years,ALL,True,United Therapeutics,INDUSTRY,0,30.0,ESTIMATED,2025-09-01T16:18:20.963284,v2_robust,True,True,True,False,True,
NCT01709227,Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass,Early Renal Replacement Therapy vs. Furosemide for Neonates With Oliguria After Cardiopulmonary Bypass,Furosemide,"['Furosemide', 'Lasix']",2,INTERVENTIONAL,['NA'],,,Acute Kidney Injury,['Acute Kidney Injury'],"['Acute kidney injury', 'AKI', 'cardiopulmonary bypass']",COMPLETED,,2011-10,2015-06,"[{'measure': 'Number of Participants With Negative Fluid Balance on Postop Day 1', 'description': 'Difference of inputs and outputs, including urine output and PD drainage.', 'timeFrame': 'Postop day 1'}]","[{'measure': 'Respiratory Support Administered', 'description': 'Duration of initial course of postoperative mechanical ventilation', 'timeFrame': 'Duration of postoperative intubation (average time approximately- 1 week)'}, {'measure': 'NGAL Concentration', 'timeFrame': 'Pre-op, and postop (2hr, 6hr, 12hr, 24hr, 48hr)'}, {'measure': 'Duration of Cardiac ICU Stay', 'description': 'Total days of initial postoperative stay in cardiac ICU', 'timeFrame': 'Average 2 weeks'}, {'measure': 'Duration of Hospital Stay', 'description': 'Total days of initial postoperative stay in hospital', 'timeFrame': 'Average 4 weeks'}, {'measure': 'All Cause Mortality', 'description': 'In-hospital mortality', 'timeFrame': 'duration of hospitalization (an average of 2 weeks)'}, {'measure': 'Renal/Electrolyte Abnormalities', 'description': 'Total sum of renal and electrolyte abnormalities over the first 5 postoperative days as defined in the protocol', 'timeFrame': 'Postop morning 1-5'}, {'measure': 'Doses of Potassium Chloride or Arginine Chloride Required', 'description': 'Total doses of potassium chloride or arginine chloride given during the first five postoperative days.', 'timeFrame': 'Postop day 0-5'}, {'measure': 'B-Natriuretic Peptide', 'description': 'BNP measured at 24 and 48 hours postoperatively', 'timeFrame': 'At 24hours and 48 hours postoperative'}, {'measure': 'Modified Oxygenation Index', 'description': 'Product of Mean airway pressure delivered by mechanical ventilation and FiO2 of administered oxygen', 'timeFrame': 'at 24 and 48 hours postoperative'}]",10,,6 Months,ALL,False,"Children's Hospital Medical Center, Cincinnati",OTHER,0,73.0,ACTUAL,2025-09-01T16:18:20.963295,v2_robust,True,True,True,False,False,
NCT04422561,Prophylactic Ivermectin in COVID-19 Contacts,Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19,Ivermectin Tablets,['Ivermectin Tablets'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,COVID,['COVID'],[],COMPLETED,,2020-05-31,2020-07-27,"[{'measure': 'Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)', 'description': 'history taking and clinical examination', 'timeFrame': 'within 14 days after enrollement'}]","[{'measure': 'Development of COVID', 'description': 'by swab', 'timeFrame': 'within 14 days after enrollement'}]",2,16 Years,70 Years,ALL,True,Zagazig University,OTHER_GOV,0,340.0,ACTUAL,2025-09-01T16:18:20.963368,v2_robust,True,True,True,False,False,
NCT05621161,ESPB vs FICB for Pain Management Following Total Hip Prosthesis Surgery,Comparison of Ultrasound-Guided Lumbar Erector Spinae Plane Block And Fascia Iliaca Compartment Block for Pain Management Following Total Hip Prosthesis Surgery,Postoperative analgesia management,['Postoperative analgesia management'],1,INTERVENTIONAL,['NA'],,,Knee Osteoarthritis,"['Knee Osteoarthritis', 'Knee Disease', 'Knee Arthritis']","['Total hip prosthesis surgery', 'Postoperative analgesia', 'Erector spina plan block', 'Fascia iliaca compartment block']",COMPLETED,,2022-11-28,2023-09-15,"[{'measure': 'Opioid consumption', 'description': 'The tramadol consumption on PCA device will be evaluated', 'timeFrame': 'Changes from baseline opioid consumption at postoperative 1, 2, 4, 8, 16 and 24 hours.'}]","[{'measure': 'Postoperative pain score', 'description': 'Postoperative pain assessment will be performed using the Numerical Rating Scale (0 = no pain, 10 = the most severe pain felt)', 'timeFrame': 'Postoperative 1, 2, 4, 8, 16 and 24 hours'}]",2,18 Years,80 Years,ALL,False,Mursel Ekinci,OTHER_GOV,0,60.0,ACTUAL,2025-09-01T16:18:20.963378,v2_robust,True,True,True,False,False,
NCT00036361,Broad Effectiveness: Study With Aripiprazole,Broad Effectiveness: Study With Aripiprazole,Aripiprazole,['Aripiprazole'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Schizophrenia,"['Schizophrenia', 'Schizoaffective Disorder']",[],COMPLETED,,2002-07,2003-01,[{'measure': 'Safety Assessments'}],[{'measure': 'Safety Assessments'}],2,18 Years,75 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,1,444.0,,2025-09-01T16:18:20.963401,v2_robust,True,True,True,False,True,
NCT02680561,A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma,"A Double-Blind (Incorporating an Open Label Comparator), 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Tolerability of Single Doses of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler Compared to ADVAIR® DISKUS® in Patients With Persistent Asthma 4 Through 11 Years of Age",Fluticasone Propionate MDPI,"['Fluticasone Propionate MDPI', 'Fluticasone propionate/salmeterol', 'FS MDPI', 'DISKUS', 'Fp MDPI', 'ADVAIR', 'Fluticasone Propionate/Salmeterol MDPI']",7,INTERVENTIONAL,['PHASE1'],PHASE1,,Asthma,['Asthma'],[],COMPLETED,,2016-04,2016-08,"[{'measure': 'Maximum observed plasma drug concentration (Cmax)', 'timeFrame': '4 months'}, {'measure': 'Area under the plasma drug concentration-time curve (AUCO-t)', 'timeFrame': '4 months'}]","[{'measure': 'Time to maximum observed plasma drug concentration (tmax)', 'timeFrame': '4 months'}]",3,4 Years,11 Years,ALL,False,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:20.963410,v2_robust,True,True,True,False,False,
NCT03084861,A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy,"A Multicenter, Randomized, Open-label, Two-arms Phase I/II Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy",Cord Blood Eye Drops,"['Cord Blood Eye Drops', 'Conventional treatment']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Neurotrophic Keratopathy,['Neurotrophic Keratopathy'],[],TERMINATED,Low recruitment. No safety issue associated.,2017-02-24,2020-03-12,"[{'measure': 'Corneal lesion size', 'description': 'Variation percentage in corneal lesion size', 'timeFrame': 'after 3 weeks post-treatment,'}]","[{'measure': 'Incidence of Adverse Events', 'description': 'Safety evaluation through laboratory data and adverse events', 'timeFrame': 'From date of randomization until the date of the last visit (6 weeks post-treatment)'}, {'measure': 'Corneal lesion size', 'description': 'Variation percentage in corneal lesion size', 'timeFrame': 'at 2-3 days post-treatment and at 1, 2 and 6 weeks post-treatment'}, {'measure': 'Stage on the corneal lesion', 'description': 'Changes stage on the corneal lesion (cured, stage 1, stage 2, stage 3) from baseline', 'timeFrame': 'at 3 weeks post-treatment'}, {'measure': 'Qualitative scale of corneal sensibility', 'description': 'Changes in qualitative scale of corneal sensibility (normoesthesia, hypoesthesia, anesthesia)', 'timeFrame': 'at 2-3 days post-treatment and at 1, 2, 3 and 6 weeks post-treatment'}, {'measure': 'Corneal opacity', 'description': 'Changes on corneal opacity from baseline (not response, improvement, worse)', 'timeFrame': 'at 2-3 days post-treatment and at 1, 2, 3 and 6 weeks post-treatment'}, {'measure': 'Visual acuity', 'description': 'Line variation in relation to visual acuity', 'timeFrame': 'at 2-3 days post-treatment and at 1, 2 and 6 weeks post-treatment'}, {'measure': 'Neurotrophic keratopathy', 'description': 'Number of neurotrophic keratopathy complications', 'timeFrame': 'From date of randomization until the date of the last visit (6 weeks post-treatment)'}]",8,18 Years,,ALL,False,Banc de Sang i Teixits,OTHER,0,9.0,ACTUAL,2025-09-01T16:18:20.963429,v2_robust,True,True,False,True,True,Low recruitment. No safety issue associated.
NCT00740961,Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer,The Vulnerable Elders Survey Study of Older Cancer Patients,systemic chemotherapy,['systemic chemotherapy'],1,OBSERVATIONAL,[],,,Breast Cancer,"['Breast Cancer', 'Cognitive/Functional Effects', 'Colorectal Cancer', 'Psychosocial Effects of Cancer and Its Treatment']","['psychosocial effects of cancer and its treatment', 'cognitive/functional effects', 'breast cancer', 'colon cancer']",TERMINATED,low accrual,2008-03,2011-09,"[{'measure': 'Number of impaired domains on Comprehensive Geriatric Assessment (CGA)', 'timeFrame': 'at baseline and 12 months later.'}, {'measure': 'Chemotherapy adherence as measured by dose reduction, dose delay, and grade 3-5 toxicities', 'timeFrame': 'Patients are followed for 1 year for chemotherapy adherence and survival.'}, {'measure': 'Vulnerable Elders Survey scores', 'timeFrame': 'at baseline and 12 months later.'}, {'measure': 'Functional decline', 'timeFrame': 'at baseline and 12 months later.'}, {'measure': 'Time to death', 'timeFrame': 'Patients are followed for 1 year for chemotherapy adherence and survival.'}]","[{'measure': 'Scores of individual battery of tools included in the CGA', 'timeFrame': 'at baseline and 12 months later'}]",6,65 Years,,ALL,False,Case Comprehensive Cancer Center,OTHER,0,63.0,ACTUAL,2025-09-01T16:18:20.963518,v2_robust,False,True,False,True,False,low accrual
NCT02016261,Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine,"Open Label, Non-comparative Study to Evaluate Cognitive Functioning in Remitted Depression Outpatients During Long-term Preventive Treatment With Fluvoxamine",Fluvoxamine,"['Fluvoxamine', 'Fevarin®']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Recurrent Depressive Disorder,['Recurrent Depressive Disorder'],['Cognitive function'],COMPLETED,,2013-12,2015-07,"[{'measure': 'Change of time difference between Part I and Part II of Stroop Test', 'timeFrame': 'From baseline up to Week 24'}]","[{'measure': 'Change of total Frontal Assessment Battery score', 'timeFrame': 'From baseline up to Week 24'}, {'measure': 'Proportion of patients maintained remission status', 'timeFrame': 'Week 24'}, {'measure': ""Changes of Addenbrooke's Cognitive Examination general score"", 'timeFrame': 'From baseline up to Week 24'}, {'measure': 'Change of The Social Adaptation Self-evaluation Scale total score', 'timeFrame': 'From baseline up to Week 24'}]",5,18 Years,65 Years,ALL,False,Moscow Research Institute of Psychiatry,OTHER,1,50.0,ACTUAL,2025-09-01T16:18:20.963532,v2_robust,True,True,True,False,False,
NCT06737042,Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants,"EFFICACY and SAFETY of GZR18 INJECTED EVERY 2 WEEKS (Q2W) in PARTICIPANTS WITHOUT TYPE 2 DIABETES, WHO HAVE OBESITY or ARE OVERWEIGHT: a RANDOMIZED, TIRZEPATIDE- and PLACEBO-CONTROLLED STUDY",GZR18,"['GZR18', 'Tirzepatide']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Obesity and Overweight,['Obesity and Overweight'],"['GLP-1, Obesity, Overweight, Weight loss']",NOT_YET_RECRUITING,,2025-02-12,2026-06-22,"[{'measure': 'Primary Objective', 'description': 'To demonstrate that GZR18 24 mg, 36 mg, and 48 mg is superior to placebo based on percentage change in body weight after 36 weeks of treatment', 'timeFrame': '36 weeks'}]",[],1,18 Years,75 Years,ALL,False,"Gan and Lee Pharmaceuticals, USA",INDUSTRY,0,285.0,ESTIMATED,2025-09-01T16:18:20.963544,v2_robust,True,True,False,False,False,
NCT01868542,A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs),"A 20-week, Randomised, Multi-centre, Open-labelled Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Titration Algorithms (3-0-3 Algorithm and 2-4-6-8 Algorithm) After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment in Korea",insulin detemir,['insulin detemir'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],COMPLETED,,2013-06,2015-05,"[{'measure': 'Change in Glycosylated Haemoglobin A1c (HbA1c) From Baseline.', 'description': 'Change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline after 20 weeks of treatment. Only the subjects in the full analysis set with HbA1c values after 20 weeks of treatment were included.', 'timeFrame': 'Week 0, week 20'}]","[{'measure': 'Change in HbA1c', 'description': 'Change in HbA1c at 12 weeks of treatment from visit 2.', 'timeFrame': 'Week 0, week 12'}, {'measure': 'Proportion of Subjects Achieving HbA1c Below 7.0%', 'description': 'Responder was a dichotomous endpoint (responder/non-responder) that was defined based on whether a subject had met the ADA HbA1c target at end of trial (HbA1c \\< 7.0% at end of trial) during 20 weeks of treatment.', 'timeFrame': 'Week 20'}, {'measure': 'Change in Fasting Plasma Glucose From Baseline', 'description': 'Change in fasting plasma glucose from baseline.', 'timeFrame': 'week 0, week 12'}, {'measure': 'Incidence of Hypoglycaemic Episodes : Nocturnal (23:00-05:59) and Over 24 Hours.', 'description': 'A hypoglycaemic episode was defined as treatment emergent if the onset of the episode occurred after the first administration of the investigational medicinal product (IMP), and no later than the last day on trial product. Hypoglycaemic episodes were defined as nocturnal if the time of onset was between 23:00 and 05:59 inclusive. All plasma glucose values: · equal or below 3.9 mmol/L (70 mg/dL) or · higher than 3.9 mmol/L (70 mg/dL) when they occur in conjunction with hypoglycaemic symptoms.', 'timeFrame': 'For 20 weeks of treatment and over 24 hours'}, {'measure': 'Change in Fasting Plasma Glucose From Baseline', 'description': 'Change in fasting plasma glucose from baseline.', 'timeFrame': 'Week 0, week 20'}, {'measure': 'Incidence of Adverse Events', 'description': 'A treatment emergent adverse event (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than the day of visit 22.(week 20)', 'timeFrame': 'Week 20'}]",7,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,46.0,ACTUAL,2025-09-01T16:18:20.963593,v2_robust,True,True,True,False,True,
NCT01804842,Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM,"A Randomized, Crossover Study Assessing the Effect of EFB0027 on Plasma Glucose and Pharmacokinetics in Subjects With Type 2 Diabetes Mellitus",Met DR,"['Met DR', 'EFB0027']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],[],COMPLETED,,2012-12,2013-04,"[{'measure': 'AUC (0-24) of Plasma Metformin', 'description': 'AUC (0-24) = Area under the curve from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.', 'timeFrame': 'Times points to create the AUC (0-24) were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.'}, {'measure': 'Cmax of Plasma Metformin', 'description': 'Cmax = maximum response from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.', 'timeFrame': 'Times points to determine Cmax were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.'}, {'measure': 'AUC (0-24) of Plasma Glucose', 'description': 'AUC (0-24) = Area under the curve from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.', 'timeFrame': 'Times points to create the AUC (0-24) were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.75, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 18.5, 19, 19.5, 20, 21, 22, 23, and 24 hours relative to the time of the standardized dinner.'}, {'measure': 'Rmax (0-24) of Plasma Glucose', 'description': 'Rmax (0-24) = maximum response from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.', 'timeFrame': 'Times points to determine Rmax were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.75, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 18.5, 19, 19.5, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.'}]",[],4,18 Years,70 Years,ALL,False,"Elcelyx Therapeutics, Inc.",INDUSTRY,0,26.0,ACTUAL,2025-09-01T16:18:20.963624,v2_robust,True,True,True,False,False,
NCT04584242,Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes,"Prospective, Multicenter, Randomized, and Comparative Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes",gluconon tab 15mg,"['suganon tab 5mg', 'gluconon tab 15mg']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes,['Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes'],[],UNKNOWN,,2020-09-03,2022-05,"[{'measure': 'Changes from baseline LSM (Liver Stiffness measurement) at week 24 (±7days)', 'description': 'Changes in the Liver Stiffness measurement after 24 weeks (±7days) compared to Baseline within and between arms', 'timeFrame': 'Baseline'}, {'measure': 'Changes from baseline LSM (Liver Stiffness measurement) at week 24 (±7days)', 'description': 'Changes in the Liver Stiffness measurement after 24 weeks (±7days) compared to Baseline within and between arms', 'timeFrame': 'Baseline to 24 weeks (±7days)'}]","[{'measure': 'Changes from baseline CAP (Controlled Attenuation Parameter) at week 24 (±7days) within and between arms', 'description': 'Change from baseline at Week 24 (±7days) is defined as \\[(Baseline CAP value) - (Follow-up CAP value)\\] / (Baseline CAP value) \\* 100 (%)', 'timeFrame': '1) Baseline, 2) Baseline to 24 weeks (±7days)'}, {'measure': 'Changes from baseline HbA1c at week 24 (±7days) within and between arms', 'description': 'Change from baseline at Week 24 (±7days) is defined as HbA1c at Week 24 (±7days) minus HbA1c at Week 0', 'timeFrame': '1) Baseline, 2) Baseline to 24 weeks (±7days)'}, {'measure': 'Changes from baseline Insulin at week 24 (±7days) within and between arms', 'description': 'Change from baseline at Week 24 (±7days) is defined as insulin at Week 24 (±7days) minus insulin at Week 0', 'timeFrame': '1) Baseline, 2) Baseline to 24 weeks (±7days)'}, {'measure': 'Changes from baseline lipid profile (total cholesterol, HDL, LDL, TG) at week 24 (±7days) within and between arms', 'description': 'Change from baseline at Week 24 (±7days) is defined as lipid profile (total cholesterol, HDL, LDL, TG) at Week 24 (±7days) minus lipid profile at Week 0', 'timeFrame': '1) Baseline, 2) Baseline to 24 weeks (±7days)'}, {'measure': 'Changes from baseline AST/ALT at week 24 (±7days) within and between arms', 'description': 'Change form baseline at Week 24 (±7days) is defined as the proportion of AST/ALT values who are normalized at Week 24 (±7days)', 'timeFrame': '1) Baseline, 2) Baseline to 24 weeks (±7days)'}, {'measure': 'Changes from baseline Body weight at week 24 (±7days) within and between arms', 'description': 'Change from baseline at Week 24 (±7days) is defined as body weight at Week 24 minus body weight at Week 0', 'timeFrame': '1) Baseline, 2) Baseline to 24 weeks (±7days)'}, {'measure': 'Changes from baseline Liver fibrosis and fatty liver at week 24 (±7days) among the MRE+MRI PDFF enforcement arms within and between arms', 'description': 'Change from baseline at Week 24 (±7days) is defined by MRE+MRI PDFF', 'timeFrame': '1) Baseline, 2) Baseline to 24 weeks (±7days)'}, {'measure': 'Proportions of adverse effects and drug interruptions or changes between baseline and week 24 (±7days) within and between arms', 'description': 'Compare between baseline at Week 24 (±7days) is defined as the occurrence rate of adverse events and drug interruptions or changes', 'timeFrame': '1) Baseline, 2) Baseline to 24 weeks (±7days)'}, {'measure': 'Prognostic factor of the Improvement of Liver fibrosis between baseline and week 24 (±7days) within and between arms', 'description': 'Prediction Factor Analysis of the Improvement of Liver fibrosis after 24 (±7days) weeks compared to Baseline within and between arms', 'timeFrame': '1) Baseline, 2) Baseline to 24 weeks (±7days)'}, {'measure': 'Prognostic factor of the Improvement of Fatty liver between baseline and week 24 (±7days) within and between arms', 'description': 'Prediction Factor Analysis of the Improvement of Fatty liver after 24 weeks (±7days) compared to Baseline within and between arms', 'timeFrame': '1) Baseline, 2) Baseline to 24 weeks (±7days)'}, {'measure': 'Prognostic factor of the Improvement of HbA1 between baseline and week 24 (±7days) within and between arms', 'description': 'Prediction Factor Analysis of the Improvement of HbA1c after 24 weeks (±7days) compared to Baseline within and between arms', 'timeFrame': '1) Baseline, 2) Baseline to 24 weeks (±7days)'}]",13,20 Years,80 Years,ALL,False,Yonsei University,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:20.963647,v2_robust,True,True,False,False,True,
NCT00051142,A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT),A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma or Ocular Hypertension,Travoprost,"['Travoprost', 'Latanoprost']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Glaucoma, Open-Angle","['Glaucoma, Open-Angle', 'Ocular Hypertension']","['Glaucoma', 'POAG', 'OAG', 'OHT']",COMPLETED,,2001-02,2004-06,[],[],0,18 Years,,ALL,False,Alcon Research,INDUSTRY,0,,,2025-09-01T16:18:20.963776,v2_robust,True,True,True,False,False,
NCT00003342,Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer,"Phase I Trial of Dose-Dense Gemcitabine, Doxorubicin, Then Paclitaxel Plus Carboplatin In Patients With Transitional Cell Carcinoma of the Urothelium and Impaired Renal Function",carboplatin,"['doxorubicin hydrochloride', 'paclitaxel', 'carboplatin', 'gemcitabine hydrochloride']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Bladder Cancer,"['Bladder Cancer', 'Transitional Cell Cancer of the Renal Pelvis and Ureter']","['stage III bladder cancer', 'stage IV bladder cancer', 'transitional cell carcinoma of the bladder', 'metastatic transitional cell cancer of the renal pelvis and ureter', 'localized transitional cell cancer of the renal pelvis and ureter', 'regional transitional cell cancer of the renal pelvis and ureter']",COMPLETED,,1997-12,2007-07,[],[],0,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,30.0,ESTIMATED,2025-09-01T16:18:20.963783,v2_robust,True,True,True,False,False,
NCT02614742,SFX-01 After Subarachnoid Haemorrhage,SFX-01 After Subarachnoid Haemorrhage,SFX-01,"['Cyclodextrin', 'Sulforadex', 'SFX-01', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Subarachnoid Hemorrhage, Spontaneous","['Subarachnoid Hemorrhage, Spontaneous']",[],COMPLETED,,2016-04,2019-11,"[{'measure': 'Number of participants with treatment-related adverse events as assessed by Common Toxicity Criteria', 'description': 'To evaluate the safety of up to 28 days of SFX-01 dosed at up to 96 mg Sulforaphane (SFN) per day', 'timeFrame': 'up to 28 days'}, {'measure': 'Maximum CSF Concentration [Cmax],', 'description': 'To detect the presence of SFN in Cerebrospinal Fluid (CSF)', 'timeFrame': 'up to 28 days'}, {'measure': 'Number of participants with treatment related reduction in middle cerebral artery (MCA) peak flow velocity following Subarachnoid Haemorrhage (SAH) measured by trans cranial doppler ultrasound', 'description': 'To determine if a minimum of 7 days treatment with SFX-01 reduces Middle Cerebral Artery (MCA) peak flow velocity following Subarachnoid Haemorrhage (SAH).', 'timeFrame': 'up to 28 days'}]","[{'measure': 'modified Rankin Scale', 'description': 'To determine if a minimum of 7 days treatment with SFX-01 improves clinical outcome following SAH as measured using the modified Rankin Scale assessed at 7 , 28, 90 and 180 days post ictus.', 'timeFrame': 'up to 180 days post ictus'}, {'measure': 'Plasma PK', 'description': 'To determine plasma SFN levels (and its metabolites) with treatment with SFX-01 (300mg bid).', 'timeFrame': 'up to 28 days'}, {'measure': 'CSF drug levels', 'description': 'To determine CSF drug levels following treatment with SFX-01 (300mg bid).', 'timeFrame': 'up to 14 days'}, {'measure': 'Serum Haptoglobin levels', 'description': 'To determine if up to 28 days treatment with SFX-01 increases serum haptoglobin (HP) levels following SAH', 'timeFrame': 'Up to 28 days'}, {'measure': 'Delayed Cerebral Ischaemia', 'description': 'To determine if up to 28 days treatment with SFX-01 can reduce the incidence of Delayed Cerebral Ischaemia (DCI) following SAH.', 'timeFrame': 'Up to 28 days'}]",8,18 Years,80 Years,ALL,False,Evgen Pharma,INDUSTRY,0,90.0,ACTUAL,2025-09-01T16:18:20.963789,v2_robust,True,True,True,False,True,
NCT00365742,Statin Therapy Vs. Therapeutic Lifestyle Changes and Supplements,Simvastatin Vs Therapeutic Lifestyle Changes and Supplements: A Primary Prevention Randomized Trial,simvastatin,"['red yeast rice', 'simvastatin', 'pharmaceutical grade fish oil']",3,INTERVENTIONAL,['NA'],,,Hyperlipidemia,['Hyperlipidemia'],"['red yeast rice', 'pharmaceutical grade fish oil', 'simvastatin', 'primary prevention']",COMPLETED,,2006-04,2006-06,[{'measure': 'LDL-c cholesterol'}],"[{'measure': 'total cholesterol'}, {'measure': 'HDL'}, {'measure': 'Triglycerides'}, {'measure': 'cardiac CRP'}]",5,18 Years,75 Years,ALL,True,Chestnut Hill Health System,OTHER,0,80.0,,2025-09-01T16:18:20.963796,v2_robust,True,True,True,False,False,
NCT03900442,Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort,Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies,PTX-100,['PTX-100'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Cancer,"['Advanced Cancer', 'PTCL']",['PTCL'],ACTIVE_NOT_RECRUITING,,2019-09-01,2025-07-30,"[{'measure': 'Investigate the time- and dose-dependent PD of multiple doses of PTX-100 in patients with advanced malignancies (RAP-1)', 'description': 'PD endpoints will be based on analysis of level of RAP-1 geranylgeranylation proteins in PBMNCs and tumor biopsies:', 'timeFrame': 'One Cycle (cycle = 14 days)'}, {'measure': 'Investigate the time- and dose-dependent PD of multiple doses of PTX-100 in patients with advanced malignancies (PD endpoints)', 'description': 'PD endpoints will be based on analysis of the level of DJ2 farnesylation proteins in PBMNCs and tumor biopsies:', 'timeFrame': 'One Cycle (cycle = 14 days)'}, {'measure': 'Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (cmax)', 'description': 'Pharmacokinetics will be evaluated by PK parameters calculated from plasma concentrations of PTX 100. Individual and mean plasma concentrations of PTX-100 versus time as well as individual and mean PK parameters will be determined, for the following:\n\n• Maximum observed plasma concentration (Cmax)', 'timeFrame': 'One Cycle (cycle = 14 days)'}, {'measure': 'Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (Tmax)', 'description': 'Pharmacokinetics will be evaluated by PK parameters calculated from plasma concentrations of PTX 100. Individual and mean plasma concentrations of PTX-100 versus time as well as individual and mean PK parameters will be determined, for the following:\n\n• Time to maximum observed plasma concentration (Tmax)', 'timeFrame': 'One Cycle (cycle = 14 days)'}, {'measure': 'Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (half life)', 'description': 'Pharmacokinetics will be evaluated by PK parameters calculated from plasma concentrations of PTX 100. Individual and mean plasma concentrations of PTX-100 versus time as well as individual and mean PK parameters will be determined, for the following:\n\n• Apparent elimination half-life (t1/2)', 'timeFrame': 'One Cycle (cycle = 14 days)'}]",[],5,18 Years,,ALL,False,"Prescient Therapeutics, Ltd.",INDUSTRY,0,25.0,ESTIMATED,2025-09-01T16:18:20.963805,v2_robust,True,True,False,False,False,
NCT02259686,Cardiovascular Effects of Apelin In Healthy Volunteers,Cardiovascular Effects of Apelin In Healthy Volunteers,Apelin 1mg subcutaneous,"['5mg Sc', 'Apelin 5mg subcutaneous', '1mg iv', 'Apelin 1mg subcutaneous', '5mg iv', 'Apelin 5mg intravenous', 'Apelin 10 mg subcutaneous', '1mg Sc', '10mg sc', 'Apelin 1mg intravenous']",10,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Healthy,['Healthy'],"['Apelin', 'volunteers']",COMPLETED,,2014-11,2015-05,"[{'measure': 'Change in cardiac output between different methods of apelin administration.', 'description': 'Difference in cardiac output between different treatment arms. This will be assessed by recording cardiac index in L/min/m2 and Stroke volume index mL/min/m2', 'timeFrame': '10 hours'}, {'measure': 'Change in blood pressure between different methods of apelin administration.', 'description': 'Difference in blood pressure between different treatment arms assessed by measuring mean blood pressure in mmHg. Mean arterial pressure (MAP) will be calculated as diastolic blood pressure plus a third of the pulse pressure', 'timeFrame': '10 hours'}]","[{'measure': 'Change in apelin concentrations between the different methods of administration', 'description': 'Difference in temporal profile of apelin concentrations produced by different methods of apelin administration', 'timeFrame': '24 hours'}]",3,18 Years,85 Years,ALL,True,University of Edinburgh,OTHER,1,14.0,ACTUAL,2025-09-01T16:18:20.963889,v2_robust,True,True,True,False,False,
NCT01621386,Ventilatory Heterogeneity in Participants With Asthma (MK-0476-513),A Study Comparing Measures of Ventilatory Heterogeneity (VH) in Asthma Patients,Montelukast,"['Prednisone', 'Singulair', 'Montelukast']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Asthma,['Asthma'],[],COMPLETED,,2013-01,2016-03,"[{'measure': 'Change from baseline in VH assessed by oxygen-enhanced 1H MRI (Oe 1H MRI) after two weeks of montelukast or prednisone treatment', 'timeFrame': 'Baseline and after two weeks of drug treatment'}, {'measure': 'Change from baseline in VH assessed by 19F-perfluoropropane MRI (19F MRI) after two weeks of montelukast or prednisone treatment', 'timeFrame': 'Baseline and after two weeks of drug treatment'}, {'measure': 'Change from baseline in VH assessed by Lung Clearance Index (LCI) after two weeks of montelukast or prednisone treatment', 'timeFrame': 'Baseline and after two weeks of drug treatment'}, {'measure': 'Change from baseline in VH assessed by Conducting Airway Heterogeneity (Scond) after two weeks of montelukast or prednisone treatment', 'timeFrame': 'Baseline and after two weeks of drug treatment'}, {'measure': 'Change from baseline in VH assessed by Forced Expiratory Volume in 1 second (FEV1) after two weeks of montelukast or prednisone treatment', 'timeFrame': 'Baseline and after two weeks of drug treatment'}]","[{'measure': 'Comparison of VH assessed by Oe 1H MRI, 19F MRI, LCI, Scond and FEV1 at baseline', 'timeFrame': 'Baseline'}, {'measure': 'Short-term test-retest repeatability of VH by Oe 1H MRI and 19F MRI', 'timeFrame': 'Visit 2 and Visit 3'}, {'measure': 'Mid-term test-retest repeatability of VH by Oe 1H MRI and 19F MRI', 'timeFrame': 'Visit 3 and Visit 4/Visit 5'}]",8,18 Years,65 Years,ALL,False,Hal C Charles,OTHER,1,34.0,ACTUAL,2025-09-01T16:18:20.963939,v2_robust,True,True,True,False,False,
NCT01652586,Sedation Regimen in Patients Undergoing Cardiac Electrophysiology Study and Ablation : a Comparison Between Dexmedetomidine-remifentanil and Midazolam-remifentanil Combinations,,dexmedetomidine-remifentanil,"['midazolam-remifentanil', 'dexmedetomidine-remifentanil']",2,INTERVENTIONAL,['NA'],,,Cardiac Arrhythmia,['Cardiac Arrhythmia'],['cardiac ablation'],COMPLETED,,2011-04,2011-12,"[{'measure': 'change of sedation depth', 'description': '1. Ramsay sedation score (1 = anxious and agitated, restless; 2 = cooperative, oriented, tranquil; 3 = responsive to verbal commands, drowsy; 4 = asleep, responsive to light stimulation; 5 = asleep, slow response to stimulation; 6 = no response to stimulation)\n2. the bispectral index', 'timeFrame': '5 min after study drug adminstration, and every 10 min thereafter'}]",[],1,20 Years,70 Years,ALL,False,Yonsei University,OTHER,0,90.0,ACTUAL,2025-09-01T16:18:20.964011,v2_robust,True,True,True,False,False,
NCT00344786,"Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL","A Phase 1, Dose-Escalation Study of CNF2024 Administered Orally to Patients With B Cell Chronic Lymphocytic Leukemia (CLL)",CNF2024 (BIIB021),"['CNF2024 (BIIB021)', 'Single arm trial; no comparator']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,B-Cell Chronic Lymphocytic Leukemia,['B-Cell Chronic Lymphocytic Leukemia'],"['CLL', 'CNF2024', 'Hsp90 inhibitor']",TERMINATED,Sponsor's decision,2006-02,2008-09,"[{'measure': 'Safety and toxicity (maximum tolerated dose (MTD))', 'timeFrame': '4 week periods until MTD is reached'}, {'measure': 'Pharmacokinetics', 'timeFrame': 'Dosing period'}, {'measure': 'Pharmacodynamics', 'timeFrame': 'Dosing period'}]","[{'measure': 'To determine clinical and hematological response', 'timeFrame': 'Study Duration'}, {'measure': 'To determine the recommended Phase 2 dose', 'timeFrame': 'Study duration'}]",5,18 Years,,ALL,False,Biogen,INDUSTRY,0,15.0,ACTUAL,2025-09-01T16:18:20.964069,v2_robust,True,True,False,True,True,Sponsor's decision
NCT04715386,Feasibility in the Prophylaxis of Radiation Dermatitis Severity,Evaluation of Feasibility in the Prophylaxis of Radiation Dermatitis Severity in Cancer Patients,StrataXRT,['StrataXRT'],1,OBSERVATIONAL,[],,,Radiation Dermatitis,['Radiation Dermatitis'],[],TERMINATED,slow accrual; investigator retired,2020-06-22,2024-01-30,"[{'measure': 'To compare radiation dermatitis severity in irradiated skin protected by an agent versus uncovered skin (internal control) based on photographs.', 'timeFrame': 'First day of treatment and last day of radiation therapy (approximately 6 weeks, but will vary per patient) +/- 4 days'}]","[{'measure': 'Patient reported outcomes', 'description': 'Patients will be asked to complete a survey at the end of study that will ask them to provide feedback on the agent used during their treatment.', 'timeFrame': 'Upon study completion, on average 6 weeks, but will vary per patient'}]",2,18 Years,,ALL,False,Mayo Clinic,OTHER,0,14.0,ACTUAL,2025-09-01T16:18:20.964089,v2_robust,False,True,False,True,False,slow accrual; investigator retired
NCT05895786,A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)],"A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS)",PF-06823859,"['PF-06823859', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Myositis,['Myositis'],"['Dermatomyositis', 'Polymyositis']",RECRUITING,,2023-05-20,2026-07-28,"[{'measure': 'Moderate change in Total Improvement Score (TIS)', 'description': 'Total Improvement Score 0 to 100 with higher scores indicating a better outcome.', 'timeFrame': '24 weeks outside of the United States (US) and 52 weeks in the US'}]","[{'measure': 'Change from baseline in Manual Muscle Testing - 8 designated muscles (MMT-8)', 'description': 'Manual Muscle Testing (8 designated muscles) 0 to 150 with higher scores indicating a better outcome', 'timeFrame': '24 weeks outside of the US and 52 weeks in the US'}, {'measure': 'Change from baseline in Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A) in participants with dermatomyositis (DM)', 'description': 'Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score 0 to 100 with higher scores indicating a worse outcome. Only participants with baseline CDASI-A score \\>14 will be assessed.', 'timeFrame': 'Week 24 outside the US'}, {'measure': 'Change from baseline in Investigator Global Assessment severity scale (IGA) in participants with dermatomyositis', 'description': 'Investigator Global Assessment severity scale 0 to 4 with higher scores indicating a worse outcome. Only participants with baseline IGA ≥2 will be assessed', 'timeFrame': '24 and 52 weeks in the US only'}, {'measure': 'Corticosteroid (CS) dose assessment', 'description': 'Normalized Area Under the Curve (AUC) of corticosteroid dose', 'timeFrame': '52 weeks'}, {'measure': 'Moderate change in Total Improvement Score', 'description': 'Total Improvement Score 0 to 100 with higher scores indicating a better outcome.', 'timeFrame': '24 weeks in the US and 52 weeks outside of the US'}, {'measure': 'Change from baseline in Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS-PF)', 'description': 'Patient-Reported Outcomes Measurement Information System - Physical Function 0 to 100 with higher scores indicating a better outcome', 'timeFrame': '24 weeks outside of the US and 52 weeks in the US'}, {'measure': 'Change from baseline in 5-D Itch Scale Score', 'description': '5-D Pruritis Scale 5 to 25 with higher scores indicating a worse outcome. Only participants with baseline CDASI-A score \\>14 will be assessed.', 'timeFrame': '24 weeks outside of the US and 52 weeks in the US'}, {'measure': 'Change from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)', 'description': 'Functional Assessment of Chronic Illness Therapy - Fatigue 0 to 52 with higher scores indicating a better outcome', 'timeFrame': '24 weeks outside of the US and 52 weeks in the US'}, {'measure': 'Response in corticosteroid tapering', 'description': 'At least 50% reduction from baseline or reduction in corticosteroid (CS) dose to \\<7.5 mg/day at Week 52 for participants with baseline CS dose ≥10 mg/day.', 'timeFrame': '52 weeks US only'}]",10,18 Years,,ALL,False,Pfizer,INDUSTRY,0,318.0,ESTIMATED,2025-09-01T16:18:20.964118,v2_robust,True,True,False,False,False,
NCT01553786,Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL),STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL),Lenalidomide,['Lenalidomide'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,T-cell Lymphoma,['T-cell Lymphoma'],"['T-cell lymphoma', 'CHOp', 'lenalidomide']",COMPLETED,,2011-11,2019-03-21,"[{'measure': 'Complete response rate', 'timeFrame': 'maximum 60 days after last study drug intake'}]",[],1,60 Years,80 Years,ALL,False,The Lymphoma Academic Research Organisation,OTHER,0,80.0,ACTUAL,2025-09-01T16:18:20.964159,v2_robust,True,True,True,False,False,
NCT02089386,Tamoxifen to Treat Barrett's Metaplasia,Tamoxifen to Treat Barrett's Metaplasia,Tamoxifen,"['Tamoxifen', 'Nolvadex®', 'Soltamox®']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Barrett Metaplasia,['Barrett Metaplasia'],[],TERMINATED,Insufficient funding,2014-07-09,2016-06-21,"[{'measure': ""Extent of Barrett's involvement and changes in histology"", 'description': 'The biopsy procedures with 4 quadrant biopsies/2 cm for histology and additional biopsies for freezing for macromolecular analysis to assess the preliminary diagnostic value of this marker pair in identifying levels of metaplasia in BE and as an indicator of response to tamoxifen treatment. The tissue from the two endoscopic procedures will be assessed for changes in the following related to tamoxifen therapy.', 'timeFrame': 'End of 12 weeks (at the time of second endoscopy)'}]","[{'measure': 'Changes in SOX2 and CDX2 expression', 'description': 'The main outcome measurements are SOX2 and CDX2, analyzed as a ratio. We will use a one sample paired non-parametric Wilcoxon test to test the significant difference if the ratio difference is not normally distributed. Normality assumption can be examined by visual Q-Q plot and formal Kolmogorov-Smirnov statistic. In addition, we will explore the patient level characteristics on treatment effect using a linear regression model. Specifically, we will use the difference ratio as the response variable and patient characteristics of interest as explanatory variables. Regression coefficients associated with the explanatory variables quantify the effect of these variables on the difference ratio, with t or F statistic testing for the statistical significance.', 'timeFrame': 'End of 12 weeks (at the time of second endoscopy)'}, {'measure': 'Tolerance of tamoxifen', 'description': 'As measured by toxicities using CTCAE version 4.0', 'timeFrame': '4 months (30 days after cessation of tamoxifen or after second endoscopy - whichever occurs later)'}, {'measure': ""Changes in the length of Barrett's esophagus involvement"", 'timeFrame': 'End of 12 weeks (at the time of second endoscopy)'}]",4,18 Years,,ALL,False,Washington University School of Medicine,OTHER,0,7.0,ACTUAL,2025-09-01T16:18:20.964166,v2_robust,True,True,False,True,False,Insufficient funding
NCT00379886,Comparison of Thiopental and Propofol as Anaesteticum During ECT,Comparison of Thiopental and Propofol as Anaesteticum During ECT,Propofol Thiopental,['Propofol Thiopental'],1,INTERVENTIONAL,['NA'],,,Depression,['Depression'],"['ECT', 'Depression', 'Anesthiticum', 'Propofol', 'Thiopental']",UNKNOWN,,2003-01,2007-12,"[{'measure': 'Number of ECT-treatments required to treat depression'}, {'measure': 'Duration of seizures'}, {'measure': 'Amount of energy required to initiate seizure'}]","[{'measure': 'EEG-related parameters'}, {'measure': 'Changes in seizure-threshold'}, {'measure': 'Haemodynamic parameters'}, {'measure': 'Cognitive impairment'}]",7,18 Years,,ALL,False,"Rigshospitalet, Denmark",OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:20.964238,v2_robust,True,True,False,False,False,
NCT04977570,A Study of SYHA1805 in Healthy Subjects,"A Randomized, Double-blind, Placebo-controlled, Multiple-dose Escalation Phase Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of SYHA1805 in Chinese Healthy Adult Subjects.",SYHA1805 tablets,"['SYHA1805 tablets', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Subjects,['Healthy Subjects'],[],UNKNOWN,,2021-07,2022-05,"[{'measure': 'Safety and tolerability of multiple-dose of SYHA1805', 'description': 'The safety and tolerability of multiple-dose of SYHA1805 administered orally will be assessed by incidence and severity of adverse events (AEs), ECG, changes in vital signs, physical Examination, and laboratory examinations.', 'timeFrame': 'Baseline through Day 28'}]","[{'measure': 'Area under the plasma concentration versus time curve (AUC）', 'description': 'Area under the plasma concentration versus time curve (AUC) after administration of of SYHA1805 under fasting conditions or under the food effect of high-fat, high-calorie meals', 'timeFrame': 'Baseline through Day 28'}, {'measure': 'Peak Plasma Concentration (Cmax）', 'description': 'Peak Plasma Concentration (Cmax) after administration of of SYHA1805 under fasting conditions or under the food effect of high-fat, high-calorie meals', 'timeFrame': 'Baseline through Day 28'}, {'measure': 'Time to maximum plasma concentration（Tmax）', 'description': 'Time to maximum plasma concentration（Tmax）after administration of of SYHA1805 under fasting conditions or under the food effect of high-fat, high-calorie meals', 'timeFrame': 'Baseline through Day 28'}, {'measure': 'Half time (t1/2)', 'description': 'The half time of SYHA1805 after administration are calculated under fasting conditions or under the food effect of high-fat, high-calorie meals', 'timeFrame': 'Baseline through Day 28'}, {'measure': 'Apparent clearance (CL/F)', 'description': 'To assess the apparent clearance (CL/F) after administration of SYHA1805 under fasting conditions or under the food effect of high-fat, high-calorie meals', 'timeFrame': 'Baseline through Day 28'}]",6,18 Years,45 Years,ALL,True,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",INDUSTRY,0,36.0,ESTIMATED,2025-09-01T16:18:20.964289,v2_robust,True,True,False,False,True,
NCT01282970,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses (5 to 100 mg q.d. for 14 Days) of BI 135585 XX in Patients With Type 2 Diabetes Mellitus (Randomized, Double-blind Placebo-controlled Within Dose Groups)",BI 135585,"['Placebo to BI 135585', 'BI 135585']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],COMPLETED,,2011-02,,"[{'measure': 'Safety and tolerability of BI 135585 will be assessed in a descriptive way using physical examinations (occurence of findings), vital signs, electrocardiograms, laboratory tests, and incidence and severity of adverse events.', 'timeFrame': 'up to 16 days post treatment'}]","[{'measure': 'Assessment of Pharmacokinetic parameter Cmax (maximum measured concentration of the analyte in plasma) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter tmax (time from dosing to maximum measured concentration) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the first dose)', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter λz (terminal rate constant in plasma) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter λz,ss (terminal rate constant in plasma at steady state) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter t1/2,ss (terminal half-life of the analyte in plasma at steady state) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter MRTpo,ss (mean residence time of the analyte in the body after multiple oral administrations at steady state) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter CL/F,ss (apparent clearance of the analyte in the plasma at steady state following extravascular multiple dose administration) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter PTF (Peak-Trough Fluctuation) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter Cavg (average concentration of the analyte in plasma at steady state) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter Aet1-t2,ss (amount of analyte that is eliminated in urine at steady state from the time point t1 to time point t2) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter fet1-t2,ss (fraction of analyte eliminated in urine at steady state from time point t1 to time point t2) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter CLR,t1-t2,ss (renal clearance of the analyte in plasma from the time point t1 until the time point t2 at steady state) of BI 135585 following single and multiple dose oral administration', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter RA,Cmax (Accumulation ratio of the analyte in plasma at steady state after multiple dose oral administration over a uniform dosing interval τ, expresses ratio of Cmax at steady state and after single dose)', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter RA,AUC (Accumulation ratio of the analyte in plasma at steady state after multiple dose oral administration over a uniform dosing interval τ, expresses ratio of AUC at steady state and after single dose)', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Assessment of Pharmacokinetic parameter Cpre,N (the predose concentration of the analyte in plasma immediately before administration of the Nth dose after N-1 doses were administered)', 'timeFrame': 'up to 10 days post treatment'}, {'measure': 'Exploratory evaluation of the pharmacodynamics of BI 135585 by determination of 11beta-hydroxysteroid dehydrogenase type 1 activity in adipose tissue (ex vivo)', 'timeFrame': 'up to 24 hours post treatment'}, {'measure': 'Exploratory evaluation of the pharmacodynamics of BI 135585 by measuring of cortisol and cortisone and their metabolites in urine', 'timeFrame': 'up to 24 hours post treatment'}]",27,20 Years,70 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,72.0,ACTUAL,2025-09-01T16:18:20.964296,v2_robust,True,True,True,False,True,
NCT00370370,Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD,,bevacizumab,"['bevacizumab', 'bevacizumab + triamcinolone acetonide']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Neovascular Age-Related Macular Degeneration,['Neovascular Age-Related Macular Degeneration'],"['Bevacizumab,', 'Triamcinolone', 'Age-related macular degeneration', 'Choroidal neovascular membrane']",UNKNOWN,,2005-11,,[{'measure': 'visual acuity'}],"[{'measure': 'central macular thickness'}, {'measure': 'leakage in fluorescein angiography'}, {'measure': 'intraocular pressure'}, {'measure': 'anterior chamber reaction'}]",5,50 Years,,ALL,False,Shahid Beheshti University of Medical Sciences,OTHER,0,,,2025-09-01T16:18:20.964303,v2_robust,True,True,False,False,False,
NCT02013570,Efficacy of Peritonsillar Dexmedetomidine Infiltration for Postadenotonsillectomy Pain,,Dexmedetomidine,"['Precedex', 'Dexmedetomidine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pain Postoperative, Intraoperative Hemorrhage","['Pain Postoperative, Intraoperative Hemorrhage']",['postoperative pain; dexmedetomidine; adenotonsillectomy'],COMPLETED,,2013-09,2013-12,"[{'measure': 'post adenotonsillectomy pain', 'description': 'Modified Hannallah pain scale, nausea, vomiting, bleeding, rescue analgesia, sedation and Aldrete scores were recorded on arrival in the postanesthesia care unit, at 15th, 30th, 60th, 90th and 120th min. Patient with pain scores \\>4, for a patient request for pain medication, received 1mg/kg Tramadol drop as supplementary analgesia. The first analgesic requirement time recorded. Agitation was measured with Pediatric anesthesia emergence delirium scale. Patients with an Aldrete score of 9 were transferred to the postoperative surgical ward.\n\nPain, nausea and vomiting, bleeding and sedation were assessed in the postoperative surgical ward. Analgesic requirement were recorded. Pain was measured at rest and with swallowing. All patients were discharged at the end of the day and stayed home at night. Postoperative pain during the first 24 h was assessed using a four-point scale. Patients were interviewed on the day after surgery to ases.', 'timeFrame': '24 hours'}]",[],1,3 Years,9 Years,ALL,False,TC Erciyes University,OTHER,0,71.0,ACTUAL,2025-09-01T16:18:20.964312,v2_robust,True,True,True,False,False,
NCT05699070,Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects,An Open-label Phase 1 Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interactions and Safety/Tolerability of DWC202211 and DWC202212 Compared to Coadministration in Healthy,DWC202211 100mg,"['DWC202212 5mg', 'DWC202211 100mg + DWC202212 5mg', 'DWC202211 100mg']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Drug-drug Interaction,['Drug-drug Interaction'],[],UNKNOWN,,2023-02-15,2023-06-01,"[{'measure': 'Cmax', 'timeFrame': 'up to 27 days'}, {'measure': 'AUClast', 'timeFrame': 'up to 27 days'}]","[{'measure': 'DWC202211 Tmax,ss', 'timeFrame': 'up to 27 days'}, {'measure': 'DWC202211 T1/2,ss', 'timeFrame': 'up to 27 days'}, {'measure': 'DWC202211 Cmin,ss', 'timeFrame': 'up to 27 days'}, {'measure': 'DWC202211 Cavg,ss', 'timeFrame': 'up to 27 days'}, {'measure': 'DWC202211 CLss/F', 'timeFrame': 'up to 27 days'}, {'measure': 'DWC202211 Vdss/f', 'timeFrame': 'up to 27 days'}, {'measure': 'DWC202211 PTF', 'timeFrame': 'up to 27 days'}, {'measure': 'DWC202212 Tmax,ss', 'timeFrame': 'up to 27 days'}, {'measure': 'DWC202212 T1/2,ss', 'timeFrame': 'up to 27 days'}, {'measure': 'DWC202212 Cmin,ss', 'timeFrame': 'up to 27 days'}, {'measure': 'DWC202212 Cavg,ss', 'timeFrame': 'up to 27 days'}, {'measure': 'DWC202212 CLss/F', 'timeFrame': 'up to 27 days'}, {'measure': 'DWC202212 Vdss/f', 'timeFrame': 'up to 27 days'}, {'measure': 'DWC202212 PTF', 'timeFrame': 'up to 27 days'}]",16,19 Years,50 Years,ALL,True,Daewoong Pharmaceutical Co. LTD.,INDUSTRY,0,24.0,ESTIMATED,2025-09-01T16:18:20.964466,v2_robust,True,True,False,False,False,
NCT04501770,A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity Profiles of the Recombinant Anti-HER2 and Anti-CD3 Humanized Bispecific Antibody (M802) in HER2-Positive Advanced Solid Tumors",Chort 1 of M802,"['Cohort 4 of M802', 'Cohort 7 of M802', 'Cohort 6 of M802', 'Chort 2 of M802', 'Cohort 5 of M802', 'Cohort 8 of M802', 'Cohort 3 of M802', 'Chort 1 of M802']",8,INTERVENTIONAL,['PHASE1'],PHASE1,,HER2-Positive Solid Tumors,['HER2-Positive Solid Tumors'],[],COMPLETED,,2018-09-27,2022-09-14,"[{'measure': 'MTD', 'description': 'Number of DLTs (dose limiting toxicities) during the first 28 days after the first administrations of study drug in each cohort.', 'timeFrame': 'From the time of first dosing (Day 1) until the forth dosing (Day 28)'}, {'measure': 'RP2D', 'description': 'Incidence and severity of AEs, and SAEs, including but not limited to laboratory values, PK and biomarkers. All AEs will be classified as Grades 1 through 5 as defined by NCI CTCAE v5.0.', 'timeFrame': 'From the start of administration to the end of the study or 28 days after the administration is stopped (up to 1 years and 28 days)'}]","[{'measure': 'Area under the curve (AUC) of M802', 'description': 'The endpoints for assessment of PK of M802 include serum concentrations of M802 at different timepoints after M802 administration.', 'timeFrame': 'From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).'}, {'measure': 'Maximum observed concentration (Cmax) of M802', 'description': 'The endpoints for assessment of PK of M802 include serum concentrations of M802 at different timepoints after M802 administration.', 'timeFrame': 'From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).'}, {'measure': 'Minimum observed concentration (Cmin) of M802', 'description': 'The endpoints for assessment of PK of M802 include serum concentrations of M802 at different timepoints after M802 administration.', 'timeFrame': 'From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).'}, {'measure': 'Expression levels of CEA', 'description': 'As tumor marker, expression levels of CEA will be tested in hospitals.', 'timeFrame': 'From the time of screening period until disease progression or toxicity intolerance (up to 1 years and 28 days).'}, {'measure': 'Expression levels of CA15-3', 'description': 'As tumor marker, expression levels of CA15-3 will be tested in hospitals.', 'timeFrame': 'From the time of screening period until disease progression or toxicity intolerance (up to 1 years and 28 days).'}, {'measure': 'Expression levels of CA125', 'description': 'As tumor marker, expression levels of CA125 will be tested in hospitals.', 'timeFrame': 'From the time of screening period until disease progression or toxicity intolerance (up to 1 years and 28 days).'}, {'measure': 'Expression levels of CA19-9', 'description': 'As tumor marker, expression levels of CA19-9 will be tested in hospitals.', 'timeFrame': 'From the time of screening period until disease progression or toxicity intolerance (up to 1 years and 28 days).'}, {'measure': 'Expression levels of CA72-4', 'description': 'As tumor marker, expression levels of CA72-4 will be tested in hospitals.', 'timeFrame': 'From the time of screening period until disease progression or toxicity intolerance (up to 1 years and 28 days).'}, {'measure': 'Cytokines', 'description': 'The levels of pharmacodynamic cytokines will be determined at the PD central laboratory.', 'timeFrame': 'From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).'}, {'measure': 'Number of subjects who develop detectable anti-drug antibodies (ADAs)', 'description': 'The immunogenicity of M802 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).', 'timeFrame': 'From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).'}, {'measure': 'The antibody titer of the neutralizing antibody', 'description': 'The immunogenicity of M802 will be collected by testing the antibody titer of the neutralizing antibody.', 'timeFrame': 'From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).'}, {'measure': 'ORR', 'description': 'Objective response rate (ORR) is defined as the proportion of patients with complete response (CR) and partial response (PR), based on RECIST Version 1.1.', 'timeFrame': 'From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).'}, {'measure': 'DCR', 'description': 'Disease Control Rate (DCR) is defined as the proportion of patients with complete response (CR) and partial response (PR), based on RECIST Version 1.1.', 'timeFrame': 'From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).'}]",15,18 Years,,ALL,False,"Wuhan YZY Biopharma Co., Ltd.",INDUSTRY,0,34.0,ACTUAL,2025-09-01T16:18:20.964550,v2_robust,True,True,True,False,False,
NCT03682770,Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy),"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)",Dupilumab,"['Dupilumab', 'Placebo matching dupilumab', 'AR101']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Peanut Allergy,['Peanut Allergy'],[],COMPLETED,,2018-10-03,2021-07-23,"[{'measure': 'Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Up-dosing Double-blind, Placebo-controlled Food Challenge (DBPCFC) With 2044 mg (Cumulative) Peanut Protein at Visit 16 (Week 28 to 40)', 'description': 'Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab plus AR101 vs placebo plus AR101 who passed a post up-dosing DBPCFC with 2044 mg (Cumulative) peanut protein at Visit 16 (Week 28 to 40) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).', 'timeFrame': 'At Visit 16 (Week 28 to 40)'}]","[{'measure': 'Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 16 (Week 28 to 40) in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101', 'description': 'Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 16 (Week 28 to 40) in participants treated with dupilumab plus AR101 vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 28 to Week 40).', 'timeFrame': 'Baseline, Visit 16 (Week 28 to 40)'}, {'measure': 'Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Reached the 300 mg/Day Dose of AR101 by Visit 16 (Week 28 to 40)', 'description': 'Percentage of participants treated with dupilumab plus AR101 vs placebo plus AR101 who reached the 300 mg/day dose of AR101 by Visit 16 (Week 28 to 40) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).', 'timeFrame': 'At Visit 16 (Week 28 to 40)'}, {'measure': 'Time From Randomization to the First Time When Participants Reached the 300 mg/Day Dose of AR101 During the Up-dosing Treatment Phase by Visit 16 (Week 28 to 40)', 'description': 'Time (in days) from randomization to the first time when participants reached the 300 mg/day dose of AR101 during the up-dosing treatment phase by Visit 16 (Week 28 to 40) was reported. If participants did not reach the 300 mg/day dose of AR101 during the 28-week treatment period, they were censored at the date of their last visit during pre-AR101 dosing and AR101 up-dosing treatment period. Analysis was performed using Kaplan-Meier Estimated method.', 'timeFrame': 'At Visit 16 (Week 28 to 40)'}, {'measure': 'Percentage of Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64)', 'description': 'Symptoms considered to be allergic were graded using the CoFAR Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants (continuously) treated with dupilumab plus AR101 vs placebo plus AR101 who passed a post maintenance DBPCFC with 2044 mg (cumulative) peanut protein at Visit 22 (Week 52 to 64) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).', 'timeFrame': 'At Visit 22 (Week 52 to 64)'}, {'measure': 'Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101', 'description': 'Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 22 (Week 52 to 64) in participants (continuously) treated with dupilumab plus AR101 vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 52 to Week 64).', 'timeFrame': 'Baseline, Visit 22 (Week 52 to 64)'}, {'measure': 'Percentage of Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64)', 'description': 'Symptoms considered to be allergic were graded using the CoFAR Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants (previously) treated with dupilumab plus AR101 (and re-randomized to placebo plus AR101) vs placebo plus AR101 who ""pass"" a post maintenance DBPCFC with 2044 mg (cumulative) peanut protein at Visit 22 (Week 52 to 64) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).', 'timeFrame': 'At Visit 22 (Week 52 to 64)'}, {'measure': 'Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101', 'description': 'Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 22 (Week 52 to 64) in participants (previously) treated with dupilumab plus AR101 (and re-randomized to placebo plus AR101) vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 52 to Week 64).', 'timeFrame': 'Baseline, Visit 22 (Week 52 to 64)'}, {'measure': 'Percent Change From Baseline in Peanut-specific IgE in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 16 (Week 28 to 40)', 'description': 'Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 16 (Week 28 to 40) was reported. Analysis was performed using Last observation carried forward (LOCF) method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).', 'timeFrame': 'Baseline up to Visit 16 (Weeks 28 to 40)'}, {'measure': 'Percent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 22 (Week 52 to 64)', 'description': 'Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 22 (Week 52 to 64) was reported. Analysis was performed using LOCF method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).', 'timeFrame': 'Baseline up to Visit 22 (Week 52 to 64)'}, {'measure': 'Percent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 25 (Weeks 64 to 76)', 'description': 'Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 25 (Week 64 to 76) was reported. Analysis was performed using LOCF method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 64 to Week 76).', 'timeFrame': 'Baseline up to Visit 25 (Weeks 64 to 76)'}]",11,6 Years,17 Years,ALL,False,Regeneron Pharmaceuticals,INDUSTRY,2,148.0,ACTUAL,2025-09-01T16:18:20.964590,v2_robust,True,True,True,False,False,
NCT02140073,Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity,Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity,omeprazole+domperidone SR,"['omeprazole+domperidone SR', 'Omez DSR', 'Omez', 'omeprazole']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,GERD,['GERD'],"['GERD', 'Omez', 'Omez DSR', 'heartburn', 'esophagitis', 'omeprazole', 'omeprazole+domperidone']",UNKNOWN,,2013-12,2014-06,"[{'measure': 'change incidence of heartburn after 8 weeks of treatment with Omez-DSR preparation in comparison with OMEZ preparation', 'description': 'questionnaire', 'timeFrame': 'change from baseline incidence of heartburn after 8 weeks of treatment'}, {'measure': 'change severity of heartburn after 8 weeks of treatment with Omez-DSR preparation in comparison with OMEZ preparation', 'description': 'questionnaire', 'timeFrame': 'change from baseline severity of heartburn at 8 weeks'}]","[{'measure': 'proportion of patients with completely jugulated heartburn', 'description': 'number of patients with completely jugulated heartburn after 4 weeks of treatment and 8 weeks of treatment', 'timeFrame': '4 and 8 weeks of treatment'}, {'measure': 'number of days without heartburn', 'description': 'questionnaire', 'timeFrame': '4 weeks of treatment'}, {'measure': 'proportion of patients with resolved esophagitis', 'description': 'based on Esophagogastroduodenoscopy in subjects with esophagitis at the time of enrollment', 'timeFrame': 'after 8 weeks of treatment'}]",5,18 Years,70 Years,ALL,False,Belarusian Medical Academy of Post-Graduate Education,OTHER,1,60.0,ESTIMATED,2025-09-01T16:18:20.964683,v2_robust,True,True,False,False,False,
NCT02795273,Efficacy and Safety of Grass-SPIRE Registration Study,"A Combined Phase 2b/3, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Assess the Efficacy and Safety of Grass-SPIRE in Subjects With Grass Pollen-Induced Allergic Rhinitis, With or Without Conjunctivitis",Grass-SPIRE,"['Grass-SPIRE', 'Placebo']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Rhinitis,"['Rhinitis', 'Conjunctivitis']","['Rhinitis', 'Conjunctivitis', 'Grass', 'Allergy']",WITHDRAWN,Decision made to stop study following availability of results from another study,2016-05,,"[{'measure': 'Combined Score of symptoms and allergy medication', 'description': 'Measurement of subject allergy symptoms (eg sneezing, watery eyes) and use of allergy medication', 'timeFrame': 'Approximately 66 weeks'}, {'measure': 'Safety of Grass-SPIRE', 'description': 'Measurement of adverse events', 'timeFrame': 'Approximately 66 weeks'}]","[{'measure': 'Symptom Scores', 'description': 'Categorical scores of allergy symptoms (eg sneezing, watery eyes) as assessed by subjects', 'timeFrame': 'Approximately 66 weeks'}, {'measure': 'Rescue Medication Use', 'description': 'Use of allergy medication to help allergy symptoms', 'timeFrame': 'Approximately 66 weeks'}, {'measure': 'Quality of Life', 'description': 'Assessment of Quality of Life measured by responses to a questionnaire', 'timeFrame': 'Approximately 66 weeks'}]",5,12 Years,75 Years,ALL,False,Circassia Limited,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:20.964700,v2_robust,True,True,False,True,True,Decision made to stop study following availability of results from another study
NCT04373473,Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis,"A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation (PRIM-DJ2727) Administered Orally in Combination With Standard of Care Therapy for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis",PRIM-DJ2727,"['Placebos', 'PRIM-DJ2727']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Adults With Ulcerative Colitis,['Adults With Ulcerative Colitis'],[],RECRUITING,,2020-09-14,2025-12-31,"[{'measure': 'Patients in remission after administering 12 weeks of PRIM-DJ2727 capsules will be measured by partial Mayo score ≤ 3', 'timeFrame': '9 months'}]","[{'measure': 'Quality of life will be characterized by health-related quality of life score.', 'timeFrame': '9 months'}, {'measure': 'Subject-reported score in Hospital Anxiety and Depression Scale', 'description': 'After administering 12 weeks of PRIM-DJ2727', 'timeFrame': '9 months'}]",3,18 Years,,ALL,False,"The University of Texas Health Science Center, Houston",OTHER,0,58.0,ESTIMATED,2025-09-01T16:18:20.964915,v2_robust,True,True,False,False,False,
NCT02623673,Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema,Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema,simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.,['simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.'],1,OBSERVATIONAL,[],,,Macular Edema,['Macular Edema'],[],COMPLETED,,2015-09,2016-02,"[{'measure': 'Improvement in BCVA', 'timeFrame': '6 months'}]",[],1,18 Years,,ALL,False,"Retina Clinic, Sao Paulo, Brazil",OTHER,0,20.0,ACTUAL,2025-09-01T16:18:20.964928,v2_robust,False,True,True,False,False,
NCT04662073,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol,"COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19",Camostat,"['Camostat', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Covid19,['Covid19'],['Outpatient'],TERMINATED,Enrollment into the camostat subprotocol was halted prematurely as a result of loss of equipoise due to external findings including those related to monoclonal antibodies.,2021-04-23,2022-03-04,"[{'measure': 'For the Viral Domain: Change in Viral Shedding', 'description': 'The number of participants who had viral shedding at Day 10 is reported. Change in shedding of SARS-CoV-2 virus through day 10 attained from self-collected nasal swab RT-PCR data after transformation using a referenced standard curve.', 'timeFrame': '10 days'}]","[{'measure': 'For Clinical Domain: Time-to-sustained-resolution', 'description': 'The number of participants with sustained resolution by Day 28 is reported. Resolution is defined as the first day where no symptoms are self-reported on all succeeding days through and including day 28, not including sense of taste or smell, and defining recovery for fatigue and cough as mild or none.', 'timeFrame': '28 days'}, {'measure': 'Time to Viral Cessation', 'description': 'Defined as the time in days from randomization to the first of two consecutive negative RT-PCR results of self-collected nasal swabs.', 'timeFrame': '28 days'}, {'measure': 'Time to First Resolution', 'description': 'The number of participants with first resolution by Day 28 is reported. First resolution is defined as the first study day where no symptoms are self-reported, not including sense of taste or smell, and defining recovery for fatigue and cough as mild or none.', 'timeFrame': '28 days'}, {'measure': 'Time to Full Resolution', 'description': 'The number of participants with full resolution by Day 28 is reported. Full resolution is defined as the study day where no symptoms are first self-reported.', 'timeFrame': '28 days'}, {'measure': 'Indicator of SARS-CoV-2 Related Hospitalizations, ED Visits, or Death in Outpatients With COVID-19 Disease.', 'description': 'Count (%) of participants that experienced SARS-CoV-2 a related hospitalization, emergency department (ED) visit, or death.', 'timeFrame': '28 days'}, {'measure': 'Indicator Participant Has Developed Antibodies to SARS-CoV-2', 'timeFrame': '28 days'}, {'measure': 'Indicator Participant Has a Negative SARS-CoV2 RT-PCR Test', 'description': 'Count (%) of participants with a negative SARS-CoV2 RT-PCR test at day 14', 'timeFrame': 'day 14'}, {'measure': 'Indicator Participant Has a Negative SARS-CoV2 RT-PCR Test', 'description': 'Count (%) of participants with a negative SARS-CoV2 RT-PCR test at day 28', 'timeFrame': 'day 28'}]",9,18 Years,80 Years,ALL,False,Stanford University,OTHER,0,2.0,ACTUAL,2025-09-01T16:18:20.964935,v2_robust,True,True,False,True,False,Enrollment into the camostat subprotocol was halted prematurely as a result of loss of equipoise due to external findings including those related to monoclonal antibodies.
NCT00565773,Belatacept Post Depletional Repopulation to Facilitate Tolerance,Use of Belatacept During Post Depletional Repopulation to Facilitate Tolerance in Renal Allograft Recipients,Belatacept,"['Lemtrada', 'Rapamycin', 'Belatacept', 'Alemtuzumab', 'Campath', 'LEA29Y', 'Sirolimus', 'Nulojix']",8,INTERVENTIONAL,['PHASE2'],PHASE2,,Organ Transplantation,['Organ Transplantation'],[],COMPLETED,,2007-12,2017-07-01,"[{'measure': 'Number of Patients Successfully Withdrawn From Oral Immunosuppression', 'description': 'The primary endpoint is the number of patients successfully withdrawn from oral immunosuppression (sirolimus) for one year after their last dose of sirolimus. After taking sirolimus for one year, participants meeting certain pre-specified criteria were offered the opportunity to wean from sirolimus and continue with belatacept monotherapy. To be eligible for weaning of sirolimus, participants were required to have a kidney biopsy negative for all signs of rejection, including borderline findings.', 'timeFrame': 'Year 2'}]","[{'measure': 'Number of Participants Experiencing Costimulation Blockade-resistant Rejection (CoBRR)', 'description': 'Assessment of the proposed therapies to prevent biopsy proven acute rejection, also known as CoBRR, was determined by the number of participants experiencing CoBRR at 1, 3 and 5 years post-transplant.', 'timeFrame': 'Year 1, Year 3, Year 5'}, {'measure': 'Number of Participants Experiencing Chronic Allograft Nephropathy (CAN)', 'description': 'Assessment of biopsy proven chronic allograft nephropathy at 1, 3 and 5 years post-transplant is presented as the number of participants experiencing CAN.', 'timeFrame': 'Year 1, Year 3, Year 5'}, {'measure': 'Number of Participants With BK Viremia', 'description': 'The number of participants experiencing BK viremia, an opportunistic infection, during the study is presented here.', 'timeFrame': 'Up to Year 5'}, {'measure': 'Number of Participants Developing Donor-specific Alloantibody (DSA)', 'description': 'Long term assessment of donor-specific immune responsiveness after prolonged therapy with belatacept (with or without sirolimus), and during and following drug withdrawal as determined by in vitro alloresponsiveness in carboxyfluorescein succinimidyl ester (CFSE) mixed lymphocyte reactivity and intracellular cytokine staining (ICCS).', 'timeFrame': 'Up to Year 5'}, {'measure': 'Number of Participants With Surviving Grafts', 'description': 'The number of participants whose grafts survived without graft failure at each follow up time point is presented here.', 'timeFrame': 'Year 1, Year 3, Year 5'}, {'measure': 'Estimated Glomerular Filtration Rate (eGFR)', 'description': 'Graft function was assessed throughout the study by the estimated glomerular filtration rate. The eGFR indicates the percentage of kidney function that a person has based on creatinine, age, body size, and gender. An eGFR of below 60 indicates chronic kidney disease. A higher eGFR means that there is greater kidney function.', 'timeFrame': 'Year 1, Year 3, Year 5'}]",7,18 Years,,ALL,False,"Allan D Kirk, MD, PhD",OTHER,2,40.0,ACTUAL,2025-09-01T16:18:20.964975,v2_robust,True,True,True,False,False,
NCT04144569,PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC,the Effectiveness and Safety Study on PD-1 Combined With Pyrotinib for First-line Chemotherapy Failed HER2 Insertion Mutation Advanced Non-small Cell Lung Cancer,PD-1 Combined With Pyrotinib,['PD-1 Combined With Pyrotinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,HER2 Insertion Mutation Positive Advanced NSCLC,['HER2 Insertion Mutation Positive Advanced NSCLC'],[],RECRUITING,,2019-01-30,2024-12-31,"[{'measure': 'PFS', 'description': 'Progression free survival', 'timeFrame': 'Approximately 1 years'}]","[{'measure': 'ORR', 'description': ""To measure the patients's overall response rate"", 'timeFrame': 'Approximately 1 years'}, {'measure': 'OS', 'description': 'Overall survival', 'timeFrame': 'Approximately 1 years'}]",3,18 Years,75 Years,ALL,False,Yongchang Zhang,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:20.965026,v2_robust,True,True,False,False,False,
NCT05791669,Arrest of Interproximal Caries Lesion With 38% Silver Diamine Fluoride Solution,Arrest of Interproximal Caries Lesion in Primary Molars With 38% Silver Diamine Fluoride Solution and 5% Sodium Fluoride Varnish: A Randomized Clinical Trial,Silver diamine fluoride,"['VOCO profluorid varnish', 'Silver diamine fluoride', 'FAgamin SDF38%', 'Sodium fluoride varnish']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Caries Arrested,['Caries Arrested'],"['Caries arrest ,interproximal caries, primary molars, SDF']",COMPLETED,,2021-08-01,2022-11-08,"[{'measure': 'Caries arrest', 'description': 'Assessment with bitewing radiographs based on ICCMS radiographic scoring system', 'timeFrame': '12 months'}]",[],1,5 Years,9 Years,ALL,False,Postgraduate Institute of Dental Sciences Rohtak,OTHER,0,45.0,ACTUAL,2025-09-01T16:18:20.965163,v2_robust,True,True,True,False,False,
NCT01924169,Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL),A Study of Immune-adjuvant Effect of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Hypogammaglobulinemia and Impaired Response to Vaccinations - RV-CL-CLL-PI-002544,Lenalidomide,"['Lenalidomide', 'Revlimid', 'CC-5013']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Hematologic Disorder,['Hematologic Disorder'],"['Hematologic Disorder', 'Chronic Lymphocytic Leukemia', 'CLL', 'Hypogammaglobulinemia', 'Impaired Response to Vaccinations', 'Immunoglobulins', ""Immune system's function"", 'Lenalidomide', 'CC-5013', 'Revlimid', 'Flu vaccine', 'TIV', 'Pneumonia vaccine']",TERMINATED,Slow Accrual,2014-11-24,2017-02-21,"[{'measure': 'Number of Participants With IgG Response', 'description': 'IgG response defined as having improvement in IgG level by at least 25% at 6 months, compared to baseline.', 'timeFrame': '6 months'}]","[{'measure': 'Seroconversion Response', 'description': 'Study considered positive in regard to the secondary endpoints if seroconversion is observed in 60% or more of the subjects for at least one of the vaccinations given.', 'timeFrame': '4 weeks after flu vaccine administered'}]",2,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,3.0,ACTUAL,2025-09-01T16:18:20.965171,v2_robust,True,True,False,True,False,Slow Accrual
NCT04457869,A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL),"A Phase 2, Open-label, Single-arm, Multicenter Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)",F520,['F520'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Primary Central Nervous System Lymphoma,"['Primary Central Nervous System Lymphoma', 'Secondary Central Nervous System Lymphoma']",[],UNKNOWN,,2020-11-01,2023-01-01,"[{'measure': 'Objective response rate (ORR) by Independent Review Committee (IRC) Independent Review Committee (IRC).', 'description': 'Response assessment will be performed according to modified IPCG response. criteria on contrastenhanced cranial MRI-scans.', 'timeFrame': 'Approximately 24 months'}]","[{'measure': 'Objective response rate (ORR) based on the investigator assessment.', 'description': 'Response assessment will be performed according to modified IPCG response.', 'timeFrame': 'Approximately 24 months'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Based on IRC and the investigator assessments.', 'timeFrame': 'Approximately 24 months'}, {'measure': 'Duration of response (DOR)', 'description': 'Based on IRC and the investigator assessments.', 'timeFrame': 'Approximately 24 months'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'Approximately 24 months'}, {'measure': 'Safety of F520', 'description': 'AE/SAE will be assessed by CTCAE v5.0', 'timeFrame': 'Approximately 24 months'}]",6,18 Years,,ALL,False,"Shandong New Time Pharmaceutical Co., LTD",INDUSTRY,0,43.0,ESTIMATED,2025-09-01T16:18:20.965316,v2_robust,True,True,False,False,True,
NCT05296369,Folic Acid Interferes With Radiation Esophagitis,Randomized Controlled Clinical Study of Folic Acid Treatment of Radiation Esophagitis After Chemoradiation in Lung Cancer,Folic acid,['Folic acid'],1,INTERVENTIONAL,['NA'],,,Lung Cancer,['Lung Cancer'],[],UNKNOWN,,2022-03-01,2023-05,"[{'measure': 'Progression-free survival(PFS)', 'description': 'PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.', 'timeFrame': 'up to 12 months'}]","[{'measure': 'Severity of radiation esophagitis', 'description': 'A modified NCI-CTC score (the sum of dysphagia pain score and dysphagia pain score) was used to evaluate the occurrence of radioactive esophagitis.', 'timeFrame': 'day 1 up to 4 weeks after the end of treatment'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v5.0', 'description': 'To assess and record nausea, vomiting, hematologic toxicity,radiation pneumonitis and other treantment complications by CTCAE v5.0.Hematotoxicity includes white blood cell count (The normal range count is 3.5 to 9.5×10\\^9/L), neutrophil count(The normal range count is 1.8 to 6.3×10\\^9/L), platelet count(The normal range count is 125 to 350×10\\^9/L), hemoglobin count(The normal range count is 115 to 175g/L),measuring creatinine value（The normal value of creatinine is 44to106μmol/L）, endogenous creatinine clearanceThe normal value of creatinine is 80 to120 mo/min）, bilirubin（Including total bilirubin, direct bilirubin and indirect bilirubin,), aspartate aminotransferase(AST, The normal value of AST is 13 to 40u/L)and alanine aminotransferase(ALT, The normal value of ALT is 7 to 50u/L).The severity of radiational pneumonitis can be evaluated by the Radiation Therapy Oncology Group（RTOG）morbidity grading criteria.', 'timeFrame': 'day 1 up to 4 weeks after the end of treatment'}]",3,18 Years,75 Years,ALL,False,Guizhou Medical University,OTHER,0,90.0,ESTIMATED,2025-09-01T16:18:20.965364,v2_robust,True,True,False,False,True,
NCT05249569,"Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma","Multi-center Phase II Open-label Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma",Axitinib,"['Bavituximab', 'Avelumab', 'Axitinib']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Hepatocellular Carcinoma,['Hepatocellular Carcinoma'],[],TERMINATED,Sponsor pulled support for one of the study drugs.,2022-11-04,2022-12-30,"[{'measure': 'Response Rate of Combination Therapy', 'description': 'To determine the objective response rate of combination axitinib,avelumab, and bavituximab in advanced HCC not previously treated with systemic therapy.', 'timeFrame': 'Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason up to 24 months.'}]","[{'measure': 'Disease Control Rate', 'description': 'To determine the disease control rate of response of combination axitinib, bavituximab, and avelumab compared to historical controls.', 'timeFrame': 'Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason up to 48 months.'}, {'measure': 'Overall Survival', 'description': 'To determine the overall survival, 6 of combination axitinib, bavituximab, and avelumab compared to historical controls.', 'timeFrame': 'Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason up to 48 months.'}, {'measure': '6-month Progression-free Survival', 'description': 'To determine the 6-month progression-free survival of combination axitinib, bavituximab, and avelumab compared to historical controls.', 'timeFrame': 'Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason up to 48 months.'}, {'measure': 'Duration of Response', 'description': 'To determine the duration of response of combination axitinib, bavituximab, and avelumab compared to historical controls.', 'timeFrame': 'Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason up to 48 months.'}, {'measure': 'Safety Profile as Measured by the Number of Participants With AEs (Serious / Non-serious) as Graded by NCI CTCAE v5.0', 'description': 'Safety profile of combination axitinib, bavituximab, and avelumab will be measured by the number of participants with Adverse Events (AEs) (serious / non-serious) as graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0', 'timeFrame': 'Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason up to 48 months.'}, {'measure': 'Safety Profile as Measured by the Number of Participants With Lab Abnormalities as Graded by NCI CTCAE v5.0', 'description': 'Safety profile of combination axitinib, bavituximab, and avelumab will be measured by the number of participants with lab abnormalities as graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0', 'timeFrame': 'Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason up to 48 months.'}]",7,18 Years,,ALL,False,University of Texas Southwestern Medical Center,OTHER,1,1.0,ACTUAL,2025-09-01T16:18:20.965398,v2_robust,True,True,False,True,True,Sponsor pulled support for one of the study drugs.
NCT01860183,Effect of 3g Versus 2 g MMF in Combination With Tacrolimus on Progression of Renal Allograft Interstitial Fibrosis,Comparison of 3g Versus 2g Mycophenolate Mofetil in Combination With Tacrolimus on Progression of Chronic Histology Changes in Kidney Transplant Recipients,Mycophenolate mofetil,['Mycophenolate mofetil'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Kidney Transplantation,"['Kidney Transplantation', 'Kidney Failure']","['kidney transplantation', 'chronic allograft dysfunction', 'mycophenolate mofetil', 'Chronic']",COMPLETED,,2013-05,2016-06-01,"[{'measure': 'Progression of interstitial fibrosis (ci)', 'timeFrame': '1 year'}]","[{'measure': 'Estimated glomerular filtration rate', 'timeFrame': '1 year'}, {'measure': 'Time to first acute rejection episode', 'timeFrame': 'up to 1 year'}, {'measure': 'Progression of other chronic scores', 'timeFrame': '1 year'}, {'measure': 'Graft loss', 'timeFrame': '1 year'}, {'measure': 'Patient survival', 'timeFrame': '1 year'}]",6,18 Years,,ALL,False,Clinical Hospital Merkur,OTHER,2,76.0,ACTUAL,2025-09-01T16:18:20.965430,v2_robust,True,True,True,False,False,
NCT01818583,Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter,Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter,Potassium chloride,"['Potassium chloride', 'Glucose 50 MG/ML']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Atrial Fibrillation,"['Atrial Fibrillation', 'Atrial Flutter']","['Atrial fibrillation', 'Atrial flutter', 'Potassium', 'Cardioversion']",COMPLETED,,2013-03,2017-11,"[{'measure': 'Cardioversion (time and percentage)', 'timeFrame': '24 hours'}]","[{'measure': 'Atrial fibrillation at 3 months follow up visit and during 72 hours ECG-monitoring period.', 'description': 'The patients will be followed up with a resting ECG about three months after study intervention, and subsequently on-demand ECG will be monitored for 72 hours.', 'timeFrame': 'At about 3 months follow up, plus additional 3 days ECG-monitoring'}]",2,18 Years,,ALL,False,Diakonhjemmet Hospital,OTHER,0,143.0,ACTUAL,2025-09-01T16:18:20.965499,v2_robust,True,True,True,False,False,
NCT01905683,Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy,"Open-label, Non-controlled, Multicenter Long-term Study to Investigate the Safety and Efficacy of Xeomin® (Incobotulinumtoxin A, NT 201) for the Treatment of Spasticity of the Lower Limb(s) or of Combined Spasticity of Upper and Lower Limb in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy",IncobotulinumtoxinA (16-20 Units per kg body weight),"['Botulinum toxin type A (150 kiloDalton), free from complexing proteins', 'NT 201', 'IncobotulinumtoxinA (16-20 Units per kg body weight)', 'Xeomin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy,['Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy'],[],COMPLETED,,2013-08,2017-01,"[{'measure': 'Occurrence of Treatment Emergent Adverse Events (TEAEs) Overall and Per Injection Cycle', 'description': 'TEAEs are events observed from the time point of first injection until end of study visit (Week 50-66). Values reported here refer to the number of participants affected.', 'timeFrame': 'From the timepoint of first injection up to end of study visit (Week 50-66)'}, {'measure': 'Occurrence of Treatment Emergent Adverse Events of Special Interest (TEAESI) Overall and Per Injection Cycle', 'description': 'TEAEs occurring after treatment that were thought to possibly indicate toxin spread throughout the trial conduct are defined as TEAESI. Values reported here refer to the number of participants affected.', 'timeFrame': 'From the timepoint of first injection until end of study visit (Week 50-66)'}, {'measure': 'Occurrence of Treatment-emergent Serious Adverse Events (TESAEs) Overall and Per Injection Cycle', 'description': 'TESAEs are events observed from the time point of first injection until end of study visit (Week 50-66). Values reported here refer to the number of participants affected.', 'timeFrame': 'From the timepoint of first injection until end of study visit (Week 50-66)'}]","[{'measure': ""Investigator's Global Assessment of Tolerability at Day 99 (Week 14) of Each Injection Cycle"", 'description': ""The investigator's global assessment of tolerability was assessed on a 4-point ordinal scale where 1 = very good, 2 = good, 3 = moderate, and 4 = poor. Results for Day 99 (Week 14) of 4th injection cycles were collected at the end of study visit."", 'timeFrame': 'Day 99 (Week 14) of 1st, 2nd, 3rd and 4th injection cycle'}, {'measure': 'Changes in AS Score of Left and Right Plantar Flexors (PF) From Baseline to All Other Visits, From Day 1 of Each Injection Cycle to Day 29 (Week 4), Day 57 (Week 8, 1st Injection Cycle Only) and Day 99 (Week 14) of the Respective Injection Cycle', 'description': 'The Ashworth Scale (AS) is a well-known and commonly used scale in clinical trials with spasticity. In spastic muscles the resistance to passive movement is assessed. It is a 5-point scale that ranges from 0 (= no increase in tone) to 4 (=limb rigid in flexion or extension). For participants with bilateral pes equinus, the body side for efficacy analysis that is, ""primary body side"" was decided by investigator at screening and was kept throughout the entire study. V3 = Week 4 of 1st Injection Cycle; V4 = Week 8 of 1st Injection Cycle; V5 = Day 1 of 2nd Injection Cycle; V6= Week 4 of 2nd Injection Cycle; V7 = Day 1 of 3rd Injection Cycle; V8 = Week 4 of 3rd Injection Cycle; V9 = Day 1 of 4th Injection Cycle; V10 = Week 4 of 4th Injection Cycle; V11= Week 14th of 4th Injection Cycle = end of study visit.', 'timeFrame': 'Baseline (Day 1, Visit [V] 2) to all other visits (V3, V4, V5, V6, V7, V8, V9, V10, and V11); From Day 1 of Each Injection Cycle to Day 29 (Week 4), Day 57 (Week 8, 1st Injection Cycle only) and Day 99 (Week 14) of the respective Injection Cycle'}, {'measure': ""Investigator's, Child's/Adolescent's, and Parent's/Caregiver's Global Impression of Change Scale (GICS) at Day 29 (Week 4) of Each Injection Cycle"", 'description': ""The GICS are global outcomes to assess the impression of change due to treatment. GICS were assessed by the investigator, by the participant (if feasible) and by parents'/caregiver (if applicable). GICS is 7-Point Likert Scale ranging from +3 (very much improved function) to -3 (very much worse function)."", 'timeFrame': 'Day 29 (Week 4) of 1st, 2nd, 3rd and 4th injection cycle'}, {'measure': ""Investigator's Global Impression of Change of Plantar Flexor Spasticity Scale (GICS-PF) of Left and Right PF at Day 29 (Week 4) of Each Injection Cycle"", 'description': 'The GICS are global outcomes to assess the impression of change due to treatment. GICS were assessed by the investigator, by the participant (if feasible) and by parents\'/caregiver (if applicable). GICS is a 7-Point Likert Scale ranging from +3 (very much improved function) to -3 (very much worse function). For participants with bilateral pes equinus, the body side for efficacy analysis that is ""primary body side"" was decided by investigator at screening and was kept throughout the entire study.', 'timeFrame': 'Day 29 (Week 4) of 1st, 2nd, 3rd and 4th injection cycle'}, {'measure': 'Changes in Modified Tardieu Scale (MTS) of Left and Right PF From Baseline to All Other Visits, From Day 1 of Each Injection Cycle (IC) to Day 29 (Week 4), Day 57 (Week 8, 1st IC Only) and Day 99 (Week 14) of the Respective Injection Cycle', 'description': 'The MTS assesses spastic muscle tone by subtraction of two angles measured at different conditions of passive muscle stretch. R2 is the angle of passive range of motion with a passive movement at slow speed. R1 is the angle where a ""catch-and-release"" or clonus can be triggered at the fastest possible speed. Score values represent the measured (R2-R1) difference, that is, the dynamic tone component of the examined muscle(s). Decreases of (R2-R1) represent reductions in the dynamic component of spasticity, that is, improvement of dynamic muscle spasticity. V3 = Week 4 of 1st IC; V4 = Week 8 of 1st IC; V5 = Day 1 of 2nd IC; V6 = Week 4 of 2nd IC; V7 = Day 1 of 3rd IC; V8 = Week 4 of 3rd IC; V9 = Day 1 of 4th IC; V10 = Week 4 of 4th IC; V11 = Week 14 of 4th IC = end of study visit.', 'timeFrame': 'Baseline (Day 1, Visit [V] 2) to all other visits (V3, V4, V5, V6, V7, V8, V9, V10, and V11); From Day 1 of Each IC to Day 29 (Week 4), Day 57 (Week 8, 1st IC cycle only) and Day 99 (Week 14) of the respective IC'}, {'measure': 'Change in Scores of Pain Intensity (From Participants) and Frequency (From Parent/Caregiver) From Baseline to All Visits, From Day 1 of Each IC to Day 29 (Week 4), Day 57 (Week 8, 1st IC Cycle Only) and Day 99 (Week 14) of Respective Injection', 'description': ""The questionnaire on pain caused by Spasticity (QPS) is a participant-reported outcome for children and adolescents (2-17 years) with cerebral palsy on spasticity-related pain. Pain intensity (from participants) and pain frequency (from parent/caregiver) to be assessed with QPS. The QPS total score for pain intensity ranges from 0 ('No Hurt') to 10 ('Hurt Worst'). The QPS total score for the observed pain frequency ranges from 0 (Never) to 4 (Always). V3 = Week 4 of 1st IC; V4 = Week 8 of 1st IC; V5= Day 1 of 2nd IC; V6 = Week 4 of 2nd IC; V7 = Day 1 of 3rd IC; V8 = Week 4 of 3rd IC; V9 = Day 1 of 4th IC; V10 = Week 4 of 4th IC; V11 = Week 14 of 4th IC = end of study visit."", 'timeFrame': 'Baseline (Day 1, Visit [V] 2) to all other visits (V3, V4, V5, V6, V7, V8, V9, V10, and V11); From Day 1 of Each IC to Day 29 (Week 4), Day 57 (Week 8, 1st IC cycle only) and Day 99 (Week 14) of the respective IC'}, {'measure': 'Changes in Gross Motor Function Measure (GMFM)-66 Score From Baseline to All Injection Visits and End of Study', 'description': 'The GMFM-66 is a standardized observational 66-item instrument designed and validated to measure change in gross motor function over time in participants with cerebral palsy. Score values represent the total GMFM-66 score. Total GMFM scores range from 0 (worst) to 100 (best).', 'timeFrame': 'Baseline to Day 1 of 2nd (V5), 3rd (V7), 4th (V9) IC and End of study (Week 44-68) (V11)'}]",10,2 Years,17 Years,ALL,False,Merz Pharmaceuticals GmbH,INDUSTRY,0,370.0,ACTUAL,2025-09-01T16:18:20.965631,v2_robust,True,True,True,False,True,
NCT00688883,Fludara (Oral) Phase II Study for Indolent Lymphoma,"A Multicenter, Open Study to Assess the Antitumor Effect and Safety of Oral Fludarabine Phosphate (Fludara (SH T 586): 40 mg/m2/Day) Administered in 3 - 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by a Observation Period of 23 Days) in Patients With Indolent Lymphoma",Fludarabine Phosphate (Fludara),"['Fludarabine Phosphate (Fludara)', 'BAY86-4864']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Lymphoma,['Lymphoma'],"['Fludarabine', 'Purine analog', 'Indolent lymphoma']",COMPLETED,,2003-02,2004-08,"[{'measure': 'Best overall response rate; Antitumor effect', 'timeFrame': 'at screening and re-evaluation, at 4th week or at the time of discontinuation of treatment cycles 1, 3 and 6, and at 12th week after last observation of last treatment cycle'}]","[{'measure': 'CR rate', 'timeFrame': 'after last observation of last treatment cycle'}, {'measure': 'Time to treatment failure', 'timeFrame': 'after last observation of last treatment cycle'}, {'measure': 'Overall survival', 'timeFrame': 'after last observation of last treatment cycle'}, {'measure': 'Adverse events collection', 'timeFrame': 'after last observation of last treatment cycle'}]",5,20 Years,74 Years,ALL,False,"Genzyme, a Sanofi Company",INDUSTRY,0,52.0,ACTUAL,2025-09-01T16:18:20.965642,v2_robust,True,True,True,False,True,
NCT04795583,Corticosteroids for COVID-19,A Randomized Clinical Trial Comparing 7 Days Treatment With Corticosteroids Versus Placebo for Early COVID-19,Prednisone,['Prednisone'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Covid19,['Covid19'],[],WITHDRAWN,Funding Issues,2021-08-01,2022-08,"[{'measure': 'Hospital admission or death in the first 2 weeks after randomization', 'description': 'Need to be admitted to hospital or death during the first 2 weeks after randomization', 'timeFrame': '14 days'}]","[{'measure': 'Hospitalization at 30 days', 'description': 'Need of hospital admission in the first 30 days after randomization', 'timeFrame': '30 days'}, {'measure': 'Mortality at 30 days', 'description': 'Death in the first 30 days after randomization', 'timeFrame': '30 days'}, {'measure': 'Serious adverse events at 30 days', 'description': 'Occurrence of SAEs in the first 30 days after randomization', 'timeFrame': '30 days'}, {'measure': 'Death at week 12', 'description': 'Death in the first 12 weeks after randomization', 'timeFrame': 'Week 12'}, {'measure': 'Duration of symptoms', 'description': 'COVID-19 symptoms duration in days', 'timeFrame': 'Week 12'}]",6,18 Years,,ALL,False,University of Alberta,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:20.965655,v2_robust,True,True,False,True,True,Funding Issues
NCT03669783,"Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm)","Randomized Open-label Non-inferiority Phase 3 Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm)",treatment Vincristin,"['treatment Vincristin', 'Etoposide', 'treatment Carboplatin', 'treatment Actinomycin-D', 'treatment Doxorubicin']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Childhood Renal Tumor,['Childhood Renal Tumor'],[],RECRUITING,,2023-02-03,2033-10-03,"[{'measure': 'Metastatic response assessment by neoadjuvant chemotherapy only', 'description': 'percentage of patients with complete response (CR) or Very Good Partial Response (VGPR) of metastasis of nephroblastoma after 6 weeks of preoperative chemotherapy', 'timeFrame': '6 weeks'}]","[{'measure': 'Secondary metastatic response assessment', 'description': 'percentage of patients after 6 weeks of preoperative chemotherapy achieving a CR after surgery of metastasis at time of nephrectomy', 'timeFrame': '6 weeks'}, {'measure': 'Clinical outcome after treatment', 'description': 'stage of local tumor (for each arm)', 'timeFrame': '2 and 5 years'}, {'measure': 'Histological response to preoperative treatment', 'description': 'stage distribution of local tumor histological subtype distribution of local tumor (low, intermediate or high risk (LR, IR, HR))', 'timeFrame': '6 weeks'}]",4,,17 Years,ALL,False,Assistance Publique Hopitaux De Marseille,OTHER,1,110.0,ESTIMATED,2025-09-01T16:18:20.965815,v2_robust,True,True,False,False,False,
NCT03502083,Human Vasodilatory Effect of GLP-1,Vasodilatory Effect of GLP-1,GLP-1 (7-36)Amide,['GLP-1 (7-36)Amide'],1,INTERVENTIONAL,['NA'],,,Coronary Stenosis,"['Coronary Stenosis', 'Type2 Diabetes', 'Angina, Stable']",[],COMPLETED,,2015-12-01,2017-03-01,"[{'measure': 'Change in IMR (index of microcirculatory resistance) with GLP-1 compared with baseline', 'description': 'Change in coronary microcirculatory resistance from baseline', 'timeFrame': 'Change from baseline'}, {'measure': 'Forearm bloodflow ratio with GLP-1', 'description': 'Peripheral vasodilatory response of GLP-1', 'timeFrame': 'Change from baseline'}]",[],2,18 Years,,ALL,False,Papworth Hospital NHS Foundation Trust,OTHER_GOV,0,11.0,ACTUAL,2025-09-01T16:18:20.965829,v2_robust,True,True,True,False,False,
NCT05121883,Edaravone Dexborneol Combining With Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke,An Observational Trial of Edaravone Dexborneol Combining With Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke,Edaravone Dexborneol,['Edaravone Dexborneol'],1,OBSERVATIONAL,[],,,Stroke,['Stroke'],[],UNKNOWN,,2021-11-01,2024-01-31,"[{'measure': 'Proportion of functional independence at 90 days', 'description': 'Functional independence will be assessed by ratio of modefied Rankin Scale (mRS) score of 0-2 mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome', 'timeFrame': '90 days'}]","[{'measure': 'Growth in infarct volume (mL)', 'description': '24 hour infarct volume (mL) - 7 day infarct volume (mL)', 'timeFrame': 'from 24 hours to 7 days'}, {'measure': 'Salvaged ischemic tissue index (%)', 'description': '100%\\*(baseline hypoperfusion (mL) - 7 day infarction lesion (mL))/ baseline hypoperfusion (mL)', 'timeFrame': 'from baseline to 7 days'}, {'measure': 'Frequency of parenchymal hemorrhage (PH) (%)', 'description': 'The presence of PH is defined according the standard from ECASS-2 study thrombectomy', 'timeFrame': '24 hours'}, {'measure': 'Change on the National Institute of Health stroke scale (NIHSS) score from baseline to 1 day', 'description': 'NIHSS: minimum value = 0, maximum value = 42, and higher scores mean severer symptoms', 'timeFrame': 'from baseline to 1 day'}, {'measure': 'Change on the National Institute of Health stroke scale (NIHSS) score from 1 day to 7 day', 'description': 'NIHSS: minimum value = 0, maximum value = 42, and higher scores mean severer symptoms', 'timeFrame': 'from 1 day to 7 days'}, {'measure': 'Excellent recovery assessed by the ratio of modefied Rankin Scale (mRS) score of 0-1', 'description': 'mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome', 'timeFrame': '90 days'}, {'measure': 'Recovery assessed by modefied Rankin Scale (mRS) score', 'description': 'mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome', 'timeFrame': '90 days'}]",8,18 Years,80 Years,ALL,False,"Second Affiliated Hospital, School of Medicine, Zhejiang University",OTHER,0,200.0,ESTIMATED,2025-09-01T16:18:20.965837,v2_robust,False,True,False,False,False,
NCT03348683,Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients,Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients: a Double-blind Randomized Controlled Trial,Propranolol,"['Propranolol', 'saline', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Induction of Labor Affected Fetus / Newborn,['Induction of Labor Affected Fetus / Newborn'],"['Induction', 'Labor', 'Propranolol']",COMPLETED,,2017-12-11,2018-12-11,"[{'measure': 'Time From Beginning of Induction to Delivery', 'description': 'The time of induction (based on time of foley balloon placement for cervical ripening or misoprostol administration) to the time of delivery of the infant.', 'timeFrame': 'average of 24 hours'}]","[{'measure': 'Number of Participants With Various Mode of Delivery', 'description': 'Number of various mode of delivery - count of Vaginal delivery, vacuum assisted vaginal delivery, forceps assisted vaginal delivery, cesarean section', 'timeFrame': 'average of 24 hours'}, {'measure': 'Duration of Latent', 'description': 'Time of latent labor defined as \\<6cm of cervical dilation.', 'timeFrame': 'average of 24 hours'}, {'measure': 'Number of Participants With Maternal Morbidity Composite Score = 1', 'description': 'Composite maternal morbidity score consists of a count of postpartum hemorrhage, transfusion, hysterectomy, placental abruption, chorioamnionitis, shoulder dystocia, episiotomy, higher order laceration, and ICU admission.\n\nThe composite score was computed as a score of 1 for any indication of maternal morbidity, that is the participant experienced at least one maternal morbidity, and the components are given equal weights. Participants who had no evidence of the predefined maternal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1.', 'timeFrame': 'average of 24 hours'}, {'measure': 'Number of Participants With Postpartum Hemorrhage', 'description': 'Greater than 500cc of blood expelled during a vaginal delivery or greater than 1000cc of blood expelled during a cesarean section', 'timeFrame': '30 minutes from drug administration'}, {'measure': 'Number of Fetus With Heart Rate Decelerations', 'description': 'Count of fetus with fetal heart rate decelerations within 30 minutes of study drug administration', 'timeFrame': '30 minutes from drug administration'}, {'measure': 'Number of Fetus With Fetal Bradycardia', 'description': 'Count of fetus with fetal bradycardia (\\<110bpm for \\>10 minutes within 30 minutes of study drug administration)', 'timeFrame': '30 minutes from drug administration'}, {'measure': 'Number of Neonates With Neonatal Outcome Composite Score = 1', 'description': 'Composite neonatal outcome score was for any of the following morbidity: Neonatal Intensive Care Unit (NICU) admission, respiratory support (CPAP, nasal cannula, intubation), culture proven sepsis, radiographically proven intracranial hemorrhage, necrotizing enterocolitis, hypoglycemia (for those infants who had sugar checked), and neonatal death.\n\nThe composite score was computed as a score of 1 for any indication of neonatal morbidity - neonates who experienced at least one morbidity and the components are given equal weights. Patients who had no evidence of the predefined neonatal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1.', 'timeFrame': 'Day 1'}, {'measure': 'Number of Neonates With Hypoglycemia', 'description': ""Neonatal outcome - Number of neonates with hypoglycemia (blood glucose \\<50).\n\nThis population includes only the neonates who had heelsticks to check their blood glucose, which is not a universal practice and was not required by the protocol or IRB. The neonates included were those who met the nursery's risk-based protocol to check blood glucose after birth (ex: infants of diabetic mothers, fetal growth restriction, macrosomia, or symptoms suggestive of hypoglycemia)"", 'timeFrame': 'Day 1'}]",9,18 Years,50 Years,FEMALE,False,Icahn School of Medicine at Mount Sinai,OTHER,0,240.0,ACTUAL,2025-09-01T16:18:20.965860,v2_robust,True,True,True,False,False,
NCT00336141,Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer,Phase I/II Clinical Trial With Vorinostat and Infusional 5-FU/LV in Patients With Metastatic Colorectal Cancer Who Failed 5-FU-Based Chemotherapy,Suberoylanilide hydroxamic acid,['Suberoylanilide hydroxamic acid'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Colorectal Cancer,['Colorectal Cancer'],[],COMPLETED,,2006-06,2009-04,"[{'measure': 'Toxicity', 'timeFrame': 'Weekly'}]","[{'measure': 'Response', 'timeFrame': 'Every 2 months'}]",2,18 Years,,ALL,False,University of Southern California,OTHER,1,10.0,ACTUAL,2025-09-01T16:18:20.965899,v2_robust,True,True,True,False,False,
NCT01918241,Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia,Saftey and Efficacy Phase II Study of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia,"pegfilgrastim,30mcg/kg","['pegfilgrastim, 60mcg/kg', 'PEG-rhG-CSF,30mcg/kg', 'rhG-CSF,5mcg/kg', 'filgrastim, 5mcg/kg', 'PEG-rhG-CSF,60mcg/kg', 'pegfilgrastim, 100mcg/kg', 'pegfilgrastim,30mcg/kg', 'PEG-rhG-CSF,100mcg/kg']",8,INTERVENTIONAL,['PHASE2'],PHASE2,,Neutropenia,['Neutropenia'],"['Pegylation', 'G-CSF', 'Efficacy', 'Satety']",UNKNOWN,,2013-07,,"[{'measure': 'Duration of ≥grade 3 neutropenia in cycle 2', 'timeFrame': '21 days'}]","[{'measure': 'change of Neutropenia and ANC in cycle 2', 'description': ""1. Incidence of ≥grade 3 neutropenia;\n2. Incidence of febrile neutropenia;\n3. Measurement the duration from chemotherapy finished to the ANC reached the nadir and the value of ANC's nadir;\n4. Time to ANC recovery,the time from chemotherapy administration until the patient's ANC increasd to 2.0\\*109/L after the expected nadir"", 'timeFrame': '21 days'}]",2,18 Years,70 Years,ALL,False,"Hangzhou Jiuyuan Gene Engineering Co. Ltd.,",INDUSTRY,11,200.0,ESTIMATED,2025-09-01T16:18:20.965951,v2_robust,True,True,False,False,False,
NCT02574741,Combination Treatment for Augmenting Language in Children With ASD,Augmenting Language Interventions in ASD: A Translational Approach (ACE Project 3),Aripiprazole,"['abilify', 'inactive study medication', 'Placebo', 'Aripiprazole']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Autism Spectrum Disorder,['Autism Spectrum Disorder'],[],COMPLETED,,2012-06,2019-12,"[{'measure': 'Number of words as assessed in a naturalistic language assessment', 'description': 'word usage coded as assessed by a clinician-administered assessment', 'timeFrame': '12 weeks post baseline'}]",[],1,5 Years,11 Years,ALL,False,"University of California, Los Angeles",OTHER,0,58.0,ACTUAL,2025-09-01T16:18:20.965970,v2_robust,True,True,True,False,False,
NCT01520441,BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH),H-25362: Effect of Botulinum Neurotoxin Type A Prostate Injections on Neurogenesis and Gene Profile Expression in Men With Localized Prostate Cancer and Lower Urinary Tract Symptoms/BPH (Protocol # 05-09-30-03),BOTOX,"['BOTOX', 'onabotulinumtoxinA']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Prostate Cancer,"['Prostate Cancer', 'Benign Prostatic Hyperplasia', 'Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)']","['Botulinum Toxin', 'Prostate Cancer', 'BPH', 'LUTS']",WITHDRAWN,,2011-03,2014-03,"[{'measure': 'Determination the effects of BoNT-A injection on BPH and prostate cancer tissues.', 'description': 'The prostate tissue taken from each lobe will be compared to determine if the injection of BOTOX has effected the genetic profile.', 'timeFrame': '3 years'}]","[{'measure': 'Determination of BOTOX prostate injection on vas deferens tissue', 'description': 'Any changes to the vas deferens tissue after BOTOX injection, will be noted.', 'timeFrame': '3 years'}]",2,50 Years,,MALE,False,"The University of Texas Health Science Center, Houston",OTHER,0,0.0,ACTUAL,2025-09-01T16:18:20.965978,v2_robust,True,True,False,True,False,
NCT04762641,"This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors","A Phase 1 Dose Escalation and Expansion Study of ABL503, a Bispecific Antibody of 4-1BB and PD-L1, As a Single Agent in Subjects with Any Progressive Locally Advanced (unresectable) or Metastatic Solid Tumors",ABL503,['ABL503'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumor,['Advanced Solid Tumor'],[],RECRUITING,,2021-04-01,2026-06-15,"[{'measure': 'Number of Subjects with Dose-Limiting Toxicities (DLT)', 'description': 'Number of subjects with Dose-Limiting Toxicity (DLT)', 'timeFrame': 'From Day 1 until disease progression or Day 28, whichever came first'}, {'measure': 'Number of subjects with AE, IrAEs, IRRs, SAEs and abnormalities in Lab', 'description': 'Number of subjects with Adverse Event, Immune-related Adverse Event, Infusion-related Reactions (IRRs), serious AEs, and abnormalities in lab parameters', 'timeFrame': ""From Day 1 until confirmed CR, disease progression, initiation of a new anticancer therapy, unacceptable AEs, or subject's consent withdrawal, or investigator's decision to discontinue treatment, which came first, assessed up to approx. 12 months""}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'Proportion of subject with best overall response of complete response (CR) or partial response (PR) per RECIST v1.1', 'timeFrame': ""From Day 1 until confirmed CR, disease progression, initiation of a new anticancer therapy, unacceptable AEs, or subject's consent withdrawal, or investigator's decision to discontinue treatment, which came first, assessed up to approx. 12 months""}, {'measure': 'Pharmacokinetic (PK) of ABL503', 'description': 'Serum concentrations of ABL503 will be collected and analyzed to evaluate the PK of ABL503', 'timeFrame': ""From Day 1 until confirmed CR, disease progression, initiation of a new anticancer therapy, unacceptable AEs, or subject's consent withdrawal, or investigator's decision to discontinue treatment, which came first, assessed up to approx. 12 months""}, {'measure': 'Immunogenicity of ABL503', 'description': 'Incidence of anti-ABL503 antibody will be analyzed to evaluate the Immunogenicity of ABL503', 'timeFrame': ""From Day 1 until confirmed CR, disease progression, initiation of a new anticancer therapy, unacceptable AEs, or subject's consent withdrawal, or investigator's decision to discontinue treatment, which came first, assessed up to approx. 12 months""}]",5,18 Years,,ALL,False,"ABL Bio, Inc.",INDUSTRY,0,100.0,ESTIMATED,2025-09-01T16:18:20.966000,v2_robust,True,True,False,False,True,
NCT03847441,Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata,Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata: A Randomized Controlled Trial,Calcipotriol,['Calcipotriol'],1,INTERVENTIONAL,['NA'],,,Alopecia Areata,['Alopecia Areata'],"['Alopecia Areata', 'Calcipotriol', 'Narrow Band-UVB', 'Vitamin D3']",COMPLETED,,2017-10-01,2018-12-31,"[{'measure': 'Clinical improvement of Alopecia Areata After treatment As assessed by Severity of Alopecia tool (SALT) score', 'description': 'calculation of SALT score before and after treatment', 'timeFrame': '3 months'}, {'measure': 'Improvement of serum Vitamin D levels in (ng/ml) after treatment', 'description': 'measurement of serum vitamin D before and after treatment', 'timeFrame': '3 months'}]",[],2,14 Years,40 Years,ALL,False,Aswan University Hospital,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:20.966110,v2_robust,True,True,True,False,False,
NCT05637541,"Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets","A Randomized, Double-blind, Placebo-controlled and Multicenter Phase Ⅱ Clinical Trials To Evaluate the Safety, Efficacy and Pharmacokinetics of GST-HG141 Tablets in Treated Chronic Hepatitis B (CHB) Patients With Low Viremia",GST-HG141,['GST-HG141'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Hepatitis b,['Chronic Hepatitis b'],['Chronic Hepatitis b'],COMPLETED,,2023-01-03,2024-08-24,"[{'measure': 'Serum HBV DNA', 'description': 'At the end of treatment, serum HBV DNA was lower than the lower limit of quantitative detection value (HBV DNA ≤ 20 IU/mL)percentage of subjects.', 'timeFrame': '12 or 24 weeks'}]","[{'measure': 'Serum HBV DNA quantification', 'description': 'Changes in serum HBV DNA quantitative detection values from baseline', 'timeFrame': '12 or 24 weeks'}]",2,18 Years,70 Years,ALL,False,"Fujian Akeylink Biotechnology Co., Ltd.",INDUSTRY,0,90.0,ACTUAL,2025-09-01T16:18:20.966192,v2_robust,True,True,True,False,False,
NCT04328441,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Reducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial.",BCG Vaccine,"['NaCl 0,9%', 'Danish strain 1331', 'BCG Vaccine', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,COVID-19,['COVID-19'],['Health care workers'],COMPLETED,,2020-03-25,2021-03-31,"[{'measure': 'Health Care Workers absenteeism', 'description': 'Number of days of unplanned absenteeism for any reason', 'timeFrame': 'Maximum of 365 days'}]","[{'measure': 'the cumulative incidence of documented COVID-19', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of Hospital Admission due to documented COVID-19', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the number of days of unplanned absenteeism, because of documented COVID-19', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of self-reported acute respiratory symptoms or fever', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of death due to documented COVID-19', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of Intensive Care Admission due to documented COVID-19', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the number of days of absenteeism, because of imposed quarantine as a result of exposure to COVID-19', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented COVID-19', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the number of days of unplanned absenteeism because of self-reported acute respiratory symptoms', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the number of days of self-reported fever (≥38 gr C)', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of self-reported fever (≥38 gr C)', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the number of days of self-reported acute respiratory symptoms', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of self-reported acute respiratory symptoms', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of death for any reason', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of Intensive Care Admission for any reason', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence of Hospital Admission for any reason', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence and magnitude of plasma/serum antibodies (IgA,M,G) and SARS-CoV-2-specific antibodies at 12 weeks after vaccination and at the end of the study period', 'description': 'Exploratory', 'timeFrame': 'Maximum of 365 days'}, {'measure': 'the cumulative incidence and magnitude of plasma/serum antibodies (IgA,M,G) and SARS-CoV-2-specific antibodies at 12 weeks after vaccination and at the end of the study period', 'description': 'Exploratory', 'timeFrame': '3-6 months after inclusion'}]",19,18 Years,,ALL,True,UMC Utrecht,OTHER,1,1511.0,ACTUAL,2025-09-01T16:18:20.966204,v2_robust,True,True,True,False,False,
NCT00425841,Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer,Lokal Fortgeschrittenes Pankreas-Karzinom: Stereotaktische Radiotherapie Gefolfgt Von Gemox-Chemotherapie,gemcitabine hydrochloride,"['oxaliplatin', 'gemcitabine hydrochloride']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Pancreatic Cancer,['Pancreatic Cancer'],"['adenocarcinoma of the pancreas', 'stage III pancreatic cancer', 'stage II pancreatic cancer']",COMPLETED,,2006-05,2009-12,[{'measure': 'Clinical response rate as assessed by RECIST criteria'}],"[{'measure': 'Toxicity as assessed by NCI-CTC criteria'}, {'measure': 'Time to progression'}, {'measure': 'Time to death'}, {'measure': 'Perioperative morbidity and mortality'}, {'measure': 'Rate of R0 resections'}, {'measure': 'Histologic response rate'}]",7,18 Years,,ALL,False,Technical University of Munich,OTHER,0,29.0,ESTIMATED,2025-09-01T16:18:20.966297,v2_robust,True,True,True,False,False,
NCT06690541,Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC,A Real-world Study to Explore Therapeutic Changing Mode of Locally Therapy During 1L Lorlatinib Treatment in Unresectable ALK+ NSCLC Patients,Lorlatinib 100 mg,['Lorlatinib 100 mg'],1,OBSERVATIONAL,[],,,"Lung Cancer, Non-Small Cell","['Lung Cancer, Non-Small Cell']",[],NOT_YET_RECRUITING,,2024-11-10,2030-10-31,"[{'measure': 'Time-to treatment discontinuation (TTD)', 'description': 'Time-to treatment discontinuation is defined as the time from start of treatment to the date of discontinuation of these therapeutic methods.', 'timeFrame': 'From November 2024 to April 2027'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'proportion of patients with a Complete Response (CR) or Partial Response (PR) as a best response during the lorlatinib treatment. Responses to treatment will be defined according to investigator', 'timeFrame': 'From November 2024 to April 2027'}, {'measure': 'Duration of response (DOR)', 'description': 'time between the first documentation of objective response and the first documentation of disease progression or death from any cause whichever occurred first, for participants with a confirmed objective response of CR or PR.', 'timeFrame': 'From November 2024 to April 2027'}, {'measure': 'Time to Progression (TTP)', 'description': ""Based on Investigator's Assessment"", 'timeFrame': 'From November 2024 to April 2027'}, {'measure': 'Intracranial Objective Response Rate (IC-ORR)', 'description': 'proportion of patients with intracranial objective response of complete response (CR) or partial response (PR) as a best response in the subset of patients with at least 1 intracranial lesion assessed by investigator.', 'timeFrame': 'From November 2024 to April 2027'}, {'measure': 'Intracranial Time to Progression (IC-TTP)', 'description': 'Time from inclusion to the date of the first documentation of disease progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases.', 'timeFrame': 'From November 2024 to April 2027'}, {'measure': 'Overall Survival (OS)', 'description': 'Time from inclusion to date of death from any cause.', 'timeFrame': 'From November 2024 to April 2027'}, {'measure': 'Safety: To explore the adverse events (AEs), the dose modification and the reason for interruption or discontinuation of lorlatinib in first line for Chinese patients with ALK-positive locally advanced or metastatic NSCLC recorded in medical records', 'timeFrame': 'From November 2024 to April 2027'}, {'measure': 'Proportion of patients experiencing a 10-points change from baseline in total score for the EORTC QLQ-C30', 'description': 'evaluate Health-related Quality of life (HRQoL) of ALK- positive locally advanced or metastatic NSCLC patients treated with lorlatinib in first-line using the EORTC QLQ-C30 questionnaires', 'timeFrame': 'From November 2024 to April 2027'}, {'measure': 'Dynamic molecular response', 'description': 'Mutational Analysis; measured by next-generation sequencing (NGS) if available in real world setting;', 'timeFrame': 'From November 2024 to April 2027'}, {'measure': 'Safety and tolerability of the therapeutic changing mode', 'description': 'Safety profile according to CTCAE v.5', 'timeFrame': 'From November 2024 to April 2027'}]",11,18 Years,,ALL,False,Peking University Cancer Hospital & Institute,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:20.966315,v2_robust,False,True,False,False,True,
NCT01766154,Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function,"A Pharmacokinetic, Pharmacodynamic, and Safety Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Normal Renal Function and Subjects With Moderate-to-Severe Renal Impairment With Non-Dialysis-Dependent Renal Insufficiency (NDDRI)",Tirofiban,"['Aggrastat', 'Tirofiban']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Renal Insufficiency,['Renal Insufficiency'],"['tirofiban', 'pharmacokinetic', 'renal insufficiency', 'Phase 1', 'pharmacodynamic']",COMPLETED,,2013-01,2013-03,"[{'measure': 'An analysis of tirofiban plasma concentration in normal, moderate and severe renal impaired adult subjects following a single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg).', 'timeFrame': ""Subject's participation in this study will last 3 days (confinement of 48 hours).""}]","[{'measure': 'An analysis of platelet aggregation inhibition in normal, moderate and severe renal impaired adult subjects following a single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg).', 'timeFrame': 'Baseline (prior to administration of tirofiban), 15 minutes, 1 hour, and 6 hours following the end of the tirofiban administration.'}]",2,18 Years,85 Years,ALL,True,Medicure,INDUSTRY,0,25.0,ACTUAL,2025-09-01T16:18:20.966337,v2_robust,True,True,True,False,False,
NCT06712654,"A Study to Evaluate Safety, Tolerability and Efficacy of AP306 At Fixed Doses in Patients with Hyperphosphatemia","A Phase 2b, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Serum Phosphate Lowering Effect of Fixed Dosed AP306 in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia",AP306 75mg TID,"['AP306 100mg TID', 'AP306 150mg BID', 'AP306 75mg TID', 'AP306 125mg BID', 'AP306 125mg TID', 'Placebo TID']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Hyperphosphatemia,"['Hyperphosphatemia', 'Chronic Kidney Disease Requiring Hemodialysis']",[],NOT_YET_RECRUITING,,2025-04-10,2025-12-30,"[{'measure': 'To evaluate the efficacy of AP306 assessed by serum phosphate lowering', 'description': 'The change in serum phosphate from the baseline to the end of treatment or before the initiation of rescue therapy', 'timeFrame': '12 weeks'}]",[],1,18 Years,,ALL,False,Alebund Pharmaceuticals,INDUSTRY,0,144.0,ESTIMATED,2025-09-01T16:18:20.966380,v2_robust,True,True,False,False,False,
NCT03519854,"Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).","A Multi-center, Randomized, Assessor-blinded, Placebo Controlled, Phase II, Parallel Dose-finding Trial in Male Subjects of ASA 1-2 to Assess the Efficacy, Safety and Pharmacokinetics of 5 Doses of Org 25969 When Administered After 0.6 mg.Kg-1 Esmeron® at 3, 5 or 15 Minutes",Placebo,"['Esmeron®', 'Sugammadex', 'Placebo', 'Org 25969; MK-8616; Bridion®.', 'Rocuronium bromide']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Neuromuscular Blockade,['Neuromuscular Blockade'],[],COMPLETED,,2002-12-01,2003-06-01,"[{'measure': 'Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.9', 'description': 'Mean time from start of study treatment administration to recovery of participant T4/T1 ratio to 0.9 was assessed through the repeated application (every 15 seconds) of an electrical stimulation protocol. Specifically, 4 electrical stimulations were applied to the ulnar nerve and the magnitude of the twitch response of the adductor pollicis muscle (i.e. thumb twitch response) was assessed. With T4 and T1 referring to the respective magnitude of the fourth and first thumb twitch during nerve stimulation, the T4/T1 ratio indicates the current degree of neuromuscular blockade (NMB) present in the participant as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Further, reduced recovery time of the T4/T1 ratio to 0.9 indicates faster recovery from NMB. Summary data, originally presented in the format of units ""minutes:seconds"" (mm:ss), was reformatted to be presented in the single unit of ""minutes"" (min).', 'timeFrame': 'Up to 70 minutes following administration of study treatment'}]","[{'measure': 'Mean Heart Rate at Baseline', 'description': 'Mean heart rate at baseline was assessed. Baseline heart rate was defined as the heart rate measured under stable anesthesia prior to administration of study treatment.', 'timeFrame': 'Up to 45 minutes prior to study treatment administration'}, {'measure': 'Mean Heart Rate at 2 Minutes Following Administration of Study Treatment', 'description': 'Mean heart rate at 2 minutes following administration of study treatment was assessed.', 'timeFrame': '2 minutes following administration of study treatment'}, {'measure': 'Mean Heart Rate at 30 Minutes Following Administration of Study Treatment', 'description': 'Mean heart rate at 30 minutes following administration of study treatment was assessed.', 'timeFrame': '30 minutes following administration of study treatment'}, {'measure': 'Mean Corrected QT Interval (QTc) at Baseline', 'description': ""Mean QTc interval at baseline was assessed. Baseline QTc interval was defined as the QTc interval measured under stable anesthesia prior to administration of study treatment. The baseline QTc interval is corrected for participant heart rate at baseline prior to study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)\\^(1/3). RR interval = 60/heart rate."", 'timeFrame': 'Up to 45 minutes prior to study treatment administration'}, {'measure': 'Mean Corrected QT Interval (QTc) at 2 Minutes Following Administration of Study Treatment', 'description': ""Mean QTc interval at 2 minutes following administration of study treatment was assessed. The QTc interval is corrected for participant heart rate at 2 minutes following study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)\\^(1/3). RR interval = 60/heart rate."", 'timeFrame': '2 minutes following administration of study treatment'}, {'measure': 'Mean Corrected QT Interval (QTc) at 30 Minutes Following Administration of Study Treatment', 'description': ""Mean QTc interval at 30 minutes following administration of study treatment was assessed. The QTc interval is corrected for participant heart rate at 30 minutes following study treatment administration using Fridericia's correction, where QTc = QT interval/(RR interval)\\^(1/3). RR interval = 60/heart rate."", 'timeFrame': '30 minutes following administration of study treatment'}, {'measure': 'Number of Participants Experiencing an Adverse Event', 'description': 'The number of participants experiencing an adverse event (AE) was assessed. An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product.', 'timeFrame': 'Up to 7 days following administration of study treatment'}]",8,18 Years,64 Years,MALE,False,Merck Sharp & Dohme LLC,INDUSTRY,0,99.0,ACTUAL,2025-09-01T16:18:20.966389,v2_robust,True,True,True,False,True,
NCT02297854,Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition,"Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Cross Over, Single Dose, Oral Bioequivalence Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition",Valganciclovir Hydrochloride,"['Valcyte', 'Valganciclovir Hydrochloride']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2011-07,2011-08,"[{'measure': 'Area under curve (AUC)', 'timeFrame': '0.00 and at 0.167, 0.333, 0.50, 0.667, 0.833, 1.00, 1.25, 1.50, 1.75, 2.00, 2.333, 2.667, 3.00, 3.333, 3.667, 4.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post dose'}]",[],1,18 Years,55 Years,ALL,True,Dr. Reddy's Laboratories Limited,INDUSTRY,0,83.0,ACTUAL,2025-09-01T16:18:20.966428,v2_robust,True,True,True,False,False,
NCT01941654,ATOM_local Ablative Therapy,A Single-arm Phase II Study to Determine the Efficacy of Preemptive Local Ablative Therapy to Residual Metabolic Active Oligo-metastases in Those EGFR Mutation Positive Non-small Cell Lung Cancer Patients Who Have Achieved a Good Partial Response With First-line EGFR TKI (ATOM),Oral TKI,['Oral TKI'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,NSCLC,"['NSCLC', 'Activating EGFR Mutation']",[],COMPLETED,,2013-09-18,2020-05-28,"[{'measure': 'PFS rate at 1 year', 'timeFrame': '2 years'}]","[{'measure': 'Overall survival', 'timeFrame': '2 years'}, {'measure': 'Progression-free survival', 'timeFrame': '2 years'}, {'measure': 'radiologic change on PET-CT scan 3 months after SABR', 'timeFrame': '3 months'}, {'measure': 'Number of Participants with Adverse Events as a Measure of safety', 'timeFrame': '2 years'}]",5,18 Years,,ALL,False,Chinese University of Hong Kong,OTHER,1,18.0,ACTUAL,2025-09-01T16:18:20.966461,v2_robust,True,True,True,False,True,
NCT00206154,"A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients","A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT® pMDI 2 x 160/4.5 µg & 80/4.5 µg Bid Compared to Formoterol TBH, Budesonide pMDI (& the Combination) & Placebo in COPD Patients",Budesonide/formoterol pMDI,"['Budesonide/formoterol pMDI', 'Formoterol Turbuhaler', 'Budesonide pMDI']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Obstructive Pulmonary Disease,['Chronic Obstructive Pulmonary Disease'],[],COMPLETED,,2005-04,2006-12,[{'measure': 'Pre-dose and 1-hour post-dose FEV1 over the 6 months treatment period'}],"[{'measure': 'Patient-reported outcome variables regarding disease status (incl. PEF), collected via questionnaires and diaries'}, {'measure': 'Health care utilization'}, {'measure': 'Pharmacokinetics (subgroup)'}, {'measure': 'Safety variables, including adverse events, vital signs, ECG, physical examination, hematology, and clinical chemistry.'}, {'measure': '- all variables assessed over the 6 months treatment period'}]",6,40 Years,,ALL,False,AstraZeneca,INDUSTRY,0,1500.0,ESTIMATED,2025-09-01T16:18:20.966482,v2_robust,True,True,True,False,True,
NCT03779854,Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant,Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults,Thiotepa,"['Busulfanum', 'Claphene', '2-Fluoro-9-beta-arabinofuranosyladenine', 'Thiophosphoramide', 'Carloxan', 'Prograf', 'Rheumatrex', '1,1\',1""-phosphinothioylidynetrisaziridine', 'Busulphan', 'Bussulfam', 'Protopic', 'Tepadina', 'Cicloxal', 'Ciclofosfamide', 'Fujimycin', 'Busulfan', 'Emtexate', 'Cycloblastin', 'Cyclophosphamide', 'Misulban', 'Emthexat', 'Farmitrexat', 'Alpha-Methopterin', 'Fludarabine', 'Thiotepa', 'Tacrolimus', 'Medsatrexate', 'Methotrexate', 'Thiofosfamide', 'Thiofozil', 'Methoblastin', 'Thio-Tepa', 'STEPA', '2-Fluorovidarabine', 'Misulfan', 'Clafen', 'Hecoria', 'Abitrexate', 'Thiophosphamide', 'Oncotiotepa', 'triethylenethiophosphoramide', 'Emthexate', 'Brimexate', 'Tespamine', 'Busulfex', 'Cytophosphane', 'Amethopterin', 'Ciclofosfamida', 'Mitosan', 'Myeleukon', 'Fluradosa', 'Tespamin']",52,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Biphenotypic Leukemia,"['Acute Biphenotypic Leukemia', 'Acute Leukemia', 'Acute Leukemia of Ambiguous Lineage', 'Acute Lymphoblastic Leukemia', 'Acute Undifferentiated Leukemia', 'Allogeneic Hematopoietic Stem Cell Transplantation Recipient', 'Blastic Plasmacytoid Dendritic Cell Neoplasm', 'Blasts Under 25 Percent of Bone Marrow Nucleated Cells', 'Blasts Under 5 Percent of Bone Marrow Nucleated Cells', 'Mixed Phenotype Acute Leukemia', 'Myelodysplastic Syndrome With Excess Blasts-1', 'Myelodysplastic Syndrome/Acute Myeloid Leukemia', 'Burkitt Leukemia', 'Chronic Monocytic Leukemia', 'Lymphoblastic Lymphoma', 'Mast Cell Leukemia', 'Myeloproliferative Neoplasm']",[],RECRUITING,,2019-08-29,2027-12-31,"[{'measure': 'Feasibility achievement', 'description': 'Success defined as achievement of cell selection goals for two consecutive Naive T cells (TN)-depleted peripheral blood stem cells (PBSC) hematopoietic cell transplantation (HCTs) at each study site (Feasibility)', 'timeFrame': 'Up to 2 years'}, {'measure': 'Engraftment of neutrophils by day 28 (Feasibility)', 'description': 'Success defined as achievement neutrophil engraftment (absolute neutrophil count \\[ANC\\] \\>= 500/mm\\^3) on first day of three consecutive laboratory values obtained on different days.', 'timeFrame': 'At day 28'}, {'measure': 'Current-graft versus host disease (GVHD)-free, relapse-free survival (Randomized Controlled Trial [RCT])', 'description': 'Defined as alive, no relapse after HCT, no current GVHD requiring prednisone, no graft rejection or graft failure. The proportion of subjects meeting the primary endpoint will be described in each arm with 90% confidence intervals (CI) and compared between arms using the chi-square test. A two-sided 10% significance level will be used for this comparison.', 'timeFrame': 'At 1 year'}]","[{'measure': 'Chronic GVHD (cGVHD) meeting National Institutes of Health (NIH) criteria and requiring prednisone (RCT)', 'description': ""Cumulative incidence curve will be computed for each arm along with a 90% CI at 1 year and 2 years post-HCT. Death and/or relapse prior to occurrence of cGVHD will be considered as competing risks. The cumulative incidence curves will be compared between arms using Gray's test. The maximum severity of cGVHD will also be described in each arm and compared using the chi-squared test."", 'timeFrame': 'At 1 and 2 years'}, {'measure': 'Proportion of subjects alive and off prednisone (or equivalent systemic corticosteroid) for treatment of GVHD (RCT)', 'description': 'Proportions of subjects alive without requiring use of prednisone (or equivalent systemic corticosteroid) for GVHD will be estimated with 90% CI for both arms at time points over 24 months, and compared using the chi-squared test.', 'timeFrame': 'At 3, 6, 9, 12, 15, 18, 21 and 24 months post HCT'}]",5,6 Months,26 Years,ALL,True,Fred Hutchinson Cancer Center,OTHER,1,68.0,ESTIMATED,2025-09-01T16:18:20.966651,v2_robust,True,True,False,False,False,
NCT01646554,Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases,BOS3: Randomized Phase II/III Trial Evaluating the Efficacy of FOLFOX Alone Versus FOLFOX Plus Aflibercept in K-ras Mutant as Perioperative Treatment in Patients With Resectable Liver Metastases From Colorectal Cancer.,Modified FOLFOX6,"['5-FU, folinic acid, oxaliplatin', 'Modified FOLFOX6']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Colorectal Cancer Metastatic,"['Colorectal Cancer Metastatic', 'Liver Metastases', 'KRAS Mutated Colorectal Cancer']","['Liver metastases', 'Colorectal Cancer', 'KRAS mutated', 'FOLFOX', 'Aflibercept', 'Randomized', 'Phase II-III', 'Perioperative treatment', 'Adjuvant', 'Neo-adjuvant', 'Surgery', 'Progression Free Survival']",WITHDRAWN,,2012-12,2016-12,"[{'measure': 'Progression free survival', 'description': 'Increase in progression free survival rate at 1 year in the experimental arm (mFOLFOX6 + aflibercept) compared to mFOLFOX6 alone arm.', 'timeFrame': '1 year'}]","[{'measure': 'Pathological response rate', 'description': 'Increase in major pathological response rate between mFOLFOX6 alone arm and each experimental arm.', 'timeFrame': '4 years'}, {'measure': 'Resection rate', 'description': 'Compare the percentage of patients with total resection with these three treatments.', 'timeFrame': '4 years'}, {'measure': 'Overall survival', 'description': 'Overall survival is defined as the time interval between the date of randomization and the date of death. Patients who are still alive when last traced will be censored at the date of last follow-up.', 'timeFrame': '8 years'}, {'measure': 'Safety', 'description': 'All adverse events will be recorded; the investigator will assess whether those events are drug related (reasonable possibility, no reasonable possibility) and this assessment will be recorded in the database for all adverse events.', 'timeFrame': '4 years'}]",5,18 Years,75 Years,ALL,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,1,0.0,ACTUAL,2025-09-01T16:18:20.966720,v2_robust,True,True,False,True,True,
NCT03516305,Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smokers Versus Non-Smokers,"A Phase 1 Open-Label, Non-Randomized, Single-Dose, Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smoker Versus Non-Smoker Healthy Adult Volunteers",Staccato Alprazolam 1 mg,['Staccato Alprazolam 1 mg'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2018-04-06,2018-08-01,"[{'measure': 'Pharmacokinetics (PK) : Maximum observer drug concentration (Cmax)', 'description': 'Cmax of alprazolam in smokers compared to non-smokers', 'timeFrame': 'Sequential time points : pre-dose, and at 2, 5, 10 and 30 minutes, and at 1, 2, 4, 6, 12, 24 and 36 hours post-dose.'}, {'measure': 'PK: Area under the concentration versus time curve (AUC)from Zero to Infinity (AUC[0-∞]', 'description': 'AUC\\[0-∞\\] of alprazolam in smokers compared to non-smokers', 'timeFrame': 'Sequential time points : pre-dose, and at 2, 5, 10 and 30 minutes, and at 1, 2, 4, 6, 12, 24 and 36 hours post-dose.'}]","[{'measure': 'PK;: time after administration of a drug when the maximum plasma concentration is reached (Tmax)', 'description': 'Tmax of alprazolam in smokers compared to non-smokers', 'timeFrame': 'Sequential time points : pre-dose, and at 2, 5, 10 and 30 minutes, and at 1, 2, 4, 6, 12, 24 and 36 hours post-dose.'}, {'measure': 'PK: half-life (t1/2)', 'description': 't1/2 of alprazolam in smokers compared to non-smokers', 'timeFrame': 'Sequential time points : pre-dose, and at 2, 5, 10 and 30 minutes, and at 1, 2, 4, 6, 12, 24 and 36 hours post-dose.'}]",4,21 Years,50 Years,ALL,True,"Engage Therapeutics, Inc.",INDUSTRY,1,36.0,ACTUAL,2025-09-01T16:18:20.966827,v2_robust,True,True,True,False,False,
NCT03673605,Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin,Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin in Patients With Atrial Fibrillation and Mitral Stenosis Among Pakistani Population,Rivaroxaban 15 mg,"['Warfarin', 'Rivaroxaban 15 mg']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Mitral Valve Stenosis,"['Mitral Valve Stenosis', 'Atrial Fibrillation']",[],WITHDRAWN,No patients Enrollment,2016-12-30,2017-12-30,"[{'measure': 'Number of Participants With Intracranial Bleeding and/or Recurrent Ischemic Lesion as Confirmed by MRI Imaging', 'description': 'Intracranial bleeding: symptomatic hemorrhage confirmed by CT or MRI or asymptomatic hemorrhage on follow-up GRE or SWI imaging at 1 month Recurrent ischemic lesion: symptomatic ischemic stroke confirmed by relevant neuroimagings or asymptomatic recurrent ischemic lesion on follow-up or FLAIR imaging at 12 month', 'timeFrame': '12 months'}]","[{'measure': 'Adverse effects/complications of Rivaroxiban as compared to Warfarin in patients with Mitral Stenosis and AF.', 'timeFrame': '12 months'}]",2,18 Years,55 Years,ALL,False,PharmEvo Pvt Ltd,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:20.966847,v2_robust,True,True,False,True,True,No patients Enrollment
NCT02454205,An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis,Evaluating a New Treatment Regimen for Patients With Multidrug-resistant TB (MDR-TB) - a Prospective Open-label Randomised Controlled Trial,Linezolid,"['Isoniazid', 'Kanamycin', 'Levofloxacin', 'Linezolid', 'Moxifloxacin', 'Pyrazinamide', 'PZA', 'Ethionamide', 'Bedaquiline', 'Terizidone', 'INH']",11,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Tuberculosis,"['Tuberculosis', 'Multidrug Resistant Tuberculosis', 'Extensively-drug Resistant Tuberculosis']",[],COMPLETED,,2015-11-12,2021-08-30,"[{'measure': 'Treatment success', 'description': 'In the conventional arm treatment success is defined as the sum of cured or treatment completed cases. In the intervention arm treatment success is defined as the sum of cured and treatment completed cases, without subsequent relapse, re-infection or death during the 15-18 month follow up period.', 'timeFrame': '24 months after initiation of treatment in either arm.'}]","[{'measure': 'Favourable outcome rate', 'timeFrame': 'At 6-9 months for the intervention arm and 21-24 months for the conventional arm.'}, {'measure': 'Time specific rate of treatment failure.', 'timeFrame': '6-36 months'}, {'measure': 'Time specific culture conversion proportions and rates.', 'timeFrame': '6-36 months'}, {'measure': 'Time specific relapse rate.', 'timeFrame': '6-36 months.'}, {'measure': 'Rate of re-infection.', 'timeFrame': '6-36 months.'}, {'measure': 'All cause mortality', 'timeFrame': '0-36 months.'}, {'measure': 'Composite measure of QT interval on ECG, grade 3 and 4 adverse events, stopping drugs Safety and tolerability end-points.', 'timeFrame': '0-36 months.'}, {'measure': 'Default rate', 'description': 'Rate at which participants interrupt treatment for two or more consecutive months for any reason without medical approval.', 'timeFrame': '2-24 months'}, {'measure': 'Rate of loss of follow-up.', 'description': 'Rate at which a participant becomes untraceable at any point in the study, and remains untraceable at completion of study despite every effort being made by researchers to locate the participant.', 'timeFrame': '0-36 months.'}]",10,18 Years,,ALL,False,University of Cape Town,OTHER,4,154.0,ACTUAL,2025-09-01T16:18:20.966875,v2_robust,True,True,True,False,True,
NCT00502905,Busulfan and Fludarabine in Patients With AML and MDS,A Phase II Study of High-Dose Intravenous Busulfan and Fludarabine With Allogeneic Marrow and Peripheral Blood Progenitor Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes,Busulfan,"['Fludara', 'Fludarabine Phosphate', 'Busulfex', 'Myleran', 'Busulfan', 'Fludarabine']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Leukemia,['Leukemia'],"['Acute Myeloid Leukemia', 'Myelodysplastic Syndromes', 'Busulfan', 'Busulfex', 'Myleran', 'Fludarabine', 'Fludarabine Phosphate', 'Fludara']",COMPLETED,,2003-10,2008-11,"[{'measure': 'Number of Participants With Successful Engraftment', 'description': 'Successful Engraftment defined as first of 3 consecutive days with Absolute neutrophil count (ANC) equal to or more than 0.5 \\* 10\\^9/L. Failure to engraft by day +30 considered primary engraftment failure. Study period one week prior to transplant through post Day 28.', 'timeFrame': 'Study period one week prior to transplant through post Day 28'}]",[],1,,66 Years,ALL,False,M.D. Anderson Cancer Center,OTHER,0,200.0,ACTUAL,2025-09-01T16:18:20.966924,v2_robust,True,True,True,False,False,
NCT05631405,Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study),Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone,Dexamethasone,"['Dexamethasone', 'Placebo']",2,INTERVENTIONAL,['NA'],,,Severe Dengue,['Severe Dengue'],"['Severe Dengue', 'Dexamethasone', 'Steroid']",RECRUITING,,2022-10-16,2026-12-31,"[{'measure': 'Mortality', 'description': 'The use of steroids in dengue will reduce mortality in rate', 'timeFrame': '28 days'}]","[{'measure': 'Length of hospital stay', 'description': 'The use of steroids in dengue will reduce Length of hospital stay in day', 'timeFrame': '28 days'}]",2,7 Years,99 Years,ALL,False,Chulalongkorn University,OTHER,0,200.0,ESTIMATED,2025-09-01T16:18:20.966959,v2_robust,True,True,False,False,False,
NCT01584505,Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD,"Randomized, Double-Blind, Active Controlled, 3-Arm Parallel Group, Multi-National, Multi-Centre Study To Evaluate The Cardiac Safety Of Two Doses Of CHF5993 BID Delivered Via HFA PMDI Both Combined With CHF1535 BID Delivered Via HFA PMDI Versus CHF1535 BID Delivered Via HFA PMDI In Patients With Moderate To Severe COPD",CHF1535 + CHF5992 dose 1 BID,"['CHF1535 + CHF5992 dose 1 BID', 'CHF1535 + CHF5992 dose2 BID', 'CHF1535 daily dose']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),['Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)'],['COPD'],COMPLETED,,2012-04,2013-01,"[{'measure': 'Change from baseline in average 24-hour heart rate at Final visit', 'description': 'To assess the effect on change from baseline in average 24h Heart Rate at Day 14 of study treatment', 'timeFrame': 'Day 14 of study treatment'}]","[{'measure': 'Heart Rate and ECG parameters variation', 'description': 'Pre and post-dose', 'timeFrame': 'Day 1 and Day 14 of Study Treatment'}]",2,40 Years,80 Years,ALL,False,Chiesi Farmaceutici S.p.A.,INDUSTRY,0,191.0,ACTUAL,2025-09-01T16:18:20.967088,v2_robust,True,True,True,False,False,
NCT06362005,The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus,The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus (Randomized Clinical Trial),Triamcinolone Acetonide 0.1% Oint,"['Group IV', 'Selenium& Tacrollimus topical', 'Tacrollimus Topical', 'Selenium & Triamcinolone Acetonide 0.1% Oint', 'Triamcinolone Acetonide 0.1% Oint', 'Group I', 'Group V', 'Group III', 'Selenium', 'Group II']",10,INTERVENTIONAL,['PHASE4'],PHASE4,,"Lichen Planus, Oral","['Lichen Planus, Oral']","['seleinum', 'Antioxidant', 'Glutathione-S-transferases', 'Reactive oxygen species']",ACTIVE_NOT_RECRUITING,,2024-05-01,2025-10-01,"[{'measure': 'to assess a visual analog scale (VAS)of the oral lichen planus lesion', 'description': 'qualitative', 'timeFrame': 'baseline, 1, 3 and 6 months after treatment'}]","[{'measure': 'to assess The associated Oral Disease Severity Score 3- Glutathione biomarker level as an antioxidant enzyme in saliva by ELISA analysis', 'description': 'qualitative ,and quantitiave', 'timeFrame': 'baseline, 1, 3 and 6 months after treatment'}, {'measure': 'Biochemical evaluation of salivary Glutathione level using (ELISA)', 'description': 'Quantity', 'timeFrame': 'baseline, 1, 3 and 6 months after treatment'}]",3,20 Years,55 Years,ALL,False,Al-Azhar University,OTHER,1,20.0,ESTIMATED,2025-09-01T16:18:20.967100,v2_robust,True,True,False,False,False,
NCT02569905,Effect of Parecoxib Sodium and Flurbiprofen Injection on Postoperative Shivering,"Tumor Hospital of Guangxi Medical University, China",parecoxib sodium,"['flurbiprofen', 'parecoxib sodium', 'saline']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Postoperative Shivering,['Postoperative Shivering'],"['flurbiprofen', 'Parecoxib sodium', 'Postoperative Shivering']",COMPLETED,,2014-04,2015-04,"[{'measure': 'shivering', 'timeFrame': 'in one hour after extubation.'}]","[{'measure': 'visual analogue score', 'timeFrame': 'at the time of extubation, 30min and 60min after extubation.'}, {'measure': 'sedation scores', 'timeFrame': 'at the time of extubation, 30min and 60min after extubation.'}, {'measure': 'incidence of postoperative nausea and vomiting', 'timeFrame': 'in one hour after extubation.'}]",4,21 Years,62 Years,ALL,True,Guangxi Medical University,OTHER,0,166.0,ACTUAL,2025-09-01T16:18:20.967112,v2_robust,True,True,True,False,False,
NCT02993705,Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS),Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS),Trabectedin,"['Yondelis', 'Trabectedin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Carcinosarcoma, Ovarian","['Carcinosarcoma, Ovarian', 'Carcinosarcomas Uterine']",[],COMPLETED,,2017-02-22,2019-11-13,"[{'measure': 'Objective response rate (ORR)', 'description': 'The primary endpoint of this study is to evaluate the activity of trabectedin in terms of the objective response rate (ORR) in patients with advanced uterine and ovarian carcinosarcoma.', 'timeFrame': 'three years'}]","[{'measure': 'Duration of response', 'timeFrame': 'three years'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'the diagnosis of progression will be assessed by radiological criteria; CA 125 increases alone (GCIG criteria of progression) will not be considered as progression of disease without a radiological confirmation of progression', 'timeFrame': 'three years'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'three years'}, {'measure': 'Adverse events', 'description': 'Incidence of adverse events, according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) v 4.03.', 'timeFrame': 'three years'}]",5,18 Years,100 Years,FEMALE,False,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,OTHER,0,45.0,ACTUAL,2025-09-01T16:18:20.967152,v2_robust,True,True,True,False,True,
NCT01890005,Low Dose Aspirin for the Prevention of Preeclampsia,"Low Dose Aspirin Between 13 and 16 Weeks of Pregnancy for the Prevention of Preeclampsia. Double Blind, Randomized, Controlled Trial.",Aspirin,"['Aspirin', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Preeclampsia,['Preeclampsia'],"['Preeclampsia', 'Low dose aspirin', 'Fetal growth restriction', 'Neonatal death', 'Stillbirth', 'Abruptio placenta']",UNKNOWN,,2013-07,2014-01,"[{'measure': 'Prevention of preeclampsia', 'description': 'The number of cases of preeclampsia that appear in both groups before 34 weeks of pregnancy', 'timeFrame': '6 months'}]","[{'measure': 'Prevention of preeclampsia at term', 'description': 'The number of cases of preeclampsia that appear in both groups between 37 and 41 weeks of pregnancy.', 'timeFrame': '6 months'}, {'measure': 'Stillbirth', 'description': 'The number of cases of stillbirths that appear in both groups at any given time during pregnancy.', 'timeFrame': '6 months'}, {'measure': 'Neonatal deaths', 'description': 'The number of cases of neonatal deaths that appear in both groups, regardless of the cause.', 'timeFrame': '6 months'}, {'measure': 'Neonatal intensive care unit admissions.', 'description': 'The number of cases that require admittance to the Neonatal Intensive Care Unit in both groups in the first 28 days after birth.', 'timeFrame': '28 days'}, {'measure': 'Abruptio placenta', 'description': 'The number of cases of abruptio placenta that appear in both groups at any given time during pregnancy.', 'timeFrame': '6 months'}, {'measure': 'Fetal Growth Restriction', 'description': 'The number of cases of fetal growth restriction, defined as a fetal weight below the 10th percentile and an abnormal umbilical cord doppler that appear in both groups at any given time during pregnancy.', 'timeFrame': '6 months'}]",7,,,FEMALE,False,"Saint Thomas Hospital, Panama",OTHER,0,476.0,ESTIMATED,2025-09-01T16:18:20.967173,v2_robust,True,True,False,False,False,
NCT00551005,Etoposide and Celecoxib in Patients With Advanced Cancer,Phase I Trial of Oral Etoposide in Combination With Celecoxib in Patients With Advanced Malignancies,celecoxib,"['etoposide', 'celecoxib']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Unspecified Adult Solid Tumor, Protocol Specific","['Unspecified Adult Solid Tumor, Protocol Specific']","['unspecified adult solid tumor, protocol specific']",COMPLETED,,2001-12,2012-02,"[{'measure': 'Toxicity'}, {'measure': 'Maximum tolerated dose'}, {'measure': 'Survival'}, {'measure': 'Time to failure'}]",[],4,18 Years,,ALL,False,City of Hope Medical Center,OTHER,1,58.0,ACTUAL,2025-09-01T16:18:20.967192,v2_robust,True,True,True,False,False,
NCT03768505,Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL),"A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study)",Zandelisib (ME-401),['Zandelisib (ME-401)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Follicular Lymphoma (FL),"['Follicular Lymphoma (FL)', 'Non Hodgkin Lymphoma', 'Marginal Zone Lymphoma']",[],TERMINATED,discontinuation of zandelisib program,2019-06-25,2023-03-24,"[{'measure': 'Objective Response Rate (ORR) of ME-401 in Relapsed or Refractory FL or MZL', 'description': 'ORR is measured as the proportion of subjects achieving the best response rating of CR or PR prior to first PD', 'timeFrame': '3 years 9 months'}]","[{'measure': 'Duration of Response (DOR)', 'description': 'Duration of Response will be measured as the time from documentation from CR or PR to time of disease progression', 'timeFrame': '3 years 9 months'}, {'measure': 'Complete Response (CR) Rate', 'description': 'Complete response rate will be measured by the number of subjects that achieve CR', 'timeFrame': '3 years 9 months'}, {'measure': 'Progression-free Survival (PFS)', 'description': 'Progression-free survival will be measurement of time from initiation of treatment (Day 1) until disease progression or death', 'timeFrame': '3 years 9 months'}, {'measure': 'Overall Survival', 'description': 'Overall survival will be measured as the time from initiation of treatment (Day 1) until death', 'timeFrame': '2 years'}, {'measure': 'Overall Incidence of Treatment Emergent Adverse Events (TEAEs)', 'description': 'The incidence of TEAEs is measured by the proportion of subjects with at least one TEAE.', 'timeFrame': '3 years 9 months'}, {'measure': 'PK of ME-401', 'description': 'The PK of ME-401 will be determined by the peak plasma concentration (Cmax)', 'timeFrame': '3 years 9 months'}]",7,18 Years,,ALL,False,"MEI Pharma, Inc.",INDUSTRY,0,169.0,ACTUAL,2025-09-01T16:18:20.967200,v2_robust,True,True,False,True,True,discontinuation of zandelisib program
NCT01905605,Phosphatidylcholine Supplementation in Infants,Phosphatidylcholine Supplementation in Infants With Diminished Sensory Gating,phosphatidylcholine supplementation,"['phosphatidylcholine supplementation', 'Phosphatidylcholine, phosphatidylcholine concentrate', 'Corn Oil', 'placebo']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Schizophrenia,"['Schizophrenia', 'Diminished P50 Sensory Gating']",[],WITHDRAWN,Funding not secured. IRB approval has been withdrawn as of January 2017.,2013-09,2017-01,"[{'measure': 'Ratio of P50 auditory sensory gating', 'description': 'In an auditory evoked potential paradigm while in active sleep (the infant equivalent of rapid eye movement sleep) with two identical sounds presented 500 ms apart, the ratio of the amplitude of the P50 response to the second sound divided by the amplitude of the P50 response to the first sound.', 'timeFrame': '8 weeks post initiation of treatment'}]","[{'measure': 'Incidence of adverse events', 'description': 'Percentage of infants with adverse events', 'timeFrame': '4 weeks and 8 weeks after initiation of intervention'}]",2,1 Week,7 Weeks,ALL,True,"University of Colorado, Denver",OTHER,0,0.0,ACTUAL,2025-09-01T16:18:20.967226,v2_robust,True,True,False,True,True,Funding not secured. IRB approval has been withdrawn as of January 2017.
NCT01032694,Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia,Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia,Azithromycin SR,"['Azithromycin SR', 'Amoxiclav']",2,OBSERVATIONAL,[],,,Community-Acquired Pneumonia,['Community-Acquired Pneumonia'],"['Community-Acquired Pneumonia', 'Azithromycin SR', 'Amoxiclav']",TERMINATED,"This study was terminated January 11, 2011 due to low enrollment. This study is not being terminated because of safety or efficacy concerns.",2010-04,2010-12,"[{'measure': 'Percentage of Participants With Response of Very Convenient or Somewhat Convenient', 'description': ""Participant reported outcome questionnaire was the assessment of participant's convenience with drug treatment based on following categories: very convenient or somewhat convenient and not convenient or not at all convenient. Value of 1 was reported if participant answered 'very convenient' or 'somewhat convenient' and 0 if participant answered 'not convenient' or 'not at all convenient'."", 'timeFrame': 'Days 11-12'}]","[{'measure': 'Percent Compliance With the Prescribed Treatment Regimen', 'description': 'Percent compliance with the prescribed treatment regimen was calculated as 100 multiplied by (number of tablets taken by the participant divided by number of tablets prescribed).', 'timeFrame': 'Days 11-12'}, {'measure': 'Percentage of Participants Who Were 100 Percent Compliant With Prescribed Treatment Regimen', 'description': 'Percent compliance with the prescribed treatment regimen was calculated as 100 multiplied by (number of tablets taken by the participant divided by number of tablets prescribed). Value of 1 was reported if percent compliance equals to 100, and 0 if percent compliance was non-missing and less than 100.', 'timeFrame': 'Days 11-12'}]",3,18 Years,80 Years,ALL,False,Pfizer,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:20.967237,v2_robust,False,True,False,True,False,"This study was terminated January 11, 2011 due to low enrollment. This study is not being terminated because of safety or efficacy concerns."
NCT02510794,Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration,"A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration",Ranibizumab,"['Lucentis®', 'Ranibizumab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Macular Degeneration,['Macular Degeneration'],[],COMPLETED,,2015-09-28,2019-03-28,"[{'measure': 'Time Until a Participant First Requires the Implant Refill According to Protocol-Defined Refill Criteria', 'description': 'Protocol-Defined Refill Criteria\n\nAt 1 month after initial fill:\n\n* Decrease of ≥ 10 letters in BCVA at the current visit compared with the baseline BCVA, due to nAMD disease activity OR\n* Increase in CFT of ≥ 100 um at the current visit compared with the baseline CFT, due to nAMD disease activity OR\n* Presence of new macular hemorrhage, due to nAMD disease activity\n\nFor subsequent assessments:\n\n* Increase in CFT of ≥ 75 μm on SD-OCT at the current visit compared with the average CFT over the last 2 available measurements, due to nAMD disease activity OR\n* Increase in CFT of ≥ 100 um from the lowest CFT measurement on study, due to nAMD disease activity OR\n* Decrease of ≥ 5 letters in BCVA at the current visit compared with the average BCVA over the last 2 available measurements, due to nAMD disease activity OR\n* Decrease of ≥ 10 letters from best recorded BCVA on study, due to nAMD disease activity OR\n* Presence of new macular hemorrhage, due to nAMD disease activity', 'timeFrame': 'Baseline up to approximately 38 months'}]","[{'measure': 'Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged At Month 9 and 10', 'description': 'Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. The minimum score possible is 0 and maximum possible is 100. A higher score represents better functioning.', 'timeFrame': 'Baseline, Months 9, 10'}, {'measure': 'Change From Baseline in BCVA Over Time', 'description': 'Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. The minimum score possible is 0 and maximum possible is 100. A higher score represents better functioning.', 'timeFrame': 'Baseline up to Month 10'}, {'measure': 'Adjusted Average Change From Baseline in BCVA Over Time (MMRM Analysis)', 'description': 'Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. The minimum score possible is 0 and maximum possible is 100. A higher score represents better functioning. Here, the adjusted mean from MMRM analysis is presented).', 'timeFrame': 'Baseline up to Month 10'}, {'measure': 'Change From Baseline in Central Foveal Thickness (CFT) Over Time as Assessed on Spectral Domain-Optical Coherence Tomography (SD-OCT)', 'description': 'Central foveal thickness (CFT) is defined as the retinal thickness in the center of the fovea', 'timeFrame': 'Baseline up to Month 9'}, {'measure': 'Number of Implant Clogging at Month 9', 'description': 'Removed implants identified as meeting serum PK criteria for possible clogging were assessed via lab-based investigation (in vitro drug release testing) to determine whether there was any implant clogging.', 'timeFrame': 'Month 9'}, {'measure': 'Observed Maximum Serum Concentration (Cmax) of Ranibizumab', 'description': 'The serum pharmacokinetics of ranibizumab were characterized by estimating Cmax between dose intervals. Estimates for these parameters were tabulated and summarized by descriptive statistics.', 'timeFrame': 'Predose (0 hour) on Day 1 up to 38 months'}, {'measure': 'Area Under the Concentration-Time Curve From Dosing to Last Observation (AUClast) of Ranibizumab', 'description': 'AUCLast is defined as area under the concentration-time curve from dosing (implant or refill) to last observation before next refill or exiting the study. The serum pharmacokinetics of ranibizumab were characterized by estimating AUC between dose intervals. Estimates for these parameters were tabulated and summarized by descriptive statistics.', 'timeFrame': 'Predose (0 hour) on Day 1 up to approximately 38 months (detailed timeframe is provided in description field)'}, {'measure': 'Time to Maximum Concentration (Tmax) of Ranibizumab', 'description': 'The serum pharmacokinetics of ranibizumab were characterized by estimating Tmax between dose intervals. Estimates for these parameters were tabulated and summarized by descriptive statistics.', 'timeFrame': 'Predose (0 hour) on Day 1 up to 38 months'}, {'measure': 'Terminal Half-Life (t1/2) of Ranibizumab', 'description': 'The serum pharmacokinetics of ranibizumab were characterized by estimating t1/2 between dose intervals. Estimates for these parameters were tabulated and summarized by descriptive statistics.', 'timeFrame': 'Predose (0 hour) on Day 1 up to 38 months'}, {'measure': 'Observed Steady-State Serum Concentration at the End of a Dosing Interval (Ctrough) of Ranibizumab', 'timeFrame': 'Predose (0 hour) on Day 1 up to 38 months'}, {'measure': 'Number of Participants With Ocular and Non-Ocular Adverse Events (AEs) and Serious AEs (SAEs)', 'timeFrame': 'Baseline up to approximately Month 38'}, {'measure': 'Percentage of Participants With Positive Serum Antibodies to Ranibizumab', 'timeFrame': 'Baseline up to 38 months'}]",13,50 Years,,ALL,False,"Genentech, Inc.",INDUSTRY,0,225.0,ACTUAL,2025-09-01T16:18:20.967302,v2_robust,True,True,True,False,True,
NCT02839694,Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy,Phase I Evaluation of Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in Patients Undergoing Pulmonary Metastasectomy,decitabine (DAC),"['decitabine (DAC)', 'Celecoxib', 'Tetrahydrouridine (THU)']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Neoplasm Metastasis,"['Neoplasm Metastasis', 'Sarcoma', 'Neoplasms, Germ Cell and Embryonal', 'Melanoma']","['Lung Resection', 'Surgery', 'Bilateral Lung Metastases']",WITHDRAWN,,2016-07-07,2017-04-26,"[{'measure': 'Maximum tolerated dose', 'timeFrame': '4 weeks after the start of study therapy'}, {'measure': 'Table of toxicities including type, severity, time of onset, time of resolution and probable association with study regimen', 'timeFrame': '30 days after treatment initiation'}]",[],2,18 Years,99 Years,ALL,False,National Cancer Institute (NCI),NIH,0,0.0,ACTUAL,2025-09-01T16:18:20.967362,v2_robust,True,True,False,True,False,
NCT02976766,Gypenosides Treatment for Optic Neuritis,"Gypenosides Treatment for Optic Neuritis: a Randomised, Double-blind, Placebo-controlled Trial",Gypenosides,"['Jiaogulan Zongdai', 'Placebo', 'Gypenosides']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Optic Neuritis,['Optic Neuritis'],"['Neuroprotection', 'Clinical trial', 'Traditional Chinese medicine', 'Axonal loss', 'Jiaogulan', 'Gynostemma pentaphyllum', 'Optical coherence tomography']",TERMINATED,Low enrolment,2017-02-04,2020-12-31,"[{'measure': 'Mean retinal nerve fibre layer thickness', 'timeFrame': '6 months'}]","[{'measure': 'Total macular volume', 'timeFrame': '6 months'}, {'measure': 'Best corrected visual acuity', 'timeFrame': '6 months'}, {'measure': 'Latency and amplitude of visual evoked potentials', 'timeFrame': '6 months'}, {'measure': 'Mean visual field defect', 'timeFrame': '6 months'}, {'measure': 'Number of participants with Adverse events', 'timeFrame': 'Screening until end of study'}]",6,18 Years,60 Years,ALL,False,First Affiliated Hospital of Guangxi Medical University,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:20.967436,v2_robust,True,True,False,True,True,Low enrolment
NCT03391466,Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma,"A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)","Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.","['Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.', 'Fludarabine', 'Cyclophosphamide']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL),['Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)'],[],COMPLETED,,2018-01-25,2024-11-25,"[{'measure': 'Event Free Survival (EFS) Per Blinded Central Assessment', 'description': 'EFS:Time from randomization to disease progression (PD), best response of SD up to and including Day 150, commencement of subsequent new anti-lymphoma therapy including stem cell transplant, or death from any cause. PD=score 4 (uptake moderately\\>liver)/5 (uptake markedly \\>liver and/or new lesions) with an increase in intensity of uptake from baseline;new fluorodeoxyglucose (FDG)-avid foci consistent with lymphoma at interim/EOT assessment, rather than another etiology or in bone marrow;an individual node/lesion must be abnormal with LDi \\>1.5 cm, increase by ≥50% from cross-product of LDi and perpendicular diameter nadir, increase in LDi or shortest axis perpendicular to LDi from nadir, splenic length must increase by \\>50% of extent of its prior increase beyond Baseline. If no prior splenomegaly, increase must be ≥2 cm from baseline;new/recurrent splenomegaly;new/clear progression of pre-existing NMLs;new lesion;new/recurrent bone marrow involvement. KM estimates was used for analysis.', 'timeFrame': 'From randomization date up to a median follow-up: 24.9 months'}]","[{'measure': 'Objective Response Rate (ORR) Per Blinded Central Assessment', 'description': 'ORR: Percentage of participants with CR \\[CMR;CRR\\] or PR \\[partial metabolic response (PMR); partial radiologic response (PRR)\\].CMR: PET 5PS scores of 1 (no uptake above background, 2(uptake≤mediastinum), 3(uptake\\>mediastinum but≤liver) with/without a residual mass;no new lesions; no evidence of FDG-avid disease in BM. CRR:target nodes/nodal masses regressed to ≤ 1.5 cm in LDi;no extralymphatic sites of disease;absent non-measured lesions (NMLs);organ enlargement regress to normal;no new sites;bone marrow morphology normal. PMR:scores 4 (uptake moderately\\>liver),5(uptake markedly \\> liver, new lesions) with reduced uptake compared with baseline and residual mass;no new lesions;responding disease at interim/residual disease at end of treatment (EOT).PRR: ≥50% decrease in sum of the product of perpendicular diameters (SPD) of up to 6 target measurable nodes and extra-nodal sites;absent/normal, regressed, but no increase of NMLs;spleen regressed by \\>50% in length beyond normal;no new sites.', 'timeFrame': 'From randomization date up to a median follow-up: 24.9 months'}, {'measure': 'Overall Survival (OS)', 'description': 'Overall survival is defined as the time from randomization to death from any cause. Kaplan-Meier (KM) estimates was used for analysis.', 'timeFrame': 'From randomization date up to a median follow-up: 47.2 months'}, {'measure': 'Duration of Response (DOR) Per Blinded Central Assessments', 'description': 'DOR is defined only for participants who experience an objective response after axicabtagene ciloleucel infusion and is the time from the first objective response per Lugano classification to disease progression or death from any cause. Objective response is defined in outcome measure 2 and disease progression is defined in outcome measure 1. KM estimates were used for analysis.', 'timeFrame': 'From the date of first confirmed objective response (CR or PR) to disease progression or death regardless of cause (Up to 37.8 months)'}, {'measure': 'Modified Event Free Survival (mEFS) Per Blinded Central Assessment', 'description': 'Modified event free survival is defined the same way as EFS, except that a best response of SD up to and including Day 150 assessment post randomization was not considered an event. KM estimates were used for analysis.', 'timeFrame': 'From randomization date up to a median follow-up: 24.9 months'}, {'measure': 'Event Free Survival Per Investigator Disease Assessments', 'description': 'EFS was defined as the time from randomization to the earliest date of disease progression per the IWG Lugano Classification, best response of stable disease (SD) up to and including Day 150, commencement of new lymphoma therapy, or death from any cause. Disease progression is defined in outcome measure 1.', 'timeFrame': 'From randomization date up to a median follow-up: 47.2 months'}, {'measure': 'Progression-Free Survival (PFS) Per Investigator Disease Assessments', 'description': 'PFS is defined as the time from the randomization date to the date of disease progression per Lugano classification or death from any cause. Disease progression is defined in outcome measure 1. KM estimates was used for analysis.', 'timeFrame': 'From randomization date up to a median follow-up: 47.2 months'}, {'measure': 'Modified Event Free Survival (mEFS) Per Investigator Assessment', 'description': 'Modified event free survival is defined the same way as EFS, except that a best response of SD up to and including Day 150 assessment post randomization was not considered an event. KM estimates were used for analysis.', 'timeFrame': 'From randomization date up to a median follow-up: 47.2 months'}, {'measure': 'Change From Baseline in Global Health Status Scores', 'description': 'Global health status was measured using European Organization for Research and Treatment of Cancer (EORTC) Quality Life Questionnaire (QLQ) C-30. This health related quality of life (HRQoL) questionnaire was comprised of 15 questions on functional scales, 13 questions on symptom scales and 2 on global health status scale. Global Health Status used a 7 point Likert-type scale of 1 (Very poor) to 7 (Excellent). All scores were transformed to 0-100. Higher scores for Global Health Status indicated better HRQoL.', 'timeFrame': 'Baseline, Days 50, 100, and 150; Months 9, 12, 15, 18, 21 and 24'}, {'measure': 'Change From Baseline in EORTC QLQ-C30 Physical Functioning Score', 'description': 'The EORTC QLQ-C30 is composed of global health status/QoL scale; five functional domains (physical, role, emotional, cognitive, and social); three symptom domains (fatigue, nausea and vomiting, and pain); and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).\n\nThe Physical Functioning domain includes 5 questions in which participants were asked to rate their overall health and overall quality of life as it relates to physical functioning during the past week on a scale from 1 (very poor) to 7 (excellent). The 5 scores were transformed to a scale from 0 to 100, where a high score indicated better QoL. A positive change from baseline indicates better QoL.', 'timeFrame': 'Baseline, Days 50, 100, 150, Months 9, 12, 15, 18, 21 and 24'}, {'measure': 'Changes From Baseline in the European Quality of Life Five Dimensions Five Levels Scale (EQ-5D-5L) Index Score', 'description': 'The Euro-QOL, Five Dimensions, Five Levels (EQ-5D-5L) questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L comprises 2 components: a questionnaire covering 5 dimensions and a tariff of values based upon direct valuations of health states using a visual analog scale (VAS). The total score for EQ-5D-5L index- is presented on a range from 0 to 1 where higher scores indicate better outcome. A positive change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Days 50, 100, 150; Months 9, 12, 15, 18, 21 and 24'}, {'measure': 'Change From Baseline in EQ-5D-5L VAS Scale Score', 'description': 'The EQ-5D-5L VAS is a 20-cm VAS for recording self-rated current HRQoL state and is used to describe the participants\' health status on the day of the assessment. The EQ-5D-5L VAS score is recorded by each participant for his or her current HRQoL state and scored 0 (""the worst health you can imagine"") to 100 (""the best health you can imagine""). The value 100 indicates improvement.', 'timeFrame': 'Baseline, Days 50, 100, 150; Months 9, 12, 18, 21 and 24'}, {'measure': 'Number of Participants With Anti-Axicabtagene Ciloleucel Antibodies', 'timeFrame': 'From first dose of axicabtagene up to a median follow-up: 24 months'}, {'measure': 'Percentage of Participants Experiencing Treatment-emergent Adverse Events', 'description': 'A TEAE is defined as any AE that begins on or after the first dose of study treatment (axicabtagene ciloleucel infusion or SOC), excluding bridging therapy. Participant incidence rates of TEAEs, including all, serious, fatal, CTCAE Grade 3 or higher, and treatment related AEs reported will be tabulated by preferred term and system organ class coded with the Medical Dictionary for Regulatory Activities (MedDRA).', 'timeFrame': 'Up to 5 years'}, {'measure': 'Percentage of Participants With Clinically Significant Changes in Laboratory Values Reported as Grade 3 or Higher TEAEs', 'description': 'Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening.', 'timeFrame': 'Up to 5 years'}]",15,18 Years,,ALL,False,"Kite, A Gilead Company",INDUSTRY,0,359.0,ACTUAL,2025-09-01T16:18:20.967502,v2_robust,True,True,True,False,True,
NCT02638766,Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST,"Phase II, Single Arm, Non-randomized and Multicenter Clinical Trial of Regorafenib as a Single Agent in the First-line Setting for Patients With Metastatic and/or Unresectable KIT/PDGFR Wild Type GIST",regorafenib,"['regorafenib', 'Stivarga']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastrointestinal Stromal Tumors,['Gastrointestinal Stromal Tumors'],"['metastatic', 'unresectable', 'KIT/PDGFR wild type GIST']",COMPLETED,,2015-11,2021-08-31,"[{'measure': 'Disease Control Rate', 'description': 'the sum of complete responses (CR) + partial responses (PR) + stable disease (SD).', 'timeFrame': 'every 8 weeks during 36 months'}]","[{'measure': 'Progression free survival', 'description': 'Number of months without progression', 'timeFrame': 'every 8 weeks during 36 months'}, {'measure': 'Overall survival', 'description': 'Number of months alive', 'timeFrame': 'Every 8 weeks during 36 months'}, {'measure': 'Responses determined by CHOI', 'description': 'Measure tumor size', 'timeFrame': 'every 8 weeks during 36 months'}, {'measure': 'Correlation with translational research', 'description': 'Relation between the clinical data obtained and the data obtained from translational research', 'timeFrame': 'After 36 months of recruitment'}, {'measure': 'Safety (adverse events following CTCAE v4.03)', 'description': 'Evaluation of adverse events following CTCAE v4.03', 'timeFrame': 'Every 28 days until 30 days after last dose'}, {'measure': 'Early metabolic response by PET scan', 'description': 'Evaluation of metabolic response to treatment', 'timeFrame': 'After 1 month of starting treatment'}, {'measure': 'Quality of life by EORCT QLQ C30 questionnaire', 'description': 'EORCT QLQ C30 questionnaires', 'timeFrame': 'Day 1 of each cycle. Pre-treatment administration'}, {'measure': 'Quality of life by EQ-ED-5L questionnaire', 'description': 'EQ-ED-5L questionnaires', 'timeFrame': 'Day 1 of each cycle. Pre-treatment administration'}]",9,18 Years,,ALL,False,Grupo Espanol de Investigacion en Sarcomas,OTHER,1,15.0,ACTUAL,2025-09-01T16:18:20.967667,v2_robust,True,True,True,False,True,
NCT00651066,Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam,Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in Vietnam : A Phase II Trial,rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1,"['rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2', 'rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV Infections,"['HIV Infections', 'Tuberculosis']","['HIV', 'Tuberculosis', 'Rifabutin', 'Pharmacokinetics', 'Vietnam']",COMPLETED,,2010-06,2012-09,"[{'measure': 'Area under the curve (AUC) of rifabutine measured (a)before introduction of ART;(b)after ART initiation (two different doses of RBT in combination with lopinavir/ritonavir)', 'timeFrame': '2, 5 and 8 weeks after randomisation'}]","[{'measure': 'Area under the curve (AUC) of lopinavir/ritonavir in combination with two doses of rifabutine', 'timeFrame': '5 and 8 weeks after randomisation'}, {'measure': 'Safety : proportion of patients with grade 3 and grade 4 adverse events', 'timeFrame': 'through out the trial'}]",3,18 Years,65 Years,ALL,False,French National Agency for Research on AIDS and Viral Hepatitis,OTHER_GOV,0,47.0,ACTUAL,2025-09-01T16:18:20.967706,v2_robust,True,True,True,False,True,
NCT06200766,"A Multicenter, Randomized, Double-blind, Three-arm, Parallel Clinical Endpoint Bioequivalence Study of Monometasone Furoate Nasal Spray in Patients With Seasonal Allergic Rhinitis","A Multicenter, Randomized, Double-blind, Three-arm, Parallel Clinical Endpoint Bioequivalence Study of Monometasone Furoate Nasal Spray in Patients With Seasonal Allergic Rhinitis",Mometasone furoate as a nasal spray,['Mometasone furoate as a nasal spray'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Seasonal Allergic Rhinitis,['Seasonal Allergic Rhinitis'],[],RECRUITING,,2023-08-25,2024-06-30,"[{'measure': 'Change in the mean rTNSS versus baseline rTNSS', 'description': 'The rTNSS (Reflective Total Nasal Symptom Score) is a scale used to measure nasal symptom severity based on how the patient felt during the previous 12 hours. It is measured on a scale ranging from 0 to 12. Higher scores indicate more severe nasal symptoms, while lower scores indicate less severe nasal symptoms.', 'timeFrame': '4 weeks'}]","[{'measure': 'Change in the iTNSS mean from the baseline iTNSS mean during the treatment period.', 'description': 'The iTNSS (Instantaneous Total Nasal Symptom Score) is a scale used to measure nasal symptom severity based on how the patient was feeling just before taking each dose of study medication. It is measured on a scale ranging from 0 to 12. Higher scores indicate more severe nasal symptoms, while lower scores indicate less severe nasal symptoms.', 'timeFrame': '4 weeks'}]",2,18 Years,65 Years,ALL,False,Zheng Liu ENT,OTHER,1,640.0,ESTIMATED,2025-09-01T16:18:20.967844,v2_robust,True,True,False,False,False,
NCT03408756,Comparison of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis,A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis,methotrexate,"['methotrexate', 'neotrexate', 'Folitrax']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Psoriasis Vulgaris,['Psoriasis Vulgaris'],[],UNKNOWN,,2018-04-01,2019-12-30,"[{'measure': 'Achievement of PASI 90', 'description': 'PASI 90 refers to 90 % reduction in psoriasis area severity score (PASI) compared to baseline', 'timeFrame': '12 weeks'}]","[{'measure': 'Improvement in DLQI (dermatology life quality index)', 'description': 'Improvement in DLQI (dermatology life quality index) as compared to baseline', 'timeFrame': '12 weeks'}]",2,18 Years,,ALL,False,"Post Graduate Institute of Medical Education and Research, Chandigarh",OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:20.968151,v2_robust,True,True,False,False,False,
NCT05701956,Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion,"Intravenous Tenecteplase Plus Endovascular Thrombectomy Versus Endovascular Thrombectomy Alone on 4.5 to 24 Hours After Stroke Due to Basilar Artery Occlusion -a Multicenter, Randomized Controlled, Clinical Trial",Tenecteplase,"['Tenecteplase', 'TNK-tPA', 'TNK', 'rhTNK-tPA', 'TNKase']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Basilar Artery Occlusion,"['Basilar Artery Occlusion', 'Acute Cerebrovascular Accident', 'Stroke Due to Basilar Artery Occlusion']","['Thrombectomy', 'Tenecteplase', 'Mechanical Thrombectomy']",RECRUITING,,2023-03-16,2026-03,"[{'measure': 'Proportion of patients with modified Rankin Score 0-2 at day 90 (±14 days)', 'description': 'modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)', 'timeFrame': '90 (± 14 days) after procedure'}]","[{'measure': 'Proportion of patients with modified Rankin Score 0-3 at day 90 (±14 days)', 'description': 'modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)', 'timeFrame': '90 (± 14 days) after procedure'}, {'measure': 'Ordinal Shift analysis of modified Rankin Score at day 90 (±14 days)', 'description': 'modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)', 'timeFrame': '90 (± 14 days) after procedure'}, {'measure': 'Score on the NIHSS at 24 hours', 'description': ""The NIHSS is an ordinal hierarchical scale to evaluate the severity of stroke by assessing a patient's performance. Scores range from 0 to 42, with higher scores indicating a more severe deficit."", 'timeFrame': '24 hours after procedure'}, {'measure': 'Score on the NIHSS at 5-7 days or discharge', 'description': ""The NIHSS is an ordinal hierarchical scale to evaluate the severity of stroke by assessing a patient's performance. Scores range from 0 to 42, with higher scores indicating a more severe deficit."", 'timeFrame': '5-7 days or discharge after procedure'}, {'measure': 'Proportion of patients with modified Rankin Score 0-1 at day 90 (±14 days)', 'description': 'modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)', 'timeFrame': '90 (± 14 days) after procedure'}, {'measure': 'Proportion of patients with modified Rankin Score 0-4 at day 90 (±14 days)', 'description': 'modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)', 'timeFrame': '90 (± 14 days) after procedure'}, {'measure': 'Score on the EuroQoL 5-dimensions 5-level (EQ5D-5L) at 90 days (±14 days)', 'description': 'Health-related quality of life, assessed with EQ-5D-5L', 'timeFrame': '90 (± 14 days) after procedure'}, {'measure': 'level of activities of daily living (Barthel index, BI) at 90 days (±14 days)', 'description': 'Level of activities of daily living', 'timeFrame': '90 (± 14 days) after procedure'}, {'measure': 'Successful reperfusion (Extended thrombolysis in cerebral infarction [eTICI] score 2b50-3) on digital substraction angiography (DSA) prior to thrombectomy', 'description': 'Evaluate effect of intravenous thrombolysis on reperfusion', 'timeFrame': 'within 5 minutes at angiography'}, {'measure': 'Successful reperfusion on final angiography of thrombectomy', 'description': 'Evaluate effect of thrombectomy on reperfusion', 'timeFrame': 'Within 5 minutes at final angiography of thrombectomy'}, {'measure': 'Successful recanalization on CT or MR angiography within 72 hours', 'description': 'Evaluate vascular patency after treatment', 'timeFrame': 'Within 72 hours after procedure'}, {'measure': 'Infarct volume (Posterior Circulation Acute Stroke Prognosis Early Computed Tomography Score, PC-ASPECTS) evaluated on CT or MRI within 72 hours', 'description': 'PC-ASPECTS=10 indicates a normal scan, PC-ASPECTS=0 indicates early ischemic changes or hypoattenuation in all above territories. 1 or 2 points each are subtracted for early ischemic changes or hypoattenuation in: left or right thalamus, cerebellum or posterior cerebral artery territory, respectively (1 point); any part of midbrain or pons (2 points)', 'timeFrame': 'Within 72 hours after procedure'}]",13,18 Years,,ALL,False,The First Affiliated Hospital of University of Science and Technology of China,OTHER,0,332.0,ESTIMATED,2025-09-01T16:18:20.968161,v2_robust,True,True,False,False,False,
NCT02176356,"Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)",,bimatoprost ophthalmic solution 0.03%,"['LATISSE®', 'bimatoprost ophthalmic solution 0.03%']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Facial Rhytides,"['Facial Rhytides', ""Crow's Feet Lines"", 'Glabellar Lines', 'Nasolabial Fold']",[],COMPLETED,,2014-06-30,2015-05-03,"[{'measure': 'Change From Baseline in Satisfaction With Facial Appearance Overall Using a 10-item Questionnaire', 'description': 'Participants assessed their satisfaction with the way they look right now with their entire face in mind using a 10-item questionnaire. Possible responses to each question were: 1=Very dissatisfied, 2=Somewhat dissatisfied, 3-=Somewhat satisfied and 4=Very satisfied. The responses were added across items and transformed to a Rasch scale ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Month 4'}]","[{'measure': 'Change From Baseline in Aging Appearance Using a 7-item Questionnaire', 'description': 'Participants rated how they look now using a 7-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4=Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Month 4'}, {'measure': 'Change From Baseline in Age Appraisal Using a Visual Analogue Scale (VAS)', 'description': 'Participants assessed how old they think they look compared to their actual age using a VAS by placing a mark on a number on a horizontal line where the far left of the line= -15 (look 15 years younger), 0=look current age, to the far right of the line=15 (look 15 years older). A positive change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Month 4'}, {'measure': 'Change From Baseline in Social Confidence Using an 8-item Questionnaire', 'description': 'Participants assessed their social confidence with their facial appearance in mind in the past week using an 8-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4= Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Month 4'}, {'measure': 'Change From Baseline in Psychological Well-Being Using a 10-item Questionnaire', 'description': 'Participants assessed their psychological well-being with their facial appearance in mind using a 10-item questionnaire. Possible responses for each question are 1=Definitely disagree, 2=Somewhat disagree, 3=Somewhat agree or 4= Definitely agree. The responses were added across items and transformed to a Rasch score ranging from 0 (worst) to 100 (best). A positive change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Month 4'}, {'measure': ""Participant's Self- Perception of Age (SPA)"", 'description': 'Participants assessed SPA by answering the question: How do you think your facial appearance looks compared to your age today? Participants recorded how many years younger or older they thought their facial appearance made them look. A negative result indicates improvement (a younger appearance).', 'timeFrame': 'Baseline, Month 4'}, {'measure': ""Change From Baseline in Investigator's Assessment of Severity of Glabellar Lines (GLs) at Maximum Frown Using the Facial Wrinkle Scale (FWS)"", 'description': ""The investigator assessed the severity of the participant's GLs using the 4-point FWS where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement."", 'timeFrame': 'Baseline, Month 4'}, {'measure': ""Change From Baseline in Investigator's Assessment of the Severity of Crow's Feet Lines (CFLs) at Maximum Smile Using the FWS"", 'description': ""The investigator assessed the severity of the participant's CFLs using the 4-point FWS where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement."", 'timeFrame': 'Baseline, Month 4'}, {'measure': ""Change From Baseline in Investigator's Global Eyelash Assessment Score (GEAS)"", 'description': ""The investigator assessed the participant's eyelash prominence using the 4-point GEAS where: 1=Minimal (worst), 2=Moderate, 3=Marked and 4=Very Marked (best). A positive change from Baseline indicates improvement."", 'timeFrame': 'Baseline, Month 4'}, {'measure': ""Change From Baseline in the Investigator's Assessment of the Participant's Overall Mid-Face Volume Deficit Using the 6-Point MFVDS"", 'description': 'The investigator assessed overall mid-face volume deficit using the Mid-face Volume Deficit Scale (MFVDS) where: 0=None (moon face; fullness) \\[best\\], 1=Minimal (flattening), 2=Mild (mild concavity), 3=Moderate (moderate concavity, 4=Significant (significant concavity) and 5=Severe (wasting) \\[worst\\]. A negative change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Month 4'}, {'measure': ""Change From Baseline in the Investigator's Assessment of the Participant's Nasolabial Folds Severity"", 'description': 'The investigator assessed the participants nasolabial folds severity using the 5-Point Nasolabial Fold Severity (NLFS) Scale where: 0=None (no wrinkles) \\[best\\], 1=Mild (shallow, just perceptible wrinkle), 2=Moderate (moderately deep wrinkle), 3=Severe (deep wrinkle) or 4= Extreme (very deep wrinkle). A negative change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Month 4'}, {'measure': ""Change From Baseline in the Investigator's Assessment of the Participant's Oral Commissures Severity"", 'description': ""The investigator assessed the participant's oral commissure using the 4-Point Oral Commissure Severity Scale (OCSS) where: 0=None, 1=Mild, 2=Moderate or 3=Severe. A negative change from Baseline indicates improvement."", 'timeFrame': 'Baseline, Month 4'}, {'measure': ""Change From Baseline in the Investigator's Assessment of the Participant's Perioral Lines Severity"", 'description': ""The investigator assessed the participant's perioral lines severity using the 4-Point Perioral Lines at Rest Severity Scale (POLSS) where: 0=None (no lines) \\[best\\], 1=Mild (few, shallow lines), 2=Moderate (some moderate lines) or 3=Severe (many deep lines or crevices)\\[worst\\]. A negative change from Baseline indicates improvement."", 'timeFrame': 'Baseline, Month 4'}, {'measure': 'Change From Baseline in the Participant Satisfaction With Appearance of Periorbital Area', 'description': 'Participants assessed how their overall eye appearance has affected them over the past 7 days using the 9-item Periorbital Aesthetic Appearance Questionnaire (PAAQ). Possible responses to each question were: 0=Never (best), 1=Rarely, 2=Some of the time, 3=Most of the time and 4=All of the time with a total possible score of 0 to 36. A negative change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Month 4'}]",14,35 Years,65 Years,ALL,False,Allergan,INDUSTRY,0,116.0,ACTUAL,2025-09-01T16:18:20.968257,v2_robust,True,True,True,False,False,
NCT06227156,"Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer","A Multicenter Open Phase II to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer",Disitamab Vedotin Injection,"['DV,RC48', 'Disitamab Vedotin Injection']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Castration-resistant Prostate Cancer,['Castration-resistant Prostate Cancer'],"['Metastatic Castration-resistant prostate cancer.', 'HER2- expression']",RECRUITING,,2024-04-08,2026-06,"[{'measure': 'Radiographic progression free survival，rPFS', 'description': 'Define imaging disease progression according to RECIST v1.1 (for all lesions except bone lesions) or PCWG3 (for bone lesions) as the time from the first dose of the drug to the time when the imaging shows disease progression or death.', 'timeFrame': 'Up to approximately 2 years'}]","[{'measure': 'Objective remission rate (ORR)', 'description': 'ORR assessed according to the evaluation criteria for the efficacy of solid tumors (RECIST 1.1)', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'Percentage of patients with complete response, partial response, or stable disease for a certain period of time according to RECIST v1.1.', 'timeFrame': 'Until progression, assessed up to approximately 2 years'}, {'measure': 'Time to PSA progression(TTPP)', 'description': 'Defined as time from date of first dose to first PSA progression', 'timeFrame': 'Until progression, assessed up to approximately 2 years'}, {'measure': 'Duration of response (DoR)', 'description': 'Defined as the time from the date of first documented response (CR/PR) until the first progression or death in the absence of disease progression by Investigators assessment according to RECIST 1.1', 'timeFrame': 'Until progression, assessed up to approximately 2 years'}, {'measure': 'PSA response rate', 'description': 'Percent of subjects with different degree of decrease in PSA compared to baseline', 'timeFrame': 'Until progression, assessed up to approximately 2 years'}, {'measure': 'Time to first symptomatic bone-related event (SSE)', 'description': 'Defined as the time from the first dose to the first occurrence of SSE.', 'timeFrame': 'Until progression, assessed up to approximately 2 years'}, {'measure': 'Overall Survival (OS)', 'description': 'OS was defined as the time from the date of randomization to the date of death from any cause.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Cmax of RC48', 'description': 'Peak Plasma Concentration of RC48', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'AUC of RC48', 'description': 'Area under the plasma concentration versus time curve of RC48', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'AUC of MMAE', 'description': 'Area under the plasma concentration versus time curve of MMAE', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Immunogenicity of RC48', 'description': 'Anti-drug antibody (ADA) of RC48 positive samples, etc.', 'timeFrame': 'up to approximately 2 years'}, {'measure': 'Percentage of Participants With Adverse Events (AEs)', 'description': 'Number of participants with adverse effects of treatment. Frequency and severity of adverse effects of treatment as assessed by NCI CTCAE v5.0', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Incidence of laboratory tests abnormalities', 'description': 'To be summarized using descriptive statistics', 'timeFrame': 'Up to follow-up period, approximately 2 years'}, {'measure': 'Incidence of ECG abnormalities', 'description': 'To be summarized using descriptive statistics', 'timeFrame': 'Up to follow-up period, approximately 2 years'}]",15,18 Years,,MALE,False,"RemeGen Co., Ltd.",INDUSTRY,0,40.0,ESTIMATED,2025-09-01T16:18:20.968345,v2_robust,True,True,False,False,True,
NCT00057356,Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure,"A Randomized, Double-blind, Placebo-controlled, Dose-ranging Pilot Study Evaluating the Efficacy and Safety of YM087 in Patients With Decompensated Chronic Heart Failure",conivaptan,"['Vaprisol', 'YM087', 'placebo', 'conivaptan']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Heart Failure,['Chronic Heart Failure'],"['Chronic Heart Failure', 'YM078']",COMPLETED,,2002-11,2004-03,"[{'measure': 'Change from baseline in respiratory Visual analog Scale (VAS)', 'timeFrame': '48 hours'}]","[{'measure': 'Change from baseline in global VAS', 'timeFrame': '48 hours'}, {'measure': 'Total urine output vs. baseline', 'timeFrame': '72 hours'}]",3,18 Years,,ALL,False,Cumberland Pharmaceuticals,INDUSTRY,0,170.0,ACTUAL,2025-09-01T16:18:20.968478,v2_robust,True,True,True,False,False,
NCT01856556,Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers,"A Randomized, Double-Blind, Placebo-Controlled Single Intravenous and Oral Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers",NRX-1074,"['NRX-1074', 'NMDA receptor functional glycine-site partial agonist', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['safety', 'tolerability', 'pharmacokinetics']",COMPLETED,,2013-05,2014-11,"[{'measure': 'Observed and laboratory-confirmed safety', 'timeFrame': '28 days'}]","[{'measure': 'Plasma concentration of parent drug will be assessed over time to estimate duration of pharmacodynamics in future efficacy trials. Plasma concentration and pharmacokinetics will be related in time to observed side effects.', 'timeFrame': '24 hours'}]",2,18 Years,55 Years,ALL,True,"Naurex, Inc, an affiliate of Allergan plc",INDUSTRY,0,100.0,ACTUAL,2025-09-01T16:18:20.968489,v2_robust,True,True,True,False,True,
NCT00813956,A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer,,gemcitabine plus carboplatin plus BSI-201,['gemcitabine plus carboplatin plus BSI-201'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Triple Negative Breast Cancer,['Triple Negative Breast Cancer'],['triple negative breast cancer'],COMPLETED,,2008-12,2012-10,"[{'measure': 'pathologic complete response', 'timeFrame': '4 months'}]",[],1,18 Years,,FEMALE,False,Sanofi,INDUSTRY,1,80.0,ACTUAL,2025-09-01T16:18:20.968578,v2_robust,True,True,True,False,False,
NCT00659022,Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth,Accelerated Growth of Synchronous Colorectal Liver Metastases: Effects of Neo-adjuvant Therapy,neo-adjuvant treatment with bevacizumab,"['neo-adjuvant treatment with bevacizumab', 'neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin', 'Xeloda', 'neoadjuvant treatment with capecitabine and oxaliplatin', 'Eloxatin', 'Avastin']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Colorectal Neoplasms,"['Colorectal Neoplasms', 'Liver Neoplasms']","['colorectal cancer', 'liver metastases', 'angiogenesis', 'metabolism']",UNKNOWN,,2008-07,2014-04,"[{'measure': 'Difference in response of liver metastases between control group and experimental groups determined by histopathological scoring of vascular density,apoptotic and mitotic index', 'timeFrame': '12 weeks'}, {'measure': 'Difference in response of liver metastases between control group and experimental groups determined by FDG-PET', 'timeFrame': '12 weeks'}]","[{'measure': 'Toxicity of neo-adjuvant treatment', 'timeFrame': '12 weeks'}, {'measure': 'Complications of surgery', 'timeFrame': '4 weeks'}]",4,18 Years,80 Years,ALL,False,Radboud University Medical Center,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:20.968731,v2_robust,True,True,False,False,False,
NCT00991822,A Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma,A Double-masked Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma,Dorzolamide 2%,"['Timolol 0.5%', 'Dorzolamide 2%']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,"Glaucoma, Open-Angle","['Glaucoma, Open-Angle']","['open angle glaucoma', 'timolol', 'dorzolamide']",COMPLETED,,1999-05,2003-12,"[{'measure': 'Percent change over baseline after 3 months of treatment of optic disk blood flow measured with the Heidelberg Retina Flowmeter', 'timeFrame': '5 minutes measurement of optic disk blood flow on 3 study days'}, {'measure': 'Percent change over baseline after 3 months of treatment of fundus pulsation amplitude (FPA) in the optic disk as assessed with laser interferometry', 'timeFrame': '5 minutes measurement of FPA on 3 study days'}]",[],2,19 Years,,ALL,False,Medical University of Vienna,OTHER,0,160.0,ACTUAL,2025-09-01T16:18:20.968743,v2_robust,True,True,True,False,False,
NCT03093922,A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer,Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Urothelial Cancer: A Multicenter Randomized Phase II Study of Two Alternative Dosing Schedules,Atezolizumab,"['Gemcitabine', 'Atezolizumab', 'Cisplatin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Urothelial Carcinoma,"['Urothelial Carcinoma', 'Locally Advanced', 'Unresectable']","['Gemcitabine', 'Atezolizumab', 'Cisplatin', '16-1621']",ACTIVE_NOT_RECRUITING,,2017-03-22,2026-03,"[{'measure': 'overall response rate', 'description': 'with response determined according to RECIST v1.1', 'timeFrame': '1 year'}]",[],1,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,4,32.0,ACTUAL,2025-09-01T16:18:20.968809,v2_robust,True,True,False,False,False,
NCT02323022,Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML),IAC Regimen Versus IA Regimen as Induction Treatment for Initially Diagnosed AML Patients: a Randomized Controlled Phase III Clinical Trial,IAC regimen,"['IA regimen', 'IAC regimen']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],['Acute Myeloid Leukemia'],COMPLETED,,2014-12,2022-01,"[{'measure': 'Complete Remission Rate', 'description': 'complete remission (CR) rate after the induction courses', 'timeFrame': '1-2 months'}]","[{'measure': 'Overall Survival', 'description': '2-year overall survival (OS)', 'timeFrame': '2 years'}, {'measure': 'Disease-Free Survival', 'description': '2-year disease-free survival (DFS)', 'timeFrame': '2 years'}, {'measure': 'Cumulative Incidence of Relapse (CIR)', 'description': '2-year cumulative incidence of relapse (CIR)', 'timeFrame': '2 years'}]",4,18 Years,60 Years,ALL,False,The First Affiliated Hospital of Soochow University,OTHER,0,618.0,ACTUAL,2025-09-01T16:18:20.968855,v2_robust,True,True,True,False,False,
NCT00702351,A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788),"A Phase II, Uncontrolled Pilot Trial to Evaluate That a Single Dose of 100 μg or 150 μg Org 36286 (Corifollitropin Alfa) is Able to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI Using a Long Protocol of GnRH Agonist (Study 38833)",Org 36286 (corifollitropin alfa),"['corifollitropin alfa', 'Org 36286 (corifollitropin alfa)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,In Vitro Fertilization,['In Vitro Fertilization'],"['Infertility', 'Pharmacological effects of drugs', 'Drug therapy', 'Hormones', 'GnRH agonist', 'RecFSH', 'Corifollitropin alfa', 'Open-label']",COMPLETED,,2005-12-09,2007-07-11,"[{'measure': 'serum inhibin-B levels; follicle number and follicle size distribution', 'timeFrame': 'One cycle'}]","[{'measure': 'Amount of recFSH needed from Stimulation Day 8 onwards to the Day of hCG; Endocrinological parameters (FSH, LH, E2, P); Number and quality of oocytes retrieved', 'timeFrame': 'One cycle'}, {'measure': 'Number of fertilized oocytes; Fertilization rate; Number and quality of embryos; Implantation rate; Miscarriage rate; Clinical outcome', 'timeFrame': 'One cycle'}]",3,18 Years,39 Years,FEMALE,False,Organon and Co,INDUSTRY,0,50.0,ACTUAL,2025-09-01T16:18:20.968919,v2_robust,True,True,True,False,False,
NCT04612751,Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer,"A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)",Datopotamab deruxtecan,"['Imfinzi', 'sabestomig', 'AZD2936', 'volrustomig', 'Carboplatin', 'Datopotamab deruxtecan', 'rilvegostomig', 'MEDI5752', 'Dato-DXd', 'AZD7789', 'Durvalumab']",11,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced or Metastatic NSCLC,['Advanced or Metastatic NSCLC'],"['Advanced or Metastatic NSCLC', 'Datopotamab deruxtecan (Dato-DXd)', 'DS-1062a', 'Durvalumab', 'AZD2936', 'MEDI5752', 'AZD7789']",RECRUITING,,2021-02-02,2026-01-30,"[{'measure': 'Number of participants with DLTs; TEAEs and other safety parameters during the study.', 'description': 'DLTs, TEAEs, SAEs, AESIs, ECOG PS, vital sign measurements, standard clinical laboratory parameters (hematology, clinical chemistry, and urinalysis), ECG parameters, ECHO/MUGA scan findings, and ophthalmologic findings', 'timeFrame': 'DLTs: within first cycle (21 days); TEAEs and other safety parameters: when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up (approximately 60 months)'}]","[{'measure': 'ORR as assessed by investigator per RECIST Version 1.1', 'description': 'ORR is defined as the proportion of participants with measurable disease at baseline who achieved a BOR of confirmed CR or confirmed PR.', 'timeFrame': 'At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).'}, {'measure': 'Duration of Response as assessed by investigator per RECIST version 1.1', 'description': 'Duration of Response is defined as the time from the date of the first documentation of objective response (confirmed CR or confirmed PR) to the date of the first documentation of objective PD, or death due to any cause, whichever occurs first.', 'timeFrame': 'At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).'}, {'measure': 'Disease Control Rate as assessed by the investigator per RECIST version 1.1', 'description': 'Disease Control Rate is defined as the proportion of participants who achieved a Best Overall Response of confirmed complete response, confirmed partial response, or stable disease.', 'timeFrame': 'At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).'}, {'measure': 'Progression-free Survival as assessed by the investigator per RECIST v1.1', 'description': 'Progression-free Survival is defined as the time interval from the date of the start of study treatment to the earlier of the dates of the first documentation of objective PD or death due to any cause, whichever occurs first', 'timeFrame': 'At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).'}, {'measure': 'Time to Response as assessed by investigator per RECIST Version 1.1', 'description': 'Time to Response is defined as the time from the date of the start of study treatment to the date of the first documentation of objective response (confirmed complete response or confirmed partial response)', 'timeFrame': 'At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).'}, {'measure': 'Best percentage change in the Sum of Diameters of measurable tumors', 'description': 'The best percentage change in the Sum of Diameters of measurable tumors is defined as the percentage change in the smallest Sum of Diameters from all postbaseline tumor assessments, taking as reference the baseline Sum of Diameters.', 'timeFrame': 'At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).'}, {'measure': 'Overall Survival', 'description': 'Overall Survival is defined as the time from the date of the start of study treatment to the date of death due to any cause', 'timeFrame': 'At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).'}, {'measure': 'Pharmacokinetic Parameter Maximum Plasma/Serum Concentration (Cmax) of Dato-DXd, Total anti-TROP2 antibody, and MAAA-1181a. Serum concentrations of durvalumab and MEDI5752, AZD2936, MEDI5752 and AZD7789.', 'description': 'Cmax = Maximum concentration', 'timeFrame': 'At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).'}, {'measure': 'Pharmacokinetic Parameter Time to Maximum Plasma/Serum Concentration (Tmax) of Dato-DXd, Total anti-TROP2 antibody, and MAAA-1181a.', 'description': 'Tmax = time to reach maximum concentration.', 'timeFrame': 'At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).'}, {'measure': 'Pharmacokinetic Parameter Area Under the Plasma Concentration-Time Curve (AUC) of Dato-DXd, Total anti-TROP2 antibody, and MAAA-1181a.', 'description': 'Area under the plasma concentration-time curve up to last quantifiable time (AUClast) and area under the plasma concentration-time curve during dosing interval (AUCtau) will be assessed.', 'timeFrame': 'At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).'}, {'measure': 'Prevalence of Dato-Dxd, durvalumab, AZD2936, MEDI5752 and AZD7789 ADA', 'description': 'ADA prevalence is defined as the proportion of all participants having ADA at any point in time (including pre-existing ADA at baseline and treatment-emergent ADA)', 'timeFrame': 'At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).'}, {'measure': 'Incidence of Dato-DXd, durvalumab, AZD2936, MEDI5752 and AZD7789 ADA', 'description': 'ADA incidence is defined as the proportion of participants having treatment-emergent ADA during the study period', 'timeFrame': 'At the time of the final analysis (when all participants have either discontinued the study or the last participant enrolled in the study has completed at least 9 months of follow-up, approximately 60 months).'}]",13,18 Years,,ALL,False,AstraZeneca,INDUSTRY,1,371.0,ESTIMATED,2025-09-01T16:18:20.968933,v2_robust,True,True,False,False,True,
NCT03745651,TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis,"Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis",Ruxolitinib cream,"['INCB018424 phosphate cream', 'Ruxolitinib cream', 'Vehicle cream']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Atopic Dermatitis,['Atopic Dermatitis'],"['Atopic dermatitis', 'pruritus', 'eczema', 'topical therapy', 'JAK inhibitor']",COMPLETED,,2018-12-20,2020-11-09,"[{'measure': ""VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8"", 'description': 'The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. The IGA-TS is defined as an IGA score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 grade improvement from Baseline.', 'timeFrame': 'Baseline to Week 8'}]","[{'measure': 'VC Period: Percentage of Participants Who Achieved Eczema Area and Severity Index 75 (EASI75) at Week 8', 'description': 'EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.', 'timeFrame': 'Baseline to Week 8'}, {'measure': 'VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch Numerical Rating Scale (NRS) Score From Baseline to Week 8', 'description': 'The Itch NRS is a daily participant-reported measure (24-hour recall), of the worst level of itch intensity using a diary. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours.', 'timeFrame': 'Baseline to Week 8'}, {'measure': 'VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep Disturbance (8b - 24-Hour Recall) Score at Week 8', 'description': ""The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance."", 'timeFrame': 'Baseline to Week 8'}, {'measure': 'VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a - 24-Hour Recall) Score at Week 8', 'description': ""The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. Each item asks the participant to rate the severity of the participant's sleep impairment."", 'timeFrame': 'Baseline to Week 8'}, {'measure': 'VC Period: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Treatment-Emergent Serious Adverse Event (SAE)', 'description': 'An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or an important medical event may be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first dose of study drug.', 'timeFrame': 'From date of randomization up to Week 8'}, {'measure': 'LTS Period: Percentage of Participants With at Least One TEAE and Treatment Emergent SAE', 'description': 'An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or an important medical event may be considered serious when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first dose of study drug.', 'timeFrame': 'From first dose date in LTS Period (Week 8) until last follow-up visit (up to 52 weeks)'}, {'measure': 'VC Period: Percentage of Participants Who Achieved an IGA-TS at Weeks 2 and 4', 'description': 'The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting. The IGA-TS is defined as an IGA score of 0 (clear skin) or 1 (almost clear skin) with ≥ 2 grade improvement from Baseline.', 'timeFrame': 'Baseline to Weeks 2 and 4'}, {'measure': 'VC Period: Percentage of Participants Achieving an IGA of 0 or 1', 'description': 'The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting.', 'timeFrame': 'Weeks 2, 4 and 8'}, {'measure': 'LTS Period: Percentage of Participants Achieving an IGA of 0 or 1', 'description': 'The IGA is an overall eczema severity rating on a 5-point scale ranging from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, induration/papulation, and oozing/crusting.', 'timeFrame': 'Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52'}, {'measure': 'VC Period: Percentage of Participants With a ≥ 4-Point Improvement in Itch NRS Score From Baseline to Weeks 2 and 4', 'description': 'The Itch NRS is a daily participant-reported measure (24-hour recall), of the worst level of itch intensity using a diary. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours.', 'timeFrame': 'Baseline to Weeks 2 and 4'}, {'measure': 'VC Period: Percentage of Participants Who Achieved EASI50', 'description': 'EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI50 responder was defined as a participant achieving 50% or greater improvement from Baseline in EASI score.', 'timeFrame': 'Baseline to Weeks 2, 4 and 8'}, {'measure': 'VC Period: Percentage of Participants Who Achieved EASI75 at Weeks 2 and 4', 'description': 'EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.', 'timeFrame': 'Baseline to Weeks 2 and 4'}, {'measure': 'VC Period: Percentage of Participants Who Achieved EASI90', 'description': 'EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI90 responder was defined as a participant achieving 90% or greater improvement from Baseline in EASI score.', 'timeFrame': 'Baseline to Weeks 2, 4 and 8'}, {'measure': 'VC Period: Percent Change From Baseline in EASI Score', 'description': 'EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2 and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 and the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. A negative change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Weeks 2, 4 and 8'}, {'measure': 'VC Period: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score', 'description': 'The SCORAD is a tool to assess extent and severity of eczema. To determine the extent, the rule of nines or handprint method is used to assess eczema affected area (A). To determine disease severity (B) it evaluates 6 clinical characteristics: 1. redness, 2. swelling, 3. oozing/crusting, 4. scratch marks, 5. lichenification, and 6. dryness on a 4-point scale of 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), added to give B with maximum score of 18. Subjective symptoms (C) of itch and sleeplessness are assessed using a visual analogue scale where 0 is no itch (or no sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), added to give C with maximum score of 20. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \\& subjective symptoms (C: 0-20) combined using A/5 + 7\\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. A negative change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Weeks 2, 4 and 8'}, {'measure': 'VC Period: Change From Baseline in Itch NRS Score', 'description': 'The Itch NRS is a daily participant-reported measure (24-hour recall), of the worst level of itch intensity using a diary. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. A negative change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Weeks 2, 4 and 8'}, {'measure': 'VC Period: Time to Achieve Itch NRS Score Improvement of at Least 2, 3, or 4 Points', 'description': 'The Itch NRS is a daily participant-reported measure (24-hour recall), of the worst level of itch intensity using a diary. Participants are asked to rate the itching severity because of their AD by selecting a number from 0 (no itch) to 10 (worst imaginable itch) that best describes their worst level of itching in the past 24 hours. Kaplan-Meier estimation method was used for analyses.', 'timeFrame': 'Up to Week 8'}, {'measure': 'VC Period: Change From Baseline in Skin Pain NRS Score', 'description': 'The Skin Pain NRS is a daily patient-reported measure (24-hour recall), of the worst level of pain intensity from 0 (no pain) to 10 (worst imaginable pain) using a diary. Participants will be asked, ""Rate the pain severity from your atopic dermatitis skin changes by selecting a number that best describes your worst level of pain in the past 24 hours."" A negative change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Weeks 2, 4 and 8'}, {'measure': 'VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score at Weeks 2 and 4', 'description': ""The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance."", 'timeFrame': 'Weeks 2 and 4'}, {'measure': 'VC Period: Percentage of Participants With a Clinically Meaningful (≥ 6-Point) Improvement in the PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score at Weeks 2 and 4', 'description': ""The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment."", 'timeFrame': 'Weeks 2 and 4'}, {'measure': 'VC Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 24-Hour Recall Score', 'description': ""The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. A negative change from Baseline indicates improvement."", 'timeFrame': 'Baseline, Weeks 2, 4 and 8'}, {'measure': 'VC Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 24-Hour Recall Score', 'description': ""The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. A negative change from Baseline indicates improvement."", 'timeFrame': 'Baseline, Weeks 2, 4 and 8'}, {'measure': 'LTS Period: Change From Baseline in PROMIS Short Form - Sleep-Related Impairment (8a) 7-Day Recall Score', 'description': ""The PROMIS Short Form - Sleep-Related Impairment (8a) questionnaire assesses participant's self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. The questionnaire is filled in the evening where each item asks the participant to rate the severity of the participant's sleep impairment. It has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep-related impairment. A negative change from Baseline indicates improvement."", 'timeFrame': 'Baseline, Weeks 12, 24, and 52'}, {'measure': 'LTS Period: Change From Baseline in PROMIS Short Form - Sleep Disturbance (8b) 7-Day Recall Score', 'description': ""The PROMIS Short Form - Sleep Disturbance (8b) questionnaire assesses participant's self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This questionnaire is completed in the morning by the participant where each item asks the participant to rate the severity of the participant's sleep disturbance. It is a 5-point scale with a range in score from 8 to 40, with higher scores indicating greater severity of sleep disturbance. A negative change from Baseline indicates improvement."", 'timeFrame': 'Baseline, Weeks 12, 24, and 52'}, {'measure': 'VC Period: Change From Baseline in Atopic Dermatitis Afflicted Percentage of Body Surface Area (%BSA)', 'description': 'Body surface area affected by AD was assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region was assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage was reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\\*BSA head and neck + 0.3\\*BSA trunk + 0.2\\* BSA upper limbs + 0.4\\*BSA lower limbs. A negative change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Weeks 2, 4 and 8'}, {'measure': 'LTS Period: Change From Baseline in Atopic Dermatitis Afflicted %BSA', 'description': 'Body surface area affected by AD was assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region was assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage was reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\\*BSA head and neck + 0.3\\*BSA trunk + 0.2\\* BSA upper limbs + 0.4\\*BSA lower limbs. A negative change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52'}, {'measure': 'VC Period: Change From Baseline in Patient-Oriented Eczema Measure (POEM) Score', 'description': 'The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. It assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. A negative change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Weeks 2, 4 and 8'}, {'measure': 'LTS Period: Change From Baseline in POEM Score', 'description': 'The POEM is a 7-question quality-of-life assessment that asks how many days the participant has been bothered by various aspects of their skin condition during the past 7 days. It assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life. A negative change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Weeks 12, 24 and 52'}, {'measure': 'VC Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Score', 'description': 'The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 (""no impact on participant\'s life"") to 30 (""extremely large effect on participant\'s life""), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant\'s life.', 'timeFrame': 'Baseline, Weeks 2, 4, and 8'}, {'measure': 'LTS Period: Change From Baseline in DLQI Score', 'description': 'The DLQI is a simple, 10 question (Q) validated quality-of-life questionnaire to measure how much the skin problem has affected the participant. It covers 6 domains including symptoms and feelings (Q1 and Q2), daily activities (Q3 and Q4), leisure (Q5 and Q6), work and school (Q7), personal relationships (Q8 and Q9), and treatment(Q10). The recall Period of this scale is over the last week. Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. Scores range from 0 (""no impact on participant\'s life"") to 30 (""extremely large effect on participant\'s life""), and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant\'s life.', 'timeFrame': 'Baseline, Weeks 12, 24, and 52'}, {'measure': 'VC Period: Change From Baseline in Children Dermatology Life Quality Index (CDLQI) Score', 'description': ""CDLQI is the youth/children's version of the DLQI. The CDLQI is a simple 10 question (Q) validated quality-of-life questionnaire. It covers 6 domains including symptoms and feelings (Q1 and Q2), leisure (Q4, Q5, and Q6), school or holidays (Q7), personal relationships (Q3 and Q8), sleep (Q9) and treatment (Q10). Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. The total DLQI score is calculated by adding the score of each question resulting in a maximum score of 30 (extremely large effect on participant's life) and a minimum score of 0 (no impact on participant's life) and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life."", 'timeFrame': 'Baseline, Weeks 2, 4, and 8'}, {'measure': 'LTS Period: Change From Baseline in CDLQI Score', 'description': ""CDLQI is the youth/children's version of the DLQI. The CDLQI is a simple 10 question (Q) validated quality-of-life questionnaire. It covers 6 domains including symptoms and feelings (Q1 and Q2), leisure (Q4, Q5, and Q6), school or holidays (Q7), personal relationships (Q3 and Q8), sleep (Q9) and treatment (Q10). Response categories include 0-not at all, 1-a little, 2-a lot, and 3-very much, and unanswered or not relevant responses scored as 0. The total DLQI score is calculated by adding the score of each question resulting in a maximum score of 30 (extremely large effect on participant's life) and a minimum score of 0 (no impact on participant's life) and a 4-point change from Baseline is considered as the minimal clinically important difference threshold. A negative change from Baseline indicates less impact of the skin problem on participant's life."", 'timeFrame': 'Baseline, Weeks 12, 24, and 52'}, {'measure': 'VC Period: Mean Patient Global Impression of Change (PGIC) Score at Weeks 2, 4, and 8', 'description': ""The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement."", 'timeFrame': 'Weeks 2, 4 and 8'}, {'measure': 'VC Period: Percentage of Participants With Each Score on the PGIC at Weeks 2, 4, and 8', 'description': ""The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement."", 'timeFrame': 'Weeks 2, 4 and 8'}, {'measure': 'VC Period: Percentage of Participants With a Score of Either 1 or 2 on the PGIC at Weeks 2, 4, and 8', 'description': ""The PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment. It is a 7-point scale where participants rate the questions as: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The lower score indicates improvement."", 'timeFrame': 'Weeks 2, 4 and 8'}, {'measure': 'VC Period: Change From Baseline in EuroQuality of Life Five Dimensions (EQ-5D-5L) Visual Analogue Scale (VAS) Score', 'description': 'EQ-5D-5L questionnaire has 2 parts: EQ-5D-5L descriptive system \\& EQ-VAS. EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 5L indicates that for each dimension, there are 5 levels:1=no problems,2=slight problems,3=moderate problems,4=severe problems, and 5=extreme problems. EQ-5D-5L score is assessed using VAS that ranges from 0 to 100 millimetres (mm), where 0 indicates ""worst health you can imagine"" and 100 indicates ""best health you can imagine"". The participant was asked to indicate his/her health state over past 7 days in each of the 5 dimensions. Digits for the 5 dimensions can be combined into a 5-digit number that describes the participant\'s health state. In the EQ-VAS, participants had to record their health state on a scale ranging from 0 to 100. A positive change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Weeks 2, 4 and 8'}, {'measure': 'VC Period: Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) Version 2.0 (v2.0)', 'description': 'The WPAI-SHP is a 6-item participant questionnaire developed to measure the effect of overall health and specific symptoms on productivity at work and regular activities outside of it in the past 7 days. The WPAI-SHP consists of 6 questions as follows: 1=currently employed; 2=hours missed due to AD; 3=hours missed other reasons; 4=hours actually worked; 5=degree AD affected productivity while working; 6=degree AD affected regular activities and the computed percentage, range for each sub scale is from 0 to 100, with higher values indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Weeks 2, 4, and 8'}, {'measure': 'LTS Period: Change From Baseline in WPAI-SHP v2.0', 'description': 'The WPAI-SHP is a 6-item participant questionnaire developed to measure the effect of overall health and specific symptoms on productivity at work and regular activities outside of it in the past 7 days. The WPAI-SHP consists of 6 questions as follows: 1=currently employed; 2=hours missed due to AD; 3=hours missed other reasons; 4=hours actually worked; 5=degree AD affected productivity while working; 6=degree AD affected regular activities and the computed percentage, range for each sub scale is from 0 to 100, with higher values indicating greater impairment and less productivity. A negative change from Baseline indicates improvement.', 'timeFrame': 'Baseline, Weeks 12, 24, 36, and 52'}, {'measure': 'VC Period: Trough Plasma Concentrations of Ruxolitinib', 'description': 'Plasma samples were collected just before the morning application of study drug during each specified time point.', 'timeFrame': 'Pre-dose at Weeks 2, 4 and 8'}, {'measure': 'LTS Period: Trough Plasma Concentrations of Ruxolitinib', 'description': 'Plasma samples were collected just before the morning application of study drug during each specified time point.', 'timeFrame': 'Pre-dose at Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52'}]",41,12 Years,,ALL,False,Incyte Corporation,INDUSTRY,0,618.0,ACTUAL,2025-09-01T16:18:20.969091,v2_robust,True,True,True,False,True,
NCT03246529,"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)","A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma - The GENESIS Study",BL-8040 1.25 mg/kg + G-CSF,"['BL-8040 1.25 mg/kg + G-CSF', 'Placebo +G-CSF']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Multiple Myeloma,['Multiple Myeloma'],[],ACTIVE_NOT_RECRUITING,,2018-03-23,2029-09-30,"[{'measure': 'Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg With up to 2 Apheresis Sessions', 'description': 'Percentage of subjects mobilizing ≥6 × 10\\^6 CD34+ cells/kg with up to 2 apheresis sessions in preparation for autologous hematopoetic cell transplantation (auto-HCT) after treatment with G-CSF + single administration of BL-8040/placebo.\n\nBased on central laboratory data.', 'timeFrame': 'From first day of study treatment (G-CSF) until day of second apheresis which was planned to occur on Day 6'}]","[{'measure': 'Percentage of Subjects Mobilizing ≥2 × 10^6 CD34+ Cells/kg in 1 Apheresis Session', 'description': 'Percentage of subjects mobilizing ≥2 × 10\\^6 CD34+ cells/kg in 1 apheresis session after treatment with G-CSF + single administration of BL-8040/ placebo.', 'timeFrame': 'From first day of study treatment (G-CSF) until day of first apheresis which was planned to occur on Day 5'}, {'measure': 'Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg in 1 Apheresis Session', 'description': 'Percentage of subjects mobilizing ≥6 × 10\\^6 CD34+ cells/kg in 1 apheresis session after treatment with G-CSF + single administration of BL-8040/ placebo.', 'timeFrame': 'From first day of study treatment (G-CSF) until day of first apheresis which was planned to occur on Day 5'}, {'measure': 'Time to Neutrophil Engraftment, After Auto-HCT', 'description': 'Time to neutrophil engraftment after auto-HCT, where engraftment was defined as absolute neutrophil count (ANC) ≥0.5 × 10\\^9/L for 3 days or ≥1.0 × 10\\^9/L for 1 day following the conditioning regimen associated nadir.', 'timeFrame': 'End of engraftment period, which was defined as 29 days post transplantation'}, {'measure': 'Time to Platelet Engraftment, After Auto-HCT', 'description': 'Time to platelet engraftment, after auto-HCT, where engraftment was defined as the first of 3 consecutive measurements of platelet count ≥20 × 10\\^9/L without platelet transfusion support for 7 days following the conditioning regimen associated nadir.', 'timeFrame': 'End of engraftment period, which was defined as 29 days post transplantation'}, {'measure': 'Subjects With Graft Durability at 100 Days Post Transplant/ Early Termination', 'description': 'Subjects achieving graft durability were defined as meeting the following 2 criteria:\n\n* Platelet count ≥50 × 10\\^9/L without transfusion for at least 2 weeks.\n* Hemoglobin level ≥10 g/dL with no erythropoietin support or transfusions for at least 1 month.\n\nThis analysis was performed in part 2 of the study only.', 'timeFrame': 'Day 100 Post-Transplantation (± 7 days)'}, {'measure': 'Graft Durability at 6 Months Post Transplantation', 'description': 'Comparability of the graft durability between the BL-8040 + G-CSF arm and the placebo + G-CSF arm at 6 months post transplantation', 'timeFrame': '6 Months Post Transplantation'}, {'measure': 'Graft Durability at 9 Months Post Transplantation', 'description': 'Comparability of the graft durability between the BL-8040 + G-CSF arm and the placebo + G-CSF arm at 9 months post transplantation', 'timeFrame': '9 Months Post Transplantation'}, {'measure': 'Graft Durability at 12 Months Post Transplantation', 'description': 'Comparability of the graft durability between the BL-8040 + G-CSF arm and the placebo + G-CSF arm at 12 months post transplantation', 'timeFrame': '12 Month Post Transplantation'}]",9,18 Years,78 Years,ALL,False,"BioLineRx, Ltd.",INDUSTRY,0,180.0,ACTUAL,2025-09-01T16:18:20.969320,v2_robust,True,True,False,False,False,
NCT02135029,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins,"A Phase 3, Double-blind, Double-dummy, Randomized, Placebo And Active Controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Dyslipidemia Who Are Intolerant To Statins",Bococizumab (PF-04950615;RN316),"['Bococizumab (PF-04950615;RN316)', 'Atorvastatin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Hyperlipidemia,['Hyperlipidemia'],"['Hyperlipidemia', 'statin intolerance']",COMPLETED,,2014-06,2015-11,"[{'measure': 'Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12', 'timeFrame': 'Baseline, Week 12'}]","[{'measure': 'Percent Change From Baseline in Fasting Total Cholesterol (TC) at Weeks 12 and 24', 'timeFrame': 'Baseline, Week 12, 24'}, {'measure': 'Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Weeks 12 and 24', 'timeFrame': 'Baseline, Week 12, 24'}, {'measure': 'Percent Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non HDL-C) at Weeks 12 and 24', 'timeFrame': 'Baseline, Week 12, 24'}, {'measure': 'Percent Change From Baseline in Fasting Lipoprotein (a) (Lp[a]) at Weeks 12 and 24', 'timeFrame': 'Baseline, Week 12, 24'}, {'measure': 'Percent Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Weeks 12 and 24', 'timeFrame': 'Baseline, Week 12, 24'}, {'measure': 'Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Percent Change From Baseline in Fasting Triglycerides (TG) at Weeks 12 and 24', 'timeFrame': 'Baseline, Week 12, 24'}, {'measure': 'Percent Change From Baseline in Fasting Apolipoprotein A-I (ApoA-I) at Weeks 12 and 24', 'timeFrame': 'Baseline, Week 12, 24'}, {'measure': 'Percent Change From Baseline in Fasting Apolipoprotein A-II (ApoA-II) at Weeks 12 and 24', 'timeFrame': 'Baseline, Week 12, 24'}, {'measure': 'Percent Change From Baseline in Fasting Very Low Density Lipoprotein Cholesterol (VLDL-C) at Weeks 12 and 24', 'timeFrame': 'Baseline, Week 12, 24'}, {'measure': 'Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Absolute Change From Baseline in Fasting Total Cholesterol (TC) at Week 12', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Absolute Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Absolute Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Absolute Change From Baseline in Fasting Triglycerides (TG) at Week 12', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Absolute Change From Baseline in Apolipoprotein B (ApoB) at Week 12', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Absolute Change From Baseline in Lipoprotein (A) (Lp[A]) at Week 12', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Absolute Change From Baseline in Fasting Total Cholesterol (TC)/ High Density Lipoprotein Cholesterol (HDL-C) Ratio at Weeks 12 and 24', 'timeFrame': 'Baseline, Week 12, 24'}, {'measure': 'Absolute Change From Baseline in Fasting Apolipoprotein B (ApoB)/Apolipoprotein A-I (ApoA-I) Ratio at Weeks 12 And 24', 'timeFrame': 'Baseline, Week 12, 24'}, {'measure': 'Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (<=) 100 Milligram Per Deciliter (mg/dL) at Weeks 12 and 24', 'timeFrame': 'Week 12, 24'}, {'measure': 'Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (<=) 70 Milligram Per Deciliter (mg/dL) at Weeks 12 and 24', 'timeFrame': 'Week 12, 24'}, {'measure': 'Plasma PF-04950615 Concentrations at Weeks 12 and 24', 'description': 'Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLOQ =0.4 micrograms per milliliter \\[mcg/mL\\]) to zero. Participants who received PF-04950615 150 mg were evaluable for this outcome measure.', 'timeFrame': 'Week 12 and 24'}, {'measure': 'Number of Participants With Adverse Events Related to Type 1 and 3 Hypersensitivity Reactions, Injection Site Reactions, Myalgia, Myopathy, Creatinine Kinase (CK) and Liver Function Tests (LFT) Elevations', 'timeFrame': 'Baseline (Day 1) up to Week 30'}, {'measure': 'Number of Participants With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (nAb)', 'description': 'Participants with at least one positive ADA titer greater than or equal to (\\>=) 6.23 or positive nAb titer \\>=4.32 were reported. Titers are expressed as log2 reciprocal dilution at assay cutpoint.', 'timeFrame': 'Baseline up to Week 30'}, {'measure': 'Anti-drug Antibody (ADA) and Neutralizing Anti-body (nAb) Titer Level in Participants Who Tested Positive for ADA and nAb Respectively', 'description': 'Titer levels of participants who tested positive for ADA and nAb are reported. Titers are expressed as log2 reciprocal dilution at assay cutpoint.', 'timeFrame': 'Week 4, 12, 24 and 30 (Follow-up)'}, {'measure': 'Percentage of Participants Discontinued Due to Myalgia, Myopathy, Creatinine Kinase (CK) and Liver Function Tests (LFT) Elevations', 'timeFrame': 'Baseline (Day 1) up to Week 30'}]",27,18 Years,,ALL,False,Pfizer,INDUSTRY,0,184.0,ACTUAL,2025-09-01T16:18:20.969456,v2_robust,True,True,True,False,True,
NCT00051831,Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults,A Pilot Study to Measure the Clearance of Replication-Competent HIV-1 in Resting Memory CD4+ Cells in HIV-1-Infected Subjects Who Receive Enfuvirtide Plus Oral Combination Antiretroviral Therapy,Emtricitabine,"['Ritonavir', 'Enfuvirtide', 'Norvir', 'Saquinavir', 'T-20', 'TDF', 'Invirase', 'Emtricitabine', 'Tenofovir disoproxil fumarate', 'Fuzeon', 'Viread', 'Saquinavir mesylate', 'RTV', 'ENF', 'FTC', 'Emtriva']",16,INTERVENTIONAL,['NA'],,,HIV Infections,['HIV Infections'],"['Treatment Naive', 'HIV-1', 'Virus Replication', 'CD4-Positive T-Lymphocytes', 'Immunologic Memory', 'Pentafuside', 'Anti-HIV Agents', 'Drug Therapy, Combination', 'Saquinavir', 'Ritonavir', 'Tenofovir Disoproxil Fumarate', 'RNA, Viral', 'Viral Load', 'Fusion Inhibitors', 'Entry Inhibitors']",COMPLETED,,2003-10,2008-05,"[{'measure': 'Frequency of latently infected CD4+ T cells from peripheral blood with replication-competent HIV-1 (in infectious units per million cells)', 'timeFrame': 'Throughout study'}]","[{'measure': 'Any Grade 3 or 4 adverse experience, including Grade 3 or 4 laboratory value, sign or symptom, and all deaths.', 'timeFrame': 'Throughout study'}, {'measure': 'Targeted events and toxicities will also be considered and these include injection site reactions (any grade), bacterial pneumonia, cellulitis', 'timeFrame': 'Throughout study'}, {'measure': '- Level of HIV-1 RNA in plasma as measured by the Roche Ultrasensitive assay', 'timeFrame': 'Throughout study'}, {'measure': '- Level of HIV-1 DNA in PBMC', 'timeFrame': 'Throughout study'}, {'measure': '- Frequency of 2-LTR in PBMC', 'timeFrame': 'Throughout study'}, {'measure': '-Sequence of HIV env and HIV pol genes', 'timeFrame': 'Throughout study'}, {'measure': '-CD8/CD38 antibody binding capacity (ABC)', 'timeFrame': 'Throughout study'}, {'measure': '- Level of HIV-1 RNA in cerebrospinal fluid', 'timeFrame': 'Throughout study'}, {'measure': '- Level of HIV-1 RNA in genital fluid', 'timeFrame': 'Throughout study'}, {'measure': '- Level of HIV-1 RNA in plasma as measured by an ultra-ultrasensitive assay', 'timeFrame': 'Throughout study'}, {'measure': '- Measures of cell surface density of chemokine (CCR5, CXCR5) receptors', 'timeFrame': 'Throughout study'}, {'measure': '- Responses to subject preferences and injection administration concerns questionnaires', 'timeFrame': 'Throughout study'}]",13,18 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1,19.0,ACTUAL,2025-09-01T16:18:20.969512,v2_robust,True,True,True,False,True,
NCT01497431,Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants,Phase I Multiple Dose Study of 12-Week Treatment by Se-Methyl-L-Cysteine(MSC) and L SeMet in Adult Males,Methylselenocysteine,"['Se-Methyl-seleno-L-cysteine', 'Methylselenocycteine', 'SeMSC', 'Methylselenocysteine', 'L-Se-Methylselenocysteine', 'MSC']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,No Evidence of Disease,"['No Evidence of Disease', 'Prostate Carcinoma']",[],COMPLETED,,2011-11,2014-07,"[{'measure': 'Clinical toxicity of Se-methyl-seleno-L-cysteine according to the NCI CTCAE version 4.0', 'description': 'The safety and tolerability data will be summarized using descriptive statistics, by cohort and for all cohorts combined compared to placebo. Reported adverse events will be looked at for possible differences, where appropriate, using graphical methods.', 'timeFrame': 'Up to 112 days'}, {'measure': 'Clinical toxicity of Se-methyl-L-cysteine compared to selenium after multiple doses, according to the NCI CTCAE version 4.0', 'description': 'The safety and tolerability data will be summarized using descriptive statistics, by cohort and for all cohorts combined compared to placebo. Reported adverse events will be looked at for possible differences, where appropriate, using graphical methods.', 'timeFrame': 'Up to 112 days'}]","[{'measure': 'Characterization of the pharmacokinetics of Se in the forms Se-methyl-seleno-L-cysteine and selenium at multiple doses', 'description': 'The pharmacokinetic variables will be tabulated, and descriptive statistics calculated for each cohort, using established pharmacokinetic analysis methods. Plasma and urine pharmacokinetic parameters will be summarized graphically and by arithmetic or geometric means and coefficients of variations for each cohort.', 'timeFrame': 'At baseline, and at and .5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hrs after dosing on days 1 and between days 70 and 84'}]",3,40 Years,80 Years,MALE,True,National Cancer Institute (NCI),NIH,0,66.0,ACTUAL,2025-09-01T16:18:20.969531,v2_robust,True,True,True,False,True,
NCT01731431,Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes,Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes,Glyburide,['Glyburide'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Diabetes,"['Diabetes', 'Gestational']","['Gestational Diabetes,', 'Insulin,', 'Glyburide,', 'Glycemia']",COMPLETED,,2012-05-18,2017-06-02,"[{'measure': 'Composite criterion of neonatal complications associated with gestational diabetes: macrosomia or birth weight ≥ 90th percentile for gestational age, neonatal hypoglycemia and neonatal hyperbilirubinemia', 'timeFrame': 'At birth until neonatal discharge from maternity'}]","[{'measure': 'Rates of caesarean section, preterm delivery rate, neonatal mortality rate, number of neonatal and maternal trauma related to delivery, number of respiratory distress, number of prenatal visits, number of days of hospitalization', 'description': 'Maternal glycemic control, rates of caesarean section, preterm delivery rate, neonatal mortality rate, number of neonatal and maternal trauma related to delivery, number of respiratory distress, number of prenatal visits, number of days of hospitalization and maternal satisfaction', 'timeFrame': 'during pregnancy until maternal discharge from maternity'}]",2,18 Years,45 Years,FEMALE,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,914.0,ACTUAL,2025-09-01T16:18:20.969545,v2_robust,True,True,True,False,False,
NCT01940731,Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults,"A Prospective, Open, Non-controlled, Multi-center Study of Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults.",Colistimethate sodium,['Colistimethate sodium'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Hospital-acquired Pneumonia,['Hospital-acquired Pneumonia'],[],UNKNOWN,,2013-10,,"[{'measure': 'Per subject clinical cure rate', 'timeFrame': '14-28 days'}, {'measure': 'Per subject microbiological cure rate', 'timeFrame': '14-28 days'}]",[],2,18 Years,75 Years,ALL,False,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",INDUSTRY,0,60.0,ESTIMATED,2025-09-01T16:18:20.969590,v2_robust,True,True,False,False,False,
NCT01743131,Abatacept as GVHD Prophylaxis Phase 2,Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial,Abatacept,"['Orencia', 'Abatacept', 'placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Graft vs Host Disease,"['Graft vs Host Disease', 'Malignancy']",[],COMPLETED,,2013-02,2024-03,"[{'measure': 'Percentage of Participants With Cumulative Incidence of Severe aGVHD at Day +100 Post-transplant', 'description': 'The primary analysis will consist of estimating the cumulative incidence of severe aGVHD at day +100 post-transplant in the standard and investigational study arms. All registered patients will be considered for this analysis. The primary null hypothesis of the study is that there will be no difference in severe aGVHD between the investigational and standard GVHD prophylaxis arms. The primary outcome will be assessed in a final analysis to be performed after the last enrolled patient has been followed for 100 days post-transplant. The cumulative incidence and confidence interval will be calculated. The cumulative incidence will be compared between treatment arms using logistic regression models. Relapse will be considered a competing risk for aGVHD to negate the effect of measures, such as withdrawal of immune suppression and donor-lymphocyte infusion, often used in response to relapse.', 'timeFrame': 'First 100 days after transplant'}]","[{'measure': 'A Cumulative Incidence of Serious Infection, Engraftment, Relapse, and Overall Survival Will be Computed.', 'description': 'A cumulative incidence of infection, serious infection, CMV viremia, CMV invasive disease, EBV viremia, PTLD, BK viremia and disease, adenovirus viremia and disease, engraftment of: neutrophils, platelets, lymphocyte count, total T cell counts, CD4+ T cell counts, and CD8+ T cell counts, secondary graft failure, graft rejection, all grades of early and late aGvHD, overlap syndrome, chronic GvHD, RRT, TRM, DFS, immunosuppression-free survival, immunosuppressive-free/relapse-free survival, relapse, and OS.', 'timeFrame': '5 years post transplant'}, {'measure': 'Percentage of Participants With Severe (Grade III-IV) aGVHD Free Survival (GFS) up to Day +180', 'description': 'To compare severe (Grade III-IV) aGVHD free survival (GFS) up to Day 180 post-transplantation between the abatacelpt + standard GVHD prophylaxis and standard GVHD prophylaxis regimen. The aGVHD events in this definition of GFS are the adjudicated grade (III-IV) aGVHD events. (This is a pre-determined endpoint for the 8/8 cohort and a retrospective endpoint for the 7/8 cohort).', 'timeFrame': 'First 180 days after transplant'}, {'measure': 'Rate of Severe (Grade III-IV) aGVHD (Based on Adjudicated aGVHD Events) up to Day +180', 'description': 'To compare the cumulative incidence of severe (grade III-IV) aGVHD (based on adjudicated aGVHD events) up to Day 180 post-transplant between the abatacept + standard GVHD prophylaxis and standard GVHD prophylaxis regimen. (This is a pre-determined endpoint for the 8/8 cohort and a retrospective endpoint for the 7/8 cohort).', 'timeFrame': 'First 180 days after transplant'}]",4,6 Years,,ALL,False,Boston Children's Hospital,OTHER,1,186.0,ACTUAL,2025-09-01T16:18:20.969610,v2_robust,True,True,True,False,False,
NCT03235531,Assessment of Valproate on Ethanol Withdrawal,Prospective Assessment of Valproate on Ethanol Withdrawal,Valproate,"['Valproate', 'Lorazepam']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Alcohol Dependence,"['Alcohol Dependence', 'Alcohol Withdrawal Syndrome', 'Trauma', 'Heavy Drinking', 'Alcohol Use Disorder']","['alcohol withdrawal syndrome', 'trauma', 'alcohol use disorder', 'alcohol', 'lorazepam', 'benzodiazepine', 'valproate']",UNKNOWN,,2017-07-11,2020-01-01,"[{'measure': 'Lorazepam use in patient monitored with CIWA', 'description': 'Amount of lorazepam administration in response to CIWA score', 'timeFrame': 'Time between CIWA initiation and discontinuation for up to 3 weeks'}]","[{'measure': 'CIWA score', 'description': 'CIWA is a ten item scale used in the assessment and management of alcohol withdrawal.', 'timeFrame': 'During patient hospital stay for up to 6 months'}, {'measure': 'Hospital Length of Stay', 'description': 'Date of admission to date of discharge from the hospital', 'timeFrame': 'During patient hospital stay for up to 6 months'}, {'measure': 'Intensive Care Unit Length of Stay', 'description': 'Date of admission to date of discharge from the Intensive Care Unit', 'timeFrame': 'During patient Intensive Care Unit stay for up to 6 months'}, {'measure': 'In-hospital Mortality', 'description': 'Number of deaths', 'timeFrame': 'During patient hospital stay for up to 6 months'}, {'measure': 'Valproate associated side effects', 'description': 'Known side effects associated with valproate use, such as thrombocytopenia, transaminitis, pancreatitis, and hyperammonemia', 'timeFrame': 'During patient hospital stay for up to 6 months'}]",6,18 Years,,ALL,False,CAMC Health System,OTHER,0,210.0,ESTIMATED,2025-09-01T16:18:20.969684,v2_robust,True,True,False,False,False,
NCT00725231,Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP,Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly,chemotherapy,"['chemotherapy', 'chemotherapy cylcophosphamide, hydroxyldaunorubicin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Peripheral T Cell Lymphoma, Unspecified","['Peripheral T Cell Lymphoma, Unspecified', 'Angioimmunoblastic Lymphadenopathy', 'Extranodal NK/T-cell Lymphoma']",['T cell lymphoma'],UNKNOWN,,2008-02,2014-03,"[{'measure': 'Event free survival', 'timeFrame': '3 years'}]","[{'measure': 'Rate of complete and partial remissions', 'timeFrame': '4 months after inclusion'}, {'measure': 'treatment related deaths', 'timeFrame': 'time of occurence'}, {'measure': 'Overall survival', 'timeFrame': '@ 3 years'}, {'measure': 'protocol adherence', 'timeFrame': '4 months of treatment'}, {'measure': 'immune reconstitution after alemtuzumab CHOP', 'timeFrame': '3 years'}]",6,61 Years,80 Years,ALL,False,University of Göttingen,OTHER,2,274.0,ESTIMATED,2025-09-01T16:18:20.969712,v2_robust,True,True,False,False,False,
NCT05272202,Investigation of Cerebral Motor Activity Modulations Following Median Nerve Stimulation During General Anaesthesia,Study of Modulations of Motor Brain Activity Following Stimulation of the Median Nerve During General Anesthesia,Propofol,['Propofol'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Accidental Awareness During General Anesthesia,['Accidental Awareness During General Anesthesia'],[],RECRUITING,,2023-01-15,2026-12-31,"[{'measure': 'Amplitude of the ERD (event-related desynchronization)/ERS (event- related synchronization)', 'description': 'The main evaluation outcome will be the amplitude of the ERD (event-related desynchronization)/ERS (event- related synchronization) after median nerve stimulation, within 4 s of the stimulation, at various propofol concentrations. This amplitude will be calculated using a baseline taken before each stimulation. The amplitudes of the ERD and ERS will be extracted. The ERDs and ERSs will be displayed from the time each stimulation is performed until 4 s after the stimulation is completed.', 'timeFrame': 'From the time each stimulation is performed until 4 seconds after the stimulation is completed.'}]","[{'measure': 'Detection of ERD patterns via new machine-learning algorithms (percent of correct detection)', 'description': 'Verify the detection of ERD patterns via new machine-learning algorithms at different propofol concentrations. ERD patterns will be analysed manually, as well as automated by a machine-learning algorythm. Endpoint will be the percentage (%) of correctly identified ERD pattern by the algorythm.', 'timeFrame': 'From the time each stimulation is performed until 4 seconds after the stimulation is completed.'}, {'measure': 'Modulation of ERD patterns by anesthetics drugs. Percentage of variation in amplitude.', 'description': 'Another secondary criteria will to describe how the ERD generated by an MNS would be modulated by anesthetics drugs. Amplitude of ERD patterns will be recorded (microV) and the effect of anesthetic drugs on this amplitude will be described as percentage change.', 'timeFrame': 'From the time each stimulation is performed until 4 seconds after the stimulation is completed.'}, {'measure': 'Detection of ERS patterns via new machine-learning algorithms (percentage of correct detection)', 'description': 'Verify the detection of ERS patterns via new machine-learning algorithms at different propofol concentrations. ERS patterns will be analysed manually, as well as automated by a machine-learning algorythm. Endpoint will be the percentage (%) of correctly identified ERS pattern by the algorythm.', 'timeFrame': 'From the time each stimulation is performed until 4 seconds after the stimulation is completed.'}, {'measure': 'Modulation of ERS patterns by anesthetics drugs via new machine-learning algorithms (percentage change in amplitude)', 'description': 'Another secondary criteria will to describe how the ERS generated by an MNS would be modulated by anesthetics drugs. Amplitude of ERS patterns will be recorded (microV) and the effect of anesthetic drugs on this amplitude will be described as percentage change.', 'timeFrame': 'From the time each stimulation is performed until 4 seconds after the stimulation is completed.'}]",5,18 Years,81 Years,MALE,False,Brugmann University Hospital,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:20.969763,v2_robust,True,True,False,False,False,
NCT00044902,Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade),,epratuzumab,['epratuzumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Non-Hodgkin's Lymphoma,"[""Non-Hodgkin's Lymphoma""]",[],COMPLETED,,,,[],[],0,18 Years,,ALL,False,Amgen,INDUSTRY,0,,,2025-09-01T16:18:22.192188,v2_robust,True,True,True,False,False,
NCT01580202,Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine,"A Randomized, Open Labeled, Multicenter Study Comparing Entecavir Versus Lamivudine as Antiviral Prophylaxis for Patients With Hepatitis B Infection Undergoing Cytotoxic Chemotherapy for Malignant Tumors",Entecavir,"['Entecavir', 'Lamivudine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Malignancy,"['Malignancy', 'Hepatitis B']","['malignancy', 'hepatitis B', 'lamivudine', 'entecavir', 'prophylaxis']",COMPLETED,,2012-04,2017-06,"[{'measure': 'The cumulative probability of HBV reactivation', 'description': '10-fold or more elevation in serum HBV DNA titers above nadir', 'timeFrame': 'From the time of randomization until 24week after discontinuation of antiviral prophylaxis'}]","[{'measure': 'Incidence of HBV-related hepatitis flare', 'description': 'greater than 3-fold increase of ULN (upper limit of a normal reference value) of a serum ALT level that exceeded 100 IU/L during antiviral prophylaxis and 24 week after discontinuation of antiviral prophylaxis', 'timeFrame': 'From the time of randomization until 24week after discontinuation of antiviral prophylaxis'}, {'measure': 'Cumulative probability of emergence of genotypic resistance', 'description': 'detection of mutations that have been shown in in vitro studies to confer resistance to either ETV or LAM', 'timeFrame': 'From the time of randomization until 24week after discontinuation of antiviral prophylaxis'}, {'measure': 'Incidence of hepatic decompensation and liver-related mortality', 'timeFrame': 'From the time of randomization until 24week after discontinuation of antiviral prophylaxis'}]",4,18 Years,,ALL,False,Seoul National University Hospital,OTHER,0,180.0,ACTUAL,2025-09-01T16:18:22.192208,v2_robust,True,True,True,False,False,
NCT02135302,"A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects","A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects",eravacycline,"['TP-434', 'eravacycline']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Impaired Hepatic Function,['Impaired Hepatic Function'],['hepatic'],COMPLETED,,2013-10,2014-03,"[{'measure': 'This study is being conducted to assess the pharmacokinetic (PK) profile of eravacycline', 'description': 'To assess the pharmacokinetic (PK) profile of eravacycline after administration of a single intravenous (IV) dose (1.5 mg/kg) to subjects with mild, moderate, and severe impaired hepatic function compared with normal healthy subjects', 'timeFrame': 'one year'}]","[{'measure': 'Safety and tolerability of Eravacycline', 'description': 'To determine the safety and tolerability of eravacycline after administration of a single IV dose (1.5 mg/kg) in subjects with mild, moderate, and severe impaired hepatic function compared with normal healthy subjects.', 'timeFrame': 'one year'}]",2,18 Years,,ALL,True,"Tetraphase Pharmaceuticals, Inc",INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:22.192650,v2_robust,True,True,True,False,True,
NCT02707653,Sublingual Misoprostol for the Treatment of Incomplete Abortion: Operations Research,Sublingual Misoprostol for the Treatment of Incomplete Abortion: Operations Research,Misoprostol,"['Misoprostol', 'cytotec']",2,INTERVENTIONAL,['NA'],,,Incomplete Abortion,['Incomplete Abortion'],[],COMPLETED,,2016-03,2016-11,"[{'measure': 'Percentage of women with complete uterine evacuation with study medication alone.', 'timeFrame': '14 days'}]","[{'measure': 'Percentage of women experiencing side effects', 'description': 'occurrence of side effects, if any, including fever, chills, nausea, vomiting, headache, diarrhea, and pain.', 'timeFrame': '7-14 days'}, {'measure': 'Level of self-reported acceptability of treatment', 'description': ""Woman's satisfaction with the treatment, woman's likelihood to use the treatment in the future, woman's likelihood of recommending the treatment to a friend, providers' satisfaction with the treatment, likelihood provider would recommend the treatment in a similar situation."", 'timeFrame': '7-14 days'}]",3,12 Years,55 Years,FEMALE,True,Gynuity Health Projects,OTHER,1,75.0,ACTUAL,2025-09-01T16:18:22.192672,v2_robust,True,True,True,False,False,
NCT01971853,Does Preventive Analgesia Improve the Outcome of Demerol-Vistaril Procedural Sedations in Pediatric Dentistry,Does Preventive Analgesia Improve the Outcome of Demerol-Vistaril Procedural Sedations in Pediatric Dentistry?,oral placebo,"['oral placebo', 'Flavored liquid', 'Oral Analgesics']",3,INTERVENTIONAL,['NA'],,,Pain,['Pain'],['Analgesia'],TERMINATED,Insufficient number of participants recruited,2013-10,2016-12-31,"[{'measure': 'Improved Sedation Effectiveness Based on Numerical Value for Effectiveness as Noted in Description', 'description': 'A Sedation effectiveness evaluation criteria chart will be utilized to determine a numerical value for the effectiveness as follows:\n\n1 = Effective/Excellent; 2 = Partially effective/good; 3 = Ineffective/fair; 4 = Aborted/Poor', 'timeFrame': '60 minutes treatment started'}]","[{'measure': 'Difference in Heart Rate as Measured by Numerical Delta Value', 'description': 'A baseline heart rate will be determined at the beginning of the appointment, and a maximum heart rate will be determined during the appointment. The differences between baseline and maximum heart rates for each study arm will be compared.', 'timeFrame': 'From state of treatment (time 0) 60 minutes'}]",2,2 Years,8 Years,ALL,True,"University of Colorado, Denver",OTHER,0,88.0,ACTUAL,2025-09-01T16:18:22.192695,v2_robust,True,True,False,True,False,Insufficient number of participants recruited
NCT00102453,Pentoxifylline in Duchenne Muscular Dystrophy,An Open-Label Pilot Study of Pentoxifylline in Steroid-naive Duchenne Muscular Dystrophy,Pentoxifylline,"['Formula weight: 278.35', 'Product: Pentoxifylline BP', ""Supplier: Frank's Pharmacy, Ocala, Fl. 34474."", 'Chemical formula: C13H18N4O3', 'CAS number: 5/6/6493', 'Pentoxifylline']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Muscular Dystrophy, Duchenne","['Muscular Dystrophy, Duchenne']","['Duchenne', 'Genetics']",COMPLETED,,2002-03,2007-05,"[{'measure': 'QMT measurements', 'description': 'Quantitative muscle testing (QMT) is a technique utilized to assess muscle strength. Measurements of force are collected using a load cell while performing a maximum voluntary isometric contraction. This set-up is able to measure changes in strength of 0.25 lb which provides accurate and sensitive measurement of muscular strength. QMT is performed by a CINRG physical therapist.', 'timeFrame': 'Each study visit'}]","[{'measure': 'Change in manual muscle test (MMT) at 12 months', 'description': ""Manual muscle testing (MMT), which is graded according to the modified Medical Research Council (MRC) scale, is a test of a participant's muscle strength, or ability of the muscle to move a part of the body against resistance. A CINRG physical therapist will perform MMT testing with each participant."", 'timeFrame': 'Each study visit'}]",2,4 Years,7 Years,MALE,False,Cooperative International Neuromuscular Research Group,NETWORK,0,17.0,ACTUAL,2025-09-01T16:18:22.192774,v2_robust,True,True,True,False,False,
NCT05380453,Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission,"A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Efficacy and Safety of Subcutaneously Administered Secukinumab in Patients With New-onset of Giant Cell Arteritis (GCA) Who Are in Clinical Remission and Eligible for Treatment With Glucocorticoid-monotherapy","Placebo to match Secukinumab, s.c.","['Placebo to match Secukinumab, s.c.']",1,INTERVENTIONAL,['PHASE3'],PHASE3,,Giant Cell Arteritis,['Giant Cell Arteritis'],"['Giant Cell Arteritis', 'GCA', 'Vasculitis', 'Vascular Diseases', 'Secukinumab', 'Subcutaneous', 'Vessel Inflammation', 'Polymyalgia Rheumatica', 'Arteritis']",ACTIVE_NOT_RECRUITING,,2022-09-21,2026-11-30,"[{'measure': 'Time from baseline to first Giant cell arteritis (GCA) clinical relapse', 'description': 'To demonstrate the superiority of secukinumab 300 mg s.c. compared to placebo (both arms in combination with a prednisolone or equivalent taper regimen as per treatment guideline) in delaying the time to first GCA clinical relapse from baseline in participants with new onset of GCA who are in clinical remission and eligible for treatment with glucocorticoid-monotherapy.\n\nGCA clinical relapse is defined as both:\n\n1. The recurrence of signs or symptoms attributable to active GCA after clinical remission, which are considered clinically significant by the investigator AND\n2. The requirement of a change in the treatment prompted by the recurrence of signs and symptoms i. an increase in prednisolone or equivalent dose AND/OR ii. the addition of a rescue treatment.\n\nDefinition of clinical remission: absence of signs and symptoms attributable to active GCA as determined by the investigator.', 'timeFrame': 'Time from baseline to first GCA clinical relapse, assessed at least up to Week 24'}]","[{'measure': 'Proportion of participants in sustained clinical remission at Week 52', 'description': 'To demonstrate the superiority of secukinumab 300 mg s.c. compared to placebo, measured by the proportion of participants in sustained clinical remission at Week 52.\n\nDefinition of sustained clinical remission: absence of signs and symptoms attributable to active GCA between BSL until Week 52.', 'timeFrame': 'Baseline until Week 52'}, {'measure': 'Changes from Baseline to Week 52 in disease activity and quality of life for the PGA score (VAS)', 'description': 'To assess the effect of secukinumab compared to placebo measured by disease activity and quality of life measures at Week 52 for patient global assessment (PGA) of disease activity using a visual analogue scale (VAS)', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Changes from Baseline to Week 52 in disease activity and quality of life for the SF-36 (PCS and MCS) score', 'description': 'To assess the effect of secukinumab compared to placebo measured by disease activity and quality of life measures at Week 52 for Short form 36 (SF-36 PCS and MCS)', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Changes from Baseline to Week 52 in disease activity and quality of life for Patient assessment of pain (NRS)', 'description': 'To assess the effect of secukinumab compared to placebo measured by disease activity and quality of life measures at Week 52 for patient assessment of pain using a numeric rating scale (NRS)', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Time from Baseline to reach prednisolone or equivalent dose below ≤7.5 mg/day', 'description': 'Time to reach prednisolone or equivalent dose below Cushing threshold of ≤7.5 mg/day', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Proportion of participants on prednisolone or equivalent dose below Cushing threshold of ≤7.5 mg/day', 'description': 'Proportion of participants on prednisolone or equivalent dose below Cushing threshold of ≤7.5 mg/day', 'timeFrame': 'Bseline to Week 52'}, {'measure': 'Cumulative prednisolone or equivalent dose', 'description': 'Cumulative prednisolone or equivalent dose through Week 52', 'timeFrame': 'Baseline through Week 52'}, {'measure': 'Number of participants with Adverse Events', 'description': 'Safety and tolerability assessments over time: incidence and severity of AEs and SAEs; routine safety laboratory parameters\n\nTo evaluate safety and tolerability of secukinumab 300 mg s.c. in participants with new-onset of GCA who are eligible for treatment with glucocorticoid-monotherapy', 'timeFrame': 'Baseline up to 52 weeks'}]",9,50 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,151.0,ACTUAL,2025-09-01T16:18:22.192790,v2_robust,True,True,False,False,True,
NCT00802737,Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL),"A Single-arm, International, Multi-center Trial Investigating the Efficacy and Safety of Ofatumumab Retreatment and Maintenance in CLL Patients Who Progressed Following Response or Stable Disease After Ofatumumab Treatment in Hx-CD20-406",Ofatumumab,"['Ofatumumab', 'HuMax-CD20']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,"Leukaemia, Lymphocytic, Chronic","['Leukaemia, Lymphocytic, Chronic']","['Maintenance', 'Retreatment', 'Chronic lymphocytic leukemia', 'B-Cell Chronic Lymphocytic Leukemia', 'Ofatumumab']",COMPLETED,,2009-01,2013-05,"[{'measure': 'Number of Participants (Par.) Classified as Responders (Rs) and Non-responders (NRs) for Objective Response in Accordance With the National Cancer Institute Working Group (NCIWG) 1996 Guidelines', 'description': 'Par. with complete remission (CR), nodular partial remission (nPR), and partial remission (PR) on 2 consecutive visits \\>=56 days apart were classified as Rs; those with stable disease (SD)/progressive disease (PD) were classified as NRs. Per the NCIWG 1996 guidelines: CR; no lymphadenopathy/hepatomegaly/splenomegaly/constitutional symptoms, normal hematology, normocellular bone marrow sample for age, \\<30% lymphocytes (LC), no lymphoid nodule; PR: \\>=50% decrease in LC/lymphadenopathy; nPR: persistent bone marrow nodules; PD: new lesion or increase by \\>=50% from baseline; SD: no CR, PR, or PD.', 'timeFrame': 'Start of treatment (Week 0/Visit 2) until Week 52'}]","[{'measure': 'Duration of Response', 'description': 'Duration of response is defined as the time from the initial response (first visit at which response is observed) to progression or death. If the participant had progression between scheduled visits, no progression at the end of the trial, treatment discontinuation for undocumented progression, treatment discontinuation for toxicity or other reason, new anti-cancer treatment, and experienced death or progression after two or more missed visits in a row the endpoint was censored.', 'timeFrame': 'From the time of the initial response until progression or death (average of 14.1 study months)'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS is defined as the time from randomization until progression (prog.)/death. Prog. events are defined by well-documented and verifiable data; other data are censored. If the par. had prog. between scheduled visits, died before the first assessment, or died between adequate visits, the endpoint was considered progressed. If there was no prog. at the end of the trial, treatment discontinuation for undocumented prog./toxicity/other reason, new anti-cancer treatment, and death/prog. after \\>=2 missed visits in a row, the endpoint was censored. Clinical prog. is not considered as a prog. endpoint.', 'timeFrame': 'Start of treatment (Week 0 of Visit 2) until progression or death (average of 14.1 study months)'}, {'measure': 'Time to Next Chronic Lymphocytic Leukemia (CLL) Treatment', 'description': 'Time to next chronic lymphocytic leukemia (CLL) treatment is defined as the time from treatment allocation/randomization (Visit 2) until the time of the first administration of the next CLL treatment other than ofatumumab (or HuMaxCD20, a fully human monoclonal antibody to CD20 that is expressed on the surface of B-cells).', 'timeFrame': 'Time from start of study treatment (Week 0 of Visit 2) until the time of first administration of a CLL treatment other than ofatumumab (average of 14.8 study months)'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from allocation to death.', 'timeFrame': 'Time from start of study treatment (Week 0 of Visit 2) until date of death or time that participant was no longer followed (median of 18.0 months)'}, {'measure': 'Median Percent Change of Tumor Size (Sum of Products Dimensions [SPD]) From Baseline (Visit 2) at Month 4', 'description': 'Reduction in tumor size was measured as the percent change in the sum of the products of the diameters of the largest abnormal lymph nodes from Baseline to Week 24. Percent change was calculated as (Week 24 SPD minus Baseline SPD)/Baseline SPD \\* 100.', 'timeFrame': 'Baseline (Visit 2) and Month 4'}, {'measure': 'Median Percent Change of Tumor Size (Sum of Products Dimensions [SPD]) From Baseline (Visit 2) at Month 12', 'description': 'Reduction in tumor size was measured by the percentage change in the sum of products of the diameters of the largest abnormal lymph nodes from Baseline to Month 12. Percent change was calculated as (Month 12 SPD minus Baseline SPD)/Baseline SPD \\* 100.', 'timeFrame': 'Baseline (Visit 2) and Month 12'}, {'measure': 'Median Percent Change of Tumor Size (Sum of Products Dimensions [SPD]) From Baseline (Visit 2) at Month 24', 'description': 'Reduction in tumor size was measured by the percentage change in the sum of products of the diameters of the largest abnormal lymph nodes from Baseline to Month 24. Percent change was calculated as (Month 24 SPD minus Baseline SPD)/Baseline SPD \\* 100.', 'timeFrame': 'Baseline (Visit 2) and Month 24'}, {'measure': 'Number of Participants With Negative and Positive Human Anti-human Antibody (HAHA) Results at the Time of Screening and Post Ofatumumab', 'description': 'HAHAs are indicators of immunogenicity to ofatumumab. HAHA levels were assessed for each participant at the end of participation in the study (at their last visit). A positive HAHA status indicates a positive enzyme-linked immunosorbent assay (ELISA) result, an inconclusive status indicates a negative ELISA result at ofatumumab concentration above the threshold at which ofatumumab may interfere with the assay, and a negative status indicates a negative ELISA result at ofatumumab concentration below the threshold.', 'timeFrame': 'Screening and post ofatumumab (up to Study Month 32)'}, {'measure': 'Number of Participants Who Experienced Any Adverse Event', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. A list of AEs experienced in the study with a frequency threshold of 5% can be found in the AE section of this results record.', 'timeFrame': 'From the first infusion (Visit 2/Week 0) until the last visit of the Extended Follow-up Phase (up to Study Month 26 [visit 34])'}, {'measure': 'Number of Participants With the Indicated Major Infections', 'description': 'The data collected for this analysis are reported in the overall Serious Adverse Events (SAEs) of infections rather than reported separately for this specific analysis. This is a conservative approach for reporting all infectious SAEs in order to ensure that all of the infectious SAEs are represented.', 'timeFrame': 'From the first infusion (Visit 2/Week 0) until the last visit of the Extended Follow-up Phase (up to Study Month 26 [visit 34])'}, {'measure': 'Number of Participants With Infections Requiring Hospitalization or Intravenous Antibiotics', 'description': 'The data collected for this analysis are reported in the overall SAEs of infections rather than reported separately for this specific analysis. This is a conservative approach for reporting all infectious SAEs in order to ensure that all of the infectious SAEs are represented.', 'timeFrame': 'From the first infusion (Visit 2/Week 0) until the last visit of the Extended Follow-up Phase (up to Study Month 26 [visit 34])'}, {'measure': 'Cmax and Ctrough at Visit 2 (Week 0) and at Visit 14 (Month 4)', 'description': 'Cmax is defined as the maximum concentration of drug in plasma samples (collected at the end of the infusion). Ctrough is defined as the concentration of drug in plasma samples at the end of a dosing interval (collected directly before next administration). Ctrough before the first infusion represents residual ofatumumab from participation in Study Hx-CD20-406.', 'timeFrame': 'Visit 2 (Week 0) and Visit 14 (Month 4)'}]",13,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,1,29.0,ACTUAL,2025-09-01T16:18:22.192930,v2_robust,True,True,True,False,True,
NCT05238337,"A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200","A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200 Following a Single Oral Dose in Healthy Male Subjects",[14C]-PBI-200,['[14C]-PBI-200'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,"Absorption, Metabolism and Excretion in Healthy Volunteers","['Absorption, Metabolism and Excretion in Healthy Volunteers']",[],COMPLETED,,2022-02-24,2022-03-24,"[{'measure': 'Total Radioactivity in Urine and Feces', 'timeFrame': '28 days'}, {'measure': 'Area Under the Concentration-Time Curve (AUC) of PBI-200 from time zero to infinity [AUC(0-inf)]', 'timeFrame': '28 days'}, {'measure': 'Area Under the Concentration-Time Curve (AUC) of PBI-200 from time zero to the time of the last quantifiable concentration [AUC(0-tlast)', 'timeFrame': '28 days'}, {'measure': 'Maximum Observed Concentration [C(max)]', 'timeFrame': '28 days'}, {'measure': 'Time to Maximum Concentration [T(max)]', 'timeFrame': '28 days'}, {'measure': 'Apparent Terminal Elimination Half-life [t(1/2)]', 'timeFrame': '28 days'}, {'measure': 'Total Radioactivity in Plasma and Whole Blood', 'timeFrame': '28 days'}, {'measure': 'Ratio for AUC(0-inf) Blood / Plasma', 'timeFrame': '28 days'}, {'measure': 'Ratio for AUC(0-inf) Plasma PBI-200 / Total Radioactivity', 'timeFrame': '28 days'}]",[],9,18 Years,65 Years,MALE,True,Pyramid Biosciences,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:22.193049,v2_robust,True,True,True,False,False,
NCT00189137,Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma,Phase II Evaluation of Ifosfamide Plus Doxorubicin & Filgrastim Versus Gemcitabine Plus Docetaxel & Filgrastim in the Treatment of Localized Poor Prognosis Soft Tissue Sarcoma,ifosfamide and doxorubicin vs gemcitabine and docetaxel,['ifosfamide and doxorubicin vs gemcitabine and docetaxel'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Sarcoma, Soft Tissue","['Sarcoma, Soft Tissue']",[],COMPLETED,,2004-08,2015-10,"[{'measure': 'Percentage of Patients Hospitalized in Each Arm.', 'description': 'To contrast the proportion of treated patients hospitalized subsequent to treatment with gemcitabine and docetaxel as compared to doxorubicin and ifosfamide as neoadjuvant or adjuvant therapy of poor prognosis soft tissue sarcoma.', 'timeFrame': '12 weeks'}]","[{'measure': 'The Percentage of Patients Alive Without Disease at 2 Years', 'description': 'Disease-free survival', 'timeFrame': '2 years'}]",2,10 Years,,ALL,False,University of Michigan Rogel Cancer Center,OTHER,0,84.0,ACTUAL,2025-09-01T16:18:22.193092,v2_robust,True,True,True,False,False,
NCT01470937,Early Diabetes Intervention Program,Early Diabetes Intervention Program,Acarbose,"['Precose', 'Acarbose', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],['diabetes acarbose alphaglucosidase prevention'],COMPLETED,,1998-02,2004-09,"[{'measure': 'Progression of fasting glucose >140 mg/dL', 'description': 'Fasting plasma glucose was measured quarterly for up to 5 years. Two consecutive measures above 140 mg/dL defined progression.', 'timeFrame': 'From date of randomization until the date of first documented progression or censoring, up to 5 years post randomization'}]",[],1,25 Years,80 Years,ALL,False,Indiana University School of Medicine,OTHER,1,219.0,ACTUAL,2025-09-01T16:18:22.193319,v2_robust,True,True,True,False,False,
NCT06014437,Study on Regeneration of Skin Defects in Diabetic Ulcers Treated With New Electrospun Material PLCL/Fg,Study on Regeneration of Skin Defects in Diabetic Ulcers Treated With New Electrospun Material Poly (L-lactide-co-caprolactone) and Formulated Porcine Fibrinogen,PLCL/Fg group,"['PLCL/Fg group', 'PLCL/Fg dressing', 'alginate dressing', 'control group']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetic Foot,['Diabetic Foot'],[],RECRUITING,,2023-03-01,2024-03-31,"[{'measure': 'Incidence of complete wound closure during treatment and follow-up (12 weeks). (Outpatient follow-up 2-3 times per week, standardized photographs and measurement of wound size)', 'description': 'Complete healing is defined as complete re-epithelialization of the ulcer bed with no discharge. Speed of healing is calculated by measuring the size or percentage reduction in wound area per week.', 'timeFrame': '12 weeks'}]",[],1,18 Years,90 Years,ALL,False,Guili Wang,OTHER,0,52.0,ESTIMATED,2025-09-01T16:18:22.193393,v2_robust,True,True,False,False,False,
NCT04273737,Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy,Use of Amantadine in Treating Cognitive and Motor Impairments in Adolescents and Adults With Cerebral Palsy,Amantadine Hydrochloride,"['Symmetrel', 'Amantadine Hydrochloride', 'Osmolex ER', 'Gocovri', 'Symadine']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Cerebral Palsy,['Cerebral Palsy'],"['cerebral palsy', 'amantadine', 'cognitive function', 'gross motor skills', 'fine motor skills', 'mood']",TERMINATED,PI left institution.,2020-02-28,2022-02-22,"[{'measure': 'Mean Brief-A Score', 'description': ""The BRIEF-A is a standardized measure that captures views of an adult's executive functions or self-regulation in his or her everyday environment. Both a self-report and an informant report are used. The BRIEF-A includes 75 items within nine non-overlapping theoretically and empirically derived clinical scales: Inhibit, Self-Monitor, Plan/Organize, Shift, Initiate, Task Monitor, Emotional Control, Working Memory, and Organization of Materials. All 75 items are rated in terms of frequency on a 3-point scale: 1 (never), 2 (sometimes), 3 (often). Raw scores for each scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Composite scores are calculated and are scored from a range of 75 (better outcome) to 225."", 'timeFrame': 'Baseline'}, {'measure': 'Mean Brief-A Score', 'description': ""The BRIEF-A is a standardized measure that captures views of an adult's executive functions or self-regulation in his or her everyday environment. Both a self-report and an informant report are used. The BRIEF-A includes 75 items within nine non-overlapping theoretically and empirically derived clinical scales: Inhibit, Self-Monitor, Plan/Organize, Shift, Initiate, Task Monitor, Emotional Control, Working Memory, and Organization of Materials. All 75 items are rated in terms of frequency on a 3-point scale: 1 (never), 2 (sometimes), 3 (often). Raw scores for each scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Composite scores are calculated and are scored from a range of 75 (better outcome) to 225."", 'timeFrame': '3 weeks'}, {'measure': 'Mean Brief-A Score', 'description': ""The BRIEF-A is a standardized measure that captures views of an adult's executive functions or self-regulation in his or her everyday environment. Both a self-report and an informant report are used. The BRIEF-A includes 75 items within nine non-overlapping theoretically and empirically derived clinical scales: Inhibit, Self-Monitor, Plan/Organize, Shift, Initiate, Task Monitor, Emotional Control, Working Memory, and Organization of Materials. All 75 items are rated in terms of frequency on a 3-point scale: 1 (never), 2 (sometimes), 3 (often). Raw scores for each scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Composite scores are calculated and are scored from a range of 75 (better outcome) to 225."", 'timeFrame': '6 weeks'}]","[{'measure': 'Mean PHQ-9 Score', 'description': 'The Patient Health Questionnaire (PHQ-9) is a self-administered, nine-item depression scale of the patient health questionnaire. The nine items of the PHQ-9 are based directly on the nine diagnostic criteria for major depressive disorder in the DSM-IV.\n\nThe PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as ""0"" (not at all) to ""3"" (nearly every day). Total scores can range from 0 to 27.\n\nA total score of 0-4 indicates minimal depression severity, 5-9 indicates mild depression severity, 10-14 indicates moderate depression severity, 15-19 indicates moderately severe, 20-27 indicates severe depression severity. Therefore, a high score indicates a worse outcome.\n\nOutcome measures will be assessing a change in scores pre- and post- prescription of Amantadine.', 'timeFrame': 'Baseline'}, {'measure': 'Mean PHQ-9 Score', 'description': 'The Patient Health Questionnaire (PHQ-9) is a self-administered, nine-item depression scale of the patient health questionnaire. The nine items of the PHQ-9 are based directly on the nine diagnostic criteria for major depressive disorder in the DSM-IV.\n\nThe PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as ""0"" (not at all) to ""3"" (nearly every day). Total scores can range from 0 to 27.\n\nA total score of 0-4 indicates minimal depression severity, 5-9 indicates mild depression severity, 10-14 indicates moderate depression severity, 15-19 indicates moderately severe, 20-27 indicates severe depression severity. Therefore, a high score indicates a worse outcome.\n\nOutcome measures will be assessing a change in scores pre- and post- prescription of Amantadine.', 'timeFrame': '3 weeks'}, {'measure': 'Mean PHQ-9 Score', 'description': 'The Patient Health Questionnaire (PHQ-9) is a self-administered, nine-item depression scale of the patient health questionnaire. The nine items of the PHQ-9 are based directly on the nine diagnostic criteria for major depressive disorder in the DSM-IV.\n\nThe PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as ""0"" (not at all) to ""3"" (nearly every day). Total scores can range from 0 to 27.\n\nA total score of 0-4 indicates minimal depression severity, 5-9 indicates mild depression severity, 10-14 indicates moderate depression severity, 15-19 indicates moderately severe, 20-27 indicates severe depression severity. Therefore, a high score indicates a worse outcome.\n\nOutcome measures will be assessing a change in scores pre- and post- prescription of Amantadine.', 'timeFrame': '6 weeks'}]",6,12 Years,65 Years,ALL,False,Columbia University,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:22.193489,v2_robust,True,True,False,True,False,PI left institution.
NCT00009737,A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer,An Open-Label Randomized Phase III Study Comparing Xeloda (Capecitabine) With IV Bolus 5-Fluorouracil in Combination With Low-Dose Leucovorin as Adjuvant Chemotherapy in Patients Who Underwent Surgery for Dukes C Colon Cancer,5-Fluorouracil,"['Leucovorin', 'Capecitabine [Xeloda]', '5-Fluorouracil']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Colorectal Cancer,['Colorectal Cancer'],[],COMPLETED,,1998-11,2004-04,"[{'measure': 'Disease-free Survival', 'description': 'Participants with disease-free survival were reported. Disease-free survival was assessed as the number of days between randomization and the first time at which relapse, a new occurrence of colon cancer, or death was recorded, or the last time at which a participant was known to be disease free (censoring time).', 'timeFrame': 'Approximately 3 years'}]","[{'measure': 'Relapse-Free Survival', 'description': 'Participants with relapse-free survival were reported. Relapse-free survival was assessed as the number of days between randomization and the first time at which relapse, a new occurrence of colon cancer, or death was recorded, or the last time at which a participants was known to be disease free (censoring time), excluding deaths that were not related to treatment or to disease progression.', 'timeFrame': 'Approximately 3 years'}, {'measure': 'Overall Survival', 'description': 'Participants with overall survival were reported. Overall survival was assessed as the number of days between randomization and death or the last time at which a participant was known to be alive (censoring time).', 'timeFrame': 'Approximately 3 years'}, {'measure': 'Mean Change From Baseline in Global Health Status at Week 25', 'description': 'Global health status was assessed as a sub scale of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. It was scored on a scale of 0-100; where higher score indicates better quality of life. Wherever the scores for the participants were not available, the last value carried forward (LVCF) were used.', 'timeFrame': 'Baseline (Days -7 to 1) and at Week 25'}, {'measure': 'Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters', 'description': 'Laboratory abnormalities were categorized according to the National Cancer Institute of Canada Common Toxicity Criteria (NCIC - CTC) grading system (May 1991 revised) as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (life- threatening). Participants with abnormalities in hemoglobin, granulocytes, lymphocytes, neutrophils, neutrophils/granulocytes, platelets, white blood cell, potassium, serum creatinine, sodium, total bilirubin, alanine transaminase, aspartate aminotransferase, alkaline phosphatase, calcium (hyper), and calcium (hypo) with Grades 1-4 were presented.', 'timeFrame': 'Up to Week 25'}, {'measure': 'Number of Participants With Any Adverse Events and Serious Adverse Events', 'description': 'An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An Serious Adverse Events (SAEs) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.', 'timeFrame': 'Up to Week 29'}]",6,18 Years,75 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,1987.0,ACTUAL,2025-09-01T16:18:22.193550,v2_robust,True,True,True,False,True,
NCT03439345,Lowering Events in Non-proliferative Retinopathy in Scotland,A Randomised Placebo-controlled Trial of Fenofibrate to Prevent Progression of Non-proliferative Retinopathy in Diabetes,Fenofibrate 145 mg,"['Fenofibrate 145 mg', 'Placebo Oral Tablet']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetic Retinopathy,['Diabetic Retinopathy'],[],COMPLETED,,2018-07-23,2024-02-16,"[{'measure': 'Number of Participants With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment', 'description': ""Primary outcome was a composite of the development of referable diabetic retinopathy or referable maculopathy, or treatment for diabetic retinopathy or maculopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication). Referable diabetic retinopathy was defined by the NHS Scotland's grading criteria as any development of R3, R4 or M2 disease. R3 (referable background diabetic retinopathy): any of four or more blot hemorrhages in both inferior and superior hemi-fields, or venous beading, or intraretinal microvascular abnormalities (IRMA); R4 (proliferative diabetic retinopathy): any active new vessels, or vitreous hemorrhage; M2 (referable maculopathy): any blot hemorrhages, or hard exudates within a radius of ≤1 optic disc diameter of the centre of the fovea. Adverse event reports of eye procedures, vitreous haemorrhages and macular oedema were adjudicated by experienced doctors at the Central Co-ordinating Office (CCO), masked to treatment allocation."", 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}]","[{'measure': 'Number of Participants With the Individual Component of the Composite Primary Outcome: Development of Referable Diabetic Retinopathy or Maculopathy', 'description': 'Progression of Diabetic Retinopathy/Maculopathy to a referable grade (R3 or R4 or M2) based on the NHS Scotland grading scheme in at least one eye.', 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants With the Individual Component of Composite Primary Outcome: Treatment for Diabetic Retinopathy or Maculopathy', 'description': 'Treatment for diabetic retinopathy or maculopathy (including intravitreal injection of medication, retinal laser therapy, or vitrectomy) in either eye.', 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants With Any Progression of Diabetic Retinopathy or Maculopathy Across the NHS Scotland Retinopathy Grading Scale', 'description': 'Any progression of diabetic retinopathy or maculopathy across the NHS Scotland retinopathy grading scale. R4 = Proliferative DR, R3 = Referable background DR, R2 = Observable background DR. R1 = Mild background DR, R0 = No DR anywhere (where R4 is the highest severity grade and R0 is the lowest grade); M2 = Referable maculopathy, M1 = Observable maculopathy, M0 = No Maculopathy (where M2 is the highest severity grade and M0 is the lowest grade).', 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants With Referable Maculopathy (Exudates or Blot Haemorrhages Within One Disc Diameter of the Fovea)', 'description': 'The presence of hard exudates or blot haemorrhages within 1 disc diameter of the macula/fovea', 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants With The Development of Macular Oedema', 'description': 'The accumulation of macular fluid as determined by optical coherence tomography (OCT) imaging or on adverse event report', 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Visual Acuity', 'description': ""Based on measurement of visual acuity at retinal screening visits. Baseline visual acuity was taken from routine measurement within NHS Scotland's Diabetic Eye Screening programme (using the latest value within 18 months of randomisation). Visual acuity after randomisation was obtained by averaging available results for a participant. Conversion from Snellen to LogMAR was applied where necessary. This analysis is based on the better eye: if only 1 eye with results, analyse that eye; if 2 eyes, use eye with better acuity; if identical acuity in both eyes, use the right eye. LogMAR typically ranges from -0.3 (20/10 vision on the Snellen chart) to 1 (20/200 vision). Lower scores indicate better vision."", 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Visual Function, Based on the National Eye Institute Visual Functioning Questionnaire 25 (VFQ-25).', 'description': 'Visual function is based on the Visual Function Questionnaire-25. Visual function was defined by the composite score derived from the VFQ-25. VFQ-25 data were collected at the screening visit, after two years and at the end of the study. Results from two years and end-of-study were averaged to provide a trial-averaged result for a participant. The VFQ-25 composite score ranges from 0 to 100, where higher scores indicate better visual function. It is calculated by averaging results from up to 11 vision-related sub-scales.', 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Quality of Life, Based on the EQ-5D Index Score', 'description': 'Quality of life was measured using the EQ-5D instrument, and valued by mapping to the EQ-5D-3L UK value set using the mapping function developed by Hernandez Alava et al. Pharmaco Economics (2022). EQ-5D data were collected at the screening visit, after two years and at the end of the study. Results from two years and end-of-study were averaged to provide a trial-averaged result for a participant. Possible scores range from -0.59 to 1.00, where 1 is the best possible health state and 0 represents a quality of life considered equivalent to death.', 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Quality of Life, Based on the EQ-5D Visual Analogue Scale.', 'description': 'EQ-5D Visual Analogue Scale data were collected at the screening visit, after two years and at the end of the study. Results from two years and end-of-study were averaged to provide a trial-averaged result for a participant. EQ VAS scores range from 0 to 100, where 100 is the best possible health state.', 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Cost to the Health Service', 'description': 'Health economic analysis: cost to the health service over 2 years. This included (i) hospital inpatient and outpatient activity (costed with nationally representative NHS costs); (ii) costs of fenofibrate (based on 200mg NHS cost); (iii) laboratory tests (NHS cost (including nurse/doctor time)); (iv) community prescribed medicines (NHS costs); (v) NHS Scotland retinal screening (published NHS unit costs); (vi) treatment for advanced retinopathy: for relevant participants, application of assumptions regarding usual number of injections from UK cohort study.', 'timeFrame': '2 years'}, {'measure': 'Cost-effectiveness (Incremental Cost Per QALY Gained)', 'description': 'Health economic analysis: Cost-effectiveness (incremental cost per QALY gained). The result is the value of GBP (British Pound) expenditure required to gain 1 quality adjusted life year for fenofibrate therapy vs. standard care. Years gained are presented by arm with 95% credible intervals taken as 2.5th and 97.5th percentile of simulated probabilistic output.', 'timeFrame': 'Projected over 10 year horizon'}, {'measure': 'Number of Participants in Subgroup Sex - Male With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment', 'description': ""Composite primary outcome in prespecified subgroup according to the baseline characteristic: Sex - male. The primary outcome was a composite of the development of referable diabetic retinopathy, or treatment for diabetic retinopathy or maculopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication). The definition for referable diabetic retinopathy is provided above in '1. Primary Outcome: Number of Participants with Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment."", 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants in Subgroup Sex - Female With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment', 'description': ""Composite primary outcome in prespecified subgroup according to the baseline characteristic: Sex - female. The primary outcome was a composite of the development of referable diabetic retinopathy, or treatment for diabetic retinopathy or maculopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication). The definition for referable diabetic retinopathy is provided above in '1. Primary Outcome: Number of Participants with Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment."", 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants in Subgroup Age <60y With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment', 'description': ""Composite primary outcome in prespecified subgroup according to the baseline characteristic: Age \\<60 years. The primary outcome was a composite of the development of referable diabetic retinopathy, or treatment for diabetic retinopathy or maculopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication). The definition for referable diabetic retinopathy is provided above in '1. Primary Outcome: Number of Participants with Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment."", 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants in Subgroup Age ≥60y With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment.', 'description': ""Composite primary outcome in prespecified subgroup according to the baseline characteristic: Age ≥60 years. The primary outcome was a composite of the development of referable diabetic retinopathy, or treatment for diabetic retinopathy or maculopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication). The definition for referable diabetic retinopathy is provided above in '1. Primary Outcome: Number of Participants with Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment."", 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants in Subgroup - Type 1 Diabetes With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment', 'description': ""Composite primary outcome in prespecified subgroup according to the baseline characteristic: Type of Diabetes - type 1 diabetes. The primary outcome was a composite of the development of referable diabetic retinopathy, or treatment for diabetic retinopathy or maculopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication). The definition for referable diabetic retinopathy is provided above in '1. Primary Outcome: Number of Participants with Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment."", 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants in Subgroup - Type 2 or Other Type of Diabetes With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment', 'description': ""Composite primary outcome in prespecified subgroup according to the baseline characteristic: Type 2 and other diabetes. The primary outcome was a composite of the development of referable diabetic retinopathy, or treatment for diabetic retinopathy or maculopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication). The definition for referable diabetic retinopathy is provided above in '1. Primary Outcome: Number of Participants with Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment."", 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants in Subgroup - eGFR <60 mL/Min/1.73m^2 With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment', 'description': ""Primary outcome in prespecified subgroup according to the baseline characteristic: Renal function at Randomisation - eGFR \\<60mL/min/1.73m\\^2). The primary outcome was a composite of the development of referable diabetic retinopathy, or treatment for diabetic retinopathy or maculopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication). The definition for referable diabetic retinopathy is provided above in '1. Primary Outcome: Number of Participants with Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment."", 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants in Subgroup - eGFR ≥60 mL/Min/1.73m^2 With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment', 'description': ""Composite primary outcome in prespecified subgroup according to the baseline characteristic: Renal function at Randomisation - eGFR ≥60mL/min/1.73m\\^2. The primary outcome was a composite of the development of referable diabetic retinopathy, or treatment for diabetic retinopathy or maculopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication). The definition for referable diabetic retinopathy is provided above in '1. Primary Outcome: Number of Participants with Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment."", 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants in Subgroup - HbA1c <70 mmol/Mol With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment', 'description': ""Primary outcome in prespecified subgroup according to the baseline characteristic: HbA1c at Screening \\<70mmol/mol. The primary outcome was a composite of the development of referable diabetic retinopathy, or treatment for diabetic retinopathy or maculopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication). The definition for referable diabetic retinopathy is provided above in '1. Primary Outcome: Number of Participants with Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment."", 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants in Subgroup - HbA1c ≥70 mmol/Mol With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment', 'description': ""Primary outcome in prespecified subgroup according to the baseline characteristic-HbA1c at Screening - ≥70mmol/mol. The primary outcome was a composite of the development of referable diabetic retinopathy, or treatment for diabetic retinopathy or maculopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication). The definition for referable diabetic retinopathy is provided above in '1. Primary Outcome: Number of Participants with Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment."", 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants in Subgroup - HbA1c Unknown With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment', 'description': ""Composite primary outcome in prespecified subgroup according to the baseline characteristic - HbA1c at Screening - Unknown. The primary outcome was a composite of the development of referable diabetic retinopathy, or treatment for diabetic retinopathy or maculopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication). The definition for referable diabetic retinopathy is provided above in '1. Primary Outcome: Number of Participants with Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment."", 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years'}, {'measure': 'Number of Participants in Subgroup With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment, Within 1 Year of Randomization', 'description': ""Composite primary outcome in prespecified subgroup according to the baseline characteristic: Timing of primary outcome - Within first year. The primary outcome was a composite of the development of referable diabetic retinopathy, or treatment for diabetic retinopathy or maculopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication). The definition for referable diabetic retinopathy is provided above in '1. Primary Outcome: Number of Participants with Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment."", 'timeFrame': 'Up to 1 year from randomisation.'}, {'measure': 'Number of Participants in Subgroup With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment, After 1 Year From Randomization', 'description': ""Composite primary outcome in prespecified subgroup according to the baseline characteristic: Timing - After first year. The primary outcome was a composite of the development of referable diabetic retinopathy, or treatment for diabetic retinopathy or maculopathy (including retinal laser therapy, vitrectomy or intravitreal injection of medication). The definition for referable diabetic retinopathy is provided above in '1. Primary Outcome: Number of Participants with Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment."", 'timeFrame': '4.0 years (interquartile range, 3.6 to 4.3) years, excluding any primary outcome events within the first year of randomisation.'}]",25,18 Years,,ALL,False,University of Oxford,OTHER,6,1151.0,ACTUAL,2025-09-01T16:18:22.193596,v2_robust,True,True,True,False,True,
NCT05611645,Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence,A Randomized Phase II Trial of Concurrent Low-dose Bevacizumab and HSRT Versus Bevacizumab Alone for Glioblastoma at First Recurrence: HSCK-005,Bevacizumab,"['Avastin', 'rhuMAb VEGF', 'anti-VEGF monoclonal antibody', 'Bevacizumab']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Glioma,"['Glioma', 'Recurrent Glioma']",[],ACTIVE_NOT_RECRUITING,,2022-10-01,2025-12,"[{'measure': 'Progression-free Survival rate at 6 Months', 'description': 'Prgression was defined using Response Assessment in Neuro-Oncology (RANO) Criteria. Progression-free at 6 months means patient alive without progression at 6 months. Survival rates are estimated by the Kaplan-Meier method.', 'timeFrame': 'From randomization to six months'}]","[{'measure': 'Overall Survival', 'description': 'Survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Survival rates are estimated by the Kaplan-Meier method.', 'timeFrame': 'From randomization to last follow-up, up to approximately 24 months'}, {'measure': 'Progression-free Survival', 'description': 'Prgression was defined using Response Assessment in Neuro-Oncology (RANO) Criteria. Progression-free survival time is defined as time from randomization to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method.', 'timeFrame': 'From randomization to last follow-up, up to approximately 24 months'}, {'measure': 'Objective response rate', 'description': 'ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Assessment in Neuro-Oncology (RANO) prior to progression or any further therapy.', 'timeFrame': 'Bimonthly up to intolerance the toxicity or progressive disease (PD), up to approximately 24 months'}, {'measure': 'Number of Participants With Grade 3+ Toxicity rate', 'description': 'Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Grade refers to the severity of the AE. Estimated using an exact binomial distribution together with 95% confidence interval. The difference between the two groups will be tested using a chi square test.', 'timeFrame': 'Bimonthly up to intolerance the toxicity or PD, up to approximately 24 months'}, {'measure': 'Quality of Life score (QoL)', 'description': 'EORTC QLQ-C30 (version 3.0) questionnaire to evaluate the quality of life. All scales range in score from 0 to 100. A high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.', 'timeFrame': 'Bimonthly up to intolerance the toxicity or PD, up to approximately 24 months'}, {'measure': 'Cognitive function', 'description': 'Mini-Mental State Exam (MMSE, score range 0 to 30) to evaluate the cognitive function. Any score of 24 or more (out of 30) indicates a normal cognition. Below this, scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment.', 'timeFrame': 'Bimonthly up to intolerance the toxicity or PD, up to approximately 24 months'}]",7,18 Years,70 Years,ALL,False,Huashan Hospital,OTHER,0,42.0,ESTIMATED,2025-09-01T16:18:22.193821,v2_robust,True,True,False,False,True,
NCT01650545,Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients,A Pilot Study to Demonstrate Efficacy and Safety of Aerosol Liposomal Cyclosporine (L-CsA) in the Treatment of Bronchiolitis Obliterans Syndrome After Lung Transplantation,Liposomal aerosol cyclosporine,"['cyclosporine', 'Liposomal aerosol cyclosporine']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Disorder Related to Lung Transplantation,"['Disorder Related to Lung Transplantation', 'Bronchiolitis Obliterans', 'Decreased Immunologic Activity', 'Chronic Rejection of Lung Transplant']","['case-control study', 'aerosolized liposomal cyclosporine A', 'bronchiolitis obliterans syndrome', 'Lung Transplantation', 'Lung function']",COMPLETED,,2012-07,2019-11,"[{'measure': 'Number Of Participants With Chronic Rejection Who Met Primary Combined End-point', 'description': 'Treatment failure defined as: BOS progression (\\> 20% decline lung function), re-transplant, or death', 'timeFrame': 'approximately 1 year'}]","[{'measure': 'Cytokine Analysis From BAL Fluid in Lung', 'description': 'Multiple cytokines were assessed as markers of lung inflammation that may be used in addition to biopsy data, collected per patient as clinically indicated during the follow-up interval. Values are reported as mean change from baseline in each group, per week', 'timeFrame': 'baseline to approximately 1 year'}, {'measure': 'Overall Survival at 5 Years Follow-up', 'description': 'Number of participants surviving at 5 year follow-up', 'timeFrame': '5 years'}]",3,18 Years,,ALL,False,"University of Maryland, Baltimore",OTHER,0,21.0,ACTUAL,2025-09-01T16:18:22.193844,v2_robust,True,True,True,False,False,
NCT03074045,LCS16 vs. COC User Satisfaction and Tolerability Study,"Multi-center, Randomized, Open-label, Parallel-group Study to Evaluate User Satisfaction With and Tolerability of the Low-dose Levonorgestrel (LNG) Intrauterine Delivery System (IUS) With 16 μg LNG/Day Initial in Vitro Release Rate (LCS16) in Comparison to a Combined Oral Contraceptive (COC) Containing 30 μg Ethinyl Estradiol and 3 mg Drospirenone (Yarina®) in Young Nulliparous and Parous Women (18 - 29 Years) Over 12 Months of Use (With an Option for Extended Use of LCS16 for up to 5 Years)","Levonorgestrel (Kyleena, BAY86-5028)","['Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)', 'Levonorgestrel (Kyleena, BAY86-5028)']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Contraception,['Contraception'],"['Intrauterine', 'Birth control']",COMPLETED,,2017-03-13,2022-08-05,"[{'measure': 'Overall satisfaction rate', 'description': '5-point Likert item\n\n1. Very satisfied\n2. Satisfied\n3. Neither satisfied nor dissatisfied\n4. Dissatisfied\n5. Very dissatisfied', 'timeFrame': '12 months'}]","[{'measure': 'Number of adverse events', 'description': 'at 1, 6 and 12 months for all subjects during the comparative part of the study.\n\nat the end of Year 2, Year 3, Year 4 and Year 5 only for subjects, who elect to enter the LCS16 extension phase.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Discontinuation rates', 'description': 'at 1, 6 and 12 months for all subjects during the comparative part of the study.\n\nat the end of Year 2, Year 3, Year 4 and Year 5 only for subjects, who elect to enter the LCS16 extension phase.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Bleeding pattern', 'description': 'Only during the comparative part of the study', 'timeFrame': 'Up to 12 months'}, {'measure': 'User satisfaction and bleeding questionnaire', 'description': 'At 6 and 12 months after the start of study treatment (or at early termination for those subjects discontinuing the study before completion of the 12 months) for all subjects during the comparative part of the study.', 'timeFrame': 'Up to 12 months'}]",5,18 Years,29 Years,FEMALE,False,Bayer,INDUSTRY,0,145.0,ACTUAL,2025-09-01T16:18:22.193886,v2_robust,True,True,True,False,True,
NCT01697345,"Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy","Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: A Pilot Study on the Effects of Vaginal Testosterone Therapy",Testosterone,['Testosterone'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Breast Cancer,"['Breast Cancer', 'Vaginal Dryness', 'Dyspareunia', 'Sexual Health Quality of Life']","['Vaginal Testosterone', 'Vaginal atrophy', 'Female Sexual Dysfunction', 'Aromatase Inhibitors']",COMPLETED,,2013-02,2013-05,"[{'measure': 'Total Female Sexual Function Index (FSFI) Score', 'description': 'The Female Sexual Function Index (FSFI) questionnaire was administered to participants prior to starting vaginal testosterone therapy and the survey was repeated after using the study drug for 4 weeks. The participants served as their own controls. The FSFI assesses six domains of sexual functioning (desire, arousal, lubrication, orgasm, satisfaction, and pain) over the past 4 weeks. The sum of all domain scores equals the total FSFI score. The total FSFI score ranges from 2-36 and a total FSFI score \\< 26.5 suggests female sexual dysfunction.', 'timeFrame': 'Baseline, 4 weeks'}, {'measure': 'FSFI Desire Domain', 'description': 'The desire score is calculated by adding the individual scores from the desire domain (question #1 and #2) and multiplying the sum by the domain factor of 0.6. The domain score for desire ranges from 1.2 (minimum) to 6 (maximum) and a higher value represents a better outcome.', 'timeFrame': 'Baseline, 4 weeks'}, {'measure': 'FSFI Arousal Domain', 'description': 'The arousal score is calculated by adding the individual scores from the arousal domain (question #3, #4, #5, #6) and multiplying the sum by the domain factor of 0.3. The arousal domain score ranges from 0 (minimum) to 6 (maximum)and a higher value represents a better outcome.', 'timeFrame': 'Baseline, 4 weeks'}, {'measure': 'FSFI Lubrication Domain', 'description': 'The lubrication score is calculated by adding the individual scores from the lubrication domain (question #7, #8, #9, #10) and multiplying the sum by the domain factor of 0.3. The domain score for lubrication ranges from 0 (minimum) to 6 (maximum) and a higher value represents a better outcome.', 'timeFrame': 'Baseline, 4 weeks'}, {'measure': 'FSFI Orgasm Domain', 'description': 'The orgasm score is calculated by adding the individual scores from the orgasm domain (question #11, #12, #13) and multiplying the sum by the domain factor of 0.4. The domain score for orgasm ranges from 0 (minimum) to 6 (maximum) and a higher value represents a better outcome.', 'timeFrame': 'Baseline, 4 weeks'}, {'measure': 'FSFI Satisfaction Domain', 'description': 'The satisfaction score is calculated by adding the individual scores from the satisfaction domain (question #14, #15, #16) and multiplying the sum by the domain factor of 0.4. The satisfaction domain score ranges from 0.8 (minimum) to 6 (maximum) and a higher value represents a better outcome.', 'timeFrame': 'Baseline, 4 weeks'}, {'measure': 'FSFI Pain Domain', 'description': 'The score for pain is calculated by adding the individual scores from the pain domain (question #17, #18, #19) and multiplying the sum by the domain factor of 0.4. The domain score for pain ranges from 0 (minimum) to 6 (maximum) and a higher value represents a better outcome.', 'timeFrame': 'Baseline, 4 weeks'}]","[{'measure': 'Number of Participants Who Continued Vaginal Testosterone Upon Completion of the Study', 'timeFrame': 'After 4 weeks'}]",8,50 Years,,FEMALE,False,Creighton University,OTHER,0,12.0,ACTUAL,2025-09-01T16:18:22.193931,v2_robust,True,True,True,False,False,
NCT02686645,Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection,Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection,vancomycin,"['metronidazole', 'vancomycin', 'Loperamide']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Clostridium Difficile Infection,['Clostridium Difficile Infection'],['Fecal Microbiota Transplantation'],UNKNOWN,,2016-12,2021-12,"[{'measure': 'Resolution of CDI', 'description': 'Resolution of CDI will be defined as \\< 3 bowel movements per day for 7 consecutive days or stool negative for Clostridium difficile (CD) on 2 consecutive stool sample at least 1 day apart within 30 days of the treatment.', 'timeFrame': '30 days'}]","[{'measure': 'Success of treatment', 'description': 'Success of treatment with be absence of recurrence of CDI within 3 months of treatment. A recurrence will be defined as ≥ 3 bowel movements per day after a period of resolution with a positive stool for CD toxin within 3 months for treatment.', 'timeFrame': '3 months'}, {'measure': 'Adverse effects', 'description': 'Adverse effects experienced with treatment up to 6 months after treatment.', 'timeFrame': '6 months'}, {'measure': 'Quality of life', 'description': 'Quality of Life Assessment (prior to, 3 month and 6 months after FMT) using the Short Form 36 (SF-36) Health Survey.', 'timeFrame': 'day 0, 3 months and 6 months'}, {'measure': 'Recipient Satisfaction', 'description': 'Recipient Satisfaction Survey which will be completed within 1 week of the FMT and again at 3 and 6 months post FMT.', 'timeFrame': '1week, 3 months and 6 months'}, {'measure': 'Donor Satisfaction', 'description': 'The donor will complete a satisfaction survey within 1 week after the stool donation.', 'timeFrame': '1 week'}]",6,18 Years,,ALL,False,Queen Elizabeth II Health Sciences Centre,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:22.193974,v2_robust,True,True,False,False,True,
NCT04988945,TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma,Sequential TransArterial Chemoembolization and Stereotactic RadioTherapy Followed by Durvalumab (MEDI4736) and Tremelimumab for Downstaging Hepatocellular Carcinoma for Hepatectomy,Durvalumab,"['Tremelimumab', 'Durvalumab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,HCC,['HCC'],"['HCC', 'TACE', 'SBRT', 'immunotherapy', 'hepatocellular carcinoma', 'liver cancer', 'unresectable', 'large liver tumour']",RECRUITING,,2020-12-01,2026-12-01,"[{'measure': 'Downstaging for hepatectomy', 'description': 'To assess the number of patients amendable to curative surgical interventions (resection or radiofrequency ablation) after successful down-sizing of tumor(s) by intervention in HCC patients treated with combined TACE and SBRT followed by Durvalumab plus Tremelimumab', 'timeFrame': 'From the date of first study treatment to the date of last study treatment, an average of 3 years'}]","[{'measure': 'Response rate measured by mRECIST criteria', 'description': 'Complete response (CR): Disappearance of any intra-tumoral arterial enhancement in all target lesions Partial response (PR): At least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions Stable disease (SD): Any cases that do not qualify for either partial response or progressive disease Progressive disease (PD): An increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started', 'timeFrame': 'From the date of screening to radiographically documented progression according to mRECIST 1.1, assessed up to 3 years'}, {'measure': 'Time to progression (TTP)', 'description': 'measured from the date of first study treatment to radiographically documented progression according to mRECIST 1.1. This does not include death from any cause.', 'timeFrame': 'From the date of first study treatment to radiographically documented progression according to mRECIST 1.1, assessed up to 3 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'measured from the date of first study treatment to radiographically documented progression according to mRECIST 1.1 or death from any cause (whichever occurs first). Participants alive and without disease progression or lost to follow-up will be censored at the date of their last radiographic assessment.', 'timeFrame': 'From the date of first study treatment to radiographically documented progression according to mRECIST 1.1 or death from any cause, whichever occurs first, assessed up to 3 years'}, {'measure': 'Overall survival (OS)', 'description': 'measured from date of first study treatment to the date of death from any cause', 'timeFrame': 'From the date of first study treatment to the date of death from any cause, assessed up to 5 years'}, {'measure': 'Toxicity tolerability measurement in treatment related procedure', 'description': 'To measure the toxicities in HCC patients treated with combined TACE and SBRT followed by Durvalumab plus Tremelimumab. Dosage used will be recorded each time together with the response of patients. If any adverse event happens, the highest dosage will be noted down.', 'timeFrame': 'From the date of screening to 90 days after last treatment, around 3 years and 90 days'}, {'measure': 'Questionnaire based Quality of Life (QoL) assessment', 'description': 'To evaluate the patient-reported quality of life (QoL) treated with combined TACE and SBRT followed by Durvalumab plus Tremelimumab. Questionnaires EORTC-QLQ-C30 and FACT Hep will be used', 'timeFrame': 'From the date of screening to radiographically documented progression according to mRECIST 1.1, an average of 3 years'}, {'measure': 'Pathological response', 'description': 'Defined as the percentage of surface with non-viable cancer cells (represented by necrosis or fibrosis, the ultimate stage of necrosis) in relation to the total tumor area and will be equal to: 100% - viable cancer cells (%). If there are multiple tumors, the mean percentage will be used. Pathological complete response (pCR) is defined by the absence of viable tumor cells in any nodule.', 'timeFrame': 'From the date of first study treatment to amendable to surgery after receiving combined TACE and SBRT followed by Durvalumab plus Tremelimumab, whichever occurs first, assessed up to 5 years'}]",8,18 Years,,ALL,False,The University of Hong Kong,OTHER,0,33.0,ESTIMATED,2025-09-01T16:18:22.193996,v2_robust,True,True,False,False,True,
NCT01064245,Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests,Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests,high-dose methacholine challenge test,"['Provocholine', 'high-dose methacholine challenge test']",2,INTERVENTIONAL,['NA'],,,Asthma,"['Asthma', 'Cough Variant Asthma']","['Asthma', 'Cough Variant Asthma', 'Mannitol', 'Methacholine', 'Cough', 'Hypersensitivity']",COMPLETED,,2010-02-01,2021-12-31,"[{'measure': 'PD15 (15% fall in forced expiratory volume in one second (FEV1) from baseline during challenge test visits)', 'timeFrame': 'baseline and several time points collected throughout test (high-dose methacholine challenge test or mannitol challenge test)'}]","[{'measure': '%ΔFEV1 (percentage change in forced expiratory volume in one second)', 'timeFrame': 'baseline and several time points collected throughout test (high-dose methacholine challenge test or mannitol challenge test)'}, {'measure': 'Plateau response', 'timeFrame': 'baseline and several time points collected throughout test (high-dose methacholine challenge test or mannitol challenge test)'}, {'measure': 'Dose-response slope', 'timeFrame': 'baseline and several time points collected throughout test (high-dose methacholine challenge test or mannitol challenge test)'}, {'measure': 'Expiratory Flow Limitation (EFL)', 'timeFrame': 'baseline and several time points collected throughout test (high-dose methacholine challenge test or mannitol challenge test)'}]",5,18 Years,65 Years,ALL,False,Dr. Diane Lougheed,OTHER,2,29.0,ACTUAL,2025-09-01T16:18:22.194108,v2_robust,True,True,True,False,False,
NCT04532645,"Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK","A Pan-European Non-interventional, Retrospective Observational Cohort Study of Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Treated With Olaparib Tablets in the First-line Maintenance Setting",Olaparib,"['Lynparza', 'Olaparib']",2,OBSERVATIONAL,[],,,Ovary Cancer,['Ovary Cancer'],"['Ovary cancer', 'Ovarian neoplasm', 'BRCA mutated advanced (FIGO stage III-IV) ovarian cancer']",COMPLETED,,2021-01-07,2024-09-27,"[{'measure': 'Progression', 'description': 'Progression-free survival (PFS)', 'timeFrame': '36 months'}]","[{'measure': 'Overall Survival', 'description': 'Overall survival over 36 months', 'timeFrame': '36 months'}]",2,18 Years,,FEMALE,False,AstraZeneca,INDUSTRY,0,342.0,ACTUAL,2025-09-01T16:18:22.194129,v2_robust,False,True,True,False,False,
NCT05905172,Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Entecavir-based, Phase IIIb Clinical Trial of Hydronidone Capsule in the Treatment of Liver Fibrosis Associated With Chronic Hepatitis B",Hydronidone capsules,"['The placebo capsules', 'N', 'Hydronidone capsules', 'F351']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Liver Fibrosis,['Liver Fibrosis'],[],RECRUITING,,2023-08-12,2028-10-20,"[{'measure': 'Cumulative incidence of clinical endpoint events (defined as the occurrence of any clinical endpoint event).', 'description': 'For non-cirrhotic patients, clinical endpoints include progression to cirrhosis, decompensated cirrhosis complications \\[ascites, esophagogastric vein rupture and bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy, portal vein thrombosis and cirrhotic cardiomyopathy, etc.\\], hepatocellular carcinoma, liver transplantation or liver disease-related death / all-cause death; for patients with cirrhosis, clinical endpoints include occurrence of decompensated cirrhosis complications, hepatocellular carcinoma, liver transplantation or liver disease-related death or all-cause death.', 'timeFrame': '5years'}]",[],1,18 Years,65 Years,ALL,False,"Beijing Continent Pharmaceutical Co, Ltd.",INDUSTRY,0,248.0,ESTIMATED,2025-09-01T16:18:22.194177,v2_robust,True,True,False,False,False,
NCT00671372,A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer,"A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Multiple Doses of Dulanermin Administered Intravenously in Combination With Camptosar®/Erbitux® Chemotherapy or the Folfiri Regimen With or Without Bevacizumab in Subjects With Previously Treated Metastatic Colorectal Cancer",FOLFIRI regimen,"['bevacizumab', 'dulanermin', 'irinotecan', 'cetuximab', 'FOLFIRI regimen']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Colorectal Cancer,['Colorectal Cancer'],"['CRC', 'Metastatic CRC', 'APO2L/TRAIL']",COMPLETED,,2006-07,2012-03,"[{'measure': 'The safety and tolerability of dulanermin administered in combination with Camptosar and Erbitux', 'timeFrame': 'Length of study'}, {'measure': 'The safety and tolerability of dulanermin administered in combination with FOLFIRI (with or without Bevacizumab)', 'timeFrame': 'Length of study'}]",[],2,18 Years,,ALL,False,"Genentech, Inc.",INDUSTRY,0,42.0,ACTUAL,2025-09-01T16:18:22.194253,v2_robust,True,True,True,False,True,
NCT06971172,Low-level Laser Therapy on Oral Pemphigus Vulgaris Patients.,EFFECT OF LOW LEVEL LASER THERAPY ON ORAL PIMPHIGUS VULGARIS,Medication,['Medication'],1,INTERVENTIONAL,['NA'],,,Pemphigus Vulgaris,['Pemphigus Vulgaris'],[],NOT_YET_RECRUITING,,2025-06-01,2025-09-01,"[{'measure': 'wound margins in millimeters', 'description': 'Measurement', 'timeFrame': '1 month'}]",[],1,18 Years,60 Years,ALL,False,Cairo University,OTHER,0,22.0,ESTIMATED,2025-09-01T16:18:22.194355,v2_robust,True,True,False,False,False,
NCT00142272,Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial,"Randomised, Open, Parallel Group Clinical Trial to Compare the Efficacy and Safety of a Single Dose of Ciprofloxacin Oral Suspension 20 mg/kg With a 3-day Course of Erythromycin Oral Suspension Administered in a Dose of 12.5 mg/kg Every 6 Hours (12 Doses) in the Treatment of Children,With Clinically Severe Cholera Due to V. Cholerae O1 or O139.",Ciprofloxacin,['Ciprofloxacin'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Cholera,['Cholera'],"['Ciprofloxacin', 'children', 'V.cholerae O1 and O139', 'drug resistance', 'Bangladesh']",COMPLETED,,2001-05,2002-07,[{'measure': 'Rates of clinical success'}],"[{'measure': 'Rates of bacteriologic success at test of cure visit.'}, {'measure': 'Duration of diarrhoea.'}, {'measure': 'Rates of clinical relapse.'}, {'measure': 'Rates of bacteriologic relapse.'}, {'measure': 'Duration of faecal excretion of V. cholerae O1 or V. cholerae O139.'}, {'measure': 'Measurements of six-hourly volume of watery stool will be done for the period in which patients are hospitalised.'}, {'measure': 'Proportion of patients requiring unscheduled intravenous fluids.'}, {'measure': 'Frequency of vomiting and its volume.'}, {'measure': 'Frequency of stool per day.'}, {'measure': 'Frequency of vomit per day.'}, {'measure': 'Safety.'}, {'measure': 'PK-assessment of serum and stool.'}]",13,2 Years,15 Years,MALE,False,"International Centre for Diarrhoeal Disease Research, Bangladesh",OTHER,2,180.0,,2025-09-01T16:18:22.194363,v2_robust,True,True,True,False,True,
NCT02109172,A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD),"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Cross-Over Study of QD and BID Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease",TD-4208,"['TD-4208', 'Placebo', 'Revefenacin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Obstructive Pulmonary Disease,"['Chronic Obstructive Pulmonary Disease', 'COPD']","['Chronic Obstructive Pulmonary Disease', 'COPD']",COMPLETED,,2014-04,2014-10,"[{'measure': 'Weighted Mean (0-24hr) Change From Baseline FEV1 (Forced Expiratory Volume in 1 Second)', 'description': 'Weighted mean (0-24hr) Change from baseline FEV1 (forced expiratory volume in 1 second). Measurement is change from baseline.', 'timeFrame': 'Following the Day 7 AM dose -12 hours post-dose and 24 hours post-dose'}]",[],1,40 Years,,ALL,False,Mylan Inc.,INDUSTRY,1,64.0,ACTUAL,2025-09-01T16:18:22.194412,v2_robust,True,True,True,False,False,
NCT03093272,A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer,A Phase 2 Study of Docetaxel Plus Apalutamide in Castration-Resistant Prostate Cancer Patients Post Abiraterone Acetate,Leuprolide Acetate,"['Leuprolide Acetate', 'Apalutamide', 'Taxotere', 'Deltasone', 'ARN-509', 'Docefrez', 'Prednisone', 'Docetaxel', 'Lupron Injection']",9,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,['Prostate Cancer'],['Prostate Cancer'],TERMINATED,Safety concerns,2017-06-23,2019-12-31,"[{'measure': 'To Evaluate Progression-free Survival on the Combination of Docetaxel Plus Apalutamide', 'description': 'Progression free survival (PFS) is defined as the time from treatment initiation until the occurrence of one of the following:\n\n1. A participant was considered to have progressed by bone scan if\n\n   1. the first bone scan with greater than or equal to (≥) 2 new lesions compared to baseline was observed in less than (\\<) 12 weeks from study drug initiation and was confirmed by a second bone scan taken ≥6 weeks later showing ≥2 additional new lesions (a total of ≥4 new lesions compared to baseline);\n   2. the first bone scan with ≥2 new lesions compared to baseline was observed in ≥12 weeks from study drug initiation and the new lesions were verified on the next bone scan ≥6 weeks later (a total of ≥2 new lesions compared to baseline);\n2. Progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) by RECIST v. 1.1; or\n3. Death from any cause.', 'timeFrame': 'Disease was evaluated radiologically at baseline and every 12 weeks on treatment; PFS follow up was up to 9.4 months'}]","[{'measure': 'Number of Participants With Dose-Limiting Toxicities in the Safety Lead-in Group (First 6 Patients)', 'description': 'Specific adverse events will be recorded during the safety lead-in phase of 6 patients. Any toxicities considered unacceptable during this time will be considered a dose-limiting toxicity and will be summarized among all patients evaluable for a dose-limiting toxicity (DLT).', 'timeFrame': 'First 3 weeks of treatment'}, {'measure': 'Maximum Blood Concentration (Cmax) for Docetaxel Pharmacokinetic Analysis', 'description': 'The pharmacokinetic (PK) parameters of the first 9 patients enrolled at Dana-Farber Cancer Institute will be determined using noncompartmental methods with WinNonLin version 5.2. Maximum blood concentration (Cmax) will be determined by visual inspection. Due to the premature termination of the study, only 9 patients were evaluated. The PK samples were collected on Days 1 and 2 of the first two treatment cycles.', 'timeFrame': 'Cycle 1, 2: During infusion at pre-dose, 15 minutes and 30 minutes post-dose, end of dose, and 0.5, 1, 1.5, 2, 4, 6, 8, 24 hours post dose.'}, {'measure': 'Area Under the Curve (AUC) for Docetaxel Pharmacokinetic Analysis', 'description': 'The area under the blood concentration-time curve (linear trapezoidal rule) will be determined between 0-24 hours (AUC0-24). The PK samples were collected during the first two days of cycles 1 and 2.', 'timeFrame': 'Cycle 1, 2: During infusion at pre-dose, 15 minutes and 30 minutes post-dose, end of dose, and 0.5, 1, 1.5, 2, 4, 6, 8, 24 hours post dose.'}, {'measure': 'Serum PSA Change From Baseline to 12 Weeks on Treatment', 'description': 'The maximum percent PSA change (rise or fall) from baseline to after 12 weeks on study. For patients who discontinue on or before the 12 week assessment or for whom the 12 week assessment is missing, the last observation prior to the week 12 assessment will be utilized. Patients with no post-baseline PSA data will be excluded from the summary.', 'timeFrame': 'PSA was measured on Cycle 1 Day 1 (Baseline) and at 12 weeks on treatment.'}, {'measure': 'Overall Survival', 'description': 'Overall Survival (OS) is defined as the time from trial treatment start to death due to any cause, or censored at date last known alive.', 'timeFrame': 'Measured from end of study treatment to death due to any cause; OS measured as 22.4 months'}]",6,18 Years,,MALE,False,Dana-Farber Cancer Institute,OTHER,1,9.0,ACTUAL,2025-09-01T16:18:22.194453,v2_robust,True,True,False,True,True,Safety concerns
NCT00409695,Thymoglobulin (ATG) Dose Finding Study,Dose Finding Study of Thymoglobulin (ATG) in Patients With Steroid-Refractory Acute Graft Versus Host Disease (aGVHD),Low Dose Thymoglobulin (ATG),"['Antithymocyte Globulin', 'ATG', 'High Dose Thymoglobulin (ATG)', 'Low Dose Thymoglobulin (ATG)']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Graft vs Host Disease,['Graft vs Host Disease'],"['Acute Graft versus Host Disease', 'aGVHD', 'Blood And Marrow Transplantation', 'Thymoglobulin', 'ATG']",TERMINATED,Lack of Accrual,2006-12,2007-08,"[{'measure': 'Response Rate', 'description': 'Response assessed at day 56, and a complete response or partial response considered a success. A toxic event defined as a life threatening infection, any death due to infection, or any death considered to be directly related to the administration of ATG.', 'timeFrame': 'Day 56'}]",[],1,,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1.0,ACTUAL,2025-09-01T16:18:22.194606,v2_robust,True,True,False,True,False,Lack of Accrual
NCT00830895,RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC),A Phase II Study to Evaluate the Efficacy of RAD001 in Metastatic Non-clear Cell Renal Cell Carcinoma,RAD001,['RAD001'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Renal Cell Carcinoma,['Renal Cell Carcinoma'],"['Renal cell carcinoma', 'Non-clear cell', 'RAD001', 'Metastatic, non-clear cell, renal cell carcinoma']",COMPLETED,,2009-01,2012-12,"[{'measure': 'Progression-free survival', 'description': 'It is the time from treatment initiation until disease progression.', 'timeFrame': '2 months, 4 months, 6 months'}]","[{'measure': 'Response rate', 'description': 'It is the percentage of patients whose cancer shrinks or disappears after treatment.', 'timeFrame': '2 months, 4 months, 6 months'}, {'measure': 'Disease-control rate', 'description': 'It is the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention.', 'timeFrame': '2 months, 4 months, 6 months'}, {'measure': 'Overall survival', 'description': 'The length of time from either the date of diagnosis or the start of treatment for a disease that patients diagnosed with the disease are still alive.', 'timeFrame': '2 months, 4 months, 6 months'}, {'measure': 'Metabolic response rate by FDG-PET', 'description': 'It is assesed target lesions and non- target lesions by FDG-PET.', 'timeFrame': '2 months, 4 months, 6 months'}, {'measure': 'Safety', 'timeFrame': 'monthly'}]",6,18 Years,,ALL,False,Seoul National University Hospital,OTHER,0,49.0,ACTUAL,2025-09-01T16:18:22.194616,v2_robust,True,True,True,False,True,
NCT05695495,Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study),Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study).,"N,N-Dimethyltryptamine (5mg)","['N,N-Dimethyltryptamine (5mg)', 'N,N-Dimethyltryptamine (15mg)', 'N,N-Dimethyltryptamine (20mg)', 'Placebo (saline)', 'N,N-Dimethyltryptamine (25mg)', 'N,N-Dimethyltryptamine (10mg)']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2024-06-12,2025-03-04,"[{'measure': 'Altered states of consciousness profile (OAV)', 'description': 'Altered states of consciousness profile (OAV) consisting of 42 items to be rated on a visual analog scale (0-100 mm), with higher values indicating stronger effects with higher scores representing more intense effects', 'timeFrame': 'Repeatedly 1 hour after each bolus application'}, {'measure': 'Subjective effect ratings over time', 'description': 'Participants will be asked by the investigator to repeatedly rate their subjective effects verbally on a Likert scale from 0 to 10 for: ""any drug effect"", ""good drug effect"", ""bad drug effect"", and ""fear"". Ratings will be performed before and repeatedly after substance administration and will take approximately 30 sec complete.', 'timeFrame': 'Repeatedly 1 hour after each bolus application'}]","[{'measure': 'Psychedelic experience questionnnaire (PEQ)', 'description': 'Assesses the emergence and intensity of phenomenons occurring in altered states of consciousness on a 6-point Likert scale ranging from 0 (""not at all"") to 5 (""extremely"").', 'timeFrame': 'Repeatedly 1 hour after each bolus application'}, {'measure': 'Near death experience content scale (NDE-C)', 'description': 'The Near-Death Experience Content (NDE-C) scale is a tool to assess dimensions of near-death experience on a Likert scale ranging from 0 (""not at all"") to 4 (""extremely"").', 'timeFrame': 'Repeatedly 1 hour after each bolus application'}, {'measure': 'Spiritual Realms Questionnaire (SRQ)', 'description': 'Assesses the spiritual phenomenons elicited by psychedelic substances through 11 main questions to be answered on a total of 65 sub-ordered 100mm visual analog scales once on each study day', 'timeFrame': 'Once at the end of study day'}, {'measure': 'Blood pressure', 'description': 'Assessed multiple times on each study day via systolic and diastolic blood pressure', 'timeFrame': 'Repeatedly in short intervals (2-10 minutes) after each bolus application'}, {'measure': 'Heart rate', 'description': 'Assessed multiple times on each study day.', 'timeFrame': 'Repeatedly in short intervals (2-10 minutes) after each bolus application'}, {'measure': 'Plasma level DMT', 'description': 'Assessed multiple times on each study day.', 'timeFrame': 'Repeatedly in short intervals (2-10 minutes) after each bolus application'}, {'measure': 'Urine recovery of DMT', 'description': 'Assessed once on each study day', 'timeFrame': 'Once at the end of study day'}, {'measure': 'NEO-Five-Factor-Inventory (NEO-FFI)', 'description': 'The NEO-FFI is a self-description questionnaire with 60 items for the measurement of the ""big five"": neuroticism, extraversion, openness, agreeableness, and consciousness. It uses a 5-point Likert scale ranging from ""completely disagree"" to ""fully agree.', 'timeFrame': 'Baseline'}, {'measure': 'Saarbrücker Personality Questionnaire (SPF)', 'description': 'The SPF defines empathy as the ""reactions of one individual to the observed experiences of another."" It assesses 28- items on a 5-point Likert scale ranging from ""Does not describe me well"" to ""Describes me very well"". The measure has 4 subscales (Perspective Taking, Fantasy, Empathic Concern, Personal Distress) each made up of 7 different items.', 'timeFrame': 'Baseline'}, {'measure': 'Elliot Humility Scale (EHS)', 'description': 'The Elliot Humility Scale (EHS) is a validated 13-item self-rating measure assessing four subscales, i.e. openness, self-forgetfulness, accurate self-assessment, and focus on others on a 5-point Likert scale ranging from ""strongly disagree"" to ""strongly agree""', 'timeFrame': 'Baseline'}]",12,25 Years,65 Years,ALL,True,"University Hospital, Basel, Switzerland",OTHER,0,36.0,ACTUAL,2025-09-01T16:18:22.194635,v2_robust,True,True,True,False,False,
NCT02305095,Genomic Response Analysis of Heart Failure Therapy in African Americans,Genomic Analysis of the Enhanced Response to Heart Failure Therapy in African Americans,FDC I/H,"['BiDil', 'FDC I/H']",2,OBSERVATIONAL,[],,,Heart Failure,['Heart Failure'],[],COMPLETED,,2015-05-01,2022-09-30,"[{'measure': 'Composite score (CS) no units. (survival, heart failure hospitalization, and change in the raw quality of life score on the Minnesota Living with Heart Failure Questionnaire)', 'description': 'The CS combines three outcome variables into a single ""score"". Composite score adds points for survival over 2 years of follow up (death at any time yields -3 points, survival to end of study results in 0), heart failure hospitalization over 2 years of follow up (yes at any time results in -1 point, no results in 0), and the change in the raw quality of life score on the Minnesota Living with Heart Failure Questionnaire from entry to 6 months (change of ten units or greater=increase +2, decrease-2; change 5 to 9= increase+1, decrease -1; change \\< 5 units for the raw score yields 0 points). The CS will range from -6 to +2 for each patient.', 'timeFrame': '2 years'}]","[{'measure': 'Survival', 'description': 'Comparison of survival on therapy by GNB3 genotype', 'timeFrame': '2 years'}, {'measure': 'Survival free from heart failure hospitalization', 'description': 'Comparison of event free survival by GNB3 genotype.', 'timeFrame': '2 years'}, {'measure': 'Change in Quality of Life Assessment by Minnesota Living with Heart Failure Questionnaire', 'description': 'Evaluate the change in the raw score of the Quality of Life questionnaire by GNB3 genotype.', 'timeFrame': '6 months'}]",4,18 Years,,ALL,False,University of Pittsburgh,OTHER,0,225.0,ACTUAL,2025-09-01T16:18:22.194677,v2_robust,False,True,True,False,False,
NCT00821795,Veterans Inpatient Insulin Study and Transition to Outpatient Therapy,Veterans Inpatient Insulin Study and Transition Algorithm: Efficacy of Insulin Analogs for Inpatient Glycemic Control and Transition to Outpatient Therapy,NPH/Regular 70/30 mix,"['insulin aspart protamine/insulin aspart 70/30 mix', 'Novolog Mix 70/30', 'NPH/Regular 70/30 mix', 'Novolin 70/30']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],"['Diabetes Mellitus, Type 2', 'insulin', 'therapy']",COMPLETED,,2009-03-11,2013-04-23,"[{'measure': 'For Transition From Inpatient to Outpatient Care, Evaluate Glycemic Control in Subjects Randomized to Receive 70/30 NPH/Regular Insulin or Aspart Analog 70/30 Mix Bid- Main Outcome Will be HbA1c During Transition Outpatient Therapy Phase.', 'description': 'Hemoglobin A1c', 'timeFrame': '16 weeks'}]","[{'measure': 'Seven Point Blood Glucose Profiles', 'description': 'mg/dl', 'timeFrame': '2 weeks'}, {'measure': 'Patient-reported Outcomes - Diabetes Symptom Checklist to Evaluate Perception of Diabetes Control', 'timeFrame': '16 weeks'}, {'measure': 'Hypoglycemia', 'timeFrame': 'daily'}, {'measure': 'Twice Daily Blood Glucose Monitoring Using Telehealth Transmitter', 'timeFrame': 'daily'}]",5,40 Years,,ALL,False,"Dennis G. Karounos, M.D.",FED,1,120.0,ACTUAL,2025-09-01T16:18:22.194698,v2_robust,True,True,True,False,False,
NCT00420095,A Study for Patients With Diabetes Mellitus (IOPA),Comparison of HbA1c in Type 1 or Type 2 Diabetic Patients Using Insulin Treated Twice Daily With Either Insulin Lispro Low Mixture or Human Insulin Mix 30/70,Human insulin 30/70,"['LM', 'Insulin lispro low mix', 'Humalog', 'Low Mix', 'Human insulin 30/70']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,"Diabetes Mellitus, Type 1","['Diabetes Mellitus, Type 1', 'Diabetes Mellitus, Type 2']","['diabetes', 'type 1', 'type 2']",COMPLETED,,2007-01,2008-01,"[{'measure': 'Glycosylated Hemoglobin (HbA1c) Value at 12 Week Endpoint', 'description': 'Glycosylated hemoglobin reflects the average blood glucose level over the previous 12 weeks of treatment.', 'timeFrame': 'Baseline and 12 weeks of each treatment'}]","[{'measure': 'Changes in Glycosylated Hemoglobin (HbA1c) From Baseline to 12 Weeks of Treatment', 'description': 'Changes in glycosylated hemoglobin reflect the change in average blood glucose level between baseline and 12 weeks of treatment. Change = Baseline - Endpoint.', 'timeFrame': 'Baseline and at 12 weeks of each treatment'}, {'measure': 'Change in Fasting Blood Glucose Values From Baseline to 12 Weeks of Treatment', 'description': 'Values obtained after at least an 8 hour fast. Change = Baseline - Endpoint', 'timeFrame': 'Baseline and 12 weeks of each treatment'}, {'measure': 'Change in Total Daily Insulin Dose Values From Baseline to 12 Weeks of Treatment', 'description': 'Insulin lispro low mix was to be administered within 15 minutes of morning and evening meals. Human insulin mix 30/70 was to be administered within 30 minutes of morning and evening meals. Change = Baseline - Endpoint', 'timeFrame': 'Baseline and 12 weeks of each treatment'}, {'measure': 'Number of Participants Achieving Target Glycosylated Hemoglobin (HbA1c) Values <=7% and <=6.5%', 'description': 'Number of patients in each treatment group achieving the target HbA1c value during 12 weeks of each treatment.', 'timeFrame': '12 weeks of each treatment'}, {'measure': 'Number of Participants With Laboratory Parameters Significantly Different From Baseline', 'description': 'Number of participants with laboratory parameters (hematology, chemistry, and urinalysis) that were significantly different from baseline after 12 weeks of each treatment.', 'timeFrame': 'Baseline and 12 weeks of each treatment'}, {'measure': 'Hypoglycemia Rate Per Participant Per 30 Days', 'description': 'Hypoglycemia rate per patient per 30 days = (number of reported hypogylcemia events/number of days within the period) \\* 30 days. Since this was a 2x2 cross-over design (2 treatments and 2 periods), then the hypogyclemia rate was calculated per patient for each of the 2 periods by treatment.', 'timeFrame': 'over 12 weeks of each treatment period'}]",7,18 Years,70 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,117.0,ACTUAL,2025-09-01T16:18:22.194723,v2_robust,True,True,True,False,False,
NCT04469595,A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME),"A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)",Iluvien 0.19 MG Drug Implant,"['Aflibercept', 'Iluvien 0.19 MG Drug Implant', 'Eylea', 'ILUVIEN']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetic Macular Edema,['Diabetic Macular Edema'],"['DME', 'CI-DME', 'Diabetic Macular Edema', 'Diabetic Retinopathy']",ACTIVE_NOT_RECRUITING,,2020-08-31,2024-12-31,"[{'measure': 'The mean total number of supplemental aflibercept injections needed during the study', 'description': 'The mean total number of supplemental aflibercept injections needed during', 'timeFrame': 'Baseline to 18 months'}]","[{'measure': 'Proportion of subjects with 15, 10 and 5 letter (ETDRS) gains from baseline', 'description': 'Proportion of subjects with 15, 10 and 5 letter (ETDRS) gains from baseline', 'timeFrame': 'At 18 months'}, {'measure': 'Area under the curve (AUC) of Best Corrected Visual Acuity (BCVA)', 'description': 'Area under the curve (AUC) of Best Corrected Visual Acuity (BCVA)', 'timeFrame': 'Baseline to 18 months'}, {'measure': 'Mean change from baseline in Center Subfield Thickness (CST)', 'description': 'Mean change from baseline in Center Subfield Thickness (CST)', 'timeFrame': 'Baseline to 18 months'}, {'measure': 'Area under the curve (AUC) of Center Subfield Thickness (CST)', 'description': 'Area under the curve (AUC) of Center Subfield Thickness (CST)', 'timeFrame': 'Baseline to 18 months'}, {'measure': 'Mean change from baseline in the National Eye Institute Visual Function Questionnaire (NEI VFQ-25) composite score and subscale scores', 'description': 'The NEI VFQ-25 is a questionnaire that allows the individual to report on their level of visual function. Scores range from 0-100, with a score of 0 being the worst outcome and 100 being the best outcome.', 'timeFrame': 'At 18 months'}, {'measure': 'Safety Outcome Endpoints: The incidence and severity of treatment-related adverse events', 'description': 'The incidence and severity of treatment-related adverse events', 'timeFrame': 'Baseline to 18 months'}]",7,18 Years,,ALL,False,Alimera Sciences,INDUSTRY,0,300.0,ESTIMATED,2025-09-01T16:18:22.194751,v2_robust,True,True,False,False,True,
NCT03148795,A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer,"TALAPRO-1: A PHASE 2, OPEN-LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE-BASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT (ENZALUTAMIDE AND/OR ABIRATERONE ACETATE/PREDNISONE)",Talazoparib,"['Talazoparib', 'MDV3800']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,['Prostate Cancer'],[],COMPLETED,,2017-07-04,2023-03-31,"[{'measure': 'Best Objective Response Rate (ORR)', 'description': 'Best ORR was defined as the percentage of participants with best overall soft tissue response of complete response (CR) or partial response (PR) as per RECIST1.1 by an independent central review. RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than 10 millimeter (mm). Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (less than 10 mm short axis); PR: at least 30 percent (%) decrease in sum of diameters of target lesions taking as reference baseline sum diameters.', 'timeFrame': 'From first dose of study drug to best overall soft tissue response CR or PR (maximum duration of 25 months)'}]","[{'measure': 'Time to Objective Response', 'description': 'Time to objective response was defined as the time from first dose of talazoparib to the first objective evidence of soft tissue response with no evidence of confirmed bone disease progression on bone scan per prostate cancer working Group 3 (PCWG3). Soft tissue response is defined as a best overall response of CR or PR per RECIST 1.1 by independent central review. RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than 10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (less than 10 mm short axis); PR: at least 30 % decrease in sum of diameters of target lesions taking as reference baseline sum diameters.', 'timeFrame': 'From first dose of study drug to first objective response (maximum duration of 25 months)'}, {'measure': 'Duration of Response (DOR)', 'description': 'DOR was defined as the time from the first objective evidence of soft tissue response (CR or PR, whichever is earlier) per RECIST 1.1 and no evidence of confirmed bone disease progression per PCWG3 to the date of first objective evidence of radiographic progression or death due to any cause without evidence of radiographic progression, whichever occurs first. RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than 10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (less than 10 mm short axis); PR: at least 30 % decrease in sum of diameters of target lesions taking as reference baseline sum diameters.', 'timeFrame': 'From the first objective evidence of soft tissue response (CR or PR, whichever is earlier) to radiographic progression or death due to any cause without evidence of radiographic progression, whichever occurs first (maximum duration of 25 months)'}, {'measure': 'Percentage of Participants With Prostate-Specific Antigen (PSA) Response of Greater Than or Equal to (>=) 50 Percentage (%)', 'description': 'Percentage of participants with PSA response of \\>= 50% was reported in this outcome measure. PSA response was calculated as a decline from baseline PSA (ng/mL) by at least 50% measured by central laboratory.', 'timeFrame': 'From the date of first dose of study treatment until confirmed PSA progression or start of new anticancer treatment given after the first dose of study treatment (maximum duration of 25 months)'}, {'measure': 'Percentage of Participants With Conversion of Circulating Tumor Cell (CTC) Count', 'description': 'Percentage of participants with conversion of CTC count was defined as percentage of participants with a CTC count \\>= 5 CTC per 7.5 milliliter (mL) of blood at baseline that decreased to \\< 5 CTC per 7.5 mL of blood any time on study.', 'timeFrame': 'Baseline to anytime on study during final analysis of the outcome measure, up to maximum duration of 25 months'}, {'measure': 'Percentage of Participants With a Null CTC Count', 'description': 'Percentage of participants with a null CTC count was defined as percentage of participants with CTC count \\>=1 CTC per 7.5 mL of blood at baseline that decreased to CTC = 0 per 7.5 mL of blood any time on study.', 'timeFrame': 'Baseline to anytime on study during final analysis of the outcome measure, up to maximum duration of 25 months'}, {'measure': 'Percentage of Participants With Baseline CTC Count <5 CTC Showed Increased CTC Counts at Any Time on Study', 'description': 'Percentage of participants with CTC count \\<5 CTC per 7.5 mL of blood at baseline those who showed an increased CTC count, compared to baseline, any time on study was reported in this study.', 'timeFrame': 'Baseline to anytime on study during final analysis of the outcome measure, up to maximum duration of 25 months'}, {'measure': 'Time to Prostate-Specific Antigen (PSA) Progression', 'description': 'Time to PSA progression was defined as the time from first dose of study treatment to the date of PSA progression, which was subsequently confirmed. The time from first dose of talazoparib to the date that a \\>=25% increase in PSA with an absolute increase of \\>=2micogram per liter (2 nanogram per mL) above the nadir (or baseline for participants with no PSA decline) was documented, confirmed by a second consecutive PSA value obtained \\>=3 weeks (21 days) later. Kaplan-Meier method was used for analysis.', 'timeFrame': 'From the date of first dose of study treatment until confirmed PSA progression or start of new anticancer treatment given after the first dose of study treatment (maximum duration of 25 months)'}, {'measure': 'Radiographic Progression-Free Survival (PFS)', 'description': 'Radiographic PFS was defined as the time from date of first dose of talazoparib to first objective evidence of radiographic progression as assessed in soft tissue per modified RECIST 1.1 or confirmed progression in bone per PCWG3 guidelines by independent central review or death without documented radiographic progression, whichever occurs first.', 'timeFrame': 'From date of first dose of study drug to first objective evidence of radiographic progression or death without documented radiographic progression, whichever occurs first (maximum duration of 25 months)'}, {'measure': 'Overall Survival (OS)', 'description': 'OS was defined as the time from start date (the date of first dose of treatment) to the date of death due to any cause. Participants who had not died were censored at the date of last contact. Kaplan-Meier method was used for analysis.', 'timeFrame': 'From first dose of study treatment up to death due to any cause during study or date of last contact (approximately 36 months)'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs)', 'description': 'An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included both serious AEs and all non-serious AEs. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.', 'timeFrame': 'First dose of study drug up to 28 days after last dose of study drug (study treatment was approximately for 36 months, safety follow up to approximately 37 months)'}, {'measure': 'Number of Participants With Permanent Treatment Discontinuation Due to Adverse Events', 'description': 'Treatment discontinuation was defined as permanent cessation of study drug treatment administration.', 'timeFrame': 'During study treatment (approximately up to 36 months)'}, {'measure': 'Number of Participants With Clinically Significant Abnormalities in Vital Signs', 'description': 'Vital sign abnormalities criteria included: 1) Systolic blood pressure (SBP) in millimeters of mercury (mmHg): absolute result greater than (\\>) 180 mmHg and increase from baseline greater than or equal to (\\>=) 40 mmHg or absolute result \\< 90 mmHg and decrease from baseline \\> 30 mmHg; 2) Diastolic blood pressure (DBP) (mmHg): absolute result \\> 110 mmHg and increase from baseline \\>= 30 mmHg or absolute result \\< 50 mmHg and decrease from baseline \\> 20 mmHg or \\>= 20 mmHg increase from baseline; 3) Heart rate in beats per minutes (bpm): absolute result \\< 50 bpm and decrease from baseline \\> 20 bpm or absolute result \\> 120 bpm and increase from baseline \\> 30 bpm; Weight in kilogram: \\> 10% decrease from baseline.', 'timeFrame': 'During study treatment (approximately up to 36 months)'}, {'measure': 'Number of Participants With Shift in Laboratory Parameter Values (Hematology) From Grade Less Than Equal to (<=) 2 at Baseline to Grade 3 or 4 Post-baseline', 'description': 'Hematology parameters included anemia, hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, Leukocytosis and white blood cell decreased. Severity was graded as Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or non-invasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE.', 'timeFrame': 'During study treatment (approximately up to 36 months)'}, {'measure': 'Number of Participants With Shift in Laboratory Parameter Values (Chemistry) From Grade <=2 at Baseline to Grade 3 or 4 Post-baseline', 'description': 'Chemistry parameters:alanine aminotransferase increased(inc), alkaline phosphatase inc, aspartate aminotransferase inc, blood bilirubin inc, chronic kidney disease, creatinine inc, gamma-glutamyl transferase (GGT) inc, hypercalcemia, Hyperglycemia, hyperkalemia, hypermagnesemia, hypocalcemia, Hyponatremia, hypoglycemia, hypokalemia, hypomagnesemia, hypernatremia, Hypoalbuminemia and hypophosphatemia. Severity was graded as Grade(G)1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G2:moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G3:severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; G4:life-threatening consequence, urgent intervention indicated; G5: death related to AEs.', 'timeFrame': 'During study treatment (approximately up to 36 months)'}, {'measure': 'Number of Participants With Dose Modification', 'description': 'Number of participants with dose modification due to adverse events was reported.', 'timeFrame': 'During study treatment (approximately up to 36 months)'}, {'measure': 'Time to Deterioration in Pain Symptom Scores', 'description': 'Time deterioration is based on BPI-SF question 3: ""Please rate your pain by marking the box beside the number that best describes your pain at its worst in the last 24 hours."" Pain intensity was to be answered on a range of 0 to 10, where 0 corresponded to no pain and 10 worst pain. Time to this event is defined as the time from the date of first dose of study treatment to onset of pain progression, where pain progression is defined as a 2-point or more increase from baseline in the question 3 score. Kaplan-Meier method was used for analysis. Average of all assessments visits is reported in this outcome measure.', 'timeFrame': 'Baseline till final analysis of the outcome measure, up to maximum duration of 25 months'}, {'measure': 'Change From Baseline in Participant Reported Pain Scores Per BPI-SF Question 3', 'description': ""BPI-SF is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions. BPI-SF have 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each question is answered on a scale ranging from 0 to 10; '0=No pain and 10=Pain as bad as you can imagine'. Measure can be scored by item, with lower scores being indicative of less pain or pain interference. BPI-SF question 3 was related to participant experiencing pain at its worst in last 24 hours, score range 0 to 10, where large values corresponded to worse outcomes."", 'timeFrame': 'Baseline, Week 1, 3, 5, 7, 9, 13, 17, 21, 25, 37, 49, 61, 73, 85, Follow-up Visit (28 days after last dose) [maximum duration of 25 months]'}, {'measure': 'Change From Baseline in European Quality of Life 5-Domain 5-Level Scale (EQ-5D-5L) Visual Analogue Scores (VAS)', 'description': 'The EQ-5D VAS score was a participant rated questionnaire where participants rated how they felt at assessment visit on a vertical VAS that ranged from 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating a better health condition.', 'timeFrame': 'Baseline, Week 1, 3, 5,7, 9, 13, 17, 21, 25, 37, 49, 61, 73, 85, 97, Follow-up Visit (28 days after last dose) [maximum duration of 25 months]'}, {'measure': 'Number of Participants With 5 Response Levels for EQ-5D-5L Mobility Domain', 'description': 'EQ-5D-5L: participant rated assessed level of current health using 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety, and depression. EQ-5D mobility domain had 5 responses: no problem, slight problem, moderate problem, severe problem and extreme problem.', 'timeFrame': 'Baseline, Week 1, 3, 5,7, 9, 13, 17, 21, 25, 37, 49, 61, 73, 85, 97, Follow-up Visit (28 days after last dose) [maximum duration of 25 months]'}, {'measure': 'Number of Participants With 5 Response Levels for EQ-5D-5L Self-Care Domain', 'description': 'EQ-5D-5L: participant rated assessed level of current health using 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety, and depression. EQ-5D self-care domain had 5 responses: no problem, slight problem, moderate problem, severe problem and extreme problem.', 'timeFrame': 'Baseline, Week 1, 3, 5,7, 9, 13, 17, 21, 25, 37, 49, 61, 73, 85, 97, Follow-up Visit (28 days after last dose) [maximum duration of 25 months]'}, {'measure': 'Number of Participants With 5 Response Levels for EQ-5D-5L Usual Activity Domain', 'description': 'EQ-5D-5L: participant rated assessed level of current health using 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety, and depression. EQ-5D usual activities domain had 5 responses: no problem, slight problem, moderate problem, severe problem and extreme problem.', 'timeFrame': 'Baseline, Week 1, 3, 5,7, 9, 13, 17, 21, 25, 37, 49, 61, 73, 85, 97, Follow-up Visit (28 days after last dose) [maximum duration of 25 months]'}, {'measure': 'Number of Participants With 5 Response Levels for EQ-5D-5L Pain and Discomfort Domain', 'description': 'EQ-5D-5L: participant rated assessed level of current health using 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety, and depression. EQ-5D pain and discomfort domain had 5 responses: no problem, slight problem, moderate problem, severe problem and extreme problem.', 'timeFrame': 'Baseline, Week 1, 3, 5,7, 9, 13, 17, 21, 25, 37, 49, 61, 73, 85, 97, Follow-up Visit (28 days after last dose) [maximum duration of 25 months]'}, {'measure': 'Number of Participants With 5 Response Levels for EQ-5D-5L Anxiety and Depression Domain', 'description': 'EQ-5D-5L: participant rated assessed level of current health using 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety, and depression. EQ-5D anxiety and depression domain had 5 responses: no problem, slight problem, moderate problem, severe problem and extreme problem.', 'timeFrame': 'Baseline, Week 1, 3, 5,7, 9, 13, 17, 21, 25, 37, 49, 61, 73, 85, 97, Follow-up Visit (28 days after last dose) [maximum duration of 25 months]'}, {'measure': 'Pre-dose Plasma Concentration (Ctrough) of Talazoparib', 'description': 'Ctrough was defined as pre-dose plasma concentration during dosing and observed directly from data.', 'timeFrame': 'Pre-dose at Week 1, 5, 9 and 13'}, {'measure': 'Post-dose Plasma Concentration (Ctrough) of Talazoparib', 'description': 'Plasma concentration was measured 2 hours after dosing and observed directly from data.', 'timeFrame': '2 hours post-dose at Week 1 and 5'}]",26,18 Years,,MALE,False,Pfizer,INDUSTRY,1,128.0,ACTUAL,2025-09-01T16:18:22.194926,v2_robust,True,True,True,False,True,
NCT03289039,"Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer","A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer",Neratinib,"['Neratinib', 'Nerlynx', 'Faslodex', 'Fulvestrant']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],['Breast Cancer'],TERMINATED,Slow accrual,2017-10-25,2021-07-20,"[{'measure': 'Progression Free Survival', 'description': 'Progression-Free Survival (PFS) is defined as the time from randomization (or registration) to the earlier of progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation.\n\nProgression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Disease assessment were conducted at baseline and every two cycles after the first cycle.', 'timeFrame': 'Participants were followed for PFS up to 20.3 months from registration.'}]","[{'measure': 'Overall Survival', 'description': 'Overall Survival (OS) is defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive. Participants will be evaluated every 6 months for survival until death. Participants removed from protocol therapy for unacceptable adverse event(s) will be followed until resolution or stabilization of the adverse event.', 'timeFrame': 'Participants were followed for up to 38.4 months (3 years and 2 months) from registration to removal from protocol therapy or death.'}, {'measure': 'Overall Response Rate', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Overall Response Rate(ORR) = (CR + PR)/sample size.', 'timeFrame': '2 years'}, {'measure': 'Duration Of Responses', 'description': 'The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started, or death due to any cause. Participants without events reported are censored at the last disease evaluation).', 'timeFrame': '2 years'}]",4,18 Years,,FEMALE,False,Dana-Farber Cancer Institute,OTHER,1,21.0,ACTUAL,2025-09-01T16:18:22.195024,v2_robust,True,True,False,True,True,Slow accrual
NCT00777439,Domperidone for Refractory Gastrointestinal Disorders,An Investigational New Drug Program for the Use of Domperidone in the Treatment of Refractory Gastroesophageal Reflux Disease and Other Gastrointestinal Motility Disorders,Domperidone,"['Domperidone maleate, Motilium', 'Domperidone']",2,INTERVENTIONAL,['NA'],,,Gastroparesis,['Gastroparesis'],"['Dopamine', 'Domperidone', 'Gastroparesis', 'Gastrointestinal Diseases', 'Neurologic Manifestations', 'Stomach Diseases', 'Digestive System Diseases', 'Esophagitis', 'Esophageal Disorders', 'Paralysis']",UNKNOWN,,2008-10,2018-01,"[{'measure': 'Improvement of symptoms for patients with gastrointestinal disorders who have failed or suffered adverse effects from standard medical treatment.', 'timeFrame': 'Domperidone will be prescrided as long as patients benefit from taking it.'}]",[],1,18 Years,,ALL,False,"Arnold, George, M.D.",INDIV,0,75.0,ESTIMATED,2025-09-01T16:18:22.195045,v2_robust,True,True,False,False,True,
NCT04693039,"Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets","A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets in Patients With Parkinson's Disease in the Early and Middle Stages",Phenlarmide,"['Placebo-600mg', 'FLZ-300mg', 'Placebo-150mg', 'FLZ-150mg', 'FLZ-600mg', 'Phenlarmide', 'Placebo-900mg', 'Placebo', 'Placebo-300mg', 'FLZ-900mg']",10,INTERVENTIONAL,['PHASE1'],PHASE1,,Parkinson Disease,['Parkinson Disease'],[],COMPLETED,,2021-02-23,2021-10-29,"[{'measure': 'the dose limiting toxicity (DLT)', 'description': 'The occurrence of Dose limiting toxicity.', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'Tmax, ss', 'description': 'After administration, the time when the highest concentration of drug appeared in plasma', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'Efficacy evaluation', 'description': ""explore the efficacy of fenolamide tablets in the treatment of early and middle stage Parkinson's disease, and observe the changes of UPDRS and CGI."", 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'maximum tolerable dose (MTD)', 'description': 'The occurrence of Maximum tolerable dose.', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'adverse events', 'description': 'The occurrence rate of adverse events.', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'adverse reactions', 'description': 'The occurrence rate of adverse reactions', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'blood routine', 'description': 'Check whether the red blood cell system, white blood cell system and platelet system are normal', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'blood biochemistry', 'description': 'The contents of various ions, sugars, lipids, proteins, enzymes, hormones and metabolites in blood were detected', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'coagulation function', 'description': 'Four coagulation parameters including prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and fibrinogen (FIB) were evaluated.', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'urine routine', 'description': 'Urine routine examination includes urine color, transparency, pH, red blood cells, white blood cells, epithelial cells, tube type, protein, specific gravity and urine sugar.', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'stool routine', 'description': 'Routine stool tests include the detection of red and white blood cells in feces, bacterial sensitivity test, occult blood test (OB) and inspection of eggs.', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'Body temperature', 'description': 'One of the vital signs.', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': '12 lead ECG', 'description': 'Evaluation of QT interval', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'Blood pressure', 'description': 'Assess whether systolic blood pressure and diastolic blood pressure are normal.', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'Heart rate', 'description': 'One of the vital signs.', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'Breathing', 'description': 'Assess if breathing is normal', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'Cmax, ss', 'description': 'The highest concentration of the drug in the plasma after administration', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'Cavg, ss', 'description': 'The quotient of the area under the plasma concentration time curve divided by the interval time within a dose interval after the plasma concentration reaches the steady state.', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'Ke', 'description': 'The ratio of the amount of compound eliminated from the body to the total amount in the body in unit time', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 't1/2', 'description': 'The time required for the concentration of a drug to drop by half in an organism', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'CL/F (fenoxamide prototype only)', 'description': 'The amount of a substance excreted by the kidney per minute', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'Vz/F (fenoxamide prototype only)', 'description': 'After the drug reaches dynamic equilibrium in the body, the ratio of the drug dose in the body to the blood concentration is called the apparent distribution volume', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'AUC0-24, ss', 'description': 'After administration, the area under the 0-24 hour time curve of blood concentration absorbed into human circulation', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'AUCinf, ss', 'description': 'After administration, the area under the time curve of 0-infinity of the blood concentration absorbed into human circulation', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'AUC0-last，ss', 'description': 'After administration, the area under the time curve of 0-the last accurately determined sample collection time of the blood concentration absorbed into human circulation', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'AUC_%Extrap', 'description': 'the area under the curve that has been derived after extrapolation of Residual Area', 'timeFrame': 'through study completion, an average of 6 months'}, {'measure': 'DF', 'description': 'The index reflecting the unbalanced situation of transportation in time', 'timeFrame': 'through study completion, an average of 6 months'}]",[],27,30 Years,,ALL,False,Shijiazhuang Yiling Pharmaceutical Co. Ltd,INDUSTRY,1,40.0,ACTUAL,2025-09-01T16:18:22.195063,v2_robust,True,True,True,False,True,
NCT04374539,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Standar medical treatmen,['Standar medical treatmen'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Coronavirus,['Coronavirus'],[],TERMINATED,inability to recruit more patients,2020-04-29,2021-06-29,"[{'measure': 'Impact of plasma exchange', 'description': 'Number of exitus at 28 days after plasma exchange in patients with COVID-19 disease and invasive mechanical ventilation.', 'timeFrame': '28 days'}]",[],1,18 Years,80 Years,ALL,False,Fundacion Clinic per a la Recerca Biomédica,OTHER,0,36.0,ACTUAL,2025-09-01T16:18:22.195147,v2_robust,True,True,False,True,False,inability to recruit more patients
NCT05790239,MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder,"A Randomized, Double-Blind, Single-Site Phase II 2-Arm Study to Compare the Safety and Preliminary Efficacy of Manualized MDMA-Assisted Therapy to Low Dose D-Amphetamine Assisted Therapy in Veterans For The Treatment of Moderate to Severe PTSD","3,4-methylenedioxymethamphetamine","['3,4-methylenedioxymethamphetamine', 'MDMA', 'd-amphetamine']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Post Traumatic Stress Disorder,['Post Traumatic Stress Disorder'],"['MDMA', 'Post Traumatic Stress Disorder', 'PTSD', 'Functional Impairment', 'Veteran', 'Substance Use Disorder', 'Chronic Pain']",RECRUITING,,2025-03-01,2026-03,"[{'measure': 'Compare changes in PTSD symptom severity in the MDMA vs active control group.', 'description': 'The Primary Outcome measure will be the change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score from Baseline to Visit 17, assessed by a blinded study staff rater.\n\nThe total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.', 'timeFrame': 'Visit 17 (approximately 14 weeks after enrollment)'}]","[{'measure': 'Compare changes in clinician-rated functional impairment in the MDMA vs active control group.', 'description': 'The secondary outcome measure will be the change in the Sheehan Disability Scale (SDS), assessed by a blinded study staff rater.\n\nThe SDS is a 5-item measure of functional impairment. The items indicate the degree of impairment in the domains of work/school, social life, and home life, with response options based on a 10-point scale (0=not at all to 10=extremely), and five verbal tags (not at all, mildly, moderately, markedly, extremely). The first three items indicate the degree of impairment in the domains of work/school, social life, and home life, with response options based on a 10-point scale (0=not at all to 10=extremely), and five verbal tags (not at all, mildly, moderately, markedly, extremely). The remaining two items assess Days Lost and Days Unproductive during the reporting period.\n\nThe three numerical items can be scored, and total scores range from 0 to 30, with higher scores indicating higher impairment.', 'timeFrame': 'Visit 17 (approximately 14 weeks after enrollment)'}]",2,18 Years,,ALL,False,Stephen Robert Marder,FED,0,40.0,ESTIMATED,2025-09-01T16:18:22.195333,v2_robust,True,True,False,False,False,
NCT00994539,Dose Proportionality and Food Effect of Morphine Sulfate,"A Single Dose, Three-Period, Three-Treatment, Six-Sequence, Three-Way Crossover Study of the Dose Proportionality of and Effect of Food on Morphine Sulfate Tablets.",morphine sulfate,['morphine sulfate'],1,INTERVENTIONAL,['NA'],,,Pain,['Pain'],[],COMPLETED,,2007-01,2007-02,"[{'measure': 'bioequivalence determined by statistical comparison Cmax', 'timeFrame': '15 days'}]",[],1,18 Years,45 Years,ALL,True,Roxane Laboratories,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:22.195357,v2_robust,True,True,True,False,False,
NCT03335839,"Adjunctive, Low-dose tPA in Primary PCI for STEMI","Adjunctive, Low-dose Intracoronary Recombinant Tissue Plasminogen Activator (tPA) Versus Placebo for Primary PCI in Patients With ST-segment Elevation Myocardial Infarction",tissue plasminogen activator,['tissue plasminogen activator'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Myocardial Infarction,"['Myocardial Infarction', 'Percutaneous Coronary Intervention']",['tPA'],COMPLETED,,2018-04-01,2025-02-12,"[{'measure': 'Post-procedural MBG 0/1 or Distal Embolization.', 'description': 'Composite of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.', 'timeFrame': '30 days'}]","[{'measure': 'Complete ST-segment resolution.', 'description': 'Complete (≥70%) ST-segment resolution (worst lead) at 30 minutes post-PCI', 'timeFrame': '30 minutes'}, {'measure': 'CV Death, MI, Cardiogenic Shock or New Onset HF', 'description': 'Composite of cardiovascular death, myocardial re-infarction, cardiogenic shock or new onset heart failure.', 'timeFrame': '30 Days'}]",3,18 Years,,ALL,False,Population Health Research Institute,OTHER,1,210.0,ACTUAL,2025-09-01T16:18:22.195383,v2_robust,True,True,True,False,False,
NCT03177239,"Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)","A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).",Nivolumab,"['Ipilimumab', 'Nivolumab', 'Opdivo', 'Yervoy']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Renal Cell Carcinoma,"['Renal Cell Carcinoma', 'Papillary Renal Cell Carcinoma Type 1', 'Papillary Renal Cell Carcinoma Type 2', 'Chromophobe Renal Cell Carcinoma', 'Sarcomatoid Renal Cell Carcinoma', 'Xp11 Translocation Carcinoma']",[],UNKNOWN,,2017-10-19,2022-12-31,"[{'measure': 'The objective tumour response rate, as assessed by RECIST1.1', 'description': 'This is defined as the proportion of participants in the analysis set with a confirmed complete response (CR) or partial response (PR) divided by the number of participants in the analysis set.', 'timeFrame': 'Through study completion, on average 5 years.'}]","[{'measure': 'Duration of objective tumour response, as assessed by RECIST1.1', 'description': 'Measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that progressive disease is objectively documented.', 'timeFrame': 'Through study completion, on average 5 years.'}, {'measure': 'Progression-free survival (PFS), as assessed by RECIST1.1', 'description': 'For Part 1, PFS is defined as the interval from date of registration to the date of first evidence of disease progression or death, whichever occurs first. For Part 2, PFS is defined as the interval from date of progressive disease on nivolumab monotherapy until the date of first evidence of disease progression or death, whichever occurs first.', 'timeFrame': 'Through study completion, on average 5 years.'}, {'measure': 'Immune-related tumour response rate, as assessed by irRECIST.', 'description': 'Defined as the proportion of participants in the analysis set with an immune related complete response (irCR), or immune related partial response (irPR), divided by the number of participants in the analysis set.', 'timeFrame': 'Through study completion, on average 5 years.'}, {'measure': 'Immune-related disease control rate (irDCR6), as assessed by irRECIST.', 'description': 'For Part 1, irDCR6 is defined as an assessment of CR or iPR or iSD according to modified irRECIST. For Part 2, irDCR6 is defined in the same way except that the extent of disease defining the baseline tumour burden is measured at the date of disease progression on nivolumab monotherapy.', 'timeFrame': 'At 6 months during treatment.'}, {'measure': 'The number of patients alive at the end of the study, as assessed by date of death.', 'description': 'Overall survival (OS) is defined as the time between the date of registration to part 1 of the study and the date of death due to any cause.', 'timeFrame': 'Through study completion, on average 5 years.'}, {'measure': 'The number of patients with adverse events, particularly immune-related adverse events, that are related to study drug, as assessed and graded according to CTCAE v4.03.', 'timeFrame': 'From time of patient registration, until 30 days after the last dose of treatment.'}, {'measure': 'The number of participants with permanent discontinuation of treatment or delays due to toxicity, as assessed and graded according to CTCAE v4.03.', 'timeFrame': 'From time of patient registration, until 30 days after the last dose of treatment.'}]",8,18 Years,,ALL,False,Australian and New Zealand Urogenital and Prostate Cancer Trials Group,OTHER,1,85.0,ACTUAL,2025-09-01T16:18:22.195400,v2_robust,True,True,False,False,True,
NCT02042339,Hyperbaric Oxygenation in Diabetic Ulcer,Hyperbaric Oxygenation (HBO) in Chronic Diabetic Leg Ulcer.,Hyperbaric oxygen,"['Hyperbaric oxygen', 'Hyperbaric oxygenation', 'HBO']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Diabetes Mellitus,['Diabetes Mellitus'],"['Hyperbaric Oxygen', 'Diabetic ulcer', 'Wound healing', '3-D life-viz- system', 'Indocyanine green video angiography', 'Transcutaneous oxygen pressure', 'Endothelial progenitor cells']",UNKNOWN,,2019-12,2022-12,"[{'measure': 'ICG (indocyanine green) video angiography', 'description': 'Change in ICG-adsorption measured by ICG video angiography from baseline to week/month xxx', 'timeFrame': 'Weeks 1-3, 6; Months 3, 6, 12'}]","[{'measure': 'High performance 3D LifeViz™ system', 'description': 'Change of size/configuration of wound from baseline to week/month xxx', 'timeFrame': 'Week 1-6; Months 3, 6, 12'}]",2,18 Years,80 Years,ALL,False,Medical University of Graz,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:22.195443,v2_robust,True,True,False,False,False,
NCT01245439,A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis,"Local Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD",tocilizumab [RoActemra/Actemra],['tocilizumab [RoActemra/Actemra]'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],[],COMPLETED,,2011-09,2014-08,"[{'measure': 'Safety: Percentage of Participants With Treatment Emergent Adverse /Serious Adverse Events', 'description': 'An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An AE was considered treatment emergent if the date of onset of the AE was on or after the date of first dose of study medication. AEs of special interest included Major Adverse Cardiovascular Events (MACE) (including strokes), infections, and infusion reactions. An AE was considered an infection if the preferred term was in the predefined infection AE group term. A serious infection was an infection which was also considered as an AE. An AE was considered an infusion reaction if it occurred during or within 24 hours of an infusion.', 'timeFrame': '24 weeks'}]","[{'measure': 'Percentage of Participants With All-Cause Discontinuation', 'description': 'Participants who discontinued treatment due to any reason were included in this measure.', 'timeFrame': '24 weeks'}, {'measure': 'Number of Participants With Alanine Transaminase (ALT) and Asapartate Transaminase (AST) Elevations of Greater Than (>) 1.5 Upper Limit of Normal (ULN), >3 ULN and > 5 ULN', 'description': 'Elevations in ALT and AST could indicate hepatotoxicity.', 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Percentage of Participants With ALT and AST Elevations of >1.5 ULN, >3 ULN and > 5 ULN', 'description': 'Elevations in ALT and AST could indicate hepatotoxicity.', 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Percentage of Participants With Serious Infections', 'description': 'A serious infection was an infection which was also considered as an SAE. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly', 'timeFrame': 'Weeks 4 (Visit 3), 8 (Visit 4), and 16 (Visit 6)'}, {'measure': 'Number of Participants With Serious Infections', 'description': 'A serious infection was an infection which was also considered as an SAE. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly', 'timeFrame': 'Weeks 4 (Visit 3), 8 (Visit 4), and 16 (Visit 6)'}, {'measure': 'Change From Baseline to Highest Values for ALT and AST', 'description': 'Elevations in ALT and AST could indicate hepatotoxicity. These enzymes were measured as International Units per Liter (IU/L). The change from baseline was calculated as: baseline value minus the highest value observed post-baseline for each enzyme.', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Change From Baseline to Highest Values for Low Density Lipoprotein (LDL) and Total Cholesterol', 'description': 'Elevations in LDL and total cholesterol could lead to heart disease. The change from baseline was calculated as: baseline value minus the highest value observed post-baseline and was measured as milligrams per deciliter (mg/dL).', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Change From Baseline to Lowest Value for Absolute Neutrophil Count (ANC)', 'description': 'ANC is a measure of number of neutrophil granulocytes. An ANC less than 500 cells per microliter (cells/µL) is defined as neutropenia and significantly increases risk of infection. The change from baseline was calculated as: baseline value minus the highest value observed post-baseline. ANC was measured in cells/µL.', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Number of Participants With Elevations in Lipids According to Adult Treatment Panel (ATP) III Guidelines', 'description': 'ATP III guidelines classify LDL cholesterol \\>160 mg/dL, Total cholesterol \\>240 mg/dL, High Density Lipoprotein (HDL) \\>60 mg/dL and Triglycerides (TG) \\>199 as elevated.', 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4),12 (Visit 5),16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Percentage of Participants With Elevations in Lipids According to ATP III Guidelines', 'description': 'ATP III guidelines classify LDL cholesterol \\>160 mg/dL , Total cholesterol \\>240 mg/dL, HDL \\>60 mg/dL and TG \\>199 as elevated.', 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Number of Participants Who Achieved Clinically Meaningful Improvement in Disease Activity Score 28 (DAS28) At Every Visit', 'description': ""The DAS28 is a combined index for measuring disease activity in Rheumatoid Arthritis (RA). The index includes swollen and tender joint counts, acute phase response, and general health status. The DAS28, which uses a 28 joint count, is derived from the original DAS. The index is calculated using the following formula:\n\nDAS28 = 0.56 x (TJC28)\\^0.5 + 0.28 x (SJC28)\\^0.5 + 0.70 x In(ESR) + 0.014 x GH Where TJC28 = tender joint count on 28 joints, SJCz8 = swollen joint count on 28 joints, ın = natural log, ESR = erythrocyte sedimentation rate and GH = general health (participant's global assessment of disease activity). DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A score of less than (\\<) 2.6 represents clinical remission, a score of: \\<3.2 represents low disease activity (LDA), and a score of \\> 5.1 represents severe disease. A reduction from previous visit of at least 1.2 units in DAS28 is considered to be a clinically meaningful improvement."", 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Percentage of Participants Who Achieved Clinically Meaningful Improvement in DAS28 At Every Visit', 'description': ""The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen and tender joint counts, acute phase response, and general health status. The DAS28, which uses a 28 joint count, is derived from the original DAS. The index is calculated using the following formula:\n\nDAS28 = 0.56 x (TJC28)\\^0.5 + 0.28 x (SJC28)\\^0.5 + 0.70 x In(ESR) + 0.014 x GH Where TJC28 = tender joint count on 28 joints, SJCz8 = swollen joint count on 28 joints, ın = natural log, ESR = erythrocyte sedimentation rate and GH = general health (participant's global assessment of disease activity). DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A score of \\< 2.6 represents clinical remission, a score of: \\< 3.2 represents LDA, and a score of \\> 5.1 represents severe disease. A reduction of at least 1.2 units from previous visit in DAS28 is considered to be a clinically meaningful improvement."", 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4),12 (Visit 5),16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Number of Participants Who Achieved LDA By Visit', 'description': ""The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen and tender joint counts, acute phase response, and general health status. The DAS28, which uses a 28 joint count, is derived from the original DAS. The index is calculated using the following formula:\n\nDAS28 = 0.56 x (TJC28)\\^0.5 + 0.28 x (SJC28)\\^0.5 + 0.70 x In(ESR) + 0.014 x GH Where TJC28 = tender joint count on 28 joints, SJCz8 = swollen joint count on 28 joints, ın = natural log, ESR = erythrocyte sedimentation rate and GH = general health (participant's global assessment of disease activity). DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A score of \\< 2.6 represents clinical remission, a score of: \\<3.2 represents LDA, and a score of \\> 5.1 represents severe disease. A reduction of at least 1.2 units from previous visit in DAS28 is considered to be a clinically meaningful improvement."", 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Percentage of Participants Who Achieved LDA By Visit', 'description': ""TThe DAS28 is a combined index for measuring disease activity in RA. The index includes swollen and tender joint counts, acute phase response, and general health status. The DAS28, which uses a 28 joint count, is derived from the original DAS. The index is calculated using the following formula:\n\nDAS28 = 0.56 x (TJC28)\\^0.5 + 0.28 x (SJC28)\\^0.5 + 0.70 x In(ESR) + 0.014 x GH Where TJC28 = tender joint count on 28 joints, SJCz8 = swollen joint count on 28 joints, ın = natural log, ESR = erythrocyte sedimentation rate and GH = general health (participant's global assessment of disease activity). DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A score of \\< 2.6 represents clinical remission, a score of: \\<3.2 represents LDA, and a score of \\> 5.1 represents severe disease. A reduction of at least 1.2 units from previous visit in DAS28 is considered to be a clinically meaningful improvement."", 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Time to LDA (DAS28 ) Based on First Visit When LDA Was Observed', 'description': ""The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen and tender joint counts, acute phase response, and general health status. The DAS28, which uses a 28 joint count, is derived from the original DAS. The index is calculated using the following formula:\n\nDAS28 = 0.56 x (TJC28)\\^0.5 + 0.28 x (SJC28)\\^0.5 + 0.70 x In(ESR) + 0.014 x GH Where TJC28 = tender joint count on 28 joints, SJCz8 = swollen joint count on 28 joints, ın = natural log, ESR = erythrocyte sedimentation rate and GH = general health (participant's global assessment of disease activity). DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A score of \\< 2.6 represents clinical remission, a score of: \\<3.2 LDA, and a score of \\> 5.1 represents severe disease. A reduction of at least 1.2 units from previous visit in DAS28 is considered to be a clinically meaningful improvement."", 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Number of Participants Who Achieved Remission (DAS28) By Visit', 'description': ""The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen and tender joint counts, acute phase response, and general health status. The DAS28, which uses a 28 joint count, is derived from the original DAS. The index is calculated using the following formula:\n\nDAS28 = 0.56 x (TJC28)\\^0.5 + 0.28 x (SJC28)\\^0.5 + 0.70 x In(ESR) + 0.014 x GH Where TJC28 = tender joint count on 28 joints, SJCz8 = swollen joint count on 28 joints, ın = natural log, ESR = erythrocyte sedimentation rate and GH = general health (participant's global assessment of disease activity). DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A score of \\< 2.6 represents clinical remission, a score of: \\<3.2 LDA, and a score of \\> 5.1 represents severe disease. A reduction of at least 1.2 units in DAS28 is considered to be a clinically meaningful improvement."", 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Percentage of Participants Who Achieved Remission (DAS28) At Every Visit', 'description': ""The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen and tender joint counts, acute phase response, and general health status. The DAS28, which uses a 28 joint count, is derived from the original DAS. The index is calculated using the following formula:\n\nDAS28 = 0.56 x (TJC28)\\^0.5 + 0.28 x (SJC28)\\^0.5 + 0.70 x In(ESR) + 0.014 x GH Where TJC28 = tender joint count on 28 joints, SJCz8 = swollen joint count on 28 joints, ın = natural log, ESR = erythrocyte sedimentation rate and GH = general health (participant's global assessment of disease activity). DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A score of \\< 2.6 represents clinical remission, a score of: \\<3.2 LDA, and a score of \\> 5.1 represents severe disease. A reduction of at least 1.2 units in DAS28 is considered to be a clinically meaningful improvement."", 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Percentage of Participants Achieving Their First Remission Status By Visit', 'description': ""The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen and tender joint counts, acute phase response, and general health status. The DAS28, which uses a 28 joint count, is derived from the original DAS. The index is calculated using the following formula:\n\nDAS28 = 0.56 x (TJC28)\\^0.5 + 0.28 x (SJC28)\\^0.5 + 0.70 x In(ESR) + 0.014 x GH Where TJC28 = tender joint count on 28 joints, SJCz8 = swollen joint count on 28 joints, ın = natural log, ESR = erythrocyte sedimentation rate and GH = general health (participant's global assessment of disease activity). DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A score of \\< 2.6 represents clinical remission, a score of: \\<3.2 LDA, and a score of \\> 5.1 represents severe disease. A reduction of at least 1.2 units in DAS28 is considered to be a clinically meaningful improvement."", 'timeFrame': 'Weeks 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Disease Activity Score as Measured By DAS28 at Each Visit', 'description': ""The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen and tender joint counts, acute phase response, and general health status. The DAS28, which uses a 28 joint count, is derived from the original DAS. The index is calculated using the following formula:\n\nDAS28 = 0.56 x (TJC28)\\^0.5 + 0.28 x (SJC28)\\^0.5 + 0.70 x In(ESR) + 0.014 x GH Where TJC28 = tender joint count on 28 joints, SJCz8 = swollen joint count on 28 joints, ın = natural log, ESR = erythrocyte sedimentation rate and GH = general health (participant's global assessment of disease activity). DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. A score of \\< 2.6 represents clinical remission, a score of: \\<3.2 LDA, and a score of \\> 5.1 represents severe disease. A reduction of at least 1.2 units in DAS28 is considered to be a clinically meaningful improvement."", 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Number of Participants Who Achieved American College of Rheumatology (ACR) 20, ACR 50, ACR 70 and ACR 90 Response', 'description': 'ACR20/50/70/90 response: greater than or equal to (≥) 20/50/70/90 percent (%) improvement in TJC; ≥20/50/70/90% improvement in SJC; and ≥20/50/70/90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP). Improvements were assessed on the basis of prior visit.', 'timeFrame': 'Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4),12 (Visit 5),16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Percentage of Participants Who Achieved ACR 20, ACR 50, ACR 70 and ACR 90 Response', 'description': 'ACR20/50/70/90 response: ≥ 20/50/70/90 % improvement in TJC; ≥20/50/70/90% improvement in SJC; and ≥20/50/70/90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP). Improvements were assessed on the basis of prior visit. .', 'timeFrame': 'Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4),12 (Visit 5),16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'C-Reactive Protein Levels', 'description': 'CRP is an inflammatory marker used to measure inflammation in RA and is measured as mg/dL.', 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Erythrocyte Sedimentation Rate', 'description': 'ESR is an inflammatory marker used to measure inflammation in RA and is measured as millimeters per hour (mm/hr).', 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Mean Number of Tender and Swollen Joints', 'description': 'Participants were asked to classify 28 joints as tender or not tender and swollen or not swollen to count the total number of tender and swollen joints by visit.', 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': ""Participant's (PT) and Investigator's (IN) Assessment of Disease Activity"", 'description': ""VAS is a visual scale of 100 mm for the assessment of disease activity by participants or investigator. Disease activity/pain increases while approaching 100 mm. For the screening visit (baseline visit) there's only investigator assessment data, for other visits participant's pain assessment, participant's disease activity assessment and investigator's disease activity assessment parameters were collected."", 'timeFrame': 'Screening (Visit 1), Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': ""Participant's Assessment of Pain"", 'description': ""VAS is a visual scale of 100 mm for the assessment of disease activity by participants or investigator. Disease activity/pain increases while approaching 100 mm. For the screening visit (baseline visit) there's only investigator assessment data, for other visits participant's pain assessment, participant's disease activity assessment and investigator's disease activity assessment parameters were collected."", 'timeFrame': 'Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}, {'measure': 'Health Assessment Questionnaire Score (General Score)', 'description': 'The Stanford HAQ disability index is a participant completed questionnaire specific for RA. It consists of 20 questions referring to 8 component sections: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The questionnaire was provided in validated translation into the local languages at the participating sites and was scored. Every question in each section was scored at a scale from 0 to 3 by the participant where 0 = able to perform the activity without any difficulty and 3 = unable to perform the activity. General score was calculated as an average of the 8 sections.', 'timeFrame': 'Weeks 0 (Visit 2), 4 (Visit 3), 8 (Visit 4), 12 (Visit 5), 16 (Visit 6), 20 (Visit 7) and 24 (Visit 8)'}]",28,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,65.0,ACTUAL,2025-09-01T16:18:22.195482,v2_robust,True,True,True,False,True,
NCT04455477,Nesiritide for Ventilated Congestive Heart Failure,Hemodynamic Effects of Nesiritide on Congestive Heart Failure Patients Receiving Mechanical Ventilation: A Prospective Observational Study,Nesiritide,['Nesiritide'],1,OBSERVATIONAL,[],,,Congestive Heart Failure,"['Congestive Heart Failure', 'Mechanical Ventilation', 'Using Nesiritide', 'Venous Return', 'Cardiac Function']","['Congestive Heart Failure', 'Nesiritide']",UNKNOWN,,2020-05-14,2021-12-31,"[{'measure': 'Changes of cardiac output', 'description': 'Changes of cardiac output measured by hemodynamical monitoring tools', 'timeFrame': 'Before and 30-min after using a standard dose of Nesiritide'}, {'measure': 'Changes of systemic filling pressure', 'description': 'Changes of the intercept of regression line of paired VR-RAP points at different PEEP levels.', 'timeFrame': 'Before and 30-min after using a standard dose of Nesiritide'}]","[{'measure': 'Changes of cardiac function curve', 'description': 'Using body position changes (±15°) to simulate the change of preload, and therefore depicte the Starling curve', 'timeFrame': 'Before and 30-min after using a standard dose of Nesiritide'}, {'measure': 'Changes of venous return curve', 'description': 'Changes of venous return curve depicted by different PEEP setting', 'timeFrame': 'Before and 30-min after using a standard dose of Nesiritide'}]",4,18 Years,,ALL,,Shanghai Zhongshan Hospital,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:22.195799,v2_robust,False,True,False,False,False,
NCT05732077,Fractional Flow Reserve to Determine Atherosclerosis Renovascular Hypertension Stenting,Fractional Flow Reserve to Determine the ApproprIateness of Percutaneous Renal Artery Intervention in Atherosclerosis Renovascular Hypertension Patients: a Pilot Randomized Trial,Dopamine,['Dopamine'],1,INTERVENTIONAL,['NA'],,,Renal Artery Stenosis Atherosclerotic,"['Renal Artery Stenosis Atherosclerotic', 'Secondary Hypertension Renal Arterial']",[],RECRUITING,,2023-01-31,2025-03-31,"[{'measure': 'Change in daytime mean systolic blood pressure as measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)', 'timeFrame': 'From baseline to 3 months post-procedure'}, {'measure': 'Change in the composite index of antihypertensive drugs', 'description': 'Change in the composite index of antihypertensive drugs. Drug Composite Index = Weight (number of classes of antihypertensive drugs) × (sum of doses)', 'timeFrame': 'From baseline to 3 months post-procedure'}]","[{'measure': 'Change in systolic blood pressure as measured by 24-hour ABPM', 'timeFrame': 'From baseline to 3 months post-procedure'}, {'measure': 'Change in diastolic blood pressure as measured by 24-hour ABPM', 'timeFrame': 'From baseline to 3 months post-procedure'}, {'measure': 'Change in home blood pressure', 'timeFrame': 'From baseline to 3 months post-procedure'}, {'measure': 'Change in office blood pressure', 'timeFrame': 'From baseline to 3 months post-procedure'}, {'measure': 'Change in the composite index of antihypertensive drugs to reach target blood pressure', 'description': 'Change in the composite index of antihypertensive drugs to reach target blood pressure. Drug Composite Index = Weight (number of classes of antihypertensive drugs) × (sum of doses)', 'timeFrame': 'From baseline to 1 year post-procedure'}, {'measure': 'Change in ABPM', 'timeFrame': 'From baseline to 6 months, 1 year post-procedure'}, {'measure': 'All-cause death', 'timeFrame': 'From baseline to 1 year post-procedure'}, {'measure': 'Cardiac death', 'timeFrame': 'From baseline to 1 year post-procedure'}, {'measure': 'Acute myocardial infarction incidence', 'description': 'Based on universal definition of acute myocardial infarction', 'timeFrame': 'From baseline to 1 year post-procedure'}, {'measure': 'Non-fatal stroke incidence', 'description': ""Based on medical records under outcome committee's judge"", 'timeFrame': 'From baseline to 1 year post-procedure'}, {'measure': 'Rehospitalization due to heart failure incidence', 'description': ""Based on medical records under outcome committee's judge"", 'timeFrame': 'From baseline to 1 year post-procedure'}, {'measure': 'Increase in serum creatinine or dialysis', 'timeFrame': 'From baseline to 1 year post-procedure'}]",14,18 Years,,ALL,False,Peking University First Hospital,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:22.195843,v2_robust,True,True,False,False,False,
NCT06392477,A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma,"A Multicenter, Multiple Expansion Cohort Phase 1 Study Evaluating the Safety and Activity of DR-0201 as Multiple Ascending Doses in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma",DR-0201,['DR-0201'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,B-cell Non Hodgkin Lymphoma,['B-cell Non Hodgkin Lymphoma'],"['B-NHL', 'Non-Hodgkin Lymphoma', 'NHL']",RECRUITING,,2024-07-15,2026-12,"[{'measure': 'Incidence and severity of adverse events as assessed by CTCAE v5.0.(Safety and Tolerability)', 'description': 'To determine the incidence and severity of adverse events as assessed by CTCAE v5.0.', 'timeFrame': 'Up to 12 months'}]",[],1,18 Years,,ALL,False,Dren Bio,INDUSTRY,0,48.0,ESTIMATED,2025-09-01T16:18:22.195965,v2_robust,True,True,False,False,True,
NCT00827177,Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors,A Phase 1 Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors,Treatment with ARQ 197 in combination with sorafenib,['Treatment with ARQ 197 in combination with sorafenib'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumors,['Advanced Solid Tumors'],"['dose escalation', 'safety', 'tolerability', 'tumor', 'PK', 'hepatocellular carcinoma', 'renal cell carcinoma', 'melanoma', 'non-small cell lung cancer', 'breast cancer']",COMPLETED,,2009-09,2013-05,"[{'measure': 'To identify maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of ARQ 197 when administered in combination with sorafenib.', 'timeFrame': '6 to 9 months. Patients will remain on study until progression of disease, unacceptable toxicity, or other discontinuation criterion is met.'}]","[{'measure': 'To determine the pharmacokinetic profiles of ARQ 197 and sorafenib.', 'timeFrame': 'Patients will remain on study until progression of disease, unacceptable toxicity, or other discontinuation criterion is met.'}, {'measure': 'To assess the preliminary anti-tumor activity of ARQ 197 when administered in combination with sorafenib.', 'timeFrame': 'Patients will remain on study until progression of disease, unacceptable toxicity, or other discontinuation criterion is met.'}, {'measure': ""To evaluate dynamic changes of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and soluble c-Met in patients' peripheral blood that are associated with treatment of ARQ 197 plus sorafenib."", 'timeFrame': 'Patients will remain on study until progression of disease, unacceptable toxicity, or other discontinuation criterion is met.'}]",4,18 Years,,ALL,False,"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)",INDUSTRY,0,87.0,ACTUAL,2025-09-01T16:18:22.195990,v2_robust,True,True,True,False,False,
NCT06946277,Assessing the Time-Course of Dexmedetomidine-Induced Analgesia Via EEG,Mapping the Temporal Profile of Dexmedetomidine-Induced Analgesia Via EEG Signatures in Brain,Preemptive Analgesia Of Dexmedetomidine,['Preemptive Analgesia Of Dexmedetomidine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Total Hip Arthroplasty (THA),"['Total Hip Arthroplasty (THA)', 'Intrathecal Anesthesia', 'Hip Osteoarthritis']",[],NOT_YET_RECRUITING,,2025-04-25,2025-05-26,"[{'measure': 'Resting EEG', 'description': 'Resting-state electroencephalography (rsEEG) was recorded at three phases: before dexmedetomidine infusion (non-dosing phase), during dexmedetomidine infusion (DEX phase), and after dexmedetomidine infusion cessation (Cessation phase).', 'timeFrame': 'During the whole operation'}]","[{'measure': 'ERP', 'description': 'Event-related potential (ERP) was measured at three phases: before dexmedetomidine infusion (Non-dosing phase), during dexmedetomidine infusion (DEX phase), and after infusion cessation (Cessation phase)', 'timeFrame': 'During the whole operation'}]",2,18 Years,70 Years,ALL,False,China International Neuroscience Institution,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:22.196051,v2_robust,True,True,False,False,False,
NCT06866977,"A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer","A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer",Oncolytic virus VRT106,"['Chemotherapy', 'VRT106', 'Oncolytic virus VRT106']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Pancreatic Cancer,['Pancreatic Cancer'],['Advanced pancreatic cancer'],NOT_YET_RECRUITING,,2025-03-12,2025-12-31,"[{'measure': 'Safety and tolerability', 'description': 'Incidence rate of TRAE', 'timeFrame': 'About 3 years'}]","[{'measure': 'Overall survival rate', 'description': 'Overall survival rates at 12, 18, and 24 months', 'timeFrame': 'About 3 years'}]",2,18 Years,,ALL,False,Xiangya Hospital of Central South University,OTHER,1,10.0,ESTIMATED,2025-09-01T16:18:22.196075,v2_robust,True,True,False,False,True,
NCT05298475,Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome,Short-term Effect of Modified 、Low-dose Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome : the Singe-center 、Real-world Study,Statin,"['Statin', 'PCSK9 inhibitor']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Acute Coronary Syndrome,['Acute Coronary Syndrome'],"['Acute coronary syndrome', 'Serum lipids', 'PCSK9 inhibitor', 'Statin']",UNKNOWN,,2022-04-01,2024-04-01,"[{'measure': 'The level of total cholesterol(TC)', 'description': 'The level of total cholesterol(TC) at 6 month', 'timeFrame': '6 month'}, {'measure': 'The level of triglyceride(TG)', 'description': 'The level of triglyceride(TG) at 6 month', 'timeFrame': '6 month'}, {'measure': 'The level of high-density lipoprotein cholesterol(HDL-C)', 'description': 'The level of high-density lipoprotein cholesterol(HDL-C) at 6 month', 'timeFrame': '6 month'}, {'measure': 'The level of low-density lipoprotein cholesterol(LDL-C)', 'description': 'The level of low-density lipoprotein cholesterol(LDL-C) at 6 month', 'timeFrame': '6 month'}]",[],4,18 Years,85 Years,ALL,False,The First Affiliated Hospital with Nanjing Medical University,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:22.196121,v2_robust,True,True,False,False,False,
NCT06112275,"A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children with SCN1A-positive Dravet Syndrome (Australia Only)","WAYFINDER: a Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children with SCN1A-positive Dravet Syndrome",ETX101,['ETX101'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Dravet Syndrome,['Dravet Syndrome'],"['Dravet', 'SCN1A', 'DEE', 'developmental and epileptic encephalopathy', 'Dravet Syndrome', 'SCN1A-positive', 'SCN1A+']",RECRUITING,,2024-02-28,2030-06,"[{'measure': 'Proportion of participants experiencing any treatment-emergent adverse events (AEs), serious adverse events (SAEs), related AEs, AEs with severity Grade ≥ 3, AEs resulting in study discontinuation, and AEs with a fatal outcome.', 'timeFrame': 'Day 1 through Study Completion, an average of 5 years'}, {'measure': 'Percent change from Baseline in monthly countable seizure frequency (MCSF) at Week 52, with countable seizures defined as generalized tonic-clonic/clonic, focal motor with clearly observable clinical signs, tonic bilateral, and atonic seizures.', 'timeFrame': 'Between the 8-week baseline period and the 48-week post-dosing assessment period (defined as Week 5 to Week 52 following administration of ETX101)'}, {'measure': 'Proportion of participants free from episodes of prolonged seizures and/or status epilepticus at Week 52.', 'timeFrame': 'Week 5 through Week 52'}]","[{'measure': 'Proportion of participants with ≥ 90% reduction in monthly countable seizure frequency (MCSF) from Baseline at Week 52.', 'timeFrame': 'Between the 8-week baseline period and the 48-week post-dosing assessment period (defined as Week 5 to Week 52 following administration of ETX101)'}, {'measure': 'Change from Baseline in the Vineland-Third Edition Expressive Communication raw score at Week 52.', 'timeFrame': 'Baseline through Week 52. Higher scores correspond to better outcomes.'}]",5,6 Months,83 Months,ALL,False,Encoded Therapeutics,INDUSTRY,0,4.0,ESTIMATED,2025-09-01T16:18:22.196165,v2_robust,True,True,False,False,True,
NCT04869475,Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation,Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation,Arsenic trioxide,['Arsenic trioxide'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Refractory Solid Tumors,['Refractory Solid Tumors'],[],UNKNOWN,,2021-04-20,2024-04-30,"[{'measure': 'Disease control rate (DCR)', 'timeFrame': '12 months'}]","[{'measure': 'Overall response rate (ORR)', 'timeFrame': '12 months'}, {'measure': 'Progression free survival (PFS)', 'timeFrame': '12 months'}, {'measure': 'Duration of response (DOR)', 'timeFrame': '12 months'}, {'measure': 'Safety: adverse events as assessed by CTCAE v5.0', 'timeFrame': '36 months'}]",5,18 Years,,ALL,False,Ruijin Hospital,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:22.196178,v2_robust,True,True,False,False,True,
NCT02156375,A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations,"A Phase 1, Randomized, Open-label, Parallel-design Study to Compare Single-dose Pharmacokinetics of Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations",Ustekinumab,"['STELARA®', 'Ustekinumab']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Healthy', 'Ustekinumab', 'STELARA®']",COMPLETED,,2014-05,2014-12,"[{'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'description': 'The Cmax is the maximum observed plasma concentration of study drug.', 'timeFrame': 'Day 0 through Day 113'}, {'measure': 'Area under the serum concentration versus time curve from time zero to infinity (AUC[0-inf])', 'description': 'The AUC(0-inf) is the area under the serum concentration versus time curve from time zero to infinity with extrapolation of the terminal phase.', 'timeFrame': 'Day 0 through Day 113'}]","[{'measure': 'Number of participants with adverse events (AEs) and serious adverse events (SAEs)', 'description': 'An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product and does not necessarily have a causal relationship with the treatment. An SAE is any untoward medical occurrence that meets any of the following conditions: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.', 'timeFrame': 'Baseline up to Day 141'}, {'measure': 'Area under the serum concentration versus time curve from time zero to the time corresponding to the last quantifiable concentration (AUC[0-last])', 'description': 'The AUC(0-last) is the area under the serum concentration versus time curve from time zero to the time corresponding to the last quantifiable concentration.', 'timeFrame': 'Day 0 through Day 113'}, {'measure': 'Terminal half-life (T1/2)', 'description': 'The T1/2 is the terminal half-life, that is, time required for the plasma concentration to decrease by one half.', 'timeFrame': 'Day 0 through Day 113'}, {'measure': 'Total systemic clearance (CL)', 'description': 'The CL is a quantitative measure of the rate at which a drug substance is removed from the body.', 'timeFrame': 'Day 0 through Day 113'}, {'measure': 'Volume of distribution (Vz)', 'description': 'The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.', 'timeFrame': 'Day 0 through Day 113'}, {'measure': 'Number of participants with antibodies to ustekinumab', 'description': 'Number of participants with antibodies to ustekinumab (tested using a validated immunoassay method) will be reported.', 'timeFrame': 'Baseline, Days 57 and 113'}]",8,18 Years,55 Years,ALL,True,"Janssen Research & Development, LLC",INDUSTRY,0,140.0,ACTUAL,2025-09-01T16:18:22.196209,v2_robust,True,True,True,False,True,
NCT00790075,Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children,Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children,risperidone,['risperidone'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Agitation,['Agitation'],"['agitation', 'Episodes of agitation regardless of diagnosis']",COMPLETED,,2003-01,2004-12,"[{'measure': 'reduced time to end of agitation episode compared to unmedicated agitation episode', 'timeFrame': 'Duration of ""time out"" or time in seclusion'}]",[],1,4 Years,12 Years,ALL,False,Stony Brook University,OTHER,0,24.0,ACTUAL,2025-09-01T16:18:22.196686,v2_robust,True,True,True,False,False,
NCT02100475,"A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification","A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)",insulin degludec/liraglutide,"['insulin degludec/liraglutide', 'insulin aspart']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],COMPLETED,,2014-04,2015-04,"[{'measure': 'Change From Baseline in HbA1c (Glycosylated Haemoglobin)', 'description': 'Change from baseline in HbA1c after 26 weeks of treatment.', 'timeFrame': 'Week 0, week 26'}]","[{'measure': 'Change From Baseline in Body Weight', 'description': 'Change from baseline in body weight after 26 weeks of treatment.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Number of Treatment-emergent Confirmed Hypoglycaemic Episodes', 'description': 'Treatment-emergent hypoglycaemic episodes: if the onset of the episode occurred on or after the first day of investigational medicinal product administration, and no later than 7 days after the last day on investigational medicinal product. Confirmed hypoglycaemia: subject unable to treat himself/herself and/or have a recorded plasma glucose \\< 3.1 mmol/L (56 mg/dL).', 'timeFrame': 'Week 0 - 26'}]",3,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,31.0,ACTUAL,2025-09-01T16:18:22.196779,v2_robust,True,True,True,False,False,
NCT01191775,A Study of PNT2258 in Patients With Advanced Solid Tumors,A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors,PNT2258,"['PNT2258', 'PNT-2258']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Cancer,"['Cancer', 'Lymphoma', 'Prostate Cancer', 'Melanoma']","['Oligonucleotide', 'DNAi', 'Oncology', 'Antineoplastic agent', 'Lymphoma', 'PNT2258']",COMPLETED,,2010-08,2012-04,"[{'measure': 'To determine the safety of PNT2258 in patients with advanced solid tumors', 'description': 'Safety and tolerability of PNT2258 and the determination of dose-limiting toxicities (DLTs) and the recommended Phase 2 dose', 'timeFrame': 'Ongoing'}]","[{'measure': 'Pharmacokinetic profile of PNT2258', 'timeFrame': 'Ongoing'}]",2,18 Years,,ALL,False,Sierra Oncology LLC - a GSK company,INDUSTRY,0,22.0,ACTUAL,2025-09-01T16:18:22.196816,v2_robust,True,True,True,False,True,
NCT01978457,Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction,Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction,cocaine hydrochloride,"['cocaine hydrochloride', 'propranolol', 'placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Cocaine Dependent Subjects,['Cocaine Dependent Subjects'],[],TERMINATED,Not funded,2012-10,2019-12,"[{'measure': 'Total number of patient controlled analgesic (PCA) pump activations (responses)', 'description': 'Data on cocaine self-administration (total number of responses) will be checked for normality prior to analysis using Kolmogorov-Smirnov statistics and normal probability plots. Data that is not normally distributed will be log transformed. If it remains highly skewed after transformation, it will be analyzed using non-parametric approaches (e.g., a non-parametric, ANOVA-Type Statistic). Normally distributed data will be analyzed employing a mixed model design, 3-way ANOVA with co-factors of placebo vs propranolol (between subjects), non-cocaine predicting cues vs. cocaine predicting cues (within subjects) and non-reactivated cocaine cues vs. reactivated cocaine cues (within subjects).', 'timeFrame': '3 days'}]",[],1,18 Years,50 Years,ALL,False,Yale University,OTHER,0,6.0,ACTUAL,2025-09-01T16:18:22.196885,v2_robust,True,True,False,True,False,Not funded
NCT05024357,A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL,A Randomized Controlled Study of Tyrosine Kinase Inhibitor Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed Philadelphia Chromesome Positive Adult Acute Lymphoblastic Leukemia,Dasatinib,"['Dasatinib tablet', 'Dasatinib']",2,INTERVENTIONAL,['NA'],,,Precursor Cell Lymphoblastic Leukemia-Lymphoma,"['Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'Philadelphia-Positive Acute Lymphoblastic Leukemia', 'ALL, Adult']","['Philadelphia-Positive', 'Adult Acute Lymphoblastic Leukemia', 'Allogeneic Hematopoietic Stem Cell Transplantation', 'Tyrosine Kinase Inhibitors']",UNKNOWN,,2021-09-06,2023-06-30,"[{'measure': 'Percentage of Patients with Measurable Residual Disease (MRD) Positivity', 'description': 'MRD means the subclinical levels of residual leukemia.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.'}, {'measure': 'Percentage of Patients with Complete Remission (CR)', 'description': 'CR means that the blood counts have returned to normal, the leukemia cannot be seen when a bone marrow sample is examined under the microscope, and the signs and symptoms of the ALL are gone.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.'}]","[{'measure': 'Disease-free Survival (DFS), months', 'description': 'The measure of time after allo-HSCT during which no sign of ALL is found.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.'}, {'measure': 'Overall Survival (OS), months', 'description': 'The length of time from the date of allo-HSCT that Ph+ ALL patients are still alive.', 'timeFrame': 'From date of randomization until the date of death from any cause, whichever came first, assessed up to 36 months.'}, {'measure': 'Non-relapse Mortality (NRM), rate or percentage', 'description': 'NRM means death without recurrent or progressive disease after allo-HSCT.', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.'}, {'measure': 'Incidence of graft versus host disease (GVHD), rate or percentage', 'description': ""GVHD is a condition that might occur after allo-HSCT. In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body."", 'timeFrame': 'From date of randomization until the date of GVHD occurrence or date of death from any cause, whichever came first, assessed up to 36 months.'}, {'measure': 'Adverse Effects (AE)', 'description': 'An adverse effect is any untoward medical occurrence in clinical investigation subject administered dasatinib and which does not necessarily have a causal relationship with this treatment.', 'timeFrame': 'From date of randomization until the date of death from any cause, whichever came first, assessed up to 36 months.'}]",7,18 Years,65 Years,ALL,False,First Affiliated Hospital Xi'an Jiaotong University,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:22.196898,v2_robust,True,True,False,False,True,
NCT03574857,Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance,Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance,Metolazone Oral Tablet,"['Chlorothiazide Injection', 'Zaroxolyn', 'Metolazone Oral Tablet', 'Diuril']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Heart Failure,"['Heart Failure', 'Heart Failure With Reduced Ejection Fraction', 'Heart Failure Acute', 'Cardiovascular Diseases']","['Loop diuretics', 'Heart failure', 'Diuretic resistance', 'Thiazide diuretics']",TERMINATED,Low enrollment,2018-06-01,2021-01-01,"[{'measure': 'Net urine output at 24 hours', 'description': 'Milliliters of urine output minus the oral plus intravenous intake', 'timeFrame': '24 hours'}]","[{'measure': 'Net urine output at 48 hours', 'description': 'Milliliters of urine output minus the oral plus IV intake', 'timeFrame': '48 hours'}, {'measure': 'Net fluid balance over 12 hours', 'description': 'the net fluid balance over 12 and 24 hours prior to the addition of metolazone or chlorothiazide compared to the 12 hours after addition of the study drug', 'timeFrame': '24 hours'}, {'measure': 'Net fluid balance over 24 hours', 'description': 'Net fluid balance over 24 hours prior to the addition of metolazone or chlorothiazide compared to the 24 hours after addition of the study drug', 'timeFrame': '48 hours'}, {'measure': 'Weight change', 'description': 'Change in documented weight in kg at 48 hours after starting metolazone or chlorothiazide', 'timeFrame': '48 hours'}]",5,18 Years,,ALL,False,University of Virginia,OTHER,0,5.0,ACTUAL,2025-09-01T16:18:22.196929,v2_robust,True,True,False,True,False,Low enrollment
NCT03218657,"Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole","A Prospective, Randomized, Controlled Clinical Study of Non Transfusion Dependent Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole Hydrochloride",levamisole hydrochloride,"['levamisole hydrochloride', 'Cyclosporins', 'levamisole', 'Androgens']",4,INTERVENTIONAL,['NA'],,,Aplastic Anemia,['Aplastic Anemia'],"['Aplastic Anemia', 'levamisole hydrochloride', 'clinical study']",UNKNOWN,,2018-01-01,2022-07-01,"[{'measure': 'Routine blood test', 'description': 'hemoglobin；white blood cell；Platelet', 'timeFrame': 'up to 4 weeks'}]","[{'measure': 'Bone marrow', 'description': 'The proliferation of cells in bone marrow', 'timeFrame': '1 year'}, {'measure': 'biochemical test', 'description': 'Alanine aminotransferase；Aspartate aminotransferase', 'timeFrame': 'up to 4 weeks'}]",3,18 Years,70 Years,ALL,False,Shengyun Lin,OTHER,0,248.0,ESTIMATED,2025-09-01T16:18:22.197031,v2_robust,True,True,False,False,False,
NCT00226057,Efalizumab for Moderate to Severe Atopic Dermatitis,Efalizumab for Moderate to Severe Atopic Dermatitis - A Phase I Pilot Study in Adults,Raptiva,"['Raptiva', 'Efalizumab']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Dermatitis, Atopic","['Dermatitis, Atopic']","['Atopic dermatitis', 'Raptiva']",COMPLETED,,2005-06,2006-05,"[{'measure': 'Evaluate the safety and effectiveness of Raptiva in patients with moderate to severe atopic dermatitis', 'description': 'The primary efficacy outcome measure will be the change in mean Eczema Area and Severity Index (EASI) score from baseline', 'timeFrame': 'EASI Score collected at 12 weeks following baseline'}]","[{'measure': 'Improvement in EASI score', 'description': 'Total percent of patients reaching 50% improvement in EASI score', 'timeFrame': 'Assessed 12 weeks after baseline'}, {'measure': 'Improvement in IGA score', 'description': 'Numbers of patient reaching clear, almost clear or mild disease on the Investigator Global Assessment (IGA) Score', 'timeFrame': 'Assessed 12 weeks after baseline'}, {'measure': ""Subject's assessment of overall response"", 'description': ""Subject's assessment of overall response"", 'timeFrame': 'End of study'}, {'measure': 'Change in serum IgE level', 'description': 'Change in serum IgE Level', 'timeFrame': 'Serum IgE collected at 12 weeks following baseline'}, {'measure': 'Pruritis (0-10 VAS Scale) change', 'description': 'Pruritis (0-10 VAS Scale) change', 'timeFrame': 'VAS scale collected at 12 weeks following baseline'}, {'measure': 'Time to first response', 'description': 'Time to first response as defined by a decrease of 25% in EASI score', 'timeFrame': 'Assessed on Days 28,56, and 84'}]",7,18 Years,,ALL,True,Oregon Health and Science University,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:22.197047,v2_robust,True,True,True,False,True,
NCT04334057,Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®,"Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®. A Multi-centre, Prospective, Observational, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Effectiveness of Esperoct® in Haemophilia A Patients Under Routine Clinical Practice Conditions in Japan",Turoctocog alfa pegol,['Turoctocog alfa pegol'],1,OBSERVATIONAL,[],,,Haemophilia A,['Haemophilia A'],[],COMPLETED,,2021-03-31,2024-01-10,"[{'measure': 'Number of adverse reactions (ARs) reported during the observation period', 'description': 'Count', 'timeFrame': 'From baseline (week 0) to end of study (week 104)'}]","[{'measure': 'Number of serious adverse events (SAEs) reported during the observation period', 'description': 'Count', 'timeFrame': 'From baseline (week 0) to end of study (week 104)'}, {'measure': 'Number of serious adverse reactions (SARs) reported during the observation period', 'description': 'Count', 'timeFrame': 'From baseline (week 0) to end of study (week 104)'}, {'measure': 'Number of patients who have confirmed inhibitory antibodies against FVIII during the observation period', 'description': 'Count', 'timeFrame': 'From baseline (week 0) to end of study (week 104)'}, {'measure': 'Number of bleeding episodes requiring treatment for patients using Esperoct® during the observation period assessed by annual bleeding rate (ABR)', 'description': 'Count', 'timeFrame': 'From baseline (week 0) to end of study (week 104)'}, {'measure': 'Evaluation of the haemostatic response of Esperoct® measured as number of successes for treatment requiring bleeds', 'description': 'Count, assessed based on a four-point scale (excellent, good, moderate and poor) by counting excellent and good as success and moderate and poor as failure', 'timeFrame': 'From baseline (week 0) to end of study (week 104)'}, {'measure': 'Evaluation of the haemostatic response of Esperoct® measured as number of successes in treatment of bleeds in perioperative management during surgical procedures', 'description': 'Count, assessed as success/failure based on a four-point scale for haemostatic response (excellent, good, moderate and poor) by counting excellent and good as success and moderate and poor as failure', 'timeFrame': 'From baseline (week 0) to end of study (week 104)'}]",7,,,ALL,,Novo Nordisk A/S,INDUSTRY,0,23.0,ACTUAL,2025-09-01T16:18:22.197093,v2_robust,False,True,True,False,True,
NCT04445857,Efficacy of Coadministration of Calcitonin and Hyperbaric Bupivacaine in Spinal Anesthesia in Tramadol-abuse Patients,Efficacy of Coadministration of Calcitonin and Hyperbaric Bupivacaine in Spinal Anesthesia in Lower Abdominal and Limb Surgeries in Tramadol-abuse Patients: a Randomized Controlled Trial,Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intrathecally,"['Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intrathecally', 'Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intravenously']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Analgesia,['Analgesia'],[],COMPLETED,,2020-09-01,2021-01-31,"[{'measure': 'The total dose of rescue analgesia (mg)', 'description': 'The total dose of rescue analgesia (mg)', 'timeFrame': 'The first 24 hours after surgery'}]",[],1,18 Years,60 Years,ALL,False,Ain Shams University,OTHER,0,90.0,ACTUAL,2025-09-01T16:18:22.197124,v2_robust,True,True,True,False,False,
NCT06489457,The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity,The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity,Semaglutide,"['Semaglutide', 'Testosterone Undecanoate']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Type 2 Diabetes Mellitus,"['Type 2 Diabetes Mellitus', 'Obesity', 'Functional Hypogonadism']","['Functional Hypogonadism', 'Type 2 Diabetes', 'Obesity', 'Tesrosterone Replacement Therapy', 'Semaglutide', 'GLP-1 agonist', 'Semen', 'Sperm']",COMPLETED,,2020-09-20,2023-06-30,"[{'measure': 'Change in semen volume from baseline and between the treatment arms', 'description': 'The semen volume will be measured and reported in mililiters (mL). The higher the value the better the outcome.', 'timeFrame': 'Baseline and 24 weeks'}, {'measure': 'Change in sperm concentration from baseline and between the treatment arms', 'description': 'The sperm concentration will be measured and reported in number times 10\\^6 per mililiter (10\\^6/mL). The higher the value the better the outcome.', 'timeFrame': 'Baseline and 24 weeks'}, {'measure': 'Change in total motility of sperm from baseline and between the treatment arms', 'description': 'The total motility will be assessed as total number of motile sperm and reported as number times 10\\^6 per ejaculate (10\\^6/ejaculate). The higher the value the better the outcome.', 'timeFrame': 'Baseline and 24 weeks'}, {'measure': 'Change in normal sperm forms from baseline and between the treatment arms', 'description': 'The normal sperm forms will be assessed as total number of sperm with normal morphology and reported as number times 10\\^6 per ejaculate (10\\^6/ejaculate). The higher the value the better the outcome.', 'timeFrame': 'Baseline and 24 weeks'}, {'measure': 'Change in total number of sperm from baseline and between the treatment arms', 'description': 'The total number of sperm will be measured and reported in number times 10\\^6 per ejaculate (10\\^6/ejaculate). The higher the value the better the outcome.', 'timeFrame': 'Baseline and 24 weeks'}]","[{'measure': 'Change in International index of erectile function 15 (IIEF-15) score from baseline and between the treatment arms', 'description': 'IIEF-15 assesses male sexual function. It has 5 domains. Erectile function with scoring range from 30 (max) to 1 (min). Orgasmic function with scoring range from 10 (max) to 1 (min). Sexual desire with scoring range from 10 (max) to 2 (min). Intercourse satisfaction with scoring range from 15 (max) to 0 (min). Overall satisfaction with scoring range from 10 (max) to 2 (min). The subdomains combine to overall score with scoring range from 75 (max) to 6 (min). The higher score indicates the better sexual function.', 'timeFrame': 'Baseline and 24 weeks'}, {'measure': 'Change in Aging male symptoms (AMS) score from baseline and between the treatment arms', 'description': 'The AMS score assesses male symptoms os hypogonadism. It has 3 subdomains. Psychological symptoms with scoring range from 25 (max) to 5 (min). Somatic with scoring range from 35 (max) to 7 (min). Sexual with scoring range from 25 (max) to 5 (min). The subdomains combine to overall score with scoring range from 85 (max) to 17 (min). The lower the score the less symptoms are present.', 'timeFrame': 'Baseline and 24 weeks'}, {'measure': 'Change in HbA1c from baseline and between the treatment arms', 'description': 'The HbA1c will be measured and reported in % and milimoles per mole (mmol/mol). The lower the value the better the outcome.', 'timeFrame': 'Baseline and 24 weeks'}, {'measure': 'Change in follicle-stimulating hormone (FSH) from baseline and between the treatment arms', 'description': 'The FSH will be measured and reported in international units per liter (IU/L). The higher the value the better the outcome.', 'timeFrame': 'Baseline and 24 weeks'}, {'measure': 'Change in luteinizing hormone (LH) from baseline and between the treatment arms', 'description': 'The LH will be measured and reported in international units per liter (IU/L). The higher the value the better the outcome.', 'timeFrame': 'Baseline and 24 weeks'}, {'measure': 'Change in estimated visceral adipose tissue from baseline and between the treatment arms', 'description': 'Measured by dual-energy X-ray absorptiometry the estimated visceral adipose tissue will be reported in grams (g). The lower the value the better the outcome.', 'timeFrame': 'Baseline and 24 weeks'}, {'measure': 'Change in percentage of body fat from baseline and between the treatment arms', 'description': 'Measured by dual-energy X-ray absorptiometry the procentage of body fat will be reported in %. The lower the value the better the outcome.', 'timeFrame': 'Baseline and 24 weeks'}, {'measure': 'Change in fasting serum low-density lipoproteins (LDL) cholesterol from baseline and between the treatment arms', 'description': 'The LDL cholesterol will be measured and reported in milimoles per liter (mmol/L). The lower the value the better the outcome.', 'timeFrame': 'Baseline and 24 weeks'}, {'measure': 'Change in fasting serum total cholesterol from baseline and between the treatment arms', 'description': 'The total cholesterol will be measured and reported in milimoles per liter (mmol/L). The lower the value the better the outcome.', 'timeFrame': 'Baseline and 24 weeks'}, {'measure': 'Change in fasting serum high-density lipoproteins (HDL) cholesterol from baseline and between the treatment arms', 'description': 'The HDL cholesterol will be measured and reported in milimoles per liter (mmol/L). The higher the value the better the outcome.', 'timeFrame': 'Baseline and 24 weeks'}, {'measure': 'Change in fasting triglycerides from baseline and between the treatment arms', 'description': 'Triglycerides will be measured and reported in milimoles per liter (mmol/L). The lower the value the better the outcome.', 'timeFrame': 'Baseline and 24 weeks'}]",16,18 Years,65 Years,MALE,False,University Medical Centre Ljubljana,OTHER,0,25.0,ACTUAL,2025-09-01T16:18:22.197146,v2_robust,True,True,True,False,False,
NCT04239001,Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer,"Prospective, Open, One-arm Clinical Study Evaluating the Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer",PEG-rhG-CSF,['PEG-rhG-CSF'],1,INTERVENTIONAL,['NA'],,,Advanced Pancreatic Cancer,['Advanced Pancreatic Cancer'],['PEG-rhG-CSF'],UNKNOWN,,2020-02,2021-06,"[{'measure': 'Incidence of degree 3-4 neutropenia in each cycle of chemotherapy', 'description': 'Incidence of degree 3-4 neutropenia in each cycle of chemotherapy', 'timeFrame': 'It lasts 4 cycles(each cycle is 21 days)'}]","[{'measure': 'The incidence of febrile neutropenia in each cycle of chemotherapy', 'description': 'Febrile neutropenia (FN) is defined as oral temperature \\>38.3 ° C (underarm temperature \\>38.1 ° C) or continuous measurement of oral temperature \\>38 ° C (underarm temperature \\>37.8 ° C) in 2 h, and ANC \\<0.5×10\\^9/L, or expected to be \\<0.5×10\\^9/L', 'timeFrame': 'It lasts 4 cycles(each cycle is 21 days)'}, {'measure': 'Incidence of chemotherapy dose adjustment due to neutropenia in each cycle of chemotherapy', 'description': 'Incidence of chemotherapy dose adjustment due to neutropenia in each cycle of chemotherapy', 'timeFrame': 'It lasts 4 cycles(each cycle is 21 days)'}, {'measure': 'The proportion of patients hospitalized due to neutropenia', 'description': 'The proportion of patients hospitalized due to neutropenia', 'timeFrame': 'It lasts 4 cycles(each cycle is 21 days)'}, {'measure': 'The proportion of patients receiving antibiotics during the entire chemotherapy period.', 'description': 'The proportion of patients receiving antibiotics during the entire chemotherapy period.', 'timeFrame': 'It lasts 4 cycles(each cycle is 21 days)'}]",5,18 Years,70 Years,ALL,False,"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.",INDUSTRY,0,20.0,ESTIMATED,2025-09-01T16:18:22.197194,v2_robust,True,True,False,False,False,
NCT01414101,"Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis","A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 329993 in Subjects With Rheumatoid Arthritis",ISIS CRP Rx or Placebo,['ISIS CRP Rx or Placebo'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],['Rheumatoid Arthritis'],COMPLETED,,2011-08,2013-05,"[{'measure': 'Safety', 'description': 'Adverse events, laboratory tests, and vital signs', 'timeFrame': '155 Days'}]","[{'measure': 'hsCRP', 'description': 'The effects of treatment with ISIS CRP Rx or Placebo on hsCRP', 'timeFrame': '155 Days'}]",2,18 Years,75 Years,ALL,False,"Ionis Pharmaceuticals, Inc.",INDUSTRY,0,51.0,ACTUAL,2025-09-01T16:18:22.197268,v2_robust,True,True,True,False,True,
NCT05620901,DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia,The Evaluation of the Safety and Efficacy of Sustained Release Dexamethasone Intracanalicular Insert (DEXTENZA) in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (TENDER),Dextenza 0.4Mg Ophthalmic Insert,"['Pred Forte', 'Dextenza 0.4Mg Ophthalmic Insert']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Vitreoretinopathy,"['Vitreoretinopathy', ""Coats' Disease"", 'Exudative Retinopathy', 'Lattice Degeneration', 'Retinal Hole', ""Sickler's Syndrome"", 'Retinal Detachment Rhegmatogenous', 'Retinal Detachment Exudative', 'Retinal Detachment Traction']",[],COMPLETED,,2023-02-01,2025-02-24,"[{'measure': 'Pain as measured by the FLACC pain scale', 'description': 'The Face, Legs, Activity, Cry and Consolability (FLACC) scale is an observational scale. comprised five behavioural indicators that are scored from zero to two. The pain score is the sum of the item scores and ranges from zero to 10. A lower score indicates minimal to no pain while high scores indicate moderate to severe discomfort.', 'timeFrame': 'up to Day 45 post-op'}]","[{'measure': 'Incidence of adverse events', 'description': 'Adverse events are addressed/ assessed at each visit', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Severity of Adverse Events', 'description': 'Adverse events are addressed/ assessed at each visit', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Degree of inflammation (AC cell count)', 'description': 'Inflammation is evaluated at each visit during the slit lamp and fundus exam as measured by the ocular inflammation grading scale', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Resolution of inflammation or less cell on follow up post op exams', 'description': 'Inflammation is evaluated during slit lamp and fundus exams during each post-op visit', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Resolution of pain', 'description': 'This will be measured by using the FLACC Pain Rating Scale. The Face, Legs, Activity, Cry and Consolability (FLACC) scale is an observational scale comprised five behavioural indicators that are scored from zero to two. The pain score is the sum of the item scores and ranges from zero to 10', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Ratio of Intraocular pressure increase with insert', 'description': 'Intraocular pressure is assessed at each visit', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Percentage of patients with rebound inflammation from baseline through post-op care', 'description': 'Level of inflammation is evaluated at each post-op visit during slip lamp and fundus exams', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Percentage of patients that were given supplementary prednisolone drops', 'description': 'Supplemental treatment and additional drops needed will be documented at each subsequent visit', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'The number of drops needed in these patients', 'description': 'Supplemental treatment and additional drops needed will be documented at each subsequent visit', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Mean change in Best Corrected Visual Assessment (BCVA)', 'description': 'Determined by using either ETDRS or HOTV chart testing depending on age.', 'timeFrame': 'up to Day 45 post-op'}, {'measure': 'Caregivers Treatment Adherence', 'description': ""Documented at each subsequent visits and with the primary caregiver satisfaction survey at Day 45. This is a subjective survey for each participants' family."", 'timeFrame': 'up to Day 45 post-op'}]",12,3 Years,17 Years,ALL,True,"Lejla Vajzovic, MD, FASRS",OTHER,0,16.0,ACTUAL,2025-09-01T16:18:22.197420,v2_robust,True,True,True,False,True,
NCT04618601,Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart Failure,Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart Failure,Spironolactone,"['Aldactone', 'Spironolactone']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Heart Failure Acute,"['Heart Failure Acute', 'Heart Failure; With Decompensation']","['diuretic resistance', 'spironolactone', 'cardio-renal syndrome', 'diuretics', 'natriuresis', 'heart failure']",UNKNOWN,,2020-10-20,2022-03-01,"[{'measure': 'Daily urine output', 'description': 'Urine output in liters per 24 hours will be tracked from enrollment to day 5.', 'timeFrame': '5 days'}]","[{'measure': 'Total urine output', 'description': 'Urine output in total liters from enrollment to day 5 will be measured.', 'timeFrame': '5 days'}, {'measure': 'Total weight change', 'description': 'Patient weight in kilos will be tracked from enrollment to day 5.', 'timeFrame': '5 days'}, {'measure': 'Daily weight change', 'description': 'Patient weight in kilos will be tracked from enrollment to day 5.', 'timeFrame': '5 days'}, {'measure': 'Natriuresis on days 1, 3 and 5', 'description': 'Urine sodium will be measured on days 1, 3 and 5', 'timeFrame': '5 days'}, {'measure': 'Changes in natriuresis between days 1, 3 and 5', 'description': 'Urine sodium will be measured on days 1, 3 and 5', 'timeFrame': '5 days'}, {'measure': 'Changes in NT-proBNP between days 1 and 5', 'description': 'NT-proBNP will be measured on days 1, 3 and 5', 'timeFrame': '5 days'}]",7,18 Years,,ALL,False,"Laikο General Hospital, Athens",OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:22.197440,v2_robust,True,True,False,False,False,
NCT06329401,A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Participants With PPF",AP01,"['AP01', 'Pirfenidone Solution']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Progressive Pulmonary Fibrosis,['Progressive Pulmonary Fibrosis'],"['Chronic-Fibrosing-ILD with progressive phenotype, PF-ILD']",RECRUITING,,2024-04-03,2026-04,"[{'measure': 'To evaluate the effect of AP01 high dose twice a day (BID) or AP01 low dose twice a day (BID) compared to placebo twice a day (BID)', 'description': 'Change from baseline in forced vital capacity (FVC) (mL)', 'timeFrame': 'Week 52'}]","[{'measure': 'To evaluate the effect of AP01 high dose, AP01 low dose compared to placebo on quality of life (QoL)', 'description': 'Absolute change from Baseline in QoL measurements as assessed by Living with Pulmonary Fibrosis Symptoms and Impact Questionnaire (L-PF) total score. The L-PF is a 44-item questionnaire to assess how impacted a participant is by disease symptoms on a scale from 0 (Not at all) to 4 (Extremely). The higher the summary score, the greater the impairment.', 'timeFrame': '52 weeks'}, {'measure': 'To evaluate the effect of AP01 high dose and AP01 low dose compared to placebo on disease progression (defined as absolute FVC percent predicted decline of ≥10% prior to Week 52)', 'description': 'Time to disease progression', 'timeFrame': '52 weeks'}, {'measure': 'To evaluate the change from baseline in quantitative lung fibrosis score.', 'description': 'Change in lung fibrosis score.', 'timeFrame': '52 weeks'}]",4,18 Years,,ALL,False,Avalyn Pharma Inc.,INDUSTRY,1,300.0,ESTIMATED,2025-09-01T16:18:22.197457,v2_robust,True,True,False,False,False,
NCT00339001,Erythropoietin and Early Iron Supplement and Retinopathy of Prematurity,The Possible Influence of Erythropoietin and Early Iron Supplements on the Prevalence and Severity of Retinopathy of Prematurity and Other Short Term Outcome of Prematurity,erythropoietin and early iron supplements,['erythropoietin and early iron supplements'],1,OBSERVATIONAL,[],,,Retinopathy of Prematurity,['Retinopathy of Prematurity'],"['Erythropoietin', 'Iron', 'Retinopathy of prematurity']",UNKNOWN,,2006-04,2006-12,[],[],0,2 Weeks,3 Months,ALL,False,Sheba Medical Center,OTHER_GOV,0,400.0,,2025-09-01T16:18:22.197528,v2_robust,False,True,False,False,False,
NCT01072201,To Access the Effects of Mucositis in Adults With Dental Implants,To Access the Effects of Mucositis in Adults With Dental Implants,Triclosan and Fluoride,"['Total Toothpaste', 'Triclosan and Fluoride', 'Fluoride', 'Ultrabrite toothpaste']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Mucositis,['Mucositis'],[],COMPLETED,,2007-06,2007-12,"[{'measure': 'Bleeding on Probing', 'description': 'Percentage of Bleeding Scale: The bleeding sites are identified by either a 0 or 1. (0=no bleeding \\& 1= bleeding) The number of spots between teeth that bleed are divided by number of spots between teeth that are scored.', 'timeFrame': '6 months'}, {'measure': 'Mean Pocket Depth', 'description': 'Measurement scale: 0 millimeter measurement= no pocket depth. 3, 4, 5, \\& 6 millimeter are indications of deeper Pocket depth.', 'timeFrame': '6 Months'}, {'measure': 'Mean Percentage of Plaque Scores', 'description': 'Mean Percentage (%) of dental plaque on all tooth surfaces, including implants and natural teeth. Plaque Scale is 0=no plaque and 1= dental plaque present. Percentage is derived from sum of all plaque scores divided by the number of tooth surfaces scored.', 'timeFrame': '6 Months'}]",[],3,30 Years,70 Years,ALL,True,Colgate Palmolive,INDUSTRY,0,60.0,ACTUAL,2025-09-01T16:18:22.197535,v2_robust,True,True,True,False,False,
NCT03323801,RA-4: 13-cis Retinoic Acid for Treatment of Men With Azoospermia,A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Azoospermia,13-cis retinoic acid,"['13-cis retinoic acid', 'Accutane, Isotretinoin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Male Infertility, Azoospermia","['Male Infertility, Azoospermia']",['Infertility'],COMPLETED,,2017-07-25,2019-05-31,"[{'measure': 'Total Motile Sperm', 'description': 'Number of participants with undetectable or detectable sperm in their ejaculates.', 'timeFrame': 'up to 32 weeks'}, {'measure': 'Total Sperm and Percentage of These Sperm That Were Motile', 'description': 'Number of total sperm in ejaculate and percentage of these sperm that were motile', 'timeFrame': '32 weeks'}]","[{'measure': 'Serious and Non-Serious Adverse Effects', 'description': 'Number of participants with Serious and Non-Serious Adverse effects associated with treatment with 13-cis retinoic acid', 'timeFrame': '32 weeks'}]",3,21 Years,60 Years,MALE,False,University of Washington,OTHER,1,10.0,ACTUAL,2025-09-01T16:18:22.197560,v2_robust,True,True,True,False,True,
NCT02619812,Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT,"A Randomized, Placebo-Controlled, Pilot Study of Colesevelam and Serum-Derived Bovine Immunoglobulin/Protein Isolate to Manage Diarrhea in Patients With Multiple Myeloma Receiving Conditioning Chemotherapy for Autologous Stem Cell Transplantation (SCT)",Colesevelam,"['Welchol', 'Colesevelam']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma,['Multiple Myeloma'],[],TERMINATED,Difficulty recruiting; pill burden and nausea were barriers,2016-04,2016-12,"[{'measure': 'Stool Frequency', 'description': 'Stool frequency was self reported in a daily bowel pattern diary for 30 days.', 'timeFrame': '30 days'}, {'measure': 'Stool Consistency', 'description': 'The subjects rated their stool consistency using the Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the ""ideal stools"" especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea.', 'timeFrame': '30 days'}]",[],2,18 Years,,ALL,False,Mayo Clinic,OTHER,1,4.0,ACTUAL,2025-09-01T16:18:22.197580,v2_robust,True,True,False,True,False,Difficulty recruiting; pill burden and nausea were barriers
NCT05219812,A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain,"A Randomized, Double-blind, Cross-over, Placebo-controlled, Multi-center, Phase 2a Study to Assess the Safety and Signal in Efficacy of BAY 2395840 in Patients With Diabetic Neuropathic Pain",BAY2395840,"['BAY2395840', 'Placebo for BAY2395840']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Neuropathic Pain Associated With Diabetic Peripheral Neuropathy,"['Neuropathic Pain Associated With Diabetic Peripheral Neuropathy', 'Peripheral Neuropathic Pain', 'Diabetes Mellitus']",['Neuropathic Pain'],COMPLETED,,2022-02-16,2022-11-21,"[{'measure': 'Change in weekly mean 24-hour average pain intensity score using the 11-point Numeric Rating Scale (NRS) from baseline to the end of intervention', 'description': 'NRS is an one-item assessment of average neuropathic pain intensity which is presented as an 11-point Likert scale with 0 as ""no pain"" and 10 as ""worst imaginable pain"".', 'timeFrame': 'Baseline to end of intervention (in total up to 16 weeks)'}]","[{'measure': 'Change in Neuropathic Pain Symptom Inventory (NPSI) score from baseline to the end of intervention.', 'description': 'The Neuropathic Pain Symptom Inventory (NPSI) is a PRO developed to evaluate different symptoms of neuropathic pain.', 'timeFrame': 'At visit 2, visit 4, visit 6, visit 8, visit 10 and at visit 12 end of intervention (EOI).'}, {'measure': 'Change in Patient Global Impression of Severity (PGI-S) score from baseline to the end of intervention.', 'description': 'The PGI-S is a one-item self-reported instrument used to assess to assess patients\' impression of disease severity with a 6-point scale response options, scores ranging from 1 (""none"") to 6 (""very severe).', 'timeFrame': 'At visit 2, visit 4, visit 6, visit 8, visit 10 and at visit 12 end of intervention (EOI).'}, {'measure': 'The proportion of participants achieving a ≥30% and a ≥50% reduction in weekly mean 24-hour average pain intensity score (i.e. responder rates using NRS)', 'timeFrame': 'From baseline to end of intervention (in total up to 12 weeks)'}, {'measure': 'Number of participants with treatment emergent adverse events (TEAE)', 'timeFrame': 'From start of study intervention to 14 days after last dose.'}]",5,18 Years,,ALL,False,Bayer,INDUSTRY,0,80.0,ACTUAL,2025-09-01T16:18:22.197593,v2_robust,True,True,True,False,True,
NCT02480712,Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection,"A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection",SOF/VEL,"['GS-7977/GS-5816', 'Epclusa®', 'SOF/VEL']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Hepatitis C Virus Infection,['Hepatitis C Virus Infection'],[],COMPLETED,,2015-07-01,2016-06-22,"[{'measure': 'Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)', 'description': 'SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.', 'timeFrame': 'Posttreatment Week 12'}, {'measure': 'Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event', 'timeFrame': 'Up to 12 weeks'}]","[{'measure': 'Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)', 'description': 'SVR4 and SVR24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.', 'timeFrame': 'Posttreatment Weeks 4 and 24'}, {'measure': 'Percentage of Participants With HCV RNA < LLOQ on Treatment', 'timeFrame': 'Up to 12 Weeks'}, {'measure': 'HCV RNA Change From Baseline/Day 1', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Percentage of Participants With Virologic Failure', 'description': 'Virologic failure was defined as:\n\n* On-treatment virologic failure:\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n  * Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n* Virologic relapse:\n\n  * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit', 'timeFrame': 'Up to Posttreatment Week 24'}, {'measure': 'Percentage of Participants That Maintained HIV-1 RNA < 50 Copies/mL While On HCV Treatment', 'timeFrame': 'Up to 12 Weeks'}, {'measure': 'Serum Creatinine Change From Baseline At the End of Treatment and At Posttreatment Week 12', 'timeFrame': 'Week 12; Posttreatment Week 12'}]",8,18 Years,,ALL,False,Gilead Sciences,INDUSTRY,0,107.0,ACTUAL,2025-09-01T16:18:22.197640,v2_robust,True,True,True,False,True,
NCT05901012,Safety and Tolerability of DMT in Healthy Adults,"Inhaled N,N-Dimethyltryptamine: a Safety and Tolerability Study in Healthy Adults","N,N-Dimethyltryptamine","['DMT', 'N,N-Dimethyltryptamine', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Safety Issues,"['Safety Issues', 'Healthy Volunteers']","['N,N-DMT', 'N,N-Dimethyltryptamine', 'DMT', 'placebo', 'psychedelic']",COMPLETED,,2023-04-26,2023-07-17,"[{'measure': 'Systolic Blood Pressure', 'description': 'Assessed 7 times on each session', 'timeFrame': 'up to 2 hours'}, {'measure': 'Diastolic Blood Pressure', 'description': 'Assessed 7 times on each session', 'timeFrame': 'up to 2 hours'}, {'measure': 'Heart rate', 'description': 'Assessed 7 times on each session', 'timeFrame': 'up to 2 hours'}, {'measure': 'Respiratory rate', 'description': 'Assessed 7 times on each session', 'timeFrame': 'up to 2 hours'}, {'measure': 'Oxygen saturation', 'description': 'Assessed 7 times on each session', 'timeFrame': 'up to 2 hours'}]","[{'measure': 'Plasma level of glucose', 'description': 'Assessed 2 times on each session', 'timeFrame': 'up to 2 hours'}, {'measure': 'Plasma level of total cholesterol', 'description': 'Assessed 2 times on each session', 'timeFrame': 'up to 2 hours'}, {'measure': 'Plasma level of C-reactive protein (CRP)', 'description': 'Assessed 2 times on each session', 'timeFrame': 'up to 2 hours'}, {'measure': 'Plasma level of urea', 'description': 'Assessed 2 times on each session', 'timeFrame': 'up to 2 hours'}, {'measure': 'Plasma level of creatinine', 'description': 'Assessed 2 times on each session', 'timeFrame': 'up to 2 hours'}, {'measure': 'Plasma level of aspartate transaminase (AST)', 'description': 'Assessed 2 times on each session', 'timeFrame': 'up to 2 hours'}, {'measure': 'Plasma level of alanine transaminase (ALT)', 'description': 'Assessed 2 times on each session', 'timeFrame': 'up to 2 hours'}, {'measure': 'Plasma level of cortisol', 'description': 'Assessed 2 times on each session', 'timeFrame': 'up to 2 hours'}, {'measure': 'Plasma level of subjective effects of DMT', 'description': 'Assessed 2 times on each session', 'timeFrame': 'up to 2 hours'}, {'measure': 'Evaluate the subjective effects of DMT', 'description': 'Assessment of the acute subjective effects of DMT, compared to placebo, by 5D-ASC (5 Dimensions- Altered States of consciousness). Scores range from 0 to 94, where higher scores indicate more intense psychedelic subjective effects.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Evaluate the subjective effects of DMT', 'description': 'Assessment of the acute subjective effects of DMT, compared to placebo, by HRS (Hallucinogen Rating Scale). Scores range from 0 to 400, where higher scores indicate more intense psychedelic subjective effects.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Evaluate the subjective effects of DMT', 'description': 'Assessment of the acute subjective effects of DMT, compared to placebo, by MEQ (Questionnaire of Mystical Experiences). Scores range from 0 to 150, where higher scores indicate more intense psychedelic subjective effects.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Evaluate acute effects on alpha waves using electroencephalography before, during and after the dosing', 'description': 'Assessment of the electrical cerebral activity in different bandwidth as alpha waves by EEG before, during and after each session.', 'timeFrame': 'up to 1 hours'}, {'measure': 'Evaluate acute effects on beta waves using electroencephalography before, during and after the dosing', 'description': 'Assessment of the electrical cerebral activity in different bandwidth as beta waves by EEG before, during and after each session.', 'timeFrame': 'up to 1 hours'}, {'measure': 'Evaluate acute effects on theta waves using electroencephalography before, during and after the dosing', 'description': 'Assessment of the electrical cerebral activity in different bandwidth as theta waves by EEG before, during and after each session.', 'timeFrame': 'up to 1 hours'}, {'measure': 'Evaluate the subacute effects of DMT, compared to placebo, on electroencephalography markers', 'description': 'Assessment of the subacute effects of DMT on EEG, including ERP (event-related potential ) generated from visual and auditory stimulation by applying a visual and auditory perception and imagination task.', 'timeFrame': 'up to 0.5 hours'}, {'measure': 'Evaluate the acute effects of DMT, compared to placebo, on electroencephalography markers', 'description': 'Assessment of the acute effects of DMT in ERP (event-related potential) generated from auditory stimulation in an oddball protocol.', 'timeFrame': 'up to 0.5 hours'}, {'measure': 'Evaluate the subacute effects of DMT on suggestibility', 'description': 'Assessment of the subacute effects of DMT on suggestibility by applying a suggestibility task named Creative Imagination Scale (CIS). Scores range from 0 to 40. Higher scores indicate more intense suggestibility.', 'timeFrame': 'up to 1 hours'}, {'measure': 'Evaluate the influence of expectations', 'description': 'Assessment of the influence of expectations variables on subjective experience', 'timeFrame': 'up to 0.5 hours'}, {'measure': 'Evaluate the influence of personality trait', 'description': 'Assessment of the influence of personality trait on suggestibility', 'timeFrame': 'up to 0.5 hours'}, {'measure': 'Assess DMT Plasma Concentration-Time Profile using High-performance liquid chromatography', 'description': 'Evaluate changes in serum DMT concentration over time measured in baseline, 2 and 50 minutes after each session.', 'timeFrame': 'up to 50 minutes'}]",26,18 Years,60 Years,ALL,True,Universidade Federal do Rio Grande do Norte,OTHER,0,25.0,ACTUAL,2025-09-01T16:18:22.197708,v2_robust,True,True,True,False,False,
NCT06066112,Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body,"Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets (200 mg) in Chinese Healthy Subjects Under Single Dose, Randomized, Open, Two Formulation, Two Sequence, Two Cycle, Double Crossover, Fasting, and Postprandial Conditions","Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.","['Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.', 'Reference (R) Amisulpride tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Bioequivalence,"['Bioequivalence', 'Schizophrenia']",['amisulpride orally disintegrating tablets'],RECRUITING,,2023-09-20,2024-03-31,"[{'measure': 'Cmax', 'description': 'Evaluation of Peak Plasma Concentration (Cmax)', 'timeFrame': '48 hours'}, {'measure': 'Area under the plasma concentration versus time curve (AUC0-t)', 'description': 'Area under the drug concentration-time curve from time 0 to the last accurately measurable concentration at sample collection time t', 'timeFrame': '48 hours'}, {'measure': 'Area under the plasma concentration versus time curve (AUC0-∞)', 'description': 'Area Under the Plasma Drug Concentration-Time Curve from Time 0 to Infinite Time', 'timeFrame': '48 hours'}]",[],3,18 Years,,ALL,True,The Affiliated Hospital of Qingdao University,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:22.197932,v2_robust,True,True,False,False,False,
NCT01631812,A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients,An Open-label Long-term Extension Trial From Late Phase II of SPM962 (243-05-001) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa,SPM 962,['SPM 962'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Parkinson's Disease,"[""Parkinson's Disease""]","['SPM 962', 'rotigotine', ""Parkinson's disease"", 'concomitant use of L-dopa']",COMPLETED,,2006-12,2010-02,"[{'measure': 'Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters.', 'description': 'Incidence and severity of adverse events, vital signs, and laboratory parameters after dosing.\n\n\\*decrease in difference between supine and standing systolic blood pressure', 'timeFrame': 'Up to 55 weeks after dosing'}, {'measure': 'Skin Irritation Score of the Application Site', 'description': 'Skin irritation score of the application site were evaluated according to the criteria below. The worst score throughout the treatment period was used in the analysis.\n\n-: no reaction, ±: mild erythema, +: erythema, ++: erythema and Oedema, +++: erythema and oedema and rash papular, or serous papule, or vesicles, ++++: bullosum', 'timeFrame': 'Up to 55 weeks after dosing'}]","[{'measure': ""Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score"", 'description': ""Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) up to 54 weeks after dosing UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement."", 'timeFrame': 'Baseline, Up to 54 weeks after dosing'}, {'measure': 'UPDRS Part 2 Sum Score', 'description': 'Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average scores of on state and off state) up to 54 weeks after dosing UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.', 'timeFrame': 'Baseline, Up to 54 weeks after dosing'}, {'measure': 'Absolute Time Spent ""Off""', 'description': 'Mean number of hours in ""off state"" during a 24-hour period.', 'timeFrame': 'Up to 54 weeks after dosing'}]",5,,,ALL,False,"Otsuka Pharmaceutical Co., Ltd.",INDUSTRY,0,130.0,ACTUAL,2025-09-01T16:18:22.197949,v2_robust,True,True,True,False,True,
NCT01579812,"Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients","A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",Metformin,"['Fortamet, Glucophage, Glumetza, Riomet', 'Metformin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Ovarian, Fallopian Tube, and Primary Peritoneal Cancer","['Ovarian, Fallopian Tube, and Primary Peritoneal Cancer']","['Ovarian, Fallopian Tube, and Primary Peritoneal Cancer']",COMPLETED,,2011-10,2017-07,"[{'measure': 'Recurrence-Free Survival', 'description': 'Determine the percentage of patients alive without recurrence at 18 months. Investigators will also determine recurrence free survival when patients with persistent disease are excluded.\n\nDefinition of progression or recurrence and survival will be defined as increasing clinical, radiological or histological evidence of disease since study entry or two serum values of CA-125 greater than or equal to two times the upper limits of normal (ULN) performed at least one week apart, regardless of CT scan results.\n\nRecurrence-Free Interval will be defined as date from start of chemotherapy to the date of first clinical, biochemical, or radiological evidence of progression or death due to any cause.', 'timeFrame': '18 months'}]","[{'measure': 'Overall Survival', 'description': 'Determine the median overall survival time for all patients who complete treatment as well as for patients presenting with stage IIc/ III and stage IV ovarian cancer.', 'timeFrame': 'Up to 3 Years'}]",2,19 Years,79 Years,FEMALE,False,University of Michigan Rogel Cancer Center,OTHER,0,90.0,ACTUAL,2025-09-01T16:18:22.198156,v2_robust,True,True,True,False,False,
NCT05609812,Atacicept in Subjects With Active Lupus Nephritis (COMPASS),"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Active Lupus Nephritis",Atacicept,"['VT-001', 'Atacicept', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Lupus Nephritis (LN),['Lupus Nephritis (LN)'],"['Systemic Lupus erythematosus (SLE)', 'estimated glomerular filtration rate (eGFR)', 'protenuria']",WITHDRAWN,"Study recruitment is paused due to business reasons, but not due to regulatory or safety concerns.",2022-11-02,2028-12-15,"[{'measure': 'Renal Response as definedas UPCR ≤0.5 mg/mg, and eGFR ≥60 mL/min/1.73 m^2 or eGFR <60 mL/min/1.73 m^2 with no confirmed decrease from baseline of >20%', 'timeFrame': 'Week 52'}]","[{'measure': 'Renal Response with alternative success criteria', 'timeFrame': 'Weeks 52 and 104'}, {'measure': 'Time to UPCR of≤0.5 mg/mg', 'timeFrame': 'Week 52'}, {'measure': 'Renal Response at Week 104', 'timeFrame': 'Week 104'}, {'measure': 'Time to Death or Renal-Related Event', 'timeFrame': 'Week 104'}]",5,18 Years,75 Years,ALL,False,"Vera Therapeutics, Inc.",INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:22.198174,v2_robust,True,True,False,True,False,"Study recruitment is paused due to business reasons, but not due to regulatory or safety concerns."
NCT03311412,"Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas","A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) as Monotherapy, in Combination With Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3), and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas",Sym021,"['Anti-LAG-3', 'Sym022', 'Sym023', 'Anti-TIM-3', 'Sym021', 'Anti-PD-1']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Metastatic Cancer,"['Metastatic Cancer', 'Solid Tumor', 'Lymphoma']","['Locally advanced/unresectable', 'Metastatic solid tumor', 'Lymphoma', 'Anti-PD-1', 'PD-1', 'PD1', 'Anti-LAG-3', 'LAG-3', 'LAG3', 'Anti-TIM-3', 'TIM-3', 'TIM3']",COMPLETED,,2017-11-20,2022-03-23,"[{'measure': 'Part 1: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.', 'description': 'Assess the safety and tolerability of Sym021 monotherapy on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1.', 'timeFrame': '12 months'}, {'measure': 'Part 2: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.', 'description': 'Assess the safety and tolerability of the Sym021 RP2D in combination with sequential escalating doses of Sym022 or Sym023 on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1.', 'timeFrame': '12 months'}, {'measure': 'Part 3: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.', 'description': 'Assess the safety and tolerability of the Sym021 RP2D in combination with sequential escalating doses of Sym022 and Sym023 on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1.', 'timeFrame': '12 months'}]","[{'measure': 'Evaluation of the immunogenicity of Sym021 as a single agent and in combination with Sym022 and Sym023.', 'description': 'Serum sampling to assess the potential for anti-drug antibody (ADA) formation.', 'timeFrame': '24 months'}, {'measure': 'Evaluation of objective response (OR) or stable disease (SD).', 'description': 'Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), Response Evaluation Criteria in Lymphomas 2017 (RECIL 2017), or Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST), depending on tumor type.', 'timeFrame': '24 months'}, {'measure': 'Time to progression (TTP) of disease.', 'description': 'Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1, RECIL 2017, or iRECIST, depending on tumor type.', 'timeFrame': '24 months'}, {'measure': 'Area under the concentration-time curve in a dosing interval (AUC)', 'description': 'Will be estimated using non-compartmental methods and actual timepoints.', 'timeFrame': '24 months'}, {'measure': 'Maximum concentration (Cmax)', 'description': 'Will be derived from observed data.', 'timeFrame': '24 months'}, {'measure': 'Time to reach maximum concentration (Tmax)', 'description': 'Will be derived from observed data.', 'timeFrame': '24 months'}, {'measure': 'Trough concentration (Ctrough)', 'description': 'Will be derived from observed data.', 'timeFrame': '24 months'}, {'measure': 'Terminal elimination half-life (T½)', 'description': 'Will be estimated using non-compartmental methods and actual timepoints.', 'timeFrame': '24 months'}, {'measure': 'Clearance (CL)', 'description': 'Will be estimated using non-compartmental methods and actual timepoints.', 'timeFrame': '24 months'}]",12,18 Years,,ALL,False,Symphogen A/S,INDUSTRY,0,89.0,ACTUAL,2025-09-01T16:18:22.198239,v2_robust,True,True,True,False,True,
NCT02278081,The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate,The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate. A Randomized Controlled Trial,lansoprazole,"['lansoprazole', 'placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Rhinitis,"['Rhinitis', 'Nasal Obstruction', 'GERD']",['Rhinitis (nasal obstruction) and GERD'],UNKNOWN,,2015-01,2017-01,"[{'measure': 'improvement of the nasal signs and symptoms.', 'description': 'after three months of treatment the patient symptoms will be evaluated using subjective questionnaires and nasal endoscopic exam .', 'timeFrame': 'three months'}]",[],1,7 Years,18 Years,ALL,False,McGill University Health Centre/Research Institute of the McGill University Health Centre,OTHER,0,98.0,ESTIMATED,2025-09-01T16:18:22.198247,v2_robust,True,True,False,False,False,
NCT05856981,Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors,"An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors",ADU-1805,"['Pembrolizumab', 'ADU-1805', 'Keytruda']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,"Solid Tumor, Adult","['Solid Tumor, Adult', 'Metastatic Solid Tumor', 'Refractory Cancer']",['Immunotherapy'],RECRUITING,,2023-04-03,2025-12,"[{'measure': 'Incidence and severity of dose limiting toxicity (DLT), treatment-emergent adverse events (TEAEs), and changes from baseline in safety parameters', 'description': 'Incidence of DLTs and incidence and severity of TEAEs, classified according to NCI-CTCAE v. 5.0', 'timeFrame': 'First 21 days of treatment'}]","[{'measure': 'Pharmacokinetics of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab, serum concentration-time profile and PK parameters', 'description': 'Maximum concentration (Cmax)', 'timeFrame': 'Through study completion, up to 2,5 years'}, {'measure': 'Pharmacokinetics of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab, serum concentration-time profile and PK parameters', 'description': 'Time of maximum concentration (Tmax)', 'timeFrame': 'Through study completion, up to 2,5 years'}, {'measure': 'Pharmacokinetics of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab, serum concentration-time profile and PK parameters', 'description': 'Area under the curve (AUC)', 'timeFrame': 'Through study completion, up to 2,5 years'}, {'measure': 'Immunogenicity of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab', 'description': 'Incidence of anti-ADU-antibodies', 'timeFrame': 'Through study completion, up to 2,5 years'}, {'measure': 'Pharmacodynamics of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab', 'description': 'DNA sequencing of SIRPα alleles', 'timeFrame': 'Through end of treatment, up to 2 years'}, {'measure': 'Pharmacodynamics of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab', 'description': 'Target engagement by ADU-1805', 'timeFrame': 'Through end of treatment, up to 2 years'}, {'measure': 'Preliminary Clinical activity of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab', 'description': 'Overall response per (i)RECIST.', 'timeFrame': 'Through study completion, up to 2,5 years'}, {'measure': 'Preliminary Clinical activity of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab', 'description': 'Duration of response per (i)RECIST.', 'timeFrame': 'Through study completion, up to 2,5 years'}, {'measure': 'Preliminary Clinical activity of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab', 'description': 'Disease control per (i)RECIST', 'timeFrame': 'Through study completion, up to 2,5 years'}, {'measure': 'Preliminary Clinical activity of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab', 'description': 'Duration of disease control per (i)RECIST', 'timeFrame': 'Through study completion, up to 2,5 years'}, {'measure': 'Preliminary Clinical activity of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab', 'description': 'Progression-free survival per (i)RECIST', 'timeFrame': 'Through study completion, up to 2,5 years'}]",12,18 Years,,ALL,False,Sairopa B.V.,INDUSTRY,0,90.0,ESTIMATED,2025-09-01T16:18:22.198274,v2_robust,True,True,False,False,True,
NCT00251381,Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.,"Open Label Randomized Phase II, Multicentre, Pilot Study to Evaluate Safety and Efficacy of the Combination of Cetuximab and Concomitant-Boost Accelerated Radiotherapy Followed or Not by a Complementary Treatment With Cetuximab in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.",Cetuximab,['Cetuximab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Oropharyngeal Neoplasms,['Oropharyngeal Neoplasms'],"['Oropharyngeal Neoplasms', 'Cetuximab', 'Concomitant-boost accelerated radiotherapy']",UNKNOWN,,2005-11,2009-11,"[{'measure': '1-year rate of Locoregional Disease Control in the experimental arm, deffined as complete and persistent disappearance of disease in the primary tumour and regional lymph nodes.'}]","[{'measure': 'Toxicity and safety of treatment will be evaluated using the Common Toxicity Criteria (CTC) of the NCI, version 3.0.; and late toxicity from radiotherapy, using RTOG/EORTC Late Radiation Morbidity Scoring Scheme.'}]",2,18 Years,80 Years,ALL,False,Trial Form Support S.L.,OTHER,1,90.0,,2025-09-01T16:18:22.198294,v2_robust,True,True,False,False,True,
NCT03424681,Modafinil for the Treatment of Alcohol Use Disorders,Modafinil for the Treatment of Alcohol Use Disorders: Targeting Impaired Response Inhibition,Modafinil,"['Provigil', 'Modafinil']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Alcohol Use Disorder,['Alcohol Use Disorder'],[],COMPLETED,,2017-12-11,2018-08-31,"[{'measure': 'Time to Relapse', 'description': 'Time to relapse, starting 7 days after treatment initiation (after medication has reached maximum tolerated dose), to heavy drinking days (\\>4 standard drinks for men, \\>3 standard drinks for women); abstinent is coded as 9\\*7=63; dropout not included', 'timeFrame': 'over 9 weeks'}]","[{'measure': 'Drinks Per Drinking Day', 'description': 'drinks per drinking day weeks 4-6', 'timeFrame': 'Weeks 4-6'}, {'measure': 'Drinks Per Week', 'description': 'drinks per week weeks 4-6', 'timeFrame': 'Weeks 4-6'}, {'measure': 'Percent Days Abstinent', 'description': 'percent days abstinent weeks 4-6', 'timeFrame': 'Weeks 4-6'}]",4,18 Years,65 Years,ALL,False,The Mind Research Network,OTHER,0,12.0,ACTUAL,2025-09-01T16:18:22.198304,v2_robust,True,True,True,False,False,
NCT00135681,Immune Dysregulation in Children and Adults With Asthma,,nedocromil budesonide,['nedocromil budesonide'],1,INTERVENTIONAL,['NA'],,,Asthma,"['Asthma', 'Lung Diseases']",[],COMPLETED,,1996-12,2001-11,[],[],0,,100 Years,ALL,False,University of New Mexico,OTHER,1,,,2025-09-01T16:18:22.198375,v2_robust,True,True,True,False,False,
NCT00016081,Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation,A Randomized Phase III Study To Evaluate The Safety And Efficacy Or Ribavirin Inhaled Solution In Preventing Progression Of Upper Respiratory Tract Respiratory Syncytial Virus (RSV) Infection To RSV Pneumonia In Blood And Bone Marrow Transplant (BMT) Recipients,ribavirin,['ribavirin'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Infection,['Infection'],['infection'],COMPLETED,,1998-03,2003-03,[],[],0,2 Years,,ALL,False,Fred Hutchinson Cancer Center,OTHER,1,,,2025-09-01T16:18:22.198399,v2_robust,True,True,True,False,False,
NCT02462681,Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery,Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery,paravertebral block,"['paravertebral block', 'ketamine hydrochloride']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Acute Pain,"['Acute Pain', 'Chronic Pain']","['ketamine', 'adjuvant', 'paravertebral block']",COMPLETED,,2015-05,2017-06,"[{'measure': 'changes in pain intensity score from baseline', 'description': 'Visual analogue scale (VAS) Scored from 0-10 (where 0= no pain and 10= the worst pain imaginable) as it measured as VAS at rest (VAS.R) and during movement or ipsilateral arm abduction (VAS.M)', 'timeFrame': 'at 2,4,6,12,24,36and 48 hour postoperatively'}]","[{'measure': 'side effect', 'description': 'nausea, vomiting, hypotension, bradycardia, sedation, dizziness and nystagmus will recorded and treated also postoperative complications of the block such as accidental pneumothorax and vascular puncture will be recorded and treated', 'timeFrame': '2,4,6,12,24,36and 48 hour postoperatively.'}, {'measure': 'chronic neuropathic pain', 'description': '(Douleur Neuropathique 4 questions) (DN4) questionnaire will be used for assessment of development of neuropathic pain', 'timeFrame': '1st,2nd and 3rd postoperative months'}]",3,25 Years,70 Years,FEMALE,False,Assiut University,OTHER,0,90.0,ACTUAL,2025-09-01T16:18:22.198405,v2_robust,True,True,True,False,False,
NCT00021281,Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer,"A Phase III, Randomized, Open-Label Multicenter, International Study Comparing The Combination Of SU5416/Irinotecan/5-Fluorouracil/Leucovorin Versus Irinotecan/Fluorouracil/Leucovorin Alone As First-Line Therapy Of Patient With Previously Untreated Metastatic Colorectal Cancer",FOLFIRI regimen,"['fluorouracil', 'irinotecan hydrochloride', 'leucovorin calcium', 'semaxanib', 'FOLFIRI regimen']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Colorectal Cancer,['Colorectal Cancer'],"['stage IV colon cancer', 'stage IV rectal cancer', 'recurrent colon cancer', 'recurrent rectal cancer', 'adenocarcinoma of the colon', 'adenocarcinoma of the rectum']",UNKNOWN,,2000-12,,[],[],0,18 Years,,ALL,False,Jonsson Comprehensive Cancer Center,OTHER,1,,,2025-09-01T16:18:22.198442,v2_robust,True,True,False,False,False,
NCT00738881,Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer,MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib,Erlotinib Hydrochloride,"['Erlotinib Hydrochloride', 'OSI-774', 'N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt', 'Cp-358,774', 'Pemetrexed Disodium', 'Alimta', 'Tarceva', 'LY231514']",8,INTERVENTIONAL,['PHASE3'],PHASE3,,Recurrent Non-Small Cell Lung Carcinoma,"['Recurrent Non-Small Cell Lung Carcinoma', 'Stage IIIA Non-Small Cell Lung Cancer', 'Stage IIIB Non-Small Cell Lung Cancer', 'Stage IV Non-Small Cell Lung Cancer']",[],TERMINATED,Slow accrual,2008-10,2014-12,"[{'measure': 'Progression-free Survival (PFS)', 'description': 'Estimated using the method of Kaplan-Meier survival curves to compare PFS between the erlotinib and pemetrexed arms using an intent-to-treat (ITT) analysis. Due to the small sample size (21 of the required 954 patients \\~2%), analyses within the FISH(+) and FISH(-) groups were not performed, and no formal analyses for the primary or the secondary efficacy outcomes were performed.', 'timeFrame': 'Time from randomization to the first date of documented disease progression or death, assessed up to 5 years'}]","[{'measure': 'Time to Treatment Failure', 'description': 'The distribution of all time to event data will be estimated using the method of Kaplan-Meier survival curves.', 'timeFrame': 'The time from date of randomization to the date at which the patient is removed from the treatment, assessed up to 5 years'}, {'measure': 'Overall Survival', 'description': 'Will be estimated using the method of Kaplan-Meier survival curves. A 1-sided stratified log rank test \\[accounting for all the stratification factors except FISH status and cooperative group\\] will be used to compare overall survival between the erlotinib and pemetrexed arms within the FISH(+) and FISH(-) subgroups, compare overall and progression free survival between the erlotinib and pemetrexed arms within the subgroups defined on the basis of the epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC), and EGFR gene mutation status (MUT). Cox proportional hazards model will be used to assess potential differences.', 'timeFrame': 'Time from randomization to time of death from any cause, assessed up to 5 years'}, {'measure': 'Confirmed Response Rate Defined as Complete Response (CR) or a Partial Response (PR) Per Response Evaluation Criteria In Solid Tumors (RECIST)', 'description': ""Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease. The proportion of patients with confirmed CR and PR will be computed within each treatment arm and exact binomial confidence intervals for the true proportion computed. Chi-square test and Fisher's exact test will be used to compare the response rates between the treatment arms within the subgroups defined by FISH status, IHC, and MUT."", 'timeFrame': 'Up to 5 years'}]",4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,4,23.0,ACTUAL,2025-09-01T16:18:22.198451,v2_robust,True,True,False,True,False,Slow accrual
NCT06783881,Single-ascending Dose Study of Kylo-12 in Healthy Subjects,"A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Kylo-12 in Healthy Subjects",Kylo-12,"['Kylo-12', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Hypertriglyceridemia,['Hypertriglyceridemia'],[],NOT_YET_RECRUITING,,2025-02-17,2026-08-30,"[{'measure': 'Incidence of adverse events', 'timeFrame': 'up to Week 24'}]","[{'measure': 'Incidence of adverse events', 'timeFrame': 'up to week 48'}, {'measure': 'Pharmacokinetics (PK) parameter of maximum observed concentration (Cmax)', 'timeFrame': 'up to Week 48'}, {'measure': 'PK parameter of time of maximum observed concentration (Tmax)', 'timeFrame': 'up to Week 48'}, {'measure': 'PK parameter of area under the concentration time curve (AUC)', 'timeFrame': 'up to Week 48'}, {'measure': 'Change in serum ApoC3 and TG over time', 'timeFrame': 'up to Week 48'}, {'measure': 'Percent change in serum ApoC3 and TG over time', 'timeFrame': 'up to Week 48'}]",7,18 Years,55 Years,ALL,True,"Kylonova (Xiamen) Biopharma co., LTD.",INDUSTRY,0,50.0,ESTIMATED,2025-09-01T16:18:22.198558,v2_robust,True,True,False,False,True,
NCT00179881,Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma,Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma,Carboplatin,"['Thalomid', 'Carboplatin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Brain Stem Neoplasms, Primary","['Brain Stem Neoplasms, Primary', 'Neoplasms, Brain Stem']",['Brain stem glioma'],COMPLETED,,1999-12,2007-04,"[{'measure': 'To determine overall and event free survival for newly diagnosed brain stem glioma with the protocol regimen.'}, {'measure': 'To determine the overall survival and progression free survival of patients with recurrent brain stem glioma.'}, {'measure': 'To determine the toxicity of this drug regimen.'}]","[{'measure': 'To determine whether the multi-agent chemotherapy regimen of thalidomide and carboplatin, in patients with recurrent brain stem gliomas will extend their survival as compared to historical controls.'}, {'measure': 'To formulate experimentally derived hypothesis in order to establish a basis for future investigational studies.'}]",5,3 Years,21 Years,ALL,False,Ann & Robert H Lurie Children's Hospital of Chicago,OTHER,0,47.0,ESTIMATED,2025-09-01T16:18:22.198578,v2_robust,True,True,True,False,False,
NCT03691519,Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells,Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells,Omega-3 treatment,"['Omega-3 treatment', 'Dietary intervention']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Alzheimer Disease,['Alzheimer Disease'],"['Low OMega 3', 'Preventive trial', 'low RBC DHA/EPA index']",COMPLETED,,2018-04-17,2020-03-31,"[{'measure': 'Change from Baseline of Composite Z-score which evaluate cognitive performance', 'description': 'This composite score will be built of Z-scores of these components. As this criterion will be assessed during each visit (the enrolment visit and the 4 follow-up visits), the analysis will be carried out by taking repeat measurements, taking the correlated of the data into consideration, evaluating Change from Baseline', 'timeFrame': '18 months'}]","[{'measure': 'FCSRT Test', 'description': 'Tests included in the composite score will be analyzed independently The Free and Cued Selective Reminding test (FCSRT) is a memory test that controls attention and acquisition : Verbal learning with 16-word free and indexed recall test. Each word is identified by a semantic category. Word encoding is controlled. The total learning score is equal to the sum of the free and indexed recall. The maximum score is 48.', 'timeFrame': '18 months'}, {'measure': 'MMSE total score', 'description': 'MMSE (MINI MENTAL STATE EXAMINATION) total score : 30-question general cognitive function assessment. The maximum score is 30.', 'timeFrame': '18 months'}, {'measure': 'Category Naming Test (CNT)', 'description': 'The CNT is a semantic verbal fluency test which assesses spontaneous production of words belonging to the same category within a certain time (i.e. the animal category).', 'timeFrame': '18 months'}]",4,70 Years,,ALL,False,"University Hospital, Toulouse",OTHER,0,774.0,ACTUAL,2025-09-01T16:18:22.198618,v2_robust,True,True,True,False,False,
NCT03388619,"Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy","A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy",ADT,"['ADT', 'androgen deprivation therapy']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Cancer Of Prostate,"['Cancer Of Prostate', 'Prostate Neoplasms', 'Prostate Cancer', 'Neoplasms of Prostate', 'Prostatic Cancer']","['Rising PSA', 'No evidence of metastatic disease', 'Entire Prostate Bed', 'Quality of Life', 'Irradiation']",ACTIVE_NOT_RECRUITING,,2018-01-17,2025-12-08,"[{'measure': 'Maximum Tolerated Dose (MTD) of Radiation Dose to Prostate Bed and Dose to Tumor Reported in Gray (Gy)', 'description': 'Maximum tolerated dose (MTD) of image guided hypofractionated, focally dose escalated post-prostatectomy radiation is defined as the dose level at which no more than 1 of up to 6 participants experience dose limiting toxicity (DLT) during the DLT period, and the dose below that at which at least 2 (of ≤6) participants have DLT as a result of treatment. A DLT is defined as any of the following: Grade 3 rectal, small bowel, or urinary toxicity that does not resolve to Grade 2 or less within 4 days with appropriate medical management. Other grade 3 in-field toxicities attributable to radiation that does not resolve to Grade 2 or less within 4 days with appropriate medical management. And delays of more than one week in completing radiation treatment due to toxicity.', 'timeFrame': '3 weeks after radiation'}, {'measure': 'Maximum Tolerated Dose (MTD) of Radiation Dose to Prostate Bed and Dose to Tumor Reported in Fractions', 'description': 'Maximum tolerated dose (MTD) of image guided hypofractionated, focally dose escalated post-prostatectomy radiation is defined as the dose level at which no more than 1 of up to 6 participants experience dose limiting toxicity (DLT) during the DLT period, and the dose below that at which at least 2 (of ≤6) participants have DLT as a result of treatment. A DLT is defined as any of the following: Grade 3 rectal, small bowel, or urinary toxicity that does not resolve to Grade 2 or less within 4 days with appropriate medical management. Other grade 3 in-field toxicities attributable to radiation that does not resolve to Grade 2 or less within 4 days with appropriate medical management. And delays of more than one week in completing radiation treatment due to toxicity.', 'timeFrame': '3 weeks after radiation'}]","[{'measure': 'Biochemical Progression Free Survival (bPFS)', 'description': 'bPFS is defined as the duration of time from start of treatment to time of prostate-specific antigen (PSA) progression or death, whichever occurs first. PSA progression (also known as biochemical failure) is defined based on elevation of PSA beyond 0.1 ng/dL. Kaplan-Meier survival analysis and effects of clinical variables on bPFS will be assessed by the Cox proportional hazards model.', 'timeFrame': '1 and 2 years after treatment'}, {'measure': 'Proportion of Participants That Have Improvement in Quality of Life After Treatment', 'description': 'The quality-of-life scores will be summarized at baseline and for each visit. Linear mixed effects model will be used to model quality of life scores at baseline and during and after treatment in which random intercept and random slope are used to account for participant-specific trajectory of quality-of-life scores.', 'timeFrame': '1 and 2 years after treatment'}, {'measure': 'Sexual Health Inventory for Men (SHIM)', 'description': 'Participants completed a 6-question questionnaire to assess erectile dysfunction.', 'timeFrame': '2 years after treatment'}, {'measure': 'American Urologic Association Symptom Index Score (AUA-SI)', 'description': 'The AUA-SI is used to measure radiation morbidity and to make treatment decisions.', 'timeFrame': '2 years after treatment'}, {'measure': 'Patient-Reported Outcomes Measurement Information System (PROMIS) - Depression Short Form (SF) 4a:', 'description': 'Participants complete a form to assess negative mood (i.e., sadness, guilt), views of self (i.e., self-criticism, worthlessness) social cognition (loneliness, interpersonal alienation), decreased positive effect, and decreased engagement (loss of interest, meaning, and purpose) and are scored using item-level calibrations.', 'timeFrame': '2 years after treatment'}, {'measure': 'Patient-Reported Outcomes Measurement Information System (PROMIS) - Anxiety Short Form (SF) 4a:', 'description': 'Participants complete a form and rate anxiety such as fear (fearfulness, panic), anxious misery (worry, dread), hyperarousal (tension, nervousness, restlessness), and somatic symptoms related to arousal (racing heart, dizziness).', 'timeFrame': '2 years after treatment'}, {'measure': 'Patient-Reported Outcomes Measurement Information System (PROMIS) - Psychosocial Impact Positive Short Form (SF) 4a', 'description': 'Participants complete a form to assess positive psychosocial (emotional and social) outcomes of illness.', 'timeFrame': '2 years after treatment'}, {'measure': 'Decision Regret Scale (DRS)', 'description': 'The DRS is a 5-item scale measuring distress or remorse after a health case decision. The score correlated with satisfaction with the decision (r=-0.40 to -0.60), decisional conflict (r=0.31 to 0.52), and overall rated quality of life (r=-0.25 to -0.27).', 'timeFrame': '2 years after treatment'}, {'measure': 'Grade 2-5 Serious and/or Non-serious Adverse Events Unlikely, Probably, Possibly and Definitely Attributable to Research', 'description': 'Grade 2-5 serious and/or non-serious adverse events attributable to protocol treatment. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 2 is moderate. Grade 3 is serious. Grade 4 is life-threatening. And Grade 5 is death related to adverse event.', 'timeFrame': '3 weeks after radiation'}]",11,18 Years,,MALE,False,National Cancer Institute (NCI),NIH,0,30.0,ACTUAL,2025-09-01T16:18:22.198650,v2_robust,True,True,False,False,True,
NCT06660719,Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care,"A Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase III Clinical Study to Evaluate Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Requiring Thrombolytic Therapy as Standard of Care",SP-8203,"['Placebo', 'SP-8203', 'Otaplimastat (SP-8203)']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Ischemic Stroke,['Ischemic Stroke'],"['SP-8203 (Otaplimastat)', 'rtPA (recombinant tissue Plasminogen Activator)', 'Thrombolytic therapy']",RECRUITING,,2025-02-14,2027-03-30,"[{'measure': 'Proportion of participants with modified Rankin Scale (mRS) 0-1', 'description': 'Proportion of participants with modified Rankin Scale (mRS) 0-1 at Day 90 in patients with acute ischemic stroke requiring thrombolytic standard of care', 'timeFrame': 'Day 90'}]","[{'measure': 'Incidence of parenchymal hematoma observed on brain Computed Tomography (CT) scan', 'description': 'Incidence of parenchymal hematoma observed on brain Computed Tomography (CT) scan performed at 24±3 hours in accordance with European Cooperative Acute Stroke Study (ECASS) I and II criteria, after the administration of SP-8203 in conjunction with thrombolytic standard of care', 'timeFrame': 'Day 1'}, {'measure': 'Proportion of participants with modified Rankin Scale (mRS) 0-1', 'description': 'Proportion of participants with modified Rankin Scale (mRS) 0-1 at Day 30 in patients with acute ischemic stroke requiring thrombolytic standard of care', 'timeFrame': 'Day 30'}, {'measure': 'Proportion of participants with modified Rankin Scale (mRS) 0-2', 'description': 'Proportion of participants with modified Rankin Scale (mRS) 0-2 at Day 30 and Day 90 in the patients with acute ischemic stroke requiring thrombolytic standard of care', 'timeFrame': 'Day 30 and Day 90'}, {'measure': 'Change from Baseline in National Institute of Health Stroke Scale (NIHSS) scores', 'description': 'The change in the National Institute of Health Stroke Scale (NIHSS) scores until 90 day in subjects with acute ischemic stroke requiring rtPA standard of care. The maximum total score is 42 points, which indicates the most critical condition and the minimum total score is 0, which indicates no neurologic deficit.', 'timeFrame': 'Day 0 (baseline), Day 3, Day 5, Day 30 and Day 90'}, {'measure': 'Fold change in infarct growth classified by modified treatment in cerebral ischemia (mTICI) grade within 5 days', 'description': 'MRI (DWI) imaging outcomes', 'timeFrame': 'Day 5'}, {'measure': 'The incidence of serious adverse events', 'description': 'The incidence of serious adverse events', 'timeFrame': 'follow-up to 90 days after the first study intervention administration'}, {'measure': 'The rate of death', 'description': 'The rate of death due to any cause', 'timeFrame': 'follow-up to 90 days after the first study intervention administration'}, {'measure': 'The incidence rate of adverse events, and adverse drug reaction', 'description': 'The incidence rate of adverse events, and adverse drug reaction', 'timeFrame': 'follow-up to 90 days after the first study intervention administration'}, {'measure': 'The incidence of symptomatic Intracranial Hemorrhage (sICH)', 'description': 'The incidence of symptomatic Intracranial Hemorrhage (sICH) occurring within 5 days of administration according to the definition described on the protocol', 'timeFrame': 'within 5 days from the first study intervention administration'}, {'measure': 'The Incidence of major systemic bleeding', 'description': 'The Incidence of major systemic bleeding according to the International Society of Thrombosis and Hemostasis (ISTH) definition', 'timeFrame': 'within 5 days after the first study intervention administration'}]",11,19 Years,85 Years,ALL,False,Shin Poong Pharmaceutical Co. Ltd.,INDUSTRY,0,852.0,ESTIMATED,2025-09-01T16:18:22.198726,v2_robust,True,True,False,False,True,
NCT03792919,Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK),Virological Response After Cessation of Long Term Anti-HBV Nucleos(t)Ide Analogues (NAs) vs. Keeping on NAs Among Chronic Hepatitis B (CHB) Patients,Stop current treatment (anti-HBV neucleos(t)ides),"['Keep current treatment (anti-HBV neucleos(t)ides)', 'Stop current treatment (anti-HBV neucleos(t)ides)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Hepatitis B,['Chronic Hepatitis B'],[],RECRUITING,,2018-12-01,2025-12-31,"[{'measure': 'Incidence of HBsAg clearance', 'description': 'The incidence of HBsAg clearance during the off-treatment period', 'timeFrame': 'From baseline to the end of the fifth year after cessation of anti-HBV treatment.'}]","[{'measure': 'Incidence of HBsAg seroconversion', 'description': 'The incidence of HBsAg seroconversion during the off-treatment period', 'timeFrame': 'From baseline to the end of the fifth year after cessation of anti-HBV treatment.'}, {'measure': 'Incidence of sustain HBV viral submission', 'description': 'The incidence of sustain HBV viral submission during the off-treatment period', 'timeFrame': 'rom baseline to the end of the fifth year after cessation of anti-HBV treatment.'}, {'measure': 'Incidence of sustain biological response', 'description': 'The incidence of sustain biological response during the off-treatment period', 'timeFrame': 'rom baseline to the end of the fifth year after cessation of anti-HBV treatment.'}, {'measure': 'Incidence of hepatocellular carcinoma', 'description': 'The incidence of hepatocellular carcinoma during the off-treatment period', 'timeFrame': 'rom baseline to the end of the fifth year after cessation of anti-HBV treatment.'}, {'measure': 'Incidence of Liver failure', 'description': 'The incidence of Liver failure during the off-treatment period', 'timeFrame': 'rom baseline to the end of the fifth year after cessation of anti-HBV treatment.'}]",6,,,ALL,False,Humanity & Health Medical Group Limited,OTHER,0,2000.0,ESTIMATED,2025-09-01T16:18:22.198761,v2_robust,True,True,False,False,False,
NCT00542919,A Study for Patients With Non-Hodgkin's Lymphomas,"A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas",enzastaurin,"['LY317615', 'enzastaurin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,T-Cell Lymphoma,"['T-Cell Lymphoma', 'B-Cell Lymphoma']",[],COMPLETED,,2007-11,2018-02-27,"[{'measure': 'Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR])', 'description': 'Tumor RR is defined as the number of responders divided by the number of treated participants for that tumor subtype. A responder was a participant who exhibited: a CR defined as a modified severity-weighted assessment tool (mSWAT) value of zero or a partial response (PR) defined as a mSWAT value \\> 50% decrease from baseline \\[for participants with cutaneous T-cell lymphoma (CTCL) using the mSWAT or CR, unconfirmed CR (Cru), or PR as defined by Abrey et al., (2005) (for participants with central nervous system (CNS) Lymphoma); or for all other participants a CR or complete response - unconfirmed (CRu) or PR as defined by Cheson et al., (1999).', 'timeFrame': 'Baseline to Measured Progressive Disease (Up to 114 Months)'}]","[{'measure': 'Progression Free Survival (PFS)', 'description': 'Progression-free survival is defined as the time from the date of study enrollment to the first date of objectively determined progressive disease or death from any cause. Progressive disease (PD) is an increase of Sézary cell percentage by greater than or equal to 40% in cluster of differentiation (CD4+/CD7- or 30% in CD4+/CD26- as compared to each respective nadir. mSWAT, primary central nervous system lymphoma (PCSNSL) and International Workshop Response Criteria (IWRC) response criteria were used for CTCL, primary central nervous system lymphoma (CNSL) and all other participants respectively. PFS was censored at the date of the last objective progression-free assessment.', 'timeFrame': 'Baseline to Measured Progressive Disease or Death From Any Cause (Up to 114 Months)'}, {'measure': 'Time to Progressive (TTP) Disease', 'description': 'TTP disease is defined as the time from the date of study enrollment to the date of objectively determined disease progression. Objectively determined progressive disease (PD) was interpreted as meeting the criteria for PD. For patients who died without documented objective PD (including death from study disease); TTP was censored at the date of the last objective progression-free disease assessment prior to death. For participants not known to have died as of the data cut-off date and who did not have objective PD, TTP was censored at the date of the last objective progression-free disease assessment. For participants who received subsequent anticancer therapy (after discontinuation from study treatment) prior to objectively determined disease progression, TTP was censored at the date of the last objective progression free disease assessment prior to post-discontinuation therapy.', 'timeFrame': 'Baseline to Measured Progressive Disease (Up to 114 Months)'}, {'measure': 'Duration of Response (DOR)', 'description': 'DoR is defined as the time from the date when the measurement criteria were met for CR, CRu, or PR (whichever status was recorded first) until the date of first observation of objectively determined disease progression (CR, CRu, or PR see above definition of responder). For responding participants who died without PD (including death from study disease), DoR was censored at the last assessment demonstrating lack of progression. For responding patients not known to have died as of the data cut-off date and who did not have PD, DoR was censored at the last assessment demonstrating objective response prior to the data cut-off date. For responding participants who received subsequent anticancer therapy (after discontinuation from the study treatment) prior to disease progression, DoR was censored at the last assessment demonstrating objective response prior to the initiation of post-discontinuation anticancer therapy.', 'timeFrame': 'Baseline to Measured Progressive Disease (Up to 97 Months)'}, {'measure': 'Percentage of Participants With Progression Free Survival (PFS) at 1-Year', 'description': 'PFS at 1 year was defined as the probability of being alive and having not progressed at 1 year and calculated from the PFS Kaplan-Meier analysis. PFS was censored at the date of the last objective progression-free assessment. Progressive disease (PD) is an increase of Sézary cell percentage by greater than or equal to 40% in cluster of differentiation (CD4+/CD7- or 30% in CD4+/CD26- as compared to each respective nadir. mSWAT, primary central nervous system lymphoma (PCSNSL) and International Workshop Response Criteria (IWRC) response criteria were used for CTCL, primary central nervous system lymphoma (CNSL) and all other participants respectively. PFS was censored at the date of the last objective progression-free assessment.', 'timeFrame': 'Baseline to Measured Progressive Disease or Death From Any Cause (1 Year)'}, {'measure': 'Number of Participants With One or More Drug-Related Adverse Events', 'description': 'Number of participants with one or more Drug-Related Adverse Events. Clinically significant events are defined as serious adverse events, regardless of causality. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module.', 'timeFrame': 'Baseline to End of Study (Up to 114 Months)'}]",6,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,57.0,ACTUAL,2025-09-01T16:18:22.198967,v2_robust,True,True,True,False,True,
NCT04951219,"A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)","A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)",Resmetirom,"['MGL-3196', 'Resmetirom']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-Alcoholic Fatty Liver Disease,['Non-Alcoholic Fatty Liver Disease'],"['NAFLD', 'NASH', 'Hyperlipidemia', 'Resmetirom', 'Thyroid hormone receptor beta', 'Hepatic', 'Fibrosis', 'NASH resolution', 'Thyroid hormone receptor agonist', 'Cardiovascular', 'Dyslipidemia', 'Fatty liver disease', 'Nonalcoholic steatohepatitis']",ACTIVE_NOT_RECRUITING,,2021-07-09,2026-04,"[{'measure': 'The effect of once daily, oral administration of resmetirom on the incidence of adverse events.', 'timeFrame': '52 weeks'}]","[{'measure': 'Percent change in the hepatic fat fraction as determined by MRI-PDFF from baseline', 'timeFrame': '16 weeks'}, {'measure': 'Percent change in the hepatic fat fraction as determined by MRI-PDFF from baseline', 'timeFrame': '52 weeks'}, {'measure': 'Percent change in LDL-C from baseline', 'timeFrame': '28 weeks'}]",4,18 Years,,ALL,False,"Madrigal Pharmaceuticals, Inc.",INDUSTRY,0,1000.0,ESTIMATED,2025-09-01T16:18:22.199031,v2_robust,True,True,False,False,True,
NCT02209519,Randomized Controlled Trial of Treatment of Male Partners of Women With BV,Randomized Controlled Trial of Treatment of Male Partners of Women With BV,Metronidazole (male partner),['Metronidazole (male partner)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Recurrent Bacterial Vaginosis,['Recurrent Bacterial Vaginosis'],"['bacterial vaginosis', 'recurrence', 'male partner']",COMPLETED,,2015-02,2019-03,"[{'measure': 'Number of Female Partners Whose Male Partners Received Metronidazole Versus Females Whose Male Partners Did Not Receive Metrodiazole With Recurrence of BV in the Female', 'description': 'the female partners will be assessed for recurrence/persistence of BV. tRecurrence/persistence is measured by - Positive 3 - 4 Amsel criteria (vaginal pH \\> 4.7, clue cells, positive whiff test, homogenous discharge); Nugent score \\>3\n\nNo Recurrence/Persistence is measured by:\n\n\\- Presence of 0 -2 Amsel criteria; Nugent score 0-3.', 'timeFrame': '16 weeks post start of receipt of study drug'}]","[{'measure': 'Time to Recurrence of BV in Women Whose Partner Received Metronidazole Versus Females Whose Partners Did Not Receive Metronidazole', 'description': 'time to recurrence measured in days', 'timeFrame': 'from the end of week 1 up to 16 weeks'}]",2,19 Years,50 Years,ALL,False,University of Alabama at Birmingham,OTHER,1,214.0,ACTUAL,2025-09-01T16:18:22.199047,v2_robust,True,True,True,False,False,
NCT00046319,Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension,"A Phase II, Randomized, Double-Blind, Dose-Controlled, Dose-Ranging, Multicenter Study of BSF 208075 Evaluating Exercise Capacity in Patients With Moderate to Severe Pulmonary Arterial Hypertension",BSF 208075,['BSF 208075'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Pulmonary Hypertension,['Pulmonary Hypertension'],"['Pulmonary Arterial Hypertension', 'Primary Pulmonary Hypertension']",COMPLETED,,2002-09,2003-06,[{'measure': 'Change from baseline to Week 12 in six minute walk distance'}],"[{'measure': 'Change from baseline to Week 12 in:'}, {'measure': 'Borg Dyspnea Index'}, {'measure': 'WHO Functional Classification'}, {'measure': 'Subject Global Assessment'}]",5,18 Years,,ALL,False,Gilead Sciences,INDUSTRY,0,60.0,,2025-09-01T16:18:22.199111,v2_robust,True,True,True,False,False,
NCT06650930,Pharmacokinetics of Oral Calcium Carbonate in Parturients,Pharmacokinetics of Oral Calcium Carbonate in Parturients,Oral calcium carbonate,['Oral calcium carbonate'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Pregnancy,"['Pregnancy', 'Pharmacokinetics', 'Postpartum Hemorrhage']","['calcium', 'oral calcium', 'calcium carbonate', 'calcium pharmacokinetics', 'pharmacokinetics in pregnancy', 'postpartum hemorrhage', 'ionized calcium', 'pharmacokinetics']",NOT_YET_RECRUITING,,2025-01,2025-10,"[{'measure': 'Ionized calcium concentration', 'description': 'Ionized calcium (mmol/L) is measured at baseline and over 5 additional convenience timepoints over the 4 hours after ingestion of calcium carbonate 3000mg.', 'timeFrame': '4 hours'}]",[],1,18 Years,45 Years,FEMALE,False,Stanford University,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:22.199121,v2_robust,True,True,False,False,False,
NCT03577730,Caffeine and Neurologic Recovery Following Surgery and General Anesthesia,Caffeine and Neurologic Recovery Following Surgery and General Anesthesia,Caffeine Citrate,"['Caffeine Citrate', 'Dextrose Water']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,"Pain, Postoperative","['Pain, Postoperative']","['Opioid Use', 'Opioid Dependence', 'Opioid-Related Disorders', 'Opioid Abuse', 'Opioid-use Disorder', 'Pain', 'Pain, Postoperative', 'Cognitive Impairment', 'Delirium', 'Delirium on Emergence', 'Depression', 'Anxiety', 'Anxiety Disorders', 'Affect']",COMPLETED,,2018-07-10,2020-01-17,"[{'measure': 'Cumulative Opioid Consumption: Postoperative Opioid Consumption, Oral Morphine Equivalents (mg)', 'description': 'Postoperative opioid consumption, oral morphine equivalents (mg)', 'timeFrame': 'through postoperative day 3'}]","[{'measure': 'Acute Pain (Patient-reported) as Assessed by Visual Analogue Scale', 'description': 'Visual Analogue Scale (mm, 0-100, 0 = no pain, 100 = worst pain imaginable)', 'timeFrame': 'Data gathered from postoperative day 0-3. Final results were based on all values combined over this time period, per protocol.'}, {'measure': 'Acute Pain (Observer-reported) as Assessed by Behavioral Pain Scale', 'description': 'Behavioral Pain Scale, on a scale ranging from 3 to 12 when 3 is no pain and 12 is maximum pain', 'timeFrame': 'Data gathered from postoperative day 0-3. Final results were based on all values combined over this time period, per protocol.'}, {'measure': 'Time Until Anesthetic Emergence', 'description': 'Time from surgical dressing on to anesthetic emergence (min)', 'timeFrame': 'Duration of time from surgical dressing completion to anesthetic emergence (min); generally expected to be between 10 and 60 minutes'}, {'measure': 'Number of Participants With Depression as Assessed by the Hospitalized Anxiety and Depression Scale (HADS-D)', 'description': 'Number (n) of participants with positive screens (score ≥8) using the Hospitalized Anxiety and Depression Scale (HADS-D) (n, 0-21, 0 = normal, 21 = presence of severe depression symptoms)', 'timeFrame': 'baseline through postoperative day 3'}, {'measure': 'Number of Participants With Anxiety as Assessed by the Hospitalized Anxiety and Depression Scale (HADS-A)', 'description': 'Number (n) of participants with positive screens (score ≥8) using the Hospitalized Anxiety and Depression Scale (HADS-A) (n, 0-21, 0 = normal, 21 = presence of severe anxiety symptoms)', 'timeFrame': 'baseline through postoperative day 3'}, {'measure': 'Cognitive Function as Assessed by Trail Making Test', 'description': 'Trail Making Test scores (seconds, 10-300,10 = fastest reported completion, 300 = maximum time allowed for completion). The change was calculated from the value at post anesthesia minus value at baseline. Higher values are considered to be worse outcomes.', 'timeFrame': 'morning of surgery baseline compared to postanesthesia care unit. Postanesthesia care unit measurement approximately 60 minutes after end of surgery'}, {'measure': 'Positive Affect as Assessed by PANAS (Positive and Negative Affect Schedule)', 'description': 'Positive Affect Score (n, 10-50, 10 = least positive affect, 50 = most positive affect) via PANAS (Positive and Negative Affect Schedule)', 'timeFrame': 'postoperative day 3'}, {'measure': 'Negative Affect as Assessed by PANAS (Positive and Negative Affect Schedule)', 'description': 'Negative Affect Score (n, 10-50, 10 = least negative affect, 50 = most negative affect) via PANAS (Positive and Negative Affect Schedule)', 'timeFrame': 'postoperative day 3'}, {'measure': 'Percentage of Delirious Patients Per Group', 'description': 'Number (n) of participants who has experienced at least one episode of delirium by the postoperative day 3 time point, as determined by daily Confusion Assessment Method (CAM).', 'timeFrame': 'By afternoon of postoperative day (POD) 3'}]",10,18 Years,,ALL,False,University of Michigan,OTHER,0,71.0,ACTUAL,2025-09-01T16:18:22.199130,v2_robust,True,True,True,False,False,
NCT00966030,Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042),"An Open-Label, Randomized, 2-Period Crossover Study to Demonstrate the Definitive Bioequivalence of a Single Dose of a Tablet Form of MK0974 Ethanolate Vs. a Single Dose of the Reference MK0974 Liquid Filled Capsule in Healthy Subjects",MK0974 tablet,"['MK0974 tablet', 'Comparator: MK0974 liquid filled capsule']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Migraine,['Migraine'],[],COMPLETED,,2008-03,2008-05,"[{'measure': 'Area under the curve (AUC(0 to infinity)) following single dose administration of MK0974 tablet formulation and MK0974 liquid filled capsule formulation', 'timeFrame': 'Through 48 Hours Post Dose'}, {'measure': 'Peak plasma concentration (Cmax) following single dose administration of MK0974 tablet formulation and MK0974 liquid filled capsule formulation', 'timeFrame': 'Through 48 Hours Post Dose'}]",[],2,18 Years,55 Years,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,50.0,ACTUAL,2025-09-01T16:18:22.199292,v2_robust,True,True,True,False,False,
NCT05153330,"Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL","A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)",BMF-219,"['BMF-219', 'Covalent Menin Inhibitor']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Myeloid Leukemia,"['Acute Myeloid Leukemia', 'Acute Lymphoblastic Leukemia', 'Acute Mixed-Phenotype Leukemia', 'Cancer', 'Refractory', 'Progression', 'Diffuse Large B Cell Lymphoma', 'Multiple Myeloma', 'Lymphoma', 'Lymphoma, Non-Hodgkin', 'Myeloma, Plasma-Cell', 'Myelomatosis', 'Plasma Cell Myeloma', 'Chronic Lymphocytic Leukemia', 'Small Lymphocytic Lymphoma']",[],TERMINATED,"Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure.",2022-01-24,2025-05-02,"[{'measure': 'Determine Optimal Biologic Dose (OBD) and RP2D of BMF-219 monotherapy for (Cohorts 1, 2, 3 & 4)', 'description': 'Determine Optimal Biologic Dose (OBD) and recommended Phase 2 dose (RP2D) of BMF-219 monotherapy in subjects with refractory or relapsed (R/ R) acute leukemia (Cohort 1), diffuse large B-cell lymphoma (Cohort 2), multiple myeloma (Cohort 3), and chronic lymphocytic leukemia/ small lymphocytic lymphoma (Cohort 4).', 'timeFrame': 'At the end of Cycle 1 (each Cycle is 28 Days in duration)'}]","[{'measure': 'Evaluate the Safety treatment-emergent TEAEs and SAEs', 'description': 'Evaluate the Safety of BMF-219 as expressed by treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).', 'timeFrame': '28 Days after last dose.'}]",2,18 Years,,ALL,False,Biomea Fusion Inc.,INDUSTRY,0,55.0,ACTUAL,2025-09-01T16:18:22.199449,v2_robust,True,True,False,True,True,"Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure."
NCT01359930,Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study,Phase 1 Study of Interactions Between Oral Naltrexone and Bupropion and Intravenous Methamphetamine in Methamphetamine Experienced Volunteers,Naltrexone and Bupropion SR,['Naltrexone and Bupropion SR'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Methamphetamine Dependence,['Methamphetamine Dependence'],[],COMPLETED,,2011-08,2012-06,"[{'measure': 'Cardiovascular System Effects', 'description': 'Heart rate, blood pressure, ECGs,and monitoring adverse events', 'timeFrame': 'daily during the 10 day treatment period'}, {'measure': 'Number of subjects with adverse events', 'timeFrame': 'Day 0 through Day 10'}]","[{'measure': 'Plasma concentrations obtained at specific timepoints', 'description': '* PK of IV (meth) and its metabolites before and during Naltrexone/BUP exposure\n* PK of bupropion, naltrexone and their metabolites', 'timeFrame': 'daily during the 10 day treatment period'}, {'measure': 'Assessment of Vital Signs and Clinical Chemistries', 'description': 'Respiration rate and clinical laboratory measures', 'timeFrame': 'Daily during the 10 day treatment period'}, {'measure': 'Cognitive Assessments as reported by the subject', 'description': 'Subject reported effects measured with VAS, BSCS, and POMS', 'timeFrame': 'Dailly during the 10 day treatment period'}]",5,21 Years,50 Years,ALL,True,National Institute on Drug Abuse (NIDA),NIH,0,16.0,ESTIMATED,2025-09-01T16:18:22.199551,v2_robust,True,True,True,False,True,
NCT00191230,Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer,A Randomized Phase II Trial of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/ Cisplatin)When Used as Preoperative Chemotherapy for Patients With Stage I and II NSCLC,gemcitabine,"['gemcitabine', 'carboplatin', 'cisplatin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,"Carcinoma, Non Small Cell Lung","['Carcinoma, Non Small Cell Lung']",[],COMPLETED,,2001-09,2006-07,[{'measure': 'Complete pathological response'}],"[{'measure': 'Response rate, disease free survival, toxicity including pulmonary toxicity,operative mortality and quality of life.'}]",2,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,70.0,,2025-09-01T16:18:22.199561,v2_robust,True,True,True,False,False,
NCT01288430,A Study of DS-2248 in Participants With Advanced Solid Tumors,"A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors",DS-2248,['DS-2248'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumors,"['Solid Tumors', 'Non-small Cell Lung Carcinoma']","['Heat shock protein 90', 'Advanced solid tumors', 'Non-small cell lung carcinoma', 'Epidermal growth factor receptor', 'Tyrosine kinase inhibitor acquired resistance', 'Non-small cell lung carcinoma with acquired resistance to erlotinib, gefitinib, afatinib or others.']",TERMINATED,The trial was terminated as per Sponsor decision.,2011-03-29,2014-02-13,"[{'measure': 'Summary of Objective Response Rate Following Oral Administration of DS-2248 in Participants With Advanced Solid Tumors', 'description': 'Objective response rate was defined as the sum of complete response (CR) and partial response (PR) rates. CR was defined as a disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have had a reduction in short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.', 'timeFrame': 'Baseline up to disease progression, discontinuation of study, or death, up to 2 years 11 months'}]","[{'measure': 'Summary of Best Overall Response Rate Following Oral Administration of DS-2248 in Participants With Advanced Solid Tumors', 'description': 'Complete response (CR) was defined as a disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have had a reduction in short axis to \\<10 mm. Partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Objective response rate (ORR) was defined as the sum of CR and PR rates.', 'timeFrame': 'Baseline up to disease progression, discontinuation of study, or death, up to 2 years 11 months'}, {'measure': 'Summary of Disease Control Rate Following Oral Administration of DS-2248 in Participants With Advanced Solid Tumors', 'description': 'Disease control rate (DCR) was defined as the sum of complete response (CR) and partial response (PR) rates, and stable disease (SD) rate for a minimum of 12 weeks. Complete response (CR) was defined as a disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have had a reduction in short axis to \\<10 mm. Partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (at least a 20% increase in the sum of diameters of target lesions), taking as reference the smallest sum diameters while on study.', 'timeFrame': 'Baseline up to disease progression, discontinuation of study, or death, up to 2 years 11 months'}, {'measure': 'Duration of Stable Disease Following Oral Administration of DS-2248 in Participants With Advanced Solid Tumors', 'description': 'Duration of response measured from the time at which criteria were first met for complete (CR) or partial response (PR) until the first date that progressive disease (PD) was objectively documented. Participants who had not progressed at the data cut-off date were censored at their last evaluable tumor assessment date. Duration of stable disease (SD) measured from the date of enrollment until the first date that criteria for disease progression were met. The minimum time interval for the duration of SD was 6 weeks. Participants who had not progressed at the data cut-off date were censored at their last evaluable tumor assessment date.', 'timeFrame': 'Baseline up to disease progression, discontinuation of study, or death, up to 2 years 11 months'}, {'measure': 'Summary of Progression-free Survival Following Oral Administration of DS-2248 in Participants With Advanced Solid Tumors', 'description': 'Progression-free survival (PFS) defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of radiographic disease progression (as per RECIST V1.1) or death due to any cause. Participants who were alive with no objective documentation of (radiographic) disease progression by the data cut-off date were censored at the date of their last evaluable tumor assessment. Participants who were lost to follow-up or withdrew early from the study with no documented disease progression were censored at the last evaluable tumor assessment.', 'timeFrame': 'Baseline up to disease progression, discontinuation of study, or death, up to 2 years 11 months'}, {'measure': 'Summary of Pharmacokinetic Parameter Area Under the Concentration Versus Time Curve From Zero to Infinity Following Oral Administration of DS-2248 in Participants With Advanced Solid Tumors', 'timeFrame': 'Cycle 1, Day 1 predose, 0.5, 1, 2, 3, 4, 6, and 8 h postdose; Cycle 1, Day 2 and Day 15; Cycle 1, Day 8 predose, 1 and 6 h postdose; Cycle 2 and 3, Day 1, 8, and 15'}, {'measure': 'Summary of Pharmacokinetic Parameter Maximum Concentration Following Oral Administration of DS-2248 in Participants With Advanced Solid Tumors', 'timeFrame': 'Cycle 1, Day 1 predose, 0.5, 1, 2, 3, 4, 6, and 8 h postdose; Cycle 1, Day 2 and Day 15; Cycle 1, Day 8 predose, 1 and 6 h postdose; Cycle 2 and 3, Day 1, 8, and 15'}, {'measure': 'Summary of Pharmacokinetic Parameter Time at Maximum Concentration Following Oral Administration of DS-2248 in Participants With Advanced Solid Tumors', 'timeFrame': 'Cycle 1, Day 1 predose, 0.5, 1, 2, 3, 4, 6, and 8 h postdose; Cycle 1, Day 2 and Day 15; Cycle 1, Day 8 predose, 1 and 6 h postdose; Cycle 2 and 3, Day 1, 8, and 15'}, {'measure': 'Summary of Pharmacokinetic Parameter Terminal Half-life Following Oral Administration of DS-2248 in Participants With Advanced Solid Tumors', 'timeFrame': 'Cycle 1, Day 1 predose, 0.5, 1, 2, 3, 4, 6, and 8 h postdose; Cycle 1, Day 2 and Day 15; Cycle 1, Day 8 predose, 1 and 6 h postdose; Cycle 2 and 3, Day 1, 8, and 15'}, {'measure': 'Summary of Pharmacokinetic Parameter Total Body Clearance Following Oral Administration of DS-2248 in Participants With Advanced Solid Tumors', 'timeFrame': 'Cycle 1, Day 1 predose, 0.5, 1, 2, 3, 4, 6, and 8 h postdose; Cycle 1, Day 2 and Day 15; Cycle 1, Day 8 predose, 1 and 6 h postdose; Cycle 2 and 3, Day 1, 8, and 15'}, {'measure': 'Summary of Drug Related Treatment Emergent Adverse Events Following Oral Administration of DS-2248 in Participants With Advanced Solid Tumors', 'description': 'A treatment-emergent adverse event (TEAE) is defined as an adverse event that emerges during treatment, having been absent at pre-treatment; or reemerges during treatment, having been present at baseline but stopped prior to treatment; or worsens in severity after starting treatment relative to the pre-treatment state, when the AE is continuous. A DS-2248-related TEAE is an TEAE that is related to DS-2248 in the relationship.', 'timeFrame': 'Baseline up to 30 days post last dose, up to 2 years 11 months'}]",11,18 Years,,ALL,False,Daiichi Sankyo,INDUSTRY,1,60.0,ACTUAL,2025-09-01T16:18:22.199611,v2_robust,True,True,False,True,True,The trial was terminated as per Sponsor decision.
NCT00609128,Effect of Olopatadine on Allergic Tear Mediators,Expression of Inflammatory Mediators in Allergic Conjunctivitis,olopatadine,['olopatadine'],1,INTERVENTIONAL,['NA'],,,Allergic Conjunctivitis,['Allergic Conjunctivitis'],"['tears', 'conjunctival epithelial cells', 'olopatadine', 'eosinophils']",COMPLETED,,2000-09,2009-11,"[{'measure': 'Study Examined Whether the Incubation of Human Conjunctival Epithelial Cells With Tears Pooled From Allergic Subjects (One Eye With and Other Eye Without Olopatadine Treatment) Promotes Eosinophil Adhesion', 'description': 'Outcome:\n\nThe collected tears (from 10 subjects)were pooled, incubated with primary conjunctival epithelial cells before eosinophil adhesion was measured via eosinophil peroxidase assay.\n\nEosinophils in eosinophils / square cm measured.', 'timeFrame': '1 week for tear collection, tears stored at - 80 C until used'}]",[],1,18 Years,65 Years,ALL,True,"University of Wisconsin, Madison",OTHER,1,21.0,ACTUAL,2025-09-01T16:18:22.199792,v2_robust,True,True,True,False,False,
NCT06300528,Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas,Pemi in R/R B-cell NHL: A Phase II Study of Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas,Pemigatinib,['Pemigatinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,['Relapsed or Refractory B-cell Non-Hodgkin Lymphoma'],[],RECRUITING,,2025-02-04,2030-12,"[{'measure': 'Overall Response Rate (ORR) at Cycle 7 per IWG Response Criteria in subjects with R/R MCL.', 'description': 'To assess the efficacy of pemigatinib in subjects with R/R MCL.', 'timeFrame': '8 months'}, {'measure': 'To determine the ORR at Cycle 7 per IWG Response Criteria in subjects with R/R MZL.', 'description': 'To assess the efficacy of pemigatinib in subjects with R/R MZL.', 'timeFrame': '8 months'}]","[{'measure': 'Complete Response (CR) rate at Cycle 7 per IWG Response Criteria.', 'description': 'To assess the CR rate at Cycle 7.', 'timeFrame': '8 months'}, {'measure': 'Duration of response (DoR), defined as the interval of time from the date of initial documented response (PR or better per IWG Response Criteria) to the time of progression from the best response, the start of a new therapy, or death from any cause.', 'description': 'To assess the DoR of the study population.', 'timeFrame': '4 years'}, {'measure': 'Progression-free survival (PFS) as defined as the time from study drug initiation to the time documented disease progression (as assessed by IWG Response Criteria), or death from any cause.', 'description': 'To assess median and 2 year PFS.', 'timeFrame': '4 years'}, {'measure': 'Overall survival (OS) as defined as the time from registration until death from any cause.', 'description': 'To assess median and 2 year OS in this study population.', 'timeFrame': '4 years'}]",6,18 Years,,ALL,False,University of Utah,OTHER,1,27.0,ESTIMATED,2025-09-01T16:18:22.199825,v2_robust,True,True,False,False,False,
NCT00001028,A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides,"A Randomized, Comparative, Prospective Study of Monthly Aerosolized Pentamidine and Thrice Weekly Dapsone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant to Trimethoprim and/or Sulfonamides",Pentamidine isethionate,"['Pentamidine isethionate', 'Dapsone']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Pneumonia, Pneumocystis Carinii","['Pneumonia, Pneumocystis Carinii', 'HIV Infections']","['Pneumonia, Pneumocystis carinii', 'Pentamidine', 'Dapsone', 'Acquired Immunodeficiency Syndrome', 'AIDS-Related Complex']",COMPLETED,,,1994-06,[],[],0,13 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,2,400.0,,2025-09-01T16:18:22.199865,v2_robust,True,True,True,False,False,
NCT05021328,Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC,A Phase Ib Study on Toripalimab Combined With Anlotinib and SBRT for Patients With Untreated Brain Metastases of Driven Gene-negative Non-small Cell Lung Cancer,Toripalimab,"['JS001', 'Anlotinib Hydrochloride Capsules', 'FuKeWei', 'SBRT 7Gy✖️5 QD', 'AL3818', 'Toripalimab', 'Teruipuli dankang Zhusheye', 'Anlotinib', 'Toripalimab Injection', 'TuoYI']",10,INTERVENTIONAL,['PHASE1'],PHASE1,,NSCLC,['NSCLC'],"['Brain metastasis', 'Toripalimab', 'Anlotinib', 'SBRT', 'Drive gene negative']",COMPLETED,,2021-10-01,2025-02-05,"[{'measure': 'Treatment-related adverse events', 'description': 'AEs per Common Terminology Criteria for Adverse Events (CTCAE V5.0)', 'timeFrame': 'up to 24 month'}, {'measure': 'Intracranial response rate (iORR)', 'description': 'Proportion of patients with a complete or partial response in intracranial metastases as measured using RECIST 1.1 criteria (modified for brain metastases - bm RECIST).', 'timeFrame': '4 weeks after Radiotherapy.'}]","[{'measure': 'Intracranial progression-free survival (iPFS)', 'description': 'Defined as the time from randomisation to progression of intracranial disease or death from any cause.', 'timeFrame': 'Tumor assesment at 4 weeks and 12 weeks after radiotherapy, and then every 12 weeks, up to 24 months'}, {'measure': 'Local Control Rate (LCR)', 'description': 'Local recurrence is defined as the onset or progression of nodular contrast grafting within the resection cavity according to the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria.', 'timeFrame': 'Tumor assesment at 4 weeks and 12 weeks after radiotherapy, and then every 12 weeks, up to 24 months'}, {'measure': 'Overall survival (OS)', 'description': 'Defined as the time from randomisation to death from any cause', 'timeFrame': 'Tumor assesment at 4 weeks and 12 weeks after radiotherapy, and then every 12 weeks, up to 24 months'}]",5,18 Years,,ALL,False,Hubei Cancer Hospital,OTHER,0,13.0,ACTUAL,2025-09-01T16:18:22.199873,v2_robust,True,True,True,False,True,
NCT06112028,Clinical Study of Tongxinluo Capsule in Preventing and Treating Restenosis After Intracranial and External Arterial Stenting,Clinical Study of Tongxinluo Capsule in Preventing and Treating Restenosis After Intracranial and External Arterial Stenting,Tongxinluo capsule,['Tongxinluo capsule'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Stent Restenosis,['Stent Restenosis'],"['traditional Chinese medicine', 'Stent Restenosis']",NOT_YET_RECRUITING,,2023-10,2026-11,"[{'measure': 'Changes of vascular stenosis rate after intracranial and extracranial arterial stenting', 'description': 'According to NASCET experimental measurement standards, stenosis rate = (normal vascular lumen diameter - residual diameter at stenosis)/normal vascular lumen diameter \\*100%. Comparison of CTA or DSA to evaluate the change of vascular stenosis rate after intracranial and extracranial arterial stenting; The incidence of cerebral ischemic events and intracranial hemorrhage events (responsible vessels and non-responsible vessels) were assessed by MR. Blood routine, liver and kidney function, blood lipids and hsCRP were recorded. The incidence and mortality of symptomatic intracranial hemorrhage were analyzed. Adverse events (e.g. abdominal pain, diarrhea, nausea, vomiting, bleeding, etc.)', 'timeFrame': 'The 12th month'}]",[],1,45 Years,80 Years,ALL,False,Yanbin Li,OTHER,0,200.0,ESTIMATED,2025-09-01T16:18:22.199930,v2_robust,True,True,False,False,True,
NCT04691128,Desflurane and Brain Relaxation in Craniotomy,Comparison of Desflurane and Propofol for Brain Relaxation in Patients Undergoing Supratentorial Craniotomy：a Randomized Controlled Study,Desflurane,"['TIVA', 'Desflurane', 'Propofol', 'inhalational anesthesia', 'total intravenous anesthesia']",5,INTERVENTIONAL,['NA'],,,Supratentorial Tumor,['Supratentorial Tumor'],[],COMPLETED,,2021-01-26,2021-08-31,"[{'measure': 'Proportion of satisfactory brain relaxation', 'description': 'Assessed by the neurosurgeon using a 4-point scale (1= perfectly relaxed, 2= satisfactorily relaxed, 3= firm brain, 4=bulging brain) at the opening of the dura mater, score 1 and 2 represent satisfactory brain relaxation', 'timeFrame': 'during surgery'}]","[{'measure': 'Emergence time', 'description': 'from drug discontinuation to eye opening', 'timeFrame': 'from drug discontinuation to eye opening, assessed up to 1 hours'}, {'measure': 'Extubation time', 'description': 'from drug discontinuation to tracheal extubation', 'timeFrame': 'from drug discontinuation to tracheal extubation, assessed up to 1 hours'}, {'measure': 'Postoperative complications', 'description': 'incidence of hypoxemia, hypotension, hypertension, tachycardia, bradycardia, agitation, shivering.', 'timeFrame': 'from drug discontinuation to discharge from PACU (Postanesthesia care unit), assessed up to 3 hours'}, {'measure': 'Postoperative pain and postoperative nausea and vomiting (PONV)', 'description': 'evaluated by Visual Analogue Score(VAS).', 'timeFrame': 'during the PACU stay and postoperative day 1.'}, {'measure': 'Duration in PACU (Postanesthesia care unit)', 'description': 'time from entering PACU to exiting PACU', 'timeFrame': 'from entering PACU to exiting PACU, an expected average of 1 hour'}, {'measure': 'Early postanesthesia cognitive recovery', 'description': 'evaluated by Short Orientation Memory Concentration Test (SOMCT)', 'timeFrame': 'at 15, 30min after tracheal extubation'}, {'measure': 'Dural tension', 'description': 'evaluated using a 4-point scale after bone flap removal.', 'timeFrame': 'during surgery'}, {'measure': 'Quality of anesthesia recovery', 'description': 'assessed by quality of recovery-15 scale (QoR-15)', 'timeFrame': 'at postoperative day 1'}, {'measure': 'Anesthesia expenses', 'description': 'Total cost of anesthesia', 'timeFrame': 'at postoperative day 1'}]",10,18 Years,60 Years,ALL,False,Beijing Tiantan Hospital,OTHER,0,111.0,ACTUAL,2025-09-01T16:18:22.199959,v2_robust,True,True,True,False,False,
NCT05686928,Healing Ointment Usage Post-surgical Procedure,"A Multi-center, Prospective Pilot Study on Safety and Effectiveness of a Healing Ointment as a Post-surgical Care",Cetaphil Healing Ointment,['Cetaphil Healing Ointment'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Surgical Wound,['Surgical Wound'],[],COMPLETED,,2022-08-17,2022-11-30,"[{'measure': 'Objective Erythema Assessment Using Clinical Grading Analog Scale', 'description': 'Summary of change in tolerability from baseline to day 28, at the surgical area after using the Healing Ointment daily. Lower scores reflect a better outcome. Erythema assessment was graded clinically based on a scale from 0 to 3 (0 = none, 1 = mild, 2 = moderate, 3 = severe).', 'timeFrame': 'Immediately post-procedure (on the same day of the procedure), day 7/14, and day 28 from baseline'}, {'measure': 'Objective Edema Assessment Using Clinical Grading Analog Scale', 'description': 'Summary of change in tolerability from baseline to day 28, at the surgical area after using the Healing Ointment daily. Lower scores reflect a better outcome. Edema assessment was graded clinically based on a scale from 0 to 3 (0 = none, 1 = mild, 2 = moderate, 3 = severe).', 'timeFrame': 'Immediately post-procedure (on the same day of the procedure), day 7/14, and day 28 from baseline'}, {'measure': 'Objective Overall Wound Appearance Assessment Using Clinical Grading Analog Scale', 'description': 'Summary of change in tolerability from baseline to day 28, at the surgical area after using the Healing Ointment daily. Lower scores reflect a better outcome. Overall wound appearance was graded clinically based on a scale from 0 to 3 (0 = excellent, 1 = good, 2 = fair, 3 = poor).', 'timeFrame': 'Immediately post-procedure (on the same day of the procedure), day 7/14, and day 28 from baseline'}, {'measure': 'Objective Scabbing/Crusting Assessment Using Clinical Grading Analog Scale', 'description': 'Summary of change in tolerability from baseline to day 28, at the surgical area after using the Healing Ointment daily. Lower scores reflect a better outcome. Scabbing/crusting assessment was graded based on a scale from 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = extensive, 4 = almost complete/complete).', 'timeFrame': 'Immediately post-procedure (on the same day of the procedure), day 7/14, and day 28 from baseline'}, {'measure': 'Subjective Burning Assessment Using an Analog Scale', 'description': 'Summary of change in tolerability from baseline to day 28, at the surgical area after using the Healing Ointment daily. Lower scores reflect a better outcome. Burning assessment was graded by subjects based on a scale from 0 to 3 (0 = none, 1 = mild, 2 = moderate, 3 = severe).', 'timeFrame': 'Immediately post-procedure (on the same day of the procedure), day 7/14, and day 28 from baseline'}, {'measure': 'Subjective Itching Assessment Using an Analog Scale', 'description': 'Summary of change in tolerability from baseline to day 28, at the surgical area after using the Healing Ointment daily. Lower scores reflect a better outcome. Itching assessment was graded by subjects based on a scale from 0 to 3 (0 = none, 1 = mild, 2 = moderate, 3 = severe).', 'timeFrame': 'Immediately post-procedure (on the same day of the procedure), day 7/14, and day 28 from baseline'}, {'measure': 'Subjective Pain Assessment Using an Analog Scale', 'description': 'Summary of change in tolerability from baseline to day 28, at the surgical area after using the Healing Ointment daily. Lower scores reflect a better outcome. Pain assessment was graded by subjects based on a scale from 0 to 3 (0 = none, 1 = mild, 2 = moderate, 3 = severe).', 'timeFrame': 'Immediately post-procedure (on the same day of the procedure), day 7/14, and day 28 from baseline'}]","[{'measure': 'Subject Satisfaction Using a Self-assessment Questionnaire', 'description': 'Subjects are asked about their satisfaction with the treatment product and overall improvement at the treated area. Scale consists of 5 questions at every follow-up visit and subjects select level of satisfaction for each question from/to strongly agree, agree, neither, disagree, and strongly disagree. Upon study completion, subjects also provide their perception on recommendation, purchase intent, preference, and testimonial.', 'timeFrame': 'Day 7/14'}, {'measure': 'Subject Satisfaction Using a Self-assessment Questionnaire', 'description': 'Subjects are asked about their satisfaction with the treatment product and overall improvement at the treated area. Scale consists of 5 questions at every follow-up visit and subjects select level of satisfaction for each question from/to strongly agree, agree, neither, disagree, and strongly disagree. Upon study completion, subjects also provide their perception on recommendation, purchase intent, preference, and testimonial.', 'timeFrame': 'Day 28'}]",9,18 Years,85 Years,ALL,True,Galderma R&D,INDUSTRY,0,15.0,ACTUAL,2025-09-01T16:18:22.199984,v2_robust,True,True,True,False,False,
NCT03686228,Treatment of No-option CLI by G-CSF-mobilized PB-MNC,Treatment of No-option CLI Patients by G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells,No-PB-MNC therapy,['No-PB-MNC therapy'],1,INTERVENTIONAL,['NA'],,,PAD,"['PAD', 'Critical Limb Ischemia', 'Atherosclerotic Ischemic Disease']",[],UNKNOWN,,2018-10-01,2023-12-31,"[{'measure': 'Amputation free survival', 'description': 'Rate of non amputated limb', 'timeFrame': '3 month'}]","[{'measure': 'Amputation free survival', 'description': 'Rate of non amputated limb', 'timeFrame': '1,6,12 month'}, {'measure': 'Ankle brachial index (ABI)', 'description': 'Ankle brachial indexThe Ankle Brachial Index (ABI) is the systolic pressure at the ankle, divided by the systolic pressure at the arm. It has been shown to be a specific and sensitive metric for the diagnosis of Peripheral Arterial Disease (PAD)', 'timeFrame': '1,3,6,12 month'}, {'measure': 'Toe brachial index (TBI)', 'description': 'Toe brachial indexThe toe brachial index is the ratio between toe pressure and the highest of the two brachial pressures', 'timeFrame': '1,3,6,12 month'}, {'measure': 'Transcutaneous oxygen measurement (TCOM)', 'description': 'Transcutaneous oxygen measurement', 'timeFrame': '1,3,6,12 month'}, {'measure': '36-Item Short Form Health Survey (SF36)', 'description': 'SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting.', 'timeFrame': '1,3,6,12 month'}]",6,18 Years,80 Years,ALL,False,Mahidol University,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:22.200043,v2_robust,True,True,False,False,False,
NCT05193565,Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients,"Multi-center, Open-label, Randomized Controlled Phase 4 Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients Undergoing Maintenance Therapy With CNI Plus MPA.[CORAL Study]",Sirolimus,"['Mycophenolate mofetil', 'Myrept® Cap./Tab.', 'RaparoBell® Tab.', 'Sirolimus']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Kidney Transplantation,['Kidney Transplantation'],"['Kidney Transplantation', 'Sirolimus']",UNKNOWN,,2021-11-19,2024-06,"[{'measure': 'Incidence of composite efficacy failure', 'description': 'Composite efficacy failure include biopsy-confirmed acute rejection, graft loss, death, or follow-up failure', 'timeFrame': 'Until 24 weeks'}]","[{'measure': 'Incidence of biopsy-confirmed acute rejection(TCMR, AMR)', 'description': 'The frequency and Incidence', 'timeFrame': 'Until 24 weeks'}, {'measure': 'Pathologic Results, Occurrence, Treatment Methods, and Results of Acute Rejection Confirmed by Biopsy', 'description': 'By Banff classification categories', 'timeFrame': 'Until 24 weeks'}, {'measure': 'Survival rate of transplanted organ', 'description': 'Kaplan-Meier', 'timeFrame': 'Until 24 weeks'}, {'measure': 'Survival rate of Patients', 'description': 'Kaplan-Meier', 'timeFrame': 'Until 24 weeks'}, {'measure': 'Serum-Cr, eGFR', 'description': 'eGFR using MDRD', 'timeFrame': 'Until 24 weeks'}, {'measure': 'Incidence of BKV, CMV infection', 'description': 'The frequency and Incidence', 'timeFrame': 'Until 24 weeks'}]",7,20 Years,,ALL,False,Chong Kun Dang Pharmaceutical,INDUSTRY,0,206.0,ESTIMATED,2025-09-01T16:18:22.200112,v2_robust,True,True,False,False,False,
NCT06726265,Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004),"TACTI-004, a Double-Blinded, Randomized Phase 3 Trial in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination With Pembrolizumab (PD-1 Antagonist) and Chemotherapy.",carboplatin plus paclitaxel,"['cisplatin or carboplatin + pemetrexed', 'carboplatin plus paclitaxel']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC),['Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)'],[],RECRUITING,,2025-03-21,2029-09,"[{'measure': 'Determination of Overall survival (OS)', 'timeFrame': 'Up to approximately 54 months'}, {'measure': 'Determination of Progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)', 'timeFrame': 'Up to approximately 54 months'}]","[{'measure': 'Determination of Objective response rate (ORR) per RECIST 1.1', 'timeFrame': 'Up to approximately 54 months'}, {'measure': 'Frequency of adverse events (AEs)', 'timeFrame': 'Up to approximately 27 months'}, {'measure': 'Severity of adverse events (AEs) according to the United States National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v5.0', 'timeFrame': 'Up to approximately 27 months'}, {'measure': 'Determination of Time to Response (TTR) by RECIST 1.1.', 'timeFrame': 'Up to approximately 54 months'}, {'measure': 'Determination of Duration of Response (DOR) by RECIST 1.1.', 'timeFrame': 'Up to approximately 54 months'}, {'measure': 'Determination of PFS on next line therapy (PFS2)', 'timeFrame': 'Up to approximately 54 months'}]",8,18 Years,,ALL,False,Immutep S.A.S.,INDUSTRY,1,756.0,ESTIMATED,2025-09-01T16:18:22.200171,v2_robust,True,True,False,False,True,
NCT00296465,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Administered Intravenously or Subcutaneously (Via Portable Infusion Pump) Compared to Oral Treatment With Clomiphene Citrate in Anovulatory or Oligoovulatory Infertile Females",Pulsatile gonadotropin-releasing hormone (GnRH),"['Placebo Pulsatile GnRH', 'Pulsatile gonadotropin-releasing hormone (GnRH)', 'Clomiphene Citrate', 'Placebo Clomiphene Citrate', 'Lutrepulse®', 'Clomid']",6,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,InFertility,['InFertility'],[],COMPLETED,,2005-02,2005-11,"[{'measure': 'Pregnancy rate', 'timeFrame': 'Day 16'}]","[{'measure': 'Adverse events, including ovarian hyperstimulation syndrome (OHSS)', 'timeFrame': 'Day 1 to week 5'}]",2,18 Years,40 Years,FEMALE,True,Ferring Pharmaceuticals,INDUSTRY,0,132.0,ACTUAL,2025-09-01T16:18:22.200185,v2_robust,True,True,True,False,True,
NCT01227265,Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037),"A Phase 3, 12 Week, Double-blind, Placebo-controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease.",Preladenant,"['Preladenant', 'SCH 420814', 'Placebo', 'MK-3814']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Parkinson Disease,"['Parkinson Disease', 'Idiopathic Parkinson Disease', ""Idiopathic Parkinson's Disease""]",[],COMPLETED,,2010-11-19,2013-04-16,"[{'measure': 'Change From Baseline in Average ""Off"" Time (Hours Per Day) at Week 12', 'description': 'The ""on"" state is defined as the period of time during which a patient\'s symptoms of PD improve or disappear following treatment with L-dopa or dopamine agonists. The ""off"" state is defined as the period of time characterized by the return of symptoms (i..e. tremor, slowness, and rigidity) following treatment with L-dopa or dopamine agonists. Study participants reported their symptoms at half-hour intervals as ""off"", ""on"", or ""asleep"" on their daily diary for 3 days before randomization (baseline) and for the 3 days immediately before their Week 12 visit. The mean change from baseline in ""off"" time was based on a constrained longitudinal data analysis (cLDA) with treatment, time, and treatment-by-time interaction as fixed effects and subject as random effect.', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Number of Participants With Systolic Blood Pressure (SBP) ≥180 mmHg and 20 mmHg Increase', 'description': 'The number of participants with Systolic Blood Pressure (SBP) ≥180 mmHg and 20 mmHg increase was reported. Participants lie supine at rest for 5 minutes, then have a single BP measurement taken (ie, 1 reading). Participants then stand for 3 minutes at rest, followed by a single BP measurement (1 reading) in the standing position.', 'timeFrame': 'Up to Week 14'}, {'measure': 'Number of Participants With Diastolic Blood Pressure (DBP) ≥105 mmHg and 15 mmHg Increase', 'description': 'The number of participants with Diastolic Blood Pressure (DBP) ≥105 mmHg and 15 mmHg increase was reported. Participants lie supine at rest for 5 minutes, then have a single BP measurement taken (ie, 1 reading). Participants then stand for 3 minutes at rest, followed by a single BP measurement (1 reading) in the standing position.', 'timeFrame': 'Up to Week 14'}, {'measure': 'Percentage of Participants With Suicidality', 'description': 'The percentage of participants with suicidality using the Columbia - Suicide Severity Rating Scale (C-SSRS) was reported. The C-SSR was used in this study only for the purpose of safety monitoring by measuring the incidence of different types of suicidality categories during treatment. The assessment was done by the nature of the responses, not by a numbered scale. Participants who reported at least one occurrence of suicidal behavior or suicidal ideation were counted as having experienced suicidality. Suicidal behavior included suicide attempt, aborted attempt, interrupted attempt, or preparatory behavior. Suicidal ideation included a wish to die or active suicidal thought with or without method, intent or plan.', 'timeFrame': 'Up to Week 12'}, {'measure': 'Change From Baseline in Total Epworth Sleepiness Scale (ESS) at Week 12', 'description': ""The ESS is a self-administered questionnaire providing a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. The scale consists of 8 situations in which the participant rates their tendency to become sleepy on a scale of 0=no chance of dozing to 3=high chance of dozing. The overall score is the sum of the scores for the 8 situations for a minimum of 0 and a maximum of 24 with a higher score indicating greater sleepiness. The mean change from baseline in total EES was based on a cLDA with treatment, time, and treatment-by-time interaction as fixed effects and subject as random effect."", 'timeFrame': 'Baseline and Week 12'}]","[{'measure': 'Percentage of Participants With >30% Change (Reduction) From Baseline at Week 12 in Mean ""Off"" Time', 'description': 'A participant with at least a 30% reduction in mean ""off"" time from Baseline to End of Treatment (Week 12) is considered as ""responder"". The ""on"" state is defined as the period of time during which a patient\'s symptoms of PD improve or disappear following treatment with L-dopa or dopamine agonists. The ""off"" state is defined as the period of time characterized by the return of symptoms (i..e. tremor, slowness, and rigidity) following treatment with L-dopa or dopamine agonists. Study participants reported their symptoms at half-hour intervals as ""off"", ""on"", or ""asleep"" on their daily diary for 3 days before randomization and for the 3 days immediately before their Week 12 visit.', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Change From Baseline in Average ""On"" Time (Hours Per Day) Without Troublesome Dyskinesia at Week 12', 'description': '""On"" time is when a PD participant\'s symptoms are improved. Mean ""on"" time without troublesome dyskinesias is derived from the available diary data collected for 3 days immediately prior to a clinic visit. ""On"" time without troublesome dyskinesia is the sum of ""on"" time without dyskinesia plus ""on"" time with non-troublesome dyskinesia as recorded in the diary. The mean change from baseline in ""on"" time was based on a cLDA with treatment, time, and treatment-by-time interaction as fixed effects and subject as random effect.', 'timeFrame': 'Baseline and Week 12'}]",7,30 Years,85 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,476.0,ACTUAL,2025-09-01T16:18:22.200194,v2_robust,True,True,True,False,True,
NCT00839865,Trial of Herb Yuyang Ointment to Diabetic Foot Ulcer,Phase 1 Study of Herb Yuyang Ointment That Expressed Good Effect in Diabetic Foot Ulcer,herb ointment,"['herb ointment', 'TANGZUYUYANGGAO']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Diabetic Foot Ulcer,['Diabetic Foot Ulcer'],"['Evidence-based evaluation', 'Multi-center randomized controlled clinical trials', 'Traditional Chinese Medicine', 'therapy', 'diabetic foot ulcer', 'clinical trails']",UNKNOWN,,2008-11,2011-03,"[{'measure': 'The primary objective is to determine the effect of this ointment on the incidence of complete wound closure.', 'timeFrame': '6 months'}]","[{'measure': ""Secondary objectives include: evaluating the acceleration of ulcer closure or facilitation of surgical closure, reduction of ulcer surface area over time, reduction in complications, the quality of life and it's safety."", 'timeFrame': '6 months'}]",2,18 Years,,ALL,False,Guiyang No.1 People's Hospital,OTHER,2,100.0,ESTIMATED,2025-09-01T16:18:22.200238,v2_robust,True,True,False,False,True,
NCT06467565,NALIRIFOX as Induction Therapy in LAPC,"A Phase II Study of Liposomal Irinotecan (Nal-IRI) With 5 Fluorouracil, Leucovorin, and Oxaliplatin (NALIRIFOX) in Patients With Locally Advanced Pancreatic Cancer",Liposomal irinotecan,['Liposomal irinotecan'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Pancreatic Ductal Adenocarcinoma,['Pancreatic Ductal Adenocarcinoma'],[],RECRUITING,,2023-12-25,2025-12-31,"[{'measure': 'Objective response rate (ORR)', 'description': 'ORR is defined as the percentage of participants who have a confirmed complete response or partial response according to RECIST 1.1.', 'timeFrame': 'Up to 1 year'}]","[{'measure': 'Progression free survival (PFS)', 'description': 'PFS is defined as the time from enrollment of the trial to the first documented disease progression or death due to any cause.', 'timeFrame': 'Up to two years'}, {'measure': 'Overall survival (OS)', 'description': 'The duration from the date of recruitment to the date of death from any cause.', 'timeFrame': 'Up to two years'}, {'measure': 'Adverse events (safety)', 'description': 'Adverse events (safety ) will be evaluated according to the NCI CTCAE Version 5.0.The number and severity of treatment-related side effects, including AE and SAE, will be recorded during treatment.', 'timeFrame': 'Up to two years'}]",4,18 Years,70 Years,ALL,False,The First Affiliated Hospital with Nanjing Medical University,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:22.200260,v2_robust,True,True,False,False,True,
NCT00601965,Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults,CBT Augmentation of SSRI Treatment for Geriatric GAD,Escitalopram,"['Escitalopram', 'Lexapro', 'Sugar pill', 'Placebo']",4,INTERVENTIONAL,['NA'],,,Generalized Anxiety Disorder,['Generalized Anxiety Disorder'],[],COMPLETED,,2007-10,2011-09,"[{'measure': 'Hamilton Anxiety Rating Scale', 'description': ""The Hamilton Anxiety Rating Scale is a clinician-rated measure of cognitive and somatic anxiety symptoms. It consists of 14 items, each of which is scored on a 0-4 scale, summed for a total score ranging from 0 to 56. Inclusion criteria for this study included a Hamilton score \\>= 17. The Hamilton, administered by blind raters, will be used to test hypotheses number 1 and 2. The outcome of interest is the number of participants who relapse, defined as having a Hamilton increase of \\>=5, for a total Hamilton \\>=14, relative to the end of the continuation phase (week 28), for a duration of at least 2 weeks, plus both clinician's and participant's judgment that the participant is experiencing a recurrence of anxiety symptoms. HAMA scores range from 0 (no anxiety) to 56 (high anxiety)."", 'timeFrame': '56 weeks'}, {'measure': 'Penn State Worry Questionnaire', 'description': 'The Penn State Worry Questionnaire is a 16-item measure of pathological worry. Scores range from 16-80, with higher scores indicating higher levels of worry.', 'timeFrame': '56 weeks'}]",[],2,60 Years,,ALL,False,Veterans Medical Research Foundation,OTHER,1,73.0,ACTUAL,2025-09-01T16:18:22.200282,v2_robust,True,True,True,False,False,
NCT01131065,Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients,Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients.,Hepatitis B immune globulin,"['Hepatitis B immune globulin', 'Niuliva']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Hepatitis B,"['Hepatitis B', 'Liver Transplantation']","['Hepatitis B', 'HBV', 'Orthotopic liver transplantation', 'Liver transplantation', 'Recurrence', 'Reinfection', 'Protective titers', 'HBsAb', 'Hepatitis B virus immune globulin', 'Niuliva']",COMPLETED,,2010-07,2014-06,"[{'measure': 'HBV Recurrence', 'description': 'HBV recurrence is measured by seroconversion or reappearance of HBsAg and HBV DNA positivity', 'timeFrame': 'First six and twelve months after liver transplantation'}, {'measure': 'HBsAb Pre-infusion Levels (Trough Levels Before Each Niuliva Administration)', 'timeFrame': 'Days 3 to 7, Weeks 2 to 4, Months 2 to 6, and Months 7 to 12'}]","[{'measure': 'Safety and Tolerance', 'description': 'Safety and tolerance to the product administration will be measured by the detection of adverse events or clinically relevant changes in vital signs.', 'timeFrame': 'During and after each product administration (during the 12 month treatment period)'}]",3,18 Years,70 Years,ALL,False,"Instituto Grifols, S.A.",INDUSTRY,0,15.0,ACTUAL,2025-09-01T16:18:22.200311,v2_robust,True,True,True,False,True,
NCT04901065,Xylocaine to Freeze During Unpleasant Nasopharyngeal Swabs,"Xylocaine to Freeze During Unpleasant Nasopharyngeal Swabs: a Randomized, Double-Blinded, Placebo Controlled-Trial",Xylocaine,"['Xylocaine', 'Xylocaine spray', 'Placebo']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Covid19,['Covid19'],[],COMPLETED,,2021-05-11,2021-06-07,"[{'measure': 'Pain during the procedure', 'description': 'Self-reported pain immediately after the NPS as measured using a validated self-reported pain scale: the Visual Analog Scale (VAS', 'timeFrame': 'During procedure'}]","[{'measure': 'Anxiety during the procedure', 'description': ""● Evaluation of fear prior to the administration of the study intervention and the NPS using the Children's Fear Scale"", 'timeFrame': 'During procedure'}, {'measure': 'Discomfort', 'description': 'Discomfort at administration of the study intervention using a yes/no question', 'timeFrame': 'During procedure'}, {'measure': 'Pain 2 NRS', 'description': 'Evaluation of pain immediately after the NPS using a clinically relevant tool, the verbal Numeric Rating Scale', 'timeFrame': 'During procedure'}, {'measure': 'Number of patients with physical restriction', 'description': 'Evaluation of the patient position (sitting, lying down, standing) and if physical restraints was done (none, redirection of movements, comfort position/minimal comfortable restriction or actively restrain) to perform the swab and to which extent', 'timeFrame': 'During procedure'}, {'measure': 'Utility according to nurses', 'description': '● Triage nurses evaluation on the efficiency of the intervention in reducing pain in the patient, using a likert scale of 1 to 5', 'timeFrame': 'During procedure'}, {'measure': 'Adverse event', 'description': 'Adverse effects reported by caregivers in the 24-48hrs following administration of medication', 'timeFrame': '48 hours following intervention'}, {'measure': 'Desire to reuse the intervention in a futur procedure, at follow up', 'description': 'Asking caregivers in the 24-48hrs following intervention if they would recommend the intervention before a NPS as standard of care for pediatric patients. Yes/no question.', 'timeFrame': '48 hours following intervention'}]",8,8 Years,17 Years,ALL,False,Evelyne D.Trottier,OTHER,0,88.0,ACTUAL,2025-09-01T16:18:22.200342,v2_robust,True,True,True,False,True,
NCT06081465,A Phase I Study of Single and Multiple Doses of VG290131 in Healthy Subjects,"A Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Orally Administered VG290131 in Healthy Adult Subjects",VG290131,['VG290131'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],RECRUITING,,2023-10-20,2024-12,"[{'measure': 'To evaluate the safety and tolerability of VG290131 by TEAEs', 'description': 'To evaluate the safety and tolerability of VG290131 after SAD and MAD doses to healthy volunteers by assessing the incidence, severity, and causality of treatment-emergent adverse events (TEAEs).', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate the safety and tolerability of VG290131 by 12-Lead ECG', 'description': 'To evaluate the safety and tolerability of VG290131 after SAD and MAD doses to healthy volunteers by assessing the number and percentage of subjects with clinically significant changes in 12-Lead ECG (RR, PR, QRSD, QT, and QTc).', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate the safety and tolerability of VG290131 by vital signs', 'description': 'To evaluate the safety and tolerability of VG290131 after SAD and MAD doses to healthy volunteers by assessing the number and percentage of subjects with clinically significant changes in vital signs (Blood pressure, heart rate, body temperature, and respiration rate).', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate the safety and tolerability of VG290131 by physical examinations', 'description': 'To evaluate the safety and tolerability of VG290131 after SAD and MAD doses to healthy volunteers by assessing the number and percentage of subjects with clinically significant changes in physical examinations (Skin and mucosa, lymph nodes, head, eyes, ears, nose, and throat (HEENT), chest, abdomen, spine and limbs, musculoskeletal system, and nervous system).', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate the safety and tolerability of VG290131 by clinical laboratory tests', 'description': 'To evaluate the safety and tolerability of VG290131 after SAD and MAD doses to healthy volunteers by assessing the number and percentage of subjects with clinically significant changes in clinical laboratory tests (hematology, coagulation, biochemistry and urine analysis).', 'timeFrame': 'From admission to discharge, up to 12 days.'}]","[{'measure': 'To evaluate PK parameter Cmax of VG290131 after a single dose', 'description': 'Cmax of VG290131 under fasted and fed conditions will be calculated after a single dose.', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate PK parameter Tmax of VG290131 after a single dose', 'description': 'Tmax of VG290131 under fasted and fed conditions will be calculated after a single dose.', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate PK parameter AUC0-t of VG290131 after a single dose', 'description': 'AUC0-t of VG290131 under fasted and fed conditions will be calculated after a single dose.', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate PK parameter AUC0-inf of VG290131 after a single dose', 'description': 'AUC0-inf of VG290131 under fasted and fed conditions will be calculated after a single dose.', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate PK parameter t1/2 of VG290131 after a single dose', 'description': 't1/2 of VG290131 under fasted and fed conditions will be calculated after a single dose.', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate PK parameter CL/F of VG290131 after a single dose', 'description': 'CL/F of VG290131 under fasted and fed conditions will be calculated after a single dose.', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate PK parameter Vz/F of VG290131 after a single dose', 'description': 'Vz/F of VG290131 under fasted and fed conditions will be calculated after a single dose.', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate PK parameter MRT of VG290131 after a single dose', 'description': 'MRT of VG290131 under fasted and fed conditions will be calculated after a single dose.', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate PK parameter λz of VG290131 after a single dose', 'description': 'λz of VG290131 under fasted and fed conditions will be calculated after a single dose.', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate PK parameter Cmax,ss of VG290131 after multiple doses', 'description': 'The maximum observed concentration at steady state (Cmax,ss) of VG290131 will be calculated after multiple doses from Day 1 to Day 7.', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate PK parameter Cmin,ss of VG290131 after multiple doses', 'description': 'The minimum observed concentration at steady state (Cmin,ss) of VG290131 will be calculated after multiple doses from Day 1 to Day 7.', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate PK parameter Cav,ss of VG290131 after multiple doses', 'description': 'The average concentration during a dosing interval at steady state (Cav,ss) of VG290131 will be calculated after multiple doses from Day 1 to Day 7.', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate PK parameter AUCss of VG290131 after multiple doses', 'description': 'The area under the concentration-time curve from zero to the end of the dosing interval at steady state (AUCss) of VG290131 will be calculated after multiple doses from Day 1 to Day 7.', 'timeFrame': 'From admission to discharge, up to 12 days.'}, {'measure': 'To evaluate PK parameter Rac of VG290131 after multiple doses', 'description': 'The accumulation ratio (Rac) of VG290131 will be calculated after multiple doses from Day 1 to Day 7.', 'timeFrame': 'From admission to discharge, up to 12 days.'}]",19,18 Years,45 Years,ALL,True,"Zhejiang Vimgreen Pharmaceuticals, Ltd.",INDUSTRY,1,86.0,ESTIMATED,2025-09-01T16:18:22.200387,v2_robust,True,True,False,False,True,
NCT05258565,TPA in Acute Stroke With COVID Verus Non-COVID-19 Patients,Tissue Plasminogen Activator (tPA) Therapy for Acute Ischemic Stroke in Covid -19 and Non Covid -19 Patients,IV tPA (Activase),"['IV tissue plasminogen activator', 'IV tPA (Activase)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Ischemic Stroke,['Acute Ischemic Stroke'],[],COMPLETED,,2022-03-01,2022-09-15,"[{'measure': 'primary out come', 'description': 'Barthel Index scale BIS (pre-post drug administration and 2 month later)The Barthel includes 10 personal activities: feeding, personal toileting, bathing, dressing and undressing, getting on and off a toilet, controlling bladder, controlling bowel, moving from wheelchair to bed and returning, walking on level surface (or propelling a wheelchair if unable to walk) and ascending and descending stairs.\n\nThe original Index is a three-item ordinal rating scale completed by a therapist or other observer in 2-5 minutes. Each item is rated in terms of whether the patient can perform the task independently, with some assistance, or is dependent on help based on observation (0=unable, 1=needs help, 2=independent). The final score is x 5 to get a number on a 100 point score. Proposed guidelines for interpreting Barthel scores are that scores of 0-20 indicate ""total"" dependency, 21-60 indicate ""severe"" dependency, 61-90 indicate ""moderate"" dependency, and 91-99 indicates ""slight"" dependency.', 'timeFrame': '2 months'}]","[{'measure': 'secondary outcome', 'description': ""NIHSS (pre-post drug administration and 2 month later a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items( Level of Consciousness ,Horizontal Eye Movement, Visual field test, Facial Palsy, Motor Arm, Motor Leg, Limb Ataxia ,Sensory, Language and Speech)\n\n, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.Score 0 means No stroke symptoms. score 1-4 means Minor stroke .Score 5-15 means Moderate stroke. score 16-20 means Moderate to severe stroke. Score 21-42 means Severe stroke"", 'timeFrame': '2 months'}]",2,18 Years,80 Years,ALL,True,Assiut University,OTHER,1,50.0,ACTUAL,2025-09-01T16:18:22.200394,v2_robust,True,True,True,False,False,
NCT00760565,A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).,"A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease",RO4905417,"['RO4905417', 'placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Peripheral Arterial Disease (PAD),['Peripheral Arterial Disease (PAD)'],[],COMPLETED,,2008-09,2011-06,"[{'measure': 'Safety: Adverse events; clinical laboratory tests; physical examination; vital signs including ECG.', 'timeFrame': 'Throughout study'}]","[{'measure': 'Pharmacodynamics: bleeding time; protein/vascular markers', 'timeFrame': 'Throughout study'}, {'measure': 'Pharmacokinetics of RO4905417', 'timeFrame': 'Throughout study'}]",3,18 Years,75 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,72.0,ACTUAL,2025-09-01T16:18:22.200455,v2_robust,True,True,True,False,True,
NCT00074165,Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen,"A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen",Rituxan,"['Etoposide', 'filgrastim', 'Etoposide phosphate', 'STS', 'Sodium thiosulfate', 'G-CSF', 'Rituxan', 'Cytarabine', 'Carboplatin', 'Rituximab', 'Pegfilgrastim', 'Cyclophosphamide', 'Neupogen', 'Neulasta']",14,INTERVENTIONAL,['PHASE2'],PHASE2,,Brain and Central Nervous System Tumors,"['Brain and Central Nervous System Tumors', 'Drug/Agent Toxicity by Tissue/Organ', 'Lymphoma', 'Thrombocytopenia']","['drug/agent toxicity by tissue/organ', 'thrombocytopenia', 'intraocular lymphoma', 'primary central nervous system non-Hodgkin lymphoma', 'primary central nervous system Hodgkin lymphoma']",TERMINATED,Lack of accrual,2003-01,2010-12,"[{'measure': 'Number of Participants With a Complete Response Rate to Chemotherapy Regimen Assessed by Radiographic Response at 2 Years.', 'description': 'Per RECIST criteria (v1.1) and assessed by magnetic resonance imaging (MRI): Complete response (CR), Disappearance of all target lesions.', 'timeFrame': '2 years'}]","[{'measure': 'Number of Participants With Overall Survival Assessed by Clinical and Radiographic Response', 'description': 'Overall survival is measured from entry onto study until death from any cause or until death or progression of disease, respectively.', 'timeFrame': '5 years'}, {'measure': 'Progression-free Survival Assessed by Clinical and Radiographic Response From First Day of Treatment Until Tumor Progression', 'timeFrame': '5 years'}, {'measure': 'Quality of Life Assessed by EORTC QOL Before Treatment and Then Every 3 Months', 'timeFrame': '5 years'}, {'measure': 'Ototoxicity Assessed by Audiology Hearing Test Done Monthly During Treatment', 'timeFrame': '2 years'}, {'measure': 'Effect of Sodium Thiosulfate (STS) on Granulocytes and Erythrocytes Assessed by Complete Blood Count Lab Values Done Weekly During Treatment', 'timeFrame': '2 years'}]",6,18 Months,75 Years,ALL,False,OHSU Knight Cancer Institute,OTHER,1,17.0,ACTUAL,2025-09-01T16:18:22.200466,v2_robust,True,True,False,True,False,Lack of accrual
NCT00586365,Naproxen for the Prevention of HO After Complex Elbow Trauma,Effectiveness of Naproxen for the Prevention of Heterotopic Ossification After Complex Elbow Trauma: a Prospective Randomized Trial,Naproxen,['Naproxen'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Heterotopic Ossification,['Heterotopic Ossification'],"['complex elbow trauma', 'prevention', 'complication', 'naproxen', 'NSAIDS']",WITHDRAWN,Too difficult to satisfy all the inclusion criteria.,2007-10,2010-10,"[{'measure': 'There is no difference in ulnohumeral flexion', 'timeFrame': '2 weeks'}]",[],1,18 Years,,ALL,True,Massachusetts General Hospital,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:22.200496,v2_robust,True,True,False,True,False,Too difficult to satisfy all the inclusion criteria.
NCT06095765,Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention,Colchicine in Belgium in Patients With Coronary Artery Disease,Colchicine 0.5 MG Oral Tablet,"['Colchicine 0.5 MG Oral Tablet', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Coronary Artery Disease,['Coronary Artery Disease'],"['percutaneous coronary intervention', 'colchicine']",RECRUITING,,2024-01-29,2028-03-01,"[{'measure': 'Time from randomisation to first occurrence of a composite endpoint consisting of: all-cause death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B & C), non-fatal stroke, or coronary revascularisation.', 'timeFrame': '44 months'}]","[{'measure': 'Time from randomisation to first occurrence of a composite of specific cardiovascular endpoints', 'description': 'Time from randomisation to first occurrence of a composite of: cardiovascular death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B \\& C), non-fatal stroke or coronary revascularisation', 'timeFrame': '44 months'}, {'measure': 'Time from randomisation to first occurrence of a composite of hard endpoints consisting of: all-cause death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B & C), non-fatal stroke', 'timeFrame': '44 months'}, {'measure': 'Time from randomisation to first occurrence of breakdown components of primary endpoint and atherosclerosis-related diseases', 'description': 'Time from randomisation to first occurrence of: all-cause death, cardiovascular death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B \\& C), non-fatal stroke, coronary revascularisation, ischemia driven coronary revascularisation, stent thrombosis, peripheral artery revascularisation, transient ischemic attack (TIA) treated with carotid revascularisation', 'timeFrame': '44 months'}, {'measure': 'Time from randomisation to occurrence of first as well as recurrent endpoints consisting of: all-cause death, spontaneous (non-procedural) non-fatal myocardial infarction (Type 1, 4B & C), non-fatal stroke, or coronary revascularisation.', 'timeFrame': '44 months'}, {'measure': 'Change from randomisation to year 1 and to end of study of participants reported outcomes (based on ICHOM Standard Set for CAD): Angina Frequency scale', 'description': 'Change from randomisation to year 1 and to end of study of participants reported outcomes:\n\nSeattle Angina Questionnaire (SAQ) Angina Frequency Scale: categorizes angina (chest pain) frequency as following: daily angina (score = 0-30), weekly angina (score = 31-60), monthly angina (score = 61-99), and no angina (score = 100). Higher score indicates better outcome.', 'timeFrame': '44 months'}, {'measure': 'Change from randomisation to year 1 and to end of study of participants reported outcomes (based on ICHOM Standard Set for CAD): Dyspnea', 'description': ""Change from randomisation to year 1 and to end of study of participants reported outcomes:\n\nDyspnea (Rose Dyspnea Scale): a four-item questionnaire that assesses a patients' dyspnea level with common activities. One point is assigned to each activity associated with dyspnea. Scores range from 0 to 4. Higher score indicates worse outcome."", 'timeFrame': '44 months'}, {'measure': 'Change from randomisation to year 1 and to end of study of participants reported outcomes (based on ICHOM Standard Set for CAD): Depression.', 'description': 'Change from randomisation to year 1 and to end of study of participants reported outcomes:\n\nDepression (Patient Health Questionnaire PHQ-2): inquires about the frequency of depressed mood and anhedonia. Scores range from 0 to 6. Higher score indicates worse outcome.', 'timeFrame': '44 months'}, {'measure': 'Change from randomisation to year 1 and to end of study of participants reported outcomes (based on ICHOM Standard Set for CAD): Health-related quality of life.', 'description': 'EuroQol five dimensions five level (EQ-5D-5L): consists of a descriptive system of self-perceived health status along fve dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and a visual analogue scale (VAS) which provides a self-rating of the general health status on a scale from 0 (worst imaginable state of health) to 100 (best imaginable state of health).', 'timeFrame': '44 months'}]",9,45 Years,,ALL,False,AZ Sint-Jan AV,OTHER,2,2770.0,ESTIMATED,2025-09-01T16:18:22.200504,v2_robust,True,True,False,False,False,
NCT06015165,Outcomes for Anesthesiologist-Led Care of Analgesic Protocol in Anorectal Surgery,Outcomes for Anesthesiologist-Led Care of Analgesic Protocol in Anorectal Surgery,Analgesia plan for Anes. Group,"['Analgesia plan for Anes. Group', 'Anes Group', 'Analgesia plan for Surg. Group', 'Surg. Group']",4,INTERVENTIONAL,['NA'],,,Postoperative Pain,['Postoperative Pain'],"['ambulatory surgery', 'anorectal surgery', 'postoperative analgesia', 'anesthesiologist-led care']",RECRUITING,,2024-09-10,2025-10-10,"[{'measure': 'the time of recovery of work and life after surgery day', 'description': 'not requiring any additional medication and resuming full pre-operative work life content', 'timeFrame': 'up to 21 days'}]","[{'measure': 'postoperative rest pain', 'description': 'postoperative rest pain in Numeric Rating Scales (NRS) 1-10, when 0 means painless, and 10 means the highest level of unbearable pain', 'timeFrame': 'up to 21 days'}, {'measure': 'postoperative defecation pain', 'description': 'postoperative defecation pain in Numeric Rating Scales (NRS) 1-10, when 0 means painless, and 10 means the highest level of unbearable pain', 'timeFrame': 'up to 21 days'}, {'measure': 'adverse reactions', 'description': 'adverse reactions including postoperative nausea and vomiting(PONV), dizziness, respiratory depression, etc.', 'timeFrame': 'up to 21 days'}, {'measure': ""patients' satisfaction"", 'description': ""patients' satisfaction self-rating 1-10"", 'timeFrame': 'up to 21 days'}, {'measure': 'total opioid use after surgery', 'description': 'Total opioid use from postoperative period till the discontinuation of surgery-related therapy.', 'timeFrame': 'up to 21 days'}]",6,18 Years,85 Years,ALL,False,China-Japan Friendship Hospital,OTHER,0,216.0,ESTIMATED,2025-09-01T16:18:22.200559,v2_robust,True,True,False,False,True,
NCT03871465,Effect of Combined Ultrasound-guided Subdeltoid Corticosteroid Injections and Physiotherapy in Treatment of Patients With Chronic Subacromial Bursitis,Effect of Combined Ultrasound-guided Subdeltoid Corticosteroid Injections and Physiotherapy in Treatment of Patients With Chronic Subacromial Bursitis,Triamcinolone SASD injection,"['Triamcinolone SASD injection', 'Triamcinolone injections & Physiotherapy']",2,INTERVENTIONAL,['NA'],,,Subacromial Bursitis,"['Subacromial Bursitis', 'Subacromial Impingement Syndrome', 'Physical Therapy', 'Therapeutic Exercise', 'Rehabilitation']","['subacromial bursitis', 'subacromial impingement syndrome', 'corticosteroid', 'physical therapy', 'therapeutic exercise', 'rehabilitation']",COMPLETED,,2018-08-01,2020-07-31,"[{'measure': 'The pain VAS score', 'description': 'The pain VAS score is obtained using a 100-mm-long horizontal line, with 0 mm on the left indicating no pain and 100 mm on the right indicating very severe pain.', 'timeFrame': 'change between baseline and at 8 weeks after the beginning of the treatment.'}, {'measure': 'The scores of the Shoulder Pain and Disability Index (SPADI)', 'description': 'The total SPADI score, which ranges between 0 and 100, is calculated by averaging the scores from the pain and disabilities subclasses.', 'timeFrame': 'change between baseline and at 8 weeks after the beginning of the treatment.'}]","[{'measure': 'The active ROM', 'description': 'The maximal active ROMs of the affected shoulder will be measured using a goniometer under the guidelines of the American Academy of Orthopedic Surgeons. These measurements included abduction in the frontal plane, forward flexion, internal rotation, and external rotation with the arm at 0 degrees of abduction.', 'timeFrame': 'change between baseline and at 8 weeks after the beginning of the treatment.'}, {'measure': 'Change of the Shoulder Disability Questionnaire (SDQ)', 'description': ""The SDQ is a symptoms-related questionnaire containing 16 items describing common situations that may induce symptoms in patients with shoulder disorders. By responding 'yes', 'no', or 'not applicable', the final score is obtained by dividing the number of positively scored items by the total number of applicable items and then multiplying this number by 100, which results in a final score ranging between 0 (no disability) and 100 (the worst situation)."", 'timeFrame': 'change between baseline and at 8 weeks after the beginning of the treatment.'}, {'measure': 'The Western Ontario Rotator Cuff Index (WORC).', 'description': 'It is composed of 5 subscales: physical symptoms, sports/recreation, work, lifestyle, and emotions. Each item has a score range of 0 to 100.Scores can be computed for individual subscales and summated for a total score, which can range from 0-2100, with a higher score representing lower quality of life.', 'timeFrame': 'change between baseline and at 8 weeks after the beginning of the treatment.'}]",5,20 Years,,ALL,False,Shin Kong Wu Ho-Su Memorial Hospital,OTHER,1,111.0,ACTUAL,2025-09-01T16:18:22.200574,v2_robust,True,True,True,False,False,
NCT05520567,"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy",Gilteritinib,"['Venclexta', 'Azacitidine', 'ASP2215', 'XOSPATA®', 'ABT199', 'Gilteritinib', 'Venetoclax']",7,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Acute Myeloid Leukemia (AML),"['Acute Myeloid Leukemia (AML)', 'FLT3-mutated Acute Myeloid Leukemia']","['Cancer', 'Acute Myeloid Leukemia', 'AML']",RECRUITING,,2023-01-31,2028-07-31,"[{'measure': 'Number of Participants with Dose Limiting Toxicities (DLTs)', 'description': 'A DLT is defined as any of the events meeting DLT criteria that occur with the first dose on Cycle 1 Day 1 (C1D1) and that is considered to be possibly or probably related to the study treatment regimen.', 'timeFrame': 'Up to 42 Days'}, {'measure': 'Number of Participants with Adverse Events (AEs)', 'description': 'An AE is any untoward medical occurrence in a patient or clinical study participant temporally associated with the use of study investigational product (IP), whether or not considered related to the study IP.\n\nAn AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study IP. This includes events related to the comparator and events related to the (study) procedures.', 'timeFrame': 'Up to 49 months'}, {'measure': 'Number of Participants with Serious AEs (SAEs)', 'description': 'An SAE is defined as any untoward medical occurrence that, at any dose:\n\n* results in death\n* is life threatening\n* requires inpatient hospitalization or prolongation of existing hospitalization\n* results in persistent or significant disability/incapacity\n* is a congenital anomaly/birth defect\n* other situations where medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed above. These events should usually be considered serious.', 'timeFrame': 'Up to 49 months'}, {'measure': 'Number of Participants with laboratory value abnormalities and/or AEs', 'description': 'Number of participants with potentially clinically significant laboratory values.', 'timeFrame': 'Up to 48 months'}, {'measure': 'Number or Participants with electrocardiogram (ECG) abnormalities and/or AEs', 'description': 'Number of participants with potentially clinically significant ECG values.', 'timeFrame': 'Up to 48 months'}, {'measure': 'Number of Participants with vital sign abnormalities and/or AEs', 'description': 'Number of participants with potentially clinically significant vital sign values.', 'timeFrame': 'Up to 48 months'}, {'measure': 'Number of Participants with physical exam abnormalities and/or AEs', 'description': 'Number of participants with potentially clinically significant physical exam values.', 'timeFrame': 'Up to 48 months'}, {'measure': 'Number of Participants at each grade of the Eastern Cooperative Oncology Group (ECOG) performance status scores', 'description': 'The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.', 'timeFrame': 'Up to 48 months'}, {'measure': 'Percentage of Participants with Complete Remission (CR)', 'description': 'CR rate is defined as the number of participants who achieve the best response of CR divided by the number of participants in the analysis population.\n\nCR is defined as participants having bone marrow regenerating normal hematopoietic cells and achieve a morphologic leukemia-free state and must have bone marrow blasts \\< 5% by morphological examination, absolute neutrophil count (ANC) \\> 1 x 10\\^9/L, platelet count \\> 100 x 10\\^9/L, and an absence of leukemic blasts in the peripheral blood by morphological examination. There should be no evidence of extramedullary disease. Other participants who do not relapse on study are considered nonevents and censored at the last', 'timeFrame': 'Up to 24 months'}, {'measure': 'Pharmacological activity by Plasma Inhibitory Activity Assay (PIA)', 'description': 'Inhibition of FLT3 phosphorylation after drug treatment will be determined relative to pretreatment phosphorylated FLT3 levels in participants to assess the relationship with gilteritinib dose. Phosphorylated FLT3 will be measured by plasma inhibitory activity (PIA) assay.', 'timeFrame': 'Up to 2 months'}, {'measure': 'Pharmacokinetics (PK) of ASP2215 in plasma: concentration', 'description': 'Concentration will be recorded from the PK plasma samples collected.', 'timeFrame': 'Up to 6 months'}]","[{'measure': 'Percentage of Participants with Complete Remission and Complete Remission with Partial Hematological Recovery (CR/CRh) rate', 'description': 'The CR/CRh rate is defined as the number of participants who achieved either CR or CRh at any of the post baseline visits divided by the number of participants in the analysis population.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Percentage of Participants with Composite Complete Remission (CRc)', 'description': 'CRc rate is defined as the number of participants who achieve the best response of CRc divided by the number of participants in the analysis population.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Duration of Remission (DOR)', 'description': 'Duration of remission includes duration of CRc, CR, CR/CRh, CRh, complete remission with incomplete hematologic recovery (CRi), complete remission with incomplete platelet recovery (CRp).\n\nDuration of CRc is defined as the time from the date of first CRc until the date of confirmed relapse or death due to any cause for participants who achieve CRc. Participants without confirmed relapse or death will be censored at their last relapse-free disease assessment date. The duration of CR, CR/CRh, CRh, CRp or CRi is defined similarly as duration of CRc.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Duration of Overall Survival (OS)', 'description': 'OS is defined as the time from the date of enrollment until the date of death from any cause. For a participant who is not known to have died by the end of study follow-up, OS is censored at the date of last contact.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Duration of Event free survival (EFS)', 'description': 'EFS is defined as the number of days from the date of enrollment to the date of earliest evidence of relapse, treatment failure, or death.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Pharmacokinetics (PK) of ASP2215 in plasma: area under the plasma concentration-time curve during a dosage interval (AUCtau)', 'description': 'AUCtau will be recorded from the PK plasma samples collected.', 'timeFrame': 'Up to 6 months'}, {'measure': 'PK of ASP2215 in plasma: maximum observed concentration (Cmax)', 'description': 'Cmax will be recorded from PK plasma samples collected.', 'timeFrame': 'Up to 6 months'}, {'measure': 'PK of ASP2215 in plasma: pre-dose trough concentration (Ctrough)', 'description': 'Ctrough will be recorded from PK plasma samples collected.', 'timeFrame': 'Up to 6 months'}, {'measure': 'PK of ASP2215 in plasma: area under the curve from time 0 to the time of the last measurable concentration (AUClast)', 'description': 'AUClast will be recorded from PK plasma samples collected.', 'timeFrame': 'Up to 6 months'}, {'measure': 'PK of ASP2215 in plasma: time to Cmax (tmax)', 'description': 'tmax will be recorded from PK plasma samples collected.', 'timeFrame': 'Up to 6 months'}, {'measure': 'Number of participants with negative minimal residual disease (MRD) status', 'description': 'MRD testing will be performed on left over bone marrow samples taken at different time points during the study, and at end of treatment.', 'timeFrame': 'Up to 48 months'}, {'measure': 'Transplantation rate', 'description': 'Transplantation rate is defined as the percentage of participants undergoing hematopoietic stem cell transplantation (HSCT) during the study treatment period.', 'timeFrame': '24 months'}]",23,18 Years,,ALL,False,"Astellas Pharma Global Development, Inc.",INDUSTRY,0,70.0,ESTIMATED,2025-09-01T16:18:22.200608,v2_robust,True,True,False,False,True,
NCT03025867,Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer,Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer,Niraparib,['Niraparib'],1,EXPANDED_ACCESS,[],,,Recurrent Ovarian Cancer,['Recurrent Ovarian Cancer'],[],APPROVED_FOR_MARKETING,,,,[],[],0,18 Years,,FEMALE,,"Tesaro, Inc.",INDUSTRY,0,,,2025-09-01T16:18:22.200721,v2_robust,False,True,False,False,False,
NCT03569267,A Study to Evaluate Safety and PK Profiles of OLX10010 in Healthy Subjects,"A Phase 1, Single Center, Placebo-controlled, Interventional Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles in Healthy Subjects Compared to Placebo",OLX10010,"['OLX10010', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Cicatrix, Hypertrophic","['Cicatrix, Hypertrophic']",[],COMPLETED,,2018-05-21,2019-06-27,"[{'measure': 'Number of subjects with treatment-related adverse events as assessed by CTCAE v4.0', 'description': 'Incidence and severity of adverse events; vital sign measurements; 12-lead electrocardiogram (ECG) parameters; incidence of clinical laboratory abnormalities, based on haematology, clinical chemistry, and urinalysis test results; analysis of coagulation parameters; physical examinations; local tolerability assessments of subcutaneous and intradermal injection sites', 'timeFrame': 'Day 14 (single dose)'}]",[],1,18 Years,60 Years,ALL,True,"Olix Pharmaceuticals, Inc.",INDUSTRY,0,48.0,ACTUAL,2025-09-01T16:18:22.200831,v2_robust,True,True,True,False,True,
NCT03762967,Autologous Adipose-Derived Adult Stromal Vascular Cell Administration for Male Patients With Infertility,Efficiency Evaluation of Adipose-Derived Adult Stromal Vascular Cells in Patients With Spermatogenesis Disorders.,Standard therapy.,"['Standard therapy.', 'healthy diet, physical exertion eliminate. hormone therapy.']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Azoospermia,"['Azoospermia', 'Oligozoospermia']","['Autologous Stem Cell', 'Male infertility', 'Adipose-Derived stem cell', 'Azoospermia', 'Oligospermia']",UNKNOWN,,2018-03-12,2021-12-30,"[{'measure': 'sperm concentration in ejaculate', 'description': 'Sperm quantity and quality will be evaluated with automatic sperm cout analyzer a month, two and three after injection of SVF. Total measures - 3.', 'timeFrame': '1, 2, 3 month'}, {'measure': 'Spermatozoa in testicular biopsy', 'description': 'Testicular sperm aspiration (TESA) will be performed after 3 month after SVF injection.', 'timeFrame': '3 month'}]","[{'measure': 'Testosterone', 'description': 'Testosterone will be measured a three month after injection of SVF.', 'timeFrame': '3 month'}, {'measure': 'Inhibin-B', 'description': 'Inhibin-B will be measured a three month after injection of SVF.', 'timeFrame': '3 month'}, {'measure': 'Follicle stimulating hormone (FSH)', 'description': 'Follicle stimulating hormone will be measured a three month after injection of SVF.', 'timeFrame': '3 month'}]",5,18 Years,60 Years,MALE,False,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:22.200841,v2_robust,True,True,False,False,False,
NCT00548067,"Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension","A Multi-center, Multiple Dose, Open-label, Four-cohort, Parallel Study to Assess the Pharmacokinetic Drug Interaction Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension.",Valsartan/hydrochlorothiazide (HCTZ),"['Valsartan/amlodipine/hydrochlorothiazide(HCTZ)', 'Valsartan/amlodipine', 'Valsartan/hydrochlorothiazide (HCTZ)', 'Amlodipine/hydrochlorothiazide(HCTZ)']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypertension,['Hypertension'],"['High blood pressure, hypertension, drug interaction, steady state, valsartan, hydrochlorothiazide, amlodipine']",COMPLETED,,2007-09,2008-03,[{'measure': 'Potential drug interaction and effect on blood level of drugs when co-administered for 17 days'}],[{'measure': 'Safety and tolerability of co-administered assessed by capturing adverse events and safety laboratory'}],2,18 Years,60 Years,ALL,False,Novartis,INDUSTRY,0,111.0,ACTUAL,2025-09-01T16:18:22.200865,v2_robust,True,True,True,False,True,
NCT02252367,Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms,"Double-blind, Placebo-controlled Study on Men With Lower Urinary Tract Symptoms to Assess Changes in Pressure Flow Study and in Molecular Profile of Prostatic Tissue After 12 Weeks Treatment With Tadalafil.",Tadalafil,"['Tadalafil', 'Cialis']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Prostatic Hyperplasia,"['Prostatic Hyperplasia', 'Lower Urinary Tract Symptoms']","['Phosphodiesterase 5 Inhibitors', 'BPH/LUTS']",COMPLETED,,2015-12,2020-06,"[{'measure': 'Improvement of LUTS/BPH symptoms', 'description': 'BPH-associated inflammatory symptoms will be assessed by using the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI). BPH-associated LUTS will be assessed by using International Prostate Symptom Score (IPSS).', 'timeFrame': '12 weeks'}]","[{'measure': 'Improvement of pressure flow study (PFS) parameters', 'description': 'Maximum flow rate (Qmax), average flow rate (Qave), voided volume (Vcomp), post void residual volume (PVR) will be evaluated. An abdominal ultrasound immediately after voiding for uroflowmetry will be performed in order to determine the PVR.', 'timeFrame': '12 weeks'}, {'measure': 'Volumetric change of the prostate', 'description': 'Prostate volume as assessed by transrectal ultrasound', 'timeFrame': '12 weeks'}, {'measure': 'Change in prostate inhomogeneity and in the number of prostatic macrocalcifications', 'description': 'BPH-associated prostate inhomogeneity and presence of micro-calcifications will be assessed by using male genital tract male genital tract colour-Doppler ultrasonography.', 'timeFrame': '12 weeks'}, {'measure': 'Variation in genic expression of prostatic inflammation markers', 'description': 'BPH-associated prostate inflammation, fibrosis, and hypoxia will be measured by immunohistochemical and quantitative RT-PCR (qRT-PCR) analyses of inflammatory-, fibrosis- and hypoxia-related markers.', 'timeFrame': '12 weeks'}, {'measure': 'Variation in serum inflammation markers CRP (C-reactive protein) and ESR (Erythrocyte Sedimentation Rate)', 'description': 'CRP measured on serum and ESR measured on blood drawn at baseline and after 12 weeks', 'timeFrame': '12 weeks'}, {'measure': 'Improvement in metabolic profile', 'description': 'Metabolic parameters will be evaluated (glycaemia, insulinemia, total cholesterol, HDL, triglycerides, HbA1c, mean arterial pressure, waist circumference, body mass index)', 'timeFrame': '12 weeks'}, {'measure': 'Variation in seminal plasma IL-8 (interleukin-8) levels', 'description': 'Seminal IL-8, a chemokine involved in male genital tract infection/inflammation, will be evaluated.', 'timeFrame': '12 weeks'}, {'measure': 'Improvement in erectile function', 'description': 'Erectile function will be assessed by using the International Index of Erectile Function-5 (IIEF-5) score.', 'timeFrame': '12 weeks'}]",9,18 Years,,MALE,False,University of Florence,OTHER,1,86.0,ACTUAL,2025-09-01T16:18:22.200921,v2_robust,True,True,True,False,False,
NCT06329167,Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery,Clinical Trial of Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery,Daphnetin,"['Aescuven', 'Daphnetin', 'gradient compression stocking']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Lower Extremity Lymphedema,['Lower Extremity Lymphedema'],"['Lower Extremity Lymphedema', 'gynaecological malignancy surgery', 'daphnetin', 'Aescuven']",RECRUITING,,2024-03-25,2025-07-31,"[{'measure': 'The difference in the circumference of the lower limbs', 'description': 'The patient was in the supine position with both lower limbs relaxed. The clinician measured the limb circumference at the dorsum of the foot, the lateral malleolus, the upper edge of the patella and 10 cm above and below with a tape measure and calculated the difference in limb circumference between the two lower limbs.', 'timeFrame': 'day 14, day 21, day 28'}, {'measure': 'Gynaecological Cancer Lymphedema Questionnaire', 'description': ""The GCLQ has good reliability and validity and is easy to administer. It is widely used in the diagnosis and assessment of lower extremity lymphoedema. The questionnaire consisted of 20 questions scored on 7 dimensions: heaviness, oedema (global), swelling (local), numbness, infection, pain and limb function. The answer 'yes' to each question was worth 1 point and the answer 'no' was worth 0 point. A total score of ≥4 points was considered to be lower limb lymphedema (see Appendix II)."", 'timeFrame': 'day 14, day 21, day 28'}, {'measure': 'Fibrinogen content', 'description': '2ml of peripheral venous blood was collected from patients and stored in EDTA anticoagulant test tubes. FIB was detected by automatic haemagglutination analyser (STAGO MAXR) in the laboratory department of our hospital.', 'timeFrame': 'day 14, day 21, day 28'}]",[],3,18 Years,75 Years,FEMALE,False,The First Hospital of Jilin University,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:22.200949,v2_robust,True,True,False,False,False,
NCT00744900,Pemetrexed Plus Cisplatin for Brain Metastasis of Advanced Non - Small Cell Lung Cancer (NSCLC),A Phase II Trial With Pemetrexed Plus Cisplatin as First Line Chemotherapy for Advanced Non - Small Cell Lung Cancer (NSCLC) Patients With Measurable Asymptomatic Brain Metastasis (GFPC 07-01/METAL).,"Pemetrexed, cisplatin","['Pemetrexed, cisplatin']",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Lung Cancer,['Lung Cancer'],"['Pemetrexed, Non-Small Cell Lung Cancer, brain metastasis']",COMPLETED,,2008-09,,"[{'measure': 'Objective of this study is overall response rate on brain metastasis according to RECIST criteria.', 'timeFrame': 'After cycles 2, 4 and 6 and every 6 weeks after study drug completion in absence of disease progression.'}]","[{'measure': 'Overall response rate, PFS after first-line CDDP plus pemetrexed, safety profile, quality of life, neurological symptoms and overall survival.', 'timeFrame': 'After cycles 2, 4 and 6 and every 6 weeks after study drug completion.'}]",2,18 Years,,ALL,False,"University Hospital, Brest",OTHER,0,45.0,ACTUAL,2025-09-01T16:18:22.201051,v2_robust,True,True,True,False,True,
NCT00687700,A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers,A Study to Investigate the Relative Pharmacological Activity of Aninhaled B2-agonist/Anticholinergic Dual Pharmacophore Inhealthy Volunteers,GSK961081,"['Propranolol', 'GSK961081', 'GSK961081 matching placebo', 'Propranolol matching placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,"Pulmonary Disease, Chronic Obstructive","['Pulmonary Disease, Chronic Obstructive']","['propranolol', 'B2-agonist,', 'B-antagonist,']",COMPLETED,,2008-03-10,2008-05-27,"[{'measure': 'To assess the bronchodilation of single doses of GSK961081 over 24 hours following ß blockade with the ß antagonist propranolol as measured by sGaw in healthy subjects.', 'timeFrame': 'Up to 32 hours'}]","[{'measure': 'Assess safety of GSK961081 after single doses of it with&without ß blockade with propranolol as measured by specific indicators', 'timeFrame': 'Up to 71 days'}, {'measure': 'Adverse events, clinical laboratory safety tests, FEV1, vital signs, 12-lead ECG parameters, blood glucose and serum potassium.', 'timeFrame': 'Up to 71 days'}, {'measure': 'Propranolol and GSK961081blood levels to derive pharmacokinetics', 'timeFrame': 'Up to 32 hours'}, {'measure': 'Assess systemic pharmacokinetics of GSK961081 and propranolol after single doses of both', 'timeFrame': 'Up to 32 hours'}]",5,18 Years,50 Years,MALE,True,Theravance Biopharma,INDUSTRY,1,23.0,ACTUAL,2025-09-01T16:18:22.201116,v2_robust,True,True,True,False,True,
NCT01517100,The Role of Endocannabinoids in Insulin Production and Action,The Roles of Endocannabinoids in Insulin Secretion and Action,"CP-945,598","['CP-945,598']",1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['Glucose', 'Insulin Secretion', 'Insulin Action', 'Endocannabinoids', 'Insulin', 'Metabolism']",COMPLETED,,2012-01-05,2014-10-06,"[{'measure': 'Changes in insulin sensitivity.', 'description': 'This study will give us a better understanding of the regulators of insulin secretion from B cells and insulin sensitivity in humans and this new understanding is of importance to finding new treatments for type 2 diabetes', 'timeFrame': 'CB1R antagonist CP-945,598 will enhance while CR receptor agonist nabilone will suppress first phase insulin response fromB cells in humans'}]","[{'measure': 'Changes in insulin and other hormones and the brain response to picture of food items evidenced by functional MRI of the brain.', 'timeFrame': '90 minutes'}]",2,21 Years,55 Years,ALL,False,National Institute on Aging (NIA),NIH,0,45.0,ACTUAL,2025-09-01T16:18:22.201156,v2_robust,True,True,True,False,False,
NCT03420300,EBR/GZR for HCV-1b Patients Receiving Hemodialysis,Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis,EBR/GZR,"['Zepatier', 'EBR/GZR']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Hepatitis C,['Hepatitis C'],"['Hepatitis C virus', 'Hemodialysis', 'Direct acting antiviral agent']",COMPLETED,,2018-06-05,2020-02-03,"[{'measure': 'Sustained Virologic Response (SVR12) Rate', 'description': 'Proportion of patients who had undetectable serum HCV RNA 12 weeks after the completion of elbasvir/grazoprevir (EBR/GZR)', 'timeFrame': '24 weeks'}]","[{'measure': 'Treatment-emergent Adverse Event (AE)-Related Withdrawal Rate', 'description': 'Proportion of participants who withdrew from the study due to any adverse events (AEs) which were judged related to elbasvir/grazoprevir (EBR/GZR)', 'timeFrame': '12 weeks'}, {'measure': 'Sustained Virologic Response (SVR24) Rate', 'description': 'Proportion of patients who had undetectable serum HCV RNA 24 weeks after the completion of elbasvir/grazoprevir (EBR/GZR)', 'timeFrame': '36 weeks'}, {'measure': 'Rapid Virologic Response (RVR) Rate', 'description': 'Proportion of patients who had undetectable serum HCV RNA at week 4 of elbasvir/grazoprevir (EBR/GZR) treatment', 'timeFrame': '4 weeks'}, {'measure': 'End-of-treatment Virological Response (EOTVR) Rate', 'description': 'Proportion of patients who had undetectable serum HCV RNA at the time point of treatment completion for elbasvir/grazoprevir (EBR/GZR)', 'timeFrame': '12 weeks'}, {'measure': 'Week 12 Virologic Response (W12VR)', 'description': 'Proportion of patients who completed 12 weeks of elbasvir/grazoprevir (EBR/GZR) treatment and who had undetectable serum HCV RNA at week 12 of treatment', 'timeFrame': '12 weeks'}]",6,20 Years,,ALL,False,National Taiwan University Hospital,OTHER,1,40.0,ACTUAL,2025-09-01T16:18:22.201168,v2_robust,True,True,True,False,True,
NCT01807000,"Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers","A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C] Prucalopride Succinate Following a Single Oral Dose in Healthy Male Subjects",Radiolabeled Prucalopride Succinate,['Radiolabeled Prucalopride Succinate'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2013-03-18,2013-04-28,"[{'measure': 'Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled Prucalopride Succinate', 'description': 'AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.', 'timeFrame': 'Over 240 hours post-dose'}, {'measure': 'Maximum Plasma Concentration (Cmax) of Radiolabelled Prucalopride Succinate', 'description': 'Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administered.', 'timeFrame': 'Over 240 hours post-dose'}, {'measure': 'Time to Maximum Plasma Concentration (Tmax) of Radiolabelled Prucalopride Succinate', 'description': 'Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.', 'timeFrame': 'Over 240 hours post-dose'}, {'measure': 'Plasma Half-Life (T1/2) of Radiolabelled Prucalopride Succinate', 'description': 'The time it takes for the blood plasma concentration of a substance to halve.', 'timeFrame': 'Over 240 hours post-dose'}, {'measure': 'Total Body Clearance (CL/F) of Radiolabelled Prucalopride Succinate', 'description': 'The rate at which a drug is removed from the body.', 'timeFrame': 'Over 240 hours post-dose'}, {'measure': 'Volume of Distribution (Vz/F) of Radiolabelled Prucalopride Succinate', 'description': 'The distribution of a medication between plasma and the rest of the body.', 'timeFrame': 'Over 240 hours post-dose'}, {'measure': 'AUC 0→∞ Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate', 'timeFrame': 'Over 240 hours post-dose'}, {'measure': 'Cmax Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate', 'timeFrame': 'Over 240 hours post-dose'}, {'measure': 'Tmax Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate', 'timeFrame': 'Over 240 hours post-dose'}, {'measure': 'Half-Life Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate', 'timeFrame': 'Over 240 hours post-dose'}, {'measure': 'AUC 0→∞ Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate', 'timeFrame': 'Over 240 hours post-dose'}, {'measure': 'Cmax Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate', 'timeFrame': 'Over 240 hours post-dose'}, {'measure': 'Tmax Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate', 'timeFrame': 'Over 240 hours post-dose'}, {'measure': 'Half-Life Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate', 'timeFrame': 'Over 240 hours post-dose'}, {'measure': 'Percent Total Radioactivity Excreted in Urine of Radiolabelled Prucalopride Succinate', 'timeFrame': '240 hours post-dose'}, {'measure': 'Percent Total Radioactivity Excreted in Stool of Radiolabelled Prucalopride Succinate', 'timeFrame': 'Over 240 hours post-dose'}]",[],16,18 Years,50 Years,MALE,True,Shire,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:22.201188,v2_robust,True,True,True,False,False,
NCT02400307,Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function,"A Phase 1, Open-Label, Parallel-Group, Adaptive Single-dose Study to Evaluate the Pharmacokinetics of GS-9883 in Subjects With Normal and Impaired Renal Function",Bictegravir,"['Bictegravir', 'GS-9883']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,HIV,['HIV'],"['Phase 1', 'Renally Impaired']",COMPLETED,,2015-04-17,2015-07-13,"[{'measure': 'Pharmacokinetic (PK) Parameter: AUCinf of Bictegravir (Total)', 'description': 'AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1'}, {'measure': 'PK Parameter: AUCinf of Bictegravir (Free)', 'description': 'Free AUCinf was calculated based on unbound plasma bictegravir (AUCinf × percentage unbound bictegravir ÷ 100 for each participant).', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1'}, {'measure': 'PK Parameter: AUClast of Bictegravir (Total)', 'description': 'AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1'}, {'measure': 'PK Parameter: AUClast of Bictegravir (Free)', 'description': 'Free AUClast was calculated based on unbound plasma bictegravir (AUClast × percentage unbound bictegravir ÷ 100 for each participant).', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1'}, {'measure': 'PK Parameter: Cmax of Bictegravir (Total)', 'description': 'Cmax is defined as the maximum observed plasma concentration of drug.', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1'}, {'measure': 'PK Parameter: Cmax of Bictegravir (Free)', 'description': 'Free Cmax was calculated based on unbound plasma bictegravir (Cmax × percentage unbound bictegravir ÷ 100 for each participant).', 'timeFrame': 'Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1'}]","[{'measure': 'Percentage of Participants Who Experienced Treatment-Emergent Adverse Events', 'description': 'Treatment-emergent adverse events (TEAEs) are defined as any adverse events (AEs) with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.', 'timeFrame': 'First dose date to Day 31'}, {'measure': 'Percentage of Participants Who Experienced Treatment-Emergent Laboratory Abnormalities', 'description': 'A treatment-emergent graded laboratory abnormality was defined as an increase of at least 1 abnormality grade from the predose assessment and occurring after the predose visit and on or before the date of the administration of study drug plus 30 days. The most severe graded abnormality from all tests was counted for each participant. Toxicity grade was defined as follows: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, and Grade 4 = Life-threatening.', 'timeFrame': 'First dose date to Day 31'}]",8,18 Years,79 Years,ALL,True,Gilead Sciences,INDUSTRY,0,19.0,ACTUAL,2025-09-01T16:18:22.201372,v2_robust,True,True,True,False,True,
NCT01156207,Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure,Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure: Effects of Endothelial Progenitor Cells and a Direct Renin Inhibitor,Aliskiren,['Aliskiren'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Heart Failure,['Heart Failure'],"['To establish the coupling between components of arterial load ( and components of LV myocardial deformations at baseline and 6 months after randomization.', 'To establish the role of EPCs on modulation of the components of arterial load and LV myocardial deformations and their coupling.']",UNKNOWN,,2010-07,,"[{'measure': 'LV systolic function, the global longitudinal strain', 'description': 'During 1-year treatment, ventricular systolic functions would be measured by using speckle tracking and presented as global longitudinal, circumferential, and radial strain at baseline and at the end of study. The changes of strain would be compared between 2 study groups.', 'timeFrame': '1 year'}]","[{'measure': 'plasma NT-proBNP level', 'description': 'After 1 year, plasma NT-proBNP will be re-checked. The differences between on-treatment and baseline NT-proBNP levels will be compared between 2 groups.', 'timeFrame': '1 year'}]",2,18 Years,90 Years,ALL,False,"Taipei Veterans General Hospital, Taiwan",OTHER_GOV,1,120.0,ESTIMATED,2025-09-01T16:18:22.201516,v2_robust,True,True,False,False,False,
NCT01019707,Safety Assessment of Atomoxetine With MA IV Administration,"A Study to Assess the Cardiovascular, Cognitive and Subjective Effects of Atomoxetine in Combination With Intravenous Methamphetamine","Atomoxetine, then Placebo","['Placebo, then Atomoxetine', 'Strattera', 'Atomoxetine, then Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Methamphetamine Abuse,"['Methamphetamine Abuse', 'Methamphetamine Dependence']","['crystal meth', 'methamphetamine', 'substance abuse']",TERMINATED,End in funding,2009-10,2010-12,"[{'measure': 'Systolic Blood Pressure', 'description': 'Based on 8 timepoints post MA infusion, data were pooled and the mean value and standard deviation are presented. Timepoints assessed were collected at 2, 5, 10, 15, 30, 45, 60, 90 minutes following infusion.', 'timeFrame': 'Timepoints post MA infusion'}, {'measure': 'Diastolic Blood Pressure', 'description': 'Based on 8 timepoints post MA infusion, data were pooled and the mean value and standard deviation are presented. Timepoints assessed were collected at 2, 5, 10, 15, 30, 45, 60, 90 minutes following infusion.', 'timeFrame': 'Timepoints post MA infusion'}, {'measure': 'Heart Rate', 'description': 'Based on 8 timepoints post MA infusion, data were pooled and the mean value and standard deviation are presented. Timepoints assessed were collected at 2, 5, 10, 15, 30, 45, 60, 90 minutes following infusion.', 'timeFrame': 'Timepoints post MA infusion'}]",[],3,18 Years,50 Years,ALL,False,"University of California, Los Angeles",OTHER,1,6.0,ACTUAL,2025-09-01T16:18:22.201528,v2_robust,True,True,False,True,False,End in funding
NCT02509507,Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611,"A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and to Evaluate the Efficacy and Safety of Intratumoral Talimogene Laherparepvec in Combination With Systemic Pembrolizumab to Treat Subjects With Advanced Solid Tumors in Phase 2 (MASTERKEY-318)",Talimogene Laherparepvec,"['Talimogene Laherparepvec', 'Pembrolizumab']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Hepatocellular Carcinoma,"['Hepatocellular Carcinoma', 'Liver Metastases', 'Cutaneous or Subcutaneous Lymph Node', 'Liver Tumors']",['Liver tumours'],COMPLETED,,2016-02-05,2023-07-11,"[{'measure': 'Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)', 'description': 'All toxicities were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03:\n\n* Grade 1: Mild\n* Grade 2: Moderate\n* Grade 3: Severe or medically significant but not immediately life threatening\n* Grade 4: Life threatening consequences\n* Grade 5: Death related to adverse event (AE)\n\nThe occurrence of specific pre-defined toxicities during the DLT evaluation period were considered a DLT if judged by the investigator to be related to talimogene laherparepvec and/or pembrolizumab.\n\nAll Grade 5 toxicities, intolerable toxicities that lead to permanent discontinuation of talimogene laherparepvec and/or pembrolizumab and Grade 3 or higher AEs related to talimogene laherparepvec and/or pembrolizumab that resulted in a study treatment delay by \\> 2 weeks were considered DLTs.', 'timeFrame': 'Cycle 1 and Cycle 2: Day 1 to Day 21'}, {'measure': 'Part 2 Only: Objective Response Rate (ORR) Per Modified Immune-related Response Criteria Simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST).', 'description': 'ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) per modified irRC-RECIST.\n\n* CR: Disappearance of all lesions (whether measurable or not and whether baseline or new) and confirmation by a repeat, consecutive assessment no less than 4 weeks (28 days) from the date first documented. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n* PR: Decrease in tumor burden ≥ 30% relative to baseline confirmed by a consecutive assessment at least 4 weeks (28 days) after first documentation.', 'timeFrame': 'Up to 154 weeks'}, {'measure': 'Part 2 Only: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)', 'description': 'A TEAE was defined as an event that emerged during treatment, having been absent pretreatment, or worsened relative to the pretreatment state.\n\nA treatment-related TEAE was defined as a TEAE that was suspected to be related to the study treatment.', 'timeFrame': 'Day 1 to 30 days post-last dose of talimogene laherparepvec or pembrolizumab, whichever is later. The maximum duration of talimogene laherparepvec treatment was 102.4 weeks and pembrolizumab treatment was 109.3 weeks in Part 2.'}]","[{'measure': 'Part 1 Only: ORR Per Modified irRC-RECIST', 'description': 'ORR was defined as the percentage of participants with a best overall response of CR or PR per modified irRC-RECIST.\n\n* CR: Disappearance of all lesions (whether measurable or not and whether baseline or new) and confirmation by a repeat, consecutive assessment no less than 4 weeks (28 days) from the date first documented. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n* PR: Decrease in tumor burden ≥ 30% relative to baseline confirmed by a consecutive assessment at least 4 weeks (28 days) after first documentation.', 'timeFrame': 'Up to 297 weeks'}, {'measure': 'Best Overall Response (BOR) Per Modified irRC-RECIST', 'description': 'BOR was defined as the number of participants with a best visit response in the following order: CR, PR, stable disease (SD), progressive disease (PD), or unevaluable (UE) as per modified irRC-RECIST.\n\n* CR: Disappearance of all lesions and confirmation by assessment no less than 4 weeks (28 days) from the date first documented. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n* PR: Decrease in tumor burden ≥ 30% relative to baseline confirmed by a consecutive assessment at least 4 weeks (28 days) after first documentation.\n* SD: Neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD.\n* PD: Increase in tumor burden ≥ 20 % and at least 5 mm absolute increase relative to nadir confirmation by a repeat, consecutive assessment no less than 4 weeks (28 days) from the date first documented PD.\n* UE: Any lesion present at baseline which was not assessed or was unable to be evaluated.', 'timeFrame': 'Up to 297 weeks'}, {'measure': 'Durable Response Rate (DRR) Per Modified irRC-RECIST', 'description': 'DRR per modified irRC-RECIST was defined as the percentage of participants with an objective response (CR/PR) with a duration of response of at least 6 months.\n\n* CR: Disappearance of all lesions and confirmation by assessment no less than 4 weeks (28 days) from the date first documented. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n* PR: Decrease in tumor burden ≥ 30% relative to baseline confirmed by a consecutive assessment at least 4 weeks (28 days) after first documentation.', 'timeFrame': 'Up to 297 weeks'}, {'measure': 'Duration of Response (DOR) Per Modified irRC-RECIST', 'description': 'DOR per modified irRC-RECIST was defined as the time from the date of an initial response (CR/PR) that was subsequently confirmed to the earlier of PD or death. DOR was estimated using the Kaplan-Meier method.\n\n* CR: Disappearance of all lesions and confirmation by assessment no less than 4 weeks (28 days) from the date first documented. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n* PR: Decrease in tumor burden ≥ 30% relative to baseline confirmed by a consecutive assessment at least 4 weeks (28 days) after first documentation.\n* PD: Increase in tumor burden ≥ 20 % and at least 5 mm absolute increase relative to nadir confirmation by a repeat, consecutive assessment no less than 4 weeks (28 days) from the date first documented PD.', 'timeFrame': 'Up to 297 weeks'}, {'measure': 'Disease Control Rate (DCR) Per Modified irRC-RECIST', 'description': 'DCR per modified irRC-RECIST was defined as percentage of participants that had a BOR in 1 of the following: CR, PR or SD.\n\n* CR: Disappearance of all lesions and confirmation by assessment no less than 4 weeks (28 days) from the date first documented. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n* PR: Decrease in tumor burden ≥ 30% relative to baseline confirmed by a consecutive assessment at least 4 weeks (28 days) after first documentation.\n* SD: Neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD.', 'timeFrame': 'Up to 297 weeks'}, {'measure': 'Progression Free Survival (PFS) Per Modified irRC-RECIST', 'description': 'PFS was defined as the time from first dose to the date of first of PD per modified irRC-RECIST criteria, or death, whichever occurs first. PFS was estimated using the Kaplan-Meier method. Participants that did not have an event of death or disease progression were censored at the latter of their last evaluable tumor assessment date or first dose date.\n\n* PD: Increase in tumor burden ≥ 20 % and at least 5 mm absolute increase relative to nadir confirmation by a repeat, consecutive assessment no less than 4 weeks (28 days) from the date first documented PD.', 'timeFrame': 'Up to 297 weeks'}, {'measure': 'Overall Survival (OS)', 'description': 'OS was defined as the time from the date of first dose date to the date of death from any cause. OS time was censored at the last date the participant was known to be alive when the confirmation of death was absent or unknown, or at the date 24 months after the last participant enrolled if the last known to be alive/death date was beyond it. One month = 365.25/12 days. OS was estimated using the Kaplan-Meier method.', 'timeFrame': 'Up to 297 weeks'}, {'measure': 'Part 1 Only: Number of Participants Who Experienced a TEAE', 'description': 'A TEAE was defined as an event that emerged during treatment, having been absent pretreatment, or worsened relative to the pretreatment state.\n\nA treatment-related TEAE was defined as a TEAE that was suspected to be related to the study treatment.', 'timeFrame': 'Day 1 to 30 days post-last dose of talimogene laherparepvec or pembrolizumab, whichever is later. The maximum duration of talimogene laherparepvec treatment was 34.1 weeks and pembrolizumab treatment was 98.3 weeks in Part 1.'}, {'measure': 'Percentage of Participants With Detectable Talimogene Laherparepvec Deoxyribonucleic Acid (DNA) in Blood', 'description': 'Blood samples were tested using real-time polymerase chain reaction (qPCR). Detectable DNA was defined as a positive result by qPCR analysis.', 'timeFrame': 'Week 1 to Week 10'}, {'measure': 'Percentage of Participants With Detectable Talimogene Laherparepvec DNA in Urine', 'description': 'Urine samples were tested using qPCR. Detectable DNA was defined as a positive result by qPCR analysis.', 'timeFrame': 'Week 1 to Week 10'}, {'measure': 'Percentage of Participants With Clearance of Talimogene Laherparepvec in Blood', 'description': 'Blood samples were tested using qPCR.\n\nA participant was defined as having cleared talimogene laherparepvec if a negative qPCR in a sample was obtained following a prior positive test and if there were no subsequent positive test results in the same cycle.', 'timeFrame': 'Cycles 2, 3 and 4: Day 1 pre-dose. Each cycle was 21 days.'}, {'measure': 'Percentage of Participants With Clearance of Talimogene Laherparepvec in Urine', 'description': 'Urine samples were tested using qPCR.\n\nA participant was defined as having cleared talimogene laherparepvec if a negative qPCR in a sample was obtained following a prior positive test and if there were no subsequent positive test results in the same cycle.', 'timeFrame': 'Cycles 2, 3 and 4: Day 1 pre-dose. Each cycle was 21 days.'}, {'measure': 'Percentage of Participants With Detectable Talimogene Laherparepvec DNA at the Surface of Injection Site', 'description': 'The number of participants with positive qPCR and subsequent positive plaque assays were evaluated from swabs of skin surface of injections. Detectable DNA was defined as a positive result by qPCR analysis.', 'timeFrame': 'Week 1 to Week 10'}, {'measure': 'Percentage of Participants With Detectable Talimogene Laherparepvec Virus at the Surface of Injection Site', 'description': 'The percentage of participants with detectable virus were evaluated from swabs of skin surface of injections. Detectable virus was defined as a positive result by TCID50.', 'timeFrame': 'Week 1 to Week 10'}, {'measure': 'Percentage of Participants With Detectable Talimogene Laherparepvec DNA at the Exterior of the Occlusive Dressing', 'description': 'The percentage of participants with positive qPCR and subsequent positive plaque assays were evaluated from swabs of the exterior of the occlusive dressing. Detectable DNA was defined as a positive result by qPCR analysis.', 'timeFrame': 'Week 1 to Week 7'}, {'measure': 'Percentage of Participants With Detectable Talimogene Laherparepvec Virus at the Exterior of the Occlusive Dressing', 'description': 'The percentage of participants with detectable virus were evaluated from swabs of the exterior of the occlusive dressings. Detectable virus was defined as a positive result by TCID50.', 'timeFrame': 'Week 1 to Week 7'}, {'measure': 'Percentage of Participants With Detectable Talimogene Laherparepvec DNA at the Oral Mucosa', 'description': 'The percentage of participants with positive qPCR and subsequent positive plaque assays were evaluated from swabs of the oral mucosa. Detectable DNA was defined as a positive result by qPCR analysis.', 'timeFrame': 'Part 1: Week 1 to Week 37. Part 2: Week 1 to Week 43'}, {'measure': 'Percentage of Participants With Detectable Talimogene Laherparepvec Virus at the Oral Mucosa', 'description': 'The percentage of participants with detectable virus were evaluated from swabs of the oral mucosa. Detectable virus was defined as a positive result by TCID50.', 'timeFrame': 'Week 1 to Week 7'}, {'measure': 'Percentage of Participants With Detectable Talimogene Laherparepvec DNA in Lesions Suspected to be Herpetic in Origin', 'description': 'The percentage of participants with positive qPCR were evaluated in any swab of a lesion suspected to be herpetic in origin. Detectable DNA was defined as a positive result by qPCR analysis.\n\nParticipants returned to the clinic within 3 days of the occurrence of reportable lesion suspected to be herpetic in origin such as cold sores or vesicles. The lesion was evaluated by the Investigator and swabbed if herpes simplex virus infection was suspected.', 'timeFrame': 'Day 1 to 30 days post-last dose of talimogene laherparepvec. The maximum duration of talimogene laherparepvec treatment was 102.4 weeks and pembrolizumab treatment was 109.3 weeks.'}]",22,18 Years,,ALL,False,Amgen,INDUSTRY,1,127.0,ACTUAL,2025-09-01T16:18:22.201654,v2_robust,True,True,True,False,True,
NCT05346107,PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer,PLD Plus Cyclophosphamide Followed by Nab-paclitaxel (Nab-P) as Primary Chemotherapy Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer: A Single-arm Phase 2 Trial(Brecan Trial),"pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage","['pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage']",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,"['Breast Cancer', 'HER2-positive Breast Cancer']",[],UNKNOWN,,2020-01-01,2023-12-31,"[{'measure': 'Rate of pathological complete response', 'description': 'absence of invasive carcinoma in the breast and axillary lymph nodes, while residual ductal carcinoma in situ was accepted (ypT0orTisypN0)', 'timeFrame': 'At the end of Cycle 1 (each cycle is 14 days)'}]","[{'measure': 'adverse effects', 'description': 'Serious adverse effect occur within neoadjuvant chemotherapy', 'timeFrame': 'during the period of neadjuvant chemotherapy, an average of 14 days'}]",2,18 Years,80 Years,FEMALE,False,Xijing Hospital,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:22.201711,v2_robust,True,True,False,False,True,
NCT03703492,Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS,Positron Emission Tomography/Magnetic Resonance Imaging of Estrogen Receptor Expression n Non-Invasive Breast Cancer,(18F)FES,"['MultiHance', '(18F)FES', '11.2 16α-[18F]-fluoro-17β-estradiol', 'Gadobenate dimeglumine', 'FES']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,"['Breast Cancer', 'Ductal Carcinoma in Situ - Category']",[],COMPLETED,,2019-01-03,2024-01-02,"[{'measure': '18F-FES Uptake in DCIS', 'description': '18F-FES uptake of biopsy-proven ductal carcinoma in situ (DCIS) measured using PET/MRI will be reported in Standardized Uptake Values (SUV).', 'timeFrame': '1 day'}]","[{'measure': 'Prognostic Risk Categories Determined Using Van Nuys Prognostic Index, the MSKCC Nomogram', 'description': 'ROC curve analysis will be performed to determine the optimal cut-point for 18F-FES SUVmax to distinguish low-risk DCIS and intermediate/high-risk DCIS. Risk categories will be determined using the Van Nuys Prognostic Index, the Memorial Sloan-Kettering Cancer Center Nomogram, and the research-based Oncotype DX DCIS score. Sensitivity and specificity will be determined with two-sided 95% confidence intervals. The area under the curve (AUCs) for the ROCs and their respective two-sided 95% confidence intervals will be calculated using logistic regression.\n\nThe optimal cut-off point will be determined by considering the 18F-FES uptake value with the maximum sensitivity and specificity.\n\nThis analysis will be done separately for each risk assessment model.', 'timeFrame': '2 months'}, {'measure': 'Research-based Oncotype DX DCIS Scores', 'description': ""To estimate the association of quantitative 18F-FES uptake (continuous SUVmax) with research-based Oncotype DX DCIS scores (0-100), scatter plots of continuous quantitative 18F-FES uptake (SUVmax) on the y-axis and research-based Oncotype DX DCIS scores (unitless) on the x-axis will be created to explore the distribution of the measurements. Pearson's or Spearman's rank correlation will be used to evaluate the association between quantitative 18F-FES uptake and research-based Oncotype DX DCIS score. The correlation coefficient (rho) and 95% confidence interval will be reported."", 'timeFrame': '12 months'}, {'measure': 'Number of Participants With Invasive Cancer at Surgical Excision', 'description': 'This percentage will be calculated by dividing the number of patients with invasive breast cancer diagnosed at the time of surgical excision by the number of patients with percutaneous biopsy-proven DCIS in the study.', 'timeFrame': '2 months'}, {'measure': 'Serum Estradiol Levels', 'description': 'Mean serum estradiol levels will be reported to summarize the outcome measure.', 'timeFrame': '1 day'}, {'measure': 'Serum Sex Hormone Binding Globulin Levels', 'description': ""A correlation analysis of sex hormone binding globulin levels will be performed using Pearson's or Spearman's rank correlation. Scatter plots, correlation coefficients (rho) and 95% confidence intervals will be reported."", 'timeFrame': '1 day'}]",6,18 Years,,FEMALE,False,"University of Wisconsin, Madison",OTHER,2,12.0,ACTUAL,2025-09-01T16:18:22.201803,v2_robust,True,True,True,False,False,
NCT00164892,Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial,Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial,Oral Vioxx (Rofecoxib),['Oral Vioxx (Rofecoxib)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Cancer of Stomach,['Cancer of Stomach'],[],UNKNOWN,,2004-10,,[{'measure': 'Recurrence free survival and the quality of life score within the two years of study period'}],[{'measure': 'Overall survival in long term'}],2,18 Years,80 Years,ALL,False,Chinese University of Hong Kong,OTHER,0,214.0,,2025-09-01T16:18:22.201856,v2_robust,True,True,False,False,False,
NCT01207492,Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor,A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor,nilotinib,['nilotinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Pigmented Villonodular Synovitis,"['Pigmented Villonodular Synovitis', 'Diffuse-type Giant Cell Tumor', 'Tenosynovial Giant Cell Tumor']",['nilotinib'],ACTIVE_NOT_RECRUITING,,2010-09,2026-07,"[{'measure': 'Percentage of Participants With Progression Free Survival', 'description': 'To estimate progression free survival at 6 months in participants with recurrent PVNS treated with nilotinib. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.', 'timeFrame': '6 months'}]","[{'measure': 'Overall Tumor Response Rate (OR)', 'description': 'To determine overall tumor response rate \\[% complete response (CR) + % partial response (PR) by RECIST 1.1\\]. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR) is a disappearance of all target lesions. Partial Response (PR) is a \\>=30% decrease in the sum of the longest diameter of target lesions. Overall Response (OR) = CR + PR.', 'timeFrame': '2 years'}, {'measure': 'Clinical Benefit Rate', 'description': 'To determine the clinical benefit rate \\[% CR + % PR + % stable disease by RECIST 1.1\\] at 6 months. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR) is a disappearance of all target lesions. Partial Response (PR) is a \\>=30% decrease in the sum of the longest diameter of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.', 'timeFrame': '6 months'}]",3,18 Years,,ALL,False,"Andrew J. Wagner, MD, PhD",OTHER,3,17.0,ACTUAL,2025-09-01T16:18:22.201874,v2_robust,True,True,False,False,False,
NCT02039492,Sympathetic Renal Denervation Versus Increment of Pharmacological Treatment in Resistant Arterial Hypertension.,Sympathetic Renal Denervation Versus Increment of Pharmacological Treatment in Resistant Arterial Hypertension,Treatment with aldactone,['Treatment with aldactone'],1,INTERVENTIONAL,['NA'],,,Resistant Arterial Hypertension,['Resistant Arterial Hypertension'],[],COMPLETED,,2012-09,2015-12,"[{'measure': 'Changes in ambulatory 24h-systolic blood pressure (SBP).', 'timeFrame': 'From baseline (Visit 0) to Final Examination (6 months).'}]","[{'measure': 'Changes in ambulatory 24h-diastolic blood pressure (DBP), pulse pressure (PP) and heart rate (HR)', 'timeFrame': 'From baseline (Visit 0) to Final Examination (6 months).'}]",2,18 Years,80 Years,ALL,False,Parc de Salut Mar,OTHER,0,38.0,ACTUAL,2025-09-01T16:18:22.201960,v2_robust,True,True,True,False,False,
NCT01940692,Topical and Intravenous Administration of TXA Are Equally Effective in DAA THA,TOPICAL AND INTRAVENOUS ADMINISTRATION OF TRANEXAMIC ACID ARE EQUALLY EFFECTIVE IN DIRECT ANTERIOR TOTAL HIP ARTHROPLASTY - A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL,1.5g intravenous Exacyl,"['1.5g intravenous Exacyl', '3.0g intra-articular Exacyl']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Osteoarthrosis,['Osteoarthrosis'],[],COMPLETED,,2014-07,2015-11,"[{'measure': 'Postoperative Bloodloss', 'description': 'Measured with a simple blood sample on day one after surgery', 'timeFrame': 'Day 1 after surgery'}]","[{'measure': 'Rate of perioperative and postoperative blood transfusion', 'timeFrame': 'Patients will be followed for the duration of hospital stay, an expected average of 5 days'}, {'measure': 'Number of blood units transfused', 'timeFrame': 'Patients will be followed for the duration of hospital stay, an expected average of 5 days'}, {'measure': 'Length of hospital stay', 'timeFrame': 'Measured when patient goes home, minimum 5 days after surgery'}, {'measure': 'Severity of pain at rest as determined with use of a visual analog scale', 'description': 'possible range 0 to 10', 'timeFrame': 'Patients will be followed for the duration of hospital stay, an expected average of 5 days'}, {'measure': 'Perioperatively given intravenous isotonic fluid', 'description': 'Done for calculation of the factor dilution after surgery', 'timeFrame': 'Patients will be followed for the duration of hospital stay, an expected average of 5 days'}]",6,18 Years,,ALL,False,Ziekenhuis Oost-Limburg,OTHER,0,120.0,ACTUAL,2025-09-01T16:18:22.202010,v2_robust,True,True,True,False,False,
NCT02229292,Prevention of Intraoperative Bleeding and Postoperative Swelling in Orthognathic Surgery Through the Use of Tranexamic Acid,Prevention of Bleeding and Edema in Bimaxillary Orthognathic Surgery; the Effectiveness of Tranexamic Acid on Intraoperative Bleeding and Postoperative Swelling in Orthognathic Surgery.,Tranexamic Acid,"['Tranexamsyre ""Pfizer"", D.SP.NR.: 22646, ATC code: B 02 AA 02', 'Saline', 'Natriumklorid ""B. Braun"", D.SP.NR.: 6856, ATC code: V 07 AB', 'Tranexamic Acid']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Intraoperative Bleeding,"['Intraoperative Bleeding', 'Postoperative Edema']",[],COMPLETED,,2014-08-19,2016-09-26,"[{'measure': 'Intra-operative bleeding volume (ml)', 'timeFrame': 'Within 10 minutes after ended surgery'}]","[{'measure': 'Change in hemostatic profile', 'description': 'Changes in the hemostatic profile measured through thrombelastography, thrombin generation test and fibrin structure analysis.', 'timeFrame': 'Baseline, 5.5 hours, 48 hours and 4 months postoperatively'}, {'measure': 'Change in inflammatory profile', 'description': 'Changes in the inflammatory profile are investigated through measures of surface induced activation, inflammation and plasminogen binding.', 'timeFrame': 'Baseline, 5.5 hours, 48 hours and 4 months postoperatively'}, {'measure': 'Postoperative edema formation', 'description': 'The degree of postoperative swelling in connection with TXA /or not, is determined by non-invasive 3D face scans and quantified using the ""Landmarker"" software. Scans are carried out along with the 3rd and 4th blood samples, 48 hours and 4 months postoperatively.', 'timeFrame': '48 hours and 4 months postoperatively'}]",4,18 Years,,ALL,True,Esbjerg Hospital - University Hospital of Southern Denmark,OTHER,2,104.0,ACTUAL,2025-09-01T16:18:22.202036,v2_robust,True,True,True,False,False,
NCT00445692,"Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma","Maintenance Therapy With Lenalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma",Clarithromycin,"['CDC 501', 'Dexa-sine', 'Alin', 'Deronil', 'Desameton', 'Dexameth', 'Dexa-Rhinosan', 'Fluorodelta', 'Dinormon', 'Dexacortin', 'Dexinoral', 'Hexadrol', 'Mymethasone', 'Biaxin', 'Cortidexason', 'Dexalocal', 'Dexafluorene', 'Lenalidomide', 'Lokalison-F', 'Millicorten', 'CC5013', 'Auxiloson', 'Methylfluorprednisolone', 'Desamethasone', 'Alin Depot', 'Clarithromycin', 'Aknichthol Dexa', 'Abbott-56268', 'Hexadecadrol', 'Orgadrone', 'Decacort', 'Dexa-Scheroson', 'Decalix', 'Dexapos', 'Baycuten N', 'Gammacorten', 'Revlimid', 'Auricularum', 'Decadron', 'Dexafarma', 'Dexamecortin', 'Dexone', 'Visumetazone', 'Baycuten', 'Anemul mono', 'Dexa-Mamallet', 'Fortecortin', 'CC-5013', 'Cortisumman', 'Alin Oftalmico', 'Aacidexam', 'Dexamethasone', 'Alba-Dex', 'Decadrol', 'Decasone R.p.', 'Amplidermis', 'Spersadex', 'Dexacortal', 'Dectancyl', 'Loverine', 'Dexamethasonum', 'Dexamonozon', 'Dekacort', 'Decameth', 'Deltafluorene', 'Adexone']",66,INTERVENTIONAL,['PHASE2'],PHASE2,,DS Stage I Plasma Cell Myeloma,"['DS Stage I Plasma Cell Myeloma', 'DS Stage II Plasma Cell Myeloma', 'DS Stage III Plasma Cell Myeloma', 'Refractory Plasma Cell Myeloma']",[],COMPLETED,,2007-01-10,2017-04-24,"[{'measure': 'Episodes of Grade 3-4 Non Infectious, Non-dermatological or Non-neurological Toxicities, Episodes of Any Infections, Grade 3-4 Dermatological or Episodes of Grade 2-3 Peripheral Neuropathy Common Terminology Criteria for Adverse Events Version 3', 'timeFrame': 'First year of therapy'}, {'measure': 'Time to Disease Progression', 'description': 'International Myeloma Working Group Uniform Response Criteria was used', 'timeFrame': 'Up to 10.25 years'}]","[{'measure': 'Survival', 'description': 'number of patients alive or dead', 'timeFrame': 'From date of transplant until the date of death from any cause, assessed up to 10.25 years'}]",3,18 Years,,ALL,False,Fred Hutchinson Cancer Center,OTHER,1,32.0,ACTUAL,2025-09-01T16:18:22.202063,v2_robust,True,True,True,False,True,
NCT06056336,Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma,"Perioperative Immunoagent (Tislelizumab) Plus Chemotherapy for Locally Advanced Resectable Thoracic Oesophageal Squamous Cell Carcinoma Trail:A Prospective Single-arm,Phase II Study (PILOT Trail)",Tislelizumab,"['Tislelizumab', 'Albumin-bound Paclitaxel', 'Carboplatin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Esophageal Squamous Cell Carcinoma,"['Esophageal Squamous Cell Carcinoma', 'Neoadjuvant Chemoimmunotherapy', 'Adjuvant Therapy']","['esophageal Squamous Cell Carcinoma', 'neoadjuvant chemotherapy', 'neoadjuvant immunotherapy', 'adjuvant therapy']",RECRUITING,,2023-09-07,2026-12-31,"[{'measure': '2-year disease-free survival in non-pCR patients', 'description': 'The time from the first day of surgery to the first occurrence of local or distant recurrence and metastasis or death from any cause in non-pCR patients', 'timeFrame': 'Disease free survival time for recurrence or death within 2 years of surgery'}]","[{'measure': 'pCR rate', 'description': 'Pathological complete response (pCR) rate of all patients', 'timeFrame': '4 weeks after surgery'}, {'measure': 'major pathological response', 'description': 'MPR was defined as the presence of viable tumor cells≤10% in the resected tumor specimen', 'timeFrame': '4 weeks after surgery'}, {'measure': '2-year DFS in pCR patients', 'description': 'The time from the first day of surgery to the first occurrence of local or distant recurrence and metastasis or death from any cause in pCR patients', 'timeFrame': 'Disease free survival time for recurrence or death within 2 years of surgery'}, {'measure': 'R0 resection rate', 'description': 'No vital tumor is presented at the proximal, distal, or circumferential resection margin, then it is considered R0 resection', 'timeFrame': '4 weeks after surgery'}, {'measure': 'adverse events', 'description': 'Safety will be evaluated for all treated patients using CTCAE V 5.0.', 'timeFrame': 'Up to 100 months'}, {'measure': 'overall survival', 'description': 'The date of death of any causes since the date of randomization.', 'timeFrame': 'Up to 5 years'}]",7,18 Years,75 Years,ALL,False,Guo Xufeng,OTHER,0,73.0,ESTIMATED,2025-09-01T16:18:22.202221,v2_robust,True,True,False,False,True,
NCT00359736,Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis,Vasodilator Therapy and Exercise Tolerance in IPF Patients,sildenafil,"['sildenafil', 'Revatio']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Alveolitis, Fibrosing","['Alveolitis, Fibrosing', 'Fibrosis, Pulmonary', 'Hypertension, Pulmonary']","['alveolitis, fibrosing', 'exercise, aerobic', 'fibrosis, pulmonary', 'hypertension, pulmonary']",COMPLETED,,2006-07,2009-06,"[{'measure': 'Change in 6-minute Walk Test', 'description': 'Distance in meters -- Distance (meters) walked in 6 minutes', 'timeFrame': '0 - 6 months'}]","[{'measure': 'Dyspnea Score (Borg Scale)', 'description': ""The Dyspnea score or Borg Rating of Perceived Exertion (RPE) Scale score is a subjective rating of perceived exertion. In medicine this is used to document the patient's effort and exertion, breathlessness and fatigue during a physical test.\n\nThe Dyspnea score ranges from 0 (No breathlessness at all) to 10 (Maximum or extremely strong breathlessness).\n\nIN this study the Specific Objective 2 was to assess and compare changes from baseline in pre- and post-exercise dyspnea in the sildenafil and placebo control groups."", 'timeFrame': '0 - 6 months'}]",2,40 Years,85 Years,ALL,False,VA Office of Research and Development,FED,0,29.0,ACTUAL,2025-09-01T16:18:22.202282,v2_robust,True,True,True,False,False,
NCT03308136,The Effect of Local Anesthetic Injection Depth on Procedural Pain and Discomfort During Fluoroscopically Guided Lumbar Transforaminal Epidural Injections,The Effect of Local Anesthetic Injection Depth on Procedural Pain and Discomfort During Fluoroscopically Guided Lumbar Transforaminal Epidural Injections,1% Lidocaine,['1% Lidocaine'],1,INTERVENTIONAL,['NA'],,,Lumbar Radiculopathy Due to Spinal Nerve Compression,['Lumbar Radiculopathy Due to Spinal Nerve Compression'],"['epidural steroid injection', 'procedural pain', 'local Anesthetic Injection']",COMPLETED,,2017-10-16,2018-02-28,"[{'measure': 'Procedural Pain score (NRS)', 'description': 'Numeric Rating Scale(NRS) score : from 0 (No pain) to 10 (worst pain imaginable)', 'timeFrame': 'Immediately after the procedure'}]","[{'measure': 'At the next outpatient visit, whether the injection site pain(Yes) or not(No)', 'description': 'At the next outpatient visit, subjects asked about injection site pain (Yes / No) after the last injection.', 'timeFrame': '2 weeks'}]",2,20 Years,80 Years,ALL,False,Yonsei University,OTHER,0,68.0,ACTUAL,2025-09-01T16:18:22.202297,v2_robust,True,True,True,False,False,
NCT00003136,Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer,A Phase I/II Dose Escalation Trial of Carboplatin With Amifostine Pretreatment to Augment High Dose Cyclophosphamide With Autologous Peripheral Blood Stem Cell Support for the Treatment of Patients With Epithelial Ovarian Cancer,amifostine trihydrate,"['amifostine trihydrate', 'cyclophosphamide', 'carboplatin']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Ovarian Cancer,"['Ovarian Cancer', 'Primary Peritoneal Cavity Cancer']","['recurrent ovarian epithelial cancer', 'primary peritoneal cavity cancer']",COMPLETED,,1996-12,2001-10,"[{'measure': 'Maximum tolerated dose', 'timeFrame': '4 years'}]",[],1,,65 Years,FEMALE,False,University of Chicago,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:22.202329,v2_robust,True,True,True,False,False,
NCT06004336,A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs),A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs),Pembrolizumab,['Pembrolizumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Oligometastatic Renal Cell Carcinoma,['Oligometastatic Renal Cell Carcinoma'],[],RECRUITING,,2023-10-31,2029-01-01,"[{'measure': 'Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0', 'timeFrame': 'through study completion; an average of 2 years.'}]",[],1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,2,144.0,ESTIMATED,2025-09-01T16:18:22.202358,v2_robust,True,True,False,False,True,
NCT02533336,The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania,The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania: Cluster Randomized Trial,abamectin and fenpyroximate,['abamectin and fenpyroximate'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Malaria,['Malaria'],"['Malaria control', 'Insecticide treated durable Wall Liners', 'Malaria incidence', 'Randomized Trial']",TERMINATED,futility ground,2015-11-09,2017-03-31,"[{'measure': 'Incidence of malaria parasitemia', 'description': 'The primary end point of the study is the cumulative incidence of malaria parasitaemia (asymptomatic or symptomatic) defined as the number of mRDT-confirmed episodes of parasitaemia per person-year', 'timeFrame': '1 year'}]","[{'measure': 'Effectiveness of DL on anemia', 'description': 'change in mean haemoglobin in the intervention arm compared to the control', 'timeFrame': '1 year'}]",2,6 Months,11 Years,ALL,False,"National Institute for Medical Research, Tanzania",OTHER_GOV,5,4917.0,ACTUAL,2025-09-01T16:18:22.202366,v2_robust,True,True,False,True,False,futility ground
NCT05445011,Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia,Safety and Efficacy of Anti-FLT3 CAR- T Cell (TAA05 Cell Injection) in the Treatment of Relapsed/ Refractory Acute Myeloid Leukemia,Fludarabine + Cyclophosphamide + TAA05 Cell Injection,"['Fludarabine + Cyclophosphamide + TAA05 Cell Injection', 'Fludarabine + Cyclophosphamide + Anti-FLT3 CAR-T Cell']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],['FLT3 positive Acute Myeloid Leukemia'],RECRUITING,,2022-06-14,2027-06-14,"[{'measure': 'Maximal tolerable dose (MTD)', 'description': 'Fludarabine + Cyclophosphamide + TAA05 Cell Injection Patients will receive lymphodepletion with fludarabine (25 mg/kg) and cyclophosphamide (250 mg/kg) for 3 days on day -7\\~-2, followed by the infusion of TAA05 Cell with the dose of 1×10\\^8, 2×10\\^8 or 4×10\\^8 cells on day 0. If no dose-limited toxicity(DLT) emerges in the group, then the subsequent higher dose will be used in the next group. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. MTD is defined as the highest dose at which DLT occurs in no more than 2 of the 6 patients. After the end of dose climbing, if the maximum dose group(MTD) is still not observed, the highest dose group is defined as MTD.', 'timeFrame': 'within 2 yeas after infusion'}]","[{'measure': 'Incidence of Treatment-related Adverse Events', 'description': 'Adverse events will be assessed according to NCI-CTCAE v5.0, cytokine release syndrome and CAR-T cell-related encephalopathy syndrome will be assessed according to ASTCT criteria.', 'timeFrame': 'within 2 yeas after infusion'}, {'measure': 'Overall response rate(ORR) of administering Anti-FLT3 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia', 'description': 'OR will be assessed from CAR T cell infusion to death or last follow-up (censored).', 'timeFrame': 'within 2 yeas after infusion'}, {'measure': 'Complete response rate(CRR) of administering Anti-FLT3 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia', 'description': 'CRR will be assessed from CAR T cell infusion to death or last follow-up (censored).', 'timeFrame': 'within 2 yeas after infusion'}, {'measure': 'Overall survival(OS) of administering Anti-FLT3 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia', 'description': 'OS will be assessed from CAR T cell infusion to death or last follow-up (censored).', 'timeFrame': 'within 2 yeas after infusion'}, {'measure': 'Progress-free survival(PFS) of administering Anti-FLT3 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia', 'description': 'PFS will be assessed from CAR T cell infusion to death or last follow-up (censored).', 'timeFrame': 'within 2 yeas after infusion'}, {'measure': 'Duration of Response(DOR) of administering Anti-FLT3 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia', 'description': 'DOR will be assessed from CAR T cell infusion to death or last follow-up (censored).', 'timeFrame': 'within 2 yeas after infusion'}, {'measure': 'In vivo expansion and survival of Anti-FLT3 CAR-T Cell', 'description': 'Quantity of CAR copies in bone marrow and peripheral blood will be determined by using qPCR.', 'timeFrame': 'within 2 yeas after infusion'}]",8,18 Years,70 Years,ALL,False,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",OTHER,1,12.0,ESTIMATED,2025-09-01T16:18:22.202450,v2_robust,True,True,False,False,True,
NCT02451111,Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma,"Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.",Ibrutinib,"['Ibrutinib', 'Rituximab', 'MabThera®', 'Imbruvica®']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Follicular Lymphoma,['Follicular Lymphoma'],"['Rituximab', 'Ibrutinib', 'Follicular Lymphoma']",TERMINATED,"The premature termination is based on the decision by the SAKK board on November 14, 2020 due to the lack of further financial support for the follow up period.",2015-11-06,2023-07-15,"[{'measure': 'CR at 24 months determined by PET/CT scan by the IRR panel', 'description': 'The evaluation of CR is outlined according to Cheson Criteria.. Any assessment within a window of week 102 to week 118 (inclusive) will be considered as the 24 months response assessment for determining the CR status. In addition, the CR status will be determined as follows for these specific cases:', 'timeFrame': 'at 24 months'}]","[{'measure': 'CR at 30 months determined by PET/CT scan by the IRR panel', 'timeFrame': 'at 30 months'}, {'measure': 'MRD evaluation', 'description': 'MRD evaluation will be performed using real-time PCR (polymerase chain reaction) based methods in peripheral blood and bone marrow at baseline and week 106. The proportion of patients achieving MRD negativity will be calculated for each time point of interest.', 'timeFrame': 'baseline and week 106'}, {'measure': 'Overall response (OR)', 'description': 'OR is defined as either:\n\n* the disappearance of all evidence of disease (CR)\n* the regression of measurable disease with no new sites (PR)', 'timeFrame': 'at 24 weeks'}, {'measure': 'Duration of complete response (DUR)', 'description': 'The duration of CR will be calculated from when the criteria for CR are met, until documentation of relapse thereafter. Only patients with a CR will be included in this analysis.', 'timeFrame': 'at 12 or 24 weeks or thereafter'}, {'measure': 'Progression-free survival (PFS) (PFS)', 'description': 'PFS will be calculated from randomization until the first event of interest:\n\n* disease progression or relapse according to criteria of Cheson et al. 2014\n* death from any cause', 'timeFrame': 'at 12 or 24 weeks or thereafter'}, {'measure': 'Event-free survival (EFS)', 'description': 'Event-free survival (time to treatment failure) will be calculated from randomization to premature discontinuation of trial treatment for any reason (e.g., insufficient response at first or second restaging at 12 or 24 weeks or at the third assessment at 52 weeks, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, secondary malignancy or death).', 'timeFrame': '12, 24 or 52 weeks'}, {'measure': 'Time to next anti-lymphoma therapy (TTNT)', 'description': 'This will be calculated from randomization until the start of the first off-trial anti-lymphoma treatment. Patients not receiving any off-trial anti-lymphoma treatment will be censored at the last follow-up visit.', 'timeFrame': 'at 12 or 24 weeks or thereafter'}, {'measure': 'Adverse Events (AEs)', 'description': 'AEs will be evaluated using the NCI CTCAE v4.0', 'timeFrame': 'record throughout treatment phase (until 30 days after last drug administration)'}]",9,18 Years,85 Years,ALL,False,Swiss Cancer Institute,OTHER,1,190.0,ACTUAL,2025-09-01T16:18:22.202477,v2_robust,True,True,False,True,True,"The premature termination is based on the decision by the SAKK board on November 14, 2020 due to the lack of further financial support for the follow up period."
NCT00485511,A Trial of Hydroxyurea in Spinal Muscular Atrophy,"A Randomized, Double-Blind, Placebo-Controlled Trial of Hydroxyurea in Spinal Muscular Atrophy",Hydroxyurea,['Hydroxyurea'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Spinal Muscular Atrophy,['Spinal Muscular Atrophy'],[],COMPLETED,,2007-06,2009-06,[],[],0,4 Years,,ALL,,Kaohsiung Medical University Chung-Ho Memorial Hospital,OTHER,0,,,2025-09-01T16:18:22.202582,v2_robust,True,True,True,False,False,
NCT02347111,Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation,"A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs",Flecainide,"['Flecainide', 'Sotalol']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Atrial Fibrillation,['Atrial Fibrillation'],[],RECRUITING,,2020-12-31,2026-06-30,"[{'measure': 'AF burden (Percent of time subject is in atrial fibrillation)', 'description': 'Subjects will be monitored with the Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) system to assess AF burden. The device will be programmed to optimize the memory for storing AF episode.', 'timeFrame': '12 months'}]","[{'measure': 'AF Effect on QualiTy-of-life [AFEQT]', 'description': 'Quality of life assessment: Patients will be asked to fill out the AFEQT quality of life questionnaire baseline (study randomization), two, four, six, eight, ten, and 12 months (completion of the study). The questionnaire at the end of the 6rd month will be administered just prior to stopping the first study drug. The validated questionnaire is comprised of 20 questions about AF symptoms with answers given on a Likert scale. The questionnaire will be provided to the patients in paper format either in person or by mail, as applicable. A follow-up phone call will be made to each patient to ensure that the questionnaire is completed and returned.\n\nThe responses on the 20-item AFEQT are scored on a 1 to 7 Likert scale ranging from 1: ""Not at all"", 2:"" Hardly"", 3: ""A little "", 4: ""Moderately"", 5: ""Quite a bit, 6:"" Very"" to 7: ""Extremely"".\n\nA total score of 0 corresponds to complete disability, while a score of 100 describes the highest level of QualiTy-of-life', 'timeFrame': '12 months'}]",2,18 Years,100 Years,ALL,False,University of Illinois at Chicago,OTHER,1,162.0,ESTIMATED,2025-09-01T16:18:22.202596,v2_robust,True,True,False,False,False,
NCT02484911,"Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting","Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting---A Randomized Single Center Phase III Trial",Olanzapine,"['Aprepitant', 'Palonosetron', 'Dexamethasone', 'Olanzapine']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Chemotherapy-induced Nausea and Vomiting,['Chemotherapy-induced Nausea and Vomiting'],['chemotherapy nausea vomiting'],COMPLETED,,2015-05,2017-01,"[{'measure': 'Proportion of Participants Receiving HEC With Complete Response in Overall Phase', 'description': 'Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.\n\nComplete response was defined as no vomiting with no rescue therapy.', 'timeFrame': '0 to 120 hours'}, {'measure': 'Proportion of Participants Receiving MEC With Complete Response in Overall Phase', 'description': 'Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.\n\nComplete response was defined as no vomiting with no rescue therapy.', 'timeFrame': '0 to 120 hours'}]","[{'measure': 'Proportion of Participants Receiving HEC With Complete Response in the Acute Phase', 'description': 'Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.', 'timeFrame': '0 to 24 hours'}, {'measure': 'Proportion of Participants Receiving HEC With Complete Response in the Delayed Phase', 'description': 'Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.\n\nComplete response was defined as no vomiting with no rescue therapy.', 'timeFrame': '24 to 120 hours'}, {'measure': 'Proportion of Participants Receiving HEC With No Vomiting in the Overall Phase', 'description': 'Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.\n\nNo vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy).', 'timeFrame': '0 to 120 hours'}, {'measure': 'Proportion of Participants Receiving HEC With No Vomiting in the Acute Phase', 'description': 'Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.\n\nNo vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue ）', 'timeFrame': '0 to 24 hours'}, {'measure': 'Proportion of Participants Receiving HEC With No Vomiting in the Delayed Phase', 'description': 'Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.\n\nNo vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy).', 'timeFrame': '24 to 120 hours'}, {'measure': 'Proportion of Participants Receiving MEC With Complete Response in the Acute Phase', 'description': 'Acute phase was defined as 0 to 24 hours following initiation of chemotherapy. Complete response was defined as no vomiting with no rescue therapy.', 'timeFrame': '0 to 24 hours'}, {'measure': 'Proportion of Participants Receiving MEC With Complete Response in the Delayed Phase', 'description': 'Delayed phase was defined as 24 to 120 hours following initiation of chemotherapy.\n\nComplete response was defined as no vomiting with no rescue therapy.', 'timeFrame': '24 to 120 hours'}, {'measure': 'Proportion of Participants Receiving MEC With No Vomiting in the Overall Phase', 'description': 'Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.\n\nNo vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy).', 'timeFrame': '0-120 hours'}, {'measure': 'Proportion of Participants Receiving MEC With No Vomiting in the Acute Phase', 'description': 'Overall Phase was defined as 0 to 24 hours following initiation of chemotherapy.\n\nNo vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy).', 'timeFrame': '0 to 24 hours'}, {'measure': 'Proportion of Participants Receiving MEC With No Vomiting in the Delayed Phase', 'description': 'Overall Phase was defined as 24 to 120 hours following initiation of chemotherapy.\n\nNo vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy).', 'timeFrame': '24 to 120 hours'}]",12,18 Years,,ALL,False,First Affiliated Hospital of Harbin Medical University,OTHER,1,120.0,ACTUAL,2025-09-01T16:18:22.202618,v2_robust,True,True,True,False,False,
NCT04050371,Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy,I-BrEATHe - Interactions Between Antiretrovirals And Transgender Hormones,200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate,"['Truvada', '200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,HIV Prevention,"['HIV Prevention', 'Transgender Health']","['Pre Exposure Prophylaxis', 'HIV prevention', 'Emtricitabine, Tenofovir Disoproxil Fumarate', 'transgender health', 'transgender persons', 'drug combination', 'androgens', 'estrogens', 'drug combinations', 'transmen', 'non binary', 'Truvada', 'daily observed therapy']",COMPLETED,,2017-08-03,2018-05-23,"[{'measure': 'Tenofovir Diphosphate Concentration in Dried Blood Spots (DBS)', 'description': 'Tenofovir diphosphate concentration in dried blood spots at week 4', 'timeFrame': 'After 4 weeks of daily observed dosing of FTC/TDF'}]",[],1,18 Years,65 Years,ALL,True,"University of California, San Francisco",OTHER,2,48.0,ACTUAL,2025-09-01T16:18:22.202695,v2_robust,True,True,True,False,False,
NCT00290771,Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM),"A Phase II, Open-label, Multicenter Study Evaluating the Efficacy of Imatinib Plus Hydroxyurea (HU) in Patients With Progressive Glioblastoma Multiforme (GBM) Receiving or Not Receiving Enzyme-inducing Anticonvulsant Drugs (EIACDs)",Imatinib tablets,"['Glivec®', 'Hydroxyurea capsules', 'Imatinib tablets']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Recurrent Glioblastoma Multiforme (GBM),['Recurrent Glioblastoma Multiforme (GBM)'],"['imatinib mesylate', 'hydroxyurea', 'protein tyrosine kinases', 'glioma', 'glioblastoma multiforme', 'recurrent glioblastoma multiforme', 'GBM', 'MacDonald criteria']",TERMINATED,Lack of efficacy,2006-02,2008-08,"[{'measure': 'Percentage of Patients With an Objective Overall Response (OOR)', 'description': 'Patients with an OOR were those whose best response to treatment was a complete response (CR) or a partial response (PR) assessed with magnetic resonance imaging. A patient had a CR if the target tumors disappeared. A patient had a PR if there was a ≥ 50% reduction in the sum of the products of the largest perpendicular diameters of the target tumors compared to the baseline value. A best response of CR required at least 2 determinations of CR at least 4 weeks apart. A best response of PR required at least 2 determinations of PR or better at least 4 weeks apart (and not qualifying for CR).', 'timeFrame': 'Baseline to end of study (Month 24)'}]","[{'measure': 'Duration of Objective Overall Response (OOR)', 'description': 'Duration of OOR only included patients whose best overall response was complete response (CR) or partial response (PR). The start date was the date of the first documented response (CR or PR); the end date was the date of the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, the duration of OOR was censored at the time of the last OOR assessment.', 'timeFrame': 'Baseline to end of study (Month 24)'}, {'measure': 'Percentage of Patients Who Had Clinical Benefit', 'description': 'Patients who had clinical benefit were patients with a best response of complete response (CR), partial response (PR), or stable disease (SD) lasting for more than 6 months from the start of treatment until the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. SD was defined as insufficient tumor shrinkage to qualify for PR or CR and no increase in lesions which would qualify as PD.', 'timeFrame': 'Baseline to end of study (Month 24)'}, {'measure': 'Percentage of Patients With Progression-free Survival at Months 6 and 12', 'description': 'Progression-free survival (PFS) was defined as the time from the start of treatment to the date of the first documented disease progression (PD) or death due to any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, progression-free survival was censored at the time of the last overall response assessment.', 'timeFrame': 'Months 6 and 12'}, {'measure': 'Percentage of Patients Surviving at Months 6, 12, and 24', 'description': 'Patients not known to have died were censored at the time of last survival follow-up.', 'timeFrame': 'Months 6, 12, and 24'}, {'measure': 'Number of Patients With at Least 1 Adverse Event', 'description': 'An adverse event (AE) is any undesirable sign, symptom, or medical condition occurring after starting study drug even if the event is not considered to be related to study drug. Study drug refers to imatinib or hydroxyurea. The study treatment is the combination of these two study drugs.', 'timeFrame': 'Baseline to end of study (Month 24)'}]",6,18 Years,,ALL,False,Novartis,INDUSTRY,0,231.0,ACTUAL,2025-09-01T16:18:22.202706,v2_robust,True,True,False,True,True,Lack of efficacy
NCT03211871,Dexmedetomidine Infusion as an Analgesic Adjuvant During Laparoscopic Cholecystectomy,Dexmedetomidine Infusion as an Analgesic Adjuvant During Laparoscopic Cholecystectomy: Randomized Controlled Study,Dexmedetomidine,"['Normal Saline Flush, 0.9% Injectable Solution_#1', 'Dexmedetomidine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Pain, Postoperative","['Pain, Postoperative']","['pain management, dexmedetomidine']",UNKNOWN,,2016-05-01,2017-10-01,"[{'measure': 'number of patients with severe pain', 'description': 'number of patients with severe pain estimated as VAS≥7 during 30% or more time in first 48 hours after surgery', 'timeFrame': '48 hours after surgery'}, {'measure': 'Time to first rescue analgesia', 'description': 'time from end of anesthesia to the time postoperatively when patient ask for analgesia or have VAS≥4', 'timeFrame': '24 hours after surgery'}, {'measure': 'morphine consumption', 'description': 'total morphine consumption after surgery in mg', 'timeFrame': '48 hours'}]","[{'measure': 'Time of extubation', 'description': 'Time from end of surgery to extubation', 'timeFrame': '24 hours after surgery'}, {'measure': 'Incidence of chronic postoperative pain', 'description': 'number of patients with chronic postoperative pain', 'timeFrame': '6 month after surgery'}]",5,18 Years,79 Years,ALL,False,Bogomolets National Medical University,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:22.203005,v2_robust,True,True,False,False,False,
NCT00273871,Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients,"A Multi-centre, Randomized, Open-label, Study to Compare Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients on Maintenance Therapy With Mild to Moderate Renal Insufficiency.",Cyclosporin or tacrolimus,['Cyclosporin or tacrolimus'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Graft Rejection,"['Graft Rejection', 'Kidney Failure', 'Kidney Transplantation']",['kidney transplant'],COMPLETED,,2002-01,2006-09,[{'measure': 'Difference between treatment groups in renal function at 12 months.'}],"[{'measure': 'Incidence of acute rejection, patient and graft survival at 12 months, labs and physical examinations, quality of life etc.'}]",2,18 Years,,ALL,False,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,190.0,,2025-09-01T16:18:22.203028,v2_robust,True,True,True,False,False,
NCT00190671,A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients,A Phase 1/2 Dose-Escalating Study of ALIMTA and Cyclophosphamide Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer,pemetrexed,"['LY231514', 'cyclophosphamide', 'Alimta', 'pemetrexed']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Breast Cancer,['Breast Cancer'],['Advanced Breast Cancer'],COMPLETED,,2005-06,2008-03,"[{'measure': 'Best Tumor Response', 'description': 'Tumor response was assessed using radiological imaging, which was repeated every 6 weeks prior to every other cycle. Confirmation of response was to occur no less than 4 weeks (28 days) after the first evidence of response.', 'timeFrame': 'baseline to measured progressive disease'}]","[{'measure': 'Time to Progressive Disease', 'description': 'Time to progressive disease was defined as the time from the date of the first treatment dose to the first date of progressive disease or death from study disease.', 'timeFrame': 'baseline to measured progressive disease'}, {'measure': 'Progression Free Survival', 'description': 'Defined as date of first treatment dose to first date of progressive disease or death from any cause. For patients not known to have died as of data cutoff date and who did not have progressive disease, the progression free survival date was censored at last contact date.', 'timeFrame': 'baseline to measured progressive disease'}, {'measure': 'Pharmacokinetics - Maximum Observed Drug Concentration (Cmax)', 'timeFrame': 'cycle 1 (Day 1: <1 min prior to end of pemetrexed infusion; 1/2, 1, 1.5, 2, 3, 4, 6, 8, 24, 48, 72 hours after start of pemetrexed infusion)'}, {'measure': 'Pharmacokinetics - Area Under the Curve (AUC)', 'description': 'Area under the gemcitabine concentration-time curve from zero to last quantifiable concentration \\[AUC(0-t)\\] was calculated by combination of linear and logarithmic trapezoidal methods. Linear trapezoidal method was employed up to tmax (time to reach maximal concentration), and then log trapezoidal method was used for those data after tmax.', 'timeFrame': 'cycle 1 (Day 1: <1 min prior to end of pemetrexed infusion; 1/2, 1, 1.5, 2, 3, 4, 6, 8, 24, 48, 72 hours after start of pemetrexed infusion)'}, {'measure': 'Pharmacokinetics - Clearance (CL)', 'description': 'Total body clearance of drug calculated after intravenous administration.', 'timeFrame': 'cycle 1 (Day 1: <1 min prior to end of pemetrexed infusion; 1/2, 1, 1.5, 2, 3, 4, 6, 8, 24, 48, 72 hours after start of pemetrexed infusion)'}, {'measure': 'Pharmacokinetics - Volume of Distribution', 'description': 'Central volume (V1) and peripheral volume (V2) of distribution.', 'timeFrame': 'cycle 1 (Day 1: <1 min prior to end of pemetrexed infusion; 1/2, 1, 1.5, 2, 3, 4, 6, 8, 24, 48, 72 hours after start of pemetrexed infusion)'}, {'measure': 'Pharmacokinetics - Half-Life (t½)', 'description': 'The half-life associated with the terminal elimination rate constant.', 'timeFrame': 'cycle 1 (Day 1: <1 min prior to end of pemetrexed infusion; 1/2, 1, 1.5, 2, 3, 4, 6, 8, 24, 48, 72 hours after start of pemetrexed infusion)'}]",8,18 Years,,FEMALE,False,Eli Lilly and Company,INDUSTRY,0,103.0,ACTUAL,2025-09-01T16:18:22.203067,v2_robust,True,True,True,False,False,
NCT06351371,Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2),MATCH Treatment Subprotocol K2: Phase 2 Study of Erdafitinib (JNJ-42756493) in Patients With Tumors With FGFR Mutations or Fusions,Erdafitinib,"['Balversa', 'JNJ 42756493', 'JNJ42756493', 'JNJ-42756493', 'Erdafitinib']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Malignant Solid Neoplasm,['Malignant Solid Neoplasm'],[],ACTIVE_NOT_RECRUITING,,2018-07-03,2025-12-31,"[{'measure': 'Objective Response Rate (ORR)', 'description': 'ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among analyzable (ie, eligible, treated and PIK3CA mutation status confirmed) patients. Objective response is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Details about how to define complete response and partial response can be found in the master protocol. 90% two-sided binomial exact confidence interval is calculated for ORR.', 'timeFrame': 'Tumor assessments occurred at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration'}]","[{'measure': '6-month Progression-free Survival (PFS) Rate', 'description': 'Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point.', 'timeFrame': 'Assessed at baseline, then every 2 cycles for the first 26 cycles, and every 3 cycles thereafter until disease progression, up to 3 years post registration, from which 6-month PFS rate is determined'}, {'measure': 'Progression Free Survival', 'description': 'PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression.', 'timeFrame': 'Assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration'}]",3,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,35.0,ACTUAL,2025-09-01T16:18:22.203160,v2_robust,True,True,False,False,False,
NCT00367471,"Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.","A Phase I, Dose Escalation Study to Assess the Safety and Tolerability of Lapatinib in Combination With Carboplatin, Paclitaxel, With and Without Trastuzumab in Subjects With Metastatic Breast Cancer",lapatinib,"['trastuzumab', 'carboplatin', 'paclitaxel', 'lapatinib']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,"Neoplasms, Breast","['Neoplasms, Breast']","['metastatic', 'paclitaxel', 'lapatinib', 'trastuzumab', 'carboplatin', 'breast cancer']",COMPLETED,,2006-12-07,2019-09-12,"[{'measure': 'Adverse events and safety evaluations', 'description': '* The OTR for Treatment Group A (lapatinib, paclitaxel, carboplatin, and trastuzumab) will be defined as the maximum dose level at which no more than one subject out of six experiences a dose-limiting toxicity (DLT) after completing one treatment cycle.\n* The OTR for Treatment Group B (lapatinib, paclitaxel, carboplatin) will be defined as the maximum dose level at which no more than one subject out of six experiences a DLT after completing one treatment cycle.\n* Adverse events and changes from baseline in laboratory values, Multiple-gated Acquisition (MUGA) scanning/Echocardiogram (ECHO), and vital signs will be evaluated to assess safety and tolerability.', 'timeFrame': '28 days'}]","[{'measure': 'Tumor response by RECIST version 1.0', 'description': 'Tumor response is assessed using Response Evaluation Criteria In Solid Tumors (RECIST), version 1.0. RECIST has 4 response categories:\n\n* Complete Response (CR) = disappearance of all target and non-target lesions.\n* Partial Response (PR) = at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of diameters.\n* Progressive Disease (PD) = At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline.\n* Stable Disease (SD) = neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.\n\nA CR or PR should be confirmed within 4 weeks.', 'timeFrame': 'From date of randomization until the date of first documented progression or death from any cause,whichever came first, assessed up to 48.5 months'}, {'measure': 'Duration of Response (DOR)', 'description': 'Duration of Response is defined as the time from the first documented evidence of CR or PR until the first documented sign of PD or death due to breast cancer.', 'timeFrame': 'From date of randomization until the date of first documented progression or death from any cause,whichever came first, assessed up to 48.5 months'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Progression-free survival is defined as the time from first dose until the first documented sign of disease progression or death due to any cause. For subjects who do not progress or die, but who permanently discontinue Lapatinib treatment, progression-free survival will be censored at the time of last radiological scan preceding the initiation of alternative anti-cancer therapy. For subjects who do not progress or die and who complete the study, progression-free survival will be censored at the time of last radiological scan preceding the date of the study conclusion.', 'timeFrame': 'From date of randomization until the date of first documented progression or death from any cause,whichever came first, assessed up to 48.5 months'}]",4,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,31.0,ACTUAL,2025-09-01T16:18:22.203258,v2_robust,True,True,True,False,True,
NCT01655771,TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects,"A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of TD-1211 Administered Orally to Elderly and Young Healthy Subjects",TD-1211 Dose 1,"['TD-1211 Dose 1', 'TD-1211 Dose 2']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Constipation,['Constipation'],"['Opioid induced constipation', 'Constipation']",COMPLETED,,2012-08,2013-03,"[{'measure': 'Cmax', 'timeFrame': '0-96 hours'}, {'measure': 'AUCt', 'timeFrame': 'Based on samples collected 0-96 hours'}, {'measure': 'AUCinf', 'timeFrame': 'Based on samples collected 0-96 hours'}]","[{'measure': 'Number of patients with treatment-emergent adverse events', 'timeFrame': 'Days 1-14'}, {'measure': 'Number patients with abnormal vital sign measurements', 'timeFrame': 'Days 1-5'}, {'measure': 'Number of patients with abnormal clinical laboratory results', 'timeFrame': 'Days 1-5'}, {'measure': 'Number of patients with abnormal corrected QTc interval', 'timeFrame': 'Days 1-5'}]",7,18 Years,85 Years,ALL,True,Theravance Biopharma,INDUSTRY,0,47.0,ACTUAL,2025-09-01T16:18:22.203270,v2_robust,True,True,True,False,True,
NCT02099071,"Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949","Single-center, Double-blind, Randomized, Placebo-controlled, Single-ascending Dose and Food Interaction Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Male Subjects",ACT-389949 1 mg,"['ACT-389949 20 mg', 'ACT-389949 5 mg', 'ACT-389949 100 mg', 'ACT-389949 50 mg', 'ACT-389949 1 mg', 'Placebo', 'ACT-389949 200 mg', 'ACT-389949 500 mg', 'ACT-389949 1000 mg']",9,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Subjects,['Healthy Subjects'],['ACT-389949'],COMPLETED,,2011-11,2012-05,"[{'measure': 'Change from baseline up to 60 hours in supine systolic blood pressure', 'description': 'Blood pressure will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand)', 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in standing systolic blood pressure', 'description': 'Blood pressure will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand)', 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in supine diastolic blood pressure', 'description': 'Blood pressure will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand)', 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in standing diastolic blood pressure', 'description': 'Blood pressure will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand)', 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in pulse rate', 'description': 'Pulse rate will be measured using an automatic oscillometric device, always on the dominant arm (i.e., dominant arm right = writing with right hand)', 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in body temperature', 'description': 'Body temperature will be measured in the sitting position using the same thermometer(s) for all the subjects and throughout the study.', 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in body weight', 'description': 'Body weight will be measured using the same weighing scale for all subjects and throughout the study. The weighing scale should have a precision of at least 0.5 kg.', 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in QTcB interval', 'description': ""A standard 12-lead electrocardiogram (ECG) is to be recorded at rest with the subject in the supine position for a 5-minute period. The QTcB interval is the QT interval (interval from beginning of the Q wave until end of the T wave) corrected for heart rate with Bazett's formula (QTcB = QT/RR\\^0.5 where RR is 60/heart rate)."", 'timeFrame': '60 hours'}, {'measure': 'Change from baseline up to 60 hours in QTcF interval', 'description': ""A standard 12-lead ECG is to be recorded at rest with the subject in the supine position for a 5-minute period. The QTcF interval is the QT interval (interval from beginning of the Q wave until end of the T wave) corrected for heart rate with Fridericia's formula (QTcF = QT/RR\\^0.33 where RR is 60/heart rate)."", 'timeFrame': '60 hours'}, {'measure': 'Treatment-emergent ECG abnormalities from baseline up to 60 hours', 'description': 'Treatment-emergent abnormalities will be determined from standard 12-lead ECGs recorded in the supine position, after a 5-minute period of resting. Treatment-emergent ECG abnormalities are defined as ECG abnormalities occurring up to 60 h after study drug administration in each treatment period.', 'timeFrame': '60 hours'}]","[{'measure': 'Maximum plasma concentration (Cmax) of ACT-389949', 'description': 'Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-389949, and at 20 min, 40 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 60 hours after dosing. Cmax will be calculated on the basis of the blood sampling time points.', 'timeFrame': '60 hours'}, {'measure': 'Area under the plasma concentration-time curve (AUC(0-t)) of ACT-389949', 'description': 'Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-389949, and at 20 min, 40 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 60 hours after dosing. AUC(0-t) will be calculated according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification.', 'timeFrame': '60 hours'}, {'measure': 'Area under the plasma concentration-time curve (AUC(0-infinity)) of ACT-389949', 'description': 'Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-389949, and at 20 min, 40 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 60 hours after dosing. AUC(0-infinity) will be calculated by combining AUC(0-t) and AUC(extra). AUC(extra) represents an extrapolated value obtained by Ct/λz, where Ct is the last plasma concentration measured above the limit of quantification and λz represents the terminal elimination rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal elimination phase.', 'timeFrame': '60 hours'}, {'measure': 'Time to maximum plasma concentration (tmax) of ACT-389949', 'description': 'Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-389949, and at 20 min, 40 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 60 hours after dosing. tmax will be calculated on the basis of the blood sampling time points.', 'timeFrame': '60 hours'}, {'measure': 'Plasma half life (t1/2) of ACT-389949', 'description': 'Blood samples for pharmacokinetic analysis will be taken immediately prior to dosing with ACT-389949, and at 20 min, 40 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 60 hours after dosing. t1/2 will be calculated on the basis of the blood sampling time points.', 'timeFrame': '60 hours'}]",15,18 Years,45 Years,MALE,True,Idorsia Pharmaceuticals Ltd.,INDUSTRY,0,65.0,ACTUAL,2025-09-01T16:18:22.203342,v2_robust,True,True,True,False,False,
NCT01694771,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,"A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]",Tiotropium,"['Tiotropium', 'Olodaterol', 'Placebo matching Olodaterol']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,"Pulmonary Disease, Chronic Obstructive","['Pulmonary Disease, Chronic Obstructive']",[],COMPLETED,,2012-09,2013-08,"[{'measure': 'FEV1 AUC0-3h Response at 12 Weeks; Defined as Change From Baseline to Week 12', 'description': 'FEV1 (Forced expiratory volume in 1 second) AUC0-3h (area under the curve) response at 12 weeks; defined as change from baseline to Week 12', 'timeFrame': 'baseline and 12 weeks'}, {'measure': 'Trough FEV1 Response at 12 Weeks; Defined as Change From Baseline to Week 12', 'description': 'Trough FEV1 (Forced expiratory volume in 1 second) response at 12 weeks; defined as change from baseline to Week 12', 'timeFrame': 'baseline and 12 weeks'}]","[{'measure': 'Peak FEV1 Response at 12 Weeks - Defined as Change From Baseline', 'description': 'Peak FEV1 (Forced Expiratory Volume in 1 second) response at 12 Weeks - defined as changes from baseline', 'timeFrame': 'baseline and 12 weeks'}, {'measure': 'FVC AUC0-3h Response at 12 Weeks - Defined as Change From Baseline', 'description': 'Forced Vital Capacity (FVC) AUC0-3h response at 12 weeks - defined as change from baseline.', 'timeFrame': 'baseline and 12 weeks'}, {'measure': 'Trough FVC Response at 12 Weeks- Defined as Change From Baseline', 'description': 'Trough Forced Vital Capacity (FVC) response at 12 weeks- defined as change from baseline.', 'timeFrame': 'baseline and 12 weeks'}, {'measure': 'Peak FVC Response at 12 Weeks - Defined as Change From Baseline', 'description': 'Peak FVC response at 12 weeks - defined as change from baseline.', 'timeFrame': 'baseline and 12 weeks'}, {'measure': 'Rescue Medication Usage - Percentage of Rescue Free Days', 'description': 'Rescue medication usage - the percentage of rescue free days. The percentage of rescue free days is defined as: number of rescue free days divided by total exposure, multiplied by 100%. The baseline for the number of rescue-free days was defined as the number of rescue-free days observed during the last week of the baseline period (i.e., the 7 days prior to administration of the first dose of randomized treatment).', 'timeFrame': 'over 12 weeks'}, {'measure': 'Rescue Medication Usage - Mean Weekly Rescue Usage (Total Daily)', 'description': 'Rescue medication usage - mean weekly rescue usage (total daily). The baseline for the rescue use was the mean of the observations during the last week of the baseline period. Administration of rescue medication could occur at any point during the trial as deemed necessary by the patient or the investigator. Open label albuterol MDI (100 μg per puff) was provided as rescue medication . Daily, between clinic visits, patients recorded the number of puffs of albuterol in a paper diary.', 'timeFrame': 'over 12 weeks'}, {'measure': 'Rescue Medication Usage - Mean Weekly Rescue Usage (Daytime)', 'description': 'Rescue medication usage - Mean weekly rescue usage during daytime hours. Administration of rescue medication could occur at any point during the trial as deemed necessary by the patient or the investigator. Open label albuterol MDI (100 μg per puff) was provided as rescue medication by BI, and only the albuterol MDI provided by BI was allowed for rescue medication use. Daily, between clinic visits, patients recorded the number of puffs of albuterol in a paper diary.', 'timeFrame': 'over 12 weeks'}, {'measure': 'Rescue Medication Usage - Mean Weekly Rescue Usage (Nighttime)', 'description': 'Rescue medication usage - Mean weekly rescue usage during nighttime hours. Administration of rescue medication could occur at any point during the trial as deemed necessary by the patient or the investigator. Open label albuterol MDI (100 μg per puff) was provided as rescue medication by BI, and only the albuterol MDI provided by BI was allowed for rescue medication use. Daily, between clinic visits, patients recorded the number of puffs of albuterol in a paper diary.', 'timeFrame': 'over 12 weeks'}]",10,40 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,1134.0,ACTUAL,2025-09-01T16:18:22.203409,v2_robust,True,True,True,False,False,
NCT01347671,Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy,"A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy.",GRT6005,"['GRT6005', 'Matching Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Pain,"['Pain', 'Diabetic Neuropathies']","['analgesia', 'analgesics', 'pain', 'chronic pain', 'neuropathic pain']",COMPLETED,,2011-05,2012-01,"[{'measure': 'Change in mean daily pain intensity score', 'description': 'Participants will be selected based on their medical history and clinical examination.\n\nEfficacy of the treatment (i.e., reduction of pain) will be evaluated with the 11-point numeric rating scale (NRS), where 0 represents no pain and 10 represents ""pain as bad as you can imagine"".', 'timeFrame': 'Baseline to Week 4'}]","[{'measure': 'Response measured in percentage change of pain intensity from baseline', 'timeFrame': 'End of 4 Weeks'}, {'measure': 'Changes in Quantitative Sensory Testing from baseline', 'timeFrame': 'Baseline, week 1 and week 4'}, {'measure': 'Neuropathic Pain Scale, changes from baseline', 'timeFrame': 'End of 4 weeks'}, {'measure': 'Short Form of the Brief Pain Inventory, changes from baseline', 'timeFrame': 'End of 4 weeks'}, {'measure': 'Leeds Sleep Evaluation Questionnaire', 'timeFrame': 'End of treatment'}, {'measure': 'Quality of Life Index -Short-Form-12®, from baseline', 'timeFrame': 'End of treatment'}, {'measure': ""Patient's Global Impression of Change"", 'timeFrame': 'End of treatment'}, {'measure': 'Quality of Life EuroQoL-5 Dimension score, change from baseline', 'timeFrame': 'End of 4 weeks'}, {'measure': 'Rescue medication use', 'timeFrame': 'End of 4 weeks'}, {'measure': 'Clinical Opioid Withdrawal Scale', 'timeFrame': 'End of 4 weeks'}, {'measure': 'Plasma concentration', 'timeFrame': 'End of 4 weeks'}]",12,18 Years,75 Years,ALL,False,"Tris Pharma, Inc.",INDUSTRY,1,189.0,ACTUAL,2025-09-01T16:18:22.203508,v2_robust,True,True,True,False,False,
NCT03479671,Low Dose Fat-Induced Insulin Resistance,A Dose Finding Study for Fat-Induced Insulin Resistance in Healthy Volunteers,"Intralipid, 20% Intravenous Emulsion","['Intralipid, 20% Intravenous Emulsion']",1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2', 'Insulin Resistance', 'Insulin Sensitivity']",[],RECRUITING,,2020-01-01,2026-01,"[{'measure': 'Insulin Sensitivity', 'description': 'Rate of Glucose Disposal (mg/kg/min)', 'timeFrame': '6 hours'}]",[],1,18 Years,44 Years,ALL,True,University of Pennsylvania,OTHER,0,12.0,ESTIMATED,2025-09-01T16:18:22.203533,v2_robust,True,True,False,False,False,
NCT00754871,Pharmacodynamic Characterization of Dienogest,"A Double-blind, Randomized, Dose-controlled Study to Evaluate Pharmacodynamic Properties of Four Oral Doses of Dienogest (DNG) in 100 Healthy Young Female Volunteers Over a Period of Two Cycles up to a Maximum of 72 Days",Dienogest (81150037),"['Dienogest (81150037)', 'Dienogest (81150746)', 'Dienogest (81150231)', 'Dienogest (SH T00660A)']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Pharmacodynamics,['Pharmacodynamics'],[],COMPLETED,,2008-09,2009-09,"[{'measure': 'No primary variables defined, all variables are considered exploratory since no confirmatory statistical analysis planned', 'timeFrame': 'No primary variables defined, all variables are considered exploratory since no confirmatory statistical analysis planned'}]","[{'measure': 'Course of gonadotropins (FSH, LH, P, E2)', 'timeFrame': 'During pre-treatment and treatment cycles (3 months)'}, {'measure': 'Endometrial thickness', 'timeFrame': 'During pre-treatment and treatment cycles (3 months)'}, {'measure': 'Grading of ovarian activity', 'timeFrame': 'During pre-treatment and treatment cycles (3 months)'}, {'measure': 'Effects on the cervix and the cervical mucus', 'timeFrame': 'During pre-treatment and treatment cycles (3 months)'}, {'measure': 'mRNA expression profile of endometrial biopsies and in blood', 'timeFrame': 'once in pre-treatment and during treatment'}, {'measure': 'Concentrations of DNG in serum', 'timeFrame': 'During pre-treatment and treatment cycles (3 months)'}, {'measure': 'Safety and tolerability', 'timeFrame': 'During pre-treatment and treatment cycles (3 months)'}]",8,18 Years,35 Years,FEMALE,True,Bayer,INDUSTRY,0,102.0,ACTUAL,2025-09-01T16:18:22.203541,v2_robust,True,True,True,False,True,
NCT00929344,Duloxetine Versus Pregabalin for Alcohol Dependence,Duloxetine Versus Pregabalin for Alcohol Dependence,Pregabalin,"['Placebo', 'Cymbalta', 'Lyrica', 'Pregabalin', 'Duloxetine']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Alcohol Dependence,['Alcohol Dependence'],"['Alcohol', 'Alcohol treatment', 'Alcoholism', 'Alcohol Abuse', 'Alcohol Dependence']",COMPLETED,,2009-07,2014-10,"[{'measure': 'Change From Baseline in Drinking Quantity and Frequency Using Drinks Per Week at Week 12', 'description': 'Standard drinks are equivalent to 14 grams of pure alcohol and number of drinks are assessed with Timeline Follow-Back (TLFB) methods. Change = (Week 12 - Baseline). More negative values indicate less use of alcohol.', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Change From Baseline in Drinking Quantity and Frequency Using Drinking Days Per Week at Week 12', 'description': 'Standard drinks are equivalent to 14 grams of pure alcohol and number of drinks are assessed with Timeline Follow-Back (TLFB) methods. A drinking day is a day where any alcohol is consumed. Change = (Week 12 - Baseline). More negative values indicate less use of alcohol.', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Change From Baseline in Drinking Quantity and Frequency Using Drinks Per Drinking Day at Week 12', 'description': 'Standard drinks are equivalent to 14 grams of pure alcohol and number of drinks are assessed with Timeline Follow-Back (TLFB) methods. A drinking day is a day where any alcohol is consumed. Change = (Week 12 - Baseline). More negative values indicate less use of alcohol.', 'timeFrame': 'Baseline and Week 12'}]",[],3,18 Years,,ALL,False,The Scripps Research Institute,OTHER,1,150.0,ACTUAL,2025-09-01T16:18:22.203639,v2_robust,True,True,True,False,False,
NCT05129644,Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects,"Phase I, Randomized Double-Blind, Active Control, Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects",P1101 (24 mcg),"['Pegasys', 'P1101 (180 mcg)', 'P1101 (90 mcg)', 'P1101 (270 mcg)', 'P1101 (48 mcg)', 'peginterferon alfa-2a', 'P1101 (24 mcg)', 'P1101 (225 mcg)']",8,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['P1101, phase 1, healthy volunteers']",COMPLETED,,2009-11-07,2010-06-26,"[{'measure': 'Adverse Event', 'description': 'Frequency and severity of all adverse events among subjects, including frequency and severity of drug-related adverse events.', 'timeFrame': 'Through study Day 35'}, {'measure': 'AUC of P1101 and Pegasys', 'description': 'Area under the serum concentration-time curve from time 0 to infinity', 'timeFrame': 'Samples were collected within 1 hour pre-dose, and at 1, 3, 6, 9, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192, 240, 288, 336, 504, and 672 hours post-dose.'}, {'measure': 'AUC0-t of P1101 and Pegasys', 'description': 'Area under the serum concentration-time curve from time zero to the last measurable concentration (AUC0-t)', 'timeFrame': 'Samples were collected within 1 hour pre-dose, and at 1, 3, 6, 9, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192, 240, 288, 336, 504, and 672 hours post-dose.'}, {'measure': 'Cmax of P1101 and Pegasys', 'description': 'Maximum serum concentration; the highest concentration observed during a dosage interval.', 'timeFrame': 'Samples were collected within 1 hour pre-dose, and at 1, 3, 6, 9, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192, 240, 288, 336, 504, and 672 hours post-dose.'}, {'measure': 'Ct of P1101 and Pegasys', 'description': 'The last measured serum concentration, the last concentration above the lower limit of quantification following dose', 'timeFrame': 'Samples were collected within 1 hour pre-dose, and at 1, 3, 6, 9, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192, 240, 288, 336, 504, and 672 hours post-dose.'}, {'measure': 'Tmax of P1101 and Pegasys', 'description': 'The time that Cmax was observed', 'timeFrame': 'Samples were collected within 1 hour pre-dose, and at 1, 3, 6, 9, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192, 240, 288, 336, 504, and 672 hours post-dose.'}, {'measure': 'T½ of P1101 and Pegasys', 'description': 'Terminal elimination half-life', 'timeFrame': 'Samples were collected within 1 hour pre-dose, and at 1, 3, 6, 9, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192, 240, 288, 336, 504, and 672 hours post-dose.'}, {'measure': 'λz (Ke) of P1101 and Pegasys', 'description': 'The terminal elimination rate constant; calculated using linear regression on the terminal portion of the Ln-concentration versus time curve', 'timeFrame': 'Samples were collected within 1 hour pre-dose, and at 1, 3, 6, 9, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192, 240, 288, 336, 504, and 672 hours post-dose.'}]","[{'measure': ""2',5' oligoadenylate synthetase (OAS): Emax"", 'description': 'Maximum serum biomarker response; the highest biomarker concentration observed during a dosage interval.', 'timeFrame': 'Samples were collected within 1 hour pre-dose and at 24, 48, 72, 96, 120, 168, 240, 336, 504, and 672 hours post-dose'}, {'measure': ""2',5' oligoadenylate synthetase (OAS): Tmax"", 'description': 'The time that Emax was observed.', 'timeFrame': 'Samples were collected within 1 hour pre-dose and at 24, 48, 72, 96, 120, 168, 240, 336, 504, and 672 hours post-dose'}, {'measure': ""2',5' oligoadenylate synthetase (OAS): AUC0-t"", 'description': 'Area under the biomarker concentration versus time curve from time 0 to the last measured concentration.', 'timeFrame': 'Samples were collected within 1 hour pre-dose and at 24, 48, 72, 96, 120, 168, 240, 336, 504, and 672 hours post-dose'}, {'measure': 'Neopterin: Emax', 'description': 'Maximum serum biomarker response; the highest biomarker concentration observed during a dosage interval.', 'timeFrame': 'Samples were collected within 1 hour pre-dose and at 24, 48, 72, 96, 120, 168, 240, 336, 504, and 672 hours post-dose'}, {'measure': 'Neopterin: Tmax', 'description': 'The time that Emax was observed.', 'timeFrame': 'Samples were collected within 1 hour pre-dose and at 24, 48, 72, 96, 120, 168, 240, 336, 504, and 672 hours post-dose'}, {'measure': 'Neopterin: AUC0-t', 'description': 'Area under the biomarker concentration versus time curve from time 0 to the last measured concentration.', 'timeFrame': 'Samples were collected within 1 hour pre-dose and at 24, 48, 72, 96, 120, 168, 240, 336, 504, and 672 hours post-dose'}]",14,18 Years,45 Years,MALE,True,PharmaEssentia,INDUSTRY,0,48.0,ACTUAL,2025-09-01T16:18:22.203723,v2_robust,True,True,True,False,True,
NCT04675944,Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil,"An Open-Label, Three Period, Fixed Sequence Study to Assess the Effect of a Single Dose of BIA 5 1058 200 mg on the Steady State Pharmacokinetics of Treprostinil in Healthy Subjects Under Fed Conditions",BIA 5-1058,"['treprostinil', 'Orenitram', 'Zamicastat', 'BIA 5-1058']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Pulmonary Arterial Hypertension,['Pulmonary Arterial Hypertension'],[],COMPLETED,,2018-02-28,2018-05-25,"[{'measure': 'Maximum observed plasma concentration - Cmax', 'description': 'Primary Pharmacokinetic Parameters - BIA 5 1058', 'timeFrame': 'Pre-dose (Treatment Period 1, Day 1 and Treatment Period 3, Day 6) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours'}, {'measure': 'Area under the plasma concentration-time curve (AUC) from time zero to the last quantifiable concentration - AUC0-t', 'description': 'Primary Pharmacokinetic Parameters - BIA 5 1058', 'timeFrame': 'Pre-dose (Treatment Period 1, Day 1 and Treatment Period 3, Day 6) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours'}, {'measure': 'AUC from time zero extrapolated to infinity - AUC0-inf', 'description': 'Primary Pharmacokinetic Parameters - BIA 5 1058', 'timeFrame': 'Pre-dose (Treatment Period 1, Day 1 and Treatment Period 3, Day 6) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours'}, {'measure': 'Maximum observed plasma concentration at steady state - Cmax,ss', 'description': 'Primary Pharmacokinetic Parameters - Treprostinil', 'timeFrame': 'Pre-last dose (Treatment Period 2, Day 6 and Treatment Period 3, Day 6) and post-last dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours.'}, {'measure': 'AUC over the dosing interval at steady state - AUC0-τ,ss', 'description': 'Primary Pharmacokinetic Parameters - Treprostinil', 'timeFrame': 'Pre-last dose (Treatment Period 2, Day 6 and Treatment Period 3, Day 6) and post-last dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours.'}]",[],5,18 Years,45 Years,ALL,True,Bial - Portela C S.A.,INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:22.203776,v2_robust,True,True,True,False,False,
NCT06794944,Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients with Inflammatory Bowel Disease,Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients with Inflammatory Bowel Disease,Vancomycin (POC),"['Vancomycin (POC)', 'Fidaxomicin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Inflammatory Bowel Disease (IBD),"['Inflammatory Bowel Disease (IBD)', 'Clostridioides Difficile Infection']","['C. difficile', 'Crohn&#39;s Disease', 'Ulcerative Colitis']",NOT_YET_RECRUITING,,2025-09,2031-09,"[{'measure': 'C. difficile decolonization', 'description': 'Absence of C. difficile via PCR in Week 8 stool sample', 'timeFrame': '8 weeks'}, {'measure': 'Safety and tolerability', 'description': 'Subject incidence of treatment-emergent adverse events (including treatment-emergent adverse events for clinically significant changes in laboratory parameters and vital signs)', 'timeFrame': '8 weeks'}]","[{'measure': 'Biomass of C. difficile', 'description': 'Change in stool C. difficile biomass in patients at week 8 by quantitative culture and qPCR', 'timeFrame': '8 weeks'}, {'measure': 'Long-term effect of C. difficile decolonization on IBD clinical outcomes', 'description': ""Change in IBD clinical scores from baseline at week 8 and week 26. IBD clinical scores are used to assess IBD patient symptoms. The assessments are separated between scores for Ulcerative Colitis (UC) and Crohn's Disease (CD). The Harvey Bradshaw Index (HBI) is a clinical assessment for IBD patients with Crohn's disease while Partial Mayo Score is a clinical assessment for Ulcerative Colitis. The scores will be collected at study visit in form of a survey. The HBI score can vary but a score above 8 or 9 is considered severe disease activity. The Partial Mayo Score can range from 0 to 9 and a score above 7 is considered severe disease activity. A decrease in score from baseline to follow-up timepoints is indicative of improved IBD patient symptoms."", 'timeFrame': '26 weeks'}, {'measure': 'C. difficile infection surveillance', 'description': 'Incidence of patients developing CDI through Week 26', 'timeFrame': '26 weeks'}]",5,18 Years,,ALL,False,Brigham and Women's Hospital,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:22.203809,v2_robust,True,True,False,False,True,
NCT06013644,"Acupuncture, Dry Needle and Botox Injection in Management of Patient With Myofascial Pain Dysfunction Syndrome","Comparative Efficacy of Acupuncture, Dry Needle and Botox Injection in Management of Patient With Myofascial Pain Dysfunction Syndrome Using Electromyography and Visual Analogue Scale: A Randomized Clinical Trial",Botox Injectable Product,['Botox Injectable Product'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Myofascial Trigger Point Pain,"['Myofascial Trigger Point Pain', 'Myofascial Pain Syndrome']","['botox injection', 'dry needle', 'myofascial trigger point pain', 'acupuncture']",RECRUITING,,2023-06-03,2024-02-01,"[{'measure': 'change of electrical activity of mastication muscles from the baseline measurement', 'description': 'change of electrical activity of mastication muscles from the baseline measurement through assessment of muscle tone using electromyography (EMG) in microvolts and refer to the behavior of muscles: at (rest /open, chewing, clenching)', 'timeFrame': '2 months after treatment'}, {'measure': 'change of electrical activity of mastication muscles from the baseline measurement', 'description': 'change of electrical activity of mastication muscles from the baseline measurement through assessment of muscle tone using electromyography (EMG) in microvolts and refer to the behavior of muscles: at (rest /open, chewing, clenching)', 'timeFrame': '6 months after treatment'}]","[{'measure': 'change of Pain perception from baseline measurement during maximum mouth opening in millimetres and rest by a Visual Analog Score (where Zero means no pain and 10 means the worst pain possible)', 'description': 'change of Pain perception from the baseline measurement during maximum mouth opening in millimetres and rest by a Visual Analog Score (where Zero means no pain and 10 means the worst pain possible)', 'timeFrame': '2 months after treatment'}, {'measure': 'change of Pain perception from baseline measurement during maximum mouth opening in millimetres and rest by a Visual Analog Score (where Zero means no pain and 10 means the worst pain possible)', 'description': 'change of Pain perception from the baseline measurement during maximum mouth opening in millimetres and rest by a Visual Analog Score (where Zero means no pain and 10 means the worst pain possible)', 'timeFrame': '6 months after treatment'}]",4,15 Years,60 Years,ALL,True,Cairo University,OTHER,0,39.0,ESTIMATED,2025-09-01T16:18:22.203896,v2_robust,True,True,False,False,False,
NCT05154734,Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders,Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders (BEAT NMO),Belimumab,['Belimumab'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,NMO Spectrum Disorder,['NMO Spectrum Disorder'],[],COMPLETED,,2021-12-12,2024-04-09,"[{'measure': 'The number of attacks', 'description': 'An acute attack was defined as a new neurological worsening lasting for at least 24 hours and occurring more than 30 days after the previous attack.', 'timeFrame': 'From baseline to one year after'}]","[{'measure': 'Worsening in EDSS', 'description': 'The Expanded Disability Status Scale (EDSS) is a rating system that is frequently used for classifying and standardizing the severity and progression. EDSS ranges from 0 to 10.', 'timeFrame': 'Worsening from baseline in EDSS to 52 weeks'}, {'measure': 'Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Optic nerve,brain and spinal cord Magnetic Resonance Imaging (MRI)', 'description': 'The total number of new and/or enlarging T2 lesions for all participants was calculated as the sum of the individual number of lesions at Weeks 12, 24, and 52', 'timeFrame': 'From baseline to 52 weeks'}, {'measure': 'Counts of peripheral blood B cell subsets', 'description': 'Compare peripheral blood plasma cells before and one year after initial intervention', 'timeFrame': 'From baseline to 52 weeks'}, {'measure': 'Determination of serum AQP4 antibodies', 'description': 'Compare serum AQP4-ab titers before and one year after initial intervention', 'timeFrame': 'From baseline to 52 weeks'}, {'measure': 'Incidence of treatment-emergent adverse events [safety and tolerability]', 'description': 'Adverse events related to belimumab are recorded', 'timeFrame': 'From baseline to 52 weeks'}]",6,18 Years,,ALL,True,Tianjin Medical University General Hospital,OTHER,1,14.0,ACTUAL,2025-09-01T16:18:22.203942,v2_robust,True,True,True,False,True,
NCT04504734,Bucillamine in Treatment of Patients With COVID-19,"Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19",Bucillamine,"['Placebo', 'Bucillamine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Covid19,['Covid19'],[],TERMINATED,Met definition of futility according to DSMB,2020-11-27,2023-06-12,"[{'measure': 'Efficacy: Frequency of hospitalization or death', 'description': 'Proportion of patients meeting a composite endpoint of hospitalization or death', 'timeFrame': 'From time of first dose through Day 28 following randomization'}]","[{'measure': 'Safety: Changes in adverse events from baseline to end of study', 'description': 'Number of adverse events', 'timeFrame': 'From time of first dose through Day 28 following randomization'}]",2,18 Years,80 Years,ALL,False,"Revive Therapeutics, Ltd.",INDUSTRY,0,713.0,ACTUAL,2025-09-01T16:18:22.204140,v2_robust,True,True,False,True,True,Met definition of futility according to DSMB
NCT01211834,Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis,"A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy and the Safety During Treatment With Tocilizumab vs Placebo in Combination With Traditional DMARD Therapy in Patients With Moderate to Severe Active RA and an Inadequate Response to Current DMARD Therapy",tocilizumab,"['DMARDs', 'tocilizumab', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],[],COMPLETED,,2009-10,2010-10,"[{'measure': 'Proportion of patients with ACR20 responses', 'description': 'Proportion of patients with ACR20 responses at post therapy', 'timeFrame': '24weeks'}]","[{'measure': 'Proportion of patients with ACR50 and ACR70 responses at post therapy', 'timeFrame': '24weeks'}, {'measure': 'Change of DAS28, HAQ, individual parameter in ACR core set, hemoglobin', 'timeFrame': '24weeks'}]",3,18 Years,,ALL,False,JW Pharmaceutical,INDUSTRY,0,90.0,ESTIMATED,2025-09-01T16:18:22.204260,v2_robust,True,True,True,False,False,
NCT01660334,Voriconazole (Vfend) Special Investigation (Regulatory Post Marketing Commitment Plan),Special Investigation of Vfend on Scedosporisis,Voriconazole,"['VFEND for Intravenous Use, Voriconazole for Intravenous Use, VFEND Tablets, Voriconazole Tablet', 'Voriconazole']",2,OBSERVATIONAL,[],,,Scedosporium Infection,['Scedosporium Infection'],"['Systemic Mycosis', 'Scedosporium infection', 'Scedosporisis', 'Japanese', 'voriconazole', 'VFEND', 'Regulatory Post Marketing Commitment Plan.']",COMPLETED,,2006-07,2012-05,"[{'measure': 'Number of Participants With Serious Treatment Related Adverse Events.', 'description': 'Adverse events mean all unfavorable events that occur in participants after administration of Voriconazole, irrespective of causal relationship to Voriconazole (including clinically problematic abnormal changes in laboratory test values). Serious adverse events were defined as those including death, fatal risk, hospitalization or prolongation of hospitalization period, continuous dysfunction, those causing malformation, and serious ones like the above-cited events. Treatment related Adverse Events were evaluated in company with the causal relationship to Voriconazole.', 'timeFrame': '16 weeks'}]","[{'measure': 'Number of Participants With Clinical Response of Cure at the Test-of-Cure(TOC) Visit.', 'description': 'The primary endpoint was the efficacy ratio (number of effective cases/number of evaluable cases for efficacy assessment) among the cohort comprising the participants for efficacy analysis.\n\nClinical response of cure was assessed comprehensively by physicians in the three categories, which were ""effective"", ""ineffective"", and ""not evaluable"", based on the clinical symptoms, imaging diagnosis and endoscopy, fungal tests, and serological tests.', 'timeFrame': '16 weeks'}]",2,,,ALL,False,Pfizer,INDUSTRY,0,13.0,ACTUAL,2025-09-01T16:18:22.204271,v2_robust,False,True,True,False,True,
NCT03068234,Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis,"A Randomized, Double-blinded, Placebo Controlled Study to Evaluate Clinical Efficacy and Safety of Pirfenidone for Skin Fibrosis in Systemic Sclerosis",Pirfenidone,"['Pirfenidone', 'Placebo oral capsule', 'Steroids']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Systemic Sclerosis,['Systemic Sclerosis'],[],UNKNOWN,,2017-05,2019-12,"[{'measure': 'Modified Rodnan Skin Score (mRSS）', 'description': 'A semi-quantitative score for skin fibrosis of every subjects', 'timeFrame': 'Week 52'}]","[{'measure': 'Modified Rodnan Skin Score', 'description': 'A semi-quantitative score for skin fibrosis of every subjects', 'timeFrame': 'Week 24'}, {'measure': 'Assessment of chest CT', 'description': 'Semi-quantitative scale for fibrotic changes in chest CT images from an individual patient', 'timeFrame': 'Week 52'}, {'measure': 'Assessment of chest CT', 'description': 'Semi-quantitative scale for fibrotic changes in chest CT images from an individual patient', 'timeFrame': 'Week 24'}, {'measure': 'Forced vital capacity', 'description': 'A marker for lung function that may decrease with pulmonary fibrosis', 'timeFrame': 'Week 52'}, {'measure': 'Forced vital capacity', 'description': 'A marker for lung function that may decrease with pulmonary fibrosis', 'timeFrame': 'Week 24'}, {'measure': 'Diffusing capacity', 'description': 'Another marker for lung function that may decrease with pulmonary fibrosis', 'timeFrame': 'Week 52'}, {'measure': 'Diffusing capacity', 'description': 'Another marker for lung function that may decrease with pulmonary fibrosis', 'timeFrame': 'Week 24'}, {'measure': '6 minute walk test', 'description': 'A simple, well-accepted and quantitative clinical exam to test heart and lung function', 'timeFrame': 'Week 52'}, {'measure': '6 minute walk test', 'description': 'A simple, well-accepted and quantitative clinical exam to test heart and lung function', 'timeFrame': 'Week 24'}, {'measure': 'Hand function assessment', 'description': 'Hand function will be measured by Cochin Hand Function Scale', 'timeFrame': 'Week 52'}, {'measure': 'Hand function assessment', 'description': 'Hand function will be measured by Cochin Hand Function Scale', 'timeFrame': 'Week 24'}, {'measure': 'Proportion of subjects with increased mRSS', 'description': 'Proportion of subjects with ∆mRSS≥5', 'timeFrame': 'Week 52'}, {'measure': 'Proportion of subjects with increased mRSS', 'description': 'Proportion of subjects with ∆mRSS≥5', 'timeFrame': 'Week 24'}, {'measure': 'Quality of life', 'description': 'Assessed by the health assessment questionnaire disability index', 'timeFrame': 'Week 52'}, {'measure': 'Quality of life', 'description': 'Assessed by the health assessment questionnaire disability index', 'timeFrame': 'Week 24'}, {'measure': 'Safety and Tolerability', 'description': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': 'Week 52'}, {'measure': 'Safety and Tolerability', 'description': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': 'Week 24'}]",18,18 Years,70 Years,ALL,False,RenJi Hospital,OTHER,0,72.0,ESTIMATED,2025-09-01T16:18:22.204298,v2_robust,True,True,False,False,True,
NCT01603134,Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition,"A Randomized, Open Label, Two-Period, Two-Treatment, Two-Sequence, Single Dose, Crossover Comparative Bioequivalence Study of Allopurinol 300 mg Tablets USP With Zyloprim® 300 mg in Normal, Healthy, Adult, Human Male Subjects Under Fasting Condition.",Allopurinol,"['Allopurinol', 'Test Product', 'Zyloprim®']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Fasting State,['Fasting State'],[],COMPLETED,,2007-11,2008-04,"[{'measure': 'Bioequivalence is based on Cmax and AUC parameters.', 'description': 'Area Under Curve (AUC) and Cmax Sampling Hours: Pre-dose and at 00.25, 00.50, 00.75, 01.00, 01.25, 01.50, 01.75, 02.00, 02.25, 02.50, 02.75, 03.00, 03.50, 04.00, 04.50, 05.00, 05.50, 06.00, 06.50, 07.00, 08.00, 10.00, 12.00, 16.00, 24.00, 48.00, 72.00 and 96.00 hours post-dose.', 'timeFrame': '6 months'}]",[],1,18 Years,45 Years,MALE,True,IPCA Laboratories Ltd.,INDUSTRY,0,32.0,ACTUAL,2025-09-01T16:18:22.204334,v2_robust,True,True,True,False,False,
NCT00573534,Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse,Pilot Study of Vyvanse™ (Lisdexamfetamine Dimesylate) in Adolescents (Ages 11-15) With ADHD and an Older Sibling With ADHD and Substance Dependence,Vyvanse,"['Lisdexamphetamine is marketed as Vyvanse', 'Vyvanse']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Attention Deficit Hyperactivity Disorder,['Attention Deficit Hyperactivity Disorder'],"['Attention Deficit Hyperactivity Disorder', 'ADHD', 'ADD', 'Prevention', 'Substance use', 'Adolescent']",COMPLETED,,2008-03,2010-03,"[{'measure': 'Number of Participants With at Least 70% Reduction in ADHD Symptoms as Measured by Change in ADHD Rating Scale From First to Last Visit', 'description': ""The outcome is the number of subjects who achieved a clinically meaningful reduction in ADHD symptoms. This is defined as a 70% reduction from baseline as measured by change in the ADHD Rating Scale (ADHD-RS). The ADHD RS quantifies symptoms on a 0-3 scale, 0 meaning never present, 1 sometimes, 2 often present, 3 very often present. For this study, the scale was clinician administered using both parent and adolescent to achieve a consensus score, or a best estimate on the clinician's part when consensus could not be achieved"", 'timeFrame': 'up to 24 weeks'}]","[{'measure': 'Number of Participants With Low or no Substance Use During the Study vs the Number With Intermittent Use Judged by (1)Time Line Follow Back (Confidential Clinician Administered Record of Recent Substance Use) (2) Urine Toxicology.', 'description': 'This outcome measure integrates data from self report supplied in the Time Line Follow Back (a self report summary of all substance and alcohol use over the previous week or month) with evidence from periodic (weekly to monthly) urine toxicologies.', 'timeFrame': 'up to 24 weeks'}]",2,11 Years,15 Years,ALL,False,New York State Psychiatric Institute,OTHER,0,8.0,ACTUAL,2025-09-01T16:18:22.204373,v2_robust,True,True,True,False,False,
NCT02315534,A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma,A Phase Ib/II Clinical Study of BBI608 in Combination With Temozolomide for Adult Patients With Recurrent or Progressed Glioblastoma,BBI608,"['BB608', 'Temozolomide', 'BBI-608', 'BBI608', 'Napabucasin', 'Temodar']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Glioblastoma,['Glioblastoma'],"['GBM', 'Malignant Glioma']",COMPLETED,,2015-03,2019-06-24,"[{'measure': 'Dose-limiting Toxicities (DLTs)', 'description': 'Number of patients who experienced a dose limiting toxicity following a dosing of BBI608', 'timeFrame': '28 days after first administration of combination treatment (BBI608+TMZ)'}, {'measure': 'Progression Free Survival (PFS)-6', 'description': 'To assess the effect of BBI608 + temozolomide (TMZ) therapy defined as the percentage of patients who have survived without objective disease progression for at least 6 months after treatment per neuro-oncology (RANO) criteria who had evaluable disease at baseline. PFS-6 is defined as the percentage of patients who survived without objective disease progression per RANO criteria for at least 6 months after treatment.', 'timeFrame': 'From the time of exposure to study drug to first objective documentation of disease progression or death due to any cause, assessed up to 6 months'}]","[{'measure': 'Progression Free Survival (PFS)-12', 'description': 'To assess the effect of BBI608 + temozolomide (TMZ) therapy defined as the percentage of patients who have survived without objective disease progression for at least 12 months after treatment per neuro-oncology (RANO) criteria who had evaluable disease at baseline. PFS-12 is defined as the percentage of patients who survived without objective disease progression per RANO criteria for at least 12 months after treatment.', 'timeFrame': 'From the time of exposure to study drug to first objective documentation of disease progression or death due to any cause, up to 12 months'}, {'measure': 'Overall Survival (OS)', 'description': 'To assess the effect of BBI608 + temozolomide (TMZ) on the overall survival of patients with recurrent or progressive glioblastoma multiforme (GBM) who had not received prior treatment with bevacizumab or other anti-vascular endothelial growth factor agents who either were eligible or not eligible for surgical resection.', 'timeFrame': 'From the time of exposure to study drug to death from any cause. If patient discontinued study drug, they were assessed the first 3 months after discontinuation, then every 3 months up to 1 year, then every 6 months thereafter until death.'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'To assess the percentage of patients that had evaluable disease at baseline with a documented complete response, partial response, and stable disease (CR + PR + SD) based on the Response Assessment in Neuro-Oncology (RANO) criteria out of all patients who received at least one dose of any study drug and had evaluable disease at baseline.', 'timeFrame': '4 weeks'}, {'measure': 'Overall Response Rate (ORR)', 'description': 'The proportion of patients with a documented complete response and partial response (CR + PR) based on RANO criteria.', 'timeFrame': '4 weeks'}, {'measure': 'Pharmacokinetic Profile of BBI608 and Temozolomide When Administered in Combination With Temozolomide as Assessed by the Area Under the Curve', 'description': 'The area under the curve of BBI608, from time 0 to the last quantifiable concentration, calculated by a combination of linear and logarithmic trapezoidal methods (linear up/log down method)', 'timeFrame': 'On Day 1 and Day 5 after the first dosing, prior to dosing and 1, 2, 3, 5, 5h40m (day 1 only), 6, 7, 8 and 24 hours after first dose of BBI608'}, {'measure': 'Pharmacodynamic Activity of BBI608 When Administered in Combination With Temozolomide as Assessed by Tumor Biopsy and Cancer Stem Cell Assays as Well as the Concentration of Study Drug in Tumors', 'description': 'Tumor samples to provide information of the biomarkers by histopathology and Cancer Stem Cell assays as well as the concentration of study drug in tumors.', 'timeFrame': 'At the time of surgical resection'}]",8,18 Years,,ALL,False,"Sumitomo Pharma America, Inc.",INDUSTRY,0,34.0,ACTUAL,2025-09-01T16:18:22.204407,v2_robust,True,True,True,False,False,
NCT02149264,A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males,"A Phase 3, Open-Label, Non-Randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males",Testosterone gel (FE 999303),['Testosterone gel (FE 999303)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Adult Male Hypogonadism,['Adult Male Hypogonadism'],[],COMPLETED,,2014-07,2015-06,"[{'measure': 'The Percentage of Subjects Whose Average Concentration (Cave(0-24)) Serum Total Testosterone Levels Are ≥300 and ≤1050 ng/dL', 'description': 'The data were presented using descriptive statistics. The 95% confidence interval (CI) of the proportion (response) was estimated using the normal approximation to the binomial distribution. The study was considered to have met its efficacy criteria if the percentage was ≥ 75% and the lower bound of the 95% CI was ≥ 65%.', 'timeFrame': 'At Day 90'}]","[{'measure': 'The Percentage of Subjects Whose Cave(0-24) Serum Total Testosterone Levels Are ≥300 and ≤1050 ng/dL', 'description': 'The data were presented using descriptive statistics. No statistical analysis was performed.', 'timeFrame': 'At 14, 35 and 56'}, {'measure': 'Change From Baseline in International Index of Erectile Function (IIEF) Score', 'description': 'Data collected from the five domains of sexual functions were summarized by descriptive statistics. The domains were:\n\n1. Erectile function (6 items, questions 1-5 and 15) (Score range:1-30)\n2. Orgasmic function (2 items, questions 9-10) (Score range: 0-10)\n3. Sexual desire (2 items, questions 11-12) (Score range: 2-10)\n4. Intercourse satisfaction (3 items, questions 6-8) (Score range: 0-15)\n5. Overall satisfaction (2 items, questions 13-14) (Score range: 2-10)\n\nA score of 0-5 is awarded to questions 1 to 10 and a score of 1-5 is awarded to questions 11 to 15. Total score was calculated by summing up scores of each domain and ranged from 5 to 75. Low score indicates severe dysfunction and a high score indicates no dysfunction in sexual function.', 'timeFrame': 'At Days 35 and 90'}, {'measure': 'Change From Baseline in Multidimensional Assessment of Fatigue (MAF) Score', 'description': ""The MAF contains four sub-domains:\n\n1. Severity (2 items, questions 1-2) (Score range: 2-20)\n2. Distress (1 item, question 3) (Score range: 1-10)\n3. Degree of interference in activities of daily living (11 items, questions 4-14) (Score range: 11-110)\n4. Timing (2 items, questions 15-16) (Score range: 5-20)\n\nA score of 1-10 is awarded to each of the 14 questions across the 3 domains. The timing domain (categorical in nature) are scored from 1-4. The scores are converted to 1-10 scale by multiplying each score by 2.5. Lower score in each domain indicates improvement in fatigue.\n\nTo calculate GFI : Score of question 15 is converted to a 0-10 scale by multiplying each score by 2.5 and then sum questions 1, 2, 3, average of 4-14, and newly scored question 15. A score of zero is assigned to question 2-16, if patient select 'no fatigue' to question 1. Question 16 is not included in GFI calculation. The GFI ranged from 1 (no fatigue) to 50 (severe fatigue)."", 'timeFrame': 'At Days 35 and 90'}, {'measure': 'Change From Baseline in Short Form-12 Health Survey (SF-12) Score', 'description': 'Data collected from the SF-12 questionnaire, based on the norm-based scores was used to assess improvement in the psychometrically-based physical component summary (PCS) and mental component summary (MCS). Both PCS and MCS contained four sub-domains:\n\nPCS:\n\n1. Physical Functioning (2 items, questions 2-3)\n2. Role-Physical (2 items, questions 4-5)\n3. Bodily Pain (1 item, question 8)\n4. General Health (1 item, question 1)\n\nMCS:\n\n1. Vitality (1 item, question 10)\n2. Social Functioning (1 item, question 12)\n3. Role-Emotional (2 items, questions 6-7)\n4. Mental Health (2 items, questions 9 and 11)\n\nPCS and MCS composite scores are computed using the scores of the 12 questions and range from 0-100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. Positive change from baseline indicated improvement in physical and mental health.', 'timeFrame': 'At Days 35 and 90'}, {'measure': 'Pharmacokinetic Parameter - Average Concentration (Cave) for Total Testosterone and Dihydrotestosterone', 'description': 'A validated high pressure liquid chromatography with tandem mass spectrometry detection (LC/MS/MS) method was used to determine the levels of total testosterone and dihydrotestosterone.', 'timeFrame': 'Samples collected at pre-dose, 2, 4, 6, 8 & 24 hours post-dose on Days 14, 35 & 56, and at pre-dose, 2, 4, 6, 8, 10, 12, 18 & 24 hours post-dose on Day 90'}, {'measure': 'Pharmacokinetic Parameter - Area Under the Concentration-time Curve (AUCτ) for Total Testosterone and Dihydrotestosterone', 'description': 'A validated LC/MS/MS method was used to determine the levels of total testosterone and dihydrotestosterone.', 'timeFrame': 'Samples collected at pre-dose, 2, 4, 6, 8 & 24 hours post-dose on Days 14, 35 & 56, and at pre-dose, 2, 4, 6, 8, 10, 12, 18 & 24 hours post-dose on Day 90'}, {'measure': 'Pharmacokinetic Parameter - Time at Which the Maximum Concentration Occurs (Tmax) for Total Testosterone and Dihydrotestosterone', 'description': 'A validated LC/MS/MS method was used to determine the levels of total testosterone and dihydrotestosterone.', 'timeFrame': 'Samples collected at pre-dose, 2, 4, 6, 8 & 24 hours post-dose on Days 14, 35 & 56, and at pre-dose, 2, 4, 6, 8, 10, 12, 18 & 24 hours post-dose on Day 90'}, {'measure': 'Pharmacokinetic Parameter - Maximum Concentration Observed (Cmax) for Total Testosterone and Dihydrotestosterone', 'description': 'A validated LC/MS/MS method was used to determine the levels of total testosterone and dihydrotestosterone.', 'timeFrame': 'Samples collected at pre-dose, 2, 4, 6, 8 & 24 hours post-dose on Days 14, 35 & 56, and at pre-dose, 2, 4, 6, 8, 10, 12, 18 & 24 hours post-dose on Day 90'}, {'measure': 'Pharmacokinetic Parameter - Minimum Concentration Observed (Cmin) for Total Testosterone and Dihydrotestosterone', 'description': 'A validated LC/MS/MS method was used to determine the levels of total testosterone and dihydrotestosterone.', 'timeFrame': 'Samples collected at pre-dose, 2, 4, 6, 8 & 24 hours post-dose on Days 14, 35 & 56, and at pre-dose, 2, 4, 6, 8, 10, 12, 18 & 24 hours post-dose on Day 90'}]",10,18 Years,75 Years,MALE,False,Ferring Pharmaceuticals,INDUSTRY,0,160.0,ACTUAL,2025-09-01T16:18:22.204482,v2_robust,True,True,True,False,False,
NCT00199264,Efficacy Vulvovaginitis Candida,"A Single-Blind, Randomized, Dose-Finding Study Versus Fluconazole to Assess the Efficacy and Tolerability of Five Single Doses of Albaconazole in the Treatment of Acute Non-Recurrent Candida Spp Vulvovaginitis",Albaconazole oral solution,['Albaconazole oral solution'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Candidiasis Vulvaginitis,['Candidiasis Vulvaginitis'],"['antifungal oral therapy', 'efficacy acute candidiasis vulvaginitis']",TERMINATED,,2004-06,2004-10,"[{'measure': ""Primary Efficacy VariableThe primary efficacy assessment will be carried out 24 ± 4 (FV) days following treatment or at the last patient's.""}]",[],1,18 Years,,ALL,False,J. Uriach and Company,INDUSTRY,0,60.0,,2025-09-01T16:18:22.204580,v2_robust,True,True,False,True,False,
NCT05326464,Tofacitinib in Recurrent GBM Patients,Tofacitinib: Suppressing Tumor Invasion in Recurrent GBM Patients,Tofacitinib 10mg,['Tofacitinib 10mg'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Glioblastoma,['Glioblastoma'],[],ACTIVE_NOT_RECRUITING,,2022-10-07,2027-06-01,"[{'measure': 'Progression-free survival (PFS) of the study cohort as defined by RANO criteria.', 'description': 'Median progression-free survival from initiation of Tofacitinib until disease progression as defined by the RANO criteria, unacceptable toxicity, withdrawal of consent, or discontinuation from the trial for any other reason.', 'timeFrame': 'Up to 2 years after study treatment'}]","[{'measure': 'Overall survival (OS) of the study cohort.', 'description': 'Median OS of the study patients from time of study entry until death or lost to follow-up.', 'timeFrame': 'Up to 2 years after study treatment'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability].', 'description': 'Assess safety and tolerability associated with Tofacitinib 5 mg orally twice daily when administered to GBM patients. NCI Common terminology criteria for adverse events (CTCAE v.5) will be used to assess the adverse events.', 'timeFrame': 'Up to 2 years after study treatment'}, {'measure': 'Tumor response by RANO criteria.', 'description': 'Tumor response will be assessed using contrast and non-contrast brain magnetic resonance imaging (MRI) with assessments based on the international criteria proposed by the Response Assessment in Neuro-Oncology (RANO) Working Group, until progression of disease. For patients who do not progress or die, PFS will be censored at the last adequate radiologic assessment.', 'timeFrame': 'Up to 2 years after study treatment'}]",4,18 Years,,ALL,False,University of Texas Southwestern Medical Center,OTHER,1,17.0,ACTUAL,2025-09-01T16:18:22.204590,v2_robust,True,True,False,False,True,
NCT00117364,Effect of SACCHACHITIN on Healing of a Chronic Wound,Effect of SACCHACHITIN on Healing of Chronic Wound ---A Clinical Trial,SACCHACHITIN patch,['SACCHACHITIN patch'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Wounds,['Wounds'],"['chronic ulcer', 'poor healing', 'The patients with a poorly healed wound, in which skin graft is clinically indicated, are included in this study']",UNKNOWN,,2005-01,2005-06,[],[],0,16 Years,80 Years,ALL,False,Min-Sheng General Hospital,OTHER,0,30.0,,2025-09-01T16:18:22.204602,v2_robust,True,True,False,False,False,
NCT05685264,A Study to Learn How the Study Medicine (Ponsegromab) is Changed and Eliminated From Healthy Chinese Adults,"A PHASE 1, OPEN-LABEL, SINGLE DOSE STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF PONSEGROMAB ADMINISTERED SUBCUTANEOUSLY IN HEALTHY ADULT CHINESE PARTICIPANTS",Ponsegromab,['Ponsegromab'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Ponsegromab', 'Healthy Volunteers']",COMPLETED,,2023-01-18,2023-07-07,"[{'measure': 'Area Under the Serum Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Unbound and Total Ponsegromab', 'description': 'AUCinf was defined as area under the serum concentration-time profile from time 0 extrapolated to infinite time.', 'timeFrame': 'Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127'}, {'measure': 'Area Under the Serum Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Unbound and Total Ponsegromab', 'description': 'AUClast was defined as area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration.', 'timeFrame': 'Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127'}, {'measure': 'Maximum Observed Serum Concentration (Cmax) of Unbound and Total Ponsegromab', 'description': 'Cmax was defined as maximum observed concentration. Cmax was observed directly from data.', 'timeFrame': 'Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127'}, {'measure': 'Time for Cmax (Tmax) of Unbound and Total Ponsegromab', 'description': 'Tmax was defined as time for Cmax. Tmax was observed directly from data as time of first occurrence.', 'timeFrame': 'Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127'}, {'measure': 'Terminal Half Life (t1/2) of Unbound and Total Ponsegromab', 'description': 't1/2 was defined as terminal half life. t1/2 was calculated as Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve.', 'timeFrame': 'Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127'}]","[{'measure': 'Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'description': 'Adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as events that started on or after the first dose but before the end of the study (approximately 18 weeks post dose on Day 1). An SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect.', 'timeFrame': 'From the first dose of study intervention on Day 1 to Day 127'}, {'measure': 'Number of Participants With Treatment-Related TEAEs and SAEs', 'description': 'AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as events that started on or after the first dose but before the end of the study (approximately 18 weeks post dose on Day 1). An SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect. Causality of the TEAEs and SAEs was judged by the investigator.', 'timeFrame': 'From the first dose of study intervention on Day 1 to Day 127'}, {'measure': 'Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality', 'description': 'Hematology parameters included hemoglobin, hematocrit, red blood cell, white blood cell and platelet count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean platelet volume, total neutrophils, eosinophils, monocytes, basophils and lymphocytes. Chemistry parameters included blood urea nitrogen, glucose (fasting), calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, and creatinine. Urine parameters included pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin, microscopy. Only those categories in which at least 1 participant had data were reported.', 'timeFrame': 'From the first dose of study intervention on Day 1 to Day 127'}, {'measure': 'Number of Participants With Clinically Significant Change in Vital Signs', 'description': 'Vital sign measurements included supine blood pressure and pulse rate. Any safety assessments (vital sign measurements) including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator or were considered meeting the AE definition and are listed below.', 'timeFrame': 'From the first dose of study intervention on Day 1 to Day 127'}, {'measure': 'Number of Participants With Clinically Significant Change in Electrocardiogram (ECG)', 'description': 'ECG abnormalities criteria included: 1) maximum QTc interval adjusted according to Fridericia formula (QTcF) (msec): \\>450, \\>480, \\>500, increase from baseline \\>30, increase from baseline \\>30, \\>60; 2) maximum pulse rate (msec): ≥300, baseline \\>200 and maximum increase ≥25%, baseline ≤200 and maximum increase ≥50%; 3) maximum QRS (msec): ≥140, increase ≥50%.', 'timeFrame': 'From the first dose of study intervention on Day 1 to Day 127'}]",10,18 Years,55 Years,ALL,True,Pfizer,INDUSTRY,0,18.0,ACTUAL,2025-09-01T16:18:22.204632,v2_robust,True,True,True,False,True,
NCT03393364,Pain Management in Outpatient Urologic Procedures,Pain Management in Outpatient Urologic Procedures,Oxycodone,"['Oxycodone', 'Ketorolac']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Urologic Diseases,['Urologic Diseases'],[],COMPLETED,,2018-04-01,2020-06-01,"[{'measure': 'Pain control', 'description': 'Survey evaluating how well pain was controlled', 'timeFrame': 'within 6 weeks of surgery'}]","[{'measure': 'Number of pills used', 'description': 'Survey evaluating number of pills used', 'timeFrame': 'within 6 weeks of surgery'}]",2,18 Years,,ALL,True,University Hospitals Cleveland Medical Center,OTHER,0,150.0,ACTUAL,2025-09-01T16:18:22.204661,v2_robust,True,True,True,False,False,
NCT02502864,Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide,Multicenter Study Investigating Utilization of Pharmacokinetic(PK)-Guided Docetaxel in Senior Adult Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy,Standard of Care: Docetaxel,"['Taxotere®', 'Standard of Care: Docetaxel', 'Standard of Care: Cyclophosphamide', 'Cytoxan®']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Breast Cancer,"['Breast Cancer', 'Breast Cancer Female']","['senior adult', 'postmenopausal']",COMPLETED,,2016-02-09,2019-01-31,"[{'measure': 'Rate of Achieving Targeted Area Under the Curve (AUC)', 'description': 'Rate of PK guided dosing of docetaxel chemotherapy improving the ability to achieve a targeted AUC ( 2.5-3.7 mg\\*hr/L) within 4 cycles of therapy in patients \\> 65 years of age with breast cancer receiving TC (docetaxel and cyclophosphamide) as compared with historical non-PK guided therapy from patients receiving a similar regimen.', 'timeFrame': 'Cycle 4 - Up to 6 months'}]","[{'measure': 'Incidence of Grade 3 and 4 Neutropenia and Febrile Neutropenia', 'description': 'The incidence of grade 3 and 4 neutropenia and febrile neutropenia in cycles following PK adjustment (cycles 2-4) will be compared with cycle 1 and historical non-PK guided therapy using the Wilcoxon-Rank sum assessment.', 'timeFrame': 'Up to 6 months'}, {'measure': 'Association Between Scores - Chemotherapy Risk Assessment Scale for High-Age Patients', 'description': 'The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score will be reported as ordinal data (low, intermediate-low, intermediate-high, or high risk).', 'timeFrame': 'Baseline and Post Cycle 1'}, {'measure': 'Association Between Scores - Instrumental Activities of Daily Living', 'description': 'The Instrumental Activities of Daily Living (IADL) total score will be reported as binomial data (greater or less than 26 based on how it is incorporated into the CRASH score).', 'timeFrame': 'Baseline and Post Cycle 1'}, {'measure': 'Association Between Scores - Cumulative Illness Rating Scale for Geriatrics', 'description': 'The Cumulative Illness Rating Scale for Geriatrics (CIRS-G) will be reported as discrete data out of a possible score of 65. The Wilcoxon-Rank sum and Chi-squared tests will be used as appropriate.', 'timeFrame': 'Baseline and Post Cycle 1'}]",5,65 Years,,FEMALE,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,9.0,ACTUAL,2025-09-01T16:18:22.204672,v2_robust,True,True,True,False,False,
NCT06948864,Evaluate the Outcomes of Ferric Carboxymaltose in Patients With Perioperative Anemia,Evaluation of the Role of Preoperative Intravenous Iron in Patients Undergoing Surgery,Ferric Carboxymaltose (FCM),"['infusion', 'Ferric Carboxymaltose (FCM)']",2,OBSERVATIONAL,[],,,Anemia,"['Anemia', 'Anemia (Iron-Loading)', 'Perioperative Bleeding', 'Infection Prevention', 'Readmission, Hospital', 'Surgical Complication', 'Length of Hospital Stay', 'Iron Deficiency Anemia Treatment', 'Prehabilitation']","['infection', 'anemia', 'length of stay', 'prehabilitation']",COMPLETED,,2020-01-01,2024-12-31,"[{'measure': 'Analyze levels of Hemoglobine', 'description': 'To analyze the levels of:\n\nHemoglobin (Hb) g/dL at three time points:\n\nBefore the administration of intravenous ferric carboxymaltose (FCM), At the time of inclusion on the surgical waiting list, 30 days after surgery. And to compare the incidence of postoperative complications between patients who received FC and those who did not.', 'timeFrame': 'From Jan 2019 to Dec 2022'}, {'measure': 'Analyze levels of ferritin', 'description': 'To analyze the levels of:\n\nFerritin (ng/mL)\n\nat three time points:\n\nBefore the administration of intravenous ferric carboxymaltose (FCM), At the time of inclusion on the surgical waiting list, 30 days after surgery. And to compare the incidence of postoperative complications between patients who received FC and those who did not.', 'timeFrame': 'From Jan 2019 to Dec 2022'}, {'measure': 'Analyze levels of transferrine', 'description': 'To analyze the levels of:\n\nTransferrin (mg/dL)\n\nat three time points:\n\nBefore the administration of intravenous ferric carboxymaltose (FCM), At the time of inclusion on the surgical waiting list, 30 days after surgery. And to compare the incidence of postoperative complications between patients who received FC and those who did not.', 'timeFrame': 'From Jan 2019 to Dec 2022'}, {'measure': 'Analyze levels of transferrine saturation', 'description': 'To analyze the levels of:\n\nTransferrin saturation (%)\n\nat three time points:\n\nBefore the administration of intravenous ferric carboxymaltose (FCM), At the time of inclusion on the surgical waiting list, 30 days after surgery. And to compare the incidence of postoperative complications between patients who received FC and those who did not.', 'timeFrame': 'From Jan 2019 to Dec 2022'}]","[{'measure': 'Compare ferric carboxymaltose vs control (other)', 'description': 'To compare between the groups (ferric carboxymaltose vs. control):\n\nHospital length of stay (in days)', 'timeFrame': 'from january 2019 to decembre 2022'}, {'measure': 'Compare ferric carboxymaltose vs control (other)', 'description': 'To compare between the groups (ferric carboxymaltose vs. control):\n\nICU admission (yes/no)', 'timeFrame': 'from january 2019 to decembre 2022'}, {'measure': 'Compare ferric carboxymaltose vs control (other)', 'description': 'To compare between the groups (ferric carboxymaltose vs. control):\n\nICU length of stay (in days)', 'timeFrame': 'from january 2019 to decembre 2022'}, {'measure': 'Compare ferric carboxymaltose vs control (other)', 'description': 'To compare between the groups (ferric carboxymaltose vs. control):\n\nNeed for hospital readmission (yes/no)', 'timeFrame': 'from january 2019 to decembre 2022'}, {'measure': 'Compare ferric carboxymaltose vs control (other)', 'description': 'To compare between the groups (ferric carboxymaltose vs. control):\n\nNeed for blood transfusion (yes/no)', 'timeFrame': 'from january 2019 to decembre 2022'}, {'measure': 'Compare ferric carboxymaltose vs control (other)', 'description': 'To compare between the groups (ferric carboxymaltose vs. control):\n\nSurgical wound infection (Yes/no)', 'timeFrame': 'from january 2019 to decembre 2022'}, {'measure': 'Compare ferric carboxymaltose vs control (other)', 'description': 'To compare between the groups (ferric carboxymaltose vs. control):\n\nComplications (yes/no)', 'timeFrame': 'from january 2019 to decembre 2022'}, {'measure': 'Compare ferric carboxymaltose vs control (other)', 'description': 'To compare between the groups (ferric carboxymaltose vs. control):\n\nSepsis (yes/no)', 'timeFrame': 'from january 2019 to decembre 2022'}, {'measure': 'Compare ferric carboxymaltose vs control (other)', 'description': 'To compare between the groups (ferric carboxymaltose vs. control):\n\nPleural effusion (yes/no)', 'timeFrame': 'from january 2019 to decembre 2022'}, {'measure': 'Compare ferric carboxymaltose vs control (other)', 'description': 'To compare between the groups (ferric carboxymaltose vs. control):\n\nRespiratory infection (yes/no)', 'timeFrame': 'from january 2019 to decembre 2022'}, {'measure': 'Compare ferric carboxymaltose vs control (other)', 'description': 'To compare between the groups (ferric carboxymaltose vs. control):\n\nAbdominal colection (yes/no)', 'timeFrame': 'from january 2019 to decembre 2022'}, {'measure': 'Compare ferric carboxymaltose vs control (other)', 'description': 'To compare between the groups (ferric carboxymaltose vs. control):\n\nParalytic ileum (yes/no)', 'timeFrame': 'from january 2019 to decembre 2022'}, {'measure': 'Compare ferric carboxymaltose vs control (other)', 'description': 'To compare between the groups (ferric carboxymaltose vs. control):\n\nBleeding (yes/no)', 'timeFrame': 'from january 2019 to decembre 2022'}, {'measure': 'Compare ferric carboxymaltose vs control (other)', 'description': 'To compare between the groups (ferric carboxymaltose vs. control):\n\nUrinary tract infection (yes/no)', 'timeFrame': 'from january 2019 to decembre 2022'}]",18,18 Years,,ALL,False,Hospital Universitario Infanta Cristina,OTHER,0,152.0,ACTUAL,2025-09-01T16:18:22.204786,v2_robust,False,True,True,False,False,
NCT01257464,Sitagliptin in Cystic Fibrosis-Related Diabetes,The Effects of the DPPIV Inhibitor Sitagliptin in Cystic Fibrosis-related Diabetes,Sitagliptin,"['Sitagliptin', 'Januvia, MK-0431, Dipeptidyl peptidase IV inhibitor (DPP-4 inhibitor)', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Cystic Fibrosis,['Cystic Fibrosis'],"['CFRD', 'sitagliptin', 'cystic fibrosis-related diabetes', 'incretins', 'hyperglycemia', 'GIP', 'GLP-1']",TERMINATED,Lack of recruitment,2010-09,2012-06,"[{'measure': 'Insulin release', 'description': 'The study protocol is a iv-oral hyperglycemic glucose clamp. We will assess insulin release during the clamp, comparing placebo to sitagliptin.', 'timeFrame': '180 minutes (during clamp)'}]","[{'measure': 'Incretin Response', 'description': 'We will assess incretin release \\[glucoagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide(GIP)\\] during the glucose clamp.', 'timeFrame': '180 minutes (during clamp)'}]",2,19 Years,,ALL,False,University of British Columbia,OTHER,0,3.0,ACTUAL,2025-09-01T16:18:22.204901,v2_robust,True,True,False,True,False,Lack of recruitment
NCT01445964,Effect of SLCO2B1 Genotype and Apple Juice on Pharmacokinetics of Atenolol After Oral Administration in Healthy Male Korean,"An Open-label, Single-dose, Three-treatment, Three-period Study to Investigate the Effect of SLCO2B1 Genotype and Apple Juice on Pharmacokinetics of Atenolol After Oral Administration in Healthy Male Korean",Atenolol,"['Atenolol', 'Atenolol with apple juice 600 mL', 'Atenolol with apple juice 1200 mL']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Healthy,['Healthy'],"['SLCO2B1 genotype', 'effect of apple juice']",COMPLETED,,2011-05,2011-12,"[{'measure': 'AUC of atenolol according to the SLCO2B1 genotypes', 'description': 'The area under the plasma concentration versus time curve, from time 0 to the last measurable concentration, as calculated by the linear/log trapezoidal method will be summarized by treatment and genotype group using descriptive statistics.', 'timeFrame': '0-48 hr after drug administration'}]","[{'measure': 'Blood pressure of the subjects who administered atenolol according to the SLCO2B1 genotypes', 'description': 'Blood pressure measurement will be presented as descriptive statistics for the difference from baseline where appropriate.', 'timeFrame': '0-48 hr after drug admnistration'}, {'measure': 'Number of Participants with Adverse Events as a Measure of Safety and Tolerability', 'description': 'Number of participants with adverse event as a measure of safety and tolerability\n\n\\*Measure of safety and tolerability: physical examinations, ECG, Laboratory tests (including hematology, chemistry, urinalysis)\n\n\\- Descriptive statistics will be calculated for quantitative safety data as well as for the difference from baseline where appropriate.', 'timeFrame': '0-48 hr after drug admnistration'}]",3,20 Years,50 Years,MALE,True,Seoul National University Hospital,OTHER,0,12.0,ACTUAL,2025-09-01T16:18:22.205042,v2_robust,True,True,True,False,True,
NCT03822364,Staccato Apomorphine Single and Multi Dose PK,"A Randomized Study of the Safety, Tolerability, and Pharmacokinetics of AZ-009 (Staccato Apomorphine) in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZ-009 in Subjects With Parkinson's Disease",009-1,"['009-3', '009-4', '009-0', '009-2', 'active comparator', '009-1', '009-5']",7,INTERVENTIONAL,['PHASE1'],PHASE1,,Parkinson Disease,['Parkinson Disease'],"['apomorphine', 'aerosol']",COMPLETED,,2018-11-26,2019-03-26,"[{'measure': 'A-Relative bioavailability of inhaled Staccato apomorphine dose compared to the subcutaneous administration', 'description': 'Relative bioavailability of inhaled Staccato apomorphine compared to active comparator injection based on the Geometric Least Squares Mean Ratio of AUCinf for all subjects completing the crossover part of the trial', 'timeFrame': '24 hours'}, {'measure': 'B-Dose Proportionality by Power Analysis of AUCinf', 'description': 'Dose proportionality of inhaled Staccato apomorphine AUCinf across all doses administered in the single ascending dose portions of the study (Parts B and C) using a power model \\[regression of log(AUCinf) versus log(dose)\\]', 'timeFrame': '24 hours'}]",[],2,18 Years,60 Years,ALL,True,"Alexza Pharmaceuticals, Inc.",INDUSTRY,0,56.0,ACTUAL,2025-09-01T16:18:22.205059,v2_robust,True,True,True,False,False,
NCT03810664,A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations,"A Phase 1, Single-Center, Randomized, Cross-Over, Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations",Somatrogon,['Somatrogon'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Male Volunteers,['Healthy Male Volunteers'],[],COMPLETED,,2019-01-18,2019-04-19,"[{'measure': 'Area under the curve (AUC) of the serum concentration-time from time 0 to a specific time (AUCt)', 'timeFrame': '30 days'}, {'measure': 'Area under the curve (AUC) of the serum concentration-time from time 0 to infinity (AUC∞)', 'timeFrame': '30 days'}, {'measure': 'Serum concentration from of maximum concentration (Cmax) of somatrogon levels in serum', 'timeFrame': '30 days'}]","[{'measure': 'AUCt of IGF-1 and IGFBP-3 levels', 'timeFrame': '30 days'}, {'measure': 'AUC∞ of IGF-1 and IGFBP-3 levels', 'timeFrame': '30 days'}, {'measure': 'Cmax of IGF-1 and IGFBP-3 levels', 'timeFrame': '30 days'}, {'measure': 'Time to maximum concentration (Tmax)', 'timeFrame': '30 days'}, {'measure': 'Apparent Terminal Rate Constant (λz) and t½', 'timeFrame': '30 days'}]",8,18 Years,55 Years,MALE,True,"OPKO Health, Inc.",INDUSTRY,0,49.0,ACTUAL,2025-09-01T16:18:22.205071,v2_robust,True,True,True,False,False,
NCT00460564,Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity,"A Multicenter Study to Evaluate the Efficacy and Safety in Patients With Post-Stroke Upper Limb Spasticity Receiving a Double-Blind, Placebo-Controlled GSK1358820 Treatment Followed by an Open-Label GSK1358820 Treatment",GSK1358820,"['GSK1358820', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Post-Stroke Spasticity,"['Post-Stroke Spasticity', 'Cerebrovascular Accident']","['Spasticity', 'Post-Stroke', 'botulinum toxin type A', 'Upper Limb']",COMPLETED,,2007-05,2008-12,"[{'measure': 'Area Under the Curve (AUC) for the Change From Baseline in Modified Ashworth Scale (MAS) Wrist Score to the End of the DB Phase (Week 12) in the High-dose Groups', 'description': 'Change from baseline in MAS wrist score using a 6-point scale (0, 1, 1+ \\[regarded as 1.5\\], 2, 3, and 4; 0=no increase in muscle tone; 4=affected part\\[s\\] rigid in flexion/extension) to each time point in the DB phase was calculated. In the graph plotting time points on the horizontal axis and changes from baseline on the vertical axis, the area surrounded by the MAS wrist score change curve and the horizontal axis was calculated and used as a summary index (AUC) for assessment of the MAS wrist score. Negative changes from baseline indicate improvement, and the AUC has a negative sign.', 'timeFrame': 'Baseline, Week 12'}]","[{'measure': 'Area Under the Curve (AUC) for the Change From Baseline in Modified Ashworth Scale (MAS) Wrist Score to the End of the DB Phase (Week 12) in the Low-dose Groups', 'description': 'Change from baseline in MAS wrist score using a 6-point scale (0, 1, 1+ \\[regarded as 1.5\\], 2, 3, and 4; 0=no increase in muscle tone; 4=affected part\\[s\\] rigid in flexion/extension) to each time point in the DB phase was calculated. In the graph plotting time points on the horizontal axis (HA) and changes from baseline on the vertical axis, the area surrounded by the MAS wrist score change curve and the HA was calculated and used as a summary index (AUC) for assessment of the MAS wrist score. Negative changes from baseline indicate improvement, and the area under the AUC has a negative sign.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Mean Change From Baseline in MAS Wrist Score From Baseline to Week 12 of the Double-blind Phase', 'description': 'The investigator assessed MAS wrist score using a 6-point scale (0, 1, 1+, 2, 3, and 4; 0=No increase in muscle tone to 4=Affected part\\[s\\] rigid in flexion or extension) at each time point in the double-blind phase. The ""+1"" (slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder \\[less than half\\] of ROM \\[range of motion\\]) of MAS score is regarded as score 1.5.', 'timeFrame': 'Baseline; Weeks 1, 4, 6, 8, and 12'}, {'measure': 'Mean Change From Baseline in MAS Finger Score From Baseline to Week 12 of the Double-blind Phase', 'description': 'The investigator assessed MAS finger score using a 6-point scale (0, 1, 1+, 2, 3, and 4; 0=No increase in muscle tone to 4=Affected part\\[s\\] rigid in flexion or extension) at each time point in the double-blind phase. The ""+1"" (slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder \\[less than half\\] of ROM \\[range of motion\\]) of MAS score is regarded as score 1.5.', 'timeFrame': 'Baseline; Weeks 1, 4, 6, 8, and 12'}, {'measure': 'Mean Change From Baseline in Disability Assessment Scale (DAS) Score of Principal Measure From Baseline to Week 12 of the Double-blind Phase', 'description': 'DAS scores of Hygiene, Pain, Dressing, and Limb posture were assessed using a 4-point scale (0=No functional disability to 3=Severe disability). Prior to the first injection, the investigator, in consultation with the participant, selected one functional disability item and assessed it as a principal measure at each time point in the double-blind phase.', 'timeFrame': 'Baseline; Weeks 1, 4, 6, 8, and 12'}, {'measure': 'Mean Change From Baseline in Disability Assessment Scale (DAS) Score of Hygiene From Baseline to week12 of the Double-blind Phase', 'description': 'DAS score of Hygiene was assessed using a 4-point scale (0=No functional disability to 3=Severe disability) at each time point in double-blind phase.', 'timeFrame': 'Baseline; Weeks 1, 4, 6, 8, and 12'}, {'measure': 'Mean Change From Baseline in Disability Assessment Scale (DAS) Score of Pain From Baseline to Week 12 of the Double-blind Phase', 'description': 'DAS score of pain was assessed using a 4-point scale (0=No functional disability to 3=Severe disability) at each time point in the double-blind phase.', 'timeFrame': 'Baseline; Weeks 1, 4, 6, 8, and 12'}, {'measure': 'Mean Change From Baseline in Disability Assessment Scale (DAS) Score of Dressing From Baseline to Week 12 of the Double-blind Phase', 'description': 'DAS score of Dressing was assessed using a 4-point scale (0=No functional disability to 3=Severe disability) at each time point in the double-blind phase.', 'timeFrame': 'Baseline; Weeks 1, 4, 6, 8, and 12'}, {'measure': 'Mean Change From Baseline in Disability Assessment Scale (DAS) Score of Limb Posture From Baseline to Week 12 of the Double-blind Phase', 'description': 'DAS score of Limb Posture was assessed using a 4-point scale (0=No functional disability to 3=Severe disability) at each time point in the double-blind phase.', 'timeFrame': 'Baseline; Weeks 1, 4, 6, 8, and 12'}, {'measure': 'Mean Change From Baseline in Clinical Global Impression (CGI) Score of Functional Disability Assessed by the Investigator From Baseline to Week 12 of the Double-blind Phase', 'description': 'The CGI score of functional disability was assessed at each visit using the 11-point Numeric Rating Scale (NRS) (-5=Worst Possible to 5=Best Possible) at each time point in the double-blind phase.', 'timeFrame': 'Baseline; Weeks 1, 4, 6, 8, and 12'}, {'measure': 'Mean Change From Baseline in Clinical Global Impression (CGI) Score of Functional Disability Assessed by the Participant From Baseline to Week 12 of the Double-blind Phase', 'description': 'The CGI score of functional disability was assessed at each visit using the 11-point Numeric Rating Scale (NRS) (-5=Worst Possible to 5=Best Possible) at each time point in the double-blind phase.', 'timeFrame': 'Baseline; Weeks 1, 4, 6, 8, and 12'}, {'measure': 'Mean Change From Baseline in Clinical Global Impression (CGI) Score of Functional Disability Assessed by the Physiotherapist/Occupational Therapist From Baseline to Week 12 of the Double-blind Phase', 'description': 'The CGI score of functional disability was assessed at each visit using the 11-point Numeric Rating Scale (NRS) (-5=Worst Possible to 5=Best Possible) at each time point in the double-blind phase.', 'timeFrame': 'Baseline; Weeks 1, 4, 6, 8, and 12'}, {'measure': 'Mean Change From Baseline (at the Start of the Double-blind Phase) in the MAS Wrist Score at 4, 8, and 12 Weeks After Each Injection in the Open-label Phase', 'description': 'The investigator assessed the MAS wrist score using a 6-point scale (0, 1, 1+, 2, 3, and 4; 0=no increase in muscle tone to 4=affected part\\[s\\] rigid in flexion or extension) at each time point from baseline (at the start of the double-blind phase) to week 48. The ""+1"" (slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (\\[less than half\\] of ROM \\[range of motion\\]) of MAS score is regarded as score 1.5.', 'timeFrame': 'Baseline; Weeks 4, 8, and 12 after each injection (up to Week 48; injections given from Week 12 to Week 36)'}, {'measure': 'Mean Change From Baseline (at the Start of the Double-blind Phase) in the MAS Finger Score From at 4, 8, and 12 Weeks After Each Injection in the Open-label Phase', 'description': 'The investigator assessed the MAS finger score using a 6-point scale (0, 1, 1+, 2, 3, and 4; 0=No increase in muscle tone to 4=Affected part\\[s\\] rigid in flexion or extension) at each time point from baseline (at the start of the double-blind phase) to week 48. The ""+1"" (slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder \\[less than half\\] of ROM \\[range of motion\\]) of MAS score is regarded as score 1.5.', 'timeFrame': 'Baseline; Weeks 4, 8, and 12 after each injection (up to Week 48; injections given from Week 12 to Week 36)'}, {'measure': 'Mean Change From Baseline (at the Start of the Double-blind Phase) in the Disability Assessment Scale (DAS) Score of Principal Measure at 4, 8, and 12 Weeks After Each Injection in the Open-label Phase', 'description': 'DAS scores of Hygiene, Pain, Dressing, and Limb posture were assessed using a 4-point scale (0=No functional disability to 3=Severe disability). Prior to the first injection, the investigator, in consultation with the participant, selected one functional disability item and assessed it as a principal measure at each time point from baseline (at the start of the double-blind phase) to Week 48.', 'timeFrame': 'Baseline; Weeks 4, 8, and 12 after each injection (up to Week 48; injections given from Week 12 to Week 36)'}, {'measure': 'Mean Change From Baseline (at the Start of the Double-blind Phase) in the Disability Assessment Scale (DAS) Score of Hygiene at 4, 8, and 12 Weeks After Each Injection in the Open-label Phase', 'description': 'The DAS score of Hygiene was assessed using a 4-point scale (0=No functional disability; 3=Severe disability) at each time point from baseline (at the start of the double-blind phase) to Week 48. BTX was injected in participants up to 3 times from Week 12 to Week 36 when participants met re-injection criteria. Measurements were taken at each point until Week 48 and summarized by the number of weeks after the re-injection in individuals (4, 8, and 12 weeks after each injection) in open-label phase; thus, measurements could have been taken up to Week 48 (12 weeks after the Week 36 injection).', 'timeFrame': 'Baseline; Weeks 4, 8, and 12 after each injection (up to Week 48; injections given from Week 12 to Week 36)'}, {'measure': 'Mean Change From Baseline (at the Start of the Double-blind Phase) in the Disability Assessment Scale (DAS) Score of Pain at 4, 8, and 12 Weeks After Each Injection in the Open-label Phase', 'description': 'The DAS score of Pain was assessed using a 4-point scale (0=No functional disability to 3=Severe disability) at each time point from baseline (at the start of the double-blind phase) to Week 48. BTX was injected in participants up to 3 times from Week 12 to Week 36 when participants met re-injection criteria. Measurements were taken at each point until Week 48 and summarized by the number of weeks after the re-injection in individuals (4, 8, and 12 weeks after each injection) in open-label phase; thus, measurements could have been taken up to Week 48 (12 weeks after the Week 36 injection).', 'timeFrame': 'Baseline; Weeks 4, 8, and 12 after each injection (up to Week 48; injections given from Week 12 to Week 36)'}, {'measure': 'Mean Change From Baseline (at the Start of the Double-blind Phase) in the Disability Assessment Scale (DAS) Score of Dressing at 4, 8, and 12 Weeks After Each Injection in the Open-label Phase', 'description': 'The DAS score of Dressing was assessed using a 4-point scale (0=No functional disability to 3=Severe disability) at each time point from baseline (at the start of the double-blind phase) to Week 48. BTX was injected in participants up to 3 times from Week 12 to Week 36 when participants met re-injection criteria. Measurements were taken at each point until Week 48 and summarized by the number of weeks after the re-injection in individuals (4, 8, and 12 weeks after each injection) in open-label phase; thus, measurements could have been taken up to Week 48 (12 weeks after the Week 36 injection).', 'timeFrame': 'Baseline; Weeks 4, 8, and 12 after each injection (up to Week 48; injections given from Week 12 to Week 36)'}, {'measure': 'Mean Change From Baseline (at the Start of the Double-blind Phase) in the Disability Assessment Scale (DAS) Score of Limb Posture at 4, 8, and 12 Weeks After Each Injection in the Open-label Phase', 'description': 'The DAS score of Limb Posture was assessed using a 4-point scale (0=No functional disability to 3=Severe disability) at each time point from baseline (at the start of the double-blind phase) to Week 48. BTX was injected in participants up to 3 times from Weeks 12 to 36 when participants met re-injection criteria. Measurements were taken at each point until Week 48 and summarized by the number of weeks after the re-injection in individuals (4, 8, and 12 weeks after each injection) in open-label phase; thus, measurements could have been taken up to Week 48 (12 weeks after the Week 36 injection).', 'timeFrame': 'Baseline; Weeks 4, 8, and 12 after each injection (up to Week 48; injections given from Week 12 to Week 36)'}, {'measure': 'Mean Change From Baseline (at the Start of the Double-blind Phase) in the Clinical Global Impression (CGI) Score of Functional Disability Assessed by the Investigator at 4, 8, and 12 Weeks After Each Injection in the Open-label Phase', 'description': 'The CGI score of functional disability was assessed at each visit using the 11-point Numeric Rating Scale (NRS) (-5=Worst Possible to 5=Best Possible) at each time point from baseline (at the start of the double-blind phase) to Week 48.', 'timeFrame': 'Baseline; Weeks 4, 8, and 12 after each injection (up to Week 48; injections given from Week 12 to Week 36)'}, {'measure': 'Mean Change From Baseline (at the Start of the Double-blind Phase) in the Clinical Global Impression (CGI) Score of Functional Disability Assessed by the Participant at 4, 8, and 12 Weeks After Each Injection in the Open-label Phase', 'description': 'The CGI score of functional disability was assessed at each visit using the 11-point Numeric Rating Scale (NRS) (-5=Worst Possible to 5=Best Possible) at each time point from baseline (at the start of the double-blind phase) to Week 48.', 'timeFrame': 'Baseline; Weeks 4, 8, and 12 after each injection (up to Week 48; injections given from Week 12 to Week 36)'}, {'measure': 'Mean Change From Baseline (at the Start of the DB Phase) in the Clinical Global Impression (CGI) Score of Functional Disability Assessed by the Physiotherapist/Occupational Therapist at 4, 8, and 12 Weeks After Each Injection in the Open-label Phase', 'description': 'The CGI score of functional disability was assessed at each visit using the 11-point Numeric Rating Scale (NRS) (-5=Worst Possible to 5=Best Possible) at each time point from baseline (at the start of the double-blind phase) to Week 48.', 'timeFrame': 'Baseline; Weeks 4, 8, and 12 after each injection (up to Week 48; injections given from Week 12 to Week 36)'}]",22,20 Years,80 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,109.0,ACTUAL,2025-09-01T16:18:22.205097,v2_robust,True,True,True,False,False,
NCT06795009,Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer,Phase I/IB Study of Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer,Zanzalintinib,"['Taxol', 'Paclitaxel', 'Zanzalintinib', 'XL092']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Uterine Cancer,"['Uterine Cancer', 'Endometrial Cancer']","['Recurrent endometrial cancer', 'AXL/GAS6', 'p53 mutation', 'High risk']",NOT_YET_RECRUITING,,2025-10-31,2035-04-30,"[{'measure': 'Recommended Phase 2 dose (RP2D)', 'timeFrame': 'Through completion of first cycle (each cycle is 21 days) of all enrolled patients (estimated to be 48 months and 3 weeks)'}]","[{'measure': 'Frequency and severity of treatment-emergent adverse events', 'timeFrame': 'From start of treatment through 30 days after last dose of zanzalinitinib (estimated to be 7 months)'}, {'measure': 'Overall response rate (ORR)', 'description': 'ORR is defined as the proportion of subjects who have a partial or complete response per RECIST criteria after 3 cycles of treatment with zanzalintinib plus paclitaxel.', 'timeFrame': 'After 3 cycles of treatment (each cycle is 21 days - estimated to be 63 days)'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS is defined as the time from start of treatment to the first radiologically documented disease progression, or death, whichever comes first. The alive patients without radiologically documented disease progression are censored at the last follow-up.', 'timeFrame': 'From start of treatment through completion of follow-up (estimated to be 5.5 years)'}, {'measure': 'Overall survival (OS)', 'description': 'OS is defined as the time from start of treatment to death. The alive patients are censored at the last follow-up.', 'timeFrame': 'From start of treatment through completion of follow-up (estimated to be 5.5 years)'}]",5,18 Years,,FEMALE,False,Washington University School of Medicine,OTHER,2,36.0,ESTIMATED,2025-09-01T16:18:22.205199,v2_robust,True,True,False,False,True,
NCT06992609,Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.,A Phase IIIb Study of Durvalumab as Consolidation Treatment for Patients Diagnosed With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Definitive Concurrent or Sequential Platinum-based Chemoradiation Therapy in Spain (ALBORAN).,Durvalumab,"['Consolidation treatment', 'Durvalumab']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Small Cell Lung Carcinoma,['Small Cell Lung Carcinoma'],[],NOT_YET_RECRUITING,,2025-06-30,2029-06-30,"[{'measure': 'To describe the safety profile of durvalumab for patients with LS-SCLC who have not progressed following CRT.', 'description': '* Incidence of grade ≥ 3 AEs\n* Incidence of imAE, defined as an AE that is associated with drug exposure and is consistent with an immune-mediated mechanism of action and there is no clear alternate etiology.\n* Incidence of AEs that lead to treatment delays/interruptions or permanent discontinuation.', 'timeFrame': '90 days after last dose of durvalumab of the last patient.'}]","[{'measure': 'To describe effectiveness of durvalumab for patients with LS-SCLC who have not progressed following CRT.', 'description': '• Progression-Free Survival (PFS). Progression-Free Survival defined as the time from the date of first dose of durvalumab until the date of objective disease progression according RECIST 1.1 criteria assessed by investigator, or death (by any cause in the absence of progression). The measure of interest is the median PFS.', 'timeFrame': 'From the date of first dose of durvalumab until the date of disease progression, death, withdrawn from study, or end of study (approximately 56 months)'}, {'measure': 'To describe effectiveness of durvalumab for patients with LS-SCLC who have not progressed following CRT.', 'description': '• Overall Survival (OS) rate at 36 months, defined as the percentage of patients that are still alive at 36 months.', 'timeFrame': 'Up to 36 months'}, {'measure': 'To further describe safety profile of durvalumab for patients with LS-SCLC who have not progressed following CRT.', 'description': '* All AEs.\n* Serious AEs.', 'timeFrame': '90 days after last dose of durvalumab of the last patient.'}]",4,18 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,0,70.0,ESTIMATED,2025-09-01T16:18:22.205218,v2_robust,True,True,False,False,True,
NCT02845609,Efficacy of Sialic Acid GNE Related Thrombocytopenia,A Phase 2 Study to Evaluate the Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Related Thrombocytopenia,Sialic Acid-Extended Release,"['Sialic Acid-Extended Release', 'aceneuramic acid, UX001']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Thrombocytopenia,['Thrombocytopenia'],"['Congenital macrothrombocytopenia', 'Sialic acid', 'Bleeding']",COMPLETED,,2016-09,2017-09,"[{'measure': 'Increase in platelet count from baseline', 'timeFrame': '3 month'}]","[{'measure': 'Incidence and frequency of AEs and SAEs (Safety)', 'timeFrame': '3 months'}]",2,18 Years,45 Years,ALL,False,Hadassah Medical Organization,OTHER,0,5.0,ACTUAL,2025-09-01T16:18:22.205271,v2_robust,True,True,True,False,True,
NCT01611909,Citriodiol® and Impetigo,"A Randomised, Double-blinded, Pilot Study Investigating the Safety and Efficacy of Topical P-menthane-3,8-diol Oil Extract in the Treatment of Childhood Impetigo.","p-menthane-3,8-diol oil","['p-menthane-3,8-diol oil']",1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Impetigo,['Impetigo'],"['p-menthane-3,8-diol oil extract', 'topical therapy']",UNKNOWN,,2012-07,2013-03,"[{'measure': 'Improvement in severity score of impetigo', 'timeFrame': '2 weeks'}]",[],1,12 Months,12 Years,ALL,False,Royal North Shore Hospital,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:22.205279,v2_robust,True,True,False,False,False,
NCT01940809,"Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery",A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of Combined CTLA-4 Blockade and PD-1 Blockade for BRAF Mutant Melanoma,Dabrafenib,"['BRAF Inhibitor GSK2118436', 'Trametinib', 'MEK Inhibitor GSK1120212', 'GSK-2118436', 'Dabrafenib', 'GSK2118436', 'GSK1120212', 'GSK-2118436A', 'JTP-74057']",9,INTERVENTIONAL,['PHASE1'],PHASE1,,BRAF V600E Mutation Present,"['BRAF V600E Mutation Present', 'BRAF V600K Mutation Present', 'Metastatic Melanoma', 'Stage III Cutaneous Melanoma AJCC v7', 'Stage IIIA Cutaneous Melanoma AJCC v7', 'Stage IIIB Cutaneous Melanoma AJCC v7', 'Stage IIIC Cutaneous Melanoma AJCC v7', 'Stage IV Cutaneous Melanoma AJCC v6 and v7']",[],TERMINATED,Inadequate accrual rate,2013-08-28,2022-03-04,"[{'measure': 'Incidence of grade 3 or higher immune-related adverse events (irAEs), graded according to the National Cancer Institute (NCI) CTCAE v4.0', 'description': 'Presented with 90% confidence intervals calculated using exact binomial methods.', 'timeFrame': 'Up to 3 weeks after end of ipilimumab induction'}]","[{'measure': 'Proportion of patients receiving dabrafenib and trametinib with grade 3 or higher irAEs after disease progression on ipilimumab, according to the NCI CTCAE v4.0', 'description': 'Presented with 90% confidence intervals calculated using exact binomial methods by randomized treatment arm.', 'timeFrame': 'Up to 4 weeks after completion of study treatment'}, {'measure': 'Response rate for the total treatment period according to Response Evaluation Criteria in Solid Tumors v1.1', 'description': ""Summarized by treatment arm and presented with 90% exact binomial confidence intervals. Fisher's exact test will be used."", 'timeFrame': 'Up to 4 weeks after completion of study treatment'}, {'measure': 'Disease-control rate', 'description': ""Summarized by treatment arm and presented with 90% exact binomial confidence intervals. Fisher's exact test will be used."", 'timeFrame': 'Up to 4 weeks after completion of study treatment'}]",4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,15.0,ACTUAL,2025-09-01T16:18:22.205297,v2_robust,True,True,False,True,True,Inadequate accrual rate
NCT05951309,Myoinositol Treatment and Asprosin Levels in PCOS,Effect of Myoinositol on Serum Asprosin Levels in PCOS Patients,inofolic combi,"['inofolic combi, ITF company', 'Glucophage 500Mg Tablet', 'glucophage, Merck company', 'inofolic combi']",4,INTERVENTIONAL,['NA'],,,PCOS,"['PCOS', 'Insulin Resistance']","['Polycystic ovary syndrome', 'Myoinositol', 'Metformin', 'Insulin resistance', 'Asprosin']",COMPLETED,,2021-09-01,2023-06-03,"[{'measure': 'Serum asprosin levels 1', 'description': 'First measurement of serum asprosin level at initial examination', 'timeFrame': 'Second or third day of menstruation'}, {'measure': 'Serum asprosin levels 2', 'description': 'Serum asprosin levels after 12-16 weeks from initial examination', 'timeFrame': 'After 12-16 weeks from first examination'}]",[],2,18 Years,40 Years,FEMALE,False,"Near East University, Turkey",OTHER,0,30.0,ACTUAL,2025-09-01T16:18:22.205307,v2_robust,True,True,True,False,False,
NCT03203499,A Study to Evaluate the Safety of the Coadministration of ANS-6637 and Ethanol,"A Phase 1b, Proof of Concept, Dose-Ranging Study to Evaluate the Safety of the Coadministration of Ascending Doses of ANS-6637 and Ethanol in Healthy Male Moderate Drinkers",ANS-6637 Oral Tablet,"['Placebo Oral Tablet', 'ANS-6637 Oral Tablet']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],['Substance abuse disorder'],COMPLETED,,2017-02-27,2017-11-15,"[{'measure': 'Incidence and severity of adverse events', 'timeFrame': 'Up to 36 hours postdose'}]","[{'measure': 'Maximum observed serum concentration (Cmax)', 'timeFrame': 'Up to 48 hours postdose'}, {'measure': 'Time to maximum observed serum concentration (Tmax)', 'timeFrame': 'Up to 48 hours postdose'}, {'measure': 'Areas under the plasma concentration-time curve from time zero to last quantifiable concentration (AUClast)', 'timeFrame': 'Up to 48 hours postdose'}, {'measure': 'Ethanol Consumption', 'timeFrame': 'Up to 6 hours postdose'}, {'measure': 'Modified 5-Item Drug Effects Questionnaire (mDEQ-5)', 'timeFrame': 'Up to 6 hours postdose'}]",6,21 Years,45 Years,MALE,True,"Amygdala Neurosciences, Inc.",INDUSTRY,0,48.0,ACTUAL,2025-09-01T16:18:22.205493,v2_robust,True,True,True,False,True,
NCT00322699,Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer,Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer,Photofrin,"['Photofrin', 'Porfimer Sodium, Photofrin,photosensiter,dye']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Superficial Bladder Cancer,['Superficial Bladder Cancer'],"['Bladder Cancer', 'Photodynamic Therapy', 'Photofrin', 'Photosensitization', 'Photoradiation']",COMPLETED,,2005-02,2011-03,"[{'measure': 'Dose Limiting Toxicity', 'timeFrame': '18 months'}]","[{'measure': 'Disease progression', 'timeFrame': '18 months'}]",2,18 Years,,ALL,True,North Florida/South Georgia Veterans Health System,OTHER,2,22.0,ACTUAL,2025-09-01T16:18:22.205526,v2_robust,True,True,True,False,False,
NCT02509299,Effect of Physiotherapy in Hospitalized COPD Patients,Effect of Different Physiotherapy Treatments in Hospitalized COPD Patients,Standard medical treatment,"['Drugs', 'Standard medical treatment']",2,INTERVENTIONAL,['NA'],,,COPD,['COPD'],"['COPD', 'NEMS']",COMPLETED,,2019-09-01,2019-12-14,"[{'measure': 'Lower limb strength', 'description': 'Lower limb strength was evaluated by a dynamometer. The assessor placed the limb to be examined in the starting position (a knee flexion of 90º) and instructed each participant to hold the limb in that position against the increasing resistance applied to it by the examiner. During each test the assessor counted out loud for seconds and at the end of the test period advised the participant to relax the limb.', 'timeFrame': 'Participants will be followed for the duration of hospital stay, an expected average of 9 days.'}, {'measure': 'Balance', 'description': 'Balance was evaluated by the one-leg standing balance test, that measured the time that the patient balance on one leg as long as possible. We asked the subject being tested to choose a leg to stand on (whichever he felt more comfortable with), flex the opposite knee allowing the foot to clear the floor, and balance on one leg as long as possible', 'timeFrame': 'Participants will be followed for the duration of hospital stay, an expected average of 9 days.'}]","[{'measure': 'Respiratory function', 'description': 'Spirometry is regarded as the gold standard measure of respiratory function. The indicators of forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) will be tested. Spirometry will be performed according to American Thoracic Society (ATS) criteria.', 'timeFrame': 'Participants will be followed for the duration of hospital stay, an expected average of 9 days.'}, {'measure': 'Anxiety and depression', 'description': 'The hospital anxiety and depression scale (HADS) will be used to evaluate psychological status. HADS is a 14-items self-report questionnaire designed to detect psychological morbidity in medically ill patients. It contains depression and anxiety subscales, each with scores ranging from 0 to 21.', 'timeFrame': 'Participants will be followed for the duration of hospital stay, an expected average of 9 days.'}]",4,40 Years,,ALL,False,Universidad de Granada,OTHER,0,49.0,ACTUAL,2025-09-01T16:18:22.205534,v2_robust,True,True,True,False,False,
NCT01846299,To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema,"A 12-month, Randomized, Double-masked, Sham-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 0.5mg Ranibizumab Intravtitreal Injections in Patients With Visual Impairment Due to Vascular Endothelial Growth Factor (VEGF)Driven Macular Edema",Ranibizumab,['Ranibizumab'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Macular Edema (ME),['Macular Edema (ME)'],['Vision Impairment'],COMPLETED,,2013-10,2015-09,"[{'measure': 'Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye', 'description': 'BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.', 'timeFrame': 'Baseline, Month 2'}]","[{'measure': 'Change From Baseline in BCVA in Study Eye up to Month 2', 'description': 'BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.', 'timeFrame': 'Baseline, Month 1, Month 2'}, {'measure': 'Change From Baseline in Central Subfield Thickness (CSFT) in Study Eye', 'description': 'CSFT wasassessed by optical coherence tomography (OCT). A negative change from baseline indicates improvement.', 'timeFrame': 'Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12'}, {'measure': 'Change From Baseline in Central Subfield Volume (CSFV) in Study Eye', 'description': 'CSFV was assessed OCT. A negative change from baseline indicates improvement.', 'timeFrame': 'Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12'}, {'measure': 'Number of Participants With Presence or Absence of Intra-retinal Fluid in Study Eye Compared to Baseline', 'description': 'The presence of intra-retinal fluid was assessed by OCT.', 'timeFrame': 'Month 2, Month 6, Month 12'}, {'measure': 'Number of Participants With Presence or Absence of Subretinal Fluid in Study Eye Compared to Baseline', 'description': 'The presence of subretinal fluid was assessed by OCT.', 'timeFrame': 'Month 2, Month 6, Month 12'}, {'measure': 'Number of Participants With Presence of Active Macular Edema (ME) Leakage', 'description': 'The presence of active ME leakage was assessed by fluorescein angiography (FA).', 'timeFrame': 'Month 2'}, {'measure': 'Number of Participants Requiring Rescue Treatment at Month 1', 'description': 'Rescue treatment with laser photocoagulation or periocular treatment could be administered at Month 1 only if the participant had a visual acuity loss of \\> 5 letters due to disease activity from baseline to Month 1.', 'timeFrame': 'Month 1'}, {'measure': 'Average Change From Baseline in BCVA', 'description': 'BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.', 'timeFrame': 'Baseline (BL), month 1 through month 6, month 1 through month 12'}, {'measure': 'Number of Participants With ≥ 1, ≥ 5, ≥ 10 and ≥ 15 Letters Gain or Reaching 84 Letters', 'description': 'VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.', 'timeFrame': 'Month 2, Month 6 , Month 12'}, {'measure': 'Number of Participants With > 1, > 5, > 10 and > 15 Letters Loss', 'description': 'VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.', 'timeFrame': 'Month 2, Month 6, Month 12'}, {'measure': 'Number of Participants With Ranibizumab Treatments', 'description': 'The number of participants administered study treatments, according to treatment frequency, was assessed.', 'timeFrame': 'Month 12'}, {'measure': 'Number of Participants With Re-treatments', 'description': 'The number of participants, administered re-treatments according to treatment frequency, was assessed. Re-treatment was defined as an administration of study medication following at least one non-missed visit where treatment was not administered in the study eye. Up to Month 12, the maximum number of retreatments was 5.', 'timeFrame': 'Month 6, month 12'}, {'measure': 'Number of Primary Reasons for Decision to Treat by Investigator', 'description': 'The total number of primary reasons for decisions to treat was assessed. A single participant could have had multiple primary reasons for treatment.', 'timeFrame': '12 months'}]",14,12 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,181.0,ACTUAL,2025-09-01T16:18:22.205680,v2_robust,True,True,True,False,False,
NCT03969732,Multimodal Biomarkers for Diagnosis and Prognosis in CAA,Multimodal Biomarkers for Diagnosis and Prognosis in Cerebral Amyloid Angiopathy,1. amyloid PET；2. T807 PET,['1. amyloid PET；2. T807 PET'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Cerebral Amyloid Angiopathy,"['Cerebral Amyloid Angiopathy', 'Intracranial Hemorrhages', 'Alzheimer Disease']","['Stroke', 'intracerebral hemorrhage', 'cerebral amyloid angiopathy', 'amyloid PET', 'tau PET', 'MRI', 'Aβ', 'ApoE']",UNKNOWN,,2018-09-27,2022-07-31,"[{'measure': 'PET imaging', 'description': 'PET data will reconstruct with ordered set expectation maximization, corrected for attenuation, and each frame will be evaluated to verify adequate count statistics and absence of head motion.', 'timeFrame': 'in 3 days'}]",[],1,20 Years,,ALL,True,National Taiwan University Hospital,OTHER,0,240.0,ESTIMATED,2025-09-01T16:18:22.205750,v2_robust,True,True,False,False,False,
NCT03816332,"Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers",Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers,Prednisone,"['FK506', 'Paracort', 'Prednidib', 'Deltasone', 'Ofisolona', 'Deltra', 'Prograf', 'Prednisone', 'Delta 1-Cortisone', 'Delta-Dome', 'Prednitone', 'Deltison', 'Econosone', 'Prednicen-M', 'Perrigo Prednisone', 'Promifen', 'FK-506', 'Adasone', 'Protopic', '.delta.1-Cortisone', '1, 2-Dehydrocortisone', 'Fujimycin', 'Decorton', 'Deltacortisone', 'Prednilonga', 'Panafcort', 'Tacrolimus', 'Tacforius', 'Predicor', 'Servisone', 'DeCortin', 'Orasone', 'Predicorten', 'Dacortin', 'Meprosona-F', 'PRED', 'Meticorten', 'Rayos', 'Hecoria', 'Metacortandracin', 'Panasol-S', 'Prednisone Intensol', 'Predniment', 'Decortisyl', 'Deltacortene', 'Cortancyl', 'Deltadehydrocortisone', 'Prednicort', 'FK 506', 'Prednisonum', 'SK-Prednisone', 'Lisacort']",52,INTERVENTIONAL,['PHASE1'],PHASE1,,Clinical Stage III Cutaneous Melanoma AJCC v8,"['Clinical Stage III Cutaneous Melanoma AJCC v8', 'Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8', 'Clinical Stage IV Cutaneous Melanoma AJCC v8', 'Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8', 'Metastatic Basal Cell Carcinoma', 'Metastatic Melanoma', 'Metastatic Merkel Cell Carcinoma', 'Metastatic Skin Squamous Cell Carcinoma', 'Pathologic Stage III Cutaneous Melanoma AJCC v8', 'Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8', 'Pathologic Stage IIIA Cutaneous Melanoma AJCC v8', 'Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8', 'Pathologic Stage IIIB Cutaneous Melanoma AJCC v8', 'Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8', 'Pathologic Stage IIIC Cutaneous Melanoma AJCC v8', 'Pathologic Stage IIID Cutaneous Melanoma AJCC v8', 'Pathologic Stage IV Cutaneous Melanoma AJCC v8', 'Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8', 'Unresectable Basal Cell Carcinoma', 'Unresectable Melanoma', 'Unresectable Merkel Cell Carcinoma']",[],ACTIVE_NOT_RECRUITING,,2019-11-08,2025-09-22,"[{'measure': 'Number (and Percentage) of Outcome Responses After Receiving Nivolumab, Tacrolimus, and Prednisone', 'description': 'Percentage of kidney transplant recipients who experienced complete response (CR), partial response (PR) or stable disease (SD) without allograft loss.', 'timeFrame': 'At 16 weeks'}]","[{'measure': 'Objective Response (CR or PR) Rate (ORR) After Receiving Nivolumab, Tacrolimus, and Prednisone', 'description': 'Number (and percentage) of patients with a complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria after receiving at least one dose of nivolumab.', 'timeFrame': 'Up to 4 months'}, {'measure': 'Rate of Allograft Loss After Receiving Nivolumab, Tacrolimus, and Prednisone', 'description': 'Number of subjects who experienced allograft loss after receiving at least one dose of nivolumab.', 'timeFrame': 'Up to 4 months'}, {'measure': 'Duration of Progression-free Survival After Receiving Nivolumab, Tacrolimus, and Prednisone', 'description': 'From the first dose of nivolumab to the date of the first documented tumor progression or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to 4 months'}, {'measure': 'Duration of Overall Survival After Receiving Nivolumab, Tacrolimus, and Prednisone', 'description': ""The time from the participant's first dose of nivolumab to the date of death from any cause."", 'timeFrame': 'Up to 3 years'}, {'measure': 'Overall Response Rate (ORR) in Patients After Receiving Ipilimumab, Nivolumab, Tacrolimus, and Prednisone', 'description': 'The number of participants with a CR or PR response after receiving ipilimumab, nivolumab, tacrolimus, and prednisone.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Rate of Allograft Loss After Receiving Ipilimumab, Nivolumab, Tacrolimus, and Prednisone', 'description': 'Number of patients who experienced allograft loss after receiving nivolumab, ipilimumab, tacrolimus, and prednisone.', 'timeFrame': 'Up to 3 years'}]",7,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,12.0,ACTUAL,2025-09-01T16:18:22.205791,v2_robust,True,True,False,False,False,
NCT05310032,"A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses","A Randomized, Open-label or Double-blind, Placebo Controlled, Single and Multiple Dosing, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect After Oral Administration of HSG4112 in Healthy Subjects",HSG4112,"['Placebo', '2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol', 'HSG4112']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Obesity,['Obesity'],[],COMPLETED,,2022-04-21,2023-03-31,"[{'measure': 'Pharmacokinetic Assessment by Maximum Plasma Concentration of HSG4112', 'description': 'Maximum Plasma Concentration of HSG4112 (Cmax)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Maximum Plasma Concentration of HSG4112 at Steady State', 'description': 'Maximum Plasma Concentration of HSG4112 at Steady State (Cmax,ss)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Minimum Plasma Concentration of HSG4112 at Steady State', 'description': 'Minimum Plasma Concentration of HSG4112 at Steady State (Cmin,ss)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Average Plasma Concentration of HSG4112 at Steady State', 'description': 'Average Plasma Concentration of HSG4112 at Steady State (Cavg,ss)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity', 'description': 'Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity (AUCinf)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity at Steady State', 'description': 'Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity at Steady State (AUCinf,ss)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 Over Dosing Interval', 'description': 'Area Under the Plasma Concentration-Time Curve of HSG4112 Over Dosing Interval (AUCtau)', 'timeFrame': 'Hour 0 to 24'}, {'measure': 'Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 Over Dosing Interval at Steady State', 'description': 'Area Under the Plasma Concentration-Time Curve of HSG4112 Over Dosing Interval at Steady State (AUCtau,ss)', 'timeFrame': 'Hour 0 to 24'}, {'measure': 'Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to the Last Measurable Point', 'description': 'Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to the Last Measurable Point (AUClast)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to the Last Measurable Point at Steady State', 'description': 'Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to the Last Measurable Point at Steady State (AUClast,ss)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Half-Life of HSG4112', 'description': 'Half-life of HSG4112 (T1/2)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Half-Life of HSG4112 at Steady State', 'description': 'Half-life of HSG4112 at Steady State (T1/2,ss)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Time to Maximum Observed Plasma Concentration of HSG4112', 'description': 'Time to Maximum Observed Plasma of HSG4112 (Tmax)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Time to Maximum Observed Plasma Concentration of HSG4112 at Steady State', 'description': 'Time to Maximum Observed Plasma Concentration of HSG4112 at Steady State (Tmax,ss)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Oral Clearance of HSG4112', 'description': 'Oral Clearance of HSG4112 (CL/F)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Oral Clearance of HSG4112 at Steady State', 'description': 'Oral Clearance of HSG4112 at Steady State (CLss/F)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Volume of Distribution of HSG4112', 'description': 'Volume of Distribution of HSG4112 (Vd/F)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Pharmacokinetic Assessment by Volume of Distribution of HSG4112 at Steady State', 'description': 'Volume of Distribution of HSG4112 at Steady State (Vdss/F)', 'timeFrame': 'Hour 0 to 192'}, {'measure': 'Safety and Tolerability Assessment by Adverse Event Monitoring', 'description': 'Number of participants with observed advese events', 'timeFrame': 'Day 1 to 9 following the last administration'}, {'measure': 'Safety and Tolerability Assessment by Number of Participants with Change in Vital Signs', 'description': 'Number of participants with clinically significant change in vital signs including blood pressure (mmHg) measured with blood pressure monitor, heart rate (beats per minute) measured with pulse oximeter, and body temperature (degrees Celcius) measured with thermometer', 'timeFrame': 'Day 1 to 9 following the last administration'}, {'measure': 'Safety and Tolerability Assessment by Number of Patients with Change in Physical Examination', 'description': 'Number of participants with clinically significant change in physical examination', 'timeFrame': 'Day 1 to 9 following the last administration'}, {'measure': 'Safety and Tolerability Assessment by Number of Participants with Change in Laboratory Test', 'description': 'Number of participants with clinically significant change in laboratory test assessed through hematology, blood biochemistry, urinalysis, and blood coagulation test', 'timeFrame': 'Day 1 to 9 following the last administration'}, {'measure': 'Safety and Tolerability Assessment by Number of Participants with Change in 12-Lead Electrocardiogram', 'description': 'Number of participants with clinically significant change in 12-lead electrocardiogram', 'timeFrame': 'Day 1 to 9 following the last administration'}]","[{'measure': 'Pharmacodynamic Assessment by Change in Body Weight [Part 2]', 'description': 'Change in body weight', 'timeFrame': 'Days 1 to 17, Day 18, Day 20, Day 22 post-dose before first meal'}, {'measure': 'Pharmacodynamic Assessment by Change in Waist Circumference [Part 2]', 'description': 'Change in waist circumference', 'timeFrame': 'Day 1, Day 8, Day 15, Day 22 post-dose before first meal'}, {'measure': 'Pharmacodynamic Assessment by Change in Body Fat Mass [Part 2]', 'description': 'Change in body fat mass', 'timeFrame': 'Day 1, Day 8, Day 15, Day 22 post-dose before first meal'}, {'measure': 'Pharmacodynamic Assessment by Change in Body Fat Percentage [Part 2]', 'description': 'Change in body fat percentage', 'timeFrame': 'Day 1, Day 8, Day 15, Day 22 post-dose before first meal'}, {'measure': 'Pharmacodynamic Assessment by Change of Biomarkers [Part 2]', 'description': 'Measurement of biomarkers including leptin, adiponectin, insulin, C-peptide (connecting peptide), IL6 (interleukin 6), TNF-alpha (tumor necrosis factor alpha), and CCL2 (C-C motif ligand 2) from baseline to day of last dosing will be combined to assess the weight loss effect of HSG4112', 'timeFrame': 'Day 1 and 14 pre-dose'}]",28,19 Years,50 Years,ALL,True,Glaceum,INDUSTRY,1,36.0,ACTUAL,2025-09-01T16:18:22.205814,v2_robust,True,True,True,False,True,
NCT02647632,Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir,Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir,Grazoprevir/Elbasvir,"['Grazoprevir/Elbasvir is also known as MK-5172A or Zepatier', 'Sofosbuvir is also known as Sovaldi', 'Ribavirin is also known as Rebetol', 'Sofosbuvir', 'Ribavirin', 'Grazoprevir/Elbasvir']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Hepatitis C,['Hepatitis C'],"['HCV genotype 1 or 4', 'failure to DAA']",COMPLETED,,2016-01,2017-04,"[{'measure': 'rate of the Sustained Virological Response 12 weeks after the end of the therapy (SVR12), i.e. at W28 or W36 for treatment duration of 16 weeks and 24 weeks respectively.', 'description': 'The primary endpoint is the rate of the Sustained Virological Response defined as HCV RNA \\< LLOQ (either TD\\[u\\] or TND) 12 weeks after the end of the therapy associating Grazoprevir/Elbasvir, Sofosbuvir and Ribavirin (SVR12), i.e. at W28 or W36 for treatment duration of 16 weeks and 24 weeks respectively.', 'timeFrame': 'Week 28 (W28) or Week 36 (W36)'}]","[{'measure': 'SVR rate 4 weeks after the end of treatment (i.e. at week 20 or week 28 for treatment duration of 16 weeks and 24 weeks respectively) and 24 weeks after the end of treatment (i.e. at week 40 or week 48).', 'timeFrame': 'Week 20 (W20) or Week 28 (W28), and W40 or W48'}, {'measure': 'HCV viral load assessment', 'timeFrame': 'from Day 0 (D0) to Week 40 (W40) or Week 48 (W48)'}, {'measure': 'Assessment of HCV subtypic distribution at baseline', 'timeFrame': 'Pre-inclusion'}, {'measure': 'Numbers and proportions of patients presenting variants of resistance (RAV) at baseline', 'description': 'The numbers and proportions of patients presenting variants of resistance (RAV) and their characteristics will be studied', 'timeFrame': 'Pre-inclusion'}, {'measure': 'Assessment of liver fibrosis by Hepatic impulse elastometry (Fibroscan®), or biological parameters (FibroMeter® or Fibrotest®)', 'timeFrame': 'Pre-inclusion, Week 40 or Week 48'}, {'measure': 'For cirrhotic patients, description of the risk of cirrhosis evolution (decompensation, hepatocarcinoma)', 'description': 'Cirrhosis evaluation (Child-Pugh)', 'timeFrame': 'Pre-inclusion, Day 0 (D0), Week 16 (W16), W20, W24, W28, W36, W40 or W48'}, {'measure': 'For cirrhotic patients, description of the risk of cirrhosis evolution (decompensation, hepatocarcinoma)', 'description': 'Cirrhosis evaluation (MELD score)', 'timeFrame': 'Pre-inclusion, Day 0 (D0), Week 16 (W16), W20, W24, W28, W36, W40 or W48'}, {'measure': 'Clinical and biological adverse events occurring during the treatment and until 24 weeks after the end of the treatment', 'timeFrame': 'from Day 0(D0) to Week 40 (W40) or W48'}, {'measure': 'Numbers and proportions of patients who interrupted the treatments of the study', 'timeFrame': 'from Day 0 (D0) to Week 40 (W40) or W48'}, {'measure': ""Patient's reported outcomes evaluation with questionnaires"", 'description': ""Evaluation of patient's quality of life"", 'timeFrame': 'Day 0 (D0), Week 4 (W4), W16, W28, W40 or D0, W4, W16, W24, W36, W48 (24 weeks treatment-arm))'}, {'measure': ""Patient's reported outcomes evaluation with questionnaires"", 'description': 'Evaluation of perceived symptoms (ANRS questionnaire)', 'timeFrame': 'Day 0 (D0), Week 4 (W4), W16, W28, W40 or D0, W4, W16, W24, W36, W48 (24 weeks treatment-arm))'}]",12,18 Years,,ALL,False,"ANRS, Emerging Infectious Diseases",OTHER_GOV,0,26.0,ACTUAL,2025-09-01T16:18:22.205872,v2_robust,True,True,True,False,True,
NCT00784732,A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber,"A Randomized, Partially-blinded, Placebo-controlled, Two-way Crossover, Proof of Concept Study to Compare the Relative Efficacy of CRTh2 Receptor Antagonist, QAV680 Against Placebo in the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model",QAV680,"['Mometasone Furoate', 'QAV680']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Seasonal Allergic Rhinitis,['Seasonal Allergic Rhinitis'],"['Seasonal Allergic Rhinitis', 'Environmental Exposure Chamber', 'nasal lavage']",COMPLETED,,2008-09,2008-12,"[{'measure': 'Total Nasal Symptom Score (TNSS) over the last 2 hours of exposure in the EEC Percentage nasal lavage eosinophil count post EEC', 'timeFrame': 'TNSS: 6-8h during EEC exposure on Day 10'}]","[{'measure': 'Measure of nasal cytokines (ECP, IL-5, IL-13, PGD2, Eotaxin)', 'timeFrame': 'After 8h exposure in EEC'}, {'measure': 'Absolute eosinophil count from nasal lavage collected', 'timeFrame': 'During exposure in EEC'}, {'measure': 'Nasal airway patency assessed by acoustic rhinometry during exposure in the EEC', 'timeFrame': 'During exposure in EEC'}, {'measure': 'Total Ocular Symptom Score measured during exposure in the EEC', 'timeFrame': 'During exposure in EEC'}, {'measure': 'Assess pharmacokinetics of plasma QAV680 in patients with seasonal allergic rhinitis', 'timeFrame': 'Through out study'}]",6,18 Years,65 Years,ALL,False,Novartis,INDUSTRY,0,44.0,ACTUAL,2025-09-01T16:18:22.205988,v2_robust,True,True,True,False,False,
NCT00003032,High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer,A Randomized Trial of High-Dose Chemotherapy and Autologous Stem Cell Therapy Versus Standard Therapy in Women With Metastatic Breast Cancer Who Have Responded to Anthracycline or Taxane-Based Induction Chemotherapy,cisplatin,"['cisplatin', 'cyclophosphamide', 'tamoxifen citrate', 'mitoxantrone hydrochloride']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,['Breast Cancer'],"['stage IV breast cancer', 'recurrent breast cancer']",COMPLETED,,1997-04-25,2008-12-15,[],[],0,16 Years,60 Years,FEMALE,False,NCIC Clinical Trials Group,NETWORK,0,224.0,ACTUAL,2025-09-01T16:18:22.206015,v2_robust,True,True,True,False,False,
NCT01140932,The Electroretinogram in Healthy and Glucose Intolerant Young Men,"Electroretinographic Changes in Healthy Young Men Before and After Induction of Glucose Intolerance by Glucocorticoids Treatment, Hyperphagia and Lack of Exercise",Prednisolone,"['Prednisolone', 'Prednisolon DAK, Nycomed, Zurich, Switzerland']",2,INTERVENTIONAL,['NA'],,,Electroretinography,['Electroretinography'],"['Retina', 'Electroretinography', 'Diabetes Mellitus', 'Glucose Intolerance', 'Physiology']",COMPLETED,,2010-02,2010-06,"[{'measure': 'ERG', 'description': 'Characteristics of the scotopic ERG at normo-/hyperglycaemia before vs. after prednisolone treatment', 'timeFrame': '12 days'}]","[{'measure': 'Retinal Vessel Caliber', 'description': 'Measurement of retinal vessel caliber from fundus photographs before and after treatment with glucocorticoids.', 'timeFrame': '12 days'}]",2,18 Years,35 Years,MALE,True,"Glostrup University Hospital, Copenhagen",OTHER,0,10.0,ACTUAL,2025-09-01T16:18:22.206088,v2_robust,True,True,True,False,False,
NCT00971932,Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN),"Open-label, Single-arm, Multicenter, Phase II Study Investigating Cetuximab in Combination With Chemotherapy in the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) in Japanese Subjects",Cetuximab,"['Cetuximab', 'Cisplatin/Carboplatin', '5-Fluorouracil']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Squamous Cell Carcinoma of the Head and Neck,['Squamous Cell Carcinoma of the Head and Neck'],"['Recurrent and/or metastatic', 'SCCHN']",COMPLETED,,2009-07,,"[{'measure': 'Best Overall Response (BOR) According to Modified World Health Organization (WHO) Criteria', 'description': 'Percentage of participants experiencing a complete response \\[CR\\] (complete disappearance of measurable and evaluable disease without new lesions) or partial response \\[PR\\] (greater than or equal to 50 percent decrease in the sum of the products of diameters \\[SOPD\\] of index lesions compared to the baseline SOPD, with no evidence of PD) confirmed by a subsequent assessment no less than 28 days after criteria for response were first met based on modified WHO criteria as assessed by Independent Review Committee (IRC).', 'timeFrame': 'Evaluations performed every 6 weeks until progressive disease (PD) reported between day of first participant treated, until cut-off date, 02 March 2011'}]","[{'measure': 'Best Overall Response (BOR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Criteria', 'description': 'Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST as assessed by IRC. CR are those that persist on repeat imaging study at least 28 days after initial documentation of response. PR are those with greater than or equal to 30 percent decrease in the SOPD of index lesions compared to the baseline SOPD, with no evidence of PD.', 'timeFrame': 'Evaluations performed every 6 weeks until PD reported between day of first participant treated, until cut-off date, 02 March 2011'}, {'measure': 'Disease Control Rate', 'description': 'Percentage of participants experiencing a CR (complete disappearance of measurable and evaluable disease without new lesions) or PR (\\>=50 percent decrease in sum of the products of diameters \\[SOPD\\] of index lesions compared to baseline SOPD, with no evidence of PD) confirmed by subsequent assessment no less than 28 days after criteria for response were first met) or stable disease \\[SD\\] (neither sufficient decrease to qualify for PR nor sufficient increase to qualify for PD) at least once no less than 42 days after first dose of trial treatment based on modified WHO criteria as assessed by IRC.', 'timeFrame': 'Evaluations performed every 6 weeks until PD reported between day of first participant treated, until cut-off date, 02 March 2011'}, {'measure': 'Duration of Response', 'description': 'Duration of response according to modified WHO criteria as assessed by IRC was defined as the time from the first assessment of CR or PR until the date of the first occurrence of PD, or until the date of death when death occurred within 60 days of the last tumor assessment or first administration of trial treatment (whichever was last).', 'timeFrame': 'Time from first assessment of CR or PR to PD, death or last tumor assessment, reported between day of first participant treated, until cut-off date, 02 March 2011'}, {'measure': 'Progression-Free Survival (PFS) Time', 'description': 'The PFS time according to modified WHO criteria as assessed by IRC was defined as duration from first administration of trial treatment until PD (radiological or clinical, if radiological progression is not available) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment.', 'timeFrame': 'Time from first administration of trial treatment to PD, death or last tumor assessment, reported between day of first participant treated, until cut-off date, 02 March 2011'}, {'measure': 'Overall Survival (OS) Time', 'description': 'Time from first administration of trial treatment to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.', 'timeFrame': 'Time from first administration of trial treatment or last day known to be alive, reported between day of first participant treated, until cut-off date, 02 March 2011'}, {'measure': 'Time to Treatment Failure', 'description': 'Time to treatment failure according to modified WHO criteria as assessed by IRC was defined as the time from first administration of trial treatment until the date of the first occurrence of one of the events defining treatment failure: PD assessed by the investigator, discontinuation of treatment due to PD, discontinuation of treatment due to an adverse event (AE), start of any new anticancer therapy, or withdrawal of consent or death within 60 days of the last tumor assessment or first administration of trial treatment.', 'timeFrame': 'Time from first administration of trial treatment to treatment failure or last tumor assessment, reported between day of first participant treated, until cut-off date, 02 March 2011'}]",7,20 Years,,ALL,False,"Merck KGaA, Darmstadt, Germany",INDUSTRY,0,33.0,ACTUAL,2025-09-01T16:18:22.206217,v2_robust,True,True,True,False,True,
NCT03623932,Contribution of a Non Medicamentous Approach by Hypnosis on Quality of Life in Crohn Disease,Contribution of a Non Medicamentous Approach by Hypnosis on Quality of Life in Crohn Disease,immunosuppressor/TNFalpha,['immunosuppressor/TNFalpha'],1,INTERVENTIONAL,['NA'],,,Crohn Disease,['Crohn Disease'],[],UNKNOWN,,2018-11-13,2021-11-13,"[{'measure': 'Mid term hypnosis efficacy with IBDQ', 'description': 'Efficacy evaluation of hypnosis 6 months after the beginning of hypnosis sessions on the quality of life with Inflammatory Bowel Disease Questionnaire (IBDQ)', 'timeFrame': '6 months'}]","[{'measure': 'Short term hypnosis efficacy with IBDQ', 'description': 'Efficacy evaluation of hypnosis 3 months after the beginning of hypnosis sessions on the quality of life with Inflammatory Bowel Disease Questionnaire (IBDQ)', 'timeFrame': '3 months'}, {'measure': 'Disease acceptance with ICQ-18', 'description': 'Impact of hypnosis on the disease acceptance short and mid term with the Evolution of the Illness Cognition Questionnaire for chronic disease', 'timeFrame': '3 months and 6 months'}, {'measure': 'Clinical score with Harvey-Bradshaw Index short and mid term', 'description': 'Evolution of the clinical score short and mid term with Harvey-Bradshaw Index', 'timeFrame': '3 months and 6 months'}, {'measure': 'Vagal tonus with electrocardiogram', 'description': 'Evolution of the vagal tonus with electrocardiogram short and mid term', 'timeFrame': '3 months and 6 months'}, {'measure': 'Inflammatory status with C Reactive Protein', 'description': 'Evolution of the C Reactive Protein concentration in the plasma', 'timeFrame': '3 months and 6 months'}, {'measure': 'Stress with Perceived Stress Scale', 'description': 'Evolution of stress status short and mid term with Perceived Stress Scale which goes from 10 to 50. Lower values represent better outcome.', 'timeFrame': '3 months and 6 months'}, {'measure': 'Fatigue with Multidimensional Fatigue Inventory', 'description': 'Evolution of fatigue status short and mid term', 'timeFrame': '3 months and 6 months'}, {'measure': 'Long term hypnosis efficacy', 'description': 'Efficacy evaluation of hypnosis 12 months after the beginning of hypnosis sessions on the quality of life with Inflammatory Bowel Disease Questionnaire (IBDQ) which goes from 32 to 224. Higher values represent better outcome.', 'timeFrame': '12 months'}, {'measure': 'Clinical score with Harvey-Bradshaw Index long term', 'description': 'Evolution of the clinical score long term with Harvey-Bradshaw Index', 'timeFrame': '12 months'}]",10,18 Years,65 Years,ALL,False,"University Hospital, Grenoble",OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:22.206263,v2_robust,True,True,False,False,False,
NCT00310232,Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20),Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20),Epoetin Alfa,['Epoetin Alfa'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-Small-Cell Lung Carcinoma,"['Non-Small-Cell Lung Carcinoma', 'Lung Cancer', 'Anemia']","['Quality of Life', 'Blood transfusion']",TERMINATED,"Recommendation of DSMB for safety issue, increased mortality with study drug.",2001-02,2004-04,"[{'measure': 'Change in anemia and fatigue related QoL at 12 weeks following randomization', 'timeFrame': '12 weeks following randomization'}]","[{'measure': 'Overall QoL and domain-specific QoL scores', 'timeFrame': '16 weeks following randomization'}, {'measure': 'hemoglobin and hematocrit levels', 'timeFrame': '6 months from randomization'}, {'measure': 'number of transfusions', 'timeFrame': '6 months from randomization'}]",4,18 Years,,ALL,False,Ontario Clinical Oncology Group (OCOG),OTHER,1,70.0,ACTUAL,2025-09-01T16:18:22.206290,v2_robust,True,True,False,True,False,"Recommendation of DSMB for safety issue, increased mortality with study drug."
NCT02828098,Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors,"An Exploratory First in Human Phase I Clinical and Pharmacokinetic Study of Intra-tumoral Administration of BO-112 in Adult Patients With Aggressive Solid Tumors, With an Extension Cohort in Combination With Anti-PD1 Treatment",Part 1: BO-112,"['Part 1: BO-112', 'anti-PD1 monoclonal antibody', 'Part 2: BO-112']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Cancer,['Cancer'],['aggressive solid tumors'],COMPLETED,,2016-06,2020-07,"[{'measure': 'Number of subjects with adverse events', 'description': 'To evaluate the safety and tolerability of B0-112 in terms of adverse events at every visit', 'timeFrame': 'Part 1: Day 30 after administration of the last dose. Part 2: 12 weeks and for patients who continue up to 1 year'}]","[{'measure': 'Circulating cytokines including type I IFNs, TNFalpha and IL6 (by ELISA)', 'timeFrame': 'Part 1: At three independent points during the study. Day 7-1 prior to administration, 24 hours after administration and 7-14 days after administration of the agent. Part 2: 12 weeks'}, {'measure': 'Plasma levels of BO-112', 'description': 'To characterize the pharmacokinetics (PK) of BO-112 by measuring the amount in plasma at regular timepoints during the study', 'timeFrame': 'Part 1: 0-15-30-240 minutes and 24 hours after administration of the drug. Part 2: 1 day'}, {'measure': 'Anti-tumor activity', 'description': 'Part 2 only: To evaluate the antitumor activity of the combination of BO-112 and anti-PD1 treatment', 'timeFrame': '12 weeks and for patients who continue up to 1 year'}]",4,18 Years,,ALL,False,Highlight Therapeutics,INDUSTRY,1,44.0,ACTUAL,2025-09-01T16:18:22.206404,v2_robust,True,True,True,False,True,
NCT05688098,Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers,"A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of Irbesartan/Amlodipine High Fixed Dose Combination in Comparison With Co-administration of Mono Compounds in Healthy Volunteers",Irbesartan/Amlodipine High FDC,"['Irbesartan/Amlodipine High FDC', 'Irbesartan', 'Amlodipine High']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2022-09-23,2023-04-21,"[{'measure': 'AUCt of Irbesartan and Amlodipne High', 'timeFrame': '72 hours'}, {'measure': 'Cmax Irbesartan and Amlodipne High', 'timeFrame': '72 hours'}]","[{'measure': 'AUCinf of Irbesartan and Amlodipine High', 'timeFrame': '72 hours'}, {'measure': 'AUCt/AUCinf of Irbesartan and Amlodipine High', 'timeFrame': '72 hours'}, {'measure': 'tmax of Irbesartan and Amlodipine High', 'timeFrame': '72 hours'}, {'measure': 'half-life of Irbesartan and Amlodipine High', 'timeFrame': '72 hours'}, {'measure': 'CL/F of Irbesartan and Amlodipine High', 'timeFrame': '72 hours'}, {'measure': 'Vz/F of Irbesartan and Amlodipine High', 'timeFrame': '72 hours'}]",8,19 Years,,ALL,True,Handok Inc.,INDUSTRY,0,44.0,ACTUAL,2025-09-01T16:18:22.206433,v2_robust,True,True,True,False,False,
NCT03751098,Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation,"A Multi-Center, Double-Masked, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Fixed Combination Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution Administered With a Microdose Dispenser for Dilation of the Pupil",Tropicamide/Phenylephrine ophthalmic solution (TR/PE),"['Tropicamide/Phenylephrine ophthalmic solution (TR/PE)', 'Mydcombi', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Mydriasis,['Mydriasis'],[],COMPLETED,,2018-12-01,2019-01-21,"[{'measure': 'Change in Pupil Diameter From Baseline', 'description': 'Difference in 35-minute pupil diameter vs. baseline measured using pupillometry in highly photopic conditions.\n\nPupil diameter is reported in millimeters. For the change in pupil diameter, larger measurements indicate a better outcome.', 'timeFrame': '35 minutes after initial dose'}]",[],1,,,ALL,True,Eyenovia Inc.,INDUSTRY,0,76.0,ACTUAL,2025-09-01T16:18:22.206461,v2_robust,True,True,True,False,False,
NCT06243198,A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants,"A Phase 1, Participant- and Investigator-blinded, Randomized, Single-dose Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants",Lebrikizumab,"['LY3650150', 'Lebrikizumab', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Pharmacokinetics', 'Safety', 'Lebrikizumab', 'Chinese']",COMPLETED,,2024-03-28,2024-09-03,"[{'measure': 'Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration', 'description': 'A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module', 'timeFrame': 'Baseline up to 120 days'}]","[{'measure': 'Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lebrikizumab', 'description': 'PK: Cmax of Lebrikizumab', 'timeFrame': 'Predose up to Day 120'}, {'measure': 'PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC [0-∞]) of Lebrikizumab', 'description': 'PK: AUC0-∞ of Lebrikizumab', 'timeFrame': 'Predose up to Day 120'}, {'measure': 'PK: Area Under the Concentration Versus Time Curve from Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Lebrikizumab', 'description': 'PK: AUC0-tlast of Lebrikizumab', 'timeFrame': 'Predose up to Day 120'}]",4,18 Years,65 Years,ALL,True,Eli Lilly and Company,INDUSTRY,0,25.0,ACTUAL,2025-09-01T16:18:22.206483,v2_robust,True,True,True,False,True,
NCT01066598,A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD),A Phase II Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease,Rituximab,"['Rituxan', 'Rituximab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Graft Versus Host Disease,['Graft Versus Host Disease'],"['graft versus host disease', 'chronic graft versus host disease', 'cGVHD']",TERMINATED,Poor Accrual,2010-05,2011-08,"[{'measure': 'The efficacy of the combination of rituximab and prednisone as initial therapy for C-GVHD, which is defined as discontinuation of immunosuppressive therapy at 12 months with resolution of reversible manifestations of C-GVHD', 'timeFrame': '12 months'}]","[{'measure': 'To determine the response rate to treatment, defined as complete response plus partial response (PR) for rituximab and prednisone', 'timeFrame': '3 years'}, {'measure': 'To determine the rate of recurrent C-GVHD following initial therapy with rituximab and prednisone', 'timeFrame': '3 years'}, {'measure': 'To determine the relapse rate of the underlying malignancy for which the allo-SCT was performed from time of study registration after treatment with rituximab and prednisone', 'timeFrame': '3 years'}, {'measure': 'To determine the rate of infection requiring treatment with anti-bacterial, anti-fungal or anti-viral therapy from time of study registration after treatment with rituximab and prednisone', 'timeFrame': '3 years'}, {'measure': 'To determine overall survival of treated patients from time of study registration to a maximum of 3 years following study registration for patients receiving rituximab and prednisone', 'timeFrame': '3 years'}]",6,18 Years,,ALL,False,"University Health Network, Toronto",OTHER,1,1.0,ACTUAL,2025-09-01T16:18:22.206492,v2_robust,True,True,False,True,False,Poor Accrual
NCT00151398,Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD),"A 3-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study Of 3 Doses Of Lecozotan (SRA-333) SR In Outpatients With Mild To Moderate Alzheimer's Disease With Donepezil As Active Control.",lecozotan SR,"['Donepezil', 'lecozotan SR']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Alzheimer Disease,['Alzheimer Disease'],[],COMPLETED,,2005-10-06,2008-03-15,"[{'measure': 'The primary endpoints will be the change from baseline in ADAS-Cog total score and ADCS-CGIC total score.', 'timeFrame': 'weeks 12, 14, 26 and 40.'}]","[{'measure': 'Secondary efficacy outcome variables include additional cognitive, functional,and behavioral measures.', 'timeFrame': 'weeks 12, 14, 26 and 40.'}]",2,50 Years,,ALL,False,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,229.0,ACTUAL,2025-09-01T16:18:22.206571,v2_robust,True,True,True,False,False,
NCT04544098,"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","A Pilot Study Investigating Intrahepatic Arterial And Intravenous Infusion Of The Radiolabeled Somatostatin Agonist 177Lu-DOTATATE In Patients With Liver-Dominant Metastatic Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Well Differentiated Neuroendocrine Tumors",177Lu-DOTATATE,['177Lu-DOTATATE'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Neuroendocrine Tumors,"['Neuroendocrine Tumors', 'Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors']","['177Lu-DOTATATE', 'Pan-NETs', 'Intrahepatic Arterial', 'Intravenous Infusion', 'Gastroenteropancreatic (GEP),', 'Bronchial or Unknown Primary Well Differentiated Neuroendocrine Tumors']",ACTIVE_NOT_RECRUITING,,2020-09-02,2026-09,"[{'measure': 'number of patients who successfully complete 2 IA injections', 'description': 'Feasibility will be defined as at least 7 or more patients out of 10 patients who successfully complete 2 IA injections.', 'timeFrame': '2 years'}, {'measure': 'Objective response', 'description': 'classified according to RECIST 1.1 criteria', 'timeFrame': '1 year'}]",[],2,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:22.206580,v2_robust,True,True,False,False,False,
NCT00745498,Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy,Efficacy Study of Pre- and Intra-operative Intravitreal Bevacizumab Injection on Postoperative Vitreous Hemorrhage After Diabetic Vitrectomy,Bevacizumab,"['avastin', 'Bevacizumab']",2,INTERVENTIONAL,['NA'],,,Proliferative Diabetic Retinopathy,"['Proliferative Diabetic Retinopathy', 'Vitreous Hemorrhage']","['Proliferative diabetic retinopathy', 'vitrectomy', 'bevacizumab', 'vitreous hemorrhage']",COMPLETED,,2008-06,2010-10,"[{'measure': 'Recurrent VH Incidence (Early and Late)', 'description': 'Recurrent VH was defined as a new episode of grade 1 or more VH occurring more than 1 week after surgery. ""Early recurrent VH"" was VH occurring \\<= 4 weeks and ""late recurrent VH"" was VH occurring \\>4 weeks after surgery.', 'timeFrame': '6 months'}]","[{'measure': 'Initial Time of Vitreous Clearing (ITVC)', 'description': 'The interval in number of days for VH of grade 1 or more observed at postoperative day 1 to clear-up completely. VH of grade 1 was defined as mild vitreous hemorrhage with visible fundus details, but difficult to evaluate the retinal nerve fiber layer or small vessels.', 'timeFrame': '6 months'}, {'measure': 'Visual Outcome', 'description': 'Best-corrected visual acuity (BCVA) at postoperative 6 months', 'timeFrame': '6 months'}, {'measure': 'Postoperative Resolution of Neovascularization', 'timeFrame': '6 months'}]",4,20 Years,,ALL,False,Seoul National University Bundang Hospital,OTHER,0,126.0,ACTUAL,2025-09-01T16:18:22.206610,v2_robust,True,True,True,False,False,
NCT02756598,"Stress, Anxiety and Type A Personality and Analgesics","Stress, Anxiety and Type A Personality and Analgesics. Impact on Induction Time and Consumption of Analgesics During Cardiac Surgery",Sufentanil I,"['Propofol I', 'Propofol II', 'Sufentanil II', 'Sufenta', 'Propofol', 'Sufentanil I']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Postoperative; Dysfunction Following Cardiac Surgery,['Postoperative; Dysfunction Following Cardiac Surgery'],"['sufentanil', 'propofol', 'personality/stress test', 'fast-track']",COMPLETED,,2015-01,2018-06-30,"[{'measure': 'Association between preoperative personality/stress/anxiety and time (minutes) to reach anaesthetic depth goal by bi-spectral index (BIS)', 'description': 'Minutes to reach BIS 50', 'timeFrame': 'Up to 30 minutes'}, {'measure': 'Potential of sufentanil regime on fast-track measured by ventilation time and association with eligible discharge from intensive care unit.', 'description': 'Postoperative ventilation time (hours/minutes) and the association to eligible discharge from ICU.', 'timeFrame': 'Up to 24 hours'}]","[{'measure': 'Sufentanil regime and association to haemodynamic parameters (blood pressures, heart rate, cardiac output, oxygenation)', 'description': 'Perioperative changes in haemodynamic parameters (analysis of varians) of haemodynamic parameters according to sufentanil regime', 'timeFrame': 'up to 24 hours'}, {'measure': 'Association between preoperative personality/stress/anxiety tests and postoperative care using postoperative quality score', 'description': 'Association of preoperative tests and the postoperative ICU quality scoring', 'timeFrame': 'up to 24 hours'}, {'measure': 'Association between preoperative personality/stress/anxiety and total amounts of sufentanil and propofol', 'description': 'Amounts of drugs as pr kg pr time unit of involved drugs', 'timeFrame': 'Up to 12 hours'}]",5,16 Years,90 Years,,False,Aarhus University Hospital,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:22.206629,v2_robust,True,True,True,False,False,
NCT00692198,Long-term Oxygen Treatment Trial,Effectiveness of Long-term Oxygen Therapy in Treating People With Chronic Obstructive Pulmonary Disease With Moderate Desaturation,Supplemental oxygen therapy,['Supplemental oxygen therapy'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Obstructive Pulmonary Disease,['Chronic Obstructive Pulmonary Disease'],['COPD'],COMPLETED,,2009-01,2015-08,"[{'measure': 'Death or Hospitalization, Whichever Occurs First', 'description': 'The primary outcome event is death or hospitalization, whichever occurs first. The difference between treatment groups on the primary outcome was assessed with a time-to-event analysis by calculation of the between group hazard ratio for the primary composite outcome; the statistical significance of the hazard ratio was determined from the log rank test. The uncertainty in the hazard ratio is expressed in the 95% confidence interval on the hazard ratio.', 'timeFrame': 'Through study completion. Median follow-up was 18.4 months.'}]","[{'measure': 'Death', 'description': 'The difference between treatment groups in mortality is assessed with a time-to-event analysis by calculation of the between group hazard ratio for death; the statistical significance of the hazard ratio was determined from the log rank test. The uncertainty in the hazard ratio is expressed in the 95% confidence interval on the hazard ratio.', 'timeFrame': 'Through study completion. Median follow-up was 41.5 months.'}, {'measure': 'Health Care Utilization', 'description': 'Health care utilization is measured by the rate of all hospitalizations.', 'timeFrame': 'Through study completion. Median follow-up was 18.4 months.'}, {'measure': 'Adherence', 'description': 'Adherence is measured by self-reported hours of home oxygen per day', 'timeFrame': 'Through study completion. Median follow-up was 18.4 months.'}, {'measure': 'COPD Exacerbation', 'description': 'Rate of all COPD exacerbations', 'timeFrame': 'Through study completion. Median follow-up was 11.4 months'}, {'measure': 'Preference-weighted Health-related Quality of Life', 'description': 'Preference-weighted health-related quality of life is measured by change in the Quality of Well-being Scale total daily score, follow-up value minus baseline value. The total daily score ranges from 0 to 1 with higher score indicating more better quality of life. Death is scored 0. Greater change, follow-up minus baseline, indicates improvement in quality of life compared to baseline. Change scores may range from -1 to +1.', 'timeFrame': 'Baseline to 1 year'}, {'measure': 'Disease-specific Quality of Life', 'description': ""Disease-specific quality of life is measured by the change in the St George's Respiratory Questionnaire total score, follow-up value minus baseline value. The total score ranges from 0 to 100 with lower score indicating fewer respiratory symptoms. Change in score, follow-up minus baseline may range from -100 to +100, with lower values indicating improvement in disease-specific quality of life."", 'timeFrame': 'Baseline to 1 year'}, {'measure': 'General Quality of Life', 'description': 'General quality of life is measured by the change in the physical component summary subscale of the SF-36 quality of life questionnaire, follow-up value minus baseline value. The physical component summary subscale score ranges from 0 to 100 with higher values indicating better physical functioning. The change in score, follow-up minus baseline value, ranges from -100 to +100 with higher values indicating improvement in physical functioning.', 'timeFrame': 'Baseline to 1 year'}, {'measure': 'Sleep Quality', 'description': 'Sleep quality is measured by the change in the Pittsburgh Sleep Quality Index total score, follow-up value minus baseline value. The Pittsburgh Sleep Quality Index total score ranges from 0 to 21 with higher values indicating worse sleep quality. The change in score, follow-up minus baseline value, ranges from -21 to +21 with higher values indicating worsening in sleep quality.', 'timeFrame': 'Baseline to 1 year'}, {'measure': 'Anxiety', 'description': 'Anxiety is measured by the change in the Hospital Anxiety and Depression Scale (HADS) anxiety score, follow-up value minus baseline value. The HADS anxiety score ranges from 0 to 21 with higher values indicating greater anxiety. The change in score, follow-up minus baseline value, ranges from -21 to +21 with higher values indicating increase in anxiety', 'timeFrame': 'Baseline to 1 year'}, {'measure': 'Depression', 'description': 'Depression is measured by the change in the Hospital Anxiety and Depression Scale (HADS) depression score, follow-up value minus baseline value. The HADS depression score ranges from 0 to 21 with higher values indicating greater depression. The change in score, follow-up minus baseline value, ranges from -21 to +21 with higher values indicating increase in depression', 'timeFrame': 'Baseline to 1 year'}, {'measure': 'Development of Severe Resting Desaturation', 'description': 'Severe resting desaturation is defined as resting room air SpO2 \\<=88%', 'timeFrame': 'Baseline to 1 year'}, {'measure': '6-minute Walk Distance', 'description': 'Change in distance walked during 6-minute walk test, follow-up value minus baseline value (feet)', 'timeFrame': 'Baseline to 1 year'}, {'measure': 'Dyspnea', 'description': ""Change in dyspnea is measured by change in the St George's Respiratory Questionnaire (SGRQ) total score, follow-up value minus baseline value. The SGRQ total score ranges from 0 to 100, with higher values indicating worse dyspnea. The change in score, follow-up value minus baseline value, ranges from -100 to +100, with higher values indicating increase in dyspnea."", 'timeFrame': 'Baseline to 1 year'}]",14,40 Years,,ALL,False,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,1,738.0,ACTUAL,2025-09-01T16:18:22.206700,v2_robust,True,True,True,False,False,
NCT04390763,Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC),"A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)",gemcitabine,"['gemcitabine', 'nab-paclitaxel', 'abraxane']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Pancreatic Ductal Adenocarcinoma,['Metastatic Pancreatic Ductal Adenocarcinoma'],"['NIS793', 'spartalizumab', 'gemcitabine', 'nab-paclitaxel', 'mPDAC', 'TGFβ', 'PD-1', 'Phase II']",TERMINATED,"The study was early terminated following the NIS793 treatment halt and urgent safety measure issued in July 2023, as the continued evaluation of Standard of Care alone will not support the original purpose of this phase 2 clinical trial.",2020-10-16,2024-05-02,"[{'measure': 'Safety run-in Part: Number of Participants With Dose-Limiting Toxicities (DLTs)', 'description': 'A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 where the relationship to study treatment cannot be ruled out and is not clearly related solely to disease, disease progression, inter-current illness or concomitant medications, which occurs within the DLT evaluation period. The DLT evaluation period is the first 28 days of treatment with NIS793 with spartalizumab in combination with gemcitabine/nab-paclitaxel. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.', 'timeFrame': 'First cycle of treatment (28 days)'}, {'measure': 'Safety run-in Part: Number of Participants With AEs and SAEs During the On-treatment Period', 'description': 'Number of participants with AEs (any adverse events regardless of seriousness) and serious adverse events (SAEs), including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs.\n\nAE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. For CTCAE v5.0, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE.\n\nThe on-treatment period is defined from the day of first administration of any study treatment up to 30 days after the date of the last actual administration of any study drug.', 'timeFrame': 'Up to approximately 0.8 years'}, {'measure': 'Safety run-in Part: Number of Participants With Dose Reductions and Dose Interruptions of NIS793, Spartalizumab, Gemcitabine and Nab-paclitaxel', 'description': 'Number of participants with at least one dose reduction and at least one dose interruption of study drugs. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule.\n\nNo dose reductions were allowed for NIS793 and spartalizumab beyond the first 28 days period of Safety run-in part.', 'timeFrame': 'Up to approximately 0.7 years'}, {'measure': 'Safety run-in Part: Dose Intensity of NIS793 and Spartalizumab', 'description': 'Dose intensity of NIS973 and spartalizumab was calculated as cumulative actual dose in milligrams divided by duration of exposure in days and multiplied by 28 days. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule.', 'timeFrame': 'Cycle 1 and Cycle 3. The duration of each cycle was 28 days.'}, {'measure': 'Safety run-in Part: Dose Intensity of Gemcitabine and Nab-paclitaxel', 'description': 'Dose intensity of gemcitabine and nab-paclitaxel was calculated as cumulative actual dose in milligrams/m\\^2 divided by duration of exposure in days and multiplied by 28 days.', 'timeFrame': 'Cycle 1 and Cycle 3. The duration of each cycle was 28 days.'}, {'measure': 'Randomized Part: Progression-Free Survival (PFS) Per RECIST v1.1 - Bayesian Model', 'description': 'PFS was based on local review of tumor assessments, using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria. PFS is defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. If a subject had not had an event, PFS was censored at the date of last adequate tumor assessment.\n\nPFS was estimated using a Bayesian model. For each comparison (arm 1 versus arm 3 and arm 2 versus arm 3), PFS was modeled using a two-piece hazard model, with specifying hazard rates before and after the possible delayed effect for arms 1 and 2 and constant hazard rate for arm 3.\n\nResults in the table as expressed as estimated posterior median hazard rate and one-sided 90% credible interval.', 'timeFrame': 'Up to approximately 2 years. Risk changing timepoint=approximately 0.3 years.'}, {'measure': 'Randomized Part: Progression-Free Survival (PFS) Per RECIST v1.1 - Kaplan-Meier Curves and Cox Model', 'description': 'PFS was based on local review of tumor assessments, using RECIST 1.1 criteria. PFS is defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. If a subject had not had an event, PFS was censored at the date of last adequate tumor assessment.\n\nPFS was analyzed based on the Kaplan-Meier curves and the Cox model.', 'timeFrame': 'Up to approximately 2 years'}]","[{'measure': 'Randomized Part: Number of Participants With AEs and SAEs During the On-treatment Period', 'description': 'Number of participants with AEs (any adverse events regardless of seriousness) and serious adverse events (SAEs), including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs.\n\nAE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. For CTCAE v5.0, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE.\n\nThe on-treatment period is defined from the day of first administration of any study treatment up to 30 days after the date of the last actual administration of any study drug.', 'timeFrame': 'Up to approximately 1.8 years'}, {'measure': 'Randomized Part: Number of Participants With Dose Reductions and Dose Interruptions of NIS793, Spartalizumab, Gemcitabine and Nab-paclitaxel', 'description': 'Number of participants with at least one dose reduction and at least one dose interruption of study drugs. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule.\n\nNo dose reductions were allowed for NIS793 and spartalizumab in the Randomized part.', 'timeFrame': 'Up to approximately 1.7 years'}, {'measure': 'Randomized Part: Dose Intensity of NIS973 and Spartalizumab', 'description': 'Dose intensity of NIS973 and spartalizumab was calculated as cumulative actual dose in milligrams divided by duration of exposure in days and multiplied by 28 days. Dose adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule.', 'timeFrame': 'Cycle 1 and Cycle 3. The duration of each cycle was 28 days'}, {'measure': 'Randomized Part: Dose Intensity of Gemcitabine and Nab-paclitaxel', 'description': 'Dose intensity of gemcitabine and nab-paclitaxel was calculated as cumulative actual dose in milligrams/m\\^2 divided by duration of exposure in days and multiplied by 28 days.', 'timeFrame': 'Cycle 1 and Cycle 3. The duration of each cycle was 28 days'}, {'measure': 'Randomized Part: Overall Response Rate (ORR) Per RECIST v1.1', 'description': 'ORR is the percentage of patients with a confirmed best overall response of complete response (CR) or partial response (PR), based on local investigator assessment per Response Evaluation Criteria for Solid Tumors (RECIST) v1.1.\n\nFor RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.', 'timeFrame': 'Up to approximately 1.7 years'}, {'measure': 'Randomized Part: Duration of Response (DOR) Per RECIST v1.1', 'description': 'DOR per RECIST v1.1 is defined as the time from the first documented response of CR or PR to the date of the first documented progression or death. DOR only applies to patients with a best overall response of CR or PR by investigator assessment per RECIST v1.1. Participants continuing without progression or death were censored at the date of their last adequate tumor assessment.\n\nDOR was analyzed using the Kaplan-Meier method.', 'timeFrame': 'Up to approximately 1.7 years'}, {'measure': 'Randomized Part: Time to Progression (TTP) Per RECIST v1.1', 'description': 'TTP per RECIST v1.1 is defined as the time from the date of randomization to the date of event defined as the first documented progression per RECIST v1.1 or death due to underlying cancer. If a participant had no progression or death, the participant was censored at the date of last adequate tumor assessment.\n\nDOR was analyzed using the Kaplan-Meier method.', 'timeFrame': 'Up to approximately 1.7 years'}, {'measure': 'Randomized Part: Overall Survival (OS)', 'description': 'Overall survival is defined as the time from the date of randomization to the date of death due to any cause.\n\nOS was analyzed using the Kaplan-Meier method.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Randomized Part: Change From Baseline in PD-L1 Expression', 'description': 'The tumor expression of programmed cell death-ligand 1 (PD-L1) was measured by immunohistochemical methods. Results are expressed as absolute change from baseline in PD-L1 expression.', 'timeFrame': 'Baseline (Screening), on-treatment (anytime between Cycle 3 Day 2 and Day 4). The duration of each cycle was 28 days.'}, {'measure': 'Randomized Part: Change From Baseline in CD8 Expression', 'description': 'The tumor expression of CD8 was measured by immunohistochemical methods. Results are expressed as absolute change from baseline in CD8 expression.', 'timeFrame': 'Baseline (Screening), on-treatment (anytime between Cycle 3 Day 2 and Day 4). The duration of each cycle was 28 days.'}, {'measure': 'Randomized Part: Number of Participants With Anti-NIS793 Antibodies', 'description': 'The immunogenicity (IG) against NIS793 was assessed in serum using a validated enhanced electrochemiluminescence immunoassay (ECLIA).\n\nPatient anti-drug antibodies (ADA) status was defined as follows:\n\n* ADA-negative at baseline: ADA-negative sample at baseline\n* ADA-positive at baseline: ADA-positive sample at baseline\n* ADA-negative post-baseline: patient with ADA-negative sample at baseline and at least 1 post baseline sample, all of which are ADA-negative samples\n* ADA-inconclusive post-baseline = patient who does not qualify as ADA-positive or ADA-negative post-baseline\n* Treatment-induced ADA-positive = ADA-negative sample at baseline and at least 1 treatment-induced ADA-positive sample', 'timeFrame': 'Baseline (before first dose) and post-baseline (assessed throughout the treatment up to approximately 1.7 years)'}, {'measure': 'Randomized Part: Number of Participants With Anti-spartalizumab Antibodies', 'description': 'The immunogenicity (IG) against spartalizumab was assessed in serum using a validated a validated homogenous enzyme-linked immunosorbent assay (ELISA).\n\nPatient anti-drug antibodies (ADA) status was defined as follows:\n\n* ADA-negative at baseline: ADA-negative sample at baseline\n* ADA-inconclusive at baseline: patient who does not qualify as ADA-positive or ADA-negative at baseline\n* ADA-positive at baseline: ADA-positive sample at baseline\n* ADA-negative post-baseline: patient with ADA-negative sample at baseline and at least 1 post baseline sample, all of which are ADA-negative samples\n* ADA-inconclusive post-baseline = patient who does not qualify as ADA-positive or ADA-negative post-baseline\n* Treatment-induced ADA-positive = ADA-negative sample at baseline and at least 1 treatment-induced ADA-positive sample', 'timeFrame': 'Cycle 1 and Cycle 3. The duration of each cycle was 28 days'}, {'measure': 'Randomized Part: Maximum Observed Serum Concentration (Cmax) of NIS793', 'description': 'Pharmacokinetic (PK) parameters were calculated based on NIS793 serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.', 'timeFrame': 'Cycle 1 and Cycle 3: pre-dose, 1, 24, 168 and 336 hours after the end of the infusion on Day 1. The duration of the infusion was 30 minutes. One cycle=28 days'}, {'measure': 'Randomized Part: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of NIS793', 'description': 'PK parameters were calculated based on NIS793 serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.', 'timeFrame': 'Cycle 1 and Cycle 3: pre-dose, 1, 24, 168 and 336 hours after the end of the infusion on Day 1. The duration of the infusion was 30 minutes. One cycle=28 days'}, {'measure': 'Randomized Part: Trough Serum Concentration (Ctrough) of NIS793', 'description': 'Ctrough is defined as the concentration reached immediately before the next dose is administered. All drug concentrations below the lower limit of quantification were treated as zero for the calculation of PK parameters.', 'timeFrame': 'Cycle 1: pre-dose on Day 1. Cycle 3: pre-dose on Day 1 and Day 15 (combined). One cycle=28 days'}, {'measure': 'Randomized Part: Maximum Observed Serum Concentration (Cmax) of Spartalizumab', 'description': 'PK parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.', 'timeFrame': 'Cycle 1 and Cycle 3: pre-dose, 1, 24, 168 and 648 hours after the end of the infusion on Day 1. The duration of the infusion was 30 minutes. One cycle=28 days'}, {'measure': 'Randomized Part: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Spartalizumab', 'description': 'PK parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.', 'timeFrame': 'Cycle 1 and Cycle 3: pre-dose, 1, 24, 168 and 648 hours after the end of the infusion on Day 1. The duration of the infusion was 30 minutes. One cycle=28 days'}, {'measure': 'Randomized Part: Trough Serum Concentration (Ctrough) of Spartalizumab', 'description': 'Ctrough is defined as the concentration reached immediately before the next dose is administered. All drug concentrations below the lower limit of quantification were treated as zero for the calculation of PK parameters.', 'timeFrame': 'Cycle 2, 3 and 4: pre-dose on Day 1. One cycle=28 days'}, {'measure': 'Randomized Part: Maximum Observed Plasma Concentration (Cmax) of Gemcitabine', 'description': 'PK parameters were calculated based on gemcitabine plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.', 'timeFrame': 'Cycle 1 and Cycle 4: pre-dose, end of infusion, and 2, 3, 5 and 24 hours after the start of infusion on Day 1. The duration of the infusion was according to the product labelling and local guidance. One cycle=28 days'}, {'measure': 'Randomized Part: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Gemcitabine', 'description': 'PK parameters were calculated based on gemcitabine plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.', 'timeFrame': 'Cycle 1 and Cycle 4: pre-dose, end of infusion, and 2, 3, 5 and 24 hours after the start of infusion on Day 1. The duration of the infusion was according to the product labelling and local guidance. One cycle=28 days'}, {'measure': 'Randomized Part: Trough Serum Concentration (Ctrough) of Gemcitabine', 'description': 'Ctrough is defined as the concentration reached immediately before the next dose is administered. All drug concentrations below the lower limit of quantification were treated as zero for the calculation of PK parameters.', 'timeFrame': 'Cycle 4: pre-dose on Day 1. One cycle=28 days'}, {'measure': 'Randomized Part: Maximum Observed Plasma Concentration (Cmax) of Nab-paclitaxel', 'description': 'PK parameters were calculated based on nab-paclitaxel plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.', 'timeFrame': 'Cycle 1 and Cycle 4: pre-dose, end of infusion, and 2, 3, 5 and 24 hours after the start of infusion on Day 1. The duration of the infusion was according to the product labelling and local guidance. One cycle=28 days'}, {'measure': 'Randomized Part: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Nab-paclitaxel', 'description': 'PK parameters were calculated based on nab-paclitaxel plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.', 'timeFrame': 'Cycle 1 and Cycle 4: pre-dose, end of infusion, and 2, 3, 5 and 24 hours after the start of infusion on Day 1. The duration of the infusion was according to the product labelling and local guidance. One cycle=28 days'}, {'measure': 'Randomized Part: Trough Serum Concentration (Ctrough) of Nab-paclitaxel', 'description': 'Ctrough is defined as the concentration reached immediately before the next dose is administered. All drug concentrations below the lower limit of quantification were treated as zero for the calculation of PK parameters.', 'timeFrame': 'Cycle 4: pre-dose on Day 1. One cycle=28 days'}]",31,18 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,164.0,ACTUAL,2025-09-01T16:18:22.206774,v2_robust,True,True,False,True,True,"The study was early terminated following the NIS793 treatment halt and urgent safety measure issued in July 2023, as the continued evaluation of Standard of Care alone will not support the original purpose of this phase 2 clinical trial."
NCT01701063,An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus,"A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17 Infected With Genotype 1 Hepatitis C Virus",Telaprevir,"['Rebetol®', 'PegIntron®', 'Peginterferon alfa-2b', 'Telaprevir', 'Ribavirin']",5,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Hepatitis C,['Hepatitis C'],[],TERMINATED,,2013-01,2015-04,"[{'measure': 'Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'AE: any adverse change from the participant\'s baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. ""Study drug"" includes all investigational agents administered during the course of the study.', 'timeFrame': 'Baseline up to Week 52'}]","[{'measure': 'Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)', 'description': 'SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (less than \\[\\<\\] lower limit of quantification) at 12 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/High Pure System (HPS) RNA assay version 2.0. The lower limit of quantification was 25 international units per milliliter (IU/mL).', 'timeFrame': '12 weeks after last planned dose of study drug (up to Week 60)'}, {'measure': 'Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)', 'description': 'SVR24 was defined as an undetectable HCV RNA Levels (\\< lower limit of quantification) at 24 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL.', 'timeFrame': '24 weeks after last planned dose of study drug (up to Week 72)'}, {'measure': 'Percentage of Participants With Rapid Virologic Response (RVR)', 'description': 'The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL. RVR was defined as an undetectable HCV RNA (\\<lower limit of quantification) 4 weeks after the start of study treatment.', 'timeFrame': 'Week 4'}, {'measure': 'Percentage of Participants With Extended Rapid Virologic Response (eRVR)', 'description': 'The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL. eRVR was defined as an undetectable HCV RNA (\\<lower limit of quantification) at both 4 weeks and 12 weeks after the start of study treatment.', 'timeFrame': 'Week 4 and Week 12'}, {'measure': 'Percentage of Participants With Undetectable HCV RNA at Week 12', 'description': 'The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay version 2.0. The lower limit of quantification was 25 IU/mL.', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants With On-treatment Virologic Failure', 'description': 'On treatment virologic failure was defined as meeting any futility rule or completing assigned treatment duration and having detectable HCV RNA at EOT. The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay Version 2.0. The lower limit of quantification was 25 IU/mL. Futility rules: 1) HCV RNA \\>1000 IU/mL at Week 4; 2) HCV RNA \\>1000 IU/mL at Week 12; 3) Detectable HCV RNA after Week 12 to end of treatment.', 'timeFrame': 'Baseline up to Week 48'}, {'measure': 'Percentage of Participants With Virologic Relapse', 'description': 'The plasma HCV RNA level was measured using Roche COBAS TaqMan HCV/HPS RNA assay Version 2.0. The lower limit of quantification was 25 IU/mL. Viral relapse was defined as having detectable HCV at follow-up in participants who had HCV RNA less than (\\<) lower limit of quantification (LLOQ) at planned EOT.', 'timeFrame': '12 weeks after planned EOT (up to Week 60)'}, {'measure': 'Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region', 'description': 'Sequence analysis of the HCV NS3-4A region was performed to monitor telaprevir-resistant variants. HCV RNA was isolated from the plasma, amplified by reverse transcription-polymerase chain reaction (RT-PCR), and sequenced (sequencing assay limit of detection HCV RNA \\>=1000 IU/mL). Results of this outcome measure were to be reported for overall participants instead of by age.', 'timeFrame': 'Baseline, On treatment (up to Week 48)'}, {'measure': 'Maximum Plasma Concentration (Cmax) of Telaprevir', 'description': 'Cmax was measured for telaprevir only.', 'timeFrame': 'Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7'}, {'measure': 'Time to Reach Maximum Plasma Concentration (Tmax) of Telaprevir', 'description': 'Tmax was measured for telaprevir only.', 'timeFrame': 'Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve (AUC) of Telaprevir', 'description': 'AUC was measured for telaprevir only. AUC 0-t last was defined as the area under the concentration-time curve from the time of dosing to the last measurable concentration. AUC 0-12 hour (AUC 0-12h) was calculated by respecifying predose concentrations as 12 hour concentrations. AUC 0-24h was calculated as AUC 0-12h multiplied by 2. Dose adjusted AUC (AUC 0-24h\\_Adj) was calculated by multiplying AUC 0-24h by the dose adjustment factor to obtain projected exposures in participants who were misdosed. Data were presented for AUC 0-t last, AUC 0-12h, AUC 0-24h, AUC 0-24h\\_Adj.', 'timeFrame': 'Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7'}, {'measure': 'Elimination Half-Life (T1/2) of Telaprevir', 'description': 'T1/2 was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.', 'timeFrame': 'Cohort 1: Pre-dose and 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 2: Pre-dose and 0.5, 2.0, 4.0, 5.0, 6.0, and 8.0 hours post-dose on Day 7, Cohort 3: Pre-dose and 1.5, 4.0, and 8.0 hours post-dose on Day 7'}]",13,3 Years,17 Years,ALL,False,Vertex Pharmaceuticals Incorporated,INDUSTRY,1,42.0,ACTUAL,2025-09-01T16:18:22.206803,v2_robust,True,True,False,True,True,
NCT01494363,Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer,"Multicenter Phase II Study of Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) in Patients With Locally Advanced or Metastatic Biliary Tract Cancer",Fluorouracil,"['Leucovorin', 'Fluorouracil', 'Irinotecan', 'Oxaliplatin']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Biliary Tract Cancer,['Biliary Tract Cancer'],[],UNKNOWN,,2011-10,2013-12,"[{'measure': 'Response rate', 'description': 'Assessment of response will be assessed according to RECIST v1.1 criteria after completion of every two cycles. Evaluation will be conducted by physical examination, X-ray, or CT scan', 'timeFrame': '2 years'}]","[{'measure': 'Treatment-related toxicities', 'description': 'Assessment of toxicity will be assessed according to NCI CTCAE version 4.0.', 'timeFrame': '2 years'}, {'measure': 'Progression free survival', 'timeFrame': '2 years'}, {'measure': 'Overall survival', 'timeFrame': '2 years'}]",4,18 Years,75 Years,ALL,False,Soon Chun Hyang University,OTHER,0,53.0,ESTIMATED,2025-09-01T16:18:22.206821,v2_robust,True,True,False,False,False,
NCT00909363,Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients,"Effects Of Eltrombopag On Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia.",Promacta,"['eltrombopag, revolade', 'Promacta']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Wiskott-Aldrich Syndrome,"['Wiskott-Aldrich Syndrome', 'Thrombocytopenia', 'Bleeding']",[],TERMINATED,retirement of PI,2009-06,2017-06-30,"[{'measure': 'How Many WAS Patients Will Achieve Platelet Counts Above 50,000/ul.', 'description': 'number of WAS patients achieving this increase to \\> 50,000/uL without rescue medication in the previous 3 weeks during eltrombopag treatment', 'timeFrame': '12 weeks'}]","[{'measure': 'Number of Patients With Wiskott-Aldrich Syndrome (WAS) With Grade 3 or Higher Bleeding or SAE (on WHO Scale)', 'description': 'number of patients with bleeding SAEs while on treatment and/or number of patients with grade 3 or higher bleeding on WHO (World Health Organization) scale: the scale is from 1 to 5 with 5 = fatality and 1=very little bleeding', 'timeFrame': '12 Weeks'}, {'measure': 'How Many Patients With WAS Had Abnormal Platelet Function Including Activation', 'description': 'in how many patients with WAS were platelets dysfunctional or activated before treatment as measured by flow cytometry to a substantial degree and the same after treatment with eltrombopag', 'timeFrame': '12 weeks'}, {'measure': 'How Many Patients With WAS Had Substantially Increased Platelet Production After Eltrombopag', 'description': 'in how many patients with WAS did eltrombopag increase platelet production as measured by the immature platelet fraction (IPF), a variable derived from the Sysmex auto analyzer, which is considered to be a measure of newly formed platelets ie reticulated platelets', 'timeFrame': '12 weeks'}]",4,3 Months,80 Years,MALE,True,Weill Medical College of Cornell University,OTHER,1,24.0,ACTUAL,2025-09-01T16:18:22.206834,v2_robust,True,True,False,True,False,retirement of PI
NCT03976063,Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation,Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation: a Double-blinded Randomized Controlled Trial,Nifedipine,"['Placebo of Nifedipine', 'Nifedipine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Preterm Premature Rupture of Membrane,['Preterm Premature Rupture of Membrane'],"['Preterm premature rupture of membranes', 'Tocolysis', 'Nifedipine', 'Latency', 'Neonatal outcome', 'Preterm birth', 'Randomized controlled trial']",RECRUITING,,2019-10-07,2030-11,"[{'measure': 'Perinatal morti-morbidity', 'description': 'Composite outcome including fetal death, neonatal death and/or neonatal severe morbidity (mechanical ventilation ≥ 48 hrs, severe bronchopulmonary dysplasia, severe intraventricular hemorrhage, cystic periventricular leucomalacia, neonatal early-onset sepsis, necrotizing enterocolitis, retinopathy of prematurity).', 'timeFrame': 'Up to discharge from hospital, with a maximum of 24 weeks after birth.'}]","[{'measure': 'Prolongation of gestation', 'description': 'Latency duration (defined as the duration from PPROM to delivery)', 'timeFrame': 'Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)'}, {'measure': 'Prolongation of gestation', 'description': 'Pregnancy prolongation beyond 48 hours after randomization', 'timeFrame': 'Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)'}, {'measure': 'Prolongation of gestation', 'description': 'Pregnancy prolongation beyond 1 week after randomization', 'timeFrame': 'Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)'}, {'measure': 'Prolongation of gestation', 'description': 'Gestational age at delivery', 'timeFrame': 'Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)'}, {'measure': 'Prolongation of gestation', 'description': 'Delivery after 37 weeks of gestation', 'timeFrame': 'Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)'}, {'measure': 'Maternal morbidity', 'description': 'Endometritis, based on clinical diagnosis associating fever (temperature ≥ 38.0°C) with uterine tenderness, purulent or foul-smelling lochia, and in the absence of any other cause.', 'timeFrame': 'During the first 10 days postpartum'}, {'measure': 'Maternal morbidity', 'description': 'Intra-uterine infection, defined as fever (maternal temperature ≥38 °C), with no alternative cause identified, associated with at least two of the following criteria: persistent fetal tachycardia \\> 160 bpm, uterine pain or painful uterine contractions or spontaneous labor, purulent amniotic fluid.', 'timeFrame': 'At delivery'}, {'measure': 'Fetal mortality', 'description': 'Fetal death', 'timeFrame': 'Up to delivery so up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)'}, {'measure': 'Neonatal mortality', 'description': 'Neonatal death', 'timeFrame': 'From birth to discharge from hospital, with a maximum of 24 weeks after birth.'}, {'measure': 'Neonatal severe morbidity', 'description': 'Mechanical ventilation ≥ 48 hrs', 'timeFrame': 'From birth to discharge from hospital, with a maximum of 24 weeks after birth.'}, {'measure': 'Neonatal severe morbidity', 'description': 'Severe bronchopulmonary dysplasia', 'timeFrame': 'From birth to discharge from hospital, with a maximum of 24 weeks after birth.'}, {'measure': 'Neonatal severe morbidity', 'description': 'Severe intraventricular hemorrhage', 'timeFrame': 'From birth to discharge from hospital, with a maximum of 24 weeks after birth.'}, {'measure': 'Neonatal severe morbidity', 'description': 'Cystic periventricular leucomalacia', 'timeFrame': 'From birth to discharge from hospital, with a maximum of 24 weeks after birth.'}, {'measure': 'Neonatal severe morbidity', 'description': 'Early-onset sepsis', 'timeFrame': 'From birth to Day 3 after birth.'}, {'measure': 'Neonatal severe morbidity', 'description': 'Necrotizing enterocolitis', 'timeFrame': 'From birth to discharge from hospital, with a maximum of 24 weeks after birth.'}, {'measure': 'Neonatal severe morbidity', 'description': 'Retinopathy of prematurity', 'timeFrame': 'From birth to discharge from hospital, with a maximum of 24 weeks after birth.'}, {'measure': 'Neonatal morbidity', 'description': 'Severe fetal acidemia', 'timeFrame': 'At birth.'}, {'measure': 'Neonatal morbidity', 'description': 'Respiratory distress syndrome', 'timeFrame': 'From birth to discharge from hospital, with a maximum of 24 weeks after birth.'}, {'measure': 'Neonatal morbidity', 'description': 'Mild or moderate bronchopulmonary dysplasia', 'timeFrame': 'From birth to discharge from hospital, with a maximum of 24 weeks after birth.'}, {'measure': 'Neonatal morbidity', 'description': 'Grades I-II intraventricular hemorrhage', 'timeFrame': 'From birth to discharge from hospital, with a maximum of 24 weeks after birth.'}, {'measure': 'Neonatal morbidity', 'description': 'Late-onset sepsis.', 'timeFrame': 'From Day 3 after birth to discharge from hospital, with a maximum of 24 weeks after birth.'}, {'measure': 'Vital status', 'description': 'Death between discharge and follow up at 2 years', 'timeFrame': 'At 22-26 months of corrected age'}, {'measure': 'Frequency of Gross motor impairment among children alive at 2 years of corrected age', 'description': 'Cerebral palsy', 'timeFrame': 'At 22-26 months of corrected age'}, {'measure': 'Frequency of Neurosensory impairment among children alive at 2 years of corrected age', 'description': 'Visual impairment', 'timeFrame': 'At 22-26 months of corrected age'}, {'measure': 'Frequency of Neurosensory impairment among children alive at 2 years of corrected age', 'description': 'Hearing impairment', 'timeFrame': 'At 22-26 months of corrected age'}]",26,18 Years,,FEMALE,False,Assistance Publique - Hôpitaux de Paris,OTHER,3,850.0,ESTIMATED,2025-09-01T16:18:22.206856,v2_robust,True,True,False,False,False,
NCT00749463,"Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment","Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment",Nicotine Gum,"['Nicotine Gum', 'Nicotine Patch', 'Nicorette® Patch', 'Nicorette® Gum']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Tobacco Dependence,['Tobacco Dependence'],"['nicotine dependence, smoking cessation, NRT']",COMPLETED,,2009-02,2009-11,"[{'measure': 'Treatment-Related Adverse Events', 'description': 'Percentage of subjects with treatment-related adverse events by preferred term, included if the percentage in any single arm was 1% or higher', 'timeFrame': '24 Weeks'}, {'measure': 'Self-Reported Smoking Reduction', 'description': 'Percentage of subjects self-reporting reduction from baseline in number of cigarettes smoked per day', 'timeFrame': '24 Weeks'}, {'measure': 'Smoking Abstinence', 'description': 'Continuous carbon monoxide (CO)-verified Smoking Abstinence from Quit day', 'timeFrame': '24 Weeks'}]","[{'measure': 'Carbon Monoxide (CO)-Verified Smoking Reduction', 'description': 'Percentage of participants with carbon monoxide (CO)-verified reduction from baseline in number of cigarettes smoked per day (%)', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Smoking Consumption Per Day', 'description': 'Number of cigarettes smoked by subjects reporting smoking since last visit - total during the day (for daily smokers)', 'timeFrame': '24 Weeks from last visit:'}, {'measure': 'Smoking Consumption Per Week', 'description': 'Number of cigarettes smoked by subjects reporting smoking since last visit - total during the the week (for non-daily smokers)', 'timeFrame': '24 Weeks from last visit:'}, {'measure': 'Point Prevalence Smoking Abstinence (PPSA)', 'description': 'Point Prevalence Smoking Abstinence since last visit. Point prevalence abstinence is defined as the percentage of former smokers who are not smoking at a particular point in time, typically at the time of assessment.', 'timeFrame': '24 Weeks'}]",7,18 Years,,ALL,False,McNeil AB,INDUSTRY,0,300.0,ACTUAL,2025-09-01T16:18:22.206938,v2_robust,True,True,True,False,True,
NCT05994287,Pain Treatment With Combinations of NSAIDs,"Pain Treatment After Joint Surgery With a Combination of Aspirin, Ketorolac, and Celecoxib.",Aspirin,"['Aspirin', 'Celecoxib', 'Ketorolac']",3,INTERVENTIONAL,['NA'],,,"Postoperative Pain, Acute","['Postoperative Pain, Acute']","['Postoperative pain', 'Non-steroidal anti-inflammatory drugs', 'Combination of NSAID', 'Aspirin', 'Ketorolac', 'Celecoxib']",COMPLETED,,2021-01-01,2023-01-01,"[{'measure': 'Measuring postoperative pain using the visual analog scale for pain (VAS-P)', 'description': ""The patients choose the score on the 10 cm line scale with (VAS-P) rage from 0 ('no pain') to 10 (severe pain)."", 'timeFrame': '5 days'}]","[{'measure': 'Arachidonic acid-stimulated platelet tests', 'description': 'Assessed by Multiplate ASPItest, Roche Diagnostics GmbH. The platelet aggregation expressed in arbitrary aggregation units (AU) multiplied by the recorded time in minutes (AU\\*min).', 'timeFrame': '5 days'}, {'measure': 'Hemoglobin', 'description': 'Hemoglobin (HGB) level in g/L', 'timeFrame': '5 days'}, {'measure': 'Hematocrit', 'description': 'Hematocrit level in %', 'timeFrame': '5 days'}, {'measure': 'Erythrocytes', 'description': 'Erythrocytes (RBC) number in 1 litter', 'timeFrame': '5 days'}, {'measure': 'Platelets cells', 'description': 'Platelets cells (PLT) number in 1 litter', 'timeFrame': '5 days'}, {'measure': 'Fibrinogen', 'description': 'Fibrinogen level in g/L', 'timeFrame': '5 days'}, {'measure': 'Partial thromboplastin time', 'description': 'Partial thromboplastin time (PTT) in seconds', 'timeFrame': '5 days'}, {'measure': 'Prothrombin time', 'description': 'Prothrombin time in %', 'timeFrame': '5 days'}]",9,18 Years,80 Years,ALL,False,"Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty",OTHER,0,105.0,ACTUAL,2025-09-01T16:18:22.206949,v2_robust,True,True,True,False,False,
NCT00291187,VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 and Matching Placebo in Healthy Male and Female Subjects With Induced Transient Insomnia",20 mg VEC-162,"['50 mg VEC-162', '100 mg VEC-162', '20 mg VEC-162', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Insomnia,['Insomnia'],[],COMPLETED,,2006-02,2006-08,"[{'measure': 'Average Improvement of Latency to Persistent Sleep (LPS)', 'description': 'The average improvement in Latency to persistent sleep (the number of minutes between Lights Off and the onset of at least 10 minutes of persistent sleep, as measured by polysomnography) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.', 'timeFrame': 'Night 1'}]","[{'measure': 'Average Improvement of Wake After Sleep Onset (WASO)', 'description': 'The average improvement of wake after sleep onset (time spent awake between onset of sleep and lights on, determined by PSG) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.', 'timeFrame': 'Night 1'}]",2,21 Years,50 Years,ALL,True,Vanda Pharmaceuticals,INDUSTRY,0,411.0,ACTUAL,2025-09-01T16:18:22.207006,v2_robust,True,True,True,False,False,
NCT01267487,Clinical Trial Comparing Heparin and Protamine Fixed and Titrated Doses in Cardiac Surgery With Cardiopulmonary Bypass,Phase 4 Study of Fixed-dose and Titration Schemes of Heparin and Protamine in Cardiopulmonary Bypass Cardiac Surgeries : Evaluation of Post-operatory Blood Loss and Transfusion Requirements,Heparin fixed doses,"['Heparin and protamine titration', 'PO continuous infusion of Protamine', 'Heparin fixed doses']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Cardiac Surgery,"['Cardiac Surgery', 'Cardiopulmonary Bypass', 'Anticoagulation']","['Heparin', 'Protamine', 'Cardiopulmonary Bypass', 'Titration']",COMPLETED,,2009-07,2010-11,"[{'measure': 'Mediastinal blood drainage (ml)', 'description': 'The mediastinal blood drainage was measured hourly during the first 6 post-operatory (PO) hours, and every 6 hours from the 7th to 24th PO hours.', 'timeFrame': 'First 24 PO hours'}]","[{'measure': 'Transfusion of blood components', 'description': 'We measured the incidence(%) of transfusion of Packed Red Blood Cells, Plasma or Platelet during first 24 PO hours', 'timeFrame': 'First 24 PO hours'}]",2,18 Years,75 Years,ALL,False,SANE-Society of Anesthesiology,OTHER,2,240.0,ACTUAL,2025-09-01T16:18:22.207058,v2_robust,True,True,True,False,False,
NCT04529187,Effect of Midazolam and Dexmedetomidine on Heart Function - A Randomized MRI-based Study.,Effect of Midazolam and Dexmedetomidine on Heart Function - A Randomized MRI-based Study.,Midazolam,"['Midazolam', 'Dormicum® (Roche, F. Hoffmann-La Roche Ltd Basel, Switzerland)', 'Dexmedetomidine', 'Dexdor® (Orion Corporation, Nasdaq OMX Helsinki: ORNAV and ORNBV, Finland)']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Cardiac Function,"['Cardiac Function', 'Sedation', 'Magnetic Resonance Imaging']",[],COMPLETED,,2018-01-01,2019-12-31,"[{'measure': 'Changes in cardiac output following sedation administration', 'description': 'Using cardiac MRI stroke volume (measured in mL) of both heart ventricles will be registered prior and after sedation administration.', 'timeFrame': '5 minutes following sedation administration.'}, {'measure': 'Changes in diastolic heart function following sedation administration', 'description': 'Using cardiac MRI maximum flow velocity through the mitral valve (measured in mL/s) during early and late diastole will be measured prior and after sedation administration.', 'timeFrame': '5 minutes following sedation administration.'}]",[],2,18 Years,65 Years,ALL,True,Masaryk Hospital Krajská zdravotní a.s.,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:22.207107,v2_robust,True,True,True,False,False,
NCT01922687,Amlodipine Plus/Minus Atorvastatin for Protection of Arteries,Amlodipine Plus/Minus Atorvastatin for Protection of Arteries,amlodipine plus atorvastatin (Caduet),"['amlodipine plus atorvastatin (Caduet)', 'amlodipine (Norvasc)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Arterial and Arteriolar Disorders,['Arterial and Arteriolar Disorders'],[],UNKNOWN,,2011-04,2014-12,"[{'measure': 'flow-mediated dilation (FMD)', 'description': 'After 12-week maintenance treatment or at 24-week final visit.', 'timeFrame': '12-24 weeks'}]","[{'measure': 'pulse wave velocity (cf-PWV, ba-PWV)', 'description': 'After 12-week maintenance treatment or at 24-week final visit.', 'timeFrame': '12-24 weeks'}, {'measure': 'liver function', 'description': 'After 6-week maintenance treatment or at 24-week final visit.\n\nIntolerable adverse events which may or may not be related to the trial treatment, including:\n\n1. Levels of AST or ALT more than three times the upper limit of normal;\n2. Myalgia symptoms appear with no or only a moderate increase in CK (3 to 10 times above upper limit of normal), but repeated measurements of CK is progressively increasing;\n3. Myalgia symptoms appear, the concentration of CK is 10 times higher than the upper limit of normal.', 'timeFrame': '6-24weeks'}, {'measure': 'ankle-brachial index (ABI)', 'description': 'After 12-week maintenance treatment or at 24-week final visit.', 'timeFrame': '12-24 weeks'}, {'measure': 'augmentation index (AIx)', 'description': 'After 12-week maintenance treatment or at 24-week final visit.', 'timeFrame': '12-24 weeks'}, {'measure': 'carotid intima-media thickness (IMT)', 'description': 'After 12-week maintenance treatment or at 24-week final visit.', 'timeFrame': '12-24 weeks'}, {'measure': 'cholesterol level', 'description': 'After 12-week maintenance treatment or at 24-week final visit.', 'timeFrame': '12-24 weeks'}]",7,40 Years,75 Years,ALL,False,Shanghai Institute of Hypertension,OTHER,0,109.0,ESTIMATED,2025-09-01T16:18:22.207120,v2_robust,True,True,False,False,True,
NCT05855187,"Bioequivalence Study of Modafinil From Bravamax 200 mg Scored Tablets (Chemipharm Pharmaceutical Industries, Egypt) Versus Vigil 200 mg Tablets (Teva GmbH, Germany)","Comparative Randomized, Single Dose, Two-way Crossover Bioequivalence Study to Determine the Bioequivalence of Modafinil From Bravamax 200 mg Scored Tablets (Chemipharm Pharmaceutical Industries, Egypt) Versus Vigil 200 mg Tablets (Teva GmbH, Germany)",Bravamax 200 mg (Modafinil),"['Vigil', 'Bravamax 200 mg (Modafinil)', 'Vigil 200 mg (Modafinil)']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2022-11-15,2023-01-10,"[{'measure': 'Cmax', 'description': 'to measure the maximal measured plasma concentration', 'timeFrame': 'Up to 72 hours post dose in each treatment period'}]","[{'measure': 'Tmax', 'description': 'time of the maximum plasma concentration', 'timeFrame': 'Up to 72 hours post dose in each treatment period'}]",2,18 Years,55 Years,ALL,True,"Genuine Research Center, Egypt",INDUSTRY,1,30.0,ACTUAL,2025-09-01T16:18:22.207267,v2_robust,True,True,True,False,False,
NCT02954887,Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7),"A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol (CBD; GWP42003-P) in Infants With Infantile Spasms Following an Initial Open-label Pilot Study",GWP42003-P,"['Cannabidiol', 'CBD', 'GWP42003-P']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Infantile Spasms,['Infantile Spasms'],"['GWP42003-P', 'Cannabidiol']",COMPLETED,,2017-05-12,2019-06-13,"[{'measure': 'Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs)', 'description': 'TEAEs were collected in members of the Safety Population, comprised of all participants who received at least 1 dose of GWP42003-P. TEAEs are defined as all adverse events not present prior to the first investigational medicinal product (IMP) or placebo administration or any event already present that worsened in severity or frequency following IMP.', 'timeFrame': 'From signing of informed consent up to Day 417'}, {'measure': 'Number of Participants With Any Low or High Hematology Laboratory Parameter Value', 'timeFrame': 'Days 19, 29, 43, 71, 127, 211, 295, 379, and 389'}, {'measure': 'Number of Participants With Any Low or High Biochemistry Laboratory Parameter Value', 'timeFrame': 'Days 19, 29, 43, 71, 127, 211, 295, 379, and 389'}, {'measure': 'Number of Participants With Any Clinically Relevant Urinalysis Parameter Value', 'description': 'Clinical relevance was determined by the investigator.', 'timeFrame': 'Days 19, 29, 43, 71, 127, 211, 295, 379, and 389'}, {'measure': 'Number of Participants With Clinically Significant Electrocardiogram Findings', 'description': 'Clinical significance was determined by the investigator.', 'timeFrame': 'From signing of informed consent up to Day 389'}, {'measure': 'Number of Participants With Clinically Significant Vital Sign Findings', 'description': 'Clinical significance was determined by the investigator.', 'timeFrame': 'From signing of informed consent up to Day 389'}, {'measure': 'Number of Participants With Clinically Significant Physical Examination Findings', 'description': 'Clinical significance was determined by the investigator.', 'timeFrame': 'From signing of informed consent up to Day 389'}]","[{'measure': 'Number of Participants Free of Clinical Spasms', 'description': 'Clinical spasms were determined by video-electroencephalography (VEEG) for at least 8 hours and up to 24 hours.', 'timeFrame': 'Days 29, 43, 127, 211, 295, and 379'}, {'measure': 'Percentage of Participants Free of Clinical Spasms', 'description': 'Clinical spasms were determined by VEEG for at least 8 hours and up to 24 hours.', 'timeFrame': 'Days 29, 43, 127, 211, 295, and 379'}, {'measure': 'Number of Participants With a Resolution of Hypsarrhythmia', 'description': 'Resolution of hypsarrhythmia was determined by VEEG for at least 8 hours and up to 24 hours.', 'timeFrame': 'Days 29, 43, 127, 211, 295, and 379'}, {'measure': 'Percentage of Participants With a Resolution of Hypsarrhythmia', 'description': 'Resolution of hypsarrhythmia was determined by VEEG for at least 8 hours and up to 24 hours.', 'timeFrame': 'Days 29, 43, 127, 211, 295, and 379'}, {'measure': 'Number of Participants Experiencing Spasms and Seizures by Subtype', 'description': ""Caregivers recorded the participant's spasms and seizures by category in a daily diary. Subtypes of spasms and seizure included, clonic, tonic-clonic, myoclonic, focal, and absence."", 'timeFrame': 'Days 19, 29, 127, 211, 295, and 379'}, {'measure': 'Caregiver Global Impression of Change (CGIC)', 'description': ""The CGIC is a single-question assessment completed by the caregiver. The question assessed the status of the participant's condition since treatment start. The caregiver provided a rating on a 7-point scale: 1, very much improved; 2, much Improved; 3, slightly improved; 4, no change; 5, slightly worse; 6, much worse; 7, very much worse."", 'timeFrame': 'Baseline; Days 29, 43, 71, 127, 211, 295, and 379'}, {'measure': 'Physician Global Impression of Change (PGIC)', 'description': ""The PGIC is a single-question assessment completed by the investigator. The question assessed the status of the participant's condition since treatment start. The investigator provided a rating on a 7-point scale: 1, very much improved; 2, much Improved; 3, slightly improved; 4, no change; 5, slightly worse; 6, much worse; 7, very much worse."", 'timeFrame': 'Baseline; Days 29, 43, 71, 127, 211, 295, and 379'}, {'measure': 'Number of Responders', 'description': 'A responder is defined as a participant experiencing a resolution of hypsarrhythmia and free of spasms. Test for responders was conducted by VEEG for at least 8 hours and up to 24 hours.', 'timeFrame': 'Days 29, 43, 127, 211, 295, and 379'}, {'measure': 'Percentage of Responders', 'description': 'A responder is defined as a participant experiencing a resolution of hypsarrhythmia and free of spasms. Test for responders was conducted by VEEG for at least 8 hours and up to 24 hours.', 'timeFrame': 'Days 29, 43, 127, 211, 295, and 379'}, {'measure': 'Change From Baseline in Height', 'description': ""A positive change indicates an increase in the average participant's height. A negative change indicates a decrease in the average participant's height. Change from Baseline was calculated as the post-Baseline value minus the Baseline value."", 'timeFrame': 'Baseline (Day 1 of Pilot Study); Days 29, 43, 71, 127, 211, 295, 379, and 389'}, {'measure': 'Change From Baseline in Body Weight.', 'description': ""A positive change indicates an increase in the average participant's weight. A negative change indicates a decrease in the average participant's weight. Change from Baseline was calculated as the post-Baseline value minus the Baseline value."", 'timeFrame': 'Baseline (Day 1 of Pilot Study); Days 29, 43, 71, 127, 211, 295, 379, and 389'}, {'measure': 'Change From Baseline in Head Circumference', 'description': ""A positive change indicates an increase in the average participant's head circumference. A negative change indicates a decrease in the average participant's head circumference. Change from Baseline was calculated as the post-Baseline value minus the Baseline value."", 'timeFrame': 'Baseline (Day 1 of PIlot Study); Days 29, 43, 71, 127, 211, 295, 379, and 389'}, {'measure': 'Change From Baseline in Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score', 'description': 'The Vineland-II scores were assessed by the participant\'s caregiver. Caregivers were asked to score questions in the following categories: the participant\'s communication, daily living, physical activity, problem behaviors, and social skills and relationships. Scoring was slightly different for each section, but generally ranged from ""usually"" (2) to ""never"" (0). The total score is calculated as the sum of standard scores from the domains and converted into the adaptive behavior composite score (ranging from 20 to 160). Higher scores represent greater levels of functioning, and lower scores represent lower levels of functioning. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.', 'timeFrame': 'Baseline (Day 1 of Pilot Study); Day 211, Day 379'}, {'measure': 'Number of Participants With Relapse of Spasms', 'description': 'Analysis could not be conducted for this outcome measure because the study met No Go Criteria. The Pilot Phase concluded after 9 participants completed treatment and demonstrated continued hypsarrhythmia and spasms on follow-up VEEG. The Pivotal Phase was not initiated; however, participants completing the Pilot Phase could roll into the Open Label Extension Phase for up to 1 year.', 'timeFrame': 'Day 16 to Day 379'}, {'measure': 'Percentage of Participants With Relapse of Spasms', 'description': 'Analysis could not be conducted for this outcome measure because the study met No Go Criteria. The Pilot Phase concluded after 9 participants completed treatment and demonstrated continued hypsarrhythmia and spasms on follow-up VEEG. The Pivotal Phase was not initiated; however, participants completing the Pilot Phase could roll into the Open Label Extension Phase for up to 1 year.', 'timeFrame': 'Day 16 to Day 379'}, {'measure': 'Average Time to Cessation of Spasms', 'description': 'Analysis could not be conducted for this outcome measure because the study met No Go Criteria. The Pilot Phase concluded after 9 participants completed treatment and demonstrated continued hypsarrhythmia and spasms on follow-up VEEG. The Pivotal Phase was not initiated; however, participants completing the Pilot Phase could roll into the Open Label Extension Phase for up to 1 year.', 'timeFrame': 'Day 1 to Day 379'}, {'measure': 'Average Time to Relapse', 'description': 'Analysis could not be conducted for this outcome measure because the study met No Go Criteria. The Pilot Phase concluded after 9 participants completed treatment and demonstrated continued hypsarrhythmia and spasms on follow-up VEEG. The Pivotal Phase was not initiated; however, participants completing the Pilot Phase could roll into the Open Label Extension Phase for up to 1 year.', 'timeFrame': 'Day 16 to Day 379'}]",24,1 Month,24 Months,ALL,False,Jazz Pharmaceuticals,INDUSTRY,0,9.0,ACTUAL,2025-09-01T16:18:22.207319,v2_robust,True,True,True,False,True,
NCT02752087,A Study to Compare the Effects of a Test and Reference Formulation of LY900014 in Healthy Participants,A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY900014 Test Versus Reference Formulations in Healthy Subjects,LY900014,"['Ultra-Rapid Lispro', 'LY900014']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2016-04,2016-05,"[{'measure': 'Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 8 Hours (AUC[0-8 Hours])', 'description': 'PK: Insulin Lispro Area Under the Concentration Curve From Time Zero to 8 Hours (AUC\\[0-8 Hours\\])', 'timeFrame': '5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 90, 120, 150, 180, 240, 300, 360, 420, and 480 minutes post study dose for each treatment'}]","[{'measure': 'Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot)', 'description': 'Gtot is the total glucose infusion over the clamp duration. It is used to measure the study drug action over time as measured by the euglycemic clamp procedure.', 'timeFrame': 'Blood glucose was measured approximately every 2.5 minutes for the first 30 minutes, then every 5 minutes until 120 minutes post dose, and then every 10 minutes until 480 minutes post dose'}]",2,21 Years,65 Years,ALL,True,Eli Lilly and Company,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:22.207335,v2_robust,True,True,True,False,False,
NCT06460987,Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy,Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA,Finerenone,"['RASI', 'Finerenone', 'FINE', 'Immune Suppressant', 'immunosupressive', 'RAS inhibitor']",6,OBSERVATIONAL,[],,,Finerenone,"['Finerenone', 'IgA Nephropathy', 'Proteinuria', 'Safety Issues']","['finerenone', 'IgA Nephropathy']",COMPLETED,,2022-12-01,2024-03-31,"[{'measure': 'percentage change in PCR from baseline to 6 months', 'description': 'Collect PCR data before enrolment and at month 6 and calculate the percentage change', 'timeFrame': '6 month'}]","[{'measure': 'percentage change in PCR from baseline to 1, 2 and 3 months', 'description': 'Collec PCR before enrolment and at months 1, 2 and 3, then calculate the percentage change', 'timeFrame': '1, 2 and 3 month'}, {'measure': 'frequency of patients with a 30% and 50% decrease in PCR', 'description': 'Calculate the number of patients with \\>30% or \\>50% reduction in proteinuria during the 6-month follow-up period', 'timeFrame': '6 month'}, {'measure': 'the level of change in eGFR', 'description': 'Collection of eGFR before enrolment and at months 6', 'timeFrame': '6 month'}, {'measure': 'the level of change in blood sodium', 'description': 'Collection of blood sodium before enrolment and at months 6', 'timeFrame': '6 month'}, {'measure': 'the level of change in serum creatinine', 'description': 'Collection of serum creatinine before enrolment and at months 6', 'timeFrame': '6 month'}, {'measure': 'the level of change in albumin', 'description': 'Collection of albumin before enrolment and at months 6', 'timeFrame': '6 month'}]",7,18 Years,75 Years,ALL,False,The Fourth Affiliated Hospital of Zhejiang University School of Medicine,OTHER,0,245.0,ACTUAL,2025-09-01T16:18:22.207363,v2_robust,False,True,True,False,False,
NCT02024087,Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma,"A Phase 1b, Open Label Study of Dalantercept Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma",Dalantercept plus sorafenib,"['ACE-041', 'Dalantercept plus sorafenib']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Advanced Adult Hepatocellular Carcinoma,['Advanced Adult Hepatocellular Carcinoma'],[],COMPLETED,,2014-08-04,2017-09-22,"[{'measure': 'Number of Participants With Adverse Events as a Measure of Safety and Tolerability.', 'description': 'Assessed by monitoring AEs using the current active minor version on the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 4.0 (NCI-CTCAE v4 current minor version), physical examinations, vital signs, clinical laboratory test, ECHO, ECG and ADA testing; through final study visit, up to approximately 20 weeks from first dose of dalantercept.', 'timeFrame': 'up to approximately 20 weeks'}]","[{'measure': 'Best Overall Response', 'description': 'The Best Overall Response (BOR) is the best response recorded from the start of the study treatment until the disease progression/recurrence, scored as one of the following: Complete Response (CR); Partial Response (PR); Stable Disease (SD) or Progressive Disease (PD).\n\nPer Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), a CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. A PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD is defined as At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.', 'timeFrame': 'up to approximately 20 weeks'}, {'measure': 'Overall Survival (OS)', 'description': 'The proportion of participants alive from the initiation of treatment through end of study', 'timeFrame': 'up to approximately 20 weeks'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'Percentage of patients whose disease improves or remains stable over a certain time period. DCR is the sum of the complete, partial and stable disease rates.', 'timeFrame': 'up to approximately 20 weeks'}]",4,18 Years,,ALL,False,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",INDUSTRY,0,21.0,ACTUAL,2025-09-01T16:18:22.207382,v2_robust,True,True,True,False,True,
NCT01166087,Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's Under Fed Condition,"A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's and Prozac®Weekly 90 mg Delayed Release Capsules of Eli Lilly and Company, USA in Healthy Adult Human Subjects Under Fed Conditions.",Fluoxetine Hydrochloride,"['Prozac ® weekly 90 mg Delayed Release Capsules', 'Fluoxetine Hydrochloride']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Bioequivalence', 'Crossover', 'Fluoxetine Hydrochloride']",COMPLETED,,2006-02,2006-09,"[{'measure': 'Bioequivalence based on Cmax and AUC parameters', 'timeFrame': '8 months'}]",[],1,18 Years,50 Years,ALL,True,Dr. Reddy's Laboratories Limited,INDUSTRY,0,54.0,ACTUAL,2025-09-01T16:18:22.207390,v2_robust,True,True,True,False,False,
NCT00014287,Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer,Intravesical Gemcitabine Therapy for BCG-Refractory Superficial Bladder Cancer: A Phase I and Pharmacokinetic Study,gemcitabine hydrochloride,['gemcitabine hydrochloride'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Bladder Cancer,['Bladder Cancer'],"['stage 0 bladder cancer', 'stage I bladder cancer', 'recurrent bladder cancer']",WITHDRAWN,,2000-09,,[],[],0,18 Years,,ALL,False,University of Pittsburgh,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:22.207398,v2_robust,True,True,False,True,False,
NCT00622193,Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Anamorelin HCl Dose Range Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC",anamorelin HCl,"['ST-1291', 'anamorelin HCl', 'placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,"Carcinoma, Non-Small-Cell Lung","['Carcinoma, Non-Small-Cell Lung']",['NSCLC'],COMPLETED,,2008-03,2009-12,"[{'measure': 'Hand grip strength and body weight', 'timeFrame': 'Twelve weeks'}]","[{'measure': 'Quality of Life and Biomarker', 'timeFrame': 'Twelve weeks'}]",2,18 Years,85 Years,ALL,False,"Helsinn Therapeutics (U.S.), Inc",INDUSTRY,0,228.0,ACTUAL,2025-09-01T16:18:22.207405,v2_robust,True,True,True,False,False,
NCT03898193,"Bioequivalence Study of Montelukast, 5 mg Chewable Tablets (Pharmtechnology LLC, Belarus), and Singulair®, 5 mg Chewable Tablets (Merck Sharp & Dohme B.V., the Netherlands), in Healthy Volunteers Under Fasting Conditions","Single-Dose Open-label Randomized Crossover, in Two Periods and in Two Sequences, Single-Center Comparative Bioequivalence Study of Montelukast, 5 mg Chewable Tablets (Pharmtechnology LLC, Republic of Belarus), and Singulair®, 5 mg Chewable Tablets (Merck Sharp & Dohme B.V., the Netherlands), in Healthy Volunteers Under Fasting Conditions",Montelukast,"['Singulair', 'The reference product', 'The test product', 'Montelukast']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Adults,['Healthy Adults'],"['Bioequivalence', 'Montelukast', 'Singulair']",COMPLETED,,2019-03-23,2019-04-08,"[{'measure': 'Cmax of montelukast for the test and the reference products', 'description': 'Maximum concentration in plasma among observed concentrations at pre-specified time points', 'timeFrame': 'Time points: 0.00 (withing 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.25, 3.5, 4.00, 4.5, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00 hours after dosing'}, {'measure': 'AUC0-t of montelukast for the test and the reference products', 'description': 'Area under the plasma concentration versus time curve from time 0 to the last measured concentration', 'timeFrame': 'Time points: 0.00 (withing 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.25, 3.5, 4.00, 4.5, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00 hours after dosing'}]","[{'measure': 'AUC0-∞ of montelukast for the test and the reference products', 'description': 'Area under the plasma concentration versus time curve from time 0 to infinite time', 'timeFrame': 'Time points: 0.00 (withing 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.25, 3.5, 4.00, 4.5, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00 hours after dosing'}, {'measure': 'Tmax of montelukast for the test and the reference products', 'description': 'Time to maximum measured plasma concentration', 'timeFrame': 'Time points: 0.00 (withing 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.25, 3.5, 4.00, 4.5, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00 hours after dosing'}, {'measure': 'T1/2 of montelukast for the test and the reference products', 'description': 'Elimination or terminal half-life', 'timeFrame': 'Time points: 0.00 (withing 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.25, 3.5, 4.00, 4.5, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00 hours after dosing'}, {'measure': 'Kel of montelukast for the test and the reference products', 'description': 'Elimination rate constant', 'timeFrame': 'Time points: 0.00 (withing 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.25, 3.5, 4.00, 4.5, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00 hours after dosing'}, {'measure': 'AUCresid of montelukast for the test and the reference products', 'description': 'Residual area under the pharmacokinetic curve from the time of the last measured concentration to infinite time', 'timeFrame': 'Time points: 0.00 (withing 30 minutes before dosing) and 0.5, 1.00, 1.5, 1.75, 2.00, 2.25, 2.5, 2.75, 3.00, 3.25, 3.5, 4.00, 4.5, 5.00, 6.00, 8.00, 12.00, 16.00, 24.00 hours after dosing'}, {'measure': 'Number of treatment-related adverse events (AE) for the test and the reference products as assessed by guidance predefined in the protocol', 'description': 'An AE is defined as any untoward medical occurrence in a subject will be administered an investigational product and which does not necessarily have a causal relationship with the treatment. The data from subjects who will take at least one investigational product will be analyzed.', 'timeFrame': '8 days'}]",8,18 Years,45 Years,ALL,True,Pharmtechnology LLC,INDUSTRY,1,34.0,ACTUAL,2025-09-01T16:18:22.207414,v2_robust,True,True,True,False,True,
NCT04444193,Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma,Safety and Efficacy Study of Durvalumab in Combination With Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma--DULECT Trial,Durvalumab,"['LENVIMA', 'Durvalumab', 'Durvalumab injection', 'Lenvatinib Oral Product']",4,INTERVENTIONAL,['NA'],,,Endometrial Cancer,['Endometrial Cancer'],['endometrial cancer'],UNKNOWN,,2020-08-31,2021-05-31,"[{'measure': 'Progression Free Survival (PFS)', 'description': 'Defined as time from randomisation to first progression by investigator assessment using modified RECIST 1.1 or death (by any cause in the absence of progression)', 'timeFrame': 'Up to 3 years'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'Objective response rate is defined as the proportion of patients with measurable disease at baseline who have confirmed complete response (CR) or partial response (PR) as determined by the Investigator at local site', 'timeFrame': 'Up to 3 years'}]","[{'measure': 'Overall Survival (OS)', 'description': 'Defined as the time from randomisation to death due to any cause', 'timeFrame': 'Up to 5 years'}, {'measure': 'Percentage of Participants who Experience an Adverse Event (AE)', 'description': 'An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined.', 'timeFrame': 'Up to 1 years'}]",4,18 Years,80 Years,FEMALE,False,Shanghai First Maternity and Infant Hospital,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:22.207558,v2_robust,True,True,False,False,True,
NCT02694393,Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis,Phase I/II Study of Inhaled Sodium Nitrite as an Antimicrobial for Pseudomonas Infection in Cystic Fibrosis,sodium nitrite,"['AIR001', 'sodium nitrite']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Cystic Fibrosis,['Cystic Fibrosis'],[],TERMINATED,Protocol closed due to difficulty recruiting subjects and then expiration of investigational product and lack of a manufacturer.,2016-02,2022-07-21,"[{'measure': 'Pulmonary Function', 'description': 'forced expiratory volume in one second (FEV1) after inhalation will assess safety', 'timeFrame': 'Day 7'}, {'measure': 'Pulmonary Function', 'description': 'forced expiratory volume in one second (FEV1) after inhalation will assess safety', 'timeFrame': 'Day 28'}]","[{'measure': 'Exhaled Nitric Oxide', 'description': 'concentration of nitric oxide in exhaled breath', 'timeFrame': 'Day 7'}, {'measure': 'Exhaled Nitric Oxide', 'description': 'concentration of nitric oxide in exhaled breath', 'timeFrame': 'Day 28'}, {'measure': 'Sputum Nitrite Concentration', 'description': 'concentration of nitrite in sputum', 'timeFrame': 'day 7'}, {'measure': 'Sputum Nitrite Concentration', 'description': 'concentration of nitrite in sputum', 'timeFrame': 'day 28'}, {'measure': 'Pseudomonas Density in Sputum', 'description': 'density of Pseudomonas in sputum', 'timeFrame': 'day 28'}, {'measure': 'CF Questionnaire - Respiratory', 'description': 'respiratory symptom questionnaire', 'timeFrame': 'day 28'}]",8,18 Years,,ALL,False,"Schmidhofer, Mark, MD",INDIV,2,4.0,ACTUAL,2025-09-01T16:18:22.207636,v2_robust,True,True,False,True,True,Protocol closed due to difficulty recruiting subjects and then expiration of investigational product and lack of a manufacturer.
NCT00792493,Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741,"Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study With Multiple Ascending Doses of ORM-12741",ORM-12741,['ORM-12741'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],['Healthy volunteer study'],COMPLETED,,2008-12,2009-09,"[{'measure': 'Safety measures, i.e. assessing adverse events, vital signs, ECG, safety laboratory values', 'timeFrame': 'about a month'}]","[{'measure': 'Pharmacokinetics', 'timeFrame': '12 days per period'}]",2,18 Years,45 Years,MALE,True,"Orion Corporation, Orion Pharma",INDUSTRY,0,51.0,ACTUAL,2025-09-01T16:18:22.207656,v2_robust,True,True,True,False,True,
NCT03036293,"Tenoten® in the Treatment of Somatoform, Stress-related and Other Neurotic Disorders","International Multicenter, Double-blind, Randomized Placebo-controlled Phase IV Clinical Trial of Different Dosing Regimens of Tenoten® in the Treatment of Anxiety in Patients With Somatoform, Stress-related and Other Neurotic Disorders",Tenoten,"['Tenoten', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Anxiety,['Anxiety'],[],COMPLETED,,2017-02-08,2018-09-22,"[{'measure': 'Change From Baseline in the Mean HAM-A Score at 12 Weeks of Treatment: 1. Group 1 (Tenoten®, 4 Tablets a Day); 2. Group 3 (Tenoten®, 8 Tablets a Day).', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome', 'timeFrame': '12 weeks'}]","[{'measure': 'Change From Baseline in the Mean HAM-A Score at 4 Weeks of Treatment: 1.1. Group 1 (Tenoten®, 4 Tablets a Day); 1.2. Group 3 (Tenoten®, 8 Tablets a Day).', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome', 'timeFrame': '4 weeks'}, {'measure': 'The Mean HAM-A Score at 8 Weeks of Treatment: 2.1. Group 1 (Tenoten®, 4 Tablets a Day); 2.2. Group 3 (Tenoten®, 8 Tablets a Day).', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome', 'timeFrame': '8 weeks'}, {'measure': 'Percentage of Patients Had at Least a 50% Improvement in the HAM-A Score: 3.1. Group 1 (Tenoten® 4 Tablets a Day): After 4, 8 and 12 Weeks; 3.2. Group 3 (Tenoten® 8 Tablets a Day): After 4, 8 and 12 Weeks.', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome', 'timeFrame': '4,8,12 weeks'}, {'measure': 'Percentage of Patients With no Anxiety (HAM-A Score <14) in: 4.1. Group 1 (Tenoten®, 4 Tablets a Day); After 4, 8 and 12 Weeks; 4.3. Group 3 (Tenoten®, 4 Tablets a Day); After 4, 8 and 12 Weeks.', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A). Personality questionnaire designed to identify constitutive anxiety and situational anxiety. The scale consists of 14 items and measures both psychic anxiety and somatic anxiety. Total score is in range 0-56. Includes the symptoms of anxious mood, phobic, emotional, sleep disorders, depressive mood, somatic symptoms - muscular (pain, convulsions, etc.), sensory (e.g. tinnitus), cardiovascular, respiratory, gastrointestinal, genitourinary, neurovegetative. Major role belongs to behaviour during this interview.\n\nAnxiety scoring:\n\n≤13 - no anxiety; 14-17 - mild anxiety disorder; 18-24 - moderate anxiety disorder;\n\n≥25 - severe anxiety.\n\nHigher values represent a worse outcome', 'timeFrame': '4,8,12 weeks'}, {'measure': 'Change From Baseline in the Total EQ-5D-3L Score at 12 Weeks of Treatment in Patients From: 5.1. Group 1 (Tenoten®, 4 Tablets a Day); 5.2. Group 3 (Tenoten®, 8 Tablets a Day).', 'description': 'European Quality of Life Instrument questionnaire (EQ-5D-3L) is designed for the evaluation of the quality of life.The score ranges between 5-15. Higher values represent a worse outcome.', 'timeFrame': '12 weeks'}, {'measure': 'Total CGI Scores in Patients From: 6.1. Group 1 (Tenoten®, 4 Tablets a Day); 6.2. Group 3 (Tenoten®, 8 Tablets a Day).', 'description': ""Clinical Global Impession (CGI) provides a brief assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication. Total range 0-16. Higher values represent a worse outcome"", 'timeFrame': '12 weeks'}]",7,18 Years,45 Years,ALL,False,Materia Medica Holding,INDUSTRY,0,390.0,ACTUAL,2025-09-01T16:18:22.207670,v2_robust,True,True,True,False,False,
NCT03025893,"A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme","A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme: the STELLAR Study",Sunitinib,"['Lomustine', 'CCNU', 'Sutent', 'Sunitinib']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Glioblastoma Multiforme,"['Glioblastoma Multiforme', 'Glioblastoma, Adult', 'Glioblastoma', 'Recurrent Brain Tumor', 'GBM']","['Sunitinib', 'Lomustine', 'High-dose', 'Intermittent']",UNKNOWN,,2018-08-31,2022-01-01,"[{'measure': 'Six-month progression-free survival (PFS-6)', 'timeFrame': 'From the date of randomization up to the date of first progression or death (any cause) whichever comes first, assessed up to 36 months (End of Study).'}]","[{'measure': 'Overall survival (OS)', 'timeFrame': 'From the date of randomization up to the date of death, assessed up to 36 months. If study medication is discontinued for any reason, survival follow-up takes place every 12 weeks, also assessed up to 36 months (End of Study).'}, {'measure': 'Objective radiological response rate', 'description': 'Response will be assessed according to the RANO criteria.', 'timeFrame': 'Disease will be assessed by MRI every 6 weeks for the first 6 months and every 12 weeks until documented progression, assessed up to 36 months (End of Study).'}, {'measure': 'Adverse events (AEs)', 'description': 'At the end of the study, after 36 months, the number of participants with adverse events that are related to both treatments will be assessed and compared.', 'timeFrame': 'AEs will be monitored at every visit during study treatment or after discontinuation of study treatment in the case adverse events have not subsided, assessed up to 36 months (End of Study).'}, {'measure': 'Health-related quality of life (HRQoL)', 'description': 'Steroid use will be documented at every treatment cycle as an objective parameter for HRQoL. Furthermore, HRQoL will also be measured via EORTC questionnaires, which will be filled in by the participants every 6 weeks BEFORE their MRI.', 'timeFrame': 'HRQoL assessments will be performed at baseline and every 6 weeks until documented progression, assessed up to 36 months (End of Study).'}, {'measure': 'Blood markers (TEP: tumor educated platelets, and miRNA)', 'description': 'The five specific time points during study treatment are: (1) at baseline; (2) at the first outpatient visit; (3) after two weeks of treatment; (4) at the first response evaluation (first MRI); and (5) at the time of progression.', 'timeFrame': 'Blood samples for RNA profiling will be drawn simultaneously with regular blood samples on five specific time points during study treatment and will be assessed after 36 months (End of Study).'}, {'measure': 'MGMT promoter methylation status', 'description': 'Previously obtained resection or biopsy material from the first-line treatment of these participants will be requested at the time of inclusion and used to determine the MGMT methylation status. After the End of Study (after 36 months) the MGMT promoter methylation status will be correlated with the response to treatment.', 'timeFrame': 'At the end of the study (after 36 months), the treatment outcomes of all patients will be correlated with the MGMT promoter methylation status.'}]",7,18 Years,,ALL,False,"Amsterdam UMC, location VUmc",OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:22.207783,v2_robust,True,True,False,False,True,
NCT04492293,An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer,"A Phase 2, Multicenter, Single Arm, Open-lable Study of ICP-192 in Subjects With Surgically Unresectable or Metastatic Bladder Urothelial Cancer With FGFR Genetic Aberrations.",ICP-192,['ICP-192'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Bladder Urothelial Cancer,['Bladder Urothelial Cancer'],[],RECRUITING,,2020-05-27,2025-06-30,"[{'measure': 'ORR', 'description': 'Objective Response Rate', 'timeFrame': 'From the time of first dose until objective disease progression, an average of 6 months'}]","[{'measure': 'DOR', 'description': 'Duration of response', 'timeFrame': 'From the time of first dose until objective disease progression, an average of 6 months'}, {'measure': 'DCR', 'description': 'Disease Control Rate', 'timeFrame': 'From the time of first dose until objective disease progression, an average of 6 months'}, {'measure': 'PFS', 'description': 'Progression Free Survival', 'timeFrame': 'From the time of first dose until objective disease progression, an average of 6 months'}, {'measure': 'OS', 'description': 'Overall survival', 'timeFrame': 'From the time of first dose until objective disease progression, an average of 1 months'}]",5,18 Years,,ALL,False,"Beijing InnoCare Pharma Tech Co., Ltd.",INDUSTRY,0,115.0,ESTIMATED,2025-09-01T16:18:22.207872,v2_robust,True,True,False,False,False,
NCT04899193,Pergoveris FD and Liquid China BE Study,"A Phase I, Open-label, Randomized, Three-period, Crossover, Single-center Trial to Assess the Bioequivalence of the Co-administration of 900 IU of Follitropin Alfa (Gonal-f) and 450 IU of Lutropin Alfa (Luveris) Versus the Fixed Combination of 900 IU Follitropin Alfa and 450 IU Lutropin Alfa in Pergoveris, Administered SC as Liquid and FD Formulation, in Pituitary Suppressed Healthy Premenopausal Female Chinese Participants",Pergoveris FD,"['Luveris', 'Gonal-f', 'Pergoveris Liquid', 'Pergoveris FD']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Healthy', 'Pergoveris', 'Bioequivalence', 'Infertility']",COMPLETED,,2021-05-08,2022-05-28,"[{'measure': 'Baseline Adjusted Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Sampling Time After Administration (AUC0-t, adj) of Follitropin Alfa', 'timeFrame': 'Pre-dose, 2, 4, 6, 7, 8, 9, 10, 12, 15, 18, 24, 36, 48, 72, 96, 120 and 168 hours post-dose in each period'}, {'measure': 'Baseline Adjusted Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Sampling Time After Administration (AUC0-t, adj) of Lutropin Alfa', 'timeFrame': 'Pre-dose, 2, 4, 6, 7, 8, 9, 10, 12, 15, 18, 24, 36, 48, 72, 96, 120 and 168 hours post-dose in each period'}, {'measure': 'Baseline Adjusted Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC0-inf,adj) of Follitropin Alfa', 'timeFrame': 'Pre-dose, 2, 4, 6, 7, 8, 9, 10, 12, 15, 18, 24, 36, 48, 72, 96, 120 and 168 hours post-dose in each period'}, {'measure': 'Baseline Adjusted Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC0-inf,adj) of Lutropin Alfa', 'timeFrame': 'Pre-dose, 2, 4, 6, 7, 8, 9, 10, 12, 15, 18, 24, 36, 48, 72, 96, 120 and 168 hours post-dose in each period'}, {'measure': 'Baseline Adjusted Maximum Observed Serum Concentration (Cmax,adj) of Follitropin Alfa', 'timeFrame': 'Pre-dose, 2, 4, 6, 7, 8, 9, 10, 12, 15, 18, 24, 36, 48, 72, 96, 120 and 168 hours post-dose in each period'}, {'measure': 'Baseline Adjusted Maximum Observed Serum Concentration (Cmax,adj) of Lutropin Alfa', 'timeFrame': 'Pre-dose, 2, 4, 6, 7, 8, 9, 10, 12, 15, 18, 24, 36, 48, 72, 96, 120 and 168 hours post-dose in each period'}]","[{'measure': 'Number of Participants with Clinically Significant Changes From Baseline in Laboratory Parameters', 'timeFrame': 'Baseline up to Day 55'}, {'measure': 'Number of Participants with Clinically Significant Changes From Baseline in Vital Signs', 'timeFrame': 'Baseline up to Day 55'}, {'measure': 'Number of Participants with Clinically Significant Changes From Baseline in Electrocardiogram (ECGs) Findings', 'timeFrame': 'Baseline up to Day 55'}, {'measure': 'Number of Participants with Treatment Emergent Adverse Events (TEAEs)', 'timeFrame': 'Baseline up to Day 55'}, {'measure': 'Absolute Value and Change From Baseline in Serum Estradiol Levels', 'timeFrame': 'Baseline, Day 14 and 39'}, {'measure': 'Change From Baseline in Follicle Size Assessed by Trans Vaginal Ultrasound Scan', 'timeFrame': 'Baseline, Day 8, 14, 22, 39 and 55'}, {'measure': 'Change From Baseline in Follicle Number Assessed by Trans Vaginal Ultrasound Scan', 'timeFrame': 'Baseline, Day 8, 14, 22, 39 and 55'}, {'measure': 'Number of Participants With Local Tolerability/Injection Site Reactions (ISRs)', 'timeFrame': 'At 5 minutes and 1, 2, 4, 6, 12 and 24 hours post-dose'}, {'measure': 'Time to Reach the Maximum Observed Serum Concentration (Tmax) of Follitropin Alfa and Lutropin Alfa', 'timeFrame': 'Pre-dose, 2, 4, 6, 7, 8, 9, 10, 12, 15, 18, 24, 36, 48, 72, 96, 120 and 168 hours post-dose in each period'}, {'measure': 'Apparent Terminal Half-Life (T1/2) of Follitropin Alfa and Lutropin Alfa', 'timeFrame': 'Pre-dose, 2, 4, 6, 7, 8, 9, 10, 12, 15, 18, 24, 36, 48, 72, 96, 120 and 168 hours post-dose in each period'}, {'measure': 'Apparent Terminal Elimination Rate Constant (Lambda z) of Follitropin Alfa and Lutropin Alfa', 'timeFrame': 'Pre-dose, 2, 4, 6, 7, 8, 9, 10, 12, 15, 18, 24, 36, 48, 72, 96, 120 and 168 hours post-dose in each period'}]",17,18 Years,40 Years,FEMALE,True,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",INDUSTRY,0,72.0,ACTUAL,2025-09-01T16:18:22.207898,v2_robust,True,True,True,False,True,
NCT00732121,Bone Turnover in Type 2 Diabetes Patients,Effects of Sitagliptin On Markers of Bone Turnover in Patients With Type 2 Diabetes,Sitagliptin,"['Sitagliptin', 'Januvia (brand name for sitagliptin)', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes,['Type 2 Diabetes'],['Type 2 Diabetes'],UNKNOWN,,2008-08,2010-08,"[{'measure': 'Change from baseline in the integrated response to the mixed meal test of markers of bone turnover following 8 weeks of treatment with sitagliptin vs. placebo.', 'timeFrame': '8 weeks per subject'}]","[{'measure': 'Change in the active GIP in response to the mixed meal test', 'timeFrame': '8 weeks'}, {'measure': 'Change in the active GLP-1 in response to the mixed meal test.', 'timeFrame': '8 weeks'}, {'measure': 'Change in the active GLP-2 in response to the mixed meal test.', 'timeFrame': '8 weeks'}, {'measure': 'Change in glucose response during the mixed meal test.', 'timeFrame': '8 weeks'}, {'measure': 'Change in insulin secretion during the mixed meal test.', 'timeFrame': '8 weeks'}]",6,18 Years,80 Years,ALL,False,University of Vermont,OTHER,1,20.0,ESTIMATED,2025-09-01T16:18:22.207928,v2_robust,True,True,False,False,False,
NCT00257621,GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults,"A Pilot, Phase II, Open-label, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GW640385 When Administered With Ritonavir in Combination With NRTIs for 48 Weeks in HIV-1 Infected Adults",GW640385,"['Ritonavir', 'GW640385']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Infection, Human Immunodeficiency Virus I","['Infection, Human Immunodeficiency Virus I', 'HIV Infection']",['HIV-1 protease inhibitor GW640385 ritonavir RTV'],COMPLETED,,2004-10,2007-01,"[{'measure': 'Percentage of subjects with plasma HIV-1 RNA <400 copies/ml. Incidence of serious adverse events, rash and thyroid function abnormalities. GW640385 PK parameters.', 'timeFrame': 'throughout the study'}]","[{'measure': 'Changes over time in HIV-1 viral load and CD4+ cell counts. Incidence of adverse events and laboratory abnormalities. GW640385 and RTV PK parameters. Development of resistance in subjects with virologic failure.', 'timeFrame': 'throughout the study'}]",2,18 Years,,ALL,False,ViiV Healthcare,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:22.207941,v2_robust,True,True,True,False,True,
NCT04607421,A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer,"AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER",Encorafenib,"['Erbitux', 'Campostar', 'Leucovorin', 'Wellcovorin, Fusilev, Khapzory', 'Oxaliplatin', 'Encorafenib', 'Irinotecan', 'Xeloda', 'Eloxatin', 'Capecitabine', 'Fluorouracil', 'Zirabev', 'Braftovi, PF-07263896, LGX818, ONO-7702', 'Cetuximab', 'Bevacizumab', '5-FU']",16,INTERVENTIONAL,['PHASE3'],PHASE3,,Neoplasms,['Neoplasms'],"['Colorectal cancer', 'Colon cancer', 'Rectal cancer', 'Colorectal Neoplasms', 'Intestinal cancer', 'Intestinal Neoplasms', 'Gastrointestinal cancer', 'Gastrointestinal Neoplasms', 'Digestive system cancer', 'Digestive System Neoplasms', 'Digestive System Diseases', 'Gastrointestinal Diseases', 'Colonic Diseases', 'Intestinal Diseases', 'Rectal Diseases', 'BREAKWATER Study']",ACTIVE_NOT_RECRUITING,,2020-12-21,2027-12-28,"[{'measure': 'Safety Lead-in Study: Incidence of Dose Limiting Toxicities (DLTs)', 'description': 'Incidence of dose limiting toxicity defined as any adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness or concomitant medications/therapies occurring during the first 28 days of treatment', 'timeFrame': 'After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months'}, {'measure': 'Phase 3: Progression free survival, by blinded independent review', 'description': 'Progression free survival, defined as the time from the date of randomization to the earliest documented disease progression or death due to any cause: encorafenib and cetuximab + mFOLFOX6 (Arm B) vs the Control Arm (Arm C)', 'timeFrame': 'Duration of Phase 3, approximately 36 months'}, {'measure': 'Phase 3: Objective response rate by blinded independent review', 'description': 'Objective response defined as complete response (CR), or partial response (PR) according to RECIST v1.1 based on BICR assessment, from the date of randomization until the date of the first documentation of progression of disease (PD)', 'timeFrame': 'Duration of Phase 3, approximately 23 months'}, {'measure': 'Cohort 3: Objective response rate by blinded independent review', 'description': 'Defined as CR, or PR according to RECIST v1.1 based on BICR assessment, from the date of randomization until the date of the first documentation of PD, death or start of new anticancer therapy', 'timeFrame': 'Duration of Cohort 3, approximately 15 months.'}]","[{'measure': 'Safety Lead-in: Incidence of adverse events', 'description': 'An adverse event is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship as assessed by CTCAE 4.03', 'timeFrame': 'After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months'}, {'measure': 'Safety Lead-in: Incidence of abnormal clinical laboratory parameters, abnormal vital signs and abnormal electrocardiograms', 'description': ""Changes in clinical laboratory parameters, vital signs and electrocardiograms determined clinically significant at the investigator's discretion."", 'timeFrame': 'After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months'}, {'measure': 'Safety Lead-in: Incidence of dose interruptions, dose modifications and discontinuations due to adverse events', 'timeFrame': 'After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months'}, {'measure': 'Safety Lead-in: Overall response rate by investigator', 'description': 'Overall response rate, defined as the proportion of participants who have achieved a confirmed best overall response per RECIST v1.1: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI', 'timeFrame': 'After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months'}, {'measure': 'Safety Lead-in: Duration of response by Investigator', 'description': 'Duration of response, defined as the time from the date of first radiographic evidence of response to the earliest documented disease progression per RECIST v1.1, or death due to any cause: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI', 'timeFrame': 'After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months'}, {'measure': 'Safety Lead-in:Progression free survival by Investigator', 'description': 'Progression free survival, defined as the time from the first dose to the earliest documented disease progression per RECIST v1.1, or death due to any cause: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI', 'timeFrame': 'After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months'}, {'measure': 'Safety Lead-in: Time to response by Investigator', 'description': 'Time to response, defined as the time from first dose to first radiographic evidence of response per RECIST v1.1: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI', 'timeFrame': 'After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months'}, {'measure': 'Safety Lead-in: Overall survival', 'description': 'Overall survival defined as the time from the first dose to death due to any cause: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI', 'timeFrame': 'After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 36 months'}, {'measure': 'Phase 3: Overall survival', 'description': 'Overall survival, defined as the time from the date of randomization to death due to any cause: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)', 'timeFrame': 'Duration of Phase 3, approximately 50 months'}, {'measure': 'Phase 3: Overall response rate by Investigator and by blinded independent review', 'description': 'Overall response rate, defined as the proportion of participants who have achieved a confirmed best overall response per RECIST v1.1: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)', 'timeFrame': 'Duration of Phase 3, approximately 36 months'}, {'measure': 'Phase 3: Duration of response by Investigator and blinded independent review', 'description': 'Duration of response, defined as the time from the date of first radiographic evidence of response to the earliest documented disease progression per RECIST v1.1, or death due to any cause: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)', 'timeFrame': 'Duration of Phase 3, approximately 36 months'}, {'measure': 'Phase 3: Time to response by blinded independent review and by Investigator', 'description': 'Time to response, defined as the time from first dose to first radiographic evidence of response per RECIST v1.1: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)', 'timeFrame': 'Duration of Phase 3, approximately 36 months'}, {'measure': 'Phase 3: Progression free survival by Investigator and by blinded independent review', 'description': 'Progression free survival, defined as the time from the first dose to the earliest documented disease progression per RECIST v1.1, or death due to any cause:: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)', 'timeFrame': 'Duration of Phase 3, approximately 36 months'}, {'measure': 'Phase 3: Progression free survival 2 by Investigator', 'description': 'Progression free survival 2, defined as the time from the date of randomization to the second objective disease progression per RECIST v1.1, or death from any cause, whichever occurs first: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6', 'timeFrame': 'Duration of Phase 3, approximately 36 months'}, {'measure': 'Phase 3: Incidence of adverse events', 'description': 'An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship: encorafenib + cetuximab (Arm A) and encorafenib + cetuximab +mFOLFOX6 (Arm B)', 'timeFrame': 'Duration of Phase 3, approximately 36 months'}, {'measure': 'Phase 3: Incidence of abnormal clinical laboratory parameters, abnormal vital signs and abnormal electrocardiograms', 'description': ""Changes in clinical laboratory parameters, vital signs and electrocardiograms determined clinically significant at the investigator's discretion: encorafenib + cetuximab (Arm A) and encorafenib + cetuximab +mFOLFOX6 (Arm B)"", 'timeFrame': 'Duration of Phase 3, approximately 36 months'}, {'measure': 'Phase 3: Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)', 'description': ""EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms."", 'timeFrame': 'Duration of Phase 3, approximately 36 months'}, {'measure': 'Phase 3: Change from Baseline in the EuroQol-5D-5L (EQ-5D-5L) Questionnaire', 'description': ""The EQ-5D-5L is a standardized measure of health utility that provides a single index value for the participant's health status. It is frequently used for economic evaluations of health care and has been shown to be a valid and reliable instrument, and comprises a short descriptive system questionnaire and a visual analogue scale (EQ VAS) that are cognitively undemanding, taking about 2 minutes to complete"", 'timeFrame': 'Duration of Phase 3, approximately 36 months'}, {'measure': 'Phase 3: Change from Baseline in the Patient Global Impression of Severity (PGIS)', 'description': ""The PGIS is a single-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time."", 'timeFrame': 'Duration of Phase 3, approximately 36 months'}, {'measure': 'Phase 3: Change from Baseline in the Patient Global Impression of Change (PGIC) questionnaires', 'description': ""The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change in symptoms or quality of life since starting treatment."", 'timeFrame': 'Duration of Phase 3, approximately 36 months'}, {'measure': 'Phase 3: Confirm the MSI-status in tumor tissue', 'description': 'Summarize MSI-status as determined by retrospective central testing of baseline tumor tissue', 'timeFrame': 'Once, pre-treatment'}, {'measure': 'Phase 3: To determine the correlation between ctDNA levels, BRAF V600 alterations, and clinical outcome', 'description': 'ctDNA levels and BRAF V600 VAF from ctDNA analysis of plasma samples collected at baseline and on treatment', 'timeFrame': 'Predose on Cycle 1 Day 1, 15, Cycle 2 Day 15, Cycle 7 Day 1 and EOT. Arm C sampling on Day 1 of Cycles 1-3, 9 and EOT. EOT is approx 36 months.'}, {'measure': 'Safety Lead-in: Maximum plasma concentration of encorafenib, LHY746, irinotecan and SN-38', 'timeFrame': 'Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days'}, {'measure': 'Safety Lead-in: Area under the plasma concentration time curve of encorafenib, LHY746, irinotecan and SN-38', 'timeFrame': 'Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days.'}, {'measure': 'Safety Lead-in: Time to maximim plasma concentration time curve of encorafenib, LHY746, irinotecan and SN-38', 'timeFrame': 'Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days'}, {'measure': 'Safety Lead-in: Maximum plasma concentration of encorafenib, LHY746 and oxaliplatin', 'timeFrame': 'Cycle 1 Day 1 and Day 15: predose, and 1, 2, 3, 4, 6 and 8 hours after dosing, Cycle 1 Day 3 and Day 17: predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days'}, {'measure': 'Safety Lead-in: Area under the plasma concentration time curve of encorafenib, LHY746 and oxaliplatin', 'timeFrame': 'Cycle 1 Day 1 and Day 15: predose, and 1, 2, 3, 4, 6 and 8 hours after dosing, Cycle 1 Day 3 and Day 17: predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days'}, {'measure': 'Safety Lead-in: Clearance of irinotecan, SN-38 and oxaliplatin', 'description': 'Changes in exposures of irinotecan and its metabolite (SN-38) on Cycle 1 Day 15 compared to Cycle 1 Day 1 in Cohort 1 (encorafenib and cetuximab + FOLFIRI) Changes in exposures of oxaliplatin on Cycle 1 Day 15 compared to Cycle 1 Day 1 in Cohort 2 (encorafenib and cetuximab + mFOLFOX6)', 'timeFrame': 'Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days'}, {'measure': 'Safety Lead-in: Time to maximim plasma concentration time curve of encorafenib, LHY746 and oxaliplatin', 'timeFrame': 'Cycle 1 Day 1 and Day 15: predose, and 1, 2, 3, 4, 6 and 8 hours after dosing, Cycle 1 Day 3 and Day 17: predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days'}, {'measure': 'Phase 3: Trough concentrations of encorafenib and its metabolite LHY746', 'description': 'Trough plasma concentrations in all patients in Arm A and Arm B', 'timeFrame': 'Predose on Cycle 1 through Cycle 6. Each cycle is 28 days'}, {'measure': 'Cohort 3: Progression free survival by Investigator and by blinded independent review', 'description': 'Progression free survival, defined as the time from the first dose to the earliest documented disease progression per RECIST v1.1, or death due to any cause.', 'timeFrame': 'Duration of Cohort 3, approximately 21 months'}, {'measure': 'Cohort 3: Overall response rate by investigator', 'description': 'Overall response rate, defined as the proportion of participants who have achieved a confirmed best overall response per RECIST v 1.1', 'timeFrame': 'Duration of Cohort 3, approximately 21 months'}, {'measure': 'Cohort 3: Duration of response by Investigator and by blinded independent review', 'description': 'Duration of response, defined as the time from the date of first radiographic evidence of response to the earliest documented disease progression per RECIST v1.1, or death due to any cause', 'timeFrame': 'Duration of Cohort 3, approximately 21 months'}, {'measure': 'Cohort 3: Time to response by Investigator and by blinded independent review', 'description': 'Time to response, defined as the time from the date of randomization to first radiographic evidence of response per RECIST v1.1', 'timeFrame': 'Duration of Cohort 3, approximately 21 months'}, {'measure': 'Cohort 3: Overall survival', 'description': 'Overall survival, defined as the time from the date of randomization to death due to any cause', 'timeFrame': 'Duration of Cohort 3, approximately 36 months'}, {'measure': 'Cohort 3: Incidence of adverse events', 'description': 'An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship: encorafenib + cetuximab (Arm A) and encorafenib + cetuximab +mFOLFOX6 (Arm B)', 'timeFrame': 'Duration of Cohort 3, approximately 21 months'}, {'measure': 'Cohort 3: Incidence of abnormal clinical laboratory parameters, abnormal vital signs and abnormal electrocardiograms', 'description': ""Changes in clinical laboratory parameters, vital signs and electrocardiograms determined clinically significant at the investigator's discretion: encorafenib + cetuximab (Arm A) and encorafenib + cetuximab +mFOLFOX6 (Arm B)"", 'timeFrame': 'Duration of Cohort 3, approximately 21 months'}, {'measure': 'Cohort 3: Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)', 'description': ""EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms."", 'timeFrame': 'Duration of Cohort 3, approximately 21 months'}, {'measure': 'Cohort 3: Change from Baseline in the EuroQol-5D-5L (EQ-5D-5L) Questionnaire', 'description': ""The EQ-5D-5L is a standardized measure of health utility that provides a single index value for the participant's health status. It is frequently used for economic evaluations of health care and has been shown to be a valid and reliable instrument, and comprises a short descriptive system questionnaire and a visual analogue scale (EQ VAS) that are cognitively undemanding, taking about 2 minutes to complete"", 'timeFrame': 'Duration of Cohort 3, approximately 21 months'}, {'measure': 'Cohort 3: Change from Baseline in the Patient Global Impression of Severity (PGIS)', 'description': ""The PGIS is a single-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time."", 'timeFrame': 'Duration of Cohort 3, approximately 21 months'}, {'measure': 'Cohort 3: Change from Baseline in the Patient Global Impression of Change (PGIC) questionnaires', 'description': ""The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change in symptoms or quality of life since starting treatment."", 'timeFrame': 'Duration of Cohort 3, approximately 21 months'}, {'measure': 'Cohort 3: Confirm the MSI-status in tumor tissue', 'description': 'Summarize MSI-status as determined by retrospective central testing of baseline tumor tissue', 'timeFrame': 'Once, pre-treatment'}, {'measure': 'Cohort 3: To determine the correlation between ctDNA levels, BRAF V600 alterations, and clinical outcome', 'description': 'ctDNA levels and BRAF V600 VAF from ctDNA analysis of plasma samples collected at baseline and on treatment', 'timeFrame': 'Predose on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 15, Cycle 7 Day 1 and End of Treatment (Duration of Cohort 3, approximately 21 months). Each cycle is 28 days.'}, {'measure': 'Cohort 3: Trough concentrations of encorafenib and its metabolite LHY746', 'description': 'Trough plasma concentrations in all patients in Arm D', 'timeFrame': 'Predose on Cycle 1 through Cycle 6. Each cycle is 28 days'}]",48,16 Years,,ALL,False,Pfizer,INDUSTRY,3,831.0,ACTUAL,2025-09-01T16:18:22.207988,v2_robust,True,True,False,False,True,
NCT04820621,Study of the Influence of Liver Function on Blood Concentrations of Runcaciguat in Participants With Different Degrees of Liver Impairment,"Investigation of the Pharmacokinetics, Safety and Tolerability of Runcaciguat in Participants With Hepatic Impairment (Classified as Child Pugh A or B) and in a Control Group of Age-, Weight-, and Gender-matched Participants Following a Single Oral 15 mg Modified Release (MR) Tablet Dose in a Non-randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification",Runcaciguat (BAY1101042),['Runcaciguat (BAY1101042)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Chronic Kidney Disease,['Chronic Kidney Disease'],[],TERMINATED,This study is prematurely terminated due to changes in sponsor's overall development strategy. The decision of termination is not related to any safety concern of the compound.,2021-04-07,2021-07-01,"[{'measure': 'Area under the concentration vs. time curve from zero to infinity after single (first) dose (AUC) of BAY1001042', 'description': 'AUC(0-tlast) will be used as main parameters if mean AUC(tlast - ∞) \\>20% of AUC', 'timeFrame': 'From dosing day (Day 1) up to 12 days post dose'}, {'measure': 'Unbound AUC (AUCu) of BAY1001042', 'description': 'AUC(0-tlast)u will be used as main parameters if mean AUC(tlast - ∞) \\>20% of AUC', 'timeFrame': 'From dosing day (Day 1) up to 12 days post dose'}, {'measure': 'Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of BAY1001042', 'timeFrame': 'From dosing day (Day 1) up to 12 days post dose'}, {'measure': 'Unbound Cmax (Cmax,u) of BAY1001042', 'timeFrame': 'From dosing day (Day 1) up to 12 days post dose'}]","[{'measure': 'Numbers of participants with treatment-emergent adverse events (TEAEs) and study intervention related TEAE', 'timeFrame': 'From start of treatment up to 10 days after the treatment'}]",5,18 Years,79 Years,ALL,True,Bayer,INDUSTRY,0,5.0,ACTUAL,2025-09-01T16:18:22.208136,v2_robust,True,True,False,True,True,This study is prematurely terminated due to changes in sponsor's overall development strategy. The decision of termination is not related to any safety concern of the compound.
NCT03031821,Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome,A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study,Metformin,"['Placebo Oral Tablet', 'Placebo', 'Metformin']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Prostate Cancer,"['Prostate Cancer', 'Metabolic Syndrome']","['Prostate Cancer', 'ADT', 'Metabolic Syndrome', 'Androgen Deprivation Therapy', 'Phase III', 'Phase 3', 'Randomized']",TERMINATED,Manufacturer discontinued the production of study drugs.,2018-07-12,2023-11-24,"[{'measure': 'Proportion of participants who meet the diagnostic criteria for metabolic syndrome after 18 months of study treatment', 'description': 'A diagnosis of metabolic syndrome will be made according to the harmonized definition of the metabolic syndrome as defined in the joint statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and the International Association for the Study of Obesity. A patient will be classified as having metabolic syndrome if he possesses ≥3 of the aforementioned criteria: Increased waist circumference, elevated triglycerides, reduced high-density lipoprotein cholesterol, elevated blood pressure, and elevated fasting blood glucose.\n\nThe prevalence of metabolic syndrome at 18 months post randomization will be calculated and compared between treatment arms using the two-sample t-test.', 'timeFrame': '18 months'}]","[{'measure': 'Proportion of participants who meet the diagnostic criteria for metabolic syndrome after 9 months of study treatment', 'description': 'A diagnosis of metabolic syndrome will be made according to the harmonized definition of the metabolic syndrome as defined in the joint statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and the International Association for the Study of Obesity. A patient will be classified as having metabolic syndrome if he possesses ≥3 of the aforementioned criteria: Increased waist circumference, elevated triglycerides, reduced high-density lipoprotein cholesterol, elevated blood pressure, and elevated fasting blood glucose.\n\nThe prevalence of metabolic syndrome at 9 months post randomization will be calculated and compared between treatment arms using the two-sample t-test.', 'timeFrame': '9 months'}, {'measure': 'Proportion of participants who meet the diagnostic criteria for metabolic syndrome after 12 months of study treatment', 'description': 'A diagnosis of metabolic syndrome will be made according to the harmonized definition of the metabolic syndrome as defined in the joint statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and the International Association for the Study of Obesity. A patient will be classified as having metabolic syndrome if he possesses ≥3 of the aforementioned criteria: Increased waist circumference, elevated triglycerides, reduced high-density lipoprotein cholesterol, elevated blood pressure, and elevated fasting blood glucose.\n\nThe prevalence of metabolic syndrome at 12 months post randomization will be calculated and compared between treatment arms using the two-sample t-test.', 'timeFrame': '12 months'}, {'measure': 'Proportion of participants who meet the diagnostic criteria for metabolic syndrome after 24 months of study treatment', 'description': 'A diagnosis of metabolic syndrome will be made according to the harmonized definition of the metabolic syndrome as defined in the joint statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and the International Association for the Study of Obesity. A patient will be classified as having metabolic syndrome if he possesses ≥3 of the aforementioned criteria: Increased waist circumference, elevated triglycerides, reduced high-density lipoprotein cholesterol, elevated blood pressure, and elevated fasting blood glucose.\n\nThe prevalence of metabolic syndrome at 24 months post randomization will be calculated and compared between treatment arms using the two-sample t-test.', 'timeFrame': '24 months'}, {'measure': 'Proportion of participants who meet the criteria of reduced high-density lipoprotein cholesterol assessed at 18 months of follow-up.', 'description': 'Reduced High-Density Lipoprotein Cholesterol defined as: \\< 1.0 mmol/L; or drug treatment for reduced HDL cholesterol\\*\n\n\\*Patient taking fibrates (Bezafibrate, Ciprofibrate, Clofibrate, Gemfibrozil, or Fenofibrate) or nicotinic acid can be presumed to have high TG and reduced HDL-cholesterol levels; Patients taking high dose omega-3 fatty acids can be presumed to have high TG levels', 'timeFrame': '18 months'}, {'measure': 'Proportion of participants who meet the criteria of elevated triglycerides assessed at 18 months of follow-up.', 'description': 'Elevated Triglycerides defined as: ≥1.7 mmol/L; or drug treatment for elevated triglycerides\\*\n\n\\*Patient taking fibrates (Bezafibrate, Ciprofibrate, Clofibrate, Gemfibrozil, or Fenofibrate) or nicotinic acid can be presumed to have high TG and reduced HDL-cholesterol levels; Patients taking high dose omega-3 fatty acids can be presumed to have high TG levels', 'timeFrame': '18 months'}, {'measure': 'Proportion of participants who meet the criteria of elevated blood pressure assessed at 18 months of follow-up.', 'description': 'Elevated Blood Pressure defined as:\n\nSystolic Blood Pressure of ≥ 130 mm of Hg; or Diastolic Blood Pressure of ≥ 85 mm of Hg; or drug treatment for elevated blood pressure\n\nBlood pressures will be taken with patients sitting for 5 minutes in a quiet environment prior to measurement and two measurements taken (with a minimum of 5 minutes between each blood pressure measurement), with the mean recorded for this study.', 'timeFrame': '18 months'}, {'measure': 'Proportion of participants who meet the criteria of elevated fasting blood glucose levels assessed at 18 months of follow-up.', 'description': 'Elevated Fasting Blood Glucose defined as:\n\nHbA1c ≥ 6.5%; or Fasting plasma glucose ≥ 7.0 mmol/L; or drug treatment for elevated blood glucose', 'timeFrame': '18 months'}, {'measure': 'Proportion of participants who meet the criteria of increased waist circumference assessed at 18 months of follow-up.', 'description': ""Increased Waist Circumference defined as:\n\nMales (population and country specific) A) Canadians ≥102cm B) Chinese ≥ 85cm C) Japanese ≥ 85 cm D) Other Asians ≥ 90 cm E) Middle Eastern \\& Mediterranean ≥ 94cm F) Sub-Saharan African ≥ 94 cm G) Central \\& South American ≥ 90cm H) Europid ≥ 94 cm\n\nMeasurement of waist circumference will be performed by a dedicated research nurse for this study that is blinded to the patient's treatment allocation."", 'timeFrame': '18 months'}, {'measure': 'Health-related Quality of Life assessed at 18 months of follow-up.', 'description': 'Patients will undergo quality of life measurements by the EORTC QLQ-C30 core questionnaire (63) and prostate-specific module. The instruments are well validated and widely used in the population of interest. The questionnaire items are transformed for 5 functional domains, global QOL, and specific symptom scales/items relevant to the study intervention.\n\nThe statistical analysis plan will use the standard CCTG QOL approach (Osoba et al., 1998), and will focus on change of mean scores from baseline over time by treatment allocation group. Depending on the amount of missing data, generalized linear equation modeling of mean scores may be required. The analysis will also consider the proportion of patients improved, stable or deteriorated at 18 months compared to baseline using a cut-point minimal clinical difference of 10 points on all scales. A sensitivity analysis will be executed using a cut-point of 7 points.', 'timeFrame': '18 months'}, {'measure': 'Treatment-related toxicity', 'description': ""Treatment related toxicity (NCI CTCAE 4.0)\n\nAll men will be evaluated for toxicity from the time of their first oral dose of study medication. Toxicities will be graded using the current CTCAE version 4.0. The incidence of toxicities by arm will be summarized by type of adverse effect. A Fisher's Exact Test will be used to compare toxicities between the two arms."", 'timeFrame': '18 months'}]",11,18 Years,,MALE,False,Canadian Urologic Oncology Group,OTHER,3,168.0,ACTUAL,2025-09-01T16:18:22.208247,v2_robust,True,True,False,True,True,Manufacturer discontinued the production of study drugs.
NCT00108121,Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma,"A Multi-center, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Nodular Basal Cell Carcinoma",PEP005,['PEP005'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Basal Cell Carcinoma,['Basal Cell Carcinoma'],"['Nodular basal cell carcinoma', 'basal cell carcinoma', 'nBCC', 'BCC', 'PEP005', 'Topical', 'Dermatology']",COMPLETED,,2005-03,2006-05,[{'measure': 'Safety'}],[{'measure': 'Resolution of nodular basal cell carcinoma'}],2,18 Years,,ALL,False,Peplin,INDUSTRY,0,60.0,,2025-09-01T16:18:22.208416,v2_robust,True,True,True,False,True,
NCT01103414,"Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients","Phase 2B, Randomized, Double-Blind, Comparator- & Placebo-Controlled, Dose Ranging Study to Evaluate Safety, Tolerability & Efficacy of 3 Dose Levels of Mitoglitazone in Type 2 Diabetic Patients",Mitoglitazone,"['Pioglitazone', 'Mitoglitazone', 'Placebo', 'ACTOS', 'MSDC-0160']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Type 2 Diabetes,['Type 2 Diabetes'],['Diabetes'],COMPLETED,,2010-09,2011-12,"[{'measure': 'Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12.', 'description': 'Change from baseline in fasting plasma glucose in response to three different doses of Mitoglitazone as compared to pioglitazone following once-daily dosing for 84 consecutive days (12 weeks) in patients with Type 2 diabetes.', 'timeFrame': 'Baseline, Week 12'}]","[{'measure': 'Change From Baseline in HbA1c', 'description': 'Change from baseline in plasma glucose measured by hemoglobin A1c in response to three different doses of Mitoglitazone and pioglitazone as compared to placebo following once-daily dosing for 84 consecutive days (12 weeks) in patients with Type 2 diabetes.', 'timeFrame': '12 weeks'}, {'measure': 'Percent Change From Baseline to Week 12 Endpoint in HMW Adiponectin', 'description': 'Percent change from baseline to week 12 endpoint in high molecular weight adiponectin', 'timeFrame': '12 weeks'}, {'measure': 'Change From Baseline to Week 12 Endpoint in Hematocrit', 'description': 'Change from baseline to week 12 endpoint in hematocrit as an indication of fluid retention', 'timeFrame': '12 weeks'}, {'measure': 'Change From Baseline in Hemoglobin', 'description': 'Change from baseline at week 12 endpoint in hemoglobin concentration', 'timeFrame': '12 weeks'}, {'measure': 'Change From Baseline in RBC', 'description': 'Change from baseline at week 12 endpoint in red blood cell concentration', 'timeFrame': '12 week'}, {'measure': 'Change in Body Weight From Baseline to Week 12 Endpoint', 'description': 'Effects of 3 different doses of Mitoglitazone and pioglitazone as compared to placebo on body weight following once-daily dosing for 12', 'timeFrame': '12 weeks'}, {'measure': 'Change From Baseline in Waist Circumference at Week 12 Endpoint', 'description': 'Effects of 3 different doses of Mitoglitazone and pioglitazone as compared to placebo on waist circumference following once-daily dosing for 12 weeks', 'timeFrame': '12 weeks'}, {'measure': 'Presence of Edema Post Baseline During 12 Weeks Active Treatment', 'description': 'Effects of 3 different doses of Mitoglitazone and pioglitazone as compared to placebo on presence of edema following once-daily dosing for 12 weeks', 'timeFrame': '12 weeks'}, {'measure': 'Changes in HDL Particle Size Subfractions From Baseline to Week 12', 'description': 'Effects of 3 different doses of Mitoglitazone and pioglitazone as compared to placebo on HDL particle size profile as characterized by changes in NMR analysis of subfractions following once-daily dosing for 12 weeks', 'timeFrame': '12 weeks'}, {'measure': 'Changes in LDL Particle Size Subfractions From Baseline to Week 12', 'description': 'Effects of 3 different doses of Mitoglitazone and pioglitazone as compared to placebo on LDL particle size profile as characterized by changes in NMR analysis of subfractions following once-daily dosing for 12 weeks', 'timeFrame': '12 week'}]",11,18 Years,75 Years,ALL,False,Metabolic Solutions Development Company,INDUSTRY,0,356.0,ACTUAL,2025-09-01T16:18:22.208476,v2_robust,True,True,True,False,False,
NCT05579314,XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM),"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose Study to Assess Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus",XW014,"['XW014', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],[],ACTIVE_NOT_RECRUITING,,2022-09-26,2025-03-01,"[{'measure': 'Number and percentage of treatment emergent adverse events (TEAE) and serious adverse events (SAE)', 'timeFrame': '11 weeks'}, {'measure': 'Mean change from baseline in clinical laboratory values, vital signs, clinical findings from physical exam and ECG abnormalities', 'timeFrame': '11 weeks'}]",[],2,18 Years,70 Years,ALL,True,"Sciwind Biosciences USA Co., Ltd.",INDUSTRY,0,152.0,ESTIMATED,2025-09-01T16:18:22.208643,v2_robust,True,True,False,False,True,
NCT03249714,Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab,"A 24-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Ofatumumab in Patients With Relapsing Multiple Sclerosis Followed by an Extended Treatment of at Least 24 Weeks With Open-label Ofatumumab",Ofatumumab,"['Ofatumumab', 'Matching placebo of ofatumumab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Relapsing Multiple Sclerosis,['Relapsing Multiple Sclerosis'],"['double-blind', 'placebo controlled', 'ofatumumab', 'relapsing multiple sclerosis', 'Japanese patients', 'MS', 'RMS', 'adult', 'OMB157']",COMPLETED,,2018-03-15,2020-07-29,"[{'measure': 'Number of Gadolinium-enhancing T1 Lesions Per MRI Scan - Core Part', 'description': ""Total number of Gd-enhancing T1 lesions across scans at Week 12, 16, 20, and 24 were adjusted for the different numbers of scans. This was calculated as a rate for population, rather than at patient level, using a negative binomial regression model with log link. The model included each patient's total number of Gd-enhancing T1 lesions as the response variable, and treatment, region, and subgroup of baseline number of Gd-enhancing T1 lesions (0 or \\>=1) as explanatory variables, and logarithm of the patient's number of scans as the offset variable."", 'timeFrame': 'Baseline up to Week 24'}]","[{'measure': 'Number of Gadolinium-enhancing T1 Lesions Per MRI Scan - Japan vs Non-Japan - Core Part', 'description': ""Total number of Gd-enhancing T1 lesions across scans at Week 12, 16, 20, and 24 were adjusted for the different numbers of scans. This was calculated as a rate for population, rather than at patient level, using a negative binomial regression model with log link. The model included each patient's total number of Gd-enhancing T1 lesions as the response variable, and treatment, region, subgroup of baseline number of Gd-enhancing T1 lesions (0 or \\>=1), and the treatment-by-region interaction term as explanatory variables, and the patient's number of scans as the offset variable."", 'timeFrame': 'Baseline up to Week 24'}, {'measure': 'Number of New or Enlarging T2 Lesions on MRI Scans (Annualized T2 Lesion Rate) - Core Part', 'description': ""Number of new/enlarging T2 lesions on the last available MRI scan in the Core Part (up to Week 24) relative to baseline, adjusted for different follow-up times. This was calculated as a rate for population, rather than at patient level, using a negative binomial regression model with log-link. The model included each patient's last available number of new or enlarging T2 lesions relative to baseline as the response variable, and treatment, region, subgroup of baseline number of Gd-enhancing T1 lesions (0 or \\>=1), and baseline volume of T2 lesions as explanatory variables, and the patient's follow-up time as the offset variable."", 'timeFrame': 'Baseline up to Week 24'}, {'measure': 'Annualized Relapse Rate (ARR) - Core Part', 'description': ""ARR was the number of confirmed MS relapses in a year. A confirmed MS relapse was defined as one accompanied by a clinically-relevant change in the EDSS performed by the Independent EDSS rater, i.e. an increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional scores or 2 points on one functional score (excluding changes involving bowel/bladder or cerebral functional system). ARR was calculated as a rate for population, rather than at patient-level, using a negative binomial regression model with log-link. The model included each patient's number of confirmed relapses as the response variable, and treatment and region as explanatory variables, and the patient's follow-up time as the offset variable."", 'timeFrame': 'Baseline up to Week 24'}, {'measure': 'Pharmacokinetic (PK) Concentrations of Ofatumumab - Core Part', 'description': 'Blood samples were collected at the scheduled visit. Summary statistics of PK concentrations from trough samples.', 'timeFrame': 'Pre-dose at Baseline, Days 2, 5, 7, 14, Weeks 4, 12, 24'}, {'measure': 'B-cell Counts - Japan vs Non-Japan - Core Part', 'description': 'Blood samples were collected at the scheduled visits. The CD19+ B-cell counts were measured by the central laboratory.', 'timeFrame': 'Baseline, Days 2, 5, 7, 14, Weeks 4, 12, 24'}, {'measure': 'Number of Gadolinium-enhancing T1 Lesions Per MRI Scan - Extension Part', 'description': ""Total number of Gd-enhancing T1 lesions per scan during the Extension Part (up to Week 48) calculated as a rate for population, rather than at patient-level. It was calculated as sum of each patient's total number of Gd-enhancing T1 lesions across scans at Week 36 and 48, divided by sum of each patient's total number of scans."", 'timeFrame': 'Week 24 up to Week 48'}, {'measure': 'Number of New or Enlarging T2 Lesions on MRI Scans (Annualized T2 Lesion Rate) - Extension Part', 'description': ""Number of new/enlarging T2 lesions on the last available MRI scan in the Extension Part (up to Week 48) relative to Week 24, adjusted for different follow-up times. Annualized rate of new or enlarging T2 lesions was calculated by dividing the sum of each patient's number of new or enlarging T2 lesions relative to Week 24 by the sum of each patient's number of MRI assessment days during the Extension part, and then multiplying it by 365.25."", 'timeFrame': 'Week 24 up to Week 48'}, {'measure': 'Annualized Relapse Rate (ARR) - Extension Part', 'description': ""ARR was the number of confirmed MS relapses in a year. A confirmed MS relapse was defined as one accompanied by a clinically-relevant change in the EDSS performed by the Independent EDSS rater, i.e. an increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional scores or 2 points on one functional score (excluding changes involving bowel/bladder or cerebral functional system). ARR (time-based) was calculated by summing each patient's number of confirmed relapses observed during the Extension part, divided by the total number of each patient's days in a study of all patients during the Extension part, and multiplied by 365.25."", 'timeFrame': 'Week 24 up to Week 48'}, {'measure': 'Pharmacokinetic (PK) Concentrations of Ofatumumab - Extension Part', 'description': 'Blood samples were collected at the scheduled visits. Summary statistics of PK concentrations from trough samples.', 'timeFrame': 'Weeks 24, 28, 36, 48'}, {'measure': 'B-cell Counts - Extension Part', 'description': 'Blood samples were collected at the scheduled visits. The CD19+ B-cell counts were measured by the central laboratory.', 'timeFrame': 'Weeks 24, 36 and 48'}, {'measure': 'Participants With Confirmed Relapse - Core and Extension Parts', 'description': 'A confirmed MS relapse was defined as one accompanied by a clinically-relevant change in the EDSS performed by the Independent EDSS rater, i.e. an increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional scores or 2 points on one functional score (excluding changes involving bowel/bladder or cerebral functional system).', 'timeFrame': 'Baseline up to Week 48'}]",12,18 Years,55 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,64.0,ACTUAL,2025-09-01T16:18:22.208658,v2_robust,True,True,True,False,False,
NCT05827614,"Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications","An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications",BBI-355,"['Erlotinib', 'BBI-355', 'BBI-825', 'Futibatinib']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Triple Negative Breast Cancer (TNBC),"['Triple Negative Breast Cancer (TNBC)', 'High Grade Serous Ovarian Carcinoma', 'High Grade Endometrial Carcinoma', 'Anogenital Cancer', 'Head and Neck (HNSCC)', 'Cutaneous Squamous Cell Carcinoma (CSCC)', 'Cervical Squamous Cell Carcinoma', 'ER+ Breast Cancer', 'Leiomyosarcoma (LMS)', 'Undifferentiated Pleomorphic Sarcoma (UPS)', 'Pancreatic Cancer Metastatic', 'Small Cell Lung Cancer']","['ecDNA', 'extrachromosomal DNA', 'Amplification', 'Oncogene Amplification', 'Checkpoint kinase 1', 'CHK1', 'RNR', 'ribonucleotide reductase']",RECRUITING,,2023-03-24,2027-03-31,"[{'measure': 'Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-355 as a single agent and in combination with each of the following agents: erlotinib, futibatinib, or BBI-825', 'description': 'TEAEs will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.', 'timeFrame': 'Start of Cycle 1 until 30 days following last dose (each cycle is 28 days)'}, {'measure': 'Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of BBI-355 as a single agent and in combination with erlotinib, futibatinib, or BBI-825', 'description': 'The MTD and/or RP2D of BBI-355 as a single agent and in combination with erlotinib, futibatinib, or BBI-825 will be determined.', 'timeFrame': 'Start of Cycle 1 until 30 days following last dose (each cycle is 28 days)'}]","[{'measure': 'Maximum observed plasma concentration (Cmax) of BBI-355, erlotinib, futibatinib, and BBI-825', 'description': 'Maximum observed plasma concentration (Cmax) of BBI-355, erlotinib, futibatinib, and BBI-825 will be determined.', 'timeFrame': 'Start of Cycle 1 until Day 1 of last treatment cycle (each cycle is 28 days)'}, {'measure': 'Trough observed plasma concentration (Ctrough) of BBI-355, erlotinib, futibatinib, and BBI-825', 'description': 'Trough observed plasma concentration (Ctrough) of BBI-355, erlotinib, futibatinib and BBI-825 will be determined.', 'timeFrame': 'Start of Cycle 1 until Day 1 of last treatment cycle (each cycle is 28 days)'}, {'measure': 'Time to Cmax (Tmax) of BBI-355, erlotinib, futibatinib, and BBI-825', 'description': 'Time to Cmax (Tmax) of BBI-355, erlotinib, futibatinib, and BBI-825 will be determined.', 'timeFrame': 'Start of Cycle 1 until Day 1 of last treatment cycle (each cycle is 28 days)'}, {'measure': 'Area under the concentration time curve (AUC) of BBI-355, erlotinib, futibatinib, and BBI-825', 'description': 'Area under the concentration time curve (AUC) of BBI-355, erlotinib, futibatinib and BBI-825 will be determined.', 'timeFrame': 'Start of Cycle 1 until Day 1 of last treatment cycle (each cycle is 28 days)'}, {'measure': 'Anti-tumor activity of BBI-355 as a single agent and in combination with erlotinib, futibatinib, or BBI-825', 'description': 'Tumor response will be determined by RECISTv1.1.', 'timeFrame': '1-2 years: Start of Cycle 1 until documented disease progression or death (each cycle is 28 days)'}]",7,18 Years,,ALL,False,Boundless Bio,INDUSTRY,0,127.0,ESTIMATED,2025-09-01T16:18:22.208722,v2_robust,True,True,False,False,True,
NCT06356714,Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status,An Open Intervention Study of Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD(Stable Disease) Status,Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens,['Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Colorectal Cancer,"['Colorectal Cancer', 'Colorectal Neoplasms']","['Nocardia Rubra Cell Wall Skeleton', 'Colorectal Cancer', 'Colorectal Neoplasms']",RECRUITING,,2025-03-15,2027-10-01,"[{'measure': 'Progression-free survival(PFS)', 'description': 'Time between the start of a treatment regimen and tumor progression or death', 'timeFrame': '1 year'}]","[{'measure': 'Overall survival (OS)', 'timeFrame': '2 year'}, {'measure': 'Objective remission rate (ORR)', 'timeFrame': '1 year'}, {'measure': 'Disease Control Rate (DCR)', 'timeFrame': '1 year'}, {'measure': 'Incidence and extent of major security incidents', 'timeFrame': '1 year'}, {'measure': 'Quality of Life Score (QoL) for tumor patients', 'timeFrame': '1 year'}]",6,18 Years,,ALL,False,Sun Jing,OTHER,0,22.0,ESTIMATED,2025-09-01T16:18:22.208823,v2_robust,True,True,False,False,False,
NCT03009214,A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours,"A Safety, Tolerability and Pharmacokinetic Dose Escalation and Expansion, Phase I/Ib Study of AMC303 as Monotherapy in Patients With Advanced or Metastatic, Malignant Solid Tumour of Epithelial Origin",AMC303,"['CD44v6 inhibitor', 'AMC303']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Malignant Solid Tumor,['Malignant Solid Tumor'],"['solid epithelial cancer', 'CD44v6', 'c-Met', 'VEGFR-2', 'RON', 'receptor tyrosine kinase']",COMPLETED,,2016-12,2021-05-07,"[{'measure': 'Safety and tolerability of AMC303', 'description': 'Number of patients with treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': '6 months'}]","[{'measure': 'Pharmacokinetic properties of AMC303 (Cmax)', 'description': 'Determine maximum plasma concentration (Cmax)', 'timeFrame': '2 days'}, {'measure': 'Pharmacokinetic properties of AMC303 (AUC)', 'description': 'Determine systemic exposure (AUC) after intravenous infusion', 'timeFrame': '2 days'}, {'measure': 'Pharmacokinetic properties of AMC303 (t1/2)', 'description': 'Determine half-life of AMC303 after intravenous infusion', 'timeFrame': '2 days'}, {'measure': 'Response rate of treatment with AMC303 in patients with metastatic solid tumors', 'description': 'Determination of the complete response (CR) and partial response (PR) in patients treated with AMC303', 'timeFrame': '12 months'}]",5,18 Years,,ALL,False,amcure GmbH,INDUSTRY,0,55.0,ACTUAL,2025-09-01T16:18:22.208864,v2_robust,True,True,True,False,True,
NCT00699114,"Analgesic Effect of Ibuprofen, Paracetamol (Acetaminophen), and Paracetamol (Acetaminophen) Plus Codeine on Acute Pain","Analgesic Effect of Ibuprofen 400, 600 and 800 mg, Paracetamol 500 and 1000 mg, and Paracetamol 1000 mg Plus 60 mg Codeine: Single-dose, Randomized, Placebo-controlled and Double-blind Study on Acute Pain After Third Molar Surgery",Placebo,"['M01A E01 Ibuprofen', 'N02B E01 Paracetamol (acetaminophen)', 'Paracetamol (acetaminophen) 1000 mg + codeine 60 mg', 'Paracetamol (acetaminophen) 1000 mg', 'Lactose', 'Placebo', 'N02B E01 Paracetamol (acetaminophen) + R05D A04 codeine', 'Ibuprofen 400 mg', 'Ibuprofen 800 mg', 'Paracetamol (acetaminophen) 500 mg', 'Ibuprofen 600 mg']",11,INTERVENTIONAL,['PHASE4'],PHASE4,,Surgery,['Surgery'],"['Pain', 'Analgesics', 'Molar', 'Third', 'Acetaminophen', 'Paracetamol', 'Ibuprofen', 'Codeine', 'Placebo']",COMPLETED,,2007-06,2009-12,"[{'measure': 'Sum Pain Intensity Score(SPI)', 'timeFrame': '3 hour observation period'}]","[{'measure': 'Sum Pain Intensity Difference Score (SPID)', 'timeFrame': '3 hours'}, {'measure': 'Sum Pain Intensity Score (SPI)', 'timeFrame': '6 hours'}, {'measure': 'Sum Pain Intensity Difference Score (SPID)', 'timeFrame': '6 hours'}, {'measure': 'Maximum Pain Intensity Difference Score (MAXPID)', 'timeFrame': 'Unknown, calculated variable'}, {'measure': 'Time to Maximum Pain Intensity Difference Score', 'timeFrame': 'Unknown, calculated variable'}, {'measure': 'Self-reported Occurrence of Adverse Effects', 'timeFrame': '3 hours'}, {'measure': 'Self-reported Occurrence of Adverse Effects', 'timeFrame': '6 hours'}]",8,18 Years,30 Years,ALL,True,Ullevaal University Hospital,OTHER,1,350.0,ESTIMATED,2025-09-01T16:18:22.208901,v2_robust,True,True,True,False,True,
NCT04844814,Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation,"Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation: a Randomized, Double Blinded, Multicenter Study",Anakinra 100Mg/0.67Ml Inj Syringe,"['Prednisone', 'Anakinra 100Mg/0.67Ml Inj Syringe', 'Placebo of Prednisone', 'Placebo of Anakinra']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Gout,"['Gout', 'Chronic Kidney Disease', 'Renal Transplantation']","['Gout', 'Flare', 'Urate crystals', 'Chronic kidney disease', 'Anakinra', 'IL-1b', 'Corticosteroid', 'Renal transplantation']",SUSPENDED,"Peremption of treatments, difficulty of patients recrutment (28 patients in 3 years) and lack of funding to pursue the study.",2022-06-02,2026-03-12,"[{'measure': 'Pain difference between Day 3 and treatment initiation', 'description': 'Pain difference between day 3 and treatment initiation assessed by visual analogical scale (VAS) from 0 to 10 VAS = 0, no pain VAS =10, maximal pain', 'timeFrame': 'Day 3'}]","[{'measure': 'Percentage of responders (improvement ≥ 50%) at day 5', 'description': 'Percentage of responders (improvement ≥ 50%) at day 5', 'timeFrame': 'Day 5'}, {'measure': 'Percentage of flare resolution (improvement ≥ 80%) at day 5', 'description': 'Percentage of flare resolution (improvement ≥ 80%) at day 5', 'timeFrame': 'Day 5'}, {'measure': 'Time to treatment response', 'description': 'Time to treatment response', 'timeFrame': 'Day 3 or Day 5'}, {'measure': 'Time to flare resolution', 'description': 'Time to flare resolution', 'timeFrame': 'Day 3 or Day 5'}, {'measure': 'Treatment duration', 'description': 'Treatment duration', 'timeFrame': 'Day3 or Day 5'}, {'measure': 'Duration of hospitalization', 'description': 'Duration of hospitalization', 'timeFrame': 'Day 3 or Day 5'}, {'measure': 'Healthcare consumption at month 1 : number of consultations and hospitalizations related to gout flare', 'description': 'Healthcare consumption at month 1 assessed by number of consultations and hospitalizations related to gout flare', 'timeFrame': 'Month 1'}, {'measure': 'Healthcare consumption at month 1: total hospital stay', 'description': 'Healthcare consumption at month 1 assessed by total hospital stay', 'timeFrame': 'Month 1'}, {'measure': 'Healthcare consumption at month 1', 'description': 'Healthcare consumption at month 1 assessed by number and cumulative duration of sick leave related to gout', 'timeFrame': 'Month 1'}, {'measure': 'Side effects', 'description': 'Side effects', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1 : DT2 decompensation', 'description': 'Comorbidity decompensations at month 1 assessed by DT2 decompensation measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood pressure', 'description': 'Comorbidity decompensations at month 1 assessed by Blood pressure measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Hypertension', 'description': 'Comorbidity decompensations at month 1 assessed by hypertension measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Weight', 'description': 'Comorbidity decompensations at month 1 assessed by Weight measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: number of Cardiovascular events : coronary disease, heart attack, stroke', 'description': 'Comorbidity decompensations at month 1 assessed by number of Cardiovascular events : coronary disease, heart attack, stroke', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of serum creatinine level', 'description': 'Comorbidity decompensations at month 1 assessed by serum creatinine level measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of epidermal Growth Factor Receptor (eGFR)', 'description': 'Comorbidity decompensations at month 1 assessed by eGFR measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of C reactive protein (CRP)', 'description': 'Comorbidity decompensations at month 1 assessed by CRP measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of HbA1C', 'description': 'Comorbidity decompensations at month 1 assessed by HbA1C measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of total cholesterol', 'description': 'Comorbidity decompensations at month 1 assessed by total cholesterol measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of LDL cholesterol', 'description': 'Comorbidity decompensations at month 1 assessed by HDL cholesterol measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of HDL cholesterol', 'description': 'Comorbidity decompensations at month 1 assessed by HDL cholesterol measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of triglyceride', 'description': 'Comorbidity decompensations at month 1 assessed by triglyceride measure', 'timeFrame': 'Month 1'}, {'measure': 'Comorbidity decompensations at month 1: Blood analysis of glycaemia', 'description': 'Comorbidity decompensations at month 1 assessed by glycaemia measure', 'timeFrame': 'Month 1'}, {'measure': 'site injection reaction during day 0 to day 5: pain', 'description': 'site injection reaction during day 0 to day 5 assessed by pain (0-10 scale VAS) measure', 'timeFrame': 'Dat 3 or day 5'}, {'measure': 'site injection reaction during day 0 to day 5: inflammatory reaction', 'description': 'site injection reaction during day 0 to day 5 assessed by CRP level measure', 'timeFrame': 'Dat 3 or day 5'}, {'measure': 'site injection reaction during day 0 to day 5: swelling (yes/no)', 'description': 'site injection reaction during day 0 to day 5 assessed by swelling (yes/no)', 'timeFrame': 'Dat 3 or day 5'}, {'measure': 'site injection reaction during day 0 to day 5: itching (yes/no)', 'description': 'site injection reaction during day 0 to day 5 assessed by itching (yes/no)', 'timeFrame': 'Dat 3 or day 5'}, {'measure': 'site injection reaction during day 0 to day 5: redness (yes/no)', 'description': 'site injection reaction during day 0 to day 5 assessed by redness (yes/no)', 'timeFrame': 'Dat 3 or day 5'}]",30,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,204.0,ESTIMATED,2025-09-01T16:18:22.208945,v2_robust,True,True,False,True,False,"Peremption of treatments, difficulty of patients recrutment (28 patients in 3 years) and lack of funding to pursue the study."
NCT03553914,PLM60 for Peripheral T Cell Lymphoma (PTCL),A Randomized Phase 1-2 Study of PLM60 in Patients With Peripheral T-Cell Lymphoma,PLM60,['PLM60'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Peripheral T Cell Lymphoma,['Peripheral T Cell Lymphoma'],[],WITHDRAWN,IND Inactive Status,2021-01,2025-01,"[{'measure': 'Percentage of subjects experiencing AEs and SAEs after treatment with PLM60', 'description': 'Percentage of subjects experiencing AEs and SAEs, by evaluating physical examinations, vital signs, ECOG score, ECGs, ECHO or MUGA scans, and clinical laboratory findings', 'timeFrame': '8 Months'}, {'measure': 'Overall response rate in patients with PTCL after treatment PLM60', 'description': 'Assessing the overall response rate (ORR) by Lugano Classification', 'timeFrame': '19 months'}]",[],2,18 Years,,ALL,False,"Conjupro Biotherapeutics, Inc.",INDUSTRY,1,0.0,ACTUAL,2025-09-01T16:18:22.209086,v2_robust,True,True,False,True,False,IND Inactive Status
NCT04194814,Skin bioMARkers for Atopic Eczema Therapy Evaluation,Validation of a Novel Composite of Skin Biomarkers as a Primary Outcome Measure for Evaluating the Safety of Treatments for Atopic Dermatitis: a Randomized Controlled Trial (Phase 2) Comparing the Effects of Crisaborole 2% Ointment to Betamethasone Valerate 0.1% Cream on Skin Structure and Function in Participants With Atopic Dermatitis.,crisaborole (2%) ointment,"['Eucrisa', 'betamethasone valerate 0.1% cream', 'Betnovate cream', 'crisaborole (2%) ointment']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Atopic Eczema/Dermatitis (Non-Specific),['Atopic Eczema/Dermatitis (Non-Specific)'],[],COMPLETED,,2020-11-20,2021-09-30,"[{'measure': 'Change in Epidermal Thickness', 'description': 'The difference in the change in epidermal thickness, measured by structural OCT, between the sites treated with crisaborole (2%) ointment and betamethasone valerate (0.1%) cream.', 'timeFrame': 'Day 1 - Day 57'}]","[{'measure': 'Analysis of Change in Objective Erythema', 'description': 'Analysis of the difference in the change in skin redness/erythema (relating to tolerability) during and after 28 days treatment determined by Mexameter measured on day 1, day 15, day 29 and day 57.\n\nThe Mexameter device has a range of 0-999AU (arbitrary units) and the lower the value, the better the condition of the skin. Objective redness can be classified using the following scale: 0-170AU - No erythema; 170-330AU - Minimal erythema; 330-450AU - Diffuse erythema; 450-570AU - High erythema; over 570AU - Extreme erythema', 'timeFrame': 'Day 1, Day 15, Day 29 and Day 57'}, {'measure': 'TEWL - Skin Barrier Function', 'description': 'Analysis of the change in Trans-Epidermal Water Loss (TEWL, relates to skin barrier function) during and after treatment. TEWL measurements on day 1, day 15, day 29 and day 57.', 'timeFrame': 'Day 1, Day 15, Day 29 and Day 57'}, {'measure': 'TEWL - After Tape-stripping', 'description': 'The difference in skin barrier integrity (TEWLts20) after 28 days treatment. TEWL measurements after tape-stripping (TEWLts20) on day 29', 'timeFrame': 'on Day 29, after 28 days treatment'}, {'measure': 'Comparison of TEWL - After Tape-stripping', 'description': 'The difference in skin barrier integrity (TEWLts20) after 28 days treatment. TEWL measurements after tape-stripping (TEWLts20) on day 29', 'timeFrame': 'on Day 29, after 28 days treatment'}, {'measure': 'Skin Dryness', 'description': 'The difference in the change in visual skin dryness during and after treatment. Visual skin dryness scored on day 1, day 15, day 29 and day 57. Visual skin dryness was scored using the following: 0 - Absent; 1 - Faint scaling, faint roughness and dull appearance; 2 - Small scales in combination with a few larger scales, slight roughness, whitish appearance; 3 - Small and larger scales uniformly distributed, definite roughness, possibly slight redness and possibly a few superficial cracks; 4 - Dominated by large scales, advanced roughness, redness present, eczematous changes and cracks. The lower the visual dryness score, the better the condition of the skin.', 'timeFrame': 'Visual skin dryness scored on day 1, day 15, day 29 and day 57'}, {'measure': 'Natural Moisturising Factor (NMF)', 'description': 'The difference in Natural Moisturising Factor (NMF, filaggrin breakdown products) levels at the end of treatment.\n\n3 NMF components were measured: Urocanic acid (UCA), Pyrrolidone carboxylic acid (PCA) and Free amino acids (FAA) and are expressed together as total NMF (tNMF).', 'timeFrame': 'Day 29'}, {'measure': 'Comparison of Natural Moisturising Factor (NMF) Between Treatments', 'description': 'The difference in Natural Moisturising Factor (NMF, filaggrin breakdown products) levels at the end of treatment.\n\n3 NMF components were measured: Urocanic acid (UCA), Pyrrolidone carboxylic acid (PCA) and Free amino acids (FAA) and are expressed together as total NMF (tNMF).', 'timeFrame': 'Day 29'}, {'measure': 'Change in Visual Redness/Erythema During and After 28 Days Treatment', 'description': 'The difference in the change in visual skin redness during and after treatment. Visual skin redness scored on day 1, day 15, day 29 and day 57 by an experienced grader. Visual skin redness was scored using the following: 0 - No redness; 0.5/+ - Slight patchy erythema, barely perceptible; 1 - Slight uniform erythema, mild erythema; 2 - Moderate uniform erythema, moderate erythema; 3 - Strong erythema, marked erythema. The higher the visual redness score, the more inflamed the skin looks to the naked eye.', 'timeFrame': 'Visual skin redness scored on day 1, day 15, day 29 and day 57'}]",9,18 Years,65 Years,ALL,False,Sheffield Teaching Hospitals NHS Foundation Trust,OTHER,1,37.0,ACTUAL,2025-09-01T16:18:22.209110,v2_robust,True,True,True,False,False,
NCT06158516,A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors,"A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors",Surufatinib,"['Surufatinib', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Pancreatic Neuroendocrine Tumor,['Pancreatic Neuroendocrine Tumor'],[],NOT_YET_RECRUITING,,2023-11-30,2026-11-29,"[{'measure': '2-year disease-free survival (2y-DFS)', 'description': '2-year disease-free survival (2y-DFS)', 'timeFrame': 'From the date of surgery to 2 years, assessed up to 24 months'}]","[{'measure': 'Disease-free survival time', 'description': 'Disease-free survival time', 'timeFrame': 'From the date of surgery to the date of distant metastasis or recurrence or death due to any cause, whichever came first, assessed up to 120 months'}, {'measure': '2-year Overall survival', 'description': '2-year Overall survival', 'timeFrame': 'From the date of surgery to 2 years, assessed up to 24 months'}]",3,18 Years,75 Years,ALL,False,Changhai Hospital,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:22.209191,v2_robust,True,True,False,False,False,
NCT04351516,Test and Treat COVID 65plus+,Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients,Hydroxychloroquine,['Hydroxychloroquine'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,SARS-CoV 2,"['SARS-CoV 2', 'COVID-19']",[],WITHDRAWN,No Patients enrolled,2020-04-21,2021-05-01,"[{'measure': '● Rate of hospitalization or death at day 7 after study inclusion', 'timeFrame': '7 days'}]",[],1,65 Years,,ALL,False,University Hospital Tuebingen,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:22.209203,v2_robust,True,True,False,True,False,No Patients enrolled
NCT00733616,Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status,Phase II Study of Adjusted-dose Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status.,"DOX: Docetaxel, oxaliplatin, Capecitabine","['DOX: Docetaxel, oxaliplatin, Capecitabine']",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastric Cancer,['Gastric Cancer'],"['advanced gastric adenocarcinoma', 'docetaxel', 'oxaliplatin', 'capecitabine', 'intermediate general status']",COMPLETED,,2008-11,2012-05,"[{'measure': 'objective response rate', 'timeFrame': '2008-2011'}]","[{'measure': 'adverse events', 'timeFrame': '2008-2011'}, {'measure': 'Progression free survival (PFS), time to treatment failure (TTF), overall survival and dose intensity', 'timeFrame': '2008-2011'}]",3,18 Years,,ALL,False,Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD),OTHER,2,44.0,ACTUAL,2025-09-01T16:18:22.209257,v2_robust,True,True,True,False,True,
NCT01097616,Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK-4305 in Patients With Primary Insomnia - Study A",Suvorexant High Dose (HD),"['Suvorexant High Dose (HD)', 'Suvorexant Low Dose (LD)', 'Comparator: Placebo', 'MK-4305']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Primary Insomnia,['Primary Insomnia'],[],COMPLETED,,2010-05-05,2011-12-07,"[{'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) at Month 1', 'description': ""sTSTm is the average over a defined day range of the participant's report of the total amount of time spent asleep before waking for the day, as recorded in a daily electronic diary (e-diary). Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any polysomnography \\[PSG\\] nights) falling within the day range; Month 1 range is Days 23-30 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in sTSTm at Month 3', 'description': ""sTSTm is the average over a defined day range of the participant's report of the total amount of time spent asleep before waking for the day, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Month 3 range is Days 76-90 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in Wakefulness After Persistent Sleep Onset (WASO) at Month 1', 'description': 'WASO is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of wakefulness from the onset of persistent sleep (i.e., 10 consecutive minutes of sleep) to the end of PSG assessment the following morning. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in WASO at Month 3', 'description': 'WASO is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of wakefulness from the onset of persistent sleep (i.e., 10 consecutive minutes of sleep) to the end of PSG assessment the following morning. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in Mean Subjective Time to Sleep Onset (sTSOm) at Month 1', 'description': ""sTSOm is the average over a defined day range of the participant's report of the duration of time that it took to fall asleep, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Month 1 range is Days 23-30 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in sTSOm at Month 3', 'description': ""sTSOm is the average over a defined day range of the participant's report of the duration of time that it took to fall asleep, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Month 3 range is Days 76-90 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in Latency to Onset of Persistent Sleep (LPS) at Month 1', 'description': 'LPS is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of time from the beginning of PSG assessment (""Lights-Off"") to the first interval of 10 consecutive minutes of sleep. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant HD Versus Placebo: Change From Baseline in LPS at Month 3', 'description': 'LPS is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of time from the beginning of PSG assessment (""Lights-Off"") to the first interval of 10 consecutive minutes of sleep. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Number of Participants With an Adverse Event (AE) During Initial 3-Month DB TRT Phase', 'description': 'An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. Participants with an AE occurring during the initial 3-month DB TRT Phase are counted once in this summary.', 'timeFrame': 'Up to 3 months'}, {'measure': 'Number of Participants Who Discontinued Study Drug Due to an AE Occurring During Initial 3-Month DB TRT Phase', 'description': 'An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. Participants who discontinued study drug treatment due to an AE occurring during the initial 3-month DB TRT Phase are counted once in this summary.', 'timeFrame': 'Up to 3 months'}]","[{'measure': 'Suvorexant LD/HD Versus Placebo: Change From Baseline in sTSTm at Week 1', 'description': ""sTSTm is the average over a defined day range of the participant's report of the total amount of time spent asleep before waking for the day, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Week 1 range is Days 2-8 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Week 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in sTSTm at Month 1', 'description': ""sTSTm is the average over a defined day range of the participant's report of the total amount of time spent asleep before waking for the day, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Month 1 range is Days 23-30 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in sTSTm at Month 3', 'description': ""sTSTm is the average over a defined day range of the participant's report of the total amount of time spent asleep before waking for the day, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Month 3 range is Days 76-90 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Suvorexant LD/HD Versus Placebo: Change From Baseline in WASO at Night 1', 'description': 'WASO is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of wakefulness from the onset of persistent sleep (i.e., 10 consecutive minutes of sleep) to the end of PSG assessment the following morning. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Night 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in WASO at Month 1', 'description': 'WASO is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of wakefulness from the onset of persistent sleep (i.e., 10 consecutive minutes of sleep) to the end of PSG assessment the following morning. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in WASO at Month 3', 'description': 'WASO is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of wakefulness from the onset of persistent sleep (i.e., 10 consecutive minutes of sleep) to the end of PSG assessment the following morning. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Suvorexant LD/HD Versus Placebo: Change From Baseline in sTSOm at Week 1', 'description': ""sTSOm is the average over a defined day range of the participant's report of the duration of time that it took to fall asleep, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Week 1 range is Days 2-8 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Week 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in sTSOm at Month 1', 'description': ""sTSOm is the average over a defined day range of the participant's report of the duration of time that it took to fall asleep, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Month 1 range is Days 23-30 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in sTSOm at Month 3', 'description': ""sTSOm is the average over a defined day range of the participant's report of the duration of time that it took to fall asleep, as recorded in a daily e-diary. Averages were derived by taking the mean of all available daily measurements (excluding the mornings following any PSG nights) falling within the day range; Month 3 range is Days 76-90 (Day 1 is day of first double-blind dose). A participant must have at least 3 days of data during the defined day range to calculate an average for the day range; otherwise, the mean value was considered missing for that day range. The baseline value is the mean of the last 7 daily measurements obtained during the placebo Run-in period."", 'timeFrame': 'Baseline and Month 3'}, {'measure': 'Suvorexant LD/HD Versus Placebo: Change From Baseline in LPS at Night 1', 'description': 'LPS is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of time from the beginning of PSG assessment (""Lights-Off"") to the first interval of 10 consecutive minutes of sleep. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Night 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in LPS at Month 1', 'description': 'LPS is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of time from the beginning of PSG assessment (""Lights-Off"") to the first interval of 10 consecutive minutes of sleep. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 1'}, {'measure': 'Suvorexant LD Versus Placebo: Change From Baseline in LPS at Month 3', 'description': 'LPS is measured during overnight sleep laboratory (PSG) assessments at baseline, Night 1, Month 1 and Month 3, and is defined as the duration of time from the beginning of PSG assessment (""Lights-Off"") to the first interval of 10 consecutive minutes of sleep. Beginning of PSG assessment (""Lights-Off"") is at approximately the participant\'s habitual bedtime. The participant is awakened, or allowed to get out of bed if already awake, after 8 hours of PSG recording (""Lights-On""). PSG assessments consist of electronic measurement of brain activity and eye and muscle movements. PSG data was scored by a Centralized PSG reading center.', 'timeFrame': 'Baseline and Month 3'}]",22,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,1023.0,ACTUAL,2025-09-01T16:18:22.209302,v2_robust,True,True,True,False,True,
NCT02067416,PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer,"Prospective Study To Validate The Predictive Value Of Mammostrat Score, DDR Score And TLE3 Gene When A Taxane-Based Chemo Agents Or Anthracycline-Based Chemo Agent Is Used In The Neo-Adjuvant Setting",Anthracycline based chemotherapy,"['Adriamycin', 'Paclitaxel', 'taxane-based chemotherapy', 'Ixabepilone', 'Epirubicin', 'Abraxane', 'Docetaxel', 'Anthracycline based chemotherapy']",8,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],"['neoadjuvant', 'mammostrat', 'TLE3', 'DDR', 'breast cancer']",WITHDRAWN,Funding agent withdrew funding,2012-07,2014-06,"[{'measure': 'Compare Mammostrat score clinical response rates to chemotherapy', 'description': 'The percentage of patients undergoing chemotherapy who have Mammostrat low risk scores will be calculated', 'timeFrame': '2 years'}]","[{'measure': 'pathological complete response rate compare to predictors', 'description': 'The percentage of patients undergoing chemotherapy who have Mammostrat low risk scores will be calculated', 'timeFrame': '2 years'}]",2,18 Years,,ALL,False,"Jenny C. Chang, MD",OTHER,2,0.0,ACTUAL,2025-09-01T16:18:22.209367,v2_robust,True,True,False,True,False,Funding agent withdrew funding
NCT02558816,"A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients","A Phase I/II Trial of Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma Patients",Ibrutinib + GA101 +GDC-0199,"['Ibrutinib', 'GA101 : Obinutuzumab', 'GDC-0199', 'Ibrutinib + GA101 +GDC-0199']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Mantle Cell Lymphoma,['Mantle Cell Lymphoma'],[],COMPLETED,,2015-10-14,2025-05-13,"[{'measure': 'Step A : occurrence of unacceptable toxicity of the combination of GA101 and Ibrutinib during the first cycle of treatment', 'description': '4 weeks after initiation of treatment.', 'timeFrame': 'week 4'}, {'measure': 'Step B : occurrence of unacceptable toxicity (definition p3) of the combination of GA101 and Ibrutinib plus GDC-0199 during the cycle 2 in terms of Dose-Limiting Toxicities (DLTs)', 'description': 'No unacceptable toxicity has been observed during step A, thefore the second step (step B) was initiated', 'timeFrame': 'At the end of cycle 2 (each cycle is 28 days)'}, {'measure': 'Step C : occurrence of unacceptable toxicity of the combination of GA101 and Ibrutinib and GDC-0199 at the end of the cycle 2', 'description': 'The third step started, because no unacceptable toxicity has been observed during the second step', 'timeFrame': 'At the end of cycle 2 (each cycle is 28 days)'}]","[{'measure': 'Response (CR, PR, SD, PD) and overall response (CR+ PR) rates', 'description': 'Response (CR, PR, SD, PD) and overall response (CR+ PR) rates assessed by Cheson 99 and 07 criteria and Working Group Revised Response Criteria for Malignant Lymphomas 14', 'timeFrame': '48 months'}, {'measure': 'Time to progression', 'timeFrame': '48 months'}, {'measure': 'Overall survival', 'timeFrame': '48 months'}, {'measure': 'Safety measured by type, frequency, severity of related treatment adverse event as Assessed by CTCAE v4.0.', 'timeFrame': '48 months'}, {'measure': 'Incidence of Serious Adverse Event (SAE), Adverse Event (AE) and laboratory abnormalities.', 'timeFrame': '48 months'}, {'measure': 'Incidence and severity of tumor lysis syndrome', 'timeFrame': '48 months'}]",9,16 Years,,ALL,False,Nantes University Hospital,OTHER,2,48.0,ACTUAL,2025-09-01T16:18:22.209378,v2_robust,True,True,True,False,True,
NCT04356716,Sildenafil for Treatment of Choroidal Ischemia,Sildenafil for Treatment of Choroidal Ischemia,Sildenafil,"['Sildenafil', 'Viagra', 'Revatio']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Choroidal Ischemia,"['Choroidal Ischemia', 'Vitelliform Macular Dystrophy', 'Age-related Macular Degeneration', 'Central Serous Retinopathy', 'Retinitis Pigmentosa']","['Sildenafil', 'Viagra', 'Revatio']",COMPLETED,,2014-11-11,2020-02-18,"[{'measure': 'Change in Visual Acuity (Sildenafil Group)', 'description': 'Patients are evaluated for progression of disease/dystrophy via visual acuity (improved/stable/worsened) and appearance of fluid layer and drusen on OCT testing.', 'timeFrame': 'Up to 63 months'}, {'measure': 'Change in Visual Acuity (Medical Record Review Group)', 'description': 'Patients are evaluated for progression of disease/dystrophy via visual acuity (improved/stable/worsened) and appearance of fluid layer and drusen on OCT testing.', 'timeFrame': '22 months'}]",[],2,18 Years,,ALL,False,Columbia University,OTHER,0,22.0,ACTUAL,2025-09-01T16:18:22.209505,v2_robust,True,True,True,False,False,
NCT01095016,A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients,"An Open-label, Randomized, Cross-over, Active-controlled Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients",Meptin swinghaler,"['Meptin swinghaler', 'Berotec']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Asthma,['Asthma'],[],COMPLETED,,2010-03,2012-10,"[{'measure': 'The change of Forced Expiratory Volume in 1 second (FEV1) value', 'timeFrame': '12 months'}]","[{'measure': 'The change of Peak Expiratory Flow Rate (PEFR)', 'timeFrame': '12 months'}, {'measure': 'The change of Forced Vital Capacity (FVC)', 'timeFrame': '12 months'}, {'measure': 'Device acceptance', 'description': '5-point score of evaluation form to test preference on Meptin swinghaler/ Berotec device by investigator or patient', 'timeFrame': '12 months'}]",4,18 Years,,ALL,False,"Taiwan Otsuka Pharm. Co., Ltd",INDUSTRY,0,32.0,ESTIMATED,2025-09-01T16:18:22.209548,v2_robust,True,True,True,False,False,
NCT05577416,A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma,A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma,Part A: Safusidenib Erbumine,"['Part A: Safusidenib Erbumine', 'Part B: Safusidenib Erbumine']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Glioma,['Glioma'],"['IDH1', 'Diffuse Astrocytoma', 'oligodendroglioma', 'phase 0', 'perioperative']",RECRUITING,,2022-10-11,2025-12-01,"[{'measure': 'Phase 0: Feasibility of Phase 0 study in patient population', 'description': 'Number of patients to complete all planned investigations and procedures', 'timeFrame': '14 months'}, {'measure': 'Phase 0: pharmacokinetic analysis of tumour tissue', 'description': 'Total and unbound AB-218 in tumour tissue', 'timeFrame': '4 weeks'}, {'measure': 'Phase 0: pharmacokinetic analysis of cerebrospinal fluid (CSF)', 'description': 'Total and unbound AB-218 in CSF', 'timeFrame': '4 weeks'}, {'measure': 'Phase 2: Number of Adverse events', 'description': 'Number of adverse events (AEs) according to NCI CTCAE v 5', 'timeFrame': 'up to 30 days after last study dose'}, {'measure': 'Phase 2: Incidence of drug related adverse events', 'description': 'Drug related adverse events', 'timeFrame': 'up to 30 days after last study dose'}, {'measure': 'Phase 2: Incidence of dose limiting toxicity', 'description': 'Dose limiting toxicity events', 'timeFrame': 'up to 30 days after last study dose'}]","[{'measure': 'Phase 0: Incidence of treatment emergent Adverse events', 'description': 'Treatment emergent adverse events (AEs) according to NCI CTCAE v 5', 'timeFrame': 'during 1 cycle of AB-128, prior to maximal resection (4 weeks)'}, {'measure': 'Phase 0: Safety of planned craniotomy and resection after stereotactic biopsy and treatment with AB-218', 'description': '30-day morbidity and mortality post surgery', 'timeFrame': '30 days after maximal resection'}, {'measure': 'Phase 0: Pharmacodynamic (PD) analysis of AB-218 in tumour', 'description': 'Changes in 2-hydroxyglutarate (2-HG) levels in tumour', 'timeFrame': 'after maximal resection (4 weeks), at progression (optional)'}, {'measure': 'Phase 0: Pharmacodynamic (PD) analysis of AB-218 in cerebrospinal fluid (CSF)', 'description': 'Changes in 2-hydroxyglutarate (2-HG) levels in cerebrospinal fluid (CSF)', 'timeFrame': 'after maximal resection (4 weeks), at progression (optional)'}, {'measure': 'Phase 0: Pharmacodynamic (PD) analysis of AB-218 in plasma', 'description': 'Changes in 2-hydroxyglutarate (2-HG) levels in plasma', 'timeFrame': 'after maximal resection (4 weeks), monthly during treatment, at progression (optional)'}, {'measure': 'Phase 0: anti-tumour activity', 'description': 'Objective response (LGG RANO assessment)', 'timeFrame': '4 weeks'}, {'measure': 'Phase 0: Identify factors that can improve the patient experience quality of the service provided to participants using Research Participant Perception Survey short form (RPPS)', 'description': ""Understanding the patients' perspective on the peri-operative design and satisfaction with study procedures"", 'timeFrame': '4 months post op'}, {'measure': 'Phase 2: Identify factors that can improve the patient experience quality of the service provided to participants using Research Participant Perception Survey short form (RPPS)', 'description': ""Understanding the patients' perspective on the peri-operative design and satisfaction with study procedures"", 'timeFrame': '4 months post op'}, {'measure': 'Phase 2: anti-tumour activity', 'description': 'Objective response (LGG RANO assessment)', 'timeFrame': '12 weekly until progression'}]",15,18 Years,,ALL,False,Melbourne Health,OTHER,2,15.0,ESTIMATED,2025-09-01T16:18:22.209620,v2_robust,True,True,False,False,True,
NCT00045916,Optimizing Electroconvulsive Therapy for Depression,Optimization of Electroconvulsive Therapy,Nortriptyline,"['Lithium', 'Venlafaxine', 'Nortriptyline']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Depression,"['Depression', 'Depressive Disorder', 'Bipolar Disorder']","['Electroconvulsive therapy', 'Antidepressive Agents']",COMPLETED,,2001-02,2006-12,"[{'measure': 'Neurocognitive battery', 'timeFrame': 'Measured at baseline and at 2 and 6 months after the acute ECT course'}, {'measure': 'Clinical evaluations, side effect evaluations, and blood level determinations', 'timeFrame': 'Measured weekly for the first month, every 2 weeks until Week 12, and every 4 weeks for the remaining 12 weeks'}]","[{'measure': 'Memory function', 'timeFrame': 'Measured before and after ECT'}]",3,18 Years,,ALL,False,New York State Psychiatric Institute,OTHER,1,340.0,ACTUAL,2025-09-01T16:18:22.209661,v2_robust,True,True,True,False,False,
NCT05982106,To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects,"A Randomized, Open-label, Single-center, Two-cycle, Two-crossover Phase I Clinical Trial Evaluating the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects",TQ05105 Tablets,['TQ05105 Tablets'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Myelofibrosis,['Myelofibrosis'],[],COMPLETED,,2021-07-19,2021-07-28,"[{'measure': 'Area under the drug-time curve (AUC)', 'description': 'Area under the drug-time curve', 'timeFrame': '1 hour before administration and 10, 20, 30, 45 minuets, 1, 1.5, 2, 2.5, 3 ,3.5, 4, 6, 8, 12, 24 hours after administration'}, {'measure': 'Maximum Concentration (Cmax)', 'description': 'Maximum concentration', 'timeFrame': '1 hour before administration and 10, 20, 30, 45 minuets, 1, 1.5, 2, 2.5, 3 ,3.5, 4, 6, 8, 12, 24 hours after administration'}]","[{'measure': 'Time to maximum concentration following drug administration (Tmax)', 'description': 'Time to maximum concentration following drug administration', 'timeFrame': '1 hour before administration and 10, 20, 30, 45 minuets, 1, 1.5, 2, 2.5, 3 ,3.5, 4, 6, 8, 12, 24 hours after administration'}, {'measure': 'Apparent terminal elimination half-life following drug administration (t1/2)', 'description': 'Apparent terminal elimination half-life following drug administration', 'timeFrame': '1 hour before administration and 10, 20, 30, 45 minuets, 1, 1.5, 2, 2.5, 3 ,3.5, 4, 6, 8, 12, 24 hours after administration'}, {'measure': 'Apparent volume of distribution (Vd/F)', 'description': 'Apparent volume of distribution', 'timeFrame': '1 hour before administration and 10, 20, 30, 45 minuets, 1, 1.5, 2, 2.5, 3 ,3.5, 4, 6, 8, 12, 24 hours after administration'}, {'measure': 'Clearance rate (CL/F)', 'description': 'Clearance rate', 'timeFrame': '1 hour before administration and 10, 20, 30, 45 minuets, 1, 1.5, 2, 2.5, 3 ,3.5, 4, 6, 8, 12, 24 hours after administration'}, {'measure': 'Adverse event rate', 'description': 'The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).', 'timeFrame': 'Baseline up to 24 hours after administration'}, {'measure': 'Body temperature', 'description': 'Monitor the safety indicators of subjects during the trial', 'timeFrame': '1 hour before administration and 1, 4, 12, 24 hours after administration'}, {'measure': 'Pulse', 'description': 'Monitor the safety indicators of subjects during the trial', 'timeFrame': '1 hour before administration and 1, 4, 12, 24 hours after administration'}, {'measure': 'Blood pressure', 'description': 'Monitor the safety indicators of subjects during the trial', 'timeFrame': '1 hour before administration and 1, 4, 12, 24 hours after administration'}]",10,18 Years,65 Years,ALL,True,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:22.209708,v2_robust,True,True,True,False,True,
NCT01919606,EXPAREL Administered Into the TAP for Analgesia in Subjects Undergoing Open Total Abdominal Hysterectomy,Evaluation of the Safety and Efficacy of EXPAREL(R) (Bupivacaine Liposome Injectable Suspension) When Administered Into the Transversus Abdominis Plane (TAP) for Prolonged Postoperative Analgesia in Subjects Undergoing Open Total Abdominal Hysterectomy,EXPAREL,"['EXPAREL', 'Bupivacaine liposome injectable suspension']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Postoperative Pain,['Postoperative Pain'],"['hysterectomy', 'analgesia']",TERMINATED,Lack of enrollment,2012-08,2012-10,"[{'measure': 'Duration of Analgesia', 'timeFrame': ""End of surgery to time of subject's first postsurgical opioid administration (through 72 hours)""}]","[{'measure': 'Incidence of Adverse Events', 'timeFrame': '10 days post surgery plus or minus 3 days'}]",2,18 Years,75 Years,FEMALE,False,"Pacira Pharmaceuticals, Inc",INDUSTRY,0,1.0,ACTUAL,2025-09-01T16:18:22.209752,v2_robust,True,True,False,True,True,Lack of enrollment
NCT03798106,A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma,A Phase II Trial of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma,"Durvalumab, pazopanib","['Durvalumab, pazopanib']",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Sarcoma,['Sarcoma'],[],COMPLETED,,2019-04-10,2022-08-10,"[{'measure': 'Objective Response Rate', 'description': 'antitumor efficacy of durvalumab and pazopanib', 'timeFrame': '12 weeks'}]",[],1,19 Years,,ALL,False,Yonsei University,OTHER,0,46.0,ACTUAL,2025-09-01T16:18:22.209771,v2_robust,True,True,True,False,False,
NCT01676506,Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD),The Impact of Genetic Polymorphisms on Ranibizumab Treatment Outcomes in Wet Age-Related Macular Degeneration (AMD),Ranibizumab,"['Lucentis', 'Ranibizumab']",2,INTERVENTIONAL,['NA'],,,Age-Related Macular Degeneration,['Age-Related Macular Degeneration'],"['Wet AMD', 'genetic polymorphisms', 'Ranibizumab']",UNKNOWN,,2011-10,2015-10,"[{'measure': 'Visual acuity', 'description': 'Best corrected visual acuity will be assessed by standardized vision testing, early treatment diabetic retinopathy study (ETDRS) test.', 'timeFrame': 'Baseline and month 3'}]",[],1,50 Years,,ALL,False,Russian Academy of Medical Sciences,OTHER,0,300.0,ESTIMATED,2025-09-01T16:18:22.209779,v2_robust,True,True,False,False,False,
NCT05025306,Healing Effect of Ziziphus Honey on Extracted Tooth Socket in Humans by Evaluating the Levels of BMP-2 and OPN,Healing Effect of Ziziphus Honey on Extracted Tooth Socket in Humans by Evaluating the Levels of BMP-2 and OPN,ziziphus honey,"['honey', 'ziziphus honey', 'sidr honey']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Healing Wound,['Healing Wound'],[],COMPLETED,,2020-01-01,2020-06-01,"[{'measure': 'levels of BMP-2', 'description': 'bone morphogenetic protein-2 levels to access amount of bone healing', 'timeFrame': '1 week'}, {'measure': 'levels of OPN', 'description': 'Osteopontin levels to access amount of bone healing', 'timeFrame': '1 week'}, {'measure': 'Relative bone density', 'description': 'bone quality confirmed on periapical radiographs in both groups', 'timeFrame': '40 days'}]",[],3,18 Years,40 Years,ALL,True,"Postgraduate Medical Institute, Lahore",OTHER,0,30.0,ACTUAL,2025-09-01T16:18:22.209787,v2_robust,True,True,True,False,False,
NCT02621606,[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001),A Three-Part Trial to Qualify [11C]MK-6884 Positron Emission Tomography for Use as a Biomarker for Regional M4 PAM Receptor Density Quantification in the Human Brain,[11C]MK-6884,['[11C]MK-6884'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Alzheimer's Disease,"[""Alzheimer's Disease""]",[],COMPLETED,,2016-01-08,2017-12-28,"[{'measure': 'Number of Participants Experiencing an Adverse Event (AE)', 'description': ""The number of participants experiencing an adverse event (AE) was assessed. An AE is defined as any unfavorable and unintended medical occurrence, sign, symptom, or disease temporally associated with the use of a pharmaceutical product or protocol-specified procedure, whether or not considered related to the pharmaceutical product or protocol-specified procedure. Any worsening of a preexisting condition, temporally associated with the use of the Sponsor's product, is also an AE."", 'timeFrame': 'Up to 15 days'}, {'measure': 'Number of Participants Discontinuing the Study Due to an Adverse Event (AE)', 'description': ""The number of participants discontinuing the study due to an AE was assessed. An AE is defined as any unfavorable and unintended medical occurrence, sign, symptom, or disease temporally associated with the use of a pharmaceutical product or protocol-specified procedure, whether or not considered related to the pharmaceutical product or protocol-specified procedure. Any worsening of a preexisting condition, temporally associated with the use of the Sponsor's product, is also an AE."", 'timeFrame': 'Up to 15 days'}, {'measure': '[Part 1] Mean Effective Dose of [11C]MK-6884', 'description': 'Mean effective dose (ED) of \\[11C\\]MK-6884 was calculated as a measure of risk associated with exposure of the whole body (WB) to low levels of ionizing radiation. Following \\[11C\\]MK-6884 injection, WB positron emission tomography (PET) scans were collected to visually identify organs absorbing \\[11C\\]MK-6884 in significant amounts. Around identified organs, three-dimensional (3D) volumes were drawn to estimate the percentage of injected activity absorbed. These data were converted into time-activity curves (TACs) and retention of radioactivity in these regions was entered into a human biodistribution model to determine ED of \\[11C\\]MK-6884. ED is expressed in units millisieverts (mSv) / MBq.', 'timeFrame': 'Up to 2 hours post-dose'}, {'measure': '[Part 1] Mean Organ Effective Dose of [11C]MK-6884', 'description': 'Mean organ ED of \\[11C\\]MK-6884 was calculated as a measure of risk associated with exposure of individual organs to low levels of ionizing radiation. Following \\[11C\\]MK-6884 injection, WB PET scans were collected to visually identify organs absorbing \\[11C\\]MK-6884 in significant amounts. Around identified organs, 3D volumes were drawn to estimate the percentage of injected activity absorbed. These data were converted into TACs and retention of radioactivity in these regions was used to calculate organ-specific ED of \\[11C\\]MK-6884. For sex organs (testes/ovaries), organ EDs were derived for participants of the respective sex. However, organ ED for the uterus was estimable in all participants as the male radiologic phantom was sufficiently hermaphroditic.', 'timeFrame': 'Up to 2 hours post dose'}, {'measure': '[Part 2] Mean Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest (ROI)', 'description': 'Mean BPND of \\[11C\\]MK-6884 in each brain ROI was assessed. BPND is the ratio at equilibrium of specifically bound \\[11C\\]MK-6884 to that of non-displaceable \\[11C\\]MK-6884 in tissue. At time ""0"", a single IV bolus of \\[11\\]MK-6884 is administered and PET scanning initiated, yielding brain regional TACs. These TACs are then used to determine peak standard uptake value (SUV) and area under the curve (AUC) in order to quantify brain regional \\[11C\\]MK-6884 uptake. The target region BPND is estimated using the cerebellum as the reference region with the transient equilibrium tissue ratio (TE-TR) method. Higher values indicate increased specific \\[11C\\]MK-6884 binding in the brain ROI.', 'timeFrame': 'Up to 90 minutes post dose'}, {'measure': '[Part 2] Intra-subject Test-Retest (T-RT) Variability of Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest (ROI)', 'description': 'Intra-subject T-RT variability in BPND of \\[11C\\]MK-6884 in each brain ROI was assessed. For each healthy elderly participant receiving 2 doses of \\[11C\\]MK-6884 in study Part 2, the BPND calculated during the first dose (BPND-1) was compared to the BPND calculated during the second dose (BPND-2) to determine the percent T-RT variability of the BPND of \\[11C\\]MK-6884 for each brain ROI.\n\nPercent T-RT variability = \\[absolute value (BPND-1 - BPND-2) / (average BPND)\\] \\* 100. A percent T-RT variability = 0, indicates no variability between BPND-1 and BPND-2.', 'timeFrame': 'Up to 24 hours post dose'}, {'measure': '[Part 3] Mean Regional Non-displaceable Binding Potential (BPND) of [11C]MK-6884 in Brain Regions of Interest', 'description': 'Mean BPND of \\[11C\\]MK-6884 in each brain ROI was assessed. BPND is the ratio at equilibrium of specifically bound \\[11C\\]MK-6884 to that of non-displaceable \\[11C\\]MK-6884 in tissue. At time ""0"", a single IV bolus of \\[11\\]MK-6884 is administered and PET scanning initiated, yielding brain regional TACs. These TACs are then used to determine SUV and AUC in order to quantify brain regional \\[11C\\]MK-6884 uptake. The target region BPND is estimated using the cerebellum as the reference region with the TE-TR method. Higher values indicate increased specific \\[11C\\]MK-6884 binding in the brain ROI.', 'timeFrame': 'Up to 90 minutes post dose'}]",[],7,18 Years,85 Years,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:22.209805,v2_robust,True,True,True,False,True,
NCT02901106,Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate,Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate SURV-SEP,Dimethyl fumarate,['Dimethyl fumarate'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,"Multiple Sclerosis, Relapsing-Remitting","['Multiple Sclerosis, Relapsing-Remitting']","['Multiple Sclerosis, Relapsing-Remitting', 'Dimethyl fumarate']",TERMINATED,"Another surveillance protocol was initiated by the OFSEP (OFSEP cohort) which allows to follow all the patients, whatever their treatment.",2017-05-23,2017-10-17,"[{'measure': 'Number of patients with a relapse and/or progressive worsening of disease (EDSS score)', 'timeFrame': 'After one year of treatment'}]",[],1,18 Years,,ALL,False,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK,0,11.0,ACTUAL,2025-09-01T16:18:22.209818,v2_robust,True,True,False,True,False,"Another surveillance protocol was initiated by the OFSEP (OFSEP cohort) which allows to follow all the patients, whatever their treatment."
NCT00069706,Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients,Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients,AL-12182 0.003% Ophthalmic Solution,"['AL-12182 0.01% Ophthalmic Solution', 'AL-12182 0.03% Ophthalmic Solution', 'Latanoprost 0.005% Ophthalmic Solution', 'AL-12182 0.003% Ophthalmic Solution']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Open-angle Glaucoma,"['Open-angle Glaucoma', 'Ocular Hypertension']","['open-angle', 'glaucoma', 'ocular', 'hypertension', 'POAG']",COMPLETED,,2003-07,2003-10,[{'measure': 'Mean Intraocular Pressure (IOP)'}],[],1,18 Years,,ALL,False,Alcon Research,INDUSTRY,0,118.0,ACTUAL,2025-09-01T16:18:22.209826,v2_robust,True,True,True,False,False,
NCT03274206,A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3),A Phase 2b Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3),Placebo,['Placebo'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Cervical Intraepithelial Neoplasia Grade 2/3,['Cervical Intraepithelial Neoplasia Grade 2/3'],"['Cervical Intraepithelian Neoplasia Grade 2/3', 'CIN 2/3', 'HPV']",UNKNOWN,,2017-08-30,2020-08,"[{'measure': 'Regression rate', 'description': 'The rate of complete histopathological regression from baseline as compared to placebo', 'timeFrame': 'Baseline through Week 16'}]","[{'measure': 'CIN classification', 'description': 'Change from baseline of CIN classification', 'timeFrame': 'Baseline through Week 16'}, {'measure': ""Change of Reid's Colposcopic Index (RCI)"", 'description': 'Change from baseline of RCI', 'timeFrame': 'Baseline through Week 16 and Week 32'}, {'measure': 'Cytopathological classification', 'description': 'Change from baseline of cytopathological classification based on bethesda system', 'timeFrame': 'Baseline through Week 16 and Week 32'}, {'measure': 'Expression rate of P16/Ki-67', 'description': 'Change from baseline as compared to placebo of the expression rate of P16/Ki-67', 'timeFrame': 'Baseline through Week 16'}, {'measure': 'The number of CD8 positive cells in the cervix', 'description': 'Change from baseline as compared to placebo in the number of CD8 positive cells in the cervix', 'timeFrame': 'Baseline through Week 16'}, {'measure': 'HPV 16 clearance rate', 'description': 'Change from baseline as compared to placebo in HPV 16 clearance rate', 'timeFrame': 'Baseline through Week 16'}, {'measure': 'Change of RCI', 'description': 'Change of RCI based on the histopathological regression at Week 16', 'timeFrame': 'Week 16 and Week 32'}]",8,20 Years,49 Years,FEMALE,False,BioLeaders Corporation,INDUSTRY,0,126.0,ESTIMATED,2025-09-01T16:18:22.209839,v2_robust,True,True,False,False,False,
NCT02075606,Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients,"A Phase IV, Multicentre, Open Label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients Receiving Deep Subcutaneous Administrations of Somatuline® (Lanreotide) Autogel® to Treat the Symptoms of Functioning Midgut NeuroEndocrine Tumours (NET)",lanreotide acetate,['lanreotide acetate'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,NeuroEndocrine Tumours,['NeuroEndocrine Tumours'],"['NET', 'Symptomatic response', 'Functioning NeuroEndocrine Tumours', 'midgut region']",COMPLETED,,2014-05,2017-06,"[{'measure': 'Assessment of Clinical Symptomatic Response', 'description': 'This endpoint was assessed using 2 efficacy variables:\n\n* CTCs, enumerated at baseline and Weeks 5, 17, 25, 53\n* Clinical symptomatic response, assessed by the use of symptom reporting\n\nSubjects recorded 24-hour symptom frequency and severity for 7 days prior to first treatment (baseline), throughout the study, and up to 28 days following final drug administration. Symptoms were recorded by answering predetermined questions on the interactive voice response system (IVRS).\n\nSubjects were considered to have a clinical symptomatic response between baseline and last study visit if any 1 of the following criteria were fulfilled: the average number of episodes of diarrhoea decreased by at least 50%, the average number of episodes of flushing decreased by at least 50%, the mode severity of flushing decreased by at least 1 level. Clinical symptomatic response was assessed as a qualitative variable (Yes/No) and reported according to CTC presence at baseline and overall.', 'timeFrame': 'From baseline up to Week 53.'}, {'measure': 'Percentage of Subjects With Time Point Responses According to Response Evaluation Criteria in Solid Tumours (RECIST) Assessments at Weeks 25 and 53', 'description': 'Subjects underwent Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scans at baseline, Visit 8 (Week 25) and Visit 15 (Week 53). Progression was assessed by investigators using RECIST v1.1, and classified as a complete response, partial response, stable disease, progressive disease or non evaluable.\n\nThe time point responses at Week 25 and Week 53 were analysed by CTC presence at baseline and overall. The percentage of subjects within each response category are presented. Percentages are based on the number of subjects in the concerned population with available responses.', 'timeFrame': 'Week 25 and Week 53.'}]","[{'measure': 'Mean Change From Baseline in Number of Episodes of Diarrhoea and Flushing', 'description': 'The effect of lanreotide Autogel on the symptoms of diarrhoea and flushing in subjects was assessed through subject reporting of symptoms every 24-hours for the 7 days prior to treatment (baseline), for the first 16 weeks and on days 11 to 17 after each subsequent injection interval. After the final study drug injection at Week 49, subjects provided 24-hour symptom frequency on days 11 to 28 (up to Week 53). Symptom frequency was recorded by answering predetermined questions on the IVRS.\n\nMean change from baseline in frequency (number of episodes) of diarrhoea and flushing are described at Visit 2 (average number of episodes in Week 1) and at Visit 14 (average number of episodes over days 11 to 17 after Week 49 injection and over days 11 to 28 after Week 49 injection) by CTC presence at baseline and overall. A negative change indicates an improvement in symptoms from baseline.', 'timeFrame': 'From baseline up to Week 53.'}, {'measure': 'Mode Symptom Severity of Episodes of Flushing', 'description': 'The effect of lanreotide Autogel on the mode severity of flushing was assessed through subject reporting of symptoms every 24-hours for the 7 days prior to treatment (baseline), for the first 16 weeks and on days 11 to 17 after each subsequent injection interval until Week 49. After the final study drug injection at Week 49, subjects provided 24-hour symptom severity on days 11 to 28 (up to Week 53). Symptom severity was recorded by answering predetermined questions on the IVRS using a three-point system (mild, moderate or severe). The mode (most frequent) intensity of flushing are reported at baseline and at Visit 14 (average number of episodes over days 11 to 17 after Week 49 injection and over days 11 to 28 after Week 49 injection). Percentages of subjects in each severity category are based on the number of subjects in the analysis set with available responses. Data is presented according to CTC presence at baseline and overall.', 'timeFrame': 'From baseline up to Week 53.'}, {'measure': 'Quality of Life (QoL) Questionnaire: European Organisation for Research and Treatment of Cancer (EORTC) QoL Questionnaire (QLQ)-C30', 'description': 'The effect of lanreotide Autogel treatment on QoL was assessed using the EORTC QLQ-C30 at baseline, Weeks 13 (Visit 5), 25 (Visit 8) and 53 (Visit 15/end of study). The 30 item scale is divided into 9 multi item scales (including 5 functional scales, 1 global health status/QoL scale and 3 general symptom scales) and 6 single items. Possible answers to the first 28 items (all items except the 2 concerning global quality of life) go from 1 (Not at all) to 4 (Very much). The answers for the 2 last questions (Q29- 30) go from 1 (Very poor) to 7 (Excellent). All of the scales and single-item measures range in score from 0 to 100. For multi-item scales, the raw score will be calculated by the addition of item responses divided by the number of items. Higher scores for global health and functional domains indicate a better QoL, while higher symptom scores indicate worse symptoms.\n\nThe mean change from baseline at each time point is reported for each of the category subscores.', 'timeFrame': 'From baseline up to Week 53.'}, {'measure': 'QoL Questionnaire: EORTC QLQ-G.I.NET21', 'description': 'The effect of lanreotide Autogel treatment on QoL was assessed using the EORTC QLQ-G.I.NET21 at baseline, Weeks 13 (Visit 5), 25 (Visit 8) and 53 (Visit 15/end of study). The QLQ-G.I.NET21 questionnaire contained 21 questions that used a 4-point scale (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much) to evaluate 3 defined multi-item symptom scales (endocrine, gastrointestinal and treatment related side effects), 2 single item symptoms (bone/muscle pain and concern about weight loss), 2 psychosocial scales (social function and disease-related worries) and 2 other single items (sexuality and communication). Each individual subscore was transformed to range from 0 to 100. Higher scores indicate worse symptoms or more problems. The mean change from baseline at each time point is reported for each of the category subscores.', 'timeFrame': 'From baseline up to Week 53.'}, {'measure': 'Percentage of Subjects Alive and Progression Free at One Year', 'description': 'Subjects underwent CT or MRI scans at baseline and Week 53. Progression was assessed by investigators using RECIST v1.1. The best overall response to study treatment is the highest time point response achieved by the subject and was assessed as a complete response, partial response, stable disease, progressive disease or non evaluable. For analysis of PFS, event dates were assigned to the first time that progressive disease was noted or the date of death. In case of progressive disease followed by death, the first event was considered in the analysis. Censoring dates were defined in subjects with no progressive disease or death before end of study.\n\nAt one year (end of study), the mean percentage of subjects who were alive and progression free, as calculated using the Kaplan-Meier method, is reported by CTC presence and overall.', 'timeFrame': 'From baseline up to Week 53.'}]",7,18 Years,,ALL,False,Ipsen,INDUSTRY,0,50.0,ACTUAL,2025-09-01T16:18:22.209883,v2_robust,True,True,True,False,False,
NCT01129206,Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy,Phase II Study of Pralatrexate and Docetaxel in Patients With Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-based Therapy.,pralatrexate,"['FOLOTYN', 'pralatrexate', 'Taxotere', 'RP 56976', 'PDX', 'docetaxel', 'TXT']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Adenocarcinoma of the Esophagus,"['Adenocarcinoma of the Esophagus', 'Adenocarcinomas of the Gastroesophageal Junction', 'Recurrent Esophageal Cancer', 'Squamous Cell Carcinoma of the Esophagus', 'Stage IV Esophageal Cancer']","['Gastroesophageal Cancer', 'Gastroesophageal Carcinoma', 'Adenocarcinoma']",COMPLETED,,2010-07,,"[{'measure': 'Overall Response', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR', 'timeFrame': 'Approximately three years'}]","[{'measure': 'Progression-free Survival (PFS)', 'description': 'Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions', 'timeFrame': 'Approximately three years'}, {'measure': 'Overall Survival (OS)', 'description': 'OS was determined from the date of start of therapy to death frm any cause.', 'timeFrame': 'Approximately five years'}, {'measure': 'Correlation of FDG PET Response With Response Rate', 'description': 'Radiological assessment of tumor response was performed by computed tomography (CT) and positron emission tomography (PET) every four cycles of therapy and responses were measured according to RECIST and PERCIST criteria.', 'timeFrame': 'Approximately three years'}]",4,18 Years,,ALL,False,Ohio State University Comprehensive Cancer Center,OTHER,2,6.0,ACTUAL,2025-09-01T16:18:22.209956,v2_robust,True,True,True,False,False,
NCT02468206,Secondary Prophylaxis of Gastric Variceal Bleed,Endoscopic Cyanoacrylate Injection vs. Balloon-occluded Retrograde Transvenous Obliteration in the Prevention of Gastric Variceal Rebleeding,N-butyl-2-cyanoacrylate,"['N-butyl-2-cyanoacrylate', 'Lauromacrogol']",2,INTERVENTIONAL,['NA'],,,Gastric Varices,['Gastric Varices'],[],COMPLETED,,2015-06,2019-01-07,"[{'measure': 'Rebleeding rate from gastric varices', 'timeFrame': '3 years'}]","[{'measure': 'Eradication rate of gastric varices', 'timeFrame': '3 years'}, {'measure': 'Number of participants with increase or decrease in the size of gastric varices', 'timeFrame': '3 years'}, {'measure': 'Number of participants with appearance or worsening of new oesophageal varices', 'timeFrame': '3 years'}, {'measure': 'Number of participants with appearance or worsening of portal hypertensive gastropathy', 'timeFrame': '3 years'}, {'measure': 'Number of participants with appearance or worsening of ascites', 'timeFrame': '3 years'}, {'measure': 'Number of participants with complication', 'timeFrame': '3 years'}, {'measure': 'Average in-hospital stay', 'timeFrame': '3 years'}, {'measure': 'Cost of treatment', 'timeFrame': '3 years'}, {'measure': 'Mortality rate', 'timeFrame': '3 years'}]",10,18 Years,75 Years,ALL,False,West China Hospital,OTHER,0,64.0,ACTUAL,2025-09-01T16:18:22.210136,v2_robust,True,True,True,False,False,
NCT00693004,Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of PRX-03140 as Monotherapy in Subjects With Alzheimer's Disease",PRX-03140,"['Donepezil', 'PRX-03140', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Alzheimer's Disease,"[""Alzheimer's Disease""]",[],TERMINATED,,2008-05,,"[{'measure': ""Alzheimer's Disease Assessment Scale-Cognitive subscale.""}]",[],1,50 Years,90 Years,ALL,False,"Epix Pharmaceuticals, Inc.",INDUSTRY,0,236.0,ESTIMATED,2025-09-01T16:18:22.210189,v2_robust,True,True,False,True,False,
NCT00366704,Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint,"A Multicenter, Randomized, Double-blind, Parallel-group Fixed-dose Study of the Effect on Weight of Bifeprunox Versus Risperidone in the Treatment of Outpatients With Schizophrenia.",bifeprunox,"['bifeprunox', 'risperidone']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Schizophrenia,['Schizophrenia'],['Schizophrenia'],TERMINATED,,2006-11,2008-03,"[{'measure': 'The primary analysis will be the change from baseline on body weight at the final evaluation.', 'timeFrame': '8 weeks'}]","[{'measure': 'Secondary outcomes include: Change from baseline in triglyceride level, Change from baseline in waist circumference, and Change from baseline in total Positive and Negative Syndrome Scale (PANSS) score.', 'timeFrame': '8 weeks'}]",2,18 Years,65 Years,ALL,False,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,1,400.0,ESTIMATED,2025-09-01T16:18:22.210287,v2_robust,True,True,False,True,False,
NCT00154804,CCRT With Twice Weekly Paclitaxel and Cisplatin Followed by Surgery for Locally Advanced Esophageal Cancer,A Phase II Study of Concurrent Chemoradiotherapy With Twice Weekly Paclitaxel and Cisplatin (Twice Weekly TP) Followed by Surgery for Locally Advanced Esophageal Cancer,"Paclitaxel, Cisplatin,Surgery, CCRT","['Paclitaxel, Cisplatin,Surgery, CCRT']",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Esophageal Cancer,['Esophageal Cancer'],"['Concurrent Chemoradiotherapy', 'Esophageal Cancer']",COMPLETED,,2001-08,2004-04,"[{'measure': 'Clinical and pathological response rates', 'timeFrame': '2000~2004'}]","[{'measure': 'Progression free survival', 'timeFrame': '2000~2004'}, {'measure': 'overall survival', 'timeFrame': '2000~2004'}, {'measure': 'Toxicity', 'timeFrame': '2000~2004'}]",4,18 Years,,ALL,False,National Taiwan University Hospital,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:22.210297,v2_robust,True,True,True,False,False,
NCT00895804,"Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)","Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)",MDMA,"['MDMA', 'Pindolol']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Mood Disorder,"['Mood Disorder', 'Substance-Related Disorders', 'Amphetamine-Related Disorders']","['MDMA', 'beta adrenergic', 'Ecstasy']",COMPLETED,,2001-06,2002-03,"[{'measure': 'Effect of pindolol on subjective response to MDMA', 'timeFrame': '24h'}]","[{'measure': 'Effect of pindolol on physiological response to MDMA', 'timeFrame': '24h'}]",2,18 Years,45 Years,MALE,True,"University Hospital, Basel, Switzerland",OTHER,1,16.0,ACTUAL,2025-09-01T16:18:22.210367,v2_robust,True,True,True,False,False,
NCT00577304,A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon,"A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon",Nitroglycerin,"['Topical AmphiMatrix', 'Nitroglycerin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Raynaud's Disease,"[""Raynaud's Disease"", ""Raynaud's Disease Secondary to Scleroderma"", ""Raynaud's Disease Secondary to Other Autoimmune Disease""]","[""Raynaud's"", 'Nitroglycerin', 'Scleroderma']",UNKNOWN,,2007-12,2008-03,"[{'measure': ""Reduction in Raynaud's Condition Score"", 'timeFrame': 'three months'}]","[{'measure': 'Frequency and severity of adverse events.', 'timeFrame': 'three months'}]",2,15 Years,70 Years,ALL,False,MediQuest Therapeutics,INDUSTRY,0,200.0,ESTIMATED,2025-09-01T16:18:22.210376,v2_robust,True,True,False,False,True,
NCT06462404,"A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1","A Randomized, Double-Blind, Single-Dose, 5-Period Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Subjects With Narcolepsy Type 1",E2086,"['E2086', 'Active Comparator', 'Active Comparator Placebo', 'E2086 Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Narcolepsy Type 1 (NT1),['Narcolepsy Type 1 (NT1)'],"['Narcolepsy', 'E2086']",COMPLETED,,2024-06-20,2025-03-17,"[{'measure': 'Mean Sleep Latency (MSL) as Assessed by the 4 Maintenance of Wakefulness Tests (MWTs) for E2086 Versus Placebo at Day 1', 'description': 'Sleep latency is defined as the amount of time a person takes to fall asleep. The MWT is an objective assessment of excessive daytime sleepiness (EDS) which consists of measurement tests. A participant undergoes four 40-minute wake trials, where an increased ability to stay awake in the context of trying to remain awake is reflected in a prolonged sleep latency. These measurements of sleep latency at regular intervals across the day are averaged to calculate the mean sleep latency. The MWT will be performed as per the 2021 guidance of the American Academy of Sleep Medicine.', 'timeFrame': 'At Day 1'}, {'measure': 'MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 5', 'description': 'Sleep latency is defined as the amount of time a person takes to fall asleep. The MWT is an objective assessment of EDS which consists of measurement tests. A participant undergoes four 40-minute wake trials, where an increased ability to stay awake in the context of trying to remain awake is reflected in a prolonged sleep latency. These measurements of sleep latency at regular intervals across the day are averaged to calculate the mean sleep latency. The MWT will be performed as per the 2021 guidance of the American Academy of Sleep Medicine.', 'timeFrame': 'At Day 5'}, {'measure': 'MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 9', 'description': 'Sleep latency is defined as the amount of time a person takes to fall asleep. The MWT is an objective assessment of EDS which consists of measurement tests. A participant undergoes four 40-minute wake trials, where an increased ability to stay awake in the context of trying to remain awake is reflected in a prolonged sleep latency. These measurements of sleep latency at regular intervals across the day are averaged to calculate the mean sleep latency. The MWT will be performed as per the 2021 guidance of the American Academy of Sleep Medicine.', 'timeFrame': 'At Day 9'}, {'measure': 'MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 13', 'description': 'Sleep latency is defined as the amount of time a person takes to fall asleep. The MWT is an objective assessment of EDS which consists of measurement tests. A participant undergoes four 40-minute wake trials, where an increased ability to stay awake in the context of trying to remain awake is reflected in a prolonged sleep latency. These measurements of sleep latency at regular intervals across the day are averaged to calculate the mean sleep latency. The MWT will be performed as per the 2021 guidance of the American Academy of Sleep Medicine.', 'timeFrame': 'At Day 13'}, {'measure': 'MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 17', 'description': 'Sleep latency is defined as the amount of time a person takes to fall asleep. The MWT is an objective assessment of EDS which consists of measurement tests. A participant undergoes four 40-minute wake trials, where an increased ability to stay awake in the context of trying to remain awake is reflected in a prolonged sleep latency. These measurements of sleep latency at regular intervals across the day are averaged to calculate the mean sleep latency. The MWT will be performed as per the 2021 guidance of the American Academy of Sleep Medicine.', 'timeFrame': 'At Day 17'}]","[{'measure': 'MSL as Assessed by the 4 MWTs for E2086 Versus Active Comparator', 'description': 'Sleep latency is defined as the amount of time a person takes to fall asleep. The MWT is an objective assessment of EDS which consists of measurement tests. A participant undergoes four 40-minute wake trials, where an increased ability to stay awake in the context of trying to remain awake is reflected in a prolonged sleep latency. These measurements of sleep latency at regular intervals across the day are averaged to calculate the mean sleep latency. The MWT will be performed as per the 2021 guidance of the American Academy of Sleep Medicine.', 'timeFrame': 'Days 1, 5, 9, 13 and 17'}, {'measure': 'Karolinska Sleepiness Scale (KSS) Score for E2086 Versus Active Comparator', 'description': ""The KSS is a subjective measure of an individual's level of sleepiness during the last 10 minutes, as assessed at a particular time of day. The KSS is rated on a 10-point scale, from 1 = extremely alert, to 10 = extremely sleepy, falls asleep all the time. Higher score indicates more sleepiness."", 'timeFrame': 'Day 1 up to Day 18'}, {'measure': 'KSS Score for E2086 Versus Placebo', 'description': ""The KSS is a subjective measure of an individual's level of sleepiness during the last 10 minutes, as assessed at a particular time of day. The KSS is rated on a 10-point scale, from 1 = extremely alert, to 10 = extremely sleepy, falls asleep all the time. Higher score indicates more sleepiness."", 'timeFrame': 'Day 1 up to Day 18'}, {'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'timeFrame': 'From first dose of study drug up to Day 20'}, {'measure': 'Number of Participants With Markedly Abnormal Clinical Laboratory Values', 'description': 'Clinical laboratory will include hematology, chemistry, and urinalysis.', 'timeFrame': 'Baseline up to Day 20'}, {'measure': 'Number of Participants With Markedly Abnormal Vital Sign Values', 'description': 'Vital sign parameters will include systolic and diastolic blood pressure, pulse, respiratory rate, body temperature.', 'timeFrame': 'Baseline up to Day 20'}, {'measure': 'Number of Participants With Markedly Abnormal Electrocardiogram (ECGs) Findings', 'timeFrame': 'Baseline up to Day 20'}, {'measure': 'Number of Participants With Markedly Abnormal Electroencephalogram (EEGs) Findings', 'timeFrame': 'Baseline up to Day 20'}, {'measure': 'Number of Participants With Suicidality as Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS)', 'description': 'Suicidality will be assessed using the C-SSRS. The C-SSRS assesses an individual\'s degree of suicidality, including suicidal ideation and suicidal behavior. The C-SSRS is an interview-based rating scale to systematically assess any suicidality, suicidal behavior, or suicidal ideation. Any suicidality is emergence of any suicidal ideation or suicidal behavior. Any suicidal behavior is indicated when response is ""yes"" for any these questions- actual attempt to suicide, engaged in non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts. Any suicidal ideation is indicated when response is ""yes"" for any of these questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide.', 'timeFrame': 'Baseline up to Day 20'}, {'measure': 'Cmax: Maximum Observed Plasma Concentration of E2086 and its Metabolite M1', 'timeFrame': 'Days 1, 5, 9, 13 and 17: 0-24 hours post-dose'}, {'measure': 'Tmax: Time to Reach Cmax of E2086 and its Metabolite M1', 'timeFrame': 'Days 1, 5, 9, 13 and 17: 0-24 hours post-dose'}, {'measure': 'AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to Time of Last Quantifiable Concentration of E2086 and its Metabolite M1', 'timeFrame': 'Days 1, 5, 9, 13 and 17: 0-24 hours post-dose'}, {'measure': 'AUC(0-inf): Area Under the Plasma Concentration-time Curve From Zero Time Extrapolated to Infinite of E2086 and its Metabolite M1', 'timeFrame': 'Days 1, 5, 9, 13 and 17: 0-24 hours post-dose'}, {'measure': 't½: Terminal Phase Half-life of E2086 and its Metabolite M1', 'timeFrame': 'Days 1, 5, 9, 13 and 17: 0-24 hours post-dose'}, {'measure': 'MRp: Metabolite Ratio of AUC(0-inf)', 'description': 'MRp will be calculated as ratio of plasma AUC(0-inf) of metabolite to parent following molar correction.', 'timeFrame': 'Days 1, 5, 9, 13 and 17: 0-24 hours post-dose'}]",20,18 Years,,ALL,False,Eisai Inc.,INDUSTRY,0,22.0,ACTUAL,2025-09-01T16:18:22.210385,v2_robust,True,True,True,False,True,
NCT01902004,Brain Aging and Treatment Response in Geriatric Depression,Treatment of Geriatric Depression With Mild Cognitive Impairment: A Double-blind Placebo-Controlled Trial of Namenda (Memantine) Augmentation of Lexapro (Escitalopram) in Depressed Patients at Least 60 Years of Age,Escitalopram,"['Namenda', 'Memantine', 'inactive substance', 'Placebo', 'Lexapro', 'Escitalopram']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Mild Cognitive Impairment (MCI),"['Mild Cognitive Impairment (MCI)', 'Depression']","['Major Depression', 'Geriatric Major Depression', 'Executive Cognitive Dysfunction', 'Mild Cognitive Impairment', 'Older Adults', 'Geriatric', 'Executive Cognitive Impairment', 'Quality of Life', 'Disability', 'Comorbidity', 'Medical Burden', 'Safety', 'Candidate Genes']",COMPLETED,,2013-10,2019-01-23,"[{'measure': 'Change in Hamilton Depression Rating Scale', 'description': 'Clinician administered scale measures severity of depressive symptoms. This measure includes 24 items. Response options vary item to item and include the following ranges: \\[0-2\\], \\[0-3\\], and \\[0-4\\]. A score of 0 suggests absence of symptoms and/or difficulties and higher scores represent more severe difficulties. Possible overall score range \\[0-74\\], higher scores representing more severe difficulties.', 'timeFrame': 'Measured at 3 months; 6 months and 12 months'}]","[{'measure': 'Change in Montgomery Asberg Depression Rating Scale', 'description': 'Clinician administered item scale measures severity of depressive symptoms. The 10 items are measured on a 7-point scale ranging from 0 to 6; creating a total range of 0-60. A score of 0 suggests absence of symptoms and higher scores represent greater severity of depression.Severity gradations for the MADRS have been proposed (9-17 = mild, 18-34 = moderate, and ≥ 35 = severe). Treatment remission is defined as an endpoint total score ≤ 10.', 'timeFrame': 'Measured at 3 months; 6 months and 12 months'}, {'measure': 'Change in Cognitive Domain Scores', 'description': 'Neuropsychological battery of tests which included the following domains: learning, delayed recall, and executive functioning. Raw scores were transformed to z-scores for each test score of interest for each participant, and then averaged. These z-scores were averaged within each neuropsychological domain to produce composite scores and then averaged over all tests to calculate a global performance score. Higher scores are indicative of better performance.', 'timeFrame': 'Measured at 6 months and 12 months'}]",3,60 Years,,ALL,False,"University of California, Los Angeles",OTHER,1,115.0,ACTUAL,2025-09-01T16:18:22.210444,v2_robust,True,True,True,False,False,
NCT00015704,Effect of Interleukin-2 on HIV Treatment Interruption,"An Open-Label, Pilot Study Utilizing CD4 T-Cell Counts Lower Than 350 Cells/mm3 as the Threshold for Restarting Therapy With Potent Antiretroviral Therapy With or Without Interleukin-2 to Determine the Effect of Pulse Therapy on the Characteristics of Treatment Interruptions",Aldesleukin,['Aldesleukin'],1,INTERVENTIONAL,['NA'],,,HIV Infections,['HIV Infections'],"['Treatment Experienced', 'Treatment Interruption', 'Drug Administration Schedule', 'CD4 Lymphocyte Count', 'Anti-HIV Agents', 'Tetanus Toxoid', 'Aldesleukin', 'Diphtheria Toxoid']",COMPLETED,,,2004-11,[],[],0,18 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,80.0,,2025-09-01T16:18:22.210473,v2_robust,True,True,True,False,False,
NCT04629404,A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of Multiple Intramuscular Doses of LY03003 in Patients With Early Parkinson's Disease",LY03003,"['LY03003', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Parkinson Disease,['Parkinson Disease'],"['parkinson disease', 'LY03003']",COMPLETED,,2018-11-05,2019-03-14,"[{'measure': 'Pharmacodynamic Measures', 'description': 'Change from baseline in (II + III) total score, Part II, Part III scores of the UPDRS', 'timeFrame': 'From titration to dose-maintenance at day 50'}, {'measure': 'Safety Measures', 'description': 'Blood Pressure', 'timeFrame': 'From titration to dose-maintenance at day 50'}]","[{'measure': 'Cmax,ss', 'description': 'Peak concentration', 'timeFrame': 'From titration to dose-maintenance at day 50'}]",3,30 Years,,ALL,False,Luye Pharma Group Ltd.,INDUSTRY,0,32.0,ACTUAL,2025-09-01T16:18:22.210547,v2_robust,True,True,True,False,True,
NCT05170204,"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)","A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer",Alectinib,"['Entrectinib', 'Durvalumab', 'Alectinib']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-Small Cell Lung Cancer,['Non-Small Cell Lung Cancer'],[],RECRUITING,,2022-11-01,2033-09-01,"[{'measure': 'Progression-free survival (PFS)', 'timeFrame': 'From randomization to the first documented disease progression as determined by blinded independent central review (BICR) per Response Evaluation Criterial in Solid Tumors (RECIST) v1.1, or death from any cause, whichever occurs first (up to 3 years)'}]","[{'measure': 'Time to central nervous system (CNS) progression', 'timeFrame': 'From randomization to the first occurrence of disease progression in the CNS as determined by BICR per RECIST v1.1 (up to 3 years)'}, {'measure': 'Distant metastasis-free survival (DMFS)', 'timeFrame': 'From randomization to the first occurrence of distant metastasis or death (whichever occurs first) as determined by BICR per RECIST v1.1 (up to 3 years)'}, {'measure': 'Objective response rate (ORR), defined as the percentage of participants with measurable disease who attain a complete response (CR) or partial response (PR) as determined by the investigator per RECIST v1.1', 'timeFrame': 'Up to 3 years'}, {'measure': 'PFS', 'timeFrame': 'From randomization to the first documented disease progression as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurs first (up to 3 years)'}, {'measure': 'Duration of response (DOR)', 'timeFrame': 'From the first documented CR or PR to the first documented disease progression or death (whichever occurs first) as determined by the investigator per RECIST v1.1 (up to 3 years)'}, {'measure': 'ORR, defined as the percentage of participants with measurable disease who attain a CR or PR as determined by BICR per RECIST v1.1', 'timeFrame': 'Up to 3 years'}, {'measure': 'DOR', 'timeFrame': 'From the first documented CR or PR to the first documented disease progression or death (whichever occurs first) as determined by BICR per RECIST v1.1 (up to 3 years)'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'From randomization to death from any cause (up to 5 years)'}, {'measure': 'Time to CNS progression', 'timeFrame': 'From randomization to the first occurrence of disease progression in the CNS as determined by the investigator per RECIST v1.1 (up to 3 years)'}, {'measure': 'Time-to-confirmed deterioration (TTCD)', 'timeFrame': 'From randomization to the first deterioration of >/= 10 points that is either maintained for two consecutive assessments or followed by death from any cause within 3 weeks (up to 3 years)'}, {'measure': 'Proportion of participants who have maintained or improved baseline health as measured by the European Organisation for the Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 physical functioning and role functioning scales', 'timeFrame': '5, 11, and 17 months'}, {'measure': 'Proportion of participants who have maintained or improved from their baseline health in cough, chest pain, and dyspnea symptoms as measured using the EORTC QLQ-LC13', 'timeFrame': '5, 11, and 17 months'}, {'measure': 'Percentage of participants with adverse events (AEs)', 'timeFrame': 'Up to 3 years'}]",14,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,71.0,ESTIMATED,2025-09-01T16:18:22.210556,v2_robust,True,True,False,False,True,
NCT05130684,Neo-NTP-CRT for Locally Advanced ESCC,Neoadjuvant Nivolumab Plus Paclitaxel/ Cisplatin- Chemo- Radiotherapy (Neo-NTP-CRT) Followed by Esophagectomy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC),Nivolumab,"['radiation', 'Nivolumab', 'paclitaxel', 'cisplatin']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Locally Advanced Esophageal Squamous Cell Carcinoma,['Locally Advanced Esophageal Squamous Cell Carcinoma'],[],UNKNOWN,,2021-02-22,2024-03-01,"[{'measure': 'change in treatment related death', 'description': 'no increase of treatment-related death within 30 days after esophagectomy', 'timeFrame': '30 days'}, {'measure': 'rate of completion of protocol treatment', 'description': 'successful completion of preoperative therapy and processing to surgery without any extended treatment-related delay, which is defined as \\> 19 weeks after the first dose of nivolumab (d-14) in neo-NTP-CRT (19 weeks include 15 weeks of protocol treatment plus 4 weeks of flexibility.).', 'timeFrame': '5 months'}]",[],2,20 Years,75 Years,ALL,False,National Taiwan University Hospital,OTHER,0,43.0,ESTIMATED,2025-09-01T16:18:22.210588,v2_robust,True,True,False,False,False,
NCT02762084,"Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients","Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients",Patidegib,"['Study drug', 'Placebo', 'Patidegib', 'Vehicle gel']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Basal Cell Nevus Syndrome,['Basal Cell Nevus Syndrome'],"['Gorlin Syndrome', 'Basal Cell', 'Nevus Syndrome', 'BCNS', 'nevoid basal cell carcinoma syndrome', 'Basal cell carcinoma', 'Hedgehog', 'Surgically Eligible Basal Cell Carcinomas']",COMPLETED,,2016-06-06,2017-04-24,"[{'measure': 'Clinical Efficacy: Percent Change in Tumor Size of Treatment-targeted Surgically Eligible Basal Cell Carcinomas (SEBs) From Baseline', 'description': 'SEBs were defined as clinically diagnosed basal cell carcinoma (BCC) 5 millimeters (mm) or greater in diameter on the face, excluding the nose and periorbital skin, and 9 mm or greater at sites other than the face. The percent change in greatest diameters of treatment-targeted surgically eligible basal cell carcinomas (SEBs) from Baseline to Week 26 was calculated as follows: (sum \\[Baseline\\] - sum \\[Week 26\\] / sum \\[Baseline\\] \\* 100), where sum = the greatest diameters of Baseline treatment-targeted SEBs and positive numbers represent decrease in tumor size and negative numbers to represent increase in tumor size. Missing values were imputed using Last-Observation Carried Forward (LOCF).', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Molecular Efficacy: Percent Change in the Hedgehog (HH) Signaling Pathway Target Gene Glioma-associated Oncogene Homolog 1 (GLI1) Messenger Ribonucleic Acid (mRNA) Levels From Baseline', 'description': 'SEBs were defined as clinically diagnosed BCC 5 mm or greater in diameter on the face, excluding the nose and periorbital skin, and 9-mm or greater at sites other than the face. A single baseline SEB designated as a treatment targeted tumor at Baseline was biopsied first at Baseline and again following 6 weeks of treatment. This was used to assess percent change in GLI1 mRNA levels as follows: (Baseline - Week 6) / Baseline \\* 100, where positive numbers to represent decrease in GL1 mRNA level and negative numbers to represent increase in GL1 mRNA level. Any missing values were not imputed; all available data is summarized.', 'timeFrame': 'Baseline, Week 6'}, {'measure': 'Safety and Tolerability Assessment of Treatment With Patidegib Gel: Number of Participants With a Treatment-emergent Adverse Event Causally Related to Study Drug', 'description': 'All serious adverse events (SAEs) and all other non-serious adverse events (AEs) regardless of causality are located in the Reported AE Module. AEs considered as related where categorized by the Investigator as either definitely related, probably related, or possibly related. Treatment-emergent AEs are those with an onset after use of study drug.', 'timeFrame': 'Baseline through Week 26'}, {'measure': 'Safety and Tolerability Assessment of Treatment With Patidegib Gel: Number of Participants With Treatment-emergent Administrative Site Skin Condition AEs Causally Related to Study Drug', 'description': 'All SAEs and all other non-serious AEs, regardless of causality, are located in the Reported AE Module. The number of participants reporting administrative-site, skin condition treatment-emergent AEs considered related to study drug by the Investigator are presented below. Treatment-emergent AEs are those with an onset after use of study drug.', 'timeFrame': 'Baseline through Week 26'}]","[{'measure': 'The Number of Participants Reporting New SEBs on the Face From Baseline for the Combined Patidegib Treatment Groups', 'description': 'Facial SEBs were defined as clinically diagnosed BCC 5 mm or greater in diameter on the face, excluding the nose and periorbital skin. A new facial SEB was defined as an SEB first noted on the face after Week 2 that developed at a site where there was no visible BCC of any size at Baseline or Week 2. New facial SEBs were investigated for participants on vehicle gel versus participants on patidegib 2% and 4% gel. Missing values were imputed using LOCF.', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'The Mean Number of New SEBs on the Face for the Combined Patidegib Treatment Groups', 'description': 'Facial SEBs were defined as clinically diagnosed BCC 5 mm or greater in diameter on the face, excluding the nose and periorbital skin. A new facial SEB was defined as an SEB first noted on the face after Week 2 that developed at a site where there was no visible BCC of any size at Baseline or Week 2. New facial SEBs were investigated for participants on vehicle gel versus participants on patidegib 2% and 4% gel. Missing values were imputed using LOCF. The mean number of new SEBs (number per participant) are presented. No measure of dispersion/precision was calculated.', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'The Mean Number of New SEBs on the Face for the Combined Patidegib Treatment Groups by Tumor Population', 'description': 'Facial SEBs were defined as clinically diagnosed BCC 5 mm or greater in diameter on the face, excluding the nose and periorbital skin. A new facial SEB was defined as an SEB first noted on the face after Week 2 that developed at a site where there was no visible BCC of any size at Baseline or Week 2. New facial SEBs were investigated for participants on vehicle gel versus participants on patidegib 2% and 4% gel. Missing values were imputed using LOCF. The mean number of new SEBs (number per participant) are presented. No measure of dispersion/precision was calculated.', 'timeFrame': 'Baseline, Week 26'}, {'measure': 'Percent Change in Baseline Treatment-targeted SEBs Tumor Size From Baseline', 'description': 'SEBs were defined as clinically diagnosed BCC 5 mm or greater in diameter on the face, excluding the nose and periorbital skin, and 9 mm or greater at sites other than the face. The percent change in greatest diameters of Baseline treatment-targeted SEBs from Baseline to Week x (Week 6, 10, 14, 18, or 22) was calculated as follows: (sum \\[Baseline\\] - sum \\[Week x\\] / sum \\[Baseline\\] \\* 100), where sum = the greatest diameters of Baseline treatment-targeted SEBs, and positive numbers to represent decrease in tumor size and negative numbers to represent increase in tumor size. Missing values were imputed using LOCF.', 'timeFrame': 'Baseline and Weeks 6, 10, 14, 18, and 22'}, {'measure': 'Percent Change in Central Facial SEBs From Baseline', 'description': 'Central facial SEBs were defined as those located on the nose or periorbital area (eyelids) which were 3 mm or greater at Baseline. The percent change from Baseline to Week x (Week x = Weeks 6, 10, 14, 18, 22, or 26) in central facial SEBs was calculated as follows: \\[sum (Baseline) - sum (Week x)\\] / \\[sum (Baseline)\\] \\* 100 where sum = the greatest diameters of Baseline treatment-targeted SEBs where positive numbers to represent decrease in tumor size and negative numbers to represent increase in tumor size. Missing values were imputed using LOCF.', 'timeFrame': 'Baseline and Weeks 6, 10, 14, 18, 22, and 26'}, {'measure': 'Proportion of Non-central Facial BCCs Increasing to ≥ 5 mm From Baseline', 'description': 'The proportion of non-central facial BCCs that at Baseline measured a greatest diameter of \\< 5 mm and increased to a diameter of ≥ 5 mm by Week x (Week x = Weeks 6, 10, 14, 18, 22, or 26) were calculated for each participant as follows: (Number of non-central facial BCCs with greatest diameter ≥ 5 mm at Week x) / (Number of non-central facial BCCs with greatest diameter \\< 5 mm at Baseline). Missing values were imputed using LOCF.', 'timeFrame': 'Baseline and Weeks 6, 10, 14, 18, 22, and 26'}, {'measure': 'Proportion of Treatment-Targeted SEBs No Longer Classified as SEBs After 26 Weeks', 'description': 'SEBs were defined as clinically diagnosed BCC 5 mm or greater in diameter on the face, excluding the nose and periorbital skin, and 9 mm or greater at sites other than the face. The proportion of Baseline treatment-targeted SEBs that at the end of 26 weeks of treatment were no longer large enough to be classified as SEBs (that is, the proportion of Baseline treatment targeted SEBs on the face that became \\< 5 mm in greatest diameter and non-facial Baseline treatment targeted SEBs that became \\< 9 mm in greatest diameter) were calculated for each participant as follows:\n\n(Number of Baseline treatment-targeted facial SEBs with greatest diameter \\< 5 mm) + (Baseline treatment targeted non-facial SEBs with greatest diameter \\< 9 mm) / Number of baseline treatment targeted SEBs.\n\nMissing values were imputed using LOCF.', 'timeFrame': 'Baseline and Weeks 6, 10, 14, 18, 22, and 26'}]",11,18 Years,85 Years,ALL,False,"PellePharm, Inc.",INDUSTRY,0,17.0,ACTUAL,2025-09-01T16:18:22.210606,v2_robust,True,True,True,False,True,
NCT05857384,"Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs","A Randomised Four-Period Cross-Over Phase I Study to Assess Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs in Healthy Volunteers",IHL42X,"['IHL-42X', 'Dronabinol 2.5 MG', 'Marinol', 'IHL42X', 'Acetazolamide 250 MG', 'Taro Acetazolamide']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Obstructive Sleep Apnea,['Obstructive Sleep Apnea'],[],COMPLETED,,2023-09-08,2024-07-31,"[{'measure': 'Bioavailability of IHL-42X', 'description': 'Assess the proportion of IHL-42X that is taken up and enters the circulation post dose.', 'timeFrame': '28 days'}, {'measure': 'Bioequivalence of IHL-42X', 'description': 'Compare the proportion of IHL-42X taken up and enters the circulation to the reference listed drugs for dronabinol and acetazolamide. It will be determined whereby 90% confidence interval for the ratio of averages of measures Cmax and AUC0-inf for IHL-42X and the reference listed drug.', 'timeFrame': '28 days'}, {'measure': 'Effect of food on IHL-42X - maximum observed drug concentration', 'description': 'Assess the effect of food on the uptake and absorption of IHL-42X by measuring Cmax (Maximum observed drug concentration)', 'timeFrame': '7 days'}, {'measure': 'Effect of food on IHL-42X - time of the maximum drug concentration', 'description': 'Assess the effect of food on the uptake and absorption of IHL-42X by measuring Tmax (time of the maximum drug concentration)', 'timeFrame': '7 days'}, {'measure': 'Effect of food on IHL-42X - area under the drug concentration time curve from time zero to time of last measurable concentration', 'description': 'Assess the effect of food on the uptake and absorption of IHL-42X by measuring AUC0-last (Area under the drug concentration-time curve, from time zero to time of last measurable concentration)', 'timeFrame': '7 days'}, {'measure': 'Effect of food on IHL-42X - area under the drug concentration time curve from time zero to infinity', 'description': 'Assess the effect of food on the uptake and absorption of IHL-42X by measuring AUC0-inf (Area under the drug concentration-time curve from time zero to infinity)', 'timeFrame': '7 days'}, {'measure': 'Effect of food on IHL-42X - area under the drug concentration time curve from time zero to 12 hours', 'description': 'Assess the effect of food on the uptake and absorption of IHL-42X by measuring AUC0-12h (Area under the drug concentration-time curve from time zero to 12 hours)', 'timeFrame': '7 days'}, {'measure': 'Effect of food on IHL-42X - area under the drug concentration time curve from time zero to 24 hours', 'description': 'Assess the effect of food on the uptake and absorption of IHL-42X by measuring AUC0-24h (Area under the drug concentration-time curve from time zero to 24 hours)', 'timeFrame': '7 days'}, {'measure': 'Effect of food on IHL-42X - the elimination half-life', 'description': 'Assess the effect of food on the uptake and absorption of IHL-42X by measuring t1/2 (the elimination half-life)', 'timeFrame': '7 days'}, {'measure': 'Effect of food on IHL-42X - terminal elimination rate constant', 'description': 'Assess the effect of food on the uptake and absorption of IHL-42X by measuring kel (Terminal elimination rate constant)', 'timeFrame': '7 days'}, {'measure': 'Effect of food on IHL-42X - apparent total body clearance', 'description': 'Assess the effect of food on the uptake and absorption of IHL-42X by measuring CL/F (Apparent total body clearance)', 'timeFrame': '7 days'}, {'measure': 'Effect of food on IHL-42X - apparent volume of distribution', 'description': 'Assess the effect of food on the uptake and absorption of IHL-42X by measuring Vz/F (Apparent volume of distribution)', 'timeFrame': '7 days'}]","[{'measure': 'Safety and tolerability', 'description': 'Assess the number of treatment emergent adverse events (TEAEs) and serious treatment emergent adverse events associated with the dosing of IHL-42X in comparison to the reference listed drugs, dronabinol and acetazolamide.', 'timeFrame': '28 days'}]",13,18 Years,65 Years,ALL,True,Incannex Healthcare Ltd,INDUSTRY,0,125.0,ACTUAL,2025-09-01T16:18:22.210744,v2_robust,True,True,True,False,True,
NCT03322384,"UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma","UCDCC#271: A Phase I/II Trial of Epacadostat (Indolamine 2,3 Dioxygenase Inhibitor), Intralesional SD101 (Toll-receptor 9 Agonist), and Radiotherapy in Patients With Advanced Solid Tumors and Lymphoma",epacadostat,"['SD-101', 'epacadostat']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Advanced Solid Tumors,"['Advanced Solid Tumors', 'Lymphoma']",[],COMPLETED,,2018-01-17,2020-04-08,"[{'measure': 'Maximum Tolerated Dose (MTD)', 'description': 'To determine the maximum tolerated dose (MTD) of epacadostat that can be given with radiotherapy and intralesional SD-101 immunotherapy for the phase I portion of the study. The MTD will be determined using a standard 3+3 design. Patients will be monitored weekly during a 30-day dose-limiting toxicity (DLT) period. MTD can be defined as The maximum dose at which \\<2 of 6 patients experienced a DLT.', 'timeFrame': 'Up to 30 days of treatment'}, {'measure': 'Incidence of Related Adverse Events [Safety and Tolerability]', 'description': 'To characterize the safety profile of this regimen using CTCAE v4.03 (Common Toxicity Criteria for Adverse Events version 4.03) in the phase II expansion . The expansion phase (phase II) will be conducted using the MTD defined as the highest dose at which no more than one of six patients develops a DLT or Dose Level 1 if the MTD is not reached. Patients will be monitored every week during the first 30 days of study and then monthly thereafter up to a period of 1 year.', 'timeFrame': 'Through study completion, an average of one year'}]","[{'measure': 'Abscopal Response Rate', 'description': 'Abscopal Response Rate (ARR) is defined as objective response rate (the percentage of patient that achieve a partial or complete response) at unirradiated sites using irRECIST criteria using imaging obtained every 60 days during the 1 year study period.', 'timeFrame': 'Through study completion, an average of one year'}]",3,18 Years,,ALL,False,"University of California, Davis",OTHER,0,20.0,ACTUAL,2025-09-01T16:18:22.210775,v2_robust,True,True,True,False,True,
NCT06429033,Purified Exosome Product (PEP) Injected Into the Hypodermis,A Phase 1 Controlled Study to Evaluate the Safety and Tolerability of Intradermal Administered Purified Exosome Product (PEP) in Healthy Adults,PEP (Purified Exosome Product),['PEP (Purified Exosome Product)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Safety,['Safety'],[],RECRUITING,,2025-03-17,2026-01-31,"[{'measure': 'Safety: Dose limiting toxicities', 'description': 'The number of subjects with acute dose-limiting toxicities', 'timeFrame': '14-days'}, {'measure': 'Maximum Tolerated Dose', 'description': 'The maximum tolerated dose determined by testing increasing doses of PEP', 'timeFrame': '14-days'}, {'measure': 'Incidence of withdrawls from the study due to treatment-emergent adverse events', 'description': 'The number of subjects withdrawn from the study due to treatment-emergent adverse events', 'timeFrame': '30 days'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events', 'description': 'The number of subjects experiencing treatment emergent adverse events', 'timeFrame': '30 days'}, {'measure': 'Common Treatment Responses', 'description': 'The number of subjects experiencing injection site reactions as noted in the patient diary', 'timeFrame': '14-days'}, {'measure': 'Laboratory Changes', 'description': 'The number of subjects with changes and shifts from baseline in laboratory measurements', 'timeFrame': '30 days'}, {'measure': 'Application Site Reactions', 'description': 'The number of subjects experiencing changes from baseline in treatment application site reactions', 'timeFrame': '14 days'}]",[],7,18 Years,65 Years,ALL,True,Clinical Testing of Beverly Hills,OTHER,0,9.0,ESTIMATED,2025-09-01T16:18:22.211005,v2_robust,True,True,False,False,True,
NCT05344833,Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma,Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma,Isatuximab,"['Lenalidomide', 'Isatuximab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma,['Multiple Myeloma'],[],RECRUITING,,2023-01-05,2030-12,"[{'measure': 'Number of participants that have MRD-negative CR rate, defined as 10-6', 'description': 'Evaluate the number of participants that have MRD-negative at 1 year that were MRD-positive multiple myeloma (MM) treated with isatuximab and lenalidomide based maintenance after ASCT', 'timeFrame': '1 year'}]","[{'measure': 'Observed length of time of progressive free survival (PFS)', 'description': 'Number of days participants remain PFS', 'timeFrame': '3 years'}, {'measure': 'Observed length of time of overall survival (OS)', 'description': 'Number of days participants remain OS', 'timeFrame': '3 years'}, {'measure': 'Number of participants that achieve a deeper MRD-negative CR rate, defined as 10-6', 'description': 'Evaluate the number of participants that achieve a deeper MRD-negative at 1 year that were MRD-positive in MM treated with isatuximab and lenalidomide based maintenance after ASCT', 'timeFrame': '1 year'}, {'measure': 'Number of participants that convert from MRD-positive to MRD-negative disease status in MM patients', 'description': 'Evaluate number of participants that convert from MRD-positive to MRD-negative disease status in MM patients receiving isatuximab and lenalidomide based maintenance', 'timeFrame': '3 years'}, {'measure': 'Number of participants that have an International Myeloma Working Group (IMWG) defined response rate of MM patients receiving isatuximab and lenalidomide based maintenance', 'description': 'Evaluate the number of participants that have an IMWG defined response rate', 'timeFrame': '3 years'}, {'measure': 'Number of participants that have MRD-negative CR rates of MM patients receiving isatuximab and lenalidomide based maintenance', 'description': 'Evaluate the number of participants that have MRD-negative CR rates', 'timeFrame': '3 years'}, {'measure': 'Number of occurrences of treatment-related adverse events (AE) in MM patients receiving isatuximab and lenalidomide based maintenance', 'description': 'Evaluate the number of occurrences of treatment-related AES', 'timeFrame': '3 years'}, {'measure': 'Evaluate health related quality of life in MM patients receiving isatuximab and lenalidomide based maintenance', 'description': ""Complete European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-C30 questionnaire at 3 years. The higher the score the worse the subject's health is and the lower the score the better the subject's health is"", 'timeFrame': '3 years'}, {'measure': 'Evaluate health related quality of life in MM patients receiving isatuximab and lenalidomide based maintenance', 'description': ""Complete European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Multiple Myeloma Module at 3 years. The higher the score the worse the subject's health is and the lower the score the better the subject's health is and the lower the score the better the subject's health is"", 'timeFrame': '3 years'}, {'measure': 'Evaluate health related quality of life in MM patients receiving isatuximab and lenalidomide based maintenance', 'description': ""Complete European Quality of Life Five Dimensions Questionnaire-5-level at 3 years. The higher the score the worse the subject's health is and the lower the score the better the subject's health is"", 'timeFrame': '3 years'}]",11,18 Years,,ALL,False,University of Illinois at Chicago,OTHER,1,50.0,ESTIMATED,2025-09-01T16:18:22.211012,v2_robust,True,True,False,False,True,
NCT02553733,Effect of Beetroot Juice on Coronary Blood Flow and Walking Performance in PAD,Effects of Dietary Nitrate Supplementation on Coronary Blood Flow and Walking Performance in Peripheral Arterial Disease,Beetroot juice,"['Beet-It organic placebo', 'Beet-It Organic Shot', 'Beetroot juice', 'Beetroot juice placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Peripheral Arterial Disease,['Peripheral Arterial Disease'],"['Dietary nitrate supplementation', 'Beetroot juice']",UNKNOWN,,2015-12,2024-12,"[{'measure': 'Exercise performance', 'description': 'Exercise capacity will be assessed using a graded treadmill walking test to peak exertion with expired gas analysis and determination of peak oxygen uptake, calf muscle oxygenation, blood pressure, claudication onset time, and peak walking time.', 'timeFrame': '5 to 7 days after initiating daily ingestion of beetroot juice'}]","[{'measure': 'Coronary vascular function', 'description': 'Coronary artery (transthoracic ultrasound) blood flow responses to plantar flexion and handgrip exercise.', 'timeFrame': '4 days after initiating daily ingestion of beetroot juice'}, {'measure': 'Leg vascular function', 'description': 'Popliteal artery and near infrared spectroscopy (NIRS) responses to plantar flexion and handgrip exercise.', 'timeFrame': '4 days after initiating daily ingestion of beetroot juice'}]",3,21 Years,85 Years,ALL,False,"David N. Proctor, PhD",OTHER,2,12.0,ESTIMATED,2025-09-01T16:18:22.211035,v2_robust,True,True,False,False,False,
NCT00673933,Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris,"A Blinded, Randomized, Intra-individual, Vehicle-controlled and Multi-centre Study of Photodynamic Therapy With MAL Cream in Patients With Skin Type V or VI With Acne Vulgaris",Methyl aminolevulinate (MAL) PDT,['Methyl aminolevulinate (MAL) PDT'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Acne Vulgaris,['Acne Vulgaris'],[],COMPLETED,,2008-05,2008-12,"[{'measure': 'Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment', 'timeFrame': '4 weeks after last treatment, 6 weeks after baseline'}]","[{'measure': 'Erythema Score (Mild and Moderate)Immediately After First PDT', 'description': 'Patients with mild or moderate erythema after first treatment at baseline.', 'timeFrame': 'Immediately after treatment at baseline'}, {'measure': 'Change in Inflammatory Lesion Counts From Baseline', 'timeFrame': '4 weeks after last treatment, 6 weeks after baseline'}, {'measure': 'Change in Noninflammatory Lesion Counts From Baseline', 'timeFrame': '4 weeks after last treatment, 6 weeks after baseline'}, {'measure': 'Erythema Score (Mild and Moderate)Immediately After Second Treatment', 'description': 'Patients with mild or moderate erythema after second treatment.', 'timeFrame': 'Immediately after second treatment, 2 weeks after baseline'}, {'measure': 'Erythema Score (Mild and Moderate)1 Day After First Treatment', 'description': 'Patients with mild or moderate erythema 1 day after first treatment.', 'timeFrame': '1 day after 1st treatment and baseline'}]",6,15 Years,40 Years,ALL,False,Photocure,INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:22.211129,v2_robust,True,True,True,False,False,
NCT00536952,Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy,A Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation and Chemotherapy,Pulmozyme,"['dornase alfa inhalation solution', 'Placebo', 'Pulmozyme']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Head and Neck Cancer,['Head and Neck Cancer'],"['recurrent squamous cell carcinoma of the hypopharynx', 'stage III squamous cell carcinoma of the hypopharynx', 'stage IV squamous cell carcinoma of the hypopharynx', 'stage III squamous cell carcinoma of the larynx', 'stage IV squamous cell carcinoma of the larynx', 'recurrent squamous cell carcinoma of the larynx', 'recurrent squamous cell carcinoma of the lip and oral cavity', 'stage III squamous cell carcinoma of the lip and oral cavity', 'stage IV squamous cell carcinoma of the lip and oral cavity', 'recurrent squamous cell carcinoma of the nasopharynx', 'stage III squamous cell carcinoma of the nasopharynx', 'stage IV squamous cell carcinoma of the nasopharynx', 'recurrent squamous cell carcinoma of the oropharynx', 'stage III squamous cell carcinoma of the oropharynx', 'stage IV squamous cell carcinoma of the oropharynx']",UNKNOWN,,2008-02,2016-12,"[{'measure': 'Treatment-related symptoms as assessed daily by the Head and Neck Symptom Inventory Scale (MD Anderson Symptom Inventory)', 'timeFrame': '5 times per week during study treatment and once per month up to 3 months post-treatment'}, {'measure': 'Quality of life as assessed weekly by the Functional Assessment of Cancer Therapy - Head & Neck Neck questionnaire', 'timeFrame': 'Weekly during study treatment and once per month up to 3 months post-treatment.'}, {'measure': 'Patient comfort and/or disturbance during radiotherapy treatment as assessed daily by Radiation Treatment Disturbance Disturbance Measures questionnaire', 'timeFrame': 'Daily during radiation treatment'}]","[{'measure': 'Reduction in amount of thick oropharyngeal secretions associated with cancer therapy.', 'timeFrame': 'At baseline, prior to radiation and study treatment, and after radiation.'}, {'measure': 'Incidence of mucositis, infections, and aspiration pneumonia', 'timeFrame': 'Weekly during study treatment.'}]",5,18 Years,,ALL,False,Northwestern University,OTHER,1,36.0,ESTIMATED,2025-09-01T16:18:22.211275,v2_robust,True,True,False,False,False,
NCT01017952,A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),HZC102970: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD),FF/GW642444 Inhalation Powder,"['GW642444 Inhalation Powder', 'FF/GW642444 Inhalation Powder']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Pulmonary Disease, Chronic Obstructive","['Pulmonary Disease, Chronic Obstructive']","['Safety', 'COPD', 'FEV1', 'Efficacy']",COMPLETED,,2009-09-25,2011-10-17,"[{'measure': 'Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean', 'description': 'The annual rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations during the treatment (trt) period (per participant \\[par.\\] per year) was assessed. An exacerbation of COPD, is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence \\[color\\]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. The COPD exacerbation was categorized as mild, moderate and severe by the investigator. Mild: worsening symptoms of COPD that were self-managed by the par. without the use of oral corticosteroids or antibiotics; Moderate: worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics; Severe: worsening symptoms of COPD that required treatment with in-patient hospitalization.', 'timeFrame': 'From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal'}]","[{'measure': 'Time to First Occurrence of Moderate or Severe COPD Exacerbation', 'description': 'Time to first occurrence analyzed by using a Cox proportional hazards model with covariates of treatment, smoking status at screening (stratum), baseline disease severity (pre-dose Day 1 % predicted FEV1) and centre grouping. An exacerbation of COPD is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence \\[color\\]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. A moderate exacerbation is defined as worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics. A severe exacerbation is defined as worsening symptoms of COPD that required treatment with in-patient hospitalization. The number of participants with a moderate or severe COPD exacerbation while on treatment are presented.', 'timeFrame': 'From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal'}, {'measure': 'Annual Rate of Exacerbations Requiring Systemic/Oral Corticosteroids Expressed as Least Square Mean', 'description': 'The annual rate of COPD exacerbations during the treatment period (per participant per year) that required systemic/oral corticosteroids was assessed. An exacerbation of COPD is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence \\[color\\]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptom (sore throat, cold, fever without other cause, increased cough, increased wheeze) for at least two consecutive days. The COPD exacerbation was categorized as mild, moderate, and severe by the investigator. Mild: worsening symptoms of COPD that were self-managed by the participant. Mild exacerbations were not associated with the use of oral corticosteroids or antibiotics. Moderate: worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics. Severe: worsening symptoms of COPD that required treatment with in-patient hospitalization.', 'timeFrame': 'From the start of the double blind study medication until Visit 11 (Week 52)/Early Withdrawal'}, {'measure': 'Change From Baseline in Trough FEV1 at Week 52 (Visit 11)', 'description': 'Pulmonary function was measured by forced expiratory volume in one second (FEV1). Trough FEV1 was defined as the 24-hour post-dose FEV1 assessment, which was obtained at each visit. Analysis performed using a repeated measures model with covariates of treatment, smoking status at Screening (stratum), baseline (pre-dose Day 1), centre grouping, Week, Week by Baseline, and Week by treatment interactions.', 'timeFrame': 'Baseline to Visit 11 (Week 52)/Early Withdrawal'}]",4,40 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,1635.0,ACTUAL,2025-09-01T16:18:22.211291,v2_robust,True,True,True,False,False,
NCT00007852,Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma,A Phase II Trial of Rituxan and BEAM High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Transplant for Lymphoma,carmustine,"['BCNU', 'melphalan', 'cytarabine', 'carmustine', 'etoposide', 'BEAM chemotherapy regimen']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Lymphoma,['Lymphoma'],"['recurrent grade 1 follicular lymphoma', 'recurrent grade 2 follicular lymphoma', 'recurrent grade 3 follicular lymphoma', 'recurrent adult diffuse small cleaved cell lymphoma', 'recurrent adult diffuse mixed cell lymphoma', 'recurrent adult diffuse large cell lymphoma', 'recurrent adult immunoblastic large cell lymphoma', 'recurrent adult Burkitt lymphoma', 'recurrent mantle cell lymphoma', 'recurrent marginal zone lymphoma', 'recurrent small lymphocytic lymphoma', 'extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue', 'nodal marginal zone B-cell lymphoma', 'splenic marginal zone lymphoma']",COMPLETED,,2000-09-01,2011-01-01,"[{'measure': '100 day (complete + partial) response rate', 'description': 'The primary endpoint for this study is 100 day (complete + partial) response rate', 'timeFrame': '100 days'}]",[],1,19 Years,,ALL,False,University of Nebraska,OTHER,2,44.0,ACTUAL,2025-09-01T16:18:22.211631,v2_robust,True,True,True,False,False,
NCT00895752,Riluzole in Fragile X Syndrome,Riluzole in Fragile X Syndrome: A Pilot Study Incorporating Biomarker Assay,Riluzole,['Riluzole'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Fragile X Syndrome,['Fragile X Syndrome'],[],COMPLETED,,2009-04,2010-07,"[{'measure': 'Clinical Global Impression-Improvement (CGI-I)', 'description': ""The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse"", 'timeFrame': 'Obtained at Week 6'}, {'measure': ""Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)"", 'description': 'The CY-BOCS PDD has been utilized in a largescale clinical treatment study of repetitive behavior in idiopathic ASDs. CYBOCS-PDD scores range from 0 to 20 and measure repetitive/compulsive behavior and not obsessions. Higher score indicate worse outcome.', 'timeFrame': 'Obtained at Baseline and Week 6'}]","[{'measure': 'Aberrant Behavior Checklist', 'description': 'The Aberrant Behavior Checklist (ABC) is a 58-item measure of maladaptive behaviors and is used as a measure of drug effects. The ABC has 5 subscales: Social Withdrawal (16 items) ranging from 0 (not at all) to 48 (severe), Irritability (15 items) ranging from 0 (not at all) to 45 (severe), Inappropriate Speech (4 items) ranging from 0 (not at all) to 12 (severe), Hyperactivity (16 items) ranging from 0 (not at all) to 48 (severe), and Stereotypy (7 items) ranging from 0 (not at all) to 21 (severe). Items are rated from 0 (not at all) to 3 (severe).', 'timeFrame': 'Week 6'}, {'measure': 'The ADHD Rating Scale', 'description': 'The ADHD Rating Scale is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder. The ADHD Rating Scale-IV is completed by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. The total score can range from 0 to 54, with a higher score indicating greater severity', 'timeFrame': 'Week 6'}, {'measure': 'The Clinical Global Impression - Severity Scale', 'description': ""The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill"", 'timeFrame': 'Week 6'}, {'measure': 'The Peabody Picture Vocabulary Test', 'description': 'The Peabody Picture Vocabulary Test is one of the most commonly used assessment tests that measure verbal ability in standard American English vocabulary. This test has been nationally standardized using examinees from various age groups, from children to adults. Thus, the raw scores are equated to mental age, using the norms obtained from standardization. The total standard scores range from 40 (worse receptive vocabulary) to 160 (better receptive vocabulary). The scores can also be converted to percentile rank.', 'timeFrame': 'Week 6'}, {'measure': 'The Social Reciprocity Scale', 'description': 'The 65-item SRS is a standardized measure of the core symptoms of autism. Each item is scored on a 4-point Likert scale. The score of each individual item is summed to create a total raw score. A total scores results are as follows: 0-62: Within normal limits 63-79: Mild range of impairment 80-108: Moderate range of impairment 109-149: Severe range of impairment.', 'timeFrame': 'Week 6'}, {'measure': 'Extra-cellular Signal-relatedness Kinase (ERK)', 'description': 'ERK activations times, as defined as the time in minutes for ERK phosphorylation to reach the half maximal level.', 'timeFrame': 'Screen and Week 6'}]",8,18 Years,,ALL,False,Indiana University,OTHER,1,6.0,ACTUAL,2025-09-01T16:18:22.211651,v2_robust,True,True,True,False,False,
NCT04227652,Control of Fever in Septic Patients,Control of Fever in Septic Patients,Ibuprofen administration,['Ibuprofen administration'],1,INTERVENTIONAL,['NA'],,,Sepsis,"['Sepsis', 'Severe Sepsis', 'Septic Shock']","['sepsis', 'severe sepsis', 'septic shock', 'fever', 'ibuprofen', 'physiological reserves']",COMPLETED,,2013-09-03,2019-03-31,"[{'measure': 'SOFA score value', 'description': 'The SOFA score (Sequential Organ Failure Assessment) was measured on Day 3 and Day 7', 'timeFrame': 'up to 7 days'}]","[{'measure': 'Serum interleukin-6 level', 'description': 'The serum interleukin-6 level was measured on Day 3 and Day 7', 'timeFrame': 'up to 7 days'}, {'measure': 'Serum procalcitonine level', 'description': 'The serum procalcitonine level was measured on Day 3 and Day 7', 'timeFrame': 'up to 7 days'}, {'measure': 'Serum lactate level', 'description': 'The serum lactate level was measured on Day 3 and Day 7', 'timeFrame': 'up to 7 days'}, {'measure': 'Central venous oxygen saturation', 'description': 'The central venous oxygen saturation was measured on Day 3 and Day 7', 'timeFrame': 'up to 7 days'}, {'measure': 'Duration of artificial ventilation', 'description': 'The duration of artificial ventilation in days was observed', 'timeFrame': '1 month'}, {'measure': 'Duration of vasopressor support', 'description': 'The duration of vasopressor support in days was observed', 'timeFrame': '1 month'}, {'measure': 'Length of ICU stay', 'description': 'The length of ICU stay in days was observed', 'timeFrame': '1 month'}, {'measure': 'Length of hospital stay', 'description': 'The length of hospital stay in days was observed', 'timeFrame': '3 months'}]",9,18 Years,,ALL,False,University Hospital Ostrava,OTHER,0,140.0,ACTUAL,2025-09-01T16:18:22.211695,v2_robust,True,True,True,False,False,
NCT01015547,Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis,"Comparison of Anti-TNF Therapy Plus Methotrexate, Combination Therapy of DMARDs, and Methotrexate Alone in Very Early Polyarticular Juvenile Idiopathic Arthritis. A National Randomized Multicenter Clinical Trial.",Infliximab plus methotrexate,"['IFX: Remicade, MTX: Trexan or Methotrexate', 'Methotrexate alone', 'Combination of DMARDs', 'MTX: Trexan or Methotrexate', 'Infliximab plus methotrexate', 'MTX: Trexan or Methotrexate, SSZ: Salazopyrin, HCQ: Oxiklorin']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Juvenile Idiopathic Arthritis,['Juvenile Idiopathic Arthritis'],"['juvenile idiopathic arthritis', 'polyarthritis', 'combination therapy', 'biologic agents', 'TNF antagonists', 'infliximab']",COMPLETED,,2003-05,2013-12,"[{'measure': 'ACR Pedi 75 response', 'timeFrame': '54 weeks from baseline (0)'}]","[{'measure': 'clinically inactive disease', 'timeFrame': 'at 54 weeks'}, {'measure': 'time spent in inactive disease', 'timeFrame': '0 to 54 weeks'}, {'measure': 'time spent in ACR Pedi 75', 'timeFrame': '0 to 54 weeks'}, {'measure': 'Other ACR Pedi responses (30, 50, 70, 90, 100)', 'timeFrame': '0 to 54 weeks'}, {'measure': 'drug survival', 'timeFrame': '54 weeks'}, {'measure': 'occurrence of side-effects and adverse events', 'timeFrame': '0 to 54 weeks'}, {'measure': 'cost-benefit ratio in each treatment arm', 'timeFrame': '0 to 54 weeks'}]",8,4 Years,15 Years,ALL,False,Helsinki University Central Hospital,OTHER,5,60.0,ACTUAL,2025-09-01T16:18:22.211739,v2_robust,True,True,True,False,True,
NCT00378547,"Effect of Paracetamol, Pregabalin and Dexamethasone on Pain and Opioid Requirements in Patients Having a Tonsillectomy",Effect of Paracetamol Versus Paracetamol Combined With Pregabalin Versus Paracetamol Combined With Pregabalin and Dexamethasone on Pain and Opioid Requirements in Patients Scheduled for Tonsillectomy,paracetamol + placebo + placebo,"['paracetamol + pregabalin + dexamethasone', 'paracetamol + placebo + placebo', 'paracetamol + pregabalin + placebo', 'Acetaminophen', 'Pregabalin', 'Dexamethasone']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pain, Postoperative","['Pain, Postoperative']","['Tonsillectomy', 'pregabalin', 'dexamethasone', 'multimodal postoperative analgesia']",TERMINATED,ENT surgery stopped at the recruiting hospital,2006-01,2009-12,"[{'measure': 'Pain score (VAS) 2, 4, and 24 hours postoperatively.', 'timeFrame': '0-24 hours'}, {'measure': 'Both at rest and when swallowing 50 ml of water.', 'timeFrame': '0-24 hours'}]","[{'measure': 'Total amount of morphine and ketobemidone used 0-24 hours postoperatively.', 'timeFrame': '0-24 hours'}, {'measure': 'Nausea and vomiting 2, 4, and 24 hours postoperatively.', 'timeFrame': '0-24 hours'}, {'measure': 'Dizziness and sedation 2, 4, and 24 hours postoperatively.', 'timeFrame': '0-24 hours'}]",5,18 Years,50 Years,ALL,False,"Glostrup University Hospital, Copenhagen",OTHER,0,147.0,ACTUAL,2025-09-01T16:18:22.211770,v2_robust,True,True,False,True,False,ENT surgery stopped at the recruiting hospital
NCT01659047,"A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia","A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia",GS-1101,"['GS-1101', 'CAL-101']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Lymphocytic Leukemia,['Chronic Lymphocytic Leukemia'],"['Chronic Lymphocytic Leukemia', 'CLL', 'CAL-101', 'Ofatumumab']",WITHDRAWN,,2012-08,2015-12,"[{'measure': 'Progression-free survival', 'timeFrame': '18 mon'}, {'measure': 'Patient Well-Being', 'description': 'Health-related quality-of-life questionnaire', 'timeFrame': '18 months'}, {'measure': 'Disease-related Biomarkers', 'timeFrame': '18 months'}, {'measure': 'Pharmacokinetics', 'description': 'Evaluation of plasma concentrations at peak (Cmax) and trough (Cmin)', 'timeFrame': '6 months'}, {'measure': 'Incidence of Adverse Events', 'timeFrame': '18 months'}, {'measure': 'Health Resource Utilization', 'timeFrame': '18 months'}]",[],6,18 Years,,ALL,False,Gilead Sciences,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:22.211823,v2_robust,True,True,False,True,True,
NCT03326947,Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC,A Randomized Phase II Trial of Low Stathmin Expression as a Predictive Biomarker for OSCC Patients Receiving TPF Induction Chemotherapy Followed by Radical Surgery and Radiotherapy/Chemoradiotherapy,"docetaxel, cisplatin and 5-fluorouracil","['docetaxel, cisplatin and 5-fluorouracil']",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Neoplasm Neck,['Neoplasm Neck'],"['TPF induction chemotherapy, randomized, trial,OSCC']",RECRUITING,,2018-01-01,2027-01-01,"[{'measure': 'Overall survival', 'description': 'Overall survival was calculated from the date of randomization to death from any cause', 'timeFrame': '12 weeks.'}]","[{'measure': 'Disease free survival', 'description': 'Disease free survival was calculated from the date of randomization to recurrence, locoregional recurrence, or death from any cause', 'timeFrame': '12 weeks.'}]",2,18 Years,75 Years,ALL,False,Shanghai Jiao Tong University School of Medicine,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:22.211961,v2_robust,True,True,False,False,False,
NCT00866047,A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma,A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL),brentuximab vedotin,"['brentuximab vedotin', 'ADCETRIS', 'SGN-35']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,"Lymphoma, Large-Cell, Anaplastic","['Lymphoma, Large-Cell, Anaplastic', 'Lymphoma, Non-Hodgkin']","['Antigens, CD30', 'Antibody-Drug Conjugate', 'Antibodies, Monoclonal', 'Lymphoma, Non-Hodgkin', 'Lymphoma, Large-Cell, Anaplastic', 'monomethyl auristatin E', 'Drug Therapy', 'Immunotherapy', 'Hematologic Diseases', 'Lymphoma']",COMPLETED,,2009-03,2016-06,"[{'measure': 'Objective Response Rate by Independent Review Group', 'description': 'Percentage of participants who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.', 'timeFrame': 'up to 12 months'}]","[{'measure': 'Complete Remission Rate by Independent Review Group', 'description': 'Percentage of participants who achieved a best response of CR (disappearance of all evidence of disease) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.', 'timeFrame': 'up to 12 months'}, {'measure': 'Duration of Objective Response by Kaplan-Meier Analysis', 'description': 'Duration of objective response (CR + PR) by independent review group, defined as time of initial response until disease progression or death.', 'timeFrame': 'up to approximately 3 years'}, {'measure': 'Duration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis', 'description': 'Duration of response from start of first objective tumor response (CR or PR) by independent review group to disease progression or death due to any cause in participants with CR.', 'timeFrame': 'up to approximately 3 years'}, {'measure': 'Progression-free Survival by Kaplan-Meier Analysis', 'description': 'Time from start of study treatment to disease progression per independent review group or death due to any cause.', 'timeFrame': 'up to approximately 3 years'}, {'measure': 'Overall Survival', 'description': 'Time from start of study treatment to date of death due to any cause.', 'timeFrame': 'up to approximately 7 years'}, {'measure': 'Adverse Events by Severity, Seriousness, and Relationship to Treatment', 'description': 'Counts of participants who had adverse events or treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.', 'timeFrame': 'up to 12 months'}, {'measure': 'Hematology Laboratory Abnormalities >/= Grade 3', 'description': 'Counts of study participants with post-baseline hematology laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.', 'timeFrame': 'up to 12 months'}, {'measure': 'Chemistry Laboratory Abnormalities >/= Grade 3', 'description': 'Counts of study participants with post-baseline chemistry laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.', 'timeFrame': 'up to 12 months'}, {'measure': 'Area Under the Curve', 'description': 'Area under the serum concentration-time curve from time 0 to 21 days following the first dose of brentuximab vedotin', 'timeFrame': '3 weeks'}, {'measure': 'Maximum Serum Concentration', 'description': 'Maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin', 'timeFrame': '3 weeks'}, {'measure': 'Time of Maximum Serum Concentration', 'description': 'Time of maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin', 'timeFrame': '3 weeks'}]",12,12 Years,,ALL,False,Seagen Inc.,INDUSTRY,1,58.0,ACTUAL,2025-09-01T16:18:22.211971,v2_robust,True,True,True,False,True,
NCT01449747,Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus,Mechanism of Reduced Response to DPP-4 Inhibitor in Patients With Type 2 Diabetes Mellitus,Sitagliptin,"['Sitagliptin', 'Januvia']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],"['Type 2 diabetes mellitus', 'Dipeptidyl peptidase IV inhibitors', 'Glucagon-like peptide 1']",COMPLETED,,2011-12,2015-07,"[{'measure': 'Plasma Concentration of Active Glucagon-like Peptide 1 (GLP-1) Before and After Sitagliptin Treatment', 'description': 'Plasma concentrations of active GLP-1 were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test (MTT). Second measurement of active GLP-1 were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.', 'timeFrame': '0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose'}, {'measure': 'Plasma Concentration of Total GLP-1 Before and After Sitagliptin Treatment', 'description': 'Plasma concentrations of total GLP-1 were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurement of total GLP-1 were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.', 'timeFrame': '0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose'}, {'measure': 'Plasma Concentration of Total Glucose-dependent Insulinotropic Polypeptide (GIP) Before and After Sitagliptin Treatment', 'description': 'Plasma concentrations of total GIP were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurement of total GIP were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.', 'timeFrame': '0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose'}, {'measure': 'Change in AUC of Active GLP-1, Total GLP-1 and Total GIP Between Before and After Sitagliptin Treatment', 'description': 'Plasma concentrations of active GLP-1, total GLP-1 and total GIP were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test. Second measurements were measured with MTT after taking sitagliptin 100 mg 1 hour before the test. Comparisons were made using Area under the curve (AUC) values and incremental area under the curve (ΔAUC) of active GLP-1, total GLP-1 and total GIP before and after the addition of sitagliptin.', 'timeFrame': '0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose'}]","[{'measure': 'Differences of DPP-4 Activity After Sitagliptin Treatment Between Responder and Non-responder Groups', 'description': 'The DPP-4 activity was measured at baseline and 0, 15, 30, 45 and 60 min during the meal tolerance test. Second measurement of DPP-4 activity was measured with MTT after taking sitagliptin 100 mg 1 hour before the test. Plasma DPP-4 activity during meal tolerance test is expressed as percentage activity relative to baseline. DPP-4 activity % was calculated using the following formula : (DPP-4 activity at time t / Baseline DPP-4 activity) × 100.', 'timeFrame': '0, 15, 30, 45, 60 min post-dose'}]",5,20 Years,70 Years,ALL,False,The Catholic University of Korea,OTHER,1,24.0,ACTUAL,2025-09-01T16:18:22.212039,v2_robust,True,True,True,False,False,
NCT02654847,Norepinephrine To Prevent Hypotension After Spinal Anesthesia For Cesarean Delivery: A Dose Finding Study,Norepinephrine To Prevent Hypotension After Spinal Anesthesia For Cesarean Delivery: A Dose Finding Study,Norepinephrine,"['Norepinephrine', 'Norepinephrine bitartrate', 'sodium chloride', 'Normal Saline']",4,INTERVENTIONAL,['NA'],,,Hypotension,['Hypotension'],"['vasopressor', 'blood pressure', 'Cesarean section', 'spinal anesthesia']",COMPLETED,,2016-01,2016-04,"[{'measure': 'Systolic blood pressure', 'description': 'The primary outcome of this study will be the success/response of the norepinephrine dose to maintain the systolic blood pressure at or above 80% of baseline, from induction of spinal anesthesia to delivery of the fetus.', 'timeFrame': '30 minutes'}]","[{'measure': 'Presence of Nausea', 'description': 'Presence of nausea in patients from induction of spinal anesthesia to delivery of the fetus.', 'timeFrame': '30 minutes'}, {'measure': 'Presence of Vomiting', 'description': 'Presence of vomiting in patients from induction of spinal anesthesia to delivery of the fetus.', 'timeFrame': '30 minutes'}, {'measure': 'Hypertension: Systolic blood pressure at or above 120% of baseline', 'description': 'Systolic blood pressure at or above 120% of baseline, from induction of spinal anesthesia to delivery of the fetus.', 'timeFrame': '30 minutes'}, {'measure': 'Bradycardia: Heart rate less than 50 bpm', 'description': 'Heart rate less than 50 bpm, from induction of spinal anesthesia', 'timeFrame': '30 minutes'}, {'measure': 'Upper sensory level of anesthetic block, assessed by pinprick upon delivery', 'description': 'Upper sensory level of anesthesia, assessed by pinprick upon delivery', 'timeFrame': '30 minutes'}, {'measure': 'Umbilical artery pH', 'description': 'Umbilical artery pH', 'timeFrame': '24 hours'}, {'measure': 'Umbilical artery partial pressure of carbon dioxide', 'description': 'Umbilical artery partial pressure of carbon dioxide', 'timeFrame': '24 hours'}, {'measure': 'Umbilical artery partial pressure of oxygen', 'description': 'Umbilical artery partial pressure of oxygen', 'timeFrame': '24 hours'}, {'measure': 'Umbilical artery bicarbonate', 'description': 'Umbilical artery bicarbonate', 'timeFrame': '24 hours'}, {'measure': 'Umbilical artery base excess', 'description': 'Umbilical artery base excess', 'timeFrame': '24 hours'}, {'measure': 'Umbilical vein pH', 'description': 'Umbilical vein pH', 'timeFrame': '24 hours'}, {'measure': 'Umbilical vein partial pressure of carbon dioxide', 'description': 'Umbilical vein partial pressure of carbon dioxide', 'timeFrame': '24 hours'}, {'measure': 'Umbilical vein partial pressure of oxygen', 'description': 'Umbilical vein partial pressure of oxygen', 'timeFrame': '24 hours'}, {'measure': 'Umbilical vein bicarbonate', 'description': 'Umbilical vein bicarbonate', 'timeFrame': '24 hours'}, {'measure': 'Umbilical vein base excess', 'description': 'Umbilical vein base excess', 'timeFrame': '24 hours'}]",16,18 Years,50 Years,FEMALE,True,"Samuel Lunenfeld Research Institute, Mount Sinai Hospital",OTHER,0,40.0,ACTUAL,2025-09-01T16:18:22.212171,v2_robust,True,True,True,False,False,
NCT06610747,Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT,Home Care Monitoring of Visual Acuity and OCT Versus Standard Hospital/Clinic Care Monitoring During Diabetic Macular Edema Management: A Non-inferiority Randomized Clinical Trial,"Aflibercept 2Mg/0.05Ml Inj,Oph","['Aflibercept 2Mg/0.05Ml Inj,Oph', 'Aflibercept 2-mg/0.05mL intravitreal ophthalmic injection']",2,INTERVENTIONAL,['NA'],,,Diabetic Macular Edema,['Diabetic Macular Edema'],"['Diabetic macular edema', 'Diabetic retinopathy', 'Aflibercept', 'Anti-VEGF', 'Home care monitoring', 'Home OCT', 'Best-corrected visual acuity', 'Visit burden', 'Randomized clinical trial']",RECRUITING,,2024-10-28,2027-04-30,"[{'measure': 'Change in best-corrected visual acuity (letter score) in the study eyes from the randomization visit to 96 week visit', 'description': 'The randomization visit is defined as the visit of the 5th loading dose. Best-corrected visual acuity (letter score) will be measured by masked optometrists using the ETDRS tumbling-E eye chart. The testing procedures are detailed in the study protocol.', 'timeFrame': 'From the randomization visit to 96 week visit'}]","[{'measure': 'Hospital/clinic visits with the home-based care group versus standard hospital/clinic-based care group', 'description': 'Hospital/clinic visits for DME or DR is the principal secondary outcome.', 'timeFrame': 'from the randomization visit to 96 week visit'}, {'measure': 'Proportion of study eyes with at least 5, 10 and 15 letter gains or losses in visual acuity', 'description': 'Proportion of study eyes with at least 5, 10 and 15 letter gains or losses in visual acuity from the randomization visit to 96 week visit. Distribution of visual acuity outcomes (20/20 or better; 20/25 or better; 20/40 or better; 20/80 or better; 20/200 or better) will also be described.', 'timeFrame': 'from the randomization visit to 96 week visit'}, {'measure': 'Change in OCT central subfield thickness', 'description': 'OCT examinations will be conducted by masked, experienced technicians. The same machine type should be used throughout the study for each participant. The outcomes include change in OCT central subfield thickness and retinal volume.', 'timeFrame': 'from the randomization visit to 96 week visit'}, {'measure': 'Change in OCT retinal volume', 'description': 'OCT examinations will be conducted by masked, experienced technicians. The same machine type should be used throughout the study for each participant. The outcomes include change in OCT central subfield thickness and retinal volume.', 'timeFrame': 'from the randomization visit to 96 week visit'}, {'measure': 'Long lapses in care', 'description': 'Lapse in care will be defined as more than 2 weeks past the target date for a visit that is scheduled either 4 or 8 weeks after a completed visit or more than 4 weeks past the target date for a visit scheduled 16 or more weeks after a completed visit. Detailed definition is provided in the protocol.', 'timeFrame': 'from the randomization visit to 96 week visit'}, {'measure': 'Ability to Work and Perform Regular Activities', 'description': 'The Work Productivity and Activity Impairment Questionnaire Global Health (WPAI-GH, Simplified Chinese version) will be used to evaluate the ability to work and perform regular activities. The WPAI-GH is a validated survey tool that consists of 6 questions assessing the impact of health problems on work performance and on regular daily activities outside of work.', 'timeFrame': 'from the randomization visit to 96 week visit'}]",7,18 Years,,ALL,False,"Zhongshan Ophthalmic Center, Sun Yat-sen University",OTHER,2,308.0,ESTIMATED,2025-09-01T16:18:22.212285,v2_robust,True,True,False,False,False,
NCT02324049,"Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)","A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously",SBC-103,"['recombinant human alpha-N-acetylglucosaminidase', 'SBC-103']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Mucopolysaccharidosis IIIB,['Mucopolysaccharidosis IIIB'],"['MPS IIIB', 'Mucopolysaccharidosis', 'Mucopolysaccharidosis type IIIB', 'Sanfilippo Syndrome', 'Metabolism, Inborn Errors', 'Metabolic Diseases', 'Genetic Diseases, Inborn', 'Carbohydrate Metabolism, Inborn Errors', 'Connective Tissue Diseases', 'Lysosomal Storage Diseases', 'Mucinoses', 'Mucopolysaccharidoses', 'Pathologic Processes']",COMPLETED,,2015-01-22,2017-10-16,"[{'measure': 'Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)', 'description': 'TEAEs were defined as any adverse event (AE) that occurred after administration of the first dose of study drug on Day 1 (Part A). A severe AE was defined as an AE that was incapacitating and required medical intervention. TEAEs were summarized cumulatively over the entire study and separately for Part C, data for all severe TEAEs throughout the entire study is presented. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.', 'timeFrame': 'Baseline to Week 142'}]",[],1,2 Years,12 Years,ALL,False,"Alexion Pharmaceuticals, Inc.",INDUSTRY,0,11.0,ACTUAL,2025-09-01T16:18:22.212439,v2_robust,True,True,True,False,True,
NCT00001049,A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV,A Phase I Evaluation of the Safety and Toxicity of Zidovudine and Didanosine in Combination in HIV-Infected or Exposed Infants and a Phase II Study of the Effect of Didanosine vs. Combination Therapy With Zidovudine and Didanosine on HIV-1 RNA in Infants With HIV Infection,Zidovudine,"['Didanosine', 'Zidovudine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,HIV Infections,['HIV Infections'],"['Didanosine', 'Drug Therapy, Combination', 'Acquired Immunodeficiency Syndrome', 'AIDS-Related Complex', 'Zidovudine']",COMPLETED,,,1998-06,[],[],0,1 Day,3 Months,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,180.0,,2025-09-01T16:18:22.212465,v2_robust,True,True,True,False,False,
NCT00296049,Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy,"An Open-Label, Pilot Study of Daptomycin vs. Vancomycin for Treatment of Gram-Positive Bacteremia in Neutropenic Cancer Patients",daptomycin,"['vancomycin', 'daptomycin']",2,INTERVENTIONAL,['NA'],,,Infection,"['Infection', 'Neutropenia', 'Unspecified Adult Solid Tumor, Protocol Specific', 'Unspecified Childhood Solid Tumor, Protocol Specific']","['unspecified adult solid tumor, protocol specific', 'infection', 'neutropenia', 'unspecified childhood solid tumor, protocol specific']",WITHDRAWN,,2005-07,2006-03,"[{'measure': 'determine the efficacy of daptomycin to treat gram positive infections', 'timeFrame': 'day 7'}, {'measure': 'determine the safety of daptomycin in neutropenic patients', 'timeFrame': 'day 7'}]",[],2,,120 Years,ALL,False,Wake Forest University Health Sciences,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:22.212485,v2_robust,True,True,False,True,True,
NCT02777749,Adductor Canal Block Versus Periarticular Bupivicaine Injection in Total Knee Arthroplasty,Adductor Canal Block Versus Periarticular Bupivicaine Injection in Total Knee Arthroplasty,Bupivacaine,"['Bupivacaine Hydrochloride', 'Marcaine', 'Bupivacaine']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Osteoarthritis,['Osteoarthritis'],[],COMPLETED,,2016-07-19,2017-11-01,"[{'measure': 'Change in VAS Pain Scores', 'description': 'Post-operatively, visual analog scale (VAS) pain scores will be recorded two times/day from Post-Operative Day (POD) 0 through POD3. VAS Scores range from 0 to 10, with 0 being ""No Pain"" and 10 being the ""Worst Pain""', 'timeFrame': 'Day 0 through Day 3'}]","[{'measure': 'Change in Activity Level', 'description': 'Daily steps taken will be recorded. The more steps taken daily the better. Minimum is 0 steps, maximum is unlimited.', 'timeFrame': 'Day 0 and Day 1'}, {'measure': 'Opioid Consumption', 'description': 'Total amount of opioid consumption post-operatively will be recorded. The less opioids consumed (mg) postoperatively the better. A morphine equivalence metric will be used for equianalgesic comparison. Minimum is 0 mg, maximum is unlimited.', 'timeFrame': 'Day 0 through Day 3'}, {'measure': 'Range of Knee Flexion', 'description': 'Range of knee flexion for active motion will be recorded at 3 week follow-up for all groups. The greater range of motion the better, with a good outcome considered at least 115 degrees of motion.', 'timeFrame': 'Postoperative day 21'}, {'measure': 'Length of Hospital Stay', 'description': 'Total length of hospital stay from time of surgery through time of discharge will be recorded. The shorter the length of stay (days) the better. Range 0 days to 5 days.', 'timeFrame': 'Up to Day 5'}]",5,,,ALL,False,Columbia University,OTHER,0,155.0,ACTUAL,2025-09-01T16:18:22.212582,v2_robust,True,True,True,False,False,
NCT02582749,Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases,Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170,LHRH agonist/antagonist,"['Casodex', 'LHRH agonist/antagonist', 'Bicalutamide', 'Per treating physician']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,"['Prostate Cancer', 'Bone Metastases', 'Prostate Neoplasms']","['Androgen Deprivation Therapy', 'Androgen Receptor Antagonist', 'Radium-223 Dichloride', 'Placebo']",TERMINATED,Funding withdrawn,2016-04,2017-09-14,"[{'measure': 'Radiological Progression-Free Survival (rPFS)', 'description': 'rPFS assessed using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) to compare outcomes of subjects on experimental arm vs control arm', 'timeFrame': 'From date of randomization to disease progression or death from any cause, up to a maximum of 24 months.'}]","[{'measure': 'Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug, Graded According to NCI Common Terminology Criteria for Adverse Events v 4.0 (CTCAE)', 'description': 'The intensity of AEs for subjects on both arms graded according to CTCAE v4.0 on a five-point scale (Grade 1 to 5: Mild, Moderate, Severe, Life-threatening and Death)', 'timeFrame': 'From date of first dose until 30 days after the last treatment, assessed for a maximum of 24 months'}, {'measure': 'Time to First Skeletal-Related Event (SRE)', 'description': 'SRE of subjects on both arms assessed by bone scan or axial imaging', 'timeFrame': 'From date of first dose until 30 days after the last treatment, assessed for a maximum of 24 months'}, {'measure': 'Secondary Neoplasms', 'description': 'Secondary neoplasms of subjects on both arms assessed by bone scan or axial imaging', 'timeFrame': 'From date of first dose until 30 days after the last treatment, assessed for a maximum of 24 months'}, {'measure': 'PSA Complete Response Rates', 'description': 'Subjects on both arms with PSA ≤ 0.2 ng/mL after 7 months of androgen deprivation therapy', 'timeFrame': 'From date of first dose of androgen deprivation therapy (ADT) until completion of 7 cycles (28 weeks)'}, {'measure': 'PSA Partial Response Rates', 'description': 'Subjects on both arms with PSA between 0.2 and ≤ 4 ng/mL after 7 months of androgen deprivation therapy.', 'timeFrame': 'From date of first dose of ADT until completion of 7 cycles (28 weeks)'}, {'measure': 'Median Time to Castration Resistance', 'description': 'Castration resistance for subjects on both arms determined by first PSA level increase and/or radiographic progression by first imaging assessment showing progression', 'timeFrame': 'From date of ADT (first LHRH agonist/antagonist/surgical castration) to date of PSA and/or radiographic progression, assessed for a maximum of 24 months'}, {'measure': '2-Year PSA Progression Free Survival (PFS)', 'description': 'PSA PFS for subjects on both arms defined as first PSA level increase', 'timeFrame': 'From date of randomization to first occurrence of PSA progression, symptomatic deterioration, or death due to any cause, assessed up to 24 months'}, {'measure': '2-Year Overall Survival (OS)', 'description': 'OS for subjects on both arms', 'timeFrame': 'From date of randomization to death from any cause, assessed up to 24 months'}, {'measure': '12-Week Alkaline Phosphatase (ALP) Normalization', 'description': 'ALP normalization for subjects with abnormal ALP at randomization', 'timeFrame': 'From date of randomization until completion of 12 weeks of therapy'}, {'measure': 'Time to ALP Progression', 'description': 'ALP progression of 25% or greater from baseline/nadir for subjects on both arms', 'timeFrame': 'From date of randomization until date of ALP progression, assessed up to 24 months'}, {'measure': 'Change in Pain Over Time', 'description': 'Subjects on both arms self-reported evaluation of worst pain item, as well as the subscale scores for pain severity and pain interference as determined by subject responses on the BPI-SF questionnaire.', 'timeFrame': 'From baseline until 30 days after the last treatment, assessed for a maximum of 24 months'}, {'measure': 'Analgesic Use by WHO Ladder Score', 'description': ""Analgesic use scores for subjects on both arms will be assigned by the treating physician based on the subject's daily analgesic use on average. A single numeric score (0, 1, 2 or 3) will be assigned based on the 3-step WHO pain ladder."", 'timeFrame': 'From baseline until 30 days after the last treatment, assessed for a maximum of 24 months'}]",13,18 Years,,MALE,False,"Ajjai Alva, MD",OTHER,2,16.0,ACTUAL,2025-09-01T16:18:22.212724,v2_robust,True,True,False,True,True,Funding withdrawn
NCT06262438,CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients,"A Phase II, Single Arm, Open Label, Study on the Safety, Efficacy, Pharmacokinetics & Pharmacodynamics of Quizartinib + Chemotherapy and as Single-agent After High Dose Therapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients",Quizartinib,"['Etoposide', 'Quizartinib dihydrochoride', 'Methotrexate', 'AC220', 'Vanflyta', 'Cytarabine', 'Daunorubicin', 'Mitoxantrone', 'Quizartinib', 'Fludarabine', 'Dexrazoxane']",11,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Myeloid Leukemia in Children,['Acute Myeloid Leukemia in Children'],['FLT3-ITD+ NPM1wt AML'],RECRUITING,,2024-02-06,2032-06,"[{'measure': 'Primary objective (efficacy)', 'description': 'The percentage of patients with (Minimal Residual Disease) MRD levels \\<0.1% (MRD negativity) after up to 2 courses of induction chemotherapy plus quizartinib, as measured in the bone marrow using multiparameter flow cytometry (MFCM) before start of consolidation therapy, in the evaluable population for response.\n\no Patients to be evaluated at baseline, end of cycle 1, and end of cycle 2', 'timeFrame': '2 induction courses (maximum of 56+/-2 days per course)'}, {'measure': 'Primary objective (safety)', 'description': 'Incidence of Dose-Limiting Toxicities (DLTs) assessed during Induction course 1 and 2 (until day 56 of each course) for the DLTs evaluable patients.', 'timeFrame': '2 induction courses (maximum of 56+/-2 days per course)'}]","[{'measure': 'Secondary objectives (efficacy_1)', 'description': 'Morphological overall response rate (ORR)', 'timeFrame': '2 induction courses (maximum of 56+/-2 days per course)'}, {'measure': 'Secondary objectives (efficacy_2)', 'description': 'MRD by multiparameter flow cytometry (MFCM)', 'timeFrame': 'Multiple time points, last time point after continuation treatment (1.5 years)'}, {'measure': 'Secondary objectives (efficacy_3)', 'description': 'Event free survival (EFS)', 'timeFrame': '3 years'}, {'measure': 'Secondary objectives (efficacy_4)', 'description': 'Overall survival (OS)', 'timeFrame': '3 years'}, {'measure': 'Secondary objectives (efficacy_5)', 'description': 'Disease free survival (DFS)', 'timeFrame': '3 years'}, {'measure': 'Secondary objectives (efficacy_6)', 'description': 'Duration of response', 'timeFrame': '3 years'}, {'measure': 'Secondary objectives (efficacy_7)', 'description': 'Cumulative incidence of relapse (CIR)', 'timeFrame': '3 years'}, {'measure': 'Secondary objectives (efficacy_8)', 'description': 'Number and percentage of patients actually being treated with hematopoietic stem cell transplantation (HSCT)', 'timeFrame': '1 year'}, {'measure': 'Secondary objectives (efficacy_9)', 'description': 'Number of patients starting and completing continuation treatment post-HSCT.', 'timeFrame': '1.5 years'}, {'measure': 'Secondary objectives (safety) - Adverse Events, Laboratory Abnormalities and cumulative incidence of non-relapse mortality', 'description': 'Safety and tolerability of combining quizartinib with conventional treatment and quizartinib given as single-agent after HSCT.\n\n* Adverse events (AEs), as characterized by type, frequency, severity (as graded using CTCAE, v5.0).\n* Laboratory abnormalities (including time to recovery of ANC and PLT), electrocardiograms and changes in vital signs as characterized by type, frequency, severity and timing will be tabulated, and reported as AEs when considered clinically significant by the investigator.\n* The cumulative incidence of non-relapse mortality, defined as the cumulative probability of non-relapse mortality, with time calculated between start of study treatment and death due to other causes than relapsed or refractory leukemia, accounting for competing events.', 'timeFrame': '1.5 years'}, {'measure': 'Pharmacokinetics (PK_1)', 'description': 'Population PK analysis to estimate AUC (tau) for quizartinib and AC886', 'timeFrame': '1.5 years'}, {'measure': 'Pharmacokinetics (PK_2)', 'description': 'Population PK analysis to estimate Cmax for quizartinib and AC886', 'timeFrame': '1.5 years'}, {'measure': 'Pharmacokinetics (PK_3)', 'description': 'Population PK analysis to estimate clearance (CL/F) for quizartinib.', 'timeFrame': '1.5 years'}, {'measure': 'Pharmacokinetics (PK_4)', 'description': 'Population PK analysis to estimate volume of distribution (Vss/F) for quizartinib.', 'timeFrame': '1.5 years'}, {'measure': 'Palatability of quizartinib formulations', 'description': 'Patients and/or parents or legal guardians will answer using a Hedonic scale for the taste and ability to swallow the medicine.', 'timeFrame': '1.5 years'}]",17,1 Month,18 Years,ALL,False,Princess Maxima Center for Pediatric Oncology,OTHER,1,60.0,ESTIMATED,2025-09-01T16:18:22.212766,v2_robust,True,True,False,False,True,
NCT01657838,Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects,"A Phase 1, Randomized, Open-Label, Two-Arm, Parallel Group Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects",Isavuconazole,"['BAL4815', 'BAL8557', 'Isavuconazole', 'Ketoconazole']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Pharmacokinetics of Isavuconazole,"['Pharmacokinetics of Isavuconazole', 'Pharmacokinetics of Ketoconazole', 'Healthy Adult Volunteers']","['Isavuconazole', 'Ketoconazole', 'Healthy Volunteers', 'BAL8557', 'BAL4815']",COMPLETED,,2012-05,2012-05,"[{'measure': 'Pharmacokinetic (PK) profile for isavuconazole (in plasma): AUClast , Cmax', 'description': 'Area under the concentration-time curve from time of dosing to the last quantifiable concentration (AUClast) and maximum concentration (Cmax)', 'timeFrame': 'Day 1 (Arm 1) and Day 4 (Arm 2): predose and 0.5, 1, 2, 4, 6, 8, 10, 12, 20, 24, 36, 48, 72, 96,120,144,168,192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480 and 504 hours post-dose'}]","[{'measure': 'PK profile for isavuconazole (in plasma): AUCinf, tmax, CL/F, Vz/F, and t1/2', 'description': 'Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf), Time to attain Cmax (tmax), apparent body clearance after oral dosing (CL/F), apparent volume of distribution (Vz/F), and apparent terminal elimination half-life (t1/2)', 'timeFrame': 'Day 1(Arm 1) and Day 4 (Arm 2): predose and 0.5, 1, 2, 4, 6, 8, 10, 12, 20, 24, 36, 48, 72, 96,120,144,168,192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480 and 504 hours post-dose'}, {'measure': 'PK for ketoconazole (in plasma): trough concentration (Ctrough)', 'timeFrame': 'Day 2 (Arm 2): predose'}, {'measure': 'PK profile for ketoconazole (in plasma): AUCtau, Cmax, and tmax', 'description': 'AUC during time interval between consecutive dosing (AUCtau)', 'timeFrame': 'Days 3 and 4: predose and 0.5,1, 2, 4, 6, 8,12 and 24 hours post-dose'}, {'measure': 'Safety assessed by recording of adverse events, clinical laboratory evaluation, electrocardiograms (ECGs) and vital signs', 'timeFrame': 'Day 1 through Day 25 (± 2 days)'}]",5,18 Years,55 Years,ALL,True,"Astellas Pharma Global Development, Inc.",INDUSTRY,1,24.0,ACTUAL,2025-09-01T16:18:22.212781,v2_robust,True,True,True,False,True,
NCT07060638,Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial,Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial,IL-22,"['F-652', 'IL-22', 'IL-22 (F-652) Placebo', 'Prednisone placebo', 'Placebo', 'Acamprosate', 'Prednisone']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Alcohol-associated Hepatitis,['Alcohol-associated Hepatitis'],"['Severe AH, AUD']",NOT_YET_RECRUITING,,2025-08,2029-12,"[{'measure': 'Death', 'description': 'Number (%) of participants who die from any cause', 'timeFrame': '6 months'}, {'measure': 'Liver transplant', 'description': 'Number (%) of participants who receive liver transplant', 'timeFrame': '6 months'}, {'measure': 'Ascites', 'description': 'Number (%) of participants with new onset of clinically detectable', 'timeFrame': '6 months'}, {'measure': 'Hepatic encephalopathy', 'description': 'Number (%) of participants with hepatic encephalopathy ≥ New Haven grade 2', 'timeFrame': '6 months'}, {'measure': 'Portal hypertensive bleeding', 'description': 'Number (%) of participants with gastroesophageal varices or portal gastropathy', 'timeFrame': '6 months'}, {'measure': 'Liver-related hospital admission', 'description': 'Number (%) of participants with liver-related hospital admission for ascites, hepatic encephalopathy, infection, GI bleeding', 'timeFrame': '6 months'}, {'measure': 'Increase in MELD score > 5 points', 'description': 'Number (%) of participants with increase in MELD score \\> 5 points', 'timeFrame': '6 months'}, {'measure': 'Return to drinking', 'description': 'Number (%) of participants that return to drinking defined as \\<100% abstinence-using timeline follow back questionnaire', 'timeFrame': '6 months'}]","[{'measure': 'Transplant-free survival', 'description': 'Time participants live without liver transplant', 'timeFrame': '30 days, 90 days, 180 days, 1 year, and 2 years'}]",9,18 Years,70 Years,ALL,False,Samer Gawrieh,OTHER,1,216.0,ESTIMATED,2025-09-01T16:18:22.212803,v2_robust,True,True,False,False,False,
NCT06895538,Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy,"An Exploratory, Non-Randomized, Controlled Study of the Effect of Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG) Versus Anti-Thymocyte Immunoglobulin (ATG) on Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematologic Diseases",Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG),['Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG)'],1,OBSERVATIONAL,[],,,Leukemia,"['Leukemia', 'MDS', 'Lymphoma']","['ATLG', 'ATG', 'immune reconstitution', 'allo-HSCT']",RECRUITING,,2025-05-03,2027-01-01,"[{'measure': 'Incidence of viral infections after hematopoietic stem cell transplantation', 'description': 'Incidence of CMV reactivation (CMV DNA ≥10\\^3) and CMV disease, incidence of EBV reactivation (incidence of EBV DNA ≥10\\^5) and lymphoproliferative disorders (PTLD), incidence of hemorrhagic cystitis, incidence of herpes simplex, adenovirus, or other viruses in both groups.', 'timeFrame': 'From enrollment to 1 year after allo-HSCT'}]",[],1,18 Years,,ALL,False,Peking University First Hospital,OTHER,0,24.0,ESTIMATED,2025-09-01T16:18:22.212827,v2_robust,False,True,False,False,False,
NCT03861338,An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder,An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder,Sublocade,"['buprenorphine extended-release injection', 'Sublocade']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Opioid-use Disorder,['Opioid-use Disorder'],"['opioid use disorder, sublocade, buprenorphine']",COMPLETED,,2019-03-01,2020-02-28,"[{'measure': 'Sublocade Induction', 'description': 'Number of participants successfully inducted onto Sublocade (BXR)', 'timeFrame': 'Study week 1'}]",[],1,18 Years,65 Years,ALL,False,New York State Psychiatric Institute,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:23.443995,v2_robust,True,True,True,False,False,
NCT03145038,Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects,Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects,"Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed","['Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast', 'Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast', 'Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed', 'Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast', 'Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed', 'Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Pharmacokinetics,['Pharmacokinetics'],[],COMPLETED,,2017-05-16,2017-10-09,"[{'measure': 'Vericiguat area under the plasma concentration vs. time curve divided by dose (AUC/D)', 'description': 'AUC is the area under the curve (mathematically known as definite integral) in a plot of concentration of vericiguat after single dose administration in blood plasma against time (pre-dose until 72 hours after administration). AUC from time 0 to the last data point greater than lower limit of quantification divided by dose (AUC(0-tlast)/D) will be used as primary parameter if AUC cannot be calculated for all profiles, or mean AUC from the last data point to infinity \\[AUC(tlast-∞)\\] \\>20% of AUC. AUC will be analyzed by means of descriptive statistics.', 'timeFrame': '0 - 72 hours'}, {'measure': 'Vericiguat maximum plasma concentration divided by dose (Cmax/D))', 'description': 'Cmax is the maximum observed vericiguat concentration in measured plasma after single dose administration (pre-dose until 72 hours after administration). Cmax/D is the maximum observed drug concentration in measured matrix after single dose administration divided by dose.Cmax will be analyzed by means of descriptive statistics', 'timeFrame': '0 - 72 hours'}]","[{'measure': 'Number of Adverse Events', 'description': 'As a secondary objective of this study the numbers of AEs will be used to assess safety and tolerability of vericiguat.\n\nIn a clinical study, an AE is any untoward medical occurrence (i.e. any unfavorable and unintended sign \\[including abnormal laboratory findings\\], symptom or disease) in a patient or clinical investigation subject after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.\n\nIndividual listings of AEs will be provided. The incidence of treatment-emergent AEs an drug-related AEs, respectively, will be summarized by treatment using MedDRA terms (highly specific standardised medical terminology).', 'timeFrame': 'pre-dose until 7 to 14 days after last administration of vericiguat'}, {'measure': 'Palatability of the oro-dispersible tablets and the crushed IR tablets assessed by questionnaire', 'description': 'As a secondary objective of this study the taste and texture of pediatric formulation (palatability) (mini tablets) and of the crushed IR tablet will be assessed', 'timeFrame': 'up to 5 minutes after drug administration'}]",4,18 Years,45 Years,MALE,True,Bayer,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:23.444034,v2_robust,True,True,True,False,True,
NCT07032038,First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant,"First In Human, Multi-Center Open-Label Randomized Trial to Assess Safety of Rincell-1 Otic Neural Progenitor Cell-Based Therapy and Standard Care vs Standard Care Alone, in Adults With Neural Hearing Loss Eligible for Cochlear Implantation",Otic neural progenitors,['Otic neural progenitors'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Sensorineural Hearing Loss,"['Sensorineural Hearing Loss', 'Presbyacusis', 'Auditory Neuropathy']","['neural hearing loss', 'presbycusis', 'ANSD', 'auditory neuropathy', 'cell therapy', 'first in human']",NOT_YET_RECRUITING,,2025-10,2027-07,"[{'measure': 'Frequency and severity of AEs', 'description': 'Frequency and severity of AEs considered related to Rincell-1 alone, the procedure used to administer Rincell-1, and to the CI device and/or the administered concomitant NIMP regime.', 'timeFrame': 'From baseline (at screening) to 52 weeks post-implantation'}]","[{'measure': 'Changes in mean ECAP thresholds', 'description': 'Change from baseline to primary evaluation timepoint in mean ECAP threshold, measured at each electrode for each participant', 'timeFrame': 'From post-implantation baseline to 40 weeks post-implantation'}, {'measure': 'Feasibility of administration of Rincell-1', 'description': 'Evaluated in terms of:\n\n* On-time delivery to theatre of the DP\n* Successful in-theatre DP preparation\n* Injection of the full DP into the target anatomical structure\n* DP sterility and viability', 'timeFrame': 'At time of administration'}]",3,18 Years,74 Years,ALL,False,Rinri Therapeutics,INDUSTRY,1,20.0,ESTIMATED,2025-09-01T16:18:23.444182,v2_robust,True,True,False,False,False,
NCT00337038,Endothelial Function as a Marker for Blood Pressure Control Among Hypertensive Diabetic Patients,,N-acetylcystein(drug),"['siran', 'N-acetylcystein(drug)']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Hypertension,"['Hypertension', 'Diabetes Mellitus Type 2']",[],COMPLETED,,2006-06,2010-07,"[{'measure': 'endothelial function', 'timeFrame': 'half of year'}]","[{'measure': 'blood pressure and glycemic control', 'timeFrame': 'half of year'}]",2,18 Years,,ALL,False,Soroka University Medical Center,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:23.444200,v2_robust,True,True,True,False,False,
NCT03928158,LCZ696 in Advanced LV Hypertrophy and HFpEF,"Sacubitril/Valsartan (LCZ696) in Patients With Advanced Hypertensive Left Ventricular Hypertrophy and Heart Failure With Preserved Ejection Fraction: Clinical, Haemodynamic and Neurohumoral Effects (a Phase 2, Randomized, Single-center, Parallel Group Study)",LCZ 696,"['Valsartan', 'LCZ 696']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Heart Failure,"['Heart Failure', 'Essential Hypertension']","['left ventricular hypertrophy', 'diastolic dysfunction', 'LCZ696', 'HFpEF', 'HF', 'LV filling pressures']",COMPLETED,,2019-05-31,2023-12-31,"[{'measure': 'Change in 6-minute walking distance (6MWD)', 'description': 'Difference in distance walked during 6-minute walking test (6MWT) between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}]","[{'measure': 'Change in exercise time during diastolic stress-test (DST)', 'description': 'Difference in exercise time during DST between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}, {'measure': 'Change in left atrial volume index (LAVI)', 'description': 'Difference in LAVI assessed by echocardiography between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}, {'measure': ""Change in average E/e' ratio"", 'description': ""Difference in E/e' ratio assessed by echocardiography both at rest and at peak exercise during diastolic stress test (DST) between 24 weeks after baseline and at baseline"", 'timeFrame': '24 weeks'}, {'measure': 'Change estimated pulmonary artery systolic pressure (PASP)', 'description': 'Difference in PASP assessed by echocardiography at peak exercise both at rest and at peak exercise during diastolic stress test (DST) between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}, {'measure': 'Change in left ventricular mass index (LVMI)', 'description': 'Difference in LVMI assessed by echocardiography between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}, {'measure': 'Change of New York Heart Association (NYHA) functional classification', 'description': 'Difference in NYHA class between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}, {'measure': 'Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) score', 'description': ""Difference in MLHFQ score between 24 weeks after baseline and at baseline. The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. After receiving brief standardized instructions, the patient marks a 0 (zero) to 5 scale to indicate how much each itemized adverse of heart failure has prevented the patient from living as he or she wanted to live during the past 4 weeks. The questionnaire is simply scored by summation of all 21 responses. Score ranges from 0 (best quality of life) to 105 (worst quality of life)."", 'timeFrame': '24 weeks'}, {'measure': 'Change in N-terminal pro b-type natriuretic peptide (NT-proBNP)', 'description': 'Difference in NT-proBNP plasma levels between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}, {'measure': 'Change in high-sensitivity C-reactive protein (hsCRP)', 'description': 'Difference in hsCRP plasma levels between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}, {'measure': 'Change in carboxyterminal propeptide of type I collagen (PICP)', 'description': 'DIfference in PICP plasma levels between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}, {'measure': 'Change in carboxyterminal telopeptide of type I collagen (CITP)', 'description': 'Difference in CITP plasma levels between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}, {'measure': 'Change in N-Propeptide Of Type III Procollagen (PIIINP)', 'description': 'Difference in PIIINP plasma levels between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}, {'measure': 'Change in Growth/differentiation factor 15 (GDF-15)', 'description': 'Difference in GDF-15 plasma levels between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}, {'measure': 'Change in sST2', 'description': 'Difference in sST2 plasma levels between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}, {'measure': 'Change in Galectin-3', 'description': 'Difference in Galectin-3 plasma levels between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}, {'measure': 'Change in monocyte chemoattractant-1 (MCP-1)', 'description': 'DIfference in MCP-1 plasma levels between 24 weeks after baseline and at baseline', 'timeFrame': '24 weeks'}]",17,40 Years,80 Years,ALL,False,"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation",OTHER_GOV,0,61.0,ACTUAL,2025-09-01T16:18:23.444235,v2_robust,True,True,True,False,True,
NCT05891158,A Study About Fazirsiran in People With and Without Liver Problems,"An Open-Label, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics in Response to a Single Subcutaneous Dose of Fazirsiran (TAK-999) in Subjects With or Without Hepatic Impairment",Fazirsiran,"['Fazirsiran', 'TAK-999']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Hepatic Impairment,['Hepatic Impairment'],[],ACTIVE_NOT_RECRUITING,,2023-10-05,2025-09-15,"[{'measure': 'Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for Fazirsiran', 'timeFrame': 'From pre-dose up to Month 6 post-dose'}, {'measure': 'Area Under the Plasma Concentration-time Curve from Time 0 to Infinity (AUC0-inf) for Fazirsiran', 'timeFrame': 'From pre-dose up to Month 6 post-dose'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) for Fazirsiran', 'timeFrame': 'From pre-dose up to Month 6 post-dose'}]","[{'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs)', 'timeFrame': 'From the first dose of study drug up to end of follow-up (up to 6 months)'}, {'measure': 'Number of Participants With Clinically Significant Abnormal Values for Laboratory Parameters', 'timeFrame': 'From the first dose of study drug up to end of follow-up (up to 6 months)'}, {'measure': 'Number of Participants With Clinically Significant Abnormal Values for Vital Signs Parameters', 'timeFrame': 'From the first dose of study drug up to end of follow-up (up to 6 months)'}, {'measure': 'Number of Participants With Clinically Significant Abnormal Values for Electrocardiogram (ECG) Parameters', 'timeFrame': 'From the first dose of study drug up to end of follow-up (up to 6 months)'}, {'measure': 'Number of Participants With Clinically Significant Abnormal Values for Pulmonary Function Parameters', 'timeFrame': 'From the first dose of study drug up to end of follow-up (up to 6 months)'}, {'measure': 'Number of Participants With Injection Site Reaction', 'timeFrame': 'From the first dose of study drug up to end of follow-up (up to 6 months)'}, {'measure': 'Amount of Drug Excreted in Urine From Time 0 to Time 24 hours (Ae0-24hrs) for Fazirsiran', 'timeFrame': 'Pre-dose, 0 to 24 hours post-dose'}, {'measure': 'Amount of Drug Excreted in Urine From Time 0 to Time 6 hours (Ae0-6hrs) for Fazirsiran', 'timeFrame': 'Pre-dose, 0 to 6 hours post-dose'}, {'measure': 'Amount of Drug Excreted in Urine From Time 6 to Time 24 hours (Ae6-24h) for Fazirsiran', 'timeFrame': 'From 6 to 24 hours post-dose'}, {'measure': 'Percent of Recovered Drug in Urine Compared With the Dose (%Dose [u])', 'timeFrame': 'Pre-dose, 0 to 24 hours post-dose'}, {'measure': 'Renal Clearance (CLr) for Fazirsiran', 'timeFrame': 'Pre-dose, 0 to 24 hours post-dose'}, {'measure': 'Absolute Change in Serum Alpha-1 Antitrypsin (AAT) at Nadir', 'timeFrame': 'From Day 1 Pre-dose Baseline up to end of follow-up (up to 6 months)'}, {'measure': 'Percentage Change in Serum AAT at Nadir', 'timeFrame': 'From Day 1 Pre-dose Baseline up to end of follow up (up to 6 months)'}, {'measure': 'Absolute Change in Serum AAT', 'timeFrame': 'From Day 1 Pre-dose Baseline and at Days 15, 29, 57'}, {'measure': 'Percentage Change in Serum AAT', 'timeFrame': 'From Day 1 Pre-dose Baseline and at Days 15, 29, 57'}]",18,18 Years,85 Years,ALL,True,Takeda,INDUSTRY,0,34.0,ACTUAL,2025-09-01T16:18:23.444418,v2_robust,True,True,False,False,True,
NCT04895358,Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49),"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)",paclitaxel,"['DOXIL®', 'paclitaxel', 'nab-paclitaxel', 'dextrose', 'liposomal doxorubicin', 'normal saline', 'ABRAXANE®', 'XELODA®', 'TAXOL®', 'capecitabine']",10,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Neoplasms,['Breast Neoplasms'],"['programmed cell death receptor 1 (PD-1, PD1)', 'programmed cell death receptor ligand 1 (PD-L1, PDL1)', 'programmed cell death receptor ligand 2 (PD-L2, PDL2)', 'human epidermal growth factor 2 negative (HER2-)', 'hormone receptor positive (HR+)', 'estrogen receptor positive (ER+)', 'progesterone receptor positive (PR+)', 'metastatic', 'inoperable']",ACTIVE_NOT_RECRUITING,,2021-06-18,2027-12-18,"[{'measure': 'Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥1', 'description': 'PFS is defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The PFS in participants with a CPS of ≥1, as assessed by BICR, will be presented.', 'timeFrame': 'Up to approximately 50 months'}]","[{'measure': 'Overall Survival (OS) in Participants With Combined Positive Score (CPS) ≥1', 'description': 'OS is defined as the time from randomization to death due to any cause. OS for participants with a CPS of ≥1 will be presented.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥10', 'description': 'PFS is defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The PFS in participants with a CPS of ≥10, as assessed by BICR, will be presented.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'OS in Participants With CPS ≥10', 'description': 'OS is defined as the time from randomization to death due to any cause. OS for participants with a CPS of ≥10 will be presented.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Investigator in Participants With Combined Positive Score (CPS) ≥10', 'description': 'PFS is defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The PFS in participants with a CPS of ≥10, as assessed by investigator, will be presented.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Investigator in Participants With Combined Positive Score (CPS) ≥1', 'description': 'PFS is defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The PFS in participants with a CPS of ≥1, as assessed by investigator, will be presented.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥10', 'description': 'ORR is defined as the percentage of participants in the analysis population who achieve confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. ORR for participants with a CPS of ≥10 will be presented.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥1', 'description': 'ORR is defined as the percentage of participants in the analysis population who achieve confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. ORR for participants with a CPS of ≥1 will be presented.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥10', 'description': 'DCR is defined as the percentage of participants who achieve Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions), or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \\[PD: ≥20% increase in the sum of diameters of target lesions and an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD\\]) for at least 24 weeks. The percentage of participants who experience a confirmed CR, PR, or SD with a CPS of ≥10 will be presented.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥1', 'description': 'DCR is defined as the percentage of participants who achieve Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions), or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \\[PD: ≥20% increase in the sum of diameters of target lesions and an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD\\]) for at least 24 weeks. The percentage of participants who experience a confirmed CR, PR, or SD with a CPS of ≥1 will be presented.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥10', 'description': 'For participants who demonstrate CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the time from the first documented evidence of CR or PR until disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, or death from any cause, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. DOR for participants with a CPS of ≥10 will be presented.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥1', 'description': 'For participants who demonstrate CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the time from the first documented evidence of CR or PR until disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, or death from any cause, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. DOR for participants with a CPS of ≥1 will be presented.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Change From Baseline in Global Health Status/Quality of Life Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10', 'description': 'The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to the questions regarding Global Health Status (GHS; ""How would you rate your overall health during the past week?"") and Quality of Life (QoL; ""How would you rate your overall quality of life during the past week?"") are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QoL (EORTC QLQ-C30 Item 30) combined score will be presented in participants with a CPS of ≥10. A higher score indicates a better outcome.', 'timeFrame': 'Baseline and up to approximately 76 months'}, {'measure': 'Change From Baseline in Global Health Status/Quality of Life Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1', 'description': 'The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to the questions regarding Global Health Status (GHS; ""How would you rate your overall health during the past week?"") and Quality of Life (QoL; ""How would you rate your overall quality of life during the past week?"") are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QoL (EORTC QLQ-C30 Item 30) combined score will be presented in participants with a CPS of ≥1. A higher score indicates a better outcome.', 'timeFrame': 'Baseline and up to approximately 76 months'}, {'measure': 'Change From Baseline in Physical Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10', 'description': 'The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning (Items 1-5) are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in the physical functioning score will be presented in participants with a CPS of ≥10. A higher score indicates a better level of function.', 'timeFrame': 'Baseline and up to approximately 76 months'}, {'measure': 'Change From Baseline in Physical Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1', 'description': 'The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning (Items 1-5) are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in the physical functioning score will be presented in participants with a CPS of ≥1. A higher score indicates a better level of function.', 'timeFrame': 'Baseline and up to approximately 76 months'}, {'measure': 'Change From Baseline in Emotional Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10', 'description': 'The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 4 questions about their emotional functioning (Items 21-24) are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in the emotional functioning score will be presented in participants with a CPS of ≥10. A higher score indicates a better level of function.', 'timeFrame': 'Baseline and up to approximately 76 months'}, {'measure': 'Change From Baseline in Emotional Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1', 'description': 'The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 4 questions about their emotional functioning (Items 21-24) are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in the emotional functioning score will be presented in participants with a CPS of ≥1. A higher score indicates a better level of function.', 'timeFrame': 'Baseline and up to approximately 76 months'}, {'measure': 'Change From Baseline in Fatigue Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10', 'description': 'The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 3 questions about their fatigue (Items 10, 12, 18) are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in the fatigue score will be presented in participants with a CPS of ≥10. A lower score indicates a better outcome.', 'timeFrame': 'Baseline and up to approximately 76 months'}, {'measure': 'Change From Baseline in Fatigue Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1', 'description': 'The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 3 questions about their fatigue (Items 10, 12, 18) are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in the fatigue score will be presented in participants with a CPS of ≥1. A lower score indicates a better outcome.', 'timeFrame': 'Baseline and up to approximately 76 months'}, {'measure': 'Change From Baseline in Diarrhea Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10', 'description': 'The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire, including a single-item scale score for diarrhea (QLQ-C30 Item 17). For this item, individual responses to the question ""Have you had diarrhea?"" are given on a 4-point scale (1=Not at all; 4=Very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in the diarrhea score will be presented in participants with a CPS of ≥10. A lower score indicates a better outcome.', 'timeFrame': 'Baseline and up to approximately 76 months'}, {'measure': 'Change From Baseline in Diarrhea Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1', 'description': 'The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire, including a single-item scale score for diarrhea (QLQ-C30 Item 17). For this item, individual responses to the question ""Have you had diarrhea?"" are given on a 4-point scale (1=Not at all; 4=Very much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in the diarrhea score will be presented in participants with a CPS of ≥1. A lower score indicates a better outcome.', 'timeFrame': 'Baseline and up to approximately 76 months'}, {'measure': 'Time to Deterioration (TTD) in Global Health Status/Quality of Life Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10', 'description': 'TTD is defined as the time to the first onset of a ≥10-point deterioration (decrease) from baseline in Global Health Status (GHS; EORTC QLQ-C30 Item 29) \\& Quality of Life (QoL; EORTC QLQ-C30 Item 30) combined score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point deterioration (decrease) from baseline in GHS and QoL combined score, will be presented in participants with a CPS of ≥10. A longer TTD indicates a better outcome.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Time to Deterioration (TTD) in Global Health Status/Quality of Life Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1', 'description': 'TTD is defined as the time to the first onset of a ≥10-point deterioration (decrease) from baseline in Global Health Status (GHS; EORTC QLQ-C30 Item 29) \\& Quality of Life (QoL; EORTC QLQ-C30 Item 30) combined score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point deterioration (decrease) from baseline in GHS and QoL combined score, will be presented in participants with a CPS of ≥1. A longer TTD indicates a better outcome.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Time to Deterioration (TTD) in Physical Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10', 'description': 'TTD is defined as the time to the first onset of a ≥10-point deterioration (decrease) from baseline in physical functioning score (EORTC QLQ-C30 Items 1-5). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point deterioration (decrease) from baseline in physical functioning score, will be presented in participants with a CPS of ≥10. A longer TTD indicates a better outcome.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Time to Deterioration (TTD) in Physical Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1', 'description': 'TTD is defined as the time to the first onset of a ≥10-point deterioration (decrease) from baseline in physical functioning score (EORTC QLQ-C30 Items 1-5). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point deterioration (decrease) from baseline in physical functioning score, will be presented in participants with a CPS of ≥1. A longer TTD indicates a better outcome.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Time to Deterioration (TTD) in Diarrhea Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10', 'description': 'TTD is defined as the time to the first onset of a ≥10-point deterioration (decrease) from baseline in diarrhea score (EORTC QLQ-C30 Item 17). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point deterioration (decrease) from baseline in diarrhea score, will be presented in participants with a CPS of ≥10. A longer TTD indicates a better outcome.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Time to Deterioration (TTD) in Emotional Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10', 'description': 'TTD is defined as the time to the first onset of a ≥10-point deterioration (decrease) from baseline in emotional functioning score (EORTC QLQ-C30 Items 21-24). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point deterioration (decrease) from baseline in emotional functioning score, will be presented in participants with a CPS of ≥10. A longer TTD indicates a better outcome.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Time to Deterioration (TTD) in Emotional Functioning Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1', 'description': 'TTD is defined as the time to the first onset of a ≥10-point deterioration (decrease) from baseline in emotional functioning score (EORTC QLQ-C30 Items 21-24). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point deterioration (decrease) from baseline in emotional functioning score, will be presented in participants with a CPS of ≥1. A longer TTD indicates a better outcome.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Time to Deterioration (TTD) in Fatigue Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥10', 'description': 'TTD is defined as the time to the first onset of a ≥10-point deterioration (decrease) from baseline in fatigue score (EORTC QLQ-C30 Items 10, 12, 18). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point deterioration (decrease) from baseline in fatigue score, will be presented in participants with a CPS of ≥10. A longer TTD indicates a better outcome.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Time to Deterioration (TTD) in Fatigue Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1', 'description': 'TTD is defined as the time to the first onset of a ≥10-point deterioration (decrease) from baseline in fatigue score (EORTC QLQ-C30 Items 10, 12, 18). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point deterioration (decrease) from baseline in fatigue score, will be presented in participants with a CPS of ≥1. A longer TTD indicates a better outcome.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Time to Deterioration (TTD) in Diarrhea Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in Participants with CPS ≥1', 'description': 'TTD is defined as the time to the first onset of a ≥10-point deterioration (decrease) from baseline in diarrhea score (EORTC QLQ-C30 Item 17). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point deterioration (decrease) from baseline in diarrhea score, will be presented in participants with a CPS of ≥1. A longer TTD indicates a better outcome.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Percentage of Participants who Experience an Adverse Event (AE)', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experience one or more adverse events will be presented.', 'timeFrame': 'Up to approximately 76 months'}, {'measure': 'Percentage of Participants who Discontinue Study Drug due to an AE', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinue study treatment due to an adverse event will be presented.', 'timeFrame': 'Up to approximately 76 months'}]",34,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,340.0,ESTIMATED,2025-09-01T16:18:23.444459,v2_robust,True,True,False,False,True,
NCT06244758,Finerenone and Renal Oxidative Stress,Effects of Finerenone on Renal Hemodynamics and Oxidative Stress,Finerenone 20 MG Oral Tablet,"['Finerenone 20 MG Oral Tablet', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Type2diabetes,['Type2diabetes'],[],RECRUITING,,2024-01-18,2025-12-31,"[{'measure': 'the impact of finerenone on the oxidative stress level of renal vasculature by the increase of renal perfusion following vitamin C infusion compared to placebo', 'description': 'the impact of finerenone on the oxidative stress level of renal vasculature by the increase of renal perfusion following vitamin C infusion compared to placebo', 'timeFrame': 'at baseline and after 3 months on finerenone'}]","[{'measure': 'impact of finerenone on renal plasma flow (para-aminohippurate (PAH) clearance) compared to placebo', 'description': 'impact of finerenone on renal plasma flow (para-aminohippurate (PAH) clearance) compared to placebo', 'timeFrame': 'at baseline and after 3 months on finerenone'}, {'measure': 'impact of finerenone on glomerular filtration rate (iohexol clearance) compared to placebo', 'description': 'impact of finerenone on glomerular filtration rate (iohexol clearance) compared to placebo', 'timeFrame': 'at baseline and after 3 months on finerenone'}, {'measure': 'impact of finerenone on filtration fraction compared to placebo', 'description': 'impact of finerenone on filtration fraction compared to placebo', 'timeFrame': 'at baseline and after 3 months on finerenone'}, {'measure': 'impact of finerenone on total renal vascular resistance compared to placebo', 'description': 'impact of finerenone on total renal vascular resistance compared to placebo', 'timeFrame': 'at baseline and after 3 months on finerenone'}, {'measure': 'impact of finerenone on intraglomerular resistances (resistance of the afferent and efferent arterioles) and intraglomerular pressure (GOMEZ formulae) compared to placebo', 'description': 'impact of finerenone on intraglomerular resistances (resistance of the afferent and efferent arterioles) and intraglomerular pressure (GOMEZ formulae) compared to placebo', 'timeFrame': 'at baseline and after 3 months on finerenone'}, {'measure': 'impact of finerenone on the magnitude of stimulation of renal nitric oxide activity due 318 to L-arginine infusion compared to placebo', 'description': 'impact of finerenone on the magnitude of stimulation of renal nitric oxide activity due 318 to L-arginine infusion compared to placebo', 'timeFrame': 'at baseline and after 3 months on finerenone'}]",7,18 Years,75 Years,ALL,False,University of Erlangen-Nürnberg Medical School,OTHER,1,75.0,ESTIMATED,2025-09-01T16:18:23.444917,v2_robust,True,True,False,False,False,
NCT05170958,A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors,"A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of LBL-024 in Patients With Advanced Malignant Tumors",LBL-024 for Injection,"['LBL-024 for Injection', 'LBL-024']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Advanced Solid Tumor,['Advanced Solid Tumor'],[],RECRUITING,,2022-01-06,2026-12,"[{'measure': 'Maximum tolerated dose (MTD)', 'description': 'During the dose-escalation phase, the highest dose of dose-limiting toxicity for subjects less than or equal to 1/6 of the study drug within 3 weeks of starting treatment in Phase I study.', 'timeFrame': 'All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal （Visit 30 days after discontinuation of treatment or withdraw from the visit）'}, {'measure': 'Dose-limiting toxicities（DLT)', 'description': 'During the DLT observation period, the subject has an event that is reasonably related to the test drug (possibly, likely or definitely related) in Phase I study.', 'timeFrame': 'Within 3 weeks after receiving the first dose of the test drug'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'Defined as the percentage of subjects having a Complete Response or Partial Response(ORR, including after immunotherapy complete response (iCR) and partial response (iPR)),will be determined by investigator assessment of radiographic disease assessments per RECIST V1.1. It was used to evaluate the efficacy of LBL-024 in Phase II study.', 'timeFrame': 'All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal （Visit 30 days after discontinuation of treatment or withdraw from the visit）'}]","[{'measure': 'Adverse events and serious adverse events', 'description': 'Laboratory examination, physical examination, vital signs and electrocardiogram, etc.', 'timeFrame': 'All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal （Visit 30 days after discontinuation of treatment or withdraw from the visit）'}, {'measure': 'Maximum serum concentration (Cmax)', 'description': 'To determine the PK profile of LBL-024', 'timeFrame': 'All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal （Visit 30 days after discontinuation of treatment or withdraw from the visit）'}, {'measure': 'Immunogenicity', 'description': 'Incidence of subjects with anti-drug antibody (ADA) and neutralizing antibody (if applicable)', 'timeFrame': 'All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal （Visit 30 days after discontinuation of treatment or withdraw from the visit）'}, {'measure': 'Disease Control Rate(DCR)', 'description': 'Defined as percentage of participants having CR, PR, iCR，iPR or SD as best on-study response', 'timeFrame': 'Visit 30 days after discontinuation of treatment or withdraw from the visit'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Defined as the time from random assignment in a clinical trial to disease progression or death from any cause, has recently become an endpoint of considerable interest in the study of new oncology drugs.', 'timeFrame': 'All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal（Visit 30 days after discontinuation of treatment or withdraw from the visit）'}]",8,18 Years,80 Years,ALL,False,"Nanjing Leads Biolabs Co.,Ltd",INDUSTRY,0,396.0,ESTIMATED,2025-09-01T16:18:23.445023,v2_robust,True,True,False,False,True,
NCT04063358,Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery,Timing of Anti-vascular Endothelial Growth Factor（Anti-VEGF） Intravitreous Injections for Diabetic Macular Edema(DME) in Patients Undergoing Cataract Surgery,Lucentis,['Lucentis'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Diabetic Macular Edema,"['Diabetic Macular Edema', 'Cataract']",[],UNKNOWN,,2019-08-22,2021-08-31,"[{'measure': 'Change in best-corrected visual acuity (BCVA)', 'description': 'BCVA is a measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if uncorrected eyesight is 20/200, but patient can see 20/20 with glasses, the BCVA is 20/20.', 'timeFrame': '1 month, 3 months , 6 months and 12 months after cataract surgery'}, {'measure': 'Change in optical coherence tomography (OCT) central subfield (CSF) thickness', 'description': 'Optical coherence tomography (OCT) is an important imaging modality in the evaluation and management of retinal diseases. Change in central subfield (CSF) thickness will be measured and recorded.', 'timeFrame': '24 hours post-operatively, 1 month, 3 months , 6 months and 12 months after cataract surgery'}]","[{'measure': 'Total number of postoperative injections', 'description': 'Total number of postoperative injections will be calculated', 'timeFrame': '12 months after cataract surgery'}, {'measure': 'percentage of patients with diabetic retinopathy progression', 'description': 'patients with diabetic retinopathy progression will be calculated', 'timeFrame': '12 months after cataract surgery'}]",4,18 Years,,ALL,False,Second Military Medical University,OTHER,0,90.0,ESTIMATED,2025-09-01T16:18:23.445166,v2_robust,True,True,False,False,False,
NCT00853658,Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure,"A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE).",Enalapril,"['Enalapril', 'Aliskiren', 'SPP100']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Heart Failure,['Chronic Heart Failure'],"['Chronic Heart Failure', 'Cardiovascular death', 'CHF hospitalization', 'morbi-mortality trial', 'outcome study', 'endpoint driven', 'plasma renin activity', 'renin angiotensin aldosterone system', 'direct renin inhibitors', 'BNP', 'KCCQ', 'eGFR', '(NYHA class II to IV) with elevated', 'BNP and reduced LVEF']",COMPLETED,,2009-03,2015-10,"[{'measure': 'Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization', 'description': 'Number of participants that had first occurrence of the composite endpoint, which is defined as either CV death or HF hospitalization due to HF.', 'timeFrame': 'up to End of Study (78 months)'}]","[{'measure': 'Change From Baseline to Month 12 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score', 'description': 'Change from baseline to Month 12 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score. KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ clinical summary score is a composite assessment of physical limitations and total symptom scores. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.', 'timeFrame': 'Baseline, Month 12'}, {'measure': 'All Cause Death', 'description': 'Number of patients - All-cause death. All-cause death is common in Heart Failure HF patients this measures how many patients had this event.', 'timeFrame': 'up to end of study (78 months)'}]",3,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,7064.0,ACTUAL,2025-09-01T16:18:23.445205,v2_robust,True,True,True,False,False,
NCT06258148,A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial of TG103 Injection Monotherapy Subjects With Type 2 Diabetes Mellitus",TG103,"['TG103', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],[],ACTIVE_NOT_RECRUITING,,2024-03-15,2026-11,"[{'measure': 'Changes in glycosylated hemoglobin (HbA1c)', 'timeFrame': 'Baseline through Week28'}]","[{'measure': 'Changes in HbA1c', 'timeFrame': 'Baseline through Week52'}, {'measure': 'The percentage of HbA1c≤6.5% and the percentage of HbA1c≤7%', 'timeFrame': 'Week28 and 52'}, {'measure': 'Change in fasting plasma glucose (FPG)', 'timeFrame': 'Baseline through Week 28 and 52'}, {'measure': 'Change in weight', 'timeFrame': 'Baseline through Week 28 and 52'}, {'measure': 'Change in 2h-postprandial plasma glucose (2h-PPG)', 'timeFrame': 'Baseline through Week 28 and 52'}, {'measure': 'Change in mean 7-point blood glucose curve ， Change in mean postprandial blood glucose increment .', 'timeFrame': 'Baseline through Week 28 and 52'}, {'measure': 'Change in blood lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol)', 'timeFrame': 'Baseline through Week 28 and 52'}, {'measure': 'Proportion of subjects receiving remedial therapy', 'timeFrame': 'Week 28 and 52'}, {'measure': 'Incidence of adverse events', 'timeFrame': 'Week-2 through 52'}, {'measure': 'Blood concentrations of TG103', 'timeFrame': 'Week 0, 4, 8,16, 28,36, 44,52 and 55'}, {'measure': 'The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (NAb)', 'timeFrame': 'Week 0, 4, 8,16, 28,36, 44,52 and 55'}]",12,18 Years,75 Years,ALL,False,"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.",INDUSTRY,0,465.0,ACTUAL,2025-09-01T16:18:23.445292,v2_robust,True,True,False,False,True,
NCT00215748,Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel,Feasibility of A Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Treated With Weekly Docetaxel,Dexamethasone,['Dexamethasone'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,"['Breast Cancer', 'Lung Cancer']","['Elderly', 'Weekly']",TERMINATED,slow accrual,2004-08,2007-04,"[{'measure': 'To evaluate the feasibility of a reduced dexamethasone pre-medication dose in elderly lung and breast cancer patients receiving weekly docetaxel therapy with respect to incidence of: Grade 3/4 fluid retention'}, {'measure': 'Grade 3/4 hypersensitivity'}]","[{'measure': 'To evaluate the incidence of toxicity of a reduced dexamethasone pre-medication dose in elderly lung and breast cancer patients receiving weekly docetaxel with respect to: fluid retention (all grades)'}, {'measure': 'hypersensitivity (all grades)'}]",4,65 Years,,ALL,False,Geriatric Oncology Consortium,OTHER,1,40.0,ESTIMATED,2025-09-01T16:18:23.445316,v2_robust,True,True,False,True,False,slow accrual
NCT04401748,Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome,"A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)",Venetoclax,"['Azacitidine', 'Venclexta', 'AZA', 'GDC-0199', 'Placebo', 'ABT-199', 'Venetoclax']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Myelodysplastic Syndrome (MDS),['Myelodysplastic Syndrome (MDS)'],"['MDS', 'Myelodysplastic Syndrome', 'Venetoclax', 'Azacitidine', 'AZA', 'Venclexta']",ACTIVE_NOT_RECRUITING,,2020-09-10,2026-03,"[{'measure': 'Overall survival (OS)', 'description': 'OS is defined as the number of days from the date of randomization to the date of death of any cause, or last known date to be alive.', 'timeFrame': 'Up To 5 Years'}]","[{'measure': 'Modified Overall Response (mOR)', 'description': 'mOR \\[complete remission (CR) + marrow complete remission (mCR) + partial response (PR)\\] is defined as achieving a CR, mCR, or PR at any time point during the study per the modified International Working Group (IWG) 2006 criteria for myelodysplastic syndrome (MDS).', 'timeFrame': 'Up To 5 Years'}, {'measure': 'Percentage of Participants Achieving Overall Hematological Improvement (HI)', 'description': 'Overall HI is defined as achieving the response of HI-platelet or HI-neutrophil, or HI-erythroid at any time point during the study prior to post-treatment therapy per the modified IWG 2006 criteria for MDS.', 'timeFrame': 'Up to 5 Years'}, {'measure': 'Complete Remission (CR)', 'description': 'CR is defined as achieving a complete remission at any time point during the study per the modified International Working Group (IWG) 2006 criteria for myelodysplastic syndrome (MDS).', 'timeFrame': 'Up To 36 Months'}, {'measure': 'Percentage of Participants Achieving Transfusion Independence (TI) Who are Transfusion Dependent at Baseline', 'description': 'TI is when the participants who were transfusion dependent on red blood cell (RBC) and/or Platelet at baseline achieve transfusion independence post baseline. TI is a period of at least 56 days with no transfusion after the date of the first dose of study drug to the last dose of study drug + 30 days, or 1 day before the date of progressive disease/ relapse from CR or PR per the modified IWG 2006 criteria for MDS, or 1 day before the initiation of post-treatment therapy or 1 day before death, whichever is earliest.', 'timeFrame': 'Up To 5 Years'}, {'measure': 'Time to Deterioration in Physical Functioning as Measured by Physical Functioning Domain of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Scale', 'description': 'Time to deterioration in physical functioning, as measured by the EORTC QLQ-C30 physical functioning score is defined as the time from the date of randomization to the date of death of any cause, or the first time worsening of score from baseline \\>= a pre-specified threshold. Participants rate items on a 4-point scale, with 1 as ""not at all"" and 4 as ""very much.""', 'timeFrame': 'Up To 5 Years'}, {'measure': 'Change in Patient-Reported Outcomes Measurement Information System (PROMIS)-Fatigue Short Form (SF) 7a Scale Score', 'description': 'Fatigue will be assessed using the PROMIS Fatigue SF 7a Global Fatigue Score. PROMIS Fatigue SF 7a is a 7-item questionnaire that assesses the impact and experience of fatigue over the past 7 days. Participants rate items on a 5-point scale, with 1 as ""never"" an 5 as ""always"".', 'timeFrame': 'Up To 5 Years'}, {'measure': 'Overall Response (OR)', 'description': 'OR \\[complete remission (CR) + partial response (PR)\\] is defined as achieving a CR or PR at any time point during the study per the modified IWG 2006 criteria for MDS.', 'timeFrame': 'Up To 5 Years'}]",8,18 Years,,ALL,False,AbbVie,INDUSTRY,1,531.0,ACTUAL,2025-09-01T16:18:23.445331,v2_robust,True,True,False,False,False,
NCT02820155,Phase I Single and Multiple Escalating Dose Study of RGN1016 in Healthy Male Subjects,"A Double-Blind, Randomized, Placebo-Controlled, Dose-Escalating, Single Dose and Multiple Dose Study to Evaluate the Safety and Pharmacokinetics of RGN1016 in Healthy Male Subjects",RGN1016,"['RGN1016', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"[""Alzheimer's disease,cognitive function""]",UNKNOWN,,2016-06,2017-02,"[{'measure': 'Number of incidence of Adverse Events.', 'timeFrame': 'up to14 days'}]","[{'measure': 'Area under the plasma concentration-time curve (AUC)', 'timeFrame': '8 days'}, {'measure': 'Time to peak drug concentration (Tmax)', 'timeFrame': '8 days'}, {'measure': 'Maximum Plasma Concentration (Cmax)', 'timeFrame': '8 days'}, {'measure': 'Half-life T1/2', 'timeFrame': '8 days'}]",5,20 Years,45 Years,MALE,True,National Taiwan University Hospital,OTHER,1,80.0,ESTIMATED,2025-09-01T16:18:23.445505,v2_robust,True,True,False,False,True,
NCT00412555,A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.,An Open-label Multi-center Trial of Oseltamivir for the Seasonal Prophylaxis of Influenza in Children.,oseltamivir [Tamiflu],['oseltamivir [Tamiflu]'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Influenza,['Influenza'],[],COMPLETED,,2006-12,2007-05,"[{'measure': 'AEs, laboratory parameters, vital signs.', 'timeFrame': 'Throughout study'}, {'measure': 'Percentage of patients with laboratory confirmed clinical influenza', 'timeFrame': 'Throughout study'}]","[{'measure': 'Percentage of subjects with asymptomatic influenza; percentage with an influenza-like illness.', 'timeFrame': 'Throughout study'}]",3,1 Year,12 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,52.0,ACTUAL,2025-09-01T16:18:23.445640,v2_robust,True,True,True,False,False,
NCT01781455,A Study of BBI503 in Adult Patients With Advanced Solid Tumors,A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors,BBI503,['BBI503'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,"Cancer, Advanced Solid Tumors","['Cancer, Advanced Solid Tumors']",[],COMPLETED,,2012-02,2020-06,"[{'measure': 'Number of participants with Adverse Events as a Measure of Safety and Tolerability', 'description': 'Assessment of safety of BBI503 by reporting of adverse events and serious adverse events.', 'timeFrame': 'Adverse events will be assessed at baseline, while the participant is taking BBI503, and for 30 days after stopping therapy. The average length of this duration is expected to be approximately 4 months.'}, {'measure': 'Determination of the recommended Phase 2 dose', 'timeFrame': 'Up to treatment discontinuation + 30 days with an estimated treatment duration of 4 weeks'}]","[{'measure': 'Pharmacokinetic profile (Area under the curve) of BBI503', 'description': 'Blood sampling to assess the pharmacokinetic profile (Area under the curve) of BBI503.', 'timeFrame': 'During the first 28 days of treatment'}, {'measure': 'Pharmacodynamic activity', 'description': 'Tumor Biopsy(s) to provide information on analysis of the targets and downstream genes/ effect of BBI503 on cancer stem cells through immunohistochemistry.', 'timeFrame': 'During the first 28 days of treatment'}, {'measure': 'Anti-tumor activity', 'description': 'To assess the preliminary anti-tumor activity of BBI503.', 'timeFrame': 'Participants will be assessed every eight weeks for anti-tumor activity.'}]",5,18 Years,,ALL,False,"Sumitomo Pharma America, Inc.",INDUSTRY,0,311.0,ACTUAL,2025-09-01T16:18:23.445650,v2_robust,True,True,True,False,True,
NCT00285155,Assessment of Bupropion on Cognitive Function and Behaviour in Healthy Volunteers,Assessment of Bupropion on Cognitive Function and Behaviour in Healthy Volunteers,Bupropion,['Bupropion'],1,INTERVENTIONAL,['NA'],,,Healthy,['Healthy'],"['bupropion', 'repeated dose', 'healthy volunteers', 'cognitive function', 'behaviour', 'tolerance', 'Persons']",COMPLETED,,2004-11,2006-02,"[{'measure': 'Cognitive and executive functions after the first dose and the 14-day treatment.Subjective feelings after the first dose and the 14-day treatment : ARCI, Norris and POMS scales.'}]",[{'measure': 'Sleep questionnaire after the 14-day treatment. Energy intake after the 14-day treatment. Blood pressure after one dose and the 14-day treatment'}],2,18 Years,35 Years,MALE,True,"University Hospital, Montpellier",OTHER,0,12.0,ESTIMATED,2025-09-01T16:18:23.445658,v2_robust,True,True,True,False,False,
NCT01240655,A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors,A Phase Ib Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors,LCL161,"['LCL161', 'Paclitaxel']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumors,['Solid Tumors'],"['LCL161', 'solid tumors', 'paclitaxel']",COMPLETED,,2011-04,2015-01,"[{'measure': 'Maximum tolerated dose (MTD)/RP2D of LCL161 when administered in combination with once weekly paclitaxel', 'timeFrame': '24 months'}]","[{'measure': 'Safety and tolerability of the combination, including acute and chronic toxicities', 'timeFrame': '24 months'}, {'measure': 'Pharmacokinetics of both LCL161 and paclitaxel when administered in combination (AUC0-∞, Cmax, tmax and other parameters as appropriate)', 'timeFrame': '24 months'}, {'measure': 'Preliminary anti-tumor activity associated with this combination treatment', 'timeFrame': '24 months'}, {'measure': 'Target inhibition, cell death, and cytokines in surrogate and tumor tissues', 'timeFrame': '24 months'}]",5,18 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,76.0,ACTUAL,2025-09-01T16:18:23.445744,v2_robust,True,True,True,False,True,
NCT02821026,Omental Islet Transplant,Allogeneic Islet Cells Transplanted Into the Omentum,Anti-Thymocyte Globulin,"['Anti-Thymocyte Globulin', 'Mycophenolate mofetil', 'Sirolimus', 'Etanercept', 'Thymoglobulin®', 'Tacrolimus']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Type 1 Diabetes,['Type 1 Diabetes'],[],COMPLETED,,2016-05,2019-11-13,"[{'measure': 'The incidence of Serious Adverse Events', 'timeFrame': '2 years following islet transplant'}, {'measure': 'The proportion of subjects with HbA1c ≤ 6.5% at 1 year AND free of severe hypoglycemic events from Day 28 to Day 365, inclusive, after the islet transplant', 'timeFrame': 'From Day 28 to Day 365 inclusive after islet transplant'}]","[{'measure': 'The percent reduction in insulin requirements at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'The percent reduction in insulin requirements at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'The percent reduction in insulin requirements at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in HbA1c at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in HbA1c at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in HbA1c at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in Mean Amplitude of Glycemic Excursions at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in Mean Amplitude of Glycemic Excursions at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in Mean Amplitude of Glycemic Excursions at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in Lability Index at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in Lability Index at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in Lability Index at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in Ryan hypoglycemia severity score at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in Ryan hypoglycemia severity score at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in Ryan hypoglycemia severity score at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in Clarke score at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in Clarke score at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in Clarke score at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in number of severe hypoglycemic episodes at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in number of severe hypoglycemic episodes at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in number of severe hypoglycemic episodes at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in basal (fasting) and 90- min glucose and c-peptide derived from the mixed-meal tolerance test at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in basal (fasting) and 90- min glucose and c-peptide derived from the mixed-meal tolerance test at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in basal (fasting) and 90- min glucose and c-peptide derived from the mixed-meal tolerance test at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in beta-score at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in beta-score at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in beta-score at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in C-peptide creatinine ratio at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in C-peptide creatinine ratio at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in C-peptide creatinine ratio at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in acute insulin response to glucose at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in acute insulin response to glucose at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in acute insulin response to glucose at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in insulin sensitivity at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in insulin sensitivity at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in insulin sensitivity at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in disposition index derived from the insulin-modified frequently-sampled intravenous glucose tolerance (FSIGT) test at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in disposition index derived from the insulin-modified frequently-sampled intravenous glucose tolerance (FSIGT) test at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in disposition index derived from the insulin-modified frequently-sampled intravenous glucose tolerance (FSIGT) test at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in glucose variability and hypoglycemia duration derived from the continuous glucose monitoring system® (CGMS) at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in glucose variability and hypoglycemia duration derived from the continuous glucose monitoring system® (CGMS) at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in glucose variability and hypoglycemia duration derived from the continuous glucose monitoring system® (CGMS) at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in diabetes distress scores measured by Diabetes Distress scale at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in diabetes distress scores measured by Diabetes Distress scale at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in diabetes distress scores measured by Diabetes Distress scale at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in health status measured by EQ-5D at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in health status measured by EQ-5D at Day 365± 14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in health status measured by EQ-5D at Day 730± 14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in the score measured by Hypoglycemia Fear Survey-HFS at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in the score measured by Hypoglycemia Fear Survey-HFS at Day 365±14after islet transplant', 'timeFrame': 'Baseline and Day 365± 4 after islet transplant'}, {'measure': 'Change from baseline in the score measured by Hypoglycemia Fear Survey-HFS at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Change from baseline in health scores obtained through SF-36v2 health survey at Day 75±7 after islet transplant', 'timeFrame': 'Baseline and Day 75±7 after islet transplant'}, {'measure': 'Change from baseline in health scores obtained through SF-36v2 health survey at Day 365±14 after islet transplant', 'timeFrame': 'Baseline and Day 365±14 after islet transplant'}, {'measure': 'Change from baseline in health scores obtained through SF-36v2 health survey at Day 730±14 after islet transplant', 'timeFrame': 'Baseline and Day 730±14 after islet transplant'}, {'measure': 'Incidence of AEs associated with conventional immunosuppression', 'timeFrame': '2 years following islet transplant'}, {'measure': 'Renal function (serum creatinine and GFR)', 'timeFrame': 'Day 75 ± 7, Day 365 ± 14 and Day 730± 14 after islet transplant'}, {'measure': 'Lipid profiles (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol)', 'timeFrame': 'Day 75 ± 7, Day 365 ± 14 and Day 730± 14 after islet transplant'}, {'measure': 'The incidence of AEs related to the islet transplant procedure', 'timeFrame': '2 years following islet transplant'}, {'measure': 'The incidence of immune sensitization defined by presence of anti-HLA antibodies absent prior to transplantation', 'timeFrame': '2 years following islet transplant'}, {'measure': 'The incidence of discontinuation of immunosuppression', 'timeFrame': '2 years following islet transplant'}]",62,18 Years,65 Years,ALL,False,University of Alberta,OTHER,0,4.0,ACTUAL,2025-09-01T16:18:23.445920,v2_robust,True,True,True,False,True,
NCT04500626,Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients,Multicentre Randomized Controlled Trial of Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients,Oxygen,['Oxygen'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Covid19,['Covid19'],['Hyperbaric oxygen therapy'],UNKNOWN,,2021-04-15,2022-08,"[{'measure': '7-level COVID Ordinal Outcome Scale', 'description': ""7-level scale based on patient's current status and need for oxygenation, also ability to resume normal activities (at higher levels). Range is 1-7. Higher number indicates better clinical outcome."", 'timeFrame': 'Measured on Day 7'}]","[{'measure': 'Length of hospital stay', 'description': 'Measured in days', 'timeFrame': 'Duration of study (to Day 28)'}, {'measure': 'Days with oxygen supplementation', 'description': 'Number of days with oxygen supplementation', 'timeFrame': 'Duration of study (to Day 28)'}, {'measure': 'Daily oxygen flow values required to obtain saturation values ≥90%,', 'description': 'Measured in L/min', 'timeFrame': 'Duration of study (to Day 28)'}, {'measure': 'ICU admission', 'description': 'Yes/No', 'timeFrame': 'Duration of study (to Day 28)'}, {'measure': 'ICU length of stay', 'description': 'Measured in days, if applicable', 'timeFrame': 'Duration of study (to Day 28)'}, {'measure': 'Days on invasive mechanical ventilation or high flow oxygenation', 'description': 'Number of days on ventilator', 'timeFrame': 'Duration of study (to Day 28)'}, {'measure': 'Major arterial and venous thrombotic events', 'description': 'e.g. stroke, pulmonary embolism, deep vein thrombosis', 'timeFrame': 'Duration of study (to Day 28)'}, {'measure': 'Sleep quality', 'description': 'Sleep Quality Scale, measured from 0 to 10. Higher number indicates worse sleep quality: 0 = ""best possible sleep"", 10 = ""worst possible sleep"". Capelleri et. al; Health and Quality of Life Outcomes 2009: 7:54', 'timeFrame': 'Duration of study (to Day 28)'}, {'measure': 'Fatigue', 'description': 'Single-Item Fatigue Report Mark, measured from 1 to 10. Higher number indicates worse fatigue: 1 = ""not at all"", 10 = ""extremely"". van Hooff et al; J Occup Health 2007; 49:224-234.', 'timeFrame': 'Duration of study (to Day 28)'}, {'measure': '7-level COVID Ordinal Outcome Scale', 'description': 'Same scale as the primary outcome; different timing as a secondary outcome. Range is 1-7. Higher number indicates better clinical outcome.', 'timeFrame': 'Measured on Day 28'}, {'measure': 'Mortality', 'description': 'Number of deaths', 'timeFrame': 'Duration of study (to Day 28)'}, {'measure': 'Incidence of any adverse events related to HBOT', 'description': 'Number of adverse events', 'timeFrame': 'Duration of study (to Day 28)'}]",13,18 Years,,ALL,False,Ottawa Hospital Research Institute,OTHER,1,234.0,ESTIMATED,2025-09-01T16:18:23.445943,v2_robust,True,True,False,False,True,
NCT00529126,Phase 2 Dose-Ranging Study of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy,"A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy",SKY0402,"['EXPAREL', 'Bupivacaine HCl', 'SKY0402', 'Marcaine 0.25% with epinephrine 1:200,000']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Postoperative Pain,['Postoperative Pain'],"['hemorrhoidectomy', 'pain', 'Postoperative', 'analgesia']",COMPLETED,,2007-09,2008-07,"[{'measure': 'Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) Pain Intensity Scores From 0 Through 72 Hours', 'description': 'To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain. The subject was to rest in this position for at least 5 minutes before responding to the following question: ""On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain are you having right now?""', 'timeFrame': '0 to 72 hours'}]","[{'measure': 'Participants With Adverse Events Through 72 Hours or Serious Adverse Events Through 30 Days', 'timeFrame': 'Up to 30 days'}]",2,18 Years,,ALL,False,"Pacira Pharmaceuticals, Inc",INDUSTRY,0,100.0,ACTUAL,2025-09-01T16:18:23.445978,v2_robust,True,True,True,False,True,
NCT06658626,"A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)","An Open-label Phase 1 Study to Evaluate Metabolism, Excretion, and Mass Balance of [¹⁴C]MK-0616 in Healthy Participants",[¹⁴C]Enlicitide chloride,"['[¹⁴C]Enlicitide chloride', 'MK-0616']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2023-03-10,2023-08-02,"[{'measure': 'Cumulative Amount of Radioactivity Excreted in Urine (Aeu)', 'description': 'Urine samples will be collected to determine the Aeu of \\[¹⁴C\\]enlicitide chloride.', 'timeFrame': 'At designated timepoints (up to 15 days)'}, {'measure': 'Cumulative Amount of Radioactivity Excreted in Feces (Aef)', 'description': 'Fecal samples will be collected to determine the Aef of \\[¹⁴C\\]enlicitide chloride.', 'timeFrame': 'At designated timepoints (up to 15 days)'}, {'measure': 'Cumulative Percentage of Radioactivity Excreted in Urine (feu)', 'description': 'Urine samples will be collected to determine the feu of \\[¹⁴C\\]enlicitide chloride.', 'timeFrame': 'At designated timepoints (up to 15 days)'}, {'measure': 'Cumulative Percentage of Radioactivity Excreted in Feces (fef)', 'description': 'Fecal samples will be collected to determine the fef of \\[¹⁴C\\]enlicitide chloride.', 'timeFrame': 'At designated timepoints (up to 15 days)'}, {'measure': 'Plasma Enlicitide Chloride: Area Under the Concentration-Time Curve from Time 0 to the Last Measurable Concentration (AUC0-t)', 'description': 'Plasma samples will be collected to determine the AUC0-t of enlicitide chloride.', 'timeFrame': 'At designated timepoints (up to 15 days)'}, {'measure': 'Plasma Enlicitide Chloride: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-inf)', 'description': 'Plasma samples will be collected to determine the AUC0-inf of enlicitide chloride.', 'timeFrame': 'At designated timepoints (up to 15 days)'}, {'measure': 'Plasma Enlicitide Chloride: Maximum Plasma Concentration (Cmax)', 'description': 'Plasma samples will be collected to determine the Cmax of enlicitide chloride.', 'timeFrame': 'At designated timepoints (up to 15 days)'}, {'measure': 'Plasma Enlicitide Chloride: Apparent Terminal Half-life (t1/2)', 'description': 'Plasma samples will be collected to determine the t1/2 of enlicitide chloride.', 'timeFrame': 'At designated timepoints (up to 15 days)'}, {'measure': 'Plasma Enlicitide Chloride: Time to Maximum Plasma Concentration (Tmax)', 'description': 'Plasma samples will be collected to determine the Tmax of enlicitide chloride.', 'timeFrame': 'At designated timepoints (up to 15 days)'}, {'measure': 'Plasma Total Reactivity: AUC0-t', 'description': 'Plasma samples will be collected to determine the AUC0-t of total reactivity.', 'timeFrame': 'At designated timepoints (up to 15 days)'}, {'measure': 'Plasma Total Reactivity: AUC0-inf', 'description': 'Plasma samples will be collected to determine the AUC0-inf of total reactivity.', 'timeFrame': 'At designated timepoints (up to 15 days)'}, {'measure': 'Plasma Total Reactivity: Cmax', 'description': 'Plasma samples will be collected to determine the Cmax of total reactivity.', 'timeFrame': 'At designated timepoints (up to 15 days)'}, {'measure': 'Plasma Total Reactivity: t1/2', 'description': 'Plasma samples will be collected to determine the t1/2 of total reactivity.', 'timeFrame': 'At designated timepoints (up to 15 days)'}, {'measure': 'Plasma Total Reactivity: Tmax', 'description': 'Plasma samples will be collected to determine the Tmax of total reactivity.', 'timeFrame': 'At designated timepoints (up to 15 days)'}, {'measure': 'Enlicitide Chloride to Total Radioactivity Ratio of Area Under the Concentration-Time Curve from Time 0 to the Last Detectable Sample (enlicitide chloride AUC0-x/total radioactivity AUC0-x)', 'description': 'Plasma samples will be collected to determine the enlicitide chloride AUC0-x/total radioactivity AUC0-x.', 'timeFrame': 'At designated timepoints (up to 15 days)'}]","[{'measure': 'Number of Participants Who Experience an Adverse Event (AE)', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.', 'timeFrame': 'Up to approximately 29 days'}, {'measure': 'Number of Participants Who Discontinue the Study Due to an AE', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.', 'timeFrame': 'Up to approximately 29 days'}]",17,18 Years,60 Years,MALE,True,Merck Sharp & Dohme LLC,INDUSTRY,0,8.0,ACTUAL,2025-09-01T16:18:23.446003,v2_robust,True,True,True,False,True,
NCT03092726,A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia,"A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia",ASP8062,"['ASP8062', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Fibromyalgia,['Fibromyalgia'],"['ASP8062', 'Fibromyalgia']",COMPLETED,,2017-05-08,2018-03-06,"[{'measure': 'Change From Baseline to Week 8 in Mean Daily Average Pain Score as Assessed by Numerical Rating Scale (NRS)', 'description': 'The mean daily average pain score was assessed thorugh the Daily Average Pain NRS, which is a generic instrument for the assessment of pain that consists of a single question that asks participants to record their daily average pain on an 11-point scale, where 0 anchors ""no pain"" and 10 ""pain as bad as you can imagine."" The mean daily average pain score was calculated from data recorded by participants daily in the electronic diary, and the recall period was the last 24 hours. A negative change indicated a reduction/improvement from baseline (i.e., a favorable outcome).', 'timeFrame': 'Baseline and week 8'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs)', 'description': 'Safety was assessed by adverse events (AEs), which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study drug or was clinically significant. A TEAE was defined as any AE that started or worsened after the first dose of study drug up to 30 days after the last dose of study drug. AEs were considered serious (SAEs) if the AE resulted in death, was life-threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly, or birth defect or required inpatient hospitalization or led to prolongation of hospitalization. TEAEs in drug abuse, dependence and withdrawal standardized MedDRA query (SMQ) are special AEs of interest grouped together using the SMQ tool (MedDRA v20.0).', 'timeFrame': 'From first dose of study drug up to 30 days after last dose of study drug (up to 87 days)'}, {'measure': 'Number of Participants With an Affirmative Response to Columbia Suicide Severity Rating Scale (C-SSRS): Suicidal Ideation', 'description': 'The Columbia Suicide Severity Rating Scale (C-SSRS) is a questionnaire used for suicide risk assessment. Affirmative or negative responses were provided to 5 items to suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods (not plan) without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent).', 'timeFrame': 'Weeks 1 to 8'}, {'measure': 'Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behavior', 'description': 'The C-SSRS is a questionnaire used for suicide risk assessment. Affirmative or negative responses were provided to 5 items to suicidal behavior (1. Preparatory acts or behavior, 2. Aborted attempt, 3. Interrupted attempt, 4. Actual attempt, 5. Completed suicide).', 'timeFrame': 'Weeks 1 to 8'}]","[{'measure': 'Percentage of Participants With ≥ 30% Reduction From Baseline to Week 8 and End of Treatment (EOT) in Mean Daily Average Pain Score as Assessed by NRS', 'description': 'The mean daily average pain score was assessed through the Daily Average Pain NRS, which is a generic instrument for the assessment of pain that consists of a single question that asks participants to record their daily average pain on an 11-point scale, where 0 anchors ""no pain"" and 10 ""pain as bad as you can imagine."" The mean daily average pain score was calculated from data recorded by participants daily in the electronic diary, and the recall period was the last 24 hours. For the week 8 analysis, participants with missing baseline or week 8 data were classified as nonresponders. For EOT analysis, participants with missing baseline or EOT data were classified as nonresponders.', 'timeFrame': 'Baseline to week 8'}, {'measure': 'Percentage of Participants With ≥ 50% Reduction From Baseline to Week 8 and EOT in Mean Daily Average Pain Score as Assessed by NRS', 'description': 'The mean daily average pain score was assessed thorugh the Daily Average Pain NRS, which is a generic instrument for the assessment of pain that consists of a single question that asks participants to record their daily average pain on an 11-point scale, where 0 anchors ""no pain"" and 10 ""pain as bad as you can imagine."" The mean daily average pain score was calculated from data recorded by participants daily in the electronic diary, and the recall period was the last 24 hours. For the week 8 analysis, participants with missing baseline or week 8 data were classified as nonresponders. For EOT analysis, participants with missing baseline or EOT data were classified as nonresponders.', 'timeFrame': 'Baseline to week 8'}, {'measure': 'Change From Baseline to Weeks 2, 4, 8 and EOT in the Fibromyalgia Impact Questionnaire Revised (FIQR) Function Subscale Score', 'description': 'The FIQR was developed to capture total spectrum of problems related to fibromyalgia and the responses to therapy. The 21-item FIQR contains 3 subscales: function (9 questions), overall impact (2 questions), and symptoms (10 questions). Participants answer each question on an 11-point NRS, with anchors appropriate to each question on a tablet device during a visit. The recall period was the last 7 days or the last time the activity was performed if not within the 7-day recall period. The Function subscale has a range of scores of 0 to 90, with a lower score indicating better (higher) function. A negative change indicated a reduction/improvement from baseline (i.e., a favorable outcome).', 'timeFrame': 'Baseline and weeks 2, 4, 8'}, {'measure': 'Change From Baseline to Weeks 2, 4, 8, and EOT in the FIQR Symptoms Subscale Score', 'description': 'The FIQR was developed to capture the total spectrum of problems related to fibromyalgia and the responses to therapy. The 21-item FIQR contains 3 subscales: function (9 questions), overall impact (2 questions), and symptoms (10 questions). Participants answer each question on an 11-point NRS, with anchors appropriate to each question on a tablet device during a visit. The recall period was the last 7 days. The Symptoms subscale range of scores is 0 to 100, with a lower score indicating a better (lower) level of symptoms. A negative change indicates a reduction/improvement from baseline (i.e., a favorable outcome).', 'timeFrame': 'Baseline and weeks 2, 4, 8'}, {'measure': 'Change From Baseline to Weeks 2, 4, 8, and EOT in the FIQR Overall Impact Subscale Score', 'description': 'The FIQR was developed to capture the total spectrum of problems related to fibromyalgia and the responses to therapy. The 21-item FIQR contains 3 subscales: function (9 questions), overall impact (2 questions), and symptoms (10 questions). Participants answer each question on an 11-point NRS, with anchors appropriate to each question on a tablet device during a visit. The recall period was the last 7 days. The Overall Impact subscale has a range of scores from 0 to 20, with a lower score indicating better (lower) impact. A negative change indicated a reduction/improvement from baseline (i.e., a favorable outcome).', 'timeFrame': 'Baseline and weeks 2, 4, 8'}, {'measure': 'Overall Participant Improvement as Assessed by Patient Global Impression of Change (PGIC)', 'description': 'The PGIC is a self-administered 7-point Likert scale that asks participants to evaluate their fibromyalgia relative to baseline. This is a single question and the grade ranges from 1 (""Very Much Improved"") to 7 (""Very Much Worse"").', 'timeFrame': 'Weeks 2, 4, 8'}]",10,18 Years,80 Years,ALL,False,"Astellas Pharma Global Development, Inc.",INDUSTRY,0,183.0,ACTUAL,2025-09-01T16:18:23.446151,v2_robust,True,True,True,False,True,
NCT00512278,Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C,Infliximab (Remicade®) as an Adjunct to Pegylated- Interferon α-2b and Ribavirin in the Treatment of Hepatitis C Virus Infection,Infliximab,"['Remicade', 'Infliximab', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Hepatitis C,['Hepatitis C'],"['Hepatitis', 'HCV', 'Hepatitis C']",COMPLETED,,2007-07,2012-05,"[{'measure': 'A Comparison of the Percentage of Chronic Hepatitis C Subjects (Treatment Naive,Genotype 1) Who Achieve SVR at Week 72, After 48 Weeks of Treatment.', 'description': 'A comparison of the Proportion of Chronic Hepatitis C Subjects (Treatment Naive,Genotype 1) Who Achieve SVR at Week 72, After 48 Weeks of TreatmentSVR in both study arms', 'timeFrame': '72 Weeks from initiation of treatment'}, {'measure': 'Number of Participants Achieving Sustained Virological Response (SVR)', 'description': 'HCV RNA negativity at 24 weeks after completion of all study medications', 'timeFrame': '24 weeks after completion of all study medications'}]","[{'measure': 'A Comparison of the Percentage of Participants With Non-detectable HCV-RNA After 24 Weeks of Therapy.', 'description': 'A comparison of the proportion of the subject population with non-detectable HCV-RNA after 24 wks of therapy.', 'timeFrame': '24 weeks'}, {'measure': 'Percentage of Participants Experiencing Serious Adverse Events', 'description': 'The severity of adverse events was graded according to modified World Health Organization grades as mild, moderate, severe, or life-threatening', 'timeFrame': '72 Weeks from initiation of treatment'}, {'measure': 'Percentage of Participants Experiencing Medically Significant Infections', 'description': 'Medically significant infection was defined as an infection requiring the use of intravenous antibiotics or hospitalization.', 'timeFrame': '72 weeks from initiation of treatment'}]",5,18 Years,,ALL,False,Nizar Zein,OTHER,1,146.0,ACTUAL,2025-09-01T16:18:23.446199,v2_robust,True,True,True,False,True,
NCT03235778,A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China,"A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalated Phase I Clinical Study Trial to Evaluate the Tolerance and Pharmacokinetics of Felbinac Trometamol Injection in Healthy Subjects",Felbinac Trometamol Injection,"['4-Biphenylacetic Acid Trishydroxymettiylaminometnane', 'Felbinac Trometamol Injection', 'normal saline', 'Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],['Tolerance; Pharmacokinetic characteristics'],COMPLETED,,2017-07-17,2018-06-15,"[{'measure': 'Tolerance evaluation index', 'description': 'percent of subjects with adverse reactions', 'timeFrame': 'up to 48.5 hours'}]","[{'measure': 'Tmax', 'description': 'The amount of time that a drug is present at the maximum concentration in serum.', 'timeFrame': 'up to 48.5 hours'}, {'measure': 'Peak Plasma Concentration (Cmax)', 'description': 'The PK parameters of the plasma sample', 'timeFrame': 'up to 48.5 hours'}, {'measure': 't1/2', 'description': 'The PK parameters of the plasma sample', 'timeFrame': 'up to 48.5 hours'}, {'measure': 'Vd', 'description': 'The PK parameters of the plasma sample', 'timeFrame': 'up to 48.5 hours'}, {'measure': 'Mean residence time (MRT) parameter.', 'description': 'The PK parameters of the plasma sample', 'timeFrame': 'up to 48.5 hours'}, {'measure': 'Ke', 'description': 'The PK parameters of the plasma sample', 'timeFrame': 'up to 48.5 hours'}, {'measure': 'Area under the plasma concentration versus time curve (AUC0-∞)', 'description': 'The PK parameters of the plasma sample', 'timeFrame': 'up to 48.5 hours'}, {'measure': 'AUC0-48.5', 'description': 'The PK parameters of the plasma sample', 'timeFrame': 'up to 48.5 hours'}, {'measure': 'Ae0-48.5', 'description': 'The PK parameters of the urine and the stool sample', 'timeFrame': 'up to 48.5 hours'}, {'measure': 'Fe', 'description': 'The PK parameters of the urine and the stool sample', 'timeFrame': 'up to 48.5 hours'}, {'measure': 'CLr', 'description': 'The PK parameters of the urine sample', 'timeFrame': 'up to 48.5 hours'}]",12,18 Years,45 Years,ALL,True,Yiling Pharmaceutical Inc.,INDUSTRY,0,58.0,ACTUAL,2025-09-01T16:18:23.446370,v2_robust,True,True,True,False,True,
NCT00289978,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis,"A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis",Fingolimod 1.25 mg,"['Fingolimod 0.5 mg', 'Fingolimod 1.25 mg', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Relapsing-remitting Multiple Sclerosis,['Relapsing-remitting Multiple Sclerosis'],"['Multiple Sclerosis', 'FTY720', 'Fingolimod']",COMPLETED,,2006-01,2009-07,"[{'measure': 'Estimated Annualized Aggregate Relapse Rate (ARR)', 'description': 'The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group calculated as the total number of confirmed relapses divided by the total number of days on study, multiplied by 365.25.', 'timeFrame': 'Baseline to end of study (Month 24)'}]","[{'measure': 'Percentage of Patients Free of Disability Progression at Month 24 Assessed With the Expanded Disability Status Scale (EDSS)', 'description': 'EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the following: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. A 3-month confirmed disability progression required onset EDSS, 3-month confirming EDSS, and all EDSS in between to meet the disability progression criteria. Percent of free of disability progression was calculated using the Kaplan Meier method.', 'timeFrame': 'Baseline to end of study (Month 24)'}, {'measure': 'Number of New or Newly Enlarged T2 Lesions at Month 24 in Comparison With Baseline', 'description': 'The number of new or newly enlarged T2 lesions at Month 24 in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.', 'timeFrame': 'Baseline to end of study (Month 24)'}]",3,18 Years,55 Years,ALL,False,Novartis,INDUSTRY,0,1272.0,ACTUAL,2025-09-01T16:18:23.446458,v2_robust,True,True,True,False,False,
NCT00990678,Study of Vitamin D Supplementation to Male HIV Sero-positive Patients,Study of Vitamin D Supplementation to Male HIV Sero-positive Patients,Rocaltrol,"['Rocaltrol', 'Vitamin D', 'Calcium']",3,INTERVENTIONAL,['NA'],,,HIV Seropositive,['HIV Seropositive'],"['HIV-1', 'humans', 'vitamin D', '1-hydroxy-vitamin D', 'Rocaltrol', 'calcium', 'complementary therapies']",COMPLETED,,2008-04,2011-01,"[{'measure': 'serum-vitamin D metabolites', 'timeFrame': 'week 0'}, {'measure': 'serum-vitamin D metabolites', 'timeFrame': 'week 2'}, {'measure': 'serum-vitamin D metabolites', 'timeFrame': 'week 4'}, {'measure': 'serum-vitamin D metabolites', 'timeFrame': 'week 8'}, {'measure': 'serum-vitamin D metabolites', 'timeFrame': 'week 12'}, {'measure': 'serum-vitamin D metabolites', 'timeFrame': 'week 16'}]","[{'measure': 'T-lymphocyte fractions Parathyroid hormone ionized calcium', 'timeFrame': 'week 0'}, {'measure': 'T-lymphocyte fractions Parathyroid hormone ionized calcium', 'timeFrame': 'week 2'}, {'measure': 'T-lymphocyte fractions Parathyroid hormone ionized calcium', 'timeFrame': 'week 4'}, {'measure': 'T-lymphocyte fractions Parathyroid hormone ionized calcium', 'timeFrame': 'week 8'}, {'measure': 'T-lymphocyte fractions Parathyroid hormone ionized calcium', 'timeFrame': 'week 12'}, {'measure': 'T-lymphocyte fractions Parathyroid hormone ionized calcium', 'timeFrame': 'week 16'}]",12,18 Years,,MALE,True,Hvidovre University Hospital,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:23.446488,v2_robust,True,True,True,False,False,
NCT02076178,"Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)","A Phase IIa Study to Evaluate the Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)",744 Tablet,"['Placebo Injection', '744 LA Injection', '744 Tablet', 'Placebo Tablet']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Infection, Human Immunodeficiency Virus","['Infection, Human Immunodeficiency Virus']","['Pre-Exposure Prophylaxis', 'HIV integrase', 'Intramuscular Injection', 'GSK1265744']",COMPLETED,,2014-03-27,2016-02-23,"[{'measure': 'Number of Participants With Any Grade 2 or Higher Event in the Injection Phase', 'description': 'Clinical adverse event (AE) were graded using the Division of Acquired Immunodeficiency Syndrome (DAIDS) table for grading the severity of adult and pediatric AE Version 1.0, December 2004; Clarification August 2009. The grades were: 1 (mild)=Symptoms causing no or minimal interference with usual social and functional activities; 2 (moderate)= Symptoms causing greater than minimal interference with usual social and functional activities; 3 (severe)= Symptoms causing inability to perform usual social and functional activities; 4 (potentially life threatening): Symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. Data has been presented for any Grade 2 or higher event in the injection phase for injection phase (Week 5- Week 41).', 'timeFrame': 'Up to Week 41'}, {'measure': 'Number of Participants Who Recieved Injection Site Reaction (ISR) Related Concomitant Medication in the Injection Phase', 'description': 'The concurrent medications that were consumed by participants during the injection phase were of the class nervous system, musculo-skeletal system, genito urinary systems and sex hormones, various, respiratory system, dermatologicals, alimentary tract and metabolism, sensory organs, systemic hormonal preparations, excluding sex hormones, blood and blood forming organs, cardiovascular system. The participants who took medication from any of the above class of during the injection phase (Week 5-Week 41) have been presented.', 'timeFrame': 'Up to Week 41'}, {'measure': 'Number of Participants Who Experienced Grade 2 or Higher Laboratory Results in the Injection Phase', 'description': 'The severity of laboratory results was graded according to the DAIDS table for grading the severity of adult and pediatric AE Version 1.0, December 2004; Clarification August 2009. The DAIDS displays events as Grades 1-5 based on this general guideline: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening. Data for Number of participants who experienced grade 2 or higher laboratory results in the injection phase (Week 5-Week 14) have been presented.', 'timeFrame': 'Up to Week 41'}, {'measure': 'Number of Participants Who Had Abnormal Electrocardiogram (ECG) Findings in the Injection Phase', 'description': 'Full 12-lead ECGs included heart rate, PR, QRS, QT and QTc intervals. Measurements were taken from the participant following 5 minutes of rest in a semi-supine position. ECGs were performed at Week 5, Week 17, Week 29 and Week 41 in the injection phase (Week 5-Week 41). ECG abnormalities characterized as abnormal-not clinically significant (A-NCS) and abnormal-clinically significant (A-CS) upto Week 41 have been presented. There were no A-CS findings for ECG in the injection phase.', 'timeFrame': 'Up to Week 41'}, {'measure': 'Change From Baseline in Vital Sign Assessment for Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in the Injection Phase', 'description': 'Vital signs measurements were performed for SBP and DBP following 5 minutes of rest. Baseline was defined as the first injection at Week 5 for the injection phase. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value at Week 17, Week 29 and Week 41.', 'timeFrame': 'Baseline (Week 5) to Week 41'}, {'measure': 'Change From Baseline in Vital Sign Assessment for Heart Rate (HR) in the Injection Phase', 'description': 'Vital signs measurements were performed for HR following 5 minutes of rest. Baseline was defined as the first injection at Week 5 for the injection phase. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value at Week 17, Week 29 and Week 41.', 'timeFrame': 'Baseline (Week 5) to Week 41'}, {'measure': 'Number of Participant With ISR for the Injection Phase Defined by Maximum Grades', 'description': 'Common ISR included pain, erythema, nodules and any other ISR with greater or equal to 5 participants. The number of participants who experienced pain events by needle length, swelling events by needle length, bump events by needle length for injection phase by maximum grades have been presented for the injection phase (Week 5-Week 41).', 'timeFrame': 'Up to Week 41'}]","[{'measure': 'Plasma Pharmacokinetic Assessment for Area Under the Plasma Concentration-time Curve Over the Dosing Interval [AUC(0-tau)] in the Injection Phase', 'description': 'Blood samples for pharmacokinetic analysis were collected starting on the first day of the First Injection Phase prior to the injection. At each injection visit a blood sample was collected prior to the injection at Week 5, Week 17 and Week 29, 1 Week post-injection at Week 6, Week 18, and Week 30, and 12 Week post-injection at Week 17, Week 29, and Week 41. The sample collected 12 Week following each injection served as the pre-dose sample for the subsequent dosing interval. Two additional samples were collected 4 and 8 Week after the first injection (Week 9 and Week 13), and 1 additional sample was collected 6 Week following the second and third injections (Week 23 and Week 35). Assessment was carried out for AUC(0-tau) a measure of the amount of drug available at target tissue (in plasma) for a fixed dosing interval (i.e.12 hours).', 'timeFrame': 'Up to Week 41'}, {'measure': 'Plasma Pharmacokinetic Assessment for Concentration at the End of the Dosing Interval (Ctau) and Maximum Observed Concentration (Cmax) in the Injection Phase', 'description': 'Blood samples for pharmacokinetic analysis were collected starting on the first day of the First Injection Phase prior to the injection. At each injection visit a blood sample was collected prior to the injection at Week 5, Week 17 and Week 29, 1 Week post-injection at Week 6, Week 18, and Week 30, and 12 Week post-injection at Week 17, Week 29, and Week 41. The sample collected 12 Week following each injection served as the pre-dose sample for the subsequent dosing interval. Two additional samples were collected 4 and 8 Week after the first injection (Week 9 and Week 13), and 1 additional sample was collected 6 Week following the second and third injections (Week 23 and Week 35). Assessment was carried out for Ctau defined as the concentration at the end of the dosing interval and Cmax defined as the maximum observed plasma concentration.', 'timeFrame': 'Up to Week 41'}, {'measure': 'Plasma Pharmacokinetic Assessment for Time to Maximum Observed Concentration (Tmax), Apparent Terminal Phase Half-life for (t½) in the Injection Phase', 'description': 'Blood samples for pharmacokinetic analysis were collected starting on the first day of the First Injection Phase prior to the injection. At each injection visit a blood sample was collected prior to the injection at Week 5, Week 17 and Week 29, 1 Week post-injection at Week 6, Week 18, and Week 30, and 12 Week post-injection at Week 17, Week 29, and Week 41. The sample collected 12 Week following each injection served as the pre-dose sample for the subsequent dosing interval. Two additional samples were collected 4 and 8 Week after the first injection (Week 9 and Week 13), and 1 additional sample was collected 6 Week following the second and third injections (Week 23 and Week 35). Assessment was carried out for tmax defined as the time to the maximum observed plasma concentration and t½ defined as the time taken for the concentration of drug in the blood to decrease by half of the original amount.', 'timeFrame': 'Up to Week 41'}, {'measure': 'Plasma Pharmacokinetic Assessment for AUC(0-tau) by Demographic Factor Body Mass Index (BMI) and Needle Length in the Injection Phase', 'description': 'The median BMI was 26 kilogram per meter square. Plasma pharmacokinetic assessments were performed for AUC (0-tau) by BMI, either above or below the median BMI (50 percent upper and lower, where upper summary included all participants with BMI greater than or equal to the median BMI of the population and lower summary included all participants with BMI below the median BMI). Assessments was also performed for AUC (0-tau) by needle length (1.5 inch and 2 inch). Needle length and BMI were correlated in that the longer needle was recommended for participants with BMI greater than 30 kilogram per meter square.', 'timeFrame': 'Up to Week 41'}, {'measure': 'Plasma Pharmacokinetic Assessment for Ctau and Cmax by Demographic Factor BMI and Needle Length in the Injection Phase', 'description': 'The median BMI was 26 kilogram per meter square. Plasma pharmacokinetic assessments were performed for Ctau and Cmax by BMI, either above or below the median BMI (50 percent upper and lower, where upper summary included all participants with BMI greater than or equal to the median BMI of the population and lower summary included all participants with BMI below the median BMI.\n\n). Assessments was also performed for Ctau and Cmax by needle length (1.5 inch and 2 inch). Needle length and BMI were correlated in that the longer needle was recommended for participants with BMI greater than 30 kilogram per meter square.', 'timeFrame': 'Up to Week 41'}, {'measure': 'Plasma Pharmacokinetic Assessment for Tmax and t½ by Demographic Factor BMI and Needle Length in the Injection Phase', 'description': 'The median BMI was 26 kilogram per meter square. Plasma pharmacokinetic assessments were performed for tmax and t½ by BMI, either above or below the median BMI (50 percent upper and lower, where upper summary included all participants with BMI greater than or equal to the median BMI of the population and lower summary included all participants with BMI below the median BMI). Assessments was also performed for tmax and t½ by needle length (1.5 inch and 2 inch). Needle length and BMI were correlated in that the longer needle was recommended for participants with BMI greater than 30 kilogram per meter square.', 'timeFrame': 'Up to Week 41'}, {'measure': 'Number of Participants With Severity of ISRs and ISR Symptoms for Injection Phase Defined by Grades and Needle Length', 'description': 'Acceptability of cabetogravir injections was assessed number of participants who had severe ISRs and ISR symptom. ISR examination for severity included an assessment of pain, pruritis, warm to touch, bruising, discoloration, erythema, swelling, induration and bump events. Common ISR Symptoms for Injection Phase included pain, erythema, nodules and any other ISRs with greater or equal to five participants. Data has been presented for the injection phase (W5-W41) by grades and needle length.', 'timeFrame': 'Up to Week 41'}, {'measure': 'Number of Participants With AE, Grade 2-4 AE and Serious Adverse Events (SAE) in the Oral Phase', 'description': 'Clinical AE were graded using the DAIDS table for grading the severity of adult and pediatric AE Version 1.0, December 2004; Clarification August 2009. The grades were: 1 (mild)=Symptoms causing no or minimal interference with usual social and functional activities; 2 (moderate)= Symptoms causing greater than minimal interference with usual social and functional activities; 3 (severe)= Symptoms causing inability to perform usual social and functional activities; 4 (potentially life threatening): Symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. Data has been presented for any Grade 2 or higher event in the injection phase for injection phase (Week 5- Week 41).', 'timeFrame': 'Up to Week 4'}, {'measure': 'Number of Participants Who Received Concurrent Medication in Overall Study Duration', 'description': 'The concurrent medications that were consumed by participants during the injection phase were of the class nervous system, musculo-skeletal system, genito-urinary systems and sex hormones, various, respiratory system, dermatologicals, alimentary tract and metabolism, anti-infectives for systemic use, sensory organs, systemic hormonal preparations excluding sex hormones, blood and blood forming organs, cardiovascular system, anti-neoplastic and immunomodulating agents, anti-parasitic products, insecticides and repellents . The participants who took medication from any of the above class of during the during the overall study duration injection phase (Day 1 until Week 41) have been presented.', 'timeFrame': 'Up to Week 41'}, {'measure': 'Number of Participants Who Experienced Maximum Clinical Chemistry Including Liver Chemistry and Hematology Toxicities in the Oral Phase by Grades', 'description': 'The severity of clinical chemistry including liver chemistry and hematology toxicities was graded according to the DAIDS table for grading the severity of adult and pediatric AE Version 1.0, December 2004; Clarification August 2009. The DAIDS displays events as Grades 1-5 based on this general guideline: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening. Data for maximum clinical chemistry and hematology toxicities for oral phase (Day 1 upto Week 4) by grades have been presented.', 'timeFrame': 'Up to Week 4'}]",17,18 Years,65 Years,MALE,True,ViiV Healthcare,INDUSTRY,1,127.0,ACTUAL,2025-09-01T16:18:23.446543,v2_robust,True,True,True,False,True,
NCT04234178,Dural Puncture Epidural Versus Combined Spinal Epidural With Epidural Volume Extension in Labor Analgesia,The Effects of Dural Puncture Epidural Versus Combined Spinal Epidural With Epidural Volume Extension Techniques on Birth Variables in Labor Analgesia,Epidural,"['Epidural', 'Intrathecal+Epidural']",2,INTERVENTIONAL,['NA'],,,Labor Pain,['Labor Pain'],[],COMPLETED,,2020-02-01,2021-02-07,"[{'measure': 'First Epidural top-up time', 'description': 'Time elapsed between the end of local anesthetic injection and the return of pain \\>4 on the NPRS.', 'timeFrame': 'First 24 hours'}]","[{'measure': 'Sacral analgesia time', 'description': 'Blockade of the S2 dermatome', 'timeFrame': 'First 24 hours'}, {'measure': 'Performance time', 'description': 'interval between skin disinfection and epidural catheter fixation to the skin', 'timeFrame': 'First 24 hours'}, {'measure': 'Incidence of Side Effect', 'description': 'maternal motor block, hypotension, pruritis, headache and fetal bradycardia', 'timeFrame': 'First 24 hours'}]",4,18 Years,45 Years,FEMALE,False,Ataturk University,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:23.446586,v2_robust,True,True,True,False,False,
NCT00246285,A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia,The Efficacy And Safety Of Risperidone In The Treatment Of Adolescents With Schizophrenia: A Six-Month Open-Label Study.,risperidone,['risperidone'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Schizophrenia,"['Schizophrenia', 'Psychotic Disorders']","['schizophrenia', 'antipsychotic agents', 'risperidone', 'adolescents']",COMPLETED,,2001-04,2006-12,[{'measure': 'Change of Positive and Negative Syndrome Scale for Schizophrenia (PANSS) score from baseline to each visit during treatment; incidence of adverse events throughout study'}],"[{'measure': ""Clinical Global Impression-Severity of Illness (CGI-Severity) and Clinical Global Impression-Improvement (CGI-Improvement) at each visit; Children's Global Assessment Scale at start and end of study; clinical laboratory tests, vital signs, weight, ECGs.""}]",2,13 Years,17 Years,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,0,381.0,ACTUAL,2025-09-01T16:18:23.446784,v2_robust,True,True,True,False,True,
NCT01375985,Safety Study of Single Administration Intravenous Treatment for Influenza,"A Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AVI-7100 in Healthy Subjects",AVI-7100,"['AVI-7100', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Influenza,['Influenza'],[],TERMINATED,The study was halted after enrollment of the first cohort because of lack of funding,2011-06,2011-11,"[{'measure': 'Number of subjects experiencing adverse events', 'timeFrame': '28 days'}]","[{'measure': 'Plasma drug concentration', 'timeFrame': '28 days'}, {'measure': 'Urine drug concentration', 'timeFrame': '28 days'}]",3,18 Years,50 Years,ALL,True,"Sarepta Therapeutics, Inc.",INDUSTRY,0,8.0,ACTUAL,2025-09-01T16:18:23.446792,v2_robust,True,True,False,True,True,The study was halted after enrollment of the first cohort because of lack of funding
NCT00918385,Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer,A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer,Nilutamide,"['Sprycel', 'Nilandron', 'Nilutamide', 'Dasatinib']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,['Prostate Cancer'],"['hormone resistant prostate cancer', 'castration resistant prostate cancer', 'hormone refractory prostate cancer', 'metastatic prostate cancer', 'hormonal therapy', 'antiandrogen therapy', 'androgen receptor', 'nilutamide', 'dasatinib', 'genomics', 'genomic signature', 'genomic predictor', 'genomic analysis', 'genomic expression profile']",TERMINATED,Permanent closure of trial to further accrual based on IDE disapproval,2009-05,2013-08,"[{'measure': 'Progression Free Survival (PFS)', 'description': 'PFS is the interval from start of monotherapy until first disease progression or death, whichever occurred first.', 'timeFrame': 'During monotherapy ( at least 12 weeks)'}]","[{'measure': 'Overall Response Rate of Men With High AR Activity', 'description': 'Tumor response was based on Response Criteria in Solid Tumors (RECIST). Complete response (CR) is defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.', 'timeFrame': 'During monotherapy (at least 12 weeks)'}, {'measure': 'Overall Response Rate of Men With Low AR Activity', 'description': 'Tumor response is based on Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.', 'timeFrame': 'During dasatinib monotherapy ( at least 12 weeks)'}]",3,18 Years,,MALE,False,Duke University,OTHER,1,57.0,ACTUAL,2025-09-01T16:18:23.446807,v2_robust,True,True,False,True,False,Permanent closure of trial to further accrual based on IDE disapproval
NCT01602185,Study of NMDA Antagonists and Neuropathic Pain,Antagonists NMDA in Relay to Ketamine in Neuropathic Pain,Dextromethorphan (drug used like antitussive),"['Dextromethorphan (drug used like antitussive)', ""Memantine (drug used in Alzheimer's disease)"", 'Placebo (lactose)']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Neuropathic Pain,['Neuropathic Pain'],"['NMDA (N-Methyl-D-Aspartate) antagonists', 'ketamine', 'memantine', 'dextromethorphan', 'Neuropathic pain']",COMPLETED,,2012-05,2016-09-07,"[{'measure': 'Measure of pain by numerical scale', 'timeFrame': 'at Day 30'}]","[{'measure': 'Measure of pain by numerical scale', 'timeFrame': 'at day 60 and at day 90'}, {'measure': 'Patient Global Impression if Change (PGIC)', 'timeFrame': 'at day 30, at day 60 and at day 90'}, {'measure': ""Leed's slip questionnaire"", 'timeFrame': 'at day 30, at day 60 and at day 90'}, {'measure': 'Questionnaire of quality of life SF 36', 'timeFrame': 'at day 30, at day 60 and at day 90'}, {'measure': 'DN4 scale', 'timeFrame': 'at day 30, at day 60 and at day 90'}, {'measure': 'Neuropathic Pain Symptoms Inventory (NPSI)', 'timeFrame': 'at day 30, at day 60 and at day 90'}, {'measure': 'Saint-Antoine questionnaire (QDSA)', 'timeFrame': 'at day 30, at day 60 and at day 90'}, {'measure': 'HAD scale', 'timeFrame': 'at day 30, at day 60 and at day 90'}, {'measure': 'Questionnaire of identification of pain (QCD)', 'timeFrame': 'at day 30, at day 60 and at day 90'}, {'measure': 'Evaluation of cognitive impact (Cantab, Cambridge)', 'timeFrame': 'at day 30, at day 60 and at day 90'}]",11,18 Years,,ALL,False,"University Hospital, Clermont-Ferrand",OTHER,7,7.0,ACTUAL,2025-09-01T16:18:23.446827,v2_robust,True,True,True,False,False,
NCT02226185,Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence,"A Randomized, Placebo-controlled, Multicenter, Prospective Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas",Berberine hydrochloride,"['Berberine hydrochloride', 'placebo']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Colorectal Adenoma,['Colorectal Adenoma'],[],COMPLETED,,2014-11,2018-12-29,"[{'measure': 'Recurrence rates of CRA', 'description': 'The primary objective of this study is to investigate recurrence rates of colorectal adenoma (CRA) after Berberine hydrochloride or placebo intervention.', 'timeFrame': 'until the last patient reached the 2 years follow-up'}]","[{'measure': 'The incidence of all polypoid lesions or advanced colorectal adenoma or colorectal cancer', 'description': 'The incidence of all polypoid lesions or advanced colorectal adenoma or colorectal cancer after Berberine hydrochloride or placebo intervention', 'timeFrame': 'until the last patient reached the 2 years follow-up'}]",2,18 Years,75 Years,ALL,False,Shanghai Jiao Tong University School of Medicine,OTHER,0,1108.0,ACTUAL,2025-09-01T16:18:23.446878,v2_robust,True,True,True,False,False,
NCT00244985,Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,A Phase I/II Pilot Study of the Safety and Efficacy of Rituxan (Chimeric Anti-CD20 Antibody) in Combination With Doxil (Liposomal Doxorubicin) Chemotherapy in Patients With Relapsing or Refractory Indolent or Aggressive B-Cell Lymphoma,pegylated liposomal doxorubicin hydrochloride,['pegylated liposomal doxorubicin hydrochloride'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Lymphoma,['Lymphoma'],"['recurrent grade 1 follicular lymphoma', 'recurrent grade 2 follicular lymphoma', 'recurrent grade 3 follicular lymphoma', 'recurrent mantle cell lymphoma', 'recurrent small lymphocytic lymphoma', 'recurrent adult diffuse large cell lymphoma', 'recurrent adult diffuse mixed cell lymphoma', 'recurrent marginal zone lymphoma', 'extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue', 'nodal marginal zone B-cell lymphoma', 'splenic marginal zone lymphoma']",COMPLETED,,2005-09,2012-12,"[{'measure': 'Complete Response Rate at 20 Weeks', 'description': 'Complete Response (CR): During observation no disease is apparent, including measurable and non-measurable disease, for at least 28 days, as confirmed by a second assessment following the original observation of no disease. All nodes visualized on imaging studies or palpable on exams must have regressed to normal size their greatest transverse diameter for nodes \\> 1.5 em before therapy). Previously involved nodes that were 1.1 to 1.5 in their greatest transverse diameter before treatment must have decreased to 1 cm in their greatest transverse diameter after treatment or by more than 75% in the sum of the products of the greatest diameters (SPD). The patient must also be free from symptoms related to lymphoma, if present before therapy with no worsening in performance status from baseline. Bone marrow, if initially positive at baseline, must be histologically negative for lymphoma and the liver and spleen, if enlarged due to lymphoma at baseline, should be normalized.', 'timeFrame': '20 weeks'}]","[{'measure': 'Partial Response Rate at 20 Weeks', 'description': 'Partial Response (PR): A 50% or greater decrease from baseline in the sum of the products of the longest perpendicular diameters of all the measured lesions is noted for at least 28 days as confirmed by a second assessment following the observation of the \\> or = to 50% decrease. Additionally, no appearance of new lesions is noted.', 'timeFrame': '20 weeks'}, {'measure': 'Overall Response Rate (Complete and Partial Responses) at 20 Weeks', 'description': 'Complete Response (CR): During observation no disease is apparent, including measurable and non-measurable disease, for at least 28 days, as confirmed by a second assessment following the original observation of no disease. All nodes visualized on imaging studies or palpable on exams must have regressed to normal size their greatest transverse diameter for nodes \\> 1.5 before therapy. Partial Response (PR): A 50% or greater decrease from baseline in the sum of the products of the longest perpendicular diameters of all the measured lesions is noted for at least 28 days as confirmed by a second assessment following the observation of the \\> or = to 50% decrease. Additionally, no appearance of new lesions is noted.', 'timeFrame': '20 weeks'}, {'measure': 'Progression Free Survival (PFS) Rate at 2 Years', 'description': 'Progressive disease is defined as at least a 20% increase in the sum of the longest diameter of target lesions or the appearance of new lesions.', 'timeFrame': '2 years'}, {'measure': 'Overall Survival (OS) Rate at 2 Years', 'description': 'Overall survival was defined as time from date of treatment initiation until date of death due to any cause.', 'timeFrame': '2 years'}]",5,18 Years,120 Years,ALL,False,Roswell Park Cancer Institute,OTHER,1,42.0,ACTUAL,2025-09-01T16:18:23.446901,v2_robust,True,True,True,False,False,
NCT06466785,A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis,"A Phase III, Randomized, Investigator-Blinded, Active-Controlled Study of Efficacy and Safety of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis",Efepoetin Alfa,"['Aranesp®', 'Darbepoetin Alfa', 'GX-E4', 'Efepoetin Alfa']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Anemia of Chronic Kidney Disease,['Anemia of Chronic Kidney Disease'],[],RECRUITING,,2024-01-25,2027-09,"[{'measure': 'Mean change in hemoglobin (Hb)', 'description': 'Mean change from Baseline in Hb averaged over Week 20 to Week 28 without the use of rescue therapy (i.e., transfusion, or any approved ESA for all patients) within 6 weeks prior to and during the 8-week evaluation period.', 'timeFrame': 'Over Week 20 to Week 28'}]",[],1,18 Years,,ALL,False,"Genexine, Inc.",INDUSTRY,1,429.0,ESTIMATED,2025-09-01T16:18:23.446996,v2_robust,True,True,False,False,False,
NCT00139685,Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception,Depo-Provera: Evaluation of Bone Mineral Density and Total Body Calcium in Adolescent DP 150 CI Users and Matched Controls,Depo-Provera Contraceptive Injection - DP150CI,['Depo-Provera Contraceptive Injection - DP150CI'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Contraception,"['Contraception', 'Bone Density']",[],COMPLETED,,1998-04,2007-07,"[{'measure': 'Changes in Bone Mineral Density in adolescent Depo-Provera Contraceptive'}, {'measure': 'Injection (DP150CI) users will be evaluated and compared during depo'}, {'measure': 'medroxyprogesterone acetate (DMPA) therapy and following discontinuation of'}, {'measure': 'DMPA.Another group electing non-hormonal contraception or abstinence is'}, {'measure': 'recruited as a reference population, across all study sites.'}]","[{'measure': 'Secondary variables are: Total Body Composition & Total Body Calcium (TBC),'}, {'measure': 'measured by Dual Energy X-ray Absorptiometry (DXA)Surrogate biologic BMD'}, {'measure': 'markers'}]",8,12 Years,18 Years,FEMALE,True,Pfizer,INDUSTRY,0,350.0,,2025-09-01T16:18:23.447006,v2_robust,True,True,True,False,False,
NCT00657943,The Copenhagen Insulin and Metformin Therapy Trial,"The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial",metformin,"['NovoRapid', 'insulin aspart + insulin aspart protamin', 'novomix', 'Levemir', 'Insulin aspart', 'metformin', 'glucophage', 'insulin detemir']",8,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes,"['Type 2 Diabetes', 'Atherosclerosis', 'Arteriosclerosis']","['carotid', 'intima', 'media', 'thickness', 'insulin', 'metformin']",COMPLETED,,2008-04,2012-12,"[{'measure': 'Carotid intima media thickness', 'timeFrame': '18 months'}]","[{'measure': 'adverse events', 'timeFrame': '18 months'}]",2,30 Years,,ALL,False,Steno Diabetes Center Copenhagen,OTHER,10,415.0,ACTUAL,2025-09-01T16:18:23.447022,v2_robust,True,True,True,False,True,
NCT02267343,Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer,"ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer",ONO-4538,"['ONO-4538', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Gastric Cancer,['Gastric Cancer'],[],COMPLETED,,2014-10,2021-01,"[{'measure': 'Overall survival', 'timeFrame': 'Up to study completion (estimated time frame: 30 months), every 2 weeks in principle'}]","[{'measure': 'Progression-free survival', 'timeFrame': 'Up to study completion (estimated time frame: 30 months), every 2 weeks in principle'}, {'measure': 'Objective response rate', 'timeFrame': 'Up to study completion (estimated time frame: 30 months), every 6 weeks in principle'}, {'measure': 'Duration of response', 'timeFrame': 'Up to study completion (estimated time frame: 30 months), every 6 weeks in principle'}, {'measure': 'Safety will be analyzed through the incidence of adverse events, serious adverse events', 'timeFrame': 'Continuously throughout study treatment and up to 28 days from last dose'}, {'measure': 'Safety will be analyzed through the incidence of laboratory abnormalities', 'timeFrame': 'Continuously throughout study treatment and up to 28 days from last dose'}]",6,20 Years,,ALL,False,Ono Pharmaceutical Co. Ltd,INDUSTRY,0,493.0,ACTUAL,2025-09-01T16:18:23.447066,v2_robust,True,True,True,False,True,
NCT06325943,Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy,An Italian Database-based Randomized Controlled Trial With Rituximab in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP),Rituximab,['Rituximab'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","['Polyradiculoneuropathy, Chronic Inflammatory Demyelinating']",[],COMPLETED,,2019-04-01,2023-11-30,"[{'measure': 'Inflammatory Neuropathy Cause and Treatment (INCAT) scale, range 0-10 points with higher values meaning more severe disability', 'description': 'proportion of patients with CIDP who worsen by at least one point in the INCAT score within six months after suspension of six-month treatment with intravenous or subcutaneous immunoglobulin', 'timeFrame': '6 months'}, {'measure': 'Medical Research Council (MRC), range 0-60 with lower values meaning more severe disability', 'description': 'proportion of patients with CIDP who worsen by at least two points in the MRC sum score within six months after suspension of six-month treatment with intravenous or subcutaneous immunoglobulin', 'timeFrame': '6 months'}, {'measure': 'Inflammatory Rasch-built Overall Disability Scale (I-RODS), range 0-48 with lower values meaning more severe disability', 'description': 'proportion of patients with CIDP who worsen by at least four points in the I-RODS scale within six months after suspension of six-month treatment with intravenous or subcutaneous immunoglobulin', 'timeFrame': '6 months'}]","[{'measure': 'Inflammatory Neuropathy Cause and Treatment (INCAT) scale, , range 0-10 points with higher values meaning more severe disability', 'description': 'improvement of disability (INCAT score) compared to placebo after 6, 12 and 18 months from the start of treatment', 'timeFrame': '6,12,18 months'}, {'measure': 'Inflammatory Neuropathy Cause and Treatment (INCAT) scale, range 0-10 points with higher values meaning more severe disability', 'description': 'efficacy of rituximab compared to placebo in reducing the number of patients with CIDP who worsen by at least one point in the INCAT score within 12 months after suspension of six-month treatment with intravenous or subcutaneous immunoglobulin', 'timeFrame': '12 months'}, {'measure': 'treatment suspension', 'description': 'proportion of patients who suspend the treatment with rituximab or placebo for adverse events or for voluntary reasons or who develop adverse events in the 12 months following the start of treatment.', 'timeFrame': '12 months'}, {'measure': 'time to worsening', 'description': 'to compare the mean time for patients with CIDP treated with rituximab or placebo to worsen by at least one point in the INCAT score after suspension of six-month treatment with intravenous or subcutaneous immunoglobulin', 'timeFrame': '6 months'}, {'measure': 'Short Form Health Survey 36 (SF-36), range from 0 to 100, with a higher score defining a more favorable health state', 'description': 'to determine whether the association of rituximab to intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) in patients with CIDP may improve compared to placebo the quality of life of the patients determined by SF-36 after 6, 12 and 18 months from the start of treatment.', 'timeFrame': '6,12,18 months'}]",8,18 Years,,ALL,False,Istituto Clinico Humanitas,OTHER,8,37.0,ACTUAL,2025-09-01T16:18:23.447082,v2_robust,True,True,True,False,True,
NCT00683943,Lithium Treatment for Patients With Spinocerebellar Ataxia Type I,Pilot Study of Tolerability of Lithium Therapy in Patients With Spinocerebellar Ataxia Type I (SCA1),Lithium Carbonate,['Lithium Carbonate'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Spinocerebellar Ataxia Type I,['Spinocerebellar Ataxia Type I'],"['Spinocerebellar Ataxia', 'Lithium']",COMPLETED,,2008-05-18,2010-02-25,"[{'measure': 'Incidence of side effects, side effect profile, and number of falls.'}]","[{'measure': 'ICARS scores, SARA scores, Quantitative Sway/Balance assessment, Tremor Rating Scale scores, dexterity evaluation, sleep questionnaire, Computerized Continuous Performing Tasks assessment'}]",2,18 Years,65 Years,ALL,False,National Institute of Neurological Disorders and Stroke (NINDS),NIH,0,13.0,ACTUAL,2025-09-01T16:18:23.447105,v2_robust,True,True,True,False,False,
NCT00643643,"Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus","A Randomised, Double Blind, Placebo-Controlled, Multicentre Study Of UK-427,857 25mg O.D. , 50mg B.I.D., 100mg B.I.D And 300mg B.I.D. In Asymptomatic HIV Infected Patients To Investigate Pharmacodynamics, Pharmacokinetics, Safety And Toleration.","Maraviroc (UK-427,857)","['Maraviroc (UK-427,857)', 'Celsentri, Selzentry']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV Infections,['HIV Infections'],"['HIV', 'Treatment Naïve']",COMPLETED,,2002-10,2003-06,"[{'measure': 'Change from baseline in viral load', 'timeFrame': 'Day 11'}, {'measure': 'Pharmacokinetic profile of UK-427,857', 'timeFrame': 'Days 1 and 10'}, {'measure': 'Receptor saturation', 'timeFrame': 'Days 1, 5, 10, 11, 13, 15, 19, 40'}]","[{'measure': '12-lead electrocardiography', 'timeFrame': 'Days 1-11 and Day 40'}, {'measure': 'Time course of viral load from baseline to follow-up', 'timeFrame': 'Days 1-15 and Days 19, 22, 25, 40'}, {'measure': 'Time to rebound of viral load', 'timeFrame': 'Days 1-15 and Days 19, 22, 25, 40'}, {'measure': 'The relationship of change in viral load (from baseline to day 11) versus average (Days 1-11) and trough (Day 10) plasma concentrations', 'timeFrame': 'Days 1-11'}, {'measure': 'The relationship of change in viral load (from baseline to day 11) versus mean receptor saturation (Day 10)', 'timeFrame': 'Days 1-11'}, {'measure': 'The relationship of change from baseline in viral load versus baseline virus susceptibility (IC 50 and IC 90)', 'timeFrame': 'Days 1-11'}, {'measure': 'Adverse events', 'timeFrame': 'Days 1-40'}, {'measure': 'Laboratory safety testing', 'timeFrame': 'Days 1, 3, 7, 11, 15, 40'}, {'measure': 'Physical examination', 'timeFrame': 'Days 1, 11, 40'}, {'measure': 'Supine and standing blood pressure and pulse rate', 'timeFrame': 'Days 1-11 and Day 40'}]",13,18 Years,55 Years,ALL,False,ViiV Healthcare,INDUSTRY,1,41.0,ACTUAL,2025-09-01T16:18:23.447268,v2_robust,True,True,True,False,True,
NCT00650143,Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction,Safety and Efficacy of Sitagliptin Plus Granulocyte-colony Stimulating Factor in Patients Suffering From Acute Myocardial Infarction,Lenograstim (GRANOCYTE)=GCSF,"['Gelatin', 'Sitagliptin (Januvia)', 'Sodium Chloride (NaCl) 0.9 %', 'Lenograstim (GRANOCYTE)=GCSF']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Acute Myocardial Infarction,['Acute Myocardial Infarction'],"['Stem cell', 'Myocardial infarction', 'G-CSF', 'CD26-inhibition']",COMPLETED,,2008-03,2013-06,"[{'measure': 'Change of global myocardial function from baseline to 6 months of follow-up.', 'timeFrame': 'Recruitment period: 4,5 years. Follow-up assessment: 1 year. Analyses and reporting: 6 months. Overall duration: 6 years.'}]","[{'measure': 'Segmental end-diastolic myocardial thickness, segmental systolic wall thickening, regional contractile reserve, end-diastolic and end-systolic volumes, stroke volume, and cardiac output in MRI', 'timeFrame': '6 months of follow-up'}, {'measure': 'Extent of non-viable myocardium will be monitored from baseline up to 6 months measured by MRI delayed enhancement.', 'timeFrame': '6 months follow up'}, {'measure': 'Change of myocardial perfusion at rest up to 6 months as measured by signal-time curve parameters using first-pass perfusion MRI', 'timeFrame': '6 month follow up'}, {'measure': 'Occurrence of major adverse cardiac events (death, myocardial infarction, CABG, or re-intervention) up to 12 months.', 'timeFrame': '12 months follow up'}, {'measure': 'Safety of a treatment of Sitagliptin in combination with G-CSF in CAD patients suffering from MI (spontaneously reported adverse events (AEs) up to 12 months).', 'timeFrame': '12 months follow up'}, {'measure': 'Change of peripheral blood stem cell populations: CD34, CD34/KDR and CD34/CD26 positive cells prior to and 5 days after therapy initiation.', 'timeFrame': '1 week follow up'}, {'measure': 'Change of plasma levels of NT-pro-BNP, glucose, complete blood count, CRP, platelets, CK, cTnI prior to and 5 and 28 days, and 6 months after therapy initiation', 'timeFrame': '12 month follow up'}, {'measure': 'Assessment of in stent restenosis using angiography 6 months after facultative PCI', 'timeFrame': '6 month follow up'}]",9,18 Years,,ALL,False,Ludwig-Maximilians - University of Munich,OTHER,0,174.0,ACTUAL,2025-09-01T16:18:23.447288,v2_robust,True,True,True,False,True,
NCT00122343,AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED),"A Phase II Study of AP23573, an mTOR Inhibitor, in Female Adult Patients With Recurrent or Persistent Endometrial Cancer",ridaforolimus,"['ridaforolimus', 'MK-8669', 'deforolimus', 'AP23573', 'ridaforolimus was also known as deforolimus until May 2009']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Endometrial Cancer,['Endometrial Cancer'],"['Endometrial', 'Cancer']",COMPLETED,,2005-08,2008-01,"[{'measure': 'The primary objective of the study is to assess the efficacy of AP23573 in patients with recurrent or persistent endometrial cancer when administered once daily for 5 consecutive days (QDx5) every two weeks at a dose of 12.5 mg/day.', 'timeFrame': 'Duration of the study'}]","[{'measure': 'Assess the safety and tolerability of this study drug regimen in this patient population', 'timeFrame': 'Duration of the study'}, {'measure': 'Evaluate secondary efficacy endpoints of time to tumor progression, progression-free survival and duration of response', 'timeFrame': 'Duration of the study'}, {'measure': 'Examine pharmacokinetic characteristics of AP23573', 'timeFrame': 'Duration of the study'}]",4,18 Years,,FEMALE,False,Merck Sharp & Dohme LLC,INDUSTRY,1,45.0,ACTUAL,2025-09-01T16:18:23.447314,v2_robust,True,True,True,False,True,
NCT03459443,A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471,An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471,Danicopan,"['Danicopan', 'ACH4471', 'ALXN2040', '4471', 'ACH-4471']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,C3 Glomerulonephritis,"['C3 Glomerulonephritis', 'C3 Glomerulopathy', 'Immune Complex Membranoproliferative Glomerulonephritis', 'IC-MPGN', 'Dense Deposit Disease']","['factor D', 'fD', 'alternative pathway', 'complement mediated disease', 'C3GN', 'DDD', 'idiopathic MPGN', 'MPGN Type I', 'MPGN Type II', 'MPGN Type III', 'Primary MPGN', 'MCGN', 'Mesangiocapillary Glomerulonephritis']",TERMINATED,The reason for terminating study early was inconclusive efficacy results. No safety findings were identified.,2018-06-20,2021-03-29,"[{'measure': 'Change From Baseline In Composite Biopsy Score At End Of Initial 12-Month Treatment Period', 'description': 'The composite biopsy score was based on a score incorporating changes in the activity index, glomerular C3c staining, and glomerular macrophage infiltration at the end of the initial 12 months of treatment. The composite renal biopsy index scoring system ranged from 0 to 21, with higher scores indicating worse outcomes.', 'timeFrame': 'Baseline, end of initial 12-Month Treatment Period'}, {'measure': 'Participants With Reduction In Proteinuria At End Of Initial 12-Month Treatment Period', 'description': 'Proteinuria reduction was defined as ≥30% decrease from baseline based on 24-hour urine protein (mg/day).', 'timeFrame': 'Baseline, end of initial 12-Month Treatment Period'}]","[{'measure': 'Change From Baseline In Proteinuria At End Of Initial 12-Month Treatment Period', 'description': 'Proteinuria was assessed based on 24-hour urine collections at baseline and end of the initial 12-month Treatment Period.', 'timeFrame': 'Baseline, end of initial 12-Month Treatment Period'}, {'measure': 'Percent Change From Baseline In Proteinuria At End Of Initial 12-Month Treatment Period', 'description': 'Proteinuria was assessed based on 24-hour urine collections at baseline and end of initial 12-month Treatment Period.', 'timeFrame': 'Baseline, end of initial 12-Month Treatment Period'}, {'measure': 'Slope Of Estimated Glomerular Filtration Rate (eGFR) From Baseline To End Of Initial 12-Month Treatment Period', 'description': 'Slope of eGFR was estimated using a simple linear regression for each participant, including all data values from baseline until the end of the Initial 12-Month Treatment Period, with eGFR as the dependent variable and time as the independent variable.', 'timeFrame': 'End of initial 12-Month Treatment Period'}, {'measure': 'Change From Baseline In eGFR At End Of Initial 12-Month Treatment Period', 'description': 'Change from baseline in eGFR at end of initial 12-Month Treatment Period is presented.', 'timeFrame': 'Baseline, end of initial 12-Month Treatment Period'}, {'measure': 'Participants With Significant Improvement In eGFR Relative To Baseline At End Of Initial 12-Month Treatment Period', 'description': 'Significant improvement relative to baseline was defined as a ≥ 25% increase from baseline in eGFR.', 'timeFrame': 'Baseline, end of initial 12-Month Treatment Period'}, {'measure': 'Change From Baseline in eGFR Over 12 Months of Treatment For Participants Meeting eGFR Inclusion Criteria', 'description': 'Participants were eligible for enrollment if inclusion criteria were met including having an eGFR \\>=30 milliliters (mL)/minute (min)/1.73 square meter (m\\^2) at the time of screening or at any time over the preceding 4 weeks. This Outcome Measure was registered in case there were participants who were enrolled and ended up not meeting the Eligibility Criteria and was intended to report data for change from baseline in eGFR for only the participants who met the eligibility criteria (that is, participants who did not meet the eligibility criteria would have been excluded from analysis for this Outcome Measure). Since all enrolled participants met the Eligibility Criteria, none of the participants were excluded from this analysis. Therefore, this data is the same data that is presented in Outcome Measure #6 ""Change From Baseline In eGFR At End Of Initial 12-Month Treatment Period"". Change from baseline in eGFR at end of initial 12-Month Treatment Period is presented.', 'timeFrame': 'End of initial 12-Month Treatment Period'}, {'measure': 'Change From Baseline In Measured GFR At The End Of The Initial 12-Month Treatment Period', 'description': 'Data for this Outcome Measure was to be collected where available. None of the sites collected data for this Outcome Measure.', 'timeFrame': 'End of initial 12-Month Treatment Period'}]",9,12 Years,,ALL,False,"Alexion Pharmaceuticals, Inc.",INDUSTRY,0,22.0,ACTUAL,2025-09-01T16:18:23.447325,v2_robust,True,True,False,True,False,The reason for terminating study early was inconclusive efficacy results. No safety findings were identified.
NCT00295243,Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies,A Phase I Trial of the Dual Kinase Inhibitor GW572016 in Combination With Topotecan in Patients With Advanced Solid Malignancies,Topotecan,['Topotecan'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Malignancies,['Advanced Solid Malignancies'],[],COMPLETED,,2004-09,2006-11,"[{'measure': 'find the highest dose of GW572016 and Topotecan that can be safely given together'}, {'measure': 'Learn the side effects of GW572016 and Topotecan when given together'}, {'measure': 'Learn whether GW572016 changes how the body handles or processesTopotecan'}, {'measure': 'Learn whether Topotecan changes how the body handles or processes GW572016'}]",[],4,18 Years,,ALL,False,Mayo Clinic,OTHER,1,25.0,ESTIMATED,2025-09-01T16:18:23.447389,v2_robust,True,True,True,False,False,
NCT01205243,ZIAGEN® Post-marketing Surveillance,"An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ZIAGEN® Administered in Korean Patients According to the Prescribing Information",ZIAGEN®,['ZIAGEN®'],1,OBSERVATIONAL,[],,,"Infection, Human Immunodeficiency Virus I","['Infection, Human Immunodeficiency Virus I']","['Abacavir', 'post-marketing surveillance']",COMPLETED,,2010-11-01,2015-02-05,"[{'measure': 'Occurrence of adverse event after ZIAGEN® administration', 'timeFrame': '12month'}]","[{'measure': 'Occurrence of serious adverse event after ZIAGEN® administration', 'timeFrame': '12month'}, {'measure': 'efficacy after ZIAGEN® administration', 'timeFrame': '12month'}, {'measure': 'Occurrence of unexpected adverse drug reaction after ZIAGEN® administration', 'timeFrame': '12 month'}]",4,,,ALL,False,ViiV Healthcare,INDUSTRY,1,671.0,ACTUAL,2025-09-01T16:18:23.447399,v2_robust,False,True,True,False,True,
NCT04781543,"A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis","A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis",HZN-825 BID,"['Placebo', 'HZN-825 QD', 'HZN-825 BID']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Diffuse Cutaneous Systemic Sclerosis,"['Diffuse Cutaneous Systemic Sclerosis', 'Sclerosis, Systemic']",['Scleroderma'],TERMINATED,The study was terminated due to meeting pre-defined criteria for futility.,2022-11-04,2025-02-24,"[{'measure': 'Change in FVC (forced vital capacity) percent predicted from Baseline to Week 52', 'description': 'As measured by a pulmonary function test called a spirometry.', 'timeFrame': 'Baseline to Week 52'}]","[{'measure': 'Change from Baseline in HAQ-DI (Health Assessment Questionnaire - Disability Index) at Week 52', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Change from Baseline in MDGA (Physician Global Assessment) at Week 52', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Change from Baseline in PTGA (Patient Global Assessment) at Week 52', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Change from Baseline in the Physical Effects subscale of the scleroderma skin patient-reported outcome (SSPRO-18) at Week 52', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Change from Baseline in the Physical Limitations subscale of the scleroderma skin patient-reported outcome SSPRO-18 at Week 52', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Proportion of participants with an mRSS (modified Rodnan skin score) decrease of ≥5 points and 25% from Baseline at Week 52', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Responder rate (defined as ACR-CRISS [predicted probability] of at least 0.6) at Week 52', 'description': 'American College of Rheumatology-Composite Response Index in Systemic Sclerosis', 'timeFrame': 'Week 52'}, {'measure': 'Proportion of participants with an improvement in ≥3 of 5 core measures from Baseline: ≥20% in mRSS, ≥20% in HAQ-DI, ≥20% in PTGA, ≥20% in MDGA and ≥5% for FVC % predicted at Week 52 (ACR-CRISS-20)', 'description': 'American College of Rheumatology-Composite Response Index in Systemic Sclerosis', 'timeFrame': 'Baseline to Week 52'}]",9,18 Years,75 Years,ALL,False,Amgen,INDUSTRY,0,301.0,ACTUAL,2025-09-01T16:18:23.447500,v2_robust,True,True,False,True,False,The study was terminated due to meeting pre-defined criteria for futility.
NCT00750243,Comparator Study of LT-NS001 in Healthy Subjects With Endoscopic Evaluation,"A Double-Blind, Randomized, Active Comparator Study of LT-NS001 Versus Naprosyn for Seven Days in Healthy Subjects With Endoscopic Evaluation",LT-NS001,"['Naprosyn®', 'LT-NS001']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2008-09,2009-04,"[{'measure': 'Assessment of GI mucosal injury by endoscopy', 'timeFrame': '7 days'}]","[{'measure': 'Comparison of naproxen PK at steady state', 'timeFrame': '7.5 days'}]",2,45 Years,70 Years,ALL,True,Logical Therapeutics,INDUSTRY,0,120.0,ACTUAL,2025-09-01T16:18:23.447565,v2_robust,True,True,True,False,False,
NCT06610643,Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients,Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients,combination therapy,"['combination therapy', 'SOC', 'remdesivir and Nirmatrelvir/Ritonavir']",3,INTERVENTIONAL,['NA'],,,COVID-19,"['COVID-19', 'SARS-CoV-2', 'Immunocompromised']",['Extended RDV infusion combination therapy for SARS-CoV-2 infection in immunocompromised patients'],NOT_YET_RECRUITING,,2024-09-21,2026-12-31,"[{'measure': 'The proportion of SARS-CoV-2 CT &gt; 30 on Day 14', 'description': 'The proportion of SARS-CoV-2 CT \\&gt; 30 on Day 14 of each group.', 'timeFrame': 'From enrollment to the end of treatment on Day 14.'}]","[{'measure': 'The proportion of mortality or respiratory failure requiring intubation and mechanical ventilation.', 'description': 'The proportion of mortality or respiratory failure requiring intubation and mechanical ventilation within 28 days after antiviral agent initiation of each group.', 'timeFrame': 'From enrollment to the end of treatment on Day 28.'}, {'measure': 'The proportion of patients developing anti-viral treatment emerging adverse events.', 'description': 'The proportion of patients developing anti-viral treatment emerging adverse events.', 'timeFrame': 'From enrollment to the end of treatment on Day 28.'}, {'measure': 'The proportion of secondary bacterial or fungal infection of each group.', 'description': 'The proportion of secondary bacterial or fungal infection of each group.', 'timeFrame': 'From enrollment to the end of treatment on Day 28.'}, {'measure': 'The proportion of viral rebound within 28 days after antiviral agent initiation.', 'description': 'The proportion of viral rebound within 28 days after antiviral agent initiation of each group.', 'timeFrame': 'From enrollment to the end of treatment on Day 28.'}]",5,18 Years,,ALL,False,National Taiwan University Hospital,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:23.447609,v2_robust,True,True,False,False,True,
NCT03709043,Addressing Heavy Alcohol Use Consumption With Kudzu,A-HACK Project: Addressing Heavy Alcohol Use Consumption With Kudzu,Standardized kudzu,['Standardized kudzu'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Alcohol Use Disorder,"['Alcohol Use Disorder', 'Sexually Transmitted Diseases']",[],ACTIVE_NOT_RECRUITING,,2019-07-11,2024-06-30,"[{'measure': 'number of binge drinking days', 'description': 'Binge-drinking (five or more drinks on a single occasion for men; four or more drinks for women)', 'timeFrame': '7 days'}]","[{'measure': 'proportion of ethyl glucuronide (EtG) positive urines', 'description': 'Urine samples will be collected weekly and tested for ethyl glucuronide (EtG) to determine recent alcohol consumption in the past three days.', 'timeFrame': '7 days'}]",2,18 Years,70 Years,ALL,True,Glenn-Milo Santos,OTHER,1,120.0,ACTUAL,2025-09-01T16:18:23.447623,v2_robust,True,True,False,False,False,
NCT00473343,"Metvix PDT in Participant With ""High Risk"" Basal Cell Carcinoma","An Open Multicenter, Phase III Study of Photodynamic Therapy With Metvix® Cream 160 mg/g in Patients With ""High Risk"" Basal Cell Carcinoma",Metvix® cream,"['Metvix® cream', 'Methyl 5-aminolevulinate hydrochloride']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Basal Cell Carcinoma,['Basal Cell Carcinoma'],"['Photodynamic therapy (PDT)', 'PDT with Metvix cream', '""High risk"" BCC', 'Basal Cell carcinoma', 'Histologically confirmed complete response']",COMPLETED,,2000-09,2006-06,"[{'measure': 'Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle', 'description': 'Patient Complete Response (CR) was defined as 100 percentage of the lesions within the participant having negative findings for nodular basal cell carcinoma (BCC) in the histological examination.', 'timeFrame': '3 months after last Metvix PDT cycle, up to 6 months'}]","[{'measure': 'Number of Lesion With Complete Response 3 Months After Last Metvix PDT Cycle', 'description': 'Complete response was defined as no clinically visible BCC lesions in the treatment area.', 'timeFrame': '3 months after last Metvix PDT cycle, up to 6 months'}, {'measure': 'Overall Cosmetic Outcome Assessed by Investigator 3 Months After the Last Metvix PDT Cycle', 'description': 'Cosmetic outcome was assessed by both investigator and participants in participants with 100% of lesions in complete response. Overall cosmetic outcome was assessed with regard to occurrence of the following signs or symptoms; scarring, atrophy, induration, redness or change in pigmentation. The investigator graded the cosmetic outcome as:\n\n* excellent: no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared lo adjacent skin\n* good: no scarring, atrophy or induration but moderate redness or change in pigmentation compared to adjacent skin\n* fair: slight to moderate occurrence of scarring, atrophy or induration\n* poor: extensive occurrence of scarring, atrophy or induration.', 'timeFrame': '3 months after the last metvix PDT cycle, up to 6 months'}, {'measure': 'Overall Cosmetic Outcome Assessed by Participants 3 Months After the Last Metvix PDT Cycle', 'description': 'Cosmetic outcome was assessed by both investigator and participants in participants with 100% of lesions in complete response. Overall cosmetic outcome was assessed with regard to occurrence of the following signs or symptoms; scarring, atrophy, induration, redness or change in pigmentation. The participants graded the cosmetic outcome as:\n\nexcellent: no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared lo adjacent skin good: no scarring, atrophy or induration but moderate redness or change in pigmentation compared to adjacent skin fair: slight to moderate occurrence of scarring, atrophy or induration poor: extensive occurrence of scarring, atrophy or induration.', 'timeFrame': '3 months after the last metvix PDT cycle, up to 6 months'}, {'measure': 'Recurrence Rate in Complete Clearance Group', 'description': 'Recurrence rate in complete clearance(CC) group was analyzed.', 'timeFrame': '12, 24, 36, 48 and 60 months after last Metvix PDT cycle, up to 5 years'}, {'measure': 'Overall Cosmetic Outcome Assessed by Investigator 24, 36, 48, and 60 Months After the Last Metvix PDT Cycle', 'description': 'Cosmetic outcome was assessed by both investigator and participants in participants with 100% of lesions in complete response. Overall cosmetic outcome was assessed with regard to occurrence of the following signs or symptoms; scarring, atrophy, induration, redness or change in pigmentation. The investigator graded the cosmetic outcome as:\n\nexcellent: no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared lo adjacent skin good: no scarring, atrophy or induration but moderate redness or change in pigmentation compared to adjacent skin fair: slight to moderate occurrence of scarring, atrophy or induration poor: extensive occurrence of scarring, atrophy or induration.', 'timeFrame': '24, 36, and 60 Months After the Last Metvix PDT Cycle, up to 5 years'}]",6,18 Years,,ALL,False,Galderma R&D,INDUSTRY,0,102.0,ACTUAL,2025-09-01T16:18:23.447635,v2_robust,True,True,True,False,False,
NCT06867315,The Safety and Effectiveness of Steep Pulse Therapy System for the Ablation of Benign Prostatic Hyperplasia,"Prospective, Multicenter, Randomized, Controlled, and Superiority Clinical Trial on the Safety and Effectiveness of Steep Pulse Therapy System for the Ablation of Benign Prostatic Hyperplasia",Tamsulosin Hydrochloride,['Tamsulosin Hydrochloride'],1,INTERVENTIONAL,['NA'],,,Benign Prostatic Hyperplasia,['Benign Prostatic Hyperplasia'],['steep pulse ablation'],RECRUITING,,2024-05-29,2026-05-29,"[{'measure': 'The change in maximum urinary flow rate', 'description': 'compare the maximum urinary flow rate of the patients post treatment to the baseline level of the patients', 'timeFrame': '3 months'}]","[{'measure': 'changes in the international prostate symptoms score(IPSS) before and after treatment', 'description': 'compare the IPSS of the patients in screening stage, 30 days after treatment and 3 months after treatment', 'timeFrame': 'screening, 30 days and 3 months'}]",2,50 Years,,MALE,False,First Affiliated Hospital of Zhejiang University,OTHER,4,10.0,ESTIMATED,2025-09-01T16:18:23.447704,v2_robust,True,True,False,False,False,
NCT04022915,PET Fibrin Imaging of DVT and PE,PET Fibrin Imaging of DVT and PE,64Cu-FBP8,['64Cu-FBP8'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Pulmonary Embolism,"['Pulmonary Embolism', 'Deep Vein Thrombosis', 'Venous Thromboembolism']",[],RECRUITING,,2019-05-13,2024-12-31,"[{'measure': 'Location of the thrombus within the lungs', 'description': 'To determine the location of the thrombus regions of interest (ROIs) within the lungs using PET-CT imaging in comparison to the ROI of filling defects on CT-angiogram.', 'timeFrame': '4 hours'}, {'measure': 'Location of clot burden measurements within the thigh', 'description': 'To determine the location of the thrombus ROI within the thigh using PET-CT imaging in comparison to the clot on venous duplex ultrasound.', 'timeFrame': '4 hours'}, {'measure': 'Assessment of 64Cu-FBP8 fibrin activity in the pelvic and upper extremity', 'description': ""The prevalence of high 64Cu-FBP8 fibrin activity in the pelvic ROI and upper extremity ROI's will be reported."", 'timeFrame': '4 hours'}]","[{'measure': 'Correlation between normalized 64Cu-FBP8 fibrin activity and plasma D-dimer', 'description': 'Correlation of the total fibrin activity in the imaged fields, excluding the liver, gallbladder, kidneys and urinary bladder normalized by injected dose with the plasma D-dimer.', 'timeFrame': '4 hours'}, {'measure': 'Overall clot burden within the lungs', 'description': 'Overall clot burden calculated as sum of 64Cu-FBP8 activity within a thrombus ROI(s) within the lungs.', 'timeFrame': '4 hours'}, {'measure': 'Overall clot burden within the thigh', 'description': 'Overall clot burden calculated as sum of 64Cu-FBP8 activity within a thrombus ROI(s) within the thigh.', 'timeFrame': '4 hours'}]",6,18 Years,,ALL,False,Peter Caravan,OTHER,1,80.0,ESTIMATED,2025-09-01T16:18:23.447715,v2_robust,True,True,False,False,False,
NCT05432115,Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.,Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.,Tetracyclin,"['Amoxicillin', 'Bismuth', 'Tetracyclin', 'Esomeprazole']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Helicobacter Pylori Infection,['Helicobacter Pylori Infection'],"['Helicobacter pylori', 'tetracycline', 'bismuth quadruple therapy']",UNKNOWN,,2022-06-25,2023-10,"[{'measure': 'Eradication rate', 'description': 'Both intention to treat (ITT) and per-protocol (PP) analyses will be used for the assessment of the eradication rates of Helicobacter pylori infections in two groups. The ITT analysis includes all randomly assigned patients who take at least one dose of the study medications. The PP analysis is limited to patients who take over 90% of the study medications and complete follow-up.', 'timeFrame': 'Immediately after follow-up check'}]","[{'measure': 'Rate of adverse reactions', 'description': 'Rate of adverse reactions', 'timeFrame': 'Immediately after follow-up check'}, {'measure': 'Patient compliance', 'description': 'Good compliance is defined as the actual dosage is within the range of 80%-100% of the dosage that should be taken.', 'timeFrame': 'Immediately after follow-up check'}]",3,18 Years,70 Years,ALL,False,Shandong University,OTHER,5,407.0,ESTIMATED,2025-09-01T16:18:23.447798,v2_robust,True,True,False,False,True,
NCT05341115,A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty,"An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP)",Leuprorelin Acetate Depot 3M,"['Leuprolide acetate Depot 3M', 'Leuprorelin Acetate Depot 3M']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Central Precocious Puberty,['Central Precocious Puberty'],['Drug Therapy'],COMPLETED,,2023-03-14,2025-03-10,"[{'measure': 'Percentage of Participants with Peak Luteinizing Hormone (LH) Suppression in Gonadotropin-Releasing Hormone (GnRH) Stimulation at Week 24', 'description': 'The LH suppression is defined as LH peak value in GnRH stimulation ≤3.0 international unit per liter (IU/L).', 'timeFrame': 'Week 24'}]","[{'measure': 'Percentage of Participants with Tanner Stage Regression or No Progression at Week 24', 'description': 'Tanner Stage is used to measure pubertal development. Tanner Stage is based on progression through 5-stages. The progression was defined that either breast/genitals or pubic hair score had increased score compared with baseline score. Otherwise, the status was classified as regression or no progression. Baseline is defined as the assessment prior to the first dose of study drug.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Concentrations of Basal Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH)', 'description': 'Plasma LH and FSH peak concentrations under GnRH stimulation will be assessed.', 'timeFrame': 'Baseline, Week 24 and 36'}, {'measure': 'Percentage of Participants With Decreased Ratio of Bone Age Over Chronological Age at Week 24', 'description': 'Bone age will be determined by Greulich and Pyle standards or Tanner-Whitehouse 3 (TW3) standards.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Percentage of Participants with Decreased First Morning Voided (FMV) Urinary Gonadotropin (Gn) at Week 24', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAE)', 'description': 'An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAE is defined as an adverse event with an onset that occurs after receiving study drug.', 'timeFrame': 'From first dose of study drug up to 12 weeks post last dose or early termination Visit (ET) (Up to approximately 38 weeks)'}]",6,,10 Years,ALL,False,Takeda,INDUSTRY,0,80.0,ACTUAL,2025-09-01T16:18:23.447811,v2_robust,True,True,True,False,True,
NCT05634915,Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation,Clinical Study of rATG Individualized Administration for Prevention of GVHD and Maintenance of GVL in Haploidentical Hematopoietic Stem Cell Transplantation.,Individual ATG,"['ATG', 'Individual ATG']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Hematopoietic Stem Cell Transplantation,"['Hematopoietic Stem Cell Transplantation', 'Acute Leukemia']","['Antithymocyte Globulin', 'Population pharmacokinetic model', 'Haploidentical Hematopoietic Stem Cell Transplantation', 'Acute Leukemia']",UNKNOWN,,2022-12-20,2025-05-01,"[{'measure': 'Cumulative incidences of aGVHD', 'description': 'The diagnosis and grading of aGVHD are based on the modified Glucksberg grading standard.', 'timeFrame': '100 days after transplantation'}, {'measure': 'CD4+ immune reconstitution', 'description': 'CD4+ T-cells \\>0·05 × 10⁹/L twice within 3 months after transplantation', 'timeFrame': '3 months after transplantation'}, {'measure': 'Leukemia-free survival (LFS)', 'description': 'Leukemia-free survival (LFS) is defined as the time from enrollment to relapse of primary disease or death from any cause, whichever occurred first.', 'timeFrame': '1 years after transplantation'}]","[{'measure': 'Cumulative incidences of cGVHD', 'description': 'Chronic GVHD can be classified as ""limited"" or ""extensive"" according to the Seattle criteria, and also be classified as ""mild"" or ""moderate"" or ""severe"" according to the National Institutes of Health (NIH) criteria.', 'timeFrame': '1 years after transplantation'}, {'measure': 'Cumulative incidences of EBV reactivation', 'description': 'The cumulative incidences of EBV reactivation after transplantation', 'timeFrame': '1 years after transplantation'}, {'measure': 'Cumulative incidence of CMV reactivation', 'description': 'The cumulative incidences of CMV reactivation after transplantation.', 'timeFrame': '1 years after transplantation'}, {'measure': 'Neutrophil engraftment', 'description': 'Neutrophil engraftment is defined as the first of 3 consecutive days with an absolute neutrophil count \\> 0.5 × 10\\^9/L.', 'timeFrame': '1 month after transplantation'}, {'measure': 'Platelet engraftment', 'description': 'Platelet engraftment is defined as the first of 7 consecutive days with an absolute platelet count \\> 20 × 10\\^9/L independent from transfusion.', 'timeFrame': '1 month after transplantation'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival (OS) is defined as the time from randomization to death resulting from any cause.', 'timeFrame': '1 years after transplantation'}, {'measure': 'GVHD-free and relapse-free survival (GRFS)', 'description': 'GRFS is defined as the time from graft infusion to the onset of grades 3 to 4 aGVHD, moderate to severe cGVHD, or relapse/disease progression/death.', 'timeFrame': '1 years after transplantation'}, {'measure': 'Non-relapse mortality (NRM)', 'description': 'Non-relapse mortality (NRM) is defined as the time from enrollment to death of any causes other than hematologic disease relapse.', 'timeFrame': '1 years after transplantation'}, {'measure': 'Relapse-related mortality (RRM)', 'description': 'Relapse-related mortality (RRM) is defined as the time from enrollment to death of relapse.', 'timeFrame': '1 years after transplantation'}]",12,16 Years,60 Years,ALL,False,The First Affiliated Hospital of Soochow University,OTHER,0,90.0,ESTIMATED,2025-09-01T16:18:23.447856,v2_robust,True,True,False,False,False,
NCT04853615,SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?,Is SGLT2 Inhibitors a Better Prophylactic Agent Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease? A Multicenter Prospective Randomized Controlled Study,Empagliflozin 25 MG,"['SGLT2 inhibitors', 'Empagliflozin 25 MG']",2,OBSERVATIONAL,[],,,SGLT2i Kideny Protection Against Contrast in Diabetic Kidney,['SGLT2i Kideny Protection Against Contrast in Diabetic Kidney'],[],UNKNOWN,,2021-07-01,2024-08-01,"[{'measure': 'SGLT2i proves protective effect', 'description': 'SGLT2i shows protected the kidneys against contrast injury', 'timeFrame': '72hours after contrast'}]","[{'measure': 'SGLT2i is non inferior to allopurinol', 'description': 'SGLT2i showed noninferiorty whencompared to allopurinol', 'timeFrame': '72hours after contrast'}]",2,30 Years,,ALL,False,Fayoum University,OTHER,1,800.0,ESTIMATED,2025-09-01T16:18:23.447897,v2_robust,False,True,False,False,False,
NCT00141115,Levetiracetam for the Treatment of Alcohol Dependence and Anxiety,Pilot Trial of Levetiracetam in the Treatment of Alcohol Dependence With Comorbid Anxiety,levetiracetam,"['keppra', 'levetiracetam']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Alcoholism,"['Alcoholism', 'Generalized Anxiety Disorder', 'Panic Disorder', 'Social Phobia', 'Anxiety Disorders']",['Substance-induced anxiety disorder'],COMPLETED,,2004-03,2008-01,"[{'measure': 'Participants Who Reported Reductions in Alcohol Consumption', 'description': 'Number of participants who reduced drinking during the trial', 'timeFrame': 'over 9 weeks of study or length of participation'}]","[{'measure': 'Percent of Drinking Days', 'description': 'daily drinking assessed each of study participation, reported percent of drinking days for 28 days prior to study initiation compared to last 28 days of study participation-as reported on the Time line follow back', 'timeFrame': 'assessed daily, reported for baseline 28 days compared to last 28 days of study participation'}]",2,18 Years,65 Years,ALL,False,New York State Psychiatric Institute,OTHER,1,3.0,ACTUAL,2025-09-01T16:18:23.448018,v2_robust,True,True,True,False,False,
NCT06802315,"Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)","A Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Myeloablative Fludarabine/Busulfan and Post-Transplant Cyclophosphamide (PTCY) for Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk AML, CML, and MDS",Cyclophosphamide (CTX),"['Cyclophosphamide (CTX)', 'Busulfan (conditioning for ALLO Transplant)', 'Fludarabine (Fludara)']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,"Acute Myeloid Leukemia, Relapsed, Adult","['Acute Myeloid Leukemia, Relapsed, Adult', 'Acute Myeloid Leukemia Refractory', 'Chronic Myeloid Leukemia - Accelerated Phase', 'Myelodysplastic Syndromes']","['Total Marrow Irradiation', 'Stem Cell Transplant', 'Allogenic Transplant']",RECRUITING,,2025-02-04,2032-03,"[{'measure': 'GVHD-Free Relapse-Free Survival after Stem Cell Transplant', 'description': 'The 1-year GVHD- free relapse-free survival after HSCT (hematopoietic stem cell transplantation) conditioned with a 9Gy TMI in combination with FluBu4 and PTCY in patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), Myelodysplastic Syndrome (MDS) at high risk of relapse.', 'timeFrame': '1 Year Post-Stem Cell Transplant'}]","[{'measure': 'Overall Survival', 'description': 'The number of participants who have overall survival', 'timeFrame': '2 Years Post-Stem Cell Transplant'}, {'measure': 'Time To Engraftment', 'timeFrame': '30 Days Post-Stem Cell Transplant'}, {'measure': 'Adverse Events', 'description': 'The number of adverse events and grades of severity per Common Terminology of Criteria for Adverse Events (version 5.0) and the Bearman scale.', 'timeFrame': '30 Days Post-Stem Cell Transplant'}, {'measure': 'Adverse Events', 'description': 'The number of adverse events and grades of severity per Common Terminology of Criteria for Adverse Events (version 5.0).', 'timeFrame': '60 Days Post-Stem Cell Transplant'}, {'measure': 'Adverse Events', 'description': 'The number of adverse events and grades of severity per Common Terminology of Criteria for Adverse Events (version 5.0)', 'timeFrame': '90 Days Post-Stem Cell Transplant'}, {'measure': 'Adverse Events', 'description': 'The number of adverse events and grades of severity per Common Terminology of Criteria for Adverse Events (version 5.0).', 'timeFrame': '180 Days Post-Stem Cell Transplant'}, {'measure': 'Adverse Events', 'description': 'The number of adverse events and grades of severity per Common Terminology of Criteria for Adverse Events (version 5.0).', 'timeFrame': '1 Year Post-Stem Cell Transplant'}, {'measure': 'Incidence of Acute Graft Versus Host Disease', 'description': 'The number of participants with Acute Graft Versus Host Disease', 'timeFrame': '30 Days Post-Stem Cell Transplant'}, {'measure': 'Incidence of Acute Graft Versus Host Disease', 'description': 'The number of participants with Acute Graft Versus Host Disease', 'timeFrame': '60 Days Post-Stem Cell Transplant'}, {'measure': 'Incidence of Acute Graft Versus Host Disease', 'description': 'The number of participants with Acute Graft Versus Host Disease', 'timeFrame': '90 Days Post-Stem Cell Transplant'}, {'measure': 'Incidence of Acute Graft Versus Host Disease', 'description': 'The number of participants with Acute Graft Versus Host Disease', 'timeFrame': '180 Days Post-Stem Cell Transplant'}, {'measure': 'Incidence of Acute Graft Versus Host Disease', 'description': 'The number of participants with Acute Graft Versus Host Disease', 'timeFrame': '1 Year Post-Stem Cell Transplant'}, {'measure': 'Incidence of Chronic Graft Versus Host Disease', 'description': 'The number of participants with Chronic Graft Versus Host Disease', 'timeFrame': '180 Days Post-Stem Cell Transplant'}, {'measure': 'Incidence of Chronic Graft Versus Host Disease', 'description': 'The number of participants with Chronic Graft Versus Host Disease', 'timeFrame': '1 Year Post-Stem Cell Transplant'}, {'measure': 'Transplant-Related Mortality', 'description': 'The number of participants with transplant-related mortality', 'timeFrame': '30 Days Post-Stem Cell Transplant'}, {'measure': 'Transplant-Related Mortality', 'description': 'The number of participants with transplant-related mortality', 'timeFrame': '60 Days Post-Stem Cell Transplant'}, {'measure': 'Transplant-Related Mortality', 'description': 'The number of participants with transplant-related mortality', 'timeFrame': '90 Days Post-Stem Cell Transplant'}, {'measure': 'Transplant-Related Mortality', 'description': 'The number of participants with transplant-related mortality', 'timeFrame': '180 Days Post-Stem Cell Transplant'}, {'measure': 'Transplant-Related Mortality', 'description': 'The number of participants with transplant-related mortality', 'timeFrame': '1 Year Post-Stem Cell Transplant'}]",20,18 Years,65 Years,ALL,False,University of Illinois at Chicago,OTHER,0,38.0,ESTIMATED,2025-09-01T16:18:23.448195,v2_robust,True,True,False,False,True,
NCT02765815,A Comparison of Exparel Local Anesthetic in Total Knee Arthroplasty (TKA) Patients,A Prospective Randomized Case Series Comparison on the Clinical Efficacy of Exparel Local Anesthetic in Total Knee Arthroplasty Patients,"Liposomal bupivacaine, 266mg","['Exparel Injection', 'Bupivacaine 0.5 % with Epinephrine', 'Ketorolac 30mg', 'Bupivacaine 0.25% with Epinephrine', 'Morphine 10mg', 'Liposomal bupivacaine, 266mg']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,"Osteoarthritis, Knee","['Osteoarthritis, Knee', 'Arthroplasty, Replacement, Knee']","['TKA', 'Knee replacement', 'Arthritis', 'Knee']",WITHDRAWN,competing protocol,2016-02,2017-01,"[{'measure': 'Patient reported Visual Analog Scale (VAS) pain intensity score. Post-surgery hours 4-24.', 'description': 'The area under the curve (AUC) of the VAS scores from 4-24 hours will be compared between the two treatment groups.', 'timeFrame': 'VAS pain intensity scores will be collected starting four hours after end of surgery and every 4 hours thereafter until hour 24.'}, {'measure': 'Patient reported VAS pain intensity score. Post-surgery hours 24-48.', 'description': 'The AUC of the VAS scores from 24-48 hours or until discharge will be compared between the two treatment groups.', 'timeFrame': 'VAS pain intensity scores will be collected starting 24 hours after end of surgery and every 4 hours thereafter until hour 48, or discharge.'}, {'measure': 'Patient reported VAS pain intensity score. Post-surgery hours 48-72.', 'description': 'The AUC of the VAS scores from 48-72 hours or until discharge will be compared between the two treatment groups.', 'timeFrame': 'VAS pain intensity scores will be collected starting 48 hours after end of surgery and every 4 hours thereafter until hour 72, or discharge.'}]","[{'measure': 'Cost:benefit analysis', 'description': 'Correlation between hospital charges and improvement in VAS pain intensity score from baseline to the 2-week and 6-week follow-up time points.', 'timeFrame': 'TKA hospitalization charges, and VAS pain intensity scores pre-operative on day of surgery, 2-week and 6-week followup visits.'}]",4,18 Years,88 Years,ALL,False,"Holy Cross Hospital, Florida",OTHER,0,0.0,ACTUAL,2025-09-01T16:18:23.448213,v2_robust,True,True,False,True,False,competing protocol
NCT01134315,Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice,"A Prospective, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules as Determined by Hypercalcemia in Pediatric Patients Ages 0 to 16 With Chronic Kidney Disease (CKD) Stage 5 Receiving Peritoneal Dialysis (PD) Within Current Clinical Practice",Paricalcitol,"['Zemplar', 'Calcitriol', 'Paricalcitol', 'ABT-358']",4,OBSERVATIONAL,[],,,Secondary Hyperparathyroidism,"['Secondary Hyperparathyroidism', 'End-Stage Renal Disease']",['Evaluating incidence of hypercalcemia in pediatric patients'],TERMINATED,Terminated after FDA agreement.,2010-06,2012-05,"[{'measure': 'Percentage of Participants With at Least One Incidence of Hypercalcemia', 'description': 'Hypercalcemia was defined as calcium \\>10.2 mg/dL. Percentage of participants with hypercalcemia is presented for the overall population, the subgroup of participants in the study for less than 3 months, and those in the study for greater than or equal to 3 months.', 'timeFrame': 'Monitored from time of informed consent through end of study + 30 days (total of 745 days).'}]","[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs', 'description': 'AE: any untoward medical occurrence that does not necessarily have a causal relationship with treatment; any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered causally related to the use of the product (either paricalcitol or calcitriol); can result from use of the drug as stipulated in the labeling, as well as from accidental or intentional overdose, drug abuse, or drug withdrawal; any worsening of a pre-existing condition or illness. Severity was categorized as mild, moderate, or severe. SAE: AE that results in the death; is life-threatening; results in hospitalization or prolongation of hospitalization; is a congenital anomaly; results in persistent or significant disability/incapacity; is an important medical event requiring medical or surgical intervention to prevent serious outcome; is a spontaneous or elective abortion. For more details, please see the AE section of this record.', 'timeFrame': 'Monitored from time of informed consent through end of study + 30 days (total of 745 days).'}, {'measure': 'Mean Baseline (BL) and Change From Baseline in Potassium, Sodium, Chloride, Bicarbonate at Final Visit (FV)', 'description': 'Normal ranges for these chemistry measurements varied according to the age of the participant.', 'timeFrame': 'Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])'}, {'measure': 'Mean Baseline (BL) and Change From Baseline in Calcium, Inorganic Phosphate (IP), Blood Urea Nitrogen (BUN), Creatinine at Final Visit (FV)', 'description': 'Normal ranges for these chemistry measurements varied according to the age of the participant.', 'timeFrame': 'Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])'}, {'measure': 'Mean Baseline and Change From Baseline in 25-Hydroxy Vitamin D3 at Final Visit (FV)', 'description': 'Normal ranges for these chemistry measurements varied according to the age of the participant.', 'timeFrame': 'Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])'}, {'measure': 'Mean Baseline and Change From Baseline in 1,25-Dihydroxy Vitamin D3 at Final Visit (FV)', 'description': 'Normal ranges for these chemistry measurements varied according to the age of the participant.', 'timeFrame': 'Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])'}, {'measure': 'Mean Baseline and Change From Baseline in Parathyroid Hormone at Final Visit (FV)', 'description': 'Normal ranges for these chemistry measurements varied according to the age of the participant.', 'timeFrame': 'Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])'}, {'measure': 'Mean Baseline and Change From Baseline in Albumin at Final Visit (FV)', 'description': 'Normal ranges for these chemistry measurements varied according to the age of the participant.', 'timeFrame': 'Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days])'}]",8,,16 Years,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,1,61.0,ACTUAL,2025-09-01T16:18:23.448354,v2_robust,False,True,False,True,True,Terminated after FDA agreement.
NCT00239915,"Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS)","An 8-week, Double-Blind, Randomized, Multicenter, Flexible-Dose, Placebo-Controlled Pilot Study of Pagoclone in Patients With Persistent Developmental Stuttering Followed by a 52-week Open-Label Extension.",Pagoclone,['Pagoclone'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Persistent Developmental Stuttering,['Persistent Developmental Stuttering'],[],COMPLETED,,2005-04,2006-12,[],[],0,18 Years,65 Years,ALL,,Pharmacology Research Institute,OTHER,0,,,2025-09-01T16:18:23.448376,v2_robust,True,True,True,False,False,
NCT02865915,MLE4901 vs. Placebo for the Treatment of PCOS,"A Double-blind, Randomized, Parallel-group, Placebo-controlled Study of MLE4901 for the Treatment of Polycystic Ovary Syndrome (PCOS)",MLE4901,"['Placebo', 'MLE4901']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Polycystic Ovary Syndrome (PCOS),['Polycystic Ovary Syndrome (PCOS)'],"['Acne', 'Hirsutism', 'Menstrual Irregularity', 'Alopecia']",TERMINATED,The risk/benefit profile no longer indicated continued development.,2016-07,2017-09,"[{'measure': 'Menstrual Cycle Duration', 'description': 'Assessment of the number of days between menstrual cycles (i.e., days between the start of a menstrual period and the start of the next consecutive menstrual period) from baseline to end of 28 week double blind treatment period', 'timeFrame': '28 Week double blind treatment period'}]","[{'measure': 'Number of Menstrual Periods', 'description': 'Number of menstrual periods from baseline to the end of the 28 week double blind treatment period', 'timeFrame': '28 Week double blind treatment period'}]",2,18 Years,45 Years,FEMALE,False,"Millendo Therapeutics US, Inc.",INDUSTRY,2,55.0,ACTUAL,2025-09-01T16:18:23.448409,v2_robust,True,True,False,True,False,The risk/benefit profile no longer indicated continued development.
NCT01721915,"Vitamin D Treatment, Pharmacogenetics and Glucose Metabolism","A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Metabolic and Fertility Parameters in PCOS Women",Vitamin D supplementation,"['Vitamin D supplementation', 'A11CC05 Colecalciferol', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Polycystic Ovary Syndrome,"['Polycystic Ovary Syndrome', 'Healthy', 'Vitamin D Deficiency']","['Polycystic Ovary Syndrome (PCOS)', 'glucose metabolism', 'Vitamin D deficiency', 'vitamin D supplementation', 'pharmakogenetics', 'women']",COMPLETED,,2012-10,2017-10-12,"[{'measure': 'Metabolic response during an oral glucose tolerance test (oGTT) as defined by AUCgluc', 'timeFrame': 'Change from Baseline in AUC gluc at 24 weeks'}]","[{'measure': 'Insulin resistance assessed by homeostatic model assessment-insulin resistance (HOMA-IR)', 'timeFrame': 'Change from Baseline in insulin resistance at 24 weeks'}, {'measure': 'Lipid levels (total cholesterol)', 'timeFrame': 'Change from Baseline in total cholesterol at 24 weeks'}, {'measure': 'HbA1c', 'timeFrame': 'Change from Baseline in HbA1c at 24 weeks'}, {'measure': 'Testosterone', 'timeFrame': 'Change from Baseline in testosterone at 24 weeks'}, {'measure': 'Menstrual frequency', 'timeFrame': 'Change from Baseline in menstrual frequency at 24 weeks'}, {'measure': 'Insulin sensitivity assessed by Quantitative Insulin-sensitivity Check Index (QUICKI)', 'timeFrame': 'Change from baseline in QUICKI at 24 weeks'}, {'measure': 'Free testosterone (FT)', 'timeFrame': 'Change from Baseline in FT at 4 weeks'}, {'measure': 'Triglycerides', 'timeFrame': 'Change from Baseline in triglycerides at 24 weeks'}]",9,18 Years,44 Years,FEMALE,True,Medical University of Graz,OTHER,1,330.0,ACTUAL,2025-09-01T16:18:23.448422,v2_robust,True,True,True,False,False,
NCT02759835,"Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib","A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment With Osimertinib (AZD9291, Tagrisso)",osimertinib,"['osimertinib', 'Tagrisso']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Lung Adenocarcinoma,"['Lung Adenocarcinoma', 'Lung Neoplasms']","['EGFR Tyrosine Kinase Inhibitors', 'T790M Mutation', 'Local Ablative Therapies', 'Oligoprogressive Disease', 'Acquired Resistance']",COMPLETED,,2016-04-13,2022-09-20,"[{'measure': 'Progression Free Survival 1 (PFS 1) for ALL Participants Who Started Osimertinib on Trial Until First Progression of Disease or Clinical Progression, or Death Any Cause', 'description': 'PFS1 = time from initiation of osimertinib to first progression of disease or clinical progression, or death any cause. Progression was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and reported using the Kaplan Meier curve. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progression).', 'timeFrame': 'Cycle 1 Day 1 (each cycle is 28 days) to progression of disease, range 36-1231 days'}, {'measure': 'Progression Free Survival 2 (PFS 2) - Local Ablative Therapy (LAT Eligible Only)', 'description': 'PFS2 = time from osimertinib re-challenge after LAT following first progression on osimertinib until second progression on osimertinib. Progression was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and reported using the Kaplan Meier curve. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progression).', 'timeFrame': 'Retreatment Cycle 1 Day 1 (cycle is 28 days) to progression of disease, range 29-721 days'}, {'measure': 'Progression Free Survival 2 (PFS 2) - Local Ablative Therapy (LAT Eligible Only) - Cohort 1, Cohort 2, and Cohort 3', 'description': 'PFS2 = time from osimertinib re-challenge after LAT following first progression on osimertinib until second progression on osimertinib. Progression was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and reported using the Kaplan Meier curve. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progression).', 'timeFrame': 'Retreatment Cycle 1 Day 1 (cycle is 28 days) to progression of disease, range 29-721 days'}, {'measure': 'Serious Adverse Events Possibly, Probably, and/or Definitely Related to Treatment', 'description': 'Adverse events were assessed by the by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.', 'timeFrame': 'Date treatment consent signed to date off study, approximately 74 months and 16 days, 65 months and 16 days, and 40 months and 4 days for the first, second and third group respectively.'}, {'measure': 'All Grades 1, Grade 2, Grade 3, Grade 4, and/or Grade 5 Adverse Events Possibly, Probably, and/or Definitely Related to Local Ablative Therapy (LAT)', 'description': 'Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse events.', 'timeFrame': 'Date treatment consent signed to date off study, approximately 74 months and 16 days, 65 months and 16 days, and 40 months and 4 days for the first, second and third group respectively.'}, {'measure': 'All Grades 1, Grade 2, Grade 3, Grade 4, and/or Grade 5 Adverse Events Possibly, Probably, and/or Definitely Related to Osimertinib', 'description': 'Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse events.', 'timeFrame': 'Date treatment consent signed to date off study, approximately 74 months and 16 days, 65 months and 16 days, and 40 months and 4 days for the first, second and third group respectively.'}, {'measure': 'Number of Participants Who Had Osimertinib Acquired Resistant Mechanisms Identified on Tumors', 'description': 'Whole-exome sequencing (WES), targeted sequencing and ribonucleic acid (RNA)-seq was performed on tumors to identify Osimertinib acquired resistant mechanisms. Sequencing can help identify mutations/heterogeneity that may impact a participant prognosis.', 'timeFrame': 'up to 757 days'}, {'measure': 'Number of Participants Who Had Osimertinib Acquired Resistant Mechanisms Identified on Tumors With First Line and/or Second Line Treatment', 'description': 'Whole-exome sequencing (WES), targeted sequencing and ribonucleic acid (RNA)-seq was performed on tumors for first and second line Osimertinib treatment to identify Osimertinib acquired resistant mechanisms. Sequencing can help identify mutations (i.e., NE-differentiation, ribonucleic acid (RNA), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), other amps, etc.)/heterogeneity that may impact a participant prognosis.', 'timeFrame': 'up to 757 days'}]","[{'measure': 'Best Overall Response (BOR)', 'description': ""Best Overall Response is defined as a Complete Response (CR) + Partial Response (PR) and is recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The participant's best response assignment will depend on the achievement of both measurement and confirmation criteria. Response was evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete Response (CR) is disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. Any pathological lymph nodes must have reduction in short axis to \\<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions."", 'timeFrame': 'end of treatment, up to 693 days'}, {'measure': 'Best Overall Response - All Participants', 'description': ""Best Overall Response is defined as a Complete Response (CR) + Partial Response (PR) and is recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The participant's best response assignment will depend on the achievement of both measurement and confirmation criteria. Response was evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete Response (CR) is disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. Any pathological lymph nodes must have reduction in short axis to \\<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions."", 'timeFrame': 'end of treatment, up to 693 days'}, {'measure': 'Overall Survival', 'description': 'Overall survival is defined as the duration of time from start of treatment to death from any cause.', 'timeFrame': 'Duration of time from start of treatment to death from any cause. An average of 35.95 months.'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'DCR is defined as a Complete Response (CR) + Partial Response (PR) + Stable Disease (SD). Response was evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete Response (CR) is disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. Any pathological lymph nodes must have reduction in short axis to \\<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD), taking as reference the smallest sum diameters while on study. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progression.', 'timeFrame': 'end of treatment, up to 693 days'}, {'measure': 'Disease Control Rate (DCR) - All Participants', 'description': 'DCR is defined as a Complete Response (CR) + Partial Response (PR) + Stable Disease (SD). Response was evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete Response (CR) is disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. Any pathological lymph nodes must have reduction in short axis to \\<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD), taking as reference the smallest sum diameters while on study. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progression.', 'timeFrame': 'end of treatment, up to 693 days'}]",13,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,37.0,ACTUAL,2025-09-01T16:18:23.448478,v2_robust,True,True,True,False,True,
NCT04014335,"A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy","An Open-Label Phase 2a Clinical Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Subjects With Primary IgA Nephropathy",IONIS-FB-LRx,['IONIS-FB-LRx'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Primary IgA Nephropathy,['Primary IgA Nephropathy'],[],COMPLETED,,2019-12-04,2024-04-11,"[{'measure': 'Percent Reduction in 24-hour Urine Protein Excretion', 'timeFrame': 'Baseline to Week 29 (If participant discontinues Study Drug prior to Week 25, Baseline and 4 weeks after the last dose of Study Drug will be measured)'}]","[{'measure': 'Absolute Reduction in 24-hour Urine Protein Excretion', 'timeFrame': 'Baseline to Week 29 (If participant discontinues Study Drug prior to Week 25, Baseline and 4 weeks after the last dose of Study Drug will be measured)'}, {'measure': 'Absolute Reduction in Albuminuria (UACr Ratio)', 'timeFrame': 'Baseline to Week 29'}, {'measure': 'Absolute Reduction in Proteinuria (UPCr Ratio)', 'timeFrame': 'Baseline to Week 29'}, {'measure': 'Percent Change from Baseline in Plasma Factor B (FB)', 'timeFrame': 'Up to Week 29'}, {'measure': 'Percent Change from Baseline in Plasma AH50', 'timeFrame': 'Up to Week 29'}]",6,18 Years,75 Years,ALL,False,"Ionis Pharmaceuticals, Inc.",INDUSTRY,0,23.0,ACTUAL,2025-09-01T16:18:23.448510,v2_robust,True,True,True,False,False,
NCT05064735,Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis,Effect of Subcutaneous Semaglutide 2.4 mg Once-weekly Compared to Placebo in Subjects With Obesity and Knee Osteoarthritis,semaglutide 2.4 mg,"['semaglutide 2.4 mg (placebo)', 'semaglutide 2.4 mg']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Obesity,['Obesity'],[],COMPLETED,,2021-10-01,2023-09-08,"[{'measure': 'Percentage Change in Body Weight', 'description': 'Percentage change in body weight from baseline (week 0) to end of treatment (week 68) is presented. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'Baseline (week 0), end of treatment (week 68)'}, {'measure': 'Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score', 'description': 'WOMAC is a disease-specific patient-reported outcome measure designed to assess changes in symptoms and lower extremity functioning associated with treatment in patients with osteoarthritis of the hip and/or knee. WOMAC is a 24 item questionnaire which assesses clinically important, participant-relevant symptoms in area of pain, stiffness, and physical function in participants with osteoarthritis (OA). It consists of 3 subscales: pain, stiffness and physical function. The WOMAC raw pain score is derived as the sum of the 5 item scores in the pain domain. It will be normalised and expressed on a 0-100 scale. This is done by dividing raw score by the highest possible value of the raw score for the pain domain (i.e. 50) and multiplying by 100. Higher scores indicate worse outcome. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'Baseline (week 0), end of treatment (week 68)'}]","[{'measure': 'Percentage of Participants Achieving Body Weight Reduction Greater Than or Equal to (≥) 5 Percent (%) (Yes/No)', 'description': ""Percentage of participants who achieved ≥ 5% body weight reduction (yes/no) from baseline (week 0) to end of treatment (week 68) is presented. In the reported data, 'Yes' infers percentage of participants who have achieved ≥5% weight reduction whereas 'No' infers percentage of participants who have not achieved ≥5% weight reduction. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site."", 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Percentage of Participants Achieving Body Weight Reduction ≥ 10% (Yes/No)', 'description': ""Percentage of participants who achieved ≥10% body weight reduction (yes/no) from baseline (week 0) to end of treatment (week 68) is presented. In the reported data, 'Yes' infers percentage of participants who have achieved ≥10% weight reduction whereas 'No' infers percentage of participants who have not achieved ≥10% weight reduction. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site."", 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Change in WOMAC Physical Function Score', 'description': 'Change in WOMAC physical function score is presented. WOMAC is a 24 item questionnaire which assesses clinically important, participant-relevant symptoms in area of pain, stiffness, and physical function in participants with osteoarthritis (OA). It consists of 3 subscales: pain, stiffness and physical function. WOMAC physical function is 17-item questionnaire used to assess degree of difficulty experienced due to OA in knee. It is calculated as the sum of the 17 item scores in the physical function domain. It is normalized and expressed on a 0-100 scale. This is done by dividing raw score by the highest possible value of the raw score for the physical function domain (i.e. 170) and multiplying by 100. Higher scores indicate worse outcome. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'Baseline (week 0), end of treatment (week 68)'}, {'measure': 'Change in Short Form 36 (SF-36) Physical Functioning Score', 'description': 'SF-36 is self-administered questionnaire that measures each of following 8 health domains: physical functioning, role limitations due to physical problems (role-physical), social functioning, bodily pain, mental health, role limitations due to emotional problems (role-emotional), vitality, and general health perception. There are also 2 component scores derived from the 8 subscale scores: physical component summary (including physical functioning, role-physical, bodily pain and general health) and mental component summary (including vitality, social functioning, role-emotional and mental health). Each SF-36 domain and component summary score ranges from 0 to 100, higher scores reflect better participant health status. A positive change score indicates an improvement since baseline. The outcome measure was evaluated based on data from in-trial period. In-trial period was defined as uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'Baseline (week 0), end of treatment (week 68)'}, {'measure': 'Change in Waist Circumference', 'description': 'Change in waist circumference from baseline (week 0) to end of the treatment (visit 68) is presented. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'Baseline (week 0), end of treatment (week 68)'}, {'measure': 'Change in WOMAC Stiffness Score', 'description': 'WOMAC is a disease-specific patient-reported outcome measure designed to assess changes in symptoms and lower extremity functioning associated with treatment in patients with osteoarthritis of the hip and/or knee. WOMAC is a 24 item questionnaire which assesses clinically important, participant-relevant symptoms in area of pain, stiffness, and physical function in participants with OA. It consists of 3 subscales: pain, stiffness and physical function. The WOMAC raw stiffness score is derived as the sum of the 2 item scores in the stiffness domain. It will be normalized and expressed on a 0-100 scale. This is done by dividing raw score by the highest possible value of the raw score for the stiffness domain (i.e. 20) and multiplying by 100. Higher scores indicate worse outcome. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'Baseline (week 0), end of treatment (week 68)'}, {'measure': 'Change in WOMAC Total Score', 'description': 'WOMAC is a disease-specific patient-reported outcome measure designed to assess changes in symptoms and lower extremity functioning associated with treatment in patients with osteoarthritis of the hip and/or knee. WOMAC is a 24 item questionnaire which assesses clinically important, participant-relevant symptoms in area of pain, stiffness, and physical function in participants with OA. The WOMAC raw total score is derived as the sum of the 24 item scores respectively on pain, stiffness and physical function domain. It will be normalized and expressed on a 0-100 scale. This is done by dividing raw score by the highest possible value of the raw score for the total domain (i.e. 240) and multiplying by 100. Higher scores indicate worse outcome. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'Baseline (week 0), end of treatment (week 68)'}, {'measure': 'Change in SF-36 Bodily Pain Score', 'description': 'Change in SF-36 Bodily Pain Score from baseline (week 0) to end of treatment (week 68) is presented. SF-36 is self-administered questionnaire that measures each of following 8 health domains: physical functioning, role limitations due to physical problems (role-physical), social functioning, bodily pain, mental health, role limitations due to emotional problems (role-emotional), vitality, and general health perception. There are also 2 component scores derived from the 8 subscale scores: physical component summary and mental component summary. Each SF-36 domain and component summary score ranges from 0 to 100, higher scores reflect better participant health status. A positive change score indicates an improvement since baseline. The outcome measure was evaluated based on data from in-trial period. In-trial period was defined as uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'Baseline (week 0), end of treatment (week 68)'}, {'measure': 'Change in SF-36 Physical Component Summary', 'description': 'Change in SF-36 physical component summary is presented. It is self-administered questionnaire that measures each of following 8 health domains: physical functioning, role limitations due to physical problems (role-physical), social functioning, bodily pain, mental health, role limitations due to emotional problems (role-emotional), vitality, and general health perception. There are also 2 component scores derived from the 8 subscale scores: physical component summary and mental component summary. Physical component summary contains physical functioning, role-physical, bodily pain and general health. Each SF-36 domain and component summary score ranges from 0 to 100, higher scores reflect better participant health status. A positive change score indicates an improvement since baseline. The outcome measure was evaluated based on data from in-trial period. In-trial period was defined as uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'Baseline (week 0), end of treatment (week 68)'}, {'measure': 'Change in SF-36 Mental Component Summary', 'description': 'Change in SF-36 mental component summary is presented. SF-36 is self-administered questionnaire that measures each of following 8 health domains: physical functioning, role limitations due to physical problems (role-physical), social functioning, bodily pain, mental health, role limitations due to emotional problems (role-emotional), vitality, and general health perception. There are also 2 component scores derived from the 8 subscale scores: mental component summary and physical component summary. Mental component summary contain vitality, social functioning, role-emotional and mental health. Each SF-36 domain and component summary score ranges from 0 to 100, higher scores reflect better participant health status. A positive change score indicates an improvement since baseline. The outcome measure was evaluated based on data from in-trial period. In-trial period was defined as uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'Baseline (week 0), end of treatment (week 68)'}, {'measure': 'Percentage of Participants Using Allowed Rescue Analgesics During Wash Out (Yes/No)', 'description': ""Percentage of participants using allowed rescue analgesics during wash out at end of treatment (week 68) is presented. In the reported data, 'Yes' infers percentage of participants who have used allowed rescue analgesics during wash out whereas 'No' infers percentage of participants who have not used allowed rescue analgesics during wash out. Use of allowed rescue analgesics is evaluated based on use of acetaminophen reported in the pain medication diary from one up to 3 days prior to WOMAC assessment. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site."", 'timeFrame': 'At end of treatment (week 68)'}, {'measure': 'Amount of Allowed Rescue Analgesics Used During Wash Out', 'description': 'Amount of allowed rescue analgesics used during wash out at end of treatment (week 68) is presented. Allowed rescue analgesic during washout is defined as acetaminophen taken 24-72 hour before the visit. The outcome measure is approximated by a total dose of acetaminophen reported in the pain medication diary from one and up to 3 days prior to WOMAC assessment. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'At end of treatment (week 68)'}, {'measure': 'Percentage of Participants With Use of Pain Medication', 'description': 'Percentage of participants with use of pain medication from baseline (week 0) to end of treatment (week 68) is presented. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Change in Pain Intensity (Numerical Rating Scale [NRS])', 'description': 'Pain intensity was assessed on an 11-point NRS over the past 24 hours (before each specified visit), where a score of 0 indicated ""no pain"" and a score of 10 indicated ""worst possible pain"", where higher the score, greater the pain intensity. Response at visit was derived from the pain diary data as an average score over 4 days interval leading up to visit-related washout period for pain medication. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'Baseline (week 0), end of treatment (week 68)'}, {'measure': 'Percentage of Participants Achieving Body Weight Reduction ≥ 15% (Yes/No)', 'description': ""Percentage of participants who achieved ≥15% body weight reduction (yes/no) from baseline (week 0) to end of treatment (week 68) is presented. In the reported data, 'Yes' infers percentage of participants who have achieved ≥15% weight reduction whereas 'No' infers percentage of participants who have not achieved ≥15% weight reduction. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site."", 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Percentage of Participants Achieving Body Weight Reduction ≥ 20% (Yes/No)', 'description': ""Percentage of participants who achieved ≥20% body weight reduction (yes/no) from baseline (week 0) to end of treatment (week 68) is presented. In the reported data, 'Yes' infers percentage of participants who have achieved ≥20% weight reduction whereas 'No' infers percentage of participants who have not achieved ≥20% weight reduction. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site."", 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Percentage of Participants Achieving WOMAC Pain Reduction ≥ 30% (Yes/No)', 'description': ""Percentage of participants who achieved ≥30% WOMAC pain reduction (yes/no) is presented. In the reported data, 'Yes' infers percentage of participants who have achieved ≥30% WOMAC pain reduction whereas 'No' infers percentage of participants who have not achieved ≥30% WOMAC pain reduction. WOMAC raw pain score is derived as sum of 5 item scores in pain domain. It will be normalized and expressed on 0-100 scale. This is done by dividing raw score by highest possible value of raw score for pain domain (i.e. 50) and multiplying by 100. Higher scores indicate worse outcome. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site."", 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Percentage of Participants Achieving WOMAC Pain Reduction ≥ 50% (Yes/No)', 'description': ""Percentage of participants who achieved ≥50% WOMAC pain reduction (yes/no) from baseline (week 0) to end of treatment (week 68) is presented. In the reported data, 'Yes' infers percentage of participants who have achieved ≥50% WOMAC pain reduction whereas 'No' infers percentage of participants who have not achieved ≥50% WOMAC pain reduction. WOMAC raw pain score is derived as sum of 5 item scores in pain domain. It will be normalized and expressed on 0-100 scale. This is done by dividing raw score by highest possible value of raw score for pain domain (i.e. 50) and multiplying by 100. Higher scores indicate worse outcome. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site."", 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Percentage of Participants Achieving Threshold for Clinically Meaningful Within-participant Change in WOMAC Pain Score (Yes/No)', 'description': ""Percentage of participants who achieved threshold for clinically meaningful within-participant change in WOMAC pain score from baseline (week 0) to end of treatment (week 68) is presented. The threshold refers to the decrease of at least 37.3 in the WOMAC pain score and it is derived based on 1-category improvement on patient global impression of status (PGI-S) scale. In reported data, 'Yes' infers percentage of participants who have achieved threshold whereas 'No' infers percentage of participants who have not achieved threshold. WOMAC raw pain score is derived as sum of 5 item scores in pain domain. It will be normalized and expressed on 0-100 scale. This is done by dividing raw score by highest possible value of raw score for pain domain (i.e. 50) and multiplying by 100. Higher scores=worse outcome. Outcome measure was evaluated based on data from in-trial period and it was defined as uninterrupted time interval from date of randomization to date of last contact with trial site."", 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Percentage of Participants Achieving Threshold for Clinically Meaningful Within-participant Change in WOMAC Physical Function Score (Yes/No)', 'description': ""Percentage of participants who achieved threshold for clinically meaningful within-participant change in WOMAC physical function score from baseline (week 0) to end of treatment (week 68) is presented. The threshold refers to the decrease of at least 41.2 in the WOMAC physical function score and it is derived based on 1-category improvement on PGI-S scale. In reported data, 'Yes' infers percentage of participants who have achieved threshold whereas 'No' infers percentage of participants who have not achieved threshold. WOMAC raw pain score is derived as sum of 5 item scores in pain domain. It will be normalized and expressed on 0-100 scale. This is done by dividing raw score by highest possible value of raw score for pain domain (i.e. 50) and multiplying by 100. Higher scores indicate worse outcome. Outcome measure was evaluated based on data from in-trial period and it was defined as uninterrupted time interval from date of randomization to date of last contact with trial site."", 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Percentage of Participants Achieving Threshold for Clinically Meaningful Within-participant Change in SF-36 Physical Functioning Score (Yes/No)', 'description': ""Percentage of participants who achieved threshold for clinically meaningful within-participant change in SF-36 physical function score is presented. Threshold refers to increase of at least 11.4 in SF-36 physical functioning score \\& it is derived based on 1-category improvement on PGI-S scale. 'Yes' infers percentage of participants who achieved threshold; 'No' infers percentage of participants who have not achieved threshold. SF-36: self-administered questionnaire that measures each of following 8 health domains: physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, \\& general health perception. Each SF-36 domain and component summary score ranges from 0-100, higher scores mean better participant health status. Outcome measure was evaluated based on data from in-trial period: uninterrupted time interval from date of randomization to date of last contact with trial site."", 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Percentage of Participants Achieving Pain Intensity (Numerical Rating Scale [NRS]) Reduction ≥ 30% (Yes/No)', 'description': 'Percentage of participants who achieved ≥30% pain intensity reduction (yes/no) from baseline (week 0) to end of treatment (week 68) is presented. In the reported data, \'Yes\' infers percentage of participants who have achieved ≥30% pain intensity reduction whereas \'No\' infers percentage of participants who have not achieved ≥30% pain intensity reduction. Response at visit was derived from the pain diary data as an average score over 4 days interval leading up to visit-related washout period for pain medication. Pain intensity was assessed on an 11-point NRS over the past 24 hours (before each specified visit), where a score of 0 indicated ""no pain"" and a score of 10 indicated ""worst possible pain"", where higher the score, greater the pain intensity. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Percentage of Participants Achieving Pain Intensity (Numerical Rating Scale [NRS]) Reduction ≥ 50% (Yes/No)', 'description': 'Percentage of participants who achieved ≥50% pain intensity reduction (yes/no) from baseline (week 0) to end of treatment (week 68) is presented. In the reported data, \'Yes\' infers percentage of participants who have achieved ≥50% pain intensity reduction whereas \'No\' infers percentage of participants who have not achieved ≥50% pain intensity reduction. Response at visit was derived from the pain diary data as an average score over 4 days interval leading up to visit-related washout period for pain medication. Pain intensity was assessed on an 11-point NRS over the past 24 hours (before each specified visit), where a score of 0 indicated ""no pain"" and a score of 10 indicated ""worst possible pain"", where higher the score, greater the pain intensity. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}]",25,,,ALL,True,Novo Nordisk A/S,INDUSTRY,0,407.0,ACTUAL,2025-09-01T16:18:23.448587,v2_robust,True,True,True,False,False,
NCT04283435,Endometrial Effects of Sildenafil in Frozen-Thawed Cycles in Women With Thin Endometrium,Effect of Sildenafil on Uterine and Endometrial Vasculature in Women With Thin Endometrium Having Frozen-Thawed IVF Cycles,Sildenafil Citrate,"['Estradiol Valerate', 'Sildenafil Citrate']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,IVF,"['IVF', 'Endometrial Receptivity']",[],UNKNOWN,,2021-09-01,2022-03-01,"[{'measure': 'Clinical Pregnancy rate', 'timeFrame': '2 weeks after embryo transfer'}]","[{'measure': 'endometrial thickness', 'timeFrame': 'at the time of embryo transfer'}, {'measure': 'Endometrial volume', 'timeFrame': 'at the time of embryo transfer'}, {'measure': 'Uterine artery doppler indices', 'timeFrame': 'at the time of embryo transfer'}, {'measure': '3D endometrial and subendometrial vascular indices(VI,FI.VFI)', 'timeFrame': 'at the time of embryo transfer'}]",5,25 Years,40 Years,FEMALE,False,Cairo University,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:23.448830,v2_robust,True,True,False,False,False,
NCT03662035,Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer,Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer,Apatinib,"['Apatinib', 'S-1']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Pancreatic Cancer,['Advanced Pancreatic Cancer'],[],UNKNOWN,,2018-09-15,2020-08-01,"[{'measure': 'Progression Free Survival', 'description': 'Progression-free survival is defined as the time from registration to the earlier of death or disease progression.', 'timeFrame': 'one year.'}]","[{'measure': 'Overall Survival', 'description': 'OS refers to the date of registration to the date of death for any cause.', 'timeFrame': 'one year.'}, {'measure': 'Duration of response', 'description': 'DOR refers to the time from the time the measurement first conforms to the CR or PR criteria (whichever is first measured) to the time the first true record of disease recurrence or progression (using the minimum measurements recorded in the trial as a reference for disease progression).', 'timeFrame': 'one year.'}, {'measure': 'Objective response rate', 'description': 'ORR refers to the proportion of patients whose tumors have shrunk to a certain extent for a certain period of time, including CR and PR cases', 'timeFrame': 'one year.'}, {'measure': 'Disease Control Rate', 'description': 'DCR refers to the percentage of patients with confirmed complete remission, partial remission, and disease stabilization (\\> 8 weeks) who can evaluate efficacy', 'timeFrame': 'one year.'}]",5,18 Years,70 Years,ALL,False,Changzhou No.2 People's Hospital,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:23.448851,v2_robust,True,True,False,False,False,
NCT04002635,Letrozole for Frozen Embryo Transfer (FET) in Patients With Polycystic Ovary Syndrome (PCOS),Endometrial Preparation Using Letrozole Compared to Artificial Cycle for Frozen Embryo Transfer in PCOS Patients,Letrozole,"['estradiol valerate', 'progesterone', 'Letrozole']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,"Infertility, Female","['Infertility, Female', 'Polycystic Ovary Syndrome', 'IVF', 'Ovulation Disorder']",['frozen embryo transfer'],WITHDRAWN,Practical issues,2020-12-01,2022-04-01,"[{'measure': 'early pregnancy loss', 'timeFrame': '12 weeks after frozen embryo transfer'}]","[{'measure': 'cancellation rate', 'timeFrame': '2 months'}, {'measure': 'number of visits to the clinic', 'timeFrame': '2 months'}, {'measure': 'endometrial thickness on the day of planning of FET', 'timeFrame': '1 day'}, {'measure': 'implantation rate', 'timeFrame': '1 day'}, {'measure': 'biochemical and clinical pregnancy rate', 'timeFrame': '12 weeks'}, {'measure': 'live birth rate', 'timeFrame': '1 year'}, {'measure': 'neonatal birth weight', 'timeFrame': '1 year'}, {'measure': 'term of delivery', 'timeFrame': '1 year'}, {'measure': 'hypertensive disorders of pregnancy', 'timeFrame': '1 year'}]",10,18 Years,40 Years,FEMALE,True,CRG UZ Brussel,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:23.448889,v2_robust,True,True,False,True,False,Practical issues
NCT00757835,24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG,"24-hour IOP Control With the Travoprost/Timolol Fixed Combination Compared With the Latanoprost/Timolol Fixed Combination, When Both Are Dosed in the Evening in Patients With Exfoliative Glaucoma",treatment with latanoprost/timolol fixed combination,"['treatment with latanoprost/timolol fixed combination', 'latanoprost/timolol fixed combination drops']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Glaucoma,['Glaucoma'],"['24-hour IOP', 'exfoliative glaucoma', 'travoprost/timolol', 'latanoprost/timolol', 'fixed combinations']",COMPLETED,,2008-05,2009-03,"[{'measure': 'Travoprost/timolol fixed combination will demonstrate better quality of 24-hour IOP control than latanoprost/timolol', 'timeFrame': '3 months'}]","[{'measure': 'Incidence of side effects with the two medications', 'timeFrame': '3 months'}]",2,21 Years,85 Years,ALL,False,Aristotle University Of Thessaloniki,OTHER,1,40.0,ACTUAL,2025-09-01T16:18:23.448906,v2_robust,True,True,True,False,False,
NCT06515535,Efficacy of Topical Tranexamic Acid in Reducing Blood Loss During CS in Patients With Placenta Previa,Efficacy of Topical Tranexamic Acid in Reducing Blood Loss During Elective Cesarean Delivery in Patients With Placenta Previa,Topical tranexamic acid,"['Intravenous tranexamic acid', 'Topical tranexamic acid']",2,INTERVENTIONAL,['NA'],,,Placenta Previa,['Placenta Previa'],[],NOT_YET_RECRUITING,,2024-07-24,2024-12-31,"[{'measure': 'Amount of blood loss', 'description': 'amount of intraoperative blood loss during CS in patients with placenta previa', 'timeFrame': 'during operation'}]","[{'measure': 'operative time', 'timeFrame': 'during operation'}]",2,20 Years,40 Years,FEMALE,True,Cairo University,OTHER,0,56.0,ESTIMATED,2025-09-01T16:18:23.448958,v2_robust,True,True,False,False,False,
NCT01104935,National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT],Evaluation of Trastuzumab Without Chemotherapy as a Postoperative Adjuvant Therapy in HER2 Positive Elderly Breast Cancer Patients: Randomized Controlled Trial,trastuzumab monotherapy,"['EC', 'AC', 'FEC', 'TCb (CBDCA)', 'trastuzumab monotherapy', 'CMF', 'Herceptin', 'PTX', 'DTX', 'TC', 'trastuzumab and chemotherapy']",11,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,['Breast Cancer'],[],COMPLETED,,2009-10-28,2018-10-15,"[{'measure': 'Disease free survival', 'description': 'Disease-free survival is defined as the interval from the date of enrollment to the date of any of the following events.\n\n1. Local recurrence, distant metastasis\n2. Metachronous breast cancer, secondary cancer\n3. Death', 'timeFrame': 'Patients are followed up for 8 years after initial enrollment (from Oct. 2009 through Oct. 2017).'}]","[{'measure': 'Overall survival', 'description': 'Overall survival is defined as the interval from the date of enrollment to the date of death from any cause.', 'timeFrame': 'Patients are followed up for 8 years after initial enrollment (from Oct. 2009 through Oct. 2017).'}, {'measure': 'Relapse-free survival', 'description': 'Relapse-free survival is defined as the interval from the date of enrollment to the date of any of the following events.\n\n1. Local recurrence, distant metastasis\n2. Death', 'timeFrame': 'Patients are followed up for 8 years after initial enrollment (from Oct. 2009 through Oct. 2017).'}, {'measure': 'Percentage of participants with adverse events as a measure of safety', 'description': 'The following variables are evaluated: left ventricular ejection fraction, white-cell count, neutrophil count, platelet count, bilirubin level, alanine aminotransferase level, aspartate aminotransferase level, alkaline phosphatase level, and creatinine level.', 'timeFrame': 'Evaluations are performed at the time of starting the specified treatment and 2, 6, and 9 month, 1 year, 1 year 6 months, 2 years, 2 years 6 months, and 3 years after the start of treatment. Subsequently, evaluations are done at 1-year intervals.'}, {'measure': 'Health-related QOL (HRQOL)', 'description': 'The following QOL questionnaire forms (in Japanese) are used for evaluations: FACT-G, HADS, EQ-5D, and PNQ.', 'timeFrame': 'Evaluations are performed at the time of starting the specified treatment and 2 months, 1 year, and 3 years after the start of treatment.'}, {'measure': 'Cost effectiveness analysis', 'description': 'Survey items are as follows.\n\n1. Direct medical costs: medical costs associated with therapy, the management of adverse events, etc.\n2. Direct nonmedical costs: transportation expenses required for medical examinations, costs of health foods, etc.\n3. Indirect costs: work-loss costs associated with treatment that are incurred directly by the patient and by their caregivers', 'timeFrame': 'Data on direct medical costs for the 3-year period after the start of the treatment are obtained from CRF. Data on direct nonmedical costs and indirect costs are obtained from questionnaires 2, 12, and 36 months after starting the treatment.'}]",6,70 Years,80 Years,FEMALE,False,Comprehensive Support Project for Oncology Research,OTHER,0,275.0,ACTUAL,2025-09-01T16:18:23.448999,v2_robust,True,True,True,False,True,
NCT01509508,Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence,"A Cluster Randomised Trial Comparing the Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence. The ARNS 12249 TasP (Treatment as Prevention) Trial in Hlabisa Sub-district, KwaZulu-Natal, South Africa.",Immediate ARV treatment initiation with TDF/FTC/EFV,['Immediate ARV treatment initiation with TDF/FTC/EFV'],1,INTERVENTIONAL,['NA'],,,HIV Infection,['HIV Infection'],"['HIV', 'Prevention', 'Treatment', 'South Africa']",COMPLETED,,2012-03,2016-06,"[{'measure': 'Uptake of initial and repeat HIV counselling and testing (Feasibility phase)', 'description': 'Percentage of the target population tested for HIV', 'timeFrame': '14 months'}, {'measure': 'Uptake of ARV treatment among HIV-infected individuals (Feasibility phase)', 'description': 'Percentage of HIV-infected patients followed-up in the trial clinics receiving ARV treatment when eligible', 'timeFrame': '14 months'}, {'measure': 'HIV infection incidence', 'description': 'Serology will be done on Dry Blood Spot collected during repeated surveys', 'timeFrame': '4 years after enrolment initiation'}]","[{'measure': 'Sexual partnerships', 'description': 'Percentage of participants reporting a certain number of sexual partnerships in the last 12 months', 'timeFrame': 'Repeated measure every 6 months during follow-up'}, {'measure': 'Safe sex and condom use', 'description': 'Percentage of participants using a male condom with their partner during the last sexual intercourse', 'timeFrame': 'Repeated measure every 6 months during follow-up'}, {'measure': 'Quality of life', 'description': '* the EQ-5D scale among the whole sample\n* the Patient Reported Outcomes Quality Of Life specific to HIV (PROQOL-HIV) instrument and the HIV/AIDS stigma instrument for PLWHA (HASI-P) tool among HIV-infected participants', 'timeFrame': 'Repeated measure every 6 months during follow-up'}, {'measure': 'Health care use and health care expenditures', 'description': 'Percentage of participants reporting health care visits (primary care centre, pharmacy, hospitalisation) in the past four weeks and cost incurred', 'timeFrame': 'Repeated measure every 6 months during follow-up'}, {'measure': 'Stigma at community level', 'description': 'Percentage of participants agreeing that people in the community do not blame people for having HIV Percentage of participants agreeing that people in the community avoid people with HIV', 'timeFrame': 'Repeated measure every 6 months during follow-up'}, {'measure': 'Adherence to ART', 'description': 'Measured three-monthly using a visual analogue scale, pill identification test and pill count', 'timeFrame': 'Repeated measure every 6 months during follow-up'}, {'measure': 'Retention', 'description': 'Proportion of HIV-infected participants still under active follow-up in the trial at key timepoints', 'timeFrame': 'Repeated measure every 6 months during follow-up'}]",10,16 Years,,ALL,True,"ANRS, Emerging Infectious Diseases",OTHER_GOV,2,28153.0,ACTUAL,2025-09-01T16:18:23.449133,v2_robust,True,True,True,False,False,
NCT03233308,Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT),"A Double-Masked, Randomized, Placebo-Controlled Study of Trabecular Outflow Facility Following Treatment With Netarsudil Ophthalmic Solution 0.02% (AR-13324) in Subjects With Elevated Intraocular Pressure",Netarsudil Ophthalmic Solution 0.02%,['Netarsudil Ophthalmic Solution 0.02%'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Primary Open Angle Glaucoma or Ocular Hypertension,['Primary Open Angle Glaucoma or Ocular Hypertension'],"['Aqueous Humor Dynamics', 'Trabecular Outflow', 'Netarsudil']",COMPLETED,,2017-10-20,2018-04-19,"[{'measure': 'Mean Change From Baseline in the Mean Diurnal Trabecular Outflow Facility', 'description': 'Mean diurnal change from baseline in trabecular (tonographic) outflow facility.', 'timeFrame': 'Study treatment was administered for 7 days, and outcome measures collected on Day 8'}, {'measure': 'Mean Percent Change From Baseline in the Mean Diurnal Trabecular Outflow Facility.', 'description': 'Mean diurnal change from baseline in trabecular (tonographic) outflow facility.', 'timeFrame': 'Study treatment was administered for 7 days, and outcome measures collected on Day 8'}]","[{'measure': 'Mean Change From Baseline in Episcleral Venous Pressure (EVP) and in Intraocular Pressure (IOP)', 'description': 'Mean diurnal change from baseline in mean diurnal IOP measured using a Pneumatonometer and mean diurnal EVP using a custom-modified slit-lamp mounted venomanometer. (EVP conducted at a single site in only 9 participants)', 'timeFrame': 'Study treatment was administered for 7 days, and outcome measures collected on Day 8'}, {'measure': 'Mean Percent Change From Baseline in Episcleral Venous Pressure (EVP) and in Intraocular Pressure (IOP)', 'description': 'Mean diurnal change from baseline in mean diurnal IOP measured using a Pneumatonometer and mean diurnal EVP using a custom-modified slit-lamp mounted venomanometer. (EVP conducted at a single site in only 9 participants)', 'timeFrame': 'Study treatment was administered for 7 days, and outcome measures collected on Day 8'}]",4,18 Years,,ALL,False,Aerie Pharmaceuticals,INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:23.449219,v2_robust,True,True,True,False,False,
NCT04906408,The Effects of Post-Operative Interventions on Surgical Site Occurrences in AWR,The Effects of Post-Operative Interventions on Surgical Site Occurrences in Abdominal Wall Reconstructions: A Randomized Controlled Trial,Traditional,['Traditional'],1,INTERVENTIONAL,['NA'],,,Abdomen Hernia,['Abdomen Hernia'],"['Infection', 'seroma', 'hematoma', 'skin necrosis', 'EC fistula', 'Mesh infection', 'Hernia recurrence', 'Bulge', 'Prevena', 'Prineo', 'Abdominal wall reconstruction', 'SSO', 'dressings']",RECRUITING,,2021-09-17,2028-05-01,"[{'measure': 'Rate of Infection', 'timeFrame': 'At 6 weeks postoperatively'}, {'measure': 'Rate of Seroma', 'timeFrame': 'At 6 weeks postoperatively'}, {'measure': 'Rate of Hematoma', 'timeFrame': 'At 6 weeks postoperatively'}, {'measure': 'Rate of Dehiscence', 'timeFrame': 'At 6 weeks postoperatively'}, {'measure': 'Rate of Skin necrosis', 'timeFrame': 'At 6 weeks postoperatively'}, {'measure': 'Rate of Enterocutaneous fistula', 'timeFrame': 'At 6 weeks postoperatively'}, {'measure': 'Rate of Mesh infection', 'timeFrame': 'At 6 weeks postoperatively'}, {'measure': 'Rate of Hernia recurrence', 'timeFrame': 'At 6 weeks postoperatively'}, {'measure': 'Rate of Bulge', 'timeFrame': 'At 6 weeks postoperatively'}]","[{'measure': 'Average Cost', 'description': 'In USD of postoperative wound care and complications', 'timeFrame': 'At 6 weeks postoperatively'}, {'measure': 'Average Cost', 'description': 'In USD of postoperative wound care and complications', 'timeFrame': 'At 3 months postoperatively'}, {'measure': 'Average Cost', 'description': 'In USD of postoperative wound care and complications', 'timeFrame': 'At 1 year postoperatively'}, {'measure': 'Average pain assessment score: PROMIS Pain Intensity survey', 'description': 'Minimum 3, Maximum 15, higher scores are worse pain/outcomes', 'timeFrame': 'At 6 weeks postoperatively'}, {'measure': 'Average pain assessment score: PROMIS Pain Intensity survey', 'description': 'Minimum 3, Maximum 15, higher scores are worse pain/outcomes', 'timeFrame': 'At 3 months postoperatively'}, {'measure': 'Average pain assessment score: PROMIS Pain Intensity survey', 'description': 'Minimum 3, Maximum 15, higher scores are worse pain/outcomes', 'timeFrame': 'At 1 year postoperatively'}, {'measure': 'Average scar assessment score: POSAS (Patient and Observer Scar) Assessment Scale) 2.0 survey', 'description': 'Provider score: Minimum 7, Maximum 70, higher scores are worse appearance/outcome.\n\nPatient score: Minimum 7, Maximum 70, higher scores are worse appearance/outcome.', 'timeFrame': 'At 1 year postoperatively'}, {'measure': 'Average scar assessment score: POSAS (Patient and Observer Scar) Assessment Scale) 2.0 survey', 'description': 'Provider score: Minimum 7, Maximum 70, higher scores are worse appearance/outcome.\n\nPatient score: Minimum 7, Maximum 70, higher scores are worse appearance/outcome.', 'timeFrame': 'At 6 weeks postoperatively'}, {'measure': 'Average scar assessment score: POSAS (Patient and Observer Scar) Assessment Scale) 2.0 survey', 'description': 'Provider score: Minimum 7, Maximum 70, higher scores are worse appearance/outcome.\n\nPatient score: Minimum 7, Maximum 70, higher scores are worse appearance/outcome.', 'timeFrame': 'At 3 months postoperatively'}, {'measure': 'Rate of infection', 'timeFrame': 'At 3 months postoperatively'}, {'measure': 'Rate of infection', 'timeFrame': 'At 1 year postoperatively'}, {'measure': 'Rate of Seroma', 'timeFrame': 'At 3 months postoperatively'}, {'measure': 'Rate of Seroma', 'timeFrame': 'At 1 year postoperatively'}, {'measure': 'Rate of Hematoma', 'timeFrame': 'At 1 year postoperatively'}, {'measure': 'Rate of Hematoma', 'timeFrame': 'At 3 months postoperatively'}, {'measure': 'Rate of Dehiscence', 'timeFrame': 'At 3 months postoperatively'}, {'measure': 'Rate of Dehiscence', 'timeFrame': 'At 1 year postoperatively'}, {'measure': 'Rate of Skin Necrosis', 'timeFrame': 'At 3 months postoperatively'}, {'measure': 'Rate of Skin Necrosis', 'timeFrame': 'At 1 year postoperatively'}, {'measure': 'Rate of Enterocutaneous fistula', 'timeFrame': 'At 3 months postoperatively'}, {'measure': 'Rate of Enterocutaneous fistula', 'timeFrame': 'At 1 year postoperatively'}, {'measure': 'Rate of Mesh infection', 'timeFrame': 'At 3 months postoperatively'}, {'measure': 'Rate of Mesh infection', 'timeFrame': 'At 1 year postoperatively'}, {'measure': 'Rate of Hernia Recurrence', 'timeFrame': 'At 3 months postoperatively'}, {'measure': 'Rate of Hernia Recurrence', 'timeFrame': 'At 1 year postoperatively'}, {'measure': 'Rate of Bulge', 'timeFrame': 'At 3 months postoperatively'}, {'measure': 'Rate of Bulge', 'timeFrame': 'At 1 year postoperatively'}]",36,18 Years,,ALL,True,Ohio State University,OTHER,0,300.0,ESTIMATED,2025-09-01T16:18:23.449238,v2_robust,True,True,False,False,False,
NCT03898908,Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain,"Phase II, Multicentre Clinical Trial to Evaluate the Activity of Encorafenib and Binimetinib Administered Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain",encorafenib,"['Braftovi', 'encorafenib', 'Mektovi', 'binimetinib']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Melanoma,"['Metastatic Melanoma', 'Brain Metastases']","['metastases', 'melanoma', 'encorafenib', 'binimetinib']",COMPLETED,,2019-07-18,2023-07-31,"[{'measure': 'Intracranial Objective Response (iORR) by Modified RECIST 1.1 Before Local Radiotherapy Treatment in Full Dataset', 'description': 'iORR calculated as the proportion of patient with a best overall intracranial response of complete response (CR) or partial response (PR) before local treatment according to modified RECIST 1.1.\n\nModified RECIST 1.1 consists of:\n\nUp to 5 intracranial lesions could be selected as target lesions Target lesions might have a longest diameter ≥ 5 mm when evaluated by contrast-enhanced MRI\n\nThis endpoint was also independently reported in patients with symptomatic and asymptomatic brain metastasis.', 'timeFrame': '24 months after start of treatment'}]","[{'measure': 'Duration of Intracranial Response', 'description': 'Calculated as the time from the date of first documented CR or PR to the first documented intracranial progression or death due to underlying cancer accoridng to modified RECIST 1.1, in patients with documented intracranial CR or PR before local treatment.', 'timeFrame': 'Throughout the study period, up to approximately 24 months'}, {'measure': 'Intracranial Progression-free Survival (iPFS) by RECIST 1.1', 'description': ""Defined as the time from the date of inclusion to the date of the first documented intracranial disease progression or death due to any cause, whichever occurs first. PFS was determined based on tumor assessment (modified RECIST version 1.1 criteria). The local Investigator's assessments was used for analyses. Those patients who were alive and had not progressed at the last follow-up, date of progression was censored at the date of the last follow-up. Patients with no additional image test other than baseline were censored the day after inclusion."", 'timeFrame': 'Throughout the study period, up to approximately 24 months'}, {'measure': 'Extracranial Progression-free Survival (ePFS) in Both Cohorts', 'description': ""Defined as the time from the date of inclusion to the date of the first documented extracranial disease progression or death due to any cause, whichever occurs first. PFS was determined based on tumor assessment (RECIST version 1.1 criteria). The local Investigator's assessments was used for analyses. Those patients who were alive and had not progressed at the last follow-up, date of progression was censored at the date of the last follow-up. Patients with no additional image test other than baseline were censored the day after inclusion."", 'timeFrame': 'Throughout the study period, up to approximately 24 months'}, {'measure': 'Intracranial Progression-free Rates', 'description': 'Proportion of patients free of intracranial progression assessed by modified RECIST at 6 months (week 24), 12 months (week 48) and 24-month (week 96) considering date of inclusion estimated through Kaplan-Meier method', 'timeFrame': 'at 6 months (week 24), 12 months (week 48) and 24-month (week 96)'}, {'measure': 'Overall Survival', 'description': 'Calculated as the time from date of inclusion to date of death due to any cause.', 'timeFrame': 'Throughout the study period, up to approximately 24 months'}, {'measure': 'Overall Survival Rates', 'description': 'Proportion of of patients alive at 6 months, 12 month and 24-month considering date of inclusion estimated using Kaplan-Meier.\n\nPatients alive at the moment of the analysis were censored on the date of their last follow-up.', 'timeFrame': 'at 6 months, 12 month and 24-month'}, {'measure': 'Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0', 'description': 'Number of patients experiencing treatment related adverse events. These events were graded accrding to CTCAE, a scale that ranges from 0 (less intense; no event) to 5 (death) .\n\nHere we report the number of patients experiencing any grade toxicities and the number of patients experiencing high grade (grade 3-5) toxicities.', 'timeFrame': 'Throughout the study period, up to approximately 24 months'}, {'measure': 'Change on Quality of Life at Week 8 in Both Cohorts Based on the EORTC QLQ 30 Scale', 'description': ""The EORTC QLQ-C30 questionnaire is validated for cancer. It is composed of 30 questions or items that assess QoL. The questionnaire is structured in 5 functional scales physical functioning, daily activities, emotional functioning, cognitive functioning and social functioning), 3 symptom scales (fatigue, pain and nausea, vomiting), 1 global health status scale, and 6 independent items (dyspnea, insomnia, anorexia, constipation, diarrhea and economic impact). Values between 1 and 4 (1: not at all, 2: a little, 3: quite, 4: a lot) are assigned according to the patient's responses to the item, only in items 29 and 30 are they evaluated with a score of 1 to 7 (1: dreadful, 7: excellent).\n\nThe scores obtained are standardized and a score between 0 and 100 is obtained, which determines the level of impact of the cancer on the patient on each of the scales. Higher values indicate better performance"", 'timeFrame': '8 weeks'}, {'measure': 'Change on Quality of Life at Week 24 in Both Cohorts Based on the EORTC QLQ 30 Scale', 'description': ""The EORTC QLQ-C30 questionnaire is validated for cancer. It is composed of 30 questions or items that assess QoL. The questionnaire is structured in 5 functional scales physical functioning, daily activities, emotional functioning, cognitive functioning and social functioning), 3 symptom scales (fatigue, pain and nausea, vomiting), 1 global health status scale, and 6 independent items (dyspnea, insomnia, anorexia, constipation, diarrhea and economic impact). Values between 1 and 4 (1: not at all, 2: a little, 3: quite, 4: a lot) are assigned according to the patient's responses to the item, only in items 29 and 30 are they evaluated with a score of 1 to 7 (1: dreadful, 7: excellent).\n\nThe scores obtained are standardized and a score between 0 and 100 is obtained, which determines the level of impact of the cancer on the patient on each of the scales. Higher values indicate better performance"", 'timeFrame': '24 weeks'}, {'measure': 'Extracranial Progression-free Rates', 'description': 'Proportion of patients free of extracranial progression assessed by modified RECIST at 6 months (week 24), 12 months (week 48) and 24-month (week 96) considering date of inclusion estimated through Kaplan-Meier method', 'timeFrame': 'at 6 months (week 24), 12 months (week 48) and 24-month (week 96)'}]",11,18 Years,,ALL,False,Grupo Español Multidisciplinar de Melanoma,OTHER,2,48.0,ACTUAL,2025-09-01T16:18:23.449394,v2_robust,True,True,True,False,True,
NCT00383708,Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients,"Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg Alone",lanreotide (Autogel formulation),"['Pegvisomant', 'lanreotide (Autogel formulation)']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Acromegaly,['Acromegaly'],[],COMPLETED,,2006-10,2008-10,"[{'measure': 'Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period', 'description': 'Serum IGF-1 is a well known and validated marker of acromegaly. IGF-1 assessments were performed at Visit (V) 1, V2, V3, V5, V7, V9 and V11 (or in case of premature study discontinuation, at the early withdrawal visit) and were based on a single serum sample taken in fasting conditions, prior to investigational medicinal product (IMP) administration. Percentage of subjects with a normalised (age and sex adjusted) IGF-1 level at the end of the co-administration period are presented. The last observation carried forward (LOCF) was used to replace missing IGF-1 values.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period; Summarised by Previous Treatment and by Final Dose of Pegvisomant', 'description': 'Serum IGF-1 is a well known and validated marker of acromegaly. IGF-1 assessments were performed at V1, V2, V3, V5, V7, V9 and V11 (or in case of premature study discontinuation, at the early withdrawal visit) and were based on a single serum sample taken in fasting conditions, prior to IMP administration. Percentage of subjects with a normalised (age and sex adjusted) IGF-1 level at the end of the co-administration period, summarised by previous treatment and by final pegvisomant dose are presented. The denominator used to calculate percentages was the number of subjects in each subgroup, comprising previous treatment with pegvisomant, lanreotide Autogel and octreotide long acting repeatable (LAR) and final pegvisomant dose as either 40 mg, 60 mg or 80 mg once a week or 40 mg or 60 mg twice per week. The LOCF approach was used to replace missing IGF-1 values.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period; Summarised by Diabetic Status at Baseline', 'description': 'Serum IGF-1 is a well known and validated marker of acromegaly. IGF-1 assessments were performed at V1, V2, V3, V5, V7, V9 and V11 (or in case of premature study discontinuation, at the early withdrawal visit) and were based on a single serum sample taken in fasting conditions, prior to IMP administration. Percentage of subjects with a normalised (age and sex adjusted) IGF-1 level at the end of the co-administration period, summarised by diabetic status are presented. The denominator used to calculate percentages was the number of subjects in each subgroup (diabetic and non diabetic). The LOCF approach was used to replace missing IGF-1 values.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}]","[{'measure': 'Percentage of Subjects With a Normalised (Age and Sex Adjusted) IGF-1 Level at Any Time During the Co-administration Period', 'description': ""Serum IGF-1 is a well known and validated marker of acromegaly. IGF-1 assessments were performed at V1, V2, V3, V5, V7, V9 and V11 (or in case of premature study discontinuation, at the early withdrawal visit) and were based on a single serum sample taken in fasting conditions, prior to IMP administration. Percentage of subjects with a normalised (age and sex adjusted) IGF-1 level at least once during the co-administration period, summarised by 'while taking the final dose during co-administration' and 'at any time during co-administration' are presented."", 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Percentage of Subjects With Normalised (Age and Sex Adjusted) IGF-1 at Each Assessment', 'description': 'Serum IGF-1 is a well known and validated marker of acromegaly. IGF-1 assessments were performed at V1, V2, V3, V5, V7, V9 and V11 (or in case of premature study discontinuation, at the early withdrawal visit) and were based on a single serum sample taken in fasting conditions, prior to IMP administration. The percentage of subjects with a normalised (age and sex adjusted) IGF-1 level is presented. The denominator used to calculate the percentages was the number of ITT population subjects with an assessment at the visit. In addition to the data for each individual visit, the last value available (LVA) data is also presented. None of the ITT population subjects had serum IGF-1 normalised at V3, consistent with the criterion to continue in the study and be treated in the co-administration period.', 'timeFrame': 'V1 (Screening) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Serum IGF-1 Levels (Expressed as Z-scores) During the Co-administration Period', 'description': 'The change in serum IGF-1 levels, expressed as z-scores calculated using the age and sex specific mean and standard deviation \\[SD\\] values from Baseline to V11 and to LVA are presented. A z-score between +/- 2 indicates a normal IGF-1 concentration.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Acromegaly Symptoms During the Co-administration Period', 'description': 'Acromegaly symptoms, including arthralgia, excessive perspiration, fatigue, headache and soft tissue swelling were assessed with scores ranging from 0 (no symptoms) to 8 (severe, incapacitating symptoms). Symptoms were assessed by the subject in paper format before any other procedure planned during the visit. The change in acromegaly symptoms from Baseline to V11 and to LVA are presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Acromegaly Quality of Life (ACROQoL) Assessments During the Co-administration Period', 'description': 'The ACROQoL is a health-related quality of life (QoL) questionnaire for patients with acromegaly consisting of 22 items measured on a 5-point Likert-type scale that assesses frequency of occurrence (always to never) or degree of agreement (completely agree to completely disagree) with the statements. The ACROQoL consists of questions that evaluate physical (8 items) and psychological aspects related to appearance and personal relations (7 items each). Answers are transformed to a percentage value, where 100 is the maximal (best) and 0 the minimum (worse) score depicting self-perceived quality QoL. An increase in ACROQoL score is associated with an improved QoL. The change in ACROQoL global score, physical and psychological dimension scores and appearance and personal relationships sub-dimension scores from Baseline to V11 and to LVA are presented. Relnship = Relationship; Dim = Dimension.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Correlation Between the Changes in ACROQoL Assessments With the Corresponding Changes in Z-score of IGF-1 Levels Over the Run-in Period and Co-administration Period', 'description': ""The correlation between the changes in ACROQoL (expressed as standardised scores and undertaken for global score, physical and psychological dimension scores and appearance and personal relationships sub-dimension scores) over the run-in period (V3 minus V2) and co-administration period (V11 and LVA minus V3) with the corresponding changes in z-score for the IGF-1 level is presented. A decrease in IGF-1 z-score represents an improvement and an increase in ACROQoL score represents an improvement. Spearman's rank correlation (r) values are presented for change from V2 to V3 (Baseline) and from Baseline to V11/LVA for each of the specified ACROQoL categories. Corr = Correlation; Dim = Dimension; Relnship = Relationship."", 'timeFrame': 'At V2 (Day 1; Run-in), V3 (Week 12; Baseline) and V11 (Week 44)'}, {'measure': 'Change From Baseline in Mean Weight From Baseline During the Co-administration Period', 'description': 'Weight was recorded at V2, V3 and V11 (or in case of premature study discontinuation, at the early withdrawal visit). The change in mean weight from Baseline to V11 and to LVA are presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Mean Supine Systolic and Diastolic Blood Pressure (BP) During the Co-administration Period', 'description': 'Blood pressure (supine after resting for 3 minutes) was recorded at V1, V2, V3, V5, V7, V9 and V11 (or in case of premature study discontinuation, at the early withdrawal visit). The change in mean BP (systolic and diastolic) from Baseline to V11 and to LVA are presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Mean Supine Heart Rate During the Co-administration Period', 'description': 'Heart rate (supine after resting for 3 minutes) was recorded at V1, V2, V3, V5, V7, V9 and V11 (or in case of premature study discontinuation, at the early withdrawal visit). The change in mean heart rate from Baseline to V11 and to LVA are presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate During the Co-administration Period', 'description': 'Twelve-lead ECG recordings were performed at V2, V3 and V11. Sinus rhythm, heart rate, PR interval, RR interval, QRS interval and QT interval were measured and heart rate corrected QT interval using the Fridericia method (QTcF) was calculated. The change in ECG mean heart rate from Baseline to V11 and to LVA is presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Mean PR Interval, QRS Interval, QT Interval, RR Interval and QTcF During the Co-administration Period', 'description': 'Twelve-lead ECG recordings were performed at V2, V3 and V11. Sinus rhythm, heart rate, PR interval, RR interval, QRS interval and QT interval were measured and QTcF was calculated. The change in mean ECG parameter for PR interval, QRS interval, QT interval, RR interval and QTcF from Baseline to V11 and to LVA are presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Number of Subjects With Shift in Presence/Absence of Lithiasis and/or Sludge During Co-administration Period', 'description': 'A gallbladder ultrasound was performed at V2, V3, and V11 (or in case of premature study discontinuation, at the early withdrawal visit). Presence of lithiasis and sludge was recorded. Number of subjects who developed or resolved lithiasis and developed or resolved sludge, comparing Baseline to V11 and to LVA are presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Mean Pituitary Tumour Size During the Co-administration Period', 'description': 'Pituitary tumour size was assessed by Magnetic Resonance Imaging at V2, V3 and V11 (or in case of premature study discontinuation, at the early withdrawal visit). The two longest diameters of the pituitary tumour were to be measured. The change in mean pituitary tumour size from Baseline to V11 and to LVA is presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Mean Blood Glucose Maximum Concentration (Cmax) From Oral Glucose Tolerance Test (OGTT) During the Co-administration Period; Assessed in Non Diabetic Subjects', 'description': 'Glucose tolerance was only evaluated in non diabetic subjects. Glucose tolerance was assessed based on measurement of fasting blood glucose and insulin levels taken at V2 and OGTT performed at V3 and V11 (or in case of premature study discontinuation, at the early withdrawal visit). A dose of 75 g oral glucose was given to subjects and blood samples then taken at 30, 60, 90 and 120 minutes after oral glucose to measure glucose, insulin and GH levels, and to evaluate the GH nadir level. The OGTT was performed after the assessment of IGF-1 and all safety laboratory tests, but before IMPs administration at V3. Glucose, insulin and GH levels were assessed before OGTT in fasting conditions and at the same time as IGF-1 assessment. The change in mean blood glucose Cmax (as determined from OGTT) from Baseline to V11 and to LVA is presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Mean Fasting Insulin Concentration During the Co-administration Period; Assessed in Non Diabetic Subjects', 'description': 'Glucose tolerance was only evaluated in non diabetic subjects. Glucose tolerance was assessed based on measurement of fasting blood glucose and insulin levels taken at V2 and OGTT performed at V3 and V11 (or in case of premature study discontinuation, at the early withdrawal visit). A dose of 75 g oral glucose was given to subjects and blood samples then taken at 30, 60, 90 and 120 minutes after oral glucose to measure glucose, insulin and GH levels, and to evaluate the GH nadir level. The OGTT was performed after the assessment of IGF-1 and all safety laboratory tests, but before IMPs administration at V3. Glucose, insulin and GH levels were assessed before OGTT in fasting conditions and at the same time as IGF-1 assessment. The change in mean fasting insulin concentration from Baseline to V11 and to LVA is presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Mean Fasting Glucose Concentration During the Co-administration Period; Assessed in Non Diabetic Subjects', 'description': 'Glucose tolerance was only evaluated in non diabetic subjects. Glucose tolerance was assessed based on measurement of fasting blood glucose and insulin levels taken at V2 and OGTT performed at V3 and V11 (or in case of premature study discontinuation, at the early withdrawal visit). A dose of 75 g oral glucose was given to subjects and blood samples then taken at 30, 60, 90 and 120 minutes after oral glucose to measure glucose, insulin and GH levels, and to evaluate the GH nadir level. The OGTT was performed after the assessment of IGF-1 and all safety laboratory tests, but before IMPs administration at V3. Glucose, insulin and GH levels were assessed before OGTT in fasting conditions and at the same time as IGF-1 assessment. The change in mean fasting glucose concentration from Baseline to V11 and to LVA is presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Mean Fasting Insulin / Glucose Ratio During the Co-administration Period; Assessed in Non Diabetic Subjects', 'description': 'Glucose tolerance was only evaluated in non diabetic subjects. Glucose tolerance was assessed based on measurement of fasting blood glucose and insulin levels taken at V2 and OGTT performed at V3 and V11 (or in case of premature study discontinuation, at the early withdrawal visit). A dose of 75 g oral glucose was given to subjects and blood samples then taken at 30, 60, 90 and 120 minutes after oral glucose to measure glucose, insulin and GH levels, and to evaluate the GH nadir level. The OGTT was performed after the assessment of IGF-1 and all safety laboratory tests, but before IMPs administration at V3. Glucose, insulin and GH levels were assessed before OGTT in fasting conditions and at the same time as IGF-1 assessment. The change in mean fasting insulin / glucose ratio from Baseline to V11 and to LVA is presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Mean Glycosylated Haemoglobin (HbA1C) During the Co-administration Period; Assessed in Non Diabetic and Diabetic Subjects', 'description': 'Glycosylated haemoglobin (HbA1C) was measured at V2, V3 and V11 (or in case of premature discontinuation, at the early withdrawal visit). The change in mean HbA1C in diabetic and non diabetic subjects from Baseline to V11 and to LVA are presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Liver Function Test Parameters During the Co-administration Period', 'description': 'Blood samples for clinical laboratory tests were taken at V1, V2, V3 and V11 (or in case of premature study discontinuation, at the early withdrawal visit). During the co-administration period, hepatic toxicity was assessed at each visit (V5 to V10) by measuring alanine amino transferase (ALT), aspartate amino transferase (AST), alkaline phosphatase, gamma glutamyl transferase (GGT), prothrombin time and total bilirubin. The change in mean ALT, AST, GGT and alkaline phosphatase from Baseline to V11 and to LVA are presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Total Bilirubin During the Co-administration Period', 'description': 'Blood samples for clinical laboratory tests were taken at V1, V2, V3 and V11 (or in case of premature study discontinuation, at the early withdrawal visit). During the co-administration period, hepatic toxicity was assessed at each visit (V5 to V10) by measuring ALT, AST, alkaline phosphatase, GGT, prothrombin time and total bilirubin. The change in mean total bilirubin from Baseline to V11 and to LVA is presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Change From Baseline in Prothrombin Time (Expressed as a Percentage of Normal) During the Co-administration Period', 'description': 'Blood samples for clinical laboratory tests were taken at V1, V2, V3 and V11 (or in case of premature study discontinuation, at the early withdrawal visit). During the co-administration period, hepatic toxicity was assessed at each visit (V5 to V10) by measuring ALT, AST, alkaline phosphatase, GGT, prothrombin time and total bilirubin. Prothrombin time was expressed as a percentage of the time taken for a control blood sample to clot (designated as 100%) and the mean change from Baseline to V11 and to LVA is presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}, {'measure': 'Number of Subjects With Putative Antibodies to Lanreotide and to Pegvisomant During the Co-administration Period', 'description': 'Presence of putative antibodies to lanreotide and antibodies to pegvisomant were assessed prior to IMP administration at V2, V4 and V11 (or in case of premature study discontinuation, at the early withdrawal visit). The number of subjects with putative antibodies to lanreotide and to pegvisomant during the co-administration period (Baseline up to V11) is presented.', 'timeFrame': 'V3 (Week 12; Baseline) up to V11 (Week 44)'}]",25,18 Years,75 Years,ALL,False,Ipsen,INDUSTRY,0,125.0,ACTUAL,2025-09-01T16:18:23.449479,v2_robust,True,True,True,False,True,
NCT05477108,"Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","A Phase I, Randomized, Double-blind, Single-dose, Partial Replicate, 3-way Cross-over Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA",Treatment A (BGF MDI HFO with oral activated charcoal),"['Treatment A (BGF MDI HFO with oral activated charcoal)', 'Budesonide / Glycopyronium / Formoterol fumarate pressurized inhalation suspension, HFA', 'Treatment B (BGF MDI HFA with oral activated charcoal)', 'Budesonide / Glycopyronium / Formoterol fumarate pressurized inhalation suspension, HFO']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Chronic Obstructive Pulmonary Disease,['Chronic Obstructive Pulmonary Disease'],"['Corticosteroid', 'Long acting muscarine agonist (LAMA)', 'Long acting beta agonist', 'Propellant', 'Bioequivalence', 'Lung exposure', 'Healthy subjects', 'Inhaled corticosteroid (ICS)', 'Long-acting β2 agonist (LABA)', 'Next generation propellant (NGP)']",COMPLETED,,2022-07-29,2023-04-11,"[{'measure': 'Maximum Observed Plasma (Peak) Drug Concentration (Cmax )', 'description': 'Bioequivalence (Cmax) of the lung exposure of budesonide, glycopyrronium, and formoterol administered as BGF MDI HFO compared with BGF MDI HFA was assessed.', 'timeFrame': 'Pre-dose, 2 minutes, 5 minutes,10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hours (h), 2 h, 4 h, 8 h, 12h and 24 hours post-dose on Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)'}, {'measure': 'Area Under Plasma Concentration Time Curve From Zero to Infinity (AUCinf)', 'description': 'Bioequivalence (AUCinf) of the lung exposure of budesonide, glycopyrronium, and formoterol administered as BGF MDI HFO compared with BGF MDI HFA was assessed.', 'timeFrame': 'Pre-dose, 2 minutes, 5 minutes,10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 h, 2 h, 4 h, 8 h, 12 h and 24 hours post-dose on Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)'}, {'measure': 'Area Under the Plasma Concentration Curve From Zero to the Last Quantifiable Concentration (AUClast)', 'description': 'Bioequivalence (AUClast) of the lung exposure of budesonide, glycopyrronium, and formoterol administered as BGF MDI HFO compared with BGF MDI HFA was assessed.', 'timeFrame': 'Pre-dose, 2 minutes, 5 minutes,10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 h, 2 h, 4 h, 8 h, 12 h and 24 hours post-dose on Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)'}]","[{'measure': 'Time to Reach Peak or Maximum Observed Concentration or Response Following Drug Administration (Tmax)', 'description': 'The tmax as PK profiles of BGF administered as BGF MDI HFO and BGF MDI HFA with oral activated charcoal was assessed.', 'timeFrame': 'Pre-dose, 2 minutes, 5 minutes,10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 h, 2 h, 4 h, 8 h, 12 h and 24 hours post-dose on Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)'}, {'measure': 'Half Life Associated With Terminal Slope (λz) of a Semi Logarithmic Concentration Time Curve (t½λz)', 'description': 'The t½λz as PK profiles of BGF administered as BGF MDI HFO and BGF MDI HFA with oral activated charcoal was assessed.', 'timeFrame': 'Pre-dose, 2 minutes, 5 minutes,10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 h, 2 h, 4 h, 8 h, 12 h and 24 hours post-dose on Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)'}, {'measure': 'Terminal Rate Constant (λz)', 'description': 'The λz PK profiles of BGF administered as BGF MDI HFO and BGF MDI HFA with oral activated charcoal was assessed.', 'timeFrame': 'Pre-dose, 2 minutes, 5 minutes,10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 h, 2 h, 4 h, 8 h, 12 h and 24 hours post-dose on Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)'}, {'measure': 'Mean Residence Time of the Unchanged Drug in the Systemic Circulation From Zero to Infinity (MRTinf)', 'description': 'The MRTinf PK profiles of BGF administered as BGF MDI HFO and BGF MDI HFA with oral activated charcoal was assessed.', 'timeFrame': 'Pre-dose, 2 minutes, 5 minutes,10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 h, 2 h, 4 h, 8 h, 12 h and 24 hours post-dose on Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)'}, {'measure': 'Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F)', 'description': 'The CL/F PK profiles of BGF administered as BGF MDI HFO and BGF MDI HFA with oral activated charcoal was assessed.', 'timeFrame': 'Pre-dose, 2 minutes, 5 minutes,10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 h, 2 h, 4 h, 8 h, 12 h and 24 hours post-dose on Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)'}, {'measure': 'Volume of Distribution (Apparent) at Steady State Following Extravascular Administration (Based on Terminal Phase) (Vz/F)', 'description': 'The Vz/F PK profiles of BGF administered as BGF MDI HFO and BGF MDI HFA with oral activated charcoal was assessed.', 'timeFrame': 'Pre-dose, 2 minutes, 5 minutes,10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 h, 2 h, 4 h, 8 h, 12 h and 24 hours post-dose on Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)'}, {'measure': 'Number of Participants With Adverse Events', 'description': 'The safety and tolerability of single doses of BGF MDI HFO and BGF MDI HFA with oral activated charcoal in healthy subjects was assessed.', 'timeFrame': 'From screening (Day -28 to Day -1) up to 55 days'}]",10,18 Years,60 Years,ALL,True,AstraZeneca,INDUSTRY,1,108.0,ACTUAL,2025-09-01T16:18:23.449577,v2_robust,True,True,True,False,True,
NCT00002625,Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma,PHASE I STUDY OF TOPOTECAN AND THORACIC RADIATION,topotecan hydrochloride,['topotecan hydrochloride'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Esophageal Cancer,"['Esophageal Cancer', 'Lung Cancer', 'Lymphoma']","['stage III adult Hodgkin lymphoma', 'stage IV adult Hodgkin lymphoma', 'recurrent non-small cell lung cancer', 'recurrent adult Hodgkin lymphoma', 'recurrent esophageal cancer', 'stage III cutaneous T-cell non-Hodgkin lymphoma', 'stage IV cutaneous T-cell non-Hodgkin lymphoma', 'recurrent cutaneous T-cell non-Hodgkin lymphoma', 'recurrent small cell lung cancer', 'stage III grade 1 follicular lymphoma', 'stage III grade 2 follicular lymphoma', 'stage III grade 3 follicular lymphoma', 'stage III adult diffuse small cleaved cell lymphoma', 'stage III adult diffuse mixed cell lymphoma', 'stage III adult diffuse large cell lymphoma', 'stage III adult immunoblastic large cell lymphoma', 'stage III adult lymphoblastic lymphoma', 'stage III adult Burkitt lymphoma', 'stage IV grade 1 follicular lymphoma', 'stage IV grade 2 follicular lymphoma', 'stage IV grade 3 follicular lymphoma', 'stage IV adult diffuse small cleaved cell lymphoma', 'stage IV adult diffuse mixed cell lymphoma', 'stage IV adult diffuse large cell lymphoma', 'stage IV adult immunoblastic large cell lymphoma', 'stage IV adult lymphoblastic lymphoma', 'stage IV adult Burkitt lymphoma', 'recurrent grade 1 follicular lymphoma', 'recurrent grade 2 follicular lymphoma', 'recurrent grade 3 follicular lymphoma', 'recurrent adult diffuse small cleaved cell lymphoma', 'recurrent adult diffuse mixed cell lymphoma', 'recurrent adult diffuse large cell lymphoma', 'recurrent adult immunoblastic large cell lymphoma', 'recurrent adult lymphoblastic lymphoma', 'recurrent adult Burkitt lymphoma', 'stage III adult T-cell leukemia/lymphoma', 'stage IV adult T-cell leukemia/lymphoma', 'recurrent adult T-cell leukemia/lymphoma', 'stage III mantle cell lymphoma', 'stage IV mantle cell lymphoma', 'recurrent mantle cell lymphoma', 'recurrent marginal zone lymphoma', 'recurrent small lymphocytic lymphoma', 'stage III small lymphocytic lymphoma', 'stage III marginal zone lymphoma', 'stage IV small lymphocytic lymphoma', 'stage IV marginal zone lymphoma', 'extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue', 'nodal marginal zone B-cell lymphoma', 'splenic marginal zone lymphoma']",COMPLETED,,1995-03,2000-09,[],[],0,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,5.0,ACTUAL,2025-09-01T16:18:23.449734,v2_robust,True,True,True,False,False,
NCT03749525,Shenfu Injection Improves Arterial Vascular Reactivity,Effect of Shenfu Injection on Arterial Vascular Reactivity in Patients With Septic Shock,shenfu injection,"['shenfu injection', '5% GS solution']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Septic Shock,"['Septic Shock', 'Shenfu', 'Vascular Reactivity']",[],UNKNOWN,,2018-12-01,2019-09,"[{'measure': 'The change of peripheral vascular resistance', 'description': 'Peripheral vascular resistance will be measured by PiCCO or Swan-Ganz and the change between day 0 and day 3', 'timeFrame': 'day 0(before shenfu injection is used), day 3 (after shenfu injection is used for 72 hours)'}]","[{'measure': 'Diastolic blood pressure', 'description': 'We will measure blood pressure every hour and diastolic blood pressure will be recorded per hour.', 'timeFrame': 'day 1, day 2, day 3'}, {'measure': 'Dosage of vasoactive drugs', 'description': 'dosages of noradrenaline, adrenaline or any other kinds of vasoactive drugs\n\n4/5000 dosages of adrenaline and norepinephrine', 'timeFrame': 'day 1, day 2,day 3'}]",3,18 Years,75 Years,ALL,False,Jianfeng Xie,OTHER,0,26.0,ESTIMATED,2025-09-01T16:18:23.449784,v2_robust,True,True,False,False,False,
NCT03583125,Study of EOC317 in Chinese Patients With Advanced Solid Tumors,A Phase 1 Dose Escalation Study of EOC317 in Chinese Patients With Advanced Solid Tumors,EOC317,['EOC317'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumor,['Solid Tumor'],"['bladder cancer', 'cholangiocarcinoma', 'gastric cancer', 'breast cancer', 'hepatocellular carcinoma']",UNKNOWN,,2018-05-29,2020-11-29,"[{'measure': 'DLT', 'description': 'DLT and its incidence at each dose level', 'timeFrame': 'From the initiation of protocol treatment to the occurrence of any of the following events: disease progression or disease recurrence or death from any cause, assessed up to 12 months'}]","[{'measure': 'ORR', 'description': 'Overall Objective Response Rate', 'timeFrame': 'up to 24 months'}, {'measure': 'DCR', 'description': 'Disease Control Rate', 'timeFrame': 'up to 24 months'}, {'measure': 'DOR', 'description': 'Duration of Response', 'timeFrame': 'up to 24 months'}, {'measure': 'PFS', 'description': 'Progression-free Survival', 'timeFrame': 'up to 24 months'}, {'measure': 'Cmax', 'description': 'Maximum Plasma Concentration', 'timeFrame': 'Day1: pre-dose; after EOC317 administration 0.5h、1h、2h、3h、4h、6h、8h、12h, Day2：24h, Day3：48h'}, {'measure': 'Tmax', 'description': 'Time at which maximum plasma concentration was observed.', 'timeFrame': 'Day1: pre-dose; after EOC317 administration 0.5h、1h、2h、3h、4h、6h、8h、12h, Day2：24h, Day3：48h'}, {'measure': 'AUC 0-inf', 'description': 'Area under the plasma concentration-time curve from time zero to infinity.', 'timeFrame': 'Day1: pre-dose; after EOC317 administration 0.5h、1h、2h、3h、4h、6h、8h、12h, Day2：24h, Day3：48h'}, {'measure': 'T1/2', 'description': 'Elimination Half-life', 'timeFrame': 'Day1: pre-dose; after EOC317 administration 0.5h、1h、2h、3h、4h、6h、8h、12h, Day2：24h, Day3：48h'}]",9,18 Years,,ALL,False,"Taizhou EOC Pharma Co., Ltd.",INDUSTRY,0,140.0,ESTIMATED,2025-09-01T16:18:23.450016,v2_robust,True,True,False,False,False,
NCT00983125,Systematic Clonidine for Epidural Analgesia in Labour,Effects of a Systematic Addition of Clonidine in the Local Anaesthetic and Opiate Solution for Epidural Patient Controlled Analgesia in Labour (Levobupivacaine 0.568 mg.mLl-1 + Sufentanil 0.45 µg.mL-1),Clonidine,['Clonidine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Labour,['Labour'],"['Labour', 'Epidural analgesia', 'Clonidine', 'Levobupivacaine', 'Opiates', 'Patient-controlled', 'Active spontaneous labour requiring epidural analgesia']",COMPLETED,,2009-08,2010-03,"[{'measure': 'Number of required additional epidural boluses, either self-administered or medically given as a rescue', 'timeFrame': 'during labour'}]","[{'measure': 'Spontaneous pain during labour (on VAS)', 'timeFrame': 'during labour'}, {'measure': 'Pain at delivery', 'timeFrame': 'at delivery'}, {'measure': 'Pain at post-delivery sutures', 'timeFrame': 'at post-delivery sutures'}, {'measure': 'Motor block', 'timeFrame': 'during labour'}, {'measure': 'Duration of labour', 'timeFrame': 'during labour'}, {'measure': 'Obstetrical events (caesarean section, instrumental delivery)', 'timeFrame': 'after delivery'}]",7,18 Years,,FEMALE,True,"University Hospital, Clermont-Ferrand",OTHER,0,124.0,ACTUAL,2025-09-01T16:18:23.450346,v2_robust,True,True,True,False,False,
NCT02847325,Study of AC0058TA in Healthy Male and Female Subjects,"A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single- and Multiple-Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of AC0058TA in Healthy Male and Female Subjects",AC0058TA,"['AC0058TA', 'Placebo capsules', 'AC0058', 'Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2016-05,2017-04,"[{'measure': 'Safety and tolerability of single and multiple oral doses of AC0058TA determined by adverse events', 'description': 'Frequency and severity of AEs and serious AEs', 'timeFrame': 'within 6 days after single dose in part 1, within 14 days after last dose in part 2.'}]","[{'measure': 'Plasma concentrations of single dose or multiple doses of AC0058TA', 'description': 'Maximum observed concentration (Cmax)', 'timeFrame': 'within 6 days after single dose in part 1, within 14 days after last dose in part 2.'}, {'measure': 'Time to maximum observed concentration (Tmax)', 'description': 'Time to maximum observed concentration (Tmax)', 'timeFrame': 'within 6 days after single dose in part 1, within 14 days after last dose in part 2.'}, {'measure': 'Area under the concentration-time curve (AUC)', 'description': 'Area under the concentration-time curve (AUC)', 'timeFrame': 'within 6 days after single dose in part 1, within 14 days after last dose in part 2.'}, {'measure': 'The effect of food on AUC of the single-oral-dose AC0058TA', 'description': 'Area under the concentration-time curve (AUC)', 'timeFrame': 'within 6 days after single dose in part 1'}]",5,18 Years,65 Years,ALL,True,"ACEA Therapeutics, Inc.",INDUSTRY,0,56.0,ACTUAL,2025-09-01T16:18:23.450381,v2_robust,True,True,True,False,True,
NCT03346525,Determining the Impact of Penicillin in Latent RHD: The GOAL Trial,The GOAL (GwokO Adunu pa Lutino) Trial: Determining the Impact of Penicillin on Latent Rheumatic Heart Disease: A Randomized Controlled Trial in Uganda,intramuscular benzathine penicillin G (BPG) prophylaxis,"['penicillin prophylaxis', 'BPG', 'benzathine penicillin G', 'intramuscular benzathine penicillin G (BPG) prophylaxis']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Rheumatic Heart Disease in Children,"['Rheumatic Heart Disease in Children', 'Latent Rheumatic Heart Disease', 'Rheumatic Heart Disease', 'Heart Diseases']","['echocardiography', 'penicillin prophylaxis', 'intramuscular benzathine penicillin G', 'benzathine penicillin G', 'low-resource setting']",UNKNOWN,,2018-06-26,2020-11-30,"[{'measure': 'progression of valvular changes on echocardiogram at 2 years', 'description': 'To compare the proportion of children (aged 5-17 years) with latent RHD receiving BPG prophylaxis who progress to worse valvular disease at 2-years compared to children not receiving BPG prophylaxis', 'timeFrame': '2 years'}]","[{'measure': 'regression of vavular changes on electrocardiogram at 2 years', 'description': 'To compare the proportion of children (aged 5-17 years) with latent RHD receiving BPG prophylaxis who regress to improved valvular disease at 2-years compared to children not receiving BPG prophylaxis', 'timeFrame': '2 years'}]",2,5 Years,17 Years,ALL,False,Children's National Research Institute,OTHER,6,807.0,ACTUAL,2025-09-01T16:18:23.450389,v2_robust,True,True,False,False,False,
NCT00452725,Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome,Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome,"MAXOMAT ®, biosynthetic growth hormone","['MAXOMAT ®, biosynthetic growth hormone']",1,INTERVENTIONAL,['PHASE3'],PHASE3,,Noonan Syndrome,['Noonan Syndrome'],[],COMPLETED,,1997-10,2010-07,"[{'measure': 'Evaluation of height : gain in height and rate of growth', 'timeFrame': 'at each visit (every 3 months) or every 6 months'}]","[{'measure': 'Clinical and laboratory test safety', 'timeFrame': 'every 6 months'}]",2,3 Years,15 Years,ALL,False,Sanofi,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:23.450401,v2_robust,True,True,True,False,True,
NCT01544725,Ketamine-propofol Versus Ketamine Alone for Procedural Sedation in Adults,"Ketamine-propofol Versus Ketamine Alone for Procedural Sedation in Adults : a Blinded, Randomized Controlled Trial",Procedural sedation with ketamine-propofol combination,"['Procedural sedation with ketamine alone', 'Procedural sedation with ketamine-propofol combination']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Fracture,"['Fracture', 'Dislocation']","['Procedural sedation', 'Ketamine-propofol', 'Ketamine']",COMPLETED,,2012-04,2016-01,"[{'measure': 'Proportion of recovery agitation', 'description': 'Patient will be followed during the procedural sedation, for an average time of thirty minutes after the first injection', 'timeFrame': 'Recovery agitation is noted after procedural sedation for each patient (30 minutes)'}]","[{'measure': 'Time from first injection to optimal sedation', 'timeFrame': 'Patient will be followed during the procedural sedation, for an average time of thirty minutes after the first injection (30 minutes)'}, {'measure': 'Proportion of respiratory depression', 'description': 'Patient will be followed during the procedural sedation, for an average time of thirty minutes after the first injection', 'timeFrame': 'respiratory depression is assessed during procedural sedation for each patient (30 minutes)'}, {'measure': 'Proportion of arterial hypotension', 'description': 'Patient will be followed during the procedural sedation, for an average time of thirty minutes after the first injection', 'timeFrame': 'Hypotension is assessed during procedural sedation for each patient (30 minutes)'}, {'measure': 'Proportion of vomiting', 'description': 'Patient will be followed duriong the procedural sedation, for an average time of thirty minutes after the first injection', 'timeFrame': 'vomiting is assessed after procedural sedation for each patient (30 minutes)'}, {'measure': 'Recovery time', 'description': 'Patient will be followed duriong the procedural sedation, for an average time of thirty minutes after the first injection', 'timeFrame': 'Recovery time is assessed after procedural sedation for each patient (30 minutes)'}, {'measure': 'Proportion of procedural failures', 'description': 'Patient will be followed duriong the procedural sedation, for an average time of thirty minutes after the first injection', 'timeFrame': ""Procedural failure is noted for each patient if it's happened (30 minutes)""}, {'measure': ""Level of patient's satisfaction"", 'description': 'Patient will be followed during the procedural sedation, for an average time of thirty minutes after the first injection', 'timeFrame': ""after procedural sedation, patient's satisfaction is recorded (30 minutes)""}, {'measure': ""Level of care giver's satisfaction"", 'description': 'Patient will be followed during the procedural sedation, for an average time of thirty minutes after the first injection', 'timeFrame': ""after procedural sedation, care giver's satisfaction is recorded (30 minutes)""}]",9,18 Years,,ALL,False,Centre Hospitalier Universitaire de Nice,OTHER,0,150.0,ACTUAL,2025-09-01T16:18:23.450425,v2_robust,True,True,True,False,False,
NCT03473925,Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034),A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors,Navarixin,"['SCH 527123', 'MK-7123', 'Navarixin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Solid Tumors,"['Solid Tumors', 'Non-small Cell Lung Cancer', 'Castration Resistant Prostate Cancer', 'Microsatellite Stable Colorectal Cancer']",[],COMPLETED,,2018-04-10,2021-05-19,"[{'measure': 'Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)', 'description': 'ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. ORR was estimated using an exact method based on the binomial distribution, and the 95% confidence interval was estimated by the method of Clopper-Pearson.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Number of Participants With Dose-limiting Toxicities (DLTs) During Treatment Cycle 1', 'description': 'The following toxicities are considered a DLT, assessed as related to study treatment: Grade 4 non-hematologic toxicity, Grade 4 anemia, Grade 3 anemia lasting \\>7 days or requiring transfusion, Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia, a) Grade 4 thrombocytopenia of any duration, b) Grade 3 thrombocytopenia associated with bleeding, Grade 3 non-hematologic toxicity lasting \\>3 days, any Grade 3 or Grade 4 non-hematologic laboratory value if: medical intervention is required or the abnormality leads to hospitalization or persists for \\>72 hours, Liver test abnormalities: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3X Upper Limit of Normal (ULN) with total bilirubin (TBL) \\>2X ULN with no elevation in alkaline phosphatase (AP \\<2X ULN), Grade 3 or Grade 4 febrile neutropenia, inability to administer ≥75% of the planned navarixin dose due to drug-related tolerability, delay in Cycle 2 start by \\>2 weeks due to toxicity', 'timeFrame': 'Up to 21 days'}, {'measure': 'Number of Participants Who Experience at Least One Adverse Event (AE)', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.', 'timeFrame': 'Up to approximately 27 months'}, {'measure': 'Number of Participants Who Discontinue Study Treatment Due to an AE', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.', 'timeFrame': 'Up to approximately 2 years'}]","[{'measure': 'Objective Response Rate (ORR) Per Modified RECIST 1.1 for Immune-based Therapeutics (iRECIST)', 'description': 'An objective response is defined as an immune-based Complete Response (iCR: Disappearance of all target lesions) or immune-based Partial Response (iPR: At least a 30% decrease in the sum of diameters of target lesions). ORR will be assessed by the investigator based on iRECIST following administration of navarixin in combination with pembrolizumab. The percentage of participants with progressive disease per RECIST 1.1 who experience an iCR or iPR are presented.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Progression-free Survival (PFS) Per RECIST 1.1', 'description': 'PFS is defined as the time from the first dose of study treatment to the first confirmed documented disease progression, or death due to any cause, whichever occurs first. Per RECIST 1.1, progressive disease is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered progression. Median PFS per RECIST 1.1 was assessed by the investigator from product-limit (Kaplan-Meier) method for censored data in participants with microsatellite stable colorectal cancer (CRC); with castration-resistant prostate cancer (CRPC), and with programmed cell death ligand 1 (PD-\\[L\\]1) refractory non-small cell lung cancer (NSCLC).', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'PFS Per iRECIST', 'description': 'PFS is defined as the time from the first dose of study treatment to the first documented disease progression or death due to any cause, whichever occurs first. Per iRECIST, progressive disease (PD) is defined as ≥20% increase in the sum of diameters of target lesions. Disease progression is to be confirmed by a consecutive assessment at least 4-8 weeks after first documentation and will be assessed by the investigator. Median PFS per iRECIST was assessed by the investigator from product-limit (Kaplan-Meier) method for censored data in participants with microsatellite stable colorectal cancer (CRC); with castration-resistant prostate cancer (CRPC), and with programmed cell death ligand 1 (PD-\\[L\\]1) refractory non-small cell lung cancer (NSCLC).', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from the first dose of study treatment to death due to any cause. Median OS was assessed from product-limit (Kaplan-Meier) method for censored data in participants with microsatellite stable colorectal cancer (CRC); with castration-resistant prostate cancer (CRPC), and with programmed cell death ligand 1 (PD-\\[L\\]1) refractory non-small cell lung cancer (NSCLC).', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Absolute Neutrophil Counts (ANC)', 'description': 'Peripheral blood neutrophil counts were performed at Cycle 1 Day 3: Predose, to determine the concentration of ANC.', 'timeFrame': 'Day 3: Predose'}, {'measure': 'Navarixin Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Infinity (AUC0-inf)', 'description': 'Plasma samples from participants with selected advanced/metastatic solid tumors were collected to determine the navarixin plasma AUC0-inf', 'timeFrame': 'Cycle 1 Day 1: Predose & 1, 2, 4, 6 & 8-12 hours postdose; Cycle 1 Days 3 & 8: Predose & 6-12 hours postdose; Cycle 2 Day 1: Predose & 1, 2, 4, 6 & 8-12 hours postdose (Up to approximately 23 days)'}, {'measure': 'Navarixin Area Under the Plasma Concentration-Time Curve From Time 0 to Last (AUC0-last)', 'description': 'Plasma samples from participants with selected advanced/metastatic solid tumors were collected to determine the navarixin plasma AUC0-last.', 'timeFrame': 'Cycle 1 Day 1: Predose & 1, 2, 4, 6 & 8-12 hours postdose; Cycle 1 Days 3 & 8: Predose & 6-12 hours postdose; Cycle 2 Day 1: Predose & 1, 2, 4, 6 & 8-12 hours postdose(Up to approximately 23 days)'}, {'measure': 'Navarixin Maximum Plasma Concentration (Cmax)', 'description': 'Plasma samples from participants with selected advanced/metastatic solid tumors were collected to determine the navarixin plasma Cmax.', 'timeFrame': 'Cycle 1 Day 1: Predose & 1, 2, 4, 6 & 8-12 hours postdose; Cycle 1 Days 3 & 8: Predose & 6-12 hours postdose; Cycle 2 Day 1: Predose & 1, 2, 4, 6 & 8-12 hours postdose (Up to approximately 23 days)'}, {'measure': 'Navarixin Trough Plasma Concentration (Ctrough)', 'description': 'Plasma samples from participants with selected advanced/metastatic solid tumors were collected at steady state on Cycle 2 Day 21 to determine navarixin Ctrough. The Arithmetic Mean and CV% are presented.', 'timeFrame': 'Cycle 2 Day 21 (Up to approximately 43 days)'}]",13,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,107.0,ACTUAL,2025-09-01T16:18:23.450460,v2_robust,True,True,True,False,True,
NCT00688376,Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment,"Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment",Donepezil hydrochloride,"['Donepezil hydrochloride', 'Aricept', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Attention Impairment,['Attention Impairment'],"['Attention', 'cancer', 'chemotherapy', 'donepezil', 'acetylcholinesterase', 'inhibitor']",COMPLETED,,2008-07-02,2009-05-26,"[{'measure': 'Change From Baseline in the Test of Variables in Attention-Continuous Performance Test (TOVA-CPT) ""D-prime"" Standard Score (SS) at Week 12', 'description': 'TOVA-CPT test has a standardized computer game-like format that tests attention and simple impulse control. It precisely measures a person\'s reaction time to clicking on correct targets versus incorrect targets. Scores are based on the number of ""Hits"" (correct responses), omission errors (failure to respond), commission errors/""False Alarms"" (incorrect responses), response time, and sensitivity (""d-prime""). ""D-prime"" a dimensionless statistics is a measure of distractibility and reflects how well a person reacts correctly versus incorrectly. A higher value of ""d-prime"" is reached by having more ""Hits"" (correct response) and fewer ""False Alarms"" (incorrect response). Analysis was based on three factors: the ""d-prime"" standard score, reaction time variability standard score, and response time standard score. Standard scores less than or equal to 80 were significant for an attention deficit disorder. Standard scores greater than 80 were not significant for an attention deficit disorder.', 'timeFrame': 'Baseline and Week 12'}]","[{'measure': 'Change From Baseline in the TOVA-CPT ""D-prime"" Standard Score (SS) at Week 6', 'description': 'TOVA-CPT test has a standardized computer game-like format that tests attention and simple impulse control. It precisely measures a person\'s reaction time to clicking on correct targets versus incorrect targets. Scores are based on the number of ""Hits"" (correct responses), omission errors (failure to respond), commission errors/""False Alarms"" (incorrect responses), response time, and sensitivity (""d-prime""). ""D-prime"" a dimensionless statistics is a measure of distractibility and reflects how well a person reacts correctly versus incorrectly. A higher value of ""d-prime"" is reached by having more ""Hits"" (correct response) and fewer ""False Alarms"" (incorrect response). Analysis was based on three factors: the ""d-prime"" standard score, reaction time variability standard score, and response time standard score. Standard scores less than or equal to 80 were significant for an attention deficit disorder. Standard scores greater than 80 were not significant for an attention deficit disorder.', 'timeFrame': 'Baseline and Week 6'}, {'measure': 'Change From Baseline in the Reaction Time Variability Standard Score (RTVSS) and Response Time Standard Score (RTSS) at Weeks 6 and 12', 'description': 'The Reaction Time Variability is defined as the time measurement of how consistently the switch is pressed. The Response Time is the measurement of how fast or slow information is processed and responded to by the participant. The testing process was as described in a previous outcome measure. Standard scores less than or equal to 80 were significant for an attention deficit disorder. Standard scores greater than 80 were not significant for an attention deficit disorder.', 'timeFrame': 'Baseline, Weeks 6 and 12'}, {'measure': 'Change From Baseline in the Global Executive Composite Score, Behavioral Regulation Index, Metacognition Index, and Working Memory Subscale', 'description': ""Behavioral Rating Inventory of Executive Functioning test evaluates impairment of executive function(planning and organization),memory,and sustained attention in children aged 5-18 years with wide range of developmental and acquired neurological conditions.Survey assess parent/guardian's perception of their child's executive functioning in home and school environments,which relate to daily function(as judged by parent).Each survey contains 86 items scored as;1(behavior is never a problem),2(behavior is sometimes a problem),or 3(behavior is often a problem).Data was presented as t-scores(raw scale scores are used to generate t-scores)for Global Executive Composite Score(t-score range 72-216),Behavioral Regulation Index(t-score range 28-84;inhibit,shift,and emotional control),Metacognition Inde (t-score range 44-132;initiate,working memory,plan/organize,organization of materials, and monitor),and Working Memory Subscale(t-score range 35-90).Higher scores indicate decline in performance."", 'timeFrame': 'Baseline and Week 12'}]",4,6 Years,17 Years,ALL,False,Eisai Inc.,INDUSTRY,1,72.0,ACTUAL,2025-09-01T16:18:23.450500,v2_robust,True,True,True,False,False,
NCT02959476,Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery,"A Double Blind, Multi-center, Randomized, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery",Ropivacaine,"['Placebos', 'Ropivacaine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Pain, Postoperative","['Pain, Postoperative']","['Postoperative pain', 'Postsurgical pain']",COMPLETED,,2017-03-13,2018-08-10,"[{'measure': 'Cumulative analgesic effect', 'timeFrame': '48 hours'}]","[{'measure': 'Use of other analgesics', 'timeFrame': '48 hours'}, {'measure': 'Local safety and tolerability using descriptive statistics of the evaluation of physical exams, wound healing and treatment-emergent adverse events local to the surgical wound', 'timeFrame': '7 days'}, {'measure': 'Overall safety using descriptive statistics of the evaluation of physical exam, vital signs, clinical laboratory tests, and treatment-emergent adverse events', 'timeFrame': '7 days'}, {'measure': 'Analgesic effect at specified intervals', 'timeFrame': '48 hours'}]",5,,,FEMALE,False,"BioQ Pharma, Inc.",INDUSTRY,1,132.0,ACTUAL,2025-09-01T16:18:23.450564,v2_robust,True,True,True,False,True,
NCT04319276,Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma,A Phase 1 Clinical Trial of Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma,Gallium maltolate (500 mg),"['Gallium maltolate (2,500 mg)', 'Gallium maltolate (1,500 mg)', 'Chemical Abstracts Service (CAS) 108560-70-9', 'Gallium maltolate (recommended phase 2 dose)', 'Gallium maltolate (2,000 mg)', 'Gallium maltolate (500 mg)', 'CAS 108560-70-9', 'Gallium maltolate (1,000 mg)']",8,INTERVENTIONAL,['PHASE1'],PHASE1,,Glioblastoma,['Glioblastoma'],"['gallium maltolate', 'Glioblastoma']",RECRUITING,,2022-11-11,2025-10-10,"[{'measure': 'Maximum-tolerated dose.', 'description': 'This will be determined from the incidence of dose limiting toxicities at each dosage.', 'timeFrame': 'Each 28-day cohort'}]","[{'measure': 'Progression-free survival', 'description': 'This measure is the number of months participants remain free from evidence of disease. Imaging will be done every eight weeks and reported at six months.', 'timeFrame': '6 months'}, {'measure': 'Overall survival', 'description': 'Overall survival is determined as the average number of months subjects survived following enrollment.', 'timeFrame': '6 months'}, {'measure': 'Dose-limiting toxicity', 'description': 'Number of participants experiencing a dose limiting toxicity.', 'timeFrame': '28 days for each cohort'}]",4,18 Years,,ALL,False,Medical College of Wisconsin,OTHER,0,36.0,ESTIMATED,2025-09-01T16:18:23.450632,v2_robust,True,True,False,False,False,
NCT00615576,Repeat Dose Study in Male Healthy Volunteer Smokers,"A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SB-656933 Following 14 Days Repeat Dosing in Healthy Male Smokers",SB-656933,"['SB-656933', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Pulmonary Disease, Chronic Obstructive","['Pulmonary Disease, Chronic Obstructive']","['Smoker,', 'Male,', 'Chronic Obstructive Lung Disease', 'Cystic Fibrosis,', 'Healthy Volunteer,']",COMPLETED,,2008-03-26,2008-07-24,"[{'measure': '-what the body does to the drug over a 17 day of dosing with 100mg of SB656933. -Safety of SB-656933: Adverse events, blood pressure, heart rate, electrocardiogram, epididymal ultrasound and lab tests', 'timeFrame': '17 days'}, {'measure': '-what the body does to the drug over a 17 day of dosing with 100mg of SB656933 by taking PK samples at:', 'timeFrame': 'pre-dose and at 0.5,1,2,3,4,6,8,12 and 24 hours post-dose on days 1 and 14; pre-dose on Day7. Additional samples at 32, 48 and 72 hours post-dose wil'}, {'measure': '-Safety of SB-656933: Adverse events every day for entire study period: blood pressure , heart rate and temperature', 'timeFrame': 'taken pre-dose, 30min, 1hr, and 2hr on Day1, Day2, Day7 and Day14 (supine only);'}, {'measure': 'electrocardiogram', 'timeFrame': 'pre-dose, 2hr and 4 hr on Day1'}]","[{'measure': '- Looking at the actual sample size data to determine a larger theoretical population. -What the drug does to the body when present at its lowest level on day 14 as compared before drug given.', 'timeFrame': '17 days'}, {'measure': 'Safety and tolerability of SB-656933 in subjects with cystic fibrosis, including adverse events, vital signs, clinical laboratory assessments, electrocardiographic (ECG) parameters, and lung function (FVC, FEV1)', 'timeFrame': 'Up to Day 28'}, {'measure': 'Fluorocytometric quantitation of CXCL1-induced CD11b expression on peripheral blood neutrophils in ex-vivo assay.', 'timeFrame': 'Up to Day 14'}, {'measure': 'Neutrophil shape change in response to stimulation with CXCL-1 in whole blood ex-vivo gated autofluorescence forward scatter (GAFS) assay.', 'timeFrame': 'Up to Day 14'}, {'measure': 'Looking at the actual sample size data to determine a larger theoretical population.', 'timeFrame': 'Up to Day 14'}, {'measure': 'What the drug does to the body when present at its lowest level on day 14 as compared before drug given.', 'timeFrame': 'on day 14'}]",10,18 Years,65 Years,MALE,True,GlaxoSmithKline,INDUSTRY,0,13.0,ACTUAL,2025-09-01T16:18:23.450647,v2_robust,True,True,True,False,True,
NCT05182476,"Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia, Followed by Open-Label Treatment",Placebo,"['NBI-1065844', 'TAK-831', 'Luvadaxistat', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Schizophrenia,['Schizophrenia'],"['Schizophrenia', 'Cognitive Impairment', 'Luvadaxistat', 'NBI-1065844', 'TAK-831', 'CIAS', 'BAC', 'ERUDITE', 'Neurocrine']",TERMINATED,Failed to meet the primary endpoint,2021-12-07,2024-10-14,"[{'measure': 'Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BAC) Composite Score', 'timeFrame': 'Baseline, Day 98'}]","[{'measure': 'Change From Baseline on the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Score', 'timeFrame': 'Baseline, Day 98'}, {'measure': 'Change From Baseline on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)', 'timeFrame': 'Baseline, Day 98'}, {'measure': 'Change From Baseline on the Clinical Global Impression-Severity Scale (CGI-S) Score', 'timeFrame': 'Baseline, Day 98'}]",4,18 Years,50 Years,ALL,False,Neurocrine Biosciences,INDUSTRY,0,216.0,ACTUAL,2025-09-01T16:18:23.450667,v2_robust,True,True,False,True,False,Failed to meet the primary endpoint
NCT02601976,Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population,Response Evaluation of Peginterferon Alfa-2a 180µg 20kDa (Unipeg®) Plus Ribavirin (Ribazole®) in Treatment naïve Pakistani Population With Chronic Hepatitis C Infection,Peginterferon alfa-2a,"['Ribazole', 'Unipeg', 'Ribavirin', 'Peginterferon alfa-2a']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Hepatitis C,['Hepatitis C'],"['PegInterferon alpha-2a', 'Ribavirin', 'Hepatitis C Virus', 'Sustained Virological Response', 'End of Treatment Response', 'Unipeg', 'Ribazole']",COMPLETED,,2010-08,2014-09,"[{'measure': 'Number of Participants With Sustained Virological Response (SVR)', 'description': 'To determine the SVR at 24 weeks after completion of treatment, among those who achieved ETR', 'timeFrame': 'Post treatment Week 24'}, {'measure': 'Number of Participants With End Treatment Response', 'description': 'To determine the End Treatment Response (ETR) rate of all patients treated with PegInterferon alfa-2a plus Ribavirin', 'timeFrame': 'Upto 48 weeks'}]","[{'measure': 'Number of Participants Who Reported Adverse Events', 'description': 'To determine the number of patients treated with PegInterferon Alfa-2a plus Ribavirin who experience any adverse drug reaction. All ADR are reported as per patient information leaflet', 'timeFrame': 'Upto 48 weeks'}]",3,18 Years,55 Years,ALL,False,Getz Pharma,INDUSTRY,1,64.0,ACTUAL,2025-09-01T16:18:23.450698,v2_robust,True,True,True,False,True,
NCT03102476,Environmental Effects Type 1 Diabetes Mellitus,A Study to Assess Environmental Effects of Temperature and Humidity on Pharmacokinetics and Pharmacodynamics of Prandial Insulin in Subjects With Type 1 Diabetes,Humalog,"['Humalog', 'Insulin lispro']",2,INTERVENTIONAL,['NA'],,,Type1diabetes,['Type1diabetes'],[],COMPLETED,,2016-06,2018-02-02,"[{'measure': 'Area under the glucose infusion rate curve from 0 hours until the end of clamp.', 'timeFrame': '1 Year'}, {'measure': 'Onset of action, time from trial product administration until the blood glucose concentration has decreased at least 0.3 mmol/L (5 mg/dL) from the baseline', 'timeFrame': 'I year'}]","[{'measure': 'Area under the glucose infusion rate curve from 0 hours until 2 hours', 'timeFrame': '1 year'}, {'measure': 'Area under the glucose infusion rate curve from 0 hours until 4 hours', 'timeFrame': '1 year'}, {'measure': 'Area under the glucose infusion rate curve from 0 hours until 6 hours', 'timeFrame': '1 year'}, {'measure': 'Area under the glucose infusion rate curve from 4 hours until 6 hours', 'timeFrame': '1 year'}, {'measure': 'Maximum glucose infusion rate', 'timeFrame': '1 year'}, {'measure': 'Time to maximum glucose infusion rate curve', 'timeFrame': '1 year'}]",8,18 Years,55 Years,MALE,False,University of Hull,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:23.450721,v2_robust,True,True,True,False,False,
NCT03585517,Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T),Safety and Efficacy Evaluation of IM23 CAR-T Cells On CD123+ AML Patients,IM23,['IM23'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,AML,['AML'],[],COMPLETED,,2018-07-21,2020-10-01,"[{'measure': 'Occurrence of study related adverse events', 'description': 'defined as \\>= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment Adverse events assessed according to NCI-CTCAE v4.0 criteria 2', 'timeFrame': '2 years'}]",[],1,3 Years,80 Years,ALL,False,"Beijing Immunochina Medical Science & Technology Co., Ltd.",INDUSTRY,0,10.0,ACTUAL,2025-09-01T16:18:23.450777,v2_robust,True,True,True,False,True,
NCT05256017,Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects,Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Non-parasitologically Confirmed Subjects: a Multicentre Randomised Double-blind Placebo-controlled Study,Acoziborole,"['Acoziborole', 'Placebo']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,"Trypanosomiasis, African","['Trypanosomiasis, African', 'Trypanosoma Brucei Gambiense; Infection', 'Sleeping Sickness']","['Human African Trypanosomiasis', 'Trypanosoma Brucei Gambiense', 'Sleeping sickness', 'g-HAT', 'g-HAT seropositive individuals']",COMPLETED,,2021-12-30,2023-08-03,"[{'measure': 'Occurrence of Any TEAEs', 'description': 'Occurrence and excess rate (95% CI) of any TEAEs.', 'timeFrame': 'From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Occurrence of TEAEs - Malaria', 'description': 'Occurrence and excess rate (95% CI) of common TEAEs (by PT, for PTs reported in ≥1% of participants in either arm).', 'timeFrame': 'From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Occurrence of TEAEs - Acarodermatitis', 'description': 'Occurrence and excess rate (95% CI) of common TEAEs (by PT, for PTs reported in ≥1% of participants in either arm).', 'timeFrame': 'From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Occurrence of TEAEs - Abdominal Pain', 'description': 'Occurrence and excess rate (95% CI) of common TEAEs (by PT, for PTs reported in ≥1% of participants in either arm).', 'timeFrame': 'From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Occurrence of TEAEs - Enteritis', 'description': 'Occurrence and excess rate (95% CI) of common TEAEs (by PT, for PTs reported in ≥1% of participants in either arm).', 'timeFrame': 'From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Occurrence of TEAEs - Nausea', 'description': 'Occurrence and excess rate (95% CI) of common TEAEs (by PT, for PTs reported in ≥1% of participants in either arm).', 'timeFrame': 'From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Occurrence of TEAEs - Gastritis', 'description': 'Occurrence and excess rate (95% CI) of common TEAEs (by PT, for PTs reported in ≥1% of participants in either arm).', 'timeFrame': 'From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Occurrence of TEAEs - Headache', 'description': 'Occurrence and excess rate (95% CI) of common TEAEs (by PT, for PTs reported in ≥1% of participants in either arm).', 'timeFrame': 'From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Occurrence of TEAEs - Fatigue', 'description': 'Occurrence and excess rate (95% CI) of common TEAEs (by PT, for PTs reported in ≥1% of participants in either arm).', 'timeFrame': 'From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Occurrence of TEAEs - Blood Potassium Increased', 'description': 'Occurrence and excess rate (95% CI) of common TEAEs (by PT, for PTs reported in ≥1% of participants in either arm).', 'timeFrame': 'From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Occurrence of TEAEs by Period of Occurrence', 'description': 'Occurrence and excess rate (95% CI) of any TEAEs, by period of occurrence.', 'timeFrame': 'During hospitalization: from investigational product administration (Day 1) to Day 5 (End of Hospitalization); After hospitalization: from Day 5 (discharge) to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Occurrence of Serious TEAEs', 'description': 'Occurrence and excess rate (95% CI) of any serious TEAEs.', 'timeFrame': 'From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Occurrence of Severe Treatment-related TEAEs', 'description': 'Occurrence and excess rate (95% CI) of any serious TEAEs.', 'timeFrame': 'From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Occurrence of Any Treatment-related TEAEs', 'description': 'Occurrence of any treatment-related TEAEs by arm', 'timeFrame': 'From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Occurrence of Treatment-related TEAEs by PT', 'description': 'Occurrence of any treatment-related TEAEs by PT and by arm', 'timeFrame': 'From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).'}]","[{'measure': 'Occurrence of Adverse Events (AEs)', 'description': 'Occurrence of any Adverse Event from Inform Consent signature to 4 month follow-up visit.\n\nOf note, all AEs reported during this study were TEAEs.', 'timeFrame': 'From Inform Consent signature (up to 2 days before treatment) to the Month 4 follow up visit (End of Study)'}, {'measure': 'Change From Baseline in Biochemistry Parameter: Alanine Aminotransferase', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Biochemistry Parameter: Albumin', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Biochemistry Parameter: Alkaline Phosphatase', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Biochemistry Parameter: Aspartate Aminotransferase', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Biochemistry Parameter: Calcium', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Biochemistry Parameter: Chloride', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Biochemistry Parameter: Creatinine', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Biochemistry Parameter: Glucose', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Biochemistry Parameter: Potassium', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Biochemistry Parameter: Sodium', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Biochemistry Parameter: Total Bilirubin', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Biochemistry Parameter: Bicarbonate', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Biochemistry Parameter: Total Protein', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Biochemistry Parameter: Blood Urea Nitrogen', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Hematology Parameter: Hemoglobin', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Hematology Parameter: Platelet Count', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in Hematology Parameter: Leukocytes', 'description': 'Changes from baseline to Day 5, Month 1 and Month 4; presented by treatment arm.', 'timeFrame': 'From baseline to the Month 4 follow-up visit (End of Study).'}, {'measure': 'Change From Baseline in ECG (Electrocardiogram) Parameter: Heart Rate (HR)', 'description': 'Actual values at baseline (Day 1 pre-dose) and Day 5. Change from baseline at Day 5 (Δ). Placebo-corrected change from baseline (ΔΔ), calculated using an analysis of covariance (ANCOVA) model adjusted for sex and age.', 'timeFrame': 'From baseline (Day 1 pre-dose) to Day 5 (End of Hospitalization)'}, {'measure': 'Change From Baseline in ECG Parameter: RR Interval', 'description': 'Actual values at baseline (Day 1 pre-dose) and Day 5. Change from baseline at Day 5 (Δ). Placebo-corrected change from baseline (ΔΔ), calculated using an ANCOVA model adjusted for sex and age.', 'timeFrame': 'From baseline (Day 1 pre-dose) to Day 5 (End of Hospitalization)'}, {'measure': 'Change From Baseline in ECG Parameter: PR Interval', 'description': 'Actual values at baseline (Day 1 pre-dose) and Day 5. Change from baseline at Day 5 (Δ). Placebo-corrected change from baseline (ΔΔ), calculated using an ANCOVA model adjusted for sex and age.', 'timeFrame': 'From baseline (Day 1 pre-dose) to Day 5 (End of Hospitalization)'}, {'measure': 'Change From Baseline in ECG Parameter: QRS Interval', 'description': 'Actual values at baseline (Day 1 pre-dose) and Day 5. Change from baseline at Day 5 (Δ). Placebo-corrected change from baseline (ΔΔ), calculated using an ANCOVA model adjusting for sex and age.', 'timeFrame': 'From baseline (Day 1 pre-dose) to Day 5 (End of Hospitalization)'}, {'measure': 'Change From Baseline in ECG Parameter: QT Interval', 'description': 'Actual values at baseline (Day 1 pre-dose) and Day 5. Change from baseline at Day 5 (Δ). Placebo-corrected change from baseline (ΔΔ), calculated using an ANCOVA model adjusted for sex and age.', 'timeFrame': 'From baseline (Day 1 pre-dose) to Day 5 (End of Hospitalization)'}, {'measure': 'Change From Baseline in ECG Parameter: QTcF', 'description': 'Actual values at baseline (Day 1 pre-dose) and Day 5. Change from baseline at Day 5 (Δ). Placebo-corrected change from baseline (ΔΔ), calculated using an ANCOVA model adjusted for sex and age.', 'timeFrame': 'From baseline (Day 1 pre-dose) to Day 5 (End of Hospitalization)'}, {'measure': 'Change From Baseline in ECG Parameter: QTcB', 'description': 'Actual values at baseline (Day 1 pre-dose) and Day 5. Change from baseline at Day 5 (Δ). Placebo-corrected change from baseline (ΔΔ), calculated using an ANCOVA model adjusted for sex and age.', 'timeFrame': 'From baseline (Day 1 pre-dose) to Day 5 (End of Hospitalization)'}, {'measure': 'Placebo-corrected Baseline-adjusted QTcF (ΔΔQTcF), Computed From a Concentration-response (C-R) Model Between Dry Blood Spot Concentration and Changes From Baseline in QTcF Parameter', 'description': 'Mixed linear model developed based on the model defined by Garnett et al (2017).\n\nThe fixed effect parameters of the pre-specified model were intercept, slope for acoziborole concentrations, influence of baseline (centered on mean), and a treatment specific intercept (0=acoziborole, 1=Placebo). Sex and age were included in the model as fixed covariates.', 'timeFrame': 'From baseline (Day 1 pre-dose) to Day 5 (End of Hospitalization)'}, {'measure': 'Incidence of Abnormal Values for PR, QRS, QTcB and QTcF According to Pre-defined Thresholds', 'description': 'Incidence of abnormal values for PR, QRS, QTcB and QTcF at Day 1 and/or Day 5, according to pre-defined thresholds', 'timeFrame': 'From baseline (Day 1 pre-dose) to Day 5 (End of Hospitalization)'}]",42,15 Years,,ALL,False,Drugs for Neglected Diseases,OTHER,0,1208.0,ACTUAL,2025-09-01T16:18:23.451103,v2_robust,True,True,True,False,True,
NCT04991740,A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors,"A Phase 1 Study of JNJ-78306358, a T Cell Redirecting Bispecific Antibody Targeting HLA-G for Advanced Stage Solid Tumors",JNJ-78306358,['JNJ-78306358'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Neoplasms,['Neoplasms'],"['Kidney cancer', 'Ovarian cancer', 'Colorectal cancer']",COMPLETED,,2021-10-24,2023-02-09,"[{'measure': 'Number of Participants with Incidence of Adverse Events (AEs)', 'description': 'An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.', 'timeFrame': 'Up to 2 years and 4 months'}, {'measure': 'Number of Participants with AEs by Severity', 'description': 'Number of participants with AEs by severity will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 with the exception of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) events, which will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) guidelines. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.', 'timeFrame': 'Up to 2 years and 4 months'}, {'measure': 'Part 1: Number of Participants with Dose-limiting Toxicity (DLT)', 'description': 'Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.', 'timeFrame': 'Up to 21 days'}]","[{'measure': 'Maximum Serum Concentration (Cmax) of JNJ-78306358', 'description': 'Cmax is defined as maximum serum concentration of JNJ-78306358.', 'timeFrame': 'Up to 2 years and 4 months'}, {'measure': 'Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-78306358', 'description': 'Tmax is defined as time to reach maximum observed serum concentration of JNJ-78306358.', 'timeFrame': 'Up to 2 years and 4 months'}, {'measure': 'Area Under the Serum Concentration-time Curve From Time t1 to t2 (AUC[t1-t2]) of JNJ-78306358', 'description': 'AUC(t1-t2) is defined as the area under the serum concentration-time curve from time t1 to t2.', 'timeFrame': 'Up to 2 years and 4 months'}, {'measure': 'Accumulation Ratio (RA) of JNJ-78306358', 'description': 'RA is calculated as area under the plasma concentration-time curve from time zero to 24 hours (AUC \\[0-24\\]) value at steady state divided by AUC (0-24) value after first dose.', 'timeFrame': 'Up to 2 years and 4 months'}, {'measure': 'Number of Participants with Anti-JNJ-78306358 Antibodies', 'description': 'Number of participants with anti-JNJ-78306358 antibodies will be reported.', 'timeFrame': 'Up to 2 years and 4 months'}, {'measure': 'Overall Response Rate (ORR)', 'description': 'ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR), according to response evaluation criteria in solid tumors (RECIST) version 1.1 and gynecological cancer inter group (GCIG) Cancer antigen 125 (CA 125) response criteria (for ovarian cancer participants only).', 'timeFrame': 'Up to 2 years and 4 months'}, {'measure': 'Duration of Response (DOR)', 'description': 'Duration of response (DOR) will be calculated among responders (PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the RECIST version 1.1 response criteria and GCIG CA 125 response criteria (for ovarian cancer participants only) or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to 2 years and 4 months'}]",10,18 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,39.0,ACTUAL,2025-09-01T16:18:23.451191,v2_robust,True,True,True,False,True,
NCT02733640,Does Pantoprazole Reduce the Anti-platelet Effect of Clopidogrel?,,Pantoprazole,"['Ranitidine', 'Pantoprazole']",2,INTERVENTIONAL,['NA'],,,Antiplatelet Effect,['Antiplatelet Effect'],[],COMPLETED,,2012-10,2015-05,"[{'measure': 'Number of participants with more than 5 Ω of impedance after intervention by an aggregometer which measures platelet aggregation in whole blood samples', 'description': '8 days after administration of pantoprazole (or ranitidine)', 'timeFrame': '8 days'}]","[{'measure': 'Change of the impedance value (Ω) by an aggregometer which measures platelet aggregation in whole blood samples', 'description': '8 days after administration of pantoprazole (or ranitidine)', 'timeFrame': 'baseline and 8days'}, {'measure': 'Number of participants with gastrointestinal bleeding', 'timeFrame': 'up to 2weeks'}, {'measure': 'Number of participants with reccured coronary artery disease', 'timeFrame': 'up to 2weeks'}]",4,18 Years,79 Years,ALL,False,Seoul National University Bundang Hospital,OTHER,0,42.0,ACTUAL,2025-09-01T16:18:23.451216,v2_robust,True,True,True,False,False,
NCT03226340,S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension,Evaluation of the Efficacy and Safety of S-amlodipine+Chlorthalidone Combination Therapy and S-amlodipine+Telmisartan Combination Therapy in Hypertensive Patients Inadequately Controlled With Calcium Channel Blocker Monotherapy,S-amlodipine 2.5mg + Chlorthalidone 25mg,"['S-amlodipine 2.5mg + Telmisartan 40mg', 'S-amlodipine 2.5mg + Chlorthalidone 25mg']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Essential Hypertension,['Essential Hypertension'],[],UNKNOWN,,2015-12-02,2018-03-31,"[{'measure': 'sit diastolic blood pressure', 'description': 'Mean change in sit diastolic blood pressure after 12 weeks compared to baseline.', 'timeFrame': '12 weeks'}]","[{'measure': 'sit diastolic blood pressure', 'description': 'Mean change in sit diastolic blood pressure after 6 weeks compared to baseline.', 'timeFrame': '6 weeks'}, {'measure': 'sit systolic blood pressure', 'description': 'Mean change in sit systolic blood pressure after 6 weeks and 12 weeks compared to baseline.', 'timeFrame': '12 weeks'}, {'measure': 'Blood pressure normalization', 'description': 'Blood pressure normalization ratio after 12 weeks compared to baseline( sit systolic blood pressure \\<140 mmHg or sit diastolic blood pressure \\<90 mmHg).', 'timeFrame': '12 weeks'}]",4,19 Years,79 Years,ALL,False,Seoul National University Bundang Hospital,OTHER,1,170.0,ESTIMATED,2025-09-01T16:18:23.451327,v2_robust,True,True,False,False,False,
NCT00654940,A Study To Assess The Ability Of A Crossover Study Design To Detect The Efficacy Of Pregabalin In Post-Traumatic Neuropathic Pain Patients,"Methodology Study To Assess The Ability Of A Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover Study To Detect The Effect Of Pregabalin In Post-Traumatic Neuropathic Pain Patients",Pregabalin (Lyrica),"['Placebo', 'Pregabalin (Lyrica)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Nerve Pain,['Nerve Pain'],[],COMPLETED,,2008-05,2009-02,"[{'measure': 'Change From Baseline to Treatment Week 2 in Daily Pain Rating Scale', 'description': 'Daily Pain Rating Scale by treatment and sequence using an 11-point Likert scale: range 0 (no pain) to 10 (worst possible pain) over the past 24 hours. Self-assessment was performed daily on rising from bed (for the final time in the case of interrupted sleep). Average daily pain score: mean of the previous 7 days daily pain scores. Baseline was defined as the mean of the last 7 pre-treatment pain scores for each period. End of treatment was defined as the mean of the last 7 on treatment pain scores for each period.', 'timeFrame': 'Week 0 to Week 2, Week 4 to Week 6 (Baseline to Week 2 [End of Treatment] for each treatment period)'}]","[{'measure': 'Neuropathic Pain Symptom Inventory (NPSI)', 'description': 'NPSI at end of treatment: 10-item self-administered questionnaire assessing 5 dimensions of pain (burning superficial spontaneous pain, pressing deep spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia). Each item consists of a question about the specific qualities of pain and an 11-point numerical scale range: 0 (absence of pain) to 10 (maximum intensity imaginable), and 2 temporal items related to spontaneous and paroxysmal pain. Maximum total score possible = 100.', 'timeFrame': 'Week 0 to Week 2, Week 4 to Week 6 (Baseline to End of Treatment in Treatment Periods 1 and 2)'}, {'measure': 'Subject Activity as Captured by the Actiwatch Score Device: Total Activity Score at End of Treatment', 'description': 'Total activity score: Day (8 am to 8 pm) at end of treatment. Accelerometer measured physical activity by monitoring degree and intensity of body motion. Data is reported as activity counts. Subject activity was collected hourly for the variables: peak, average, and total activity. Higher score indicates greater activity (no activity = 0; total possible score was not defined).', 'timeFrame': 'Week 0 to Week 2, Week 4 to Week 6 (Baseline to End of Treatment in Treatment Periods 1 and 2)'}]",3,18 Years,80 Years,ALL,False,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,0,25.0,ACTUAL,2025-09-01T16:18:23.451393,v2_robust,True,True,True,False,False,
NCT02200640,A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM),"A Prospective, Randomized, Double-Blind, Double-Dummy, Titration-to-Response Trial Comparing MICARDIS® (Telmisartan) (40 & 80 mg QD) and COZAAR® (Losartan) (50 & 100 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring","High dose of Micardis®, once daily","['High dose of COZAAR®, once daily', 'High dose of Micardis®, once daily', 'Placebo', 'Low dose of Micardis®, once daily', 'Low dose of COZAAR®, once daily', 'Telmisartan', 'Losartan']",7,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypertension,['Hypertension'],[],COMPLETED,,2000-03,,"[{'measure': 'Change from baseline in mean diastolic blood pressure', 'description': 'Measured during the last 6 hours of the 24-hour dosing interval using ABPM', 'timeFrame': 'Up to 8 weeks after start of treatment'}]","[{'measure': 'Change from baseline in mean systolic blood pressure', 'description': 'Measured during the last 6 hours of the 24-hour dosing interval using ABPM', 'timeFrame': 'Up to 8 weeks after start of treatment'}, {'measure': 'Changes from baseline in diastolic and systolic blood pressure', 'description': 'Measured during other times of the 24-hour ABPM profile (e.g. 24-hour mean, morning mean, daytime mean and nighttime mean)', 'timeFrame': 'Up to 8 weeks after start of treatment'}, {'measure': 'Changes from baseline in mean seated trough diastolic blood pressure and systolic blood pressure', 'description': 'Triplicate measurement in two minute intervals after 5 minutes of rest, in seated position using sphygmomanometer', 'timeFrame': 'Up to 8 weeks after start of treatment'}, {'measure': 'Assessment of responder rates on ABPM', 'timeFrame': 'Baseline, 8 weeks after start of treatment'}, {'measure': 'Assessment of responder rates on trough cuff blood pressure', 'timeFrame': 'Baseline up to 8 weeks after start of treatment'}]",6,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,333.0,ACTUAL,2025-09-01T16:18:23.451466,v2_robust,True,True,True,False,False,
NCT03157089,Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung,"LUX-Lung IO: A Phase II, Open Label, Non-randomised Study of Afatinib in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung",Afatinib,"['KEYTRUDA®', 'Afatinib', 'GILOTRIF, GIOTRIF, XOVOLTIB', 'pembrolizumab']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Carcinoma, Non-Small-Cell Lung","['Carcinoma, Non-Small-Cell Lung']",[],COMPLETED,,2017-11-02,2020-01-13,"[{'measure': 'Objective Response Rate (ORR)', 'description': 'Objective response rate is defined as percentage of participants with the best overall response of complete response (CR, disappearance of all target lesions) or confirmed partial response (PR, at least a 30% decrease in sum of diameter (SoD, longest diameter (LD) measured for all lesions except lymph nodes, where shortest diameter (ShD) was used) of target lesions, reference is baseline SoD). Tumour response was assessed based on local radiological image (Computerised tomography (CT) or Magnetic resonance imaging (MRI)) evaluation by the investigators according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1.', 'timeFrame': 'Tumour assessment performed at screening (-28 days), week 9 (day 56-63) after study treatment (afatinib or pembrolizumab) start and every 9th week thereafter, up to 556 days.'}]","[{'measure': 'Recommended Phase II Dose (RP2D)', 'description': 'Recommended Phase II Dose (RP2D) was to be calculated through a Bayesian logistic regression model (BLRM) with overdose control that was to be fitted to binary toxicity outcomes. After 12 patients had completed at least one cycle (one cycle equals 21 days and consists of one time infusion of pembrolizumab at Day 1 + daily intake of afatinib) of treatment, the prior distributions were to be updated through Gibbs sampling procedures with the accumulated dose limiting toxicity (DLT) data from the first treatment cycle. The estimate of parameters was to be updated as data were accumulated using the BLRM. At the end of the dose confirmation, the toxicity probability at each dose level was to be calculated to determine an estimate of the RP2D. Posterior probabilities for the rate of DLT were to be summarised from BLRM. Confirmation of the RP2D by the Safety Monitoring Committee (SMC) was to be based on these probabilities as well as on the review of other safety and laboratory data.', 'timeFrame': '21 days (1 treatment cycle) from study treatment (afatinib and pembrolizumab) administration.'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'Disease control rate was calculated as percentage of participants with CR, PR, or stable disease (SD, neither sufficient shrinkage to qualify for PR, taking as reference the baseline sum of diameters (SoD), nor sufficient increase to qualify for progressive disease (PD, at least a 20% increase in the SoD of target lesions, taking as reference the smallest SoD recorded on study (including baseline), together with an absolute increase in the SoD of at least 5 millimeter (mm ) or the appearance of one or more new lesions). Tumour response was assessed based on local radiological image (Computerised tomography (CT) or Magnetic resonance imaging (MRI)) evaluation by the investigators according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1.', 'timeFrame': 'Tumour assessment performed at screening (-28 days), week 9 (day 56-63) after study treatment (afatinib or pembrolizumab) start and every 9th week thereafter, up to 556 days.'}, {'measure': 'Duration of Objective Response (DOR)', 'description': 'For participants who showed objective response, duration of objective response (DoR), was defined as the time from first documented complete response (CR) or partial response (PR) until the earliest of disease progression (PD) or death. Tumour response was assessed based on local radiological image (CT or MRI) evaluation by the investigators according to RECIST version 1.1. The number of participants with objective response who experienced the event ""disease progression or death (whichever came first)"" is reported instead of a metric summarizing the time-to-event data with unit of time, as the number analyzed was too small to perform a Kaplan-Meier-analysis.', 'timeFrame': 'Tumour assessment performed at screening (-28 days), week 9 (day 56-63) after study treatment (afatinib or pembrolizumab) start and every 9th week thereafter, up to 436 days.'}, {'measure': 'Progression-free Survival (PFS)', 'description': 'Progression-free survival was defined as the time (weeks) from the date of the first afatinib or pembrolizumab administration to the date of disease progression (at least a 20% increase in the sum of diameter (SoD, longest diameter (LD) measured for all lesions except lymph nodes, where shortest diameter (ShD) was used) of target lesions, taking as reference the smallest SoD recorded on study (including baseline), together with an absolute increase in the SoD of at least 5 mm or the appearance of one or more new lesions) or death (if the patient died without progression). The date of progression for the primary analyses was determined based on investigator assessment. Tumour response was assessed based on local radiological image (Computerised tomography (CT) or Magnetic resonance imaging (MRI)) evaluation by the investigators according to RECIST version 1.1. Median and 95% Confidence Interval were calculated using Kaplan-Meier estimates.', 'timeFrame': 'Tumour assessment performed at screening (-28 days), week 9 (day 56-63) after study treatment (afatinib or pembrolizumab) start and every 9th week thereafter, up to 556 days.'}, {'measure': 'Overall Survival (OS)', 'description': 'Overall survival is defined as the time from the date of treatment start to the date of death from any cause. Participants without event were censored. Median and 95% Confidence Interval were calculated using Kaplan-Meier estimates.', 'timeFrame': 'From Day 1 of study treatment (afatinib or pembrolizumab) administration up to a total of 574 days.'}, {'measure': 'Tumour Shrinkage', 'description': 'Tumour shrinkage (in millimeters) is defined as the difference between the minimum post-baseline sum of diameters of target lesions (SoD, longest for non-nodal lesions, short axis for nodal lesions) and the baseline sum of diameters of the same set of target lesions. Tumour shrinkage is reported as percentage change from baseline and represents the maximum decrease or the minimum increase from baseline in SoD in percentage of the baseline SoD. Negative values indicate a reduction in the SoD; positive values indicate an increase in the SoD. Tumour response was assessed based on local radiological image (CT or MRI) evaluation by the investigators according to RECIST 1.1.', 'timeFrame': 'Tumour assessment performed at screening (-28 days), week 9 (day 56-63) after study treatment (afatinib or pembrolizumab) start and every 9th week thereafter, up to 556 days.'}]",7,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:23.451502,v2_robust,True,True,True,False,True,
NCT01361789,COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined,COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined,"parecoxib, valdecoxib, etoricoxib","['parecoxib, valdecoxib, etoricoxib', 'Dexamethasone', 'parecoxib, valdecoxib, parecoxib and dexamethasone']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Rupture of Anterior Cruciate Ligament,['Rupture of Anterior Cruciate Ligament'],"['Arthroscopic reconstruction', 'Anterior crucial ligament', 'Coxib', 'Dexamethasone']",COMPLETED,,2004-01,2009-12,"[{'measure': 'Postoperative VAS score at rest 24 hours after surgery', 'timeFrame': '24 hours'}]","[{'measure': 'Cumulated opioid consumption', 'timeFrame': '24 hours'}]",2,18 Years,90 Years,ALL,False,Asker & Baerum Hospital,OTHER,0,93.0,ACTUAL,2025-09-01T16:18:23.451561,v2_robust,True,True,True,False,False,
NCT01998789,Everolimus Post Orthotopic Liver Transplant,"A Single Center, Open-label, Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Everolimus Conversion Versus Standard Immunosuppression in Liver Transplant Recipients",Everolimus,"['Zortress', 'Everolimus', 'Standard Tacrolimus', 'Prograf']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Orthotopic Liver Transplant,['Orthotopic Liver Transplant'],"['Liver Transplantation', 'Everolimus', 'Immunosuppression']",UNKNOWN,,2013-10,2019-02,"[{'measure': 'Change in estimated Glomerular Filtration Rate (eGFR)', 'description': 'Comparison of change in Renal function, as measured by eGFR from baseline to 12 months post liver transplantation, in subjects maintained on an everolimus conversion regimen versus those maintained on a standard tacrolimus based regimen.', 'timeFrame': 'Baseline and 12 months post transplant'}]","[{'measure': 'Change in estimated Glomerular Filtration Rate (eGFR)', 'description': '1. Comparison of renal function, as measured eGFR from baseline to 24 months post liver transplantation, in subjects maintained on an everolimus conversion regimen versus those maintained on a standard tacrolimus based regimen.\n2. To compare the incidence of renal insufficiency, defined as GFR\\<30 or need for dialysis at 12 months and 24 months post liver transplantation, in subjects maintained on an everolimus conversion regimen versus those maintained on a standard tacrolimus based regimen.', 'timeFrame': 'Baseline and 24 months post liver transplantation'}, {'measure': 'Proportion of HCV patients who develop stage 2 of 4 or greater fibrosis, liver failure, or fibrosing cholestatic hepatitis (FCH) at month 12 and 24', 'description': 'To determine whether everolimus conversion post liver transplantation reduces progression of fibrosis at 12 and 24 months post transplant as compared to standard tacrolimus based immunosuppression in liver transplant recipients with Hepatitis C as measured by:\n\nProportion of patients who develop stage 2 of 4 or greater fibrosis, liver failure, or fibrosing cholestatic hepatitis (FCH) at month 12 and 24', 'timeFrame': 'Up to 24 months post liver transplantation'}, {'measure': 'Composite Efficacy Failure Rate', 'description': 'To compare the composite efficacy failure rates of treated biopsy proven acute rejection, graft loss, death, or loss to follow up with Everolimus conversion arm to standard immunosuppression with Tacrolimus based arm at 12 and 24 months after liver transplant.\n\nTo compare each component of the composite efficacy failure rates between Everolimus conversion and standard Tacrolimus arm.\n\nTo compare the composite graft failure or death or loss of follow up between the two arms.\n\nTo Evaluate acute rejection by incidence, time to interval and severity.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Incidence of Hepatocellular Carcinoma (HCC) Recurrence', 'description': 'In subjects with Hepatocellular carcinoma (HCC), to compare the incidence of HCC recurrence at 12 months post transplantation between the Everolimus conversion arm and the standard tacrolimus based arm, as evaluated by radiological studies, biopsy findings, and/or AFP levels.', 'timeFrame': 'Up to 12 months post transplant'}]",5,18 Years,,ALL,False,Tomoaki Kato,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:23.451570,v2_robust,True,True,False,False,False,
NCT02569489,Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer,Phase I Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer,HBI-8000,"['HBI-8000', 'Trastuzumab', 'Paclitaxel']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Breast Cancer,['Breast Cancer'],[],WITHDRAWN,Reconsideration of Study Design; plan for alternative protocol,2015-12,2015-12,"[{'measure': 'MTD of HBI-8000 twice weekly in combination with weekly paclitaxel and trastuzumab in women with HER2+ breast cancer', 'timeFrame': '28 days'}]",[],1,18 Years,,FEMALE,False,"HUYABIO International, LLC.",INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:23.451726,v2_robust,True,True,False,True,False,Reconsideration of Study Design; plan for alternative protocol
NCT05125068,Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN),"A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy",AT-1501,['AT-1501'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,IgA Nephropathy,"['IgA Nephropathy', 'IgAN']","['IgA Nephropathy', 'IgAN', 'AT-1501', 'CD40L', 'Monoclonal antibody', 'Proteinuria', 'eGFR', 'UPCR']",TERMINATED,An administrative decision was made to terminate the AT-1501-N205 study. This voluntary business-related decision was not related to the safety of tegoprubart (AT-1501). Available safety data demonstrated tegoprubart to be safe and well tolerated.,2022-03-21,2023-07-31,"[{'measure': 'Efficacy - change in participants UPCR', 'description': 'The change in 24-hour urine protein to creatinine ratio (UPCR) from baseline to 24 weeks', 'timeFrame': 'Up to 24 weeks'}, {'measure': 'Safety- Number of participants with treatment related adverse events', 'description': 'Incidence of serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and AEs of special interest (AEoSI)', 'timeFrame': 'Through study completion, an average of 100 weeks'}]","[{'measure': 'Change in eGFR slope', 'description': 'The change in eGFR slope from baseline to 96 weeks', 'timeFrame': 'Baseline- 96 weeks'}, {'measure': 'Change in urine protein excretion (mg/mg)', 'description': 'The change in urine protein excretion over time', 'timeFrame': 'Up to 96 weeks'}, {'measure': 'Development of Anti drug Antibodies (ADAs)', 'description': 'The percentage of participants who develop ADAs', 'timeFrame': 'Up to 96 weeks'}]",5,18 Years,99 Years,ALL,False,Eledon Pharmaceuticals,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:23.451742,v2_robust,True,True,False,True,True,An administrative decision was made to terminate the AT-1501-N205 study. This voluntary business-related decision was not related to the safety of tegoprubart (AT-1501). Available safety data demonstrated tegoprubart to be safe and well tolerated.
NCT00130468,TREAD-20: Trial of Hyalgan Three Injection-Regimen for the Treatment of Knee Pain Due to Osteoarthritis,"A Double Blind, Randomized Trial of Intra-Articular Injections of 20 mg of Hyalgan® for the Treatment of Knee Pain Due to Osteoarthritis (Three Injection-Regimen for Efficacy And Duration-20 mg/2mL Dose: Tread-20)",Hyalgan (sodium hyaluronate),['Hyalgan (sodium hyaluronate)'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Osteoarthritis,['Osteoarthritis'],[],COMPLETED,,2004-11,2006-05,[{'measure': 'Improvement in pain due to OA of the knee after 50-foot walk on a flat surface based upon 100 mm VAS score for up to 6 months after Baseline for the HYALGAN treated group compared to PB-Saline control'}],[],1,40 Years,,ALL,False,Sanofi,INDUSTRY,0,150.0,,2025-09-01T16:18:23.451761,v2_robust,True,True,True,False,False,
NCT00776568,Treatment of Refractory Angina Pectoris by Shock Wave Therapy,Extracorporeal Shock Wave Therapy (ESWT) for the Treatment of Refractory Angina Pectoris,Anti-hypertensive drugs,['Anti-hypertensive drugs'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Angina Pectoris,['Angina Pectoris'],[],UNKNOWN,,2008-02,,"[{'measure': 'Alleviation of anginal symptoms', 'timeFrame': '06 months'}]","[{'measure': 'The change in SPECT in perfusion from baseline to 6 months post-baseline (17 segments model', 'timeFrame': '6 months'}]",2,18 Years,80 Years,ALL,False,Universal Research Group,NETWORK,1,60.0,ACTUAL,2025-09-01T16:18:23.451784,v2_robust,True,True,False,False,False,
NCT00771368,Reduction of Bacteria in MRSA Positive Ulcers,A Clinical Trial on the Reduction of Bacteria (Including MRSA) in MRSA Positive Ulcers and Lesions,Nitric Oxide,['Nitric Oxide'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Leg Ulcer,"['Leg Ulcer', 'Pressure Ulcer']",[],TERMINATED,limited recruitment,2009-01,2009-06,"[{'measure': 'Reduction in bacteria', 'timeFrame': 'Post Treatment Day 3'}]","[{'measure': 'Incidence of adverse events', 'timeFrame': '3 days'}]",2,19 Years,,ALL,False,"Nitric BioTherapeutics, Inc",INDUSTRY,0,20.0,ESTIMATED,2025-09-01T16:18:23.451792,v2_robust,True,True,False,True,True,limited recruitment
NCT06107868,Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer,Phase I Study of the PKMYT1 Inhibitor RP-6306 in Combination With Carboplatin and Paclitaxel for the Treatment of Recurrent TP53 Ovarian and Uterine Cancer,RP-6306,"['Paclitaxel', 'Carboplatin', 'RP-6306']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Recurrent Ovarian Cancer,"['Recurrent Ovarian Cancer', 'Recurrent Uterine Cancer', 'Metastatic Cancer', 'Advanced Cancer']",[],ACTIVE_NOT_RECRUITING,,2024-03-20,2026-12-04,"[{'measure': 'Frequency of dose-limiting toxicities (DLTs) at Dose Level 1', 'timeFrame': '21 days'}, {'measure': 'Frequency of dose-limiting toxicities (DLTs) at Dose Level 2', 'timeFrame': '21 days'}, {'measure': 'Frequency of dose-limiting toxicities (DLTs) at Dose Level -1', 'timeFrame': '21 days'}, {'measure': 'Frequency of dose-limiting toxicities (DLTs) at Dose Level -2', 'timeFrame': '21 days'}]","[{'measure': 'Incidence of treatment-emergent adverse events (TEAEs)', 'timeFrame': '4 years'}, {'measure': 'Progression-free survival', 'description': 'Time from the first day of study treatment to disease progression.', 'timeFrame': '6 months'}, {'measure': 'Objective response rate', 'description': 'Proportion of patients with confirmed complete response (CR) or partial response (PR)', 'timeFrame': '4 years'}, {'measure': 'Disease Control Rate', 'description': 'Proportion of patients with a confirmed best response of CR or PR, or stable disease', 'timeFrame': 'At least 4 months after first dose of study treatment'}, {'measure': 'Duration of Response', 'description': 'Time interval between the date of the earliest qualifying response (CR or PR) and the date of disease progression or death for any cause, whichever occurs earlier', 'timeFrame': '4 years'}, {'measure': 'Average change in tumour size', 'timeFrame': '4 years'}, {'measure': 'Plasma concentrations of RP-6306', 'timeFrame': 'Cmax, time to Tmax'}]",11,18 Years,,FEMALE,False,"University Health Network, Toronto",OTHER,0,24.0,ESTIMATED,2025-09-01T16:18:23.451893,v2_robust,True,True,False,False,True,
NCT05918068,Pyridoxine Effect on the Blood Glucose Level in Type 2 Diabetic Patients,Evaluation of the Role of Pyridoxine Adjuvant Therapy on the Blood Glucose Level in Type 2 Diabetic Patients,Metformin 500 mg/day,"['Metformin 500 mg/day', 'Metformin group']",2,INTERVENTIONAL,['NA'],,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],COMPLETED,,2022-11-01,2023-04-01,"[{'measure': 'Fasting plasma glucose (FPG).', 'description': 'A fasting plasma glucose test, also known as a fasting glucose test (FGT), is a test that can be used to help diagnose diabetes or pre-diabetes.The expected values for normal fasting blood glucose concentration are between 70 mg/dL (3.9 mmol/L) and 100 mg/dL (5.6 mmol/L). When fasting blood glucose is between 100 to 125 mg/dL (5.6 to 6.9 mmol/L), changes in lifestyle and monitoring glycemia are recommended', 'timeFrame': 'Change from baseline, to one month'}, {'measure': 'Glycated Hemoglobin (HbAlc)', 'description': 'A normal A1C level is below 5.7%, a level of 5.7% to 6.4% indicates prediabetes and a level of 6.5% or more indicates diabetes.', 'timeFrame': 'Change from baseline, to one month'}]","[{'measure': 'Vitamin B6', 'description': 'The reference range for pyridoxal phosphate (PLP), the biologically active form of vitamin B6, is 5-50 µg/L.', 'timeFrame': 'Change from baseline, to one month'}, {'measure': 'Fasting plasma insulin (F.P.I.).', 'description': 'The insulin fasting blood test is chiefly used to test insulin levels and diagnose diabetes and insulin resistance.', 'timeFrame': 'Change from baseline, to one month'}, {'measure': 'Insulin resistance (HOMA-IR).', 'description': 'Less than 1.0 means you are insulin-sensitive which is optimal. Above 1.9 indicates early insulin resistance. Above 2.9 indicates significant insulin resistance.', 'timeFrame': 'Change from baseline, to one month'}, {'measure': 'Indoleamine 2,3 dioxygenase (IDO)', 'description': 'Has the potential role of indoleamine 2,3 dioxygenase (IDO) as a predictive and therapeutic target for diabetes treatment', 'timeFrame': 'Change from baseline, to one month'}]",6,30 Years,65 Years,ALL,False,Al-Rasheed University College,OTHER,0,108.0,ACTUAL,2025-09-01T16:18:23.452072,v2_robust,True,True,True,False,False,
NCT02302950,"A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas","A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas",raltegravir,"['raltegravir', 'issentress']",2,OBSERVATIONAL,[],,,HIV Infection,['HIV Infection'],"['HIV infection', 'raltegravir use', 'women']",UNKNOWN,,2014-09,2017-12,"[{'measure': 'Assess the efficacy of raltegravir in study participants by measuring CD4 count and viral load', 'timeFrame': '24 weeks of therapy'}]","[{'measure': 'Capture data on concomitant conditions that may have led to participants switching to raltegravir from medical records (eg. Diabetes mellitus)', 'timeFrame': '24 weeks of therapy'}, {'measure': 'Assess tolerability of raltegravir by capturing symptoms', 'timeFrame': '24 weeks of therapy'}]",3,18 Years,,FEMALE,False,"The University of Texas Health Science Center, Houston",OTHER,0,254.0,ACTUAL,2025-09-01T16:18:23.452201,v2_robust,False,True,False,False,False,
NCT00004450,Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy,,glyceryl trierucate,"['thalidomide', 'interferon beta', 'glyceryl trierucate', 'glyceryl trioleate']",4,INTERVENTIONAL,['NA'],,,Adrenoleukodystrophy,['Adrenoleukodystrophy'],"['adrenoleukodystrophy', 'inborn errors of metabolism', 'rare disease', 'sphingolipidoses']",COMPLETED,,1998-08,2000-11,[],[],0,4 Years,,MALE,False,FDA Office of Orphan Products Development,FED,1,60.0,,2025-09-01T16:18:23.452220,v2_robust,True,True,True,False,False,
NCT00073450,Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530),An Open-Label Phase 2 Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck,Farnesyl Protein Transferase Inhibitor,['Farnesyl Protein Transferase Inhibitor'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Carcinoma, Squamous Cell","['Carcinoma, Squamous Cell', 'Head and Neck Neoplasms']",['Squamous Cell Carcinoma of the Head & Neck'],TERMINATED,,2003-09,2004-06,[],[],0,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,15.0,ACTUAL,2025-09-01T16:18:23.452243,v2_robust,True,True,False,True,False,
NCT04509050,Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children,A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function in Infants and Young Children (BEGIN Study),Ivacaftor or elexacaftor/tezacaftor/ivacaftor,"['Kalydeco or Trikafta', 'Ivacaftor or elexacaftor/tezacaftor/ivacaftor', 'Vertex (VX)-770 or VX-445/VX-661/VX-770']",3,OBSERVATIONAL,[],,,Cystic Fibrosis,['Cystic Fibrosis'],"['Cystic Fibrosis', 'CF', 'CFTR Modulator', 'triple combination therapy', 'elexacaftor', 'tezacaftor', 'ivacaftor']",RECRUITING,,2020-11-18,2029-12-01,"[{'measure': 'Part A Primary Outcome Measure: Change in weight-for-age z-scores', 'description': 'Weight-for-age z-scores over time', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Part A Primary Outcome Measure: Change in height-for-age z-scores', 'description': 'Height-for-age z-scores over time', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Part B Primary Outcome Measure: Change in weight-for-age z-scores', 'description': 'Change in weight-for-age z-scores from baseline', 'timeFrame': 'Baseline to 12 months'}, {'measure': 'Part B Primary Outcome Measure: Change in height-for-age z-scores', 'description': 'Change in height-for-age z-scores from baseline', 'timeFrame': 'Baseline to 12 months'}]",[],4,,10 Years,ALL,False,Sonya Heltshe,OTHER,3,210.0,ESTIMATED,2025-09-01T16:18:23.452334,v2_robust,False,True,False,False,False,
NCT04457050,Effect of Hepatitis C Clearance on Insulin Resistance,Insulin Resistance and Resistin In Non-Diabetic Patients With Chronic Hepatitis C Before and After Direct-Acting Antiviral Drugs.,Sofosbuvir 400 milligram,"['Soflanork plus', 'Gratisovir 400 milligram', 'Riba 400 milligram', 'Daklanork 60 milligram', 'Daclatasvir 60 milligram', 'HARVONI', 'Ribavirin 400 milligram', 'Soflanork 400 milligram', 'Sofosbuvir 400 milligram', 'Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab', 'Daktavira 60 milligram']",11,INTERVENTIONAL,['PHASE4'],PHASE4,,Insulin Resistance,"['Insulin Resistance', 'Hepatitis C']",[],COMPLETED,,2017-10-30,2019-12-30,"[{'measure': 'Change in the insulin resistance before and after hepatitis C clearance', 'description': 'Assess the change in the value of Homeostatic Model Assessment for Insulin resistance (Homeostatic Model Assessment for Insulin Resistance) after hepatitis C treatment by calculating the HOMA-IR for all patients at baseline and the re-calculation at 12 weeks after viral clearance to clarify the impact of hepatitis C treatment by direct antiviral drugs on insulin sensitivity.', 'timeFrame': 'at baseline and 12 weeks after sustained virologic response'}]","[{'measure': 'Prevalence of insulin resistance among hepatitis C patients', 'description': 'Prevalence of insulin resistance among hepatitis C patients', 'timeFrame': 'at baseline'}, {'measure': 'Sustained virologic response', 'description': 'Sustained virologic response', 'timeFrame': 'at 12 weeks after treatment'}]",3,18 Years,70 Years,ALL,False,Alexandria University,OTHER,0,160.0,ACTUAL,2025-09-01T16:18:23.452477,v2_robust,True,True,True,False,False,
NCT03905850,A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects,"A Randomised, Double-blind, Single Dose, Three Period, Complete Cross Over Trial in Healthy Subjects Investigating the Pharmacokinetics of Subcutaneous Injections of Somapacitan 5 mg/1.5 mL and 10 mg/1.5 mL",somapacitan,['somapacitan'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,"['Healthy Volunteers', 'Growth Hormone Deficiency']",[],COMPLETED,,2019-03-29,2019-07-15,"[{'measure': 'Area under the somapacitan serum concentration time curve from time 0 to the time of the last quantifiable concentration after dosing', 'description': 'ng\\*h/mL', 'timeFrame': '0 to 504 hours after trial product administration'}, {'measure': 'Maximum serum concentration of somapacitan', 'description': 'ng/mL', 'timeFrame': '0 to 504 hours after trial product administration'}]","[{'measure': 'Area under the somapacitan serum concentration time curve from time 0 to 168 hours after dosing', 'description': 'ng\\*h/mL', 'timeFrame': '0 to 168 hours after trial product administration'}, {'measure': 'Area under the somapacitan serum concentration time curve from time 0 to infinity', 'description': 'ng\\*h/mL', 'timeFrame': '0 to 504 hours after trial product administration'}, {'measure': 'Time to maximum serum concentration of somapacitan', 'description': 'Hours', 'timeFrame': '0 to 504 hours after trial product administration'}, {'measure': 'Terminal half-life of somapacitan', 'description': 'Hours', 'timeFrame': '0 to 504 hours after trial product administration'}, {'measure': 'Area under the insulin-like growth factor I (IGF-I) serum concentration time curve from time 0 to 168 hours after dosing', 'description': 'ng\\*h/mL', 'timeFrame': '0 to 168 hours after trial product administration'}, {'measure': 'Maximum serum concentration of IGF-I after dosing', 'description': 'ng/mL', 'timeFrame': '0 to 504 hours after trial product administration'}, {'measure': 'Time to maximum serum concentration of IGF-I after dosing', 'description': 'Hours', 'timeFrame': '0 to 504 hours after trial product administration'}]",9,18 Years,45 Years,ALL,True,Novo Nordisk A/S,INDUSTRY,0,33.0,ACTUAL,2025-09-01T16:18:23.452523,v2_robust,True,True,True,False,False,
NCT07128550,A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide,"A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)",Tobevibart,"['Elebsiran', 'Tobevibart', 'Bulevirtide', 'Hepcludex', 'VIR-2218', 'VIR-3434']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Viral Hepatitis,['Viral Hepatitis'],"['HDV', 'Hepatitis D Virus', 'Hepatitis', 'Chronic Hepatitis D Virus', 'Hepatitis D', 'Hepatitis D, Chronic', 'Hepatitis Delta Virus', 'Digestive System Diseases', 'Liver Diseases']",RECRUITING,,2025-07-30,2031-07,"[{'measure': 'HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24', 'timeFrame': 'Week 24'}, {'measure': 'HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) 24 weeks after end of treatment.', 'timeFrame': '24 Weeks after End of Treatment'}]","[{'measure': 'Incidence of Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 24, Week 48, Week 96', 'timeFrame': 'Week 24, Week 48 and Week 96'}, {'measure': 'HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 48, Week 96, Week 144, Week 192 and Week 240', 'timeFrame': 'Week 48 , Week 96, Week 144, Week 192 and Week 240'}, {'measure': 'Change from baseline in ALT at Week 24, Week 48 and Week 96', 'timeFrame': 'Week 24, Week 48 and Week 96'}]",5,18 Years,70 Years,ALL,False,"Vir Biotechnology, Inc.",INDUSTRY,0,150.0,ESTIMATED,2025-09-01T16:18:23.452687,v2_robust,True,True,False,False,True,
NCT00934791,Polycystic Liver Disease in Kidney Transplant,"Single Center, Open-label Randomized Prospective Trial: Effect of Sirolimus on Polycystic Liver Disease",Tacrolimus,"['Rapamycin', 'Mycophenolate Mofetil', 'Rapamune', 'Deltasone', 'Sirolimus', 'Cellcept', 'Prograf', 'Prednisone', 'Tacrolimus']",9,INTERVENTIONAL,['NA'],,,Polycystic Liver Disease,['Polycystic Liver Disease'],"['Kidney Transplant', 'Autosomal dominant polycystic kidney disease', 'Polycystic liver disease']",TERMINATED,Terminated due to inadequate enrollment,2009-02,2012-12,"[{'measure': 'Liver Volume at 2 Years After Kidney Transplantation', 'description': 'Liver volume at 2 years will be compared between the sirolimus and control (tacrolimus) groups using analysis of covariance (ANCOVA).', 'timeFrame': '2 years'}]",[],1,18 Years,,ALL,False,Mayo Clinic,OTHER,1,2.0,ACTUAL,2025-09-01T16:18:23.452822,v2_robust,True,True,False,True,False,Terminated due to inadequate enrollment
NCT06506591,"A Single-And Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-890 Tablets in Healthy Chinese Subjects","A Single-And Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics,Pharmacodynamics and Food Effect of WD-890 Tablets in Healthy Chinese Subjects",WD-890,"['WD-890', 'WD-890 Tablets Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Participants,['Healthy Participants'],['TYK2 Inhibitor'],COMPLETED,,2023-10-26,2024-08-15,"[{'measure': 'Safety of a single oral dose of WD-890 based on number of incidence of AE, SAEs, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, telemetry, and physical examinations', 'timeFrame': 'Days 1 to 5'}, {'measure': 'Tolerability of a single oral dose of WD-890 based on number of incidence of AE, SAEs, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, telemetry, and physical examinations', 'timeFrame': 'Days 1 to 5'}, {'measure': 'Safety of a multiple oral dose of WD-890 based on number of incidence of AE, SAEs, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, telemetry, and physical examinations', 'timeFrame': 'Days 1 to 19'}, {'measure': 'Tolerability of a multiple oral dose of WD-890 based on number of incidence of AE, SAEs, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, telemetry, and physical examinations', 'timeFrame': 'Days 1 to 19'}, {'measure': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and Food Effect (FE) Cohorts: Maximum Observed Plasma Concentration (Cmax) of WD-890；', 'timeFrame': 'SAD: Days 1 to 4 ; MAD: Day 1, Day 6, Day 9 and Day 12; FE: Days 1 to 5, Days 8 to 12'}, {'measure': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and Food Effect (FE) Cohorts: Area Under The Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) of WD-890', 'timeFrame': 'SAD: Days 1 to 4 ; MAD: Day 1, Day 6, Day 9 and Day 12 FE: Days 1 to 5, Days 8 to 12'}, {'measure': 'Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and Food Effect (FE) Cohorts: Area Under The Plasma Concentration-Time Curve From Time Zero Extrapolated To Infinite Time (AUC(INF)) of WD-890', 'timeFrame': 'SAD: Days 1 to 4 ; MAD: Day 1, Day 6, Day 9 and Day 12 FE: Days 1 to 5, Days 8 to 12'}, {'measure': 'Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts: Time to Maximum Observed Plasma Concentration (Tmax) of WD-890', 'timeFrame': 'SAD: Days 1 to 4 ; MAD: Day 1, Day 6, Day 9 and Day 12'}, {'measure': 'Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts: Apparent Plasma Elimination Half-Life (T-HALF) of WD-890', 'timeFrame': 'SAD: Days 1 to 4 ; MAD: Day 1, Day 6, Day 9 and Day 12'}, {'measure': 'Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts: Apparent Volume of Distribution (Vz/F) of WD-890', 'timeFrame': 'SAD: Days 1 to 4 ; MAD: Day 1, Day 6, Day 9 and Day 12'}, {'measure': 'Multiple Ascending Dose (MAD) Cohorts: Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of WD-890', 'timeFrame': 'Day 1, Day 6, Day 9 and Day 12'}, {'measure': 'Multiple Ascending Dose (MAD) Cohorts: Time to Reach the Maximum Plasma Concentration at Steady State (Tmax,ss) of WD-890', 'timeFrame': 'Day 1, Day 6, Day 9 and Day 12'}, {'measure': 'Multiple Ascending Dose (MAD) Cohorts: Apparent Volume of Distribution at Steady State (Vss/F) of WD-890', 'timeFrame': 'Day 1, Day 6, Day 9 and Day 12'}]","[{'measure': 'Food Effect Cohorts: Time to Maximum Observed Plasma Concentration (Tmax) of WD-890', 'timeFrame': 'Days 1 to 5, Days 8 to 12,'}, {'measure': 'Food Effect Cohorts: Apparent Volume of Distribution (Vz/F) of WD-890', 'timeFrame': 'Days 1 to 5, Days 8 to 12'}, {'measure': 'Food Effect Cohorts: Apparent Plasma Elimination Half-Life (T-HALF) of WD-890', 'timeFrame': 'Days 1 to 5, Days 8 to 12,'}]",16,18 Years,50 Years,ALL,True,"Zhejiang Wenda Medical Technology Co., Ltd.",OTHER,0,106.0,ACTUAL,2025-09-01T16:18:23.452906,v2_robust,True,True,True,False,True,
NCT00106691,Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia),"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN)",Toremifene 20 mg,"['Toremifene 20 mg', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Preneoplastic Conditions,"['Preneoplastic Conditions', 'Prostatic Intraepithelial Neoplasia']","['neoplasia', 'chemoprevention', 'cancer', 'premalignant', 'precancerous', 'Chemoprophylaxis', 'Intraepithelial Prostatic Neoplasia', 'Neoplasia, Prostatic Intraepithelial']",COMPLETED,,2005-01,2010-02,"[{'measure': 'Efficacy of Toremifene in the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN)', 'description': 'To measure the efficacy of toremifene citrate in men with high grade prostatic intraepithelial neoplasia (PIN). Prostate cancer-free survival distributions (Kaplan-Meier)', 'timeFrame': 'The outcome measurement time is up to 36 months'}, {'measure': 'Occurrence of a Positive Cancer Biopsy', 'description': 'To measure the occurrence of a positive cancer biopsy', 'timeFrame': 'Up to 36 months'}]","[{'measure': 'The Effect of Toremifene on Lipid Levels', 'description': 'Measure lipid levels including total cholesterol, LDL, HDL and Triglycerides % change from baseline', 'timeFrame': 'Up to 36 months'}, {'measure': 'The Effect of Toremifene on Hormone Levels', 'description': '% Change from baseline hormone levels, including total testosterone, free testosterone, dihydrotestosterone (DHT) and estradiol', 'timeFrame': 'Up to 36 months'}, {'measure': 'The Effect of Toremifene on Total PSA (Prostate Specific Antigen) Levels', 'description': 'To assess the effect of toremifene in the total PSA (prostate specific antigen) levels from baseline', 'timeFrame': 'Up to 36 months'}, {'measure': 'The Effect of Toremifene on the Mean Change at 36 Months in AUA (American Urological Association) Symptom Score', 'description': 'To assess the effect of toremifene on the AUA (American Urological Association) symptom score mean change from baseline. Scores of 0-7=mild severity, 8-9, moderate, and 20-30, severe with possible responses of 0 (not at all) 1 (\\<1/5), 2 (\\<50% time), 3 (about 50% time), 4 (\\> 50% time) \\& 5 (Almost Always). There are 7 questions (1)Incomplete emptying (2)Frequency (3)Intermittency (4)Urgency (5)Weak-stream (6)Straining \\& (7)Nocturia. Analysis is change from baseline at final evaluation (36 months) for quality of life due to urinary symptoms. The P Value is from a Wilcoxon signed-rank test. Scores can range from 0-35, highest representing worse symptoms', 'timeFrame': '36 months'}, {'measure': 'Occurrence of High Grade PIN at the 12, 24, 36 Month Biopsies', 'description': 'To measure the occurrence of high grade PIN at the 12, 24, 36 Month intervals in the 360 days study.', 'timeFrame': 'Up to 36 months'}, {'measure': 'The Effect of Toremifene on % Free Serum PSA (Prostate Specific Antigen) Levels, Change From Baseline', 'description': 'To assess the effect of toremifene in % free serum PSA (prostate specific antigen) levels, change from baseline', 'timeFrame': '36 months'}]",8,30 Years,,MALE,False,GTx,INDUSTRY,0,1589.0,ACTUAL,2025-09-01T16:18:23.452919,v2_robust,True,True,True,False,False,
NCT02762591,Expanded Access of Pimavanserin for Patients With PD Psychosis,Expanded Access Program of Pimavanserin in Patients With Parkinson's Disease Psychosis,Pimavanserin tartrate,['Pimavanserin tartrate'],1,EXPANDED_ACCESS,[],,,Parkinson's Disease Psychosis,"[""Parkinson's Disease Psychosis""]",[],APPROVED_FOR_MARKETING,,,,[],[],0,40 Years,,ALL,,ACADIA Pharmaceuticals Inc.,INDUSTRY,0,,,2025-09-01T16:18:23.452964,v2_robust,False,True,False,False,False,
NCT01179191,Conversion to Embeda With Rescue Trial,"A Multi-Center, Primary Care-Based, Open-Label Study to Assess the Success of Converting Opioid-Experienced Patients, With Chronic, Moderate to Severe Pain, to EMBEDA Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse, and Diversion",morphine sulfate and naltrexone hydrochloride (EMBEDA),['morphine sulfate and naltrexone hydrochloride (EMBEDA)'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Disease,"['Chronic Disease', 'Pain']","['chronic pain', 'Embeda', 'opioid', 'moderate pain', 'severe pain', 'conversion', 'converting', 'switching', 'morphine', 'aberrant behavior', 'Pain (DT) + Chronic Disease (DT)']",TERMINATED,See termination reason in detailed description.,2010-08,2011-04,"[{'measure': 'Percentage of Participants Achieving Stable Dose of EMBEDA Within 6 Weeks Titration Phase', 'description': 'A dose was considered to be stable dose if it met all of the following criteria: dose was taken for at least 48 hours; investigator deemed the balance between an acceptable level of analgesia and/or function and tolerance of side effects had been achieved; and rescue medication use less than or equal to 2 doses per day.', 'timeFrame': 'Baseline through Week 6'}, {'measure': 'Percentage of Participants Achieving Stable Dose of EMBEDA Within 6 Weeks Titration Phase Stratified by Prior Opioid Therapy', 'description': 'A dose was considered to be stable dose if it met all of the following criteria: dose was taken for at least 48 hours; investigator deemed the balance between an acceptable level of analgesia and/or function and tolerance of side effects had been achieved; and rescue medication use less than or equal to 2 doses per day.', 'timeFrame': 'Baseline through Week 6'}]","[{'measure': 'Duration to Titrate Participants to Stable Dose', 'description': 'A dose was considered to be stable dose if it met all of the following criteria: dose was taken for at least 48 hours; investigator deemed the balance between an acceptable level of analgesia and/or function and tolerance of side effects had been achieved; and rescue medication use less than or equal to 2 doses per day.', 'timeFrame': 'Baseline through Week 6'}, {'measure': 'Duration to Titrate Participants to Stable Dose Stratified by Prior Opioid Therapy', 'description': 'A dose was considered to be stable dose if it met all of the following criteria: dose was taken for at least 48 hours; investigator deemed the balance between an acceptable level of analgesia and/or function and tolerance of side effects had been achieved; and rescue medication use less than or equal to 2 doses per day.', 'timeFrame': 'Baseline through Week 6'}, {'measure': 'Number of Titration Steps to Achieve Stable Dose', 'description': 'A dose was considered to be stable dose if it met all of the following criteria: dose was taken for at least 48 hours; investigator deemed the balance between an acceptable level of analgesia and/or function and tolerance of side effects had been achieved; and rescue medication use less than or equal to 2 doses per day.', 'timeFrame': 'Baseline through Week 6'}, {'measure': 'Number of Titration Steps to Achieve Stable Dose Stratified by Prior Opioid Therapy', 'description': 'A dose was considered to be stable dose if it met all of the following criteria: dose was taken for at least 48 hours; investigator deemed the balance between an acceptable level of analgesia and/or function and tolerance of side effects had been achieved; and rescue medication use less than or equal to 2 doses per day.', 'timeFrame': 'Baseline through Week 6'}, {'measure': 'Percentage of Participants With Rescue Medications Usage During Titration', 'description': 'Rescue pain medications were used for supplemental analgesia for breakthrough pain during titration phase. Morphine sulfate IR tablet (less than 20 percent of the total daily dose of EMBEDA per IR dose), ibuprofen (up to 400 milligram (mg)/dose; not to exceed 1200 mg/day), and acetaminophen (up to 1000 mg/dose, not to exceed 4000 mg/day) were used as rescue medications.', 'timeFrame': 'Baseline through Week 6'}, {'measure': 'Change From Baseline in Brief Pain Inventory (BPI) at Visit 3 (First Visit After Successful Titration)', 'description': ""BPI is an 11-item self-report questionnaire: consist of 4 questions that assess pain intensity (worst, least, average, relief) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each question answered on a scale range:0-10 (0%-100% for relief), '0=No pain/no relief/no interference and 10=Pain as bad as you can imagine/complete relief/ complete interference'.Measure can be scored by item, with lower scores being indicative of less pain or pain interference."", 'timeFrame': 'Baseline, Visit 3 (up to Week 6)'}, {'measure': ""Investigator's Level of Satisfaction With the EMBEDA Conversion Guide"", 'description': ""The conversion assessment survey is a brief questionnaire using multiple choice options and numeric rating scale (NRS) with specified anchored responses ranging on a scale from 0-10 (0 = very dissatisfied, 5 = neutral, and 10=very satisfied) to assess the Investigator's level of satisfaction with the EMBEDA Conversion Guide."", 'timeFrame': 'Week 6'}]",9,21 Years,,ALL,False,Pfizer,INDUSTRY,0,684.0,ACTUAL,2025-09-01T16:18:23.452988,v2_robust,True,True,False,True,False,See termination reason in detailed description.
NCT06594991,"A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma","A Phase 2 Study of Fianlimab, Cemiplimab, and Ipilimumab in Anti-PD-1 Refractory Melanoma",Fianlimab,"['Ipilimumab', 'Fianlimab', 'Cemiplimab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Melanoma,['Advanced Melanoma'],"['Fianlimab', 'Cemiplimab', 'Ipilimumab', 'anti-PD-1 refractory melanoma', 'unresectable Stage III/IV melanoma', '24-166']",RECRUITING,,2024-09-10,2027-09,"[{'measure': 'Determine best objective response rate (ORR) (cohort A)', 'description': 'by RECIST v1.1', 'timeFrame': '6 weeks'}, {'measure': 'Determine best objective response rate (ORR) (cohort B)', 'description': 'by RECIST v1.1', 'timeFrame': '6 weeks'}]",[],2,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,88.0,ESTIMATED,2025-09-01T16:18:23.453141,v2_robust,True,True,False,False,False,
NCT00473174,Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension,"A Prospective, Randomized, Open Label, Blinded-endpoint Study to Compare Awakening Versus Bedtime Administration of 5-10 mg Ramipril in Terms of Systolic Blood Pressure Lowering Determined by ABPM in Subjects With Mild-to-moderate Essential",Ramipril,['Ramipril'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypertension,['Hypertension'],"['Ramipril', 'Ambulatory blood pressure monitoring', 'Chronotherapy', 'Circadian', 'Non-dipper']",COMPLETED,,2007-03,2008-12,"[{'measure': 'To demonstrate the efficacy of bedtime administration of ramipril in subjects with essential hypertension by testing the hypothesis of superior nocturnal SBP lowering in ABPM measurements compared with ramipril administered on awakening', 'timeFrame': 'Three months'}]","[{'measure': 'To demonstrate that ramipril at bedtime is more effective than ramipril upon awakening in terms of nocturnal DBP lowering in ABPM', 'timeFrame': 'Three months'}, {'measure': 'To demonstrate that ramipril at bedtime is not inferior to ramipril upon awakening in terms of 24-hour SBP/DBP lowering in ABPM', 'timeFrame': 'Three months'}, {'measure': 'To demonstrate that ramipril at bedtime is more effective than ramipril upon awakening in terms of increasing the diurnal/nocturnal SBP and DBP ratio determined by ABPM', 'timeFrame': 'Three months'}, {'measure': 'To demonstrate that ramipril at bedtime offers a similar safety profile than ramipril upon awakening', 'timeFrame': 'Three months'}, {'measure': 'To demonstrate that compliance with ramipril at bedtime is similar to compliance of ramipril upon awakening', 'timeFrame': 'Three months'}]",6,18 Years,,ALL,False,University of Vigo,OTHER,1,120.0,ACTUAL,2025-09-01T16:18:23.453161,v2_robust,True,True,True,False,True,
NCT04898374,Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma,Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma: A Randomized Phase III Trial,Gemcitabin/cisplatin,['Gemcitabin/cisplatin'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Nasopharyngeal Carcinoma,['Nasopharyngeal Carcinoma'],"['Induction chemotherapy', 'neoadjuvant', 'adjuvant', 'non-metastatic', 'Nasopharyngeal Carcinoma']",RECRUITING,,2021-05-01,2026-04-30,"[{'measure': 'Acute and late toxicity assessment', 'description': 'Incidence of acute toxicity is calculated for each adverse event respectively, and severity evaluated on based of common terminology criteria for adverse event (CTCAE)', 'timeFrame': '3-5 years'}, {'measure': 'Late radiation toxicity', 'description': 'assessed using the radiation therapy oncology group and Europe organization for research and treatment of cancer late radiation morbidity scoring scheme', 'timeFrame': '5-7 years'}, {'measure': 'Loco regional control rates (LCR)', 'description': 'Defined as the time from the date of randomization to 1st failure in nasopharynx or neck lymph nodes', 'timeFrame': '3-5 years'}, {'measure': 'Progression free survival (PFS)', 'description': 'Defined as the time from the date of randomization to 1st failure locally or systemically', 'timeFrame': '3-5 Years'}]","[{'measure': 'Overall Survival (OS)', 'description': 'Defined as the time from the date of randomization to death from any cause', 'timeFrame': '5 years'}, {'measure': 'Distance Metastasis free survival (DMFS)', 'description': 'It is evaluated and calculated from the date of random assignment until date of first distance metastasis or until the date of last follow-up visit', 'timeFrame': '5 years'}]",6,18 Years,70 Years,ALL,False,Kuwait Cancer Control Center,OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:23.453175,v2_robust,True,True,False,False,True,
NCT03226574,Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain,"A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer",Resiniferatoxin,"['Resiniferatoxin', 'RTX']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Intractable Cancer Pain,['Intractable Cancer Pain'],"['Resiniferatoxin', 'RTX', 'Cancer pain']",COMPLETED,,2017-09-01,2020-06-18,"[{'measure': 'Dose limiting toxicity (DLT)', 'description': 'Grade 3 or 4 Toxicity associated with RTX administration', 'timeFrame': '3-month'}, {'measure': 'Maximum tolerated dose (MTD)', 'description': 'Maximum dose without a Grade 3 or 4 toxicity', 'timeFrame': '3-month'}]","[{'measure': 'Numeric Pain Rating Scale (NPRS)', 'description': 'Daily average pain and daily worst pain on a 0-10 scale', 'timeFrame': 'Day-28 to Day90 daily'}]",3,18 Years,,ALL,False,"Sorrento Therapeutics, Inc.",INDUSTRY,0,17.0,ACTUAL,2025-09-01T16:18:23.453184,v2_robust,True,True,True,False,False,
NCT01262274,Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer,Randomized Phase II Trial of Anastrozole in Combination With/Without Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Primary Breast Cancer,Anastrozole,"['Anastrozole plus tegafur-uracil', 'Anastrozole']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Neoplasms,['Breast Neoplasms'],[],TERMINATED,Due to an adverse event revelation.,2010-12,2014-04,"[{'measure': 'Response Rate (confirmed by calipers CT or MRI)', 'timeFrame': 'six months'}]","[{'measure': 'Reduction Rate, Pathological response, Breast-conserving surgery rate, Adverse event rate, Predictive factor', 'timeFrame': 'seven months'}]",2,,,FEMALE,False,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",OTHER,1,57.0,ACTUAL,2025-09-01T16:18:23.453198,v2_robust,True,True,False,True,True,Due to an adverse event revelation.
NCT02580474,The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure,The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure,Daclatasvir plus Asunaprevir,['Daclatasvir plus Asunaprevir'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Hepatitis C,['Hepatitis C'],[],COMPLETED,,2016-02,2018-04,"[{'measure': 'the proportion of subjects with plasma HCV RNA levels below 15 IU/mL at Week 12 After End of Treatment', 'timeFrame': '36 Week'}]","[{'measure': 'To evaluate the percentage of subjects with Sustained Virologic Response at Week 12 After End of Treatment', 'timeFrame': '36 Week'}, {'measure': 'Percentage of subjects with ALT normalization at each visit from the baseline', 'timeFrame': '4, 12, 24, 36 week'}, {'measure': 'Change in HCV RNA at each visit from the baseline', 'timeFrame': '4, 12, 24, 36 week'}, {'measure': 'Percentage of subjects who experience viral breakthrough at each visit from the baseline', 'timeFrame': '4, 12, 24, 36 week'}, {'measure': 'Percentage of subjects who shows Tolerability of Daclatasvir and Asunaprevir at each visit from', 'timeFrame': '4, 12, 24, 36 week'}]",6,19 Years,,ALL,False,Myeong Jun Song,OTHER,12,21.0,ACTUAL,2025-09-01T16:18:23.453497,v2_robust,True,True,True,False,False,
NCT01164774,"Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited, Under Non-Fasting Conditions",A Two-way Open Label Crossover Experimental Evaluation of Relative Bioavailabilities of Ramipril 10 mg Capsules of Dr.Reddy's Laboratories and ALTACE@ 10 mg Capsules of King Pharmaceuticals in Healthy Adult Human Male Subjects Under Non-fasting Conditions,Ramipril,"['Altace@10 mg Capsules', 'Ramipril', 'Altace']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Bioavailability', 'Crossover', 'Ramipril']",COMPLETED,,2005-10,2005-11,"[{'measure': 'Bioavailability based on Cmax and AUC parameters', 'timeFrame': '2 months'}]",[],1,18 Years,45 Years,MALE,True,Dr. Reddy's Laboratories Limited,INDUSTRY,0,54.0,ACTUAL,2025-09-01T16:18:23.453563,v2_robust,True,True,True,False,False,
NCT06809374,Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer,Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer,gemcitabine,['gemcitabine'],1,OBSERVATIONAL,[],,,Pancreatic Cancer Resectable,['Pancreatic Cancer Resectable'],[],COMPLETED,,2015-01-01,2024-12-31,"[{'measure': 'Investigating the Presence of Occult Metastatic Lesions Detected During Neoadjuvant Therapy.', 'timeFrame': 'within 6 months'}]",[],1,,,ALL,True,Kochi University,OTHER,0,100.0,ACTUAL,2025-09-01T16:18:23.453571,v2_robust,False,True,True,False,False,
NCT00967174,Cumulative Skin Irritation Potential of a New 25 mg Nicotine Patch,"Study on the Cumulative Skin Irritation Potential of a Newly Developed 25 mg Nicotine Transdermal Therapeutic System. A Double Blind, Randomized, Repeat Patch Test, Single Center Study in 42 Healthy Male and Female Subjects",Nicotine Patch,"['SLS Comparator', 'Experimental Nicotine Patch', 'Nicotine Patch', 'Placebo Paatch Comparator', 'SLS Comparator Patch', 'Placebo Patch']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Smoking Cessation,['Smoking Cessation'],[],COMPLETED,,2005-05,2005-06,"[{'measure': 'Cumulative Irritation Score (CIS10)', 'timeFrame': '@24 hours post- application for 21 days'}]","[{'measure': 'Cumulative Individual Irritation Score (CIIS)', 'timeFrame': '@24 hours post- application for 21 days'}, {'measure': 'Frequency Indices (FI) of irritation score', 'timeFrame': '@24 hours post- application for 21 days'}, {'measure': 'Time to irritation reaction', 'timeFrame': '@24 hours post- application for 21 days'}, {'measure': 'Patch adhesion score', 'timeFrame': 'directly before patch removal'}, {'measure': 'Tolerability', 'timeFrame': 'at each visit'}]",6,18 Years,65 Years,ALL,False,McNeil AB,INDUSTRY,0,42.0,ACTUAL,2025-09-01T16:18:23.453580,v2_robust,True,True,True,False,False,
NCT00240474,A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study),"A Comparison of Telmisartan 80 mg + Hydrochlorothiazide 12.5 mg With Amlodipine 10 mg + Hydrochlorothiazide 12.5 mg in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension. A Prospective, Randomised, Open-label, Blinded End-point Evaluation. (ATHOS Study)",Telmisartan 80 mg + hydrochlorothiazide 12.5 mg,"['Amlodipine 10 mg + hydrochlorothiazide 12.5 mg', 'Telmisartan 80 mg + hydrochlorothiazide 12.5 mg']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypertension,['Hypertension'],[],COMPLETED,,2002-12,2004-03,"[{'measure': 'Change from baseline in the last 6-hour mean (relative to dose time) in SBP as measured by 24-hour ABPM at the end-of-study visit', 'timeFrame': '14 weeks'}]","[{'measure': 'Change from baseline in DBP in the last six hours of the 24-hour dose period', 'timeFrame': 'week 8 and 14'}, {'measure': 'Change from baseline in pulse pressure (PP) in the last six hours of the 24-hour dose period', 'timeFrame': 'week 8 and 14'}, {'measure': 'Change from baseline SBP and DBP for other time intervals ( i.e. 24-hour mean, morning mean (06:00-11:59), daytime mean (06:00-21:59), and night-time mean (22:00-05:59))', 'timeFrame': 'week 8 and 14'}, {'measure': 'Change from baseline in patient HRQL as measured by the Psychological General Well-Being (PGWB) index.', 'timeFrame': 'week 8 and 14'}, {'measure': 'Change from baseline in SBP in the last six hours of the 24-hour dose period (as measured by 24-hour ABPM).', 'timeFrame': '8 weeks'}, {'measure': 'Proportion of patients achieving a target response in SBP', 'timeFrame': '14 weeks'}, {'measure': 'Proportion of patients achieving SBP control', 'timeFrame': '14 weeks'}, {'measure': 'Proportion of patients achieving normal blood pressure', 'timeFrame': '14 weeks'}, {'measure': 'Proportion of patients achieving high-normal blood pressure', 'timeFrame': '14 weeks'}, {'measure': 'Change from baseline in trough seated SBP', 'timeFrame': '14 weeks'}, {'measure': 'Change from baseline in trough seated DBP', 'timeFrame': '14 weeks'}, {'measure': 'Safety and tolerability of the combination of telmisartan 80 mg and HCTZ 12.5 mg compared with amlodipine 10 mg and HCTZ 12.5 mg', 'timeFrame': '14 weeks'}]",13,60 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,1000.0,,2025-09-01T16:18:23.453594,v2_robust,True,True,True,False,True,
NCT01033318,A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED),"A Double-Blind, Double Dummy, Randomized, Placebo-Controlled, Alternating Panel, Single Oral Rising Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of MK1809 in Healthy Young Volunteers",MK1809,"['Comparator: Placebo', 'MK1809', 'Losartan', 'Comparator: Losartan']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Hypertension,['Hypertension'],['Hypertension'],COMPLETED,,2007-09-11,2008-06-19,"[{'measure': 'Part I: Area under the plasma concentration (AUC) versus time curve in healthy adult male subjects in the fasted state', 'timeFrame': 'Through 32 hours postdose'}, {'measure': 'Part 1: Trough plasma concentration in healthy adult male subjects in the fasted state', 'timeFrame': '24 hours postdose'}, {'measure': 'Part 2: Safety and tolerability of rising single oral doses of MK1809 in adult hypertensive patients based on an assessment of clinical and laboratory adverse experiences', 'timeFrame': 'Duration of study and up to 14 days after administration of the last dose of study drug'}]","[{'measure': 'Part 1: Area under the plasma concentration (AUC) versus time curve resulting from a single oral dose of MK1809 following a standard high-fat breakfast (compared to that observed with the identical dose level administered in the fasted state)', 'timeFrame': '24 hours postdose'}, {'measure': 'Part 1: Maximum concentration of drug in the plasma (Cmax) resulting from a single oral dose of MK1809 following a standard high-fat breakfast (compared to that observed with the identical dose level administered in the fasted state)', 'timeFrame': 'Through 32 hours postdose'}, {'measure': 'Part 1: Number of clinical and laboratory adverse experiences (AEs) to assess safety and tolerability', 'timeFrame': 'Duration of study and up to 14 days after administration of the last dose of study drug'}, {'measure': 'Part 2: Area under the plasma concentration (AUC) versus time curve of the E3174 metabolite', 'timeFrame': 'Through 32 hours postdose'}, {'measure': 'Part 2: Trough plasma concentration of the E3174 metabolite', 'timeFrame': 'Through 32 hours postdose'}]",8,18 Years,55 Years,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:23.453687,v2_robust,True,True,True,False,True,
NCT01373918,Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders,Low Dose Parenteral Fat for the Prevention of Parenteral Nutrition Associated Cholestasis in Neonates With Congenital/Acquired Gastrointestinal Disorders,Intralipid,"['soybean oil', 'Intralipid']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Cholestasis,['Cholestasis'],"['cholestasis', 'neonates', 'parenteral nutrition', 'gastrointestinal disorders']",TERMINATED,The study was terminated due to slow enrollment.,2010-12,2014-07,"[{'measure': 'Presence of Cholestasis', 'description': 'Cholestasis will be defined by a direct bilirubin \\> 2 mg/dL', 'timeFrame': 'prior to 100 days of life, hospital discharge, or death whichever comes first'}]","[{'measure': 'Mortality Rate', 'description': 'death', 'timeFrame': 'at the end of the hospital stay which is expected to be an average of 5 weeks'}, {'measure': 'Anthropometric Measurements', 'description': 'Growth will be assessed by growth velocity at 28 days of age', 'timeFrame': '28 days of age'}, {'measure': 'Anthropometric Measurements', 'description': 'Growth will be assessed by weight at the time of hospital discharge (approximately 5 weeks)', 'timeFrame': 'approximately 5 weeks'}]",4,1 Minute,5 Days,ALL,False,"University of California, Los Angeles",OTHER,1,41.0,ACTUAL,2025-09-01T16:18:23.453698,v2_robust,True,True,False,True,False,The study was terminated due to slow enrollment.
NCT03749018,Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma,A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma,Cyclophosphamide,"['Vincristine, sulfate', 'Doxorubin', 'Carloxan', 'Cyclophosphan', 'Adrimedac', 'Lastet', 'Cytoxan', 'WR- 138719', 'Adriblastine', 'Delta-Dome', '2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate', 'Doxorubicin Hydrochloride', 'Promifen', 'Cycloblastine', '1, 2-Dehydrocortisone', 'Ciclofosfamide', 'Cyclostin', '(-)-Cyclophosphamide', 'Cycloblastin', 'Cyclophosphamide', 'Decorton', 'Prednilonga', 'Leurocristine, sulfate', 'Meprosona-F', 'Kyocristine', 'Decortisyl', 'Toposar', 'FI-106', 'Cytophosphane', 'Ciclofosfamida', 'Prednicort', 'Vincrex', 'VP 16-213', 'DOX', 'Lisacort', 'Prednisone', 'hydroxydaunorubicin', 'Genuxal', 'Econosone', 'Adriamycine', 'Vepesid', 'Vincosid', 'Cyclophosphamidum', 'Deltacortisone', 'Cyclostine', 'Cyclophospham', 'Predicor', 'Doxorubicin.HCl', 'CP monohydrate', 'CTX', 'Orasone', 'Predicorten', 'FI 106', 'PRED', 'Clafen', 'Genoxal', 'Etoposide', 'Panasol-S', 'Rubex', 'Syklofosfamid', 'Cyclophosphanum', 'VP-16-213', 'Cyclophosphamid monohydrate', 'Adriamycin PFS', 'SK-Prednisone', 'Metacortandracin', 'Paracort', 'Delta 1-Cortisone', 'Doxolem', 'Prednitone', 'Deltison', 'Prednicen-M', 'Adriamycin Hydrochloride', 'Farmiblastina', 'Adasone', '.delta.1-Cortisone', 'ADRIAMYCIN, HYDROCHLORIDE', '5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)', 'Vincristine Sulfate', 'Cytophosphan', 'DOXO-CELL', 'Deltacortene', 'Oncovin', 'Deltadehydrocortisone', 'ADM', 'Chloridrato de Doxorrubicina', 'EPEG', 'Mitoxan', 'Fosfaseron', 'Claphene', 'Prednidib', 'Adriacin', 'Adriblastina', 'Deltasone', 'Ofisolona', 'Deltra', 'Neosar', 'Revimmune', 'Cicloxal', 'Ledoxina', 'Vincasar', 'Panafcort', 'Servisone', 'Adriamycin RDF', 'DeCortin', 'Dacortin', 'Meticorten', 'Cyclophosphane', 'VP-16', 'Adriamycin', 'Demethyl Epipodophyllotoxin Ethylidine Glucoside', 'Predniment', 'Cortancyl', 'Prednisonum', 'Leurocristine sulfate', 'CYCLO-cell']",116,INTERVENTIONAL,['PHASE2'],PHASE2,,Aggressive Non-Hodgkin Lymphoma,"['Aggressive Non-Hodgkin Lymphoma', 'Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma', 'Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma', 'Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma', 'Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma', 'Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma', 'Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma', 'Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma', 'Diffuse Large B-Cell Lymphoma', 'High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements', 'High Grade B-Cell Lymphoma, Not Otherwise Specified', 'Indolent Non-Hodgkin Lymphoma', 'Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma', 'Transformed Non-Hodgkin Lymphoma']",[],ACTIVE_NOT_RECRUITING,,2019-01-02,2025-12-31,"[{'measure': 'Progression-free survival (PFS)', 'description': 'Will be estimated by the method of Kaplan-Meier and the estimate will be provided with 95% confidence intervals. Depending on the number of events, Cox regression model may be used to explore the association between baseline clinical variables and PFS in a univariable manner.', 'timeFrame': 'From start of treatment to progression or death, whichever occurs first, assessed at 2 years'}]","[{'measure': 'Objective response rate', 'description': 'Will be calculated with patients who achieve complete response (CR) or partial response (PR) at end of induction therapy as the numerator and all eligible patients who start treatment as the denominator, with a 95% binomial confidence interval provided. CR rate will be analyzed in the same way.', 'timeFrame': 'Up to 8 years'}, {'measure': 'Duration of response defined for all patients who have achieved an objective response (CR or PR)', 'description': 'Will be described using the method of Kaplan-Meier.', 'timeFrame': 'From date of which patient?s response is documented to the date of progression or death, censoring event-free patients at the time of last follow-up, assessed up to 8 years'}, {'measure': 'Incidence of adverse events per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0', 'description': 'All adverse events will be summarized and tabulated across all patients who received any treatment with a focus on severe (grade 3+) adverse events and toxicities that are deemed at least possibly related to study treatment.', 'timeFrame': 'Up to 30 days post-treatment'}]",4,18 Years,,ALL,False,"David Bond, MD",OTHER,1,30.0,ESTIMATED,2025-09-01T16:18:23.453879,v2_robust,True,True,False,False,True,
NCT05188118,Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma,"A Pilot, Rapid Sequencing of First Line Cabozantinib, Ipilimumab and Nivolumab, and Lenvatinib and Everolimus in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma",Cabozantinib,"['Ipilimumab', 'Nivolumab', 'Everolimus', 'Lenvatinib', 'Cabozantinib']",5,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Renal Cell Carcinoma,['Renal Cell Carcinoma'],"['Clear cell', 'Renal cell carcinoma', 'Metastatic', 'Unresectable', 'Immunotherapy', 'Targeted therapy']",RECRUITING,,2023-02-15,2026-12,"[{'measure': 'Best Overall Response Rate (ORR)', 'description': 'ORR is defined as the proportion of subjects who achieved a best response of CR or PR using the RECIST 1.1.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum longest diameters', 'timeFrame': '9 months'}]","[{'measure': 'Diagnostic Odds Ratio (DoR)', 'description': 'Diagnostic Odds Ratio - the ratio of the odds of the test being positive if the subject has a disease relative to the odds of the test being positive if the subject does not have the disease.', 'timeFrame': '9 months'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS is defined as the time from randomization until objective tumor progression or death, whichever occurs first.', 'timeFrame': '9 months'}, {'measure': 'Overall Survival (OS)', 'description': 'The length of time from either the date of diagnosis or the start of treatment that patients diagnosed with the disease are still alive.', 'timeFrame': '9 months'}, {'measure': 'Functional Assessment of Cancer Therapy Kidney Symptom Index-19 (FKSI-19)', 'description': 'Patient quality of life measured by the FKSI-19. Total scale ranges from 0-76, with higher scores indicating fewer symptoms.', 'timeFrame': '9 months'}]",5,18 Years,99 Years,ALL,False,Icahn School of Medicine at Mount Sinai,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:23.454008,v2_robust,True,True,False,False,False,
NCT04999618,A New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology,"DOUBLE-SKIN: a New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology: a Randomised, Double-blind, Placebo-controlled Trial",Haemoblock,['Haemoblock'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Vascular Diseases,"['Vascular Diseases', 'Vascular Malformation', 'Capillary Malformation-Arteriovenous Malformation', 'Port-Wine Stain', 'Sturge-Weber Syndrome', 'Vascular Tumor']","['Vascular Diseases', 'Laser treatment', 'Capillary Malformation', 'Port-Wine Stain', 'Vascular Tumor']",COMPLETED,,2020-01-01,2021-10-27,"[{'measure': 'Preventing negative outcomes of postoperative infection', 'description': 'Validated scales', 'timeFrame': 'Early postoperative period and at 3 weeks'}]","[{'measure': 'Preventing prolonged functional recovery', 'description': 'Validated scales', 'timeFrame': 'Early postoperative period and at 3 weeks'}]",2,6 Months,18 Years,ALL,False,"Center for Vascular Pathology, Moscow",OTHER,0,200.0,ACTUAL,2025-09-01T16:18:23.454038,v2_robust,True,True,True,False,False,
NCT02482818,Efficacy of Pregabalin on Chronic Cough,"Efficacy of Pregabalin on Chronic Cough: A Double Blind, Randomized Control Trial Comparing Pregabalin With Placebo in Patients With Non-asthmatic Chronic Cough",Pregabalin,"['Pregabalin', 'Lactose Pills.', 'Control-Placebo']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Cough,['Cough'],"['chronic cough', 'cough hypersensitivity', 'Lyrica', 'Pregabalin', 'cough reflex sensitivity']",UNKNOWN,,2015-09,2021-12-31,"[{'measure': 'Determine the impact of pregabalin on a cough specific quality of life questionnaire (Leicester Cough Questionnaire)', 'description': 'All patients will be required to fill out the questionnaire in the follow up visits. This questionnaire is validated, reliable and subjective method for assessing the response to therapy', 'timeFrame': '42 days'}]","[{'measure': 'Evaluate the impact of pregabalin on cough reflex sensitivity, which can be objectively measured using citric acid cough challenge', 'description': 'Citric acid has been used extensively in the literature as an effective inhaled compound that can induce cough. The changes in the concentration of citric acid that can cause 2 or 5 consecutive coughs (C2 or C5) has been used to objectively determine the impact of various therapies on cough receptors.', 'timeFrame': '42 days'}]",2,18 Years,84 Years,ALL,False,Ottawa Hospital Research Institute,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:23.454048,v2_robust,True,True,False,False,False,
NCT02059018,The Mechanisms of Diameter Changes in Retinal Vessels During Hypoxia,The Underlying Mechanisms of Diameter Changes in Retinal Vessels During Hypoxia,COX-inhibitor,"['Nitroglycerin', 'Glyceryl Nitrate', 'Eye drops diclofenac 1mg/ml', 'COX-inhibitor', 'COX-inhibitor + Nitroglycerin', 'Voltaren eye drops']",6,INTERVENTIONAL,['NA'],,,Retinal Hypoxia,['Retinal Hypoxia'],[],COMPLETED,,2014-02,2015-08,"[{'measure': 'Diameter changes of retinal vessels', 'description': 'Comparing the differences of diameter changes occuring during each of interventions', 'timeFrame': 'Examination day 1 and 2'}]",[],1,20 Years,60 Years,ALL,True,University of Aarhus,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:23.454075,v2_robust,True,True,True,False,False,
NCT00374218,Effect of Replacing HFCS With Sucromalt in Subjects With Raised Waist Circumference,"Effect of Replacing HFCS With Sucromalt on Glucose Tolerance, Blood Lipids and Inflammatory Markers in Subjects With Raised Waist Circumference",High Fructose Corn Syrup,"['High Fructose Corn Syrup', 'Sucromalt']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Abdominal Obesity,['Abdominal Obesity'],"['Carbohydrate', 'Glycemic index', 'Randomized', 'Double-blind', 'Glucose', 'Insulin', 'C-reactive protein']",COMPLETED,,2006-09,2007-04,"[{'measure': 'Fasting and 2h glucose after 75g oral glucose tolerance test', 'timeFrame': '4 weeks'}]","[{'measure': 'Fasting and 2h insulin after 75g oral glucose', 'timeFrame': '4 weeks'}, {'measure': 'Gut hormone responses (eg. GLP-1) after 75g oral glucose', 'timeFrame': '4 weeks'}, {'measure': 'Postprandial glucose and insulin elicited by control and test foods/drinks', 'timeFrame': 'Baseline'}, {'measure': 'Fasting blood lipids (total, HDL and LDL cholesterol and triglycerides)', 'timeFrame': 'Baseline and 4 weeks'}, {'measure': 'Fasting C-reactive protein', 'timeFrame': 'Baseline and 4 weeks'}, {'measure': 'Fasting apolipoproteins A1 and B100', 'timeFrame': 'Baseline and 4 weeks'}, {'measure': 'Body weight', 'timeFrame': 'Weekly for 4 weeks'}, {'measure': 'Waist circumference', 'timeFrame': '4 weeks'}, {'measure': 'Blood pressure', 'timeFrame': '4 weeks'}, {'measure': 'Symptoms', 'timeFrame': '4 weeks'}]",11,20 Years,50 Years,ALL,True,University of Toronto,OTHER,0,28.0,ACTUAL,2025-09-01T16:18:23.454089,v2_robust,True,True,True,False,False,
NCT04484818,"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study",A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE),Darolutamide,"['Leuprorelin Acetate', 'Lucrin Depot', 'Darolutamide', 'Lupron Depot-3 Month', 'Leuplin', 'Procrin', 'Ginecrin', 'Lucrin', 'Lupron', 'Trenantone', '6-D-Tryptophan-LH-RH', 'Detryptoreline', 'Enantone-Gyn', 'Enantone', 'Abbott 43818', 'TAP-144', 'ZDX', 'Lupron Depot-Ped', 'ODM 201', 'Lupron Depot', 'Carcinil', 'Enanton', 'Triptorelin', 'Abbott-43818', 'ODM-201', 'Viadur', 'LEUP', 'Uno-Enantone', 'Lupron Depot-4 Month', 'Leuprolide Acetate', 'Zoladex', 'Eligard', 'BAY 1841788', 'Placebo Administration', 'AY-25650', 'CL-118,532', 'Lutrate', 'Antiandrogen ODM-201', 'BAY1841788', '6-D-Tryptophanluteinizing Hormone-releasing Factor', 'Procren', 'Goserelin Acetate', 'Depo-Eligard', 'A-43818', 'BAY-1841788', 'Prostap']",46,INTERVENTIONAL,['PHASE3'],PHASE3,,Prostate Carcinoma,['Prostate Carcinoma'],[],ACTIVE_NOT_RECRUITING,,2021-03-01,2028-05-31,"[{'measure': 'Metastasis-free survival (MFS)', 'description': 'The primary comparison will be an intention-to-treat analysis of all randomized patients. The method of Kaplan and Meier will be used to characterize the time-to-event endpoints, and a logrank test will be used to compare these endpoints across treatments.', 'timeFrame': 'From randomization to development of metastatic disease or death, whichever occurs first, assessed up to 36 months'}]","[{'measure': 'Recurrence-free survival (RFS)', 'description': 'The method of Kaplan and Meier will be used to characterize the time-to-event endpoints, and a logrank test will be used to compare these endpoints across treatments.', 'timeFrame': 'From randomization to any of the MFS events, pelvic lymph node recurrence or detectable prostate-specific antigen (PSA) (PSA >= 0.2 ng/mL, confirmed by a second PSA of the same level or higher), whichever occurs first, assessed up to 36 months'}, {'measure': 'Event-free survival', 'description': 'The method of Kaplan and Meier will be used to characterize the time-to-event endpoints, and a logrank test will be used to compare these endpoints across treatments.', 'timeFrame': 'From randomization to any of the RFS events, treatment with salvage radiation therapy with or without systemic therapy, or initiation of systemic therapy for presumed recurrence, whichever occurs first, assessed up to 36 months'}, {'measure': 'Overall survival', 'description': 'The method of Kaplan and Meier will be used to characterize the time-to-event endpoints, and a logrank test will be used to compare these endpoints across treatments.', 'timeFrame': 'From randomization to death by any cause or date last known alive, assessed up to 36 months'}, {'measure': 'Testosterone recovery rate', 'description': 'Exact binomial confidence intervals will be used to describe the proportions of patients with testosterone recovery in each arm.', 'timeFrame': 'At time of disease progression, assessed up to 36 months'}, {'measure': 'Time to testosterone recovery', 'description': 'The method of Kaplan and Meier will be used to characterize the time-to-event endpoints, and a logrank test will be used to compare these endpoints across treatments.', 'timeFrame': 'From randomization to a return of serum testosterone level to greater than or equal to lower limit of normal for the testosterone assay, assessed up to 36 months'}, {'measure': 'Incidence of adverse events', 'description': 'Toxicity will be defined using the Common Terminology Criteria for Adverse Events version 5.0.', 'timeFrame': 'Up to 78 weeks'}, {'measure': 'Change in quality of life: Functional Assessment of Cancer Therapy (FACT)', 'description': 'Will be assessed by the Functional Assessment of Cancer Therapy (FACT) - Prostate, FACT - Cognitive, and Functional Assessment of Chronic Illness Therapy - Fatigue. Fatigue instruments at baseline, 6, 12 and 18 months, and descriptive statistics will be used to characterize quality of life over time in each arm. Each item is answered on a 5-point Likert-type scale, where a value of 0 indicates the statement is not applicable, and a value of 5 indicates the statement is applicable to the respondent. Subgroup analysis will be performed among patients who receive adjuvant radiation therapy and patients who do not receive adjuvant radiation therapy in each arm. Mixed effect models will be constructed as an exploratory analysis to estimate the time profile of quality of life assessments in the two arms and to evaluate treatment-by-time interactions.', 'timeFrame': 'Baseline up to 18 months'}, {'measure': 'Overall quality of life: Functional Assessment of Cancer Therapy (FACT)', 'description': 'Will be assessed by the Functional Assessment of Cancer Therapy (FACT) - Prostate total score. The total score can range from 0 to 156, where a higher value indicates a better quality of life. Mixed effect models will be constructed as an exploratory analysis to estimate the time profile of quality of life assessments in the two arms and to evaluate treatment-by-time interactions.', 'timeFrame': 'At 18 months'}, {'measure': 'Change in Functional Assessment of Cancer Therapy (FACT) - Prostate score', 'description': 'A paired t test will be used to compare Functional Assessment of Cancer Therapy (FACT) - Prostate scores at these two time points in each arm. The total score can range from 0 to 156, where a higher value indicates a better quality of life. A two-sample t test will be performed to compare the changes in FACT - Prostate scores from baseline to 18 months between the two arms. Mixed effect models will be constructed as an exploratory analysis to estimate the time profile of quality of life assessments in the two arms and to evaluate treatment-by-time interactions.', 'timeFrame': 'Baseline up to 18 months'}]",10,18 Years,,MALE,False,ECOG-ACRIN Cancer Research Group,NETWORK,1,27.0,ACTUAL,2025-09-01T16:18:23.454116,v2_robust,True,True,False,False,True,
NCT00034918,This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer,"An Open-label, Multicenter Phase II Study to Assess the Response of Subjects With Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy With or Without Capecitabine to ZD6474 (100-mg or 300-mg Daily Oral Dose).",ZD6474,['ZD6474'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Neoplasms,"['Breast Neoplasms', 'Metastases, Neoplasm']",['Metastatic breast cancer'],COMPLETED,,2002-05,2003-11,[],[],0,18 Years,,FEMALE,False,"Genzyme, a Sanofi Company",INDUSTRY,0,44.0,,2025-09-01T16:18:23.454145,v2_robust,True,True,True,False,False,
NCT00446290,"Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer","A Phase I Study of Docetaxel, Capecitabine and Oxaliplatin (DXO) in Patients With Advanced Stomach Cancer","Docetaxel, Capecitabine and Oxaliplatin","['Docetaxel, Capecitabine and Oxaliplatin']",1,INTERVENTIONAL,['PHASE1'],PHASE1,,Stomach Cancer,['Stomach Cancer'],['To determine maximal tolerated dose of DXO regimen'],COMPLETED,,2006-03,2007-10,"[{'measure': 'Number of Participants With DLTs', 'description': 'Dose limiting toxicity (DLTs) was determined during the Wrst two cycles of treat- ment. The definitions of DLTs were as follows: (1) grade 4 neutropenia lasting for more than 5 days, or grade 3/4 neu- tropenia with fever; (2) grade 4 thrombocytopenia; (3) any other grade 3 non-hematological toxicity (excluding alope- cia); or (4) treatment delay of more than 2 weeks following the time of planned treatment. Maximal tolerated dose was defined as that the DLTs were observed in two or more patients from a cohort of two to six patients', 'timeFrame': '2 years'}]",[],1,18 Years,70 Years,ALL,False,Asan Medical Center,OTHER,0,22.0,ACTUAL,2025-09-01T16:18:23.454159,v2_robust,True,True,True,False,False,
NCT03679390,The Electroencephalogram and Clinical Effect of Ketamine,The Effect of Ketamine Between Generations in Operation Theater- Focus on Electroencephalogram Changes,Ketamine,"['Ketamine', 'control']",2,INTERVENTIONAL,['NA'],,,Electroencephalogram,"['Electroencephalogram', 'Consciousness, Loss of']",[],TERMINATED,no funding,2017-03-01,2020-09-01,"[{'measure': 'Ketamine increase the dissociation energy in EEG', 'description': 'ANOVA measurement', 'timeFrame': 'one year'}]",[],1,10 Years,,ALL,False,National Taiwan University Hospital,OTHER,0,17.0,ACTUAL,2025-09-01T16:18:23.454273,v2_robust,True,True,False,True,False,no funding
NCT02448290,"Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy","Phase II, Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy",docetaxel plus selumetinib,['docetaxel plus selumetinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastric Adenocarcinoma,['Gastric Adenocarcinoma'],"['gastric adenocarcinoma patients with low/high MEK signature,']",COMPLETED,,2014-11-12,2018-05-17,"[{'measure': 'response rate', 'timeFrame': '24 weeks'}]","[{'measure': 'duration of response', 'timeFrame': '24 weeks'}, {'measure': 'disease control rate', 'timeFrame': '8weeks'}, {'measure': 'overall survival', 'timeFrame': 'up to 100weeks'}, {'measure': 'progression-free survival', 'timeFrame': 'up to 100weeks'}, {'measure': 'safety assessed by safety( AEs/SAEs)', 'description': 'The following parameters will be recorded for each ECG: date and time of ECG, heart rate (beats/min), QT (ms), QTcB (ms), sinus rhythm (yes/no), and overall evaluation (normal/abnormal)', 'timeFrame': 'up to 100weeks'}]",6,20 Years,,ALL,False,Samsung Medical Center,OTHER,0,25.0,ACTUAL,2025-09-01T16:18:23.454306,v2_robust,True,True,True,False,True,
NCT04433390,Effect of Naloxegol on Postoperative Ileus in Patients Undergoing Cardiac Surgery,Time to Transit Recovery After Treatment With Naloxegol in Cardiac Surgery Intensive Care Trial,Naloxegol,"['Naloxegol', 'inert tablet']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Postoperative Ileus (Post Cardiac Surgery Constipation),['Postoperative Ileus (Post Cardiac Surgery Constipation)'],"['Opioid induced constipation', 'cardiac surgery', 'transit recovery']",COMPLETED,,2020-10-14,2022-03-03,"[{'measure': 'Evaluate the effect of perioperative naloxegol administration on the duration of postoperative ileus after cardiac surgery', 'description': 'Time (hour) to transit recovery after cardiac surgery', 'timeFrame': '5 days'}]","[{'measure': 'Incidence of digestive complications', 'description': 'rate of digestive complications', 'timeFrame': '30 days'}, {'measure': 'Evaluate the effect of the administration of Naloxegol on respiratory complications', 'description': 'rate of respiratory complications', 'timeFrame': '30 days'}, {'measure': 'Evaluate the effect of the administration of Naloxegol on infectious complications', 'description': 'rate of infectious complications', 'timeFrame': '30 days'}, {'measure': 'Verify the effectiveness of analgesia', 'description': 'Pain Visual Analogue Scale (VAS) ranging from 0 to 10 (0=no pain, 10=worst possible pain)', 'timeFrame': 'day 1, day2, day3'}, {'measure': 'Compare the length of hospital stay', 'description': 'Duration of hospital stay (days)', 'timeFrame': '30 days'}, {'measure': 'Compare the length of ICU stay', 'description': 'Duration of ICU stay (days)', 'timeFrame': '30 days'}]",7,18 Years,,ALL,False,CMC Ambroise Paré,OTHER,0,305.0,ACTUAL,2025-09-01T16:18:23.454340,v2_robust,True,True,True,False,False,
NCT00584090,Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease,,Solifenacin Succinate (VESIcare),"['Solifenacin Succinate (VESIcare)', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Urinary Incontinence,"['Urinary Incontinence', ""Parkinson's Disease""]","['urinary incontinence', ""parkinson's disease"", 'vesicare', 'solifenacin succinate']",WITHDRAWN,"Study withdrawn with intent of persuing larger, multi-site study.",2007-11,,"[{'measure': ""The primary purpose of this study is to measure the efficacy of solifenacin succinate (VESIcare) on treating urinary incontinence in Parkinson's disease patients."", 'timeFrame': '1 month'}]","[{'measure': ""The secondary objective of this study is to examine the effect of solifenacin succinate (VESIcare) on symptoms of PD and the patient's quality of life."", 'timeFrame': '1 month'}]",2,30 Years,80 Years,ALL,False,University of South Florida,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:23.454382,v2_robust,True,True,False,True,False,"Study withdrawn with intent of persuing larger, multi-site study."
NCT02554890,Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.,"A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril/Valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF).",sacubitril/valsartan (LCZ696),"['enalapril matching placebo', 'sacubitril/valsartan (LCZ696) matching placebo', 'Enalapril', 'sacubitril/valsartan (LCZ696)', 'LCZ696']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Acute Heart Failure,['Acute Heart Failure'],"['Acute', 'Heart Failure', 'reduced ejection fraction', 'NTproBNP', 'Heart failure with reduced ejection fraction (HFREF)']",COMPLETED,,2016-04-29,2018-07-24,"[{'measure': 'N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Time-averaged Change From Baseline', 'description': 'To assess the effect of in-hospital initiation of sacubitril/valsartan vs. enalapril on the time-averaged percentage change of NT-proBNP from baseline in patients who have been stabilized following hospitalization for ADHF and reduced ejection fraction (left ventricular ejection fraction \\[LVEF\\] ≤ 40%) between week 4 and 8.\n\nNumber of patients with both a baseline value and a value at Week 4 or Week 8. Plasma NT-proBNP (pg/mL) values were averaged from Week 4 and Week 8 visits. N-terminal pro b-type natriuretic peptide (NTproBNP) are peptide (small proteins) that are either hormones or part of the peptide that contained the hormone at one time. They are continually produced in small quantities in the heart and released in larger quantities when the heart senses that it needs to work harder, as in heart failure.', 'timeFrame': 'Baseline, Week 4 and Week 8'}]","[{'measure': 'Number of Patients With Incidences of Symptomatic Hypotension', 'description': ""Examine the effect of LCZ696 vs. enalapril on incidence of symptomatic hypotension during 8 weeks of treatment Hypotension is low blood pressure. Patients with hypotension may experience symptoms when their blood pressure drops, compared to the patient's normal values. Symptoms of hypotension can include dizziness, lightheadedness, blurred vision, weakness, fatigue, nausea, palpitations, and headache."", 'timeFrame': '8 weeks of treatment'}, {'measure': 'Number of Patients With Incidences of Hyperkalemia', 'description': ""Hyperkalemia is defined as Potassium level \\>5.5 mEq/L. Hyperkalemia is the medical term that describes a potassium level in your blood that's higher than normal. Potassium is a chemical that is critical to the function of nerve and muscle cells, including those in your heart."", 'timeFrame': '8 weeks of treatment'}, {'measure': 'Number of Patients With Incidences of Angioedema', 'description': 'Angioedema is a type of abrupt swelling that occurs under the skin and/or mucous membranes and is often localized to the head, neck, throat, and/or tongue, but may occur elsewhere, including the genitalia and intestines. Severe cases may be associated with difficulty in breathing.', 'timeFrame': '8 weeks of treatment'}, {'measure': 'Change From Baseline in High Sensitivity Troponin (Hs-Troponin)', 'description': 'time-averaged (Weeks 4 and 8) change from baseline in hs-troponin T. hs-Troponin-T is a biomarker that is released from the heart under stress or injury conditions.', 'timeFrame': 'Baseline, Week 4/Week 8'}, {'measure': 'Change From Baseline in Urinary cGMP', 'description': 'Time-averaged (Weeks 4 and 8) change from baseline in urinary cGMP. Urinary Cyclic GMP (cGMP) is a biomarker measured in the urine that reflects the activity of biomarkers such as BNP (Brain Natriuretic Peptide)', 'timeFrame': 'Baseline, Week 4 and Week 8'}, {'measure': 'Change From Baseline in Urinary cGMP to Urinary Creatinine Ratio', 'description': 'Time-averaged (Weeks 4 and 8) change from baseline in urinary cGMP to urinary creatinine ratio.\n\nUrinary cGMP to urinary creatinine ratio is how much urinary cGMP (which reflects natriuretic peptide activity) compared to a compound in the urine called creatinine (which helps your doctor evaluate how well your kidneys are functioning).', 'timeFrame': 'Baseline, Week 4 and Week 8'}, {'measure': 'Change From Baseline in BNP to NTproBNP Ratio', 'description': 'Time-averaged (Weeks 4 and 8) change from baseline in BNP to NT-proBNP ratio. BNP and NT-proBNP are small proteins produced in large amounts when the heart senses it needs to work harder, such as in heart failure. The test measuring BNP to NT-proBNP is measuring how much of each of these biomarkers are present in order to evaluate heart failure.', 'timeFrame': 'baseline, Week 4 and Week 8'}, {'measure': 'N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Change From Baseline at Week 8', 'description': 'BNP and NT-proBNP are small proteins produced in large amounts when the heart senses it needs to work harder, such as in heart failure. The test measuring BNP to NT-proBNP is measuring how much of each of these biomarkers are present in order to evaluate heart failure.\n\nPlasma NT-proBNP (pg/mL) values were Week 8 visit.', 'timeFrame': 'Baseline, Week 8'}]",9,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,887.0,ACTUAL,2025-09-01T16:18:23.454394,v2_robust,True,True,True,False,False,
NCT07016490,A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors,"A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SSGJ-709 in Patients With Advanced Malignant Tumors",SSGJ-709,['SSGJ-709'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Malignant Tumors,['Advanced Malignant Tumors'],[],RECRUITING,,2025-06-06,2027-12-30,"[{'measure': 'Incidence of DLT', 'description': 'Dose limiting toxicity', 'timeFrame': '21 days'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events', 'description': 'TEAE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.', 'timeFrame': 'through study completion, an average of 1 year'}]","[{'measure': 'Cmax of SSGJ-709', 'description': 'Peak Plasma Concentration', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Tmax of SSGJ-709', 'description': 'Time to peak drug concentration', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'AUC0-last of SSGJ-709', 'description': 'the area under the curve (AUC) up to the last measurable concentration', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Incidence of ADA', 'description': 'Number of subjects with detectable anti-drug antibodies (ADA)', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'ORR', 'description': 'ORR ( objective response rate) is the proportion of subjects with complete response(CR) or partial response(PR), evaluated by the investigators per RECIST v1.1', 'timeFrame': 'every 6 weeks after first dose, through study completion, an average of 1 year'}, {'measure': 'PFS assessed by investigator per RECIST v1.1', 'description': 'Progression-free survival (PFS) is defined as the time from the date of randomization till the first documentation of disease progression assessed by the investigator or death due to any cause (whichever occurs first).', 'timeFrame': 'through study completion, an average of 1 year'}]",8,18 Years,,ALL,False,"Shenyang Sunshine Pharmaceutical Co., LTD.",INDUSTRY,1,10.0,ESTIMATED,2025-09-01T16:18:23.454455,v2_robust,True,True,False,False,True,
NCT00001090,"A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers","A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205, Combined With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Healthy, HIV-1 Uninfected Volunteers",Sargramostim,['Sargramostim'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,HIV Infections,['HIV Infections'],"['Reference Values', 'Granulocyte-Macrophage Colony-Stimulating Factor', 'AIDS Vaccines', 'HIV Seronegativity', 'Dose-Response Relationship, Immunologic', 'HIV Preventive Vaccine']",COMPLETED,,,1999-10,[],[],0,18 Years,,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,36.0,,2025-09-01T16:18:23.454515,v2_robust,True,True,True,False,False,
NCT03481790,Lactoferrin Versus Ferrous Sulphate for Treatment of Iron Deficiency Anaemia During Pregnancy,The Effect of Orally Administered Iron-saturated Lactoferrin on Systemic Iron Homeostasis in Pregnant Women Suffering From Iron Deficiency and Iron Deficiency Anaemia,Lactoferrin,"['MamyVital', 'Lactoferrin', 'Pravotin', 'ferrous sulphate + folic acid (vitamin B9)', 'Ferrofol']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Iron Deficiency Anemia of Pregnancy,['Iron Deficiency Anemia of Pregnancy'],['iron deficiency anemia of pregnancy - lactoferrin'],COMPLETED,,2017-09-01,2018-03-05,"[{'measure': 'Hemoglobin (Hb) level.', 'description': 'to be measured before and after treatment.', 'timeFrame': '4 weeks'}]","[{'measure': 'serum ferritin level.', 'description': 'to be measured before and after treatment.', 'timeFrame': '4 weeks'}]",2,20 Years,35 Years,FEMALE,False,Ain Shams Maternity Hospital,OTHER,0,200.0,ACTUAL,2025-09-01T16:18:23.454535,v2_robust,True,True,True,False,False,
NCT06049290,A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma,"A Multicenter, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-034 in Patients With Relapsed/Refractory Multiple Myeloma",LBL-034 for Injection,"['LBL-034', 'LBL-034 for Injection']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Relapsed/Refractory Multiple Myeloma,['Relapsed/Refractory Multiple Myeloma'],[],RECRUITING,,2023-10-20,2027-05-20,"[{'measure': 'Objective Response Rate (ORR)', 'description': 'ORR \\[including the rates of Strin-gent complete response(sCR),complete response (CR) ,Very good partial response(VGPR),and partial response (PR)\\], evaluated based on the 2016 IMWG criteria(Cohorts 1, 2, and 3) and 2013 IMWG criteria(Cohort 4), refers to the percentage of study subjects who achieve a complete response or partial response. It was used to evaluate the efficacy of LBL-034 in Phase IIa study .', 'timeFrame': 'From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy).'}, {'measure': 'Dose-limiting toxicities（DLT）', 'description': 'DLT describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.DLT is defined as toxicity (possible adverse events related to LBL-034) during the DLT observation period . It was used to evaluate the safety of LBL-034 in Phase I study .', 'timeFrame': 'The DLT observation period starts from the first dose until 4 weeks after the full dose first administration (including the step-up dosing period, if any).'}, {'measure': 'Maximum tolerated dose (MTD)', 'description': 'MTD is defined as the hightest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first cycles. It was used to evaluate the tolerability in Phase I.', 'timeFrame': 'The MTD observation period starts from the first dose until 4 weeks after the full dose first administration (including the step-up dosing period, if any).'}]","[{'measure': 'Cmax', 'description': 'Maximum drug concentration in plasma after administration.', 'timeFrame': 'From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)'}, {'measure': 'Tmax', 'description': 'After administration,Time to reach maximum drug concentration in plasma.', 'timeFrame': 'From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)'}, {'measure': 'Immunogenicity', 'description': 'The immunogenicity is evaluated by the incidence of anti-drug antibodies (ADA) and neutralizing antibodies (if applicable) in subjects.Immunogenicity refers to the performance that can elicit an immune response.', 'timeFrame': 'From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)'}, {'measure': 'Minimal Residual Disease (MRD)', 'description': 'MRD-negative rate: Refers to the percentage of subjects who achieve MRD negativity at any time point after the initial dose and before disease progression or the initiation of a new anti-tumor therapy.', 'timeFrame': 'From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)'}, {'measure': 'Duration of Response(DOR）', 'description': 'DOR is defined as the duration from earliest date of disease response (CR、PR 、iCR or iPR) until earliest date of disease progression or death from any cause(if occurring sooner than progression).', 'timeFrame': 'From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)'}, {'measure': 'sBCMA', 'description': 'serum B-cell maturation antigen(Detect the change of sBCMA in serum)', 'timeFrame': 'From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)'}]",9,18 Years,,ALL,False,"Nanjing Leads Biolabs Co.,Ltd",INDUSTRY,0,342.0,ESTIMATED,2025-09-01T16:18:23.454544,v2_robust,True,True,False,False,True,
NCT06834490,Safety and Efficacy of Sequential Treatment with Mexidol® in Patients with Chronic Cerebral Ischemia,"International Multicenter Randomized Double-blind Placebo-controlled Adaptive Design Study to Evaluate Safety and Efficacy of Sequential Treatment with Mexidol® Solution for Intravenous and Intramuscular Administration, 50 Mg/ml (OOO ""NPK ""PHARMASOFT"", Russia) and Mexidol® FORTE 250 Film-coated Tablets, 250 Mg (OOO ""NPK ""PHARMASOFT"", Russia) in Patients with Chronic Cerebral Ischemia (MEMO)",Mexidol,"['Ethylmethylhydroxypyridine Succinate', 'Mexidol', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Cerebral Ischemia,['Chronic Cerebral Ischemia'],"['Chronic Cerebral Ischemia', 'CCI', 'Ischemia', 'Cerebral', 'Brain', 'Stroke', 'Cognitive', 'Neurobehavioral Manifestations', 'Neuroprotection', 'Mexidol', 'Ethylmethylhydroxypyridine Succinate', 'Cerebrovascular Disorders', 'Antioxidant Therapy', 'Stroke Recovery', 'Central Nervous System Disorders', 'Chronic Brain Hypoxia', 'Post-stroke Cognitive Impairment', 'Cognitive Impairment', 'Neurodegenerative', 'Neurodegenerative Processes', 'Neurological Rehabilitation', 'Oxidative Stress', 'Oxidative Stress Reduction', 'Energy Metabolism Enhancement', 'Central Nervous System', 'Cerebral Hypoxia']",COMPLETED,,2019-11-05,2020-12-08,"[{'measure': 'Mean Score of Montreal Cognitive Assessment (MoCA) at Visit 5 in comparison with reference score at Visit 0', 'description': 'The Montreal Cognitive Assessment (MoCA) is used to measure the degree of cognitive impairment in patients with CCI. MoCA scores range between 0 and 30. A score of 26 or over is considered to be normal. Higher score than shown at Visit 0 is expected after treatment.', 'timeFrame': 'up to 83 days'}]","[{'measure': 'Changes in the severity of cognitive impairment assessed with the Montreal Cognitive Assessment scale between Visit 0 and Visits 2 and 4', 'description': 'The Montreal Cognitive Assessment (MoCA) is used to measure the changes in the severity of cognitive impairment at Visits 2 and 4 in comparison to Visit 0. MoCA scores range between 0 and 30. A score of 26 or over is considered to be normal. Higher score than shown at Visit 0 is expected.', 'timeFrame': 'up to 83 days'}, {'measure': ""Changes in patients' quality of life assessed with SF-36 questionnaire"", 'description': 'The SF-36 questionnaire is used between Visit 1 and Visits 2, 4, 5. The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. To score the SF-36, scales are standardized with a scoring algorithm or by the SF-36v2 scoring software to obtain a score ranging from 0 to 100. Higher scores indicate better health status, and a mean score of 50 has been articulated as a normative value for all scales.', 'timeFrame': 'up to 83 days'}, {'measure': 'Changes in the severity of asthenia assessed with the Multidimensional Fatigue Inventory (MFI-20)', 'description': 'The Multidimensional Fatigue Inventory (MFI-20) is used between Visit 1 and Visits 2, 4, 5. MFI-20 is a 20-item self-administered questionnaire designed to measure fatigue in five four-item subscales: General fatigue, Physical fatigue, Reduced activity, Reduced motivation and Mental fatigue. MFI-20 has an even proportion of positively and negatively worded items that are rated on a 5-point Likert scale. Subscale scores (range 4-20) are calculated as the sum of item ratings and a total fatigue score (range 20-100) is calculated as the sum of subscale scores. Higher scores indicate a higher level of fatigue.', 'timeFrame': 'up to 83 days'}, {'measure': 'Changes in the anxiety level according to the Beck Anxiety Inventory', 'description': 'The Beck Anxiety Inventory (BAI) consists of 21 self-reported items (four-point scale) used to assess the intensity of physical and cognitive anxiety symptoms during the past week. Scores may range from 0 to 63: minimal anxiety levels (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63).', 'timeFrame': 'up to 83 days'}, {'measure': ""Autonomic changes according to the A.M.Wein's questionnaire"", 'description': ""The A.M.Wein's questionnaire is used between Visit 1 and Visit 2, 4, 5. It includes 11 main signs of autonomic disorders. Each autonomic symptom is assessed using scores from 7 to 3. The total sum of the scores reflects the degree of the severity of vegetative dystonia."", 'timeFrame': 'up to 83 days'}, {'measure': 'Changes in cognitive impairment assessed with Digit Symbol Substitution Test', 'description': 'The Digit Symbol Substitution Test is used between Visit 1 and Visits 2, 4, 5. The DSST is used to measure attention, processing speed and executive function.\n\nIt is a pencil and paper test of psychomotor performance in which the subject is given a key grid of numbers and matching symbols and a test section with numbers and empty boxes. The test consists of filling as many empty boxes as possible with a symbol matching each number. The score is the number of correct number-symbol matches achieved in 90 s.', 'timeFrame': 'up to 83 days'}, {'measure': 'Motor changes assessed with the Tinetti test', 'description': 'The Tinetti test is used between Visit 1 and Visits 2, 4, 5. The Tinetti test is a clinical test for the assessment of balance and gait. It has a gait score and a balance score using a 3-point ordinal scale of 0, 1 and 2. Gait is scored over 12 and balance is scored over 16 totalling 28. The lower the score on the Tinetti test, the higher the risk of falling.', 'timeFrame': 'up to 83 days'}, {'measure': 'Changes in global illness severity assessed with the Clinical Global Impressions Scale', 'description': ""The Clinical Global Impressions (CGI) Scale is used between Visit 1 and Visits 2, 5. The CGI Scale is a standardized assessment tool used to rate the severity of illness, change over time, and efficacy of medication. It consists of 3 subscales. The first one, Severity of Illness, which is often used both before and after treatment, is a 7-point scale that rates the severity of the patient's mental illness at the time of assessment as: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. The second subscale, Clinical Global Impression-Improvement (CGI-I), is also a 7-point scale that assesses how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention, and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse."", 'timeFrame': 'up to 83 days'}]",9,40 Years,90 Years,ALL,False,Pharmasoft,INDUSTRY,0,318.0,ACTUAL,2025-09-01T16:18:23.454566,v2_robust,True,True,True,False,False,
NCT02978690,Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis,"Multi-centre, Open-label, Single Arm, Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacogenomics and Efficacy of a Single Intravenous Dose of Spesolimab in Patients With Active Generalized Pustular Psoriasis",Spesolimab,"['BI 655130', 'Spesolimab']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Psoriasis,['Psoriasis'],[],COMPLETED,,2016-12-19,2018-01-10,"[{'measure': 'Percentage of Patients With Adverse Reactions, Defined as Drug-related Adverse Events (AE)', 'description': 'Percentage of patients with adverse reactions, defined as drug-related Adverse Events is presented.', 'timeFrame': 'Up to 140 days from the administration of spesolimab.'}]","[{'measure': 'Percent Change From Baseline in Generalized Pustular Psoriasis Area and Severity Index (GPPASI) Total Score at Week 2', 'description': 'The GPPASI is an adaptation for Generalized Pustular Psoriasis (GPP) patients of the Psoriasis Area and Severity Index (PASI), an established measure of severity and area of psoriatic lesions in patients with psoriasis. It is a tool which provides a numeric scoring for patients overall GPP disease state, ranging from 0 (no disease) to 72 (worse disease state). It is a linear combination of percent of surface area of skin that is affected and the severity of erythema, pustules, and scaling (desquamation) over four body regions. % GPPASI change from baseline=100\\* (GPPASI at baseline - GPPASI at post-baseline visit)/(GPPASI at baseline). For %GPPASI change, positive numbers show reduction in GPPASI with higher values representing a larger improvement or recovery of disease, while negative numbers show an increase in GPPASI, i.e. worsening of disease.', 'timeFrame': 'At baseline and at Week 2.'}, {'measure': 'Proportion of Patients With Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Total Score of 0 (Clear) or 1 (Almost Clear) at Week 2', 'description': ""GPPGA relies on clinical assessment of the GPP patient's skin presentation. It is a modified Physician Global Assessment (PGA), a physician's assessment of psoriatic lesions, which has been adapted to the evaluation of GPP patients.\n\nThe investigator (or qualified site personnel) scores the erythema, pustules and scaling of all psoriatic lesions from 0 - 4. Each component is graded separately, the average is calculated and the final GPPGA is determined from this composite score. A lower score then indicates a lesser severity, with 0 being clear and 1 being almost clear. To receive a score of 0 or 1, the patient should be afebrile, in addition to skin presentation requirements."", 'timeFrame': 'At Week 2.'}, {'measure': 'Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score at Week 2', 'description': 'Change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale scale score at Week 2 is presented.\n\nThe FACIT-Fatigue scale is a brief and reliable instrument for monitoring fatigue and its effects on patients. It is a comprehensive compilation of questions that measure health-related quality of life in patients with chronic illnesses. It comprises 13 questions, the responses to which are each recorded on a 5-point Likert scale. Scores range from 0 to 52, with lower scores representing greater fatigue, i.e. higher changes from baseline indicate higher improvement (compared to baseline)', 'timeFrame': 'At baseline and at Week 2.'}, {'measure': 'Change From Baseline in Pain Visual Analog Scale (VAS) Score at Week 2', 'description': ""The pain VAS is a unidimensional measure of pain intensity. It is a continuous scale comprised of a horizontal or vertical line, usually 10 centimeters (100 millimeters (mm) in length, anchored by word descriptors at each end ('no pain', 'very severe pain'). The pain VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the 'no pain' anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity, i.e., a negative change from baseline indicates an improvement (compared to baseline)."", 'timeFrame': 'At baseline and at Week 2.'}, {'measure': 'Area Under the Concentration-time Curve of Spesolimab in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)', 'description': 'Area under the concentration-time curve of spesolimab in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported.', 'timeFrame': 'Within 1.5 hours (h) before and 0.5 h, 24 h, 48 h, 72 h, 96 h, 120 h, 144 h, 312 h, 480 h, 648 h, 1992 h, 3336 h after spesolimab administration.'}, {'measure': 'Maximum Measured Concentration of Spesolimab in Plasma (Cmax)', 'description': 'Maximum measured concentration of spesolimab in plasma (Cmax) is reported.', 'timeFrame': 'Within 1.5 hours (h) before and 0.5 h, 24 h, 48 h, 72 h, 96 h, 120 h, 144 h, 312 h, 480 h, 648 h, 1992 h, 3336 h after spesolimab administration.'}]",7,18 Years,75 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,7.0,ACTUAL,2025-09-01T16:18:23.454635,v2_robust,True,True,True,False,True,
NCT05746897,"A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors","A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors",NM1F Injection,"['NM1F Injection', 'Pembrolizumab injection']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Ovarian Cancer,"['Ovarian Cancer', 'Melanoma', 'Triple Negative Breast Cancer', 'Colorectal Cancer']",['solid tumors，NM1F，Pembrolizumab'],RECRUITING,,2023-04-13,2027-09-30,"[{'measure': 'Dose-limiting Toxicity (DLT)', 'description': 'The incidence of DLTs during the DLT assessment period.', 'timeFrame': 'First 21 days of treatment.'}, {'measure': 'Dose-Finding', 'description': 'Determination of the MTD or maximum tested dose, and the RP2D.', 'timeFrame': 'Approximately 3 years.'}, {'measure': 'Frequency and Severity of Adverse Events (AE)', 'description': 'The incidences and percentages of patients experiencing AEs summarized by NCI CTCAE version 5.0 grade and by causality.', 'timeFrame': 'Screening to 30 days from last dose'}]","[{'measure': 'Pharmacokinetics of NM1F', 'description': 'Maximum Plasma Concentration (Cmax)', 'timeFrame': 'Day 1 of dosing through 30 days post last dose'}, {'measure': 'Pharmacokinetics of NM1F', 'description': 'Area Under the Curve (AUC)', 'timeFrame': 'Day 1 of dosing through 30 days post last dose'}, {'measure': 'Number of subjects with Anti-NM1F antibody positive .', 'description': 'Immunogenicity of NM1F monotherapy and in combination with pembrolizumab', 'timeFrame': 'Day 1 of dosing through 30 days post last dose'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'ORR according to RECIST v1.1.', 'timeFrame': 'Approximately 3 years.'}, {'measure': 'Duration of Response (DoR)', 'description': 'Time from the date measurement criteria are first met for PR or CR to the date measurement criteria are first met for progressive disease.', 'timeFrame': 'Approximately 3 years.'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'The proportion of subjects who have best overall response of CR or PR, or stable disease (SD).', 'timeFrame': 'Approximately 3 years.'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'Time from the date of initiation of study therapy to the date measurement criteria are first met for progressive disease or death from any cause, whichever occurs first.', 'timeFrame': 'Approximately 3 years.'}, {'measure': 'Overall Survival (OS)', 'description': 'Time from the date of initiation of study therapy to the date of death from any cause.', 'timeFrame': 'Approximately 3 years.'}]",11,18 Years,,ALL,False,"Hefei TG ImmunoPharma Co., Ltd.",OTHER,0,38.0,ESTIMATED,2025-09-01T16:18:23.454666,v2_robust,True,True,False,False,True,
NCT05024097,A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.,A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.,Etrumadenant (AB928),"['FOLFOX regimen', 'Zimberelimab (AB122)', 'Etrumadenant (AB928)']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Rectal Cancer,['Rectal Cancer'],[],RECRUITING,,2022-03-31,2030-12,"[{'measure': 'Number of treated patients who achieve complete pathologic response', 'description': 'The primary endpoint is the proportion of treated rectal cancer patients who achieve a complete pathologic response.\n\nAll patients will be offered surgical resection however those who achieve a clinical CR at the time of clinical response assessment may choose a non-operative management approach. Due to practicality the latter will be included as complete responders at the time of analysis for this trial.', 'timeFrame': 'Week 24'}]","[{'measure': 'Number of patients who experience treatment-related adverse events', 'description': 'Number of patients with treatment-related early and late adverse events as assessed by the CTCAE version 5.0', 'timeFrame': 'Day 5 of radiation therapy'}, {'measure': 'Number of patients who experience treatment-related adverse events', 'description': 'Number of patients with treatment-related early and late adverse events as assessed by the CTCAE version 5.0', 'timeFrame': '3 months'}, {'measure': 'Number of patients who experience treatment-related adverse events', 'description': 'Number of patients with treatment-related early and late adverse events as assessed by the CTCAE version 5.0', 'timeFrame': '6 months'}, {'measure': 'Number of patients who experience treatment-related adverse events', 'description': 'Number of patients with treatment-related early and late adverse events as assessed by the CTCAE version 5.0', 'timeFrame': '12 months'}, {'measure': 'Number of patients who experience treatment-related adverse events', 'description': 'Number of patients with treatment-related early and late adverse events as assessed by the CTCAE version 5.0', 'timeFrame': '60 months'}, {'measure': 'Progression free survival', 'description': 'PFS is defined as the duration of time from start of treatment to time of progression.', 'timeFrame': '36 months'}, {'measure': 'Overall survival', 'description': 'Overall Survival is defined as the duration of time from start of treatment until death.', 'timeFrame': '60 months'}]",8,18 Years,90 Years,ALL,False,Weill Medical College of Cornell University,OTHER,1,43.0,ESTIMATED,2025-09-01T16:18:23.454723,v2_robust,True,True,False,False,True,
NCT02481297,"Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients","Lirilumab (Anti-KIR mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",Lirilumab,"['Rituxan', 'Rituximab', 'Lirilumab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Leukemia,"['Leukemia', 'Chronic Lymphocytic Leukemia', 'Lymphocytic Leukemia']","['Leukemia', 'Chronic Lymphocytic Leukemia', 'CLL', 'Refractory/Relapsed', 'Untreated with high-risk molecular features', 'Small lymphocytic leukemia', 'SLL', 'Lirilumab', 'Rituximab', 'Rituxan']",COMPLETED,,2015-06-23,2019-08-15,"[{'measure': 'Participants With a Response', 'description': 'Response is defined as complete remission (CR), complete remission with incomplete marrow recovery (CRi) or partial remission (PR) that occurs during the first 6 months of therapy. CR requires the absence of peripheral blood clonal lymphocytes by immunophenotyping, absence of lymphadenopathy, absence of hepatomegaly or splenomegaly, absence of constitutional symptoms and satisfactory blood counts. CRi is Complete remission with incomplete bone marrow recovery. PR, defined as ≥ 50% fall in lymphocyte count, ≥ 50% reduction in lymphadenopathy or ≥ 50% reduction in liver or spleen, together with improvement in peripheral blood counts', 'timeFrame': '6 months'}]","[{'measure': 'Overall Survival', 'description': 'Time from date of treatment start until date of death due to any cause or last Follow-up.', 'timeFrame': 'Up to 4 years'}, {'measure': 'Progression Free Survival', 'description': 'Time from date of treatment start until the date of first objective documentation of disease-relapse.', 'timeFrame': 'Up to 4 years'}]",3,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,7.0,ACTUAL,2025-09-01T16:18:23.454885,v2_robust,True,True,True,False,False,
NCT00368797,Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease,"A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.",XRP0038 (NV1FGF),['XRP0038 (NV1FGF)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Peripheral Arterial Disease,['Peripheral Arterial Disease'],"['Gene Therapy', 'PAOD', 'CLI']",COMPLETED,,2002-03,2005-04,"[{'measure': 'Primary efficacy parameter: ulcer healing.'}, {'measure': 'Ulcers will be evaluated at each visit primarily by collecting quantitative and qualitative information.'}]","[{'measure': 'Hemodynamic parameters:ABI, TcPO2'}, {'measure': 'Pain'}, {'measure': 'Amputation (Date of amputation, Indication for amputation, amputation level (minor and major)'}, {'measure': 'Death'}]",6,40 Years,,ALL,False,Sanofi,INDUSTRY,0,125.0,ACTUAL,2025-09-01T16:18:23.454948,v2_robust,True,True,True,False,False,
NCT01009697,Dose Linearity Study of Codeine Sulfate Under Fasted Conditions,"A Single Dose, 3-Period, 3-Treatment, 6-Sequence, 3-Way Crossover Study of the Dose Linearity of Codeine Sulfate Tablets Under Fasting Conditions",Codeine Sulfate,['Codeine Sulfate'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Pain,['Pain'],[],COMPLETED,,2008-03,2008-04,"[{'measure': 'bioequivalence determined by statistical comparison Cmax', 'timeFrame': '21 Days'}]",[],1,18 Years,45 Years,ALL,True,Roxane Laboratories,INDUSTRY,0,34.0,ACTUAL,2025-09-01T16:18:23.454960,v2_robust,True,True,True,False,False,
NCT02355197,Antioxidants in Gestational Diabetes,Physiological Effects of Gestational Diabetes on the Placenta and Neonatal Outcome; Role of Antioxidant Administration,L-ascorbic acid,"['L-ascorbic acid', 'vitamin C']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Gestational Diabetes Mellitus,['Gestational Diabetes Mellitus'],"['antioxidants', 'Gestational diabetes mellitus', 'oxidative stress']",COMPLETED,,2013-01,2015-02,"[{'measure': 'neonatal outcome assessed by neonatal ICU admission', 'timeFrame': '1 week after delivery'}]","[{'measure': 'oxidative stress parameters: non enzymatic and enzymatic oxidative stress parameters in placental tissue homogenates in women with GDM named glutathione ,malondialdahyde,superoxide dismutase ,catalase and glutathione peroxidase', 'timeFrame': '9 months of pregnancy'}, {'measure': 'oxidative stress parameters: non enzymatic and enzymatic oxidative stress parameters in maternal blood plasma/lysate in women with GDM named glutathione,superoxide dismutase ,catalase and glutathione peroxidase', 'timeFrame': '9 months of pregnancy'}, {'measure': 'oxidative stress parameters: non enzymatic and enzymatic oxidative stress parameters in neonatal blood in women with GDM named malondialdahyde and superoxide dismutase', 'timeFrame': '9 months of pregnancy'}]",4,20 Years,40 Years,FEMALE,False,Cairo University,OTHER,0,200.0,ACTUAL,2025-09-01T16:18:23.454968,v2_robust,True,True,True,False,False,
NCT00124397,Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study),Effect of High Dose Statin Therapy on Endothelial Function in Patients With Type 2 Diabetes Mellitus Without CAD,Atorvastatin,['Atorvastatin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],[],COMPLETED,,2001-07,2004-12,[{'measure': 'Flow mediated vasodilatation (FMD) on atorvastatin'}],"[{'measure': 'FMD on combined treatment'}, {'measure': 'FMD in relation to lipid levels'}, {'measure': 'FMD in relation to BP lowering'}, {'measure': 'CV events'}]",5,0 Years,,ALL,False,University of Southern Denmark,OTHER,1,186.0,,2025-09-01T16:18:23.455012,v2_robust,True,True,True,False,False,
NCT04182997,Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy,Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy for Herniated Lumbar Discs Is There a Role? - A Randomized Control Trial,Dexamethasone,"['Dexamethasone', 'saline 0.9%', 'Decadron', 'sterile saline']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Lumbar Disc Herniation,['Lumbar Disc Herniation'],[],RECRUITING,,2019-11-21,2026-10,"[{'measure': 'Post Operative Pain Scores', 'description': 'Comparing post operative pain scores between treatment and placebo group. Using Visual Analogue Scale (VAS) pain score with scale 0 to 10 with 0 being no pain and 10 being the worst pain of your life.', 'timeFrame': 'Until final follow up (up to 8 weeks)'}, {'measure': 'Post Operative Oswestry Disability Index', 'description': ""Comparing post operative disability scores between treatment and placebo group. Using Oswestry Disability Index (ODI) to measure a patient's permanent functional disability and low back functional outcome tools."", 'timeFrame': 'Until final follow up (up to 8 weeks'}]","[{'measure': 'Length of stay', 'description': 'Determining how long patient is in hospital', 'timeFrame': 'Until final follow up (up to 8 weeks)'}, {'measure': 'Post Operative Opioid Usage', 'description': 'comparing opioid usage post operatively', 'timeFrame': 'Until final follow up (up to 8 weeks)'}, {'measure': 'Post Operative Complications', 'description': 'comparing rate of post-op infections', 'timeFrame': 'Until final follow up (up to 8 weeks)'}]",5,18 Years,,ALL,False,University of Missouri-Columbia,OTHER,0,200.0,ESTIMATED,2025-09-01T16:18:23.455035,v2_robust,True,True,False,False,False,
NCT00574197,Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients,Assessment of Gastrointestinal Tolerability and Efficacy of Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients,Mycophenolate Sodium,"['Myfortic', 'Mycophenolate Sodium']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Gastrointestinal Symptoms,"['Gastrointestinal Symptoms', 'Heart Transplantation']","['Heart Transplant', 'gastrointestinal', 'Cellcept', 'Myfortic', 'GI', 'GI symptoms with Mycophenolate Mofetil post heart transplant']",COMPLETED,,2006-06,2009-12,"[{'measure': 'GI Tolerability as Measured by GSRS', 'description': 'Side-effects using the GSRS (Gastrointestinal Symptoms Rating Scale)\n\nGSRS has 15 items, each rated on a 7-point scale from 1 (no discomfort) to 7 (very severe discomfort). GSRS total minimum value is 15; maximum value is 105. Higher scores represent greater discomfort.', 'timeFrame': 'Baseline and 6 months'}]","[{'measure': 'Number of Biopsy Proven Acute Rejection, Graft Loss and Death Due to Rejection.', 'description': 'Number of biopsy proven acute rejection, graft loss, and death due to rejection.\n\nNumber of rejection episodes where rejection is defined as Grade 1B or higher on myocardial biopsy as measured by the 1990 Grading System of the International Society of Heart and Lung Transplantation for Acute Cellular Rejection. Grading system has:\n\n* grade 0 (no acute rejection)\n* grade 1A (Focal, mild acute rejection)\n* grade 1B (Diffuse, mild acute rejection)\n* grade 2 (Focal, moderate acute rejection)\n* grade 3A (multifocal moderate rejection)\n* grade 3B (Diffuse, borderline severe acute rejection)\n* grade 4 (Severe acute rejection).', 'timeFrame': '6 months'}]",2,18 Years,,ALL,False,Cedars-Sinai Medical Center,OTHER,1,11.0,ACTUAL,2025-09-01T16:18:23.455053,v2_robust,True,True,True,False,False,
NCT04825197,Late Surfactant After a Recruitment Maneuver in Extremely Low Gestational Age Newborns - LATE-REC-SURF Trial,Effects of Late Surfactant Treatment Delivered After a Recruitment Maneuver on Respiratory Outcomes in Extremely Low Gestational Age Newborns: a Randomized Controlled Trial - LATE-REC-SURF Trial,Poractant Alfa Intratracheal Suspension [Curosurf],"['Poractant Alfa Intratracheal Suspension [Curosurf]', 'Surfactant endotracheal administration following a recruitment HFOV manoeuvre']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Bronchopulmonary Dysplasia,"['Bronchopulmonary Dysplasia', 'Chronic Pulmonary Insufficiency of Prematurity']","['surfactant', 'preterm', 'recruitment', 'bronchopulmonary dysplasia', 'hfov']",UNKNOWN,,2021-12-01,2025-02-01,"[{'measure': 'First successful extubation', 'description': 'The time to first successful extubation ( expressed as day of life).', 'timeFrame': 'From date of randomization until the date of first documented progression, assessed up to 40 weeks of post menstrual age'}]","[{'measure': 'Rate of Bronchopulmonary dysplasia', 'description': 'Oxygen-dependance at 36 weeks of post-menstrual age', 'timeFrame': 'At 36 weeks of post-menstrual age'}, {'measure': 'Rate of Interstitial emphysema', 'description': 'Xray-documented', 'timeFrame': 'In the 21 days following experimental treatment'}, {'measure': 'Rate of Pneumothorax', 'description': 'Ultrasound or Xray-documented', 'timeFrame': 'In the 21 days following experimental treatment'}, {'measure': 'Rate of Pulmonary haemorrhage', 'description': 'Clinically diagnosed', 'timeFrame': 'In the 21 days following experimental treatment'}, {'measure': 'Rate of Necrotising enterocolitis', 'description': ""Bell's Criteria"", 'timeFrame': 'Up to 40 weeks post-mestrual age'}, {'measure': 'Rate of intraventricular haemorrhage', 'description': ""Ultrasound documented intraventricular haemorrhage of any grade (Volpe's classification)"", 'timeFrame': 'From date of randomization - up to 40 weeks post-mestrual age'}, {'measure': 'Rate of Periventricular leukomalacia', 'description': ""Ultrasound documented periventricular leukomalacia (DeVries's classification)"", 'timeFrame': 'From date of randomization up to 40 weeks post-mestrual age'}, {'measure': 'Length of hospital stay', 'description': 'Number of days of hospital stay', 'timeFrame': 'Through study completion, an average of 1 year'}, {'measure': 'Length of invasive mechanical ventilation', 'description': 'Number of days of invasive mechanical ventilation', 'timeFrame': 'Up to 40 weeks post-mestrual age'}, {'measure': 'Length of oxygen-therapy', 'description': 'Number of days of oxygen-therapy', 'timeFrame': 'Up to 40 weeks post-mestrual age'}, {'measure': 'Length of respiratory support', 'description': 'Number of days of respiratory support', 'timeFrame': 'Up to 40 weeks post-mestrual age'}, {'measure': 'Use of postnatal steroids', 'description': 'Use of postnatal steroids to prevent or treat bronchopulmonary dysplasia', 'timeFrame': 'Up to 40 weeks post-mestrual age'}, {'measure': 'Rehospitalisation for respiratory problems in the first year of life', 'description': 'Number of rehospitalisation for respiratory problems in the first year of life', 'timeFrame': 'One year of life'}]",14,7 Days,10 Days,ALL,False,VENTO GIOVANNI,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:23.455127,v2_robust,True,True,False,False,False,
NCT04026997,A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Dose Response of Oral CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis",CIN-102 Dose 1,"['CIN-102 Dose 1', 'CIN-102 Dose 3', 'Placebo', 'CIN-102 Dose 2']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastroparesis,['Gastroparesis'],[],COMPLETED,,2019-09-11,2020-12-17,"[{'measure': 'Change from baseline in gastric emptying', 'timeFrame': 'Baseline (gathered on Days -10 to -3) to Day 14'}]","[{'measure': 'Change from baseline in gastric emptying terminal phase elimination half life', 'timeFrame': 'Baseline (gathered on Days -10 to -3) to Day 14'}, {'measure': 'The change from baseline in ANMS GCSI-DD total scores', 'timeFrame': 'Day -14 to 14'}, {'measure': 'The change from baseline in ANMS GCSI-DD subscale scores', 'timeFrame': 'Day -14 to 14'}]",4,18 Years,70 Years,ALL,False,"CinDome Pharma, Inc.",INDUSTRY,0,73.0,ACTUAL,2025-09-01T16:18:23.455161,v2_robust,True,True,True,False,False,
NCT05274997,A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma,"A Single-arm, Phase II Study to Evaluate the Efficacy and Safety of Linperlisib (YY-20394) Monotherapy in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma",YY-20394,"['YY-20394', 'Linperlisib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Peripheral T/NK Cell Lymphoma (R/R PTCL),['Peripheral T/NK Cell Lymphoma (R/R PTCL)'],[],UNKNOWN,,2022-05-01,2023-12-01,"[{'measure': 'overall response rate (ORR)', 'description': 'Overall response rate (ORR = CR + PR), from start of treatment to first documented response, measured by Lugano 2014 Response Criteria for NHL (Cheson 2014)', 'timeFrame': 'Throughout the study for approximately 2 years'}]","[{'measure': 'duration of response (DOR)', 'description': 'DOR, defined as time from first documentation of a response (PR or CR) to the first documented disease progression or death due to any cause, whichever occurs first, for those patients with a PR or CR.', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'progression-free survival (PFS),', 'description': 'PFS, defined as the time from start of treatment to first documented disease progression or death due to any cause, whichever occurs first.', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'Time to response (TTR)', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'AE', 'description': 'Incidence of Adverse events (AEs) using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'AUClast', 'description': 'PK parameters', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'AUCinf', 'description': 'PK parameters', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'Cmin', 'description': 'PK parameters', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'Cmax', 'description': 'PK parameters', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'T1/2', 'description': 'PK parameters', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'Tmax', 'description': 'PK parameters', 'timeFrame': 'Throughout the study for approximately 2 years'}]",12,18 Years,,ALL,False,Shanghai YingLi Pharmaceutical Co. Ltd.,INDUSTRY,0,97.0,ESTIMATED,2025-09-01T16:18:23.455173,v2_robust,True,True,False,False,True,
NCT02971397,Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,Cytarabine Plus Continuous Infusion Daunorubicin Induction Therapy for Adults With Acute Myeloid Leukemia: A Feasibility Study With Cardiac MRI Monitoring,Cytarabine,"['1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', 'Aracytine', 'U 19920', 'Alexan', 'RP-13057', 'ARA-cell', 'Cytosar-U', '.beta.-Cytosine arabinoside', 'Daunomycin Hydrochloride', 'Daunorubicin.HCl', '1-.beta.-D-Arabinofuranosylcytosine', 'Cerubidin', 'WR-28453', 'Erpalfa', 'Cytarbel', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', 'FI-6339', 'Cytosar', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', 'Rubilem', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', 'CHX-3311', 'Cloridrato de Daunorubicina', 'Daunorubicin Hydrochloride', 'Udicil', 'Ara-C', 'Cytosine Arabinoside', 'Aracytidine', 'Ondena', 'Cytosine-beta-arabinoside', 'Rubidomycin Hydrochloride', 'Cytosine-.beta.-arabinoside', 'Beta-Cytosine Arabinoside', 'Cytarabinum', 'U-19920', 'Arabinofuranosylcytosine', 'Aracytin', 'Cerubidine', 'Daunoblastin', 'Starasid', 'Daunoblastine', '1.beta.-D-Arabinofuranosylcytosine', 'Daunoblastina', 'Daunorubicini Hydrochloridum', 'Cytarabine', 'Arabinosylcytosine', 'Tarabine PFS', '1-Beta-D-arabinofuranosylcytosine', 'Arabine', 'Daunomycin, hydrochloride']",50,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],[],COMPLETED,,2016-11,2018-08-08,"[{'measure': 'Change in incidence of cardiac toxicity, defined as reduction in LVEF of >= 10% compared to baseline LVEF and EF =< 50% on the follow-up scan, assessed using MRI', 'description': 'In addition to point estimates of these rates, 95% confidence intervals will be calculated.', 'timeFrame': 'Baseline up to 3 months after last dose of study drug'}, {'measure': 'Incidence of other unexpected toxicities, measured by Common Terminology Criteria for Adverse Events version 4.0', 'description': 'In addition to point estimates of these rates, 95% confidence intervals will be calculated.', 'timeFrame': 'Up to 6 months after last dose of study drug'}, {'measure': 'Proportion of patients who complete the infusion therapy', 'description': 'Will report these proportions with 95% confidence intervals.', 'timeFrame': 'Up to 4 months'}, {'measure': 'Proportion of patients with study-related deviations', 'description': 'Will report these proportions with 95% confidence intervals.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Change in incidence of cardiac toxicity, defined as reduction in LVEF of >= 10% compared to baseline LVEF and EF =< 50% on the follow-up scan, assessed using ECHO', 'description': 'In addition to point estimates of these rates, 95% confidence intervals will be calculated.', 'timeFrame': 'Baseline up to 3 months after last dose of study drug'}]","[{'measure': 'Change in EF, assessed by MRI and ECHO', 'description': 'Will determine the correlation between ECHO and MRI assessments performed pre-chemotherapy. Will assess correlations between post-chemotherapy ECHO and MRI assessments. Will assess correlations between each of the time points. Paired t-tests will be performed to compare the actual values of each ECHO/MRI measurement to each other at each time point. Bland-Altman plots will be generated at baseline, follow-up and using the change in measure for each of the MRI/ECHO derived measures.', 'timeFrame': 'Baseline up to 6 months after last dose of study drug'}, {'measure': 'Change in incidence of cardiac toxicity, defined as reduction in LVEF of >= 10% compared to baseline LVEF and EF =< 50% on the follow-up scan, assessed using MRI and ECHO', 'description': 'Will determine the correlation between ECHO and MRI assessments performed pre-chemotherapy. Will assess correlations between post-chemotherapy ECHO and MRI assessments. Will assess correlations between each of the time points. Paired t-tests will be performed to compare the actual values of each ECHO/MRI measurement to each other at each time point. Bland-Altman plots will be generated at baseline, follow-up and using the change in measure for each of the MRI/ECHO derived measures.', 'timeFrame': 'Baseline up to 6 months after last dose of study drug'}, {'measure': 'Change in left ventricular end diastolic volume, assessed by MRI and ECHO', 'description': 'Will determine the correlation between ECHO and MRI assessments performed pre-chemotherapy. Will assess correlations between post-chemotherapy ECHO and MRI assessments. Will assess correlations between each of the time points. Paired t-tests will be performed to compare the actual values of each ECHO/MRI measurement to each other at each time point. Bland-Altman plots will be generated at baseline, follow-up and using the change in measure for each of the MRI/ECHO derived measures.', 'timeFrame': 'Baseline up to 6 months after last dose of study drug'}, {'measure': 'Change in left ventricular end systolic volume, assessed by MRI and ECHO', 'description': 'Will determine the correlation between ECHO and MRI assessments performed pre-chemotherapy. Will assess correlations between post-chemotherapy ECHO and MRI assessments. Will assess correlations between each of the time points. Paired t-tests will be performed to compare the actual values of each ECHO/MRI measurement to each other at each time point. Bland-Altman plots will be generated at baseline, follow-up and using the change in measure for each of the MRI/ECHO derived measures.', 'timeFrame': 'Baseline up to 6 months after last dose of study drug'}, {'measure': 'Change in myocardial strain, assessed by MRI and ECHO', 'description': 'Will determine the correlation between ECHO and MRI assessments performed pre-chemotherapy. Will assess correlations between post-chemotherapy ECHO and MRI assessments. Will assess correlations between each of the time points. Paired t-tests will be performed to compare the actual values of each ECHO/MRI measurement to each other at each time point. Bland-Altman plots will be generated at baseline, follow-up and using the change in measure for each of the MRI/ECHO derived measures.', 'timeFrame': 'Baseline up to 6 months after last dose of study drug'}, {'measure': 'Disease-free survival for those patients who achieve remission', 'timeFrame': 'From the date of CR until relapse from CR or death, assessed for up to 2 years'}, {'measure': 'Induction death rate', 'timeFrame': 'Up to 28 days'}, {'measure': 'Overall response rate, defined as CR + CRi', 'timeFrame': 'Up to 2 years'}]",13,18 Years,,ALL,False,Wake Forest University Health Sciences,OTHER,1,40.0,ACTUAL,2025-09-01T16:18:23.455205,v2_robust,True,True,True,False,True,
NCT04205097,Deep vs Moderate Neuromuscular Blocks on Remifentanil for Laparoscopic Gastrectomy,Deep Versus Moderate Neuromuscular Blocks on Remifentanil Requirements in Patients Undergoing Surgical Pleth Index-guided Analgesia for Laparoscopic Gastrectomy,Neostigmine + glycopyrate,"['Neostigmine + glycopyrate', 'Sugammadex']",2,INTERVENTIONAL,['NA'],,,Gastric Cancer,['Gastric Cancer'],[],COMPLETED,,2019-12-23,2020-12-02,"[{'measure': 'total dose of remifentanil', 'description': 'remifentanil infusion using target effect-site concentration to achieve an surgical pleth index of range between 20 and 50', 'timeFrame': 'from pneumoperitoneum to removal of laparoscope'}]",[],1,19 Years,85 Years,ALL,False,Ajou University School of Medicine,OTHER,0,120.0,ACTUAL,2025-09-01T16:18:23.455217,v2_robust,True,True,True,False,False,
NCT02750410,A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes,A Phase 4 Study of Efficacy and Safety of Dulaglutide When Added to Insulin Treatment With or Without Oral Antidiabetic Medication in Patients With Type 2 Diabetes,Dulaglutide,"['Dulaglutide', 'Placebo', 'LY2189265']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes,['Type 2 Diabetes'],[],COMPLETED,,2016-08,2018-06-18,"[{'measure': 'Change From Baseline in Hemoglobin A1c (HbA1c)', 'description': 'HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean in HbA1c was calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) and adjusted by, baseline HbA1c, treatment, visit, and treatment-by-visit insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.', 'timeFrame': 'Baseline, Week 16'}]","[{'measure': 'Percentage of Participants With HbA1c <7.0% or ≤6.5%', 'description': 'Percentage of participants whose HbA1c was \\<7.0% or ≤6.5%. HbA1c \\<7.0% is presented.', 'timeFrame': 'Week 16'}, {'measure': 'Change From Baseline in Fasting Serum Glucose (FSG)', 'description': 'The LS mean change from baseline in FSG was calculated using a REML based MMRM and adjusted by, baseline value, treatment, visit, treatment-by-visit, baseline HbA1c Group (\\<8.5%, \\>=8.5%) + insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Change From Baseline in Plasma Glucose From 7-Point Self-Monitored Blood Glucose Profiles (SMBG)', 'description': 'The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: prebreakfast blood glucose (BG), breakfast 2-hour postprandial blood glucose (PPBG), prelunch BG, lunch 2-hour PPBG, predinner BG, dinner 2-hour PPBG, and bedtime BG. LS mean was calculated with fixed effect test of analysis of covariance (ANCOVA) model and adjusted by, baseline value, treatment, baseline HbA1c Group (\\<8.5%, ≥8.5%), insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin).', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Change From Baseline in Body Weight', 'description': 'LS mean change from baseline in body weight was calculated using a REML based MMRM and was adjusted by, baseline value, treatment, visit, treatment-by-visit, baseline HbA1c group (\\<8.5%, \\>=8.5%), insulin regimen (basal insulin, premixed insulin, or basal/mealtime insulin), where participant treated as a random effect.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Change From Baseline in Daily Total Insulin Dose', 'description': 'Mean change from baseline in total insulin dose was measured in each treatment groups.', 'timeFrame': 'Baseline, Week 16'}]",6,20 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,159.0,ACTUAL,2025-09-01T16:18:23.455244,v2_robust,True,True,True,False,False,
NCT00770510,A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126),A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia,Eszopiclone 1 mg,"['Eszopiclone 3 mg', 'Zolpidem Tartrate 10 mg', 'SEP-190', 'Placebo', 'Eszopiclone 2 mg', 'Eszopiclone 1 mg']",6,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Primary Insomnia,['Primary Insomnia'],['Primary insomnia'],COMPLETED,,2008-09,2010-05,"[{'measure': 'Latency To Persistent Sleep (LPS)', 'description': ""The objective measure, LPS, defined as the amount of time measured in minutes it takes to fall asleep was based on polysomnography (PSG) objective assessments of sleep disturbance. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. During the screening period, participants were provided a diary in which they recorded the time of lights out before bedtime for 1 week pror to PSG evaluations. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert."", 'timeFrame': '10 days (5 intervals of two consecutive nights)'}, {'measure': 'Sleep Latency (SL)', 'description': ""The subjective measure, SL, defined as the amount of time measured in minutes it takes to fall asleep was based on participant-reported subjective assessments of sleep disturbance and was obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period."", 'timeFrame': '10 days (5 intervals of two consecutive nights)'}]","[{'measure': 'Total Sleep Time (Objective & Subjective)', 'description': ""Total sleep time defined as total sleeping time from bedtime to final awakening (measured in minutes) was objectively determined by polysomnography and subjectively determined based on participant-reported measures following treatment.\n\nThe objective total sleep time was based on PSG-based assessments. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.\n\nThe subjective measure was based on participant-reported subjective assessments of sleep disturbance and were obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period."", 'timeFrame': '10 days (5 intervals of two consecutive nights)'}, {'measure': 'Sleep Efficiency', 'description': ""Sleep efficiency (SE) was an assessment obtained from PSG during the treatment period and was defined as the ratio of total sleep time to the total time in bed of 8 hours \\* 100, expressed as a percent.\n\nPSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the patient's median bedtime as recorded in the sleep diary. During the screening period, participants were provided a diary in which they recorded the time of lights out before bedtime for 1 week pror to PSG evaluations. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert."", 'timeFrame': '10 days (5 intervals of two consecutive nights)'}, {'measure': 'Wake Time After Sleep Onset (WASO)- Objective & Subjective', 'description': ""Wake Time After Sleep Onset (WASO) defined as total awakening time from falling asleep to final awakening was objectively determined by polysomnography and subjectively determined based on participant-reported measures following treatment.\n\nThe objective WASO was based on PSG assessments. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.\n\nThe subjective measure was based on participant-reported subjective assessments and were obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period."", 'timeFrame': '10 days (5 intervals of two consecutive nights)'}, {'measure': 'Number of Awakenings (Objective & Subjective)', 'description': ""Number of awakenings defined as the total number of spontaneous awakenings from falling asleep to final awakening was objectively determined by polysomnography and subjectively determined based on participant-reported measures following treatment.\n\nThe objective number of awakenings was based on PSG assessments. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.\n\nThe subjective measure was based on participant-reported subjective assessments and were obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period."", 'timeFrame': '10 days (5 intervals of two consecutive nights)'}]",6,21 Years,64 Years,ALL,False,"Eisai Co., Ltd.",INDUSTRY,0,192.0,ACTUAL,2025-09-01T16:18:23.455290,v2_robust,True,True,True,False,False,
NCT05675410,"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab",A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma,Brentuximab Vedotin,"['Vincristine, sulfate', 'VP16213', 'Delta- Cortef', 'Delta-F', 'Procarbazine Hydrochloride', 'Doxorubin', ""p-(N'-methylhydrazinomethyl)-N-isopropylbenzamide hydrochloride"", 'Adcetris', 'Carloxan', 'VP-16213', 'Cyclophosphan', 'Adrimedac', 'Lastet', 'Deltasolone', 'Cytoxan', 'WR- 138719', 'Adriblastine', '(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione', 'Delta-Dome', '2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate', 'Ibenzmethyzine hydrochloride', 'Doxorubicin Hydrochloride', 'Anti-CD30 Antibody-Drug Conjugate SGN-35', 'Hostacortin H', 'Promifen', 'Cycloblastine', '1, 2-Dehydrocortisone', 'Ciclofosfamide', 'Cyclostin', '(-)-Cyclophosphamide', 'Cycloblastin', 'Cyclophosphamide', 'Decorton', 'Velban', 'Prelone', 'Estilsona', 'Prednilonga', 'dimethyl-triazeno-imidazole carboxamide', 'Dacarbazina', 'Klismacort', 'Leurocristine, sulfate', 'Detimedac', 'Meprosona-F', 'Rayos', 'Delta-Cortef', 'Kyocristine', 'Opredsone', '.delta.1-Hydrocortisone', 'Decortisyl', 'PCB Hydrochloride', 'Toposar', 'FI-106', 'Exal', 'Cytophosphane', 'Ciclofosfamida', 'Asercit', 'Lenisolone', 'Prednicort', 'Vincrex', 'VP 16-213', 'DOX', 'Lisacort', 'ADC SGN-35', 'WR-139007', 'Longiprednil', 'DTIC-Dome', 'Sterane', 'Dakarbazin', 'NCIC01810', 'Dacarbazine - DTIC', 'Brentuximab Vedotin', 'Prednisolone', 'VP 16213', 'Deltahydrocortisone', 'Prednisone', 'Deltidrosol', 'MIH hydrochloride', '4-(Dimethyltriazeno)imidazole-5-carboxamide', 'NCI-C01810', 'Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35', 'Genuxal', 'hydroxydaunorubicin', 'Biocarbazine', 'Econosone', 'Frisolona', 'Metacortandralone', 'Adriamycine', 'Vepesid', 'WR138719', 'Vincosid', 'Natulan', 'Etoposide Phosphate', 'Cyclophosphamidum', 'Linola-H-Fett N', 'Deltacortisone', 'Cyclostine', 'Delta1-dehydro-hydrocortisone', 'Deticene', 'Cyclophospham', 'Predicor', 'Doxorubicin.HCl', 'CP monohydrate', 'CTX', 'Orasone', 'Dimethyl Triazeno Imidazole Carboxamide', 'DIC', 'Predicorten', 'Deltacortril', 'FI 106', 'PRED', 'Leurocristine Sulfate', 'Precortisyl', 'Clafen', 'Dontisolon D', 'Genoxal', 'Etoposide', 'Panasol-S', 'Rubex', 'Prednisone Intensol', 'Syklofosfamid', 'DTIC', 'Cyclophosphanum', 'Meti Derm', 'VP-16-213', 'Hydeltra', 'cAC10-vcMMAE', 'Cyclophosphamid monohydrate', 'Adriamycin PFS', 'SK-Prednisone', 'Metacortandracin', 'SGN35', 'Fisopred', 'FI106', 'Velbe', 'Prednicortelone', 'Ro 4 6467/1', 'B-518', 'Paracort', 'Vinblastine Sulfate', 'Panafcortelone', 'Delta(1)Hydrocortisone', 'Natunalar', 'Delta 1-Cortisone', 'Doxolem', 'Prednitone', 'Dimethyl Triazeno Imidazol Carboxamide', 'Deltison', 'Cyclophosphamide Monohydrate', 'Anti-CD30 Monoclonal Antibody-MMAE SGN-35', 'Prednicen-M', 'Adriamycin Hydrochloride', 'Perrigo Prednisone', 'Farmiblastina', 'Adasone', '.delta.1-Cortisone', 'Dimethyl (triazeno) imidazolecarboxamide', 'Delta-Diona', 'Dhasolone', 'Imidazole Carboxamide Dimethyltriazeno', 'ADRIAMYCIN, HYDROCHLORIDE', 'Decortin H', 'PCZ', 'Cortisolone', 'Prednisolonum', 'Imidazole Carboxamide', 'Hydeltrasol', 'Velsar', '5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)', 'Vincristine Sulfate', 'B 518', 'Cytophosphan', 'Di-Adreson-F', 'Predni-Helvacort', '29060-LE', 'Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino) methyl]-, monohydrochloride (9CI)', 'Pred-Clysma', 'DOXO-CELL', 'PCB', 'Linola-H N', 'Deltacortene', 'Decaprednil', 'Oncovin', 'Deltadehydrocortisone', 'Dacarbazina Almirall', 'Gupisone', 'ADM', 'VP 16', 'Predeltilone', 'p-Toluamide, N-isopropyl-.alpha.-(2-methylhydrazino)-, monohydrochloride (8CI)', 'Chloridrato de Doxorrubicina', 'Fauldetic', 'VP16', 'EPEG', 'Mitoxan', 'Predni-Coelin', 'Fosfaseron', 'Claphene', 'Lepi-Cortinolo', 'Prednidib', 'Matulane', 'Adriacin', 'Adriblastina', 'Deltasone', 'Ofisolona', 'Deltra', 'Neosar', 'Cortalone', 'Prenilone', 'Asta B 518', 'Adnisolone', 'Revimmune', 'Dimethyl-triazeno-imidazole-carboximide', 'Delta-Phoricol', 'Cicloxal', 'WR 138719', 'Ledoxina', 'Meticortelone', 'Kuhlprednon', 'Vincasar', 'Capsoid', 'Panafcort', 'WR-138719', 'Servisone', 'Adriamycin RDF', 'DeCortin', 'SGN 35', 'Doxorubicin HCl', 'Etopophos', 'Dacortin', 'SGN-35', 'Ro 4-6467/1', 'Meticorten', 'Cyclophosphane', 'VP-16', 'NCI C01810', '29060 LE', 'Adriamycin', 'Demethyl Epipodophyllotoxin Ethylidine Glucoside', 'Predniment', 'Dacarbazine', 'Dacatic', 'Cortancyl', 'Natulanar', '5-(Dimethyltriazeno)imidazole-4-carboxamide', 'VINCALEUKOBLASTINE', 'Prednisonum', 'Dacortin H', 'B518', 'CYCLO-cell', 'Aprednislon']",250,INTERVENTIONAL,['PHASE3'],PHASE3,,Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8,['Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8'],[],RECRUITING,,2023-05-11,2031-04-28,"[{'measure': 'Progression-free survival (PFS) in rapid early responder (RER) patients', 'description': 'Will compare the PFS of RER patients randomized to immunotherapy (IO) therapy (brentuximab vedotin \\[Bv\\]-nivolumab \\[Nivo\\]) against those randomized to standard therapy. PFS curves will be estimated separately by arm using Kaplan Meier methodology, and the test will be a 1-sided log-rank test between the (pooled) IO and standard arms, stratified according to the stratification factors at randomization and including all eligible and evaluable randomized patients.', 'timeFrame': 'From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 124 events, whichever comes first'}, {'measure': 'PFS in slow-early responder (SER) patients', 'description': 'Will compare PFS among SER patients randomized to IO therapy and involved-site radiation therapy (ISRT) against arms containing standard therapy. PFS curves will be estimated separately by arm using Kaplan Meier methodology, and the test will be a 1-sided log-rank test between the (pooled) IO and standard arms, stratified according to the stratification factors at randomization and including all eligible and evaluable randomized patients.', 'timeFrame': 'From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 71 events, whichever comes first'}]","[{'measure': 'Overall survival (OS) in RER patients', 'description': 'The non-inferiority of IO therapy to standard therapy will be tested in the randomized and eligible RER cohort using a confidence interval approach performed 12 years after the last patient not lost to follow-up has reached more than 12 years of follow-up (patients are followed up to 13 years).', 'timeFrame': 'Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment'}, {'measure': 'OS in SER patients', 'description': 'Will be compared between a standard chemotherapy approach and an IO therapy approach among the SER patients.', 'timeFrame': 'Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment'}, {'measure': 'OS for entire patient population', 'description': 'Will be based on a confidence interval approach conducted after the last patient not lost to follow-up has been followed for at least 12 years from randomization. Twelve-year OS and its corresponding 90% confidence interval will be estimated with the Kaplan-Meier method for each study arm within the entire randomized and evaluable trial population.', 'timeFrame': 'Time from randomization to death due to any cause, assessed at 12 years after the last enrollment'}, {'measure': 'PFS for favorable risk patients', 'description': 'Will be estimated in patients with favorable features at diagnosis. PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.', 'timeFrame': 'Up to 12 years'}, {'measure': 'PFS for unfavorable risk patients', 'description': 'Will be estimated in patients with unfavorable features at diagnosis. PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.', 'timeFrame': 'Up to 12 years'}, {'measure': 'PFS for entire population', 'description': 'PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.', 'timeFrame': 'Up to 12 years'}, {'measure': 'Event-free survival (EFS)', 'description': 'Pooling IO treatment arms and standard treatment arms, EFS and corresponding confidence intervals will be estimated with the Kaplan-Meier approach for patients assigned vs. not assigned to receive RT, and compared using the log-rank test.', 'timeFrame': 'Time from randomization to the earliest of progression, relapse, second malignancy, or death due to any cause, assessed up to 12 years from last enrollment'}, {'measure': 'Incidence of adverse events (AEs)', 'description': 'Will use the American Society of Clinical Oncology and the Society for Immunotherapy of Cancer guidelines to capture immune-related AEs. Physician-reported treatment related AEs will be reported for all grades using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Rates of individual toxicities with grades greater or equal to 3 will be compared between the pooled IO and standard arms using exact binomial tests. The maximum grade for each toxicity will be recorded for each patient. The rates and confidence intervals for these toxicities will be provided. Comparison of AEs will also be conducted for physician-reported treatment-related AEs between RT and non-RT patients.', 'timeFrame': 'Assessed up to 12 years from last enrollment'}, {'measure': 'Patient reported outcomes (PRO)-CTCAE', 'description': 'Targeted patient-reported AEs will be collected at each time point using the PRO-CTCAE for patients 7 years and older. For youth (7-17 years) the Pediatric PRO-CTCAE form will be used and for those 18 years and older adult the PRO-CTCAE form will be used. For information collected by each of the above forms, the scores for each attribute together with frequency, severity and/or interference will be presented descriptively using summary statistics at each assessment time. Additionally, the worst severity and/or interference over the entire course will be summarized. The changes among main time points will be calculated. The results will be provided for the whole population and compared between subpopulations by arms and by age groups. Regression models based on longitudinal measurements can be constructed by considering the following covariates besides age groups: baseline demographics, clinical risk factors, and study arms.', 'timeFrame': 'Assessed up to 12 years from last enrollment'}, {'measure': 'Patient-reported fatigue', 'description': 'Will be measured by validated short forms from the Patient Reported Outcomes Measurement Information System (PROMIS) initiatives. Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The minimal clinically important difference (MCID) in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Our primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.', 'timeFrame': 'Baseline up to 1 year from end of study treatment'}, {'measure': 'Patient-reported cognitive deficits', 'description': 'Will be measured by validated short forms from the Neuro-QoL initiative. Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The MCID in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.', 'timeFrame': 'Baseline up to 1 year from end of study treatment'}, {'measure': 'Patient-reported health-related quality of life', 'description': 'Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The MCID in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.', 'timeFrame': 'Baseline up to 1 year from end of study treatment'}, {'measure': 'Incidence of self-reported late morbidities', 'description': 'Will be collected by using validated measures from the St. Jude Life Cohort. The cumulative incidence of late-morbidities (e.g., cardiovascular, pulmonary and endocrine) will be compared between the standard chemotherapy and the IO therapy and among different age groups (7-14; 15-40 and 41-60) with K-sample method. The frequencies of selected organ toxicities will be compared between two treatment arms, among the three age groups and between RT and non-RT with chi-square tests.', 'timeFrame': 'Assessed up to 12 years from last enrollment'}, {'measure': 'Effect of metabolic tumor burden (MTV) on PFS', 'description': 'MTV will be measured at baseline using fludeoxyglucose F-18 (FDG)-PET. The Kaplan-Meier curves of PFS will be compared between the two levels with log-rank tests.', 'timeFrame': 'At baseline prior to initiation of therapy'}, {'measure': 'Effect of total lesion glycolysis (TLG) on PFS', 'description': 'TLG will be measured at baseline using FDG-PET. The Kaplan-Meier curves of PFS will be compared between the two levels with log-rank tests.', 'timeFrame': 'At baseline prior to initiation of therapy'}, {'measure': 'Contribution of social determinants of health (SDOH) to PET2 response by race and ethnicity', 'timeFrame': 'After Cycle 2 of treatment (1 cycle = 28 days)'}, {'measure': 'Contribution of SDOH to PFS by race and ethnicity', 'description': 'Kaplan-Meier (K-M) curves of PFS will be generated by racial/ethnic groups (e.g., non-Hispanic white \\[NHW\\], non-Hispanic black \\[NHB\\], Hispanic). The p values for the K-M curve comparison will be obtained from log-rank tests. Associations between race/ethnicity and PFS will be evaluated with univariable and multivariable Cox proportional hazard models by considering other covariates such as baseline clinical conditions, toxicities, SDOH, and treatment arm (standard vs. IO). Backward selection will be used to select those factors with p-value \\< 0.2, which will be included in final multivariable models.', 'timeFrame': 'Assessed up to 12 years after last enrollment'}, {'measure': 'Contribution of SDOH to OS by race and ethnicity', 'description': 'K-M curves of OS will be generated by racial/ethnic groups (e.g., NHW, NHB, Hispanic). The p values for the K-M curve comparison will be obtained from log-rank tests. Associations between race/ethnicity and OS will be evaluated with univariable and multivariable Cox proportional hazard models by considering other covariates such as baseline clinical conditions, toxicities, SDOH, and treatment arm (standard vs. IO). Backward selection will be used to select those factors with p-value \\< 0.2, which will be included in final multivariable models.', 'timeFrame': 'Assessed up to 12 years after last enrollment'}]",20,5 Years,60 Years,ALL,False,National Cancer Institute (NCI),NIH,0,1875.0,ESTIMATED,2025-09-01T16:18:23.455410,v2_robust,True,True,False,False,True,
NCT03588910,Ambulatory Gynecologic Surgery: Finding the Optimal Opioid Prescription,Ambulatory Gynecologic Surgery: Finding the Optimal Postoperative Opioid Prescription,Acetaminophen,"['Oxycodone', 'Acetaminophen', 'Tylenol', 'Motrin', 'Ibuprofen 600 mg']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Surgery,['Surgery'],"['ambulatory', 'narcotics', 'opioids', 'postoperative', 'gynecology', 'laparoscopy', 'pain', 'surgery']",COMPLETED,,2018-08-08,2019-08-04,"[{'measure': 'Number of Oxycodone Tablets Used Day 1', 'description': 'During the survey phone call on day 1, participants will be asked to report the total number of oxycodone tablets use since the surgery.', 'timeFrame': '24 hours post-operative'}, {'measure': 'Number of Oxycodone Tablets Used as Reported by Participants 1 Week After Surgery', 'description': 'During the survey phone call on day 7, participants will be asked to report the total number of oxycodone tablets used since the surgery.', 'timeFrame': '7 days post-operative'}]","[{'measure': 'Self Reported Pain Score on Post Operative Day 1 (Numeric Pain Reporting Score: NRS)', 'description': 'Participants will be surveyed during the phone call survey to rate pain score on a scale from 0 (no pain), to 10 (severe pain)', 'timeFrame': '1 day post operative'}, {'measure': 'Self Reported Pain Score on Post Operative Day 7 (Numeric Pain Reporting Score: NRS)', 'description': 'Participants will be surveyed during the phone call survey to rate pain score on a scale from 0 (no pain), to 10 (severe pain)', 'timeFrame': '7 days post operative'}, {'measure': 'Additional Contacts With Provider', 'description': 'By chart review, unscheduled interactions with the healthcare system related to pain will be counted.These will include phone calls related to pain, unscheduled visits to the office or emergency department', 'timeFrame': '1 week post operative'}]",5,18 Years,,FEMALE,True,Montefiore Medical Center,OTHER,0,120.0,ACTUAL,2025-09-01T16:18:23.455570,v2_robust,True,True,True,False,False,
NCT01664910,CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies,"Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies",Bendamustine Hydrochloride,"['CL 14377', 'Tremetex', 'Cytostasan Hydrochloride', 'Trixilem', 'Novatrex', 'Folex', 'Bendamustin Hydrochloride', 'Methotrexatum', 'Prograf', 'Metotrexato', 'Fludara', 'Rheumatrex', 'Maxtrex', 'Protopic', 'SyB L-0501', 'Treanda', 'SH T 586', 'Emthexat', 'Emtexate', 'Levact', 'Farmitrexat', 'Lantarel', 'Fujimycin', 'Ledertrexate', 'Alpha-Methopterin', 'Mexate', 'Methotrexate LPF', 'Tacrolimus', 'Medsatrexate', 'Methotrexate', '2-F-ara-AMP', 'MTX', 'Methoblastin', 'Beneflur', 'Lumexon', 'Bendamustine Hydrochloride', 'Metex', 'WR-19039', 'Hecoria', 'Folex PFS', 'Methotrexate Methylaminopterin', 'Abitrexate', 'Metrotex', 'Emthexate', 'Trexeron', 'Ribomustin', 'Fludarabine Phosphate', 'Brimexate', 'CL-14377', '9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-', 'Amethopterin', 'FK 506', 'Texate', 'Mexate-AQ', 'Fauldexato']",55,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Hematopoietic and Lymphoid Cell Neoplasm,['Hematopoietic and Lymphoid Cell Neoplasm'],[],COMPLETED,,2012-10-29,2023-06-28,"[{'measure': 'Maximum-tolerated Dose (MTD) of Inotuzumab Without DLT', 'description': 'Number of participants received inotuzumab in each cohort without DLT', 'timeFrame': 'Up to 30 days'}]","[{'measure': 'Overall Response', 'description': 'Overall response (CR+PR) with estimated with a 95% confidence interval in the dose that is declared the MTD. Complete Response is no clinical or radiological evidence of disease. Partial remission is equal to or more than 50% reduction in lymphadenopathy, liver and or spleen if abnormal at pre-treatment.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Overall Survival (OS)', 'description': 'Participants are disease free and alive at 3 years post transplant.', 'timeFrame': 'Up to 3 years'}]",3,18 Years,70 Years,ALL,False,M.D. Anderson Cancer Center,OTHER,1,27.0,ACTUAL,2025-09-01T16:18:23.455596,v2_robust,True,True,True,False,False,
NCT01878513,Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis,Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis,risperidone,"['Risperdal', 'risperidone']",2,INTERVENTIONAL,['NA'],,,Schizophrenia,"['Schizophrenia', 'Schizoaffective Disorder', 'Psychotic Disorder Not Otherwise Specified', 'Severe Bipolar Disorder With Psychotic Features']",[],COMPLETED,,2009-09-23,2018-07-31,"[{'measure': 'Efficacy', 'description': 'Scores on:\n\n1. Schedule for Assessment of Negative Symptoms (SANS)\n2. Brief Psychiatric Rating Scale (BPRS)\n3. Global Impression - Improvement scale (CGI-I)', 'timeFrame': '6 weeks or discharge up to 6 weeks'}]","[{'measure': 'Adverse Drug Effects', 'description': 'As measured by:\n\n1. Hillside Hospital Adverse Events Rating Scale\n2. Abnormal Involuntary Movement Scale (AIMS)\n3. Barnes Rating Scale for Drug-Induced Akathisia\n4. Simpson-Angus Rating Scale for Extrapyramidal symptoms', 'timeFrame': '6 weeks, discharge or discontinuation up to 6 weeks'}]",2,18 Years,60 Years,ALL,False,Northwell Health,OTHER,0,88.0,ACTUAL,2025-09-01T16:18:23.455636,v2_robust,True,True,True,False,True,
NCT01133613,"Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee",,Bone morphogenetic protein 7,['Bone morphogenetic protein 7'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Osteoarthritis of the Knee,['Osteoarthritis of the Knee'],[],COMPLETED,,2010-05,2011-10,"[{'measure': 'Safety (physical examination, vital signs, clinical laboratory measurements, adverse events)', 'timeFrame': 'Baseline, Day 2, Week 1, Week 2, Week 4, Week 8, Week 12, Week 24'}]","[{'measure': 'WOMAC pain and function', 'timeFrame': 'Baseline, Week 4, Week 8, Week 12, Week 24'}, {'measure': 'Patient and physician global VAS', 'timeFrame': 'Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 24'}, {'measure': 'Quality of life measurement (SF-36) and pain medication use', 'timeFrame': 'Baseline, Week 4, Week 8, Week 12, Week 24'}]",4,40 Years,,ALL,False,Stryker Biotech,INDUSTRY,0,51.0,ACTUAL,2025-09-01T16:18:23.455793,v2_robust,True,True,True,False,True,
NCT00986713,Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation,,Amphotericin B,['Amphotericin B'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Invasive Pulmonary Aspergillosis,['Invasive Pulmonary Aspergillosis'],[],UNKNOWN,,2008-06,2010-10,"[{'measure': 'invasive pulmonary aspergillosis', 'timeFrame': '3 years'}]",[],1,18 Years,65 Years,ALL,False,Capital Medical University,OTHER,0,400.0,ESTIMATED,2025-09-01T16:18:23.455813,v2_robust,True,True,False,False,False,
NCT02670213,A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan,"A Multicentre, Non-interventional Post Marketing Study of Safety and Effectiveness of NovoThirteenR (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan",recombinant factor XIII,['recombinant factor XIII'],1,OBSERVATIONAL,[],,,Congenital Bleeding Disorder,"['Congenital Bleeding Disorder', 'Congenital FXIII Deficiency']",[],COMPLETED,,2016-03-16,2024-09-30,"[{'measure': 'Adverse drug reactions in patients with congenital FXIII A-subunit deficiency treated with NovoThirteen®, comprising FXIII antibodies, allergic reactions, embolic and thrombotic events and lack of therapeutic effect', 'timeFrame': 'Year 0-9'}]","[{'measure': 'All serious adverse events', 'timeFrame': 'Year 0-9'}, {'measure': 'All adverse events', 'timeFrame': 'Year 0-9'}, {'measure': 'All medical event of special interest', 'timeFrame': 'Year 0-9'}, {'measure': 'All medication errors collected', 'timeFrame': 'Year 0-9'}, {'measure': 'All technical complaints', 'timeFrame': 'Year 0-9'}, {'measure': 'Use of NovoThirteen® for other uses than for the approved indication', 'timeFrame': 'Year 0-9'}, {'measure': 'Frequency of bleeding episodes', 'timeFrame': 'Year 0-9'}]",8,,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,8.0,ESTIMATED,2025-09-01T16:18:23.455836,v2_robust,False,True,True,False,True,
NCT00799513,Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma,"A Phase II Trial to Evaluate the Safety and Activity of Single-agent Lenalidomide Given as Maintenance Therapy After Response to Second-line Therapy in Patients With Relapsed DLBCL, Not Eligible for High-dose Chemotherapy and ASCT (Autologous Stem-Cell Transplantation)",Lenalidomide,"['Lenalidomide', 'Revlimid']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Diffuse Large B-cell Lymphoma,['Diffuse Large B-cell Lymphoma'],"['Lenalidomide', 'revlimid', 'large B-cell lymphoma', 'relapse']",COMPLETED,,2009-03,2021-08,"[{'measure': '1-year Progression-free Survival', 'description': 'It is defined as the number of participants alive after 1 year from enrolment to progression or relapse of lymphoma (if post-induction disease status was PR (Partial Response) or CR (Complete Response), respectively). Patients alive at last follow-up will be censored.', 'timeFrame': '1-year'}]","[{'measure': 'Progression Free Survival', 'description': 'Secondary measures to describe long term outcome of treatment\n\n-Progression free survival It is defined as the number of participants, on a 5 yrs follow up, free from disease progression', 'timeFrame': '5 years'}, {'measure': 'Progression', 'description': 'Progression It is defined as the number of participants with disease recurrence observed on a 5 yrs follow up.', 'timeFrame': '5 years'}, {'measure': 'Duration of Response', 'description': 'Secondary measures to describe long term outcome of treatment\n\n* Duration of response It is defined as the number of participants experiencing a PFS (Progression Free Survival) from study therapy longer than previous line of treatment', 'timeFrame': '5 years'}, {'measure': 'Overall Survival', 'description': 'Secondary measures to describe long term outcome of treatment\n\n-Overall survival It is defined as the number of participants alive at 5ys from enrolment (death for any cause). Patients alive at last follow-up will be censored.', 'timeFrame': '5 years'}]",5,18 Years,,ALL,False,IRCCS San Raffaele,OTHER,1,48.0,ACTUAL,2025-09-01T16:18:23.455868,v2_robust,True,True,True,False,False,
NCT00061113,Substance Dependent Teens - Impact of Treating Depression Study 1 - 1,Substance Dependent Teens - Impact of Treating Depression Study 1,Fluoxetine + outpatient cognitive behavioral therapy,"['fluoxetine', 'prozac', 'Fluoxetine + outpatient cognitive behavioral therapy', 'placebo + CBT', 'Prozac']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Alcohol-Related Disorders,"['Alcohol-Related Disorders', 'Marijuana Abuse', 'Substance-Related Disorders']","['alcohol dependence', 'marijuana dependence']",COMPLETED,,2001-02,2006-08,"[{'measure': 'To determine whether fluoxetine + CBT is a more effective treatment than placebo + CBT for substance outcomes, depression, and behavior problems.', 'timeFrame': '16 weeks'}]","[{'measure': 'To determine if the treatment of depression with fluoxetine + CBT, in depressed adolescents with SUD and CD will be more effective than placebo + CBT in reducing substance use and improving conduct symptoms.', 'timeFrame': '16 weeks'}]",2,13 Years,19 Years,ALL,False,National Institute on Drug Abuse (NIDA),NIH,0,126.0,ACTUAL,2025-09-01T16:18:23.455953,v2_robust,True,True,True,False,False,
NCT00551213,"A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)","A Fixed-Sequence, Open-Label Study to Determine the Activity of SCH 717454 as Assessed by Positron Emission Tomography in Subjects With Relapsed or Recurrent Colorectal Cancer",Irinotecan,"['FOLFOX', 'Irinotecan', 'Capecitabine', 'CAPEOX/XELOX', 'FOLFIRI']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Colorectal Cancer,['Colorectal Cancer'],['anti-IGF-1R'],COMPLETED,,2007-11-21,2009-06-04,"[{'measure': 'Number of Participants With a >20% Decrease in Positron Emission Tomography (PET)-Assessed Tumor Glucose Metabolism: Fluorodeoxyglucose (FDG) Standardized Uptake Value (SUV) in the Target Lesion', 'description': 'FDG-PET was used in this study to detect the biological activity of modulation of the target within the tumor. Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 was used to select the target lesion. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs were identified as target lesions and recorded and measured at Baseline. The changes in SUVmax were calculated using the formula: (endpoint SUVmax - baseline SUVmax)/baseline SUVmax as a percentage. If multiple lesions had been measured at a visit, percentages calculated for all target lesions were averaged to find the decrease during the treatment period per participant. FDG SUVmax responder was defined as participants with \\>20% decrease in SUVmax after the first cycle of robatumumab in Period 2.', 'timeFrame': 'After the first robatumumab dose in Period 2 (Up to approximately 4 weeks after first robatumumab dose in Period 1)'}]","[{'measure': 'Number of Participants Who Experienced One or More Adverse Events (AEs)', 'description': 'An AE is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the study drug. AEs may include the onset of new illness and the exacerbation of pre-existing conditions.', 'timeFrame': 'Up to 30 days after last dose of study drug (Up to approximately 22 weeks)'}, {'measure': 'Best Overall Tumor Response Per Investigator Review', 'description': 'Tumor response was assessed by computed tomography (CT) or magnetic resonance imaging (MRI) scans using RECIST v 1.0 criteria at Screening, at every 8 weeks of robatumumab treatment during Period 2 and at post study. A sum of the longest diameter (LD) for all target lesions was calculated and reported as the baseline sum LD. Overall tumor responses were defined as: Complete Response (CR) - Disappearance of all target lesions; Partial Response (PR) - At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; Progressive Disease (PD) - At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or Stable Disease (SD) - Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.', 'timeFrame': 'Up to 30 days after last dose of study drug (Up to approximately 22 weeks)'}, {'measure': 'Number of Participants Who Discontinued Study Drug Due to an AE', 'description': 'An AE is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the study drug. AEs may include the onset of new illness and the exacerbation of pre-existing conditions.', 'timeFrame': 'Up to last dose of study drug (Up to approximately 18 weeks)'}, {'measure': 'Best Overall Tumor Response Per Central Review', 'description': 'Tumor response was assessed by CT or MRI scan using RECIST v1.0 criteria at Screening, at every 8 weeks of robatumumab treatment during Period 2 and at post study. A sum of the LD for all target lesions was calculated and reported as the baseline sum LD. Overall tumor responses were defined as: Complete Response (CR) - Disappearance of all target lesions; Partial Response (PR) - At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; Progressive Disease (PD) - At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or Stable Disease (SD) - Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.', 'timeFrame': 'Up to 30 days after last dose of study drug (Up to approximately 22 weeks)'}, {'measure': 'Change From Baseline in Tumor Growth Rate', 'description': 'Tumor growth rate was assessed by CT or MRI scans using RECIST criteria at Screening, at every 8 weeks of robatumumab treatment and at post study. For Pre Baseline 1, tumor growth rate=(sum of longest diameter of target lesions at Baseline - the most recent prior to Baseline)/duration between Baseline and Pre Baseline. For all other cycles, tumor growth rate=(sum of longest diameter of target lesions at a cycle - Baseline)/ duration between Baseline and the cycle. The cycles presented below are relative to the first dose of robatumumab in Period 1.', 'timeFrame': 'Baseline and up to approximately 22 weeks'}]",6,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,67.0,ACTUAL,2025-09-01T16:18:23.455965,v2_robust,True,True,True,False,True,
NCT00375713,Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema,"A Multi-centre, Double-blind, Double-dummy, Randomized, Active-controlled Phase III Study to Evaluate the Efficacy and Safety of Xyzal® 5mg od vs Zyrtec® 10mg od in Subjects Aged 15 Years and Above With Dermatitis and Eczema",Levocetirizine,"['Zyrtec®', 'Placebo-Levocetirizine', 'Standard topical steroid (1% hydrocortisone) ointment', 'Placebo-Cetirizine', 'Cetirizine', 'Levocetirizine', 'Xyzal®']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Dermatitis,"['Dermatitis', 'Eczema']","['Dermatitis', 'Eczema', 'Pruritus', 'Xyzal', 'Zyrtec', 'Levocetirizine', 'Cetirizine']",COMPLETED,,2005-10,2006-05,"[{'measure': 'Responder Status According to Pruritus Severity Score (Response = Mild or None in Pruritus Severity Score).', 'description': 'A participant is a responder if the pruritus severity score is assessed as mild or none, otherwise it is a non-responder. The responder status is defined at day 14, except if the investigator assessed the subject as a responder at day 7. The Pruritus Score is in general defined as: 3 for Severe, 2 for Moderate, 1 for Mild and 0 for None.', 'timeFrame': 'Day 7 and 14'}]","[{'measure': 'Change From Baseline in the Mean Pruritus Severity Score at Endpoint During the 14 Day Treatment Period', 'description': 'The Pruritus Score Scale ranges from 0 to 3 (3 for Severe, 2 for Moderate, 1 for Mild and 0 for None). Endpoint is at visit 4 on day 14 or at an earlier timepoint at study completion.', 'timeFrame': 'Baseline and at endpoint during the 14 day treatment period'}, {'measure': 'Duration of Pruritus (Stated in Categories) at Endpoint During the 14 Day Treatment Period', 'description': 'Duration of pruritus was categorized as follows: 3 if \\> 6 hours/24hr, 2 if 1 to 6 hours/24hr, 1 if less than 1 hour/24hr, and 0 if No pruritus. The endpoint is visit 4 on day 14 or at an earlier time point at study completion.', 'timeFrame': 'At endpoint during the 14 day treatment period'}, {'measure': 'Global Improvement at Endpoint During the 14 Day Treatment Period', 'description': 'Global improvement is measured on an ordered nominal scale ranging from marked improvement to exacerbation (see categories in the table). The endpoint is visit 4 on day 14 or at an earlier time point at study completion.', 'timeFrame': 'At endpoint during the 14 day treatment period'}]",4,15 Years,,ALL,False,UCB Pharma,INDUSTRY,0,466.0,ACTUAL,2025-09-01T16:18:23.456031,v2_robust,True,True,True,False,False,
NCT06414460,Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors,"A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors",ISM3412,['ISM3412'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Locally Advanced/Metastatic Solid Tumors,['Locally Advanced/Metastatic Solid Tumors'],"['Methionine adenosyltransferase 2A (MAT2A)', 'homozygous MTAP deletion', 'MAT2A inhibitor', 'ISM3412']",RECRUITING,,2025-04-25,2029-03-31,"[{'measure': 'Incidence of dose-limiting toxicity (DLT) events', 'description': 'To evaluate the safety and tolerability of ISM3412.', 'timeFrame': '31 days'}, {'measure': 'Incidence and severity of adverse events (AEs)', 'description': 'To evaluate the safety and tolerability of ISM3412.', 'timeFrame': 'Approximately 30 months'}, {'measure': 'Recommended phase 2 dose (RP2D)', 'description': 'To determine the RP2D of ISM3412.', 'timeFrame': 'Approximately 30 months'}]","[{'measure': 'Maximum observed concentration (Cmax)', 'description': 'To assess PK of ISM3412 in plasma following a single and multiple doses of ISM3412', 'timeFrame': 'Approximately 30 months'}, {'measure': 'Time of maximum observed concentration (Tmax)', 'description': 'To assess PK of ISM3412 in plasma following a single and multiple doses of ISM3412', 'timeFrame': 'Approximately 30 months'}, {'measure': 'Area under the concentration-time curve (AUC)', 'description': 'To assess PK of ISM3412 in plasma following a single and multiple doses of ISM3412', 'timeFrame': 'Approximately 30 months'}, {'measure': 'Terminal half-life (t1/2)', 'description': 'To assess PK of ISM3412 in plasma following a single and multiple doses of ISM3412', 'timeFrame': 'Approximately 30 months'}, {'measure': 'Objective response rate (ORR)', 'description': 'To evaluate the preliminary efficacy of ISM3412 in participants with locally advanced/metastatic solid tumors.', 'timeFrame': 'Approximately 30 months'}, {'measure': 'Best objective response (BOR)', 'description': 'To evaluate the preliminary efficacy of ISM3412 in participants with locally advanced/metastatic solid tumors.', 'timeFrame': 'Approximately 30 months'}, {'measure': 'Duration of response (DoR)', 'description': 'To evaluate the preliminary efficacy of ISM3412 in participants with locally advanced/metastatic solid tumors.', 'timeFrame': 'Approximately 30 months'}]",10,18 Years,,ALL,False,InSilico Medicine Hong Kong Limited,INDUSTRY,0,80.0,ESTIMATED,2025-09-01T16:18:23.456122,v2_robust,True,True,False,False,True,
NCT00647660,Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg,Single-Dose Fasting Bioequivalence Study of Nadolol/Bendroflumethiazide Tablets (80 mg/5 mg; Mylan) to Corzide® Tablets (80 mg/5 mg; King) in Healthy Volunteers,Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg,"['Corzide® Tablets 80 mg/5 mg', 'Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2006-07,2006-08,"[{'measure': 'Bioequivalence', 'timeFrame': 'within 30 days'}]",[],1,18 Years,,ALL,True,Mylan Pharmaceuticals Inc,INDUSTRY,0,66.0,ACTUAL,2025-09-01T16:18:23.456131,v2_robust,True,True,True,False,False,
NCT05863260,Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer,"Tislelizumab (Anti-PD-1) Combined With Definitive Chemoradiotherapy in Recurrent Cervical Cancer (PILOT-2020-511): a Single-arm, Phase 2 Trial",Treatment Group,['Treatment Group'],1,OBSERVATIONAL,[],,,Cervical Cancer,"['Cervical Cancer', 'Immune Checkpoint Inhibitor', 'Chemoradiotherapy']",[],UNKNOWN,,2020-11-09,2024-12-31,"[{'measure': 'ORR', 'description': 'Objective response rate', 'timeFrame': '1 year'}]","[{'measure': '1-year PFS', 'description': '1-year PFS', 'timeFrame': '1 year'}, {'measure': '1-year OS', 'description': '1-year OS', 'timeFrame': '1 year'}]",3,18 Years,70 Years,FEMALE,False,Fudan University,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:23.456138,v2_robust,False,True,False,False,False,
NCT06419660,A Study in Healthy Men to Test Whether Esomeprazole Influences the Amount of BI 3000202 in the Blood,"The Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of a Single Oral Dose BI 3000202 in Healthy Male Subjects (an Open-label, Randomized, Two-way Cross-over Study)",BI 300202,"['esomeprazole', 'BI 300202']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2024-05-22,2024-07-08,"[{'measure': 'Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)', 'timeFrame': 'Up to 4 days'}, {'measure': 'Maximum measured concentration of the analyte in plasma (Cmax)', 'timeFrame': 'Up to 4 days'}]","[{'measure': 'Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)', 'timeFrame': 'Up to 4 days'}]",3,18 Years,55 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,15.0,ACTUAL,2025-09-01T16:18:23.456253,v2_robust,True,True,True,False,False,
NCT00876460,"BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I","A Phase I Study of Continuous, Concomitant Oral Treatment With BIBF 1120 and Docetaxel - a Phase I, Open-label, Dose-escalation Study in Japanese Patients With Stage IIIB/IV or Recurrent Non-small-cell Lung Cancer After Failure of Chemotherapy",BIBF 1120 M + docetaxel M,"['BIBF 1120 L + docetaxel M', 'BIBF 1120 M + docetaxel M', 'BIBF 1120 H + docetaxel H', 'BIBF 1120 H + docetaxel M', 'BIBF 1120 M + docetaxel H']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,"Carcinoma, Non-Small-Cell Lung","['Carcinoma, Non-Small-Cell Lung']",[],COMPLETED,,2009-03,2015-07,"[{'measure': 'Number of Participants Who Experienced Dose Limited Toxicity in Combination Therapy of Nintedanib and Docetaxel', 'description': 'Number of participants experienced Dose Limited Toxicity (DLT) in combination therapy of nintedanib and docetaxel.\n\nMaximum tolerated dose (MTD) of nintedanib combination with docetaxel were to be determined separately in the patient groups of body surface area (BSA) \\<1.5 m2 and BSA ≥1.5 m2. The MTD were to be determined as a combination of a dose equal to or less than 200 mg b.i.d. of nintedanib and 60 mg/m2 and 75 mg/m2 every 3 weeks of docetaxel at which either 0 out of 3, 1 out of 6, or 2 out of 6 patients experienced DLT.', 'timeFrame': 'During the first treatment course, up to 3 weeks'}, {'measure': 'Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 for All Courses', 'description': 'Number of participants with adverse events according to Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 for all courses.\n\nThe CTCAE grades are: 1 (mild AE), 2 (moderate AE), 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related to AE).', 'timeFrame': 'Between the first administration of docetaxel and 28 days after last administration of docetaxel and/or nintedanib, up to 1367 days'}]","[{'measure': 'Objective Tumor Response', 'description': 'Number of participants with objective response defined as complete response (CR) or partial response (PR) according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0', 'timeFrame': 'Pre-treatment, every 6 weeks from treatment course 3, end of treatment (up to 1367 days)'}, {'measure': 'Disease Control', 'description': 'Number of participants with disease control, defined as complete response (CR) or partial response (PR) or stable disease (SD) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.0', 'timeFrame': 'Pre-treatment, every 6 weeks from treatment course 3, end of treatment (up to 1367 days)'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'For participants with known date of progression or death (of any cause): PFS \\[days\\] = earlier of date of progression or death - date the study treatment started + 1.\n\nFor participants known to be alive without progression by the end of trial or follow-up visit: PFS (censored) \\[days\\] = date of last imaging when the participant is known to be progression-free and alive - date the study treatment started + 1.\n\nProgression is assessed according to RECIST version 1.0.', 'timeFrame': 'Pre-treatment, every 6 weeks from treatment course 3, end of treatment (up to 1367 days)'}, {'measure': 'Time to Treatment Failure (TTF)', 'description': 'For participants with known date of discontinuation of the study treatment (or progression \\[not necessarily confirmed by tumour imaging; can also be based on any clinical sign of tumour progression\\] or death): TTF \\[days\\] = earlier of date of discontinuation of the study treatment, progression, or death - date the study treatment started + 1.\n\nFor participants known to be alive without progression by the end of trial or follow-up visit: TTF (censored) \\[days\\] = date when the patient is known to be progression-free and alive - date the study treatment started + 1.\n\nProgression is assessed according to RECIST version 1.0.', 'timeFrame': 'Pre-treatment, every 6 weeks from treatment course 3, end of treatment (up to 1367 days)'}, {'measure': 'Clinical Relevant Abnormalities in Laboratory Parameters', 'description': 'Number of participants with clinically relevant abnormalities in laboratory parameters reported as adverse events', 'timeFrame': 'Between the first administration of docetaxel and 28 days after last administration of docetaxel and/or nintedanib, up to 1367 days'}, {'measure': 'AUC0-inf of Nintedanib in Course 1', 'description': 'AUC0-inf (area under the plasma concentration-time curve over the time interval from 0 extrapolated to infinity) after the first administration of nintedanib in course 1', 'timeFrame': '-0:05 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 7h, 10h and 23:55h after drug administration in course 1'}, {'measure': 'Cmax of Nintedanib in Course 1', 'description': 'Cmax (maximum measured plasma concentration) after the first administration of nintedanib in course 1', 'timeFrame': '-0:05h before drug administration and 1h, 2h, 3h, 4h, 6h, 7h, 10h and 23:55h after drug administration in course 1'}, {'measure': 'AUC0-inf of Docetaxel in Course 1', 'description': 'AUC0-inf (area under the plasma concentration-time curve over the time interval from 0 extrapolated to infinity) after the first administration of docetaxel in course 1', 'timeFrame': '-0:05h before drug administration and 1h, 1.5h, 2h, 3h, 4h, 7h, 23:55h and 47:55h after drug administration'}, {'measure': 'Cmax of Docetaxel in Course 1', 'description': 'Cmax (maximum measured plasma concentration) after the first administration of docetaxel in course 1', 'timeFrame': '-0:05h before drug administration and 1h, 1.5h, 2h, 3h, 4h, 7h, 23:55h and 47:55h after drug administration'}, {'measure': 'AUC0-inf of Docetaxel in Course 2', 'description': 'AUC0-inf (area under the plasma concentration-time curve over the time interval from 0 extrapolated to infinity) after the first administration of docetaxel in course 2.\n\nDocetaxel 50 mg/m2 patients were assigned to Docetaxel 60 mg/m2 in Cycle 1, but the dose was reduced to 50 mg/m2 in Cycle 2 as defined in the Clinical Trial Protocol.', 'timeFrame': '-0:05h before drug administration and 1h, 1.5h, 2h, 3h, 4h, 7h, 23:55h and 47:55h after drug administration'}, {'measure': 'Cmax of Docetaxel in Course 2', 'description': 'Cmax (maximum measured plasma concentration) after the first administration of docetaxel in course 2.\n\nDocetaxel 50 mg/m2 patients were assigned to Docetaxel 60 mg/m2 in Cycle 1, but the dose was reduced to 50 mg/m2 in Cycle 2 as defined in the Clinical Trial Protocol.', 'timeFrame': '-0:05h before drug administration and 1h, 1.5h, 2h, 3h, 4h, 7h, 23:55h and 47:55h after drug administration'}]",13,20 Years,74 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,43.0,ACTUAL,2025-09-01T16:18:23.456267,v2_robust,True,True,True,False,True,
NCT05388760,Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1),"A Single (Assessor) Blinded, Randomized, Parallel-group, Monotherapy Trial to Evaluate the Pharmacokinetics and Safety of Tralokinumab in Children (Age 6 to <12 Years) With Moderate-to-severe Atopic Dermatitis",Tralokinumab,['Tralokinumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Atopic Dermatitis,['Atopic Dermatitis'],[],ACTIVE_NOT_RECRUITING,,2022-09-07,2026-04-23,"[{'measure': 'Ctrough (trough concentration)', 'timeFrame': 'at Week 16'}, {'measure': 'Cmax (maximum serum concentration)', 'timeFrame': 'between Week 12-Week 14 for Q2W (Week 12-Week 16 for Q4W)'}, {'measure': 'AUC (area under the curve)', 'timeFrame': 'between Week 12-Week 14 for Q2W (Week 12-Week 16 for Q4W)'}, {'measure': 'Tmax (time to maximum serum concentration)', 'timeFrame': 'between Week 12-Week 14 for Q2W (Week 12-Week 16 for Q4W)'}]","[{'measure': 'Number of treatment-emergent adverse events in the initial treatment period', 'description': 'An Adverse Event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An event will be considered treatment-emergent if started after the first use of IMP or if started before the first use of IMP and worsened in severity after first dose of IMP.', 'timeFrame': 'Week 0-Week 16'}, {'measure': 'Anti-drug antibodies (status) in the initial treatment period', 'timeFrame': 'Week 0-Week 16'}, {'measure': 'Number of treatment-emergent adverse events in the open-label treatment period', 'description': 'An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An event will be considered treatment-emergent if started after the first use of IMP or if started before the first use of IMP and worsened in severity after first dose of IMP.', 'timeFrame': 'Week 16-Week 68'}, {'measure': 'Anti-drug antibodies (status) in the open-label treatment period', 'timeFrame': 'Week 16-Week 68'}, {'measure': 'Change in Scoring Atopic Dermatitis (SCORAD)', 'description': 'The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis (AD) lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.', 'timeFrame': 'from Week 0-Week 68'}, {'measure': 'Change in Patient-Oriented Eczema Measure (POEM)', 'description': ""The POEM is a validated questionnaire used to assess disease symptoms in atopic eczema patients in both clinical practice and clinical trials (30, 31). The tool consists of 7 items each addressing a specific symptom (itching, sleep, bleeding, weeping, cracking, flaking, and dryness). POEM for proxy completion is used, where the caregiver will report their perception of how often the subject has experienced each symptom over the previous week on a 5-point categorical response scale (0 = 'no days'; 1 = '1 to 2 days'; 2 = '3 to 4 days'; 3 = '5 to 6 days'; 4 = 'every day'). The total score is the sum of the 7 items (range 0 to 28) and reflects disease-related morbidity; a high score is indicative of a worse disease severity."", 'timeFrame': 'from Week 0-Week 68'}, {'measure': 'Change in Eczema Area and Severity Index (EASI)', 'description': 'The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe or more extensive condition.', 'timeFrame': 'from Week 0-Week 68'}]",11,6 Years,11 Years,ALL,False,LEO Pharma,INDUSTRY,0,24.0,ESTIMATED,2025-09-01T16:18:23.456412,v2_robust,True,True,False,False,True,
NCT02739360,"Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820","An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820",Idelalisib,"['Zydelig®', 'Idelalisib']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Lymphoid Malignancies,['Lymphoid Malignancies'],[],TERMINATED,,2016-05-04,2017-12-28,"[{'measure': 'Number of Participants Experiencing Treatment-Emergent ≥ Grade 3 Adverse Events, Serious Adverse Events (SAEs), and Deaths', 'description': 'The severity of Adverse Events were graded using the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. An SAE was defined as an event that, at any dose, resulted in one or more of the following: 1) Death, 2) Life-threatening, 3) In-patient hospitalization or prolongation of existing hospitalization, 4) Persistent or significant disability/incapacity, 5) A congenital anomaly/birth defect, or 6) A medically important event or reaction.', 'timeFrame': 'Up to Day 602 plus 30 days'}]",[],1,18 Years,,ALL,False,Gilead Sciences,INDUSTRY,0,3.0,ACTUAL,2025-09-01T16:18:23.456484,v2_robust,True,True,False,True,True,
NCT04047160,"Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)","An Open-Label, Dose-Finding Study for the CBP / β-catenin Inhibitor OP-724 in Patients With Primary Biliary Cholangitis (Phase I)",OP-724,"['PRI-724 (former name)', 'CBP-beta-catenin inhibitor', 'OP-724']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Primary Biliary Cholangitis (PBC),"['Primary Biliary Cholangitis (PBC)', 'Liver Cirrhosis, Biliary']","['Primary Biliary Cholangitis (PBC)', 'Liver Cirrhosis, Biliary', 'Cholangitis, Chronic Nonsuppurative Destructive', 'Liver Cirrhosis, Obstructive', 'Secondary Biliary Cholangitis', 'Primary Biliary Cirrhosis', 'Secondary Biliary Cirrhosis']",COMPLETED,,2019-08-29,2022-03-31,"[{'measure': 'Occurrence Rate of Serious Adverse Events (Side Effects)', 'description': 'Occurrence Rate of Serious Adverse Events (Side Effects) whose causal relationship with the investigational drug can not be denied. The data will be aggregated by each adverse event and cohort.', 'timeFrame': '28 days after the last administration of OP-724'}]","[{'measure': 'Expression Ratio of Adverse Events', 'description': 'The data will be aggregated by each adverse event and cohort.', 'timeFrame': '28 days after the last administration of OP-724'}, {'measure': 'Percentage of Occurrence of Side Effects', 'description': 'The data will be aggregated by each side effect and cohort.', 'timeFrame': '28 days after the last administration of OP-724'}, {'measure': 'Drug Concentration (OP-724 and C-82) in Plasma', 'description': 'The data will be aggregated by each cohort.', 'timeFrame': 'A) Single administration part: pre-dose and post-dose at 0.5, 1, 2, 4, 5, 9 and 24 hours. / B) Continuous administration part: pre-dose and post-dose at 4 hours on Day 1 and 4 in Cycle 1, 5, 9 and 12 (each cycle is 7 days)'}, {'measure': 'Parameters on Pharmacokinetics (OP-724 and C-82) : Maximum Plasma Concentration (Cmax)', 'description': 'The data will be aggregated by each cohort.', 'timeFrame': 'A) Single administration part: pre-dose and post-dose at 0.5, 1, 2, 4, 5, 9 and 24 hours. / B) Continuous administration part: pre-dose and post-dose at 4 hours on Day 1 and 4 in Cycle 1, 5, 9 and 12 (each cycle is 7 days)'}, {'measure': 'Parameters on Pharmacokinetics (OP-724 and C-82) : Area Under the Curve (AUC 0-24h)', 'description': 'The data will be aggregated by each cohort.', 'timeFrame': 'A) Single administration part: pre-dose and post-dose at 0.5, 1, 2, 4, 5, 9 and 24 hours. / B) Continuous administration part: pre-dose and post-dose at 4 hours on Day 1 and 4 in Cycle 1, 5, 9 and 12 (each cycle is 7 days)'}, {'measure': 'Liver Tissue Fibrotic Area Ratio by Liver Biopsy', 'description': 'Amount of change from baseline in liver tissue fibrotic area ratio by liver biopsy at 12 weeks after administration. The data will be aggregated by each cohort.', 'timeFrame': '12 weeks after administration of OP-724'}, {'measure': 'Liver Stiffness by Fibro Scan', 'description': 'Amount of change from baseline of liver stiffness by Fibro Scan at 12 weeks after administration. The data will be aggregated by each cohort.', 'timeFrame': '12 weeks after administration of OP-724'}, {'measure': 'Child-Pugh Score', 'description': 'Amount of change from baseline of Child-Pugh Score at 12 weeks after administration. Child Pugh score (scale range 5-15 points, the severity increases sequentially from 5 to 15 points) is obtained by adding the score for each parameter (hepatic encephalopathy, ascites, bilirubin, albumin, PT). Based on the total points score (Child-Pugh Score) of each diagnostic parameter shown above, the severity of the disease is classified into Grades A to C shown below. The data will be aggregated by each cohort and score.\n\n* Grade A: 5-6 points -\\> Compensated cirrhosis\n* Grade B: 7-9 points -\\> Decompensated cirrhosis\n* Grade C: 10-15 points -\\> Decompensated cirrhosis', 'timeFrame': '12 weeks after administration of OP-724'}, {'measure': 'MELD Score', 'description': ""Amount of change from baseline in MELD score at 12 weeks after administration. The Model for End-Stage Liver Disease (MELD) is a scoring system for assessing the severity of chronic liver disease and uses the subject's values for total bilirubin, serum creatinine, and the international normalized ratio (INR) for prothrombin time to predict survival. MELD is calculated according to the following formula:\n\n\\* MELD score = 3.78×ln\\[serum bilirubin (mg/dL)\\] + 11.2×ln\\[INR\\] + 9.57×ln\\[serum creatinine (mg/dL)\\] + 6.43 The data will be aggregated by each cohort and score."", 'timeFrame': '12 weeks after administration of OP-724'}, {'measure': 'Modified Histological Activity Index (HAI)', 'description': 'Amount of change from baseline of modified Histological Activity Index (HAI) and classification of Nakanuma et al. by liver biopsy at 12 weeks after administration. The data will be aggregated by each cohort and index', 'timeFrame': '12 weeks after administration of OP-724'}, {'measure': 'Serum Alkaline Phosphatase (ALP) Level', 'description': 'Amount of change from baseline in serum ALP level at 12 weeks after administration. The data will be aggregated by each cohort and Child-Pugh score.', 'timeFrame': '12 weeks after administration of OP-724'}, {'measure': 'Serum Total Bilirubin Value', 'description': 'Amount of change from baseline in serum total bilirubin value at 12 weeks after administration. The data will be aggregated by each cohort and Child-Pugh score.', 'timeFrame': '12 weeks after administration of OP-724'}, {'measure': 'Enhanced Liver Fibrosis Panel (ELF) Score', 'description': 'Amount of change from baseline of ELF score at 12 weeks after administration. Observation items: hyaluronic acid, procollagen III peptide, TIMP-1\n\n\\* ELF score = 2.278 + 0.851 ln (hyaluronic acid) + 0.75 ln (P3 NP) + ln (TIMP). The data will be aggregated by each cohort and score.', 'timeFrame': '12 weeks after administration of OP-724'}]",14,20 Years,74 Years,ALL,False,"Kiminori Kimura, MD",OTHER,2,7.0,ACTUAL,2025-09-01T16:18:23.456504,v2_robust,True,True,True,False,True,
NCT01160120,Therapeutic Drug Monitoring (TDM) in Generic Tenofovir/Lamivudine/Efavirenz,Generic Fixed Dose Combination (FDC) of Tenofovir(TDF) /Lamivudine(3TC)/Efavirenz (EFV) Tablets 300/300/600 mg,generic FDC of TDF/3TC/EFV,['generic FDC of TDF/3TC/EFV'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV,['HIV'],"['fixed dose combinations', 'tenofovir', 'lamivudine', 'efavirenz', 'therapeutic drug levels', 'safety and efficacy', 'HIV', 'To evaluation new formulations of FDC of TDF/3TC/EFV']",COMPLETED,,2010-06,2015-06,"[{'measure': 'mid levels of TDF, 3TC, and EFV between brand and generic', 'description': 'mid levels of TDF, 3TC, and EFV between brand and generic', 'timeFrame': '144 weeks'}]","[{'measure': 'kidney, liver, CD4 and viral load overtime', 'description': 'kidney, liver, CD4 and viral load overtime', 'timeFrame': '144 weeks'}]",2,18 Years,,ALL,False,The HIV Netherlands Australia Thailand Research Collaboration,OTHER,1,100.0,ACTUAL,2025-09-01T16:18:23.456608,v2_robust,True,True,True,False,False,
NCT01711320,Effect of Omeprazole on Metformin,"Effect of Omeprazole, an OCT Inhibitor, on the Pharmacodynamics and Pharmacokinetics of Metformin, Involved the Mechanism of Attenuating AMPK Phosphorylation",Placebo,"['Omeprazole', 'PPI', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Omeprazole', 'Metformin']",COMPLETED,,2012-09,2012-12,"[{'measure': 'Whether the pharmacokinetics of metformin would be effected by omeprazole', 'description': 'Pharmacokinetic parameters such as the area under the concentration-time curve (AUC), the elimination half-life(t½) and maximum metformin concentration (Cmax)', 'timeFrame': '24 weeks'}]","[{'measure': 'Whether the pharmacodynamics of metformin would be effected by omeprazole', 'description': 'oral glucose tolerance tests (OGTTs) before and after receiving two doses of metformin', 'timeFrame': '24 weeks'}]",2,18 Years,45 Years,MALE,True,Xijing Hospital,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:23.456619,v2_robust,True,True,True,False,False,
NCT01243320,In Vivo Assessment of Silver Biomaterial Nano-Toxicity,In Vivo Assessment of Silver Biomaterial Nano-Toxicity,10ppm Oral Silver Particle,"['32ppm Oral Silver Particle', '10ppm Oral Silver Particle']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2010-12,2011-07,"[{'measure': 'Change in Sodium Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change in Potassium Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change in Chloride Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change in Carbon Dioxide Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change in Urea Nitrogen Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In CreatinineBlood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Glucose Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Alkaline Phosphatase Blood Level', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Aspartate Aminotransferase Blood Level', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Alanine Aminotransferase Blood Level', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Total Protein Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Total Bilirubin Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change in Albumin Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Calcium Blood Level', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In White Blood Count Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Red Blood Count Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Hemoglobin Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Hematocrit Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Mean Corpuscular Volume Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 days'}, {'measure': 'Change In Mean Corpuscular Hemoglobin Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Mean Corpuscular Hemoglobin Concentration Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 days'}, {'measure': 'Change In Platelet Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Granulocytes Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Lymphocytes Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change In Monocytes Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change in Basophils Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change in Eosinophil Blood Levels', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Sputum Reactive Oxygen Species Change', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change to Interleukin-8 Receptor', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change to Interleukin-1 Alpha Receptor', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change to Interleukin-1 Beta Receptor', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change in Monocyte Chemotactic Protein 1', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Change in Quinone Oxidoreductase 1 Gene', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}]","[{'measure': 'Change Systolic Blood Pressure', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Mean Change in Diastolic Blood Pressure', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}, {'measure': 'Mean Change in Heart Rate', 'description': 'All participants received the 10ppm Silver, then progressed to the 32 ppm Silver.', 'timeFrame': '14 Days'}]",36,18 Years,80 Years,ALL,True,University of Utah,OTHER,0,36.0,ACTUAL,2025-09-01T16:18:23.456667,v2_robust,True,True,True,False,False,
NCT02828020,"Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",Ubrogepant,"['Ubrogepant', 'Placebo-matching Ubrogepant']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Migraine, With or Without Aura","['Migraine, With or Without Aura']",[],COMPLETED,,2016-07-22,2017-12-14,"[{'measure': 'Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose', 'description': 'Pain freedom was defined as a reduction in headache severity from moderate/severe at baseline to no pain at 2 hours after the initial dose. Participants were provided with an electronic diary (eDiary) to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing postdose pain severity assessment at or before 2 hours after initial dose.', 'timeFrame': 'Baseline (Predose) to 2 hours after initial dose'}, {'measure': 'Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose', 'description': ""The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'. Participants were provided with an eDiary to record absence or presence of migraine-associated symptoms. Number analyzed is the number of participants with non-missing postdose most bothersome migraine-associated symptoms."", 'timeFrame': 'Baseline (Predose) to 2 hours after initial dose'}]","[{'measure': 'Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose', 'description': 'Pain relief was defined as a reduction of a moderate/severe migraine headache to a mild headache or to no headache. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing pain severity assessment at or before 2 hours after initial dose.', 'timeFrame': 'Baseline (Predose) to 2 hours after initial dose'}, {'measure': 'Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose', 'description': 'Sustained pain relief was defined as a pain relief at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with determinable sustained pain relief from 2 to 24 hours after initial dose.', 'timeFrame': '2 to 24 hours after initial dose'}, {'measure': 'Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose', 'description': 'Sustained pain freedom was defined as a pain freedom at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a mild/moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with determinable sustained pain freedom from 2 to 24 hours after initial dose.', 'timeFrame': '2 to 24 hours after initial dose'}, {'measure': 'Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose', 'description': 'Photophobia was defined as sensitivity to light, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence photophobia. Number analyzed is the number of participants with non-missing postdose photophobia assessment at or before 2 hours after initial dose.', 'timeFrame': '2 hours after initial dose'}, {'measure': 'Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose', 'description': 'Phonophobia was defined as sensitivity to sound, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of phonophobia. Number analyzed is the number of participants with non-missing postdose phonophobia assessment at or before 2 hours after initial dose.', 'timeFrame': '2 hours after initial dose'}, {'measure': 'Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose', 'description': 'Nausea was a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of nausea. Number analyzed is the number of participants with non-missing postdose nausea assessment at or before 2 hours after initial dose.', 'timeFrame': '2 hours after initial dose'}]",8,18 Years,75 Years,ALL,False,Allergan,INDUSTRY,0,1672.0,ACTUAL,2025-09-01T16:18:23.456761,v2_robust,True,True,True,False,False,
NCT07085520,A Clinical Study Evaluating the Dermal Safety of Soluble Denosumab Microneedle Patches,A Clinical Study Evaluating the Dermal Safety of Soluble Denosumab Microneedle Patches,Microneedle with 0.24mg Denosumab,"['Microneedle with 1.2mg Denosumab', 'Microneedle with 6mg Denosumab', 'Saline Microneedle Patch', 'Microneedle with 0.24mg Denosumab', 'Soluble Denosumab Microneedle Patch']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Osteoarthritis,"['Osteoarthritis', 'Osteoarthritis (OA) of the Knee', 'Osteoporosis', 'Osteoporosis (Senile)', 'Healthy']",[],NOT_YET_RECRUITING,,2025-07-31,2026-05-31,"[{'measure': 'Number of Participants With Adverse Reactions', 'description': 'Evaluate through skin response sheets: erythema, pain, swelling, etc.', 'timeFrame': 'Assessed at 15 minutes, 24 hours, 48 hours, and 2 weeks post-application.'}, {'measure': 'Amount of pain', 'description': 'Pain will be measured using the faces pain scales revised (0-2-4-6-8-10, 0: no pain, 10: very much pain).', 'timeFrame': 'Assessed at 15 minutes, 24 hours, 48 hours, and 2 weeks post-application.'}, {'measure': 'Number of injection site reactions', 'description': 'Injection site assessment for the following:\n\nPain (grade 1/2/3) Tenderness (grade 1/2/3) Pruritus (grade 1/2/3) Erythema (absent/present) Induration (grade 1/2/3) Blister (absent/present) Ulceration (absent/present) Necrosis (absent/present) Ecchymosis (absent/present) If any of these signs or symptoms is present, it is regarded an injection site reaction.', 'timeFrame': 'Assessed at 15 minutes, 24 hours, 48 hours, and 2 weeks post-application.'}]","[{'measure': 'Soluble Denosumab Microneedle Patch Subject Satisfaction Questionnaire', 'description': 'Assessed through questionnaires at the end of the study.\n\n1. How satisfied are you with the application process of the microneedle patch?\n2. How satisfied are you with the overall skin condition around the knee after using the microneedle patch?\n3. Overall, how satisfied are you with the ease of using the microneedle patch?\n4. Overall, now that you have tried this microneedle patch and completed the study, how likely are you to use this treatment again in the future?\n5. Overall, how likely are you to recommend this microneedle patch treatment to a family member or friend? 5 = Very Likely; 4 = Somewhat Likely; 3 = Neutral; 2 = Somewhat Unlikely; 1 = Very Unlikely', 'timeFrame': 'Assessed at 2 weeks post-application.'}, {'measure': 'Number of participants with abnormal laboratory tests results', 'description': ""Evaluation of blood routine and blood electrolytes to monitor participants' health status and safety."", 'timeFrame': 'Assessed at 2 weeks post-application.'}]",5,18 Years,70 Years,ALL,True,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",OTHER,0,12.0,ESTIMATED,2025-09-01T16:18:23.456816,v2_robust,True,True,False,False,True,
NCT00191620,Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.,Randomized Phase II Study of Cisplatin + Gemcitabine Administered Either as Short Infusion or at a Fixed Dose Rate in Non-Small Cell Lung Cancer,Gemcitabine,"['Gemcitabine', 'cisplatin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Non-Small-Cell Lung Carcinoma,['Non-Small-Cell Lung Carcinoma'],[],COMPLETED,,2004-03,2006-05,[{'measure': 'To evaluate the objective response rate (ORR) of the standard (30 minute infusion) versus a fixed dose rate (10 mg/m2/minute) of gemcitabine combined with cisplatin as treatment for advanced NSCLC after treatment completion.'}],"[{'measure': 'To evaluate progression-free survival of the standard versus a fixed dose rate of gemcitabine combined with cisplatin as treatment for advanced NSCLC.'}, {'measure': 'To evaluate incidence of laboratory and non laboratory adverse events by maximum Common Toxicity Criteria (CTC) toxicity grade and relationship to study drug of the standard versus a fixed dose rate of gemcitabine combined with cisplatin as treatment for'}]",3,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,64.0,,2025-09-01T16:18:23.456916,v2_robust,True,True,True,False,True,
NCT03662620,Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers,"A Randomized, Open-label, Single Dose, Replicate Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers",Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg,"['Study drug', 'Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg', 'Comparator drug']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Hypertension,['Hypertension'],[],COMPLETED,,2018-10-05,2018-12-22,"[{'measure': 'AUClast of Telmisartan/amlodipine/chlorthalidone', 'description': 'AUClast', 'timeFrame': '0-168 hrs'}, {'measure': 'Cmax of Telmisartan/amlodipine/chlorthalidone', 'description': 'Cmax', 'timeFrame': '0-168 hrs'}]","[{'measure': 'AUCinf of Telmisartan/amlodipine/chlorthalidone', 'description': 'AUCinf', 'timeFrame': '0-168 hrs'}, {'measure': 'Tmax of Telmisartan/amlodipine/chlorthalidone', 'description': 'Tmax', 'timeFrame': '0-168 hrs'}, {'measure': 't1/2 of Telmisartan/amlodipine/chlorthalidone', 'description': 't1/2', 'timeFrame': '0-168 hrs'}]",5,19 Years,55 Years,MALE,True,Yuhan Corporation,INDUSTRY,0,67.0,ACTUAL,2025-09-01T16:18:23.457008,v2_robust,True,True,True,False,False,
NCT01266720,HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1),"Phase 1 Study of HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer",Gemcitabine,"['Gemcitabine', 'Gemzar']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Pancreatic Cancer,['Pancreatic Cancer'],"['pancreatic cancer', 'peptide vaccine', 'VEGFR', 'gemcitabine']",UNKNOWN,,2008-04,2012-03,"[{'measure': 'Toxicities as assessed by NCI-CACAE ver3', 'timeFrame': '3 months'}]","[{'measure': 'Differences of peptide specific CTL response in vitro among sequence of gemcitabine and peptide vaccine administration', 'timeFrame': '3 months'}, {'measure': 'CD8 population', 'timeFrame': '3 months'}, {'measure': 'Change in level of regulatory T cells', 'timeFrame': '3 months'}, {'measure': 'Objective response rate', 'timeFrame': '1 year'}, {'measure': 'Feasibility', 'timeFrame': '1 year'}, {'measure': 'Survival', 'timeFrame': '1 year'}]",7,20 Years,80 Years,ALL,False,Fukushima Medical University,OTHER,1,6.0,ACTUAL,2025-09-01T16:18:23.457021,v2_robust,True,True,False,False,False,
NCT02254720,"Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers","A Randomised, Single-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses (2.5 μg, 7.5 μg, 25 μg, 50 μg, 100 μg, 200 μg, 350 μg, 500 μg Free Cation) BEA 2180 BR in Healthy Male Volunteers With an Additional Arm by Inhalation in One Dose Group (1600 μg)",BEA 2180 BR solution for infusion,"['BEA 2180 BR solution for infusion', 'BEA 2180 BR solution for inhalation', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2006-09,,"[{'measure': 'Number of participants with abnormal findings in physical examination', 'timeFrame': 'Up to day 12 after drug administration'}, {'measure': 'Number of participants with clinically significant changes in vital signs', 'timeFrame': 'Up to day 12 after drug administration'}, {'measure': 'Number of participants with abnormal findings in 12 - lead ECG (electrocardiogram)', 'timeFrame': 'Up to day 12 after drug administration'}, {'measure': 'Number of participants with abnormal changes in clinical laboratory parameters', 'timeFrame': 'Up to day 12 after drug administration'}, {'measure': 'Number of participants with adverse events', 'timeFrame': 'Up to day 12 after drug administration'}, {'measure': 'Investigator assessed tolerability on a 4-point scale', 'timeFrame': 'Up to day 12 after drug administration'}]","[{'measure': 'Cmax (maximum measured concentration of the analyte in plasma)', 'timeFrame': 'Up to 72 hours after drug administration'}, {'measure': 'tmax (time from dosing to maximum measured concentration)', 'timeFrame': 'Up to 72 hours after drug administration'}, {'measure': 'AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)', 'timeFrame': 'Up to 72 hours after drug administration'}, {'measure': '%AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)', 'timeFrame': 'Up to 72 hours after drug administration'}, {'measure': 'AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)', 'timeFrame': 'Up to 72 hours after drug administration'}, {'measure': 'λz (terminal rate constant in plasma)', 'timeFrame': 'Up to 72 hours after drug administration'}, {'measure': 't1/2 (terminal half-life of the analyte in plasma)', 'timeFrame': 'Up to 72 hours after drug administration'}, {'measure': 'MRT(mean residence time of the analyte in the body)', 'timeFrame': 'Up to 72 hours after drug administration'}, {'measure': 'CL (total clearance of the analyte in plasma)', 'timeFrame': 'Up to 72 hours after drug administration'}, {'measure': 'Vz (apparent volume of distribution during the terminal phase λz)', 'timeFrame': 'Up to 72 hours after drug administration'}, {'measure': 'Vss (apparent volume of distribution at steady state following intravascular administration)', 'timeFrame': 'Up to 72 hours after drug administration'}, {'measure': 'Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2)', 'timeFrame': 'Up to 72 hours after drug administration'}, {'measure': 'fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)', 'timeFrame': 'Up to 72 hours after drug administration'}, {'measure': 'CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)', 'timeFrame': 'Up to 72 hours after drug administration'}]",20,21 Years,50 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,71.0,ACTUAL,2025-09-01T16:18:23.457048,v2_robust,True,True,True,False,True,
NCT03175120,A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD),A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other OAD,Insulin degludec/liraglutide,"['Insulin degludec/liraglutide', 'Insulin degludec']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],COMPLETED,,2017-05-26,2019-04-04,"[{'measure': 'Change in HbA1c', 'description': 'Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}]","[{'measure': 'Change in Body Weight', 'description': 'Change in body weight from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Number of Treatment-emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes', 'description': 'Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \\< 3.1 millimoles per liter (mmol/L) with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed hypoglycaemic episodes during 26 weeks of treatment is presented.', 'timeFrame': 'Up to 26 weeks'}, {'measure': 'Change in Fasting Plasma Glucose (FPG)', 'description': 'Change in FPG from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Waist Circumference', 'description': 'Change in waist circumference from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Mean of the 9-point Self-measured Plasma Glucose (SMPG) Profile', 'description': 'Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. The mean of profile is defined as the area under the profile divided by measurement time and is calculated using the trapezoidal method. Change in mean of the 9-point SMPG profile from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in SMPG-mean Post Prandial Increments', 'description': 'Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. Change in SMPG-mean postprandial increment over all meals from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Insulin Dose', 'description': 'The mean of actual daily total insulin dose after 26 weeks of treatment is presented.', 'timeFrame': 'Week 26'}, {'measure': 'SMPG-9-point Profile (Individual Points in the Profile)', 'description': 'Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. SMPG-9-point profile (individual points in the profile) at week 26 is presented.', 'timeFrame': 'Week 26'}, {'measure': 'Change in Fasting High-density Lipoprotein (HDL) Cholesterol- Ratio to Baseline', 'description': 'Change in fasting HDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Fasting Low-density Lipoprotein (LDL) Cholesterol- Ratio to Baseline', 'description': 'Change in fasting LDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Fasting Very Low-density Lipoprotein (VLDL) Cholesterol- Ratio to Baseline', 'description': 'Change in fasting VLDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Fasting Total Cholesterol- Ratio to Baseline', 'description': 'Change in fasting total cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Fasting Triglycerides- Ratio to Baseline', 'description': 'Change in fasting triglycerides (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Fasting Free Fatty Acids- Ratio to Baseline', 'description': 'Change in fasting free fatty acids (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Fasting C-peptide- Ratio to Baseline', 'description': 'Change in fasting C-peptide (measured in nanomoles per liter (nmol/L)) from baseline (week 0) to week 26 is presented as ratio to baseline.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Fasting Insulin- Ratio to Baseline', 'description': 'Change in fasting insulin (measured in picomoles per liter (pmol/L)) from baseline (week 0) to week 26 is presented as ratio to baseline.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Fasting Glucagon- Ratio to Baseline', 'description': 'Change in fasting glucagon (measured in picograms per milliliter (pg/mL)) from baseline (week 0) to week 26 is presented as ratio to baseline.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in HOMA-B (Beta-cell Function)- Ratio to Baseline', 'description': 'Change in HOMA-B from baseline (week 0) to week 26 is presented as ratio to baseline.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Participants Who Achieved HbA1c < 7.0%, ADA Target (Yes/no)', 'description': 'Participants who achieved HbA1c \\< 7.0%, ADA target (yes/no) is presented.', 'timeFrame': 'Week 26'}, {'measure': 'Participants Who Achieved HbA1c ≤ 6.5%, American Association of Clinical Endocrinologists (AACE) Target (Yes/no)', 'description': 'Participants who achieved HbA1c ≤ 6.5%, AACE target (yes/no) is presented.', 'timeFrame': 'Week 26'}, {'measure': 'Participants Who Achieved HbA1c < 7.0% and Change From Baseline in Body Weight Below or Equal to Zero', 'description': 'Participants who achieved HbA1c \\< 7.0% and change from baseline in body weight below or equal to zero is presented.', 'timeFrame': 'Week 26'}, {'measure': 'Participants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero', 'description': 'Participants who achieved HbA1c ≤ 6.5% and change from baseline in body weight below or equal to zero is presented.', 'timeFrame': 'Week 26'}, {'measure': 'Participants Who Achieved HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes', 'description': 'Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \\< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c \\< 7.0% at week 26 without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.', 'timeFrame': 'Week 26'}, {'measure': 'Participants Who Achieved HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes', 'description': 'Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \\< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c ≤ 6.5% at week 26 without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.', 'timeFrame': 'Week 26'}, {'measure': 'Participants Who Achieved HbA1c < 7.0% and Change From Baseline in Body Weight Below or Equal to Zero and Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes', 'description': 'Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \\< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c \\< 7.0% and change from baseline in body weight below or equal to zero and without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.', 'timeFrame': 'Week 26'}, {'measure': 'Participants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero and Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes', 'description': 'Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \\< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c ≤ 6.5% and change from baseline in body weight below or equal to zero and without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.', 'timeFrame': 'Week 26'}, {'measure': 'Number of Treatment-emergent Adverse Events (TEAEs)', 'description': 'A TEAE was defined as an adverse event with onset date on or after the first day of exposure to randomised treatment and no later than seven days after the last day of randomised treatment. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.', 'timeFrame': 'Weeks 0-27'}, {'measure': 'Number of Treatment-emergent Nocturnal Severe or BG Confirmed Hypoglycaemic Episodes', 'description': 'Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \\< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 a.m. both inclusive. Number of treatment-emergent nocturnal severe or BG confirmed hypoglycaemic episodes is presented.', 'timeFrame': 'Weeks 0-27'}, {'measure': 'Number of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes', 'description': 'Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \\< 3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes is presented.', 'timeFrame': 'Weeks 0-27'}, {'measure': 'Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes', 'description': 'Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \\< 3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 a.m. both inclusive. Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes is presented.', 'timeFrame': 'Weeks 0-27'}, {'measure': 'Number of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition', 'description': 'Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent hypoglycaemic episodes according to ADA definition is presented.', 'timeFrame': 'Weeks 0-27'}, {'measure': 'Change in Physical Examination', 'description': 'Physical examination parameters are categorised as cardiovascular system; central and peripheral nervous system; gastrointestinal system including mouth; general appearance; head, ears, eyes, nose, throat, neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at week -2 and week 26 is presented.', 'timeFrame': 'Week -2, week 26'}, {'measure': 'Eye Examination', 'description': 'Dilated fundoscopy or fundus photography was performed by the investigator at week -2 and week 26. The results of the examination were interpreted for each eye (left/right) are categorised as normal, abnormal NCS or abnormal CS. Number of participants in each category at week -2 and week 26 were presented.', 'timeFrame': 'Week -2, week 26'}, {'measure': 'Change in Electrocardiogram (ECG)', 'description': 'The ECG was assessed by the investigator at baseline (week -2) and week 26 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 26 were presented.', 'timeFrame': 'Week -2, week 26'}, {'measure': 'Change in Pulse', 'description': 'Change in pulse from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Blood Pressure (Systolic and Diastolic Blood Pressure)', 'description': 'Change in blood pressure (systolic and diastolic blood pressure) from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Biochemical Parameter- Amylase, Lipase, Creatinine Kinase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP)', 'description': 'Change in amylase, lipase, creatinine kinase, ALT, AST, ALP from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Biochemical Parameter-calcium (Total), Albumin Corrected Calcium, Potassium, Sodium, Urea', 'description': 'Change in calcium (total), albumin corrected calcium, potassium, sodium, urea from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Albumin', 'description': 'Change in albumin from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Total Bilirubin', 'description': 'Change in total bilirubin from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Creatinine', 'description': 'Change in creatinine from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Total Protein', 'description': 'Change in total protein from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Haematological Parameter- Haematocrit', 'description': 'Change in haematocrit from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Haematological Parameter- Haemoglobin', 'description': 'Change in haemoglobin from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Haematological Parameter- Leukocytes and Thrombocytes', 'description': 'Change in leukocytes and thrombocytes from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Haematological Parameter- Erythrocytes', 'description': 'Change in erythrocytes from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Haematological Parameter- Basophils', 'description': 'Change in basophils from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Haematological Parameter- Eosinophils', 'description': 'Change in eosinophils from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Haematological Parameter- Lymphocytes', 'description': 'Change in lymphocytes from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Haematological Parameter- Monocytes', 'description': 'Change in monocytes from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Haematological Parameter- Neutrophils', 'description': 'Change in neutrophils from baseline (week 0) to week 26 is presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Change in Calcitonin', 'description': 'Calcitonin levels were measured and were categorised as low, normal or high. Number of participants in each category at week 0 and week 26 were presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Urinalysis (Erythrocytes, Protein, Glucose and Ketones)', 'description': 'The urinalysis was the measurements of protein, glucose, erythrocytes and ketones at week 0 and week 26 and categorised as negative, trace, 1+, 2+ and 3+. Number of participants in each category at week 0 and week 26 are presented.', 'timeFrame': 'Week 0, week 26'}, {'measure': 'Anti-insulin Degludec Specific Antibodies', 'description': 'Serum samples were analysed for the presence of anti-insulin degludec specific antibodies. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).', 'timeFrame': 'Week 27'}, {'measure': 'Antibodies Cross-reacting to Human Insulin', 'description': 'Serum samples were analysed for the presence of antibodies cross-reacting to human insulin. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).', 'timeFrame': 'Week 27'}, {'measure': 'Total Insulin Antibodies', 'description': 'Serum samples were analysed for the presence of total insulin antibodies. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).', 'timeFrame': 'Week 27'}, {'measure': 'Occurrence of Anti-liraglutide Antibodies (Yes/no)', 'description': 'This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with anti-liraglutide antibodies at week 27 are presented.', 'timeFrame': 'Week 27'}, {'measure': 'Occurrence of Anti-liraglutide Antibodies Cross Reacting Native Glucagon-like Peptide-1 (GLP-1)', 'description': 'This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with anti-liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.', 'timeFrame': 'Week 27'}, {'measure': 'Occurrence of Neutralising Liraglutide Antibodies', 'description': 'This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with neutralising liraglutide antibodies at week 27 are presented.', 'timeFrame': 'Week 27'}, {'measure': 'Occurrence of Neutralising Liraglutide Antibodies Cross Reacting Native GLP-1', 'description': 'This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with neutralising liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.', 'timeFrame': 'Week 27'}]",61,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,453.0,ACTUAL,2025-09-01T16:18:23.457062,v2_robust,True,True,True,False,True,
NCT06762782,Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery,Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery,Postoperative adjuvant lenvatinib,['Postoperative adjuvant lenvatinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Hepatocellular Carcinoma (HCC),"['Hepatocellular Carcinoma (HCC)', 'Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation']",['lenvatinib；adjuvant therapy；hepatocellular carcinoma'],RECRUITING,,2025-02,2027-10,"[{'measure': '1-year cumulative recurrence-free patient percentage', 'description': 'Proportion of patients with high-risk recurrent hepatocellular carcinoma who are free of tumor recurrence within one year after curative surgery.', 'timeFrame': 'The patient started taking lenvatinib after radical surgery for hepatocellular carcinoma and continued treatment for up to 1 year.'}]","[{'measure': 'Recurrence Free Survival', 'description': 'The time elapsed from the date of enrollment to tumor recurrence or death from any cause (if the subject died before disease recurrence). Surviving subjects without confirmed tumor recurrence at the database cutoff date were censored based on the date of the last imaging tumor assessment. The date of tumor recurrence was the date of the first imaging confirmation of tumor recurrence.', 'timeFrame': 'The patient started taking lenvatinib after radical surgery for hepatocellular carcinoma and continued treatment for up to 3 years.'}, {'measure': 'Overall Survival', 'description': 'The elapsed time from the date of enrollment to the date of death from any cause. If the subject was still alive at the database cutoff date, the subject was censored at the date of the last survival follow-up in the database.', 'timeFrame': ""The time span from the date of surgery to the date of the patient's last follow-up visit or death, assessed up to 3 years.""}, {'measure': 'Time To Recurrence', 'description': 'The time elapsed from the date of enrollment to the date of tumor recurrence. Subjects who did not experience tumor recurrence at the database cutoff date were censored at the date of last imaging tumor assessment.', 'timeFrame': 'The time span from the date of radical liver resection to the date of first documented tumor recurrence, assessed up to 3 years.'}, {'measure': 'Diachronic changes in quality of life scores based on FACT-Hep scale', 'description': 'The FACT-Hep scale is a 46-item, self-assessed, multidimensional, validated questionnaire used to assess health-related quality of life in subjects with liver cancer types. FACT-Hep assessment dimensions include physical status, social/family status, emotional status, functional status and additional symptoms of hepatocellular carcinoma. Subjects responded to each item on the scale on a scale from 0 (not at all) to 4 (extremely). The average time required to complete the questionnaire is less than 10 minutes. Five subscale scores and one overall score can be calculated.', 'timeFrame': 'From enrollment date to database deadline, assessed up to 3 years.'}]",5,18 Years,80 Years,ALL,False,The First Affiliated Hospital with Nanjing Medical University,OTHER,10,276.0,ESTIMATED,2025-09-01T16:18:23.457286,v2_robust,True,True,False,False,False,
NCT01283282,Investigation of the Athero-Protective Effects of Clopidogrel,"Phase 4 Study of Clopidogrel in Patients With Stable Coronary Artery Disease to Determine Effects on Vascular Function, Biomarkers and Endothelial Progrenitor Cells",Clopidogrel,"['Placebo', 'Plavix', 'Clopidogrel']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Coronary Artery Disease,['Coronary Artery Disease'],[],COMPLETED,,2008-01,2010-12,"[{'measure': 'Flow-mediated Dilation (FMD)', 'description': 'Flow-mediated dilation (FMD) collected by an ultrasound and is measured by the percent change in diameter of the brachial artery from baseline to 12 weeks.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Nitroglycerin-mediated Vasodilation', 'description': 'Nitroglycerin (NTG)-mediated vasodilation was measured after 0.4 mg of NTG was administered sublingually. Brachial artery images were obtained via ultrasound after three minutes of NTG administration. Measurements from the twelve frames will be averaged to calculate the percent change in diameter of the brachial artery from baseline to 12 weeks.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Endothelial Progenitor Cells (EPCs)', 'description': 'The circulating progenitor-enriched population of cells was measured by the expression of surface antigens using direct flow cytometry for CD34+, CD34+/CD133+, CD34+/ VEGF2R+ and CD34+/CD133+/VEGF2R+', 'timeFrame': 'Week 12'}]","[{'measure': 'Pulse Wave Velocity (PWV)', 'description': 'PWV was measured between the carotid and femoral arteries using the SphygmoCor device. Pressure waveforms at the carotid and femoral arteries were acquired using EKG gating. Velocity (distance per time in seconds) was calculated using the foot-to-foot method and the distance between the sites was measured manually.', 'timeFrame': 'Week 12'}, {'measure': 'Oxidative Stress Markers', 'description': 'Oxidative stress was measured by using liquid chromatography to collect plasma cystine, cysteine, gluthione, and oxidized glutathione levels.', 'timeFrame': 'Week 12'}, {'measure': 'Inflammatory Marker High-sensitivity C-reactive Protein (hsCRP)', 'description': 'High-sensitivity C-reactive protein (hsCRP) was measured. The hsCRP levels were measured by Dade Behring nephelometry.', 'timeFrame': 'Week 12'}, {'measure': 'Inflammatory Marker CD40 Ligand', 'description': 'CD40 ligand levels were measured. The level of CD40 ligand were measured using the Flurokine MultiAnalyte profiling (MAP) Human Base Kit B.', 'timeFrame': 'Week 12'}]",7,21 Years,80 Years,ALL,False,Emory University,OTHER,0,48.0,ACTUAL,2025-09-01T16:18:23.457332,v2_robust,True,True,True,False,False,
NCT03866382,Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors,"A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)",Cabozantinib S-malate,"['Cabometyx', 'BMS-907351', 'XL-184', 'XL 184', 'XL184', 'Cometriq', 'Cabozantinib S-malate']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Bladder Adenocarcinoma,"['Bladder Adenocarcinoma', 'Bladder Clear Cell Adenocarcinoma', 'Bladder Mixed Adenocarcinoma', 'Bladder Neuroendocrine Carcinoma', 'Bladder Small Cell Neuroendocrine Carcinoma', 'Bladder Squamous Cell Carcinoma', 'Chromophobe Renal Cell Carcinoma', 'Collecting Duct Carcinoma', 'Invasive Bladder Giant Cell Urothelial Carcinoma', 'Invasive Bladder Lymphoepithelioma-Like Carcinoma', 'Invasive Bladder Nested Urothelial Carcinoma', 'Invasive Bladder Plasmacytoid Urothelial Carcinoma', 'Invasive Bladder Sarcomatoid Urothelial Carcinoma', 'Invasive Bladder Urothelial Carcinoma', 'Kidney Medullary Carcinoma', 'Large Cell Neuroendocrine Carcinoma', 'Malignant Testicular Leydig Cell Tumor', 'Malignant Testicular Sertoli Cell Tumor', 'Metastatic Bladder Carcinoma', 'Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma', 'Metastatic Bladder Giant Cell Urothelial Carcinoma', 'Metastatic Bladder Large Cell Neuroendocrine Carcinoma', 'Metastatic Bladder Lipid-Rich Urothelial Carcinoma', 'Metastatic Bladder Micropapillary Urothelial Carcinoma', 'Metastatic Bladder Plasmacytoid Urothelial Carcinoma', 'Metastatic Bladder Sarcomatoid Urothelial Carcinoma', 'Metastatic Bladder Small Cell Neuroendocrine Carcinoma', 'Metastatic Bladder Squamous Cell Carcinoma', 'Metastatic Chromophobe Renal Cell Carcinoma', 'Metastatic Kidney Medullary Carcinoma', 'Metastatic Malignant Genitourinary System Neoplasm', 'Metastatic Papillary Renal Cell Carcinoma', 'Metastatic Penile Carcinoma', 'Metastatic Prostate Small Cell Neuroendocrine Carcinoma', 'Metastatic Sarcomatoid Renal Cell Carcinoma', 'Metastatic Urethral Carcinoma', 'Papillary Renal Cell Carcinoma', 'Sarcomatoid Renal Cell Carcinoma', 'Stage IV Bladder Cancer AJCC v8', 'Stage IV Penile Cancer AJCC v8', 'Stage IV Renal Cell Cancer AJCC v8', 'Stage IV Urethral Cancer AJCC v8', 'Stage IVB Prostate Cancer AJCC v8', 'Urachal Adenocarcinoma', 'Urethral Clear Cell Adenocarcinoma']",[],RECRUITING,,2019-05-13,2026-02-28,"[{'measure': 'Objective response rate (ORR)', 'description': 'An objective response is defined as a confirmed complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. A confirmed tumor response is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Will be estimated by the number of confirmed objective responses divided by the total number of evaluable patients. Confidence intervals for the true ORR will be calculated.', 'timeFrame': 'Up to 5 years'}]","[{'measure': 'Duration of response', 'description': ""Defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest best objective status is first noted to be either a CR or PR to the earliest date progression is documented."", 'timeFrame': 'From time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 5 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'The median its 95% confidence interval will be determined and will be summarized using the Kaplan-Meier estimator.', 'timeFrame': 'From start of treatment to time of progression or death, whichever occurs first, assessed up to 5 years'}, {'measure': 'Overall survival', 'description': 'The median its 95% confidence interval will be determined and will be summarized using the Kaplan-Meier estimator.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Clinical benefit rate (CBR)', 'description': 'A confirmed clinical benefit is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart or a confirmed stable disease at two consecutive tumor assessments at least 3 months apart. The CBR will be estimated by the number of patients with confirmed clinical benefit divided by the total number of evaluable patients. Confidence intervals for the true CBR will be calculated using exact binomial confidence intervals.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Incidence of adverse events (AE)', 'description': 'Will be assessed using Common Terminology Criteria for Adverse Events version 5.0. The maximum of a particular AE will be determined for each patient. Tables will summarize the number and relative frequency of patients observing an AE as well as the number and relative frequency of patients experiencing any AE of grade 3 or greater.', 'timeFrame': 'Up to 5 years'}]",6,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,314.0,ESTIMATED,2025-09-01T16:18:23.457366,v2_robust,True,True,False,False,True,
NCT00408382,Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque,,"atorvastatin, Lipitor","['atorvastatin, Lipitor']",1,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypercholesteremia,"['Hypercholesteremia', 'Coronary Artery Disease']","['Lipitor', 'atorvastatin', 'Hypercholesteremia', 'yellow coronary plaque']",COMPLETED,,,,"[{'measure': 'Changes in plaque characteristics as observed by coronary angioscopy'}, {'measure': '(the amount of yellow plaque and grade shall be determined by the coronary angioscopic findings evaluation committee)'}, {'measure': 'Changes in the volume and the echogenicity as observed by intravascular ultrasound'}]","[{'measure': 'Rate of change in serum lipid level'}, {'measure': 'Changes in the surface character and size of plaque as observed by coronary angioscopy (determined by the angioscopic findings evaluation committee)'}]",5,20 Years,74 Years,ALL,False,Astellas Pharma Inc,INDUSTRY,0,50.0,,2025-09-01T16:18:23.457397,v2_robust,True,True,True,False,False,
NCT00144482,A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy,"A Randomized, Double-Blind Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy",recombinant human erythropoietin,"['recombinant human erythropoietin placebo', 'recombinant human erythropoietin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Chemotherapy Induced Anemia,['Chemotherapy Induced Anemia'],[],COMPLETED,,2003-12,2005-08,"[{'measure': 'The increase in Hb concentration', 'timeFrame': 'week 8'}]","[{'measure': 'Changes in QOL scores', 'timeFrame': '8 weeks'}]",2,20 Years,79 Years,ALL,False,Chugai Pharmaceutical,INDUSTRY,0,122.0,ACTUAL,2025-09-01T16:18:23.457417,v2_robust,True,True,True,False,False,
NCT01595282,Intramuscular Ketorolac Versus Oral Ibuprofen for Pain Relief in First Trimester Suction Curettage,Intramuscular Ketorolac Versus Oral Ibuprofen for Pain Relief in First Trimester Suction Curettage: a Randomized Clinical Trial.,Ketorolac,"['Ibuprofen', 'Ketorolac', 'Toradol']",3,INTERVENTIONAL,['NA'],,,Pain,['Pain'],"['pain', 'suction curettage']",COMPLETED,,2011-06,2012-06,"[{'measure': 'Immediate Post-procedure Pain Score', 'description': ""The primary endpoint is subjects' immediate post-procedure pain score on a 21-point 0 to 100 scale, 0 = no pain and 100 = worst possible pain (in increments of five). This scale has been previously validated and used for research purposes, including for pain research evaluating suction curettage elsewhere and at our institution (Jensen 1986, Williamson 2004, Allen 2009)."", 'timeFrame': 'Immediately (within 1 minute) after suction and speculum removal'}]","[{'measure': 'Pain Scores Immediately After Cervical Dilation', 'description': '21-point 0 to 100 scale where 0 = no pain and 100 = worst possible pain (in increments of five)', 'timeFrame': 'Immediately (within 1 minute) after cervical dilation prior to the introduction of the suction cannula'}, {'measure': 'Pain Scores 15 Minutes Post-procedure', 'description': '21-point 0 to 100 scale, where 0 = no pain and 100 = worst possible pain (in increments of five)', 'timeFrame': 'Fifteen minutes after the procedure'}]",3,18 Years,,FEMALE,True,Planned Parenthood League of Massachusetts,OTHER,1,94.0,ACTUAL,2025-09-01T16:18:23.457462,v2_robust,True,True,True,False,False,
NCT02647424,A Comparison of Letrozole and Clomifene Citrate,A Comparison of Hormonal Profile and the Follicular Development Between Letrozole and Clomifene Citrate in Anovulatory Women With Polycystic Ovary Syndrome and Ovulatory Women,Letrozole,"['Letrozole group', 'Clomiphene group', 'Clomiphene', 'Letrozole']",4,INTERVENTIONAL,['NA'],,,Polycystic Ovarian Syndrome,"['Polycystic Ovarian Syndrome', 'Subfertility']",[],UNKNOWN,,2015-12,2017-12,"[{'measure': 'FSH concentrations', 'timeFrame': 'Alternative day during ovulation induction cycle (for about 3 month)'}]","[{'measure': 'LHconcentration', 'timeFrame': 'Alternative day during ovulation induction cycles (for about 3 month)'}, {'measure': 'Endometrial Thickness', 'timeFrame': 'Monitoring during ovulation induction cycle (for about 3 month)'}, {'measure': 'Oestradiol concentration', 'timeFrame': 'Alternative day during ovulation induction cycles (for about 3 month)'}, {'measure': 'Progesterone concentration', 'timeFrame': 'Alternative day during ovulation induction cycles (for about 3 month)'}, {'measure': 'Number of growing follicles', 'timeFrame': 'Monitoring during OI cycles (for about 3 month)'}]",6,18 Years,39 Years,FEMALE,False,The University of Hong Kong,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:23.457524,v2_robust,True,True,False,False,False,
NCT01711424,An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease,,OPTIVE PLUS®,['OPTIVE PLUS®'],1,OBSERVATIONAL,[],,,Dry Eye Syndromes,['Dry Eye Syndromes'],[],COMPLETED,,2012-09,2013-03,"[{'measure': 'Number of Participants Very Satisfied or Satisfied With OPTIVE PLUS®', 'description': 'Patients rated their satisfaction with OPTIVE PLUS® as treatment for dry eye signs and symptoms using a 4-point scale (Very satisfied, Satisfied, Dissatisfied or Very dissatisfied).', 'timeFrame': 'Week 4'}]","[{'measure': 'Number of Participants Where Physician Was Very Satisfied or Satisfied With OPTIVE PLUS®', 'description': ""The physician rated their satisfaction with OPTIVE PLUS® for the treatment of their patient's dry eye signs and symptoms using a 4-point scale (Very satisfied, Satisfied, Dissatisfied or Very dissatisfied)."", 'timeFrame': 'Week 4'}, {'measure': 'Tear Break Up Time (TBUT)', 'description': 'TBUT is the time in seconds required for dry spots to appear on the corneal surface after blinking. The longer it takes, the more stable the tear film.', 'timeFrame': 'Baseline, Week 4'}, {'measure': 'Schirmer Score', 'description': 'The Schirmer Test measures the rate of the secretion of tears produced by the eye over 5 minutes (min). The results indicate the presence of dry eye (Normal = greater than or equal to 10 millimeters (mm) of tears, Dry Eye = less than 10 mm of tears). The smaller the number, the more severe the dry eye.', 'timeFrame': 'Baseline, Week 4'}]",4,18 Years,,ALL,False,Allergan,INDUSTRY,0,1209.0,ACTUAL,2025-09-01T16:18:23.457547,v2_robust,False,True,True,False,False,
NCT06453824,"SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants","A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants",MDI-2517,['MDI-2517'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Safety and Tolerability,['Safety and Tolerability'],[],COMPLETED,,2024-05-17,2024-11-11,"[{'measure': 'To evaluate the incidence of treatment emergent adverse events [safety and tolerability] of a single-ascending oral dose of MDI-2517 in healthy participants', 'description': 'Adverse reactions to the study drug MDI-2517 will be measured', 'timeFrame': '5 days'}]","[{'measure': 'To evaluate the levels of MDI-2517 in blood plasma following a single oral dose of MDI-2517 in healthy participants', 'description': 'The levels of MDI-2517 in blood plasma following an oral single-dose of MDI-2517 tablets will be measured.', 'timeFrame': '5 days'}]",2,18 Years,55 Years,ALL,True,"MDI Therapeutics, Inc.",INDUSTRY,0,48.0,ACTUAL,2025-09-01T16:18:23.457577,v2_robust,True,True,True,False,True,
NCT05233124,Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia,A Randomized Controlled Trial of Dual Antiplatelet Therapy Versus Antiplatelet Monotherapy and Oral Anticoagulation in Patients With Acute Coronary Syndrome and Coronary Artery Ectasia: OVER-TIME,Rivaroxaban 15 MG,"['Aspirin', 'Clopidogrel 75 Mg Oral Tablet', 'Acetylsalicylic acid 100mg', 'Clopidogrel 75mg', 'Rivaroxaban 15 MG', 'Plavix']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Coronary Syndrome,"['Acute Coronary Syndrome', 'Coronary Artery Ectasia']","['Coronary artery ectasia', 'Antithrombotic therapy', 'Acute coronary syndrome', 'Coronary dilatation']",UNKNOWN,,2021-09-01,2024-07-30,"[{'measure': 'Composite of cardiovascular death, recurrent MI and repeated revascularization', 'description': 'Main efficacy combined outcome of cardiovascular death, recurrent MI and repeated revascularization', 'timeFrame': '1 year.'}, {'measure': 'Composite of minor and major bleeding events.', 'description': 'Main safety combined outcome of minor and major events, measured by BARC scale.', 'timeFrame': '1 year'}]","[{'measure': 'Net clinical benefit composite endpoint, including cardiovascular death, recurrent MI, repeated revascularization and minor/major bleeding', 'description': 'Composite of cardiovascular death, recurrent MI, repeated revascularization and minor/major bleeding', 'timeFrame': '1 year'}, {'measure': 'Clot lysis time by turbidimetry', 'description': 'Time (in seconds) taken for turbidity to drop by 50% from maximum as a measure of lysis potential', 'timeFrame': '6 months'}]",4,18 Years,99 Years,ALL,False,Instituto Nacional de Cardiologia Ignacio Chavez,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:23.457594,v2_robust,True,True,False,False,True,
NCT03482024,A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function,Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal Function,Tirzepatide,"['LY3298176', 'Tirzepatide']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Renal Insufficiency,"['Renal Insufficiency', 'End Stage Renal Disease']",[],COMPLETED,,2018-03-30,2019-08-19,"[{'measure': 'Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast])', 'description': 'Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to tlast (AUC\\[0-tlast\\]) of Tirzepatide was evaluated.', 'timeFrame': 'Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose'}, {'measure': 'PK: Maximum Concentration of Tirzepatide', 'description': 'Cmax is the maximum observed concentration of Tirzepatide.', 'timeFrame': 'Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose'}, {'measure': 'PK: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC[0-inf])', 'description': 'Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\\[0-inf\\]) of Tirzepatide was evaluated.', 'timeFrame': 'Predose, 8hours(h), 12h, 24h, 48h, 72h, 96h, 168h, 336h postdose'}]",[],3,18 Years,85 Years,ALL,True,Eli Lilly and Company,INDUSTRY,0,45.0,ACTUAL,2025-09-01T16:18:23.457635,v2_robust,True,True,True,False,False,
NCT06418724,Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma,Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma,Cetuximab,"['Cetuximab', 'Libtayo', 'Cemiplimab', 'Erbitux']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Locally Advanced Cutaneous Squamous Cell Carcinoma,['Locally Advanced Cutaneous Squamous Cell Carcinoma'],"['immunotherapy', 'neoadjuvant therapy', 'PD-1 inhibitor', 'EGFR inhibitor', 'cetuximab', 'cemiplimab']",NOT_YET_RECRUITING,,2025-12-11,2028-12-01,"[{'measure': 'Preliminary activity', 'description': 'The primary preliminary activity endpoint will be the achievement of clinical downstaging from borderline resectable status to either resectable status or surgery avoidance due to complete metabolic response with no residual pathological disease as deemed by Multi-Disciplinary Team (MDT) consensus evaluation following up to 4 cycles of neoadjuvant therapy.', 'timeFrame': '3 months'}]","[{'measure': 'Treatment safety and feasibility as assessed by NCI CTCAE v5', 'description': 'Safety and feasibility by assessment of Common Terminology Criteria for Adverse Events (CTCAE) V5.0 with the incidence of ≥ Grade 3 adverse events, \\< Grade 3 adverse events and SAEs and AEs leading to study treatment discontinuation.', 'timeFrame': '12 months'}, {'measure': 'Treatment safety and feasibility as assessed by rate of R0 resection', 'description': 'Safety and feasibility by assessment of change in rate of R0 resection. R0 resection is defined no residual tumour in surgically removed specimen of curative intent per local and central pathology review.', 'timeFrame': '12 months'}, {'measure': 'Pathological response rate', 'description': 'Preliminary efficacy by assessment of pathological response rate, including complete (0% residual tumour cells) and major (0-10% residual tumour cells) pathological responses, by blinded central pathology review. Complete pathological response (pCR) defined as absence of viable tumor cells in surgical specimen. Major pathological response (MPR) defined as 0-10% viable tumor cells in surgical specimen.', 'timeFrame': '12 months'}, {'measure': 'Overall response rate (ORR)', 'description': 'Preliminary efficacy by assessment of overall response rate (ORR) as per Modifed Response Evaluation Criteria in Solid Tumors for immune based therapeutics (iRECIST) criteria or investigator caliper assessment where disease is un-measurable by CT or MRI modalities', 'timeFrame': '12 months'}, {'measure': 'Progression free survival (PFS)', 'description': 'Preliminary efficacy by assessment of 12-month and median PFS using the Kaplan-Meier method. PFS is defined as the interval from date of registration to the date of first evidence of disease progression or death, whichever occurs first.', 'timeFrame': '12 months'}, {'measure': 'Event-free survival (EFS)', 'description': 'Preliminary efficacy by assessment of 12-month and median EFS using the Kaplan-Meier method. EFS is defined as the interval from date of registration to progressive disease or adverse events precluding surgery, inability to undergo complete (R0) resection, disease recurrence or death from any cause.', 'timeFrame': '12 months'}, {'measure': 'Overall survival (OS)', 'description': 'Preliminary efficacy by assessment of 12-month and median OS using the Kaplan-Meier method. OS is defined as the interval from date of registration to date of death from any cause, or the date of last known follow-up alive.', 'timeFrame': '12 months'}, {'measure': 'Change in predicted difficulty of surgical resection and repair', 'description': 'Change in predicted difficulty of surgical resection and repair pre- and post-neoadjuvant therapy as measured with paired surgeon-rated scaling ""scale for predicted operability of cutaneous SCC"". Scale scores range from Inoperable disease (A) to Complete response (F)', 'timeFrame': '3 months'}]",9,18 Years,,ALL,False,Melanoma and Skin Cancer Trials Limited,OTHER,0,27.0,ESTIMATED,2025-09-01T16:18:23.457650,v2_robust,True,True,False,False,True,
NCT00963924,D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia,A Placebo-controlled Trial of D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia,D-cycloserine,"['Cycloserine', 'Placebo', 'D-cycloserine']",3,INTERVENTIONAL,['NA'],,,Schizophrenia,['Schizophrenia'],"['Cognitive Impairment', 'Neuroplasticity', 'D-cycloserine', 'NMDA', 'Anti-Bacterial Agents', 'Mental Disorders', 'Psychotic Disorders', 'Antitubercular Agents', 'Schizophrenia and Disorders with Psychotic Features', 'Schizoaffective Disorder']",COMPLETED,,2009-08,2011-06,"[{'measure': 'Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS)', 'description': 'Change of a composite score from baseline to week 8 on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS). The MATRICS consists of 10 cognitive tasks that are used to calculate scores in 7 cognitive domains: speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. The raw scores on each cognitive task are transformed on a normative scale into t-scores, and then these scores are combined to calculate the domain scores. The composite score is calculated by averaging all domain t-scores to come up with one overall cognitive composite t-score. For all scores on the assessment, the higher the score the better the performance on the task.', 'timeFrame': 'Baseline vs. Week 8'}, {'measure': 'Scale for Assessment of Negative Symptoms (SANS)', 'description': 'The total scores from baseline and week 8 on the scale for the assessment of negative symptoms (SANS) total score. Total SANS scores range from 0-100. The SANS is comprised of 5 subscores: Affective Flattening or Blunting (score range 0-35), Alogia (score range 0-20), Avolition-Apathy (score range 0-15), Anhedonia-Asociality (score range 0-20), and Attention (0-10). For each scale, the higher the score the more prominent the negative symptoms were. The total score was computed by adding all the sub-scale total scores. Scores are reported for baseline and week 8.', 'timeFrame': 'Baseline vs. Week 8'}, {'measure': 'Auditory Discrimination Task: Interstimulus Interval (ISI)', 'description': 'The auditory discrimination task involved trials in which the subject differentiated between rapidly-presented frequency-modulated sweeps separated by a short interstimulus interval (ISI). In this task, sustained successful performance is more difficult with shorter stimulus presentations and ISIs (which were equal within a trial). Thus, our dependent measure was the shortest stimulus duration/ISI, in ms, for trials in which subjects were able to perform the task at 85% accuracy, referred to as ISI for simplicity. The shorter the score the better the performance on the task. Scores are reported for baseline and week 8.', 'timeFrame': 'Baseline vs. Week 8'}]","[{'measure': 'Positive and Negative Syndrome Scale (PANSS)', 'description': 'The baseline score on the positive symptom sub-scale of the Positive and Negative Syndrome Scale (PANSS). Total PANSS positive symptom sub-scale scores range from 7-49. The PANSS positive symptom sub-scale is comprised of 7 items rated on a scale of 1-7: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. A score of one on each item 1 absent, 2 is minimal, 3 is mild, 4 is moderate, 5 is moderately severe, 6 is severe, and 7 is extreme. The total score was computed by adding all the items on the sub-scale together. The higher a score the more prominent a positive symptom is.', 'timeFrame': 'Baseline'}, {'measure': 'Global Assessment of Functioning Scale (GAS)', 'description': ""The Global Assessment of Functioning Scale (GAS) measured at baseline. This scale measures social, occupational, and psychological functioning, on a scale of 0-100. The higher the score, the greater a participant's functioning level."", 'timeFrame': 'Baseline'}, {'measure': 'Heinrich Quality of Life Scale (QoL)', 'description': 'Baseline scores of the Heinrich Quality of Life Scale, a 21 item scale designed and validated to measure intrapsychic foundations, interpersonal relations, instrumental role, and common objects and activities in patients diagnosed with Schizophrenia. Patients are rated on each of the 21 items on a scale of 0-6. Total scores are computed by adding up the scores of each individual item, with a total score ranging from 0-126. Higher scores reflect higher functioning.', 'timeFrame': 'Baseline'}, {'measure': 'Calgary Depression Scale for Schizophrenia (CDSS)', 'description': 'Baseline scores on the Calgary Depression Scale for Schizophrenia (CDSS). Total CDSS scores range from 0-27. The assessment is comprised of 9 questions covering the topics of Depression, Hopelessness, Self Depreciation, Guilty Ideas of Reference, Pathological Guilt, Morning Depression, Early Wakening, Suicide, Observed Depression. Each item is scored on a scale from 0-3 (0 = absent, 1 = mild, 2 = moderate, 3 = severe). The total score is computed by adding up the individual scores of each item. The higher the score, the more prominent the symptoms of depression are for the participant.', 'timeFrame': 'Baseline'}, {'measure': 'Clinical Global Impression (CGI)', 'description': 'Considering you total clinical experience with this patient population, how mentally ill is the patient at this time?\n\n1=Normal, not at all, 2=Borderline mentally ill, 3=Mildy ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, 7=Among the most extremely ill patients; a higher score indicates worse outcome', 'timeFrame': 'Weeks 0 and 8, and Month 6 after cognitive remediation completion'}, {'measure': 'Side Effects Checklist (SEC)', 'description': 'Each side effect is entered as either yes or no for having had any severity of the side effect at each visit.', 'timeFrame': 'Weeks 0 - 8, and Month 6 after cognitive remediation completion'}]",9,18 Years,65 Years,ALL,False,Massachusetts General Hospital,OTHER,1,54.0,ACTUAL,2025-09-01T16:18:23.457692,v2_robust,True,True,True,False,False,
NCT02150824,"Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin","A Randomized, Double-blind, Placebo-controlled, Parallel Groups Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Three BI 187004 Doses Given Once Daily as Mono-therapy and of the Highest BI 187004 Dose Given Once Daily as Add on Treatment to Metformin Over 28 Days in Patients With Type 2 Diabetes Mellitus",Placebo,"['BI 187004', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],COMPLETED,,2014-07,2015-08,"[{'measure': 'The percentage of patients with drug- related adverse events', 'timeFrame': '6 weeks'}]","[{'measure': 'Change from baseline in fasting plasma glucose (FPG) after 28 days of treatment', 'timeFrame': '4 weeks'}]",2,18 Years,80 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,103.0,ACTUAL,2025-09-01T16:18:23.457776,v2_robust,True,True,True,False,True,
NCT05911724,Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.,Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Coronary Heart Disease and Heart Failure Patients Treated With Empagliflozin.,CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study,"['HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study', 'Empa- CAD', 'CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study', 'Empa-HF']",4,OBSERVATIONAL,[],,,Stable Angina,"['Stable Angina', 'Heart Failure']","['vaspin', 'visfatin', 'lipoprotein A', 'high-sensitivity C-reactive protein', 'sortilin', 'homocysteine', 'troponin I', 'fetuin A']",COMPLETED,,2023-03-01,2024-09-30,"[{'measure': 'All Cause 30 day hosptial admission', 'description': 'Number of patients admited to hospital during 1 month.', 'timeFrame': '1 month'}, {'measure': 'All Cause 90 day hosptial admission', 'description': 'Number of patients admited to hospital during 3 month.', 'timeFrame': '3 months'}, {'measure': 'vaspin (ng/ml)', 'description': 'vaspin blood concentration', 'timeFrame': '1 month'}, {'measure': 'visfatin (ng/ml)', 'description': 'visfatin blood concentration', 'timeFrame': '1 month'}, {'measure': 'Sortillin (pg/ml)', 'description': 'Sortillin blood concentration', 'timeFrame': '1 month'}, {'measure': 'Homocystien(umol/L)', 'description': 'Homocystien blood concentration', 'timeFrame': '1 Month'}, {'measure': 'Troponin.I (ng/ml)', 'description': 'Troponin.I blood concentration', 'timeFrame': '1 Month'}]",[],7,18 Years,80 Years,ALL,False,Damanhour University,OTHER,1,180.0,ACTUAL,2025-09-01T16:18:23.457840,v2_robust,False,True,True,False,False,
NCT00862524,A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer,,"ARRY-334543, EGFR/ErbB2 inhibitor; oral","['Gemcitabine, nucleoside analogue; intravenous', 'ARRY-334543, EGFR/ErbB2 inhibitor; oral']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Advanced Cancer,"['Advanced Cancer', 'Pancreatic Cancer']",[],COMPLETED,,2009-03,2011-02,"[{'measure': 'Establish the maximum tolerated dose (MTD) of study drug in combination with gemcitabine.', 'timeFrame': 'Part 1'}, {'measure': 'Characterize the safety profile of study drug in combination with gemcitabine in terms of adverse events, clinical laboratory tests and electrocardiograms.', 'timeFrame': 'Part 1'}, {'measure': 'Characterize the pharmacokinetics (PK) of study drug, gemcitabine and a gemcitabine metabolite.', 'timeFrame': 'Part 1'}, {'measure': 'Assess the efficacy of the study drug in combination with gemcitabine in terms of progression-free survival (PFS) at 16 weeks.', 'timeFrame': 'Part 2'}]","[{'measure': 'Assess the efficacy of the study drug in combination with gemcitabine in terms of tumor response.', 'timeFrame': 'Part 1'}, {'measure': 'Characterize the safety profile of study drug in combination with gemcitabine in terms of adverse events, clinical laboratory tests and electrocardiograms.', 'timeFrame': 'Part 2'}]",6,18 Years,,ALL,False,Array BioPharma,INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:23.457877,v2_robust,True,True,True,False,True,
NCT05395624,"Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers","A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers",18F-OP-801,"['18F-OP-801', '18F Hydroxyl Dendrimer']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Amyotrophic Lateral Sclerosis (ALS),"['Amyotrophic Lateral Sclerosis (ALS)', 'Parkinson Disease (PD)', 'Alzheimer Disease (AD)', 'Multiple Sclerosis (MS)']",[],RECRUITING,,2023-02-02,2026-05-01,"[{'measure': 'The number of participants with treatment emergent adverse events (Safety and Tolerability)', 'description': 'Safety of single dose of 18F-OP-801 as measured by treatment-related adverse events as assessed by CTCAE v5.0', 'timeFrame': 'Safety and tolerability of 18F-OP-801 as assessed by the frequency, and severity of treatment-emergent adverse events (TEAEs) from Day 1 to Day 15 or Day 18-29'}]","[{'measure': 'Measurement of biodistribution of 18F-OP-801 for each participant', 'description': 'Measure biodistribution of 18F-OP-801 using whole body PET/MRI or PET/computed tomography (CT) scans', 'timeFrame': 'Through study completion at Day 15 or Day 18-29'}, {'measure': 'Measurement of clearance of 18F-OP-801 for each participant', 'description': 'Measure clearance of 18F-OP-801 using whole body PET/MRI or PET/computed tomography (CT) scans', 'timeFrame': 'Through study completion at Day 15 or Day 18-29'}, {'measure': 'Assess ability of 18F-OP-801 to detect regions of neuroinflammation in ALS, AD, MS, and PD participants', 'description': 'Determine correlation between MRI and PET images in each subject, quantifying the extent of 18F-OP-801 uptake in the region of neuroinflammation relative to normal brain section in the same subject as measured by whole body PET/MRI or PET/CT scans', 'timeFrame': 'Through study completion at Day 15 or Day 18-29'}, {'measure': 'Assess test/retest imaging repeatability', 'description': 'Compare regional and global brain uptake of 18F-OP-801 on two separate occasions', 'timeFrame': 'Through study completion at Day 18-29'}, {'measure': 'Correlation between plasma NfL levels and degree of 18F-OP-801 uptake in each participant', 'description': 'Correlation of plasma NfL levels with brain PET signal', 'timeFrame': 'Screening and Day 1'}, {'measure': 'Correlation between relevant clinical scales and degree of 18F-OP-801 uptake in each participant', 'description': 'Correlation of ALSFRS-R/PUMNS, MMSE, EDSS or SE-ADL scores with brain PET signal', 'timeFrame': 'Screening and Day 1'}]",7,18 Years,80 Years,ALL,True,"Ashvattha Therapeutics, Inc.",INDUSTRY,0,65.0,ESTIMATED,2025-09-01T16:18:23.457886,v2_robust,True,True,False,False,True,
NCT02044224,Effects of Dexmedetomidine During IRE Procedures for Solid Tumours,Effects of Dexmedetomidine on Anaesthesia During IRE Procedures for Solid Tumours,Dexmedetomidine,['Dexmedetomidine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Cancer of Liver,"['Cancer of Liver', 'Cancer of Pancreas']",[],COMPLETED,,2014-01,2015-09,"[{'measure': 'Patient Satisfaction With Anaesthesia Technique', 'description': 'Rating of how satisfied the patient was with their sedation on a scale of 1-5 with 1 being very dissatisfied and 5 being extreme', 'timeFrame': 'At the discharge from post-anaesthesia care room (up to 4 hours after the procedure)'}]","[{'measure': 'Evaluation of anaesthetic consumption', 'timeFrame': 'During anaesthesia'}, {'measure': 'Vital signs: blood pressure, oxygen saturation, heart rate, breathing rate', 'timeFrame': 'During procedure and up to 4 hours stay at the post-anesthesia care unit'}, {'measure': 'Postoperative analgesic requirements', 'timeFrame': 'During the first 24 hours after procedure'}, {'measure': 'Maximal pain intensity', 'description': 'The 11-point Numerical Rating Scale (NRS) to assess periprocedural pain. Scale of 0-10, with 0:no pain and 10: pain as bad as it could be', 'timeFrame': 'During stay at the post-anesthesia care unit (up to 4 hr) and during the first 24 hours after procedure'}, {'measure': 'Description of patient characteristics', 'description': 'Primary disease, concomitant diseases, medications, allergies', 'timeFrame': 'During one week before preoperative visit at anaesthesia clinic'}]",6,18 Years,85 Years,ALL,False,Uppsala University Hospital,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:23.457986,v2_robust,True,True,True,False,False,
NCT04311424,Study of Tirzepatide in Healthy Participants,Disposition of [14C]-Tirzepatide Following Subcutaneous Administration in Healthy Male Subjects,14C Tirzepatide,"['LY3298176', '14C Tirzepatide']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2020-07-28,2020-10-02,"[{'measure': 'Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered', 'description': 'Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered.', 'timeFrame': 'Pre-dose and up to 63 days post-dose'}, {'measure': 'Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered', 'description': 'Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered.', 'timeFrame': 'Pre-dose and up to 63 days post-dose'}]","[{'measure': 'Total Number of Metabolites', 'description': 'Total Number of Metabolites.', 'timeFrame': 'Pre-dose and up to 63 days post-dose'}, {'measure': 'Total Radioactivity Recovered in Urine, Feces, and Expired Air (if Applicable)', 'description': 'Total Radioactivity Recovered in Urine, Feces, and Expired Air (if Applicable).', 'timeFrame': 'Pre-dose and up to 63 days post-dose'}, {'measure': 'Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC[0-∞]) of Tirzepatide', 'description': 'Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC\\[0-∞\\]) of tirzepatide.', 'timeFrame': 'Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose'}, {'measure': 'PK: Maximum Concentration (Cmax) of Tirzepatide', 'description': 'PK: Maximum Concentration (Cmax) of tirzepatide.', 'timeFrame': 'Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose'}, {'measure': 'Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC[0-∞]) of Total Radioactivity', 'description': 'Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC\\[0-∞\\]) of Total Radioactivity. Total radioactivity is reported as hours\\*nanogram equivalents per milliliter (h\\*ng Eq/mL).', 'timeFrame': 'Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose'}, {'measure': 'PK: Maximum Concentration (Cmax) of Total Radioactivity', 'description': 'PK: Cmax of total radioactivity in plasma and whole blood. The Cmax of total radioactivity in plasma and whole blood are reported as nanogram equivalents per milliliter (ng Eq/mL).', 'timeFrame': 'Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose'}]",8,30 Years,55 Years,MALE,True,Eli Lilly and Company,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:23.458005,v2_robust,True,True,True,False,False,
NCT00767624,TRIAD - Treatment of Insomnia and Depression,Improving Depression Outcome by Adding Insomnia Therapy to Antidepressants,Antidepressant,['Antidepressant'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Sleep Initiation and Maintenance Disorders,"['Sleep Initiation and Maintenance Disorders', 'Depression']",[],COMPLETED,,2008-12,2015-06,"[{'measure': 'Percent of Participants With Depression Remission', 'description': 'Depression remission was defined if both a and b below are satisfied\n\n1. absence of both depressed mood and anhedonia for at least three consecutive weeks\n2. no more than two other diagnostic criterion symptoms of depression met for at least three consecutive weeks', 'timeFrame': '16 weeks'}]","[{'measure': 'Percentage of Participants in Insomnia Remission', 'description': 'Remission was defined as endpoint ISI\\<8. The ISI scale score ranges from 0 to 28 with lower scores representing less severe insomnia. A score of 0-7 is interpreted as absence of insomnia.', 'timeFrame': '16 weeks'}]",2,18 Years,75 Years,ALL,False,Stanford University,OTHER,3,150.0,ACTUAL,2025-09-01T16:18:23.458148,v2_robust,True,True,True,False,False,
NCT03353324,Comparison of Therapeutic Effects Between Intravitreal Injection of Bevacizumab With Intravitreal Injection of Bevacizumab and Targeted Laser Photocoagulation of Non Perfused Areas of Retina in Patients With Acute Retinal Vein Occlusion,Comparison of Therapeutic Effects Between Intravitreal Injection of Bevacizumab With Intravitreal Injection of Bevacizumab and Targeted Laser Photocoagulation of Non Perfused Areas of Retina in Patients With Acute Retinal Vein Occlusion,intravitreal injection of bevacizumab,['intravitreal injection of bevacizumab'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Retinal Vein Occlusion With Macular Edema,['Retinal Vein Occlusion With Macular Edema'],[],UNKNOWN,,2017-11-01,2018-09,"[{'measure': 'Visual acuity', 'description': 'Snellen chart', 'timeFrame': 'Every month'}]","[{'measure': 'macular thickness', 'description': 'OCT', 'timeFrame': 'every month'}]",2,18 Years,80 Years,ALL,True,Shahid Beheshti University of Medical Sciences,OTHER,0,74.0,ESTIMATED,2025-09-01T16:18:23.458162,v2_robust,True,True,False,False,False,
NCT00128323,"A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis","A Comparison of Gentian Violet Mouth Washes, Nystatin Drops and Ketoconazole Tabs in the Treatment of Oropharyngeal Candidiasis",Gentian violet 1% solution,"['Nystatin solution', 'Gentian violet 1% solution', 'Gentian violet 0.00165% solution']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,"Candidiasis, Oral","['Candidiasis, Oral']","['Children', 'oropharyngeal candidiasis', 'GV solution', 'nystatin drops']",COMPLETED,,2002-11,2005-04,"[{'measure': 'Clinical clearance of oral candidiasis by day 12'}, {'measure': 'Fungal clearance of oral candidiasis by saliva culture'}]",[{'measure': 'Clinical and saliva fungal clearance in HIV infected and HIV uninfected children at 12 days and at 21 days'}],3,,14 Years,ALL,False,Kamuzu University of Health Sciences,OTHER,1,558.0,,2025-09-01T16:18:23.458171,v2_robust,True,True,True,False,False,
NCT00310323,Hepatic Drug Biotransformation in Children With Obstructive Sleep Apnea,Effect of Chronic Intermittent Nocturnal Hypoxia on Hepatic Drug Biotransformation in Children With Obstructive Sleep Apnea,Dextromethorphan,"['Caffeine', 'Dextromethorphan']",2,INTERVENTIONAL,['NA'],,,Sleep Apnea,['Sleep Apnea'],"['sleep apnea', 'phenotyping', 'cytochrome P450', 'drug metabolism', 'child']",COMPLETED,,2003-01,2006-02,"[{'measure': 'Caffeine urinary molar ratio', 'timeFrame': 'Pre and post T&A'}, {'measure': 'Dextromethorphan urinary molar ratio', 'timeFrame': 'Pre and post T&A'}]",[],2,4 Years,16 Years,ALL,False,Virginia Commonwealth University,OTHER,1,69.0,ACTUAL,2025-09-01T16:18:23.458182,v2_robust,True,True,True,False,False,
NCT02174523,Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects,Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects,40mg lurasidone,"['40mg lurasidone', 'placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Schizophrenia,['Schizophrenia'],"['pharmacokinetic', 'lurasidone', 'multiple dose']",COMPLETED,,2014-04,2014-04,"[{'measure': 'Lurasidone Cmax', 'description': 'Maximum (peak) observed drug serum concentration.', 'timeFrame': 'pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose'}, {'measure': 'Lurasidone AUC 0-24', 'timeFrame': 'pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose'}, {'measure': 'Lurasidone AUC 0-τ', 'timeFrame': 'pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose'}, {'measure': 'Lurasidone AUC0-∞', 'timeFrame': 'pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose'}, {'measure': 'Lurasidone Tmax', 'timeFrame': 'pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose'}, {'measure': 'Lurasidone λz', 'timeFrame': 'pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose'}, {'measure': 'Lurasidone t1/2', 'timeFrame': 'pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose'}, {'measure': 'Lurasidone MRT', 'timeFrame': 'pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose'}, {'measure': 'Lurasidone CL/F', 'timeFrame': 'pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose'}, {'measure': 'CLss/F', 'timeFrame': 'Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8'}, {'measure': 'Lurasidone Vz/F', 'timeFrame': 'pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose'}, {'measure': 'Lurasidone Vzss/F', 'timeFrame': 'Day 8'}, {'measure': 'Accumulation Ratios Lurasidone,Ratio of Cmax,Ratio of AUC0-∞,Ratio of AUC0-τ,', 'timeFrame': 'Day 8/Day 1'}, {'measure': 'Summary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 4 and Day 5', 'timeFrame': 'Pre-dose (-0.5h) of Day4 and Day5'}, {'measure': 'Summary of Concentration (ng/mL) of Lurasidone - PK Population the Mean (SD) of Day 6 and Day 7', 'timeFrame': 'Pre-dose (-0.5h) of Day6 and Day7'}, {'measure': 'Lurasidone Cmax', 'description': 'Maximum (peak) observed drug serum concentration.', 'timeFrame': 'Day8'}, {'measure': 'Lurasidone AUC 0-24', 'timeFrame': 'Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8'}, {'measure': 'Lurasidone AUC 0-τ', 'timeFrame': 'Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8'}, {'measure': 'Lurasidone AUC0-∞', 'timeFrame': 'Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8'}, {'measure': 'Lurasidone Tmax', 'timeFrame': 'Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8'}, {'measure': 'Lurasidone λz', 'timeFrame': 'Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8'}, {'measure': 'Lurasidone t1/2', 'timeFrame': 'Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8'}, {'measure': 'Lurasidone MRT', 'timeFrame': 'Day8 0.5hours pre-dose, 0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose in day 8'}]",[],23,18 Years,40 Years,MALE,True,"Sumitomo Pharma (Suzhou) Co., Ltd.",INDUSTRY,1,14.0,ACTUAL,2025-09-01T16:18:23.458232,v2_robust,True,True,True,False,False,
NCT02511223,Efficacy and Safety of PARPi to Treat Pancreatic Cancer,PHASE II Study - EFFICACY AND SAFETY OF (PARPi )Polyadenosine Diphosphoribose [Poly Polymerisation inhibitorTO TREAT PANCREATIC CANCER,OLAPARIB,"['PARPi', 'OLAPARIB']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Pancreatic Cancer,['Pancreatic Cancer'],[],COMPLETED,,2016-07,2021-04-18,"[{'measure': 'Objective Response Rate (ORR) by using RECIST 1.1', 'description': 'Due to lack of results, study has been early terminated', 'timeFrame': 'approximately- 24 months'}]",[],1,18 Years,,ALL,False,Sheba Medical Center,OTHER_GOV,0,24.0,ACTUAL,2025-09-01T16:18:23.458276,v2_robust,True,True,True,False,False,
NCT00212823,The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain,AXERT® 12.5mg Time vs Intensity Migraine Study (AIMS): An Open-label Multicenter Trial to Evaluate the Efficacy of Almotriptan Malate (AXERT®) 12.5 Milligram Intervention at Onset of Migraine Pain,almotriptan malate,['almotriptan malate'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Migraine,['Migraine'],['Migraine'],COMPLETED,,2004-06,2005-02,[{'measure': 'Duration of migraine pain measured from onset of pain to no pain.'}],[],1,18 Years,65 Years,ALL,False,"Ortho-McNeil Neurologics, Inc.",INDUSTRY,0,1450.0,ACTUAL,2025-09-01T16:18:23.458426,v2_robust,True,True,True,False,False,
NCT07062523,Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT,Application of [68Ga]Ga-FAPI-04 PET/CT in the Assessment of Inflammatory Activity in Sjögren's Syndrome,68Ga-FAPI,"['68Ga-Fibroblast activation protein Inhibitor', '68Ga-FAPI']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Sjogren's Syndrome,"[""Sjogren's Syndrome""]",[],RECRUITING,,2024-07-01,2025-12-01,"[{'measure': 'Optimal imaging time', 'description': ""Patients were included for PET dynamic imaging to find the optimal imaging time for FAPI PET in Sjögren's syndrome"", 'timeFrame': 'up to 3 month'}, {'measure': 'Correlation with inflammatory markers', 'description': 'Inflammatory and immune markers (e.g., IL-6, TNF-α, CRP) were measured using enzyme-linked immunosorbent assay (ELISA) in all patients, and correlational analysis was performed with PET uptake values.', 'timeFrame': '6 weeks'}]",[],2,18 Years,80 Years,ALL,True,Peking Union Medical College Hospital,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:23.458459,v2_robust,True,True,False,False,False,
NCT00866723,"Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer","Phase II Study of Single-Agent Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous, Papillary Serous Endometrial or Fallopian Tube Cancer Who Have Recurred After Prior Therapy With Maintenance Avastin",bevacizumab,"['bevacizumab', 'Avastin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Cancer,"['Ovarian Cancer', 'Primary Peritoneal Serous Cancer', 'Fallopian Tube Cancer']","['Avastin', 'bevacizumab']",TERMINATED,Recruitment has been terminated prematurely because of poor enrollment.,2009-03,2012-06,"[{'measure': 'Clinical Response Rate', 'description': 'For measurable disease (MD) patients, clinical response on treatment was based on RECIST 1.0 criteria with overall response defined as achieving partial response (PR) or complete response (CR). Per RECIST 1.0 for target lesions, CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions. For non-MD patients, clinical response based on modified Gynecologic Cancer Intergroup (GCIG) criteria was defined as at least a 50% decrease in CA-125 levels.', 'timeFrame': 'Disease was evaluated at baseline and every 3 cycles on treatment. Treatment continued until disease progression or unacceptable toxicity. Patients underwent radiologic assessment (CT or MRI scans) and CA-125 levels were measured.'}, {'measure': 'Clinical Benefit Response Rate', 'description': 'Clinical benefit response was defined as absence of disease progression at 18 weeks (ie after 6 cycles). Disease progression (PD) could occur per RECIST 1.0 or based on CA-125 levels. Per RECIST 1.0 for target lesions, PD is at least a 20% increase in sum LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or appearance of new lesions. For non-target lesions, PD is the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Disease progression based on CA-125 level was doubling of the CA-125 level from baseline. For patients with normal baseline CA-125 (who by definition had MD) the criterion for progression based on CA-125 doubling was doubling of CA-125 from the upper limit of normal (i.e. more than 70).', 'timeFrame': 'Disease was evaluated at baseline and every 3 cycles on treatment. Treatment continued until disease progression or unacceptable toxicity. Patients underwent radiologic assessment (CT or MRI scans) and CA-125 levels were measured.'}]",[],2,18 Years,,ALL,False,Beth Israel Deaconess Medical Center,OTHER,3,5.0,ACTUAL,2025-09-01T16:18:23.458477,v2_robust,True,True,False,True,False,Recruitment has been terminated prematurely because of poor enrollment.
NCT02967159,"A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants","A RANDOMIZED OPEN LABEL CROSS-OVER STUDY TO EVALUATE PHARMACOKINETICS AND SAFETY OF SINGLE INHALED DOSES OF ABEDITEROL AND AZD7594 GIVEN ALONE, IN FIXED DOSE COMBINATION (FDC) AND IN FREE COMBINATION, USING DPI, IN MALE HEALTHY VOLUNTEERS",Abediterol,"['AZD7594', 'Treatment B', 'Treatment D', 'AZD7594/abediterol', 'Treatment C', 'Abediterol', 'AZD7594 and abediterol', 'Treatment A']",8,INTERVENTIONAL,['PHASE1'],PHASE1,,Chronic Obstructive Pulmonary Disease (COPD),"['Chronic Obstructive Pulmonary Disease (COPD)', 'Asthma']","['chronic obstructive pulmonary disease (COPD)', 'asthma']",COMPLETED,,2016-11-24,2017-04-06,"[{'measure': 'Area under the plasma concentration time curve (AUC) of abediterol and AZD7594 from time zero extrapolated to infinity. AUC is estimated by AUClast + Clast/λz where Clast is the last observed quantifiable concentration', 'description': 'Pharmacokinetics of AZD7594 and abediterol following single inhaled doses of AZD7594 alone, abediterol alone and the 2 compounds in FDC or in free combination via 2 separate DPIs', 'timeFrame': 'Day -1 to Day 3. Subjects will also return to the Unit at 72, 96, 144 and 240 hours post-dose (Days 4, 5, 7 and 11 respectively) for PK measurements'}, {'measure': 'Maximum observed plasma concentration (AUClast), taken directly from the individual concentration time curve of abediterol and AZD7594.', 'description': 'Pharmacokinetics of AZD7594 and abediterol following single inhaled doses of AZD7594 alone, abediterol alone and the 2 compounds in FDC or in free combination via 2 separate DPIs', 'timeFrame': 'Day -1 to Day 3. Subjects will also return to the Unit at 72, 96, 144 and 240 hours post-dose (Days 4, 5, 7 and 11 respectively) for PK measurements'}, {'measure': 'Observed maximum concentration (Cmax) of abediterol and AZD7594, taken directly from the individual concentration time curve.', 'description': 'Pharmacokinetics of AZD7594 and abediterol following single inhaled doses of AZD7594 alone, abediterol alone and the 2 compounds in FDC or in free combination via 2 separate DPIs', 'timeFrame': 'Day -1 to Day 3. Subjects will also return to the Unit at 72, 96, 144 and 240 hours post-dose (Days 4, 5, 7 and 11 respectively) for PK measurements'}, {'measure': 'Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t½λz) of abediterol and AZD7594 using plasma concentrations, estimated as (ln2)/λz.', 'description': 'Pharmacokinetics of AZD7594 and abediterol following single inhaled doses of AZD7594 alone, abediterol alone and the 2 compounds in FDC or in free combination via 2 separate DPIs', 'timeFrame': 'Day -1 to Day 3. Subjects will also return to the Unit at 72, 96, 144 and 240 hours post-dose (Days 4, 5, 7 and 11 respectively) for PK measurements'}, {'measure': 'Time to reach maximum observed plasma concentration (tmax) of abediterol and AZD7594 using plasma concentrations, taken directly from the individual concentration time curve.', 'description': 'Pharmacokinetics of AZD7594 and abediterol following single inhaled doses of AZD7594 alone, abediterol alone and the 2 compounds in FDC or in free combination via 2 separate DPIs', 'timeFrame': 'Day -1 to Day 3. Subjects will also return to the Unit at 72, 96, 144 and 240 hours post-dose (Days 4, 5, 7 and 11 respectively) for PK measurements'}, {'measure': 'Mean residence time (MRT) of abediterol and AZD7594.', 'description': 'Pharmacokinetics of AZD7594 and abediterol following single inhaled doses of AZD7594 alone, abediterol alone and the 2 compounds in FDC or in free combination via 2 separate DPIs', 'timeFrame': 'Day -1 to Day 3. Subjects will also return to the Unit at 72, 96, 144 and 240 hours post-dose (Days 4, 5, 7 and 11 respectively) for PK measurements'}, {'measure': 'Apparent estimated as dose divided by AUC.total body clearance of drug from plasma after extravascular administration (CL/F) of abediterol and AZD7594,', 'description': 'Pharmacokinetics of AZD7594 and abediterol following single inhaled doses of AZD7594 alone, abediterol alone and the 2 compounds in FDC or in free combination via 2 separate DPIs', 'timeFrame': 'Day -1 to Day 3. Subjects will also return to the Unit at 72, 96, 144 and 240 hours post-dose (Days 4, 5, 7 and 11 respectively) for PK measurements'}, {'measure': 'The time interval (h) of the log linear regression to determine t1/2λz (λz upper and λz lower) of abediterol and AZD7594.', 'description': 'Pharmacokinetics of AZD7594 and abediterol following single inhaled doses of AZD7594 alone, abediterol alone and the 2 compounds in FDC or in free combination via 2 separate DPIs', 'timeFrame': 'Day -1 to Day 3. Subjects will also return to the Unit at 72, 96, 144 and 240 hours post-dose (Days 4, 5, 7 and 11 respectively) for PK measurements'}, {'measure': 'Terminal elimination rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz, N) of abediterol and AZD7594.', 'description': 'Pharmacokinetics of AZD7594 and abediterol following single inhaled doses of AZD7594 alone, abediterol alone and the 2 compounds in FDC or in free combination via 2 separate DPIs', 'timeFrame': 'Day -1 to Day 3. Subjects will also return to the Unit at 72, 96, 144 and 240 hours post-dose (Days 4, 5, 7 and 11 respectively) for PK measurements'}, {'measure': 'Regression coefficient adjusted for λz, N observations, goodness of fit statistic for calculation of λz (Rsq_adj) of abediterol and AZD7594', 'description': 'Pharmacokinetics of AZD7594 and abediterol following single inhaled doses of AZD7594 alone, abediterol alone and the 2 compounds in FDC or in free combination via 2 separate DPIs', 'timeFrame': 'Day -1 to Day 3. Subjects will also return to the Unit at 72, 96, 144 and 240 hours post-dose (Days 4, 5, 7 and 11 respectively) for PK measurements'}, {'measure': 'Percentage of AUC obtained by extrapolating the area under the plasma concentration time curve from the time of the last quantifiable concentration to infinity (%AUCextr) of abediterol and AZD7594', 'description': 'Pharmacokinetics of AZD7594 and abediterol following single inhaled doses of AZD7594 alone, abediterol alone and the 2 compounds in FDC or in free combination via 2 separate DPIs', 'timeFrame': 'Day -1 to Day 3. Subjects will also return to the Unit at 72, 96, 144 and 240 hours post-dose (Days 4, 5, 7 and 11 respectively) for PK measurements'}]","[{'measure': 'Safety and tolerability of single inhaled doses of AZD7594 and abediterol alone and in combination assessed by recording the AEs, physical examination, electrocardiogram readings, vital signs, spirometry and clinical laboratory assessments.', 'description': 'Safety and tolerability of single inhaled doses of AZD7594 and abediterol alone and in combination in healthy male subjects will be assessed by recording the AEs, physical examination, electrocardiogram (12-lead paper print-out ECG \\[pECG\\], digital ECG \\[dECG\\] and telemetry), vital signs (pulse rate, BP and oral body temperature), spirometry and clinical laboratory assessments (hematology, clinical chemistry including serum potassium and glucose and urinalysis).', 'timeFrame': 'From Screening (maximum of 28 days) till Follow up visit (10 to 14 days post final dose), an average of 24 weeks'}]",12,18 Years,55 Years,MALE,True,AstraZeneca,INDUSTRY,1,14.0,ACTUAL,2025-09-01T16:18:23.458553,v2_robust,True,True,True,False,True,
NCT01785459,Bupivacaine for Benign Headache in the ED,Treatment of Benign Headache in the Emergency Department Population With Lower Cervical Paraspinous Bupivacaine Injections Versus Anti-Emetic Treatment in the Emergency Department Population: Randomized Prospective Control Trial,0.5% bupivacaine,"['0.5% bupivacaine', 'Reglan', 'Standard Care', 'Prochlorperazine']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Benign Headache,['Benign Headache'],"['headache', 'migraine', 'bupivacaine']",TERMINATED,Unable to enroll adequate number of patients.,2013-10,2016-07,"[{'measure': 'Length of Stay', 'description': 'Length of stay will be calculated as total time of encounter as well as time from doctor encounter to disposition decision', 'timeFrame': 'enrollment day'}, {'measure': 'Incidence of Immediate and Post-discharge Complications.', 'description': 'Subjects will be monitored for both immediate and post discharge complications up to 72 hours after enrollment that include: persistent local pain, bleeding, infection, and inadvertent intravascular injection resulting in seizure or possible cardiovascular collapse.', 'timeFrame': '72 hours'}]","[{'measure': 'Symptomatic Relief of Headache', 'description': 'Symptomatic relief of headache will be measured by:\n\n1. Change from pre-intervention pain using a visual analog scale and ordinal scale:\n\n   1. Headache relief\n   2. Partial headache relief\n   3. No headache relief\n   4. Headache worsened\n2. Treatment failure, defined as requirement for additional medication administered in the ED due to incomplete pain relief from the paraspinous bupivacaine injections or the initial dose of intravenous prochlorperazine.\n3. Repeat visit for headache pain within 72 hour time period, excluding routine follow up care, determined by electronic medical record review and telephone follow up.', 'timeFrame': '20 minutes'}]",3,18 Years,65 Years,ALL,False,Wake Forest University Health Sciences,OTHER,0,23.0,ACTUAL,2025-09-01T16:18:23.458703,v2_robust,True,True,False,True,False,Unable to enroll adequate number of patients.
NCT02431559,"Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer","Phase 1/2 Study of Chemoimmunotherapy With Toll-like Receptor 8 Agonist Motolimod (VTX-2337) + Anti-PD-L1 Antibody MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin is Indicated",Durvalumab,"['VTX-2337', 'Caelyx', 'MEDI4736', 'PLD', 'Pegylated Liposomal Doxorubicin', 'Doxil', 'Motolimod', 'Lipodox', 'Durvalumab']",9,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Ovarian Cancer,['Ovarian Cancer'],"['Ovarian Cancer', 'Motolimod', 'Immunotherapy', 'PD-L1', 'MEDI4736', 'Pegylated', 'Liposomal', 'Doxorubicin', 'PLD', 'TLR-8', 'Durvalumab']",COMPLETED,,2015-12-02,2021-06-10,"[{'measure': 'Number of Subjects With Treatment-emergent Adverse Events (TEAEs)', 'description': 'The primary endpoint in Phase 1 and a secondary endpoint in Phase 2 is the safety/tolerability of study treatment. Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, and any other medically indicated assessments, including subject interviews, from the time informed consent is signed through 90 days after the last dose of study treatment. Treatment-emergent AEs are those that occurred or worsened after administration of the first dose of study treatment.', 'timeFrame': 'Up to 3.05 years'}, {'measure': 'Progression-free Survival Rate at 6 Months (PFS-6) by the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Estimated Using the Kaplan-Meier Method', 'description': 'PFS-6 according to RECIST 1.1 is the primary endpoint in Phase 2 and a secondary endpoint in Phase 1, where PFS is measured from the date of the first dose of study treatment to the date of earliest disease progression or to the date of death, if disease progression does not occur. Per RECIST 1.1, progressive disease (PD) is defined as a ≥ 20% increase in the sum of the longest diameter of target lesions (Eisenhauer et al 2009).', 'timeFrame': 'Up to 6 months for each subject'}]","[{'measure': 'Number of Subjects With Best Overall Tumor Response by RECIST 1.1', 'description': 'Tumor responses were evaluated using appropriate imaging and categorized according to RECIST 1.1 at Screening (up to 14 days before the first dose of study treatment), every 3 cycles during study treatment, and during on-study follow-up approximately 3 months after the last disease assessment. Per RECIST 1.1, target lesions are categorized as follows: complete response (CR): disappearance of all target lesions; partial response (PR): ≥ 30% decrease in the sum of the longest diameter of target lesions; PD: ≥ 20% increase in the sum of the longest diameter of target lesions; stable disease (SD): small changes that do not meet above criteria (Eisenhauer et al 2009).', 'timeFrame': 'Up to 36.6 months'}, {'measure': 'Median PFS by RECIST 1.1 as Estimated Using the Kaplan-Meier Method', 'description': 'PFS is measured from the date of the first dose of study treatment to the date of earliest disease progression according to RECIST 1.1 or to the date of death, if disease progression does not occur. Per RECIST 1.1, PD is defined as a ≥ 20% increase in the sum of the longest diameter of target lesions (Eisenhauer et al 2009).', 'timeFrame': 'Up to 36.6 months'}, {'measure': 'PFS-12 by RECIST 1.1 as Estimated Using the Kaplan-Meier Method', 'description': 'PFS is measured from the date of the first dose of study treatment to the date of earliest disease progression according to RECIST 1.1 or to the date of death, if disease progression does not occur. Per RECIST 1.1, PD is defined as a ≥ 20% increase in the sum of the longest diameter of target lesions (Eisenhauer et al 2009).', 'timeFrame': 'Up to 12 months for each subject'}, {'measure': 'Number of Subjects With Best Overall Tumor Response by the Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST)', 'description': 'Tumor responses were evaluated using appropriate imaging and categorized according to irRECIST at Screening (up to 14 days before the first dose of study treatment), every 3 cycles during study treatment, and during on-study follow-up approximately 3 months after the last disease assessment. Per irRECIST, measurable lesions are categorized as follows: irCR: Complete disappearance of all target lesions; irPR: ≥ 30% decrease from baseline in the total measurable tumor burden (TMTB); irPD: ≥ 20% increase from nadir in TMTB; irSD: not meeting above criteria (Bohnsack et al 2014).', 'timeFrame': 'Up to 36.6 months'}, {'measure': 'PFS-6 by irRECIST as Estimated Using the Kaplan-Meier Method', 'description': 'PFS is measured from the date of the first dose of study treatment to the date of earliest disease progression according to irRECIST or to the date of death, if disease progression does not occur. Per irRECIST, irPD is defined as a ≥ 20% increase from nadir in the TMTB (Bohnsack et al 2014).', 'timeFrame': 'Up to 6 months for each subject'}, {'measure': 'PFS-12 by irRECIST as Estimated Using the Kaplan-Meier Method', 'description': 'PFS is measured from the date of the first dose of study treatment to the date of earliest disease progression according to irRECIST or to the date of death, if disease progression does not occur. Per irRECIST, irPD is defined as a ≥ 20% increase from nadir in the TMTB (Bohnsack et al 2014).', 'timeFrame': 'Up to 12 months for each subject'}, {'measure': 'Median PFS by irRECIST as Estimated Using the Kaplan-Meier Method', 'description': 'PFS is measured from the date of the first dose of study treatment to the date of earliest disease progression according to irRECIST or to the date of death, if disease progression does not occur. Per irRECIST, irPD is defined as a ≥ 20% increase from nadir in the TMTB (Bohnsack et al 2014).', 'timeFrame': 'Up to 36.6 months'}, {'measure': 'Median Overall Survival (OS) as Estimated Using the Kaplan-Meier Method', 'description': 'After completion of treatment, all subjects are followed for survival every 3 months for up to 3 years following initiation of study treatment or or for subjects continuing treatment, completion of study treatment whichever was longer. OS is measured from the date of the first dose of study treatment to the date of death or last follow-up. Subjects lost to follow-up are censored on the date when they were last known to be alive.', 'timeFrame': 'Up to 36.6 months'}]",10,18 Years,,FEMALE,False,Ludwig Institute for Cancer Research,OTHER,3,53.0,ACTUAL,2025-09-01T16:18:23.458813,v2_robust,True,True,True,False,True,
NCT04078659,Propofol and Magnesium Sulfate Intravenous Infusion During Endoscopic Sinus Surgery,Controlled Hypotension During Endoscopic Sinus Surgery: A Comparison of Propofol and Magnesium Sulfate,Propofol infusion,"['Propofol infusion', 'Atracurium', 'Lidocaine', 'Magnesium Sulfate infusion', 'Propofol', 'Fentanyl']",6,INTERVENTIONAL,['NA'],,,Endoscopic Sinus Surgery,['Endoscopic Sinus Surgery'],[],UNKNOWN,,2019-09,2020-02,"[{'measure': 'Mean arterial blood pressure (MAP)', 'description': 'automatically non invasive measured every 3 minutes , recorded every 15 minutes till the end and 15 minutes after extubation the end and 15 minutes after extubation', 'timeFrame': '15 minutes after the induction of the hypotensive agent'}]","[{'measure': 'The blood loss', 'description': 'The blood loss would be calculated using the following formula Blood Loss = Blood Volume. In )Hct 1 / Hct2)', 'timeFrame': 'at the end of the surgery'}, {'measure': 'The number of patients will need nitroglycerine and dose', 'description': 'The number of patients will need nitroglycerine', 'timeFrame': 'at the end of the surgery'}, {'measure': 'Use of Ephedrine', 'description': 'The number of patients will need ephedrine', 'timeFrame': 'at the end of the surgery'}, {'measure': 'Need for blood transfusion', 'description': 'The number of patient need for blood transfusion', 'timeFrame': 'at the end of the surgery'}, {'measure': 'Postoperative Ramsey sedation', 'description': 'patient awake, anxious, agitated or restless 2 patient awake -1co operative, oriented and tranquil 3 patient drowsy with respond to command 4 patient asleep brisk response to glabella tap or loud auditory sound 5 patient asleep with sluggish response to stimulus 6 patient hasno response to nail bed pressure or othernoxious stimuli', 'timeFrame': 'for the first hour postoperative'}, {'measure': 'Simplified post operative nausea and vomiting score', 'description': 'using impact scale score evaluation', 'timeFrame': 'for the first 24 hour postoperative'}, {'measure': 'Recovery time', 'description': 'time needed to reach modified aldrete score\\> or=9)', 'timeFrame': 'one hour after extubation'}, {'measure': 'Heart rate (HR)', 'timeFrame': '15 minutes after the start of the hypotensive agent'}, {'measure': 'surgical field assessment', 'description': 'By the surgeon interms of bleeding and visibility using a 6-option Liker-scale scale adapted from Fromme el al. (26): 0 = no bleeding; 1 = minor bleeding, but no aspiration required; 2 = minor bleeding, aspiration required; 3 = minor bleeding, frequent aspiration required; 4 = moderate bleeding, visible� only with aspiration; 5 = severe bleeding, continuous aspiration required', 'timeFrame': '2 hours intraoperative'}]",10,18 Years,45 Years,ALL,False,Mansoura University,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:23.458832,v2_robust,True,True,False,False,False,
NCT00120380,Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH),Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension,Aerosolized iloprost,"['Aerosolized iloprost', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypertension,['Hypertension'],['Idiopathic pulmonary arterial hypertension'],TERMINATED,Futility analysis,2004-09,2006-05,[{'measure': '6 minute walk test'}],[],1,18 Years,75 Years,ALL,False,Hannover Medical School,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:23.459032,v2_robust,True,True,False,True,False,Futility analysis
NCT04792580,The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease,"A Single-Center Randomized Double-Masked Placebo-Controlled Parallel-Group, Study of the Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease",Lifitegrast 5% Ophthalmic Solution,"['Placebo', 'Lifitegrast 5% Ophthalmic Solution']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Graft-versus-host-disease,"['Graft-versus-host-disease', 'Ocular Graft-versus-host Disease']","['Ocular surface', 'Bone marrow transplant', 'stem cell transplant', 'ocular Graft-versus-Host Disease', 'GVHD']",COMPLETED,,2022-10-22,2024-04-30,"[{'measure': 'Change from baseline in Symptoms questionnaire (SANDE) scores to Week 4', 'description': 'The SANDE score is calculated by taking the square root of the product of the severity of symptoms scores and the frequency of symptoms score. The SANDE scale ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount or absence of dry eye symptoms.', 'timeFrame': 'Baseline to Week 4'}]","[{'measure': 'Change from baseline in Schirmer I test (without anesthesia) to Week 4', 'description': 'Without previously instilling anesthetic drops, the Schirmer strip will be inserted into the lower conjunctival sac at the junction of the lateral and middle thirds, avoiding contact with the cornea.\n\nThe patients will be instructed to close their eyes gently. After 5 minutes have elapsed, the Schirmer test strip will be removed and the length of the tear absorption on the strip will be measured (millimeters/5 minutes)', 'timeFrame': 'Baseline to Week 4'}]",2,18 Years,85 Years,ALL,False,"Richard W Yee, MD",OTHER,1,30.0,ACTUAL,2025-09-01T16:18:23.459090,v2_robust,True,True,True,False,False,
NCT03149679,The p53 Colorectal Cancer Trial,Treatment of Patients With Metastatic Colorectal Cancer Harboring TP53 Mutations With Dose-dense Cyclophosphamide - the p53 Colorectal Cancer Trial,Cyclophosphamide,"['Cyclophosphamide', 'Sendoxan']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Colorectal Cancer Metastatic,"['Colorectal Cancer Metastatic', 'Colorectal Cancer Stage IV', 'TP53 Gene Mutation']","['Cyclophosphamide', 'Colorectal Cancer Metastatic', 'TP53 Gene Mutation']",TERMINATED,The study was discontinued after the first pre-planned interim analysis due to insufficient response rates.,2017-05-09,2020-08-07,"[{'measure': 'Objective response rate (ORR)', 'description': 'Partial response (PR) or complete response (CR) as defined by the RECIST criteria', 'timeFrame': '4 months'}]","[{'measure': 'Possible molecular markers of therapy response/resistance and survival outcome beyond TP53 mutations will be examined.', 'description': 'Tissue and blood sampling at baseline and whenever treatment is changed', 'timeFrame': '10 years'}, {'measure': 'Number of patients with treatment response among patients harboring TP53 mutations belonging to particular mutation subgroups', 'description': 'Tissue and blood sampling at baseline and whenever treatment is changed', 'timeFrame': '10 years'}, {'measure': 'Clinical benefit rate (CBR)', 'description': 'Stable disease (SD) \\>6 months, PR or CR', 'timeFrame': '5 years'}, {'measure': 'Recurrence-free and overall survival, compared to historical data', 'description': 'Survival analyses', 'timeFrame': 'All patients will be followed for 5 years or until death to record survival outcome'}, {'measure': 'Safety and tolerability of the study treatment including recording of number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'description': 'Clinical examination and blood samples', 'timeFrame': 'Every second week during the treatment period from start of treatment, and thereafter every second month for 5 years or until death'}]",6,18 Years,,ALL,False,Haukeland University Hospital,OTHER,0,12.0,ACTUAL,2025-09-01T16:18:23.459188,v2_robust,True,True,False,True,True,The study was discontinued after the first pre-planned interim analysis due to insufficient response rates.
NCT00972179,Safety Study of Tezepelumab (AMG 157) in Healthy Adults,"A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 157 in Healthy Subjects",Placebo,"['AMG 157', 'Tezepelumab', 'Tezspire', 'Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],['healthy volunteers'],COMPLETED,,2009-09-15,2011-01-09,"[{'measure': 'Number of Participants With Treatment-emergent Adverse Events', 'description': 'Adverse events (AEs) include any untoward medical occurrence in a trial participant administered a study drug and does not necessarily have a causal relationship with this treatment. AEs include worsening of a pre-existing medical condition and laboratory value changes requiring therapy or adjustment in prior therapy.\n\nAEs were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 3, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = severe AE, Grade 4 = life-threatening AE and Grade 5 = death due to AE.\n\nRelationship to study treatment was determined by the investigator.\n\nA serious adverse event (SAE) is defined as an AE that met 1 or more of below criteria:\n\n* was fatal;\n* was life threatening;\n* required in-patient hospitalization or prolongation of existing hospitalization;\n* resulted in persistent or significant disability/incapacity;\n* was a congenital anomaly/birth defect;\n* other significant medical hazard.', 'timeFrame': 'From first dose of study drug up to day 169'}, {'measure': 'Number of Participants Who Developed Anti-tezepelumab Antibodies After Initiation of Treatment', 'description': 'All study samples (tezepelumab and placebo) were tested using an electrochemiluminescence (ECL) based immunoassay to detect and confirm the presence of antibodies capable of binding to tezepelumab. Samples identified as positive in the immunoassay were tested in a receptor-binding ECL-based assay to detect neutralizing or inhibitory effects toward tezepelumab.\n\nThe number of participants with positive anti-tezepelumab binding antibodies / neutralizing antibodies at any time post-baseline with a negative or no result at baseline is reported.', 'timeFrame': 'For Q28D groups: Days 28, 56, 85, 113, and 169; For Q14D and Q7D groups: Days 29, 57, 85, 113, 141, and 169'}]","[{'measure': 'Time of Maximum Observed Concentration (Tmax) of Tezepelumab', 'description': 'The pharmacokinetic (PK) parameter Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods.\n\nThe concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/ml.', 'timeFrame': 'First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose'}, {'measure': 'Maximum Observed Concentration (Cmax) of Tezepelumab', 'description': 'The PK parameter Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/ml.', 'timeFrame': 'First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose'}, {'measure': 'Area Under the Concentration-time Curve Over the Dosing Interval (AUCtau) for Tezepelumab', 'description': 'The PK parameter AUCtau was estimated based on the serum concentrations of tezepelumab using noncompartmental methods.\n\nThe dosing interval (tau) was 28 days, 14 days or 7 days depending on the treatment arm.\n\nThe concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/ml.', 'timeFrame': 'First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose'}, {'measure': 'Accumulation Ratio Based on AUCtau', 'description': 'Accumulation ratio (AR) based on AUCtau was calculated as AUCtau after last dose / AUCtau after first dose, except for the Q7D cohort where AR was calculated as AUCtau after last dose / area under the concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) after first dose.', 'timeFrame': 'First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose'}, {'measure': 'Accumulation Ratio Based on Cmax', 'description': 'Accumulation ratio based on Cmax calculated as Cmax after last dose / Cmax after first dose', 'timeFrame': 'First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose'}]",7,18 Years,45 Years,ALL,True,Amgen,INDUSTRY,0,49.0,ACTUAL,2025-09-01T16:18:23.459347,v2_robust,True,True,True,False,True,
NCT01297179,A Study to Evaluate the Possible Effects of Taking Mirabegron While Taking a Contraceptive Pill,A Double-blind Two-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics (PK) of an Ethinyl Estradiol and Levonorgestrel Containing Combined Oral Contraceptive (COC),Mirabegron,"['Minidril', 'Mirabegron', 'YM178', 'Placebo', 'ethinyl estradiol', 'levonorgestrel']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,"['Healthy Volunteers', 'Pharmacokinetics of Mirabegron']","['Pharmacokinetics', 'Oral contraceptives', 'Drug interactions', 'Pharmacokinetics of mirabegron']",COMPLETED,,2008-10,2009-03,"[{'measure': 'Assessment of pharmacokinetics of Ethinyl estradiol (EE) and Levonorgestrel (LNG) by analysis of blood samples.', 'timeFrame': 'Day 21 + Day 29'}]","[{'measure': 'Assessment of pharmacokinetics of mirabegron by analysis of blood samples.', 'timeFrame': 'Day 21 + Day 49'}]",2,18 Years,45 Years,FEMALE,True,Astellas Pharma Inc,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:23.459366,v2_robust,True,True,True,False,False,
NCT04791579,Antibiotic Prophylaxis for Neurogenic Bladder Botox,Prophylactic Antibiotics Following Treatment of Neurogenic Overactive Bladder With Intradetrusor onabotulinumtoxinA for the Reduction of Postoperative UTI: a Randomized Blinded Placebo-controlled Trial,Ciprofloxacin,"['Ciprofloxacin', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Neurogenic Bladder,"['Neurogenic Bladder', 'Post-operative Urinary Tract Infections']","['prophylaxis', 'post-operative infection', 'Botox']",RECRUITING,,2025-02-01,2026-08-31,"[{'measure': 'Rate of Postoperative Urinary Tract Infection', 'description': 'new or worsening symptoms (dysuria, hematuria, frequency, urgency, suprapubic/flank pain, fever) AND positive urine culture (\\>10\\^5 CFU/mL)', 'timeFrame': '2 weeks following the procedure'}]","[{'measure': 'Rate of Postoperative Urinary Tract Infection', 'description': 'new or worsening symptoms (dysuria, hematuria, frequency, urgency, suprapubic/flank pain, fever) AND positive urine culture (\\>10\\^5 CFU/mL)', 'timeFrame': '1 and 6 weeks following the procedure'}, {'measure': 'Rate of Other Adverse Events', 'description': 'New onset of side effects possibly related to Ciprofloxacin (nausea/vomiting, headache, abdominal pain, constipation, diarrhea, other)', 'timeFrame': '1, 2 and 6 weeks following the procedure'}]",3,18 Years,100 Years,ALL,False,University of Alberta,OTHER,0,160.0,ESTIMATED,2025-09-01T16:18:23.459376,v2_robust,True,True,False,False,True,
NCT05431179,A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma",Zilovertamab,"['Ibrutinib', 'Imbruvica', 'UC961', 'Placebo', 'Zilovertamab', 'Cirmtuzumab']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,"Lymphoma, Mantle-Cell","['Lymphoma, Mantle-Cell', 'Lymphoma', 'Lymphoproliferative Disorders', 'Lymphatic Diseases', 'Immunoproliferative Disorders', 'Immune System Diseases', 'Lymphoma, Non-Hodgkin', 'Lymphoma, B-Cell']","['Mantle cell lymphoma', 'Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)', 'Bruton Tyrosine Kinase (BTK) inhibitor', 'Ibrutinib', 'Zilovertamab']",WITHDRAWN,Due to a strategic reprioritization based on the rapidly changing clinical and commercial landscape for Bruton's tyrosine kinase inhibitors (BTK inhibitors),2023-03,2026-12,"[{'measure': 'Progression-free survival (PFS)', 'description': 'PFS as assessed by Blinded Independent Central Review (BICR) per Lugano Classification is superior for ibrutinib plus zilovertamab compared to ibrutinib plus placebo among subjects with relapsed or refractory (R/R) mantle cell lymphoma (MCL) that had a PR or SD after 16 weeks of ibrutinib monotherapy.', 'timeFrame': 'Approximately 2 years'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'Assessed by BICR per Lugano Classification, among the subjects who received the combination of zilovertamab plus ibrutinib compared with the subjects who received ibrutinib plus placebo.', 'timeFrame': 'Approximately 4 years'}, {'measure': 'Duration of Response (DOR)', 'description': 'Assessed by BICR per Lugano Classification, among the subjects who received the combination of zilovertamab plus ibrutinib compared with the subjects who received ibrutinib plus placebo.', 'timeFrame': 'Approximately 4 years'}, {'measure': 'Complete Response Rate', 'description': 'Assessed by BICR per Lugano Classification Classification among the subjects who received the combination of zilovertamab plus ibrutinib compared with the subjects who received ibrutinib plus placebo.', 'timeFrame': 'Approximately 4 years'}, {'measure': 'Proportion of subjects experiencing Grade 3 to 4 neutrophil count decrease', 'description': 'Proportion of subjects experiencing Grade 3 to 4 neutrophil count decrease among the subjects who received the combination of zilovertamab plus ibrutinib compared with the subjects who received ibrutinib plus placebo based on laboratory abnormalities.', 'timeFrame': 'Approximately 4 years'}, {'measure': 'Overall Survival (OS)', 'description': 'OS among the subjects who received the combination of zilovertamab plus ibrutinib compared with the subjects who received ibrutinib plus placebo.', 'timeFrame': 'Approximately 4 years'}, {'measure': 'Overall Safety Profile', 'description': 'Overall safety profile among the subjects who received the combination of zilovertamab plus ibrutinib compared with the subjects who received ibrutinib plus placebo. This would include incidence of treatment-emergent adverse events and laboratory abnormalities.', 'timeFrame': 'Approximately 4 years'}]",7,18 Years,,ALL,False,"Oncternal Therapeutics, Inc",INDUSTRY,1,0.0,ACTUAL,2025-09-01T16:18:23.459391,v2_robust,True,True,False,True,True,Due to a strategic reprioritization based on the rapidly changing clinical and commercial landscape for Bruton's tyrosine kinase inhibitors (BTK inhibitors)
NCT05468879,Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects,Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects,Glimepiride,"['Amaryl®', 'Glimepiride']",2,INTERVENTIONAL,['NA'],,,Drug Use,['Drug Use'],"['Bioequivalence study', 'Glimepiride', 'Indonesia', 'cross-over design study', 'pharmacokinetics']",COMPLETED,,2020-09-21,2021-01-06,"[{'measure': 'Maximum plasma concentration (Cmax)', 'description': '90% Confidence Interval', 'timeFrame': 'before dosing (0 hour) and at 15, 30, 45 minutes, and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12, 18, 24, and 30 hours after drug administration'}, {'measure': 'Area Under Curve from 0 to 30 hours (AUCt)', 'description': '90% Confidence Interval', 'timeFrame': 'before dosing (0 hour) and at 15, 30, 45 minutes, and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12, 18, 24, and 30 hours after drug administration'}]","[{'measure': 'Maximum plasma concentration (Cmax)', 'description': 'Pharmacokinetics Parameter', 'timeFrame': 'before dosing (0 hour) and at 15, 30, 45 minutes, and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12, 18, 24, and 30 hours after drug administration'}, {'measure': 'Area Under Curve from 0 to 30 hours (AUCt)', 'description': 'Pharmacokinetics Parameter', 'timeFrame': 'before dosing (0 hour) and at 15, 30, 45 minutes, and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12, 18, 24, and 30 hours after drug administration'}]",4,18 Years,55 Years,ALL,True,PT Harsen Laboratories,INDUSTRY,1,34.0,ACTUAL,2025-09-01T16:18:23.459415,v2_robust,True,True,True,False,False,
NCT03941496,Azacytidine During Anti-tuberculosis Therapy,Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy,Azacitidine Injection,"['Azacitidine Injection', 'AZA Group']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Tuberculosis, Pulmonary","['Tuberculosis, Pulmonary']","['Tuberculosis', 'TB', 'Mycobacterium tuberculosis', 'Mtb', 'anti-TB therapy', 'ATT', 'rifampin (R), isoniazid (H) pyrazinamide (Z) ethambutol (E)', 'RHZE', 'rifampin (R), isoniazid (H)', 'RH']",WITHDRAWN,The study was halted prematurely due to Bristol-Myers Squibb's (BMS) decision to withdraw support for this study.,2022-10,2023-05,"[{'measure': 'Overall incidence of all IP-related adverse events', 'description': 'using Common Terminology Criteria for Adverse Events (CTCAE) v 5.0.', 'timeFrame': '2 years'}, {'measure': 'Overall severity of all IP-related adverse events', 'description': 'using Common Terminology Criteria for Adverse Events (CTCAE) v 5.0', 'timeFrame': '4 months'}, {'measure': 'Measurement of epigenetic-mediated immune exhaustion', 'description': 'measured by using 1) a standardized mycobacterial growth inhibition assay (MGIA) that measures ex vivo mycobacterial killing; 2) 18-parameter flow cytometry based multi-dimensional immune profiling (MDIP); and 3) epigenetic assays', 'timeFrame': 'baseline and Week 16'}]",[],3,18 Years,,ALL,True,Andrew Dinardo,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:23.459557,v2_robust,True,True,False,True,True,The study was halted prematurely due to Bristol-Myers Squibb's (BMS) decision to withdraw support for this study.
NCT01267396,Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg Under Fasting Conditions,"Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr. Reddy's Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg Tablet (Pfizer, USA)Under Fasting Conditions in Healthy Human Adult Subjects.",Sertraline,"['Sertraline', 'Zoloft']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Bioequivalence', 'Sertraline', 'crossover']",COMPLETED,,2006-09,2006-10,"[{'measure': 'Bioequivalence based on Cmax and AUC parameters', 'timeFrame': '3 months'}]",[],1,18 Years,45 Years,MALE,True,Dr. Reddy's Laboratories Limited,INDUSTRY,0,32.0,ACTUAL,2025-09-01T16:18:23.459619,v2_robust,True,True,True,False,False,
NCT01688362,Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears,"Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Thickness Rotator Cuff Tears. A Randomized, Prospective, Double Blinded Trial.",Corticosteroid,"['Bupivacaine', 'Corticosteroid', 'Kenalog', 'Dexamethasone']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Rotator Cuff Tear,['Rotator Cuff Tear'],"['Prospective Randomized Controlled Double Blinded Trial', 'Rotator Cuff Tear', 'Platelet Rich Plasma', 'Corticosteroid', 'Ultrasound']",TERMINATED,Did not meet target enrollment deadlines.,2012-11,2014-05,"[{'measure': 'Percent change in Disabilities of the Arm, Shoulder, and Hand score. (DASH)', 'description': 'Disabilities of the Arm, Shoulder, and Hand (DASH) is a 30-item self-reported questionnaire used assess shoulder function. The DASH is widely used in orthopaedic research and is considered valid and reliable.', 'timeFrame': 'baseline and one year'}]","[{'measure': 'Percent change in Disabilities of the Arm, Shoulder, and Hand score. (DASH)', 'timeFrame': 'baseline six weeks, 3 months, 6 months'}, {'measure': 'Percent change in Visual Analog Pain scale (VAS)', 'description': 'Visual Analog Pain scale (VAS) is a self-reported questionnaire used to measure a patients pain level on a scale from 0 (no pain) to 10 (extreme pain).', 'timeFrame': 'Baseline, six weeks, three months, six months, one year'}, {'measure': 'Percent change in American Shoulder and Elbow Surgeons (ASES) scale', 'description': 'American Shoulder and Elbow Surgeons (ASES) scale is used to measure shoulder function. It is combines both physician assessment and patient self-reported questionnaire date to create the functional score.', 'timeFrame': 'Baseline, six weeks, three months, six months, one year'}, {'measure': 'Size of rotator cuff tear size.', 'description': 'Rotator cuff tear size will be determined using ultrasound imaging. The mean size at six months and one year will be compared to baseline per-treatment size.', 'timeFrame': 'Baseline, six months and one year'}]",5,18 Years,65 Years,ALL,False,"University of North Carolina, Chapel Hill",OTHER,0,12.0,ACTUAL,2025-09-01T16:18:23.459692,v2_robust,True,True,False,True,False,Did not meet target enrollment deadlines.
NCT06785662,Budesonide Irrigation in Allergic Rhinitis,"The Efficacy of Budesonide Nasal Irrigation in Allergic Rhinitis Patients: A Randomized, Controlled Trial.",The budesonide nasal irrigation,"['The budesonide nasal irrigation', 'The budesonide nasal spray']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Allergic Rhinitis,['Allergic Rhinitis'],"['intranasal corticosteroid', 'budesonide nasal irrigation', 'Budesonide nasal spray', 'Allergic rhinitis']",NOT_YET_RECRUITING,,2025-02-12,2026-06-01,"[{'measure': 'Total Nasal Symptom Score (TNSS)', 'description': 'Full Name: Total Nasal Symptom Score Scale Range: 0 to 12 Scoring Interpretation: Higher scores indicate a worse outcome\n\nEach symptom is rated by the participant on a scale (0 to 3), based on severity:\n\n0: No symptoms\n\n1. Mild symptoms (present but not bothersome)\n2. Moderate symptoms (noticeable and somewhat bothersome)\n3. Severe symptoms (very bothersome and interfering with daily activities)', 'timeFrame': 'Follow-up visits were scheduled at 2 and 4 weeks after starting treatment.'}]","[{'measure': 'Postnasal Drip Symptom Score (PND)', 'description': 'Postnasal Drip Symptom Score (PND) determines the severity of post nasal drip sensation\n\nFull Name: Postnasal Drip Symptom Score Scale Range: 0 to 3 Scoring Interpretation: Higher scores indicate a worse outcome. The PND focuses specifically on the severity of postnasal drip symptoms, with scores representing none (0), mild (1), moderate (2), or severe (3) symptoms.', 'timeFrame': 'Follow-up visits were scheduled at 2 and 4 weeks after starting treatment.'}, {'measure': 'Rhinoconjunctivitis Quality of Life Questionnaire (RCQ-36)', 'description': 'Rhinoconjunctivitis Quality of Life Questionnaire (RCQ-36) determine disease-specific quality of life\n\nFull Name: Rhinoconjunctivitis Quality of Life Questionnaire - 36 Items Scale Range: 0 to 6 for each item, summing up to a total score. Scoring Interpretation: Higher scores indicate a worse outcome. This questionnaire assesses the impact of rhinoconjunctivitis symptoms on quality of life, covering domains such as sleep, activities, emotional well-being, and social functioning.', 'timeFrame': 'Follow-up visits were scheduled at 2 and 4 weeks after starting treatment.'}, {'measure': 'Peak Nasal Inspiratory Flow (PNIF)', 'description': 'Peak Nasal Inspiratory Flow (PNIF) is an objective measurement to determine nasal patency\n\nFull Name: Peak Nasal Inspiratory Flow Scale Range: Measured in liters per minute (L/min); there is no fixed maximum value, as it depends on individual physiology.\n\nScoring Interpretation: Higher values indicate a better outcome. PNIF measures the maximum airflow through the nasal passages during inspiration and is used as an objective measure of nasal patency (openness).', 'timeFrame': 'Follow-up visits were scheduled at 2 and 4 weeks after starting treatment.'}, {'measure': 'Adverse events', 'description': 'All adverse events occurred during the usage of budesonide nasal irrigation were reported.', 'timeFrame': 'Follow-up visits were scheduled at 2 and 4 weeks after starting treatment.'}]",5,18 Years,60 Years,ALL,False,Siriraj Hospital,OTHER,0,78.0,ESTIMATED,2025-09-01T16:18:23.459979,v2_robust,True,True,False,False,True,
NCT00002946,Penclomedine in Treating Patients With Solid Tumors or Lymphoma,A Phase I Trial of Oral Penclomedine,penclomedine,['penclomedine'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Lymphoma,"['Lymphoma', 'Unspecified Adult Solid Tumor, Protocol Specific']","['stage I adult Hodgkin lymphoma', 'stage II adult Hodgkin lymphoma', 'stage III adult Hodgkin lymphoma', 'stage IV adult Hodgkin lymphoma', 'recurrent adult Hodgkin lymphoma', 'unspecified adult solid tumor, protocol specific', 'stage I grade 1 follicular lymphoma', 'stage I grade 2 follicular lymphoma', 'stage I grade 3 follicular lymphoma', 'stage I adult diffuse small cleaved cell lymphoma', 'stage I adult diffuse mixed cell lymphoma', 'stage I adult diffuse large cell lymphoma', 'stage I adult immunoblastic large cell lymphoma', 'stage I adult lymphoblastic lymphoma', 'stage I adult Burkitt lymphoma', 'stage III grade 1 follicular lymphoma', 'stage III grade 2 follicular lymphoma', 'stage III grade 3 follicular lymphoma', 'stage III adult diffuse small cleaved cell lymphoma', 'stage III adult diffuse mixed cell lymphoma', 'stage III adult diffuse large cell lymphoma', 'stage III adult immunoblastic large cell lymphoma', 'stage III adult lymphoblastic lymphoma', 'stage III adult Burkitt lymphoma', 'stage IV grade 1 follicular lymphoma', 'stage IV grade 2 follicular lymphoma', 'stage IV grade 3 follicular lymphoma', 'stage IV adult diffuse small cleaved cell lymphoma', 'stage IV adult diffuse mixed cell lymphoma', 'stage IV adult diffuse large cell lymphoma', 'stage IV adult immunoblastic large cell lymphoma', 'stage IV adult lymphoblastic lymphoma', 'stage IV adult Burkitt lymphoma', 'recurrent grade 1 follicular lymphoma', 'recurrent grade 2 follicular lymphoma', 'recurrent grade 3 follicular lymphoma', 'recurrent adult diffuse small cleaved cell lymphoma', 'recurrent adult diffuse mixed cell lymphoma', 'recurrent adult diffuse large cell lymphoma', 'recurrent adult immunoblastic large cell lymphoma', 'recurrent adult lymphoblastic lymphoma', 'recurrent adult Burkitt lymphoma', 'stage I adult T-cell leukemia/lymphoma', 'stage II adult T-cell leukemia/lymphoma', 'stage III adult T-cell leukemia/lymphoma', 'stage IV adult T-cell leukemia/lymphoma', 'recurrent adult T-cell leukemia/lymphoma', 'AIDS-related peripheral/systemic lymphoma', 'AIDS-related primary CNS lymphoma', 'stage I mantle cell lymphoma', 'contiguous stage II grade 1 follicular lymphoma', 'contiguous stage II grade 2 follicular lymphoma', 'contiguous stage II grade 3 follicular lymphoma', 'contiguous stage II adult diffuse small cleaved cell lymphoma', 'contiguous stage II mantle cell lymphoma', 'contiguous stage II adult diffuse mixed cell lymphoma', 'contiguous stage II adult immunoblastic large cell lymphoma', 'contiguous stage II adult diffuse large cell lymphoma', 'contiguous stage II adult Burkitt lymphoma', 'contiguous stage II adult lymphoblastic lymphoma', 'noncontiguous stage II grade 1 follicular lymphoma', 'noncontiguous stage II grade 2 follicular lymphoma', 'noncontiguous stage II grade 3 follicular lymphoma', 'noncontiguous stage II adult diffuse small cleaved cell lymphoma', 'noncontiguous stage II mantle cell lymphoma', 'noncontiguous stage II adult diffuse mixed cell lymphoma', 'noncontiguous stage II adult immunoblastic large cell lymphoma', 'noncontiguous stage II adult diffuse large cell lymphoma', 'noncontiguous stage II adult Burkitt lymphoma', 'noncontiguous stage II adult lymphoblastic lymphoma', 'stage III mantle cell lymphoma', 'stage IV mantle cell lymphoma', 'recurrent mantle cell lymphoma', 'angioimmunoblastic T-cell lymphoma', 'anaplastic large cell lymphoma', 'noncontiguous stage II small lymphocytic lymphoma', 'noncontiguous stage II marginal zone lymphoma', 'recurrent marginal zone lymphoma', 'recurrent small lymphocytic lymphoma', 'stage I marginal zone lymphoma', 'stage I small lymphocytic lymphoma', 'stage III small lymphocytic lymphoma', 'stage III marginal zone lymphoma', 'stage IV small lymphocytic lymphoma', 'stage IV marginal zone lymphoma', 'contiguous stage II marginal zone lymphoma', 'contiguous stage II small lymphocytic lymphoma', 'extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue', 'nodal marginal zone B-cell lymphoma', 'splenic marginal zone lymphoma']",COMPLETED,,1997-10,,[],[],0,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,30.0,ACTUAL,2025-09-01T16:18:23.460076,v2_robust,True,True,True,False,False,
NCT00025246,Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery,A Phase II Study of Adjuvant STI571 (Gleevec TM) Therapy in Patients Following Completely Resected High-risk Primary GastroIntestinal Stromal Tumor (GIST),imatinib mesylate,"['CGP 57148', 'Gleevec', 'Glivec', 'imatinib mesylate']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastrointestinal Stromal Tumor,['Gastrointestinal Stromal Tumor'],[],COMPLETED,,2001-09,,"[{'measure': 'Determination whether patients with completely resected high-risk primary GIST who undergo adjuvant treatment with imatinib mesylate have prolonged survival compared to historical controls', 'timeFrame': 'Up to 5 years'}]","[{'measure': 'Prevalence of recurrence free survival', 'description': 'Marginal point and two-sided 95% (pointwise) confidence bands, based on Kaplan-Meier estimator will be produced.', 'timeFrame': '2 years'}, {'measure': 'Prevalence of recurrence', 'description': 'Marginal point and two-sided 95% (pointwise) confidence bands, based on Kaplan-Meier estimator will be produced.', 'timeFrame': '5 years'}, {'measure': 'Overall survival', 'description': 'Marginal point and two-sided 95% (pointwise) confidence bands, based on Kaplan-Meier estimator will be produced.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Toxicities, graded according to the National Cancer Institute Common Toxicity Criteria', 'timeFrame': 'Up to 10 years'}]",5,16 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,89.0,ACTUAL,2025-09-01T16:18:23.460104,v2_robust,True,True,True,False,False,
NCT01388946,Analgesia in Laparoscopic Cholecystectomy,Perioperative Ropivacaine Wound Infusion in Laparoscopic Cholecystectomy. A Randomized Controlled Double-blind Trial,Ropivacaine 0.75,"['Naropeine', '0.9% saline', 'Normal saline', 'Ropivacaine 0.75']",4,INTERVENTIONAL,['NA'],,,"Pain, Postoperative","['Pain, Postoperative', 'Chronic Postoperative Pain']","['acute postoperative pain', 'late pain', 'chronic pain', 'wound irrigation with local anesthetic']",COMPLETED,,2010-05,2014-01,"[{'measure': 'VAS Score Changes ( Cough) During 24 h Postoperatively', 'description': 'Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.', 'timeFrame': '24 h'}]","[{'measure': 'Pain Scores in the Postoperative Care Unit (PACU) at Rest', 'description': 'Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.', 'timeFrame': 'in PACU'}, {'measure': 'Pain Scores at Rest 2 h Postoperatively', 'description': 'Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.', 'timeFrame': '2 h postoperatively'}, {'measure': 'Pain Scores at Rest 4 h Postoperatively', 'description': 'Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.', 'timeFrame': '4 h'}, {'measure': 'Pain Scores at Rest 8 h Postoperatively', 'description': 'Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.', 'timeFrame': '8 h'}, {'measure': 'Pain Scores at Rest 24 h Postoperatively', 'description': 'Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.', 'timeFrame': '24h'}, {'measure': 'Pain Scores at Rest 48 h Postoperatively', 'description': 'Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.', 'timeFrame': '48 h'}, {'measure': 'Pain Scores During Cough in the PACU', 'description': 'Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.', 'timeFrame': 'PACU'}, {'measure': 'Pain Scores During Cough 2 h Postoperatively', 'description': 'Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.', 'timeFrame': '2 h'}, {'measure': 'Pain Scores During Cough 4 h Postoperatively', 'description': 'Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.', 'timeFrame': '4 h'}, {'measure': 'Pain Scores During Cough 8 h Postoperatively', 'description': 'Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.', 'timeFrame': '8 h'}, {'measure': 'Pain Scores During Cough 48 h Postoperatively', 'description': 'Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.', 'timeFrame': '48 h'}, {'measure': 'Chronic Pain', 'description': 'Number and incidence of patients with persisting pain (burning pain, loss of sensation) one month postoperatively', 'timeFrame': 'one month postoperatively'}, {'measure': 'Chronic Pain', 'description': 'Number and incidence of patients with persisting pain (burning pain, loss of sensation) three month postoperatively', 'timeFrame': 'three months'}]",14,30 Years,70 Years,ALL,False,University of Athens,OTHER,0,110.0,ACTUAL,2025-09-01T16:18:23.460151,v2_robust,True,True,True,False,False,
NCT05121246,"A PK Study Comparing MB05, EU-sourced Synagis® and US-sourced Synagis® in Healthy Volunteers.","A Randomized, Double-Blind, 3-arm Parallel Study to Compare PK, Safety, IMM and Tolerability of MB05, EU-sourced Synagis® and US-sourced Synagis®, as a Single Dose Intramuscular Injection in Healthy Volunteers.",MB05 (Proposed palivizumab biosimilar),"['MB05 (Proposed palivizumab biosimilar)', 'US-Synagis®', 'EU-Synagis®']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2022-06-15,2023-03-31,"[{'measure': 'Comparison of the Pharmacokinetic (PK) Profiles Between MB05 and EU-Synagis®, Between MB05 and US-Synagis® and Between EU-Synagis® and US-Synagis® in Terms of Area Under the Serum Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf)', 'description': 'Bioequivalence between MB05 and EU Synagis®, between MB05 and US-Synagis® and between EU-Synagis® and US-Synagis® will be investigated for AUC0-inf and Cmax by analysis of variance using log-transformed PK parameter values. Bioequivalence will be assessed by calculating the 90% CIs for the ratio of the least squares geometric means for each pairwise comparison and each PK parameter. Bioequivalence will be concluded where the 90% CIs for the ratio of least squares geometric means are contained within the range 80.00% to 125.00%.\n\nBlood samples collection timepoints: pre-dose (within 60 minutes prior); 4 hr (+/- 15 min); 12 hr (+/- 15 min); 24 hr (+/- 1 hr); 48 hr (+/- 5 hr); 72 hr (+/- 5 hr); 96 hr (+/- 5 hr); 120 hr (+/- 5 hr); 168 hr (+/- 5 hr) post-dose, and then at Days 15; 22; 29; 36; 43; 57; 71; 85; and 99 (end of study).', 'timeFrame': 'Day 1 - Day 100'}, {'measure': 'Compare the Pharmacokinetic (PK) Profiles Between MB05 and EU-Synagis®, Between MB05 and US-Synagis® and Between EU-Synagis® and US-Synagis® in Terms of Maximum Observed Serum Concentration Cmax.', 'description': 'Bioequivalence between MB05 and EU Synagis®, between MB05 and US-Synagis® and between EU-Synagis® and US-Synagis® will be investigated for AUC0-inf and Cmax by analysis of variance using log-transformed PK parameter values. Bioequivalence will be assessed by calculating the 90% CIs for the ratio of the least squares geometric means for each pairwise comparison and each PK parameter. Bioequivalence will be concluded where the 90% CIs for the ratio of least squares geometric means are contained within the range 80.00% to 125.00%.\n\nBlood samples collection timepoints: pre-dose (within 60 minutes prior); 4 hr (+/- 15 min); 12 hr (+/- 15 min); 24 hr (+/- 1 hr); 48 hr (+/- 5 hr); 72 hr (+/- 5 hr); 96 hr (+/- 5 hr); 120 hr (+/- 5 hr); 168 hr (+/- 5 hr) post-dose, and then at Days 15; 22; 29; 36; 43; 57; 71; 85; and 99 (end of study).', 'timeFrame': 'Day 1 - Day 100'}, {'measure': 'Pharmacokinetics (PK)- (AUC0-inf)', 'description': 'Pharmacokinetic (PK) profiles for each arm (AUC0-inf)', 'timeFrame': 'Day 1 - Day 100'}, {'measure': 'Pharmacokinetics (PK) - (Cmax)', 'description': 'Pharmacokinetic (PK) profiles for each arm (Cmax)', 'timeFrame': 'Day 1 - Day 100'}]","[{'measure': 'Tmax', 'description': 'Time to reach maximum observed serum concentration (Cmax)', 'timeFrame': 'Day 1 - Day 100'}, {'measure': 't1/2', 'description': 'Apparent terminal elimination half-life (t1/2)', 'timeFrame': 'Day 1 - Day 100'}, {'measure': 'Vz', 'description': 'Apparent volume of distribution (Vz)', 'timeFrame': 'Day 1- Day 100'}, {'measure': 'CL', 'description': 'Apparent total serum clearance ((CL)', 'timeFrame': 'Day 1- Day 100'}, {'measure': 'Safety and Tolerability', 'description': 'Treatment-related Adverse Events', 'timeFrame': 'Day 1- Day 100'}, {'measure': 'Immunogenicity', 'description': 'Assessment of anti-drug antibodies (ADA) against palivizumab', 'timeFrame': 'Day 1- Day 100'}]",10,18 Years,55 Years,ALL,True,mAbxience Research S.L.,INDUSTRY,0,150.0,ACTUAL,2025-09-01T16:18:23.460183,v2_robust,True,True,True,False,True,
NCT04928846,A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC),"A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer",Docetaxel,['Docetaxel'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Non Small Cell Lung Cancer,['Non Small Cell Lung Cancer'],"['c-Met Overexpressing Non-Small Cell Lung Cancer', 'c-Met NSCLC', 'Telisotuzumab Vedotin', 'ABBV-399', 'Docetaxel', 'Cancer', 'Non Small Cell Lung Cancer', 'NSCLC', 'TeliMET NSCLC-01', 'Teliso-V']",RECRUITING,,2022-03-25,2028-03,"[{'measure': 'Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR)', 'description': 'PFS is defined as the time from randomization to the first occurrence of radiographic progression based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) per BICR or death from any cause.', 'timeFrame': 'Up to approximately 39 months'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from randomization to the event of death from any cause.', 'timeFrame': 'Up to approximately 39 months'}]","[{'measure': 'Objective Response Rate (ORR), per BICR.', 'description': 'ORR is defined as the proportion of participants with a complete response (CR) or partial response (PR) based on RECIST v1.1', 'timeFrame': 'Up to approximately 58.25 months'}, {'measure': 'Duration of Response (DoR), per BICR', 'description': 'DoR is defined for responders as the time from response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause.', 'timeFrame': 'Up to approximately 58.25 months'}, {'measure': 'PFS per Investigator Assessment', 'description': 'PFS is defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 per investigator or death from any cause. Participants with no PFS event will be censored at the last evaluable radiographic assessment per investigator. Participants with no event and no evaluable post-baseline assessment will be censored at randomization.', 'timeFrame': 'Up to approximately 58.25 months'}, {'measure': 'Change from Baseline of Physical Functioning as measured by the Physical Functioning domain of the EORTC-QLQ-Core 30 (EORTC QLQ-C30).', 'description': 'The EORTC QLQ-C30 assesses health-related quality of life in cancer patients participating in clinical trials. The EORTC QLQ-C30 comprises 5 functional scales (physical, role, emotional, social, cognitive), 8 single-item symptom scales (fatigue, pain, nausea/vomiting, appetite loss, constipation, diarrhea, insomnia, and dyspnea), as well as subscales assessing global health/quality of life and financial impact. Raw scores are transformed to a scale of 0 to 100, with higher scores representing better functioning/quality of life and greater symptom burden.', 'timeFrame': 'Up to approximately 12 Weeks'}, {'measure': 'Change from Baseline in Quality of Life as measured by the Global Health Status/Quality of Life Domain of the EORTC QLQ-C30.', 'description': 'The EORTC QLQ-C30 assesses health-related quality of life in cancer patients participating in clinical trials. The EORTC QLQ-C30 comprises 5 functional scales (physical, role, emotional, social, cognitive), 8 single-item symptom scales (fatigue, pain, nausea/vomiting, appetite loss, constipation, diarrhea, insomnia, and dyspnea), as well as subscales assessing global health/quality of life and financial impact. Raw scores are transformed to a scale of 0 to 100, with higher scores representing better functioning/quality of life and greater symptom burden.', 'timeFrame': 'Up to approximately 12 Weeks'}]",7,18 Years,,ALL,False,AbbVie,INDUSTRY,0,698.0,ESTIMATED,2025-09-01T16:18:23.460233,v2_robust,True,True,False,False,False,
NCT00144846,Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children,"A Randomized, Double-Blind, Parallel-group, Multi-Center Study of Albuterol Sulfate HFA Inhalation Aerosol Delivered Cumulatively With a Valved Holding Chamber and an Attached Facemask in Subjects Between Birth to 23 Months of Age With Acute Wheezing Due to Obstructive Airways Disease",albuterol sulfate inhalation aerosol,['albuterol sulfate inhalation aerosol'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Asthma,['Asthma'],"['wheezing', 'bronchospasm', 'albuterol sulfate HFA']",COMPLETED,,2004-09,2006-02,"[{'measure': 'To evaluate safety (adverse events, vital signs, physical exams, ECG monitoring etc.) of cumulative dosing of albuterol sulfate inhalation aerosol'}]","[{'measure': 'To assess the efficacy measures (percent change from baseline over entire treatment period in the TAL score, respiratory rate, wheezing etc.) of cumulative dosing of albuterol sulfate inhalation aerosol.'}]",2,,23 Months,ALL,False,GlaxoSmithKline,INDUSTRY,0,80.0,ACTUAL,2025-09-01T16:18:23.460283,v2_robust,True,True,True,False,True,
NCT05286346,Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis B,"A Multi-Center, Randomized, Open-label, Parallel, Active-controlled, Non-inferiority, Phase IV Clinical Trial to Evaluate the Safety and Efficacy of Switching to Tenolid Tab (Tenofovir Disoproxil) From Viread Tab (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients on Treatment With Tenofovir Disoproxil Fumarate",Tenofovir disoproxil 245mg,"['Tenofovir disoproxil fumarate 300mg', 'Tenofovir disoproxil 245mg']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Hepatitis b,['Chronic Hepatitis b'],[],COMPLETED,,2018-10-12,2020-08-10,"[{'measure': 'Inhibiting† rate of HBV virus at 48 weeks after baseline †HBV DNA < 400 copies/mL (=69 IU/mL*) *IU/mL is converting to copies/mL by unit for each institution. (ex: 5.8 copies/mL = 1 IU/mL)', 'timeFrame': '48 weeks'}]","[{'measure': 'Inhibiting† rate of HBV virus at 12, 24 and 36 weeks after baseline †HBV DNA < 400 copies/mL (=69 IU/mL*) * IU/mL is converting to copies/mL by unit for each institution. (ex: 5.8 copies/mL = 1 IU/mL)', 'timeFrame': '12, 24, 36 and 48 weeks'}, {'measure': ""Undetected‡ rate of HBV virus at 12, 24, 36 and 48 weeks after baseline ‡ The lower limit of quantification (LLOQ) for each institution is used, and if it is less than the LLOQ, the HBV DNA level is set to '0'."", 'timeFrame': '12, 24, 36 and 48 weeks'}, {'measure': 'Change of HBV DNA(log10 copies/mL) at 12, 24, 36 and 48 weeks from baseline', 'timeFrame': '12, 24, 36 and 48 weeks'}, {'measure': 'Loss rate of HBeAg in HBeAg(+) patients at 12, 24, 36 and 48 weeks after baseline', 'timeFrame': '12, 24, 36 and 48 weeks'}, {'measure': 'Seroconversion† rate of HBeAg in HBeAg(+) patients at 12, 24, 36 and 48 weeks after baseline †Generation of anti-HBe', 'timeFrame': '12, 24, 36 and 48 weeks'}, {'measure': 'Loss rate of HBsAg in HBsAg(+) patients at 12, 24, 36 and 48 weeks after baseline ④ Seroconversion† rate of HBsAg in HBsAg(+) patients at 12, 24, 36 and 48 weeks after baseline †Generation of anti-HBs', 'timeFrame': '12, 24, 36 and 48 weeks'}, {'measure': 'Seroconversion† rate of HBsAg in HBsAg(+) patients at 12, 24, 36 and 48 weeks after baseline †Generation of anti-HBs', 'timeFrame': '12, 24, 36 and 48 weeks'}, {'measure': 'Normal rate of ALT at 12, 24, 36 and 48 weeks after baseline', 'timeFrame': '12, 24, 36 and 48 weeks'}, {'measure': 'Change of ALT at 12, 24, 36 and 48 weeks from baseline', 'timeFrame': '12, 24, 36 and 48 weeks'}, {'measure': 'Virologic breakthrough* rate within 48 weeks after baseline *HBV DNA ≥ 400 copies/mL: twice in a row at intervals of 2 weeks or more or HBV DNA levels: increasing by 1log10 from Nadir levels of each subject twice in a row (HBV DNA <400 copies/mL)', 'timeFrame': '12, 24, 36 and 48 weeks'}]",11,19 Years,,ALL,False,"Samjin Pharmaceutical Co., Ltd.",INDUSTRY,0,113.0,ACTUAL,2025-09-01T16:18:23.460323,v2_robust,True,True,True,False,False,
NCT02171988,Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS),"Comparison of Effect of Propranolol, Bisoprolol, Pyridosgitmine in Postural Orthostatic Tachycardia Syndrome (POTS) and Prognosis After Medical Treatment",Propranolol,"['Propranolol', 'Propranolol+pyridostigmine', 'Bisoprolol+pyridostgmine', 'Bisoprolol']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Postural Orthostatic Tachycardia Syndrome,['Postural Orthostatic Tachycardia Syndrome'],"['Postural Orthostatic Tachycardia Syndrome', 'propranolol', 'bisoprolol', 'pyridostigmine']",COMPLETED,,2014-03,2016-12,"[{'measure': 'The change of the subjective symptom survey result after 3-month medical treatment.', 'timeFrame': '3 month after medical treatment'}]","[{'measure': 'Normalization of orthostatic BP-HR test after 6-month medical treatment.', 'timeFrame': '6 month'}, {'measure': 'The change of the subjective symptom after 6-month medical treatment.', 'timeFrame': '6 month'}, {'measure': 'Change of quality of life score after treatment', 'timeFrame': '6 month'}, {'measure': 'Change of depression score after treatment', 'timeFrame': '6 month'}]",5,15 Years,85 Years,ALL,False,Seoul National University Hospital,OTHER,0,150.0,ACTUAL,2025-09-01T16:18:23.460415,v2_robust,True,True,True,False,False,
NCT02090088,Nplate® Pregnancy Exposure Registry,Nplate® Pregnancy Exposure Registry (NPER),Not applicable- observational study,['Not applicable- observational study'],1,OBSERVATIONAL,[],,,Birth Defect,"['Birth Defect', 'Spontaneous Abortions', 'Low Birth Weight']",[],TERMINATED,,2009-05,2014-01,"[{'measure': 'Number of Children Born With Major Birth Defects', 'description': 'An external, independent Congenital Malformation Adjudication Panel (CMAP) comprised of two clinical dysmorphologists and/or teratologists organized malformations based upon organ system and embryology, and determined whether structural defects were major or minor according to a modification of the Metropolitan Atlanta Congenital Defects Program (MACDP) birth defect classification system. A major structural defect is defined as a defect which has either cosmetic or functional significance to the child (eg, a cleft lip), require surgery, or are life-limiting).', 'timeFrame': 'At birth'}]","[{'measure': 'Number of Children Born With Any 3 or More Minor Birth Defects', 'description': 'An external, independent Congenital Malformation Adjudication Panel (CMAP) comprised of two clinical dysmorphologists and/or teratologists organized malformations based upon organ system and embryology, and determined whether structural defects were major or minor according to a modification of the Metropolitan Atlanta Congenital Defects Program (MACDP) birth defect classification system. A minor structural defect is defined as a defect which occurs in less than 4% of the population but which has neither cosmetic nor functional significance to the child (eg, complete 2,3 syndactyly of the toes).', 'timeFrame': 'At birth'}, {'measure': 'Number of Children Born With a Specific Pattern of Minor Birth Defects', 'description': 'Only those infants who have received medical evaluation and who have three or more minor defects will be considered ""affected"" for purposes of the evaluation of a pattern of minor defects.', 'timeFrame': 'At birth'}, {'measure': 'Number of Participants With Spontaneous and Elective Abortions or Stillbirths', 'description': 'Number of each of spontaneous abortions, elective abortions, and stillbirths among mothers who received Nplate® therapy at any time during the pregnancy.', 'timeFrame': '9 months (during pregnancy)'}, {'measure': 'Number of Children With Preterm Birth or Low Birth Weight', 'description': 'Number of children with preterm birth (\\<37 weeks gestation) or low birth weight (\\<2,500 grams) among children born to mothers who have received Nplate® therapy at any time during the pregnancy.', 'timeFrame': 'At birth'}, {'measure': 'Number of Children Born With Intrauterine Growth Restriction', 'description': 'Number of children born with intrauterine growth restriction (weight, length or head circumference less than tenth percentile for sex and gestational age) among mothers who have received Nplate® therapy at any time during the pregnancy.', 'timeFrame': 'At birth'}, {'measure': 'Number of Infants With Adverse Events', 'description': 'In the first year of life, the incidence of all serious adverse events, as well as of nevi (birthmarks) and angiomata (benign tumors with blood vessels or lymph vessels), among infants whose mothers received Nplate® therapy at any time during the pregnancy.', 'timeFrame': '12 months from birth'}, {'measure': 'Number of Participants With Adverse Events', 'timeFrame': 'Throughout pregnancy and for up to 6 weeks after delivery'}]",8,,,,False,Amgen,INDUSTRY,0,4.0,ACTUAL,2025-09-01T16:18:23.460428,v2_robust,False,True,False,True,True,
NCT00110188,Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017),A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC),ridaforolimus,"['ridaforolimus', 'MK-8669', 'deforolimus', 'AP23573', 'ridaforolimus was also known as deforolimus until May 2009']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,['Prostate Cancer'],"['prostate', 'cancer']",COMPLETED,,2005-05,2007-08,"[{'measure': 'Best Overall Response (BOR) per Response Evaluation Criteria in Solid Tumors (RECIST)', 'timeFrame': 'Up to 24 months'}]","[{'measure': 'Number of Participants Experiencing at Least One Adverse Event', 'timeFrame': 'Up to 25 months'}, {'measure': 'Change from Baseline in Prostate-Specific Antigen (PSA)', 'timeFrame': 'Baseline and up to 24 months'}, {'measure': 'Time to Tumor Progression (TTP)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Progression-Free Survival (PFS)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Duration of Response (DOR)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Change from Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Score', 'timeFrame': 'Baseline and up to 24 months'}, {'measure': 'Change from Baseline in Plasma Vascular Endothelial Growth Factor (VEGF)', 'timeFrame': 'Baseline and Day 28 of Cycles 1 and 2 (Up to 56 days)'}]",9,18 Years,,MALE,False,Merck Sharp & Dohme LLC,INDUSTRY,1,39.0,ACTUAL,2025-09-01T16:18:23.460523,v2_robust,True,True,True,False,True,
NCT03347188,A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH),"A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study, Including an Open-Label Period, Evaluating the Efficacy and Safety of 1 Subcutaneous Dose Regimen of Fremanezumab for the Treatment of Posttraumatic Headache (PTH)",Fremanezumab,"['Fremanezumab', 'Placebo', 'TEV-48125']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Post-Traumatic Headache,['Post-Traumatic Headache'],['posttraumatic headache (PTH)'],COMPLETED,,2017-12-18,2020-06-03,"[{'measure': 'DB Period: Mean Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 12-Week Treatment Period After the First Dose of Fremanezumab', 'description': 'A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \\* 28. The change was calculated as post-baseline value - baseline value. Least square (LS) mean was calculated using analysis of covariance (ANCOVA) model with the duration of post traumatic headache history (less than 12 month since the brain injury or greater or equal to 12 month since the brain injury) and treatment as fixed effects and the baseline monthly average number of headache days of at least moderate severity as a covariate.', 'timeFrame': 'Baseline (Day -28 to Day -1), up to Week 12'}]","[{'measure': 'DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in Monthly Average Number of Headache Days of Any Severity During 12-Week Treatment With Fremanezumab', 'description': 'Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \\* 28.', 'timeFrame': 'Baseline (Day -28 to Day-1) up to Week 12'}, {'measure': 'DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in the Monthly Average Number of Headache Days of at Least Moderate Severity During 12-Week Treatment With Fremanezumab', 'description': 'A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \\* 28.', 'timeFrame': 'Baseline (Day -28 to Day-1) up to Week 12'}, {'measure': 'DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in the Monthly Average Number of Headache Days of at Least Moderate Severity During First 4-Week (Month 1), 5- to 8-Week (Month 2), and 9- to 12-Week (Month 3)', 'description': 'A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \\* 28.', 'timeFrame': 'Baseline (Day -28 to Day-1) up to Months 1, 2, and 3'}, {'measure': 'DB Period: Change From Baseline in the Number of Headache Days of At Least Moderate Severity During the First 4-Week (Month 1), 5- to 8-Week (Month 2), and 9- to 12-Week (Month 3)', 'description': 'A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \\* 28. The change was calculated as post-baseline value - baseline value. LS mean was calculated using ANCOVA model with the duration of post traumatic headache history (less than 12 month since the brain injury or greater or equal to 12 month since the brain injury) and treatment as fixed effects and the baseline monthly average number of headache days of at least moderate severity as a covariate. This approach was used in generating the LS mean values only and was not considered to be an additional statistical analysis, no additional statistical analyses are reported for this outcome measure.', 'timeFrame': 'Baseline (Day -28 to Day -1), up to Months 1, 2, and 3'}, {'measure': 'DB Period: Change From Baseline in Disability Score, as Measured by the 6-Item Headache Impact Test (HIT-6) Total Score at Week 12 After the First Dose of Fremanezumab', 'description': ""HIT-6 is a tool used to measure the impact headaches have on a participant's normal daily life and ability to function. The HIT-6 consists of 6 items, including pain, social functioning, role functioning, vitality, cognitive functioning, and psychological distress. Each item was answered on a 5-point Likert scale (6=never, 8=rarely, 10=sometimes, 11=very often, or 13=always), which were summed to produce a total score that ranged from 36 to 78, with larger scores reflecting greater impact of headache on the daily life of the participant."", 'timeFrame': 'Baseline (Day -28 to Day -1), Week 12'}, {'measure': 'DB Period: Number of Participants (Responder and Non-Responder) With the Patient Global Impression of Change (PGIC) Scale at Weeks 4, 8, and 12 After the First Dose of Fremanezumab', 'description': 'The PGIC scale is a validated generic tool for the assessment of overall change in the severity of illness following treatment. Participants rated how they felt during assigned time points compared with how they felt before receiving study drug on a 7-point scale, where 1 = No change (or it got worse); 2 = Almost the same, hardly any change at all; 3 = A little better, but no noticeable change; 4 = Somewhat better, but the change has not made any real difference; 5 = Moderately better, and a slight but noticeable change; 6 = Better, and a definite improvement that has made a real and worthwhile difference; and 7 = A great deal better, and a considerable improvement that has made all the difference. Responders were those with a scale of 5 to 7 and non-responders were those with a scale of 1 to 4.', 'timeFrame': 'Weeks 4, 8, and 12'}, {'measure': 'DB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)', 'description': 'An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring at or after the first dose of the study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.', 'timeFrame': 'Baseline (Day -28 to -1) up to Week 12'}, {'measure': 'OL Period: Number of Participants With TEAEs', 'description': 'An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring at or after the first dose of the study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.', 'timeFrame': 'Week 12 up to Week 24'}, {'measure': 'DB Period: Number of Participants Who Did Not Complete the Study', 'description': 'Number of participants who did not complete the study due to any reason and due to AEs are reported.', 'timeFrame': 'Baseline (Day -28 to Day -1) up to Week 12'}, {'measure': 'OL Period: Number of Participants Who Did Not Complete the Study', 'description': 'Number of participants who did not complete the study due to any reason and due to AEs are reported.', 'timeFrame': 'Week 12 up to Week 24'}, {'measure': 'DB Period: Number of Participants Who Received Concomitant Medications', 'description': 'Concomitant medications included: agents acting on renin-angiotensin system, analgesics, anesthetics, anti-parkinson drugs, antianemic preparations, antibacterials for systemic use, antidiarrheals, intestinal antiinflammatory/antiinfective agents, antiemetics and antinauseants, antiepileptics, antifungals for dermatologiocal use, antihistamines for systemic use, antihypertensives, antiinflammatory and antirheumatics, antineoplastic agents, antiobesity preparations, antipruritics, antithrombotics, antivirals for systemic use, beta blocking agents, calcium channel blockers, cardiac therapy, corticosteroids, cough and cold preparations, diuretics, lipid modifying agents, nasal preparations, thyroid therapy, urologicals, vaccines, psycholeptics, psycoanaleptics, ophthalmologicals, general nutrients, mineral supplements, muscle relaxants, vitamins, drugs used in diabetes, sex hormones and modulators of the genital system, immunosuppresants, drugs for acid related disorders etc.', 'timeFrame': 'Baseline (Day -28 to Day -1) up to Week 12'}, {'measure': 'OL Period: Number of Participants Who Received Concomitant Medications', 'description': 'Concomitant medications included: agents acting on renin-angiotensin system, analgesics, anti-parkinson drugs, antianemic preparations, antibacterials for systemic use, antiemetics and antinauseants, antihistamines for systemic use, antihypertensives, antiinflammatory and antirheumatics, antineoplastic agents, antithrombotics, beta blocking agents, calcium channel blockers, corticosteroids for systemic use, cough and cold preparations, diuretics, lipid modifying agents, nasal preparations, other gynecologicals, other nervous system drugs, thyroid therapy, unspecified herbal and traditional medicine, urologicals, vaccines, psycholeptics, psycoanaleptics, general nutrients, mineral supplements, muscle relaxants, vitamins, sex hormones and modulators of the genital system, drugs for acid related disorders, drugs for constipation, drugs for obstructive airways disease etc.', 'timeFrame': 'Week 12 up to Week 24'}, {'measure': 'Number of Participants With Positive Findings on Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)', 'description': ""eC-SSRS is a questionnaire to assess suicidal ideation (severity and intensity) and behavior. Suicidal ideation: A series of 1 -5 questions (with 'yes' or 'no' response) with 5 types of ideation of increasing severity: 1. wish to be dead, 2. non-specific active suicidal thoughts, 3. active suicidal ideation with any methods (not plan) without intent to act, 4. active suicidal ideation with some intent to act, without specific plan, 5. active suicidal ideation with specific plan and intent. A positive finding was defined as a 'yes' response to question 4 or 5."", 'timeFrame': 'Baseline (Day -28 to Day -1) up to Week 24'}, {'measure': 'Number of Participants With Treatment-Emergent Antidrug Antibodies (ADA)', 'description': 'Number of participants with treatment-emergent antidrug antibodies reported.', 'timeFrame': 'Baseline (Day -28 to Day -1) up to Week 24'}]",15,18 Years,70 Years,ALL,False,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,0,87.0,ACTUAL,2025-09-01T16:18:23.460693,v2_robust,True,True,True,False,True,
NCT06453603,Efficacy of Platelet-rich Plasma Injection Compare With Corticosteroid in Pes Anserinus Pain Syndrome,"Efficacy of Platelet-rich Plasma Injection Compare With Corticosteroid in Pes Anserinus Pain Syndrome, Randomized Controlled Trial Study",PRP injection,"['PRP injection', 'corticosteroid injection']",2,INTERVENTIONAL,['NA'],,,Pes Anserine Bursitis,"['Pes Anserine Bursitis', 'Steroid Injection', 'PRP Injection']","['Pes Anserine Bursitis', 'Steroid Injection', 'PRP injection']",NOT_YET_RECRUITING,,2024-07-01,2026-12-31,"[{'measure': 'Visual analogue scale (VAS)', 'description': 'Pain relief outcome : Visual analogue scale (VAS) scale 0(minimum pain) to 10(maximum pain)', 'timeFrame': '6 months'}]","[{'measure': 'WOMAC score', 'description': 'Functional outcomes : The Western Ontario and McMaster Universities Arthritis Index(WOMAC) version 3.01 Thai version', 'timeFrame': '6 months'}]",2,18 Years,,ALL,False,Ramathibodi Hospital,OTHER,0,24.0,ESTIMATED,2025-09-01T16:18:23.460816,v2_robust,True,True,False,False,False,
NCT01494103,Administration of Donor T Cells With the Caspase-9 Suicide Gene,Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene,AP1903,"['AP1903', 'AP1903 Dimerizer Drug']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Lymphoblastic Leukemia,"['Acute Lymphoblastic Leukemia', 'Myelodysplastic Syndrome', 'Acute Myeloid Leukemia', 'Chronic Myelogenous Leukemia', 'Non Hodgkin Lymphoma', 'Hemophagocytic Lymphohistiocytosis', 'Familial Hemophagocytic Lymphohistiocytosis', 'Hemophagocytic Syndrome', 'Epstein Barr Virus Infection', 'X-linked Lymphoproliferative Disease']","['Acute lymphoblastic leukemia', 'Myelodysplastic syndrome', 'Acute myeloid leukemia', 'Chronic myelogenous leukemia', 'Non Hodgkin lymphoma', 'Hemophagocytic lymphohistiocytosis', 'Familial hemophagocytic lymphohistiocytosis', 'Hemophagocytic syndrome', 'Epstein Barr virus infection', 'X-linked lymphoproliferative disease']",ACTIVE_NOT_RECRUITING,,2011-11,2029-05,"[{'measure': 'Clinical and immunological effects of AP1903 administration.', 'description': 'To evaluate the clinical and immunological effects of AP1903 administration, a dimerizer drug used to activate an iCaspase9 suicide gene mechanism, to subjects who have received escalating doses of T lymphocytes expressing the iCaspase9 gene and developed acute graft-versus-host-disease (GvHD).', 'timeFrame': '14 days'}]","[{'measure': 'T cell dose that produces a greater than 25% risk of Grade II or greater GvHD.', 'description': 'To discover the number of T cells/kg (up to 5 x 10\\^6/kg) that produce a greater than 25% risk of inducing Grade II or greater acute GvHD in these subjects.', 'timeFrame': '42 days'}, {'measure': 'Immune reconstitution and relative contribution of iCaspase9-modified T cells post-infusion.', 'description': 'To measure the subsequent immune reconstitution of recipients of iCaspase9 modified T cells (and dimerizer drug), and assess the relative contribution of endogenous T cell recovery and infused gene-modified T cells.', 'timeFrame': 'Up to 15 years'}, {'measure': 'Overall and disease-free survival.', 'description': 'To measure the overall and disease-free survival of recipients of iCaspase9 T cells at 100 days and at 1 year post-transplant.', 'timeFrame': '100 days and 1 year'}]",4,,,ALL,False,Baylor College of Medicine,OTHER,2,15.0,ACTUAL,2025-09-01T16:18:23.460865,v2_robust,True,True,False,False,False,
NCT00619203,Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis,"Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis - A Prospective, Randomized, and Double-Blind Clinical Study Using a Two-by-Two Factorial Design",Glycerol and paracetamol,"['Glycerol', 'Glycerol and paracetamol', 'Paracetamol', 'Paracetamol and glycerol', 'Placebo']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Bacterial Meningitis,['Bacterial Meningitis'],"['Bacterial meningitis', 'glycerol', 'high dose paracetamol', 'children']",COMPLETED,,2008-03,2012-03,"[{'measure': 'Primary end points are death, severe neurological sequelae, hearing loss.', 'timeFrame': '2008-2011'}]","[{'measure': 'Secondary end points are audiological or neurological sequelae (according to the Denver-II developmental screening test).', 'timeFrame': '2008-2011'}]",2,2 Months,15 Years,ALL,False,Kamuzu University of Health Sciences,OTHER,0,466.0,ACTUAL,2025-09-01T16:18:23.460887,v2_robust,True,True,True,False,False,
NCT00446303,A Phase II Study of Maintenance With Azacitidine in MDS Patients,A Phase II Study of Maintenance With Azacitidine in MDS Patients Achieving Complete or Partial Remission (CR or PR) After Intensive Chemotherapy,Azacitidine,['Azacitidine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Leukemia, Myelocytic, Acute","['Leukemia, Myelocytic, Acute', 'Myelodysplastic Syndromes']","['MDS', 'Myelodysplastic Syndromes', 'AML', 'Intensive chemotherapy', 'azacitidine']",TERMINATED,,2006-07,2010-07,"[{'measure': 'Reponse duration and cumulative incidence of relapses', 'timeFrame': '1-24 months'}]","[{'measure': 'Toxicity according to WHO', 'timeFrame': '1-24 months'}, {'measure': 'Overall survival'}]",3,18 Years,85 Years,ALL,False,Groupe Francophone des Myelodysplasies,OTHER,1,39.0,ACTUAL,2025-09-01T16:18:23.460962,v2_robust,True,True,False,True,False,
NCT00731003,The Effect of Serotonergic Modulation on Intestinal Permeability and Visceral Hypersensitivity in Healthy Individuals and Irritable Bowel Syndrome (IBS) Patients,The Effect of Serotonergic Modulation on Intestinal Permeability and Visceral Hypersensitivity in Healthy Individuals and IBS Patients,Oxitriptan,"['Placebo capsule', 'Oxitriptan']",2,INTERVENTIONAL,['NA'],,,Irritable Bowel Syndrome,['Irritable Bowel Syndrome'],"['serotonin', 'gut permeability', 'visceral sensitivity', 'irritable bowel syndrome']",COMPLETED,,2009-04,2011-05,"[{'measure': 'The primary aim is to assess intestinal permeability under altered serotonergic conditions by means of sugar permeability test', 'timeFrame': '2010'}]","[{'measure': 'To assess tight junction functionality and serotonin metabolism To assess visceral hypersensitivity under altered serotoninergic conditions To examine biopsy specimens for serotonergic and intestinal permeability parameters in ex vivo circumstances', 'timeFrame': '2010'}]",2,18 Years,65 Years,ALL,True,Maastricht University Medical Center,OTHER,1,60.0,ACTUAL,2025-09-01T16:18:23.461001,v2_robust,True,True,True,False,False,
NCT04645303,Injection of Hyaluronic Acid Versus Corticosteroid for Treatment of Trigger Finger,Ultrasound-Guided Injection of Hyaluronic Acid Versus Corticosteroid for Treatment of Trigger Finger: Randomized Controlled Study,hyaluronic acid (20 mg/2 mL),"['hyaluronic acid (20 mg/2 mL)', 'Triamcinolone acetonide 10mg/ml', 'Kenalog 10 mg/ml', 'Hyalgan 20 mg in 2 ML Prefilled Syringe']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Trigger Finger,['Trigger Finger'],"['Trigger finger', 'Hyaluronic Acid', 'Corticosteroid', 'Ultrasound-guided injection']",UNKNOWN,,2020-11-06,2021-06-04,"[{'measure': 'Change in Quinnell trigger finger grading system:', 'description': 'Change in Quinnell grading overtime within 3 months after injection. Trigger fingers are rated as follows: Grade 0: normal finger movements, Grade 1: uneven finger movements, Grade 2: actively correctable triggering, Grade 3: passively correctable triggering, and Grade 4: locked digit.', 'timeFrame': '1 and 3 months post-injection'}]","[{'measure': 'Visual analogue scale (VAS) of pain', 'description': 'Change in pain Visual analogue scale will be recorded. The patient marks on the 100 mm in length line the point that he/she feels to represent his/her perception of pain at the current state. The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks ( a higher score indicates greater pain intensity). Categorization of none, mild, moderate and severe pain will be also used (none = 0, mild = 1-4, moderate = 5-6, and severe = 7-10).', 'timeFrame': '1 and 3 months post-injection'}, {'measure': 'Frequency of tender trigger nodules', 'description': 'Identifying the presence of tender nodules at A1-pulley of the affected finger by palpation', 'timeFrame': '1 and 3 months post-injection'}, {'measure': 'The Quick Disability of the Arm, Shoulder and Hand score', 'description': 'Patients will be asked to fill a questionnaire form. It is an 11-item form that assesses the upper limb function on a scale of 1-5, with scores ranging from 11 to 55, with the higher scores representing more disability and worse upper limb function.', 'timeFrame': '1 and 3 months post-injection'}, {'measure': 'Changes in Grip strength', 'description': 'Measured by the dynamometer strength test (Jamar grip dynamometer)', 'timeFrame': '1 and 3 months post-injection'}, {'measure': 'Patient satisfaction with therapy', 'description': 'Participating patients will be asked to classify their result into 1 of 4 categories: (1) complete resolution of symptoms, (2) improved result, but incomplete resolution of symptoms, not warranting further treatment, (3) partial response, but unsatisfactory, warranting further treatment, and (4) no response.', 'timeFrame': '1 and 3 months post-injection'}, {'measure': 'Ultrasound evaluation of A1-Pulley', 'description': 'Detailed ultrasonography evaluation of A1-Pulley. Comparing the A1-Pulley ultrasonographic parameters over 3 months after injection (at the follow-up appointment)', 'timeFrame': '1 and 3 months post-injection'}]",7,19 Years,,ALL,False,Dubai Health Authority,OTHER_GOV,0,100.0,ESTIMATED,2025-09-01T16:18:23.461012,v2_robust,True,True,False,False,False,
NCT03827603,Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia,Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia: ELaboration of Treatment Approach,Ibrutinib,"['Ibrutinib', 'Imbruvica']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,AIHA - Warm Autoimmune Hemolytic Anemia,['AIHA - Warm Autoimmune Hemolytic Anemia'],[],UNKNOWN,,2017-02-21,2022-03-31,"[{'measure': 'Response rate', 'description': 'Response rate defined by transfusion independence, hemoglobin level, DAT and duration of response of autoimmunity (DR-AI), defined as the interval between time point of best response and relapse of AIC. Relapses of CLL will be censored.', 'timeFrame': '3 month after treatment'}]",[],1,18 Years,,ALL,False,Eugene Nikitin,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:23.461242,v2_robust,True,True,False,False,False,
NCT01425827,Duloxetine for Pain in Older Adults With Knee Osteoarthritis (OA),,duloxetine HCL,"['duloxetine HCL', 'placebo']",2,INTERVENTIONAL,['NA'],,,Pain Reduction,"['Pain Reduction', 'Function Improvement']","['duloxetine', 'osteoarthritis', 'pain', 'function']",COMPLETED,,2010-11,2011-07,"[{'measure': 'Pain reduction', 'timeFrame': '16 weeks'}]",[],1,50 Years,85 Years,ALL,True,University of Alexandria,OTHER,0,288.0,ACTUAL,2025-09-01T16:18:23.461260,v2_robust,True,True,True,False,False,
NCT05545527,Neuroimaging Ancillary Study,Neuroimaging Ancillary Study of the IV Iron RAPIDIRON Trial,Ferric carboxymaltose,"['Ferric derisomaltose', 'Iron isomaltoside', 'Ferric Sulfate', 'Ferric sulphate', 'Ferric carboxymaltose']",5,OBSERVATIONAL,[],,,Iron Deficiency Anemia,"['Iron Deficiency Anemia', 'Iron Deficiency Anemia of Pregnancy', 'Neurodevelopmental Disorder of Foetus', 'Iron Deficiency Anemia Treatment', 'Fetal Neurodevelopmental Disorder', 'Child Development']","['India', 'Neuroimaging', 'Intravenous iron', 'MRI', 'Pediatrics']",COMPLETED,,2023-02-21,2025-04-07,"[{'measure': 'Fetal hippocampal volume', 'description': 'Fetal hippocampus volume, measured via fetal MRI', 'timeFrame': '32-35 weeks fetal gestational age'}, {'measure': 'Fetal diffusion parameters: fractional anisotropy (FA)', 'description': 'Fetal white matter microstructure will be measured via FA at the posterior limb of internal capsule using fetal MRI', 'timeFrame': '32-35 weeks fetal gestational age'}, {'measure': 'Fetal diffusion parameters: mean diffusivity', 'description': 'Fetal white matter microstructure will be measured via MD at the posterior limb of internal capsule using fetal MRI', 'timeFrame': '32-35 weeks fetal gestational age'}]","[{'measure': 'Fetal sub-cortical gray matter structures', 'description': 'Fetal sub-cortical gray matter structures in the brain using fetal MRI', 'timeFrame': '32-35 weeks fetal gestational age'}, {'measure': 'Fetal white matter microstructure measures', 'description': 'Additional fetal white matter microstructure measures using fetal MRI, including qualitative T2 MRI measures and NODDI metrics', 'timeFrame': '32-35 weeks fetal gestational age'}, {'measure': 'Child hippocampal volume', 'description': 'Child hippocampal volume, measured via MRI', 'timeFrame': '4 - 24 months of age'}, {'measure': 'Child white matter volume', 'description': 'Child white matter volume, measured via MRI', 'timeFrame': '4 - 24 months of age'}, {'measure': 'Child white matter microstructure', 'description': 'Child white matter microstructure, including myelination, fiber coherence, and architecture, measured via MRI', 'timeFrame': '4 - 24 months of age'}, {'measure': 'Child white matter connectivity', 'description': 'Child white matter connectivity, measured via MRI', 'timeFrame': '4 - 24 months of age'}, {'measure': 'Child functional connectivity', 'description': 'Child functional connectivity, measured via MRI', 'timeFrame': '4 - 24 months of age'}, {'measure': 'Child cerebral metabolism', 'description': 'Child cerebral metabolism, including perfusion and spectroscopy, measured via MRI', 'timeFrame': '4 - 24 months of age'}]",11,18 Years,40 Years,FEMALE,False,Thomas Jefferson University,OTHER,1,184.0,ACTUAL,2025-09-01T16:18:23.461298,v2_robust,False,True,True,False,False,
NCT01557127,"Nexavar Dosing in Renal Cancer Patients in ""Real-life"" Setting",Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma,"Sorafenib (Nexavar, BAY43-9006)","['Sorafenib (Nexavar, BAY43-9006)']",1,OBSERVATIONAL,[],,,"Carcinoma, Renal Cell","['Carcinoma, Renal Cell']","['Renal cell carcinoma,', 'Sorafenib', 'Dosing']",COMPLETED,,2011-11-01,2016-03-31,"[{'measure': 'Percentage of patients in whom the actual dose of sorafenib equaled the planned dose', 'timeFrame': '12 months'}]","[{'measure': 'Overall tolerability of treatment as measured by rate of adverse events', 'timeFrame': '12 months'}]",2,18 Years,,ALL,False,Bayer,INDUSTRY,0,205.0,ACTUAL,2025-09-01T16:18:23.461324,v2_robust,False,True,True,False,True,
NCT01427127,Effect of Ramosetron on Bowel Motility After Colorectal Resection,Effect of Ramosetron on Bowel Motility and PONV After Laparoscopic Stomach and Colorectal Resection,Ramosetron,"['Ramosetron', 'nasea (Astellas Pharma Korea, Inc.)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Postoperative Nausea and Vomiting,['Postoperative Nausea and Vomiting'],[],UNKNOWN,,2010-12,2011-12,"[{'measure': 'time from surgery to passage of gas', 'timeFrame': 'within 10days after surgery'}, {'measure': 'time from surgery to defecation', 'timeFrame': 'within 10 days after surgery'}]","[{'measure': 'incidence and severity of postoperative nausea and vomiting', 'description': 'incidence: number of patients who experienced postoperative nausea and vomiting severity: verbal rating scale (VRS, 11 point scale) 0= no nausea to 10 = worst possible nausea', 'timeFrame': '0 - 6 hours, 6-24 hours, and 24-48 hours after surgery'}]",3,20 Years,70 Years,ALL,False,Kyunghee University Medical Center,OTHER,0,64.0,ESTIMATED,2025-09-01T16:18:23.461333,v2_robust,True,True,False,False,False,
NCT00220727,Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP,"Randomized, Controlled, Open Study Investigating IGIV-C, 10% Given at Different Infusion Rates on Intravascular Hemolysis in Patients With Idiopathic (Immune) Thrombocytopenic Purpura (ITP)","Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified","['NDC 13533-645-24', 'IGIVnex®', 'IVIG', 'Immune Globulin (Human), 10% (IGIV)', 'NDC 13533-645-15', 'IGIV-C', 'NDC 13533-645-71', 'BAY 41-1000', 'Immune Globulin Intravenous, 10% by Chromatography Process', 'NDC 13533-645-12', 'Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified', 'TAL-05-00004', 'Gamunex®', 'Gaminex', 'NDC 13533-645-20', 'IGIV-C, 10%']",16,INTERVENTIONAL,['PHASE2'],PHASE2,,"Purpura, Thrombocytopenic, Idiopathic","['Purpura, Thrombocytopenic, Idiopathic']","['Idiopathic (Immune) Thrombocytopenic Purpura', 'Immunoglobulin G']",COMPLETED,,2003-07,2003-10,"[{'measure': 'Free Hemoglobin', 'description': 'Free hemoglobin as a measure to assess hemolysis.', 'timeFrame': '24 hours after treatment'}, {'measure': 'Hematocrit', 'description': 'Hematocrit as a measure to assess hemolysis', 'timeFrame': '24 hrs after treatment'}, {'measure': 'Red Blood Cells', 'description': 'Red blood cells as a measure to assess hemolysis', 'timeFrame': '24 hrs after treatment'}, {'measure': 'Change From Baseline in Platelet Levels', 'timeFrame': '24 hours Post infusion and Day 7'}]","[{'measure': 'Number of Subjects With Infusion Related Adverse Events', 'timeFrame': '48 hours after treatment'}]",5,12 Years,75 Years,ALL,False,Grifols Therapeutics LLC,INDUSTRY,0,8.0,ACTUAL,2025-09-01T16:18:23.461347,v2_robust,True,True,True,False,True,
NCT01464827,ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients,"A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 With Ritonavir (ABT-450/r) in Combination With ABT-267 and/or ABT-333 With and Without Ribavirin (RBV) for 8, 12 or 24 Weeks in Treatment-Naïve and Null Responder Subjects With Genotype 1 Chronic Hepatitis C Virus Infection",ABT-450,"['ABT-333', 'Ritonavir', 'Ombitasvir', 'ABT-450', 'ABT-267', 'Ribavirin', 'Norvir', 'Dasabuvir']",8,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Hepatitis C,"['Chronic Hepatitis C', 'Hepatitis C (HCV)', 'Hepatitis C Genotype 1']","['Hepatitis C Genotype 1', 'Hepatitis C', 'Interferon-Free', 'HCV', 'Chronic Hepatitis C']",COMPLETED,,2011-10,2013-09,"[{'measure': 'Number of Participants With Adverse Events (AEs)', 'description': ""An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment.\n\nThe investigator assessed the relationship of each AE to the use of direct-acting antiviral agents (DAAs) and to ribavirin, and rated the severity of each event as either:\n\nMild: The AE was transient and easily tolerated by the participant; Moderate: The AE caused the participant discomfort and interrupted usual activities; Severe: The AE caused considerable interference with the participant's usual activities and could have been incapacitating or life-threatening.\n\nA serious adverse event was any event that resulted in death, was life-threatening, resulted in or prolonged hospitalization, resulted in a congenital anomaly or persistent or significant disability or was any other important medical event requiring medical or surgical intervention."", 'timeFrame': 'From the time of study drug administration until 30 days following discontinuation of study drug administration (up to 28 weeks).'}, {'measure': 'Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose for 8 Weeks Versus 12 Weeks of Treatment With 3 DAAs and Ribavirin', 'description': 'The percentage of participants achieving sustained virologic response 24 weeks after the last dose of study drug (SVR24), defined as hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantitation (LLOQ), without any confirmed quantifiable (≥ LLOQ) post-treatment value before that time point. HCV RNA levels were measured from plasma by a central laboratory. The LLOQ for the assay was 25 IU/mL.\n\nThe primary efficacy endpoint was the comparison between treatment-naïve participants following 8 weeks of treatment with 3 DAAs and ribavirin and those with 12 weeks of treatment with 3 DAAs and ribavirin (Group A versus Group G).', 'timeFrame': 'Post Treatment Week 24'}]","[{'measure': 'Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment of Different Durations With 3 Direct-acting Antiviral Agents (DAAs) and Ribavirin', 'description': 'This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks after the last dose of study drug (HCV RNA \\< LLOQ at post-treatment Week 24) following treatment with 3 DAAs (ABT-450/ritonavir, ABT-267, and ABT-333) and ribavirin in both treatment naïve and null-responder participants for 8 weeks (Group A) versus 12 weeks (Groups F + G + K + L) versus 24 weeks (Groups H + I + M + N).', 'timeFrame': 'Post-Treatment Week 24'}, {'measure': 'Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 2 DAAs and Ribavirin Versus 3 DAAs and Ribavirin', 'description': 'This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA \\< LLOQ at post-treatment Week 24) following treatment with 2 DAAs (ABT-450/ritonavir plus ABT-333 \\[Group B\\] or ABT-450/ritonavir plus ABT-267 \\[Groups C + D + J\\]) and ribavirin versus 3 DAAs (ABT-450/ritonavir plus ABT-333 and ABT-267) and ribavirin (Groups F + G + K + L).', 'timeFrame': 'Post-Treatment Week 24'}, {'measure': 'Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 3 DAAs With Versus Without Ribavirin', 'description': 'This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA \\< LLOQ at post-treatment Week 24) following treatment with 3 DAAs with or without ribavirin (Group E versus Groups F + G + K + L).', 'timeFrame': 'Post-Treatment Week 24'}, {'measure': 'Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose in Treatment-naïve Versus Null-responders', 'description': 'This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA \\< LLOQ at post-treatment Week 24) following treatment with 3 DAAs and ribavirin in participants who were treatment-naïve versus those who were null-responders to previous HCV therapy (Groups F + G + H + I versus Groups K + L + M + N).', 'timeFrame': 'Post-Treatment Week 24'}]",6,18 Years,70 Years,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,0,580.0,ACTUAL,2025-09-01T16:18:23.461362,v2_robust,True,True,True,False,True,
NCT01041027,"Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer","A Pilot Phase II Trial of Radiation Therapy ""Sandwiched"" Between Paclitaxel and Carboplatin in Patients With High-Risk Endometrial Cancer After Standard Surgical Staging",Paclitaxel,"['Anzatax', 'Paclitaxel', 'Carboplatin', 'TAX']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Endometrial Adenocarcinoma,"['Endometrial Adenocarcinoma', 'Stage IA Uterine Corpus Cancer', 'Stage IB Uterine Corpus Cancer', 'Stage II Uterine Corpus Cancer', 'Stage IIIA Uterine Corpus Cancer', 'Stage IIIB Uterine Corpus Cancer', 'Stage IIIC Uterine Corpus Cancer', 'Stage IVA Uterine Corpus Cancer', 'Stage IVB Uterine Corpus Cancer']",[],TERMINATED,Due to slow accrual. Results from the PORTEC3 the study rendered the hypothesis no longer valid.,2009-01-16,2019-10-01,"[{'measure': 'Progression-free Survival (PFS)', 'description': 'PFS will be analyzed using standard survival analytic methods, including the Kaplan-Meier approach for estimating the survival distribution. Median time to progression and 95% confidence intervals will be estimated from the Kaplan-Meier curves.', 'timeFrame': 'From randomization until documented tumor recurrence or death from any cause, assessed up to 5 years'}]","[{'measure': 'Expression Levels of IGF-1', 'description': 'Associations of PFS with tumor tissue expression levels of IGF-1 will be evaluated. Provided the number of events is sufficient, Cox proportional hazards models will be fit to the data to explore these associations.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Expression Levels of IGF-2', 'description': 'Associations of PFS with tumor tissue expression levels of IGF-2 will be evaluated. Provided the number of events is sufficient, Cox proportional hazards models will be fit to the data to explore these associations.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Expression Levels of IGFBP-1', 'description': 'Associations of PFS with tumor tissue expression levels of IGFBP-1 will be evaluated. Provided the number of events is sufficient, Cox proportional hazards models will be fit to the data to explore these associations.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Expression Levels of IGFBP-3', 'description': 'Associations of PFS with tumor tissue expression levels of IGFBP-3 will be evaluated. Provided the number of events is sufficient, Cox proportional hazards models will be fit to the data to explore these associations.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Expression Levels of Insulin Receptor', 'description': 'Associations of PFS with tumor tissue expression levels of insulin receptor will be evaluated. Provided the number of events is sufficient, Cox proportional hazards models will be fit to the data to explore these associations.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Expression Levels of IGF-1 Receptor', 'description': 'Associations of PFS with tumor tissue expression levels of IGF-1 receptor will be evaluated. Provided the number of events is sufficient, Cox proportional hazards models will be fit to the data to explore these associations.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Expression Levels of Estrogen Receptor', 'description': 'Associations of PFS with tumor tissue expression levels of estrogen receptor will be evaluated. Provided the number of events is sufficient, Cox proportional hazards models will be fit to the data to explore these associations.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Expression Levels of Progesterone Receptor', 'description': 'Associations of PFS with tumor tissue expression levels of progesterone receptor will be evaluated. Provided the number of events is sufficient, Cox proportional hazards models will be fit to the data to explore these associations.', 'timeFrame': 'Up to 5 years'}]",9,18 Years,,FEMALE,False,Albert Einstein College of Medicine,OTHER,1,31.0,ACTUAL,2025-09-01T16:18:23.461417,v2_robust,True,True,False,True,False,Due to slow accrual. Results from the PORTEC3 the study rendered the hypothesis no longer valid.
NCT00004927,BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy,Phase I Study of BMS-247550 Given Every Three Weeks in Patients With Advanced Malignancies,ixabepilone,['ixabepilone'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,"Unspecified Adult Solid Tumor, Protocol Specific","['Unspecified Adult Solid Tumor, Protocol Specific']","['unspecified adult solid tumor, protocol specific']",COMPLETED,,1999-07,2002-10,[],[],0,18 Years,120 Years,ALL,False,R-Pharm,INDUSTRY,2,,,2025-09-01T16:18:23.461455,v2_robust,True,True,True,False,False,
NCT02773927,Combination of Metformin/Inulin vs Inulin on Adiponectin in Metabolic Syndrome,Effect of the Combination Metformin/Inulin vs Inulin on Adiponectin in Patients With Metabolic Syndrome,Metformin,"['GLUCOPHAGE', 'Metformin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Metabolic Syndrome,['Metabolic Syndrome'],"['Agave inulin', 'Adiponectin', 'Metabolic syndrome', 'Metformin', 'Insulin resistance']",COMPLETED,,2013-01,2015-06,"[{'measure': 'Change from Baseline on adiponectin levels (ng/mL) at 12 weeks', 'description': 'Before and after intervention determination of adiponectin using ELISA following the suppliers recommendations', 'timeFrame': '12 weeks'}]","[{'measure': 'Change from Baseline in Fasting plasma glucose at 12 weeks', 'description': 'Before and after intervention by glucose oxidase', 'timeFrame': '12 weeks'}, {'measure': 'Change from Baseline in Total cholesterol at 12 weeks', 'description': 'Before and after intervention by spectrophotometry', 'timeFrame': '12 weeks'}, {'measure': 'Change from Baseline in Triglycerides at 12 weeks', 'description': 'Before and after intervention by spectrophotometry', 'timeFrame': '12 weeks'}, {'measure': 'Change from baseline in High-density lipoprotein cholesterol at 12 weeks', 'description': 'Before and after intervention by spectrophotometry', 'timeFrame': '12 weeks'}, {'measure': 'Changes of Insulin levels from baseline to 12 weeks', 'description': 'Before and after intervention by ELISA', 'timeFrame': '12 weeks'}, {'measure': 'Change of HOMA-IR from base line to 12 weeks', 'description': 'Before and after intervention by using the formula for the homeostasis model assessment index (FI x (fasting glucose (mmol/l)/22.5)', 'timeFrame': '12 weeks'}, {'measure': 'Change of waist circumference', 'description': 'Measured with a non elastic tape at baseline and after intervention', 'timeFrame': '12 weeks'}, {'measure': 'Change of body mass index', 'description': 'before and after intervention using a tetrapolar bioelectrical impedance analyzer (body composition analyzer', 'timeFrame': '12 weeks'}, {'measure': 'Change from baseline in Peripheral systolic blood pressure', 'description': 'Before and after intervention using a digital sphygmomanometer', 'timeFrame': '12 weeks'}, {'measure': 'Change from baseline in Peripheral diastolic blood pressure', 'description': 'Before and after intervention using a digital sphygmomanometer', 'timeFrame': '12 weeks'}]",11,40 Years,80 Years,MALE,False,"Centro Universitario de Ciencias de la Salud, Mexico",OTHER,0,40.0,ACTUAL,2025-09-01T16:18:23.461462,v2_robust,True,True,True,False,False,
NCT01470027,N-Acetylcysteine for Neuroprotection in Parkinson's Disease,N-Acetylcysteine for Neuroprotection in Parkinson's Disease,N-acetylcysteine,"['NAC', 'N-acetylcysteine', 'Placebo']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Parkinson Disease,['Parkinson Disease'],"['magnetic resonance spectroscopy', 'N-acetylcysteine', 'antioxidant', 'glutathione']",COMPLETED,,2012-01,2016-08,"[{'measure': 'Change of Cerebral Glutathione Levels as Measured by Proton Magnetic Resonance Spectroscopy', 'description': 'In vivo brain GSH measured with 1H MRS in the unmedicated patients with idiopathic PD and in sex- and age-matched healthy controls prior to and following 4 weeks supplementation with either placebo, 1800mg/day or 3600 mg/day of NAC. Striatal and occipital cortex glutathione levels as measured in vivo by 1H MRS at baseline and following 4 weeks of treatment with placebo, 1800mg NAC/day and 3600mg NAC/day.\n\nThe area under the GSH spectral peak was obtained by frequency-domain fitting of the GSH resonance in the edited spectrum to a pseudo-Voigt lineshape function using a robust and highly optimized public-domain Levenberg-Marquardt nonlinear least-squares minimization routine. The resulting peak areas were then expressed as ratios relative to the synchronously acquired and similarly fitted unsuppressed voxel water signal.', 'timeFrame': 'at baseline and 4 weeks after intervention start'}]","[{'measure': ""Unified Parkinson's Disease Rating Scale (UPDRS) Parts I-V (Total Score Reported)"", 'description': ""The UPDRS is considered the gold standard for determining disease severity and progression in patients with Parkinson's disease. It consists of the following five elements:\n\n1. Evaluation of mentation, behavior and mood.\n2. Self evaluation of the activities of daily living (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, etc.\n3. Motor evaluation by a clinician.\n4. Hoehn and Yahr scale (Hoehn 1967) for the description of the overall disease severity in PD with 8 stages.\n5. Schwab and England activities of daily living scale (Schwab and England 1969) for the estimation of the general abilities in PD patients. The Schwab and England ADL scale is graduated in 10% steps with 100% indicating complete independence and 0% indicating an individual in whom the vegetative functions are completely impaired.\n\nA total of 199 points are possible for UPDRS, with 199 representing the worst disability and 0 no disability."", 'timeFrame': 'at baseline and 4 weeks after intervention start'}, {'measure': 'Mini Mental State Examination (MMSE)', 'description': 'The MMSE is a brief questionnaire-based test that is used to screen for cognitive impairment. Domains tested are orientation to time and place, registration, attention and calculation, recall, language, repetition and complex commands. Scores lower than 25/30 points indicate mild (21-24 points), moderate (10-20 points) or severe (\\<10 points) cognitive impairment, but scores may need to be corrected for educational attainment, age and interfering impairments such as motor deficits that affect drawing skills.', 'timeFrame': 'at baseline and 4 weeks after intervention start'}, {'measure': 'Hamilton Depression Rating Scale (HAM-D)', 'description': ""The Hamilton Depression Rating Scale (HAM-D) is a 21-item instrument designed to measure the severity of illness in adults already diagnosed as having depression. The Hamilton Depression Rating Scale (HAM-D) has proven useful for many years as a way of determining a patient's level of depression before, during, and after treatment. It is clinician-administered and requires 15 to 20 minutes complete the interview and score the results. Although the HAM-D form lists 21 items, the scoring is based on the first 17. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2.\n\nThe minimum score is 0 and maximum score is 50. The scale has been widely used in clinical practice and become a standard in pharmaceutical trials.\n\nHAM-D Scoring Instructions are following:\n\n0-7 = Normal; 8-13 = Mild Depression; 14-18 = Moderate Depression; 19-22 = Severe Depression;\n\n≥ 23 = Very Severe Depression."", 'timeFrame': 'at baseline and 4 weeks after intervention start'}, {'measure': '9-Hole Peg Board Test (9-HPT)', 'description': 'The 9-HPT is a standardized, quantitative timed test of upper extremity motor function. Individuals are asked to place and remove nine pegs, one at a time, from nine holes in a board as quickly as possible. The task is performed twice with the dominant and twice with the non-dominant hand, and the average time to complete the task once is calculated for each hand. The 9-HPT has a high inter- and intra-rater reliability, is validated and is sensitive to detect minor impairments of hand function.', 'timeFrame': 'at baseline and 4 weeks after intervention start'}, {'measure': '10-Meter Walk Test', 'description': 'The 10-meter walk test is a standardized, quantitative timed test of lower body motor function. The maximal gait speed is measured during a 10-meter walk. The task will be performed three times and the average time to complete the task once will be recorded. The 10-meter walk test is a reliable and sensitive measure of gait function in elderly individuals and PD patients.\n\nCut-off values:\n\n\\< 0.4 m/s more likely to be household ambulators; 0.4 - 0.8 m/s limited community ambulators; \\> 0.8 m/s community ambulators.', 'timeFrame': 'at baseline and 4 weeks after intervention start'}, {'measure': 'Beck Anxiety Inventory', 'description': 'The Beck Anxiety Inventory (BAI) is a clinician-administered and validated instrument to discriminate anxiety from depression. The standardized BAI cutoffs are:\n\n0-9: minimal anxiety; 10-16: mild anxiety; 17-29: moderate anxiety; 30-63: severe anxiety.', 'timeFrame': 'at baseline and 4 weeks after intervention start'}, {'measure': ""Parkinson's Disease Quality of Life Questionnaire (PDQLQ)"", 'description': ""The Parkinson's Disease Quality of Life Questionnaire is a self completion PRO designed to address aspects of functioning and well-being for those affected by Parkinson's disease.\n\nThe Parkinson's Disease Quality of Life Questionnaire is coded on a scale of 0 to 185, with 185 indicating perfect health and 0 indicating very poor health."", 'timeFrame': 'at baseline and 4 weeks after intervention start'}]",8,50 Years,75 Years,ALL,True,Weill Medical College of Cornell University,OTHER,1,50.0,ACTUAL,2025-09-01T16:18:23.461487,v2_robust,True,True,True,False,False,
NCT06835361,Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis,"International Open-label Randomized Comparative Clinical Study of Efficacy and Safety of Clotrimazole+Lactulose, Vaginal Suppositories (AVVA RUS JSC, Russia) Vs. a Clotrimazole Monocomponent Product in Adult Female Patients with Candidal Vaginitis/vulvovaginitis",Clotrimazole+Lactulose.,"['Clotrimazole+Lactulose.', 'Lactulose', 'Canesten (Clotrimazole)']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Candidal Vulvovaginitis (ICD-10 Code: B37.3),"['Candidal Vulvovaginitis (ICD-10 Code: B37.3)', 'Vulvovaginal Candidiasis (VVC)']","['Clotrimazole+Lactulose', 'Candidal Vulvovaginitis', 'Vulvovaginal Candidiasis', 'Clotrimazole', 'Lactulose', 'Antifungal Therapy', 'Prebiotic', 'Vaginal Suppositories', 'Canesten', 'Microbiological Recovery', 'Women&#39;s Health', 'Vaginal Microbiota']",RECRUITING,,2024-02-29,2025-11-30,"[{'measure': 'Proportion (%) of patients with clinical and microbiological response (recovery)', 'timeFrame': 'Day 25 (Visit 4)'}]","[{'measure': 'Proportion (%) of patients with clinical response (recovery)', 'timeFrame': 'by Visits 2 (Day 8) and 3 (Day 15)'}, {'measure': 'Proportion (%) of patients with microbiological recovery', 'timeFrame': 'by Visits 2 (Day 8) and 3 (Day 15)'}, {'measure': 'Assessment of the severity of subjective and objective signs and symptoms on a 4-point scale', 'timeFrame': 'by Visits 2 (Day 8), 3 (Day 15), and 4 (Day 25)'}, {'measure': 'Patient evaluation of therapy efficacy using a 5-point scale', 'timeFrame': 'at Visits 2 (Day 8), 3 (Day 15), and 4 (Day 25)'}, {'measure': 'Change in Lactobacillus content as determined by molecular biological examination of vaginal secretions (real-time PCR) compared to baseline', 'timeFrame': 'by Visits 3 (Day 15) and 4 (Day 25)'}]",6,18 Years,60 Years,FEMALE,False,AVVA Pharmaceuticals Ltd.,INDUSTRY,0,264.0,ESTIMATED,2025-09-01T16:18:23.461612,v2_robust,True,True,False,False,False,
NCT01597661,Bupropion & Cardio Birth Defect (Slone),Bupropion and Cardiac Birth Defects (Slone Epidemiology Center),Exposure to any bupropion during the first trimester,"['Exposure to any bupropion during the first trimester', 'Exposure to bupropion alone during the first trimester']",2,OBSERVATIONAL,[],,,Depressive Disorder,['Depressive Disorder'],"['first trimester', 'left outflow tract obstruction', 'Bupropion', 'cardiovascular malformation', 'antidepressants', 'pregnancy', 'cardiovascular defect', 'congenital malformation']",COMPLETED,,2011-09,2012-08,"[{'measure': 'Diagnosis of left outflow tract defects', 'timeFrame': 'Within 6 months of delivery'}, {'measure': 'Diagnosis of coarctation of the aorta', 'timeFrame': 'Within 6 months of delivery'}, {'measure': 'Diagnosis of hypoplastic left heart syndrome', 'timeFrame': 'Within 6 months of delivery'}]","[{'measure': 'Diagnosis of other congenital heart defects', 'timeFrame': 'Within 6 months of delivery'}]",4,,,ALL,False,GlaxoSmithKline,INDUSTRY,0,1.0,ACTUAL,2025-09-01T16:18:23.461628,v2_robust,False,True,True,False,False,
NCT05144061,A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) of HRS2398 in Subjects With Advanced Malignant Tumors",HRS2398 Tablets,['HRS2398 Tablets'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Malignant Tumor,['Advanced Malignant Tumor'],[],COMPLETED,,2021-12-20,2024-02-21,"[{'measure': 'Dose-limiting toxicity（DLT）', 'timeFrame': 'up to 21 days'}, {'measure': 'Maximum tolerated dose（MTD）', 'timeFrame': 'up to 6 months'}, {'measure': 'Recommended Phase II Dose (RP2D)', 'timeFrame': 'up to 21 days'}]","[{'measure': 'Number of subjects with adverse events and the severity of adverse events', 'timeFrame': 'from the first drug administration to within 30 days for the last treatment dose'}, {'measure': 'Cmax of HRS2398 of Single administration', 'timeFrame': 'Single administration : 30min before administration of Day1, 5min, 0.25 hour, 0.5 hour, 0.75 hour, 1 hour , 2hours, 4hours, 6hours, 8hours, 10hours, 24hours, 48hours, 72hours after administration of Day1'}, {'measure': 'Tmax of HRS2398 of Single administration', 'timeFrame': 'Single administration : 30min before administration of Day1, 5min, 0.25 hour, 0.5 hour, 0.75 hour, 1 hour , 2hours, 4hours, 6hours, 8hours, 10hours, 24hours, 48hours, 72hours after administration of Day1'}, {'measure': 'AUC0-t of HRS2398 of Single administration', 'timeFrame': 'ingle administration : 30min before administration of Day1, 5min, 0.25 hour, 0.5 hour, 0.75 hour, 1 hour , 2hours, 4hours, 6hours, 8hours, 10hours, 24hours, 48hours, 72hours after administration of Day1'}, {'measure': 'AUC0-12 of HRS2398 of Single administration', 'timeFrame': 'Single administration : 30min before administration of Day1, 5min, 0.25 hour, 0.5 hour, 0.75 hour, 1 hour , 2hours, 4hours, 6hours, 8hours, 10hours after administration of Day1'}, {'measure': 'T1/2 of HRS2398 of Single administration', 'timeFrame': 'Single administration : 30min before administration of Day1, 5min, 0.25 hour, 0.5 hour, 0.75 hour, 1 hour , 2hours, 4hours, 6hours, 8hours, 10hours, 24hours, 48hours, 72hours after administration of Day1'}, {'measure': 'Cmax of HRS2398 of Multiple doses', 'timeFrame': 'Multiple administration: Day8, Day15, Day17 of Cycle1, Day1 of Cycle2-4 (each cycle is 21 days)'}, {'measure': 'Tmax of HRS2398 of Multiple administration', 'timeFrame': 'Multiple administration: Day8, Day15, Day17 of Cycle1, Day1 of Cycle2-4 (each cycle is 21 days)'}, {'measure': 'AUC0-t of HRS2398 of Multiple administration', 'timeFrame': 'Multiple administration: Day8, Day15, Day17 of Cycle1, Day1 of Cycle2-4 (each cycle is 21 days)'}, {'measure': 'AUC0-12 of HRS2398 of Multiple administration', 'timeFrame': 'Multiple administration: Day8, Day15, Day17 of Cycle1, Day1 of Cycle2-4 (each cycle is 21 days)'}, {'measure': 'T1/2 of HRS2398 of Multiple administration', 'timeFrame': 'Multiple administration: Day8, Day15, Day17 of Cycle1, Day1 of Cycle2-4 (each cycle is 21 days)'}, {'measure': 'Bioavailability of fasting state', 'description': 'PK blood samples from subjects were collected for bioavailability ，Postprandial AUC divided by fasting AUC', 'timeFrame': 'up to 4 months'}, {'measure': 'Objective Response Rate(ORR)', 'description': 'Radiological scans performed at baseline then every 6 weeks until objective radiological disease progression', 'timeFrame': 'up to 4 months'}, {'measure': 'Disease Control Rate(DCR)', 'description': 'Complete response + Partial response + Stable disease (CR+PR+SD) based on RECIST 1.1', 'timeFrame': 'up to 4 months'}, {'measure': 'Duration of response (DoR)', 'description': 'Time from documentation of tumor response to disease progression assessed among patients who had an objective response', 'timeFrame': 'up to 4 months'}, {'measure': 'Progression free survival(PFS)', 'description': ""Defined as Progression free survival per RECIST 1.1 criteria according to Investigator's assessment"", 'timeFrame': 'up to 4 months'}]",19,18 Years,70 Years,ALL,False,"Shanghai Hengrui Pharmaceutical Co., Ltd.",INDUSTRY,0,28.0,ACTUAL,2025-09-01T16:18:23.461638,v2_robust,True,True,True,False,True,
NCT03621761,"Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue","A Randomized Controlled Trial of Telephone-delivered Cognitive Behavioral-therapy, Modafinil, and Combination Therapy of Both Interventions for Fatigue in Multiple Sclerosis",Modafinil,"['Provigil', 'Modafinil']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Multiple Sclerosis,['Multiple Sclerosis'],"['cognitive behavioral therapy', 'modafinil', 'Provigil', 'fatigue', 'MS']",COMPLETED,,2018-11-15,2021-11-30,"[{'measure': 'Change in the Modified Fatigue Impact Scale (MFIS) Score', 'description': ""The Modified Fatigue Impact Scale is a 21-item self-report survey. Each item is rated 0-4, Total scores range from 0-84. . Higher scores indicate a greater impact of fatigue on a person's activities. The primary outcome measure will be the mean within-subject difference between baseline and 12-week Modified Fatigue Impact Scale values (delta-MFIS), compared between the 3 treatment groups."", 'timeFrame': 'Baseline-12 weeks'}]","[{'measure': 'Change in Fatigue Intensity as Assessed by Self-reported Numerical Rating Scale (NRS) Score.', 'description': 'Fatigue intensity was assessed using a wearable monitor, the PRO-Diary (CamNtech) - a wrist-worn accelerometer-based activity monitor which also contains a self-report user interface. Using a 0-10 numerical rating scale, participants entered fatigue intensity ratings into the user-interface on the PRO-Diary 4 times each day, for 7 days, at baseline (pre-intervention) and at 12 weeks post-intervention. All scores over the 7 days were averaged to produce an aggregate fatigue intensity score. Higher scores indicate greater fatigue intensity. Change in fatigue intensity between baseline and 12 weeks was compared between the 3 treatment groups.', 'timeFrame': 'Baseline-12 weeks'}, {'measure': 'Change in Fatigue Interference as Assessed by Self-reported Numerical Rating Scale (NRS) Score', 'description': 'Fatigue interference will be assessed using a wearable monitor, the PRO-Diary (CamNtech) - a wrist-worn accelerometer-based activity monitor which also contains a self-report user interface. Using a 0-10 numerical rating scale, participants entered fatigue interference ratings into the user-interface on the PRO-Diary 4 times each day, for 7 days, at baseline (pre-intervention) and at 12 weeks post-intervention. All scores over the 7 days were averaged to produce an aggregate fatigue impact score. Higher scores indicate greater fatigue impact. Change in fatigue interference between baseline and 12 weeks will be compared between the 3 treatment groups.', 'timeFrame': 'Baseline-12 weeks'}, {'measure': 'Change in Fatigability as Assessed by the Self-reported Fatigue Intensity Numerical Rating Scale (NRS) Score and Physical Activity Level', 'description': ""Fatigability will be assessed using a wearable monitor, the PRO-Diary (CamNtech) - a wrist-worn accelerometer-based activity monitor which also contains a self-report user interface. The fatigability score will be calculated as the ratio of the self-reported fatigue intensity rating (using a 0-10 numerical rating score) divided by the participant's concurrent physical activity level (measured as the average number of activity counts per minute via actigraphy). All fatigability scores will be averaged over the 7 days to create an aggregate fatigability score. Higher scores indicate greater fatigability. Change in fatigability between baseline and 12 weeks will be compared between the 3 treatment groups."", 'timeFrame': 'Baseline-12 weeks'}]",4,18 Years,,ALL,False,University of Michigan,OTHER,3,343.0,ACTUAL,2025-09-01T16:18:23.461757,v2_robust,True,True,True,False,False,
NCT02232061,"Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks","Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod",Fingolimod,"['Fingolimod', 'FTY720']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Multiple Sclerosis,['Multiple Sclerosis'],"['multiple sclerosis, fingolimod, adult, FTY720, inflammatory disease, demyelination, auto-inflammatory disease, relapsing-remitting MS, CFTY720D2406']",COMPLETED,,2014-09-29,2020-01-24,"[{'measure': 'Participants Who Experienced at Least One Qualifying Cardiovascular Adverse Event', 'description': 'Participants from study CFTY720D2406 who experienced a qualifying cardiovascular adverse event were transferred to this study. Qualifying cardiovascular events included, but were not limited to, sudden unexplained death, cardiovascular death, myocardial infarction (MI), Q-wave MI, stroke (ischemic or hemorrhagic), unstable angina requiring hospitalization, congestive heart failure requiring hospitalization, complete heart block, ventricular fibrillation, torsade de pointes, hypertensive emergency and any other suspected life threatening cardiovascular condition.', 'timeFrame': 'Within 6 months of qualifying event up to 64 months'}]",[],1,18 Years,60 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:23.461789,v2_robust,True,True,True,False,True,
NCT06425861,A First in Human Trial Evaluating THB335 in Healthy Participants,"A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Food Effect of THB335 in Healthy Participants",THB335 single dose,"['THB335 multiple dose', 'Single dose placebo', 'THB335 fasted/fed', 'THB335 single dose', 'Placebo fasted/fed', 'Multiple dose placebo']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],RECRUITING,,2024-05-02,2025-03-15,"[{'measure': 'Number of Participants with Treatment-Related Adverse Events', 'timeFrame': 'Part 1 Day 1 through Day 9 (end of study), and Part 2 Day 1 through Day 29 (end of study)'}]","[{'measure': 'Maximum observed plasma concentration (Cmax)', 'timeFrame': 'Part 1, and Part 2 on Day 1. Part 2 on Day 14'}, {'measure': 'Time to Cmax (Tmax)', 'timeFrame': 'Part 1, and Part 2 on Day 1. Part 2 on Day 14'}, {'measure': 'Area under the plasma concentration-time curve (AUC)', 'timeFrame': 'Part 1, and Part 2 on Day 1. Part 2 on Day 14'}]",4,18 Years,65 Years,ALL,True,"Third Harmonic Bio, Inc.",INDUSTRY,0,56.0,ESTIMATED,2025-09-01T16:18:23.461928,v2_robust,True,True,False,False,True,
NCT05076461,Ondansetron Versus Domperidone for Treating Vomiting in Acute Gastroenteritis in Children,Comparison of Ondansetron Versus Domperidone for Treating Vomiting in Acute Gastroenteritis in Children At a Resource Limited Setting,Ondansetron,['Ondansetron'],1,INTERVENTIONAL,['NA'],,,Vomiting in Infants and/or Children,"['Vomiting in Infants and/or Children', 'Acute Gastroenteritis']",[],COMPLETED,,2020-07-01,2021-06-30,"[{'measure': 'Cessation of vomiting', 'description': 'Children in ondansetron group received oral suspension of ondansetron as 0.15mg per body weight while in domperidone group, oral suspension of domperidone was given as 0.5 mg per kg body weight. Children in both study groups were administered designated drugs in the emergency department. Children were observed in the emergency department for 6-hours and discharged if they were vomiting free. All children were asked to follow up after 24 hours for the assessment of the effectiveness of the treatment for cessation of vomiting.', 'timeFrame': '24 hours'}]",[],1,1 Day,12 Years,ALL,True,Tehsil Headquarter Hospital,OTHER_GOV,0,300.0,ACTUAL,2025-09-01T16:18:23.462046,v2_robust,True,True,True,False,False,
NCT01498861,Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol,A Double-Blind Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol When Co-administered With Dolutegravir in Healthy Adult Female Subjects,Ortho-Cyclen,"['Dolutegravir', 'Ortho-Cyclen', 'GSK1349572', 'Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,"Infection, Human Immunodeficiency Virus","['Infection, Human Immunodeficiency Virus']",[],COMPLETED,,2011-12,2012-03,"[{'measure': 'AUC(0-tau) of norelgestromin and ethinylestradiol after Ortho-Cyclen alone and after Ortho-Cyclen with dolutegravir', 'description': 'Samples will be collected at predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 10 and 21', 'timeFrame': 'Up to 24 hours post-dose'}]","[{'measure': 'Safety and tolerability of all treatments as assessed by vital signs, AEs, and clinical laboratory tests', 'timeFrame': 'Up to 8 weeks'}, {'measure': 'Composite of norelgestromin pharmacokinetic parameters on Day 10 and Day 21: Cmax, Cmin, tmax, tmin and half life', 'description': 'Samples will be collected at predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 10 and 21', 'timeFrame': 'Up to 24 hours post dose'}, {'measure': 'Predose serum levels of luteinizing hormone and follicle stimulating hormone from Periods 1 and 2', 'description': 'Samples will be collected at predose on Days 1, 10, 11, 21 and 22', 'timeFrame': 'predose on Days 1, 10, 11, 21 and 22'}, {'measure': 'Predose serum levels of progesterone from Periods 1 and 2', 'description': 'Samples will be collected at predose on Days 1, 10, 11, 21 and 22', 'timeFrame': 'predose on Days 1, 10, 11, 21 and 22'}, {'measure': 'Composite of dolutegravir pharmacokinetic parameters on Day 10 and Day 21: AUC(0-t), Cmax, tmax, Cmin, C0, Ct and CL/F', 'description': 'Samples will be collected at predose and at 1, 2, 3, 4, 6, 8, and 12 hours post dose on Day 10 and Day 21', 'timeFrame': 'Up to 12 hours post dose'}]",6,18 Years,40 Years,FEMALE,True,ViiV Healthcare,INDUSTRY,2,16.0,ACTUAL,2025-09-01T16:18:23.462174,v2_robust,True,True,True,False,True,
NCT01596842,Effect of Omega-3 Fatty Acid on Vitamin D Activation,Effect of Omega-3 Fatty Acid on Vitamin D Activation in Hemodialysis Patients,Omega-3 fatty acid ethylester 90,"['Omacor®', 'Omega-3 fatty acid ethylester 90']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Hemodialysis Patients,"['Hemodialysis Patients', 'Vitamin D Insufficiency', 'Vitamin D Deficiency']","['Omega-3 fatty acid', 'vitamin D', 'ergocalciferol', 'hemodialysis']",COMPLETED,,2012-05,2012-12,"[{'measure': '25-hydroxyvitamin D Levels at 12 Weeks', 'timeFrame': '12 weeks'}]","[{'measure': 'Hemoglobin Levels at 12 Weeks', 'timeFrame': '12 weeks'}, {'measure': 'Changes of Calcium Levels', 'timeFrame': '4 weeks, 8 weeks and 12 weeks'}, {'measure': 'Change of Intact Parathyroid Hormone', 'timeFrame': '12 weeks'}, {'measure': 'Change of Fetuin-A Levels', 'timeFrame': '12 weeks'}, {'measure': 'Change of FGF-23 Levels', 'timeFrame': '12 weeks'}, {'measure': 'Changes of Phosphorous Levels', 'timeFrame': '4 weeks, 8 weeks and 12 weeks'}, {'measure': 'Changes of Erythropoietin Doses', 'timeFrame': '4 weeks, 8 weeks and 12 weeks'}, {'measure': 'Changes of Phosphate Binder Doses', 'timeFrame': '4 weeks, 8 weeks and 12 weeks'}]",9,20 Years,80 Years,ALL,False,Dong-A University,OTHER,0,17.0,ACTUAL,2025-09-01T16:18:23.462299,v2_robust,True,True,True,False,False,
NCT04429542,Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors,"First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors",BCA101,"['Pembrolizumab', 'Ficerafusp alfa', 'BCA101']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Head and Neck Squamous Cell Carcinoma,"['Head and Neck Squamous Cell Carcinoma', 'Squamous Cell Carcinoma of Anal Canal', 'Colorectal Cancer', 'Squamous Cell Carcinoma of the Lung', 'EGFR Amplification', 'Epithelial Ovarian Cancer', 'Pancreas Cancer', 'Cutaneous Squamous Cell Carcinoma', 'Head and Neck Neoplasms', 'Carcinoma, Squamous Cell', 'Squamous Cell Carcinoma of Head and Neck']","['TGFβ', 'EGFR', 'pembrolizumab', 'ficerafusp alfa']",RECRUITING,,2020-06-01,2027-06-01,"[{'measure': 'Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs', 'description': 'Incidence and severity of AEs and SAEs', 'timeFrame': '24 months'}, {'measure': 'Tolerability of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs', 'description': 'Incidence and severity of AEs and SAEs', 'timeFrame': '24 months'}, {'measure': 'Incidence of Dose Limiting Toxicities (DLTs)', 'description': 'Incidence of DLTs during the first cycle of treatment with BCA101 monotherapy or the combination of BCA101 and pembrolizumab.', 'timeFrame': '21 days'}]","[{'measure': 'Objective Response Rate', 'description': 'Determine objective response rate in each part of the study, per RECIST v1.1 and iRECIST', 'timeFrame': '24 months'}, {'measure': 'Clinical Benefit Rate', 'description': 'Determine clinical benefit rate in each part of the study, per RECIST v1.1 and iRECIST', 'timeFrame': '24 months'}, {'measure': 'Progression free survival', 'description': 'Determine PFS in each part of the study, per RECIST v1.1 and iRECIST', 'timeFrame': '24 months'}, {'measure': 'Duration of Response', 'description': 'Determine duration of response in each part of the study, per RECIST v1.1 and iRECIST', 'timeFrame': '24 months'}, {'measure': 'Overall Survival', 'description': 'Determine survival rates in each part of the study.', 'timeFrame': '24 months'}, {'measure': 'AUC of BCA101 and pembrolizumab', 'description': 'AUC', 'timeFrame': '24 months'}, {'measure': 'Cmax of BCA101 and pembrolizumab', 'description': 'Cmax', 'timeFrame': '24 months'}, {'measure': 'Tmax of BCA101 and pembrolizumab', 'description': 'Tmax', 'timeFrame': '24 months'}, {'measure': 'Concentration vs time profile of BCA101 and pembrolizumab', 'description': 'Ctrough', 'timeFrame': '24 months'}, {'measure': 'Half-life of BCA101 and pembrolizumab', 'description': 'Half-life', 'timeFrame': '24 months'}, {'measure': 'Immunogenicity of BCA101 and pembrolizumab', 'description': 'Incidence and titer of anti-drug-antibodies', 'timeFrame': '24 months'}]",14,18 Years,,ALL,False,Bicara Therapeutics,INDUSTRY,1,292.0,ESTIMATED,2025-09-01T16:18:23.462314,v2_robust,True,True,False,False,True,
NCT03308942,Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants,"Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With a PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer",Niraparib,['Niraparib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Neoplasms,['Neoplasms'],"['Niraparib', 'NSCLC', 'Pembrolizumab', 'Dostarlimab', 'TSR-042']",COMPLETED,,2017-09-29,2021-08-31,"[{'measure': 'Stage 1: Cohort 1: Objective Response Rate (ORR)', 'description': 'ORR is the percentage of participants with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR) in the analysis population where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 millimeters (mm) in the short axis. PR=At least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. Tumor assessment was done by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Data has been presented for participants with NSCLC whose tumors have high PD-L1 expression (TPS\\>=50%). Confidence interval was calculated using binomial exact method.', 'timeFrame': 'Up to a maximum of 29 months'}, {'measure': 'Stage 1: Cohort 2: Objective Response Rate', 'description': 'ORR is the percentage of participants with a confirmed BOR of CR or PR in the analysis population where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. Tumor assessment was done by the Investigator per RECIST v1.1. Data has been presented for participants with NSCLC having PD-L1 expression in tumors (TPS: 1 to 49%). Confidence interval was calculated using binomial exact method.', 'timeFrame': 'Up to a maximum of 17 months'}, {'measure': 'Stage 1: Cohort 3: Objective Response Rate', 'description': 'ORR is the percentage of participants with a confirmed BOR of CR or PR in the analysis population where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. Tumor assessment was done by the Investigator per RECIST v1.1. Data is presented for participants with locally advanced and metastatic squamous NSCLC. Confidence interval was calculated using binomial exact method.', 'timeFrame': 'Up to a maximum of 6 months'}, {'measure': 'Stage 2: Cohort 1A and Cohort 2A: Objective Response Rate', 'description': 'ORR is the percentage of participants with a confirmed BOR of CR or PR in the analysis population where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. Tumor assessment was done by the Investigator per RECIST v1.1. Confidence interval was calculated using binomial exact method.', 'timeFrame': 'Up to a maximum of 17 months'}]","[{'measure': 'Stage 1: Cohort 1: Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)', 'description': 'An adverse event (AE) is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events', 'timeFrame': 'Up to a maximum of 45 months'}, {'measure': 'Stage 1: Cohort 2: Number of Participants With Non-SAEs and SAEs', 'description': 'An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events', 'timeFrame': 'Up to a maximum of 17 months'}, {'measure': 'Stage 1: Cohort 3: Number of Participants With Non-SAEs and SAEs', 'description': 'An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events', 'timeFrame': 'Up to a maximum of 6 months'}, {'measure': 'Stage 2: Cohorts 1A and 2A: Number of Participants With Non-SAEs and SAEs', 'description': 'An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events.', 'timeFrame': 'Up to a maximum of 29 months'}, {'measure': 'Stage 1: Cohort 1: Number of Participants Discontinuing the Study Due to AEs', 'description': 'An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Number of participants discontinuing the study due to AEs have been summarized.', 'timeFrame': 'Up to a maximum of 45 months'}, {'measure': 'Stage 1: Cohort 2: Number of Participants Discontinuing the Study Due to AEs', 'description': 'An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Number of participants discontinuing the study due to AEs have been summarized.', 'timeFrame': 'Up to a maximum of 17 months'}, {'measure': 'Stage 1: Cohort 3: Number of Participants Discontinuing the Study Due to AEs', 'description': 'An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Number of participants discontinuing the study due to AEs have been summarized.', 'timeFrame': 'Up to a maximum of 6 months'}, {'measure': 'Stage 2: Cohorts 1A and 2A: Number of Participants Discontinuing the Study Due to AEs', 'description': 'An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Number of participants discontinuing the study due to AEs have been summarized.', 'timeFrame': 'Up to maximum 29 months'}, {'measure': 'Stage 1: Cohort 1: Duration of Response', 'description': 'Duration of Response was defined as the time from first documented CR or PR until the subsequently documented disease progression by RECIST v1.1 or death, whichever occurs earlier; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 millimeter (mm) in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.', 'timeFrame': 'Up to a maximum of 45 months'}, {'measure': 'Stage 1: Cohort 2: Duration of Response', 'description': 'Duration of Response was defined as the time from first documented CR or PR until the subsequently documented disease progression by RECIST v1.1 or death, whichever occurs earlier; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.', 'timeFrame': 'Up to a maximum of 17 months'}, {'measure': 'Stage 1 : Cohort 3: Duration of Response', 'description': 'Duration of Response was defined as the time from first documented CR or PR until the subsequently documented disease progression by RECIST v1.1 or death, whichever occurs earlier; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.', 'timeFrame': 'Up to a maximum of 6 months'}, {'measure': 'Stage 2: Cohorts 1A and 2A: Duration of Response', 'description': 'Duration of Response was defined as the time from first documented CR or PR until the subsequently documented disease progression by RECIST v1.1 or death, whichever occurs earlier; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.', 'timeFrame': 'Up to a maximum of 29 months'}, {'measure': 'Stage 1 : Cohort 1: Disease Control Rate', 'description': 'Disease Control Rate was defined as the percentage of participants with a best overall response of CR, PR or SD per RECIST v1.1; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. Confidence interval was calculated using binomial exact method.', 'timeFrame': 'Up to a maximum of 45 months'}, {'measure': 'Stage 1 : Cohort 2: Disease Control Rate', 'description': 'Disease Control Rate was defined as the percentage of participants with a best overall response of CR, PR or SD per RECIST v1.1; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. Confidence interval was calculated using binomial exact method.', 'timeFrame': 'Up to a maximum of 17 months'}, {'measure': 'Stage 1 : Cohort 3: Disease Control Rate', 'description': 'Disease Control Rate was defined as the percentage of participants with a best overall response of CR, PR or SD per RECIST v1.1; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. Confidence interval was calculated using binomial exact method.', 'timeFrame': 'Up to a maximum of 6 months'}, {'measure': 'Stage 2: Cohorts 1A and 2A: Disease Control Rate', 'description': 'Disease Control Rate was defined as the percentage of participants with a best overall response of CR, PR or SD per RECIST v1.1; where CR=Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. Confidence interval was calculated using binomial exact method.', 'timeFrame': 'Up to a maximum of 29 months'}, {'measure': 'Stage 1 : Cohort 1: Progression-free Survival', 'description': 'Progression-free survival was defined as the time from the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. Progression was defined using RECIST v1.1 as a 20% increase in the sum of the diameter of target lesions or unequivocal progression of existing non-target lesions or the appearance of one or more new lesions.', 'timeFrame': 'Up to a maximum of 45 months'}, {'measure': 'Stage 1 : Cohort 2: Progression-free Survival', 'description': 'Progression-free survival was defined as the time from the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. Progression was defined using RECIST v1.1 as a 20% increase in the sum of the diameter of target lesions or unequivocal progression of existing non-target lesions or the appearance of one or more new lesions.', 'timeFrame': 'Up to a maximum of 17 months'}, {'measure': 'Stage 1 : Cohort 3: Progression-free Survival', 'description': 'Progression-free survival was defined as the time from the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. Progression was defined using RECIST v1.1 as a 20% increase in the sum of the diameter of target lesions or unequivocal progression of existing non-target lesions or the appearance of one or more new lesions.', 'timeFrame': 'Up to a maximum of 6 months'}, {'measure': 'Stage 2: Cohorts 1A and 2A: Progression-free Survival', 'description': 'Progression-free survival was defined as the time from the date of first dose to the date of disease progression or death due to any cause, whichever occurs earlier. Progression was defined using RECIST v1.1 as a 20% increase in the sum of the diameter of target lesions or unequivocal progression of existing non-target lesions or the appearance of one or more new lesions.', 'timeFrame': 'Up to a maximum of 29 months'}, {'measure': 'Stage 1: Cohort 1: Plasma Concentration of Niraparib Following Combination Therapy of Niraparib and Pembrolizumab', 'description': 'Blood samples were collected at indicated time points.', 'timeFrame': 'Cycle 1 Day 1(Pre-dose and 30 Minutes, 1 Hour, 2 Hours, 4 Hours, 8 Hours, 96 Hours, 168 Hours Post-dose); Cycles 2, 4, 8 (Pre-dose and 4 Hours Post-dose) (each cycle of 21 days)'}, {'measure': 'Stage 1: Cohort 2: Plasma Concentration of Niraparib Following Combination Therapy of Niraparib and Pembrolizumab', 'description': 'Blood samples were collected at indicated time points.', 'timeFrame': 'Cycle 1 Day 1 (Pre-dose and 30 Minutes, 1, 2, 4, 8, 24, 168, 336 Hours Post-dose), Cycles 2, 8 (Pre-dose and 4 Hours Post-dose), Cycle 4 (Pre-dose and 30 Minutes, 1, 2, 4, 8, 24, 96, 168, 336 Hours Post-dose) (each cycle of 21 days)'}, {'measure': 'Stage 1: Cohort 3: Plasma Concentration of Niraparib Following Niraparib Monotherapy', 'description': 'Blood samples were collected at indicated time points.', 'timeFrame': 'Cycle 1 Day 1 (Pre-dose and 4 Hours Post-dose), Cycles 2, 4 and 8 (Pre-dose and 4 Hours Post-dose) (each cycle of 21 days)'}, {'measure': 'Stage 2: Cohorts 1A and 2A: Plasma Concentration of Niraparib Following Combination Therapy of Niraparib and TSR-042 (Dostarlimab)', 'description': 'Blood samples were collected at indicated time points.', 'timeFrame': 'Cycle 1 Day 1 (Pre-dose and 4 Hours Post-dose), Cycles 2, 4 and 9 (Pre-dose and 4 Hours Post-dose) (each cycle of 21 days)'}]",28,18 Years,,ALL,False,"Tesaro, Inc.",INDUSTRY,0,53.0,ACTUAL,2025-09-01T16:18:23.462368,v2_robust,True,True,True,False,True,
NCT01971242,Trial of Exenatide for Parkinson's Disease,"A Randomised, Double Blind, Placebo Controlled, Single Centre, 60 Week Trial of Exenatide Once Weekly for the Treatment of Moderate Severity Parkinson's Disease",Exenatide,"['Exenatide', 'Bydureon']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Parkinson's Disease,"[""Parkinson's Disease""]","[""Parkinson's"", ""Parkinson's Disease"", 'Exenatide', 'Bydureon']",COMPLETED,,2014-06,2016-08,"[{'measure': 'Efficacy', 'description': 'The primary objective is to compare the effectiveness of Exenatide versus placebo on the MDS UPDRS part 3 motor subscale in the ""practically defined OFF medication state"" in patients with moderate severity PD.', 'timeFrame': '60 weeks'}]","[{'measure': 'Safety and tolerability', 'description': ""• Compare differences at 48 and 60 weeks between the Exenatide and placebo trial arms in:\n\n* Movement Disorder Society Unified Parkinson's Disease Rating Scale part 1,2,3 and 4 On medication scores\n* Movement Disorder Society Unified Parkinson's Disease Rating Scale part 3 Motor subsection Off medication score at 48 weeks.\n* Mattis Dementia Rating scale (DRS-2).\n* Safety and tolerability of Exenatide as indicated by changes in Vital signs, weight, clinical laboratory measures and Adverse Effects"", 'timeFrame': '60 weeks'}]",2,25 Years,75 Years,ALL,False,"University College, London",OTHER,0,60.0,ACTUAL,2025-09-01T16:18:23.462404,v2_robust,True,True,True,False,True,
NCT03988842,Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism,Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism,Alteplase,"['Alteplase', 'Apixaban', 'Heparin sodium', 'Placebo', 'Activase', 'tissue-type plasminogen activator', 'Placebo (for Alteplase)', 'Eliquis', 'Unfractionated heparin']",9,INTERVENTIONAL,['PHASE4'],PHASE4,,Pulmonary Embolism With Acute Cor Pulmonale,"['Pulmonary Embolism With Acute Cor Pulmonale', 'Pulmonary Embolism', 'Pulmonary Embolism With Pulmonary Infarction', 'Pulmonary Embolism Subacute Massive', 'Right Ventricular Dysfunction', 'Right Ventricular Failure']",[],TERMINATED,COVID-19 pandemic,2019-07-25,2020-04-05,"[{'measure': 'Change in Extent of Clot Lysis in the Experimental Arm', 'description': 'Change in percentage of clot lysis in the experimental arm only as measured using the Refined Modified Miller Score (RMMS) from the baseline CTA to the 24 hour CTA after 24mg of systemic (IV) tPA + standard anticoagulation therapy (experimental arm).', 'timeFrame': 'Baseline, 24 hours'}]","[{'measure': 'Change in Extent of Clot Lysis Between the Experimental Arm and the Active Comparator Arm', 'description': 'Change in percentage of clot lysis between the experimental arm and the active comparator arm as measured using the Refined Modified Miller Score (RMMS) from the baseline CTA to the 24 hour CTA after 24mg of systemic (IV) tPA + standard anticoagulation therapy (experimental arm) compared to 24mg of systemic (IV) placebo + standard anticoagulation therapy (active comparator arm).', 'timeFrame': 'Baseline, 24 hours'}, {'measure': 'Change in Right Ventricular to Left Ventricular Diameter (RV/LV) Ratio', 'description': 'RV/LV ratio as measured by chest CTA from baseline to 24 ± 6 hours after the infusion of very low dose systemic (IV) tPA in patients with acute intermediate-high risk PE compared with placebo.', 'timeFrame': 'Baseline, 24 hours'}, {'measure': 'Change in RV/LV Ratio From Baseline Echocardiogram', 'description': 'Change from baseline in echocardiographic parameters as measured by the RV/LV ratio within 24 hours ± 6 hours and at 30 ± 5 days after the end of the systemic (IV) tPA infusion compared with placebo.', 'timeFrame': 'Baseline, 24 hours and 30 days'}, {'measure': 'Change in Tricuspid Annular Plane Systolic Excursion (TAPSE) From Baseline Echocardiogram', 'description': 'Change from baseline in echocardiographic parameters as measured by the tricuspid annular plane systolic excursion (TAPSE) within 24 hours ± 6 hours and at 30 ± 5 days after the end of the systemic (IV) tPA infusion compared with placebo.', 'timeFrame': 'Baseline, 24 hours and 30 days'}, {'measure': 'Change in Right Ventricular Systolic Pressure (RVSP) From Baseline Echocardiogram', 'description': 'Change from baseline in echocardiographic parameters as measured by the estimated right ventricular systolic pressure (RVSP) within 24 hours ± 6 hours and at 30 ± 5 days after the end of the systemic (IV) tPA infusion compared with placebo.', 'timeFrame': 'Baseline, 24 hours and 30 days'}, {'measure': 'Change in the Collapse of the Inferior Vena Cava (IVC) From Baseline Echocardiogram', 'description': 'Change from baseline in echocardiographic parameters as measured by the collapse of the inferior vena cava (IVC) with respiration within 24 hours ± 6 hours and at 30 ± 5 days after the end of the systemic (IV) tPA infusion compared with placebo.', 'timeFrame': 'Baseline, 24 hours and 30 days'}, {'measure': 'Change in the Requirement for Oxygen Therapy After 6 Minute Walk Test (6MWT)', 'description': '6MWT distance as measured by the requirement for oxygen therapy at 30 day, 60 day and one year ± 14 days clinic follow-up compared with placebo.', 'timeFrame': '30 days, 60 days, and 1 year'}, {'measure': 'Change in Borg Dyspnea Scale Score After 6 Minute Walk Test (6MWT)', 'description': '6MWT distance as measured by the Borg Dyspnea Scale score (Borg score) at 30 day, 60 day and one year ± 14 days clinic follow-up compared with placebo. The Borg Scale measures self-reported intensity and severity of breathlessness (dyspnea) and fatigue before, during, and after a 6MWT. Each item is scored 0 - 10 (0 = no breathlessness at all; 10 = most severe breathlessness that you have ever experienced), yielding a total between 0 and 20.', 'timeFrame': '30 days, 60 days, and 1 year'}, {'measure': 'Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Questionnaire', 'description': 'Quality of life (QOL) as measured by the PROMIS PF-6at 30 days, 6 months and one year ± 14 days clinic follow-up compared with placebo. The PROMIS PF-6 measures self-reported physical function for everyday tasks (i.e., yard work, shopping, walking up/down stairs). Each item is score 1 - 5 (1 = unable to do/cannot do; 5 = without any difficulty/not at all), yielding a total between 6 and 30.', 'timeFrame': '30 days, 6 months, and 1 year'}, {'measure': 'Change in Pulmonary Embolism Quality of Life (PEmb-QOL) Questionnaire', 'description': 'Quality of life (QOL) as measured by the PEmb-QOL at 30 days, 6 months and one year ± 14 days clinic follow-up compared with placebo. The PEmb-QOL measures self-reported QOL after a Pulmonary Embolism. The PEmb-QOL has nine sub-scales with higher scores indicating worse outcomes. Each item is score 1 - 5 (1 = unable to do/cannot do; 5 = without any difficulty/not at all), yielding a total between 6 and 30.', 'timeFrame': '30 days, 6 months, and 1 year'}, {'measure': 'Number of Recurrent Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) Events', 'description': 'Measured as the number of recurrent DVT and/or PE events in patients at 30 days, 60 days, 6 months, and 1 year compared to placebo.', 'timeFrame': '30 days, 60 days, 6 months, and 1 year'}]",12,18 Years,75 Years,ALL,False,"Victor Tapson, MD",OTHER,1,4.0,ACTUAL,2025-09-01T16:18:23.462421,v2_robust,True,True,False,True,False,COVID-19 pandemic
NCT00817986,A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of XP19986 in Subjects With Acute Back Spasms","Arbaclofen placarbil, 20 mg","['XP19986 SR3', 'Arbaclofen placarbil, 40 mg', 'Sugar Pill', 'XP19986 SR3 tablets', 'Arbaclofen placarbil, 30 mg', 'Placebo', 'Arbaclofen placarbil, 20 mg']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Back Pain,['Back Pain'],['Acute back pain in the lumbar region'],COMPLETED,,2008-12,2009-07,"[{'measure': 'Incidence of treatment-emergent adverse events', 'description': 'Safety was assessed based on the incidence, intensity and relationship of treatment emergent AEs', 'timeFrame': '14 Days'}]","[{'measure': 'Change in pain severity score using the VAS', 'timeFrame': '4 Days'}]",2,18 Years,65 Years,ALL,False,"XenoPort, Inc.",INDUSTRY,0,161.0,ACTUAL,2025-09-01T16:18:23.462546,v2_robust,True,True,True,False,True,
NCT03388086,Efficacy of Two Onabotulinum Toxin Doses,Comparing the Efficacy of Two Doses of Onabotulinum Toxin for the Treatment of Neurogenic Detrusor Overactivity - a Retrospective Cohort Study,Injection of Onabotulinum toxin,['Injection of Onabotulinum toxin'],1,OBSERVATIONAL,[],,,Neurogenic Bladder,"['Neurogenic Bladder', 'Overactive Detrusor']",[],COMPLETED,,2018-02-01,2019-07-31,"[{'measure': 'change in detrusor pressure post-injection', 'description': 'bladder detrusor pressure during storage phase', 'timeFrame': 'within 3 months before injection; within 2 months after injection'}]","[{'measure': 'maximum bladder volume', 'timeFrame': 'within 3 months before injection; within 2 months after injection'}, {'measure': 'bladder compliance', 'description': 'The relationship between a change in bladder volume and the change in detrusor pressure (ΔDV/ΔDP).', 'timeFrame': 'within 3 months before injection; within 2 months after injection'}, {'measure': 'reflexive bladder volume', 'timeFrame': 'within 3 months before injection; within 2 months after injection'}, {'measure': 'complications', 'timeFrame': 'within 2 months after injection'}, {'measure': 'presence of urinary incontinence', 'timeFrame': 'within 3 months before injection; within 2 months after injection'}]",6,18 Years,99 Years,ALL,False,"Swiss Paraplegic Research, Nottwil",NETWORK,0,56.0,ACTUAL,2025-09-01T16:18:23.462553,v2_robust,False,True,True,False,False,
NCT05397886,Comparison of Remimazolam With Flumazenil vs. Propofol During RFCA for Atrial Fibrillation,Comparison of Remimazolam With Flumazenil vs. Propofol TIVA During RFCA for Atrial Fibrillation,Remimazolam Besylate,"['Propofol', 'Remimazolam Besylate', 'Flumazenil']",3,INTERVENTIONAL,['NA'],,,Recovery,['Recovery'],"['recovery', 'remimazolam', 'flumazenil', 'propofol', 'radiofrequency catheter ablation']",COMPLETED,,2022-08-02,2023-04-25,"[{'measure': 'Time to eye opening', 'description': ""Time to first eye opening responding to doctor's command from discontinuation of main anesthetics"", 'timeFrame': 'up to 1 hour'}]","[{'measure': 'Time to remove laryngeal mask airway', 'description': 'Time to removal of supraglottic laryngeal mask airway from discontinuation of main anesthetics', 'timeFrame': 'up to 1 hour'}, {'measure': 'Incidence of hypotension', 'description': 'Incidence of three consecutive hypotension, which is defined as systolic blood pressure under 80 mmHg, at 2.5 min-intervals', 'timeFrame': 'During anesthesia for radiofrequency ablation procedure'}, {'measure': 'Vasoactive-inotropic score', 'description': 'Intraprocedural vasoactive-inotropic score, which is calculated as: dopamine dose (μg/kg/min) + dobutamine dose (μg/kg/min) + 100 х epinephrine (μg/kg/min) + 100 х norepinephrine (μg/kg/min) + 10000 х vasopressin (unit/kg/min)', 'timeFrame': 'During anesthesia for radiofrequency ablation procedure'}]",4,20 Years,75 Years,ALL,False,Seoul National University Hospital,OTHER,0,54.0,ACTUAL,2025-09-01T16:18:23.462604,v2_robust,True,True,True,False,False,
NCT07054086,Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma,Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma,Neoadjuvant Chemotherapy (NACT),['Neoadjuvant Chemotherapy (NACT)'],1,OBSERVATIONAL,[],,,Esophageal Cancer,['Esophageal Cancer'],[],RECRUITING,,2025-03-01,2026-07-31,"[{'measure': 'Organoid Culture Success Metrics', 'description': 'Assessment of the success rate in establishing patient-derived organoids (PDOs) from esophageal squamous cell carcinoma tissue samples, confirmed histologically and genomically consistent with tumor tissue.', 'timeFrame': 'before NACT accomplishment'}]","[{'measure': 'Clinical Efficacy Evaluation', 'description': 'Quantitative assessment of tumor response to neoadjuvant therapy using criteria from RECIST version 1.1 criteria (Complete Response \\[CR\\], Partial Response \\[PR\\], Stable Disease \\[SD\\], Progressive Disease \\[PD\\]).', 'timeFrame': '4-6 weeks after NACT complete'}, {'measure': 'Drug Sensitivity Concordance', 'description': 'Evaluation of consistency between in vitro drug sensitivity results from PDO models and clinical tumor response following neoadjuvant therapy. Key parameter: Maximum percent inhibition rate of tumor organoids exposed to programmed drug regimens (e.g., paclitaxel, pembrolizumab combinations).', 'timeFrame': 'before NACT treatment accomplishment'}]",3,18 Years,75 Years,ALL,False,Shanghai Zhongshan Hospital,OTHER,1,30.0,ESTIMATED,2025-09-01T16:18:23.462652,v2_robust,False,True,False,False,False,
NCT01020786,A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients,Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer,Pemetrexed,"['Alimta', 'Carboplatin', 'Pemetrexed', 'LY231514']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Non Small Cell Lung Cancer,['Non Small Cell Lung Cancer'],['Non-squamous'],COMPLETED,,2009-11,2012-06,"[{'measure': 'Progression Free Survival (PFS) During the Induction and Maintenance Therapy Periods', 'description': 'PFS defined as time from enrollment date to first date of objective progression of disease or of death from any cause. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.0, which define when cancer participants improve (""respond""), stay the same (""stabilize""), or worsen (""progression"") during treatments. Participants receiving any subsequent systemic anticancer therapy before objective progression or death were censored at date of last objective progression-free disease assessment before starting subsequent systemic anticancer therapy.', 'timeFrame': 'Enrollment to the date of progressive disease (PD) or the date of death from any cause (up to 18 months)'}]","[{'measure': 'Overall Survival (OS) During the Induction and Maintenance Therapy Periods', 'description': 'OS was defined as the time from the enrollment date to the date of death from any cause. For participants who were alive, OS was censored at the last contact.', 'timeFrame': 'Enrollment to the date of death from any cause (up to 30.8 months)'}, {'measure': 'Percentage of Participants Who Achieve a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) During the Induction and Maintenance Therapy Periods', 'description': 'Calculated as the percentage of participants who achieved a confirmed CR, PR, or SD. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.0, which define when cancer participants improve (""respond""), stay the same (""stabilize""), or worsen (""progression"") during treatments. CR = disappearance of all target lesions. PR = 30% decrease in the sum of the longest diameter of target lesions. Progressive Disease (PD) = 20% increase in the sum of the longest diameter of target lesions. SD = small changes that do not meet above criteria.', 'timeFrame': 'Enrollment to date of progressive disease (up to 18 months)'}, {'measure': 'Percentage of Participants Who Achieved a Complete Response (CR) or Partial Response (PR) During the Induction and Maintenance Therapy Periods', 'description': 'Calculated as the percentage of participants who achieved a confirmed CR or PR. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.0, which define when cancer participants improve (""respond""), stay the same (""stabilize""), or worsen (""progression"") during treatments. CR = disappearance of all target lesions. PR = 30% decrease in the sum of the longest diameter of target lesions. Progressive Disease (PD) = 20% increase in the sum of the longest diameter of target lesions. Stable Disease (SD) = small changes that do not meet above criteria.', 'timeFrame': 'Enrollment to date of progressive disease (up to 18 months)'}, {'measure': 'Progression Free Survival (PFS) During the Maintenance Therapy Period', 'description': 'Measured from the date of the first dose of the maintenance therapy. Calculated by subtracting induction therapy period from PFS. Tumor response assessed using Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.0; define when cancer participants improve (""respond""), stay the same (""stabilize""), or worsen (""progression"") during treatments. Participants receiving any subsequent systemic anticancer therapy before objective progression or death were censored at date of last objective progression-free disease assessment before starting subsequent systemic anticancer therapy.', 'timeFrame': 'From the start of maintenance therapy in Cycle 5 (21-day cycle) until the date of measured progressive disease (PD) or death from any cause (up to 24.4 months)'}, {'measure': 'Overall Survival (OS) During the Maintenance Therapy Period', 'description': 'OS was defined as the duration from the date of the first dose of the maintenance therapy to the date of death from any cause and was calculated by subtracting the induction therapy period from OS. Participants receiving any subsequent systemic anticancer therapy before objective progression or death were censored at date of last objective progression-free disease assessment before starting subsequent systemic anticancer therapy. For participants who were alive, OS was censored at the last contact.', 'timeFrame': 'From the start of maintenance therapy in Cycle 5 (21-day cycle) until the date of measured progressive disease (PD) or death from any cause (up to 26.3 months)'}, {'measure': 'Percentage of Participants Who Achieved a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) During the Maintenance Therapy Period', 'description': 'Percentage of participants who achieved confirmed CR (disappearance of all target lesions), PR (30% decrease in sum of longest diameter of target lesions), or SD (small changes that do not meet above criteria). Response derived from target lesion assessments performed before maintenance therapy (as baseline), during maintenance therapy (as post-baseline), and non-target lesion assessments performed during maintenance therapy according to RECIST guideline version 1.0, defines when cancer participants improve (""respond""), stay the same (""stabilize""), or worsen (""progression"") during treatments.', 'timeFrame': 'From the start of maintenance therapy in Cycle 5 (21-day cycle) until the date of measured progressive disease (PD) or death from any cause (up to 18 months)'}, {'measure': 'Percentage of Participants Who Observe a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) During the Induction Therapy Period', 'description': 'Calculated as the percentage of participants who achieved a CR, PR, or SD (confirmed or not). Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.0, which define when cancer participants improve (""respond""), stay the same (""stabilize""), or worsen (""progression"") during treatments. CR = disappearance of all target lesions. PR = 30% decrease in the sum of the longest diameter of target lesions. Progressive Disease (PD) = 20% increase in the sum of the longest diameter of target lesions. SD = small changes that do not meet above criteria.', 'timeFrame': 'Enrollment to the date of PD, or end of induction period up to Cycle 4 (21-day cycle)'}, {'measure': 'Percentage of Participants Who Achieve a Complete Response (CR) or a Partial Response (PR) During the Induction Therapy Period', 'description': 'Calculated as percentage of participants who achieved a CR or PR (confirmed or not). Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.0, which define when cancer participants improve (""respond""), stay the same (""stabilize""), or worsen (""progression"") during treatments. CR = disappearance of all target lesions. PR = 30% decrease in sum of the longest diameter of target lesions. Progressive Disease (PD) = 20% increase in the sum of longest diameter of target lesions. Stable Disease (SD) = small changes that do not meet above criteria.', 'timeFrame': 'Enrollment to date of PD, or end of induction period up to Cycle 4 (21-day cycle)'}]",9,20 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,109.0,ACTUAL,2025-09-01T16:18:23.462689,v2_robust,True,True,True,False,False,
NCT02881086,"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Nelarabine in T-ALL Patients",Rituximab,"['Nelarabine', 'Methotrexate', 'Adriamycin', 'Imatinib', 'Cytarabine', 'Rituximab', 'Vincristine', 'PEG-Asparaginase', 'Mercaptopurine', 'Prednisolone', 'Vindesine', 'Cyclophosphamide', 'Idarubicin', 'VP16', 'Daunorubicin (DNR)', 'Dexamethasone', 'Fludarabine']",17,INTERVENTIONAL,['PHASE3'],PHASE3,,Acute Lymphoblastic Leukemia,"['Acute Lymphoblastic Leukemia', 'Lymphoblastic Lymphoma']","['Acute lymphoblastic leukemia', 'Lymphoblastic lymphoma', 'Nelarabine', 'BCR-ABL', 'MRD', 'PEG-Asparaginase', 'Rituximab']",COMPLETED,,2016-08,2024-12,"[{'measure': 'Event free survival', 'timeFrame': '3.5 years'}]","[{'measure': 'Time until consolidation treatment I', 'timeFrame': 'approximately 70 days'}, {'measure': 'Disease free survival', 'timeFrame': '1 year'}]",3,18 Years,55 Years,ALL,False,Goethe University,OTHER,0,1000.0,ACTUAL,2025-09-01T16:18:23.462776,v2_robust,True,True,True,False,False,
NCT01959386,A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer,Clinical Practice Surveillance of the Use of Herceptin® Subcutaneous in Patients With HER2-Positive Early Breast Cancer (HerSCin),Trastuzumab,"['Trastuzumab', 'Herceptin']",2,OBSERVATIONAL,[],,,Breast Neoplasms,['Breast Neoplasms'],[],COMPLETED,,2013-11-07,2019-01-31,"[{'measure': 'Percentage of Participants With Pathologic Complete Response (pCR) (For Participants Treated in Neo-Adjuvant Setting), According to Response Evaluation Criteria in Solid Tumor (RECIST), or Modified RECIST, or Cheson Criteria (As per Center Practice)', 'timeFrame': 'Baseline up to approximately 3 years (assessed according to routine center practice)'}, {'measure': 'Percentage of Participants Who Were Alive and Disease Free at Year 2 (For Participants Treated in the Adjuvant Setting), According to RECIST, or Modified RECIST, or Cheson Criteria (As per Center Practice)', 'timeFrame': 'Year 2'}]","[{'measure': 'Percentage of Participants with Adverse Events', 'timeFrame': 'Baseline up to approximately 3 years'}, {'measure': 'European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Scores', 'timeFrame': 'Baseline, every 12 weeks up to Year 1'}, {'measure': 'European Organization for Research and Treatment of Cancer Breast Cancer Module (EORTC QLQ BR23) Questionnaire Score', 'timeFrame': 'Baseline, every 12 weeks up to Year 1'}, {'measure': 'Mean Trastuzumab Dose', 'timeFrame': 'Baseline up to Year 1'}, {'measure': 'Duration of Trastuzumab Treatment', 'timeFrame': 'Baseline up to Year 1'}, {'measure': 'Percentage of Participants By Reason for Trastuzumab Discontinuation or Interruption', 'timeFrame': 'Baseline up to Year 1'}, {'measure': 'Percentage of Participants Who Received Concomitant Treatment (Chemotherapy or Any Other Treatment)', 'timeFrame': 'Baseline up to Year 1'}]",9,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,1006.0,ACTUAL,2025-09-01T16:18:23.462786,v2_robust,False,True,True,False,True,
NCT00756886,Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study,Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study,Atorvastatin,"['Atorvastatin', 'Placebo']",2,INTERVENTIONAL,['NA'],,,Arrhythmia,['Arrhythmia'],[],COMPLETED,,2008-09,2011-05,"[{'measure': 'Atrial Fibrillation', 'timeFrame': '0-21 days post-operative'}]",[],1,19 Years,,ALL,True,University of Alabama at Birmingham,OTHER,1,73.0,ACTUAL,2025-09-01T16:18:23.462820,v2_robust,True,True,True,False,False,
NCT03106870,Adding Metformin to Insulin in Controlling Pregestational and Gestational Diabetes Mellitus,Adding Metformin to Insulin in Controlling Pregestational and Gestational Diabetes Mellitus and Improving Neonatal Outcome Regarding Birth Weight,Insulin Mixtard,"['Metformin Hydrocloride', 'insulin mixtures', 'Metformin', 'Insulin Mixtard']",4,INTERVENTIONAL,['NA'],,,Gestational Diabetes Mellitus in Pregnancy,['Gestational Diabetes Mellitus in Pregnancy'],[],COMPLETED,,2016-06,2016-12,"[{'measure': 'Number of Participants With Glycemic Control Over Period From 20 Weeks to 36 Weeks Gestation', 'description': 'Fasting and two-hours postprandial blood glucose every 48 hours, till reaching the target blood glucose concentrations:\n\n60 - 95 mg/dl and \\< 120 mg/dl (for fasting and two-hour postprandial status, respectively) If patient reached blood glucose concentrations, she considered as controlled Diabetes Mellitus If patient did not reach blood glucose concentrations, she considered as uncontrolled Diabetes Mellitus', 'timeFrame': 'from 20 weeks to 36 weeks gestation'}]","[{'measure': 'Number of Participants With a Macrosomic Baby', 'description': 'Fetal macrosomia has been defined birth weight greater than 4500 gm', 'timeFrame': '24 hours after delivery'}, {'measure': 'Number of Participants With Neonates Who Were Hypoglycemic', 'description': 'Neonatal hypoglycemia defined as a plasma glucose level of less than 30 mg/dL in the first 24 hours after delivery', 'timeFrame': '24 hours after delivery'}]",3,20 Years,35 Years,FEMALE,True,Ain Shams University,OTHER,0,62.0,ACTUAL,2025-09-01T16:18:23.463018,v2_robust,True,True,True,False,False,
NCT00123370,Trial of Modafinil for Methamphetamine Dependence,Randomised Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence,Modafinil,['Modafinil'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Amphetamine Dependence,['Amphetamine Dependence'],"['Modafinil', 'Amphetamine Dependence', 'Randomised placebo-controlled trial']",UNKNOWN,,2006-07,2007-09,"[{'measure': 'Urinalysis results negative for methamphetamine over 10 weeks', 'timeFrame': '10 weeks'}, {'measure': 'Adverse events', 'timeFrame': '10 weeks'}, {'measure': 'Compliance', 'timeFrame': '10 weeks'}, {'measure': 'Retention', 'timeFrame': '10 weeks'}]","[{'measure': 'Self reported drug use', 'timeFrame': '10 weeks'}, {'measure': 'Health outcomes', 'timeFrame': '10 weeks'}, {'measure': 'Psychosocial outcomes', 'timeFrame': '10 weeks'}]",7,18 Years,,ALL,False,The University of New South Wales,OTHER,3,87.0,ESTIMATED,2025-09-01T16:18:23.463147,v2_robust,True,True,False,False,True,
NCT06622070,A Study of SPY002-072 in Healthy Volunteers,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY002-072 in Healthy Participants",SPY002-072,['SPY002-072'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],RECRUITING,,2024-11-18,2026-08-08,"[{'measure': 'Treatment emergent adverse events', 'description': 'Incidence, severity, and causal relationship of TEAEs', 'timeFrame': 'Up to 40 weeks'}]","[{'measure': 'Cmax', 'description': 'Maximum concentration after single dose', 'timeFrame': 'Up to 40 weeks'}, {'measure': 't1/2', 'description': 'Half life after single dose', 'timeFrame': 'Up to 40 weeks'}, {'measure': 'Tmax', 'description': 'Time to reach maximum concentration after single dose', 'timeFrame': 'Up to 40 weeks'}, {'measure': 'ADA', 'description': 'Incidence of anti-drug antibody after single dose', 'timeFrame': 'Up to 40 weeks'}, {'measure': 'AUC', 'description': 'Area under the curve after single dose', 'timeFrame': 'Up to 40 weeks'}]",6,18 Years,60 Years,ALL,True,"Spyre Therapeutics, Inc.",INDUSTRY,1,56.0,ESTIMATED,2025-09-01T16:18:23.463154,v2_robust,True,True,False,False,True,
NCT05608070,IV Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy,Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy: A Randomized Placebo-Controlled Trial,Oxytocin,"['0.9% NaCl, Saline', 'Placebo', 'Pitocin', 'Oxytocin']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pain, Postoperative","['Pain, Postoperative', 'Analgesia', 'Postoperative Pain', 'Pain, Post Operative', 'Oxytocin']","['Postoperative pain', 'Oxytocin', 'Non-opioid analgesia', 'Multimodal analgesia', 'Female', 'Humans']",WITHDRAWN,Sponsor declined to fund,2023-06-01,2025-06,"[{'measure': 'Total opioids consumption', 'description': 'Average Opioid Oral Morphine Milligram Equivalent (MME) during intra-operative and post-operative period', 'timeFrame': '3 days'}]","[{'measure': 'Post Operative Pain scores', 'description': '11-point (0-10) pain scores on Numerical Rating Scale (NRS) in Post Anesthesia Care Unit (PACU), Post-Operative Day (POD) 0 and POD1.', 'timeFrame': '2 days'}, {'measure': 'Anxiety score', 'description': 'State-Trait Anxiety Inventory (STAI-6)', 'timeFrame': '3 days'}, {'measure': 'Quality of Recovery Score', 'description': 'Postoperative Quality of Recovery Score (QoR-15)', 'timeFrame': '3 days'}, {'measure': 'Catastrophizing Scale', 'description': 'Daily Pain Catastrophizing Scale (DPCS)', 'timeFrame': '3 days'}, {'measure': 'Patient-rated Satisfaction', 'description': '11-point (0-10) patient satisfaction scores on Numerical Rating Scale (NRS) in PACU and POD0', 'timeFrame': '1 day'}]",6,18 Years,65 Years,FEMALE,False,Beth Israel Deaconess Medical Center,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:23.463284,v2_robust,True,True,False,True,False,Sponsor declined to fund
NCT05470270,Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.,"An Open-label, Non-comparative, Multicentre Study to Evaluate the Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.",Hydroxycarbamide,['Hydroxycarbamide'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Sickle Cell Disease,['Sickle Cell Disease'],"['hydroxycarbamide', 'pediatric', 'acceptability']",COMPLETED,,2022-07-08,2022-10-28,"[{'measure': 'Acceptability score', 'description': 'Acceptability score evaluated by the parent(s) of the child (2-6 years old) and by the child (4-6 years old)', 'timeFrame': 'At Day 1 (inclusion visit at study drug administration)'}]","[{'measure': 'Percentage of children with acceptable acceptability score (neutral to positive scores)', 'description': 'Neutral to positive scores reported by the parent(s) of the child (2-6 years old), and by the child (4-6 years old)', 'timeFrame': 'At Day 1 (inclusion visit at study drug administration)'}, {'measure': 'Distribution of the scores related to the ease of administration', 'description': 'Score reported by parent(s), based on a 5-point Likert scale,', 'timeFrame': 'At Day 1 (inclusion visit at study drug administration)'}, {'measure': 'Distribution of the scores related to the ease of preparation including the ease of constitution of the liquid form and the ease to follow the prescription', 'description': 'Score reported by the parent(s) based on a 5-point Likert scale,', 'timeFrame': 'At Day 1 (inclusion visit at study drug administration)'}, {'measure': 'Score related to the usefulness of the dispersible form, compared with the tablets currently used', 'description': 'Score reported by the parent(s), based on a 5-point Likert scale', 'timeFrame': 'At Day 1 (inclusion visit at study drug administration)'}, {'measure': 'Free comments collected by the investigator', 'description': 'Questions from child/parent, reactions before/after drug intake', 'timeFrame': 'At Day 1 (inclusion visit at study drug administration)'}, {'measure': 'Number of adverse events', 'description': 'Number of adverse events and percentage of patients reporting at least one adverse event', 'timeFrame': 'At Day 1 (inclusion visit at study drug administration)'}]",7,2 Years,6 Years,ALL,False,Theravia,INDUSTRY,0,33.0,ACTUAL,2025-09-01T16:18:23.463299,v2_robust,True,True,True,False,True,
NCT07069270,A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy,"A Prospective, Single-center, Single-arm Clinical Study of Adebrelimab in Combination With Vunakizumab and Chemotherapy as First-line Treatment for Extensious-stage Small Cell Lung Cancer",Vunakizumab (IL-17A inhibitor),"['Chemotherapy', 'Adebrelimab', 'Vunakizumab (IL-17A inhibitor)']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Vunakizumab,"['Vunakizumab', 'Adebrelimab', 'Small Cell Lung Cancer']","['Small cell lung cancer', 'Adebrelimab', 'Vunakizumab']",NOT_YET_RECRUITING,,2025-09-01,2028-01-01,"[{'measure': '12-month PFS rate', 'timeFrame': '12-month'}]","[{'measure': 'Progression-free survival (PFS）', 'timeFrame': '12- months'}, {'measure': 'Overall survival (OS）', 'timeFrame': '24-months'}, {'measure': 'Objective response rate (ORR）', 'timeFrame': 'Each 2 cycles can last up to 3 months (each cycle is 21 days).'}, {'measure': 'Disease Control Rate (DCR）', 'timeFrame': 'Each 2 cycles can last up to 3 months (each cycle is 21 days).'}, {'measure': 'The incidence and severity of adverse events (AE) and serious adverse events (SAE)', 'timeFrame': 'As long as two years'}]",6,18 Years,75 Years,ALL,False,Fujian Cancer Hospital,OTHER_GOV,0,28.0,ESTIMATED,2025-09-01T16:18:23.463340,v2_robust,True,True,False,False,True,
NCT05753670,Effect of Preoperative Tamsulosin on Postoperative Urinary Retention,"Effect of Preoperative Single-dose Tamsulosin on Postoperative Urinary Retention After Mid-urethral Sling Placement: a Randomized, Double-blinded, Placebo-controlled Trial",Tamsulosin,"['Tamsulosin', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Postoperative Retention of Urine,['Postoperative Retention of Urine'],[],COMPLETED,,2023-07-01,2024-06-02,"[{'measure': 'Postoperative urinary retention', 'description': 'Determine the postoperative urinary retention rates after preoperative administration of tamsulosin compared with placebo. This will be determined immediately postoperative in the postoperative recovery room based on whether patients pass or fail their voiding trial described above. The result will be documented in electronic medical records and obtained from chart review.', 'timeFrame': 'Immediate postoperative evaluation (1 day)'}]","[{'measure': 'Postoperative pain', 'description': 'Compare differences in postoperative pain (postoperative nursing documentation performed in the recovery area based on a Likert scale of 0-10 where 0 is no pain and 10 is extreme pain) after preoperative administration of tamsulosin compared with placebo.', 'timeFrame': 'Immediate postoperative evaluation (1 day)'}, {'measure': 'Postoperative UTI', 'description': 'Compare differences in the incidence of postoperative UTI (% of patients diagnosed with a UTI within 30 days of procedure) after preoperative administration of tamsulosin compared with placebo.', 'timeFrame': 'Chart review of 30 days postoperative after surgery'}, {'measure': 'Unplanned admission or unplanned healthcare encounter', 'description': 'Evaluate the difference in unplanned admission the day or surgery or unplanned admission within 30 days after surgery, unplanned office visits within 30 days after surgery or Northshore encounters within 30 days after surgery after preoperative administration tamsulosin compared with placebo. These medical encounters will include any need for additional medical treatment, phone calls, complications or patient concerns within 30 days postoperatively. This data will be collected via chart review.', 'timeFrame': 'Chart review of 30 days postoperative after surgery'}, {'measure': 'Postoperative hypotension', 'description': 'Compare the rates of hypotension (immediately postoperative) after preoperative administration of tamsulosin compared with placebo.', 'timeFrame': 'Immediate postoperative evaluation (1 day)'}]",5,18 Years,99 Years,FEMALE,True,Endeavor Health,OTHER,0,183.0,ACTUAL,2025-09-01T16:18:23.463358,v2_robust,True,True,True,False,False,
NCT05108870,TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers,A Randomized Phase I/II Trial of TheraT® Vectors Expressing HPV16 Specific Antigens in Combination With Neoadjuvant Chemotherapy Followed by Transoral Robotic Surgery or Risk/Response Stratified Chemoradiotherapy for Locoregional HPV16+ Oropharyngeal Cancer,HB-201,"['Paclitaxel', 'Carboplatin', 'TheraT® Vectors', 'HB-201', 'HB-202']",5,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Human Papilloma Virus,"['Human Papilloma Virus', 'HPV', 'HPV Positive Oropharyngeal Squamous Cell Carcinoma', 'Head and Neck Cancer']","['throat cancer', 'human papilloma virus', 'HPV16', 'head and neck cancer']",RECRUITING,,2024-07-17,2026-01-01,"[{'measure': 'Phase 1 Primary Outcome: Phase 1 Dose of HB-201 and HB-201/202 Combined with Chemotherapy', 'description': 'The phase 1 dose of HB-201 monotherapy and alternating HB-201 and 202 therapy in combination with chemotherapy in patients with HPV 16 head and neck cancer as assessed by data on reported dose-limiting toxicities (side effects) among participants. These side effects will be measures according to the Common Terminology Criteria for Adverse Events version 5', 'timeFrame': '2 years'}, {'measure': 'Phase 2 Primary Outcome: Deep Response Rate of Participants Treated with HB-201 or HB-201/202 Combined with Chemotherapy', 'description': 'The deep response rate (DRR) of participants who receive neoadjuvant HB-201 monotherapy combined with chemotherapy or alternating doses of HB-201 and HB-202 combined with chemotherapy. This response rate will be assessed by tumor shrinkage according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).', 'timeFrame': '2 years'}]","[{'measure': 'Correlation Between Plasma HPV-DNA and Tumor HPV-DNA', 'description': 'Correlation between plasma HPV-DNA and tumor HPV-DNA as assessed by an analysis of plasma and sputum samples of participants using next generation sequencing analysis.', 'timeFrame': '2 years'}, {'measure': 'Changes in Plasma HPV-DNA During Study Treatment with HB-201 and Alternating HB201/202 Combined with Chemotherapy', 'description': ""Changes in the amount of HPV-DNA found in plasma during neoadjuvant HB-201 monotherapy and HB-201 and HB-202 alternating two-vector therapy combined with chemotherapy as assessed by next generation sequencing analysis of participants' plasma samples."", 'timeFrame': '2 years'}, {'measure': 'Pathologic Response in Participants Undergoing Transoral Robotic Surgery (TORS)', 'description': 'Pathologic response in patients undergoing TORS following neoadjuvant HB-201 monotherapy and HB-202 alternating two-vector therapy combined with chemotherapy. Response will be assessed by tumor shrinkage according to Response Evaluation Criteria in Solid Tumors 1.1.', 'timeFrame': '2 years'}, {'measure': 'Progression Free Survival', 'description': 'Progression-free survival of participants as assessed by data recorded in study/clinical records and statistical analysis.', 'timeFrame': '2 years'}, {'measure': 'Overall Survival', 'description': 'Overall survival of participants as assessed by data recorded in study/clinical records and statistical analysis.', 'timeFrame': '2 years'}, {'measure': 'Locoregional Control', 'description': 'Locoregional control of participants as assessed by data recorded in study/clinical records and statistical analysis.', 'timeFrame': '2 years'}]",8,18 Years,,ALL,False,University of Chicago,OTHER,0,98.0,ESTIMATED,2025-09-01T16:18:23.463424,v2_robust,True,True,False,False,True,
NCT05774873,"IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","A Phase I/II Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors",IBI334 D,"['IBI334 C', 'IBI334 A', 'IBI334 F', 'IBI334 D', 'IBI334 E', 'IBI334 B']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Solid Tumors,['Solid Tumors'],[],RECRUITING,,2023-08-09,2026-06-30,"[{'measure': 'Number of patients with treatment-related adverse events', 'description': 'Number of patients who experienced a treatment related AEs from the first dose until 60 days after the last dose', 'timeFrame': 'Up to 60 days post last dose'}, {'measure': 'Percentage of subjects woth Dose-Limitine toxicities(DLTs)', 'description': 'To evaluate the safety and tolerability of IBI334', 'timeFrame': 'Up to 28 days following first dose'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'Objective Response Rate (ORR) is the percentage of Complete Response (CR) plus partial response(PR) assessed per RECIST v1.1 criteria .', 'timeFrame': 'Up to 60 days post last dose'}, {'measure': 'Duration of response (DoR)', 'description': 'For subjects with CR or PR, duration of response(DoR) is the time from the first documented CR or PR to disease progression or death assessed per RECIST V1.1 criteria.', 'timeFrame': 'Up to 60 days post last dose'}, {'measure': 'Disease control rate (DCR)', 'description': 'Disease control rate (DCR) is the percentage of CR plus PR Plus stable disease (SD) assessed per RECIST v1.1 criteria.', 'timeFrame': 'Up to 60 days post last dose'}, {'measure': 'Time to Response (TTR)', 'description': 'For subjects with CR or PR, time to response(TTR) is the time from first dose of study drugs to the first documented CR or PR assessed per RECIST v1.1 criteria.', 'timeFrame': 'Up to 60 days post last dose'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Time from randomization to first documented disease progression (radiographic) assessed by investigator per RECIST v1.1 criteria or death due to any cause.', 'timeFrame': 'Up to 60 days post last dose'}, {'measure': 'Overall survival (OS)', 'description': 'Time from randomization to death of the subject due to any cause.', 'timeFrame': 'Up to 60 days post last dose'}]",8,18 Years,,ALL,False,Innovent Biologics (Suzhou) Co. Ltd.,INDUSTRY,0,128.0,ESTIMATED,2025-09-01T16:18:23.463599,v2_robust,True,True,False,False,True,
NCT01204073,A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies,"A Multicenter, Open-Label, Dose-Escalation, Phase 1 Study of TAK-441, an Oral Hedgehog Signaling Pathway Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies",TAK-441,['TAK-441'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Nonhematologic Malignancies,"['Advanced Nonhematologic Malignancies', 'Carcinoma, Basal Cell']",[],COMPLETED,,2010-10,2013-01,"[{'measure': 'Safety profile, maximum tolerated dose (MTD) or maximum feasible dose (MFD) of TAK-441 administered as an oral formulation in patients wtih advanced nonhematologic malignancies', 'description': 'Adverse events, serious adverse events, dose-limiting toxicities, assessments of clinical laboratory values, electrocardiogram parameters and vital sign measurements', 'timeFrame': 'From first dose of TAK-441 through 30 days after the last dose of TAK-441'}]","[{'measure': 'Single-dose and multiple-dose plasma pharmacokinetics (PK) of TAK-441', 'description': 'Including but not limited to maximum plasma concentration (Cmax), first time to plasma concentration (Tmax) and area under the plasma concentration versus time curve (AUC)', 'timeFrame': 'Sampling during Cycle 1 (Days 1-28)'}, {'measure': 'Pharmacodynamic effect of TAK-441 on Gli 1 expression in skin', 'timeFrame': 'Cycle 1 Day 22'}, {'measure': 'Pharmacodynamic effect of TAK-441 on Gli 1 expression in tumors (expansion cohorts only)', 'timeFrame': 'Cycle 1 Day 15'}, {'measure': ""Antitumor activity of TAK-441 administered as a single-agent therapy based on investigators' assessments of tumor response in patients who have advanced basal cell carcinoma"", 'description': ""Based on the investigator's assessment using the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)"", 'timeFrame': 'Days 15-21 of cycles 2, 4 and every fourth cycle thereafter; and end of study'}]",5,18 Years,,ALL,False,"Millennium Pharmaceuticals, Inc.",INDUSTRY,0,34.0,ACTUAL,2025-09-01T16:18:23.463631,v2_robust,True,True,True,False,True,
NCT06349473,"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)","A Phase 1 Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Healthy Participants (Part A) and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SR604 in Participants With Hemophilia A or Hemophilia B (Part B)",SR604,"['SR604', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Participants,"['Healthy Participants', 'Hemophilia A', 'Hemophilia B']","['Single ascending dose', 'Multiple ascending dose', 'Factor IX', 'Factor VIII']",RECRUITING,,2024-05-10,2026-04-27,"[{'measure': 'Parts A and B: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'description': 'Safety and tolerability of a single ascending SC dose of SR604 in healthy participants and multiple ascending SC doses of SR604 in participants with Hemophilia A or Hemophilia B will be evaluated.', 'timeFrame': 'Part A: From Baseline (Day 1) up to Day 57; Part B: From Baseline (Day 1) up to 3 months'}, {'measure': 'Parts A and B: Number of Participants with Clinical Abnormal Changes in Coagulations Markers', 'description': 'Safety and tolerability of a single ascending SC dose of SR604 in healthy participants and multiple ascending SC doses of SR604 in participants with Hemophilia A or Hemophilia B will be evaluated.', 'timeFrame': 'Part A: From Baseline (Day 1) till Day 57; Part B: From Baseline (Day 1) till Day 90'}]","[{'measure': 'Part A: Area Under the Serum Concentration-time Curve from time Zero to the Last Quantifiable Time Point (AUC[0-t])', 'description': 'The PK profile (AUC\\[0-t\\]) of a single ascending SC dose of SR604 in healthy participants will be assessed.', 'timeFrame': 'From Baseline (Day 1) up to Day 57'}, {'measure': 'Part A: Area Under the Serum Concentration-time Curve from time Zero Extrapolated to Infinity (AUC[0-inf])', 'description': 'The PK profile (AUC\\[0-inf\\]) of a single ascending SC dose of SR604 in healthy participants will be assessed.', 'timeFrame': 'From Baseline (Day 1) up to Day 57'}, {'measure': 'Parts A and B: Maximum Concentration (Cmax) of SR604', 'description': 'The PK profile (Cmax) of a single ascending and multiple ascending SC dose of SR604 will be assessed.', 'timeFrame': 'Part A: From Baseline (Day 1) up to Day 57; Part B: From Baseline (Day 1) up to Day 90'}, {'measure': 'Parts A and B: Time to Maximum Concentration (tmax) of SR604', 'description': 'The PK profile (tmax) of a single ascending and multiple ascending SC dose of SR604 will be assessed.', 'timeFrame': 'Part A: From Baseline (Day 1) up to Day 57; Part B: From Baseline (Day 1) up to Day 90'}, {'measure': 'Parts A and B: Terminal Half-life (T1/2) of SR604', 'description': 'The PK profile (T1/2) of a single ascending and multiple ascending SC dose of SR604 will be assessed.', 'timeFrame': 'Part A: From Baseline (Day 1) up to Day 57; Part B: From Baseline (Day 1) up to Day 90'}, {'measure': 'Part A: Clearance Following Extravascular Administration (CL/F) of SR604', 'description': 'The PK profile (CL/F) of a single ascending SC dose of SR604 in healthy participants will be assessed.', 'timeFrame': 'From Baseline (Day 1) up to Day 57'}, {'measure': 'Part A: Volume of Distribution in Terminal Phase Following Extravascular Administration (Vz/F) of SR604', 'description': 'The PK profile (Vz/F) of a single ascending SC dose of SR604 in healthy participants will be assessed.', 'timeFrame': 'From Baseline (Day 1) up to Day 57'}, {'measure': 'Parts B: Concentration before the next dose administration (Ctrough)', 'description': 'The PK profile (Ctrough) of SR604 following repeated SC injections will be assessed.', 'timeFrame': 'From Baseline (Day 1) up to Day 90'}, {'measure': 'Parts B: Accumulation Ratio (R) of SR604', 'description': 'The PK profile (accumulation R) of SR604 following repeated SC injections will be assessed.', 'timeFrame': 'From Baseline (Day 1) up to Day 90'}, {'measure': 'Parts B: Number of Bleeding Events', 'description': 'The preliminary clinical activity of SR604 will be assessed. Bleeding event (record traumatic or non-traumatic bleeding, number of bleeding sites \\[joints or non-joints\\], bleeding frequency (intervals), associated with any external triggers, level of physical activity) will be evaluated.', 'timeFrame': 'From Baseline (Day 1) up to 3 months'}, {'measure': 'Parts B: Annualized Bleeding Rate (ABR) in Body and Targeted Joints', 'description': 'The preliminary clinical activity of SR604 will be assessed. ABR in body and targeted joined will be evaluated.', 'timeFrame': 'From Baseline (Day 1) up to 3 months'}, {'measure': 'Parts A and B: Number of Participants with Positive Antidrug Antibodies (ADAs)', 'description': 'Number of participants with positive ADAs will be assessed.', 'timeFrame': 'Part A: From Baseline (Day 1) till Day 57; Part B: From Baseline (Day 1) till Day 90'}]",14,18 Years,60 Years,MALE,True,Equilibra Bioscience LLC,INDUSTRY,0,36.0,ESTIMATED,2025-09-01T16:18:23.463638,v2_robust,True,True,False,False,True,
NCT02604173,Altitude Sickness Prevention and Efficacy of Comparative Treatments,A Randomized Controlled Trial of Altitude Sickness Prevention and Efficacy of Comparative Treatments,Budesonide,"['Diamox', 'entocort, pulmicort', 'Acetazolamide', 'Placebo', 'sugar pill', 'Budesonide']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Acute Mountain Sickness,['Acute Mountain Sickness'],[],COMPLETED,,2016-08,2016-09,"[{'measure': 'Number of Participants With Acute Mountain Sickness', 'description': 'Number of participants with acute mountain sickness (AMS) by Lake Lousie Questionnaire (LLQ)', 'timeFrame': '24 hours'}]","[{'measure': 'Number of Participants With Severe Acute Mountain Sickness', 'description': 'Number of participants with severe acute mountain sickness (AMS) by Lake Lousie Questionnaire (LLQ) (score \\> 5).', 'timeFrame': '24 hours'}, {'measure': 'Oxygen Saturation', 'description': 'measurement of oxygen saturation (%) by finger tip pulse oximeter.', 'timeFrame': '24 hours'}]",3,18 Years,65 Years,ALL,True,Stanford University,OTHER,0,103.0,ACTUAL,2025-09-01T16:18:23.463647,v2_robust,True,True,True,False,False,
NCT01846273,Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT),"A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy",Ranibizumab,"['Sham PDT', 'Verteporfin PDT', 'Lucentis', 'Ranibizumab']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Age-related Macular Degeneration,"['Age-related Macular Degeneration', 'Polypoidal Choroidal Vasculopathy']","['Polypoidal choroidal vasculopathy', 'Visual acuity', 'Ranibizumab', 'Verteporfin PDT']",COMPLETED,,2013-08-07,2017-03-02,"[{'measure': 'Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 - Study Eye', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.', 'timeFrame': 'Baseline, Month 12'}, {'measure': 'Number of Patients With Complete Polyp Regression From Baseline at Month 12 - Study Eye', 'description': 'Polyp regression was based on the Indocyanine green angiography (ICGA) assessment by the Central Reading Center (CRC). A patient was considered to have complete polyp regression if the presence of polyps, as assessed by CRC, had value ""No."" Polyp regression which may lead to disease stabilization and consequently better vision.', 'timeFrame': 'Baseline, Month 12'}]","[{'measure': 'Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) at Month 24 - Study Eye', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.', 'timeFrame': 'Baseline, Month 24'}, {'measure': 'Percentage of Patients With BCVA (Letters) Change From Baseline at Month 24 - Study Eye', 'description': 'BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20.', 'timeFrame': 'Baseline, Month 24'}, {'measure': 'Maintenance of BCVA (Within 5 Letter Change) at Month 12 and 24 Compared to BCVA at the Time Point of First Ranibizumab Treatment Interruption', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 4 meters.', 'timeFrame': 'Month 3, Month 12, Month 24'}, {'measure': 'Change in BCVA at Month 12 and 24 Compared to the Time Point of First Ranibizumab Treatment Interruption', 'description': 'Best Corrected Visual Acuity (BCVA) was assessed using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 4 meters.', 'timeFrame': 'Month 3, Month 12, Month 24'}, {'measure': 'Percentage of Patients With Complete Polyp Regression at Months 6 and 24 - Study Eye', 'description': 'Polyp regression was based on the Indocyanine green angiography (ICGA) assessment by the Central Reading Center (CRC). A patient was considered to have complete polyp regression if the presence of polyps, as assessed by CRC, had value ""No."" Polyp regression which may lead to disease stabilization and consequently better vision.', 'timeFrame': 'Month 6, Month 24'}, {'measure': 'Percentage of Patients With Presence of Leakage at Month 6, Month 12 and Month 24 - Study Eye', 'description': 'Presence of lesion leakage was based on Fluorescein Angiography (FA) as assessed by the Central Reading Center (CRC). The presence of leakage may lead to disease progression and worsening vision.', 'timeFrame': 'Month 6, Month 12 and Month 24'}, {'measure': 'Mean Change From Baseline in Investigator-Assessed Central Subfield Retinal Thickness (CSFT) at Month 24 - Study Eye', 'description': 'The thickness of the retina was measured using Spectral Domain (SD) optical coherence tomography (OCT) equipment (SD-OCT) and reported as a difference, in micrometers. A negative number indicates a reduction in thickness, whereas a positive number indicates an increase. An increase in thickness may indicate a progression of the underlying disease.', 'timeFrame': 'Baseline, Month 24'}, {'measure': 'Total Number of Ranibizumab Injections Received in the Study Eye Prior to Month 12', 'timeFrame': 'Baseline, Month 12'}, {'measure': 'Total Number of Verteporfin/Sham PDT Injections Received in the Study Eye Prior to Month 12', 'timeFrame': 'Baseline, Month 12'}, {'measure': 'Total Number of Ranibizumab Injections Received in the Study Eye Prior to Month 24', 'timeFrame': 'Baseline, Month 24'}, {'measure': 'Total Number of Verteporfin/Sham PDT Injections Received in the Study Eye Prior to Month 24', 'timeFrame': 'Baseline, Month 24'}, {'measure': 'Total Number of Ranibizumab Injections Received in the Study Eye From Month 3 to Month 12', 'timeFrame': 'Month 3, Month 12'}, {'measure': 'Total Number of Ranibizumab Injections Received in the Study Eye From Month 3 to Month 24', 'timeFrame': 'Month 3, Month 24'}, {'measure': 'Mean Change From Baseline in Composite Scores, National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) at Months 3, 12 and 24', 'description': ""The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure a patient's subjective assessment of vision-related quality of life at Months 3, 12 and 24. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated poorer function."", 'timeFrame': 'Baseline, Month 3, Month 12, Month 24'}, {'measure': 'Number of Ocular Adverse Events of the Study Eye Regardless of Study Drug Relationship up to Month 24, Any Primary System Organ Class', 'description': 'Reported categorically: Mild, Moderate, Severe', 'timeFrame': 'Up to Month 24'}, {'measure': 'Number of Non-Ocular Adverse Events of the Study Eye Regardless of Study Drug Relationship up to Month 24, Any Primary System Organ Class', 'description': 'Reported categorically: Mild, Moderate, Severe', 'timeFrame': 'Up to Month 24'}]",18,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,321.0,ACTUAL,2025-09-01T16:18:23.463661,v2_robust,True,True,True,False,True,
NCT04220073,"Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers","Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Tolerability, Safety, Immunogenicity and Pharmacokinetic Profile of Single Dose of JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) Injection in Healthy Volunteers",placebo,['placebo'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,"Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005","['Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005']",[],UNKNOWN,,2020-01-05,2021-01-17,"[{'measure': 'Number of Participants With Clinically Significant Events .', 'description': 'Clinically significant events were defined as abnormal laboratory values and/or adverse events that are related to treatment.', 'timeFrame': 'From baseline through 12 weeks.'}]","[{'measure': 'Pharmacokinetics (PK) of JS005.', 'description': 'Time to Reach the Maximum Concentration After Drug Administration (Tmax) in JS005 group.', 'timeFrame': 'From baseline through 12 weeks.'}, {'measure': 'Pharmacokinetics (PK) of JS005.', 'description': 'Observed Maximum Serum Concentration Following Drug Administration (Cmax) in JS005 group.', 'timeFrame': 'From baseline through 12 weeks.'}, {'measure': 'Pharmacokinetics (PK) of JS005.', 'description': 'Area Under the Serum Concentration-time Cure From Time Zero to the Time of Last Quantifiable Concentration (AUClast) in JS005 group.', 'timeFrame': 'From baseline through 12 weeks.'}, {'measure': 'Pharmacokinetics (PK) of JS005.', 'description': 'Area Under the Serum Concentration-time Curve From Time Zero to (AUCinf) in JS005 group.', 'timeFrame': 'From baseline through 12 weeks.'}, {'measure': 'Pharmacokinetics (PK) of JS005.', 'description': 'Mean residence time (MRT) in JS005 group.', 'timeFrame': 'From baseline through 12 weeks.'}, {'measure': 'Pharmacokinetics (PK) of JS005.', 'description': 'Systemic Clearance From Serum Following Intravenous Administration (CL) in JS005 group.', 'timeFrame': 'From baseline through 12 weeks.'}, {'measure': 'Pharmacokinetics (PK) of JS005.', 'description': 'Terminal Elimination Half-life (T1/2) in JS005 group', 'timeFrame': 'From baseline through 12 weeks.'}, {'measure': 'Pharmacokinetics (PK) of JS005.', 'description': 'Apparent terminal elimination rate constant in JS005 group.', 'timeFrame': 'From baseline through 12 weeks.'}, {'measure': 'Pharmacokinetics (PK) of JS005.', 'description': 'Apparent volume of distribution (Vd) in JS005 group.', 'timeFrame': 'From baseline through 12 weeks.'}, {'measure': 'Percentage of Participants With Anti-JS005 Antibodies.', 'description': 'Percentage of participants with treatment-emergent positive anti-JS005 antibodies was summarized by treatment group. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-JS005 antibodies / number of evaluable participants \\* 100%.', 'timeFrame': 'From baseline through 24 weeks.'}]",11,18 Years,45 Years,ALL,True,"Shanghai Junshi Bioscience Co., Ltd.",OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:23.463770,v2_robust,True,True,False,False,True,
NCT00877773,Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients,"Histology-Independent Study of the mTOR Inhibitor, Temsirolimus, in Patients With Advanced Cancer",Temsirolimus,"['Torisel', 'Temsirolimus', 'CCI-779']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Advanced Cancers,['Advanced Cancers'],"['Advanced cancer', 'Advanced Cancer with genetic mutation', 'Phosphoinositides 3-kinase', 'PI3K', 'PIK3 mutations', 'Temsirolimus', 'CCI-779', 'Torisel', 'mTOR inhibitor']",TERMINATED,Slow Accrual,2009-04,2014-06,"[{'measure': 'Tumor Response', 'description': 'For solid tumors, initial responses defined by Response Evaluation Criteria in Solid (RECIST) criteria in the evaluable lesion(s) per Complete Response (CR): Disappearance of all target lesions; confirmed at 4 weeks; Partial Response (PR): At least 30% decrease; confirmed at 4 weeks; Stable Disease (SD): Neither PR nor PD criteria met; Progressive Disease (PD): 20% increase; no CR, PR or SD documented before increased disease, or new lesion(s).', 'timeFrame': 'Baseline to Disease Progression (restaged at 8 weeks and at 4 months)'}]",[],1,,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,44.0,ACTUAL,2025-09-01T16:18:23.463779,v2_robust,True,True,False,True,False,Slow Accrual
NCT05720273,Neutrophil Gelatinase-associated Lipocalin VS Vascular Calcification in Maintenance Hemodialysis Patients,The Effect of Neutrophil Gelatinase-associated Lipocalin Derived From Osteoblasts and Vascular Smooth Muscle Cells on Vascular Calcification in Chronic Kidney Desease and the Intervention of Paliscalcitol - Clinical Research Section,palicalcitol,"['Calcimimetics', 'palicalcitol', 'Calcitriol']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Kidney Disease-Mineral and Bone Disorder,['Chronic Kidney Disease-Mineral and Bone Disorder'],"['Chronic Kidney Disease-Mineral and Bone Disorder', 'Calcitriol Receptor', 'Lipocalin-2', 'Vascular Calcification']",RECRUITING,,2023-04-01,2025-03-31,"[{'measure': 'Change from Baseline plasma NGAL levels at 12months', 'description': 'Elisa', 'timeFrame': '12months'}]","[{'measure': 'Change from baseline vascular calcification at 12months', 'description': 'Coronary calcification scores (CACS) from serial computed tomographic images with the Agatston method is used to evaluate cardio-vascular calcification, 1 point=130\\~199HU；2 points=200\\~299HU；3 points =300\\~399HU；4 points≥400HU. Abdominal aortic calcification score (AACS) is measured by Kauppila method from lateral dual-energy X-ray absorptiometry spine, 0-3 points. Anterior chest radiographs is used to perform simple calcification scores for aortic arch knob, 0-100%. Higher scores mean a worse outcome.', 'timeFrame': '12months'}]",2,18 Years,65 Years,ALL,False,Xiaoyan Jia,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:23.463797,v2_robust,True,True,False,False,False,
NCT00329173,PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.,"A 6-Week Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-Group Study to Compare the Efficacy and Safety of Rosuvastatin (10 mg) With Atorvastatin (20 mg) in Subjects With Hypercholesterolaemia and Either a History of CHD or Clinical Evidence of CHD",Rosuvastatin,"['Atorvastatin', 'Rosuvastatin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypercholesterolaemia,['Hypercholesterolaemia'],[],COMPLETED,,2003-11,2004-08,[{'measure': 'Reduction in LDL-c after 6 weeks'}],"[{'measure': 'Changes in other lipids and lipoproteins'}, {'measure': 'Achievement of NCEP -ATP III target goal LDL-Cholesterol and non HDL-C'}, {'measure': 'Achievement of EAS LDL-c and non HDL-C target goals after 6 weeks treatment.'}, {'measure': 'Comparison of cost effectiveness and also safety'}]",5,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,1000.0,,2025-09-01T16:18:23.463957,v2_robust,True,True,True,False,True,
NCT04724473,A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris,"A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris",Tretinoin Cream 0.025%,"['Tretinoin Cream 0.025%', 'Tretinoin']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Acne Vulgaris,['Acne Vulgaris'],[],COMPLETED,,2019-12-10,2020-11-21,"[{'measure': 'Demonstration of Bioequivalence', 'description': 'To evaluate the percentage change in the inflammatory and non-inflammatory lesion counts', 'timeFrame': 'Baseline to Week 12'}]",[],1,12 Years,40 Years,ALL,True,"Sun Pharmaceutical Industries, Inc.",INDUSTRY,0,1030.0,ACTUAL,2025-09-01T16:18:23.463968,v2_robust,True,True,True,False,False,
NCT01890473,Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe,"Phase Ib, Multicenter, Randomized, Open-Label, Parallel-Group Study to Characterize the Pharmacokinetics of a Single Dose of Abatacept 125 mg Administered Subcutaneously Using the BD Physioject™ Autoinjector or the UltraSafe Passive Needle Guard Prefilled Syringe",Abatacept,"['Orencia', 'Abatacept', 'BMS-188667']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],[],COMPLETED,,2013-07,2014-11,"[{'measure': 'Adjusted Geometric Mean of Maximum Observed Serum Concentration (Cmax) of a Single Dose of Subcutaneous (SC) Abatacept - PK-Evaluable Analysis Population', 'description': 'Serum concentrations of abatacept were analyzed using a validated enzyme-linked immunosorbent assay (ELISA). Cmax was measured in micrograms per milliliter (μg/mL). Blood samples for pharmacokinetic (PK) parameters were collected at Day 1 pre-dose at 0 hour (h), 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC.', 'timeFrame': 'Day 1 to Day 71'}, {'measure': 'Adjusted Geometric Mean of Area Under the Serum Concentration-time Curve (AUC) From Zero to the Last Time of the Last Quantifiable Concentration (0-T) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population', 'description': 'Serum concentrations of abatacept were analyzed using ELISA. AUC (0-T) was measured in μg\\*h/mL. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC.', 'timeFrame': 'Day 1 to Day 71'}, {'measure': 'Adjusted Geometric Mean of Area Under the Serum Concentration-time Curve From Time Zero to Extrapolated to Infinity, AUC (INF), of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population', 'description': 'Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 hour (h), 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. AUC (INF) was measured in μg\\*h/mL', 'timeFrame': 'Day 1 to Day 71'}]","[{'measure': 'Median of Time to Reach Cmax in Serum (Tmax) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population', 'description': 'Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. Tmax was measured in hours (h).', 'timeFrame': 'Day 1 to Day 71'}, {'measure': 'Mean of Terminal Phase Elimination Half-life in Serum (T-HALF) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population', 'description': 'Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. T-HALF was measured in hours (h).', 'timeFrame': 'Day 1 to Day 71'}, {'measure': 'Geometric Mean of Total Body Clearance (CL/F) of a Single Dose of SC Abatacept - PK-Evaluable Analysis Population', 'description': 'Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. CL/F was measured in milliliters per hour per kilogram body weight (mL/h/kg).', 'timeFrame': 'Day 1 to Day 71'}, {'measure': 'Geometric Mean of Volume of Distribution (V/F) of a Single Dose of Subcutaneous (SC) Abatacept - PK-Evaluable Analysis Population', 'description': 'Serum concentrations of abatacept were analyzed using ELISA. Blood samples were collected at Day 1 pre-dose at 0 h, 1, 2, and 8 h post dose, and on subsequent Days, 2 (24 h post dose), 3 (48 h), 5 (96 h), 8 (168 h), 15 (336 h), 29 (672 h) , 43 (1008 h), 57 (1344 h) and 71 (1680 h) following the single administration of abatacept SC. V/F was measured in liters per kilogram body weight (L/kg)', 'timeFrame': 'Day 1 to Day 71'}, {'measure': 'Number of Participants Who Had Serious Adverse Events (SAEs), Adverse Events (AEs) That Led to Discontinuation, or Who Died', 'description': 'AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Includes data Day 1 up to 76 days (71 days + 5 day window) post the single dose of study drug.', 'timeFrame': 'Day 1 to 76 days post single dose'}, {'measure': 'Number of Participants With Adverse Events of Special Interest', 'description': 'Prospectively identified events of special interest which were a subset of all AEs, and were either SAEs or non-serious AEs, included the following categories: Infections, Autoimmune Disorders, Malignancy, local site reactions, any AE occurring within 24 hours of SC injection. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.', 'timeFrame': 'Day 1 to 76 days post single dose'}, {'measure': 'Number of Participants With a Positive Immunogenicity Response Relative to Baseline', 'description': ""Blood samples were screened at baseline, Day 57 and Day 71 for the presence of drug-specific antibodies using Electrochemiluminescence (ECL). A positive immunogenicity response relative to baseline for Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4) and 'possibly immunoglobulin (Ig)', and 'Ig and/or Junction Region', respectively, was defined as: A missing baseline immunogenicity measurement and a positive analytical laboratory reported immunogenicity response post-baseline; A negative baseline immunogenicity response and a positive analytical laboratory reported immunogenicity response post-baseline; A positive baseline immunogenicity response and a positive analytical laboratory reported immunogenicity response post-baseline that has a titer value strictly greater than the baseline titer value. Baseline=Pre-dose value."", 'timeFrame': 'Day 57, Day 71'}, {'measure': 'Number of Participants With Blood Hematology, Chemistry Laboratory Values and Urinalysis Laboratory Values Meeting the Marked Abnormality Criteria', 'description': 'Marked abnormality criteria: lower limit of normal (LLN); upper limit of normal (ULN); pretreatment (preRX); cells per microliter (cµ/L); milligram per deciliter (mg/dL); milliequivalent (mEq): Hematology: leukocytes (\\*10\\^3 c/µL): \\<0.75\\*LLN or \\>1.25\\*ULN, or if preRX \\<LLN, use \\<0.8\\*preRX or \\>ULN, or if preRX\\>ULN, use \\>1.2\\*preRX or \\<LLN; eosinophils (\\*10\\^3 cµ/L): if value \\>0.750\\*10\\^3 c/µL; lymphocytes (\\*10\\^3 cµ/L): if value \\<0.750\\*10\\^3 c/µL or if value \\>7.50\\*10\\^3 c/µL. Chemistry: blood urea nitrogen (mg/dL): \\>2\\*preRX; creatinine (mg/dL): \\>1.5\\*preRX; potassium (mEq/L): \\<0.9\\*LLN or \\>1.1\\*ULN, or if preRX\\<LLN, use \\<0.9\\*preRX or \\>ULN, or if preRX\\>ULN, use 1.1\\*preRX or \\<LLN; glucose (mg/dL): \\<65 mg/dL (low) or \\>220 mg/dL (high). Urine Blood, urine red blood cell (RBC), urine white blood cell (WBC): if missing PreRX use \\>= 2, or if Value \\>= 4, or if preRX = 0 or 0.5 then use \\>= 2, or if preRX = 1 then use \\>= 3, or if preRX = 2 or 3 then use \\>= 4.', 'timeFrame': 'Day 1 to 76 days post last dose'}]",11,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,356.0,ACTUAL,2025-09-01T16:18:23.463983,v2_robust,True,True,True,False,True,
NCT04095273,"Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug","A Multicenter, Non-randomized, Open-label Phase 1b Study to Determine the Maximum Tolerated and Recommended Phase 2 Dose of the ATR Inhibitor Elimusertib in Combination With Pembrolizumab and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Participants With Advanced Solid Tumors",Elimusertib (BAY1895344),"['Pembrolizumab (Keytruda®)', 'Elimusertib (BAY1895344)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumors,['Advanced Solid Tumors'],"['DDR (Deoxyribonucleic acid damage repair),', 'ATR (ataxia-telangiectasia and Rad3 related protein)inhibitor,']",COMPLETED,,2019-09-30,2023-04-11,"[{'measure': 'Incidence of Treatment Emergent Adverse Events (TEAEs) including Treatment Emergent Serious Adverse Events (TESAEs)', 'timeFrame': 'Up to 30 days after last study intervention administration'}, {'measure': 'Severity of Treatment Emergent Adverse Events (TEAEs) including Treatment Emergent Serious Adverse Events (TESAEs)', 'timeFrame': 'Up to 30 days after last study intervention administration'}, {'measure': 'Frequency of Dose limiting toxicities (DLTs) at each dose level during dose escalation of BAY1895344', 'timeFrame': 'Cycle 1 (21 days)'}, {'measure': 'Recommended phase II dose (RP2D) of BAY1895344', 'description': 'The RP2D will be determined in dose expansion part based on multiple parameters (i.e., safety, tolerability, PK, pharmacodynamics, efficacy) and will be a dose equal to or lower than the MTD (Maximum Tolerated Dose).', 'timeFrame': 'Up to 24 months'}]","[{'measure': 'Cmax of Elimusertib', 'timeFrame': 'Cycle 1 (21 days), Day 8 (dosing schedule 1) or Cycle 1 (21 days), Day 1 (dosing schedule 2)'}, {'measure': 'AUC(0-12) of Elimusertib', 'description': 'If the main parameters AUC(0-12) cannot be calculated reliably, it might become necessary to appoint the additional parameters AUC(0-tlast) as secondary variables.', 'timeFrame': 'Cycle 1 (21 days), Day 8 (dosing schedule 1) or Cycle 1 (21 days), Day 1 (dosing schedule 2)'}, {'measure': 'Cmax,md of Elimusertib', 'timeFrame': 'Cycle 1 (21 days), Day 17 (dosing schedule 1) or Cycle 1 (21 days), Day 10 (dosing schedule 2)'}, {'measure': 'AUC(0-12)md of Elimusertib', 'description': 'If the main parameters AUC(0-12)md cannot be calculated reliably, it might become necessary to appoint the additional parameters AUC(0-tlast)md as secondary variables.', 'timeFrame': 'Cycle 1 (21 days), Day 17 (dosing schedule 1) or Cycle 1 (21 days), Day 10 (dosing schedule 2)'}, {'measure': 'Incidence of Complete response (CR)', 'description': 'Per RECIST 1.1 and for participants with mCRPC consistent with recommendations of the Prostate Cancer Working Group (PCWG3)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Incidence of partial response (PR)', 'description': 'Per RECIST 1.1 and for participants with mCRPC consistent with recommendations of the Prostate Cancer Working Group (PCWG3)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Incidence of stable disease (SD)', 'description': 'Per RECIST 1.1 and for participants with mCRPC consistent with recommendations of the Prostate Cancer Working Group (PCWG3)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Incidence of progressive disease (PD)', 'description': 'Per RECIST 1.1 and for participants with mCRPC consistent with recommendations of the Prostate Cancer Working Group (PCWG3)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Objective Response Rate (ORR)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Disease control rate (DCR)', 'timeFrame': 'Up to 24 months'}]",14,18 Years,,ALL,False,Bayer,INDUSTRY,1,56.0,ACTUAL,2025-09-01T16:18:23.464095,v2_robust,True,True,True,False,True,
NCT01529073,Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection,Phase II Clinical Trial to Evaluate the Antiviral Activity of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in Individuals With Chronic Hepatitis Due to HCV Genotype 4 and Coinfected by HIV,Nitazoxanide,"['Alinia', 'Annita', 'Daxon', 'Mitafar', 'Zox', 'Toza', 'Pacovanton', 'Nitax', 'Paramix', 'Nitazox', 'Niazid', 'Nitazoxanide', 'Dexidex', 'Kidonax']",14,INTERVENTIONAL,['PHASE2'],PHASE2,,HCV Coinfection,"['HCV Coinfection', 'HIV Infection']","['HIV', 'genotype 4 HCV', 'pegylated interferon', 'ribavirin', 'nitazoxanide']",UNKNOWN,,2012-02,2015-02,"[{'measure': 'Sustained virological response', 'description': 'The proportion of patients with HCV RNA ≤10 IU/ml 24 weeks after finishing the programmed length of treatment (52 weeks).', 'timeFrame': '24 weeks after finishing the scheduled treatment'}]","[{'measure': 'Safety of Peg-interferon plus ribavirin plus nitazoxanide', 'description': 'The proportion of patients with grade 3 or 4 adverse events according to the WHO classification.', 'timeFrame': 'Every 4 weeks until 28 weeks of treatment, then every 8 weeks until the end of treatment (52 weeks)'}]",2,18 Years,65 Years,ALL,False,Juan Macías,OTHER_GOV,1,45.0,ESTIMATED,2025-09-01T16:18:23.464106,v2_robust,True,True,False,False,True,
NCT05772273,"PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT","Efficacy and Safety of PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation",Azacitidine,"['Azacitidine', 'Camrelizumab']",2,INTERVENTIONAL,['NA'],,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],"['PD-1 inhibitor', 'Azacitidine', 'low-dose DLI']",RECRUITING,,2023-03-15,2025-12-31,"[{'measure': 'Overall response rate (ORR)', 'description': 'The overall response (completed remission, completed remission with incomplete blood count recovery)', 'timeFrame': 'ORR assessment is at day 39 (±2).'}]","[{'measure': 'Overall Survival (OS)', 'description': 'OS is measured from the time of enrollment to this trial to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive.', 'timeFrame': '2 years'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS is measured from the time of enrollment to this study to progression or death.', 'timeFrame': '2 years'}, {'measure': 'Adverse events', 'description': 'It is evaluated and graded according to CTCAE 5.0.', 'timeFrame': '1 month'}]",4,,,ALL,False,The First Affiliated Hospital of Soochow University,OTHER,1,43.0,ESTIMATED,2025-09-01T16:18:23.464122,v2_robust,True,True,False,False,True,
NCT02485873,Real-Life Evidence on Stroke Prevention in SPAF,REal-LIfe Evidence on Stroke Prevention in Patients With Atrial Fibrillation,"Rivaroxaban (Xarelto, BAY59-7939)","['Rivaroxaban (Xarelto, BAY59-7939)', 'Vitamin K antagonists']",2,OBSERVATIONAL,[],,,Atrial Fibrillation (Prevention of Stroke),['Atrial Fibrillation (Prevention of Stroke)'],"['Non-valvular atrial fibrillation (NVAF)', 'Pevention', 'Stroke']",COMPLETED,,2015-05,2015-09,"[{'measure': 'Time to first occurrence of any of the following: Ischemic stroke (IS), Transient ischemic attack (TIA), Intracerebral hemorrhage (IH), Other non-traumatic intracranial hemorrhage including subdural hemorrhage, Myocardial infarction (MI)', 'description': 'Composite cardiovascular endpoint', 'timeFrame': 'Within 1 year after treatment start'}]","[{'measure': 'Time to first occurrence of IS', 'description': 'Single cardiovascular event', 'timeFrame': 'Within 1 year after treatment start'}, {'measure': 'Time to first occurrence of TIA', 'description': 'Single cardiovascular event', 'timeFrame': 'Within 1 year after treatment start'}, {'measure': 'Time to first occurrence of IH', 'description': 'Single cardiovascular event', 'timeFrame': 'Within 1 year after treatment start'}, {'measure': 'Time to first occurrence of Other non-traumatic intracranial hemorrhage including subdural hemorrhage', 'description': 'Single cardiovascular event', 'timeFrame': 'Within 1 year after treatment start'}, {'measure': 'Time to first occurrence of MI', 'description': 'Single cardiovascular event', 'timeFrame': 'Within 1 year after treatment start'}, {'measure': 'Incidence density in study population of IS', 'timeFrame': 'Within 1 year after treatment start'}, {'measure': 'Incidence density in study population of TIA', 'timeFrame': 'Within 1 year after treatment start'}, {'measure': 'Incidence density in study population of IH', 'timeFrame': 'Within 1 year after treatment start'}, {'measure': 'Incidence density in study population of Other non-traumatic intracranial hemorrhage including subdural hemorrhage', 'timeFrame': 'Within 1 year after treatment start'}, {'measure': 'Incidence density in study population of MI', 'timeFrame': 'Within 1 year after treatment start'}, {'measure': 'Incidence density in study population of any of the following: IS, TIA, IH, Other non-traumatic intracranial hemorrhage including subdural hemorrhage, MI', 'timeFrame': 'Within 1 year after treatment start'}]",12,18 Years,,ALL,False,Bayer,INDUSTRY,1,8607.0,ACTUAL,2025-09-01T16:18:23.464184,v2_robust,False,True,True,False,False,
NCT01600573,Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ),A Phase I/II Study of Pazopanib and Weekly Topotecan in Patients With Platinum-resistant or Intermediate-sensitive Recurrent Ovarian Cancer,pazopanib in combination with weekly topotecan,"['pazopanib in combination with weekly topotecan', 'pazopanib in combination with weekly topotean']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Ovarian Cancer,['Ovarian Cancer'],['ovarian cancer'],UNKNOWN,,2012-05,2017-03,"[{'measure': 'Phase I: Assessment of dose-limiting toxicity in order to determine the maximum tolerated dose (MTD) of pazopanib in combination with weekly topotecan', 'description': 'Dose-limiting toxicities are defined as follows:\n\n* grade 3 or 4 non-hematologic toxicity other than nausea or vomiting\n* grade 3 or 4 thrombocytopenia (platelet count less than 50000/µl)\n* grade 4 neutropenia lasting ≥ 7 days or febrile neutropenia defined as ANC \\<1000/µl concurrent with fever\n* Any grade 2 and more toxicity of cycle 1 other than nausea, vomiting, rash, alopecia or anemia, that persisted over 35 days.', 'timeFrame': 'after 4 weeks'}, {'measure': '• Phase II: Progression-free survival according to RECIST criteria', 'description': '• Phase II: Progression-free survival according to RECIST criteria', 'timeFrame': 'up to 3.5 years'}]","[{'measure': '• Overall survival', 'description': '• Overall survival', 'timeFrame': 'up to 3.5 years'}, {'measure': '• Response rate (CR, PR) according to RECIST criteria', 'description': '• Response rate (CR, PR) according to RECIST criteria', 'timeFrame': 'up to 3.5 years'}, {'measure': '• Clinical benefit rate (CR, PR, SD)', 'description': '• Clinical benefit rate (CR, PR, SD)', 'timeFrame': 'up to 3.5 years'}, {'measure': '• Duration of response', 'description': '• Duration of response', 'timeFrame': 'up to 3.5 years'}, {'measure': '• Time to progression (TTP)', 'description': '• Time to progression (TTP)', 'timeFrame': 'up to 3.5 years'}, {'measure': '• Evaluation of CA-125 tumour response', 'description': '• Evaluation of CA-125 tumour response', 'timeFrame': 'up to 3.5 years'}, {'measure': 'Safety and tolerability of pazopanib in combination with weekly topotecan', 'description': 'Incidence and type of AE in terms of:\n\n* All AE,\n* Related AE,\n* SAE,\n* Related SAE,\n* NCI-CTC (version 4.0) grade 3 and 4 AE,\n* Related NCI-CTC (version 4.0) grade 3 and 4 AE,\n* AE leading to treatment discontinuation,\n* Incidence of, and reason for, deaths.', 'timeFrame': 'up to 3.5 years'}, {'measure': '• Quality of life as defined by EORTC-QLQ C 30 and Ovar 28 questionnaire', 'description': '• Quality of life as defined by EORTC-QLQ C 30 and Ovar 28 questionnaire', 'timeFrame': 'up to 3.5 years'}]",10,18 Years,,FEMALE,False,JSehouli,OTHER,1,68.0,ESTIMATED,2025-09-01T16:18:23.464207,v2_robust,True,True,False,False,True,
NCT01956669,Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors,"A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors",Pazopanib,"['GW786034', 'Pazopanib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Solid Tumours,['Solid Tumours'],"['VEGF', 'Pazopanib', 'Sarcoma', 'GW786034', 'Refractory Solid Tumors']",COMPLETED,,2014-10-08,2019-11-05,"[{'measure': ""Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Primary Interest (RMS, NRSTS or Ewing Sarcoma/pPNET)"", 'description': 'ORR was defined as the percentage of participants achieving either a Complete Response (CR) or partial Response (PR) based on the Investigator review. The responses were assessed by CT or MRI based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST1.1). CR, disappearance of all target and non-target lesions; PR, at least a 30% decrease in the disease measurement, taking as reference the disease measurement done to confirm measurable disease at study enrollment, also no new lesion or progression of any non-target measurable lesion. Confirmation was based on the disease assessment at 1 cycle or at the next scheduled visit after the initial response. Only descriptive analysis performed.', 'timeFrame': 'From date of first dose of study treatment up to 55 months'}]","[{'measure': ""Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Secondary Interest (Osteosarcoma, mNeuroblastoma, eNeuroblastoma or Hepatoblastoma)"", 'description': 'ORR was defined as the percentage of participants achieving either a Complete Response (CR) or partial Response (PR) based on the Investigator review. For solid tumors with measurable diseases, such as osteosarcoma, the responses was based on RECIST1.1. CR, disappearance of all target and non target lesions; PR, at least a 30% decrease in the disease measurement, taking as reference the disease measurement done to confirm measurable disease at study enrollment, also no new lesion or progression of any non-target measurable lesion. For neuroblastoma with bone marrow response, morphology was determined by hematoxylin and eosin staining of the marrow and aspirates. For neuroblastoma MIBG+ only, the responses was assessed using Curie scale for lesion scoring; For hepatoblastoma, assessment may have included the serum AFP response, in addition to the RECIST1.1 methodology. Only descriptive analysis performed.', 'timeFrame': 'From date of first dose of study treatment up to 55 months'}, {'measure': 'Progression Free Survival (PFS) as Assessed by the Investigator by Cohort', 'description': 'PFS was defined as the interval between the date of first dose of study medication and the earliest date of disease progression or death due to any cause. Disease progression was based on radiographic evidence, and assessments made by the investigator. According to RECIST1.1, disease progression was defined as at least a 20% increase in the sum of the disease measurements for measurable lesions, taking as reference the smallest disease measurement recorded since the start of treatment, or the appearance of one or more new lesions. For participants who did not progress or die, PFS was censored at the date of last adequate assessment or date of last adequate assessment prior to initiation of new anti-cancer therapy. Only descriptive analysis performed.', 'timeFrame': 'From date of first dose of study treatment up to 59 months'}, {'measure': 'Time to Progression (TTP) by Cohort', 'description': 'The TTP was defined as the interval between the date of first dose of protocol therapy and the earliest date of disease progression or death due to disease under study. Subjects were considered to have progressive disease if they had documented progression based on radiologic assessment as determined by investigator review. According to RECIST1.1, disease progression was defined as at least a 20% increase in the sum of the disease measurements for measurable lesions, taking as reference the smallest disease measurement recorded since the start of treatment, or the appearance of one or more new lesions. Only descriptive analysis performed.', 'timeFrame': 'From date of first dose of study treatment up to 59 months'}, {'measure': 'Percentage of Participants Achieving Clinical Benefit Rate (CBR) by Cohort', 'description': 'CBR was defined as the percentage of participants achieving either a confirmed complete response (CR) or confirmed partial response (PR) or Stable Disease (SD) for at least two protocol scheduled disease assessments based on RECIST1.1. CR, disappearance of all target and non-target lesions; PR, at least a 30% decrease in the disease measurement, taking as reference the disease measurement done to confirm measurable disease at study enrollment, also no new lesion or progression of any non-target measurable lesion; SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Only descriptive analysis performed.', 'timeFrame': 'From date of first dose of study treatment up to 55 months'}, {'measure': 'Duration of Response (DOR) by Cohort', 'description': 'DoR was defined as the time from initial response to the first documented disease progression or death due to any cause, and was determined only for those participants from the mITT population with a confirmed response (CR or PR). Only descriptive analysis performed.', 'timeFrame': 'From date of first dose of study treatment up to 59 months'}, {'measure': 'Overall Survival (OS) by Cohort', 'description': 'OS was defined as the time from the first dose of the study medication until death due to any cause. Only descriptive analysis performed.', 'timeFrame': 'From date of first dose of study treatment up to 61 months'}, {'measure': 'Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort', 'description': 'AUC0-8h and AUClast were calculated using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) and the LLOQ was 0.100 µg/mL. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed.', 'timeFrame': 'Day 1 of Cycle 1 (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose); Cycle 1 Day 15 ± 1 day (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose)'}, {'measure': 'Observed Maximum Plasma Concentration (Cmax) of Pazopanib by Cohort', 'description': 'Cmax was calculated using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) and the LLOQ was 0.100 µg/mL. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed.', 'timeFrame': 'Day 1 of Cycle 1 (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose); Cycle 1 Day 15 ± 1 day (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose)'}, {'measure': 'Time to Reach Peak or Maximum Concentration (Tmax) of Pazopanib by Cohort', 'description': 'Tmax was calculated using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) and the LLOQ was 0.100 µg/mL. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed.', 'timeFrame': 'Day 1 of Cycle 1 (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose); Cycle 1 Day 15 ± 1 day (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose)'}, {'measure': 'Pazopanib Steady-state Trough (Ctrough) Levels for Participants With Drug-related Grade 2 and Above Hypertension', 'description': 'The relationship between toxicity (including hypertension) and pharmacokinetic parameters (pazopanib trough concentration) was analyzed. Only descriptive analysis performed.', 'timeFrame': 'From date of first dose of study treatment up to 61 months'}, {'measure': 'Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1', 'description': 'The frequency of genetic alterations observed in participants was presented by high and low baseline plasma levels for Vascular endothelial growth factor A (VEGF-A) and Vascular endothelial growth factor receptor 1 (VEGFR-1) biomarkers. The VEGFA and VEGFR1 levels above the median were classified as high and participants with median levels or below were classified as low. Only descriptive analysis performed for participants presenting with a genetic alteration.', 'timeFrame': 'predose Cycle 1 Day 1, Cycle 2 Day 1'}, {'measure': 'Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort', 'description': 'The following biomarker parameters were analyzed: proto-oncogene c-KIT (c-KIT), Fibroblast growth factor (FGF), Placental growth factor PGF), Angiopoietin-1 receptor (TIE2), Vascular endothelial growth factor A (VEGF-A), Vascular endothelial growth factor C (VEGF-C), Vascular endothelial growth factor D (VEGF-D), Vascular endothelial growth factor receptor 1 (VEGFR-1) and Vascular endothelial growth factor receptor 2 (VEGFR-2)). Only descriptive analysis performed.', 'timeFrame': 'predose Cycle 1 Day 1, Cycle 2 Day 1'}, {'measure': 'Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort', 'description': 'Participants with steady state trough concentration median levels for the following biomarker parameters (proto-oncogene c-KIT (c-KIT), Fibroblast growth factor (FGF), Placental growth factor PGF), Angiopoietin-1 receptor (TIE2), Vascular endothelial growth factor A (VEGF-A), Vascular endothelial growth factor C (VEGF-C), Vascular endothelial growth factor D (VEGF-D), Vascular endothelial growth factor receptor 1 (VEGFR-1) and Vascular endothelial growth factor receptor 2 (VEGFR-2)) above the median levels were classified as high or below median levels were classified as low. Only descriptive analysis performed.', 'timeFrame': 'predose Cycle 1 Day 1, Cycle 2 Day 1'}]",14,1 Year,18 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,1,57.0,ACTUAL,2025-09-01T16:18:23.464257,v2_robust,True,True,True,False,False,
NCT03703869,"Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.","A 12-month Prospective Observational Study Assessing the Real-world Clinical Effectiveness, Safety and Health-economic Benefits of Toujeo® Initiation After Oral Antidiabetic Drug Failure in Insulin-naïve Patients With Type 2 Diabetes Mellitus",Insulin glargine (U300),"['Insulin glargine (U300)', 'HOE901, Toujeo, Toujeo Solostar']",2,OBSERVATIONAL,[],,,Diabetes,['Diabetes'],[],COMPLETED,,2018-03-06,2020-02-24,"[{'measure': 'Change in HbA1c at month 6', 'description': 'Percentage of patients achieving Hemoglobin A1c \\<7.0%.', 'timeFrame': 'Baseline, month 6'}]","[{'measure': 'Change in HbA1c', 'description': 'Change from baseline in HbA1c at 3, 6, and 12 months', 'timeFrame': 'Baseline, months 3, 6, 12'}, {'measure': 'Change in fasting plasma glucose', 'description': 'Change from baseline in Fasting Plasma Glucose at 3, 6, and 12 months', 'timeFrame': 'Baseline, months 3, 6, 12'}, {'measure': 'Change in Self-Monitored Plasma Glucose', 'description': 'Change from baseline in Self-Monitored Plasma Glucose at 3, 6, and 12 months', 'timeFrame': 'Baseline, months 3, 6, 12'}, {'measure': 'Hypoglycemia', 'description': 'Number of participants with symptomatic hypoglycemic events', 'timeFrame': 'Baseline to month 12'}, {'measure': 'Adverse events', 'description': 'Number of participants with Adverse Events', 'timeFrame': 'Baseline to month 12'}, {'measure': 'Serious adverse events', 'description': 'Number of participants with Serious Adverse Events', 'timeFrame': 'Baseline to month 12'}, {'measure': 'Body weight', 'description': 'Change in average body weight', 'timeFrame': 'Baseline to month 12'}]",8,18 Years,,ALL,False,Sanofi,INDUSTRY,0,4589.0,ACTUAL,2025-09-01T16:18:23.464347,v2_robust,False,True,True,False,True,
NCT02351869,Nitrous Oxide as a Putative Novel Dual-Mechanism Treatment for Bipolar Disorder,Nitrous Oxide as a Putative Novel Dual-Mechanism Treatment for Bipolar Disorder,Nitrous Oxide,"['Nitrous Oxide', 'Midazolam']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Bipolar Disorder,['Bipolar Disorder'],[],TERMINATED,This study was terminated due to COVID-19 pandemic-related halting of recruitment in the context of an upcoming replacement of the study MRI scanner.,2015-08,2020-06-07,"[{'measure': 'Change in Montgomery-Asberg Depression Scale (MADRS) score', 'description': 'Measures mood symptom severity, used to select patients and assess treatment efficacy. Although other time-points will be examined, 24h was selected as the primary outcome to minimize the impact of acute sedation and psychoactive effects.', 'timeFrame': 'Assessed at baseline, an average of 3 days later, again at up to 5 days after baseline on the day of drug administration, and participants will be followed for 7 days after the drug administration'}]","[{'measure': 'Young Mania Rating Scale (YMRS)', 'description': 'Measures symptom severity', 'timeFrame': 'Assessed at baseline, an average of 3 days later, again at up to 5 days after baseline on the day of drug administration, and participants will be followed for 7 days after the drug administration'}, {'measure': 'Blood Pressure', 'timeFrame': 'Measured an average of 3 days post-baseline and again approximately every hour on the drug administration day'}, {'measure': 'Weight', 'timeFrame': 'Assessed an average of 3 days after baseline'}, {'measure': 'Beck Depression Inventory (BDI-II)', 'description': 'Self-report measure of mood severity', 'timeFrame': 'Assessed on the drug administration day and followed for 7 days post-drug administration'}, {'measure': 'Heart Rate', 'timeFrame': 'Measured an average of 3 days post-baseline and again approximately every hour on the drug administration day'}, {'measure': 'Brief Psychiatric Rating Scale', 'timeFrame': 'Assessed on the drug administration day and followed for 7 days post-drug administration'}, {'measure': 'The Clinician Administered Dissociative States Scale (CADSS)', 'timeFrame': 'Assessed on the drug administration day and followed for 7 days post-drug administration'}, {'measure': 'General Information Sheet (Demographics)', 'description': 'Demographics', 'timeFrame': 'Collected at baseline'}, {'measure': 'Hamilton Anxiety Rating Scale (HAM-A)', 'description': 'Interview measure used to assess anxiety severity', 'timeFrame': 'Assessed on the drug administration day and followed for 7 days post-drug administration'}, {'measure': 'Hamilton Depression Rating Scale (HDRS)', 'description': 'Interview measure used to assess mood severity', 'timeFrame': 'Assessed on the drug administration day and followed for 7 days post-drug administration'}, {'measure': 'Patient Rated Inventory of Side Effects', 'description': 'Self-report used to assess side effects', 'timeFrame': 'Assessed on the drug administration day and followed for 7 days post-drug administration'}, {'measure': 'CANTAB Medication Listing', 'description': 'Used to collect medications taken the day before and on the day of blood work', 'timeFrame': 'Assessed an average of 3 days after baseline'}, {'measure': 'Structured Clinical Interview for DSM Disorders', 'description': 'Interview measure used to assess DSM disorders', 'timeFrame': 'Assessed at baseline'}, {'measure': 'Visual Analogue Scale', 'timeFrame': 'Assessed on the drug administration day and followed for 7 days post-drug administration'}, {'measure': 'Height', 'timeFrame': 'Assessed an average of 3 days after baseline'}, {'measure': 'Endothelial Function assessed via RH-PAT using the EndoPAT.', 'description': 'Will be assessed via RH-PAT using the EndoPAT.', 'timeFrame': 'Assessed an average of 3 days after baseline and lasts approximately 30 minutes'}, {'measure': 'Frontal Perfusion assessed using an MRI scan', 'description': 'Will be assessed using an MRI scan.', 'timeFrame': 'Assessed approximately 5 days after baseline and post-drug administration'}, {'measure': 'Biomarkers (B12 and nitric oxide (NO))', 'description': 'B12 and nitric oxide (NO) will be examined as predictors of response owing to known associations with the mechanism of action of N2O.', 'timeFrame': 'Assessed an average of 3 days after baseline'}]",19,20 Years,60 Years,ALL,False,Sunnybrook Health Sciences Centre,OTHER,0,25.0,ACTUAL,2025-09-01T16:18:23.464504,v2_robust,True,True,False,True,False,This study was terminated due to COVID-19 pandemic-related halting of recruitment in the context of an upcoming replacement of the study MRI scanner.
NCT01188369,Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy,Effects of Levosimendan on Systolic Deformation and Diastolic Function in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy,levosimendan,"['Simdax', 'levosimendan', 'Placebo', 'placebo drug']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Diastolic Dysfunction,"['Diastolic Dysfunction', 'Left Ventricular Hypertrophy']","['levosimendan', 'heart failure', 'inotropics', 'diastolic dysfunction', 'left ventricular hypertrophy', 'aortic valve stenosis']",TERMINATED,Terminated prematurely due to high incidence of postoperative atrial fibrillation.,2010-09,2013-03,"[{'measure': ""E/E'(Unitless)"", 'description': ""Ration between early transmitral flow (E) and mitral annular tissue velocity(E'). This ratio is an echocardiographic index of diastolic function"", 'timeFrame': '4 hours before operation until 21 hour after operation'}]","[{'measure': 'Isovolumetric Relaxation Time (IVRT) (s)', 'description': 'Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function', 'timeFrame': '4 hours before surgery until 1 hour before operation'}, {'measure': 'Ejection Fraction (Per Cent)', 'description': 'Transeosophageal echocardiography: Measure of systolic function', 'timeFrame': 'At start of operation until end of operation, approximately 3 hours'}, {'measure': 'Cardiac Index (l/Min/m2)', 'description': 'Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula)', 'timeFrame': '4 hours before operation until 1 hour before operation'}, {'measure': 'Central Venous Pressure (mmHg)', 'description': 'Invasive measurement of pressure in the vena cava', 'timeFrame': '4 hours before operation until 1 hours before operation'}, {'measure': 'Pulmonary Artery Pressures (mmHg)', 'description': 'Invasive measurement of mean pressure in the pulmonary artery', 'timeFrame': '4 hours before operation until 1 hour before operation'}, {'measure': 'Systemic Arterial Pressure (mmHg)', 'description': 'Invasive measurements of arterial mean pressure', 'timeFrame': '4 hours before operation until 1 hour before operation'}, {'measure': 'N-terminal Pro Brain Natriuretic Peptide (NT proBNP)(pg/ml)', 'description': 'blood sample reflecting stretch of the atrium/ventricle', 'timeFrame': '4 hours before operation until 4 hours after operation'}, {'measure': 'Troponin T (ug/l)', 'description': 'Blood sample expressing damage to the myocytes', 'timeFrame': '4 hours before operation until 4 hours after operation'}, {'measure': 'Lactate (mmol/l)', 'description': 'Arterial sampling of blood lactate', 'timeFrame': '4 hours before operation until 4 hour after operation'}, {'measure': 'Mixed Venous Oxygenation (Per Cent)', 'description': 'Oxygen content (per cent of hemoglobin saturated) of venous blood in pulmonary artery', 'timeFrame': '4 hours before operation until 4 hour after operation'}, {'measure': 'E/A Ratio (Unitless)', 'description': 'TEE ratio between early (E) transmitral flow and late (A) transmitral flow. An index of diastolic function althought not validated properly yet when measured from the oesophagus', 'timeFrame': 'At the start of operation until the end of operationon, approximately 3 hours'}, {'measure': 'Regional Longitudinal Strain (Unitless)', 'description': 'Transoesophageal echocardiographic (TEE) measure of systolic function. At this time not validated properly against acknowledged indices of systolic function.', 'timeFrame': 'At the start of operation until the end of operation, approximately 3 hours'}, {'measure': 'Need for Conventional Inotropical Agents', 'description': 'Conventional inotropics are comprised of all inotropics acting primarily through alfa- or beta- stimulation.', 'timeFrame': 'From start of operation until 5 days after operation'}, {'measure': 'Intravenous Fluid Requirement (l)', 'description': 'Total volume of intravenous fluid required including blood products.', 'timeFrame': 'Within 24 hours from start of operation'}, {'measure': 'Operation Time (Minutes)', 'timeFrame': 'From ""knife start"" until ""knife end"", approximately 3 hours'}, {'measure': 'Time on Heart-lung Machine (Minutes)', 'timeFrame': 'From time of cardioplegia until selfsufficient cardiac action, approximately 1 hour'}, {'measure': 'Intubation Time (Minutes)', 'description': 'Total time intubated including time of operation and in the intensive care ward', 'timeFrame': 'From intubation until extubation, approximately 6 hours'}, {'measure': 'Postoperative Admission Time at Intensive Care Unit (Hours)', 'description': 'Total admission time in the intensive care after operation', 'timeFrame': 'From admission to the intensive care unit until discharge from intensive care unit, approximately 24 hours'}, {'measure': 'No. of Patients With Adverse Events', 'description': 'Development of Ventricular tachycardia', 'timeFrame': '-4 hours until + 96 hours with respect to start of operation'}, {'measure': 'No. of Patients With Adverse Event', 'description': 'Development of atrial flutter/fibrillation', 'timeFrame': '-4 hours until + 96 hours with respect to start of operation'}, {'measure': 'No. of Patients With Adverse Event', 'description': 'Need for norepinephrine as an antagonist to the vasodilatatory effect of levosimendan', 'timeFrame': '4 hours before operaton until 1 hour before operaton'}, {'measure': 'No. of Patients With Adverse Event.', 'description': 'Occurence of nausea', 'timeFrame': '4 hours before operation until 1 hour before operation'}, {'measure': 'No. of Patients With Adverse Event', 'description': 'Occurence of headache', 'timeFrame': '4 hours before operation until approximately 1 hour before operation'}, {'measure': 'Regional Longitudinal Strain (Unitless)', 'description': 'Index of systolic function derived from single transthoracic echocardiographic (TTE) projection', 'timeFrame': '4 hours before until 1 hour before start of operation'}, {'measure': 'Ejection Fraction (Per Cent)', 'description': 'TTE: Index of systolic function', 'timeFrame': '1 hour before until 21 hour after start of operation'}, {'measure': 'Ejection Fraction (Per Cent)', 'description': 'TTE: Index of systolic function', 'timeFrame': '21 hours after operation until 96 hours after start of operation'}, {'measure': 'Ejection Fraction (Per Cent)', 'description': 'TTE: Index of systolic function', 'timeFrame': '96 hours after operation until 6 months after operation'}, {'measure': 'Regional Longitudinal Strain (Unitless)', 'description': 'Transoesophageal echocardiographic (TEE) measure of systolic function. At this time not validated properly against acknowledged indices of systolic function.', 'timeFrame': 'Froml the end of operation until approx 4 hours after operation'}, {'measure': 'E/A Ratio (Unitless)', 'description': 'TEE ratio between early (E) transmitral flow and late (A) transmitral flow. An index of diastolic function althought not validated properly yet when measured from the oesophagus', 'timeFrame': 'At the end of operationon until approx 4 hours after operation'}, {'measure': 'Left Ventricular Rotation (Degrees)', 'description': 'TTE: Index of both systolic and diastolic function', 'timeFrame': '96 hour after operation until 6 months after operation'}, {'measure': 'Mixed Venous Oxygenation (Per Cent)', 'description': 'Oxygen content (per cent of hemoglobin saturated) of venous blood in pulmonary artery', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'Lactate (mmol/l)', 'description': 'Arterial sampling of blood lactate', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'Troponin T (ug/l)', 'description': 'Blood sample expressing damage to the myocytes', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'Troponin T (ug/l)', 'description': 'Blood sample expressing damage to the myocytes', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'N-terminal Pro Brain Natriuretic Peptide (NT proBNP)(pg/ml)', 'description': 'blood sample reflecting stretch of the atrium/ventricle', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'N-terminal Pro Brain Natriuretic Peptide (NT proBNP)(pg/ml)', 'description': 'blood sample reflecting stretch of the atrium/ventricle', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'Systemic Arterial Pressure (mmHg)', 'description': 'Invasive measurements of arterial mean pressure', 'timeFrame': '1 hour before operation until start of operation'}, {'measure': 'Systemic Arterial Pressure (mmHg)', 'description': 'Invasive measurements of arterial mean pressure', 'timeFrame': 'Start of operation until the end of operation, approximately 3 hours'}, {'measure': 'Systemic Arterial Pressure (mmHg)', 'description': 'Invasive measurements of arterial mean pressure', 'timeFrame': 'End of operation until approx 4 hours after operation'}, {'measure': 'Systemic Arterial Pressure (mmHg)', 'description': 'Invasive measurements of arterial mean pressure', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'Pulmonary Artery Pressures (mmHg)', 'description': 'Invasive measurement of mean pressure in the pulmonary artery', 'timeFrame': '1 hour before operation until start of operation'}, {'measure': 'Pulmonary Artery Pressures (mmHg)', 'description': 'Invasive measurement of mean pressure in the pulmonary artery', 'timeFrame': 'Start of operation until end of operation, approximately 3 hours'}, {'measure': 'Pulmonary Artery Pressures (mmHg)', 'description': 'Invasive measurement of mean pressure in the pulmonary artery', 'timeFrame': 'End of operation until approx 4 hours after operation'}, {'measure': 'Pulmonary Artery Pressures (mmHg)', 'description': 'Invasive measurement of mean pressure in the pulmonary artery', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'Regional Longitudinal Strain (Unitless)', 'description': 'Index of systolic function derived from single transthoracic echocardiographic (TTE) projection', 'timeFrame': '1 hour before start of operation until 21 hours after operation'}, {'measure': 'Regional Longitudinal Strain (Unitless)', 'description': 'Index of systolic function derived from single transthoracic echocardiographic (TTE) projection', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'Regional Longitudinal Strain (Unitless)', 'description': 'Index of systolic function derived from single transthoracic echocardiographic (TTE) projection', 'timeFrame': '96 hours after operation until 6 months after operation'}, {'measure': 'Central Venous Pressure (mmHg)', 'description': 'Invasive measurement of pressure in the vena cava', 'timeFrame': '1 hour before operation until start of operation'}, {'measure': 'Central Venous Pressure (mmHg)', 'description': 'Invasive measurement of pressure in the vena cava', 'timeFrame': 'Start of operation until end of operation, approximately 3 hours'}, {'measure': 'Central Venous Pressure (mmHg)', 'description': 'Invasive measurement of pressure in the vena cava', 'timeFrame': 'End of operation until approx 4 hours after operation'}, {'measure': 'Central Venous Pressure (mmHg)', 'description': 'Invasive measurement of pressure in the vena cava', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'Peak Systolic Velocity (m/s)', 'description': 'Tissue Doppler measure of systolic function', 'timeFrame': '1 hour before operation until 21 hours after operation'}, {'measure': 'Peak Systolic Velocity (m/s)', 'description': 'Tissue Doppler measure of systolic function', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'Peak Systolic Velocity (m/s)', 'description': 'Tissue Doppler measure of systolic function', 'timeFrame': '96 hours after operation until 6 months after operation'}, {'measure': 'Tricuspid Annular Plane Systolic Excursion (TAPSE) (mm)', 'description': 'Transthoracic echocardiographic measure of systolic function', 'timeFrame': '1 hour before operation until 21 hours after operation'}, {'measure': 'Tricuspid Annular Plane Systolic Excursion (TAPSE) (mm)', 'description': 'Transthoracic echocardiographic measure of systolic function', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'Tricuspid Annular Plane Systolic Excursion (TAPSE) (mm)', 'description': 'Transthoracic echocardiographic measure of systolic function', 'timeFrame': '96 hours after operation until 6 months after operation'}, {'measure': 'E/A-ratio (Unitless)', 'description': 'Transthoracic echocardiographic ratio between early (E) and late (A) transmitral blood velocities. Index of diastolic function.', 'timeFrame': '1 hour before operation until 21 hours after operation'}, {'measure': 'E/A-ratio (Unitless)', 'description': 'Transthoracic echocardiographic ratio between early (E) and late (A) transmitral blood velocities. Index of diastolic function.', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'E/A-ratio (Unitless)', 'description': 'Transthoracic echocardiographic ratio between early (E) and late (A) transmitral blood velocities. Index of diastolic function.', 'timeFrame': '96 hours after operation until 6 months after operation'}, {'measure': ""E'/A'-Ratio (Unitless)"", 'description': 'Tissue Doppler transthoracic echocardiography: Ratio between tissue velocities at the mitral plan during early (E) diastole and late (A) diastole. Index of diastolic function.', 'timeFrame': '1 hour before operation until 21 hours after roperation'}, {'measure': ""E'/A'-Ratio (Unitless)"", 'description': 'Tissue Doppler transthoracic echocardiography: Ratio between tissue velocities at the mitral plan during early (E) diastole and late (A) diastole. Index of diastolic function.', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': ""E'/A'-Ratio (Unitless)"", 'description': 'Tissue Doppler transthoracic echocardiography: Ratio between tissue velocities at the mitral plan during early (E) diastole and late (A) diastole. Index of diastolic function.', 'timeFrame': '96 hours after operation until 6 months after operation'}, {'measure': 'Isovolumetric Relaxation Time (IVRT) (s)', 'description': 'Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function', 'timeFrame': '1 hour before operation until 21 hours after operation'}, {'measure': 'Isovolumetric Relaxation Time (IVRT) (s)', 'description': 'Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'Isovolumetric Relaxation Time (IVRT) (s)', 'description': 'Transthoracic measure of the time from aortic valve closure until mitral valve opening. A measure of diastolic function', 'timeFrame': '96 hours after operation until 6 months after operation'}, {'measure': 'Ejection Fraction (Per Cent)', 'description': 'Transeosophageal echocardiography: Measure of systolic function', 'timeFrame': 'End of operation until approx. 4 hours after operation'}, {'measure': 'Isovolumetric Relaxation Time (IVRT) (s)', 'description': 'Transeosophageal echocardiography: Time from closure of aortic valve to opening of mitral valve. Measure of diastolic function.', 'timeFrame': 'End of operation until approx. 4 hours after operation'}, {'measure': 'Cardiac Index (l/Min/m2)', 'description': 'Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula)', 'timeFrame': '1 hour before operation until start of operation'}, {'measure': 'Cardiac Index (l/Min/m2)', 'description': 'Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula)', 'timeFrame': 'Start of operation until end of operation, approximately 3 hours'}, {'measure': 'Cardiac Index (l/Min/m2)', 'description': 'Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula)', 'timeFrame': 'End of operation operation until approx. 4 hours after operation'}, {'measure': 'Cardiac Index (l/Min/m2)', 'description': 'Invasive measurement measuring the cardiac output divided by calculated body surface area (DuBois formula)', 'timeFrame': '4 hours after operation until 21 hours after operation'}, {'measure': 'Inflammatory Parameters', 'description': 'Blood sample values of pro- and antiinflammatory mediators', 'timeFrame': '4 hours before operation until 21 hours after operation'}, {'measure': 'Inflammatory Parameters', 'description': 'Blood sample values of pro- and antiinflammatory mediators', 'timeFrame': '21 hours after operation until 96 hours after operation'}, {'measure': 'E/A-ratio (Transoesophageal)', 'description': 'Transoesophageal echocardiographic measure of diastolic heart function', 'timeFrame': 'from start of operation until end of operation, approximately 3 hours'}, {'measure': 'E/A-ratio (Transoesophageal)', 'description': 'Transoesophageal echocardiographic measure of diastolic heart function', 'timeFrame': 'from end of operation until approximately 4 hours after operation'}, {'measure': 'Urine Clearance', 'description': 'Urine analysis. Measure of kidney function.', 'timeFrame': 'from start of operation until 24 hours after operation'}]",78,30 Years,90 Years,ALL,False,University of Aarhus,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:23.464568,v2_robust,True,True,False,True,True,Terminated prematurely due to high incidence of postoperative atrial fibrillation.
NCT03336983,Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients,"Bone Response After Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients With Hormone Sensitive Metastatic Bone Disease: a Prospective, Phase II, Randomized, Multicenter Study",Zoledronic Acid,"['Xtandi', 'Zoledronic Acid', 'Zoledronate', 'Enzalutamide']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,"['Prostate Cancer', 'Bone Metastases']","['prostate cancer', 'bone metastasis', 'enzalutamide', 'zoledronic acid']",COMPLETED,,2017-12-01,2023-04-01,"[{'measure': 'Evaluation of change in bone response after 6 and 12 months of treatment compared to baseline', 'description': 'Whole-body Diffusion MRI', 'timeFrame': 'Exam will be performed at baseline and after 6 and 12 months of treatment'}]","[{'measure': 'Evaluation of bone repair', 'description': 'CT Scan', 'timeFrame': 'Screening visit; 12 months of treatment'}, {'measure': 'Changes in bone mineral density after 18 months of treatment compared to baseline', 'description': 'Dual energy x-ray absorptiometry (DEXA Scan)', 'timeFrame': 'Screening visit; 18 months of treatment'}, {'measure': 'Functional Assessment of Cancer Therapy-Prostate', 'description': 'Functional Assessment of Cancer Therapy-Prostate (FACT- P) Questionnaire will be collected from patients.It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce subscale scores for each domain, as well as a global Qquality of Life (QoL) score.', 'timeFrame': 'Monthly until end of treatment (18 months)'}, {'measure': 'Brief Pain Inventory-Short Form Questionnaire', 'description': 'Brief Pain Inventory-Short Form (BPI-SF) Questionnaire will be collected from patients.In particular, a 0-10 numerical rating scale was used to measure pain severity items where 0=no pain and 10=pain as bad as you can imagine or with 0=pain did not interfere with my normal life and 10=pain interferes ompletely. A question about the percentage and duration of pain relief was also included.', 'timeFrame': 'Monthly until end of treatment (18 months)'}, {'measure': 'Weight evaluation', 'description': 'Evaluation of patient weight expressed in kg after 18 months of treatment compared to baseline', 'timeFrame': 'Screening visit; 18 months of treatment'}, {'measure': 'C-terminal telopeptide analysis', 'description': 'C-terminal telopeptide analysis (CTX, ng/ml) evaluation on peripheral blood samples', 'timeFrame': 'Screening visit; 2, 4, 6, 9, 12, 18 months of treatment'}, {'measure': 'Bone alkaline phosphatase analysis', 'description': 'Bone alkaline phosphatase analysis (U/uL) evaluation on peripheral blood samples', 'timeFrame': 'Screening visit; 2, 4, 6, 9, 12, 18 months of treatment'}]",8,18 Years,,MALE,False,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,OTHER,0,126.0,ACTUAL,2025-09-01T16:18:23.464793,v2_robust,True,True,True,False,False,
NCT00864383,Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis,"A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening Regimen Comparing Two Months Moxifloxacin, Isoniazid, Rifampicin, Pyrazinamide Followed by Two Months Moxifloxacin, Isoniazid, Rifampicin Versus the Standard Regimen (Two Months Ethambutol, Isoniazid, Rifampicin, Pyrazinamide Followed by Four Months Isoniazid and Rifampicin) for the Treatment of Adults With Pulmonary Tuberculosis","Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin","['Nydrazid', 'Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin', 'Rifadin', 'Avelon', 'Avelox', 'Avalox', 'Myambutol', 'Rifampin']",8,INTERVENTIONAL,['PHASE3'],PHASE3,,Pulmonary Tuberculosis,['Pulmonary Tuberculosis'],[],COMPLETED,,2008-01,2014-02,"[{'measure': 'Combined Failure of Bacteriological Cure and Relapse Within One Year of Completion of Therapy as Defined by Culture Using Solid Media (Lowenstein-Jensen - LJ).', 'description': 'The primary efficacy outcome was the proportion of patients who had bacteriologically or clinically defined failure or relapse within 18 months after randomization (a composite unfavorable outcome). Culture-negative status was defined as two negative-culture results at different visits without an intervening positive result. The date of culture-negative status was defined as the date of the first negative-culture result. This status continued until there were two positive cultures, without an intervening negative culture, or until there was a single positive culture that was not followed by two negative cultures. Relapse strains were those shown to be identical on 24-locus Mycobacterial interspersed repetitive units (MIRU) analysis. For the final 18 month study visit when both L-J samples were contaminated or missing, if the subject could not be brought back, liquid medium culture results were used in place of solid medium culture results.', 'timeFrame': '18 months (within one year of completion of therapy)'}, {'measure': 'Number of Patients With Grade 3 or 4 Adverse Events (Using a Modified Division of Acquired Immunodeficiency Syndrome National Institute of Allergy and Infectious Diseases [DAIDS] Scale of Adverse Event Reporting)', 'description': 'The number of participants includes all patients who had at least one grade 3 or 4 adverse event.', 'timeFrame': '18 months (within one year of completion of therapy)'}]","[{'measure': 'Combined Failure of Bacteriological Cure and Relapse as Defined by Culture Using Liquid Media (Mycobacteria Growth Indicator Tube-MGIT).', 'description': 'The secondary analysis of efficacy outcome was the proportion of patients who had bacteriologically or clinically defined failure or relapse within 18 months after randomization (a composite unfavorable outcome) based on MGIT. Culture-negative status was defined as two negative-culture results at different visits without an intervening positive result. The date of culture-negative status was defined as the date of the first negative-culture result. This status continued until there were two positive cultures, without an intervening negative culture, or until there was a single positive culture that was not followed by two negative cultures. Relapse strains were those shown to be identical on 24-locus Mycobacterial interspersed repetitive units (MIRU) analysis.', 'timeFrame': '18 months (within one year of completion of therapy)'}, {'measure': 'Number of Patients Who Are Culture Negative (Solid LJ Culture)', 'description': 'Number of patients who are TB LJ culture negative at 8 weeks.', 'timeFrame': '8 weeks'}, {'measure': 'Number of Patients Who Are Culture Negative (Liquid MGIT Culture)', 'description': 'Number of patients who are TB MGIT culture negative at 8 weeks.', 'timeFrame': '8 weeks'}, {'measure': 'Time to First Culture Negative Sputum Sample (LJ Solid Media)', 'description': 'Culture negative for TB using LJ cultures.', 'timeFrame': '18 months'}, {'measure': 'Time to First Culture Negative Sputum Sample (MGIT Liquid Media)', 'timeFrame': '18 months'}, {'measure': 'Sensitivity Analysis Assuming All Losses to Follow-up and Non-tuberculous Deaths Have an Unfavorable Outcome Using Solid (L-J) Media.', 'description': 'Sensitivity Analysis of Primary Efficacy Results of All Randomized Subjects Imputing Unfavorable for Missing Outcomes. Analysis is the number of subjects with an unfavorable outcome. Favorable outcome is defined as the number of subjects with a negative TB culture status at 18 months (at or after 72 weeks), who had not already been classified as having an unfavorable outcome, and whose last positive TB culture result (""isolated positive culture"") was followed by at least two negative culture results.', 'timeFrame': '18 months'}, {'measure': 'Sensitivity Analyses Assuming All Losses to Follow-up and Non-tuberculous Deaths Have a Favourable Outcome Using Solid (L-J) Media.', 'description': 'Sensitivity Analysis of Primary Efficacy Results of All Randomized Subjects Imputing Favorable for Missing Outcomes. Analysis is the number of subjects with an unfavorable outcome. Favorable outcome is defined as the number of subjects with a negative TB culture status at 18 months (at or after 72 weeks), who had not already been classified as having an unfavorable outcome, and whose last positive TB culture result (""isolated positive culture"") was followed by at least two negative culture results.', 'timeFrame': '18 months'}]",9,18 Years,,ALL,False,Global Alliance for TB Drug Development,OTHER,4,1931.0,ACTUAL,2025-09-01T16:18:23.464849,v2_robust,True,True,True,False,True,
NCT05053841,Implication of Metformin Plus Aromatase Inhibitor in Obese Postmenopausal Breast Cancer Women,Implication of Combined Adjuvant Metformin and Aromatase Inhibitor in Overweight or Obese Postmenopausal Breast Cancer Women,Metformin,"['Glucophage', 'Metformin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Metformin,"['Metformin', 'Breast Cancer']",[],COMPLETED,,2014-02,2015-06,"[{'measure': 'change in serum level of the study biomarkers after treatment when compared with baseline values', 'description': 'measuring the serum levels of the studied biomarkers', 'timeFrame': 'six months'}]",[],1,40 Years,,FEMALE,False,Tanta University,OTHER,0,45.0,ACTUAL,2025-09-01T16:18:23.464971,v2_robust,True,True,True,False,False,
NCT05814341,Citrate Anticoagulation in Renal Replacement Therapy: Impact of a High Post-filter Calcium Target on Efficacy,The Effect of Increasing Post-Filter Ionized Target on the Efficacy of Regional Citrate Anticoagulation During Continuous Renal Replacement Therapy in Intensive Care: a Multicenter Randomized Controlled Non-Inferiority Trial,Citrate,"['Citrate', 'REGIOCIT®']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Renal Replacement Therapy,['Renal Replacement Therapy'],"['Acute kidney injury', 'Continuous renal replacement therapy', 'Regional citrate anticoagulation', 'Ionized calcium', 'Intensive care']",COMPLETED,,2023-07-01,2024-12-15,"[{'measure': 'Incidence of filter clotting', 'description': 'Filter clotting was defined by increased transmembrane pressure greater than 300 mmHg', 'timeFrame': '72 hours'}, {'measure': 'Incidence of filter clotting', 'description': 'Filter clotting was defined by visible thrombus in circuit or filter', 'timeFrame': '72 hours'}, {'measure': 'Incidence of filter clotting', 'description': 'Filter clotting was defined by inability to rotate the blood pump due to an obstructing thrombus', 'timeFrame': '72 hours'}]","[{'measure': 'Filter lifespan until clotting and filter lifespan, including all causes of stoppage', 'description': 'The lifespan of each hemofilter measured in hours. The cause of CRRT discontinuation will be defined by filter clotting', 'timeFrame': '72 hours'}, {'measure': 'Filter lifespan until clotting and filter lifespan, including all causes of stoppage', 'description': 'The lifespan of each hemofilter measured in hours. The cause of CRRT discontinuation will be defined by catheter dysfunction : excessively negative inlet pressure (less than -150mmHg) or excessively positive outlet pressure (greater than +150mmHg)', 'timeFrame': '72 hours'}, {'measure': 'Filter lifespan until clotting and filter lifespan, including all causes of stoppage', 'description': 'The lifespan of each hemofilter measured in hours. The cause of CRRT discontinuation will be defined by transport: removal of the patient for mobilization', 'timeFrame': '72 hours'}, {'measure': 'Filter lifespan until clotting and filter lifespan, including all causes of stoppage', 'description': 'The lifespan of each hemofilter measured in hours. The cause of CRRT discontinuation will be defined by futility: no indication to continue CRRT', 'timeFrame': '72 hours'}, {'measure': 'Filter lifespan until clotting and filter lifespan, including all causes of stoppage', 'description': 'The lifespan of each hemofilter measured in hours. The cause of CRRT discontinuation will be defined by end of session: CRRT has been ongoing for more than 72 hours', 'timeFrame': '72 hours'}, {'measure': 'Filter lifespan until clotting and filter lifespan, including all causes of stoppage', 'description': 'The lifespan of each hemofilter measured in hours. The cause of CRRT discontinuation will be defined by citrate accumulation', 'timeFrame': '72 hours'}, {'measure': 'Filter lifespan until clotting and filter lifespan, including all causes of stoppage', 'description': 'The lifespan of each hemofilter measured in hours. The cause of CRRT discontinuation will be defined by Intensive Care Unit discharge', 'timeFrame': '72 hours'}, {'measure': 'Filter lifespan until clotting and filter lifespan, including all causes of stoppage', 'description': 'The lifespan of each hemofilter measured in hours. The cause of CRRT discontinuation will be defined by death', 'timeFrame': '72 hours'}, {'measure': 'Proportion of post-filter iCa in the target range and last psot-filter iCa value before clotting', 'description': 'Post-filter iCa levels (in mmol/L) measured during the CRRT session', 'timeFrame': '72 hours'}, {'measure': 'Total dose of citrate infused', 'description': 'Citrate infusion rates, in mmol/day', 'timeFrame': '72 hours'}, {'measure': 'Incidence of metabolic events (hypocalcemia, metabolic acidosis, metabolic alkalosis, hypernatremia, hypomagnesemia, citrate accumulation)', 'description': 'The occurrence of the following 6 metabolic complications:\n\n* Hypocalcemia \\[Ca2+ \\< 0.95mmol/L\\]\n* Metabolic acidosis \\[pH \\< 7.3 and HCO3- \\< 20mmol/L\\]\n* Metabolic alkalosis \\[pH \\> 7.5 and HCO3- \\> 30mmol/L\\]\n* Hypernatremia \\[Na+ \\> 145mmol/L\\]\n* Hypomagnesemia \\[Mg2+ \\< 0.70mmol/L\\]\n* Citrate accumulation \\[total calcium/ionized calcium ratio \\> 2.5\\]', 'timeFrame': '72 hours'}, {'measure': 'Financial costs associated with filter changes and citrate use', 'description': 'The costs (in euros) incurred by each filter change and the amount of citrate infused', 'timeFrame': '72 hours'}, {'measure': 'Blood loss during the procedure', 'description': 'Inability to return the CRRT circuit at the end of the session (equivalent to 200mL of blood loss)', 'timeFrame': '72 hours'}]",16,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,108.0,ACTUAL,2025-09-01T16:18:23.465181,v2_robust,True,True,True,False,False,
NCT02136641,Study of Comparison of the Effectiveness of Three Diagrams for Sedation in Spinal Anesthesia,Study of Comparison of the Effectiveness of Three Diagrams for Sedation in Spinal Anesthesia,Midazolam,"['Ketamine hydrochloride', 'Midazolam', 'Midazolam+Ketamine Combination', 'Midazolam+Fentanyl Combination', 'Fentanyl']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Anesthesia; Reaction,['Anesthesia; Reaction'],"['Anesthesia', 'Spinal Anesthesia', 'Conscious Sedation', 'Operating Rooms.']",COMPLETED,,2011-06,2012-06,"[{'measure': 'Sedation level reached according RANSAY SCALE with the use of three schemes sedation to spinal anesthesia', 'description': 'Sedation/Analgesia conscious was considered adequate when a RANSAY 2 or 3 was achieved (BASED ON THE RANSAY SCALE), without the need for other anesthetic drugs are different from the protocol, has been the gold standard in many studies that evaluated sedation; as you increase the level on the scale, increasing the degree of sedation . Being awake patient can be found in a level 1, referring to an anxious and / or agitated patients in level 2, when partner is quiet and focused and have spontaneous eye opening, or a level 3 when has closed eyelids, but quickly responds to verbal stimuli. When the patient was found asleep, level 4 will be called if you are still with closed eyes and responds quickly to tactile and verbal stimuli strong, level 5 when it has a slower response and only responds to important and / or painful stimuli and level 6 when does not respond to any stimulu', 'timeFrame': 'one year'}]","[{'measure': 'Number of participants satisfied with the use of three schemes sedation to spinal anesthesia', 'description': 'The Satisfaction was measured with a SATISFACTION SCALE TYPE LIKERT, this scale was used to subjectively evaluate how satisfied was the patient with spinal anesthesia under sedation, the scale is not validated, giving a score of 1 to refer to be very satisfied, 2 if only felt satisfied, a score of 3 to be dissatisfied, 4 if it meant feeling unsatisfied and finally a rating of 5 if it meant being very dissatisfied.', 'timeFrame': 'one year'}]",2,18 Years,60 Years,ALL,True,Universidad de Cartagena,OTHER,0,75.0,ACTUAL,2025-09-01T16:18:23.465223,v2_robust,True,True,True,False,False,
NCT05603741,Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers,Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers,0.9% Sodium Chloride Injection,"['Lidocaine Injection 2%', 'Lignocaine', 'Xylocaine', '0.9% Sodium Chloride Injection', 'Saline']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Ehlers-Danlos Syndrome,"['Ehlers-Danlos Syndrome', 'Anesthesia, Local']","['Ehlers-Danlos Syndrome', 'Local Anesthesia Resistance']",ACTIVE_NOT_RECRUITING,,2022-11-10,2027-06,"[{'measure': 'Delta Pain Scores Lidocaine at 5 min [ Time Frame: 5 minutes post-injection ]', 'description': 'Difference between the pain score at the Lidocaine injection locations (compared to a control location) and the saline injection location (compared to a control location). The pain scale is .a 4 level scale from 0 (""absent sensation""), to 1 (""dull pressure""), to 2 (""sharp but less than a control \\[non-injected\\] region) to 3 (same or worse than the control region).', 'timeFrame': '5 minutes post-injection'}]","[{'measure': 'Delta Pain Scores Lidocaine at 30 min', 'description': 'Difference between the pain score at the Lidocaine injection locations (compared to a control location) and the saline injection location (compared to a control location). The pain scale is .a 4 level scale from 0 (""absent sensation""), to 1 (""dull pressure""), to 2 (""sharp but less than a control \\[non-injected\\] region) to 3 (same or worse than the control region).', 'timeFrame': '30 minutes post-injection'}]",2,18 Years,,ALL,True,University of Calgary,OTHER,1,155.0,ESTIMATED,2025-09-01T16:18:23.465268,v2_robust,True,True,False,False,False,
NCT03907241,"CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL","Title for SCGAM-03: CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES WHO HAVE COMPLETED THE SCGAM-01 TRIAL Title for SCGAM-03 in Canada: CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL",Octanorm 16.5%,['Octanorm 16.5%'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Primary Immunodeficiency,['Primary Immunodeficiency'],[],COMPLETED,,2016-03-01,2019-09-05,"[{'measure': 'Occurrence of All Treatment-emergent Adverse Events (TEAEs)', 'description': 'Number of TEAEs', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Occurrence of Temporally Associated TEAEs', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Number of Temporally Associated TEAEs by Infusion Rate', 'description': 'Number of temporally associated TEAEs by infusion rate. Only includes systemic TEAEs without infections and without infusion site reactions', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Local Injection-site Reactions', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Blood Pressure', 'description': 'Systolic and diastolic.', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Body Temperature', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Respiratory Rate', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Sodium', 'description': 'Changes in sodium levels from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Potassium', 'description': 'Changes in potassium levels from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Blood Glucose', 'description': 'Changes in blood glucose from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'ALAT', 'description': 'Changes in ALAT (alanine transaminase) from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'ASAT', 'description': 'Changes in ASAT (aspartate aminotransferase) from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'LDH', 'description': 'Changes in LDH (lactate dehydrogenase) from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Total Bilirubin', 'description': 'Changes in total bilirubin from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Blood Urea Nitrogen', 'description': 'Changes in blood urea nitrogen from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Creatinine', 'description': 'Changes in creatinine from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Urine pH', 'description': 'Changes in urine pH from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Number of Participants With a Change in Urine Glucose', 'description': 'Number of Participants with a Change in Urine Glucose', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Number of Participants With a Change in Urine Ketones', 'description': 'Number of Participants With a Change in Urine Ketones at baseline and end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Number of Participants With a Change in Urine Leukocytes', 'description': 'Number of participants with a change in urine leukocytes at baseline and end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Number of Participants With a Change in Urine Hemoglobin', 'description': 'Number of participants with a change in urine hemoglobin at baseline and end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Complete Red Blood Cell Count', 'description': 'Changes in complete red blood cell count from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Haematocrit', 'description': 'Changes in haematocrit from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Haemoglobin', 'description': 'Changes in haemoglobin from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Complete White Blood Cell Count', 'description': 'Changes in complete white blood cell count from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}]","[{'measure': 'Measurement of Trough Total IgG Levels', 'description': 'Measurement of trough total IgG levels from baseline to end of study', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'Number of Participants With Serious Bacterial Infections (SBIs).', 'description': 'Number of participants with serious bacterial infections', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'SF-36 Health Survey.', 'description': 'Quality of Life for patients \\>= age 14 assessed using the Short Form 36 Health survey. Likert like scale.\n\nThe responses given by patients were combined to create 8 SF-36 scores: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, mental health\n\n36 questions that fall into 4 Sub scale scoring ranges: Score 1-5: Where 1 is more favorable than 5 Score 1-3: Where 3 is more favorable than 1 Score 1-5: Where 5 is more favorable than 1 Score 1-6: Where 1 is more favorable than 6 The raw subscale scores are converted into a scale score between 0 to 100 using the Quality Metric Health Outcomes™ Scoring Software 2.0 Scale Title of final scales is: Physical and Mental Health Component Summary Scores Range: Lowest = 0 and highest = 100 where a high score equates to a more favorable health state', 'timeFrame': 'From study start to end, up to 3.5 years'}, {'measure': 'CHQ-PF50 (Child Health Questionnaire-Parent Form)', 'description': 'Quality of Life for patients ages \\<14 years assessed using the CHQ-PF50. Measured values represent change in score from baseline to end of study.\n\nTwo summary scores were derived: physical and psychosocial. In accord with the scoring manual, computed scores were transformed giving each scale a possible range from 0 to 100, with the exception of change in health, with a possible range from 1 to 5. For all CHQ-PF50 scales, higher scores indicated more positive functioning or better health status.', 'timeFrame': 'From study start to end, up to 3.5 years'}]",29,2 Years,75 Years,ALL,False,Octapharma,INDUSTRY,0,27.0,ACTUAL,2025-09-01T16:18:23.465283,v2_robust,True,True,True,False,True,
NCT04831541,68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer,68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer,68Ga-PSMA-11,"['Diagnostic Test: PET/CT scan', '68Ga-PSMA-11']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Prostate Cancer,"['Prostate Cancer', 'Positron-Emission Tomography']",[],RECRUITING,,2020-10-10,2024-12-30,"[{'measure': 'Standardized uptake value (SUV)', 'description': 'Standardized uptake value (SUV) of 68Ga-PSMA-11 for each target lesion of subject or suspected primary tumor or/and metastasis.', 'timeFrame': '30 days'}]","[{'measure': 'Diagnostic efficacy', 'description': 'The sensitivity, specificity and accuracy of 68Ga-PSMA-11 PET/CT were calculated.', 'timeFrame': '30 days'}]",2,18 Years,90 Years,ALL,False,First Affiliated Hospital of Fujian Medical University,OTHER,0,600.0,ESTIMATED,2025-09-01T16:18:23.465307,v2_robust,True,True,False,False,False,
NCT04866654,Radiation Free Chemotherapy for Early Hodgkin Lymphoma,"Radiation-Free Therapy for the Initial Treatment of Good Prognosis Early Non-bulky HL, Defined by a Low Metabolic Tumor Volume and a Negative Interim PET After 2 Chemotherapy Cycles- RAFTING",Nivolumab 10 MG/ML,['Nivolumab 10 MG/ML'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Hodgkin Lymphoma,['Hodgkin Lymphoma'],[],RECRUITING,,2021-03-04,2026-07-02,"[{'measure': 'Efficacy exploration in terms of 3-Y PFS of chemotherapy alone', 'description': 'To explore the efficacy, in terms of 3-Y PFS of chemotherapy alone in low-risk early-stage I-IIA HL patients, defined by both a low MTV and a negative interim PET after 2 courses of ABVD', 'timeFrame': 'During follow-up (36 months) after the end of treatment'}]","[{'measure': 'Efficacy exploration in terms of 3-Y PFS of chemotherapy plus Nivolumab', 'description': 'To explore the efficacy in terms of 3-Y PFS of CMT plus Nivolumab in high-risk early-stage (I-IIA) HL (eHL), defined either by a positive PET- 2 or a high baseline MTV or both', 'timeFrame': 'During follow-up (36 months) after the end of treatment'}, {'measure': 'Efficacy exploration in terms of 3-Y freedom from 2nd treatment failure (3-Y FF2TF) of chemotherapy followed by radiotherapy ""on demand"" plus Nivolumab maintenance', 'description': 'To explore the efficacy in terms of 3-Y freedom from 2nd treatment failure (3-Y FF2TF) of chemotherapy followed by radiotherapy ""on demand"" plus Nivolumab maintenance in patients relapsing with the pattern of ""limited relapse"" (see below) for the entire group (relapsed and non-relapsed) of low-risk patients (with low MTV and negative PET- 2) high-risk early-stage (I-IIA) HL (eHL), defined either by a positive PET- 2 or a high baseline MTV or both', 'timeFrame': 'During follow-up (36 months) after the end of treatment'}, {'measure': 'Safety exploration in terms of 3-Y OS of a treatment with chemotherapy alone', 'description': 'To explore the safety in terms of 3-Y OS of a treatment with chemotherapy alone in low-risk early-stage (I-IIA) HL patients, defined by a low Metabolic Tumor Volume negative interim PET after 2 ABVD courses', 'timeFrame': 'During follow-up (36 months) after the end of treatment'}, {'measure': 'Evaluation the ability of cell-free DNA (cfDNA) assay', 'description': 'To evaluate the ability of cell-free DNA (cfDNA) assay to detect an impending relapse during follow-up in low-risk patients treated with chemotherapy alone�k�', 'timeFrame': 'During follow-up (36 months) after the end of treatment'}]",5,18 Years,60 Years,ALL,False,Medical University of Gdansk,OTHER,0,160.0,ESTIMATED,2025-09-01T16:18:23.465328,v2_robust,True,True,False,False,True,
NCT04581954,Inflammatory Signal Inhibitors for COVID-19 (MATIS),Randomised Multi-arm Trial of Ruxolitinib (RUX) and Fostamatinib (FOS) for COVID-19 Pneumonia,Ruxolitinib,"['Fostamatinib', 'Ruxolitinib']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Coronavirus,"['Coronavirus', 'Covid19', 'Pneumonia']","['coronavirus', 'covid19', 'pneumonia', 'ruxolitinib', 'fostamatinib']",UNKNOWN,,2020-10-02,2022-06-30,"[{'measure': 'All-cause mortality', 'timeFrame': 'Day 14'}, {'measure': 'Number and proportion of patients requiring invasive ventilation', 'timeFrame': 'Day 14'}, {'measure': 'Number and proportion of patients requiring non-invasive ventilation (CPAP and high flow nasal oxygen)', 'timeFrame': 'Day 14'}, {'measure': 'Number and proportion of patients with O2 saturation < 90% on >/=60% inspired oxygen', 'timeFrame': 'Day 14'}]","[{'measure': 'All-cause mortality', 'timeFrame': 'Day 28'}, {'measure': 'Number and proportion of patients requiring invasive ventilation or extracorporeal membrane oxygenation (ECMO)', 'timeFrame': 'Day 14, 28'}, {'measure': 'Number and proportion of patients requiring non-invasive ventilation including continuous positive airway pressure (CPAP) or high flow nasal oxygen', 'timeFrame': 'Day 14, 28'}, {'measure': 'Number and proportion of patients requiring renal replacement therapy', 'timeFrame': 'Day 14, 28'}, {'measure': 'Number and proportion of patients experiencing venous thromboembolism events', 'timeFrame': 'Day 14, 28'}, {'measure': 'Length of stay', 'timeFrame': 'Day 14, 28'}, {'measure': 'Number and proportion of serious adverse events and discontinuations', 'timeFrame': 'Day 14, 28'}, {'measure': 'Absolute change in pneumonia severity on the modified WHO COVID-19 Ordinal Scale', 'description': 'Scale range from 0 (uninfected) to 9 (dead)', 'timeFrame': 'Day 14, 28'}, {'measure': 'Inflammatory markers: CRP, LDH, ferritin, D-dimer', 'timeFrame': 'Day 14, Day 28'}]",13,18 Years,,ALL,False,Imperial College London,OTHER,3,456.0,ESTIMATED,2025-09-01T16:18:23.465372,v2_robust,True,True,False,False,True,
NCT00588354,Epidural Clonidine for Lumbosacral Radiculopathy,Pilot Study of Transforaminal Epidural Injection of Clonidine for the Treatment of Acute Lumbosacral Radiculopathy,Clonidine,"['Trilone', 'Kenacort', 'Aristocort', 'lignocaine', 'Lidocaine HCl', 'Tri-Nasal', 'Triaderm', 'Volon A', 'Kapvay', 'Nexiclon', 'Xylocaine', 'Triamcinolone hexacetonide', 'Clonidine', 'Tristoject', 'Azmacort', 'Catapres', 'Tricortone']",17,INTERVENTIONAL,['NA'],,,Lumbar and Other Intervertebral Disc Disorders With Radiculopathy,['Lumbar and Other Intervertebral Disc Disorders With Radiculopathy'],"['herniated disk', 'radiculopathy', 'clonidine', 'epidural', 'steroid', 'corticosteroid', 'nucleus pulposus', 'transforaminal']",TERMINATED,Targeted enrollment was not reached.,2006-10,2009-02,"[{'measure': 'Pain Intensity Score at 4 Weeks as Measured by Pain Intensity Numerical Rating Scale (PI-NRS)', 'description': '11-point ordinal scale measuring patient pain, ranging from 0 (no pain) to 10 (most severe/disabling pain).', 'timeFrame': '4 weeks'}]","[{'measure': 'Pain Intensity Score at 2 Weeks as Measured by Pain Intensity Numerical Rating Scale (PI-NRS)', 'description': '11-point ordinal scale measuring patient pain, ranging from 0 (no pain) to 10 (most severe/disabling pain).', 'timeFrame': '2 weeks'}, {'measure': 'Pain Disability Score at 2 Weeks as Measured by the Roland-Morris Disability Questionnaire', 'description': 'This scale measures functional disability due to back pain. The score of the scale is the total number of items checked, from a minimum of 0 (no disability) to a maximum of 24 (great disability). Roland MO, Morris RW. A study of the natural history of back Pain. Part 1: development of a reliable and sensitive measure of disability in low back pain. Spine 1983; 8:141-144.', 'timeFrame': '2 weeks'}, {'measure': 'Pain Disability Score at 4 Weeks as Measured by the Roland-Morris Disability Questionnaire', 'description': 'This scale measures functional disability due to back pain. The score of the scale is the total number of items checked, from a minimum of 0 (no disability) to a maximum of 24 (great disability). Roland MO, Morris RW. A study of the natural history of back Pain. Part 1: development of a reliable and sensitive measure of disability in low back pain. Spine 1983; 8:141-144.', 'timeFrame': '4 weeks'}, {'measure': 'Pain Disability Score at 2 Weeks as Measured by Oswestry Low Back Pain Disability Questionnaire (ODI)', 'description': ""This questionnaire measures a patient's permanent functional disability. The questionnaire consists of 10 sections with 6 statements each of increasing point value (from 0 to 5). The score is a percentage of the total, with higher score showing greater disability. Minimum detectable change is 10%, with a 90% CI. Change of less than this may be attributable to error in measurement."", 'timeFrame': '2 weeks'}, {'measure': 'Pain Disability Score at 4 Weeks as Measured by Oswestry Low Back Pain Disability Questionnaire', 'description': ""This questionnaire measures a patient's permanent functional disability. The questionnaire consists of 10 sections with 6 statements each of increasing point value (from 0 to 5). The score is a percentage of the total, with higher score showing greater disability. Minimum detectable change is 10%, with a 90% CI. Change of less than this may be attributable to error in measurement."", 'timeFrame': '4 weeks'}, {'measure': 'Pain Score at 2 Weeks as Measured by the Multidimensional Pain Inventory (MPI)', 'description': 'The MPI is a comprehensive instrument comprised of 12 scales divided into three parts for assessing a number of dimensions of the chronic pain experience including pain intensity, emotional distress, cognitive and functional adaptation, and social support. Reference: Kearns RO, Turk DC, Rudy TC. The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). Pain 1985; 23:345-356. Subscales were not used; the DOS WHYMPI computer program version 2.1 was used to score the instrument. Scores range from 0 (no pain) to 100 (highest pain). A score of 50 is the mean for patients with chronic pain.', 'timeFrame': '2 weeks'}, {'measure': 'Pain Score at 4 Weeks as Measured by the Multidimensional Pain Inventory (MPI)', 'description': 'The MPI is a comprehensive instrument comprised of 12 scales divided into three parts for assessing a number of dimensions of the chronic pain experience including pain intensity, emotional distress, cognitive and functional adaptation, and social support. Reference: Kearns RO, Turk DC, Rudy TC. The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). Pain 1985; 23:345-356. Subscales were not used; the DOS WHYMPI computer program version 2.1 was used to score the instrument. Scores range from 0 (no pain) to 100 (highest pain). A score of 50 is the mean for patients with chronic pain.', 'timeFrame': '4 weeks'}]",8,18 Years,,ALL,True,Mayo Clinic,OTHER,1,26.0,ACTUAL,2025-09-01T16:18:23.465393,v2_robust,True,True,False,True,False,Targeted enrollment was not reached.
NCT03114254,A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis,A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis,Cabazitaxel,"['Jetvana', 'Cabazitaxel']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Penile Neoplasm,['Penile Neoplasm'],"['Recurrent', 'Locally advanced', 'Metastatic']",COMPLETED,,2014-12-05,2016-11-16,"[{'measure': 'Complete response', 'description': 'Complete response recorded from the start of the treatment to completion of 6 cy-cles of treatment determined by radiological response assessment', 'timeFrame': '18 weeks'}, {'measure': 'Partial response', 'description': 'Partial response recorded from the start of the treatment to completion of 6 cy-cles of treatment determined by radiological response assessment', 'timeFrame': '18 weeks'}]","[{'measure': 'Progression free survival', 'description': 'Progression free survival defined as the time from registration to the first of one of the following: development of radiological disease progression (RECIST 1.1) or death from any cause', 'timeFrame': 'Until patient progresses, which is approximately 6 weeks after randomisation'}, {'measure': 'Overall survival', 'description': 'Overall survival defined as time from registration to the date of death due to from any cause', 'timeFrame': 'Until patient dies, which is approximately 3 months after randomisation'}, {'measure': 'Acute toxicity (Defined by number of CTCAE v4.03 Adverse Events, Adverse Reactions and by grades and the worst grade).', 'description': 'Acute toxicity (Defined by number of CTCAE v4.03 Adverse Events, Adverse reactions and by grades experienced by the patient collected at study visits and recorded on an Adverse Event Case report form. .', 'timeFrame': 'After each cycle (every 3 weeks) for maximally 6 cycles therefore 18 weeks whilst on treatment and at the 3 month visit timepoint'}, {'measure': 'Late toxicity (Defined by number of CTCAE v4.03 Adverse Events, Adverse Reactions and by grades and the worst grade).', 'description': 'Late toxicity (Defined by number of CTCAE v4.03 Adverse Events, Adverse reactions and by grades experienced by the patient collected at study visits and recorded on an Adverse Event Case report form. .', 'timeFrame': 'From 3 months post treatment Cycle 1 Day 1 to up to 6 months recorded at the 3 month and 6 month timepoint.'}]",6,18 Years,,MALE,False,University Hospitals Bristol and Weston NHS Foundation Trust,OTHER,1,17.0,ACTUAL,2025-09-01T16:18:23.465440,v2_robust,True,True,True,False,True,
NCT05270954,"Safety, Tolerability and Immunogenicity of Recombinant COVID-19 Vaccine Betuvax-CoV-2","Randomized, Double-blind, Multicenter Parallel-group Clinical Study of Safety, Tolerability and Immunogenicity of the Betuvax-CoV-2 Recombinant COVID-19 Vaccine, Suspension for Intramuscular Administration in Healthy Adult Volunteers",Placebo,"['0.9% NaCl', 'Placebo']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,COVID-19,['COVID-19'],"['SARS-CoV-2', 'coronavirus', 'recombinant vaccine', 'virus-like vaccine', 'betulin']",UNKNOWN,,2021-10-14,2022-07-24,"[{'measure': 'Total specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with an increased level of the total specific anti-SARS-CoV-2 antibodies by 4 times or more (ELISA test)', 'timeFrame': '21 days after the second administration of the study drug/placebo'}, {'measure': 'Total specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with an increased level of the total specific anti-SARS-CoV-2 antibodies by 4 times or more (ELISA test)', 'timeFrame': '90±5 days after the first administration of the study drug/placebo'}, {'measure': 'Neutralizing anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers tested positive for the presence of neutralizing anti-SARS-CoV-2 antibodies (SARS-CoV-2 Surrogate Virus Neutralization Test)', 'timeFrame': '21 days after the second administration of the study drug/placebo'}, {'measure': 'Neutralizing anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers tested positive for the presence of neutralizing anti-SARS-CoV-2 antibodies (SARS-CoV-2 Surrogate Virus Neutralization Test)', 'timeFrame': '90±5 days after the first administration of the study drug/placebo'}, {'measure': 'Adverse events', 'description': 'The proportion of the volunteers with any adverse events', 'timeFrame': 'Within 50 days of the first dose of the study drug/placebo'}, {'measure': 'Severe adverse events', 'description': 'The proportion of the volunteers with severe adverse events', 'timeFrame': 'Within 50 days of the first dose of the study drug/placebo'}]","[{'measure': 'Total specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with an increased level of the total specific anti-SARS-CoV-2 antibodies by 4 times or more (ELISA test)', 'timeFrame': '180±5 days after the first administration of the study drug/placebo'}, {'measure': 'IgG-specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with an increased level of the IgG-specific anti-SARS-CoV-2 antibodies by 4 times or more (ELISA test)', 'timeFrame': '21 days after the second administration of the study drug/placebo'}, {'measure': 'IgG-specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with an increased level of the IgG-specific anti-SARS-CoV-2 antibodies by 4 times or more (ELISA test)', 'timeFrame': '90±5 days after the first dose of the study drug/placebo'}, {'measure': 'IgG-specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with an increased level of the IgG-specific anti-SARS-CoV-2 antibodies by 4 times or more (ELISA test)', 'timeFrame': '180±5 days after the first dose of the study drug/placebo'}, {'measure': 'IgM-specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with an increased level of the IgM-specific anti-SARS-CoV-2 antibodies by 4 times or more (ELISA test)', 'timeFrame': '21 days after the second administration of the study drug/placebo'}, {'measure': 'IgM-specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with an increased level of the IgM-specific anti-SARS-CoV-2 antibodies by 4 times or more (ELISA test)', 'timeFrame': '90±5 days after the first dose of the study drug/placebo'}, {'measure': 'IgM-specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with an increased level of the IgM-specific anti-SARS-CoV-2 antibodies by 4 times or more (ELISA test)', 'timeFrame': '180±5 days after the first dose of the study drug/placebo'}, {'measure': 'Neutralizing anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers tested positive for the presence of neutralizing anti-SARS-CoV-2 antibodies (SARS-CoV-2 Surrogate Virus Neutralization Test)', 'timeFrame': '180±5 days after the first administration of the study drug/placebo'}, {'measure': 'Geometric mean titers of the total anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with geometric mean titers of the total anti-SARS-CoV-2 antibodies (ELISA test)', 'timeFrame': '21 days after the second administration of the study drug/placebo'}, {'measure': 'Geometric mean titers of the total anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with geometric mean titers of the total anti-SARS-CoV-2 antibodies (ELISA test)', 'timeFrame': '90±5 days after the first administration of the study drug/placebo'}, {'measure': 'Geometric mean titers of the total anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with geometric mean titers of the total anti-SARS-CoV-2 antibodies (ELISA test)', 'timeFrame': '180±5 days after the first administration of the study drug/placebo'}, {'measure': 'Geometric mean titers of the IgG-specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with geometric mean titers of the IgG-specific anti-SARS-CoV-2 antibodies (ELISA test)', 'timeFrame': '21 days after the second administration of the study drug/placebo'}, {'measure': 'Geometric mean titers of the IgG-specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with geometric mean titers of the IgG-specific anti-SARS-CoV-2 antibodies (ELISA test)', 'timeFrame': '90±5 days after the first administration of the study drug/placebo'}, {'measure': 'Geometric mean titers of the IgG-specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with geometric mean titers of the IgG-specific anti-SARS-CoV-2 antibodies (ELISA test)', 'timeFrame': '180±5 days after the first administration of the study drug/placebo'}, {'measure': 'Geometric mean titers of the IgM-specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with geometric mean titers of the IgM-specific anti-SARS-CoV-2 antibodies (ELISA test)', 'timeFrame': '21 days after the second administration of the study drug/placebo'}, {'measure': 'Geometric mean titers of the IgM-specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with geometric mean titers of the IgM-specific anti-SARS-CoV-2 antibodies (ELISA test)', 'timeFrame': '90±5 days after the first administration of the study drug/placebo'}, {'measure': 'Geometric mean titers of the IgM-specific anti-SARS-CoV-2 antibodies', 'description': 'The proportion of the volunteers with geometric mean titers of the IgM-specific anti-SARS-CoV-2 antibodies (ELISA test)', 'timeFrame': '180±5 days after the first administration of the study drug/placebo'}, {'measure': 'Specific anti-SARS-CoV-2 cellular immune response (Phase 1)', 'description': 'The proportion of the volunteers with a specific anti-SARS-CoV-2 cellular immune response (flow cytometry)', 'timeFrame': '21 days after the second dose of the study drug (only in Phase 1)'}, {'measure': 'Specific anti-SARS-CoV-2 cellular immune response (Phase 1)', 'description': 'The proportion of the volunteers with a specific anti-SARS-CoV-2 cellular immune response (flow cytometry)', 'timeFrame': '90±5 days after the first dose of the study drug (only in Phase 1)'}, {'measure': 'Specific anti-SARS-CoV-2 cellular immune response', 'description': 'The proportion of the volunteers with a specific anti-SARS-CoV-2 cellular immune response (ELISPOT)', 'timeFrame': '21 days after the second dose of the study drug/placebo'}, {'measure': 'Specific anti-SARS-CoV-2 cellular immune response', 'description': 'The proportion of the volunteers with a specific anti-SARS-CoV-2 cellular immune response (ELISPOT)', 'timeFrame': '90±5 days after the first dose of the study drug/placebo'}, {'measure': 'Specific anti-SARS-CoV-2 cellular immune response', 'description': 'The proportion of the volunteers with a specific anti-SARS-CoV-2 cellular immune response (ELISPOT)', 'timeFrame': '180±5 days after the first dose of the study drug/placebo'}, {'measure': 'COVID-19 symptoms', 'description': 'The proportion of the volunteers with at least one COVID-19 symptom (fever, chills, dyspnoea, difficulty breathing, cough, sore throat, fatigue, muscle pain, loss or decrease in taste and/or odor, nasal congestion, runny nose, headache, nausea, vomiting, diarrhea) and a PCR-confirmed SARS-CoV-2 infection', 'timeFrame': 'From the 7th day after the second administration of the study drug/placebo till the 90±5 day after the first dose of study drug/placebo'}, {'measure': 'COVID-19 symptoms', 'description': 'The proportion of the volunteers with at least one COVID-19 symptom (fever, chills, dyspnoea, difficulty breathing, cough, sore throat, fatigue, muscle pain, loss or decrease in taste and/or odor, nasal congestion, runny nose, headache, nausea, vomiting, diarrhea) and a PCR-confirmed SARS-CoV-2 infection', 'timeFrame': 'From the 7th day after the second administration of the study drug/placebo till the 180±5 day after the first dose of study drug/placebo'}, {'measure': 'Moderate, severe or extremely severe course of COVID-19, or lethal outcome', 'description': 'The proportion of the volunteers with COVID-19 of moderate, severe or extremely severe course, or with a lethal outcome, and a PCR-confirmed SARS-CoV-2 infection', 'timeFrame': 'From the 7th day after the second administration of the study drug/placebo till the 90±5 day after the first dose of the study drug/placebo'}, {'measure': 'Moderate, severe or extremely severe course of COVID-19, or lethal outcome', 'description': 'The proportion of the volunteers with COVID-19 of moderate, severe or extremely severe course, or with a lethal outcome, and a PCR-confirmed SARS-CoV-2 infection', 'timeFrame': 'From the 7th day after the second administration of the study drug/placebo till the 180±5 day after the first dose of the study drug/placebo'}, {'measure': 'Severe or extremely severe course of COVID-19, or lethal outcome', 'description': 'The proportion of the volunteers with COVID-19 of severe or extremely severe course, or with a lethal outcome, and a PCR-confirmed SARS-CoV-2 infection', 'timeFrame': 'From the 7th day after the second administration of the study drug/placebo till the 90±5 day after the first dose of the study drug/placebo'}, {'measure': 'Severe or extremely severe course of COVID-19, or lethal outcome', 'description': 'The proportion of the volunteers with COVID-19 of severe or extremely severe course, or with a lethal outcome, and a PCR-confirmed SARS-CoV-2 infection', 'timeFrame': 'From the 7th day after the second administration of the study drug/placebo till the 180±5 day after the first dose of the study drug/placebo'}, {'measure': 'Lethal outcome', 'description': 'The proportion of the volunteers with lethal outcome, and a PCR-confirmed SARS-CoV-2 infection', 'timeFrame': 'From the 7th day after the second administration of the study drug/placebo till the 90±5 day after the first dose of the study drug/placebo'}, {'measure': 'Lethal outcome', 'description': 'The proportion of the volunteers with lethal outcome, and a PCR-confirmed SARS-CoV-2 infection', 'timeFrame': 'From the 7th day after the second administration of the study drug/placebo till the 180±5 day after the first dose of the study drug/placebo'}, {'measure': 'Allergic reactions', 'description': 'The proportion of the volunteers with immediate side effects (allergic reactions)', 'timeFrame': 'Within 2 hours of the first study drug/placebo administration'}, {'measure': 'Allergic reactions', 'description': 'The proportion of the volunteers with immediate side effects (allergic reactions)', 'timeFrame': 'Within 2 hours of the second study drug/placebo administration'}, {'measure': 'Local post-vaccination reactions', 'description': 'The proportion of the volunteers with local post-vaccination reactions', 'timeFrame': 'Within 7 days after the first administration of the study drug/placebo'}, {'measure': 'Local post-vaccination reactions', 'description': 'The proportion of the volunteers with local post-vaccination reactions', 'timeFrame': 'Within 7 days after the second administration of the study drug/placebo'}, {'measure': 'Severe local post-vaccination reactions', 'description': 'The proportion of the volunteers with \\>grade 3 of local post-vaccination reactions', 'timeFrame': 'Within 7 days of the first study drug/placebo administration'}, {'measure': 'Severe local post-vaccination reactions', 'description': 'The proportion of the volunteers with \\>grade 3 of local post-vaccination reactions', 'timeFrame': 'Within 7 days of the second study drug/placebo administration'}, {'measure': 'Systemic post-vaccination reactions', 'description': 'The proportion of the volunteers with systemic post-vaccination reactions', 'timeFrame': 'Within 7 days after the first administration of the study drug/placebo'}, {'measure': 'Systemic post-vaccination reactions', 'description': 'The proportion of the volunteers with systemic post-vaccination reactions', 'timeFrame': 'Within 7 days after the second administration of the study drug/placebo'}, {'measure': 'Severe systemic post-vaccination reactions', 'description': 'The proportion of the volunteers with \\>grade 3 of severe systemic post-vaccination reactions', 'timeFrame': 'Within 7 days after the first administration of the study drug/placebo'}, {'measure': 'Severe systemic post-vaccination reactions', 'description': 'The proportion of the volunteers with \\>grade 3 of severe systemic post-vaccination reactions', 'timeFrame': 'Within 7 days after the second administration of the study drug/placebo'}, {'measure': 'Any adverse events', 'description': 'The proportion of the volunteers with any adverse events', 'timeFrame': 'Within 90±5 days after the first dose of the study drug/placebo'}, {'measure': 'Any adverse events', 'description': 'The proportion of the volunteers with any adverse events', 'timeFrame': 'Within 180±5 days after the first dose of the study drug/placebo'}, {'measure': 'Adverse events of special interest', 'description': 'The proportion of the volunteers with adverse events of special interest, adverse reactions that require medical attention, with newly developed chronic diseases', 'timeFrame': 'Within 50 days after the first dose of the study drug/placebo'}, {'measure': 'Adverse events of special interest', 'description': 'The proportion of the volunteers with adverse events of special interest, adverse reactions that require medical attention, with newly developed chronic diseases', 'timeFrame': 'Within 90±5 days after the first dose of the study drug/placebo'}, {'measure': 'Adverse events of special interest', 'description': 'The proportion of the volunteers with adverse events of special interest, adverse reactions that require medical attention, with newly developed chronic diseases', 'timeFrame': 'Within 180±5 days after the first dose of the study drug/placebo'}, {'measure': 'Severe adverse events', 'description': 'The proportion of the volunteers with severe adverse events', 'timeFrame': 'Within 90±5 days after the first dose of the study drug/placebo'}, {'measure': 'Severe adverse events', 'description': 'The proportion of the volunteers with severe adverse events', 'timeFrame': 'Within 180±5 days after the first dose of the study drug/placebo'}, {'measure': 'Prematurely terminated participation', 'description': 'The proportion of the volunteers who prematurely terminated their participation in the study due to the development of adverse events or severe adverse events associated with the use of the study drug', 'timeFrame': 'Within 50 days after the administration of the first dose of the study drug/placebo'}, {'measure': 'Prematurely terminated participation', 'description': 'The proportion of the volunteers who prematurely terminated their participation in the study due to the development of adverse events or severe adverse events associated with the use of the study drug', 'timeFrame': 'Within 90±5 days after the administration of the first dose of the study drug/placebo'}, {'measure': 'Prematurely terminated participation', 'description': 'The proportion of the volunteers who prematurely terminated their participation in the study due to the development of adverse events or severe adverse events associated with the use of the study drug', 'timeFrame': 'Within 180±5 days after the administration of the first dose of the study drug/placebo'}]",56,18 Years,60 Years,ALL,True,Artgen Biotech,OTHER,2,116.0,ACTUAL,2025-09-01T16:18:23.465543,v2_robust,True,True,False,False,True,
NCT00558454,Iron Supplementation of Marginally Low Birth Weight Infants,"Randomized, Controlled Study of Iron Supplementation of Infants With Birth Weights 2000-2500 g",Iron,"['Ferromyn S, AstraZeneca, Södertälje, Sweden', 'Iron']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Anemia,"['Anemia', 'Iron-Deficiency', 'Child Behavior Disorders', 'Cognitive Manifestations']","['Iron supplements', 'Infant', 'Low birth weight', 'Prevention of iron deficiency and its physiological consequences', 'Safety']",COMPLETED,,2004-03,2014-11,"[{'measure': 'Neurological developement', 'description': '6 mo: Auditory brain stem response (central conduction time) 3 y: CBCL - Parental questionnaire assessing behavioral problems and WIPPSI - test of cognitive functions 7 y: SDQ, 5-15 and CBCL - Parental questionnaires assessing behavioral problems, TeAch - test of behavioral problems and WISC - test of cognitive functions.', 'timeFrame': '6 months, 3 years and 7 years'}]","[{'measure': 'Growth (weight, length, head circumference, knee-heel length), Morbidity and Iron status (Hemoglobin, ferritin etc)', 'timeFrame': '6 months'}, {'measure': 'Growth, Iron status, and Morbidity', 'timeFrame': '3 years and 7 years'}]",3,39 Days,45 Days,ALL,True,Umeå University,OTHER,3,380.0,ACTUAL,2025-09-01T16:18:23.465566,v2_robust,True,True,True,False,False,
NCT00039754,A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma,A Multicenter Dosimetry Trial to Evaluate Radiation Absorbed Dose From Holmium-166-DOTMP in Patients With Multiple Myeloma,Holmium-166-DOTMP,['Holmium-166-DOTMP'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Multiple Myeloma,['Multiple Myeloma'],"['Multiple myeloma', 'Transplant', 'Skeletal Targeted Radiotherapy', 'Holmium']",TERMINATED,business reasons,2002-03,,[],[],0,18 Years,70 Years,ALL,False,Poniard Pharmaceuticals,INDUSTRY,0,,,2025-09-01T16:18:23.465658,v2_robust,True,True,False,True,False,business reasons
NCT00476554,A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma,A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma,Sapacitabine,"['CYC682', 'Sapacitabine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Cutaneous T-cell Lymphoma (CTCL),['Cutaneous T-cell Lymphoma (CTCL)'],['CTCL'],TERMINATED,slow accrual and financial resource limitation,2007-04,2012-03-01,"[{'measure': 'response rate in overall skin disease', 'description': 'Decrease of lesion from baseline', 'timeFrame': 'over the course of study'}]",[],1,18 Years,,ALL,False,"Cyclacel Pharmaceuticals, Inc.",INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:23.465665,v2_robust,True,True,False,True,False,slow accrual and financial resource limitation
NCT01125254,Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major,Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major,Amlodipine,['Amlodipine'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Thalassemia Major,['Thalassemia Major'],"['thalassemia major', 'calcium channel blockade', 'magnetic resonance imaging']",COMPLETED,,2008-09,2011-07,"[{'measure': 'Myocardium T2*', 'description': 'Heart T2\\* by MRI at 12 months', 'timeFrame': '12 months'}]","[{'measure': 'Liver T2*', 'description': 'Liver T2\\* by MRI every 6 months for 2 years. First year with active treatment; second year with withdrawal.', 'timeFrame': '24 months'}, {'measure': 'Heart volumes', 'description': 'Diastolic and systolic volumes by MRI every 6 months for 2 years. First year with active treatment; second year with withdrawal.', 'timeFrame': '24 months'}, {'measure': 'Left ventricle ejection fraction', 'description': 'LVEF by MRI every 6 months for 2 years. First year with active treatment; second year with withdrawal.', 'timeFrame': '24 months'}, {'measure': 'Serum ferritin', 'description': 'Serum ferritin every 6 months for 2 years. First year with active treatment; second year with withdrawal.', 'timeFrame': '24 months'}, {'measure': 'Myocardium T2*', 'description': 'Heart T2\\* by MRI every 6 months until 24 months', 'timeFrame': '6-18-24 months'}]",6,6 Years,90 Years,ALL,False,"University of Campinas, Brazil",OTHER,1,10.0,ACTUAL,2025-09-01T16:18:24.740720,v2_robust,True,True,True,False,False,
NCT01287754,A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations,A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor,erlotinib [Tarceva],['erlotinib [Tarceva]'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Non-Small Cell Lung Cancer,['Non-Small Cell Lung Cancer'],[],COMPLETED,,2011-10,2013-11,"[{'measure': 'Progression-Free Survival (PFS) Among Erlotinib-Treated Participants With the EGFR Mutation', 'description': 'PFS was defined as the time from the first dose of erlotinib to the first documentation of disease progression or death, whichever occurred first. Tumor progression was determined using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), which defines progression as a 20 percent (%) or greater increase in the sum of diameters of target lesions with an absolute increase of at least 5 millimeters (mm), or the appearance of one or more new lesions. PFS was calculated in months as \\[first event date minus first dose date plus 1\\] divided by 30.44.', 'timeFrame': 'Per standard of care (every 3 months) until discontinuation for up to approximately 2 years'}]","[{'measure': 'Number of Erlotinib-Treated Participants With the EGFR Mutation With an Objective Response Per RECIST v1.1', 'description': 'Objective tumor response was assessed by the investigator using RECIST v1.1 and recorded as complete response (CR), partial response (PR), or unmeasurable. RECIST v1.1 defines CR as disappearance of all target lesions, with short-axis reduction to less than (\\<) 10 mm for any pathological lymph nodes, and PR as a 30% or greater reduction from baseline in the sum of diameters of target lesions.', 'timeFrame': 'Per standard of care (every 3 months) until discontinuation for up to approximately 2 years'}, {'measure': 'Overall Survival (OS) Among Erlotinib-Treated and Untreated Participants', 'description': 'OS was defined as the time from recorded diagnosis to death from any cause or last patient last visit. OS was calculated in months as \\[death date or last-known alive date minus diagnosis date plus 1\\] divided by 30.44.', 'timeFrame': 'Per standard of care (every 3 months) until discontinuation for up to approximately 2 years'}, {'measure': 'Percentage of Participants Alive at 6 and 12 Months', 'description': 'Death from any cause was documented at 6 and 12 months from recorded diagnosis. The percentage of participants alive at each timepoint was calculated as \\[number of participants alive divided by number enrolled\\] multiplied by 100.', 'timeFrame': 'At 6 and 12 months'}, {'measure': 'Percentage of Participants With EGFR Mutation at Screening', 'description': 'Participants were tested at Screening for the presence of activating mutations in the tyrosine kinase domain of EGFR. The percentage of participants with mutation was calculated as \\[number of mutation-positive participants divided by number tested\\] multiplied by 100.', 'timeFrame': 'Screening'}]",5,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:24.740782,v2_robust,True,True,True,False,False,
NCT00567554,"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer","A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer",epirubicin - cyclophosphamide / docetaxel,"['epirubicin - cyclophosphamide / docetaxel', 'paclitaxel', 'epirubicin - cyclophosphamide / docetaxel + lapatinib', 'epirubicin - cyclophosphamide / docetaxel + trastuzumab', 'epirubicin - cyclophosphamide / docetaxel + bevacizumab', 'paclitaxel + everolimus (RAD001)']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,['Breast Cancer'],"['breast cancer', 'primary systemic therapy', 'pCR Rates', 'Bevacizumab', 'Trastuzumab', 'Lapatinib', 'Everolimus']",COMPLETED,,2007-10,2015-10,"[{'measure': 'To compare the pCR rates of neoadjuvant treatment in all 3 Settings', 'timeFrame': '2009'}]","[{'measure': 'To assess the toxicity of and compliance to all six treatments.', 'timeFrame': '2009'}, {'measure': 'To determine the breast conservation rate after each treatment.', 'timeFrame': '2009'}, {'measure': 'To determine the (loco-regional and distant) disease-free and overall survival after each treatment. In Her-2 positive disease the cerebral disease-free survival will be determined separately.', 'timeFrame': '2012'}, {'measure': 'To assess treatment efficacies in subgroups defined according to tumor stage (T2-3 vs T4) receptor status (ER and/or PR pos. vs ER and PR neg.) and response by best appropriate imaging method to the first 4 cycles of treatment (complete vs partial vs no)', 'timeFrame': '2009'}, {'measure': 'To examine and compare prespecified molecular markers on core biopsy before and after end of chemotherapy', 'timeFrame': '2012'}]",6,18 Years,,FEMALE,False,GBG Forschungs GmbH,OTHER,1,2600.0,ACTUAL,2025-09-01T16:18:24.740827,v2_robust,True,True,True,False,False,
NCT00382954,Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML,"A Phase I Study Using Bortezomib (Velcade, Formerly Known as PS-341) With Weekly Idarubicin for the Treatment of Elderly (>/= 60 Years) and Relapsed Patients With Acute Myelogenous Leukemia",Velcade,"['Bortezomib', 'Idarubicin', 'Velcade']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Myelogenous Leukemia,['Acute Myelogenous Leukemia'],"['Acute Myelogenous Leukemia', 'AML', 'Relapse', 'Elderly', 'Velcade', 'Idarubicin', 'Bortezomib']",COMPLETED,,2004-02,2008-10,"[{'measure': 'Maximum tolerated dose of bortezomib & idarubicin given in combination, with idarubicin given once weekly for 4 consecutive weeks & bortezomib given twice weekly over the same time.', 'timeFrame': 'week 4'}, {'measure': 'Dose limiting toxicities associated with bortezomib in combination with idarubicin.', 'timeFrame': 'week 4'}]","[{'measure': 'Response to the combination of Idarubicin and Bortezomib.', 'timeFrame': 'Days 18 & 50'}, {'measure': 'Pre- & post-treatment inhibition of NF-kB activity in the malignant & normal hematopoietic cell populations.', 'timeFrame': '24 hours after the initial dose of Bortezomib'}, {'measure': 'Induction of p53 levels in the malignant cell populations.', 'timeFrame': '2 and 24 hours post day +1 Bortezomib'}, {'measure': 'Bortezomib PK when administered to patients with acute leukemia receiving concomitant medications that could lead to drug interactions. In the case of altered pharmacokinetics, a pharmacodynamic assay to check proteasome inhibition may also be applied.', 'timeFrame': 'Days 1, 4, 8, 11, 15'}, {'measure': 'Idarubicin PK in order to observe any alteration in metabolism/elimination of Idarubicin & its active metabolite idarubicinol when it is combined with Bortezomib.', 'timeFrame': 'Days 1, 4, 8, 11, 15'}]",7,18 Years,,ALL,False,University of Kentucky,OTHER,1,55.0,ESTIMATED,2025-09-01T16:18:24.741028,v2_robust,True,True,True,False,False,
NCT00396305,Th1 Response to Influenza: Aging and Vaccine Efficacy,Th1 Response to Influenza: Aging and Vaccine Efficacy,Placebo,['Placebo'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Influenza,['Influenza'],"['Influenza, vaccine, efficacy, elderly']",TERMINATED,,2006-11,2008-01,"[{'measure': 'Immunogenicity: measured by frequency of IS-Th1 and antibody and T cell responses.', 'timeFrame': 'Days 7, 28, 56, and 84 following the initial vaccination.'}, {'measure': 'Safety: including rates of serious adverse events (SAEs) and their relationship to vaccination; rates of local or systemic solicited adverse events (AEs) and their categories; and reported unsolicited AEs following vaccination.', 'timeFrame': 'Safety evaluation at 4, 14, and 28 days post-vaccination.'}]",[],2,21 Years,,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,41.0,ACTUAL,2025-09-01T16:18:24.741158,v2_robust,True,True,False,True,True,
NCT02329405,The Effects of PXR Activation on Hepatic Fat Content,PXR-aktivaation Vaikutus Maksan Rasvoittumiseen,Rifampicin,"['Rifampicin', 'Rifampin', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Non-alcoholic Fatty Liver Disease,['Non-alcoholic Fatty Liver Disease'],[],COMPLETED,,2014-12,2017-01,"[{'measure': 'Hepatic fat fraction', 'timeFrame': 'Day 8'}]",[],1,18 Years,40 Years,ALL,True,University of Oulu,OTHER,1,16.0,ACTUAL,2025-09-01T16:18:24.741170,v2_robust,True,True,True,False,False,
NCT01191905,Effects of HIgh Volume COntinuous REnal Replacement Therapy in Patients With Septic Acute Kidney Injury,Effects of HIgh Volume COntinuous REnal Replacement Therapy in Patients With Septic Acute Kidney Injury,high dose CRRT,"['high dose CRRT', 'Conventional dose CRRT']",2,INTERVENTIONAL,['NA'],,,Sepsis,"['Sepsis', 'Kidney Failure, Acute', 'Renal Replacement Therapy']",[],COMPLETED,,2011-01,2015-07,"[{'measure': 'Overall mortality', 'timeFrame': '0 to 28 days'}]","[{'measure': '60-day mortality', 'timeFrame': '0 to 60 days'}, {'measure': '90-day mortality', 'timeFrame': '0 to 90 days'}, {'measure': 'ICU mortality', 'timeFrame': '0 to 90 days'}, {'measure': 'In-hospital mortality', 'timeFrame': '0 to 90 days'}, {'measure': 'duration of CRRT', 'timeFrame': '0 to 90 days'}, {'measure': 'duration of renal replacement therapy', 'timeFrame': '0 to 90 days'}, {'measure': 'duration of mechanical ventilation', 'timeFrame': '0 to 90 days'}, {'measure': 'cytokine removal rate', 'timeFrame': '0 to 12h'}, {'measure': 'changes in SOFA and APACHE II score', 'timeFrame': '0 to 72 hr'}, {'measure': 'hemofilter circuit life', 'timeFrame': '0 to 72 hr]'}]",11,20 Years,80 Years,ALL,False,Seoul National University Hospital,OTHER,1,212.0,ACTUAL,2025-09-01T16:18:24.741177,v2_robust,True,True,True,False,False,
NCT02125305,Clinical Study to Investigate the Pharmacokinetics and Pharmacodynamics of Metformin in the Elderly,A Phase I Clinical Study to Investigate the Pharmacokinetics and Pharmacodynamics of Metformin in Elderly Healthy Male Volunteers,Metformin,"['Diabex', 'Metformin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Elderly,['Healthy Elderly'],"['Metformin', 'Pharmacokinetics/ Pharmacodynamics']",COMPLETED,,2013-08,,"[{'measure': 'AUC(area under the plasma concentration-time curve)', 'description': 'AUC(area under the plasma concentration-time curve), Cmax(maximum plasma concentration), t1/2', 'timeFrame': 'Predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12h postdose'}]","[{'measure': 'AUGC(total area under the serum concentration-time curve for glucose concentration)', 'description': 'AUG (total area under the serum concentration-time curve for glucose) Gmax(maximum serum glucose concentration)', 'timeFrame': 'predose and 15, 30, 45, 60, 90, 120 min oral glucose tolerance test'}]",2,65 Years,85 Years,MALE,True,Seoul National University Hospital,OTHER,0,12.0,ACTUAL,2025-09-01T16:18:24.741215,v2_robust,True,True,True,False,False,
NCT07015905,REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults,"A Phase 3, Multicenter, Randomized, Open-Label, Sponsor-Blinded, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX)",REGN7508,"['Apixaban', 'Enoxaparin', 'Inhixa', 'Placebo', 'REGN7508']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Venous Thromboembolism (VTE),['Venous Thromboembolism (VTE)'],"['Unilateral Total Knee Arthroplasty (TKA)', 'Factor XI (FXI)']",RECRUITING,,2025-06-25,2027-05-12,"[{'measure': 'Incidence of the composite endpoint of asymptomatic or symptomatic Venous Thromboembolism (VTE) [including VTE-related death]', 'timeFrame': 'Through day 12 visit, approximately 14 days'}]","[{'measure': 'Incidence of confirmed symptomatic Deep Venous Thrombosis (DVT)', 'timeFrame': 'Through day 12 visit, approximately 14 days'}, {'measure': 'Incidence of confirmed Pulmonary Embolism (PE)', 'timeFrame': 'Through day 12 visit, approximately 14 days'}, {'measure': 'Incidence of VTE-related death', 'timeFrame': 'Through day 12 visit, approximately 14 days'}, {'measure': 'Incidence of the composite endpoint of major and clinically relevant non-major (CRNM) bleeding', 'timeFrame': 'Through day 12 visit, approximately 14 days'}, {'measure': 'Incidence of the composite endpoint of asymptomatic or symptomatic VTE (including VTE-related death)', 'timeFrame': 'Through day 12 visit, approximately 14 days'}, {'measure': 'Incidence of minor bleeding', 'timeFrame': 'Through day 12 visit, approximately 14 days'}, {'measure': 'Incidence of Treatment Emergent Adverse Events (TEAEs)', 'timeFrame': 'Approximately day 90'}, {'measure': 'Incidence of Anti-Drug Antibodies (ADA) to REGN7508', 'timeFrame': 'Approximately day 90'}, {'measure': 'Titer of ADA to REGN7508', 'timeFrame': 'Approximately day 90'}, {'measure': 'Concentrations of REGN7508', 'timeFrame': 'Approximately day 90'}]",11,18 Years,,ALL,False,Regeneron Pharmaceuticals,INDUSTRY,0,2000.0,ESTIMATED,2025-09-01T16:18:24.741229,v2_robust,True,True,False,False,True,
NCT04790305,Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer,"Effect of Huaier Granule on Postoperative Adjuvant Treatment for High-risk Early-stage Triple-negative Invasive Ductal Carcinoma: a Prospective, Multicenter, Randomized, Controlled, Open-label Study",Huaier Granule,"['Z20000109（NMPA Approval Number）', 'Huaier Granule']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Carcinoma Breast,"['Carcinoma Breast', 'Triple-negative Breast Cancer', 'Invasive Ductal Carcinoma, Breast']","['Huaier Granule', 'Triple-negative Breast Cancer', 'Invasive Ductal Carcinoma, Breast', 'Adjuvant Treatment']",RECRUITING,,2021-06-18,2028-07-28,"[{'measure': '3-year rates of disease-free survival', 'description': 'Disease-free survival (DFS)：The time from randomization until the date of the first occurrence of one of the following events: recurrence of ipsilateral invasive breast tumor, local recurrence, distant metastasis, death from any cause, contralateral invasive breast cancer, ipsilateral ductal carcinoma in situ, contralateral ductal carcinoma in situ, second primary invasive carcinoma (except breast cancer).\n\n3-year rates of disease-free survival: The percentage of participants who have not occurred events described in the DFS definition within 3 years.', 'timeFrame': 'Start of treatment until 3-year follow-up'}]","[{'measure': '3-year rates of overall survival', 'description': 'Overall survival (OS): The time from randomization until the date of death from any cause.\n\n3-year rates of overall survival: The percentage of participants who have not died from any cause within 3 years.', 'timeFrame': 'Start of treatment until 3-year follow-up'}, {'measure': '3-year rates of invasive-disease-free survival', 'description': 'Invasive-disease-free survival (iDFS): The time from randomization until the date of the first occurrence of one of the following events: recurrence of ipsilateral invasive breast tumor, local recurrence, distant metastasis, death from any cause, contralateral invasive breast cancer, second primary invasive carcinoma (except breast cancer).\n\n3-year rates of invasive-disease-free survival: The percentage of participants who have not occurred events described in the iDFS definition within 3 years.', 'timeFrame': 'Start of treatment until 3-year follow-up'}, {'measure': '5-year rates of disease-free survival', 'description': '5-year rates of disease-free survival: The percentage of participants who have not occurred events described in the DFS definition within 5 years.', 'timeFrame': 'Start of treatment until 5-year follow-up'}, {'measure': '5-year rates of overall survival', 'description': '5-year rates of overall survival: The percentage of participants who have not died from any cause within 5 years.', 'timeFrame': 'Start of treatment until 5-year follow-up'}, {'measure': '5-year rates of invasive-disease-free survival', 'description': '5-year rates of invasive-disease-free survival: The percentage of participants who have not occurred events described in the iDFS definition within 5 years.', 'timeFrame': 'Start of treatment until 5-year follow-up'}, {'measure': 'Changes in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire', 'description': 'Quality of Life (QOL) will be measured by European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). The scope of each domain is 0 to 100. Higher scores in the functional and general health areas indicate better functional status and quality of life, and higher scores in the symptomatic areas indicate more symptoms or problems (poorer quality of life).', 'timeFrame': 'Up to 5 years since the start of treatment'}, {'measure': 'Incidence and severity of AE or SAE', 'description': 'AE: Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.\n\nSAE: A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.', 'timeFrame': 'Start of treatment until 3 year after enrollment'}, {'measure': 'Incidence and severity of ADR，SUSAR or SADR', 'description': 'All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions. A SADR is a serious ADR according to the above criteria of SAE. A SUSAR is an unexpected SADR.', 'timeFrame': 'Start of treatment until 3 year after enrollment'}]",9,18 Years,70 Years,ALL,False,Fudan University,OTHER,2,1072.0,ESTIMATED,2025-09-01T16:18:24.741248,v2_robust,True,True,False,False,True,
NCT01831505,Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents,Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents Using the CIVO(tm) Microdosing System,"Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them","['Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them']",1,INTERVENTIONAL,['PHASE1'],PHASE1,,Lymphoma,['Lymphoma'],"['personalized medicine', 'in vivo drug sensitivity', 'chemotherapy', 'lymphoma', 'microinjection']",COMPLETED,,2012-11,2013-07,"[{'measure': 'Evaluation of the response to locally injected drugs', 'timeFrame': '1-3 days post injection after injection'}]","[{'measure': 'Evaluate the safety profile of multiple simultaneous microinjections using custom syringe', 'timeFrame': 'up to 28 days'}]",2,18 Years,,ALL,False,Presage Biosciences,INDUSTRY,3,4.0,ACTUAL,2025-09-01T16:18:24.741300,v2_robust,True,True,True,False,True,
NCT05452005,Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer,"Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography for Staging, Response Assessment, and Patient Selection in Metastatic Non-Small Cell Lung Cancer",[18F]-αvβ6-BP,['[18F]-αvβ6-BP'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Lung Cancer,"['Lung Cancer', 'Lung Cancer Metastatic', 'Brain Metastases', 'Non Small Cell Lung Cancer']",['Positron Emission Tomography'],RECRUITING,,2022-09-13,2025-12-31,"[{'measure': '[18F]-αvβ6-BP PET/CT imaging compared to immunohistochemistry', 'description': 'Standard uptake value (SUV) values from \\[18F\\]-αvβ6-BP PET/CT will be compared to immunohistochemistry (IHC) αvβ6 staining of archival tissue to assess the sensitivity of \\[18F\\]-αvβ6-BP PET/CT to detect αvβ6 positive metastasis in NSCLC', 'timeFrame': 'Up to six months'}]","[{'measure': 'Comparison of standard-of-care MRI and [18F]-αvβ6-BP PET/CT imaging', 'description': 'Detection of lesions with \\[18F\\]-αvβ6-BP will be compared to the number of lesions identified during standard-of-care MRI imaging', 'timeFrame': 'Up to six months'}, {'measure': 'Comparison of standard-of-care [18F]-FDG PET/CT and [18F]-αvβ6-BP PET/CT imaging', 'description': 'SUVmax values obtained during standard-of-care FDG/PET will be compared to SUVmax values obtained from \\[18F\\]-αvβ6-BP PET/CT imaging', 'timeFrame': 'Up to six months'}, {'measure': 'Comparison of standard-of-care MRI brain and [18F]-FDG PET/CT and [18F]-αvβ6-BP PET/CT imaging post treatment', 'description': 'Lesion response will be assessed based on standard-of-care MRI images, \\[18F\\]-FDG PET/CT and \\[18F\\]-αvβ6-BP PET/CT post treatment.', 'timeFrame': 'Up to six months'}]",4,18 Years,,ALL,False,"University of California, Davis",OTHER,1,20.0,ESTIMATED,2025-09-01T16:18:24.741329,v2_robust,True,True,False,False,False,
NCT00304005,VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders,A Phase I/II Study of Cloretazine in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia or Richter's Syndrome,laromustine,['laromustine'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Leukemia,"['Leukemia', 'Lymphoma']","['refractory chronic lymphocytic leukemia', 'recurrent adult diffuse large cell lymphoma', 'recurrent adult Hodgkin lymphoma']",COMPLETED,,2005-07,2008-08,"[{'measure': 'Maximum tolerated dose'}, {'measure': 'Toxicity'}, {'measure': 'Efficacy'}]",[],3,18 Years,,ALL,False,Vion Pharmaceuticals,INDUSTRY,0,35.0,ESTIMATED,2025-09-01T16:18:24.741368,v2_robust,True,True,True,False,False,
NCT02930005,Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders,A Pilot Open-label Trial of Pentosan Polysulfate Sodium and Meclofenamic Acid As Adjunctive Treatments in Patients With Psychotic Disorders,Meclofenamic acid,"['Hemoclar', 'Elmiron', 'Fibrase', 'Pentosan polysulfate sodium', 'Meclomen', 'Meclofenamic acid', 'Anarthron']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Psychotic Disorders,"['Psychotic Disorders', 'Schizophrenia', 'Schizoaffective Disorder', 'Bipolar Disorder']","['Psychotic', 'Schizophrenia', 'Schizoaffective', 'Bipolar']",COMPLETED,,2015-08-07,2016-10-06,"[{'measure': 'Change in Cognitive Function as Assessed by the NIH Toolbox Cognitive Test Battery (NCTB) Composite Score', 'description': 'A higher composite score on the NCTB indicates better cognitive performance. The NCTB consists of 7 tests and 8 sub-scores, and the NIH Toolbox software calculates total composite score by averaging the normalized scores of each subscale and then deriving scale scores. The ""NIH Toolbox Scoring and Interpretation Guide"" (found online) doesn\'t indicate a total composite score range (because the score ranges are infinite), but describes scoring as follows: To get a normalized composite score, the score of the test taker is compared to the scores in the NIH Toolbox nationally representative normative sample. The mean score is 100 and the standard deviation (SD) is 15. A score at or near 100 indicates average ability compared with others. Scores around 115 suggest above-average ability. Scores around 130 suggest superior ability (in the top 2 percent nationally). A score around 85 suggests below-average ability. A score in the range of 70 or below suggests significant impairment.', 'timeFrame': 'baseline, 8 weeks'}]","[{'measure': 'Change in Severity of Psychotic Symptoms as Assessed by Positive and Negative Syndrome Scale (PANSS)', 'description': 'Change in the Positive and Negative Syndrome Scale (PANSS) total score after 8 weeks. The range of scores on the PANSS is 30 to 210, with higher scores associated with better outcomes.', 'timeFrame': 'baseline, 8 weeks'}]",2,18 Years,60 Years,ALL,False,"The University of Texas Health Science Center, Houston",OTHER,0,8.0,ACTUAL,2025-09-01T16:18:24.741378,v2_robust,True,True,True,False,False,
NCT06451705,Pecs Block vs Local Infiltration in Mastectomy,"Comparison Between Pectoral Nerve Block II and Local Anesthesia Infiltration of Isobaric Bupivacaine 0.25% 50 MG on Neutrophil-Lymphocyte Ratio, Interleukin-6 Levels, Pain Intensity, and Post-surgical Opioid Requirements in Modified Radical Mastectomy Patients",PECS II block,"['PECS II block', 'LIA']",2,INTERVENTIONAL,['NA'],,,"Pain, Postoperative","['Pain, Postoperative']","['postoperative pain', 'modified radical mastectomy', 'peripheral nerve block', 'local infiltration anesthesia', 'pectoralis nerve block']",COMPLETED,,2024-03-01,2024-04-30,"[{'measure': 'Concentration of Plasma Interleukin-6', 'description': 'in pg/dL', 'timeFrame': '1 hour before surgery, 2 hour after surgery, 12 hour after surgery'}, {'measure': 'Neutrophil-lymphocyte ratio', 'description': 'Neutrophil divided by lymphocyte', 'timeFrame': '1 hour before surgery, 2 hour after surgery, 12 hour after surgery'}, {'measure': 'Pain intensity (Using Numeric Rating Scale)', 'description': 'Scale from 0-10, lower score = better outcome', 'timeFrame': 'hour 0, 2, 4, 6, 12, 24'}, {'measure': 'Rescue opioid requirement', 'description': 'Using fentanyl at a dose of 0.5-1 μg/kg/IV titrated as needed, in mcg (given if the patient had NRS of \\>4/10)', 'timeFrame': 'Within 24 hours after surgery'}]","[{'measure': 'Demographic baseline data', 'description': 'Medical record number, age, body weight (in kilogram), height (in centimeter), BMI (in kg/m2), ASA PS class, duration of surgery (in minutes)', 'timeFrame': 'baseline (before the surgery)'}, {'measure': 'Time until first rescue opioid requirement', 'description': 'in minutes', 'timeFrame': 'Within 24 hours after surgery'}, {'measure': 'Nausea and vomiting', 'description': 'Nausea and vomiting were assessed using a numerical scale (0 = no nausea, 1 = mild nausea, 2 = severe nausea or vomiting once, and 3 = vomiting more than once). If the score was \\> 2, rescue antiemetics with ondansetron 0.1 mg/IV were given.', 'timeFrame': 'Within 24 hours after surgery'}]",7,18 Years,60 Years,ALL,True,Hasanuddin University,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:24.741402,v2_robust,True,True,True,False,False,
NCT00000805,A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease,A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease,Ganciclovir,['Ganciclovir'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Cytomegalovirus Infections,"['Cytomegalovirus Infections', 'HIV Infections']","['Ganciclovir', 'Cytomegalovirus Infections', 'Acquired Immunodeficiency Syndrome']",COMPLETED,,,1998-03,[],[],0,14 Days,20 Years,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,32.0,,2025-09-01T16:18:24.741429,v2_robust,True,True,True,False,False,
NCT00648505,Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg,Single-Dose Food In Vivo Bioequivalence Study of Glipizide and Metformin HCl Tablets (5 mg/500 mg; Mylan) to Metaglip® Tablets (5 mg/500 mg; Bristol-Myers Squibb) in Healthy Volunteers,Glipizide and Metformin HCl Tablets 5 mg/500 mg,"['Glipizide and Metformin HCl Tablets 5 mg/500 mg', 'Metaglip® Tablets 5 mg/500 mg']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2005-06,2005-06,"[{'measure': 'Bioequivalence', 'timeFrame': 'within 30 days'}]",[],1,18 Years,,ALL,True,Mylan Pharmaceuticals Inc,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:24.741435,v2_robust,True,True,True,False,False,
NCT01247805,A Pivotal Bioequivalence Study Between The Sildenafil Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions,"A Pivotal Randomised, Open-Label 3-Way Crossover Study To Demonstrate Bioequivalence Of The Sildenafil Citrate Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil Citrate 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions",sildenafil citrate,"['sildenafil citrate', 'Revatio', 'Sildenafil citrate']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Pulmonary Arterial Hypertention,['Pulmonary Arterial Hypertention'],"['Bioequivalence', 'Powder for oral suspention']",COMPLETED,,2011-01,2011-02,"[{'measure': 'Area under the curve (AUC0-T) of sildenafil plasma concentrations from time zero to the time T of last measurable concentration.', 'timeFrame': 'Pre-dose, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 14 hours post dose'}, {'measure': 'Maximum sildenafil plasma concentration (Cmax)', 'timeFrame': 'Pre-dose, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 14 hours post dose'}]","[{'measure': 'AUCinf, AUC of sildenafil from time zero to time infinity. AUCinf = AUC0-T+AUCextrapolated', 'timeFrame': 'Pre-dose, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 14 hours post dose'}, {'measure': 'AUC%extrapolated of sildenafil.', 'timeFrame': 'Pre-dose, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 14 hours post dose'}, {'measure': 'Tmax - time at which maximum sildenafil plasma concentration occurs', 'timeFrame': 'Pre-dose, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 14 hours post dose'}, {'measure': 'Adverse events', 'timeFrame': 'From FSFV to LSLV, up to 5 weeks'}, {'measure': 'terminal half-life of sildenafil.', 'timeFrame': 'Pre-dose, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 14 hours post dose'}]",7,18 Years,55 Years,ALL,True,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,0,42.0,ESTIMATED,2025-09-01T16:18:24.741444,v2_robust,True,True,True,False,True,
NCT03781505,Intravenous Paracetamol in Combination With Caudal Ropivacaine,Effect of Intravenous Paracetamol Combination With Caudal Ropivacaine on Quality of Postoperative Recovery in Pediatric Patients Undergoing Hypospadias Repair.A Randomized Controlled Trial.,Paracetamol +caudal ropivacaine,"['Paracetamol +caudal ropivacaine', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Postoperative Analgesia,['Postoperative Analgesia'],[],COMPLETED,,2019-01-31,2022-05-01,"[{'measure': 'Postoperative Analgesia Requirement', 'description': ""The requirement of postoperative analgesia of the patient will be evaluated by using Children's Hospital of Eastern Ontario Pain Scale (CHEOPS). This scale has 5 domains. It includes crying, facial expression, verbal response, touching the wound and torso and leg movement. It is a behavioural scale and measures each domain on a numerical scale of 0 to 2. Minimum score is 0 while maximum score is 10. Aggregate score will be added. Score less than 4 will be consider adequate analgesia while score greater than 4 will be consider inadequate analgesia. CHEOPS Pain Score less than four in participants of C and P groups will be reported at different time points."", 'timeFrame': 'follow till 6 hours postoperatively'}]","[{'measure': 'Sedation', 'description': 'Sedation will be assessed by using Pasero Opioid-Induced Sedation Scale (POSS). This scale measures sedation on numerical score of 0 to 4. Minimum score is 0 while maximum score is 4.\n\nIt comprises of; 0: awake; 1: mild sedation; 2: sleeping, but able to wake; 3: Frequently drowsy, arousable, drifts off to sleep during conversation, unable to wake and 4: Somnolent, minimal or no response to verbal or physical stimulation.\n\nA POSS score of 0, 1, or 2 indicates an acceptable level of sedation, whereas a score of 3 or 4 indicates over-sedation and the need for a reversal agent. This score is just a numerical number with no other value attached to it.', 'timeFrame': 'follow till 4 hours postoperatively'}]",2,3 Years,10 Years,ALL,False,Aga Khan University,OTHER,0,64.0,ACTUAL,2025-09-01T16:18:24.741462,v2_robust,True,True,True,False,False,
NCT00003305,Aminopterin in Treating Patients With Refractory Leukemia,A Phase II Trial of Aminopterin in Adults and Children With Refractory Acute Leukemia Grant Application Title: A Phase II Trial of Aminopterin in Acute Leukemia,aminopterin,"['aminopterin', 'leucovorin calcium']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Leukemia,['Leukemia'],"['recurrent childhood acute lymphoblastic leukemia', 'recurrent childhood acute myeloid leukemia', 'recurrent adult acute myeloid leukemia', 'recurrent adult acute lymphoblastic leukemia']",COMPLETED,,1997-07,2007-09,[],[],0,,,ALL,False,"Genzyme, a Sanofi Company",INDUSTRY,0,75.0,ESTIMATED,2025-09-01T16:18:24.741486,v2_robust,True,True,True,False,False,
NCT01364805,New Treatment Option for Pancreatic Cancer,Translation of in Vitro and in Vivo Ascorbate Research Into a New Treatment Option for Pancreatic Cancer: Phase I/IIa Clinical Trial,Intravenous Vitamin C,"['Gemcitabine', 'Intravenous Vitamin C', 'IV ascorbic acid', 'Gemsar']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Pancreatic Cancer,['Pancreatic Cancer'],[],COMPLETED,,2011-04,2015-10,"[{'measure': 'Determine safety of combined gemcitabine chemotherapy with IV ascorbate.', 'description': 'This will be accomplished by enrolling up to 14 participants fitting inclusion criteria into the Phase I portion of the trial: 7 participants will be enrolled at the determined dose levels and if no significant adverse event is identified, then 7 additional participants will be enrolled. Safety will be assessed by obtaining the following evaluations: toxicity graded by the NCI CTCAE v 4.0, urinalysis pre- and post-infusion, ECG, basic metabolic panel, bicarbonate (pH surrogate marker), CBC, and osmolality.', 'timeFrame': '12 months'}]","[{'measure': 'Assess pharmacokinetic and pharmacodynamic interactions when adding IV AA to front-line gemcitabine chemotherapy in the treatment of locally advanced or metastatic pancreatic cancer not eligible for surgical resection.', 'description': 'By measuring PK data when combining gemcitabine chemotherapy along with IV ascorbate on the same day, it will be determined if there are reduced gemcitabine levels in the presence of ascorbate. Initially 7 participants will be enrolled and if no significant interaction defined, an additional 7 will be enrolled.', 'timeFrame': '12 months'}]",2,21 Years,,ALL,False,"Jeanne Drisko, MD, CNS, FACN",OTHER,2,14.0,ACTUAL,2025-09-01T16:18:24.741535,v2_robust,True,True,True,False,True,
NCT06333405,Fecal Microbiota Transplantation (FMT) as a Prophylaxis of Necrotizing Enterocolitis (NEC) - Clinical Study,Evaluation of the Safety of Fecal Microbiota Transplantation (FMT) as a Prophylaxis of Necrotizing Enterocolitis (NEC) in a Group of Newborns at Increased Risk for the Disease,Fecal Microbiota Transplantation,['Fecal Microbiota Transplantation'],1,INTERVENTIONAL,['NA'],,,Necrotizing Enterocolitis,['Necrotizing Enterocolitis'],"['Enterocolitis, Necrotizing; Fecal Microbiota Transplantation; Necrotizing Enterocolitis prophylaxis']",NOT_YET_RECRUITING,,2024-05-01,2025-01-31,"[{'measure': 'Adverse reactions monitoring', 'description': 'The safety of the procedure will be assessed on the basis of:\n\n1. number of episodes of oral feeding intolerance, diarrhoea, blood/mucus/pus in stools\n2. appearance of symptoms of infection or significant change in vital parameters (heart rate ECG and oxygen saturation - continuous measurement, blood pressure 4x/day, temperature, possibly HERO)\n3. number of developed NEC\n4. assessment of blood flow in the upper mesenteric artery by ultrasound\n5. observation of other symptoms - convulsions, unbridled crying, anxiety\n6. the number of positive blood cultures, the percentage of antibiotic therapy\n7. number of serious side effects - death, serious threat to health and/or life and/or deterioration of health\n8. Length of hospitalization', 'timeFrame': 'Up to the discharge from the hospital (approximately from 2 weeks to 3 months)'}]",[],1,24 Weeks,36 Weeks,ALL,False,Medical University of Warsaw,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:24.741546,v2_robust,True,True,False,False,True,
NCT01524705,FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR),FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR,Insulin Glargine,"['Exenatide', 'Prandial insulin', 'Aspart or glulisine or lispro', 'Glucagon-like polypeptide-1-agonist (GLP-1-agonist)', 'Generic metformin', 'Byetta', 'Insulin Glargine', 'Basal insulin', 'Metformin']",9,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes,['Type 2 Diabetes'],"['Pilot Study', 'Prospective Randomized Trial', 'Comparative Effectiveness', 'Glycemic Variability', 'insulin glargine', 'exenatide', 'basal insulin', 'bolus insulin']",COMPLETED,,2012-08,2014-07,"[{'measure': 'Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline', 'description': 'The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM)', 'timeFrame': 'At baseline, 6 months of intervention'}]","[{'measure': 'Number of Participants With Hypoglycemia', 'description': 'Severe hypoglycemia-documented glucose \\<50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel.', 'timeFrame': '26 weeks'}, {'measure': 'Weight Change During Trial', 'description': 'Weight in kg at 26 weeks minus weight at baseline.', 'timeFrame': 'Baseline vs 26 weeks'}]",3,40 Years,75 Years,ALL,False,University of Washington,OTHER,10,102.0,ACTUAL,2025-09-01T16:18:24.741561,v2_robust,True,True,True,False,False,
NCT05004805,COVID-19 Methylene Blue Antiviral Treatment,COVID-19 Methylene Blue Antiviral Treatment,Methylene Blue,"['Saline nasal spray', 'MB Spray', 'Methylene Blue', 'Placebo Spray']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Covid19,['Covid19'],[],COMPLETED,,2021-08-06,2021-12-12,"[{'measure': 'Recovery', 'description': 'A negative PCR test result for the SARS-CoV-2 using nasopharyngeal and oropharyngeal swabs', 'timeFrame': 'Day 14 after randomization'}, {'measure': 'Recovery', 'description': 'A negative PCR test result for the SARS-CoV-2 using nasopharyngeal and oropharyngeal swabs', 'timeFrame': 'Day 28 after randomization'}]","[{'measure': 'Clinical responce', 'description': 'Determined by the investigator', 'timeFrame': 'Day 28 after randomization'}, {'measure': 'Overall therapeutic response', 'description': 'The overall therapeutic response defined as a ""general cure"" or ""treatment failure"" and is calculated for each patient according to the patient\'s combination of clinical, radiological response, and PCR result.', 'timeFrame': 'Day 28 after randomization'}, {'measure': 'Resolution rate', 'description': 'The rate of resolution of fever, normalization of SpO2 (NEWS2), dynamics of target laboratory parameters (C-reactive protein, D-dimer)', 'timeFrame': 'Day 28 after randomization'}, {'measure': 'Clinical responce FUV', 'description': 'Determined by the investigator', 'timeFrame': 'Follow up visit, week 4 ± 3 days after discharge from the hospital'}, {'measure': 'Overall therapeutic response FUV', 'description': 'The overall therapeutic response defined as a ""general cure"" or ""treatment failure"" and is calculated for each patient according to the patient\'s combination of clinical, radiological response, and PCR result.', 'timeFrame': 'Follow up visit, week 4 ± 3 days after discharge from the hospital'}]",7,18 Years,,ALL,False,Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences,OTHER_GOV,1,24.0,ACTUAL,2025-09-01T16:18:24.741580,v2_robust,True,True,True,False,False,
NCT00884494,Ghrelin and Insulin Resistance,Role of Ghrelin in the Improvement of Insulin Resistance After Roux-en-Y Gastric Bypass Surgery,Ghrelin infusion to assess effects on insulin sensitivity,['Ghrelin infusion to assess effects on insulin sensitivity'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Obesity,"['Obesity', 'Insulin Resistance', 'Normal Weight,Healthy Controls']","['Obesity', 'Insulin resistance', 'Ghrelin']",COMPLETED,,2011-08,2014-05,"[{'measure': 'Evaluate the effect of ghrelin on insulin resistance in obese subject, as well as subjects in the immediate post-RYGB period.', 'timeFrame': '1 year'}]",[],1,18 Years,65 Years,ALL,True,Vanderbilt University Medical Center,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:24.741608,v2_robust,True,True,True,False,False,
NCT02634294,Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT,Induction of Graft Versus Tumor Effect of Pegylated Interferon Alpha-2b for Patients With Relapsed Hematological Malignancies After Allogeneic Stem Cell Transplantation,Peg interferon alfa-2b,"['PEG INTRON®', 'Peg interferon alfa-2b']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Hematological Neoplasms,"['Hematological Neoplasms', 'Recurrence']","['Hematological Neoplasms', 'recurrence', 'Hematopoietic Stem Cell Transplantation', 'peginterferon alfa-2b', 'Graft vs Host Disease']",COMPLETED,,2015-08,2021-12,"[{'measure': 'response rate of Peg interferon alpha-2b', 'description': 'the percentage of patients acquiring complete remission and partial remission to Peg interferon alpha-2b in 90 days after treatment', 'timeFrame': '90 days'}]","[{'measure': 'overall survival after relapsing', 'description': 'the percentage of patients still alive after 1 year', 'timeFrame': 'one year'}, {'measure': 'disease free survival after relapsing', 'description': 'the percentage of patients still alive and disease free after 1 year', 'timeFrame': 'one year'}]",3,14 Years,60 Years,ALL,False,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",OTHER,0,30.0,ACTUAL,2025-09-01T16:18:24.741617,v2_robust,True,True,True,False,False,
NCT02227394,Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients,"A Double Blind, Double Dummy, Randomized, Two Way Cross-over Study to Compare the Effects of Z7200 and Symbicort® Turbohaler on Functional Respiratory Imaging Parameters in Asthmatic Patients.",Z7200,"['Reference product', 'Test product', 'Symbicort® Turbohaler®', 'Z7200']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Asthma,"['Asthma', 'Asthma Chronic', 'Asthma Bronchial', 'Asthmatic']","['Asthma', 'Functional Respiratory Imaging', 'Computational Fluid Dynamic']",COMPLETED,,2014-08,2014-11,"[{'measure': 'Total Airway Volume (iVaw)', 'description': 'The Total Airway Volume is the amount of air that can be inhaled or exhaled during one respiratory cycle. This depicts the functions of the respiratory centers, respiratory muscles and the mechanics of the lung and chest wall. The higher the volume, the better the outcome.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'Total Airway Resistance (iRaw)', 'description': 'The Total Airway Resistance refers to degree of resistance to the flow of air through the respiratory tract during inspiration and expiration. The degree of resistance depends on many things, particularly the diameter of the airway and whether flow is laminar or turbulent. The higher the resistance, the worse the outcome.\n\nIn healthy men and women values range between 0.22 to 0.25 kPa/l.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'Number of Deposited Particles Per Pre-defined Airway Section', 'description': 'To evaluate the particle deposition in the lungs, the Computational Fluid Dynamic (CFD) was used. With CFD, based on the computed tomography (CT) derived geometries of the airways, it is possible to measure the resistance of all airways or subdivisions such as the smaller airways starting from the 3rd bifurcation onwards. The three-dimensional (3D) reconstruction in this CT-based imaging technique allows for an accurate measurement of local volume changes in the central and peripheral airways after the administration of the product. The increased sensitivity of this technique makes it possible to detect changes in airway caliber in early stages of asthma.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}]","[{'measure': 'Spirometry - FEV1', 'description': 'FEV1 = Forced Expiratory Volume in one second. Forced expiratory volume is the most important measurement of lung function. It measures how much air a person can exhale during a forced breath. The amount of air exhaled may be measured during the first (FEV1), second (FEV2), and/or third seconds (FEV3) of the forced breath.\n\nValues of between 80% and 120% of the average value are considered normal.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'Spirometry - FVC', 'description': 'FVC = Forced Vital Capacity: is the total amount of air exhaled during the FEV test.\n\nValues of between 80% and 120% of the average value are considered normal.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'Spirometry - PEF', 'description': 'PEF = Peak Expiratory Flow: is the maximum flow rate generated during a forceful exhalation, starting from full lung inflation.\n\nPEF rate primarily reflects large airway flow and depends on the voluntary effort and muscular strength of the patient.\n\nNormal adult peak expiratory flow ranges between around 400 and 700 liters per minute, although in older it can be lower.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'Spirometry - MEF25', 'description': 'MEF25 = Maximal Expiratory Flow at 25% of Forced Vital Capacity (FVC). This parameter is linked to the pathology/obstruction of small airways. Patients with airway obstruction frequently exhibit a marked decrease in MEF25.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'Spirometry - MEF50', 'description': 'MEF50 = Maximal Expiratory Flow at 50% of Forced Vital Capacity (FVC). MEF50 is the flow where half of forced vital capacity (FVC) remains to be exhaled. Also this parameter is linked to the pathology/obstruction of small airways. Patients with airway obstruction frequently exhibit a marked decrease in MEF50.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'Spirometry - FEV1/FVC Ratio', 'description': ""FEV1/FVC ratio = Tiffeneau Index. It is a calculated ratio use to diagnose obstructive and restrictive lung disease. It represents the proportion of a patient's vital capacity that he/she is able to expire in the first second of forced expiration to the full forced vital capacity. The result of this ratio is expressed as FEV1%.\n\nNormal values are approximately 75%."", 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'Body Plethysmography - FRC', 'description': 'FRC = Functional Residual Capacity. It is the volume in the lungs at the end of passive expiration. It is determined by opposing forces of the expanding chest wall and the elastic recoil of the lung. A normal FRC = 1.7 to 3.5 L.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'Body Plethysmography - TLC', 'description': 'TLC = Total Lung Capacity. It is the volume of air in the lungs upon the maximum effort of inspiration. Among healthy adults, the average lung capacity is about 6 liters. Age, gender, body composition, and ethnicity are factors affecting the different ranges of lung capacity among individuals.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'Body Plethysmography - Raw', 'description': 'Raw = Airway resistance. It is defined as the change in transpulmonary pressure (proximal airway pressure minus the alveolar pressure) required to produce a unit flow of gas through the airways of the lung.\n\nAre considered as normal all values up to 2.8 kPas/L', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'Body Plethysmography - SRaw', 'description': 'SRaw = Specific airway resistance: also called volumic airway resistance. sRaw is a corrected index (Raw multiplied by thoracic gas volume) that describes airway behaviour regardless of lung volume. Normal values of sRaw in adult subjects have never been formally defined.\n\nsRaw is the product of Functional Residual Capacity (FRC) and Airways Resistance (Raw) and can be calculated from the relationship of plethysmographic box pressure (Pbox) to flow during spontaneous breathing.\n\nsRaw can be derived from the tangent of the slope of box Pressure/Flow. Since Raw has a strong inverse relationship to lung volume, sRaw provides a relatively stable index with which to distinguish effects of disease from those of growth and development. sRaw is significantly increased in asthmatic patients, in those with wheezing disorders, and cystic fibrosis. It has also been shown to be a useful outcome measure for bronchodilator responsiveness studies.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'Inhalation Profile', 'description': ""The patients' inhalation profile was assessed using a respiration belt. The inhalation profile through device was to be recorded at the moment of study drug administration. Respiratory belts are useful in measuring changes in thoracic or abdominal circumference during respiration. These measurements can indicate inhalation, expiration and breathing strength and can be used to derive breathing rate and characterize breathing patterns"", 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': '6MWT', 'description': '6MWT = 6 Minutes Walk Test (in meters). The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. The longer the walk in that timespan, the better the outcome.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'Borg CR10 Scale (Pre-6MWT)', 'description': 'Borg category (C) ratio (R) 10 scale = The original Borg CR10 Scale is used to measure the intensity of dyspnoea and fatigue during an exercise (in this case before the walk test). The original one was referred to as a numerical category scale going from 0 to 10. The top of the scale, ""0 or nothing at all,"" means no breathlessness at all.\n\nThe bottom of the scale, ""10 or maximal,"" means the most severe breathlessness that patients have ever experienced or could imagine experiencing.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'Borg CR10 Scale (Post-6MWT)', 'description': 'Borg category (C) ratio (R) 10 scale = The original Borg CR10 Scale is used to measure the intensity of dyspnoea and fatigue during an exercise (in this case after the walk test). The original one was referred to as a numerical category scale going from 0 to 10. The top of the scale, ""0 or nothing at all,"" means no breathlessness at all.\n\nThe bottom of the scale, ""10 or maximal,"" means the most severe breathlessness that patients have ever experienced or could imagine experiencing.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'VAS (Pre-6MWT)', 'description': 'VAS = Visual Analogue Scale. A VAS is typically scored by measuring the distance from the bottom of the scale (or left side if oriented horizontally) (In this case before the walk test) to the level indicated by the subject. VAS is typically represented as a vertical or horizontal line, usually 100 millimeters (mm) in length, with descriptors positioned at the extremes of the scale. These extremes go from ""not breathless at all""/no shortness of breath"" at the bottom or at the far left of the line, to ""shortness of breath as bad as can be"" on the top or on the right of the line, depending on the patient\'s opinion.\n\nmeasure of the difference in dyspnoea before and after treatment', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}, {'measure': 'VAS (Post-6MWT)', 'description': 'VAS = Visual Analogue Scale. A VAS is typically scored by measuring the distance from the bottom of the scale (or left side if oriented horizontally) (in this case after the walk test) to the level indicated by the subject. VAS is typically represented as a vertical or horizontal line, usually 100 millimeters (mm) in length, with descriptors positioned at the extremes of the scale. These extremes go from ""not breathless at all""/no shortness of breath"" at the bottom or at the far left of the line, to ""shortness of breath as bad as can be"" on the top or on the right of the line, depending on the patient\'s opinion.', 'timeFrame': 'Predose and postdose at the dosing visit V2 [ 7 (minimum) to 31 (maximum) days after Screening] or V3 [ 3 (minimum) to 31(maximum) days after visit 2] up to a maximun of Day 83.'}]",19,18 Years,,ALL,False,Zambon SpA,INDUSTRY,1,20.0,ACTUAL,2025-09-01T16:18:24.741643,v2_robust,True,True,True,False,False,
NCT00532194,An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer,"A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer",cediranib,"['Recentin', 'cediranib', 'AZD2171']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Ovarian Cancer,['Ovarian Cancer'],"['ovarian cancer', 'fallopian tube cancer', 'primary serous peritoneal cancer', 'gynaecological carcinoma', 'randomised controlled trial', 'Cediranib', 'AZD2171', 'efficacy']",UNKNOWN,,2007-07,2016-12,"[{'measure': 'Progression-free survival', 'timeFrame': 'Apr 2013'}]","[{'measure': 'Overall survival', 'timeFrame': 'Q2 2016'}, {'measure': 'Toxicity', 'timeFrame': 'Q2 2015'}, {'measure': 'Quality of Life', 'timeFrame': 'Q2 2015'}]",4,18 Years,,FEMALE,False,Medical Research Council,OTHER_GOV,6,486.0,ACTUAL,2025-09-01T16:18:24.741764,v2_robust,True,True,False,False,False,
NCT04049266,"A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.","A Phase 2b/3, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects With Neovascular (Wet) Age-related Macular Degeneration.",KSI-301,"['KSI-301', 'Aflibercept', 'Eylea']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Wet Macular Degeneration,['Wet Macular Degeneration'],"['AMD', 'Wet AMD', 'choroidal neovascularization secondary to age-related macular degeneration', 'KSI-301', 'Aflibercept', 'Vascular endothelial growth factor', 'VEGF', 'Anti-VEGF', 'Antibody biopolymer conjugate', 'Macular Degeneration', 'Wet Macular Degeneration', 'Retinal Degeneration', 'Retinal Diseases', 'Eye Diseases', 'Vision Disorders', 'Vision, low', 'Kodiak']",TERMINATED,Primary Endpoint Not Met,2019-10-08,2022-04-26,"[{'measure': 'Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48 and 52, Full Analysis Set Year 1', 'description': 'Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity.', 'timeFrame': 'Year 1'}]","[{'measure': 'Percentage of Subjects on KSI-301 Arm With a Once Every 12-Weeks, 16-Weeks or 20-Weeks Treatment Interval', 'description': 'Percentage of subjects on KSI-301 arm achieving a Once Every 12-Weeks, 16-Weeks or 20-Weeks Treatment Interval based on individualized treatment response', 'timeFrame': 'Year 1'}, {'measure': 'Percentage of Subjects Gaining ≥ 5, ≥10 and ≥15 Letters in BCVA From Baseline in the Study Eye, Full Analysis Set Year 1', 'description': 'Categorical improvements in Best Corrected Visual Acuity (BCVA) of clinically relevant BCVA measurements corresponding to 1, 2 and 3 lines of the ETDRS vision testing chart', 'timeFrame': 'Year 1'}, {'measure': 'Percentage of Subjects Who Achieving BCVA Snellen Equivalent of 20/40 or Better in the Study Eye at Year 1', 'description': 'Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. BCVA Snellen equivalent of 20/40 was defined as ≥69 ETDRS letters', 'timeFrame': 'Year 1'}, {'measure': 'Percentage of Subjects With BCVA Snellen Equivalent of 20/200 or Worse in the Study Eye at Year 1', 'description': 'Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. BCVA Snellen equivalent of 20/200 or Worse was defined as BCVA ≤ 38 ETDRS Letters.', 'timeFrame': 'Year 1'}, {'measure': 'Mean Change in OCT Central Subfield Retinal Thickness (CST) From Day 1', 'description': 'Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) as assessed by a central reading center.', 'timeFrame': 'Year 1'}]",6,50 Years,,ALL,False,Kodiak Sciences Inc,INDUSTRY,0,559.0,ACTUAL,2025-09-01T16:18:24.742115,v2_robust,True,True,False,True,False,Primary Endpoint Not Met
NCT04623866,Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules,A Single Center Randomized Controlled Clinical Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules,Huaiqinhuang,"['Valsartan capsule', 'valsartan', 'Huaiqihuang granules', 'Huaiqinhuang']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Henoch Schönlein Purpura Nephritis,['Henoch Schönlein Purpura Nephritis'],[],UNKNOWN,,2020-11-01,2021-08-30,"[{'measure': 'change of urinary protein', 'description': '24-hour urinary protein quantitative, urinary microprotein', 'timeFrame': 'before Clinical trials; 1 month, 2 months, 3 months, 6 months after randomization'}, {'measure': 'Change in renal function of the patients', 'description': 'blood chemistry', 'timeFrame': 'before Clinical trials; 1 month, 2 months, 3 months, 6 months after randomization'}, {'measure': 'change of lymphocyte subsets', 'description': 'including Th1 cells, Th2 cells, Th17 cells, cytokines (IL-16, IL-10, IL-17, etc.)', 'timeFrame': 'before Clinical trials; 1 month, 2 months, 3 months, 6 months after randomization'}, {'measure': 'change of immunoglobulin + complement', 'description': 'immunoglobulin + complement', 'timeFrame': 'before Clinical trials; 1 month, 2 months, 3 months, 6 months after randomization'}, {'measure': 'change of urine red blood cells', 'description': 'red blood cells routine urine', 'timeFrame': 'before Clinical trials; 1 month, 2 months, 3 months, 6 months after randomization'}]","[{'measure': 'Change of blood pressure', 'description': 'blood pressure', 'timeFrame': 'before Clinical trials; 1 month, 2 months, 3 months, 6 months after randomization'}, {'measure': 'change of BMI(Body Mass Index)', 'description': 'calculated by dividing weight in kilograms by height in meters squared( kg/m\\^2)', 'timeFrame': 'before Clinical trials; 1 month, 2 months, 3 months, 6 months after randomization'}]",7,6 Years,14 Years,ALL,False,The Children's Hospital of Zhejiang University School of Medicine,OTHER,0,10.0,ESTIMATED,2025-09-01T16:18:24.742437,v2_robust,True,True,False,False,False,
NCT05641766,Multimodal Magnetoencephalography and Electroencephalography Exploration of the Acute Effects of THC Exposure on Neural Noise and Information Transmission Within Working Memory Networks,Multimodal Magnetoencephalography and Electroencephalography Exploration of the Acute Effects of THC Exposure on Neural Noise and Information Transmission Within Working Memory Networks,THC,['THC'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,THC,['THC'],"['MEG', 'EEG', 'THC', 'Placebo', 'Working Memory', 'Neural Noise', 'Cognitive Process']",NOT_YET_RECRUITING,,2025-08-31,2025-12-01,"[{'measure': 'Changes in brain dynamics during the Sternberg Working Memory Task', 'description': 'Changes in brain dynamics will be characterized during the Sternberg Working Memory Task where participants are presented with a list of items to memorize, followed by a memory maintenance period during which the subject must maintain the list of items in memory.', 'timeFrame': 'Baseline and starting at +15 minutes after start of IV THC or placebo administration'}]","[{'measure': 'Visual Analog Scale (VAS)', 'description': 'To confirm the acute effects of THC, feeling states associated with cannabis intoxication will be measured using a self-reported visual analogue scale of four feeling states (""high"",""anxious"",""calm and relaxed"", and ""tired"") associated with cannabis effects. Subjects will be asked to score the perceived intensity of these feeling states at that moment on a 11mm line from 0=not at all to 100=extremely.', 'timeFrame': 'Baseline and starting at +15 minutes after start of IV THC or placebo administration'}, {'measure': 'Clinician Administered Dissociative Symptoms Scale (CADSS)', 'description': 'To confirm the acute effects of cannabis, perceptual alterations will be measured using the CADSS. This is a scale consisting of 19 self-report items and 8 clinician-rated items scored 0=not at all to 4=extremely. The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment.', 'timeFrame': 'Baseline and starting at +15 minutes after start of IV THC or placebo administration'}]",3,21 Years,65 Years,ALL,True,Yale University,OTHER,1,50.0,ESTIMATED,2025-09-01T16:18:24.742456,v2_robust,True,True,False,False,False,
NCT07047066,A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma,A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma,Fluzoparib with Temozolomide,['Fluzoparib with Temozolomide'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Glioblastoma,['Glioblastoma'],[],NOT_YET_RECRUITING,,2025-07-10,2027-07-31,"[{'measure': 'OS', 'description': 'Defined as the time from the date of randomization to death from any cause.', 'timeFrame': 'Patients were assessed up to 36 months from enrollment to first death (whichever occurred first)'}]","[{'measure': 'PFS', 'description': 'PFS is defined as the time (in days) from the first use of study drug to the first observation of disease progression.', 'timeFrame': 'From enrollment to the first appearance of disease progression or date death from any cause,whichever came first,assessed up to 36 mounths'}, {'measure': 'ORR', 'description': 'Objective response rate', 'timeFrame': 'From enrollment to initial efficacy evaluation ,assessed up to 6 months'}]",3,18 Years,70 Years,ALL,False,Tongji Hospital,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:24.742494,v2_robust,True,True,False,False,False,
NCT02472366,"A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy",,ILUVIEN,['ILUVIEN'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Diabetic Macular Edema,['Chronic Diabetic Macular Edema'],[],COMPLETED,,2014-01,2015-05,"[{'measure': 'Changes in Best Corrected Visual Acuity From Baseline', 'description': 'Best Corrected Visual Acuity is measured using an ETDRS eye chart and is reported as the number of letters read correctly in the study and/or fellow eye.', 'timeFrame': 'Change from Baseline to 12 months post ILUVIEN administration'}]","[{'measure': 'Changes in Intraocular Pressure (IOP)', 'timeFrame': 'Change from Baseline to 12 months post ILUVIEN administration'}, {'measure': 'Changes in Central Subfield Thickness', 'timeFrame': 'Change from Baseline to 12 months post ILUVIEN administration'}, {'measure': 'Changes in Macular Volume', 'timeFrame': 'Change from Baseline to 12 months post ILUVIEN administration'}]",4,18 Years,,ALL,False,Alimera Sciences,INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:24.742508,v2_robust,True,True,True,False,False,
NCT00004066,"Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma",A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma,docetaxel,"['gemcitabine hydrochloride', 'docetaxel']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Cancer,"['Ovarian Cancer', 'Sarcoma', 'Small Intestine Cancer']","['adult leiomyosarcoma', 'recurrent adult soft tissue sarcoma', 'small intestine leiomyosarcoma', 'stage IV uterine sarcoma', 'recurrent uterine sarcoma', 'uterine leiomyosarcoma', 'ovarian sarcoma', 'recurrent small intestine cancer', 'stage IV adult soft tissue sarcoma']",COMPLETED,,1999-06,2003-10,[],[],0,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,82.0,ESTIMATED,2025-09-01T16:18:24.742538,v2_robust,True,True,True,False,False,
NCT02016066,"A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants","A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Japanese Subjects to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 Following Single Intravenous Administration",CR6261,"['CR6261', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Healthy', 'CR6261', 'Japanese', 'Safety', 'Pharmacokinetics', 'Immunogenicity']",WITHDRAWN,Study terminated due to business decision,2013-12,2014-04,"[{'measure': 'Number of participants with adverse events', 'timeFrame': 'Up to 76 days'}]","[{'measure': 'Maximum observed serum CR6261 concentration', 'timeFrame': 'Day 1 (predose, 0.5, 2.25, 4, and 8 hours), Day 2, Day 3, Day 4, Day 8, Day 15, Day 29, Day 43, Day 57, Day 76 or early withdrawal day'}, {'measure': 'Time to reach the maximum observed serum CR6261 concentration', 'timeFrame': 'Day 1 (predose, 0.5, 2.25, 4, and 8 hours), Day 2, Day 3, Day 4, Day 8, Day 15, Day 29, Day 43, Day 57, Day 76 or early withdrawal day'}, {'measure': 'Area under the serum CR6261 concentration-time curve', 'timeFrame': 'Day 1 (predose, 0.5, 2.25, 4, and 8 hours), Day 2, Day 3, Day 4, Day 8, Day 15, Day 29, Day 43, Day 57, Day 76 or early withdrawal day'}, {'measure': 'Level of antibodies to CR6261 in serum samples', 'description': 'Level of antibodies to CR6261 in serum samples will evaluate immunogenecity.', 'timeFrame': 'Day 1 (predose), Day 29, Day 57, Day 76 or early withdrawal day'}]",5,20 Years,50 Years,MALE,True,Janssen Pharmaceutical K.K.,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:24.742595,v2_robust,True,True,False,True,True,Study terminated due to business decision
NCT06504966,"Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®","A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Sourced From the European Union in Postmenopausal Women With Osteoporosis",MAB-22,"['Prolia®', 'MAB-22']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Osteoporosis,['Osteoporosis'],[],WITHDRAWN,Business decision not to proceed with the study.,2025-10,2027-10,"[{'measure': 'To compare MAB-22 and Prolia® (EU-authorized) in postmenopausal women with osteoporosis to demonstrate biosimilarity and non-inferiority with respect to efficacy profile in terms of bone mineral density (BMD).', 'description': 'Efficacy coprimary endpoint: percentage change from baseline (%CfB) in lumbar spine bone mineral density (BMD) (LS-BMD)', 'timeFrame': 'Day 1 to Week 52'}, {'measure': 'To compare MAB-22 and Prolia® (EU-authorized) in postmenopausal women with osteoporosis to demonstrate biosimilarity and non-inferiority with respect to Pharmacodynamic (PD) profile in terms of serum cross-linked C telopeptide of type I collagen (sCTX).', 'description': 'PD coprimary endpoint: area under the effect curve (AUEC) of C telopeptide of type I collagen (sCTX) over the initial 6-month period', 'timeFrame': 'Day 1 to Week 26 [Predose]'}]",[],2,55 Years,80 Years,FEMALE,False,"Xentria, Inc.",INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:24.742639,v2_robust,True,True,False,True,False,Business decision not to proceed with the study.
NCT06582966,"Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya","Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya",Doxycyclin,['Doxycyclin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,STI,['STI'],['STI'],COMPLETED,,2024-08-13,2024-12-31,"[{'measure': 'doxyPEP DOT adherence', 'description': 'Confirmation of weekly doxyPEP DOT dosing each week will be recorded on weekly CRFs and quarterly surveys on acceptability will be completed.', 'timeFrame': '6 months'}]",[],1,18 Years,30 Years,FEMALE,False,University of Washington,OTHER,1,60.0,ACTUAL,2025-09-01T16:18:24.742681,v2_robust,True,True,True,False,False,
NCT00799266,An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids,"A Multicenter, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly Compared to Placebo in Osteoporotic Children Treated With Glucocorticoids.",Zoledronic acid,"['Zoledronic acid', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Osteoporosis,['Osteoporosis'],"['Osteoporosis, children and adolescents, zoledronic acid, chronic inflammation, Duchenne muscular dystrophy, glucocorticoids, chronic inflammatory conditions']",COMPLETED,,2008-12-04,2018-03-05,"[{'measure': 'Mean Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-score at Month 12', 'description': 'Lumbar Spine Bone Mineral Density (BMD) Z-score was determined by the central imaging vendor before first treatment and at Month 12. The methods to be used to measure Lumbar Spine BMD Z-score were described in the respective DXA Manuals provided by central imaging vendor. Positive changes from baseline indicated an improvement in condition.', 'timeFrame': 'Month 12'}]","[{'measure': 'Mean Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-score at Month 6', 'description': 'Lumbar Spine Bone Mineral Density (BMD) Z-score was determined by the central imaging vendor before first treatment and at Month 6. The methods to be used to measure Lumbar Spine BMD Z-score were described in the respective DXA Manuals provided by central imaging vendor. Positive changes from baseline indicated an improvement in condition.', 'timeFrame': 'Month 6'}, {'measure': 'Mean Change From Baseline in Lumbar Spine BMC at Month 6 and 12', 'description': 'Lumbar Spine BMC was determined by the central imaging vendor before first treatment and at Months 6 and 12. The methods to be used to measure BMC were described in the respective DXA Manuals.', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Mean Change From Baseline in Total Body BMC at Month 6 and 12', 'description': 'Total body BMC was all determined by the central imaging vendor before first treatment and at Months 6 and 12. The methods to be used to measure BMC were described in the respective DXA Manuals.', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Mean Change From Baseline in Serum P1NP at Months 6 and 12', 'description': 'Serum Procollagen type 1 amino-terminal propeptide (P1NP) was collected before first treatment (baseline) and at Months 6 and Month 12 according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory.', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Mean Change From Baseline in BSAP at Months 6 and 12', 'description': 'Bone specific alkaline phosphatase (BSAP) were collected before first treatment (baseline) and at Months 6 and Month 12 according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory.', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Mean Change From Baseline in Serum NTX at Months 6 and 12', 'description': 'Serum Cross linked N-telopeptide (NTX) were collected before first treatment (baseline) and at Months 6 and Month 12 according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory.', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Mean Change From Baseline in Serum TRAP-5b at Months 6 and 12', 'description': 'Serum Tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) was collected before first treatment (baseline) and at Months 6 and Month 12 according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory.', 'timeFrame': 'Month 6, Month 12'}, {'measure': 'Number of Participants With New Vertebral Fractures at Month 12', 'description': 'New vertebral fractures were defined as fractures of Genant Grade 1 or higher that occurred at lumbar or thoracic spine from first dose infusion to the end of the study.', 'timeFrame': 'Month 12'}, {'measure': 'Mean Change From Baseline in Vertebral Morphometry at Month 12', 'description': 'Vertebral morphometry (or concave index) was calculated using the average ratio between mid-height and posterior height from L1 to L4 and performed by a central reader.', 'timeFrame': 'Month 12'}, {'measure': 'Percentage of Patients With Reduction in Pain at Months 3, 6, 9 and 12', 'description': ""Pain was evaluated at each visit (in office and telephone visit) at randomization, Months 3, 6, 9 and 12 using the Faces Pain Scale-Revised (FPS-R). Children were selecting the face that best fits their pain. The pain score ranged from 0 (No Pain) to 10 (Very Much Pain). The reduction in pain from baseline by visit was evaluated based on whether or not patients had a decrease in their FPS-R from baseline. If pain remained the same or worsened from baseline a patient was classified as '0' and if the pain scale decreased then the patient was classified as '1'."", 'timeFrame': 'Month 3, Month 6, Month 9 and Month 12'}, {'measure': 'Mean Change From Baseline in 2nd Metacarpal Cortical Width at Month 12', 'description': 'Left posteroanterior (PA) hand/wrist X-ray were taken at Visit 1 and at the Month 12 visit to assess bone age and the between-treatment differences for change in 2nd metacarpal cortical width at Month 12 relative to baseline. If a fracture of the left upper extremity precluded radiographic imaging, then the right hand was evaluated for this purpose. In this case, the right hand was be imaged at both Visit 1 and at Month 12. The information was used in the assessment of bone density.', 'timeFrame': 'Month 12'}, {'measure': 'Urinary Concentration of Zoledronic Acid at Month 12', 'description': 'Urine was collected overnight or for at least 4 waking hours from all patients able to provide specimens, to measure urinary concentration of zoledronic acid at Month 12. Only descriptive analysis done.', 'timeFrame': 'Month 12'}, {'measure': 'Safety of Zoledronic Acid for the Treatment of Osteoporotic Children Treated With Glucocorticoids', 'description': 'Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that zoledronic acid is safe for the treatment of osteoporotic children treated with glucocorticoids through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive analysis done.', 'timeFrame': 'Baseline through Month 12'}]",14,5 Years,17 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,34.0,ACTUAL,2025-09-01T16:18:24.742690,v2_robust,True,True,True,False,True,
NCT02805556,Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing,Study of the Absolute Bioavailability of BMS-626529 in Healthy Subjects Following Oral Dosing of BMS-663068 and Intravenous Dosing of BMS-626529,BMS-663068,"['BMS-626529', 'BMS-663068']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Infection, Human Immunodeficiency Virus","['Infection, Human Immunodeficiency Virus']",[],COMPLETED,,2016-03-15,2016-05-05,"[{'measure': 'The absolute bioavailability of BMS-626529 after single oral (BMS-663068) and single intravenous dosing ([13C]-BMS-626529) by assessing the primary endpoints AUC(inf)', 'timeFrame': 'up to 11 days'}]","[{'measure': 'Safety and tolerability of single oral dose of BMS-663068 as determined by medical review of adverse event reports, vital sign measurements, electrocardiograms (ECGs), and results of physical examination and laboratory tests', 'timeFrame': 'up to 31 days'}, {'measure': 'Safety and tolerability of single intravenous dose of [13C]-BMS-626529 as determined by medical review of adverse event reports, vital sign measurements, electrocardiograms (ECGs), and results of physical examination and laboratory tests', 'timeFrame': 'up to 31 days'}]",3,18 Years,50 Years,MALE,True,ViiV Healthcare,INDUSTRY,1,36.0,ACTUAL,2025-09-01T16:18:24.742751,v2_robust,True,True,True,False,True,
NCT06998056,Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis,"A Phase 2, Open Label, 4-Week, Safety Study of Roflumilast Cream 0.05% Administered Once Daily in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis",ARQ-151 cream 0.05%,['ARQ-151 cream 0.05%'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Atopic Dermatitis (Eczema),['Atopic Dermatitis (Eczema)'],"['atopic dermatitis', 'eczema']",RECRUITING,,2025-06-09,2026-06,"[{'measure': 'Subject incidence of adverse events', 'description': 'Number of participants with adverse events during treatment will be assessed', 'timeFrame': '4 weeks'}, {'measure': 'Subject incidence of serious adverse events', 'description': 'Number of participants with serious adverse events during treatment will be assessed', 'timeFrame': '4 weeks'}, {'measure': 'Incidence of application site reactions', 'description': 'Number of subjects that experience an application site skin reaction by investigator assessment and application site reactions reported as adverse events will be assessed', 'timeFrame': '4 weeks'}]",[],3,3 Months,2 Years,ALL,False,"Arcutis Biotherapeutics, Inc.",INDUSTRY,0,100.0,ESTIMATED,2025-09-01T16:18:24.742760,v2_robust,True,True,False,False,True,
NCT05348356,Nirogacestat in Ovarian Granulosa Cell Tumors,A Phase 2 Trial of Nirogacestat in Patients With Recurrent Ovarian Granulosa Cell Tumors,Nirogacestat,"['PF-03084014', 'Nirogacestat']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Granulosa-Stromal Tumor,"['Ovarian Granulosa-Stromal Tumor', 'Ovarian Granulosa Cell Tumor', 'Ovarian Cancer']",[],ACTIVE_NOT_RECRUITING,,2022-08-30,2027-12,"[{'measure': 'Objective Response Rate (ORR)', 'description': 'The proportion of participants with complete response (CR) + partial response (PR) assessed using RECIST v1.1 criteria.', 'timeFrame': '2.5 years'}]","[{'measure': 'Progression Free Survival at 6 months (PFS-6)', 'description': 'The number of participants without progression according to RECIST v1.1 or death at 6 months.', 'timeFrame': 'First day of cycle 7 (approximately 6 months after the first dose of study treatment). Each cycle is 28 days.'}, {'measure': 'Overall Survival', 'description': 'The number of participants who have not died of any cause.', 'timeFrame': '2 years after first dose of study treatment'}, {'measure': 'Participant reported ovarian cancer symptoms', 'description': 'Change from baseline as measured by Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI).', 'timeFrame': 'At each study visit until study completion (estimated to be an average of 2.5 years)'}, {'measure': 'Duration of Response', 'description': 'The time from response (CR + PR using RECIST v.1.) to disease progression and/or death', 'timeFrame': 'First day of every other cycle (each cycle is 28 days) for the first year, and then every 3 cycles thereafter until study completion (estimated to be an average of 2.5 years).'}]",5,18 Years,,FEMALE,False,"SpringWorks Therapeutics, Inc.",INDUSTRY,0,53.0,ACTUAL,2025-09-01T16:18:24.742808,v2_robust,True,True,False,False,False,
NCT00238056,Effect of Domperidone on QT Interval in Premature Infants,Effect of Domperidone on QT Interval in Premature Infants,domperidone Drug,['domperidone Drug'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Prematurity and Feeding Intolerance,['Prematurity and Feeding Intolerance'],"['Domperidone, QT, prematurity']",COMPLETED,,,,[],[],0,10 Days,,ALL,False,Nantes University Hospital,OTHER,0,,,2025-09-01T16:18:24.742903,v2_robust,True,True,True,False,False,
NCT00322556,Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID),A Multicenter Extension Study on the Safety and Efficacy of IgPro10 in Patients With Primary Immunodeficiency (PID),Immunoglobulins Intravenous (Human),['Immunoglobulins Intravenous (Human)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Agammaglobulinemia,"['Agammaglobulinemia', 'IgG Deficiency', 'Common Variable Immunodeficiency']","['Immunoglobulin Intravenous', 'Agammaglobulinemia', 'Hypogammaglobulinemia', 'Common variable immunodeficiency', 'Immunoglobulin G', 'Children']",COMPLETED,,2005-11,2008-04,"[{'measure': 'The Proportion of Infusions With One or More Temporally-associated Adverse Events (AEs).', 'description': 'AEs were considered temporally-associated AEs if they occurred during the infusion or in the period from the start of the infusion until either 48 or 72 hours after the end of the infusion.', 'timeFrame': 'During each infusion, and within 48 or 72 hours after the end of each infusion.'}, {'measure': 'Influence of Infusion Rate on Temporally-Associated AEs', 'description': 'The total and most frequent (1% or more) number of infusions for which subjects experienced temporally-associated AEs occurring within 72 hours of infusion, by infusion rate (≤ 4 mg/kg/min, ≤ 8 mg/kg/min, and \\> 8 and ≤ 12 mg/kg/min).\n\nAEs were considered to be temporally-associated AEs if they occurred in the period from the start of the infusion until 72 hours after the end of the infusion.', 'timeFrame': 'Within 72 hours after each infusion'}, {'measure': 'Rate of AEs by Severity and Relationship', 'description': 'The AE rate was the number of AEs over the number of infusions administered.\n\nMild AEs: Did not interfere with daily activities; Moderate AEs: Interfered with routine daily activities; Severe AEs: Impossible to perform routine daily activities.\n\nAt least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.', 'timeFrame': 'For the duration of the study, up to approximately 29 months'}, {'measure': 'Number of Subjects With Clinically Significant Changes in Vital Signs.', 'description': 'Vital signs included heart rate, systolic blood pressure, diastolic blood pressure, and body temperature.', 'timeFrame': 'Before, during, and after each infusion.'}]","[{'measure': 'Annualized Rate of Acute Serious Bacterial Infections.', 'description': 'The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.\n\nAcute serious bacterial infections included pneumonia, bacteremia / septicemia, osteomyelitis / septic arthritis, bacterial meningitis, and visceral abscess.', 'timeFrame': 'For the duration of the study, up to approximately 29 months'}, {'measure': 'Number of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Illness.', 'timeFrame': 'For the duration of the study, up to approximately 29 months.'}, {'measure': 'Number of Days of Hospitalization.', 'timeFrame': 'For the duration of the study, up to approximately 29 months'}, {'measure': 'Annualized Rate of Any Infection.', 'description': 'The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.\n\nInfections were classified as all AEs with the system organ class ""infections and infestations"" and AEs with the preferred term ""conjunctivitis"".', 'timeFrame': 'For the duration of the study, up to approximately 29 months.'}, {'measure': 'Trough Levels of Total Immunoglobulin (IgG) Serum Concentrations.', 'description': ""Mean IgG trough concentration. For this analysis, each subject's values were first aggregated to their median and the median values were then analyzed."", 'timeFrame': 'Prior to each infusion; every 3 or 4 weeks depending upon the dosing schedule.'}]",9,4 Years,71 Years,ALL,False,CSL Behring,INDUSTRY,0,55.0,ACTUAL,2025-09-01T16:18:24.742926,v2_robust,True,True,True,False,True,
NCT00287456,Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.,,Insulin,"['0', 'Insulin']",2,INTERVENTIONAL,['NA'],,,Cystic Fibrosis Related Diabetes,['Cystic Fibrosis Related Diabetes'],[],WITHDRAWN,,2006-02-02,2006-02-02,[],[],0,12 Years,32 Years,ALL,False,University of Texas Southwestern Medical Center,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:24.743023,v2_robust,True,True,False,True,False,
NCT06973356,Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia,An Exploratory Clinical Study of Anti-CD19/BCMA CAR Gene Vector Injection (LCAR1901) for the Treatment of Relapsed and Refractory Immune Thrombocytopenia,Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.,['Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.'],1,INTERVENTIONAL,['NA'],,,Immune Thrombocytopenia (ITP),['Immune Thrombocytopenia (ITP)'],"['immune thrombocytopenia', 'Autoimmune diseases']",RECRUITING,,2025-08-16,2029-06-30,"[{'measure': '1. Adverse events', 'description': 'Total number, incidence and severity of adverse events (AEs) in patients of LCAR1901 infusion. The AEs will be assessed according to the 2019 Consensus on Cytokine Release Syndrome and Immune-cell-associated Neurotoxicity published by the American Society of Transplantation and Cell Therapy (ASTCT), the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 and EBMT 2019 consensus', 'timeFrame': 'up to 1 years'}]","[{'measure': '2. The persistence of CAR gene vector injection', 'description': 'Assessing the trafficking of CAR gene vector injection in the peripheral blood at the time of each infusion as well as at each time of follow-up by flow cytometry. Peripheral blood will be collected prior to the initial infusion and will be set as baseline', 'timeFrame': 'up to 1 years'}, {'measure': 'Overall remission rate', 'description': 'Complete response (CR): Platelet count ≥ 100 × 10\\^9/L and no bleeding; Partial response (PR): platelet count\\<100 × 10\\^9/L, but increased by at least 2 times compared to baseline platelet count, with no bleeding symptoms', 'timeFrame': 'up to 1 years'}]",3,18 Years,,ALL,False,Anhui Provincial Hospital,OTHER_GOV,0,18.0,ESTIMATED,2025-09-01T16:18:24.743056,v2_robust,True,True,False,False,True,
NCT01211756,Oxytocin Add-on for Stable Depressed Patients,"Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study of Intranasal Oxytocin Augmentation of Antidepressant Medication in Depressed Patients.",Oxytocin,"['Placebo', 'Oxytocin']",2,INTERVENTIONAL,['NA'],,,Major Depressive Disorder,"['Major Depressive Disorder', 'Dysthymia Disorder']",[],TERMINATED,Break in funding,2010-10,2015-12,"[{'measure': 'Total Score on Montgomery-Asberg Depression Rating Score (MADRS)', 'description': 'The MADRS is a clinician-rated assessment used to measure the severity of depressive episodes in patients with mood disorders. The measure contains 10 items and each item is scored in a range of 0 to 6 points, with higher score indicating increased depressive symptoms.', 'timeFrame': 'Performed at each visit (weekly)'}]","[{'measure': 'Global Assessment of Functioning (GAF)', 'description': 'The GAF considers psychological, social, and occupational functioning on a hypothetical continuum of mental health illness. Scores on the GAF range from 1 (extremely severe) to 100 (superior functioning).', 'timeFrame': 'Performed at each visit (weekly)'}, {'measure': 'Clinical Global Impression-Severity of Illness (CGI-S)', 'description': 'The CGI-S is used to evaluate changes in overall severity of illness. Scores on the CGI-S range from 1 (not at all) to 7(among the most extremely ill).', 'timeFrame': 'Performed at each visit (weekly)'}, {'measure': 'Clinical Global Impression-Global Improvement (CGI-I)', 'description': ""The CGI-I is a global assessment to evaluate the subjects' improvement or worsening from baseline. Scores on the CGI-I scale range from 1 (very much improved) to 7 (very much worse)."", 'timeFrame': 'Performed at each visit (weekly)'}, {'measure': 'Young Mania Rating Scale (YMRS)', 'description': 'The YMRS is an 11-item assessment used to assess the severity of mania in patients with a diagnosis of bipolar disorder. Ratings are based on patient self-reporting, combined with clinician observed.', 'timeFrame': 'Performed at each visit (weekly)'}, {'measure': 'Hamilton-Anxiety Scale (HAM-A)', 'description': 'The HAM-A is a clinician administered scale for the evaluation of anxiety symptoms. The HAM-A consists of 14 items of which each item is scored 0 (not present) to 4 (very severe).', 'timeFrame': 'Performed at each visit (weekly)'}, {'measure': ""Reading Trust in the Mind's Eye Test"", 'description': 'The subject will view approximately 16 faces and asked to rate trustfulness of the person in the picture.', 'timeFrame': 'Performed at the beginning and end of each treatment arm.'}, {'measure': 'Profile of Mood States (POMS)', 'description': 'The POMS is a self-rated scale to assess current mood states. The POMS consists of 65 words that the subject will rate from 1 (not at all) to 5 (extremely) based on how he/she feels at the time.', 'timeFrame': 'Performed at the beginning and end of each treatment arm'}, {'measure': 'Arizona Sexual Experience Scale (ASEX)', 'description': 'The ASEX is a self-rated scale to assess sexual functioning. The ASEX consists of 5 items that the subject will rate from 1 (Extremely strong, easily, or satisfying) to 6 (Absent or never) based on how he/she feels at the time.', 'timeFrame': 'Performed at each visit (weekly)'}, {'measure': 'Peabody Picture Vocabulary Test', 'description': 'The subject is read a series of words and is shown line drawings and is asked to match the word to the drawing.', 'timeFrame': 'Performed at the beginning of the study'}, {'measure': 'California Verbal Learning Test', 'description': 'The subject is read a list of words and asked to repeat them back first after the list is read and again 20 minutes later.', 'timeFrame': 'Performed at the beginning and end of each treatment arm'}, {'measure': 'Letter Number Sequencing Memory Test', 'description': 'The examinee is read a combination of numbers and letters and is asked to recall the numbers first in ascending order and then the letters in alphabetical order. Each item consists of three trials, and each trial is a different combination of numbers and letters.', 'timeFrame': 'Performed at the beginning and end of each treatment arm'}, {'measure': 'Continuous Performance Test (CPT)', 'description': 'Patients are told that they will see a series of letters presented on a screen. They are told to click a computer mouse only when they see the ""target"" stimulus, for instance the letter ""X"", and must refrain from clicking if they see any other letter presented.', 'timeFrame': 'Performed at the beginning and end of each treatment arm'}]",13,18 Years,,ALL,False,David Feifel,OTHER,0,1.0,ACTUAL,2025-09-01T16:18:24.743165,v2_robust,True,True,False,True,False,Break in funding
NCT05647356,The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2,The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2,Bicalutamide 50 mg,['Bicalutamide 50 mg'],1,INTERVENTIONAL,['NA'],,,Polycystic Ovary Syndrome,"['Polycystic Ovary Syndrome', 'Androgen Excess', 'Metabolic Disease']",[],NOT_YET_RECRUITING,,2023-01-01,2025-09-01,"[{'measure': 'To examine the impact of androgen receptor blockade (AR) on systemic and muscle-specific energy metabolism in women with PCOS and androgen excess', 'description': 'Change in whole body fatty acid oxidation on stable isotope breath after 28 days of androgen receptor (AR) blockade compared to baseline', 'timeFrame': '2.5 years'}]","[{'measure': 'To determine the relationship between androgen excess and serum/muscle non-targeted metabolomics', 'description': 'Changes in metabolomic pathways relating to energy balance and mitochondrial function in serum and muscle after AR blockade', 'timeFrame': '2.5 years'}, {'measure': 'To determine the impact of androgen receptor blockade on skeletal muscle mitochondrial morphology and function ex vivo', 'description': 'Changes in mitochondrial morphology ex vivo post AR blockade', 'timeFrame': '2.5 years'}, {'measure': 'To determine the impact of androgen receptor blockade on skeletal muscle mitochondrial morphology and function ex vivo', 'description': 'Differences in mitochondrial oxygen consumption and oxidative phosphorylation using Seahorse technology pre and post AR blockade', 'timeFrame': '2.5'}]",4,18 Years,40 Years,FEMALE,False,"Royal College of Surgeons, Ireland",OTHER,4,16.0,ESTIMATED,2025-09-01T16:18:24.743208,v2_robust,True,True,False,False,False,
NCT01469156,Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy,Treatment of Polypoidal Choroidal Vasculopathy With High Dose Ranibizumab (Lucentis): A Phase I Safety Study.,ranibizumab 0.5 or 2.0 mg/0.05 cc,"['ranibizumab 0.5 or 2.0 mg/0.05 cc', 'Lucentis']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Polypoidal Choroidal Vasculopathy,['Polypoidal Choroidal Vasculopathy'],"['polypoidal choroidal vasculopathy', 'choroidal neovascularization', 'ranibizumab', 'Lucentis']",COMPLETED,,2011-09,2015-02,"[{'measure': 'Incidence and Severity of Ocular and Systemic Adverse Events Will be Compared Between the 2.0mg or 1.0mg (HIGH DOSE) and 0.5 mg Groups.', 'description': 'Examples include 30 letter loss, major subretinal hemorrhage, involving 75% or more clinical macula (arcade to arcade), disease related vitreous hemorrhage, injection-related endophthalmitis, retinal detachment, vitreous hemorrhage, study drug/procedure - related uveitis, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs.', 'timeFrame': '2 years'}]","[{'measure': 'Mean Best Corrected Visual Acuity Letter Change at 4 Meters Between Baseline and 12 Months', 'timeFrame': '12 months'}, {'measure': 'Change in Mean Central Foveal Thickness From Baseline', 'timeFrame': '12 Months'}, {'measure': 'Mean Change From Baseline in Total Area of FA CNV Leakage Over 12 Months', 'timeFrame': '12 Months'}, {'measure': 'Number of Participants at Month 3 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters', 'timeFrame': '3 Months'}, {'measure': 'Number of Participants at Month 6 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters', 'timeFrame': '6 months'}, {'measure': 'Number of Participants at Month 9 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters', 'timeFrame': '9 Months'}, {'measure': 'Number of Participants at Month 12 With Best Corrected Visual Acuity Gain of 5, 10, and 15 or More Letters', 'timeFrame': '12 Months'}, {'measure': 'Mean Change Best Corrected Visual Acuity at 4 Meters at Baseline, Month 3, Month 6, Month 9, and Month 12', 'timeFrame': '12 months'}, {'measure': 'Number of Participants at Month 3 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters', 'timeFrame': '3 months'}, {'measure': 'Number of Participants at Month 6 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters', 'timeFrame': '6 months'}, {'measure': 'Number of Participants at Month 9 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters', 'timeFrame': '9 months'}, {'measure': 'Number of Participants at Month 12 With Best Corrected Visual Acuity Loss at 4 Meters of 5, 10 and 15 or More Letters', 'timeFrame': '12 months'}]",13,18 Years,,ALL,True,"Southeast Retina Center, Georgia",OTHER,1,20.0,ACTUAL,2025-09-01T16:18:24.743233,v2_robust,True,True,True,False,True,
NCT05391022,Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies,"A Phase 1, 2-Part Study to Evaluate the Effect of Food on Pharmacokinetics of Pelabresib (CPI-0610) and the Effect of Pelabresib on QTc in Patients With Advanced Malignancies",Pelabresib,"['Pelabresib', 'CPI 0610']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Malignancies,"['Advanced Malignancies', 'Solid Tumor', 'Hematological Malignancy']","['Pelabresib', 'CPI 0610']",COMPLETED,,2021-07-20,2024-02-29,"[{'measure': 'Run-In Food Effect Period: Area under the concentration time curve (AUC) based on pelabresib concentrations in plasma measured using validated plasma assay', 'description': 'The primary endpoint for the food effect is to investigate the effects high and low-fat meals have on the oral bioavailability of single doses of pelabresib', 'timeFrame': '21 days'}, {'measure': 'Run-In Food Effect Period: maximal plasma concentration (Cmax) based on pelabresib concentrations in plasma measured using validated plasma assay', 'description': 'The primary endpoint for the food effect is to investigate the effects high and low-fat meals have on the oral bioavailability of single doses of pelabresib', 'timeFrame': '21 days'}, {'measure': 'Run-In Food Effect Period: Time to maximal plasma concentration (Tmax) based on pelabresib concentrations in plasma measured using validated plasma assay', 'description': 'The primary endpoint for the food effect is to investigate the effects high and low-fat meals have on the oral bioavailability of single doses of pelabresib', 'timeFrame': '21 days'}, {'measure': 'Continuous Treatment Period: Changes in QT and QTc intervals', 'description': 'The primary endpoint of the QT portion is to determine the effect of single and multiple doses of pelabresib on QT/QTc prolongation', 'timeFrame': '12 months'}]","[{'measure': '-In Food Effect Period: Total amount (Ae[∞]) and fraction of dose (fe) of pelabresib', 'description': 'Ae(∞) and fe of pelabresib excreted into urine', 'timeFrame': '24 hours'}, {'measure': 'Run-In Food Effect Period and Continuous Treatment Period: incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs)', 'description': 'Safety: TEAEs and treatment-emergent SAEs', 'timeFrame': '12 months'}]",6,18 Years,,ALL,False,Constellation Pharmaceuticals,INDUSTRY,0,35.0,ACTUAL,2025-09-01T16:18:24.743281,v2_robust,True,True,True,False,True,
NCT00400322,Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection,A Randomized Double Blind Controlled Proof of Concept Study of the Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma With Successful Surgical Resection of at Least 90 % of the Initial Tumor and CMV Infection Demonstrated Histologically and Immunohistochemically.,Valganciclovir (Valcyte),['Valganciclovir (Valcyte)'],1,INTERVENTIONAL,['NA'],,,Glioblastoma Multiforme,"['Glioblastoma Multiforme', 'Cytomegalovirus Infection']","['glioblastoma multiforme', 'cytomegalovirus infection', 'antiviral treatment', 'valganciclovir']",COMPLETED,,2006-08,2008-06,"[{'measure': 'Tumor size', 'timeFrame': 'Week twelve'}, {'measure': 'Tumor size', 'timeFrame': 'Week twenty four'}]","[{'measure': 'Disease status', 'timeFrame': '24 months'}, {'measure': 'Patient survival', 'timeFrame': '24 months'}]",4,18 Years,,ALL,False,Karolinska Institutet,OTHER,1,42.0,ACTUAL,2025-09-01T16:18:24.743304,v2_robust,True,True,True,False,False,
NCT01207622,Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD,Efficacy of Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents and Young Adults With Substance Use Disorders (SUD),Atomoxetine,"['Atomoxetine', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Attention Deficit Hyperactivity Disorder,"['Attention Deficit Hyperactivity Disorder', 'Substance Use Disorder']",[],WITHDRAWN,Poor enrollment,,,[],[],0,15 Years,30 Years,ALL,False,Massachusetts General Hospital,OTHER,2,0.0,ACTUAL,2025-09-01T16:18:24.743314,v2_robust,True,True,False,True,False,Poor enrollment
NCT06571422,Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors,"A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of WJ47156 Monotherapy and in Combination With Other Anti-Tumor Therapies in Patients With Advanced Malignant Solid Tumors",WJ47156,"['Toripaliman injection+Bevacizumab Injection', 'WJ47156', 'JS001+Bevacizumab', 'JS207']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Malignant Solid Tumors,['Advanced Malignant Solid Tumors'],['Solid Tumors'],RECRUITING,,2024-10-23,2027-04-30,"[{'measure': '1.DLT', 'description': 'Safety endpoints: incidence and severity of DLT', 'timeFrame': '1 years'}, {'measure': '2、AE', 'description': 'Safety endpoints: incidence and severity of adverse events (AE); Abnormal changes in laboratory and other tests with clinical significance', 'timeFrame': '2.5 years'}, {'measure': '3、SAE', 'description': 'Safety endpoints: incidence and severity of serious adverse events (SAE); Abnormal changes in laboratory and other tests with clinical significance', 'timeFrame': '2.5 years'}, {'measure': '4.MTD', 'description': 'Maximum tolerated dose (MTD)', 'timeFrame': '1 year'}, {'measure': '5.RP2D', 'description': 'Recommended dose for phase II trial', 'timeFrame': '1 year'}]","[{'measure': '6.ORR', 'description': 'Efficacy endpoints: Objective response rate (ORR) per RECIST v1.1', 'timeFrame': '2 years'}, {'measure': '7.DOR', 'description': 'Efficacy endpoints: Duration of response (DOR) per RECIST v1.1', 'timeFrame': '2 years'}, {'measure': '8.DCR', 'description': 'Efficacy endpoints: Disease control rate (DCR) per RECIST v1.1', 'timeFrame': '2 years'}, {'measure': '9.PFS', 'description': 'Efficacy endpoints: Progression-free survival (PFS) per RECIST v1.1', 'timeFrame': '2 years'}, {'measure': '10.OS', 'description': 'Efficacy endpoints: Overall survival (OS)', 'timeFrame': '2.5 years'}, {'measure': '11.Peak concentration（Cmax）', 'description': 'The pharmacokinetic parameters of WJ47156：peak concentration (Cmax)', 'timeFrame': '2 years'}, {'measure': '12.The time to receive Cmax（Tmax）', 'description': 'The pharmacokinetic parameters of WJ47156 ：the time to receive Cmax（Tmax）', 'timeFrame': '2 years'}, {'measure': '13. Area under the plasma concentration-time curve (AUC0-t, AUC0-∞)', 'description': 'The pharmacokinetic parameters of WJ47156 ：area under the plasma concentration-time curve (AUC0-t, AUC0-∞)', 'timeFrame': '2 years'}, {'measure': '14.Apparent volume of distribution (Vd/F)', 'description': 'The pharmacokinetic parameters of WJ47156 ：apparent volume of distribution (Vd/F)', 'timeFrame': '2 years'}, {'measure': '15.Apparent clearance (CL/F)', 'description': 'The pharmacokinetic parameters of WJ47156 ：apparent clearance (CL/F)', 'timeFrame': '2 years'}, {'measure': '16.Terminal half-life (t1/2)', 'description': 'The pharmacokinetic parameters of WJ47156 ：terminal half-life (t1/2)', 'timeFrame': '2 years'}, {'measure': '17.Steady-state peak concentration(Cmax,ss)', 'description': 'The pharmacokinetic parameters of WJ47156 ：steady-state peak concentration(Cmax,ss) for the main PK parameters for multiple dose', 'timeFrame': '2 years'}, {'measure': '18.Plasma trough concentration at steady state(Cmin,ss)', 'description': 'The pharmacokinetic parameters of WJ47156 ：Plasma trough concentration at steady state(Cmin,ss) for the main PK parameters for multiple dose', 'timeFrame': '2 years'}, {'measure': '19.Mean plasma concentration at steady state(Cav,ss)', 'description': 'The pharmacokinetic parameters of WJ47156 ：mean plasma concentration at steady state for the main PK parameters for multiple dose', 'timeFrame': '2 years'}, {'measure': '20.The time to receive Cmax at steady state（Tmax,ss）', 'description': 'The pharmacokinetic parameters of WJ47156 ：the time to receive Cmax at steady state（Tmax,ss）for the main PK parameters for multiple dose)', 'timeFrame': '2 years'}, {'measure': '21.Area under the plasma concentration-time curve at steady state (AUC0-t, ss)', 'description': 'The pharmacokinetic parameters of WJ47156 ：area under the plasma concentration-time curve at steady state (AUC0-t, ss)for the main PK parameters for multiple dose)', 'timeFrame': '2 years'}, {'measure': '22.Accumulation factor(RAC)', 'description': 'The pharmacokinetic parameters of WJ47156 ：accumulation factor(RAC) at steady state for the main PK parameters for multiple dose)', 'timeFrame': '2 years'}, {'measure': '23.Fluctuation coefficient(FD)', 'description': 'The pharmacokinetic parameters of WJ47156 ：fluctuation coefficient(FD) at steady state for the main PK parameters for multiple dose)', 'timeFrame': '2 years'}]",23,18 Years,75 Years,ALL,False,"Shanghai Junshi Bioscience Co., Ltd.",OTHER,1,93.0,ESTIMATED,2025-09-01T16:18:24.743321,v2_robust,True,True,False,False,True,
NCT06371222,Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm,Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm - a Randomized Control Trial,Ivabradine,"['Beta blocker', 'Ivabradine', 'metoprolol']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Mitral Stenosis,['Mitral Stenosis'],[],COMPLETED,,2023-02-01,2024-02-01,"[{'measure': 'effect of ivabradine in MS patients', 'description': 'effect of ivabradine from baseline with the study drugs on heart rate', 'timeFrame': 'three months'}]","[{'measure': 'quality of life of MS patients', 'description': 'Questionnaire to assess quality of life changes', 'timeFrame': 'three months'}]",2,17 Years,80 Years,ALL,False,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",OTHER,0,42.0,ACTUAL,2025-09-01T16:18:24.743465,v2_robust,True,True,True,False,False,
NCT05874622,A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.,"A Randomized, Double-blind, Dose-escalating, Placebo-controlled Phase Ib Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.",VC005 tablets,"['VC005 tablets', 'VC005 Tablets Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],[],COMPLETED,,2023-06-12,2023-10-25,"[{'measure': 'Peak time in plasma(Tmax)', 'timeFrame': 'Day1、Day8、Day15、Day22、Day28'}, {'measure': 'Peak Plasma Concentration (Cmax）', 'timeFrame': 'Day1、Day8、Day15、Day22、Day28'}]",[],2,18 Years,70 Years,ALL,False,"Jiangsu vcare pharmaceutical technology co., LTD",INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:24.743513,v2_robust,True,True,True,False,False,
NCT05029622,A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.,"A Phase III, Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Chinese Paediatric Participants With Central Precocious Puberty.",Triptorelin Pamoate,['Triptorelin Pamoate'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Central Precocious Puberty,['Central Precocious Puberty'],[],COMPLETED,,2021-08-10,2023-02-13,"[{'measure': 'Percentage of Participants With Luteinising Hormone (LH) Suppression', 'description': 'LH response was defined as a peak LH \\<=5 international units per liter (IU/L) after intravenous (IV) gonadotropin-releasing hormone (GnRH) stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of serum LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.', 'timeFrame': 'At Month 6'}]","[{'measure': 'Percentage of Participants With LH Response to GnRH Test', 'description': 'LH response was defined as a peak LH \\<=5 IU/L after IV GnRH stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of serum LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.', 'timeFrame': 'At Months 3 and 12'}, {'measure': 'Change From Baseline in Basal Serum LH and Follicle-Stimulating Hormone (FSH) Levels', 'description': 'Basal LH and FSH serum concentrations were analyzed centrally. Change from baseline was defined as the values for LH and FSH at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.', 'timeFrame': 'Baseline and at Months 3, 6, 9 and 12'}, {'measure': 'Change From Baseline in Peak Serum LH and FSH Level After the GnRH Stimulation Test', 'description': 'Peak LH and FSH serum concentrations were analyzed centrally. Change from baseline was defined as the values for LH and FSH at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered. Blood samples were collected prior to gonadorelin injection (timepoint T0) and at 30 minutes (T30), 60 minutes (T60) and 90 minutes (T90) after a single IV injection of gonadorelin. A suppressed LH response to GnRH stimulation test was defined as peak serum LH \\<=5 IU/L among the four timepoints (T0, T30, T60 and T90). The FSH response to GnRH stimulation was the peak serum FSH level among the four timepoints (T0, T30, T60 and T90).', 'timeFrame': 'Baseline and at Months 3, 6 and 12'}, {'measure': 'Percentage of Participants With LH Response (Peak LH <=5 IU/L) From Month 6 to Month 12', 'description': 'Peak LH serum concentration was analyzed centrally. LH response was defined as a peak LH \\<=5 IU/L after IV GnRH stimulation. The GnRH stimulation test was performed by using an IV injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of peak LH levels. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.', 'timeFrame': 'Month 6 to Month 12'}, {'measure': 'Percentage of Participants With Prepubertal Levels of Sex Steroids', 'description': 'Prepubertal sex steroids assessment included estradiol in female participants and testosterone in male participants. Prepubertal sex steroids levels were defined as: estradiol \\<=20 picogram (pg)/ milliliter (mL) in female participants and testosterone \\<=30 nanogram (ng)/ deciliter (dL) in male participants. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.', 'timeFrame': 'At Months 3, 6, 9 and 12'}, {'measure': 'Change From Baseline in Mean Height for Age (Z-Score)', 'description': 'Z-scores are calculated using Centers for Disease Control and Prevention (CDC) Growth Charts. Change from baseline was defined as the values for Z-score at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to study treatment administration. Negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.', 'timeFrame': 'Baseline and at Months 6 and 12'}, {'measure': 'Change From Baseline in Percentile for Height for Age', 'description': 'Z-scores were calculated using CDC growth charts, that contained Box-Cox transformation (L), the median (M) and the generalized coefficient of variation (S). Percentile was obtained using the following equation M (1 + LSZ) \\*\\* (1/L), where \\*\\* indicated an exponent, such that m (1+LSZ)\\*\\* (1/L) meant raising (1+LSZ) to the (1/L)th power and then multiplying the M. Z was the Z-score that corresponds to the percentile. Negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline was defined as the values for percentile of Z-score at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.', 'timeFrame': 'Baseline and at Months 6 and 12'}, {'measure': 'Change From Baseline in Growth Velocity', 'description': 'Growth velocity analysis was part of auxological parameter. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.', 'timeFrame': 'Baseline and at Months 6 and 12'}, {'measure': 'Percentage of Participants With Bone Age (BA)/Chronological Age (CA) Ratio Not Risen', 'description': 'BA was determined using X-rays of the hand and wrist by Greulich and Pyle method. CA was calculated as (visit date -birth date + 1)/365.25. Percentage of response was calculated as n/N\\*100, where n was number of participants in the specified category and N was number of participants in the analysis population.', 'timeFrame': 'At Months 6 and 12'}, {'measure': 'Change From Baseline in BA:CA Ratio', 'description': 'BA was determined using X-rays of the hand and wrist by Greulich and Pyle method. CA was calculated as (visit date -birth date + 1)/365.25. Change from baseline was defined as the values for BA:CA ratio at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.', 'timeFrame': 'Baseline, Months 6 and 12'}, {'measure': 'Percentage of Participants With Stabilized Pubertal Stage', 'description': 'Pubertal stage parameters were analyzed using Tanner method. Pubertal stage parameters included genital development stage (GDS) in male participants, breast development stage (BDS) in female participants and pubic hair development (PHD) stage in both sexes. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.', 'timeFrame': 'At Months 6 and 12'}, {'measure': 'Percentage of Participants With Regression of Uterine Length', 'description': 'Uterine length was determined by transabdominal ultrasound. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.', 'timeFrame': 'At Months 6 and 12'}, {'measure': 'Percentage of Participants With Absence of Progression of Testis Volumes', 'description': 'Testis volume was a clinical assessment with orchidometer. Percentage of response was calculated by number of participants in the specified category divided by number of participants in the analysis population multiplied by 100.', 'timeFrame': 'At Months 6 and 12'}, {'measure': 'Change From Baseline in Body Mass Index (BMI)', 'description': 'BMI analysis was part of auxological parameter assessment. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.', 'timeFrame': 'Baseline and at Months 6 and 12'}, {'measure': 'Change From Baseline in Weight', 'description': 'Weight analysis was part of auxological parameter assessment. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first study treatment administered.', 'timeFrame': 'Baseline and at Months 6 and 12'}, {'measure': 'Plasma Concentrations of Triptorelin', 'description': 'Blood samples were collected at specified timepoints.', 'timeFrame': 'Day 1, 4 hours post-injection; Month 3; Month 6, predose; Month 6, 4 hours post-injection; and Month 12'}]",17,,10 Years,ALL,False,Ipsen,INDUSTRY,0,66.0,ACTUAL,2025-09-01T16:18:24.743525,v2_robust,True,True,True,False,False,
NCT06575322,"Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma","Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma",Carboplatin（ neoadjuvant）,"['Carboplatin（ neoadjuvant）', 'Anti-PD-1 Drugs', 'Paclitaxel （neoadjuvant）']",3,OBSERVATIONAL,[],,,Head and Neck Squamous Cell Carcinoma,['Head and Neck Squamous Cell Carcinoma'],[],RECRUITING,,2024-09-01,2027-03-01,"[{'measure': 'Brief Pain Inventory (Short Form)', 'description': 'The BPI-SF contains 15 items that measure pain severity and pain interference, with each item assessed on an 11-point numeric rating scale ranging from ""no pain"" (0) to ""worst pain imaginable"" (10).', 'timeFrame': 'Baseline, 9 weeks, 6 months, 12 months'}, {'measure': 'HADS', 'description': 'HADS is a 14-item self-report scale, including two subscales: anxiety (HADS-A) and depression (HADS-D). The total HADS score ranges from 0 to 42, and the subscales range from 0 to 21.', 'timeFrame': 'Baseline, 9 weeks, 6 months, 12 months'}]","[{'measure': 'Major pathological response rate', 'description': 'Defined as the proportion of subjects with ≤10% viable tumor cells in resection specimens to total subjects', 'timeFrame': 'Within 30 days after surgery'}, {'measure': 'Complete pathological response rate', 'description': 'Defined as the proportion of subjects without viable tumor cells in the resection specimen to the total subjects', 'timeFrame': 'Within 30 days after surgery'}]",4,18 Years,80 Years,ALL,False,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,OTHER,0,302.0,ESTIMATED,2025-09-01T16:18:24.743624,v2_robust,False,True,False,False,False,
NCT01797822,Effects of Dry Eye Treatments on the Ocular Surface,Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca.,Dexamethasone,"['corticosteroid, vehicle', 'Artificial tear', 'Dexamethasone']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Keratoconjunctivitis Sicca,"['Keratoconjunctivitis Sicca', 'Dry Eye Syndrome']",[],COMPLETED,,2013-02,2015-12,"[{'measure': 'Changes in Corneal Fluorescein Staining', 'description': 'Subjects will be treated with preservative-free artificial tears for 2 weeks then exposed to a low humidity environment for 90 minutes, then treated with preservative-free dexamethasone 0.1% for 2 weeks and exposed to a low humidity environment again. The change in corneal fluorescein staining before and after the low humidity exposure was measured after each treatment. Fluorescein staining was graded using the CCLR scale (0-100) in 5 zones on the cornea for a maximum score of 500 (range 0-500). A lower change in staining indicates less severe disease in response to the low humidity stress. Negative number indicates staining after exposure was lower than pre.', 'timeFrame': 'Two weeks after treatment and exposure to a low humidity environment'}]",[],1,18 Years,,ALL,True,Baylor College of Medicine,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:24.743644,v2_robust,True,True,True,False,False,
NCT01397422,Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study),Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study),ADS-5102 (extended release amantadine HCl),['ADS-5102 (extended release amantadine HCl)'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Dyskinesia,"['Dyskinesia', 'Levodopa Induced Dyskinesia', ""Parkinson's Disease""]","['Levodopa-induced dyskinesia', 'Parkinsonism']",COMPLETED,,2011-07,2013-10,"[{'measure': 'Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score From Baseline to Week 8', 'description': 'The UDysRS is a dyskinesia rating scale from 0-104, and it evaluates involuntary movements associated with PD. A higher score indicates more severe PD. The last observation carried forward (LOCF) method was used for analysis. Participants were summarized according to the actual treatment received.', 'timeFrame': 'Baseline (Day 1) and Week 8'}]","[{'measure': 'Change in the Fatigue Severity Score (FSS) From Baseline to Week 8', 'description': 'The FSS is a 9-item self-reported scale, rating subject experience of fatigue during the previous 7 days. The total score, on a scale from 1-7, is represented by the mean of all answered items. The higher the score, the greater the fatigue severity.', 'timeFrame': 'Baseline (Day 1) and Week 8'}, {'measure': 'Change in Total Objective Score (III, IV) of the UDysRS From Baseline to Week 8', 'description': 'UDysRS Part III measures objective impairment (dyskinesia severity, anatomic distribution, and type, based on 4 observed activities); and Part IV measures objective disability based on Part III activities. The scores for the 2 Parts combined range from 0-44; a higher score represents more severe dyskinesia.', 'timeFrame': 'Baseline (Day 1) and Week 8'}, {'measure': 'Change in ON Time Without Troublesome Dyskinesia (ON Without Dyskinesia Plus ON With Non-troublesome Dyskinesia) From Baseline to Week 8; Based on a Standardized PD Home Diary', 'description': 'A PD home diary was used to score 5 different conditions in 30-minute time intervals: ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia. The results were based on 2 consecutive 24-hour diaries taken prior to the day of randomization and prior to the Week 8 visit.', 'timeFrame': 'Baseline (Day 1) and Week 8'}, {'measure': ""Change in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Combined Scores (Parts I, II, III) From Baseline to Week 8"", 'description': 'The MDS-UPDRS Parts I, II, and III examined non-motor experiences of daily living, motor experiences of daily living, and motor examination, respectively. Each part had sub scales ranging from normal = 0 to severe = 4.', 'timeFrame': 'Baseline (Day 1) and Week 8'}, {'measure': ""Clinician's Global Impression of Change (CGI-C) in Overall PD Symptoms From Baseline to Week 8"", 'description': ""The CGI-C consisted of a single question that assessed the investigator's global impression of the subject's change from Baseline in overall PD symptoms, including but not limited to LID. The CGI-C required that the investigator rate the extent to which the subject's PD had improved or worsened (from marked worsening to marked improvement)."", 'timeFrame': 'Baseline (Day 1) and Week 8'}]",6,30 Years,85 Years,ALL,False,"Adamas Pharmaceuticals, Inc.",INDUSTRY,0,83.0,ACTUAL,2025-09-01T16:18:24.743664,v2_robust,True,True,True,False,False,
NCT00665951,Pharmacokinetic Study of Two Generic Co-formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF),The Pharmacokinetics of Two Generic Co-formulations of Lopinavir/Ritonavir for HIV Infected Children: a Pilot Study of Lopimune vs. the Branded Product (SURF Study).,Lopinavir/ritonavir,"['Lopimune tablets', 'Lopimune granules', 'Kaletra', 'Lopinavir/ritonavir']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,HIV Infections,['HIV Infections'],"['pediatric', 'pharmacokinetics', 'HIV infection']",COMPLETED,,2008-09,2009-02,"[{'measure': 'Plasma concentrations of lopinavir and ritonavir.', 'timeFrame': '0 (predose), 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 24 and 32 hours post ingestion (11 samples) on Days 1, 8 and 15.'}]","[{'measure': 'safety: adverse events', 'timeFrame': 'entire study'}]",2,18 Years,55 Years,ALL,True,Radboud University Medical Center,OTHER,0,12.0,ACTUAL,2025-09-01T16:18:24.743708,v2_robust,True,True,True,False,True,
NCT00725751,Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255),Evaluation of Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Patients With/Without Substitution Therapy in Austria,Ribavirin,"['Rebetol', 'Ribavirin', 'SCH 18908']",3,OBSERVATIONAL,[],,,"Hepatitis C, Chronic","['Hepatitis C, Chronic']",[],COMPLETED,,2007-09,2011-03,"[{'measure': 'Number of Participants Who Completed Treatment With PegIFN-2b/Ribavirin', 'description': 'For participants with Genotype 1 or 4 completion of treatment was at Week 48; for participants with Genotype 2, 3, or 1 with low viral load or rapid virologic response, completion of therapy was at Week 24.', 'timeFrame': '24 to 48 weeks'}]","[{'measure': 'Number of Participants Who Achieved Sustained Virologic Response (SVR)', 'description': 'SVR was defined as a hepatitis C virus (HCV) ribonucleic acid (RNA) value below the limit of detection by polymerase chain reaction (PCR) analysis. For participants with Genotype 1 or 4 completion of treatment was at Week 48; for participants with Genotype 2, 3, or 1 with low viral load or rapid virologic response, completion of therapy was at Week 24.', 'timeFrame': '24 weeks after the end of treatment (i.e. 48 or 72 weeks depending on genotype)'}, {'measure': 'Number of Participants Who Received Antiviral Treatment Who Were Also on Substitution Therapy', 'description': 'This measure was the number of all of the participants who received antiviral treatment who also received substitution therapy.', 'timeFrame': 'Day 1'}]",3,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,353.0,ACTUAL,2025-09-01T16:18:24.743813,v2_robust,False,True,True,False,False,
NCT01405651,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects","A Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects",ONO-6950,['ONO-6950'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Adult Subjects,['Healthy Adult Subjects'],"['ONO-6950', 'Healthy adult subjects']",COMPLETED,,2011-07,,"[{'measure': 'Safety and tolerability of ONO-6950 using vital signs, pulmonary function tests ECGs, laboratory tests and physical examinations', 'timeFrame': 'At protocol-specified timepoints before and after study drug administration up to 21 days'}]","[{'measure': 'Characterization of PK ( Cmax, Tmax, AUC, ty2, etc.) and PD profiles of ONO-6950 using plasma concentration of ONO-6950 in blood and pulmonary function tests', 'timeFrame': 'At protocol-specified timepoints before and after study drug administration up to 21 days'}]",2,18 Years,55 Years,ALL,True,Ono Pharma USA Inc,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:24.743829,v2_robust,True,True,True,False,True,
NCT03792451,Nutrition Status of Adults Treated With Pegvaliase,Nutrition Status of Adults With Phenylketonuria Treated With Pegvaliase,Pegvaliase,"['Pegvaliase', 'Palynziq']",2,OBSERVATIONAL,[],,,Phenylketonurias,['Phenylketonurias'],[],COMPLETED,,2019-01-17,2020-12-31,"[{'measure': 'Mean concentrations of serum marker(s) of protein status', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Mean concentrations of serum marker(s) of micronutrient status', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Mean concentrations of serum marker(s) of essential fatty acid status', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Mean concentrations of serum marker(s) of cardiovascular status', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Mean protein intake (g/day) as reported on a three-day food record', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Mean micronutrient intake (%DRI) as reported on a three-day food record', 'timeFrame': 'through study completion, an average of 1 year'}]","[{'measure': 'Mean Healthy Eating Index-2015 scores calculated from the Diet History Questionnaire III', 'description': '""The Healthy Eating Index-2015 (HEI-2015) is… used to assess how well a set of foods aligns with the 2015-2020 Dietary Guidelines for Americans. The HEI-2015 includes 13 components that can be summed to a maximum total score of 100 points. The components capture… adequacy components and… moderation components. For the adequacy components, higher scores reflect higher intakes that meet or exceed the standards. For the moderation components, higher scores reflect lower intakes because lower intakes are more desirable. A higher total score indicates a diet that aligns better with the Dietary Guidelines."" - https://www.cnpp.usda.gov/sites/default/files/healthy\\_eating\\_index/HEI2015-ScoresForAmericans.pdf\n\nAdequacy components include total fruits, whole fruits, total vegetables, greens and beans, whole grains, dairy, total protein foods, seafood and plant proteins, fatty acids. Moderation components include refined grains, sodium, added sugars, and saturated fats.', 'timeFrame': 'through study completion, an average of 1 year'}, {'measure': 'Correlation between serum micronutrient concentrations and average micronutrient intake', 'timeFrame': 'through study completion, an average of 1 year'}]",8,18 Years,65 Years,ALL,False,Boston Children's Hospital,OTHER,1,18.0,ACTUAL,2025-09-01T16:18:24.743864,v2_robust,False,True,True,False,False,
NCT02251951,Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer,"A Multicenter, Phase II, Single-Arm Clinical Trial of Nab-Paclitaxel as Salvage Treatment for Patients With Locally Advanced or Metastatic Adenocarcinomas of the Stomach and Gastro-esophageal Junction.",nab-Paclitaxel,"['nab-Paclitaxel', 'Abraxane']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Stomach and Gastro-Esophageal Junction (GEJ) Cancer,['Stomach and Gastro-Esophageal Junction (GEJ) Cancer'],"['Cancer', 'Stomach', 'Gastro-Esophageal Junction', 'Salvage treatment', 'Nab-paclitaxel']",COMPLETED,,2012-09,2015-06,"[{'measure': 'Overall Response Rate', 'description': 'Documented response rate will be assessed every two months (8 weeks) until disease progression according to common criteria for tumor response', 'timeFrame': 'Disease evaluation every 8 weeks up to 108 weeks'}]","[{'measure': 'Disease control rate', 'description': 'Documented disease control rate will be assessed every two months (8 weeks) until disease progression according to common criteria for tumor response', 'timeFrame': 'Disease evaluation every 8 weeks up to 108 weeks'}, {'measure': 'Progression Free Survival', 'description': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever come first, assessed up to 108 weeks', 'timeFrame': 'Up to 108 weeks'}, {'measure': 'Overall Survival', 'description': 'From date of randomization until the date of last follow up or death from any cause, assessed up to 108 weeks', 'timeFrame': 'Up to 108 weeks'}, {'measure': 'Number of Participants with Adverse Events', 'timeFrame': 'Every two weeks up to 24 weeks'}]",5,19 Years,,ALL,False,Hellenic Oncology Research Group,OTHER,0,39.0,ACTUAL,2025-09-01T16:18:24.744083,v2_robust,True,True,True,False,True,
NCT05552651,Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma,"A Single-arm, Exploratory Clinical Study of Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma",Envafolimab,"['Carboplatin', 'Albumin-Bound Paclitaxel', 'Envafolimab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Esophageal Squamous Cell Carcinoma,['Esophageal Squamous Cell Carcinoma'],['neoadjuvant therapy'],UNKNOWN,,2022-09-20,2023-12-20,"[{'measure': 'Rate of pCR', 'description': 'Rate of pathological complete remission', 'timeFrame': 'From Baseline to primary completion date, about 6 months'}]","[{'measure': 'Rate of MPR', 'description': 'Rate of major pathological remission', 'timeFrame': 'From Baseline to primary completion date, about 6 months'}]",2,18 Years,75 Years,ALL,False,Tao Jiang,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:24.744135,v2_robust,True,True,False,False,False,
NCT02665351,Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections,"A Phase 2, Pilot, Open-label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Adult Hospitalized Subjects With Confirmed Influenza Infection",Peramivir,"['Peramivir', 'intravenous neuraminidase inhibitor']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Influenza,['Influenza'],[],COMPLETED,,2011-02,2014-03,"[{'measure': 'change in influenza RNA load', 'description': '5-10 days', 'timeFrame': '5 days'}]","[{'measure': 'viral shedding indicated by PCR and culture negativity', 'timeFrame': '5 days'}]",2,18 Years,,ALL,False,Chinese University of Hong Kong,OTHER,1,16.0,ACTUAL,2025-09-01T16:18:24.744166,v2_robust,True,True,True,False,False,
NCT02601651,Effect of Perioperative Intravenous Lidocaine on Opioid Consumption and Pain After Laparoscopic Totally Extraperitoneal Inguinal Hernioplasty,Effect of Perioperative Intravenous Lidocaine on Opioid Consumption and Pain After Laparoscopic Totally Extraperitoneal Inguinal Hernioplasty,Lidocaine,"['Normal saline', 'Loxicard', 'Lidocaine', 'Lignocaine']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pain, Postoperative","['Pain, Postoperative']","['Totally Extraperitoneal Inguinal Hernioplasty', 'Lidocaine infusion', 'Postoperative opioid consumption']",COMPLETED,,2015-12,2017-03,"[{'measure': 'Total morphine requirement during the first 24 h postoperatively', 'timeFrame': '24h'}]","[{'measure': 'Pain at rest and with coughing or movement using the NRS scale', 'timeFrame': '24h'}, {'measure': 'Time to first perception of pain', 'timeFrame': '24h'}, {'measure': 'Incidence of postoperative nausea and vomiting (PONV) will be evaluated on a three-point ordinal scale.', 'description': '0 = none, 1 = nausea, 2 = vomiting', 'timeFrame': '24h'}, {'measure': 'Sedation score using five point scale', 'description': '0=alert, 1=arouses to voice, 2=arouses with gentle tactile stimulation, 3 = arouses with vigorous tactile stimulation, 4 = lack of responsiveness', 'timeFrame': '24h'}, {'measure': 'Time to first voiding.', 'timeFrame': '24h'}, {'measure': 'Quality of Recovery based on QoR-40 questionnaire at 24 h of the surgery.', 'timeFrame': '24h'}, {'measure': 'Patient satisfaction using Likert Satisfaction Scale at 24 h following surgery', 'description': '1-Highly satisfied, 2-Satisfied, 3-Neutral, 4-Not satisfied, 5-Strongly dissatisfied', 'timeFrame': '24h'}, {'measure': 'Other side effects such as light headedness, tinnitus, perioral numbness, arrythmia and pruritus will be documented.', 'timeFrame': '24h'}, {'measure': 'Incidence of Chronic pain after TEP Repair', 'timeFrame': '3 months'}]",10,18 Years,65 Years,MALE,False,B.P. Koirala Institute of Health Sciences,OTHER,0,64.0,ACTUAL,2025-09-01T16:18:24.744193,v2_robust,True,True,True,False,False,
NCT00381251,Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.,"An Open-Label, Single-Dose, Randomized, 3-Period, Crossover, Bioequivalence Study Between Two New Formulations of 0.45 mg/1.5 mg Premarin / Medroxyprogesterone Acetate (MPA) Compared With a Reference Formulation of 0.45mg/1.5mg Premarin / MPA (Prempro™) in Healthy Postmenopausal Women.",Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg,['Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Postmenopausal Osteoporosis,"['Postmenopausal Osteoporosis', 'Postmenopause']","['vaginal atrophy', 'postmenopausal osteoporosis', 'menopause', 'hot flashes']",COMPLETED,,2006-09,2007-01,"[{'measure': 'Pharmacokinetic blood samples for unconjugated and total (unconjugated plus conjugated) estrogens and MPA will be obtained. The following pharmacokinetic parameters will be determined: Cmax, Tmax, t½, AUC0-T, AUC0-¥.'}]",[],1,35 Years,70 Years,FEMALE,True,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,,,2025-09-01T16:18:24.744265,v2_robust,True,True,True,False,False,
NCT05747729,"A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.","A Single-arm, Open-label, Single-center Clinical Trial of Surufatinib and Serplulimab Combined With Standard Chemotherapy (Platinum/Etoposide) in Neuroendocrine Carcinoma.",Surufatinib and Serplulimab,['Surufatinib and Serplulimab'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Neuroendocrine Carcinoma,['Neuroendocrine Carcinoma'],[],NOT_YET_RECRUITING,,2023-02-28,2026-02-28,"[{'measure': 'Progression-Free Survival', 'description': 'Progression-Free Survival (PFS) According to RECIST v1.1 criteria', 'timeFrame': '7 years'}]",[],1,18 Years,,ALL,False,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:24.744504,v2_robust,True,True,False,False,False,
NCT03367429,The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination,The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination,Botox,['Botox'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Stroke,"['Stroke', 'Muscle Spasticity']","['stroke', 'spasticity']",TERMINATED,too difficult to recruit subjects for the study - muscles naive to botulinum toxin were required and seems that wide availability of the toxin has severely depleted potential subjects.,2018-06-15,2019-09-18,"[{'measure': 'Botulinum Toxin Muscle Effect (BTME) Volume of Abnormal Voxels Per MRI Slice in Muscles After Research Injections', 'description': 'BTME volume is calculated by counting the number of abnormal voxels (each voxel volume is .0015 cc) on MRI2, which have a relaxation time greater than or equal to 3 standard deviations above the baseline mean for a subject and their muscle found on their baseline MRI.', 'timeFrame': 'At MRI 2, 2 Months after Research Injection'}]","[{'measure': 'Change in Botulinum Toxin Muscle Effect (BTME) Volume of Abnormal Voxels Per MRI Slice in Muscles After Clinical Injections', 'description': 'Change in volume of BTME in injected muscle after clinical injection recorded on MRI3 compared to BTME volume on MRI 2.', 'timeFrame': 'At MRI 3, 2 Months after Clinical Injections'}]",2,30 Years,75 Years,ALL,False,Weill Medical College of Cornell University,OTHER,1,4.0,ACTUAL,2025-09-01T16:18:24.744519,v2_robust,True,True,False,True,False,too difficult to recruit subjects for the study - muscles naive to botulinum toxin were required and seems that wide availability of the toxin has severely depleted potential subjects.
NCT00468429,Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery,Comparative Study of the Safety and Effectiveness Between Off-Label Subconjunctival Bevacizumab and Mitomycin C in Glaucoma Filtering Surgery.,Subconjunctival Bevacizumab,['Subconjunctival Bevacizumab'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Glaucoma,['Glaucoma'],"['Glaucoma', 'Bevacizumab', 'Glaucoma Filtration Surgery', 'Mitomycin C', 'Intraocular Pressure']",UNKNOWN,,2007-05,2007-12,"[{'measure': 'IOP < 18mmHg without anti- glaucoma medications at 6 months follow up after surgery or at least a 20% reduction from baseline IOP.', 'timeFrame': '6 months'}]","[{'measure': 'adverse reaction to bevacizumab at site of injection', 'timeFrame': '6 months'}]",2,40 Years,80 Years,ALL,False,Grewal Eye Institute,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:24.744533,v2_robust,True,True,False,False,True,
NCT00403429,MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer,Phase II Study With Capecitabine as Monotherapy in the Treatment of Platinum Resistant or Refractory Ovarian Cancer.,capecitabine,['capecitabine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Cancer,['Ovarian Cancer'],"['oral chemotherapy', 'platinum resistant', 'platinum refractory', 'second line']",COMPLETED,,2006-03,2008-07,"[{'measure': 'objective response rate', 'timeFrame': '6 months'}, {'measure': 'toxicity', 'timeFrame': 'up to 6 months'}]",[],2,,75 Years,FEMALE,False,"National Cancer Institute, Naples",OTHER,0,36.0,ACTUAL,2025-09-01T16:18:24.744542,v2_robust,True,True,True,False,False,
NCT05555329,Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study,"Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day: Reduction in Costs, Same Efficacy? A PKPD Bioequivalence Pilot Study; the POMAlternative Study",Pomalidomide 4 mg every day in cycle 1,"['Cycle 2 (Group B)', 'Cycle 3 (Group B)', 'Cycle 3 (Group A)', 'Pomalidomide 2 mg every day in cycle 3', 'Cycle 2 (Group A)', 'Pomalidomide 4 mg every other day in cycle 3', 'Pomalidomide 4 mg every other day in cycle 2', 'Pomalidomide 4 mg every day in cycle 1', 'Cycle 1', 'Pomalidomide 2 mg every day in cycle 2']",10,INTERVENTIONAL,['PHASE4'],PHASE4,,Multiple Myeloma in Relapse,"['Multiple Myeloma in Relapse', 'Multiple Myeloma', 'Multiple Myeloma, Refractory']","['Multiple myeloma', 'Pomalidomide', 'Pharmacokinetics/dynamics', 'Cost-effectiveness']",COMPLETED,,2022-12-01,2024-02-14,"[{'measure': 'The AUC/MIC ratio', 'description': 'The AUC/MIC ratio during usage of pomalidomide 4 mg QD on day 1-21, 4 mg EOD on day 1-21, and 2 mg QD on day 1-28 in cycles of 28 days.', 'timeFrame': 'During three cycles of 28 days'}, {'measure': 'The level of the Ctrough', 'description': 'The level of the Ctrough during usage of pomalidomide 4 mg QD on day 1-21, 4 mg EOD on day 1-21, and 2 mg QD on day 1-28 in cycles of 28 days.', 'timeFrame': 'During three cycles of 28 days'}]","[{'measure': 'Cmax', 'description': 'The Cmax during usage of pomalidomide 4 mg QD on day 1-21, 4 mg EOD on day 1- 21, and 2 mg QD on day 1-28 in cycles of 28 days.', 'timeFrame': 'During three cycles of 28 days'}, {'measure': 'Time above EC50', 'description': 'The time above the EC50 during usage of pomalidomide 4 mg QD on day 1-21, 4 mg EOD on day 1- 21, and 2 mg QD on day 1-28 in cycles of 28 days.', 'timeFrame': 'During three cycles of 28 days'}, {'measure': 'Toxicity and side effects', 'description': 'Toxicity and side effects during usage of pomalidomide 4 mg every day on day 1-21, pomalidomide 4 mg every other day on day 1-21, and pomalidomide 2 mg every day on day 1-28 in cycles of 28 days.', 'timeFrame': 'During three cycles of 28 days'}, {'measure': 'Overall response rate (ORR)', 'description': 'Overall response rate (ORR), based on the IMWG criteria', 'timeFrame': 'During three cycles of 28 days'}]",6,18 Years,,ALL,False,"Amsterdam UMC, location VUmc",OTHER,0,12.0,ACTUAL,2025-09-01T16:18:24.744588,v2_robust,True,True,True,False,False,
NCT02840929,Effect of Second-look Endoscopy on Peptic Ulcer Rebleeding in Patients With Early Resumption of Antiplatelet Agents,Effect of Second-look Endoscopy on Peptic Ulcer Rebleeding in Patients With Early Resumption of Antiplatelet Agents,Esomeprazole,['Esomeprazole'],1,INTERVENTIONAL,['NA'],,,OGD,"['OGD', 'Gastric Ulcer Induced by Anti-platelet Agent', 'Duodenal Ulcer Induced by Anti-platelet Agent']",[],TERMINATED,Slow recruitment,2016-07,2017-09,"[{'measure': 'Rebleeding', 'description': 'Detect difference in the rate of rebleeding within 30 days of primary esophagogastroduodenoscopy (OGD)\n\nRebleeding is suspected clinically by the presence of fresh haematemesis, or haematochezia/melaena after a normal stool, or unstable haemodynamics with systolic blood pressure ≤ 90 mmHg or pulse ≥ 100 beats/min (after ruling out other causes of shock, e.g. cardiogenic or septic shock), or a drop in haemoglobin level by 2 g/dL or more within 24 hours despite transfusion of 2 or more units of blood during the same period. If any one of the features is present, we will perform emergency endoscopy to confirm the diagnosis of recurrent peptic ulcer bleeding by either the persistence of ulcers of high-risk stigma or fresh blood in the stomach). Rebleeding is only defined if it is confirmed by the presence of both clinical and endoscopic features.', 'timeFrame': '30 days'}]","[{'measure': 'cardiovascular/cerebrovascular events', 'description': 'Detect difference in the rate of cardiovascular/cerebrovascular events within 30 days of primary OGD', 'timeFrame': '30 days'}, {'measure': 'all-cause mortality', 'description': 'Detect difference in the rate of all-cause mortality within 30 days of primary OGD', 'timeFrame': '30 days'}, {'measure': 'days of hospital stay', 'description': 'Detect difference in the days of hospital stay within 30 days of primary OGD', 'timeFrame': '30 days'}, {'measure': 'units of packed cell transfused', 'description': 'Detect difference in the units of packed cell transfused', 'timeFrame': '30 days'}, {'measure': 'radiological and/or surgical interventions (as documented in Clinical Management System and medical records)', 'description': 'Detect difference in the need of radiological and/or surgical interventions', 'timeFrame': '30 days'}, {'measure': 'gastrointestinal mortality, vascular mortality, combined gastrointestinal and vascular mortality', 'description': 'Detect difference in the days of gastrointestinal mortality, vascular mortality, combined gastrointestinal and vascular mortality within 30 days of primary OGD', 'timeFrame': '30 days'}]",7,18 Years,,ALL,False,The University of Hong Kong,OTHER,0,2.0,ACTUAL,2025-09-01T16:18:24.744608,v2_robust,True,True,False,True,False,Slow recruitment
NCT00404729,Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases,Phase 4 Study of Evaluation of Neural Conduction Along the Visual Pathways Before and After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases,Citicoline,['Citicoline'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Glaucoma,"['Glaucoma', 'Optic Neuropathy, Ischemic', 'Visual Pathway Disorder', 'Optic Nerve', 'Neural Conduction']","['Glaucoma', 'Optic Neuropathy, Ischemic', 'Visual Pathways,', 'Optic nerve', 'Neural conduction']",COMPLETED,,2005-02-28,2006-07-30,"[{'measure': 'VEPs responses', 'description': 'P100 Implicit time and N75-P100 Amplitude', 'timeFrame': '24 months'}]","[{'measure': 'Visual Field Defects', 'description': 'Humphrey 24/1: Mean Deviation and Corrected Pattern Standard Deviation', 'timeFrame': '24 months'}]",2,40 Years,70 Years,ALL,True,"Fondazione G.B. Bietti, IRCCS",OTHER,0,60.0,ACTUAL,2025-09-01T16:18:24.744658,v2_robust,True,True,True,False,False,
NCT01959529,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,insulin degludec,"['insulin glargine', 'insulin degludec']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],COMPLETED,,2013-10-29,2016-10-16,"[{'measure': 'Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke', 'description': 'Time from randomisation to first occurrence of an event adjudication committee (EAC)-confirmed 3-component major adverse cardiovascular event (MACE): cardiovascular death, non-fatal myocardial infarction, or nonfatal stroke. Events with EAC-confirmed onset date between randomisation and individual end of trial were included in the analyses. The number of subjects experiencing first EAC-confirmed MACEs, date between randomisation to the end of trial, both days included were presented. The trial was event driven and planned to last up to a maximum of 60.5 months. The actual trial duration (time from first subject first visit to last subject last visit) was 35.6 months. The maximum trial duration for a single subject was 33.1 months.', 'timeFrame': 'From randomisation to individual end of trial date (maximum patient year observation: 2.75 years)'}]","[{'measure': 'Number of EAC-confirmed Severe Hypoglycaemic Episodes', 'description': 'Number of severe hypoglycaemic episodes from week 0 to the last assessment (up to 35.6 months). The episode of severe hypoglycaemia is an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. The trial was event driven and planned to last up to a maximum of 60.5 months. The actual trial duration (time from first subject first visit to last subject last visit) was 35.6 months. The maximum trial duration for a single subject was 33.1 months.', 'timeFrame': 'From randomisation to individual end of trial (maximum patient year observation: 2.75 years)'}, {'measure': 'Occurrence of at Least One EAC Confirmed Severe Hypoglycaemic Episode Within a Subject (Yes/no)', 'description': 'Occurrence of at least one EAC-confirmed severe hypoglycaemic episode within a subject from week 0 to the last assessment (up to 35.6 months). The episode of severe hypoglycaemia is an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions.', 'timeFrame': 'From randomisation to individual end of trial date (maximum patient year observation: 2.75 years)'}, {'measure': 'Change in Glycosylated Haemoglobin (HbA1c)', 'description': 'Mean change in HbA1c from week 0 to month 24.', 'timeFrame': 'Randomisation to 24 months'}]",4,50 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,7637.0,ACTUAL,2025-09-01T16:18:24.744669,v2_robust,True,True,True,False,True,
NCT04621331,"Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD","An Open-label, Multicenter Study Investigating the Efficacy, Safety and Pharmacokinetics of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease",Roxadustat,"['FG-4592', 'Roxadustat']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Anemia Associated With Chronic Kidney Disease,['Anemia Associated With Chronic Kidney Disease'],"['Anemia, Chronic Kidney Disease (CKD)']",WITHDRAWN,Sponsor's decision,2022-05-23,2022-05-23,"[{'measure': 'Proportion of patients with mean Hb ≥ 11.0 g/dL', 'timeFrame': 'Averaged over weeks 16-24'}]","[{'measure': 'Mean change in Hb', 'timeFrame': 'Baseline to averaged over weeks 16-24'}, {'measure': 'Time to first Hb response (this only applies to NDD patients)', 'timeFrame': 'From baseline without rescue therapy'}]",3,2 Years,18 Years,ALL,False,FibroGen,INDUSTRY,1,0.0,ACTUAL,2025-09-01T16:18:24.744693,v2_robust,True,True,False,True,False,Sponsor's decision
NCT04902131,A Study Comparing MENOPUR in a Pen Formulation With a Powder and Solvent Formulation in Healthy Women,"An Open-label, Randomised, 2-way Crossover, Single-dose, Bioequivalence Trial Comparing MENOPUR Solution for Injection in Pre-filled Pen and MENOPUR Powder and Solvent for Solution for Injection, After Subcutaneous Administration in Healthy Women","A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL","['A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL', 'A MENOPUR powder including solvent for solution for injection, 75 IU', 'Highly purified menotropin']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,"Infertility, Female","['Infertility, Female']",[],COMPLETED,,2021-11-02,2022-08-15,"[{'measure': 'Pharmacokinetic parameter of FSH: AUCt', 'description': 'AUCt is defined as area under the concentration-time curve from dosing to the last time point when the baseline adjusted concentration is above zero.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before investigational medicinal product [IMP] administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of FSH: Cmax', 'description': 'Cmax is defined as baseline adjusted maximum observed concentration.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}]","[{'measure': 'Pharmacokinetic parameter of FSH: AUCinf', 'description': 'AUCinf is defined as area under concentration-time curve from dosing to infinity using baseline adjusted concentrations.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of FSH: Tmax', 'description': 'Tmax is defined as time of maximum observed concentration.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of FSH: CL/F', 'description': 'CL/F is defined as apparent systemic clearance.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of FSH: Vz/F', 'description': 'Vz/F is defined as apparent volume of distribution during terminal phase.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of FSH: λz', 'description': 'λz is defined as first-order rate constant associated with the terminal (log-linear) portion of the concentration-time curve.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of FSH: t½', 'description': 't½ is defined as terminal half-life.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of human chorionic gonadotrophin (hCG): AUCt', 'description': 'AUCt is defined as area under the concentration-time curve from dosing to the last time point when the baseline adjusted concentration is above zero.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of hCG: AUCinf', 'description': 'AUCinf is defined as area under concentration-time curve from dosing to infinity using baseline adjusted concentrations.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of hCG: Cmax', 'description': 'Cmax is defined as baseline adjusted maximum observed concentration.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration'}, {'measure': 'Pharmacokinetic parameter of LH: AUCt', 'description': 'AUCt is defined as area under the concentration-time curve from dosing to the last time point when the baseline adjusted concentration is above zero.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and 4, 8, 12, 24 and 48 hours after administration'}, {'measure': 'Pharmacokinetic parameter of LH: Cmax', 'description': 'Cmax is defined as baseline adjusted maximum observed concentration.', 'timeFrame': 'At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and 4, 8, 12, 24 and 48 hours after administration'}, {'measure': 'Frequency of adverse events (AEs) stratified by intensity', 'description': 'The frequency of subjects with total AEs and AEs by categories of intensity (mild, moderate, severe) are presented.\n\nAn AE was any untoward medical occurrence in a subject participating in clinical trial. The intensity of AE was classified using the following 3-point scale: mild = awareness of signs or symptoms, but no disruption of usual activities); moderate = disruption of usual activities (disturbing); or severe = inability to work or perform usual activities (unacceptable).', 'timeFrame': 'From signing of the informed consent up to the end-of-trial (11 to 18 days after the last IMP administration)'}, {'measure': 'Frequency of injection site reactions stratified by intensity', 'description': 'The presence of injection site reactions (redness, pain, itching, swelling and bruising) immediately, 0.5 hours and 24 hours after the injection are presented.\n\nThe injection site reactions were assessed as none, mild, moderate and severe. The number of injection site reactions (mild, moderate or severe) based on all assessments performed is presented.', 'timeFrame': 'Immediately after administration, and at 0.5 and 24 hours after administration on Day 1 and Day 2 of Treatment period 1 (TP1) and Time period 2 (TP2)'}, {'measure': 'Change from baseline of vital signs (systolic and diastolic blood pressure)', 'description': 'Vital signs comprising systolic and diastolic blood pressure will be presented.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of vital sign (pulse)', 'description': 'Vital sign comprising pulse will be presented.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of vital sign (body temperature)', 'description': 'Vital sign comprising body temperature will be presented.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of 12-lead electrocardiogram (ECG): Heart rate', 'description': 'Change from baseline for 12-lead ECG (heart rate) parameter will be reported.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of 12-lead ECG: PR interval', 'description': 'Change from baseline for 12-lead ECG (PR interval) parameter will be reported.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of 12-lead ECG: RR interval', 'description': 'Change from baseline for 12-lead ECG (RR interval) parameter will be reported.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of 12-lead ECG: QRS interval', 'description': 'Change from baseline for 12-lead ECG (QRS interval) parameter will be reported.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of 12-lead ECG: QT interval', 'description': 'Change from baseline for 12-lead ECG (QT interval) parameter will be reported.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of 12-lead ECG: QTc interval', 'description': 'Change from baseline for 12-lead ECG (QTc interval) parameter will be reported.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of 12-lead ECG: QRS axis', 'description': 'Change from baseline for 12-lead ECG (QRS axis) parameter will be reported.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameters including: Alanine aminotransferase, Alkaline phosphatase, Aspartate aminotransferase, and Gamma glutamyl transferase.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Albumin', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Albumin.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Glucose', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Glucose.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Calcium', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Calcium.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Chloride', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Chloride.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Cholesterol', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Cholesterol.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Phosphate', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Phosphate.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Potassium', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Potassium.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Sodium', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Sodium.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Urea (blood urea nitrogen)', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Urea (blood urea nitrogen).', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: C-reactive protein', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: C-reactive protein.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Creatinine, Total bilirubin', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameters including: Creatinine, Total bilirubin.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Thyroid stimulating hormone', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Thyroid stimulating hormone.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Free triiodothyronine', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Free triiodothyronine.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Free thyroxine', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Free thyroxine.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: FSH', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: FSH.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of clinical chemistry: Estradiol', 'description': 'Blood samples were collected for the analysis of clinical chemistry parameter including: Estradiol.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Haematocrit', 'description': 'Blood samples were collected for the analysis of haematology parameter including: Haematocrit.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Haemoglobin', 'description': 'Blood samples were collected for the analysis of haematology parameter including: Haemoglobin.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Mean cellular volume', 'description': 'Blood samples were collected for the analysis of haematology parameter including: Mean cellular volume.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Mean corpuscular haemoglobin content', 'description': 'Blood samples were collected for the analysis of haematology parameter including: Mean corpuscular haemoglobin content.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Mean corpuscular haemoglobin concentration', 'description': 'Blood samples were collected for the analysis of haematology parameter including: Mean corpuscular haemoglobin concentration.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Red blood cell (RBC) count', 'description': 'Blood samples were collected for the analysis of haematology parameter including: RBC count.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Platelet count', 'description': 'Blood samples were collected for the analysis of haematology parameter including: Platelet count.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: Reticulocytes', 'description': 'Blood samples were collected for the analysis of haematology parameter including: Reticulocytes.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of haematology parameter: White blood cell count', 'description': 'Blood samples were collected for the analysis of haematology parameter including: White blood cell count.', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Protein', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Glucose', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Bilirubin', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: pH and Specific Gravity', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Nitrite', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Ketone', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Urobilinogen', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Blood', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}, {'measure': 'Change from baseline of urinalysis parameter: Leukocytes', 'timeFrame': 'On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)'}]",60,21 Years,40 Years,FEMALE,True,Ferring Pharmaceuticals,INDUSTRY,0,95.0,ACTUAL,2025-09-01T16:18:24.744707,v2_robust,True,True,True,False,True,
NCT05740631,The Effect of Obeticholic Acid in Healthy Volunteers,"The Effect of Obeticholic Acid on Gut Microbiota, Gastric Motility, Accommodation, Gastrointestinal Peptide in Healthy Volunteers",Ocaliva,"['obeticholic acid', 'Ocaliva', 'Placebo Oral Tablet (Starch)', 'Placebo']",4,INTERVENTIONAL,['NA'],,,Healthy,['Healthy'],"['Obeticholic acid', 'Farnesoid X receptor', 'gastric accommodation', 'gastrointestinal hormones', 'gut microbiota']",UNKNOWN,,2022-08-22,2023-07-22,"[{'measure': 'Changes in appetite after administration of obeticholic acid compared to placebo', 'description': 'Assessment by questionnaire(100mm Visual Analogue Scale) every 10 minutes.', 'timeFrame': 'During MMCⅢ (300 min)'}]","[{'measure': 'Change in serum GI hormones concentrations', 'description': 'Blood samples to assess GI hormones concentrations', 'timeFrame': 'During MMCⅢ (300 min)'}, {'measure': 'Change in gastric motility', 'description': 'IGP(Intragastric pressure) will be measured.', 'timeFrame': 'During MMCⅢ (300 min)'}, {'measure': 'Change in gut microbiota', 'description': 'Stool samples will be collected for analyze gut microbiota.', 'timeFrame': '12 days'}]",4,18 Years,65 Years,ALL,True,Universitaire Ziekenhuizen KU Leuven,OTHER,1,12.0,ESTIMATED,2025-09-01T16:18:24.744770,v2_robust,True,True,False,False,False,
NCT02946931,All-Case Surveillance of Prizbind®,The Drug Use-results Survey (All-Case Surveillance) on Prizbind® for Intravenous Solution 2.5 g in Japan,Prizbind®,"['Prizbind®', 'Idarucizumab']",2,OBSERVATIONAL,[],,,Hemorrhage,['Hemorrhage'],[],COMPLETED,,2016-11-18,2020-11-03,"[{'measure': 'Number of Patients With Adverse Drug Reactions (ADRs)', 'description': 'Adverse reaction was defined as a response to the medicinal product which was noxious and unintended. Number of participants with Adverse Drug Reactions (ADRs) is reported.', 'timeFrame': 'From the first intake of Prizbind® for Intravenous Solution 2.5 g to the end of the observation period for each patient, up to 74 days.'}]","[{'measure': 'Maximum Reversal of Anticoagulation as Measured by Activated Partial Thromboplastin Time (aPTT)', 'description': 'Maximum reversal of anticoagulation as measured by activated partial thromboplastin time (aPTT) is reported.\n\nMaximum reversal was calculated as:｛(predose aPTT - minimum postdose aPTT)/(predose aPTT - upper limit of normal (ULN))｝ × 100%. If calculated reversal is \\> 100, it was set to 100.', 'timeFrame': 'From the end of the first infusion up to 4 hours after the last infusion on Day 1.'}, {'measure': 'Number of Patients in Each Category of Maximum Reversal of Anticoagulation as Measured by Activated Partial Thromboplastin Time (aPTT)', 'description': 'Number of patients in each category of maximum reversal of anticoagulation as measured by activated partial thromboplastin time (aPTT) is reported.\n\nMaximum reversal was calculated as:｛(predose aPTT - minimum postdose aPTT)/(predose aPTT - upper limit of normal (ULN))｝ × 100%. If calculated reversal is \\> 100, it was set to 100.\n\nMaximum Reversal was categorized in the following 4 categories:\n\n100% 80% \\<= and \\< 100% 50% \\<= and \\< 80% \\< 50%', 'timeFrame': 'From the end of the first infusion up to 4 hours after the last infusion on Day 1.'}]",3,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,1402.0,ACTUAL,2025-09-01T16:18:24.744833,v2_robust,False,True,True,False,True,
NCT06762431,Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.,Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.,Lenalidomide,"['Lenalidomide', 'Revlimid']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Chronic Lymphocytic Leukaemia (CLL),"['Chronic Lymphocytic Leukaemia (CLL)', 'Small Lymphocytic Lymphoma (SLL)']","['anti-CD19 CAR T-cells', 'Lenalidomide', 'Ibrutinib']",ENROLLING_BY_INVITATION,,2024-11-04,2026-08-31,"[{'measure': 'Adverse events incidence', 'timeFrame': '24 months'}]",[],1,18 Years,,ALL,False,Vitebsk Regional Clinical Cancer Centre,OTHER,1,60.0,ESTIMATED,2025-09-01T16:18:24.744947,v2_robust,True,True,False,False,True,
NCT05485831,"Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY","Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox- Gastaut Syndrome (LGS), Dravet Syndrome (DS) and Tuberous Sclerosis Complex (TSC)",Epidiolex 100 mg/mL Oral Solution,['Epidiolex 100 mg/mL Oral Solution'],1,OBSERVATIONAL,[],,,Lennox Gastaut Syndrome,"['Lennox Gastaut Syndrome', 'Dravet Syndrome', 'Tuberous Sclerosis Complex']","['seizures', 'Epidyolex', 'cannabidiol oral solution']",RECRUITING,,2025-02-24,2026-01,"[{'measure': 'Number of Participants Remaining on Therapy from Enrollment', 'description': 'Treatment retention will be evaluated through the proportion of participants remaining on therapy from the enrollment visit (baseline, V0) to each study visit (Weeks 4 \\[V1\\], 16 \\[V2\\], 28 \\[V3\\], 40 \\[V4\\], 52 \\[V5\\]).', 'timeFrame': 'Baseline up to Week 52 post-dose.'}]","[{'measure': 'Average Number of Seizure-Free Days in the Last 28 Days', 'timeFrame': 'Weeks 4 (V1), 16 (V2), 28 (V3), 40 (V4) and 52 (V5)'}, {'measure': 'Longest Duration of Seizure Free Days in the Last 28 Days', 'timeFrame': 'Weeks 4 (V1), 16 (V2), 28 (V3), 40 (V4) and 52 (V5)'}, {'measure': 'Average Maintenance Dose of Epidyolex®', 'timeFrame': 'Weeks 4 (V1), 16 (V2), 28 (V3), 40 (V4) and 52 (V5)'}, {'measure': 'Maximum Maintenance Dose of Epidyolex®', 'timeFrame': 'Weeks 4 (V1), 16 (V2), 28 (V3), 40 (V4) and 52 (V5)'}, {'measure': 'Type, Dosage, and Frequency of Concomitant Anti-Seizure Medications (ASMs)', 'timeFrame': 'Weeks 4 (V1), 16 (V2), 28 (V3), 40 (V4) and 52 (V5)'}, {'measure': 'Number of Participants Reducing Number/Dosage of Concomitant Medication Related to Epilepsy', 'timeFrame': 'Weeks 4 (V1), 16 (V2), 28 (V3), 40 (V4) and 52 (V5)'}, {'measure': 'Change from Baseline to Week 28 (V3) in the Child Behavior Check List (CBCL)', 'description': ""The CBCL is a standardized form that parents fill out to describe their children's behavioral and emotional problems(e.g., anxiety, depression, social problems). The CBCL is also scored on (optional) competence scales for activities, social relations, school and total competence. The CBCL consists of 113 questions, scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often). A higher score indicates a worse outcome."", 'timeFrame': 'Baseline to week 28 (V3) post-dose.'}, {'measure': 'Change from Baseline to Week 52 (V5) in the Child Behavior Check List (CBCL)', 'description': ""The CBCL is a standardized form that parents fill out to describe their children's behavioral and emotional problems(e.g., anxiety, depression, social problems). The CBCL is also scored on (optional) competence scales for activities, social relations, school and total competence. The CBCL consists of 113 questions, scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often). A higher score indicates a worse outcome."", 'timeFrame': 'Baseline to week 52 (V5) post-dose.'}, {'measure': 'Change from Baseline to Week 28 (V3) in the Visual Analog Scale (VAS) of 10 Non-seizure Related Outcomes (NSRO)', 'description': 'VAS assessments are based on 10 NSRO (i.e., Alertness, Sleep Disorder, Motor Skills, Attention, Cognition, Communication, Behavior, Emotional/Social Functioning, Activities of Daily Living, and Participation). VAS is measured on a scale of 0-100; a score of 0 indicates a better outcome, and a score of 100 indicates a worse outcome.', 'timeFrame': 'Baseline to week 28 (V3) post-dose.'}, {'measure': 'Change from Baseline to Week 52 (V5) in the VAS of 10 NSRO', 'description': 'VAS assessments are based on 10 NSRO (i.e., Alertness, Sleep Disorder, Motor Skills, Attention, Cognition, Communication, Behavior, Emotional/Social Functioning, Activities of Daily Living, and Participation). VAS is measured on a scale of 0-100; a score of 0 indicates a better outcome, and a score of 100 indicates a worse outcome.', 'timeFrame': 'Baseline to week 52 (V5) post-dose.'}, {'measure': 'Average Caregiver Global Impression of Change (CGIC) Score at Week 28 (V3)', 'description': 'The CGIC evaluates efficacy and quality of life. At enrollment the investigator will be asked to write a brief description of the patient\'s overall condition as a memory aid for assessment at each subsequent appointment. The CGIC comprises of the following question: ""Since your child started treatment, please assess the status of your child\'s overall condition (comparing their condition now to their condition before treatment) using the scale below."" The questionnaire is rated on a seven-point scale: ""Very Much Improved"" (1); ""Much Improved"" (2);Slightly Improved"" (3); ""No Change"" (4); ""Slightly Worse"" (5); ""Much Worse"" (6); ""Very Much Worse"" (7). A score of 1 indicates a better outcome and a score of 7 indicates a worse outcome.', 'timeFrame': 'Week 28 (V3) post-dose.'}, {'measure': 'Average CGIC Score at Week 52 (V5)', 'description': 'The CGIC evaluates efficacy and quality of life. At enrollment the investigator will be asked to write a brief description of the patient\'s overall condition as a memory aid for assessment at each subsequent appointment. The CGIC comprises of the following question: ""Since your child started treatment, please assess the status of your child\'s overall condition (comparing their condition now to their condition before treatment) using the scale below."" The questionnaire is rated on a seven-point scale: ""Very Much Improved"" (1); ""Much Improved"" (2);Slightly Improved"" (3); ""No Change"" (4); ""Slightly Worse"" (5); ""Much Worse"" (6); ""Very Much Worse"" (7). A score of 1 indicates a better outcome and a score of 7 indicates a worse outcome.', 'timeFrame': 'Week 52 (V5) post-dose.'}, {'measure': 'Average Caregiver Global Impression of Change in Seizure Duration (CGICSD) Score at Week 28 (V3)', 'description': ""The CGICSD comprises the following question to be rated on a three-point scale for each seizure subtype: Since the patient started treatment, please assess the average duration of the patient's seizures (comparing their condition now to their condition before treatment) using the scale below. The scale markers are: 1=Average duration of seizures has decreased; 2=Average duration of seizures has stayed the same; 3=Average duration of seizures has increased. Higher scores indicate a worse outcome."", 'timeFrame': 'Week 28 (V3) post-dose.'}, {'measure': 'Average CGICSD Score at Week 52 (V5)', 'description': ""The CGICSD comprises the following question to be rated on a three-point scale for each seizure subtype: Since the patient started treatment, please assess the average duration of the patient's seizures (comparing their condition now to their condition before treatment) using the scale below. The scale markers are: 1=Average duration of seizures has decreased; 2=Average duration of seizures has stayed the same; 3=Average duration of seizures has increased. Higher scores indicate a worse outcome."", 'timeFrame': 'Week 52 (V5) post-dose.'}, {'measure': 'Average Physician Global Impression of Change (PGIC) Score at Week 28 (V3)', 'description': 'The PGIC evaluates efficacy and quality of life. At enrollment the investigator will be asked to write a brief description of the patient\'s overall condition as a memory aid for assessment at each subsequent appointment. The PGIC comprises of the following question: ""Please assess the change in the patient\'s general functional abilities since enrolment."" The questionnaire is rated on a seven-point scale: ""Very Much Improved"" (1); ""Much Improved"" (2);Slightly Improved"" (3); ""No Change"" (4); ""Slightly Worse"" (5); ""Much Worse"" (6); ""Very Much Worse"" (7). A score of 1 indicates a better outcome and a score of 7 indicates a worse outcome.', 'timeFrame': 'Week 28 (V3) post-dose.'}, {'measure': 'Average PGIC Score at Week 52 (V5)', 'description': 'The PGIC evaluates efficacy and quality of life. At enrollment the investigator will be asked to write a brief description of the patient\'s overall condition as a memory aid for assessment at each subsequent appointment. The PGIC comprises of the following question: ""Please assess the change in the patient\'s general functional abilities since enrolment."" The questionnaire is rated on a seven-point scale: ""Very Much Improved"" (1); ""Much Improved"" (2);Slightly Improved"" (3); ""No Change"" (4); ""Slightly Worse"" (5); ""Much Worse"" (6); ""Very Much Worse"" (7). A score of 1 indicates a better outcome and a score of 7 indicates a worse outcome.', 'timeFrame': 'Week 52 (V5) post-dose.'}]",17,2 Years,,ALL,False,Jazz Pharmaceuticals,INDUSTRY,1,100.0,ESTIMATED,2025-09-01T16:18:24.744970,v2_robust,False,True,False,False,False,
NCT02402231,Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy,"Explorative Open Phase II-study, Food Allergy Suppression Therapy During Protection With Xolair",Omalizumab,['Omalizumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Peanut Allergy,['Peanut Allergy'],[],UNKNOWN,,2013-10,2020-10,"[{'measure': 'Peanut challenge. The peanut challenge can be positive i.e. the study object reacts to peanuts with allergic symptoms or negative i.e. no reaction in two hours after completed challenge.', 'timeFrame': 'The participants will be followed for the duration of Xolair treatment and oral immunotherapy, an expected average of 1 year'}]",[],1,12 Years,22 Years,ALL,False,Caroline Nilsson,OTHER,0,23.0,ACTUAL,2025-09-01T16:18:24.745131,v2_robust,True,True,False,False,False,
NCT04971031,A Clinical Trial to Assess Subjects With Dry Eye Disease.,"A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease",Reproxalap Ophthalmic Solution (0.25%),"['Reproxalap Ophthalmic Solution (0.25%)', 'Vehicle Ophthalmic Solution']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Dry Eye,['Dry Eye'],[],COMPLETED,,2021-06-15,2021-09-08,"[{'measure': 'Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber', 'description': 'Change from baseline comparison of reproxalap to vehicle for conjunctival redness on a 0 to 4 scale ( 0 = normal, 4 = prominent), where a high score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measure for change from baseline included baseline, treatment group, and nominal time point as fixed effects.', 'timeFrame': 'The efficacy assessment period was assessed during the 90-minute dry eye chamber at Day 2; baseline was Pre-Dose #1 at Day 1.'}, {'measure': 'Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS))', 'description': 'Change from baseline comparison of reproxalap to vehicle for subject-reported ocular dryness score VAS (0 = no discomfort, 100 = maximal discomfort), where a high score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measure for change from baseline included baseline, treatment group, and nominal time point as fixed effects.', 'timeFrame': 'The efficacy assessment period was assessed during the 90-minute dry eye chamber at Day 2; baseline was Pre-Dose #1 at Day 1.'}, {'measure': 'Schirmer Test Change From Baseline After the First Dose on Day 1', 'description': 'Change from baseline comparison of reproxalap to vehicle for Schirmer test on a millimeter line (0 = none, 35 = maximum), where a shorter length indicates a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measure for change from baseline included baseline and treatment group as fixed effects.', 'timeFrame': 'The efficacy assessment period was before and after the final dose on Day 1; baseline was Pre-Dose #1 at Day 1.'}]",[],3,18 Years,,ALL,False,"Aldeyra Therapeutics, Inc.",INDUSTRY,0,158.0,ACTUAL,2025-09-01T16:18:24.745140,v2_robust,True,True,True,False,False,
NCT01560702,Comparative Study of Autologous Blood Injection Versus Diluted Epinephrine in Treating Actively Bleeding Gastroduodenal Ulcers,Endoscopic Injection of Autologous Blood Versus Diluted Epinephrine for Control of Actively Bleeding Gastroduodenal Ulcers,Epinephrine,['Epinephrine'],1,INTERVENTIONAL,['NA'],,,"Blood, Injection, Injury Type Phobia","['Blood, Injection, Injury Type Phobia', 'Gastrointestinal Ulcer Haemorrhage', 'Adverse Reaction to Epinephrine']","['autologous blood', 'epinephrine', 'endoscopy', 'ulcer', 'hemostasis']",COMPLETED,,2012-03,2013-09,"[{'measure': 'hemostasis from the ulcer after injection and/or stoppage of haematemesis and melena one day after the procedure.', 'timeFrame': '12 months'}]","[{'measure': 'development of re-bleeding after 24 hours after the procedure (occurrence of hematemesis or melena or drop of hemoglobin level >2gm/dl).', 'timeFrame': '12 months'}]",2,16 Years,60 Years,ALL,False,Zagazig University,OTHER_GOV,0,100.0,ACTUAL,2025-09-01T16:18:24.745185,v2_robust,True,True,True,False,False,
NCT02512302,Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).,A Crossover Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of SUN-101 and Seebri® Breezhaler® Administered With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),SUN-101 via eFlow nebulizer,"['Seebri® Breezhaler®', 'SUN-101 via eFlow nebulizer with activated charcoal', 'Glycopyrrolate Injection', 'SUN-101 via eFlow nebulizer', 'glycopyrronium, glycopyrronium bromide', 'Glycopyrrolate', 'Seebri® Breezhaler® with activated charcoal']",7,INTERVENTIONAL,['PHASE1'],PHASE1,,COPD,['COPD'],['COPD'],COMPLETED,,2015-10,2016-04,"[{'measure': 'Cmax', 'description': 'maximum observed concentration-Cmax is calculated from plasma concentrations analyzed from blood samples collected between 0 and 48 hr.', 'timeFrame': 'Up to Week 5'}, {'measure': 'Area Under the Curve From Time Zero to 24 Hours (AUC0_24)', 'description': 'Area under the drug concentration-time curve from time zero to 24 hours postdose pk parameteres are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr', 'timeFrame': 'Up to Week 5'}, {'measure': 'Area Under the Curve From Time Zero to Infinity (AUC0_infinity)', 'description': 'calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity: AUC0-∞ = AUC0-last+ Clast / \\| λz \\| Clast / \\| λz \\| is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing.\n\nPk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.', 'timeFrame': 'Up to Week 5'}]","[{'measure': 'Clearance (CL) for IV Infusion of 50 mcg of Glycopyrrolate', 'description': 'calculated as Dose/AUC0-inf after the IV dose administration. If AUC0-inf is missing, then CL was considered as missing.\n\nPk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.', 'timeFrame': 'Up to Week 5'}, {'measure': 'Volume of Distribution During the Elimination Phase (Vz) for IV Infusion of 50 mcg of Glycopyrrolate', 'description': 'calculated as Dose/(AUC0-inf\\*λz). Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.', 'timeFrame': 'Up to Week 5'}, {'measure': 'Time of Occurrence of Cmax (Tmax) for IV Infusion of 50 mcg of Glycopyrrolate', 'description': 'The time 0 is based on start of the infusion. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.', 'timeFrame': 'Up to Week 5'}, {'measure': 'Terminal Half Life (t1/2) for IV Infusion of 50 mcg of Glycopyrrolate', 'description': 'calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½.\n\nPk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.', 'timeFrame': 'Up to Week 5'}, {'measure': 'Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri Breezhaler and Sun-101 AUC0-48, CL/F, Vz/F, Tmax, t½, and Dose Normalized Cmax, AUC0-24, AUC0-48, AUC0-∞ - AUC0-∞ -', 'description': 'Area under the drug concentration-time curve from time zero to 48 hours postdose Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.', 'timeFrame': 'Up to Week 5'}, {'measure': 'Apparent Clearance Calculated as Dose/AUC0-INF After Extravascular Dose Administration of Seebri Breezhaler and SUN-101', 'description': 'calculated as Dose/AUC0-∞ after extravascular dose administration, where F = Bioavailability. If AUC0-∞ is missing, then CL/F is considered as missing.\n\nPk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.', 'timeFrame': 'up to week 5'}, {'measure': 'Apparent Volume of Distribution (Vz/F) After Extravascular Dose Administration of Seebri Breezhaler and SUN-101', 'description': 'calculated as Dose/(AUC0-∞\\* λz), where F = Bioavailability. If AUC0-∞ is missing, then Vz/F is considered as missing.\n\nPk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr', 'timeFrame': 'up to week 5'}, {'measure': 'Time of Occurrence of Cmax (Tmax) for Seebri Breezhaler and SUN-101', 'description': 'The time 0 is based on start of the inhalation. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.', 'timeFrame': 'up to week 5'}, {'measure': 'Terminal Half Life (t1/2) for for Seebri Breezhaler and SUN-101', 'description': 'calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½.\n\nPk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.', 'timeFrame': 'up to week 5'}, {'measure': 'Dose Normalized Cmax for Seebri and SUN-101.', 'description': 'Maximum observed concentration multiplied by the dose normalization factor. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.\n\nThe dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.', 'timeFrame': 'up to week 5'}, {'measure': 'Dose Normalized Area Under the Curve Zero to 24 Hours (AUC0_24) for Seebri and SUN-101', 'description': 'Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.\n\nArea under the drug concentration-time curve from time zero to 24 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.', 'timeFrame': 'up to week 5'}, {'measure': 'Dose Normalized Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri and SUN-101', 'description': 'Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.\n\nArea under the drug concentration-time curve from time zero to 48 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.', 'timeFrame': 'up to week 5'}, {'measure': 'Dose Normalized Area Under the Curve Zero From Zero to Infinity (AUC0_inf) for Seebri and SUN-101', 'description': 'Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.\n\nArea under the drug concentration-time curve from zero to infinity, calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity multiplied by the dose normalization factor: dose normalization factor\\* (AUC0-∞ = AUC0-last+ Clast / \\| λz \\| ) Clast / \\| λz \\| is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing.\n\nThe dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50mcg , the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.', 'timeFrame': 'up to week 5'}, {'measure': 'The Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation', 'description': 'An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.', 'timeFrame': 'Up to Week 5'}, {'measure': 'The Percentage of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation', 'description': 'An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.', 'timeFrame': 'Up to Week 5'}]",18,40 Years,70 Years,ALL,False,Sunovion Respiratory Development Inc.,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:24.745383,v2_robust,True,True,True,False,True,
NCT00418002,Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.,"A Randomized, Double-Blind, Ascending Dose, Placebo-Controlled Single Dose Study in Non-Smoking Healthy Elderly Subjects Interleaved With a 2-Week Multiple Once Daily Dose Study to Explore Safety, Tolerability, Pharmacokinetics and Cognitive Effects After Oral Administration of AQW051",AQW051,['AQW051'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Single-rising dose , multiple rising dose, elderly, cognitive, , pharmacokinetic, impairment.', 'Healthy elderly male and female subjects']",COMPLETED,,2006-05,,[{'measure': 'Safety and tolerability.'}],"[{'measure': 'Pharmacokinetics at the end of the study.'}, {'measure': 'Effect of AQW051 on cognition as assessed by a computerized cognitive test battery.'}, {'measure': 'To assess a potential food effect on pharmacokinetics of AQW051.'}, {'measure': 'To explore the drug abuse liability potential of AQW051.'}]",5,60 Years,80 Years,ALL,True,Novartis,INDUSTRY,0,72.0,ESTIMATED,2025-09-01T16:18:24.745514,v2_robust,True,True,True,False,True,
NCT06516302,A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy, Safety, and Immunogenicity of GR1802 in Participants With Chronic Rhinosinusitis With Nasal Polyps",GR1802,"['GR1802', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Rhinosinusitis With Nasal Polyps,['Chronic Rhinosinusitis With Nasal Polyps'],[],RECRUITING,,2024-09-19,2026-10,"[{'measure': 'Change from baseline in nasal polyps score at week 24.', 'description': 'Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.', 'timeFrame': 'At week 24'}, {'measure': 'Change from baseline in nasal congestion score at week 24.', 'description': 'Nasal congestion score (0-3), higher score means worse nasal symptom.', 'timeFrame': 'At week 24'}]","[{'measure': 'Change from baseline in reduction/loss of smell at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 and 60.', 'description': 'The reduction/loss of smell severity was reported by the participant on a daily basis using a 0 to 3 categorical scale. Higher score means a worse sense of smell.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Change from baseline in nasal discharge (anterior/posterior) at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 and 60.', 'description': 'The nasal discharge severity was reported by the participant on a daily basis using a 0 to 3 categorical scale. Higher score means a worse nasal symptom.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Change from baseline in Total Nasal Symptom Score (TNSS) at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 and 60.', 'description': 'TNSS score (0-9). Higher score means worse nasal symptom.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Change from baseline in nasal endoscopy nasal polyps score in participants with a high power field of vision < 55 eosinophil granulocytes in nasal polyp tissue at week 24.', 'description': 'Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.', 'timeFrame': 'At week 24'}, {'measure': 'Change from baseline in nasal congestion score in participants with a high power field of vision < 55 eosinophil granulocytes in nasal polyp tissue at week 24.', 'description': 'Nasal congestion score (0-3), higher score means worse nasal symptom.', 'timeFrame': 'At week 24'}, {'measure': 'Change from baseline in nasal polyps score at weeks 2、4、8、16、32、40、52 and 60.', 'description': 'Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Proportion of participants with improvement by at least 1 point in nasal polyps score at weeks 2、4、8、16、24、32、40、52 and 60.', 'description': 'Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Proportion of participants with improvement by at least 2 point in nasal polyps score at weeks 2、4、8、16、24、32、40、52 and 60.', 'description': 'Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Time to first response (≥1 point improvement) in nasal polyps score.', 'description': 'Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Change from baseline in nasal congestion score at weeks 4、8、12、16、20、28、32、36、40、44、48、52、56 and 60.', 'description': 'Nasal congestion score (0-3), higher score means worse nasal symptom.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Proportion of participants with improvement by at least 1 point in nasal congestion score at weeks 4、8、12、16、20、24、28、32、36、40、44、48、52、56 and 60.', 'description': 'Nasal congestion score (0-3), higher score means worse nasal symptom.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Proportion of participants with improvement by at least 2 point in nasal congestion score at weeks 4、8、12、16、20、24、28、32、36、40、44、48、52、56 and 60.', 'description': 'Nasal congestion score (0-3), higher score means worse nasal symptom.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Change from baseline in Lund-Mackay score at week 24 and 52.', 'description': 'The range of LM score is 0-24. Higher score means worse rhinosinusitis.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Change from baseline in 22-item Sinonasal Outcome Test (SNOT-22) at weeks 2, 4, 8, 16, 24, 32, 40, 52 and 60.', 'description': 'The range of SNOT-22 score is 0 to 110. Higher scores indicating more severe disease.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT) at weeks 2, 4, 16, 24, 32, 40, 52 and 60.', 'description': 'UPSIT score (0-40). Higher score means better sense of smell.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Change from baseline in five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) at weeks 4、16、24、40、52 and 60.', 'description': 'The EQ-5D-5L descriptive system comprises five dimensions (MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION), and each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. The respondent is asked to indicate his/her health state by checking the box next to the most appropriate response level for each of the five dimensions.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Safety parameters.', 'description': 'Incidence of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious AEs (TESAEs), etc.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Pharmacokinetics, include Ctrough, etc.', 'description': 'GR1802 concentrations were measured in CRSwNP population using sparse sampling (samples collected at predose, during treatment, and the follow up period).', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Pharmacodynamics.', 'description': 'Levels of the type 2 inflammation biomarkers were assessed as markers for disease activity/severity.', 'timeFrame': 'From baseline to week 60'}, {'measure': 'Immunogenicity, include ADA and Nab.', 'description': 'Anti GR1802 antibody status was determined at baseline and at prespecified time points.', 'timeFrame': 'From baseline to week 60'}]",22,18 Years,75 Years,ALL,False,"Genrix (Shanghai) Biopharmaceutical Co., Ltd.",INDUSTRY,0,228.0,ESTIMATED,2025-09-01T16:18:24.745540,v2_robust,True,True,False,False,True,
NCT05997602,"To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH","A Multi-center, Open-label, Single Arm Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent Langerhans Cell Histiocytosis",FCN-159,['FCN-159'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Langerhans Cell Histiocytosis,"['Langerhans Cell Histiocytosis', 'LCH']",[],RECRUITING,,2023-09-28,2027-05-14,"[{'measure': 'Objective Response Rate (ORR) Evaluated by Independent Review Committee (IRC) Based on PET Response Criteria (PRC)', 'description': 'ORR Evaluated by Independent Review Committee (IRC) Based on PET Response Criteria (PRC) is defined as the percentage of participants who achieved a best overall response of CMR or PMR assessed by IRC .', 'timeFrame': 'up to 24months'}]","[{'measure': 'Objective Response Rate (ORR) Evaluated by Investigator Based on PET Response Criteria (PRC) and Langerhans Cell Histiocytosis Evaluation and Treatment Guidelines (Histiocyte Society, April 2009, hereinafter referred to as ""Guidelines"")', 'description': 'The ORR Evaluated by Investigator Based on PRC is defined as the percentage of participants who achieved a best overall response of CMR or PMR assessed by investigator.\n\nThe ORR Evaluated by Investigator Based on ""Guidelines"" is defined as the percentage of participants who achieved confirmed NAD or AD-better assessed by investigator.', 'timeFrame': 'up to 24months'}, {'measure': 'Disease Control Rate (DCR) Evaluated by Investigator Based on PET Response Criteria (PRC) and ""Guidelines"".', 'description': 'The DCR Evaluated by Investigator based on PRC is defined as the percentage of participants who achieved a best overall response of CMR or PMR or SMD assessed by investigator.\n\nThe DCR Evaluated by Investigator Based on ""Guidelines"" is defined as the percentage of participants who achieved a confirmed NAD or AD-better or AD-stable assessed by investigator.', 'timeFrame': 'up to 24months'}, {'measure': 'Clinical benefit rate (CBR) Evaluated by Investigator Based on PRC and ""Guidelines"".', 'description': 'The CBR Evaluated by Investigator based on PRC is defined as the percentage of participants who achieved a best overall response of CMR or PMR or SMD for a duration of ≥ 24 weeks assessed by investigator.\n\nThe CBR Evaluated by Investigator Based on ""Guidelines"" is defined as the percentage of participants who achieved confirmed NAD or AD-better or AD stable for a duration of ≥ 24 weeks assessed by investigator.', 'timeFrame': 'up to 24months'}, {'measure': 'Time to Response (TTR) Evaluated by Investigator Based on PET Response Criteria (PRC) and ""Guidelines""', 'description': 'The TTR Evaluated by Investigator based on PRC is defined as the time from the first documented achievement of CMR or PMR (whichever comes first) assessed by investigator.\n\nThe TTR Evaluated by Investigator based on the ""Guidelines"" criteria is defined as the time from the first documented achievement of NAD or AD-better (whichever comes first) assessed by investigator.', 'timeFrame': 'up to 24months'}, {'measure': 'One-year Progressive Free Survival (PFS) Rate Evaluated by Investigator Based on PET Response Criteria (PRC) and ""Guidelines""', 'description': 'The 1-year PFS Rate Evaluated by Investigator based on PRC is defined as the percentage of participants who did not achieve the first documented occurrence of PMD or death (whichever comes first) within one year after first administration of the study drug assessed by investigator.\n\nThe 1-year PFS Rate Evaluated by Investigator based on ""Guidelines"" is defined as the percentage of participants who did not achieve the first documented occurrence of AD-progression or death (whichever comes first) within one year after first administration of the study drug assessed by investigator.', 'timeFrame': 'up to 12months'}, {'measure': 'Progressive Free Survival (PFS) Evaluated by Investigator Based on PET Response Criteria (PRC) and ""Guidelines""', 'description': 'The PFS Evaluated by Investigator based on PRC is defined as the time from the first administration of the study drug to the first documented occurrence of PMD or death (whichever comes first) assessed by investigator.\n\nThe PFS Evaluated by Investigator based on ""Guidelines"" is defined as the time from the first administration of the study drug to the first documented occurrence of AD-progression or death (whichever comes first) assessed by investigator.', 'timeFrame': 'up to 24months'}, {'measure': 'Overall Survival (OS)', 'description': 'The OS is defined as the time from the first administration of the study drug in patients to death from any cause. Data from the patient without events will be censored at the date the patient is last known to be alive', 'timeFrame': 'up to 24months'}, {'measure': 'One-year Overall Survival (OS) Rate', 'description': 'The 1year OS Rate is defined as as the percentage of participants who did not achieve death due to any cause within one year after first administration of the study drug.', 'timeFrame': 'up to 12months'}, {'measure': 'Two-year Progressive Free Survival (PFS) rate Evaluated by the PRC and ""Guidelines""', 'description': 'The 2-year PFS Rate Evaluated by Investigator based on PRC is defined as the percentage of participants who did not achieve the first documented occurrence of PMD or death (whichever comes first) within two year after first administration of the study drug.\n\nThe 2-year PFS Rate Evaluated by Investigator based on ""Guidelines"" is defined as the percentage of participants who did not achieve the first documented occurrence of AD-progression or death (whichever comes first) within two year after first administration of the study drug.', 'timeFrame': 'up to 24months'}, {'measure': 'Two-year Overall Survival (OS) Rate', 'description': 'The 2 year OS Rate is defined as the percentage of participants who did not achieve death due to any cause within two year after first administration of the study drug.', 'timeFrame': 'up to 24months'}, {'measure': 'Treatment-emergent adverse events (TEAEs)', 'description': 'Type and frequency of treatment-emergent adverse events (TEAEs) with toxicity grades evaluated according to the National Cancer Institute-Common Toxicity Criteria Adverse Event (NCI-CTCAE) version 5.0.', 'timeFrame': 'up to 24months'}, {'measure': 'Plasma Concentration of FCN-159', 'description': 'Evaluation of the pharmacokinetic characteristics of FCN-159', 'timeFrame': 'up to 24months'}]",13,2 Years,16 Years,ALL,False,Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.,INDUSTRY,0,56.0,ESTIMATED,2025-09-01T16:18:24.745635,v2_robust,True,True,False,False,True,
NCT00004002,PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma,Phase I Trial of PS-341 in Advanced Cancers,bortezomib,['bortezomib'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Lymphoma,"['Lymphoma', 'Small Intestine Cancer', 'Unspecified Adult Solid Tumor, Protocol Specific']","['stage IV adult Hodgkin lymphoma', 'recurrent adult Hodgkin lymphoma', 'stage IV cutaneous T-cell non-Hodgkin lymphoma', 'recurrent cutaneous T-cell non-Hodgkin lymphoma', 'small intestine lymphoma', 'unspecified adult solid tumor, protocol specific', 'stage IV grade 1 follicular lymphoma', 'stage IV grade 2 follicular lymphoma', 'stage IV grade 3 follicular lymphoma', 'stage IV adult diffuse small cleaved cell lymphoma', 'stage IV adult diffuse mixed cell lymphoma', 'stage IV adult diffuse large cell lymphoma', 'stage IV adult immunoblastic large cell lymphoma', 'stage IV adult lymphoblastic lymphoma', 'stage IV adult Burkitt lymphoma', 'recurrent grade 1 follicular lymphoma', 'recurrent grade 2 follicular lymphoma', 'recurrent grade 3 follicular lymphoma', 'recurrent adult diffuse small cleaved cell lymphoma', 'recurrent adult diffuse mixed cell lymphoma', 'recurrent adult diffuse large cell lymphoma', 'recurrent adult immunoblastic large cell lymphoma', 'recurrent adult lymphoblastic lymphoma', 'recurrent adult Burkitt lymphoma', 'stage IV adult T-cell leukemia/lymphoma', 'recurrent adult T-cell leukemia/lymphoma', 'primary central nervous system non-Hodgkin lymphoma', 'AIDS-related peripheral/systemic lymphoma', 'AIDS-related primary CNS lymphoma', 'intraocular lymphoma', 'stage IV mantle cell lymphoma', 'recurrent mantle cell lymphoma', 'angioimmunoblastic T-cell lymphoma', 'anaplastic large cell lymphoma', 'stage IV mycosis fungoides/Sezary syndrome', 'recurrent mycosis fungoides/Sezary syndrome', 'recurrent marginal zone lymphoma', 'recurrent small lymphocytic lymphoma', 'stage IV small lymphocytic lymphoma', 'stage IV marginal zone lymphoma', 'extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue', 'nodal marginal zone B-cell lymphoma', 'splenic marginal zone lymphoma']",COMPLETED,,1999-07,,[],[],0,18 Years,,ALL,False,NYU Langone Health,OTHER,1,,,2025-09-01T16:18:24.745701,v2_robust,True,True,True,False,False,
NCT03651102,Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia,Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia Patients of Pakistan,Thalidomide and Hydroxyurea,['Thalidomide and Hydroxyurea'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Thalassemia,['Thalassemia'],"['Thalidomide', 'Thalassemia']",COMPLETED,,2018-01-01,2022-03-01,"[{'measure': 'Haemoglobin Level', 'description': 'mg/dL', 'timeFrame': '6-24 months'}, {'measure': 'Response Rate (Excellent, Good, Partial and No response)', 'timeFrame': '6-24 months'}, {'measure': 'Adverse Effects', 'timeFrame': '6-24 months'}]",[],3,1 Year,,ALL,False,Blood Diseases Clinic,OTHER,1,654.0,ACTUAL,2025-09-01T16:18:24.745791,v2_robust,True,True,True,False,True,
NCT00540202,Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children,Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children,artemether-lumefantrine,"['Oral quinine', 'Coartem', 'artemether-lumefantrine']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Uncomplicated Malaria,['Uncomplicated Malaria'],"['Effectiveness', 'Oral quinine', 'Coartem', 'Uncomplicated malaria', 'Children']",UNKNOWN,,2007-09,2008-04,"[{'measure': '1. PCR adjusted parasitological cure rate on day 28. 2. Clinical cure rates on day 28.', 'timeFrame': '28 days'}]","[{'measure': '1. Fever clearance time assessed by self report. 2. Hemoglobin changes on day 0, 7, 14 and 28. 3. Safety profiles. 4. Adherence: measured by patient report and pill count on day 3 for the artemether-Lumefantrine group and day 7 for the quinine group.', 'timeFrame': '28 days'}]",2,6 Months,5 Years,ALL,False,Makerere University,OTHER,2,302.0,ESTIMATED,2025-09-01T16:18:24.745802,v2_robust,True,True,False,False,True,
NCT01931202,Mechanisms of Antidepressant Non-Response in Late-Life Depression,Mechanisms of Antidepressant Non-Response in Late-Life Depression,Escitalopram,"['Escitalopram', 'Placebo oral tablet', 'Lexapro', 'placebo']",4,INTERVENTIONAL,['NA'],,,Major Depressive Disorder,['Major Depressive Disorder'],[],COMPLETED,,2014-02-19,2020-01-17,"[{'measure': 'Hamilton Rating Scale for Depression (HRSD)', 'description': 'Our target is depressive symptomatology as measured by the Hamilton Rating Scale for Depression (HRSD). The HRSD is a 24-item questionnaire used as an indication of depression and a guide to evaluate recovery. Total scores range from 0-74, not including atypical symptoms sub-scale. A score of 16 or above is typically considered to indicate the presence of depressive symptoms. Higher scores indicate greater severity.', 'timeFrame': 'Baseline'}]","[{'measure': 'Hamilton Rating Scale for Depression (HRSD)', 'description': 'Our target is depressive symptomatology as measured by the Hamilton Rating Scale for Depression (HRSD). The HRSD is a 24-item questionnaire used as an indication of depression and a guide to evaluate recovery. Total scores range from 0-74, not including atypical symptoms sub-scale. A score of 16 or above is typically considered to indicate the presence of depressive symptoms. Higher scores indicate greater severity.', 'timeFrame': 'Week 8'}, {'measure': 'Quick Inventory of Depressive Symptoms (QIDS-SR)', 'description': 'QIDS-SR is a 16 item scale self-report form that was used to measure depression outcomes. This self-report is valuable in this study, because it is less susceptible to clinician and rater bias. The QIDS-SR has been increasingly used in antidepressant studies due to its equivalent weightings for each symptom item, clearly understandable anchor points, and inclusion of all DSM criteria for depression. The scores range from 0-27 with 27 being worse depressive symptoms.', 'timeFrame': 'Baseline'}, {'measure': 'Quick Inventory of Depressive Symptoms (QIDS-SR)', 'description': 'QIDS-SR is a 16 item scale self-report form that was used to measure depression outcomes. This self-report is valuable in this study, because it is less susceptible to clinician and rater bias. The QIDS-SR has been increasingly used in antidepressant studies due to its equivalent weightings for each symptom item, clearly understandable anchor points, and inclusion of all DSM criteria for depression. The scores range from 0-27 with 27 being worse depressive symptoms.', 'timeFrame': 'Week 8'}, {'measure': 'Credibility and Expectancy Scale-Better (CES)', 'description': ""CES is an 8 item scale in which subjects rate their impression of the credibility of the treatment and how they estimate their expectation of improvement. The CES is the most widely used measure of expectancy and has demonstrated good psychometric properties in multiple studies. Question 2 ('Better') asks the patient the chances of their depression being completely better at the end of this study, from 1 = very poor to 7 = very good. The higher the number, the higher the expectancy that they will be better."", 'timeFrame': 'Pre-Baseline'}, {'measure': 'Credibility and Expectancy Scale-Better (CES)', 'description': ""CES is an 8 item scale in which subjects rate their impression of the credibility of the treatment and how they estimate their expectation of improvement. The CES is the most widely used measure of expectancy and has demonstrated good psychometric properties in multiple studies. Question 2 ('Better') asks the patient the chances of their depression being completely better at the end of this study, from 1 = very poor to 7 = very good. The higher the number, the higher the expectancy that they will be better."", 'timeFrame': 'Week 0'}, {'measure': 'Credibility and Expectancy Scale-Depression', 'description': ""CES is an 8 item scale in which subjects rate their impression of the credibility of the treatment and how they estimate their expectation of improvement. The CES is the most widely used measure of expectancy and has demonstrated good psychometric properties in multiple studies. CES question 3 ('Depression') asks how the patient's depression will be at the end of the study, compared with now, from 1 = much worse to 7= much better. The higher the number, the higher the expectancy that their depression will be much better."", 'timeFrame': 'Pre-baseline'}, {'measure': 'Credibility and Expectancy Scale-Depression', 'description': ""CES is an 8 item scale in which subjects rate their impression of the credibility of the treatment and how they estimate their expectation of improvement. The CES is the most widely used measure of expectancy and has demonstrated good psychometric properties in multiple studies. CES question 3 ('Depression') asks how the patient's depression will be at the end of the study, compared with now, from 1 = much worse to 7= much better. The higher the number, the higher the expectancy that their depression will be much better."", 'timeFrame': 'Week 0'}, {'measure': 'Quick Inventory of Depression Scale (QIDS-SR): Expectancy', 'description': 'This 16-items assessment is used to rate the 9 criterion symptom domains of a major depressive episode: 4 items are used to rate sleep disturbance (early, middle, and late insomnia plus hypersomnia); 2 items are used to rate psychomotor disturbance (agitation and retardation); 4 items are used to rate appetite/weight disturbance (appetite increase or decrease and weight increase or decrease). Only 1 item is used to rate the remaining 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, and suicidal ideation). Each item is rated 0-3. For symptom domains that require more than 1 item, the highest score of the item relevant for each domain is taken. The total score ranges from 0-27. A lower rating indicates higher expectancy of improvement and lower expectation of depressive symptomatology, and a higher rating indicates lower expectancy of improvement, higher expectation of depression.', 'timeFrame': 'Pre-Baseline'}, {'measure': 'Quick Inventory of Depression Scale (QIDS-SR): Expectancy', 'description': 'This 16-items assessment is used to rate the 9 criterion symptom domains of a major depressive episode: 4 items are used to rate sleep disturbance (early, middle, and late insomnia plus hypersomnia); 2 items are used to rate psychomotor disturbance (agitation and retardation); 4 items are used to rate appetite/weight disturbance (appetite increase or decrease and weight increase or decrease). Only 1 item is used to rate the remaining 6 domains (depressed mood, decreased interest, decreased energy, worthlessness/guilt, concentration/decision making, and suicidal ideation). Each item is rated 0-3. For symptom domains that require more than 1 item, the highest score of the item relevant for each domain is taken. The total score ranges from 0-27. A lower rating indicates higher expectancy of improvement and lower expectation of depressive symptomatology, and a higher rating indicates lower expectancy of improvement, higher expectation of depression.', 'timeFrame': 'Week 0'}, {'measure': 'Executive Dysfunction: Stroop Color Word', 'description': 'Stroop Color Word test asks patients to name the color of a word rather than reading the word. Stroop Color Word is how many colors they can name in 45 sec (higher is better, e.g., less executive dysfunction).', 'timeFrame': 'Pre-Baseline'}, {'measure': 'Executive Dysfunction: Stroop Interference', 'description': 'The Stroop is a measure of inhibition under distracting conditions that is sensitive to frontal lobe dysfunction. in Stroop Color Word test patients are to name the color of a word rather than reading the word. Stroop Color Word is how many colors they can name in 45 sec (higher is better, e.g., less executive dysfunction). Stroop Interference is this score adjusted for age and education.', 'timeFrame': 'Pre-Baseline'}, {'measure': 'White Matter Hyperintensity (WMH) Outcome- Total WMH', 'description': 'Magnetic Resonance Imaging (MRI) of the Brain was acquired. We rated the severity of WMH on axial T2 FLAIR images using the Fazekas modified Coffey Rating Scale. Deep WMH are scored as 0 (absent), 1 (punctate foci), 2 (beginning confluence of foci), and 3 (large confluent areas); subcortical gray matter HIs (basal ganglia) are scored as 0 (absent), 1 (punctate), 2 (multipunctate), and 3 (diffuse); periventricular HIs are scored as 0 (absent), 1 (caps), 2 (smooth halo), and 3 (irregular and extending into the deep white matter). Our primary measure of WMH burden will be DWMH score, which has been used to establish the only empirically validated diagnostic criteria for vascular depression, where scores of 0-1 were normal, but 2-3 indicated WHM.', 'timeFrame': 'Pre-Baseline'}]",13,60 Years,90 Years,ALL,False,New York State Psychiatric Institute,OTHER,0,138.0,ACTUAL,2025-09-01T16:18:24.745812,v2_robust,True,True,True,False,False,
NCT05024253,Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.,Does Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Reduce Blood Loss and Transfusion Requirements? A Double-blinded Randomized Controlled Trial,Tranexamic acid injection,"['Cyklokapron®', 'Tranexamic acid injection']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Ewing Sarcoma of Bone,"['Ewing Sarcoma of Bone', 'Osteosarcoma']",['tranexamic acid'],COMPLETED,,2021-08-02,2024-02-01,"[{'measure': 'Intraoperative blood loss will be changed by by Tranexamic acid when compared with saline or Not.', 'description': 'will be calculated based on measurement of number and weights of blood-soaked surgical swabs. As well as measurement of total volume of blood collected in suction container, after subtracting volume of saline used for washing wound.', 'timeFrame': 'during surgery'}, {'measure': 'postoperative blood loss will be changed by Tranexamic acid when compared with saline or Not.', 'description': 'will be calculated based on measurement of number and weights of blood-soaked surgical swabs. As well as measurement of total volume of blood collected in suction container, after subtracting volume of saline used for washing wound.', 'timeFrame': 'after surgery , approximately 1-4 days'}]","[{'measure': 'blood transfusion will be changed by Tranexamic acid when compared with saline or Not.', 'description': 'Calculation of blood volume to be transfused (no of units in mls) = (Estimated blood volume ×(target HCT -actual HCT))/HCT of one unit of packed RBCs', 'timeFrame': 'during surgery and approximately 1-7 days'}]",3,4 Years,18 Years,ALL,False,Children's Cancer Hospital Egypt 57357,OTHER,0,48.0,ACTUAL,2025-09-01T16:18:24.745885,v2_robust,True,True,True,False,False,
NCT01198353,Effectiveness of Ziprasidone for Patients With Schizophrenia,Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder,Ziprasidone,"['Zeldox', 'Ziprasidone']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Schizophrenia,"['Schizophrenia', 'Schizoaffective Disorder']","['Schizophrenia', 'Schizoaffective Disorder', 'Ziprasidone', 'Switch', 'Metabolic syndrome']",COMPLETED,,2010-09,2013-12,"[{'measure': 'A change in the Brief Psychotic Rating Scale (BPRS)', 'timeFrame': 'baseline and 12 weeks'}]","[{'measure': 'A change in the Lipid profile (Triglyceride, HDL, LDL, Total cholesterol)', 'timeFrame': 'baseline and 12 weeks'}, {'measure': 'A change in the Body Mass Index (BMI)', 'timeFrame': 'baseline and 12 weeks'}, {'measure': 'A change in the Waist-to-hip ratio', 'timeFrame': 'baseline and 12 weeks'}, {'measure': 'UKU side effect rating scale - patient (UKU-SERS-Pat)', 'timeFrame': 'baseline'}, {'measure': 'UKU side effect rating scale - patient (UKU-SERS-Pat)', 'timeFrame': '4 weeks'}, {'measure': 'UKU side effect rating scale - patient (UKU-SERS-Pat)', 'timeFrame': '8 weeks'}, {'measure': 'UKU side effect rating scale - patient (UKU-SERS-Pat)', 'timeFrame': '12 weeks'}, {'measure': 'A change in the Clinical Global Impression (CGI)', 'timeFrame': 'Baseline and 12 weeks'}, {'measure': 'A change in the Global Assessment of Functioning (GAF)', 'timeFrame': 'Baseline and 12 weeks'}, {'measure': 'Blood chemistry tests including CBC, electrolyte, LFT, Nitrogen Elements, and protein', 'timeFrame': 'Baseline'}, {'measure': 'Blood chemistry tests including CBC, electrolyte, LFT, Nitrogen Elements, and protein', 'timeFrame': '12 weeks'}, {'measure': 'Urinalysis', 'timeFrame': 'Baseline'}, {'measure': 'Urinalysis', 'timeFrame': '12 weeks'}, {'measure': 'Electrocardiogram (ECG)', 'timeFrame': 'Baseline'}, {'measure': 'Electrocardiogram (ECG)', 'timeFrame': '12 weeks'}]",16,18 Years,55 Years,ALL,False,Soonchunhyang University Hospital,OTHER,1,67.0,ACTUAL,2025-09-01T16:18:24.745904,v2_robust,True,True,True,False,False,
NCT02051153,Neurochemical Modulation Cognitive Performance and Subjective Wellbeing In Healthy Controls,Neurochemical Modulation Cognitive Performance and Subjective Wellbeing In Healthy Controls,Modafinil,"['Drug: Placebo', 'Modafinil:', 'Modafinil', 'Placebo']",4,INTERVENTIONAL,['NA'],,,Cognitive Performance,"['Cognitive Performance', 'Creativity', 'Motivation', 'Reward', 'Healthy Volunteers', 'Subjective Pleasure']","['Modafinil', 'Cognitive', 'Performance']",COMPLETED,,2009-10,2011-09,"[{'measure': 'Neuropsychological measures', 'description': ""The cognitive measures used in this work will be drawn from the Cambridge Neuropsychological Test Automated Battery (CANTAB) battery and the from the Cued Reinforcement Reaction Task (CRRT):\n\nParticipants will be assessed on the computerised neuropsychological tests and subjective questionnaires 2 hours post drug administration for 2 hour period in one study session. Outcome measures are: Errors made by the participant, the number of trials required to locate the pattern(s) correctly, memory scores, and stages completed and strategy score. The percentage of correct trials and latency (speed of participant's response) will be calculated. For the span, scores for both the forwards and backwards tests were summed to yield an overall span score.\n\nFor the CRRT participants' responses and reaction times will be recorded. Mean change in Subjective Well-being and subjective pleasure between 1, 2, 3, 4 hours will be calculated."", 'timeFrame': '2 hours post drug administration'}]","[{'measure': 'Physiological measures', 'description': 'Blood pressure and pulse measurements will be taken using a Criticare Systems Inc. Comfort Cuff (Model 507NJ) at five time points: immediately upon arrival, before drug administration, immediately prior to testing (2 h post-drug), 1 h into testing (3 h post-drug), and on completion of the study (4 h post-drug). To monitor adverse events, this will measure number of participants on active and non-active agent with high or low blood pressure and plus. Outcome measure: Change from Baseline in Systolic Blood Pressure at Hour 1, 2, 3, and 4.', 'timeFrame': 'Baseline and hourly observation for 4 hours'}]",2,16 Years,40 Years,ALL,True,Cambridge University Hospitals NHS Foundation Trust,OTHER,0,64.0,ACTUAL,2025-09-01T16:18:24.745990,v2_robust,True,True,True,False,True,
NCT00471653,Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy,A Pharmacokinetic and Pharmacogenomic Study of Patients With High-Grade Gliomas Receiving Daily Radiation Therapy and Temozolomide,temozolomide,['temozolomide'],1,OBSERVATIONAL,[],,,Brain and Central Nervous System Tumors,"['Brain and Central Nervous System Tumors', 'Thrombocytopenia']","['thrombocytopenia', 'adult anaplastic oligodendroglioma', 'adult brain stem glioma', 'adult mixed glioma', 'adult giant cell glioblastoma', 'adult gliosarcoma', 'adult glioblastoma', 'adult anaplastic astrocytoma', 'adult anaplastic ependymoma', 'adult pineal gland astrocytoma']",TERMINATED,low accrual,2006-11-11,2009-08-18,"[{'measure': 'Pharmacokinetics (PK) of temozolomide (TMZ) in patients with severe thrombocytopenia after standard first-line therapy as measured by Area Under the Curve (AUC)', 'description': 'AUC (mg\\*h/L)in patients who develop severe thrombocytopenia after receiving standard first-line therapy of temozolomide (TMZ) for management of newly diagnosed high-grade gliomas.', 'timeFrame': 'Day 1, Day 22, Day 43'}, {'measure': 'Pharmacokinetics (PK) of temozolomide (TMZ) in patients with severe thrombocytopenia after standard first-line therapy as measured by maximum drug concentration (Cmax)', 'description': 'Cmax in patients who develop severe thrombocytopenia after receiving standard first-line therapy of temozolomide (TMZ) for management of newly diagnosed high-grade gliomas.', 'timeFrame': 'Day 1, Day 22, Day 43'}, {'measure': 'Pharmacokinetic (PK) profile of temozolomide (TMZ) in patients without severe thrombocytopenia after standard first-line therapy as measured by AUC', 'description': 'AUC in patients in patients who do not develop severe thrombocytopenia after receiving standard first-line therapy of TMZ for management of newly diagnosed high-grade gliomas.', 'timeFrame': 'Day 1, Day 22, Day 43'}, {'measure': 'Pharmacokinetic (PK) profile of temozolomide (TMZ) in patients without severe thrombocytopenia after standard first-line therapy as measured by Cmax', 'description': 'Cmax in patients in patients who do not develop severe thrombocytopenia after receiving standard first-line therapy of TMZ for management of newly diagnosed high-grade gliomas.', 'timeFrame': 'Day 1, Day 22, Day 43'}]","[{'measure': 'Presence of single nucleotide polymorphisms in the O6-methylguanine-DNA methyltransferase gene.', 'description': 'Presence of single nucleotide polymorphisms in the O6-methylguanine-DNA methyltransferase gene of patients who develop thrombocytopenia after receiving standard first-line therapy for management of newly diagnosed high-grade gliomas.', 'timeFrame': 'Day 1'}]",5,18 Years,120 Years,ALL,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,1,10.0,ACTUAL,2025-09-01T16:18:24.746024,v2_robust,False,True,False,True,False,low accrual
NCT02005653,Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection,Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection: Double Blind Randomised Clinical Trial (RCT) to Study the Efficacy of Different Co-administration and Sequential Administration,Diethylcarbamazine,"['Doxy', 'DEC', 'Albendazole', 'Doxycycline', 'Diethylcarbamazine', 'Alb']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Filarial; Infestation,['Filarial; Infestation'],"['Lymphatic filariasis', 'W. bancrofti', 'DEC', 'Albendazole', 'Doxycycline']",COMPLETED,,2009-02,2013-08,"[{'measure': 'complete clearance of mf in 80% of the infected', 'timeFrame': 'At 13th week (91 days) post therapy'}]","[{'measure': 'Complete clearance Mf and complete clearance of antigen from the infected', 'description': 'a)Complete clearance of Mf by 26 weeks (180 days) post therapy. b) Complete clearance of antigen by 52 weeks (365days) post therapy', 'timeFrame': '26 and 52 weeks post therapy'}]",2,18 Years,65 Years,ALL,False,Indian Council of Medical Research,OTHER_GOV,0,146.0,ACTUAL,2025-09-01T16:18:24.746046,v2_robust,True,True,True,False,False,
NCT01185353,A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy",LY3009104,"['Methotrexate', 'JAK1/2 Inhibitor', 'Janus Kinase (JAK)1/JAK2 Inhibitor', 'baricitinib', 'Placebo', 'INCB028050', 'LY3009104']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,"Arthritis, Rheumatoid","['Arthritis, Rheumatoid']","['Rheumatoid Arthritis', 'RA']",COMPLETED,,2010-10,2014-03,"[{'measure': 'Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12', 'description': ""ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \\* 100."", 'timeFrame': 'Baseline through Week 12'}]","[{'measure': 'Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 12 - Model Based Dose Response', 'description': ""ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \\* 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval."", 'timeFrame': 'Baseline through Week 12'}, {'measure': 'Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 24', 'description': ""ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) \\* 100."", 'timeFrame': 'Baseline through Weeks 2, 4, 8, 12, 16, 20, 24'}, {'measure': 'Percentage of Participants Who Achieved an ACR20 Response Baseline Through Weeks 76 and 128', 'description': ""ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \\* 100."", 'timeFrame': 'Baseline through Weeks 76 and 128'}, {'measure': 'Percentage of Participants Who Achieved an ACR 50 Responder Index Response Baseline Through Week 24', 'description': ""ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \\* 100."", 'timeFrame': 'Baseline through Weeks 2, 4, 8, 12, 16, 20, 24'}, {'measure': 'Percentage of Participants Who Achieved an ACR50 Response Baseline Through Weeks 76 and 128', 'description': ""ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \\* 100."", 'timeFrame': 'Baseline through Weeks 76 and 128'}, {'measure': 'Percentage of Participants Who Achieved an ACR70 Responder Index Response Baseline Through Week 24', 'description': ""ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \\* 100."", 'timeFrame': 'Baseline through Weeks 2, 4, 8, 12, 16, 20, 24'}, {'measure': 'Percentage of Participants Who Achieved an ACR70 Response Baseline Through Weeks 76 and 128', 'description': ""ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \\* 100."", 'timeFrame': 'Baseline through Weeks 76 and 128'}, {'measure': 'Percentage of Participants Who Achieved an ACR50 Response Baseline Through Week 12 - Model Based Dose Response', 'description': ""ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \\* 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval."", 'timeFrame': 'Baseline through Week 12'}, {'measure': 'ACR Percent Improvement (ACR-N)', 'description': 'ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in RA that characterizes percentage (%) of improvement in disease activity from baseline based on ACR core set. This index was calculated as minimum of a) % of improvement in TJC, b) % of improvement in SJC, and c) third highest percentage of improvement of remaining 5 ACR core criteria: If ≥3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Percentage of improvement was truncated to a range of -100 to 100 to minimize impact of outliers (greater scores indicate greater % improvement) and negative scores indicate a decline. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.', 'timeFrame': 'Baseline through Week 12'}, {'measure': 'Mean Change From Baseline to Weeks 12 and 24 in Tender and Swollen Joint Counts (TJC and SJC)', 'description': 'TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.', 'timeFrame': 'Baseline, Weeks 12 and 24'}, {'measure': 'Mean Change From Baseline to Weeks 76 and 128 in TJC and SJC', 'description': 'TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.', 'timeFrame': 'Baseline, Weeks 76 and 128'}, {'measure': 'Mean Change From Baseline to Weeks 12 and 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score', 'description': ""The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \\[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition."", 'timeFrame': 'Baseline, Weeks 12 and 24'}, {'measure': 'Mean Change From Baseline to Weeks 76 and 128 in HAQ-DI Score', 'description': ""The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \\[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition."", 'timeFrame': 'Baseline, Weeks 76 and 128'}, {'measure': 'Mean Change From Baseline to Weeks 12 and 24 in High-Sensitivity C-Reactive Protein (hsCRP)', 'description': 'hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.', 'timeFrame': 'Baseline, Weeks 12 and 24'}, {'measure': 'Mean Change From Baseline to Weeks 76 and 128 in hsCRP', 'description': 'hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.', 'timeFrame': 'Baseline, Weeks 76 and 128'}, {'measure': 'Mean Change From Baseline to Weeks 12 and 24 in Erythrocyte Sedimentation Rate (ESR)', 'description': 'ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.', 'timeFrame': 'Baseline, Weeks 12 and 24'}, {'measure': 'Mean Change From Baseline to Weeks 76 and 128 in ESR', 'description': 'ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.', 'timeFrame': 'Baseline, Weeks 76 and 128'}, {'measure': ""Mean Change From Baseline to Weeks 12 and 24 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain"", 'description': ""Physician's and Patient's Assessments of Disease Activity (DA) assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeters (mm), where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis was also assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain)."", 'timeFrame': 'Baseline, Weeks 12 and 24'}, {'measure': ""Mean Change From Baseline to Weeks 76 and 128 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain"", 'description': ""Physician's and Patient's assessments of DA assessed using a VAS that ranged from 0 to 100 mm, where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain)."", 'timeFrame': 'Baseline, Weeks 76 and 128'}, {'measure': 'Mean Change From Baseline to Weeks 12 and 24 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)', 'description': ""Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\\*square root (sqrt)(TJC28)+0.28\\*sqrt(SJC28)+0.36\\*natural log(CRP+1)+0.014\\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, and remission was DAS28-CRP \\<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition."", 'timeFrame': 'Baseline, Weeks 12 and 24'}, {'measure': 'Mean Change From Baseline to Weeks 76 and 128 in DAS28-CRP', 'description': ""Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (patient's global VAS). DAS28-CRP=0.56\\*square root (sqrt)(TJC28)+0.28\\*sqrt(SJC28)+0.36\\*natural log(CRP+1)+0.014\\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP \\<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition."", 'timeFrame': 'Baseline, Weeks 76 and 128'}, {'measure': 'Percentage of Responders According to European League Against Rheumatism Responder Index Based on 28-joint Count (EULAR28) Baseline Through Weeks 12 and 24', 'description': ""EULAR28 categorizes clinical response based upon improvement since baseline in DAS modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: TJC28, SJC28, CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score \\>5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by \\>0.6 units but ≤1.2 units or post-baseline DAS28 score \\>3.2 with improvement by \\>1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by \\>1.2 units)."", 'timeFrame': 'Baseline through Weeks 12 and 24'}, {'measure': 'Percentage of Responders According to EULAR28 Baseline Through Weeks 76 and 128', 'description': ""EULAR28 categorizes clinical response based upon improvement since baseline in Disease Activity Score modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score \\>5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by \\>0.6 units but ≤1.2 units or post-baseline DAS28 score \\>3.2 with improvement by \\>1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by \\>1.2 units)."", 'timeFrame': 'Baseline, Weeks 76 and 128'}, {'measure': 'Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 12 and 24', 'description': ""Disease Activity Score (DAS) modified to include 28-joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP \\[milligrams per liter (mg/L)\\], and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores \\<2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders."", 'timeFrame': 'Baseline through Weeks 12 and 24'}, {'measure': 'Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 76 and 128', 'description': ""Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores \\<2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders."", 'timeFrame': 'Baseline through Weeks 76 and 128'}, {'measure': 'Mean Change From Baseline Through Week 12 in Duration (Minutes) of Morning Stiffness', 'description': 'The Investigator asked participants about the duration of their morning stiffness (in minutes) in and around the joints and recorded the duration. The Investigator asked the participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses.', 'timeFrame': 'Baseline, Weeks 4, 8, 12'}, {'measure': 'Mean Change From Baseline to Week 12 in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores', 'description': ""The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains (physical functioning, bodily pain, role limitations due to physical problems and also emotional problems, general health, mental health, social functioning and vitality) and 2 component scores (PCS and MCS). The PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. The MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100 with higher scores indicating better health or functioning."", 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Mean Change From Baseline to Week 12 in Brief Pain Inventory Modified Short Form (BPI-sf Modified) Worst-Pain-in-the Past-24-hours Item Score', 'description': 'The BPI-sf modified is a self-administered questionnaire developed for the rapid assessment of pain. The BPI-sf modified provides information on the intensity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The questionnaire asks questions about pain relief, pain quality, and the participant\'s perception of the cause of pain. The BPI-sf modified uses a numeric rating scale from 0 (""No pain"") to 10 (""Pain as bad as you can imagine""). Since pain can be quite variable over a day, the BPI-sf modified asked participants to rate their pain at the time of responding to the questionnaire (right now), and also at its worst, least and average over the last 24 hours.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Mean Change From Baseline to Week 12 in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Score', 'description': 'The FACIT-F Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 (""Not at all"") to 4 (""Very much"") for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104', 'timeFrame': 'Baseline through 24 weeks'}, {'measure': 'Population PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104', 'timeFrame': 'Baseline through 24 weeks'}, {'measure': 'Mean Change From Baseline Through Week 12 in the ENSEMBLE Minimum Data Set 1.0', 'timeFrame': 'Baseline, 12 weeks'}]",33,18 Years,75 Years,ALL,False,Eli Lilly and Company,INDUSTRY,1,301.0,ACTUAL,2025-09-01T16:18:24.746169,v2_robust,True,True,True,False,False,
NCT05919537,"Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation",A Phase 1b Study to Evaluate HMBD-001 With or Without Chemotherapy in Participants With Advanced Solid Tumors Harboring NRG1 Gene Fusions or Selected HER3 Mutations,HMBD-001,"['Gemcitabine', 'Docetaxel', 'HMBD-001', 'Nab-paclitaxel']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Non-Small Cell Lung Cancer,"['Non-Small Cell Lung Cancer', 'Pancreatic Cancer', 'Locally Advanced Solid Tumor', 'Metastatic Solid Tumor']","['HMBD-001', 'NRG1 fusion', 'NRG1', 'Neuregulin 1', 'ErbB3', 'HER3']",ACTIVE_NOT_RECRUITING,,2023-09-06,2031-03-01,"[{'measure': 'Incidence and Nature of Adverse Events (AEs)', 'description': 'An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered to be related to the study treatment.', 'timeFrame': 'From the time the ICF is signed until 30 days after last dose of study treatment'}, {'measure': 'Arm A and B only: Incidence and nature of dose-limiting toxicities (DLTs) during the first cycle of treatment', 'description': 'DLTs will be assessed during the safety run-in phase and are defined as toxicities that meet pre-defined severity criteria and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle (4 weeks for Arm A, 3 weeks for Arm B) of treatment', 'timeFrame': 'Arm A: During the first four weeks of study treatment Arm B: During the first three weeks of study treatment'}, {'measure': 'Objective Response Rate (ORR) by RECIST V1.1', 'description': 'The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1', 'timeFrame': 'Up to 24 months'}]",[],3,18 Years,,ALL,False,Hummingbird Bioscience,INDUSTRY,0,68.0,ESTIMATED,2025-09-01T16:18:24.746519,v2_robust,True,True,False,False,True,
NCT03336437,Estrogen and the Urogenital Microbiome in GSM,The Impact of Local Estrogen on the Urogenital Microbiome in Genitourinary Syndrome of Menopause (GSM),Estradiol vaginal ring,['Estradiol vaginal ring'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Menopause,['Menopause'],"['Menopause', 'Vaginal dryness', 'Vaginal atrophy', 'Postmenopause', 'Estrogen', 'Urinary microbiome', 'Estradiol vaginal ring', 'Genitourinary Syndrome of Menopause', 'Vaginal microbiome']",COMPLETED,,2018-02-01,2019-08-23,"[{'measure': 'Urinary Microbiome: change in the relative abundance of urinary lactobacillus between baseline and 12 weeks post intervention', 'description': 'Investigators will collect catheterized urine samples from participants at time of enrollment in the study and again after 12 weeks of their assigned vaginal ring intervention. Bacteria will be extracted from the urine and the resident microbial community will be characterized by amplifying the bacterial 16S ribosomal RNA gene via PCR. The de-identified samples containing amplified 16S DNA will be sequenced using Illumina MiSeq. The genetic sequences will be processed to generate a table of bacterial identity and relative quantity. Statistical tests designed for microbiome data will be used in order to determine differences between the relative amount of lactobacillus (via the lactobacillus ratio) before and after the intervention.', 'timeFrame': 'Baseline to 12 weeks post-intervention'}]","[{'measure': 'Change in prevalence of GSM symptoms', 'description': 'Validated symptom questionnaires will be collected at baseline and again after 12 weeks of assigned intervention to assess common symptoms associated with Genitourinary Syndrome of Menopause (GSM), such as vaginal dryness, painful intercourse and urinary urgency.', 'timeFrame': 'Baseline to 12 weeks post-intervention'}]",2,40 Years,89 Years,FEMALE,True,Oregon Health and Science University,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:24.746530,v2_robust,True,True,True,False,False,
NCT06898437,Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer,Clinical Trial to Evaluate the Antitumor Efficacy and Safety of 177Lu-LNC1004 Injection in Patients With Fibroblast Activating Protein (FAP)-Positive Radioiodine-refractory Differentiated Thyroid Cancer (RAIR-DTC) Who Have Failed TKIs Treatment or Refuse Standard Treatment,177Lu-LNC1004 Injection,['177Lu-LNC1004 Injection'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Radioiodine Refractory Differentiated Thyroid Cancer,['Radioiodine Refractory Differentiated Thyroid Cancer'],"['Thyroid cancer', '177Lu-LNC1004', 'FAP']",RECRUITING,,2025-03-24,2027-03-23,"[{'measure': 'Overall Response Rate (ORR)', 'description': 'ORR is defined as the the proportion of subjects who achieve a best overall response of Complete Response (CR) or Partial Response (PR).', 'timeFrame': 'up to 24 months'}]","[{'measure': 'Disease Control Rate (DCR)', 'description': 'DCR is defined as the proportion of subjects who achieve a best overall response of CR, PR or Stable Disease (SD).', 'timeFrame': 'up to 24 months'}, {'measure': 'Duration of Response (DoR)', 'description': 'DoR is defined as the time from the earliest date of documented CR or PR until documented disease progression or death, whichever occurs first.', 'timeFrame': 'up to 24 months'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'PFS is defined as the time from the first dose of 177Lu-LNC1004 Injection to the date of documented disease progression or death, whichever occurs first.', 'timeFrame': 'up to 24 months'}, {'measure': 'Biochemical Response (BR)', 'description': 'BR is defined as the percentage of change in serum Thyroglobulin (Tg) from baseline.', 'timeFrame': 'up to 24 months'}, {'measure': 'Safety', 'description': 'Adverse Event (AE), Serious Adverse Event (SAE), Treatment related Adverse Event (TRAE).', 'timeFrame': 'up to 24 months'}]",6,18 Years,85 Years,ALL,False,Peking Union Medical College Hospital,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:24.746548,v2_robust,True,True,False,False,True,
NCT03855137,"Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (Progress)",Atogepant 30 mg,"['Atogepant 30 mg', 'Placebo', 'Atogepant 60 mg']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Migraine,['Chronic Migraine'],[],COMPLETED,,2019-03-11,2022-01-20,"[{'measure': 'Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population', 'description': 'Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days were defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from Mixed-effects model for repeated measures (MMRM) was used to obtain the average treatment effects across the 12-week treatment period.', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in Off-Treatment Hypothetical Estimand Population', 'description': 'Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days were defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from Mixed-effects model for repeated measures (MMRM) was used to obtain the average treatment effects across the 12-week treatment period.', 'timeFrame': 'Baseline to Week 12'}]","[{'measure': 'Change From Baseline in Mean Monthly Headache Days Across 12-Week Treatment Period in mITT Population', 'description': 'Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache pain lasting 2 hours or longer unless an acute headache medication was used after the start of the headache. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of headache days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change From Baseline in Mean Monthly Headache Days Across 12-Week Treatment Period in Off-Treatment Hypothetical Estimand Population', 'description': 'Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache pain lasting 2 hours or longer unless an acute headache medication was used after the start of the headache. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of headache days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change From Baseline in Mean Monthly Acute Medication Use Days Across 12-Week Treatment Period in mITT Population', 'description': 'An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) to treat an acute migraine. The monthly (4-week) acute medication use days were defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. A negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change From Baseline in Mean Monthly Acute Medication Use Days Across 12-Week Treatment Period in Off-treatment Hypothetical Estimand Population', 'description': 'An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) to treat an acute migraine. The monthly (4-week) acute medication use days were defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. A negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Percentage of Participants With at Least a 50% Reduction in 3-Month Average of Monthly Migraine Days in mITT Population', 'description': 'Data is reported for 50% responders averaged at each 4-week period. 50% responders are participants with at least a 50 percent reduction from baseline in 3-month average of monthly migraine days. Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days is equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. The values are rounded off to the first decimal value.', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Percentage of Participants With at Least a 50% Reduction in 3-Month Average of Monthly Migraine Days in Off-Treatment Hypothetical Estimand Population', 'description': 'Data is reported for 50% responders averaged at each 4-week period. 50% responders are participants with at least a 50 percent reduction from baseline in 3-month average of monthly migraine days. Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days is equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. The values are rounded off to the first decimal value.', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change From Baseline in Migraine Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score at Week 12 in Off-Treatment Hypothetical Estimand Population', 'description': ""The MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality of life impairments attributed to migraine in the past 4 weeks. It is divided into 3 domains: Role Function Restrictive (question numbers 1-7, score ranges 7 to 42) assesses how migraines limit one's daily social and work-related activities; Role Function Preventive (question numbers 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the Emotional Function (question numbers 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale ranging from none of the time to all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores indicate better quality of life. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period."", 'timeFrame': 'At Week 12'}, {'measure': 'Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the AIM-D Across 12-Week Treatment Period in mITT Population', 'description': 'The AIM-D is a 11-item patient-reported outcome (PRO) measure that assesses the impact of migraine on the performance of daily activities which include, 7 items: difficulty with household chores, errands, leisure activities at home, leisure or social activities outside the home, strenuous physical activities, concentrating, and thinking clearly and physical impairment; 4 items: difficulty walking, moving body, bending forward, moving head using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw performance of daily activities domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D Across 12-Week Treatment Period in mITT Population', 'description': 'The AIM-D is a 11-item PRO measure that assesses the impact of migraine on the performance of daily activities which includes 7 items: difficulty with household chores, errands, leisure activities at home, leisure or social activities outside the home, strenuous physical activities, concentrating, and thinking clearly and physical impairment; 4 items: difficulty walking, moving body, bending forward, moving head using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw physical impairment domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Change From Baseline in the Headache Impact Test (HIT-6) Total Score at Week 12 in Off-Treatment Hypothetical Estimand Population', 'description': 'HIT-6 is a 6-question assessment used to measure the impact headaches have on a participant\'s ability to function on the job, at school, at home, and in social situations. It assesses the effect that headaches have on normal daily life and the participant\'s ability to function. Responses are based on frequency using a 5-point scale ranging from ""never"" to ""always."" The HIT-6 total score, which ranges from 36 to 78, is the sum of the responses - each of which is assigned a score ranging from 6 points (never) to 13 points (always). MMRM was used for the analyses.', 'timeFrame': 'At Week 12'}]",12,18 Years,80 Years,ALL,False,Allergan,INDUSTRY,0,778.0,ACTUAL,2025-09-01T16:18:24.746580,v2_robust,True,True,True,False,False,
NCT00792337,The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids in Asthma,The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids in Asthma,simvastatin,"['vitamin B1-6-12', 'B1-6-12', 'simvastatin', 'zocor']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Asthma,['Asthma'],[],COMPLETED,,2008-12,2009-09,"[{'measure': 'Sputum eosinophil', 'timeFrame': '8 WEEKS'}]","[{'measure': 'FEV1', 'timeFrame': '8 WEEKS'}, {'measure': 'PC20', 'timeFrame': '8 weeks'}]",3,18 Years,70 Years,ALL,False,Mahidol University,OTHER,0,53.0,ACTUAL,2025-09-01T16:18:24.746661,v2_robust,True,True,True,False,False,
NCT00536237,MK0524A Phase IIb Study (0524A-011)(COMPLETED),"Part A: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of MK0524 Compared to Placebo Part B: A Dose-Ranging Study to Evaluate the Tolerability of MK0524 and Its Effects on Niacin-Induced Flushing in Lipid Clinic Patients",Comparator: niacin / Duration of Treatment: 17 Weeks,"['Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks', 'MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks', 'Comparator: niacin / Duration of Treatment: 17 Weeks']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Flushing,['Flushing'],[],COMPLETED,,2004-08,2006-12,"[{'measure': 'To determine the effect of MK0524A on lipids and blood glucose', 'timeFrame': '17 Weeks'}]","[{'measure': 'To establish the dose for limiting flushing symptoms induced by NIASPAN (R)', 'timeFrame': '17 Weeks'}]",2,18 Years,70 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,154.0,ACTUAL,2025-09-01T16:18:24.746671,v2_robust,True,True,True,False,False,
NCT07016737,Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy,Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy (ESO-Nanjing12),Sintilimab Combined With Docetaxel Monotherapy,"['salvage radiotherapy', 'Sintilimab Combined With Paclitaxel Monotherapy', 'Paclitaxel Combined With Carboplatin', 'Loperamide Hydrochloride Capsules', 'Ultrasound', 'Gastroscopy', 'Dexamethasone', 'Camrelizumab Combined With Irinotecan Monotherapy', 'Smectite Powder', 'Positron Emission Tomography - Computed Tomography', 'Atropine Hydrochloride', 'Sintilimab Combined With Docetaxel Monotherapy', 'Camrelizumab Combined With Docetaxel Monotherapy', 'Sintilimab Combined With Irinotecan Monotherapy', 'Omeprazole', 'Computed Tomography', 'Camrelizumab Combined With Paclitaxel Monotherapy', 'Digital Gastrointestinal Radiography']",18,INTERVENTIONAL,['PHASE3'],PHASE3,,Esophageal Squamous Cell Carcinoma (ESCC),['Esophageal Squamous Cell Carcinoma (ESCC)'],"['Esophageal squamous cell carcinoma', 'Local recurrence at the primary tumor site', 'Programmed cell death protein 1', 'Salvage Chemoradiotherapy', 'Immunochemotherapy']",ENROLLING_BY_INVITATION,,2024-08-01,2029-09-01,"[{'measure': '2-year ARS rate', 'description': 'the proportion of patients surviving 2 years from the time of recurrence', 'timeFrame': 'From date of Immunochemotherapy until the date of death from any cause, assessed up to 24 months'}]","[{'measure': 'progression-free survival (PFS)', 'description': 'From Initiation of Immunochemotherapy to Disease Progression', 'timeFrame': 'From date of Immunochemotherapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months'}, {'measure': 'safety assessed by adverse events (TEAEs)', 'description': 'All treatment-emergent adverse events (TEAEs) related to the investigational drug were documented and graded according to the CTCAE v5.0 criteria during the treatment period.', 'timeFrame': 'Up to 2 years after treatment initiation until new treatment'}]",3,18 Years,,ALL,False,Ye jinjun,OTHER,0,79.0,ESTIMATED,2025-09-01T16:18:24.746683,v2_robust,True,True,False,False,True,
NCT02463045,Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects,A Phase I Study to Evaluate the Safety/Tolerability and Pharmacokinetics of TOP1288 Rectal Single and Multiple Ascending Doses in Healthy Subjects and Multiple Doses in Subjects With Ulcerative Colitis,TOP1288,"['TOP1288', 'TOP1288 Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Ulcerative Colitis,['Ulcerative Colitis'],[],COMPLETED,,2015-05,2016-07,"[{'measure': 'Safety as measured by adverse events', 'timeFrame': 'To 7 days after the last dose'}, {'measure': 'Safety as measured by clinical laboratory tests', 'timeFrame': 'To 7 days after the last dose'}, {'measure': 'Safety as measured by vital signs', 'timeFrame': 'To 7 days after the last dose'}, {'measure': 'Safety as measured by ECGs', 'timeFrame': 'To 7 days after the last dose'}]","[{'measure': 'Pharmacokinetics profile single dose (AUC(0-24)); (Cmax); time to Cmax (tmax); apparent clearance (CL/F); apparent volume of distribution (Vz/F); mean residence time (MRT); elimination half-life (t½); elimination rate constant (λz)', 'description': 'Single-dose PK (Day 1 Part 1, Part 2 and Part 3): Area under the concentration-time curve (AUC) from zero extrapolated to infinity (AUC(0-inf)); AUC from zero to the time of the last quantifiable concentration (AUC(0-t)); AUC from zero to the time of 12 hours (AUC(0-12)); AUC from zero to the time of 24 hours (AUC(0-24)); observed maximum concentration (Cmax); time to Cmax (tmax); apparent clearance (CL/F); apparent volume of distribution (Vz/F); mean residence time (MRT); elimination half-life (t½); elimination rate constant (λz).', 'timeFrame': 'To 72 hours post dose'}, {'measure': 'Pharmacokinetics profile multiple dose AUC(0-t); (Ctrough); (Cmax,ss); (tmax,ss); (CLss/F); (Vz,ss/F); t½; λz; MRT; (0-tau) (RAUC); (RCmax);', 'description': 'Multiple-dose PK (Day 4 in Part 2 and Part 3): AUC(0-t); AUC during the dosing interval (AUC(0-tau)); predose concentration (Ctrough); observed maximum concentration after multiple dosing (Cmax,ss); time to Cmax,ss (tmax,ss); apparent clearance at steady state (CLss/F); apparent volume of distribution at steady state (Vz,ss/F); t½; λz; MRT; accumulation ratio for AUC(0-tau) (RAUC); accumulation ratio for Cmax (RCmax); time independency factor.', 'timeFrame': 'To 72 hours post dose'}]",6,18 Years,55 Years,ALL,True,Topivert Pharma Ltd,INDUSTRY,0,67.0,ACTUAL,2025-09-01T16:18:24.746737,v2_robust,True,True,True,False,True,
NCT01872845,A Trial Comparing the Effect of Pravastatin and Rosuvastatin on Atherosclerosis Progression Measured by Carotid Intima Media Thickness in Patients With Coronary Artery Disease After Biolimus Eluting Stent (Nobori®) Implantation: CPR IMT,,Pravastatin 40mg,"['Pravastatin 40mg', 'Rosuvastatin']",2,INTERVENTIONAL,['NA'],,,Coronary Artery Occlusive Disease,['Coronary Artery Occlusive Disease'],"['Statin', 'CIMT', 'BES']",COMPLETED,,2013-06-12,2017-05-25,"[{'measure': 'Change of carotid intima media thickness 1 year after pravastatin or rosuvastatin treatment', 'timeFrame': '1 year after drug-eluting stent implantation'}]",[],1,20 Years,80 Years,ALL,False,Yonsei University,OTHER,0,671.0,ACTUAL,2025-09-01T16:18:24.746763,v2_robust,True,True,True,False,False,
NCT05174845,Real Word Evidence With 1L Polyethylene Glycol (PEG)+ Ascorbic Acid in Iberia,"An Observational, Retrospective and Multicenter Study to Evaluate the Effectiveness and Safety of 1L (PEG)+ Ascorbic Acid Given for Bowel Preparation Prior to Colonoscopy in Iberia",1L PEG + ASCORBIC ACID,"['PLEINVUE', 'PLENVU', '1L PEG + ASCORBIC ACID', 'NER1006']",4,OBSERVATIONAL,[],,,Colon Cancer,"['Colon Cancer', 'Colon Disease', 'Colon Cleansing']",[],COMPLETED,,2021-10-01,2022-03-01,"[{'measure': 'Number of patients With Successful Bowel Cleansing (Overall Colon)', 'description': 'The proportion of patients with adequate total colon cleansing is defined as a Boston Bowel preparation scale (BBPS) score ≥ 2 in all segments (BBPS\\> 6).', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}, {'measure': ""Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens)"", 'description': 'Proportion of patients with a high-quality cleaning in the right colon defined as a BBPS score = 3.', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}]","[{'measure': 'Polyps Detection Rate in the total colon and in the right colon', 'description': 'Proportion of colonoscopies where at least one polyp was found and removed in total and right colon', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}, {'measure': 'Adenoma Detection Rate in the total colon and in the right colon', 'description': 'Proportion of colonoscopies where at least one adenoma is found based on histological analysis in total and right colon', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}, {'measure': 'Cecal intubation rate', 'description': 'Defined as the visualization of the ileocecal valve and / or appendicular orifice', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}, {'measure': 'Cecal intubation time', 'description': 'Defined as the time required for the introduction of the colonoscope to reach the base of the cecum.', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}, {'measure': 'Withdrawal time', 'description': 'Defined as the minutes spent inspecting the colon wall.', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}, {'measure': 'Tolerability of the preparation, if available', 'description': 'Defined as good, fair or poor.', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}, {'measure': 'Tolerability of the preparation, if available', 'description': 'Defined with a semi-quantitative scale of 1-5 (1 = totally agree, 2 = agree, 3 = Neutral, 4 = disagree, 5 = totally disagree)', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}, {'measure': 'Adherence to the preparation, if available.', 'description': 'Percentage of patients with adherence to the preparation, defined as ingestion of at least 75% of each of the two doses', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}, {'measure': 'Treatment satisfaction, if available', 'description': 'Percentage of patients satisfied with the preparation', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}, {'measure': 'Quality of the preparation (BBPS> 2 in all colon segments) depending on the dietary guideline', 'description': 'Quality of the preparation (BBPS\\> 2 in all colon segments) depending on the dietary guideline', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}, {'measure': 'Safety of the preparation', 'description': 'Safety from registered adverse effects.', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}, {'measure': 'Sub-analyzes will be conducted in different patient populations', 'description': 'Patients ≥ 65 years, patients with chronic constipation, with diabetes mellitus, with hypertension, with mild to moderate renal failure and with inflammatory bowel disease.', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}, {'measure': 'Sub-analyzes of the primary and secondary outcomes', 'description': 'Sub-analyzes will be carried out by country, by the reason for the colonoscopy and by the recommended dietary regimen', 'timeFrame': 'Up to 2 days (from day of first dosing to day of colonoscopy)'}]",15,18 Years,,ALL,,Norgine,INDUSTRY,1,13393.0,ACTUAL,2025-09-01T16:18:24.746772,v2_robust,False,True,True,False,True,
NCT06589245,Inhaled Ciclesonide Study in Preterm Infants,"The Safety and Toxicity of Inhaled Ciclesonide (i.e., Alvesco) in Preterm Infants at Risk for Developing Bronchopulmonary Dysplasia",Alvesco Inhalant Product,"['ciclesonide', 'Alvesco Inhalant Product']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Bronchopulmonary Dysplasia,['Bronchopulmonary Dysplasia'],[],RECRUITING,,2025-09-30,2026-08-31,"[{'measure': 'Number of hyperglycemia events (blood glucose >150mg/dL) during treatment.', 'description': 'Blood Glucose (BG) levels will be collected 24 hours prior to initiation of study drug and then every 12 hours after initiation of study drug for 2 weeks. BG will be monitored daily for a week after cessation of drug treatment and as per NICU protocol thereafter.', 'timeFrame': 'Through study completion, an average of 4 months.'}, {'measure': 'Average change in z-scores for weight, length, and head circumference.', 'description': 'Baseline weight, head circumference, and length measurements will be measured as per routine NICU standards, which is daily weights and weekly length and head circumference. Weights, lengths and weights/lengths are routinely plotted in the growth chart for each baby in the NICU, and z-scores trajectories deviations (positive or negative) derived against published reference standards for this population. We will compare the average z-score deviations for growth parameters among infants exposed to the study drug and controls unexposed to study drug.', 'timeFrame': 'Through the time of discharge, an average of 4 months.'}, {'measure': 'Number of high systolic blood pressure events defined as >95% centile for gestational age and day of life.', 'description': 'Blood Pressure will be collected 48 hours prior to initiation of study drug as per NICU protocol (at least twice a day) and then every 8 hours after initiation of study drug for 2 weeks. Blood pressure will also be monitored at least daily for first two weeks after cessation of drug treatment, and as per NICU protocol till discharge (at least once a day). Blood pressure is usually monitored using appropriate BP cuff size for weights. If indwelling arterial catheters are present, then blood pressures will be measured that way.', 'timeFrame': 'Through the time of discharge, an average of 4 months.'}, {'measure': 'Number of infants who do not pass the Adrenocorticotrophic Hormone (ACTH) stimulation test.', 'description': 'Measured via Adrenocorticotropic Hormone (ACTH) Stimulation Test, which quantifies the increase in cortisol after ACTH administration.', 'timeFrame': '6 weeks or later after last postnatal steroid course, prior to discharge'}, {'measure': 'Number of episodes of bronchospasm related to inhaled ciclesonide administration.', 'description': 'The investigators will quantify any episodes of bronchospasm as evaluated by changes in oxygenation/ventilation status, auscultation for wheezes and changes in ventilator loops. This is evaluated by experienced respiratory therapists and bedside nurses.', 'timeFrame': 'The entire duration of the study drug treatment (14 days).'}, {'measure': 'Number of infants who develop oral thrush that require treatment.', 'description': 'Bedside nurses routinely evaluate for this common, mostly benign complication of prematurity. We will collect data on % of infants who develop oral thrush and % of infants that require topical treatment among infants exposed to inhaled ciclesonide and the control group.', 'timeFrame': 'The duration of study drug treatment (14 days).'}, {'measure': 'Compare rates of BPD and severe BPD between cases and controls.', 'description': 'Investigators will collect and report data on BPD and severity on each infant in the study irrespective of whether they were treated with inhaled ciclesonide or served as a control. We will also compare rates of BPD and severe BPD among the two groups.', 'timeFrame': 'BPD and severe BPD are ascertained at 36 weeks post-menstrual age.'}, {'measure': 'Systemic Absorption of inhaled Ciclesonide', 'description': 'Investigators will measure serum levels of ciclesonide and its active metabolite, des-ciclesonide 3 hour after inhaled drug administration (based on T1/2 in prior studies in children) in peripheral blood by mass spectrometry. This will provide us information on CIC to des-CIC conversion in preterm neonates, as well correlation with doses administered. Measured in picomol/ml (pmol/mL).', 'timeFrame': 'Day 1, 3, 7, 15 of study (during drug administration).'}]","[{'measure': 'Compare rates of extubation success between infants exposed to study drug and controls receiving standard NICU clinical care', 'description': 'Investigators will compare the rates of extubation (weaning from invasive endotracheal tube-delivered mechanical ventilation to nasal respiratory support) between infants receiving study drug and controls not receiving study drug. Successful extubation will be considered as staying extubated for 72 hours.', 'timeFrame': 'Extubation rates will be calculated from the day of study drug initiation to 7 days after cessation of study drug, i.e., a 21 day window.'}, {'measure': 'Assess changes in lung injury and need in mechanical ventilation support.', 'description': 'Lung injury is difficult to characterize in preterm neonates. The pulmonary severity score that combines level and type of support (high frequency oscillator vs. conventional ventilator), oxygen requirements and respiratory drug therapy to calculate a score is accepted as a measure of lung injury and lung disease severity in this population. We will measure pulmonary severity scores to assess lung injury and lung disease severity. Temporal trends will assess whether PSS decreased after initiation of CIC therapy. Higher score indicate a worse outcome. PSS scores range between 0.21 to 2.95', 'timeFrame': 'Baseline, and daily from study drug initiation to 1 week after study drug cessation.'}]",10,8 Days,28 Days,ALL,False,Children's Mercy Hospital Kansas City,OTHER,2,30.0,ESTIMATED,2025-09-01T16:18:24.746812,v2_robust,True,True,False,False,False,
NCT04506645,"Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans","A Randomized, Double-Blind, Placebo-Controlled, Two-Part Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Humans",REGN5381,['REGN5381'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Normal Blood Pressure (BP)', 'Mildly Elevated BP']",COMPLETED,,2020-09-01,2022-12-14,"[{'measure': 'Incidence of Treatment-Emergent Adverse Events', 'timeFrame': 'Up to Day 78'}]","[{'measure': 'Change from baseline in Systolic Blood Pressure (SBP)', 'timeFrame': 'Up to Day 78'}, {'measure': 'Change from baseline in Diastolic Blood Pressure (DBP)', 'timeFrame': 'Up to Day 78'}, {'measure': 'Change from baseline in Mean Arterial Pressure (MAP)', 'timeFrame': 'Baseline to Day 4'}, {'measure': 'Change from baseline in Pulse Pressure (PP)', 'timeFrame': 'Baseline to Day 4'}, {'measure': 'Change from baseline in Heart Rate (HR)', 'timeFrame': 'Up to Day 78'}, {'measure': 'Change from baseline in Stroke Volume (SV)', 'timeFrame': 'Baseline to Day 4'}, {'measure': 'Maximum change from baseline in SBP across the first 24 hours postdose', 'timeFrame': 'Baseline to Day 2 (24-hours post dose)'}, {'measure': 'Maximum change from baseline in DBP across the first 24 hours postdose', 'timeFrame': 'Baseline to Day 2 (24-hours post dose)'}, {'measure': 'Maximum change from baseline in MAP across the first 24 hours postdose', 'timeFrame': 'Baseline to Day 2 (24-hours post dose)'}, {'measure': 'Maximum change from baseline in PP across the first 24 hours postdose', 'timeFrame': 'Baseline to Day 2 (24-hours post dose)'}, {'measure': 'Maximum change from baseline in HR across the first 24 hours postdose', 'timeFrame': 'Baseline to Day 2 (24-hours post dose)'}, {'measure': 'Maximum change from baseline in SV across the first 24 hours postdose', 'timeFrame': 'Baseline to Day 2 (24-hours post dose)'}, {'measure': 'Change from baseline in the 24-hour mean SBP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose', 'description': 'Baseline 24-hour mean SBP is measured from 0 to 24 hours pre-dose', 'timeFrame': 'Baseline to 24 hours postdose, 24 hours to 48 hours postdose, 48 hours to 72 hours postdose'}, {'measure': 'Change from baseline in the 24-hour mean DBP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose', 'description': 'Baseline 24-hour mean DBP is measured from 0 to 24 hours pre-dose', 'timeFrame': 'Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose'}, {'measure': 'Change from baseline in the 24-hour mean MAP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose', 'description': 'Baseline 24-hour mean MAP is measured from 0 to 24 hours pre-dose', 'timeFrame': 'Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose'}, {'measure': 'Change from baseline in the 24-hour mean PP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose', 'description': 'Baseline 24-hour mean PP is measured from 0 to 24 hours pre-dose', 'timeFrame': 'Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose'}, {'measure': 'Change from baseline in the 24-hour mean HR measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose', 'description': 'Baseline 24-hour mean HR is measured from 0 to 24 hours pre-dose', 'timeFrame': 'Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose'}, {'measure': 'Concentrations of REGN5381 over time', 'timeFrame': 'Up to Day 78'}, {'measure': 'Number of subjects who develop anti-drug antibodies (ADA) and titers', 'timeFrame': 'Up to Day 78'}, {'measure': 'Percentage of subjects who develop anti-drug antibodies (ADA) and titers', 'timeFrame': 'Up to Day 78'}]",21,18 Years,55 Years,ALL,True,Regeneron Pharmaceuticals,INDUSTRY,0,90.0,ACTUAL,2025-09-01T16:18:24.746871,v2_robust,True,True,True,False,True,
NCT05287945,Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma,"A Phase I/II, Open-Label, Single-Arm Study on Safety, Tolerability and Anti-Tumour Efficacy of Orellanine Treatment in Patients With Metastatic Clear-Cell or Papillary Renal Cell Carcinoma",Orellanine,['Orellanine'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Carcinoma, Renal Cell","['Carcinoma, Renal Cell']",[],RECRUITING,,2023-08-04,2025-08,"[{'measure': 'Adverse events and laboratory abnormalities as graded by NCI CTCAE v5.0.', 'timeFrame': 'Through study completion, approximately 1 year'}, {'measure': 'Changes in arterial blood pressure measurements', 'timeFrame': 'Through study completion, approximately 1 year'}, {'measure': 'Changes in pulse rate measurements', 'timeFrame': 'Through study completion, approximately 1 year'}, {'measure': 'Changes in respiratory rate measurements', 'timeFrame': 'Through study completion, approximately 1 year'}, {'measure': 'Changes in temperature measurements', 'timeFrame': 'Through study completion, approximately 1 year'}, {'measure': 'Changes in physical examination findings', 'timeFrame': 'Through study completion, approximately 1 year'}, {'measure': 'Maximum tolerable dose of orellanine', 'timeFrame': 'Through study completion, approximately 1 year'}]","[{'measure': 'Efficacy of orellanine based on time to tumor response', 'timeFrame': 'Through study completion, approximately 1 year.'}, {'measure': 'Efficacy of orellanine based on best overall response', 'timeFrame': 'Through study completion, approximately 1 year.'}, {'measure': 'Area under the curve extrapolated to infinity', 'timeFrame': 'Through study completion, approximately 1 year.'}, {'measure': 'Terminal half-life', 'timeFrame': 'Through study completion, approximately 1 year.'}, {'measure': 'Partial area under the curve', 'timeFrame': 'Through study completion, approximately 1 year.'}, {'measure': 'Dose proportionality', 'timeFrame': 'Through study completion, approximately 1 year.'}, {'measure': 'Time to maximum plasma concentration', 'timeFrame': 'Through study completion, approximately 1 year.'}, {'measure': 'Maximum plasma concentration', 'timeFrame': 'Through study completion, approximately 1 year.'}, {'measure': 'Total body clearance', 'timeFrame': 'Through study completion, approximately 1 year.'}, {'measure': 'Volume of distribution', 'timeFrame': 'Through study completion, approximately 1 year.'}]",17,18 Years,,ALL,False,Oncorena AB,INDUSTRY,0,50.0,ESTIMATED,2025-09-01T16:18:24.746878,v2_robust,True,True,False,False,True,
NCT01326845,Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study,"A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.",Deferasirox,"['Deferasirox', 'ICL670']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Myelodysplastic Syndrome,"['Myelodysplastic Syndrome', 'Transfusional Iron Overload']","['Gastrointestinal adverse events,', 'myelodysplastic syndrome,', 'transfusional iron overload diarrhea,', 'constipation abdominal pain,', 'vomiting']",TERMINATED,The trial was terminated due to insufficient enrollment.,2011-12,2012-09,"[{'measure': 'Difference in the Frequency of Overall Newly Occurring GI Adverse Events (AEs) in the Two Treatment Arms', 'description': 'Study was prematurely terminated and not powered for efficacy. Frequency of GI AEs during the overall study period is available in the AE tables reported in the safety section.', 'timeFrame': '3 months'}]","[{'measure': 'Difference in Frequency of Overall Newly Occurring GI AEs Between the Two Treatment Groups at Month 6.', 'description': 'Study was prematurely terminated and not powered for efficacy.', 'timeFrame': '6 months'}, {'measure': 'Difference in Frequency of Specific Commonly Reported GI AEs Between the Two Treatment Groups', 'description': 'Study was prematurely terminated and not powered for efficacy.', 'timeFrame': 'months 3 and 6.'}, {'measure': 'Difference in Severity of Overall GI AEs Between the Two Treatment Groups', 'description': 'Study was prematurely terminated and not powered for efficacy.', 'timeFrame': 'months 3 and 6.'}, {'measure': 'Difference in Severity of Specific Commonly Reported GI Symptoms Between the Two Treatment Groups', 'description': 'Study was prematurely terminated and not powered for efficacy.', 'timeFrame': 'months 3 and 6'}, {'measure': 'Difference in Frequency and Severity of All Non-GI AEs Between the Two Treatment Groups', 'description': 'Study was prematurely terminated and not powered for efficacy.', 'timeFrame': 'months 3 and 6'}, {'measure': 'the Difference Between the Time From Baseline to the First Occurrence of GI AEs Between the Two Treatment Groups', 'description': 'Study was prematurely terminated and not powered for efficacy.', 'timeFrame': '3 months, 6 months'}, {'measure': ""Difference in Severity of GI Symptoms, Bowel Habits and Level of Satisfaction From the Patient's Perspective Between the Two Treatment Groups"", 'timeFrame': '3 months, 6 months'}, {'measure': 'Difference in Reducing Serum Ferritin After Each Month of Study Drug Administration Between the Two Groups', 'description': 'Study was prematurely terminated and not powered for efficacy.', 'timeFrame': '3 months, 6 months'}]",9,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:24.747009,v2_robust,True,True,False,True,True,The trial was terminated due to insufficient enrollment.
NCT05368545,Influence of Lipid Lowering on Impaired Coronary Flow,Influence of Intensive Lipid-lowering Witgh Statin and Ezetimibe Prescription on Computed Tomography Derived Fractional Flow Reserve in Patients With Stable Chest Pain,High intensity lipid lowering,"['High intensity lipid lowering', 'Usual care lipid lowering']",2,INTERVENTIONAL,['NA'],,,Coronary Artery Disease,['Coronary Artery Disease'],"['fractional flow reserve', 'CT derived fractional flow reserve', 'coronary artery disease', 'ischemic heart disease', 'stable chest pain', 'statin', 'blood cholesterol level']",COMPLETED,,2020-05-15,2024-04-17,"[{'measure': 'Changes in FFRct values', 'description': 'CT derived FFR', 'timeFrame': '18 months'}]","[{'measure': 'Changes in FFRct values', 'description': 'CT derived FFR', 'timeFrame': '9 months'}, {'measure': 'Changes in low density plaque volumes', 'description': 'CT determined plaque volumes', 'timeFrame': '0-9, and 0-18 months'}]",3,35 Years,,ALL,False,Aarhus University Hospital,OTHER,1,109.0,ACTUAL,2025-09-01T16:18:24.747032,v2_robust,True,True,True,False,False,
NCT06056245,Methadone Pharmacokinetics in End-stage Renal Disease,Postoperative Pharmacokinetics of Methadone in Patients With Chronic Kidney Disease,Intraoperative,"['Methadone boluses administered by IV-PCA pump', 'Intraoperative', 'Methadone administration during surgery', 'Post-operative']",4,OBSERVATIONAL,[],,,Chronic Kidney Diseases,"['Chronic Kidney Diseases', 'Post Operative Pain', 'Pain, Acute']","['Methadone', 'Patient Controlled Anesthesia', 'Chronic Kidney Diseases', 'Post Operative Pain']",RECRUITING,,2024-04-05,2024-12-31,"[{'measure': 'Plasma concentration', 'description': 'Blood samples will be taken, collected in heparin tubes, and centrifuged. The extracted serum will be placed in cryotubes that will be stored at -80 °C until analysis.\n\nMethadone samples will be analyzed using a high performance liquid chromatography (HPLC) spectrofluorometric method.\n\nLower limits of quantification (LLOQ) will be determined and samples below the LLOQ will not be included in the analysis.', 'timeFrame': '5, 15, 30, 60 minutes and 2, 4, 6, 9, 12, 24, 36 and 72 hours after the intraoperative bolus of methadone'}]","[{'measure': 'Total use of methadone', 'description': 'The administered and demanded boluses of the IV-PCA device will be assessed along with the intravenous methadone administered by the nursing staff.', 'timeFrame': '2, 4, 6, 9, 12, 24, 36 and 48 hours after the intraoperative bolus of methadone'}, {'measure': 'Post-operative Pain', 'description': 'The numeric rating scale will be used, being 0, no pain and 10, worst pain imaginable.\n\nIf pain intensity is greater than 3 at rest, 3mg methadone boluses will be administered until an intensity of less than 3 is achieved or the patient presents a respiratory rate of less than 10/minute.', 'timeFrame': '2, 4, 6, 9, 12, 24, 36 and 48 hours after the intraoperative bolus of methadone'}, {'measure': 'Nausea or vomiting', 'description': 'Presence of nausea or vomiting in the postoperative acute care unit and the surgical ward.', 'timeFrame': '2, 4, 6, 9, 12, 24, 36 and 48 hours after the intraoperative bolus of methadone'}, {'measure': 'Respiratory depression', 'description': ""Presence of respiratory depression in the postoperative acute care unit and the surgical ward. The patient's clinical record will be reviewed.\n\nIt will be considered as episodes of respiratory depression when the respiratory rate is less than 8/minute"", 'timeFrame': '2, 4, 6, 9, 12, 24, 36 and 48 hours after the intraoperative bolus of methadone'}, {'measure': 'Hypoxemia', 'description': ""Presence of peripheral oxygen saturation less than 90%. The patient's clinical record will be reviewed."", 'timeFrame': '2, 4, 6, 9, 12, 24, 36 and 48 hours after the intraoperative bolus of methadone'}, {'measure': 'Sedation', 'description': 'The degree of sedation will be assessed using a five point sedation scale Score 1 (Barely arousable)= Asleep, needs shaking or shouting to arise Score 2 (Asleep)= Eyes closed, arousable with soft voice or light touch Score 3 (Sleepy)= Eyes opened, less active, and responsive Score 4= Awake Score 5= Agitated', 'timeFrame': '2, 4, 6, 9, 12, 24, 36 and 48 hours after the intraoperative bolus of methadone'}]",7,18 Years,,ALL,False,Pontificia Universidad Catolica de Chile,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:24.747083,v2_robust,False,True,False,False,False,
NCT01710345,Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy,,Sufentanil NanoTab 20 mcg,"['Sufentanil NanoTab 30 mcg', 'Placebo NanoTab', 'Sufentanil NanoTab 20 mcg']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Pain,['Acute Pain'],[],COMPLETED,,2012-10,2013-02,"[{'measure': 'SPID-12', 'description': 'The primary outcome measure is the summed pain intensity difference over the 12-hour study period (SPID-12). A pain intensity score ranging from 0 (no pain) to 10 (worst possible pain) is obtained at baseline and throughout the 12 hour study period. The SPID-12 is calculated by summing the difference between baseline pain score and pain score at each assessment time point.\n\nThe SPID-12 ranges from -120 (indicative of an increase in pain) to 120 (indicative of a decrease in pain). A higher SPID-12 score is better.', 'timeFrame': '12 hours'}]",[],1,18 Years,80 Years,ALL,False,"Talphera, Inc",INDUSTRY,0,101.0,ACTUAL,2025-09-01T16:18:24.747241,v2_robust,True,True,True,False,False,
NCT01061645,Study of MOC31-PE in Antigen Positive Carcinomas,Phase I Study of MOC31-PE in Antigen Positive Carcinomas,MOC31-PE,['MOC31-PE'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Carcinoma,['Carcinoma'],['MDT and DLT'],COMPLETED,,2010-09,2012-02,"[{'measure': 'The documentation of the Maximum Tolerated Dose (MID)', 'timeFrame': '2 years'}, {'measure': 'The identification of the dose limiting toxicity (DLT)', 'timeFrame': '2 years'}]",[],2,18 Years,75 Years,ALL,False,Oslo University Hospital,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:24.747253,v2_robust,True,True,True,False,False,
NCT03742245,Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer,Multicenter Phase I/Ib Trial of Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer,Olaparib,"['Olaparib', 'Zolinza', 'Suberanilohydroxamic acid', 'Vorinostat', 'KU-0059436', 'AZD2281', 'Lynparza']",7,INTERVENTIONAL,['PHASE1'],PHASE1,,Breast Cancer Metastatic,"['Breast Cancer Metastatic', 'Breast Cancer']","['breast cancer', 'relapsed', 'refractory', 'metastatic']",RECRUITING,,2019-06-11,2026-03-01,"[{'measure': 'MTD', 'description': 'Determine the MTD of the olaparib and vorinostat combination', 'timeFrame': '16 weeks'}]","[{'measure': 'Dose-limiting toxicities (DLTs) and other adverse events', 'description': 'Determine the DLTs and other adverse events associated with the olaparib and vorinostat combination, as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.03', 'timeFrame': '16 weeks'}, {'measure': 'Recommended Phase 2 dose (RP2D)', 'description': 'Determine the RP2D of the olaparib and vorinostat combination', 'timeFrame': '16 weeks'}, {'measure': 'Antitumor activity', 'description': 'Assess the antitumor activity of the olaparib and vorinostat combination in an expansion cohort of patients with relapsed/refractory and/or metastatic breast cancer, as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) 1:1', 'timeFrame': '16 weeks'}]",4,18 Years,,ALL,False,The Methodist Hospital Research Institute,OTHER,2,28.0,ESTIMATED,2025-09-01T16:18:24.747296,v2_robust,True,True,False,False,True,
NCT03675672,Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer,Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer: a Double-blind Randomised Trial on Misoprostol Combined With Lansoprazole Versus Lansoprazole Alone (NRT_MISO Study),Misoprostol Oral Tablet,"['Misoprostol', 'Placebo Oral Tablet', 'Misoprostol Oral Tablet', 'Placebo']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Active Peptic Ulcer Disease/GI Bleeding,['Active Peptic Ulcer Disease/GI Bleeding'],[],RECRUITING,,2018-06-21,2027-03-31,"[{'measure': 'Recurrent ulcer bleeding', 'description': 'Recurrent ulcer bleeding confirmed endoscopically. Clinical gastrointestinal bleeding is as defined as haematemesis, per-rectal bleeding and/or melena confirmed and documented by the attending doctor, or a drop in haemoglobin level of 2 g/dL from baseline or more. An ulcer is defined as a circumscribed mucosal break at least 5 mm in the largest diameter and with an observable depth. Bleeding erosion is defined as a break in gastric or duodenal mucosa of any size with the co-existence of blood in the upper gastrointestinal tract.', 'timeFrame': '24 months'}]","[{'measure': 'Recurrent gastrointestinal bleeding', 'description': 'Recurrent gastrointestinal bleeding (both upper and lower gastrointestinal bleeding) as defined according to the clinical criteria stated in primary endpoint', 'timeFrame': '24 months'}]",2,18 Years,,ALL,False,Chinese University of Hong Kong,OTHER,0,154.0,ESTIMATED,2025-09-01T16:18:24.747323,v2_robust,True,True,False,False,False,
NCT07115472,Fluoxetine in Refractory Superior Mesenteric Artery Syndrome by Targeting Comorbid Somatic Symptom Disorder,Fluoxetine as a Non-Surgical Intervention for Refractory Superior Mesenteric Artery Syndrome With Comorbid Somatic Symptom Disorder: A Prospective Case Series Study,Fluoxetine,['Fluoxetine'],1,INTERVENTIONAL,['NA'],,,Superior Mesenteric Artery Syndrome,"['Superior Mesenteric Artery Syndrome', 'Somatic Symptom Disorder (DSM-5)']",['Fluoxetine'],COMPLETED,,2024-01-01,2025-06-01,"[{'measure': 'Proportion of patients achieving GOOSS ≥ 2 at 6 months', 'description': ""Treatment efficacy was evaluated using the Gastric Outlet Obstruction Scoring System (GOOSS), a validated 4-point scale assessing the patient's ability to tolerate oral intake: 0 = no oral intake, 1 = liquids only, 2 = semi-solids, and 3 = low-residue or full diet. The primary efficacy endpoint was the proportion of patients achieving a GOOSS score ≥ 2 at 6 months, indicating the ability to tolerate at least a semi-solid diet."", 'timeFrame': '6 months after treatment initiation'}]",[],1,,,ALL,False,Xijing Hospital of Digestive Diseases,OTHER,0,45.0,ACTUAL,2025-09-01T16:18:24.747343,v2_robust,True,True,True,False,False,
NCT06695572,Clinical Study to Evaluate the Food Effect of CKD-383 0.5/10/1000mg in Healthy Volunteers,"An Open Label, Randomized, Single Dose, Crossover, Phase I Study to Evaluate the Effects of Food on Pharmacokinetics and the Safety of CKD-383 in Healthy Adult Volunteers",CKD-383,['CKD-383'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Type 2 Diabetes Mellitus (T2DM),['Type 2 Diabetes Mellitus (T2DM)'],[],COMPLETED,,2024-11-06,2024-12-13,"[{'measure': 'AUCt of CKD-383', 'description': 'Area under the CKD-383 concentration in blood-time curve from 0 to t', 'timeFrame': '0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hours'}, {'measure': 'Cmax of CKD-383', 'description': 'The maximum CKD-383 concentration in blood sampling time t', 'timeFrame': '0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hours'}]",[],2,19 Years,55 Years,ALL,True,Chong Kun Dang Pharmaceutical,INDUSTRY,1,30.0,ACTUAL,2025-09-01T16:18:24.747364,v2_robust,True,True,True,False,False,
NCT02826772,"Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer","A Phase 1/2, Multi-Center, Open-Label, Two-Stage Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GT0918 in Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC)",GT0918,"['proxalutamide', 'GT0918', 'androgen receptor antagonist']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Metastatic Castrate Resistant Prostate Cancer (mCRPC),['Metastatic Castrate Resistant Prostate Cancer (mCRPC)'],[],COMPLETED,,2016-02-10,2020-02-15,"[{'measure': 'dose-limiting toxicities (DLTs)', 'description': 'abnormal laboratory value', 'timeFrame': '1 month'}, {'measure': 'maximum tolerated dose (MTD),biological dose or minimal effective dose, (MED), and recommended Phase 2 dose(s) (RP2D).', 'description': '50 mg, 100 mg, 200 mg, 300 mg, 400 mg or 500 mg of GT0918', 'timeFrame': '1 month'}]","[{'measure': 'maximum concentration (Cmax)', 'description': 'Pharmacokinetics', 'timeFrame': '6 months'}, {'measure': 'time that maximum concentration is observed (tmax)', 'description': 'Pharmacokinetics', 'timeFrame': '6 months'}, {'measure': 'area under the concentration time-curve from time zero to infinity (AUC0∞)', 'description': 'Pharmacokinetics', 'timeFrame': '6 months'}, {'measure': 'area under the plasma concentration-time curve from time zero hours to time (t hrs), (AUC0-t)', 'description': 'Pharmacokinetics', 'timeFrame': '6 months'}, {'measure': 'area under the plasma concentration-time curve from time zero hours to 24 hours (AUC0-24)', 'description': 'Pharmacokinetics', 'timeFrame': '6 months'}, {'measure': 'terminal elimination rate constant (λz)', 'description': 'Pharmacokinetics', 'timeFrame': '6 months'}, {'measure': 'terminal elimination half life (t½)', 'description': 'Pharmacokinetics', 'timeFrame': '6 months'}, {'measure': 'volume of distribution (Vz)', 'description': 'Pharmacokinetics', 'timeFrame': '6 months'}, {'measure': 'volume of plasma cleared of the drug per unit time (C)', 'description': 'Pharmacokinetics', 'timeFrame': '6 months'}, {'measure': 'circulating tumor deoxyribonucleic acid (ctDNA)', 'description': 'antitumor activities', 'timeFrame': '6 months'}, {'measure': 'circulating messenger ribonucleic acid (mRNA)', 'description': 'antitumor activities', 'timeFrame': '6 months'}, {'measure': 'circulating tumor cells (CTC)', 'description': 'antitumor activities', 'timeFrame': '6 months'}, {'measure': 'prostate-specific antigen (PSA)', 'description': 'biomarker', 'timeFrame': '6 months'}]",15,18 Years,,MALE,False,"Suzhou Kintor Pharmaceutical Inc,",INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:24.747438,v2_robust,True,True,True,False,False,
NCT01781572,A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,"A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma",LEE011,"['MEK162', 'LEE011']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Locally Advanced or Metastatic NRAS Mutant Melanoma,['Locally Advanced or Metastatic NRAS Mutant Melanoma'],[],COMPLETED,,2013-06,2018-02-20,"[{'measure': 'Number of Dose Limiting Toxicities (Phase Ib)', 'description': 'To estimate the maximum tolerate doses (MTDs) and/or identify the RP2D and schedule of LEE011 and MEK162 combination. A dose-limiting toxicity (DLT) was defined as an AE or clinically significant abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first cycle of treatment with ribociclib and binimetinib.', 'timeFrame': 'first 28 days of treatment'}, {'measure': 'Objective Response Rate (ORR) (Phase II)', 'description': ""ORR is the proportion of patients with best overall response of complete response (CR) or partial response (PR) by month 2 assessed according to RECIST 1.1 criteria. ORR is done to describe the anti-tumor activity of LEE011 and MEK162 combination. The primary analysis of the ORR was based on the Investigator's assessment of overall lesion responses per RECIST 1.1."", 'timeFrame': 'Approximately 12 months after the FPFV'}]","[{'measure': 'Plasma Concentration-time Profile (AUCtau) of LEE011 (Phase Ib)', 'description': 'To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'Cycle 1 Day 1'}, {'measure': 'Plasma Concentration-time Profile (AUCtau) of MEK162 (Phase Ib)', 'description': 'To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'Cycle 1 Day 1'}, {'measure': 'Plasma Concentration-time Profile (AUCtau,ss) of LEE011 (Phase Ib)', 'description': 'To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14'}, {'measure': 'Plasma Concentration-time Profile (AUCtau,ss) of MEK162 (Phase Ib)', 'description': 'To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14'}, {'measure': 'Plasma Concentration-time Profile (Cmin,ss) of LEE011 (Phase Ib)', 'description': 'To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'For the 28-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 14'}, {'measure': 'Plasma Concentration-time Profile (Cmin,ss) of MEK162 (Phase Ib)', 'description': 'To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'For the 28-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 14'}, {'measure': 'Plasma Concentration-time Profile (Cmax) of LEE011 (Phase Ib)', 'description': 'To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'Cycle 1 Day 1'}, {'measure': 'Plasma Concentration-time Profile (Cmax) of MEK162 (Phase Ib)', 'description': 'To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'Cycle 1 Day 1'}, {'measure': 'Plasma Concentration-time Profile (Cmax,ss) of LEE011 (Phase Ib)', 'description': 'To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14'}, {'measure': 'Plasma Concentration-time Profile (Cmax,ss) of MEK162 (Phase Ib)', 'description': 'To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14'}, {'measure': 'Plasma Concentration-time Profile (Tmax) of LEE011 (Phase Ib)', 'description': 'To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'Cycle 1 Day 1'}, {'measure': 'Plasma Concentration-time Profile (Tmax) of MEK162 (Phase Ib)', 'description': 'To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'Cycle 1 Day 1'}, {'measure': 'Plasma Concentration-time Profile (Tmax,ss) of LEE011 (Phase Ib)', 'description': 'To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14'}, {'measure': 'Plasma Concentration-time Profile (Tmax,ss) of MEK162 (Phase Ib)', 'description': 'To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14'}, {'measure': 'Plasma Concentration-time Profile (Accumulation Ratio, Racc_AUC) of LEE011 (Phase Ib)', 'description': 'To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14'}, {'measure': 'Plasma Concentration-time Profile (Accumulation Ratio, Racc_AUC) of MEK162 (Phase Ib)', 'description': 'To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14'}, {'measure': 'Plasma Concentration-time Profile (T1/2,ss) of LEE011 (Phase Ib)', 'description': 'To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14'}, {'measure': 'Plasma Concentration-time Profile (T1/2,ss) of MEK162 (Phase Ib)', 'description': 'To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14'}, {'measure': 'Plasma Concentration-time Profile (CL/F) of LEE011 (Phase Ib)', 'description': 'To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'Cycle 1 Day 1'}, {'measure': 'Plasma Concentration-time Profile (CL/F) of MEK162 (Phase Ib)', 'description': 'To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).', 'timeFrame': 'Cycle 1 Day 1'}, {'measure': 'Number of Participants With Adverse Drug Reactions', 'description': 'Safety and tolerability will be characterized through the incidence and severity of adverse drug reactions, serious adverse drug reactions, changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, dose reduction and dose intensity.', 'timeFrame': 'Approximately 12 months after FPFV'}, {'measure': 'Duration of Response (DoR) - Phase 2', 'description': 'To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.\n\nPlease note: As clinicaltrials.gov only allows numerical data entry, the value of 999 indicates ""not estimable"" for confidence interval.', 'timeFrame': 'Approximately 12 months after the FPFV'}, {'measure': 'Time to Progression (TTP) - Phase 2', 'description': 'To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.', 'timeFrame': 'Approximately 12 months after the FPFV'}, {'measure': 'Progression Free Survival (PFS) - Phase 1b and Phase 2', 'description': 'To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.\n\nIn the Phase 1b part, patients were combined for purposes of PFS analyses based on schedule received, since too few patients received any individual dose level to allow for valid PFS estimates within the respective dose levels. This is how the data were analyses and presented for the clinical study report.', 'timeFrame': 'Approximately 12 months after the FPFV'}, {'measure': 'Overall Survival (OS) - Phase ll', 'description': 'To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.', 'timeFrame': 'Approximately 12 months after the FPFV'}, {'measure': 'Best Overall Response (BOR) - Phase II', 'description': 'To assess clinical safety according to RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.', 'timeFrame': 'Approximately 12 months after the FPFV'}]",28,18 Years,,ALL,False,Pfizer,INDUSTRY,0,102.0,ACTUAL,2025-09-01T16:18:24.747531,v2_robust,True,True,True,False,True,
NCT04581772,A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers,"A Phase 1 Open-Label, Randomized, Crossover Study to Evaluate the Bioavailability, Effect of Food, Palatability, and Safety of Various DNL343 Oral Formulations in Healthy Participants",DNL343,"['DNL343', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2020-12-23,2021-06-04,"[{'measure': 'PK parameter: Maximum observed concentration (Cmax) of DNL343 in plasma', 'timeFrame': 'Up to 15 days'}, {'measure': 'PK parameter: Time to maximum observed concentration (Tmax) of DNL343 in plasma', 'timeFrame': 'Up to 15 days'}, {'measure': 'PK Parameter: Area under the concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of DNL343 in plasma', 'timeFrame': 'Up to 15 days'}, {'measure': 'PK parameter: The area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of DNL343 in plasma', 'timeFrame': 'Up to 15 days'}]","[{'measure': 'PK parameter: Maximum observed concentration (Cmax) of DNL343 in plasma in the fed versus fasted states', 'timeFrame': 'Up to 15 days'}, {'measure': 'PK parameter: Time to maximum observed concentration (Tmax) of DNL343 in plasma in the fed versus fasted states', 'timeFrame': 'Up to 15 days'}, {'measure': 'PK Parameter: Area under the concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of DNL343 in plasma in the fed versus fasted states', 'timeFrame': 'Up to 15 days'}, {'measure': 'PK parameter: The area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of DNL343 in plasma in the fed versus fasted states', 'timeFrame': 'Up to 15 days'}, {'measure': 'Incidence of treatment-emergent adverse events (TEAEs)', 'timeFrame': 'Up to 15 days'}]",9,18 Years,55 Years,ALL,True,Denali Therapeutics Inc.,INDUSTRY,0,31.0,ACTUAL,2025-09-01T16:18:24.747619,v2_robust,True,True,True,False,True,
NCT06598072,"Comparative Study to Evaluate the Efficacy of an Alcohol-free Mouthwash Regimen With CPC+Zn, Flossing and Brushing, and an Alcohol-based Mouthwash Regimen With Essential Oils in Reducing Plaque and Gingivitis.",Clinical Study to Evaluate the Efficacy of a Regimen Including Rinsing With an Alcohol Free Mouthwash Containing CPC+Zn as Compared to Dental Flossing and Brushing and a Regimen Including Rising With an Essential Oils Containing Alcohol Mouthwash in Reducing Dental Plaque and Gingivitis.,Mouthwash CPC+Zn+F,"['Mouthwash CPC+Zn+F', 'CPC+Zn', 'Essential oils mouthwash']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Gingival Bleeding,"['Gingival Bleeding', 'Plaque Induced Gingival Disease', 'Gingival Diseases', 'Gingivitis and Periodontal Diseases']","['gingivitis', 'dental plaque']",COMPLETED,,2024-09-17,2024-12-16,"[{'measure': 'Modified Gingival Index', 'description': 'The Modified Gingival Index (MGI) is used to evaluate the severity of gingivitis by measuring the extent of gingival inflammation. It categorizes gingival health/inflammation on a scale from 0 to 4, where 0 signifies normal gingiva with no inflammation, and 4 indicates severe inflammation characterized by erythema, edema, and spontaneous bleeding.', 'timeFrame': '12 weeks'}]","[{'measure': 'Turesky modification of Quigley-Hein Plaque Index', 'description': 'The Turesky modification of the Quigley-Hein Plaque Index is a method for assessing dental plaque accumulation by scoring plaque presence on six surfaces of each tooth on a scale from 0 to 5.', 'timeFrame': '12 weeks'}, {'measure': 'Bleeding on probing', 'description': 'Bleeding on probing (BOP) is a diagnostic technique used to assess gingival inflammation by gently probing the gum tissue; the presence of bleeding indicates inflammation and potential periodontal disease.', 'timeFrame': '12 weeks'}, {'measure': 'Probing depth', 'description': 'Probing depth measures the distance between the gingival margin and the bottom of the periodontal pocket using a calibrated periodontal probe, indicating the severity of periodontal disease.', 'timeFrame': '12 weeks'}]",4,18 Years,65 Years,ALL,False,Colgate Palmolive,INDUSTRY,1,120.0,ACTUAL,2025-09-01T16:18:24.747688,v2_robust,True,True,True,False,False,
NCT06039072,Clinical Observation of Long-term Cardiac Function Prognosis in Patients With PPCM Who Have Recovered Cardiac Function,Clinical Observation on the Prognosis of Long-term Cardiac Function by Drug Withdrawal in Patients With Peripartum Cardiomyopathy With Cardiac Function Recovery,Patients with cardiac function recovered for more than one year and discontinued were in the discontinuation group.,['Patients with cardiac function recovered for more than one year and discontinued were in the discontinuation group.'],1,OBSERVATIONAL,[],,,"Cardiomyopathy, Dilated","['Cardiomyopathy, Dilated']",[],NOT_YET_RECRUITING,,2023-10-10,2024-12-01,"[{'measure': 'deterioration in cardiac function within 1 year of the subgroup study', 'description': '(i) a decrease in LVEF \\<10% and LVEF \\<50%; (ii) an increase in LVEDV of more than 10% and above the normal range; (iii) a 2-fold increase in NT-proBNP concentration of more than 400 ng/L; and (iv) the development of signs and symptoms of heart failure)', 'timeFrame': '1 year'}]","[{'measure': 'patient cardiovascular accidents, rehospitalization-related adverse events', 'description': 'sustained arrhythmias, difficult-to-control hypertension, rehospitalization, and death', 'timeFrame': '1 year'}]",2,20 Years,45 Years,FEMALE,False,Qilu Hospital of Shandong University,OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:24.747719,v2_robust,False,True,False,False,True,
NCT00578695,THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation,THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation,lixivaptan,"['lixivaptan', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Hyponatremia,['Hyponatremia'],"['Hyponatremia', 'Serum Sodium', 'Fluid Overload', 'Heart Failure', 'Acute Heart Failure', 'Vasopressin Antagonist']",COMPLETED,,2007-01,,"[{'measure': 'To determine whether lixivaptan can effectively and safely produce an increase in serum sodium from Baseline in heart failure subjects with hyponatremia and volume overload. Effects on body weight and other clinical measures will be evaluated.', 'timeFrame': '60 days'}]",[],1,18 Years,,ALL,False,CardioKine Inc.,INDUSTRY,2,652.0,ACTUAL,2025-09-01T16:18:24.747804,v2_robust,True,True,True,False,False,
NCT02446795,Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial,Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial,Sunitinib,"['Background therapy', 'Sunitinib', 'Isoquercetin', 'Placebo', 'PL1', 'PR1']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Renal Cell Carcinoma,"['Renal Cell Carcinoma', 'Kidney Cancer']","['Renal cell carcinoma', 'Isoquercetin', 'kidney cancer', 'sunitinib', 'fatigue']",UNKNOWN,,2016-11,2017-12,"[{'measure': 'Change of activity of isoquercetin as an anti-fatigue agent (FACT-F questionnaire)', 'description': 'To evaluate the activity of isoquercetin as an anti-fatigue agent in patients with kidney cancer receiving sunitinib by using the FACT-F questionnaire after 2 sunitinib cycles.', 'timeFrame': 'At baseline, and at day 70'}, {'measure': 'The maximum tolerated dose of isoquercetin administered concomitantly with sunitinib', 'description': '• The maximum tolerated dose (450/900 mg daily) of isoquercetin administered concomitantly with sunitinib is the primary end point of the phase I part of the trial;', 'timeFrame': 'From baseline to Day 70'}]","[{'measure': 'Effect of isoquercetin on quality of life (FACT-G score)', 'description': 'To evaluate the effect of isoquercetin on quality of life as assessed by the FACT-G score', 'timeFrame': 'Up to 12 months'}, {'measure': 'Effect of isoquercetin on serum markers of inflammation (C reactive protein, IL-6, IL10)', 'description': 'To evaluate the effect of isoquercetin on serum markers of inflammation (C reactive protein, IL-6, IL10)', 'timeFrame': 'Up to 12 months'}, {'measure': 'Effect of isoquercetin on dose density and patient compliance, as determined by dose reductions of sunitinib and requirements of schedule modification', 'description': 'To evaluate the effect of isoquercetin on dose density and patient compliance', 'timeFrame': 'Up to 12 months'}, {'measure': 'Safety and tolerability: To evaluate the safety and tolerability (including AEs, SAEs, withdrawal of treatment due to AE, vital signs, ECG and clinical laboratory)', 'timeFrame': 'Up to 12 months'}, {'measure': 'Effect of isoquercetin on muscle index (CT scans)', 'description': 'To evaluate the effect of isoquercetin on muscle index using CT scans', 'timeFrame': 'Up to 12 months'}, {'measure': 'Incidence of deep venous thrombosis (doppler ultrasound)', 'description': 'Incidence of deep venous thrombosis, as assessed by doppler ultrasound', 'timeFrame': 'Up to 12 months'}, {'measure': 'Effect of isoquercetin on patient compliance (questionnaire)', 'description': 'To evaluate the effect of isoquercetin on patient compliance will be used a questionnaire', 'timeFrame': 'Up to 12 months'}]",9,18 Years,,ALL,False,Consorzio Oncotech,OTHER,2,104.0,ESTIMATED,2025-09-01T16:18:24.747850,v2_robust,True,True,False,False,True,
NCT01050595,Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit,Methylnaltrexone for the Reversal of Opiate-Induced Constipation in the Intensive Care Unit,Methylnaltrexone Bromide,"['Placebo-Normal Saline', 'Relistor', 'Methylnaltrexone Bromide']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Opioid-induced Constipation,['Opioid-induced Constipation'],"['Intensive Care Unit', 'Constipation', 'Bowel Management']",UNKNOWN,,2009-12,2010-12,"[{'measure': 'A significantly higher incidence of a rescue free laxation with methylnaltrexone within 4 hours +- 45 minutes.', 'timeFrame': 'Nine months'}]","[{'measure': 'Decreased need for rescue medications to have a bowel movement in the treatment arm vs placebo.', 'timeFrame': 'Nine months'}]",2,18 Years,,ALL,False,"St. John Health System, Michigan",OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:24.747875,v2_robust,True,True,False,False,False,
NCT00841295,Effects of Parenteral L-carnitine Supplementation in Premature Neonates,Effects of Parenteral L-carnitine Supplementation in Premature Neonates,Parenteral L-carnitine supplementation,"['Parenteral supplementation with sterile water', 'Parenteral L-carnitine supplementation']",2,INTERVENTIONAL,['NA'],,,Complication of Prematurity,['Complication of Prematurity'],[],COMPLETED,,2008-07,2013-07,"[{'measure': 'Plasma Gamma Glutamyl Transferase level', 'timeFrame': 'After 21 days of parenteral supplementation.'}]","[{'measure': 'Liver function: levels of ammonemia, hyaluronic acid, bilirubin, prothrombin time test, use of ursodeoxycholic acid therapy.', 'timeFrame': 'Short- (during parenteral supplementation) and long- (3 to 5 months of age) term outcome'}, {'measure': 'Cardiac function: echocardiography, EKG.', 'timeFrame': 'Short- (during parenteral supplementation) and long- (3 to 5 months of age) term outcome'}, {'measure': 'Muscle integrity: CK levels.', 'timeFrame': 'Short- (during parenteral supplementation) and long- (3 to 5 months of age) term outcome'}, {'measure': 'Neurological injuries: brain ultrasound and MRI.', 'timeFrame': 'Short- (during parenteral supplementation, ultrasound) and long- (3 to 5 months of age, MRI) term outcome'}, {'measure': 'Respiratory immaturity', 'timeFrame': 'Short- (during parenteral supplementation) and long- (3 to 5 months of age) term outcome'}, {'measure': 'Acylcarnitine profile, and other fatty acid derivative levels.', 'timeFrame': 'Short- (during parenteral supplementation) and long- (3 to 5 months of age) term outcome'}]",7,,28 Weeks,ALL,False,"University Hospital, Tours",OTHER,0,53.0,ACTUAL,2025-09-01T16:18:24.747897,v2_robust,True,True,True,False,False,
NCT00001495,A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors,A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors,irinotecan (CPT-11),['irinotecan (CPT-11)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Neoplasms,['Neoplasms'],"['Camptothecin', 'Cancer', 'Chemotherapy', 'Natural Products', 'Neoplasms']",COMPLETED,,1995-11,2000-10,[],[],0,,,ALL,False,National Cancer Institute (NCI),NIH,0,40.0,,2025-09-01T16:18:24.747948,v2_robust,True,True,True,False,False,
NCT02418195,"miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome",Plasma Exosomal MicroRNAs as Promising Novel Biomarkers for Suicidality and Treatment Outcome,ketamine,"['ketalar', 'ketamine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Major Depressive Disorder,['Major Depressive Disorder'],"['Depression', 'Ketamine', 'Suicide Attempt', 'Suicidal Ideation', 'Suicidality']",COMPLETED,,2015-04-20,2020-12-30,"[{'measure': 'Beck Scale for Suicide Ideation (BSS)', 'description': 'The Beck Scale for Suicidal Ideation (BSSI) is a 21-item, self-report rating scale that measures the current intensity of specific attitudes, behaviors, and plans to commit suicide. Each item consists of 3 options graded according to intensity on a 3-point scale (0-2). Scores range from 0-42, with higher scores indicating more severe symptoms.\n\nThe participant numbers below correlate to the number of usable lab samples. This is the reason for discrepancy in numbers.', 'timeFrame': '180 minutes post dose'}]","[{'measure': 'Montgomery Asberg Depression Rating Scale (MADRS)', 'description': 'The Montgomery-Åsberg Depression Rating Scale revised to reflect shorter timeframes will be the primary measure of change in depression. The Montgomery-Asberg Depression Rating Scale is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. A total score ranging from 0 to 6 indicates that the patient is in the normal range (no depression), a score ranging from 7 to 19 indicates mild depression, 20 to 34 indicates moderate depression, a score of 35 and greater indicates severe depression, and a total score of 60 indicates very severe depression. Scores range form 0-60, with higher scores indicating more severe symptoms.\n\nThe participant numbers below correlate to the number of usable lab samples. This is the reason for discrepancy in numbers', 'timeFrame': '180 minutes post dose'}, {'measure': 'Beck Depression Inventory (BDI)', 'description': 'The Beck Depression Inventory is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. The inventory contains 21 items on a 4-point scale from 0 (symptom absent) to 3 (severe symptoms). Anxiety symptoms are not assessed but affective, cognitive, somatic and vegetative symptoms are covered. Scoring is achieved by adding the highest ratings for all 21 items. The minimum score is 0 and maximum score is 63. Higher scores indicate greater symptom severity.\n\nThe participant numbers below correlate to the number of usable lab samples. This is the reason for discrepancy in numbers.', 'timeFrame': '180 minutes post dose'}, {'measure': 'Beck Anxiety Inventory (BAI)', 'description': 'The scale is a 21-item self-report of anxiety. The total score is calculated by finding the sum of the 21 items. The scores range form 0-63, with higher scores indicating more severe symptoms.\n\nScore of 0 - 21 = low anxiety Score of 22 - 35 = moderate anxiety Score of 36 and above = potentially concerning levels of anxiety', 'timeFrame': '180 minutes post dose'}, {'measure': 'Beck Hopelessness Scale (BHS)', 'description': 'The Beck Hopelessness Scale is a 20-item self-report index of pessimism about the future, loss of motivation, and negative expectations. Each optimistic response is scored as 0 and each pessimistic response is scored as 1. A total score is calculated by summing the pessimistic responses for each of the 20 items. Minimum possible score is 0.\n\nThe participant numbers below correlate to the number of usable lab samples. This is the reason for discrepancy in numbers.', 'timeFrame': '180 minutes post dose'}, {'measure': '4-item Brief Psychiatric Rating Scale (BPRS)', 'description': 'The Brief Psychiatric Rating Scale is used to assess the presence of psychotic symptoms. This 4-item version assesses conceptual disorganization, suspiciousness/persecution, hallucinatory behavior, and unusual thought content. Each item is rated on a scale from 0 (not present) to 6 (extreme). The scores range from 0-24, with higher scores indicating more severe symptoms.\n\nThe participant numbers below correlate to the number of usable lab samples. This is the reason for discrepancy in numbers.', 'timeFrame': '180 minutes post dose'}, {'measure': 'Clinician-Administered Dissociative States Scale (CADSS)', 'description': 'The Clinician-Administered Dissociative States Scale, ascertains the presence or absence of dissociative symptoms. There are 23 clinician-administered items, each scored from 0 (not at all) to 4 (extreme). Scores range from 0-92, with higher scores indicating more severe symptoms. Items assess impairment in body sensation, perception of time and environment, memory impairment, and feelings of unreality.\n\nThe participant numbers below correlate to the number of usable lab samples. This is the reason for discrepancy in numbers.', 'timeFrame': '180 minutes post dose'}, {'measure': 'Young Mania Rating Scale (YMRS)', 'description': ""This scale assesses for manic symptoms. The scale has 11 items and is based on the patient's subjective report of his or her clinical condition over the previous 48 hours. 13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania."", 'timeFrame': '180 minutes post dose'}, {'measure': 'Systematic Assessment for Treatment Emergent Events (SAFTEE)', 'description': 'The Systematic Assessment for Treatment Emergent Events, is a 56 item, self-report inventory for adverse events. Each item is categorized by severity as: 0-none, 1-mild, 2-moderate, 3-severe. Score range is 0-168, with higher scores indicating more severe symptoms. It is designed to report adverse health events, regardless of whether or not they are suspected to be drug related, in order to reduce the under-reporting of unanticipated events compared with ""known or expected"" events.\n\nThe participant numbers below correlate to the number of usable lab samples. This is the reason for discrepancy in numbers.', 'timeFrame': '180 minutes post dose'}]",9,18 Years,65 Years,ALL,True,University of Alabama at Birmingham,OTHER,1,247.0,ACTUAL,2025-09-01T16:18:24.747964,v2_robust,True,True,True,False,True,
NCT06592495,Bioepuivalence Study for the Safety and the Pharmacokinetics of DWJ1589 and DWC202315,Bioepuivalence Study for the Safety and the Pharmacokinetics of DWJ1589 and DWC202315 in Healthy Adult Volunteers Under Fasting Conditions,Period 1,"['Period 3', 'Period 4', 'Period 2', 'Period 1']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],NOT_YET_RECRUITING,,2024-10,2025-10,"[{'measure': 'The maximum serum concentration(Cmax) of DWJ1589 and DWC202315', 'description': 'Cmax of DWJ1589 and DWC202315', 'timeFrame': 'At pre-dose (0 hour), and post-dose 0.83 to 72 hour.'}, {'measure': 'The Area under the curve(AUC)last of DWJ1589 and DWC202315', 'description': 'AUClast of DWJ1589 and DWC202315', 'timeFrame': 'At pre-dose (0 hour), and post-dose 0.83 to 72 hour.'}]",[],2,19 Years,,ALL,True,Daewoong Pharmaceutical Co. LTD.,INDUSTRY,0,52.0,ESTIMATED,2025-09-01T16:18:24.748056,v2_robust,True,True,False,False,False,
NCT05495295,"First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours","An Adaptive First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Patients With Advanced Solid Tumours (PhAST Trial)",PhOx430,"['Dose Escalation Phase - STEP 3 (Dosing-optimization Cohort)', 'PhOx430', 'Dose Escalation Phase - STEP 1 and STEP 2']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Malignant Tumor,"['Malignant Tumor', 'Advanced Solid Tumor', 'Glioblastoma Multiforme', 'Metastatic Cancer']",[],RECRUITING,,2022-07-18,2027-07-31,"[{'measure': 'DOSE ESCALATION PRIMARY OUTCOME (Dose Limiting Toxicities (DLTs))', 'description': 'Dose Limiting Toxicities (DLTs)', 'timeFrame': 'At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)'}, {'measure': 'DOSE EXPANSION PRIMARY OUTCOME (treatment-emergent Adverse Events)', 'description': 'Incidence, severity and seriousness of treatment-emergent Adverse Events (AEs)', 'timeFrame': 'Through study completion, up to 5 years'}]","[{'measure': 'DOSE ESCALATION SECONDARY OUTCOME #1 (treatment-emergent Adverse Events)', 'description': 'Incidence, severity and seriousness of treatment-emergent Adverse Events (AEs)', 'timeFrame': 'Through study completion, up to 5 years'}, {'measure': 'DOSE ESCALATION SECONDARY OUTCOME #2 (Plasma concentration levels of PhOx430)', 'description': 'Plasma concentration levels of PhOx430', 'timeFrame': 'During Cycle1 and Cycle 2 (each cycle is 21 days)'}, {'measure': 'DOSE ESCALATION SECONDARY OUTCOME #3 (Objective response rate)', 'description': 'Objective response rate (ORR)', 'timeFrame': 'Through dose escalation completion, an average of 1 year'}, {'measure': 'DOSE EXPANSION SECONDARY OUTCOME #1 (Plasma concentration levels of PhOx430 )', 'description': 'Plasma concentration levels of PhOx430', 'timeFrame': 'During Cycle1 and Cycle 2 (each cycle is 21 days)'}, {'measure': 'DOSE EXPANSION SECONDARY OUTCOME #2 (Objective response rate)', 'description': 'Objective response rate (ORR)', 'timeFrame': 'Through dose expansion completion, an average of 1.5 year'}, {'measure': 'DOSE ESCALATION SECONDARY OUTCOME #4 (progression-free survival)', 'description': 'progression-free survival (PFS)', 'timeFrame': 'Through study completion, up to 5 years'}, {'measure': 'DOSE ESCALATION SECONDARY OUTCOME #5 (overall survival)', 'description': 'overall survival (OS)', 'timeFrame': 'Through study completion, up to 5 years'}, {'measure': 'DOSE EXPANSION SECONDARY OUTCOME #3 (progression-free survival)', 'description': 'progression-free survival (PFS)', 'timeFrame': 'Through study completion, up to 5 years'}, {'measure': 'DOSE EXPANSION SECONDARY OUTCOME #4 ( overall survival)', 'description': 'overall survival (OS)', 'timeFrame': 'Through study completion, up to 5 years'}]",11,18 Years,80 Years,ALL,False,Phost'In Therapeutics,INDUSTRY,0,149.0,ESTIMATED,2025-09-01T16:18:24.748067,v2_robust,True,True,False,False,True,
NCT06930495,The Effect of Adiposity on Muscle and Microvascular Function in HFpEF,The Effect of Adiposity on Muscle and Microvascular Function in HFpEF,Weight loss SOC Treatment with second generation anti-diabetic medications,['Weight loss SOC Treatment with second generation anti-diabetic medications'],1,OBSERVATIONAL,[],,,Heart Failure With Preserved Ejection Fraction (HFPEF),['Heart Failure With Preserved Ejection Fraction (HFPEF)'],"['HFpEF', 'Weight loss', 'adiposity', 'inflammation', 'RNA sequencing', 'skeletal muscle']",RECRUITING,,2024-12-10,2026-06-01,"[{'measure': 'Peak muscle perfusion during exercise', 'description': 'Peak muscle perfusion (Aβ) during exercise will be assessed by Contrast enhanced ultrasound (CEU)', 'timeFrame': 'Pre intervention (Day 1)'}, {'measure': 'Peak muscle perfusion during exercise', 'description': 'Peak muscle perfusion (Aβ) during exercise will be assessed by Contrast enhanced ultrasound (CEU)', 'timeFrame': 'Post intervention (Post Day 1)'}, {'measure': 'Single cell RNA sequencing of skeletal muscle', 'description': 'Skeletal muscle biopsies will be taken from the vastus lateralis using the modified Bergstrom technique and immediately prepared for single cell RNA sequencing. Samples will be digested, filtered, washed and resuspended in freezing media and checked for concentration and viability before single cell RNA sequencing is performed', 'timeFrame': 'Pre intervention (Day 2)'}, {'measure': 'Single cell RNA sequencing of skeletal muscle', 'description': 'Skeletal muscle biopsies will be taken from the vastus lateralis using the modified Bergstrom technique and immediately prepared for single cell RNA sequencing. Samples will be digested, filtered, washed and resuspended in freezing media and checked for concentration and viability before single cell RNA sequencing is performed', 'timeFrame': 'Post intervention (Day 2)'}, {'measure': 'Muscle to fat ratio of leg', 'description': 'MRI of the leg will be performed to acquire clear visualization of fasciae separating different muscle groups and thus allowing for quantification of intermuscular fat (muscle:fat ratio)', 'timeFrame': 'Pre intervention (Day 3)'}, {'measure': 'Peak change in microvascular perfusion from rest to exercise', 'description': 'MRI of the leg will be performed utilizing the PIVOT sequence which will measure global and regional perfusion of blood to the muscles in the lower leg at rest and during exercise. the peak change will be reported as the change from baseline to peak exercise', 'timeFrame': 'Pre intervention (Day 3)'}, {'measure': 'Muscle to fat ratio of leg', 'description': 'MRI of the leg will be performed utilizing the PIVOT sequence which will measure the change in perfusion of blood to the muscles in the lower leg from rest to during exercise', 'timeFrame': 'Post intervention (Day 3)'}, {'measure': 'Peak change in microvascular perfusion from rest to exercise', 'description': 'MRI of the leg will be performed utilizing the PIVOT sequence which will measure global and regional perfusion of blood to the muscles in the lower leg at rest and during exercise. the peak change will be reported as the change from baseline to peak exercise', 'timeFrame': 'Post intervention (Day 3)'}]","[{'measure': 'Vascular function - endothelium dependent vasodilation', 'description': 'A small ultrasound probe will be placed over the brachial artery and a small blood pressure cuff will be positioned on the lower arm, just below the elbow. Images of the vessel will be continuously recorded for 1 min (baseline) before the cuff is inflated to a high pressure (220mmHg) for 5minutes and immediately after the cuff is deflated for 3 minutes. The change in brachial artery diameter following deflation of cuff from baseline will represent a marker of vascular function', 'timeFrame': 'Pre intervention (Day1)'}, {'measure': 'Vascular function - endothelium dependent vasodilation', 'description': 'A small ultrasound probe will be placed over the brachial artery and a small blood pressure cuff will be positioned on the lower arm, just below the elbow. Images of the vessel will be continuously recorded for 1 min (baseline) before the cuff is inflated to a high pressure (220mmHg) for 5minutes and immediately after the cuff is deflated for 3 minutes. The change in brachial artery diameter following deflation of cuff from baseline will represent a marker of vascular function', 'timeFrame': 'Post intervention (Day 1)'}, {'measure': 'Blood volume measurement', 'description': 'The carbon monoxide rebreathe technique will be performed to measure blood volume', 'timeFrame': 'Pre intervention (Day1)'}, {'measure': 'Blood volume measurement', 'description': 'The carbon monoxide rebreathe technique will be performed to measure blood volume', 'timeFrame': 'Post intervention (Day 1)'}, {'measure': '2min walk endurance test', 'description': 'Participants will be asked to walk on a flat surface back and forth between 2 cones for 2minutes. the total distance covered (in meters) during the 2-minutes will be recorded as a marker of endurance', 'timeFrame': 'Pre intervention (Day 2)'}, {'measure': 'Hand grip strength', 'description': 'Participants will squeeze a handheld dynamometer as hard as they can to measure handgrip strength (in kg). This will be performed on both hands', 'timeFrame': 'Pre intervention (Day 2)'}, {'measure': '2min walk endurance test', 'description': 'Participants will be asked to walk on a flat surface back and forth between 2 cones for 2minutes. the total distance covered (in meters) during the 2-minutes will be recorded as a marker of endurance', 'timeFrame': 'Post intervention (Day2)'}, {'measure': 'Hand grip strength', 'description': 'Participants will squeeze a handheld dynamometer as hard as they can to measure handgrip strength (in kg). This will be performed on both hands', 'timeFrame': 'Post intervention (Day2)'}, {'measure': 'Body composition', 'description': 'measured using dual xray absorptiometry (DEXA) to get lean mass, muscle mass, body fat percentage', 'timeFrame': 'Pre intervention (Day 0)'}, {'measure': 'Body composition', 'description': 'measured using dual xray absorptiometry (DEXA) to get lean mass, muscle mass, body fat percentage', 'timeFrame': 'Post intervention (Day 1)'}, {'measure': 'Apnea hypopnea index', 'description': 'Participants will be given an at home sleep apnea test that is incorporated into a wrist-based wearable that enables non-invasive tracking of sleep apnea burden.\n\nSleep apnea will be determined from the apnea hypopnea index measured by the device. Apnea hypopnea index will be calculated as the average number of apneas or hypopneas that occurs per hour of sleep', 'timeFrame': 'Pre intervention (Day 2)'}, {'measure': 'Apnea hypopnea index', 'description': 'Participants will be given an at home sleep apnea test that is incorporated into a wrist-based wearable that enables non-invasive tracking of sleep apnea burden.\n\nSleep apnea will be determined from the apnea hypopnea index measured by the device. Apnea hypopnea index will be calculated as the average number of apneas or hypopneas that occurs per hour of sleep', 'timeFrame': 'Post intervention (Day 2)'}]",20,18 Years,,ALL,True,University of Texas Southwestern Medical Center,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:24.748092,v2_robust,False,True,False,False,False,
NCT00111995,Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis,"A Randomized, Double-Blind Study Comparing Aranesp® (Darbepoetin Alfa) and Recombinant Human Erythropoietin (rHuEPO) in the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis",Aranesp®,['Aranesp®'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Renal Failure,"['Chronic Renal Failure', 'Anemia']","['Chronic Renal Failure (CRF)', 'Anemia']",COMPLETED,,2002-05,,[{'measure': 'Mean hemoglobin level during the evaluation period'}],"[{'measure': 'The nature, frequency, severity, relationship to treatment, and outcome of adverse events with specific attention to hypertensive events'}]",2,18 Years,,ALL,False,Amgen,INDUSTRY,0,400.0,,2025-09-01T16:18:24.748244,v2_robust,True,True,True,False,True,
NCT01873339,Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects,"An Open-label, Single-sequence Study to Evaluate the Potential CYP 3A4 Pharmacokinetic Interaction of Darapladib (SB-480848) in Healthy Subjects",Darapladib,"['Midazolam', 'Darapladib']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Atherosclerosis,['Atherosclerosis'],"['Drug interaction, healthy volunteer, SB-480848, Lp-PLA2, darapladib, atherosclerosis, midazolam']",COMPLETED,,2013-06-19,2013-09-12,"[{'measure': 'Maximum concentration (Cmax), and area under the time-concentration curve (AUC[0-inf]) of midazolam at Day 1and 14', 'description': 'The effects of repeat oral dosing of darapladib (160mg enteric coated \\[EC\\] tablet once daily \\[QD\\]) on the pharmacokinetic parameters - Cmax and AUC(0-infinity\\[inf\\]) of a single oral dose of midazolam (5 mg) will be evaluated', 'timeFrame': 'Day 1 and 14'}]","[{'measure': 'AUC(0-inf), Cmax, time to maximum concentration (tmax) and terminal half-life (t1/2) of midazolam at Days 3 and 14', 'description': 'The effects of single oral dose of darapladib (160mg EC tablet QD) as compared to multiple oral doses of darapladib on the pharmacokinetic parameters - Cmax, AUC(0-inf), tmax and t1/2 of the single oral dose of midazolam (5mg) will be evaluated', 'timeFrame': 'Day 3 and 14'}, {'measure': 'tmax and t1/2 of midazolam at Days 1 and 14', 'description': 'The effects of repeat oral dosing of darapladib (160mg EC tablet QD) on the other pharmacokinetic parameters- tmax and t1/2 of a single oral dose of midazolam (5mg) will be evaluated', 'timeFrame': 'Day 1 and 14'}, {'measure': 'AUC(0-inf), Cmax, tmax and t1/2 of midazolam at Days 1 and 3', 'description': 'The effects of single oral dose of darapladib (160mg EC tablet QD) on the other pharmacokinetic parameters- AUC(0-inf), Cmax, tmax and t1/2 of a single oral dose of midazolam (5mg QD) will be evaluated', 'timeFrame': 'Day 1 and 3'}, {'measure': 'Safety and tolerability of repeated oral doses of darapladib (160mg) in combination with midazolam (5mg) as assessed by frequency and severity of adverse events (AE), 12-Lead ECG, vital signs, oxygen saturation/pulse oximetry and safety laboratory tests', 'description': 'An AE is any untoward medical occurrence temporally associated with the use of the medicinal product, whether or not considered associated with the product. A serious AE is any medical occurrence that results in death, is life-threatening, require hospitalization or prolongation of an existing hospital stay, results in disability or incapacity, congenital anomaly, or is an ""Hy\'s Law event (type of drug-induced liver injury)', 'timeFrame': 'Up to 56 days'}]",5,18 Years,65 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,26.0,ACTUAL,2025-09-01T16:18:24.748253,v2_robust,True,True,True,False,True,
NCT06424639,Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA,"A Randomized, Controlled Trial Comparing the Safety and Efficacy of Luspatercept Plus Cyclosporine Versus Cyclosporine Alone for the Treatment of Newly Diagnosed Non-transfusion-dependent Non-severe Aplastic Anemia (NSAA)",Luspatercept,"['cyclosporine', 'Luspatercept']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Aplastic Anemia,['Aplastic Anemia'],"['Aplastic Anemia', 'Luspatercept', 'CsA', 'randomized controlled study']",NOT_YET_RECRUITING,,2024-05,2025-12,"[{'measure': 'overall response rate (ORR)', 'description': 'Proportion of patients who achieved complete response, partial response and hematological response', 'timeFrame': '6 month'}]","[{'measure': 'overall response rate (ORR)', 'description': 'Proportion of patients who achieved complete response, partial response and hematological response', 'timeFrame': '12 month'}, {'measure': 'adverse event rate', 'description': 'Proportion of patients with adverse events', 'timeFrame': '12 month'}]",3,18 Years,90 Years,ALL,False,Peking Union Medical College Hospital,OTHER,0,58.0,ESTIMATED,2025-09-01T16:18:24.748416,v2_robust,True,True,False,False,True,
NCT04674839,The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals,"The Impact of MS-20 on Gut Microbiota Composition, Sera Endotoxin, Trimethylamine N-oxide, Metabolism and Immune Cell Profiling in Adult Individuals",MS-20,['MS-20'],1,INTERVENTIONAL,['NA'],,,Microbiota,['Microbiota'],[],COMPLETED,,2019-10-18,2020-11-20,"[{'measure': 'Change in Gut microbiota from baseline to 8th week', 'description': 'The composition, abundance and diversity of gut microbiota change from baseline in subjects treated with MS-20 or Placebo', 'timeFrame': 'baseline to 8th week'}]",[],1,20 Years,65 Years,ALL,True,Microbio Co Ltd,INDUSTRY,0,100.0,ACTUAL,2025-09-01T16:18:24.748454,v2_robust,True,True,True,False,False,
NCT02564939,Ramelteon Prevention of Delirium - RCT,"Randomized, Double Blind, Placebo-Controlled Clinical Trial Evaluating Ramelteon in the Prevention of Delirium",ramelteon,"['Rozerem', 'ramelteon', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Delirium,['Delirium'],['prevention'],UNKNOWN,,2017-02-23,2019-06,"[{'measure': 'delirium', 'description': 'delirium as determined by CAM screening and expert review', 'timeFrame': 'through study completion, anticipate completion at 1 year'}]",[],1,65 Years,,ALL,False,Hartford Hospital,OTHER,0,240.0,ESTIMATED,2025-09-01T16:18:24.748462,v2_robust,True,True,False,False,False,
NCT06484439,Controlled Trial to Determine Most Effective Post-Operative Analgesia After Third Molar Extraction,"""A Prospective Randomized Controlled Trial to Determine Most Effective Post-Operative Analgesia After Third Molar Extraction""",Ketorolac,"['Vicodin', 'Ibuprofen', 'Acetaminophen', 'Oxycodone', 'Oxycontin', 'Ketorolac', 'Toradol', 'Hydrocodone', 'Tylenol', 'Motrin']",10,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,"Pain, Post-operative","['Pain, Post-operative', 'Third Molar', 'Oral Surgery', 'Pain, Acute']",[],COMPLETED,,2018-02-14,2021-12-01,"[{'measure': 'Post operative pain control after third molar extraction', 'description': 'All participants will complete a daily survey on the medications taken to relieve pain.', 'timeFrame': 'Up to five days post operative procedure.'}, {'measure': 'Post operative opioid use after third molar extraction', 'description': 'Daily survey will be used to assess the amount of post operative opioid us including dosage and frequency of use.', 'timeFrame': 'Up to five days post operative procedure.'}, {'measure': 'Post operative pain assessment after third molar extraction', 'description': 'Participants fill out daily for five days post operative procedure the Numeric Pain Rating Scale (NPRS). This is a ten point scale with 0 = No pain, 5 = Moderate pain, 10 = Worst possible pain. The higher the number is a worse outcome.', 'timeFrame': 'Up to five days post operative procedure.'}, {'measure': 'Post operative quality of life assessment after third molar extraction', 'description': 'Post operative quality of life was ascertained with the 10 point Likert scaled question, ""What is your rating for your actual overall comfort?\'. 1 = Very low overall comfort, 5 = Neither low or high overall comfort, 10 = Very high overall comfort.\n\nThe higher the score means a better outcome. This question is part of the daily survey that participants filled out for five days post operative procedure.', 'timeFrame': 'Up to five days after third molar extraction.'}]",[],4,18 Years,44 Years,ALL,True,"United States Naval Medical Center, San Diego",FED,0,80.0,ACTUAL,2025-09-01T16:18:24.748499,v2_robust,True,True,True,False,False,
NCT03183739,Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female Subjects,"ASP8062 Phase 1 Study - A Placebo-controlled, Single and Multiple Ascending Oral Dose Study in Non-elderly Healthy Japanese Male and Female Subjects -",ASP8062,"['ASP8062', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['ASP8062', 'Pharmacokinetics', 'Safety']",COMPLETED,,2017-06-20,2017-10-06,"[{'measure': 'Safety assessed by incidence of adverse events', 'description': 'Adverse events (AEs) will be coded using Medical Dictionary for Regulatory Activities (MedDRA).', 'timeFrame': 'Up to Day 38'}, {'measure': 'Safety assessed by vital signs: supine blood pressure', 'description': 'To assess the vital sign as a criteria of safety and tolerability variables.', 'timeFrame': 'Up to Day 38'}, {'measure': 'Safety assessed by vital signs: supine pulse rate', 'description': 'To assess the vital sign as a criteria of safety and tolerability variables.', 'timeFrame': 'Up to Day 38'}, {'measure': 'Safety assessed by vital signs: axillary body temperature', 'description': 'To assess the vital sign as a criteria of safety and tolerability variables.', 'timeFrame': 'Up to Day 38'}, {'measure': 'Orthostatic challenge tests', 'description': 'To assess the orthostatic challenge tests as a criteria of safety and tolerability variables.', 'timeFrame': 'Up to Day 20'}, {'measure': 'Safety assessed by laboratory tests: Hematology', 'description': 'To assess hematology as a criteria of safety and tolerability variables.', 'timeFrame': 'Up to Day 38'}, {'measure': 'Safety assessed by laboratory tests: Biochemistry', 'description': 'To assess biochemistry as a criteria of safety and tolerability variables.', 'timeFrame': 'Up to Day 38'}, {'measure': 'Safety assessed by laboratory tests: Urinalysis', 'description': 'To assess urinalysis as a criteria of safety and tolerability variables.', 'timeFrame': 'Up to Day 38'}, {'measure': 'Safety assessed by 12-lead electrocardiogram', 'description': 'To assess the cardiovascular system functioning as a criteria of safety and tolerability variables.', 'timeFrame': 'Up to Day 21'}, {'measure': 'Columbia-Suicide Severity Rating Scale', 'description': 'To assess the suicide risk', 'timeFrame': 'Up to Day 20'}, {'measure': 'Safety assessed by body weight', 'description': 'To assess the body weight as a criteria of safety and tolerability variables.', 'timeFrame': 'Up to Day 38'}]","[{'measure': 'Pharmacokinetics (PK) parameter for ASP8062: Maximum observed concentration (Cmax)', 'description': 'To assess the PK of ASP8062 in single dose part and multiple dose part.', 'timeFrame': 'Up to Day 38'}, {'measure': 'PK parameter for ASP8062: Time to maximum concentration (Tmax)', 'description': 'To assess the PK of ASP8062 in single dose part and multiple dose part.', 'timeFrame': 'Up to Day 38'}, {'measure': 'PK parameter for ASP8062: Terminal elimination half-life (t1/2)', 'description': 'To assess the PK of ASP8062 in single dose part and multiple dose part.', 'timeFrame': 'Up to Day 38'}, {'measure': 'PK parameter for ASP8062: Apparent total systemic clearance after single or multiple extra-vascular dosing (CL/F)', 'description': 'To assess the PK of ASP8062 in single dose part and multiple dose part.', 'timeFrame': 'Up to Day 38'}, {'measure': 'PK parameter for ASP8062: Area under the concentration-time curve (AUC) from the time of dosing to 24 h after dosing (AUC24)', 'description': 'To assess the PK of ASP8062 in single dose part.', 'timeFrame': 'Up to Day 6'}, {'measure': 'PK parameter for ASP8062: AUC from the time of dosing extrapolated to time infinity (AUCinf)', 'description': 'To assess the PK of ASP8062 in single dose part.', 'timeFrame': 'Up to Day 6'}, {'measure': 'PK parameter for ASP8062: AUC from the time of dosing to the last measurable concentration (AUClast)', 'description': 'To assess the PK of ASP8062 in single dose part.', 'timeFrame': 'Up to Day 6'}, {'measure': 'PK parameter for ASP8062: Time point prior to the time point corresponding to the first measurable (non-zero) concentration (tlag)', 'description': 'To assess the PK of ASP8062 in single dose part.', 'timeFrame': 'Up to Day 6'}, {'measure': 'PK parameter for ASP8062: Apparent volume of distribution during the terminal elimination phase after single extra-vascular dosing (Vz/F)', 'description': 'To assess the PK of ASP8062 in single dose part.', 'timeFrame': 'Up to Day 6'}, {'measure': 'PK parameter for ASP8062: AUC from the time of dosing to the start of the next dosing interval (AUCtau)', 'description': 'To assess the PK of ASP8062 in multiple dose part.', 'timeFrame': 'From Day 7 to Day 38'}, {'measure': 'PK parameter for ASP8062: Concentration immediately prior to dosing at multiple dosing (Ctrough)', 'description': 'To assess the PK of ASP8062 in multiple dose part.', 'timeFrame': 'From Day 7 to Day 20'}, {'measure': 'PK parameter for ASP8062: Percentage of AUCinf that is estimated by extrapolation (AUCinf (%extrap))', 'description': 'To assess the PK of ASP8062 in single dose part', 'timeFrame': 'Up to Day 6'}, {'measure': 'PK parameter for ASP8062: Terminal elimination rate constant (Lambda z)', 'description': 'To assess the PK of ASP8062 in single dose part and multiple dose part.', 'timeFrame': 'Up to Day 38'}, {'measure': 'PK parameter for ASP8062: Time of the last measurable concentration (tlast)', 'description': 'To assess the PK of ASP8062 in single dose part and multiple dose part.', 'timeFrame': 'Up to Day 38'}, {'measure': 'Accumulation Ratio (Rac) of Cmax', 'description': 'To assess the PK of ASP8062 in multiple dose part.', 'timeFrame': 'From Day 7 to Day 38'}, {'measure': 'Rac of AUC', 'description': 'To assess the PK of ASP8062 in multiple dose part.', 'timeFrame': 'From Day 7 to Day 38'}, {'measure': 'Peak-Trough Ratio for last dosing in multiple dose part', 'description': 'To assess the PK of ASP8062 in multiple dose part.', 'timeFrame': 'Day 20 and Day 21'}]",28,20 Years,44 Years,ALL,True,Astellas Pharma Inc,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:24.748520,v2_robust,True,True,True,False,True,
NCT02524639,Sirolimus for the Treatment of Hyperinsulinism,Pilot Study of the Efficacy and Safety of Sirolimus in the Treatment of Congenital Hyperinsulinism.,Sirolimus,"['Sirolimus', 'Rapamune']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Hyperinsulinism,['Hyperinsulinism'],[],WITHDRAWN,Due to strict inclusion and exclusion criteria no subjects were enrolled,2015-08-12,2018-05-29,"[{'measure': 'Number of children off intravenous dextrose support', 'timeFrame': '6 weeks'}]","[{'measure': 'Change in number hypoglycemic episodes per child per day', 'timeFrame': '6 weeks'}, {'measure': 'Plasma insulin levels during fasting', 'timeFrame': '8 hours'}, {'measure': 'Number of participants with Adverse Events', 'timeFrame': '6 weeks'}]",4,,12 Months,ALL,False,Children's Hospital of Philadelphia,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:24.748680,v2_robust,True,True,False,True,True,Due to strict inclusion and exclusion criteria no subjects were enrolled
NCT03727139,"Rasagiline Tablets Special Drug Use-Results Survey ""Survey on Long-term Safety""","AZILECT Tablets Special Drug Use-Results Survey ""Survey on Long-term Safety""",Rasagiline,"['AZILECT Tablets (""AZILECT"" is a registered trademark of Teva Pharmaceutical Industries Ltd.)', 'Rasagiline']",2,OBSERVATIONAL,[],,,Parkinson's Disease,"[""Parkinson's Disease""]",[],COMPLETED,,2018-11-01,2021-10-31,"[{'measure': 'Number of Participants Who Had One or More Adverse Events', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.', 'timeFrame': '24 months'}, {'measure': 'Number of Participants Who Had One or More Adverse Drug Reactions', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Adverse drug reaction refers to AE related to administered drug.', 'timeFrame': '24 months'}]","[{'measure': ""Change From Baseline in the Unified Parkinson's Disease Rating Scale (UPDRS)"", 'description': ""UPDRS retains the four-scale structure with a reorganization of the various subscales; (Part I) Mentation, behavior and mood (4 items), (Part II) Activities of daily living (13 items), (Part III) Motor (14 items), and (Part IV) Complications (11 items). Each item on Part III has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe, some items will be scored for 2 or more body parts. Total score range on Part III is 0-108, higher scores represent more severe symptom of Parkinson's disease (worse outcome)."", 'timeFrame': 'Baseline, Up to Month 24 (Final Assessment Point)'}]",3,,,ALL,False,Takeda,INDUSTRY,0,1021.0,ACTUAL,2025-09-01T16:18:24.748720,v2_robust,False,True,True,False,True,
NCT03307577,A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris,"A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Evaluate the Safety and Efficacy of UHE-101 Cream 1% When Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris",UHE-101 Cream,['UHE-101 Cream'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Acne Vulgaris,['Acne Vulgaris'],[],COMPLETED,,2017-10-05,2018-05-31,"[{'measure': 'Investigator\'s Global Assessment (IGA) ""Success""', 'description': 'Proportion of subjects achieving success in each treatment group at Week 12 using the dichotomized IGA with success defined as a score of ""clear"" or ""almost clear"" (IGA Score of 0 or 1) and a two or more grade improvement from Baseline.', 'timeFrame': 'Week 12'}, {'measure': 'Acne Lesion Counts (Absolute Change)', 'description': 'Absolute change from Baseline in Acne Lesion Counts in each treatment group at Week 12.', 'timeFrame': 'Week 12'}]","[{'measure': 'IGA ""Success""', 'description': 'Proportion of subjects achieving success in each treatment group at Week 4.', 'timeFrame': 'Week 4'}, {'measure': 'IGA ""Success""', 'description': 'Proportion of subjects achieving success in each treatment group at Week 8.', 'timeFrame': 'Week 8'}, {'measure': 'Acne Lesion Counts (Absolute Change)', 'description': 'Absolute change from Baseline in Acne Lesion Counts in each treatment group at Week 4.', 'timeFrame': 'Week 4'}, {'measure': 'Acne Lesion Counts (Absolute Change)', 'description': 'Absolute change from Baseline in Acne Lesion Counts in each treatment group at Week 8.', 'timeFrame': 'Week 8'}, {'measure': 'Acne Lesion Counts (Percent Change)', 'description': 'Percent change from Baseline in lesion counts in each treatment group at Week 4', 'timeFrame': 'Week 4'}, {'measure': 'Acne Lesion Counts (Percent Change)', 'description': 'Percent change from Baseline in lesion counts in each treatment group at Week 8', 'timeFrame': 'Week 8'}, {'measure': 'Acne Lesion Counts (Percent Change)', 'description': 'Percent change from Baseline in lesion counts in each treatment group at Week 12', 'timeFrame': 'Week 12'}]",9,12 Years,,ALL,False,"Therapeutics, Inc.",INDUSTRY,0,52.0,ACTUAL,2025-09-01T16:18:24.748728,v2_robust,True,True,True,False,False,
NCT05748977,Short Acting Agents Vs Long Acting in Frequent Excerbator COPD Patients,"Inhaled Fenotereol,Ipratroium Plus Beclomethasone Versus Salmeterol,Tiotropium Plus Fluticasone in Frequent Excerbator COPD Patients",SABA SAMA ICS Vs LABA LAMA ICs,['SABA SAMA ICS Vs LABA LAMA ICs'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Copd,['Copd'],[],UNKNOWN,,2023-02-20,2024-03-20,"[{'measure': 'to assess improvement of symptoms mainly dyspnea', 'description': 'to assess dyspnea in two groups by mMRC,saint gorge quetsonaire', 'timeFrame': '1 year'}]",[],1,18 Years,,ALL,False,Assiut University,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:24.748748,v2_robust,True,True,False,False,False,
NCT01068977,"A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors","A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors",bevacizumab,"['bevacizumab', 'MetMAb']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Cancers,['Solid Cancers'],[],COMPLETED,,2007-08,2010-01,"[{'measure': 'Safety and tolerability of MetMAb alone or in combination with bevacizumab will be assessed (frequency and nature of dose-limiting toxicities; nature, severity, and relatedness of adverse events; changes in vital signs and clinical laboratory parameters)', 'timeFrame': 'Length of study'}]","[{'measure': 'Objective response, defined as a complete or partial response confirmed ≥4 weeks after initial documentation', 'timeFrame': 'Length of study'}, {'measure': 'Duration of objective response', 'timeFrame': 'Length of study'}, {'measure': 'Progression-free survival', 'timeFrame': 'Length of study'}]",4,18 Years,,ALL,False,"Genentech, Inc.",INDUSTRY,0,44.0,ACTUAL,2025-09-01T16:18:24.748846,v2_robust,True,True,True,False,True,
NCT00112177,"Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal","A Multicentre, Randomized, Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Itopride HCl in Patients Suffering From Functional Dyspepsia",Itopride Hydrochloride,['Itopride Hydrochloride'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Dyspepsia,['Dyspepsia'],"['Functional dyspepsia', 'Abdominal Symptom relief', 'Fullness', 'Bloating', 'Indigestion']",COMPLETED,,2004-07,2006-08,[{'measure': 'Symptom relief'}],"[{'measure': 'Impact of symptom relief on quality of life'}, {'measure': 'Safety'}]",3,18 Years,65 Years,ALL,False,Forest Laboratories,INDUSTRY,0,500.0,,2025-09-01T16:18:24.748879,v2_robust,True,True,True,False,True,
NCT00156377,Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections,Investigation of the Influence of Intranasal Mupirocin on the Prevalence of S. Aureus Nosocomial Infections by Eradication of Intranasal S. Aureus,Mupirocin,['Mupirocin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Cross Infection,"['Cross Infection', 'Staphylococcal Infections']","['Mupirocin', 'Staphylococcus aureus', 'Nasal Cavity', 'Preventive measures']",COMPLETED,,2002-11,,[{'measure': 'Staphylococcus aureus infection any time after 5 days of mupirocin ointment'}],[{'measure': 'Presence or abscence of risk factors associated with S. aureus infections at any time during the hospital stay'}],2,18 Years,,ALL,False,University Hospital Muenster,OTHER,1,1200.0,,2025-09-01T16:18:24.748888,v2_robust,True,True,True,False,False,
NCT04569877,GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia,Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID),Molgramostim nebuliser solution,['Molgramostim nebuliser solution'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Severe Acute Respiratory Syndrome (SARS) Pneumonia,"['Severe Acute Respiratory Syndrome (SARS) Pneumonia', 'COVID-19 Pneumonia']","['GM-CSF', 'COVID-19', 'ARDS']",COMPLETED,,2020-09-24,2022-09-20,"[{'measure': 'Mechanical ventilation', 'description': 'Need for mechanical ventilation within 15 days after randomization', 'timeFrame': 'During 15 days'}]","[{'measure': 'Clinical status of subject at day 15 and day 29 (on a 7-point ordinal scale):', 'description': '1. Not hospitalized, no limitations on activities\n2. Not hospitalized, limitation on activities;\n3. Hospitalized, not requiring supplemental oxygen;\n4. Hospitalized, requiring supplemental oxygen;\n5. Hospitalized, on non-invasive ventilation or high flow oxygen devices;\n6. Hospitalized, on invasive mechanical ventilation or ECMO;\n7. Death.', 'timeFrame': 'At day 15 and day 29'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]', 'description': 'Incidence of Treatment-Emergent Adverse Events \\[Safety and Tolerability\\] will be measured at day 0 (day before first dose), day 1-9, and day 15', 'timeFrame': 'At day 0 (day before first dose), day 1-9, and day 15'}, {'measure': 'Oxygen supply', 'description': 'Need for oxygen supply (l/min) to reach peripheral oxygen saturation of 98%', 'timeFrame': 'At day 0, day 1-7, day 8-9 (24 hours/48 hours post dose) and day 15'}, {'measure': 'Clinical parameter: temperature', 'description': 'Clinical parameter (4 times daily): temperature (°C degree)', 'timeFrame': 'Max. 48 hours before day 0, at day 0, day 1-7, day 8-9 and day 15'}, {'measure': 'Clinical parameter: blood pressure', 'description': 'Clinical parameter (4 times daily): blood pressure (mmHg)', 'timeFrame': 'Max. 48 hours before day 0, at day 0, day 1-7, day 8-9 and day 15'}, {'measure': 'Clinical parameter: heart beat', 'description': 'Clinical parameter (4 times daily): hear beat (beats per minute)', 'timeFrame': 'Max. 48 hours before day 0, at day 0, day 1-7, day 8-9 and day 15'}, {'measure': 'Clinical parameter: respiratory rate', 'description': 'Clinical parameter (4 times daily): respiratory rate (breaths per minute)', 'timeFrame': 'Max. 48 hours before day 0, at day 0, day 1-7, day 8-9 and day 15'}, {'measure': 'Severe acute respiratory syndrome coronavirus 2 polymerase chain reaction (PCR)', 'description': 'Presence of Severe acute respiratory syndrome coronavirus 2 nucleic acid by PCR test in swabs or tracheal aspirates/bronchoalveolar lavage', 'timeFrame': 'Max. 48 hours before day 0 and at day 8-9'}, {'measure': 'Laboratory: C-reactive protein test', 'description': 'C-reactive protein test measures the amount of C-reactive protein in blood (mg/L)', 'timeFrame': 'At day 0, day 1-7, day 8-9 and day 15'}, {'measure': 'Laboratory: ferritin', 'description': 'Ferritin test measures the amount of ferritin in the blood (ng/ml)', 'timeFrame': 'At day 0, day 1-7, day 8-9 and day 15'}, {'measure': 'Laboratory: Interleukin-6', 'description': 'Interleukin-6 test (IL-6) measures the amount of IL-6 in the blood (pg/ml)', 'timeFrame': 'At day 0, day 1-7, day 8-9 and day 15'}, {'measure': 'Laboratory: procalcitonin', 'description': 'Procalcitonin (PCT) test measures the amount of PCT in the blood in (μg/l)', 'timeFrame': 'At day 0, day 1-7, day 8-9 and day 15'}, {'measure': 'Bacterial pneumonia', 'description': 'Occurrence of secondary bacterial pneumonia', 'timeFrame': 'At day 0, day 1-7, day 8-9 and day 15'}, {'measure': 'Vaso-active drugs', 'description': 'Days on vaso-active drugs in a 29-day period', 'timeFrame': 'At day 29'}, {'measure': 'Mortality', 'description': 'All-cause mortality', 'timeFrame': 'At day 29'}, {'measure': 'GM-CSF', 'description': 'GM-CSF levels in serum', 'timeFrame': 'At day 0 and day 1-7'}]",17,18 Years,,ALL,False,University of Giessen,OTHER,0,63.0,ACTUAL,2025-09-01T16:18:24.748933,v2_robust,True,True,True,False,True,
NCT00890877,OC000459 Dose Finding Study in Patients With Mild to Moderate Persistent Asthma,"Dose Finding Study in Patients With Mild to Moderate Persistent Asthma: A Parallel Group, Randomised, Placebo Controlled, Double Blind Assessment of Oral Oc000459 Dosed At Three Dose Schedules for Twelve Weeks Finding Study In Patients With Mild To Moderate Persistent Asthma",OC000459 or placebo,['OC000459 or placebo'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Mild to Moderate Persistent Asthma,['Mild to Moderate Persistent Asthma'],"['asthma', 'treatment', 'placebo', 'efficacy', 'safety']",COMPLETED,,2009-04,2010-07,"[{'measure': 'Forced expiratory volume in one second (FEV1)', 'timeFrame': '17 weeks'}]","[{'measure': 'Asthma quality of life questionnaire (AQLQ)', 'timeFrame': '17 weeks'}]",2,18 Years,55 Years,ALL,False,Oxagen Ltd,INDUSTRY,0,480.0,ESTIMATED,2025-09-01T16:18:24.748962,v2_robust,True,True,True,False,False,
NCT02528877,"Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",A Phase I Trial of Ruxolitinib Combined With Tacrolimus and Sirolimus as Acute Graft-versus-Host Disease (aGVHD) Prophylaxis During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis,Fludarabine Phosphate,"['L-Phenylalanine Mustard', 'Ruxolitinib Phosphate', 'SILA 9268A', 'Rapamune', 'Sirolimus', 'L-PAM', 'INCB-18424 Phosphate', 'RAPA', 'Prograf', 'Sarcoclorin', 'Alanine Nitrogen Mustard', 'Fludara', 'Protopic', 'SH T 586', 'AY 22989', 'Fujimycin', 'Melphalanum', 'Melphalan', 'Tacrolimus', '2-F-ara-AMP', 'L-Sarcolysin Phenylalanine mustard', 'WR-19813', 'Beneflur', 'RAPAMYCIN', 'Oforta', 'Phenylalanine Nitrogen Mustard', 'Fludarabine Phosphate', 'WY-090217', 'L-Sarcolysin', '9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-', 'FK 506', 'Sarkolysin', 'CB-3025', 'L-Sarcolysine', 'Phenylalanine Mustard']",35,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Myeloid Leukemia in Remission,"['Acute Myeloid Leukemia in Remission', 'Primary Myelofibrosis', 'Primary Myelofibrosis, Prefibrotic Stage', 'Secondary Acute Myeloid Leukemia', 'Secondary Myelofibrosis']",[],WITHDRAWN,The study design was revised so a new protocol will be opened.,2015-11,,"[{'measure': 'Incidence of adverse events recorded using the modified Bearman scale and NCI CTCAE version 4.03', 'description': 'Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study treatment and reversibility or outcome.', 'timeFrame': 'Up to 2 years'}, {'measure': 'MTD based on dose limiting toxicity recorded using the modified Bearman scale and National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03', 'timeFrame': 'Up to 60 days post stem cell infusion'}, {'measure': 'Recommended phase II dose of ruxolitinib phosphate, when given in combination with tacrolimus and sirolimus', 'timeFrame': 'Up to 60 days post stem cell infusion'}]","[{'measure': 'aGVHD graded and staged according to the Consensus grading', 'description': 'The first day of acute GVHD onset at a certain grade will be used to calculate the cumulative incidence (grades II-IV). Calculated using the Gray method with prior death or relapse considered competing events.', 'timeFrame': 'Up to 100 days post transplant'}, {'measure': 'Changes in expression levels of biomarkers', 'description': 'For all cytokines/biomarkers that are measured repeatedly over time, a nonparametric smoothing plot will be produced in the first step to view changes in the trend. Expression level changes on the onset of aGVHD from baseline measures will be correlated with aGVHD grade (0-1 vs 2-4 or 0-2 vs 3-4). Furthermore, GVHD biomarkers, Reg-3a, TNF R1, and a composite biomarker panel of 4 proteins (IL-2Ra, TNFR1, IL-8, and hepatocyte growth factor) will be correlated with survival outcomes in a continuous manner or dichotomized manner.', 'timeFrame': 'Baseline to up to day 100'}, {'measure': 'Chronic graft versus host disease evaluated and scored according to National Health Institute consensus staging', 'description': 'The first day of chronic GVHD onset will be used to calculate the cumulative incidence. Calculated using the Gray method with prior death or relapse considered competing events.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Engraftment (recovery of granulopoiesis and megakaryopoiesis)', 'timeFrame': 'Up to 2 years'}, {'measure': 'Incidence of infection', 'description': 'Microbiologically documented infections will be reported by site of disease, date of onset, severity and resolution, if any.', 'timeFrame': 'Up to day 100 post-transplant'}, {'measure': 'Non-relapse mortality defined as death occurring in a patient from causes other than relapse or progression', 'description': 'The cumulative incidence of relapse/progression and non-relapse mortality will be calculated as competing risks using the Gray method. Descriptive statistics will also be used to assess the possible relationship between pre-HSCT disease status and outcomes. As the results of these evaluations are considered hypothesis-generating in nature, the statistics used will not include any formal statistical tests/comparisons.', 'timeFrame': 'From date of stem cell infusion until non-disease related death, or last follow-up, whichever comes first, assessed up to 2 years'}, {'measure': 'Overall survival', 'description': 'Estimate will be calculated using the Kaplan-Meier method.', 'timeFrame': 'Time from the day of stem cell infusion until death, or last follow-up, whichever comes first, assessed up to 2 years'}, {'measure': 'Progression-free survival', 'description': 'Estimate will be calculated using the Kaplan-Meier method.', 'timeFrame': 'date of stem cell infusion to the date of death, disease relapse/progression, or last follow-up, whichever occurs first, assessed up to 2 years'}, {'measure': 'Relapse/progression', 'description': 'The cumulative incidence of relapse/progression and non-relapse mortality will be calculated as competing risks using the Gray method. Descriptive statistics will also be used to assess the possible relationship between pre-hematopoietic stem cell transplant (HSCT) disease status and outcomes. As the results of these evaluations are considered hypothesis-generating in nature, the statistics used will not include any formal statistical tests/comparisons.', 'timeFrame': 'Up to 2 years'}]",12,18 Years,75 Years,ALL,False,City of Hope Medical Center,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:24.749019,v2_robust,True,True,False,True,True,The study design was revised so a new protocol will be opened.
NCT00762177,Investigate Oral Bacteria in Adult Population,Investigate Oral Bacteria in Adult Population,Fluoride,"['Fluoride', 'Fluoride, Triclosan', 'Crest Anti-Cavity toothpaste', 'Stannous Fluoride', 'Total toothpaste']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Oral Bacteria,['Oral Bacteria'],[],COMPLETED,,2008-05,2008-09,"[{'measure': 'Antimicrobial Species in Plaque(Actinomyces)', 'description': ""After 14 days of study product use, dental plaque was scraped from the subject's teeth. The plaque was placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar"", 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Saliva(Actinomyces)', 'description': 'Saliva was collected, after 14 days of product use, by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species on the Tongue(Actinomycetes)', 'description': 'After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species on the Cheek(Actinomyces)', 'description': 'After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CFAT Agar', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Plaque(Total Anaerobic)', 'description': 'After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Saliva(Total Anaerobic)', 'description': 'After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Tongue(Total Anaerobic)', 'description': 'After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species on the Cheek(Total Anaerobic)', 'description': 'After 14 day of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on ETSA Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Plaque(Fusobacteria)', 'description': 'After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Saliva(Fusobacteria)', 'description': 'After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Tongue(Fusobacteria)', 'description': 'After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species on the Cheek(Fusobacteria)', 'description': 'After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on CVE Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Plaque(Oral Streptococci)', 'description': 'After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Saliva(Oral Streptococci)', 'description': 'After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Tongue(Oral Streptococci)', 'description': 'After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species on the Cheek(Oral Streptococci)', 'description': 'After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Mitis Salivarius Agar', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Plaque(Sulfur Bacteria)', 'description': 'After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Saliva(Sulfur Bacteria)', 'description': 'After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Tongue(Sulfur Bacteria)', 'description': 'After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species on the Cheek(Sulfur Bacteria)', 'description': 'After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on OHO Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Plaque(Veillonella)', 'description': 'After 14 days of study product use, dental plaque scraped from teeth, placed in sterile phosphate buffered saline(PBS) and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Veillonella Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Saliva(Veillonella)', 'description': 'After 14 days of study product use, saliva was collected by drooling into a tube and sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in sterile phosphate buffered saline(PBS) and plated using a spiral systems autoplate 4000 spiral plater on veillonella Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species in Tongue(Veillonella)', 'description': 'After 14 days of study product use, the tongue was scraped 5 times with the edge of a tongue depressor. The sample is vortexed in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Veillonella Agar.', 'timeFrame': '14 days'}, {'measure': 'Antimicrobial Species on the Cheek(Veillonella)', 'description': 'After 14 days of study product use, the inside of the cheek was scraped with a swab and place in sterile phosphate buffered saline(PBS) and the sample is then sonicated using a Branson 450A sonicator with a cup horn for 30 seconds. Samples diluted (10 fold) in PBS and plated using a spiral systems autoplate 4000 spiral plater on Veillonella Agar.', 'timeFrame': '14 days'}]",[],24,18 Years,70 Years,ALL,True,Colgate Palmolive,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:24.749029,v2_robust,True,True,True,False,False,
NCT06817577,NG004 in Spinal Cord Injury Patients,"A First-in-human (FIH) Clinical Trial to Investigate the Human Monoclonal Antibody NG004, Administrated Intrathecally in Acute Spinal Cord Injury (SCI) Patients",NG004,['NG004'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Spinal Cord Injury (SCI),"['Acute Spinal Cord Injury (SCI)', 'Spinal Cord Diseases', 'Central Nervous System Diseases', 'Nervous System Diseases', 'Trauma, Nervous System', 'Spinal Cord Injuries (SCI)', 'Wounds and Injuries']","['Acute spinal cord injury', 'Nogo-A', 'SPROUT', 'Regeneration']",RECRUITING,,2024-12-18,2026-09,"[{'measure': 'Type, frequency, severity, and causal relationship of adverse events (AEs), serious AEs, and adverse drug reactions', 'timeFrame': 'From treatment start up to 6 months'}]","[{'measure': 'Maximum Plasma Concentration [Cmax] in serum', 'timeFrame': 'After first and last intrathecal injection, measured at pre-dose and 1, 3, 6, 24, 48 hours post-dose.'}, {'measure': 'Half-life in serum [T1/2]', 'timeFrame': 'After last intrathecal injection up to 6 months'}]",3,18 Years,70 Years,ALL,False,NovaGo Therapeutics AG,INDUSTRY,0,21.0,ESTIMATED,2025-09-01T16:18:24.749229,v2_robust,True,True,False,False,True,
NCT02318277,A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203),"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)",MEDI4736,"['INCB024360', 'MEDI4736']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Solid Tumors,"['Solid Tumors', 'Head and Neck Cancer', 'Lung Cancer', 'UC (Urothelial Cancer)']",[],COMPLETED,,2015-01-05,2020-10-16,"[{'measure': 'Phase 1 : Number of Treatment-Emergent Adverse Events (TEAE)', 'description': 'Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment', 'timeFrame': 'Duration of study treatment and up to 90 days after the last dose [approximately 3 years]'}, {'measure': 'Phase 2: Objective Response Rate (ORR) as Determined by Radiographic Disease Assessments Per Modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1', 'description': 'ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.', 'timeFrame': 'Measured every 8 weeks for duration of study treatment [approximately 12 months]'}]","[{'measure': 'Phase 1: Objective Response Rate (ORR) as Determined by Radiographic Disease Assessments Per Modified RECIST v1.1', 'description': 'ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1', 'timeFrame': 'Measured every 8 weeks for duration of study treatment [approximately 6 months]'}, {'measure': 'Phase 2: Number of Treatment-Emergent Adverse Events', 'description': 'Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment', 'timeFrame': 'Continuously for duration of study treatment and up to 90 days after the last dose [approximately 3 years]'}, {'measure': 'Phase 1 and 2: Durability of Response as Measured by the Time From the Earliest Date of Disease Response Until Earliest Date of Disease Progression', 'description': 'Defined as the time from earliest date of disease response until the earliest date of disease progression per RECIST v1.1, or death due to any cause, if occurring sooner than progression.', 'timeFrame': 'Measured every 8 weeks for duration of active study treatment [approximately 24 months]'}, {'measure': 'Phase 1 and 2: Progression-free Survival as Measured by the Duration From the Date of Enrollment Until the Earliest Date of Disease Progression or Death', 'timeFrame': 'Measured every 8 weeks for duration of active study treatment [approximately 24 months]'}, {'measure': 'Phase 1 and 2: Pharmacokinetics (PK) of INCB024360 as Measured by Peak Concentration', 'timeFrame': 'Pre dose, 0.5, 1,2, 4.6.& 8 hrs Post dose on C1D1,C1D8,C2D1'}, {'measure': 'Phase 1 and 2: Pharmacokinetics (PK) of INCB024360 as Measured by Time to Maximal Observed Concentration', 'timeFrame': 'Pre dose, 0.5, 1,2, 4.6.& 8 hrs Post dose on C1D1,C1D8,C2D1'}, {'measure': 'Phase 1 and 2: Pharmacokinetics (PK) of INCB024360 as Area Under the Concentration-time Curve', 'timeFrame': 'Pre dose, 0.5, 1,2, 4.6.& 8 hrs Post dose on C1D1,C1D8,C2D1'}, {'measure': 'Phase 1 and 2: Immunogenicity of MEDI4736 as Measured by the Number and Percentage of Subjects Who Develop Detectable Anti-drug Antibodies (ADAs)', 'timeFrame': 'Measured at defined study visits from Cycle 1 Day 1 through cycle 2 [approximately 2 weeks].'}]",10,18 Years,,ALL,False,Incyte Corporation,INDUSTRY,1,176.0,ACTUAL,2025-09-01T16:18:24.749237,v2_robust,True,True,True,False,True,
NCT02019875,CYP3A4 Activity and Mineral Homeostasis,Effect of Modulating CYP3A4 Activity on Mineral Homeostasis,Rifampin,"['Rifadin', 'Biaxin', 'Clarithromycin', 'Rifampin']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Vitamin D and Calcium Homeostasis,['Vitamin D and Calcium Homeostasis'],"['Vitamin D', 'CYP3A4', 'Calcium']",COMPLETED,,2014-06,2020-12,"[{'measure': '1, 25(OH) D3 Vitamin D', 'description': 'Serum 1, 25(OH) D3 Vitamin D', 'timeFrame': 'Samples will be collected on days 1, 4 and 7, and day 22 (last day of intervention). Treatment began on day 8. Data presented is day 22 concentration - Baseline (the average of day 1, day 4 and day 7 concentrations).'}, {'measure': '25(OH) D3 Vitamin D', 'description': 'Serum 25(OH) D3 Vitamin D', 'timeFrame': 'Samples will be collected on days 1, 4 and 7, and day 22 (last day of intervention). Treatment began on day 8. Data presented is day 22 concentration - Baseline (the average of day 1, day 4 and day 7 concentrations).'}, {'measure': 'Parathyroid Hormone', 'description': 'Blood Parathyroid Hormone', 'timeFrame': 'Samples will be collected on days 1, 4 and 7, and day 22 (last day of intervention). Treatment began on day 8. Data presented is day 22 concentration - Baseline (the average of day 1, day 4 and day 7 concentrations).'}, {'measure': 'Osteocalcin', 'description': 'Serum Osteocalcin', 'timeFrame': 'Samples will be collected on days 1, 4 and 7, and day 22 (last day of intervention). Treatment began on day 8. Data presented is day 22 concentration - Baseline (the average of day 1, day 4 and day 7 concentrations).'}, {'measure': 'Calcium, Ionized', 'description': 'Serum', 'timeFrame': 'Samples will be collected on days 1, 4 and 7, and day 22 (last day of intervention). Treatment began on day 8. Data presented is day 22 concentration - Baseline (the average of day 1, day 4 and day 7 concentrations).'}, {'measure': 'Calcium/Creatinine (mg/g)', 'description': 'Urine Calcium/Creatinine (mg/g)', 'timeFrame': 'Samples will be collected on days 1, 4 and 7, and day 22 (last day of intervention). Treatment began on day 8. Data presented is day 22 concentration - Baseline (the average of day 1, day 4 and day 7 concentrations).'}, {'measure': 'Phosphate/Creatinine (mg/g)', 'description': 'Urine Phosphate/Creatinine(mg/g)', 'timeFrame': 'Samples will be collected on days 1, 4 and 7, and day 22 (last day of intervention). Treatment began on day 8. Data presented is day 22 concentration - Baseline (the average of day 1, day 4 and day 7 concentrations).'}]",[],7,18 Years,60 Years,ALL,True,University of Washington,OTHER,1,92.0,ACTUAL,2025-09-01T16:18:24.749247,v2_robust,True,True,True,False,False,
NCT00585975,Efficacy and Safety of Bromfenac Ophthalmic Solution,,bromfenac ophthalmic solution,['bromfenac ophthalmic solution'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Cataract Surgery,['Cataract Surgery'],[],COMPLETED,,2007-10,,"[{'measure': 'Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero', 'description': 'Participants with SOIS of 1. Scale: 0=0 cells (complete absence); 0.5=1-5 cells (trace); 1=6-15 cells (very slight); 2=16-25 cells (moderate); 3=26-50 cells (marked); 4=\\>50 cells (intense)', 'timeFrame': 'Day 15'}]","[{'measure': 'Number of Participants That Are Pain Free', 'description': 'Participant description of being pain free taken from patient questionnaire with multiple possible responses', 'timeFrame': 'Day 1'}]",2,18 Years,,ALL,True,Bausch & Lomb Incorporated,INDUSTRY,0,568.0,ACTUAL,2025-09-01T16:18:24.749270,v2_robust,True,True,True,False,False,
NCT00162175,PPAR-COMBO With Sulfonylurea,"A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination With Glyburide Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone",Muraglitazar,['Muraglitazar'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Metabolics Diabetes Nos,['Metabolics Diabetes Nos'],[],COMPLETED,,2003-07,2005-11,[{'measure': 'Compare change from baseline in HbA1c after 24 weeks of treatment with muraglitazar + glyburide vs placebo + glyburide'}],"[{'measure': 'Change in FPG from basline to W24, proportion of subjects receiving therapeutic response at W24, percent change of fasting lipid levels from baseline to W11/12, change in hs-CRP from baseline to W24'}]",2,18 Years,70 Years,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,534.0,,2025-09-01T16:18:24.749282,v2_robust,True,True,True,False,False,
NCT03461575,Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome,"A Multicenter, Randomized, Double Blind, Restasis®-Controlled Non-inferiority, Moisview® Eye Drops-controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome",HU007,"['Moisview', 'Restasis', 'HU007']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Dry Eye Syndrome,['Dry Eye Syndrome'],[],COMPLETED,,2018-01-22,2018-07-12,"[{'measure': 'change from Baseline in Corneal staining(Oxford grading) score', 'timeFrame': 'Week 12'}]","[{'measure': 'change from Baseline in Corneal staining(Oxford grading) score', 'timeFrame': 'Week 4,8'}, {'measure': 'change from Baseline of Conjunctival staining(Oxford grading) score', 'timeFrame': 'Week 4,8,12'}, {'measure': 'change from Baseline of Strip meniscometry assessment', 'timeFrame': 'Week 4,8,12'}, {'measure': 'change from Baseline of Tear film break-up time', 'timeFrame': 'Week 4,8,12'}, {'measure': 'change from Baseline of Standard patient evaluation of eye dryness questionnaire', 'timeFrame': 'Week 4,8,12'}, {'measure': 'arrival time of 100% clearence in Corneal staining test', 'timeFrame': 'Week 0-12'}, {'measure': 'The number of total rescue drug usage', 'timeFrame': 'Week 0-12'}]",8,19 Years,,ALL,False,"Huons Co., Ltd.",INDUSTRY,0,209.0,ACTUAL,2025-09-01T16:18:24.749293,v2_robust,True,True,True,False,False,
NCT06083675,Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes,Efficacy and Safety of First Line Use of Oral Semaglutide 25 mg or 50 mg Once Daily Versus Empagliflozin 25 mg or Versus Metformin 2000 mg in Newly Diagnosed Treatment naïve Patients With Type 2 Diabetes,Semaglutide,"['Empagliflozin', 'Semaglutide', 'Metformin']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],WITHDRAWN,"Due to internal reprioritization, trial was cancelled.",2024-01-26,2027-05-28,"[{'measure': 'Change in glycated haemoglobin (HbA1c)', 'description': 'Measured in Percentage (%)-points.', 'timeFrame': 'From randomisation (week 0) to week 52'}]","[{'measure': 'Change in body weight', 'description': 'Measured in kilograms (kg).', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': 'Change in fasting plasma glucose (FPG)', 'description': 'Measured in millimoles per liter (mmol/L).', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': 'Change in 7 point self measured plasma glucose (SMPG) mean profile', 'description': 'Measured in mmol/L.', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': 'Change in 7-point self-measured plasma glucose (SMPG) mean post prandial increments', 'description': 'Measured in mmol/L.', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': 'Relative change in body weight', 'description': 'Measured in Percentage (%).', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': 'Change in waist circumference', 'description': 'Measured in centimeters (cm).', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': 'HbA1c less than or equal to (≤) 6.5% (Yes/No)', 'description': 'Measured as count of participants.', 'timeFrame': 'At week 52'}, {'measure': 'HbA1c less than (<) 7% (Yes/No)', 'description': 'Measured as count of participants.', 'timeFrame': 'At week 52'}, {'measure': 'Body weight reduction greater than equal to ( ≥) 5% (Yes/No)', 'description': 'Measured as count of participants.', 'timeFrame': 'At week 52'}, {'measure': 'Body weight reduction ≥10% (Yes/No)', 'description': 'Measured as count of participants.', 'timeFrame': 'At week 52'}, {'measure': 'Body weight reduction ≥15% (Yes/No)', 'description': 'Measured as count of participants.', 'timeFrame': 'At week 52'}, {'measure': 'HbA1c <7.0% and body weight reduction ≥5% (Yes/No)', 'description': 'Measured as count of participants.', 'timeFrame': 'At week 52'}, {'measure': 'Change in systolic blood pressure', 'description': 'Measured in millimeters of mercury (mmHg).', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': 'Change in diastolic blood pressure', 'description': 'Measured in mmHg.', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': 'Change in High-sensitivity C-reactive protein (hsCRP)', 'description': 'Measured in milligrams per liter (mg/L).', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': 'Time to rescue medication', 'description': 'Measured in days.', 'timeFrame': 'From randomisation (week 0) to week 104'}, {'measure': 'Change in HbA1c', 'description': 'Measured in %-points.', 'timeFrame': 'From randomisation (week 0) to week 104'}, {'measure': 'Change in body weight', 'description': 'Measured in kg.', 'timeFrame': 'From randomisation (week 0) to week 104'}, {'measure': 'Change in FPG', 'description': 'Measured in mmol/L.', 'timeFrame': 'From randomisation (week 0) to week 104'}, {'measure': 'Change in 7 point SMPG mean profile', 'description': 'Measured in mmol/L.', 'timeFrame': 'From randomisation (week 0) to week 104'}, {'measure': 'Change in 7-point SMPG mean post prandial increments', 'description': 'Measured in mmol/L', 'timeFrame': 'From randomisation (week 0) to week 104'}, {'measure': 'Relative change in body weight', 'description': 'Measured in Percentage.', 'timeFrame': 'From randomisation (week 0) to week 104'}, {'measure': 'Change in waist circumference', 'description': 'Measured in cm.', 'timeFrame': 'From randomisation (week 0) to week 104'}, {'measure': 'HbA1c ≤6.5% (Yes/No)', 'description': 'Measured as count of participants.', 'timeFrame': 'At week 104'}, {'measure': 'HbA1c <7.0% (Yes/No)', 'description': 'Measured as count of participants.', 'timeFrame': 'At week 104'}, {'measure': 'Body weight reduction ≥5% (Yes/No)', 'description': 'Measured as count of participants.', 'timeFrame': 'At week 104'}, {'measure': 'Body weight reduction ≥10% (Yes/No)', 'description': 'Measured as count of participants.', 'timeFrame': 'At week 104'}, {'measure': 'Body weight reduction ≥15% (Yes/No)', 'description': 'Measured as count of participants.', 'timeFrame': 'At week 104'}, {'measure': 'HbA1c <7.0% and body weight reduction ≥5% (Yes/No)', 'description': 'Measured as count of participants.', 'timeFrame': 'At week 104'}, {'measure': 'Change in systolic blood pressure', 'description': 'Measured in mmHg.', 'timeFrame': 'From randomisation (week 0) to week 104'}, {'measure': 'Change in diastolic blood pressure', 'description': 'Measured in mmHg.', 'timeFrame': 'From randomisation (week 0) to week 104'}, {'measure': 'Change in hsCRP', 'description': 'Measured in mg/L.', 'timeFrame': 'From randomisation (week 0) to week 104'}, {'measure': 'Treatment emergent adverse events', 'description': 'Measured as count of events.', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': 'Number of severe (level 3) or clinically significant (level 2) hypoglycaemic episodes', 'description': 'Measured as count of episodes.', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': 'Treatment emergent adverse events', 'description': 'Measured as count of events.', 'timeFrame': 'From randomisation (week 0) to follow-up visit (week 109)'}, {'measure': 'Number of severe (level 3) or clinically significant (level 2) hypoglycaemic episodes', 'description': 'Measured as count of episodes.', 'timeFrame': 'From randomisation (week 0) to follow-up visit (week 109)'}, {'measure': 'Change in Control of Eating Questionnaire (CoEQ) score - Craving Control domain', 'description': 'CoEQ is a 19-item multidimensional patient reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving control subscale, the subscale score is reversed so that a higher score represents a greater level of craving control.', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': 'Change in CoEQ score - Craving for Savory domain', 'description': 'CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving savoury food subscale, higher score represents a greater level of craving.', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': 'Change in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) score - Physical function domain', 'description': 'IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Composite scores (score range): Physical composite (0-100), Psychosocial composite (0 100), Physical Function composite (0-100). Total score range (0-100).', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': ""Change in American Heart Association (AHA) Life's Simple 7 summary score"", 'description': 'The AHA recommends focusing on 7 cardiovascular health factors (smoking, BMI, physical activity, diet, total cholesterol, blood pressure, and fasting blood glucose) for early or primary prevention of cardiovascular disease. The 7 health factors are each categorized as ideal, intermediate, or poor. Scales range from 0 (minimum) to 14 (maximum). Higher score represents a greater level of health.', 'timeFrame': 'From randomisation (week 0) to week 52'}, {'measure': 'Change in CoEQ score - Craving Control domain', 'description': 'CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving control subscale, the subscale score is reversed so that a higher score represents a greater level of craving control.', 'timeFrame': 'From randomisation (week 0) to week 104'}, {'measure': 'Change in CoEQ score - Craving for Savory domain', 'description': 'CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving savoury food subscale, higher score represents a greater level of craving.', 'timeFrame': 'From randomisation (week 0) to week 104'}, {'measure': 'Change in IWQOL-Lite-CT score - Physical function domain', 'description': 'IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Composite scores (score range): Physical composite (0-100), Psychosocial composite (0 100), Physical Function composite (0-100). Total score range (0-100).', 'timeFrame': 'From randomisation (week 0) to week 104'}, {'measure': ""Change in AHA Life's Simple 7 summary score"", 'description': 'The AHA recommends focusing on 7 cardiovascular health factors (smoking, BMI, physical activity, diet, total cholesterol, blood pressure, and fasting blood glucose) for early or primary prevention of cardiovascular disease. The 7 health factors are each categorized as ideal, intermediate, or poor. Scales range from 0 (minimum) to 14 (maximum). Higher score represents a greater level of health.', 'timeFrame': 'From randomisation (week 0) to week 104'}]",45,18 Years,60 Years,ALL,False,Novo Nordisk A/S,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:24.749321,v2_robust,True,True,False,True,True,"Due to internal reprioritization, trial was cancelled."
NCT01810575,Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction,A Study to Assess the Relative Efficacy and Safety of a Single Dose of Alprostadil Cream Combined With 2 Concentrations of WC3036 Compared to Vehicle in Subjects With Erectile Dysfunction,WC3036-11F/Alprostadil in Vehicle 2.5%,"['12F', 'WC3036-11F/Alprostadil in Vehicle 2.5%', 'Vehicle', 'WC3036-12F/Alprostadil in Vehicle 0.5%', '11F', 'WC3036-13P/Vehicle Only 0.5%']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Erectile Dysfunction,['Erectile Dysfunction'],[],TERMINATED,Re-assessment of study,2013-02,2013-04,"[{'measure': 'Penile rigidity', 'description': '≥60% at base and tip of penis lasting for ≥ 5 minutes evaluated with RigiScan. Treatment visits will be separated by at least 2 days.', 'timeFrame': 'Visit 1 / Up to 5 days ± 3 days'}, {'measure': 'Penile rigidity', 'description': '≥60% at base and tip of penis lasting for ≥ 5 minutes evaluated with RigiScan. Treatment visits will be separated by at least 2 days.', 'timeFrame': 'Visit 2 / Up to 9 days ± 3 days'}, {'measure': 'Penile rigidity', 'description': '≥60% at base and tip of penis lasting for ≥ 5 minutes evaluated with RigiScan. Treatment visits will be separated by at least 2 days.', 'timeFrame': 'Visit 3 / Up to 14 Days'}]","[{'measure': 'Quality of erection', 'description': 'Subject description of quality of erection using non-validated questionnaire. Treatment visits will be separated by at least 2 days.', 'timeFrame': 'Visit 1 / Up to 5 days ± 3 days'}, {'measure': 'Quality of erection', 'description': 'Subject description of quality of erection using non-validated questionnaire. Treatment visits will be separated by at least 2 days.', 'timeFrame': 'Visit 2 / Up to 9 days ± 3 days'}, {'measure': 'Quality of erection', 'description': 'Subject description of quality of erection using non-validated questionnaire. Treatment visits will be separated by at least 2 days.', 'timeFrame': 'Visit 3 / Up to 14 days'}]",6,40 Years,,MALE,False,Warner Chilcott,INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:24.749394,v2_robust,True,True,False,True,False,Re-assessment of study
NCT04934475,MInimal Residual Disease Adapted Strategy,MInimal Residual Disease Adapted Strategy: Frontline Therapy for Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years; a Prospective Study,Isatuximab,"['Revlimid', 'Dexamethasone', 'Isatuximab', 'Carfilzomib']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Multiple Myeloma,['Multiple Myeloma'],"['Younger patients', 'First line of treatment', 'Autograft', 'Isa-KRD']",ACTIVE_NOT_RECRUITING,,2021-12-08,2028-09-30,"[{'measure': 'Negative MRD rate', 'description': 'For both parts of the trial (A vs B and C vs D), the primary comparison of the 2 strategies will be made with respect to negative MRD rate (10-6 NGS) before maintenance using the chi square test in the ITT population.\n\nThe observed MRD negative rate will be provided along with its 2-sided 95% Confidence interval (CI). Treatment effect will be described by an Odds Ratio, along with its 2-sided 95% confidence interval, by fitting a logistic regression model adjusted on stratification variables (with high risk cytogenetics and MRD negative rate (10-5 NGS) after induction as fixed effects and center as random effects for A vs B comparison, and high risk cytogenetics as fixed effects and center as random effects for C vs D comparison). In case of missing MRD, data will be imputed as positive in all arms.\n\nSensitivity analyses will be performed using best-worst and worst-best case to check for robustness of the results.', 'timeFrame': 'Time Frame: change from post induction baseline MRD at end of consolidation phase (6 months)'}, {'measure': 'Negative MRD rate', 'description': 'For both parts of the trial (A vs B and C vs D), the primary comparison of the 2 strategies will be made with respect to negative MRD rate (10-6 NGS) before maintenance using the chi square test in the ITT population.\n\nThe observed MRD negative rate will be provided along with its 2-sided 95% Confidence interval (CI). Treatment effect will be described by an Odds Ratio, along with its 2-sided 95% confidence interval, by fitting a logistic regression model adjusted on stratification variables (with high risk cytogenetics and MRD negative rate (10-5 NGS) after induction as fixed effects and center as random effects for A vs B comparison, and high risk cytogenetics as fixed effects and center as random effects for C vs D comparison). In case of missing MRD, data will be imputed as positive in all arms.\n\nSensitivity analyses will be performed using best-worst and worst-best case to check for robustness of the results.', 'timeFrame': 'change from post induction baseline MRD at 1 years'}, {'measure': 'Negative MRD rate', 'description': 'For both parts of the trial (A vs B and C vs D), the primary comparison of the 2 strategies will be made with respect to negative MRD rate (10-6 NGS) before maintenance using the chi square test in the ITT population.\n\nThe observed MRD negative rate will be provided along with its 2-sided 95% Confidence interval (CI). Treatment effect will be described by an Odds Ratio, along with its 2-sided 95% confidence interval, by fitting a logistic regression model adjusted on stratification variables (with high risk cytogenetics and MRD negative rate (10-5 NGS) after induction as fixed effects and center as random effects for A vs B comparison, and high risk cytogenetics as fixed effects and center as random effects for C vs D comparison). In case of missing MRD, data will be imputed as positive in all arms.\n\nSensitivity analyses will be performed using best-worst and worst-best case to check for robustness of the results.', 'timeFrame': 'change from post induction baseline MRD at 2 years'}, {'measure': 'Negative MRD rate', 'description': 'For both parts of the trial (A vs B and C vs D), the primary comparison of the 2 strategies will be made with respect to negative MRD rate (10-6 NGS) before maintenance using the chi square test in the ITT population.\n\nThe observed MRD negative rate will be provided along with its 2-sided 95% Confidence interval (CI). Treatment effect will be described by an Odds Ratio, along with its 2-sided 95% confidence interval, by fitting a logistic regression model adjusted on stratification variables (with high risk cytogenetics and MRD negative rate (10-5 NGS) after induction as fixed effects and center as random effects for A vs B comparison, and high risk cytogenetics as fixed effects and center as random effects for C vs D comparison). In case of missing MRD, data will be imputed as positive in all arms.\n\nSensitivity analyses will be performed using best-worst and worst-best case to check for robustness of the results.', 'timeFrame': 'change from post induction baseline MRD at 3 years'}]","[{'measure': 'Sustained MRD rate', 'description': 'Sustained MRD rate at after consolidation phase ( 6 months) than year 1, 2, 3 post consolidation phase will be analyzed similarly to the primary endpoint', 'timeFrame': 'change from post induction baseline MRD at end of consolidation phase (6 months)'}, {'measure': 'Sustained MRD rate', 'description': 'Sustained MRD rate at after consolidation phase ( 6 months) than year 1, 2, 3 post consolidation phase will be analyzed similarly to the primary endpoint', 'timeFrame': 'change from post induction baseline MRD at 1 years'}, {'measure': 'Sustained MRD rate', 'description': 'Sustained MRD rate at after consolidation phase ( 6 months) than year 1, 2, 3 post consolidation phase will be analyzed similarly to the primary endpoint', 'timeFrame': 'change from post induction baseline MRD at 2 years'}, {'measure': 'Sustained MRD rate', 'description': 'Sustained MRD rate at after consolidation phase ( 6 months) than year 1, 2, 3 post consolidation phase will be analyzed similarly to the primary endpoint', 'timeFrame': 'change from post induction baseline MRD at 3 years'}, {'measure': 'Overall Survival (OS)', 'description': 'For Overall Survival (OS), the distribution of OS since randomization will be estimated using Kaplan Meier method. The comparison of the 2 arms will be made by log-rank test. Treatment effect will be described by Hazard Ratio and its 2-sided 95% confidence intervals will be estimated using a Cox regression model adjusted on stratification variables (with high risk cytogenetics and MRD negative rate (10-5 NGS) after induction as fixed effects and center as random effects for A vs B comparison, and high risk cytogenetics as fixed effects and center as random effects for C vs D comparison).', 'timeFrame': 'through study completion, an average of 8 year'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'Progression Free Survival, defined as time from randomization to either progression or death will be analyzed similarly to OS', 'timeFrame': 'through study completion, an average of 8 year'}, {'measure': 'Safety analyses', 'description': 'rate of adverse events that occured during treatment period', 'timeFrame': 'until 30 days post last dose of protocol treatment'}]",11,18 Years,66 Years,ALL,False,Intergroupe Francophone du Myelome,NETWORK,3,791.0,ACTUAL,2025-09-01T16:18:24.749471,v2_robust,True,True,False,False,True,
NCT02366975,TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST,Effectiveness of Testosterone Replacement Therapy (TRT) on Prostatic Gland in Hypogonadal Patients Affected by Benign Prostatic Hyperplasia (BPH) and Metabolic Syndrome (MetS). Florence-PROTEST,Testosterone gel 2%,"['tostran', 'Testosterone gel 2%']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Prostatic Hyperplasia,"['Prostatic Hyperplasia', 'Lower Urinary Tract Symptoms', 'Hypogonadism']","['BPH/LUTS', 'TRT', 'Metabolic Syndrome']",COMPLETED,,2012-11,2017-02,"[{'measure': 'NIH-CPSI', 'description': 'Evaluation in hypogonadal patients with both BPH and metabolic syndrome of the effectiveness of 6 months of treatment with testosterone compared with placebo in improving symptoms of prostatitis and the symptoms of LUTS', 'timeFrame': '6 months before surgery'}, {'measure': 'IPSS', 'description': 'Evaluation in hypogonadal patients with both BPH and metabolic syndrome of the effectiveness of 6 months of treatment with testosterone compared with placebo in improving symptoms of prostatitis and the symptoms of LUTS', 'timeFrame': '6 months before surgery'}]","[{'measure': 'ultrasound prostate characteristics', 'description': 'Evaluation in hypogonadal patients with both BPH and metabolic syndrome of the effectiveness of 6 months of treatment with testosterone compared with placebo in improving', 'timeFrame': '6 months before surgery'}, {'measure': 'Immunohistological analysis of prostatic inflammation and gene expression of inflammatory markers on the prostate', 'description': 'Evaluation in hypogonadal patients with both BPH and metabolic syndrome of the effectiveness of 6 months of treatment with testosterone compared with placebo in improving', 'timeFrame': '6 months before surgery'}, {'measure': 'metabolic parameters', 'description': 'Evaluation in hypogonadal patients with both BPH and metabolic syndrome of the effectiveness of 6 months of treatment with testosterone compared with placebo in improving', 'timeFrame': '6 months before surgery'}]",5,18 Years,,MALE,False,University of Florence,OTHER,0,143.0,ACTUAL,2025-09-01T16:18:24.749526,v2_robust,True,True,True,False,False,
NCT05886257,Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T,"Candonilimab Plus Bevacizumab as Second-line Treatment for Patients With Advanced Hepatocellular Carcinoma Who Progressed on Atezolizumab Plus Bevacizumab: a Single Arm, Phase 2 Trial",Candonilimab,"['Candonilimab', 'Bevacizumab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Hepatocellular Carcinoma,['Hepatocellular Carcinoma'],"['Hepatocellular Carcinoma', 'Candonilimab Plus Bevacizumab', 'Atezolizumab Plus Bevacizumab']",WITHDRAWN,Protocol adjustment,2022-12-07,2023-03-31,"[{'measure': 'ORR per RECIST 1.1', 'description': 'Objective response rate per RECIST 1.1', 'timeFrame': '12 months'}]","[{'measure': 'Overall survival (OS)', 'description': 'OS is the length of time from the date of randomization until death from any cause.', 'timeFrame': '12 months'}, {'measure': 'Progression free survival (PFS)', 'description': 'PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression or death due to any cause.', 'timeFrame': '12 months'}, {'measure': 'Adverse events', 'description': 'Safety will be evaluated according to the NCI CTCAE Version 4.03. All observations pertinent to the safety of the study medication will be recorded on the CRF and included in the final report.', 'timeFrame': '30 days'}, {'measure': 'PD-L1 Biomarker', 'description': 'The blood specimen and needle biopsy specimen would be collected', 'timeFrame': '12 months'}]",5,18 Years,75 Years,ALL,False,Shi Ming,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:24.749645,v2_robust,True,True,False,True,True,Protocol adjustment
NCT00075257,Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of DVS-233 SR For Prevention Of Depressive Relapse In Adult Outpatients With Major Depressive Disorder",DVS-233 SR,['DVS-233 SR'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Major Depressive Disorder,['Major Depressive Disorder'],[],COMPLETED,,,2005-08,[],[],0,18 Years,75 Years,ALL,False,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,603.0,ACTUAL,2025-09-01T16:18:24.749708,v2_robust,True,True,True,False,False,
NCT01754857,Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL,Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab and Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL),Bendamustine,"['Lenalidomide', 'Rituximab', 'Bendamustine']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Lymphoid Leukemia,"['Lymphoid Leukemia', 'Small Lymphocytic Lymphoma', 'Lymphoma, Non-Hodgkin']","['Lymphoid Leukemia', 'Bendamustine', 'Rituximab', 'Small Lymphocytic Lymphoma']",COMPLETED,,2013-11-12,2022-06-30,"[{'measure': 'Time to Progression', 'description': 'The primary objective is progression-free survival (PFS). Tumor measurements and disease assessments will be performed at the time of screening, following cycles 3 and 6 of induction chemotherapy, every 4 cycles during the maintenance portion of treatment, and at the end of treatment (EOT). Subjects with clinical evidence of progression prior to a planned disease assessment will be evaluated at the time of clinically suspected progression. Follow-up visits for disease assessment will occur every 3 months after the EOT visit until PD, initiation of alternate anti-neoplastic therapy, decision by the subject to withdraw from the study, or death. The follow-up period will begin after the EOT visit, and all subjects will be followed for at least 2 years after completion of therapy or until death or progression and until the last patient has been followed for at least 1 year following completion of therapy.', 'timeFrame': 'At least 24 months following completion of therapy, an average of 5 years'}]","[{'measure': 'Objective Response Rates', 'description': 'To determine objective response rates (CR + PR). As described in the primary objective, formal disease assessments including imaging will be performed after cycles 3 and 6 of induction chemotherapy and every 4 cycles during the maintenance portion of treatment. Response and progression in cases of SLL will be evaluated using the International Working Group Criteria30 for response in lymphoma. Response and progression in cases of CLL will be evaluated in this study using the Revised IWCLL Criteria31 for response in CLL. Radiological methodologies, techniques and/or physical examination, established at baseline for the assessment and measurement of each identified lesion will be used for all subsequent assessments.', 'timeFrame': 'Up to 30 months'}, {'measure': 'Count of Events Related to Toxicity', 'description': 'To determine toxicities observed with induction chemotherapy and maintenance therapy. Safety evaluations will be based on the incidence, intensity, and type of adverse events (AEs) and clinical laboratory results. Drug doses will be modified as required based on toxicity as assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.', 'timeFrame': 'Up to 30 months'}]",3,18 Years,,ALL,False,"University of Wisconsin, Madison",OTHER,2,36.0,ACTUAL,2025-09-01T16:18:24.749714,v2_robust,True,True,True,False,True,
NCT05661357,Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression,"Single Arm, Prospective, Exploratory Clinical Study of Disitamab Vedotin Combined With Fruquintinib for Advanced Colorectal Cancer With HER2 Expression or Mutation That Has Received at Least Two Standard Treatment Failures",Disitamab Vedotin Combined With Fruquintinib,['Disitamab Vedotin Combined With Fruquintinib'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,HER2,"['HER2', 'Colorectal Cancer']",[],ACTIVE_NOT_RECRUITING,,2023-01-01,2025-12-31,"[{'measure': 'ORR', 'description': 'Objective Response Rate', 'timeFrame': 'through study completion, an average of 2 years'}]",[],1,18 Years,75 Years,ALL,False,Zhongnan Hospital,OTHER,4,51.0,ACTUAL,2025-09-01T16:18:24.749842,v2_robust,True,True,False,False,False,
NCT00981357,"A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee","A Phase 2a Randomized, Double-blinded, Double Dummy, Placebo And Active Controlled, Two-way Cross-over, Flare-enriched Multi-centre Clinical Trial To Examine The Pain Relief Produced By 2 Weeks Of Daily Oral Administration Of A Fatty Acid Amide Hydrolase (Faah) Inhibitor Pf-04457845 In Patients With Osteoarthritis Of The Knee.",PF-04457845,"['Naproxen', 'PF-04457845']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Osteoarthritis, Knee","['Osteoarthritis, Knee']",['Cross-over evaluate the efficacy of PF-04457845 in relieving pain due to osteoarthritis OA knee osteoarthritis of knee pain due to osteoarthritis'],COMPLETED,,2009-11,2010-05,"[{'measure': 'To evaluate the efficacy of PF-04457845 (administered QD) versus placebo in relieving pain as measured by the WOMAC Pain sub-score in patients with osteoarthritis of the knee', 'timeFrame': '8 weeks'}, {'measure': 'To evaluate the safety and tolerability of PF-04457845 in patients with osteoarthritis.', 'timeFrame': '10 weeks'}]","[{'measure': 'Efficacy of PF-04457845 (administered QD) versus placebo as measured by the WOMAC Stiffness domain score (Likert scale for 2 items, overall score ranges from 0-8) in patients with osteoarthritis of the knee.', 'timeFrame': '8 weeks'}, {'measure': 'Efficacy of PF-04457845 (administered QD) versus placebo as measured by the WOMAC Physical Function domain score (Likert scale for 17 items, overall score ranges from 0-68) in patients with osteoarthritis of the knee.', 'timeFrame': '8 weeks'}, {'measure': 'Efficacy of PF-04457845 (administered QD) versus placebo as measured by the WOMAC Total Score in patients with osteoarthritis of the knee.', 'timeFrame': '8 weeks'}, {'measure': 'Efficacy of PF-04457845 (administered QD) versus placebo as measured by the Importance weighted Total WOMAC score in patients with osteoarthritis of the knee.', 'timeFrame': '8 weeks'}, {'measure': 'Efficacy of PF-04457845 (administered QD) versus placebo as measured by the Daily pain diary over weeks 1 and 2 of each treatment period using an 11-point Numeric Rating Scale (NRS) in patients with osteoarthritis of the knee.', 'timeFrame': '8 weeks'}, {'measure': ""Efficacy of PF-04457845 (administered QD) versus placebo as measured by the Subjects' use of rescue medication on either treatment."", 'timeFrame': '8 weeks'}, {'measure': 'Summary of plasma concentrations of PF-04457845.', 'timeFrame': '8 weeks'}, {'measure': 'Residual FAAH activity in leukocytes for subjects recruited prior to the interim analysis.', 'timeFrame': '8 weeks'}, {'measure': 'Plasma fatty acid amide levels (OEA, PEA, LEA and AEA) for subjects recruited prior to the interim analysis.', 'timeFrame': '8 weeks'}]",11,18 Years,75 Years,ALL,False,Pfizer,INDUSTRY,0,76.0,ACTUAL,2025-09-01T16:18:24.749870,v2_robust,True,True,True,False,True,
NCT06351501,Evaluation of the Effectiveness of Hormonal Treatment in Adolescents Suffering from Gender Dysphoria,Evaluation of the Effectiveness of Hormonal Treatment in Adolescents Suffering from Gender Dysphoria,hormonal treatment with cross sex hormones (testosterone or oestrogenes) started at 14 years old +/- 6 months,"['hormonal treatment with cross sex hormones (testosterone or oestrogenes) started at 14 years old +/- 6 months', 'Cross sex hormones ( œstrogenes or testosterone) started at 16 years old +/- 6 months']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Gender Dysphoria,['Gender Dysphoria'],"['Gender Dysphoria', 'adolescents', 'hormonal treatment', 'mental health']",RECRUITING,,2024-06-25,2031-06-24,"[{'measure': ""Global functionning using the Children's Global Assessment Scale (CGAS)"", 'description': 'The Children\'s Global Assessment Scale (CGAS), adapted from the Global Assessment Scale for adults, is a rating of general functioning for children and young people until 16 years old. The clinician assesses a range of aspects of psychological and social functioning and gives the child or young person a single score between 1 and 100, based on their lowest level of functioning. The score puts them in one of ten categories that range from ""needs constant supervision"" (1-10) to ""superior functioning"" (91-100). The measure can be used by clinicians as well as researchers to complement other scales measuring more specific symptoms.', 'timeFrame': '16 years old +/- 6 months'}]","[{'measure': 'Drug use (DEP-ADO)', 'description': 'Drug use: assessed by specific questions via the DEP-ADO questionnaire (screening grid for problem substance use among adolescents).\n\nDep-Ado is a 15 minutes questionnaire to evaluate alcohol and substance use adolescent population aged 12 to 17 years. No problem if total score \\<12; warning of \\>12 et \\<19; pathological use needing intervention if \\>20', 'timeFrame': 'T0 (14 years old +/-6 months); T1 (16 years old+/-6 months); T2 ( 18 years old +/-6 months)'}, {'measure': 'WISC-V (weschler Test)', 'description': 'cognitive test with 4 subscales (verbal comprehension index, perceptual reasoning index, logical score, working memory index, processing speed index). IQ is calculated. If \\<80, it is an non inclusion criteria. Normal range between 80 and 120. when \\> 120 précocity', 'timeFrame': 'T0 (14 years old +/-6 months); T2 ( 18 years old +/-6 months)'}, {'measure': 'UGDS (Utrecht Gender Dysphoria Scale ) and GIDYQ-AA (Gender Identity/ Gender Dysphoria Questionnaire for Adolescents and Adults scale )', 'description': 'The Utrecht Gender Dysphoria Scale (UGDS) is a validated, 12-item screening measure for both adults and adolescents used extensively in gender clinics to assess gender dysphoria. Minimal score= 12; max=60. two versions (AFAB, AMAB)', 'timeFrame': 'selection visit ; T1 (16 years old +/-6 months) ; T2 (18 years old +/-6 months)'}, {'measure': 'Beck Depression Inventory (BDI)', 'description': 'is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression.Min = 0 Max = 39 Between 0 and 3 = no Dépression', 'timeFrame': 'T0 (14 years old +/-6 mois); T1 (16 years old+/-6 monhs); T2 ( 18 years old +/-6 months)'}, {'measure': 'Body Image Scale (BIS)', 'description': 'The 10-item BIS was developed to assess changes in body image assessed with a four-point scale from ""not at all"" to ""very much."" High scores indicate higher body image.(Min=30, Max=150 )', 'timeFrame': 'T0 (14 years old +/-6 months); T1 (16 years old+/-6 months); T2 ( 18 years old +/-6 months)'}, {'measure': 'State and Anxiety Inventory for Children (STAI-C)', 'description': 'STAI-C includes 20-items that describe anxiety experiences a person might experience (e.g., item 6-""I worry too much""©). For each item, participants choose one of three options that indicate how often they experience the described situation - ""hardly-ever"", ""sometimes"" or ""often""; these options are scored with 1, 2, and 3 points, respectively (total score range: 20-60). Higher scores indicate higher anxiety', 'timeFrame': 'T0 (14 years old +/-6 mois); T1 (16 years old+/-6 monhs); T2 ( 18 years old +/-6 months)'}, {'measure': 'World Health Organization Quality Of Life - BREF (WHOQOL-BREF)', 'description': ""This 26-item instrument measures four fields, i.e. physical health, mental health, social relations and the environment. The analysis is based on the scores generated for each field (no overall score can be calculated). The user manual is comprehensive, which makes the instrument easy to use (WHO, 1996). While some studies call into question the construct validity (D'Abundo et al., 2011), the WHOQOL-BREF is generally recognized as a reliable, valid instrument to assess quality of life and is widely used in the literature for clinical and population-based surveys (Oliveira, Carvalho and Esteves, 2016; Skevington, Lotfy and O'Connell, 2004)."", 'timeFrame': 'T0 (14 years old +/-6 months); T1 (16 years old+/-6 months); T2 ( 18 years old +/-6 months)'}, {'measure': 'Satisfaction With Life Scale (SWLS)', 'description': ""The SWLS is a short 5-item instrument designed to measure global cognitive judgments of satisfaction with one's life. The scale usually requires only about one minute of a respondent's time.Min=5, Max=35. The higher score means a greater satisfaction with life"", 'timeFrame': 'T0 (14 years old +/-6 months); T1 (16 years old+/-6 months); T2 ( 18 years old +/-6 months)'}, {'measure': 'Height, bone mineral density, BMI, waist to hip ratio', 'description': ""MI is a measurement of a person's leanness or corpulence based on their height and weight, and is intended to quantify tissue mass"", 'timeFrame': 'inclusion visit (14 years old +/-6 months); T1 (16 years old+/-6 months); T2 ( 18 years old +/-6 months)'}, {'measure': 'Mini International Neuropsychiatric Interview (MINI)', 'description': 'To assess the 17 most common psychiatric disorders and suicidality in DSM-III-R, DSM-IV and DSM-5 and ICD-10. The MINI was designed as a brief structured diagnostic interview to meet the need for a short but accurate structured psychiatric interview for multicenter clinical trials and epidemiology studies and to be used as a first step in outcome tracking in nonresearch clinical settings.', 'timeFrame': 'selection visit ; T1 (16 years old+/-6 months); T2 ( 18 years old +/-6 months)'}, {'measure': 'The emotional and sexual relationship', 'description': 'The emotional and sexual relationship assessed by specific questions', 'timeFrame': 'T0 (14 years old +/-6 months); T1 (16 years old+/-6 months); T2 ( 18 years old +/-6 months)'}, {'measure': 'School drop-out / family breakdown', 'description': 'School drop-out / family breakdown assessed by specific questions', 'timeFrame': 'T0 (14 years old +/-6 months); T1 (16 years old+/-6 months); T2 ( 18 years old +/-6 months)'}, {'measure': 'Global Assesment Scale (GAS)', 'description': ""assess the adolescent's overall functioning, heteroquestionnaire, score from 1 to 100, on file and after 30-minute interview"", 'timeFrame': 'T2 : 18 years old +/-6 months'}, {'measure': 'Potential side-effects', 'timeFrame': 'T0 (14 years old +/-6 months); T1 (16 years old+/-6 months); T2 ( 18 years old +/-6 months)'}, {'measure': 'Child Behaviour Checklist (CBCL) scale', 'description': 'Emotional disorders and possible comorbidities assessed by the Child Behavior Checklist (CBCL) score, parent self-questionnaire, 15 minutes', 'timeFrame': 'T0 (14 years old +/-6 months); T1 (16 years old+/-6 months); T2 ( 18 years old +/-6 months)'}, {'measure': 'Youth Self Report (YSR) scale', 'description': 'Emotional disorders and possible comorbidities: assessed by the Youth Self Report (YSR) self-questionnaire, 15 minutes', 'timeFrame': 'T0 (14 years old +/-6 months); T1 (16 years old+/-6 months); T2 ( 18 years old +/-6 months)'}]",17,162 Months,174 Months,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:24.749919,v2_robust,True,True,False,False,False,
NCT04512001,MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis,"A Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Two-Arm Study to Evaluate the Efficacy, Safety and Immunogenicity of MSB11456 Compared to European Union-approved RoActemra® in Patients With Moderately to Severely Active Rheumatoid Arthritis (APTURA I Study)",MSB11456,"['MSB11456', 'EU-approved RoActemra']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],"['MSB11456', 'RoActemra®']",COMPLETED,,2020-08-03,2022-06-06,"[{'measure': 'Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)', 'description': ""The DAS28-ESR is a measure of disease activity in 28 joints that consists of a composite numerical score of the following variables: Tender Joint Count (TJC), Swollen Joint Count (SJC), erythrocyte sedimentation rate (ESR) and Patient's Global Assessment of Disease Activity.\n\nThe DAS28-ESR score was derived using the formula: DAS28-ESR = 0.56\\*√(TJC28) + 0.28\\*√(SJC28) + 0.014\\*GH + 0.70\\*Ln(ESR), where, TJC28 = 28 joint count for tenderness, SJC28 = 28 joint count for swelling, Ln(ESR) = natural logarithm of ESR, GH = the general health component of the DAS (i.e., Patient's Global Assessment of Disease Activity on a scale of 1 to 100 where 100 is maximal activity).\n\nHigher values mean a higher disease activity. The level of disease activity can be interpreted as:\n\n* Remission (score of \\<2.6).\n* Low (score of ≤2.6 to \\<3.2).\n* Moderate (score of ≤3.2 to ≤5.1).\n* High (score of \\>5.1)\n\nA negative change from baseline indicates an improvement."", 'timeFrame': 'Baseline; Week 24'}]","[{'measure': 'Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)', 'description': ""The DAS28-ESR is a measure of disease activity in 28 joints that consists of a composite numerical score of the following variables: TJC, SJC, ESR and Patient's Global Assessment of Disease Activity.\n\nThe DAS28-ESR score was derived using the formula: DAS28-ESR = 0.56\\*√(TJC28) + 0.28\\*√(SJC28) + 0.014\\*GH + 0.70\\*Ln(ESR), where, TJC28 = 28 joint count for tenderness, SJC28 = 28 joint count for swelling, Ln(ESR) = natural logarithm of ESR, GH = the general health component of the DAS (i.e., Patient's Global Assessment of Disease Activity on a scale of 1 to 100 where 100 is maximal activity).\n\nHigher values mean a higher disease activity. The level of disease activity can be interpreted as:\n\n* Remission (score of \\<2.6).\n* Low (score of ≤2.6 to \\<3.2).\n* Moderate (score of ≤3.2 to ≤5.1).\n* High (score of \\>5.1)\n\nA negative change from baseline indicates an improvement. For weeks 30, 42 and 52, the extended baseline (week 24) was used for the change in DAS28-ESR calculation."", 'timeFrame': 'Baseline, Week 2, Week 4, Week 8, Week 12, Week 16; Extended Period Baseline (Week 24), Week 30, Week 42, and Week 52'}, {'measure': 'Number of Participants With 20% Improvement in American College of Rheumatology (ACR20) Response', 'description': ""ACR20 was defined as the number of participants with at least 20% improvement from baseline in number of tender and swollen joints (68/66 joint count), and at least 20% improvement from baseline in three or more of the 5 ACR Core Set measures:\n\n* Patient's Assessment of Arthritis Pain\n* Physical Function Assessment (Health Assessment Questionnaire-Disability Index)\n* Acute phase reactant level (erythrocyte sedimentation rate or C-reactive protein)\n* Patient's Global Assessment of Disease Activity and\n* Physician's Global Assessment of Disease Activity"", 'timeFrame': 'Baseline; Week 24'}, {'measure': 'Number of Participants Who Experienced One or More Treatment-Emergent Adverse Event (TEAE)', 'timeFrame': 'Baseline to end of study, up to Week 63'}, {'measure': 'Number of Participants Who Experienced One or More Treatment-Emergent Serious Adverse Event (TESAE)', 'timeFrame': 'Baseline to end of study, up to Week 63'}, {'measure': 'Percentage of Participants With Positive Anti-Drug Antibodies (ADAs)', 'timeFrame': 'Baseline, Week 2, Week 12, Week 24, Week 30, Week 52 and Week 55'}, {'measure': 'Anti-Drug Antibodies (ADAs) Titer Levels', 'timeFrame': 'Baseline, Week 2, Week 12, Week 24, Week 30, Week 52 and Week 55'}, {'measure': 'Percentage of Participants With Neutralizing Antibodies (NAb)', 'timeFrame': 'Baseline, Week 2, Week 12, Week 24, Week 30, Week 52 and Week 55'}]",8,18 Years,,ALL,False,Fresenius Kabi SwissBioSim GmbH,INDUSTRY,0,604.0,ACTUAL,2025-09-01T16:18:24.750007,v2_robust,True,True,True,False,True,
NCT00635401,A Study of the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking,"A Multicenter, Open-Label Study Exploring the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking",Varenicline,"['Varenicline', 'Chantix, Champix, CP-526,555']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Smoking,['Smoking'],[],COMPLETED,,2004-05,2004-08,"[{'measure': 'Carbon monoxide (CO)-confirmed 4-week continuous quit rate (4-week CQR) from Weeks 4 to 7.', 'timeFrame': 'Weeks 4-7'}]","[{'measure': 'CO-confirmed 7-day Point Prevalence from Week 2 through Week 7.', 'timeFrame': 'Weeks 2-7'}, {'measure': 'Continuous abstinence rate from target quit date (TQD) from Week 2 through Week 7.', 'timeFrame': 'Weeks 2-7'}, {'measure': 'Average number of daily cigarettes smoked from Week 2 through Week 7.', 'timeFrame': 'Weeks 2-7'}, {'measure': 'Assessment of withdrawal symptoms by Minnesota Nicotine Withdrawal Scales (MNWS) from Week 2 through Week 7.', 'timeFrame': 'Weeks 2-7'}, {'measure': 'Assessment of satisfaction (desirable and aversive effects) obtained from smoking by Smoking Effects Inventory (SEI) (administered only to subjects who had smoked since the previous assessment) from Week 2 through Week 7.', 'timeFrame': 'Weeks 2-7'}, {'measure': 'Assessment of tobacco craving by the Brief Questionnaire of Smoking Urges (QSU-Brief) from Week 2 through Week 7.', 'timeFrame': 'Weeks 2-7'}, {'measure': ""Assessment of the effect of smoking cessation on subjects' quality of life by the Smoking Cessation Quality of Life (SCQoL) questionnaire from Week 2 through Week 7."", 'timeFrame': 'Weeks 2-7'}, {'measure': 'Adverse events, laboratory test changes throughout the study.', 'timeFrame': 'Weeks 1-7'}]",9,20 Years,75 Years,ALL,False,Pfizer,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:24.750086,v2_robust,True,True,True,False,True,
NCT00409201,Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia,Phase 1 Study of Reboxetine Adjuvant Therapy and Cognitive and Behavioral Measures,reboxetine adjuvant therapy,['reboxetine adjuvant therapy'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Schizophrenia,['Schizophrenia'],"['schizophrenia', 'reboxetine', 'cognitive', 'behavior']",UNKNOWN,,2006-03,2006-11,"[{'measure': 'sans, panss, hamilton, ham-a, calgary, physical examination, cogscan test'}]","[{'measure': 'esrs, progesterom, sexual functioning, covy, cgi, cgi improved'}]",2,18 Years,65 Years,ALL,False,Abarbanel Mental Health Center,OTHER_GOV,0,30.0,,2025-09-01T16:18:24.750106,v2_robust,True,True,False,False,False,
NCT06555601,"A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy Participants","A First-in-Human, Randomized, Investigator-Blind, Participant-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB3101 in Healthy Participants",UCB3101,"['UCB3101', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Participants,['Healthy Participants'],['UCB3101'],RECRUITING,,2024-07-31,2026-01-08,"[{'measure': 'Incidence of any treatment- emergent adverse events (TEAE)', 'description': 'An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.', 'timeFrame': 'From Baseline to Safety Follow-up (up to Week 21)'}]","[{'measure': 'Incidence of any treatment-emergent Serious Adverse Events (SAE)', 'description': 'A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:\n\n* Results in death;\n* Is life-threatening; Requires inpatient hospitalization or prolongation of existing hospitalization;\n* Results in persistent or significant disability/incapacity, or\n* Is a congenital anomaly/birth defect;\n* Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.', 'timeFrame': 'From Baseline to Safety Follow-up (up to Week 21)'}, {'measure': 'Incidence of discontinuation from treatment due to treatment- emergent adverse events (TEAE)', 'description': 'An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.', 'timeFrame': 'From Baseline to Safety Follow-up (up to Week 21)'}, {'measure': 'Maximum Serum Concentration (Cmax) of UCB3101', 'description': 'Maximum serum concentration (Cmax) of UCB3101 will be reported.', 'timeFrame': 'From Day 1 (Predose) up to Week 21'}, {'measure': 'Area Under the Serum Concentration-Time Curve (AUC) of UCB3101', 'description': 'Area under the serum concentration-time curve (AUC) of UCB3101 will be reported.', 'timeFrame': 'From Day 1 (Predose) up to Week 21'}]",5,18 Years,65 Years,ALL,True,UCB Biopharma SRL,INDUSTRY,0,64.0,ESTIMATED,2025-09-01T16:18:24.750132,v2_robust,True,True,False,False,True,
NCT00367601,Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer,A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer,Erlotinib,"['Erlotinib', 'Bevacizumab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Lung Cancer,['Lung Cancer'],[],COMPLETED,,2006-08,2008-12,"[{'measure': 'To Establish Rate of Non-progressive Disease at 4 Months in Patients With Advanced NSCLC Who Have Been Designated PS2 by Their Treating Physician', 'timeFrame': '4 months'}]","[{'measure': 'Time to Progression', 'timeFrame': '12 months'}, {'measure': 'Overall Survival', 'timeFrame': '12 months'}]",3,18 Years,,ALL,False,"Nasser Hanna, M.D.",OTHER,3,25.0,ACTUAL,2025-09-01T16:18:24.750150,v2_robust,True,True,True,False,False,
NCT00069901,Phase II CT-2103/Carboplatin in Ovarian Cancer,CT-2103/Carboplatin for Patients With Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer: A Phase 2 Study,CT-2103 (poly(L)glutamate-paclitaxel),"['carboplatin', 'CT-2103 (poly(L)glutamate-paclitaxel)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Neoplasm,['Ovarian Neoplasm'],"['ovarian cancer', 'paclitaxel', 'carboplatin']",COMPLETED,,2003-02,2006-09,[],[],0,18 Years,,FEMALE,False,CTI BioPharma,INDUSTRY,0,82.0,ACTUAL,2025-09-01T16:18:24.750161,v2_robust,True,True,True,False,False,
NCT01997801,Ketamine in Robot-assisted Thyroidectomy,The Efficacy of Intraoperative Ketamine in Patients Undergoing Robot-assisted Thyroidectomy,Ketamine infusion,"['Ketamine infusion', 'NS infusion']",2,INTERVENTIONAL,['NA'],,,Thyroid,"['Thyroid', 'Acute Pain', 'Chronic Pain']","['Thyroidectomy', 'Endoscopy', 'Ketamine', 'Acute Pain', 'Chronic Pain', 'Postoperative period']",UNKNOWN,,2013-12,2014-12,"[{'measure': 'Pain at 24 hour postoperatively', 'description': 'Pain at 24 hour postoperatively will be evaluates using 11 point scale (0:no pain, 10:worst imaginable)', 'timeFrame': 'at 24 hour postoperatively'}]","[{'measure': 'Pain at 3, 6, 12, 48 and 72 hour postoperatively', 'description': 'Pain at 3, 6, 12, 48 and 72 hour postoperatively will be evaluated using 11-point scale 0:no pain, 10:worst imaginable)', 'timeFrame': 'at 3, 6, 12, 48 and 72 hour postoperatively'}, {'measure': 'Time to the first analgesics postoperatively', 'description': 'Time from the end of anesthesia till the first analgesic agent will be recorded at 24 hours postoperatively.', 'timeFrame': 'At 24 hours postoperatively'}, {'measure': 'Analgesic requirements for 24 hours after surgery', 'description': 'Analgesic requirements for 24 hours after surgery will be evaluated.', 'timeFrame': 'at 24 hours postoperatively'}, {'measure': 'Chronic pain at 3 month after surgery', 'description': 'Chronic pain at 3 month after surgery will be evaluated.', 'timeFrame': 'At 3 month after surgery'}]",5,19 Years,80 Years,ALL,False,Seoul National University Hospital,OTHER,0,64.0,ESTIMATED,2025-09-01T16:18:24.750167,v2_robust,True,True,False,False,False,
NCT02723201,TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants,"A Randomized, Open Label Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of a Single Dose of Various Test Solid Formulations of TAK-020 Compared With a Single Dose of Reference Oral Solution and to Evaluate the Food Effect and Potentially the Dose Proportionality of the Optimal Solid Dose Formulation",TAK-020 Captisol Oral Solution,"['TAK-020 Solid Formulation', 'TAK-020 CCT', 'TAK-020 SDT', 'TAK-020 Captisol Oral Solution', 'TAK-020 IRT']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2016-04-28,2016-08-24,"[{'measure': 'Cmax: Maximum Observed Plasma Concentration for TAK-020', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose'}, {'measure': 'Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-020', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose'}, {'measure': 'AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-020', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose'}, {'measure': 'Terminal Disposition Phase Half-life (T1/2z) in Plasma for TAK-020', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose'}]","[{'measure': 'Number of Participants Who Experience at Least One or More Treatment-emergent Adverse Event (TEAE)', 'timeFrame': 'Baseline up to 30 days after last dose of study drug (Day 58 in Part 1), (Day 40 in Part 2)'}, {'measure': 'Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Post Dose', 'timeFrame': 'Baseline up to Day 2'}, {'measure': 'Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose', 'timeFrame': 'Baseline up to Day 2'}, {'measure': 'Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose', 'timeFrame': 'Baseline up to Day 2'}]",8,18 Years,55 Years,ALL,True,Takeda,INDUSTRY,0,25.0,ACTUAL,2025-09-01T16:18:24.750186,v2_robust,True,True,True,False,True,
NCT06403501,Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris,"A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Clinical Study to Evaluate the Efficacy and Safety of Clascoterone Cream 1% in Treatment of Subjects With Facial Acne Vulgaris",Clascoterone,"['Vehicle cream', 'Clascoterone', 'Winlevi (brand name)']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Acne Vulgaris,['Acne Vulgaris'],['Acne Vulgaris'],RECRUITING,,2024-05-20,2026-10,"[{'measure': ""Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)"", 'description': 'Percentage of subjects in each treatment group achieving ""success"" at Week 12, with ""success"" defined as an IGA score of ""clear (score=0)"" or ""almost clear (score=1)"" and at least a two-point reduction in IGA compared to Baseline.', 'timeFrame': 'Week 12'}, {'measure': 'Change From Baseline in Non-inflammatory Lesion (NIL) Counts', 'description': 'Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.', 'timeFrame': 'Week 12'}, {'measure': 'Change From Baseline in Inflammatory Lesion (IL) Counts', 'description': 'Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.', 'timeFrame': 'Week 12'}]","[{'measure': 'Change From Baseline in Total Lesion Counts', 'description': 'Absolute change from Baseline in total lesions counts in each treatment group at Week 12.', 'timeFrame': 'Week 12'}, {'measure': 'Percent Change From Baseline in Total Lesion Counts', 'description': 'Percent change from Baseline in total lesions counts in each treatment group at Week 12.', 'timeFrame': 'Week 12'}, {'measure': 'Percent Change From Baseline in Inflammatory Lesion Counts', 'description': 'Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.', 'timeFrame': 'Week 12'}, {'measure': 'Percent Change From Baseline in Non-inflammatory Lesion Counts', 'description': 'Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.', 'timeFrame': 'Week 12'}]",7,12 Years,,ALL,False,"Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.",INDUSTRY,0,692.0,ESTIMATED,2025-09-01T16:18:24.750205,v2_robust,True,True,False,False,False,
NCT00459901,Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer,"Phase II Trial of OSI-774 (Erlotinib, Tarceva™,) and Capecitabine for Patients With Previously Untreated Metastatic Colorectal Cancer",Erlotinib and capecitabine,['Erlotinib and capecitabine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Colorectal Cancer,['Metastatic Colorectal Cancer'],['Metastatic Colorectal Cancer'],TERMINATED,Study halted by drug manufacturer,2004-06,2005-06,"[{'measure': 'To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer', 'timeFrame': 'Time to tumor progression, time to confirmed response rate, time to treatment failure, .'}]","[{'measure': 'To determine the qualitative and quantitative toxicity of this combination and sequence of drug administration', 'timeFrame': 'Objective response rate, duration of confirmed response rate, CEA response will be assessed.'}]",2,18 Years,,ALL,False,Peter Kozuch,OTHER,2,13.0,ACTUAL,2025-09-01T16:18:24.750284,v2_robust,True,True,False,True,False,Study halted by drug manufacturer
NCT02004301,A Study to Investigate Delayed-release Tablets,"A Pilot Pharmacoscintigraphic Clinical Study to Investigate the Behaviour of Delayed-release Tablets Consisting of a Diclofenac Potassium Core Coated With Barrier Granules, in Healthy Volunteers",Radiolabelled T4 Tablet,"['Delayed release diclofenac potassium tablet', 'Radiolabelled T6 Tablet', 'Radiolabelled T4 Tablet']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Pain,['Pain'],"['Formulation behaviour', 'Drug absorption profile']",COMPLETED,,2014-01,2014-03,"[{'measure': 'Scintigraphic analysis of time and site of onset and complete release of radiolabel', 'timeFrame': '15 hours'}]","[{'measure': 'Pharmacokinetic (PK) absorption profiles and parameters of diclofenac', 'timeFrame': '15 hours'}]",2,18 Years,45 Years,MALE,True,BDD Pharma Ltd,INDUSTRY,1,12.0,ACTUAL,2025-09-01T16:18:24.750342,v2_robust,True,True,True,False,False,
NCT03307512,"PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD","Samba-AC: A Randomized, Open-Label, Cross-Over Study to Investigate the PK and PD Profiles of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Healthy Subjects and Non-Diabetic Subjects With Mild to Moderate Asthma or COPD",inhaled human insulin,"['inhaled human insulin', 'Dance 501', 'Insulin Lispro (Humalog U-100)', 'Lispro']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Safety and Tolerability,['Safety and Tolerability'],"['inhaled insulin', 'asthma', 'COPD']",TERMINATED,Termination due to incomplete enrollment; planned data analysis not performed,2018-02-06,2019-08-30,"[{'measure': 'Area under the insulin curve (AUC)', 'description': 'Area under the insulin curve (AUC)', 'timeFrame': '10 hours'}, {'measure': 'Area under the glucose infusion rate curve (GIR)', 'description': 'Area under the glucose infusion rate curve (GIR)', 'timeFrame': '10 hours'}]","[{'measure': 'Area under the insulin curve following inhalation of salbutamol', 'description': 'Area under the insulin curve following inhalation of salbutamol in subjects with asthma', 'timeFrame': '10 hours'}]",3,30 Years,70 Years,ALL,True,Dance Biopharm Inc.,INDUSTRY,1,40.0,ACTUAL,2025-09-01T16:18:24.750492,v2_robust,True,True,False,True,False,Termination due to incomplete enrollment; planned data analysis not performed
NCT02614612,Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD,"A Randomized, Parallel-Cohort Phase 1 Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute Graft Versus Host Disease",Itacitinib (200 mg),"['prednisone or methylprednisolone (corticosteroids)', 'INCB039110', 'Itacitinib (200 mg)', 'Itacitinib (300 mg)']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Graft-versus-host Disease (GVHD),['Graft-versus-host Disease (GVHD)'],['Acute Graft Versus Host Disease'],COMPLETED,,2015-12,2018-08,"[{'measure': 'Assess safety and tolerability of study treatment as measured by the frequency and severity of adverse events and serious adverse events', 'timeFrame': 'First dose of study drug to 30 days after the last dose of study drug'}]","[{'measure': 'Overall Response Rate (ORR)', 'timeFrame': 'Days 14, 28, 56 and 100'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of the two treatment groups Itacitinib', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'Time to Reach the Maximum Plasma Concentration (Tmax) of the two treatment groups Itacitinib', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'Area Under the Plasma Concentration-time Curve (AUC) of the two treatment groups Itacitinib', 'timeFrame': 'Day 1 and Day 7'}, {'measure': 'Minimum observed plasma concentration (Cmin) of the two treatment groups Itacitinib', 'timeFrame': 'Day 1 and Day 7'}]",6,18 Years,,ALL,False,Incyte Corporation,INDUSTRY,0,31.0,ACTUAL,2025-09-01T16:18:24.750533,v2_robust,True,True,True,False,True,
NCT04257812,Monitoring of Ceftolozane-Tazobactam Plasmatic Levels in Critical Patients,Monitoring of Ceftolozane-Tazobactam Plasmatic Levels in Critical Patients,Ceftolozane/tazobactam,['Ceftolozane/tazobactam'],1,OBSERVATIONAL,[],,,Serious Infection,['Serious Infection'],"['Ceftolozane-Tazobactam', 'Plasmatic Levels', 'Serious Infection', 'Dose adjustment']",UNKNOWN,,2020-02-15,2022-06-15,"[{'measure': 'Determine the Ceftolozane-Tazobactam seric concentrations and analyse the clinic impact that could have the dose regimens used until now.', 'description': 'Determination of the Ceftolozane-Tazobactam seric concentration by collecting 4 blood samples and measuring its antibiotic levels and if it´s achieved an adequate therapeutic efficacy assessed by the patient´s clinical and microbiological recovery.\n\nThe dose regimens used until now are 1+0,5 g every 8 hours in case of intra-abdominal infection or complicated urinary infection and 2 +1 g every 8 hours in case of pneumonia or septic shock of any focus.', 'timeFrame': 'Up to 12 months after the antibiotic administration'}]","[{'measure': 'Analyse if with both dose regimens are achieved the PK/PD parameters associated with the maximum therapeutic efficacy in patients with renal hyper clearance.', 'description': 'Determine if with both dose regimens are achieve the pharmacodynamic and pharmacokinetic parameters associated with the maximum therapeutic efficacy in patients that have creatinine clearance above 130 ml/min.', 'timeFrame': 'Up to 12 months after the antibiotic administration'}, {'measure': 'Determine the Ceftolozane-Tazobactam seric concentrations and analyse if with both dose regimens are achieved the PK/PD parameters associated with the maximum therapeutic efficacy in patients with morbid obesity.', 'description': 'Determination of the Ceftolozane-Tazobactam seric concentration by collecting 4 blood samples and measuring its antibiotic levels and if with both dose regimens are achieve the pharmacodynamic and pharmacokinetic parameters associated with the maximum therapeutic efficacy in patients that have BMI (body mass index) above 40', 'timeFrame': 'Up to 12 months after the antibiotic administration'}, {'measure': 'Determine the Ceftolozane-Tazobactam seric concentrations and analyse if with both dose regimens are achieved the PK/PD parameters associated with the maximum therapeutic efficacy in patients with continuous renal replacement technique.', 'description': 'Determination of the Ceftolozane-Tazobactam seric concentration by collecting 4 blood samples and measuring its antibiotic levels and if with both dose regimens are achieve the pharmacodynamic and pharmacokinetic parameters associated with the maximum therapeutic efficacy in patients that have their blood purified extracorporeally, replacing the renal function continuously 24 hours of the day.', 'timeFrame': 'Up to 12 months after the antibiotic administration'}, {'measure': 'Determine if in patients with Gram-negative bacillary bacteremia are achieved concentrations that are 100 % of the time 4 times above the minimum inhibitory concentration (MIC).', 'description': 'Determination of if in patients with Gram-negative bacillary bacteremia (patients with their bloodstream invaded by Gram-negative bacillary which is diagnosed by blood culture) are achieved concentrations that are 100 % of the time 4 times above the MIC by strips of isolated pathogen gradient .', 'timeFrame': 'Up to 12 months after the antibiotic administration'}, {'measure': 'Determine by a Monte Carlo simulation model the dose regimen that should be used.', 'description': 'Determination by a Monte Carlo simulation model of the dose regimen that should be used based on the pharmacokinetic parameters and according to the defined efficacy pharmacodynamic parameters.', 'timeFrame': 'Up to 12 months after the antibiotic administration'}, {'measure': 'Describe the frequency of resistance´s development during the Ceftolozane-Tazobactam treatment and, if it´s possible to evaluate if there´s a correlation with the seric levels.', 'description': 'Description of the rate of resistance´s development during the Ceftolozane-Tazobactam and if there´s a correlation with the Ceftolozane-Tazobactam seric levels.', 'timeFrame': 'Up to 12 months after the antibiotic administration'}, {'measure': 'Describe the Ceftolozane-Tazobactam treatment´s clinical result as well as existence of adverse effects.', 'description': 'Description of the Ceftolozane-Tazobactam clinical results as well as the rate and seriousness of adverse effects.', 'timeFrame': 'Up to 12 months after the antibiotic administration'}]",8,18 Years,,ALL,False,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:24.750541,v2_robust,False,True,False,False,True,
NCT04432012,A Study to Compare Different Ways of Steroid Administration After Total Knee Implantation,"Comparison of Perioperative Intravenous vs Periarticular Dexamethasone vs no Steroid Supplementation in Terms of Post-operative Pain, Function, Nausea, Hospitalization Length, and Risk of Complications in Patients Undergoing Primary Total Knee Arthroplasty for Knee Osteoarthritis - A Randomized Controlled Trial Clinical Study Protocol",Dexamethasone Sodium Phosphate 4 mg/ml intravenous,"['Dexamethasone Sodium Phosphate 4 mg/ml intra-articular', 'Mephameson', 'Dexamethasone Sodium Phosphate 4 mg/ml intravenous']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Total Knee Replacement,['Total Knee Replacement'],"['Knee', 'surgery', 'replacement', 'arthroplasty']",RECRUITING,,2020-07-01,2033-04-30,"[{'measure': 'Mean daily pain at rest during the first 3 days on a 0-10 numeric rating scale', 'description': 'Mean daily pain at rest during the first 3 days reported on a 0-10 numeric rating scale (NRS) by the patients.\n\nThe 0-10 NRS consists in a single 11-point numeric scale, with 0 indicating no pain and 10 reflecting the worst possible pain.', 'timeFrame': '3 days after surgery'}]","[{'measure': 'Post-operative knee pain during the first 6 weeks after surgery on a 0-10 numeric rating scale', 'description': 'Pain reported on 0-10 numeric rating scale (NRS) during the first 6 weeks and documented with a mobile application (developed at our Institution) that will ask the patients to report pain twice a day (once in the morning, once in the evening). Comparison will be performed in terms of mean daily pain during the first 6 weeks and mean daily pain during every single week.\n\nThe 0-10 NRS consists in a single 11-point numeric scale, with 0 indicating no pain and 10 reflecting the worst possible pain.', 'timeFrame': '6 weeks after surgery'}, {'measure': 'Post-operative knee pain during the first 10 years after surgery', 'description': 'reported on 0-10 NRS at 3, 6, 12, 24, 60 and 120 months using a questionnaire. The 0-10 NRS consists in a single 11-point numeric scale, with 0 indicating no pain and 10 reflecting the worst possible pain.', 'timeFrame': '10 years'}, {'measure': 'Post-operative function during the first 6 weeks after surgery', 'description': 'reported on 0-10 NRS 8see above) during the first 6 weeks, documented with a mobile application developed by our institution that will ask the patients to report pain twice a day (once in the morning, once in the evening). Comparison will be performed in terms of mean daily pain during the first 6 weeks and mean daily pain during every single week. Furthermore, pain trajectories will be created.\n\nThe 0-10 NRS consists in a single 11-point numeric scale, with 0 indicating the worst possible function and 10 reflecting the best possible function.', 'timeFrame': '6 weeks'}, {'measure': 'Post-operative knee function during the first 10 years after surgery', 'description': 'reported on 0-10 NRS at 3, 6, 12, 24, 60 and 120 months using a questionnaire. The 0-10 NRS consists in a single 11-point numeric scale, with 0 indicating the worst possible function and 10 reflecting the best possible function.', 'timeFrame': '10 years'}, {'measure': 'Post-operative knee outcome on Western Ontario and McMaster Universities Arthritis Index (WOMAC)', 'description': 'Questionnaire at 2 and 6 weeks, and at 3, 6, 12, 24, 60 and 120 months. The WOMAC questionnaire is composed of 3 sub-scores that evaluate pain (5 questions, 0-20 points), stiffness (2 questions, 0-8 points), and function (17 questions, 0-68 points) and is a validated patient-reported outcome measure (PROM) to evaluate knee osteoarthritis.\n\nHigher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.', 'timeFrame': '10 years'}, {'measure': 'Knee conditions on Knee society score (KSS)', 'description': 'Questionnaire at 2 and 6 weeks, and at 3, 6, 12, 24, 60 and 120 months. The original KSS has a ""Knee Score"" section (7 items) and a ""Functional Score"" section (3 items). Both sections are scored from 0 to 100 with lower scores being indicative of worse knee conditions and higher scores being indicative of better knee conditions.', 'timeFrame': '10 years'}, {'measure': 'Quality of pain on PainDETECT questionnaire', 'description': 'Questionnaire at 2 and 6 weeks, and at 3, 6, 12, 24, 60 and 120 months. PainDETECT consists of seven questions that address the quality of pain symptoms; it is completed by the patient and no physical examination is required. A score ≤12 indicates that pain is unlikely to have a neuropathic component (\\< 15%), while a score of ≥19 suggests that pain is likely to have a neuropathic component (\\> 90%). An intermediate score (≥13, ≤18) indicates a possible neuropathic component .', 'timeFrame': '10 years'}, {'measure': 'Patient satisfaction: numeric rating scale (NRS)', 'description': 'Patient satisfaction reported on 0-10 numeric rating scale (NRS) at 3, 6, 12, 24, 60 and 120 months using a questionnaire.\n\nThe 0-10 NRS consists in a single 11-point numeric scale, with 0 indicating that patient is not satisfied at all and 10 reflecting that patient is totally satisfied.', 'timeFrame': '10 years'}, {'measure': 'Post-operative nausea incidence', 'description': 'incidence (on a 0-10 NRS) of nausea will be evaluated in the first post-operative days.\n\nThe 0-10 NRS consists in a single 11-point numeric scale, with 0 indicating no nausea and 10 reflecting the maximum intensity of nausea.', 'timeFrame': 'During Hospitalization, approximately 3 days'}, {'measure': 'Post-operative nausea intensity', 'description': 'intensity (on a 0-10 NRS) of nausea will be evaluated in the first post-operative days.\n\nThe 0-10 NRS consists in a single 11-point numeric scale, with 0 indicating no nausea and 10 reflecting the maximum intensity of nausea.', 'timeFrame': 'During Hospitalization, approximately 3 days'}, {'measure': 'Post-operative opioids and analgesic drugs consumption', 'description': 'Medication Quantification Scale (MQS) score will be used to evaluate analgesic drug consumption.\n\nMedication Quantification Scale (MQS) scor is calculated for each medication by taking a consensus-based detriment weight for a given pharmacologic class and multiplying it by a score for dosage. The calculated values for each medication are then summed for a total MQS score. The score can provide a useful point measure of medication usage for any pain medication regimen.', 'timeFrame': 'During Hospitalization, approximately 3 days'}, {'measure': 'Post-operative C-Reactive Protein (CRP)', 'description': 'Hematic C-Reactive Protein in mg/L will be evaluated as index of post-operative inflammatory response.', 'timeFrame': 'every days 3 days from surgery'}, {'measure': 'Post-operative erythrocyte sedimentation rate (ESR)', 'description': 'Erythrocyte sedimentation rate (mm/h) will be evaluated as index of post-operative inflammatory response.', 'timeFrame': 'every days 3 days from surgery'}, {'measure': 'Time from surgery to first mobilization', 'timeFrame': 'During Hospitalization, approximately 1 days'}, {'measure': 'Time needed for climbing stairs the first time', 'timeFrame': 'approximately 1 week'}, {'measure': 'Length of hospital stay', 'timeFrame': 'approximately 1 week'}]",17,50 Years,85 Years,ALL,False,Christian Candrian,OTHER,0,159.0,ESTIMATED,2025-09-01T16:18:24.750595,v2_robust,True,True,False,False,False,
NCT00955812,STAT3 Inhibitor for Solid Tumors,"A Phase I, Open-label, Dose Escalation, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity, and Maximum Tolerated Dose of OPB-31121 in Subjects With Advanced Solid Tumors",OPB-31121,['OPB-31121'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Cancer,"['Advanced Cancer', 'Solid Tumor']","['OPB-31121', 'Advanced Solid Tumor', 'STAT3', 'IL-6-induced STAT3 phosphorylation']",COMPLETED,,2009-06,2012-11,"[{'measure': 'Maximum Tolerated Dose (MTD) of OPB-31121', 'description': 'The MTD is defined as the highest dose level at which \\< 2 of 6 subjects experience dose limiting toxicity (DLT) during the first cycle.', 'timeFrame': '4 Week Cycle'}]",[],1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,24.0,ACTUAL,2025-09-01T16:18:24.750677,v2_robust,True,True,True,False,False,
NCT01841112,"Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers","Safety, Tolerability and Pharmacokinetics of Single Oral Doses of BI 409306 (Tablet) in Healthy Chinese and Japanese Male Volunteers and Multiple Oral Doses of BI 409306 (Tablet) in Healthy Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)",Placebo,"['BI-409306 25 milligram (mg) SD', 'BI-409306 100 mg SD', 'Placebo', 'BI-409306 100 mg MD', 'BI-409306 50 mg SD']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2013-04-22,2013-07-18,"[{'measure': 'Percentage (%) of Subjects With Drug-related Adverse Events (AEs)', 'description': 'Percentage (%) of subjects with drug-related adverse events (AEs).', 'timeFrame': 'From first drug administration until 11 days after last dose of study medication, up to 18 days.'}]","[{'measure': 'Maximum Measured Concentration of a Single Dose of BI 409306 in Plasma (Cmax)', 'description': 'Maximum measured concentration of a single dose of BI 409306 in plasma (Cmax).', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Area Under the Concentration-time Curve of a Single Dose of BI 409306 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)', 'description': 'Area under the concentration-time curve of a single dose of BI 409306 in plasma over the time interval from 0 extrapolated to infinity (AUC 0-infinity).', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Area Under the Concentration-time Curve of a Single Dose of BI 409306 in Plasma Over the Time Interval 0 to the Last Quantifiable Data Point (AUC0-tz)', 'description': 'Area under the concentration-time curve of a single dose of BI 409306 in plasma over the time interval 0 to the last quantifiable data point (AUC0-tz).', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Maximum Measured Concentration of the Metabolite CD 13896 in Plasma (Cmax)', 'description': 'Maximum measured concentration of the metabolite CD 13896 in plasma (Cmax) after single administration of BI 409306.', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Maximum Measured Concentration of the Metabolite CD 14084 in Plasma (Cmax)', 'description': 'Maximum measured concentration of the metabolite CD 14084 in plasma (Cmax) after single administration of BI 409306.', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Area Under the Concentration-time Curve of the Metabolite CD 13896 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)', 'description': 'Area under the concentration-time curve of the metabolite CD 13896 in plasma over the time interval from 0 extrapolated to infinity (AUC 0-infinity) after single administration of BI 409306.', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Area Under the Concentration-time Curve of the Metabolite CD 14084 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)', 'description': 'Area under the concentration-time curve of the metabolite CD 14084 in plasma over the time interval from 0 extrapolated to infinity (AUC 0-infinity) after single administration of BI 409306.', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Area Under the Concentration-time Curve of the Metabolite CD 13896 in Plasma Over the Time Interval 0 to the Last Quantifiable Data Point (AUC0-tz).', 'description': 'Area under the concentration-time curve of the metabolite CD 13896 in plasma over the time interval 0 to the last quantifiable data point (AUC0-tz) after single administration of BI 409306.', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}, {'measure': 'Area Under the Concentration-time Curve of the Metabolite CD 14084 in Plasma Over the Time Interval 0 to the Last Quantifiable Data Point (AUC0-tz).', 'description': 'Area under the concentration-time curve of the metabolite CD 14084 in plasma over the time interval 0 to the last quantifiable data point (AUC0-tz) after single administration of BI 409306.', 'timeFrame': 'PK plasma samples: 2 hours before drug administration and 10, 20, 30, 45 minutes, 1, 1:30, 2, 2:30, 3, 4, 6, 8, 10, 12, 14, 24 hours for SD segment after drug administration.'}]",10,20 Years,45 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,65.0,ACTUAL,2025-09-01T16:18:24.750711,v2_robust,True,True,True,False,True,
NCT00188812,Safety of Donepezil in Patients With Dementia Associated With Cerebrovascular Disease,"Open-Label, Multicentre, One Year Extension of the Evaluation of the Safety of Donepezil Hcl in Patients With Dementia Associated With Cerebrovascular Disease",donepezil hcl,['donepezil hcl'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Dementia Associated With Cerebrovascular Disease,['Dementia Associated With Cerebrovascular Disease'],"['dementia', 'stroke']",COMPLETED,,2004-05,2005-08,[{'measure': 'safety assessments'}],[],1,45 Years,,ALL,,"University Health Network, Toronto",OTHER,1,,,2025-09-01T16:18:24.750842,v2_robust,True,True,True,False,True,
NCT02929212,Effect of Number of Meals on Metabolism After Weight Loss Surgery,Effect of Number of Meals on Metabolism After Weight Loss Surgery,Acetaminophen,['Acetaminophen'],1,INTERVENTIONAL,['NA'],,,Morbid Obesity,['Morbid Obesity'],"['Gastric Bypass', 'Meal Texture', 'Meal Number', 'GLP-1', 'Glucose']",COMPLETED,,2009-09,2014-04,"[{'measure': 'Difference in GLP-1 levels before and after gastric bypass surgery', 'description': 'Investigators will assess GLP-1 levels in subjects pre and post-GBP', 'timeFrame': '12-15 months'}, {'measure': 'Difference in glucose levels before and after gastric bypass surgery', 'description': 'Investigators will assess glucose in subjects pre and post-GBP', 'timeFrame': '12-15 months'}, {'measure': 'Difference in insulin levels before and after gastric bypass surgery', 'description': 'Investigators will assess insulin levels in subjects pre and post-GBP', 'timeFrame': '12-15 months'}]","[{'measure': 'Difference in GLP-1 levels in solid vs liquid meals', 'description': 'Investigators will assess GLP-1 levels in subjects eating either liquid or solid meals at both pre-surgery and post-surgery time points', 'timeFrame': '12-15 months'}, {'measure': 'Difference in glucose levels in solid vs liquid meals', 'description': 'Investigators will assess glucose levels in subjects eating either liquid or solid meals at both pre-surgery and post-surgery time points', 'timeFrame': '12-15 months'}, {'measure': 'Difference in insulin levels in solid vs liquid meals', 'description': 'Investigators will assess insulin levels in subjects eating either liquid or solid meals at both pre-surgery and post-surgery time points', 'timeFrame': '12-15 months'}]",6,21 Years,60 Years,ALL,False,Columbia University,OTHER,1,33.0,ACTUAL,2025-09-01T16:18:24.750863,v2_robust,True,True,True,False,False,
NCT03931681,A Study of OKI-179 in Patients With Solid Tumors,A Phase 1 Study of OKI-179 as a Single Agent in Patients With Advanced Solid Tumors,OKI-179,['OKI-179'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumors,['Advanced Solid Tumors'],[],COMPLETED,,2019-05-08,2021-11-27,"[{'measure': 'Determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)', 'description': 'Tolerability', 'timeFrame': '2 years'}, {'measure': 'Determine the safety of the drug according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5', 'description': '* Incidence and severity of adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5\n* Incidence and severity of Serious Adverse Events\n* Incidence and severity of dose-limiting toxicities (DLTs)\n* Findings of changes in clinical laboratory abnormalities\n* Changes in triplicate 12-lead electrocardiogram (ECG) parameters\n* Changes in the Eastern Cooperative Oncology Group (ECOG) performance status (PS)\n* Changes in physical examination findings', 'timeFrame': '2 years'}]","[{'measure': 'Maximum Concentration (Cmax) of OKI-179 and OKI-006 in Plasma', 'description': 'Plasma concentrations of OKI-179 and OKI-006 will be measured to determine the maximum observed concentration for each compound.', 'timeFrame': '2 years'}, {'measure': 'Area Under the Curve (AUC) for OKI-179 and OKI-006 in Plasma', 'description': 'Plasma concentrations of OKI-179 and OKI-006 will be measured to determine the AUC for each compound.', 'timeFrame': '2 years'}, {'measure': 'Area Under the Curve (AUC) for OKI-179 and OKI-006 in Urine', 'description': 'Urine concentrations of OKI-179 and OKI-006 will be measured to determine the AUC for each compound.', 'timeFrame': '2 years'}, {'measure': 'Time to Maximum Concentration (Tmax) for OKI-179 and OKI-006 in Plasma', 'description': 'Plasma concentrations of OKI-179 and OKI-006 will be measured to determine the Tmax for each compound.', 'timeFrame': '2 years'}, {'measure': 'Time to Maximum Concentration (Tmax) for OKI-179 and OKI-006 in Urine', 'description': 'Urine concentrations of OKI-179 and OKI-006 will be measured to determine the Tmax for each compound.', 'timeFrame': '2 years'}, {'measure': 'Efficacy as measured by periodic CT/MRI scans using the revised Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1', 'description': '* Fraction of patients who have a Complete Response\n* Fraction of patients who have a Partial Response\n* Duration of response (DOR)\n* Progression free survival\n* Overall survival', 'timeFrame': '2 years'}]",8,18 Years,,ALL,False,"OnKure, Inc.",INDUSTRY,1,34.0,ACTUAL,2025-09-01T16:18:24.751022,v2_robust,True,True,True,False,True,
NCT03258281,Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus,Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus After Elective Percutaneous Coronary Intervention,Evolocumab,"['Repatha', 'Evolocumab', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2', 'Dyslipidemia Associated With Type II Diabetes Mellitus', 'Percutaneous Coronary Intervention']",[],TERMINATED,Low enrollment,2018-05-01,2019-10-01,"[{'measure': 'Change From Baseline in Adenosine Diphosphate (ADP) Stimulated P-selectin Expression', 'description': 'Change from baseline in ADP-stimulated P-selectin expression (% Positive Cells) as measured by flow cytometry between treatment groups (420 mg evolocumab treatment and placebo).', 'timeFrame': 'Baseline and after 30 days of treatment'}]","[{'measure': 'Change in ADP-unstimulated P-selectin Expression', 'description': 'Change in ADP-unstimulated P-selectin expression (% Positive Cells) between treatment groups (420 mg evolocumab treatment and placebo)', 'timeFrame': 'Baseline and after 30 days of treatment'}, {'measure': 'Change in ADP-stimulated Lectin-like oxLDL [Oxidized Low-density Lipoprotein] Receptor-1 Mean Fluorescence Intensity (MFI)', 'description': 'Change in ADP-stimulated LOX-1 (MFI) as measured by flow cytometry between treatment groups (420 mg evolocumab treatment and placebo)', 'timeFrame': 'Baseline and after 30 days of treatment'}, {'measure': 'Change in ADP-stimulated Cluster of Differentiation (CD)-147 MFI', 'description': 'Change in ADP-stimulated CD-147 mean fluorescence intensity (MFI) as measured by flow cytometry between treatment groups (420 mg evolocumab treatment and placebo)', 'timeFrame': 'Baseline and after 30 days of treatment'}]",4,,,ALL,False,Inova Health Care Services,OTHER,0,4.0,ACTUAL,2025-09-01T16:18:24.751055,v2_robust,True,True,False,True,False,Low enrollment
NCT00003881,Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,"Phase II Pilot Trial of Carboplatin, Paclitaxel, and Herceptin in HER2/Neu (+) Advanced NSCLC",carboplatin,"['paclitaxel', 'carboplatin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Lung Cancer,['Lung Cancer'],"['recurrent non-small cell lung cancer', 'stage IIIB non-small cell lung cancer', 'stage IV non-small cell lung cancer']",COMPLETED,,1999-05,2004-07,[],[],0,18 Years,,ALL,False,Eastern Cooperative Oncology Group,NETWORK,1,,,2025-09-01T16:18:24.751097,v2_robust,True,True,True,False,False,
NCT01505881,Follow on Study From RE-ALIGN,Evaluation of the Long Term Safety of the Use of Dabigatran Etexilate in Patients With a Bileaflet Mechanical Heart Valve,dabigatran etexilate low dose,"['warfarin 1mg', 'dabigatran etexilate intermediate dose', 'warfarin 5mg', 'warfarin 3mg', 'dabigatran etexilate low dose', 'dabigatran etexilate high dose']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Thromboembolism,"['Thromboembolism', 'Heart Valve Prosthesis']",[],TERMINATED,,2011-12,2013-06,"[{'measure': 'Percentage of Patients With Any Adverse Event (AE)', 'description': 'Percentage of patients with Adverse Events. Prespecified clinical outcome events were not recorded as Adverse Events.', 'timeFrame': 'From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)'}]","[{'measure': 'Percentage of Patients With AEs Leading to Discontinuation of Trial Drug', 'description': 'Percentage of patients with Adverse Events leading to discontinuation of trial drug.\n\nPrespecified clinical outcome events were not recorded as Adverse Events.', 'timeFrame': 'From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)'}, {'measure': 'Percentage of Patients With Serious AEs', 'description': 'Percentage of patients with Serious Adverse Events (SAE). Prespecified clinical outcome events were not recorded as Adverse Events.', 'timeFrame': 'From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)'}, {'measure': 'Percentage of Deaths, Venous Thromboembolism (VTE), Myocardial Infarction (MI), Transient Ischaemic Attacks (TIA), Strokes, Systemic Embolism, and Valve Thrombosis.', 'description': 'Clinical efficacy outcome events presented are:\n\nDeath, Venous thromboembolism (VTE), Myocardial Infarction (MI), Transient Ischaemic Attack (TIA), Stroke, Systemic embolism and Valve thrombosis', 'timeFrame': 'From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days)'}]",4,18 Years,75 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,158.0,ACTUAL,2025-09-01T16:18:24.751146,v2_robust,True,True,False,True,True,
NCT02077881,Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas,Nab-Paclitaxel,"['Gemzar', 'Paclitaxel', 'Indoximod', 'D-1MT', 'Nab-Paclitaxel', 'Gemcitabine', 'Abraxane', '1-methyl-D-tryptophan']",8,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Metastatic Pancreatic Adenocarcinoma,"['Metastatic Pancreatic Adenocarcinoma', 'Metastatic Pancreatic Cancer']","['metastatic', 'metastasis', 'Pancreatic', 'Pancreas', 'Cancer', 'adenocarcinoma']",COMPLETED,,2014-08,2018-10-17,"[{'measure': 'Phase 2 Dosing', 'description': 'Phase 1 component:\n\nTo determine recommended phase 2 dose of indoximod when administered with a standard of care chemotherapy backbone consisting of gemcitabine plus nab-paclitaxel.', 'timeFrame': '10 months'}, {'measure': 'Regimen Limiting Toxicity', 'description': 'Phase 1 component:\n\nTo identify the regimen limiting toxicity (RLT) for the combination of the immunotherapeutic agent indoximod when administered in combination with standard of care chemotherapy gemcitabine plus nab-paclitaxel in subjects with metastatic adenocarcinoma of the pancreas.\n\nRLT will be considered as only grade 3 and 4 toxicities that are attributable to the test agent and result in the delay of the administration of the backbone chemotherapy, gemcitabine plus nab-paclitaxel.', 'timeFrame': '10 months'}, {'measure': 'Overall Survival', 'description': 'Phase 2 component:\n\nTo evaluate efficacy as determined by overall survival (OS) in patients with metastatic adenocarcinoma of the pancreas.', 'timeFrame': '22 months'}]","[{'measure': 'Biomarker Response', 'description': 'A secondary objective is to examine biomarker responses of gemcitabine and nab-paclitaxel with indoximod through the evaluation of serum for biomarkers of IDO activity (kynurenine and tryptophan), before and after initiation of therapy through specimen collection at protocol specified timepoints.', 'timeFrame': '22 months'}, {'measure': 'Response Rate', 'description': 'To determine the response rate of the combination indoximod with gemcitabine plus nab-paclitaxel. Imaging assessments to be performed at protocol-specified time points and evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).', 'timeFrame': '22 months'}, {'measure': 'Time to Progression of Disease', 'description': 'To determine the time to progression with the combination indoximod with gemcitabine plus nab-paclitaxel. Progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).', 'timeFrame': '22 months'}]",6,18 Years,,ALL,False,NewLink Genetics Corporation,INDUSTRY,0,157.0,ACTUAL,2025-09-01T16:18:24.751213,v2_robust,True,True,True,False,False,
NCT01846481,"A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse","A Randomized, Double-blind, Placebo-controlled, Dose of RBP-8000 Following IV Cocaine to Evaluate the Pharmacokinetics Parameters of RBP-8000 and Cocaine and to Assess the Effects of Drug on Cocaine-induced Physiologic and Behavioral Effects in Cocaine Abusing Subjects",RBP-8000 100 mg,"['Cocaine', 'Benzoylmethylecgonine', 'Placebo', 'RBP-8000 200 mg', 'T172R/G173G cocaine esterase', 'RBP-8000 100 mg']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Opioid Dependence,"['Opioid Dependence', 'Opioid Related Disorders', 'Cocaine Dependence']",['Cocaine'],COMPLETED,,2013-04,2013-06,"[{'measure': 'Maximum plasma concentration (Cmax) of Cocaine, (-)Ecgonine methyl ester and RBP-8000', 'timeFrame': '21 samples from pre-dose of cocaine up to 731 minutes after start of cocaine infusion'}, {'measure': 'Time to Maximum Plasma Concentration (Tmax) of Cocaine, (-)Ecgonine methyl ester and RBP-8000', 'timeFrame': '21 samples from pre-dose of cocaine up to 731 minutes after start of cocaine infusion'}, {'measure': 'Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast) of Cocaine, (-)Ecgonine methyl ester and RBP-8000', 'timeFrame': '21 samples from pre-dose of cocaine up to 731 minutes after start of cocaine infusion'}, {'measure': 'Elimination half-life (t1/2) of Cocaine, (-)Ecgonine methyl ester and RBP-8000', 'timeFrame': '21 samples from pre-dose of cocaine up to 731 minutes after start of cocaine infusion'}, {'measure': 'Area under the plasma concentration-time curve from time 0 to theoretical infinity (AUC0-inf) of Cocaine, (-)Ecgonine methyl ester and RBP-8000', 'timeFrame': '21 samples from pre-dose of cocaine up to 731 minutes after start of cocaine infusion'}, {'measure': 'Distribution half-life (t1/2α) of Cocaine', 'timeFrame': '21 samples from pre-dose of cocaine up to 731 minutes after start of cocaine infusion'}, {'measure': 'Clearance (CL) of Cocaine, (-)Ecgonine methyl ester and RBP-8000', 'timeFrame': '21 samples from pre-dose of cocaine up to 731 minutes after start of cocaine infusion'}, {'measure': 'Volume of distribution (Vd) of Cocaine, (-)Ecgonine methyl ester and RBP-8000', 'timeFrame': '21 samples from pre-dose of cocaine up to 731 minutes after start of cocaine infusion'}, {'measure': 'Elimination rate constant (λz) of Cocaine, (-)Ecgonine methyl ester and RBP-8000', 'timeFrame': '21 samples from pre-dose of cocaine up to 731 minutes after start of cocaine infusion'}, {'measure': 'Mean residence time (MRT) of Cocaine, (-)Ecgonine methyl ester and RBP-8000', 'timeFrame': '21 samples from pre-dose of cocaine up to 731 minutes after start of cocaine infusion'}]","[{'measure': 'Behavioral effects - as Measured by the Participant Using the Brief Substance Craving Scale', 'timeFrame': 'Post dosing 30 min,1,0, 2.0, 3.0, 4.0, 7.0, 8.0, 12.0,24.0 hours'}]",11,21 Years,50 Years,ALL,True,Indivior Inc.,INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:24.751241,v2_robust,True,True,True,False,False,
NCT04079881,Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes,Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes,Insulin,"['Pre-prandial insulin', 'Insulin', 'postprandial insulin']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Type 1 Diabetes,"['Type 1 Diabetes', 'Hyperglycemia, Postprandial']","['glucagon', 'post-prandial glucose', 'type 1 diabetes']",TERMINATED,Loss of funding,2020-02-13,2020-07-01,"[{'measure': 'AUC Postprandial Glucagon', 'description': 'Glucagon levels done fasting, 30, 60, 120, and 180 minutes', 'timeFrame': '4 hours'}]","[{'measure': 'AUC Postprandial Glucose', 'description': '* Glucose done fasting, 30, 60, 120, and 180 minutes\n* Glucagon levels done fasting, 30, 60, 120, and 180 minutes\n* Usual insulin dose will be administered 20 minutes before or after the mixed meal challenge with Ensure Plus\\*', 'timeFrame': '4 hours'}]",2,18 Years,90 Years,ALL,False,Washington University School of Medicine,OTHER,0,1.0,ACTUAL,2025-09-01T16:18:24.751291,v2_robust,True,True,False,True,False,Loss of funding
NCT04521881,Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury in Older Adults,"Intramuscular Tranexamic Acid for the Treatment of Symptomatic Mild Traumatic Brain Injury in Older Adults: a Randomised, Double-blind, Placebo-controlled Trial",Tranexamic Acid 500 MG,['Tranexamic Acid 500 MG'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Traumatic Brain Injury,['Traumatic Brain Injury'],"['Traumatic brain injury, tranexamic acid, older adults']",UNKNOWN,,2021-04-18,2025-03-31,"[{'measure': 'Emergency department discharge', 'description': 'discharge', 'timeFrame': 'within 24 hours'}]","[{'measure': 'Intracranial bleeding on CT scan', 'description': 'any bleeding on the last scan conducted within 48 hours of randomisation', 'timeFrame': 'within 48 hours'}, {'measure': 'Head injury related death', 'description': 'In-hospital head injury-related death within 48 hours of injury', 'timeFrame': 'within 48 hours'}, {'measure': 'All cause mortality', 'description': 'Cause of death will be described', 'timeFrame': 'within 28 days'}, {'measure': 'Disability', 'description': 'The Barthel scale will be used to assess functional disability', 'timeFrame': 'within 28 days'}, {'measure': 'Global assessment of ability to self-care', 'description': 'Scale of 1 to 5', 'timeFrame': 'within 28 days'}, {'measure': 'Neurosurgery', 'description': 'receipt of neurosurgery and type', 'timeFrame': 'within 28 days'}, {'measure': 'Days in ICU', 'description': 'Number of days', 'timeFrame': 'within 28 days'}, {'measure': 'Re-admission to hospital', 'description': 'readmission after discharge', 'timeFrame': 'within 28 days'}, {'measure': 'Vascular occlusive events', 'description': 'pulmonary embolism, myocardial infarction, deep vein thrombosis and stroke', 'timeFrame': 'within 28 days'}, {'measure': 'Seizures', 'timeFrame': 'within 28 days'}, {'measure': 'Intramuscular injection site reaction', 'description': 'frequency and type of reactions', 'timeFrame': 'within 28 days'}, {'measure': 'Pneumonia', 'timeFrame': 'within 28 days'}, {'measure': 'Adverse events', 'description': 'Any untoward medical occurrence (other than pre-specified outcomes)', 'timeFrame': 'within 28 days'}, {'measure': 'Dementia', 'description': 'The occurrence of all-cause dementia will be determined 12 months after randomisation. Dementia will be identified through linkage to routinely collected health-care data.', 'timeFrame': '1 year'}]",15,50 Years,,ALL,False,London School of Hygiene and Tropical Medicine,OTHER,0,10000.0,ESTIMATED,2025-09-01T16:18:24.751407,v2_robust,True,True,False,False,True,
NCT06896981,Semaglutide in Women With Polycystic Ovary Syndrome and Obesity,Comparison Between the Effects of Low-Dose Semaglutide With Metformin vs. Metformin Alone Over Metabolic Profile in Obese Polycystic Ovary Syndrome: A Phase II Randomized Controlled Trial,Metformin with Semaglutide,['Metformin with Semaglutide'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Polycystic Ovary Syndrome (PCOS) Women,"['Polycystic Ovary Syndrome (PCOS) Women', 'Obesity']","['Polycystic ovary syndrome', 'Obesity', 'Semaglutide', 'Metformin']",RECRUITING,,2025-02-01,2025-12-31,"[{'measure': 'Weight', 'description': 'in Kg, at least 5% weight loss', 'timeFrame': '12 weeks'}, {'measure': 'Body mass index', 'description': 'Kg per meter square', 'timeFrame': '12 weeks'}, {'measure': 'Waist circumference', 'description': 'Centimeter', 'timeFrame': '12 weeks'}, {'measure': 'Hip circumference', 'description': 'Centimeter', 'timeFrame': '12 weeks'}, {'measure': 'Blood pressure', 'description': 'mm of Hg', 'timeFrame': '12 weeks'}, {'measure': 'Acanthosis nigricans', 'description': 'Present or absent', 'timeFrame': '12 weeks'}, {'measure': 'Fasting plasma glucose', 'description': 'mmol/L', 'timeFrame': '12 weeks'}, {'measure': 'Fasting insulin', 'description': 'micro international unit per mL', 'timeFrame': '12 weeks'}, {'measure': 'Homeostasis model assessment of insulin resistance', 'description': ""Using formula provided by Mathew's et al. (1985)"", 'timeFrame': '12 weeks'}, {'measure': 'Total cholesterol', 'description': 'mg/dL', 'timeFrame': '12 weeks'}, {'measure': 'HDL-cholesterol', 'description': 'mg/dL', 'timeFrame': '12 weeks'}, {'measure': 'LDL-cholesterol', 'description': 'mg/dL', 'timeFrame': '12 weeks'}, {'measure': 'Triglyceride', 'description': 'mg/dL', 'timeFrame': '12 weeks'}]","[{'measure': 'Total testosterone', 'description': 'ng/dL', 'timeFrame': '12 weeks'}, {'measure': 'Sex hormone binding globulin', 'description': 'nmol/L', 'timeFrame': '12 weeks'}, {'measure': 'Free androgen index', 'description': 'in %', 'timeFrame': '12 weeks'}, {'measure': 'Alanine amino transferase', 'description': 'U/L', 'timeFrame': '12 weeks'}]",17,10 Years,45 Years,FEMALE,False,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:24.751492,v2_robust,True,True,False,False,False,
NCT04650581,Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor,Double-Blind Placebo-Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor,Ipatasertib,"['Fulvestrant', 'Ipatasertib']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,['Breast Cancer'],[],ACTIVE_NOT_RECRUITING,,2021-01-27,2026-12-31,"[{'measure': 'Progression-free survival (PFS) using RECIST 1.1', 'timeFrame': '5 years'}]","[{'measure': 'To compare the two treatment arms with respect to investigator assessed PFS (per RECIST 1.1) in the PIK3CA/AKT1/PTEN altered cohort', 'timeFrame': '5 years'}, {'measure': 'Investigator assessed PFS (per RECIST 1.1) in the PIK3CA/AKT1/PTEN non-altered cohort', 'timeFrame': '5 years'}, {'measure': 'PFS as assessed by blinded central radiology review in all enrolled patients, PIK3CA/AKT1/PTEN altered and non-altered cohorts', 'timeFrame': '5 years'}, {'measure': 'Response rate (RR) (per RECIST 1.1)', 'timeFrame': '5 years'}, {'measure': 'Duration of Response (DoR)', 'timeFrame': '5 years'}, {'measure': 'Clinical Benefit Rate (CBR);', 'timeFrame': '5 years'}, {'measure': 'Overall survival (OS)', 'timeFrame': '5 years'}, {'measure': 'Time to commencement of subsequent line of systemic therapy or death (TSST)', 'timeFrame': '5 years'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE version 5.0', 'timeFrame': '5 years'}, {'measure': 'Quality of Life (QOL) as measured using EORTC QLQ-C30 questionnaire', 'timeFrame': '5 years'}, {'measure': 'Adverse events as measured using NCI PRO-CTCAE questionnaire', 'timeFrame': '5 years'}, {'measure': 'Economic Evaluation of healthcare utilization using average cost per study subject by treatment arm to estimate an overall mean cost per study arm.', 'timeFrame': '5 years'}, {'measure': 'Economic Evaluation of health utilities measured using EQ-5D-5L', 'timeFrame': '5 years'}]",14,18 Years,,ALL,False,Canadian Cancer Trials Group,NETWORK,1,250.0,ACTUAL,2025-09-01T16:18:24.751520,v2_robust,True,True,False,False,True,
NCT02485119,Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies,"An Open Label, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks (Q3W) in Japanese Subjects With Advanced Malignancies",BAY94-9343,['BAY94-9343'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Neoplasms,['Neoplasms'],"['BAY 94-9343', 'Anetumab ravtansine', 'ADC (Antibody Drug Conjugate)', 'Phase I', 'Japan', 'solid cancers', 'Advanced, refractory solid tumors', 'mesothelin', 'endometrial', 'adenocarcinoma of lung', 'gastrointestinal, ovarian, pancreatic, cholangio, mesothelioma and triple negative breast cancers']",COMPLETED,,2015-08-14,2017-07-04,"[{'measure': 'Number of Treatment-emergent Adverse Events (TEAEs) as a measure of safety and tolerability', 'timeFrame': 'Up to 9 weeks'}, {'measure': 'Intensity of TEAEs acc. to NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v.4.03', 'timeFrame': 'Up to 9 weeks'}, {'measure': 'Cmax (maximum drug concentration in plasma after single dose administration ) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'timeFrame': 'Cycle 1, 3 ,6: pre, 30, 60min, 1.5, 2, 3, 5, 8, 48, 96, 168 and 504 hours after the start of dosing; Cycle1,2 only: 336 hours; Cycle1 only: 24 hours (each cycle is 21 days)'}, {'measure': 'Cmax,norm (Cmax divided by dose (mg) per kg body weight) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'timeFrame': 'Cycle 1, 3 ,6: pre, 30, 60min, 1.5, 2, 3, 5, 8, 48, 96, 168 and 504 hours after the start of dosing; Cycle1,2 only: 336 hours; Cycle1 only: 24 hours (each cycle is 21 days)'}, {'measure': 'Cmax/D (Cmax divided by dose (mg)) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'timeFrame': 'Cycle 1, 3 ,6: pre, 30, 60min, 1.5, 2, 3, 5, 8, 48, 96, 168 and 504 hours after the start of dosing; Cycle1,2 only: 336 hours; Cycle1 only: 24 hours (each cycle is 21 days)'}, {'measure': 'AUC(0-tlast) (area under the plasma concentration vs time curve from time 0 to the last data point) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'timeFrame': 'Cycle 1, 3 ,6: pre, 30, 60min, 1.5, 2, 3, 5, 8, 48, 96, 168 and 504 hours after the start of dosing; Cycle1,2 only: 336 hours; Cycle1 only: 24 hours (each cycle is 21 days)'}, {'measure': 'AUC(0-tlast)norm (AUC(0-tlast) divided by dose (mg) per kg body weight) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'timeFrame': 'Cycle 1, 3 ,6: pre, 30, 60min, 1.5, 2, 3, 5, 8, 48, 96, 168 and 504 hours after the start of dosing; Cycle1,2 only: 336 hours; Cycle1 only: 24 hours (each cycle is 21 days)'}, {'measure': 'AUC(0-tlast)/D (AUC(0-tlast) divided by dose (mg)) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'timeFrame': 'Cycle 1, 3 ,6: pre, 30, 60min, 1.5, 2, 3, 5, 8, 48, 96, 168 and 504 hours after the start of dosing; Cycle1,2 only: 336 hours; Cycle1 only: 24 hours (each cycle is 21 days)'}, {'measure': 'tmax (time to reach maximum drug concentration in plasma) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'timeFrame': 'Cycle 1, 3 ,6: pre, 30, 60min, 1.5, 2, 3, 5, 8, 48, 96, 168 and 504 hours after the start of dosing; Cycle1,2 only: 336 hours; Cycle1 only: 24 hours (each cycle is 21 days)'}]","[{'measure': 'Tumor response based on RECIST (Response Evaluation Criteria in Solid Tumors)', 'timeFrame': 'Up to 9 weeks'}, {'measure': 'Level of mesothelin expression using IHC (Immunohistochemistry) staining for the tumor tissue obtained from fresh or archival tumor tissue', 'timeFrame': 'Up to 9 weeks'}, {'measure': 'Plasma levels of soluble mesothelin', 'timeFrame': 'Up to 9 weeks'}, {'measure': 'Immunogenicity evaluation based on anti-BAY94-9343 antibody count', 'timeFrame': 'Up to 9 weeks'}]",13,20 Years,,ALL,False,Bayer,INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:24.751566,v2_robust,True,True,True,False,True,
NCT01814319,Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure,Initial Study on the Use of Probenecid as a Positive Inotrope for the Treatment of Systolic Heart Failure in Stable NYHA Class II to IV Patients,Probenecid 1 gr oral twice daily,"['Probenecid 1 gr oral twice daily', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Systolic Heart Failure,['Systolic Heart Failure'],"['heart failure', 'ejection fraction equal or less than 40%']",COMPLETED,,2013-03,2015-06,"[{'measure': '6 minute walk test', 'description': 'Measure for changes in the distance that the patient can walk over 6 minutes.', 'timeFrame': '1 week'}, {'measure': 'shortness of breath', 'description': 'Measure objectively if there are changes in perceived shortness of breath using a standardized scale', 'timeFrame': '1 week'}]","[{'measure': 'Ejection fraction', 'description': 'We will measure via echocardiography the systolic function of the heart', 'timeFrame': '1 week'}, {'measure': 'beta naturietic peptide', 'description': 'We will measure for changes in the beta natuiretic peptide as a marker of cardiac function and dilatation.', 'timeFrame': '1 week'}, {'measure': 'serum electrolytes', 'description': 'We will measure several important electrolytes such as Na, K and Ca.', 'timeFrame': '1 week'}]",5,18 Years,75 Years,ALL,False,University of Cincinnati,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:24.751581,v2_robust,True,True,True,False,False,
NCT00618319,"An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)","An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment",BIIB021,"['BIIB021', 'CNF2024']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,GIST,['GIST'],[],COMPLETED,,2008-02,2010-04,"[{'measure': 'Changes in FDG-PET imaging', 'timeFrame': '28 days'}]","[{'measure': 'Characterize the safety profile of BIIB021', 'timeFrame': 'Duration of study'}]",2,18 Years,,ALL,False,Biogen,INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:24.751595,v2_robust,True,True,True,False,True,
NCT07058519,A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC,"The Efficacy and Safety of Osimertinib-based Adaptive Treatment Guided by Circulating Tumour DNA (ctDNA) Epidermal Growth Factor Receptor Mutation-positive (EGFRm) Dynamic Monitoring in Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) Participants With ctDNA EGFRm Clearance After First-line Osimertinib Plus Chemotherapy: A Phase II, Multicentre, Prospective Study (Adaptive)",Osimertinib-based adaptive treatment,"['Osimertinib-based adaptive treatment', 'Osimertinib 80 MG']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC),['Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)'],"['NSCLC', 'EGFRm+', 'Osimertinib']",NOT_YET_RECRUITING,,2025-10-26,2029-01-24,"[{'measure': 'Progression-Free Survival (PFS) in Cohort 1', 'description': 'Progression-Free Survival (PFS) is defined as the time from the first dose of osimertinib during the adaptive treatment period to the first documentation of disease progression based on investigator assessment according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, or death from any cause, whichever occurs first.', 'timeFrame': 'From initiation of osimertinib in the adaptive therapy period until radiological disease progression or death (up to 33 months).'}, {'measure': 'Time to First ctDNA EGFRm Relapse or Death in Cohort 1', 'description': 'Time to ctDNA EGFR mutation-positive (EGFRm) relapse is defined as the time from the start of osimertinib treatment in the adaptive therapy period to the first detection of EGFRm in plasma circulating tumour DNA (ctDNA), as assessed by Super ARMS PCR, or death from any cause, whichever occurs first.', 'timeFrame': 'From initiation of osimertinib in the adaptive therapy period until ctDNA EGFR mutation relapse or death (up to 33 months)'}]","[{'measure': 'Overall Survival (OS) in Cohort 1', 'description': 'Overall Survival (OS) is defined as the time from the first dose of osimertinib in the adaptive therapy period to death from any cause. The 24-month landmark survival rate will be reported.', 'timeFrame': 'From initiation of osimertinib in adaptive therapy period until death (up to 33 months)'}, {'measure': 'Cumulative Duration of Chemotherapy Holiday in Cohort 1', 'description': 'The cumulative duration (in weeks) that participants in Cohort 1 receive osimertinib monotherapy without chemotherapy will be calculated during the adaptive treatment period.', 'timeFrame': 'From start of adaptive therapy to disease progression or death (up to 33 months)'}, {'measure': 'Progression-Free Survival (PFS) in Cohort 2', 'description': 'PFS in Cohort 2 is defined as the time from the start of osimertinib plus pemetrexed maintenance therapy to the first documentation of disease progression per RECIST v1.1 or death from any cause.', 'timeFrame': 'From initiation of maintenance therapy to radiological disease progression or death (up to 33 months)'}, {'measure': 'Overall Survival (OS) in Cohort 2', 'description': 'OS is defined as the time from the first dose of osimertinib plus pemetrexed maintenance therapy to death from any cause. The 24-month landmark survival rate will be reported.', 'timeFrame': 'From initiation of maintenance therapy to death (up to 33 months)'}, {'measure': 'Change from Baseline in Health-Related Quality of Life Scores (EORTC QLQ-C30)', 'description': ""The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) (0-100) will be used to evaluate participants' health-related quality of life. Higher scores on the QLQ-C30 indicate bad life quality of patient. Change from baseline in domain scores will be analyzed. The higher the score is, the worse the quality of life is."", 'timeFrame': 'From baseline through end of treatment (up to 33 months)'}, {'measure': 'Change from Baseline in Lung Cancer-Specific Symptoms (EORTC QLQ-LC13)', 'description': 'The EORTC QLQ-LC13 questionnaire will be used to assess lung cancer-specific symptoms (e.g., cough, dyspnea), with score range 0-100. Higher scores on the QLQ-LC13 indicate worse symptom severity. Changes from baseline will be reported.', 'timeFrame': 'From baseline through end of treatment (up to 33 months)'}]",8,18 Years,,ALL,False,Shanghai Chest Hospital,OTHER,1,250.0,ESTIMATED,2025-09-01T16:18:24.751617,v2_robust,True,True,False,False,False,
NCT03006419,Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients,Basiliximab vs Reduced Dose Rabbit Antithymocyte Globulin (rRTAG): Evaluation of Efficacy and Safety Outcomes in Low Immunological Risk Living Donor Kidney Transplant: 12-month Randomized Controlled Study,Basiliximab,"['Basiliximab', 'Thymoglobulin', 'rATG', 'Simulect']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Kidney Transplant Rejection,"['Kidney Transplant Rejection', 'Kidney Transplant; Complications']","['kidney transplantation', 'induction', 'thymoglobulin', 'basiliximab', 'acute rejection', 'graft loss']",COMPLETED,,2016-12-01,2019-07-30,"[{'measure': 'Biopsy proven acute rejection', 'description': 'Acute rejection described by Banff category', 'timeFrame': '12 months following transplantation'}]","[{'measure': 'Delayed graft function', 'description': 'Dialysis during first week of transplantation', 'timeFrame': '12 months following transplantation'}, {'measure': 'Slow graft function', 'description': 'Creatinine clearance \\< 50% pretransplant during first week of transplantation', 'timeFrame': '12 months following transplantation'}, {'measure': 'Infections', 'description': 'Presence of a positive culture of any microorganism in presence of clinical symptoms', 'timeFrame': '12 months following transplantation'}, {'measure': 'Hospital admissions', 'description': 'Admission to the hospital for at least 24 hours', 'timeFrame': '12 months following transplantation'}, {'measure': 'Graft function', 'description': 'Creatinine clearance measured by MDRD-4', 'timeFrame': '12 months following transplantation'}, {'measure': 'Graft loss', 'description': 'Return to dialysis', 'timeFrame': '12 months following transplantation'}, {'measure': 'Patient survival', 'description': 'Patient Death', 'timeFrame': '12 months following transplantation'}]",8,18 Years,,ALL,False,"Coordinación de Investigación en Salud, Mexico",OTHER_GOV,0,100.0,ACTUAL,2025-09-01T16:18:24.751671,v2_robust,True,True,True,False,False,
NCT02113319,Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia,"An Open-Label, Multicenter, Phase II Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia Refractory to Conventional Chemotherapy or in Molecular Relapse. Intergroupe Français Des leucémie aiguë myéloblastique",dasatinib,['dasatinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Myelogenous Leukemia,['Acute Myelogenous Leukemia'],"['Core Binding Factors', 'Acute Myelogenous Leukemia refractory to conventional chemotherapy', 'molecular relapse']",COMPLETED,,2007-04,,"[{'measure': 'measure relapse-free survival', 'description': 'Number of Participants with Adverse Events as a Measure of Safety and Tolerability', 'timeFrame': '4 years'}]",[],1,18 Years,60 Years,ALL,False,"University Hospital, Angers",OTHER_GOV,0,27.0,ACTUAL,2025-09-01T16:18:24.751695,v2_robust,True,True,True,False,True,
NCT00667719,A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension,"A 28 to 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren / Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension",Aliskiren,"['Amlodipine', 'Hydrochlorothiazide', 'Aliskiren']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Essential Hypertension,['Essential Hypertension'],"['Essential hypertension', 'High blood pressure']",COMPLETED,,2008-06-05,2009-10-05,"[{'measure': 'Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Death', 'description': 'An AE was defined as the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug, even if the event is not considered to be related to study drug. An SAE was defined as an event which was fatal or life-threatening, resulted in persistent or significant disability/incapacity, constituted a congenital anomaly/birth defect, required inpatient hospitalization or prolongation of existing hospitalization, was medically significant, i.e. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above.', 'timeFrame': '54 weeks'}]","[{'measure': 'Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)', 'description': 'The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the participant in a sitting position for five minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.', 'timeFrame': 'Baseline, Weeks 28 and 54 endpoint'}, {'measure': 'Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)', 'description': 'The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the participant in a sitting position for five minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.', 'timeFrame': 'Baseline, Weeks 28 and 54 endpoints'}, {'measure': 'Percentage of Participants Achieving the Blood Pressure Control Target of <140/90 mmHg', 'description': 'Blood pressure control was defined as having a mean sitting diastolic blood pressure \\<90 mmHg and a mean sitting systolic blood pressure \\<140 mmHg. Percentage of participants achieving the blood pressure control of \\< 140/90 mmHg were reported. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28 and Week 54 Endpoint was the last non-missing measurement value after Week 28.', 'timeFrame': 'Weeks 28 and 54 endpoints'}, {'measure': 'Percentage of Participants Who Achieved a Blood Pressure Response in Mean Sitting Diastolic Blood Pressure', 'description': 'Diastolic Blood pressure response was defined as a mean sitting diastolic blood pressure \\<90 mmHg or a \\>=10 mmHg reduction from baseline value. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.', 'timeFrame': 'Weeks 28 and 54 endpoints'}, {'measure': 'Percentage of Participants Who Achieved a Blood Pressure Response in Mean Sitting Systolic Blood Pressure', 'description': 'Systolic blood pressure response was defined as a mean sitting systolic blood pressure \\<140 mmHg or a \\>=20 mmHg reduction from baseline value. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28.', 'timeFrame': 'Weeks 28 and 54 endpoints'}]",6,18 Years,,ALL,False,Novartis,INDUSTRY,0,564.0,ACTUAL,2025-09-01T16:18:24.751703,v2_robust,True,True,True,False,True,
NCT05949619,A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors,"A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M02D1 for Injection in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Non-small Cell Lung Cancer",BL-M02D1,['BL-M02D1'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Non-small Cell Lung Cancer,['Non-small Cell Lung Cancer'],[],RECRUITING,,2023-09-04,2025-08,"[{'measure': 'Phase Ib: Recommended Phase II Dose (RP2D)', 'description': 'The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-M02D1.', 'timeFrame': 'Up to 21 days after the first dose'}, {'measure': 'Phase II: Objective Response Rate (ORR)', 'description': 'ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.', 'timeFrame': 'Up to approximately 24 months'}]","[{'measure': 'Treatment-Emergent Adverse Event (TEAE)', 'description': 'TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M02D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M02D1.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'The DCR is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \\[PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\\]).', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Duration of Response (DOR)', 'description': ""The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first."", 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Phase Ib: Objective Response Rate (ORR)', 'description': 'ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Phase II: Progression-free Survival (PFS)', 'description': ""The PFS is defined as the time from the participant's first dose of BL-M02D1 to the first date of either disease progression or death, whichever occurs first."", 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Cmax', 'description': 'Maximum serum concentration (Cmax) of BL-M02D1 will be investigated.', 'timeFrame': 'Up to 21 days after the first dose'}, {'measure': 'Tmax', 'description': 'Time to maximum serum concentration (Tmax) of BL-M02D1 will be investigated.', 'timeFrame': 'Up to 21 days after the first dose'}, {'measure': 'Ctrough', 'description': 'Ctough is defined as the lowest serum concentration of BL-M02D1 prior to the next dose will be administered.', 'timeFrame': 'Up to 21 days after the first dose'}, {'measure': 'Phase Ib: T1/2', 'description': 'Half-life (T1/2) of BL-M02D1 will be investigated.', 'timeFrame': 'Up to 21 days after the first dose'}, {'measure': 'Phase Ib: AUC0-T', 'description': 'AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration.', 'timeFrame': 'Up to 21 days after the first dose'}, {'measure': 'Phase Ib: CL', 'description': 'CL in the serum of BL-M02D1 per unit of time will be investigated.', 'timeFrame': 'Up to 21 days after the first dose'}, {'measure': 'ADA (anti-drug antibody)', 'description': 'Frequency of anti-BL-M02D1 antibody (ADA) will be investigated.', 'timeFrame': 'Up to approximately 24 months'}]",14,18 Years,,ALL,False,"Sichuan Baili Pharmaceutical Co., Ltd.",INDUSTRY,0,60.0,ESTIMATED,2025-09-01T16:18:24.751714,v2_robust,True,True,False,False,True,
NCT00449319,AML Treatment in Untreated Adult Patients,AML Treatment in Untreated Adult Patients According to EORTC-GIMEMA Protocols AML8 and AML10,Daunorubicine,['Daunorubicine'],1,INTERVENTIONAL,['NA'],,,"Leukemia, Myelocytic, Acute","['Leukemia, Myelocytic, Acute']","['AML', 'adult', 'Hydroxyurea', 'Transplant', 'Toevaluate biological characteristics at diagnosis.', 'To identify genetic alterations with prognostic relevance.', 'To follow up cases monitoring minimal disease during remission.', 'To evaluate pretreatment therapy in terms of response rate and toxicity.', 'Disease free survival.', 'Overal survival.']",UNKNOWN,,1998-11,2018-07,[],[],0,15 Years,61 Years,ALL,False,Gruppo Italiano Malattie EMatologiche dell'Adulto,OTHER,0,,,2025-09-01T16:18:24.751762,v2_robust,True,True,False,False,False,
NCT05425719,Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects,"A Pivotal, Open Label, Multi-Center, Safety and Pharmacokinetic Study of MB-102 (Relmapirazin) and the Use of the MediBeacon Transdermal GFR Measurement System in Normal and Renal Compromised Subjects for the Evaluation of Kidney Function",MB-102,"['MB-102', 'Relmapirazin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Kidney Disease,['Chronic Kidney Disease'],"['Glomerular Filtration Rate', 'Transdermal fluorescence detection', 'Relmapirazin']",COMPLETED,,2022-06-14,2023-02-15,"[{'measure': 'Proportion of Transdermal Derived Glomerular Filtration Rate (tGFR) Values Within 30% of the nGFR Plasma-derived Indexed Glomerular Filtration Rate (nGFR) Values', 'description': 'The performance measure of P30 is defined as the proportion of transdermal derived GFR values that are within 30% of the measured plasma-derived GFR. The comparison of transdermal derived glomerular filtration rate (tGFR) with respect to the plasma-derived indexed glomerular filtration rate (nGFR) was calculated with a double-sided 95% confidence interval (CI). The performance goal was 0.85, and success for the study was defined as a lower limit of the 95% CI greater than 0.85.', 'timeFrame': 'Up to 24 hours following the study dose'}]","[{'measure': 'Number of Participants With Treatment-emergent Adverse Events Associated With MB-102 Administration', 'description': 'An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.', 'timeFrame': 'From the time of dosing through the follow-up visit, up to 10 days'}, {'measure': 'Number of Participants With Treatment-emergent Adverse Events Associated With the MediBeacon Transdermal GFR Measurement System Device', 'description': 'An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.', 'timeFrame': 'From the time of dosing through the follow-up visit, up to 10 days'}]",3,18 Years,,ALL,True,MediBeacon,INDUSTRY,0,249.0,ACTUAL,2025-09-01T16:18:24.751852,v2_robust,True,True,True,False,True,
NCT03152019,Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT),"Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT) - A Double Blind, Randomized, Placebo-controlled, Multicenter Trial",Protopic® (Tacrolimus) 0.1% ointment,"['Protopic® (Tacrolimus) 0.1% ointment', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Hemorrhagic Hereditary Telangiectasia (HHT),['Hemorrhagic Hereditary Telangiectasia (HHT)'],"['Hemorrhagic Hereditary Telangiectasia (HHT)', 'Antiangiogenic therapy', 'Tacrolimus']",COMPLETED,,2017-05-22,2018-11-08,"[{'measure': 'Percentage of Patients Experiencing an Improvement in Their Nosebleeds', 'description': 'Efficacy of tacrolimus nasal ointment on nosebleeds when administered for 6 weeks', 'timeFrame': 'up to 12 weeks'}]","[{'measure': 'Adverse Events', 'description': 'Tolerance will be evaluated by recording adverse reactions and adverse events during the treatment period and the follow up period and by clinical examinations during the follow-up period.', 'timeFrame': 'up to 12 weeks'}, {'measure': 'Number of Epistaxis', 'description': 'Evaluate efficacy on clinical criteria : epistaxis frequency before and after treatment.', 'timeFrame': 'up to 12 weeks'}, {'measure': 'Epistaxis Duration', 'description': 'To evaluate efficacy of tacrolimus nasal ointment on duration of nosebleeds before and after treatment.', 'timeFrame': 'up to 12 weeks'}, {'measure': 'Hemoglobin Level', 'description': 'before and after treatment.', 'timeFrame': 'up to 12 weeks'}, {'measure': 'Ferritin Level', 'description': 'before and after treatment.', 'timeFrame': 'up to 12 weeks'}, {'measure': 'Quality of Life Assessed by SF36 Questionnaire', 'description': 'To evaluate efficacy on quality of life with SF36 before and after treatment', 'timeFrame': 'up to 12 weeks'}, {'measure': 'Severity Epistaxis Score Assessed by ESS Questionnaire', 'description': 'To evaluate efficacy on severity epistaxis score with ESS before and after treatment.', 'timeFrame': 'up to 12 weeks'}, {'measure': 'The Percentage of Patient With Tacrolimus Detection in the Blood', 'description': 'To evaluate systemic absorption after tacrolimus nasal administrations.', 'timeFrame': 'up to 6 weeks'}, {'measure': 'the Level of Exposure of Patient With Tacrolimus Detection in the Blood.', 'description': 'To evaluate systemic absorption after tacrolimus nasal administrations.', 'timeFrame': 'up to 6 weeks'}]",10,18 Years,,ALL,False,Hospices Civils de Lyon,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:24.751887,v2_robust,True,True,True,False,True,
NCT00425919,Study Evaluating PPM-204 In Subjects With Type 2 Diabetes,"A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Safety And Efficacy Of PPM-204 In Subjects With Type 2 Diabetes",PPM-204,['PPM-204'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Diabetes Mellitus,['Diabetes Mellitus'],"['Type 2 Diabetes', 'Diabetes']",TERMINATED,Study terminated as a result of interim analysis not meeting predetermined criteria.,2007-01,2007-10,[{'measure': 'Fasting Plasma Glucose'}],"[{'measure': 'Mean changes of HbA1c, Fasting Insulin, HOMA-IR and QUICKI indices, Body weight, waist measurements, total cholesterol, LDL-C, HDL-C, total/HDL, apolipoprotein A-1 & B, triglycerides, free fatty acids, hs C-reactive protein, adiponectin, edema.'}]",2,18 Years,70 Years,ALL,False,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,500.0,,2025-09-01T16:18:24.751912,v2_robust,True,True,False,True,False,Study terminated as a result of interim analysis not meeting predetermined criteria.
NCT04383119,Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma,A Randomized Phase II Trial Comparing the Activity of trabectedIn vs Gemcitabine in Patients With Metastatic or Locally Advanced Leiomyosarcoma Pretreated With Conventional Chemotherapy,Trabectedin,"['No Intervention: Observational Cohort', 'Trabectedin arm', 'Trabectedin', 'Gemcitabine arm', 'Gemcitabine']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Leiomyosarcoma of Ovary,"['Leiomyosarcoma of Ovary', 'Soft Tissue Sarcoma']",['advanced leiomyosarcoma'],RECRUITING,,2021-10-29,2025-12-31,"[{'measure': 'Compare the Growth Modulation Index (GMI) in patients treated with Trabectedin or Gemcitabine in second line', 'description': 'Ratio of Time To Progression with the nth line (TTPn) of therapy to the TTPn-1 with the n-1th line.', 'timeFrame': 'Week 6, week 12, week 18, week 27, week 36 and week 45'}]","[{'measure': 'Overall Response Rate', 'description': 'Overall response rate according Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1', 'timeFrame': 'Week 6, week 12, week 18, week 27, week 36 and week 45'}, {'measure': 'Overall Survival (OS)', 'description': 'Survival from the first dose treatment to death for any cause', 'timeFrame': '3 years and 5 years'}, {'measure': 'Progression free Survival (PFS)', 'description': 'Survival without disease progression', 'timeFrame': '6 months'}, {'measure': 'Duration of response', 'description': 'Duration of tumor control according Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1', 'timeFrame': 'Week 6, week 12, week 18, week 27, week 36 and week 45'}, {'measure': 'Adverse events related to the treatment', 'description': 'Safety in term of adverse event is evaluate from the first treatment dose throughout the study according to CTCAE 5.0', 'timeFrame': 'Week 3, week 6, week 9, week 12, week 18, week 27, week 36, week 45'}, {'measure': 'Compare the Growth Modulation Index (GMI) in patients treated with Trabectedin or Gemcitabine after second line', 'description': 'Ratio of Time To Progression with the Mth line (TTPn) of therapy to the TTPn-1 with the n-1th line.', 'timeFrame': 'Week 6, week 12, week 18, week 27, week 36 and week 45'}]",7,18 Years,,ALL,False,Italian Sarcoma Group,NETWORK,1,100.0,ESTIMATED,2025-09-01T16:18:24.751923,v2_robust,True,True,False,False,True,
NCT02777619,Pharmacodynamic Interactions of Propofol and Dexmedetomidine on Intravenous Anesthesia,Pharmacodynamic Interactions of Propofol and Dexmedetomidine on Target-controlled Infusion Intravenous Anesthesia During the Induction,0.0ng/ml Dexmedetomidine,"['0.0ng/ml Dexmedetomidine', '0.4ng/ml Dexmedetomidine', '0.6ng/ml Dexmedetomidine', 'Propofol', '0.8ng/ml Dexmedetomidine']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Pharmacodynamic Interaction,['Pharmacodynamic Interaction'],"['Pharmacodynamic', 'Dexmedetomidine', 'Propofol', 'Target-controlled Infusion Intravenous Anesthesia']",COMPLETED,,2016-01,2016-07,"[{'measure': 'The EC50 of propofol for loss of consciousness', 'description': 'The aim of the investigators study is to define the optimum target concentration (EC50) of propofol for loss of consciousness with different dexmedetomidine target plasm concentration.', 'timeFrame': 'within 30 min during the induction of anesthesia'}]","[{'measure': 'The EC95 of propofol for loss of consciousness', 'description': 'The aim of the investigators study is to define the optimum target concentration (EC95) of propofol for loss of consciousness with different dexmedetomidine target plasm concentration.', 'timeFrame': 'within 30 min during the induction of anesthesia'}]",2,18 Years,60 Years,ALL,True,Guangzhou General Hospital of Guangzhou Military Command,OTHER,0,64.0,ACTUAL,2025-09-01T16:18:24.751950,v2_robust,True,True,True,False,False,
NCT02779530,CYP4A11 and CYP4F2 Gene Variants as Makers of Cardiovascular Adverse Events of Non-steroidal Anti-inflammatory Drugs,Evaluation of CYP4A11 and CYP4F2 Gene Variants as Makers in Edema and Elevated Blood Pressure Occurrence After Nonsteroidal Anti-inflammatory (NSAID) Use,Diclofenac,['Diclofenac'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Drug-Related Side Effects and Adverse Reactions,['Drug-Related Side Effects and Adverse Reactions'],[],COMPLETED,,2011-10,2013-07,"[{'measure': 'Edema', 'description': 'Presence of edema, measured by the estimative of total body water (deuterium oxide dilution technique). The measurements will be done in the end of 6 days of use of placebo and diclofenac, and the delta between diclofenac and placebo will be used as endpoint', 'timeFrame': 'after 6 days of diclofenac and placebo'}]","[{'measure': 'Blood Pressure', 'description': 'Variation (delta) of 24h diastolic blood pressure between placebo and diclofenac phases, measured by ambulatory blood pressure monitoring (ABPM)', 'timeFrame': 'after 6 days of diclofenac and placebo'}]",2,18 Years,65 Years,ALL,True,Eduardo Barbosa Coelho,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:24.752022,v2_robust,True,True,True,False,False,
NCT03670030,"A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System","A Pilot Phase 2 Study of Albumin-bound Rapamycin Nanoparticles, ABI-009, in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System",ABI-009,"['nab-rapamycin', 'ABI-009']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Neuroendocrine Tumors,['Neuroendocrine Tumors'],[],TERMINATED,Slow enrollment,2018-11-05,2021-02-26,"[{'measure': 'Disease Control Rate at 6 Months Per RECIST v1.1.', 'description': 'Disease control rate at 6 months is the proportion of patients who have partial or complete response or stable disease at 6 months.\n\nResponse Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', 'timeFrame': '6 months'}]","[{'measure': 'Percent of Subjects Experiencing Adverse Events', 'description': 'Percent of subjects with \\>=5% adverse events or grades 3 or 4 adverse events', 'timeFrame': 'Continuous from the signing of the informed consent to 28 days after last study treatment, on average 6 months'}]",2,18 Years,,ALL,False,Robert Ramirez,OTHER,1,5.0,ACTUAL,2025-09-01T16:18:24.752117,v2_robust,True,True,False,True,True,Slow enrollment
NCT00277030,Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams,Comparative Trial of Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams,Surfactant,['Surfactant'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Respiratory Distress Syndrome,['Respiratory Distress Syndrome'],"['Respiratory Distress Syndrome', 'Surfactant', 'Nasal CPAP']",UNKNOWN,,2006-01,,[{'measure': 'The need of intubation and surfactant administration.'}],"[{'measure': 'Mechanical ventilation and CPAP duration.'}, {'measure': 'Oxygen therapy.'}, {'measure': 'BPD incidence.'}, {'measure': 'Length of stay.'}, {'measure': 'Enteral feeding tolerance.'}, {'measure': 'Air leak.'}, {'measure': 'NEC, gastric perforation.'}, {'measure': 'Death.'}]",9,5 Minutes,1 Day,ALL,False,Pontificia Universidad Catolica de Chile,OTHER,1,110.0,,2025-09-01T16:18:24.752145,v2_robust,True,True,False,False,False,
NCT06806930,Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT),Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT),Neoadjuvant endocrine therapy,['Neoadjuvant endocrine therapy'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer Stage I,"['Breast Cancer Stage I', 'Breast Cancer Stage II', 'Breast Cancer Stage III', 'Carcinoma, Breast']","['breast', 'cancer', 'HER2', 'carcinoma']",RECRUITING,,2024-10-03,2028-10,"[{'measure': 'Response to neoadjuvant endocrine therapy (NET)', 'description': 'Response to neoadjuvant endocrine therapy is defined as clear margins (defined as greater than 1mm) measured in the surgical pathology report. The proportion of women in each cohort with response will be estimated with exact 95% binomial confidence intervals.', 'timeFrame': 'From enrollment to the end of treatment at <=52 weeks'}]","[{'measure': 'Physicians will predict PEPI score after NET for subjects enrolled in cohort B or C', 'description': ""* PEPI score is determined from surgical pathology report\n* Physicians can predict the PEPI score and drop in Ki-67 based on tumor size, biology, and patient preference for duration pre-NET. See chart:\n\nSurgical factors PEPI Score Tumor size T1/T2 1 T3/T3 3 Node Size Negative 0 Positive 3 Ki67 Level 0-2.7% 0 \\>2.7-7.3% 1 \\>7.3-19.7% 1 \\>19.7-53.1% 2 \\>53.1% 3 ER Status Negative 3\n\n• The physicians will be asked to predict whether the PEPI score post-surgery will be 0 (low risk of recurrence), 1 - 3 (intermediate risk of recurrence), \\> 4 (high risk of recurrence).\n\nThe chart above is used clarify how physicians will at the subject's PEPI score."", 'timeFrame': 'From enrollment to the end of treatment at <=52 weeks'}, {'measure': 'Physicians will predict Ki67 after NET', 'description': '* Ki67 is assessed by pathologist in the tumor specimen obtained from surgical resection\n* Physicians will be asked to predict whether Ki-67 post-surgery will fall below 15% (high proliferation fraction). (see chart above for breakdown of surgical factors and PEPI score).\n* Concordance between the physician prediction and post-surgery PEPI values will be assessed using the kappa statistic. Concordance will be assessed using the kappa statistic. Thirty women per cohort will allow estimation of the percent with response to NET with standard error \\< 0.10.', 'timeFrame': 'From enrollment to the end of treatment at <=52 weeks'}]",3,21 Years,,ALL,False,George Washington University,OTHER,0,90.0,ESTIMATED,2025-09-01T16:18:24.752214,v2_robust,True,True,False,False,False,
NCT03423030,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation","Safety, Tolerability, Pharmacokinetic Profile and Ex-vivo Antitubercular Activity of PBTZ169 Formulated as Spray- Dried Dispersion Versus Native Crystal Powder: Single Ascending Doses, Randomized, Placebo- Controlled, Cross-over Phase Ia Trial in Healthy Volunteers",PBTZ169 Formulation,"['PBTZ169 NCP', 'PBTZ169 Formulation', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Tuberculosis,"['Tuberculosis', 'Tuberculosis, Pulmonary']",[],COMPLETED,,2017-12-05,2018-03-28,"[{'measure': 'Safety and tolerability of increasing single oral doses of PBTZ169 Formulation in healthy male adult subjects evaluated by Treatment Emergent Adverse Events (TEAEs).', 'description': 'Evaluation by thorough monitoring of Treatment Emergent Adverse Events (TEAEs) following doses of PBTZ169 Formulation, PBTZ169 NCP or placebo', 'timeFrame': 'Days 0-17'}]","[{'measure': 'Relative oral bioavailability assessment of the PBTZ169 Formulation in comparison to NCP in healthy male subjects', 'description': 'Estimation from the ratio of area under plasma concentration curves (AUCs) determined after the administration of each formulation', 'timeFrame': 'Days 0-2'}, {'measure': 'Pharmacokinetics (PK) of single oral doses of PBTZ169 using Cmax', 'description': 'Determination of non-compartmental PK parameter Maximum Plasma Concentration \\[Cmax\\] after determination of the amount of the parent compound and its known metabolites in plasma samples', 'timeFrame': 'Days 0-2'}, {'measure': 'Pharmacokinetics (PK) of single oral doses of PBTZ169 using Tmax', 'description': 'Determination of non-compartmental PK parameter Time of maximum observed Plasma Concentration \\[Tmax\\] after determination of the amount of the parent compound and its known metabolites in plasma samples', 'timeFrame': 'Days 0-2'}, {'measure': 'Pharmacodynamics (PD) exploration after single oral doses of PBTZ169 Formulation and NCP', 'description': 'Determination of ex-vivo antitubercular activity of serum samples obtained from subjects', 'timeFrame': 'Days 0-1'}, {'measure': 'Broncho-alveolar passage exploration after single oral doses of PBTZ169 Formulation and NCP (tentative)', 'description': 'PBTZ169 concentrations in sputum samples collected by hypertonic NaCl-induction', 'timeFrame': 'Days 0-1'}]",6,18 Years,48 Years,MALE,True,Innovative Medicines for Tuberculosis,OTHER,1,32.0,ACTUAL,2025-09-01T16:18:24.752289,v2_robust,True,True,True,False,True,
NCT01634230,Emergency Use of OCR-002 in Acute Liver Failure (ALF),Emergency Use of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure,OCR-002,"['ornithine phenylacetate', 'OCR-002']",2,EXPANDED_ACCESS,[],,,Acute Liver Failure,['Acute Liver Failure'],[],NO_LONGER_AVAILABLE,,,,[],[],0,,,ALL,False,"Ocera Therapeutics, Inc.",INDUSTRY,0,,,2025-09-01T16:18:24.752320,v2_robust,False,True,False,False,False,
NCT00280930,Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer,A Randomized Feasibility Study of Letrozole in Postmenopausal Women at Increased Risk for Development of Breast Cancer as Evidenced by High Breast Density,Letrozole,['Letrozole'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Post-Menopausal,"['Post-Menopausal', 'Breast Cancer']","['letrozole', 'breast cancer', 'menopause']",UNKNOWN,,2005-10,,[{'measure': 'To determine the proportion of women with breast density of > grade 4 who have a decrease in breast density of at least one grade after treatment with letrozole for one year.'}],"[{'measure': 'To determine if the decrease in breast density grade is sustained one year after cessation of therapy'}, {'measure': 'to determine if there is a correlation between plasma estrogen profile and breast density at baseline'}, {'measure': 'to determine the percentage of subjects with breast tissue hyperplasia and atypical hyperplasia before and after therapy'}, {'measure': 'to assess change in estrogen profile from baseline and at 1 year and 1 year after cessation of therapy'}, {'measure': 'to assess the general safety of the utilization of letrozole in healthy post-menopausal women for one year'}, {'measure': 'to compare the effects on menopause-specific quality of life.'}]",7,18 Years,,FEMALE,False,Dana-Farber Cancer Institute,OTHER,3,60.0,,2025-09-01T16:18:24.752342,v2_robust,True,True,False,False,True,
NCT03677830,Postoperative Pain Control & Relief in Neonates,Postoperative Pain Control & Relief in Neonates,Acetaminophen,"['Ofirmev 10 MG/ML Injectable Solution', 'Saline', 'Acetaminophen']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pain, Postoperative","['Pain, Postoperative', 'Premature Infant', 'Opioid Use']",[],TERMINATED,Involved investigators no longer at the investigating center,2019-04-19,2024-03-07,"[{'measure': 'Total morphine exposure', 'description': 'Total amount of morphine received by infants for pain control post-operatively in mg/kg', 'timeFrame': '72 hours following surgical procedure'}]","[{'measure': 'Total ""as needed"" morphine exposure', 'description': 'Total ""as needed"" or prn doses of morphine received by infants for pain control post-operatively in mg/kg', 'timeFrame': '72 hours following surgical procedure'}]",2,,1 Month,ALL,True,St. Louis University,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:24.752357,v2_robust,True,True,False,True,False,Involved investigators no longer at the investigating center
NCT05340530,To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects,"Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of Injectable TQD3606 in a Single Center, Randomized, Double-blind, Placebo-controlled, Single, Multiple Dosing in Healthy Subjects, and to Explore Urinary Excretion of the Product",The injectable TQD3606,"['Avibactam Sodium', 'The injectable TQD3606', 'meropenem', 'Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Infections,['Infections'],[],UNKNOWN,,2022-04,2023-12,"[{'measure': 'Maximum Concentration (Cmax)', 'description': 'Maximum Concentration', 'timeFrame': '1 hour before administration，to 24 hours after administration.'}, {'measure': 'Area under the plasma concentration-time curve from initial dosing to 24 hours (AUC0-24)', 'description': 'Area under the plasma concentration-time curve from initial dosing to 24 hours', 'timeFrame': '1 hour before administration，to 24 hours after administration.'}]","[{'measure': 'Time to maximum concentration following drug administration (Tmax)', 'description': 'Time to maximum concentration following drug administration', 'timeFrame': '1 hour before administration，to 24 hours after administration.'}, {'measure': 'Apparent terminal elimination half-life following drug administration (t1/2)', 'description': 'Apparent terminal elimination half-life following drug administration', 'timeFrame': '1 hour before administration，to 24 hours after administration.'}, {'measure': 'Area under plasma concentration-time curve from first dosing to last measurable concentration point (AUC0-t)', 'description': 'Area under plasma concentration-time curve from first dosing to last measurable concentration point', 'timeFrame': '1 hour before administration，to 24 hours after administration.'}, {'measure': 'The amount of drug excreted through urine 24 hours after administration (Ae0-24)', 'description': 'The amount of drug excreted through urine 24 hours after administration', 'timeFrame': '1 hour before administration，to 24 hours after administration.'}, {'measure': 'Cumulative excretion rate of drugs through urine', 'description': 'Cumulative excretion rate of drugs through urine', 'timeFrame': '1 hour before administration，to 24 hours after administration.'}, {'measure': 'The total clearance (CLt) The total clearance (CLt)', 'description': 'The total clearance', 'timeFrame': '1 hour before administration，to 24 hours after administration.'}, {'measure': 'Renal clearance (CLr)', 'description': 'Renal clearance', 'timeFrame': '1 hour before administration，to 24 hours after administration.'}, {'measure': 'Elimination rate constant(λz)', 'description': 'Elimination rate constant', 'timeFrame': '1 hour before administration，to 24 hours after administration.'}, {'measure': 'Apparent volume of distribution (Vd/F)', 'description': 'Apparent volume of distribution', 'timeFrame': '1 hour before administration，to 24 hours after administration.'}, {'measure': 'Mean residence time (MRT)', 'description': 'Mean residence time', 'timeFrame': '1 hour before administration，to 24 hours after administration.'}, {'measure': 'Valley concentration (Cmin,ss)', 'description': 'Valley concentration', 'timeFrame': 'Within 60 minutes before 8th to 10th administration and 24 hours after 10th administration'}, {'measure': 'Accumulation index', 'description': 'Accumulation index', 'timeFrame': 'Within 60 minutes before 8th to 10th administration and 24 hours after 10th administration'}, {'measure': 'Adverse event rate', 'description': 'The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).', 'timeFrame': 'Baseline up to 24 hours after administration'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v5.0', 'description': 'Monitor the safety indicators of subjects during the trial', 'timeFrame': 'Baseline up to 24 hours after administration'}, {'measure': 'Body temperature', 'description': 'Monitor the safety indicators of subjects during the trial', 'timeFrame': '1 hour before administration and 24 hours after administration'}, {'measure': 'Pulse', 'description': 'Monitor the safety indicators of subjects during the trial', 'timeFrame': '1 hour before administration and 24 hours after administration'}, {'measure': 'Systolic and diastolic blood pressure', 'description': 'Monitor the safety indicators of subjects during the trial', 'timeFrame': '1 hour before administration and 24 hours after administration'}, {'measure': 'Number of participants with abnormal laboratory test results', 'description': 'Monitor the safety indicators of subjects during the trial', 'timeFrame': 'Baseline up to 24 hours after administration'}]",20,18 Years,55 Years,ALL,True,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",INDUSTRY,0,56.0,ESTIMATED,2025-09-01T16:18:24.752367,v2_robust,True,True,False,False,True,
NCT05360030,Mechanism of Analgesic Effect on Prolonged Continuous Theta Burst Stimulation,Mechanism of Analgesic Effect on Prolonged Continuous Theta Burst Stimulation,Naloxone,"['Saline', 'Ketamine Hydrochloride', 'Naloxone']",3,INTERVENTIONAL,['NA'],,,Chronic Pain,"['Chronic Pain', 'rTMS']",[],COMPLETED,,2022-05-14,2022-12-31,"[{'measure': 'pain intensity at baseline', 'description': 'pain intensity on a 10-cm visual analogue scale (VAS) extending from 0 (no pain) to 100 (maximal pain possible) at baseline.', 'timeFrame': 'Baseline'}, {'measure': 'pain intensity at the posttreatment of pcTBS', 'description': 'pain intensity on a 10-cm visual analogue scale (VAS) extending from 0 (no pain) to 100 (maximal pain possible) at the posttreatment of pcTBS.', 'timeFrame': 'through study completion, an average of 8 months'}]","[{'measure': 'Motor-evoked potential (MEP)', 'description': 'Corticospinal excitability will be measured with MEP at rest of the first dorsal interosseous (FDI) muscle, A total of 20 single pulses were consecutively delivered to the hand region of the left M1 at 120% RMT (45° to the midline, handle pointing backward).', 'timeFrame': 'through study completion, an average of 8 months'}, {'measure': 'Cortical silent period (CSP)', 'description': 'Corticospinal excitability will be measured with CSP during a sustained voluntary FDI muscle contraction, A total of 20 single pulses were consecutively delivered to the hand region of the left M1 at 120% RMT (45° to the midline, handle pointing backward).', 'timeFrame': 'through study completion, an average of 8 months'}, {'measure': 'Maximum plasma concentration of opioid peptide at baseline', 'description': 'plasma opioid peptide concentrations will be measured using ELISA at baseline.', 'timeFrame': 'baseline'}, {'measure': 'Maximum plasma concentration of opioid peptide at the posttreatment of pcTBS', 'description': 'plasma opioid peptide concentrations will be measured using ELISA at the last posttreatment of pcTBS.', 'timeFrame': 'through study completion, an average of 8 months'}]",6,18 Years,85 Years,ALL,True,"Second Affiliated Hospital, School of Medicine, Zhejiang University",OTHER,0,45.0,ACTUAL,2025-09-01T16:18:24.752432,v2_robust,True,True,True,False,False,
NCT00491530,"A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia","A Year 2, Long-Term, Open-Label, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia",ABT-335,"['atorvastatin calcium', 'rosuvastatin calcium', 'ABT-335', 'Lipitor', 'simvastatin', 'fenofibric acid', 'Zocor', 'Crestor']",8,INTERVENTIONAL,['PHASE3'],PHASE3,,Mixed Dyslipidemia,['Mixed Dyslipidemia'],[],COMPLETED,,2007-06,2008-11,"[{'measure': 'Percentage of Subjects Reporting Adverse Events During Combination Therapy in the Preceding Double-Blind Studies or in the Preceding Open-Label Year 1 Study or in This Open-Label Year 2 Study', 'description': 'All serious and non-serious adverse events are reported from the time of combination study drug initiation until 30 days after discontinuation of study drug. Adverse events are unfavorable changes in health that occur in subjects during a clinical trial or within a specified period following a trial. Serious adverse events are those that result in death, require inpatient hospitalization or the prolongation of hospitalization, result in congenital anomaly/birth defect, or significant disability/incapacity or are life-threatening.', 'timeFrame': 'Anytime after initiation of combination therapy (in the preceding 12-week double-blind studies or in the preceding open-label year 1 study) up to 116 weeks, to within 30 days after the last dose of combination therapy.'}]","[{'measure': 'Median Percent Change in Triglycerides From Baseline to Week 104 of This Open-Label Year 2 Study', 'description': '\\[(Week 104 triglycerides minus baseline triglycerides)/baseline triglycerides\\] X 100. Baseline is the last value prior to the first dose of combination therapy.', 'timeFrame': 'Baseline to Week 104 (may include weeks in preceding double-blind studies [combination treatment arms], plus 52 weeks in preceding open-label year 1 study, and open-label year 2 study, up to 104 weeks)'}, {'measure': 'Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study', 'description': '\\[(Week 104 HDL-C minus baseline HDL-C)/baseline HDL-C\\] X 100. Baseline is the last value prior to the first dose of combination therapy.', 'timeFrame': 'Baseline to Week 104 (may include weeks in preceding double-blind studies [combination treatment arms], plus 52 weeks in preceding open-label year 1 study, and open-label year 2 study, up to 104 weeks)'}, {'measure': 'Mean Percent Change in Direct Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study', 'description': '\\[(Week 104 LDL-C minus baseline LDL-C)/baseline LDL-C\\] X 100. Baseline is the last value prior to the first dose of combination therapy.', 'timeFrame': 'Baseline to Week 104 (may include weeks in preceding double-blind studies [combination treatment arms], plus 52 weeks in preceding open-label year 1 study, and open-label year 2 study, up to 104 weeks)'}, {'measure': 'Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study', 'description': '\\[(Week 104 Non-HDL-C minus baseline Non-HDL-C)/baseline Non-HDL-C\\] X 100. Baseline is the last value prior to the first dose of combination therapy.', 'timeFrame': 'Baseline to Week 104 (may include weeks in preceding double-blind studies [combination treatment arms], plus 52 weeks in preceding open-label year 1 study, and open-label year 2 study, up to 104 weeks)'}, {'measure': 'Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 104 of This Open-Label Year 2 Study', 'description': '\\[(Week 104 VLDL-C minus baseline VLDL-C)/baseline VLDL-C\\] X 100. Baseline is the last value prior to the first dose of combination therapy.', 'timeFrame': 'Baseline to Week 104 (may include weeks in preceding double-blind studies [combination treatment arms], plus 52 weeks in preceding open-label year 1 study, and open-label year 2 study, up to 104 weeks)'}, {'measure': 'Mean Percent Change in Total Cholesterol (Total-C) From Baseline to Week 104 of This Open-Label Year 2 Study', 'description': '\\[(Week 104 Total-C minus baseline Total-C)/baseline Total-C\\] X 100. Baseline is the last value prior to the first dose of combination therapy.', 'timeFrame': 'Baseline to Week 104 (may include weeks in preceding double-blind studies [combination treatment arms], plus 52 weeks in preceding open-label year 1 study, and open-label year 2 study, up to 104 weeks)'}]",7,18 Years,,ALL,False,Abbott,INDUSTRY,0,310.0,ACTUAL,2025-09-01T16:18:24.752490,v2_robust,True,True,True,False,True,
NCT01308528,Prophylactic Use of Sodium Enoxaparin for Venous Thromboembolism in High-Risk Abdominal Surgery,A Non-Inferiority Study of Enoxaparin Cristalia in Relation With Enoxaparin Sanofi-Aventis for Prophylaxis Against Venous Thromboembolism in Patients With High-Risk to Develop Thromboembolic Disease Undergoing Geral Abdominal Surgery,Sodium enoxaparin,"['Sodium enoxaparin', 'Endocris', 'clexane', 'Sodium Enoxaparin clexane']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Venous Thromboembolism,['Venous Thromboembolism'],['Venous Thromboembolism'],COMPLETED,,2015-02,2017-04,"[{'measure': 'Evaluation of Sodium enoxaparin to demonstrate non-inferiority', 'description': 'Evaluation of Prophylactic use of Sodium enoxaparin to demonstrate non-inferiority for Venous Thromboembolism in High-Risk Surgery in Abdominal', 'timeFrame': '10 Days'}]","[{'measure': 'Safety of sodium enoxaparine', 'description': 'comparision between Endocris (sodium enoxaparin - Cristalia Prod. Quim. Farm.) versus Clexane (sodium enoxaparine - Sanofi-Aventis) in High-Risk Abdominal Surgery.', 'timeFrame': '10 days'}, {'measure': 'Compare the incidence of venous thromboembolism and pulmonar embolism', 'description': 'Compare the incidence of venous thromboembolism and pulmonar embolism between 2 groups after 30 days of surgery', 'timeFrame': '10 days'}]",3,18 Years,,ALL,False,Cristália Produtos Químicos Farmacêuticos Ltda.,INDUSTRY,0,243.0,ACTUAL,2025-09-01T16:18:24.752518,v2_robust,True,True,True,False,True,
NCT04737928,"Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)","Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders",Latanoprost,"['tafluprost', 'Latanoprost']",2,INTERVENTIONAL,['NA'],,,"Glaucoma, Primary Open Angle","['Glaucoma, Primary Open Angle']",[],COMPLETED,,2018-04-02,2019-01-22,"[{'measure': 'Efficacy: Changes in the Intraocular Pressure (IOP) at each visit', 'description': 'Tonometer', 'timeFrame': '3 months'}, {'measure': 'Safety:Changes in the fluorescein staining score (NEI) at Visit 2', 'description': 'fluorescein staining', 'timeFrame': '3 months'}]","[{'measure': 'Changes in the fluorescein staining score (NEI) at Visit 1', 'description': 'fluorescein staining', 'timeFrame': '1 months'}, {'measure': 'Changes in ocular symptoms (irritation/burning/stinging, foreign body sensation, tearing, itching and dry eye sensation) at each visit', 'description': 'Questionnaire', 'timeFrame': '3 months'}, {'measure': 'Changes in the Tear Break-Up Time (TBUT) at each visit', 'description': 'slit-lamp', 'timeFrame': '3 months'}, {'measure': 'Changes in the hyperaemia at each visit', 'description': 'slit-lamp', 'timeFrame': '3 months'}, {'measure': 'Treatment compliance', 'description': 'Questionnaire', 'timeFrame': '3 months'}, {'measure': 'Concomitant medication', 'description': 'Questionnaire', 'timeFrame': '3 months'}, {'measure': 'Patient satisfaction about test medication', 'description': 'Questionnaire', 'timeFrame': '3 months'}, {'measure': 'Usability of eyedrop bottle', 'description': 'Questionnaire', 'timeFrame': '3 months'}, {'measure': 'Adverse drug reactions', 'description': 'Questionnaire', 'timeFrame': '3 months'}]",11,20 Years,,ALL,False,"Santen Pharmaceutical (Taiwan) Co., LTD",INDUSTRY,0,1.0,ACTUAL,2025-09-01T16:18:24.752547,v2_robust,True,True,True,False,True,
NCT05269628,Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype,Mechanisms of Cannabidiol (CBD) in Persons With Multiple Sclerosis (MS): the Role of Sleep and Pain Phenotype,Cannabidiol (CBD),"['Placebo THC', 'Cannabidiol (CBD)', 'Tetrahydrocannabinol (THC)', 'Marinol®, dronabinol capsules', 'Epidiolex® 100 mg/mL solution', 'Placebo CBD']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Sclerosis,"['Multiple Sclerosis', 'Sleep', 'Pain']",['Cannabidiol'],RECRUITING,,2022-03-25,2027-08-30,"[{'measure': 'Mean change in sleep bout length', 'description': 'Measured with in-laboratory polysomnography, reported as average length of continuous bouts of sleep, for each sleep stage and total sleep (in minutes).', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change in Walsh Spectral Entropy', 'description': 'Measured with in-laboratory polysomnography, computed from EEG sleep stage data to quantify hypnogram regularity (dimensionless, values range from 0-1)', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change in Transition Entropy', 'description': 'Measured with in-laboratory polysomnography. Entropy measure computed from sleep stage transition matrix that quantifies hypnogram regularity (dimensionless, values range from 0-1)', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change of center of activity', 'description': 'Measured with in-laboratory polysomnography. Weighted mean temporal location over the night of all 30 second epochs scored as N3 and Rapid eye movement (REM) sleep', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change in sleep rhythmicity', 'description': 'Measured by actigraphy. Probability of being in the same sleep/wake state 24h apart', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change in sleep regularity', 'description': 'Measured by actigraphy in hours.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'Change in sleep continuity and duration', 'description': 'Measured by actigraphy in minutes to obtain time in wakefulness after sleep onset (WASO) and total sleep time.', 'timeFrame': 'Baseline, 12 weeks'}]",[],7,18 Years,65 Years,ALL,False,"Tiffany J. Braley, MD, MS",OTHER,1,166.0,ESTIMATED,2025-09-01T16:18:24.752585,v2_robust,True,True,False,False,False,
NCT04061928,Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ,The Combination of Toripalimab With Preoperative Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction,PD-1,"['Toripalimab', 'PD-1']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,PD-1,"['PD-1', 'Chemoradiotherapy', 'Gastroesophageal Junction Cancer']",[],UNKNOWN,,2019-08-26,2023-08-25,"[{'measure': 'TRG (Tumor Regression Grading)', 'description': 'The TRG of operation after neoadjuvant chemoradiotherapy and immunotherapy.', 'timeFrame': '10 days after operation'}]","[{'measure': 'Number of participants with AEs (Adverse Events)', 'description': 'The AEs during the trial, including radiation mucositis, bone marrow suppression, AEs related to immunotherapy and so on', 'timeFrame': 'Through study completion, an average of 1 year'}, {'measure': 'LC (Local Control)', 'description': 'The local control of the patients', 'timeFrame': 'Through study completion, an average of 1 year'}, {'measure': 'DFS (Disease Free Survival)', 'description': 'The disease free survival of the patients', 'timeFrame': 'Through study completion, an average of 1 year'}]",4,18 Years,75 Years,ALL,False,Peking University,OTHER,0,45.0,ESTIMATED,2025-09-01T16:18:24.752661,v2_robust,True,True,False,False,True,
NCT03228628,Nitrous Oxide for Lumbar Puncture,Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Multicenter Double-blind Randomized Controlled Trial,Fixed 50:50 mixture of nitrous oxide and oxygen,['Fixed 50:50 mixture of nitrous oxide and oxygen'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Pain,"['Pain', 'Anxiety']","['Spinal puncture', 'Pain', 'Anxiety', 'Nitrous oxyde']",UNKNOWN,,2017-10-01,2019-09-01,"[{'measure': 'Proportion of patients with significant pain', 'description': 'maximal pain perceived during the lumbar puncture evaluated using a simple numeric 0-10 pain scale', 'timeFrame': '2-3 minutes after the end of gaz inhalation'}]","[{'measure': 'Proportion of patients with significant anxiety', 'description': 'maximal anxiety perceived during the lumbar puncture evaluated using a simple numeric 0-10 scale', 'timeFrame': '2-3 minutes after the end of gaz inhalation'}, {'measure': 'Analgesic efficacy measured with pain as a continuous variable', 'description': 'maximal pain perceived during the lumbar puncture evaluated using a simple numeric 0-10 pain scale', 'timeFrame': '2-3 minutes after the end of gaz inhalation.'}, {'measure': 'Anxiolytic efficacy measured with anxiety as a continuous variable', 'description': 'maximal anxiety perceived during the lumbar puncture evaluated using a simple numeric 0-10 scale', 'timeFrame': '2-3 minutes after the end of gaz inhalation'}, {'measure': 'Pain during the procedure evaluated one hour after the end of the lumbar puncture', 'description': 'maximal pain and anxiety perceived during the lumbar puncture evaluated using a simple numeric 0-10 scale', 'timeFrame': '1 hour after the end of gaz inhalation'}, {'measure': 'Anxiety during the procedure evaluated one hour after the end of the lumbar puncture', 'description': 'maximal pain and anxiety perceived during the lumbar puncture evaluated using a simple numeric 0-10 scale', 'timeFrame': '1 hour after the end of gaz inhalation'}, {'measure': 'Side effects', 'description': 'every side effects reported by the patients during the procedure up to 24 hours after the lumbar puncture, including post-puncture puncture headache', 'timeFrame': 'from the beginning of gaz inhalation to 24 hours later'}, {'measure': 'Impact of age on side effects', 'description': 'incidence and type of side effects according to patient age', 'timeFrame': 'during the procedure and the 24 hours after'}, {'measure': 'Induced cost', 'description': 'supplementary cost induced by the use of nitrous oxide inhalation for a total of 81 patients throughout the study', 'timeFrame': 'at day 1'}]",9,18 Years,,ALL,False,"University Hospital, Clermont-Ferrand",OTHER,4,162.0,ESTIMATED,2025-09-01T16:18:24.752672,v2_robust,True,True,False,False,False,
NCT05611528,Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia,Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia in a Real Life Setting in Canada,Evinacumab,['Evinacumab'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Homozygous Familial Hypercholesterolemia,['Homozygous Familial Hypercholesterolemia'],"['ANGPTL3', 'Real-life study', 'Monoclonal antibody']",COMPLETED,,2023-02-21,2025-03-18,"[{'measure': 'Change in lipid profile', 'description': 'Change in total cholesterol, LDL-Cholesterol, HDL-Cholesterol, triglyceride, non-HDL-Cholesterol and apolipoprotein B plasma concentration', 'timeFrame': 'Every 4 weeks up to 2 years'}, {'measure': 'Change in aspartate transaminase (AST) plasma concentration', 'timeFrame': 'Every 4 weeks up to 2 years'}, {'measure': 'change in alanine aminotransferase (ALT) plasma concentration', 'timeFrame': 'Every 4 weeks up to 2 years'}]","[{'measure': 'Lipoprotein (a)', 'timeFrame': 'Yearly up to 2 years'}, {'measure': 'Complete blood count', 'timeFrame': 'Every 12 weeks up to 2 years'}, {'measure': 'Total bilirubin', 'timeFrame': 'Every 12 weeks up to 2 years'}, {'measure': 'Creatine phosphokinase', 'timeFrame': 'Every 12 weeks up to 2 years'}]",7,18 Years,,ALL,False,Daniel Gaudet,OTHER,1,10.0,ACTUAL,2025-09-01T16:18:24.752716,v2_robust,True,True,True,False,False,
NCT06960928,Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19,Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19,Low-dose sirolimus,"['Low-dose sirolimus', 'rapamycin', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Long COVID-19,['Long COVID-19'],"['Long COVID-19', 'Post-Acute Sequelae of COVID-19 (PASC)', 'Sirolimus', 'Rapamycin']",RECRUITING,,2025-04-18,2026-11-30,"[{'measure': 'European Quality of Life-Visual Analogue Scale (EQ-VAS)', 'description': ""The EQ VAS records the patient's self-rated health on a visual analogue scale where the endpoints are labelled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0), with higher scores indicating better health state. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement."", 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)'}]","[{'measure': 'The EuroQol Five-Dimensional Health Questionnaire (EQ-5D-5L)', 'description': ""The EQ-5D-5L is a validated, standardized, generic instrument that is a preference-based health- related quality of life questionnaire. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. Full scale from 5 to 25, with higher score indicating poorer health outcomes."", 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)'}, {'measure': 'Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29)', 'description': 'The PROMIS-29 v2.0 profile assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain. The values of all item responses are averaged to generate subscores for each dimension. From these subscores, a global physical health score and a global mental health score are generated. The scores are translated into T-scores according to a reference population with a mean of 50 and a standard deviation of 10.', 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)'}, {'measure': 'General Symptom Questionnaire (GSQ-30)', 'description': 'The General Symptom Questionnaire-30 (GSQ-30) is a valid and reliable instrument to assess symptom burden among patients with acute and post-treatment. The GSQ-30 total score ranges from 0 to 120, with higher scores indicating a greater symptom burden.', 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)'}, {'measure': 'Patient Health Questionnaire (PHQ-9)', 'description': 'The PHQ-9 is a series of questions assessing presence and severity of depression symptoms. It evaluates each of the DSM-IV depression criteria and scores the responses from 0 (""Not at all"") to 3 (""Nearly every day""). PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively. Full scale from 0-27, with higher score indicating more severe symptoms.', 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)'}, {'measure': 'Generalized Anxiety Disorder (GAD-7)', 'description': 'The GAD-7 is a 7-item scale developed and validated to identify generalized anxiety disorder and its severity. It assesses the frequency of 7 anxiety symptoms and scores the responses from 0 (""Not at all"") to 3 (""Nearly every day""). Total scores of 5, 10, and 15 correspond to mild, moderate, and severe generalized anxiety disorder, respectively. Full scale from 0-21, with higher score indicating more symptoms.', 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)'}, {'measure': 'Neuro-QoL™ v2.0 Cognitive Function-Short Form', 'description': 'The Neuro-QoL Cognitive Function v2.0 short form assesses perceived difficulties in cognitive abilities, including memory, attention, decision making, planning, organizing, calculating, remembering, and learning. The short form consists of 8 questions assessed on a 5-point Likert scale, resulting in a raw score range of 8 to 40. A raw score is then converted to a T-score using conversion tables. Scores 0.5 - 1.0 SD worse than the mean (T-score 40-45) = mild symptoms/impairment. Scores 1.0 - 2.0 SD worse than the mean (T-score 30-40) = moderate symptoms/impairment. Scores 2.0 SD or more worse than the mean (T-score below 30) = severe symptoms/impairment.', 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)'}, {'measure': 'Single-item Sleep Quality Scale (SQS)', 'description': 'The SQS is a visual analog scale that instructs respondents to rate their overall quality of sleep over a 7-day recall period from 0 to 10. Scores of 0, 1, 4, 7, and 10 correspond to terrible, poor, fair, good, and excellent, respectively. Higher scores indicate better sleep quality.', 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)]'}, {'measure': 'Fatigue Severity Scale', 'description': 'The Fatigue Severity Scale (FSS) uses a 7-point scale (1-7) to assess fatigue, with higher scores indicating greater severity, and a total score ranging from 9 to 63. Higher scores indicate more severe fatigue.', 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)'}, {'measure': 'Fatigue Visual Analogue Scale [F-VAS])', 'description': 'The F-VAS consists of 18 items related to fatigue and energy in a visual analogue scale from 0 to 100. A higher score indicates more fatigue.', 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)'}, {'measure': 'DePaul Post-Exertional Malaise Questionnaire (DSQ)', 'description': ""The DSQ is designed to evaluate 54 classic ME/CFS symptoms, including fatigue, post-exertional malaise, sleep, pain, neurological/cognitive impairments, and autonomic, neuroendocrine, and immune symptoms. Each symptom's frequency and intensity are rated on a 5-point scale (0-4). Frequency and severity scores are multiplied by 25, added together, and then divided by 2 to create a composite frequency/severity score for each symptom. These scores range from 0 to 100, with higher scores indicating a greater symptom burden."", 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)'}, {'measure': 'Composite Autonomic Symptom Score 31(COMPASS-31)', 'description': 'The COMPASS-31 is a 31-question self-assessment instrument of autonomic symptoms and function that is up-to-date, broadly applicable, easy to administer in a short amount of time, and based on a scientific approach. The total score ranges from 0 to 100, with higher scores indicating greater autonomic dysfunction.', 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)'}, {'measure': 'Pain (P-VAS)', 'description': 'Using a visual analogue scale, patients mark a point on a line representing a continuum from ""no pain"" to ""worst pain,"" with scores ranging from 0 to 100, where higher scores indicate greater pain.', 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)]'}, {'measure': 'University of California-Los Angeles (UCLA) Loneliness Scale (3-item)', 'description': 'The UCLA Loneliness (3-item) Scale scores range from 3 to 9, with higher scores indicating greater perceived loneliness.', 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)'}, {'measure': 'Adapted Berkman-Syme Social Network/Connection Index', 'description': 'This is a self-report questionnaire used to assess social integration and isolation, focusing on marital status, frequency of contact, and participation in social activities, particularly relevant for older adults. Each item is scored on a scale from 1-4 where higher values reflect greater frequency (e.g., 4 = ""5 or more times a week""). For each respondent, a sum score is calculated by adding the scores of all five items, yielding a possible score range of 5-25. Higher sum scores reflect higher levels of social connection and lower social isolation.', 'timeFrame': 'Baseline (Week 0) and Post-treatment (Week 12 and Week 24)'}]",15,18 Years,,ALL,False,Icahn School of Medicine at Mount Sinai,OTHER,2,80.0,ESTIMATED,2025-09-01T16:18:24.752791,v2_robust,True,True,False,False,False,
NCT00059228,Clinical Trial of Estrogen for Postpartum Depression,The Efficacy of 17Beta-Estradiol in Postpartum-Related Depressive Illness,17beta Estradiol,"['Placebos', '17beta Estradiol']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Postpartum Depression,"['Postpartum Depression', 'Depression']","['Pregnancy', 'Gonadal Steroids', 'Antidepressants', 'Puerperium', 'Depression', 'Postpartum', 'Estradiol', 'Estrogen Response Element', 'Postpartum Depression']",TERMINATED,,2003-04-17,2016-11-15,"[{'measure': 'Beck Depression Inventory', 'description': 'The Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory for measuring the severity of depression. Higher total scores indicate more severe depressive symptoms. The range of scores vary from 0 to 63 (highest possible total) for the whole test. A score of 0 - 10 indicates minimal depression, while a score of over 40 indicates extreme depression. No subscales were used for this outcome.', 'timeFrame': '6 weeks'}, {'measure': 'Beck Depression Inventory', 'description': 'The Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory for measuring the severity of depression. Higher total scores indicate more severe depressive symptoms. The range of scores vary from 0 to 63 (highest possible total) for the whole test. A score of 0 - 10 indicates minimal depression, while a score of over 40 indicates extreme depression. No subscales were used for this outcome.', 'timeFrame': 'Baseline'}]",[],2,20 Years,45 Years,FEMALE,False,National Institute of Mental Health (NIMH),NIH,0,12.0,ACTUAL,2025-09-01T16:18:24.752900,v2_robust,True,True,False,True,False,
NCT01092728,"Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma","A Phase II Study of Biological Response to Dasatinib Treatment in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma",Dasatinib,"['Sprycel', 'BMS-354825', 'Dasatinib']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Melanoma,['Melanoma'],"['Acral lentiginous melanoma', 'Mucosal melanoma', 'Chronic sun-damaged melanoma', 'Surgically removed tumor', 'biopsied', 'Sprycel', 'Dasatinib']",TERMINATED,Slow accrual.,2011-03,2014-08,"[{'measure': 'Biologic Response Evaluation of Tumors With and Without Resectable Tumors', 'description': 'Biologic response defined as either (complete or partial) metabolic tumor response after 7 days dasatinib treatment by positron emission tomography (PET) scan, \\>/= 25% decrease in Fluorodeoxyglucose (FDG) activity on PET without \\>15% increase in tumoral Ki-67 expression or \\>/=25% decrease in tumoral Ki-67 expression without \\>15% increase in FDG activity on PET scan. Complete Metabolic Response (CMR): FDG-avidity all lesions reduced to background FDG-avidity level. Partial Metabolic Response (PMR): \\>/=25% decrease in FDG-avidity as represented by change in mean Standardized Uptake Values (SUV) max. SUVmax measured by drawing region of interest slightly outside each lesion corresponding to those on CT image \\& adjusted for body weight. Measureable disease by PET scan defined as lesions that can be determined to have FDG-avidity of SUVmax of 3 and 2 x background.\n\nPR or CR confirmatory disease assessment performed \\>4 weeks (28 days) after criteria for response first met.', 'timeFrame': 'Assessment at 7 Days with confirmatory disease assessment performed no less than 4 weeks (28 days) afterwards'}]","[{'measure': 'Progression-Free Survival', 'description': 'Progression-Free Survival (PFS) is defined as the duration of time from start of treatment to date of first evidence of progression or the date of last follow-up for patients who do not progress.', 'timeFrame': 'Evaluated every 2 cycles (8 weeks) until disease progression or last follow-up, up to two years'}]",2,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,19.0,ACTUAL,2025-09-01T16:18:24.752916,v2_robust,True,True,False,True,False,Slow accrual.
NCT00685165,Fasted Bioequivalence Study of Primidone Tablets and Mysoline Tablets,"A Randomized, Two-Way, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Primidone 50 mg, Compared to an Equivalent Dose of Primidone (Mysoline®) in Healthy Adult Subjects",Primidone 50 mg Tablet,"['Primidone 50 mg Tablet', 'Mysoline®', 'Primidone (Mysoline®) 50 mg Tablet']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Therapeutic Equivalency,['Therapeutic Equivalency'],[],COMPLETED,,2004-05,2004-06,"[{'measure': 'Maximum Plasma Concentration (Cmax)', 'description': 'The maximum or peak concentration that the drug reaches in the plasma.', 'timeFrame': 'serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 18, 24, 36, 48, 60 and 72 hours after drug administration.'}, {'measure': 'Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]', 'description': 'The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule.', 'timeFrame': 'serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 18, 24, 36, 48, 60 and 72 hours after drug administration.'}, {'measure': 'Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]', 'description': 'The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.', 'timeFrame': 'serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 18, 24, 36, 48, 60 and 72 hours after drug administration.'}]",[],3,18 Years,,ALL,True,"Mutual Pharmaceutical Company, Inc.",INDUSTRY,0,22.0,ACTUAL,2025-09-01T16:18:24.752953,v2_robust,True,True,True,False,False,
NCT06601465,COgnitioN With VERiciGuat Evaluation in Heart Failure,CONVERGE-HF: COgnitioN With VERiciGuat Evaluation in Heart Failure,Vericiguat,"['Vericiguat', 'Verquvo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Heart Failure,"['Heart Failure', 'Cognitive Impairment']","['Heart Failure', 'Cognitive Impairment', 'Vericiguat']",RECRUITING,,2025-06-03,2027-05,"[{'measure': 'Change in the lateral ventricular volumes.', 'description': 'To determine whether in patients with heart failure and mild-to-moderate cognitive impairment, the 26 weeks of treatment with sGC stimulator, vericiguat versus standard of care lead to greater reduction (or smaller increase) in lateral ventricular volume in brain MRI as a proxy for the preservation of brain microvasculature and preventing brain tissue loss.', 'timeFrame': '26 weeks'}]","[{'measure': 'Blood Biomarkers (a)', 'description': 'To determine the difference in the change in cardiac ischemia and strain markers measured by cardiac troponin, IGFBP-7, and NT-proBNP between patients with heart failure and mild-to-moderate cognitive impairment who were treated for 26 weeks with sGC stimulator, vericiguat versus standard of care.', 'timeFrame': '26 weeks'}, {'measure': 'Blood Biomarkers (b)', 'description': 'To determine the difference in the change of brain-related marker of cis p-tau between patients with chronic CV disease and mild-to-moderate cognitive impairment who were treated for 26 weeks with sGC stimulator, vericiguat versus standard of care.', 'timeFrame': '26 weeks'}, {'measure': 'Imaging Biomarkers (Cardiac)', 'description': 'To determine the difference between patients with heart failure and mild-to-moderate cognitive impairment who were treated for 26 weeks with sGC stimulator, vericiguat, versus standard of care in terms of the change in CMR perfusion test results for perfusion deficits indicative of coronary microvascular impairment.', 'timeFrame': '26 weeks'}, {'measure': 'Imaging Biomarkers (Brain)', 'description': 'To determine the difference between patients with heart failure and mild-to-moderate cognitive impairment who were treated for 26 weeks with sGC stimulator, vericiguat versus standard of care in terms of the change in brain MRI peak skeletonized mean diffusivity of the white matter and change in white matter hypersensitivity volume indicative of cerebral small vessel disease.', 'timeFrame': '26 weeks'}, {'measure': 'Clinical and patient-reported outcomes (MoCA)', 'description': 'To compare the change of MoCA scores in 26 weeks between groups who were treated with vericiguat versus standard of care.', 'timeFrame': '26 weeks'}, {'measure': 'Clinical and patient-reported outcomes (KCCQ-12)', 'description': 'To compare the change of health-related quality of life (assessed via KCCQ-12) in 26 weeks between groups who were treated with vericiguat versus standard of care. The KCCQ-12 has a standardized format and has been validated for paper, electronic or telephone delivery.', 'timeFrame': '26 weeks'}, {'measure': 'Clinical and patient-reported outcomes (6MWT)', 'description': 'To compare the change of functional status assessed via 6-minute walk test (6MWT) in 26 weeks between groups who were treated with vericiguat versus standard of care. The 6MWT will be performed as outlined by the American Thoracic Society by an assessor blinded to treatment allocation.61 6MWT will be assessed both in-person and using the validated virtual approach utilizing Walk.Talk.Track app.', 'timeFrame': '26 weeks'}, {'measure': 'Clinical and patient-reported outcomes (RBANS)', 'description': 'To compare the change of Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores between groups. The RBANS is a widely-used battery for identifying and characterizing abnormal cognitive decline in elderly adults. Its level of difficulty is appropriate for the range from normal cognition to moderately severe dementia.', 'timeFrame': '26 weeks'}, {'measure': 'Clinical events - Death', 'description': '(all cause)', 'timeFrame': '26 weeks'}, {'measure': 'Clinical events - Hospitalizations', 'description': '(all cause)', 'timeFrame': '26 weeks'}, {'measure': 'Clinical events - Emergency Department Visits', 'description': '(all cause)', 'timeFrame': '26 weeks'}, {'measure': 'Clinical events - Stroke', 'timeFrame': '26 weeks'}, {'measure': 'Clinical events - Other', 'timeFrame': '26 weeks'}]",14,18 Years,,ALL,False,University of Alberta,OTHER,2,120.0,ESTIMATED,2025-09-01T16:18:24.753071,v2_robust,True,True,False,False,False,
NCT05824065,Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss,"Phase III, National, Multicenter, Randomized, Double-Blind, Superiority Clinical Trial to Evaluate the Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss",OMA102,"['OMA102', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Female Pattern Baldness,['Female Pattern Baldness'],[],NOT_YET_RECRUITING,,2025-01,2027-01,"[{'measure': 'Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of hair growth in the mid front area assessed by digital phototrichogram.', 'description': 'Variation of hair in the mid-front area after 6 months of treatment in comparison to baseline, assessed by digital phototrichogram.', 'timeFrame': '6 months'}]","[{'measure': 'Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of hair growth in the mid front area assessed by digital phototrichogram.', 'description': 'Variation of hair in the mid-front area after 3 months of treatment in comparison to baseline, assessed by digital phototrichogram.', 'timeFrame': '3 months'}, {'measure': 'Efficacy of OMA102 1 mg and OMA102 2 mg in the promotion of non vellus and vellus hair growth, in the mid frontal area, assessed by digital phototrichogram.', 'description': 'Variation of non vellus and vellus hair in the mid-front area after 3 and 6 months of treatment in comparison to baseline, assessed by digital phototrichogram.', 'timeFrame': '3 and 6 months'}, {'measure': 'Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement of global photographs, assessed by Clinical Global Impression of Improvement (CGI-I) by the investigator perception.', 'description': 'Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement global photographs assessed by Clinical Global Impression of Improvement (CGI-I) by the investigator perception, 3 and 6 months after treatment.', 'timeFrame': '3 and 6 months'}, {'measure': 'Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement of global photographs, assessed by Patient Global Impression, PGI-I, by the subject perception.', 'description': 'Efficacy of OMA102 1 mg and OMA102 2 mg in the proportion of subjects with an improvement of Global Photographs assessed by Patient Global Impression PGI-I, by the investigator perception, 3 and 6 months after treatment.', 'timeFrame': '3 and 6 months'}, {'measure': ""Efficacy of OMA102 1 mg and OMA102 2 mg in quality of life, assessed by Women's Androgenetic Alopecia Quality of Life (WAA-QoL)."", 'description': ""Efficacy of OMA102 1 mg and OMA102 2 mg in quality of life, assessed by Women's Androgenetic Alopecia Quality of Life (WAA-QoL) in comparison to baseline, 3 and 6 months after treatment."", 'timeFrame': '3 and 6 months'}]",6,18 Years,50 Years,FEMALE,False,EMS,INDUSTRY,0,504.0,ESTIMATED,2025-09-01T16:18:24.753115,v2_robust,True,True,False,False,False,
NCT05816265,Effects of IV Iron Replacement on Exercise Capacity in Individuals With Heart Failure,Effects of IV Iron Replacement on Exercise Capacity in Individuals With Heart Failure With Reduced Ejection Fraction and Iron Deficiency,IV Iron Infusion Group,"['Ferric carboxymaltose injection', 'IV Iron Infusion Group']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Heart Failure,"['Heart Failure', 'Iron-deficiency']","['Reduced ejection fraction', 'Exercise', 'iron supplementation', 'Cardiopulmonary exercise', 'peak oxygen uptake']",ENROLLING_BY_INVITATION,,2024-01-24,2027-03,"[{'measure': 'Exercise Capacity', 'description': 'Cardiopulmonary exercise testing will be administered to measure Peak V02. During the exercise testing a special mouthpiece that can measure oxygen and carbon dioxide is used to measure peak oxygen uptake.', 'timeFrame': '2 months after IV iron infusion'}, {'measure': 'Patient subjective outcome measures', 'description': 'Subjects will complete the Kansas City Cardiomyopathy Questionnaire.The lowest score is 0 and the highest score is 100. The higher the score is, the better the quality of life.', 'timeFrame': '2 months after IV iron infusion'}]","[{'measure': 'Objective Quality of Life measures', 'description': 'A 6-minute walk test will be administered to determine if the NYHA class has improved.', 'timeFrame': '2 months after IV iron infusion'}]",3,18 Years,90 Years,ALL,False,Radha Gopalan,OTHER,1,40.0,ESTIMATED,2025-09-01T16:18:24.753175,v2_robust,True,True,False,False,False,
NCT01474265,Sympathovagal Balance in Smoking Cessation,Alterations in the Autonomic Nervous System During Smoking Quit Attempts- Possible Effects of Pharmacological Interventions,Varenicline,"['Varenicline', 'Nicorette TX', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Smoking Cessation,['Smoking Cessation'],"['smoking cessation', 'varenicline', 'sympathovagal balance', 'quit attempts', 'MSNA']",COMPLETED,,2011-11,2013-04,"[{'measure': 'Assessment of muscular sympathic nervous activity (MSNA) in bursts / 100 heart beats before and while smoking cessation.', 'description': 'Patients present 7 weeks before their personal smoking-stop-day and participate in the study until week 26 after their personal smoking-stop-day. During that time, MSNA is recorded.', 'timeFrame': '33 weeks'}]","[{'measure': 'Assessment of the basal sympathetic nerve activity in smokers compared to never-smokers', 'description': 'first MSNA is carried out 4 weeks before smoking-stop-day (respectively 6 weeks for group D). second and last MSNA is carried out two days after smoking-stop-day (respectively 2 weeks before smoking-stop-day for group D)', 'timeFrame': '33 weeks'}, {'measure': 'Assessment of craving and withdrawal symptoms during smoking cessation', 'description': 'withdrawal symptoms data is collected by phone calls 3,2,1 days before smoking-stop-day, the day itself and 1 day and 11 (12 for group C and D) weeks after smoking-stop-day.\n\nAlso the withdrawal symptoms date is collected during each personal examination (means - Pre-Examination, Baseline, Follow I to III).\n\nThe data will be collected by reliable questionnaires', 'timeFrame': '33 weeks'}, {'measure': 'Assessment of smoking cues on craving and sympathovagal balance', 'description': 'smoking cues will be presented on the first follow-up-measurement to members of group A-D.', 'timeFrame': '33 weeks'}, {'measure': 'Assessment of smoking relapse rate', 'description': 'All relapses will be registered to correlate them with the obtained parameters (baroreflex-sensitivity, heartrate-variabilty, MSNA, questionnaires)', 'timeFrame': '33 weeks'}]",5,25 Years,60 Years,ALL,True,Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH,OTHER,1,85.0,ACTUAL,2025-09-01T16:18:24.753216,v2_robust,True,True,True,False,False,
NCT02423265,Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries,The Effectiveness of Ranolazine in Reducing Cardiac Ischaemia Induced by Chronic Total Occlusions of Coronary Arteries,Ranolazine,"['Ranolazine', 'Renexa', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Myocardial Ischemia,"['Myocardial Ischemia', 'Coronary Artery Disease', 'Arteriosclerosis', 'Chronic Stable Angina']","['Chronic total coronary occlusions', 'Ranolazine']",WITHDRAWN,slow recruitment; local new issues with CMR after study start,2015-06,2017-03,"[{'measure': 'Cardiac MRI (CMR) strain', 'description': 'The extent of reversibly ischaemic LV myocardium will be assessed using CMR strain at rest and stress', 'timeFrame': '8 weeks'}]","[{'measure': 'Dobutamine wall motion scoring index (WMSI)', 'description': 'CMR derived end point', 'timeFrame': '8 weeks'}, {'measure': 'Quality of Life/burden of angina', 'description': 'QoL questionnaire based assessment (Seattle Angina Quesstionnaire, SAQ; Duke Activity Status Index, DASI;Medical Outcomes Study-Short Form12 )', 'timeFrame': '8 weeks'}, {'measure': 'Treadmill ECG exercise distance', 'description': 'Functional capacity assessment', 'timeFrame': '8 weeks'}, {'measure': 'Time to ECG changes (ST depression) on exercise ECG', 'description': 'If baseline ECG permits, this will allow assessment of impact of treatment on ECG markers of ischemia', 'timeFrame': '8 weeks'}]",5,21 Years,,ALL,False,East Carolina University,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:24.753237,v2_robust,True,True,False,True,False,slow recruitment; local new issues with CMR after study start
NCT01777165,A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery,"A Phase 2b, Randomized, Double-Blind,Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery",ABT-719,"['ABT-719', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Kidney Injury,['Acute Kidney Injury'],"['GFR', 'Acute Kidney Injury', 'High Risk cardiac surgery']",COMPLETED,,2013-02,2014-03,"[{'measure': 'Number of patients developing acute kidney injury based on the Acute Kidney Injury Network (AKIN) scoring criteria by comparing the ABT-719 dose groups versus placebo group.', 'timeFrame': 'Up through Day 7'}]","[{'measure': 'Proportion of subjects developing at least one of the composite events: death, needing renal replacement therapy, or having greater than or equal to 25 percent reduction in estimated glomerular filtration rate or measured glomerular filtration rate', 'timeFrame': 'Up through Day 90'}, {'measure': 'Proportion of subjects developing at least one of the composite events: death, needing renal replacement therapy, or having greater than or equal to 25 percent reduction in serum creatinine based estimated glomerular filtration rate (GFR)', 'timeFrame': 'Up through Day 60'}, {'measure': 'Proportion of subjects developing AKI as defined by the Risk, Injury, Failure, Loss, or ESRD (RIFLE) model', 'timeFrame': 'Up through Day 7'}, {'measure': 'Proportion of subjects developing AKI as defined by the Kidney Disease Improving Global Outcomes (KDIGO) model', 'timeFrame': 'Up through Day 7'}, {'measure': 'Changes from baseline (defined as within 24 hours of day 0) in serum creatinine (SCr) and S-Cystatin C at all study visits from baseline to Day 90', 'timeFrame': 'Up through Day 90'}]",6,18 Years,,ALL,False,AbbVie,INDUSTRY,0,240.0,ACTUAL,2025-09-01T16:18:24.753253,v2_robust,True,True,True,False,False,
NCT02373865,Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes,Randomized Double Blind Parallel Design Study Comparing Risk of Nocturnal Hypoglycemia and Critical Arrhythmia With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes Insufficiently Controlled With Metformin Monotherapy,Sitagliptin,"['Glimepiride-Placebo', 'Sitagliptin', 'Glimepiride', 'Sitagliptin-Placebo']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetes Mellitus Type 2,['Diabetes Mellitus Type 2'],"['Diabetes mellitus type 2', 'nocturnal hypoglycemia', 'metformin monotherapy']",TERMINATED,Premature termination due to insufficient patient recruitement..,2015-09,2017-01,"[{'measure': 'Number of Hypoglycemic Episodes (HE) Under Treatment With Sitagliptin Compared to Glimepiride', 'description': 'measurement of hypoglycemic episodes including event duration at baseline and EOT after 12 weeks of treatment and measurement of time spent below critical values for hypoglycemic episodes are the primary objectives of this study. We will calculate overall episodes/time (5 days) and nocturnal episodes.', 'timeFrame': '12 weeks (at baseline and at EOT)'}]","[{'measure': 'Occurence and Number of Nocturnal Ventricular Arrhythmias', 'description': 'measurement of nocturnal ventricular arrhythmias at baseline and EOT (after 12 weeks of treatment) - per patient, couplets per patient, triplets per patient)', 'timeFrame': '12 weeks (at baseline and at EOT)'}, {'measure': 'Glycemic Variability (Profile) of Sitagliptin Compared to Glimepiride', 'description': 'The glycemic profile is defined as the area under the glucose-timeprofile obtained by continuous glucose monitoring (5 days baseline and 5 days after 12 weeks of each treatment)', 'timeFrame': '12 weeks (at baseline and at EOT)'}]",3,40 Years,80 Years,ALL,False,GWT-TUD GmbH,OTHER,0,4.0,ACTUAL,2025-09-01T16:18:24.753277,v2_robust,True,True,False,True,False,Premature termination due to insufficient patient recruitement..
NCT06580665,Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer,"Randomized Clinical Trials Comparing Immunotherapy Plus Cryoablation (I-CA) Versus Cryoablation Alone for Stage I, Selected Stage IIa, Non-Small Cell Lung Cancer",Serplulimab,['Serplulimab'],1,INTERVENTIONAL,['NA'],,,Non-small Cell Lung Cancer,['Non-small Cell Lung Cancer'],"['Cryoablation', 'Serplulimab', 'Early non-small cell lung cancer']",NOT_YET_RECRUITING,,2024-09-01,2030-08-11,"[{'measure': '3-year progression-free survival (PFS)', 'description': ""This refers to the length of time between the participant's first onset of disease progression or death from any cause after treatment."", 'timeFrame': '3 years'}]","[{'measure': '1-year, 2-year, and 3-year Objective Response Rate (ORR)', 'description': 'The percentage of patients that achieve complete response (CR) and partial response (PR) after treatment.', 'timeFrame': '3 years'}, {'measure': 'Overall Survival (OS)', 'description': ""The time from the start of treatment to the patient's death or the last follow-up, with a maximum observation period of 5 years from randomization."", 'timeFrame': '5 years'}, {'measure': 'Incidence of Adverse Events', 'description': 'Adverse events include those related to the cryoablation procedure occurring during or after the procedure, as well as drug-related adverse events caused by immunotherapy.', 'timeFrame': '1 year'}, {'measure': 'Potential Predictive and Immunological Biomarkers (lymphocyte phenotypes, PD-L1 expression, cytokines)', 'description': 'This refers to the changes from baseline in the immunological responses following the cryoablation (with or without Serplulimab) and comparison between the two groups, including the percentage and function of lymphocyte phenotypes, the expression of PD-L1, the concentration of IFN-γ levels, etc.', 'timeFrame': '1 year'}]",5,18 Years,,ALL,False,Shanghai Chest Hospital,OTHER,2,134.0,ESTIMATED,2025-09-01T16:18:24.753322,v2_robust,True,True,False,False,True,
NCT05504265,Perioperative Analgesia Modes in Minimally Invasive Esophagectomy,Comparison of Efficacy and Safety of Different Analgesic Modes in Minimally Invasive Esophagectomy for Esophageal Cancer,Preemptive flurbiprofen axetil,"['Postoperative flurbiprofen axetil', 'Preemptive flurbiprofen axetil']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Esophageal Cancer,"['Esophageal Cancer', 'Perioperative Analgesia', 'NSAIDs', 'Opioid', 'Patient-controlled Analgesia']",[],RECRUITING,,2022-10-10,2025-12-20,"[{'measure': 'Postoperative pain score', 'description': ""In the Visual Analog Score to be used as the pain measurement criterion, '0' is the minimum value that indicates no pain, while '10' is the maximum value that defines the most severe pain."", 'timeFrame': '4 hours after surgery'}, {'measure': 'Postoperative pain score', 'description': ""In the Visual Analog Score to be used as the pain measurement criterion, '0' is the minimum value that indicates no pain, while '10' is the maximum value that defines the most severe pain."", 'timeFrame': '12 hours after surgery'}, {'measure': 'Postoperative pain score', 'description': ""In the Visual Analog Score to be used as the pain measurement criterion, '0' is the minimum value that indicates no pain, while '10' is the maximum value that defines the most severe pain."", 'timeFrame': '24 hours after surgery'}, {'measure': 'Postoperative pain score', 'description': ""In the Visual Analog Score to be used as the pain measurement criterion, '0' is the minimum value that indicates no pain, while '10' is the maximum value that defines the most severe pain."", 'timeFrame': '36 hours after surgery'}, {'measure': 'Postoperative pain score', 'description': ""In the Visual Analog Score to be used as the pain measurement criterion, '0' is the minimum value that indicates no pain, while '10' is the maximum value that defines the most severe pain."", 'timeFrame': '48 hours after surgery'}, {'measure': 'Postoperative pain score', 'description': ""In the Visual Analog Score to be used as the pain measurement criterion, '0' is the minimum value that indicates no pain, while '10' is the maximum value that defines the most severe pain."", 'timeFrame': '60 hours after surgery'}, {'measure': 'Postoperative pain score', 'description': ""In the Visual Analog Score to be used as the pain measurement criterion, '0' is the minimum value that indicates no pain, while '10' is the maximum value that defines the most severe pain."", 'timeFrame': '72 hours after surgery'}]","[{'measure': 'Time to first postoperative flatus', 'description': 'Time from the end of surgery to the first flatus.', 'timeFrame': 'Up to 14 days after surgery'}, {'measure': 'Time to first postoperative defaecation', 'description': 'Time from the end of surgery to the first defaecation.', 'timeFrame': 'Up to 14 days after surgery'}, {'measure': 'Abdominal distension score', 'description': ""Abdominal distension was measured using a scoring system, '0' is the minimum value that indicates no abdominal distension, while '10' is the maximum value that defines the most severe abdominal distension."", 'timeFrame': '24 hours after surgery'}, {'measure': 'Abdominal distension score', 'description': ""Abdominal distension was measured using a scoring system, '0' is the minimum value that indicates no abdominal distension, while '10' is the maximum value that defines the most severe abdominal distension."", 'timeFrame': '48 hours after surgery'}, {'measure': 'Abdominal distension score', 'description': ""Abdominal distension was measured using a scoring system, '0' is the minimum value that indicates no abdominal distension, while '10' is the maximum value that defines the most severe abdominal distension."", 'timeFrame': '72 hours after surgery'}, {'measure': 'Side effects related to opioids', 'description': 'Nausea and vomiting were measured using a scoring system(0 = no nausea, 1 = only nausea, 2 = both nausea and vomiting).', 'timeFrame': '24 hours after surgery'}, {'measure': 'Side effects related to opioids', 'description': 'Nausea and vomiting were measured using a scoring system(0 = no nausea, 1 = only nausea, 2 = both nausea and vomiting).', 'timeFrame': '48 hours after surgery'}, {'measure': 'Side effects related to opioids', 'description': 'Nausea and vomiting were measured using a scoring system(0 = no nausea, 1 = only nausea, 2 = both nausea and vomiting).', 'timeFrame': '72 hours after surgery'}, {'measure': 'Time to first postoperative ambulation', 'description': 'Time from the end of surgery to the first postoperative ambulation', 'timeFrame': 'Up to 14 days after surgery'}, {'measure': 'Hospital duration from operation to discharge', 'description': 'Time from the end of surgery to discharge from the hospital', 'timeFrame': 'Up to 60 days after surgery'}, {'measure': 'Rate of pulmonary infection', 'description': 'Rate of pulmonary infection up to 30 days after surgery', 'timeFrame': 'Up to 30 days after surgery'}]",18,18 Years,75 Years,ALL,False,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",OTHER,0,102.0,ESTIMATED,2025-09-01T16:18:24.753338,v2_robust,True,True,False,False,False,
NCT00608465,Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity,Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity,Eplerenone,"['Ramipril', 'Inspra', 'Eplerenone']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Metabolic Syndrome X,['Metabolic Syndrome X'],"['Fibrolytic Dysfunction', 'Obesity', 'PAI-1']",TERMINATED,Lack of enrollment,2006-05,2011-05,"[{'measure': 'Secreted Factors From Adipocytes Have Autocrine, Paracrine and Endocrine Effects That Have a Deleterious Effect on the Fibrinolytic System, Either by Enhancing PAI-1 Production or Impairing Endothelial t-PA Release', 'timeFrame': '10-Week period'}, {'measure': ""This Study Will Analyze Patients' Genetic Make up to Identify Who May be at Greater Risk for Heart Disease and Strokes in Relationship to High Blood Pressure and Central Obesity."", 'timeFrame': '10-weeks'}]",[],2,18 Years,,ALL,True,Vanderbilt University,OTHER,0,4.0,ACTUAL,2025-09-01T16:18:24.753380,v2_robust,True,True,False,True,False,Lack of enrollment
NCT05174065,"Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Apremilast (AMG 407) in Japanese Subjects With Palmoplantar Pustulosis (PPP)",Apremilast,"['AMG 407', 'Otezla', 'Placebo', 'Apremilast']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Palmoplantar Pustulosis,['Palmoplantar Pustulosis'],"['Palmoplantar Pustulosis', 'PPP', 'AMG 407', 'Apremilast', 'Otezla']",COMPLETED,,2022-03-08,2024-06-01,"[{'measure': 'Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at Week 16', 'description': 'A PPPASI 50 response is defined as a ≥ 50% reduction in PPPASI total score from baseline.\n\nThe PPPASI is a system used for assessing and grading the severity (in terms of erythema, pustules/vesicle and desquamation/scale) and area of PPP lesions and their response to therapy. The PPPASI produces a numeric score that can range from 0 to 72, with a higher score indicating more severe disease.\n\nParticipants who discontinued investigational product before week 16 due to lack of efficacy, adverse event, or use of protocol-prohibited medication (intercurrent events) were to be considered as treatment failures as the result of the intercurrent event and the PPPASI-50 values for visits on and after the intercurrent event were imputed as non-responders. The missing PPPASI-50 values due to the other reasons were imputed using the multiple imputation method.', 'timeFrame': 'Baseline and Week 16'}]","[{'measure': 'Change From Baseline in PPPASI Total Score at Week 16', 'description': 'The PPPASI is a system used for assessing and grading the severity (in terms of erythema, pustules/vesicle and desquamation/scale) and area of PPP lesions and their response to therapy. The PPPASI produces a numeric score that can range from 0 to 72, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity.\n\nThe continuous endpoints collected on and after the participant experienced treatment failure as the result of intercurrent event (IE) (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the mixed-effects model for repeated measures (MMRM) application.', 'timeFrame': 'Baseline and Week 16'}, {'measure': 'Change From Baseline in Palmoplantar Pustulosis Severity Index (PPSI) Total Score at Week 16', 'description': 'The PPSI is a system used for assessing and grading the severity of PPP lesions and their response to therapy. Evaluation of skin lesion site are assessed separately for erythema, pustules/vesicle and desquamation/scale, where each are rated on a scale of 0 to 4 and summed to produce a numeric total score than can range from 0 to 12, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity.\n\nThe continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.', 'timeFrame': 'Baseline and Week 16'}, {'measure': 'Change From Baseline in Visual Analogue Scale (VAS) Assessment for PPP Symptoms (Pruritus) at Week 16', 'description': 'Participants assessed the degree of pruritus itching symptoms on palms and soles caused by PPP on a VAS. The VAS score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no itch and the right-hand boundary (100) represents itch as severe as can be imagined by the participant. A negative change from baseline indicates a reduction in disease severity.\n\nThe continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.', 'timeFrame': 'Baseline and Week 16'}, {'measure': 'Change From Baseline in VAS Assessment for PPP Symptoms (Pain/Discomfort) at Week 16', 'description': 'Participants assessed the degree of pain/discomfort symptoms on palms and soles caused by PPP on a VAS. The VAS score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no pain/discomfort and the right-hand boundary (100) represents pain/discomfort as severe as can be imagined by the participant. A negative change from baseline indicates a reduction in disease severity.\n\nThe continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application.', 'timeFrame': 'Baseline and Week 16'}, {'measure': 'Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16', 'description': ""The DLQI is a skin disease-specific Quality of Life (QoL) questionnaire comprised of 10 items assessing the participant's status over the previous week. The DLQI was used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The DLQI produces a numeric score ranging from 0 to 30, with a higher score indicating more severe disease. A negative change from baseline indicates a reduction in disease severity.\n\nThe continuous endpoints collected on and after the participant experienced treatment failure as the result of IE (investigational product discontinuation due to lack of efficacy, adverse event, or protocol-prohibited medication use), the baseline value of corresponding endpoint were assigned to the data on and after IE up to Week 16 regardless of the observed data. The missing data due to other reasons will not be imputed considering the MMRM application."", 'timeFrame': 'Baseline and Week 16'}, {'measure': 'Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)', 'description': 'TEAEs were defined as any untoward medical occurrence in a participant irrespective of a causal relationship with the study treatment that began or worsened on or after the first dose of study treatment.\n\nA serious TEAE met at least 1 of the following criteria:\n\n* Resulted in death.\n* Was immediately life-threatening.\n* Required in-patient hospitalization or prolongation of existing hospitalization.\n* Resulted in persistent or significant disability/incapacity.\n* Was a congenital anomaly/birth defect.\n* Was any other medically important serious event.\n\nTEAEs of interest were defined as any of the following:\n\n* Depression.\n* Serious infection.\n* Risk of triggering suicide.\n* Serious diarrhea, nausea and vomiting.\n* Malignancies.\n* Vasculitis and Vasculopathy.\n* Serious Hypersensitivity.\n* Weight change (weight decrease).\n\nClinically significant changes in body weight, vital signs and laboratory abnormalities were also recorded as TEAEs.', 'timeFrame': 'Placebo-controlled period: Day 1 to Week 16; Apremilast exposure period : Apremilast Day 1 to a maximum of Week 52 (plus 4 weeks safety follow-up)'}]",7,18 Years,99 Years,ALL,False,Amgen,INDUSTRY,0,176.0,ACTUAL,2025-09-01T16:18:24.753414,v2_robust,True,True,True,False,True,
NCT04992065,A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease,"Dose Response and Safety of an Oral PCSK9i, NNC0385-0434, in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk on Maximally Tolerated Statin Dose and Other Lipid-lowering Therapy Requiring Further LDL-C Reduction",NNC0385-0434 A 15 mg,"['NNC0385-0434 A 40 mg', 'Evolocumab 140 mg/mL, Repatha®', 'NNC0385-0434 A 100 mg', 'NNC0385-0434 A 15 mg']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Atherosclerotic Cardiovascular Disease,['Atherosclerotic Cardiovascular Disease'],[],COMPLETED,,2021-08-03,2022-06-20,"[{'measure': 'Percentage Change in Low-density Lipoprotein (LDL)-Cholesterol', 'description': ""Percentage change in LDL-cholesterol (LDL-C) (measured in milligrams per deciliter \\[mg/dL\\]) at week 12 is presented. Data is reported for the on-treatment period. The on-treatment period is the time period where participants were considered exposed to trial product. The observation period starts at the date of first dose of trial product and ends at the first date of any of the following: The follow-up visit or the last date on randomised treatment regimen + 58 days or the end-date for the 'in-trial' observation period. The in-trial period is defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site."", 'timeFrame': 'Baseline (week 0), week 12'}]","[{'measure': 'Percentage Change in Total Cholesterol', 'description': ""Percentage change in total cholesterol (measured in millimoles per iliter \\[mmol/L\\]) at week 12 is presented. Data is reported for the on-treatment period. The on-treatment period is the time period where participants were considered exposed to trial product. The observation period starts at the date of first dose of trial product and ends at the first date of any of the following: The follow-up visit or the last date on randomised treatment regimen + 58 days or the end-date for the 'in-trial' observation period."", 'timeFrame': 'Baseline (week 0), week 12'}, {'measure': 'Percentage Change in High Density Lipoprotein (HDL)-Cholesterol', 'description': ""Percentage change in HDL-cholesterol (measured in mg/dL) at week 12 is presented. Data is reported for the on-treatment period. The on-treatment period is the time period where participants were considered exposed to trial product. The observation period starts at the date of first dose of trial product and ends at the first date of any of the following: The follow-up visit or the last date on randomised treatment regimen + 58 days or the end-date for the 'in-trial' observation period."", 'timeFrame': 'Baseline (week 0), week 12'}, {'measure': 'Percentage Change in Very Low Density Lipoprotein (VLDL)-Cholesterol', 'description': ""Percentage change in VLDL-cholesterol (measured in mmol/L) at week 12 is presented. Data is reported for the on-treatment period. The on-treatment period is the time period where participants were considered exposed to trial product. The observation period starts at the date of first dose of trial product and ends at the first date of any of the following: The follow-up visit or the last date on randomised treatment regimen + 58 days or the end-date for the 'in-trial' observation period."", 'timeFrame': 'Baseline (week 0), week 12'}, {'measure': 'Percentage Change in Triglycerides', 'description': ""Percentage change in triglycerides (measured in mg/dL) at week 12 is presented. Data is reported for the on-treatment period. The on-treatment period is the time period where participants were considered exposed to trial product. The observation period starts at the date of first dose of trial product and ends at the first date of any of the following: The follow-up visit or the last date on randomised treatment regimen + 58 days or the end-date for the 'in-trial' observation period."", 'timeFrame': 'Baseline (week 0), week 12'}, {'measure': 'Percentage Change in Total Apolipoprotein B (Apo B)', 'description': ""Percentage change in Apo B (measured in mg/dL) at week 12 is presented. Data is reported for the on-treatment period. The on-treatment period is the time period where participants were considered exposed to trial product. The observation period starts at the date of first dose of trial product and ends at the first date of any of the following: The follow-up visit or the last date on randomised treatment regimen + 58 days or the end-date for the 'in-trial' observation period."", 'timeFrame': 'Baseline (week 0), week 12'}, {'measure': 'Percentage Change in Total Apolipoprotein CIII (Apo CIII)', 'description': ""Percentage change in Apo CIII (measured in mg/dL) at week 12 is presented. Data is reported for the on-treatment period. The on-treatment period is the time period where participants were considered exposed to trial product. The observation period starts at the date of first dose of trial product and ends at the first date of any of the following: The follow-up visit or the last date on randomised treatment regimen + 58 days or the end-date for the 'in-trial' observation period."", 'timeFrame': 'Baseline (week 0), week 12'}, {'measure': 'Change in Total Lipoprotein(a) (Lp[a]): Ratio to Baseline', 'description': ""Change in total Lp(a) (measured in mg/dL) at week 12 is presented as ratio to baseline. Data is reported for the on-treatment period. The on-treatment period is the time period where participants were considered exposed to trial product. The observation period starts at the date of first dose of trial product and ends at the first date of any of the following: The follow-up visit or the last date on randomised treatment regimen + 58 days or the end-date for the 'in-trial' observation period."", 'timeFrame': 'Baseline (week 0), week 12'}, {'measure': 'Number of Treatment-emergent Adverse Events (TEAEs)', 'description': ""An adverse events (AE) is any untoward medical occurrence in a clinical trial participant that is temporally associated with the use of an investigational medicinal product (IMP), whether or not considered related to the IMP. All presented AEs are TEAEs. TEAEs was the number of AEs recorded during the on-treatment period. The on-treatment period is the time period where participants were considered exposed to trial product. The observation period starts at the date of first dose of trial product and ends at the first date of any of the following: The follow-up visit or the last date on randomised treatment regimen + 58 days or the end-date for the 'in-trial' observation period."", 'timeFrame': 'From baseline (week 0) to 138 days'}]",9,40 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,267.0,ACTUAL,2025-09-01T16:18:24.753478,v2_robust,True,True,True,False,True,
NCT01992367,"Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003","A Phase 1, Randomised, Double Blind, Placebo Controlled, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of ASLAN003 in Healthy Subjects",ASLAN003 ACTIVE,"['ASLAN 003 , LAS186323', 'ASLAN003 ACTIVE']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2013-08,2014-05,"[{'measure': 'Safety', 'description': 'Safety assessments will include 12 lead ECGs, physical examiniation, vital signs measurements, pulse rate, RR, body temperature, clinical laboratory assessments and recording of adverse events', 'timeFrame': '6 months'}]",[],1,21 Years,99 Years,MALE,True,ASLAN Pharmaceuticals,OTHER,0,61.0,ACTUAL,2025-09-01T16:18:24.753607,v2_robust,True,True,True,False,True,
NCT03642067,Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer,Phase A Phase 2 Study Evaluating Response and Biomarkers in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Treated With Nivolumab in Combination With Relatlimab,Nivolumab,"['BMS-986016, anti-LAG-3', 'Nivolumab', 'Relatlimab', 'OPDIVO, BMS-936558, anti-PD-1']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Microsatellite Stable (MSS) Colorectal Adenocarcinomas,"['Microsatellite Stable (MSS) Colorectal Adenocarcinomas', 'Colorectal Adenocarcinoma']","['Relatlimab', 'Nivolumab', 'Immunotherapy', 'Anti-PD-1', 'Anti-LAG-3', 'Antibody', 'MSS', 'PD-L1', 'Microsatellite stability', 'Colorectal cancer', 'Colon cancer', 'Rectal cancer']",COMPLETED,,2019-02-12,2024-09-18,"[{'measure': 'Objective Response Rate (ORR)', 'description': 'ORR is defined as the number of patients achieving a complete response (CR) or partial response (PR) based on RECIST 1.1 criteria. CR = disappearance of all target lesions, PR is =\\>30% decrease in sum of diameters of target lesions. Participants who discontinue due to toxicity or clinical progression prior to post-baseline tumor assessments will be considered as non-responders. Participants who discontinue for other reasons prior to their first dose of study drug will not included in the analysis.', 'timeFrame': '12 months'}]","[{'measure': 'Number of Participants Experiencing Drug-Related Adverse Events (AEs) Requiring Treatment Discontinuation', 'description': 'Defined using NCI CTCAE v5.0', 'timeFrame': '12 months'}]",2,18 Years,,ALL,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,1,59.0,ACTUAL,2025-09-01T16:18:24.753638,v2_robust,True,True,True,False,True,
NCT06564467,"A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202","A Phase І, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMT202 Injection in Chinese Healthy Participants",JMT202,"['Placrbo', 'JMT202']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Subjects,['Healthy Subjects'],[],ENROLLING_BY_INVITATION,,2024-07-23,2025-07-10,"[{'measure': 'The Number of adverse events (AEs) electrocardiograms', 'description': 'To investigate the safety and tolerability by assesment of AEs following administration.', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}, {'measure': 'Number of participants with clinically significant change from baseline in vital signs', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}, {'measure': 'Number of participants with clinically significant change from baseline in electrocardiogram (ECG) findings', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}, {'measure': 'Number of participants with clinically significant abnormalities in physical examination', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}]","[{'measure': 'Area under the concentration-time curve from 0 to the collection time t (AUC0-t)', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}, {'measure': 'Area under the concentration-time curve from 0 to infinity (AUC0-∞)', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}, {'measure': 'Time to maximum concentration (Tmax)', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}, {'measure': 'Serum Maximum concentration (Cmax)', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}, {'measure': 'Half-Life (t1/2)', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}, {'measure': 'Anti-drug antibody (ADA) prevalence in blood before study treatment and at the Follow-up Visit', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}, {'measure': 'Absolute change in High molecular weight adiponectin', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}, {'measure': 'Absolute change in weight', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}, {'measure': 'Absolute change in glycosylated hemoglobin', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}, {'measure': 'Absolute change in fasting insulin level', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}, {'measure': 'Absolute change in fasting glucose', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}, {'measure': 'Absolute change in blood lipoprotein', 'timeFrame': 'Pre-dose and multiple timepoints no less than 50 days'}]",16,18 Years,60 Years,ALL,True,Shanghai JMT-Bio Inc.,INDUSTRY,0,54.0,ESTIMATED,2025-09-01T16:18:24.753754,v2_robust,True,True,False,False,True,
NCT03558867,Personalised Medicine in Pre-diabetes and Early Type 2 Diabetes,Personalised Medicine in Prediabetes - Towards Preventing Diabetes in Individuals At Risk,Metformin + Healthy diet,"['Metformin + Personalized diet', 'Metformin + Healthy (low fat) diet', 'Metformin + Healthy diet']",3,INTERVENTIONAL,['NA'],,,Pre Diabetes,"['Pre Diabetes', 'Type 2 Diabetes Mellitus']","['Pre Diabetes', 'Insulin resistance', 'Metformin', 'Gut microbiota', 'Type 2 Diabetes Mellitus']",COMPLETED,,2018-06-05,2024-07-23,"[{'measure': 'Mean change in glycated haemoglobin (HbA1C, %) from baseline', 'description': 'Difference in the reduction of HbA1C between the groups', 'timeFrame': '6 months'}]","[{'measure': 'Total daily time of interstitial glucose levels below 7.8 mmol/L (140 mg/dL)', 'description': 'Difference in the time (minutes) per day with interstitial glucose measured below 7.8 mmol/L (140 mg/dL) between the groups', 'timeFrame': '6 months'}, {'measure': 'Glycaemic variability', 'description': 'Difference in the glycaemic variability as derived from CGM between the groups', 'timeFrame': '6 months'}, {'measure': 'Body weight', 'description': 'Difference in the magnitude of weight loss between the groups', 'timeFrame': '6 months'}, {'measure': 'Body fat mass', 'description': 'Difference in body fat mass composition as assessed using dual-energy X-ray absorptiometry (DXA) between the groups', 'timeFrame': '6 months'}, {'measure': 'Abdominal visceral fat volume', 'description': 'Difference in the abdominal visceral fat volume as assessed using DXA between the groups', 'timeFrame': '6 months'}, {'measure': 'Serum low-density lipoprotein (LDL)-cholesterol concentration', 'description': 'Difference in serum LDL-cholesterol between the groups', 'timeFrame': '6 months'}, {'measure': 'Serum high-density lipoprotein (HDL)-cholesterol concentration', 'description': 'Difference in serum HDL-cholesterol concentration between the groups', 'timeFrame': '6 months'}, {'measure': 'Serum triglycerides concentration', 'description': 'Difference in serum triglycerides between the groups', 'timeFrame': '6 months'}, {'measure': 'Blood pressure', 'description': 'Difference in diastolic and systolic blood pressure between the groups', 'timeFrame': '6 months'}, {'measure': 'Liver fat', 'description': ""Difference in liver fat measured by the Fibroscan's controlled attenuation parameter (CAP) function between the groups"", 'timeFrame': '6 months'}]",11,20 Years,70 Years,ALL,False,Garvan Institute of Medical Research,OTHER,1,138.0,ACTUAL,2025-09-01T16:18:24.753831,v2_robust,True,True,True,False,False,
NCT05971667,"Effect of Tadalafil, Sildenafil and Pentoxyfylline on Frozen Embryo Transfer Outcomes","""Effect of Tadalafil, Sildenafil and Pentoxyfylline on Endometrial Thickness and Frozen Embryo Transfer Outcomes",tadalafil,"['tadalafil', 'trental', 'Sildenafil', 'cialong', 'Respatio', 'pentoxifylline']",6,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,IVF,['IVF'],"['Tadalafil', 'Sildenafil', 'pentoxyfylline', 'frozen embryo transfer']",NOT_YET_RECRUITING,,2023-07-30,2023-10-30,"[{'measure': 'endometrial thickness', 'description': 'measured by transvaginal ultrasound', 'timeFrame': 'within 16 day of menstruation'}]","[{'measure': 'pregnancy rate', 'description': 'number of cases positive serum pregnancy test', 'timeFrame': '1 month'}]",2,20 Years,40 Years,FEMALE,False,Beni-Suef University,OTHER,0,200.0,ESTIMATED,2025-09-01T16:18:24.753873,v2_robust,True,True,False,False,False,
NCT06810167,Assessing Tenapanor as a Treatment of CF-related Constipation.,"An Open-label, Single Center Study Assessing Tenapanor as a Non-CFTR-mediated Treatment of CF-related Constipation in People With CF.",Tenapanor,['Tenapanor'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Cystic Fibrosis,"['Cystic Fibrosis', 'Constipation']","['Constipation', 'Cystic Fibrosis', 'CFrC']",RECRUITING,,2025-06-01,2027-06-30,"[{'measure': 'Increase in SBM frequency', 'description': 'There will be a statistically significant increase in spontaneous bowel movement frequency (SBM) in cystic fibrosis patients with CF-related constipation receiving tenapanor.', 'timeFrame': 'Patients will record SBM frequency over the 4-week treatment period.'}]","[{'measure': 'Change in PAC-SYM questionnaire score', 'description': 'There will be a change (with use of descriptive statistics) in bowel symptoms characterized by the Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire with tenapanor administration. PAC-SYM is a PRO previously used to examine constipation in pwCF. A decreased score corresponds to improvement of bowel symptoms.', 'timeFrame': 'Patients will complete the PAC-SYM at -2 weeks, 0 weeks, 2 weeks, and 4 weeks.'}, {'measure': 'Change in PAC-QOL questionnaire score', 'description': 'There will be a change (with use of descriptive statistics) in bowel symptoms characterized by the Patient Assessment of Constipation Quality of Life (PAC-QOL) questionnaire with tenapanor administration. PAC-QOL is a PRO previously used to examine constipation in pwCF. A decreased score corresponds to improvement of bowel symptoms.', 'timeFrame': 'Patients will complete the PAC-QOL at -2 weeks, 0 weeks, 2 weeks, and 4 weeks.'}, {'measure': 'Change in IBS-SSS questionnaire score', 'description': 'There will be a 50-point change in the Irritable Bowel Syndrome Scoring System - IBS-SSS (in line with recent bowel distress related literature Ford AC, Wright-Hughes A, Alderson SLet al Lancet 2023) in pwCF and CFrC receiving tenapanor.', 'timeFrame': 'Patients will complete the IBS-SSS at -2 weeks, 0 weeks, 2 weeks, and 4 weeks.'}]",4,18 Years,75 Years,ALL,False,Massachusetts General Hospital,OTHER,1,25.0,ESTIMATED,2025-09-01T16:18:24.753916,v2_robust,True,True,False,False,False,
NCT02351700,Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors,"Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors",IV Caldolor,"['IV Caldolor', 'IV ibuprofen', 'Opioid Sparing group', 'Standard treatment group', 'IV Placebo']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Pituitary Tumor,"['Pituitary Tumor', 'Pain']",[],COMPLETED,,2015-02-01,2016-04-01,"[{'measure': 'Comparison of Mean Pain Scores Between Two Arms (Measured Every 4 Hours Over 48 Hour)', 'description': 'Comparison of pain scores between two arms using Visual Analog Scale (VAS) for Pain. Units of measure are 0=No Pain, 1=Annoying, 2=Mild Pain, 3=Troublesome, 4=Nagging Pain, Uncomfortable, 5=Distressing, 6=Miserable, 7=Horrible, 8=Intense, Dreadful, 9=Unbearable, 10=Worst Possible Pain. Higher values represent a worse outcome. There are no subscales.', 'timeFrame': 'mean pain score over 48 hours'}]","[{'measure': 'Breakthrough Narcotic Requirement', 'description': 'Rescue narcotic in both groups will be recorded and compared using a standard equianalgesic oral morphine equivalent (OME) calculation', 'timeFrame': 'until discharge from hospital, an expected stay of 2 days'}, {'measure': 'Other Adverse Events', 'description': 'Epistaxis, potentially related to IV ibuprofen, will be compared between two groups', 'timeFrame': 'until discharge from hospital, an expected stay of 2 days'}]",3,18 Years,79 Years,ALL,False,"St. Joseph's Hospital and Medical Center, Phoenix",OTHER,0,62.0,ACTUAL,2025-09-01T16:18:24.754036,v2_robust,True,True,True,False,True,
NCT01895400,Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy,"A Single-center, Prospective, Randomized, Parallel Group, Placebo-controlled Exploratory Study on the Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy",Renexin (cilostazol 100mg + gingko biloba extract 80 mg),"['Renexin (cilostazol 100mg + gingko biloba extract 80 mg)', 'Renexin', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Recurrent Vestibulopathy,['Recurrent Vestibulopathy'],['Renexin for Recurrent Vestibulopathy'],TERMINATED,Participant enrollment is much delayed. The whole design needs to be revised.,2013-07,2015-12,"[{'measure': 'equilibrium score of dynamic posturography', 'description': 'compared with pretreatment equilibrium score', 'timeFrame': 'after 8 weeks of treatment'}]","[{'measure': 'dizziness handicap inventory', 'description': 'compared with pretreatment DHI score', 'timeFrame': 'at 4 weeks, 8 weeks after treatment'}, {'measure': 'visual analogue scale (VAS) of vertigo', 'description': 'compared with pretreatment VAS score', 'timeFrame': 'at 4 weeks, 8 weeks after treatment'}, {'measure': 'Questionnaire for Quality of life (SF36)', 'description': 'compared with pretreatment SF36 score', 'timeFrame': 'at 4 weeks, 8 weeks after treatment'}]",4,20 Years,,ALL,False,Jong Woo Chung,OTHER,2,26.0,ACTUAL,2025-09-01T16:18:24.754067,v2_robust,True,True,False,True,False,Participant enrollment is much delayed. The whole design needs to be revised.
NCT01950000,Treatment of Procedural Pain Associated With Turning in Patients With Mechanical Ventilation,Efficacy and Safety of Opioid Analgesics as a Preventive Treatment of Procedural Pain Associated With Turning Among Critically Ill Patients Under Mechanical Ventilation. A Controlled Clinical Trial Comparing Placebo and Fentanyl,Fentanyl,['Fentanyl'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Critical Illness,"['Critical Illness', 'Pain']",['Pain. Analgesia. Prevention'],COMPLETED,,2011-03,2012-04,"[{'measure': 'Change in the incidence of pain at the beginning and end of rotation', 'description': 'Participants will be evaluated at the beginning and the end of rotation, an expected average of 5 minutes. The evaluation of the change in the incidence of pain will be done calculating the mean between the beginning and the end of rotation.', 'timeFrame': 'Expected average of 5 minutes'}]","[{'measure': 'Area under the curve (AUC) of incidence of pain (BPS) during mobilizations with spin', 'timeFrame': 'Since the end of the turn until 30 minutes after'}]",2,18 Years,85 Years,ALL,False,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,OTHER,0,75.0,ACTUAL,2025-09-01T16:18:24.754111,v2_robust,True,True,True,False,False,
NCT04452500,Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study),Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD),CORT108297,"['CORT108297', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,PTSD,['PTSD'],"['Glucocorticoids', 'Posttraumatic Stress Disorder', 'Quality of Life']",RECRUITING,,2022-10-15,2025-12-31,"[{'measure': 'Clinician Administered PTSD Scale for DSM-5 (CAPS)', 'description': 'The CAPS is a 30-item interview that is the gold standard assessment for PTSD. The CAPS provides a dimensional and categorical measure of PTSD, and incorporates frequency and intensity of symptoms into a single severity score.', 'timeFrame': '56 days'}, {'measure': 'Frequency, Intensity, Burden of Side Effects (FIBSER)', 'description': 'The FIBSER is a self-report 0-6 Likert-type scale that measures global frequency, intensity, and overall burden of side effects.', 'timeFrame': '56 days'}]","[{'measure': 'Columbia Suicide Severity Rating Scale', 'description': 'The C-SSRS is FDA approved for assessing severity and change of suicidality in drug studies.', 'timeFrame': '56 days'}, {'measure': 'PTSD Checklist for DSM-5', 'description': 'The PCL is a validated self-report scale assessing PTSD symptoms corresponding to DSM-5.', 'timeFrame': '56 days'}, {'measure': 'World Health Organization Quality of Life (WHOQOL-BREF)', 'description': 'The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment. The WHOQOL-BREF is a shorter version of the original WHOQOL-100 instrument and is more convenient for use in large research studies or clinical trials.', 'timeFrame': '56 days'}]",5,18 Years,69 Years,ALL,False,VA Office of Research and Development,FED,0,88.0,ESTIMATED,2025-09-01T16:18:24.754123,v2_robust,True,True,False,False,False,
NCT01550900,Prospective Trial of Metformin - Chemoprevention Role,A Prospective Placebo-control Double-blind Randomized Trial of Metformin in Chemoprevention of Metachronous Colonic Neoplastic Polyps,Metformin ER,['Metformin ER'],1,INTERVENTIONAL,['NA'],,,Colorectum,['Colorectum'],"['Colorectum', 'Metachronous ctalColonic Neoplastic Polyps', 'Chemoprevention', 'Colonic adenoma(s)', 'Pre-cancerous tumor(s) on the colon', 'Metformin ER', 'Extended Release', 'Placebo', 'Sugar pill']",WITHDRAWN,,2013-07,,"[{'measure': 'Percentage of Ki-67-Stained Nuclei in Normal Rectal Mucosa', 'description': 'Primary endpoint defined as change in overall proliferation index between baseline and first return visit, that is, percentage of Ki-67-stained nuclei, in normal rectal mucosa. Tissue samples will be obtained at baseline colonoscopy and subsequent exams for analysis including Ki67, caspase 3, and various biomarkers and immunohistochemicals studies.', 'timeFrame': '3 months'}]",[],1,40 Years,75 Years,ALL,True,M.D. Anderson Cancer Center,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:24.754210,v2_robust,True,True,False,True,False,
NCT04635800,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients","A First-in-human, Open-label, Single Ascending Dose Study to Assess Safety and Tolerability of Intravitreal MHU650 in Participants With Macular Edema From Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (nAMD), or Retinal Vein Occlusion (RVO)",MHU650,['MHU650'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Macular Edema,"['Macular Edema', 'Diabetic Macular Edema', 'Neovascular Age-related Macular Degeneration', 'Retinal Vein Occlusion']","['Macular degeneration', 'age-related macular degeneration', 'dry macular degeneration', 'wet macular degeneration', 'Diabetic Macular Edema', 'DME', 'Neovascular age-related macular edema', 'nAMD', 'Retinal Vein Occlusion', 'RVO', 'MHU650', 'macular edema']",COMPLETED,,2020-12-10,2022-05-24,"[{'measure': 'Number of participants with ocular and nonocular adverse events', 'description': 'An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \\[including abnormal laboratory findings\\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study.', 'timeFrame': 'Day 1 to Day 60'}, {'measure': 'Change from baseline in Best Correct Visual Acuity (BCVA ) by dose level and timepoint - Study Eye', 'description': 'Best Correct Visual Acuity was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.', 'timeFrame': 'Day 1 to Day 60'}, {'measure': 'Change from baseline in Central subfield thickness (CSFT) (µm) in the study eye by dose level and timepoint', 'description': 'Central subfield thickness was measured by spectral domain optical coherence tomography (SD-OCT).', 'timeFrame': 'Day 1 to Day 60'}, {'measure': 'Change from baseline in Intraocular pressure (IOP) (mmHg) in the study eye by dose level and timepoint', 'description': ""Intraocular pressure was measured per the sites' local standard operating procedures, via tonometry."", 'timeFrame': 'Day 1 to Day 60'}]","[{'measure': 'Pharmacokinetics of single dose of MHU650 - Cmax', 'description': 'Assess serum PK profile of MHU650 by Cmax (if feasibile)', 'timeFrame': 'Days 1, 2, 5, 15, 29, 43 and 60'}, {'measure': 'Pharmacokinetics of single dose of MHU650 - Tmax', 'description': 'Assess serum PK profile of MHU650 by Tmax (if feasibile)', 'timeFrame': 'Days 1, 2, 5, 15, 29, 43 and 60'}, {'measure': 'Pharmacokinetics of single dose of MHU650 - T1/2', 'description': 'Assess serum PK profile of MHU650 by T1/2 (if feasibile)', 'timeFrame': 'Days 1, 2, 5, 15, 29, 43 and 60'}, {'measure': 'Pharmacokinetics of single dose of MHU650 - AUClast', 'description': 'Assess serum PK profile of MHU650 by AUClast (if feasibile)', 'timeFrame': 'Days 1, 2, 5, 15, 29, 43 and 60'}, {'measure': 'Pharmacokinetics of single dose of MHU650 - AUCinf', 'description': 'Assess serum PK profile of MHU650 by AUCinf (if feasibile)', 'timeFrame': 'Days 1, 2, 5, 15, 29, 43 and 60'}]",9,18 Years,90 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,21.0,ACTUAL,2025-09-01T16:18:24.754227,v2_robust,True,True,True,False,True,
NCT04971200,Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo,Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo,Tildrakizumab,['Tildrakizumab'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Skin and Connective Tissue Diseases,"['Skin and Connective Tissue Diseases', 'Skin Diseases', 'Pigmentation Disorder', 'Hypopigmentation', 'Biologic', 'Vitiligo']","['Tildrakizumab', 'non-segmental vitiligo', 'interleukin-23', 'IL-23', 'biological treatment', 'pilot study', 'Anti-Inflammatory Agents', 'Anti-Inflammatory Agents, Non-Steroidal', 'Vitiligo']",COMPLETED,,2021-09-16,2024-11-10,"[{'measure': 'Percentage repigmentation: Vitiligo Area Scoring Index (VASI)', 'description': 'Percentage repigmentation is assessed through change in score from baseline. Range 0-100. Higher score=greater depigmentation/worse', 'timeFrame': 'Week 24'}, {'measure': 'Percentage repigmentation: Vitiligo Extent Score (VES)', 'description': 'Percentage repigmentation is assessed through change in score from baseline. Range 0-100. Higher score=greater depigmentation/worse', 'timeFrame': 'Week 24'}, {'measure': 'Percentage repigmentation: Photographs', 'description': 'Percentage repigmentation is assessed through comparison of photographs of vitiligo lesions from baseline.', 'timeFrame': 'Week 24'}]","[{'measure': 'Percentage repigmentation: Vitiligo Area Scoring Index (VASI)', 'description': 'Percentage repigmentation is assessed through change in score from baseline. Range 0-100. Higher score=greater depigmentation/worse', 'timeFrame': 'Week 12'}, {'measure': 'Percentage repigmentation: Vitiligo Extent Score (VES)', 'description': 'Percentage repigmentation is assessed through change in score from baseline. Range 0-100. Higher score=greater depigmentation/worse', 'timeFrame': 'Week 12'}, {'measure': 'Percentage repigmentation: Photographs', 'description': 'Percentage repigmentation is assessed through comparison of photographs of vitiligo lesions from baseline.', 'timeFrame': 'Week 12'}, {'measure': 'Time to repigmentation', 'timeFrame': 'through study treatment completion at 24-weeks'}, {'measure': 'Change in Quality of Life score from baseline: Dermatology Life Quality Index (DLQI)', 'description': ""Used to assess treatment response on subject's quality of life. Range 0-30. Higher score=larger effect on patient's life/worse"", 'timeFrame': 'Baseline through week 12 and through study treatment completion at 24-weeks'}, {'measure': 'Change in Quality of Life score from baseline: Patient Global Impression of Change (PGIC)', 'description': '1-tem questionnaire designed to assess a subject\'s impression of disease improvement. 7 point Likert scale ranging from ""Very much better"" to ""Very much worse"" with ""no change"" in the middle. Range\\[1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderately better, 6-better/a definite improvement, 7-a great deal better\\]. Higher score=better impression of change/better', 'timeFrame': 'Baseline through week 12 and through study treatment completion at 24-weeks'}, {'measure': 'Change in Quality of Life score from baseline: Self-Assessment Vitiligo Extent Score (SA-VES)', 'description': 'Validated patient reported outcome measurement to provide information about disease extent and repigmentation. Range 0-100. Higher score=greater depigmentation/worse.', 'timeFrame': 'Baseline through week 12 and through study treatment completion at 24-weeks'}, {'measure': 'Adverse events', 'description': 'incidence and nature of any adverse events', 'timeFrame': 'through study treatment completion at 24-weeks'}]",11,18 Years,,ALL,False,"Premier Specialists, Australia",OTHER,0,12.0,ACTUAL,2025-09-01T16:18:24.754265,v2_robust,True,True,True,False,True,
NCT06744400,Optimal Dose of Anti-lymphocyte Globulin in Kidney Transplant Recipients With Low Immunological Risk,Optimal Dose of Anti-lymphocyte Globulin in Kidney Transplant Recipients With Low Immunological Risk,Grafalon® administered during 5 consecutive days at 2 mg/kg/j,"['Group 3', 'Group 2', 'Grafalon® administered during 5 consecutive days at 1 mg/kg/j', 'Grafalon® administered during 5 consecutive days at 0,5 mg/kg/j', 'Grafalon® administered during 5 consecutive days at 2 mg/kg/j', 'Group 1']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Renal Transplantation,['Renal Transplantation'],"['kidney transplant', 'anti-lymphocyte globulin', 'Grafalon', 'Immunosuppression']",NOT_YET_RECRUITING,,2025-01-15,2027-01-15,"[{'measure': 'The optimal non-depleting dose (Maximum Tolerated Dose; MTD) of rabbit anti-human T-lymphocyte immunoglobulin (Grafalon®) to prevent the complications associated with prolonged CD4 T cell lymphopenia in low immunological risk renal transplant recipients.', 'description': 'The Dose Limiting Toxicity (DLT) defined by a T cell (CD3+) relative depletion above 30 % compared to baseline (Day 0) at the end of the Grafalon® induction treatment (Day 4).', 'timeFrame': 'From transplantation to the end of treatment at 4 days'}]","[{'measure': 'The tolerance of Grafalon® in each dose level.', 'description': 'Toxicities: Incidence and grade for Adverse events (AEs), drug related AEs, drug related AE leading to dose reduction or discontinuation during treatment, Serious Adverse Events (SAE) and Suspected Unexpected Severe Adverse Reaction (SUSAR), according to Common Terminology Criteria for Adverse Events (CTCAE) V5.0.', 'timeFrame': 'From transplantation to the end of the study at 1 year.'}, {'measure': 'Clearance of Grafalon® during the treatment period and until month-3 in each dose level.', 'description': 'Pharmacokinetic study (clearance of Grafalon) including for each dose level the calculation of the plasmatic clearance evaluated by the air under curve of serum active Grafalon® concentration at day 0 and day 4 and the trough level of Grafalon® at each visit until month-3.', 'timeFrame': 'From transplantation to 3 month after first treatment.'}, {'measure': 'Describe immune profile and immune restauration in each dose level.', 'description': 'The absolute count and proportion of different T and B cell subpopulations, Natural Killer (NK) cells, monocytes and neutrophils at each time point.', 'timeFrame': 'From transplantation to 1 year after.'}, {'measure': 'Describe time to event clinical endpoints since transplantation at each dose level.', 'description': 'Time to Transplant failure defined as the time since transplantation to either graft loss or death with a functioning graft. Return to dialysis or retransplantation defined graft loss.\n\nOverall survival defined as the time since transplantation to death. Time to kidney allograft acute rejection defined as the time since transplantation since to kidney allograft acute rejection.', 'timeFrame': 'From transplation to 1 year after.'}, {'measure': 'The rate of patients with infection up to 1 year after transplantation in each dose level.', 'description': 'The infection up to 1 year after transplantation defined by :\n\n* the onset of a severe bacterial infection: all bacterial infections leading to patient hospitalization)\n* or an opportunistic infection: all types of infections that occur only in patients with an immune system deficiency and never in healthy patients (i.e. pneumocystis, tuberculosis, cryptococcosis, candidosis, Kaposi sarcoma, herpesviridae infections, B EBV lymphoma, HTLV T leukemia, toxoplasmosis, cryptococosis, polyomavirus viremia or disease…)', 'timeFrame': 'From transplantation to 1 year after'}, {'measure': 'The number of infections by patients up to 1 year after transplantation in each dose level', 'description': 'The infection up to 1 year after transplantation defined by :\n\n* the onset of a severe bacterial infection: all bacterial infections leading to patient hospitalization)\n* or an opportunistic infection: all types of infections that occur only in patients with an immune system deficiency and never in healthy patients (i.e. pneumocystis, tuberculosis, cryptococcosis, candidosis, Kaposi sarcoma, herpesviridae infections, B EBV lymphoma, HTLV T leukemia, toxoplasmosis, cryptococosis, polyomavirus viremia or disease…).', 'timeFrame': 'From transplantation to 1 year after'}, {'measure': 'The rate of patients with an atherosclerotic event up to 1 year after transplantation in each dose level', 'description': 'The atherosclerotic event up to 1 year after transplantation defined by major adverse cardiovascular events defined by coronary artery disease, cerebrovascular disease, peripheral arterial disease of the lower limbs, aortic pathology.', 'timeFrame': 'From transplantation to year after'}, {'measure': 'Renal function at 1 year post transplant in each dose level', 'description': 'Renal function at 1 year post transplant evaluated by estimated glomerular filtration rate (eGFR) calculated by the creatinine clearance according to the formula CKD-EPI.', 'timeFrame': 'From transplantation to 1 year after.'}]",9,18 Years,,ALL,False,Centre Hospitalier Universitaire de Besancon,OTHER,0,18.0,ESTIMATED,2025-09-01T16:18:24.754323,v2_robust,True,True,False,False,True,
NCT00369200,AFP464 in Treating Patients With Advanced Solid Tumors,A Phase 1 Study of AFP464 (Aminoflavone Prodrug) in Patients With Advanced Solid Tumors,AFP464,['AFP464'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,"Unspecified Adult Solid Tumor, Protocol Specific","['Unspecified Adult Solid Tumor, Protocol Specific']",[],TERMINATED,,2006-06,,"[{'measure': 'Maximum tolerated dose determined by dose-limiting toxicity', 'timeFrame': '28 days'}, {'measure': 'Types and grades of toxicity', 'description': 'Full frequency distributions of grade of toxicity, by toxicity type, will be generated, by dose level. Among all treated patients, both point and exact confidence interval estimates of the rate of every specific type of Grade 3-4 toxicity will be calculated, by dose level. Grade 2 DLCO rates (point and confidence level) will also be computed, by dose level.', 'timeFrame': 'Up to 4 weeks'}]","[{'measure': 'Pharmacokinetic, pharmacodynamic, and pharmacogenomic parameters', 'timeFrame': 'Up to 4 weeks'}, {'measure': 'Response rate', 'description': 'Point and exact confidence interval estimates of response rate will be provided for all eligible patients combined, and if warranted, by specific dose levels.', 'timeFrame': 'Up to 4 weeks'}]",4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,60.0,ACTUAL,2025-09-01T16:18:24.754430,v2_robust,True,True,False,True,False,
NCT06223100,Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection,An Observational Study on the Efficacy and Safety of the Combination Regimen Based on Eravacycline in the Treatment of Multidrug-resistant Bacterial Infections in Immunocompromised Host Populations.,Eravacycline,"['XERAVA', 'Eravacycline']",2,OBSERVATIONAL,[],,,Immune Dysregulation Disorder,['Immune Dysregulation Disorder'],[],NOT_YET_RECRUITING,,2024-02-01,2025-12-31,"[{'measure': '30-day all-cause mortality', 'description': 'Evaluate the 30-day all-cause mortality of multi-drug resistant bacterial infections in immunocompromised host populations treated with the combined regimen of eravacycline.', 'timeFrame': 'during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose'}, {'measure': 'Clinical cure rate', 'description': 'Evaluate the clinical cure rate of eravacycline treatment.', 'timeFrame': 'during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose'}, {'measure': 'Symptom improvement rate', 'description': 'Evaluate the symptom improvement rate of eravacycline treatment.', 'timeFrame': 'during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose'}]","[{'measure': 'Safety and tolerance of eravacycline', 'description': 'Safety evaluation was mainly based on the incidence of adverse events / adverse reactions in the two groups of patients.', 'timeFrame': 'during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose'}, {'measure': 'Microbial clearance rate', 'description': 'In patients who met all clinical evaluation criteria and had positive bacterial culture before treatment, the microbiological efficacy was evaluated at the end of treatment and after treatment (discharge). The results of follow-up (discharge) after treatment were the main evaluation endpoints, and the bacterial clearance rate was calculated. The microbiological efficacy was determined according to the following criteria: clearance, assumed clearance, non-clearance, assumed non-clearance, partial clearance, and others.', 'timeFrame': 'during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose'}, {'measure': 'Impact of different treatment timing on eravacycline outcomes as assessed by 30-day all-cause mortality.', 'description': 'The timing of treatment refers to the time when the patients with positive previous culture results start the treatment with eravacycline, one of which assessed the 30-day all-cause mortality of multi-drug resistant bacterial infections in immunocompromised host populations treated with the combined regimen of eravacycline.', 'timeFrame': 'during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose'}, {'measure': 'Impact of different treatment timing on eravacycline outcomes as assessed by clinical cure rates.', 'description': 'The timing of treatment refers to the time when the patients with positive previous culture results start the treatment with eravacycline, one of which assessed the clinical cure rate of eravacycline treatment.', 'timeFrame': 'during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose'}, {'measure': 'Impact of different treatment timing on eravacycline outcomes as assessed by clinical improvement rates.', 'description': 'The timing of treatment refers to the time when the patients with positive previous culture results start the treatment with eravacycline, one of which assessed the symptom improvement rate of eravacycline treatment.', 'timeFrame': 'during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose'}, {'measure': 'The 30-day infection recurrence rate', 'description': 'The 30-day infection recurrence rate', 'timeFrame': 'during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose'}]",9,18 Years,,ALL,,Sichuan Provincial People's Hospital,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:24.754506,v2_robust,False,True,False,False,True,
NCT03155100,Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines,Phase 2 Study of Carfilzomib + Elotuzumab + Dexamethasone for Relapsed or Progressed Multiple Myeloma After 1-3 Prior Treatment Lines,Carfilzomib for Inj 60 milligram (MG),"['Monoclonal antibody', 'Elotuzumab 400 MG', 'Proteasome inhibitor', 'Carfilzomib for Inj 60 milligram (MG)', 'Steroid', 'Dexamethasone']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma in Relapse,['Multiple Myeloma in Relapse'],[],COMPLETED,,2017-08-07,2023-08-31,"[{'measure': 'Overall response rate', 'description': 'The proportion of patients having achieved at least partial response.', 'timeFrame': '3 years'}]","[{'measure': 'Severe adverse events', 'description': 'Non-hematological grade 3 or more severe adverse events more or at least 70 percent', 'timeFrame': '3 years'}]",2,18 Years,74 Years,ALL,False,Raija Silvennoinen,OTHER,3,15.0,ACTUAL,2025-09-01T16:18:24.754533,v2_robust,True,True,True,False,True,
NCT02218307,The Use of Antibiotic Sinonasal Rinse After Sinus Surgery,The Use of Antibiotic Sinonasal Rinse After Sinus Surgery: A Randomized Double-Blind Control Trial,Mupirocin,"['Mupirocin', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Rhinosinusitis,['Chronic Rhinosinusitis'],[],COMPLETED,,2011-11,2015-06,"[{'measure': 'Quality of Life in Chronic Rhinosinusitis Patients', 'description': ""Measuring the quality of life in chronic rhinosinusitis through completion of a questionnaire named SNOT 20 ( 20 questions for Sino-Nasal Outcome Test)\n\nSnot20:\n\nScale 1 to 5 for 20 symptoms numbered below where 5 is the worst symptom. Total SNOT is scale from 0-100 where 100 is the worst.\n\nThe following are the elements:\n\n1\\. need to blow 2. sneezing 3. runny nose 4. cough 5. postnasal drip 6. Thick nasal discharge 7. Ear fullness 8. Dizziness 9. Ear pain 10. facial pain/pressure 11. difficulty falling asleep 12. wake up at night 13. lack of a good night's sleep 14. wake up tired 15. Fatigue 16. Reduced productivity 17. Reduced concentration 18. frustrated/ restless/irritable 19. sad 20. Embarrassed"", 'timeFrame': '3 months'}]","[{'measure': 'Quality of Life in Chronic Rhinosinusitis Patients', 'description': 'Measuring the quality of life in chronic rhinosinusitis through completion of a questionnaire named Visual Analog Scale for Nasal Obstruction/Congestion. VAS for nasal obstruction is scale from 0 to 100 where 100 mean worse.', 'timeFrame': '3 months'}]",2,18 Years,,ALL,False,University of Miami,OTHER,0,68.0,ACTUAL,2025-09-01T16:18:24.754749,v2_robust,True,True,True,False,False,
NCT03077607,A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors,"A PHASE 1 OPEN-LABEL, TWO-ARM,DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND RIFAMPIN ON THE PHARMACOKINETICS OF TALAZOPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS",Talazoparib,"['Itraconazole', 'Rifampin', 'Talazoparib']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumors,['Advanced Solid Tumors'],[],COMPLETED,,2016-11-07,2018-01-20,"[{'measure': 'Maximum Observed Plasma Concentration (Cmax) of Talazoparib: Alone and in Combination With Itraconazole', 'description': 'T1= Time frame for ""Talazoparib 0.5 mg Alone"" and T2= time frame for ""Talazoparib 0.5 mg in Combination With Itraconazole 100 mg BID"".', 'timeFrame': 'T1=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 1; T2=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 23'}, {'measure': 'Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-last) of Talazoparib: Alone and in Combination With Itraconazole', 'description': 'T1= Time frame for ""Talazoparib 0.5 mg Alone"" and T2= time frame for ""Talazoparib 0.5 mg in Combination With Itraconazole 100 mg BID"".', 'timeFrame': 'T1=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 1; T2=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 23'}, {'measure': 'Area Under the Plasma Concentration-Time Profile From Time Zero to Extrapolated Infinity (AUC0-inf) of Talazoparib: Alone and in Combination With Itraconazole', 'description': 'T1= Time frame for ""Talazoparib 0.5 mg Alone"" and T2= time frame for ""Talazoparib 0.5 mg in Combination With Itraconazole 100 mg BID"".', 'timeFrame': 'T1=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 1; T2=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 23'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of Talazoparib: Alone and in Combination With Rifampin', 'description': 'T3= Time frame for ""Talazoparib 1.0 mg Alone"" and T4= time frame for ""Talazoparib 1.0 mg in Combination With Rifampin 600 mg QD"".', 'timeFrame': 'T3=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 1; T4=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 25'}, {'measure': 'Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-last) of Talazoparib: Alone and in Combination With Rifampin', 'description': 'T3= Time frame for ""Talazoparib 1.0 mg Alone"" and T4= time frame for ""Talazoparib 1.0 mg in Combination With Rifampin 600 mg QD"".', 'timeFrame': 'T3=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 1; T4=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 25'}, {'measure': 'Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of Talazoparib: Alone and in Combination With Rifampin', 'description': 'T3= Time frame for ""Talazoparib 1.0 mg Alone"" and T4= time frame for ""Talazoparib 1.0 mg in Combination With Rifampin 600 mg QD"".', 'timeFrame': 'T3=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 1; T4=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 25'}]","[{'measure': 'Time to Attain Maximum Observed Plasma Concentration (Tmax) of Talazoparib: Alone and in Combination With Itraconazole', 'description': 'T1= Time frame for ""Talazoparib 0.5 mg Alone"" and T2= time frame for ""Talazoparib 0.5 mg in Combination With Itraconazole 100 mg BID"".', 'timeFrame': 'T1=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 1; T2=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 23'}, {'measure': 'Terminal Elimination Half-Life (t1/2) of Talazoparib: Alone and in Combination With Itraconazole', 'description': 'Terminal elimination half-life was defined as time measured for the plasma concentration of talazoparib to decrease by one half. T1= Time frame for ""Talazoparib 0.5 mg Alone"" and T2= time frame for ""Talazoparib 0.5 mg in Combination With Itraconazole 100 mg BID"".', 'timeFrame': 'T1=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 1; T2=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 23'}, {'measure': 'Apparent Clearance (CL/F) of Talazoparib: Alone and in Combination With Itraconazole', 'description': 'Clearance of talazoparib was measure of the rate at which it was metabolized or eliminated by normal biological processes. T1= Time frame for ""Talazoparib 0.5 mg Alone"" and T2= time frame for ""Talazoparib 0.5 mg in Combination With Itraconazole 100 mg BID"".', 'timeFrame': 'T1=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 1; T2=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 23'}, {'measure': 'Apparent Volume of Distribution During Terminal Phase (Vz/F) of Talazoparib: Alone and in Combination With Itraconazole', 'description': 'Apparent volume of distribution was defined as the theoretical volume in which the total amount of talazoparib would need to be uniformly distributed to produce its desired plasma concentration. T1= Time frame for ""Talazoparib 0.5 mg Alone"" and T2= time frame for ""Talazoparib 0.5 mg in Combination With Itraconazole 100 mg BID"".', 'timeFrame': 'T1=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 1; T2=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 23'}, {'measure': 'Time to Attain Maximum Observed Plasma Concentration (Tmax) of Talazoparib: Alone and in Combination With Rifampin', 'description': 'T3= Time frame for ""Talazoparib 1.0 mg Alone"" and T4= time frame for ""Talazoparib 1.0 mg in Combination With Rifampin 600 mg QD"".', 'timeFrame': 'T3=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 1; T4=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 25'}, {'measure': 'Terminal Elimination Half-Life (t1/2) of Talazoparib: Alone and in Combination With Rifampin', 'description': 'Terminal elimination half-life was defined as time measured for the plasma concentration of talazoparib to decrease by one half. T3= Time frame for ""Talazoparib 1.0 mg Alone"" and T4= time frame for ""Talazoparib 1.0 mg in Combination With Rifampin 600 mg QD"".', 'timeFrame': 'T3=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 1; T4=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 25'}, {'measure': 'Apparent Volume of Distribution During Terminal Phase (Vz/F) of Talazoparib: Alone and in Combination With Rifampin', 'description': 'Apparent volume of distribution was defined as the theoretical volume in which the total amount of talazoparib would need to be uniformly distributed to produce its desired plasma concentration. T3= Time frame for ""Talazoparib 1.0 mg Alone"" and T4= time frame for ""Talazoparib 1.0 mg in Combination With Rifampin 600 mg QD"".', 'timeFrame': 'T3=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 1; T4=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 25'}, {'measure': 'Apparent Clearance (CL/F) of Talazoparib: Alone and in Combination With Rifampin', 'description': 'Clearance of talazoparib was measure of the rate at which it was metabolized or eliminated by normal biological processes. T3= Time frame for ""Talazoparib 1.0 mg Alone"" and T4= time frame for ""Talazoparib 1.0 mg in Combination With Rifampin 600 mg QD"".', 'timeFrame': 'T3=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 1; T4=Predose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 and 336 hours post Talazoparib dose on Day 25'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'description': 'An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. A TEAE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pre-treatment state. AEs included both serious and non-serious adverse events.', 'timeFrame': 'Baseline up to end of study (up to 61 days)'}, {'measure': 'Number of Participants With Clinical Significance Abnormalities in Laboratory Parameters', 'description': 'Chemistry:(sodium135-146,potassium3.5-5.5,chloride95-109,glucose3.3-5.5,urea2.8-7.2,calcium2.2-2.65,phosphate0.8-1.45,triglyceride0.4-1.7,cholesterol2.6-5.2)millimoles/L, (bilirubin\\[direct0-3,total2-21\\],creatinine53- 110)micromole/L, (albumin35-52,protein65-83)g/L,(alkaline phosphatase30-120, aspartate amino\\[A\\]transferase\\[T\\]4-46, alanine AT4-49, lactic acid dehydrogenase200-460, gammaglutamylT7-50,creatinine kinase24-170)U/L. Hematology: hemoglobin(Hb)120-177, hematocrit0.35-0.49L/L, RBC4-5.9T/L, (platelet150- 400,WBC4-10,basophil\\<0.10,eosinophil\\<0.40, neutrophil1.50-7.00,monocyte\\<1.20,lymphocyte1.0 -3.70)G/L. Urine:(glucose,protein,ketone,Hb:negative/positive), specific gravity1.010-1.030g/cm\\^3, pH4.8-7.8, pale yellow-deep amber, microscopy\\[WBC0-5,leukocyte0-5,Hb0-3,cast0-1,bacteria0-500,epithelial0-6\\])Pcs/area. Coagulation:(activated partial thromboplastine time25-43,prothrombin time13.7-15.6) seconds,international normalized ratio0.89-1.1. Investigator judged clinical significance.', 'timeFrame': 'Baseline up to end of study (up to 61 days)'}, {'measure': 'Number of Participants With Clinically Significant Abnormalities in Vital Signs', 'description': 'Vital sign abnormalities: a) systolic blood pressure (SBP): 1) minimum less than (\\<) 90 millimeter of mercury (mmHg), 2) change from baseline maximum decrease greater than equal to (\\>=) 30 mmHg, 3) change from baseline maximum increase \\>=30 mmHg; b) diastolic blood pressure (DBP): 1) minimum \\<50 mmHg, 2) change from baseline maximum decrease \\>=20 mmHg, 3) change from baseline maximum increase \\>=20 mmHg; c) supine pulse rate: 1) minimum \\<40 beats per minute (bpm), 2) maximum \\>120 bpm; d) standing pulse rate: 1) minimum \\<40 bpm and 2) maximum \\>140 bpm. Clinical significance of vital signs abnormalities was judged by investigator.', 'timeFrame': 'Baseline up to end of study (up to 61 days)'}, {'measure': 'Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)', 'description': ""ECG abnormalities: a) QT Interval: new absolute values greater than (\\>) 450, \\>480, \\>500 milliseconds (msec), increase from baseline \\>30 and \\>60 msec, b) QT interval using Fridericia's correction (QTcF) Interval: new absolute values \\>450, \\>480, \\>500 msec, increase from baseline \\>30 and \\> 60 msec, c) Heart rate: increase from baseline \\>25 percentage (%) and to a value \\>100 bpm, decrease from baseline \\>25% and to a value \\<50 bpm, d) PR Interval: increase from baseline \\> 25% and to a value \\>200 msec, e) QRS duration: increase from baseline \\> 25% and to a value \\>100 msec. Clinical significance of ECG abnormalities was judged by investigator."", 'timeFrame': 'Baseline up to end of study (up to 61 days)'}, {'measure': 'Number of Participants With Clinically Significant Physical Examination Findings', 'description': 'Physical examination included examination of abdomen, cardiovascular, eyes, ears, nose, throat, general appearance, head, neck, thyroid, lymph nodes, musculoskeletal, neurological, skin / subcutaneous tissue, thorax / lungs, abdomen including spleen size, breasts (female only) and respiratory. Clinical significance of physical examination was judged by investigator.', 'timeFrame': 'Baseline up to end of study (up to 61 days)'}]",19,18 Years,,ALL,False,Pfizer,INDUSTRY,1,36.0,ACTUAL,2025-09-01T16:18:24.754788,v2_robust,True,True,True,False,True,
NCT01607307,Daikenchuto for Intestinal Dysmotility and Prevention of Postoperative Paralytic Ielus After Pancreaticoduodenectomy,"Effect of Daikenchuto (TJ-100) on Intestinal Dysmotility and For the Prevention of Postoperative Paralytic Ileus in Patients Undergoing Pancreaticoduodenectomy: A Multicenter, Randomized, Placebo-Controlled Phase II Trial",Oral/enteral TJ-100 solution,"['Oral/enteral placebo solution', 'B', 'Oral/enteral TJ-100 solution', 'A']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Paralytic Ileus,['Paralytic Ileus'],"['daikenchuto', 'postoperative ileus', 'pancreaticoduodenectomy']",UNKNOWN,,2012-08,2016-08,"[{'measure': 'Incidence of postoperative paralytic ileus (including the duration of paralysis)', 'description': 'Delayed passage of first flatus for 72 hours (3.0 days) after surgery, or a postoperative condition that requires an intervention for the ileus. Every 12 hours is counted as 0.5 postoperative day and every 24 hours as 1.0 postoperative day.', 'timeFrame': '72 hours'}, {'measure': 'The duration until the first flatus after surgery.', 'description': 'The first passages of flatus will be confirmed by patients themselves and they will inform it to the medical staffs.', 'timeFrame': '14 days'}]","[{'measure': 'QOL assessment by the Gastrointestinal Symptom Rating Scale (GSRS) Score (Japanese Version)', 'description': 'QOL assessment by the Gastrointestinal Symptom Rating Scale (GSRS) Score (Japanese Version) on postoperative day 7.', 'timeFrame': '7 days'}, {'measure': 'Abdominal pain and abdominal distention scores on the Visual Analogue Scale.', 'description': 'Abdominal pain and abdominal distention scores on the Visual Analogue Scale on postoperative day 3.', 'timeFrame': '3 days'}, {'measure': 'The change ratio of abdominal circumference.', 'description': 'The change ratio of abdominal circumference on postoperative day 3 and operative day just after surgery', 'timeFrame': '3 days'}, {'measure': 'The incidence of postoperative complication.', 'description': ""The incidence of postoperative complication based on Dindo's classification."", 'timeFrame': '14 days'}, {'measure': 'The length of postoperative hospital day.', 'description': 'Patients were discharged only when they fulfilled the criteria as follows: a return to preoperative activities of daily living, no deep-site infections, normal laboratory data, no drains, and the possibility for oral nutrition above the basal metabolism.', 'timeFrame': '30 days'}, {'measure': 'The incidence of surgical site infection.', 'description': 'Intra-abdominal abscess was defined as intra-abdominal fluid collection with positive cultures identified by ultrasonography or computed tomography associated with persistent fever and elevations of white blood cell counts.', 'timeFrame': '30 days'}, {'measure': 'The long term incidence of postoperative ileus after surgery.', 'description': 'The follow-up investigation of the long term incidence of postoperative ileus is scheduled in two years after surgery.', 'timeFrame': '2 years'}]",9,20 Years,,ALL,False,Wakayama Medical University,OTHER,1,220.0,ESTIMATED,2025-09-01T16:18:24.754883,v2_robust,True,True,False,False,False,
NCT06590207,Convalescent Plasma for the Treatment of Patients With WNV - a Double- Blind Randomized Controlled Study,Administering Convalescent Plasma Rich With Neutralizing Abs. to Hospitalized Adults With WNV - a Double-blind Randomized Controlled Study,plasma rich with WNV neutralizing antibodies,"['plasma rich with WNV neutralizing antibodies', 'Saline', 'Neurtalizing plasma']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,West Nile Fever With Neurologic Manifestation (Diagnosis),"['West Nile Fever With Neurologic Manifestation (Diagnosis)', 'West Nile Fever Without Complications']",['WNV; Neutralizing Abs; Convalescent plasma; neuroinvasive'],COMPLETED,,2024-07-04,2025-03-30,"[{'measure': 'Unfavorable outcom = Composite outcome of mortality or functional deterioration on day 30', 'description': 'functional deterioration will be defined using Barthel Index', 'timeFrame': 'day 28-32'}]","[{'measure': 'unfavorable outcome on day 90', 'description': 'same as primary outcome but on day 90', 'timeFrame': 'day 88-92'}, {'measure': 'Serious adverse events', 'description': 'Allergic reaction, pulmonary congestion, hemolysis', 'timeFrame': 'day 2-32'}, {'measure': 'Mortality', 'description': 'Mortality by day 90', 'timeFrame': 'day 28-92'}, {'measure': 'Functional deterioration by day 30 & 90', 'description': 'decrease in Barthel index from pre-infection baseline', 'timeFrame': '28-92 days'}, {'measure': 'Neurologic deterioration by day 30 & 90', 'description': 'combined neurologic score of Barthel index, glasgow outcome score and modified minimental score', 'timeFrame': '28-92 days'}]",6,18 Years,,ALL,False,Sheba Medical Center,OTHER_GOV,0,200.0,ACTUAL,2025-09-01T16:18:24.754983,v2_robust,True,True,True,False,True,
NCT05529992,"A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease","A Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Velaglucerase Alfa in Chinese Subjects With Type 1 Gaucher Disease",Velaglucerase Alfa,"['Velaglucerase Alfa', 'VPRIV']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Gaucher Disease,['Gaucher Disease'],"['VPRIV', 'Gaucher Disease']",COMPLETED,,2023-01-03,2024-08-05,"[{'measure': 'Percentage of Participants With at Least One Serious Treatment-Emergent Adverse Event (TEAE)', 'description': 'Adverse event(AE)=any untoward medical occurrence in clinical investigation participant administered a drug;it does not necessarily have to have causal relationship with this treatment. AE can therefore be any unfavorable\\&unintended sign (example,clinically significant abnormal laboratory value),symptom/disease temporally associated with use of drug whether or not it is considered related to drug. TEAE=any event emerging or manifesting at or after initiation of investigational product or any existing event that worsens in either intensity or frequency following exposure to investigational product. SAE=any untoward clinical manifestation of signs, symptoms, or outcomes(whether considered related to investigational product or not)\\&at any dose: results in death,is life-threatening,requires in-patient hospitalization/prolongation of hospitalization,results in persistent/significant disability/incapacity,results in congenital abnormality/birth defect,or is an important medical event.', 'timeFrame': 'Up to 56.2 weeks'}]","[{'measure': 'Percentage of Participants With TEAEs', 'description': 'An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory value), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE is defined as any event emerging or manifesting at or after the initiation of the investigational product or any existing event that worsens in either intensity or frequency following exposure to the investigational product.', 'timeFrame': 'Up to 56.2 weeks'}, {'measure': 'Percentage of Participants With Infusion-related Reactions Reported as an Adverse Event', 'description': 'An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory value), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. An infusion-related AE was defined as an AE that 1) began either during or within 12 hours after the start of the infusion and 2) was judged as possibly or probably related to the study treatment.', 'timeFrame': 'Up to 56.2 weeks'}, {'measure': 'Percentage of Participants With Development of Anti-VPRIV Antibodies and Neutralizing Antibodies at Week 53', 'description': 'Percentages were rounded off to the nearest single decimal place.', 'timeFrame': 'Week 53'}, {'measure': 'Number of Participants With Clinically Significant Changes in Laboratory Assessments at Week 53', 'description': ""Clinical laboratory assessments included hematology and serum chemistry. Any clinically significant changes in the clinical laboratory assessment values based on the investigator's interpretation were reported. Only categories with at least one participant with event are presented."", 'timeFrame': 'Week 53'}, {'measure': 'Number of Participants With Abnormal Changes in Laboratory Assessments at Week 53: Urinalysis', 'description': ""Any abnormal changes in the urinalysis assessment values based on the investigator's interpretation were reported. Urinalysis comprised of the following parameters: bilirubin, ketones, glucose, nitrite, occult blood, protein, and urobilinogen."", 'timeFrame': 'Week 53'}, {'measure': 'Number of Participants With at Least One Abnormal Change in an Infusion Vital Sign Parameter at Week 53', 'description': 'Participants with atleast 1 abnormal change (above or below normal) in an infusion vital sign parameter of pulse, temperature, respiratory rate,\\& blood pressure were reported. Normal ranges for each vital sign parameter were, pulse (beats per minutes \\[bpm\\]): 40-100(≥12 years old), 55-95(≥6 but \\<12 years old), 65-110(≥2 but \\<6 years old); body temperature(degree Celsius\\[˚C\\]): 36.5 to 37.2(all age groups),respiration rate(breaths/minutes):12-24(≥12 years old),12-22 (≥6 but \\<12 years old),20-30(≥2 but \\<6 years old);systolic blood pressure(BP) \\[millimeters of mercury{mm Hg}\\]: high: ≥140 (≥18 years old), ≥20+ 80+ 2\\*age(\\<18 years old), low: \\<90 (≥18 years old), \\< -20+ 80+ 2\\*age(\\<18 years old); diastolic BP(mm Hg):high:≥90 (≥18 years old), ≥20+ (80+2\\*age)\\*(2/3) (\\<18 years old) low: \\<50 (≥18 years old), \\< -20+ (80+2\\*age)\\*(2/3) (\\<18 years old). As per planned analysis,data was collected in a combined manner for all participants irrespective of age. Only non-zero categories are presented.', 'timeFrame': 'Week 53'}, {'measure': 'Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Measurements at Week 53', 'description': ""Participants with clinically significant changes in any ECG measurement, such as PR, QRS, QT, corrected QT intervals, and heart rate based on the investigator's interpretation were reported."", 'timeFrame': 'Week 53'}, {'measure': 'Change From Baseline to Week 53 in Hemoglobin Concentration', 'timeFrame': 'Baseline, Week 53'}, {'measure': 'Change From Baseline to Week 53 in Platelet Count', 'timeFrame': 'Baseline, Week 53'}, {'measure': 'Change From Baseline to Week 53 in Normalized Liver Volume', 'description': 'Normalized liver volume was measured by abdominal magnetic resonance imaging (MRI) or computed tomography (CT) scan. Liver volume was normalized for percent body weight.', 'timeFrame': 'Baseline, Week 53'}, {'measure': 'Change From Baseline to Week 53 in Normalized Spleen Volume', 'description': 'Spleen volume was normalized for percent body weight.', 'timeFrame': 'Baseline, Week 53'}, {'measure': 'Change From Baseline to Week 53 in 36-item Short Form General Health Survey (SF-36) Scores', 'description': 'SF-36 Version 2 is a multipurpose, participant completed, short-form health survey with 36 questions that consists of an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. Physical component summary (PCS) is mostly contributed by physical function (PF), role physical (RP), bodily pain (BP), and general health (GH). Mental component summary (MCS) is mostly contributed by mental health (MH), role emotional (RE), social function (SF), and vitality (VT). Each component on the SF-36 item health survey is scored from 0 (best) to 100 (worst). Total score ranges from 0-100 for each component summary (i.e., PCS and MCS), where higher scores are associated with less disability and better quality of life.', 'timeFrame': 'Baseline, Week 53'}, {'measure': 'Change From Baseline to Week 53 in Childhood Health Questionnaire-Parent Form 50 (CHQ-PF50) Scores', 'description': 'The CHQ-PF-50 is a 50-item questionnaire to be completed by the parents or guardians of children between 5 and 18 years of age. The 50 questions measure 14 domains (global health, physical functioning, role/social limitations (emotional/behavioral and physical), bodily pain/discomfort, behavior, global behavior, mental health, self-esteem, general health perceptions, change in health, parental impact (emotional and time), family activities, and family cohesion) which were summarized as the physical and psychological summary scores. Each summary score was transformed and could range from 0 to 100, with higher score indicating better physical and psychosocial health. A positive change from Baseline indicates improved well-being.', 'timeFrame': 'Baseline, Week 53'}, {'measure': 'Cmax: Maximum Observed Serum Concentration for VPRIV at Week 1', 'timeFrame': 'Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1'}, {'measure': 'Serum Concentration for VPRIV at Week 37', 'timeFrame': 'Within 3 minutes prior to the end of the 60-minute infusion at Week 37'}, {'measure': 'Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for VPRIV', 'timeFrame': 'Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1'}, {'measure': 'AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for VPRIV', 'description': 'ng\\*min/mL denotes nanograms\\*minutes per milliliter.', 'timeFrame': 'Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1'}, {'measure': 'Terminal Phase Elimination Half-life (T1/2) for VPRIV', 'timeFrame': 'Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1'}, {'measure': 'Oral Clearance (CL) for VPRIV', 'description': 'mL/min/kg denotes milliliters per minutes per kilogram.', 'timeFrame': 'Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1'}, {'measure': 'Apparent Steady-state Volume of Distribution (Vss) for VPRIV', 'timeFrame': 'Pre-dose and at multiple timepoints(up to 120 minutes post-dose on Day 1 of Week 1'}, {'measure': 'Percent Change From Baseline to Week 53 in Biomarker: Plasma Chemokine [C-C Motif] Ligand 18', 'timeFrame': 'Baseline, Week 53'}, {'measure': 'Percent Change From Baseline to Week 53 in Biomarker: Glucopsychosine', 'timeFrame': 'Baseline, Week 53'}]",23,2 Years,,ALL,False,Takeda,INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:24.755099,v2_robust,True,True,True,False,True,
NCT01470092,Tibolone and Placebo in Adjunct to Antidepressant Medication for Women With Menopausal Depression,Double-Blind Randomised Investigation of Tibolone Alone or in Adjunct to Standard Antidepressant Treatment for Depression in Menopausal Women,Tibolone,"['Livial', 'Tibolone']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Menopausal Depression,['Menopausal Depression'],"['Menopause', 'Depression']",COMPLETED,,2012-07,2017-12,"[{'measure': 'Montgomery and Asberg Depression Rating Scale', 'description': 'A 10-item clinician rated scale validated to be most strongly sensitive to change in depression associated with treatment. This scale will be used to measure change in depression associated with treatment at weeks 2, 4, 8 and 12 compared to baseline.', 'timeFrame': 'Baseline, then at weeks 2,4, 8 and 12'}]","[{'measure': 'The Beck Depression Inventory Second Edition', 'description': 'A subjective rating scale of depressive symptoms that compliments the MADRS to measure the change of subjective rating of depressive symptoms at week 12 compared to baseline.', 'timeFrame': 'Baseline and week 12'}]",2,45 Years,65 Years,FEMALE,False,The Alfred,OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:24.755290,v2_robust,True,True,True,False,False,
NCT06987292,A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS),"Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS): a Single-center, Prospective, Exploratory, Open-label Study",IL-17i,['IL-17i'],1,OBSERVATIONAL,[],,,Psoriasis (PsO),"['Psoriasis (PsO)', 'Enthesitis', 'Psoriasis Arthritis', 'Secukinumab']",[],RECRUITING,,2025-05-01,2027-12-31,"[{'measure': 'Change of Glasgow Ultrasound Enthesitis Scoring System (GUESS) from baseline to week 24', 'description': 'Glasgow Ultrasound Enthesitis Scoring System (GUESS) is an ultrasonographic score of lower limb enthesitis including superior pole of the patella-quadriceps tendon enthesis, inferior pole of the patella-proximal patellar ligament enthesis, tibial tuberosity-distal patellar ligament enthesis, superior pole of the calcaneus-achilles tendon enthesis and inferior pole of the calcaneus-plantar aponeurosis enthesis, composed of assessments of degenerative changes such as tendon thickness, existence of enthesitis, bursitis, or erosions. It is calculated as follows: one point was scored for each abnormality at each site examined, giving a possible maximum total score for both lower extremities 36. A higher score of GUESS represents more serve inflammation and involvement of enthesis while a lower score represents better outcomes.', 'timeFrame': 'Week 24'}]","[{'measure': 'Change of Glasgow Ultrasound Enthesitis Scoring System(GUESS) from baseline to week 4, 12, 36, 52', 'description': 'Glasgow Ultrasound Enthesitis Scoring System (GUESS) is an ultrasonographic score of lower limb enthesitis including superior pole of the patella-quadriceps tendon enthesis, inferior pole of the patella-proximal patellar ligament enthesis, tibial tuberosity-distal patellar ligament enthesis, superior pole of the calcaneus-achilles tendon enthesis and inferior pole of the calcaneus-plantar aponeurosis enthesis, composed of assessments of degenerative changes such as tendon thickness, existence of enthesitis, bursitis, or erosions. It is calculated as follows: one point was scored for each abnormality at each site examined, giving a possible maximum total score for both lower extremities 36. A higher score of GUESS represents more serve inflammation and involvement of enthesis while a lower score represents better outcomes.', 'timeFrame': 'Week 4, 12, 36, 52'}, {'measure': 'Complete resolution of enthesitis from baseline to week 24', 'description': 'Complete resolution of enthesitis from baseline to week 24 based on enthesis assessed by GUESS. It means the percentage reaching a score of 0 for each enthesis. Higher percentage represents higher improvement.', 'timeFrame': 'Week 24'}, {'measure': 'Complete resolution of enthesitis from baseline to week 52', 'description': 'Complete resolution of enthesitis from baseline to week 52 based on enthesis assessed by GUESS. It means the percentage reaching a score of 0 for each enthesis. Higher percentage represents higher improvement.', 'timeFrame': 'Week 52'}, {'measure': 'New bone erosion, bursitis, osteophytes at week 24', 'description': ""New bone erosion, bursitis, osteophytes at week 24 based on enthesis assessed by GUESS. It means the percentage that the score changes from 0 to 1 in the item of 'erosion, bursitis, osteophytes' for each enthesis. Higher percentage represents more worsening of inflammation."", 'timeFrame': 'Week 24'}, {'measure': 'New bone erosion, bursitis, osteophytes at week 52', 'description': ""New bone erosion, bursitis, osteophytes at week 52 based on enthesis assessed by GUESS. It means the percentage that the score changes from 0 to 1 in the item of 'erosion, bursitis, osteophytes' for each enthesis. Higher percentage represents more worsening of inflammation."", 'timeFrame': 'Week 52'}, {'measure': 'Change of patient pain assessment based on Visual Analog Scale (VAS) at week 4, 12, 24, 36, 52', 'description': 'Change of patient pain assessment based on Visual Analog Scale (VAS) at week 4, 12, 24, 36, 52. The pain VAS is a continuous scale comprised of a horizontal (HVAS) line, usually 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors. For pain intensity, the scale is anchored by ""no pain"" (score of 0) and ""worst imaginable pain"" (score of 100 \\[100-mm scale\\]). Higher score represents more severe pain.', 'timeFrame': 'Week 4, 12, 24, 36, 52'}, {'measure': 'Change of PASI from baseline to week 24, 52', 'description': 'The Psoriasis Area and Severity Index Score (PASI) is a physician assessment that combines the assessment of the severity (erythema, induration and desquamation) of and area affected by psoriasis into a single score in the range 0 (no disease) to 72 (maximal disease). The higher the score the more severe the psoriasis.', 'timeFrame': 'Week 24, 52'}, {'measure': 'Change of BSA% from baseline to week 24, 52', 'description': ""Body Surface Area (BSA) is a measure of how much skin is impacted by psoriasis and can be used to track an individual's psoriasis over time. For context, one handprint is equal to approximately 1 percent BSA. Involvement of \\<3% BSA is considered mild, 3%-10% BSA is considered moderate and \\>10% of BSA is considered severe psoriasis."", 'timeFrame': 'Week 24, 52'}, {'measure': 'Change of mNAPSI from baseline to week 24, 52', 'description': 'The mNAPSI is a tool for physicians to evaluate the severity of nail bed psoriasis and nail matrix psoriasis by area of involvement in the nail unit. Each fingernail is rated for the presence and severity of seven features to give a total fingernail score of 0-13 (0= no involvement, 13 = greatest involvement). The total mNAPSI score is the sum of the 10 fingernail scores (range 0-130; 0= no involvement, 130= greatest involvement). The higher the score the more severe the nail bed psoriasis.', 'timeFrame': 'Week 24, 52'}, {'measure': 'Change of PSSI from baseline to week 24, 52', 'description': 'The Psoriasis Scalp Severity Index scale (PSSI) rates psoriasis severity on the scalp based on three parameters: erythema (redness), scaling, and thickness. Each parameter is assessed individually, and the scores are combined to provide an overall severity rating. The total PSSI score is a sum of scores for erythema, induration, and desquamation x involved area, ranges 0 (no disease) to 72 (maximal disease). The higher the score the more severe the scalp psoriasis is.', 'timeFrame': 'Week 24, 52'}, {'measure': 'Change of HAQ-DI from baseline to week 24, 52', 'description': 'The HAQ-DI is scored on a four-level difficulty scale ranging from zero (normal, no difficulty) to three (unable to do, extreme difficulty). There are 20 questions covering eight domains: dressing, rising, eating, talking, hygiene, reach, grip, and usual activities. The highest score for an item within each domain is taken as the score for that domain; the HAQ-DI total score is the average of the eight domain scores and therefore ranges between 0 and 3. Scores of 0-1 represent mild to moderate difficulty; 1-2 represent moderate to severe disability; 2-3 represent severe to very severe disability.', 'timeFrame': 'Week 24, 52'}, {'measure': 'Change of SJC66 and TJC68 from baseline to week 24, 52', 'description': '66/68 swollen and tender joint counts (SJC66/TJC68)', 'timeFrame': 'Week 24, 52'}, {'measure': 'Change of SPARCC enthesitis index from baseline to week 24, 52', 'description': 'Medial epicondyle (left/right (L/R)) Lateral epicondyle (L/R) Supraspinatus insertion into greater tuberosity of humerus (L/R) Greater trochanter (L/R) Quadriceps insertion into superior border of patella (L/R) Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R) Achilles tendon insertion into calcaneum (L/R) Plantar fascia insertion into calcaneum (L/R)', 'timeFrame': 'Week 24, 52'}, {'measure': 'Proportion of patients who progressed to PsA at Week 52', 'description': 'Proportion of patients who progressed to PsA at Week 52, based on CASPAR', 'timeFrame': 'Week 52'}]",15,18 Years,,ALL,False,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:24.755336,v2_robust,False,True,False,False,False,
NCT03228992,Ibuprofen Versus Placebo For Muscle Soreness,"A DOUBLE-BLIND, REPEAT-DOSE, PARALLEL GROUP, PILOT STUDY COMPARING THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED IBUPROFEN AND PLACEBO IN DELAYED ONSET MUSCLE SORENESS",Ibuprofen 400 mg,['Ibuprofen 400 mg'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Muscle Soreness,['Muscle Soreness'],[],COMPLETED,,2017-04-10,2017-07-31,"[{'measure': 'Model Sensitivity', 'description': 'Assess whether ibuprofen provides more relief than placebo in the DOMS model.', 'timeFrame': '24 hours'}]",[],1,18 Years,55 Years,ALL,True,Jean Brown Research,OTHER,0,31.0,ACTUAL,2025-09-01T16:18:24.755402,v2_robust,True,True,True,False,False,
NCT01652092,Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies,Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies,Alemtuzumab 0.3 mg,"['Fludara', 'MESNA', 'Mesnex', 'Myerlan', 'Alemtuzumab 0.3 mg', 'Fludarabine phosphate 40 mg', 'Campath-1H', 'mercaptoethane sulfonate Na (Na being the symbol for sodium)', 'Alkeran', 'Fludarabine phosphate 30 mg', 'Busulfan', 'Alemtuzumab 0.2 mg', 'Cyclophosphamide', 'Cytoxan', 'Campath 1-H', 'Melphalan']",16,INTERVENTIONAL,['NA'],,,SCID,"['SCID', ""Omenn's Syndrome"", 'Reticular Dysgenesis', 'Wiskott-Aldrich Syndrome', 'Bare Lymphocyte Syndrome', 'Common Variable Immunodeficiency', 'Chronic Granulomatous Disease', 'CD40 Ligand Deficiency', 'Hyper IgM Syndrome', 'X-linked Lymphoproliferative Disease', 'Hemophagocytic Lymphohistiocytosis', 'Griscelli Syndrome', 'Chediak-Higashi Syndrome', ""Langerhan's Cell Histiocytosis""]","['immunodeficiency disorder', 'histiocytic disorder']",RECRUITING,,2012-09-04,2026-12,"[{'measure': 'Neutrophil Engraftment', 'description': 'Neutrophil engraftment is defined as the first day of three consecutive days where the neutrophil count (absolute neutrophil count) is 500 cells/mm3 (0.5 x 109/L) or greater.', 'timeFrame': 'Day 42'}]","[{'measure': 'Incidence of Graft Failure', 'description': 'Graft failure is defined as not accepting donated cells. The donated cells do not make the new white blood cells, red blood cells and platelets.', 'timeFrame': 'Day 100'}, {'measure': 'Incidence of Chimerism', 'description': 'a state in bone marrow transplantation in which bone marrow and host cells exist compatibly without signs of graft-versus-host rejection disease.', 'timeFrame': 'Day 100, 6 Months, 1 Year'}, {'measure': 'Incidence of Acute Graft-Versus-Host Disease', 'description': 'Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.', 'timeFrame': 'Day 100'}, {'measure': 'Incidence of Chronic Graft-Versus-Host Disease', 'description': 'Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.', 'timeFrame': '6 Months and 1 Year'}, {'measure': 'Incidence of Transplant-Related Mortality', 'description': 'In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation.', 'timeFrame': '6 Months'}, {'measure': 'Disease-Free Survival', 'description': 'the length of time after treatment ends that a patient survives without any signs or symptoms of that cancer or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.', 'timeFrame': '6 Months'}, {'measure': 'Overall Survival', 'description': 'Overall survival will be defined as time from enrollment to date of death or censored at the date of last documented contact for patients still alive.', 'timeFrame': '6 Months'}]",8,,50 Years,ALL,False,"Masonic Cancer Center, University of Minnesota",OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:24.755424,v2_robust,True,True,False,False,False,
NCT06803992,Induction of Labor - Comparison Propess with Prostaglandin E2 Vaginal Gel and Balloon Catheter,Induction of Labor in Women with Unfavorable Cervix At Term - Comparison of Propess Versus Prostaglandin E2 Vaginal Gel and Extra-amniotic Balloon Catheter,Dinoprostone vaginal insert,"['Propess', 'Dinoprostone vaginal insert']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Induction of Labor,['Induction of Labor'],[],NOT_YET_RECRUITING,,2025-01-29,2027-01-29,"[{'measure': 'comparing the duration of induction-to-vaginal delivery', 'description': 'measuring the duration of Induction-of-labor by Propess versus the combined use of PGE2 gel and balloon catheter by induction-to-vaginal delivery interval from the beginning of the induction according to the chosen patient protocol and until vaginal delivery.', 'timeFrame': 'from enrollment until final outcome - a month'}]","[{'measure': 'rate of vaginal delivery in 24 and 48 hours from IOL', 'description': 'the number of participants who had vaginal delivery in 24 and 48 hours from the beginning of the induction-of-labor for both protocols', 'timeFrame': 'from enrollment until final outcome - a month'}, {'measure': 'Number of Participants with Treatment-Related Adverse Events', 'description': 'Maternal -gathering the numbers of participants who had adverse events such as chorioamnionitis, endometritis, postpartum hemorrhage, uterine rupture, Neonatal -gathering the numbers of participants who had adverse events such as uterine hypertonia (contractions exceeding more than two minutes in duration) and/or tachysystole (more than 5 contractions in 10 minutes, averaged over a 30-minute period) with and without decelerations, non-reassuring fetal heart rate according to fetal monitoring, meconium-stained amniotic liquor, umbilical artery pH less than 7.1, Apgar score less than 7 at 5 min, postpartum transfer to neonatal intensive care unit, infection of the newborn', 'timeFrame': 'from enrollment until final outcome - a month'}, {'measure': 'rate of Induction success', 'description': 'the number of participants who had ceasarean section', 'timeFrame': 'from enrollment until final outcome - a month'}, {'measure': 'rate o Cervical ripening success', 'description': 'the duration from the beginning of the induction to bishop score 5', 'timeFrame': 'from enrollment until final outcome - a month'}]",5,18 Years,60 Years,FEMALE,False,"HaEmek Medical Center, Israel",OTHER,0,140.0,ESTIMATED,2025-09-01T16:18:24.755505,v2_robust,True,True,False,False,True,
NCT02595892,"Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer,Berzosertib,"['Gemcitabine HCI', 'Gemzar', 'LY188011', 'VX970', 'LY-188011', '2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-', 'VX 970', 'Difluorodeoxycytidine', 'Difluorodeoxycytidine Hydrochloride', 'dFdCyd', 'Gemcitabine Hydrochloride', 'Gemcitabine', 'VX-970', 'dFdC', 'M 6620', 'LY 188011', 'M6620', 'Berzosertib']",18,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Serous Tumor,"['Ovarian Serous Tumor', 'Recurrent Fallopian Tube Carcinoma', 'Recurrent Ovarian Carcinoma', 'Recurrent Primary Peritoneal Carcinoma']",[],ACTIVE_NOT_RECRUITING,,2016-08-25,2026-08-05,"[{'measure': 'Progression Free Survival (PFS)', 'description': 'PFS was summarized using Kaplan-Meier analyses and compared between the two arms using the logrank test. Additionally, PFS was analyzed using a Cox Proportional Hazards Model, including the stratification factor, and will be used to estimate the hazard ratio of the gemcitabine hydrochloride (gemcitabine)/ataxia telangiectasia mutated and Rad3-related (ATR) kinase inhibitor M6620 (formerly VX-970) arm relative to the gemcitabine alone arm and the associated 90% confidence interval. Disease progression, per protocol, is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of the diameters of target lesions, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.', 'timeFrame': 'Number of days from the day the subject received the first dose of protocol therapy to the date of documented progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or death (regardless of cause), assessed up to 3 years'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'Defined as the percentage of subjects achieving a response rating of complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) in the whole population. Per RECIST v1.1 definitions for target lesions and assessed by conventional CT and MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the diameters of target lesions; Overall Response (OR) = CR + PR. ORR was summarized by counts (percentages) in each Arm.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Progression Free Survival at 6 Months (PFS-6)', 'description': 'Assessed and compared PFS-6 between gemcitabine/VX-970 and gemcitabine alone arms', 'timeFrame': 'Number of days from the day the subject received the first dose of protocol therapy to the date of documented progressive disease by RECIST version 1.1 or death (regardless of cause), assessed at 6 months'}, {'measure': 'Clinical Benefit Rate (CBR)', 'description': ""CBR is defined as the percentage of subjects achieving a response rating of stable disease \\>= 4 months, partial response (PR), or complete response (CR). Subject demographic and baseline characteristics will be summarized by mean, standard deviation, median, minimum, and maximum for continuous variables; and by counts and percentages for categorical variables. Summaries will be provided separately for each treatment group. Treatment group comparisons in CBR will be evaluated using logistic regression and expressed as odds ratios with associated 90% confidence intervals. In the event that rates are low, comparisons will be based on Fisher's exact test."", 'timeFrame': 'Up to 3 years'}, {'measure': 'Objective Response Rate by Platinum Free Status', 'description': 'Objective response rate by platinum-free status includes only informational summaries (counts of participants who met the categories outlined below) without formal statistical comparisons.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Percentage of Patients With a Reduction in CA-125', 'description': 'Determined and compared CA125 reduction by \\> 50% between gemcitabine/VX-970 and gemcitabine alone arms.', 'timeFrame': 'CA-125 serum samples were collected from participants in both Arms I and II at baseline, on Day 1 of each cycle, and at the end-of-study treatment visit, assessed up to 2 years.'}, {'measure': 'Overall Survival (OS)', 'description': 'Assessed and compared OS between gemcitabine/VX-970 and gemcitabine alone arms.', 'timeFrame': 'Number of weeks from the date of registration until date of death (regardless of cause), assessed up to 3 years.'}, {'measure': 'Number of Participants With Serious Adverse Events (SAEs)', 'description': 'Determined and compared the safety profile of gemcitabine/VX-970 and gemcitabine alone regimens.', 'timeFrame': 'AE checks occurred on D1 and D8 of each cycle for up to 2 years and at the Final Treatment Visit. Patients who were removed from study treatment for unacceptable AEs were followed until resolution/stabilization of the AE up to 3 years, or until death.'}, {'measure': 'Duration of Response', 'description': 'Duration of response was evaluated at the first instance of CR or PR through the earliest assessment of progressive disease, death, or the last follow-up where the subject had not yet progressed from her prior response. Informational summaries without formal statistical comparisons were produced.', 'timeFrame': 'Assessed for up to 3 years.'}]",9,18 Years,,FEMALE,False,National Cancer Institute (NCI),NIH,0,70.0,ACTUAL,2025-09-01T16:18:24.755587,v2_robust,True,True,False,False,True,
NCT02967692,"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma","A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma",Dabrafenib,"['Dabrafenib', 'Trametinib']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Melanoma,['Melanoma'],"['Spartalizumab (PDR001)', 'dabrafenib', 'trametinib', 'melanoma', 'immunotherapy', 'PD 1 inhibitor', 'anti PD1', 'PD-1', 'anti-PD-1', 'combination treatment', 'malignant skin cancer', 'skin cancer', 'BRAF V600', 'unresectable BRAF V600 mutated melanoma', 'metastatic BRAF V600 mutated melanoma']",TERMINATED,Sponsor decision,2017-02-17,2024-08-21,"[{'measure': 'Safety Run-In (Part 1): Number of Participants With Dose Limiting Toxicities (DLTs)', 'description': 'DLT was defined as an adverse event or abnormal laboratory value that was unrelated to disease, disease progression, inter-current illness, or concomitant medications and occured within 8 weeks of treatment with spartalizumab in combination with dabrafenib and trametinib. The DLT criteria included Grade 4 hematological adverse events, Grade 4 bilirubin elevation, specific gastrointestinal adverse events, symptomatic serum amylase or lipase elevation, Grade 3 or higher hypertension, Grade 3 or higher cardiac events, Grade 2 or higher pneumonitis, Grade 3 or higher immune-related toxicities, infusion-related reactions, other clinically significant adverse events, and toxicities leading to a dosing delay of over 12 weeks. NCI CTCAE v4.03 was used for grading DLTs', 'timeFrame': 'Up to 8 weeks (Part 1)'}, {'measure': 'Biomarker Cohort (Part 2): Change From Baseline in Programmed Cell Death-ligand 1 (PD-L1) Expression Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib', 'description': 'Change from baseline in PD-L1 expression (as determined by immunohistochemistry in tissue samples) upon treatment with spartalizumab in combination with dabrafenib and trametinib in participants from Part 2', 'timeFrame': 'Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days'}, {'measure': 'Biomarker Cohort (Part 2): Change From Baseline in CD8+ Cells Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib', 'description': 'Change from baseline in CD8+ cells (as determined by flow cytometry in blood samples) upon treatment with spartalizumab in combination with dabrafenib and trametinib in participants from Part 2', 'timeFrame': 'Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days'}, {'measure': ""Randomized (Part 3): Progression-Free Survival (PFS) as Per Investigator's Assessment by RECIST 1.1"", 'description': ""Progression-free survival was defined as the time from the date of first dose to the date of the first documented radiological progression per investigator's assessment according to RECIST 1.1 or death due to any cause. The distribution of PFS was estimated using the Kaplan-Meier (KM) method. If a patient had not had an event at the time of data cut-off, progression-free survival was censored at the date of last adequate tumor assessment."", 'timeFrame': 'Up to disease progression or death due to any cause, whichever occurs first, assessed up to 2.8 years (Part 3)'}]","[{'measure': 'Overall Survival (OS)', 'description': 'Overall survival was defined as the time from date of randomization to date of death due to any cause', 'timeFrame': 'Up to death due to any cause, assessed up to approximately 7 years'}, {'measure': ""Overall Response Rate (ORR) as Per Investigator's Assessment by RECIST 1.1"", 'description': ""ORR was defined as the percentage of subjects with confirmed best overall response of complete response (CR) or partial response (PR), as per investigator's assessment by RECIST 1.1. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\<10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters"", 'timeFrame': 'Part 1: Up to 3.3 years. Part 2: Up to 3 years. Part 3: Up to 2.8 years'}, {'measure': ""Duration of Response (DOR) as Per Investigator's Assessment by RECIST 1.1"", 'description': 'DOR was defined as the time from first documented response of CR or PR to date of first documented progression or death, according to RECIST 1.1 criteria. The distribution of DOR was estimated using the KM method. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\<10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters', 'timeFrame': 'From first documented response to date of first documented progression or death, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3)'}, {'measure': ""Disease Control Rate (DCR) as Per Investigator's Assessment by RECIST 1.1"", 'description': 'DCR was defined as the percentage of participants with CR or PR or subjects with stable disease (SD) lasting for a duration of at least 24 weeks as per local review according to RECIST 1.1 criteria. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\<10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.', 'timeFrame': 'Part 1: Up to 3.3 years. Part 2: Up to 3 years. Part 3: Up to 2.8 year'}, {'measure': 'Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Global Health Status Scores', 'description': ""The EORTC QLQ-C30 was a 30-item questionnaire that patients complete, consisting of both multi-item scales and single-item measures. It included five functional scales, three symptom scales, six single items, and a Global Health Status/Quality of Life (GHS/QoL) scale. The GHS/QoL scale had seven possible response scores ranging from 1 (very poor) to 7 (excellent), which were averaged and transformed to a 0-100 scale. A higher score on this scale indicated a better quality of life. The change from baseline in GHS/QoL scores was calculated. A positive change from baseline indicated improvement in the patient's quality of life."", 'timeFrame': 'From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)'}, {'measure': 'Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Physical Functioning Scale Scores', 'description': 'The EORTC QLQ-C30 was a patient completed 30 item questionnaire that was composed of both multi-item scales and single-item measures. These included five functional scales, three symptom scales, six single items and a global health status/QoL scale. The EORTC QLQ-C30 physical functioning scale measured a patient\'s ability to carry out daily activities and tasks requiring physical exertion. It consisted of five questions asking patients to rate their level of physical functioning, with response options ranging from 1=""not at all"" to 4=""very much"". The scores for each item were summed and transformed to a 0 to 100 scale, with higher scores indicating better physical functioning. The change from baseline in physical functioning scale scores was calculated. A positive change from baseline indicated improvement in physical functioning.', 'timeFrame': 'From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)'}, {'measure': 'Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Pain Symptom Scale Scores', 'description': 'The EORTC QLQ-C30 was a patient completed 30 item questionnaire that was composed of both multi-item scales and single-item measures. These included five functional scales, three symptom scales, six single items and a global health status/QoL scale. The EORTC QLQ-C30 pain symptom scale was one of the symptom scales in the questionnaire, which measured the severity of pain experienced by the patient. The pain symptom scale consisted of two items, one measuring the severity of pain and the other measuring the use of painkillers. The items were rated on a 4-point scale ranging from 1=""not at all"" to 4=""very much"". The scores for each item were summed and transformed to a 0 to 100 scale, with higher scores indicating more severe pain. The change from baseline in pain symptom scale scores was calculated. A negative change from baseline indicated improvement.', 'timeFrame': 'From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)'}, {'measure': 'Randomized (Part 3): Time to 10 Point Definitive Deterioration in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Global Health Status', 'description': 'The EORTC QLQ-C30 was a patient completed 30 item questionnaire that was composed of both multi-item scales and single-item measures. These included five functional scales, three symptom scales, six single items and a global health status/QoL scale. The GHS/QoL scale had seven possible response scores ranging from 1 (very poor) to 7 (excellent), which were averaged and transformed to a 0-100 scale. A higher score on this scale indicated a better quality of life. The time to definitive 10 point deterioration is defined as the time from the date of randomization to the date of event, which is defined as at least 10 points relative to baseline worsening of the GHS/QoL score or death due to any cause. If a subject had not had an event, the time to deterioration was censored at the date of the last adequate assessment. The distribution was estimated using KM method.', 'timeFrame': 'From baseline to date of at least 10 points relative to baseline worsening of the global health status score or death due to any cause, up to 2.8 years (Part 3)'}, {'measure': 'Randomized (Part 3): Change From Baseline in Function Assessment Cancer Therapy-melanoma (FACT-M) Melanoma Subscale Score', 'description': 'The Functional Assessment of Cancer Therapy-Melanoma (FACT-M) quality of life questionnaire was composed of the FACT-General (FACT-G) plus the Melanoma Subscale and the Melanoma Surgery Subscale, which complemented the general scale with items specific to quality of life (QoL) in melanoma. The Melanoma Subscale of FACT-M included 16 questions, with response options of 0= ""Not at all"", 1= ""a little bit"", 2= ""somewhat"", 3= ""quite a bit"" and 4= ""very much"". The FACT-M melanoma subscale score ranged from 0 to 64, with higher scores indicating a higher quality of life in relation to melanoma. The change from baseline in melanoma subscale scores was calculated. A positive change from baseline indicated improvement.', 'timeFrame': 'From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)'}, {'measure': 'Randomized (Part 3): Change From Baseline in EuroQoL 5-level Instrument (EQ-5D-5L)- Visual Analog Scale (VAS) Score', 'description': 'The EQ-5D-5L is a standardized questionnaire used to assess health-related quality of life, and it includes a Visual Analog Scale (VAS). The VAS score is obtained by asking the individual to rate their current health status on a scale from 0 to 100, where 0 represents the worst possible health state and 100 represents the best possible health state. The change from baseline in EQ-5D-5L VAS score was calculated. A positive change from baseline indicates improvement in the health status.', 'timeFrame': 'From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)'}, {'measure': ""Randomized (Part 3): PFS as Per Investigator's Assessment by RECIST 1.1 by PD-L1 Expression"", 'description': ""PFS was defined as the time from the date of first dose to the date of the first documented radiological progression as per investigator's assessment using RECIST 1.1 response criteria or death due to any cause. The distribution of PFS was estimated using the KM method. If a patient had not had an event at the time of data cut-off, progression-free survival was censored at the date of last adequate tumor assessment. PFS analysis was performed by PD-L1 status (positive, negative) where a positive status was defined as having ≥ 1% expression and a negative status was defined as having \\< 1% expression."", 'timeFrame': 'Up to disease progression or death due to any cause, up to 2.8 years (Part 3)'}, {'measure': 'Randomized (Part 3): OS by PD-L1 Expression', 'description': 'Overall survival was defined as the time from date of randomization to date of death due to any cause. OS analysis was performed by PD-L1 subgroup (positive, negative) where a positive status was defined as having ≥ 1% expression and a negative status was defined as having \\< 1% expression.', 'timeFrame': 'Up to death due to any cause, assessed up to approximately 7 years'}, {'measure': 'Spartalizumab Anti-drug Antibody (ADA) Prevalence at Baseline', 'description': 'Spartalizumab ADA prevalence at baseline was calculated as the percentage of participants who had an spartalizumab ADA positive result at baseline.', 'timeFrame': 'Baseline'}, {'measure': 'Spartalizumab ADA Incidence', 'description': 'Spartalizumab ADA incidence was calculated as the percentage of participants who were treatment-induced spartalizumab ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and treatment-boosted spartalizumab ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)', 'timeFrame': 'Throughout study until 150 days after the last dose of spartalizumab, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3).'}, {'measure': 'Trough Concentration (Ctrough) for Spartalizumab', 'description': 'Ctrough for spartalizumab refers to the serum concentration of spartalizumab immediately prior to the administration of a dose of spartalizumab on Day 1 of Cycle 2 and later cycles.', 'timeFrame': 'Pre-infusion on Day 1 of each Cycle starting from Cycle 2, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days'}, {'measure': 'Pre-dose Plasma Concentration for Dabrafenib', 'description': 'Plasma concentration of dabrafenib immediately prior to the administration of a dose of dabrafenib.', 'timeFrame': 'Pre-infusion on Day 1 of every cycle from Cycle 2 to 12, and then every 6 cycles from Cycle 18 to 36, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days'}, {'measure': 'Pre-dose Plasma Concentration for Trametinib', 'description': 'Plasma concentration of trametinib immediately prior to the administration of a dose of trametinib.', 'timeFrame': 'Pre-infusion on Day 1 of every cycle from Cycle 2 to 12, and then every 6 cycles from Cycle 18 to 36, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days'}, {'measure': 'Number of Participants With Dose Interruptions', 'description': 'Number of participants with dose interruptions for spartalizumab, dabrafenib and trametinib', 'timeFrame': 'From baseline to end of treatment, assessed up to approximately 7 years'}, {'measure': 'Number of Participants With Dose Reductions', 'description': 'Number of patients with dose reductions for spartalizumab, dabrafenib and trametinib', 'timeFrame': 'From baseline to end of treatment, assessed up to approximately 7 years'}, {'measure': 'Relative Dose Intensity', 'description': 'Relative dose intensity for spartalizumab, dabrafenib and trametinib computed as the ratio (expressed as percentage) of dose intensity and planned dose intensity:\n\n* Spartalizumab (PDR001) = \\[Dose intensity (mg/4W) / planned dose intensity (mg/4W)\\]\\*100.\n* Trametinib and Dabrafenib = \\[Dose intensity (mg/day) / planned dose intensity (mg/day)\\]\\*100.', 'timeFrame': 'From baseline to end of treatment, assessed up to approximately 7 years'}]",24,18 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,568.0,ACTUAL,2025-09-01T16:18:24.755633,v2_robust,True,True,False,True,True,Sponsor decision
NCT04690036,PD-1 Antibody for Reactive EBV After BMT,Reactivation of EBV for Patients With CAEBV and EBV Associated HLH After Transplantation,toripalimab injection,"['EBV-DNA positive', 'toripalimab injection']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,PD-1,"['PD-1', 'EBV Infection', 'Transplant']",[],UNKNOWN,,2021-07-01,2023-01-01,"[{'measure': 'EBV-DNA turn negative', 'description': 'after treatment, the EBV-DNA copies can not be detected in peripheral blood', 'timeFrame': '4 weeks after PD-1 antibody was used'}]","[{'measure': 'treatment-related adverse events as assessed by CTCAE v5.0', 'description': 'Adverse events including thyroid function，liver function damage, myelosuppression, infection, bleeding and so on', 'timeFrame': '4 weeks after PD-1 antibody was used'}]",2,18 Years,,ALL,False,Beijing Friendship Hospital,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:24.755654,v2_robust,True,True,False,False,True,
NCT02138136,Lubiprostone for Children With Constipation,"A Multicentre, Long-term Safety, Efficacy, and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation",Lubiprostone,"['Amitiza®', 'Lubiprostone']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Constipation - Functional,['Constipation - Functional'],[],COMPLETED,,2014-02-26,2017-05-01,"[{'measure': 'Median Number of Observed Weekly Spontaneous Bowel Movements (SBM) Per Month', 'description': 'Spontaneous bowel movements are defined as bowel movements without the aid of drugs.', 'timeFrame': 'within 9 months'}]",[],1,6 Years,17 Years,ALL,False,"Sucampo Pharma Americas, LLC",INDUSTRY,1,419.0,ACTUAL,2025-09-01T16:18:24.755672,v2_robust,True,True,True,False,False,
NCT06819436,Effect of Dexamethasone on Post-spinal Hypotension,Effect of Dexamethasone on Post-spinal Hypotension in Geriatric Patients Undergoing Orthopaedic Surgery at Tertiary Care Hospital Karachi.,Dexamethasone,['Dexamethasone'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Post Spinal Anaesthesia Hypotension,"['Post Spinal Anaesthesia Hypotension', 'Geriatric Population', 'Orthopedic Surgeries']",[],RECRUITING,,2025-02,2025-05,"[{'measure': 'Post spinal Anesthesia Hypotension', 'description': 'Hypotension will be considered if there will be 25% decrease below the baseline for (Mean Arterial Pressure) MAP and will be managed by 300 ml of (Normal Saline) NS solution with incremental intravenous 5 mg doses of ephedrine. The proportion of patients with hypotension at any time during the first 20 min after induction of the (Spinal Anesthesia) SA and before starting the surgical procedure will be considered as the outcome of the study.', 'timeFrame': 'From enrollment to 30 minutes after spinal anesthesia'}]",[],1,65 Years,85 Years,ALL,True,Shaheed Mohtarma Benazir Bhutto Institue of Trauma,OTHER,0,170.0,ESTIMATED,2025-09-01T16:18:24.755681,v2_robust,True,True,False,False,False,
NCT01154036,MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162),"A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin",ezetimibe 10 mg,"['ezetimibe 10 mg', 'atorvastatin', 'Comparator: rosuvastatin']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypercholesterolemia,['Hypercholesterolemia'],[],COMPLETED,,2010-07,2012-10,"[{'measure': 'Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)', 'description': 'LDL-C levels measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. LDL-C was calculated using the Friedewald method when triglyceride (TG)\\<350 mg/dL (3.95 mmol/L) and beta quantification ultracentrifugation when TG≥350 mg/dL (3.95 mmol/L).', 'timeFrame': 'Baseline and Week 6 (end of Phase I )'}]","[{'measure': 'Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase II).', 'description': 'LDL-C levels measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12). Baseline was defined as the average of the values at Visits 5 and 6. LDL-C was calculated using the Friedewald method when triglyceride (TG)\\<350 mg/dL (3.95 mmol/L) and beta quantification ultracentrifugation when TG ≥350 mg/dL (3.95 mmol/L).', 'timeFrame': 'Baseline (Week 6) and Week 12'}, {'measure': 'Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase I)', 'timeFrame': 'Week 6 (End of Phase I)'}, {'measure': 'Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase II)', 'timeFrame': 'Week 12 (End of Phase II)'}, {'measure': 'Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase I)', 'timeFrame': 'Week 6 (End of Phase I)'}, {'measure': 'Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase II)', 'timeFrame': 'Week 12 (end of Phase II)'}, {'measure': 'Percent Change From Baseline in Total Cholesterol (TC) (Phase I)', 'description': 'TC measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4', 'timeFrame': 'Baseline and Week 6 (end of Phase I)'}, {'measure': 'Percent Change From Baseline in Total Cholesterol (TC) (Phase II)', 'description': 'TC levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.', 'timeFrame': 'Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)'}, {'measure': 'Percent Change From Baseline in Triglycerides (TG) (Phase I)', 'description': 'TG measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.', 'timeFrame': 'Baseline and Week 6 (end of Phase I)'}, {'measure': 'Percent Change From Baseline in Triglycerides (TG) (Phase II)', 'description': 'TG levels measured at Baseline (Week 6: end of Phase I) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.', 'timeFrame': 'Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)'}, {'measure': 'Percent Change From Baseline in High-density Lipoprotein-Cholesterol (HDL-C) (Phase I)', 'description': 'HDL-C measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4', 'timeFrame': 'Baseline and Week 6 (end of Phase I)'}, {'measure': 'Percent Change From Baseline in HDL-C (Phase II)', 'description': 'HDL-C levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.', 'timeFrame': 'Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)'}, {'measure': 'Percent Change From Baseline in Apolipoprotein B (Apo B) (Phase I)', 'description': 'Apo-B measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4', 'timeFrame': 'Baseline and Week 6 (end of Phase I)'}, {'measure': 'Percent Change From Baseline in Apo B (Phase II)', 'description': 'Apo-B levels measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.', 'timeFrame': 'Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)'}, {'measure': 'Percent Change From Baseline in Apolipoprotein A-I (Apo A-I) (Phase I)', 'description': 'Apo-A-I measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4', 'timeFrame': 'Baseline and Week 6 (end of Phase I)'}, {'measure': 'Percent Change From Baseline in Apo A-I (Phase II)', 'description': 'Apo-A-I levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.', 'timeFrame': 'Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)'}, {'measure': 'Percent Change From Baseline in Non-HDL-C (Phase I)', 'description': 'Non-HDL-C measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4', 'timeFrame': 'Baseline and Week 6 (end of Phase I)'}, {'measure': 'Percent Change From Baseline in Non-HDL-C (Phase II)', 'description': 'Non-HDL-C levels calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.', 'timeFrame': 'Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)'}, {'measure': 'Percent Change From Baseline in TC/HDL-C Ratio (Phase I)', 'description': 'TC/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4', 'timeFrame': 'Baseline and Week 6 (end of Phase I)'}, {'measure': 'Percent Change From Baseline in TC/HDL-C Ratio (Phase II)', 'description': 'TC/HDL-C Ratio calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.', 'timeFrame': 'Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)'}, {'measure': 'Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase I)', 'description': 'LDL-C/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4', 'timeFrame': 'Baseline and Week 6 (end of Phase I)'}, {'measure': 'Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase II)', 'description': 'LDL-C/HDL-C Ratio calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.', 'timeFrame': 'Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)'}, {'measure': 'Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase I)', 'description': 'Apo B/Apo A-I ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4', 'timeFrame': 'Baseline and Week 6 (end of Phase I)'}, {'measure': 'Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase II)', 'description': 'Apo B/Apo A-I Ratio calculated at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.', 'timeFrame': 'Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)'}, {'measure': 'Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase I)', 'description': 'Non HDL-C/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4', 'timeFrame': 'Baseline and Week 6 (end of Phase I)'}, {'measure': 'Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase II)', 'description': 'Non HDL-C/HDL-C Ratio calculated at baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.', 'timeFrame': 'Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)'}, {'measure': 'Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) (Phase I)', 'description': 'hs-CRP measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.', 'timeFrame': 'Baseline and Week 6 (end of Phase I)'}, {'measure': 'Percent Change From Baseline in Hs-CRP (Phase II)', 'description': 'hs-CRP measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.', 'timeFrame': 'Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)'}]",28,18 Years,79 Years,ALL,False,Organon and Co,INDUSTRY,0,1547.0,ACTUAL,2025-09-01T16:18:24.755693,v2_robust,True,True,True,False,False,
NCT00052611,Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia,Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study,Celecoxib,"['Celebrex', 'Celecoxib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Head and Neck Cancer,['Head and Neck Cancer'],"['lip and oral cavity cancer', 'paranasal sinus and nasal cavity cancer', 'hypopharyngeal cancer', 'laryngeal cancer', 'oropharyngeal cancer', 'nasopharyngeal cancer', 'salivary gland cancer']",COMPLETED,,2002-06,2005-03,"[{'measure': 'Response Rate Of PGE2', 'timeFrame': '2 years'}]","[{'measure': 'Change In SEB Expression Of COX-2', 'timeFrame': '2 years'}, {'measure': 'Response Of Measurable Lesions', 'timeFrame': '2 years'}, {'measure': 'Assessing Safety', 'timeFrame': '2 years'}, {'measure': 'Change In SEB Expression Of Akt', 'timeFrame': '2 years'}, {'measure': 'Change In SEB Expression Of Ki-67', 'timeFrame': '2 years'}, {'measure': 'Change In SEB Expression Of BCL2', 'timeFrame': '2 years'}, {'measure': 'Change In SEB Expression Of BAX', 'timeFrame': '2 years'}, {'measure': 'Change In SEB Expression Of VEGF', 'timeFrame': '2 years'}, {'measure': 'Change In SEB Expression Of CD31', 'timeFrame': '2 years'}]",10,18 Years,,ALL,False,Dana-Farber Cancer Institute,OTHER,1,23.0,ACTUAL,2025-09-01T16:18:24.755962,v2_robust,True,True,True,False,True,
NCT06121011,A Global Prospective Observational Registry of Patients With Pompe Disease,A Global Prospective Observational Registry of Patients With Pompe Disease,Miglustat,"['Miglustat', 'AT2221, Opfolda']",2,OBSERVATIONAL,[],,,Pompe Disease,['Pompe Disease'],[],RECRUITING,,2024-02-16,2034-12-20,"[{'measure': 'Evaluate long-term safety of Pompe disease treatments', 'description': 'Data collection that describe the frequency of AEs/SAEs occurring in Pompe disease patients', 'timeFrame': '5 years'}]",[],1,,,ALL,False,Amicus Therapeutics,INDUSTRY,0,500.0,ESTIMATED,2025-09-01T16:18:24.756026,v2_robust,False,True,False,False,True,
NCT03942211,A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Sarcoidosis-Associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag.",Selexipag,"['JNJ-678896049; ACT-293987', 'Selexipag', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Sarcoidosis-associated Pulmonary Hypertension,['Sarcoidosis-associated Pulmonary Hypertension'],"['selexipag, sarcoidosis, pulmonary hypertension']",TERMINATED,The sponsor decided to prematurely terminate the study due to the lower-than-expected recruitment rate,2021-02-26,2023-04-19,"[{'measure': 'Pulmonary Vascular Resistance (PVR) up to Week 26', 'description': 'PVR represents the resistance against which the right ventricle needs to pump. PVR was determined by right heart catheterization (RHC). It was measured as the ratio of the PVR value post-treatment initiation up to Week 26 (post) versus the PVR value pre-treatment initiation at baseline (pre), expressed as a percentage of baseline value. The baseline reference value for PVR was based on the last RHC performed prior to study intervention initiation. PVR was calculated as 80\\*(mean pulmonary arterial pressure - pulmonary artery wedge pressure) divided by cardiac output. As specified in the statistical analysis plan, data was not planned to be summarized for this outcome measure and only individual participant wise data was collected.', 'timeFrame': 'Baseline up to Week 26'}]",[],1,18 Years,75 Years,ALL,False,Actelion,INDUSTRY,0,10.0,ACTUAL,2025-09-01T16:18:24.756034,v2_robust,True,True,False,True,False,The sponsor decided to prematurely terminate the study due to the lower-than-expected recruitment rate
NCT00574171,Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma,A Phase II Trial of Lapatinib and Capectiabine for Patients With Refractory Advanced Colorectal Adenocarcinoma (LAP109859),lapatinib,"['Tykerb', 'Xeloda', 'lapatinib', 'Capecitabine']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Colorectal Cancer,['Metastatic Colorectal Cancer'],[],COMPLETED,,2007-09,2009-08,"[{'measure': 'Response Rate of Lapatinib/Capecitabine.', 'timeFrame': 'duration of study; on average 1 year'}]",[],1,18 Years,,ALL,False,"University of Wisconsin, Madison",OTHER,1,29.0,ACTUAL,2025-09-01T16:18:24.756308,v2_robust,True,True,True,False,False,
NCT01118871,The First Failure Study,"A Randomised, Open Label, Prospective Study to Assess Two Different Therapeutic Strategies Following First Treatment Failure in HIV-1 Infected Subjects","Darunavir, Ritonavir, Truvada","['Prezista', 'Darunavir, Ritonavir and Etravirine', 'Truvada', 'Intelence', 'Darunavir, Ritonavir, Truvada', 'Norvir']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,HIV,"['HIV', 'HIV Infections']",['Treatment experienced'],TERMINATED,,2010-05,2013-05,"[{'measure': 'Mean change from baseline in peripheral and central adipose tissue', 'description': 'As measured by DEXA, between treatment arms.', 'timeFrame': 'week 48 and 96'}]","[{'measure': 'Percentage of patients <50 copies HIV-1 RNA/mL', 'description': 'At all study points to weeks 48 and 96 between treatment arms.', 'timeFrame': '96 weeks'}, {'measure': 'Mean change from baseline of absolute CD4+ T cell count', 'description': 'between treatment arms', 'timeFrame': '96 weeks'}, {'measure': 'Time to change in randomly assigned therapy', 'description': 'between treatment arms', 'timeFrame': '96 weeks'}, {'measure': 'Mean change from baseline Lipodystrophy Case Definition score', 'description': 'Between treatment arms', 'timeFrame': '96 weeks'}, {'measure': 'Mean change from baseline in fasting lipid and glycaemia parameters', 'description': 'between treatment arms', 'timeFrame': '96 weeks'}, {'measure': 'Mean change from baseline in cardiac and bone biomarker levels', 'description': 'between treatment arms', 'timeFrame': 'Week 96'}, {'measure': '• Comparison of total number of patients with any serious adverse events (SAEs), and the cumulative incidence of SAEs', 'description': 'Between the treatment arms', 'timeFrame': '96 week s'}, {'measure': 'Patterns of genotypic HIV resistance associated with virological treatment failure', 'description': 'Across the treatment arms', 'timeFrame': '96 weeks'}, {'measure': 'Describe aspects of immune reconstitution disease (IRD)', 'description': 'Across the treatment arms', 'timeFrame': '96 weeks'}, {'measure': 'Comparison of quality of life and results of adherence questionnaires', 'description': 'Between the treatment arms', 'timeFrame': '96 weeks'}]",11,18 Years,,ALL,False,Imperial College London,OTHER,0,3.0,ACTUAL,2025-09-01T16:18:24.756317,v2_robust,True,True,False,True,True,
NCT05033444,"A First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers.",PRV-002,"['PRV-002', 'Placebo control', 'Experimental drug', 'Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Traumatic Brain Injury (TBI),['Traumatic Brain Injury (TBI)'],"['Safety', 'Tolerability', 'Pharmacokinetics', 'PRV-002']",COMPLETED,,2022-02-09,2024-09-13,"[{'measure': 'Safety endpoint - Evaluation of the Incidence, severity, and relationship of AEs/SAEs (or ADEs/SADEs) (including withdrawals due to AEs (or ADEs)).', 'description': 'AEs/SAEs (or ADEs/SADEs) to be recorded as written descriptions on case report forms', 'timeFrame': 'Baseline pre-intervention (Day -28 to Day -2 and Day -1); during intervention and immediately afterwards (Day 1); Day 2; and through Day 5.'}, {'measure': 'Safety endpoint - Change from baseline in physical examination findings (Full)', 'description': 'Full physical exam including general appearance, head, ears, eyes, nose and throat, neck (including thyroid and lymph nodes), respiratory system, cardiovascular system, gastrointestinal system, renal system, neurological condition, musculoskeletal system, skin and any other focused assessments suggested by the presence of specific symptoms and measured by written descriptions.', 'timeFrame': 'Baseline pre-intervention Day -28 to -2.'}, {'measure': 'Safety endpoint - Change from baseline in physical examination findings (symptom directed)', 'description': 'Symptom-directed physical examination (focused assessments suggested by the presence of specific symptoms) will be performed if clinically indicated, as determined by the Investigator. The pre-dose physical examination assessment should be performed on the scheduled day, at any time prior to dosing. All other physical examinations will be performed within ± 1 hour of the nominated timepoint. Measured by written descriptions.', 'timeFrame': 'Baseline pre-intervention Day -1 and and Day 1; Day 2'}, {'measure': 'Safety endpoint - Change from baseline in vital signs (including changes from baseline in SpO2).', 'description': 'SpO2 measured as percent of oxygen (%)', 'timeFrame': 'Baseline pre-intervention between Day -28 to -2; Day 1 pre-intervention; Day 1 at 0.5hr, 1hr, 2hr, 6hr; Day 2 at 24 hr post intervention; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in vital signs (including changes from baseline in blood pressure).', 'description': 'Blood pressure measured for systolic and diastolic pressure as mm of mercury.', 'timeFrame': 'Baseline pre-intervention between Day -28 to -2; Day 1 pre-intervention; Day 1 at 0.5hr, 1hr, 2hr, 6hr; Day 2 at 24 hr post intervention; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in vital signs (including changes from baseline in heart rate).', 'description': 'Heart rate measured as beats per minute (BPM)', 'timeFrame': 'Baseline pre-intervention between Day -28 to -2; Day 1 pre-intervention; Day 1 at 0.5hr, 1hr, 2hr, 6hr; Day 2 at 24 hr post intervention; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in vital signs (including changes from baseline in respiration rate).', 'description': 'Respiration rate measured as breaths per minute', 'timeFrame': 'Baseline pre-intervention between Day -28 to -2; Day 1 pre-intervention; Day 1 at 0.5hr, 1hr, 2hr, 6hr; Day 2 at 24 hr post intervention; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in vital signs (including changes from baseline in body temperature).', 'description': 'Body temperature measured as degrees Celsius (C)', 'timeFrame': 'Baseline pre-intervention between Day -28 to -2; Day 1 pre-intervention; Day 1 at 0.5hr, 1hr, 2hr, 6hr; Day 2 at 24 hr post intervention; Day 5'}, {'measure': 'Safety endpoint - Changes from baseline in lung spirometry.', 'description': 'Lung spirometry measured as the ratio of forced expiratory value (FEV1)/ forced vital capacity (FVC) and reported as percentage (%)', 'timeFrame': 'Baseline pre-intervention between Day -28 to -2; Day 1 pre-intervention; Day 1 at 0.25hr, 1hr, 10hr; Day 2 at 24 hr post intervention; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in ECG parameters of heart rate', 'description': 'Heart ratel measured beats per minute (BPM)', 'timeFrame': 'Baseline pre-intervention; during intervention and immediately afterwards (Day 1); Day 2; and through Day 5.'}, {'measure': 'Safety endpoint - Change from baseline in ECG parameters of PR interval, QRS interval, and QT interval', 'description': 'PR interval, QRS interval, and QT interval as measured in milliseconds (ms)', 'timeFrame': 'Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 pre-intervention; Day 1 at 0.5hr, 2hr, 6hr; 12hr; Day 2 at 24 hr post intervention; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in hematocrit values', 'description': 'Hematocrit measured as the percentage of red blood cells in whole blood (%)', 'timeFrame': 'Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24 hr post intervention; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in hemoglobin values', 'description': 'Hemoglobin measured as the amount of hemoglobin in whole blood measured as grams per deciliter (g/dL)', 'timeFrame': 'Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24 hr post intervention; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in Red Blood Cell (RBC) indices', 'description': 'RBC measured as the number of million RBCs per microliter (mcL) of blood', 'timeFrame': 'Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24 hr post intervention; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in Thrombocyte Count (Platelets); White Blood Cells (WBC); Basophils; Eosinophils; Lymphocytes; Monocytes; and Neutrophils.', 'description': 'Platelets measured as the number of cells per microliter (mcL) of blood', 'timeFrame': 'Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24 hr post intervention; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in the blood hormone level of Dehydroepiandrosterone-sulfate (DHEAS)', 'description': 'Dehydroepiandrosterone sulfate (DHEAS) measured as the number of micrograms per deciliter (µg/dL) of blood', 'timeFrame': 'Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in the blood hormone level of dihydrotestosterone (DHT)', 'description': 'Dihydrotestosterone (DHT) measured as the number of nano moles per liter (nmol/L) of blood', 'timeFrame': 'Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in the blood hormone level of luteinizing hormone (LH)', 'description': 'Luteinizing hormone (LH) measured as the number of International units per liter (IU/L)', 'timeFrame': 'Baseline pre-intervention Days -28 to -2'}, {'measure': 'Safety endpoint - Change from baseline in the blood hormone level of dehydroepiandrosterone sulfate (DHEAS)', 'description': 'Dehydroepiandrosterone sulfate (DHEAS) measured as the number of micrograms per deciliter (mcg/dL)', 'timeFrame': 'Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in the blood hormone level of thyroid stimulating hormone (TSH)', 'description': 'Thyroid stimulating hormone (TSH) measured as the number of milli-international units per liter (mIU/L)', 'timeFrame': 'Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5'}, {'measure': 'Safety endpoint - For postmenopausal women only, change from baseline in the blood hormone level of follicle-stimulating hormone (FSH) and human chorionic gonadotropin (hGH)', 'description': 'Follicle-stimulating hormone (FSH) and human chorionic gonadotropin (hGH) measured as the number of milli-international units per milliliter (mIU/mL)', 'timeFrame': 'Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in the blood hormone level of free thyroxine (FT4), testosterone, and dihydrotestosterone (DHT)', 'description': 'Free thyroxine (FT4), testosterone, and dihydrotestosterone (DHT) measured as the number of nanograms per deciliter (ng/dL)', 'timeFrame': 'Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in the blood hormone level of progesterone', 'description': 'Progesterone measured as the number of nanograms per miiliiliter (ng/mL)', 'timeFrame': 'Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in the blood hormone level of estradiol (E2) and free trilodothyronine (FT3)', 'description': 'Estradiol (E2) and free trilodothyronine (FT3) measured as the number of picograms per milliliter (pg/mL)', 'timeFrame': 'Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5'}, {'measure': 'Safety endpoint Change in baseline in clotting factors Partial thromboplastin time (aPTT) and Prothrombin time (PT)', 'description': 'Partial thromboplastin time (aPTT) and Prothrombin time (PT) measured as time to clot in seconds (sec)', 'timeFrame': 'Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24 hr post intervention; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in the clotting factor Fibrinogen', 'description': 'Fibrinogen measured as the number of milligrams per deciliter (mg/dL)', 'timeFrame': 'Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24 hr post intervention; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in the clotting factor International Normalized Ratio (INR)', 'description': 'International Normalized Ratio (INR) measured as the ratio of patient PT/control PT', 'timeFrame': 'Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24 hr post intervention; Day 5'}, {'measure': 'Safety endpoint - Change from baseline in urinalysis parameters bilirubin, blood, glucose, nitrites, protein, and urobilinogen', 'description': 'Bilirubin, blood, glucose, nitrites, protein, and urobilinogen measured as the number of milligrams per deciliter (mg/dL)', 'timeFrame': 'Post dose Day 1 at 0 to 6hr, 6 to 12hr, and 12 to 24hr'}, {'measure': 'Safety endpoint - Change from baseline in urinalysis parameter ketones', 'description': 'Ketones measured as the number of millimoles per liter (mmol/L)', 'timeFrame': 'Post dose Day 1 at 0 to 6hr, 6 to 12hr, and 12 to 24hr'}, {'measure': 'Safety endpoint - Change from baseline in urinalysis parameter leukocyte esterase', 'description': 'Leukocyte esterase measured as negative or positive; number of WBCs per high power field', 'timeFrame': 'Post dose Day 1 at 0 to 6hr, 6 to 12hr, and 12 to 24hr'}, {'measure': 'Safety endpoint - Change from baseline in urinalysis parameter pH', 'description': 'pH measured as pH units', 'timeFrame': 'Post dose Day 1 at 0 to 6hr, 6 to 12hr, and 12 to 24hr'}, {'measure': 'Safety endpoint - Change from baseline in urinalysis parameter specific gravity', 'description': 'Specific gravity measured as specific gravity units as a ratio of density of urine/density of water', 'timeFrame': 'Post dose Day 1 at 0 to 6hr, 6 to 12hr, and 12 to 24hr'}, {'measure': 'Safety endpoint - Change from baseline in serum chemistry parameters globulin, protein, and albumin', 'description': 'Globulin, protein, and albumin measured as grams per deciliter (g/dL)', 'timeFrame': 'Baseline pre-intervention Days -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24hr; Day 5.'}, {'measure': 'Safety endpoint - Change from baseline in serum chemistry parameter alkaline phosphatase', 'description': 'Alkaline phosphatase measured as International units per liter (IU/L)', 'timeFrame': 'Baseline pre-intervention Days -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24hr; Day 5.'}, {'measure': 'Safety endpoint - Change from baseline in serum chemistry parameters bicarbonate, chloride, sodium, and magnesium', 'description': 'Bicarbonate, chloride, sodium, and magnesium measured as milliequivalents per liter (mEq/L)', 'timeFrame': 'Baseline pre-intervention Days -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24hr; Day 5.'}, {'measure': 'Safety endpoint - Change from baseline in serum calcium, glucose, phosphate, creatinine, urea, uric acid, bilirubin (conjugated and unconjugated), high density lipoproteins, low density lipoproteins, total bilirubin, total cholesterol', 'description': 'Calcium, glucose, phosphate, creatinine, urea, uric acid, bilirubin (conjugated and unconjugated), high density lipoproteins, low density lipoproteins, total bilirubin, total cholesterol, triglycerides measured as milligrams per deciliter (mg/dL)', 'timeFrame': 'Baseline pre-intervention Days -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24hr; Day 5.'}, {'measure': 'Safety endpoint - Change from baseline in serum chemistry parameters potassium', 'description': 'Potassium measured as millimoles per liter (mmol/L)', 'timeFrame': 'Baseline pre-intervention Days -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24hr; Day 5.'}, {'measure': 'Safety endpoint - Change from baseline in serum chemistry parameters lipase, creatine kinase, lactate dehydrogenase, aspartate aminotransferase, gamma-glutamyl transferase, alanine aminotransferase, and amylase', 'description': 'Lipase, creatine kinase, lactate dehydrogenase, aspartate aminotransferase, gamma-glutamyl transferase, alanine aminotransferase, and amylase measured as Units per liter (U/L)', 'timeFrame': 'Baseline pre-intervention Days -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24hr; Day 5.'}, {'measure': 'Safety endpoint - Change from baseline in virology parameters HIV-1/-2; HBsAg; HCV; SARS-COV-2', 'description': 'HIV-1/-2; HBsAg; HCV; SARS-COV-2 test results measured as negative or positive', 'timeFrame': 'Baseline pre-intervention Day -28 to -2'}, {'measure': 'Safety endpoint - Change from baseline in drug screen findings for alcohol', 'description': 'Alcohol test results measured as percentage (%)', 'timeFrame': 'Baseline pre-intervention Day -28 to -2; Day -1'}, {'measure': 'Safety endpoint - Change from baseline in urine drug screen findings for amphetamines, barbiturates, benzodiazepines, cocaine, cotinine, methamphetamines, opiates, phencyclidine, THC, and tricyclic antidepressants', 'description': 'Urine amphetamines, barbiturates, benzodiazepines, cocaine, cotinine, methamphetamines, opiates, phencyclidine, THC, and tricyclic antidepressants test results measured as nanograms per milliliter (ng/mL)', 'timeFrame': 'Baseline pre-intervention Day -28 to -2; Day -1'}, {'measure': 'Safety endpoint - Change from baseline for pregnancy test for serum hCG and urine hCG', 'description': 'Serum hCG and Urine hCG levels measured in milli-international units per liter (mIU/L)', 'timeFrame': 'Serum pregnancy test Days -28 to -2 and on Day 5; Urine pregnancy test Day -1'}, {'measure': 'Safety endpoint - Change from baseline for confirmation of postmenopausal status test for FSH', 'description': 'FSH levels measured in milli-international units per liter (mIU/L)', 'timeFrame': 'Baseline pre-intervention on Days -28 to -2'}]","[{'measure': 'Plasma pharmacokinetics - Cmax', 'description': 'Plasma PRV-002 Cmax measured as microgram per mL (mcg/mL)', 'timeFrame': 'Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.'}, {'measure': 'Plasma pharmacokinetics - Tmax', 'description': 'Plasma PRV-002 time to Cmax', 'timeFrame': 'Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.'}, {'measure': 'Plasma pharmacokinetics - area under the curve', 'description': 'Plasma PRV-002 Area under the concentration-time curve from 0 to time of last quantifiable concentration (AUC0-t) measured as min\\*kBq/mL', 'timeFrame': 'Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.'}, {'measure': 'Plasma pharmacokinetics - area under the concentration-time curve', 'description': 'Plasma PRV-002 area under the concentration-time curve from 0 to infinity (AUC0-inf) measured as mg\\*h/L', 'timeFrame': 'Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.'}, {'measure': 'Plasma pharmacokinetics - apparent terminal elimination half-life t1/2)', 'description': 'Plasma PRV-002 apparent terminal elimination half-life (t1/2) measured in minutes or hours', 'timeFrame': 'Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.'}, {'measure': 'Plasma pharmacokinetics - terminal elimination rate constant (λz)', 'description': 'Plasma PRV-002 terminal elimination rate constant (λz) measured as elimination rate measured as constant K or Ke ((λz))', 'timeFrame': 'Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.'}, {'measure': 'Plasma pharmacokinetics total apparent body clearance', 'description': 'Plasma PRV-002 total apparent body clearance measured as (CL/F)', 'timeFrame': 'Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.'}, {'measure': 'Plasma pharmacokinetics - apparent volume of distribution', 'description': 'Plasma PRV-002 apparent volume of distribution measured as (Vz/F)', 'timeFrame': 'Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.'}, {'measure': 'Urine pharmacokinetics - cumulative amount of unchanged drug excreted in urine', 'description': 'Urine PRV-002 cumulative amount of unchanged drug excreted (Ae) in urine measured in micrograms per milliliter (mcg/mL)', 'timeFrame': 'Baseline pre-intervention on Day -1; Day 1 at 0 to 6hr, 6 to 12hr, and 12 to 24 hr.'}, {'measure': 'Urine pharmacokinetics - renal clearance', 'description': 'Urine PRV-002 renal clearance measured as (CLr)', 'timeFrame': 'Baseline pre-intervention on Day -1; Day 1 at 0 to 6hr, 6 to 12hr, and 12 to 24 hr.'}]",53,18 Years,55 Years,ALL,True,"Odyssey Group International, Inc.",INDUSTRY,1,40.0,ACTUAL,2025-09-01T16:18:24.756682,v2_robust,True,True,True,False,True,
NCT02247544,Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma,A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma,Trabectedin,"['Yondelis', 'Trabectedin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Liposarcoma,"['Liposarcoma', 'Leiomyosarcoma']","['STS, leiomyosarcoma, liposarcoma, trabectedin']",COMPLETED,,2014-03,2019-03-12,"[{'measure': 'Growth Modulation Rate', 'description': 'The primary end point of the study will be the proportion of responders to trabectedin, based on the ratio, in each single patient, between PFS under trabectedin (PFS) and time to progression after previous chemotherapy treatment (TTP1).', 'timeFrame': 'From date of randomization until progressive disease, assessed up to 48 months'}]","[{'measure': 'Objective response (OR) in the overall sample', 'timeFrame': 'From date of randomization until progressive disease, assessed up to 48 months'}, {'measure': 'Pathological tumour response in the two eligible histological types, in patients undergoing surgery after treatment', 'timeFrame': 'From date of randomization until the best tumour dimensional response, assessed up to 48 months'}, {'measure': 'PFS and OR in the two eligible histological types', 'timeFrame': 'From date of randomization until progressive disease, assessed up to 48 months'}, {'measure': 'PFS in patients who undergo surgery after, or during, medical therapy and those who do not', 'timeFrame': 'From date of randomization until progressive disease, assessed up to 48 months'}, {'measure': 'Number of patients with grade>=3 adverse drug reactions, number of serious adverse events related to study drug and number of patients who will experience at least one serious adverse event', 'timeFrame': 'From date of randomization until progressive disease, assessed up to 48 months'}, {'measure': 'Efficacy of trabectedin in reducing cancer related pain', 'description': 'All patients will be administered a standardized questionnaire evaluating cancer related pain and use of antalgic medication.', 'timeFrame': 'From date of randomization until progressive disease, assessed up to 48 months'}]",7,18 Years,,ALL,False,Italian Sarcoma Group,NETWORK,1,105.0,ACTUAL,2025-09-01T16:18:24.756691,v2_robust,True,True,True,False,True,
NCT00734344,Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection,Pilot Study of Raltegravir/Tenofovir/Emtricitabine Versus Efavirenz/Tenofovir/Emtricitabine for Adults With Acute HIV-1 Infection: Exploring the Role of Integrase Inhibition in Early HIV Pathogenesis,Raltegravir,"['Emtricitibine', 'Raltegravir', 'Tenofovir disoproxil once daily', 'Tenofovir disoproxil twice daily', 'Efavirenz']",5,INTERVENTIONAL,['NA'],,,Acute HIV Infection,['Acute HIV Infection'],[],COMPLETED,,2008-09,2012-09,"[{'measure': 'Mean White Blood Cell Count Between Treatment Groups at 2 Months', 'description': 'Mean WBC count for all subjects as determined by standard lab procedures at 2 months after starting study drug as well as range. The normal number of WBCs in the blood is 4,500-10,000 white blood cells per microliter (mcL).', 'timeFrame': 'baseline to 2 months'}, {'measure': 'Mean White Blood Cell Count Between Treatment Groups at 4 Months', 'description': 'Mean WBC count of all subjects as determined by standard lab procedures at 4 months after starting study drug as well as range. The normal number of WBCs in the blood is 4,500-10,000 white blood cells per microliter (mcL).', 'timeFrame': '4 months post baseline'}, {'measure': 'Mean White Blood Cell Count Between Treatment Groups at 6 Months', 'description': 'Mean WBC count of all subjects as determined by standard lab procedures at 6 months after starting study drug as well as range. The normal number of WBCs in the blood is 4,500-10,000 white blood cells per microliter (mcL).', 'timeFrame': '6 months after baseline'}, {'measure': 'Mean White Blood Cell Count Between Treatment Groups at 8 Months', 'description': 'Mean WBC count of all subjects as determined by standard lab procedures at 8 months after starting study drug as well as range. The normal number of WBCs in the blood is 4,500-10,000 white blood cells per microliter (mcL).', 'timeFrame': '8 months after baseline'}, {'measure': 'Mean White Blood Cell Count Between Treatment Groups at 10 Months', 'description': 'Mean WBC count of all subjects as determined by standard lab procedures at 10 months after starting study drug as well as range. The normal number of WBCs in the blood is 4,500-10,000 white blood cells per microliter (mcL).', 'timeFrame': '10 months after baseline'}, {'measure': 'Mean White Blood Cell Count Between Treatment Groups at 12 Months', 'description': 'Mean WBC count of all subjects as determined by standard lab procedures at 12 months after starting study drug as well as range. The normal number of WBCs in the blood is 4,500-10,000 white blood cells per microliter (mcL).', 'timeFrame': '12 months after baseline'}, {'measure': 'Mean White Blood Cell Count Between Treatment Groups at 14 Months', 'description': 'Mean WBC count of all subjects as determined by standard lab procedures at 14 months after starting study drug as well as range. The normal number of WBCs in the blood is 4,500-10,000 white blood cells per microliter (mcL).', 'timeFrame': '14 months after baseline'}, {'measure': 'Mean Hematocrit Between Treatment Groups at 2 Months', 'description': 'Mean hematocrit of all subjects at 2 months after starting study drug. The hematocrit, also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women.', 'timeFrame': '2 months after baseline'}, {'measure': 'Mean Hematocrit Between Treatment Groups at 4 Months', 'description': 'Mean hematocrit of all subjects at 4 months after starting study drug. The hematocrit, also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women.', 'timeFrame': '4 months after baseline'}, {'measure': 'Mean Hematocrit Between Treatment Groups at 6 Months', 'description': 'Mean hematocrit of all subjects at 6 months after starting study drug. The hematocrit, also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women.', 'timeFrame': '6 months after baseline'}, {'measure': 'Mean Hematocrit Between Treatment Groups at 8 Months', 'description': 'Mean hematocrit of all subjects at 8 months after starting study drug. The hematocrit, also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women.', 'timeFrame': '8 months after baseline'}, {'measure': 'Mean Hematocrit Between Treatment Groups at 10 Months', 'description': 'Mean hematocrit of all subjects at 10 months after starting study drug. The hematocrit, also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women.', 'timeFrame': '10 months after baseline'}, {'measure': 'Mean Hematocrit Between Treatment Groups at 12 Months', 'description': 'Mean hematocrit of all subjects at 12 months after starting study drug. The hematocrit, also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women.', 'timeFrame': '12 months after baseline'}, {'measure': 'Mean Hematocrit Between Treatment Groups at 14 Months', 'description': 'Mean hematocrit of all subjects at 14 months after starting study drug. The hematocrit, also known as packed cell volume (PCV) or erythrocyte volume fraction (EVF), is the volume percentage (%) of red blood cells in blood. It is normally 45% for men and 40% for women.', 'timeFrame': '14 months after baseline'}, {'measure': 'Mean Platelet Count Between Treatment Groups at 2 Months', 'description': 'The mean platelet count between treament groups at 2 months after starting study drug. The calculated number of platelets in a volume of blood, usually expressed as platelets per cubic millimeter (cmm) of whole blood. Platelets are the smallest cell-like structures in the blood and are important for blood clotting and plugging damaged blood vessels. Platelet counts are usually done by laboratory machines that also count other blood elements such as the white and red cells. They can also be counted by use of a microscope. Normal platelet counts are in the range of 150,000 to 400,000 per microliter (or 150 - 400 x 100 per liter).', 'timeFrame': '2 months after baseline'}, {'measure': 'Mean Platelet Count Between Treatment Groups at 4 Months', 'description': 'The mean platelet count between treatment groups at 4 months after starting study drug. The calculated number of platelets in a volume of blood, usually expressed as platelets per cubic millimeter (cmm) of whole blood. Platelets are the smallest cell-like structures in the blood and are important for blood clotting and plugging damaged blood vessels. Platelet counts are usually done by laboratory machines that also count other blood elements such as the white and red cells. They can also be counted by use of a microscope. Normal platelet counts are in the range of 150,000 to 400,000 per microliter (or 150 - 400 x 109 per liter).', 'timeFrame': '4 months after baseline'}, {'measure': 'Mean Platelet Count Between Treatment Groups at 6 Months', 'description': 'The mean platelet count between treatment groups at 6 months after starting study drug. The calculated number of platelets in a volume of blood, usually expressed as platelets per cubic millimeter (cmm) of whole blood. Platelets are the smallest cell-like structures in the blood and are important for blood clotting and plugging damaged blood vessels. Platelet counts are usually done by laboratory machines that also count other blood elements such as the white and red cells. They can also be counted by use of a microscope. Normal platelet counts are in the range of 150,000 to 400,000 per microliter (or 150 - 400 x 109 per liter).', 'timeFrame': '6 months after baseline'}, {'measure': 'Mean Platelet Count Between Treatment Groups at 8 Months', 'description': 'The mean platelet count between treatment groups at 8 months after starting study drug. The calculated number of platelets in a volume of blood, usually expressed as platelets per cubic millimeter (cmm) of whole blood. Platelets are the smallest cell-like structures in the blood and are important for blood clotting and plugging damaged blood vessels. Platelet counts are usually done by laboratory machines that also count other blood elements such as the white and red cells. They can also be counted by use of a microscope. Normal platelet counts are in the range of 150,000 to 400,000 per microliter (or 150 - 400 x 109 per liter).', 'timeFrame': '8 months after baseline'}, {'measure': 'Mean Platelet Count Between Treatment Groups at 10 Months', 'description': 'The mean platelet count between treatment groups at 10 months after starting study drug. The calculated number of platelets in a volume of blood, usually expressed as platelets per cubic millimeter (cmm) of whole blood. Platelets are the smallest cell-like structures in the blood and are important for blood clotting and plugging damaged blood vessels. Platelet counts are usually done by laboratory machines that also count other blood elements such as the white and red cells. They can also be counted by use of a microscope. Normal platelet counts are in the range of 150,000 to 400,000 per microliter (or 150 - 400 x 109 per liter).', 'timeFrame': '10 months after baseline'}, {'measure': 'Mean Platelet Count Between Treatment Groups at 12 Months', 'description': 'The mean platelet count between treatment groups at 12 months after starting study drug. The calculated number of platelets in a volume of blood, usually expressed as platelets per cubic millimeter (cmm) of whole blood. Platelets are the smallest cell-like structures in the blood and are important for blood clotting and plugging damaged blood vessels. Platelet counts are usually done by laboratory machines that also count other blood elements such as the white and red cells. They can also be counted by use of a microscope. Normal platelet counts are in the range of 150,000 to 400,000 per microliter (or 150 - 400 x 109 per liter).', 'timeFrame': '12 months after baseline'}, {'measure': 'Mean Platelet Count Between Treatment Groups at 14 Months', 'description': 'The mean platelet count between treatment groups at 14 months after starting study drug. The calculated number of platelets in a volume of blood, usually expressed as platelets per cubic millimeter (cmm) of whole blood. Platelets are the smallest cell-like structures in the blood and are important for blood clotting and plugging damaged blood vessels. Platelet counts are usually done by laboratory machines that also count other blood elements such as the white and red cells. They can also be counted by use of a microscope. Normal platelet counts are in the range of 150,000 to 400,000 per microliter (or 150 - 400 x 109 per liter).', 'timeFrame': '4 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 1 Months', 'description': 'Mean CD4 count between groups 1 month after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '1 month after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 2 Months', 'description': 'Mean CD4 count between groups 2 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '2 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 3 Months', 'description': 'Mean CD4 count between groups 3 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '3 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 4 Months', 'description': 'Mean CD4 count between groups 4 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '4 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 5 Months', 'description': 'Mean CD4 count between groups 5 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '5 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 6 Months', 'description': 'Mean CD4 count between groups 6 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '6 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 7 Months', 'description': 'Mean CD4 count between groups 7 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '7 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 8 Months', 'description': 'Mean CD4 count between groups 8 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '8 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 9 Months', 'description': 'Mean CD4 count between groups 9 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '9 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 10 Months', 'description': 'Mean CD4 count between groups 10 months after starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '10 months after baseline'}, {'measure': 'Mean CD4 Count Between Treatment Groups at 11 Months', 'description': 'Mean CD4 count between groups 11 months after of starting study drug. CD4 cells are types of white blood cells called T lymphocytes or T cells that fight infection. CD4 counts are most often used to evaluate the immune system of a person diagnosed with a human immunodeficiency virus (HIV) infection to help stage and monitor progression of the disease and monitor effectiveness of antiretroviral treatment. A CD4 count is typically reported as an absolute level or count of cells (expressed as cells per cubic millimeter of blood). A normal CD4 count ranges from 410-1,590 cells/mm3 in adults and teens. Sometimes results are expressed as a percent of total lymphocytes (CD4 percent).', 'timeFrame': '11 months after baseline'}]",[],32,19 Years,,ALL,False,University of Alabama at Birmingham,OTHER,1,18.0,ACTUAL,2025-09-01T16:18:24.756749,v2_robust,True,True,True,False,False,
NCT02575144,GEM-CLARIDEX: Ld vs BiRd,GEM-CLARIDEX: Lenalidomide and Dexamethasone (Ld) Versus Clarithromycin / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma,Clarithromycin,"['Lenalidomide', 'Clarithromycin', 'Dexamethasone']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Multiple Myeloma,['Multiple Myeloma'],[],UNKNOWN,,2015-09,2024-10,"[{'measure': 'Progression free survival', 'timeFrame': 'Throught the study. Approximately 4 years'}]",[],1,18 Years,,ALL,False,PETHEMA Foundation,OTHER,1,286.0,ACTUAL,2025-09-01T16:18:24.756919,v2_robust,True,True,False,False,False,
NCT03024034,A Phase 1 TP-271 Oral PK Single Ascending Dose Study,"A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral TP-271 in Healthy Adult Subjects, Including 1 Cross-over Arm",TP-271,['TP-271'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Bacterial Infections,['Bacterial Infections'],[],COMPLETED,,2017-03-02,2018-06-04,"[{'measure': 'Adverse Events (AE)', 'description': 'The incidence, intensity, and type of adverse events (AE) and the total number of participants experiencing AEs that are related to treatment\n\nOutcome measures to be collected in support of the primary objective (safety and tolerability) include:\n\n* The incidence, intensity, and type of AEs (from time of signing of informed consent form \\[ICF\\] through EOS);\n* Changes in physical examination findings (Day -1 and EOS);\n* Changes in vital signs (Day -1 through EOS);\n* Changes in safety laboratory (chemistry, hematology, coagulation, urinalysis) results (Days -1 through EOS); and\n* Changes in ECG measurements (Days -1 through EOS).', 'timeFrame': 'Through study completion, approximately 39 days'}, {'measure': 'Physical Exams', 'description': 'Changes in physical examination findings', 'timeFrame': 'Through study completion, approximately 39 days'}, {'measure': 'Vital Signs', 'description': 'Changes in vital signs', 'timeFrame': 'Through study completion, approximately 39 days'}, {'measure': 'Safety Laboratory', 'description': 'Changes in safety laboratory (chemistry, hematology, coagulation, urinalysis) results that are considered abnormal, clinically significant and related to treatment', 'timeFrame': 'Through study completion, approximately 39 days'}, {'measure': 'ECG measurements', 'description': 'Abnormal ECG measurements that are abnormal, clinically significant and related to treatment', 'timeFrame': 'Through study completion, approximately 39 days'}]","[{'measure': 'Plasma Pharmacokinetic (PK) Analysis', 'description': 'Plasma concentrations of TP-271 and its C-4 epimer TP-9555 for PK analysis', 'timeFrame': 'Days 1-5'}, {'measure': 'Urine Pharmacokinetic (PK) Analysis', 'description': 'Urine concentrations of TP-271 and its C-4 epimer TP-9555', 'timeFrame': 'Days 1-5'}, {'measure': 'PK parameters - Cmax', 'description': 'PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Cmax \\[The maximum observed plasma concentration\\]', 'timeFrame': 'Days 1-5'}, {'measure': 'PK parameters - Tmax', 'description': 'PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Tmax \\[The time from dosing at which Cmax is apparent\\]', 'timeFrame': 'Days 1-5'}, {'measure': 'PK parameters - C8', 'description': 'PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for C8 \\[The concentration at 8 hours post-dose\\]', 'timeFrame': 'Days 1-5'}, {'measure': 'PK parameters - C12', 'description': 'PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for C8 \\[The concentration at 8 hours post-dose\\]', 'timeFrame': 'Days 1-5'}, {'measure': 'PK parameters - C24', 'description': 'PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for C24 \\[The concentration at 24 hours post-dose\\]', 'timeFrame': 'Days 1-5'}, {'measure': 'PK parameters - AUC(0-last)', 'description': 'PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for AUC(0-inf) \\[The area under the concentration vs time curve from time zero extrapolated to infinity\\]', 'timeFrame': 'Days 1-5'}, {'measure': 'PK parameters - AUC(0-inf)', 'description': 'PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for AUC(0-inf) \\[The area under the concentration vs time curve from time zero extrapolated to infinity\\]', 'timeFrame': 'Days 1-5'}, {'measure': 'PK parameters - AUC% extrapolated', 'description': 'PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for AUC%extrapolated \\[The percentage of AUC(0-inf) accounted for by extrapolation\\]', 'timeFrame': 'Days 1-5'}, {'measure': 'PK parameters - Lambda-z', 'description': 'PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for Lambda-z \\[Slope of the regression line passing through the apparent elimination phase in a concentration vs time plot\\]', 'timeFrame': 'Days 1-5'}, {'measure': 'PK parameters - T1/2el', 'description': 'PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for T1/2el \\[The elimination half-life\\]', 'timeFrame': 'Days 1-5'}, {'measure': 'PK parameters - CL', 'description': 'PK parameters will be calculated from the plasma concentration versus time data (as appropriate) for CL \\[Clearance: the volume of plasma cleared per unit time\\]', 'timeFrame': 'Days 1-5'}, {'measure': 'PK parameters - Vd', 'description': 'The PK parameters of the epimer/parent will be calculated for Cmax and AUC(0-inf).', 'timeFrame': 'Days 1-5'}, {'measure': 'PK parameters - epimer/parent', 'description': 'The PK parameters of the epimer/parent will be calculated for Cmax and AUC(0-inf).', 'timeFrame': 'Days 1-5'}]",20,18 Years,50 Years,ALL,True,"Tetraphase Pharmaceuticals, Inc",INDUSTRY,1,56.0,ACTUAL,2025-09-01T16:18:24.757050,v2_robust,True,True,True,False,True,
NCT02179034,Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 1,Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 1,Nicotine,['Nicotine'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,"Nicotine Dependence, Other Tobacco Product","['Nicotine Dependence, Other Tobacco Product']","['tobacco', 'electronic cigarettes', 'menthol', 'flavors']",COMPLETED,,2014-10-23,2017-06-12,"[{'measure': 'Liking/effect score of the e-cigarette', 'description': ""The Drug Effects Questionnaire (Soria et al) will be used to ask about participants' liking/effect of the e-cigarettes smoked during the 4 bouts of e-cigarette puffing during the lab session to determine which menthol dose is most preferred. A linear mixed-effects regression model wil be used with nicotine group (none, low, high) as between-subject factor, and menthol dose (none, low dose, high dose) as within-subject factor."", 'timeFrame': 'Every 30 min for 120 min during lab session'}]","[{'measure': 'Maximum value of money at which the e-cigarette is chosen over money', 'description': 'E-cigarette value will be determined using the Multiple Choice Procedure (Griffiths et al, 1993) to determine the reinforcing value of the e-cigarette. The MCP involves sampling the e-cigarette and then making a discrete choice between the e-cigarette or a series of monetary values.', 'timeFrame': 'Every 30 min for 120 min during lab session'}, {'measure': 'Change scores from baseline in Nicotine Withdrawal', 'description': 'The Minnesota Nicotine Withdrawal Scale (Hughes et al,1986) will be used to assess the magnitude of change in nicotine withdrawal symptoms during the lab session', 'timeFrame': 'Every 30 min for 120 min during lab session'}, {'measure': 'Change scores from baseline in Tobacco Craving', 'description': 'The Brief Questionnaire on Smoking Urges (Tiffany \\& Drobes,1991) will be used to assess the magnitude of change in tobacco craving during the lab session', 'timeFrame': 'Every 30 min for 120 min during lab session'}]",4,18 Years,20 Years,ALL,True,Yale University,OTHER,0,59.0,ACTUAL,2025-09-01T16:18:24.757093,v2_robust,True,True,True,False,False,
NCT03575234,Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer,Phase I Neo-Adjuvant Nivolumab + IRX-2 Followed by Surgery for Resectable Oral Cavity Cancer or HPV-Associated Oropharynx Cancer,Cyclophosphamide,"['Revimmune', 'Cytophosphane', 'Cyclophosphamide', 'Neosar', 'Cytoxan']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma,"['Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma', 'Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7', 'Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7', 'Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7', 'Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7']",[],WITHDRAWN,funding and drug were withdrawn,2020-07-01,2026-01-31,"[{'measure': 'Incidence of adverse events (AEs) described using Common Terminology Criteria for Adverse Events 4.03', 'description': 'Non-hematologic toxicities will be evaluated via the ordinal Common Toxicity Criteria (CTC) standard toxicity grading. Hematologic toxicity measures of thrombocytopenia, neutropenia, and leukopenia will be assessed using continuous variables as the outcome measures (primarily nadir) as well as categorization via CTC standard toxicity grading. Overall toxicity incidence as well as toxicity profiles by dose level and patient will be explored and summarized.', 'timeFrame': 'Up to 4 years'}, {'measure': 'Change in tumor size determined by central radiology review by radiologists blinded to the treatment regimen', 'description': 'Tumor changes will be determined by a comparison of the imaging studies (contrast-enhanced computed tomography \\[CECT\\] or magnetic resonance imaging \\[MRI\\]) obtained pre-treatment and just prior to surgery. Percent changes in tumor size will be determined by radiology at the site. If the change is not clear to the radiologist at the site, then the PI must be notified and two radiologists at Emory will be asked to independently review the scans and a decision will be made.', 'timeFrame': 'Baseline up to 4 years'}]",[],2,18 Years,,ALL,False,Emory University,OTHER,2,0.0,ACTUAL,2025-09-01T16:18:24.757117,v2_robust,True,True,False,True,True,funding and drug were withdrawn
NCT02546934,ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC),"A Phase III, Multicenter, Randomized Study of ABX Plus Cisplatin (AP) Versus Gemcitabine Plus Cisplatin (GP) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer","ABX, cisplatin","['Gemcitabine, Cisplatin', 'experimental arm', 'control arm', 'ABX, cisplatin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,['Breast Cancer'],"['triple negative breast cancer', 'fine line chemotherapy']",COMPLETED,,2016-03,2020-04,"[{'measure': 'PFS (Progression Free Survival)', 'timeFrame': '6 weeks'}]","[{'measure': 'Objective Response Rate (ORR)', 'timeFrame': '6 weeks'}, {'measure': 'Number of Participants with Adverse Events as a Measure of Safety and Tolerability', 'timeFrame': '6 weeks'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months'}]",4,18 Years,70 Years,FEMALE,False,Fudan University,OTHER,0,254.0,ESTIMATED,2025-09-01T16:18:24.757140,v2_robust,True,True,True,False,True,
NCT05540834,Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure,"A Phase 2 Safety, Dose-finding and Efficacy Study Evaluating Viscoelastic Testing (VET) Guided Tissue Plasminogen Activator (tPA) Treatment in Critically-ill Pro-thrombotic Acute Respiratory Failure",Alteplase,"['Alteplase', 'Tissue plasminogen activator', 'Activase', 'Actilyse', 'tPA']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Respiratory Failure,"['Acute Respiratory Failure', 'Hypercoagulability', 'Fibrinolysis Shutdown']",[],RECRUITING,,2022-05-18,2026-12-01,"[{'measure': 'Change in clot lysis time on viscoelastic testing from baseline and up to 72 hours', 'description': 'The impact of alteplase administration on the clot lysis time (in seconds) measured by the TPA-test using the ClotPro at the bedside', 'timeFrame': 'From start to end of alteplase infusion + 1 and up to 72 hours later/ equivalent timeframe in controls'}]","[{'measure': 'Change in VET coagulation parameters from baseline and up to 72 hours', 'description': 'The impact of alteplase administration on clot formation related to fibrinogen and the extrinsic pathway (maximum clot firmness (MCF) / amplitude at 10 minutes (A10) in millimeters) measured by the FIB-test and EX-test using the ClotPro at the bedside', 'timeFrame': 'From start to end of alteplase infusion + 1 and up to 72 hours later/ equivalent timeframe in controls'}, {'measure': 'Changes in oxygenation', 'description': 'Arterial partial pressure of oxygen to inspired fraction of oxygen (P/F) ratio', 'timeFrame': 'From start to end of alteplase infusion/ equivalent timeframe in controls'}, {'measure': 'Rate of participants with bleeding events', 'description': 'Any bleeding events Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or greater', 'timeFrame': 'From study entry to Day 5'}, {'measure': 'Rate of thromboembolic events', 'description': 'Any thromboembolic event', 'timeFrame': 'From study entry to Day 30 or hospital discharge, whichever occurs first'}, {'measure': 'Changes in organ function', 'description': 'Sequential Organ Failure Assessment (SOFA) score from 0 (normal) to a range of 1-4 with higher scores indicating more severe organ dysfunction', 'timeFrame': 'From start to end of alteplase infusion/ equivalent timeframe in controls'}]",6,18 Years,75 Years,ALL,False,South West Sydney Local Health District,OTHER,0,70.0,ESTIMATED,2025-09-01T16:18:24.757256,v2_robust,True,True,False,False,True,
NCT05635734,Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma,A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined with Conventional Concurrent Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma,Azeliragon 5 mg,"['Azeliragon 5 mg', 'Azeliragon 10 mg', 'Azeliragon 20 mg']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Glioblastoma,['Glioblastoma'],"['Azeliragon', 'Newly diagnosed glioblastoma', 'Dose finding', 'Temozolomide', 'Radiotherapy']",ACTIVE_NOT_RECRUITING,,2023-09-05,2025-12,"[{'measure': 'Recommended phase 2/3 dose', 'description': 'To assess the recommended phase 2/3 dose (RP2/3D) in mg/day of azeliragon in patients with newly diagnosed glioblastoma receiving concurrent radiation and temozolomide.\n\nDose limiting toxicities were defined as listed AEs, dose-reductions, treatment interruptions, or discontinuation occurring during the DLT period (28 days), which are attributable (definite, probable, possible) to azeliragon will be classified as a DLT. 6 patients must be treated at that dose level with ≤ 1 DLT observed', 'timeFrame': 'Throughout the DLT observation period, approximately 28 days per patient'}]","[{'measure': 'Incidence of adverse events (AEs)', 'description': 'Percentage of patients experiencing an adverse event', 'timeFrame': 'Throughout the study period, approximately 2 years per patient'}, {'measure': 'Incidence of serious adverse events (SAEs)', 'description': 'Percentage of patients experiencing a serious adverse event', 'timeFrame': 'Throughout the study period, approximately 2 years per patient'}, {'measure': 'Disease control rate (DCR)', 'description': 'Percentage of patients who experience a complete response, partial response or stable disease according to Response Assessment in Neuro-Oncology (RANO) criteria as their best response throughout the study', 'timeFrame': 'Throughout the study period, approximately 2 years per patient'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first', 'timeFrame': 'Throughout the study period, approximately 2 years per patient'}, {'measure': 'Overall survival (OS)', 'description': 'Defined as the duration of time from start of treatment to time of death', 'timeFrame': 'Throughout the study period, approximately 2 years per patient'}, {'measure': 'Patients with changes in the Eastern Cooperative Oncology Group (ECOG) performance status', 'description': 'Percentage of patients who experience a change in ECOG status through the study', 'timeFrame': 'Throughout the study period, approximately 2 years per patient'}, {'measure': 'S100A9 expression levels', 'description': 'Expression levels of the S100A9 molecular biomarker in blood samples from patients. Samples will be taken at baseline, Week 10 and after progression', 'timeFrame': 'Throughout the study period, approximately 2 years per patient in 3 occasions for each patient'}]",8,18 Years,70 Years,ALL,False,Cantex Pharmaceuticals,INDUSTRY,0,18.0,ESTIMATED,2025-09-01T16:18:24.757275,v2_robust,True,True,False,False,True,
NCT00563134,A Randomised Trial on the Saftely and Efficacy of GR270774 in the Treatment of Gram-negative Sepsis in Adult,"A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults",GR270774,['GR270774'],1,INTERVENTIONAL,['NA'],,,Gram-Negative Bacterial Infections,"['Gram-Negative Bacterial Infections', 'Sepsis']",['Suspected or confirmed severe Gram-negative sepsis'],SUSPENDED,,2005-10,2006-12,"[{'measure': 'Mortality', 'timeFrame': '28 days'}]","[{'measure': 'New onset organ failure', 'timeFrame': '28 days'}, {'measure': 'Safety and tolerablity', 'timeFrame': '28 days'}, {'measure': 'Long term mortality', 'timeFrame': '3, 6 and 12 months'}]",4,18 Years,,ALL,,"Hospital Authority, Hong Kong",OTHER_GOV,1,1800.0,ESTIMATED,2025-09-01T16:18:24.757330,v2_robust,True,True,False,True,True,
NCT01856634,Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis,"Phase 1, Open-label, Multiple-dose, and Age De-escalation Trial to Assess the Pharmacokinetics, Safety and Tolerability of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs",100 mg Delamanid,"['100 mg Delamanid', '10 mg Delamanid Pediatric Formulation', '25 mg Pediatric Formulation Delamanid', 'Optimized Background Regimen', 'DPF', '5 mg Delamanid Pediatric Formulation', 'OPC-67683', '50 mg Delamanid', 'OBR']",9,INTERVENTIONAL,['PHASE1'],PHASE1,,Multidrug Resistant Tuberculosis,"['Multidrug Resistant Tuberculosis', 'Pediatric']","['Tuberculosis', 'Tuberculosis, Multidrug-Resistant', 'Mycobacterium Infections', 'Actinomycetales Infections', 'Gram-Positive Infections', 'Bacterial Infections', 'Pediatric']",COMPLETED,,2013-06-14,2017-12-28,"[{'measure': 'Plasma Concentrations', 'description': 'Plasma concentrations (Cmax, tmax, AUC 0-24h, accumulation ratio, apparent terminal elimination half-life, apparent total clearance) of delamanid and its metabolites on Days 1, 2, 10, 11, 13 (Groups 1 and 2 only), 15, 18.', 'timeFrame': 'Days 1, 2, 10, 11, 13 (Groups 1 and 2 only), 15, 18'}]","[{'measure': 'Adverse Events', 'description': 'Number of reported adverse events', 'timeFrame': '40 Days'}, {'measure': 'Safety Summary', 'description': 'Summary statistics of subjects with clinically significant abnormal laboratory test results, vitals, ECGs', 'timeFrame': '40 Days'}, {'measure': 'Palatability of the Pediatric Formulation', 'description': 'Palatability of the pediatric formulation will be assessed using an age-appropriate visual hedonic scale and clinical assessment for Groups 3 and 4 only.', 'timeFrame': 'Days 1 and 10'}]",4,,17 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,0,37.0,ACTUAL,2025-09-01T16:18:24.757341,v2_robust,True,True,True,False,True,
NCT03121534,"Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation","A Phase II Study of Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation",Blinatumomab,"['Ibrutinib', 'Imbruvica™', 'Nivolumab', 'Opdivo', 'Dexamethasone', 'BLINCYTO®', 'Blinatumomab', 'Decadron']",8,INTERVENTIONAL,['PHASE2'],PHASE2,,Hematopoietic/Lymphoid Cancer,"['Hematopoietic/Lymphoid Cancer', ""Richter's Transformation""]","['Hematopoietic/Lymphoid Cancer', ""Richter's transformation"", 'RT', 'Blinatumomab', 'Dexamethasone', 'Decadron']",TERMINATED,The study was closed for slow accrual,2017-06-22,2022-02-11,"[{'measure': 'Number of Participants With a Response', 'description': 'Response is defined as complete remission (CR) plus partial remission (PR). Complete Remission (CR) is Lymph nodes None \\>/= 1.5 cm, Spleen size \\< 13 cm; normal liver size, the absence of constitutional symptoms, normal circulating lymphocyte count, platelets \\>/= 100 x 10\\^9/L, Hemoglobin \\>/= 11.0 g/dL (absence of transfusion and without erythropoietin) and marrow normocellular, no CLL cells and no B-lymphoid nodules. Partial Remission (PR) is any two of the following must decrease \\>/= 50% from baseline: lymph nodes, Liver and/or spleen size, circulating lymphocyte count in addition to one of the following: platelets \\>/= 100 x 10\\^9/L or \\>/= 50% increase from baseline, Hemoglobin \\>/= 11.0 g/dL or \\>/= 50% increase from baseline or marrow presence of CLL cells, or of B-lymphoid nodules, or not done.', 'timeFrame': '2 months'}]","[{'measure': 'Number of Participants to Achieve Complete Remission', 'description': 'Complete Remission is defined as: Complete Remission (CR) is Lymph nodes None \\>/= 1.5 cm, Spleen size \\< 13 cm; normal liver size, the absence of constitutional symptoms, normal circulating lymphocyte count, platelets \\>/= 100 x 10\\^9/L, Hemoglobin \\>/= 11.0 g/dL (absence of transfusion and without erythropoietin) and marrow normocellular, no CLL cells and no B-lymphoid nodules.', 'timeFrame': 'Up to 4 years, 8 months'}, {'measure': 'Progression Free Survival', 'description': 'Time from date of treatment start until the date of first objective documentation of disease-relapse.', 'timeFrame': 'Up to 4 years, 8 months'}, {'measure': 'Overall Survival', 'description': 'Time from date of treatment start until date of death due to any cause or last Follow-up.', 'timeFrame': 'Up to 4 years, 8 Months'}]",4,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,9.0,ACTUAL,2025-09-01T16:18:24.757354,v2_robust,True,True,False,True,False,The study was closed for slow accrual
NCT00369434,Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women,"A Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of DVS SR for Treatment of Vasomotor Symptoms Associated With Menopause",Desvenlafaxine succinate sustained-release (DVS SR),['Desvenlafaxine succinate sustained-release (DVS SR)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Menopause,"['Menopause', 'Vasomotor System']",[],COMPLETED,,2006-06,2007-02,[{'measure': 'The number and severity of hot flushes collected throughout the study after 12 weeks of therapy.'}],"[{'measure': 'The number of awakenings due to VMS and the total mood disturbance score (Profile of Mood States [POMS]).'}, {'measure': 'The scores on the Greene Climacteric Scale (GCS), the Visual Analog Scale-Pain Intensity (VAS-PI), and the Satisfaction Survey (SS).'}]",3,,,FEMALE,True,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,450.0,ESTIMATED,2025-09-01T16:18:24.757377,v2_robust,True,True,True,False,False,
NCT02935634,A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer,"A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)",Rucaparib,"['Rubraca', 'Rucaparib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Gastric Cancer,['Advanced Gastric Cancer'],[],COMPLETED,,2016-11-29,2022-05-11,"[{'measure': 'Objective Response Rate (ORR) by Investigator', 'description': 'ORR is the percent of participants whose best overall response (BOR) is complete response (CR) or partial response (PR). BOR is the best response from the start of the study treatment until objectively documented progression per RECIST v1.1 or subsequent anticancer therapy, whichever occurs first. CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have reduction in short axis to \\<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The Response Evaluation Criteria in Solid Tumors (RECIST) is a standard way to measure the response of a tumor to treatment. CR+PR, confidence interval based on Clopper and Pearson method.', 'timeFrame': 'From first dose of study treatment until progression or subsequent anticancer therapy, whichever occurs first (up to approximately 65 months)'}, {'measure': 'Median Duration of Response (DOR)', 'description': 'Duration of Response (DOR) is the time between the date of first response and the date of first documented disease progression as determined by RECIST 1.1 or death due to any cause, whichever occurred first. Complete Response (CR) is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Median computed using Kaplan -Meier method.', 'timeFrame': 'From first dose to date of first documented tumor progression or death due to any cause, whichever occurred first (up to approximately 65 months)'}, {'measure': 'Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 Weeks', 'description': 'The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Point estimates are derived from Kaplan-Meier analyses, the 95% CIs are derived from Greenwood formula.', 'timeFrame': '24 weeks after first dose'}]","[{'measure': 'Number of Participants With AEs, SAEs, AEs Leading to Discontinuation, and Death', 'description': 'An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.', 'timeFrame': 'From first dose to 100 days after last dose of study therapy (assessed up to approximately 30 months)'}, {'measure': 'Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests', 'description': 'The number of participants with laboratory abnormalities in specific thyroid tests based on US conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal.', 'timeFrame': 'From first dose to 100 days after last dose of study therapy (approximately 30 months)'}, {'measure': 'Number of Participants With Laboratory Abnormalities in Specific Liver Tests', 'description': 'The number of participants with laboratory abnormalities in specific liver tests based on US conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal', 'timeFrame': 'From first dose to 100 days after last dose of study therapy (approximately 30 months)'}]",6,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,1,190.0,ACTUAL,2025-09-01T16:18:24.757488,v2_robust,True,True,True,False,True,
NCT03210064,Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients,A Phase II Clinical Trial Study on Apatinib and 5-Fu Combination Regimen in the Treatment of Advanced Colorectal Cancer Patients,Apatinib,"['Apatinib', '5-fluorouracil', '5-Fluorouracil derivatives']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Colorectal Cancer,['Metastatic Colorectal Cancer'],['Apatinib'],UNKNOWN,,2017-05-04,2019-04-24,"[{'measure': 'ORR', 'description': 'The percentage of subjects with total number of Complete Response (CR) + total number of Partial Response (PR)', 'timeFrame': 'From assignment of the first subject to 3 months later after the last participant is recruited.'}]","[{'measure': 'DCR', 'description': 'DCR is defined as the percentage of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD)', 'timeFrame': 'From assignment of the first subject to 3 months later after the last participant is recruited.'}, {'measure': 'PFS', 'description': 'PFS was defined as the time from assignment to disease progression radiological/clinical or death due to any cause, whichever occurs first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation.', 'timeFrame': 'From assignment of the first subject to 3 months later after the last participant is recruited.'}, {'measure': 'OS', 'description': 'OS is defined as the time from date of assignment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.', 'timeFrame': 'From assignment of the first subject until 30 death events observed, up to 2 years.'}, {'measure': 'QoL', 'description': 'The general well-being of participants, outlining negative and positive features of life.', 'timeFrame': 'From assignment of the first subject to 3 months later after the last participant is recruited.'}]",5,18 Years,70 Years,ALL,False,Hui ting Xu，MD,OTHER,1,42.0,ESTIMATED,2025-09-01T16:18:24.757596,v2_robust,True,True,False,False,False,
NCT01353664,A Rollover Study for Patients Who Participated in Other Romidepsin Protocols,"An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols",Romidepsin,"['Romidepsin', 'Istodax®, ROMI']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Lymphoma,"['Lymphoma', 'Cancer']","['rollover protocol', 'romidepsin', 'Gloucester Pharmaceuticals', 'Celgene Corporation', 'continuing treatment']",COMPLETED,,2011-05-01,2012-09-05,"[{'measure': 'Summary of Participants With Treatment Emergent Adverse Events (TEAEs)', 'description': 'An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. Adverse events were assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4: On the following is the scale: Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe and Undesirable AE, Grade 4 = Life-threatening or Disabling AE, and Grade 5 = Death. Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention. A TEAE is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug.', 'timeFrame': 'All AEs were recorded by the Investigator from the time the participant signed the informed consent to 28 days after the last dose of study drug; maximum drug exposure was 231 days'}]",[],1,18 Years,,ALL,False,Celgene,INDUSTRY,1,19.0,ACTUAL,2025-09-01T16:18:24.757616,v2_robust,True,True,True,False,True,
NCT00482664,"The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.","A Phase 2a Multi-Centre, Double Blind, Placebo Controlled Cross-Over Trial To Investigate The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women Diagnosed With Female Sexual Arousal Disorder (FSAD).","CP-866,087","['CP-866,087', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Sexual Dysfunction, Physiological","['Sexual Dysfunction, Physiological']",[],COMPLETED,,2007-07,2008-10,"[{'measure': 'Diary events, including Satisfactory Sexual Experiences (SSEs) over 6 weeks.', 'timeFrame': '6 weeks'}, {'measure': 'Score in Abbreviated Sexual Function Questionnaire after 6 weeks of treatment.', 'timeFrame': '6 weeks'}]","[{'measure': 'Exit interview at end of study. Meaningful Benefit Question at end of study.', 'timeFrame': 'End of study'}, {'measure': 'Measure of Female Sexual Distress questionnaire after 6 weeks of treatment.', 'timeFrame': '6 weeks'}]",4,20 Years,45 Years,FEMALE,False,Pfizer,INDUSTRY,0,84.0,ESTIMATED,2025-09-01T16:18:24.757652,v2_robust,True,True,True,False,False,
NCT01487564,Pharmacokinetic Profile of OROS Hydromorphone in Healthy Taiwanese Participants With Different Genotypes for the UGT2B7 Gene,"A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetic Profile of OROS Hydromorphone in Healthy Adult Taiwanese Subjects Having Different Genotypes for the UGT2B7 Gene",Hydromorphone 16 mg,['Hydromorphone 16 mg'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['Healthy volunteers', 'Pharmacokinetics', 'OROS Hydromorphone', 'Hydromorphone', 'Taiwan', 'UGT2B7 Gene']",COMPLETED,,2011-10,2012-01,"[{'measure': 'Plasma hydromorphone concentration', 'timeFrame': '20 time points up to 72 hours post-dose'}]","[{'measure': 'Plasma hydromorphone 3-glucuronide concentration', 'timeFrame': '20 time points up to 72 hours post-dose'}, {'measure': 'Number of participants with adverse events as a measure of safety and tolerability', 'timeFrame': 'Approximately 33 days'}]",3,18 Years,55 Years,ALL,True,"Janssen Research & Development, LLC",INDUSTRY,0,29.0,ACTUAL,2025-09-01T16:18:24.757664,v2_robust,True,True,True,False,True,
NCT06371664,Gingival Irritation Due to Bleaching Tray Design in an At-home Bleaching Treatment,Does the Use of a 3-mm Extended Tray During an At-home Bleaching Treatment Increases Gingival Irritation Associated With This Procedure in an Adult Patient: Randomized Clinical Trial,Conventional Tray (1 mm),"['Conventional Tray (1 mm)', 'Extended Tray (3 mm)']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Gingival Inflammation,['Gingival Inflammation'],"['Tooth bleaching', 'Vital Bleaching', 'At-Home bleaching', 'Gingival Irritation', 'Bleaching tray']",COMPLETED,,2023-03-01,2023-04-05,"[{'measure': 'Subjective questionnaire of gingival irritation', 'description': 'Patients should answer daily a dental sensitivity questionnaire. They should mark a ""0"" if their gingival tissue appeared normal or a ""1"" If they observed GI, defined as the presence of a white or red layer on the gingiva.Patients who scored ""0"" during the treatment were classified as individuals without gingival irritation.', 'timeFrame': 'Daily, during 3 weeks'}, {'measure': 'Objective clinical examination of gingival irritation', 'description': ""Clinicians examined visually and with a periodontal probe the gingival tissue.Patients were categorized according to Löe and Silness' gingival index as: G0 (normal gingiva); G1(mild inflammation: slight change in color, slight edema; no bleeding on probing); G2 (moderate inflammation: redness, edema and glazing; bleeding on probing); and G3 (severe inflammation: marked redness and edema; ulceration; tendency to spontaneous bleeding).Patients will a score of 0 during the treatment will be defined as patients with no gingival irritation. The individual highest recorded score will be the grade of gingival irritation."", 'timeFrame': 'Once a week, during 3 weeks'}]","[{'measure': 'Questionnaire of dental sensitivity', 'description': 'Patients should answer a dental sensitivity questionnaire. A a 5-point subjective numerical classification scale will be used (0=no sensitivity, 1=light, 2=mild, 3=considerable and 4=severe). Patients will a score of 0 during the treatment will be defined as patients with no sensitivity. The individual highest recorded score will be the grade of intensity for each patient.', 'timeFrame': 'Daily, during 3 weeks'}, {'measure': 'Shade evaluation with a dental spectrophotometer', 'description': 'The color will be measured with a dental spectrophotometer and the parameters L (Lightness), C (Chroma) and H (Hue) will be recorded. To determine the color change between visits the CIEDE2000 formula will be used.', 'timeFrame': 'Once a week, during 3 weeks'}]",4,18 Years,,ALL,True,University of Santiago de Compostela,OTHER,0,72.0,ACTUAL,2025-09-01T16:18:24.757673,v2_robust,True,True,True,False,False,
NCT05579964,The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot,The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot,Dexmedetomidine Hcl 100 Mcg/mL Inj,"['Placebo', 'Dexmedetomidine Hcl 100 Mcg/mL Inj', 'Precedex', 'NaCl 0.9%', 'Kabimidine']",5,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Congenital Heart Disease in Children,"['Congenital Heart Disease in Children', 'Cardiopulmonary Bypass', 'Tetralogy of Fallot']","['Dexmedetomidine', 'Myocardial Protection', 'Tetralogy of Fallot', 'Total Correction', 'Double Blind Randomized Controlled Trial', 'Cardiopulmonary Bypass']",COMPLETED,,2022-10-10,2023-06-10,"[{'measure': 'Serum Troponin I at baseline', 'description': 'Troponin I serum concentration will be measured using ELABSCIENCE E-EL-H0649 reagent (ng/mL)', 'timeFrame': '5 minutes after induction of anesthesia (T1)'}, {'measure': 'Serum Troponin I at 1 hour after cardiopulmonary bypass', 'description': 'Troponin I serum concentration will be measured using ELABSCIENCE E-EL-H0649 reagent (ng/mL)', 'timeFrame': '1 hour after cardiopulmonary bypass (T2)'}, {'measure': 'Serum Troponin I at 6 hours after cardiopulmonary bypass', 'description': 'Troponin I serum concentration will be measured using ELABSCIENCE E-EL-H0649 reagent (ng/mL)', 'timeFrame': '6 hours after cardiopulmonary bypass (T3)'}, {'measure': 'Serum Troponin I at 24 hours after cardiopulmonary bypass', 'description': 'Troponin I serum concentration will be measured using ELABSCIENCE E-EL-H0649 reagent (ng/mL)', 'timeFrame': '24 hours after cardiopulmonary bypass (T4)'}, {'measure': 'Serum IL-6 at baseline', 'description': 'IL-6 serum concentration will measured using RnD Quantikine D6050 IL-6 reagent (pg/mL)', 'timeFrame': '5 minutes after induction of anesthesia (T1)'}, {'measure': 'Serum IL-6 at 1 hour after cardiopulmonary bypass', 'description': 'IL-6 serum concentration will measured using RnD Quantikine D6050 IL-6 reagent (pg/mL)', 'timeFrame': '1 hour after cardiopulmonary bypass (T2)'}, {'measure': 'Serum IL-6 at 6 hours after cardiopulmonary bypass', 'description': 'IL-6 serum concentration will measured using RnD Quantikine D6050 IL-6 reagent (pg/mL)', 'timeFrame': '6 hours after cardiopulmonary bypass (T3)'}, {'measure': 'Serum IL-6 at 24 hours after cardiopulmonary bypass', 'description': 'IL-6 serum concentration will measured using RnD Quantikine D6050 IL-6 reagent (pg/mL)', 'timeFrame': '24 hours after cardiopulmonary bypass (T4)'}]","[{'measure': 'Cardiac output', 'description': 'Cardiac output will be measured using transthoracic echocardiography (L/min)', 'timeFrame': '5 minutes after induction of anesthesia (T1), 6 hours (T3), 24 hours (T4), and 48 hours (T5) after cardiopulmonary bypass'}, {'measure': 'Cardiac Index', 'description': 'Cardiac index will be measured using transthoracic echocardiography (L/min)', 'timeFrame': '5 minutes after induction of anesthesia (T1), 6 hours (T3), 24 hours (T4), and 48 hours (T5) after cardiopulmonary bypass'}, {'measure': 'Systemic Vascular Resistance (SVR)', 'description': 'SVR will be measured using transthoracic echocardiography (L/min)', 'timeFrame': '5 minutes after induction of anesthesia (T1), 6 hours (T3), 24 hours (T4), and 48 hours (T5) after cardiopulmonary bypass'}, {'measure': 'Serum Lactate', 'description': 'Serum lactate will be measured using an enzymatic method with a blood gas analyzer machine (mmol/L)', 'timeFrame': '5 minutes after anesthesia induction (T1), and then 1 hour (T2), 6 hours (T3), and 24 hours (T4) after cardiopulmonary bypass'}, {'measure': 'VIS Score', 'description': 'Vasoinotropic score will be measured using the VIS formula', 'timeFrame': '1 hour (T2), 6 hours (T3), 24 hours (T4) after cardiopulmonary bypass'}, {'measure': 'Mechanical ventilation time', 'description': 'Mechanical ventilation time will be measured from the moment the patient arrives at the intensive care unit until the patient is extubated', 'timeFrame': '3 days (or until the patient is extubated)'}, {'measure': 'Length of stay in the intensive care unit', 'description': 'Length of stay in the intensive care unit will be measured from the moment the patient is admitted to the intensive care unit after the surgery until discharge from intensive care unit', 'timeFrame': '7 days (or until the patient is discharge from intensive care unit)'}, {'measure': 'Mortality', 'description': 'Mortality will be measured as long as patient is hospitalized until 30 days postoperative', 'timeFrame': '30 days post-operative'}]",16,1 Month,18 Years,ALL,False,National Cardiovascular Center Harapan Kita Hospital Indonesia,OTHER,0,66.0,ACTUAL,2025-09-01T16:18:24.757704,v2_robust,True,True,True,False,False,
NCT02123264,Zoledronic Acid in Rheumatoid Arthritis,Randomized Clinical Trial on the Prevention of Radiographic Progression With Zoledronic Acid in Patients With Early Rheumatoid Arthritis and Low Disease Activity,Zoledronic acid,"['Aclasta', 'Zoledronic acid']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Arthritis, Rheumatoid","['Arthritis, Rheumatoid']",[],TERMINATED,,2014-05,2018-06,"[{'measure': 'Sharp van der Heijde index', 'description': 'To assess the progression of radiographic damage in patients with early RA in current treatment with DMARDs and low disease activity to which treatment with zoledronic acid is added, compared to a no treatment control population, after two years.', 'timeFrame': 'Two years'}]",[],1,18 Years,,ALL,False,Carmen Gómez-Vaquero,OTHER,0,28.0,ACTUAL,2025-09-01T16:18:24.757763,v2_robust,True,True,False,True,False,
NCT00017264,Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma,A Phase I Evaluation of the Safety and Pharmacokinetics of ABT-627 in Adults With Recurrent Malignant Gliomas,atrasentan hydrochloride,['atrasentan hydrochloride'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Brain and Central Nervous System Tumors,['Brain and Central Nervous System Tumors'],"['recurrent adult brain tumor', 'adult glioblastoma', 'adult anaplastic astrocytoma', 'adult anaplastic oligodendroglioma', 'adult giant cell glioblastoma', 'adult gliosarcoma']",COMPLETED,,2002-06,,[],[],0,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,,,2025-09-01T16:18:24.757843,v2_robust,True,True,True,False,False,
NCT02480764,Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension,"A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension",Azilsartan medoxomil,"['Valsartan Placebo', 'Valsartan', 'Diovan®', 'Azilsartan medoxomil Placebo', 'Azilsartan medoxomil', 'Edarbi', 'TAK-491']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Essential Hypertension,['Essential Hypertension'],['Drug therapy'],COMPLETED,,2015-08-27,2017-10-13,"[{'measure': 'Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure (SBP)', 'description': ""The change in trough clinic sitting SBP measured at Week 8 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting SBP measurements. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose."", 'timeFrame': 'Baseline and Week 8'}]","[{'measure': 'Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure (DBP)', 'description': ""The change in trough clinic sitting DBP measured at Week 8 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting DBP measurements. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose."", 'timeFrame': 'Baseline and Week 8'}, {'measure': 'Percentage of Participants Who Achieved a Clinic SBP Response at Week 8', 'description': ""Clinic SBP response was defined as clinic SBP \\<140 mm Hg and/or reduction of ≥20 mm Hg from Baseline. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose."", 'timeFrame': 'Week 8'}, {'measure': 'Percentage of Participants Who Achieved a Clinic DBP Response at Week 8', 'description': ""Clinic DBP response was defined as clinic DBP \\<90 mm Hg and/or reduction of ≥10 mm Hg from Baseline. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose."", 'timeFrame': 'Week 8'}, {'measure': 'Percentage of Participants Who Achieved Both Clinic SBP and DBP Response at Week 8', 'description': ""Clinic SBP response was defined as clinic SBP \\<140 mm Hg and/or reduction of ≥20 mm Hg from Baseline and clinic DBP response was defined as clinic DBP \\<90 mm Hg and/or reduction of ≥10 mm Hg from Baseline. Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose."", 'timeFrame': 'Week 8'}, {'measure': 'Percentage of Participants Who Achieved Target Clinic SBP <140 mm Hg, Clinic DBP <90 mm Hg or Both at Week 8', 'description': ""Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose."", 'timeFrame': 'Week 8'}, {'measure': 'Percentage of Participants Who Achieved Target Clinic SBP <130 mm Hg, Target Clinic DBP <80 mm Hg or Both at Week 8', 'description': ""Blood pressure was measured using a validated, automated device after the participant had been sitting for at least 5 minutes. Week 8 blood pressure was measured approximately 24 hours after the previous day's dose."", 'timeFrame': 'Week 8'}]",7,18 Years,,ALL,False,Takeda,INDUSTRY,0,612.0,ACTUAL,2025-09-01T16:18:24.757851,v2_robust,True,True,True,False,False,
NCT02503709,Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients With Advanced Solid Tumors,CDK Inhibitor AT7519,"['AT7519M', 'AT 13387', 'AT-7519', 'AT7519', 'Cyclin-Dependent Kinase Inhibitor AT7519M', 'AT-13387', 'Onalespib', 'AT13387', 'CDK inhibitor AT7519M', 'CDK Inhibitor AT7519']",10,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Malignant Solid Neoplasm,"['Advanced Malignant Solid Neoplasm', 'Metastatic Malignant Solid Neoplasm', 'Unresectable Solid Neoplasm']",[],COMPLETED,,2016-09-30,2020-10-09,"[{'measure': 'Incidence of adverse events of onalespib and CDKI AT7519', 'description': 'Scored using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.', 'timeFrame': 'Up to 30 days after the last dose of study drug'}, {'measure': 'Tolerability of onalespib and CDKI AT7519', 'description': 'Assessed using the NCI CTCAE version 5.0.', 'timeFrame': 'Up to 30 days after the last dose of study drug'}, {'measure': 'Maximum tolerated dose of onalespib and CDKI AT7519', 'description': 'Defined as =\\< 1 out of 6 patients experiencing dose limiting toxicity.', 'timeFrame': '21 days'}]","[{'measure': 'Pharmacokinetic parameters of onalespib and CDKI AT7519', 'description': 'Individual patient plasma concentration-time curves will be analyzed by noncompartmental methods using routines supplied in the WinNonlin Professional Version 4.0.1 software package. Pharmacokinetic parameters and variables will be calculated according to standard equations. Mean values of the pharmacokinetic parameters will be statistically compared using the paired two-tailed t-test of the log-transformed data.', 'timeFrame': 'Before infusion, at 30 and 59 minutes of infusion, and at 1.5, 2, 4, 6, 8, and 24 hours at end of infusion on day 1 of course 0 and days 1 and 11 of course 1'}, {'measure': 'Pharmacodynamic (PD) parameters of onalespib and CDKI AT7519', 'description': 'PD effect of the combination of onalespib and CDKI AT7519 on Hsp70 expression and modulation of Hsp90 client proteins in peripheral blood mononuclear cells (PBMCs) will be assessed. All PD evaluations and comparisons will be done with exploratory intent, using primarily descriptive and non-parametric techniques.', 'timeFrame': 'Prior to onalespib administration during course 0, 2-4 hours after completion of onalespib on day 4 of course 0, and 2-4 hours after completion of CDKI AT7519 on day 11 of course 1'}, {'measure': 'Antitumor activity of the combination', 'description': 'Measured by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1).', 'timeFrame': 'Up to 30 days after the last dose of study drug'}]",6,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,29.0,ACTUAL,2025-09-01T16:18:24.757990,v2_robust,True,True,True,False,True,
NCT03944109,"The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia","The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia - A PhaseⅠb/Ⅱ Randomized, Double-Blind, Placebo-Controlled Clinical Study",SHR-1209,"['SHR-1209', 'Placebo']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Hyperlipidemia,['Hyperlipidemia'],[],COMPLETED,,2019-06-20,2020-12-22,"[{'measure': 'Primary efficacy end point:Percent change from baseline to end of the dosing interval in LDL-C.', 'timeFrame': 'Baseline to day 113 for group1,2,4,5 or day 169 for group 3,6'}, {'measure': 'Primary safety end point:Number of subjects with adverse events.', 'timeFrame': 'Baseline to day 169 for group 1,3,4,6 or day 141 for group 2,5'}]","[{'measure': 'Absolute change from baseline to end of the dosing interval in LDL-C.', 'timeFrame': 'Baseline to day 113 for group1,2,4,5 or day 169 for group 3,6'}, {'measure': 'Percent change from baseline to day 85 in LDL-C.', 'timeFrame': 'Baseline to day 85 for all 6 groups'}, {'measure': 'Absolute change from baseline to day 85 in LDL-C.', 'timeFrame': 'Baseline to day 85 for all 6 groups'}, {'measure': 'Percent change in PCSK9.', 'timeFrame': 'Baseline to day 169 for group 1,3,4,6 or day 141 for group 2,5'}, {'measure': 'Absolute change in PCSK9.', 'timeFrame': 'Baseline to day 169 for group 1,3,4,6 or day 141 for group 2,5'}]",7,18 Years,65 Years,ALL,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,110.0,ACTUAL,2025-09-01T16:18:24.758006,v2_robust,True,True,True,False,True,
NCT00722709,Intraperitoneal Local Anaesthetic in Colonic Surgery,Randomised Double Blind Trial to Investigate the Effects of Intraperitoneal Local Anaesthetic Following Colonic Surgery.,Ropivacaine,"['0.9% Saline', 'Ropivacaine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Colon Surgery,['Colon Surgery'],"['Pain', 'Fatigue', 'Colon', 'Surgery', 'ERAS', 'Fastrack', 'Local anaesthetic', 'Peritoneum', 'Metabolic', 'Endocrine', 'Post surgical metabolic response', 'Complications', 'Time to passage of flatus', 'Time to passage of stool', 'Time to discharge from facility', 'Re-admission rate']",COMPLETED,,2008-09,2010-01,"[{'measure': 'Post operative recovery using the Identity consequence fatigue scale (ICFS)', 'timeFrame': 'Base-line, Day 1, Day 3, Day 7, Day 14, Day 30, Day 60'}]","[{'measure': 'Post-operative rest, movement and cough pain using Visual analogue score', 'timeFrame': '2,4,6,8,12,24,48,72 hours and on day 7'}, {'measure': 'Post operative analgesia use using morphine equivalence data', 'timeFrame': 'Total use on day 1, day 2, day 3 post operatively and total use until discharge'}, {'measure': 'Serum Ropivacaine level, serum Cytokine, serum Cortisol, serum glucose and serum CRP. Albumin, haematological parameters and biochemical parameters.', 'timeFrame': 'Pre-operatively, 8, 20, 48,72 hours post operatively'}, {'measure': 'Questions aimed at symptoms of local anaesthetic toxicity', 'timeFrame': '2, 4, 6, 8, 12, 24, 48, 72 hours post operatively'}, {'measure': 'Recovery of bowel function measured by time to pass flatus and time to pass stool post-operatively.', 'timeFrame': 'Assessed at 2, 4, 6, 8, 12, 24, 36, 48, 60, 72 hours.'}, {'measure': 'Quality of care assessment based on a 100mm visual analogue scale (1-10).', 'timeFrame': 'pre-op, day1, day 2, day3, day 7, day 30 and day 60 post operatively'}]",7,18 Years,,ALL,False,"University of Auckland, New Zealand",OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:24.758044,v2_robust,True,True,True,False,False,
NCT04917809,A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer,"A Phase 2 ""Window of Opportunity"" Trial of Targeted Therapy With Erdafitinib in Patients With Recurrent FGFR3-Altered Non-Muscle Invasive Bladder Cancer",Erdafitinib,['Erdafitinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Bladder Cancer,"['Bladder Cancer', 'Recurrent Bladder Cancer', 'FGFR3 Gene Mutation']","['Non-Muscle Invasive Bladder Cancer', 'NMIBC', 'Erdafitinib', 'FGFR3', '21-166', 'Memorial Sloan Kettering Cancer Center']",ACTIVE_NOT_RECRUITING,,2022-02-17,2025-08,"[{'measure': 'Objective response rate', 'description': 'The primary endpoint of this trial is the objective response rate at the time of TURBT/biopsy (defined as the proportion of patients achieving a complete or partial pathologic response by cytologic examination, cystoscopic examination, and biopsy) following treatment with erdafitinib. A complete response is defined as the absence of tumor on TURBT/biopsy, with a negative urinary cytologic result; a partial response is defined as a decrease of at least 50% in the size of the target tumor(s), on the basis of modified RECIST 1.1 criteria (RECIT-BLADDER).', 'timeFrame': '3 weeks after first study treatment'}]",[],1,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:24.758063,v2_robust,True,True,False,False,False,
NCT03103009,Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia,Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia,Pasireotide,"['Pasireotide', 'Signifor']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Hyperinsulinemic Hypoglycemia,"['Hyperinsulinemic Hypoglycemia', 'Post Gastrointestinal Tract Surgery Hypoglycaemia']",[],COMPLETED,,2017-03-22,2017-12-22,"[{'measure': 'Recording of Hypoglycemic events', 'description': 'The primary outcome is the number of hypoglycemic events occurring.', 'timeFrame': 'Up to 2 years'}]",[],1,18 Years,,ALL,False,"University of Colorado, Denver",OTHER,1,1.0,ACTUAL,2025-09-01T16:18:24.758132,v2_robust,True,True,True,False,False,
NCT03836209,Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia,Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML),Gilteritinib,"['Ara-C', 'Cytosine Arabinoside', 'ASP2215', 'Arabinosyl', 'Cytarabine', 'Daunorubicin', 'Daunorubicin hydrochloride', 'Cytosar-U', 'Gilteritinib', 'Cerubidine', 'RYDAPT', 'Rubidomycin', 'Daunomycin', 'Midostaurin']",14,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],"['Gilteritinib', 'Midostaurin', 'Daunorubicin', 'Cytarabine', 'FLT3', 'FLT3 Mutation', 'FLT3 Internal Tandem Duplication (ITD)', 'FLT3 ITD', 'FLT3 Tyrosine Kinase Domain (TKD)', 'FLT3 TKD']",ACTIVE_NOT_RECRUITING,,2019-12-06,2026-12,"[{'measure': 'FLT3 Mutation Negative Composite Complete Response (CRc) [Includes Complete Response (CR) or CR With Incomplete Hematologic Recovery (CRi)] at End of Induction', 'description': 'FLT3 mutation negative (evaluated by polymerase chain reaction \\[PCR\\]) Composite Complete Response (CRc) \\[includes CR and CRi\\] rate after induction treatment and complete MRD assessment. The cut points used for FLT3 mutation negative are 1% (equivalent to 10-2) for FLT3-TKD and 10-4 for FLT3-ITD.', 'timeFrame': '3 months'}]","[{'measure': 'FLT3 Mutation Negative Complete Response (CR) Rate at End of Induction', 'description': 'CR evaluated by FLT3 testing after Induction', 'timeFrame': '3 months'}, {'measure': 'Minimal Residual Disease (MRD)- CRc Rate at End of Induction', 'description': 'MRD- CRc evaluated by flow cytometry after Induction', 'timeFrame': '3 months'}, {'measure': 'CRc (CR or CRi) Rate at End of Induction', 'description': 'CRc assessed in accordance with 2017 European LeukemiaNet (ELN)', 'timeFrame': '3 months'}, {'measure': 'Event Free Survival (EFS)', 'description': 'EFS assessed in accordance with 2017 ELN', 'timeFrame': '68 months'}, {'measure': 'Overall Survival (OS)', 'description': 'OS assessed in accordance with 2017 ELN', 'timeFrame': '68 months'}, {'measure': 'Number of Participants Treatment-related Adverse Events as Assessed by CTCAE v5.0', 'description': 'Number of participants with abnormal laboratory values and/or adverse events', 'timeFrame': '10 months'}]",7,18 Years,70 Years,ALL,False,"PrECOG, LLC.",OTHER,1,181.0,ACTUAL,2025-09-01T16:18:24.758143,v2_robust,True,True,False,False,True,
NCT00145509,40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786),"A Phase 3, Placebo-Controlled, Double-Blinded Continuation Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Completing a 12-week Lead-in Trial and Continuing Lithium or Valproic Acid/Divalproex Sodium for the Treatment of an Acute Manic or Mixed Episode",Asenapine,"['Asenapine', 'Org 5222', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Bipolar Disorder,['Bipolar Disorder'],[],COMPLETED,,2005-08,2007-12,"[{'measure': 'Number of Participants Who Experienced an Adverse Event', 'description': 'Participants who experienced treatment-emergent adverse events, defined as adverse events reported on or after the first dose of study medication in the 12-week lead-in study through the last dose of study drug + 7 days (or + 30 days for serious adverse events).', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Number of Participants Who Discontinued Because of an Adverse Event', 'description': 'Participants who discontinued study medication due to adverse events.', 'timeFrame': '40 weeks'}, {'measure': 'Change From Baseline to Week 52 on the Young-Mania Rating Scale (Y-MRS) Score', 'description': 'The Y-MRS is an 11-item, clinician-rated instrument used for assessing the symptoms of mania. Y-MRS total score range = 0-60; higher scores indicate greater severity of symptoms.', 'timeFrame': 'Baseline and 52 Weeks'}, {'measure': 'Change From Baseline to Week 52 on the Montgomery Asberg Depression Rating Scale (MADRS) Score', 'description': 'The MADRS is a 10-item clinician-rated scale for assessing the severity of symptoms of depression. MADRS total score range = 0-60; higher scores indicate greater severity of symptoms.', 'timeFrame': 'Baseline and 52 Weeks'}]",[],4,18 Years,,ALL,False,Organon and Co,INDUSTRY,0,77.0,ACTUAL,2025-09-01T16:18:24.758165,v2_robust,True,True,True,False,True,
NCT02658799,Effects of a Cyclic NSAID Regimen on Levels of GCF PGE-E2 and IL-1beta,A Cyclic Regimen of Diclofenac Potassium May be Efficacious in the Management of Chronic Periodontitis in Adults,cataflam (diclofenac potassium),"['Cataflam', 'cataflam (diclofenac potassium)', 'placebo gel cap', 'placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Non-steroidal Anti-inflammatory Poisoning,['Non-steroidal Anti-inflammatory Poisoning'],"['periodontitis', 'anti-inflammatory agents']",COMPLETED,,2000-01,2004-12,"[{'measure': 'Changes in gingival crevicular fluid levels of prostaglandin E2 by 50 mg diclofenac potassium administration', 'description': 'Administration of diclofenac potassium or placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. Gingival crevicular fluid levels of prostaglandin E2 was measured by using ELISA method, at baseline, 2-month, 4-month and 6-month of the study period.', 'timeFrame': 'Baseline, 2 months, 4 months and 6 months'}, {'measure': 'Changes in gingival crevicular fluid levels of interleukin-1beta by 50 mg diclofenac potassium administration', 'description': 'administration of diclofenac potassium or placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. Gingival crevicular fluid levels of interleukin-1beta were measured by using ELISA method, at baseline, 2-month, 4-month and 6-month of the study period.', 'timeFrame': 'Baseline, 2 months, 4 months and 6 months'}]","[{'measure': 'Changes in plaque index (PI) by 50 mg diclofenac potassium administration', 'description': 'At baseline, 2-, 4- and 6-month, plaque index (PI) were recorded. Plaque index (PI); 0: no visible plaque, 1: minor plaque accumulation during probing, 2: visible plaque near by gingiva, 3: full plaque accumulation of the tooth.', 'timeFrame': 'Baseline, 2 months, 4 months and 6 months'}, {'measure': 'Changes in gingival index (GI) by 50 mg diclofenac potassium administration', 'description': 'At baseline, 2-, 4- and 6-month, gingival index (GI) were recorded. Gingival index (GI); 0: healthy gingiva, 1: slightly inflammation and no bleeding on probing, 2: moderate gingival inflammation and bleeding on probing, 3: spontaneous bleeding and/or suppuration.', 'timeFrame': 'Baseline, 2 months, 4 months and 6 months'}, {'measure': 'Changes in probing depth (PD) by 50 mg diclofenac potassium administration', 'description': ""At baseline, 2-, 4- and 6-month, probing depth (PD) were recorded. Probing depth (PD): with William's periodontal probe, distance between gingival margin to bottom of the sulcus)."", 'timeFrame': 'Baseline, 2 months, 4 months and 6 months'}, {'measure': 'Changes in probing clinical attachment level by 50 mg diclofenac potassium administration', 'description': ""At baseline, 2-, 4- and 6-month, clinical attachment level (CAL) were recorded. Clinical attachment level (CAL); with William's periodontal probe, distance between enamel-cement junction to bottom of the sulcus)."", 'timeFrame': 'Baseline, 2 months, 4 months and 6 months'}]",6,32 Years,60 Years,ALL,True,Baskent University,OTHER,0,49.0,ACTUAL,2025-09-01T16:18:24.758217,v2_robust,True,True,True,False,False,
NCT04612699,A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Jaktinib in Patients With Moderate-to-Severe Plaque Psoriasis",Jaktinib,"['Jaktinib', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Moderate-to-Severe Plaque Psoriasis,['Moderate-to-Severe Plaque Psoriasis'],[],COMPLETED,,2021-03-11,2022-08-15,"[{'measure': 'Percentage of Participants Achieving Psoriasis Area and Severity Index Score ≥75% (PASI 75) Improvement (Efficacy of Jaktinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])', 'description': 'The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema (redness), and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease.', 'timeFrame': 'Week 12'}]","[{'measure': 'Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Jaktinib in Participants With Moderate to Severe Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])', 'description': ""The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear"", 'timeFrame': 'Week 8、12、16、20、24'}]",2,18 Years,65 Years,ALL,False,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",INDUSTRY,0,123.0,ACTUAL,2025-09-01T16:18:24.758281,v2_robust,True,True,True,False,False,
NCT02052999,Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients,An Open Label Pilot Study to Evaluate the Efficacy of PAC-14028 in the Treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea,PAC-14028 cream 1%,"['Rozex gel 0.75%', 'PAC-14028', 'PAC-14028 cream 1%']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Erythematotelangiectatic Rosacea,"['Erythematotelangiectatic Rosacea', 'Papulopustular Rosacea']",[],COMPLETED,,2013-02,2013-08,"[{'measure': 'Change in Investigator Global Assessment (IGA)', 'timeFrame': 'Baseline through Study Week 8'}]","[{'measure': 'Erythema severity', 'timeFrame': 'Baseline through Study Week 8'}, {'measure': 'Telangiectasia severity', 'timeFrame': 'Baseline through Study Week 8'}, {'measure': 'Inflammatory lesion counts', 'timeFrame': 'Baseline through Study Week 8'}]",4,20 Years,65 Years,ALL,False,Amorepacific Corporation,INDUSTRY,0,80.0,ACTUAL,2025-09-01T16:18:24.758310,v2_robust,True,True,True,False,False,
NCT05444699,Oral Prednisolone for Acute Rhinovirus Induced Wheezing in Children Less Than 2 Years of Age,"Oral Prednisolone for Acute Rhinovirus Induced Wheezing in Children Less Than 2 Years of Age: a Point-of-care Testing Guided Randomized, Double-blind, Placebo-controlled Trial",Prednisolone Sodium Phosphate,"['Sugar syrup', 'Prednisolone Sodium Phosphate']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Bronchiolitis Acute Viral,['Bronchiolitis Acute Viral'],[],RECRUITING,,2022-10-11,2027-09,"[{'measure': 'Length of hospital stay', 'description': 'The difference (in minutes) between the study entry and the time that the patient is deemed to be fit for discharge (sign off for discharge)\n\nSubgroup analyses for the primary outcome are performed in following subgroups:\n\n* Children presenting with first episode of wheezing\n* Children with at least one previous episode of wheezing diagnosed by a physician\n* Children with a cycle threshold number of \\< 30 for detected picornavirus\n* Children with a cycle threshold number of 30-37 for detected picornavirus\n* Children with a cycle threshold number of 38-40 for detected picornavirus', 'timeFrame': 'Within 7 days of study entry'}]","[{'measure': 'Total length of hospital stay', 'description': 'The difference (in minutes) between the study entry and the actual time of discharge from the hospital', 'timeFrame': 'Within 7 days of study entry'}, {'measure': 'Intensive care unit (ICU) admissions', 'description': 'Proportion of children admitted to ICU', 'timeFrame': 'Within 7 days of study entry'}, {'measure': 'Supplemental oxygen', 'description': 'The total duration (in minutes) of the need for supplemental oxygen', 'timeFrame': 'Within 7 days of study entry'}, {'measure': 'Pediatric Early Warning Signs (PEWS) score', 'description': ""Maximum decrease in PEWS score within 12 hours after study entry. PEWS scores range from 0 to 32 depending on the child's respiratory rate, work of breathing, saturation of peripheral oxygen, need for supplemental oxygen, blood pressure, heart rate, capillary refill and level of consciousness. 0 refers to low and \\> 7 to high risk of deterioration."", 'timeFrame': 'Within 7 days of study entry'}, {'measure': 'Recurrence of wheezing', 'description': 'Proportion of patients with recurrence of wheezing after initial episode', 'timeFrame': 'Within 56 days of study entry'}, {'measure': 'Hospital re-admission', 'description': 'Proportion of patients with re-admission to hospital or visit to emergency department after discharge from the hospital', 'timeFrame': 'Within 14 days of study entry'}, {'measure': 'Proportion of patients with cough at 14 days of study entry', 'description': 'Proportion of patients with cough at 14 days of study entry', 'timeFrame': 'At 14 days of study entry'}, {'measure': 'Duration of cough', 'description': 'Mean duration (in days) of cough without relapse for 3 days', 'timeFrame': 'Within 28 days of study entry'}, {'measure': 'Duration of cough', 'description': 'Mean duration (in days) of cough without relapse for 3 days', 'timeFrame': 'Within 14 days of study entry'}, {'measure': 'Duration of salbutamol use', 'description': 'Mean number of days in which salbutamol is used', 'timeFrame': 'Within 14 days of study entry'}, {'measure': 'Duration of respiratory distress', 'description': 'Mean duration (in days) of respiratory distress without relapse for 3 days', 'timeFrame': 'Within 14 days of study entry'}, {'measure': 'Deaths', 'description': 'Proportion of patients who died of any cause', 'timeFrame': 'Within 30 of study entry'}, {'measure': 'Recurrence of wheezing (proportion)', 'description': 'Proportion of patients with recurrence of wheezing diagnosed by a physician at 2 and 12 months of study entry', 'timeFrame': 'Within 12 months of study entry'}, {'measure': 'Recurrence of wheezing (time)', 'description': 'Time (in days) to recurrence of wheezing diagnosed by a physician', 'timeFrame': 'Within 12 months of study entry'}, {'measure': 'Daily administrated asthma medication', 'description': 'Time (in days) to prescription of daily administrated asthma medication', 'timeFrame': 'Within 24 months of study entry'}, {'measure': 'Antibiotics and asthma medications', 'description': 'Purchases of antibiotics and asthma medications', 'timeFrame': 'Within 24 months of study entry'}]",17,6 Months,24 Months,ALL,False,University of Oulu,OTHER,0,210.0,ESTIMATED,2025-09-01T16:18:24.758423,v2_robust,True,True,False,False,False,
NCT02513199,Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma,Assessment of Response of Unresectable Hepatocellular Carcinoma to Combination Chemoembolization and Stereotactic Body Radiation Therapy,TACE,"['TACE', 'Trans-Arterial Chemoembolization']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Hepatocellular Carcinoma,['Hepatocellular Carcinoma'],"['Hepatocellular Carcinoma', 'Trans-Arterial Chemoembolization', 'Stereotactic Body Radiation Therapy', 'HCC', 'TACE', 'SBRT']",COMPLETED,,2014-11,2022-01-01,"[{'measure': 'Number of Participants With Objective Response Rate', 'description': 'Tumor response will be assessed using mRECIST criteria as well diffusion weight imaging (DWI) via Magnetic Resonance Imaging (MRI) surveillance.\n\n* Complete response (CR): Disappearance of all target lesions\n* Partial response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD\n* Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started\n* Progressive disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions', 'timeFrame': 'up to 72 months'}]","[{'measure': 'Time to CR', 'description': 'Time to Complete Remission (CR)', 'timeFrame': 'up to 72 months'}, {'measure': 'Time to Progression (TTP)', 'description': 'The time to progression of the treated lesion. Median TTP, as defined as progression events (not including death), was not reached because 50% of events were not achieved. Because a sufficient number of progression events did not happen at the time of study censure, a median could not be reported. Therefore, mean is reported which can be reported irrespective of events.', 'timeFrame': 'up to 80 months'}, {'measure': 'Number of Participants With Overall Survival (OS)', 'description': 'The overall survival as defined from completion of treatment until death', 'timeFrame': '2 years'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'Progression-free survival (PFS), defined as time between enrollment and tumor progression assessed by mRECIST or death, local control (LC), and toxic effects. LC was defined as either absence of radiographic progression or a secondary intervention (ie, surgery or TACE) made to the index lesion due to a perceived incomplete treatment response.', 'timeFrame': 'up to 72 months'}, {'measure': 'Change in Child-Turcotte-Pugh (CTP) Score', 'description': 'Overall rate of toxic effects as measured by change in Child-Turcotte-Pugh (CTP) score at 3 months as compared to baseline.\n\nThe Child-Turcotte-Pugh (CTP) is a scale that assesses a patients baseline liver function and can help predict morbidity and mortality based on that score.\n\nClass A - 5 to 6 points, least severe liver disease, one- to five-year survival rate: 95 percent\n\nClass B - 7 to 9 points, moderately severe liver disease, one- to five-year survival rate: 75 percent\n\nClass C - 10 to 15 points, most severe liver disease, one- to five-year survival rate: 50 percent\n\nHigher scores correlate with more general mortality.', 'timeFrame': '3 months'}]",6,18 Years,,ALL,False,Icahn School of Medicine at Mount Sinai,OTHER,0,32.0,ACTUAL,2025-09-01T16:18:24.758466,v2_robust,True,True,True,False,False,
NCT01439399,Analgesic Efficacy of Intravenous Lidocaine and/or Ketamine,"Analgesic Efficacy of Intravenous Perfusion of Lidocaine, Ketamine or a Combination After Laparotomy in a Placebo-controlled, Randomized, Double-blind Prospective Study","Lidocaine,","['Ketamine', 'association ketamine-lidocaine', 'Placebo', 'Lidocaine,']",4,INTERVENTIONAL,['NA'],,,Postoperative Pain,['Postoperative Pain'],"['postoperative pain', 'postoperative care', 'intravenous lidocaine', 'intravenous ketamine', 'morphine consumption']",COMPLETED,,2005-12,2007-07,"[{'measure': 'Cumulative morphine consumption', 'description': 'Cumulative morphine consumption over 48 hours postoperatively', 'timeFrame': '48 hours'}]","[{'measure': 'Pain scores', 'description': 'Pain scores at rest and movement', 'timeFrame': '48 hours'}, {'measure': 'Mechanical hyperalgesia', 'description': 'Mechanical hyperalgesia using pressure algometry', 'timeFrame': '48 hours'}, {'measure': 'Occurrence of side effects', 'description': 'Occurrence of side effects: sedation, nausea, vomiting, itching, nightmares', 'timeFrame': '48 hours'}]",4,20 Years,75 Years,ALL,False,University of Lausanne Hospitals,OTHER,0,52.0,ACTUAL,2025-09-01T16:18:24.758500,v2_robust,True,True,True,False,False,
NCT03598699,A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease,"A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AXR-159 Ophthalmic Solution 3 mg/mL, 30 mg/mL, and 50 mg/mL in Patients With Dry Eye Disease (DED)",AXR-159,"['Vehicle', 'AXR-159']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Dry Eye,['Dry Eye'],[],COMPLETED,,2018-06-26,2019-01-09,"[{'measure': 'Inferior Corneal Staining Score', 'description': 'Change from Baseline in Ora Calibra® Corneal and Conjunctival Staining Scale with a range from 0 to 4 (0=None, 1=Trace, 2=Mild, 3=Moderate, 4=Severe) in the study eye. Higher negative scores mean a better outcome.', 'timeFrame': 'Month 3'}, {'measure': 'Eye Dryness', 'description': 'Change from baseline in Eye Dryness score on a subject level across both eyes. Using the visual analogue scale (VAS) subjects rated eye dryness by placing a vertical mark on the horizontal line to indicate the level of discomfort with a range of 0 to 100. 0% corresponds to ""no dryness"" (no discomfort) and 100% corresponds to ""maximal dryness"" indicating maximal discomfort. A greater negative change from baseline score means a better outcome.', 'timeFrame': 'Month 3'}]","[{'measure': 'Total Ocular Surface and Disease Index (OSDI) © for Dry Eye', 'description': 'Change from baseline in OSDI © score on a subject level. The 12-question OSDI © is assessed on a total scale from 0 to 100, where higher scores represent greater disability. A greater negative change from baseline indicates a better outcome.', 'timeFrame': 'Month 3'}, {'measure': ""Schirmer's Test"", 'description': ""Change from baseline in Schirmer's Test score in the study eye. Unanesthetized Schirmer's Test measures the length of the moistened area of a test strip, placed in the lower temporal lid margin of each eye, in mm following a 5-minute exposure period. Greater positive numbers indicate a better outcome."", 'timeFrame': 'Month 3'}, {'measure': 'Tear Film Break-up Time (TBUT)', 'description': 'Change from baseline in the study eye with a greater positive increase indicating a better outcome. Following the instillation of a sodium fluorescein solution into the inferior conjunctival cul-de-sac of each eye and several blinks over 30 seconds, the examiner monitored the integrity of the tear film with the aid of a slit lamp, noting the time it takes to form micelles from the time that the eye is opened. TBUT was measured in seconds using a stopwatch and a digital image recording system for the right eye followed by the left eye. Values reported are for the study eye.', 'timeFrame': 'Month 3'}, {'measure': 'Conjunctival Redness Score', 'description': 'Change from baseline of Ora Calibra® Conjunctival Redness Scale for Dry Eye. Scores range from 0 to 4 with 0=None, 1=Trace, 2=Mild, 3=Moderate, 4=Severe; with higher numbers indicating more conjunctival redness. Greater negative numbers indicate a better outcome. Values reported are for the study eye.', 'timeFrame': 'Month 3'}, {'measure': 'Total Lissamine Green Conjunctival Staining', 'description': 'Change from baseline of Oxford Grading Scale measuring staining within a range from 0-5 (0=None, 1=Trace, 2=Mild, 3=Moderate, 4=Severe, 5=Confluent) for each panel (temporal and nasal) and 0-10 as the sum of both panel scores for the total exposed inter-palpebral conjunctiva. Larger negative numbers indicate reduced staining and a better outcome. Values reported are for the study eye.', 'timeFrame': 'Month 3'}]",7,18 Years,,ALL,False,"AxeroVision, Inc.",INDUSTRY,1,102.0,ACTUAL,2025-09-01T16:18:24.758541,v2_robust,True,True,True,False,False,
NCT06334432,Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors,"A Phase 1/2, First-in-Human, Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors",NUV-1511,['NUV-1511'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Advanced Solid Tumor,"['Advanced Solid Tumor', 'HER2-negative Breast Cancer', 'Metastatic Castration-resistant Prostate Cancer (mCRPC)', 'Pancreatic Cancer', 'Platinum-resistant Ovarian Cancer (PROC)']",[],RECRUITING,,2024-03-14,2027-10,"[{'measure': 'Phase 1: Assess safety and tolerability of NUV-1511 in advanced solid tumors', 'description': 'Number of patients with dose limiting toxicities, treatment emergent adverse events (TEAE) and serious adverse events (SAE) and laboratory abnormalities', 'timeFrame': 'First 28 days of dosing (DLT evaluation period)'}, {'measure': 'Phase 1: Identify recommended dosing schedule(s) and corresponding Phase 2 dose(s) (RP2D(s))', 'description': 'Number of patients with DLTs, TEAEs and SAEs and laboratory abnormalities', 'timeFrame': 'First 28 days of dosing (DLT evaluation period)'}, {'measure': 'Phase 2: Evaluate the efficacy of NUV-1511 in advanced solid tumors and selected tumor type(s)', 'description': 'Efficacy measures may include tumor assessments, as assessed by CT scans, PET/CT, whole body bone scan and MRI', 'timeFrame': 'From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Confirm the optimal NUV-1511 dose level/schedule for further development', 'description': 'Overall response rate per RECIST 1.1 (Composite response rate for mCRPC patients only, if enrolled in Phase 2)', 'timeFrame': 'Periodic efficacy assessments from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Confirm the optimal NUV-1511 target tumor types for further development', 'description': 'Overall response rate per RECIST 1.1 (Composite response rate for mCRPC patients only, if enrolled in Phase 2)', 'timeFrame': 'Periodic efficacy assessments from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}]","[{'measure': 'Phase 1: Explore preliminary efficacy of NUV-1511', 'description': 'Overall response rate and duration of response per RECIST 1.1. Efficacy measures may include tumor assessments, as assessed by CT scans, PET/CT, whole body bone scan and MRI.', 'timeFrame': 'From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 1: Explore preliminary efficacy of NUV-1511', 'description': 'Overall response rate and duration of response per composite response rate (for mCRPC). Efficacy measures may include tumor assessments, as assessed by CT scans, PET/CT, whole body bone scan and MRI.', 'timeFrame': 'From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 1: Explore preliminary efficacy of NUV-1511', 'description': 'Overall response rate and duration of response per response rates in specific disease markers. Efficacy measures may include tumor assessments, as assessed by CT scans, PET/CT, whole body bone scan and MRI.', 'timeFrame': 'From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Characterize the PK profile of NUV-1511', 'description': 'Parameters include, but not limited to, maximum observed plasma concentration (Cmax)', 'timeFrame': 'Periodic PK sample collection from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first.'}, {'measure': 'Characterize the PK profile of NUV-1511', 'description': 'Parameters include, but not limited to, area under the plasma concentration-time curve (AUC)', 'timeFrame': 'Periodic PK sample collection from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first.'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'Incidence of TEAEs and SAEs', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'Laboratory abnormalities', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'Duration of response', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'Clinical best response', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'Progression free survival', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'Overall survival', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'PK exposure-response modeling, which includes measuring plasma concentration versus overall response rate', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'PK exposure-response modeling, which includes measuring plasma concentration versus progression free survival', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'PK exposure-response modeling, which includes measuring plasma concentration versus treatment emergent adverse events and serious adverse events.', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}, {'measure': 'Phase 2: Further evaluate the safety and efficacy of NUV-1511', 'description': 'Response rates in disease-specific markers', 'timeFrame': 'Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first'}]",20,18 Years,,ALL,False,Nuvation Bio Inc.,INDUSTRY,0,466.0,ESTIMATED,2025-09-01T16:18:24.758592,v2_robust,True,True,False,False,True,
NCT00210132,Analgesic Efficacy of Inter Pleural Ropivacaine Road in Post Thoracotomy Pain for Oncologic Surgery,Randomized Trial to Evaluate the Analgesic Efficacy of Inter Pleural Ropivacaine Road in Post Thoracotomy Pain for Oncologic Surgery,Ropivacaine,['Ropivacaine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Postoperative Pain,"['Postoperative Pain', 'Cancer']","['Thoracic surgery', 'postoperative pain', 'ropivacaine', 'inter pleural analgesia']",COMPLETED,,2003-10,2008-02,[{'measure': 'To compare the incidence and the score of pain between the patients with ropivacaine and the patients without ropivacaine delivered by inter pleural road'}],"[{'measure': 'To compare the morphine consumption during 48 hours'}, {'measure': 'To determine ropivacaine plasmatic concentration by inter pleural road during first 48 hours'}]",3,18 Years,,ALL,False,Institut Bergonié,OTHER,0,90.0,ACTUAL,2025-09-01T16:18:24.758655,v2_robust,True,True,True,False,False,
NCT05651932,A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma,"A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma",Cohort A1 & A2: KTX-1001,"['Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)', 'Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)', 'Pomalidomide (Pomalyst, Imnovid)', 'Mezigdomide', 'Carfilzomib (KYPROLIS®)', 'Cohort A1 & A2: KTX-1001', 'KTX-1001', 'Cohort B1 & B2: KTX-1001+Mezigdomide', 'Dexamethasone']",9,INTERVENTIONAL,['PHASE1'],PHASE1,,Multiple Myeloma,"['Multiple Myeloma', 'Myeloma', 'Myeloma Multiple']","['NSD2', 'MMSET', 'WHSC1', 'T4;14', 'T(4;14)', 'translocation', 'myeloma', 'RRMM']",RECRUITING,,2023-02-22,2026-06-30,"[{'measure': 'Dose Escalation: Determination of Recommended Phase 2 Dose (RP2D) and/or Maximum Tolerated Dose (MTD)', 'description': 'Incidence of dose-limiting toxicity (DLTs), treatment-emergent adverse events (TEAEs), treatment-related AEs, and clinically significant changes in laboratory test results', 'timeFrame': 'Cycle 1 (28 days)'}]","[{'measure': 'Disease Specific Response to KTX-1001± Combination Therapy', 'description': 'Objective Response Rate (ORR) Duration of Response (DOR) Progression Free Survival (PFS) Minimal Residual Disease (MRD)\n\nPer IMWG Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma', 'timeFrame': 'Duration of Study'}, {'measure': 'Pharmacokinetics & Pharmacodynamics KTX-1001± Combination Therapy', 'description': 'Maximum plasma concentration (Cmax) of KTX-1001 Time to achieve Cmax (tmax) for KTX-1001 Area under the plasma concentration-time curve (AUC) for KTX-1001', 'timeFrame': 'Duration of Study'}, {'measure': 'Safety profile of KTX-1001± Combination Therapy', 'description': 'Frequency and severity of TEAEs, treatment-related AEs, and clinically significant changes in laboratory test results', 'timeFrame': 'Duration of Study'}]",4,18 Years,,ALL,False,"K36 Therapeutics, Inc.",INDUSTRY,1,125.0,ESTIMATED,2025-09-01T16:18:24.758871,v2_robust,True,True,False,False,True,
NCT04564898,Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.,A Phase I/II Study Exploring the Safety and Activity of Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients,Capecitabine,"['Trifluridine/Tipiracil', 'Bevacizumab', 'Capecitabine']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Colorectal Cancer Metastatic,['Colorectal Cancer Metastatic'],[],ACTIVE_NOT_RECRUITING,,2022-01-25,2025-12,"[{'measure': 'recommended dose', 'description': 'recommended dose of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab', 'timeFrame': '2 years'}, {'measure': 'activity', 'description': 'activity of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab in terms of overaal response rate per RECIST v1.1.', 'timeFrame': '3 years'}]","[{'measure': 'quality of life for cancer patients', 'description': 'quality of life as measured by EORTC QLQ-C30 questionnaire.', 'timeFrame': '3 years'}, {'measure': 'quality of life for colorectal cancer patients', 'description': 'quality of life as measured by EORTC QLQ-CR29 questionnaire.', 'timeFrame': '3 years'}, {'measure': 'quality of life for dimensions health', 'description': 'quality of life as measured by EuroQol EQ-5D questionnaire.', 'timeFrame': '3 years'}, {'measure': 'survival', 'description': 'efficacy of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab in terms of progression-free survival and overall survival', 'timeFrame': '3 years'}]",6,18 Years,,ALL,False,Gruppo Oncologico del Nord-Ovest,OTHER,0,48.0,ESTIMATED,2025-09-01T16:18:24.758881,v2_robust,True,True,False,False,False,
NCT06427798,Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy,Phase I/II Trial of Systemic Targeted Radioligand Therapy (TRT) With Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR Positive (SSTR+) Gastrointestinal (GI) Neuroendocrine Tumors (NET) and Pheochromocytoma/Paragangliomas Previously Treated With Systemic Radioligand Therapy,68Ga-DOTATATE,"['[212Pb]VMT-alpha-NET', '68Ga-DOTATATE', '[203Pb]VMT-alpha-NET']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Somatostatin Receptor Positive,"['Somatostatin Receptor Positive', 'Gastrointestinal Neuroendocrine Tumors', 'Pheochromocytoma', 'Paragangliomas']","['212Pb', 'Targeted Therapy', 'Image-Guided Dosimetry', 'VMT- -NET']",RECRUITING,,2025-02-07,2039-07-01,"[{'measure': 'Phase I: MTD of [212Pb]VMT-alpha-NET using a 3+3 dose escalation design in GI NET and PPGL in a re-treatment setting', 'description': 'The MTD will be presented as a recommended dose to be used as the recommended phase II dose (RP2D) for the combined participant population, as well as for each disease group being studied (GI-NET, PPGL).', 'timeFrame': 'DLT period (through 12 weeks after initial 212Pb]VMT-alpha-NET administration).'}, {'measure': 'Phase II: ORR by RECIST 1.1 of participants treated with [212Pb]VMT-alpha-NET at the MTD at the completion of 4 cycles of treatment, reported by disease groups', 'description': 'The overall response rate will be presented as a percentage along with 95% confidence intervals. Only evaluable participants will be included.', 'timeFrame': 'Baseline until progression or 6 years after receiving the first infusion of study drug.'}]","[{'measure': 'Progression Free Survival', 'description': 'PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Kaplan-Meier curves of PFS will be constructed. Median PFS will be reported with 95% confidence intervals.', 'timeFrame': 'Baseline until progression or 10 years after receiving the first infusion of study drug'}, {'measure': 'Safety of [203Pb]VMT-alpha-NET and [212Pb]VMT-alpha-NET', 'description': 'Descriptive tabulations of toxicity will be provided, along with the agent attribution determination and CTCAE grade for each toxicity event. The data will be presented as an absolute count of the event at a participant level as well as a percentage of total evaluable participants.', 'timeFrame': 'Study duration'}, {'measure': 'Overall Survival', 'description': 'Kaplan-Meier curves of OS, will be constructed. Median OS will be reported with 95% confidence intervals.', 'timeFrame': 'Baseline until progression or 10 years after receiving the first infusion of study drug'}, {'measure': 'PK properties of [212Pb]VMT-alpha-NET via blood and urine sampling', 'description': 'PK data will be represented as a scatter plot graphing time vs. the amount of radioactivity found in blood and urine samples.', 'timeFrame': 'After every infusion of [212Pb]VMT-alpha-NET'}, {'measure': 'Dosimetry properties of [212Pb]VMT-alpha-NET via SPECT/CT, using [203Pb]VMT-alpha-NET as a surrogate with and without the administration of amino acids (Dosimetry Arm 1 only)', 'description': 'Biodistribution and dosimetry data will be represented in a tabular format which indicates the percentage of the injected dose calculated to be in each of the major organs using gamma scan results. Radiation dose calculations will be performed using OLINDA/EXM software. Absorbed doses in organs and the whole body will be determined using the appropriate adult phantom (e.g., adult male, adult female). Tumor lesion absorbed doses will be determined using the sphere model in OLINDA.', 'timeFrame': 'In Dosimetry Arm 1 after every [203Pb]VMT-alpha-NET infusion'}]",7,18 Years,120 Years,ALL,False,National Cancer Institute (NCI),NIH,0,66.0,ESTIMATED,2025-09-01T16:18:24.758960,v2_robust,True,True,False,False,True,
NCT01708798,Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer,A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer,Eplerenone,"['Inspra', 'Eplerenone', 'Placebo']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Breast Cancer,['Breast Cancer'],['Diastolic heart failure'],TERMINATED,Futility,2014-05,2016-11,"[{'measure': ""Change in average E' (averaged septal E' and lateral E')"", 'description': 'The average early diastolic tissue velocity of the mitral valve annulus measured by tissue Doppler echocardiography (averaged velocities of the mitral annulus measured at the lateral edge and the septal edge)', 'timeFrame': '6 months'}]","[{'measure': 'Development of worsening diastolic function', 'description': 'Development of worsening diastolic function, defined as a decline by at least one American Society of Echocardiography gradation of diastolic dysfunction', 'timeFrame': '6 months'}, {'measure': 'Development of worsening systolic function', 'description': 'Development of worsening systolic function, defined as a decline in LVEF of ≥10% to ≤50%', 'timeFrame': '6 months'}, {'measure': ""Change in septal E'"", 'description': ""Change in early diastolic tissue velocity of the septal mitral annulus (E', measured by tissue Doppler echocardiography)"", 'timeFrame': '6 months'}, {'measure': ""Change in lateral E'"", 'description': ""Change in early diastolic tissue velocity of the lateral mitral annulus (E', measured by tissue Doppler echocardiography)"", 'timeFrame': '6 months'}, {'measure': ""Change in E/E'"", 'description': ""Change in the ratio of early diastolic mitral inflow velocity (E, measured by pulse wave Doppler echocardiography) to the average early diastolic tissue velocity of the mitral annulus (E', measured by tissue Doppler echocardiography)"", 'timeFrame': '6 months'}, {'measure': 'Change in E/A', 'description': 'Change in the ratio of peak early diastolic mitral inflow velocity (E) to peak mitral inflow velocity during atrial systole (A), both measured by pulse wave Doppler echocardiography', 'timeFrame': '6 months'}, {'measure': 'Change in left atrial volume index', 'description': 'Change in the left atrial volume index, defined as the left atrial volume measured on the 2D echocardiogram indexed to body surface area', 'timeFrame': '6 months'}, {'measure': 'Change in left ventricular ejection fraction (LVEF)', 'description': ""Change in LVEF, measured by echocardiogram using Simpson's method"", 'timeFrame': '6 months'}, {'measure': 'Biomarkers', 'description': 'Change in biomarkers of myocardial injury, inflammation, and collagen turnover as predictors of cardiotoxicity', 'timeFrame': 'Baseline, 1 week, 2 weeks, 4 weeks, 6 months'}]",10,18 Years,,FEMALE,False,University of British Columbia,OTHER,2,44.0,ACTUAL,2025-09-01T16:18:24.758979,v2_robust,True,True,False,True,False,Futility
NCT00511498,Effect of Nightly Versus Prn Sildenafil on Early Return of Erectile Function Following Laparoscopic Radical Prostatectomy,Effect of Nightly Versus Prn Sildenafil on Early Return of Erectile Function Following Nerve-Sparing Laparoscopic Radical Prostatectomy,Sildenafil,"['Sildenafil', 'Viagra']",2,INTERVENTIONAL,['NA'],,,Prostate Cancer,['Prostate Cancer'],"['Laparoscopic Radical Prostatectomy', 'Nightly sildenafil']",COMPLETED,,2006-03,2008-10,"[{'measure': 'IIEF score', 'timeFrame': '13 months'}]",[],1,18 Years,64 Years,MALE,False,Johns Hopkins University,OTHER,0,100.0,ACTUAL,2025-09-01T16:18:24.759018,v2_robust,True,True,True,False,False,
NCT06301698,The Effectiveness of Stellate Ganglion Block in Managing Dysphagia in Patients With Medullary Infarction,A Double-blind Randomized Controlled Study to Explore Effectiveness of Stellate Ganglion Block in Managing Dysphagia in Patients With Medullary Infarction,Lidocaine Hydrochloride,"['Lidocaine Hydrochloride', 'Lidocaine']",2,INTERVENTIONAL,['NA'],,,Bulbar Palsy,['Bulbar Palsy'],[],NOT_YET_RECRUITING,,2024-03,2024-06,"[{'measure': 'Penetration-Aspiration Scale', 'description': 'Penetration-Aspiration Scale was used to assess dysphagia under Videofluoroscopic Swallowing Study, primarily evaluating the extent to which fluid food entered the airway and caused penetration or aspiration during the swallowing process. As the level increased, the severity of dysphagia also increased.', 'timeFrame': 'day 1 and day 10'}]","[{'measure': 'Functional Oral Intake Scale', 'description': ""During Dysphagia-Functional Oral Intake Scale assessment, evaluators engage in communication with the patient, conduct observations, and make records to assess the patient's oral intake ability. The Functional Oral Intake Scale assessment form includes seven levels of scoring, ranging from level 1 to level 7, indicating a progressive improvement in the patient's oral intake ability. In general, the result below level 6 indicates unsafe for oral intake while level 6 and above indicates that eating via mouth can be safely conducted."", 'timeFrame': 'day 1 and day 10'}, {'measure': 'Murray secretion severity scale', 'description': 'Murray secretion severity scale is used for assessment of Pharyngeal secretion. The result was divided into 0-3 levels (0, normal; 1, a small amount of secretion remained and not entering the laryngeal vestibule; 2: temporary accumulation in the laryngeal vestibule; 3: persistent accumulation in the laryngeal vestibule. A higher score indicates the worse dysphagia.', 'timeFrame': 'day 1 and day 10'}, {'measure': 'Yale pharyngeal residue severity rating scale', 'description': 'The Yale pharyngeal residue severity rating scale was recruited for assessment of Pharyngeal residue.The result would be divided into 5 levels (1, no residue; 2, the covered pharyngeal mucosa; 3, mild residue, less than 50%; 4, moderate residue, more than 50%; 5, severe residue, spillage from laryngeal vestibule observed). A higher score indicates the worse dysphagia.', 'timeFrame': 'day 1 and day 10'}]",4,18 Years,,ALL,False,Ahmadu Bello University Teaching Hospital,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:24.759081,v2_robust,True,True,False,False,False,
NCT01106898,Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery,"A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Patients",cyclophosphamide,"['Anzatax', 'paclitaxel', 'cyclophosphamide', 'Endoxan', 'Asotax', 'CTX', 'CPM', 'Endoxana', 'Taxol', 'TAX', 'Cytoxan']",11,INTERVENTIONAL,['PHASE2'],PHASE2,,Stage IA Breast Cancer,"['Stage IA Breast Cancer', 'Stage IB Breast Cancer', 'Stage IIA Breast Cancer', 'Stage IIB Breast Cancer']",[],COMPLETED,,2010-03-24,2015-09-28,"[{'measure': 'Recurrence-free Survival', 'description': 'Recurrence-free survival curves will be plotted for subjects treated with stage I and II disease.', 'timeFrame': 'Time from the start of treatment to recurrence, second malignancy, or death as a first event, assessed up to 3 years'}]",[],1,20 Years,,FEMALE,False,University of Nebraska,OTHER,1,112.0,ACTUAL,2025-09-01T16:18:24.759173,v2_robust,True,True,True,False,False,
NCT04225598,Emergency Department-Initiated Buprenorphine Validation Network Trial,Emergency Department-Initiated Buprenorphine Validation Network Trial,CAM2038,"['Buprenorphine Sublingual Product', 'CAM2038']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Opioid-use Disorder,['Opioid-use Disorder'],['Opioid-use Disorder'],COMPLETED,,2020-07-08,2024-12-06,"[{'measure': 'RCT Component: Patient engagement (yes/no) in formal addiction treatment at 7 days post randomization', 'description': ""Engagement in formal addiction treatment will be defined as enrollment and receiving formal addiction treatment on the 7th day post randomization, confirmed by contact with the facility and/or treating clinician. Formal addiction treatment will be operationally defined as those treatments consistent with the American Society of Addiction Medicine's levels of care (1-4) and can include a range of clinical settings including office-based providers of BUP or naltrexone, opioid treatment programs (OTPs), intensive outpatient, inpatient, or residential treatments. Patients do not need to be receiving MOUD at 7 days to be considered engaged in formal addiction treatment. Participation in a mutual-help program such as Alcoholics Anonymous (AA) or (Narcotics Anonymous) NA alone will not be considered as engagement in formal addiction treatment. Additional analyses evaluating the effects of patient and site characteristics will also be conducted."", 'timeFrame': '7 days post randomization'}]","[{'measure': 'RCT Component: Engagement in MOUD (yes/no) at 7 days post randomization', 'description': 'self-report verified with treatment provider(s)', 'timeFrame': '7 days post randomization'}, {'measure': 'RCT Component: Patient engagement (yes/no) in formal addiction treatment at 30 days post randomization', 'description': ""Engagement in formal addiction treatment will be defined as enrollment in formal addiction treatment on the 30th day post randomization, confirmed by direct contact with the facility and/or treating clinician. Formal addiction treatment will be operationally defined as those treatments consistent with the American Society of Addiction Medicine's levels of care (1-4) and can include a range of clinical settings including office-based providers of BUP or naltrexone, OTPs, intensive outpatient, inpatient, or residential treatments. Patients do not need to be receiving MOUD on the 30th day post randomization to be considered engaged in formal addiction treatment. Participation in a mutual-help program such as Alcoholics or Narcotics Anonymous alone will not be considered as engagement in formal addiction treatment. Additional analyses evaluating the effects of patient and site characteristics will also be conducted."", 'timeFrame': '30 days post randomization'}, {'measure': 'RCT Component: Patient Engagement in MOUD (yes/no) at 30 days post randomization', 'description': 'self report verified with treatment provider(s)', 'timeFrame': '30 days post randomization'}, {'measure': 'RCT Component: Self-reported days of illicit opioid use (past 7 days) at 7 days post randomization', 'description': ""The Timeline Follow-back procedure will be used to elicit the patient participant's self-reported days of use of opioids."", 'timeFrame': '7 days post randomization'}, {'measure': 'RCT Component: Self-reported days of illicit opioid use (past 7 days) at 30 days post randomization', 'description': ""The Timeline Follow-back procedure will be used to elicit the patient participant's self-reported days of use of opioids."", 'timeFrame': '30 days post randomization'}, {'measure': 'RCT Component: Craving scores at 7 days post randomization', 'description': 'The investigators will use visual analogue scales (VAS) to assess craving, desire to use opioids and need to use opioids with a scale of 0-100.', 'timeFrame': '7 days post randomization'}, {'measure': 'RCT Component: Healthcare services utilization (past 30 days) regarding ED visits and hospitalizations at 30 days post randomization', 'description': 'A brief, structured interview regarding health care utilization (inpatient and outpatient) will be used, which collects information on the type and amount of services received. This includes ED visits, hospitalizations, primary medical care visits (excluding those for BUP treatment and self-help sources of support (e.g., NA).', 'timeFrame': '30 days post randomization'}, {'measure': 'RCT Component: Patient satisfaction with BUP at 7 days post randomization', 'description': 'The investigators will modify the patient satisfaction scale where overall experience is rated from 1 to 5 (1 is completely ineffective and 5 is completely effective) and treatment characteristics are rated 1 to 7 (1 is not important and 7 is extremely important) based on previous published data.', 'timeFrame': '7 days post randomization'}, {'measure': 'RCT Component: Overdose Events at 30 days post randomization', 'description': 'Assessment of past 30-day overdose events will be completed at 30 days post study enrollment. In addition, Site PIs will search local electronic medical records for fatal and non-fatal overdose events.', 'timeFrame': '30 days post randomization'}, {'measure': 'Ancillary Component: Proportion of participants that experience a 5 or greater increase in COWS score within 4 hours of of XR-BUP administration', 'description': 'Clinical Opiate Withdrawal Scale (COWS) - the COWS is a validated measure of the severity of opioid withdrawal that consists of 11 subjective and objective items. Scores on the individual items are combined to a single overall score that has been used to determine the SL-BUP induction strategy. COWS scoring, and interpretation is as follows: Score: 5-12 = mild opioid withdrawal; 13-24 = moderate opioid withdrawal; 25-36 = moderately severe opioid withdrawal; more than 36 = severe opioid withdrawal.', 'timeFrame': 'Within 4 hours of XR-BUP administration'}, {'measure': 'Ancillary Component: Proportion of participants that transition to moderate withdrawal (COWS 13-24) within 4 hours of XR-BUP administration', 'description': 'Clinical Opiate Withdrawal Scale (COWS) - the COWS is a validated measure of the severity of opioid withdrawal that consists of 11 subjective and objective items. Scores on the individual items are combined to a single overall score that has been used to determine the SL-BUP induction strategy. COWS scoring, and interpretation is as follows: Score: 5-12 = mild opioid withdrawal; 13-24 = moderate opioid withdrawal; 25-36 = moderately severe opioid withdrawal; more than 36 = severe opioid withdrawal.', 'timeFrame': 'Within 4 hours of XR-BUP administration'}, {'measure': 'Ancillary Component: Proportion of participants that experience clinician determined precipitated withdrawal within 1 hour of XR-BUP administration', 'description': 'Assessment of Proportion of participants that experience clinician determined precipitated withdrawal within 1 hour of XR-BUP administration.', 'timeFrame': 'Within 1 hour post XR-BUP injection'}]",13,18 Years,,ALL,False,Yale University,OTHER,9,2000.0,ACTUAL,2025-09-01T16:18:24.759192,v2_robust,True,True,True,False,False,
NCT01097798,"To Evaluate the Efficacy and Safety Aliviador Compared to Gelol in Patients With Contusions, Sprains, Trauma and Muscle Injury.","Multicenter, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety Aliviador Compared to Gelol in the Relief in Patients With Contusons, Sprains,Trauma and Muscle Injury.",Aliviador,"['Gelol', 'Aliviador']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Contusions,"['Contusions', 'Sprains', 'Trauma', 'Muscle Injury', 'Myalgia', 'Myofascial Pain', 'Tendinitis']",['muscle injury'],UNKNOWN,,2010-06,2010-08,"[{'measure': 'To evaluate the efficacy in reducing signs and symptoms Aliviador compared to Gelol.', 'description': 'To evaluate the efficacy in reducing signs and symptoms Aliviador compared to Gelol in patients with contusions, sprains, muscle injury and trauma, starting less than 24 hours or patients with muscle pain, myofascial pain and tendinitis.', 'timeFrame': 'two days'}]","[{'measure': 'To evaluate the tolerability use Aliviador compared to Gelol.', 'description': 'To evaluete the tolerability use Aliviador compared to Gelol in patients with contusions, sprains, muscle injury and traumas starting less than 24 hours or patients with myalgia, myofascial pain and tendinitis.', 'timeFrame': 'two days'}]",2,12 Years,,ALL,False,Laboratorio Brasileiro de Biologia,OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:24.759254,v2_robust,True,True,False,False,False,
NCT01218698,"Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed Condition","An Open Label, Randomised, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed Condition",Losartan Potassium Tablets,['Losartan Potassium Tablets'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,,,"[{'measure': 'Bioequivalence based on AUC parameters'}, {'measure': 'Bioequivalence based on Cmax'}]",[],2,18 Years,45 Years,,,Torrent Pharmaceuticals Limited,INDUSTRY,0,,,2025-09-01T16:18:24.759293,v2_robust,True,True,True,False,False,
NCT06574698,Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma,"Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma: A Prospective, Single-Arm Clinical Study",Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy,['Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy'],1,OBSERVATIONAL,[],,,Neuroblastoma,"['Neuroblastoma', 'GD2 Antibody (Naxitamab)']",[],RECRUITING,,2024-05-06,2032-12-31,"[{'measure': 'The number of the patients of VGPR or CR at the end of induction therapy', 'description': 'Measured by cross-sectional computed tomography (CT) or magnetic resonance imaging (MRI) imaging and/or by methyl iodobenzylguanidine (MIBG) or positron emission tomography (PET) scans and bone marrow (BM) responses, evaluated according to the 1993 International Neuroblastoma Response Criteria (INRC), and compared with relevant historical control groups.', 'timeFrame': '5 years'}]","[{'measure': 'Objective Response Rate (ORR)', 'description': 'According to the International Neuroblastoma Response Criteria (INRC) of 1993 and 2017, the proportion of complete or partial responses was calculated in newly diagnosed high-risk group patients with neuroblastoma who received standard induction therapy. The disease status was evaluated by CT or MRI and/or MIBG or PET scans and bone marrow aspiration. After two courses of treatment, the proportion of complete or partial responses was calculated in newly diagnosed high-risk group patients with neuroblastoma who received standard induction therapy after two courses of treatment were completed.', 'timeFrame': '5 years'}, {'measure': 'The number of days a patient survives', 'description': 'The overall survival (OS) of patients receiving standard-induced chemotherapy and GD2 antibody combination therapy.', 'timeFrame': '3 years after the last patient was enrolled'}, {'measure': 'The number of days the patient survive without relapse or progression', 'description': 'The event-free survival (EFS) of patients receiving standard-induced chemotherapy and GD2 antibody combination therapy.', 'timeFrame': '3 years after the last patient was enrolled'}, {'measure': 'The objective response rate (ORR) after 6 cycles of treatment.', 'description': 'The objective response rate (ORR) after 6 cycles of treatment.', 'timeFrame': '5 years'}, {'measure': 'The number of patients with adverse events related to treatment', 'description': 'The number of patients with adverse events related to treatment', 'timeFrame': '5 years'}]",6,1 Year,21 Years,ALL,False,Guangzhou Women and Children's Medical Center,OTHER,0,64.0,ESTIMATED,2025-09-01T16:18:24.759308,v2_robust,False,True,False,False,True,
NCT01166698,"Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects","A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group, 2-part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects",AZD9819,"['AZD9819', 'Part A and B', 'Placebo', 'Part B (multiple ascending doses)']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,"['Healthy Volunteers', 'Safety', 'Tolerability']","['Safety', 'tolerability', 'healthy', 'inhalation']",COMPLETED,,2010-08,2011-01,"[{'measure': 'Safety variables (ECG variables, adverse events, blood pressure, pulse, body temp, safety lab)', 'timeFrame': 'Frequent safety measurements during the study from screening period to follow-up'}]","[{'measure': 'Pharmacokinetic variables of AZD9819 by assessment of drug concentrations in plasma', 'timeFrame': 'Multiple PK blood samples from pre-dose until 96 hours post last dose'}]",2,18 Years,50 Years,ALL,True,AstraZeneca,INDUSTRY,0,100.0,ESTIMATED,2025-09-01T16:18:24.759331,v2_robust,True,True,True,False,True,
NCT07033598,Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia,A Randomized Phase 2 Study of Pacritinib vs. Hydroxyurea in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia,Pacritinib,"['Hydroxyurea', 'Pacritinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Leukemia, Myelomonocytic, Chronic","['Leukemia, Myelomonocytic, Chronic']",[],NOT_YET_RECRUITING,,2025-12,2028-12,"[{'measure': 'Clinical benefit at Week 24, defined as achieving erythroid response in the absence of leukemic transformation.', 'description': 'For participants with baseline hemoglobin \\<10 g/dL, response is defined as either a ≥1.5 g/dL hemoglobin increase lasting ≥8 weeks without red blood cell transfusion, or, if transfusion-dependent at baseline (≥4 units in the 8 weeks pre-enrollment), achieving ≥8 weeks of red blood cell transfusion independence, excluding transfusions given for pretreatment Hb ≤8.5 g/dL.\n\nLeukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma.', 'timeFrame': 'Measured from Week 24 through the end of treatment, up to 48 weeks.'}, {'measure': 'Clinical benefit at Week 24, defined as achieving platelet response in the absence of leukemic transformation.', 'description': 'For participants with baseline platelet counts \\<100 × 10⁹/L, response is defined as one of the following: an increase to ≥20 × 10⁹/L and by ≥100% for ≥8 weeks without platelet transfusion (if baseline \\<20 × 10⁹/L); an increase of ≥30 × 10⁹/L for ≥8 weeks without transfusion (if baseline 20-\\<100 × 10⁹/L); or, if transfusion-dependent at baseline (≥4 units in the 8 weeks pre-enrollment), achieving ≥8 weeks of platelet transfusion independence.\n\nLeukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma.', 'timeFrame': 'Measured from Week 24 through the end of treatment, up to 48 weeks.'}, {'measure': 'Clinical benefit at Week 24, defined as achieving neutrophil response in the absence of leukemic transformation.', 'description': 'For participants with baseline ANC ≤1 × 10⁹/L, response is defined as either an increase to \\>0.5 × 10⁹/L and by ≥100% for ≥8 weeks without myeloid growth factors (if baseline ANC ≤0.5 × 10⁹/L), or an increase by ≥50% for ≥8 weeks without myeloid growth factors (if baseline ANC \\>0.5 to ≤1 × 10⁹/L).\n\nLeukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma.', 'timeFrame': 'Measured from Week 24 through the end of treatment, up to 48 weeks.'}, {'measure': 'Clinical benefit at Week 24, defined as achieving spleen response in the absence of leukemic transformation.', 'description': 'For participants with baseline spleen ≥5 cm below the left costal margin (midclavicular line), spleen response is defined as a ≥35% reduction in spleen volume at endpoint assessment by MRI or CT.\n\nLeukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma.', 'timeFrame': 'Measured from Week 24 through the end of treatment, up to 48 weeks.'}, {'measure': 'Clinical benefit at Week 24, defined as achieving symptom response in the absence of leukemic transformation.', 'description': 'Among participants with baseline Total Symptom Score (TSS) ≥20 per the MPN-SAF TSS: achieving ≥50% TSS reduction from baseline at the time of endpoint assessment.\n\nLeukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma.', 'timeFrame': 'Measured from Week 24 through the end of treatment, up to 48 weeks.'}]","[{'measure': 'Clinical benefit at any time, defined as achieving at least one of the primary endpoint clinical benefit response criteria at any time on study.', 'timeFrame': 'Measured from the start of study treatment to the end of treatment, for up to 48 weeks.'}, {'measure': 'Achieving response at Week 24 and 48 according to the IWG 2015 criteria), including the following subtypes: complete response, complete cytogenetic remission, partial remission, marrow response', 'timeFrame': 'Measured from Week 24 through the end of treatment, up to 48 weeks.'}, {'measure': 'Duration of response for primary endpoint (clinical benefit by Week 24)', 'timeFrame': 'Measured from Week 24 through the end of treatment, up to 48 weeks.'}, {'measure': 'Event-free survival', 'description': 'Event-free survival is defined as the time without death from any cause, transformation to AML (including granulocytic sarcoma), or disease progression after ≥3 cycles (Week 12), including CMML-1 to CMML-2 with ≥5% absolute blast increase or worsening splenomegaly.', 'timeFrame': 'Measured from the start of study treatment to the end of treatment, for up to 48 weeks.'}, {'measure': 'Leukemia-free survival, where events include death from any cause or transformation to AML (including granulocytic sarcoma)', 'timeFrame': 'Measured from the start of study treatment to the end of treatment, for up to 48 weeks.'}, {'measure': 'Overall survival', 'timeFrame': 'Measured from the date of initiating study treatment to the date of death from any cause, assessed up to 24 months.'}, {'measure': 'Incidence of allogeneic hematopoietic stem cell transplant.', 'timeFrame': 'Measured from the date of initiating study treatment to the date of allogeneic hematopoietic stem cell transplant., assessed for up to 24 months'}, {'measure': 'Adverse events and laboratory abnormalities as graded by NCI CTCAE v5.0.', 'timeFrame': 'From the start of the adverse event collection period through 30 days following the last dose of study treatment.'}, {'measure': 'Change in arterial blood pressure measured in mmHg.', 'timeFrame': 'From the start of the study treatment through 30 days following the last dose of study treatment.'}, {'measure': 'Change in pulse rate measured in beats per minute.', 'timeFrame': 'From the start of the study treatment through 30 days following the last dose of study treatment.'}, {'measure': 'Change in respiratory rate measured in breaths per minute.', 'timeFrame': 'From the start of the study treatment through 30 days following the last dose of study treatment.'}, {'measure': 'Change in corrected QT interval measured in milliseconds using 12-lead electrocardiogram.', 'timeFrame': 'From the start of the study treatment through 30 days following the last dose of study treatment.'}]",17,18 Years,,ALL,False,Theradex,INDUSTRY,2,66.0,ESTIMATED,2025-09-01T16:18:24.759373,v2_robust,True,True,False,False,True,
NCT01136798,Impact of Exenatide on Sleep in Type 2 Diabetes,Impact of Exenatide on Sleep and Circadian Function in Type 2 Diabetes: A Pilot Study,Exenatide,"['Exenatide', 'Placebo']",2,INTERVENTIONAL,['NA'],,,Type 2 Diabetes,"['Type 2 Diabetes', 'Sleep Disordered Breathing']","['slow wave sleep', 'exenatide and sleep']",COMPLETED,,2010-06-01,2016-09-01,"[{'measure': 'Non-REM Slow Wave Sleep', 'description': 'Total minutes of non-REM sleep was measured', 'timeFrame': 'baseline and after 6 weeks of treatment'}, {'measure': 'Total Amount of Slow Wave Activity', 'description': 'Total amount of slow wave activity during sleep derived from laboratory polysomnogram was measured', 'timeFrame': 'baseline and after 6 weeks of treatment'}]","[{'measure': 'Sleep Efficiency During Polysomnographic Recording', 'description': 'Sleep efficiency will be calculated as total sleep time over total recording time.', 'timeFrame': 'baseline and after 6 weeks of treatment'}, {'measure': 'Minutes of Wake After Sleep Onset During Sleep Recording', 'description': 'total amount of time spent awake after sleep onset and before morning awakening will be calculated', 'timeFrame': 'baseline and after 6 weeks of treatment'}, {'measure': 'Severity of Obstructive Sleep Apnea', 'description': 'The apnea-hypopnea index (AHI) will be calculated from polysomnographic recordings. The minimum score for AHI is 0 (zero), corresponding to total absence of apnea or hypopnea. There is no theoretical maximum score although scores above 100 are very rarely observed. The lower the AHI value, the better. Higher AHI values correspond to greater severity of sleep apnea, a worse outcome. There are no subscales. We use continuous AHI values to measure severity of obstructive sleep apnea.', 'timeFrame': 'baseline and after 6 weeks of treatment'}, {'measure': 'Mean 24-h Blood Glucose Levels', 'description': 'Mean plasma levels of glucose will be calculated from samples collected across the 24-h cycle.', 'timeFrame': 'baseline and after 6 weeks of treatment'}]",6,18 Years,,ALL,False,University of Chicago,OTHER,0,18.0,ACTUAL,2025-09-01T16:18:24.759510,v2_robust,True,True,True,False,False,
NCT02720263,"A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia","A Phase 1 Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia",ASP4345,"['Matching Placebo', 'ASP4345']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Schizophrenia,['Schizophrenia'],"['Schizophrenia', 'ASP4345']",COMPLETED,,2016-03-28,2017-06-08,"[{'measure': 'Safety and tolerability assessed as nature, frequency and severity of adverse events', 'timeFrame': 'Up to Day 21'}, {'measure': 'Change from baseline in supine blood pressure as a measure of safety and tolerability', 'timeFrame': 'Baseline and Day 21'}, {'measure': 'Change from baseline in pulse as a measure of safety and tolerability', 'timeFrame': 'Baseline and Day 21'}, {'measure': 'Change from baseline in oral body temperature as a measure of safety and tolerability', 'timeFrame': 'Baseline and Day 21'}, {'measure': 'Safety and tolerability assessed by an orthostatic challenge test', 'description': 'Incidence of positive orthostatic challenge tests will be summarized.', 'timeFrame': 'Up to Day 14'}, {'measure': 'Number of participants with abnormal laboratory values and/or adverse events related to treatment', 'description': 'Clinical laboratory tests include hematology, biochemistry and urinalysis.', 'timeFrame': 'Up to Day 21'}, {'measure': 'Safety and tolerability assessed by routine 12-lead electrocardiogram (ECG)', 'description': 'The overall interpretation of 12-lead electrocardiogram (ECG) results (normal, abnormal not clinically significant and abnormal clinically significant) will be summarized.', 'timeFrame': 'Up to Day 18'}, {'measure': 'Safety and tolerability assessed by continuous 12-lead ECG recording', 'description': 'ECGs will be collected using a 12-lead ECG continuous monitoring system which records continuous digital data.', 'timeFrame': 'Up to Day 14'}, {'measure': 'Safety and tolerability assessed by abuse liability using an Addiction Research Center Inventory (ARCI-49)', 'description': 'ARCI-49 is a 49-item short form standardized questionnaire for abuse potential liability.', 'timeFrame': 'Up to Day 17'}, {'measure': 'Safety and tolerability assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)', 'description': 'The C-SSRS is a scale that assesses the full spectrum of suicidality: suicidal ideation, intensity of ideation, suicidal behaviors and actual attempts.', 'timeFrame': 'Up to Day 18'}, {'measure': 'Safety and tolerability assessed by Bond-Lader Visual Analog Scale (VAS)', 'description': ""The VAS will be used to rate patients' feelings in terms of 16 dimensions. The dimensions will be presented as 100 mm lines, the 2 extremes of the emotion (i.e., alert - drowsy) written at each end."", 'timeFrame': 'Up to Day 17'}, {'measure': 'Safety and tolerability assessed by metabolic syndrome: weight circumference', 'timeFrame': 'Up to Day 14'}, {'measure': 'Safety and tolerability assessed by metabolic syndrome: cholesterol', 'timeFrame': 'Up to Day 21'}, {'measure': 'Safety and tolerability assessed by metabolic syndrome: triglycerides', 'timeFrame': 'Up to Day 21'}, {'measure': 'Safety and tolerability assessed by metabolic syndrome: glucose level', 'timeFrame': 'Up to Day 21'}, {'measure': 'Safety and tolerability assessed by weight', 'timeFrame': 'Up to Day 14'}, {'measure': 'Safety and tolerability assessed by movement disorder: Abnormal Involuntary Movement Scale (AIMS)', 'description': 'The AIMS is a checklist and uses a 5-point rating scale for recording scores for 7 body areas: face, lips, jaw, tongue, upper extremities, lower extremities and trunk.', 'timeFrame': 'Up to Day 14'}, {'measure': 'Safety and tolerability assessed by movement disorder: Simpson Angus Scale (SAS)', 'description': 'The SAS is a 10-item scale used to rate adverse neurological effects of antipsychotic medications more broadly. Each item is rated from 0 to 4 and a total score will be obtained.', 'timeFrame': 'Up to Day 14'}, {'measure': 'Safety and tolerability assessed by movement disorder: Barnes Akathisia Rating Scale (BARS)', 'description': 'The BARS is a rating scale used to assess the severity of drug-induced akathisia.', 'timeFrame': 'Up to Day 14'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (plasma): tlag', 'description': 'Time prior to the time corresponding to the first measurable (nonzero) concentration (tlag)', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (plasma): tmax', 'description': 'Time of maximum concentration (tmax)', 'timeFrame': 'Day 1 and Day 14'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (plasma): Cmax', 'description': 'Maximum concentration (Cmax)', 'timeFrame': 'Day 1 and Day 14'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (plasma): AUCtau', 'description': 'Area under the concentration-time curve from the time of dosing to the start of the next dosing interval (AUCtau)', 'timeFrame': 'Day 1 and Day 14'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (plasma): Ctrough', 'description': 'Concentration immediately prior to dosing at multiple dosing (Ctrough)', 'timeFrame': 'Days 2 through 14'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (plasma): t1/2', 'description': 'Terminal elimination half-life (t1/2)', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (plasma): MRTinf', 'description': 'Mean residence time extrapolated to time infinity (MRTinf)', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (plasma): terminal elimination rate constant', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (plasma): Vz/F', 'description': 'Apparent volume of distribution during the terminal elimination phase after single extravascular dosing (Vz/F)', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (plasma): CL/F', 'description': 'Apparent total systemic clearance after extravascular dosing (CL/F)', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (plasma): Rac(AUC)', 'description': 'Accumulation index area under the concentration-time curve (Rac(AUC))', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (plasma): PTR', 'description': 'Peak trough ratio (PTR)', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (urine): Aetau', 'description': 'Cumulative amount of study drug excreted into urine from the time of dosing to the start of the next dosing interval (Aetau)', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (urine): Aetau%', 'description': 'Percentage of study drug dose excreted into urine from the time of dosing to the start of the next dosing interval (Aetau%)', 'timeFrame': 'Day 14'}, {'measure': 'Pharmacokinetics of ASP4345 and its metabolites, if necessary (urine): CLR', 'description': 'Renal clearance (CLR)', 'timeFrame': 'Day 14'}]",[],34,18 Years,60 Years,ALL,False,"Astellas Pharma Global Development, Inc.",INDUSTRY,0,48.0,ACTUAL,2025-09-01T16:18:24.759588,v2_robust,True,True,True,False,True,
NCT02421263,The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals,A Randomized Controlled Trial of the Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion,Psilocybin,['Psilocybin'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Religious or Spiritual Problem,['Religious or Spiritual Problem'],"['Psilocybin', 'Pharmacologic Actions', 'Psychotropic Drugs']",COMPLETED,,2015-04,2020-06-05,"[{'measure': 'Interim Questionnaire', 'description': ""This questionnaire asks about experiences and changes in attitudes, mood and behavior that occurred during the past 5 months. The questionnaire includes questions about salient spiritual experiences, changes in spiritual practices, changes in attitudes, moods, social interactions, and other behaviors related to participants' religious/spiritual vocation."", 'timeFrame': '6-Months after enrollment'}]",[],1,25 Years,76 Years,ALL,True,NYU Langone Health,OTHER,0,12.0,ACTUAL,2025-09-01T16:18:24.759594,v2_robust,True,True,True,False,False,
NCT04884763,Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder,"A Randomized, Double Blind, Placebo-Controlled Single Center Phase 2 Pilot Study to Assess the Safety and Efficacy of Off-label Subcutaneous Administration of Erenumab-aooe in Patients With Temporomandibular Disorder",Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments,"['Aimovig®', 'Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments', 'Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Temporomandibular Disorder,['Temporomandibular Disorder'],[],COMPLETED,,2021-11-15,2024-01-04,"[{'measure': 'Brief Pain Inventory (BPI) Pain Severity at 20 Weeks', 'description': 'Assessment of pain severity using the Brief Pain Inventory (BPI) 4-item pain severity scale at 20 weeks: 0 (Better) - 10 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (secondary outcome).', 'timeFrame': '20 weeks.'}]","[{'measure': 'Brief Pain Inventory (BPI) Pain Interference at 20 Weeks', 'description': 'Assessment of pain interference using the Brief Pain Inventory (BPI) 7-item pain intensity scale at 20 weeks: 0 (Better) - 10 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (additional secondary outcome).', 'timeFrame': '20 weeks'}, {'measure': 'Average Daily Reported Pain Scores at 20 Weeks', 'description': 'Assessment of pain using average of daily reported pain scores at 20 weeks; average of daily reported scores from days \\> week 16 and \\<= week 20. Pain scale: 0 (Better) - 10 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (additional secondary outcome).', 'timeFrame': '20 weeks'}, {'measure': '% of Days Taking Medication for Pain at 20 Weeks', 'description': 'Assessment of pain using the % of days taking medication for pain at 20 weeks; percentage of days calculated from days \\> week 16 and \\<= week 20.Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (additional secondary outcome).', 'timeFrame': '20 weeks'}, {'measure': 'Pain Improvement Using the Patient Global Impression of Change in Pain at 20 Weeks', 'description': 'Assessment of pain improvement using the patient global impression of change in pain scale at 20 weeks: 1 (Better) - 7 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (additional secondary outcome).', 'timeFrame': '20 weeks'}, {'measure': 'Jaw Function Limitation Scale (JFLS-8) at 20 Weeks', 'description': 'Jaw Function Limitation Scale (JFLS-8) at 20 weeks: 0 (Better) - 10 (Worse).Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (additional secondary outcome).', 'timeFrame': '20 weeks'}, {'measure': 'Patient Health Questionnaire (PHQ-4) at 20 Weeks', 'description': 'Depressive and Anxiety symptoms using Patient Health Questionnaire (PHQ-4) at 20 weeks: 0 (Better) - 12 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (additional secondary outcome).', 'timeFrame': '20 weeks'}, {'measure': 'Somatic Symptoms Scale (SSS-8) at 20 Weeks', 'description': 'Assessment of somatic symptoms using the Somatic Symptoms Scale (SSS-8) at 20 weeks: 0 (Better) - 32 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and post-treatment at 24 weeks (additional secondary outcome).', 'timeFrame': '20 weeks'}, {'measure': 'Brief Pain Inventory (BPI) Pain Severity at 24 Weeks', 'description': 'Assessment of pain severity using the Brief Pain Inventory (BPI) 4-item pain severity scale at 24 weeks: 0 (Better) - 10 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (primary outcome).', 'timeFrame': '24 weeks.'}, {'measure': 'Brief Pain Inventory (BPI) Pain Interference at 24 Weeks', 'description': 'Assessment of pain interference using the Brief Pain Inventory (BPI) 7-item pain intensity scale at 24 weeks: 0 (Better) - 10 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (additional secondary outcome).', 'timeFrame': '24 weeks'}, {'measure': 'Average Daily Reported Pain Scores at 24 Weeks', 'description': 'Assessment of pain using average of daily reported pain scores at 24 weeks; average of daily reported scores from days \\> week 20 and \\<= week 24. Pain scale: 0 (Better) - 10 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (additional secondary outcome).', 'timeFrame': '24 weeks'}, {'measure': '% of Days Taking Medication for Pain at 24 Weeks', 'description': 'Assessment of pain using the % of days taking medication for pain at 24 weeks; percentage of days calculated from days \\> week 20 and \\<= week 24. Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (additional secondary outcome).', 'timeFrame': '24 weeks'}, {'measure': 'Pain Improvement Using the Patient Global Impression of Change in Pain at 24 Weeks', 'description': 'Assessment of pain improvement using the patient global impression of change in pain scale at 24 weeks: 1 (Better) - 7 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (additional secondary outcome).', 'timeFrame': '24 weeks'}, {'measure': 'Jaw Function Limitation Scale (JFLS-8) at 24 Weeks', 'description': 'Jaw Function Limitation Scale (JFLS-8) at 24 weeks: 0 (Better) - 10 (Worse).Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (additional secondary outcome).', 'timeFrame': '24 weeks'}, {'measure': 'Patient Health Questionnaire (PHQ-4) at 24 Weeks', 'description': 'Depressive and Anxiety symptoms using Patient Health Questionnaire (PHQ-4) at 24 weeks: 0 (Better) - 12 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (additional secondary outcome).', 'timeFrame': '24 weeks'}, {'measure': 'Somatic Symptoms Scale (SSS-8) at 24 Weeks', 'description': 'Assessment of somatic symptoms using the Somatic Symptoms Scale (SSS-8) at 24 weeks: 0 (Better) - 32 (Worse). Interim assessments were performed at 4, 8, 12 and 16 weeks and end of treatment at 20 weeks (additional secondary outcome).', 'timeFrame': '24 weeks'}]",16,18 Years,59 Years,ALL,True,Indiana University,OTHER,1,30.0,ACTUAL,2025-09-01T16:18:24.759614,v2_robust,True,True,True,False,False,
NCT00969163,A Study to Investigate Biomarkers of Skin Androgenization Following Testosterone Administration (0000-015)(COMPLETED).,A Pilot Study to Investigate Biomarkers of Skin Androgenization Following Short-Term Testosterone Administration in Healthy Postmenopausal Women,testosterone gel,"['testosterone gel', 'Comparator: placebo', 'AndroGel']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Skin Androgenization,['Skin Androgenization'],['Biomarkers of Skin Androgenization'],COMPLETED,,2004-10,2005-06,"[{'measure': 'serum free testosterone concentrations following multiple doses of AndroGel', 'timeFrame': '6 weeks'}]","[{'measure': 'mean percent change from baseline in sebum excretion', 'timeFrame': '6 weeks'}]",2,50 Years,65 Years,FEMALE,True,Merck Sharp & Dohme LLC,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:24.759752,v2_robust,True,True,True,False,False,
NCT03489863,Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study,Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease,Prasugrel,"['Prasugrel', 'Brilinta', 'Ticagrelor', 'Effient']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Coronary Artery Disease,['Coronary Artery Disease'],"['clopidogrel', 'prasugrel', 'ticagrelor']",COMPLETED,,2018-05-30,2019-03-20,"[{'measure': 'P2Y12 Reaction Unit (PRU)', 'description': 'Platelet reactivity measured by VerifyNow and reported as PRU', 'timeFrame': 'at 24 hours post loading dose'}]",[],1,18 Years,75 Years,ALL,False,University of Florida,OTHER,1,14.0,ACTUAL,2025-09-01T16:18:24.759769,v2_robust,True,True,True,False,False,
NCT05266963,Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes,Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes,CREON,"['CREON', 'Placebo']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Type 1 Diabetes,['Type 1 Diabetes'],[],COMPLETED,,2022-09-02,2024-03-22,"[{'measure': 'Improvement in Glucose Regulation', 'description': 'Mixed meal tolerance testing (MMTT) will be used to assess glucose regulation via c-peptide AUC at baseline, and after treatment with placebo and CREON in a random order.', 'timeFrame': 'through study completion (4-5 weeks)'}, {'measure': 'Patient-reported Change in Pancreatic Exocrine Insufficiency (PEI) Symptoms', 'description': 'We will use the pancreatic exocrine insufficiency questionnaire (PEI-Q) to quantitate symptoms of PEI and their relative change from baseline to after treatment with placebo and Creon in a random order. Minimum score is 0, and maximum score is 4. Higher scores correlate to worse outcome, i.e., increased abdominal symptoms and bowel movement symptoms.', 'timeFrame': 'through study completion (4-5 weeks)'}]",[],2,18 Years,,ALL,False,Vanderbilt University Medical Center,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:24.759848,v2_robust,True,True,True,False,False,
NCT05225363,Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer,A Phase 1 Study to Evaluate TAG72-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced Epithelial Ovarian Cancer,Cyclophosphamide,"['Fosfaseron', 'Claphene', 'Carloxan', 'Cyclophosphan', 'Neosar', 'Cytoxan', 'WR- 138719', '2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate', 'Cyclophosphamide Monohydrate', 'Genuxal', 'Revimmune', 'Cycloblastine', 'Cicloxal', 'Ciclofosfamide', 'Cyclostin', '(-)-Cyclophosphamide', 'Cyclophosphamidum', 'Cycloblastin', 'Cyclophosphamide', 'Ledoxina', 'Cyclostine', 'Fludarabine', 'Cyclophospham', 'CP monohydrate', 'CTX', 'Cytophosphan', 'Cyclophosphane', 'Clafen', 'Genoxal', 'Syklofosfamid', 'Cyclophosphanum', 'Cytophosphane', 'Ciclofosfamida', 'Cyclophosphamid monohydrate', 'Fluradosa', 'CYCLO-cell', 'Mitoxan']",37,INTERVENTIONAL,['PHASE1'],PHASE1,,Platinum-Resistant Ovarian Carcinoma,['Platinum-Resistant Ovarian Carcinoma'],[],RECRUITING,,2022-05-05,2027-06-05,"[{'measure': 'Incidence of dose limiting toxicities (DLTs)', 'description': 'Rates and associated 90% Clopper and Pearson binomial confidence limits will be estimated.', 'timeFrame': 'Up to 28 days'}, {'measure': 'Incidence of adverse events', 'description': 'Adverse Events are graded using NCI CTCAE v.5.', 'timeFrame': 'Up to 1 year post treatment'}]","[{'measure': 'Persistence of CAR T cells', 'description': 'Defined as CAR T cells \\> 0.1% of total CD3 cells by flow-cytometry.', 'timeFrame': 'Up to 28 days post treatment'}, {'measure': 'Expansion of CAR T cells', 'description': 'Max log10 copies/ug of genomic DNA', 'timeFrame': 'Up to 1 year post treatment'}, {'measure': 'Response (iRECIST)', 'description': 'Assessed based on Immune-Related Response Criteria. Rates and associated 90% Clopper and Pearson binomial confidence limits will be estimated.', 'timeFrame': 'Up to 1 year post treatment'}, {'measure': 'Overall survival (OS)', 'description': 'Defined as death from all causes from first treatment date (either lymphodepletion or CAR T cell infusion, as applicable. Kaplan Meier methods will be used to estimate median OS, and graph the results.', 'timeFrame': 'Up to 1 year post treatment'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Defined as survival without biochemical (CA125) or radiographic evidence of disease progression or relapse from first treatment date (either lymphodepletion or CAR T cell infusion, as applicable). Rates and associated 90% Clopper and Pearson binomial confidence limits will be estimated.', 'timeFrame': 'Up to 6 months post treatment'}, {'measure': 'Serum cytokine profile', 'description': 'Serum cytokine profile before and after CAR T cell infusion: to assess potential cytokine release syndrome (CRS) toxicity and CAR T cell effector function, sequential serum samples will be analyzed for Th1/Th2 cytokines (e.g., IL-12, IFNgamma, TNFalpha, IL-10, IL-4, IL-5) by bead array', 'timeFrame': 'Up to 1 year post treatment'}]",8,18 Years,,FEMALE,False,City of Hope Medical Center,OTHER,1,33.0,ESTIMATED,2025-09-01T16:18:24.759867,v2_robust,True,True,False,False,True,
NCT01359787,Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD),"Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of Mapracorat Ointment in Three Concentrations Over Max. 4 Weeks in Subjects With Atopic Dermatitis (AD)",Mapracorat,"['Vehicle without active', 'Mapracorat']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Atopic Dermatitis,"['Atopic Dermatitis', 'Eczema']",[],COMPLETED,,2011-05,2011-09,"[{'measure': 'Eczema Area and Severity Index (EASI)', 'timeFrame': 'Over all study visits for up to 4 weeks'}]","[{'measure': 'Subjects´ assessment of pruritus', 'description': 'Subjects´ assessment of pruritus using a visual analog scale (VAS)', 'timeFrame': 'At baseline and after 4 weeks of treatment'}]",2,18 Years,65 Years,ALL,False,Bayer,INDUSTRY,0,197.0,ACTUAL,2025-09-01T16:18:24.760052,v2_robust,True,True,True,False,False,
NCT00274287,GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere,A Phase II Pilot Study Investigating the Efficacy and Activity of Single Agent GM-CSF (Leukine) Maintenance Approach in Androgen-independent Prostate Cancer (AIPC) Patients Responding to Taxotere Chemotherapy,GM CSF,"['GM CSF', 'Leukine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,['Prostate Cancer'],[],COMPLETED,,2006-01,2010-12,"[{'measure': 'Time to Disease Progression (TTP)', 'description': 'The primary end point of this study is to evaluate time to disease progression (TTP). TTP is defined as the time from starting taxotere until there is evidence of progressive disease (PD) as defined below (radiographically and/or biochemically). PD was defined as more than 20% in the sum of longest diameter of measurable lesions compared to baseline, and/or evidence of new lesions on imaging studies. Median TTP from GM-CSF administration and Median TTP from start of chemotherapy is being reported', 'timeFrame': 'up to 21 months'}]","[{'measure': 'Response Rate (PSA)', 'description': 'Biochemical PR (Partial Response) was defined as a PSA that decreases by 50% and maintains by at least 3 weeks by confirmatory measurement. Biochemical SD (stable disease) was defined as a PSA that was increased by less than 25% or decreased by less than 50% Biochemical PD (progressive disease) was defined as an increase of at least 25% confirmed 3 weeks after.', 'timeFrame': 'up to 21 months'}, {'measure': 'Response Rate (Radiographic)', 'description': 'PR was defined as more than 30% decrease in the sum of the longest diameter of measurable lesions compared to baseline. SD was defined when lesions did not meet criteria for PR or PD. PD was defined as more than 20% increase in the sum of the longest diameter of measurable lesions compared to baseline, and/or evidence of new lesions at imaging studies. The appearance of 2 or more new boney lesions on bone scan development of cord compression, and pathologic fractures constituted PD.', 'timeFrame': 'up to 21 months'}, {'measure': 'Median Overall Survival (OS)', 'timeFrame': 'up to 44 months'}, {'measure': 'Median Number of GM-CSF Cycles', 'timeFrame': 'up to 12 months'}]",5,18 Years,,MALE,True,"Oncology Specialists, S.C.",OTHER,1,15.0,ACTUAL,2025-09-01T16:18:24.760069,v2_robust,True,True,True,False,False,
NCT05710887,N2O for Acute Suicidality and Depression in the ED,Inhaled Nitrous Oxide for Acute Suicidality and Depression in the Emergency Department,Nitrous oxide gas for inhalation,"['Nitrous oxide gas for inhalation', 'N2O', 'Placebo', 'Laughing Gas', 'Nitrous Oxide', 'Sham', 'Nitrous']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Suicidal Ideation,"['Suicidal Ideation', 'Major Depressive Disorder', 'Treatment Resistant Depression']","['Suicidal', 'Depression', 'Nitrous', 'Antidepressant', 'MDD', 'TRD']",NOT_YET_RECRUITING,,2025-10-01,2027-10-01,"[{'measure': 'Treatment Response Based on Changes in Computerized Adaptive Testing Scores', 'description': ""Monitor changes in Computerized Adaptive Testing Mental Health (CAT-MH) scores relating to suicide, depression, and anxiety; to determine whether a single 45-minute inhalation of nitrous oxide vs placebo reduces symptoms.\n\nThe CAT-MH is a validated self-reporting electronic diagnostic that adaptively selects a small optimal set of items from a large bank of approximately 1,500 items, targeted to individuals current or historical level of severity and likelihood of 'suicide', 'depression', and 'anxiety'.\n\nGenerated scores include severity and liklihood percentile:\n\n* suicide = (%) low, intermediate, high\n* depression = (%) normal, mild, moderate, severe\n* anxiety = (%) normal, mild, moderate, severe"", 'timeFrame': 'Up to 24-hours from baseline'}]","[{'measure': 'Treatment Compliance', 'description': ""Evaluate compliance of an acutely suicidal population in an Emergency Department (ED) setting, to complete a single 45-minute inhalation of nitrous oxide vs placebo.\n\nDetermined by 'ability', 'inability', or 'refusal' to complete the entire 45-minute inhalation session (nitrous oxide vs placebo)."", 'timeFrame': 'Intervention completion, 45-minutes'}, {'measure': 'Treatment Response Correlation to Lifetime Predictors Associated with Suicide', 'description': ""Evaluate if lifetime predictors (e.g., personal/family history of suicide attempts or suicide, history of alcohol dependence, and worst lifetime suicidal ideation) of eventual suicide correlate with the acute reduction in symptom severity following treatment.\n\nLifetime predictors will be determined by medical and social history, and family history related to mental health.\n\nSymptom reduction is determined by changes in CAT-MH scores, over 24-hours from baseline.\n\nThe CAT-MH is a validated self-reporting electronic diagnostic that adaptively selects a small optimal set of items from a large bank of approximately 1,500 items, targeted to individuals current or historical level of severity and likelihood of 'suicide', 'depression', and 'anxiety'.\n\nGenerated scores include severity and liklihood percentile:\n\n* suicide = (%) low, intermediate, high\n* depression = (%) normal, mild, moderate, severe\n* anxiety = (%) normal, mild, moderate, severe"", 'timeFrame': 'Up to 24-hours from baseline'}, {'measure': 'Rapid Treatment Response', 'description': ""Evaluate any acute reduction in symptoms.\n\nBased on changes in CAT-MH scores (suicide, depression, anxiety) at 30-minutes to 1-hour following treatment. Study patients ability to complete self-administered CAT-MH following inhalation may impact time-point.\n\nThe CAT-MH is a validated self-reporting electronic diagnostic that adaptively selects a small optimal set of items from a large bank of approximately 1,500 items, targeted to individuals current or historical level of severity and likelihood of 'suicide', 'depression', and 'anxiety'.\n\nGenerated scores include severity and liklihood percentile:\n\n* suicide = (%) low, intermediate, high\n* depression = (%) normal, mild, moderate, severe\n* anxiety = (%) normal, mild, moderate, severe"", 'timeFrame': 'At 30-minutes to 1-hour from intervention conclusion'}, {'measure': 'Sustained Treatment Response', 'description': ""Evaluation of sustained response based on changes in CAT-MH scores at several time-points or until the patient is transferred or discharged from the ED.\n\nThe CAT-MH is a validated self-reporting electronic diagnostic that adaptively selects a small optimal set of items from a large bank of approximately 1,500 items, targeted to individuals current or historical level of severity and likelihood of 'suicide', 'depression', and 'anxiety'.\n\nGenerated scores include severity and liklihood percentile:\n\n* suicide = (%) low, intermediate, high\n* depression = (%) normal, mild, moderate, severe\n* anxiety = (%) normal, mild, moderate, severe"", 'timeFrame': 'Up to 24-hours from intervention conclusion'}]",5,18 Years,65 Years,ALL,False,University of Chicago,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:24.760162,v2_robust,True,True,False,False,False,
NCT00759187,Evaluate Clinical Research From Commerical Oral Care Products,Evaluate Clinical Research From Commerical Oral Care Products,Fluoride,"['Chlorhexidine Gluconate', 'Fluoride', 'sodium fluoride', 'triclosan', 'Triclosan/Fluoride', 'monofluorophosphate', 'Chlorhexidine Gluconate oral rinse']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Gingival Diseases,['Gingival Diseases'],[],COMPLETED,,2008-01,2008-04,"[{'measure': 'Dental Plaque Index', 'description': 'Scale 0 to 5 (zero= no plaque to 5 = plaque covering 2/3 or more of the crown of the tooth)', 'timeFrame': '4-Day'}]",[],1,18 Years,65 Years,ALL,True,Colgate Palmolive,INDUSTRY,0,25.0,ACTUAL,2025-09-01T16:18:24.760205,v2_robust,True,True,True,False,False,
NCT03860987,Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer,A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate Cancer,goserelin,"['18F-DCFPyL', 'Enzalutamide', 'Prednisone', 'Abiraterone', 'goserelin']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Castrate Sensitive Prostate Cancer,['Castrate Sensitive Prostate Cancer'],"['Imaging', 'Prostatectomy', 'Anti-androgen Therapy', '18F-DCFPyL-PSMA']",ACTIVE_NOT_RECRUITING,,2019-04-30,2028-08-01,"[{'measure': 'disease status', 'description': 'The primary endpoint will be the disease status after completion of treatment relative to PSMA-PET imaging findings at 2 months', 'timeFrame': '2 months'}]","[{'measure': 'pathological complete response rate', 'description': 'Evaluate the pathological complete response rate after neoadjuvant treatment with ADT, enzalutamide, and abiraterone/prednisone', 'timeFrame': '5 years'}]",2,18 Years,99 Years,MALE,False,National Cancer Institute (NCI),NIH,0,12.0,ACTUAL,2025-09-01T16:18:24.760213,v2_robust,True,True,False,False,False,
NCT05675787,Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia,Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma,Medroxyprogesterone acetate + Atorvastatin,['Medroxyprogesterone acetate + Atorvastatin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Atypical Endometrial Hyperplasia,"['Atypical Endometrial Hyperplasia', 'Endometrial Carcinoma Stage I']","['Endometrial Carcinoma', 'Atypical Endometrial Hyperplasia']",RECRUITING,,2023-01-06,2025-10-31,"[{'measure': 'Pathological cumulative complete response rate;', 'description': '3 to 4 months: From date of initial therapy until the date of CR or date of hysterectomy,', 'timeFrame': 'assessed up to 4 months'}]","[{'measure': 'Pathological cumulative complete response rate;', 'description': 'From 6 to 8 months; From date of initial therapy until the date of CR or date of hysterectomy,', 'timeFrame': 'assessed up to 8 months'}, {'measure': 'The lipid content (lipid droplet, cholesterol and triglyceride) in endometrial lesion tissue', 'description': 'The lipid content (lipid droplet, cholesterol and triglyceride) in endometrial lesion', 'timeFrame': 'assessed up to 4 months'}, {'measure': 'Overall complete response rate', 'description': 'Pathological response duration', 'timeFrame': 'up to 2 years'}, {'measure': 'Pathological response rate classified by different blood lipid level', 'description': 'Pathological response rate classified by different blood lipid level', 'timeFrame': 'up to 2 years;'}, {'measure': 'Relapse rate', 'description': 'Relapse rate', 'timeFrame': 'up to 15 months after the end of treatment'}, {'measure': 'Pregnancy rate', 'description': 'Pregnancy rate', 'timeFrame': 'up to 15 months after the end of treatment'}, {'measure': 'Toxic Side Effect', 'description': 'Toxicity evaluation according to CTCAE 5.0 version.', 'timeFrame': 'up to 3 months after the end of treatment'}]",8,17 Years,45 Years,FEMALE,False,Peking University People's Hospital,OTHER,0,82.0,ESTIMATED,2025-09-01T16:18:24.760223,v2_robust,True,True,False,False,False,
NCT01615887,Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis,Effects of Lisdexamfetamine on Bradyphrenia in Multiple Sclerosis,lisdexamfetamine sulfate,"['lisdexamfetamine sulfate', 'Vyvanse', 'placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Sclerosis,['Multiple Sclerosis'],[],COMPLETED,,2009-11,2011-08,"[{'measure': 'Symbol Digit Modalities Test (SDMT)', 'description': 'The Symbol Digit Modalities Test (SDMT) presents a series of nine symbols, each paired with a single digit in a key at the top of a stimulus page. Subjects voice the number associated with each symbol as rapidly as possible. The examiner records the total amount of responses completed. The task continues for 90 seconds with the research staff recording responses. The SDMT score ranges from 0 to 110, with higher values representing a better outcome in cognitive processing speed.', 'timeFrame': '8 weeks'}, {'measure': 'Paced Auditory Serial Audition Test (PASAT)', 'description': 'The PASAT is a test requiring attention and vigilance. In this test, the patient listens to a tape recording of digits presented one at a time. The task for the patient is to add each number to the one immediately preceding it. For example, the recording might present the numbers 1, 7, 5, 4. The patient adds the first two numbers (1 + 7) and responds with the number 8. The patient then adds the second two numbers (7 + 5) and responds with the number 12. The patient then adds the third two numbers (5 + 4) and responds with the number 9. This continues for a total of 61 numbers presented in a random order. The patients score is the total number correct out of 60 (Stebbins et al. 2007). The PASAT score ranges from 0 to 60, with higher values representing a better outcome in cognitive processing speed.', 'timeFrame': '8 Weeks'}]","[{'measure': 'California Verbal Learning Test - 2nd Edition', 'description': 'The California Verbal Learning Test Second Edition (CVLT2) begins with the examiner reading a list of 16 words. Patients listen to the list and report as many of the items as possible. After recall is recorded, the entire list is read again. Altogether, there are five learning trials, the total correct of all trials is summed together creating a total verbal learning score. The CVLT-II total verbal learning score ranges from 0 to 80, with higher values representing a better outcome in verbal learning/memory.', 'timeFrame': '8 weeks'}, {'measure': 'Brief Visuospatial Memory Test - Revised', 'description': 'The Brief Visuospatial Memory Test Revised (BVMTR) presents six abstract designs for 10 seconds. The display is removed from view and patients render the stimuli via pencil on paper manual responses. There are three learning trials in which patients attempt to replicate the stimuli previously presented. Patients are given a score for all three trials based on correct location and accuracy of the replicated stimuli. Each trial can be awarded up to 12 points, the sum of total points awarded across all three trials is the total learning score. The BVMT-R total learning score ranges from 0 to 36, with higher values representing a better outcome in visuospatial learning/memory.', 'timeFrame': '8 weeks'}, {'measure': 'Vitals', 'description': 'Heart rate', 'timeFrame': '8 weeks'}, {'measure': 'Vitals (Diastolic Blood Pressure)', 'description': 'diastolic blood pressure', 'timeFrame': '8 weeks'}, {'measure': 'Vitals (Systolic Blood Pressure)', 'description': 'systolic blood pressure', 'timeFrame': '8 weeks'}]",7,18 Years,55 Years,ALL,False,State University of New York at Buffalo,OTHER,0,63.0,ACTUAL,2025-09-01T16:18:24.760307,v2_robust,True,True,True,False,False,
NCT04815187,Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease,Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease,Montelukast,"['Montelukast', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Meniere Disease,"['Meniere Disease', 'Allergic Rhinitis', 'Vertigo']",[],ACTIVE_NOT_RECRUITING,,2021-06-07,2025-12-31,"[{'measure': 'Percentage of Patients with AAO-HNS Vertigo Control Class A or B', 'description': 'Percentage of patients in each group with an AAO-HNS Vertigo Control Class A or B result (from daily diary count of number of attacks)', 'timeFrame': '1 month after treatment initiation'}, {'measure': 'Percentage of Patients with AAO-HNS Vertigo Control Class A or B', 'description': 'Percentage of patients in each group with an AAO-HNS Vertigo Control Class A or B result (from daily diary count of number of attacks)', 'timeFrame': '3 months after treatment initiation'}, {'measure': 'Percentage of Patients with AAO-HNS Vertigo Control Class A or B', 'description': 'Percentage of patients in each group with an AAO-HNS Vertigo Control Class A or B result (from daily diary count of number of attacks)', 'timeFrame': '6 months after treatment initiation'}, {'measure': 'Difference in Dizziness Between Treatment Arms', 'description': 'Difference for each group in AAO-HNS dizziness functional disability scale from pre-treatment to 3 months after treatment initiation. A score improvement of 1 point on this 6-point scale will be considered significant improvement.', 'timeFrame': '3 months after treatment initiation'}, {'measure': 'Percentage of Subjects Experiencing Significant Hearing Fluctuation', 'description': 'Percentage of subjects in each treatment arm demonstrating clinically significant change in air conduction thresholds at \\> 2 frequencies at 3 months (\\> 10 dB change from baseline) or WDS (\\> 15% change from baseline) compared to the worst audiogram and WDS in the 6 months prior to treatment initiation.', 'timeFrame': '3 months after treatment initiation'}]",[],5,18 Years,,ALL,False,House Ear Institute,OTHER,1,39.0,ACTUAL,2025-09-01T16:18:24.760338,v2_robust,True,True,False,False,False,
NCT00252187,Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure,Cardiac Hormone Replacement With BNP in Heart Failure: A Novel Therapeutic Strategy,B-type Natriuretic Peptide (BNP),"['Nesiritide', 'B-type Natriuretic Peptide (BNP)']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Congestive Heart Failure,"['Congestive Heart Failure', 'Cardiomyopathy']","['Heart failure', 'Natriuretic peptides', 'B-type natriuretic peptide', 'Kidney', 'Nesiritide', 'Natrecor', 'CHF']",COMPLETED,,2000-01,2010-06,"[{'measure': 'Change in Left Ventricular (LV) Volume Index at 8 Weeks', 'description': 'LV volume was measured for systolic volume and diastolic volume using a cardiac Magnetic Resonance Imaging (MRI) scan. All cardiac MRI images were reviewed by an independent cardiologist in a blinded fashion.', 'timeFrame': 'Baseline and 8 weeks'}, {'measure': 'Change in Left Ventricular (LV) Mass Index at 8 Weeks', 'timeFrame': 'Baseline and 8 weeks'}]","[{'measure': 'Change in Left Ventricular (LV) Filling Pressure at 8 Weeks', 'description': ""Filling pressure determined by ratio of E/e' \\[Echocardiograph Doppler mitral inflow velocity (E) to mitral annulus tissue Doppler velocity (e') ratio\\]"", 'timeFrame': 'Baseline and 8 weeks'}, {'measure': 'Change in Plasma Renin Activity at 8 Weeks', 'description': 'Plasma renin is synthesized within circulation or at tissue sites, causing vasoconstriction or vasodilation.', 'timeFrame': 'Baseline and 8 weeks'}, {'measure': 'Change in Renal Function as Measured by Glomerular Filtration Rate (GFR) at 8 Weeks', 'description': 'Kidney function was measured by GFR determined by iothalamate clearance. Glomerular filtration rate describes the flow rate of filtered fluid through the kidney measured in milliliters per minute per 1.73 m\\^2 of body-surface area. A lower GFR means the kidney is not filtering normally.', 'timeFrame': 'Baseline and 8 weeks'}, {'measure': 'Change in Heart Rate at 8 Weeks', 'description': 'Heart rate was measured when MRI was performed', 'timeFrame': 'Baseline and 8 weeks'}, {'measure': 'Change in Blood Pressure at 8 Weeks', 'description': 'Blood pressure was measured during the MRI', 'timeFrame': 'Baseline and 8 weeks'}, {'measure': 'Change in Left Ventricular Ejection Fraction at 8 Weeks', 'description': 'Left Ventricle Ejection Fraction (LVEF)is a clinical parameter used by cardiologists to describe how well the heart is pumping. LVEF is a measure of the amount of blood pumped out of the lower chamber (ventricle) of the heart during a heartbeat, measured by Magnetic Resonance Imaging (MRI).', 'timeFrame': 'Baseline and 8 weeks'}]",8,18 Years,,ALL,False,Horng Chen,OTHER,4,45.0,ACTUAL,2025-09-01T16:18:24.760358,v2_robust,True,True,True,False,False,
NCT00004787,Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes,,filgrastim,['filgrastim'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Shwachman Syndrome,"['Shwachman Syndrome', ""Fanconi's Anemia"", 'Dyskeratosis Congenita', 'Thrombocytopenia']","[""Fanconi's anemia"", 'Shwachman syndrome', 'aplastic anemia', 'dermatologic disorders', 'dyskeratosis congenita', 'hematologic disorders', 'rare disease', 'thrombocytopenia']",COMPLETED,,1994-12,,[],[],0,0 Years,,ALL,False,National Center for Research Resources (NCRR),NIH,1,20.0,,2025-09-01T16:18:24.760383,v2_robust,True,True,True,False,False,
NCT04798287,Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints,Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints,Tofacitinib,"['TNF Inhibitor', 'golimumab', 'infliximab', 'certolizumab pegol', 'adalimumab', 'Tofacitinib', 'etanercept']",7,OBSERVATIONAL,[],,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],[],COMPLETED,,2021-03-10,2022-05-16,"[{'measure': 'Time to second outpatient or inpatient diagnosis of any cancer (excluding NMSC and any carcinoma in situ diagnosis)', 'timeFrame': 'Through study time period (2012-2020)'}]","[{'measure': 'Time to second outpatient or inpatient diagnosis of lung cancer (excluding any carcinoma in situ diagnosis)', 'timeFrame': 'Through study time period (2012-2020)'}, {'measure': 'Time to second outpatient or inpatient diagnosis of colorectal cancer (excluding any carcinoma in situ diagnosis)', 'timeFrame': 'Through study time period (2012-2020)'}, {'measure': 'Time to second outpatient or inpatient diagnosis of breast cancer (excluding any carcinoma in situ diagnosis)', 'timeFrame': 'Through study time period (2012-2020)'}, {'measure': 'Time to second outpatient or inpatient diagnosis of prostate cancer (excluding any carcinoma in situ diagnosis)', 'timeFrame': 'Through study time period (2012-2020)'}, {'measure': 'Time to second outpatient or inpatient diagnosis of lymphatic/hematopoietic tissue cancers', 'timeFrame': 'Through study time period (2012-2020)'}, {'measure': 'Time to second outpatient or inpatient diagnosis of lymphoma', 'timeFrame': 'Through study time period (2012-2020)'}, {'measure': 'Time to second outpatient or inpatient diagnosis of leukemia', 'timeFrame': 'Through study time period (2012-2020)'}, {'measure': 'Time to first procedure code occurring within 60 days of an outpatient or inpatient diagnosis of NMSC', 'timeFrame': 'Through study time period (2012-2020)'}]",9,18 Years,,ALL,False,Brigham and Women's Hospital,OTHER,0,105711.0,ACTUAL,2025-09-01T16:18:24.760390,v2_robust,False,True,True,False,False,
NCT06616987,Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer,"A Multicenter, Open-label, Single-arm, Clinical Trial to Evaluate the Preventive Effect of Pegylated G-CSF (PG) on Neutropenia in Patients With Metastatic Triple-negative Breast Cancer (mTNBC) Receiving Sacituzumab Govitecan (SG)",Sacituzumab Govitecan with pegfilgrastim,['Sacituzumab Govitecan with pegfilgrastim'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer Metastatic,['Breast Cancer Metastatic'],[],RECRUITING,,2025-07-03,2027-12-31,"[{'measure': 'To evaluate the incidence of grade ≥3 neutropenia', 'description': 'Incidence of grade ≥3 neutropenia after 2 cycles of treatment', 'timeFrame': 'At the end of Cycle 2 (each cycle is 21 days)'}]","[{'measure': 'Safety and tolerability of the study regimen', 'description': 'Incidence of AEs', 'timeFrame': 'Up to 5 years'}, {'measure': 'Objective Response Rate', 'description': 'The percentage of complete response (CR) or partial response (PR) that is confirmed at least 4 weeks after initial documentation of response as assessed by investigator per RECIST v1.1', 'timeFrame': 'Up to 5 years'}, {'measure': 'Progression Free Survival', 'timeFrame': 'Up to 5 years'}, {'measure': 'Overall Survival', 'description': 'The time until defined by date of all-cause mortality from the date of 1st infusion The time until defined by date of all-cause mortality from the date of 1st infusion', 'timeFrame': 'Up to 5 years'}]",5,19 Years,,ALL,False,Yeon Hee Park,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:24.760429,v2_robust,True,True,False,False,True,
NCT06060587,Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone,A Randomized Phase II Study of ADT + Abiraterone Versus ADT + Docetaxel + Abiraterone in Patients With Low Volume Metastatic Hormone Sensitive Prostate Cancer,Docetaxel,"['Docetaxel', 'Abiraterone', 'ADT']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,['Prostate Cancer'],[],ACTIVE_NOT_RECRUITING,,2023-10-19,2030-12-22,"[{'measure': 'Assess Progression Free Survival (PFS)', 'description': 'Calculated the progression-free survival time as the time that elapses between the date of randomization and the day of first documented disease progression (per RECIST 1.1 or PCWG3) or death from any cause for all evaluable patients. PFS will be calculated based on the Kaplan-Meier estimates of PFS for each treatment arm (abiraterone+docetaxel+ADT compared to abiraterone+ADT).', 'timeFrame': 'Up to 1 year after completion of study treatment'}]","[{'measure': 'Assess Overall Survival (OS)', 'description': 'To assess the OS, this is defined as the time from date of randomization until time to death from any cause for all evaluable patients. OS will be calculated based on the Kaplan-Meier estimates of OS.', 'timeFrame': 'Up to 1 year after completion of study treatment'}, {'measure': 'Assess PSA Response Rate', 'description': 'The PSA level drawn 6 months (+/- 30 days) after randomization will be used to assess PSA response.', 'timeFrame': '6 months (+/- 30 days) after randomization'}, {'measure': 'Assessment of Time to castration resistant prostate cancer', 'description': 'This endpoint will calculate the time to the development of castration resistance from date of randomization to the time of PSA progression with serum testosterone level being at ≤ 50 ng/ml', 'timeFrame': 'Up to 1 year after completion of study treatment'}, {'measure': 'Assess time to compare for any difference in efficacy between arms', 'description': 'This endpoint will calculate the time to the initiation of the subsequent anti-neoplastic therapy for each treatment arm from the date of randomization to the date of initiation of the next (non-study) anti-neoplastic agent for prostate cancer.', 'timeFrame': 'Up to 1 year after completion of study treatment'}]",5,18 Years,,MALE,False,Northwestern University,OTHER,1,150.0,ESTIMATED,2025-09-01T16:18:24.760443,v2_robust,True,True,False,False,False,
NCT01126593,Post-Op Rotator Cuff Pain Study With Subacromial Bupivacaine Infusion,Efficacy of Continuous Subacromial Bupivacaine Infusion for Postoperative Analgesia After Arthroscopic Rotator Cuff Repair.,0.5% bupivacaine,"['0.5% bupivacaine', 'Saline', 'Normal Saline', 'Marcaine']",4,INTERVENTIONAL,['NA'],,,Rotator Cuff Tear,['Rotator Cuff Tear'],[],COMPLETED,,2008-12,2010-02,"[{'measure': 'Pain Scores', 'description': 'Pain was measured via Visual Analong Scale in measurement (0-100mm).', 'timeFrame': 'O hour, 1, 2, 3, 4, 5, 6, 12 and 72 hours.'}]",[],1,18 Years,90 Years,ALL,False,"Orlando Health, Inc.",OTHER,0,96.0,ACTUAL,2025-09-01T16:18:24.760510,v2_robust,True,True,True,False,False,
NCT02963493,A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma,"A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody",Melphalan flufenamide (Melflufen),"['Melphalan flufenamide (Melflufen)', 'Pepaxto', 'Dexamethasone']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma,['Multiple Myeloma'],['relapsed refractory multiple myeloma'],COMPLETED,,2016-12-28,2021-11-16,"[{'measure': 'Overall Response Rate (ORR)', 'description': 'The overall response rate (ORR) will be estimated as the percentage of patients who achieve sCR, CR, VGPR, or PR as their best response as assessed by the investigator. Response assessed by IMWG (International myeloma working group) criteria sCR-stringent complete response: CR plus Normal FLC (free light chain) ratio and absence of clonal cells in BM CR-complete response: Negative immunofixation in serum/urine; Disappearance of soft tissue plasmacytomas; \\<5% plasma cells in BM; If only FLC disease, normal FLC ratio (0.26-1.65) VGPR-very good partial response: Serum/urine M-protein detectable by immunofixation but not electrophoresis or ≥90% reduction in serum M-protein and urine M-protein \\<100 mg/24 h; If only FLC disease, \\>90% decrease in the difference between involved and uninvolved FLC levels PR-partial response: 50% reduction of serum M-protein and soft tissue plasmacytomas, ≥90% reduction in urinary M-protein or to \\<200 mg/24 h; other special cases if M-protein unmeasurable', 'timeFrame': 'Patients were followed until documented progression, unacceptable toxicity, patient/physician decision to withdraw or date of death, whichever came first. Longest time to response in study recorded as 15.3 months. Longest time on treatment 35 months.'}]","[{'measure': 'Progression Free Survival (PFS)', 'description': 'Time from start of treatment to either progression or death, whichever comes first as assessed by the investigator using IMWG criteria. Progression of disease is defined by an increase of 25% from the lowest response for either of Serum M-component (absolute increase of ≥ 0.5 g/dL) or Urine M-component (absolute increase of ≥200 mg/ 24h); In patients without measurable M-protein a 25% increase in the difference between involved and uninvolved FLC (free light chain) levels (absolute increase must be \\>10 mg/dL); If unmeasurable FLC levels, a 25% increase in bone marrow plasma cell percentage (absolute percentage must be \\>10%); New bone or soft tissue plasmacytomas or definite increase in existing ones; Development of hypercalcemia (corrected serum calcium \\>11.5 mg/dL) that can be attributed solely to the plasma cell proliferative disorder', 'timeFrame': 'Patients were followed until documented progression, unacceptable toxicity, patient/physician decision to withdraw or date of death, whichever came first. Longest follow-up time for PFS recorded as 37.2 months at study end.'}, {'measure': 'Duration of Response', 'description': 'Time from first response to progression based on investigator assessment. See definitions of response and progression in ORR and PFS outcomes.', 'timeFrame': 'From date of response until the date of first documented progression or date of death from any cause, whichever came first. Longest time of response recorded as 36.2 months at study end.'}, {'measure': 'Overall Survival', 'description': 'Time from start of treatment to death', 'timeFrame': 'From date of first dose of study medication until the date of death from any cause, assessed up to 24 months after study drug discontinuation.'}, {'measure': 'Functional Status and Well-being: EORTC QLQ-C30', 'description': 'Change from baseline in Patient Reported Outcome questionnaire EORTC QLQ-C30. The EORTC QLQ-C30 includes 30 items resulting in 5 functional scales, 1 Global Health Status scale, 3 symptom scales, and 6 single items. The recall period is 1 week (the past week). The scales are transformed to a 0 (worst) to 100 (best) scale. The QLQ-C30 summary score is calculated as the mean of the combined 13 QLQ-C30 scale and item scores (excluding global QoL and financial impact), with a higher score indicating a better HRQoL. If at least 50% of the items from the scale had been answered, the missing items were assumed to have values equal to the average of those items which were present for that respondent.', 'timeFrame': 'To be assessed prior to dosing at Cycle 1, 2, 4, 6, 8, and End of Treatment. 23 patients were ongoing for QoL assessments at data cutoff. QoL was added in Protocol Amendment 4 beginning in Oct. 2018.'}, {'measure': 'Functional Status and Well-being: EQ-5D-3L', 'description': 'Change from baseline in Patient Reported Outcome questionnaire EQ-5D-3L. The EQ-5D-3L questionnaire converts 5 dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression of patient-reported, current-day health status into a ""health utility"" score. For the EQ-5D-3L questionnaire, each dimension is scored on an ordinal scale with 3 available levels of response and scores ranging from 1 to 3, ""no problems,"" ""some problems,"" and ""extreme problems,"" respectively. The EQ VAS scores rates ""health today"" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). No imputation of missing items or composite scores were done. The scores for the 5 dimensions are used to compute a single utility score ranging from zero (0.0) to 1 (1.0) representing the general health status of the individual.', 'timeFrame': 'To be assessed prior to dosing at Cycle 1, 2, 4, 6, 8, and End of Treatment. 23 patients were ongoing for QoL assessments at data cutoff. QoL was added in Protocol Amendment 4 beginning in Oct. 2018.'}, {'measure': 'Clinical Benefit Rate', 'description': 'The clinical benefit rate (CBR) will be estimated as the percentage of patients who achieve sCR, CR, VGPR, PR, or MR as their best response as assessed by the investigator. See Primary Outcome (ORR) for definitions of response categories.', 'timeFrame': 'Patients were followed until documented progression, unacceptable toxicity, patient/physician decision to withdraw or date of death, whichever came first. Longest time on study treatment recorded as 35.0 months at study end.'}, {'measure': 'Time to Response', 'description': 'Duration from start of treatment to the first occurrence of a confirmed response of PR or better as assessed by the investigator. See definitions of response in Primary Outcome (ORR).', 'timeFrame': 'From start of treatment to first confirmed response. Longest time to response in study recorded as 15.3 months.'}, {'measure': 'Time to Progression', 'description': 'Duration from start of treatment to first evidence of disease progression as assessed by the investigator. See definitions of response and progression in ORR and PFS outcomes.', 'timeFrame': 'From start of treatment to first evidence of disease progression or date of death from any cause, whichever came first. Longest time to progression recorded was 37.2 months at study end.'}]",9,18 Years,,ALL,False,Oncopeptides AB,INDUSTRY,1,157.0,ACTUAL,2025-09-01T16:18:24.760618,v2_robust,True,True,True,False,False,
NCT00389493,Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder,Maximizing Treatment Outcome in OCD,Risperidone,"['Risperidone', 'Risperdal', 'PBO', 'Placebo']",4,INTERVENTIONAL,['NA'],,,Obsessive-Compulsive Disorder,['Obsessive-Compulsive Disorder'],"['OCD', 'Augmentation', 'Antipsychotics', 'Cognitive-Behavioral Therapy']",COMPLETED,,2006-10,2012-12,"[{'measure': 'Score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)', 'description': 'Y-BOCS ranges from 0-40, with 0 meaning no symptoms and higher numbers meaning greater symptom severity', 'timeFrame': 'Week 0 and Week 8'}]","[{'measure': 'Social Adjustment Scale-SR', 'description': 'SAS-SR yields a mean score between 1 and 5; the higher the score, the more severe the social adjustment problems', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form', 'description': 'QLESQ ranges from 14-70, with higher scores meaning more enjoyment and satisfaction with quality of life', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Hamilton Depression Rating Scale (Ham-D)', 'description': 'Ham-D ranges from 0=no symptoms to 52 with higher numbers indicating more severe depression', 'timeFrame': 'Week 0 and Week 8'}, {'measure': 'Brown Assessment of Beliefs (BABS)', 'description': 'Scale ranges from 0 to 24 where 0 is ""beliefs are false"" and 24 is ""convinced beliefs = reality""', 'timeFrame': 'Week 0 and Week 8'}]",5,18 Years,70 Years,ALL,False,New York State Psychiatric Institute,OTHER,1,100.0,ACTUAL,2025-09-01T16:18:24.760711,v2_robust,True,True,True,False,False,
NCT02921893,"Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome","Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome",Dexamethasone,"['CDC 501', 'TaperDex', 'Dexa-sine', 'Alin', 'Deronil', 'Desameton', 'Dexameth', 'Dexa-Rhinosan', 'Fluorodelta', 'ZoDex', 'Dinormon', 'Dexacortin', 'Dexinoral', 'Hexadrol', 'Mymethasone', 'Dexalocal', 'Cortidexason', 'Dexafluorene', 'Baycadron', 'Lenalidomide', 'Lokalison-F', 'Millicorten', 'CC5013', 'Auxiloson', 'Methylfluorprednisolone', 'Desamethasone', 'Alin Depot', 'Aknichthol Dexa', 'Dexamethasone Intensol', 'Hexadecadrol', 'Ixazomib Citrate', 'Orgadrone', 'Decacort', 'Dexa-Scheroson', 'Decalix', 'Dexapos', 'Baycuten N', 'Gammacorten', 'Revlimid', 'Auricularum', 'Decadron', 'Dexafarma', 'Dexamecortin', 'Dexone', 'Visumetazone', 'Baycuten', 'Dxevo', 'Anemul mono', 'Dexa-Mamallet', 'Fortecortin', 'MLN-9708', 'MLN9708', 'CC-5013', 'Cortisumman', 'Alin Oftalmico', 'Aacidexam', 'Dexamethasone', 'Hemady', 'Ninlaro', 'Alba-Dex', 'Decadrol', 'Decasone R.p.', 'Amplidermis', 'Spersadex', 'Dexacortal', 'Dectancyl', 'Loverine', 'Dexamethasonum', 'Decadron DP', 'Dexamonozon', 'Dekacort', 'Decameth', 'Deltafluorene', 'Adexone']",74,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Plasmacytoma,"['Plasmacytoma', 'POEMS Syndrome']",[],COMPLETED,,2016-10-31,2024-05-13,"[{'measure': 'Rate of normalization of VEGF defined as VEGF value decreasing to below upper limit of normal (86 pg/mL)', 'description': 'In each group, the rate of normalization of VEGF by 3 months (post-3 cycles) will be examined along with the prognostic factors for patients accrued to this study. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Ninety-five percent binomial confidence intervals for the true success proportion will be calculated.', 'timeFrame': 'Up to 3 months'}]","[{'measure': 'Hematologic response rate', 'description': 'Hematologic response rate after 3 cycles of therapy (or 3 months after registration) will be estimated by the number of hematologic responses (partial response, very good partial response, or complete response) observed within 3 months of registration divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true hematologic response rate after 3 cycles of therapy (or 3 months after registration) will be calculated.', 'timeFrame': 'Up to 3 months'}, {'measure': 'Hematologic response rate', 'description': 'Hematologic response rate after 13 cycles of therapy (or 12 months) will be evaluated. Exact binomial 95% confidence intervals for the true rates at 12 months will be calculated.', 'timeFrame': 'Up to 12 months'}, {'measure': 'Normalization of VEGF', 'description': 'Normalization of VEGF after 13 cycles of therapy (or 12 months after registration) will be evaluated. Exact binomial 95% confidence intervals for the true rates at 12 months will be calculated.', 'timeFrame': 'Up to 12 months'}, {'measure': 'Survival time', 'description': 'The distribution of survival time will be estimated using the method of Kaplan-Meier.', 'timeFrame': 'Time from registration to death due to any cause, assessed up to 3 years'}, {'measure': 'Incidence of adverse events evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0', 'description': 'The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.', 'timeFrame': 'Up to 3 years'}]",6,18 Years,,ALL,False,Mayo Clinic,OTHER,0,21.0,ACTUAL,2025-09-01T16:18:24.760735,v2_robust,True,True,True,False,True,
NCT05872893,Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone,Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone. Can This Modality Improve the Antiemetic Effect,Ondansetron,"['Ondansetron', 'Dexamethasone']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Pediatric Cancer,['Pediatric Cancer'],[],UNKNOWN,,2023-06-27,2025-01,"[{'measure': 'Mean nausea score per patient', 'description': 'Mean nausea score will be calculated as a weighted average of the Visual Analogue Scale (VAS) or Baxter Animated Retching Faces (BARF) scale observations during each cycle of chemotherapy.', 'timeFrame': '20 months'}]","[{'measure': 'Correlation between mean nausea score and demographic variables', 'timeFrame': '20 months'}, {'measure': 'Correlation between mean nausea score and disease characteristics', 'timeFrame': '20 months'}]",3,,18 Years,ALL,False,Immune Oncology Research Institute,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:24.760761,v2_robust,True,True,False,False,False,
NCT03866993,A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer,"A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Paclitaxel vs Placebo Combined With Carboplatin and Paclitaxel as First-line Therapy in Patients With Metastatic Squamous Non-small Cell Lung Cancer",Paclitaxel,"['Paclitaxel', 'Carboplatin', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Lung Cancer Non-small Cell Stage IV,"['Lung Cancer Non-small Cell Stage IV', 'Squamous Cell Lung Cancer']","['immuno-oncology', 'NSCLC', 'Anti-PD-1 Antibody', 'immunotherapy']",COMPLETED,,2018-12-20,2022-01-14,"[{'measure': 'Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1', 'description': 'PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by IRRC or death due to any cause (whichever occurs first).', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1', 'description': 'PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by IRRC or death due to any cause (whichever occurs first).', 'timeFrame': 'Up to approximately 2 years'}]","[{'measure': 'Overall survival (OS) in ITT population', 'description': 'OS is the time from the date of randomization to death due to any cause.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Overall survival (OS) in PD-L1-selected population', 'description': 'OS is the time from the date of randomization to death due to any cause.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'PFS assessed by the investigator in accordance with RECIST v1.1', 'description': 'PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the investigator or death due to any cause (whichever occurs first).', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'ORR is the proportion of subjects with CR or PR , based on RECIST v1.1.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Duration of response (DoR)', 'description': 'DoR is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Disease control rate (DCR)', 'description': 'DCR is defined as the proportion of subjects with CR, PR, or SD, based on RECIST v1.1.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Incidence and severity of treatment-emergent adverse events (TEAEs)', 'description': 'An adverse event (AE) is any untoward medical occurrence or the deterioration of existing medical event in a clinical study subject administered an investigational drug, which does not necessarily have an unequivocal causal relationship with the investigational product.', 'timeFrame': 'From the time of informed consent signed through 90 days after last dose of AK105'}, {'measure': 'Observed concentrations of AK105', 'description': 'The endpoints for assessment of PK of AK105 include serum concentrations of AK105 at different timepoints after AK105 administration.', 'timeFrame': 'From first dose of AK105 through 90 days after last dose of AK105'}, {'measure': 'Number of subjects who develop detectable anti-drug antibodies (ADAs)', 'description': 'The immunogenicity of AK105 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).', 'timeFrame': 'From first dose of AK105 through 90 days after last dose of AK105'}]",11,18 Years,75 Years,ALL,False,Akeso,INDUSTRY,1,350.0,ACTUAL,2025-09-01T16:18:24.760772,v2_robust,True,True,True,False,True,
NCT01270893,Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST),A Two-Arm Study of Preoperative Nilotinib for Patients With Resectable or Potentially Resectable Gastrointestinal Stromal Tumor (GIST),Nilotinib,"['AMN107', 'Tasigna', 'Nilotinib']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastrointestinal Cancer,['Gastrointestinal Cancer'],"['Gastrointestinal stromal tumor', 'GIST', 'Nilotinib', 'AMN107', 'Tasigna']",WITHDRAWN,No particapnt recruitment.,2011-01,,"[{'measure': 'Percent of Apoptotic Tumor Cells Pre- and 7 Days Post Nilotinib Treatment', 'description': 'Changes assessed by tumor cell apoptosis measured by Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay.', 'timeFrame': 'Pre treatment assessment to 7 days post treatment.'}]",[],1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:24.760801,v2_robust,True,True,False,True,False,No particapnt recruitment.
NCT05976893,Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer,Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer,Evolocumab,"['Statin', 'Repatha', 'Evolocumab']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,ASCVD,"['ASCVD', 'Atherosclerotic Cardiovascular Disease', 'Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor', 'Cancer']","['ASCVD', 'cancer', 'PCSK9']",NOT_YET_RECRUITING,,2023-08-01,2025-12-31,"[{'measure': 'Major cardiovascular adverse events', 'description': 'Major cardiovascular adverse events include cardiovascular death, recurrent unstable angina, myocardial infarction, stroke, and coronary revascularization', 'timeFrame': 'From date of randomization until the date of first documented endpoint or date of completion of follow-up, whichever came first, assessed up to 48 weeks'}]","[{'measure': 'All cause death', 'description': 'All cause death', 'timeFrame': 'From date of randomization until the date of first documented endpoint or date of completion of follow-up, whichever came first, assessed up to 48 weeks'}, {'measure': 'Composite end points', 'description': 'Composite end points include cardiogenic shock, cardiac arrest, malignant arrhythmia, heart failure, Non-coronary revascularization', 'timeFrame': 'From date of randomization until the date of first documented endpoint or date of completion of follow-up, whichever came first, assessed up to 48 weeks'}, {'measure': 'The compliance rate of lipid control', 'description': 'Main indicator: LDL-C decreased to below 1.4 mmol/L and decreased by more than 50% from baseline; secondary indicator: non HDL-C\\<2.2 mmol/L;', 'timeFrame': 'From date of randomization until the date of first documented endpoint or date of completion of follow-up, whichever came first, assessed up to 48 weeks'}, {'measure': 'The changes of carotid plaque', 'description': 'By carotid ultrasound', 'timeFrame': 'From date of randomization until the date of first documented endpoint or date of completion of follow-up, whichever came first, assessed up to 48 weeks'}]",5,18 Years,80 Years,ALL,False,Xiang Xie,OTHER,1,620.0,ESTIMATED,2025-09-01T16:18:24.760831,v2_robust,True,True,False,False,True,
NCT00304421,Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD,Comparison of the Nighttime Effects of Rabeprazole 20 mg to Pantoprazole 40 mg on Standard Meal Stimulated Gastric Acid Secretion and Intragastric pH in H. Pylori Negative Volunteer Subjects With GERD,rabeprazole,"['pantoprazole', 'rabeprazole']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Gastroesophageal Reflux Disease,['Gastroesophageal Reflux Disease'],"['Gastroesophageal Reflux Disease', 'Proton Pump Inhibitors', 'Gastric pH', 'Gastric Acid Secretion']",COMPLETED,,2004-01,2007-09,"[{'measure': 'To test the hypothesis that during the hours 2000 through 0800 following a single dose administration of medication, the median change from baseline values in gastric acid secretion with 20 mg rabeprazole is significantly less than 40 mg pantoprazole'}]",[],1,18 Years,65 Years,ALL,False,VA Greater Los Angeles Healthcare System,FED,2,23.0,ESTIMATED,2025-09-01T16:18:24.760915,v2_robust,True,True,True,False,False,
NCT04864821,Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor,Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor,Targeting CD276 CAR T cells,['Targeting CD276 CAR T cells'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Osteosarcoma,"['Osteosarcoma', 'Neuroblastoma', 'Gastric Cancer', 'Lung Cancer']",[],UNKNOWN,,2021-05-14,2023-05-14,"[{'measure': 'AE', 'description': 'adverse event', 'timeFrame': '2 years after treatment'}, {'measure': 'ORR', 'description': 'Objective remission rate', 'timeFrame': '12 weeks after treatment'}, {'measure': 'Cmax', 'description': 'The highest concentration of CAR-T cells in peripheral blood after infusion', 'timeFrame': '2 years after treatment'}]",[],3,1 Year,70 Years,ALL,False,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",INDUSTRY,1,24.0,ESTIMATED,2025-09-01T16:18:24.761110,v2_robust,True,True,False,False,True,
NCT04097821,Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients,"A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients",Ruxolitinib,"['Ruxolitinib', 'Sabatolimab', 'NIS793', 'SEG101', 'MBG453', 'Crizanlizumab', 'INC424, Jakavi', 'LTT462', 'Siremadlin', 'Rineterkib', 'HDM201']",11,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Myelofibrosis,['Myelofibrosis'],"['myelofibrosis', 'ruxolitinib', 'INC424', 'siremadlin', 'HDM201', 'crizanlizumab', 'SEG101', 'sabatolimab', 'MBG453', 'rineterkib', 'LTT462', 'NIS793', 'platform study']",TERMINATED,Sponsor Decision,2019-09-26,2024-08-28,"[{'measure': 'Incidence and Severity of Dose Limiting Toxicities Within the First 2 Cycles in Part 1', 'description': 'Incidence and severity of dose limiting toxicities within the first 2 cycles (6 or 8 weeks) in Part 1 of the study. DLTs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) criteria Version 5.0. Grade 0 was assigned for all non-missing values not graded as 1 or higher. Higher grade indicated more severity. Grade 5 was not used.', 'timeFrame': 'Baseline to the end of Cycle 2 (6 or 8 weeks)'}, {'measure': 'Response Rate at the End of Cycle 6 or Cycle 8 in Part 1', 'description': 'Composite of anemia improvement (hemoglobin level) and no spleen volume progression and no symptom worsening in Part 2 and Part 3 of the study. For a subject to be considered a responder, all three components of the composite had to be fulfilled.', 'timeFrame': 'Baseline to the end of Cycle 6 or 8 (24 weeks)'}]","[{'measure': 'Percentage of Subjects Achieving an Improvement in Hemoglobin Level of ≥ 1.5 g/dL From Baseline in Part 1', 'timeFrame': 'Week 24, Week 48'}, {'measure': 'Percentage of Subjects Achieving an Improvement in Hemoglobin Level of at Least >= 2.0 g/dL From Baseline in Part 1', 'timeFrame': 'Week 24, Week 48'}, {'measure': 'Change in Spleen Length From Baseline in Part 1', 'description': 'Change in spleen length measured in centimeters by manual palpation.', 'timeFrame': 'Baseline, Week 24, Week 48'}, {'measure': 'Percentage of Subjects With >=35% Reduction in Spleen Volume From Baseline in Part 1', 'description': 'Change in spleen volume measured by magnetic resonance imaging (MRI) or computed tomography (CT) from baseline.', 'timeFrame': 'Week 24, Week 48'}, {'measure': 'Percentage of Subjects With >=25% Reduction in Spleen Volume From Baseline in Part 1', 'description': 'Change in spleen volume measured by magnetic resonance imaging (MRI) or computed tomography (CT) from baseline.', 'timeFrame': 'Week 24, Week 48'}, {'measure': 'Percentage of Subjects in Part 1 With >=50% Reduction From Baseline in Myelofibrosis Symptom Assessment Form, Version 4.0 (MFSAF v4.0)', 'description': 'The MFSAF v4.0 questionnaire focuses on the 7 core symptoms of MF: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety and bone pain. Subjects record symptom severity at it worst for each of the 7 symptoms on an 11-point numeric rating scale, from 0 (absent) to 10 (worst imaginable). The Total Symptom Score (TSS) is the sum of all the scores for all 7 symptoms.', 'timeFrame': 'Week 12, Week 24, Week 48'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) for Siremadlin, Rineterkib, Crizanlizumab, Sabatolimab, and NIS793 in Part 1', 'timeFrame': 'Days 1 and 5 of Cycles 1 and 2 for siremadlin and Cycles 1 and 3 for crizanlizumab, sabatolimab, and NIS793; Days 1 and 15 of Cycle 1 for rineterkib'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) for Ruxolitinib in Part 1', 'timeFrame': 'Days 1 and 5 of Cycles 1 and 2; Day 15 of Cycle 1'}, {'measure': 'Maximum (Peak) Observed Plasma Drug Concentration (Cmax) for Siremadlin, Rineterkib, Crizanlizumab, Sabatolimab, and NIS793 in Part 1', 'timeFrame': 'Days 1 and 5 of Cycles 1 and 2 for siremadlin and Cycles 1 and 3 for crizanlizumab, sabatolimab, and NIS793; Days 1 and 15 of Cycle 1 for rineterkib'}, {'measure': 'Maximum (Peak) Observed Plasma Drug Concentration (Cmax) for Ruxolitinib in Part 1', 'timeFrame': 'Days 1 and 5 of Cycles 1 and 2; Day 15 of Cycle 1'}, {'measure': 'Time to Reach Maximum (Peak) Plasma, Blood, Serum or Other Body Fluid Drug Concentration After Single Dose Administration (Tmax) for Siremadlin, Rineterkib, Crizanlizumab, Sabatolimab, and NIS793 in Part 1', 'timeFrame': 'Days 1 and 5 of Cycles 1 and 2 for siremadlin and Cycles 1 and 3 for crizanlizumab, sabatolimab, and NIS793; Days 1 and 15 of Cycle 1 for rineterkib'}, {'measure': 'Time to Reach Maximum (Peak) Plasma, Blood, Serum or Other Body Fluid Drug Concentration After Single Dose Administration (Tmax) for Ruxolitinib in Part 1', 'timeFrame': 'Days 1 and 5 of Cycles 1 and 2; Day 15 of Cycle 1'}, {'measure': 'Concentration Versus Time Profile for Siremadlin in Part 1', 'timeFrame': 'Day 1 of Cycles 1 and 2; Day 6 of Cycle 1; Days 2 and 5 of Cycles 1, 2, 3, 4, 5, and 6. Each cycle was 28 days.'}, {'measure': 'Concentration Versus Time Profile for Rineterkib in Part 1', 'timeFrame': 'Days 1, 2, 15, and 16 of Cycle 1; Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle was 28 days.'}, {'measure': 'Concentration Versus Time Profile for Crizanlizumab in Part 1', 'description': 'EOI = end of infusion', 'timeFrame': 'Days 1, 2, 8, and 15 of Cycles 1, 2, and 3; Day 1 of Cycles 4, 5, 6, and 9. Each cycle was 28 days.'}, {'measure': 'Concentration Versus Time Profile for Sabatolimab in Part 1', 'description': 'EOI = end of infusion', 'timeFrame': 'Days 1, 2, 8, and 15 of Cycles 1, 2, and 3; Day 1 of Cycles 4 and 5. Each cycle was 28 days.'}, {'measure': 'Concentration Versus Time Profile for NIS793 in Part 1', 'description': 'EOI = end of infusion', 'timeFrame': 'Days 1, 2, 4, 8, 11, and 15 of Cycles 1, 2, and 3; Day 1 of Cycles 4 and 5. Each cycle was 28 days.'}, {'measure': 'Concentration Versus Time Profile for Ruxolitinib in Part 1', 'timeFrame': 'Days 1, 2, 5, 6, and 15 of Cycles 1 and 2; Day 16 of Cycle 1; Days 1, 2, and 15 of Cycle 3; Days 1 and 5 of Cycles 4, 5, and 6. Each cycle was 28 days.'}]",20,18 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,45.0,ACTUAL,2025-09-01T16:18:24.761121,v2_robust,True,True,False,True,True,Sponsor Decision
NCT03669614,SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects,"A Phase 1/2a Randomized, Double-Blind, Two-Part, Dose-Ascending, Multicenter Study of the Safety and PK of AR-501 (Gallium Citrate), Administered Via Inhalation, in Healthy Adult and P. Aeruginosa Infected Cystic Fibrosis Subjects",Inhaled AR-501,"['Inhaled Gallium Citrate', 'Inhaled AR-501', 'Inhaled Placebo', 'Control (inhaled placebo)']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Cystic Fibrosis,['Cystic Fibrosis'],"['Cystic Fibrosis', 'Gallium Citrate', 'Pseudomonas Aeruginosa']",UNKNOWN,,2018-12-07,2023-07,"[{'measure': 'Clinical safety profile (adverse events) - Single Ascending Dose', 'description': 'Evaluation of adverse events in HV subjects', 'timeFrame': '28 days following dose administration'}, {'measure': 'Clinical safety profile (adverse events) - Multiple Ascending Dose', 'description': 'Evaluation of adverse events in HV and CF subjects', 'timeFrame': 'up to 28 days after last dose administration'}]","[{'measure': 'Pharmacokinetics (PK) Profile - SAD Cmax', 'description': 'Pharmacokinetics Characteristics in Single Ascending Dose HV Subjects: Observed maximum concentration (Cmax)', 'timeFrame': '28 days following dose administration'}, {'measure': 'Pharmacokinetics (PK) Profile - SAD Tmax', 'description': 'Pharmacokinetics Characteristics in Single Ascending Dose HV Subjects: time to reach maximum concentration (Tmax)', 'timeFrame': '28 days following dose administration'}, {'measure': 'Pharmacokinetics (PK) Profile - SAD AUC0-inf', 'description': 'Pharmacokinetics Characteristics in Single Ascending Dose HV Subjects: area under the time-concentration curve (AUC) from time zero to infinity (AUC0-inf)', 'timeFrame': '28 days following dose administration'}, {'measure': 'Pharmacokinetics (PK) Profile - SAD AUC0-last', 'description': 'Pharmacokinetics Characteristics in Single Ascending Dose HV Subjects: area under the time-concentration curve (AUC) from time zero to the last dose (AUC0-last)', 'timeFrame': '28 days following dose administration'}, {'measure': 'Pharmacokinetics (PK) Profile - SAD λz', 'description': 'Pharmacokinetics Characteristics in Single Ascending Dose HV Subjects: terminal elimination rate (λz)', 'timeFrame': '28 days following dose administration'}, {'measure': 'Pharmacokinetics (PK) Profile - SAD t½', 'description': 'Pharmacokinetics Characteristics in Single Ascending Dose HV Subjects: half-life (t½)', 'timeFrame': '28 days following dose administration'}, {'measure': 'Pharmacokinetics (PK) Profile - SAD Clp', 'description': 'Pharmacokinetics Characteristics in Single Ascending Dose HV Subjects: plasma clearance (Clp)', 'timeFrame': '28 days following dose administration'}, {'measure': 'Pharmacokinetics (PK) Profile - MAD Cmax', 'description': 'Pharmacokinetics Characteristics in Multiple Ascending Dose CF Subjects: Observed maximum concentration (Cmax)', 'timeFrame': 'up to 28 days after last dose administration'}, {'measure': 'Pharmacokinetics (PK) Profile - MAD Tmax', 'description': 'Pharmacokinetics Characteristics in Multiple Ascending Dose CF Subjects: time to reach maximum concentration (Tmax)', 'timeFrame': 'up to 28 days after last dose administration'}, {'measure': 'Pharmacokinetics (PK) Profile - MAD AUC0-inf', 'description': 'Pharmacokinetics Characteristics in Multiple Ascending Dose CF Subjects: area under the time-concentration curve (AUC) from time zero to infinity (AUC0-inf)', 'timeFrame': 'up to 28 days after last dose administration'}, {'measure': 'Pharmacokinetics (PK) Profile - MAD AUC0-last', 'description': 'Pharmacokinetics Characteristics in Multiple Ascending Dose CF Subjects: area under the time-concentration curve (AUC) from time zero to the last dose (AUC0-last)', 'timeFrame': 'up to 28 days after last dose administration'}, {'measure': 'Pharmacokinetics (PK) Profile - MAD λz', 'description': 'Pharmacokinetics Characteristics in Multiple Ascending Dose CF Subjects: terminal elimination rate (λz)', 'timeFrame': 'up to 28 days after last dose administration'}, {'measure': 'Pharmacokinetics (PK) Profile - MAD t½', 'description': 'Pharmacokinetics Characteristics in Multiple Ascending Dose CF Subjects: half-life (t½)', 'timeFrame': 'up to 28 days after last dose administration'}, {'measure': 'Pharmacokinetics (PK) Profile - MAD Clp', 'description': 'Pharmacokinetics Characteristics in Multiple Ascending Dose CF Subjects: plasma clearance (Clp)', 'timeFrame': 'up to 28 days after last dose administration'}]",16,18 Years,49 Years,ALL,True,"Aridis Pharmaceuticals, Inc.",INDUSTRY,0,102.0,ESTIMATED,2025-09-01T16:18:24.761187,v2_robust,True,True,False,False,True,
NCT01291914,Study of FX005 for the Treatment of Pain in Patients With Osteoarthritis of the Knee,"A Double-Blind, Randomized,Placebo-Controlled, Two-Phase Study (a Single Ascending Dose Phase Followed by a Proof of Concept Phase) to Assess the Safety, Efficacy and Pharmacokinetics of FX005 for the Treatment of Pain in Osteoarthritis of the Knee",FX005,"['FX005', 'Placebo 1 (Carrier)', 'Placebo 2 (Diluent)']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Osteoarthritis, Knee","['Osteoarthritis, Knee']","['Osteoarthritis', 'knee', 'intra-articular', 'safety', 'efficacy', 'pharmacokinetics', 'pain']",COMPLETED,,2010-12,2012-03,"[{'measure': 'Change from baseline in the WOMAC A score (pain subscale)', 'timeFrame': 'at 4 weeks post treatment'}]","[{'measure': 'Change from baseline in WOMAC A score (pain subscale)', 'timeFrame': 'over 4, 8 and 12 weeks post treatment'}, {'measure': 'Change from baseline for WOMAC A score (pain subscale)', 'timeFrame': 'at 2, 8 and 12 weeks post treatment'}, {'measure': 'Change from baseline for WOMAC B score (stiffness subscale)', 'timeFrame': 'at 2, 4, 8 and 12 weeks post treatment'}, {'measure': 'Change from baseline for WOMAC C score (function subscale)', 'timeFrame': 'at 2, 4, 8 and 12 weeks post treatment'}, {'measure': 'Change from baseline for WOMAC A1 response (pain on walking)', 'timeFrame': 'at 2, 4, 8 and 12 weeks post treatment'}, {'measure': 'Change from baseline for WOMAC A1 response (pain on walking)', 'timeFrame': 'over 4, 8 and 12 weeks post treatment'}, {'measure': 'Change from baseline for WOMAC total score', 'timeFrame': 'at 2, 4, 8 and 12 weeks post treatment'}, {'measure': 'Change from baseline for ICOAP intermittent pain score', 'timeFrame': 'at 2, 4, 8 and 12 weeks post treatment'}, {'measure': 'Change from baseline for ICOAP constant pain score', 'timeFrame': 'at 2, 4, 8 and 12 weeks post treatment'}, {'measure': 'Change from baseline for ICOAP total score', 'timeFrame': 'at 2, 4, 8 and 12 weeks post treatment'}, {'measure': 'Percent of responders according to the OMERACT-OARSI (Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society International) criteria', 'timeFrame': 'at 4, 8 and 12 weeks post treatment'}, {'measure': ""Change in patient's global assessment score"", 'timeFrame': 'at 4, 8 and 12 weeks post treatment'}, {'measure': ""Change in clinical observer's global assessment score"", 'timeFrame': 'at 4, 8 and 12 weeks post treatment'}, {'measure': 'Average weekly consumption of analgesic medications', 'timeFrame': 'over 12 weeks post treatment'}, {'measure': 'Incidence of treatment emergent adverse events', 'timeFrame': 'up to 12 weeks post treatment'}]",16,40 Years,,ALL,False,"Pacira Pharmaceuticals, Inc",INDUSTRY,0,140.0,ACTUAL,2025-09-01T16:18:24.761207,v2_robust,True,True,True,False,True,
NCT01207414,Switching to Iloperidone From Other Antipsychotics in Schizophrenia,"A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24 mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole",iloperidone,"['iloperidone', 'Fanapt™']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Schizophrenia,['Schizophrenia'],"['Schizophrenia', 'iloperidone', 'switch', 'gradual switch', 'immediate switch']",COMPLETED,,2010-08,2012-01,"[{'measure': 'Integrated Clinical Global Impression of Change (I-CGI-C) at Week 12', 'description': 'The I-CGI-C at Week 12 was the overall impression of medically qualified raters using three separate Clinical Global Impression of Change scales: efficacy (E-CGI-C); safety and tolerability (ST-CGI-S); and overall severity (I-CGI-S) combined for a total score. The I-CGI-C scale ranged from 1 to 7 with lower scores indicating improvement (1=very much improved, 2=much improved, 3=minimally improved), higher scores indicating worsening (5=minimally worse, 6= much worse, 7=very much worse), and a score of 4 indicating no change.', 'timeFrame': 'Week 12'}]","[{'measure': 'Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) at Week 12', 'description': ""The TSQM consisted of 14 questions about the patient's satisfaction with the drug in 4 domains: Effectiveness \\[3 questions scored as 1(extremely dissatisfied) to 7(extremely satisfied)\\], Side Effects \\[question 4 scored as 0(no) or 1(yes);question 5 scored as 1(extremely bothersome) to 5(not at all bothersome);questions 6 - 8 scored as 1(a great deal) to 5(not at all)\\], Convenience \\[questions 9 and 10 scored as 1(extremely difficult) to 7 (extremely easy);question 11 scored as 1(extremely inconvenient) to 5 (extremely convenient)\\] and Global Satisfaction \\[question 12 scored as 1(not at all confident) to 7(extremely confident);question 13 scored as 1(not at all certain) to 5(extremely certain);question 14 scored as 1(extremely dissatisfied) to 5(extremely satisfied)\\]. The scores of each of the domains were added together and an algorithm used to create a score of 0 to 100. Higher scores for each domain indicate a better outcome. A positive change from baseline indicates improvement."", 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Number of Participants With Adverse Events, Serious Adverse Events or Death', 'description': 'Adverse event are defined as any unfavorable and unintended diagnosis, symptoms, sign (including an abnormal lab finding), syndrome or disease which either occurs during the study, having been absent at baseline, or if present at baseline appear to worsen.\n\nSerious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization , cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards.\n\nAdditional information about adverse events can be found in the Adverse Event section.', 'timeFrame': '12 Weeks'}, {'measure': 'Change From Baseline in the Efficacy Clinical Global Impression of Severity (E-CGI-S) at Week 12', 'description': 'Medically qualified raters use the E-CGI-S scale at Baseline and Week 12 to assess the effectiveness of treatment by examining changes in positive symptoms \\[hallucinations (false perceptions), delusions (false beliefs), paranoia (unfounded distrust), conceptual disorganization (loosening of associations), or hostility\\], negative symptoms \\[apathy (lack of interest), avolition (lack of motivation), alogia (poverty of speech), and anhedonia (absence of pleasure)\\] and cognitive symptoms \\[concentration difficulties, difficulties with executive function (integrative reasoning), and illogical thinking\\] in the previous 7 days on a scale of 1 to 7 (1=normal, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill or 7=among the most extremely ill). A negative change from baseline indicates improvement.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in the Safety and Tolerability Clinical Global Impression of Severity (ST-CGI-S) at Week 12', 'description': 'Medically qualified raters used the ST-CGI-S at Baseline and Week 12 to evaluate safety and tolerability in the previous 7 days on a scale of 1 to 7 (1=Normal-no symptoms, 2=borderline severity, 3=mild impairment, 4=moderate, 5=marked, 6=severe, 7=among the most severe.) A negative change from baseline indicates improvement.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in Integrated Clinical Global Impression of Severity (I-CGI-S) at Week 12', 'description': ""I-CGI-S incorporated the overall, combined impression of illness severity based upon the E-CGI-S and ST-CGI-S. Medically qualified raters evaluated the patient's illness in the previous 7 days at Baseline and Week 12 on a scale of 1 to 7 (1=normal not at all ill, 2=borderline mental illness or impairment, 3=mildly ill or impaired, 4=moderately ill or impaired, 5=marked ill or impaired, 6= severely ill or impaired or 7=among the most extremely ill patients. A negative change from baseline indicates improvement."", 'timeFrame': 'Baseline, Week 12'}]",6,18 Years,64 Years,ALL,False,Novartis,INDUSTRY,0,501.0,ACTUAL,2025-09-01T16:18:24.761242,v2_robust,True,True,True,False,True,
NCT00734214,Hypotonic Versus Isotonic Parenteral (HIP) Fluid Trial,Hypotonic Versus Isotonic Parenteral Fluids in Children - a Randomized Controlled Trial,0.9% NaCl,"['0.9% NaCl', 'Hypotonic saline', '0.45%NaCl', 'Isotonic saline']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Hyponatremia,"['Hyponatremia', 'Hypernatremia']","['Parenteral Fluids', 'Isotonic', 'Hypotonic', 'Pediatric', 'Fluid overload']",COMPLETED,,2008-03,2009-12,"[{'measure': 'Hospital Acquired Acute Plasma Sodium Derangements (Hypo- or Hypernatremia)', 'timeFrame': 'During the treatment and follow-up period.'}, {'measure': 'Hyponatremia', 'description': 'Plasma sodium less than 135 mmol/L', 'timeFrame': 'during the study intervention'}]","[{'measure': 'Adjudicated Morbidity Attributed to Acute Plasma Sodium Changes.', 'timeFrame': 'During the treatment and follow-up period'}]",3,6 Months,16 Years,ALL,True,Hamilton Health Sciences Corporation,OTHER,0,258.0,ACTUAL,2025-09-01T16:18:24.761252,v2_robust,True,True,True,False,False,
NCT06204614,Drug Screening Using IMD in Bladder Cancer,Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Response in Primary Bladder Tumors,Methotrexate,"['Vinblastine', 'Gemcitabine/Cisplatin II', 'Gemcitabine/Carboplatin', 'Gemcitabine', 'Enfortumab', 'Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab', 'Gemcitabine/Cisplatin/Nivolumab', 'Paclitaxel', 'Nivolumab', 'Carboplatin', 'Avelumab', 'Gemcitabine/Cisplatin I', 'Gemcitabine/Carboplatin/Nivolumab', 'Erdafitinib', 'Methotrexate', 'Cisplatin', 'Methotrexate/Vinblastine/Doxorubicin/Cisplatin', 'Pembrolizumab', 'Sacituzumab', 'Paclitaxel/Docetaxel/Ifosfamide']",20,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Muscle Invasive Bladder Urothelial Carcinoma,['Muscle Invasive Bladder Urothelial Carcinoma'],[],NOT_YET_RECRUITING,,2024-02-14,2025-07-01,"[{'measure': 'Safety of microdevice placement and removal based on assessment of adverse events', 'description': 'A device will be declared safe if and only if all implanted devices do not cause an adverse event as defined in section 5.4. The device will be declared safe if 2 or less unacceptable toxicities are observed. Safety will be monitored using a BOIN-based boundary estimated assuming a 10% event rate and a stopping probability of 0.70. The boundary will not take effect until the third patient is enrolled. The trial will be stopped for safety concerns if the investigators see at least 1 adverse event in the first nine patients, or 2 adverse events across all 18. The probability of seeing 2 or less unacceptable toxicity events is 71% if the true rate of toxicity is 10% and 94% if the true rate of toxicity is 5%. The safety estimate will be summarized as number, percentage and with a 95% binomial confidence interval', 'timeFrame': 'From the time of arrival to interventional radiology for microdevice placement up to 6 weeks.'}, {'measure': 'Feasibility of microdevice placement', 'description': ""A placement is defined as successful if the investigators can implant and extract at least one microdevice from a patient's tumor with readable tissue for pathology from at least three-quarters of the device reservoirs surrounded by at least 400um of surrounding tissue. The investigators will declare feasibility if the lower bound of the 95% binomial CI does not exceed 0.65, that is if the investigators have 2 or fewer failures. The number of patients with successful retrieval will be summarized as number, percentage and with a 95% CI. Based on prior studies, if device reservoirs are surrounded by at least 400um of tissue, this enables downstream multi-omic analysis."", 'timeFrame': '48 Hours'}]","[{'measure': 'Local intratumor response', 'description': 'To measure the local intratumor response to clinically relevant drugs in bladder cancer using quantitative histopathologic assessment of tumor tissue.\n\nThe investigators will analyze tumor sections for each drug treatment zone using a immunohistochemical stain for apoptosis (cleaved caspase 3) and report the result for each condition as a percentage of positively stained cells (vs. total number of cells) within a radius of 500 microns from the drug reservoir.\n\nA board-certified pathologist will review staining quality of the histopathological staining.', 'timeFrame': '48 Hours'}, {'measure': 'Exploration of additional potential biomarkers of drug response', 'description': 'To explore additional potential biomarkers of drug response. We will perform immunohistochemical staining for markers of proliferation (ki67) and cell death (Cleaved Parp) in the local tumor tissue adjacent to the microdevice. Results will be calculated as a percentage of positively stained cells in the 500 micron radius adjacent to each reservoir on the microdevice, and will be reported as a percentage of positively stained versus total cells in the region of interest.\n\nDescriptive statistics will be used to summarize the results for each biomarker across multiple devices and drugs.', 'timeFrame': '48 Hours'}]",4,18 Years,120 Years,ALL,True,Brigham and Women's Hospital,OTHER,0,18.0,ESTIMATED,2025-09-01T16:18:24.761286,v2_robust,True,True,False,False,True,
NCT04761614,Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer,A Phase I Study of Riluzole in Combination With mFOLFOX6/Bevacizumab in Patients With Metastatic Colorectal Cancer,Fluorouracil,"['Folinate Calcium', 'Tonofolin', 'Ro-2-9757', '5 Fluorouracil', '5FU', 'Dalisol', 'Citrec', 'Flurablastin', 'Ribofluor', 'Folinoral', 'Diaminocyclohexane Oxalatoplatinum', 'Leucovorin Calcium', 'AccuSite', 'Calcium Folinate', '5-Fluorouracil', 'Rescuvolin', 'Citofolin', 'Citrovorum Factor', 'Folaxin', '5-Fu', 'Folinic Acid Calcium Salt Pentahydrate', 'Oxalatoplatin', 'Calfolex', 'Calinat', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', 'Aiheng', 'Fluoro Uracil', 'Divical', 'Riluzole', 'RP 54780', 'Calcium (6S)-Folinate', 'JM-83', 'Disintox', 'Emovis', 'Fluroblastin', 'Wellcovorin', '1-OHP', 'Rescufolin', 'Dacplat', 'SR-96669', 'Cehafolin', 'leucovorin', 'Imo', 'Folix', 'Folidar', 'Oxaliplatin', 'Factor, Citrovorum', 'Eloxatin', 'Folaren', 'Oxalatoplatinum', 'Lederfolat', 'Ecofol', 'Folinac', 'RP-54780', '5 Fluorouracilum', 'Flynoken A', 'Rilutek', 'Ro 2-9757', 'Fluouracil', 'Fluracil', 'Fluracedyl', '5 FU', 'FOLI-cell', 'folinic acid', 'Lederfolin', 'Cromatonbic Folinico', 'Eloxatine', 'Ai Heng', 'Calcifolin', 'Foliben', 'Fluril', 'Carac', 'Leucosar', '5-Fluracil', 'Adinepar', 'Foliplus', 'Calcium Leucovorin', 'Fluorouracil', 'Folidan', 'Folinvit', 'Dacotin']",81,INTERVENTIONAL,['PHASE1'],PHASE1,,Metastatic Colorectal Carcinoma,"['Metastatic Colorectal Carcinoma', 'Stage IV Colorectal Cancer AJCC v8', 'Stage IVA Colorectal Cancer AJCC v8', 'Stage IVB Colorectal Cancer AJCC v8', 'Stage IVC Colorectal Cancer AJCC v8']",[],COMPLETED,,2021-04-02,2023-05-06,"[{'measure': 'Dose limiting toxicities (DLTs)', 'description': 'Will be defined by treatment related grade \\>= 4 adverse events or \\>= grade 3 alanine aminotransferase or aspartate aminotransferase elevation during the DLT period using the Common Terminology Criteria for Adverse Events version 5.0.', 'timeFrame': 'Up to 4 weeks (2 cycles of treatment) (1 cycle = 14 days)'}]","[{'measure': 'Pharmacokinetic (PK) profile of riluzole (Cmax)', 'description': ""K data analysis will utilize a nonlinear mixed effects approach whereby PK parameter estimates will be generated from the data, and 'dose day' will be evaluated as a covariate on clearance and volume of distribution. The PK parameters including Cmax. Peak Plasma Concentration (Cmax)"", 'timeFrame': 'Day 1 on cycle 1 (each cycle is 14 days)'}, {'measure': 'Pharmacokinetic (PK) profile of riluzole (AUC)', 'description': ""PK data analysis will utilize a nonlinear mixed effects approach whereby PK parameter estimates will be generated from the data, and 'dose day' will be evaluated as a covariate on clearance and volume of distribution. The PK parameters including AUC. Area under the plasma concentration versus time curve (AUC)"", 'timeFrame': 'Day 1 on cycle 1 (each cycle is 14 days)'}]",3,18 Years,,ALL,False,Ning Jin,OTHER,0,13.0,ACTUAL,2025-09-01T16:18:24.761323,v2_robust,True,True,True,False,True,
NCT01624714,Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects,Phase I Trial Monitoring Efficacy and Safety in Treatment of Alemtuzumab Naive Subjects and Data Collecting and Monitoring of Alemtuzumab Experienced Subjects With Refractory Multiple Sclerosis,Alemtuzumab,"['Alemtuzumab', 'Campath', 'Alemtuzumab immunotherapy', 'Lemtrada']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Multiple Sclerosis,['Multiple Sclerosis'],['Treatment Refractory'],UNKNOWN,,2012-09,2017-09,"[{'measure': 'Change in Neurostatus Expanded Disability Status Scale', 'timeFrame': 'Baseline and every 6 months over 5 years'}, {'measure': 'Change in MS Severity Scale', 'timeFrame': 'Baseline and every 6 months for 5 years'}]","[{'measure': 'Change in annualized relapse rate', 'timeFrame': 'Every 6 months during study'}, {'measure': 'Number of treatment days with high dose corticosteroids', 'timeFrame': 'Every 6 months during study'}, {'measure': 'Rate of serious adverse events', 'timeFrame': 'Duration of study'}, {'measure': 'MRI-based cerebral volumes and burden of disease (in selected subjects)', 'timeFrame': 'Baseline and yearly X 5 years'}]",6,18 Years,75 Years,ALL,False,"Samuel Forrester Hunter, MD, PhD",OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:24.761333,v2_robust,True,True,False,False,True,
NCT03889314,The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial,The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial,Rosuvastatin 20mg,['Rosuvastatin 20mg'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Cardiovascular Risk Factor,"['Cardiovascular Risk Factor', 'Cardiovascular Diseases', 'Adverse Effect']","['Statin Therapy', 'Prevention', 'High ASCVD Risk']",UNKNOWN,,2019-04-26,2022-12-31,"[{'measure': 'Musculoskeletal intolerance (as documented in study assessments)', 'description': 'Prevalence of musculoskeletal intolerance between the groups, defined by a lack of statistical difference in the mean musculoskeletal symptom score while on statin therapy compared to placebo, in patients previously identified as statin intolerant.', 'timeFrame': '6 months'}]","[{'measure': 'Statin Utilization', 'description': 'Number of individuals taking statins 3 months post study', 'timeFrame': '3 months'}]",2,21 Years,75 Years,ALL,True,Minneapolis Heart Institute Foundation,OTHER,0,25.0,ACTUAL,2025-09-01T16:18:24.761368,v2_robust,True,True,False,False,False,
NCT06007014,Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes,"A Multi-Center, Randomised, Double-blind, Placebo Parallel Controlled Clinical Study to Evaluate the Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes",Chiglitazar sodium,"['Chiglitazar sodium', 'Chiglitazar placebo']",2,INTERVENTIONAL,['NA'],,,Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients,"['Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients', 'Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect', '128 Patients Were Randomly Assigned 1:1', 'Metformin and Insulin Glargine Combined With Chiglitazar Sodium Tablets 48mg/ Day Group', 'Metformin and Insulin Glargine Combined With Placebo Group', 'InvestigatorInitiate Trial', 'Changes in HbA1C From Baseline at 18 Weeks of Treatment']","['Chiglitazar', 'T2DM', 'Randomised', 'Double-blind', 'Placebo Parallel Controlled']",NOT_YET_RECRUITING,,2023-10-31,2025-12-30,"[{'measure': 'HbA1C', 'description': 'Changes in HbA1C from baseline', 'timeFrame': '18 weeks of treatment'}]","[{'measure': 'Insulin', 'description': 'Changes in the daily dose of insulin from baseline', 'timeFrame': '6 weeks and 18 weeks of treatment'}, {'measure': 'Triglyceride', 'description': 'Changes in the daily dose of triglyceride from baseline', 'timeFrame': '18 weeks of treatment'}, {'measure': 'Fasting blood glucose', 'description': 'Changes in the daily dose of fasting blood glucose from baseline', 'timeFrame': '6 weeks and 18 weeks of treatment'}, {'measure': 'Fasting C-Peptide', 'description': 'Changes in the daily dose of fasting C-Peptide from baseline', 'timeFrame': '18 weeks of treatment'}]",5,18 Years,,ALL,False,Yanbing Li,OTHER,0,128.0,ESTIMATED,2025-09-01T16:18:24.761398,v2_robust,True,True,False,False,False,
NCT06775314,"The Effectiveness and Safety of Cleanser Containing Triethyl Citrate, Pyruvic Acid, Combination Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic Acid and Spot Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Honokiol","The Effectiveness and Safety of Cleanser Containing Triethyl Citrate, Pyruvic Acid, Combination Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic Acid and Spot Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Honokiol As Adjuvant Therapy for Mild to Moderate Acne Vulgaris",Cleanser,"['spot cream', 'Cleanser', 'Adapalene 0,1% cream', 'placebo cream combination', 'placebo cleanser', 'placebo spot cream', 'Combination cream']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Acne Vulgaris,['Acne Vulgaris'],"['acne vulgaris', 'Triethyl citrate', 'Pyruvic acid', 'Ethyl linoleate', 'GT peptide-10', 'Salicylic acid 0,5%', 'Zinc lactate', 'Hyaluronic acid', 'Honokiol']",NOT_YET_RECRUITING,,2025-03-01,2025-06-30,"[{'measure': 'Change of acne severity', 'description': 'Based on global acne severity scale (GEA score). On a scale of 0-5, 0 indicates no lesion, while 5 indicates very severy acne', 'timeFrame': 'Re-evaluation on day 28, 56 and 84 of therapy'}, {'measure': 'Change of acne severity', 'description': 'Based on Indonesia Acne Expert Meeting scale (IAEM scale). the scale consists of mild, moderate and severe.', 'timeFrame': 'Re-evaluation on day 28, 56 and 84 of therapy'}, {'measure': 'total of inflammation lesion and non inflammation lesion', 'description': 'The total lesion will be examined by dermatologist', 'timeFrame': 'Re-evaluation on day 28, 56 and 84 of therapy'}, {'measure': 'acne sequelae', 'description': 'The acne sequelae will be examined by dermatologist', 'timeFrame': 'Re-evaluation on day 28, 56 and 84 of therapy'}, {'measure': 'Quality of life', 'description': 'Based on acne quality of life (Acne-QoL). Total score of acne-QoL is 0-114, the higher score interprets better quality of life of acne vulgaris patient', 'timeFrame': 'Re-evaluation on day 28, 56 and 84 of therapy'}, {'measure': 'Erythema severity', 'description': 'based on clinician erythema assessment scale (CEA scale). on the scale of 0-4. 0 indicates no erythema, while 4 indicates severe erythema', 'timeFrame': 'Re-evaluation on day 28, 56 and 84 of therapy'}, {'measure': 'Facial analysis', 'description': 'The facial analysis will be done by using janus facial analysis system', 'timeFrame': 'Re-evaluation on day 28, 56 and 84 of therapy'}]",[],7,15 Years,50 Years,ALL,False,"Dr.dr.Irma Bernadette, SpKK (K)",OTHER,3,102.0,ESTIMATED,2025-09-01T16:18:24.761432,v2_robust,True,True,False,False,False,
NCT01366014,A Study of ARRY-371797 in Patients With Osteoarthritis of the Knee,,"ARRY-371797, p38 inhibitor; oral","['Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral', 'Placebo; oral', 'ARRY-371797, p38 inhibitor; oral']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Osteoarthritis of the Knee,['Osteoarthritis of the Knee'],"['osteoarthritis', 'knee', 'pain', 'NSAID']",COMPLETED,,2011-06,2012-06,"[{'measure': 'Assess the efficacy of the study drug (versus placebo) in terms of change from baseline to week 4 in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score (index knee).', 'timeFrame': '4 weeks'}]","[{'measure': 'Assess the efficacy of the study drug (versus placebo) in terms of change from baseline to week 4 in the WOMAC stiffness and physical function subscale scores (index knee).', 'timeFrame': '4 weeks'}, {'measure': 'Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, electrocardiograms and vital signs.', 'timeFrame': '5 weeks'}, {'measure': 'Characterize the pharmacokinetics of the study drug and metabolite as determined by plasma concentrations.', 'timeFrame': '4 weeks'}]",4,40 Years,85 Years,ALL,False,Pfizer,INDUSTRY,0,157.0,ACTUAL,2025-09-01T16:18:24.761510,v2_robust,True,True,True,False,True,
NCT00294216,Omacor and Placebo in Carotid Plaque Stability,A Double Blind Comparison of Omacor and Placebo in Patients Awaiting Endarterectomy to Investigate the Effect on Carotid Plaque Stability,Omega-3-acid ethyl ester 90 (n-3 PUFA),['Omega-3-acid ethyl ester 90 (n-3 PUFA)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Cardiovascular Disease,['Cardiovascular Disease'],"['Omacor', 'Omega-3 PUFA', 'Endarterectomy', 'Carotid Plaque stability', 'Structural changes', 'inflammation']",COMPLETED,,2003-08,2005-07,"[{'measure': 'The primary objective is to compare the carotid plaque stability after placebo versus Omega-3 fatty acid treatment by assessing structural changes associated with plaque rupture and instability. The composite endpoint includes changes in'}, {'measure': '(1) the size of the lipid pool,'}, {'measure': '(2) the number of foam cells,'}, {'measure': '(3) the presence of haemorrhage,'}, {'measure': '(4) the number of macrophages in lesions and'}, {'measure': '(5) the overall density of inflammation in the plaque as a whole and'}, {'measure': '(6) in fibrous caps of lesions.'}]","[{'measure': '(1) the size of the lipid pool,'}, {'measure': '(2) the number of foam cells,'}, {'measure': '(3) the presence of haemorrhage,'}, {'measure': '(4) the number of macrophages in lesions and'}, {'measure': '(5) the overall density of inflammation in the plaque as a whole and'}, {'measure': '(6) in fibrous caps of lesions.'}]",13,18 Years,,ALL,False,Pronova BioPharma,INDUSTRY,0,121.0,,2025-09-01T16:18:25.979767,v2_robust,True,True,True,False,False,
NCT01981616,Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab,"A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single Dose Study in Healthy Subjects to Determine the Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab",Vedolizumab,"['Vedolizumab', 'Placebo', 'MLN0002', 'MLN02', 'Entyvio', 'LDP-02']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Inflammatory Bowel Disease,['Inflammatory Bowel Disease'],['Drug therapy'],COMPLETED,,2011-09,2012-07,"[{'measure': 'Percentage of Participants With an Immune Response to Hepatitis B Vaccine at Day 74', 'description': 'Immune response was defined as hepatitis B surface antibody (anti-HBs) ≥ 10 IU/L.', 'timeFrame': 'Day 74'}]","[{'measure': 'Percentage of Participants With an Immune Response to Oral Cholera Vaccine', 'description': 'A positive immune response was defined as an increase of greater than 4-fold over the Baseline immunoglobulin M (IgM), IgG, or IgA anticholera antibodies.', 'timeFrame': 'Baseline and Day 74'}, {'measure': 'Anti-Hepatitis B Surface Antibody Over Time', 'timeFrame': 'Baseline and Days 18, 32, 60 and 74'}, {'measure': 'Number of Participants With Adverse Events (AEs)', 'description': 'An AE was defined as any untoward medical occurrence in a subject administered a pharmaceutical product; the untoward medical occurrence did not necessarily have a causal relationship with this treatment.\n\nSerious adverse event (SAE) meant any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly/birth defect or was a medically important event. Relationship of each AE to study drug was determined by the Investigator.', 'timeFrame': 'From the first dose of study medication through Day 127'}]",4,18 Years,39 Years,ALL,True,"Millennium Pharmaceuticals, Inc.",INDUSTRY,0,127.0,ACTUAL,2025-09-01T16:18:25.979791,v2_robust,True,True,True,False,True,
NCT02535416,A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers,"A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 at Varying Infusion Rates in Normal Adult Volunteers",ARC-520,"['ARC-520', 'diphenhydramine', 'cetirizine']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2015-09,2016-08,"[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs)', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence that does not necessarily have a causal relationship with this treatment. TEAEs were defined as all AEs starting or worsening after commencement of treatment with investigational product.', 'timeFrame': 'post-dose through the end of study (Day 15 ± 1 day) plus 30 days'}]","[{'measure': 'Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24) of the Analytes of ARC-520', 'description': 'Analytes include AD0009 and AD0010 (cholesterol-conjugated siRNA targeting hepatitis B virus \\[HBV\\]) and melittin-like peptide (MLP).', 'timeFrame': 'Day 1 pre-dose through 48 hours post-dose'}, {'measure': 'Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Plasma Concentration (AUClast) of the Analytes of ARC-520', 'description': 'Analytes include AD0009 and AD0010 (cholesterol-conjugated siRNA targeting HBV) and MLP.', 'timeFrame': 'Day 1 pre-dose through 48 hours post-dose'}, {'measure': 'Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Zero Extrapolated to Infinity (AUCinf) of the Analytes of ARC-520', 'description': 'Analytes include AD0009 and AD0010 (cholesterol-conjugated siRNA targeting HBV) and MLP.', 'timeFrame': 'Day 1 pre-dose through 48 hours post-dose'}, {'measure': 'Pharmacokinetics: Maximum Plasma Concentration (Cmax) of the Analytes of ARC-520', 'description': 'Analytes include AD0009 and AD0010 (cholesterol-conjugated siRNA targeting HBV) and MLP.', 'timeFrame': 'Day 1 pre-dose through 48 hours post-dose'}, {'measure': 'Pharmacokinetics: Clearance (CL) of the Analytes of ARC-520', 'description': 'Analytes include AD0009 and AD0010 (cholesterol-conjugated siRNA targeting HBV) and MLP.', 'timeFrame': 'Day 1 pre-dose through 48 hours post-dose'}, {'measure': 'Pharmacokinetics: Apparent Volume of Distribution (V) of the Analytes of ARC-520', 'description': 'Analytes include AD0009 and AD0010 (cholesterol-conjugated siRNA targeting HBV) and MLP.', 'timeFrame': 'Day 1 pre-dose through 48 hours post-dose'}, {'measure': 'Pharmacokinetics: Terminal Elimination Rate Constant (Lambda z) of the Analytes of ARC-520', 'description': 'Analytes include AD0009 and AD0010 (cholesterol-conjugated siRNA targeting HBV) and MLP.', 'timeFrame': 'Day 1 pre-dose through 48 hours post-dose'}, {'measure': 'Pharmacokinetics: Half-Life (t1/2) of the Analytes of ARC-520', 'description': 'Analytes include AD0009 and AD0010 (cholesterol-conjugated siRNA targeting HBV) and MLP.', 'timeFrame': 'Day 1 pre-dose through 48 hours post-dose'}]",9,18 Years,55 Years,ALL,True,Arrowhead Pharmaceuticals,INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:25.979865,v2_robust,True,True,True,False,True,
NCT06825416,Phase III Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty,"Multicenter, Randomized, Double-blind, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Arthroplasty",SHR-2004 injection,"['SHR-2004 placebo', 'SHR-2004 injection', 'Enoxaparin sodium injection placebo', 'Enoxaparin sodium injection']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Prevention of Arterial and Venous Thrombosis,['Prevention of Arterial and Venous Thrombosis'],[],RECRUITING,,2025-03-14,2025-12,"[{'measure': 'Incidence of asymptomatic deep vein thrombosis (DVT)', 'timeFrame': 'Day 12.'}, {'measure': 'Incidence of non-fatal pulmonary embolism (PE)', 'timeFrame': 'Day 12.'}]","[{'measure': 'Adverse events (AEs)', 'timeFrame': 'Day 65.'}, {'measure': 'Bleeding events', 'timeFrame': 'Day 12.'}]",4,18 Years,80 Years,ALL,False,"Beijing Suncadia Pharmaceuticals Co., Ltd",INDUSTRY,0,1167.0,ESTIMATED,2025-09-01T16:18:25.979927,v2_robust,True,True,False,False,True,
NCT00797316,Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension,"An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Forced-titration Study to Evaluate the Efficacy and Safety of Aliskiren Plus HCTZ Compared to Aliskiren Monotherapy in Metabolic Syndrome Patients With Stage 2 Hypertension",Aliskiren,"['Hydrochlorothiazide', 'Aliskiren']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypertension,['Hypertension'],"['Hypertension', 'Metabolic Syndrome', 'aliskiren', 'hydrochlorothiazide', 'systolic blood pressure', 'diastolic blood pressure', 'stage 2']",COMPLETED,,2008-11,2009-12,"[{'measure': 'Change From Baseline to Week 8 in Mean Sitting Systolic Blood Pressure (msSBP)', 'timeFrame': 'Baseline and Week 8'}]","[{'measure': 'Change From Baseline to Week 8 in Mean Sitting Diastolic Blood Pressure (msDBP)', 'timeFrame': '8 weeks'}, {'measure': 'Percentage of Participants With Blood Pressure Response at Week 8', 'description': 'Response is defined as a patient with msSBP \\< 140 mmHg or a decrease from baseline ≥ 20 mmHg in msSBP during eight weeks of treatment.', 'timeFrame': '8 weeks'}, {'measure': 'Percentage of Patients Achieving Blood Pressure Control at Week 8', 'description': 'Blood pressure control is defined as a patient who achieves a target Blood Pressure of mean sitting Systolic Blood Pressure / mean sitting Diastolic Blood pressure \\< 140/90 mmHg.', 'timeFrame': '8 weeks'}, {'measure': 'Change From Baseline to Week 8 in Pulse Pressure', 'timeFrame': 'Baseline and Week 8'}]",5,18 Years,,ALL,False,Novartis,INDUSTRY,0,532.0,ACTUAL,2025-09-01T16:18:25.980041,v2_robust,True,True,True,False,False,
NCT06006416,Effect of Fenugreek Fibre on Gut Microbiome,"Effect of Fenugreek Fibre (Trigonella Foenum-graecum) on the Gut Microbiome in an Adult Population - an Open Label, Self-controlled Trial",Fenugreek Fibre,['Fenugreek Fibre'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Gut Microbiome,['Gut Microbiome'],[],WITHDRAWN,The Sponsor decided not to conduct the study.,2024-12,2025-09-01,"[{'measure': 'Change in metagenomic profile of the gut microbiome', 'description': 'Change in metagenomic profile of the gut microbiome as measured by 16s rRNA gene sequencing', 'timeFrame': 'Week 0, week 4 and week 16'}]","[{'measure': 'Change in gut function', 'description': 'Change in gut function as measured by faecal short change fatty acids testing via faecal sample', 'timeFrame': 'Week 0, week 4 and week 16'}, {'measure': 'Change in intestinal permeability', 'description': 'Change in intestinal permeability as measured by plasma occludin, Muc2 and Endotoxin via blood test', 'timeFrame': 'Week, 0, week 4, week 8 and week 16'}, {'measure': 'Change in gut inflammation', 'description': 'Change in gut inflammation as measured by faecal calprotectin via faecal sample', 'timeFrame': 'Week 0, week 4 and week 16'}, {'measure': 'Change in inflammation', 'description': 'Change in inflammation as measured by inflammatory markers (IFN-g, TNF-a, il-2, MCP-2, IL-1b, TGF-b, CRP) via blood test', 'timeFrame': 'Week, 0, week 4, week 8 and week 16'}, {'measure': 'Change in GLP-1', 'description': 'Change in GLP-1 as measured by blood test', 'timeFrame': 'Week, 0, week 4, week 8 and week 16'}, {'measure': 'Change in GST', 'description': 'Change in GST as measured by blood test', 'timeFrame': 'Week, 0, week 4, week 8 and week 16'}, {'measure': 'Change in glutathione', 'description': 'Change in glutathione as measured by blood test', 'timeFrame': 'Week, 0, week 4, week 8 and week 16'}, {'measure': 'Change in FABP', 'description': 'Change in FABP as measured by blood test', 'timeFrame': 'Week, 0, week 4, week 8 and week 16'}, {'measure': 'Change in Homocysteine', 'description': 'Change in Homocysteine as measured by blood test', 'timeFrame': 'Week, 0, week 4, week 8 and week 16'}, {'measure': 'Change in diet', 'description': 'Change in diet as measured by 24hr Dietary Recall', 'timeFrame': 'Week 0 and Week 16 (completed for 3 consecutive days)'}, {'measure': 'Change in quality of life', 'description': 'Change in quality of life as measured by the SF-36 questionnaire. Consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.', 'timeFrame': 'Week, 0, week 4, week 8 and week 16'}, {'measure': 'Change in stress state', 'description': 'Change in stress as measured by the Perceived Stress Scale questionnaire. Consists of 10 items with a score range 0-40. Higher scores indicate higher perceived stress.', 'timeFrame': 'Week, 0, week 4, week 8 and week 16'}, {'measure': 'Change in sleep quality', 'description': 'Change in sleep as measured by the Leeds Sleep Evaluation Questionnaire. Consists of ten questions pertaining to four consecutive aspects of sleep: getting to sleep (GTS), quality of sleep (QOS), awakening from sleep (AFS), and behaviour following wakefulness (BFW). Higher scores indicate better sleep quality.', 'timeFrame': 'Week, 0, week 4, week 8 and week 16'}, {'measure': 'Change in safety', 'description': 'Change in safety as measured by E/LFT via blood test', 'timeFrame': 'Week 0, week 4 and week 16'}, {'measure': 'Height', 'description': 'Height as measured by stadiometer', 'timeFrame': 'Week 0, week 4 and week 16'}, {'measure': 'Change in weight', 'description': 'Change in weight as measured by digital scale', 'timeFrame': 'Week 0, week 4 and week 16'}, {'measure': 'Change in hip and weight circumference', 'description': 'Change in hip and weight circumference as measured by tape measure', 'timeFrame': 'Week 0, week 4 and week 16'}, {'measure': 'Change in blood pressure', 'description': 'Change in blood pressure as measured by blood pressure monitor', 'timeFrame': 'Week 0, week 4 and week 16'}]",19,18 Years,65 Years,ALL,False,RDC Clinical Pty Ltd,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:25.980065,v2_robust,True,True,False,True,True,The Sponsor decided not to conduct the study.
NCT00002616,Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer,"A PILOT TRIAL OF INTERLEUKIN-2 WITH G-CSF AS PRIMING THERAPY FOR PERIPHERAL BLOOD STEM CELL HARVESTING IN PATIENTS WITH ADVANCED BREAST CANCER: STAMP V HIGH DOSE CHEMOTHERAPY, STEM CELL INFUSION AND POST-INFUSION G-CSF AND INTERLEUKIN-2",carboplatin,"['cyclophosphamide', 'carboplatin', 'thiotepa']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Breast Cancer,['Breast Cancer'],"['stage IV breast cancer', 'recurrent breast cancer', 'stage IIIB breast cancer', 'inflammatory breast cancer']",UNKNOWN,,1995-02,,[],[],0,,64 Years,ALL,False,University of Illinois at Chicago,OTHER,0,36.0,ESTIMATED,2025-09-01T16:18:25.980112,v2_robust,True,True,False,False,False,
NCT06766916,Crisugabalin for Radiotherapy-Related Neuropathic Pain,"Crisugabalin Versus Pregabalin for Radiotherapy-Related Neuropathic Pain in Head and Neck Cancers: A Multicenter, Randomized, Open-Label, Non-Inferiority Trial",Crisugabalin,"['Pregabalin', 'Crisugabalin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Neuropathic Pain,['Neuropathic Pain'],"['Head and Neck Cancers', 'Radiotherapy-Related Neuropathic Pain', 'Crisugabalin']",RECRUITING,,2025-05-07,2026-12-31,"[{'measure': 'Numeric Rating Scale (NRS) Change', 'description': 'The change in NRS score from baseline to Week 4 of treatment. The NRS measures pain intensity on a scale of 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.', 'timeFrame': '4 weeks'}]","[{'measure': 'Numeric Rating Scale (NRS) Change', 'description': 'The change in NRS score from baseline to Week 1 of treatment. The NRS measures pain intensity on a scale of 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.', 'timeFrame': '1 week'}, {'measure': 'Visual Analogue Scale (VAS) Change', 'description': 'The VAS measures pain intensity on a 0-100 mm scale, with 0 representing no pain and 100 representing the worst imaginable pain.', 'timeFrame': '4 weeks'}, {'measure': 'Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD) scores', 'description': 'The HAMA and HAMD are used to evaluate anxiety and depressive symptoms, respectively.', 'timeFrame': '4 weeks'}, {'measure': 'Daily Sleep Interference Scale (DSIS)', 'description': 'The DSIS measures the impact of pain on sleep quality. Scores range from 0 (no interference) to 10 (complete interference).', 'timeFrame': '4 weeks'}, {'measure': 'Health Status According to EuroQol-5-Domain-5-Level health questionnaire (EQ-5D-5L)', 'description': ""The EQ-5D-5L assessed quality of life based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant was asked to 'check the ONE box that best describes your health TODAY,' choosing from 5 options (no problems, slight problems, moderate problems, severe problems, extreme problems) provided under each dimension.\n\nThe health state index value is a single value on a scale from 0 to 100 scores indicating better health: 0 = indicating worst health and 100 = best imaginable health."", 'timeFrame': '4 weeks'}, {'measure': 'Response Rates', 'description': 'The proportion of patients achieving ≥30% and ≥50% reductions in NRS score from baseline to Week 4.', 'timeFrame': '4 weeks'}, {'measure': 'Short-Form McGill Pain Questionnaire (SF-MPQ)', 'description': 'Participants rate their pain in three parts of the questionnaire, which are combined into a single pain intensity score:\n\nPart 1 - fifteen descriptors of pain intensity, on a scale of 0 (none) to 3 (severe); Part 2 - the VAS, in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain; Part 3 - a present pain intensity index in which the participant rates present pain intensity on a scale of 0 (no pain) to 5 (most intense pain).', 'timeFrame': '4 weeks'}, {'measure': 'Patient Global Impression of Change (PGIC)', 'description': ""PGIC is a 7 point scale depicting a patient's rating of overall improvement, with 1 representing very much improved and 7 representing very much worse."", 'timeFrame': '4 weeks'}]",9,18 Years,,ALL,False,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,OTHER,0,172.0,ESTIMATED,2025-09-01T16:18:25.980174,v2_robust,True,True,False,False,False,
NCT04121416,Comparison of Effects of Oxycodone and Sufentanil on Cardiovascular Stress Induced by Tracheal Intubation in the Patients With Coronary Heart Disease Undergoing Major Noncardiac Surgery,Comparison of Effects of Oxycodone and Sufentanil on Cardiovascular Stress Induced by Tracheal Intubation in the Patients With Coronary Heart Disease Undergoing Major Noncardiac Surgery,Oxycodone 10mg,"['Sufentanil', 'Oxycodone 10mg']",2,INTERVENTIONAL,['NA'],,,Cardiovascular,['Cardiovascular'],"['Oxycodone', 'Sufentanil', 'tracheal intubation']",COMPLETED,,2019-04-01,2019-09-19,"[{'measure': 'blood pressure(SBP)、diastolic blood pressure(DBP)、mean arterial pressure(MAP)', 'description': 'Under local anesthesia invasive artery line was put to the patients to monitor systolic blood pressure(SBP)、diastolic blood pressure(DBP)、mean arterial pressure(MAP)', 'timeFrame': 'one second before anesthesia induction, the moment when tracheal catheter passes through glottis and at 1, 3, 5 min after tracheal intubation'}]",[],1,60 Years,85 Years,FEMALE,False,Shengjing Hospital,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:25.980215,v2_robust,True,True,True,False,False,
NCT01135316,Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR,"A Phase 4, Open-Label, Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Kidney Disease Undergoing Magnetic Resonance Imaging (MRI) With Ablavar (Gadofosveset Trisodium) in Routine Clinical Practice",Ablavar,['Ablavar'],1,OBSERVATIONAL,[],,,Nephrogenic Systemic Fibrosis,['Nephrogenic Systemic Fibrosis'],"['NSF, Ablavar, Kidney Disease, Magnetic Resonance Imaging (MRI),']",COMPLETED,,2009-10,2013-09,"[{'measure': 'Incidence of Nephrogenic Systemic Fibrosis', 'timeFrame': '24 months'}]","[{'measure': 'Incidence of Severe Adverse Events (SAEs) & Adverse Events (AEs)', 'timeFrame': '48 hours'}]",2,18 Years,,ALL,False,Lantheus Medical Imaging,INDUSTRY,0,2.0,ACTUAL,2025-09-01T16:18:25.980233,v2_robust,False,True,True,False,True,
NCT00324116,Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions,"A Prospective, Open-Label Multi Center Trial Evaluating The Safety And Efficacy Of 0.3 Mg/Eye Pegaptanib Sodium (Macugen) Intravitreous Injection Given Every 6 Weeks For 54 Weeks In Patients With Small Neovascular Age-Related Macular Degeneration (AMD) Lesions",pegaptanib sodium (Macugen),"['pegaptanib sodium (Macugen)', 'MACUGEN']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Macular Degeneration,['Macular Degeneration'],[],COMPLETED,,2006-07,2008-08,"[{'measure': 'Number of Responders for Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS)', 'description': 'Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0. Responders defined as subjects having lost from baseline less than 15 letters of the best-corrected visual acuity; includes subjects with visual acuity gain.', 'timeFrame': 'Baseline, 54 Weeks'}]","[{'measure': 'Change From Baseline in Visual Acuity', 'description': 'Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0. Change: mean score at observation minus mean score at baseline.', 'timeFrame': 'Baseline, 6 weeks, 12 weeks, 54 weeks'}, {'measure': 'Number of Subjects Gaining Vision', 'description': 'Subjects gaining vision: gain from baseline of more than 15 letters of visual acuity. Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0.', 'timeFrame': '54 weeks or at early termination'}, {'measure': 'Number of Subjects Maintaining Vision', 'description': 'Subjects maintaining vision: gain from baseline of more than 0 letters of visual acuity. Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0.', 'timeFrame': '54 weeks or at early termination'}, {'measure': 'Number of Subjects With Severe Visual Loss', 'description': 'Subjects with severe visual loss: loss from baseline of \\>= 30 letters of visual acuity. Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0.', 'timeFrame': '54 weeks or at early termination'}, {'measure': 'Number of Subjects With a Distance Visual Acuity of > 20/200 at Baseline and Progressing to (<= 20/200)', 'description': 'Subjects with improving scores are those with \\> 20/200 at Baseline and progressing to =\\< 20/200 at Week 54.\n\nSubjects with no change are those with \\> 20/200 at Baseline and remaining at \\> 20/200 at Week 54.', 'timeFrame': '54 weeks'}, {'measure': 'Change in Vision-related Functioning and Quality of Life Using the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ 25).', 'description': 'Patient reported vision-related functioning and quality of life as measured using the 25 item NEI-VFQ 25. Change = Mean score at 54 weeks - mean score at baseline. A positive change represents an increase in function/health from Baseline. Items grouped as the following - Composite: mean score items 1-25; General Health: item 1; General Vision: item 2; Ocular Pain:4,19; Near Vision:5,6,7; Distance Vision:8,9,14; Social Functioning:11,13; Mental Health Activities:3,21,22,25; Role Difficulties:17,18; Dependency:20,23,24; Driving:15c,16, 16a; Color Vision: 12; Peripheral Vision: 10.', 'timeFrame': 'Baseline, 54 weeks or at early termination'}]",7,50 Years,,ALL,False,Pfizer,INDUSTRY,1,81.0,ACTUAL,2025-09-01T16:18:25.980310,v2_robust,True,True,True,False,False,
NCT00493116,Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta,"A Multi-Centre, Open Label Study to Investigate the Recovery of IFN-beta Efficacy in Relapsing-Remitting Multiple Sclerosis Patients With Neutralising IFN-beta Antibodies and Reduced Bioavailability",Interferon-beta-1a,"['Interferon-beta-1a', 'methylprednisolone', 'Avonex']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Relapsing-Remitting Multiple Sclerosis,['Relapsing-Remitting Multiple Sclerosis'],"['recovery of efficacy', 'MxA protein', 'neutralizing antibodies', 'Multiple sclerosis']",COMPLETED,,2003-10,2009-12,"[{'measure': 'return of bioavailability of AVONEX (interferon-beta-1a) as measured by induction of MxA mRNA', 'timeFrame': 'screening and every 3 months from month 6 to month 27'}]","[{'measure': 'Proportion of patients becoming neutralizing antibody negative', 'timeFrame': 'screening and every 3 months from month 3 to month 27'}, {'measure': 'proportion of patients becoming neutralizing antibody positive after treatment with AVONEX', 'timeFrame': 'at baseline and every three months'}, {'measure': 'proportion of patents relapse free', 'timeFrame': 'months 6, 12, 18 and 24'}, {'measure': 'total relapses', 'timeFrame': '27 months'}, {'measure': 'proportion of patients with an increase in EDSS of 1 point', 'timeFrame': 'screening, 3, 9, 15, 21, and 27 months'}, {'measure': 'Brain atrophy and cumulative number of enlarging T2 lesions on MRI', 'timeFrame': 'months 0, 12, and 27'}]",7,18 Years,55 Years,ALL,False,Biogen,INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:25.980410,v2_robust,True,True,True,False,False,
NCT02425306,Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma,A Trial to Evaluate the Immunogenicity and Safety of a Melanoma Helper Peptide Vaccine Plus Novel Adjuvant Combinations (MEL63),Montanide ISA-51,"['polyICLC', 'Montanide ISA-51', 'Cyclophosphamide']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Melanoma,['Melanoma'],"['peptide', 'vaccine', 'adjuvant', 'polyICLC', 'cyclophosphamide', 'Montanide ISA-51']",TERMINATED,Slow accrual to part 2 of the study. Accrual to part 1 is complete.,2015-05-12,2018-01-08,"[{'measure': 'Number of Participants With Adverse Events', 'description': 'Treatment-related adverse events, by CTCAE v4, Dose-limiting toxicities.', 'timeFrame': '30 days after administration of the last dose of 6MHP or cyclophosphamide'}, {'measure': 'Immunogenicity-CD4+ T Cell Responses', 'description': 'CD4+ T cell responses to 6 MHP: durable helper T cell response to 6MHP at 2 or more consecutive timepoints in the PBMC.', 'timeFrame': 'through day 85'}, {'measure': 'Immunogenicity-modification of the Tumor Microenvironment (Part 2 Only)', 'description': 'increased infiltration of CD4+ and CD8+ T lymphocytes into melanoma metastases', 'timeFrame': 'through day 22'}]","[{'measure': 'Immunogenicity-CD8+ T Cell Responses', 'description': 'CD8+ T cell responses to defined melanoma antigens', 'timeFrame': 'through day 85'}]",4,18 Years,,ALL,False,"Craig L Slingluff, Jr",OTHER,2,48.0,ACTUAL,2025-09-01T16:18:25.980466,v2_robust,True,True,False,True,True,Slow accrual to part 2 of the study. Accrual to part 1 is complete.
NCT04764006,Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study,"A Single Arm, Open-label, Single Center Phase II Study of Surufatinib Combined With PD-1 in Patients With Advanced MSS-Type Colorectal Cancer Treated With Standard First-line Therapy",Surufatinib,"['Surufatinib', 'HMPL-012']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Colorectal Cancer,['Advanced Colorectal Cancer'],[],UNKNOWN,,2021-10-13,2023-11-01,"[{'measure': 'Objective response rate (ORR)', 'description': 'CR + PR rate according to the RECIST version 1.1 guidelines.', 'timeFrame': 'up to 12 months'}]","[{'measure': 'Progression Free Survival (PFS)', 'description': 'To assess the efficacy of Surufatinib Combined With Chemotherapy as second-line therapy to Advanced CRC, patients by assessment of progression free survival (PFS) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).', 'timeFrame': 'up to 12 months'}, {'measure': 'Overall survival time', 'description': 'Disease control rate (DCR):CR + PR + SD rate according to the RECIST version 1.1 guidelines.', 'timeFrame': 'up to 36 months'}, {'measure': 'Assess the anti-tumor activity:DCR', 'description': 'Disease control rate (DCR):CR + PR + SD rate according to the RECIST version 1.1 guidelines.', 'timeFrame': 'up to 12 months'}]",4,18 Years,75 Years,ALL,False,Fujian Cancer Hospital,OTHER_GOV,0,10.0,ESTIMATED,2025-09-01T16:18:25.980476,v2_robust,True,True,False,False,False,
NCT06451406,Hyaluronic Acid Injection in the Glans Penis Versus Selective Serotonin Reuptake Inhibitors for Lifelong Premature,Hyaluronic Acid Injection in the Glans Penis Versus Selective Serotonin Reuptake Inhibitors for Lifelong Premature: A Randomized Controlled Trial,Selective serotonin re-uptake inhibitor,"['Hyaluronic acid', 'Selective serotonin re-uptake inhibitor']",2,INTERVENTIONAL,['NA'],,,Selective Serotonin Reuptake Inhibitor,"['Selective Serotonin Reuptake Inhibitor', 'Hyaluronic Acid', 'Glans Penis', 'Lifelong Premature']",[],COMPLETED,,2022-10-01,2023-06-01,"[{'measure': 'Intravaginal ejaculation latency time (IELT)', 'description': 'Intravaginal ejaculation latency time (IELT) is time from initiating sexual activity to ejaculation and used for diagnosis of Long-term premature ejaculation. It was assessed at the 1st, 3rd, and 6th months following treatment.', 'timeFrame': '6 months following treatment'}]","[{'measure': 'International index of erectile function-5 (IIEF-5)', 'description': 'International index of erectile function-5 (IIEF-5) was used for diagnosis of Long-term premature ejaculation and classified into five categories: no (score 22-25), mild (17-21), mild to moderate (12-16), moderate (8-11), and severe (5-7). It was assessed at the 1st, 3rd, and 6th months following treatment.', 'timeFrame': '6 months following treatment'}, {'measure': 'Index of premature ejaculation (IPE)', 'description': 'Index of premature ejaculation (IPE) is a 10 item self-administered questionnaire designed to evaluate sexual satisfaction, control and distress in men with premature ejaculation. It diagnosis premature ejaculation (PE) (≤8), possible PE (9 or 10), and no PE (≥11).It was assessed at the 1st, 3rd, and 6th months following treatment.', 'timeFrame': '6 months following treatment'}, {'measure': 'Patient satisfaction', 'description': 'Degree of patient satisfaction was assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied).\n\nDegree of patient satisfaction was assessed at the 1st, 3rd, and 6th months following treatment.', 'timeFrame': '6 months following treatment'}, {'measure': 'Incidence of side effects', 'description': 'Side effects such as nausea, dizziness, headache, dry mouth, pain at site of injection, ecchymosis, and bullae formation at site of injection were recorded.', 'timeFrame': '6 months following treatment'}]",5,18 Years,,MALE,False,New Valley University,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:25.980492,v2_robust,True,True,True,False,False,
NCT02866006,Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer,"Open-label, Dose-escalation, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre Efficacy of BVAC-C in Patients With Multiple Metastatic Progressive or Recurrent HPV Type 16 or 18 Positive Cervical Cancer After Failure to Standard Care",BVAC-C,"['BVAC-C', 'Topotecan']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Uterine Cervical Neoplasms,['Uterine Cervical Neoplasms'],"['HPV', 'Type 16, 18', 'E6E7', 'Immune therapeutic vaccine']",COMPLETED,,2016-10,2022-06,"[{'measure': 'Evaluate DLT with Clinical laboratory tests [Safety]', 'description': 'Lymphocyte subset, Serum cytokine, NKT/NK cell assay, CD4/CD8 assay', 'timeFrame': '12th week from first injection (End of trial)'}, {'measure': 'Incidence of Serious Adverse Events assessed with CTCAE [Safety]', 'timeFrame': '12th week from first injection (End of trial)'}]","[{'measure': 'Clinical laboratory tests', 'description': 'Blood chemistry, Serology', 'timeFrame': 'Screening visit and every 2 weeks from first injection (up to 12th week)'}, {'measure': '12-lead ECG', 'timeFrame': 'Screening visit and Termination visit (12th week from first injection)'}, {'measure': 'Vital signs', 'description': 'Blood pressure, Pulse rate, Respiratory rate, Tympanic temperature', 'timeFrame': 'Every 2 weeks from first injection (up to 12th week)'}, {'measure': 'Physical examination', 'description': 'Body weight', 'timeFrame': 'Screening, 6th week from first injection, 10th week from first injection and Termination visit (12th week from first injection)'}]",6,20 Years,,FEMALE,False,"Cellid Co., Ltd.",INDUSTRY,0,32.0,ACTUAL,2025-09-01T16:18:25.980523,v2_robust,True,True,True,False,True,
NCT05349006,Azathioprine in MOGAD,"A Randomized, Placebo-controlled Phase 3 Trial of Azathioprine for the Prevention of Relapse in Myelin-oligodendrocyte-glycoprotein (MOG)-Antibody Associated Disease",Azathioprine,['Azathioprine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Central Nervous System Inflammation,"['Central Nervous System Inflammation', 'MOG-IgG Associated Disease']","['MOGAD', 'azathioprine', 'optic neuritis', 'myelitis', 'neuromyelitis optica', 'MOG-IgG associated disease']",RECRUITING,,2023-12-12,2029-12-12,"[{'measure': 'Time to first relapse (in days), comparing azathioprine-treated vs placebo-treated patients during a randomized control period of a maximum of three years.', 'description': 'A definite relapse will be defined as such:\n\n* When a patient is diagnosed as experiencing a relapse by the local investigator, the anonymized file will be reviewed within 4 days by a second investigator neurologist, not aware of the randomization group nor of the center treating the patient.\n* If this second neurologist also considers the patient as experiencing a relapse, the patient will be considered as relapsing for the main analysis.\n* If the second neurologist disagrees, the opinion of a third neurologist will be asked and the majority opinion will be retained.\n\nAs to ensure a maximum of homogeneity, we also propose a protocol-defined criteria for a MOGAD relapse, validated by the steering committee and available to every investigator (see Annex 2).', 'timeFrame': 'During a randomized control period of a maximum of three years'}]","[{'measure': 'Number and type of adverse events, including serious adverse events, related to azathioprine and/or steroids and placebo', 'timeFrame': ': During a randomized control period of a maximum of three years'}, {'measure': 'Evaluation of global disability at 36 months', 'description': 'Global disability at 36 months assessed by EDSS: The EDSS scale is a method of quantifying disability and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of patients with inflammatory disorders of the central nervous system. The EDSS scale ranges from 0 to 10 in 0.5-unit increments (20 values) that represent higher levels of disability. Scoring is based on an examination by a neurologist.', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of global disability at 36 months', 'description': 'Worsening from baseline to 36 months of the EDSS', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of global disability at 36 months', 'description': 'Ambulation status at 36 months assessed by the Ambulation Score. Scoring is based on a measurement of the distance the patient is able to walk (in meters) and then classified in 12 levels.', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of global disability at 36 months', 'description': 'Worsening from baseline to 36 months of the Ambulation Score.', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of visual disability at 36 months', 'description': 'Best-corrected high contrast visual acuity at 36 months measured (each eye tested separately) using the standard Snellen chart or equivalent.', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of visual disability at 36 months', 'description': 'Worsening from baseline to 36 months of visual disability assessed by change of the best- corrected high-contrast visual acuity using the standard Snellen chart or equivalent (each eye tested separately).', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of visual disability at 36 months', 'description': 'Best-corrected low-contrast visual acuity at 36 months using the Sloan Charts at 2.5%, in each eye.', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of visual disability at 36 months', 'description': 'Worsening from baseline to 36 months of low-contrast visual acuity using the Sloan Charts at 2.5%, in each eye.', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of visual disability at 36 months', 'description': 'Inner retinal layers thicknesses at 36 months assessed by the spectral domain OCT (each eye tested separately)', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Evaluation of visual disability at 36 months', 'description': 'Worsening from baseline to 36 months of the peripapillary retinal nerve fiber layer thickness (μm) and the ganglion cell complex thickness (μm) assessed with spectral domain OCT (each eye tested separately).', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Quality of life will be assessed using the EuroQOL EQ-5D-3L at 36 months', 'description': 'https://euroqol.org', 'timeFrame': 'at 36 months'}, {'measure': 'Compliance to treatment', 'description': 'percentage of untaken pills (left in the blisters) regarding each patient', 'timeFrame': 'During a randomized control period of a maximum of three years'}, {'measure': 'Exploratory radiological features', 'description': 'Description, and comparison between the two groups, of worsening of MRI (brain and spinal cord and visual) from baseline to 36 months assessed by number of new/enlarging T2 lesions', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Exploratory radiological features', 'description': 'Description and comparison between the two groups of worsening of MRI (brain and/or spinal cord and/or visual) from baseline to 36 months assessed by number of new T1 gadolinium enhancing lesions', 'timeFrame': 'at baseline and at 36 months'}, {'measure': 'Exploratory biological features', 'description': 'In each group of treatment, association between MOG-Ab titer at first episode and the risk of relapse', 'timeFrame': 'at screening, at 6 months, at 12 months, at 36 months and in case of a relapse'}, {'measure': 'Exploratory biological features', 'description': 'In each group of treatment, association between MOG-Ab titer at onset and the level of global disability assessed by the EDSS at 36 months.', 'timeFrame': 'at screening, at 6 months, at 12 months, at 36 months and in case of a relapse'}, {'measure': 'Exploratory biological features', 'description': 'In each group of treatment, prognostic value of longitudinal MOG-Ab-titers to predict relapse.', 'timeFrame': 'at screening, at 6 months, at 12 months, at 36 months and in case of a relapse'}]",19,18 Years,,ALL,False,Hospices Civils de Lyon,OTHER,0,126.0,ESTIMATED,2025-09-01T16:18:25.980667,v2_robust,True,True,False,False,True,
NCT03565406,A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma,A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma,Mocetinostat Induction Phase + Ipilimumab + Nivolumab,"['Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab', 'Mocetinostat Induction Phase + Ipilimumab + Nivolumab']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Melanoma,['Melanoma'],[],TERMINATED,recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated,2018-04-25,2020-01-13,"[{'measure': 'Number of Dose Limiting Toxicities (DLTs), defining the maximum tolerated dose (MTD)', 'timeFrame': '60 Months'}]","[{'measure': 'Maximum observed concentration (Cmax) of Mocetinostat administered in combination with ipilimumab and nivolumab', 'timeFrame': '60 Months'}]",2,18 Years,100 Years,ALL,False,NYU Langone Health,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:25.980725,v2_robust,True,True,False,True,False,recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated
NCT00800306,Effects of Levosimendan on Microcirculation in Septic Shock,Levosimendan and Inhaled Nitric Oxide for Resuscitating the Microcirculation in Septic Shock. A Randomized Controlled Trial,Levosimendan,"['dobutamine', 'Levosimendan']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Septic Shock,['Septic Shock'],"['sepsis', 'septic shock', 'microcirculation', 'levosimendan', 'dobutamine', 'inotropes', 'inhaled nitric oxide']",COMPLETED,,2007-11,2009-04,"[{'measure': 'Systemic hemodynamic and Microcirculatory flow index of small and medium vessels (MFI)', 'timeFrame': 'over a period of 36 hrs from the time of randomization'}]","[{'measure': 'Acid-base homeostasis', 'timeFrame': 'over a period of 36 hrs from the time of randomization'}, {'measure': 'Oxygen transport variables', 'timeFrame': 'over a period of 36 hrs from the time of randomization'}, {'measure': 'Functional capillary density (mm/mm2) (FCD)', 'timeFrame': 'over a period of 36 hrs from the time of randomization'}, {'measure': 'De Backer score', 'timeFrame': 'over a period of 36 hrs from the time of randomization'}, {'measure': 'Perfused Vessel Density (PVD) (mm/mm2)', 'timeFrame': 'over a period of 36 hrs from the time of randomization'}, {'measure': 'Proportion of Perfused vessels (%) (PPV)', 'timeFrame': 'over a period of 36 hrs from the time of randomization'}]",7,18 Years,,ALL,False,University of Roma La Sapienza,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:25.980735,v2_robust,True,True,True,False,False,
NCT00467506,Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma,Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma,bispecific antibody and di-DTPA-131I,['bispecific antibody and di-DTPA-131I'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Thyroid Neoplasms,['Thyroid Neoplasms'],['Recurrence of medullary thyroid carcinoma: abnormal calcitonin level and biomarkers doubling time lower than 5 years after initial surgery'],COMPLETED,,2004-05,2011-01,[],[],0,18 Years,,ALL,False,Nantes University Hospital,OTHER,0,,,2025-09-01T16:18:25.980803,v2_robust,True,True,True,False,False,
NCT06851806,Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease,"A Multicentre, Interventional, Phase IV, Open-label, Study to Evaluate the Safety of Palivizumab in Children Less Than 24 Months of Age With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease",Palivizumab 15 mg/kg,['Palivizumab 15 mg/kg'],1,INTERVENTIONAL,['NA'],,,Respiratory Syncytial Virus (RSV),['Respiratory Syncytial Virus (RSV)'],['Phase IV'],NOT_YET_RECRUITING,,2025-08-30,2026-06-30,"[{'measure': 'To assess the safety of palivizumab prophylaxis when administered to preterm infants (≤ 35 wGA), children with BPD (< 24 months) and/or children with haemodynamically significant CHD (< 24 months).', 'description': '1\\) To determine percentage of participants with AEs and SAEs. 2) To assess nature, incidence, and severity of all AEs including unexpected adverse drug reactions 2)To determine percentage of participants with AEs that lead to study intervention discontinuation.', 'timeFrame': 'screening to day 151'}]",[],1,,,ALL,False,AstraZeneca,INDUSTRY,0,138.0,ESTIMATED,2025-09-01T16:18:25.980809,v2_robust,True,True,False,False,True,
NCT04518306,Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension,Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Placebo for the Treatment of Hypertension,Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg,"['Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg', 'Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypertension,['Hypertension'],[],COMPLETED,,2021-06-14,2023-10-18,"[{'measure': 'Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4', 'description': 'Each blood pressure (BP) measurement consisted of valid SBP values (ie. SBP\\>60 mmHg and \\<250 mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.', 'timeFrame': 'Randomization to Week 4'}]","[{'measure': 'Difference in Change in Clinic Seated Mean Mean Systolic Blood Pressure (SBP) From Randomization to Week 4', 'description': 'Each blood pressure (BP) measurement consisted of valid SBP values (ie. SBP\\>60 mmHg and \\<250 mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.', 'timeFrame': 'Randomization to Week 4'}, {'measure': 'Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4', 'description': 'Each blood pressure (BP) measurement consisted of valid DBP values (ie. DBP\\>40mmHg and \\<150mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.', 'timeFrame': 'Randomization to Week 4'}, {'measure': 'Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and DBP <90 mmHg at Week 4', 'description': 'The percentage of participants achieving averaged clinic SBP \\<140 and DBP \\<90 mmHg at Week 4 was evaluated.', 'timeFrame': 'At Week 4'}, {'measure': 'Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4', 'description': 'The percentage of participants achieving averaged clinic SBP \\<130 and DBP \\<80 mmHg at Week 4 was evaluated. Participants were analyzed in the treatment group to which they have been randomized.', 'timeFrame': 'At Week 4'}, {'measure': 'Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4', 'description': 'Each blood pressure (BP) measurement consisted of valid DBP values (ie. DBP\\>40mmHg and \\<150mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups. To evaluate the difference in change, least squares mean change value is reported.', 'timeFrame': 'Randomization to Week 4'}, {'measure': 'Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4', 'description': 'Difference in change in trough home SBP for GMRx2 vs placebo was evaluated at Week 4. Trough values were measured before morning dose of the study medication.', 'timeFrame': 'Randomization to Week 4'}, {'measure': 'Difference in Change in Trough Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4', 'description': 'Difference in change in trough home DBP for GMRx2 vs placebo was evaluated at Week 4. Trough values were measured before morning dose of the study medication. To evaluate the difference in change, least squares mean change value is reported.', 'timeFrame': 'Randomization to Week 4'}, {'measure': 'Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 4', 'description': 'The percentage of participants achieving home seated mean SBP \\<135 and DBP \\<85 mmHg at Week 4 was evaluated', 'timeFrame': 'At Week 4'}, {'measure': 'Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4', 'description': 'The percentage of participants achieving averaged home seated mean SBP \\<130 and DBP \\<80 mmHg at Week 4 was evaluated', 'timeFrame': 'Randomization to Week 4'}]",10,18 Years,,ALL,False,George Medicines PTY Limited,INDUSTRY,0,755.0,ACTUAL,2025-09-01T16:18:25.980832,v2_robust,True,True,True,False,False,
NCT01499004,"A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers","A Phase 1, Randomized, Open Label, Partial Crossover Study To Evaluate The Pharmacokinetics (PK) And Safety Of Three Modified Release (MR) And One Immediate Release (IR) Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers","tofacitinib (CP-690,550) modified-release formulation A","['tofacitinib (CP-690,550) immediate-release formulation', 'tofacitinib (CP-690,550) modified-release formulation A', 'tofacitinib (CP-690,550) modified-release formulation B2', 'tofacitinib (CP-690,550) modified-release formulation B1']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['tofacitinib', 'CP-690', '550', 'relative bioavailability', 'modified release', 'Phase 1']",COMPLETED,,2011-11,2011-12,"[{'measure': 'AUCinf: Area under the plasma concentration-time profile from time 0 exprapolated to infinite time', 'timeFrame': '72 hours post dose'}, {'measure': 'AUClast: Area under the plasma concentration-time profile from time 0 to the last with quantifiable concentration', 'timeFrame': '72 hours post dose'}, {'measure': 'Cmax: Maximum plasma concentration of tofacitinib (CP-690,550)', 'timeFrame': '72 hours post dose'}, {'measure': 'Tmax: Amount of time tofacitinib (CP-690,550) is at maximum plasma concentration', 'timeFrame': '72 hours post dose'}, {'measure': 't1/2: The time required for one half of the total amount of tofacitinib (CP-690,550) to be removed from the plasma', 'timeFrame': '72 hours post dose'}]","[{'measure': 'Frel: Relative bioavailability (Frel) of tofacitinib (CP-690,550) in the modified-release formulations compared to the immediate release formulation', 'timeFrame': '24 hours post dose'}]",6,21 Years,55 Years,ALL,True,Pfizer,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:25.980919,v2_robust,True,True,True,False,False,
NCT00966004,A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder,"Phase III Study of YM178 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients With Overactive Bladder",YM178,"['Detrol', 'Detrusitol', 'YM178', 'Placebo', 'mirabegron', 'tolterodine']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,"Urinary Bladder, Overactive","['Urinary Bladder, Overactive']","['Urge incontinence', 'YM178', 'Overactive Bladder', 'Urgency', 'Urinary incontinence', 'mirabegron', 'Micturition']",COMPLETED,,2009-07-24,2010-02-15,"[{'measure': 'Change from baseline in the mean number of micturitions per 24 hours', 'timeFrame': 'Within a 12-week treatment period'}]","[{'measure': 'Change from baseline in the mean number of urgency episodes per 24 hours', 'timeFrame': 'Within a 12-week treatment period'}, {'measure': 'Change from baseline in the mean number of urinary incontinence episode per 24 hours', 'timeFrame': 'Within a 12-week treatment period'}, {'measure': 'Change from baseline in the mean number of urge incontinence episodes per 24 hours', 'timeFrame': 'Within a 12-week treatment period'}, {'measure': 'Change from baseline in the mean volume voided per micturition', 'timeFrame': 'Within a 12-week treatment period'}, {'measure': 'Change from baseline in mean number of nocturia episodes', 'timeFrame': 'Within a 12-week treatment period'}, {'measure': ""Change from baseline in domain score of quality of life scores as assessed by King's health questionnaire"", 'timeFrame': 'Within a 12-week treatment period'}]",7,20 Years,,ALL,False,Astellas Pharma Inc,INDUSTRY,0,1139.0,ACTUAL,2025-09-01T16:18:25.980936,v2_robust,True,True,True,False,False,
NCT03914404,Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy,"A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy",γ-linoleic acid and placebo(Thioctic Acid),"['γ-linoleic acid and placebo(Thioctic Acid)', 'Thioctic Acid and placebo(γ-linoleic acid)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetic Neuropathy,['Diabetic Neuropathy'],[],COMPLETED,,2016-01-26,2018-07-25,"[{'measure': 'Changes of Visual Analog Scale(VAS)', 'description': 'The Visual Analog Scale(VAS) score is 0 point for no symptom, 10 points for the most severe symptom, and the patient is asked to mark the degree of subjective pain symptoms as an integer.', 'timeFrame': '12 weeks'}, {'measure': 'Changes of Total Symptom Score(TSS)', 'description': 'Total Symptom Score(TSS) classifies diabetic neuropathy symptoms into four categories (pain, burning pain, paresthesia, numbness). The frequency (Occasional, Frequent, Continuous) and symptom intensity (Absent, Slight, Moderate, Severe) are calculated through each question and the score is obtained according to the visual analog scale. It is calculated from 0 point up to 14.64 points.', 'timeFrame': '12 weeks'}]","[{'measure': 'Changes of Michigan Neuropathy Screening Instrument(MNSIQ)', 'description': ""A 15-item questionnaire (MNSIQ) is used to assess deformation, infection, skin thickening of the skin's stratum corneum, and ulcers.\n\nMNSIQ was designed to screen for diabetic neuropathy through questionnaires on 15 questions that are related to neuropathic symptoms (pain, temperature, and sensation). Two of 15 (number 4 and 10) are vascular symptoms and are excluded from the total score regardless of the results. If you answered 'No' to questions 7 and 13, you will get 1 point. In the end, scores ranging from 0 to 13 indicate that the higher the score, the more severe the neuropathic symptoms."", 'timeFrame': '12 weeks'}, {'measure': 'Changes of Michigan Neuropathy Screening Instrument(MNSIE)', 'description': ""A foot test (MNSIE) is used to assess deformation, infection, skin thickening of the skin's stratum corneum, and ulcers.\n\nMNSIE evaluates foot shape, foot ulceration, ankle reflex, sense of vibration of big toe, monofilament right and left. The score ranges from point 0 to 10, and when the score is above 2, it is diagnosed as neuropathy."", 'timeFrame': '12 weeks'}, {'measure': 'Changes of Current perception Threshold(CPT)', 'description': 'Sensory nerve conduction threshold (SNCT) is a unique method for evaluating all three sensory neurons (small unmyelinated fibers, small myelinated fibers, and large myelinated fibers) that make up more than 90% of sensory nerves. It seems to be possible to objectively evaluate sensory nerve of small fiber which recovered early in diabetic neuropathy(Using neurometer).', 'timeFrame': '12 weeks'}, {'measure': 'Changes of Modified Brief Pain Inventory-diabetic polyneuropathy(Modified BPI-DPN)', 'description': 'Modified Brief Pain Inventory-diabetic polyneuropathy(Modified BPI-DPN) displays the pain area on the human figure, the number of pain sites, treatment of pain, and pain medication.\n\nPain severity refers to the pain sensation- identification aspect (pain threshold). The worst pain, the least pain, the pain average, and the pain now for the last 24 hours are displayed on the 10-point scale (0 points: none, \\~ 10 Point: too big to imagine). Pain interference is the emotional-synchronous aspect of pain (pain tolerance). It classifies general activity, mood, walking, working, relationship, sleep and enjoyment of life, and use the 10-point scale (0 points: none to 10 points: completely disturbed).', 'timeFrame': '12 weeks'}, {'measure': 'Changes of EuroQol-5 Dimensions(EQ 5D)', 'description': ""EQ-5D index = 1 - (0.050 + 0.096 M2 + 0.418 x M3 + 0.046 x SC2 + 0.13 x SC3 + 0.051 x UA2 + 0.028 x UA3 + 0.037 x PD2 + 0.151 x PD3 + 0.043 x AD2 + 0.158 x AD3 + 0.050 × N3) - 1 if the variable is applicable, 0 if not (M: mobility, SC: self-care, UA: usual activity,, PD: pain / discomfort, AD: anxiety / depression)\n\n\\* Variable definition\n\n* M2: 1 if mobility is 'level 2', 0 if not\n* M3: 1 if mobility is 'level 3', 0 if not\n* SC2: 1 if self-care is 'level 2', 0 if not\n* SC3: 1 if self-care is 'level 3', 0 if not\n* UA2: 1 if usual activity is 'level 2', 0 if not\n* UA3: 1 if usual activity is 'level 3', 0 if not\n* PD2: 1 if pain / discomfort is 'level 2', 0 if not\n* PD3: 1 if pain / discomfort is 'level 3', 0 if not\n* AD2: 1 if anxiety / depression is 'level 2', 0 if not\n* AD3: 1 if anxiety / depression is 'level 3', 0 if not\n* N3: 1 if there is at least one level 3, others are 0"", 'timeFrame': '12 weeks'}]",7,20 Years,75 Years,ALL,False,Chonbuk National University Hospital,OTHER,0,100.0,ACTUAL,2025-09-01T16:18:25.980958,v2_robust,True,True,True,False,False,
NCT05721404,Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis,Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis: A Randomized Controlled Trial,Icodextrin Peritoneal Dialysis Solution,"['Hypertonic Dextrose solution', 'Icodextrin Peritoneal Dialysis Solution']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Peritoneal Dialysis,['Peritoneal Dialysis'],"['peritoneal dialysis', 'incremental peritoneal dialysis', 'icodextrin']",RECRUITING,,2023-05-24,2025-12-31,"[{'measure': 'The time that transferring from incremental PD to full dose in the first year of incremental PD', 'description': 'The time of transferring to full dose dialysis was subtracted from the time of andomization', 'timeFrame': 'From date of randomization until the date of transferring from incremental PD to full dose, assessed up to 12 months'}]","[{'measure': 'The time of the first episode of peritonitis', 'description': 'The time of the first episode of peritonitis was subtracted from the time of randomization', 'timeFrame': 'From date of randomization until the date of first documented date of peritonitis, whichever came first, assessed up to 12 months'}, {'measure': 'The time of the incidence of anuria', 'description': 'The time of the incidence of anuria was subtracted from the time of randomization', 'timeFrame': 'From date of randomization until the date of first documented date of anuria, whichever came first, assessed up to 12 months'}, {'measure': 'The time of the first incidence of hospitalization', 'description': 'The time of the first incidence of hospitalization was subtracted from the time of randomization', 'timeFrame': 'From date of randomization until the date of first documented date of hospitalization, whichever came first, assessed up to 12 months'}, {'measure': 'The time of technical failure (transferring to HD)', 'description': 'The time of technical failure was subtracted from the time of randomization', 'timeFrame': 'From date of randomization until the date of first documented date of technical failure (transferring to HD), whichever came first, assessed up to 12 months'}, {'measure': 'All cause mortality and cardiovascular mortality', 'description': 'The time of death was subtracted from the time of randomization', 'timeFrame': 'From date of randomization until the date of documented date of death due to cardiovascular cause and other causes, assessed up to 12 months'}, {'measure': 'Cardiovascular disease free survival', 'description': 'The time of the incidence of cardiovascular disease was subtracted from the time of randomization', 'timeFrame': 'From date of randomization until the date of first documented date of cardiovascular disease, whichever came first, assessed up to 12 months'}, {'measure': 'The quality of life', 'description': 'Medical Outcomes Study 36-Item Short From Survey (SF-36)', 'timeFrame': ""Record patients' quality of life at the time of randomization and the first year after randomization""}]",8,18 Years,,ALL,False,"First Affiliated Hospital, Sun Yat-Sen University",OTHER,1,194.0,ESTIMATED,2025-09-01T16:18:25.981092,v2_robust,True,True,False,False,False,
NCT01525004,Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients,"Randomized, Double Blind, Comparison of Standard Dose Trivalent Inactivated Influenza Vaccine in Pediatric Solid Organ Transplant Patients",High-Dose trivalent inactivated influenza vaccine,"['High-Dose trivalent inactivated influenza vaccine', 'Standard dose trivalent inactivated influenza vaccine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Pediatric Solid Organ Transplant Patients,['Pediatric Solid Organ Transplant Patients'],"['Solid organ transplant', 'Flu vaccine']",COMPLETED,,2011-09,2012-12,"[{'measure': 'Safety profile of high dose trivalent inactivated influenza vaccine to standard dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients', 'description': 'We will record local and systemic reactions after each vaccination for seven days. Patients will fill out a diary card. We will collect adverse events for 28 days and SAE for 6 months.', 'timeFrame': '6-9 months'}]","[{'measure': 'Humoral immune responses of pediatric Solid Organ Transplant patients to influenza virus antigens included in trivalent inactivated influenza vaccine after high and standard doses of trivalent inactivated influenza vaccine.', 'description': 'We will measure HAI titers. We will calculate the perecet of subjects who acheive HAI titers greater than and equal to 1:40 and those with 4-fold increase. We will also calculate GMTs.', 'timeFrame': '12 months'}]",2,3 Years,17 Years,ALL,False,Vanderbilt University,OTHER,2,38.0,ACTUAL,2025-09-01T16:18:25.981120,v2_robust,True,True,True,False,True,
NCT06871904,Fibrosis-Modulating Effects of Metformin and Pirfenidone in Oral Submucous Fibrosis,Exploring the Fibrosis-Modulating Potential of Metformin and Pirfenidone in Oral Submucous Fibrosis: Molecular Mechanisms to Clinical Applications,Metformin Hydrochloride 500Mg Tablet,"['Beclomaethasone and Vitamin E', 'Vitamin E', 'Metformin Hydrochloride 500Mg Tablet', 'Pirfibet', 'Pirfenidone (PFD)', 'Beclamethasone', 'Glucophage']",7,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Oral Submucous Fibrosis,['Oral Submucous Fibrosis'],"['Oral submucous fibrosis', 'Fibrosis Modulation', 'Metformin', 'Pirfenidone', 'Exosome secretion', 'Molecular Pathway', 'LCMS', 'Clinical Trial', 'Exosome Protein Profiling']",RECRUITING,,2025-04-07,2025-12-01,"[{'measure': 'Change in Exosome Secretion and Characterization in OSF Cell Lines', 'description': 'This outcome evaluates the effect of Metformin and Pirfenidone on exosome secretion and size distribution in OSF cell lines. Exosomes will be isolated and characterized using Scanning Electron Microscopy (SEM) and Dynamic Light Scattering (DLS) to assess morphological changes, size, and concentration differences across treatment groups.', 'timeFrame': '24, 48, and 72 hours post-treatment'}, {'measure': 'Changes in Fibrosis-Related Gene Expression in OSF Cell Lines', 'description': 'This outcome assesses the effect of Metformin and Pirfenidone on fibrosis-related gene expression (TGF-β, Collagen 1A1, α-SMA) in OSF cell lines. Changes will be analyzed using quantitative PCR (qPCR).', 'timeFrame': '24 and 48 hours post-treatment'}, {'measure': 'Reduction in Fibrosis Severity in OSF Patients', 'description': 'This outcome measures clinical improvement in Oral Submucous Fibrosis (OSF) patients treated with Metformin, Pirfenidone, or Supportive Care (Beclomethasone + Vitamin E). Severity will be assessed using the Burning Mouth Index by verbal numeric rating scale (0-10) at baseline and every 4 weeks during the trial and Interincisal Mouth Opening (IMO).', 'timeFrame': 'Baseline, 4 weeks, 8 weeks, and 12 weeks, 16 weeks, 20 weeks and 24 weeks'}, {'measure': 'Change in TGF-β and Collagen Levels in Exosomes from OSF Cell Lines', 'description': 'This outcome assesses whether Metformin and Pirfenidone reduce fibrosis-related molecular markers (TGF-β and Collagen) in exosomes isolated from OSF cell lines. Exosomal protein levels will be analyzed using Western Blot and Liquid Chromatography-Mass Spectrometry (LCMS) to determine drug-induced changes in fibrosis-related pathways.', 'timeFrame': '24, 48, and 72 hours post-treatment'}]","[{'measure': 'Morphological Changes in OSF Cell Lines Post-Treatment', 'description': 'This outcome evaluates the morphological alterations in OSF cell lines following treatment with Metformin and Pirfenidone. Changes in cell shape, size, and fibrosis-associated structural modifications will be assessed using Scanning Electron Microscopy (SEM).', 'timeFrame': '24, 48, and 72 hours post-treatment'}, {'measure': 'Size and Distribution of Exosomes in OSF Cell Lines', 'description': 'This outcome measures changes in exosome size, distribution, and concentration after treatment with Metformin and Pirfenidone. Characterization will be performed using Dynamic Light Scattering (DLS) and Scanning Electron Microscopy (SEM).', 'timeFrame': '24, 48, and 72 hours post-treatment'}, {'measure': 'Functional Impact of Treated OSF cells', 'description': 'This outcome evaluates whether Metformin- and Pirfenidone-treated OSF cell lines, as compared to control untreated OSF cells, influence fibroblast migration and proliferation. Cell behavior will be assessed through Scratch migration and proliferation assays to determine functional effects.', 'timeFrame': '24, 48, 72 and 96 hours post- treatment'}, {'measure': 'Safety and Viability of OSF Cell Lines Post-Treatment', 'description': 'This outcome measures the cytotoxicity and cell viability of OSF cell lines following treatment with Metformin and Pirfenidone. MTT assay will be used to assess potential toxic effects of the drugs at different concentrations.', 'timeFrame': '24, 48, and 72 hours post-treatment'}]",8,18 Years,45 Years,ALL,False,Ziauddin University,OTHER,1,45.0,ESTIMATED,2025-09-01T16:18:25.981146,v2_robust,True,True,False,False,True,
NCT06324604,"Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients","Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients",Placebo,"['MTX-101', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,"['Healthy Volunteers', 'Celiac Disease', 'Type 1 Diabetes']","['Healthy Volunteers', 'Celiac', 'Type 1 Diabetes']",RECRUITING,,2024-06-13,2026-04,"[{'measure': 'Safety of single, ascending dose levels of MTX-101', 'description': 'Assess the safety of single, ascending dose levels of MTX-101 by evaluating the incidence, severity, and seriousness of treatment-emergent adverse events', 'timeFrame': 'Enrollment to 8 weeks post dose'}, {'measure': 'Safety of multiple, ascending dose levels of MTX-101', 'description': 'Assess the safety of multiple, ascending dose levels of MTX-101by evaluating the incidence, severity, and seriousness of treatment-emergent adverse events', 'timeFrame': 'Enrollment to 11 weeks following the last dose'}]","[{'measure': 'pharmacokinetics (PK) of MTX-101', 'description': 'Characterize the pharmacokinetics (PK) of MTX-101 by measuring the maximum time of occurrence for maximum plasma drug concentration (Cmax)', 'timeFrame': 'Enrollment to 11 weeks following the last dose'}, {'measure': 'pharmacokinetics (PK) of MTX-101', 'description': 'Characterize the pharmacokinetics (PK) of MTX-101 by measuring the time of occurrence for maximum plasma drug concentration (Tmax).', 'timeFrame': 'Enrollment to 11 weeks following the last dose'}, {'measure': 'pharmacokinetics (PK) of MTX-101', 'description': 'Characterize the pharmacokinetics (PK) of MTX-101 by measuring the maximum plasma drug concentration (Cmax), minimum plasma drug concentration (Cmin), and area under the plasma drug concentration versus time curve from time 0 to last measurable concentration (AUC(0-t))', 'timeFrame': 'Enrollment to 11 weeks following the last dose'}, {'measure': 'anti-drug antibody (ADA) formation', 'description': ""Evaluate incidence of anti-drug antibody (ADA) formation by measuring the detect the presence of anti-MTX-101 antibodies in participant's blood."", 'timeFrame': 'Enrollment to 11 weeks following the last dose'}]",6,18 Years,65 Years,ALL,True,Mozart Therapeutics Australia Pty Ltd,INDUSTRY,0,96.0,ESTIMATED,2025-09-01T16:18:25.981212,v2_robust,True,True,False,False,True,
NCT01965704,Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women,AIM 2- Prevention of Neonatal Abstinence Syndrome,Ondansetron,"['IV Normal saline; oral simple syrup', 'Ondansetron', 'Zofran', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Narcotic Addiction,"['Narcotic Addiction', 'Neonatal Abstinence Syndrome']","['Narcotic addiction during pregnancy', 'Neonatal abstinence syndrome', 'NAS']",COMPLETED,,2014-09-09,2020-09-16,"[{'measure': 'Number of Participants With Neonatal Abstinence Syndrome', 'description': 'The incidence of neonatal abstinence syndrome (NAS) measured as the number of neonates who need for morphine treatment for the symptoms of neonatal opioid withdrawal syndrome (NOWS) while the neonates received study medication and for the 30 days after stopping the study medication.', 'timeFrame': '35 days'}]","[{'measure': 'Length of Hospital Stay', 'description': ""Severity of NAS will be measured by neonates' length of hospital stay (birth to discharge). Length of stay was calculated with 1) no maximum length, and 2) maximum length of stay capped at 15 days. All participants were included in both analyses."", 'timeFrame': 'At Day 15 and up to 64 days'}, {'measure': 'Total Dose of Narcotic Required to Treat the Symptoms of NAS', 'description': 'Median dose of morphine required by neonates within 15 days of delivery.', 'timeFrame': '15 days'}, {'measure': 'Number of Participants Requiring Adjunctive Medication to Treat NOWS', 'description': 'Number of neonates requiring treatment with phenobarbital or clonidine.', 'timeFrame': '15 days'}]",4,,45 Years,ALL,False,Stanford University,OTHER,2,196.0,ACTUAL,2025-09-01T16:18:25.981235,v2_robust,True,True,True,False,False,
NCT00828204,Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects,"An Open-Label, Multicenter Study to Evaluate the Safe and Effective Use of the Single-Use Autoinjector With an Avonex® Prefilled Syringe in Multiple Sclerosis Subjects",BG9418 (interferon beta-1a),"['BG9418 (interferon beta-1a)', 'Avonex']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Multiple Sclerosis,['Multiple Sclerosis'],[],COMPLETED,,2009-01,2010-10,"[{'measure': 'Percentage of Participants in the Main Subset With Overall Success Using the Avonex Single-Use Autoinjector', 'description': ""A trainer/observer documented the participant's ability to self-inject with the Avonex single-use autoinjector and completed an observation form. Overall success in using the device for each participant was defined as no failures occurring in any step (ie, device set-up, self-administration of injection, and capping/disposal of the device) during the participant's use of the single-use Avonex autoinjector."", 'timeFrame': 'Day 22'}]",[],1,18 Years,65 Years,ALL,False,Biogen,INDUSTRY,0,95.0,ACTUAL,2025-09-01T16:18:25.981254,v2_robust,True,True,True,False,False,
NCT01717404,Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C),Effects of Mexiletine on Colonic Transit in a Patient With a Known SCN5A A997T Mutation,Mexiletine,['Mexiletine'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,IBS,['IBS'],['IBS'],COMPLETED,,2012-10,2012-11,"[{'measure': 'change in the 48 hour Colon Transit', 'description': 'Colon transit will be measured using validated scintigraphy methods conducted in our Clinical Research Unit (CRU).\\[17, 18\\] The participant will ingest a Tc-99m labeled sulfur colloid in egg to be used as a stomach marker and ln-111 chloride bound to activated charcoal enclosed in a methacrylate-coated capsule to measure colonic transit.', 'timeFrame': 'Baseline to 10 days'}]",[],1,60 Years,70 Years,FEMALE,False,Mayo Clinic,OTHER,0,1.0,ACTUAL,2025-09-01T16:18:25.981267,v2_robust,True,True,True,False,False,
NCT00002104,Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV,Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV,Thalidomide,['Thalidomide'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Mycobacterium Avium-Intracellulare Infection,"['Mycobacterium Avium-Intracellulare Infection', 'HIV Infections', 'Tuberculosis, Mycobacterium Infection']","['Mycobacterium tuberculosis', 'Mycobacterium Infections', 'AIDS-Related Opportunistic Infections', 'Mycobacterium avium-intracellulare Infection', 'Acquired Immunodeficiency Syndrome', 'AIDS-Related Complex', 'Mycobacterium Infections, Atypical', 'Thalidomide']",COMPLETED,,,,[],[],0,18 Years,65 Years,ALL,False,Aaron Diamond AIDS Research Center,OTHER,0,,,2025-09-01T16:18:25.981278,v2_robust,True,True,True,False,False,
NCT02886884,Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects,"A Phase I/II, Randomized, Double Blind, Pilot Trial to Evaluate the Safety and Efficacy of Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects",20 million Allogeneic Mesenchymal Human Stem Cells,"['allo-hMSCs', 'stem cells', '20 million Allogeneic Mesenchymal Human Stem Cells', '100 million Allogeneic Mesenchymal Human Stem Cells']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']","['Diabetes', 'Endothelial dysfunction', 'Stem cells']",COMPLETED,,2017-10-20,2020-09-03,"[{'measure': 'Number of Treatment Emergent Serious Adverse Events (TE-SAEs)', 'description': 'TE-SAEs as evaluated by the investigator which may include but not limited to: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities.', 'timeFrame': 'Up to one month (post infusion)'}]","[{'measure': 'EPC-CFU Levels', 'description': 'Endothelial Progenitor Cell Colony Forming Units (EPC-CFU) will be assessed from blood samples', 'timeFrame': 'At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365'}, {'measure': 'CRP Marker Levels', 'description': 'C-Reactive Protein (CRP) levels will be assessed from blood samples and reported in mg/L', 'timeFrame': 'At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365'}, {'measure': 'Circulating Angiogenic Factor Levels', 'description': 'Circulating Angiogenic Factor levels including Vascular Endothelial Growth Factor (VEGF), Stem Cell Factor (SCF) and Stromal Cell-Derived Factor 1 (SDF-1) will be assessed from blood samples and reported in ng/mL', 'timeFrame': 'At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365'}, {'measure': 'Flow Mediated Diameter Percentage (FMD%)', 'description': 'FMD will be assessed using brachial artery ultrasound', 'timeFrame': 'At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365'}, {'measure': 'Circulating Inflammatory Marker Levels', 'description': 'Circulating inflammatory marker levels including Interleukin (IL) -1 and IL-6 will be assessed from blood samples and reported in pg/mL', 'timeFrame': 'At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365'}, {'measure': 'Tumor Necrosis Factor (TNF) Alpha Levels', 'description': 'Measured from blood samples (pg/mL)', 'timeFrame': 'At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365'}]",7,21 Years,90 Years,ALL,False,Joshua M Hare,OTHER,1,16.0,ACTUAL,2025-09-01T16:18:25.981307,v2_robust,True,True,True,False,True,
NCT02115984,"Study of the Safety and Leukostimulatory Activity of the Preparation ""Panagen"" in Patients With Breast Cancer","Double-blind Multicenter Placebo-controlled Study of the Safety and Leukostimulatory Activity of the Preparation ""Panagen"" in Patients With Breast Cancer",Panagen,"['Panagen', 'Placebo', 'sodium deoxyribonucleate', 'double-stranded human DNA']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],[],COMPLETED,,2010-05,2012-05,"[{'measure': 'The Quantity of Leukocytes and Neutrophils in the Blood of Patients', 'timeFrame': 'Baseline, Day 21 after 2nd chemotherapy (Day 42 post-baseline), Day 21 after 3rd chemotherapy (Day 63 post-baseline)'}]",[],1,18 Years,,FEMALE,False,"Panagen, Limited Liability Company",OTHER,0,80.0,ACTUAL,2025-09-01T16:18:25.981317,v2_robust,True,True,True,False,False,
NCT05295784,PK and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia,Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia,Caffeine citrate,"['Cafcit', 'Caffeine citrate']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Kidney Injury,"['Acute Kidney Injury', 'Hypoxic-Ischemic Encephalopathy', 'Caffeine']",[],WITHDRAWN,Data no longer support this study,2024-05-08,2024-05-08,"[{'measure': 'Clearance of caffeine', 'description': 'Clearance (mL h-1 kg-1)', 'timeFrame': '1 week'}, {'measure': 'Volume of distribution of caffeine', 'description': 'Volume of distribution (ml/kg)', 'timeFrame': '1 week'}, {'measure': 'Peak plasma concentration (Cmax) of caffeine', 'description': 'Peak plasma concentration (Cmax) (ng/mL)', 'timeFrame': '1 week'}, {'measure': 'Area under the plasma concentration-time curve of caffeine', 'description': 'Area under the plasma concentration-time curve from 0 to infinity (AUC0-INF) (mg\\*h/L)', 'timeFrame': '1 week'}, {'measure': 'Seizure incidence', 'description': 'Number of neonates who developed seizures based on continuous video electroencephalogram (VEEG) data', 'timeFrame': '2 weeks'}, {'measure': 'Seizure burden', 'description': 'Electrographic seizures (in minutes per hour) based on continuous video electroencephalogram (VEEG) data', 'timeFrame': '2 weeks'}]","[{'measure': 'Acute kidney injury', 'description': 'AKI incidence utilizing KDIGO criteria based on urine output and SCr.', 'timeFrame': '10 days'}, {'measure': 'Renal near infrared spectroscopy (NIRS)', 'description': 'Investigate changes in renal NIRS values during the therapeutic hypothermia and rewarming period.', 'timeFrame': '5 days'}, {'measure': 'Urine neutrophil gelatinase-associated lipocalin (NGAL) (ng/mL)', 'description': 'Urine samples will be collected at 24, 48 and 72 hours after birth. Urine will be analyzed for NGAL.', 'timeFrame': '3 days'}, {'measure': 'Urine kidney injury molecule-1 (KIM-1) (pg/mL)', 'description': 'Urine samples will be collected at 24, 48 and 72 hours after birth. Urine will be analyzed for KIM-1.', 'timeFrame': '3 days'}, {'measure': 'Urine interleukin-18 (IL-18) (pg/mL)', 'description': 'Urine samples will be collected at 24, 48 and 72 hours after birth. Urine will be analyzed for IL-18.', 'timeFrame': '3 days'}]",11,0 Hours,24 Hours,ALL,False,University of Arkansas,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:25.981336,v2_robust,True,True,False,True,False,Data no longer support this study
NCT00974584,"A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer","A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer",GDC-0941,"['bevacizumab', 'GDC-0941', 'paclitaxel', 'cisplatin', 'carboplatin', 'pemetrexed']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Non-Squamous Non-Small Cell Lung Cancer,['Non-Squamous Non-Small Cell Lung Cancer'],"['NSCLC', 'PI3K', 'Avastin']",COMPLETED,,2009-10,2015-03,"[{'measure': 'Number of Participants with Dose Limiting Toxicities (DLTs)', 'timeFrame': 'Days 1 to 22 of Cycle 1'}, {'measure': 'Percentage of Participants with Adverse Events (AEs)', 'timeFrame': 'Up to approximately 5.5 years'}]","[{'measure': 'Maximum Plasma Concentration of Paclitaxel', 'timeFrame': 'Cycle 1 Day 2: Pre-paclitaxel infusion, end of paclitaxel infusion, 0.5, 1 and 2 hours post-paclitaxel infusion; Cycle 1 Day 3: Pre-GDC-0941 dose, 24 hours post-paclitaxel Day 2 infusion'}, {'measure': 'Maximum Plasma Concentration of Carboplatin', 'timeFrame': 'Cycle 1 Day 2: Pre-carboplatin infusion, end of Carboplatin infusion, 0.5, 1.5 hours post-carboplatin infusion\\n\\n'}, {'measure': 'Maximum Plasma Concentration of Pemetrexed', 'timeFrame': 'Cycle 1 Day 2: Pre-pemetrexed infusion, end of pemetrexed infusion, 1, 3 hours post-pemetrexed infusion; Cycle 1 Day 3: Pre-GDC-0941 dose, 24 hours post-pemetrexed Day 2 infusion\\n\\nd be ""Yes"".'}, {'measure': 'Maximum Plasma Concentration of Cisplatin', 'timeFrame': 'Cycle 1 Day 2: Pre-cisplatin infusion, end of cisplatin infusion, 3 hours post-cisplatin infusion; Cycle 1 Day 3: Pre-GDC-0941 dose, 24 hours post-pemetrexed Day 2 infusion\\n\\n'}, {'measure': 'Percentage of Participants with Objective Response (Complete or Partial Response), as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST)', 'timeFrame': 'Screening, Days 15 to 21 of Cycles 2, 4, 6, 9, and every 3 cycles thereafter (up to approximately 5.5 years)\\n\\n'}, {'measure': 'Duration of Response, as Assessed Using RECIST\\n\\n\\n', 'timeFrame': 'Screening, Days 15 to 21 of Cycles 2, 4, 6, 9, and every 3 cycles thereafter (up to approximately 5.5 years)'}, {'measure': 'Progression-free Survival (PFS), as Assessed Using RECIST\\n', 'timeFrame': 'Screening, Days 15 to 21 of Cycles 2, 4, 6, 9, and every 3 cycles thereafter (up to approximately 5.5 years)\\n\\n'}, {'measure': 'Maximum Plasma Concentration of GDC-0941', 'timeFrame': 'Cycle 1 Days 1 and 2: Pre-GDC-0941 dose, 1, 2, 3 and 4 hours post-GDC-0941 dose; Cycle 1 Days 3 and 9: Pre-GDC-0941 dose; 30 days after last dose of study treatment (up to approximately 5.5 years)'}]",10,18 Years,,ALL,False,"Genentech, Inc.",INDUSTRY,0,65.0,ACTUAL,2025-09-01T16:18:25.981365,v2_robust,True,True,True,False,True,
NCT06693284,"A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]","A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]",mirdametinib and vorinostat,['mirdametinib and vorinostat'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Primary Malignant Peripheral Nerve Sheath Tumors,['Primary Malignant Peripheral Nerve Sheath Tumors'],[],RECRUITING,,2024-12-01,2026-01-01,"[{'measure': 'Assess the toxicity of the combination of mirdametinib and vorinostat in patients with NF1-associated high grade MPNSTs.', 'description': 'As a result of the vaccine, both unique CNS toxicity and edema have been previously observed as soon as 10 days from the initiation of therapy. Neurotoxicity ≤ Grade 3 is an expected risk of this treatment. This will be measured as the number of participants experiencing this adverse event.', 'timeFrame': '48 months'}, {'measure': 'Determine the response of therapeutic targets', 'description': 'measuring phospho-ERK and histone H3K27 acetylation in post-therapy tumor tissue as compared to pre-treatment tumor tissue.', 'timeFrame': '48 months'}, {'measure': 'Evaluate the utility of radiographic response to this regimen', 'description': 'using MRI and PET.\n\nEach patient will undergo MRI of the primary lesion and CT/PET scan for staging and assessment of FDG uptake in the tumor at diagnosis and after completing 28 days of therapy with mirdametinib and vorinostat. Each patient will have a diagnostic tumor biopsy performed as a condition of entry into the study and to measure specific molecular tumor markers. A second biopsy will be performed at the completion of protocol therapy to assess tumor response to the therapy and to see if the specific tumor markers have changed as a result of the therapy given.', 'timeFrame': '48 months'}]",[],3,12 Years,,ALL,False,University of Minnesota,OTHER,0,8.0,ESTIMATED,2025-09-01T16:18:25.981407,v2_robust,True,True,False,False,True,
NCT00743184,Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH),"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)",ozarelix,"['ozarelix', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Benign Prostatic Hyperplasia (BPH),"['Benign Prostatic Hyperplasia (BPH)', 'Lower Urinary Tract Symptoms (LUTS)']","['BPH', 'LUTS', 'Lower urinary tract symptoms (LUTS)']",TERMINATED,,2008-12-04,2010-01-20,"[{'measure': 'Change From Baseline International Prostate Symptom Score (IPSS) Score at Week 14', 'description': 'IPSS is a validated self-administered index for grading benign prostatic hyperplasia (BPH)-related signs and symptoms. It consists of a set of seven questions. A total score of 1-7 indicates mild disease, 8-19 moderate disease and 20-35 severe disease.', 'timeFrame': 'Week 14'}]","[{'measure': 'Change From Baseline IPSS (Including Sub-scores) at Week 52', 'description': 'The International Prostate Symptom Score (IPSS) consists of 7 questions concerning urinary symptoms and 1 question concerning quality of life (QoL) with total score and subscores (voiding, storage and QoL). 1) Voiding- The subscale voiding score is the sum of the responses to 4 voiding symptoms questions (incomplete emptying, intermittency, weak stream, and straining). 2) Storage- The subscale storage score is the sum of the responses to 3 storage symptoms questions (frequency, urgency, and nocturia). Voiding and Storage: the lowest and highest possible scores range from 0 to 15 (mildly symptomatic to severely symptomatic). Voiding and Storage: each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. And 3) QoL assessment was a single question asking the participant how he would feel about tolerating his current level of symptoms for the rest of his life. The lowest and highest possible score ranges from 0 to 6 (very pleased to terrible).', 'timeFrame': 'Week 52'}, {'measure': 'Change From Baseline Benign Prostatic Hyperplasia Impact Index (BPHII) Score at Week 14 and Week 52', 'description': 'BPH Impact Index (BII) is used to assess the impact of BPH on various aspects of health. This 4 question self administered index uses a scoring range from 0 (best) to 13 (worst).', 'timeFrame': 'Weeks 14 and 52'}, {'measure': 'Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ) Response at Week 52', 'description': 'The self administered LUTS GAQ is a ""yes"" or ""no"" response to a question asking whether overall improvement in LUTS will be observed during the treatment period.', 'timeFrame': 'Week 52'}, {'measure': 'Change From Baseline Maximum Urine Flow (Qmax) at Week 14 and Week 52', 'description': 'Qmax was measured by free flow uroflowmetry. Qmax is defined as the peak urine flow rate (measured in milliliter (mL)/second using a standard calibrated flowmeter). For a Qmax to be considered valid, the voided volume had to be at least 125 mL. The uroflowmeter is to be calibrated weekly.', 'timeFrame': 'Week 14 and Week 52'}, {'measure': 'Change From Baseline International Index of Erectile Function-15 (IIEF-EF) Score at Week 14 and Week 52', 'description': 'IIEF-EF is defined as the sum of the scores for Questions 1-5 and 15 of the IIEF questionnaire. This recall instrument is self-administered by the participant. Individual questions are graded from 1 to 5 with a maximum total score of 30. Lower IIEFEF scores represent diminished erectile function. Men with a score of ≥ 26 are interpreted as having normal erectile function.', 'timeFrame': 'Week 14 and Week 52'}, {'measure': 'Change From Baseline International Prostate Symptom Score - Quality of Life (IPSS-QOL) at Week 14 and Week 52', 'description': 'IPSS QOL is a disease-specific quality of life question, referred to as IPSS Question 8. Participants with an IPSS QOL of \\<3 at screening will be excluded from this study. The rating is as follows: 0=delighted, 1=pleased, 2=mostly satisfied, 3=mixed, 4=mostly dissatisfied, 5=unhappy, 6=terrible.', 'timeFrame': 'Week 14 and Week 52'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events', 'timeFrame': 'Up to 104 weeks'}]",8,50 Years,,MALE,False,"Spectrum Pharmaceuticals, Inc",INDUSTRY,0,28.0,ACTUAL,2025-09-01T16:18:25.981423,v2_robust,True,True,False,True,True,
NCT00834184,Safety and PK of Nikkomycin Z in Healthy Subjects,"Phase I, Randomized, Double-blind, Placebo Controlled, Multiple-dose Evaluation of the Safety Tolerance and Pharmacokinetics of Nikkomycin Z in Healthy Subjects",nikkomycin Z,['nikkomycin Z'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['nikkomycin Z', 'pharmacokinetics', 'toxicity']",COMPLETED,,2008-10,2009-09,"[{'measure': 'Determine safety and tolerance of nikkomycin Z in healthy subjects following administration of multiple doses.', 'timeFrame': 'four weeks'}]","[{'measure': 'Evaluate the multiple dose pharmacokinetics of nikkomycin Z in healthy subjects', 'timeFrame': 'two weeks'}]",2,18 Years,40 Years,ALL,True,University of Arizona,OTHER,0,32.0,ACTUAL,2025-09-01T16:18:25.981730,v2_robust,True,True,True,False,True,
NCT02665533,Evaluation of Two Pharmacological Protocols for Pre-emptive Analgesia in Impacted Third Molar Surgery,Evaluation of Two Pharmacological Protocols for Pre-emptive Analgesia in Impacted Third Molar Surgery,Dexamethasone,"['Diclofenac Sodium associated with Codeine', 'Dexamethasone Acetate', 'Dexamethasone']",3,INTERVENTIONAL,['NA'],,,Pain,"['Pain', 'Edema', 'Trismus']","['pain measurement', 'edema', 'trismus']",COMPLETED,,2016-01,2016-07,"[{'measure': 'Post-surgical swelling of third molar extraction determined using linear measures in the face', 'description': 'During the post-surgical intervals of 24, 48 and 72 hours and seven days, the swelling was determined using linear measures in the face.', 'timeFrame': 'Up to seven days post-surgical'}, {'measure': 'Post-surgical trismus of third molar extraction determined by maximum mouth opening', 'description': 'During the post-surgical intervals of 24, 48 and 72 hours and seven days, the trismus was determined by maximum mouth opening.', 'timeFrame': 'Up to seven days post-surgical'}, {'measure': 'Post-surgical pain of third molar extraction using visual analogic scale', 'description': 'The post-surgical pain was self-recorded by the patient using visual analogic scale in intervals of 24, 48 and 72 hours and seven days.', 'timeFrame': 'Up to seven days post-surgical'}]","[{'measure': 'Analgesic consumption', 'timeFrame': 'Up to seven days post-surgical'}, {'measure': 'Duration of surgery', 'timeFrame': 'Up to seven days post-surgical'}]",5,18 Years,35 Years,ALL,False,Federal University of the Valleys of Jequitinhonha and Mucuri,OTHER,0,18.0,ACTUAL,2025-09-01T16:18:25.981820,v2_robust,True,True,True,False,False,
NCT00216333,Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis,International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatment of Pulmonary Tuberculosis,combined fixed dose combination,['combined fixed dose combination'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Tuberculosis,['Tuberculosis'],"['tuberculosis', 'fixed dose combination', 'DOT', 'shot-course chemotherapy']",UNKNOWN,,2003-12,2007-06,"[{'measure': 'Efficacy : combined rate of failure at the end of treatment and relapse by 30 months.'}, {'measure': 'Safety : occurrence of serious adverse events at any time during chemotherapy'}]","[{'measure': 'Sputum culture results at two months of chemotherapy'}, {'measure': 'Rate of completion of chemotherapy according to the protocol'}]",4,18 Years,65 Years,ALL,False,International Union Against Tuberculosis and Lung Diseases,OTHER,1,1500.0,,2025-09-01T16:18:25.981836,v2_robust,True,True,False,False,True,
NCT04810533,"The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers","A Single-center, Open-label, Single-dose Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Subjects",[14C] SH-1028,['[14C] SH-1028'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Male Volunteers,['Healthy Male Volunteers'],[],COMPLETED,,2020-05-13,2021-03-05,"[{'measure': 'The percentage of radioactive dose of [14C] radiolabelled SH-1028 recovered in blood and in total, up to Day 15', 'description': 'The distribution of \\[14C\\]SH-1028 in the whole blood and plasma and whole radioactive pharmacokinetics following the single orally administered \\[14C\\]SH-1028 in healthy male volunteers.', 'timeFrame': 'Blood samples : - 0.5hrs, 1hrs, 2hrs, 3hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 48hrs, 72hrs, 120hrs, 168hrs, 216hrs, 264hrs and 336hrs'}, {'measure': 'The percentage of radioactive dose of [14C] radiolabelled SH-1028 recovered in urine, faeces and in total, up to Day 15.', 'description': 'Quantitive analysis of whole radioactivity of excrement of orally administered \\[14C\\]SH-1028 in healthy volunteers to obtain the mass balance data and the main excretion pathway in human body.', 'timeFrame': 'Day1 to Day 15'}, {'measure': 'The concentrations of SH-1028, Imp2 and Imp3 in plasma up to Day 15', 'description': 'Quantitive analysis of the concentrations of SH-1028 and Imp2,Imp3 (Metabolites of SH-1028) in plasma using the validated LC-MS/MS to obtain pharmacokinetic data.', 'timeFrame': 'Blood samples : - 0.5hrs, 1hrs, 2hrs, 3hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 48hrs, 72hrs, 120hrs, 168hrs, 216hrs, 264hrs and 336hrs'}, {'measure': 'Proportion of different metabolites', 'description': 'Proportion of different metabolites in healthy volunteers after oral administration of \\[14C\\]SH-1028', 'timeFrame': 'Blood samples : - 0.5hrs, 1hrs, 2hrs, 3hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 48hrs, 72hrs, 120hrs, 168hrs, 216hrs, 264hrs and 336hrs'}, {'measure': 'Types of adverse events', 'description': 'Types of adverse events assessed by CTCAE v5.0 that occurred during the trial', 'timeFrame': 'Baseline (Day-2) to Day 15'}]",[],5,18 Years,50 Years,MALE,True,"Nanjing Sanhome Pharmaceutical, Co., Ltd.",INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:25.981861,v2_robust,True,True,True,False,True,
NCT01698333,Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression,An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment,122-0551,['122-0551'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Plaque Psoriasis,['Plaque Psoriasis'],"['122-0551', 'steroid', 'HPA']",COMPLETED,,2012-04,2013-07,"[{'measure': 'Hypothalamic-Pituitary-Adrenal (HPA) Axis Response', 'description': 'HPA axis response to stimulation by cosyntropin, dichotomized to ""normal"" and ""abnormal"". Laboratory evidence of abnormal HPA axis response is defined as a 30-minute post-stimulation serum cortisol level that is ≤ 18 μg/dL at the end of study.', 'timeFrame': 'Day 15'}]",[],1,18 Years,,ALL,False,"Therapeutics, Inc.",INDUSTRY,0,25.0,ACTUAL,2025-09-01T16:18:25.981925,v2_robust,True,True,True,False,False,
NCT02102633,Drug Interaction Study Between Bosutinib And Dabigatran,"An Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of A Single Oral Dose Of Bosutinib On The Pharmacokinetics Of Dabigatran Etexilate Mesylate Administered Orally To Healthy Subjects",Dabigatran,"['Dabigatran', 'Bosutinib']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['bosutinib', 'dabigatran', 'drug interaction', 'p-glycoprotein', 'pharmacokinetics']",COMPLETED,,2014-05,2014-06,"[{'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)', 'description': 'Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)', 'timeFrame': '48 hours'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'description': 'Maximum Observed Plasma Concentration', 'timeFrame': '48 hours'}]","[{'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)', 'description': 'Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)', 'timeFrame': '48 hours'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax)', 'description': 'Time to Reach Maximum Observed Plasma Concentration', 'timeFrame': '48 hours'}, {'measure': 'Plasma Decay Half-Life (t1/2)', 'description': 'Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.', 'timeFrame': '48 hours'}, {'measure': 'Apparent Oral Clearance (CL/F)', 'description': 'Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.', 'timeFrame': '48 hours'}, {'measure': 'Apparent Volume of Distribution (Vz/F)', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.', 'timeFrame': '48 hours'}]",7,21 Years,55 Years,ALL,True,Pfizer,INDUSTRY,0,27.0,ACTUAL,2025-09-01T16:18:25.982003,v2_robust,True,True,True,False,False,
NCT06079333,NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study),NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study),dabrafenib/trametinib,['dabrafenib/trametinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Anaplastic Thyroid Cancer,['Anaplastic Thyroid Cancer'],[],RECRUITING,,2023-01-01,2028-01-01,"[{'measure': 'primary endpoint of the study will be R0 resection rate (efficacy).', 'description': 'primary endpoint of the study will be R0 resection rate (efficacy).', 'timeFrame': 'after 6-12 weeks braf/mek-inhibition'}]","[{'measure': 'Neo-adjuvant and adjuvant treatment related toxicity of dabrafenib/trametinib (according to CTCAE v. 5.0)', 'description': 'Neo-adjuvant and adjuvant treatment related toxicity of dabrafenib/trametinib (according to CTCAE v. 5.0) during 1 year of treatment with braf/mek-inhibition', 'timeFrame': 'during 1 year of treatment with braf/mek-inhibition'}, {'measure': '30-day postoperative surgical complications', 'description': '30-day postoperative surgical complications (within 30 days after surgery)', 'timeFrame': 'within 30 days after surgery'}, {'measure': 'Histopathological response after neo-adjuvant treatment', 'description': 'Histopathological response after neo-adjuvant treatment: complete response (\\<10% tumor cells), partial response (between more than 10% and up to 50% tumor cells), or no response (still more than 50% tumor cells)', 'timeFrame': '6-12 weeks neo-adjuvant braf/mek-inhibition'}, {'measure': 'Locoregional-free survival', 'description': 'Locoregional-free survival', 'timeFrame': 'at 2 years'}, {'measure': 'Distant metastasis-free survival', 'description': 'Distant metastasis-free survival', 'timeFrame': 'at 2 years'}, {'measure': 'Overall survival', 'description': 'Overall survival', 'timeFrame': 'at 2 years'}]",7,18 Years,,ALL,False,Leiden University Medical Center,OTHER,1,20.0,ESTIMATED,2025-09-01T16:18:25.982123,v2_robust,True,True,False,False,False,
NCT03891433,Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae,Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic Urinary Tract Infections Due to Extended-spectrum Β-lactamase (ESBL)-producing Escherichia Coli or Klebsiella Pneumoniae - (CAPITIS Study),Meropenem,"['Meropenem', 'Piperacillin, Tazobactam 4-0.5G Solution for Injection', 'Ertapenem 1000 MG']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Urinary Tract Infections,"['Urinary Tract Infections', 'Enterobacteriaceae Infections', 'Infection Due to ESBL Bacteria', 'Carbapenem', 'Escherichia Coli Infection', 'Klebsiella Pneumoniae Infection', 'Clinical Trial', 'Drug Resistance, Bacterial']","['adult', 'Equivalence Trial', 'Randomized Controlled Trial', 'Comparative Study', 'Anti-Bacterial Agents/therapeutic use*', 'Meropenem', 'Ertapenem', 'Piperacillin, Tazobactam Drug Combination', 'Escherichia coli Infections/drug therapy', 'Klebsiella Infections/drug therapy']",SUSPENDED,Low admission of patients with the condition to the hospital because it is a reference center for care of the SARS-CoV-2 pandemic,2019-04-01,2026-04-01,"[{'measure': 'Clinical cure.', 'description': 'Complete resolution of non-bacteremic urinary tract infection signs or symptoms (dysuria, urinary frequency, urinary urgency, suprapubic pain or temperature greater than 38 degrees Celsius) present at trial entry (and no new signs or symptoms) until the duration of investigational antibacterial drug therapy.\n\nInvestigators will compare the rate of clinical cure between the two treatment lines.', 'timeFrame': 'At 5-7 day after the end of treatment (cure test), or for early response after 5 days from the start of treatment.'}]","[{'measure': 'Microbiologic cure.', 'description': 'Clinical cure (primary outcome) and demonstration that the bacterial pathogen found at trial entry is reduced to fewer than 100.000 CFU/mL on control urine culture.\n\nInvestigators will compare the rate of microbiologic cure between the two treatment lines.', 'timeFrame': 'At the 5-7 day after the end of treatment (cure test).'}, {'measure': 'Mortality in patient follow-up.', 'description': 'All-cause Mortality Rate in the CAPITIS Study Population (Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic Urinary Tract Infections Due to Extended-spectrum β-lactamase (ESBL)-Producing Escherichia Coli or Klebsiella Pneumoniae.', 'timeFrame': 'Until day 30 after the first day of administration of the study drugs.'}, {'measure': 'Length of hospital stay in patient follow-up.', 'description': 'Time since the assignment of the randomization until the patient leaves the hospital.', 'timeFrame': 'Until day 30 after the first day of administration of the study drugs.'}, {'measure': 'Relapse.', 'description': 'Proportion of Subjects in the CAPITIS Study Population with a Relapse (All Indications).\n\nDevelopment of non-bacteremic urinary tract infection signs or symptoms (dysuria, urinary frequency, urinary urgency, suprapubic pain or temperature greater than 38 degrees Celsius) in patients with previous clinical and microbiological cure, plus positive urine culture with the same microorganism isolated in initial culture.\n\nInvestigators will compare the risk of relapse with each regimen.', 'timeFrame': 'Daily until day 30 after the first day of administration of the study drugs.'}, {'measure': 'Reinfection.', 'description': 'Proportion of Subjects in the CAPITIS Study Population With a Reinfection (All Indications).\n\nDevelopment of non-bacteremic urinary tract infection signs or symptoms (dysuria, urinary frequency, urinary urgency, suprapubic pain or temperature greater than 38 degrees Celsius) in patients with previous clinical and microbiological cure, plus positive urine culture with different strains isolated in initial culture.\n\nInvestigators will compare the risk of reinfection with each regimen.', 'timeFrame': 'Daily until day 30 after the first day of administration of the study drugs.'}, {'measure': 'Resistant clinical isolates in patient follow-up.', 'description': 'Proportion of Subjects in the CAPITIS Study Population With Resistant clinical isolates.\n\nAppearance of clinical isolates of Escherichia coli or Klebsiella pneumoniae resistant piperacillin/tazobactam or carbapenems demonstrated in urine cultures will be evaluated.', 'timeFrame': 'Daily until day 30 after the first day of administration of the study drugs.'}, {'measure': 'Adverse events in patient follow-up.', 'description': 'Proportion of Subjects in the CAPITIS Study Population With Adverse events (All Indications).\n\nAny related adverse event occurring from the signing the informed consent form to end of follow.\n\nInvestigators have created a data collection notebook, a daily follow-up will be made in the participants and adverse events in patient will be recorded.', 'timeFrame': 'Daily until day 30 after the first day of administration of the study drugs.'}, {'measure': 'ICU admission in patient follow-up.', 'description': 'Proportion of Subjects in the CAPITIS Study Population With ICU admission (All Indications).\n\nAny admission to intensive care unit occurs from signing the informed consent form to end of patient follow.\n\nInvestigators have created a data collection notebook, a daily follow-up will be made in the participants and all admission in ICU will be recorded.', 'timeFrame': 'Daily until day 30 after the first day of administration of the study drugs.'}, {'measure': 'Clinical or microbiological failure of antibiotic therapy in patient follow-up.', 'description': 'Proportion of Subjects in the CAPITIS Study Population With Clinical or microbiological failure of antibiotic therapy (All Indications).\n\nFailure to achieve clinical or microbiologic cure until day 30, or die at any time since signing the informed consent form to end of follow-up.\n\nAuthors defined the clinical therapeutic failure as the persistence of at least one urinary symptom in the patient at the time of follow-up despite antibiotic therapy. Microbiological failure has been defined as the persistence of bacteria isolation major to 10.000 UFC/ml in second urine culture carried out in the study participant despite antibiotic therapy.\n\nInvestigators have created a questionnaire which will be checked daily with a urinary symptoms list. All findings will be recorded in a data collection notebook.', 'timeFrame': 'Daily until day 30 after the first day of administration of the study drugs.'}]",10,18 Years,,ALL,False,Universidad del Norte,OTHER,0,198.0,ESTIMATED,2025-09-01T16:18:25.982218,v2_robust,True,True,False,True,True,Low admission of patients with the condition to the hospital because it is a reference center for care of the SARS-CoV-2 pandemic
NCT02193633,A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.,TAX-TORC: a Phase I Multi-centre Trial of the Combination of AZD2014 (dual MTORC1 and MTORC2 Inhibitor) and Weekly Paclitaxel in Patients with Solid Tumours.,AZD2014 3 on/4 off & weekly paclitaxel,"['Paclitaxel', 'AZD2014 2 days of, 5 days off', 'AZD2014', 'AZD2014 2 on/5 off & weekly paclitaxel', 'AZD2014 3 on/4 off & weekly paclitaxel', 'AZD2014 3 days on, 4 days off']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Cancer,['Advanced Cancer'],[],COMPLETED,,2013-04-26,2017-11-15,"[{'measure': 'Establish the maximum tolerated dose and recommended Phase II dose of two intermittent dosing schedules of AZD2014: 3 days on, 4 days off and 2 days on, 5 days off in combination with weekly paclitaxel in patients with solid tumours.', 'description': 'To determine the dose at which no more than one patient out of up to 6 patients at the same dose level experience a drug-related dose-limiting toxicity.', 'timeFrame': 'First cycle of treamtent (7 weeks)'}]","[{'measure': 'PK parameters for AZD2014 and paclitaxel derived from determining their plasma concentrations using validated assays.', 'description': 'To explore the effect of paclitaxel on the pharmacokinetics of AZD2014', 'timeFrame': 'First cycle of treatment (7 weeks)'}, {'measure': 'PK parameters for AZD2014 and paclitaxel derived from determining their plasma concentrations using validated assays', 'description': 'Investigate the pharmacodynamics behaviour of the combination of AZD2014 and paclitaxel.', 'timeFrame': 'First cycle of treatment (7 weeks)'}]",3,18 Years,75 Years,ALL,False,Royal Marsden NHS Foundation Trust,OTHER,2,90.0,ACTUAL,2025-09-01T16:18:25.982283,v2_robust,True,True,True,False,False,
NCT01825733,Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery,,ramosetron,"['ramosetron', 'palonosetron']",2,INTERVENTIONAL,['NA'],,,Postoperative Nausea and Vomiting,['Postoperative Nausea and Vomiting'],"['palonosetron, ramosetron, PONV, opioid']",COMPLETED,,2011-08,2012-07,"[{'measure': 'verbal numeric scale', 'description': 'At each time point, frequency and intensity (verbal numeric scale, 0-10, 0: no nausea, 10: maximum) of nausea, frequency of vomiting, rescue antiemetic use were recorded and compared between groups.', 'timeFrame': 'change of antiemetic efficacy for 5 time points ( postanesthesia care unit, 0-6 h, 6-24 h, 24-48 h, 48-72 h after operation)'}]",[],1,20 Years,65 Years,ALL,False,Yonsei University,OTHER,0,196.0,ACTUAL,2025-09-01T16:18:25.982464,v2_robust,True,True,True,False,False,
NCT02044952,Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission,Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission,"Mesalazine, Tripterygium glycosides","['Triptolide', 'Thunder god vine', 'Lei gong teng', 'Mesalazine, Tripterygium glycosides']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Inflammatory Bowel Diseases,"['Inflammatory Bowel Diseases', ""Crohn's Disease"", 'Gastrointestinal Diseases', 'Digestive System Diseases', 'Intestinal Diseases']","[""Crohn's Disease"", 'mesalazine', 'Tripterygium Glycosides', 'induction remission']",UNKNOWN,,2014-01,2016-07,"[{'measure': ""Therapeutic effect measured by Crohn's Disease Activity Index (CDAI)"", 'timeFrame': '12 weeks'}]","[{'measure': 'The Side effects of Tripterygium wilfordii (TW)', 'timeFrame': '12 weeks'}, {'measure': ""The change of Crohn's Disease Activity Index (CDAI )"", 'timeFrame': '12Weeks'}, {'measure': ""The change of Simple Endoscopic Score for Crohn's Disease(SES-CD)"", 'timeFrame': '12 Weeks'}, {'measure': 'The change of the Inflammatory Bowel Disease Questionnaire (IBDQ)', 'timeFrame': '12 Weeks'}]",5,18 Years,75 Years,ALL,False,Zhu Weiming,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:25.982486,v2_robust,True,True,False,False,False,
NCT01857752,Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala,Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala,Temozolomide,['Temozolomide'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Retinoblastoma,['Retinoblastoma'],['Retinoblastoma'],TERMINATED,accrual,2012-03,2015-06,"[{'measure': 'Response rate', 'description': 'Response rate (complete response plus partial response) of temozolomide for 8 weeks (2 cycles), in patients with retinoblastoma metastatic to the central nervous system (mass only) in two strata:\n\n1. Initial diagnosis (mass)\n2. At relapse (mass)', 'timeFrame': '8 weeks'}, {'measure': 'Evaluate the toxicity suffered during each cycle of temozolamide will be evaluated using the CTCAE v3.0', 'timeFrame': '8 weeks'}]",[],2,,21 Years,ALL,False,Stanford University,OTHER,0,3.0,ACTUAL,2025-09-01T16:18:25.982499,v2_robust,True,True,False,True,False,accrual
NCT03838952,The Efficacy of Traditional Chinese Herbal Medicine for Dementia,The Efficacy of Traditional Chinese Herbal Medicine for Dementia: a Pilot Study,Herbal medicine,['Herbal medicine'],1,INTERVENTIONAL,['NA'],,,Dementia,"['Dementia', 'Alzheimer Disease']","['Chinese Herbal Medicine', 'Herbal treatment']",UNKNOWN,,2019-02-11,2020-12-31,"[{'measure': 'Changes of Mini-Mental State Examination(MMSE)', 'description': 'Global cognition will be assessed by the MMSE,which will be conducted at baseline, 0weeks, 12weeks, and follow-up (16 weeks).', 'timeFrame': 'week 0, 12, 16'}, {'measure': 'Changes of Instrumental Activities of Daily Living (IADL)', 'description': 'The instrumental activities of daily living (IADL) contains 8 items ,such as shopping, cooking, doing laundry, handling finances, using telephone, mode of transportation, responsibility for own medication and housekeeping.The IADL wil be conducted baseline, 12weeks, and follow-up (16 weeks)', 'timeFrame': 'week 0, 12, 16'}, {'measure': 'Changes of Neuropsychiatric Inventory(NPI-Q)', 'description': 'The Neuropsychiatric Inventory Questionnaire (NPI-Q) is an informant-based instrument that measures the presence and severity of 12 Neuropsychiatric Symptoms (NPS) in patients with dementia, as well as informant distress. The NPI-Q will be conducted at baseline, 12 weeks, and follow-up (16 weeks).', 'timeFrame': 'week 0, 12, 16'}, {'measure': 'Changes of Geriatric Depression Scale (GDS)', 'description': 'The Geriatric Depression Scale (GDS) is a 30-item self-report assessment used to identify depression in the elderly, which will be conducted at baseline, 12weeks, and follow-up (16 weeks).', 'timeFrame': 'week 0, 12, 16'}]","[{'measure': 'Blood test (AST/ALT/Serum Creatinine)', 'description': 'Check liver and kidney function through blood test at baseline, and follow-up (16 weeks).', 'timeFrame': 'week 0, 16'}, {'measure': ""Changes of Quality of Life-Alzheimer's Disease (QOL-AD)"", 'description': ""The Quality of Life-Alzheimer's Disease (QOL-AD) has 13-items covering physical health, energy, mood, living situations, memory, family, marriage, friends, chores, fun, money, self and life as a whole. The QOL-AD uses straightforward language for simplicity, which will be conducted at baseline, 12 weeks, and follow-up (16 weeks)."", 'timeFrame': 'week 0, 12, 16'}, {'measure': 'Changes of Constitution in Chinese Medicine Questionnaire', 'description': 'The Constitution in Chinese Medicine Questionnaire (CCMQ) consists of 60 items to classify a person into one or more of nine Body constitution(BC) types: gentleness (8 Items), Qi-deficiency (8 Items), Yang-deficiency (7 Items), Yin-deficiency (8 Items), phlegm-wetness (8 Items), wetness-heat (6 Items), blood-stasis (7 Items), Qi-depression (7 Items), and special diathesis (7 Items). Coexistence of multiple imbalanced BC types was possible which is consistent with the TCM theories. The scoring algorithm proposed in the original CCMQ was adopted in this study. A higher score in the CCMQ BC scale indicates a higher likelihood of the specific BC type, and a score of 30 is set as threshold for case definition. The CCMQ will be conducted at baseline, 12 weeks, and follow-up (16 weeks).', 'timeFrame': 'week 0, 12, 16'}]",7,65 Years,,ALL,False,"Taipei Veterans General Hospital, Taiwan",OTHER_GOV,0,20.0,ESTIMATED,2025-09-01T16:18:25.982510,v2_robust,True,True,False,False,False,
NCT00361452,Acoustic Assessment of Nebulized Epinephrine Versus Albuterol for RSV Bronchiolitis- a Double Blind Study,Acoustic Assessment of Nebulized Epinephrine Versus Albuterol for RSV Bronchiolitis- a Double Blind Study,nebulized epinephrine and nebulized albuterol,['nebulized epinephrine and nebulized albuterol'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Rsv Bronchiolitis,['Rsv Bronchiolitis'],[],TERMINATED,,2000-12,2001-05,"[{'measure': 'respiratory clinical score'}, {'measure': 'computerized quantification of wheezing and crackles'}]",[],2,0 Years,1 Year,ALL,False,Rambam Health Care Campus,OTHER,0,30.0,,2025-09-01T16:18:25.982559,v2_robust,True,True,False,True,False,
NCT03634852,A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery,A Two Different Chemoprophylaxis Approaches After Phacoemulsification Surgery in One Thousand Patients in Iraq :a Clinical Trial,Moxifloxacin hydrochloride 0.5% eye drops,"['Moxifloxacin hydrochloride 0.5% eye drops', 'Maxidex eye drops', 'Dexamethasone 0.1% eye drops', 'Intracameral Moxifloxacin 0.1%', 'Auromox', 'Vigamox eye drops', 'Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml', 'Aurocort']",8,INTERVENTIONAL,['PHASE4'],PHASE4,,Endophthalmitis Postoperative,['Endophthalmitis Postoperative'],"['IC Moxifloxacin hydrochloride', 'SC triamcinolone acetonide']",COMPLETED,,2016-10-01,2018-02-01,"[{'measure': 'Incidence of Bacterial endophthalmitis in 1000 phacoemulsification surgeries', 'description': 'All patients assessed by slit lamp examination for possibility of early or late onset bacterial endophthalmitis after phacoemulsification surgery.', 'timeFrame': 'The duration of follow up for each patient was a 3 months postoperatively.'}]","[{'measure': 'Intraocular pressure(IOP) was measured on 1week,1month,and 3 months visits by Goldmann applanation tonometry .', 'description': 'For all patients IOP was measured during the last 3 visits to exclude the possibility of significant IOP elevation (\\> 10 mmHg from the base line) after phacoemulsification surgery with the use of 2 different methods of chemoprophylaxis and to show which of them has the more possibility to increase IOP', 'timeFrame': 'The duration of follow up for each patient was a 3 months postoperatively.'}]",2,38 Years,70 Years,ALL,False,Suzan A Rattan,OTHER,1,1000.0,ACTUAL,2025-09-01T16:18:25.982570,v2_robust,True,True,True,False,False,
NCT02819752,PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck,Phase I Dose-escalation Study of PEmbrolizumab (MK3475) Anti-PD1 Immune Checkpoint Inhibitor Combined With Radical Chemoradiotherapy in Patients With Stage IV Squamous Cell Carcinoma of the Head and Neck,Pembrolizumab,"['Chemotherapy', 'Pembrolizumab', 'MK-3475/pembrolizumab (KEYTRUDA®)']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Squamous Cell Carcinoma of the Head and Neck,"['Squamous Cell Carcinoma of the Head and Neck', 'Squamous Cell Carcinoma']","['squamous cell carcinoma', 'squamous cell carcinoma of the head and neck']",TERMINATED,funding pulled,2017-07-12,2019-11-28,"[{'measure': 'the maximum tolerated dose that can safely be combined with platin-based chemoradiotherapy in patients with HPV-ve and HPV+ve LA-SCCHN', 'timeFrame': 'Six weeks after the completion of chemoradiotherapy'}, {'measure': 'Acute toxicity as measured during treatment by CTCAE v4.0', 'timeFrame': 'Up until 6 weeks after the end of chemoradiotherapy (week 14 of the study)'}]","[{'measure': 'The Progression Free Survival', 'timeFrame': 'Six months, one year and two years'}, {'measure': 'The Overall Survival', 'timeFrame': 'Six months, one year and two years'}, {'measure': 'To measure the duration of clinical benefit using RECIST', 'timeFrame': 'Six months, one year and two years'}, {'measure': 'To evaluate late radiotherapy toxicities as measured during treatment by LENT SOMA', 'timeFrame': '52 weeks from the end of radiation therapy (week 7)'}]",6,18 Years,,ALL,False,Royal Marsden NHS Foundation Trust,OTHER,2,3.0,ACTUAL,2025-09-01T16:18:25.982586,v2_robust,True,True,False,True,False,funding pulled
NCT02704052,Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose,Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose,Real time enoxaparin dose adjustment,"['Real time enoxaparin dose adjustment', 'Standard enoxaparin dose']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Deep Venous Thrombosis,"['Deep Venous Thrombosis', 'Pulmonary Embolus', 'Venous Thromboembolism']",[],COMPLETED,,2016-03,2018-10,"[{'measure': 'Venous thromboembolism', 'description': 'Symptomatic 90-day VTE confirmed with imaging', 'timeFrame': '90 days'}]","[{'measure': 'Re-operative hematoma', 'description': 'Bleeding requiring return to the operating room within 90 days', 'timeFrame': '90 days'}]",2,18 Years,,ALL,False,University of Utah,OTHER,0,116.0,ACTUAL,2025-09-01T16:18:25.982652,v2_robust,True,True,True,False,False,
NCT03890952,Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma,"A Phase II Open Label, Two-armed Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma",Nivolumab,"['Nivolumab', 'Checkpoint inhibitor', 'Angiogenesis inhibitor', 'Bevacizumab']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Recurrent Adult Brain Tumor,['Recurrent Adult Brain Tumor'],[],COMPLETED,,2018-10-01,2024-08-01,"[{'measure': 'Number of indels as determined using mRNA sequencing', 'description': 'whole exome sequencing (WES) and mRNA sequencing on tumor versus germline-control samples. We will map cancer-specific mutations, indels, frameshifts and splice variations, and predict T cell epitopes overlapping these regions based on the patient HLA type, using available prediction tools, netMHC', 'timeFrame': '8 weeks'}]","[{'measure': 'Progression-Free Survival (PFS)', 'description': 'Progression-Free Survival (PFS) in both treatment Arms', 'timeFrame': '6 months'}]",2,18 Years,,ALL,False,Ulrik Lassen,OTHER,2,40.0,ACTUAL,2025-09-01T16:18:25.982662,v2_robust,True,True,True,False,False,
NCT02351752,Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study,"Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease",Hydroxychloroquine Sulfate,['Hydroxychloroquine Sulfate'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Primary IgA Nephropathy,['Primary IgA Nephropathy'],[],COMPLETED,,2015-01,2015-10,"[{'measure': 'proteinuia', 'timeFrame': 'total four months(proteinic will recorded every 2 months )'}]",[],1,18 Years,75 Years,ALL,False,LLiu,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:25.982675,v2_robust,True,True,True,False,False,
NCT01813552,To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006),"A Phase I, Randomized, Open-label Study to Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of IDX719 in Healthy Subjects",Samatasvir,"['Ritonavir', 'Omeprazole', 'Samatasvir']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Chronic Hepatitis C Infection,['Chronic Hepatitis C Infection'],"['HCV', 'Hepatitis C', 'antiviral drugs', 'liver']",COMPLETED,,2013-02,2013-03,"[{'measure': 'Pharmacokinetic parameter: Area under the concentration-time curve (AUC) from time zero to last measurable concentration', 'timeFrame': '0 hour (pre-dose) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours'}, {'measure': 'Pharmacokinetic parameter: AUC from time zero to infinity', 'timeFrame': '0 hour (pre-dose) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours'}, {'measure': 'Pharmacokinetic parameter: Maximum observed drug concentration (Cmax)', 'timeFrame': '0 hour (pre-dose) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours'}]","[{'measure': 'Percentage of participants who experienced at least one serious adverse event', 'timeFrame': 'Up to 17 days'}, {'measure': 'Percentage of participants who experienced at least one adverse event', 'timeFrame': 'Up to 17 days'}, {'measure': 'Percentage of participants who experienced at least one Grade 1 - 4 laboratory abnormality', 'timeFrame': 'Up to 17 days'}]",6,19 Years,65 Years,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:25.982703,v2_robust,True,True,True,False,True,
NCT03628352,Taste-masking Study for Tricaprilin in Sensory Panelists,An Open-Label Taste Assessment of Tricaprilin Formulated as a Powder for Reconstitution in Healthy Panelists,Tricaprilin,['Tricaprilin'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Taste Profile Assessments,['Taste Profile Assessments'],[],COMPLETED,,2018-09-10,2019-08-22,"[{'measure': 'Taste as assessed by trained sensory panelists', 'description': 'single dose (swish and expectorate)', 'timeFrame': '1 day'}, {'measure': 'Smell as assessed by trained sensory panelists', 'timeFrame': '1 day'}, {'measure': 'Texture as assessed by trained sensory panelists', 'description': 'single dose (swish and expectorate)', 'timeFrame': '1 day'}, {'measure': 'Palatability as assessed by trained sensory panelists', 'description': 'single dose (swish and expectorate)', 'timeFrame': '1 day'}]",[],4,25 Years,80 Years,ALL,True,Cerecin,INDUSTRY,0,9.0,ACTUAL,2025-09-01T16:18:25.982748,v2_robust,True,True,True,False,False,
NCT02349152,Remifentanil and Glycemic Response in Cardiac Surgery,"The Effect of Intraoperative Continuous Remifentanil Infusion on Glycemic Response and Variability in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Prospective, Randomized, Open Label Clinical Trial",Remifentanil,"['Fentanyl', 'Remifentanil', 'Ultiva']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Heart Diseases,"['Heart Diseases', 'Hyperglycemia']","['Cardiopulmonary bypass', 'Heart surgery']",COMPLETED,,2016-01,2017-12,"[{'measure': 'Blood Glucose Values (More Than One ) > 180 mg%', 'description': 'Percentage of patients with two or more intraoperative blood glucose levels greater than 180 mg/dl. Percentage in both groups will be estimated, then the difference in this statistic will form the primary outcome measure of this study.\n\n(Primary Outcome changed on 06/15/2015-Change Approved by University of Pittsburgh IRB on 06/22/2015- First patient enrolled January 2016)', 'timeFrame': 'Intraoperative period'}]","[{'measure': 'Insulin Requirement', 'description': 'Average dose of insulin (Units/ml) calculated for each group in the intraoperative period', 'timeFrame': 'Intraoperative period; Induction to end of surgery'}, {'measure': 'Number of Blood Glucose Values > 180 mg%', 'description': 'Blood glucose values that exceed 180 mg% will be counted', 'timeFrame': 'Intraoperative period, Induction to end of surgery'}, {'measure': 'Mean, Peak and Trough Intraoperative Blood Glucose (mg/dl)', 'description': 'Blood glucose measured every hour', 'timeFrame': 'Intraoperative period; Induction to end of surgery'}, {'measure': 'Postoperative Blood Glucose', 'description': 'Mean and peak blood glucose levels postoperatively', 'timeFrame': 'From ICU Admission (After Surgery) Until 24 hours postoperatively'}, {'measure': 'Total Postoperative Regular Insulin', 'description': 'Total units of regular insulin required post-operatively', 'timeFrame': 'From ICU Admission (After Surgery) Until 24 hours postoperatively'}, {'measure': 'Intraoperative Pre-cardiopulmonary Bypass Hemodynamic Stability', 'description': 'Blood pressure (systolic, diastolic and mean), Heart rate every 5 minutes from induction of anesthesia till systemic heparinization before cardiopulmonary bypass', 'timeFrame': 'induction of anesthesia till systemic heparinization before cardiopulmonary bypass'}, {'measure': 'Stress Hormone Levels-Cortisol (µg/dl)', 'description': 'Serum cortisol levels (measured as µg/dl) taken at: Prebypass, cardiopulmonary bypass (2 samples: at start of bypass and end of bypass), postbypass, ICU 8 hours postoperative period', 'timeFrame': 'Perioperative period (Intraoperatively and 8 hours postoperatively)'}, {'measure': 'Inflammatory Mediator Levels, Interleukin-1b, Interleukin 6 and Tumor Necrosis Factor (TNF) (pg/ml)', 'description': 'Inflammatory mediator levels, Interleukin-1b (IL-1b), Interleukin 6 (IL-6) and Tumor Necrosis Factor Alpha (TNFa) (all measured in pg/ml) taken at: Prebypass, cardiopulmonary bypass (2 samples:30 min start of bypass (CPB-30) and end of bypass (CPB-END), postbypass, ICU 8 hours postoperative period', 'timeFrame': 'Perioperative period (Intraoperatively and 8 hours postoperatively)'}, {'measure': 'Stress Hormone Levels-ACTH, GH, Glucagon (pg/ml)', 'description': 'Adreno-corticotrophic hormone (ACTH), Growth Hormone (GH) and Glucagon (measured as pg/ml) taken at: Prebypass, cardiopulmonary bypass (2 samples: 30 mins after start of bypass (CPB 30) and end of bypass (CPB END), post-bypass and ICU 8 hours postoperative period', 'timeFrame': 'Perioperative period (Intraoperatively and 8 hours postoperatively)'}, {'measure': 'Society of Thoracic Surgery Patient Outcomes', 'description': 'Postoperative outcomes collected from the Society of Thoracic Surgery (STS) database. 30 day Mortality (outcome 1) and 30 day Readmission (outcome 2) cerebral vascular accident(outcome 3), prolonged mechanical ventilation (outcome 4), renal failure (outcome 5), atrial fibrillation (outcome 6), cardiac arrest (outcome 7)', 'timeFrame': '30 day outcomes'}, {'measure': 'Postoperative Pain', 'description': 'Pain scores; Every day 6 hour for 48 hours postoperative period', 'timeFrame': 'Every day 6 hour for 48 hours postoperative period'}, {'measure': 'Emergence From Anesthesia', 'description': 'Time to extubation after completion of surgery in the operating room and intensive care unit', 'timeFrame': 'Immediate postoperative period until 30 days post-operatively'}, {'measure': 'Wound Hyperalgesia', 'description': 'Von frey hair objective testing', 'timeFrame': '96 hours postoperatively'}, {'measure': 'Development of Chronic Pain', 'description': 'Telephonic call Numeric pain scale; Scale is 0-10, with 10 being the highest pain.', 'timeFrame': '1, 3, 6 and 12 months after discharge from the hospital'}, {'measure': 'Glycemic Variability', 'description': 'Coefficient of variation in blood glucose levels. Denotes how large the fluctuations in blood glucose are. Higher numbers indicate increased variation.', 'timeFrame': 'From the start of induction till 24 hours postoperatively'}]",16,18 Years,,ALL,False,Kathirvel Subramaniam,OTHER,1,116.0,ACTUAL,2025-09-01T16:18:25.982779,v2_robust,True,True,True,False,False,
NCT05322252,Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial,Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial,Mifepristone,"['Misoprostol', 'Mifepristone']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,"Abortion, Second Trimester","['Abortion, Second Trimester', 'PPROM', 'Rupture, Spontaneous', 'Fetal Demise', 'Fetal Death', 'Fetal Demise From Miscarriage', 'Fetal Death Before 22 Weeks With Retention of Dead Fetus', 'Pregnancy Loss', 'Pregnancy Complications']",[],COMPLETED,,2022-07-01,2025-07-14,"[{'measure': 'Delivery within 12 hours', 'description': 'Delivery of fetus and placenta', 'timeFrame': '12 hours'}]","[{'measure': 'Delivery within 24 hours', 'description': 'Delivery of fetus and placenta', 'timeFrame': '24 hours'}, {'measure': 'Time to delivery', 'description': 'Time from misoprostol to delivery of fetus and placenta', 'timeFrame': 'During admission'}, {'measure': 'Failed induction of labor', 'description': 'Need for surgical evacuation of fetus via dilation and evacuation', 'timeFrame': 'During admission'}, {'measure': 'Retained placenta', 'description': 'Need for surgical evacuation of placenta or membranes via dilation and curettage or manual vacuum aspiration', 'timeFrame': 'During admission'}, {'measure': 'Diagnosis of clinical chorioamnionitis', 'description': 'Infection within the uterus during labor induction as diagnosed by obstetrician', 'timeFrame': 'During admission'}, {'measure': 'Postpartum hemorrhage', 'description': 'Blood loss of greater than 1000mL or with hemodynamic instability', 'timeFrame': 'During admission'}]",7,18 Years,,FEMALE,False,Washington University School of Medicine,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:25.982920,v2_robust,True,True,True,False,False,
NCT02524652,Local Infiltration Analgesia vs Adductor Canal Block for Analgesia After Anterior Cruciate Ligament Reconstruction,Postoperative Analgesic Efficacy of Local Infiltration Analgesia Versus Adductor Canal Block After Anterior Cruciate Ligament Reconstruction: A Randomised Controlled Double-blinded Trial,Ropivacaine 0.5% 20 mLs,"['Ropivacaine 0.5% 20 mLs', 'Naropine, Naropin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Rupture of Anterior Cruciate Ligament,"['Rupture of Anterior Cruciate Ligament', 'Infiltration', 'Regional Anesthesia Morbidity']",[],COMPLETED,,2015-09,2018-03,"[{'measure': 'Total morphine consumption (mg)', 'timeFrame': '24 h postoperatively'}]","[{'measure': 'Total morphine consumption (mg)', 'timeFrame': '2 h postoperatively'}, {'measure': 'Total morphine consumption (mg)', 'timeFrame': '48 h postoperatively'}, {'measure': 'Total morphine consumption (mg)', 'timeFrame': '72 h postoperatively'}, {'measure': 'Pain scores (numeric rating scale, 0-10) at rest and on movement', 'timeFrame': '2 h postoperatively'}, {'measure': 'Pain scores (numeric rating scale, 0-10) at rest and on movement', 'timeFrame': '12 h postoperatively'}, {'measure': 'Pain scores (numeric rating scale, 0-10) at rest and on movement', 'timeFrame': '24 h postoperatively'}, {'measure': 'Pain scores (numeric rating scale, 0-10) at rest and on movement', 'timeFrame': '36 h postoperatively'}, {'measure': 'Pain scores (numeric rating scale, 0-10) at rest and on movement', 'timeFrame': '48 h postoperatively'}, {'measure': 'Pain scores (numeric rating scale, 0-10) at rest and on movement', 'timeFrame': '60 h postoperatively'}, {'measure': 'Pain scores (numeric rating scale, 0-10) at rest and on movement', 'timeFrame': '72 h postoperatively'}, {'measure': 'Postoperative nausea and vomiting (yes/no)', 'timeFrame': '24 h postoperatively'}, {'measure': 'Postoperative nausea and vomiting (yes/no)', 'timeFrame': '48 h postoperatively'}, {'measure': 'Postoperative nausea and vomiting (yes/no)', 'timeFrame': '72 h postoperatively'}, {'measure': 'Pruritus (yes/no)', 'timeFrame': '24 h postoperatively'}, {'measure': 'Pruritus (yes/no)', 'timeFrame': '48 h postoperatively'}, {'measure': 'Pruritus (yes/no)', 'timeFrame': '72 h postoperatively'}, {'measure': 'Active flexion', 'description': 'Flexion of the knee by the patient measured in degrees', 'timeFrame': '24 h postoperatively'}, {'measure': 'Active flexion', 'description': 'Flexion of the knee by the patient measured in degrees', 'timeFrame': '48 h postoperatively'}, {'measure': 'Active flexion', 'description': 'Flexion of the knee by the patient measured in degrees', 'timeFrame': '72 h postoperatively'}, {'measure': 'Quadriceps muscle strength (numeric scale, 1-5)', 'timeFrame': '24 h postoperatively'}, {'measure': 'Quadriceps muscle strength (numeric scale, 1-5)', 'timeFrame': '48 h postoperatively'}, {'measure': 'Quadriceps muscle strength (numeric scale, 1-5)', 'timeFrame': '72 h postoperatively'}, {'measure': 'Distance walked (meters)', 'timeFrame': '24 h postoperatively'}, {'measure': 'Distance walked (meters)', 'timeFrame': '48 h postoperatively'}, {'measure': 'Distance walked (meters)', 'timeFrame': '72 h postoperatively'}, {'measure': 'Anterior Cruciate Ligament - Return to Sport after Injury scale', 'timeFrame': '4 months postoperatively'}, {'measure': 'Anterior cruciate ligament -Return to Sport after Injury scale', 'timeFrame': '8 months postoperatively'}, {'measure': 'International Knee Documentation Committee score', 'timeFrame': '4 months postoperatively'}, {'measure': 'International Knee Documentation Committee score', 'timeFrame': '8 months postoperatively'}]",30,18 Years,50 Years,ALL,False,Centre Hospitalier Universitaire Vaudois,OTHER,0,104.0,ACTUAL,2025-09-01T16:18:25.982950,v2_robust,True,True,True,False,False,
NCT06393452,"Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA","A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Efficacy of PP405 in Adults With Androgenetic Alopecia",PP405 0.05% Topical Gel,"['PP405 0.05% Topical Gel', 'PP405 Topical Vehicle Gel']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Androgenetic Alopecia,['Androgenetic Alopecia'],[],ACTIVE_NOT_RECRUITING,,2024-06-05,2025-12,"[{'measure': 'Percentage of subjects with treatment-related adverse events', 'description': 'Collection of adverse events, treatment emergent adverse events and serious adverse events.', 'timeFrame': 'Part 1: Baseline to Day 28; Part 2: Baseline-OLE to Day 84-OLE'}, {'measure': 'Change in local dermal tolerability as assessed by subject and investigator', 'description': 'Collection of local skin reactions using a 4 point scale (0-none, 1-mild, 2-moderate, 3-severe)', 'timeFrame': 'Part 1: Baseline to Day 28; Part 2: Baseline-OLE to Day 84-OLE'}]","[{'measure': 'Pharmacokinetics of PP405', 'description': 'To assess the concentration of PP405 in plasma', 'timeFrame': 'Part 1: Baseline to Day 28; Part 2: Baseline-OLE to Day 84-OLE'}]",3,18 Years,55 Years,ALL,True,"Pelage Pharmaceuticals, Inc.",INDUSTRY,0,78.0,ACTUAL,2025-09-01T16:18:25.982989,v2_robust,True,True,False,False,True,
NCT00387647,Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy,"A Multicenter, Phase 2 Study of Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia in Complete Remission After Induction Chemotherapy",Azacitidine,"['Vidaza™', 'Azacitidine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Leukemia,['Leukemia'],"['myeloid', 'acute', 'monocytic']",COMPLETED,,2006-08,2014-08,"[{'measure': 'Rate of Disease Free Survival at One Year', 'description': 'The primary efficacy variable is disease free survival measured at one year, which is the percentage of patients who remain alive and disease free one year after the confirmation of remission by bone marrow biopsy. Relapse is defined by a bone marrow specimen with \\>5% blasts or the presence of Auer rods.', 'timeFrame': '1 year'}]","[{'measure': 'Overall Survival (OS)', 'description': 'The secondary efficacy variable is overall survival measured as time to death, which is the time from remission until death from any cause.', 'timeFrame': '48 months'}, {'measure': 'Number of Participants With Adverse Events', 'description': 'Safety and tolerability of treatment as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0', 'timeFrame': '48 months'}]",3,60 Years,,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,24.0,ACTUAL,2025-09-01T16:18:25.983185,v2_robust,True,True,True,False,True,
NCT05930847,Digital Respiratory Game in Asthma,"Effect of Respiratory Training Digital Game on Respiratory Functions, and Psychological Status in Childhood Asthma",Use of medication for asthma,['Use of medication for asthma'],1,INTERVENTIONAL,['NA'],,,Asthma in Children,['Asthma in Children'],"['Digital game', 'Pediatric asthma', 'Quality of life', 'Respiratory training', 'Psychological status']",COMPLETED,,2022-02-20,2022-06-20,"[{'measure': 'Pulmonary Function Test (PFT)', 'description': 'The respiratory function of the children was evaluated with a portable spirometer (Spirobank MIR, Italy) according to the European Respiratory Society (ERS) and American Thoracic Society (ATS) criteria. The test will be performed in a sitting position, with the patient asked to inhale deeply and then exhale rapidly through the spirometer.', 'timeFrame': '6 months'}]","[{'measure': 'The Pediatric Asthma Quality of Life Questionnaire (PAQLQ)', 'description': 'It is used to evaluate the quality of life of children aged 7-17 years by measuring the physical, mental, and social impairment specific to asthma. It is a 23-item quality-of-life scale developed to measure the physical, mental, and social disorders of children with asthma. The total score for all items is 23-161. Higher scores suggest a better quality of life.', 'timeFrame': '6 months'}, {'measure': 'Childhood Depression Inventory (CDI)', 'description': 'The depression status of the children was evaluated with the Child Depression Scale. In this 27-item scale, 1,2,3 items are specified for each question and the scoring is done on a maximum of 54 points, with 0 for 1, 1 for 2 and 2 for 3. The cut-off score is recommended as 19 and the severity of depression increases as the score increases.', 'timeFrame': '4 months'}]",3,8 Years,14 Years,ALL,False,Ege University,OTHER,0,15.0,ACTUAL,2025-09-01T16:18:25.983201,v2_robust,True,True,True,False,False,
NCT00496847,Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect,"Study on the Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect - A Double-blind, Controlled, Randomised,Parallel,Multi-centre Study",PERIOGEN,"['PERIOGEN', 'Beta TCP alone']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Intrabony Periodontal Defect,['Intrabony Periodontal Defect'],"['rhPDGF,', 'periodontal disease']",COMPLETED,,2007-08,2009-08,"[{'measure': '1.Area under curve (AUC) of clinical attachment level (CAL) gain (0-24 weeks) 2.Extent of linear bone growth (LBG) and percentage of bone fill (%BF) at 6 months.', 'timeFrame': '6 months'}]","[{'measure': '1.Changes in CAL gain, probing depth and gingival recession at 3 and 6 months. 2.Incidence of adverse events.', 'timeFrame': '3 and 6 months'}]",2,25 Years,75 Years,ALL,False,Virchow Group,INDUSTRY,0,60.0,ACTUAL,2025-09-01T16:18:25.983236,v2_robust,True,True,True,False,True,
NCT05915247,Single Ascending Doses of HER-096 in Healthy Subjects,"Phase I, Randomised, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Subcutaneous Single Ascending Doses of HER-096 to Healthy Volunteer Subjects",HER-096,"['HER-096', '0.9% physiological saline', 'Sodium chloride 9 mg/ml', 'Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Parkinson Disease,['Parkinson Disease'],['Parkinson Disease'],COMPLETED,,2023-03-29,2023-09-29,"[{'measure': 'Adverse Events (AEs)', 'description': 'Incidence, type and severity of treatment-emergent AEs', 'timeFrame': '8 +/- 1 days'}, {'measure': 'Physical examination', 'description': 'Incidence of clinically significant physical examination findings', 'timeFrame': '8 +/- 1 days'}, {'measure': 'Vital signs', 'description': 'Incidence of clinically significant findings in systolic and diastolic blood pressure, heart rate and body temperature', 'timeFrame': '8 +/- 1 days'}, {'measure': '12-lead electrocardiogram (ECG)', 'description': 'Incidence of clinically significant findings in heart rate, PR interval, RR, QRS interval and QTcF', 'timeFrame': '24 hours'}, {'measure': 'Pulse oximetry', 'description': 'Incidence of clinically significant changes in blood oxygen saturation', 'timeFrame': '8 hours'}, {'measure': 'Laboratory safety assessments - Haematology', 'description': 'Incidence of clinically significant laboratory variables in haemoglobin, erythrocytes, leucocytes, thrombocytes, mean corpuscular volume (MCV), mean corpuscular haemoglobin concentration (MCHC) and differential leucocyte count', 'timeFrame': '8 +/- 1 days'}, {'measure': 'Laboratory safety assessments - Clinical chemistry', 'description': 'Incidence of clinically significant laboratory variables in alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), bilirubin total, bilirubin conjugated, albumin, creatinine, glucose, sodium, potassium, calcium, C-reactive protein (CRP), creatine kinase (CK), thyroid-stimulating hormone (TSH) and prolactin', 'timeFrame': '8 +/- 1 days'}, {'measure': 'Laboratory safety assessments - Coagulation', 'description': 'Incidence of clinically significant laboratory variables in plasma activated partial thromboplastin time (P-APTT) and international normalized ratio (INR)', 'timeFrame': '8 +/- 1 days'}, {'measure': 'Laboratory safety assessments - Urinalysis', 'description': 'Incidence of clinically significant laboratory variables in pH, erythrocytes, leukocytes, nitrite, protein, glucose and ketones', 'timeFrame': '8 +/- 1 days'}, {'measure': 'Laboratory safety assessments - CSF (Part 2 only)', 'description': 'Incidence of clinically significant laboratory variables in cell count and protein concentration', 'timeFrame': '12 hours'}, {'measure': 'Columbia-Suicide Severity Rating Scale (C-SSRS)', 'description': 'Incidence of subjects with increased suicidal tendencies measured by C-SSRS questionnaire consisting of maximum of 4 sections.\n\nSuicidal ideation: 5 yes/no questions with ""yes"" indicating suicidal ideation and ""no"" indicating no suicidal ideation.\n\nIntensity of ideation: 5 questions to be rated with respect to the most severe type if ideation (5 being the most severe intensity and 1 being the least intensity).\n\nSuicidal behavior: 5 yes/no questions with ""yes"" indicating suicidal behavior and ""no"" indicating no suicidal behavior.\n\nActual attempts only: 2 questions to be rated with respect to the most severe outcome of the suicide attempt (highest score indicating the most severe outcome and 0 indicating no harm).', 'timeFrame': '8 +/- 1 days'}]","[{'measure': 'HER-096 concentration levels', 'description': 'Changes in HER-096 concentration levels in plasma and urine', 'timeFrame': '24 hours'}, {'measure': 'HER-096 concentration in CSF (Part 2 only)', 'description': 'Changes in HER-096 concentration levels in CSF', 'timeFrame': '12 hours'}]",13,20 Years,75 Years,ALL,True,Herantis Pharma Plc.,INDUSTRY,1,60.0,ACTUAL,2025-09-01T16:18:25.983247,v2_robust,True,True,True,False,True,
NCT04508647,Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma,Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response,Ublituximab,"['Ublituximab', 'Umbralisib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Marginal Zone Lymphoma,"['Marginal Zone Lymphoma', 'Follicular Lymphoma']",[],COMPLETED,,2020-11-23,2022-07-14,"[{'measure': 'Number of Participants With Complete Response Rate (CR) at 8 Weeks Post Single Agent Induction', 'description': 'Number of subjects that reached a complete response at the end of single agent induction as defined by a Lugano score of 3 or less on arm MONO - Monotherapy: Ublituximab.\n\nComplete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.\n\nPatients who did not reach complete response at this point were then bridged to arm COMBO - Combotherapy: Ublituximab + Umbralisib.', 'timeFrame': '8 weeks post induction'}, {'measure': 'Number of Participants With Complete Response Rate (CR) at up to 12 Months Post MONO - Monotherapy: Ublituximab or Combotherapy: Ublituximab + Umbralisib.', 'description': 'Number of subjects that reached a complete response at up to 12 months post induction as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.\n\nComplete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.', 'timeFrame': 'up to 12 months post induction'}]","[{'measure': 'Overall Response Rates (ORR) for Number of Participants', 'description': 'Overall Response Rate for number of subjects as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.\n\nOverall response rate assessed via PET CT utilizing Lugano deauvile criteria where lymphoma lesions had responded and would include complete response, partial response (\\> 50% improvement) and stable disease (less than 50 % response)', 'timeFrame': 'up to 12 months post induction'}]",3,18 Years,,ALL,False,"University of Colorado, Denver",OTHER,0,4.0,ACTUAL,2025-09-01T16:18:25.983256,v2_robust,True,True,True,False,False,
NCT07020247,Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study,Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for Locally Advanced Rectal Cancer：A Randomized Controlled Study (PALACE Study),Anti-PD-1 antibody drug named Serplulimab,"['Chemotherapy', 'Anti-PD-1 antibody drug named Serplulimab']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Locally Advanced Rectal Cancer (LARC),"['Locally Advanced Rectal Cancer (LARC)', 'Immunotherapy', 'Radiotherapy', 'Total Neoadjuvant Therapy', 'Anal Function Preservation']",[],RECRUITING,,2024-11-19,2028-01-31,"[{'measure': 'Complete response rate', 'description': 'Defined as the combination of pathological complete response (pCR) and clinical complete response (cCR) sustained for over one year.', 'timeFrame': '1 year'}]","[{'measure': 'R0 resection rates', 'description': 'The proportion of patients achieved a complete resection with negative margin', 'timeFrame': '1 year'}, {'measure': 'Disease free survival', 'description': 'Time from the completion of the treatment to any recurrences or distant metastases', 'timeFrame': '3 years'}, {'measure': 'Anus-preserving rate', 'description': 'The rate of anal organ preservation patients to all patients', 'timeFrame': '1 year'}, {'measure': 'Locoregional recurrence-free survival (LRFS) rates', 'description': 'The rate of patients without local recurrence to all the patients', 'timeFrame': '3 years'}, {'measure': 'Distant metastasis free survival', 'description': 'Time from the completion of the treatment to any distant metastases', 'timeFrame': '3 years'}, {'measure': 'Overall survival', 'description': 'OS is defined as the difference between the date of study enrollment to the date death due to any cause', 'timeFrame': '3 years'}, {'measure': 'The adverse effects during the chemoradiotherapy', 'description': 'Any side effects during the chemoradiotherapy', 'timeFrame': '3 months'}, {'measure': 'Quality of life (QoL)', 'description': 'Assessed using the Chinese version of QLQ-C30 to measure quality of life', 'timeFrame': '1 year'}, {'measure': 'Surgical Safety Metrics', 'description': 'Surgical safety was assessed using the Clavien-Dindo classification system', 'timeFrame': '1 year'}]",10,18 Years,,ALL,False,West China Hospital,OTHER,0,184.0,ESTIMATED,2025-09-01T16:18:25.983292,v2_robust,True,True,False,False,True,
NCT01176747,"Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients","In-vivo Deposition Measurement of Beclometasone and Formoterol After Inhalation of a Single Dose of the Combination BDP Plus Formoterol NEXT DPI in Healthy Volunteers, Asthmatic and COPD Patients.",BDP/formoterol NEXT DPI,"['BDP/formoterol NEXT DPI', 'CHF 1535 NEXT DPI']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Pulmonary Disease, Chronic Obstructive","['Pulmonary Disease, Chronic Obstructive', 'Asthma']",[],COMPLETED,,2010-08,2010-10,"[{'measure': 'Lung deposition of BDP and Formoterol (expressed as % of emitted dose) when inhaled using the NEXT dry powder inhaler', 'description': 'Calculated using the individual Gamma camera images and the regions of interest defined from the 81mKrypton-ventilation scan.', 'timeFrame': 'Immediately after dosing'}]","[{'measure': 'Distribution of lung deposition', 'timeFrame': 'Immediately after dosing'}, {'measure': 'Extrathoracic deposition', 'timeFrame': 'Immediately after dosing'}, {'measure': 'Exhaled activity', 'timeFrame': 'Immediately after dosing'}, {'measure': 'Plasma pharmacokinetics of formoterol, BDP and its monopropionate metabolite (B17MP)', 'timeFrame': 'over 24 h post dose'}, {'measure': 'Lung function parameters', 'timeFrame': 'over 24 h post dose'}]",6,18 Years,70 Years,ALL,True,Chiesi Farmaceutici S.p.A.,INDUSTRY,0,28.0,ACTUAL,2025-09-01T16:18:25.983314,v2_robust,True,True,True,False,False,
NCT01636947,A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC),"A Korean Multicenter, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapies (MEC, Non-AC Regimes) With Broad Range of Tumor Types (KMEC Study)",Aprepitant,"['Aprepitant', 'ZOFRAN®', 'Diodex', 'MK-0869', 'dexamethasone sodium phosphate', 'Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).', 'Hexadrol', 'Dexasone', 'Ondansetron', 'EMEND® PO', 'Ondansetron Placebo', 'Aprepitant Placebo', 'Maxidex', 'dexamethasone acetate', 'Dexamethasone', 'Decadron']",16,INTERVENTIONAL,['PHASE4'],PHASE4,,Nausea,"['Nausea', 'Vomiting']","['chemotherapy', 'nausea', 'vomiting', 'emetogenic', 'cancer', 'antiemetics', 'tumor']",COMPLETED,,2012-12-12,2014-08-04,"[{'measure': 'The Percentage of Participants With No Vomiting - Overall Stage', 'description': 'A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). No vomiting during the Overall Stage was defined as no episodes of emesis during the 120 hours (Days 1-5) after initiation of moderately emetogenic chemotherapy (MEC).', 'timeFrame': 'Hour 0 on Day 1 to Day 5 (approximately 120 hours)'}]","[{'measure': 'Percentage of Participants With a Complete Response - Overall, Acute, and Delayed Stages', 'description': 'A Complete Response was defined as no vomiting or dry heaves and no use of a rescue therapy. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.', 'timeFrame': 'Hour 0 on Day 1 to Day 5 (approximately 120 hours)'}, {'measure': 'Number of Emetic Events - Overall Stage', 'description': 'The number of emetic events that occurred during the Overall Stage (0 to 120 hours after initiation of MEC) are presented.', 'timeFrame': 'Hour 0 on Day 1 to Day 5 (approximately 120 hours)'}, {'measure': 'Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage', 'description': 'Nausea was to be assessed using a 100-mm horizontal visual analogue scale (VAS) located in the participant diary labeled: ""How much nausea have you had over the last 24 hours?"" The left end of the scale (0 mm) was labeled ""no nausea,"" and the right end of the scale (100 mm) is labeled ""nausea as bad as it could be."" In this study, No Significant Nausea was defined as a VAS nausea rating \\<25 mm.', 'timeFrame': 'Days 1 to Day 5'}, {'measure': 'Percentage of Participants With No Impact on Daily Life - Overall Stage', 'description': 'The Functional Living Index-Emesis questionnaire (FLIE) is a validated, participant-reported instrument to measure the impact of chemotherapy-induced nausea and vomiting on daily life. There are 9 nausea-related items and 9 vomiting-related items, each on a 7-point scale. For the purposes of this study, ""No Impact"" on daily life was defined as an average item score of \\>6 on the 7-point scale; a total score \\>108 indicates no impact on daily life. Overall Stage=0 to 120 hours after initiation of MEC.', 'timeFrame': 'Day 6'}, {'measure': 'Number of Participants With No Use of a Rescue Therapy - Overall, Acute, and Delayed Stages', 'description': 'The percentage of participants who used no rescue therapy after initiation of MEC is presented for the Overall, Acute and Delayed Stages. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.', 'timeFrame': 'Day 1 to Day 5'}, {'measure': 'Percentage of Participants With One or More Clinical Adverse Event', 'description': 'An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition, which is temporally associated with the use of the study drug, is also an adverse event. Nausea and vomiting experienced during Days 1-6 were not counted as adverse events unless they were reported as a serious adverse event.', 'timeFrame': 'Day 1 through Day 29 (Up to 28 days after first dose of study drug)'}, {'measure': 'Percentage of Participants With No Vomiting - Acute and Delayed Stages', 'description': 'A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC.', 'timeFrame': 'Day 1, Day 2 to Day 5'}]",8,21 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,494.0,ACTUAL,2025-09-01T16:18:25.983333,v2_robust,True,True,True,False,True,
NCT00552747,Effect of Fenofibrate on Endothelial Function and High-density Lipoproteins (HDL)in Patients With Coronary Heart Disease,The Effect of Fenofibrate on Endothelial Function and HDL in Patients With Coronary Heart Disease and LDL-C at Goal,fenofibrate,"['fenofibrate', 'placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Coronary Heart Disease,"['Coronary Heart Disease', 'Hyperlipidemia']","['fenofibrate', 'coronary heart disease', 'mixed hyperlipidemia']",COMPLETED,,2007-10,2011-01,"[{'measure': 'endothelial function', 'timeFrame': '8 weeks'}]","[{'measure': 'HDL particle distribution', 'timeFrame': '8 weeks'}, {'measure': 'HDL associated antioxidant capacity', 'timeFrame': '8 weeks'}]",3,18 Years,60 Years,MALE,False,"National Heart Institute, Mexico",OTHER_GOV,0,76.0,ACTUAL,2025-09-01T16:18:25.983435,v2_robust,True,True,True,False,False,
NCT01356147,Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU),Pilot Study of Dornase Alfa (Pulmozyme) Therapy for Acquired Ventilator Associated Infection in Preterm and Late Preterm Infants in the Neonatal Intensive Care Unit,Dornase alfa,"['Sham therapy', 'Pulmozyme', 'Placebo', 'Dornase alfa']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Pulmonary Infections,['Pulmonary Infections'],['ventilator associated pulmonary infections'],COMPLETED,,2011-05,2017-04-30,"[{'measure': 'Percent Reduction in Oxygen Requirement From Baseline', 'description': 'Change in required supplemental oxygen from baseline or time to extubation from mechanical ventilation', 'timeFrame': 'First week of treatment or extubation'}]","[{'measure': 'Elimination of White Blood Cells and Bacteria From Tracheal Aspirate', 'description': 'Number of infants with Tracheal aspirate WBC present on review of smear at end of therapy Bacterial load judged on presence of positive or negative culture in Tracheal aspirate', 'timeFrame': 'During first week of treatment or until extubation whichever is earlier'}, {'measure': 'Number of Infants Requiring Ventilator Support', 'description': 'number of infants extubated during treatment/sham', 'timeFrame': '7 days'}]",3,7 Days,4 Months,ALL,False,Georgetown University,OTHER,1,11.0,ACTUAL,2025-09-01T16:18:25.983453,v2_robust,True,True,True,False,False,
NCT03174847,Prospective Study Assessing Blood Pressure and Other Outcomes Post-treatment in Patients With Primary Aldosteronism,"Prospective Study Assessing Blood Pressure, Cardiovascular, Endothelial and Other Outcomes poSt-surgical and Medical Treatment in Patients With Primary Aldosteronism",Mineralocorticoid Receptor Antagonists,"['Eplerenone', 'Amiloride', 'Mineralocorticoid Receptor Antagonists', 'Spironolactone']",4,OBSERVATIONAL,[],,,Primary Aldosteronism,"['Primary Aldosteronism', 'Primary Aldosteronism Due to Aldosterone Producing Adenoma', 'Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)']","['Primary aldosteronism', 'Blood pressure', 'Adrenalectomy', 'Mineralocorticoid-receptor Antagonists', 'Cardiovascular', 'Endothelial', 'Renal']",COMPLETED,,2017-02-20,2020-09-20,"[{'measure': 'Blood Pressure', 'description': 'Blood pressure assessed by 24hr ambulatory BP', 'timeFrame': 'Change from Baseline Blood Pressure at 12 months'}]","[{'measure': 'Use of antihypertension medications', 'description': 'Use of antihypertension medications as expressed in daily defined dosages and total number of medications', 'timeFrame': 'Change from Baseline Antihypertension medications at 12 months'}, {'measure': 'Blood Pressure', 'description': 'Clinic blood pressure', 'timeFrame': 'Change from Baseline Clinic Blood Pressure at 12 months'}, {'measure': 'Cardiac function', 'description': 'Cardiac function using 2DE', 'timeFrame': 'Change from Baseline Cardiac function at 12 months.'}, {'measure': 'Left ventricular hypertrophy', 'description': 'as assessed by 2DE and ECG', 'timeFrame': 'Change from Baseline Left ventricular hypertrophy at 12 months'}, {'measure': 'Renal Function', 'description': 'change in serum creatinine, calculated GFR, albuminuria (prevalence and severity)', 'timeFrame': 'Change from Baseline Renal Function at 12 months'}, {'measure': 'Quality of Life (RAND-36)', 'description': 'RAND-36', 'timeFrame': 'Change from Baseline Quality of Life RAND-36 at 12 months'}, {'measure': ""Quality of Life ( Beck's depression inventory II)"", 'description': ""Beck's depression inventory II"", 'timeFrame': 'Change from Baseline Quality of Life (BDI-II) at 12 months'}, {'measure': 'Quality of Life (EQ5D)', 'description': 'EQ5D', 'timeFrame': 'Change from Baseline EQ5D at 12 months'}, {'measure': 'Lipids', 'description': 'Lipids', 'timeFrame': 'Change from Baseline Lipids at 12 months'}, {'measure': 'Transaminitis', 'description': 'ALT, AST,', 'timeFrame': 'Change from Baseline transaminitis at 12 months'}, {'measure': 'Insulin Resistance', 'description': 'Measured with HOMA', 'timeFrame': 'Change from Baseline Insulin resistance at 12 months'}, {'measure': 'Fasting glucose', 'description': 'Fasting glucose', 'timeFrame': 'Change from Baseline Fasting glucose at 12 months'}, {'measure': 'weight', 'description': 'change in weight', 'timeFrame': 'Change from Baseline weight at 12 months'}, {'measure': 'Control of hypertension', 'description': 'Proportion of patients reaching normal BP (ambulatory /home BP \\<135/85 or clinic BP \\<140/90)', 'timeFrame': 'Change from Baseline Status of hypertension control at 12 months'}, {'measure': 'Cure of Primary aldosteronism', 'description': 'Proportion of patients with cure of PA after adrenalectomy', 'timeFrame': 'Change from Baseline Status of primary aldosteronism at 12 months'}]",16,21 Years,80 Years,ALL,False,Changi General Hospital,OTHER,0,57.0,ACTUAL,2025-09-01T16:18:25.983468,v2_robust,False,True,True,False,False,
NCT05371249,Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy,Seven-Day Vonoprazan-Based Triple Therapy With High-Dose Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy: A Randomized Controlled Trial in Taiwan,Vonoprazan-based triple therapy,"['S-14', 'Extended sequential therapy', 'VAC-7', 'Vonoprazan-based triple therapy']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Helicobacter Pylori,['Helicobacter Pylori'],['Proton Pump Inhibitors'],ACTIVE_NOT_RECRUITING,,2021-12-01,2024-02-28,"[{'measure': 'Eradication rate of helicobacter pylori', 'description': 'Assessed by urea breath test', 'timeFrame': 'Assessed at least 6 weeks after the therapy'}]","[{'measure': 'Adverse effects of the drugs', 'description': 'Self-reported adverse effects by patients through a questionnaire.', 'timeFrame': 'After patients completed the therapy (For VAC-7 group: 1 week after the therapy; For S-14 group: 2 weeks after the therapy)'}, {'measure': 'Compliance', 'description': 'Self-reported compliance by patients through a questionnaire.', 'timeFrame': 'After patients completed the therapy ((For VAC-7 group: 1 week after the therapy; For S-14 group: 2 weeks after the therapy)'}]",3,20 Years,,ALL,False,Fu Jen Catholic University Hospital,OTHER,0,628.0,ACTUAL,2025-09-01T16:18:25.983717,v2_robust,True,True,False,False,True,
NCT06334549,A Prospective Study of Vasopressor on Cerebral Oxygenation During General Anesthesia,Effects of Vasopressor on Cerebral Oxygenation During General Anesthesia in Abdominal Surgery,Ephedrine-P,"['Ephedrine-P', 'Phenylephrine-P', 'Norepinephrine-P', 'vasopressor', 'Phenylephrine-S', 'Ephedrine-S', 'Norepinephrine-S']",7,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypotension Drug-Induced,['Hypotension Drug-Induced'],"['Abdominal surgery', 'ephedrine', 'phenylephrine', 'norepinephrine', 'cerebral oxygen saturation', 'MAP', 'CO', 'General anesthesia', 'Propofol', 'Sevoflurane', 'Hypotension Drug-induced']",RECRUITING,,2024-03-05,2025-12-05,"[{'measure': 'Continual changes in Cerebral Oxygen Saturation', 'description': 'This outcome is measured by near-infrared spectroscopy', 'timeFrame': '10 minutes after entering the operating room; when 20% decrease in baseline MAP after both induction of anesthesia and intubation; when MAP rising to the highest point after administration of vasopressors'}]","[{'measure': 'Continual changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial blood pressure (MAP)', 'description': 'This outcome is measured by LiDCO rapidV3 monitoring system', 'timeFrame': '10 minutes after entering the operating room; when 20% decrease in baseline MAP after both induction of anesthesia and intubation; when MAP rising to the highest point after administration of vasopressors'}, {'measure': 'Continual changes in heart rate (HR)', 'description': 'This outcome is measured by LiDCO rapidV3 monitoring system', 'timeFrame': '10 minutes after entering the operating room; when 20% decrease in baseline MAP after both induction of anesthesia and intubation; when MAP rising to the highest point after administration of vasopressors'}, {'measure': 'Continual changes in stroke volume (SV)', 'description': 'This outcome is measured by LiDCO rapidV3 monitoring system', 'timeFrame': '10 minutes after entering the operating room; when 20% decrease in baseline MAP after both induction of anesthesia and intubation; when MAP rising to the highest point after administration of vasopressors'}, {'measure': 'Continual changes in cardiac output (CO)', 'description': 'This outcome is measured by LiDCO rapidV3 monitoring system', 'timeFrame': '10 minutes after entering the operating room; when 20% decrease in baseline MAP after both induction of anesthesia and intubation; when MAP rising to the highest point after administration of vasopressors'}, {'measure': 'Continual changes in systemic vascular resistance (SVR)', 'description': 'This outcome is measured by LiDCO rapidV3 monitoring system', 'timeFrame': '10 minutes after entering the operating room; when 20% decrease in baseline MAP after both induction of anesthesia and intubation; when MAP rising to the highest point after administration of vasopressors'}]",6,18 Years,80 Years,ALL,False,Dalian Municipal Central Hospital,OTHER,0,180.0,ESTIMATED,2025-09-01T16:18:25.983767,v2_robust,True,True,False,False,False,
NCT03395249,"Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994","A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of SPR994 Following Single and Multiple Ascending Doses of SPR994 Administered Orally in Healthy Volunteers",SPR994,"['Placebo', 'SPR994', 'SPR994 Oral Tablet', 'Placebo Oral Tablet', 'Orapenem® fine granules', 'Orapenem®']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['safety', 'tolerability', 'pharmacokinetics', 'SPR994']",COMPLETED,,2017-10-20,2018-08-02,"[{'measure': 'Safety measures: adverse events', 'description': 'The incidence and severity of AEs', 'timeFrame': 'SAD: 1 to 7 days or 1 to 13 (food effect cohort); MAD 1 to 20 days'}, {'measure': 'Safety measures: concomitant medications', 'description': 'The type and frequency of medications used', 'timeFrame': 'SAD: 1 to 7 days or 1 to 13 (food effect cohort); MAD: 1 to 20 days'}, {'measure': 'Safety measures: physical examination', 'description': 'Change from baseline to end of study visit', 'timeFrame': 'SAD: -1 to 7 days or -1 to 13 (food effect cohort); MAD: -1 to 20 days'}, {'measure': 'Safety measures: weight', 'description': 'Change from baseline to end of study visit', 'timeFrame': 'SAD: -1 to 7 days or -1 to 13 (food effect cohort); MAD: -1 to 20 days'}, {'measure': 'Safety measures: pulse rate', 'description': 'Change from baseline to end of study visit', 'timeFrame': 'SAD: -1 to 7 days or -1 to 13 (food effect cohort); MAD: -1 to 20 days'}, {'measure': 'Safety measures: ECG', 'description': 'Change from baseline to end of study visit', 'timeFrame': 'SAD: -1 to 7 days or -1 to 13 (food effect cohort); MAD: -1 to 20 days'}, {'measure': 'Safety measures: clinical laboratory testing', 'description': 'Change from baseline to end of study visit', 'timeFrame': 'SAD: -1 to 7 days or -1 to 13 (food effect cohort); MAD: -1 to 20 days'}, {'measure': 'Safety measures: respiratory rate', 'description': 'Change from baseline to end of study visit', 'timeFrame': 'SAD: -1 to 7 days or -1 to 13 (food effect cohort); MAD: -1 to 20 days'}, {'measure': 'Safety measures: blood pressure', 'description': 'Change from baseline to end of study visit', 'timeFrame': 'SAD: -1 to 7 days or -1 to 13 (food effect cohort); MAD: -1 to 20 days'}, {'measure': 'Safety measures: body temperature', 'description': 'Change from baseline to end of study visit', 'timeFrame': 'SAD: -1 to 7 days or -1 to 13 (food effect cohort); MAD: -1 to 20 days'}]","[{'measure': 'Pharmacokinetics: Time to maximum concentration (Tmax)', 'description': 'Plasma Sample Collection for PK Analysis:\n\nSAD Cohorts 1 and 7: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 2, 3, and 6: Day 1 at the same time-points as SAD Cohorts 1 and 7. SAD Cohorts 8 - 15: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 16 and 17: Day 1 at the same time-points as SAD Cohorts 8 - 15. MAD Cohorts 4 and 5: Day 1 at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12 h following start of the first dose (BID dosing) or pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6 and 8 h following start of first dose and prior to second dose (TID dosing); Prior to the morning dose on Days 2, 3, 5, 7, 9, 11 and 13; Pre-dose, 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8', 'timeFrame': 'SAD: Day 1 to Day 3 and Day 7 to 9 (Food Effect); MAD Day 1 to 16'}, {'measure': 'Pharmacokinetics: Maximum concentration (Cmax)', 'description': 'Plasma Sample Collection for PK Analysis:\n\nSAD Cohorts 1 and 7: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 2, 3, and 6: Day 1 at the same time-points as SAD Cohorts 1 and 7. SAD Cohorts 8 - 15: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 16 and 17: Day 1 at the same time-points as SAD Cohorts 8 - 15. MAD Cohorts 4 and 5: Day 1 at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12 h following start of the first dose (BID dosing) or pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6 and 8 h following start of first dose and prior to second dose (TID dosing); Prior to the morning dose on Days 2, 3, 5, 7, 9, 11 and 13; Pre-dose, 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8', 'timeFrame': 'SAD: Day 1 to Day 3 and Day 7 to 9 (Food Effect); MAD Day 1 to 16'}, {'measure': 'Pharmacokinetics: Area under the concentration-time curve from time 0 to last measurable time-point (AUC0-t)', 'description': 'Plasma Sample Collection for PK Analysis:\n\nSAD Cohorts 1 and 7: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 2, 3, and 6: Day 1 at the same time-points as SAD Cohorts 1 and 7. SAD Cohorts 8 - 15: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 16 and 17: Day 1 at the same time-points as SAD Cohorts 8 - 15. MAD Cohorts 4 and 5: Day 1 at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12 h following start of the first dose (BID dosing) or pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6 and 8 h following start of first dose and prior to second dose (TID dosing); Prior to the morning dose on Days 2, 3, 5, 7, 9, 11 and 13; Pre-dose, 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8', 'timeFrame': 'SAD: Day 1 to Day 3 and Day 7 to 9 (food effect); MAD Day 1 to 16'}, {'measure': 'Pharmacokinetics: Area under the concentration-time curve from time 0 to infinity (AUC0-inf)', 'description': 'Plasma Sample Collection for PK Analysis:\n\nSAD Cohorts 1 and 7: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 2, 3, and 6: Day 1 at the same time-points as SAD Cohorts 1 and 7. SAD Cohorts 8 - 15: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 16 and 17: Day 1 at the same time-points as SAD Cohorts 8 - 15. MAD Cohorts 4 and 5: Day 1 at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12 h following start of the first dose (BID dosing) or pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6 and 8 h following start of first dose and prior to second dose (TID dosing); Prior to the morning dose on Days 2, 3, 5, 7, 9, 11 and 13; Pre-dose, 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8', 'timeFrame': 'SAD: Day 1 to Day 3 and Day 7 to 9 (food effect); MAD Day 1 to 16'}, {'measure': 'Pharmacokinetics: Terminal Elimination Rate Constant (kel)', 'description': 'Plasma Sample Collection for PK Analysis:\n\nSAD Cohorts 1 and 7: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 2, 3, and 6: Day 1 at the same time-points as SAD Cohorts 1 and 7. SAD Cohorts 8 - 15: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 16 and 17: Day 1 at the same time-points as SAD Cohorts 8 - 15. MAD Cohorts 4 and 5: Day 1 at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12 h following start of the first dose (BID dosing) or pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6 and 8 h following start of first dose and prior to second dose (TID dosing); Prior to the morning dose on Days 2, 3, 5, 7, 9, 11 and 13; Pre-dose, 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8', 'timeFrame': 'SAD: Day 1 to Day 3 and Day 7 to 9 (food effect); MAD Day 1 to 16'}, {'measure': 'Pharmacokinetics: Terminal half-life (t1/2)', 'description': 'Plasma Sample Collection for PK Analysis:\n\nSAD Cohorts 1 and 7: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 2, 3, and 6: Day 1 at the same time-points as SAD Cohorts 1 and 7. SAD Cohorts 8 - 15: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 16 and 17: Day 1 at the same time-points as SAD Cohorts 8 - 15. MAD Cohorts 4 and 5: Day 1 at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12 h following start of the first dose (BID dosing) or pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6 and 8 h following start of first dose and prior to second dose (TID dosing); Prior to the morning dose on Days 2, 3, 5, 7, 9, 11 and 13; Pre-dose, 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8', 'timeFrame': 'SAD: Day 1 to Day 3 and Day 7 to 9 (food effect); MAD Day 1 to 16'}, {'measure': 'Pharmacokinetics: Terminal clearance (CL/F)', 'description': 'Plasma Sample Collection for PK Analysis:\n\nSAD Cohorts 1 and 7: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 2, 3, and 6: Day 1 at the same time-points as SAD Cohorts 1 and 7. SAD Cohorts 8 - 15: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 16 and 17: Day 1 at the same time-points as SAD Cohorts 8 - 15. MAD Cohorts 4 and 5: Day 1 at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12 h following start of the first dose (BID dosing) or pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6 and 8 h following start of first dose and prior to second dose (TID dosing); Prior to the morning dose on Days 2, 3, 5, 7, 9, 11 and 13; Pre-dose, 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8', 'timeFrame': 'SAD: Day 1 to Day 3 and Day 7 to 9 (food effect); MAD Day 1 to 16'}, {'measure': 'Pharmacokinetics: Volume of distribution', 'description': 'Plasma Sample Collection for PK Analysis:\n\nSAD Cohorts 1 and 7: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 2, 3, and 6: Day 1 at the same time-points as SAD Cohorts 1 and 7. SAD Cohorts 8 - 15: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 16 and 17: Day 1 at the same time-points as SAD Cohorts 8 - 15. MAD Cohorts 4 and 5: Day 1 at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12 h following start of the first dose (BID dosing) or pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6 and 8 h following start of first dose and prior to second dose (TID dosing); Prior to the morning dose on Days 2, 3, 5, 7, 9, 11 and 13; Pre-dose, 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8', 'timeFrame': 'SAD: Day 1 to Day 3 and Day 7 to 9 (food effect); MAD Day 1 to 16'}, {'measure': 'Pharmacokinetics: Area under the concentration-time curve from 0 to 12 hours from the start of first dose (AUC0-12h)', 'description': 'Plasma Sample Collection for PK Analysis:\n\nSAD Cohorts 1 and 7: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 2, 3, and 6: Day 1 at the same time-points as SAD Cohorts 1 and 7. SAD Cohorts 8 - 15: Days 1 and 7 (Food Effect Cohorts) at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 h post-dose.\n\nSAD Cohorts 16 and 17: Day 1 at the same time-points as SAD Cohorts 8 - 15. MAD Cohorts 4 and 5: Day 1 at pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12 h following start of the first dose (BID dosing) or pre-dose and at 15, 30, 45 min and 1, 1.5, 2, 4, 6 and 8 h following start of first dose and prior to second dose (TID dosing); Prior to the morning dose on Days 2, 3, 5, 7, 9, 11 and 13; Pre-dose, 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8', 'timeFrame': 'SAD: Day 1 to Day 3 and Day 7 to 9 (food effect); MAD Day 1 to 16'}, {'measure': 'Pharmacokinetics: SPR994 excreted in urine in each collection interval', 'description': 'SAD: Urine samples for PK will be collected at pre-dose and during the following intervals(total collection): 0-4, 4-8, 8-12, and 12-24 hours after dosing.\n\nMAD: Urine samples for PK will be collected at pre-dose on Day 1 and during the followingintervals (total collection): 0-4, 4-8, and 8-12 hours after start of first dose (BID dosing) or pre-dose on Day 1 and during the following intervals (total collection): 0-4, 4-8 prior to next dose (Days 1-2); and 0-4, 4-8, 8-12, and 12-24 hours following start of the last dose (Days 14-15).', 'timeFrame': 'SAD: Days 1-2 and 7-8 (food effect cohorts). MAD: Day 1-2 and 14-15.'}]",20,18 Years,55 Years,ALL,True,Spero Therapeutics,INDUSTRY,1,124.0,ACTUAL,2025-09-01T16:18:25.983792,v2_robust,True,True,True,False,True,
NCT00550849,"Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction","Randomized, Double-blind, Placebo-controlled, Multiple-dose, Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 (CDDO-Me) Administered Orally for 14 Days in Patients With Hepatic Dysfunction",RTA 402,['RTA 402'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Liver Disease,['Liver Disease'],[],TERMINATED,Enrollment discontinued after second cohort completed.,2007-04-30,2007-11-30,"[{'measure': 'To evaluate the safety and tolerability of multiple-dose oral administration of RTA 402 in patients with hepatic dysfunction.', 'timeFrame': '28 days'}]","[{'measure': 'To correlate the biological activity of RTA 402 with drug concentration in plasma.', 'timeFrame': '28 days'}]",2,18 Years,,ALL,False,Biogen,INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:25.983977,v2_robust,True,True,False,True,True,Enrollment discontinued after second cohort completed.
NCT01003249,Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen,Treatment of Patients With Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen: a Randomized Double-blind Placebo-controlled Cross-over Trial,Baclofen,"['Baclofen', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Overactive Bladder,"['Overactive Bladder', 'Constipation', 'Lower Urinary Tract Symptoms']","['over distention of bladder', 'Dysfunctional voiding', 'dysfunctional elimination syndrome']",TERMINATED,recruitment was going too slowly,2009-09,2013-03,"[{'measure': 'Urine Flow Rate, as Measured With Uroflometry', 'description': 'Uroflometry with patch electrodes will also be completed at the end of this four week period. Higher flow rate denotes better outcome.', 'timeFrame': 'Baseline and 4 weeks'}, {'measure': 'Number of Participants Exhibiting Abnormal EMG Activity During Voiding', 'description': 'EMG with patch electrodes was completed at the end of this four week period. The number of participants with EMG activity during voiding was collected. EMG activity during the voiding is considered abnormal and is a criteria for voiding dysfunction.Lower numbers denotes better outcomes.', 'timeFrame': 'Baseline and 4 weeks'}, {'measure': 'Average Scores on International Consultation on Incontinence Modular Questionnaire- Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol)', 'description': 'Diagnosis of dysfunctional bladder is based on symptoms demonstrating no relaxation or over stimulation of external urinary sphincter during voiding. Symptoms will be scored by International Consultation on Incontinence Modular Questionnaire- Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol). The ICIQ-LUTSqol is a patient-completed questionnaire for evaluating quality of life (QoL) in urinary incontinent patients There are 20 items and the score range is 10-200. Higher scores denotes better outcomes.', 'timeFrame': 'Baseline and 4 weeks'}, {'measure': 'Average Scores on Dysfunctional Voiding as Measured With Quality of Life (QOL) Questionnaire', 'description': 'This was measured using the Urogenital Distress Inventory (UDI-6). The UDI-6 is a symptom inventory specific to lower urinary tract dysfunction and genital prolapse. There are 6 items scored. The score range is from 0-100 Lower scores denotes better outcomes.', 'timeFrame': 'Baseline and 4 weeks'}]","[{'measure': 'Number (and Percentage) of Participants With External Anal Sphincter Muscle Dysfunction Via Patient Symptoms.', 'description': 'The percent of patient in each group who had defecation problem', 'timeFrame': 'Baseline and 4 weeks'}, {'measure': 'Efficacy of Baclofen vs. Placebo on Number of Voidings Per Day', 'description': 'The number of voiding per day before and after treatment.', 'timeFrame': 'Baseline and 4 weeks'}]",6,18 Years,64 Years,ALL,False,Wake Forest University Health Sciences,OTHER,0,12.0,ACTUAL,2025-09-01T16:18:25.984207,v2_robust,True,True,False,True,False,recruitment was going too slowly
NCT03096249,The Influence of Oxytocin on Socio-communicative Sensitivity,Monitoring the Influence of Oxytocin on Socio-communicative Sensitivity Using Fast Periodic Visual Stimulation,Oxytocin,['Oxytocin'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Oxytocin,['Oxytocin'],"['oxytocin', 'emotion recognition', 'emotion processing', 'social salience', 'face processing', 'Electroencephalography (EEG)']",COMPLETED,,2016-11-21,2017-07-30,"[{'measure': 'social salience frequency-tagging FPVS', 'description': 'EEG recording during simultaneous (superimposed) presentation of social stimuli (faces) and non-social stimuli (objects or houses), at a frequency of 6 and 7.5Hz, respectively (counterbalanced).', 'timeFrame': 'random: 30-70 minutes after nasal spray'}, {'measure': 'Oddball face detection FPVS paradigm', 'description': 'EEG recording during presentation of objects (at 6 Hz) and faces (inserted as an ""oddball"" every fifth image, thus at a frequency of 1.2 Hz)', 'timeFrame': 'random: 30-70 minutes after nasal spray'}, {'measure': 'Oddball identity discrimination FPVS paradigm', 'description': 'EEG recording during presentation of neutral faces of the same person (same identity, presented at 6 Hz) and the face of another person (inserted as an ""oddball"" every fifth image, thus at a frequency of 1.2 Hz)', 'timeFrame': 'random: 30-70 minutes after nasal spray'}, {'measure': 'Oddball expression generalization FPVS paradigm', 'description': 'EEG recording during presentation of neutral faces with different identities (at 6 Hz) and faces with an emotional expression (fear, anger, happy; inserted as an ""oddball"" every fifth image, thus at a frequency of 1.2 Hz)', 'timeFrame': 'random: 30-70 minutes after nasal spray'}]","[{'measure': 'Emotion recognition: accuracy on the Palermo Matching task (65 items)', 'description': 'Three faces are shown on the screen. Two of them display the same emotion and the participant has to indicate which face shows a different emotion', 'timeFrame': '80 minutes after nasal spray (after all EEG measures)'}, {'measure': 'resting state EEG', 'description': 'EEG recording, while presenting a fixation cross', 'timeFrame': '45-50 minutes after nasal spray (after two FPVS paradigms)'}, {'measure': 'Social responsiveness: Social Responsiveness Scale (SRS)', 'description': 'Self-report version of the SRS. In addition to a Total score reflecting severity of social deficits in the autism spectrum, the SRS generates scores for five Treatment subscales: Social Awareness, Social Cognition, Social Communication, Social Motivation, and Restricted Interests and Repetitive Behavior.', 'timeFrame': 'Baseline'}, {'measure': 'Social phobia: Social Phobia Inventory (SPIN)', 'description': 'A 17-item questionnaire that screens for, and measures, the severity of social anxiety disorder.', 'timeFrame': 'Baseline'}, {'measure': 'Attachment: State Adult Attachment Measure (SAAM)', 'description': 'The SAAM measures 3 different aspects of adult attachment: Security, Anxiety, Avoidance. There are 21 Likert-style questions with a score between 1 and 7 (7 for each of the three subscales).', 'timeFrame': 'Baseline'}, {'measure': 'Mood: Positive And Negative Affect Schedule (PANAS)', 'description': 'The Positive and Negative Affect Schedule (PANAS) comprises two mood scales, one that measures positive affect and the other which measures negative affect. It consists of 20 items (10 for each subscale).', 'timeFrame': '90 minutes after nasal spray'}]",10,18 Years,30 Years,MALE,True,KU Leuven,OTHER,0,31.0,ACTUAL,2025-09-01T16:18:25.984243,v2_robust,True,True,True,False,False,
NCT00486538,Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib,"An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib",ABT-869,['ABT-869'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Renal Cell Carcinoma,['Advanced Renal Cell Carcinoma'],[],COMPLETED,,2007-06,2012-06,"[{'measure': 'Objective Response Rate', 'timeFrame': 'From randomization until patient death or alive at 2 years'}]","[{'measure': 'Progression-free rate', 'timeFrame': 'Week 16'}, {'measure': 'Best response rate', 'timeFrame': 'From randomization until patient death or alive at 2 years'}, {'measure': 'Time to tumor progression', 'timeFrame': 'From randomization until patient death or alive at 2 years'}, {'measure': 'Progression free survival', 'timeFrame': 'Radiographic evaluation every month, clinical evaluation every 4 weeks'}, {'measure': 'Overall Survival', 'timeFrame': 'Two-year follow-up post study'}]",6,18 Years,,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,1,53.0,ACTUAL,2025-09-01T16:18:25.984443,v2_robust,True,True,True,False,False,
NCT00000138,Herpetic Eye Disease Study (HEDS) I,,Prednisolone Phosphate,"['Acyclovir', 'Prednisolone Phosphate']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Keratitis, Herpetic","['Keratitis, Herpetic', 'Ocular Herpes Simplex']",['Herpes Simplex Stromal Keratitis'],UNKNOWN,,1989-05,,[],[],0,12 Years,,ALL,False,National Eye Institute (NEI),NIH,0,,,2025-09-01T16:18:25.984458,v2_robust,True,True,False,False,False,
NCT01315938,Abatacept Treatment in Polymyositis and Dermatomyositis,Abatacept Treatment in Polymyositis and Dermatomyositis,Abatacept Active Treatment,"['Abatacept Active Treatment', 'Orencia', 'Abatacept Delayed-Onset Treatment']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Polymyositis,"['Polymyositis', 'Dermatomyositis']",[],COMPLETED,,2011-01,2013-11-28,"[{'measure': 'Change in International Myositis Assessment and Clinical Studies Group (IMACS)', 'description': 'The primary endpoint will be the number of responders, defined according to the International Myositis Assessment and Clinical Studies Group (IMACS) preliminary definition of improvement (DOI) after treatment with abatacept for 6 months. IMACS DOI is defined as relative improvement by ≥20% in three of any six core set measures, with no more than two core set measures worsening by ≥25%, which cannot be MMT.', 'timeFrame': 'Change from Baseline IMACS at 6 months'}]","[{'measure': 'Change in International Myositis Assessment and Clinical Studies Group (IMACS)', 'description': 'The number of responders in the delayed-onset arm compared with active treatment arm at 3 and 6 months, and the change in individual components of the IMACS core set measures for disease activity and in the muscle endurance as tested by FI-2, in the delayed-onset arm compared with active treatment arm at 3 and 6 months.', 'timeFrame': 'Change from 3 IMACS at 6 months'}]",2,18 Years,80 Years,ALL,False,Karolinska Institutet,OTHER,2,20.0,ACTUAL,2025-09-01T16:18:25.984511,v2_robust,True,True,True,False,False,
NCT01925638,Effect of Ketoconazole on the Pharmacokinetics of Refametinib,"An Open-label Study in Healthy Male Subjects to Assess the Effect of a Strong CYP3A4 Inhibitor, Ketoconazole, on the Pharmacokinetics of Refametinib",BAY86-9766,"['BAY86-9766', 'Ketoconazole']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Drug Interactions,['Drug Interactions'],"['Healthy Volunteers', 'Refametinib', 'Ketoconazole', 'Pharmacokinetics']",COMPLETED,,2013-09,2013-12,"[{'measure': 'Cmax(maximum observed drug concentration in measured matrix after single dose administration) of BAY86-9766', 'timeFrame': 'Day 1: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 h post-dose; Day 8: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose'}, {'measure': 'AUC(area under the concentration vs. time curve from zero to infinity after single (first) dose) of BAY86-9766', 'timeFrame': 'Day 1: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 h post-dose; Day 8: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose'}, {'measure': 't1/2(half-life associated with the terminal slope) of BAY86-9766', 'timeFrame': 'Day 1: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 h post-dose; Day 8: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose'}]","[{'measure': 'Number of participants with adverse events as a measure of safety and tolerability', 'timeFrame': '2.5 months'}, {'measure': 'AUC(0-tlast)(AUC from time 0 to the last data point > LLOQ) of BAY86-9766 and Metabolites M-11 and M-17', 'timeFrame': 'Day 1: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 h post-dose; Day 8: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose'}, {'measure': 'tmax(time to reach Cmax) of BAY86-9766 and Metabolites M-11 and M-17', 'timeFrame': 'Day 1: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 h post-dose; Day 8: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose'}, {'measure': 'tlast(time of last observed concentration value above lower limit of quantitation) of BAY86-9766 and Metabolites M-11 and M-17', 'timeFrame': 'Day 1: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 h post-dose; Day 8: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose'}, {'measure': 'Cmax(maximum observed drug concentration in measured matrix after single dose administration) of Metabolites M-11 and M-17', 'timeFrame': 'Day 1: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 h post-dose; Day 8: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose'}, {'measure': 'AUC(area under the concentration vs. time curve from zero to infinity after single (first) dose) of Metabolites M-11 and M-17', 'timeFrame': 'Day 1: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 h post-dose; Day 8: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose'}, {'measure': 't1/2(half-life associated with the terminal slope) of Metabolites M-11 and M-17', 'timeFrame': 'Day 1: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 h post-dose; Day 8: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose'}, {'measure': 'CL/F(total body clearance of drug calculated after extravascular administration) of BAY 86-9766)', 'timeFrame': 'Day 1: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 h post-dose; Day 8: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose'}]",11,18 Years,45 Years,MALE,True,Bayer,INDUSTRY,0,18.0,ACTUAL,2025-09-01T16:18:25.984557,v2_robust,True,True,True,False,True,
NCT01042938,Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients,Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients,Curcumin C3 Complex,"['Curcumin C3 Complex', 'Curcumin; curcuminoids', 'dicalcium phosphate with yellow food grade dye', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],['Radiation dermatitis in breast cancer patients'],COMPLETED,,2008-01,2011-04,"[{'measure': 'Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients', 'description': 'The severity of radiation dermatitis was measured using the Radiation Dermatitis Severity (RDS)Scale which ranges from 0.0 to 4.0 with increments of 0.5. The RDS scale is a revised form of the NIH Common Toxicity Criteria to account for color and subtle texture changes in the skin. The worst dermatitis (i.e., highest RDS score) at the end of treatment was used for the primary analysis of severity of radiation dermatitis in each treatment group. Additionally, we performed repeated measure analyses to examine the severity of dermatitis over time in each arm.', 'timeFrame': '4-7 weeks (prescribed course of radiation)'}]","[{'measure': 'Moist Desquamation at Radiation Treatment Site', 'description': 'The presence of moist desquamation at the end of radiation treatment was examined between curcumin and placebo treatment groups. We compared the number of participants (or percentage) with moist desquamation between each treatment group.', 'timeFrame': '4-7 weeks (prescribed course of radiation)'}, {'measure': 'Redness at Radiation Treatment Site', 'description': 'Redness at radiation treatment site was measured using a CR-400 Colorimeter (Konica Minolta). The colorimeter uses the L\\*a\\*b\\* color scale. We used a\\* values (redness) which range from 0.0 to 20.0. The lower the number value, the lower amount of redness. Therefore, high number values represent large amounts of redness.', 'timeFrame': '4-7 weeks (prescribed course of radiation)'}, {'measure': 'Pain at Radiation Treatment Site', 'description': 'The McGill Pain Questionnaire-Short Form (MPQ-SF) was used to determine the participants pain at treatment site. The MPQ-SF contains three subscales: affective pain, sensory pain, and perceived pain. This outcome measure compared the total pain score (range 0 to 50)and subscale scores (sensory subscale range 0 to 33; affective subscale range 0 to 12; perceived pain subscale 0 to 5) at the end of radiation therapy between the two treatment arms.', 'timeFrame': '4-7 weeks (prescribed course of radiation)'}]",4,21 Years,,FEMALE,False,University of Rochester,OTHER,0,35.0,ACTUAL,2025-09-01T16:18:25.984572,v2_robust,True,True,True,False,False,
NCT04318938,Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping,Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients,Brigatinib,"['Study treatment', 'Tyrosine kinase inhibitor', 'Brigatinib']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,NSCLC,['NSCLC'],"['ALK+ NSCLC', 'Resistance patterns', 'Molecular properties']",ACTIVE_NOT_RECRUITING,,2020-03-30,2026-01-16,"[{'measure': 'Progression-free survival (PFS) of 1st-line treatment according to RECIST v1.1', 'description': 'Time from the first dosing date of any study medication to the date of the first objectively documented tumor progression or death due to any cause', 'timeFrame': '68 months'}]","[{'measure': 'PFS of 2nd-line treatment according to RECIST v1.1', 'description': 'Time from the first dosing date of any 2nd-line TKI to the date of the objectively documented tumor progression or death due to any cause', 'timeFrame': '68 months'}, {'measure': 'TNT 1st line (TNT1, i.e. time-to-next treatment for the 1st line)', 'description': 'Time from begin of 1st-line treatment until begin of 2nd-line treatment', 'timeFrame': '68 months'}, {'measure': 'TNT 2nd line (TNT2, i.e. time-to-next treatment for the 2nd line', 'description': 'Time from begin of 2nd line until begin of 3rd-line treatment', 'timeFrame': '68 months'}, {'measure': 'TNT1/2 (time-to-next treatment for the 1st and 2nd line together)', 'description': 'Time from begin of 1st-line treatment until begin of 3rd-line treatment', 'timeFrame': '68 months'}, {'measure': 'Overall survival (OS)', 'description': 'Time from treatment start in the 1st line to the date of death (due to any cause)', 'timeFrame': '68 months'}, {'measure': 'Intracranial ORR (iORR)', 'description': 'Percentage of participants with a best overall intracranial response (BOR) of intracranial complete response (CR) or intracranial partial response (PR). Best overall intracranial response (BOR) is defined as the best response designation, recorded between the date of first dose and the date of the initial objectively documented intracranial tumor progression per RECIST criteria or the date of subsequent therapy or death, whichever occurs first.', 'timeFrame': '68 months'}, {'measure': 'Intracranial DOR (iDOR) according to RECIST v1.1', 'description': 'Time from first documentation of intracranial CR or PR according to RECIST v1.1 (whichever is first recorded) until the first date that the intracranial progressive disease (PD) is objectively documented or until death (whichever occurs first', 'timeFrame': '68 months'}, {'measure': 'Time to intracranial progression (TTiP)', 'description': 'Time from start of 1st-line treatment until the occurrence of a new central nervous system (CNS) lesion or progression of pre-existing CNS lesions', 'timeFrame': '68 months'}, {'measure': 'Safety (rate of adverse events)', 'description': 'Type, incidence and severity of adverse events (AEs) and serious adverse events (SAEs)graded according to NCI CTCAE v5.0', 'timeFrame': '68 months'}, {'measure': 'Quality of life (QoL) assessed by SF-12-questionnaire', 'description': 'Patient reported outcome assessed by the validated SF-12-questionnaire', 'timeFrame': '68 months'}, {'measure': 'Quality of life (QoL) assessed by EORTC-quality of life questionnaire (QLQ)-BN20-questionnaire', 'description': 'Patient reported outcome assessed by the validated EORTC-QLQ-BN20-questionnaire', 'timeFrame': '68 months'}]",12,18 Years,,ALL,False,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,OTHER,2,118.0,ACTUAL,2025-09-01T16:18:25.984631,v2_robust,True,True,False,False,True,
NCT03176238,"Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","A Phase IIIb, Multi-center, Open-label Study of RAD001 in Combination With EXemestane in Post-menopausal Women With EStrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Locally Advanced or Metastatic Breast Cancer",everolimus,"['everolimus', 'RAD001', 'exemestane']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Post Menopausal Breast Cancer,['Post Menopausal Breast Cancer'],"['post menopausal', 'advanced breast cancer', 'metastatic breast cancer', 'everolimus', 'exemestane', 'mTor inhibitor', 'endocrine therapy', 'human epidermal growth factor', 'estrogen receptor positive', 'adult', 'CRAD001']",COMPLETED,,2013-03-29,2019-01-29,"[{'measure': 'Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades', 'description': 'Adverse events (AEs), serious adverse events (SAEs), changes from baseline in vital signs and laboratory results (hematology, blood chemistry, lipid profile) qualifying and reported as AEs. Although a patient might had two or more adverse events the patient is only counted once in a category. The same patient might appear in different categories. AESI: Adverse events of special interest.', 'timeFrame': 'Baseline up to approximately 43 weeks for Asian countires and 32 weeks for Non-Asian countries including a 30 day post treatment follow up period'}]","[{'measure': 'Percentage of Participants Response Rates (Best Overall and Overall)', 'description': 'The best overall response for each patient is determined from the sequence of investigator overall lesion responses according to RECIST 1.1: Complete Response (CR)=disappearance of target lesions, Partial Response (PR) was \\>=30% decrease in sum of diameter of lesions, Progressive Disease (PD) was \\>=20% decrease in sum of diameter of lesions, Stable Disease (SD) does not qualify for PR, CR or PD, Unknown=not documented or assessed. To be assigned a best overall response of CR at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best overall response of PR at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required. The Overall response rate (ORR) is the percentage of patients with a best overall response of confirmed complete (CR) or partial (PR) response. The 95% confidence intervals (CI) were computed using the Clopper-Pearson method', 'timeFrame': 'Baseline up to approximately 43 weeks for Asian countires and 32 weeks for Non-Asian countries'}, {'measure': 'Percentage of Participants Clinical Benefit Rate', 'description': 'Clinical benefit rate: Patients with best overall response rate of CR (any duration), PR (any duration) and SD with duration of 24 weeks or longer according to RECIST 1.1 criteria: Complete Response (CR)=disappearance of target lesions, Partial Response (PR) was \\>=30% decrease in sum of diameter of lesions, Progressive Disease (PD) was \\>=20% decrease in sum of diameter of lesions, Stable Disease (SD) does not qualify for PR, CR or PD, Unknown=not documented or assessed. Best overall response of CR = at least two determinations of CR at least 4 weeks apart before progression are required. Best overall response of PR = at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required. The Overall response rate (ORR) is the percentage of patients with a best overall response of confirmed complete (CR) or partial (PR) response. The 95% confidence intervals (CI) were computed using the Clopper-Pearson method.', 'timeFrame': 'Baseline up to approximately 43 weeks for Asian countires and 32 weeks for Non-Asian countries'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'PFS is time from date of start of treatment to date of disease progression or death due to any cause, whichever occurs first.\n\nb Percentiles with 95% CIs are calculated from PROC LIFETEST output using method of Brookmeyer and Crowley (1982)', 'timeFrame': 'Baseline up to approximately 43 weeks for Asian countires and 40 weeks for Non-Asian countries'}, {'measure': 'Percent of Participants Event-free Probability Estimates of Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status', 'description': 'Time to deterioration of ECOG performance status, from baseline will be assessed using the ECOG Performance Status Scale (Oken, 1982). Time to deterioration is the time from date of start of treatment to the date of the event defined as deterioration. Deterioration is defined as an increase in performance status from 0 to 2 or greater, an increase in performance status from 1-2 to 3 or greater, or death due to any cause. Event-free probability estimate is the estimated probability that a patient will remain event-free up to the specified time point. Event-free probability estimates were are obtained from the Kaplan-Meier survival estimates.', 'timeFrame': 'Baseline up to approximately 50 weeks'}]",5,18 Years,,FEMALE,False,Novartis Pharmaceuticals,INDUSTRY,0,235.0,ACTUAL,2025-09-01T16:18:25.984661,v2_robust,True,True,True,False,True,
NCT00061438,A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died,"A Multicentre, Randomised, Double-blind, Placebo-controlled, Study on the Use of Prophylactic Meropenem Therapy in Subjects With Severe Acute Necrotizing Pancreatitis",meropenem,['meropenem'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pancreatitis, Acute Necrotizing","['Pancreatitis, Acute Necrotizing']","['non-infected necrotizing pancreatitis', 'pancreatic infection', 'peripancreatic infection']",COMPLETED,,2003-02,2004-12,[],[],0,18 Years,,ALL,False,Pfizer,INDUSTRY,0,240.0,,2025-09-01T16:18:25.984741,v2_robust,True,True,True,False,False,
NCT01139138,"Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer","A Phase IB/II Study of Second Line Therapy With Panitumumab, Irinotecan and Everolimus (PIE) in Metastatic Colorectal Cancer With KRAS WT",Panitumumab,"['Vectibix', 'Irinotecan', 'Everolimus', 'Panitumumab', 'RAD001']",5,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Colorectal Cancer,"['Colorectal Cancer', 'Colorectal Carcinoma', 'Colorectal Tumors', 'Neoplasms, Colorectal']","['Colorectal Cancer', 'Colorectal Carcinoma', 'Colorectal Tumors', 'Neoplasms, Colorectal']",COMPLETED,,2010-06,2017-06,"[{'measure': 'Dose limiting toxicities', 'description': 'To determine the maximum tolerated dose (MTD)of everolimus, irinotecan and panitumumab when given in combination for patients with Kras WT mCRC', 'timeFrame': 'at end of cycle 2 (each cycle is 14 days)'}]","[{'measure': 'Safety & toxicity', 'description': 'Safety and toxicity assessed weekly during the phase Ib component (as per NCI CTCAE version 3.0) and fortnightly during the phase II component', 'timeFrame': 'Approximately 24 weeks'}, {'measure': 'Response rate', 'description': 'Objective tumour response as per RECIST criteria V1.0', 'timeFrame': 'Assessed every 6 weeks until disease progression'}, {'measure': 'Progression free survival', 'timeFrame': 'Until disease progression, occurrence of new disease or death'}, {'measure': 'Overall Survival', 'timeFrame': 'Assessed 3 monthly until death'}]",5,18 Years,,ALL,False,The Queen Elizabeth Hospital,OTHER,2,49.0,ACTUAL,2025-09-01T16:18:25.984749,v2_robust,True,True,True,False,True,
NCT06664138,Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment,Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment,Remimazolam,"['Remimazolam', 'Etomidate']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Schizophenia Disorder,"['Schizophenia Disorder', 'Major Depression Disorders', 'Schizoaffective Disorder', 'Bipolar']",[],COMPLETED,,2023-04-28,2024-01-31,"[{'measure': 'Self respiration recovery time', 'description': ""After the induction of anesthesia, a shock is administered to induce a seizure. The time is measured from the end of the seizure until the patient's spontaneous tidal volume exceeds 200 ml."", 'timeFrame': 'From enrollment to the end of treatment at one week'}, {'measure': 'eye opening recovery time', 'description': ""After the induction of anesthesia, a shock is administered to induce a seizure. The time is measured from the end of the seizure until the patient's spontaneous eye opening."", 'timeFrame': 'From enrollment to the end of treatment at one week'}]","[{'measure': 'Mean Blood pressure', 'description': 'Mean Blood pressure measured using non-invasive blood pressure, immediately after induction, immediately after shock, and at awakening state, with measurements taken in mmHg', 'timeFrame': 'From enrollment to the end of treatment at one week'}, {'measure': 'Heartrate', 'description': 'Heartrate measured using electrocardigram, immediately after induction, immediately after shock, and at awakening state, with measurements taken in bpm(beats per minute)', 'timeFrame': 'From enrollment to the end of treatment at one week'}, {'measure': 'seizure duration', 'description': 'The duration of the induced seizure following the administration of the shock, with measurements taken in seconds', 'timeFrame': 'From enrollment to the end of treatment at one week'}, {'measure': 'shock energy', 'description': 'The amount of energy delivered by the shock used to induce the seizure with the ECT machine, measured in Joules.', 'timeFrame': 'From enrollment to the end of treatment at one week'}]",6,18 Years,70 Years,ALL,False,Yeongseok Yun,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:25.984759,v2_robust,True,True,True,False,False,
NCT01370538,Efficacy of Esomeprazole in Patients With Frequent Heartburn,"A Phase III Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of 14 Day Treatment With Esomeprazole 20 mg Once Daily in Subjects With Frequent Heartburn",Esomeprazole,['Esomeprazole'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Heartburn,['Heartburn'],['Heartburn'],COMPLETED,,2011-08,2011-10,"[{'measure': 'Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment', 'timeFrame': 'From randomisation to day 14'}]","[{'measure': 'Number of Subjects Reporting Heartburn 2 Days or Less During the 14 Days Randomized Treatment Period', 'description': 'Treatment period is considered to be both weeks 1 and 2 between V3 and V4.', 'timeFrame': 'From randomisation to the day 14'}, {'measure': 'Comparison of Number of Subjects With 0, 1, 2, 3 or 4 Days With no Heartburn Over Days 1 to 4 Between Esomeprazole 20 mg and Placebo', 'description': 'The first 4 consecutive days subjects were on randomized treatment, between V3 and V4.', 'timeFrame': 'From randomisation to day 14'}, {'measure': 'Number of Subjects With Heartburn 1 Day or Less During the Final Week, Second Week, First Week of Treatment', 'description': 'There were three separate 7 day time periods during the treatment period; The first week (days 1-7), the second week (days 8-14), and the last 7 consecutive days (last day subject reported and the prior 6). For a given subject, the second week and last 7 consecutive days are the same if the subject has recorded measurements for the entire 14 day treatment period. However, for subjects reporting anything less than 14 days the two will not be identical. For all three 7 day time periods, days when a subject did not call in (i.e., missing values) were imputed as a day with heartburn.', 'timeFrame': 'From randomisation to day 14'}]",4,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,341.0,ACTUAL,2025-09-01T16:18:25.984787,v2_robust,True,True,True,False,False,
NCT04949438,"A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers","A Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers",AZD4831,['AZD4831'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Renal Impairment,['Renal Impairment'],"['AZD4831', 'Pharmacokinetics', 'Estimated glomerular filtration rate']",COMPLETED,,2022-01-21,2022-03-04,"[{'measure': 'Maximum observed plasma concentration (Cmax)', 'description': 'Assessment of Cmax of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Time to reach maximum observed plasma concentration (tmax)', 'description': 'Assessment of tmax of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)', 'description': 'Assessment of t½λz of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Apparent total body clearance of drug from plasma after extravascular administration (CL/F)', 'description': 'Assessment of CL/F of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Apparent total non-renal body clearance of drug from plasma after extravascular administration (CLNR/F)', 'description': 'Assessment of CLNR/F of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)', 'description': 'Assessment of Vz/F of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUClast)', 'description': 'Assessment of AUClast of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Area under plasma concentration-time curve from time zero to infinity (AUCinf)', 'description': 'Assessment of AUCinf of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'From Day 1 to Day 15'}, {'measure': 'Renal clearance of drug from plasma (CLR)', 'description': 'Assessment of CLR of a single oral dose of AZD4831 in participants with severe renal impairment compared with that in matched healthy volunteers.', 'timeFrame': 'Days 1 and 2'}]","[{'measure': 'Number of participants with adverse events', 'description': 'Assessment of the safety and tolerability of a single oral dose administration of AZD4831 in participants with severe renal impairment and their matched healthy volunteers.', 'timeFrame': 'From Screening (Day -21 to Day -1) until Day 15 or Early Termination Visit'}]",10,18 Years,80 Years,ALL,True,AstraZeneca,INDUSTRY,1,20.0,ACTUAL,2025-09-01T16:18:25.984845,v2_robust,True,True,True,False,True,
NCT02138058,Topiramate Trial for Compulsive Buying,Double Blind Controlled Trial of Topiramate for Compulsive Buying,Topiramate,['Topiramate'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Compulsive Shopping,['Compulsive Shopping'],"['compulsive buying, compulsive shopping, topiramate']",COMPLETED,,2015-01,2016-06,"[{'measure': 'Yale-Brown Compulsive-Obsessive Scale Shopping Version', 'description': 'It is a revised version of the Yale-Brown Obsessive-Compulsive Scale (YBOCS), created to assess both the cognitive and behaviour of compulsive buying as well as to rate the severity of the problem', 'timeFrame': '12 weeks'}]","[{'measure': 'Clinical Global Impression scale (CGI)', 'description': 'The CGI scale quantifies the severity of disease and the effects of treatment, as well as overall clinical improvement.', 'timeFrame': '12 weeks'}, {'measure': 'Udvalg for KliniskeUndersøgelser Side Effect Rating Scale (UKU)', 'description': 'It was developed to provide a comprehensive side effect rating scale with well-defined and operationalized items to assess the side effects of psychopharmacological medications.', 'timeFrame': '12 weeks'}]",3,21 Years,60 Years,ALL,True,University of Sao Paulo,OTHER,0,42.0,ACTUAL,2025-09-01T16:18:25.984896,v2_robust,True,True,True,False,False,
NCT06831058,A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP),A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP),efgartigimod,['efgartigimod'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Immune-mediated Thrombotic Thrombocytopenic Purpura,['Immune-mediated Thrombotic Thrombocytopenic Purpura'],[],RECRUITING,,2025-05-01,2028-05-01,"[{'measure': 'safety of efgartigimod by the incidence of relapse', 'description': 'Relapse rate in the experimental arm compared with the historical rituximab arm', 'timeFrame': '8 weeks post-intervention'}, {'measure': 'safety and tolerability of efgartigimodhistorical rituximab arm', 'description': 'Incidence and severity of adverse events (AEs), AEs of special interest (AESIs) and serious AEs (SEAs)', 'timeFrame': '8 weeks post-intervention'}, {'measure': 'efficacy of efgartigimod to achieve a normal ADAMTS13 activity by Day 60 of the study', 'description': 'Compare the mean ADAMTS13 activity and proportion with normal ADAMTS13 activity at Day 60 and 90 between the experimental and historical cohorts', 'timeFrame': '60 days'}, {'measure': 'efficacy of efgartigimod to prevent the need for other preemptive therapy to rescue severe ADAMTS13 deficiency', 'description': 'Compare the rate use of rescue therapy between the experimental and historical cohort treated with preemptive rituximab, as required by the lack of ADAMTS13 activity increase by 20%', 'timeFrame': '8 weeks post-intervention'}]","[{'measure': 'the efficacy of efgartigimod to raise ADAMTS13 activity more rapidly than historically treated patients with rituximab', 'description': 'Compare the mean slope of ADAMTS13 rise at the end of treatment (Day 60) and at 90 days between cohorts', 'timeFrame': 'Day 60 and day 90'}, {'measure': 'the efficacy of efgartigimod to deplete pathogenic ADAMTS13 antibodies', 'description': 'Compare the mean ADAMTS13 antibody titers and proportion with \\>50% reduction in antibody titer between cohorts', 'timeFrame': '8 weeks post-intervention'}]",6,18 Years,,ALL,False,University of Minnesota,OTHER,0,15.0,ESTIMATED,2025-09-01T16:18:25.984915,v2_robust,True,True,False,False,True,
NCT04689958,The Benefits of Vitamin D 5000 IU as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient,The Benefits of Vitamin D 5000 IU as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient: Randomized Clinical Trial,Standard therapy,"['Standard therapy', 'Vitamin D 5,000IU Oral Tablet']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Painful Diabetic Neuropathy,['Painful Diabetic Neuropathy'],"['Vitamin D', 'Standard therapy', 'Neuropathy', 'Diabetic neuropathy']",UNKNOWN,,2020-11-03,2021-11,"[{'measure': 'Improvement in Visual Analogue Scale (VAS) at week 4', 'description': 'Change in pain impact on daily life as measured by Visual Analogue Scale (VAS) from its baseline value. Visual analogue scale is a continuous scale comprised of a horizontal or vertical line, usually 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme. The scale is most commonly anchored by ""no pain"" (score of 0) and ""pain as bad as it could be"" or ""worst imaginable pain"" (score of 100). The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the ""no pain"" anchor and the patient\'s mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.', 'timeFrame': '4 weeks after treatment initiation'}, {'measure': 'Improvement in Visual Analogue Scale (VAS) at week 8', 'description': 'Change in pain impact on daily life as measured by Visual Analogue Scale (VAS) from its baseline and week 4 value. Visual analogue scale is a continuous scale comprised of a horizontal or vertical line, usually 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme. The scale is most commonly anchored by ""no pain"" (score of 0) and ""pain as bad as it could be"" or ""worst imaginable pain"" (score of 100). The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the ""no pain"" anchor and the patient\'s mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.', 'timeFrame': '8 weeks after treatment initiation'}, {'measure': 'Improvement in Numeric Pain Scale at week 4', 'description': 'Change in pain impact on daily life as measured by Numeric Pain Scale from its baseline value. Numeric pain scale is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of his/her pain. Higher scores indicating greater pain intensity.', 'timeFrame': '4 weeks after treatment initiation'}, {'measure': 'Improvement in Numeric Pain Scale at week 8', 'description': 'Change in pain impact on daily life as measured by Numeric Pain Scale from its baseline and week 4 value. Numeric pain scale is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of his/her pain. Higher scores indicating greater pain intensity.', 'timeFrame': '8 weeks after treatment initiation'}, {'measure': 'Improvement in Brief Pain inventory at week 4', 'description': ""Change in pain impact on daily life as measured by Brief Pain Inventory from its baseline value. The Brief Pain Inventory evaluates a patient's pain experience through a number of different scales. There are line drawings of the front and back of a human body on which patients mark the location of their pain. Patients are asked to list the treatments or medications that they are using and how much relief they have provided in the past 24 hours. In addition, patients fill out 11 different numeric rating scale that ask about pain intensity (ranging from 0 to 10) and the effect of the pain on their ability to function during various activities of daily living. A higher score indicates greater pain intensity."", 'timeFrame': '4 weeks after treatment initiation'}, {'measure': 'Improvement in Brief Pain inventory at week 8', 'description': ""Change in pain impact on daily life as measured by Brief Pain Inventory from its baseline and week 4 value. The Brief Pain Inventory evaluates a patient's pain experience through a number of different scales. There are line drawings of the front and back of a human body on which patients mark the location of their pain. Patients are asked to list the treatments or medications that they are using and how much relief they have provided in the past 24 hours. In addition, patients fill out 11 different numeric rating scale that ask about pain intensity (ranging from 0 to 10) and the effect of the pain on their ability to function during various activities of daily living. A higher score indicates greater pain intensity."", 'timeFrame': '8 weeks after treatment initiation'}]",[],6,19 Years,,ALL,False,Duta Wacana Christian University,OTHER,1,60.0,ESTIMATED,2025-09-01T16:18:25.984973,v2_robust,True,True,False,False,False,
NCT05182658,Empagliflozin in Hypertrophic Cardiomyopathy,The Use of Empagliflozin in Patients With Hypertrophic Cardiomyopathy,Empagliflozin 10 MG,"['Jardiance', 'Empagliflozin 10 MG', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypertrophic Cardiomyopathy,"['Hypertrophic Cardiomyopathy', 'Heart Failure']","['Hypertrophic cardiomyopathy', 'Heart Failue', 'Empagliflozin', 'Sodium-glucose transport protein 2 inhibitor', 'SGLT2 inhibitor']",UNKNOWN,,2022-06-01,2024-08-01,"[{'measure': 'Primary Outcome: Change in peak VO2 measured in the cardiopulmonary exercise testing', 'description': 'Change in peak VO2 measured in the cardiopulmonary exercise testing', 'timeFrame': '12 months'}]","[{'measure': 'Secondary outcome: Change in peak VO2 measured in the cardiopulmonary exercise testing in patients with reduced left ventricular ejection fraction (EF <50%)', 'description': 'Change in peak VO2 measured in the cardiopulmonary exercise testing in patients with reduced left ventricular ejection fraction (EF \\<50%)', 'timeFrame': '12 months'}]",2,18 Years,70 Years,ALL,False,"National Institute of Cardiology, Warsaw, Poland",OTHER,3,250.0,ESTIMATED,2025-09-01T16:18:25.985108,v2_robust,True,True,False,False,False,
NCT06039358,Effects of Caffeine Ingestion on the Biomechanics of Healthy Young Subjects,"Influence of 6mg/kg of Caffeine Supplementation on the Technical Execution of General Movement Patterns Performed by Healthy Subjects, With and Without Neuromuscular Fatigue: a Randomized, Double-blind, Placebo-controlled, Crossover Trial",Cellulose.,"['Placebo.', 'Cellulose.']",2,INTERVENTIONAL,['NA'],,,Caffeine,"['Caffeine', 'Biomechanics', 'Fatigue', 'Injuries', 'Physical Activity']","['Ergogenic aids', 'Kinematics', 'Kinetics', 'Neuromuscular fatigue', 'Acute and chronic injuries', 'Jump', 'Squat', 'Running']",COMPLETED,,2023-10-06,2023-12-23,"[{'measure': 'Knee flexion angle at the midstance while running.', 'description': 'Assessment of the knee flexion angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Ankle dorsiflexion angle at the midstance while running.', 'description': 'Assessment of the ankle dorsiflexion angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Step rate while running.', 'description': 'Assessment of the step rate (in steps/minute). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Contact time while running.', 'description': 'Assessment of the time the foot is in contact with the ground (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Stride length while running.', 'description': 'Assessment of the distance between two successive placements of the same foot (in meters). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Flight time while running.', 'description': 'Assessment of the time the foot is not in contact with the ground (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Running performance modification.', 'description': 'Assessment of the time (in seconds) required to complete a specific distance running on a treadmill. The measurement will be done before and after a fatiguing protocol. Assessed using a stopwatch.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Hip angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.', 'description': 'Assessment of the hip angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Knee angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.', 'description': 'Assessment of the knee angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Ankle angle while squatting, at the initial position, bottom position, and final position, and the eccentric and the concentric range of movement.', 'description': 'Assessment of the ankle angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Execution time while squatting, for the eccentric and the concentric phases of the movement.', 'description': 'Assessment of the execution time to perform the eccentric and the concentric phases of the squat (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Peak vertical force while squatting, for the eccentric and the concentric phases of the movement.', 'description': 'Assessment of the peak vertical force (in Newtons). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Rate of force development while squatting, for the eccentric and the concentric phases of the movement.', 'description': 'Assessment of the rate of force development (in Newtons/seconds). The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Squatting performance modification.', 'description': 'Assessment of the mean propulsive bar velocity (in meters/seconds) for a specific weight lifted in barbell back squats. The measurement will be done before and after a fatiguing protocol. Assessed using a linear position transducer.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Contralateral pelvic drop angle while jumping, at the initial contact of the landing phase.', 'description': 'Assessment of the contralateral pelvic drop angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Knee valgus while jumping, at the initial contact and the deepest landing position of the landing phase, and the range of movement between these two moments.', 'description': 'Assessment of the knee valgus angle (in degrees). The measurement will be done before and after a fatiguing protocol. Assessed using kinematic instruments.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Unweighting phase duration while jumping (jumping phase).', 'description': 'Assessment of the unweighting phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Braking phase duration while jumping (jumping phase).', 'description': 'Assessment of the braking phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Propulsive phase duration while jumping (jumping phase).', 'description': 'Assessment of the propulsive phase duration (in seconds). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Relative peak power output while jumping (jumping phase).', 'description': 'Assessment of the relative peak power output (in Watts/kg). The measurement will be done before and after a fatiguing protocol. Assessed using force plates.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Jumping performance modification.', 'description': 'Assessment of the height (in meters) of countermovement jumps. The measurement will be done before and after a fatiguing protocol. Assessed using force plates.', 'timeFrame': 'During the control, placebo, and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}]","[{'measure': 'Supplementation identification.', 'description': 'Assessment of the participants\' perception regarding the ingested substance. They will have to complete a questionnaire immediately before (1 hour post-supplementation) and after the assessed exercises, indicating what substance they believe that they have consumed, with the options ""caffeine"", ""placebo"", or ""I don\'t know"", as well as the reason why they have chosen that answer.', 'timeFrame': 'During the placebo and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}, {'measure': 'Side effects.', 'description': ""Assessment of the participant's side effects related to caffeine consumption. In the morning of the day after the sessions, they will be requested to complete a questionnaire comprised of 8 questions with a yes/no answer, to evaluate the side effects of caffeine consumption during the hours after the sessions."", 'timeFrame': 'During the day after the placebo and caffeine sessions (at least 7 days between them). The length of each session will be approximately 3 hours.'}]",23,18 Years,30 Years,ALL,True,University of Vic - Central University of Catalonia,OTHER,2,15.0,ACTUAL,2025-09-01T16:18:25.985119,v2_robust,True,True,True,False,False,
NCT01533558,Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates,Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates,caspofungin,"['caspofungin', 'Cancidas']",2,OBSERVATIONAL,[],,,Invasive Fungal Infection,['Invasive Fungal Infection'],"['caspofungin', 'pharmacokinetics', 'invasive fungal infection', 'candidiasis', 'aspergillosis', 'intensive care']",COMPLETED,,2012-01,2013-06,"[{'measure': 'Area Under Curve (AUC)', 'description': 'AUC0-tau, AUC0-inf (Time Frame: predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 hours post-dose on Day 3 and predose, 1, 4, 8, 12 hours + 6 days after the dose on Day 7) of caspofungin', 'timeFrame': 'day 3 and day 7'}]","[{'measure': 'co-variates influencing PK of caspofungin', 'description': 'identify co-variates of influence on the pharmacokinetics of caspofungin', 'timeFrame': 'day 3 and day 7'}, {'measure': 'Number of Participants with Adverse Events', 'description': 'the adverse events will be recorded in IC patients during the study', 'timeFrame': '14 days'}]",3,18 Years,,ALL,False,Radboud University Medical Center,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:25.985216,v2_robust,False,True,True,False,True,
NCT00753558,Selective Digestive Decontamination in Carriers of Carbapenem-resistant Klebsiella Pneumoniae,"A Randomized,Double-Blind,Placebo-Controled Trial of Selective Digestive Decontamination Using Oral Gentamicin and Oral Polymyxin E for Eradication of Carbapenem-Resistant Klebsiella Pneumoniae Carriage",Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.,['Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.'],1,INTERVENTIONAL,['NA'],,,Carriage of Carbapemen-resistant Klebsialle Pneumoniae,['Carriage of Carbapemen-resistant Klebsialle Pneumoniae'],[],COMPLETED,,2008-11,2010-07,"[{'measure': 'Eradication of CRKP carriage measured by negative rectal swabs', 'timeFrame': 'Two days after treatment ends'}]","[{'measure': 'No new in-hospital acquisition of CRKP', 'timeFrame': 'Six weeks'}]",2,18 Years,,ALL,False,Soroka University Medical Center,OTHER,0,,,2025-09-01T16:18:25.985322,v2_robust,True,True,True,False,False,
NCT04696848,The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors,A Phase I Study to Determine the Efficacy and Safety of CKD-516 Tablet Combined With Durvalumab(MEDI4736) in Patient Refractory Solid Tumors,CKD-516 plus Durvalumab,"['CKD-516 plus MEDI4736', 'CKD-516 plus Durvalumab']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Colorectal Cancer,"['Colorectal Cancer', 'Solid Tumor']",[],TERMINATED,Recruitment difficulty,2021-02-24,2023-03-09,"[{'measure': 'Maximum tolerated dose', 'description': 'To determine maximum tolerated dose of CKD-516 in combination with durvalumab', 'timeFrame': '4 weeks'}]","[{'measure': 'To assess the safety and tolerability profile of CKD-516 in combination with Durvalumab', 'description': 'Adverse event according to NCI CTCAE v5.0', 'timeFrame': '1 year'}, {'measure': 'To assess the efficacy of CKD-516 in combination with Durvalumab; Objective Response', 'description': 'Objective Response Rate determined by Response Evaluation Criteria in Solid Tumors', 'timeFrame': '1 year'}, {'measure': 'Progression-free survival', 'description': '\\- Progression free survival will be measured from the start of treatment with investigational product until the first documentation of disease progression or death due to any cause, whichever occurs first.', 'timeFrame': '8 weeks'}, {'measure': 'Duration of response', 'description': 'the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first', 'timeFrame': '1 year'}, {'measure': 'Overall survival', 'description': 'the time from the start of treatment with investigational product until death due to any cause.', 'timeFrame': '1 year'}]",6,20 Years,,ALL,False,Tae Won Kim,OTHER,0,25.0,ACTUAL,2025-09-01T16:18:25.985499,v2_robust,True,True,False,True,True,Recruitment difficulty
NCT00087048,Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer,The Use Of Weekly Topotecan As Second Line Therapy In Small Cell Lung Cancer,topotecan hydrochloride,['topotecan hydrochloride'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Lung Cancer,['Lung Cancer'],"['extensive stage small cell lung cancer', 'recurrent small cell lung cancer']",TERMINATED,Slow accrual,2004-04,2006-02,[{'measure': 'Overall survival'}],"[{'measure': 'Safety and toxic effects'}, {'measure': 'Recurrence-free survival'}, {'measure': 'Time to response and tumor response'}, {'measure': 'Quality of life'}]",5,18 Years,,ALL,False,Case Comprehensive Cancer Center,OTHER,1,1.0,ACTUAL,2025-09-01T16:18:25.985517,v2_robust,True,True,False,True,True,Slow accrual
NCT01037348,Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen,"A Phase II, Open-label, Multicentre, 12 Month Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5mg) in Patients With Choroidal Neovascularisation Secondary to Pathological Myopia (PM)",ranibizumab 0.5mg,['ranibizumab 0.5mg'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Choroidal Neovascularisation,['Choroidal Neovascularisation'],"['Choroidal Neovascularisation', 'Pathological Myopia']",COMPLETED,,2010-01,2012-05,"[{'measure': 'The difference from baseline in mean Best Corrected Visual Acuity (BCVA)', 'timeFrame': '12 months'}]","[{'measure': 'Mean change in BCVA from baseline', 'timeFrame': '6 months'}, {'measure': 'Mean change in Central retinal Thickness (CRT) from baseline', 'timeFrame': '6 and 12 months'}, {'measure': 'Percentage of patients gaining ≥ 15 letters', 'timeFrame': '12 months'}, {'measure': 'Change in lesion size and morphology from baseline', 'timeFrame': '6 and 12 months'}, {'measure': 'Time to the first retreatment and the total number of treatments', 'timeFrame': '12 Months'}]",6,18 Years,,ALL,False,Novartis,INDUSTRY,0,65.0,ACTUAL,2025-09-01T16:18:25.985524,v2_robust,True,True,True,False,False,
NCT03119948,Partial Blocks of Rectus Femoris and Soleus With Botulinum Toxin Type A (Xeomin®) to Improve Gait in Hemiparesis,Partial Blocks of Rectus Femoris and Soleus With Botulinum Toxin Type A to Improve Gait in Hemiparesis. A Randomized Multicenter Placebo-controlled Trial,Placebo injection,"['Botulinum toxin injection', 'Placebo injection', 'Placebo injection and botulinum toxin injection']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Hemiparesis After Stroke,"['Hemiparesis After Stroke', 'Traumatic Brain Injury']","['Muscle spasticity', 'Botulinum toxin']",UNKNOWN,,2014-12,2018-12,"[{'measure': 'Change in maximum speed of barefoot ambulation without technical assistance over 10 meters, between the pre-injection visit (D1) and 3 weeks (D21) post injection', 'timeFrame': 'Preinjection visit (D1) and 3 weeks post injection (D21)'}]","[{'measure': 'Change ambulation speed at comfortable and maximal speed, barefoot and with shoes over 10 meters', 'timeFrame': 'Day 1 and Day 21'}, {'measure': 'Maximal amplitude and speed of active hip flexion and passive knee flexion during swing phase, measured in gait kinematic recording, at comfortable and maximal speed', 'timeFrame': 'Day 1 and Day 21'}, {'measure': 'Maximal amplitude and speed of passive ankle dorsiflexion at late stance phase, measured in gait kinematic recording, at comfortable and maximal speed', 'timeFrame': 'Day 1 and Day 21'}, {'measure': 'Maximal voluntary isometric EMG (MVIE) of rectus femoris and soleus, measured by surface EMG, in an isometric position with hip at 15° flexion, knee at 30° flexion, and ankle at 80° of dorsiflexion', 'description': 'calculating the mean rectified voltage over 100 ms around the peak of rectified EMG on each of these muscles', 'timeFrame': 'Day 1 and Day 21'}, {'measure': 'Mean rectified voltage of rectus femoris and soleus during the first half of swing phase (MRVSP), from toe-off to maximal hip flexion, measured by surface EMG (electrodes 2 cm apart) immediately after MVIE measure.', 'timeFrame': 'Day 1 and Day 21'}, {'measure': 'Cocontraction indices of rectus femoris and soleus during the first half of swing phase, calculating the ratio MRVSP/MVIE for each of these muscles.', 'timeFrame': 'Day 1 and Day 21'}, {'measure': 'Mean rectified voltage of soleus during the first half of stance phase (MRVSP), from heel-on to maximal knee extension, measured by surface EMG (electrodes 2 cm apart) immediately after MVIE measure.', 'timeFrame': 'Day 1 and Day 21'}, {'measure': 'Inappropriate Contraction Indices of soleus during the first half of stance phase, calculating the ratio MRVSP / MVIE', 'timeFrame': 'Day 1 and Day 21'}, {'measure': 'Spasticity Angle et grade of rectus femoris and soleus (Five Step Assessment)', 'timeFrame': 'Day 1, Day 21, Day 60'}, {'measure': 'Weakness Angle of rectus femoris and soleus (Five Step Assessment)', 'timeFrame': 'Day 1, Day 21, Day 60'}, {'measure': 'Quality of life measured by EQ5D', 'timeFrame': 'Day 1, Day 60'}, {'measure': 'Mean weekly number of steps', 'timeFrame': 'Between Day-15 and Day1, Day7 and Day21 and between Day45 and Day60'}, {'measure': 'Potential AEs of injections (pain or discomfort during the injection or post injection, or ecchymoses at insertion site) and potential AEs related to the injected drug (muscle weakening, allergies)', 'timeFrame': 'Day 1, Day 21, Day 60'}, {'measure': 'Step length at comfortable and maximal speed, barefoot and with shoes over 10 meters', 'timeFrame': 'Day 1 and Day 21'}, {'measure': 'Step cadence at comfortable and maximal speed, barefoot and with shoes over 10 meters', 'timeFrame': 'Day 1 and Day 21'}, {'measure': 'Physiological Cost Index (PCI) over a walking test of 2 minutes at maximal speed with shoes', 'timeFrame': 'Day 1 and Day 21'}]",17,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,1,66.0,ESTIMATED,2025-09-01T16:18:25.985563,v2_robust,True,True,False,False,False,
NCT04230148,"Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).","A Phase IV, Multi-center, Open-label Study to Determine the Safety, Tolerability and Clinical Outcomes Following Oral Administration of EGATEN™ (Triclabendazole) in Patients (6 Years of Age or Older) With Fascioliasis.",Egaten (Triclabendazole) 250 mg tablets,"['Egaten (Triclabendazole) 250 mg tablets', 'Triclabendazole']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Fascioliasis,['Fascioliasis'],"['Acute Fascioliasis', 'Chronic Fascioliasis', 'Clinical Cure', 'Parasitological Cure', 'Egaten', 'Triclabendazole', 'Post-Marketing commitment']",RECRUITING,,2022-02-11,2026-12-10,"[{'measure': 'Number of Participants with On-Treatments Adverse Events, Serious Adverse Events, and Deaths', 'description': 'Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that Egaten administered as two 10 mg/kg doses given 12 hours apart in subjects with Fascioliasis is safe through the monitoring of relevant clinical and laboratory safety parameters.', 'timeFrame': 'Day 90'}]","[{'measure': 'Clinical cure rate in Acute Fascioliasis subjects over time.', 'description': 'The clinical cure rate in Acute Fasciolisis subjects will be measured by the proportion of subjects with:\n\n1. Resolution of baseline signs and symptoms.\n2. Improvement in baseline laboratory parameters.\n3. Improvement in baseline ultrasound findings.', 'timeFrame': 'Day 10, Day 30, Day 60 and Day 90'}, {'measure': 'Parasitological cure rate in Chronic Fascioliasis subjects over time.', 'description': 'The parasitological cure rate in Chronic Fascioliasis subjects will be measured by the proportion of subjects with absence of fasciola eggs confirmed by stool examination.', 'timeFrame': 'Day 10, Day 30, Day 60 and Day 90'}, {'measure': 'Clinical cure rate of Chronic Fascioliasis subjects over time.', 'description': 'The clinical cure rate in Chronic Fasciolisis subjects will be measured by the proportion of subjects with:\n\n1. Resolution of baseline signs and symptoms.\n2. Improvement in baseline laboratory parameters.\n3. Improvement in baseline ultrasound findings.', 'timeFrame': 'Day 10, Day 30, Day 60 and Day 90'}]",4,6 Years,99 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,300.0,ESTIMATED,2025-09-01T16:18:25.985602,v2_robust,True,True,False,False,True,
NCT05648448,A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza,ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA),Oseltamivir,"['Oseltamivir', 'Favipiravir and Baloxavir', 'Baloxavir', 'Molnupiravir', 'Zanamivir', 'Laninamivir', 'Oseltamivir and Favipiravir', 'Oseltamivir and Baloxavir', 'Peramivir', 'Favipiravir']",10,INTERVENTIONAL,['PHASE2'],PHASE2,,Influenza,"['Influenza', 'Influenza, Human']","['Influenza', 'Phase 2', 'Antiviral Pharmacodynamics']",RECRUITING,,2023-02-22,2027-01-01,"[{'measure': 'Rate of viral clearance for currently available drugs and those with potential activity', 'description': 'Rate of viral clearance- estimated from the log10 viral density derived from qPCR of standardised duplicate oropharyngeal swabs/saliva taken daily from baseline (day 0) to day 7 for each therapeutic arm compared with the no antiviral treatment control i.e. those not receiving study drug', 'timeFrame': 'Days 0 - 5'}]","[{'measure': 'Rate of viral clearance in early influenza infection', 'description': 'Rate of viral clearance in early influenza infection to characterise the determinants of viral clearance in early influenza infection e.g. contribution of baseline serology, influenza type/subtype, prior vaccination', 'timeFrame': 'Days 0 - 5'}, {'measure': 'Rate of viral clearance for drugs shown to have considerable antiviral activity', 'description': 'Rate of viral clearance for drugs to determine optimal dosing regimens for drugs shown to have considerable antiviral activity', 'timeFrame': 'Days 0 - 5'}, {'measure': 'Time to symptom alleviation and fever duration', 'description': 'Assessment of time to symptom alleviation and fever duration to compare time to symptom resolution and fever duration between interventions', 'timeFrame': 'Days 0 - 14'}]",4,18 Years,60 Years,ALL,False,University of Oxford,OTHER,0,3000.0,ESTIMATED,2025-09-01T16:18:25.985615,v2_robust,True,True,False,False,False,
NCT02411448,A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY),"A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer",Ramucirumab,"['Ramucirumab', 'Osimertinib', 'Erlotinib', 'LY3009806', 'Placebo', 'Gefitinib']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Metastatic Non-Small Cell Lung Cancer,['Metastatic Non-Small Cell Lung Cancer'],[],ACTIVE_NOT_RECRUITING,,2015-05-06,2025-12,"[{'measure': 'Part B: Progression Free Survival (PFS)', 'description': 'PFS is defined as the time from the date of randomization to the date of radiographically documented progressive disease (PD) based on investigator assessment, or the date of death due to any cause, whichever is first assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.', 'timeFrame': 'Randomization to Measured Progressive Disease or Death from Any Cause (Up To 37 Months)'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events', 'description': 'A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.', 'timeFrame': 'Cycle 1 Day 1 through End of Study (Up To 3 Years)'}]","[{'measure': 'Part B: Overall Survival (OS)', 'description': 'OS was defined as the time from the date of randomization to the date of death from any cause. For each participant who was not known to have died as of the data-inclusion cutoff date for a particular analysis,OS was censored for that analysis at the date of last contact prior to the data-inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, lesion assessment date, visit date, and last known alive date).', 'timeFrame': 'Randomization to Date of Death from Any Cause (Up To 37 Months)'}, {'measure': 'Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])', 'description': 'ORR was defined as the percentage of randomized participants achieving a best overall response of partial response (PR) or complete response (CR) assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \\<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.', 'timeFrame': 'Randomization to Progressive Disease (Up To 37 Months)'}, {'measure': 'Part B: Percentage of Participants With CR, PR, or Stable Disease (SD) (Disease Control Rate [DCR])', 'description': 'DCR was defined as the percentage of randomized participants achieving a best overall response of CR,PR, or stable disease(SD) assessed via Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1. CR was defined as the disappearance of all lesions,pathological lymph node reduction in short axis to \\<10 mm, and normalization of tumor marker levels of non-target lesions.PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease(PD) was at least a 20% increase in the sum of the diameters of target lesions,taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of 1 or more new lesions is also considered progression.', 'timeFrame': 'Randomization to Progressive Disease (Up To 37 Months)'}, {'measure': 'Part B: Duration of Response (DoR)', 'description': 'DoR was defined as the date of first documented CR or PR (responder) to the date of progressive disease or the date of death due to any cause, whichever was earlier. If a responder was not known to have died or have progressive disease, then the participant was censored at the date of last evaluable tumor assessment.CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \\<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.', 'timeFrame': 'Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up To 37 Months)'}, {'measure': 'Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab', 'description': 'Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab', 'timeFrame': 'Cycle 2 Day 1: Predose; Cycle 4 Day 1: Predose; Cycle 7 Day 1: Predose; Cycle 14 Day 1'}, {'measure': 'Part B: Number of Participants With Anti-Ramucirumab Antibodies', 'description': 'Part B: Number of Participants With Anti-Ramucirumab Antibodies.', 'timeFrame': 'Cycle 1 Predose through Follow-up (Up To 37 Months)'}, {'measure': 'Part B: Best Change From Baseline on the Lung Cancer Symptom Scale (LCSS)', 'description': 'The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms \\[loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain\\] and 3 global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-millimeter (mm) lines. A higher score for any item represented a higher level of symptoms/problems. The LCSS total score was defined as the mean of all 9 items. Average symptom burden index (ASBI) was calculated as the mean of the six symptom-specific questions from the LCSS. Potential scores range from 0 (for best outcome) to 100 (for worst outcome).', 'timeFrame': 'Baseline, End of Study (Up To 37 Months)'}, {'measure': 'Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score', 'description': 'The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.', 'timeFrame': 'Baseline, Cycle 10 (each cycle is 2 weeks)'}, {'measure': 'Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score', 'description': 'The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.', 'timeFrame': 'Baseline, Cycle 28 (each cycle is 2 weeks)'}, {'measure': 'Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score', 'description': 'The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.', 'timeFrame': 'Baseline, Cycle 40 (each cycle is 2 weeks)'}]",12,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,545.0,ACTUAL,2025-09-01T16:18:25.985717,v2_robust,True,True,False,False,True,
NCT02632955,Drug Eluting Balloon for Early Fistula Failure Trial,Drug Eluting Balloon for Early Fistula Failure Trial,Drug Eluting Balloon,"['Lutonix drug eluting Balloon angioplasty', 'Drug Eluting Balloon']",2,INTERVENTIONAL,['NA'],,,Stenosis of Arteriovenous Dialysis Fistula,['Stenosis of Arteriovenous Dialysis Fistula'],"['arteriovenous fistula', 'hemodialysis', 'drug coated balloon']",UNKNOWN,,2015-12,2018-12,"[{'measure': 'Primary patency', 'description': 'Patency of AVF without any additional procedures. Patency is defined as supporting HD with a pump speed of at least 300ml/min.', 'timeFrame': '6 months'}]","[{'measure': 'Secondary Patency', 'description': 'Patency of AVF with additional procedures.Patency is defined as supporting HD with a pump speed of at least 300ml/min.', 'timeFrame': '6 months'}]",2,18 Years,,ALL,False,King Faisal Specialist Hospital & Research Center,OTHER,0,70.0,ESTIMATED,2025-09-01T16:18:25.985806,v2_robust,True,True,False,False,False,
NCT04547855,Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen,A Phase II Study of Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen,anlotinib combined with dose-dense temozolomide,"['Anlotinib hydrochloride capsule', 'anlotinib combined with dose-dense temozolomide']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Glioblastoma,['Glioblastoma'],[],UNKNOWN,,2020-09-11,2023-03-11,"[{'measure': '6 months Objective Response Rates', 'description': 'Percentage of Participants With Objective Response (Partial Response \\[PR\\] Plus Complete Response \\[CR\\]), as Assessed Using as Assessed by Investigator Using RANO Version 1.1', 'timeFrame': '6 month'}, {'measure': '6 months Progression-Free Survival Rates', 'description': '6 months Progression-Free Survival Rates as Assessed by Investigator Using RANO Version 1.1', 'timeFrame': '6 months'}]","[{'measure': 'Progress-free survival (PFS)', 'description': 'Progression-Free Survival (PFS) as Assessed by Investigator Using RANO Version 1.1', 'timeFrame': 'Approximately 6 months'}, {'measure': 'overall survival', 'description': 'OS was defined as the time from the date of randomization to the date of death due to any cause.', 'timeFrame': 'Approximately 1 years'}, {'measure': 'Toxic side effects', 'description': 'Toxic side effects as Assessed by Investigator Using RANO Version 1.1', 'timeFrame': 'Approximately 1 years'}]",5,18 Years,75 Years,ALL,False,Yonggao Mou,OTHER,1,54.0,ESTIMATED,2025-09-01T16:18:25.985826,v2_robust,True,True,False,False,False,
NCT04425655,Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.,A Phase II Trial of Fludarabine in Combination With Daunorubicin and Cytarabine Liposome for Adults With Newly-diagnosed Acute Myeloid Leukemia: University of California Hematologic Malignancies Consortium Protocol 1914,Fludarabine,"['CPX-351', 'Vyxeos', 'Oforta, Fludara', 'Fludarabine']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Acute Myeloid Leukemia, Adult","['Acute Myeloid Leukemia, Adult', 'AML', 'AML, Adult']","['Vyxeos', 'CPX-351', 'Fludarabine', 'Untreated AML']",TERMINATED,Original investigator for the trial has left,2020-08-05,2022-07-01,"[{'measure': 'Overall response rate after induction', 'description': 'Overall response rate after induction, defined as the sum of complete response (CR) rate and complete response with incomplete count recovery (CRi) rate after 1-2 cycles of induction therapy, in accordance with 2017 ELN criteria.', 'timeFrame': '35 days'}]","[{'measure': 'Safety and Tolerability', 'description': 'Safety and tolerability will be determined by rates of NCI CTCAE 5.0 Grade 3-5 toxicities and rate of discontinuation from study therapy due to intolerance', 'timeFrame': '6 months'}, {'measure': 'Incidence of Grade 3 Treatment Emergent Adverse Events [Safety and Tolerability]', 'description': 'Safety and tolerability will be determined by rates of NCI CTCAE 5.0 Grade 3 toxicities and rate of discontinuation from study therapy due to intolerance', 'timeFrame': '6 months'}, {'measure': 'Incidence of Grade 4 Treatment Emergent Adverse Events [Safety and Tolerability]', 'description': 'Safety and tolerability will be determined by rates of NCI CTCAE 5.0 Grade 4 toxicities and rate of discontinuation from study therapy due to intolerance', 'timeFrame': '6 months'}, {'measure': 'Incidence of Grade 5 Treatment Emergent Adverse Events [Safety and Tolerability]', 'description': 'Safety and tolerability will be determined by rates of NCI CTCAE 5.0 Grade 5 toxicities and rate of discontinuation from study therapy due to intolerance', 'timeFrame': '6 months'}, {'measure': 'CR Rate', 'description': 'CR rate defined as proportion of patients achieving a CR after 1-2 cycles of induction', 'timeFrame': '60 days'}, {'measure': 'Overall response rate', 'description': 'Overall response rate (CR +CRi) after 1 cycle of induction', 'timeFrame': '35 days'}, {'measure': 'Overall survival', 'description': 'Overall survival (OS) at 1 year, with OS defined as time from start of study therapy to death from any cause', 'timeFrame': '1 year'}, {'measure': 'Overall survival', 'description': 'Overall survival (OS) at 3 years, with OS defined as time from start of study therapy to death from any cause', 'timeFrame': '3 years'}, {'measure': 'Leukemia-free survival', 'description': 'Leukemia-free survival (LFS) at 1 year, with EFS defined as the time from start of study therapy until failure to attain CR, relapse, or death from any cause', 'timeFrame': '1 years'}, {'measure': 'Leukemia-free survival', 'description': 'Leukemia-free survival (LFS) at 3 years, with EFS defined as the time from start of study therapy until failure to attain CR, relapse, or death from any cause', 'timeFrame': '3 years'}, {'measure': 'Event free survival', 'description': 'Event Free Survival (EFS) at 1 year, with EFS defined as the time from start of study therapy until failure to attain CR, relapse, or death from any cause.', 'timeFrame': '1 year'}, {'measure': 'Event free survival', 'description': 'Event Free Survival (EFS) at 3 years, with EFS defined as the time from start of study therapy until failure to attain CR, relapse, or death from any cause.', 'timeFrame': '3 years'}, {'measure': 'Platelet Recovery', 'description': 'Platelet recovery, defined as the time from start of study therapy until absolute neutrophil count \\>1,000/mcl in patients achieving a CR', 'timeFrame': '60 days'}, {'measure': '30-day', 'description': '30-day mortality defined as death from any cause within 30 days of starting study therapy', 'timeFrame': '30 days from start of study therapy'}, {'measure': '60-day mortality', 'description': '60-day mortality defined as death from any cause within 60 days of starting study therapy', 'timeFrame': '60 days from start of study therapy'}]",16,18 Years,,ALL,False,"University of California, San Diego",OTHER,1,2.0,ACTUAL,2025-09-01T16:18:25.985858,v2_robust,True,True,False,True,True,Original investigator for the trial has left
NCT01282255,Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis,"A Randomised, Double Blind, Placebo-controlled, Multiple Dose Trial of Anti-IL-20 (109-0012) in Subjects With Rheumatoid Arthritis",NNC109-0012,"['NNC109-0012', 'placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Inflammation,"['Inflammation', 'Rheumatoid Arthritis']",[],COMPLETED,,2011-02,2012-01,"[{'measure': 'Change in DAS28-CRP (disease activity score 28 calculated with C-reactive protein value)', 'timeFrame': 'week 0, week 12'}]","[{'measure': 'Terminal serum half-life (t½)', 'timeFrame': 'end of treatment period'}, {'measure': 'Serum levels of NNC109-0012', 'timeFrame': 'end of treatment period'}]",3,18 Years,75 Years,ALL,False,Novo Nordisk A/S,INDUSTRY,0,67.0,ACTUAL,2025-09-01T16:18:25.985927,v2_robust,True,True,True,False,False,
NCT06812455,Effect of RIVAroxaban in Radial Artery Occlusion Treatment After Cardiac Catheterization,Effect of RIVAroxaban in Reducing Radial Artery Occlusion Rate After Transradial Coronary Catheterization,Rivaroxaban,['Rivaroxaban'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Radial Artery Occlusion,['Radial Artery Occlusion'],"['radial artery occlusion', 'complications', 'transradial', 'coronary catheterization', 'treatment']",RECRUITING,,2025-03-01,2029-03-01,"[{'measure': 'Radial artery patency', 'description': 'Radial artery patency at 4 weeks after the procedure, evaluated with radial artery ultrasound.', 'timeFrame': '4 weeks'}]","[{'measure': 'Bleeding events', 'description': 'To compare bleeding events (based on the BARC bleeding definition) at 4 weeks after the procedure.', 'timeFrame': '4 weeks'}]",2,18 Years,,ALL,False,AHEPA University Hospital,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:25.985938,v2_robust,True,True,False,False,False,
NCT00378755,Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM,"Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Velcade, Thalidomide, Dexamethasone) Induction Followed by HDT With ASCT and Maintenance Treatment With Velcade for Newly Diagnosed MM",velcade,['velcade'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma,['Multiple Myeloma'],"['velcade', 'myeloma', 'VAD regimen', 'Transplantation, Autologous']",UNKNOWN,,2006-03,2008-07,"[{'measure': 'response rate of sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Velcade, Thalidomide, Dexamethasone) induction therapy as a first line treatment for the patients with multiple myeloma'}]","[{'measure': 'the progression free survival'}, {'measure': 'duration of response'}, {'measure': 'overall survival'}, {'measure': 'toxicities'}]",5,15 Years,65 Years,ALL,False,Korean Multiple Myeloma Working Party,OTHER,1,62.0,,2025-09-01T16:18:25.985977,v2_robust,True,True,False,False,False,
NCT00005855,Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma,A Phase I/II Study to Evaluate the Safety and Tolerance of Escalating Doses of RSR13 Administered With a Fixed Dose of BCNU Every Six Weeks in Patients With Recurrent Malignant Glioma,carmustine,"['efaproxiral', 'carmustine']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Brain and Central Nervous System Tumors,['Brain and Central Nervous System Tumors'],"['adult glioblastoma', 'adult anaplastic astrocytoma', 'adult anaplastic oligodendroglioma', 'recurrent adult brain tumor', 'adult giant cell glioblastoma', 'adult gliosarcoma']",COMPLETED,,2000-07,2006-10,"[{'measure': 'Safety and tolerability'}, {'measure': 'Maximum tolerated dose'}, {'measure': 'Pharmacokinetic profile'}, {'measure': 'Efficacy'}]",[],4,18 Years,,ALL,False,New Approaches to Brain Tumor Therapy Consortium,OTHER,1,48.0,ESTIMATED,2025-09-01T16:18:25.985990,v2_robust,True,True,True,False,True,
NCT06506955,Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.,"An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study",futibatinib,"['TAS-120', 'futibatinib', 'futibatinib, fulvestrant', 'TAS-120 + fulvestrant']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Advanced/Metastatic Cancer,['Advanced/Metastatic Cancer'],"['Futibatinib', 'TAS-120', 'FGFR', 'Cholangiocarcinoma', 'Breast cance', 'Urothelial Carcinom']",ENROLLING_BY_INVITATION,,2024-10-01,2026-12-31,"[{'measure': 'Number of participants with serious adverse events, treatment-related adverse events, and any AEs leading to treatment discontinuation graded according to NCI-CTCAE v5.0.', 'description': 'To collect long term safety information in patients continuing to receive treatment with futibatinib as monotherapy or in combination with fulvestrant who participated in a Taiho-sponsored futibatinib study and who are deriving clinical benefit with no undue risk', 'timeFrame': 'through study completion, an average of 5 years'}]",[],1,18 Years,,ALL,False,"Taiho Oncology, Inc.",INDUSTRY,0,15.0,ESTIMATED,2025-09-01T16:18:25.986146,v2_robust,True,True,False,False,True,
NCT02516826,The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease,The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease by Smart Angioplasty Research Team: SMART-ROAD Trial,Rosuvastatin,"['Placebo of Rosuvastatin/Olmesartan(Combination)', 'Placebo of Olmesartan', 'Olmesartan', 'Rosuvastatin', 'Placebo of Rosuvastatin', 'Combination']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Coronary Syndrome,['Coronary Syndrome'],[],UNKNOWN,,2015-08,2018-08,"[{'measure': 'PAV(nominal change of percent atheroma volume) in the proximal to mid segments of major epicardial coronary arteries', 'description': 'Left main, LAD proximal to mid (from ostium to a large second diagonal branch), LCX proximal (from ostium to a large first obtuse marginal branch), RCA (from ostium to a distal bifurcation)', 'timeFrame': 'Over the 48weeks'}]","[{'measure': 'TAV (nominal change of total atheroma volume) in the proximal to mid segments of major epicardial coronary arteries', 'description': 'Left main, LAD proximal to mid (from ostium to a large second diagonal branch), LCX proximal (from ostium to a large first obtuse marginal branch), RCA (from ostium to a distal bifurcation)', 'timeFrame': 'Over the 48weeks'}, {'measure': 'LAPV (nominal change of percent low attenuation plaque volume)', 'timeFrame': 'Over the 48weeks'}, {'measure': 'Nominal change of atheroma volume in 10 mm subsegment with greatest disease severity', 'timeFrame': 'Over the 48weeks'}, {'measure': 'Change in insulin resistance', 'timeFrame': 'Over the 48weeks'}, {'measure': 'Major adverse cardiac events', 'timeFrame': 'Over the 48weeks'}]",6,19 Years,70 Years,ALL,False,Samsung Medical Center,OTHER,0,504.0,ESTIMATED,2025-09-01T16:18:25.986242,v2_robust,True,True,False,False,True,
NCT01514526,Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma,Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma,Dovitinib,"['Dovitinib', 'TKI258']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Adrenocortical Carcinoma,['Adrenocortical Carcinoma'],['Adrenocortical carcinoma'],COMPLETED,,2012-01,2016-11,"[{'measure': 'Efficacy', 'description': 'Efficacy in terms of overall response rate (ORR) of dovitinib as treatment for metastatic or locally advanced non-resectable primary adrenocortical carcinoma (measured by an external evaluator)', 'timeFrame': 'Up to 6 months (Study treatment expected duration)'}]","[{'measure': 'Safety profile of dovitinib in study population', 'description': 'Safety will be assessed considering the number of study participants with Adverse Events during the conduct of the trial, from date of patient inclusion until the date of study end, up to 24 months.', 'timeFrame': 'Up to 24 months (Study expected duration, including patient treatment and follow up)'}, {'measure': 'Efficacy of dovitinib in reducing ACC hormonal production (cortisol, testosterone, aldosterone or estrogens)', 'description': 'Efficacy of dovitinib in reducing ACC hormonal production (cortisol, testosterone, aldosterone or estrogens)', 'timeFrame': 'Up to 6 months (Study treatment expected duration)'}, {'measure': 'Progression free survival (PFS) in all treated patients (measured by an external evaluator)', 'description': 'From date of patient inclusion until the date of first documented progression, assessed up to 24 months.', 'timeFrame': 'Up to 24 months (Study expected duration, including patient treatment and follow up)'}, {'measure': 'Overall survival (OS)(measured by an external evaluator)', 'description': 'From date of patient inclusion until the date of of death from any cause, assessed up to 24 months.', 'timeFrame': 'Up to 24 months (Study expected duration, including patient treatment and follow up)'}, {'measure': 'Quality of Life (QoL)', 'description': 'From date of patient inclusion until the date of study end, up to 24 months.', 'timeFrame': 'Up to 24 months (Study expected duration, including patient treatment and follow up)'}, {'measure': 'Progression Free Survival and Overall Survival (determined by the local researchers)', 'description': 'From date of patient inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.', 'timeFrame': 'Up to 24 months (Study expected duration, including patient treatment and follow up)'}]",7,18 Years,,ALL,False,Spanish Oncology Genito-Urinary Group,OTHER,0,17.0,ACTUAL,2025-09-01T16:18:25.986259,v2_robust,True,True,True,False,True,
NCT04062526,Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT,Evaluation of in Vivo Neuroinflammation in Parkinson's Disease Using 18F-NOS Positron Emission Tomography (PET/CT),[18F]NOS,"['[18F]NOS', '[18F]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Parkinson Disease,"['Parkinson Disease', 'Healthy Volunteer']",[],ACTIVE_NOT_RECRUITING,,2019-08-14,2026-04,"[{'measure': 'Characterize the uptake of [18F]NOS', 'description': 'Characterize the uptake of \\[18F\\]NOS in the human brain for healthy controls and PD patients.', 'timeFrame': '3 years'}]","[{'measure': 'Compare patterns of uptake', 'description': 'Compare patterns of \\[18F\\]NOS brain uptake in patients with PD versus healthy controls.', 'timeFrame': '3 years'}, {'measure': 'Compare peripheral blood inflammatory biomarkers', 'description': 'Compare peripheral blood inflammatory biomarkers, including cytokines and mtDAMPs, in PD patients with healthy controls.', 'timeFrame': '3 years'}]",3,18 Years,75 Years,ALL,True,University of Pennsylvania,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:25.986269,v2_robust,True,True,False,False,False,
NCT05179226,Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia,"A Phase III, Prospective, Open-label, Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia Due to NDD-CKD or With Iron Deficiency Anemia Who Are Intolerant or Unresponsive to Oral Iron",Ferric Derisomaltose,"['Monofer®, Monoferric®', 'Ferric Derisomaltose']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Iron Deficiency, Anaemia in Children","['Iron Deficiency, Anaemia in Children']",[],RECRUITING,,2022-11-28,2026-04-30,"[{'measure': 'Incidence of subjects with a Hb increase of ≥1 g/dL (NDD-CKD) or 2 g/dL (intolerant or unresponsive to oral iron). Measurement by bloodsample.', 'description': 'Hb (g/dL), measurement by bloodsample analysis', 'timeFrame': 'From baseline at any time from week 1 to week 8'}]","[{'measure': 'Time to increase Hb ≥1 g/dL (NDD-CKD) or 2 g/dL (intolerant or unresponsive to oral iron). Measurement by bloodsample.', 'description': 'Hb (g/dL), measurement by bloodsample analysis', 'timeFrame': 'From baseline at any time from week 1 to week 8'}, {'measure': 'Incidence of subjects who achieve a serum (s-) ferritin of ≥100 ng/mL. Measurement by bloodsample.', 'description': 's-ferritin (ng/mL), measurement by bloodsample analysis', 'timeFrame': 'At weeks 1, 2, 4, and 8'}, {'measure': 'Incidence of subjects who achieve a TSAT of ≥35 % (NDD-CKD) or ≥20 % (intolerant or unresponsive to oral iron). Measurement by bloodsample.', 'description': 'TSAT (%), measurement by bloodsample analysis', 'timeFrame': 'At weeks 1, 2, 4, and 8'}, {'measure': 'Total iron PK parameters: AUC0-∞', 'description': 'Total iron (µg/dL), measurement by bloodsample analysis', 'timeFrame': 'From baseline to day 7'}, {'measure': 'Total iron PK parameters: AUC0-t', 'description': 'Total iron (µg/dL), measurement by bloodsample analysis', 'timeFrame': 'From baseline to day 7'}, {'measure': 'Total iron PK parameters: Cmax', 'description': 'Total iron (µg/dL), measurement by bloodsample analysis', 'timeFrame': 'From baseline to day 7'}, {'measure': 'Total iron PK parameters: Tmax', 'description': 'Total iron (µg/dL), measurement by bloodsample analysis', 'timeFrame': 'From baseline to day 7'}, {'measure': 'Total iron PK parameters: Ke', 'description': 'Total iron (µg/dL), measurement by bloodsample analysis', 'timeFrame': 'From baseline to day 7'}, {'measure': 'Total iron PK parameters: T½', 'description': 'Total iron (µg/dL), measurement by bloodsample analysis', 'timeFrame': 'From baseline to day 7'}, {'measure': 'Total iron PK parameters: CL', 'description': 'Total iron (µg/dL), measurement by bloodsample analysis', 'timeFrame': 'From baseline to day 7'}, {'measure': 'Total iron PK parameters: Vd', 'description': 'Total iron (µg/dL), measurement by bloodsample analysis', 'timeFrame': 'From baseline to day 7'}, {'measure': 'Type and incidence of AEs', 'description': 'Any AE', 'timeFrame': 'From baseline to week 8'}, {'measure': 'Serious or severe hypersensitivity reaction', 'description': 'Any serious or severe hypersensitivity reaction', 'timeFrame': 'From treatment (Baseline) to 24 hours'}]",14,,17 Years,ALL,False,Pharmacosmos A/S,INDUSTRY,0,200.0,ESTIMATED,2025-09-01T16:18:25.986283,v2_robust,True,True,False,False,False,
NCT02749526,Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial,,"""Endostar""","['Liposo', 'cisplatin', 'Gimeracil and Oteracil Potassium （Tegafur）', '""Endostar""']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Esophageal,['Esophageal'],['Recombinant human endostatin，Endo'],TERMINATED,low accrual rate,2016-04,2018-12,"[{'measure': 'R0 Resection rate', 'timeFrame': 'up to 8 months'}]","[{'measure': 'pCR rate', 'timeFrame': 'up to 10 months'}]",2,18 Years,75 Years,ALL,False,The First Affiliated Hospital with Nanjing Medical University,OTHER,0,70.0,ESTIMATED,2025-09-01T16:18:25.986423,v2_robust,True,True,False,True,False,low accrual rate
NCT06635226,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects","A Randomized, Double-blinded, Placebo-controlled, Multiple Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administrations of ID110521156 in Healthy Subjects",ID110521156,"['Placebo of 110521156', 'ID110521156']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Adult Subjects,['Healthy Adult Subjects'],[],RECRUITING,,2024-11-13,2025-06-19,"[{'measure': 'AEs/serious AEs (SAEs)', 'timeFrame': 'Throughout study duration, up to 47 days'}]","[{'measure': 'Maximum concentration of drug in plasma (Cmax)', 'description': 'To assess the PK of ID110521156 when given at single and multiple ascending doses in healthy participants.', 'timeFrame': 'Day 1 and Day 28'}, {'measure': 'Area under the plasma drug concentration-time curve during a dosing interval (AUCtau)', 'description': 'To assess the PK of ID110521156 when given at single and multiple ascending doses in healthy participants.', 'timeFrame': 'Day 1 and Day 28'}, {'measure': 'The time of peak concentration (Tmax)', 'description': 'To assess the PK of ID110521156 when given at single and multiple ascending doses in healthy participants.', 'timeFrame': 'Day 1 and Day 28'}, {'measure': 'Terminal half-life (t1/2)', 'description': 'To assess the PK of ID110521156 when given at single and multiple ascending doses in healthy participants.', 'timeFrame': 'Day 1 and Day 28'}, {'measure': 'Apparent clearance (CL/F)', 'description': 'To assess the PK of ID110521156 when given at single and multiple ascending doses in healthy participants.', 'timeFrame': 'Day 1 and Day 28'}, {'measure': 'Apparent volume of distribution after extravascular administration (Vd/F)', 'description': 'To assess the PK of ID110521156 when given at single and multiple ascending doses in healthy participants.', 'timeFrame': 'Day 1 and Day 28'}, {'measure': 'Renal clearance (CLR)', 'description': 'To assess the PK of ID110521156 when given at single and multiple ascending doses in healthy participants.', 'timeFrame': 'Day 1 and Day 28'}, {'measure': 'fe', 'description': 'To assess the PK of ID110521156 when given at single and multiple ascending doses in healthy participants.', 'timeFrame': 'Day 1 and Day 28'}, {'measure': 'Trough plasma concentration taken directly before the next dose (Ctrough)', 'description': 'To assess the PK of ID110521156 when given at single and multiple ascending doses in healthy participants.', 'timeFrame': 'Throughout study duration, up to 27 days'}, {'measure': 'Minimum concentration of drug in plasma at steady state (Cmin, ss)', 'description': 'To assess the PK of ID110521156 when given at multiple ascending doses in healthy participants.', 'timeFrame': 'Day 28'}, {'measure': 'Average concentration of drug in plasma at steady state (Cavg, ss)', 'description': 'To assess the PK of ID110521156 when given at multiple ascending doses in healthy participants.', 'timeFrame': 'Day 28'}, {'measure': 'peak to trough fluctuation (PTF)', 'description': 'To assess the PK of ID110521156 when given at multiple ascending doses in healthy participants.', 'timeFrame': 'Day 28'}, {'measure': 'accumulation ratio (R)', 'description': 'To assess the PK of ID110521156 when given at multiple ascending doses in healthy participants.', 'timeFrame': 'Day 28'}, {'measure': 'Serum glucose', 'description': 'To assess the pharmacodynamics of ID110521156 when given at single and multiple ascending doses in healthy participants.', 'timeFrame': 'up to 28 days'}, {'measure': 'Insulin', 'description': 'To assess the pharmacodynamics of ID110521156 when given at single and multiple ascending doses in healthy participants.', 'timeFrame': 'up to 28 days'}, {'measure': 'Hemoglobin A1c (HbA1c)', 'description': 'To assess the pharmacodynamics of ID110521156 when given at multiple ascending doses in healthy participants.', 'timeFrame': 'up to 47 days'}]",17,19 Years,50 Years,ALL,True,IlDong Pharmaceutical Co Ltd,INDUSTRY,1,36.0,ESTIMATED,2025-09-01T16:18:25.986476,v2_robust,True,True,False,False,False,
NCT04691726,Impact of Intra- and Postoperative Continuous Infusion of Lidocaine on Analgesia in Vascular Anaesthesia,"Randomized, Double-blind, Placebo-controlled Single-centre Clinical Trial Evaluating Efficacy and Safety of Intraoperative and Postoperative Continuous Lidocaine Infusion in High Cardiac Risk Vascular Surgery",lidocaine 10mg/ml,"['lidocaine 10mg/ml', 'Placebo', 'Metamizole', 'Morphine', 'Lignocaine, Lidocaine']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Abdominal Aorta Aneurysm,"['Abdominal Aorta Aneurysm', 'Abdominal Aorta Atheroma', 'Surgery', 'Pain, Postoperative']","['lidocaine', 'analgesia', 'general anesthesia', 'vascular surgery', 'aorta']",COMPLETED,,2019-01-29,2022-07-02,"[{'measure': 'Opioid consumption in the intraoperative period', 'description': 'Dose of morphine (or fentanyl changed to the equivalent dose of morphine) administered to patient to achive pain score below 4 points (VAS scale)', 'timeFrame': 'Duration of general anaesthesia'}, {'measure': 'Opioid consumption in the postoperative period', 'description': 'Dose of morphine administered to patient to achive pain score below 4 points (VAS scale)', 'timeFrame': 'First 24 hours after surgery'}, {'measure': 'Consumption of the anesthetic agent', 'description': 'The Mean/median vaule of minimal alveolar concentration (MAC) necessary to maintain general anesthesia', 'timeFrame': 'Duration of general anesthesia'}, {'measure': 'Hemodynamic stability', 'description': 'Comparison of systolic and mean blood pressure value to value (5 minutes interval, comparison of exceeding 10% of the previous value, total number of exceedances)', 'timeFrame': 'Duration of general anesthesia'}, {'measure': 'Number of hemodynamic intervations', 'description': 'Total number hemodynamic interventions (total dose of vasoactive medication use according to study protocol)', 'timeFrame': 'Duration of general anesthesia'}, {'measure': 'Intraoperative fulid therapy', 'description': 'Total amount and type of fluids, blood products administered to patient', 'timeFrame': 'Duration of general anesthesia'}]","[{'measure': 'The Incidence of postoperative delirium', 'description': 'Patient assessed with the CAM-ICU tool', 'timeFrame': 'First 72 hours (after surgery), once per shift'}, {'measure': 'Indicators of safety', 'description': 'Incidence of side effects (according to Summary Product Characteristics)', 'timeFrame': 'Intraoperatively and first 24 hours (after surgery)'}]",8,18 Years,,ALL,False,Łukasz Krzych,OTHER,0,87.0,ACTUAL,2025-09-01T16:18:25.986594,v2_robust,True,True,True,False,True,
NCT01450826,Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide,A Randomized Open Label Phase II Trial of Aprepitant (Emend) in Combination With Ondansetron Compared to Standard 5HT3 Serotonin Antagonist (Ondansetron) in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Glioma Patients Receiving a Temozolomide Based Regimen,aprepitant,"['Emend', 'aprepitant', 'Zofran', 'ondansetron']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Nausea,"['Nausea', 'Vomiting', 'Glioma']","['Chemotherapy induced nausea and vomiting', 'CINV', 'Glioma', 'Temozolomide', 'Temodar', 'Aprepitant', 'Emend', 'Ondansetron', 'Zofran', 'Pro00031206', 'Affronti', 'Peters', 'Duke', 'Preston Robert Tisch Brain Tumor Center']",COMPLETED,,2014-06-24,2017-04-21,"[{'measure': 'Proportion of Patients Achieving Complete Control (CC)', 'description': 'Complete control (CC): study days 1-7 (acute and delayed CINV) the proportion of patients achieving complete control (CC); defined as no emetic episode, no need for rescue medication during days 1-7; number of emetic episodes daily; time to first emetic episode; as captured by the MAT (MASCC Antiemesis Tool)/Osoba survey (MASCC refers to Multinational Association for Supportive Care in Cancer™). Severity of nausea and other toxicities measured daily by the NCI Common Toxicity Criteria (version 4.0).', 'timeFrame': '7 days'}]","[{'measure': 'Proportion of Patients Achieving an Acute and Delayed Complete Response (CR)', 'description': 'CR is the proportion of patients with no emetic episode and no rescue medication. (1) Assessed from the beginning of study day 1, CR is defined for acute CINV as no emetic episode and no use of rescue anti-nausea medication during the first 24 hours following chemotherapy administration. An emetic episode is defined as one episode of vomiting or a sequence of episodes in very close succession not relieved by a period of relaxation of at least 1 min, any number of unproductive emetic episodes (retches) in any given 5 minute period, or an episode of retching lasting \\<5 minutes combined with vomiting not relieved by a period of relaxation of at least 1 minute; (2) Complete response (CR) on study days 2-7 (delayed CINV) is defined as the proportion of patients achieving a CR during the delayed time period. The data will be captured by the validated ultinational Association of Supportive Care in Cancer (MASCC) Anti-emesis Tool (MAT)/Osoba survey.', 'timeFrame': '7 days'}, {'measure': ""Patient's Global Satisfaction With the Antiemetic Regimen"", 'description': 'Patients\' global satisfaction with the antiemetic regimen is measured using the Osoba survey, which was administered on days 1-7. This survey asks patients ""In the past 24 hours, did vomiting or dry heaves a) interfere with your appetite, b) affect your sleep, c) interfere with your physical activities, d) interfere with your social life, and e) interfere with your enjoyment of life?"" Patients responded on a scale of 1-4 ranging from \'Not at all\' to \'Very much.\' Global satisfaction was defined as responding \'Not at all\' for all questions related to vomiting/retching for each study day. The proportion of patients responding \'Not at all\' for all Osoba vomiting/retching questions over the study period is reported.', 'timeFrame': '7 days'}, {'measure': 'Time to Treatment Failure', 'description': 'Median time in days to first emetic episode or first need of rescue medication, whichever occurred first as measured by the MAT/Osoba survey, among those patients experiencing an emetic episode or need of rescue medication', 'timeFrame': '7 days'}]",4,18 Years,,ALL,False,Katy Peters,OTHER,1,136.0,ACTUAL,2025-09-01T16:18:25.986619,v2_robust,True,True,True,False,False,
NCT01500226,Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy,"Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy",Rolapitant,"['Varubi', 'Granisetron', 'Granisol', 'Placebo to match Rolapitant', 'Placebo', 'Rolapitant', 'Kytril', 'Dexamethasone', 'Decadron']",9,INTERVENTIONAL,['PHASE3'],PHASE3,,Chemotherapy-induced Nausea and Vomiting,['Chemotherapy-induced Nausea and Vomiting'],"['Rolapitant', 'Nausea', 'Vomiting', 'CINV', 'Chemotherapy']",COMPLETED,,2012-02,2014-02,"[{'measure': 'No Emetic Episodes and No Rescue Medication', 'description': 'The primary objective of this study is to determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (\\>24 to 120 hours) of CINV compared with administration of placebo with granisetron and dexamethasone in subjects receiving MEC. The primary outcome will be based on complete response (defined as no emesis and no rescue medication) in the delayed phase (\\>24 to 120 hours).', 'timeFrame': '>24 to 120 hours post chemotherapy'}]","[{'measure': 'Acute Phase Response', 'description': 'To determine the effect of rolapitant on complete response rates in the acute (0 to 24 hours) phase of CINV.', 'timeFrame': '0 to 24 hours'}, {'measure': 'Overall Response Rate', 'description': 'To determine the effect of rolapitant on complete response rate in the overall (0 to 120 hours) phase of CINV.', 'timeFrame': '0 to 120 hours'}]",3,18 Years,,ALL,False,"Tesaro, Inc.",INDUSTRY,0,1369.0,ACTUAL,2025-09-01T16:18:25.986706,v2_robust,True,True,True,False,False,
NCT00755326,Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee,Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee,HLXL,"['HLXL', 'Huo-Luo-Xiao-Ling (HLXL) Dan']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Osteoarthritis of the Knee,['Osteoarthritis of the Knee'],['OA'],COMPLETED,,2007-04,2010-07,"[{'measure': '‡Pain Normalized Score', 'description': '‡Pain normalized score and function normalized score are on a scale of 0-10, with 10 indicating extreme pain/difficulty related to knee arthritis and 0 indicating no pain/difficultly related to knee arthritis.', 'timeFrame': '8 weeks'}]","[{'measure': 'Function Normalized Score', 'description': 'Pain normalized score and function normalized score are on a scale of 0-10, with 10 indicating extreme pain/difficulty related to knee arthritis and 0 indicating no pain/difficultly related to knee arthritis. Overall normalized score is on a scale of 0-30, and is the sum of the pain, stiffness and function normalized scores (each on a scale of 0-10).', 'timeFrame': '8-Weeks'}, {'measure': 'Patient Global Assessment', 'description': '§Patient Global Assessment is on a scale of 1-5, with 5 indicating excellent and 1 indicating poor (in response to the question ""Considering all the ways that your osteoarthritis of the knee affects you, how are you feeling today?"")', 'timeFrame': '8 weeks'}]",3,40 Years,,ALL,False,"University of Maryland, Baltimore",OTHER,1,92.0,ACTUAL,2025-09-01T16:18:25.986724,v2_robust,True,True,True,False,False,
NCT00309478,Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients,"A Randomized Phase III Study Comparing Cyclophosphamide + Methotrexate + Fluorouracil vs. Goserelin + Tamoxifen in Premenopausal, Hormone Receptor-positive, Lymph Node-positive or -Negative Patients",Cyclophosphamide,"['Methotrexate', 'Tamoxifen', 'Zoladex', 'Nolvadex', 'Cyclophosphamide', 'Fluorouracil implant', 'Goserelin']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Early-stage Breast Cancer,['Early-stage Breast Cancer'],"['Cyclophosphamide', 'Methotrexate', 'Fluorouracil', 'Goserelin', 'Tamoxifen', 'Breast cancer']",COMPLETED,,1990-12,2004-06,"[{'measure': 'Disease-free survival'}, {'measure': 'Overall survival'}]",[{'measure': 'Toxicities'}],3,19 Years,,FEMALE,False,Austrian Breast & Colorectal Cancer Study Group,NETWORK,1,1099.0,ACTUAL,2025-09-01T16:18:25.986759,v2_robust,True,True,True,False,False,
NCT03773978,A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis,"A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)",Baricitinib,"['LY3009104', 'Placebo', 'Baricitinib']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Juvenile Idiopathic Arthritis,['Juvenile Idiopathic Arthritis'],"['Polyarticular JIA', 'Oligoarthritis', 'Juvenile psoriatic arthritis (JPsA)', 'Enthesitis-related juvenile idiopathic arthritis (ERA)']",COMPLETED,,2018-12-17,2022-01-26,"[{'measure': 'Time to Disease Flare', 'description': ""A disease flare is defined as a worsening of 30% or more in at least three of the six core Paediatric American College of Rheumatology (PedACR) criteria for juvenile rheumatoid arthritis (JIA) and an improvement of 30% or more in no more than one of the criteria. The six PedACR criteria are: 1) the number of active joints, 2) the number of joints with limited range of motion, 3) physician's global assessment of disease activity, 4) parent's global assessment of the participant's overall well-being, 5) physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ) and 6) acute-phase reactant (high-sensitivity C-reactive protein \\[hsCRP\\] and erythrocyte sedimentation rate \\[ESR\\]), the ESR measure is only used as an acute phase reactant in the core criteria."", 'timeFrame': 'Week 12 to Week 44'}]","[{'measure': 'Percentage of Participants Achieving PedACR30 Responder Index', 'description': ""The PedACR30 response is defined as at least 30% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \\>30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle visual analogue scale \\[VAS\\]), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria."", 'timeFrame': 'Week 16, 20, 24, 28, 32, 36, 40 and 44'}, {'measure': 'Percentage of Participants Achieving PedACR50 Responder Index', 'description': ""The PedACR50 response is defined as at least 50% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \\> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria."", 'timeFrame': 'Week 16, 20, 24, 28, 32, 36, 40 and 44'}, {'measure': 'Percentage of Participants Achieving PedACR70 Responder Index', 'description': ""The PedACR70 response is defined as at least 70% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \\> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria."", 'timeFrame': 'Week 16, 20, 24, 28, 32, 36, 40 and 44'}, {'measure': 'Percentage of Participants Achieving PedACR90 Responder Index', 'description': ""The PedACR90 response is defined as at least 90% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \\> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria."", 'timeFrame': 'Week 16, 20, 24, 28, 32, 36, 40 and 44'}, {'measure': 'Percentage of Participants Achieving PedACR100 Responder Index', 'description': ""The PedACR100 response is defined as at least 100% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \\> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria."", 'timeFrame': 'Week 16, 20, 24, 28, 32, 36, 40 and 44'}, {'measure': 'Percentage of Participants With Inactive Disease', 'description': ""Inactive disease is defined as the presence of all of the following:\n\n1. No joints with active arthritis based on Juvenile Arthritis Disease Activity Score (JADAS) - 27 score,\n2. No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA as assessed by the investigator,\n3. No active uveitis as assessed by the investigator,\n4. Normal ESR or hsCRP (i.e., within normal limits in the local laboratory or, if elevated, not attributable to JIA),\n5. Physician's Global Assessment of Disease Activity indicating no active disease (Score ranges are 0 to 100 and best possible score on scale is 0) and\n6. Duration of morning stiffness ≤15 minutes."", 'timeFrame': 'Week 16, 20, 24, 28, 32, 36, 40 and 44'}, {'measure': 'Percentage of Participants With Minimal Disease Activity', 'description': ""Minimal disease activity is calculated based on the scores from the\n\n1. Physician's Global Assessment of Disease Activity\n2. Parent's Global Assessment of Well-Being and\n3. the number of swollen joints. If the physician's global assessment of disease activity is ≤3.5 (score range: 0-100), the parent's global rating of patient's overall well-being is ≤2.5 (score range: 0-100), and the swollen joint count is ≤1 (score range: 0-73), then the participant reaches minimal disease activity. if not, minimal disease activity is not reached."", 'timeFrame': 'Week 16, 20, 24, 28, 32, 36, 40 and 44'}, {'measure': 'Percentage of Participants in Remission', 'description': ""Remission is defined as inactive disease for at least 24 consecutive weeks. Inactive disease is defined as the presence of all of the following: 1) No joints with active arthritis based on Juvenile Arthritis Disease Activity Score (JADAS)-27 score, 2) No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA as assessed by the investigator, 3) No active uveitis as assessed by the investigator, 4) Normal ESR or hsCRP (i.e., within normal limits in the local laboratory or, if elevated, not attributable to JIA), 5) Physician's Global Assessment of Disease Activity indicating no active disease (best possible score on scale \\[0\\]) and 6) Duration of morning stiffness ≤15 minutes."", 'timeFrame': 'Week 28, 32, 36, 40 and 44'}, {'measure': 'Change From Baseline in Juvenile Arthritis Disease Activity Score-27 (JADAS-27) Score', 'description': ""The JADAS-27 score is based on 4 components: 1) Physician's global assessment of disease activity on a 0-100 mm VAS, 2) Parent's global assessment of overall well-being on a 0-100 mm VAS, 3) normalized ESR and 4) number of joints (maximum of 27) with active arthritis (cervical spine, elbows, wrists, metacarpophalangeal joints \\[from first to third\\], proximal interphalangeal joints, hips, knees, and ankles). The scores for the each of the first 3 components range from 0 -10; the score for the final component ranges from 0-27. The overall JADAS-27 score is sum of the 4 components and it ranges from 0-57. A higher score indicates more disease activity. Least square (LS) mean was calculated using Analysis of covariance (ANCOVA) model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors."", 'timeFrame': 'Baseline, Week 44'}, {'measure': 'Change From Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item', 'description': 'CHAQ assesses the health status and physical function of children with juvenile arthritis over the past week. The CHAQ consists of a Disability Index and a Discomfort Index. The disability index consisted of 30 items grouped into the following 8 domains: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored from 0 to 3 (0 = no difficulty; 1 = some difficulty; 2 = much difficulty and 3 = unable to do or not applicable). The scores of 8 domains were averaged to calculate the CHAQ-Disability Index total score. A higher score indicates worse physical function. The discomfort index consisted of Parent\'s Global Assessment of Well-Being and pain assessment due to illness. The intensity of pain is scored on a VAS scale ranging from 0-100 mm, with zero referring to ""no pain"" and 100 referring to ""very severe pain"". A higher score indicates a worse outcome.', 'timeFrame': 'Baseline, Week 44'}, {'measure': 'Change From Baseline in Psoriasis Area and Severity Index (PASI) Score', 'description': 'PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk and legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.', 'timeFrame': 'Baseline, Week 44'}, {'measure': 'Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Index', 'description': 'The SPARCC enthesitis is an index used to measure the severity of enthesitis (sites at which tendons and ligaments attach to bones). The SPARCC assesses 16 sites for enthesitis using a score of ""0"" for no activity or ""1"" for activity. Sites assessed include Medial epicondyle (left/right \\[L/R\\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.', 'timeFrame': 'Baseline, Week 44'}, {'measure': 'Change From Baseline in Juvenile Spondyloarthritis Disease Activity (JSpADA) Index', 'description': 'The JSpADA index is used to evaluate the disease activity of juvenile spondyloarthritis. The JSpADA index scores will be determined by following 8 components: active joint count, active enthesitis count, pain over the past week, CRP level related to juvenile spondyloarthritis activity, morning stiffness greater than 15 minutes, clinical sacroiliitis, uveitis and back mobility. All items are transformed to values of 0, 0.5, or 1, and the total score ranges from 0 to 8, where higher scores indicate more disease activity. LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.', 'timeFrame': 'Baseline, Week 44'}, {'measure': 'Pharmacokinetics (PK): Maximum Plasma Baricitinib Concentration at Steady-State (Cmax, ss)', 'description': 'Maximum Plasma Baricitinib Concentration at Steady-State', 'timeFrame': 'For Safety/PK period: Day 1, Day 4, Day 14 (pre dose) and Day 14 (post dose). For OLLI period: Day 1, Day 14, Day 28, Day 56 and 84 (pre dose)'}, {'measure': 'PK: Area Under the Baricitinib Concentration-Time Curve During a Dosing Interval at Steady-State (AUCτ,ss)', 'description': 'Area under the concentration-time curve of Baricitinib during a dosing interval at steady state.', 'timeFrame': 'For Safety/PK period: Day 1, Day 4, Day 14 (pre dose) and Day 14 (post dose). For OLLI period: Day 1, Day 14, Day 28, Day 56 and 84 (pre dose)'}, {'measure': 'Change From Baseline in Immunoglobulin Levels', 'description': 'Change from baseline in Serum Immunoglobulin A, Serum Immunoglobulin G and Serum Immunoglobulin M levels at week 12 are presented.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Number of Participants With Change of Immunoglobulin G (IgG) Titers', 'description': 'Number of participants with change of IgG titers eligible for tetanus / diphtheria / acellular pertussis (tDaP) vaccine and pneumococcal conjugate are presented. Participants who were immunized with tDaP or pneumococcal conjugate vaccine had their IgG antibody titers to the antigens evaluated preimmunization and at 4 and 12 weeks postimmunization. A primary immune response was assessed in participants who had never received tDaP or pneumococcal conjugate vaccines previously and secondary/booster responses were assessed if the participants had previously received the vaccines. For pneumococcal conjugate vaccine, number of participants with \\>= 2-fold increase from baseline in \\>=6 pneumococcal serotypes at week 4 and 12 is presented. For tDaP vaccine, number of participants with \\>= 4-fold increase from baseline in participants with baseline titer \\>=0.1 IU/mL at week 4 and 12 is presented.', 'timeFrame': 'Pre-Vaccination to 4 and 12 Weeks Post-Vaccination'}, {'measure': 'Number of Participants With Product Acceptability and Palatability Assessment', 'description': 'The questionnaire for product acceptability and palatability assessed the participants ability to swallow the tablet, experience relating to the taste, smell and ease of administering and taking the suspension. The questionnaire contained following Questions: Question 1) How did you (your child) like the taste of the medicine? Question 2) How did you (your child) like the smell of the medicine? Question 3) How easy was it for you (your child) to take the medicine today? Question 4) How easy was it for you to use the oral syringe to give your child the dose today? and Question 5) How easy was it for you (your child) to swallow the medicine today? Responses: Liked Very Much, Liked, Neither Liked nor Disliked, Disliked, Disliked Very Much, Very Easy, Easy, Neither Easy nor Hard, Difficult (or Hard) and Very Difficult (or Hard). The number of participants with these responses are presented. Data is presented as ""Question Number-Response-Time point"".', 'timeFrame': 'Baseline and week 12'}]",19,2 Years,17 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,220.0,ACTUAL,2025-09-01T16:18:25.986821,v2_robust,True,True,True,False,True,
NCT01237678,A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer,A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors Including Extensive Stage Small Cell Lung Cancer,IMGN901,"['BB-10901, Lorvotuzumab mertansine', 'IMGN901', 'Toposar®, VePesid®, Etopophos®', 'Carboplatin and Etoposide']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Small Cell Lung Cancer,['Small Cell Lung Cancer'],"['Immunogen', 'Lung', 'Small Cell Lung Cancer', 'Carboplatin', 'ADC']",TERMINATED,Study was stopped early due to lack of efficacy signal and safety concerns,2010-11,2015-05,"[{'measure': 'Occurrence of Dose Limiting Toxicities (DLT)', 'description': 'The primary outcome measure for Phase I was to determine the maximum tolerated dose (MTD) and characterize the dose limiting toxicities (DLT) of IMGN901 when administered in combination with carboplatin/etoposide chemotherapy followed by IMGN901 alone in patients with solid tumors. For the purposes of dose escalation and determination of MTD, DLTs were defined as AEs or abnormal laboratory values related to study treatment which occurred in Cycle 1 of the Dose Escalation phase, including any AEs that resulted in failure to meet the criteria for re-treatment. The following events were considered DLTs (using the most current version of CTCAE): febrile neutropenia; Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding; ≥ Grade 3 peripheral neuropathy; ≥ Grade 3 vomiting, nausea, or diarrhea that persisted despite the use of optimal therapy; other ≥ grade 3 non-hematologic toxicity (with the exception of brief fatigue i.e. ≤ 72 hours and alopecia)', 'timeFrame': '21 days (Cycle 1)'}, {'measure': 'Progression Free Survival (PFS) in Phase II', 'description': 'The primary outcome measure for Phase II was to determine the efficacy of IMGN901 in combination with carboplatin/etoposide chemotherapy as first-line treatment for patients with extensive stage small cell lung cancer. PFS was defined as the time from enrollment until objective tumor progression according to RECIST 1.1 or death on study due to any cause, whichever occurred first. Only the results from the experimental arm (IMGN901 + carboplatin + etoposide) are presented as the primary objective of this phase of the study was to compare PFS in the experimental arm (triplet combination) against historical PFS rates for carboplatin and etoposide. The control arm was planned primarily to reliably assess the safety of IMGN901 and to demonstrate whether the or not the historical assumptions regarding efficacy were confirmed.', 'timeFrame': 'From randomization to objective tumor progression or death (up to post-treatment follow-up 28 days after last dose, up to 22 months)'}, {'measure': 'Maximum Tolerated Dose (MTD) of IMGN901', 'description': 'A primary outcome measure for Phase I was to determine the maximum tolerated dose (MTD) of IMGN901 when administered in combination with carboplatin/etoposide chemotherapy followed by IMGN901 alone in patients with solid tumors. The MTD was determined based on DLTs that occurred during Cycle 1.', 'timeFrame': '21 days (Cycle 1)'}]","[{'measure': 'Overview of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'description': 'To assess the type and frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs). An AE was defined as any noxious, pathologic, or unintended change un anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of the study, whether or not deemed study drug-related. An SAE was any AE resulting in death, life-threatening experience, initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, or congenital defect. All AEs were reported from the time of the first dose of study treatment until 28 days after the final dose of study drug. the severity of AEs were graded by the Investigator using National cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) version 4.0.', 'timeFrame': 'From the first dose of study drug on Cycle 1, Day 1 until 28 days after the last study treatment (up to 22 months)'}, {'measure': 'Progression Free Survival (PFS) Rate at 6 Months', 'description': 'The trial was not empowered to permit a statistically informative comparison of the randomized treatment groups with respect to PFS. The activity of IMGN901 was assessed by comparing the PFS rate at 6 months in the IMGN901 experimental arm against the historical 6-month PFS rate of 0.44 (equivalently a median PFS = 5 months). Only the results from the experimental arm (IMGN901 + carboplatin + etoposide) are presented as the objective was to compare PFS at 6 months in the experimental arm (triplet combination) against the historical PFS rate of 0.44 (equivalently a median PFS = 5 months) for carboplatin and etoposide. The control arm was planned primarily to reliably assess the safety of IMGN901 and to demonstrate whether the or not the historical assumptions regarding efficacy were confirmed.', 'timeFrame': '6 months'}, {'measure': 'Median Overall Survival (OS) in Phase II', 'description': 'A secondary outcome measure for Phase II was to determine the overall survival of patients treated with IMGN901 in combination with carboplatin/etoposide chemotherapy versus carboplatin/etoposide chemotherapy alone as first-line treatment for patients with extensive stage small cell lung cancer.', 'timeFrame': 'From the time of enrollment until death on study due to any cause (up to post-treatment follow-up 28 days after last dose, up to 22 months)'}, {'measure': 'Overall Survival (OS) Rate at 12 Months', 'description': 'OS was analyzed based on a binary definition of the number of patients dead or censored prior to 12 months and the number of patients alive at 12 months. The primary objective of this phase of the study was to compare PFS in the experimental arm (triplet combination) against historical PFS rates. The control arm was primarily planned to demonstrate whether the or not the historical assumptions regarding efficacy were confirmed. Further, the trial was not empowered to permit a statistically informative comparison of the randomized treatment groups with respect to OS and no determination of the OS rate at 12 months for the control arm was performed; therefore only the results from the experimental arm (IMGN901 + carboplatin + etoposide) are presented.', 'timeFrame': '12 months'}]",7,18 Years,,ALL,False,"ImmunoGen, Inc.",INDUSTRY,0,181.0,ACTUAL,2025-09-01T16:18:25.987005,v2_robust,True,True,False,True,True,Study was stopped early due to lack of efficacy signal and safety concerns
NCT02513485,Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa,"""Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa""; ""Inflammation Effects on Corticostriatal Connectivity and Reward: Role of Dopamine""",Levodopa+carbidopa,"['Sinemet', 'Levodopa+carbidopa', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Depression,['Depression'],"['Inflammation', 'Anhedonia', 'Psychomotor retardation']",COMPLETED,,2015-10-09,2020-08-01,"[{'measure': 'Change in Functional Corticostriatal Connectivity', 'description': ""Corticostriatal connectivity was assessed by functional magnetic resonance imaging (fMRI). Resting-state and task-based (monetary incentive delay \\[MID\\]) fMRI scans were conducted on a 3 Tesla Siemens Trio MRI scanner. Subject-level correlations for degree of cortical and striatal functional connectivity were Fisher's Z transformed {Z(R)=0.5ln\\[(1+R)/(1-R)\\]}, a standard method for calculating fMRI functional connectivity. Greater Fisher's Z-scores reflected stronger correlated fMRI activity (i.e., higher corticostriatal connectivity)."", 'timeFrame': 'Scans approximately 45 min post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)'}, {'measure': 'Correlation Coefficient Between Change in Corticostriatal Connectivity and Levels of Plasma C-reactive Protein and Other Immune Markers', 'description': 'Peripheral blood samples were analyzed for levels of immune markers like plasma C-reactive protein (CRP), interleukin-6 (IL-6), soluble interleukin-6 receptor (sIL-6R), tumor necrosis factor (TNF) -alpha, soluble cytokine receptor2 (TNFR 2), interleukin-1 beta (IL-1 beta), interleukin-1 receptor antagonist (IL-1Ra), interleukin 10 (IL-10) and monocyte chemoattractant protein-1 (MCP-1).', 'timeFrame': 'Scans approximately 45 minutes post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)'}]","[{'measure': 'Effort-Expenditure for Rewards Task (EEfRT) Neurocognitive Test', 'description': 'The Effort-Expenditure for Rewards Task (EEfRT) is a computer-based multi-trial task used to objectively assess motivation. Possible results range between 0 to1 with 1 being a better outcome. Results show mean probability of hard (high effort) choice.', 'timeFrame': 'At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)'}, {'measure': 'The Trail Making Test (TMT) Neurocognitive Assessment', 'description': 'The Trail Making Test (TMT) is used to measure basic attention and psychomotor processing speed. Time taken to complete each task is recorded in seconds, whereby the greater the number of seconds, the slower the psychomotor speed.', 'timeFrame': 'At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)'}, {'measure': 'Digit Symbol Task Neurocognitive Test', 'description': 'The Digit Symbol Task was used to assess graphomotor speed, visual scanning and memory processing speed involving numbers and a corresponding blank box where subjects are asked to fill in matching symbol as fast as they can. Results show the average number of correct symbols completed in up to 100 boxes in 90 seconds.', 'timeFrame': 'At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)'}, {'measure': 'Finger Tapping Task (FTT) Neurocognitive Test', 'description': 'The Finger Tapping Task (FTT) assesses motor speed and can detect subtle motor impairment. The test measures the average number of taps per 10 second trial. A greater number of taps reflects faster motor speed.', 'timeFrame': 'At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)'}, {'measure': 'Reaction Time Task (CANTAB) Neurocognitive Test', 'description': 'The reaction time test includes simple and choice reaction time tasks and is divided into 5 stages requiring increasingly complex chains of responses. The task provided distinction between reaction (or decision) time and movement latencies (milliseconds) based on touch responses made to a single (simple) or chosen from multiple (choice) stimuli flashed on a computer screen. Results show mean response latency in milliseconds.', 'timeFrame': 'At baseline and approximately 2-3 hours post drug/placebo administration at Visit 1, Visit 2 (spaced by approximately 1 week)'}, {'measure': 'Multidimensional Fatigue Inventory (MFI) Self-report Questionnaire', 'description': 'The Multidimensional Fatigue Inventory (MFI) is a 20-item self-report instrument designed to measure severity of fatigue based on five dimensions of fatigue, general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. The total MFI scores range from 20 to 100 where high scores indicate greater fatigue.', 'timeFrame': 'At baseline and Visit 1, Visit 2 (spaced by approximately 1 week)'}, {'measure': 'Snaith-Hamilton Pleasure Scale (SHAPS) Self-report Questionnaire', 'description': 'The Snaith-Hamilton Pleasure Scale (SHAPS), a 14-item self-report scale with high psychometric validity for assessing the presence of anhedonia, was used to assess hedonic capacity. Participants rated how much they agreed or disagreed with the 14 items phrased as ""I would enjoy \\_\\_"" based on their ability to experience pleasure. Of the four possible response categories (Definitely Agree, Agree, Disagree, and Strongly Disagree), either of the Disagree responses received a score of 1 and either of the Agree responses received a score of 0. The SHAPS score calculated as the sum of these 14 items ranged from 0 to 14, and higher SHAPS scores indicated greater anhedonia.', 'timeFrame': 'Visit 1: Pre drug/placebo, Visit 1: 1-2 hrs post drug/placebo, Visit 2: Pre drug/placebo, Visit 2: 1-2 hrs post drug/placebo'}, {'measure': 'Inventory of Depressive Symptoms-Self Report (IDS-SR) Questionnaire', 'description': 'The Inventory of Depressive Symptoms-Self Report (IDS-SR) is a 30-item self-report instrument with excellent psychometric properties for measuring symptom constructs consistent with current Diagnostic and Statistical Manual of Mental Disorders (DSM) nosology and that is widely used to measure depression severity in clinical trials. Response scores are summed and range from 0 to 84, with higher scores reflecting greater depression severity.', 'timeFrame': 'At baseline and Visit 1: Pre drug/placebo, Visit 2: Pre drug/placebo (spaced by approximately 1 week)'}, {'measure': 'Beck Depression Inventory (BDI-II), Anhedonia Subscale Score', 'description': 'The Beck Depression Inventory-II (BDI-II) is a widely used self-report for measuring depression severity over the past two weeks and the anhedonia subscale is one of several validated subscales in the BDI-II. Responses are given on a 4-point scale where 0 = the symptom of depression has not been experienced and 3 = the symptom of depression is severe. The anhedonia subscale score is created by summing responses to four items of the BDI-II that assess loss of pleasure, loss of interest, loss of energy, loss of sex drive. The total score of the anhedonia subscale ranges from 0 to 12 where higher scores reflect greater severity of anhedonia symptoms.', 'timeFrame': 'Visit 1: Pre drug/placebo, Visit 2: Pre drug/placebo (spaced by approximately 1 week)'}, {'measure': 'Profile of Mood States (POMS) Scale', 'description': 'The Profile of Mood States (POMS) scale is a 30-item psychological rating scale used to assess transient, distinct mood states. Participants rate the extent to which they feel unhappy, blue, lonely, gloomy, and worthless on a scale from 0 (not at all) to 4 (extremely). Scores range from 0 to 120 with higher scores reflecting a more negative mood state.', 'timeFrame': 'Visit 1: Pre drug/placebo, Visit 1: 1-2 hrs post drug/placebo, Visit 2: Pre drug/placebo, Visit 2: 1-2 hrs post drug/placebo'}, {'measure': 'State-Trait Anxiety Inventory (STAI) State Scale', 'description': 'The 20-item self-report State-Trait Anxiety Inventory (STAI) State scale was used to measure severity of anxiety symptoms. Total scores range from 20 to 80 with higher scores reflecting greater anxiety. Scores in the high 40s are considered clinically significant.', 'timeFrame': 'Visit 1: Pre drug/placebo, Visit 1: 1-2 hrs post drug/placebo, Visit 2: Pre drug/placebo, Visit 2: 1-2 hrs post drug/placebo'}, {'measure': 'Change in Motivation and Pleasure (MAP) Scale Score', 'description': 'The motivation and pleasure (MAP) questionnaire is an 18-item self-report inventory that was created to disentangle state-wise motivational and consummatory components of everyday activities over a 24-hour period. This scale was used to assess self-reported changes in symptoms of anhedonia before and after inflammation blockade. Respondents respond to statements about daily activities on a scale from 0 (no pleasure/not at all) to 4 (extreme pleasure/very often). Total scores range from 0 to 72 where higher scores indicate greater motivation and effort given to everyday situations.', 'timeFrame': 'Visit 1: Pre drug/placebo, Visit 1: 1-2 hrs post drug/placebo, Visit 2: Pre drug/placebo, Visit 2: 1-2 hrs post drug/placebo'}]",14,18 Years,65 Years,ALL,False,Emory University,OTHER,1,57.0,ACTUAL,2025-09-01T16:18:25.987036,v2_robust,True,True,True,False,False,
NCT03948685,Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction,"Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction : a Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Pilot Trial (CAYMUS-HFpEF)",Carvedilol SR,"['Carvedilol SR', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Heart Failure With Preserved Ejection Fraction,['Heart Failure With Preserved Ejection Fraction'],[],UNKNOWN,,2019-05,2021-01,"[{'measure': 'The Maximum NT-proBNP value change after Drug(Carvedilol SR or Placebo) administration.', 'description': 'The maximum NT-proBNP value change at baseline.', 'timeFrame': 'Baseline'}, {'measure': 'The Maximum NT-proBNP value change after Drug(Carvedilol SR or Placebo) administration.', 'description': 'The maximum NT-proBNP value change from baseline to 8 weeks.', 'timeFrame': '8 weeks'}, {'measure': 'The Maximum NT-proBNP value change after Drug(Carvedilol SR or Placebo) administration.', 'description': 'The maximum NT-proBNP value change from baseline to End of trial(24weeks).', 'timeFrame': '24 weeks'}]","[{'measure': 'The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration.', 'description': 'the change of surrogate markers(hsTn, hsCRP etc) at baseline.', 'timeFrame': 'Baseline'}, {'measure': 'The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration.', 'description': 'the change of surrogate markers(hsTn, hsCRP etc) after 8 weeks.', 'timeFrame': '8 weeks'}, {'measure': 'The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration.', 'description': 'the change of surrogate markers(hsTn, hsCRP etc) after 16 weeks.', 'timeFrame': '16 weeks'}, {'measure': 'The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration.', 'description': 'the change of surrogate markers(hsTn, hsCRP etc) from baseline to end of trial(24 weeks)', 'timeFrame': '24 weeks'}, {'measure': 'The change in degree of dyspnea using VAS questionnaire', 'description': 'the change of dyspnea at baseline.', 'timeFrame': 'Baseline'}, {'measure': 'The change in degree of dyspnea using VAS questionnaire', 'description': 'the change of dyspnea after 8 weeks.', 'timeFrame': '8 weeks'}, {'measure': 'The change in degree of dyspnea using VAS questionnaire', 'description': 'the change of dyspnea after 16 weeks.', 'timeFrame': '16 weeks'}, {'measure': 'The change in degree of dyspnea using VAS questionnaire', 'description': 'the change of dyspnea from baseline to end of trial(24 weeks)', 'timeFrame': '24 weeks'}, {'measure': 'the change of body weight', 'description': 'the change of body weight at baseline.', 'timeFrame': 'Baseline'}, {'measure': 'the change of body weight', 'description': 'the change of body weight after 8 weeks.', 'timeFrame': '8 weeks'}, {'measure': 'the change of body weight', 'description': 'the change of body weight after 16 weeks.', 'timeFrame': '16 weeks'}, {'measure': 'the change of body weight', 'description': 'the change of body weight from baseline to end of trial(24 weeks)', 'timeFrame': '24 weeks'}, {'measure': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree', 'description': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral', 'timeFrame': 'Baseline'}, {'measure': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree', 'description': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral', 'timeFrame': '8 weeks'}, {'measure': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree', 'description': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral', 'timeFrame': '16 weeks'}, {'measure': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree', 'description': 'the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral', 'timeFrame': '24 weeks'}, {'measure': 'the frequency of hypo/hyperkalemia and worsening kidney function', 'description': 'the frequency of hypo/hyperkalemia and worsening kidney function during the trial', 'timeFrame': 'Baseline'}, {'measure': 'the frequency of hypo/hyperkalemia and worsening kidney function', 'description': 'the frequency of hypo/hyperkalemia and worsening kidney function during the trial', 'timeFrame': '8 weeks'}, {'measure': 'the frequency of hypo/hyperkalemia and worsening kidney function', 'description': 'the frequency of hypo/hyperkalemia and worsening kidney function during the trial', 'timeFrame': '16 weeks'}, {'measure': 'the frequency of hypo/hyperkalemia and worsening kidney function', 'description': 'the frequency of hypo/hyperkalemia and worsening kidney function during the trial', 'timeFrame': '24 weeks'}, {'measure': 'all-cause hospitalization & mortality', 'description': 'all-cause hospitalization \\& mortality during the trial', 'timeFrame': 'Baseline'}, {'measure': 'all-cause hospitalization & mortality', 'description': 'all-cause hospitalization \\& mortality during the trial', 'timeFrame': '8 weeks'}, {'measure': 'all-cause hospitalization & mortality', 'description': 'all-cause hospitalization \\& mortality during the trial', 'timeFrame': '16 weeks'}, {'measure': 'all-cause hospitalization & mortality', 'description': 'all-cause hospitalization \\& mortality during the trial', 'timeFrame': '24 weeks'}]",27,19 Years,,ALL,False,Yonsei University,OTHER,0,300.0,ESTIMATED,2025-09-01T16:18:25.987501,v2_robust,True,True,False,False,False,
NCT01638585,Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia,Patients With Diabetic Foot Syndrome and Critical Limb Ischemia - a Randomized Clinical Trial With Urokinase,urokinase,"['Urokinase HS medac', 'urokinase']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Diabetic Foot,"['Diabetic Foot', 'Critical Limb Ischemia']",[],TERMINATED,recruition number was not reached,2011-06,2012-11,"[{'measure': 'Duration of survival without major amputation in urokinase group compared to group with standard therapy', 'timeFrame': 'within the FU of 12 months'}]","[{'measure': 'total mortality', 'timeFrame': '12 months after randomization'}, {'measure': 'minor amputation', 'timeFrame': '12 months after randomization'}, {'measure': 'Number of necessary revisions in case of minor amputation', 'timeFrame': '12 months after randomization'}, {'measure': 'complete healing of targeted lesion', 'timeFrame': 'within the FU of 12 months'}, {'measure': 'new lesions on previously affected leg', 'timeFrame': 'within the FU of 12 months'}, {'measure': 'efficacy in dialysis patients', 'timeFrame': 'within the FU of 12 months'}, {'measure': 'duration of hospital stay', 'timeFrame': 'from baseline examination until first release (expected average of 2 weeks in general)'}, {'measure': 're-hospitalization after dismissal following end of therapy with urokinase', 'timeFrame': 'within the FU of 12 months'}, {'measure': 'Necessity for parenteral therapy with vasoactive substances', 'description': 'During the follow-up it will be documented wether the administration of parenterally applied vasoactive substances or thrombocyte aggregation inhibitors was necessary.', 'timeFrame': 'from baseline to end of 12 months FU'}, {'measure': 'cardiovascular events', 'description': 'Any major cardiovascular events during the follow-up period. Duration, severity, outcome and causal relationship with urokinase therapy will be documented.', 'timeFrame': 'from baseline to end of 12 months FU'}, {'measure': 'incidence and type of bleeding events', 'timeFrame': 'from randomization until day 33'}, {'measure': 'incidence and type of other adverse events', 'timeFrame': 'from baseline to end of 12 months FU'}, {'measure': 'new lesions on the contralateral leg', 'timeFrame': 'within the FU of 12 months'}]",14,18 Years,,ALL,False,GWT-TUD GmbH,OTHER,0,34.0,ACTUAL,2025-09-01T16:18:25.987580,v2_robust,True,True,False,True,True,recruition number was not reached
NCT04661943,Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma,Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma,Tucidinostat,"['Chidamide，CS055，HBI-8000', 'Tucidinostat']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Diffuse Large B-cell Lymphoma,['Diffuse Large B-cell Lymphoma'],[],UNKNOWN,,2020-11-30,2022-11-30,"[{'measure': 'Progression-free survival', 'description': 'Progression-free survival（by IWC）', 'timeFrame': '6months'}]","[{'measure': 'Overall survival', 'description': 'Overall survival', 'timeFrame': '12months'}]",2,18 Years,75 Years,ALL,False,oubai,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:25.987703,v2_robust,True,True,False,False,False,
NCT00001443,A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection,A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection,indinavir (MK-0639),['indinavir (MK-0639)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Acquired Immunodeficiency Syndrome,"['Acquired Immunodeficiency Syndrome', 'HIV Infections']","['AIDS', 'Bioavailability', 'Immunologic Evaluations', 'Pharmacokinetics', 'Toxicity']",COMPLETED,,1995-07,2000-10,[],[],0,,,ALL,False,National Cancer Institute (NCI),NIH,0,63.0,,2025-09-01T16:18:25.987769,v2_robust,True,True,True,False,False,
NCT01384643,Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery,"Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery: A Prospective, Randomized Controlled Trial",Propofol,['Propofol'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Heart Valve Disease,['Heart Valve Disease'],[],COMPLETED,,2011-05,2012-05,"[{'measure': 'Serum creatinine', 'description': 'Comparison of serum creatinine elevation after surgery between Propofol and Control group.', 'timeFrame': 'incidence of AKI during 48 hours after the surgery incidence of AKI'}]",[],1,20 Years,75 Years,ALL,False,Yonsei University,OTHER,0,112.0,ACTUAL,2025-09-01T16:18:25.987775,v2_robust,True,True,True,False,False,
NCT03425643,"Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)","A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)",Placebo,"['PLATINOL®', 'Cisplatin', 'Placebo', 'Gemcitabine', 'Alimta®', 'Pemetrexed', 'GEMZAR®']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-small Cell Lung Cancer,['Non-small Cell Lung Cancer'],[],ACTIVE_NOT_RECRUITING,,2018-04-24,2026-06-29,"[{'measure': 'Event Free Survival (EFS)', 'description': 'EFS is defined as the time from randomization until radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause. EFS determined either by biopsy assessed by local pathologist or by investigator-assessed imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The EFS for all participants is presented (through database cut-off date of 10-Jul-2023).', 'timeFrame': 'Up to approximately 5 years'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from randomization until death from any cause. The OS for all participants is presented (through database cut-off date of 10-Jul-2023).', 'timeFrame': 'Up to approximately 5 years'}]","[{'measure': 'Major Pathological Response (mPR) Rate', 'description': 'mPR rate is defined as the percentage of participants having ≤10% viable tumor cells in the resected primary tumor and all resected lymph nodes following completion of neoadjuvant therapy. The mPR rates as assessed by blinded independent pathologist are presented.', 'timeFrame': 'Up to approximately 8 weeks following completion of neoadjuvant treatment (up to Study Week 20)'}, {'measure': 'Pathological Complete Response (pCR) Rate', 'description': 'pCR rate is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes following completion of neoadjuvant therapy. The pCR rates as assessed by blinded independent pathologist are presented.', 'timeFrame': 'Up to approximately 8 weeks following completion of neoadjuvant treatment (up to Study Week 20)'}, {'measure': 'Change From Baseline in Neoadjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score', 'description': 'Change from baseline in GHS/QoL score using the EORTC QLQ-C30 will be determined. The EORTC QLQ-C30 is the most widely used cancer-specific, health-related QoL instrument comprised of 30 individual items arranged as both multi-item scales and individual items. Specifically, these items are divided into 5 functional scales (15 items total), 3 symptom scales (7 items total), 6 individual items, and a GHS/QoL scale composed of 2 items: GHS and QoL. The GHS/QoL score measured here refers to only the composite score calculated for the GHS/QoL scale. Both items on the GHS/QoL scale are scored from 1 (very poor GHS/QoL) to 7 (excellent GHS/QoL) and scores for both items are averaged and a linear transformation applied to standardize the overall GHS/QoL score from 0 to 100, with higher overall scores indicating higher GHS/QoL.', 'timeFrame': 'Baseline (cycle 1 in neoadjuvant phase) and neoadjuvant week 11'}, {'measure': 'Change From Baseline in Adjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score', 'description': 'Change from baseline in GHS/QoL score using the EORTC QLQ-C30 will be determined. The EORTC QLQ-C30 is the most widely used cancer-specific, health-related QoL instrument comprised of 30 individual items arranged as both multi-item scales and individual items. Specifically, these items are divided into 5 functional scales (15 items total), 3 symptom scales (7 items total), 6 individual items, and a GHS/QoL scale composed of 2 items: GHS and QoL. The GHS/QoL score measured here refers to only the composite score calculated for the GHS/QoL scale. Both items on the GHS/QoL scale are scored from 1 (very poor GHS/QoL) to 7 (excellent GHS/QoL) and scores for both items are averaged and a linear transformation applied to standardize the overall GHS/QoL score from 0 to 100, with higher overall scores indicating higher GHS/QoL.', 'timeFrame': 'Baseline (cycle 1 in neoadjuvant phase) and adjuvant week 10 (up to Study Week 30)'}, {'measure': 'Number of Participants Who Experience an Adverse Event (AE)', 'timeFrame': 'Up to approximately 71 weeks'}, {'measure': 'Number of Participants Who Experience Perioperative Complications', 'description': 'Perioperative complications are a discrete set of both intraoperative and postoperative complications, potentially contributing to increased length of inpatient care and/or delay of adjuvant therapy. The number of participants experiencing perioperative complications will be assessed.', 'timeFrame': 'Up to approximately 51 weeks following surgery'}, {'measure': 'Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)', 'timeFrame': 'Up to approximately 57 weeks'}]",9,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,797.0,ACTUAL,2025-09-01T16:18:25.987852,v2_robust,True,True,False,False,True,
NCT03798743,Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study,"Single Center, Single Arm Phase II Study on Efficacy Evaluation and Bio-marker Analysis of Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer",Sintilimab Combined With Docetaxel,"['Sintilimab Combined With Docetaxel', 'SCD']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Non-small Cell Lung Cancer,['Non-small Cell Lung Cancer'],"['Non-small Cell Lung Cancer', 'Sintilimab', 'Docetaxel']",COMPLETED,,2019-01-01,2022-03-01,"[{'measure': 'ORR (Overall response rate)', 'description': 'Evaluation of objective response rates in patients with advanced or metastatic non-small cell lung cancer who failed to receive platinum-based dual-drug chemotherapy in response to RECIST 1.1 and in combination with docetaxel and docetaxel', 'timeFrame': 'Approximately 1 years'}]","[{'measure': 'PFS (progression free survival time)', 'description': 'Assessment of the disease-free progression of the subject according to RECIST 1.1', 'timeFrame': 'Approximately 1 years'}, {'measure': 'OS (overall survival time)', 'description': 'Assess the overall survival of the subject according to RECIST 1.1', 'timeFrame': 'Approximately 1 years'}, {'measure': 'DOR (duration of response)', 'description': ""Assessment of subject's duration of remission according to RECIST 1.1"", 'timeFrame': 'Approximately 1 years'}, {'measure': 'DCR (disease control rate)', 'description': ""Assessment of subject's disease control rate according to RECIST 1.1"", 'timeFrame': 'Approximately 1 years'}, {'measure': 'TTR (time to response)', 'description': ""Assessment of subject's objective response time according to RECIST 1.1"", 'timeFrame': 'Approximately 1 years'}]",6,18 Years,75 Years,ALL,False,Hunan Province Tumor Hospital,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:25.987899,v2_robust,True,True,True,False,False,
NCT00149643,Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence,Fluoxetine for Major Depressive Disorder/Cannabis Disorder in Young People,Fluoxetine,"['Prozac', 'Fluoxetine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Depressive Disorder, Major","['Depressive Disorder, Major', 'Cannabis Abuse']","['Cannabis', 'MDD']",COMPLETED,,2004-09,2012-12,"[{'measure': 'Days Per Week of Cannabis Use.', 'description': 'The number days out of the last seven days that cannabis was used.', 'timeFrame': '12 Weeks'}, {'measure': 'Depression Symptoms at Week 12', 'description': 'Average of Beck Depression Inventory (BDI) Scores measured at Weeks 1-4, 6, 8, 10 and 12. The BDI is a subject reported measure that has a minimim score of 0 and a maximum score of 63. A better outcome would consist of values near the minimum end of the scale (0) and a worse outcome would consist of values near the maximum end of the scare (63). Each DSM-IV criteron asses a different depressive symptom.', 'timeFrame': '12 Weeks'}]","[{'measure': 'Number of Cannabis Use Disorder Criterion Met at a Particular Time Point.', 'description': 'Criterion used in this study was the number of DSM-IV cannabis use disorder symptoms (criteria) that were met.', 'timeFrame': '12 Weeks'}]",3,14 Years,25 Years,ALL,False,University of Pittsburgh,OTHER,1,70.0,ACTUAL,2025-09-01T16:18:25.987920,v2_robust,True,True,True,False,False,
NCT01132443,"W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne","A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne Vulgaris","Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,","['Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,']",1,INTERVENTIONAL,['PHASE1'],PHASE1,,Acne Vulgaris,['Acne Vulgaris'],[],COMPLETED,,2010-05-06,2010-06-12,"[{'measure': 'Clindamycin plasma concentrations', 'description': 'Plasma concentrations of clindamycin in subjects with acne vulgaris', 'timeFrame': 'Baseline to Day 6'}]","[{'measure': 'Clindamycin sulfoxide plasma concentrations', 'description': 'Plasma concentrations of clindamycin sulfoxide in subjects with acne vulgaris', 'timeFrame': 'Baseline/Day 1, Day 2, 3, 4, and 5 (pre-dose and 1, 2, 4, 6, 8, 12, and 24 hours post dost - Day 6)'}]",2,12 Years,45 Years,ALL,False,"Stiefel, a GSK Company",INDUSTRY,1,72.0,ACTUAL,2025-09-01T16:18:25.987979,v2_robust,True,True,True,False,False,
NCT01656343,Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients,Belatacept and Risk of PTLD in US Renal Transplant Recipients,Calcineurin inhibitors (CNI),"['Calcineurin inhibitors (CNI)', 'Nulojix', 'Belatacept']",3,OBSERVATIONAL,[],,,Kidney Transplantation,"['Kidney Transplantation', 'Transplantation, Kidney']",[],COMPLETED,,2011-10-31,2019-08-05,"[{'measure': 'Incidence rates of post-transplant lymphoproliferative disorder (PTLD) in adult, EBV seropositive, kidney alone transplant recipients treated with belatacept at the time of transplantation', 'timeFrame': 'Every 6 months for up to 72 months'}, {'measure': 'Incidence rates of PTLD in adult, EBV seropositive, kidney alone transplant recipients treated with calcineurin inhibitors (CNI)-based regimens at the time of transplantation', 'timeFrame': 'Every 6 months for up to 72 months'}, {'measure': 'Ratio for PTLD incidence rates in adult, EBV seropositive, kidney alone, belatacept treated patients and adult EBV seropositive, kidney alone, CNI-treated patients at the time of transplantation', 'timeFrame': 'Every 6 months for up to 72 months'}]","[{'measure': 'Incidence rates of PTLD in subgroups of belatacept-treated, adult, kidney alone transplant recipients defined by recipient Epstein-Barr virus (EBV) serostatus (negative or unknown) and by donor to recipient EBV serostatus', 'timeFrame': 'Every 6 months for up to 72 months'}, {'measure': 'Ratio for PTLD incidence rates in the belatacept-treated subgroups defined by EBV serostatus (negative or unknown) to the rates in corresponding CNI-treated subgroups', 'timeFrame': 'Every 6 months for up to 72 months'}, {'measure': 'Incidence rates of PTLD in subgroups of belatacept-treated, adult, kidney alone transplant recipients defined by recipient cytomegalovirus (CMV) serostatus and by donor to recipient CMV serostatus', 'timeFrame': 'Every 6 months for up to 72 months'}, {'measure': 'Ratio for PTLD incidence rates in the belatacept-treated subgroups defined by CMV serostatus to the rates in corresponding CNI-treated subgroups', 'timeFrame': 'Every 6 months for up to 72 months'}, {'measure': 'Characteristics (age, gender, weight, BMI, use of immunosuppressive medications, and type of induction medications) of PTLD cases, and the location and mortality of PTLD', 'description': 'Characteristics in adult, kidney alone transplant recipients treated with belatacept at transplantation and in subgroups of these transplant recipients defined by EBV serostatus and CMV serostatus', 'timeFrame': 'Every 6 months for up to 72 months'}, {'measure': 'Ratio for characteristics of PTLD cases, and the location and mortality of PTLD, in adult, kidney alone transplant recipients treated with belatacept at transplantation to those treated with CNI-based regimens at transplantation', 'timeFrame': 'Every 6 months for up to 72 months'}, {'measure': 'Two year incidence rates of PTLD by calendar year of transplantation in adult, kidney alone transplant recipients treated with belatacept at transplantation, and in subgroups of these transplant recipients defined by EBV serostatus and by CMV serostatus', 'timeFrame': 'Every 6 months for up to 24 months'}, {'measure': 'Incidence rates of PTLD by immunosuppressive regimen changes in adult, kidney alone transplant recipients who switch to or from belatacept during the period from transplant to the end of one-year follow-up', 'timeFrame': 'Every 6 months for up to 12 months follow up'}]",11,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,775.0,ACTUAL,2025-09-01T16:18:25.987990,v2_robust,False,True,True,False,False,
NCT03315143,Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function",Sotagliflozin,"['Sotagliflozin', 'SAR439954', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Heart Failure,"['Heart Failure', 'Type 2 Diabetes Mellitus', 'Chronic Kidney Diseases']",[],TERMINATED,study terminated due to business decision,2017-12-19,2020-07-08,"[{'measure': 'Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF)', 'description': 'Combined endpoint of the total number of occurrences (first and potentially subsequent) of CV death, HHF, and urgent HF visits after randomization. Events that occurred during the study were calculated as the total number of events per 100 person-years of follow-up.', 'timeFrame': 'Up to 30 months'}]","[{'measure': 'Total Number of Occurrences of HHF and Urgent HF Visits', 'description': 'Combined endpoint of the total occurrences (first and potentially subsequent) of HHF and urgent HF visits after randomization. Events that occurred during the study were calculated as the total number of events per 100 person-years of follow-up.', 'timeFrame': 'Up to 30 months'}, {'measure': 'Number of Deaths From Cardiovascular Causes', 'description': 'Number of events that occurred during the study were calculated as the total number of events per 100 person-years of follow-up.', 'timeFrame': 'Up to 30 months'}, {'measure': 'Total Number of Occurrences of CV Death, HHF, Non-fatal Myocardial Infarction and Non-fatal Stroke', 'description': 'Combined endpoint of the total number of occurrences (first and potentially subsequent) of CV death, HHF, non-fatal stroke, and non-fatal myocardial infarction after randomization. Events that occurred during the study were calculated as the total number of events per 100 person-years of follow-up.', 'timeFrame': 'Up to 30 months'}, {'measure': 'Total Number of Occurrences of HHF, Urgent HF Visit, CV Death, and HF While Hospitalized', 'description': 'Combined endpoint of the total number of occurrences (first and potentially subsequent) after randomization of HHF, urgent HF visits, CV Death, and HF while hospitalized. Events that occurred during the study were calculated as the total number of events per 100 person-years of follow-up.', 'timeFrame': 'Up to 30 months'}, {'measure': 'Number of Occurrences After Randomization of the Composite of Sustained ≥50% Decrease in Estimated Glomerular Filtration Rate (eGFR) From Baseline (for ≥30 Days), Chronic Dialysis, Renal Transplant, or Sustained eGFR <15 mL/Min/1.73 m^2 (for ≥30 Days)', 'description': 'Events that occurred during the study were calculated as the total number of events per 100 person-years of follow-up.', 'timeFrame': 'Up to 30 months'}, {'measure': 'Number of Deaths From Any Cause', 'description': 'Number of events that occurred during the study were calculated as the total number of events per 100 person-years of follow-up.', 'timeFrame': 'Up to 30 months'}, {'measure': 'Total Number of Occurrences of CV Death, Non-fatal Myocardial Infarction and Non-fatal Stroke', 'description': 'Combined endpoint of the total number of occurrences (first and potentially subsequent) of CV death and urgent HF visits after randomization. Events that occurred during the study were calculated as the total number of events per 100 person-years of follow-up.', 'timeFrame': 'Up to 30 months'}]",8,18 Years,,ALL,False,Lexicon Pharmaceuticals,INDUSTRY,1,10584.0,ACTUAL,2025-09-01T16:18:25.988036,v2_robust,True,True,False,True,False,study terminated due to business decision
NCT06324435,Apremilast for Alcohol Use Disorder Treatment in Women and Men,Apremilast for Alcohol Use Disorder Treatment in Women and Men,Apremilast,"['Otezla', 'Apremilast']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Alcohol Use Disorder,['Alcohol Use Disorder'],[],ACTIVE_NOT_RECRUITING,,2024-05-08,2026-02-28,"[{'measure': 'Alcohol Consumption', 'description': 'Means mls of alcohol consumed during 120 minute alcohol self-administration sessions with personalized stress imagery vs neutral/relaxing imagery taking place at steady state.', 'timeFrame': '120 minutes'}]",[],1,21 Years,65 Years,ALL,True,Yale University,OTHER,2,10.0,ESTIMATED,2025-09-01T16:18:25.988073,v2_robust,True,True,False,False,False,
NCT01342835,Postoperative Analgesia in Children After Propofol Anesthesia,Postoperative Analgesia in Children After Propofol Anesthesia,Propofol,"['Sevorane', 'Propofol', 'Diprivan']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Postoperative Pain,['Postoperative Pain'],"['propofol', 'sevoflurane', 'postoperative pain', 'children']",UNKNOWN,,2010-09,2011-07,"[{'measure': 'postoperative pain', 'description': 'The Faces Pain Scale (FPS) (from five face drawings: 0 = no pain, 5 = extreme pain) is used to assess pain severity', 'timeFrame': '120 minutes'}]","[{'measure': 'recovery time', 'description': 'Recovery time, defined as the time until eye opening on command or the time of first response to command after anesthesia', 'timeFrame': '120 minutes'}, {'measure': 'adverse effects', 'description': 'Adverse effects during the surgery and after recovery: hypotension, bradicardia, intense coughing, hypersalivation and laryngospasm, nausea, and vomiting.', 'timeFrame': '0-120 minutes'}]",3,3 Years,6 Years,ALL,True,University Clinical Centre of Kosova,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:25.988087,v2_robust,True,True,False,False,True,
NCT03329235,Intraosseous With Intra-articular Injection of Platelet Rich Plasma in Treatment of Knee Osteoarthritis,Intraosseous With Intra-articular Injection of Platelet Rich Plasma Versus Hyaluronic Acid in Treatment of Knee Osteoarthritis,PRP,"['HA', 'PRP']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,"Osteoarthritis, Knee","['Osteoarthritis, Knee']",[],COMPLETED,,2015-01-01,2017-01-01,"[{'measure': 'WOMAC scores', 'description': 'The evaluation was performed with WOMAC, which were recorded on a five-point Likert scale scoring, with a response of ""none"" scored as 0, ""mild"" as 1, ""moderate"" as 2, ""severe"" as 3 and ""extreme"" as 4.', 'timeFrame': 'At the 18th month'}]",[],1,40 Years,73 Years,ALL,False,Cangzhou Central Hospital,OTHER,0,86.0,ACTUAL,2025-09-01T16:18:25.988120,v2_robust,True,True,True,False,False,
NCT01283035,"A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer","A Phase II Study of MK-2206 in the Treatment of Recurrent High-Grade Serous Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Akt Inhibitor MK2206,"['MK2206', 'Akt Inhibitor MK2206']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Sarcoma,"['Ovarian Sarcoma', 'Recurrent Fallopian Tube Carcinoma', 'Recurrent Ovarian Carcinoma', 'Recurrent Primary Peritoneal Carcinoma']",[],COMPLETED,,2011-04,2014-12,"[{'measure': 'Efficacy (as Measured by Objective Response Rate) of Akt Inhibitor MK2206 in Patients With Recurrent High-grade Platinum-resistant Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer', 'description': 'If 4 or more of the final set of 29 patients demonstrate a response, then the null hypothesis H0: =\\< 5% can be rejected in favor of the alternative hypothesis H1: \\>= 20% with an alpha of 0.05 and beta of 0.20 (i.e., 80% power).\n\nPer Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression', 'timeFrame': 'Up to 3 years'}]","[{'measure': 'Association Between Select Biomarkers and Response to Akt Inhibitor MK2206 (as Assessed by Objective Tumor Response, Progression-free Survival, and Overall Survival)', 'description': 'The frequency of mutations in the PI3K/AKT and RAS pathways, copy number alterations, and PTEN loss and AKT expression as assessed by IHC will be tabulated. Associations between these markers with clinical outcome such as response rate and duration of PFS will be assessed.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Development of Feedback Loop Activation and Target Inhibition With Akt Inhibitor MK2206 Via Analysis of Pre-treatment and Post-treatment Biopsies in Select Patients Enrolled in the Trial', 'timeFrame': 'Up to 3 years'}, {'measure': 'Duration of Overall Survival Following Initiation of Therapy With Akt Inhibitor MK2206 in the Cohort of Patients Enrolled on This Study', 'description': 'Distributions will be estimated using Kaplan-Meier analysis.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Duration of Progression-free Following Initiation of Therapy With Akt Inhibitor MK2206 in the Cohort of Patients Enrolled on This Study', 'description': 'Distributions will be estimated using Kaplan-Meier analysis.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Toxicities of Akt Inhibitor MK2206, as Assessed by the Active Version of the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.0)', 'timeFrame': 'Up to 3 years'}]",6,18 Years,,FEMALE,False,National Cancer Institute (NCI),NIH,0,6.0,ACTUAL,2025-09-01T16:18:25.988168,v2_robust,True,True,True,False,True,
NCT06886035,Effectiveness of Curcuminoids in Controlling Postoperative Pain Following Total Laparoscopic Hysterectomy,Effectiveness of Curcuminoids in Controlling Postoperative Pain Following Total Laparoscopic Hysterectomy,liposomal curcumin,['liposomal curcumin'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Postoperative Care,"['Postoperative Care', 'Pain Management']",[],NOT_YET_RECRUITING,,2025-03-21,2026-01-15,"[{'measure': 'the visual analogue scale (VAS)', 'description': 'The primary goal was to assess the variation in postoperative pain levels recorded on the VAS (scored from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable) 24 hours after surgery', 'timeFrame': '24 hours after surgery'}]",[],1,20 Years,80 Years,FEMALE,True,Erzincan Military Hospital,OTHER,0,126.0,ESTIMATED,2025-09-01T16:18:25.988244,v2_robust,True,True,False,False,False,
NCT06132035,Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration,Phase I Clinical Study to Evaluate the Safety of CG-P5 Peptide Eye Drops (Self-administered and Topically Applied) in Patients Diagnosed With Age-related Wet Macular Degeneration,CG-P5 peptide,"['Aflibercept Injection [Eylea]', 'CG-P5 peptide', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Age-related Wet Macular Degeneration,['Age-related Wet Macular Degeneration'],"['Age-Related Macular Degeneration', 'Macular Degeneration', 'wAMD']",RECRUITING,,2023-12-22,2025-08,"[{'measure': 'The percentage of occurrence of Adverse Events (AE)', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'The number of Adverse Events (AE) that occurs', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Change in IOP with study drug compared to placebo', 'description': 'Mean change in intraocular pressure (IOP) with study drug compared to placebo from baseline to end of study', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Change in intraocular inflammation with study drug compared to placebo', 'description': 'Mean change in intraocular inflammation with study drug compared to placebo from baseline to end of study', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Incidence and severity of ocular and non-ocular adverse events of CG-P5 peptide eye drops and Placebo', 'description': 'Mean change in incidence and severity of ocular and non-ocular adverse events of CG-P5 peptide eye drops and Placebo with study drug compared to placebo from baseline to end of study', 'timeFrame': 'Day 0, Day 28, Day 56 & Day 84'}]","[{'measure': 'Change in best corrected visual acuity (BCVA) of study drug compared to Eylea® and placebo as measured by ≥15 Early ETDRS letter score at the end of 84 days', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Change in CNV area on fluorescence angiography with study drug compared to Eylea® and placebo on day 28, day 56 and day 84', 'timeFrame': 'Day 28, Day 56 & Day 84'}, {'measure': 'Mean decrease in central retinal thickness on SD-OCT with study drug compared to Eylea® and placebo from baseline to end of study', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Mean decrease in total macular volume on optical coherence tomography with study drug compared to Eylea® and placebo from baseline to end of study', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Proportion of patients with change in BCVA with study drug compared to Eylea® and placebo from baseline to end of study', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Number of patients with change in BCVA with study drug compared to Eylea® and placebo from baseline to end of study', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Proportion of patients with change in intraocular pressure (IOP) with study drug compared to Eylea® and placebo from baseline to end of study', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Number of patients with change in intraocular pressure (IOP) with study drug compared to Eylea® and placebo from baseline to end of study', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Proportion of patients with change in intraocular inflammation with study drug compared to Eylea® and placebo from baseline to end of study', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Number of patients with change in intraocular inflammation with study drug compared to Eylea® and placebo from baseline to end of study', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Proportion of patients with change in central retinal thickness with study drug compared to Eylea® and placebo from baseline to end of study', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Number of patients with change in central retinal thickness with study drug compared to Eylea® and placebo from baseline to end of study', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Proportion of patients with change in total macular volume with study drug compared to Eylea® and placebo from baseline to end of study', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Number of patients with change in total macular volume with study drug compared to Eylea® and placebo from baseline to end of study', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Change from Baseline in Choroidal Neovascularization (CNV) area as measured by Fluorescein Angiography (FA) over the study duration', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Change from Baseline in Central Subfield Thickness (CST) as measured by spectral domain optical coherence tomography (SD-OCT) over the study duration', 'timeFrame': 'Screening, Day 0, Day 28, Day 56 & Day 84'}, {'measure': 'Area under the concentration-time curve from dosing (time 0) to time t [AUC(0-t)]', 'description': 'Pharmacokinetic profile of CG-P5 peptide eye drops measured by AUC(0-t)', 'timeFrame': 'Day 0 & Day 84'}, {'measure': 'Maximum Plasma Concentration [Cmax]', 'description': 'Pharmacokinetic profile of CG-P5 peptide eye drops measured by Cmax', 'timeFrame': 'Day 0 & Day 84'}, {'measure': 'Time of peak plasma concentration [Tmax]', 'description': 'Pharmacokinetic profile of CG-P5 peptide eye drops measured by Tmax', 'timeFrame': 'Day 0 & Day 84'}, {'measure': 'Half-life [t½]', 'description': 'Pharmacokinetic profile of CG-P5 peptide eye drops measured by t½', 'timeFrame': 'Day 0 & Day 84'}]",25,50 Years,,ALL,False,Caregen Co. Ltd.,INDUSTRY,1,45.0,ESTIMATED,2025-09-01T16:18:25.988254,v2_robust,True,True,False,False,True,
NCT03378635,A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects,"A Phase 3, Randomized, Double-blind, Parallel Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus Compared to Placebo and With Reference to GlucaGen",Dasiglucagon,"['Dasiglucagon', 'GlucaGen HypoKit', 'Placebo', 'GlucaGen', 'ZP4207', 'Placebo for dasiglucagon']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypoglycemia,"['Hypoglycemia', 'Diabetes Mellitus, Type 1']","['Dasiglucagon', 'Glucagon analog']",COMPLETED,,2017-12-07,2018-05-25,"[{'measure': 'Time to Plasma Glucose Recovery', 'description': 'Plasma glucose recovery is defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose. The outcome measure used a Kaplan-Meier estimate with 95% confidence interval. Treatment groups without censoring utilized a distribution free method to compute the confidence interval for median time.', 'timeFrame': '0-45 minutes after dosing'}]","[{'measure': 'Plasma Glucose Recovery', 'description': 'Plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after study drug injection without administration of rescue IV glucose. Plasma glucose recovery was defined as the first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose.', 'timeFrame': '0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injection'}, {'measure': 'Plasma Glucose Changes From Baseline', 'description': 'Plasma glucose changes from baseline at 30 minutes, 20 minutes, 15 minutes and 10 minutes after study drug injection without administration of rescue intravenous glucose', 'timeFrame': '0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injection'}, {'measure': 'Time to Target', 'description': 'Time to first plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) without administration of rescue intravenous glucose. The outcome measure used a Kaplan-Meier estimate with 95% confidence interval. Treatment groups without censoring utilized a distribution free method to compute the confidence interval for median time.', 'timeFrame': '0-45 minutes after dosing'}, {'measure': 'Pharmacodynamics - Area Under the Effect Curve', 'description': 'Plasma glucose response as area under the effect curve (AUE) above baseline from time zero to 30 minutes. Samples were collected pre-dose, and at 4, 6, 8, 10, 12, 15, 17, 20, 25 and 30 minutes after dosing.', 'timeFrame': '0-30 minutes after dosing'}, {'measure': 'Pharmacokinetics - Area Under the Plasma Concentration Curve', 'description': 'Area under the drug concentration curve from time zero to 90 minutes, AUC0-90min. To calculate the AUC the standard trapezoidal method was used, based on actual rather than nominal time points. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.', 'timeFrame': '0-90 minutes after dosing'}, {'measure': 'Pharmacokinetics - Area Under the Plasma Concentration Curve', 'description': 'Area under the drug concentration curve from time zero to 120 minutes, AUC0-120min. To calculate the AUC the standard trapezoidal method was used, based on actual rather than nominal time points. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.', 'timeFrame': '0-120 minutes after dosing'}, {'measure': 'Pharmacokinetics - Maximum Plasma Concentration', 'description': 'Maximum plasma drug concentration (Cmax). Maximum plasma drug concentration was determined as the maximum of all valid plasma dasiglucagon/glucagon concentrations. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.', 'timeFrame': '0-120 minutes after dosing'}, {'measure': 'Pharmacokinetics - Time to Maximum Plasma Concentration', 'description': 'Time to maximum plasma drug concentration (tmax). Median Tmax was determined as the time point where the maximum of all valid plasma dasiglucagon/glucagon concentration measurements for each measurement series was observed. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.', 'timeFrame': '0-120 minutes after dosing'}, {'measure': 'Immunogenicity - Occurence of Anti-drug Antibodies', 'description': 'Occurence of antibodies against dasiglucagon/GlucaGen', 'timeFrame': '28 days'}, {'measure': 'Rescue Infusion of IV Glucose During the Hypoglycemic Clamp Procedure', 'description': 'Number of patients receiving administration of rescue infusion of IV glucose during the hypoglycemic clamp procedure. IV = intravenous', 'timeFrame': '0-45 minutes after dosing'}, {'measure': 'Time to First Rescue Infusion of IV Glucose', 'description': 'Time to first rescue administration of rescue infusion of IV glucose. IV = intravenous', 'timeFrame': '0-45 minutes after dosing'}]",12,18 Years,75 Years,ALL,False,Zealand Pharma,INDUSTRY,0,170.0,ACTUAL,2025-09-01T16:18:25.988264,v2_robust,True,True,True,False,False,
NCT06589635,"A Drug-Drug Interaction (DDI) Study of ADC189 With Itraconazole in Healthy, Adult Subjects","A Single-center, Open-label and Sequential-dosing Clinical Trial Investigating the Drug Interaction Between ADC-189 Tablet and Itraconazole Capsule in Healthy Adult Subjects",ADC-189 and Itraconazole,"['ADC-189 and Itraconazole', 'Part 1: Single dose of ADC-189; Part 2: Itraconazole with single dose of ADC-189']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Adults,['Healthy Adults'],[],COMPLETED,,2024-07-16,2024-09-11,"[{'measure': 'AUC[0-∞] of ADC-189', 'description': 'Pharmacokinetics (PK) parameter: Area under the curve from time 0 hour to ∞', 'timeFrame': 'Part 1: Day 1 to Day 15; Part 2: Day 21 to Day 40'}, {'measure': 'Cmax of ADC-189', 'description': 'PK parameter: Maximum observed concentration', 'timeFrame': 'Part 1: Day 1 to Day 15; Part 2: Day 21 to Day 40'}, {'measure': 'AUC[0-t] of ADC-189', 'description': 'PK parameter: Area under the curve from time 0 to 336 hour', 'timeFrame': 'Part 1: Day 1 to Day 15; Part 2: Day 21 to Day 40'}, {'measure': 'Adverse events (AEs)', 'description': 'Number of subjects reporting AEs', 'timeFrame': 'Day 1 to Day 43'}]",[],4,18 Years,55 Years,ALL,True,"Jiaxing AnDiCon Biotech Co.,Ltd",INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:25.988379,v2_robust,True,True,True,False,True,
NCT04629508,"To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)","A 2-Part, Phase 2, Open-Label Study of the Safety, Tolerability, and Efficacy of Itacitinib Immediate Release in Participants With Primary Myelofibrosis or Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis) Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy",itacitinib,"['itacitinib', 'INCB039110']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Myelofibrosis,"['Myelofibrosis', 'Polycythemia Vera', 'Thrombocythemia']","['Myelofibrosis', 'Post-PV Myelofibrosis', 'Post-ET Myelofibrosis', 'LIMBER', 'LIMBER-213', 'MF', 'Myeloproliferative Neoplasms']",COMPLETED,,2021-07-12,2023-08-24,"[{'measure': 'Part 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)', 'description': 'An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug-related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as an AE that was reported for the first time or the worsening of a pre-existing event after the first dose of study treatment.', 'timeFrame': 'up to 724 days'}, {'measure': 'Part 1: Number of Participants With Any Grade 3 or Higher TEAE', 'description': 'A TEAE was defined as an AE that was reported for the first time or the worsening of a pre-existing event after the first dose of study treatment. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grades 1 through 5. The investigator made an assessment of intensity for each AE and SAE reported during the study and assigned it to 1 of the following categories: Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.', 'timeFrame': 'up to 724 days'}, {'measure': 'Part 2: Splenic Response Rate (SRR) at Week 24', 'description': 'SRR was defined as the percentage of participants who had a reduction in spleen volume (by imaging) of at least 35% when compared with Baseline.', 'timeFrame': 'Baseline; Week 24'}]","[{'measure': 'Part 2: Number of Participants With Any TEAE', 'description': 'An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug-related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as an AE that was reported for the first time or the worsening of a pre-existing event after the first dose of study treatment.', 'timeFrame': 'up to at least 24 weeks'}, {'measure': 'Part 2: Number of Participants With Any Grade 3 or Higher TEAE', 'description': 'A TEAE was defined as an AE that was reported for the first time or the worsening of a pre-existing event after the first dose of study treatment. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grades 1 through 5. The investigator made an assessment of intensity for each AE and SAE reported during the study and assigned it to 1 of the following categories: Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.', 'timeFrame': 'up to at least 24 weeks'}, {'measure': 'Part 2: Total Symptom Score (TSS) Response Rate at Week 24', 'description': 'TSS response was defined as the percentage of participants who achieved at least 50% reduction in TSS over the 28 days immediately before the end of Week 24 compared with the 7 days immediately before the initiation of itacitinib immediate release (aseline).B', 'timeFrame': 'Baseline; Week 24'}, {'measure': 'Part 2: Mean Change (From Day 1 Versus Week 12 and Week 24) in the 5 Multi-item Functional Scale Scores and the Multi-item Global Health Status Scale Score (EORTC QLQ-C30)', 'description': 'The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) was to be used to assess the improvement in quality of life.', 'timeFrame': 'Baseline; Weeks 12 and 24'}, {'measure': 'Part 2: Percentage of Participants Categorized as Improved on the Week 24 Patient Global Impression of Change (PGIC)', 'description': ""The PGIC consists of a single question pertaining to a participant's overall status since the start of the study. The questionnaire gives participants 7 options to describe their overall status including: very much improved, much improved, minimally improved, no change, minimally worse, much worse, and very much worse."", 'timeFrame': 'Baseline; Week 24'}]",8,18 Years,,ALL,False,Incyte Corporation,INDUSTRY,0,4.0,ACTUAL,2025-09-01T16:18:25.988829,v2_robust,True,True,True,False,True,
NCT00218608,Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone,Disulfiram for Cocaine Abuse in Methadone- Patients,Disulfiram,"['Antabuse', 'Disulfiram']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Cocaine-Related Disorders,"['Cocaine-Related Disorders', 'Opioid-Related Disorders']",['Cocaine Abuse'],COMPLETED,,2001-04,2007-01,"[{'measure': 'Cocaine use', 'description': 'Urine toxicology screens were conducted thrice-weekly for 14 weeks.', 'timeFrame': '14 wks'}]",[],1,18 Years,65 Years,ALL,True,University of Arkansas,OTHER,1,158.0,ACTUAL,2025-09-01T16:18:25.988866,v2_robust,True,True,True,False,False,
NCT05383625,Gardasil Versus Cervarix in the Treatment of Warts,Quadrivalent and Bivalent Human Papilloma Virus Vaccines in the Treatment of Common Recalcitrant Warts,"Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine","['Saline', 'Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine', 'Bivalent Human Papilloma Virus Vaccine']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Verruca Viral,['Verruca Viral'],[],COMPLETED,,2020-09-01,2021-12-01,"[{'measure': 'Therapeutic response', 'description': 'The percentage of patients in each group achieving complete, partial or no response at the end of the treatment sessions', 'timeFrame': 'Through study completion for a maximum of 12 weeks, evaluation held at two weeks interval and at the end of treatment sessions (12th week visit)'}]","[{'measure': 'Safety measure', 'description': 'Immediate adverse events recorded by the treating physician within 1 hour post injection', 'timeFrame': 'Through study completion every treatment session held at two weeks interval for a maximum of 5 sessions'}, {'measure': 'Safety measure', 'description': 'Delayed adverse events reported by the patients in between sessions', 'timeFrame': 'Through study completion for a maximum of 12 weeks held every two weeks till the end of the treatment sessions (12th week visit)'}, {'measure': 'Recurrence', 'description': 'Percentage of patients experiencing recurrences in each group', 'timeFrame': '6 months following the end of treatment sessions'}]",4,18 Years,,ALL,False,Zagazig University,OTHER_GOV,0,50.0,ACTUAL,2025-09-01T16:18:25.988963,v2_robust,True,True,True,False,True,
NCT04573725,Early Phase 2 Clinical Study of TS-142 in Patients with Insomnia Disorder,Early Phase 2 Clinical Study of TS-142 in Patients with Insomnia Disorder,TS-142,"['TS-142', 'Dose-matched Placebo to TS-142']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Insomnia Disorder,['Insomnia Disorder'],[],COMPLETED,,2017-07-07,2019-02-13,"[{'measure': 'LS mean difference of LPS from placebo', 'description': 'LPS is defined as the duration of time from the light off to the first persistent (10 consecutive minutes) sleep episode as measured by overnight PSG.', 'timeFrame': 'Day 1'}, {'measure': 'LS mean difference of WASO from placebo', 'description': 'WASO is defined as the time spent in wakefulness from the first persistent (10 consecutive minutes) sleep episode to the light on as measured by overnight PSG.', 'timeFrame': 'Day 1'}]","[{'measure': 'LS mean difference of TST from placebo', 'description': 'TST is defined as the time spent in sleep from the light off to the light on as measured by overnight PSG.', 'timeFrame': 'Day 1'}]",3,20 Years,64 Years,ALL,False,"Taisho Pharmaceutical Co., Ltd.",INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:25.988986,v2_robust,True,True,True,False,False,
NCT03146325,Helicobacter Pylori and Body Iron in Adults,Helicobacter Pylori and Body Iron in Adults,BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE,"['PYLERA', 'OTC OMEPRAZOLE', 'BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE', 'MATCHING PLACEBO']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Helicobacter Pylori Infection,['Helicobacter Pylori Infection'],['H. pylori infection'],WITHDRAWN,Study was not funded and PI has left the institution,2012-11,2016-08,"[{'measure': 'Serum Ferritin', 'description': 'Changes from baseline at 6 months after completing therapy, controlled by C-reactive protein', 'timeFrame': '6 months after completing therapy'}]","[{'measure': 'Body Iron', 'description': 'Changes from baseline estimated by the ratio of log base 10 of serum transferrin receptor over serum ferritin', 'timeFrame': '6 months after completing therapy'}, {'measure': 'Other markers of iron stores, and erythropoiesis', 'description': 'Changes from baseline transferrin saturation, zinc protoporphyrin to estimate free-erythrocyte protoporphyrin, and hemoglobin', 'timeFrame': '6 months after completing therapy'}]",3,18 Years,64 Years,ALL,True,"The University of Texas Health Science Center, Houston",OTHER,1,0.0,ACTUAL,2025-09-01T16:18:25.989010,v2_robust,True,True,False,True,False,Study was not funded and PI has left the institution
NCT01445925,Substrate Ablation and Remodelling in Non-paroxysmal Atrial Fibrillation (AF),Substrate Modification With Ablation and Antiarrhythmic Drugs in Non-Paroxysmal Atrial Fibrillation,Pharmacological Substrate modification,['Pharmacological Substrate modification'],1,INTERVENTIONAL,['NA'],,,Atrial Fibrillation,['Atrial Fibrillation'],[],UNKNOWN,,2011-09,2014-11,"[{'measure': 'Freedom from atrial fibrillation/ atrial tachycardia at 6 months following a single procedure.', 'description': 'Defined as \\>30 sec of AF/ atrial tachycardia identified on ECG or ambulatory ECG monitoring following a 3 month blanking period.', 'timeFrame': '12 months'}]",[],1,18 Years,,ALL,False,Liverpool Heart and Chest Hospital NHS Foundation Trust,OTHER,0,130.0,ESTIMATED,2025-09-01T16:18:25.989107,v2_robust,True,True,False,False,False,
NCT04424225,Visual Surround Suppression and Perceptual Expectation Under Psilocybin,Visual Surround Suppression and Perceptual Expectation Under Psilocybin,Psilocybin,"['Niacin', 'Vitamin B3', 'Psilocybin']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Perception Disturbance,"['Perception Disturbance', 'Visual Suppression', 'Psychedelic Experiences']",[],TERMINATED,Could not secure additional funding to continue the study. Pilot phase of study completed.,2021-08-30,2023-09-01,"[{'measure': 'Psychophysical Descrimination Threshold - No Surround Suppression (NS) Dose 1', 'description': 'No surround suppression condition for visual psychophysics tasks, consisting of perceptual judgments (e.g., subject reported which of two visual stimuli presented appeared to have higher contrast). Based on these responses, psychophysical discrimination thresholds are calculated using an adaptive staircase technique and reported in units of percent contrast.\n\n.', 'timeFrame': '3 hours after dose 1'}, {'measure': 'Psychophysical Descrimination Threshold - No Surround Suppression (NS) Dose 2', 'description': 'No surround suppression condition for visual psychophysics tasks, consisting of perceptual judgments (e.g., subject reported which of two visual stimuli presented appeared to have higher contrast). Based on these responses, psychophysical discrimination thresholds are calculated using an adaptive staircase technique and reported in units of percent contrast.\n\n.', 'timeFrame': '3 hours after dose 2'}, {'measure': 'Psychophysical Descrimination Threshold - Orthogonal Surround Suppression (OS) Dose 1', 'description': 'Orthogonal surround suppression condition for visual psychophysics tasks, consisting of perceptual judgments (e.g., subject reported which of two visual stimuli presented appeared to have higher contrast). Based on these responses, psychophysical discrimination thresholds are calculated using an adaptive staircase technique and reported in units of percent contrast. Orthogonal surround suppression condition (OS).', 'timeFrame': '3 hours after dose 1'}, {'measure': 'Psychophysical Descrimination Threshold - Orthogonal Surround Suppression (OS) Dose 2', 'description': 'Orthogonal surround suppression condition for visual psychophysics tasks, consisting of perceptual judgments (e.g., subject reported which of two visual stimuli presented appeared to have higher contrast). Based on these responses, psychophysical discrimination thresholds are calculated using an adaptive staircase technique and reported in units of percent contrast. Orthogonal surround suppression condition (OS).', 'timeFrame': '3 hours after dose 2'}, {'measure': 'Psychophysical Descrimination Threshold - Parallel Surround Suppression (PS) Dose 1', 'description': 'Parallel surround suppresion condition for visual psychophysics tasks consisting of perceptual judgments (e.g., subject reported which of two visual stimuli presented appeared to have higher contrast). Based on these responses, psychophysical discrimination thresholds are calculated using an adaptive staircase technique and reported in units of percent contrast. Parallel surround suppression condition (PS).\n\n.', 'timeFrame': '3 hours after dose 1'}, {'measure': 'Psychophysical Descrimination Threshold - Parallel Surround Suppression (PS) Dose 2', 'description': 'Parallel surround suppresion condition for visual psychophysics tasks consisting of perceptual judgments (e.g., subject reported which of two visual stimuli presented appeared to have higher contrast). Based on these responses, psychophysical discrimination thresholds are calculated using an adaptive staircase technique and reported in units of percent contrast. Parallel surround suppression condition (PS).\n\n.', 'timeFrame': '3 hours after dose 2'}]",[],6,25 Years,65 Years,ALL,True,University of Minnesota,OTHER,1,10.0,ACTUAL,2025-09-01T16:18:25.989136,v2_robust,True,True,False,True,False,Could not secure additional funding to continue the study. Pilot phase of study completed.
NCT05291325,Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy,"Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy: a Multicenter, Randomized, Controlled Clinical Study",3L PEG + Linaclotide,"['3L PEG', '3L PEG + Linaclotide', '2L PEG + Linaclotide']",3,INTERVENTIONAL,['NA'],,,Bowel Preparation for Colonoscopy,['Bowel Preparation for Colonoscopy'],"['Linaclotide', 'Bowel preparation', 'colonoscopy']",COMPLETED,,2022-05-25,2024-04-28,"[{'measure': 'Bowel preparation adequate rate', 'description': 'The proportion of participants with all colon segment scores (right colon, transverse colon, left colon) were ≥ 2 according to Boston Bowel Preparation Scale (BBPS) .', 'timeFrame': 'within 10 minute after viewing colonoscopy video.'}]","[{'measure': 'Boston bowel preparation scale score', 'description': 'The BBPS scoring rules: 0, unprepared colon segment with mucosa not seen because of solid stool that cannot be cleared; 1, portion of mucosa of the colon segment seen, but other areas of the colon segment are not well seen because of staining, residual stool, and/or opaque liquid; 2, minor amount of residual staining, small fragments of stool, and/or opaque liquid, but mucosa of colon segment is seen well; 3, entire mucosa of colon segment seen well, with no residual staining, small fragments of stool, or opaque liquid. the higher the score, the better the quality of bowel preparation. 3 intestinal segments were scored separately: the right side of the colon, the transverse section of the colon, and the left side of the colon. Total BBPS score 0-9, the higher the score, the better the quality of bowel preparation.', 'timeFrame': 'Within 10 minute after viewing colonoscopy video.'}, {'measure': 'Aronchick Scale', 'description': 'Overall bowel preparation was scored prior to irrigation or suction. The Aronchick Scale scoring rules: 1, excellent, a small amount of liquid, 95% mucous membrane is visible; 2, good, plenty of clear fluid, covering 5%-25% of mucous membrane, 90% mucous membrane is visible; 3, medium, semi-solid manure that cannot be sucked out or washed away, 90% mucous membrane is visible; 4, poor, semi-solid manure that cannot be sucked out or washed away, 90% mucous membrane is visible; 5, inadequate, repeated bowel preparation or reexamination is required. Total Aronchick score 1-5, the lower the score, the better the quality of bowel preparation.', 'timeFrame': 'Within 10 minute after viewing colonoscopy video.'}, {'measure': 'Bowel preparation excellent rate', 'description': 'The proportion of participants with total score ≥ 8 according to Boston Bowel Preparation Scale.', 'timeFrame': 'Within 10 minute after viewing colonoscopy video.'}, {'measure': 'Bowel preparation completion rate assessed by questionnaire survey', 'description': 'Proportion of subjects with laxative intake greater than 90% of the required amount in protocol.', 'timeFrame': 'Immediately after questionnaire survey.'}, {'measure': 'Subjects satisfaction rate assessed by questionnaire survey', 'description': 'Proportion of subjects satisfacted with the whole intestinal preparation process. Subjects satisfaction was divided into four grades: 4, very satisfied; 3, moderately satisfied; 2, moderately dissatisfied; 1, very dissatisfied. Subjects in grades 3 and 4 were considered satisfied; subjects in grades 1 and 2 were considered dissatisfied.', 'timeFrame': 'Immediately after questionnaire survey.'}, {'measure': 'Endoscopists satisfaction with the quality of bowel preparation', 'description': 'Proportion of endoscopists satisfacted with the quality of bowel preparation during colonoscopy. Endoscopists satisfaction was divided into four grades: 4, very satisfied; 3, moderately satisfied; 2, moderately dissatisfied; 1, very dissatisfied. Subjects in grades 3 and 4 were considered satisfied; subjects in grades 1 and 2 were considered dissatisfied.', 'timeFrame': 'Immediately after colonoscopy.'}, {'measure': 'Adenoma detection rate', 'description': 'The adenoma detection rate was calculated as the number of colonoscopies with at least one adenoma detected divided by the total number of colonoscopies in the group. Adenomatous polyps must be confirmed by pathological findings.', 'timeFrame': '14 days after colonosopy.'}, {'measure': 'Polyp detection rate', 'description': 'The polyp detection rate was calculated as the number of colonoscopies with at least one polyp detected divided by the total number of colonoscopies in the group.', 'timeFrame': 'Immediately after colonoscopy.'}, {'measure': 'Incidence of adverse events assessed by questionnaire survey', 'description': 'Proportion of subjects with adverse events occuring in intestinal preparation.', 'timeFrame': 'Immediately after questionnaire survey.'}, {'measure': 'Drug compliance in linaclotide group', 'description': 'Proportion of subjects Taking 3 linaclotide capsules according to the protocol in linaclotide group.', 'timeFrame': 'Immediately after questionnaire survey.'}]",11,18 Years,75 Years,ALL,True,Changhai Hospital,OTHER,26,1607.0,ACTUAL,2025-09-01T16:18:25.989255,v2_robust,True,True,True,False,True,
NCT01169025,Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients,Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients,Ketamine,"['Sublimaze', 'Durogesic', 'Fentanil', 'Actiq', 'Fentora', 'Ketamine hydrochloride', 'Onsolis', 'Ketamine', 'Duragesic', 'Ketalar', 'Fentanyl', 'Instanyl']",12,INTERVENTIONAL,['NA'],,,Trauma,"['Trauma', 'Pain']","['Analgesia', 'Pain']",WITHDRAWN,,2012-09,2014-10,"[{'measure': 'Change in NRS pain scores', 'description': 'The primary outcome measure will be the change in NRS pain scores at ten minutes compared between the subjects administered ketamine and those administered fentanyl.', 'timeFrame': 'Assessed every 6 months.'}]","[{'measure': 'Rates of adverse events', 'description': 'Includes comparisons of clinically significant complications between the two regimens: post-administration respiratory depression as evidenced by either a step up in supplemental oxygen requirements or the need for an airway intervention; episodes of hypotension or hypertension; significant tachycardia; new subjective participant complaints of dysphoria, anxiety, or agitation at any time following drug administration.', 'timeFrame': 'Assessed every 6 months'}, {'measure': 'Change in NRS pain scores over time', 'description': 'Evaluate the differences in the slope of the NRS pain scores over time.', 'timeFrame': '24 months from start of enrollment'}, {'measure': 'Amount of fentanyl required', 'description': ""Measurement of the total amount of fentanyl/kg body weight/minute of flight that was required to treat patients' pain."", 'timeFrame': '24 months from start of enrollment'}, {'measure': 'Participant satisfaction', 'description': 'Overall research participant satisfaction with their level of pain relief at the end of the flight.', 'timeFrame': '24 months from start of enrollment'}, {'measure': 'Pain Recall', 'description': ""The subjective ranking of pain recall in comparison to other aspects of the patient's overall episode of care (pre-hospital, emergency department, inpatient, and post-discharge care), as measured at 30 days."", 'timeFrame': '24 months from start of enrollment'}]",6,18 Years,,ALL,False,University of Utah,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:25.989392,v2_robust,True,True,False,True,True,
NCT06457425,A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis,"An Open-Label, Positive Drug-Controlled, Parallel, Multicenter Phase II Clinical Trial of the Efficacy, Safety, and Pharmacokinetics of Flonoltinib Maleate Tablets in Patients With Intermediate to High-Risk Myelofibrosis",Flonoltinib 50mg,"['Flonoltinib 50mg', 'Ruxolitinib', 'Flonoltinib 100mg']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,"MF,PMF,PPV-MF,PET-MF","['MF,PMF,PPV-MF,PET-MF']",[],RECRUITING,,2024-05-06,2026-07-06,"[{'measure': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline(Evaluation by IRC)', 'description': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline(Evaluation by IRC)', 'timeFrame': 'Week 24'}]","[{'measure': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by researcher)', 'description': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline(Evaluation by researcher)', 'timeFrame': 'Week 24'}, {'measure': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by researcher)', 'description': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by researcher)', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by IRC)', 'description': 'Percentage of subjects with ≥35% reduction in spleen volume from baseline( Evaluation by IRC)', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of subjects with ≥50% reduction in MPN-SAF TSS scale total symptom score', 'description': 'Percentage of subjects with ≥50% reduction in MPN-SAF TSS scale total symptom score', 'timeFrame': 'Week 24 and Week 12'}, {'measure': 'Objective response rate (ORR = CR + PR) per the IWG-MRT consensus criteria.', 'description': 'Objective response rate (ORR = CR + PR) per the IWG-MRT consensus criteria.', 'timeFrame': 'Week 24'}]",6,18 Years,,ALL,False,"Chengdu Zenitar Biomedical Technology Co., Ltd",INDUSTRY,0,75.0,ESTIMATED,2025-09-01T16:18:25.989407,v2_robust,True,True,False,False,False,
NCT04461925,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical Cord,Antibiotics,"['ceftriaxone and azithromycin capsules', 'Anticoagulant Therapy', 'Hormones', 'Еnoxaparin', 'dexamethasone', 'Antibiotics']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,COVID-19 Pneumonia,['COVID-19 Pneumonia'],"['Placenta-derived MMSCs', 'i/v infusions']",UNKNOWN,,2020-05-02,2021-12,"[{'measure': 'Changes of oxygenation index PaO2/FiO2, most conveniently the P/F ratio.', 'description': 'Improvement of pulmonary function. Arterial oxygen tension PaO2 (in mmHg)/fractional inspired oxygen FiO2 (expressed as a fraction, not a percentage), most conveniently the P/F ratio. The normal P/F ratio is \\~ 400-500 mmHg (\\~55-65 kPa). P/F ratio \\<300mmHg - sign of Acute Respiratory Distress Syndrome (ARDS)', 'timeFrame': 'up to 28 days'}, {'measure': 'Changes in length of hospital stay', 'description': 'Length of Hospital Stay', 'timeFrame': 'up to 28 days'}, {'measure': 'Changes in mortality rate', 'description': 'Marker for efficacy of treatment', 'timeFrame': 'up to 28 days'}]","[{'measure': 'Changes of С-reactive protein (CRP, mg/L)', 'description': 'Infection biomarker. Serum CRP levels can be used for early diagnosis of pneumonia, patients with severe pneumonia had high CRP levels.', 'timeFrame': 'At baseline, Day 1, Week 1, Week 2, Week 4, Week 8'}, {'measure': 'Evaluation of Pneumonia Improvement', 'description': 'CT assessment of pulmonary lesions and lung tissue changes', 'timeFrame': 'At baseline, Day 1, Week 1, Week 2, Week 4, Week 8'}, {'measure': 'Duration of respiratory symptoms (difficulty breathing, dry cough, fever, etc.)', 'description': 'Indirect response to lung function', 'timeFrame': 'At baseline, Day 1, Week 1, Week 2, Week 4, Week 8'}, {'measure': 'Peripheral blood count recovery time', 'description': 'Degree of infection', 'timeFrame': 'At baseline, Day 1, Week 1, Week 2, Week 4, Week 8'}]",7,18 Years,75 Years,ALL,False,Institute of Cell Therapy,INDUSTRY,1,30.0,ESTIMATED,2025-09-01T16:18:25.989494,v2_robust,True,True,False,False,False,
NCT00914576,Effect of Antioxidants on Oxygen Induced Vasoconstriction in Lipopolysaccharide (LPS) Induced Inflammatory Model in Humans,Effect of Antioxidants on Oxygen Induced Vasoconstriction in LPS Induced Inflammatory Model in Humans,Vitamin and mineral supplement,"['Vitamin and mineral supplement', 'LPS (US Standard)', 'Vitamac Day', 'Placebo', 'Escherichia coli Endotoxin', '100% Oxygen']",6,INTERVENTIONAL,['NA'],,,Healthy,['Healthy'],"['Endotoxin, Escherichia Coli', 'Retina', 'Regional Blood Flow']",COMPLETED,,2011-04,2013-07,"[{'measure': 'Retinal blood flow', 'timeFrame': '1 year'}]",[],1,18 Years,35 Years,MALE,True,Medical University of Vienna,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:25.989539,v2_robust,True,True,True,False,False,
NCT07086976,"A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Period and Long-term Extension to Assess the Efficacy and Safety of Rilzabrutinib in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)",rilzabrutinib,"['SAR444671', 'rilzabrutinib', 'placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Autoimmune Haemolytic Anaemia,['Autoimmune Haemolytic Anaemia'],[],RECRUITING,,2025-07-21,2029-12-26,"[{'measure': 'Proportion of participants achieving durable Hb response (DHR)', 'description': 'DHR is defined as an increase of Hb by ≥2 g/dL from baseline on at least two thirds of evaluable scheduled visits between Week 12 and Week 24 (inclusive) in the PAP in the absence of rescue medication and transfusion.', 'timeFrame': 'By Week 24'}]","[{'measure': 'Proportion of participants achieving overall Hb response (Response or Complete Response)', 'description': 'Response is defined as an increase in Hb by ≥2 g/dL from baseline in the absence of transfusion and rescue medication.\n\nComplete Response is defined as Hb ≥12 g/dL (women) or ≥13 g/dL (men) without evidence of hemolysis (ie, normal indirect bilirubin, lactate dehydrogenase \\[LDH\\], haptoglobin, and reticulocytes), in the absence of transfusion and rescue medication.', 'timeFrame': 'By Week 24'}, {'measure': 'The time taken (days) to achieve the first Hb increase by ≥2 g/dL from baseline during the PAP in the absence of transfusion and rescue medication', 'timeFrame': 'Until Week 24'}, {'measure': 'Change from baseline in fatigue total score as measured by Functional Assessment of Chronic Illness Therapy (FACIT) - fatigue', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Change from baseline in levels of LDH', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Proportion of participants requiring use of rescue therapy after Week 4 of treatment during the PAP', 'timeFrame': 'Until Week 24'}, {'measure': 'Change from baseline in dyspnea severity score as measured by FACIT-Dyspnea', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Incidence of treatment-emergent adverse events (TEAE), treatment-emergent serious adverse events (SAEs), treatment-emergent adverse events of special interest, as well as clinical laboratory evaluations, vital sign, physical exam, and electrocardiograms', 'timeFrame': 'Until Week 104'}]",8,18 Years,,ALL,False,Sanofi,INDUSTRY,0,90.0,ESTIMATED,2025-09-01T16:18:25.989590,v2_robust,True,True,False,False,True,
NCT03014076,Immunotherapy Vaccine and Herceptin in Breast Cancer,Phase Ib Trial of Combination Immunotherapy With HER2/Neu Peptide GP2 + GM-CSF Vaccine and Trastuzumab in Breast Cancer Patients,GP2 peptide + GM-CSF vaccine plus trastuzumab,"['Trastuzumab', 'GP2 peptide + GM-CSF vaccine plus trastuzumab', 'Herceptin']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Breastcancer,['Breastcancer'],[],COMPLETED,,2008-01,2017-01,"[{'measure': 'Treatment-Related Adverse Events as Assessed by CTCAE v4.0', 'description': 'Patients receiving treatment will be followed from baseline to completion of study for adverse events using CTCAE v4.0', 'timeFrame': '12 months'}]",[],1,18 Years,,FEMALE,True,"Cancer Insight, LLC",INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:25.989628,v2_robust,True,True,True,False,True,
NCT00143676,Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia,"A Double-blind, Randomized Placebo-controlled Study to Evaluate the Efficacy and Safety of TAK-475 50 mg, 100 mg, or Placebo When Co-administered With Atorvastatin (10 mg to 40 mg) in Subjects With Primary Hypercholesterolemia",Lapaquistat acetate and atorvastatin,"['TAK-475', 'Atorvastatin', 'Lapaquistat acetate and atorvastatin', 'TAK475', 'Lapaquistat', 'Lipitor']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypercholesterolemia,['Hypercholesterolemia'],"['Hyperlipidemia', 'Dyslipidemia', 'Drug Therapy']",COMPLETED,,2005-08,2006-08,"[{'measure': 'Change from Baseline in Low Density Lipoprotein cholesterol', 'timeFrame': 'Week 24 or Final Visit'}]","[{'measure': 'Adverse Events', 'timeFrame': 'Weeks: 2, 4, 8, 12, 16, 20, and 24 or Final Visit'}, {'measure': 'Physical Examination', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Safety Laboratory Tests', 'timeFrame': 'Weeks: 2, 4, 8, 12, 16, 20, and 24 or Final Visit'}, {'measure': 'Electrocardiogram assessments', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Best Corrected Visual Acuity results', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Vital Signs', 'timeFrame': 'Weeks: 2, 4, 8, 12, 16, 20, and 24 or Final Visit'}, {'measure': 'Change from Baseline in Triglycerides', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in Total Cholesterol', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in High Density Lipoprotein cholesterol', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in Very Low Density Lipoprotein cholesterol', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in apolipoprotein A1', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in apolipoprotein B', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in non- High Density Lipoprotein cholesterol', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density Lipoprotein cholesterol', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Change from Baseline in high-sensitivity C-reactive protein', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 1.813 mmol/L (70 mg/dL)', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 2.590 mmol/L (100 mg/dL)', 'timeFrame': 'Week 24 or Final Visit'}, {'measure': 'Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 3.367 mmol/L (130 mg/dL)', 'timeFrame': 'Week 24 or Final Visit'}]",21,18 Years,,ALL,False,Takeda,INDUSTRY,0,448.0,ACTUAL,2025-09-01T16:18:25.989639,v2_robust,True,True,True,False,True,
NCT00456976,Efficacy of Selegiline in Negative Symptoms of Schizophrenia,Efficacy of Selegiline Augmentation of Antipsychotic Medication to Treat Negative Symptoms in Inpatients With Chronic Schizophrenia,Selegiline,['Selegiline'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Schizophrenia,['Schizophrenia'],"['Seligiline', 'Negative symptoms', 'Schizopherenia']",COMPLETED,,2007-04,2007-09,[{'measure': 'decreasing in negative symptoms in case group'}],[],1,20 Years,65 Years,ALL,False,Tabriz University,OTHER,0,70.0,,2025-09-01T16:18:25.989709,v2_robust,True,True,True,False,False,
NCT04025476,Immune Profile of Acute VKH Patients PBMC,Clinical Observational Research on Changes of Peripheral Blood Mononuclear Cell（PBMC） Immunity and Expression Profile in Peripheral Blood of Different Course of of Vogt-Hoyanagi-Harada（VKH） Patients.,Steroids,['Steroids'],1,OBSERVATIONAL,[],,,VKH Syndrome,['VKH Syndrome'],['VKH; immune profile;'],UNKNOWN,,2019-07-20,2022-07-07,"[{'measure': 'T/B /NK(natural killer )/monocyte...etc, cell numbers of blood samples in VKH patients', 'description': 'use flow cytometry to count T/B /NK/monocyte...etc, cell numbers', 'timeFrame': 'one year'}, {'measure': 'T/B /NK/monocyte...etc cell subtype proportion in blood samples in VKH patients', 'description': 'use flow cytometry to measure T/B /NK/monocyte...etc cell subtype proportion', 'timeFrame': 'one year'}, {'measure': 'T/B /NK/monocyte...etc cell functional change in VKH patients', 'description': 'use ELISA(enzyme linked immunosorbent assay) to measure inflammatory cytokines level in peripheral blood', 'timeFrame': 'one year'}]","[{'measure': 'choroid and retinal thickness change in different course of VKH patients', 'description': 'Use OCT（optical coherence tomography） to measure choroid and retina thickness changes in macular zone of different course VKH patients', 'timeFrame': 'one year'}, {'measure': 'Use OCTA(optical coherence tomography angiography) to measure macular and optic disc vascular index', 'description': 'Use OCTA to measure macular and optic disc vascular index in different course VKH patients', 'timeFrame': 'one year'}, {'measure': 'Use Maia perimeter to measure macular integrality', 'description': 'Use Maia perimeter to measure macular integrality including light threshold and central fixation.', 'timeFrame': 'one year'}, {'measure': 'measure the Injury degree of choroid and retinal vessels', 'description': 'Use FFA(fluorescein fundus angiography)/ICG(Indocyanine Green Angiography) to measure the Injury degree of choroid and retinal vessels', 'timeFrame': 'one year'}]",7,18 Years,50 Years,ALL,True,"Aier School of Ophthalmology, Central South University",OTHER,0,48.0,ESTIMATED,2025-09-01T16:18:25.989716,v2_robust,False,True,False,False,False,
NCT06690476,"Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma","A Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma",Dose escalation(IPM514 monotherapy),"['Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)', 'Dose escalation(IPM514 monotherapy)', 'Dose expansion (IPM514 combined with tislelizumab)']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Esophageal Squamous Cell Carcinoma,['Esophageal Squamous Cell Carcinoma'],[],RECRUITING,,2024-10-10,2026-10,"[{'measure': 'Safety and tolerability', 'description': 'Dose escalation \\& Dose expansion：(1) Incidence and severity of adverse events (AEs), immune-related adverse events (irAEs), serious adverse events (SAEs) assessed by NCI-CTCAE v5.0. (2) The incidence and titer of anti-drug antibodies (ADA)', 'timeFrame': 'up to 12 months'}, {'measure': 'The MTD, if any, and RP2D', 'description': 'Dose escalation \\& Dose expansion：IPM514 will be determined based on safety, tolerability, PK, preliminary efficacy, and other available data', 'timeFrame': 'up to 12 months'}, {'measure': 'PK parameter', 'description': 'Dose escalation \\& Dose expansion：mRNA quantitation in blood by qPCR', 'timeFrame': 'up to 12 months'}, {'measure': 'the pCR rate', 'description': 'Neoadjuvant Treatment Cohort：The rate of pathological complete response', 'timeFrame': 'up to 12 months'}]","[{'measure': 'Objective response rate (ORR)', 'description': 'Dose escalation \\& Dose expansion：Objective response rate (ORR) per RECIST 1.1 criteria according to investigators assessment', 'timeFrame': 'up to 12 months'}, {'measure': 'disease control rate (DCR)', 'description': 'Dose escalation \\& Dose expansion：disease control rate (DCR) per RECIST 1.1 criteria according to investigators assessment', 'timeFrame': 'up to 12 months'}, {'measure': 'progression-free survival (PFS)', 'description': 'Dose escalation \\& Dose expansion：Progression free survival (PFS) rates', 'timeFrame': 'up to 12 months'}, {'measure': 'overall survival (OS)', 'description': 'Dose escalation \\& Dose expansion：Overall survival (OS) rates', 'timeFrame': 'up to 12 months'}, {'measure': 'duration of response (DOR)', 'description': 'Dose escalation \\& Dose expansion：Duration of response (DOR) per RECIST 1.1 criteria according to investigators assessment', 'timeFrame': 'up to 12 months'}, {'measure': 'the MPR rate', 'description': 'Neoadjuvant Treatment Cohort：The rate of major pathological response', 'timeFrame': 'up to 12 months'}, {'measure': 'the rate of R0 resection', 'description': 'Neoadjuvant Treatment Cohort：the rate of R0 resection', 'timeFrame': 'up to 12 months'}, {'measure': 'AE', 'description': 'Neoadjuvant Treatment Cohort：The incidence and severity of adverse events (AEs), immune-related adverse events (irAEs), and serious adverse events (SAEs) as evaluated according to NCI-CTCAE v5.0;', 'timeFrame': 'up to 12 months'}, {'measure': 'Surgical safety', 'description': 'Neoadjuvant Treatment Cohort：surgical complications within 30 days after surgery or during the postoperative hospital stay, length of hospital stay, reoperation rate, and 30-day postoperative mortality rate;', 'timeFrame': 'up to 12 months'}, {'measure': 'Biological responses', 'description': 'Neoadjuvant Treatment Cohort：(1) Lymphocyte subset analysis, including T/B/NK cell count and phenotyping of memory T cell; (2) TAA-specific T cell identification through tetramer and intracellular cytokine production via flow cytometry; (3) Immune responses of CTLs via IFN-γ ELISPOT; (4) Single-cell phenotypic analysis.', 'timeFrame': 'up to 12 months'}, {'measure': 'Predictive biomarkers', 'description': 'Neoadjuvant Treatment Cohort：including but not limited to tumor tissue antigen expression, minimal residual disease (MRD) and blood-based tumor mutational burden (bTMB)', 'timeFrame': 'up to 12 months'}]",15,18 Years,,ALL,False,Peking University,OTHER,0,74.0,ESTIMATED,2025-09-01T16:18:25.989741,v2_robust,True,True,False,False,True,
NCT05487976,Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor,A Phase III Clinical Study of the Efficacy and Safety of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitors,Recombinant human activated coagulation factor VII for injection,['Recombinant human activated coagulation factor VII for injection'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Hemophilia A,"['Hemophilia A', 'Hemophilia B']",[],UNKNOWN,,2022-04-28,2023-04,"[{'measure': 'Number of bleeding Effective rate of hemostasis', 'description': 'Hemostasis is effective after the bleeding event if the bleeding event has not received other treatment within 12 hours since the first treatment and achieved moderate or above remission (based on the four-point scoring standard)', 'timeFrame': 'Each new blood event was assessed within 12 hours of initial treatment'}, {'measure': 'Activity recovery of first dose', 'description': 'The peak coagulation factor VII activity measured within 1 hour after the end of the infusion was subtracted from the baseline coagulation factor VII activity and expressed as \\[IU/ml\\]/\\[IU/kg\\].', 'timeFrame': 'Within 1 hour of completion of infusion'}]","[{'measure': 'Number of bleeding effective rate of hemostasis within 8 hours', 'description': 'Excellent remission (based on the four-point scoring standard)', 'timeFrame': 'Each new blood event was assessed within 8 hours of initial treatment'}, {'measure': 'Number of bleeding effective rate continuous hemostatic', 'description': 'Moderate or above remission (based on grade 4 scoring criteria) without receiving other treatment within 24 hours after the occurrence of bleeding event is considered as effective hemostasis after the occurrence of bleeding event.', 'timeFrame': 'Each new blood event was assessed within 24 hours of initial treatment'}, {'measure': 'Activity recovery after repeated administration', 'description': 'The peak coagulation factor VII activity measured within 1 hour after the end of the infusion was subtracted from the baseline coagulation factor VII activity and expressed as \\[IU/ml\\]/\\[IU/kg\\].', 'timeFrame': 'Within 1 hour of completion of infusion'}, {'measure': 'Dose of injections for each new blood transfusion', 'description': 'Dose of injections for each new blood transfusion.The dose of injections (including average injection dose and total dose) of each new blood transfusion were recorded.', 'timeFrame': 'Up to 24 weeks.'}, {'measure': 'Number of injections for each new blood transfusion', 'description': 'Number of injections for each new blood transfusion.The number of injections of each new blood transfusion were recorded.', 'timeFrame': 'Up to 24 weeks.'}, {'measure': 'Coagulation tests', 'description': 'Coagulation tests: Changes of activated partial thromboplastin time (APTT).', 'timeFrame': 'First and week 24, within 30 minutes before the administration and 5 minutes after the completion of drug injection.'}, {'measure': 'Coagulation tests', 'description': 'Coagulation indicators: Changes of prothrombin time (PT).', 'timeFrame': 'First and week 24, within 30 minutes before the administration and 5 minutes after the completion of drug injection.'}, {'measure': 'Coagulation tests', 'description': 'Coagulation indicators: Changes of thrombin time(TT).', 'timeFrame': 'First and week 24, within 30 minutes before the administration and 5 minutes after the completion of drug injection.'}, {'measure': 'Coagulation tests', 'description': 'Coagulation indicators: Changes of fibrinogen (Fbg).', 'timeFrame': 'First and week 24, within 30 minutes before the administration and 5 minutes after the completion of drug injection.'}, {'measure': 'Coagulation tests', 'description': 'Coagulation indicators: thrombin production test (TGA):Changes of thrombin production potential (ETP) in TGA at each test time.', 'timeFrame': 'First and week 24，within 30 minutes before the administration and 5 minutes after the completion of drug injection.'}]",12,18 Years,65 Years,ALL,False,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",INDUSTRY,0,50.0,ESTIMATED,2025-09-01T16:18:25.989806,v2_robust,True,True,False,False,False,
NCT01924676,Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers,"An Open-label, Single-dose, Randomized, Three-way Crossover Study to Estimate the Effects of Food on Oxycodone Pharmacokinetics Following Oral 40 Mg Doses of PF-00345439 Formulation K and to Estimate Its Relative Bioavailability of Oxycodone Compared to PF-003454390 Formulation X in the Fasted State in Healthy Volunteers",Oxycodone,['Oxycodone'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['food effect', 'pharmacokinetics', 'bioavailability', 'oxycodone', 'management of moderate to severe pain']",COMPLETED,,2013-08,2013-10,"[{'measure': 'Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]', 'description': 'AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).', 'timeFrame': '0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48 hours post-dose'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'timeFrame': '0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48 hours post-dose'}]","[{'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)', 'description': 'Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)', 'timeFrame': '0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48 hours post-dose'}, {'measure': 'Concentration at time 24 hours (C24) of oxycodone, as data permit.', 'description': 'Concentration at time 24 hours (C24) of oxycodone, as data permit.', 'timeFrame': '0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48 hours post-dose'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax)', 'description': 'Time to Reach Maximum Observed Plasma Concentration (Tmax)', 'timeFrame': '0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48 hours post-dose'}, {'measure': 'Plasma Decay Half-Life (t1/2)', 'description': 'Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.', 'timeFrame': '0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48 hours post-dose'}]",6,18 Years,55 Years,ALL,True,Pain Therapeutics,INDUSTRY,0,18.0,ACTUAL,2025-09-01T16:18:25.989849,v2_robust,True,True,True,False,False,
NCT00841776,Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne,Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Moderate to Moderately Severe Facial Acne Vulgaris,Duac,"['Ziana gel', 'Duac']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Acne,['Acne'],"['Acne Vulgaris', 'Acne']",COMPLETED,,2007-08,2009-01,"[{'measure': 'Median Change in Total Propionibacterium Acne (P.Acne) Counts', 'description': 'Median change in total colony forming units of propionibacterium acne (P.acne) will be counted.', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, & 16'}]","[{'measure': 'Median Change in Clindamycin Resistant P. Acne.', 'description': 'Median change in total colony forming units of clindamycin resistant p. acne.', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16'}, {'measure': 'Median Change in Erythromycin-resistant P. Acne Counts', 'description': 'Total colony forming units of erythromycin-resistant p. acnes.', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, and 16'}, {'measure': 'Median Change in Total Acne Lesions', 'description': 'Median Change in Total Acne Lesions', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, and 16'}, {'measure': 'Median Change in Inflammatory Acne Lesion Counts', 'description': 'Median Change in Inflammatory Acne Lesion Counts', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, and 16'}, {'measure': 'Median Change in Noninflammaotry Acne Counts', 'description': 'Median Change in Noninflammaotry Acne Counts', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, and 16'}]",6,12 Years,,ALL,False,"Stiefel, a GSK Company",INDUSTRY,1,54.0,ACTUAL,2025-09-01T16:18:25.989868,v2_robust,True,True,True,False,False,
NCT00976976,"Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer: Adjuvant DXP","Phase 2 Study of Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer","docetaxel, capecitabine, cisplatin","['docetaxel, capecitabine, cisplatin', 'docetaxel,xeloda,cisplatin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Resected Advanced Gastric Cancer,['Resected Advanced Gastric Cancer'],['Resected advanced gastric cancer stage IIIB and IV'],COMPLETED,,2007-05,2011-09,"[{'measure': 'This protocol will evaluate the possible benefit of adjuvant docetaxel, capecitabine, and cisplatin combination chemotherapy in patients with resected gastric cancer pathologic stage IIIB and IV in terms of relapse free survival.', 'timeFrame': '5 years'}]","[{'measure': 'Investigate the safety profiles, patient tolerance, and overall survival in this population', 'timeFrame': '5 years'}]",2,18 Years,70 Years,ALL,False,Asan Medical Center,OTHER,0,46.0,ACTUAL,2025-09-01T16:18:25.989929,v2_robust,True,True,True,False,True,
NCT03907176,Herniorrhaphy Study for Opioid Elimination,"A Phase 3b, Randomized, Open-Label Study of HTX-011 as the Foundation of a Non-opioid, Multimodal Analgesic Regimen to Decrease Opioid Use Following Unilateral Open Inguinal Herniorrhaphy",HTX-011,"['Ibuprofen', 'Acetaminophen', 'HTX-011']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Analgesia,['Analgesia'],"['inguinal hernia', 'hernia', 'hernia surgery', 'postoperative pain', 'herniorrhaphy', 'multimodal analgesia']",COMPLETED,,2019-04-05,2021-11-22,"[{'measure': 'Proportion of subjects who do not receive an opioid prescription at discharge through the day 15 visit', 'timeFrame': 'Discharge through Day 15'}]","[{'measure': 'Proportion of subjects who do not receive an opioid prescription at discharge', 'timeFrame': 'At discharge'}, {'measure': 'Proportion of subjects who do not receive a postdischarge opioid prescription, through the Day 15 visit.', 'timeFrame': 'Postdischarge through Day 15'}, {'measure': 'Pain intensity scores at the time of discharge', 'timeFrame': 'At discharge'}, {'measure': 'Number of oxycodone pills taken between discharge and the Day 15 visit', 'timeFrame': 'Postdischarge through Day 15'}, {'measure': 'Mean TSQM-9 scores', 'timeFrame': 'Day 15 plus or minus 2 days'}]",6,18 Years,,ALL,False,Heron Therapeutics,INDUSTRY,0,115.0,ACTUAL,2025-09-01T16:18:25.990038,v2_robust,True,True,True,False,False,
NCT01309776,Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder,"Comparison of Tianeptine Versus Escitalopram for the Treatment of Depression and Cognitive Impairment in Patients With Major Depressive Disorder: A Randomized, Multicenter, Open-label Study",Tianeptine,"['Tianeptine', 'Stablon', 'Escitalopram']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Major Depressive Disorder,['Major Depressive Disorder'],[],COMPLETED,,2011-03,2012-09,"[{'measure': 'Changes in Hamilton Rating Scale for Depression(HAM-D)score from baseline', 'timeFrame': 'followed up to 2,4,8,12 weeks from baseline'}, {'measure': 'Changes in Korean version-California Verbal Learnign Test(K-CVLT) total score from baseline', 'timeFrame': 'followed up to 4,8,12 weeks from baseline'}, {'measure': 'Changes in Visual Continuous Performance Test(CPT) total score from baseline', 'timeFrame': 'followed up to 4,8,12 weeks from baseline'}, {'measure': 'Changes in Raven Progressive Matrices(RPM) total score from baseline', 'timeFrame': 'followed up to 4,8,12 weeks from baseline'}]","[{'measure': 'Changes in Hamilton Rating Scale for Anxiety(HAM-A) score from baseline', 'timeFrame': 'followed to 2,4,8,12 weeks from baseline'}, {'measure': 'Changes in Clinical Clinical Global Impression- improvement(CGI-I)', 'timeFrame': 'followed to 2,4,8,12 weeks from baseline'}, {'measure': 'Change in Response Rate from baseline', 'timeFrame': 'followed to 12 weeks from baseline'}, {'measure': 'Change in Mini-Mental status examination(MMSE) total score from baseline', 'timeFrame': 'followed to 4,8,12 weeks from baseline'}, {'measure': 'Change in Sexual Function Scale', 'timeFrame': 'followed to 2,4,8,12 weeks from baseline'}, {'measure': 'Change in Clinical Global Impression- severity(CGI-S)', 'timeFrame': 'followed to 2,4,8,12 weeks from baseline'}, {'measure': 'Change in Remission Rate from baseline', 'timeFrame': 'followed to 12 weeks from baseline'}]",11,40 Years,,ALL,False,Samsung Medical Center,OTHER,0,164.0,ACTUAL,2025-09-01T16:18:25.990240,v2_robust,True,True,True,False,False,
NCT02282917,Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma,Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma,AR-42,"['AR-42', 'OSU-HDAC42']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Vestibular Schwannoma,"['Vestibular Schwannoma', 'Meningioma', 'Acoustic Neuroma', 'Neurofibromatosis Type 2']","['NF2', 'Vestibular Schwannoma', 'Schwannoma', 'Meningioma']",TERMINATED,Drug manufacturing logistics; lack of access to drug supply,2015-12,2021-01-04,"[{'measure': 'Ratio of Phospho-AKT (p-AKT) to AKT After 3 Weeks of Oral AR-42', 'description': 'The phospho-AKT/AKT ratio was used to estimate the activity of AKT, a kinase, at the core of resected tumors. Quantitation of the normalized p-AKT/AKT ratio is depicted as a percentage relative to the untreated VS2 set as 100%. For example, a value under 100% indicates a lower level of AKT activity relative to untreated VS2 tumors. Phosphorylated AKT, or phospho-AKT, is the activated form of AKT. These measurements were derived from the core of the resected tumors.', 'timeFrame': '3 weeks'}, {'measure': 'Peripheral Phospho-AKT (p-AKT) to AKT Ratio After 3 Weeks of Oral AR-42', 'description': 'The phospho-AKT/AKT ratio was used to estimate the activity of AKT, a kinase, at the core of resected tumors. Quantitation of the normalized p-AKT/AKT ratio is depicted as a percentage relative to the untreated VS2 set as 100%. For example, a value under 100% indicates a lower level of AKT activity relative to untreated patients. Phosphorylated AKT, or phospho-AKT, is the activated form of AKT. These measurements were derived from the periphery of the resected tumors.', 'timeFrame': '3 weeks'}]","[{'measure': 'AR-42 Plasma Concentration', 'description': 'Steady-state plasma concentrations of AR-42 at the time of tumor resection are provided.', 'timeFrame': '1 week'}, {'measure': 'AR-42 Tumor Concentration (Capsule)', 'description': 'Concentrations of AR-42 at the tumor capsule are provided.', 'timeFrame': '1 week'}, {'measure': 'AR-42 Tumor Concentration (Center)', 'description': 'Intra-tumor concentrations of AR-42 at the tumor center are reported.', 'timeFrame': '1 week'}, {'measure': 'AR-42 Tumor Concentration (Capsule/Plasma)', 'description': 'Capsule/plasma intra-tumor AR-42 concentrations are provided as a ratio.', 'timeFrame': '1 week'}, {'measure': 'AR-42 Tumor Concentration (Center/Plasma)', 'description': 'Center/plasma intra-tumoral AR-42 concentrations are provided as a ratio.', 'timeFrame': '1 week'}]",7,18 Years,,ALL,False,Massachusetts Eye and Ear Infirmary,OTHER,5,7.0,ACTUAL,2025-09-01T16:18:25.990283,v2_robust,True,True,False,True,False,Drug manufacturing logistics; lack of access to drug supply
NCT02198417,Metformin Treatment in Polycystic Ovary Syndrome (PCOS),Effects of Metformin on Mitochondrial Function in Polycystic Ovary Syndrome,Metformin ER,"['Glucophage', 'Metformin ER']",2,INTERVENTIONAL,['NA'],,,Polycystic Ovary Syndrome,['Polycystic Ovary Syndrome'],"['Polycystic Ovary Syndrome', 'PCOS', 'Acne', 'Infertility', 'Irregular menses', 'Irregular period', 'Mitochondria', 'Metabolism']",UNKNOWN,,2014-07,2020-12,"[{'measure': 'Muscle Metabolism/Mitochondrial Function', 'description': 'The change in mitochondrial activity before and after metformin treatment will be analyzed in relationship to the clinical response to 3 months of metformin treatment (i.e., clinical response to metformin = changes in glucose metabolism, hormone levels, and ovulation response)', 'timeFrame': '3 months'}]","[{'measure': 'Genetic risk variants affecting mitochondrial function/metabolism', 'description': 'Blood will be analyzed for differences in genes between patients and its relationship to mitochondrial function.', 'timeFrame': '3 months'}]",2,18 Years,40 Years,FEMALE,False,Massachusetts General Hospital,OTHER,2,20.0,ESTIMATED,2025-09-01T16:18:25.990309,v2_robust,True,True,False,False,False,
NCT00286117,ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years,An Open Randomised Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ as Adjuvant Therapies in Post-Menopausal Women With Breast Cancer Already Being Treated With NOLVADEX for at Least Two Years,Anastrozole,"['Arimidex', 'Tamoxifen', 'Nolvadex', 'ZD1033', 'Anastrozole']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,['Breast Cancer'],['Breast Cancer'],COMPLETED,,1998-03,2006-05,[{'measure': 'The primary objective of this analysis was to assess the difference in disease-free survival between post-menopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued on tamoxifen'}],[{'measure': 'Assess the difference in overall survival/disease recurrence/safety and tolerability between post-menopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to receive tamoxifen.'}],2,,75 Years,FEMALE,False,AstraZeneca,INDUSTRY,1,448.0,ACTUAL,2025-09-01T16:18:25.990321,v2_robust,True,True,True,False,True,
NCT01933217,Methylphenidate for Attention Problems After Pediatric TBI,Efficacy of Methylphenidate for Management of Long-Term Attention Problems After Pediatric Traumatic Brain Injury (TBI),Methylphenidate,"['Concerta', 'Placebo', 'Methylphenidate']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Traumatic Brain Injury,"['Traumatic Brain Injury', 'TBI', 'ADHD']","['TBI', 'traumatic brain injury', 'ADHD', 'methylphenidate', 'Concerta', 'attention problems']",COMPLETED,,2013-11,2016-08,"[{'measure': 'Parent Outcome-Vanderbilt ADHD Parent Rating Scales (VADPRS)', 'description': 'Changes in symptom ratings were assessed on the Vanderbilt ADHD parent rating scales (VADPRS). A measure of ADHD symptom severity (Total Symptom Score \\[TSS\\]) is computed by totaling the scores from items 1-18 (Inattentive +Hyperactive-impulse domains), with a rating of none=0, occasionally=1, often=2, very often=3, provided. Scores for inattentive and hyperactive-impulsive domains were generated by totaling the 9 symptoms in these domains, and a TSS was computed by totaling items across domains.', 'timeFrame': 'Reported at End of Methylphenidate Arm (Week 4 or 8)'}, {'measure': 'Parent Outcome-Behavior Rating Inventory of Executive Functioning (BRIEF)', 'description': 'The Behavior Rating Inventory of Executive Functioning (BRIEF)-Parent was used to assess executive functioning behaviors. The global executive composite (GEC), behavior regulatory index (BRI), and metacognitive index (MI) T-scores were used, with higher scores reflecting poorer executive functioning. T-scores were normalized to 50 with a standard deviation of 10.', 'timeFrame': 'Reported at End of Methylphenidate Arm (Week 4 or 8)'}]","[{'measure': 'Neuropsychological Outcome- Wechsler Intelligence Scale for Children, 4th Edition Processing Speed Index (WISC-IV-PSI)', 'description': 'The Wechsler Intelligence Scale for Children, 4th Edition Processing Speed Index (WISC-IV-PSI) has been designed for children 6-16:11 years of age and provides a measure of processing speed. For this index scale, the average score is 100 with a standard deviation of 15. Higher scores reflect better processing speed. One participant was administered the Wechsler Adult Intelligence Scale 4th Edition Processing Speed Index (WAIS-IV-PSI). All scores were included in the combined WISC/WAIS processing speed variable since both measures yield highly correlated standard scores.', 'timeFrame': 'Reported at End of Methylphenidate Arm (Week 4 or 8)'}, {'measure': 'Teacher Outcome Measure', 'description': 'Used to assess child behavior.', 'timeFrame': 'January 1, 2014 - July 20, 2017'}]",4,6 Years,17 Years,ALL,False,"Children's Hospital Medical Center, Cincinnati",OTHER,0,26.0,ACTUAL,2025-09-01T16:18:25.990351,v2_robust,True,True,True,False,False,
NCT04512417,A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer,"A Multi-Center, Randomized Controlled, Phase II Clinical Study Of Camrelizumab With Or Without Radiotherapy For The Treatment Of Recurrent Or Metastatic Esophageal Cancer That Has Progressed After Chemotherapy",Camrelizumab+Radiotherapy,"['SBRT', 'Camrelizumab', 'Camrelizumab+Radiotherapy']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Esophageal Cancer,['Esophageal Cancer'],"['Esophageal Cancer', 'Camrelizumab', 'IO、Radiotherapy']",UNKNOWN,,2020-08-31,2022-08-31,"[{'measure': 'Progression-free Survival (PFS) per RECIST 1.1', 'description': 'PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to 24 months'}]","[{'measure': 'Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1', 'description': 'ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1.', 'timeFrame': 'Up to approximately 6 months.'}, {'measure': 'Overall Survival (OS)', 'description': 'defined as the time from randomization to death from any cause during the course of the study.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Number of Subjects with treatment-related adverse events (AEs)', 'description': 'Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Failure mode', 'description': 'Observe and collect the reasons for the treatment failure of the subjects during the study', 'timeFrame': 'Up to 24 months'}]",5,18 Years,75 Years,ALL,False,Zhejiang Cancer Hospital,OTHER,0,63.0,ESTIMATED,2025-09-01T16:18:25.990404,v2_robust,True,True,False,False,True,
NCT00764517,"Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma","Phase II Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) in Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Relapsed B Cell Non-Hodgkin Lymphoma",Cladribine,"['CdA', 'L-001079038', 'Leustatine', 'RWJ-26251', 'SAHA', 'Zolinza', 'Suberoylanilide Hydroxamic Acid', 'Cladribina', '2CDA', 'Vorinostat', 'Cladribine', '2-CdA', 'Leustat', 'Leustatin', 'Suberanilohydroxamic Acid']",15,INTERVENTIONAL,['PHASE2'],PHASE2,,Recurrent B-Cell Non-Hodgkin Lymphoma,"['Recurrent B-Cell Non-Hodgkin Lymphoma', 'Recurrent Chronic Lymphocytic Leukemia', 'Recurrent Indolent Adult Non-Hodgkin Lymphoma', 'Refractory B-Cell Non-Hodgkin Lymphoma']",[],COMPLETED,,2008-08,2017-03,"[{'measure': 'Objective Response Rate', 'description': 'ORR defined as the percentage of patients who achieved a complete response (CR) or a partial response (PR). Assessed per the revised Cheson criteria. Response definitions per revised International Working Group Response Criteria. 95% confidence interval will be provided. Definitions: Complete response (CR) = disappearance of all evidence of disease; Partial response (PR) = regression of measurable disease and no new sites.', 'timeFrame': '2 years'}, {'measure': 'Toxicities as Assessed Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0', 'description': 'Toxicity is determined percentage of patients that experienced an adverse event (AE) grade 3 or higher during the time frame, assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Grade refers to the severity of the AE increasing from Grade 1 to 5. Generally, Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe or medically significant but not immediately life-threatening; Grade 4 = Life-threatening consequences; Grade 5 = Death related to AE.', 'timeFrame': '6 months'}, {'measure': 'Tolerability of Treatment', 'description': 'Tolerability is determined to be the percentage of patients who completed the full duration of treatment (all 6 cycles) regardless of adverse event status. % tolerability shows the rate of patients that tolerated the treatment for the full duration.', 'timeFrame': '6 months'}]","[{'measure': 'Progression-free Survival', 'description': 'Time from treatment start until disease progression or death.\n\nEstimated using the Kaplan-Meier method. A logrank test will be used to compare progression-free survival between Group I and Group II. A p-value less that 0.05 will be considered statistically significant.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Event-free Survival', 'description': 'Time from treatment start until disease progression, death, or discontinuation of treatment for adverse event (toxicity)\n\nEstimated using the Kaplan-Meier method. A logrank test will be used to compare progression-free survival between Group I and Group II. A p-value less that 0.05 will be considered statistically significant.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Contribution (if Any) of DNA Methylation/Histone Deacetylation', 'description': 'Determine the contribution (if any) of DNA methylation/histone deacetylation to disease progression and/or response to SCR combination chemotherapy.\n\nOutcome not evaluated due to technical challenges collecting the data, and lack of budget and personnel to complete the analysis.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Scientific Correlates', 'description': 'Perform scientific correlates to determine if SCR treatment a) is associated with global and gene specific changes in transcription of mRNAs and MiRNAs b) is acting as an inhibitor of DNA methylation c) is activating or silencing specific genes or miRNAs.\n\nOutcome not evaluated due to technical challenges collecting the data, and lack of budget and personnel to complete the analysis.', 'timeFrame': 'Baseline'}]",7,18 Years,,ALL,False,OHSU Knight Cancer Institute,OTHER,1,57.0,ACTUAL,2025-09-01T16:18:25.990498,v2_robust,True,True,True,False,True,
NCT04561817,To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer,An Open Label Phase II Study to Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer,Ipatasertib,"['Paclitaxel', 'GDC-0068', 'Ipatasertib']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Neoplasms,['Ovarian Neoplasms'],"['Platinum-resistant', 'Ovarian cancer', 'Ipatasertib', 'Paclitaxel', 'Recurrent']",WITHDRAWN,Evolving data with Ipatasertib that changes the known risk / benefit background in pursuing future studies.,2020-10-01,2023-10-01,"[{'measure': 'Objective response rate (ORR)', 'description': 'ORR will be measured by the percentage of patients whose cancer decreases in size on assessment. This will be measured as the sum of complete response and partial response.', 'timeFrame': 'At the end of Cycle 1 (each cycle is 28 days)'}, {'measure': 'Objective response rate (ORR)', 'description': 'ORR will be measured by the percentage of patients whose cancer decreases in size on assessment. This will be measured as the sum of complete response and partial response.', 'timeFrame': 'At the end of Cycle 2 (each cycle is 28 days)'}, {'measure': 'Objective response rate (ORR)', 'description': 'ORR will be measured by the percentage of patients whose cancer decreases in size on assessment. This will be measured as the sum of complete response and partial response.', 'timeFrame': 'At the end of Cycle 3 (each cycle is 28 days)'}]","[{'measure': 'Progression free survival (PFS)', 'description': 'Disease status will be assessed with comprehensive radiographic studies every 3 treatment cycles (12 weeks +/- 1 week), but the development of new signs or symptoms of disease in between scheduled evaluations may prompt off-schedule radiographic or non-radiographic evaluations. Disease status will be assessed based on RECIST 1.1 criteria for measurable and non-measurable disease.', 'timeFrame': 'At the end of Cycle 1 (each cycle is 28 days)'}, {'measure': 'Progression free survival (PFS)', 'description': 'Disease status will be assessed with comprehensive radiographic studies every 3 treatment cycles (12 weeks +/- 1 week), but the development of new signs or symptoms of disease in between scheduled evaluations may prompt off-schedule radiographic or non-radiographic evaluations. Disease status will be assessed based on RECIST 1.1 criteria for measurable and non-measurable disease.', 'timeFrame': 'At the end of Cycle 2 (each cycle is 28 days)'}, {'measure': 'Progression free survival (PFS)', 'description': 'Disease status will be assessed with comprehensive radiographic studies every 3 treatment cycles (12 weeks +/- 1 week), but the development of new signs or symptoms of disease in between scheduled evaluations may prompt off-schedule radiographic or non-radiographic evaluations. Disease status will be assessed based on RECIST 1.1 criteria for measurable and non-measurable disease.', 'timeFrame': 'At the end of Cycle 3 (each cycle is 28 days)'}, {'measure': 'Disease control rate (DCR)', 'description': 'DCR will be measured by the percentage of patients whose cancer decreases in size or remains stable over the duration of the study. This will be measured as the sum of complete response, partial response, and stable disease for greater than or equal to 24 weeks.', 'timeFrame': 'average 24 weeks'}]",7,18 Years,90 Years,FEMALE,False,Icahn School of Medicine at Mount Sinai,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:25.990515,v2_robust,True,True,False,True,False,Evolving data with Ipatasertib that changes the known risk / benefit background in pursuing future studies.
NCT07020117,A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors,"NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors",[225Ac]Ac-AKY-1189 (therapeutic),"['[225Ac]Ac-AKY-1189 (therapeutic)', '[64Cu]Cu-AKY-1189 (imaging)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Urothelial Carcinoma Bladder,"['Urothelial Carcinoma Bladder', 'Triple Negative Breast Cancer (TNBC)', 'Hormone Receptor Positive Breast Adenocarcinoma', 'Non Small Cell Lung Cancer', 'Cervical Adenocarcinoma', 'Colorectal Adenocarcinoma', 'Head and Neck Cancer']",[],RECRUITING,,2025-08-19,2032-06,"[{'measure': 'Part 1: Number of Patients with Dose-Limiting Toxicities', 'description': '• Dose-limiting toxicities (DLTs) is defined as any predefined AE occurring during the DLT observation period, except those that are clearly and incontrovertibly due to extraneous circumstances. The number of patients who experience a DLT in Part 1, will be reported by dose level.', 'timeFrame': 'From enrollment to the end of Cycle 1 (each cycle is 28 days)'}, {'measure': 'Part 1: Occurence of Adverse Events by Severity', 'description': '• An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of patients experiencing an AE in Part 1 will be reported.', 'timeFrame': 'Up to the End of Treatment (30 days after the last dose)'}, {'measure': 'Part 2: Objective Response Rate (ORR)', 'description': '• Objective response rate is defined as the percentage of patients who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), as determined by the investigator based on RECIST 1.1, by tumor types.', 'timeFrame': 'Up to 30 days following last administration'}]","[{'measure': 'Part 1: Objective Response Rate (ORR)', 'description': '• Objective response rate is defined as the percentage of patients who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), as determined by the investigator based on RECIST 1.1, by dose level.', 'timeFrame': 'Up to 30 days following last adminstration'}, {'measure': 'Part 2: Occurence of Adverse Events by Severity', 'description': '• An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of patients experiencing an AE in Part 2 will be reported.', 'timeFrame': 'Up to End of Treatment (30 days after the last dose)'}, {'measure': 'Part 1 and 2: Duration of Response (DOR)', 'description': '• Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \\[CR\\] or partial response \\[PR\\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause.', 'timeFrame': 'Up to 5 years after first administration'}, {'measure': 'Part 1 and 2: Progression-Free Survival (PFS)', 'description': '• PFS is defined as the time from treatment initiation to the first documented disease progression per RECIST 1.1 or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to 5 years after first administration'}]",7,18 Years,,ALL,False,"Aktis Oncology, Inc.",INDUSTRY,0,150.0,ESTIMATED,2025-09-01T16:18:25.990702,v2_robust,True,True,False,False,True,
